cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
SARC	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	23.34	6.55e-63	1.88e-55	1.01	0.84	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	22.91	1.33e-61	3.99e-55	1.02	0.83	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	22.91	1.33e-61	3.99e-55	1.02	0.83	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	22.9	1.39e-61	3.99e-55	1.02	0.83	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	22.9	1.39e-61	3.99e-55	1.02	0.83	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	22.9	1.39e-61	3.99e-55	1.02	0.83	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	22.9	1.39e-61	3.99e-55	1.02	0.83	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	22.48	2.7e-60	6.11e-54	1.01	0.83	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	22.43	4.04e-60	8.26e-54	1.02	0.83	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	22.14	3.17e-59	5.33e-53	1.02	0.82	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	21.75	5.19e-58	7.07e-52	1.03	0.82	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	21.64	1.17e-57	8.67e-52	1.01	0.82	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	21.64	1.17e-57	8.67e-52	1.01	0.82	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	21.64	1.17e-57	8.67e-52	1.01	0.82	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	21.64	1.17e-57	8.67e-52	1.01	0.82	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	21.64	1.17e-57	8.67e-52	1.01	0.82	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	21.64	1.17e-57	8.67e-52	1.01	0.82	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	21.64	1.17e-57	8.67e-52	1.01	0.82	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	21.64	1.17e-57	8.67e-52	1.01	0.82	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	21.64	1.17e-57	8.67e-52	1.01	0.82	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	21.6	1.56e-57	1.06e-51	1	0.82	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	21.57	1.9e-57	1.26e-51	1	0.82	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	21.53	2.44e-57	1.56e-51	1.03	0.82	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	21.53	2.51e-57	1.56e-51	1.02	0.82	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	21.53	2.51e-57	1.56e-51	1.02	0.82	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	21.52	2.77e-57	1.69e-51	1.02	0.82	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	21.5	3.21e-57	1.87e-51	1.03	0.82	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	21.45	4.52e-57	2.46e-51	1.02	0.81	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	21.45	4.53e-57	2.46e-51	1.03	0.81	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	21.45	4.55e-57	2.46e-51	1.02	0.81	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	21.42	5.43e-57	2.85e-51	1.19	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
SARC	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	21.36	8.65e-57	4.06e-51	1.02	0.81	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	21.35	9.11e-57	4.06e-51	1.02	0.81	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	21.35	9.11e-57	4.06e-51	1.02	0.81	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	21.35	9.11e-57	4.06e-51	1.02	0.81	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	21.35	9.21e-57	4.06e-51	1	0.81	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	21.35	9.21e-57	4.06e-51	1	0.81	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	21.35	9.21e-57	4.06e-51	1	0.81	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	21.35	9.21e-57	4.06e-51	1	0.81	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	21.34	9.96e-57	4.32e-51	1.19	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
SARC	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	21.32	1.13e-56	4.81e-51	1.02	0.81	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	21.21	2.45e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	21.21	2.6e-56	9.65e-51	1.19	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
SARC	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	21.19	2.92e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	21.18	3.17e-56	9.65e-51	1	0.81	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	21.09	6.27e-56	1.82e-50	1	0.81	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	21.09	6.27e-56	1.82e-50	1	0.81	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-21.08	6.3e-56	1.82e-50	-1.01	-0.81	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	21.04	8.52e-56	2.41e-50	1.18	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
SARC	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	21.03	9.62e-56	2.7e-50	1.16	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
SARC	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	20.99	1.29e-55	3.58e-50	1.19	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
SARC	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	20.93	1.88e-55	5.03e-50	1	0.81	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	20.93	1.88e-55	5.03e-50	1	0.81	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	20.93	1.88e-55	5.03e-50	1	0.81	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	20.93	1.88e-55	5.03e-50	1	0.81	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
SARC	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	20.91	2.29e-55	6.08e-50	1.19	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
SARC	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	20.86	3.16e-55	8.29e-50	1.17	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
SARC	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	20.84	3.82e-55	9.94e-50	1.01	0.81	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-20.76	6.64e-55	1.71e-49	-1.02	-0.81	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	20.66	1.44e-54	3.64e-49	1.15	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
SARC	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	20.46	5.82e-54	1.45e-48	0.97	0.8	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	20.37	1.13e-53	2.77e-48	1.04	0.8	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	20.36	1.25e-53	3.03e-48	0.98	0.8	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	20.29	2.06e-53	4.88e-48	0.97	0.8	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	20.29	2.06e-53	4.88e-48	0.97	0.8	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	20.29	2.06e-53	4.88e-48	0.97	0.8	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	20.23	3.36e-53	7.03e-48	1	0.8	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	20.23	3.36e-53	7.03e-48	1	0.8	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	20.23	3.36e-53	7.03e-48	1	0.8	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	20.23	3.36e-53	7.03e-48	1	0.8	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	20.23	3.36e-53	7.03e-48	1	0.8	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	20.23	3.36e-53	7.03e-48	1	0.8	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	20.23	3.36e-53	7.03e-48	1	0.8	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
SARC	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	20.23	3.36e-53	7.03e-48	1	0.8	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	20.23	3.36e-53	7.03e-48	1	0.8	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	20.23	3.36e-53	7.03e-48	1	0.8	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	20.23	3.36e-53	7.03e-48	1	0.8	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	20.21	3.79e-53	7.85e-48	1.13	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
SARC	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	20.18	4.62e-53	9.52e-48	1.06	0.8	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
SARC	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	19.99	1.89e-52	3.83e-47	1.13	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
SARC	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	19.95	2.48e-52	4.93e-47	1.11	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
SARC	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	19.95	2.48e-52	4.93e-47	1.11	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
SARC	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	19.93	3e-52	5.92e-47	0.96	0.79	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	19.92	3.24e-52	6.34e-47	0.96	0.79	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	19.76	1.02e-51	1.94e-46	0.98	0.79	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	19.76	1.02e-51	1.94e-46	0.98	0.79	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	19.67	2.05e-51	3.86e-46	1.11	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
SARC	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	19.64	2.6e-51	4.86e-46	0.99	0.79	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	19.62	2.86e-51	5.32e-46	1	0.79	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	19.45	1.05e-50	1.87e-45	0.97	0.79	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	19.45	1.05e-50	1.87e-45	0.97	0.79	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	19.29	3.41e-50	5.84e-45	0.96	0.78	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
SARC	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	19.24	4.89e-50	8.14e-45	0.95	0.78	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
SARC	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-19.1	1.41e-49	2.34e-44	-0.99	-0.78	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
SARC	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-18.92	5.53e-49	8.84e-44	-0.99	-0.78	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-18.76	1.75e-48	2.74e-43	-1	-0.78	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-18.75	1.94e-48	3e-43	-0.97	-0.78	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	18.63	4.72e-48	7.19e-43	0.96	0.77	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
SARC	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-18.62	5.3e-48	8.02e-43	-1.01	-0.77	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	18.61	5.56e-48	8.33e-43	0.96	0.77	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	18.5	1.25e-47	1.85e-42	0.96	0.77	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
SARC	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	18.5	1.29e-47	1.87e-42	1.12	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
SARC	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	18.5	1.29e-47	1.87e-42	1.12	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
SARC	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-18.5	1.3e-47	1.87e-42	-1.02	-0.77	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	18.48	1.42e-47	2.04e-42	0.97	0.77	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	18.48	1.45e-47	2.06e-42	0.96	0.77	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	18.48	1.51e-47	2.1e-42	0.97	0.77	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	18.48	1.51e-47	2.1e-42	0.97	0.77	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	18.48	1.51e-47	2.1e-42	0.97	0.77	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	18.45	1.84e-47	2.55e-42	1.08	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
SARC	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	18.42	2.39e-47	3.27e-42	0.96	0.77	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	18.39	2.97e-47	4.05e-42	0.97	0.77	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	18.38	3.24e-47	4.35e-42	0.96	0.77	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	18.37	3.31e-47	4.35e-42	0.96	0.77	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	18.37	3.31e-47	4.35e-42	0.96	0.77	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	18.37	3.39e-47	4.35e-42	0.96	0.77	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	18.37	3.39e-47	4.35e-42	0.96	0.77	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	18.37	3.39e-47	4.35e-42	0.96	0.77	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	18.37	3.44e-47	4.35e-42	0.96	0.77	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	18.37	3.44e-47	4.35e-42	0.96	0.77	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	18.37	3.44e-47	4.35e-42	0.96	0.77	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	18.36	3.58e-47	4.52e-42	1.08	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
SARC	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	18.35	4.04e-47	4.99e-42	0.96	0.77	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	18.34	4.17e-47	5.12e-42	0.96	0.77	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
SARC	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-18.32	4.73e-47	5.71e-42	-1	-0.77	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	18.24	8.71e-47	1.03e-41	0.95	0.77	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	18.23	9.35e-47	1.07e-41	0.95	0.77	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-18.23	9.91e-47	1.13e-41	-0.97	-0.77	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	18.22	1.02e-46	1.14e-41	1.07	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
SARC	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	18.22	1.06e-46	1.14e-41	0.95	0.77	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	18.22	1.06e-46	1.14e-41	0.95	0.77	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	18.22	1.06e-46	1.14e-41	0.95	0.77	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	18.22	1.06e-46	1.14e-41	0.95	0.77	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	18.22	1.06e-46	1.14e-41	0.95	0.77	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	18.22	1.06e-46	1.14e-41	0.95	0.77	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	18.22	1.06e-46	1.14e-41	0.95	0.77	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	18.22	1.06e-46	1.14e-41	0.95	0.77	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	18.22	1.06e-46	1.14e-41	0.95	0.77	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	18.22	1.06e-46	1.14e-41	0.95	0.77	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	18.22	1.06e-46	1.14e-41	0.95	0.77	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	18.21	1.11e-46	1.18e-41	0.96	0.77	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
SARC	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-18.21	1.16e-46	1.23e-41	-0.96	-0.77	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
SARC	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-18.21	1.16e-46	1.23e-41	-0.96	-0.77	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	18.2	1.25e-46	1.31e-41	0.95	0.77	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	18.2	1.25e-46	1.31e-41	0.95	0.77	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	18.17	1.51e-46	1.57e-41	0.98	0.77	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	18.17	1.55e-46	1.57e-41	0.95	0.77	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	18.17	1.55e-46	1.57e-41	0.95	0.77	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	18.17	1.55e-46	1.57e-41	0.95	0.77	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	18.17	1.55e-46	1.57e-41	0.95	0.77	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	18.17	1.55e-46	1.57e-41	0.95	0.77	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	18.17	1.55e-46	1.57e-41	0.95	0.77	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	18.17	1.55e-46	1.57e-41	0.95	0.77	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	18.17	1.55e-46	1.57e-41	0.95	0.77	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	18.16	1.66e-46	1.68e-41	0.94	0.77	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
SARC	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-18.15	1.78e-46	1.79e-41	-1.02	-0.77	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	18.14	1.9e-46	1.89e-41	0.96	0.77	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	18.14	1.9e-46	1.89e-41	0.96	0.77	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	18.14	1.9e-46	1.89e-41	0.96	0.77	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	18.14	1.93e-46	1.92e-41	1.08	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
SARC	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	18.13	2.08e-46	2.06e-41	0.94	0.76	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	18.1	2.53e-46	2.33e-41	0.94	0.76	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	18.1	2.53e-46	2.33e-41	0.94	0.76	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	18.1	2.53e-46	2.33e-41	0.94	0.76	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	18.1	2.53e-46	2.33e-41	0.94	0.76	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	18.1	2.53e-46	2.33e-41	0.94	0.76	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	18.1	2.53e-46	2.33e-41	0.94	0.76	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	18.1	2.53e-46	2.33e-41	0.94	0.76	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	18.1	2.53e-46	2.33e-41	0.94	0.76	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	18.1	2.53e-46	2.33e-41	0.94	0.76	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
SARC	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	18.09	2.76e-46	2.54e-41	1.08	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
SARC	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	18.09	2.87e-46	2.64e-41	1.07	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
SARC	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	18.08	2.99e-46	2.73e-41	0.94	0.76	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
SARC	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-18.06	3.44e-46	3.12e-41	-1.02	-0.76	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-18.06	3.5e-46	3.16e-41	-0.99	-0.76	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	18.05	3.71e-46	3.34e-41	0.96	0.76	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
SARC	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-18.04	4e-46	3.59e-41	-1.01	-0.76	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	18.03	4.23e-46	3.76e-41	0.96	0.76	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	18.03	4.23e-46	3.76e-41	0.96	0.76	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	18.03	4.23e-46	3.76e-41	0.96	0.76	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	18.03	4.26e-46	3.77e-41	1.07	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
SARC	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-18.01	4.99e-46	4.4e-41	-0.99	-0.76	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	18.01	5.11e-46	4.48e-41	0.95	0.76	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
SARC	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	17.98	6.44e-46	5.6e-41	1.07	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
SARC	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	17.94	8.45e-46	7.29e-41	0.95	0.76	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	17.93	9.17e-46	7.88e-41	0.95	0.76	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	17.91	1.12e-45	9.62e-41	0.95	0.76	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	17.88	1.33e-45	1.13e-40	0.94	0.76	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	17.87	1.43e-45	1.22e-40	0.95	0.76	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	17.84	1.81e-45	1.54e-40	1.05	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
SARC	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	17.83	1.92e-45	1.62e-40	0.95	0.76	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	17.83	1.92e-45	1.62e-40	0.95	0.76	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	17.81	2.29e-45	1.92e-40	0.95	0.76	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	17.81	2.31e-45	1.93e-40	0.98	0.76	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	17.79	2.62e-45	2.17e-40	0.98	0.76	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	17.79	2.62e-45	2.17e-40	0.98	0.76	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	17.79	2.67e-45	2.2e-40	0.95	0.76	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	17.79	2.67e-45	2.2e-40	0.95	0.76	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	17.79	2.67e-45	2.2e-40	0.95	0.76	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	17.76	3.45e-45	2.81e-40	0.96	0.76	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	17.76	3.45e-45	2.81e-40	0.96	0.76	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	17.76	3.45e-45	2.81e-40	0.96	0.76	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	17.76	3.48e-45	2.83e-40	0.94	0.76	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
SARC	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-17.75	3.54e-45	2.87e-40	-1.01	-0.76	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
SARC	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	17.69	5.74e-45	4.63e-40	1.05	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
SARC	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	17.69	5.77e-45	4.64e-40	0.97	0.76	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
SARC	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	17.69	5.88e-45	4.71e-40	0.94	0.76	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	17.69	5.92e-45	4.72e-40	0.95	0.76	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	17.67	6.42e-45	5.08e-40	0.94	0.76	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	17.67	6.42e-45	5.08e-40	0.94	0.76	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
SARC	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	17.67	6.69e-45	5.27e-40	0.93	0.76	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	17.65	7.6e-45	5.93e-40	0.94	0.76	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	17.65	7.6e-45	5.93e-40	0.94	0.76	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
SARC	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	17.65	8.02e-45	6.24e-40	0.96	0.76	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	17.6	1.13e-44	8.73e-40	0.96	0.76	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	17.6	1.14e-44	8.79e-40	0.95	0.76	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	17.57	1.42e-44	1.09e-39	0.94	0.75	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	17.54	1.78e-44	1.36e-39	0.93	0.75	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	17.47	3.09e-44	2.34e-39	0.96	0.75	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
SARC	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	17.46	3.17e-44	2.39e-39	1.03	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
SARC	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	17.43	4.15e-44	3.11e-39	0.95	0.75	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	17.42	4.32e-44	3.23e-39	0.95	0.75	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	17.41	4.89e-44	3.61e-39	0.92	0.75	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	17.4	5.05e-44	3.72e-39	0.95	0.75	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	17.4	5.05e-44	3.72e-39	0.95	0.75	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	17.4	5.29e-44	3.87e-39	0.93	0.75	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
SARC	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-17.39	5.5e-44	4.02e-39	-1.06	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
SARC	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	17.38	5.98e-44	4.33e-39	0.93	0.75	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	17.36	6.8e-44	4.92e-39	0.92	0.75	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
SARC	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	17.35	7.63e-44	5.49e-39	0.83	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
SARC	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	17.34	8.04e-44	5.77e-39	0.94	0.75	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	17.32	9.78e-44	6.96e-39	0.95	0.75	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	17.32	9.78e-44	6.96e-39	0.95	0.75	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
SARC	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-17.3	1.12e-43	7.92e-39	-1.02	-0.75	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
SARC	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	17.3	1.14e-43	7.98e-39	0.92	0.75	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
SARC	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	17.23	1.92e-43	1.33e-38	0.96	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
SARC	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	17.21	2.26e-43	1.55e-38	0.92	0.75	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	17.21	2.26e-43	1.55e-38	0.92	0.75	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
SARC	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	17.17	2.85e-43	1.94e-38	0.83	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
SARC	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	17.17	2.88e-43	1.95e-38	0.94	0.75	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	17.17	3e-43	2.01e-38	0.94	0.75	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	17.14	3.78e-43	2.52e-38	0.93	0.75	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	17.12	4.36e-43	2.9e-38	0.96	0.75	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	17.09	5.41e-43	3.58e-38	0.93	0.75	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	17.07	6.49e-43	4.27e-38	0.93	0.75	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	17.07	6.49e-43	4.27e-38	0.93	0.75	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
SARC	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	17.07	6.55e-43	4.3e-38	0.96	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
SARC	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	16.98	1.27e-42	8.25e-38	0.92	0.74	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	16.97	1.32e-42	8.54e-38	0.93	0.74	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
SARC	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	16.97	1.34e-42	8.64e-38	1.03	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
SARC	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	16.97	1.34e-42	8.64e-38	1.03	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
SARC	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-16.97	1.4e-42	8.99e-38	-0.84	-0.74	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	16.95	1.62e-42	1.04e-37	0.93	0.74	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	16.93	1.91e-42	1.2e-37	0.93	0.74	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
SARC	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	16.89	2.59e-42	1.62e-37	0.82	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
SARC	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-16.85	3.27e-42	2.04e-37	-0.84	-0.74	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	16.85	3.29e-42	2.04e-37	0.96	0.74	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
SARC	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	16.8	4.81e-42	2.91e-37	0.83	0.74	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	16.8	4.85e-42	2.93e-37	0.83	0.74	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-16.76	6.69e-42	4.01e-37	-0.93	-0.74	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
SARC	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	16.72	9.12e-42	5.45e-37	0.95	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
SARC	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-16.71	9.6e-42	5.72e-37	-0.97	-0.74	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	16.69	1.13e-41	6.6e-37	0.94	0.74	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	16.67	1.29e-41	7.52e-37	0.97	0.74	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
SARC	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-16.63	1.81e-41	1.03e-36	-1.02	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
SARC	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-16.63	1.81e-41	1.03e-36	-1.02	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
SARC	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-16.63	1.81e-41	1.03e-36	-1.02	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
SARC	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-16.63	1.81e-41	1.03e-36	-1.02	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
SARC	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-16.63	1.81e-41	1.03e-36	-1.02	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
SARC	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-16.63	1.81e-41	1.03e-36	-1.02	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
SARC	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-16.63	1.81e-41	1.03e-36	-1.02	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
SARC	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	16.62	1.98e-41	1.12e-36	0.84	0.74	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	16.61	2.16e-41	1.21e-36	0.92	0.74	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	16.61	2.16e-41	1.21e-36	0.92	0.74	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-16.59	2.37e-41	1.31e-36	-0.93	-0.74	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	16.58	2.73e-41	1.5e-36	0.92	0.74	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
SARC	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	16.53	3.8e-41	2.05e-36	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	16.53	3.8e-41	2.05e-36	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
SARC	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	16.52	4.12e-41	2.22e-36	1	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
SARC	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	16.5	5.06e-41	2.72e-36	0.96	0.73	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
SARC	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-16.47	5.97e-41	3.17e-36	-1.01	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
SARC	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-16.47	5.97e-41	3.17e-36	-1.01	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
SARC	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	16.42	8.81e-41	4.35e-36	0.74	0.73	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
SARC	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	16.38	1.23e-40	6.04e-36	0.84	0.73	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-16.37	1.28e-40	6.26e-36	-0.84	-0.73	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	16.36	1.39e-40	6.74e-36	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
SARC	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	16.32	1.91e-40	9.24e-36	0.99	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
SARC	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	16.27	2.81e-40	1.35e-35	0.91	0.73	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
SARC	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	16.27	2.9e-40	1.39e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	16.26	3.13e-40	1.49e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	16.26	3.13e-40	1.49e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	16.26	3.13e-40	1.49e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	16.26	3.13e-40	1.49e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	16.26	3.13e-40	1.49e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	16.26	3.13e-40	1.49e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	16.26	3.13e-40	1.49e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	16.25	3.31e-40	1.57e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	16.23	3.71e-40	1.73e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	16.23	3.71e-40	1.73e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	16.23	3.71e-40	1.73e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	16.23	3.71e-40	1.73e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	16.23	3.71e-40	1.73e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	16.23	3.71e-40	1.73e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	16.22	4.09e-40	1.9e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
SARC	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	16.21	4.51e-40	2.09e-35	0.98	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
SARC	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	16.21	4.51e-40	2.09e-35	0.98	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
SARC	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	16.19	5.11e-40	2.36e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
SARC	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-16.16	6.34e-40	2.92e-35	-1.01	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
SARC	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-16.13	8.03e-40	3.68e-35	-1.01	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
SARC	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-16.12	8.97e-40	4.09e-35	-0.91	-0.73	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	16.12	9.16e-40	4.17e-35	0.92	0.73	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	16.12	9.16e-40	4.17e-35	0.92	0.73	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
SARC	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	16.11	9.27e-40	4.21e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
SARC	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	16.09	1.12e-39	5.08e-35	0.79	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
SARC	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	16.09	1.13e-39	5.12e-35	0.83	0.73	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	16.09	1.15e-39	5.19e-35	0.84	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
SARC	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-16.06	1.46e-39	6.54e-35	-0.97	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
SARC	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	16.02	1.97e-39	8.79e-35	0.83	0.72	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	15.98	2.53e-39	1.13e-34	0.93	0.72	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
SARC	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	15.95	3.27e-39	1.45e-34	0.83	0.72	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	15.94	3.6e-39	1.6e-34	0.83	0.72	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
SARC	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	15.91	4.43e-39	1.96e-34	0.97	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
SARC	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	15.91	4.52e-39	2e-34	0.97	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
SARC	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	15.89	5.13e-39	2.26e-34	0.79	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
SARC	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	15.83	8.05e-39	3.52e-34	0.93	0.72	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
SARC	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	15.82	9.07e-39	3.96e-34	0.88	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	15.8	1.05e-38	4.58e-34	0.92	0.72	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
SARC	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	15.78	1.16e-38	5.03e-34	0.83	0.72	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	15.78	1.16e-38	5.03e-34	0.83	0.72	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	15.74	1.6e-38	6.94e-34	0.94	0.72	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
SARC	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	15.67	2.88e-38	1.24e-33	0.83	0.72	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
SARC	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	15.61	4.33e-38	1.86e-33	0.82	0.72	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	15.57	5.79e-38	2.46e-33	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	15.57	5.79e-38	2.46e-33	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	15.57	5.79e-38	2.46e-33	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	15.57	5.79e-38	2.46e-33	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	15.57	5.79e-38	2.46e-33	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	15.56	6.51e-38	2.76e-33	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	15.56	6.57e-38	2.77e-33	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	15.56	6.57e-38	2.77e-33	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	15.56	6.57e-38	2.77e-33	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
SARC	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	15.55	7e-38	2.95e-33	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	15.55	7.2e-38	3.02e-33	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	15.55	7.2e-38	3.02e-33	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	15.53	8.48e-38	3.55e-33	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	15.52	8.71e-38	3.64e-33	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
SARC	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	15.51	9.36e-38	3.9e-33	0.91	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
SARC	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	15.51	9.71e-38	4.02e-33	0.82	0.71	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	15.51	9.71e-38	4.02e-33	0.82	0.71	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	15.51	9.71e-38	4.02e-33	0.82	0.71	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	15.51	9.71e-38	4.02e-33	0.82	0.71	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
SARC	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	15.47	1.33e-37	5.5e-33	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
SARC	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	15.44	1.62e-37	6.66e-33	0.96	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
SARC	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	15.43	1.73e-37	7.11e-33	0.95	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
SARC	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	15.4	2.16e-37	8.88e-33	0.82	0.71	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	15.4	2.19e-37	8.99e-33	0.81	0.71	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
SARC	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	15.36	2.93e-37	1.2e-32	0.91	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
SARC	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	15.35	3.17e-37	1.29e-32	0.82	0.71	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
SARC	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	15.35	3.31e-37	1.34e-32	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
SARC	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	15.35	3.31e-37	1.34e-32	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	15.34	3.5e-37	1.42e-32	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	15.33	3.82e-37	1.55e-32	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	15.31	4.55e-37	1.84e-32	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	15.3	4.93e-37	1.99e-32	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
SARC	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	15.29	5.19e-37	2.09e-32	0.82	0.71	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
SARC	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	15.27	6.12e-37	2.45e-32	0.93	0.71	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
SARC	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	15.26	6.53e-37	2.61e-32	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
SARC	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	15.26	6.55e-37	2.61e-32	0.82	0.71	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
SARC	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	15.25	7.03e-37	2.79e-32	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
SARC	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	15.2	1e-36	3.95e-32	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	15.2	1e-36	3.95e-32	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
SARC	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	15.2	1.01e-36	3.97e-32	0.71	0.71	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
SARC	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-15.19	1.1e-36	4.32e-32	-0.82	-0.71	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
SARC	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	15.19	1.1e-36	4.33e-32	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
SARC	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	15.18	1.18e-36	4.62e-32	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	15.17	1.32e-36	5.17e-32	0.94	0.7	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
SARC	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	15.16	1.39e-36	5.42e-32	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	15.16	1.39e-36	5.42e-32	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
SARC	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	15.16	1.42e-36	5.51e-32	0.82	0.7	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	15.13	1.72e-36	6.6e-32	0.81	0.7	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	15.13	1.72e-36	6.6e-32	0.81	0.7	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	15.13	1.72e-36	6.6e-32	0.81	0.7	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	15.13	1.72e-36	6.6e-32	0.81	0.7	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	15.13	1.72e-36	6.6e-32	0.81	0.7	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
SARC	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	15.13	1.74e-36	6.67e-32	0.95	0.7	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
SARC	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-15.13	1.8e-36	6.88e-32	-0.81	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
SARC	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	15.11	1.98e-36	7.57e-32	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	15.11	1.98e-36	7.57e-32	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	15.1	2.15e-36	8.2e-32	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	15.1	2.15e-36	8.2e-32	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	15.08	2.53e-36	9.55e-32	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	15.07	2.84e-36	1.07e-31	0.88	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	15.06	2.97e-36	1.12e-31	0.71	0.7	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-15.06	3.05e-36	1.14e-31	-0.71	-0.7	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
SARC	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	15.05	3.15e-36	1.18e-31	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	15.05	3.17e-36	1.19e-31	0.94	0.7	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
SARC	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-15.03	3.65e-36	1.36e-31	-0.8	-0.7	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
SARC	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-15.03	3.66e-36	1.37e-31	-0.71	-0.7	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
SARC	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	15.03	3.9e-36	1.45e-31	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	15.03	3.9e-36	1.45e-31	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
SARC	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	14.96	6.68e-36	2.45e-31	0.71	0.7	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
SARC	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	14.95	6.75e-36	2.47e-31	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	14.95	6.75e-36	2.47e-31	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	14.95	6.75e-36	2.47e-31	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
SARC	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	14.95	7.1e-36	2.59e-31	0.71	0.7	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
SARC	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	14.95	7.22e-36	2.63e-31	0.81	0.7	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
SARC	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	14.94	7.33e-36	2.66e-31	0.93	0.7	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
SARC	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	14.94	7.4e-36	2.68e-31	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
SARC	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	14.94	7.43e-36	2.69e-31	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
SARC	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	14.9	1.03e-35	3.65e-31	0.7	0.7	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	14.9	1.03e-35	3.65e-31	0.7	0.7	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	14.9	1.03e-35	3.65e-31	0.7	0.7	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
SARC	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	14.89	1.13e-35	4.01e-31	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
SARC	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	14.88	1.16e-35	4.1e-31	0.7	0.7	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
SARC	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-14.88	1.17e-35	4.14e-31	-0.86	-0.7	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
SARC	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	14.87	1.3e-35	4.58e-31	0.7	0.7	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	14.87	1.33e-35	4.69e-31	0.7	0.7	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
SARC	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	14.86	1.34e-35	4.73e-31	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
SARC	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	14.86	1.44e-35	5.02e-31	0.78	0.7	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
SARC	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	14.84	1.67e-35	5.78e-31	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
SARC	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-14.82	1.93e-35	6.66e-31	-0.7	-0.7	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	14.81	2.01e-35	6.91e-31	0.87	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-14.8	2.13e-35	7.31e-31	-0.89	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
SARC	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-14.77	2.8e-35	9.56e-31	-0.86	-0.7	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
SARC	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	14.77	2.85e-35	9.72e-31	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-14.76	2.9e-35	9.88e-31	-0.89	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-14.75	3.33e-35	1.12e-30	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-14.75	3.33e-35	1.12e-30	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
SARC	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-14.72	3.95e-35	1.32e-30	-0.94	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
SARC	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	14.72	4.19e-35	1.4e-30	0.91	0.69	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	14.71	4.5e-35	1.5e-30	0.91	0.69	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	14.71	4.5e-35	1.5e-30	0.91	0.69	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
SARC	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	14.7	4.9e-35	1.63e-30	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	14.69	4.98e-35	1.66e-30	0.69	0.69	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
SARC	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-14.68	5.55e-35	1.84e-30	-0.78	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-14.66	6.56e-35	2.16e-30	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-14.66	6.56e-35	2.16e-30	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-14.66	6.56e-35	2.16e-30	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	14.65	7.04e-35	2.32e-30	0.89	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-14.64	7.71e-35	2.52e-30	-0.69	-0.69	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-14.64	7.71e-35	2.52e-30	-0.69	-0.69	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-14.64	7.75e-35	2.53e-30	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-14.62	8.61e-35	2.8e-30	-0.7	-0.69	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-14.62	8.61e-35	2.8e-30	-0.7	-0.69	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
SARC	cis	rs7847628	0.587	rs12684934	ENSG00000226752.6	PSMD5-AS1	-14.61	9.53e-35	3.09e-30	-0.86	-0.69	Birth weight;	chr9:120830881	chr9:120824828~120854385:+
SARC	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	14.61	9.58e-35	3.1e-30	0.82	0.69	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
SARC	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-14.59	1.09e-34	3.49e-30	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	14.59	1.14e-34	3.64e-30	0.9	0.69	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	14.58	1.17e-34	3.72e-30	0.9	0.69	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
SARC	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-14.58	1.22e-34	3.86e-30	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-14.58	1.22e-34	3.86e-30	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-14.58	1.22e-34	3.86e-30	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-14.58	1.22e-34	3.86e-30	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-14.58	1.22e-34	3.86e-30	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-14.58	1.22e-34	3.86e-30	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-14.58	1.22e-34	3.86e-30	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
SARC	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-14.57	1.29e-34	4.07e-30	-0.86	-0.69	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
SARC	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	14.54	1.59e-34	5e-30	0.92	0.69	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
SARC	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	14.53	1.68e-34	5.25e-30	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	14.53	1.74e-34	5.44e-30	0.89	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	14.53	1.8e-34	5.61e-30	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	14.48	2.57e-34	7.93e-30	0.92	0.69	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
SARC	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	14.47	2.67e-34	8.16e-30	0.8	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	14.47	2.67e-34	8.16e-30	0.8	0.69	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	14.47	2.67e-34	8.16e-30	0.8	0.69	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
SARC	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	14.47	2.67e-34	8.16e-30	0.8	0.69	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	14.47	2.67e-34	8.16e-30	0.8	0.69	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	14.47	2.67e-34	8.16e-30	0.8	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	14.47	2.84e-34	8.64e-30	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	14.47	2.84e-34	8.64e-30	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	14.47	2.84e-34	8.64e-30	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	14.47	2.84e-34	8.64e-30	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-14.46	2.91e-34	8.83e-30	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	14.46	2.98e-34	9.03e-30	0.89	0.69	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
SARC	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-14.45	3.14e-34	9.53e-30	-0.7	-0.69	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
SARC	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-14.45	3.21e-34	9.73e-30	-0.79	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	14.45	3.26e-34	9.87e-30	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-14.45	3.28e-34	9.9e-30	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-14.44	3.45e-34	1.04e-29	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
SARC	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	14.44	3.5e-34	1.05e-29	0.78	0.69	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
SARC	cis	rs7847628	0.587	rs3793638	ENSG00000226752.6	PSMD5-AS1	-14.42	4.06e-34	1.22e-29	-0.85	-0.69	Birth weight;	chr9:120820419	chr9:120824828~120854385:+
SARC	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-14.42	4.06e-34	1.22e-29	-0.92	-0.69	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
SARC	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-14.41	4.49e-34	1.34e-29	-0.87	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
SARC	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	14.41	4.5e-34	1.34e-29	0.81	0.69	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	14.39	4.91e-34	1.46e-29	0.89	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-14.39	4.94e-34	1.47e-29	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-14.39	4.99e-34	1.48e-29	-0.84	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	14.39	5.03e-34	1.49e-29	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	14.39	5.03e-34	1.49e-29	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	14.39	5.03e-34	1.49e-29	0.88	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-14.38	5.68e-34	1.67e-29	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	14.36	6.19e-34	1.82e-29	0.86	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-14.35	6.75e-34	1.98e-29	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-14.33	7.74e-34	2.26e-29	-0.89	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-14.33	7.74e-34	2.26e-29	-0.89	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-14.33	7.74e-34	2.26e-29	-0.89	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-14.33	7.74e-34	2.26e-29	-0.89	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	14.33	7.75e-34	2.26e-29	0.69	0.68	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	14.32	8.64e-34	2.5e-29	0.7	0.68	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	14.32	8.64e-34	2.5e-29	0.69	0.68	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
SARC	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	14.29	1.1e-33	3.16e-29	0.79	0.68	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	14.28	1.18e-33	3.38e-29	0.78	0.68	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	14.27	1.24e-33	3.56e-29	0.8	0.68	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	14.26	1.36e-33	3.87e-29	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	14.26	1.36e-33	3.87e-29	0.87	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
SARC	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-14.25	1.47e-33	4.14e-29	-0.9	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
SARC	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-14.25	1.47e-33	4.14e-29	-0.9	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
SARC	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-14.25	1.47e-33	4.14e-29	-0.9	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
SARC	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-14.25	1.47e-33	4.14e-29	-0.9	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
SARC	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-14.25	1.47e-33	4.14e-29	-0.9	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
SARC	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-14.25	1.47e-33	4.14e-29	-0.9	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
SARC	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-14.25	1.47e-33	4.14e-29	-0.9	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
SARC	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	14.25	1.53e-33	4.32e-29	0.8	0.68	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
SARC	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	14.24	1.6e-33	4.51e-29	0.77	0.68	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-14.22	1.85e-33	5.14e-29	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-14.22	1.85e-33	5.14e-29	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-14.22	1.85e-33	5.14e-29	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-14.22	1.85e-33	5.14e-29	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-14.22	1.85e-33	5.15e-29	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-14.22	1.88e-33	5.2e-29	-0.87	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	14.21	2.03e-33	5.63e-29	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	14.2	2.13e-33	5.88e-29	0.88	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
SARC	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	14.2	2.16e-33	5.98e-29	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	14.2	2.2e-33	6.09e-29	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-14.19	2.37e-33	6.51e-29	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-14.19	2.37e-33	6.51e-29	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-14.19	2.37e-33	6.51e-29	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
SARC	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-14.19	2.44e-33	6.69e-29	-0.9	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
SARC	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-14.19	2.44e-33	6.69e-29	-0.9	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
SARC	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	14.18	2.58e-33	7.02e-29	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	14.18	2.58e-33	7.02e-29	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	14.18	2.58e-33	7.02e-29	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	14.18	2.58e-33	7.02e-29	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	14.18	2.58e-33	7.02e-29	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	14.18	2.58e-33	7.02e-29	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	14.18	2.58e-33	7.02e-29	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	14.18	2.58e-33	7.02e-29	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
SARC	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	14.17	2.7e-33	7.32e-29	0.78	0.68	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-14.15	3.25e-33	8.73e-29	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-14.15	3.25e-33	8.73e-29	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-14.15	3.25e-33	8.73e-29	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	14.13	3.64e-33	9.73e-29	0.88	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	14.12	3.91e-33	1.04e-28	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-14.12	3.92e-33	1.04e-28	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-14.12	3.92e-33	1.04e-28	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-14.12	3.92e-33	1.04e-28	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-14.1	4.62e-33	1.22e-28	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-14.1	4.62e-33	1.22e-28	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	14.1	4.65e-33	1.23e-28	0.85	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	14.09	4.94e-33	1.3e-28	0.87	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
SARC	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-14.09	5.08e-33	1.34e-28	-0.78	-0.68	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	14.06	6.12e-33	1.6e-28	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	14.06	6.12e-33	1.6e-28	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	14.05	6.94e-33	1.8e-28	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	14.05	6.94e-33	1.8e-28	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	14.05	6.94e-33	1.8e-28	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	14.05	7.03e-33	1.83e-28	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
SARC	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-14.04	7.5e-33	1.94e-28	-0.81	-0.68	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-14.04	7.5e-33	1.94e-28	-0.81	-0.68	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-14.04	7.5e-33	1.94e-28	-0.81	-0.68	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
SARC	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	14.04	7.53e-33	1.94e-28	0.75	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
SARC	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-14.03	8.16e-33	2.1e-28	-0.86	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	14.02	8.81e-33	2.26e-28	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	14.02	8.81e-33	2.26e-28	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
SARC	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	14.01	9.46e-33	2.43e-28	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
SARC	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-14	9.85e-33	2.52e-28	-0.8	-0.68	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	14	1e-32	2.56e-28	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	14	1.01e-32	2.57e-28	0.85	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
SARC	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	13.98	1.14e-32	2.9e-28	0.81	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
SARC	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	13.98	1.15e-32	2.93e-28	0.8	0.68	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	13.97	1.24e-32	3.15e-28	0.89	0.68	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
SARC	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	13.97	1.3e-32	3.3e-28	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	13.97	1.3e-32	3.3e-28	0.86	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	13.95	1.44e-32	3.66e-28	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	13.95	1.52e-32	3.85e-28	0.86	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-13.94	1.53e-32	3.86e-28	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
SARC	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	13.94	1.53e-32	3.86e-28	0.79	0.67	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	13.94	1.53e-32	3.86e-28	0.79	0.67	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
SARC	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-13.94	1.58e-32	3.99e-28	-0.81	-0.67	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-13.94	1.58e-32	3.99e-28	-0.81	-0.67	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
SARC	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	13.94	1.64e-32	4.12e-28	0.8	0.67	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
SARC	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-13.93	1.68e-32	4.22e-28	-0.9	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
SARC	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-13.92	1.82e-32	4.55e-28	-0.86	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-13.92	1.82e-32	4.55e-28	-0.86	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-13.92	1.82e-32	4.55e-28	-0.86	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
SARC	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	13.92	1.83e-32	4.58e-28	0.82	0.67	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
SARC	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-13.92	1.87e-32	4.65e-28	-0.84	-0.67	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
SARC	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-13.9	2.08e-32	5.18e-28	-0.86	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	13.9	2.08e-32	5.18e-28	0.86	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
SARC	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	13.89	2.36e-32	5.82e-28	0.79	0.67	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
SARC	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	13.89	2.42e-32	5.96e-28	0.68	0.67	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-13.88	2.47e-32	6.07e-28	-0.87	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-13.86	2.85e-32	6.96e-28	-0.86	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-13.86	2.87e-32	7e-28	-0.83	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	13.86	2.92e-32	7.11e-28	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	13.85	3.13e-32	7.61e-28	0.76	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
SARC	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	13.85	3.15e-32	7.65e-28	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	13.85	3.18e-32	7.71e-28	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
SARC	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	13.84	3.3e-32	8.01e-28	0.79	0.67	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-13.84	3.33e-32	8.05e-28	-0.86	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-13.84	3.33e-32	8.05e-28	-0.86	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-13.84	3.33e-32	8.05e-28	-0.86	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
SARC	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-13.84	3.53e-32	8.51e-28	-0.78	-0.67	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	13.84	3.53e-32	8.51e-28	0.78	0.67	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-13.83	3.63e-32	8.75e-28	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	13.82	3.85e-32	9.28e-28	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
SARC	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	13.82	3.89e-32	9.33e-28	0.79	0.67	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	13.82	3.89e-32	9.33e-28	0.79	0.67	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	13.82	3.89e-32	9.33e-28	0.79	0.67	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	13.82	3.89e-32	9.33e-28	0.79	0.67	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	13.82	3.9e-32	9.33e-28	0.89	0.67	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
SARC	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	13.82	3.93e-32	9.4e-28	0.79	0.67	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	13.82	3.93e-32	9.4e-28	0.79	0.67	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	13.81	4.15e-32	9.9e-28	0.79	0.67	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	13.79	5.08e-32	1.21e-27	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	13.78	5.48e-32	1.3e-27	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	13.76	6.3e-32	1.48e-27	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	13.76	6.3e-32	1.48e-27	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	13.76	6.3e-32	1.48e-27	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-13.76	6.3e-32	1.48e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-13.76	6.3e-32	1.48e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-13.76	6.3e-32	1.48e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-13.76	6.3e-32	1.48e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-13.76	6.3e-32	1.48e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-13.75	6.63e-32	1.55e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-13.75	6.63e-32	1.55e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-13.75	6.63e-32	1.55e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-13.75	6.63e-32	1.55e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
SARC	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	13.75	6.66e-32	1.55e-27	0.76	0.67	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
SARC	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-13.72	8.31e-32	1.92e-27	-0.89	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
SARC	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-13.72	8.48e-32	1.96e-27	-0.81	-0.67	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
SARC	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	13.71	9.35e-32	2.15e-27	0.74	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
SARC	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	13.71	9.43e-32	2.17e-27	0.86	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
SARC	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	13.69	1.11e-31	2.53e-27	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
SARC	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	13.68	1.11e-31	2.53e-27	0.8	0.67	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	13.68	1.13e-31	2.57e-27	0.87	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
SARC	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-13.68	1.19e-31	2.71e-27	-0.81	-0.67	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
SARC	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	13.67	1.25e-31	2.83e-27	0.77	0.67	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-13.67	1.28e-31	2.91e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-13.67	1.28e-31	2.91e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-13.67	1.28e-31	2.91e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
SARC	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-13.66	1.3e-31	2.94e-27	-0.82	-0.67	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
SARC	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	13.66	1.32e-31	2.99e-27	0.88	0.67	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
SARC	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	13.65	1.45e-31	3.27e-27	0.84	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	13.65	1.45e-31	3.27e-27	0.84	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	13.64	1.52e-31	3.4e-27	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	13.64	1.58e-31	3.54e-27	0.88	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	13.63	1.64e-31	3.65e-27	0.74	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
SARC	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-13.63	1.65e-31	3.69e-27	-0.85	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
SARC	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-13.62	1.81e-31	4.02e-27	-0.8	-0.67	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-13.62	1.81e-31	4.02e-27	-0.8	-0.67	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
SARC	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	13.62	1.87e-31	4.14e-27	0.82	0.67	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	13.62	1.89e-31	4.17e-27	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
SARC	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-13.59	2.27e-31	5e-27	-0.81	-0.66	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	13.59	2.29e-31	5.04e-27	0.84	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
SARC	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	13.59	2.37e-31	5.21e-27	0.79	0.66	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
SARC	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-13.58	2.49e-31	5.46e-27	-0.81	-0.66	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
SARC	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	13.58	2.49e-31	5.46e-27	0.81	0.66	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
SARC	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-13.56	2.9e-31	6.28e-27	-0.8	-0.66	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-13.56	2.9e-31	6.28e-27	-0.8	-0.66	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-13.56	2.9e-31	6.28e-27	-0.8	-0.66	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-13.56	2.9e-31	6.28e-27	-0.8	-0.66	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-13.56	2.9e-31	6.28e-27	-0.8	-0.66	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-13.56	2.9e-31	6.28e-27	-0.8	-0.66	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-13.56	2.9e-31	6.28e-27	-0.8	-0.66	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-13.56	2.9e-31	6.28e-27	-0.8	-0.66	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
SARC	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	13.56	2.92e-31	6.31e-27	0.74	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
SARC	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	13.56	2.92e-31	6.31e-27	0.74	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
SARC	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	13.55	3.08e-31	6.63e-27	0.77	0.66	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
SARC	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	13.55	3.14e-31	6.75e-27	0.79	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
SARC	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-13.54	3.34e-31	7.12e-27	-0.81	-0.66	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-13.54	3.34e-31	7.12e-27	-0.81	-0.66	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
SARC	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-13.49	4.89e-31	1.02e-26	-0.82	-0.66	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-13.49	4.97e-31	1.03e-26	-0.84	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-13.48	5.27e-31	1.09e-26	-0.84	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	13.48	5.44e-31	1.13e-26	0.86	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
SARC	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-13.48	5.46e-31	1.13e-26	-0.85	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
SARC	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-13.47	5.58e-31	1.14e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-13.47	5.58e-31	1.14e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-13.47	5.58e-31	1.14e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-13.47	5.58e-31	1.14e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-13.47	5.58e-31	1.14e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-13.47	5.58e-31	1.14e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-13.47	5.58e-31	1.14e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-13.47	5.58e-31	1.14e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-13.47	5.58e-31	1.14e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
SARC	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-13.47	5.68e-31	1.16e-26	-0.81	-0.66	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
SARC	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-13.45	6.87e-31	1.4e-26	-0.8	-0.66	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-13.45	6.87e-31	1.4e-26	-0.8	-0.66	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-13.45	6.87e-31	1.4e-26	-0.8	-0.66	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	13.44	7.22e-31	1.46e-26	0.84	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
SARC	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-13.43	7.61e-31	1.51e-26	-0.8	-0.66	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
SARC	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	13.43	7.73e-31	1.53e-26	0.86	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
SARC	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	13.43	7.73e-31	1.53e-26	0.86	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
SARC	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	13.43	7.78e-31	1.54e-26	0.75	0.66	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	13.43	7.78e-31	1.54e-26	0.75	0.66	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	13.43	7.78e-31	1.54e-26	0.75	0.66	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
SARC	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-13.41	8.92e-31	1.76e-26	-0.81	-0.66	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-13.41	9.14e-31	1.8e-26	-0.84	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	13.4	9.4e-31	1.84e-26	0.86	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
SARC	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-13.4	1e-30	1.96e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-13.39	1.04e-30	2.03e-26	-0.81	-0.66	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-13.39	1.04e-30	2.03e-26	-0.81	-0.66	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
SARC	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	13.39	1.04e-30	2.03e-26	0.77	0.66	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
SARC	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	13.39	1.05e-30	2.05e-26	0.74	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
SARC	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	13.39	1.05e-30	2.05e-26	0.74	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
SARC	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-13.39	1.09e-30	2.11e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-13.39	1.09e-30	2.11e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
SARC	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	13.38	1.15e-30	2.24e-26	0.76	0.66	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-13.37	1.21e-30	2.35e-26	-0.84	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
SARC	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	13.36	1.27e-30	2.47e-26	0.82	0.66	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
SARC	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-13.36	1.28e-30	2.47e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-13.36	1.28e-30	2.47e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-13.36	1.28e-30	2.47e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-13.36	1.33e-30	2.55e-26	-0.84	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-13.36	1.33e-30	2.55e-26	-0.84	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
SARC	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	13.35	1.43e-30	2.74e-26	0.78	0.66	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	13.35	1.43e-30	2.74e-26	0.78	0.66	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	13.35	1.45e-30	2.77e-26	0.78	0.66	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	13.35	1.45e-30	2.77e-26	0.78	0.66	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
SARC	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	13.35	1.47e-30	2.82e-26	0.85	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
SARC	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-13.34	1.49e-30	2.85e-26	-0.77	-0.66	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
SARC	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-13.34	1.52e-30	2.91e-26	-0.84	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
SARC	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	13.34	1.55e-30	2.97e-26	0.73	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
SARC	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	13.33	1.72e-30	3.28e-26	0.76	0.66	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
SARC	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-13.32	1.76e-30	3.36e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-13.32	1.81e-30	3.44e-26	-0.8	-0.66	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-13.32	1.81e-30	3.44e-26	-0.8	-0.66	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-13.31	1.93e-30	3.66e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-13.31	1.93e-30	3.66e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-13.31	1.93e-30	3.66e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-13.31	1.99e-30	3.76e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-13.31	2.01e-30	3.77e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-13.31	2.01e-30	3.77e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-13.31	2.01e-30	3.77e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-13.31	2.01e-30	3.77e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
SARC	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-13.3	2.02e-30	3.79e-26	-0.75	-0.66	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
SARC	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-13.3	2.03e-30	3.8e-26	-0.8	-0.66	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
SARC	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	13.3	2.09e-30	3.91e-26	0.75	0.66	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
SARC	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	13.3	2.16e-30	4.04e-26	0.74	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
SARC	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-13.29	2.17e-30	4.06e-26	-0.8	-0.66	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
SARC	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	13.29	2.21e-30	4.11e-26	0.79	0.66	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
SARC	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	13.28	2.38e-30	4.4e-26	0.86	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
SARC	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-13.27	2.53e-30	4.67e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
SARC	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	13.25	3.09e-30	5.65e-26	0.78	0.66	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
SARC	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	13.24	3.18e-30	5.82e-26	0.78	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
SARC	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	13.24	3.18e-30	5.82e-26	0.78	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
SARC	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-13.24	3.24e-30	5.91e-26	-0.78	-0.66	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-13.24	3.24e-30	5.91e-26	-0.78	-0.66	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-13.23	3.43e-30	6.21e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-13.23	3.43e-30	6.21e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-13.23	3.43e-30	6.21e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-13.23	3.43e-30	6.21e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-13.23	3.43e-30	6.21e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-13.23	3.43e-30	6.21e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-13.23	3.43e-30	6.21e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-13.23	3.43e-30	6.21e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-13.23	3.43e-30	6.21e-26	-0.79	-0.66	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
SARC	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	13.23	3.48e-30	6.28e-26	0.85	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
SARC	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	13.23	3.48e-30	6.28e-26	0.85	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
SARC	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-13.23	3.56e-30	6.41e-26	-0.78	-0.65	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-13.23	3.56e-30	6.41e-26	-0.78	-0.65	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-13.22	3.87e-30	6.95e-26	-0.8	-0.65	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-13.22	3.87e-30	6.95e-26	-0.8	-0.65	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-13.22	3.87e-30	6.95e-26	-0.8	-0.65	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-13.2	4.5e-30	8.04e-26	-0.79	-0.65	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-13.2	4.5e-30	8.04e-26	-0.79	-0.65	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
SARC	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	13.19	4.72e-30	8.43e-26	0.73	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
SARC	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	13.19	4.85e-30	8.65e-26	0.77	0.65	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
SARC	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-13.19	4.93e-30	8.76e-26	-0.79	-0.65	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-13.19	4.93e-30	8.76e-26	-0.79	-0.65	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-13.19	4.93e-30	8.76e-26	-0.79	-0.65	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-13.19	4.93e-30	8.76e-26	-0.79	-0.65	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
SARC	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-13.18	5.19e-30	9.17e-26	-0.73	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
SARC	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-13.18	5.2e-30	9.17e-26	-0.8	-0.65	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-13.18	5.2e-30	9.17e-26	-0.8	-0.65	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-13.18	5.2e-30	9.17e-26	-0.8	-0.65	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-13.18	5.2e-30	9.17e-26	-0.8	-0.65	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
SARC	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	13.17	5.49e-30	9.68e-26	0.84	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
SARC	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	13.17	5.53e-30	9.75e-26	0.78	0.65	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
SARC	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	13.17	5.64e-30	9.92e-26	0.77	0.65	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
SARC	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-13.16	6.23e-30	1.09e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-13.14	7.08e-30	1.24e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-13.13	7.38e-30	1.29e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-13.12	8.08e-30	1.41e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
SARC	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-13.11	9e-30	1.57e-25	-0.66	-0.65	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-13.1	9.38e-30	1.63e-25	-0.84	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
SARC	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-13.1	9.5e-30	1.63e-25	-0.8	-0.65	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
SARC	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-13.1	9.72e-30	1.66e-25	-0.77	-0.65	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-13.1	9.72e-30	1.66e-25	-0.77	-0.65	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	13.05	1.44e-29	2.44e-25	0.83	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
SARC	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-13.04	1.47e-29	2.49e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
SARC	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-13.04	1.54e-29	2.6e-25	-0.77	-0.65	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	13.03	1.6e-29	2.69e-25	0.76	0.65	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
SARC	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-13.03	1.64e-29	2.76e-25	-0.85	-0.65	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
SARC	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	13	2.02e-29	3.32e-25	0.74	0.65	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
SARC	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	13	2.07e-29	3.41e-25	0.65	0.65	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
SARC	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	12.99	2.15e-29	3.54e-25	0.95	0.65	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
SARC	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-12.99	2.21e-29	3.63e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
SARC	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	12.99	2.27e-29	3.73e-25	0.76	0.65	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	12.97	2.48e-29	4.07e-25	0.74	0.65	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
SARC	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	12.97	2.57e-29	4.21e-25	0.85	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
SARC	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-12.96	2.75e-29	4.49e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-12.95	3.08e-29	5.01e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-12.95	3.08e-29	5.01e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-12.95	3.08e-29	5.01e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-12.95	3.08e-29	5.01e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
SARC	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	12.94	3.11e-29	5.05e-25	0.84	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
SARC	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	12.93	3.37e-29	5.43e-25	0.74	0.65	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
SARC	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	12.93	3.41e-29	5.49e-25	0.65	0.65	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
SARC	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-12.93	3.41e-29	5.49e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
SARC	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-12.93	3.56e-29	5.72e-25	-0.65	-0.65	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	12.92	3.6e-29	5.77e-25	0.84	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-12.92	3.78e-29	6.06e-25	-0.74	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
SARC	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-12.91	4.12e-29	6.58e-25	-0.78	-0.65	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
SARC	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-12.91	4.13e-29	6.59e-25	-0.84	-0.65	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-12.91	4.13e-29	6.59e-25	-0.84	-0.65	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
SARC	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-12.91	4.13e-29	6.59e-25	-0.76	-0.65	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
SARC	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	12.9	4.18e-29	6.67e-25	0.93	0.65	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
SARC	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-12.9	4.22e-29	6.73e-25	-0.76	-0.65	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
SARC	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	12.9	4.47e-29	7.12e-25	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
SARC	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-12.89	4.68e-29	7.44e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-12.89	4.68e-29	7.44e-25	-0.79	-0.65	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
SARC	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	12.89	4.76e-29	7.57e-25	0.74	0.65	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
SARC	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	12.88	5.2e-29	8.23e-25	0.76	0.64	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-12.87	5.3e-29	8.39e-25	-0.82	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	12.87	5.62e-29	8.85e-25	0.83	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
SARC	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	12.86	5.67e-29	8.94e-25	0.93	0.64	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
SARC	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-12.86	5.87e-29	9.25e-25	-0.77	-0.64	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
SARC	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-12.85	6.21e-29	9.76e-25	-0.73	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
SARC	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-12.83	7.35e-29	1.14e-24	-0.81	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
SARC	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	12.82	7.66e-29	1.18e-24	0.92	0.64	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
SARC	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-12.82	7.87e-29	1.22e-24	-0.74	-0.64	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-12.81	8.29e-29	1.28e-24	-0.82	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
SARC	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	12.81	8.34e-29	1.29e-24	0.93	0.64	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
SARC	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	12.81	8.34e-29	1.29e-24	0.93	0.64	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
SARC	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-12.81	8.42e-29	1.3e-24	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
SARC	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	12.81	8.57e-29	1.31e-24	0.74	0.64	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	12.81	8.57e-29	1.31e-24	0.74	0.64	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	12.81	8.57e-29	1.31e-24	0.74	0.64	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	12.81	8.57e-29	1.31e-24	0.74	0.64	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	12.81	8.57e-29	1.31e-24	0.74	0.64	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	12.81	8.57e-29	1.31e-24	0.74	0.64	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
SARC	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	12.8	9.24e-29	1.41e-24	0.65	0.64	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
SARC	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-12.79	1e-28	1.52e-24	-0.74	-0.64	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
SARC	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	12.78	1.07e-28	1.63e-24	0.65	0.64	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	12.78	1.07e-28	1.63e-24	0.65	0.64	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	12.78	1.07e-28	1.63e-24	0.65	0.64	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
SARC	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	12.78	1.11e-28	1.69e-24	0.72	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
SARC	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	12.77	1.14e-28	1.72e-24	0.73	0.64	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
SARC	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	12.76	1.25e-28	1.88e-24	0.93	0.64	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
SARC	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	12.76	1.25e-28	1.88e-24	0.93	0.64	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
SARC	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-12.76	1.25e-28	1.88e-24	-0.78	-0.64	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
SARC	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	12.75	1.32e-28	1.98e-24	0.74	0.64	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
SARC	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-12.75	1.34e-28	2e-24	-0.78	-0.64	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
SARC	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	12.74	1.42e-28	2.12e-24	0.9	0.64	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
SARC	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	12.74	1.44e-28	2.15e-24	0.65	0.64	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-12.73	1.54e-28	2.29e-24	-0.65	-0.64	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
SARC	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-12.72	1.65e-28	2.45e-24	-0.79	-0.64	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-12.72	1.65e-28	2.45e-24	-0.79	-0.64	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-12.72	1.69e-28	2.51e-24	-0.78	-0.64	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-12.72	1.7e-28	2.51e-24	-0.78	-0.64	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-12.72	1.7e-28	2.51e-24	-0.78	-0.64	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-12.72	1.7e-28	2.51e-24	-0.78	-0.64	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-12.72	1.7e-28	2.51e-24	-0.78	-0.64	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-12.72	1.7e-28	2.51e-24	-0.78	-0.64	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-12.72	1.7e-28	2.51e-24	-0.78	-0.64	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
SARC	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-12.71	1.76e-28	2.61e-24	-0.83	-0.64	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
SARC	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-12.71	1.76e-28	2.61e-24	-0.83	-0.64	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-12.71	1.76e-28	2.61e-24	-0.83	-0.64	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
SARC	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
SARC	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
SARC	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-12.71	1.83e-28	2.69e-24	-0.73	-0.64	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	12.71	1.87e-28	2.74e-24	0.84	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
SARC	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	12.7	1.95e-28	2.85e-24	0.83	0.64	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	12.7	1.95e-28	2.85e-24	0.83	0.64	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	12.7	1.95e-28	2.85e-24	0.83	0.64	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
SARC	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-12.7	1.95e-28	2.85e-24	-0.83	-0.64	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-12.7	1.95e-28	2.85e-24	-0.83	-0.64	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
SARC	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	12.7	2.02e-28	2.94e-24	0.94	0.64	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
SARC	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-12.69	2.14e-28	3.11e-24	-0.83	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
SARC	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-12.68	2.21e-28	3.2e-24	-0.74	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	12.68	2.31e-28	3.35e-24	0.85	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
SARC	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-12.68	2.33e-28	3.37e-24	-0.73	-0.64	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
SARC	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	12.68	2.37e-28	3.42e-24	0.74	0.64	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
SARC	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	12.67	2.4e-28	3.46e-24	0.91	0.64	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
SARC	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-12.67	2.41e-28	3.46e-24	-0.77	-0.64	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-12.67	2.41e-28	3.46e-24	-0.77	-0.64	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-12.67	2.41e-28	3.46e-24	-0.77	-0.64	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-12.67	2.41e-28	3.46e-24	-0.77	-0.64	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-12.67	2.41e-28	3.46e-24	-0.77	-0.64	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-12.67	2.41e-28	3.46e-24	-0.77	-0.64	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-12.67	2.41e-28	3.46e-24	-0.77	-0.64	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-12.67	2.41e-28	3.46e-24	-0.77	-0.64	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-12.67	2.41e-28	3.46e-24	-0.77	-0.64	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	12.67	2.41e-28	3.46e-24	0.81	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
SARC	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-12.65	2.9e-28	4.15e-24	-0.77	-0.64	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	12.65	2.91e-28	4.15e-24	0.85	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	12.65	2.91e-28	4.15e-24	0.85	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	12.64	2.98e-28	4.24e-24	0.65	0.64	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	12.64	2.98e-28	4.24e-24	0.65	0.64	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	12.64	2.98e-28	4.24e-24	0.65	0.64	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-12.64	3.17e-28	4.49e-24	-0.65	-0.64	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	12.64	3.18e-28	4.5e-24	0.8	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
SARC	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	12.64	3.18e-28	4.5e-24	0.82	0.64	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
SARC	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-12.63	3.26e-28	4.6e-24	-0.78	-0.64	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-12.63	3.26e-28	4.6e-24	-0.78	-0.64	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
SARC	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	12.63	3.38e-28	4.76e-24	0.91	0.64	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
SARC	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	12.63	3.38e-28	4.76e-24	0.91	0.64	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
SARC	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	12.63	3.44e-28	4.84e-24	0.81	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	12.63	3.44e-28	4.84e-24	0.81	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
SARC	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	12.62	3.5e-28	4.93e-24	0.73	0.64	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
SARC	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-12.62	3.52e-28	4.95e-24	-0.84	-0.64	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-12.62	3.52e-28	4.95e-24	-0.84	-0.64	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
SARC	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-12.62	3.56e-28	4.98e-24	-0.77	-0.64	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-12.62	3.56e-28	4.98e-24	-0.77	-0.64	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-12.62	3.56e-28	4.98e-24	-0.77	-0.64	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
SARC	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-12.62	3.57e-28	5e-24	-0.74	-0.64	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
SARC	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-12.61	3.75e-28	5.23e-24	-0.73	-0.64	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-12.61	3.8e-28	5.3e-24	-0.73	-0.64	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
SARC	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	12.61	3.95e-28	5.5e-24	0.83	0.64	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	12.6	4.19e-28	5.83e-24	0.82	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-12.6	4.29e-28	5.96e-24	-0.64	-0.64	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
SARC	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-12.6	4.33e-28	5.98e-24	-0.72	-0.64	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-12.6	4.33e-28	5.98e-24	-0.72	-0.64	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-12.6	4.33e-28	5.98e-24	-0.72	-0.64	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-12.6	4.33e-28	5.98e-24	-0.72	-0.64	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-12.6	4.33e-28	5.98e-24	-0.72	-0.64	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-12.6	4.33e-28	5.98e-24	-0.72	-0.64	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-12.6	4.33e-28	5.98e-24	-0.72	-0.64	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
SARC	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	12.57	5.13e-28	7.07e-24	0.72	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
SARC	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	12.57	5.21e-28	7.18e-24	0.73	0.64	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	12.57	5.29e-28	7.28e-24	0.84	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
SARC	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-12.57	5.33e-28	7.33e-24	-0.82	-0.64	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
SARC	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-12.57	5.44e-28	7.48e-24	-0.72	-0.64	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
SARC	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	12.56	5.51e-28	7.58e-24	0.72	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
SARC	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-12.56	5.61e-28	7.66e-24	-0.83	-0.64	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
SARC	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-12.56	5.61e-28	7.66e-24	-0.83	-0.64	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-12.56	5.61e-28	7.66e-24	-0.83	-0.64	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-12.56	5.61e-28	7.66e-24	-0.83	-0.64	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-12.56	5.61e-28	7.66e-24	-0.83	-0.64	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-12.56	5.61e-28	7.66e-24	-0.83	-0.64	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-12.56	5.83e-28	7.93e-24	-0.84	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
SARC	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-12.55	6.02e-28	8.15e-24	-0.83	-0.64	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-12.55	6.02e-28	8.15e-24	-0.83	-0.64	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
SARC	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-12.55	6.02e-28	8.15e-24	-0.83	-0.64	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-12.55	6.02e-28	8.15e-24	-0.83	-0.64	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-12.55	6.02e-28	8.15e-24	-0.83	-0.64	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-12.55	6.02e-28	8.15e-24	-0.83	-0.64	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
SARC	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	12.54	6.63e-28	8.97e-24	0.74	0.63	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
SARC	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-12.53	7.23e-28	9.78e-24	-0.76	-0.63	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
SARC	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	12.52	7.76e-28	1.04e-23	0.76	0.63	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
SARC	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-12.51	8.24e-28	1.1e-23	-0.73	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	12.51	8.55e-28	1.14e-23	0.84	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
SARC	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	12.49	9.3e-28	1.24e-23	0.89	0.63	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
SARC	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-12.49	9.84e-28	1.31e-23	-0.85	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
SARC	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-12.45	1.26e-27	1.68e-23	-0.77	-0.63	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
SARC	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-12.43	1.54e-27	2.03e-23	-0.64	-0.63	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
SARC	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-12.42	1.57e-27	2.06e-23	-0.76	-0.63	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
SARC	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-12.42	1.57e-27	2.07e-23	-0.81	-0.63	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-12.42	1.65e-27	2.17e-23	-0.86	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
SARC	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	12.42	1.67e-27	2.19e-23	0.73	0.63	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
SARC	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-12.41	1.81e-27	2.37e-23	-0.77	-0.63	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-12.41	1.81e-27	2.37e-23	-0.77	-0.63	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-12.41	1.81e-27	2.37e-23	-0.77	-0.63	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-12.41	1.81e-27	2.37e-23	-0.77	-0.63	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-12.41	1.81e-27	2.37e-23	-0.77	-0.63	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-12.4	1.87e-27	2.44e-23	-0.85	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-12.4	1.87e-27	2.44e-23	-0.85	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-12.4	1.87e-27	2.44e-23	-0.85	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-12.4	1.87e-27	2.44e-23	-0.85	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-12.4	1.87e-27	2.44e-23	-0.85	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	12.4	1.89e-27	2.46e-23	0.63	0.63	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
SARC	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-12.39	1.96e-27	2.54e-23	-0.77	-0.63	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
SARC	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-12.39	1.96e-27	2.54e-23	-0.77	-0.63	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
SARC	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	12.38	2.13e-27	2.76e-23	0.79	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
SARC	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	12.38	2.21e-27	2.86e-23	0.73	0.63	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
SARC	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	12.38	2.23e-27	2.88e-23	0.77	0.63	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
SARC	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	12.38	2.25e-27	2.91e-23	0.79	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
SARC	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	12.38	2.25e-27	2.91e-23	0.88	0.63	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
SARC	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-12.37	2.36e-27	3.04e-23	-0.63	-0.63	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
SARC	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-12.36	2.49e-27	3.2e-23	-0.71	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
SARC	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	12.36	2.52e-27	3.24e-23	0.74	0.63	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
SARC	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	12.35	2.65e-27	3.4e-23	0.93	0.63	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
SARC	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.67e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
SARC	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
SARC	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
SARC	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-12.35	2.69e-27	3.42e-23	-0.72	-0.63	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
SARC	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-12.34	2.92e-27	3.69e-23	-0.71	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
SARC	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-12.34	2.92e-27	3.69e-23	-0.71	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
SARC	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-12.34	2.92e-27	3.69e-23	-0.71	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
SARC	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	12.34	2.92e-27	3.69e-23	0.64	0.63	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
SARC	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	12.33	3.11e-27	3.93e-23	0.72	0.63	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	12.33	3.11e-27	3.93e-23	0.72	0.63	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
SARC	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	12.33	3.27e-27	4.13e-23	0.63	0.63	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
SARC	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-12.32	3.32e-27	4.18e-23	-0.74	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
SARC	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-12.32	3.36e-27	4.23e-23	-0.78	-0.63	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
SARC	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-12.32	3.48e-27	4.37e-23	-0.83	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
SARC	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-12.32	3.48e-27	4.37e-23	-0.83	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
SARC	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	12.32	3.48e-27	4.37e-23	0.82	0.63	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-12.32	3.56e-27	4.47e-23	-0.83	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
SARC	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	12.31	3.63e-27	4.55e-23	0.71	0.63	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	12.31	3.8e-27	4.77e-23	0.83	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	12.31	3.8e-27	4.77e-23	0.83	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
SARC	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-12.3	3.9e-27	4.87e-23	-0.72	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
SARC	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-12.3	3.9e-27	4.87e-23	-0.72	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
SARC	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-12.3	4.04e-27	5.04e-23	-0.83	-0.63	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
SARC	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	12.29	4.26e-27	5.31e-23	0.73	0.63	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
SARC	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	12.28	4.51e-27	5.59e-23	0.75	0.63	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
SARC	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-12.28	4.53e-27	5.62e-23	-0.75	-0.63	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
SARC	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	12.28	4.63e-27	5.74e-23	0.82	0.63	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
SARC	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-12.28	4.8e-27	5.95e-23	-0.72	-0.63	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
SARC	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-12.27	4.89e-27	6.05e-23	-0.79	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
SARC	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-12.27	4.89e-27	6.05e-23	-0.79	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
SARC	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-12.27	5.03e-27	6.2e-23	-0.73	-0.63	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-12.27	5.17e-27	6.36e-23	-0.72	-0.63	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	12.26	5.22e-27	6.42e-23	0.73	0.63	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-12.26	5.24e-27	6.44e-23	-0.73	-0.63	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-12.26	5.6e-27	6.87e-23	-0.81	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	12.25	5.71e-27	7e-23	0.83	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
SARC	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	12.24	6.04e-27	7.37e-23	0.82	0.63	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	12.24	6.04e-27	7.37e-23	0.82	0.63	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	12.24	6.04e-27	7.37e-23	0.82	0.63	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
SARC	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	12.24	6.04e-27	7.37e-23	0.82	0.63	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	12.24	6.04e-27	7.37e-23	0.82	0.63	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
SARC	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	12.24	6.29e-27	7.67e-23	0.76	0.63	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
SARC	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-12.24	6.49e-27	7.88e-23	-0.72	-0.63	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
SARC	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-12.24	6.49e-27	7.88e-23	-0.72	-0.63	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-12.24	6.49e-27	7.88e-23	-0.72	-0.63	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-12.24	6.49e-27	7.88e-23	-0.72	-0.63	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-12.23	6.9e-27	8.37e-23	-0.72	-0.63	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-12.23	6.9e-27	8.37e-23	-0.72	-0.63	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
SARC	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-12.22	7.26e-27	8.78e-23	-0.7	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
SARC	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-12.22	7.35e-27	8.87e-23	-0.77	-0.62	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
SARC	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-12.22	7.45e-27	8.99e-23	-0.63	-0.62	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
SARC	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-12.21	7.95e-27	9.57e-23	-0.72	-0.62	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
SARC	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-12.21	7.97e-27	9.6e-23	-0.74	-0.62	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
SARC	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-12.19	9.34e-27	1.1e-22	-0.9	-0.62	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
SARC	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	12.18	1e-26	1.18e-22	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
SARC	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	12.18	1e-26	1.18e-22	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
SARC	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	12.18	1.02e-26	1.2e-22	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	12.17	1.03e-26	1.21e-22	0.95	0.62	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
SARC	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-12.17	1.04e-26	1.22e-22	-0.82	-0.62	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-12.17	1.04e-26	1.22e-22	-0.82	-0.62	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
SARC	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-12.16	1.15e-26	1.35e-22	-0.71	-0.62	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
SARC	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	12.16	1.17e-26	1.37e-22	0.82	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
SARC	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-12.15	1.24e-26	1.46e-22	-0.72	-0.62	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
SARC	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-12.15	1.26e-26	1.47e-22	-0.81	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
SARC	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-12.15	1.26e-26	1.48e-22	-0.64	-0.62	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-12.15	1.26e-26	1.48e-22	-0.64	-0.62	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
SARC	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-12.14	1.29e-26	1.51e-22	-0.72	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
SARC	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	12.14	1.31e-26	1.53e-22	0.63	0.62	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
SARC	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	12.13	1.41e-26	1.64e-22	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	12.13	1.43e-26	1.66e-22	0.84	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-12.12	1.56e-26	1.8e-22	-0.83	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
SARC	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-12.11	1.6e-26	1.84e-22	-0.72	-0.62	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-12.11	1.6e-26	1.84e-22	-0.72	-0.62	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-12.11	1.6e-26	1.84e-22	-0.72	-0.62	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-12.11	1.6e-26	1.84e-22	-0.72	-0.62	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-12.11	1.6e-26	1.84e-22	-0.72	-0.62	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-12.11	1.6e-26	1.84e-22	-0.72	-0.62	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-12.11	1.6e-26	1.84e-22	-0.72	-0.62	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
SARC	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-12.11	1.6e-26	1.84e-22	-0.72	-0.62	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
SARC	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-12.11	1.63e-26	1.88e-22	-0.82	-0.62	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
SARC	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-12.11	1.64e-26	1.88e-22	-0.71	-0.62	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
SARC	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	12.11	1.66e-26	1.91e-22	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
SARC	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-12.1	1.75e-26	2.01e-22	-0.82	-0.62	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
SARC	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-12.1	1.82e-26	2.09e-22	-0.7	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-12.1	1.82e-26	2.09e-22	-0.71	-0.62	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	12.09	1.91e-26	2.18e-22	0.81	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
SARC	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	12.09	1.93e-26	2.21e-22	0.79	0.62	Shingles;	chr7:38346957	chr7:38343894~38350022:-
SARC	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-12.07	2.23e-26	2.54e-22	-0.71	-0.62	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-12.07	2.29e-26	2.61e-22	-0.86	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
SARC	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-12.06	2.38e-26	2.71e-22	-0.73	-0.62	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
SARC	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	12.06	2.5e-26	2.84e-22	0.72	0.62	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
SARC	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-12.04	2.79e-26	3.16e-22	-0.72	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
SARC	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	12.04	2.79e-26	3.16e-22	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
SARC	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-12.04	2.87e-26	3.25e-22	-0.7	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
SARC	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	12.04	2.9e-26	3.27e-22	0.78	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
SARC	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	12.03	2.95e-26	3.33e-22	0.82	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
SARC	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	12.03	3.11e-26	3.51e-22	0.72	0.62	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
SARC	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-12.03	3.11e-26	3.51e-22	-0.88	-0.62	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
SARC	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-12.03	3.13e-26	3.53e-22	-0.75	-0.62	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
SARC	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-12.02	3.15e-26	3.55e-22	-0.72	-0.62	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
SARC	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-12.02	3.27e-26	3.68e-22	-0.71	-0.62	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
SARC	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-12.02	3.37e-26	3.79e-22	-0.79	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
SARC	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-12.01	3.44e-26	3.86e-22	-0.89	-0.62	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-12.01	3.44e-26	3.86e-22	-0.89	-0.62	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
SARC	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	12.01	3.45e-26	3.88e-22	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
SARC	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	12.01	3.61e-26	4.05e-22	0.62	0.62	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
SARC	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-12	3.64e-26	4.08e-22	-0.7	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
SARC	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-12	3.64e-26	4.08e-22	-0.7	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
SARC	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-12	3.71e-26	4.15e-22	-0.7	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
SARC	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-12	3.71e-26	4.15e-22	-0.7	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
SARC	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-12	3.73e-26	4.17e-22	-0.89	-0.62	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
SARC	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	12	3.77e-26	4.21e-22	0.81	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	12	3.77e-26	4.21e-22	0.81	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
SARC	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-11.99	4.04e-26	4.51e-22	-0.88	-0.62	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
SARC	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	11.99	4.11e-26	4.58e-22	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
SARC	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-11.98	4.31e-26	4.8e-22	-0.7	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	11.98	4.32e-26	4.81e-22	0.81	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
SARC	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-11.98	4.45e-26	4.95e-22	-0.7	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
SARC	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	11.97	4.73e-26	5.24e-22	0.71	0.62	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	11.96	5.09e-26	5.63e-22	0.82	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	11.96	5.09e-26	5.63e-22	0.82	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	11.96	5.09e-26	5.63e-22	0.82	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
SARC	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	11.96	5.23e-26	5.79e-22	0.8	0.62	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-11.95	5.3e-26	5.86e-22	-0.81	-0.62	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
SARC	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	11.95	5.42e-26	5.99e-22	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
SARC	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-11.95	5.47e-26	6.04e-22	-0.71	-0.62	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
SARC	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-11.95	5.65e-26	6.24e-22	-0.81	-0.62	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
SARC	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-11.94	5.78e-26	6.37e-22	-0.79	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
SARC	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-11.93	6.51e-26	7.12e-22	-0.81	-0.62	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-11.93	6.51e-26	7.12e-22	-0.81	-0.62	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-11.93	6.51e-26	7.12e-22	-0.81	-0.62	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-11.93	6.51e-26	7.12e-22	-0.81	-0.62	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-11.93	6.51e-26	7.12e-22	-0.81	-0.62	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	11.93	6.51e-26	7.12e-22	0.81	0.62	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
SARC	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	11.93	6.51e-26	7.12e-22	0.81	0.62	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	11.93	6.51e-26	7.12e-22	0.81	0.62	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
SARC	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	11.93	6.51e-26	7.12e-22	0.81	0.62	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
SARC	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	11.93	6.51e-26	7.12e-22	0.81	0.62	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
SARC	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	11.93	6.55e-26	7.16e-22	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	11.92	6.99e-26	7.63e-22	0.84	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
SARC	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-11.91	7.37e-26	8.03e-22	-0.7	-0.62	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
SARC	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	11.9	7.98e-26	8.68e-22	0.82	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	11.9	7.98e-26	8.68e-22	0.82	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	11.9	7.98e-26	8.68e-22	0.82	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	11.9	7.98e-26	8.68e-22	0.82	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
SARC	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-11.89	8.32e-26	9.02e-22	-0.69	-0.61	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
SARC	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-11.89	8.32e-26	9.02e-22	-0.69	-0.61	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
SARC	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-11.89	8.32e-26	9.02e-22	-0.69	-0.61	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
SARC	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-11.89	8.32e-26	9.02e-22	-0.69	-0.61	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	11.89	8.79e-26	9.51e-22	0.81	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	11.89	8.79e-26	9.51e-22	0.81	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
SARC	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	11.88	9.43e-26	1.02e-21	0.71	0.61	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
SARC	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	11.87	9.8e-26	1.06e-21	0.7	0.61	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-11.87	9.9e-26	1.07e-21	-0.77	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
SARC	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	11.87	1e-25	1.08e-21	0.76	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
SARC	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	11.87	1e-25	1.08e-21	0.76	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
SARC	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	11.87	1e-25	1.08e-21	0.76	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
SARC	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	11.87	1.01e-25	1.09e-21	0.7	0.61	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
SARC	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	11.86	1.04e-25	1.11e-21	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
SARC	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	11.86	1.08e-25	1.16e-21	0.71	0.61	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
SARC	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	11.85	1.19e-25	1.27e-21	0.73	0.61	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	11.84	1.26e-25	1.34e-21	0.82	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
SARC	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	11.84	1.29e-25	1.37e-21	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
SARC	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-11.83	1.32e-25	1.41e-21	-0.82	-0.61	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	11.83	1.32e-25	1.41e-21	0.81	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	11.83	1.37e-25	1.45e-21	0.82	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	11.83	1.37e-25	1.46e-21	0.79	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
SARC	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-11.81	1.52e-25	1.61e-21	-0.81	-0.61	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	11.81	1.52e-25	1.61e-21	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
SARC	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	11.81	1.53e-25	1.62e-21	0.72	0.61	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-11.81	1.54e-25	1.63e-21	-0.82	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-11.81	1.54e-25	1.63e-21	-0.82	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-11.81	1.54e-25	1.63e-21	-0.82	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-11.81	1.55e-25	1.64e-21	-0.73	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
SARC	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-11.81	1.56e-25	1.65e-21	-0.81	-0.61	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
SARC	cis	rs1799949	0.827	rs74252763	ENSG00000198496.9	NBR2	-11.8	1.73e-25	1.82e-21	-0.78	-0.61	Menopause (age at onset);	chr17:43324652	chr17:43125610~43153671:+
SARC	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-11.79	1.77e-25	1.86e-21	-0.82	-0.61	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
SARC	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-11.79	1.81e-25	1.9e-21	-0.72	-0.61	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
SARC	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-11.79	1.83e-25	1.92e-21	-0.7	-0.61	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
SARC	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	11.78	1.87e-25	1.97e-21	0.81	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-11.77	2.03e-25	2.12e-21	-0.85	-0.61	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-11.77	2.03e-25	2.12e-21	-0.85	-0.61	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-11.77	2.03e-25	2.12e-21	-0.85	-0.61	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
SARC	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-11.77	2.06e-25	2.15e-21	-0.82	-0.61	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
SARC	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-11.77	2.07e-25	2.16e-21	-0.88	-0.61	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
SARC	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	11.77	2.09e-25	2.19e-21	0.81	0.61	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
SARC	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-11.77	2.12e-25	2.21e-21	-0.77	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
SARC	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-11.77	2.16e-25	2.26e-21	-0.83	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
SARC	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	11.77	2.17e-25	2.27e-21	0.76	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
SARC	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	11.76	2.23e-25	2.33e-21	0.92	0.61	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
SARC	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	11.75	2.42e-25	2.52e-21	0.82	0.61	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
SARC	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	11.74	2.53e-25	2.63e-21	0.71	0.61	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	11.74	2.63e-25	2.73e-21	0.81	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-11.74	2.63e-25	2.73e-21	-0.82	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
SARC	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	11.74	2.67e-25	2.77e-21	0.71	0.61	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
SARC	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-11.74	2.68e-25	2.78e-21	-0.87	-0.61	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
SARC	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	11.73	2.72e-25	2.82e-21	0.71	0.61	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
SARC	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	11.73	2.76e-25	2.86e-21	0.71	0.61	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
SARC	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-11.73	2.81e-25	2.91e-21	-0.82	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
SARC	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-11.73	2.85e-25	2.96e-21	-0.88	-0.61	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
SARC	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	11.73	2.88e-25	2.98e-21	0.71	0.61	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
SARC	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	11.73	2.89e-25	2.99e-21	0.7	0.61	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
SARC	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-11.72	3.02e-25	3.12e-21	-0.73	-0.61	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
SARC	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-11.71	3.32e-25	3.42e-21	-0.71	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
SARC	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-11.71	3.35e-25	3.45e-21	-0.8	-0.61	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
SARC	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	11.7	3.54e-25	3.64e-21	0.76	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
SARC	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	11.7	3.64e-25	3.74e-21	0.76	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
SARC	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-11.69	3.85e-25	3.95e-21	-0.88	-0.61	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-11.69	3.85e-25	3.95e-21	-0.88	-0.61	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
SARC	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	11.69	3.89e-25	3.99e-21	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	11.69	3.89e-25	3.99e-21	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	11.69	3.89e-25	3.99e-21	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	11.69	3.89e-25	3.99e-21	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
SARC	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-11.69	3.92e-25	4.02e-21	-0.86	-0.61	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
SARC	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-11.68	3.99e-25	4.09e-21	-0.8	-0.61	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	11.67	4.38e-25	4.47e-21	0.81	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
SARC	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	11.67	4.44e-25	4.52e-21	0.71	0.61	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
SARC	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	11.67	4.53e-25	4.61e-21	0.89	0.61	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
SARC	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	11.67	4.53e-25	4.61e-21	0.89	0.61	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
SARC	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	11.66	4.73e-25	4.81e-21	0.69	0.61	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
SARC	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-11.66	4.8e-25	4.88e-21	-0.8	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
SARC	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	11.66	4.86e-25	4.92e-21	0.79	0.61	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	11.66	4.86e-25	4.92e-21	0.79	0.61	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
SARC	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	11.66	4.86e-25	4.92e-21	0.79	0.61	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
SARC	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-11.65	5.09e-25	5.14e-21	-0.69	-0.61	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
SARC	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-11.65	5.09e-25	5.14e-21	-0.69	-0.61	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
SARC	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-11.65	5.09e-25	5.14e-21	-0.69	-0.61	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
SARC	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-11.65	5.13e-25	5.18e-21	-0.8	-0.61	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
SARC	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	11.65	5.15e-25	5.19e-21	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
SARC	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	11.65	5.17e-25	5.21e-21	0.79	0.61	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	11.65	5.17e-25	5.21e-21	0.79	0.61	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-11.65	5.19e-25	5.23e-21	-0.81	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
SARC	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-11.64	5.31e-25	5.33e-21	-0.72	-0.61	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
SARC	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-11.64	5.32e-25	5.35e-21	-0.69	-0.61	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
SARC	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	11.63	5.73e-25	5.74e-21	0.69	0.61	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
SARC	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-11.63	5.85e-25	5.85e-21	-0.72	-0.61	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-11.63	5.85e-25	5.85e-21	-0.72	-0.61	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
SARC	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-11.63	5.9e-25	5.9e-21	-0.72	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
SARC	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	11.63	5.93e-25	5.92e-21	0.71	0.61	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
SARC	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	11.63	6.08e-25	6.06e-21	0.79	0.61	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	11.63	6.08e-25	6.06e-21	0.79	0.61	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	11.63	6.08e-25	6.06e-21	0.79	0.61	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
SARC	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	11.63	6.08e-25	6.06e-21	0.79	0.61	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
SARC	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	11.63	6.08e-25	6.06e-21	0.79	0.61	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
SARC	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	11.62	6.22e-25	6.19e-21	0.71	0.61	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	11.62	6.58e-25	6.52e-21	0.81	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
SARC	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-11.61	7e-25	6.93e-21	-0.69	-0.61	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
SARC	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	11.61	7.05e-25	6.97e-21	0.7	0.61	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
SARC	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-11.59	7.86e-25	7.74e-21	-0.7	-0.6	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-11.58	8.61e-25	8.45e-21	-0.83	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-11.58	8.61e-25	8.45e-21	-0.83	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
SARC	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-11.58	8.88e-25	8.72e-21	-0.87	-0.6	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
SARC	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-11.57	9.43e-25	9.24e-21	-0.77	-0.6	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
SARC	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	11.56	9.99e-25	9.77e-21	0.68	0.6	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
SARC	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	11.56	1.03e-24	1e-20	0.78	0.6	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
SARC	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	11.56	1.03e-24	1.01e-20	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
SARC	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	11.55	1.04e-24	1.02e-20	0.78	0.6	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
SARC	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-11.55	1.09e-24	1.07e-20	-0.75	-0.6	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
SARC	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-11.54	1.15e-24	1.12e-20	-0.82	-0.6	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
SARC	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	11.54	1.17e-24	1.14e-20	0.79	0.6	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	11.54	1.18e-24	1.15e-20	0.87	0.6	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
SARC	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	11.53	1.27e-24	1.23e-20	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
SARC	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-11.52	1.32e-24	1.27e-20	-0.71	-0.6	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-11.52	1.32e-24	1.27e-20	-0.71	-0.6	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
SARC	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-11.52	1.35e-24	1.3e-20	-0.82	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-11.52	1.35e-24	1.3e-20	-0.82	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-11.52	1.35e-24	1.3e-20	-0.82	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	11.51	1.4e-24	1.34e-20	0.84	0.6	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	11.51	1.4e-24	1.34e-20	0.84	0.6	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
SARC	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	11.51	1.41e-24	1.35e-20	0.72	0.6	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
SARC	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	11.51	1.43e-24	1.36e-20	0.78	0.6	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
SARC	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	11.5	1.61e-24	1.53e-20	0.69	0.6	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-11.49	1.73e-24	1.64e-20	-0.84	-0.6	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
SARC	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-11.48	1.75e-24	1.66e-20	-0.7	-0.6	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-11.48	1.75e-24	1.66e-20	-0.7	-0.6	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-11.48	1.75e-24	1.66e-20	-0.7	-0.6	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-11.48	1.75e-24	1.66e-20	-0.7	-0.6	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-11.48	1.75e-24	1.66e-20	-0.7	-0.6	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
SARC	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-11.48	1.77e-24	1.68e-20	-0.75	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
SARC	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-11.48	1.8e-24	1.71e-20	-0.7	-0.6	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
SARC	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-11.47	1.88e-24	1.78e-20	-0.71	-0.6	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-11.47	1.99e-24	1.88e-20	-0.7	-0.6	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
SARC	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	11.47	2e-24	1.88e-20	0.68	0.6	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
SARC	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	11.47	2e-24	1.88e-20	0.68	0.6	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
SARC	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	11.46	2.06e-24	1.94e-20	0.81	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
SARC	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	11.46	2.07e-24	1.95e-20	0.78	0.6	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
SARC	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-11.46	2.13e-24	2e-20	-0.88	-0.6	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
SARC	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	11.42	2.7e-24	2.52e-20	0.76	0.6	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-11.42	2.77e-24	2.58e-20	-0.81	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-11.42	2.77e-24	2.58e-20	-0.81	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-11.42	2.77e-24	2.58e-20	-0.81	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-11.42	2.77e-24	2.58e-20	-0.81	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-11.42	2.77e-24	2.58e-20	-0.81	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
SARC	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	11.42	2.81e-24	2.61e-20	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	11.42	2.84e-24	2.64e-20	0.86	0.6	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-11.42	2.84e-24	2.64e-20	-0.84	-0.6	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	11.41	2.96e-24	2.75e-20	0.86	0.6	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	11.41	2.96e-24	2.75e-20	0.86	0.6	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
SARC	cis	rs5760092	0.618	rs4461358	ENSG00000273295.1	AP000350.5	-11.41	2.99e-24	2.78e-20	-0.68	-0.6	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23901432~23907068:-
SARC	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	11.41	3.09e-24	2.86e-20	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-11.4	3.15e-24	2.91e-20	-0.83	-0.6	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
SARC	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-11.39	3.43e-24	3.17e-20	-0.69	-0.6	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
SARC	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	11.38	3.63e-24	3.35e-20	0.86	0.6	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	11.38	3.71e-24	3.42e-20	0.82	0.6	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
SARC	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-11.38	3.72e-24	3.42e-20	-0.69	-0.6	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-11.38	3.72e-24	3.42e-20	-0.69	-0.6	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-11.38	3.72e-24	3.42e-20	-0.69	-0.6	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
SARC	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-11.38	3.72e-24	3.42e-20	-0.69	-0.6	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
SARC	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	11.38	3.82e-24	3.52e-20	0.8	0.6	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-11.37	4e-24	3.67e-20	-0.81	-0.6	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
SARC	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-11.37	4.19e-24	3.85e-20	-0.71	-0.6	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
SARC	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	11.36	4.27e-24	3.92e-20	0.68	0.6	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
SARC	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	11.35	4.8e-24	4.4e-20	0.79	0.6	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
SARC	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	11.34	5.02e-24	4.59e-20	0.68	0.6	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
SARC	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	11.34	5.02e-24	4.59e-20	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
SARC	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	11.32	5.9e-24	5.38e-20	0.69	0.6	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
SARC	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	11.32	5.9e-24	5.38e-20	0.77	0.6	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
SARC	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-11.31	6.22e-24	5.67e-20	-0.69	-0.6	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
SARC	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	11.29	7.39e-24	6.7e-20	0.83	0.59	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
SARC	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	11.28	7.59e-24	6.87e-20	0.61	0.59	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
SARC	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	11.27	8.44e-24	7.63e-20	0.82	0.59	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
SARC	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-11.27	8.52e-24	7.7e-20	-0.7	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
SARC	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	11.26	9.1e-24	8.18e-20	0.72	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
SARC	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	11.25	9.53e-24	8.56e-20	0.77	0.59	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	11.25	9.8e-24	8.8e-20	0.77	0.59	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	11.25	1.01e-23	9.05e-20	0.77	0.59	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	11.25	1.01e-23	9.05e-20	0.77	0.59	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	11.25	1.01e-23	9.05e-20	0.77	0.59	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
SARC	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-11.24	1.03e-23	9.2e-20	-0.86	-0.59	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
SARC	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-11.22	1.23e-23	1.1e-19	-0.71	-0.59	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
SARC	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	11.21	1.28e-23	1.14e-19	0.66	0.59	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
SARC	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	11.2	1.41e-23	1.25e-19	0.68	0.59	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
SARC	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	11.19	1.56e-23	1.38e-19	0.73	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
SARC	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-11.15	2.05e-23	1.81e-19	-0.69	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
SARC	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	11.15	2.06e-23	1.81e-19	0.63	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
SARC	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	11.15	2.11e-23	1.86e-19	0.67	0.59	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
SARC	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	11.14	2.16e-23	1.89e-19	0.61	0.59	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
SARC	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-11.14	2.16e-23	1.9e-19	-0.82	-0.59	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
SARC	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	11.14	2.19e-23	1.92e-19	0.79	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	11.14	2.19e-23	1.92e-19	0.79	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
SARC	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	11.14	2.26e-23	1.98e-19	0.76	0.59	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
SARC	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	11.13	2.36e-23	2.06e-19	0.68	0.59	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
SARC	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-11.12	2.49e-23	2.18e-19	-0.66	-0.59	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
SARC	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-11.12	2.52e-23	2.21e-19	-0.7	-0.59	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
SARC	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	11.12	2.6e-23	2.27e-19	0.69	0.59	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
SARC	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-11.11	2.65e-23	2.31e-19	-0.76	-0.59	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
SARC	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-11.11	2.71e-23	2.37e-19	-0.67	-0.59	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
SARC	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-11.1	2.88e-23	2.51e-19	-0.62	-0.59	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-11.1	2.88e-23	2.51e-19	-0.62	-0.59	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-11.1	2.88e-23	2.51e-19	-0.62	-0.59	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	11.09	3.06e-23	2.66e-19	0.59	0.59	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	11.09	3.1e-23	2.7e-19	0.79	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	11.09	3.17e-23	2.76e-19	0.64	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
SARC	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	11.07	3.55e-23	3.08e-19	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-11.07	3.67e-23	3.18e-19	-0.62	-0.59	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-11.07	3.67e-23	3.18e-19	-0.62	-0.59	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-11.07	3.67e-23	3.18e-19	-0.62	-0.59	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-11.07	3.67e-23	3.18e-19	-0.62	-0.59	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-11.07	3.67e-23	3.18e-19	-0.62	-0.59	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-11.07	3.67e-23	3.18e-19	-0.62	-0.59	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-11.07	3.67e-23	3.18e-19	-0.62	-0.59	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
SARC	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	11.07	3.7e-23	3.2e-19	0.66	0.59	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
SARC	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	11.03	4.86e-23	4.19e-19	0.85	0.59	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
SARC	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	11.03	4.9e-23	4.22e-19	0.67	0.59	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
SARC	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-11.03	5e-23	4.3e-19	-0.69	-0.59	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
SARC	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-11.03	5.02e-23	4.32e-19	-0.76	-0.59	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
SARC	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-11.02	5.09e-23	4.37e-19	-0.7	-0.59	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
SARC	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	11.02	5.13e-23	4.4e-19	0.64	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
SARC	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-11.01	5.55e-23	4.76e-19	-0.68	-0.59	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
SARC	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-11.01	5.64e-23	4.82e-19	-0.84	-0.59	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
SARC	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-11.01	5.77e-23	4.93e-19	-0.69	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
SARC	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-10.98	6.99e-23	5.95e-19	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-10.98	6.99e-23	5.95e-19	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
SARC	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	10.98	7.08e-23	6.02e-19	0.7	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
SARC	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	10.98	7.08e-23	6.02e-19	0.7	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
SARC	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	10.98	7.08e-23	6.02e-19	0.7	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
SARC	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	10.98	7.1e-23	6.04e-19	0.64	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
SARC	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	10.98	7.15e-23	6.08e-19	0.63	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
SARC	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-10.97	7.34e-23	6.24e-19	-0.73	-0.58	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
SARC	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	10.97	7.53e-23	6.39e-19	0.67	0.58	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
SARC	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-10.96	8.14e-23	6.88e-19	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
SARC	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-10.96	8.33e-23	7.04e-19	-0.69	-0.58	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-10.96	8.33e-23	7.04e-19	-0.69	-0.58	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
SARC	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	10.96	8.38e-23	7.07e-19	0.85	0.58	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
SARC	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-10.96	8.42e-23	7.1e-19	-0.6	-0.58	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
SARC	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-10.95	8.8e-23	7.41e-19	-0.69	-0.58	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
SARC	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	10.94	9.12e-23	7.68e-19	0.76	0.58	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
SARC	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	10.94	9.28e-23	7.8e-19	0.69	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
SARC	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-10.93	9.98e-23	8.36e-19	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-10.93	9.98e-23	8.36e-19	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-10.93	1.02e-22	8.49e-19	-0.79	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
SARC	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	10.93	1.02e-22	8.49e-19	0.75	0.58	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
SARC	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	10.93	1.04e-22	8.71e-19	0.68	0.58	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
SARC	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-10.92	1.07e-22	8.9e-19	-0.59	-0.58	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
SARC	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-10.91	1.17e-22	9.68e-19	-0.81	-0.58	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
SARC	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-10.89	1.34e-22	1.11e-18	-0.74	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
SARC	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-10.86	1.65e-22	1.35e-18	-0.71	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
SARC	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	10.85	1.8e-22	1.47e-18	0.75	0.58	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
SARC	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	10.85	1.81e-22	1.48e-18	0.69	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
SARC	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-10.85	1.88e-22	1.53e-18	-0.7	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
SARC	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-10.85	1.88e-22	1.53e-18	-0.7	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
SARC	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-10.84	1.98e-22	1.61e-18	-0.71	-0.58	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	10.83	2.17e-22	1.75e-18	0.8	0.58	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
SARC	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-10.82	2.28e-22	1.84e-18	-0.68	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
SARC	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	10.81	2.48e-22	2e-18	0.72	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
SARC	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-10.81	2.51e-22	2.01e-18	-0.68	-0.58	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	10.81	2.51e-22	2.01e-18	0.7	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
SARC	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	10.8	2.67e-22	2.14e-18	0.6	0.58	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
SARC	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-10.79	2.75e-22	2.21e-18	-0.68	-0.58	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
SARC	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	10.79	2.85e-22	2.28e-18	0.68	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
SARC	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	10.77	3.2e-22	2.55e-18	1.08	0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
SARC	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-10.77	3.29e-22	2.63e-18	-0.62	-0.58	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
SARC	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	10.76	3.39e-22	2.7e-18	0.69	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
SARC	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-10.76	3.43e-22	2.73e-18	-0.69	-0.58	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
SARC	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	10.76	3.49e-22	2.77e-18	0.62	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
SARC	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	10.76	3.52e-22	2.79e-18	0.63	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
SARC	cis	rs8037818	1	rs11071856	ENSG00000276724.1	RP11-1000B6.7	-10.75	3.66e-22	2.9e-18	-0.78	-0.58	Obesity-related traits;	chr15:32633591	chr15:32583612~32584312:+
SARC	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	10.74	3.96e-22	3.12e-18	0.67	0.58	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
SARC	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-10.73	4.36e-22	3.43e-18	-0.66	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	10.73	4.49e-22	3.53e-18	0.7	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	10.73	4.5e-22	3.53e-18	0.6	0.57	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-10.72	4.76e-22	3.72e-18	-0.61	-0.57	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-10.72	4.76e-22	3.72e-18	-0.61	-0.57	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
SARC	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	10.71	4.87e-22	3.81e-18	0.71	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
SARC	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	10.71	4.89e-22	3.82e-18	0.75	0.57	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	10.71	4.89e-22	3.82e-18	0.75	0.57	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	10.71	5.13e-22	3.99e-18	0.7	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
SARC	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-10.71	5.14e-22	4e-18	-0.7	-0.57	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
SARC	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	10.7	5.47e-22	4.24e-18	0.65	0.57	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
SARC	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	10.7	5.51e-22	4.28e-18	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
SARC	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-10.69	5.61e-22	4.34e-18	-0.7	-0.57	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-10.69	5.61e-22	4.34e-18	-0.7	-0.57	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-10.69	5.61e-22	4.34e-18	-0.7	-0.57	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
SARC	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-10.69	5.97e-22	4.62e-18	-0.6	-0.57	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
SARC	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	10.68	6.1e-22	4.72e-18	0.68	0.57	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
SARC	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	10.68	6.29e-22	4.86e-18	0.63	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
SARC	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	10.68	6.46e-22	4.99e-18	0.58	0.57	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
SARC	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-10.67	6.59e-22	5.08e-18	-0.59	-0.57	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
SARC	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-10.67	6.6e-22	5.09e-18	-0.6	-0.57	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-10.66	6.96e-22	5.36e-18	-0.61	-0.57	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
SARC	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-10.66	7.36e-22	5.66e-18	-0.62	-0.57	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
SARC	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	10.65	7.57e-22	5.81e-18	0.83	0.57	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
SARC	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	10.64	8.28e-22	6.32e-18	0.66	0.57	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
SARC	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-10.64	8.45e-22	6.45e-18	-0.68	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
SARC	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-10.64	8.54e-22	6.51e-18	-0.67	-0.57	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
SARC	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-10.64	8.55e-22	6.51e-18	-0.67	-0.57	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
SARC	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	10.64	8.57e-22	6.53e-18	1.04	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
SARC	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	10.63	8.93e-22	6.8e-18	0.66	0.57	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
SARC	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-10.62	9.59e-22	7.28e-18	-0.67	-0.57	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-10.62	9.59e-22	7.28e-18	-0.67	-0.57	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
SARC	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-10.62	9.67e-22	7.34e-18	-0.62	-0.57	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
SARC	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-10.62	9.72e-22	7.38e-18	-0.61	-0.57	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
SARC	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-10.6	1.07e-21	8.12e-18	-0.69	-0.57	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
SARC	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	10.6	1.08e-21	8.19e-18	0.66	0.57	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
SARC	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	10.6	1.08e-21	8.19e-18	0.66	0.57	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
SARC	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-10.6	1.09e-21	8.21e-18	-0.68	-0.57	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
SARC	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	10.6	1.09e-21	8.26e-18	0.6	0.57	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
SARC	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	10.6	1.12e-21	8.45e-18	0.66	0.57	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
SARC	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-10.6	1.15e-21	8.65e-18	-0.79	-0.57	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
SARC	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-10.59	1.21e-21	9.11e-18	-0.72	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
SARC	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-10.59	1.21e-21	9.11e-18	-0.72	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
SARC	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	10.59	1.24e-21	9.31e-18	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
SARC	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	10.59	1.24e-21	9.31e-18	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
SARC	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-10.58	1.25e-21	9.42e-18	-0.62	-0.57	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
SARC	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	10.58	1.27e-21	9.58e-18	1.04	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
SARC	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	10.58	1.32e-21	9.92e-18	0.69	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
SARC	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-10.57	1.34e-21	1.01e-17	-0.61	-0.57	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
SARC	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	10.57	1.39e-21	1.04e-17	0.66	0.57	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
SARC	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	10.57	1.41e-21	1.06e-17	0.71	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
SARC	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	10.56	1.47e-21	1.1e-17	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
SARC	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-10.55	1.56e-21	1.16e-17	-0.59	-0.57	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
SARC	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	10.54	1.7e-21	1.26e-17	0.79	0.57	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
SARC	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-10.54	1.71e-21	1.27e-17	-0.59	-0.57	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	10.54	1.73e-21	1.28e-17	0.59	0.57	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
SARC	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-10.54	1.73e-21	1.28e-17	-0.68	-0.57	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-10.54	1.73e-21	1.28e-17	-0.68	-0.57	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-10.54	1.73e-21	1.28e-17	-0.68	-0.57	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-10.54	1.74e-21	1.29e-17	-0.68	-0.57	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
SARC	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	10.53	1.8e-21	1.33e-17	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
SARC	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-10.52	2.02e-21	1.49e-17	-0.68	-0.57	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
SARC	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	10.51	2.05e-21	1.51e-17	0.71	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
SARC	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-10.5	2.26e-21	1.66e-17	-0.65	-0.57	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
SARC	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-10.5	2.32e-21	1.71e-17	-0.85	-0.57	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
SARC	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-10.5	2.33e-21	1.71e-17	-0.61	-0.57	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-10.5	2.33e-21	1.72e-17	-0.61	-0.57	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
SARC	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-10.5	2.33e-21	1.72e-17	-0.61	-0.57	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
SARC	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	10.49	2.45e-21	1.8e-17	0.83	0.57	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
SARC	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-10.49	2.47e-21	1.81e-17	-0.67	-0.57	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
SARC	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	10.48	2.62e-21	1.92e-17	0.69	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
SARC	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-10.47	2.76e-21	2.02e-17	-0.61	-0.57	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
SARC	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	10.47	2.79e-21	2.04e-17	0.6	0.57	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
SARC	cis	rs1167827	0.805	rs809439	ENSG00000127957.15	PMS2P3	10.47	2.9e-21	2.11e-17	0.61	0.57	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75502930~75528148:-
SARC	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	10.46	2.95e-21	2.15e-17	0.67	0.57	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
SARC	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-10.46	3.07e-21	2.23e-17	-0.61	-0.57	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
SARC	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-10.45	3.23e-21	2.34e-17	-0.61	-0.56	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
SARC	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	10.45	3.26e-21	2.36e-17	0.83	0.56	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
SARC	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-10.45	3.28e-21	2.37e-17	-0.61	-0.56	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-10.45	3.28e-21	2.37e-17	-0.61	-0.56	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
SARC	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	10.45	3.29e-21	2.37e-17	1.05	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
SARC	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	10.45	3.29e-21	2.38e-17	0.73	0.56	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	10.44	3.43e-21	2.47e-17	1.07	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
SARC	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	10.44	3.51e-21	2.52e-17	0.69	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-10.44	3.6e-21	2.59e-17	-0.61	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
SARC	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-10.43	3.69e-21	2.65e-17	-0.61	-0.56	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
SARC	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-10.43	3.7e-21	2.65e-17	-0.59	-0.56	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	10.43	3.71e-21	2.66e-17	0.57	0.56	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
SARC	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	10.43	3.76e-21	2.69e-17	0.72	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
SARC	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	10.43	3.79e-21	2.71e-17	0.6	0.56	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	10.43	3.79e-21	2.71e-17	0.6	0.56	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	10.43	3.79e-21	2.71e-17	0.6	0.56	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	10.43	3.79e-21	2.71e-17	0.6	0.56	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
SARC	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-10.43	3.83e-21	2.74e-17	-0.61	-0.56	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
SARC	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	10.41	4.22e-21	3.01e-17	0.57	0.56	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
SARC	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	10.41	4.28e-21	3.05e-17	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
SARC	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-10.41	4.31e-21	3.07e-17	-0.66	-0.56	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
SARC	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	10.41	4.35e-21	3.1e-17	0.7	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
SARC	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-10.41	4.43e-21	3.15e-17	-0.6	-0.56	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-10.41	4.43e-21	3.15e-17	-0.6	-0.56	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-10.41	4.43e-21	3.15e-17	-0.6	-0.56	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-10.41	4.43e-21	3.15e-17	-0.6	-0.56	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-10.41	4.43e-21	3.15e-17	-0.6	-0.56	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
SARC	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	10.4	4.61e-21	3.27e-17	0.71	0.56	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
SARC	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-10.4	4.66e-21	3.3e-17	-0.6	-0.56	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
SARC	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-10.4	4.69e-21	3.32e-17	-0.61	-0.56	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
SARC	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	10.4	4.77e-21	3.38e-17	0.72	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
SARC	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-10.4	4.84e-21	3.42e-17	-0.79	-0.56	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
SARC	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-10.39	4.92e-21	3.48e-17	-0.62	-0.56	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
SARC	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-10.39	5.03e-21	3.55e-17	-0.61	-0.56	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-10.39	5.19e-21	3.66e-17	-0.61	-0.56	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
SARC	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	10.38	5.31e-21	3.74e-17	0.71	0.56	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
SARC	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	10.38	5.31e-21	3.74e-17	0.71	0.56	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
SARC	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-10.37	5.69e-21	4.01e-17	-0.59	-0.56	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
SARC	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	10.37	5.84e-21	4.11e-17	0.67	0.56	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
SARC	cis	rs3091242	0.933	rs9645452	ENSG00000224183.1	SDHDP6	10.37	5.84e-21	4.11e-17	0.64	0.56	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25294164~25294643:-
SARC	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	10.35	6.58e-21	4.61e-17	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
SARC	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-10.35	6.74e-21	4.72e-17	-0.68	-0.56	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
SARC	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-10.35	6.88e-21	4.81e-17	-0.67	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
SARC	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-10.34	7.05e-21	4.92e-17	-0.64	-0.56	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	10.34	7.15e-21	4.99e-17	0.68	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	10.34	7.26e-21	5.06e-17	0.71	0.56	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
SARC	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-10.34	7.33e-21	5.11e-17	-0.66	-0.56	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
SARC	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	10.33	7.63e-21	5.32e-17	0.73	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
SARC	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	10.33	7.8e-21	5.42e-17	0.72	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
SARC	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-10.33	7.81e-21	5.42e-17	-0.61	-0.56	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-10.33	7.81e-21	5.42e-17	-0.61	-0.56	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-10.33	7.81e-21	5.42e-17	-0.61	-0.56	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-10.33	7.81e-21	5.42e-17	-0.61	-0.56	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-10.33	7.81e-21	5.42e-17	-0.61	-0.56	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-10.33	7.81e-21	5.42e-17	-0.61	-0.56	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-10.33	7.81e-21	5.42e-17	-0.61	-0.56	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
SARC	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	10.33	7.95e-21	5.51e-17	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
SARC	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	10.32	8.13e-21	5.63e-17	0.59	0.56	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	10.32	8.22e-21	5.7e-17	0.68	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	10.32	8.3e-21	5.75e-17	0.61	0.56	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	10.32	8.3e-21	5.75e-17	0.61	0.56	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	10.32	8.3e-21	5.75e-17	0.61	0.56	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
SARC	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-10.32	8.5e-21	5.88e-17	-0.72	-0.56	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
SARC	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-10.31	8.61e-21	5.96e-17	-0.64	-0.56	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
SARC	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	10.31	9.11e-21	6.27e-17	1.03	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
SARC	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-10.3	9.29e-21	6.4e-17	-0.57	-0.56	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
SARC	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	10.3	9.74e-21	6.7e-17	0.59	0.56	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
SARC	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-10.29	1.02e-20	7.02e-17	-0.68	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
SARC	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	10.29	1.03e-20	7.07e-17	0.6	0.56	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
SARC	cis	rs3091242	0.933	rs3093584	ENSG00000224183.1	SDHDP6	10.29	1.05e-20	7.18e-17	0.64	0.56	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25294164~25294643:-
SARC	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-10.28	1.08e-20	7.36e-17	-0.59	-0.56	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	10.28	1.13e-20	7.75e-17	0.6	0.56	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	10.28	1.13e-20	7.75e-17	0.6	0.56	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	10.28	1.13e-20	7.75e-17	0.6	0.56	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	10.28	1.13e-20	7.75e-17	0.6	0.56	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
SARC	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	10.27	1.16e-20	7.88e-17	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	10.27	1.16e-20	7.88e-17	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	10.27	1.16e-20	7.88e-17	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	10.27	1.16e-20	7.88e-17	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	10.27	1.16e-20	7.88e-17	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
SARC	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	10.27	1.16e-20	7.88e-17	0.67	0.56	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	10.27	1.16e-20	7.88e-17	0.67	0.56	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
SARC	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-10.27	1.16e-20	7.92e-17	-0.6	-0.56	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
SARC	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-10.27	1.17e-20	7.96e-17	-0.58	-0.56	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
SARC	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-10.26	1.29e-20	8.78e-17	-0.61	-0.56	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-10.26	1.29e-20	8.78e-17	-0.61	-0.56	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-10.26	1.29e-20	8.78e-17	-0.61	-0.56	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
SARC	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	10.26	1.29e-20	8.78e-17	0.64	0.56	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	10.26	1.29e-20	8.78e-17	0.63	0.56	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-10.26	1.32e-20	8.92e-17	-0.64	-0.56	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
SARC	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-10.25	1.34e-20	9.07e-17	-0.61	-0.56	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
SARC	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-10.25	1.34e-20	9.1e-17	-0.7	-0.56	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	10.25	1.36e-20	9.22e-17	1.08	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
SARC	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-10.25	1.39e-20	9.41e-17	-0.72	-0.56	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
SARC	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	10.25	1.4e-20	9.43e-17	0.59	0.56	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
SARC	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-10.24	1.46e-20	9.84e-17	-0.65	-0.56	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	10.24	1.47e-20	9.94e-17	0.68	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	10.24	1.47e-20	9.94e-17	0.68	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	10.24	1.47e-20	9.94e-17	0.68	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-10.24	1.52e-20	1.02e-16	-0.79	-0.56	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
SARC	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	10.23	1.58e-20	1.07e-16	0.7	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
SARC	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-10.22	1.69e-20	1.13e-16	-0.62	-0.56	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
SARC	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-10.22	1.7e-20	1.14e-16	-0.6	-0.56	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
SARC	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-10.22	1.73e-20	1.16e-16	-0.99	-0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
SARC	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	10.21	1.78e-20	1.19e-16	0.72	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
SARC	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	10.21	1.79e-20	1.2e-16	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	10.21	1.79e-20	1.2e-16	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	10.21	1.79e-20	1.2e-16	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
SARC	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-10.21	1.86e-20	1.24e-16	-0.61	-0.56	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
SARC	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	10.2	2.01e-20	1.34e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	10.2	2.01e-20	1.34e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	10.2	2.01e-20	1.34e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	10.2	2.01e-20	1.34e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	10.2	2.01e-20	1.34e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	10.2	2.01e-20	1.34e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	10.2	2.01e-20	1.34e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
SARC	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-10.19	2.04e-20	1.36e-16	-0.61	-0.56	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
SARC	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	10.19	2.07e-20	1.36e-16	0.97	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
SARC	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	10.19	2.15e-20	1.41e-16	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
SARC	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	10.19	2.15e-20	1.41e-16	0.59	0.56	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
SARC	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	10.18	2.21e-20	1.44e-16	0.73	0.55	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	10.18	2.21e-20	1.44e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
SARC	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-10.18	2.21e-20	1.44e-16	-0.6	-0.55	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
SARC	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-10.18	2.29e-20	1.49e-16	-0.48	-0.55	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
SARC	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	10.17	2.36e-20	1.53e-16	0.56	0.55	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
SARC	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-10.17	2.42e-20	1.57e-16	-0.65	-0.55	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
SARC	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-10.17	2.46e-20	1.59e-16	-0.6	-0.55	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-10.17	2.46e-20	1.59e-16	-0.6	-0.55	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
SARC	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	10.16	2.59e-20	1.67e-16	0.68	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
SARC	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-10.16	2.64e-20	1.7e-16	-0.74	-0.55	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
SARC	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-10.16	2.65e-20	1.71e-16	-0.6	-0.55	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-10.16	2.65e-20	1.71e-16	-0.6	-0.55	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-10.16	2.65e-20	1.71e-16	-0.6	-0.55	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-10.16	2.65e-20	1.71e-16	-0.6	-0.55	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
SARC	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	10.15	2.69e-20	1.73e-16	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
SARC	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-10.15	2.7e-20	1.74e-16	-0.6	-0.55	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-10.15	2.7e-20	1.74e-16	-0.6	-0.55	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
SARC	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-10.15	2.72e-20	1.75e-16	-0.7	-0.55	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
SARC	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-10.15	2.76e-20	1.77e-16	-0.59	-0.55	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
SARC	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-10.15	2.83e-20	1.82e-16	-0.64	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
SARC	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	10.14	3.07e-20	1.97e-16	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
SARC	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-10.13	3.11e-20	1.99e-16	-0.7	-0.55	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	10.13	3.23e-20	2.07e-16	0.71	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
SARC	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-10.13	3.24e-20	2.07e-16	-0.59	-0.55	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
SARC	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	10.13	3.26e-20	2.08e-16	0.85	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
SARC	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-10.13	3.31e-20	2.12e-16	-0.59	-0.55	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
SARC	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	10.13	3.32e-20	2.12e-16	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
SARC	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	10.13	3.33e-20	2.13e-16	0.85	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	10.12	3.38e-20	2.15e-16	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
SARC	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-10.12	3.53e-20	2.24e-16	-0.7	-0.55	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
SARC	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-10.12	3.53e-20	2.24e-16	-0.7	-0.55	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
SARC	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-10.12	3.53e-20	2.24e-16	-0.7	-0.55	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
SARC	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-10.12	3.53e-20	2.24e-16	-0.7	-0.55	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
SARC	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-10.12	3.53e-20	2.24e-16	-0.7	-0.55	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
SARC	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-10.11	3.7e-20	2.35e-16	-0.7	-0.55	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
SARC	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-10.11	3.7e-20	2.35e-16	-0.7	-0.55	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
SARC	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	10.1	3.9e-20	2.48e-16	0.65	0.55	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
SARC	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-10.1	3.99e-20	2.53e-16	-0.59	-0.55	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	10.1	4.08e-20	2.58e-16	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	10.09	4.16e-20	2.63e-16	0.6	0.55	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
SARC	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-10.09	4.16e-20	2.63e-16	-0.7	-0.55	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
SARC	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-10.09	4.17e-20	2.64e-16	-0.75	-0.55	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
SARC	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-10.09	4.28e-20	2.71e-16	-0.59	-0.55	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-10.09	4.32e-20	2.73e-16	-0.59	-0.55	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
SARC	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	10.08	4.44e-20	2.8e-16	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
SARC	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	10.08	4.58e-20	2.89e-16	0.64	0.55	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
SARC	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-10.08	4.73e-20	2.98e-16	-0.7	-0.55	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
SARC	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	10.07	4.76e-20	3e-16	0.71	0.55	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	10.07	4.81e-20	3.03e-16	0.96	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
SARC	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-10.07	4.88e-20	3.07e-16	-0.7	-0.55	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
SARC	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-10.07	4.88e-20	3.07e-16	-0.7	-0.55	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
SARC	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-10.07	4.94e-20	3.1e-16	-0.6	-0.55	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-10.07	4.94e-20	3.1e-16	-0.6	-0.55	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-10.07	5.07e-20	3.17e-16	-0.59	-0.55	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-10.07	5.07e-20	3.17e-16	-0.59	-0.55	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-10.07	5.07e-20	3.17e-16	-0.59	-0.55	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
SARC	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-10.06	5.19e-20	3.25e-16	-0.58	-0.55	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
SARC	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-10.06	5.28e-20	3.3e-16	-0.59	-0.55	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-10.06	5.28e-20	3.3e-16	-0.59	-0.55	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-10.06	5.33e-20	3.33e-16	-0.6	-0.55	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
SARC	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	10.06	5.35e-20	3.34e-16	0.98	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
SARC	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	10.05	5.76e-20	3.59e-16	0.62	0.55	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
SARC	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-10.04	6.3e-20	3.92e-16	-0.64	-0.55	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
SARC	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-10.03	6.38e-20	3.97e-16	-0.67	-0.55	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
SARC	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	10.03	6.5e-20	4.04e-16	0.68	0.55	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
SARC	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	10.03	6.53e-20	4.06e-16	0.66	0.55	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
SARC	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	10.03	6.55e-20	4.07e-16	0.69	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
SARC	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	10.02	6.93e-20	4.3e-16	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
SARC	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	10.02	6.93e-20	4.3e-16	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
SARC	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	10.02	7.1e-20	4.41e-16	0.59	0.55	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	10.02	7.17e-20	4.45e-16	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
SARC	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-10.02	7.18e-20	4.45e-16	-0.71	-0.55	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
SARC	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	10.01	7.3e-20	4.52e-16	0.7	0.55	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
SARC	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-10.01	7.34e-20	4.55e-16	-0.61	-0.55	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
SARC	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-10.01	7.44e-20	4.61e-16	-0.63	-0.55	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
SARC	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-10.01	7.48e-20	4.63e-16	-0.69	-0.55	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
SARC	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	10.01	7.52e-20	4.65e-16	0.64	0.55	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
SARC	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-10.01	7.68e-20	4.74e-16	-0.59	-0.55	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
SARC	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	10.01	7.74e-20	4.78e-16	0.67	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
SARC	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	10	7.82e-20	4.83e-16	1	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
SARC	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	10	7.98e-20	4.92e-16	0.59	0.55	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
SARC	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	9.99	8.95e-20	5.5e-16	0.6	0.55	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
SARC	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	9.98	9.12e-20	5.6e-16	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
SARC	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	9.98	9.22e-20	5.65e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	9.98	9.22e-20	5.65e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	9.98	9.22e-20	5.65e-16	0.97	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
SARC	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-9.98	9.24e-20	5.66e-16	-0.7	-0.55	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
SARC	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-9.98	9.29e-20	5.68e-16	-0.59	-0.55	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-9.98	9.29e-20	5.68e-16	-0.59	-0.55	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
SARC	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-9.98	9.29e-20	5.68e-16	-0.59	-0.55	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-9.98	9.29e-20	5.68e-16	-0.59	-0.55	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-9.98	9.29e-20	5.68e-16	-0.59	-0.55	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-9.98	9.29e-20	5.68e-16	-0.59	-0.55	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
SARC	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	9.98	9.33e-20	5.7e-16	0.72	0.55	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	9.98	9.57e-20	5.84e-16	0.68	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	9.98	9.57e-20	5.84e-16	0.68	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-9.97	9.67e-20	5.91e-16	-0.67	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
SARC	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-9.97	9.9e-20	6.04e-16	-0.59	-0.55	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
SARC	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-9.97	1.02e-19	6.2e-16	-0.6	-0.55	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
SARC	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-9.97	1.02e-19	6.21e-16	-0.62	-0.55	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
SARC	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-9.97	1.02e-19	6.23e-16	-0.7	-0.55	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
SARC	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-9.97	1.02e-19	6.23e-16	-0.7	-0.55	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
SARC	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-9.97	1.03e-19	6.28e-16	-0.59	-0.55	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-9.97	1.03e-19	6.28e-16	-0.59	-0.55	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
SARC	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	9.97	1.03e-19	6.28e-16	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
SARC	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-9.96	1.04e-19	6.33e-16	-0.66	-0.55	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
SARC	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-9.96	1.05e-19	6.35e-16	-0.72	-0.55	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	9.96	1.06e-19	6.41e-16	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
SARC	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-9.96	1.06e-19	6.42e-16	-0.59	-0.55	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
SARC	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	9.96	1.09e-19	6.58e-16	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	9.96	1.09e-19	6.58e-16	0.82	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	9.96	1.09e-19	6.58e-16	0.82	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	9.96	1.1e-19	6.65e-16	0.68	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
SARC	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	9.96	1.1e-19	6.67e-16	0.68	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
SARC	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	9.95	1.11e-19	6.72e-16	0.59	0.55	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-9.95	1.12e-19	6.77e-16	-0.59	-0.55	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
SARC	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	9.95	1.14e-19	6.84e-16	0.7	0.55	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
SARC	cis	rs5760092	0.618	rs4461358	ENSG00000218537.1	MIF-AS1	-9.95	1.15e-19	6.91e-16	-0.72	-0.55	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23894426~23898930:-
SARC	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-9.95	1.15e-19	6.94e-16	-0.6	-0.55	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-9.95	1.16e-19	6.97e-16	-0.59	-0.55	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
SARC	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	9.95	1.16e-19	7e-16	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
SARC	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
SARC	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
SARC	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
SARC	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
SARC	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
SARC	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
SARC	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
SARC	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-9.94	1.2e-19	7.15e-16	-0.66	-0.55	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
SARC	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-9.94	1.22e-19	7.29e-16	-0.6	-0.55	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	9.94	1.23e-19	7.31e-16	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
SARC	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-9.94	1.25e-19	7.43e-16	-0.66	-0.55	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
SARC	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-9.94	1.25e-19	7.46e-16	-0.59	-0.55	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
SARC	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-9.94	1.25e-19	7.46e-16	-0.59	-0.55	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
SARC	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	9.93	1.28e-19	7.61e-16	0.62	0.55	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
SARC	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	9.93	1.32e-19	7.85e-16	0.7	0.55	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
SARC	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-9.93	1.33e-19	7.89e-16	-0.7	-0.55	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
SARC	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-9.93	1.33e-19	7.89e-16	-0.7	-0.55	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	9.93	1.35e-19	8.01e-16	0.68	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
SARC	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-9.92	1.38e-19	8.22e-16	-0.69	-0.55	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	9.92	1.39e-19	8.25e-16	0.66	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
SARC	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-9.92	1.41e-19	8.39e-16	-0.59	-0.54	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
SARC	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-9.92	1.42e-19	8.42e-16	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-9.92	1.45e-19	8.57e-16	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-9.92	1.45e-19	8.57e-16	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-9.92	1.45e-19	8.57e-16	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	9.92	1.45e-19	8.58e-16	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	9.92	1.45e-19	8.58e-16	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	9.92	1.45e-19	8.58e-16	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
SARC	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-9.91	1.47e-19	8.71e-16	-0.66	-0.54	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
SARC	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-9.91	1.5e-19	8.88e-16	-0.66	-0.54	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
SARC	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-9.91	1.51e-19	8.91e-16	-0.59	-0.54	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
SARC	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	9.91	1.56e-19	9.2e-16	0.71	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
SARC	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-9.91	1.56e-19	9.22e-16	-0.69	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
SARC	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-9.91	1.57e-19	9.26e-16	-0.64	-0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
SARC	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-9.9	1.62e-19	9.54e-16	-0.59	-0.54	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
SARC	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-9.9	1.62e-19	9.54e-16	-0.66	-0.54	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-9.9	1.62e-19	9.54e-16	-0.66	-0.54	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	9.9	1.63e-19	9.61e-16	0.65	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-9.89	1.71e-19	1e-15	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
SARC	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	9.89	1.77e-19	1.04e-15	0.7	0.54	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
SARC	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	9.89	1.81e-19	1.06e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	9.89	1.81e-19	1.06e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	9.89	1.81e-19	1.06e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-9.88	1.85e-19	1.08e-15	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-9.88	1.85e-19	1.08e-15	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
SARC	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-9.88	1.86e-19	1.09e-15	-0.67	-0.54	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
SARC	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	9.88	1.87e-19	1.09e-15	0.68	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	9.88	1.89e-19	1.1e-15	0.69	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
SARC	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	9.88	1.89e-19	1.11e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	9.87	1.99e-19	1.16e-15	0.65	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
SARC	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-9.87	2e-19	1.16e-15	-0.58	-0.54	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
SARC	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-9.87	2.03e-19	1.18e-15	-0.65	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
SARC	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	9.86	2.09e-19	1.21e-15	0.59	0.54	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
SARC	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-9.86	2.11e-19	1.23e-15	-0.65	-0.54	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
SARC	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	9.86	2.13e-19	1.23e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-9.86	2.15e-19	1.25e-15	-0.7	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
SARC	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-9.86	2.19e-19	1.27e-15	-0.58	-0.54	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
SARC	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	9.86	2.19e-19	1.27e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
SARC	cis	rs6003958	1	rs6003958	ENSG00000273295.1	AP000350.5	-9.86	2.2e-19	1.28e-15	-0.67	-0.54	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23901432~23907068:-
SARC	cis	rs5760092	0.755	rs6003959	ENSG00000273295.1	AP000350.5	-9.86	2.2e-19	1.28e-15	-0.67	-0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23901432~23907068:-
SARC	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	9.86	2.21e-19	1.28e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
SARC	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-9.86	2.21e-19	1.28e-15	-0.75	-0.54	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
SARC	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	9.86	2.24e-19	1.29e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
SARC	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-9.85	2.31e-19	1.34e-15	-0.59	-0.54	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-9.85	2.31e-19	1.34e-15	-0.59	-0.54	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
SARC	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-9.85	2.34e-19	1.35e-15	-0.7	-0.54	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
SARC	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-9.85	2.35e-19	1.35e-15	-0.59	-0.54	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-9.85	2.35e-19	1.35e-15	-0.59	-0.54	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-9.85	2.35e-19	1.35e-15	-0.59	-0.54	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-9.85	2.35e-19	1.35e-15	-0.59	-0.54	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-9.85	2.35e-19	1.35e-15	-0.59	-0.54	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-9.85	2.35e-19	1.35e-15	-0.59	-0.54	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-9.85	2.35e-19	1.35e-15	-0.59	-0.54	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
SARC	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	9.85	2.35e-19	1.35e-15	0.59	0.54	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
SARC	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	9.85	2.36e-19	1.36e-15	0.71	0.54	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
SARC	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	9.85	2.4e-19	1.38e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	9.85	2.4e-19	1.38e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
SARC	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-9.84	2.44e-19	1.4e-15	-0.66	-0.54	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-9.84	2.44e-19	1.4e-15	-0.66	-0.54	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
SARC	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-9.84	2.46e-19	1.41e-15	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-9.84	2.46e-19	1.41e-15	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-9.84	2.46e-19	1.41e-15	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	9.84	2.47e-19	1.42e-15	0.57	0.54	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	9.84	2.49e-19	1.43e-15	0.66	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	9.84	2.49e-19	1.43e-15	0.66	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
SARC	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-9.84	2.51e-19	1.44e-15	-0.59	-0.54	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-9.84	2.51e-19	1.44e-15	-0.59	-0.54	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
SARC	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-9.84	2.51e-19	1.44e-15	-0.59	-0.54	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-9.84	2.51e-19	1.44e-15	-0.59	-0.54	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-9.84	2.51e-19	1.44e-15	-0.59	-0.54	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-9.84	2.51e-19	1.44e-15	-0.59	-0.54	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-9.84	2.51e-19	1.44e-15	-0.59	-0.54	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-9.84	2.51e-19	1.44e-15	-0.59	-0.54	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-9.84	2.51e-19	1.44e-15	-0.59	-0.54	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-9.84	2.51e-19	1.44e-15	-0.59	-0.54	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
SARC	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-9.84	2.53e-19	1.45e-15	-0.66	-0.54	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	9.84	2.54e-19	1.46e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
SARC	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-9.83	2.65e-19	1.52e-15	-0.62	-0.54	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
SARC	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-9.83	2.69e-19	1.54e-15	-0.59	-0.54	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-9.83	2.69e-19	1.54e-15	-0.59	-0.54	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
SARC	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-9.83	2.75e-19	1.57e-15	-0.66	-0.54	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
SARC	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-9.83	2.75e-19	1.57e-15	-0.59	-0.54	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
SARC	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-9.82	2.77e-19	1.58e-15	-0.62	-0.54	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
SARC	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	9.82	2.79e-19	1.58e-15	0.7	0.54	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
SARC	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
SARC	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
SARC	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
SARC	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
SARC	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
SARC	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
SARC	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
SARC	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
SARC	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
SARC	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
SARC	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
SARC	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
SARC	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
SARC	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-9.82	2.79e-19	1.58e-15	-0.66	-0.54	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
SARC	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-9.82	2.8e-19	1.58e-15	-0.69	-0.54	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
SARC	cis	rs5760092	0.627	rs6519489	ENSG00000273295.1	AP000350.5	-9.82	2.87e-19	1.62e-15	-0.67	-0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23901432~23907068:-
SARC	cis	rs5760092	0.755	rs11090298	ENSG00000273295.1	AP000350.5	-9.82	2.87e-19	1.62e-15	-0.67	-0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23901432~23907068:-
SARC	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	9.82	2.88e-19	1.63e-15	0.68	0.54	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
SARC	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	9.82	2.88e-19	1.63e-15	0.68	0.54	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
SARC	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	9.82	2.9e-19	1.64e-15	0.73	0.54	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	9.81	2.99e-19	1.69e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	9.81	2.99e-19	1.69e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	9.81	2.99e-19	1.69e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	9.81	2.99e-19	1.69e-15	0.67	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
SARC	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	9.81	3.18e-19	1.79e-15	0.62	0.54	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
SARC	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-9.8	3.28e-19	1.84e-15	-0.68	-0.54	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
SARC	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-9.8	3.31e-19	1.86e-15	-0.64	-0.54	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
SARC	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	9.79	3.48e-19	1.95e-15	0.58	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
SARC	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-9.79	3.48e-19	1.95e-15	-0.65	-0.54	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-9.79	3.49e-19	1.96e-15	-0.66	-0.54	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
SARC	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	9.79	3.53e-19	1.98e-15	0.7	0.54	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-9.79	3.59e-19	2.01e-15	-0.58	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
SARC	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-9.78	3.81e-19	2.13e-15	-0.66	-0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
SARC	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-9.78	3.87e-19	2.16e-15	-0.58	-0.54	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
SARC	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-9.78	3.87e-19	2.16e-15	-0.58	-0.54	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
SARC	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-9.77	4.03e-19	2.25e-15	-0.7	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
SARC	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	9.77	4.09e-19	2.28e-15	0.94	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
SARC	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-9.77	4.13e-19	2.3e-15	-0.62	-0.54	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
SARC	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-9.77	4.15e-19	2.31e-15	-0.61	-0.54	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
SARC	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	9.76	4.23e-19	2.35e-15	0.66	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
SARC	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-9.76	4.25e-19	2.36e-15	-0.58	-0.54	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
SARC	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-9.76	4.26e-19	2.36e-15	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	9.76	4.34e-19	2.41e-15	0.58	0.54	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
SARC	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-9.76	4.47e-19	2.47e-15	-0.63	-0.54	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
SARC	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-9.76	4.51e-19	2.5e-15	-0.69	-0.54	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	9.75	4.58e-19	2.53e-15	0.58	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
SARC	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-9.75	4.66e-19	2.57e-15	-0.71	-0.54	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
SARC	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	9.75	4.81e-19	2.66e-15	0.59	0.54	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
SARC	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	9.73	5.38e-19	2.96e-15	0.68	0.54	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
SARC	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	9.73	5.5e-19	3.03e-15	0.63	0.54	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
SARC	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-9.73	5.56e-19	3.06e-15	-0.69	-0.54	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
SARC	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	9.71	5.99e-19	3.29e-15	0.7	0.54	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
SARC	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-9.71	6.02e-19	3.31e-15	-0.56	-0.54	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
SARC	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-9.71	6.1e-19	3.35e-15	-0.65	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
SARC	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-9.71	6.17e-19	3.38e-15	-0.54	-0.54	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
SARC	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	9.7	6.72e-19	3.68e-15	0.58	0.54	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
SARC	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	9.7	6.85e-19	3.74e-15	0.65	0.54	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-9.69	6.94e-19	3.79e-15	-0.65	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
SARC	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-9.69	6.94e-19	3.79e-15	-0.58	-0.54	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
SARC	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	9.69	7.34e-19	4e-15	0.57	0.54	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
SARC	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	9.68	7.41e-19	4.03e-15	0.63	0.54	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
SARC	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	9.68	7.5e-19	4.08e-15	0.56	0.54	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	9.68	7.82e-19	4.25e-15	0.65	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	9.66	8.53e-19	4.59e-15	0.64	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
SARC	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	9.66	8.65e-19	4.66e-15	0.68	0.53	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
SARC	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	9.66	8.8e-19	4.74e-15	0.66	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
SARC	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-9.65	9.11e-19	4.9e-15	-0.71	-0.53	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
SARC	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-9.65	9.26e-19	4.98e-15	-0.62	-0.53	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-9.65	9.26e-19	4.98e-15	-0.62	-0.53	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-9.65	9.31e-19	5e-15	-0.6	-0.53	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
SARC	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-9.65	9.33e-19	5.01e-15	-0.69	-0.53	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
SARC	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-9.65	9.33e-19	5.01e-15	-0.69	-0.53	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
SARC	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	9.65	9.74e-19	5.22e-15	0.68	0.53	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
SARC	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-9.64	9.9e-19	5.3e-15	-0.62	-0.53	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
SARC	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	9.64	9.96e-19	5.33e-15	0.66	0.53	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
SARC	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	9.63	1.06e-18	5.67e-15	0.67	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
SARC	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	9.63	1.06e-18	5.67e-15	0.66	0.53	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
SARC	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	9.63	1.07e-18	5.69e-15	0.58	0.53	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
SARC	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	9.63	1.07e-18	5.73e-15	0.66	0.53	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
SARC	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	9.63	1.12e-18	5.96e-15	0.77	0.53	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
SARC	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	9.62	1.13e-18	6.04e-15	0.65	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
SARC	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	9.62	1.14e-18	6.07e-15	0.59	0.53	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
SARC	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-9.62	1.19e-18	6.3e-15	-0.58	-0.53	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
SARC	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-9.62	1.2e-18	6.34e-15	-0.59	-0.53	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
SARC	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-9.61	1.21e-18	6.42e-15	-0.69	-0.53	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
SARC	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-9.61	1.22e-18	6.44e-15	-0.58	-0.53	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
SARC	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	9.61	1.23e-18	6.5e-15	0.65	0.53	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	9.61	1.25e-18	6.59e-15	0.67	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
SARC	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	9.6	1.33e-18	6.98e-15	0.58	0.53	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
SARC	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-9.6	1.38e-18	7.25e-15	-0.62	-0.53	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
SARC	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-9.6	1.38e-18	7.25e-15	-0.56	-0.53	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
SARC	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	9.59	1.4e-18	7.33e-15	0.67	0.53	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	9.59	1.4e-18	7.33e-15	0.67	0.53	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
SARC	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-9.59	1.45e-18	7.59e-15	-0.57	-0.53	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
SARC	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-9.59	1.48e-18	7.75e-15	-0.58	-0.53	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
SARC	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-9.58	1.53e-18	8.01e-15	-0.56	-0.53	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-9.58	1.53e-18	8.01e-15	-0.56	-0.53	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
SARC	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-9.58	1.55e-18	8.12e-15	-0.7	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
SARC	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-9.58	1.56e-18	8.18e-15	-0.69	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
SARC	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	9.58	1.57e-18	8.24e-15	0.67	0.53	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
SARC	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-9.57	1.62e-18	8.47e-15	-0.62	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
SARC	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	9.57	1.62e-18	8.48e-15	0.63	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
SARC	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-9.57	1.66e-18	8.65e-15	-0.62	-0.53	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
SARC	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-9.57	1.68e-18	8.76e-15	-0.56	-0.53	Temperament;	chr17:14007232	chr17:14024514~14025488:+
SARC	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	9.57	1.69e-18	8.79e-15	0.66	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
SARC	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-9.57	1.7e-18	8.86e-15	-0.62	-0.53	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
SARC	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	9.56	1.73e-18	9e-15	0.95	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
SARC	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	9.56	1.76e-18	9.17e-15	0.55	0.53	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
SARC	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-9.56	1.78e-18	9.28e-15	-0.63	-0.53	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
SARC	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-9.56	1.79e-18	9.33e-15	-0.58	-0.53	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
SARC	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	9.56	1.8e-18	9.35e-15	0.66	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
SARC	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	9.56	1.81e-18	9.42e-15	0.63	0.53	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	9.56	1.81e-18	9.42e-15	0.63	0.53	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
SARC	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-9.56	1.81e-18	9.44e-15	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	9.56	1.82e-18	9.45e-15	0.56	0.53	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
SARC	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	9.55	1.82e-18	9.48e-15	0.61	0.53	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
SARC	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-9.55	1.92e-18	9.96e-15	-0.58	-0.53	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
SARC	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-9.54	1.96e-18	1.02e-14	-0.64	-0.53	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
SARC	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-9.54	2.04e-18	1.05e-14	-0.78	-0.53	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
SARC	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	9.53	2.11e-18	1.09e-14	0.57	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
SARC	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-9.53	2.17e-18	1.12e-14	-0.56	-0.53	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
SARC	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	9.53	2.23e-18	1.15e-14	0.66	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
SARC	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-9.51	2.41e-18	1.24e-14	-0.56	-0.53	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-9.51	2.41e-18	1.24e-14	-0.56	-0.53	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
SARC	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-9.5	2.58e-18	1.32e-14	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-9.5	2.58e-18	1.32e-14	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-9.5	2.58e-18	1.32e-14	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-9.5	2.58e-18	1.32e-14	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
SARC	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	9.5	2.61e-18	1.34e-14	0.66	0.53	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
SARC	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-9.5	2.66e-18	1.36e-14	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-9.5	2.66e-18	1.36e-14	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-9.5	2.67e-18	1.37e-14	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-9.5	2.67e-18	1.37e-14	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-9.5	2.67e-18	1.37e-14	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-9.5	2.67e-18	1.37e-14	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
SARC	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	9.5	2.68e-18	1.37e-14	0.62	0.53	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	9.5	2.68e-18	1.37e-14	0.62	0.53	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
SARC	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	9.5	2.7e-18	1.38e-14	0.67	0.53	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
SARC	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-9.5	2.7e-18	1.38e-14	-0.63	-0.53	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
SARC	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	9.5	2.71e-18	1.38e-14	0.62	0.53	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	9.5	2.71e-18	1.38e-14	0.62	0.53	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
SARC	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-9.49	2.82e-18	1.43e-14	-0.61	-0.53	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
SARC	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-9.48	3.03e-18	1.53e-14	-0.65	-0.53	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-9.48	3.03e-18	1.53e-14	-0.65	-0.53	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
SARC	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-9.48	3.16e-18	1.6e-14	-0.56	-0.53	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
SARC	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-9.47	3.19e-18	1.61e-14	-0.72	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
SARC	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-9.47	3.25e-18	1.64e-14	-0.63	-0.53	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
SARC	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	9.47	3.27e-18	1.65e-14	0.57	0.53	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
SARC	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	9.47	3.28e-18	1.65e-14	0.67	0.53	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
SARC	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-9.47	3.32e-18	1.67e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
SARC	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-9.47	3.33e-18	1.68e-14	-0.6	-0.53	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
SARC	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-9.47	3.39e-18	1.71e-14	-0.67	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
SARC	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-9.46	3.42e-18	1.72e-14	-0.61	-0.53	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
SARC	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	9.46	3.55e-18	1.79e-14	0.56	0.53	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
SARC	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-9.46	3.57e-18	1.8e-14	-0.6	-0.53	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
SARC	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	9.45	3.75e-18	1.89e-14	0.55	0.53	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-9.45	3.79e-18	1.9e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-9.45	3.79e-18	1.9e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-9.45	3.79e-18	1.9e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-9.45	3.79e-18	1.9e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-9.45	3.79e-18	1.9e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-9.45	3.79e-18	1.9e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-9.45	3.79e-18	1.9e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-9.45	3.79e-18	1.9e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-9.45	3.79e-18	1.9e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-9.45	3.79e-18	1.9e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	9.45	3.82e-18	1.92e-14	0.55	0.53	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
SARC	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	9.45	3.86e-18	1.93e-14	0.68	0.53	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
SARC	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	9.45	3.9e-18	1.95e-14	0.55	0.53	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
SARC	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	9.44	3.9e-18	1.95e-14	0.66	0.53	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
SARC	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	9.44	4.04e-18	2.02e-14	0.58	0.53	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
SARC	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-9.44	4.04e-18	2.02e-14	-0.56	-0.53	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
SARC	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-9.44	4.05e-18	2.03e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
SARC	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	9.44	4.06e-18	2.03e-14	0.61	0.53	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
SARC	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	9.43	4.21e-18	2.11e-14	0.55	0.53	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
SARC	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	9.43	4.23e-18	2.12e-14	0.9	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
SARC	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-9.43	4.44e-18	2.22e-14	-0.57	-0.53	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
SARC	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-9.42	4.5e-18	2.24e-14	-0.62	-0.53	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	9.42	4.5e-18	2.24e-14	0.62	0.53	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
SARC	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-9.42	4.55e-18	2.27e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-9.42	4.55e-18	2.27e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
SARC	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	9.42	4.62e-18	2.3e-14	0.6	0.53	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
SARC	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-9.42	4.64e-18	2.31e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-9.42	4.64e-18	2.31e-14	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
SARC	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-9.42	4.68e-18	2.33e-14	-0.56	-0.53	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-9.42	4.77e-18	2.37e-14	-0.57	-0.53	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
SARC	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-9.41	4.91e-18	2.44e-14	-0.55	-0.52	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-9.41	4.91e-18	2.44e-14	-0.55	-0.52	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-9.41	4.91e-18	2.44e-14	-0.55	-0.52	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
SARC	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	9.41	4.92e-18	2.44e-14	0.64	0.52	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	9.41	4.92e-18	2.44e-14	0.64	0.52	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	9.41	4.92e-18	2.44e-14	0.64	0.52	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	9.41	4.92e-18	2.44e-14	0.64	0.52	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	9.41	4.92e-18	2.44e-14	0.64	0.52	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	9.41	4.92e-18	2.44e-14	0.64	0.52	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
SARC	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	9.41	4.93e-18	2.44e-14	0.55	0.52	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
SARC	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	9.41	4.93e-18	2.45e-14	0.74	0.52	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
SARC	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	9.41	4.97e-18	2.47e-14	0.59	0.52	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
SARC	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-9.41	5.01e-18	2.48e-14	-0.57	-0.52	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
SARC	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-9.41	5.02e-18	2.49e-14	-0.55	-0.52	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-9.41	5.02e-18	2.49e-14	-0.55	-0.52	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-9.41	5.02e-18	2.49e-14	-0.55	-0.52	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-9.41	5.02e-18	2.49e-14	-0.55	-0.52	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-9.4	5.21e-18	2.58e-14	-0.55	-0.52	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-9.4	5.21e-18	2.58e-14	-0.55	-0.52	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
SARC	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	9.4	5.22e-18	2.58e-14	0.64	0.52	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	9.4	5.22e-18	2.58e-14	0.64	0.52	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
SARC	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	9.4	5.24e-18	2.59e-14	0.54	0.52	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
SARC	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	9.4	5.32e-18	2.62e-14	0.88	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	9.4	5.32e-18	2.62e-14	0.88	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	9.4	5.32e-18	2.62e-14	0.88	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	9.4	5.32e-18	2.62e-14	0.88	0.52	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	9.4	5.32e-18	2.62e-14	0.88	0.52	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	9.4	5.32e-18	2.62e-14	0.88	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	9.4	5.32e-18	2.62e-14	0.88	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	9.4	5.32e-18	2.62e-14	0.88	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
SARC	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	9.4	5.36e-18	2.64e-14	0.64	0.52	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
SARC	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	9.4	5.41e-18	2.66e-14	0.55	0.52	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
SARC	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	9.4	5.43e-18	2.68e-14	0.56	0.52	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
SARC	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-9.4	5.5e-18	2.71e-14	-0.55	-0.52	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
SARC	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	9.39	5.57e-18	2.74e-14	0.66	0.52	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
SARC	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	9.39	5.58e-18	2.75e-14	0.58	0.52	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
SARC	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	9.39	5.71e-18	2.8e-14	0.57	0.52	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
SARC	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	9.39	5.75e-18	2.82e-14	0.65	0.52	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	9.39	5.75e-18	2.82e-14	0.65	0.52	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	9.39	5.75e-18	2.82e-14	0.65	0.52	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
SARC	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	9.39	5.75e-18	2.82e-14	0.64	0.52	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
SARC	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	9.39	5.76e-18	2.82e-14	0.55	0.52	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	9.39	5.76e-18	2.82e-14	0.55	0.52	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
SARC	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-9.39	5.87e-18	2.87e-14	-0.64	-0.52	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
SARC	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	9.39	5.89e-18	2.88e-14	0.66	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
SARC	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-9.38	5.93e-18	2.9e-14	-0.57	-0.52	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-9.38	5.93e-18	2.9e-14	-0.57	-0.52	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
SARC	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	9.38	6.01e-18	2.94e-14	0.57	0.52	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
SARC	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	9.38	6.03e-18	2.95e-14	0.9	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
SARC	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	9.38	6.09e-18	2.98e-14	0.55	0.52	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
SARC	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-9.38	6.09e-18	2.98e-14	-0.55	-0.52	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
SARC	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	9.38	6.24e-18	3.05e-14	0.65	0.52	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
SARC	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	9.38	6.32e-18	3.08e-14	0.74	0.52	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
SARC	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-9.37	6.36e-18	3.11e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-9.37	6.42e-18	3.13e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
SARC	cis	rs875971	0.867	rs13227219	ENSG00000226824.5	RP4-756H11.3	-9.37	6.45e-18	3.15e-14	-0.64	-0.52	Aortic root size;	chr7:66379075	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	9.37	6.47e-18	3.15e-14	0.65	0.52	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
SARC	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	9.37	6.5e-18	3.17e-14	0.58	0.52	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
SARC	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	9.37	6.57e-18	3.2e-14	0.88	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	9.37	6.57e-18	3.2e-14	0.88	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	9.37	6.57e-18	3.2e-14	0.88	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	9.37	6.57e-18	3.2e-14	0.88	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
SARC	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-9.36	6.85e-18	3.33e-14	-0.59	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
SARC	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-9.36	6.92e-18	3.37e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
SARC	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	9.36	7.01e-18	3.41e-14	0.55	0.52	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
SARC	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-9.36	7.07e-18	3.43e-14	-0.64	-0.52	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-9.36	7.07e-18	3.43e-14	-0.64	-0.52	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	9.36	7.24e-18	3.51e-14	0.87	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
SARC	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	9.35	7.28e-18	3.53e-14	0.55	0.52	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
SARC	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	9.35	7.45e-18	3.61e-14	0.56	0.52	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	9.35	7.45e-18	3.61e-14	0.56	0.52	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	9.35	7.45e-18	3.61e-14	0.56	0.52	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	9.35	7.45e-18	3.61e-14	0.56	0.52	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
SARC	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	9.35	7.56e-18	3.66e-14	0.55	0.52	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	9.35	7.62e-18	3.69e-14	0.54	0.52	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
SARC	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-9.35	7.75e-18	3.75e-14	-0.61	-0.52	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
SARC	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	9.34	7.81e-18	3.78e-14	0.64	0.52	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	9.34	7.92e-18	3.83e-14	0.66	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
SARC	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-9.34	8.26e-18	3.97e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
SARC	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-9.33	8.8e-18	4.22e-14	-0.46	-0.52	Breast cancer;	chr11:743813	chr11:779617~780755:+
SARC	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	9.32	8.91e-18	4.27e-14	0.67	0.52	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	9.32	8.91e-18	4.27e-14	0.67	0.52	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
SARC	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	9.32	9.26e-18	4.43e-14	0.57	0.52	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
SARC	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-9.32	9.31e-18	4.45e-14	-0.65	-0.52	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-9.32	9.31e-18	4.45e-14	-0.65	-0.52	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
SARC	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-9.32	9.32e-18	4.46e-14	-0.67	-0.52	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
SARC	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-9.32	9.38e-18	4.48e-14	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-9.31	9.58e-18	4.58e-14	-0.57	-0.52	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-9.31	9.58e-18	4.58e-14	-0.57	-0.52	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-9.31	9.58e-18	4.58e-14	-0.57	-0.52	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
SARC	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	9.31	9.6e-18	4.59e-14	0.63	0.52	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
SARC	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	9.31	9.79e-18	4.67e-14	0.63	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
SARC	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	9.31	9.82e-18	4.68e-14	0.58	0.52	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
SARC	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	9.31	9.83e-18	4.69e-14	0.56	0.52	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
SARC	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-9.31	1.01e-17	4.81e-14	-0.65	-0.52	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
SARC	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	9.3	1.02e-17	4.88e-14	0.61	0.52	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
SARC	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.09e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.1e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-9.3	1.08e-17	5.1e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
SARC	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	9.29	1.11e-17	5.26e-14	0.66	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
SARC	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-9.29	1.14e-17	5.37e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-9.29	1.14e-17	5.37e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-9.29	1.14e-17	5.37e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	9.29	1.15e-17	5.42e-14	0.55	0.52	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
SARC	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	9.29	1.15e-17	5.43e-14	0.66	0.52	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
SARC	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-9.29	1.16e-17	5.46e-14	-0.57	-0.52	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
SARC	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-9.28	1.18e-17	5.55e-14	-0.58	-0.52	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
SARC	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-9.28	1.24e-17	5.81e-14	-0.57	-0.52	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
SARC	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	9.28	1.24e-17	5.84e-14	0.67	0.52	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
SARC	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	9.28	1.24e-17	5.84e-14	0.67	0.52	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
SARC	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-9.28	1.25e-17	5.86e-14	-0.6	-0.52	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-9.28	1.25e-17	5.86e-14	-0.6	-0.52	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-9.28	1.25e-17	5.86e-14	-0.6	-0.52	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
SARC	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-9.27	1.29e-17	6.02e-14	-0.57	-0.52	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-9.27	1.29e-17	6.02e-14	-0.57	-0.52	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-9.27	1.32e-17	6.19e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
SARC	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	9.26	1.36e-17	6.34e-14	0.61	0.52	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
SARC	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	9.26	1.38e-17	6.42e-14	0.63	0.52	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
SARC	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	9.26	1.41e-17	6.56e-14	0.73	0.52	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
SARC	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	9.25	1.45e-17	6.74e-14	0.62	0.52	Depression;	chr6:28314871	chr6:28176188~28176674:+
SARC	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-9.25	1.48e-17	6.88e-14	-0.61	-0.52	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
SARC	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-9.25	1.5e-17	6.96e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
SARC	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-9.25	1.51e-17	7.01e-14	-0.56	-0.52	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
SARC	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	9.25	1.52e-17	7.06e-14	0.57	0.52	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	9.25	1.53e-17	7.13e-14	0.57	0.52	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
SARC	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	9.24	1.58e-17	7.34e-14	0.66	0.52	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
SARC	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	9.24	1.58e-17	7.34e-14	0.66	0.52	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
SARC	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-9.24	1.59e-17	7.38e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
SARC	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	9.24	1.6e-17	7.44e-14	0.6	0.52	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
SARC	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	9.23	1.66e-17	7.64e-14	0.66	0.52	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
SARC	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-9.23	1.73e-17	7.97e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
SARC	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-9.23	1.75e-17	8.03e-14	-0.51	-0.52	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
SARC	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	9.23	1.75e-17	8.05e-14	0.62	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
SARC	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-9.22	1.79e-17	8.2e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-9.22	1.79e-17	8.2e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-9.22	1.79e-17	8.2e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-9.22	1.79e-17	8.2e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-9.22	1.79e-17	8.2e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-9.22	1.79e-17	8.2e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
SARC	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	9.22	1.83e-17	8.37e-14	0.61	0.52	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
SARC	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-9.22	1.83e-17	8.38e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-9.22	1.83e-17	8.38e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-9.22	1.83e-17	8.38e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-9.22	1.83e-17	8.38e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
SARC	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	9.22	1.84e-17	8.42e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	9.22	1.84e-17	8.42e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	9.22	1.87e-17	8.53e-14	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
SARC	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-9.21	1.89e-17	8.62e-14	-0.64	-0.52	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-9.21	1.89e-17	8.62e-14	-0.64	-0.52	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
SARC	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	9.21	1.91e-17	8.69e-14	0.91	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
SARC	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-9.21	1.92e-17	8.69e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-9.21	1.92e-17	8.69e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-9.21	1.92e-17	8.69e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-9.21	1.92e-17	8.69e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-9.21	1.92e-17	8.69e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-9.21	1.92e-17	8.69e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-9.21	1.92e-17	8.69e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-9.21	1.92e-17	8.69e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-9.21	1.92e-17	8.69e-14	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-9.21	1.92e-17	8.73e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
SARC	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	9.21	1.95e-17	8.84e-14	0.59	0.52	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
SARC	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-9.21	1.95e-17	8.84e-14	-0.56	-0.52	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
SARC	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-9.21	1.99e-17	9e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
SARC	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	9.21	2.01e-17	9.09e-14	0.65	0.52	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
SARC	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	9.21	2.02e-17	9.14e-14	0.64	0.52	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	9.21	2.02e-17	9.15e-14	0.64	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
SARC	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-9.2	2.05e-17	9.25e-14	-0.59	-0.52	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
SARC	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	9.2	2.06e-17	9.32e-14	0.9	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
SARC	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	9.2	2.14e-17	9.66e-14	0.66	0.52	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	9.2	2.15e-17	9.71e-14	0.63	0.52	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
SARC	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-9.19	2.2e-17	9.92e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-9.19	2.2e-17	9.92e-14	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-9.19	2.24e-17	1.01e-13	-0.56	-0.52	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-9.19	2.24e-17	1.01e-13	-0.56	-0.52	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	9.19	2.26e-17	1.02e-13	0.55	0.52	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
SARC	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	9.19	2.26e-17	1.02e-13	0.63	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
SARC	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-9.19	2.29e-17	1.03e-13	-0.56	-0.52	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
SARC	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	9.19	2.3e-17	1.03e-13	0.72	0.52	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
SARC	cis	rs9326248	0.559	rs609177	ENSG00000254851.1	RP11-109L13.1	-9.19	2.3e-17	1.03e-13	-0.6	-0.52	Blood protein levels;	chr11:116899801	chr11:117135528~117138582:+
SARC	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	9.18	2.34e-17	1.05e-13	0.64	0.52	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
SARC	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	9.18	2.39e-17	1.07e-13	0.55	0.52	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
SARC	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	9.18	2.41e-17	1.08e-13	0.6	0.52	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	9.18	2.41e-17	1.08e-13	0.6	0.52	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	9.18	2.41e-17	1.08e-13	0.6	0.52	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
SARC	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-9.17	2.53e-17	1.13e-13	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-9.17	2.53e-17	1.13e-13	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-9.17	2.54e-17	1.13e-13	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	9.17	2.54e-17	1.13e-13	0.63	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	9.17	2.6e-17	1.16e-13	0.64	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
SARC	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	9.17	2.61e-17	1.17e-13	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
SARC	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	9.17	2.66e-17	1.19e-13	0.56	0.51	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
SARC	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	9.16	2.68e-17	1.19e-13	0.55	0.51	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
SARC	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-9.16	2.68e-17	1.2e-13	-0.65	-0.51	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
SARC	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-9.16	2.69e-17	1.2e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-9.16	2.69e-17	1.2e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-9.16	2.69e-17	1.2e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-9.16	2.69e-17	1.2e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-9.16	2.69e-17	1.2e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-9.16	2.69e-17	1.2e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-9.16	2.69e-17	1.2e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-9.16	2.69e-17	1.2e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-9.16	2.69e-17	1.2e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-9.16	2.69e-17	1.2e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-9.16	2.74e-17	1.22e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
SARC	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-9.16	2.78e-17	1.23e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
SARC	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-9.16	2.79e-17	1.24e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
SARC	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	9.16	2.82e-17	1.25e-13	0.73	0.51	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
SARC	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-9.16	2.82e-17	1.25e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
SARC	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-9.15	2.85e-17	1.26e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
SARC	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-9.15	2.85e-17	1.26e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
SARC	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-9.15	2.85e-17	1.26e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
SARC	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	9.15	2.88e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	9.15	2.88e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	9.15	2.88e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	9.15	2.88e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	9.15	2.88e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	9.15	2.88e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	9.15	2.88e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	9.15	2.88e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	9.15	2.88e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	9.15	2.88e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	9.15	2.88e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	9.15	2.88e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
SARC	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	9.15	2.88e-17	1.27e-13	0.61	0.51	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
SARC	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	9.15	2.89e-17	1.27e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
SARC	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	9.15	2.9e-17	1.28e-13	0.64	0.51	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
SARC	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-9.15	2.94e-17	1.3e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-9.15	2.94e-17	1.3e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-9.15	2.94e-17	1.3e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-9.15	2.95e-17	1.3e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
SARC	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	9.15	2.95e-17	1.3e-13	0.64	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
SARC	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-9.14	3.08e-17	1.35e-13	-0.55	-0.51	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
SARC	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	9.14	3.09e-17	1.36e-13	0.56	0.51	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
SARC	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	9.14	3.12e-17	1.37e-13	0.73	0.51	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
SARC	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-9.14	3.14e-17	1.37e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
SARC	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-9.14	3.14e-17	1.37e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
SARC	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-9.14	3.14e-17	1.37e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
SARC	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-9.14	3.14e-17	1.37e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
SARC	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-9.14	3.14e-17	1.37e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
SARC	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-9.14	3.14e-17	1.37e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
SARC	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-9.14	3.14e-17	1.37e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
SARC	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-9.14	3.14e-17	1.37e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
SARC	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-9.14	3.14e-17	1.37e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
SARC	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-9.14	3.14e-17	1.37e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
SARC	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-9.14	3.14e-17	1.37e-13	-0.51	-0.51	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
SARC	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-9.14	3.14e-17	1.37e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
SARC	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	9.14	3.19e-17	1.4e-13	0.54	0.51	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
SARC	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-9.14	3.26e-17	1.42e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-9.13	3.32e-17	1.45e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
SARC	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	9.13	3.37e-17	1.47e-13	0.64	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
SARC	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	9.13	3.42e-17	1.49e-13	0.63	0.51	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-9.13	3.44e-17	1.5e-13	-0.64	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
SARC	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	9.13	3.48e-17	1.52e-13	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
SARC	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	9.12	3.53e-17	1.54e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	9.12	3.53e-17	1.54e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
SARC	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-9.12	3.56e-17	1.55e-13	-0.54	-0.51	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
SARC	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-9.12	3.61e-17	1.57e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-9.12	3.61e-17	1.57e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
SARC	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	9.12	3.63e-17	1.57e-13	0.63	0.51	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
SARC	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-9.12	3.69e-17	1.6e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-9.12	3.74e-17	1.62e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-9.12	3.74e-17	1.62e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-9.12	3.74e-17	1.62e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
SARC	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	9.11	3.77e-17	1.63e-13	0.72	0.51	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
SARC	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	9.11	3.77e-17	1.63e-13	0.72	0.51	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
SARC	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	9.11	3.77e-17	1.63e-13	0.72	0.51	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
SARC	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-9.11	3.8e-17	1.65e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-9.11	3.8e-17	1.65e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-9.11	3.8e-17	1.65e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-9.11	3.85e-17	1.67e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
SARC	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-9.11	3.86e-17	1.67e-13	-0.61	-0.51	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
SARC	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-9.11	3.87e-17	1.67e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-9.11	3.87e-17	1.67e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
SARC	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-9.11	3.94e-17	1.7e-13	-0.65	-0.51	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-9.11	3.94e-17	1.7e-13	-0.65	-0.51	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
SARC	cis	rs6964833	0.935	rs7795281	ENSG00000277053.3	GTF2IP1	-9.11	3.95e-17	1.7e-13	-0.6	-0.51	Menarche (age at onset);	chr7:74708523	chr7:75185385~75237696:-
SARC	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	9.1	4.05e-17	1.74e-13	0.63	0.51	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
SARC	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-9.1	4.13e-17	1.77e-13	-0.5	-0.51	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
SARC	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-9.1	4.13e-17	1.77e-13	-0.5	-0.51	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
SARC	cis	rs9326248	0.539	rs518181	ENSG00000254851.1	RP11-109L13.1	-9.1	4.14e-17	1.78e-13	-0.6	-0.51	Blood protein levels;	chr11:116902071	chr11:117135528~117138582:+
SARC	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	9.1	4.15e-17	1.78e-13	0.63	0.51	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	9.1	4.19e-17	1.8e-13	0.63	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
SARC	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	9.1	4.29e-17	1.84e-13	0.63	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
SARC	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	9.09	4.31e-17	1.85e-13	0.63	0.51	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
SARC	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-9.09	4.34e-17	1.86e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
SARC	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-9.09	4.35e-17	1.87e-13	-0.63	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
SARC	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-9.09	4.36e-17	1.87e-13	-0.64	-0.51	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
SARC	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-9.09	4.48e-17	1.92e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	9.08	4.59e-17	1.97e-13	0.63	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
SARC	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	9.08	4.59e-17	1.97e-13	0.65	0.51	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
SARC	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	9.08	4.6e-17	1.97e-13	0.62	0.51	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
SARC	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	9.08	4.61e-17	1.97e-13	0.62	0.51	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
SARC	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-9.08	4.7e-17	2.01e-13	-0.6	-0.51	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
SARC	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	9.08	4.76e-17	2.03e-13	0.71	0.51	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
SARC	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	9.08	4.81e-17	2.05e-13	0.56	0.51	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
SARC	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	9.08	4.81e-17	2.05e-13	0.56	0.51	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
SARC	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-9.07	4.91e-17	2.1e-13	-0.65	-0.51	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
SARC	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	9.07	4.94e-17	2.11e-13	0.62	0.51	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	9.07	4.94e-17	2.11e-13	0.62	0.51	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
SARC	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	9.07	4.96e-17	2.11e-13	0.53	0.51	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
SARC	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	9.07	4.96e-17	2.11e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	9.07	4.96e-17	2.11e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	9.07	4.96e-17	2.11e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	9.07	4.96e-17	2.11e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	9.07	4.96e-17	2.11e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	9.07	4.96e-17	2.11e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	9.07	4.96e-17	2.11e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	9.07	4.96e-17	2.11e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	9.07	4.96e-17	2.11e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
SARC	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	9.07	5.03e-17	2.14e-13	0.57	0.51	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	9.07	5.03e-17	2.14e-13	0.57	0.51	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	9.07	5.03e-17	2.14e-13	0.57	0.51	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	9.07	5.03e-17	2.14e-13	0.57	0.51	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	9.07	5.03e-17	2.14e-13	0.57	0.51	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	9.07	5.03e-17	2.14e-13	0.57	0.51	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	9.07	5.03e-17	2.14e-13	0.57	0.51	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	9.07	5.03e-17	2.14e-13	0.57	0.51	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
SARC	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	9.07	5.22e-17	2.22e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
SARC	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-9.06	5.29e-17	2.25e-13	-0.57	-0.51	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
SARC	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-9.06	5.33e-17	2.26e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
SARC	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	9.06	5.49e-17	2.32e-13	0.58	0.51	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	9.06	5.49e-17	2.32e-13	0.58	0.51	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
SARC	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	9.06	5.59e-17	2.36e-13	0.59	0.51	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
SARC	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	9.06	5.61e-17	2.37e-13	0.56	0.51	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
SARC	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-9.05	5.64e-17	2.38e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-9.05	5.72e-17	2.42e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-9.05	5.72e-17	2.42e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
SARC	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	9.05	5.74e-17	2.43e-13	0.71	0.51	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
SARC	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	9.05	5.74e-17	2.43e-13	0.71	0.51	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
SARC	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-9.05	5.77e-17	2.44e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-9.05	5.94e-17	2.5e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-9.05	5.94e-17	2.5e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-9.05	5.94e-17	2.5e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-9.05	5.94e-17	2.5e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-9.05	5.94e-17	2.5e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
SARC	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-9.05	5.97e-17	2.51e-13	-0.58	-0.51	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
SARC	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-9.05	6e-17	2.52e-13	-0.64	-0.51	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
SARC	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	9.05	6e-17	2.53e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
SARC	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	9.04	6.08e-17	2.55e-13	0.64	0.51	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	9.04	6.08e-17	2.55e-13	0.64	0.51	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	9.04	6.08e-17	2.55e-13	0.64	0.51	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	9.04	6.08e-17	2.55e-13	0.64	0.51	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	9.04	6.08e-17	2.55e-13	0.64	0.51	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	9.04	6.08e-17	2.55e-13	0.64	0.51	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	9.04	6.08e-17	2.55e-13	0.64	0.51	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	9.04	6.08e-17	2.55e-13	0.64	0.51	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	9.04	6.08e-17	2.55e-13	0.64	0.51	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
SARC	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-9.04	6.12e-17	2.57e-13	-0.59	-0.51	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
SARC	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-9.04	6.18e-17	2.59e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-9.04	6.21e-17	2.6e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-9.04	6.21e-17	2.6e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-9.04	6.21e-17	2.6e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-9.04	6.21e-17	2.6e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-9.04	6.21e-17	2.6e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
SARC	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	9.04	6.24e-17	2.62e-13	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	9.04	6.25e-17	2.62e-13	0.64	0.51	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
SARC	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-9.04	6.33e-17	2.65e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
SARC	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	9.04	6.36e-17	2.66e-13	0.62	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
SARC	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-9.04	6.42e-17	2.69e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
SARC	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-9.03	6.44e-17	2.7e-13	-0.69	-0.51	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
SARC	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	9.03	6.47e-17	2.71e-13	0.62	0.51	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
SARC	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-9.03	6.58e-17	2.75e-13	-0.65	-0.51	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
SARC	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	9.03	6.83e-17	2.85e-13	0.57	0.51	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
SARC	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-9.03	6.84e-17	2.85e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-9.03	6.84e-17	2.85e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-9.02	6.92e-17	2.89e-13	-0.64	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
SARC	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-9.02	6.97e-17	2.91e-13	-0.73	-0.51	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
SARC	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-9.02	7.14e-17	2.97e-13	-0.59	-0.51	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-9.02	7.14e-17	2.97e-13	-0.59	-0.51	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
SARC	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	9.02	7.17e-17	2.98e-13	0.55	0.51	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
SARC	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-9.02	7.23e-17	3e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-9.02	7.23e-17	3e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-9.02	7.23e-17	3e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-9.02	7.23e-17	3e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-9.02	7.23e-17	3e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-9.02	7.23e-17	3e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-9.02	7.23e-17	3e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-9.02	7.23e-17	3e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-9.02	7.23e-17	3e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
SARC	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-9.02	7.33e-17	3.04e-13	-0.57	-0.51	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
SARC	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	9.02	7.37e-17	3.05e-13	0.57	0.51	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
SARC	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-9.01	7.37e-17	3.05e-13	-0.61	-0.51	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
SARC	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	9.01	7.44e-17	3.08e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
SARC	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	9.01	7.5e-17	3.11e-13	0.57	0.51	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
SARC	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	9.01	7.51e-17	3.11e-13	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
SARC	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	9.01	7.54e-17	3.12e-13	0.62	0.51	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
SARC	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	9.01	7.71e-17	3.19e-13	0.59	0.51	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
SARC	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-9.01	7.8e-17	3.21e-13	-0.6	-0.51	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
SARC	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	9	7.96e-17	3.26e-13	0.56	0.51	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	9	8.01e-17	3.28e-13	0.56	0.51	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	9	8.01e-17	3.28e-13	0.56	0.51	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
SARC	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	9	8.06e-17	3.29e-13	0.57	0.51	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	9	8.06e-17	3.29e-13	0.57	0.51	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	9	8.06e-17	3.29e-13	0.57	0.51	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	9	8.06e-17	3.29e-13	0.57	0.51	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	9	8.06e-17	3.29e-13	0.57	0.51	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	9	8.06e-17	3.29e-13	0.57	0.51	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
SARC	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	9	8.13e-17	3.32e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	9	8.13e-17	3.32e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	9	8.13e-17	3.32e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	9	8.13e-17	3.32e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	9	8.13e-17	3.32e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	9	8.13e-17	3.32e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
SARC	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	9	8.25e-17	3.36e-13	0.62	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
SARC	cis	rs9326248	0.539	rs660443	ENSG00000254851.1	RP11-109L13.1	-9	8.32e-17	3.39e-13	-0.61	-0.51	Blood protein levels;	chr11:116889977	chr11:117135528~117138582:+
SARC	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-9	8.35e-17	3.4e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
SARC	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-8.99	8.54e-17	3.48e-13	-0.65	-0.51	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
SARC	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	8.99	8.55e-17	3.48e-13	0.64	0.51	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
SARC	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	8.99	8.61e-17	3.5e-13	0.57	0.51	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
SARC	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	8.99	8.76e-17	3.56e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
SARC	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	8.98	9.11e-17	3.7e-13	0.57	0.51	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
SARC	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-8.98	9.14e-17	3.72e-13	-0.65	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
SARC	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	8.98	9.19e-17	3.73e-13	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	8.98	9.19e-17	3.73e-13	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	8.98	9.19e-17	3.73e-13	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	8.98	9.19e-17	3.73e-13	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	8.98	9.19e-17	3.73e-13	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	8.98	9.19e-17	3.73e-13	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	8.98	9.19e-17	3.73e-13	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	8.98	9.19e-17	3.73e-13	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	8.98	9.19e-17	3.73e-13	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	8.98	9.19e-17	3.73e-13	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
SARC	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	8.98	9.19e-17	3.73e-13	0.59	0.51	Depression;	chr6:28399886	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	8.98	9.19e-17	3.73e-13	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
SARC	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-8.98	9.21e-17	3.74e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
SARC	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	8.98	9.28e-17	3.76e-13	0.62	0.51	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
SARC	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-8.98	9.33e-17	3.78e-13	-0.63	-0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
SARC	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	8.98	9.49e-17	3.84e-13	0.74	0.51	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
SARC	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-8.98	9.59e-17	3.88e-13	-0.58	-0.51	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
SARC	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-8.98	9.59e-17	3.88e-13	-0.49	-0.51	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
SARC	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	8.97	1.02e-16	4.11e-13	0.59	0.51	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
SARC	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	8.96	1.04e-16	4.18e-13	0.63	0.51	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
SARC	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	8.96	1.04e-16	4.19e-13	0.62	0.51	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
SARC	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-8.96	1.04e-16	4.19e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-8.96	1.04e-16	4.19e-13	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	8.96	1.05e-16	4.22e-13	0.61	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
SARC	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	8.96	1.05e-16	4.22e-13	0.61	0.51	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	8.96	1.09e-16	4.37e-13	0.63	0.51	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	8.96	1.09e-16	4.37e-13	0.63	0.51	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	8.96	1.09e-16	4.37e-13	0.63	0.51	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
SARC	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	8.96	1.1e-16	4.42e-13	0.57	0.51	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	8.96	1.1e-16	4.42e-13	0.57	0.51	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
SARC	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-8.95	1.11e-16	4.44e-13	-0.54	-0.51	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
SARC	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-8.95	1.12e-16	4.47e-13	-0.47	-0.51	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
SARC	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-8.95	1.12e-16	4.47e-13	-0.47	-0.51	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
SARC	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-8.95	1.12e-16	4.47e-13	-0.47	-0.51	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-8.95	1.12e-16	4.47e-13	-0.47	-0.51	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
SARC	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-8.95	1.12e-16	4.47e-13	-0.47	-0.51	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-8.95	1.12e-16	4.47e-13	-0.47	-0.51	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-8.95	1.12e-16	4.47e-13	-0.47	-0.51	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-8.95	1.12e-16	4.47e-13	-0.47	-0.51	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
SARC	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-8.95	1.13e-16	4.51e-13	-0.6	-0.51	Migraine;	chr4:56956882	chr4:56960927~56961373:-
SARC	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-8.95	1.13e-16	4.51e-13	-0.6	-0.51	Migraine;	chr4:56957291	chr4:56960927~56961373:-
SARC	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	8.95	1.15e-16	4.6e-13	0.58	0.51	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
SARC	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	8.95	1.15e-16	4.61e-13	0.65	0.51	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
SARC	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	8.95	1.15e-16	4.61e-13	0.65	0.51	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
SARC	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	8.95	1.15e-16	4.61e-13	0.65	0.51	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
SARC	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	8.95	1.16e-16	4.61e-13	0.65	0.51	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
SARC	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-8.95	1.17e-16	4.65e-13	-0.58	-0.51	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-8.95	1.17e-16	4.65e-13	-0.58	-0.51	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
SARC	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-8.95	1.17e-16	4.67e-13	-0.63	-0.51	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
SARC	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-8.94	1.23e-16	4.88e-13	-0.61	-0.51	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
SARC	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	8.94	1.24e-16	4.91e-13	0.65	0.51	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
SARC	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-8.94	1.25e-16	4.98e-13	-0.47	-0.51	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
SARC	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-8.94	1.25e-16	4.98e-13	-0.47	-0.51	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
SARC	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	8.93	1.29e-16	5.12e-13	0.72	0.51	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
SARC	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-8.93	1.29e-16	5.13e-13	-0.63	-0.51	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
SARC	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-8.93	1.29e-16	5.13e-13	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
SARC	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-8.93	1.29e-16	5.14e-13	-0.73	-0.51	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
SARC	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-8.93	1.3e-16	5.15e-13	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-8.93	1.31e-16	5.19e-13	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
SARC	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-8.93	1.31e-16	5.22e-13	-0.46	-0.5	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
SARC	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-8.92	1.36e-16	5.4e-13	-0.54	-0.5	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
SARC	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	8.92	1.37e-16	5.42e-13	0.76	0.5	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
SARC	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-8.92	1.37e-16	5.42e-13	-0.63	-0.5	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
SARC	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-8.92	1.37e-16	5.42e-13	-0.54	-0.5	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
SARC	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-8.92	1.43e-16	5.64e-13	-0.54	-0.5	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
SARC	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	8.92	1.44e-16	5.72e-13	0.62	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
SARC	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-8.91	1.49e-16	5.89e-13	-0.59	-0.5	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
SARC	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-8.91	1.51e-16	5.97e-13	-0.49	-0.5	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
SARC	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-8.91	1.54e-16	6.07e-13	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
SARC	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-8.91	1.55e-16	6.1e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
SARC	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-8.9	1.55e-16	6.13e-13	-0.59	-0.5	Migraine;	chr4:56950140	chr4:56960927~56961373:-
SARC	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	8.9	1.57e-16	6.2e-13	0.55	0.5	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
SARC	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-8.9	1.58e-16	6.23e-13	-0.64	-0.5	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
SARC	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-8.9	1.61e-16	6.33e-13	-0.55	-0.5	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
SARC	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	8.9	1.62e-16	6.37e-13	0.71	0.5	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
SARC	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-8.9	1.64e-16	6.45e-13	-0.63	-0.5	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-8.9	1.64e-16	6.46e-13	-0.63	-0.5	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
SARC	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-8.9	1.65e-16	6.5e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
SARC	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-8.9	1.65e-16	6.5e-13	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
SARC	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	8.89	1.71e-16	6.7e-13	0.62	0.5	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
SARC	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-8.89	1.71e-16	6.7e-13	-0.48	-0.5	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
SARC	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	8.89	1.71e-16	6.7e-13	0.63	0.5	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
SARC	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	8.89	1.72e-16	6.76e-13	0.56	0.5	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
SARC	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	8.89	1.74e-16	6.82e-13	0.63	0.5	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
SARC	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-8.89	1.75e-16	6.85e-13	-0.48	-0.5	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
SARC	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	8.89	1.75e-16	6.86e-13	0.57	0.5	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
SARC	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-8.89	1.76e-16	6.89e-13	-0.55	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
SARC	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-8.89	1.77e-16	6.91e-13	-0.64	-0.5	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
SARC	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	8.88	1.81e-16	7.07e-13	0.56	0.5	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	8.88	1.81e-16	7.07e-13	0.56	0.5	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	8.88	1.81e-16	7.07e-13	0.56	0.5	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
SARC	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	8.88	1.81e-16	7.07e-13	0.72	0.5	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
SARC	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	8.88	1.81e-16	7.07e-13	0.57	0.5	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
SARC	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-8.88	1.83e-16	7.17e-13	-0.53	-0.5	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
SARC	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-8.88	1.85e-16	7.23e-13	-0.46	-0.5	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-8.88	1.85e-16	7.23e-13	-0.46	-0.5	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-8.88	1.85e-16	7.23e-13	-0.46	-0.5	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-8.88	1.85e-16	7.23e-13	-0.46	-0.5	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
SARC	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-8.88	1.87e-16	7.3e-13	-0.55	-0.5	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
SARC	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	8.88	1.88e-16	7.36e-13	0.71	0.5	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
SARC	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-8.87	1.91e-16	7.42e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-8.87	1.91e-16	7.42e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
SARC	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-8.87	1.96e-16	7.62e-13	-0.58	-0.5	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
SARC	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-8.87	2.01e-16	7.79e-13	-0.64	-0.5	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-8.86	2.05e-16	7.93e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
SARC	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	8.86	2.06e-16	7.94e-13	0.63	0.5	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
SARC	cis	rs6964833	1	rs13227433	ENSG00000277053.3	GTF2IP1	-8.86	2.08e-16	8.04e-13	-0.59	-0.5	Menarche (age at onset);	chr7:74680386	chr7:75185385~75237696:-
SARC	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	8.86	2.09e-16	8.06e-13	0.6	0.5	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
SARC	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-8.86	2.09e-16	8.07e-13	-0.63	-0.5	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
SARC	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	8.86	2.16e-16	8.33e-13	0.59	0.5	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
SARC	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	8.85	2.18e-16	8.41e-13	0.65	0.5	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
SARC	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	8.85	2.2e-16	8.46e-13	0.6	0.5	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
SARC	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	8.85	2.21e-16	8.51e-13	0.47	0.5	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
SARC	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	8.85	2.21e-16	8.52e-13	0.64	0.5	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-8.85	2.25e-16	8.65e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-8.85	2.27e-16	8.71e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-8.85	2.27e-16	8.71e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-8.85	2.27e-16	8.71e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-8.85	2.27e-16	8.71e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-8.85	2.27e-16	8.71e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
SARC	cis	rs6003958	1	rs6003958	ENSG00000218537.1	MIF-AS1	-8.85	2.29e-16	8.78e-13	-0.72	-0.5	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23894426~23898930:-
SARC	cis	rs5760092	0.755	rs6003959	ENSG00000218537.1	MIF-AS1	-8.85	2.29e-16	8.78e-13	-0.72	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23894426~23898930:-
SARC	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	8.85	2.29e-16	8.81e-13	0.61	0.5	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	8.85	2.29e-16	8.81e-13	0.6	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
SARC	cis	rs6538678	0.824	rs1436120	ENSG00000258343.1	RP11-536G4.2	8.85	2.3e-16	8.81e-13	0.67	0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95826872	chr12:95795345~95858839:-
SARC	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	8.85	2.3e-16	8.82e-13	0.58	0.5	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
SARC	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-8.85	2.3e-16	8.83e-13	-0.53	-0.5	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
SARC	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-8.84	2.34e-16	8.97e-13	-0.74	-0.5	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
SARC	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-8.84	2.38e-16	9.11e-13	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
SARC	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	8.84	2.39e-16	9.14e-13	0.62	0.5	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
SARC	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-8.84	2.44e-16	9.33e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-8.83	2.51e-16	9.58e-13	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
SARC	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	8.83	2.58e-16	9.85e-13	0.7	0.5	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
SARC	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-8.83	2.64e-16	1e-12	-0.64	-0.5	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
SARC	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-8.82	2.65e-16	1.01e-12	-0.54	-0.5	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-8.82	2.65e-16	1.01e-12	-0.54	-0.5	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
SARC	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-8.82	2.65e-16	1.01e-12	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-8.82	2.65e-16	1.01e-12	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-8.82	2.69e-16	1.02e-12	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
SARC	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	8.82	2.71e-16	1.03e-12	0.78	0.5	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
SARC	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-8.82	2.72e-16	1.04e-12	-0.53	-0.5	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-8.82	2.75e-16	1.05e-12	-0.53	-0.5	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-8.82	2.83e-16	1.07e-12	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
SARC	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-8.81	2.85e-16	1.08e-12	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
SARC	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-8.81	2.85e-16	1.08e-12	-0.54	-0.5	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-8.81	2.85e-16	1.08e-12	-0.54	-0.5	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
SARC	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	8.81	2.94e-16	1.11e-12	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
SARC	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-8.81	2.95e-16	1.12e-12	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-8.81	2.95e-16	1.12e-12	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-8.81	2.95e-16	1.12e-12	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-8.81	2.95e-16	1.12e-12	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-8.81	2.95e-16	1.12e-12	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-8.81	2.95e-16	1.12e-12	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-8.81	2.95e-16	1.12e-12	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-8.81	2.96e-16	1.12e-12	-0.54	-0.5	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-8.81	2.96e-16	1.12e-12	-0.54	-0.5	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
SARC	cis	rs6964833	1	rs2301907	ENSG00000277053.3	GTF2IP1	-8.81	3.01e-16	1.14e-12	-0.59	-0.5	Menarche (age at onset);	chr7:74700517	chr7:75185385~75237696:-
SARC	cis	rs6964833	0.935	rs7795282	ENSG00000277053.3	GTF2IP1	-8.81	3.01e-16	1.14e-12	-0.59	-0.5	Menarche (age at onset);	chr7:74708526	chr7:75185385~75237696:-
SARC	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	8.81	3.01e-16	1.14e-12	0.62	0.5	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
SARC	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-8.79	3.3e-16	1.24e-12	-0.54	-0.5	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
SARC	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-8.79	3.31e-16	1.25e-12	-0.59	-0.5	Migraine;	chr4:56943905	chr4:56960927~56961373:-
SARC	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-8.79	3.34e-16	1.26e-12	-0.58	-0.5	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
SARC	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-8.79	3.38e-16	1.27e-12	-0.54	-0.5	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-8.78	3.47e-16	1.3e-12	-0.54	-0.5	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-8.78	3.47e-16	1.3e-12	-0.54	-0.5	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
SARC	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-8.78	3.49e-16	1.31e-12	-0.46	-0.5	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
SARC	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-8.78	3.49e-16	1.31e-12	-0.46	-0.5	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-8.78	3.49e-16	1.31e-12	-0.46	-0.5	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
SARC	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-8.78	3.49e-16	1.31e-12	-0.46	-0.5	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-8.78	3.49e-16	1.31e-12	-0.46	-0.5	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-8.78	3.49e-16	1.31e-12	-0.46	-0.5	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
SARC	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-8.78	3.49e-16	1.31e-12	-0.46	-0.5	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
SARC	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-8.78	3.5e-16	1.32e-12	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
SARC	cis	rs5760092	0.627	rs6519489	ENSG00000218537.1	MIF-AS1	-8.78	3.55e-16	1.33e-12	-0.72	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23894426~23898930:-
SARC	cis	rs5760092	0.755	rs11090298	ENSG00000218537.1	MIF-AS1	-8.78	3.55e-16	1.33e-12	-0.72	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23894426~23898930:-
SARC	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	8.78	3.58e-16	1.34e-12	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
SARC	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	8.78	3.59e-16	1.35e-12	0.62	0.5	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
SARC	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-8.78	3.68e-16	1.38e-12	-0.63	-0.5	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
SARC	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-8.77	3.83e-16	1.43e-12	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
SARC	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	8.77	3.84e-16	1.44e-12	0.61	0.5	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
SARC	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	8.77	3.85e-16	1.44e-12	0.56	0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
SARC	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	8.77	3.93e-16	1.47e-12	0.61	0.5	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	8.77	3.93e-16	1.47e-12	0.61	0.5	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	8.77	3.93e-16	1.47e-12	0.61	0.5	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
SARC	cis	rs3091242	0.933	rs9645452	ENSG00000261349.1	RP3-465N24.5	8.76	4e-16	1.49e-12	0.52	0.5	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25266102~25267136:-
SARC	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-8.76	4.08e-16	1.52e-12	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
SARC	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	8.76	4.12e-16	1.54e-12	0.53	0.5	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
SARC	cis	rs6964833	1	rs6967152	ENSG00000277053.3	GTF2IP1	-8.76	4.22e-16	1.57e-12	-0.59	-0.5	Menarche (age at onset);	chr7:74684983	chr7:75185385~75237696:-
SARC	cis	rs6964833	1	rs6964833	ENSG00000277053.3	GTF2IP1	-8.76	4.22e-16	1.57e-12	-0.59	-0.5	Menarche (age at onset);	chr7:74687575	chr7:75185385~75237696:-
SARC	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	8.75	4.43e-16	1.65e-12	0.73	0.5	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
SARC	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-8.75	4.49e-16	1.67e-12	-0.52	-0.5	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
SARC	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-8.75	4.49e-16	1.67e-12	-0.64	-0.5	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-8.75	4.49e-16	1.67e-12	-0.64	-0.5	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-8.75	4.49e-16	1.67e-12	-0.64	-0.5	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
SARC	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-8.75	4.51e-16	1.68e-12	-0.63	-0.5	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	8.74	4.57e-16	1.7e-12	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
SARC	cis	rs7044106	0.791	rs4836831	ENSG00000226752.6	PSMD5-AS1	-8.74	4.66e-16	1.73e-12	-0.64	-0.5	Hip circumference adjusted for BMI;	chr9:120734292	chr9:120824828~120854385:+
SARC	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	8.74	4.66e-16	1.73e-12	0.52	0.5	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
SARC	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-8.73	4.84e-16	1.8e-12	-0.47	-0.5	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
SARC	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-8.73	4.84e-16	1.8e-12	-0.47	-0.5	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
SARC	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-8.73	4.84e-16	1.8e-12	-0.47	-0.5	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
SARC	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-8.73	4.92e-16	1.82e-12	-0.59	-0.5	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
SARC	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	8.73	4.95e-16	1.83e-12	0.48	0.5	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
SARC	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	8.72	5.24e-16	1.94e-12	0.78	0.5	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	8.72	5.24e-16	1.94e-12	0.78	0.5	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	8.72	5.24e-16	1.94e-12	0.78	0.5	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	8.72	5.24e-16	1.94e-12	0.78	0.5	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	8.72	5.24e-16	1.94e-12	0.78	0.5	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	8.72	5.24e-16	1.94e-12	0.78	0.5	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	8.72	5.24e-16	1.94e-12	0.78	0.5	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	8.72	5.24e-16	1.94e-12	0.78	0.5	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
SARC	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	8.72	5.24e-16	1.94e-12	0.78	0.5	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
SARC	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-8.72	5.26e-16	1.94e-12	-0.66	-0.5	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
SARC	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-8.72	5.28e-16	1.95e-12	-0.58	-0.5	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	8.72	5.33e-16	1.97e-12	0.52	0.5	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
SARC	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	8.72	5.48e-16	2.02e-12	0.75	0.5	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
SARC	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-8.71	5.53e-16	2.03e-12	-0.63	-0.5	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
SARC	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-8.71	5.53e-16	2.04e-12	-0.53	-0.5	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-8.71	5.53e-16	2.04e-12	-0.53	-0.5	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
SARC	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-8.71	5.54e-16	2.04e-12	-0.62	-0.5	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
SARC	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	8.71	5.66e-16	2.08e-12	0.77	0.5	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
SARC	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	8.71	5.66e-16	2.08e-12	0.77	0.5	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
SARC	cis	rs7044106	0.791	rs2900177	ENSG00000226752.6	PSMD5-AS1	-8.71	5.88e-16	2.16e-12	-0.64	-0.5	Hip circumference adjusted for BMI;	chr9:120735367	chr9:120824828~120854385:+
SARC	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-8.7	5.92e-16	2.18e-12	-0.51	-0.5	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
SARC	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	8.7	6.01e-16	2.2e-12	0.6	0.5	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	8.7	6.01e-16	2.2e-12	0.6	0.5	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	8.7	6.01e-16	2.2e-12	0.6	0.5	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	8.7	6.01e-16	2.2e-12	0.6	0.5	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
SARC	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	8.7	6.06e-16	2.22e-12	0.69	0.5	Depression;	chr6:28110525	chr6:28115628~28116551:+
SARC	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-8.7	6.22e-16	2.27e-12	-0.63	-0.5	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
SARC	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	8.7	6.29e-16	2.3e-12	0.73	0.49	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
SARC	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-8.69	6.31e-16	2.31e-12	-0.53	-0.49	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
SARC	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-8.69	6.34e-16	2.32e-12	-0.6	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
SARC	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	8.69	6.38e-16	2.33e-12	0.59	0.49	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
SARC	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	8.69	6.48e-16	2.36e-12	0.6	0.49	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	8.69	6.48e-16	2.36e-12	0.6	0.49	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	8.69	6.48e-16	2.36e-12	0.6	0.49	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
SARC	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	8.69	6.49e-16	2.36e-12	0.74	0.49	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	8.69	6.49e-16	2.36e-12	0.74	0.49	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
SARC	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-8.69	6.5e-16	2.37e-12	-0.63	-0.49	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
SARC	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	8.69	6.65e-16	2.41e-12	0.78	0.49	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
SARC	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	8.69	6.65e-16	2.41e-12	0.78	0.49	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
SARC	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	8.69	6.65e-16	2.41e-12	0.78	0.49	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	8.69	6.65e-16	2.41e-12	0.78	0.49	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
SARC	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-8.68	6.81e-16	2.47e-12	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-8.68	6.91e-16	2.51e-12	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
SARC	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-8.67	7.37e-16	2.66e-12	-0.57	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
SARC	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-8.67	7.39e-16	2.67e-12	-0.61	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
SARC	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-8.67	7.42e-16	2.68e-12	-0.7	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
SARC	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-8.67	7.66e-16	2.76e-12	-0.48	-0.49	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
SARC	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-8.67	7.66e-16	2.76e-12	-0.48	-0.49	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
SARC	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-8.67	7.66e-16	2.76e-12	-0.48	-0.49	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
SARC	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-8.67	7.66e-16	2.76e-12	-0.48	-0.49	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
SARC	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-8.67	7.66e-16	2.76e-12	-0.48	-0.49	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
SARC	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-8.67	7.66e-16	2.76e-12	-0.48	-0.49	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
SARC	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-8.67	7.66e-16	2.76e-12	-0.48	-0.49	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-8.67	7.66e-16	2.76e-12	-0.48	-0.49	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
SARC	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	8.66	7.84e-16	2.83e-12	0.56	0.49	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
SARC	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-8.66	7.9e-16	2.84e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-8.66	7.9e-16	2.84e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-8.66	7.9e-16	2.84e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-8.66	7.9e-16	2.84e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-8.66	7.9e-16	2.84e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-8.66	7.9e-16	2.84e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-8.66	7.9e-16	2.84e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-8.66	7.9e-16	2.84e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-8.66	7.9e-16	2.84e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-8.66	7.9e-16	2.84e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-8.66	7.9e-16	2.84e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-8.66	7.9e-16	2.84e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-8.66	8.09e-16	2.91e-12	-0.52	-0.49	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
SARC	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-8.66	8.17e-16	2.94e-12	-0.63	-0.49	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
SARC	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-8.65	8.37e-16	3e-12	-0.63	-0.49	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
SARC	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	8.65	8.44e-16	3.03e-12	0.54	0.49	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
SARC	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-8.65	8.48e-16	3.04e-12	-0.46	-0.49	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-8.65	8.48e-16	3.04e-12	-0.46	-0.49	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-8.65	8.48e-16	3.04e-12	-0.46	-0.49	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
SARC	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	8.65	8.51e-16	3.05e-12	0.62	0.49	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	8.65	8.51e-16	3.05e-12	0.62	0.49	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
SARC	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	8.65	8.51e-16	3.05e-12	0.62	0.49	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
SARC	cis	rs1930961	1	rs760554	ENSG00000100058.11	CRYBB2P1	8.65	8.65e-16	3.1e-12	0.95	0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25448105~25520854:+
SARC	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-8.64	8.81e-16	3.15e-12	-0.59	-0.49	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
SARC	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-8.64	8.88e-16	3.18e-12	-0.56	-0.49	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
SARC	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	8.64	8.9e-16	3.18e-12	0.62	0.49	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
SARC	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-8.64	8.91e-16	3.19e-12	-0.55	-0.49	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
SARC	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-8.64	9.06e-16	3.24e-12	-0.45	-0.49	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-8.64	9.06e-16	3.24e-12	-0.45	-0.49	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-8.64	9.06e-16	3.24e-12	-0.45	-0.49	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
SARC	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	8.64	9.07e-16	3.24e-12	0.61	0.49	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
SARC	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	8.64	9.15e-16	3.27e-12	0.83	0.49	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
SARC	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	8.64	9.15e-16	3.27e-12	0.59	0.49	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
SARC	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-8.64	9.21e-16	3.29e-12	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
SARC	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-8.64	9.31e-16	3.32e-12	-0.63	-0.49	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	8.63	9.49e-16	3.38e-12	0.59	0.49	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	8.63	9.49e-16	3.38e-12	0.59	0.49	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	8.63	9.49e-16	3.38e-12	0.59	0.49	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	8.63	9.76e-16	3.48e-12	0.61	0.49	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	8.63	9.76e-16	3.48e-12	0.61	0.49	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
SARC	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-8.63	9.82e-16	3.5e-12	-0.58	-0.49	Migraine;	chr4:56940917	chr4:56960927~56961373:-
SARC	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-8.62	1.01e-15	3.58e-12	-0.54	-0.49	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
SARC	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	8.62	1.01e-15	3.61e-12	0.61	0.49	Depression;	chr6:28364057	chr6:28176188~28176674:+
SARC	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-8.62	1.02e-15	3.63e-12	-0.56	-0.49	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-8.62	1.04e-15	3.71e-12	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
SARC	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	8.62	1.06e-15	3.76e-12	0.61	0.49	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
SARC	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	8.62	1.06e-15	3.76e-12	0.61	0.49	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
SARC	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-8.61	1.08e-15	3.82e-12	-0.46	-0.49	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
SARC	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	8.61	1.08e-15	3.82e-12	0.83	0.49	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
SARC	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	8.61	1.08e-15	3.82e-12	0.83	0.49	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
SARC	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-8.61	1.11e-15	3.92e-12	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-8.61	1.11e-15	3.95e-12	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
SARC	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	8.61	1.12e-15	3.98e-12	0.48	0.49	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
SARC	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-8.61	1.12e-15	3.98e-12	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
SARC	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-8.61	1.14e-15	4.05e-12	-0.58	-0.49	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
SARC	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-8.61	1.14e-15	4.05e-12	-0.58	-0.49	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
SARC	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-8.61	1.14e-15	4.05e-12	-0.58	-0.49	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
SARC	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	8.6	1.15e-15	4.06e-12	0.73	0.49	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
SARC	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	8.6	1.16e-15	4.1e-12	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	8.6	1.17e-15	4.13e-12	0.84	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
SARC	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	8.6	1.17e-15	4.14e-12	0.61	0.49	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
SARC	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-8.6	1.2e-15	4.24e-12	-0.58	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-8.6	1.2e-15	4.24e-12	-0.58	-0.49	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
SARC	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	8.6	1.22e-15	4.28e-12	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	8.6	1.22e-15	4.28e-12	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	8.6	1.22e-15	4.28e-12	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
SARC	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	8.59	1.25e-15	4.4e-12	0.57	0.49	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
SARC	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	8.59	1.25e-15	4.4e-12	0.6	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
SARC	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-8.58	1.31e-15	4.58e-12	-0.48	-0.49	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-8.58	1.31e-15	4.58e-12	-0.48	-0.49	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
SARC	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-8.58	1.31e-15	4.58e-12	-0.48	-0.49	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
SARC	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	8.58	1.31e-15	4.58e-12	0.52	0.49	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
SARC	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-8.58	1.34e-15	4.68e-12	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-8.58	1.34e-15	4.68e-12	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-8.58	1.34e-15	4.68e-12	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
SARC	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	8.58	1.37e-15	4.77e-12	0.61	0.49	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
SARC	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-8.58	1.39e-15	4.86e-12	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
SARC	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-8.57	1.41e-15	4.9e-12	-0.54	-0.49	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
SARC	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-8.57	1.41e-15	4.9e-12	-0.54	-0.49	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
SARC	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-8.57	1.42e-15	4.95e-12	-0.52	-0.49	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
SARC	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-8.57	1.45e-15	5.05e-12	-0.63	-0.49	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-8.57	1.45e-15	5.05e-12	-0.63	-0.49	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-8.57	1.45e-15	5.05e-12	-0.63	-0.49	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
SARC	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-8.56	1.5e-15	5.2e-12	-0.61	-0.49	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
SARC	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	8.56	1.59e-15	5.5e-12	0.59	0.49	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
SARC	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	8.55	1.61e-15	5.59e-12	0.7	0.49	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
SARC	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-8.55	1.64e-15	5.67e-12	-0.58	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
SARC	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-8.55	1.64e-15	5.67e-12	-0.58	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
SARC	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-8.55	1.64e-15	5.67e-12	-0.58	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
SARC	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	8.55	1.66e-15	5.73e-12	0.77	0.49	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
SARC	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-8.55	1.68e-15	5.81e-12	-0.45	-0.49	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
SARC	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-8.55	1.68e-15	5.81e-12	-0.45	-0.49	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
SARC	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	8.55	1.68e-15	5.83e-12	0.73	0.49	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	8.55	1.68e-15	5.83e-12	0.73	0.49	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
SARC	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-8.55	1.69e-15	5.83e-12	-0.58	-0.49	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
SARC	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-8.55	1.69e-15	5.83e-12	-0.58	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
SARC	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	8.55	1.7e-15	5.85e-12	0.64	0.49	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
SARC	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	8.55	1.7e-15	5.85e-12	0.64	0.49	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
SARC	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-8.55	1.7e-15	5.85e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-8.55	1.7e-15	5.85e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-8.55	1.7e-15	5.85e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-8.55	1.7e-15	5.85e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-8.55	1.7e-15	5.85e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-8.55	1.7e-15	5.85e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-8.55	1.7e-15	5.85e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-8.55	1.7e-15	5.85e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-8.55	1.7e-15	5.85e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-8.55	1.7e-15	5.85e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-8.55	1.7e-15	5.85e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-8.55	1.7e-15	5.85e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-8.54	1.7e-15	5.86e-12	-0.52	-0.49	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
SARC	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	8.54	1.7e-15	5.86e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	8.54	1.7e-15	5.86e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	8.54	1.7e-15	5.86e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	8.54	1.7e-15	5.86e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	8.54	1.7e-15	5.86e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	8.54	1.7e-15	5.86e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
SARC	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	8.54	1.7e-15	5.86e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
SARC	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-8.54	1.7e-15	5.86e-12	-0.47	-0.49	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
SARC	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	8.54	1.72e-15	5.92e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	8.54	1.72e-15	5.92e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	8.54	1.72e-15	5.92e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	8.54	1.73e-15	5.95e-12	0.76	0.49	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
SARC	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-8.54	1.76e-15	6.05e-12	-0.53	-0.49	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
SARC	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-8.54	1.79e-15	6.15e-12	-0.61	-0.49	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
SARC	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	8.53	1.83e-15	6.26e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
SARC	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-8.53	1.84e-15	6.29e-12	-0.5	-0.49	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
SARC	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-8.53	1.84e-15	6.31e-12	-0.63	-0.49	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
SARC	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-8.53	1.84e-15	6.32e-12	-0.65	-0.49	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
SARC	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	8.53	1.85e-15	6.32e-12	0.72	0.49	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
SARC	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-8.53	1.85e-15	6.34e-12	-0.47	-0.49	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
SARC	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-8.53	1.85e-15	6.34e-12	-0.47	-0.49	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
SARC	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-8.53	1.86e-15	6.36e-12	-0.61	-0.49	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
SARC	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-8.53	1.87e-15	6.41e-12	-0.61	-0.49	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	8.53	1.88e-15	6.45e-12	0.58	0.49	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
SARC	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	8.53	1.9e-15	6.48e-12	0.6	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
SARC	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	8.53	1.92e-15	6.56e-12	0.56	0.49	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
SARC	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	8.53	1.92e-15	6.58e-12	0.64	0.49	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
SARC	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-8.53	1.93e-15	6.6e-12	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
SARC	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-8.53	1.93e-15	6.6e-12	-0.54	-0.49	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
SARC	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-8.52	1.94e-15	6.64e-12	-0.55	-0.49	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-8.52	1.94e-15	6.64e-12	-0.55	-0.49	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
SARC	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	8.52	1.99e-15	6.78e-12	0.61	0.49	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
SARC	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-8.52	1.99e-15	6.8e-12	-0.51	-0.49	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-8.52	1.99e-15	6.8e-12	-0.51	-0.49	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
SARC	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	8.52	2e-15	6.8e-12	0.82	0.49	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	8.52	2e-15	6.8e-12	0.82	0.49	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	8.52	2e-15	6.8e-12	0.82	0.49	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	8.52	2e-15	6.8e-12	0.82	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
SARC	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	8.52	2.01e-15	6.85e-12	0.62	0.49	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
SARC	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	8.52	2.02e-15	6.87e-12	0.59	0.49	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	8.52	2.05e-15	6.98e-12	0.6	0.49	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
SARC	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-8.52	2.07e-15	7.03e-12	-0.46	-0.49	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
SARC	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-8.51	2.08e-15	7.07e-12	-0.57	-0.49	Migraine;	chr4:56937339	chr4:56960927~56961373:-
SARC	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	8.51	2.09e-15	7.08e-12	0.56	0.49	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
SARC	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-8.51	2.09e-15	7.1e-12	-0.61	-0.49	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-8.51	2.12e-15	7.2e-12	-0.63	-0.49	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-8.51	2.12e-15	7.2e-12	-0.63	-0.49	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-8.51	2.12e-15	7.2e-12	-0.63	-0.49	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
SARC	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-8.51	2.17e-15	7.38e-12	-0.57	-0.49	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
SARC	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	8.5	2.25e-15	7.62e-12	0.64	0.49	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
SARC	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-8.5	2.27e-15	7.68e-12	-0.61	-0.49	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-8.5	2.27e-15	7.68e-12	-0.61	-0.49	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
SARC	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-8.5	2.31e-15	7.81e-12	-0.48	-0.49	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
SARC	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	8.5	2.36e-15	7.99e-12	0.59	0.49	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
SARC	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-8.49	2.38e-15	8.06e-12	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
SARC	cis	rs1167827	0.71	rs1167836	ENSG00000127957.15	PMS2P3	-8.49	2.41e-15	8.16e-12	-0.55	-0.49	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75502930~75528148:-
SARC	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	8.49	2.44e-15	8.24e-12	0.62	0.49	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
SARC	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	8.49	2.44e-15	8.24e-12	0.59	0.49	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
SARC	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	8.49	2.45e-15	8.28e-12	0.75	0.49	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	8.49	2.46e-15	8.32e-12	0.75	0.49	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	8.49	2.49e-15	8.4e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
SARC	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	8.49	2.5e-15	8.44e-12	0.74	0.49	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
SARC	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	8.49	2.52e-15	8.51e-12	0.6	0.49	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
SARC	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-8.48	2.54e-15	8.59e-12	-0.61	-0.49	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
SARC	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	8.48	2.59e-15	8.71e-12	0.76	0.49	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
SARC	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	8.48	2.59e-15	8.71e-12	0.59	0.49	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
SARC	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-8.48	2.64e-15	8.87e-12	-0.63	-0.49	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-8.48	2.64e-15	8.87e-12	-0.63	-0.49	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
SARC	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-8.48	2.64e-15	8.87e-12	-0.63	-0.49	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
SARC	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-8.48	2.64e-15	8.87e-12	-0.63	-0.49	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-8.48	2.64e-15	8.87e-12	-0.63	-0.49	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
SARC	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-8.48	2.65e-15	8.91e-12	-0.57	-0.49	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
SARC	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-8.48	2.7e-15	9.06e-12	-0.57	-0.49	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
SARC	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-8.47	2.71e-15	9.09e-12	-0.63	-0.49	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
SARC	cis	rs1930961	1	rs6519611	ENSG00000100058.11	CRYBB2P1	8.47	2.71e-15	9.1e-12	0.91	0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25448105~25520854:+
SARC	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-8.47	2.72e-15	9.13e-12	-0.62	-0.49	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
SARC	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	8.47	2.74e-15	9.2e-12	0.73	0.49	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
SARC	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-8.47	2.75e-15	9.22e-12	-0.56	-0.49	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
SARC	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-8.46	2.89e-15	9.66e-12	-0.62	-0.48	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	8.46	2.91e-15	9.75e-12	0.59	0.48	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
SARC	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	8.46	2.96e-15	9.88e-12	0.72	0.48	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
SARC	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	8.46	2.97e-15	9.92e-12	0.54	0.48	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	8.46	2.97e-15	9.92e-12	0.54	0.48	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
SARC	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-8.46	3.02e-15	1.01e-11	-0.48	-0.48	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
SARC	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-8.46	3.02e-15	1.01e-11	-0.56	-0.48	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
SARC	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-8.46	3.02e-15	1.01e-11	-0.56	-0.48	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
SARC	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	8.46	3.03e-15	1.01e-11	0.62	0.48	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
SARC	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-8.45	3.1e-15	1.03e-11	-0.62	-0.48	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-8.45	3.1e-15	1.03e-11	-0.62	-0.48	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
SARC	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-8.45	3.12e-15	1.04e-11	-0.47	-0.48	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
SARC	cis	rs1930961	0.867	rs6423498	ENSG00000100058.11	CRYBB2P1	8.45	3.14e-15	1.05e-11	0.9	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25448105~25520854:+
SARC	cis	rs1930961	1	rs6004654	ENSG00000100058.11	CRYBB2P1	8.45	3.14e-15	1.05e-11	0.9	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25448105~25520854:+
SARC	cis	rs1930961	1	rs6004658	ENSG00000100058.11	CRYBB2P1	8.45	3.14e-15	1.05e-11	0.9	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25448105~25520854:+
SARC	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	8.44	3.32e-15	1.11e-11	0.71	0.48	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
SARC	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-8.44	3.33e-15	1.11e-11	-0.51	-0.48	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
SARC	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-8.44	3.34e-15	1.11e-11	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
SARC	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-8.44	3.37e-15	1.12e-11	-0.57	-0.48	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
SARC	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	8.44	3.37e-15	1.12e-11	0.63	0.48	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-8.44	3.38e-15	1.12e-11	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
SARC	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-8.44	3.42e-15	1.14e-11	-0.59	-0.48	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
SARC	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-8.44	3.44e-15	1.14e-11	-0.58	-0.48	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
SARC	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-8.44	3.44e-15	1.14e-11	-0.58	-0.48	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	8.44	3.44e-15	1.14e-11	0.58	0.48	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
SARC	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-8.44	3.46e-15	1.15e-11	-0.45	-0.48	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
SARC	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	8.44	3.5e-15	1.16e-11	0.72	0.48	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
SARC	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-8.43	3.52e-15	1.17e-11	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
SARC	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	8.43	3.53e-15	1.17e-11	0.58	0.48	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
SARC	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-8.43	3.66e-15	1.21e-11	-0.6	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
SARC	cis	rs1930961	1	rs9624836	ENSG00000100058.11	CRYBB2P1	8.43	3.72e-15	1.23e-11	0.9	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25448105~25520854:+
SARC	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-8.43	3.73e-15	1.23e-11	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
SARC	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-8.42	3.75e-15	1.24e-11	-0.47	-0.48	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
SARC	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-8.42	3.83e-15	1.26e-11	-0.62	-0.48	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
SARC	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	8.42	3.87e-15	1.27e-11	0.75	0.48	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
SARC	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	8.42	3.87e-15	1.27e-11	0.59	0.48	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
SARC	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	8.42	3.89e-15	1.28e-11	0.54	0.48	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
SARC	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	8.42	3.9e-15	1.28e-11	0.76	0.48	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	8.42	3.9e-15	1.28e-11	0.76	0.48	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
SARC	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	8.42	3.9e-15	1.28e-11	0.81	0.48	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
SARC	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-8.42	3.91e-15	1.28e-11	-0.6	-0.48	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
SARC	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-8.42	3.98e-15	1.3e-11	-0.7	-0.48	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
SARC	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-8.41	4e-15	1.31e-11	-0.57	-0.48	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
SARC	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-8.41	4.01e-15	1.31e-11	-0.56	-0.48	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
SARC	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-8.41	4.1e-15	1.34e-11	-0.53	-0.48	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
SARC	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-8.41	4.22e-15	1.38e-11	-0.54	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
SARC	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	8.4	4.28e-15	1.4e-11	0.53	0.48	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
SARC	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	8.4	4.29e-15	1.4e-11	0.7	0.48	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
SARC	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-8.4	4.32e-15	1.41e-11	-0.47	-0.48	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
SARC	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-8.4	4.36e-15	1.42e-11	-0.55	-0.48	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
SARC	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	8.4	4.36e-15	1.42e-11	0.76	0.48	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
SARC	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-8.4	4.39e-15	1.43e-11	-0.58	-0.48	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	8.4	4.44e-15	1.45e-11	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
SARC	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-8.4	4.5e-15	1.46e-11	-0.44	-0.48	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
SARC	cis	rs1930961	1	rs6004659	ENSG00000100058.11	CRYBB2P1	8.4	4.53e-15	1.47e-11	0.9	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25448105~25520854:+
SARC	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-8.39	4.56e-15	1.49e-11	-0.7	-0.48	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
SARC	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-8.39	4.57e-15	1.49e-11	-0.61	-0.48	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
SARC	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	8.39	4.58e-15	1.49e-11	0.52	0.48	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
SARC	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-8.39	4.6e-15	1.5e-11	-0.58	-0.48	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	8.39	4.67e-15	1.52e-11	0.82	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
SARC	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-8.39	4.7e-15	1.52e-11	-0.51	-0.48	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
SARC	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-8.39	4.73e-15	1.52e-11	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
SARC	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-8.39	4.76e-15	1.54e-11	-0.52	-0.48	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
SARC	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	8.39	4.79e-15	1.54e-11	0.53	0.48	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
SARC	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	8.39	4.81e-15	1.55e-11	0.72	0.48	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
SARC	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	8.39	4.83e-15	1.56e-11	0.59	0.48	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
SARC	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-8.38	4.86e-15	1.57e-11	-0.57	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
SARC	cis	rs1865760	0.623	rs12216125	ENSG00000272462.2	U91328.19	-8.38	4.95e-15	1.59e-11	-0.47	-0.48	Height;	chr6:25997230	chr6:25992662~26001775:+
SARC	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-8.38	4.96e-15	1.59e-11	-0.52	-0.48	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
SARC	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	8.38	4.96e-15	1.59e-11	0.53	0.48	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
SARC	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	8.38	4.98e-15	1.6e-11	0.57	0.48	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
SARC	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-8.38	4.99e-15	1.6e-11	-0.8	-0.48	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
SARC	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-8.38	5.06e-15	1.62e-11	-0.51	-0.48	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-8.38	5.06e-15	1.62e-11	-0.51	-0.48	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
SARC	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	8.38	5.12e-15	1.64e-11	0.72	0.48	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
SARC	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	8.38	5.14e-15	1.65e-11	0.59	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
SARC	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	8.38	5.16e-15	1.66e-11	0.58	0.48	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	8.37	5.23e-15	1.68e-11	0.57	0.48	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
SARC	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-8.37	5.25e-15	1.68e-11	-0.54	-0.48	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
SARC	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	8.37	5.26e-15	1.69e-11	0.51	0.48	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
SARC	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	8.37	5.26e-15	1.69e-11	0.67	0.48	Depression;	chr6:28142370	chr6:28115628~28116551:+
SARC	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-8.37	5.3e-15	1.7e-11	-0.52	-0.48	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
SARC	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	8.37	5.34e-15	1.71e-11	0.59	0.48	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	8.37	5.34e-15	1.71e-11	0.59	0.48	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	8.37	5.34e-15	1.71e-11	0.59	0.48	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
SARC	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	8.37	5.36e-15	1.72e-11	0.77	0.48	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
SARC	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-8.37	5.38e-15	1.72e-11	-0.67	-0.48	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
SARC	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	8.37	5.38e-15	1.72e-11	0.85	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
SARC	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-8.37	5.39e-15	1.72e-11	-0.5	-0.48	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
SARC	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	8.37	5.4e-15	1.72e-11	0.54	0.48	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	8.37	5.4e-15	1.72e-11	0.54	0.48	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	8.37	5.4e-15	1.72e-11	0.54	0.48	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	8.37	5.4e-15	1.72e-11	0.54	0.48	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	8.37	5.4e-15	1.72e-11	0.54	0.48	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	8.37	5.4e-15	1.72e-11	0.54	0.48	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	8.37	5.4e-15	1.72e-11	0.54	0.48	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	8.37	5.4e-15	1.72e-11	0.54	0.48	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	8.37	5.4e-15	1.72e-11	0.54	0.48	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	8.37	5.42e-15	1.73e-11	0.54	0.48	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
SARC	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	8.37	5.42e-15	1.73e-11	0.53	0.48	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
SARC	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-8.37	5.46e-15	1.74e-11	-0.55	-0.48	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
SARC	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-8.37	5.51e-15	1.76e-11	-0.58	-0.48	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
SARC	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-8.36	5.58e-15	1.78e-11	-0.47	-0.48	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
SARC	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-8.36	5.58e-15	1.78e-11	-0.57	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
SARC	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	8.36	5.63e-15	1.79e-11	0.59	0.48	Depression;	chr6:28431469	chr6:28176188~28176674:+
SARC	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-8.36	5.66e-15	1.8e-11	-0.58	-0.48	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
SARC	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	8.36	5.77e-15	1.83e-11	0.59	0.48	Depression;	chr6:28428413	chr6:28176188~28176674:+
SARC	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	8.36	5.78e-15	1.84e-11	0.58	0.48	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
SARC	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-8.36	5.88e-15	1.87e-11	-0.58	-0.48	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
SARC	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-8.36	5.88e-15	1.87e-11	-0.58	-0.48	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
SARC	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	8.35	5.91e-15	1.88e-11	0.53	0.48	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
SARC	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-8.35	5.97e-15	1.9e-11	-0.61	-0.48	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
SARC	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	8.35	6.04e-15	1.92e-11	0.57	0.48	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
SARC	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-8.35	6.05e-15	1.92e-11	-0.49	-0.48	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
SARC	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-8.35	6.17e-15	1.95e-11	-0.51	-0.48	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
SARC	cis	rs1930961	1	rs9624834	ENSG00000100058.11	CRYBB2P1	8.35	6.18e-15	1.96e-11	0.89	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25448105~25520854:+
SARC	cis	rs1930961	1	rs9624835	ENSG00000100058.11	CRYBB2P1	8.35	6.18e-15	1.96e-11	0.89	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25448105~25520854:+
SARC	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-8.35	6.19e-15	1.96e-11	-0.62	-0.48	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
SARC	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-8.35	6.2e-15	1.96e-11	-0.47	-0.48	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
SARC	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-8.35	6.26e-15	1.98e-11	-0.56	-0.48	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
SARC	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-8.34	6.34e-15	2e-11	-0.52	-0.48	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
SARC	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	8.34	6.36e-15	2.01e-11	0.58	0.48	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
SARC	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-8.34	6.37e-15	2.02e-11	-0.56	-0.48	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
SARC	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	8.34	6.43e-15	2.03e-11	0.83	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	8.34	6.43e-15	2.03e-11	0.83	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	8.34	6.43e-15	2.03e-11	0.83	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	8.34	6.43e-15	2.03e-11	0.83	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	8.34	6.47e-15	2.04e-11	0.83	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
SARC	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-8.34	6.53e-15	2.06e-11	-0.7	-0.48	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
SARC	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-8.34	6.61e-15	2.09e-11	-0.5	-0.48	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-8.34	6.61e-15	2.09e-11	-0.5	-0.48	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
SARC	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	8.34	6.62e-15	2.09e-11	0.71	0.48	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
SARC	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	8.34	6.62e-15	2.09e-11	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
SARC	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-8.34	6.65e-15	2.1e-11	-0.61	-0.48	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
SARC	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-8.34	6.66e-15	2.1e-11	-0.47	-0.48	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-8.34	6.66e-15	2.1e-11	-0.47	-0.48	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
SARC	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	8.34	6.68e-15	2.1e-11	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
SARC	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	8.33	6.75e-15	2.12e-11	0.54	0.48	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	8.33	6.75e-15	2.12e-11	0.54	0.48	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
SARC	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	8.33	6.77e-15	2.13e-11	0.58	0.48	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	8.33	6.81e-15	2.14e-11	0.58	0.48	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
SARC	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-8.33	6.91e-15	2.17e-11	-0.55	-0.48	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
SARC	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-8.33	6.98e-15	2.19e-11	-0.54	-0.48	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
SARC	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-8.33	6.98e-15	2.19e-11	-0.54	-0.48	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
SARC	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	8.33	7.02e-15	2.21e-11	0.54	0.48	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	8.33	7.1e-15	2.23e-11	0.54	0.48	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	8.33	7.1e-15	2.23e-11	0.54	0.48	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
SARC	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	8.33	7.16e-15	2.24e-11	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	8.33	7.16e-15	2.24e-11	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
SARC	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	8.33	7.18e-15	2.25e-11	0.72	0.48	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
SARC	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	8.32	7.25e-15	2.27e-11	0.55	0.48	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	8.32	7.25e-15	2.27e-11	0.55	0.48	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	8.32	7.25e-15	2.27e-11	0.55	0.48	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	8.32	7.25e-15	2.27e-11	0.55	0.48	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
SARC	cis	rs1930961	1	rs7285549	ENSG00000100058.11	CRYBB2P1	8.32	7.34e-15	2.3e-11	0.89	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25448105~25520854:+
SARC	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	8.32	7.34e-15	2.3e-11	0.58	0.48	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	8.32	7.34e-15	2.3e-11	0.58	0.48	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	8.32	7.34e-15	2.3e-11	0.58	0.48	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	8.32	7.34e-15	2.3e-11	0.58	0.48	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	8.32	7.34e-15	2.3e-11	0.58	0.48	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	8.32	7.34e-15	2.3e-11	0.58	0.48	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	8.32	7.34e-15	2.3e-11	0.58	0.48	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	8.32	7.34e-15	2.3e-11	0.58	0.48	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	8.32	7.34e-15	2.3e-11	0.58	0.48	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	8.32	7.34e-15	2.3e-11	0.58	0.48	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	8.32	7.34e-15	2.3e-11	0.58	0.48	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
SARC	cis	rs1930961	1	rs6004662	ENSG00000100058.11	CRYBB2P1	8.32	7.35e-15	2.3e-11	0.9	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25448105~25520854:+
SARC	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	8.32	7.61e-15	2.37e-11	0.54	0.48	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
SARC	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-8.32	7.64e-15	2.38e-11	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-8.32	7.64e-15	2.38e-11	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-8.32	7.64e-15	2.38e-11	-0.61	-0.48	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
SARC	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	8.32	7.66e-15	2.39e-11	0.58	0.48	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
SARC	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-8.31	7.71e-15	2.4e-11	-0.61	-0.48	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-8.31	7.71e-15	2.4e-11	-0.61	-0.48	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-8.31	7.71e-15	2.4e-11	-0.61	-0.48	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
SARC	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-8.31	7.71e-15	2.4e-11	-0.61	-0.48	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
SARC	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-8.31	7.71e-15	2.4e-11	-0.61	-0.48	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-8.31	7.71e-15	2.4e-11	-0.61	-0.48	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-8.31	7.71e-15	2.4e-11	-0.61	-0.48	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-8.31	7.71e-15	2.4e-11	-0.61	-0.48	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	8.31	7.73e-15	2.4e-11	0.6	0.48	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
SARC	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	8.31	7.86e-15	2.43e-11	0.8	0.48	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	8.31	7.86e-15	2.43e-11	0.8	0.48	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	8.31	7.86e-15	2.43e-11	0.8	0.48	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	8.31	7.86e-15	2.43e-11	0.8	0.48	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	8.31	7.86e-15	2.43e-11	0.8	0.48	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	8.31	7.86e-15	2.43e-11	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	8.31	7.86e-15	2.43e-11	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	8.31	7.86e-15	2.43e-11	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	8.31	7.86e-15	2.43e-11	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	8.31	7.86e-15	2.43e-11	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	8.31	7.86e-15	2.43e-11	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
SARC	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	8.31	8.04e-15	2.49e-11	0.45	0.48	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-8.31	8.07e-15	2.5e-11	-0.46	-0.48	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
SARC	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	8.3	8.24e-15	2.55e-11	0.58	0.48	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	8.3	8.24e-15	2.55e-11	0.58	0.48	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
SARC	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-8.3	8.39e-15	2.59e-11	-0.46	-0.48	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
SARC	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-8.3	8.41e-15	2.6e-11	-0.54	-0.48	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
SARC	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-8.3	8.54e-15	2.64e-11	-0.52	-0.48	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
SARC	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	8.3	8.56e-15	2.64e-11	0.54	0.48	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
SARC	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	8.29	8.82e-15	2.72e-11	0.81	0.48	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
SARC	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	8.29	8.82e-15	2.72e-11	0.5	0.48	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
SARC	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	8.29	8.86e-15	2.73e-11	0.67	0.48	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
SARC	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	8.29	8.86e-15	2.73e-11	0.67	0.48	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
SARC	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	8.29	8.9e-15	2.74e-11	0.59	0.48	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
SARC	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-8.29	8.97e-15	2.76e-11	-0.54	-0.48	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
SARC	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-8.29	8.97e-15	2.76e-11	-0.54	-0.48	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
SARC	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-8.29	8.99e-15	2.77e-11	-0.6	-0.48	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
SARC	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	8.29	9.02e-15	2.78e-11	0.57	0.48	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	8.29	9.02e-15	2.78e-11	0.57	0.48	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
SARC	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-8.29	9.11e-15	2.8e-11	-0.6	-0.48	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
SARC	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	8.29	9.13e-15	2.81e-11	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	8.29	9.13e-15	2.81e-11	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
SARC	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	8.29	9.25e-15	2.84e-11	0.6	0.48	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
SARC	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-8.29	9.25e-15	2.84e-11	-0.5	-0.48	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
SARC	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	8.29	9.29e-15	2.85e-11	0.58	0.48	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
SARC	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	8.28	9.41e-15	2.89e-11	0.58	0.48	Depression;	chr6:28402301	chr6:28176188~28176674:+
SARC	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-8.28	9.42e-15	2.89e-11	-0.56	-0.48	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
SARC	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	8.28	9.49e-15	2.91e-11	0.55	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
SARC	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	8.28	9.5e-15	2.91e-11	0.81	0.48	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
SARC	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	8.28	9.5e-15	2.91e-11	0.81	0.48	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
SARC	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	8.28	9.5e-15	2.91e-11	0.81	0.48	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
SARC	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	8.28	9.5e-15	2.91e-11	0.81	0.48	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
SARC	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-8.28	9.58e-15	2.93e-11	-0.62	-0.48	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	8.28	9.59e-15	2.94e-11	0.57	0.48	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	8.28	9.59e-15	2.94e-11	0.57	0.48	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	8.28	9.59e-15	2.94e-11	0.57	0.48	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	8.28	9.59e-15	2.94e-11	0.57	0.48	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
SARC	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-8.28	9.78e-15	2.99e-11	-0.47	-0.48	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-8.28	9.78e-15	2.99e-11	-0.47	-0.48	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-8.28	9.78e-15	2.99e-11	-0.47	-0.48	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
SARC	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-8.28	9.82e-15	2.99e-11	-0.57	-0.48	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
SARC	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
SARC	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	8.28	9.86e-15	2.99e-11	0.53	0.48	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
SARC	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	8.28	9.87e-15	2.99e-11	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	8.28	9.87e-15	2.99e-11	0.81	0.48	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	8.28	9.87e-15	2.99e-11	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	8.28	9.87e-15	2.99e-11	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
SARC	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	8.28	9.89e-15	3e-11	0.78	0.48	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
SARC	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-8.28	9.93e-15	3.01e-11	-0.52	-0.48	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
SARC	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	8.27	1e-14	3.04e-11	0.58	0.48	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	8.27	1.02e-14	3.08e-11	0.57	0.48	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
SARC	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	8.27	1.04e-14	3.13e-11	0.54	0.48	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
SARC	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	8.27	1.04e-14	3.15e-11	0.57	0.48	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
SARC	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	8.27	1.05e-14	3.17e-11	0.58	0.48	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
SARC	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	8.27	1.05e-14	3.17e-11	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	8.27	1.05e-14	3.17e-11	0.8	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
SARC	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	8.27	1.05e-14	3.17e-11	0.58	0.48	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	8.26	1.06e-14	3.2e-11	0.58	0.48	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	8.26	1.06e-14	3.2e-11	0.58	0.48	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	8.26	1.06e-14	3.2e-11	0.58	0.48	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	8.26	1.06e-14	3.2e-11	0.58	0.48	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	8.26	1.06e-14	3.2e-11	0.58	0.48	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	8.26	1.06e-14	3.2e-11	0.58	0.48	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	8.26	1.06e-14	3.2e-11	0.58	0.48	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	8.26	1.06e-14	3.2e-11	0.58	0.48	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	8.26	1.06e-14	3.2e-11	0.58	0.48	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
SARC	cis	rs1930961	1	rs760555	ENSG00000100058.11	CRYBB2P1	8.26	1.07e-14	3.22e-11	0.9	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25448105~25520854:+
SARC	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-8.26	1.07e-14	3.22e-11	-0.6	-0.48	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
SARC	cis	rs1930961	1	rs6004657	ENSG00000100058.11	CRYBB2P1	8.26	1.07e-14	3.23e-11	0.89	0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25459747	chr22:25448105~25520854:+
SARC	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	8.26	1.08e-14	3.26e-11	0.57	0.48	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
SARC	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-8.26	1.09e-14	3.27e-11	-0.42	-0.48	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
SARC	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-8.26	1.09e-14	3.28e-11	-0.58	-0.48	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
SARC	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	8.26	1.1e-14	3.31e-11	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
SARC	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	8.26	1.11e-14	3.33e-11	0.58	0.48	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
SARC	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-8.26	1.13e-14	3.39e-11	-0.62	-0.48	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
SARC	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-8.25	1.14e-14	3.42e-11	-0.45	-0.48	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
SARC	cis	rs1930961	1	rs1930961	ENSG00000272977.1	CTA-390C10.10	-8.25	1.15e-14	3.45e-11	-0.8	-0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25476218~25479971:+
SARC	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	8.25	1.16e-14	3.48e-11	0.59	0.48	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
SARC	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-8.25	1.17e-14	3.48e-11	-0.59	-0.48	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
SARC	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-8.25	1.17e-14	3.48e-11	-0.59	-0.48	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
SARC	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	8.25	1.17e-14	3.49e-11	0.58	0.48	Depression;	chr6:28430971	chr6:28176188~28176674:+
SARC	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	8.25	1.17e-14	3.49e-11	0.58	0.48	Depression;	chr6:28432562	chr6:28176188~28176674:+
SARC	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-8.25	1.17e-14	3.5e-11	-0.46	-0.48	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
SARC	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-8.25	1.17e-14	3.5e-11	-0.46	-0.48	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
SARC	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-8.25	1.17e-14	3.5e-11	-0.46	-0.48	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
SARC	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-8.25	1.17e-14	3.5e-11	-0.46	-0.48	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
SARC	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	8.25	1.18e-14	3.53e-11	0.45	0.48	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
SARC	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	8.25	1.19e-14	3.54e-11	0.6	0.48	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	8.25	1.19e-14	3.54e-11	0.6	0.48	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	8.25	1.2e-14	3.56e-11	0.58	0.48	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
SARC	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	8.25	1.2e-14	3.57e-11	0.5	0.48	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
SARC	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	8.25	1.2e-14	3.57e-11	0.58	0.48	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
SARC	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	8.25	1.2e-14	3.57e-11	0.58	0.48	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	8.24	1.23e-14	3.67e-11	0.61	0.48	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
SARC	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-8.24	1.24e-14	3.68e-11	-0.78	-0.48	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
SARC	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-8.24	1.24e-14	3.69e-11	-0.53	-0.48	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
SARC	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-8.24	1.27e-14	3.77e-11	-0.63	-0.47	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
SARC	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-8.24	1.28e-14	3.81e-11	-0.61	-0.47	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
SARC	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	8.23	1.3e-14	3.86e-11	0.55	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
SARC	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	8.23	1.32e-14	3.91e-11	0.57	0.47	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
SARC	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-8.23	1.32e-14	3.91e-11	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
SARC	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-8.23	1.34e-14	3.97e-11	-0.57	-0.47	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
SARC	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-8.23	1.35e-14	4.01e-11	-0.63	-0.47	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-8.23	1.35e-14	4.01e-11	-0.63	-0.47	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
SARC	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	8.23	1.36e-14	4.03e-11	0.6	0.47	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
SARC	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-8.23	1.37e-14	4.05e-11	-0.6	-0.47	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
SARC	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-8.23	1.37e-14	4.06e-11	-0.52	-0.47	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
SARC	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	8.22	1.4e-14	4.14e-11	0.6	0.47	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
SARC	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	8.22	1.43e-14	4.23e-11	0.71	0.47	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
SARC	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	8.22	1.44e-14	4.26e-11	0.94	0.47	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
SARC	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	8.22	1.46e-14	4.32e-11	0.6	0.47	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	8.22	1.46e-14	4.32e-11	0.87	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	8.22	1.46e-14	4.32e-11	0.87	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	8.22	1.46e-14	4.32e-11	0.87	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
SARC	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-8.22	1.46e-14	4.32e-11	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
SARC	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	8.22	1.46e-14	4.32e-11	0.57	0.47	Depression;	chr6:28407125	chr6:28176188~28176674:+
SARC	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-8.21	1.47e-14	4.33e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
SARC	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-8.21	1.47e-14	4.33e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
SARC	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-8.21	1.47e-14	4.33e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
SARC	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-8.21	1.47e-14	4.33e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
SARC	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-8.21	1.47e-14	4.33e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
SARC	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	8.21	1.48e-14	4.36e-11	0.62	0.47	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
SARC	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	8.21	1.48e-14	4.36e-11	0.62	0.47	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	8.21	1.49e-14	4.38e-11	0.82	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
SARC	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-8.21	1.51e-14	4.45e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
SARC	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	8.21	1.52e-14	4.47e-11	0.53	0.47	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	8.21	1.52e-14	4.47e-11	0.53	0.47	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	8.21	1.52e-14	4.47e-11	0.53	0.47	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	8.21	1.52e-14	4.47e-11	0.53	0.47	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
SARC	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	8.21	1.52e-14	4.48e-11	0.94	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
SARC	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-8.21	1.53e-14	4.51e-11	-0.52	-0.47	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
SARC	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-8.21	1.54e-14	4.52e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-8.21	1.54e-14	4.52e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
SARC	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-8.21	1.56e-14	4.58e-11	-0.47	-0.47	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-8.21	1.56e-14	4.58e-11	-0.47	-0.47	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-8.21	1.56e-14	4.58e-11	-0.47	-0.47	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-8.21	1.56e-14	4.58e-11	-0.47	-0.47	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-8.21	1.56e-14	4.58e-11	-0.47	-0.47	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
SARC	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	8.21	1.56e-14	4.59e-11	0.62	0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
SARC	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-8.2	1.57e-14	4.61e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
SARC	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	8.2	1.59e-14	4.66e-11	0.57	0.47	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
SARC	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-8.2	1.59e-14	4.67e-11	-0.47	-0.47	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
SARC	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-8.2	1.6e-14	4.68e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
SARC	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	8.2	1.61e-14	4.71e-11	0.52	0.47	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
SARC	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	8.2	1.62e-14	4.75e-11	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
SARC	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-8.2	1.63e-14	4.78e-11	-0.52	-0.47	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-8.2	1.63e-14	4.78e-11	-0.52	-0.47	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
SARC	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-8.2	1.64e-14	4.79e-11	-0.47	-0.47	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
SARC	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-8.2	1.64e-14	4.8e-11	-0.52	-0.47	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
SARC	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	8.2	1.65e-14	4.83e-11	0.54	0.47	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	8.2	1.65e-14	4.83e-11	0.54	0.47	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
SARC	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-8.2	1.66e-14	4.85e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
SARC	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-8.2	1.66e-14	4.86e-11	-0.47	-0.47	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-8.2	1.66e-14	4.86e-11	-0.47	-0.47	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
SARC	cis	rs765787	0.53	rs2413775	ENSG00000259520.4	CTD-2651B20.3	8.2	1.67e-14	4.87e-11	0.53	0.47	Uric acid levels;	chr15:45252090	chr15:45251580~45279251:-
SARC	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-8.2	1.67e-14	4.88e-11	-0.49	-0.47	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
SARC	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-8.19	1.67e-14	4.89e-11	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-8.19	1.67e-14	4.89e-11	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
SARC	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	8.19	1.68e-14	4.9e-11	0.51	0.47	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
SARC	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	8.19	1.73e-14	5.03e-11	0.74	0.47	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
SARC	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	8.19	1.74e-14	5.07e-11	0.65	0.47	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
SARC	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-8.19	1.74e-14	5.08e-11	-0.86	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
SARC	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-8.19	1.76e-14	5.12e-11	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-8.19	1.76e-14	5.12e-11	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-8.19	1.76e-14	5.12e-11	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
SARC	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	8.19	1.78e-14	5.17e-11	0.53	0.47	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
SARC	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	8.18	1.78e-14	5.18e-11	0.52	0.47	Temperament;	chr17:14068990	chr17:14024514~14025488:+
SARC	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-8.18	1.81e-14	5.25e-11	-0.6	-0.47	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
SARC	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	8.18	1.81e-14	5.26e-11	0.71	0.47	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
SARC	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	8.18	1.83e-14	5.3e-11	0.74	0.47	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
SARC	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	8.18	1.83e-14	5.32e-11	0.6	0.47	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
SARC	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-8.18	1.83e-14	5.32e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-8.18	1.83e-14	5.32e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
SARC	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	8.18	1.85e-14	5.36e-11	0.57	0.47	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
SARC	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-8.18	1.86e-14	5.39e-11	-0.6	-0.47	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
SARC	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-8.18	1.88e-14	5.45e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-8.18	1.88e-14	5.45e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-8.18	1.88e-14	5.45e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-8.18	1.88e-14	5.45e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-8.18	1.88e-14	5.45e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-8.18	1.88e-14	5.45e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-8.18	1.88e-14	5.45e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-8.18	1.88e-14	5.45e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-8.18	1.88e-14	5.45e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-8.18	1.88e-14	5.45e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
SARC	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	8.17	1.9e-14	5.49e-11	0.58	0.47	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
SARC	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	8.17	1.92e-14	5.55e-11	0.56	0.47	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
SARC	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-8.17	1.98e-14	5.71e-11	-0.54	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
SARC	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	8.17	2.01e-14	5.81e-11	0.54	0.47	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
SARC	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	8.16	2.03e-14	5.85e-11	0.45	0.47	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
SARC	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	8.16	2.03e-14	5.85e-11	0.45	0.47	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
SARC	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	8.16	2.03e-14	5.87e-11	0.58	0.47	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	8.16	2.03e-14	5.87e-11	0.58	0.47	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	8.16	2.03e-14	5.87e-11	0.58	0.47	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	8.16	2.05e-14	5.91e-11	0.58	0.47	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
SARC	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-8.16	2.07e-14	5.97e-11	-0.56	-0.47	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
SARC	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	8.16	2.09e-14	6.02e-11	0.62	0.47	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
SARC	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-8.16	2.1e-14	6.05e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
SARC	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	8.16	2.12e-14	6.11e-11	0.62	0.47	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
SARC	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-8.16	2.14e-14	6.14e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-8.16	2.14e-14	6.14e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-8.16	2.14e-14	6.14e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
SARC	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-8.16	2.14e-14	6.14e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-8.16	2.14e-14	6.14e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-8.16	2.14e-14	6.14e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
SARC	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-8.16	2.14e-14	6.14e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
SARC	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-8.16	2.14e-14	6.14e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
SARC	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-8.16	2.14e-14	6.14e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
SARC	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-8.16	2.14e-14	6.14e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
SARC	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-8.16	2.15e-14	6.16e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
SARC	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	8.16	2.15e-14	6.18e-11	0.57	0.47	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	8.15	2.18e-14	6.27e-11	0.58	0.47	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
SARC	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-8.15	2.19e-14	6.27e-11	-0.55	-0.47	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
SARC	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	8.15	2.2e-14	6.32e-11	0.61	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
SARC	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-8.15	2.22e-14	6.36e-11	-0.61	-0.47	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
SARC	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-8.15	2.22e-14	6.36e-11	-0.61	-0.47	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
SARC	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-8.15	2.23e-14	6.38e-11	-0.47	-0.47	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
SARC	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	8.15	2.23e-14	6.4e-11	0.5	0.47	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
SARC	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	8.15	2.24e-14	6.41e-11	0.58	0.47	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	8.15	2.24e-14	6.41e-11	0.58	0.47	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
SARC	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-8.15	2.25e-14	6.43e-11	-0.55	-0.47	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
SARC	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-8.15	2.26e-14	6.48e-11	-0.51	-0.47	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
SARC	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-8.15	2.27e-14	6.51e-11	-0.86	-0.47	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
SARC	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	8.15	2.29e-14	6.54e-11	0.45	0.47	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
SARC	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	8.15	2.29e-14	6.54e-11	0.45	0.47	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
SARC	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-8.15	2.3e-14	6.57e-11	-0.48	-0.47	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
SARC	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	8.15	2.3e-14	6.57e-11	0.58	0.47	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	8.15	2.3e-14	6.57e-11	0.58	0.47	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	8.15	2.3e-14	6.57e-11	0.58	0.47	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
SARC	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	8.14	2.32e-14	6.62e-11	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
SARC	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-8.14	2.34e-14	6.7e-11	-0.53	-0.47	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
SARC	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	8.14	2.35e-14	6.7e-11	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	8.14	2.35e-14	6.7e-11	0.8	0.47	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	8.14	2.35e-14	6.7e-11	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	8.14	2.35e-14	6.7e-11	0.8	0.47	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	8.14	2.35e-14	6.7e-11	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	8.14	2.35e-14	6.7e-11	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	8.14	2.35e-14	6.7e-11	0.8	0.47	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	8.14	2.35e-14	6.7e-11	0.8	0.47	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	8.14	2.35e-14	6.7e-11	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	8.14	2.35e-14	6.7e-11	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	8.14	2.35e-14	6.7e-11	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
SARC	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-8.14	2.36e-14	6.72e-11	-0.61	-0.47	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
SARC	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	8.14	2.37e-14	6.75e-11	0.51	0.47	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
SARC	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-8.14	2.39e-14	6.82e-11	-0.6	-0.47	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
SARC	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-8.14	2.39e-14	6.82e-11	-0.6	-0.47	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
SARC	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	8.14	2.43e-14	6.93e-11	0.6	0.47	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
SARC	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	8.13	2.46e-14	6.99e-11	0.58	0.47	Depression;	chr6:28379133	chr6:28176188~28176674:+
SARC	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	8.13	2.46e-14	6.99e-11	0.58	0.47	Depression;	chr6:28379168	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-8.13	2.51e-14	7.13e-11	-0.68	-0.47	Depression;	chr6:28140307	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-8.13	2.51e-14	7.13e-11	-0.68	-0.47	Depression;	chr6:28140454	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-8.13	2.51e-14	7.13e-11	-0.68	-0.47	Depression;	chr6:28141189	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-8.13	2.51e-14	7.13e-11	-0.68	-0.47	Depression;	chr6:28141484	chr6:28115628~28116551:+
SARC	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	8.13	2.51e-14	7.14e-11	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	8.13	2.51e-14	7.14e-11	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	8.13	2.51e-14	7.14e-11	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	8.13	2.51e-14	7.14e-11	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	8.13	2.51e-14	7.14e-11	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
SARC	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-8.13	2.56e-14	7.25e-11	-0.61	-0.47	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-8.13	2.56e-14	7.26e-11	-0.62	-0.47	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
SARC	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	8.13	2.57e-14	7.27e-11	0.6	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	8.13	2.57e-14	7.27e-11	0.6	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
SARC	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-8.13	2.58e-14	7.32e-11	-0.62	-0.47	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
SARC	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	8.13	2.61e-14	7.36e-11	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	8.13	2.61e-14	7.36e-11	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	8.13	2.61e-14	7.36e-11	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	8.13	2.61e-14	7.36e-11	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	8.13	2.61e-14	7.36e-11	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	8.13	2.61e-14	7.36e-11	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	8.13	2.61e-14	7.36e-11	0.81	0.47	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	8.13	2.61e-14	7.36e-11	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	8.13	2.61e-14	7.36e-11	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	8.13	2.61e-14	7.36e-11	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
SARC	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-8.12	2.62e-14	7.4e-11	-0.66	-0.47	Depression;	chr6:28133900	chr6:28115628~28116551:+
SARC	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-8.12	2.64e-14	7.46e-11	-0.61	-0.47	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
SARC	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	8.12	2.65e-14	7.47e-11	0.66	0.47	Depression;	chr6:28167882	chr6:28115628~28116551:+
SARC	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-8.12	2.65e-14	7.48e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
SARC	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-8.12	2.71e-14	7.63e-11	-0.55	-0.47	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
SARC	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-8.12	2.71e-14	7.63e-11	-0.55	-0.47	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
SARC	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-8.12	2.71e-14	7.63e-11	-0.51	-0.47	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-8.12	2.71e-14	7.63e-11	-0.51	-0.47	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
SARC	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-8.12	2.72e-14	7.66e-11	-0.43	-0.47	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
SARC	cis	rs324126	0.743	rs34221182	ENSG00000277977.1	CTD-3018O17.5	8.12	2.72e-14	7.66e-11	0.47	0.47	Colonoscopy-negative controls vs population controls;	chr19:52378107	chr19:52392659~52392755:+
SARC	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-8.12	2.79e-14	7.84e-11	-0.52	-0.47	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
SARC	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	8.12	2.79e-14	7.85e-11	0.57	0.47	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
SARC	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-8.11	2.79e-14	7.86e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-8.11	2.79e-14	7.86e-11	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
SARC	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	8.11	2.83e-14	7.96e-11	0.57	0.47	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	8.11	2.84e-14	7.99e-11	0.57	0.47	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	8.11	2.84e-14	7.99e-11	0.57	0.47	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
SARC	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-8.11	2.86e-14	8.02e-11	-0.67	-0.47	Depression;	chr6:28145952	chr6:28115628~28116551:+
SARC	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	8.11	2.87e-14	8.05e-11	0.61	0.47	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
SARC	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	8.11	2.87e-14	8.07e-11	0.75	0.47	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
SARC	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-8.11	2.88e-14	8.1e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
SARC	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-8.11	2.9e-14	8.13e-11	-0.53	-0.47	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
SARC	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	8.11	2.93e-14	8.22e-11	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
SARC	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-8.11	2.93e-14	8.22e-11	-0.67	-0.47	Depression;	chr6:28143758	chr6:28115628~28116551:+
SARC	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	8.11	2.97e-14	8.32e-11	0.85	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
SARC	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-8.1	2.98e-14	8.34e-11	-0.62	-0.47	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-8.1	2.98e-14	8.34e-11	-0.62	-0.47	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-8.1	2.98e-14	8.34e-11	-0.62	-0.47	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-8.1	2.98e-14	8.34e-11	-0.62	-0.47	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-8.1	2.98e-14	8.34e-11	-0.62	-0.47	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-8.1	2.98e-14	8.34e-11	-0.62	-0.47	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-8.1	2.98e-14	8.34e-11	-0.62	-0.47	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-8.1	2.98e-14	8.34e-11	-0.62	-0.47	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-8.1	2.98e-14	8.34e-11	-0.62	-0.47	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-8.1	2.98e-14	8.34e-11	-0.62	-0.47	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
SARC	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	8.1	2.99e-14	8.36e-11	0.67	0.47	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
SARC	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-8.1	3e-14	8.41e-11	-0.66	-0.47	Depression;	chr6:28123153	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-8.1	3e-14	8.41e-11	-0.66	-0.47	Depression;	chr6:28124529	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-8.1	3e-14	8.41e-11	-0.66	-0.47	Depression;	chr6:28126588	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-8.1	3e-14	8.41e-11	-0.66	-0.47	Depression;	chr6:28126953	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-8.1	3e-14	8.41e-11	-0.66	-0.47	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-8.1	3e-14	8.41e-11	-0.66	-0.47	Depression;	chr6:28127577	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-8.1	3e-14	8.41e-11	-0.66	-0.47	Depression;	chr6:28131566	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	8.1	3.04e-14	8.49e-11	0.57	0.47	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
SARC	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-8.1	3.04e-14	8.5e-11	-0.62	-0.47	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
SARC	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-8.1	3.04e-14	8.5e-11	-0.54	-0.47	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
SARC	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	8.1	3.04e-14	8.5e-11	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
SARC	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-8.1	3.06e-14	8.54e-11	-0.57	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
SARC	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	8.1	3.14e-14	8.76e-11	0.57	0.47	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
SARC	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	8.1	3.14e-14	8.76e-11	0.54	0.47	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	8.1	3.16e-14	8.8e-11	0.56	0.47	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	8.1	3.16e-14	8.8e-11	0.56	0.47	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	8.1	3.16e-14	8.8e-11	0.56	0.47	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
SARC	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	8.1	3.16e-14	8.8e-11	0.58	0.47	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
SARC	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-8.09	3.22e-14	8.96e-11	-0.56	-0.47	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
SARC	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	8.09	3.27e-14	9.09e-11	0.58	0.47	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
SARC	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-8.09	3.28e-14	9.11e-11	-0.67	-0.47	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
SARC	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	8.09	3.34e-14	9.29e-11	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
SARC	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	8.08	3.41e-14	9.46e-11	0.75	0.47	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	8.08	3.41e-14	9.46e-11	0.75	0.47	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
SARC	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	8.08	3.41e-14	9.46e-11	0.75	0.47	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
SARC	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Depression;	chr6:28111382	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Depression;	chr6:28111650	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Depression;	chr6:28112175	chr6:28115628~28116551:+
SARC	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Depression;	chr6:28113616	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Depression;	chr6:28113851	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Depression;	chr6:28114487	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Depression;	chr6:28114933	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Depression;	chr6:28115743	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Depression;	chr6:28116411	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-8.08	3.47e-14	9.6e-11	-0.66	-0.47	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
SARC	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	8.08	3.47e-14	9.61e-11	0.56	0.47	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
SARC	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	8.08	3.49e-14	9.65e-11	0.83	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
SARC	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-8.08	3.59e-14	9.93e-11	-0.46	-0.47	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
SARC	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-8.08	3.6e-14	9.94e-11	-0.63	-0.47	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	8.07	3.64e-14	1e-10	0.57	0.47	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
SARC	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-8.07	3.65e-14	1.01e-10	-0.58	-0.47	Depression;	chr6:28422360	chr6:28176188~28176674:+
SARC	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-8.07	3.7e-14	1.02e-10	-0.62	-0.47	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
SARC	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-8.07	3.7e-14	1.02e-10	-0.51	-0.47	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
SARC	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-8.07	3.77e-14	1.04e-10	-0.56	-0.47	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
SARC	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	8.07	3.8e-14	1.05e-10	0.53	0.47	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	8.07	3.8e-14	1.05e-10	0.53	0.47	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
SARC	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	8.07	3.82e-14	1.05e-10	0.59	0.47	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
SARC	cis	rs1930961	1	rs6004669	ENSG00000100058.11	CRYBB2P1	8.07	3.83e-14	1.06e-10	0.88	0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25448105~25520854:+
SARC	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	8.06	3.87e-14	1.06e-10	0.73	0.47	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
SARC	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	8.06	3.9e-14	1.07e-10	0.57	0.47	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	8.06	3.9e-14	1.07e-10	0.57	0.47	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	8.06	3.9e-14	1.07e-10	0.57	0.47	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	8.06	3.9e-14	1.07e-10	0.57	0.47	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	8.06	3.9e-14	1.07e-10	0.57	0.47	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	8.06	3.9e-14	1.07e-10	0.57	0.47	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	8.06	3.9e-14	1.07e-10	0.57	0.47	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	8.06	3.9e-14	1.07e-10	0.57	0.47	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
SARC	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-8.06	3.95e-14	1.08e-10	-0.46	-0.47	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
SARC	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-8.06	3.95e-14	1.08e-10	-0.46	-0.47	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
SARC	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-8.06	3.95e-14	1.08e-10	-0.46	-0.47	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
SARC	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-8.06	3.95e-14	1.08e-10	-0.46	-0.47	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
SARC	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-8.06	4.01e-14	1.1e-10	-0.62	-0.47	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-8.06	4.01e-14	1.1e-10	-0.62	-0.47	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-8.06	4.01e-14	1.1e-10	-0.62	-0.47	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-8.06	4.01e-14	1.1e-10	-0.62	-0.47	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-8.06	4.01e-14	1.1e-10	-0.62	-0.47	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-8.06	4.01e-14	1.1e-10	-0.62	-0.47	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-8.06	4.01e-14	1.1e-10	-0.62	-0.47	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-8.06	4.01e-14	1.1e-10	-0.62	-0.47	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-8.06	4.03e-14	1.1e-10	-0.62	-0.47	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
SARC	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	8.06	4.03e-14	1.1e-10	0.81	0.47	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	8.06	4.03e-14	1.1e-10	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	8.06	4.03e-14	1.1e-10	0.81	0.47	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	8.06	4.03e-14	1.1e-10	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	8.06	4.03e-14	1.1e-10	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	8.06	4.03e-14	1.1e-10	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	8.06	4.03e-14	1.1e-10	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	8.06	4.03e-14	1.1e-10	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
SARC	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-8.06	4.07e-14	1.11e-10	-0.66	-0.47	Depression;	chr6:28110254	chr6:28115628~28116551:+
SARC	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	8.06	4.08e-14	1.11e-10	0.49	0.47	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
SARC	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	8.06	4.09e-14	1.12e-10	0.57	0.47	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
SARC	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	8.06	4.1e-14	1.12e-10	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
SARC	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	8.05	4.13e-14	1.13e-10	0.58	0.47	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	8.05	4.13e-14	1.13e-10	0.58	0.47	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	8.05	4.13e-14	1.13e-10	0.58	0.47	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
SARC	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-8.05	4.17e-14	1.14e-10	-0.6	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
SARC	cis	rs324126	0.78	rs4802926	ENSG00000277977.1	CTD-3018O17.5	-8.05	4.21e-14	1.15e-10	-0.46	-0.47	Colonoscopy-negative controls vs population controls;	chr19:52377012	chr19:52392659~52392755:+
SARC	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	8.05	4.22e-14	1.15e-10	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
SARC	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-8.05	4.23e-14	1.15e-10	-0.52	-0.47	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-8.05	4.23e-14	1.15e-10	-0.52	-0.47	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
SARC	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-8.05	4.23e-14	1.15e-10	-0.52	-0.47	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-8.05	4.23e-14	1.15e-10	-0.52	-0.47	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
SARC	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-8.05	4.29e-14	1.17e-10	-0.51	-0.47	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
SARC	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	8.05	4.35e-14	1.18e-10	0.8	0.47	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
SARC	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-8.04	4.39e-14	1.19e-10	-0.59	-0.47	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
SARC	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-8.04	4.39e-14	1.19e-10	-0.59	-0.47	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
SARC	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	8.04	4.43e-14	1.2e-10	0.56	0.47	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
SARC	cis	rs1930961	1	rs6004668	ENSG00000100058.11	CRYBB2P1	-8.04	4.46e-14	1.21e-10	-0.87	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25448105~25520854:+
SARC	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	8.04	4.53e-14	1.23e-10	0.58	0.47	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
SARC	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	8.04	4.54e-14	1.23e-10	0.52	0.47	Temperament;	chr17:13996939	chr17:14024514~14025488:+
SARC	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-8.04	4.58e-14	1.24e-10	-0.61	-0.47	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
SARC	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-8.04	4.59e-14	1.24e-10	-0.61	-0.47	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-8.04	4.59e-14	1.24e-10	-0.61	-0.47	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-8.04	4.59e-14	1.24e-10	-0.61	-0.47	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-8.04	4.59e-14	1.24e-10	-0.61	-0.47	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-8.04	4.59e-14	1.24e-10	-0.61	-0.47	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
SARC	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-8.04	4.59e-14	1.24e-10	-0.61	-0.47	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-8.04	4.59e-14	1.24e-10	-0.61	-0.47	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-8.04	4.59e-14	1.24e-10	-0.61	-0.47	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
SARC	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-8.04	4.6e-14	1.25e-10	-0.76	-0.47	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
SARC	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-8.04	4.6e-14	1.25e-10	-0.76	-0.47	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
SARC	cis	rs1930961	1	rs760555	ENSG00000272977.1	CTA-390C10.10	-8.04	4.61e-14	1.25e-10	-0.81	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25476218~25479971:+
SARC	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	8.04	4.63e-14	1.25e-10	0.51	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
SARC	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-8.04	4.65e-14	1.26e-10	-0.5	-0.47	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
SARC	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-8.03	4.7e-14	1.27e-10	-0.52	-0.47	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-8.03	4.7e-14	1.27e-10	-0.52	-0.47	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
SARC	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	8.03	4.72e-14	1.28e-10	0.6	0.47	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	8.03	4.72e-14	1.28e-10	0.6	0.47	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	8.03	4.72e-14	1.28e-10	0.6	0.47	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
SARC	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	8.03	4.8e-14	1.3e-10	0.64	0.47	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
SARC	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-8.03	4.81e-14	1.3e-10	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-8.03	4.81e-14	1.3e-10	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-8.03	4.81e-14	1.3e-10	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-8.03	4.81e-14	1.3e-10	-0.49	-0.47	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
SARC	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	8.03	4.88e-14	1.32e-10	0.56	0.47	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	8.03	4.88e-14	1.32e-10	0.56	0.47	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
SARC	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	8.03	4.9e-14	1.32e-10	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	8.03	4.9e-14	1.32e-10	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
SARC	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-8.03	4.91e-14	1.32e-10	-0.59	-0.47	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
SARC	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	8.02	5.01e-14	1.35e-10	0.85	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
SARC	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	8.02	5.05e-14	1.36e-10	0.49	0.47	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
SARC	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	8.02	5.07e-14	1.36e-10	0.72	0.47	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
SARC	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-8.02	5.12e-14	1.38e-10	-0.61	-0.47	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
SARC	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	8.02	5.13e-14	1.38e-10	0.45	0.47	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
SARC	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	8.02	5.16e-14	1.39e-10	0.56	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
SARC	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-8.02	5.18e-14	1.39e-10	-0.56	-0.47	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
SARC	cis	rs1930961	1	rs7285549	ENSG00000272977.1	CTA-390C10.10	-8.02	5.22e-14	1.4e-10	-0.8	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25476218~25479971:+
SARC	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	8.02	5.23e-14	1.41e-10	0.55	0.46	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
SARC	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	8.02	5.25e-14	1.41e-10	0.8	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	8.02	5.25e-14	1.41e-10	0.8	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	8.02	5.25e-14	1.41e-10	0.8	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
SARC	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	8.02	5.29e-14	1.42e-10	0.54	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
SARC	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-8.01	5.37e-14	1.44e-10	-0.62	-0.46	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
SARC	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-8.01	5.4e-14	1.45e-10	-0.59	-0.46	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
SARC	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-8.01	5.45e-14	1.46e-10	-0.6	-0.46	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
SARC	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	8.01	5.5e-14	1.47e-10	0.57	0.46	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
SARC	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-8.01	5.55e-14	1.49e-10	-0.71	-0.46	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
SARC	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	8.01	5.61e-14	1.5e-10	0.8	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
SARC	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-8	5.69e-14	1.52e-10	-0.62	-0.46	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
SARC	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	8	5.72e-14	1.53e-10	0.49	0.46	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
SARC	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	8	5.73e-14	1.53e-10	0.58	0.46	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
SARC	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-8	5.77e-14	1.54e-10	-0.59	-0.46	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
SARC	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-8	5.86e-14	1.57e-10	-0.55	-0.46	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
SARC	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	8	5.95e-14	1.59e-10	0.54	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
SARC	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-8	6.01e-14	1.6e-10	-0.62	-0.46	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
SARC	cis	rs1930961	1	rs5996946	ENSG00000100058.11	CRYBB2P1	7.99	6.02e-14	1.61e-10	0.87	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25448105~25520854:+
SARC	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	7.99	6.08e-14	1.62e-10	0.62	0.46	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-7.99	6.16e-14	1.64e-10	-0.84	-0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
SARC	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	7.99	6.16e-14	1.64e-10	0.57	0.46	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
SARC	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-7.99	6.19e-14	1.65e-10	-0.67	-0.46	Depression;	chr6:28144784	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	7.99	6.24e-14	1.66e-10	0.61	0.46	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
SARC	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	7.99	6.31e-14	1.68e-10	0.77	0.46	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
SARC	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-7.99	6.33e-14	1.68e-10	-0.62	-0.46	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	7.98	6.46e-14	1.72e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
SARC	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	7.98	6.51e-14	1.73e-10	0.57	0.46	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
SARC	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-7.98	6.55e-14	1.74e-10	-0.62	-0.46	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
SARC	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-7.98	6.56e-14	1.74e-10	-0.52	-0.46	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-7.98	6.56e-14	1.74e-10	-0.52	-0.46	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
SARC	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	7.98	6.59e-14	1.75e-10	0.49	0.46	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
SARC	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-7.98	6.6e-14	1.75e-10	-0.53	-0.46	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	7.98	6.62e-14	1.76e-10	0.61	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
SARC	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	7.98	6.67e-14	1.77e-10	0.61	0.46	Depression;	chr6:28187640	chr6:28115628~28116551:+
SARC	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	7.98	6.76e-14	1.79e-10	0.8	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
SARC	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-7.98	6.77e-14	1.79e-10	-0.54	-0.46	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
SARC	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	7.98	6.78e-14	1.8e-10	0.53	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	7.98	6.78e-14	1.8e-10	0.53	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	7.98	6.78e-14	1.8e-10	0.53	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	7.98	6.78e-14	1.8e-10	0.53	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	7.98	6.78e-14	1.8e-10	0.53	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
SARC	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	7.97	6.87e-14	1.82e-10	0.77	0.46	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
SARC	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	7.97	6.91e-14	1.83e-10	0.57	0.46	Depression;	chr6:28386473	chr6:28176188~28176674:+
SARC	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	7.97	6.91e-14	1.83e-10	0.57	0.46	Depression;	chr6:28391932	chr6:28176188~28176674:+
SARC	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	7.97	7.11e-14	1.88e-10	0.51	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
SARC	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	7.97	7.18e-14	1.9e-10	0.57	0.46	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	7.97	7.18e-14	1.9e-10	0.57	0.46	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
SARC	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	7.97	7.27e-14	1.92e-10	0.48	0.46	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	7.97	7.27e-14	1.92e-10	0.48	0.46	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
SARC	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	7.96	7.29e-14	1.92e-10	0.8	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
SARC	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	7.96	7.43e-14	1.96e-10	0.73	0.46	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
SARC	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	7.96	7.47e-14	1.97e-10	0.61	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	7.96	7.47e-14	1.97e-10	0.61	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	7.96	7.47e-14	1.97e-10	0.61	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
SARC	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	7.96	7.51e-14	1.98e-10	0.57	0.46	Depression;	chr6:28399846	chr6:28176188~28176674:+
SARC	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	7.96	7.52e-14	1.98e-10	0.6	0.46	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
SARC	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	7.96	7.52e-14	1.98e-10	0.6	0.46	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
SARC	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	7.96	7.52e-14	1.98e-10	0.6	0.46	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	7.96	7.52e-14	1.98e-10	0.6	0.46	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	7.96	7.52e-14	1.98e-10	0.6	0.46	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
SARC	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	7.96	7.61e-14	2e-10	0.59	0.46	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
SARC	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	7.96	7.61e-14	2e-10	0.65	0.46	Depression;	chr6:28086929	chr6:28115628~28116551:+
SARC	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-7.96	7.68e-14	2.02e-10	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
SARC	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	7.96	7.72e-14	2.03e-10	0.51	0.46	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
SARC	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-7.96	7.73e-14	2.03e-10	-0.61	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	7.95	7.92e-14	2.08e-10	0.57	0.46	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
SARC	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-7.95	8.08e-14	2.12e-10	-0.54	-0.46	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
SARC	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	7.95	8.23e-14	2.16e-10	0.58	0.46	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	7.95	8.26e-14	2.17e-10	0.56	0.46	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	7.94	8.35e-14	2.19e-10	0.56	0.46	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	7.94	8.35e-14	2.19e-10	0.56	0.46	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
SARC	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	7.94	8.38e-14	2.19e-10	0.58	0.46	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	7.94	8.38e-14	2.19e-10	0.58	0.46	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
SARC	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-7.94	8.4e-14	2.2e-10	-0.6	-0.46	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	7.94	8.4e-14	2.2e-10	0.61	0.46	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	7.94	8.4e-14	2.2e-10	0.61	0.46	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	7.94	8.42e-14	2.2e-10	0.57	0.46	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
SARC	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	7.94	8.43e-14	2.21e-10	0.69	0.46	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
SARC	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-7.94	8.47e-14	2.22e-10	-0.46	-0.46	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
SARC	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	7.94	8.48e-14	2.22e-10	0.48	0.46	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	7.94	8.51e-14	2.23e-10	0.48	0.46	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
SARC	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	7.94	8.51e-14	2.23e-10	0.53	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	7.94	8.51e-14	2.23e-10	0.53	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
SARC	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	7.94	8.58e-14	2.24e-10	0.58	0.46	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	7.94	8.62e-14	2.25e-10	0.56	0.46	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	7.94	8.62e-14	2.25e-10	0.56	0.46	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
SARC	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	7.94	8.62e-14	2.25e-10	0.48	0.46	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
SARC	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	7.94	8.7e-14	2.27e-10	0.57	0.46	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	7.94	8.7e-14	2.27e-10	0.57	0.46	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	7.94	8.7e-14	2.27e-10	0.57	0.46	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
SARC	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	7.94	8.81e-14	2.3e-10	0.64	0.46	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
SARC	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	7.94	8.81e-14	2.3e-10	0.64	0.46	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
SARC	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-7.93	8.83e-14	2.3e-10	-0.59	-0.46	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
SARC	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	7.93	8.95e-14	2.33e-10	0.57	0.46	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	7.93	8.95e-14	2.33e-10	0.56	0.46	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	7.93	8.95e-14	2.33e-10	0.56	0.46	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	7.93	8.95e-14	2.33e-10	0.56	0.46	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	7.93	8.95e-14	2.33e-10	0.56	0.46	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
SARC	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	7.93	8.97e-14	2.34e-10	0.53	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
SARC	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	7.93	9.15e-14	2.38e-10	0.57	0.46	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
SARC	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-7.93	9.23e-14	2.4e-10	-0.48	-0.46	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
SARC	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	7.93	9.26e-14	2.41e-10	0.56	0.46	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
SARC	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	7.92	9.43e-14	2.45e-10	0.6	0.46	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-7.92	9.44e-14	2.46e-10	-0.6	-0.46	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
SARC	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-7.92	9.45e-14	2.46e-10	-0.62	-0.46	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-7.92	9.45e-14	2.46e-10	-0.62	-0.46	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
SARC	cis	rs6964833	1	rs6967152	ENSG00000123965.13	PMS2P5	7.92	9.52e-14	2.47e-10	0.72	0.46	Menarche (age at onset);	chr7:74684983	chr7:74894116~74897835:+
SARC	cis	rs6964833	1	rs6964833	ENSG00000123965.13	PMS2P5	7.92	9.52e-14	2.47e-10	0.72	0.46	Menarche (age at onset);	chr7:74687575	chr7:74894116~74897835:+
SARC	cis	rs1930961	1	rs760554	ENSG00000272977.1	CTA-390C10.10	-7.92	9.57e-14	2.49e-10	-0.82	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25476218~25479971:+
SARC	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	7.92	9.58e-14	2.49e-10	0.69	0.46	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
SARC	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	7.92	9.67e-14	2.51e-10	0.56	0.46	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	7.92	9.67e-14	2.51e-10	0.56	0.46	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
SARC	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	7.92	9.71e-14	2.52e-10	0.73	0.46	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
SARC	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	7.92	9.82e-14	2.55e-10	0.49	0.46	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
SARC	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	7.92	9.87e-14	2.56e-10	0.56	0.46	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
SARC	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	7.92	9.89e-14	2.57e-10	0.6	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
SARC	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	7.92	9.97e-14	2.59e-10	0.43	0.46	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
SARC	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	7.92	9.97e-14	2.59e-10	0.43	0.46	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
SARC	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	7.91	1.02e-13	2.65e-10	0.56	0.46	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
SARC	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	7.91	1.04e-13	2.7e-10	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
SARC	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-7.91	1.05e-13	2.73e-10	-0.62	-0.46	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
SARC	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-7.91	1.05e-13	2.73e-10	-0.63	-0.46	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
SARC	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-7.91	1.06e-13	2.73e-10	-0.65	-0.46	Depression;	chr6:28090857	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-7.91	1.06e-13	2.73e-10	-0.65	-0.46	Depression;	chr6:28091242	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-7.91	1.06e-13	2.73e-10	-0.65	-0.46	Depression;	chr6:28091439	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-7.91	1.06e-13	2.73e-10	-0.65	-0.46	Depression;	chr6:28091659	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-7.91	1.06e-13	2.73e-10	-0.65	-0.46	Depression;	chr6:28092227	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-7.91	1.06e-13	2.73e-10	-0.65	-0.46	Depression;	chr6:28093966	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-7.91	1.06e-13	2.73e-10	-0.65	-0.46	Depression;	chr6:28094014	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-7.91	1.06e-13	2.73e-10	-0.65	-0.46	Depression;	chr6:28096077	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-7.91	1.06e-13	2.73e-10	-0.65	-0.46	Depression;	chr6:28096855	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	7.91	1.06e-13	2.74e-10	0.59	0.46	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
SARC	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-7.91	1.06e-13	2.75e-10	-0.5	-0.46	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-7.91	1.06e-13	2.75e-10	-0.5	-0.46	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-7.91	1.06e-13	2.75e-10	-0.5	-0.46	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
SARC	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	7.9	1.07e-13	2.75e-10	0.61	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	7.9	1.07e-13	2.75e-10	0.56	0.46	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
SARC	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	7.9	1.07e-13	2.75e-10	0.49	0.46	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
SARC	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-7.9	1.07e-13	2.76e-10	-0.49	-0.46	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
SARC	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	7.9	1.09e-13	2.81e-10	0.52	0.46	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
SARC	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	7.9	1.09e-13	2.81e-10	0.56	0.46	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
SARC	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-7.9	1.11e-13	2.85e-10	-0.5	-0.46	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
SARC	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	7.9	1.11e-13	2.85e-10	0.48	0.46	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
SARC	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	7.9	1.11e-13	2.86e-10	0.56	0.46	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
SARC	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-7.9	1.12e-13	2.87e-10	-0.45	-0.46	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
SARC	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	7.9	1.12e-13	2.88e-10	0.55	0.46	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
SARC	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	7.9	1.13e-13	2.91e-10	0.79	0.46	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
SARC	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	7.89	1.14e-13	2.92e-10	0.48	0.46	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
SARC	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-7.89	1.15e-13	2.96e-10	-0.61	-0.46	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
SARC	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	7.89	1.16e-13	2.98e-10	0.55	0.46	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
SARC	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	7.89	1.16e-13	2.99e-10	0.52	0.46	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
SARC	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	7.89	1.2e-13	3.07e-10	0.59	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
SARC	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-7.89	1.2e-13	3.09e-10	-0.52	-0.46	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
SARC	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	7.88	1.21e-13	3.1e-10	0.89	0.46	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	7.88	1.21e-13	3.1e-10	0.56	0.46	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
SARC	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-7.88	1.23e-13	3.16e-10	-0.8	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
SARC	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-7.88	1.25e-13	3.2e-10	-0.43	-0.46	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
SARC	cis	rs6964833	1	rs2301907	ENSG00000123965.13	PMS2P5	7.88	1.26e-13	3.22e-10	0.71	0.46	Menarche (age at onset);	chr7:74700517	chr7:74894116~74897835:+
SARC	cis	rs6964833	0.935	rs7795282	ENSG00000123965.13	PMS2P5	7.88	1.26e-13	3.22e-10	0.71	0.46	Menarche (age at onset);	chr7:74708526	chr7:74894116~74897835:+
SARC	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-7.88	1.27e-13	3.24e-10	-0.55	-0.46	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
SARC	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-7.87	1.29e-13	3.29e-10	-0.49	-0.46	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-7.87	1.29e-13	3.29e-10	-0.49	-0.46	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-7.87	1.29e-13	3.29e-10	-0.49	-0.46	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-7.87	1.29e-13	3.29e-10	-0.49	-0.46	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-7.87	1.29e-13	3.29e-10	-0.49	-0.46	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
SARC	cis	rs324126	0.78	rs3170100	ENSG00000277977.1	CTD-3018O17.5	7.87	1.29e-13	3.29e-10	0.47	0.46	Colonoscopy-negative controls vs population controls;	chr19:52385367	chr19:52392659~52392755:+
SARC	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	7.87	1.3e-13	3.3e-10	0.6	0.46	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	7.87	1.3e-13	3.3e-10	0.8	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
SARC	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	7.87	1.3e-13	3.3e-10	0.59	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	7.87	1.3e-13	3.3e-10	0.56	0.46	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
SARC	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	7.87	1.31e-13	3.3e-10	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
SARC	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	7.87	1.32e-13	3.34e-10	0.6	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
SARC	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-7.87	1.33e-13	3.35e-10	-0.65	-0.46	Depression;	chr6:28139049	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-7.87	1.33e-13	3.35e-10	-0.65	-0.46	Depression;	chr6:28139876	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-7.87	1.33e-13	3.35e-10	-0.65	-0.46	Depression;	chr6:28139998	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-7.87	1.33e-13	3.35e-10	-0.65	-0.46	Depression;	chr6:28136698	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-7.87	1.33e-13	3.35e-10	-0.65	-0.46	Depression;	chr6:28136856	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-7.87	1.33e-13	3.35e-10	-0.65	-0.46	Depression;	chr6:28138363	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-7.87	1.33e-13	3.35e-10	-0.65	-0.46	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-7.87	1.33e-13	3.35e-10	-0.65	-0.46	Depression;	chr6:28138981	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-7.87	1.33e-13	3.35e-10	-0.65	-0.46	Depression;	chr6:28139012	chr6:28115628~28116551:+
SARC	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-7.87	1.33e-13	3.35e-10	-0.79	-0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
SARC	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-7.87	1.33e-13	3.35e-10	-0.43	-0.46	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
SARC	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	7.87	1.35e-13	3.39e-10	0.58	0.46	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
SARC	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-7.87	1.36e-13	3.42e-10	-0.6	-0.46	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
SARC	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-7.87	1.36e-13	3.43e-10	-0.57	-0.46	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
SARC	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	7.86	1.37e-13	3.46e-10	0.58	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	7.86	1.39e-13	3.5e-10	0.55	0.46	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	7.86	1.39e-13	3.5e-10	0.55	0.46	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
SARC	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-7.86	1.39e-13	3.5e-10	-0.49	-0.46	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
SARC	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	7.86	1.39e-13	3.51e-10	0.8	0.46	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
SARC	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	7.86	1.39e-13	3.51e-10	0.51	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
SARC	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	7.86	1.4e-13	3.52e-10	0.56	0.46	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
SARC	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-7.86	1.41e-13	3.55e-10	-0.53	-0.46	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
SARC	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	7.86	1.42e-13	3.56e-10	0.55	0.46	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
SARC	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	7.86	1.42e-13	3.57e-10	0.82	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	7.86	1.42e-13	3.57e-10	0.82	0.46	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	7.86	1.42e-13	3.57e-10	0.82	0.46	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	7.86	1.42e-13	3.57e-10	0.82	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	7.86	1.43e-13	3.6e-10	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	7.86	1.44e-13	3.61e-10	0.78	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
SARC	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-7.86	1.44e-13	3.62e-10	-0.51	-0.46	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
SARC	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	7.86	1.45e-13	3.63e-10	0.57	0.46	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
SARC	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	7.86	1.45e-13	3.63e-10	0.57	0.46	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	7.86	1.45e-13	3.63e-10	0.57	0.46	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
SARC	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-7.86	1.46e-13	3.65e-10	-0.59	-0.46	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
SARC	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	7.85	1.46e-13	3.67e-10	0.57	0.46	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	7.85	1.46e-13	3.67e-10	0.57	0.46	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
SARC	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-7.85	1.49e-13	3.73e-10	-0.55	-0.46	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
SARC	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-7.85	1.49e-13	3.73e-10	-0.54	-0.46	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
SARC	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	7.85	1.5e-13	3.76e-10	0.48	0.46	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
SARC	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	7.85	1.51e-13	3.78e-10	0.56	0.46	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
SARC	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-7.85	1.53e-13	3.84e-10	-0.67	-0.46	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-7.85	1.53e-13	3.84e-10	-0.67	-0.46	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-7.85	1.53e-13	3.84e-10	-0.67	-0.46	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-7.85	1.53e-13	3.84e-10	-0.67	-0.46	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
SARC	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	7.85	1.54e-13	3.86e-10	0.59	0.46	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
SARC	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	7.84	1.56e-13	3.91e-10	0.62	0.46	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	7.84	1.56e-13	3.91e-10	0.62	0.46	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	7.84	1.56e-13	3.91e-10	0.62	0.46	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	7.84	1.56e-13	3.91e-10	0.62	0.46	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	7.84	1.56e-13	3.91e-10	0.62	0.46	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	7.84	1.56e-13	3.91e-10	0.62	0.46	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	7.84	1.56e-13	3.91e-10	0.62	0.46	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	7.84	1.56e-13	3.91e-10	0.62	0.46	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
SARC	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	7.84	1.56e-13	3.91e-10	0.81	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
SARC	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-7.84	1.61e-13	4.02e-10	-0.52	-0.46	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
SARC	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	7.84	1.62e-13	4.03e-10	0.55	0.46	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
SARC	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-7.84	1.62e-13	4.03e-10	-0.61	-0.46	Depression;	chr6:28201380	chr6:28115628~28116551:+
SARC	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	7.84	1.62e-13	4.03e-10	0.61	0.46	Depression;	chr6:28199145	chr6:28115628~28116551:+
SARC	cis	rs6538678	0.824	rs2367583	ENSG00000258343.1	RP11-536G4.2	-7.84	1.63e-13	4.06e-10	-0.64	-0.46	Lupus nephritis in systemic lupus erythematosus;	chr12:95856582	chr12:95795345~95858839:-
SARC	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	7.84	1.64e-13	4.09e-10	0.51	0.46	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	7.84	1.64e-13	4.09e-10	0.59	0.46	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	7.83	1.66e-13	4.14e-10	0.56	0.46	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
SARC	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	7.83	1.66e-13	4.14e-10	0.78	0.46	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
SARC	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	7.83	1.67e-13	4.15e-10	0.49	0.46	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
SARC	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	7.83	1.68e-13	4.17e-10	0.56	0.46	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
SARC	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-7.83	1.69e-13	4.2e-10	-0.49	-0.46	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
SARC	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-7.83	1.69e-13	4.2e-10	-0.49	-0.46	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-7.83	1.69e-13	4.2e-10	-0.49	-0.46	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
SARC	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	7.83	1.69e-13	4.21e-10	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
SARC	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	7.83	1.7e-13	4.23e-10	0.82	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
SARC	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-7.83	1.73e-13	4.3e-10	-0.52	-0.46	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
SARC	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-7.83	1.73e-13	4.3e-10	-0.52	-0.46	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
SARC	cis	rs6538678	0.746	rs1865736	ENSG00000258343.1	RP11-536G4.2	-7.83	1.74e-13	4.34e-10	-0.64	-0.46	Lupus nephritis in systemic lupus erythematosus;	chr12:95854051	chr12:95795345~95858839:-
SARC	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-7.83	1.75e-13	4.35e-10	-0.6	-0.46	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
SARC	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-7.83	1.75e-13	4.35e-10	-0.6	-0.46	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-7.83	1.75e-13	4.35e-10	-0.6	-0.46	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
SARC	cis	rs324126	0.78	rs2059817	ENSG00000277977.1	CTD-3018O17.5	7.83	1.75e-13	4.35e-10	0.46	0.46	Colonoscopy-negative controls vs population controls;	chr19:52379032	chr19:52392659~52392755:+
SARC	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	7.83	1.75e-13	4.36e-10	0.62	0.46	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	7.83	1.75e-13	4.36e-10	0.62	0.46	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
SARC	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	7.82	1.77e-13	4.4e-10	0.62	0.46	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
SARC	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-7.82	1.79e-13	4.43e-10	-0.49	-0.46	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
SARC	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	7.82	1.79e-13	4.44e-10	0.6	0.46	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
SARC	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-7.82	1.8e-13	4.46e-10	-0.49	-0.46	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
SARC	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	7.82	1.8e-13	4.47e-10	0.82	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
SARC	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	7.82	1.81e-13	4.49e-10	0.57	0.46	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
SARC	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	7.82	1.82e-13	4.51e-10	0.61	0.46	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
SARC	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	7.82	1.83e-13	4.53e-10	0.59	0.46	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
SARC	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	7.82	1.83e-13	4.53e-10	0.59	0.46	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
SARC	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	7.82	1.83e-13	4.53e-10	0.59	0.46	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
SARC	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	7.82	1.83e-13	4.53e-10	0.59	0.46	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	7.82	1.83e-13	4.53e-10	0.59	0.46	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
SARC	cis	rs6538678	0.824	rs4762631	ENSG00000258343.1	RP11-536G4.2	-7.82	1.84e-13	4.55e-10	-0.64	-0.46	Lupus nephritis in systemic lupus erythematosus;	chr12:95855698	chr12:95795345~95858839:-
SARC	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-7.82	1.84e-13	4.55e-10	-0.73	-0.46	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
SARC	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-7.82	1.85e-13	4.57e-10	-0.55	-0.46	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
SARC	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	7.82	1.87e-13	4.63e-10	0.69	0.46	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
SARC	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	7.82	1.87e-13	4.63e-10	0.59	0.46	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
SARC	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-7.81	1.91e-13	4.71e-10	-0.46	-0.46	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
SARC	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-7.81	1.91e-13	4.73e-10	-0.57	-0.46	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	7.81	1.92e-13	4.76e-10	0.57	0.46	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	7.81	1.92e-13	4.76e-10	0.57	0.46	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
SARC	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-7.81	1.93e-13	4.77e-10	-0.58	-0.46	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
SARC	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	7.81	1.95e-13	4.81e-10	0.81	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	7.81	1.95e-13	4.81e-10	0.81	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	7.81	1.95e-13	4.81e-10	0.81	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	7.81	1.96e-13	4.84e-10	0.81	0.46	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	7.81	1.96e-13	4.84e-10	0.81	0.46	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	7.81	1.96e-13	4.84e-10	0.81	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	7.81	1.96e-13	4.84e-10	0.81	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	7.81	1.96e-13	4.84e-10	0.81	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
SARC	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-7.81	1.97e-13	4.85e-10	-0.53	-0.46	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
SARC	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-7.81	1.98e-13	4.89e-10	-0.65	-0.46	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
SARC	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	7.8	2.01e-13	4.96e-10	0.69	0.46	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
SARC	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	7.8	2.01e-13	4.96e-10	0.69	0.46	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
SARC	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-7.8	2.04e-13	5.03e-10	-0.45	-0.46	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
SARC	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	7.8	2.05e-13	5.05e-10	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
SARC	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	7.8	2.07e-13	5.09e-10	0.6	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	7.8	2.07e-13	5.09e-10	0.6	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	7.8	2.07e-13	5.09e-10	0.6	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	7.8	2.07e-13	5.09e-10	0.6	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
SARC	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-7.8	2.08e-13	5.12e-10	-0.51	-0.45	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
SARC	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	7.8	2.08e-13	5.13e-10	0.63	0.45	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
SARC	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-7.8	2.09e-13	5.14e-10	-0.62	-0.45	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
SARC	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-7.8	2.09e-13	5.14e-10	-0.62	-0.45	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
SARC	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-7.8	2.09e-13	5.14e-10	-0.62	-0.45	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
SARC	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-7.8	2.09e-13	5.14e-10	-0.62	-0.45	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
SARC	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-7.8	2.09e-13	5.14e-10	-0.62	-0.45	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
SARC	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-7.8	2.09e-13	5.14e-10	-0.66	-0.45	Depression;	chr6:28147378	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-7.8	2.09e-13	5.14e-10	-0.66	-0.45	Depression;	chr6:28147406	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-7.8	2.09e-13	5.14e-10	-0.66	-0.45	Depression;	chr6:28148143	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-7.8	2.09e-13	5.14e-10	-0.66	-0.45	Depression;	chr6:28149979	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-7.8	2.09e-13	5.14e-10	-0.66	-0.45	Depression;	chr6:28151096	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-7.8	2.09e-13	5.14e-10	-0.66	-0.45	Depression;	chr6:28152885	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-7.8	2.09e-13	5.14e-10	-0.66	-0.45	Depression;	chr6:28153120	chr6:28115628~28116551:+
SARC	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-7.8	2.1e-13	5.15e-10	-0.48	-0.45	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
SARC	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-7.8	2.1e-13	5.15e-10	-0.48	-0.45	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
SARC	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	7.8	2.1e-13	5.16e-10	0.78	0.45	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	7.8	2.1e-13	5.16e-10	0.78	0.45	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	7.8	2.1e-13	5.16e-10	0.78	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	7.79	2.13e-13	5.23e-10	0.78	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
SARC	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	7.79	2.22e-13	5.44e-10	0.6	0.45	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	7.79	2.22e-13	5.44e-10	0.6	0.45	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	7.79	2.22e-13	5.44e-10	0.6	0.45	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	7.79	2.22e-13	5.44e-10	0.6	0.45	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
SARC	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-7.79	2.24e-13	5.49e-10	-0.54	-0.45	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
SARC	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	7.79	2.24e-13	5.49e-10	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
SARC	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-7.79	2.26e-13	5.54e-10	-0.64	-0.45	Depression;	chr6:28099759	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-7.79	2.26e-13	5.54e-10	-0.64	-0.45	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-7.79	2.26e-13	5.54e-10	-0.64	-0.45	Depression;	chr6:28100648	chr6:28115628~28116551:+
SARC	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-7.79	2.26e-13	5.54e-10	-0.64	-0.45	Depression;	chr6:28107222	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-7.79	2.26e-13	5.54e-10	-0.64	-0.45	Depression;	chr6:28108492	chr6:28115628~28116551:+
SARC	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-7.78	2.31e-13	5.65e-10	-0.43	-0.45	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
SARC	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-7.78	2.32e-13	5.66e-10	-0.56	-0.45	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
SARC	cis	rs324126	0.78	rs60935857	ENSG00000277977.1	CTD-3018O17.5	7.78	2.32e-13	5.68e-10	0.47	0.45	Colonoscopy-negative controls vs population controls;	chr19:52382606	chr19:52392659~52392755:+
SARC	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-7.78	2.33e-13	5.7e-10	-0.49	-0.45	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
SARC	cis	rs34375054	0.553	rs12580221	ENSG00000279233.1	RP11-158L12.4	7.78	2.37e-13	5.79e-10	0.48	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125136520	chr12:125138245~125141711:+
SARC	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-7.78	2.39e-13	5.84e-10	-0.54	-0.45	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
SARC	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	7.77	2.43e-13	5.92e-10	0.7	0.45	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
SARC	cis	rs6538678	0.824	rs7299632	ENSG00000258343.1	RP11-536G4.2	-7.77	2.43e-13	5.94e-10	-0.64	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95795345~95858839:-
SARC	cis	rs6538678	0.746	rs4762630	ENSG00000258343.1	RP11-536G4.2	-7.77	2.46e-13	6.01e-10	-0.64	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95795345~95858839:-
SARC	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	7.77	2.48e-13	6.05e-10	0.6	0.45	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	7.77	2.48e-13	6.05e-10	0.6	0.45	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
SARC	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-7.77	2.49e-13	6.08e-10	-0.46	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
SARC	cis	rs1930961	1	rs6004659	ENSG00000272977.1	CTA-390C10.10	-7.77	2.5e-13	6.09e-10	-0.78	-0.45	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25476218~25479971:+
SARC	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	7.77	2.5e-13	6.09e-10	0.4	0.45	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
SARC	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-7.77	2.53e-13	6.17e-10	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
SARC	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-7.77	2.54e-13	6.18e-10	-0.52	-0.45	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
SARC	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	7.77	2.56e-13	6.25e-10	0.61	0.45	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
SARC	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-7.77	2.57e-13	6.25e-10	-0.49	-0.45	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
SARC	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-7.76	2.6e-13	6.32e-10	-0.55	-0.45	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
SARC	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	7.76	2.6e-13	6.32e-10	0.49	0.45	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	7.76	2.65e-13	6.44e-10	0.56	0.45	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
SARC	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	7.76	2.67e-13	6.5e-10	0.66	0.45	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
SARC	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	7.76	2.69e-13	6.54e-10	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
SARC	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	7.76	2.72e-13	6.62e-10	0.61	0.45	Depression;	chr6:28200948	chr6:28115628~28116551:+
SARC	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-7.75	2.79e-13	6.77e-10	-0.61	-0.45	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
SARC	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-7.75	2.79e-13	6.77e-10	-0.61	-0.45	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
SARC	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-7.75	2.79e-13	6.77e-10	-0.64	-0.45	Depression;	chr6:28082231	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-7.75	2.79e-13	6.77e-10	-0.64	-0.45	Depression;	chr6:28082261	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-7.75	2.79e-13	6.77e-10	-0.64	-0.45	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-7.75	2.79e-13	6.77e-10	-0.64	-0.45	Depression;	chr6:28082984	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-7.75	2.79e-13	6.77e-10	-0.64	-0.45	Depression;	chr6:28083994	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-7.75	2.79e-13	6.77e-10	-0.64	-0.45	Depression;	chr6:28084025	chr6:28115628~28116551:+
SARC	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-7.75	2.79e-13	6.77e-10	-0.64	-0.45	Depression;	chr6:28085319	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-7.75	2.79e-13	6.77e-10	-0.64	-0.45	Depression;	chr6:28089816	chr6:28115628~28116551:+
SARC	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-7.75	2.86e-13	6.92e-10	-0.49	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
SARC	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-7.75	2.88e-13	6.98e-10	-0.61	-0.45	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
SARC	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-7.74	2.93e-13	7.09e-10	-0.52	-0.45	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
SARC	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	7.74	2.98e-13	7.22e-10	0.61	0.45	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
SARC	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-7.74	2.98e-13	7.23e-10	-0.52	-0.45	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
SARC	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	7.74	3.02e-13	7.31e-10	0.56	0.45	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
SARC	cis	rs6964833	0.935	rs7795281	ENSG00000123965.13	PMS2P5	7.74	3.04e-13	7.36e-10	0.7	0.45	Menarche (age at onset);	chr7:74708523	chr7:74894116~74897835:+
SARC	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-7.74	3.06e-13	7.4e-10	-0.48	-0.45	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
SARC	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	7.74	3.07e-13	7.42e-10	0.8	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	7.74	3.08e-13	7.44e-10	0.78	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
SARC	cis	rs1930961	1	rs6004657	ENSG00000272977.1	CTA-390C10.10	-7.73	3.11e-13	7.52e-10	-0.78	-0.45	Bipolar disorder with mood-incongruent psychosis;	chr22:25459747	chr22:25476218~25479971:+
SARC	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	7.73	3.16e-13	7.64e-10	0.56	0.45	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	7.73	3.18e-13	7.68e-10	0.55	0.45	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
SARC	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-7.73	3.18e-13	7.68e-10	-0.53	-0.45	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
SARC	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	7.73	3.24e-13	7.81e-10	0.58	0.45	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	7.73	3.24e-13	7.81e-10	0.58	0.45	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
SARC	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-7.73	3.24e-13	7.83e-10	-0.56	-0.45	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
SARC	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-7.73	3.25e-13	7.83e-10	-0.49	-0.45	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-7.73	3.25e-13	7.83e-10	-0.49	-0.45	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
SARC	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-7.73	3.25e-13	7.85e-10	-0.49	-0.45	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
SARC	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	7.73	3.27e-13	7.89e-10	0.79	0.45	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
SARC	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	7.72	3.4e-13	8.2e-10	0.62	0.45	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
SARC	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	7.72	3.41e-13	8.23e-10	0.61	0.45	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
SARC	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-7.72	3.43e-13	8.27e-10	-0.51	-0.45	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
SARC	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-7.72	3.48e-13	8.38e-10	-0.51	-0.45	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
SARC	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-7.72	3.48e-13	8.38e-10	-0.51	-0.45	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
SARC	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	7.72	3.51e-13	8.46e-10	0.57	0.45	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-7.71	3.54e-13	8.51e-10	-0.55	-0.45	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
SARC	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-7.71	3.54e-13	8.52e-10	-0.59	-0.45	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
SARC	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-7.71	3.58e-13	8.61e-10	-0.78	-0.45	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
SARC	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-7.71	3.6e-13	8.66e-10	-0.64	-0.45	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
SARC	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	7.71	3.61e-13	8.69e-10	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	7.71	3.63e-13	8.73e-10	0.56	0.45	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	7.71	3.63e-13	8.73e-10	0.56	0.45	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
SARC	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-7.71	3.64e-13	8.75e-10	-0.68	-0.45	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
SARC	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	7.71	3.66e-13	8.79e-10	0.51	0.45	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
SARC	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	7.71	3.67e-13	8.82e-10	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	7.71	3.69e-13	8.87e-10	0.55	0.45	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
SARC	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-7.71	3.69e-13	8.87e-10	-0.59	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
SARC	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-7.71	3.7e-13	8.88e-10	-0.52	-0.45	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
SARC	cis	rs6964833	1	rs13227433	ENSG00000123965.13	PMS2P5	7.71	3.71e-13	8.92e-10	0.7	0.45	Menarche (age at onset);	chr7:74680386	chr7:74894116~74897835:+
SARC	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	7.71	3.73e-13	8.96e-10	0.54	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
SARC	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	7.7	3.74e-13	8.99e-10	0.59	0.45	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-7.7	3.81e-13	9.14e-10	-0.56	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
SARC	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	7.7	3.82e-13	9.17e-10	0.48	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
SARC	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	7.7	3.91e-13	9.38e-10	0.44	0.45	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
SARC	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-7.7	3.95e-13	9.46e-10	-0.6	-0.45	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	7.69	4.03e-13	9.67e-10	0.55	0.45	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
SARC	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	7.69	4.09e-13	9.8e-10	0.62	0.45	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
SARC	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	7.69	4.18e-13	1e-09	0.6	0.45	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
SARC	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	7.69	4.19e-13	1e-09	0.59	0.45	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	7.69	4.19e-13	1e-09	0.59	0.45	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	7.69	4.19e-13	1e-09	0.59	0.45	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	7.69	4.19e-13	1e-09	0.59	0.45	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
SARC	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	7.69	4.2e-13	1.01e-09	0.62	0.45	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
SARC	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	7.69	4.21e-13	1.01e-09	0.55	0.45	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	7.69	4.21e-13	1.01e-09	0.55	0.45	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	7.69	4.21e-13	1.01e-09	0.55	0.45	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
SARC	cis	rs324126	0.78	rs62108320	ENSG00000277977.1	CTD-3018O17.5	7.69	4.22e-13	1.01e-09	0.45	0.45	Colonoscopy-negative controls vs population controls;	chr19:52380770	chr19:52392659~52392755:+
SARC	cis	rs324126	0.752	rs62108321	ENSG00000277977.1	CTD-3018O17.5	7.69	4.22e-13	1.01e-09	0.45	0.45	Colonoscopy-negative controls vs population controls;	chr19:52380825	chr19:52392659~52392755:+
SARC	cis	rs1930961	1	rs6004662	ENSG00000272977.1	CTA-390C10.10	-7.69	4.23e-13	1.01e-09	-0.79	-0.45	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25476218~25479971:+
SARC	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	7.68	4.26e-13	1.02e-09	0.57	0.45	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
SARC	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	7.68	4.28e-13	1.02e-09	0.47	0.45	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
SARC	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-7.68	4.32e-13	1.03e-09	-0.47	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
SARC	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	7.68	4.34e-13	1.04e-09	0.55	0.45	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
SARC	cis	rs324126	0.78	rs62108319	ENSG00000277977.1	CTD-3018O17.5	7.68	4.35e-13	1.04e-09	0.45	0.45	Colonoscopy-negative controls vs population controls;	chr19:52380577	chr19:52392659~52392755:+
SARC	cis	rs34375054	0.553	rs12581512	ENSG00000279233.1	RP11-158L12.4	7.68	4.35e-13	1.04e-09	0.49	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125137716	chr12:125138245~125141711:+
SARC	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	7.68	4.35e-13	1.04e-09	0.59	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	7.68	4.39e-13	1.05e-09	0.55	0.45	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
SARC	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-7.68	4.43e-13	1.06e-09	-0.5	-0.45	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
SARC	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	7.68	4.44e-13	1.06e-09	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
SARC	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-7.67	4.6e-13	1.1e-09	-0.61	-0.45	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
SARC	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-7.67	4.6e-13	1.1e-09	-0.53	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
SARC	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-7.67	4.62e-13	1.1e-09	-0.75	-0.45	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-7.67	4.62e-13	1.1e-09	-0.75	-0.45	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
SARC	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	7.67	4.64e-13	1.11e-09	0.81	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
SARC	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-7.67	4.65e-13	1.11e-09	-0.5	-0.45	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
SARC	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	7.67	4.76e-13	1.13e-09	0.55	0.45	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	7.67	4.76e-13	1.13e-09	0.55	0.45	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	7.67	4.76e-13	1.13e-09	0.55	0.45	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	7.67	4.76e-13	1.13e-09	0.55	0.45	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	7.67	4.76e-13	1.13e-09	0.55	0.45	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	7.67	4.76e-13	1.13e-09	0.55	0.45	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	7.67	4.76e-13	1.13e-09	0.55	0.45	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	7.67	4.76e-13	1.13e-09	0.55	0.45	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	7.67	4.76e-13	1.13e-09	0.55	0.45	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
SARC	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-7.67	4.77e-13	1.13e-09	-0.64	-0.45	Depression;	chr6:28070115	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-7.67	4.77e-13	1.13e-09	-0.64	-0.45	Depression;	chr6:28071237	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-7.67	4.77e-13	1.13e-09	-0.64	-0.45	Depression;	chr6:28076559	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-7.67	4.77e-13	1.13e-09	-0.64	-0.45	Depression;	chr6:28076704	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-7.67	4.77e-13	1.13e-09	-0.64	-0.45	Depression;	chr6:28078391	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-7.67	4.77e-13	1.13e-09	-0.64	-0.45	Depression;	chr6:28079011	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-7.67	4.77e-13	1.13e-09	-0.64	-0.45	Depression;	chr6:28080757	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-7.67	4.77e-13	1.13e-09	-0.64	-0.45	Depression;	chr6:28080760	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-7.67	4.78e-13	1.13e-09	-0.64	-0.45	Depression;	chr6:28159666	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	7.67	4.79e-13	1.14e-09	0.55	0.45	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
SARC	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-7.66	4.81e-13	1.14e-09	-0.74	-0.45	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
SARC	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-7.66	4.83e-13	1.14e-09	-0.75	-0.45	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
SARC	cis	rs1930961	1	rs6004675	ENSG00000100058.11	CRYBB2P1	7.66	4.83e-13	1.15e-09	0.86	0.45	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25448105~25520854:+
SARC	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	7.66	4.99e-13	1.18e-09	0.6	0.45	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
SARC	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	7.66	4.99e-13	1.18e-09	0.6	0.45	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
SARC	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	7.66	4.99e-13	1.18e-09	0.6	0.45	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
SARC	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-7.66	5.03e-13	1.19e-09	-0.53	-0.45	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
SARC	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-7.66	5.03e-13	1.19e-09	-0.53	-0.45	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-7.66	5.03e-13	1.19e-09	-0.53	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
SARC	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-7.66	5.11e-13	1.21e-09	-0.67	-0.45	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28154567	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28156691	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28158424	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28159056	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28159843	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28159925	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28159932	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28161802	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28162053	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28162598	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28163375	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28163759	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28164580	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28164825	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28164948	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28165025	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28165528	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28168434	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28169019	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28169249	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28169676	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28169755	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28169791	chr6:28115628~28116551:+
SARC	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-7.65	5.12e-13	1.21e-09	-0.64	-0.45	Depression;	chr6:28170075	chr6:28115628~28116551:+
SARC	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	7.65	5.15e-13	1.22e-09	0.61	0.45	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	7.65	5.15e-13	1.22e-09	0.61	0.45	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	7.65	5.15e-13	1.22e-09	0.61	0.45	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	7.65	5.15e-13	1.22e-09	0.61	0.45	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	7.65	5.2e-13	1.23e-09	0.55	0.45	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	7.65	5.25e-13	1.24e-09	0.56	0.45	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
SARC	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	7.65	5.26e-13	1.24e-09	0.8	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
SARC	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-7.65	5.29e-13	1.25e-09	-0.48	-0.45	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-7.65	5.29e-13	1.25e-09	-0.48	-0.45	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-7.65	5.29e-13	1.25e-09	-0.48	-0.45	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
SARC	cis	rs324126	0.78	rs1993531	ENSG00000277977.1	CTD-3018O17.5	7.65	5.35e-13	1.26e-09	0.45	0.45	Colonoscopy-negative controls vs population controls;	chr19:52381633	chr19:52392659~52392755:+
SARC	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	7.64	5.44e-13	1.28e-09	0.51	0.45	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
SARC	cis	rs324126	0.78	rs11084153	ENSG00000277977.1	CTD-3018O17.5	7.64	5.49e-13	1.29e-09	0.45	0.45	Colonoscopy-negative controls vs population controls;	chr19:52382142	chr19:52392659~52392755:+
SARC	cis	rs324126	0.78	rs11084154	ENSG00000277977.1	CTD-3018O17.5	7.64	5.49e-13	1.29e-09	0.45	0.45	Colonoscopy-negative controls vs population controls;	chr19:52382168	chr19:52392659~52392755:+
SARC	cis	rs324126	0.78	rs11084155	ENSG00000277977.1	CTD-3018O17.5	7.64	5.49e-13	1.29e-09	0.45	0.45	Colonoscopy-negative controls vs population controls;	chr19:52383613	chr19:52392659~52392755:+
SARC	cis	rs324126	0.752	rs11084156	ENSG00000277977.1	CTD-3018O17.5	7.64	5.49e-13	1.29e-09	0.45	0.45	Colonoscopy-negative controls vs population controls;	chr19:52383634	chr19:52392659~52392755:+
SARC	cis	rs324126	0.78	rs11084157	ENSG00000277977.1	CTD-3018O17.5	7.64	5.49e-13	1.29e-09	0.45	0.45	Colonoscopy-negative controls vs population controls;	chr19:52383652	chr19:52392659~52392755:+
SARC	cis	rs324126	0.78	rs8104808	ENSG00000277977.1	CTD-3018O17.5	7.64	5.49e-13	1.29e-09	0.45	0.45	Colonoscopy-negative controls vs population controls;	chr19:52384174	chr19:52392659~52392755:+
SARC	cis	rs324126	0.78	rs8104812	ENSG00000277977.1	CTD-3018O17.5	7.64	5.49e-13	1.29e-09	0.45	0.45	Colonoscopy-negative controls vs population controls;	chr19:52384184	chr19:52392659~52392755:+
SARC	cis	rs1930961	1	rs1930961	ENSG00000100058.11	CRYBB2P1	7.64	5.5e-13	1.29e-09	0.81	0.45	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25448105~25520854:+
SARC	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-7.64	5.52e-13	1.3e-09	-0.54	-0.45	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
SARC	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	7.64	5.6e-13	1.32e-09	0.58	0.45	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
SARC	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-7.64	5.64e-13	1.33e-09	-0.55	-0.45	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
SARC	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	7.64	5.66e-13	1.33e-09	0.55	0.45	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
SARC	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	7.64	5.7e-13	1.34e-09	0.6	0.45	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
SARC	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	7.64	5.7e-13	1.34e-09	0.6	0.45	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
SARC	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	7.64	5.7e-13	1.34e-09	0.6	0.45	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
SARC	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	7.64	5.7e-13	1.34e-09	0.6	0.45	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
SARC	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-7.64	5.7e-13	1.34e-09	-0.53	-0.45	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
SARC	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-7.64	5.7e-13	1.34e-09	-0.53	-0.45	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
SARC	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-7.64	5.72e-13	1.34e-09	-0.49	-0.45	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
SARC	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	7.64	5.74e-13	1.35e-09	0.54	0.45	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
SARC	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-7.64	5.76e-13	1.35e-09	-0.52	-0.45	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
SARC	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-7.64	5.76e-13	1.35e-09	-0.52	-0.45	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
SARC	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	7.64	5.78e-13	1.35e-09	0.61	0.45	Depression;	chr6:28205232	chr6:28115628~28116551:+
SARC	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	7.63	5.85e-13	1.37e-09	0.64	0.45	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
SARC	cis	rs1930961	1	rs997872	ENSG00000100058.11	CRYBB2P1	7.63	5.91e-13	1.38e-09	0.85	0.45	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25448105~25520854:+
SARC	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-7.63	5.92e-13	1.39e-09	-0.52	-0.45	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
SARC	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	7.63	5.94e-13	1.39e-09	0.53	0.45	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
SARC	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-7.63	5.96e-13	1.39e-09	-0.49	-0.45	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
SARC	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-7.63	5.98e-13	1.4e-09	-0.49	-0.45	Temperament;	chr17:14075460	chr17:14024514~14025488:+
SARC	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	7.63	6.02e-13	1.41e-09	0.55	0.45	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
SARC	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	7.63	6.03e-13	1.41e-09	0.59	0.45	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-7.63	6.1e-13	1.43e-09	-0.55	-0.45	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
SARC	cis	rs6538678	0.824	rs2887026	ENSG00000258343.1	RP11-536G4.2	-7.62	6.24e-13	1.46e-09	-0.63	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95854713	chr12:95795345~95858839:-
SARC	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-7.62	6.26e-13	1.46e-09	-0.48	-0.45	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-7.62	6.26e-13	1.46e-09	-0.48	-0.45	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
SARC	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-7.62	6.27e-13	1.46e-09	-0.52	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-7.62	6.27e-13	1.46e-09	-0.52	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-7.62	6.27e-13	1.46e-09	-0.52	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-7.62	6.27e-13	1.46e-09	-0.52	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-7.62	6.27e-13	1.46e-09	-0.52	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-7.62	6.27e-13	1.46e-09	-0.52	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
SARC	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	7.62	6.33e-13	1.48e-09	0.59	0.45	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	7.62	6.33e-13	1.48e-09	0.59	0.45	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	7.62	6.44e-13	1.5e-09	0.55	0.45	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	7.62	6.44e-13	1.5e-09	0.55	0.45	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.651	rs9322188	ENSG00000268592.3	RAET1E-AS1	-7.62	6.52e-13	1.52e-09	-0.56	-0.45	Lung cancer;	chr6:149588355	chr6:149863494~149919507:+
SARC	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-7.61	6.59e-13	1.53e-09	-0.49	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
SARC	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-7.61	6.59e-13	1.53e-09	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
SARC	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-7.61	6.62e-13	1.54e-09	-0.52	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-7.61	6.62e-13	1.54e-09	-0.52	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
SARC	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	7.61	6.65e-13	1.55e-09	0.55	0.45	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
SARC	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-7.61	6.73e-13	1.56e-09	-0.49	-0.45	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
SARC	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	7.61	6.74e-13	1.56e-09	0.61	0.45	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	7.61	6.74e-13	1.56e-09	0.61	0.45	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	7.61	6.74e-13	1.56e-09	0.61	0.45	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
SARC	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-7.61	6.95e-13	1.61e-09	-0.52	-0.45	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
SARC	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	7.6	6.99e-13	1.62e-09	0.59	0.45	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	7.6	6.99e-13	1.62e-09	0.59	0.45	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
SARC	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	7.6	6.99e-13	1.62e-09	0.59	0.45	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
SARC	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-7.6	7e-13	1.62e-09	-0.52	-0.45	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
SARC	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-7.6	7.04e-13	1.63e-09	-0.48	-0.45	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
SARC	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	7.6	7.1e-13	1.64e-09	0.48	0.45	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
SARC	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-7.6	7.16e-13	1.66e-09	-0.52	-0.45	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
SARC	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-7.6	7.2e-13	1.67e-09	-0.48	-0.45	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
SARC	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	7.6	7.24e-13	1.68e-09	0.59	0.45	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
SARC	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-7.6	7.31e-13	1.69e-09	-0.5	-0.45	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
SARC	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-7.6	7.31e-13	1.69e-09	-0.5	-0.45	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
SARC	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	7.6	7.32e-13	1.69e-09	0.77	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	7.6	7.32e-13	1.69e-09	0.77	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	7.6	7.32e-13	1.69e-09	0.77	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
SARC	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	7.6	7.41e-13	1.71e-09	0.57	0.45	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
SARC	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	7.6	7.41e-13	1.71e-09	0.61	0.45	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
SARC	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-7.6	7.41e-13	1.71e-09	-0.48	-0.45	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
SARC	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	7.6	7.41e-13	1.71e-09	0.51	0.45	Migraine;	chr4:56881468	chr4:56960927~56961373:-
SARC	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	7.59	7.44e-13	1.72e-09	0.55	0.45	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	7.59	7.44e-13	1.72e-09	0.55	0.45	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	7.59	7.44e-13	1.72e-09	0.55	0.45	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
SARC	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	7.59	7.46e-13	1.72e-09	0.48	0.45	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
SARC	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-7.59	7.66e-13	1.77e-09	-0.52	-0.45	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
SARC	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	7.59	7.76e-13	1.79e-09	0.61	0.45	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
SARC	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-7.59	7.81e-13	1.8e-09	-0.5	-0.45	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
SARC	cis	rs7174755	0.923	rs898590	ENSG00000260657.2	RP11-315D16.4	-7.58	7.89e-13	1.82e-09	-0.42	-0.44	Major depressive disorder;	chr15:68311837	chr15:68267792~68277994:-
SARC	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	7.58	7.89e-13	1.82e-09	0.57	0.44	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	7.58	7.89e-13	1.82e-09	0.57	0.44	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
SARC	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-7.58	7.93e-13	1.83e-09	-0.52	-0.44	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
SARC	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-7.58	7.96e-13	1.84e-09	-0.59	-0.44	Depression;	chr6:28197321	chr6:28115628~28116551:+
SARC	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-7.58	7.96e-13	1.84e-09	-0.59	-0.44	Depression;	chr6:28197412	chr6:28115628~28116551:+
SARC	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-7.58	7.96e-13	1.84e-09	-0.59	-0.44	Depression;	chr6:28198669	chr6:28115628~28116551:+
SARC	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	7.58	7.99e-13	1.84e-09	0.74	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
SARC	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	7.58	7.99e-13	1.84e-09	0.74	0.44	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
SARC	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-7.58	7.99e-13	1.84e-09	-0.64	-0.44	Depression;	chr6:28137418	chr6:28115628~28116551:+
SARC	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-7.58	8.02e-13	1.85e-09	-0.75	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
SARC	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	7.58	8.07e-13	1.86e-09	0.6	0.44	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
SARC	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	7.58	8.18e-13	1.88e-09	0.45	0.44	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
SARC	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-7.58	8.2e-13	1.89e-09	-0.51	-0.44	Migraine;	chr4:56879851	chr4:56960927~56961373:-
SARC	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-7.58	8.2e-13	1.89e-09	-0.51	-0.44	Migraine;	chr4:56880007	chr4:56960927~56961373:-
SARC	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-7.58	8.2e-13	1.89e-09	-0.51	-0.44	Migraine;	chr4:56880190	chr4:56960927~56961373:-
SARC	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-7.58	8.2e-13	1.89e-09	-0.51	-0.44	Migraine;	chr4:56880659	chr4:56960927~56961373:-
SARC	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	7.58	8.22e-13	1.89e-09	0.54	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
SARC	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	7.58	8.26e-13	1.9e-09	0.59	0.44	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	7.58	8.3e-13	1.9e-09	0.6	0.44	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	7.58	8.3e-13	1.9e-09	0.6	0.44	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	7.58	8.36e-13	1.92e-09	0.54	0.44	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	7.58	8.36e-13	1.92e-09	0.54	0.44	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	7.58	8.36e-13	1.92e-09	0.54	0.44	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	7.58	8.36e-13	1.92e-09	0.54	0.44	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
SARC	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-7.57	8.49e-13	1.95e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
SARC	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-7.57	8.51e-13	1.95e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
SARC	cis	rs6538678	0.857	rs4762626	ENSG00000258343.1	RP11-536G4.2	-7.57	8.53e-13	1.96e-09	-0.61	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95795345~95858839:-
SARC	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-7.57	8.54e-13	1.96e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-7.57	8.54e-13	1.96e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
SARC	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-7.57	8.54e-13	1.96e-09	-0.52	-0.44	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
SARC	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	7.57	8.61e-13	1.97e-09	0.58	0.44	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	7.57	8.61e-13	1.97e-09	0.58	0.44	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	7.57	8.61e-13	1.97e-09	0.58	0.44	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	7.57	8.61e-13	1.97e-09	0.58	0.44	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	7.57	8.61e-13	1.97e-09	0.58	0.44	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
SARC	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	7.57	8.69e-13	1.99e-09	0.49	0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
SARC	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-7.57	8.7e-13	1.99e-09	-0.6	-0.44	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
SARC	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	7.57	8.72e-13	1.99e-09	0.59	0.44	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
SARC	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-7.57	8.74e-13	2e-09	-0.48	-0.44	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-7.57	8.75e-13	2e-09	-0.5	-0.44	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
SARC	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	7.57	8.84e-13	2.02e-09	0.61	0.44	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
SARC	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-7.57	8.87e-13	2.03e-09	-0.63	-0.44	Depression;	chr6:28173770	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-7.57	8.87e-13	2.03e-09	-0.63	-0.44	Depression;	chr6:28174809	chr6:28115628~28116551:+
SARC	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-7.57	8.87e-13	2.03e-09	-0.63	-0.44	Depression;	chr6:28175233	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-7.57	8.87e-13	2.03e-09	-0.63	-0.44	Depression;	chr6:28176973	chr6:28115628~28116551:+
SARC	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-7.57	8.87e-13	2.03e-09	-0.63	-0.44	Depression;	chr6:28180209	chr6:28115628~28116551:+
SARC	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	7.56	8.98e-13	2.05e-09	0.6	0.44	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	7.56	9.28e-13	2.12e-09	0.55	0.44	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	7.56	9.28e-13	2.12e-09	0.55	0.44	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	7.56	9.28e-13	2.12e-09	0.55	0.44	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	7.56	9.38e-13	2.14e-09	0.55	0.44	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	7.56	9.38e-13	2.14e-09	0.55	0.44	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
SARC	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-7.56	9.41e-13	2.14e-09	-0.49	-0.44	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
SARC	cis	rs1930961	1	rs997873	ENSG00000100058.11	CRYBB2P1	7.56	9.42e-13	2.15e-09	0.84	0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25448105~25520854:+
SARC	cis	rs1930961	1	rs6004671	ENSG00000100058.11	CRYBB2P1	7.56	9.42e-13	2.15e-09	0.84	0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25448105~25520854:+
SARC	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-7.56	9.48e-13	2.16e-09	-0.54	-0.44	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
SARC	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-7.56	9.49e-13	2.16e-09	-0.63	-0.44	Depression;	chr6:28074687	chr6:28115628~28116551:+
SARC	cis	rs324126	0.78	rs10445583	ENSG00000277977.1	CTD-3018O17.5	7.55	9.64e-13	2.19e-09	0.44	0.44	Colonoscopy-negative controls vs population controls;	chr19:52379480	chr19:52392659~52392755:+
SARC	cis	rs324126	0.752	rs10445584	ENSG00000277977.1	CTD-3018O17.5	7.55	9.64e-13	2.19e-09	0.44	0.44	Colonoscopy-negative controls vs population controls;	chr19:52379552	chr19:52392659~52392755:+
SARC	cis	rs324126	0.78	rs10445585	ENSG00000277977.1	CTD-3018O17.5	7.55	9.64e-13	2.19e-09	0.44	0.44	Colonoscopy-negative controls vs population controls;	chr19:52379571	chr19:52392659~52392755:+
SARC	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	7.55	9.65e-13	2.2e-09	0.69	0.44	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
SARC	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	7.55	9.71e-13	2.21e-09	0.75	0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
SARC	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-7.55	9.79e-13	2.23e-09	-0.48	-0.44	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
SARC	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-7.55	9.82e-13	2.23e-09	-0.61	-0.44	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
SARC	cis	rs1707322	0.65	rs4553239	ENSG00000280836.1	AL355480.1	-7.55	1e-12	2.28e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45581219~45581321:-
SARC	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-7.55	1.01e-12	2.29e-09	-0.53	-0.44	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
SARC	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	7.54	1.01e-12	2.3e-09	0.48	0.44	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
SARC	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	7.54	1.02e-12	2.31e-09	0.46	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	7.54	1.02e-12	2.31e-09	0.46	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-7.54	1.02e-12	2.31e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
SARC	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-7.54	1.02e-12	2.32e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-7.54	1.02e-12	2.32e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-7.54	1.02e-12	2.32e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-7.54	1.02e-12	2.32e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-7.54	1.02e-12	2.32e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-7.54	1.02e-12	2.32e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-7.54	1.02e-12	2.32e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-7.54	1.02e-12	2.32e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-7.54	1.02e-12	2.32e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-7.54	1.02e-12	2.32e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
SARC	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-7.54	1.03e-12	2.34e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
SARC	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-7.54	1.05e-12	2.38e-09	-0.53	-0.44	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
SARC	cis	rs1707322	0.647	rs6686944	ENSG00000280836.1	AL355480.1	-7.54	1.05e-12	2.39e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45581219~45581321:-
SARC	cis	rs324126	0.78	rs10445586	ENSG00000277977.1	CTD-3018O17.5	7.54	1.06e-12	2.39e-09	0.44	0.44	Colonoscopy-negative controls vs population controls;	chr19:52379870	chr19:52392659~52392755:+
SARC	cis	rs324126	0.78	rs62108317	ENSG00000277977.1	CTD-3018O17.5	7.54	1.06e-12	2.39e-09	0.44	0.44	Colonoscopy-negative controls vs population controls;	chr19:52380230	chr19:52392659~52392755:+
SARC	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	7.54	1.06e-12	2.39e-09	0.58	0.44	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	7.54	1.06e-12	2.39e-09	0.58	0.44	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
SARC	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-7.54	1.06e-12	2.4e-09	-0.54	-0.44	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
SARC	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	7.54	1.07e-12	2.42e-09	0.65	0.44	Depression;	chr6:28109824	chr6:28115628~28116551:+
SARC	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-7.54	1.07e-12	2.42e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-7.54	1.07e-12	2.42e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
SARC	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	7.53	1.08e-12	2.44e-09	0.53	0.44	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
SARC	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-7.53	1.08e-12	2.44e-09	-0.72	-0.44	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
SARC	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	7.53	1.08e-12	2.44e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
SARC	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-7.53	1.08e-12	2.45e-09	-0.48	-0.44	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
SARC	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-7.53	1.08e-12	2.45e-09	-0.48	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
SARC	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	7.53	1.08e-12	2.45e-09	0.58	0.44	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
SARC	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	7.53	1.09e-12	2.46e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
SARC	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-7.53	1.1e-12	2.47e-09	-0.48	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
SARC	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-7.53	1.1e-12	2.47e-09	-0.48	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
SARC	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-7.53	1.1e-12	2.47e-09	-0.48	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
SARC	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-7.53	1.1e-12	2.47e-09	-0.5	-0.44	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
SARC	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-7.53	1.1e-12	2.48e-09	-0.48	-0.44	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
SARC	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-7.53	1.11e-12	2.5e-09	-0.54	-0.44	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-7.53	1.14e-12	2.56e-09	-0.55	-0.44	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
SARC	cis	rs324126	0.78	rs1993530	ENSG00000277977.1	CTD-3018O17.5	-7.53	1.14e-12	2.57e-09	-0.44	-0.44	Colonoscopy-negative controls vs population controls;	chr19:52381756	chr19:52392659~52392755:+
SARC	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	7.52	1.15e-12	2.59e-09	0.66	0.44	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
SARC	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-7.52	1.15e-12	2.59e-09	-0.58	-0.44	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
SARC	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	7.52	1.15e-12	2.6e-09	0.56	0.44	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
SARC	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	7.52	1.17e-12	2.63e-09	0.5	0.44	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
SARC	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	7.52	1.17e-12	2.64e-09	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
SARC	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	7.52	1.18e-12	2.64e-09	0.6	0.44	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	7.52	1.18e-12	2.64e-09	0.6	0.44	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	7.52	1.18e-12	2.64e-09	0.6	0.44	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	7.52	1.18e-12	2.64e-09	0.6	0.44	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	7.52	1.18e-12	2.64e-09	0.6	0.44	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	7.52	1.18e-12	2.64e-09	0.6	0.44	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
SARC	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	7.52	1.19e-12	2.68e-09	0.54	0.44	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
SARC	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	7.52	1.2e-12	2.68e-09	0.47	0.44	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
SARC	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-7.52	1.2e-12	2.68e-09	-0.58	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
SARC	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-7.52	1.2e-12	2.68e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-7.52	1.2e-12	2.68e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-7.52	1.2e-12	2.68e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-7.52	1.2e-12	2.68e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-7.52	1.2e-12	2.68e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-7.52	1.2e-12	2.68e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
SARC	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	7.52	1.2e-12	2.7e-09	0.6	0.44	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	7.52	1.2e-12	2.7e-09	0.59	0.44	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	7.52	1.2e-12	2.7e-09	0.59	0.44	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	7.52	1.2e-12	2.7e-09	0.59	0.44	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	7.52	1.21e-12	2.71e-09	0.58	0.44	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
SARC	cis	rs324126	0.78	rs2059818	ENSG00000277977.1	CTD-3018O17.5	7.52	1.21e-12	2.72e-09	0.46	0.44	Colonoscopy-negative controls vs population controls;	chr19:52379267	chr19:52392659~52392755:+
SARC	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-7.51	1.22e-12	2.73e-09	-0.53	-0.44	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
SARC	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-7.51	1.22e-12	2.73e-09	-0.53	-0.44	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
SARC	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-7.51	1.22e-12	2.73e-09	-0.53	-0.44	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
SARC	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-7.51	1.22e-12	2.73e-09	-0.53	-0.44	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
SARC	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-7.51	1.22e-12	2.73e-09	-0.53	-0.44	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
SARC	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-7.51	1.22e-12	2.73e-09	-0.53	-0.44	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
SARC	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-7.51	1.22e-12	2.73e-09	-0.53	-0.44	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
SARC	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-7.51	1.22e-12	2.73e-09	-0.53	-0.44	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
SARC	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-7.51	1.22e-12	2.73e-09	-0.58	-0.44	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
SARC	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	7.51	1.23e-12	2.75e-09	0.55	0.44	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
SARC	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-7.51	1.24e-12	2.78e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
SARC	cis	rs11673344	1	rs11673344	ENSG00000226686.6	LINC01535	7.51	1.25e-12	2.79e-09	0.51	0.44	Obesity-related traits;	chr19:37194064	chr19:37251912~37265535:+
SARC	cis	rs324126	0.78	rs55748277	ENSG00000277977.1	CTD-3018O17.5	7.51	1.26e-12	2.81e-09	0.45	0.44	Colonoscopy-negative controls vs population controls;	chr19:52384992	chr19:52392659~52392755:+
SARC	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	7.51	1.26e-12	2.81e-09	0.59	0.44	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	7.51	1.26e-12	2.81e-09	0.59	0.44	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
SARC	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-7.51	1.27e-12	2.83e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-7.51	1.27e-12	2.83e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-7.51	1.27e-12	2.83e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-7.51	1.27e-12	2.83e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-7.51	1.27e-12	2.83e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-7.51	1.27e-12	2.83e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
SARC	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	7.51	1.28e-12	2.85e-09	0.54	0.44	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
SARC	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-7.51	1.29e-12	2.86e-09	-0.53	-0.44	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	7.51	1.29e-12	2.86e-09	0.54	0.44	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
SARC	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-7.51	1.29e-12	2.88e-09	-0.53	-0.44	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
SARC	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-7.5	1.29e-12	2.88e-09	-0.39	-0.44	Breast cancer;	chr11:825777	chr11:779617~780755:+
SARC	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-7.5	1.3e-12	2.88e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-7.5	1.3e-12	2.88e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-7.5	1.3e-12	2.88e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-7.5	1.3e-12	2.88e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-7.5	1.3e-12	2.88e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-7.5	1.3e-12	2.88e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-7.5	1.3e-12	2.88e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
SARC	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	7.5	1.3e-12	2.89e-09	0.55	0.44	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
SARC	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	7.5	1.3e-12	2.9e-09	0.49	0.44	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
SARC	cis	rs1707322	0.721	rs4559551	ENSG00000280836.1	AL355480.1	-7.5	1.31e-12	2.91e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45581219~45581321:-
SARC	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-7.5	1.33e-12	2.96e-09	-0.58	-0.44	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-7.5	1.33e-12	2.96e-09	-0.58	-0.44	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-7.5	1.33e-12	2.96e-09	-0.58	-0.44	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-7.5	1.33e-12	2.96e-09	-0.58	-0.44	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-7.5	1.33e-12	2.96e-09	-0.58	-0.44	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-7.5	1.33e-12	2.96e-09	-0.58	-0.44	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
SARC	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-7.5	1.33e-12	2.96e-09	-0.58	-0.44	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
SARC	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-7.5	1.33e-12	2.96e-09	-0.64	-0.44	Depression;	chr6:28104824	chr6:28115628~28116551:+
SARC	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	7.5	1.35e-12	2.99e-09	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	7.5	1.35e-12	2.99e-09	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	7.5	1.35e-12	2.99e-09	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	7.5	1.35e-12	2.99e-09	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	7.5	1.35e-12	2.99e-09	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	7.5	1.35e-12	2.99e-09	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	7.5	1.35e-12	2.99e-09	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	7.5	1.35e-12	2.99e-09	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	7.5	1.35e-12	2.99e-09	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	7.5	1.35e-12	2.99e-09	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
SARC	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	7.5	1.36e-12	3.02e-09	0.43	0.44	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
SARC	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-7.5	1.36e-12	3.02e-09	-0.53	-0.44	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
SARC	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	7.5	1.37e-12	3.03e-09	0.69	0.44	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
SARC	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	7.5	1.37e-12	3.03e-09	0.69	0.44	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
SARC	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	7.5	1.37e-12	3.03e-09	0.69	0.44	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
SARC	cis	rs1930961	1	rs6004668	ENSG00000272977.1	CTA-390C10.10	7.5	1.37e-12	3.03e-09	0.76	0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25476218~25479971:+
SARC	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-7.49	1.38e-12	3.05e-09	-0.51	-0.44	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
SARC	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-7.49	1.38e-12	3.05e-09	-0.59	-0.44	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-7.49	1.38e-12	3.05e-09	-0.59	-0.44	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
SARC	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	7.49	1.38e-12	3.06e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	7.49	1.38e-12	3.06e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	7.49	1.38e-12	3.06e-09	0.59	0.44	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
SARC	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-7.49	1.4e-12	3.1e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
SARC	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	7.49	1.41e-12	3.12e-09	0.49	0.44	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
SARC	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	7.49	1.44e-12	3.17e-09	0.5	0.44	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
SARC	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	7.49	1.44e-12	3.18e-09	0.49	0.44	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
SARC	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-7.48	1.46e-12	3.22e-09	-0.58	-0.44	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
SARC	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	7.48	1.47e-12	3.24e-09	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
SARC	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-7.48	1.48e-12	3.25e-09	-0.58	-0.44	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
SARC	cis	rs1930961	1	rs6004672	ENSG00000100058.11	CRYBB2P1	7.48	1.48e-12	3.26e-09	0.84	0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25448105~25520854:+
SARC	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	7.48	1.49e-12	3.28e-09	0.47	0.44	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	7.48	1.49e-12	3.29e-09	0.57	0.44	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
SARC	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-7.48	1.5e-12	3.3e-09	-0.6	-0.44	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
SARC	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	7.48	1.5e-12	3.3e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	7.48	1.5e-12	3.3e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-7.48	1.5e-12	3.3e-09	-0.58	-0.44	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
SARC	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-7.48	1.51e-12	3.31e-09	-0.48	-0.44	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-7.48	1.51e-12	3.31e-09	-0.48	-0.44	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-7.48	1.51e-12	3.31e-09	-0.48	-0.44	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-7.48	1.51e-12	3.31e-09	-0.48	-0.44	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-7.48	1.51e-12	3.31e-09	-0.48	-0.44	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-7.48	1.51e-12	3.31e-09	-0.48	-0.44	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
SARC	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-7.48	1.51e-12	3.31e-09	-0.63	-0.44	Depression;	chr6:28071808	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	7.48	1.51e-12	3.32e-09	0.55	0.44	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
SARC	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-7.47	1.59e-12	3.48e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
SARC	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-7.47	1.6e-12	3.5e-09	-0.51	-0.44	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
SARC	cis	rs1930961	0.867	rs6423498	ENSG00000272977.1	CTA-390C10.10	-7.47	1.61e-12	3.53e-09	-0.76	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25476218~25479971:+
SARC	cis	rs1930961	1	rs6004654	ENSG00000272977.1	CTA-390C10.10	-7.47	1.61e-12	3.53e-09	-0.76	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25476218~25479971:+
SARC	cis	rs1930961	1	rs6004658	ENSG00000272977.1	CTA-390C10.10	-7.47	1.61e-12	3.53e-09	-0.76	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25476218~25479971:+
SARC	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-7.47	1.61e-12	3.53e-09	-0.47	-0.44	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
SARC	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	7.47	1.61e-12	3.53e-09	0.59	0.44	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	7.47	1.61e-12	3.53e-09	0.58	0.44	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	7.47	1.61e-12	3.53e-09	0.58	0.44	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	7.47	1.61e-12	3.53e-09	0.55	0.44	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
SARC	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-7.47	1.63e-12	3.58e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
SARC	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	7.47	1.63e-12	3.58e-09	0.52	0.44	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-7.47	1.64e-12	3.6e-09	-0.54	-0.44	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
SARC	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	7.46	1.67e-12	3.64e-09	0.59	0.44	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
SARC	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-7.46	1.68e-12	3.68e-09	-0.48	-0.44	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
SARC	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	7.46	1.69e-12	3.7e-09	0.59	0.44	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	7.46	1.69e-12	3.7e-09	0.6	0.44	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
SARC	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-7.46	1.69e-12	3.7e-09	-0.51	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
SARC	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-7.46	1.71e-12	3.74e-09	-0.57	-0.44	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-7.46	1.71e-12	3.74e-09	-0.57	-0.44	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
SARC	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	7.46	1.73e-12	3.78e-09	0.63	0.44	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
SARC	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	7.46	1.73e-12	3.79e-09	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
SARC	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-7.46	1.74e-12	3.81e-09	-0.59	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
SARC	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	7.45	1.76e-12	3.85e-09	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	7.45	1.76e-12	3.85e-09	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
SARC	cis	rs1930961	1	rs6004675	ENSG00000272977.1	CTA-390C10.10	-7.45	1.77e-12	3.86e-09	-0.78	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25476218~25479971:+
SARC	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-7.45	1.77e-12	3.86e-09	-0.49	-0.44	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
SARC	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	7.45	1.78e-12	3.88e-09	0.59	0.44	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
SARC	cis	rs1707322	0.752	rs61784793	ENSG00000280836.1	AL355480.1	-7.45	1.78e-12	3.88e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs4586014	ENSG00000280836.1	AL355480.1	-7.45	1.78e-12	3.88e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.648	rs4439382	ENSG00000280836.1	AL355480.1	-7.45	1.78e-12	3.88e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45581219~45581321:-
SARC	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	7.45	1.78e-12	3.88e-09	0.58	0.44	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
SARC	cis	rs1707322	0.716	rs10890342	ENSG00000280836.1	AL355480.1	-7.45	1.8e-12	3.92e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs6658700	ENSG00000280836.1	AL355480.1	-7.45	1.8e-12	3.92e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs12047629	ENSG00000280836.1	AL355480.1	-7.45	1.8e-12	3.92e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs11211169	ENSG00000280836.1	AL355480.1	-7.45	1.8e-12	3.92e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs11211171	ENSG00000280836.1	AL355480.1	-7.45	1.8e-12	3.92e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs28623463	ENSG00000280836.1	AL355480.1	-7.45	1.8e-12	3.92e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.716	rs28370457	ENSG00000280836.1	AL355480.1	-7.45	1.8e-12	3.92e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs28890893	ENSG00000280836.1	AL355480.1	-7.45	1.8e-12	3.92e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45581219~45581321:-
SARC	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	7.45	1.81e-12	3.94e-09	0.49	0.44	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
SARC	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	7.45	1.82e-12	3.96e-09	0.53	0.44	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
SARC	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-7.45	1.84e-12	4e-09	-0.61	-0.44	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
SARC	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-7.44	1.89e-12	4.08e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-7.44	1.89e-12	4.08e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	7.44	1.89e-12	4.08e-09	0.47	0.44	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
SARC	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-7.44	1.9e-12	4.1e-09	-0.74	-0.44	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
SARC	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	7.44	1.91e-12	4.13e-09	0.56	0.44	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
SARC	cis	rs3002131	0.522	rs2936031	ENSG00000225265.1	TAF1A-AS1	-7.44	1.93e-12	4.18e-09	-0.82	-0.44	Interleukin-10 levels;	chr1:222582910	chr1:222589825~222593032:+
SARC	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-7.44	1.94e-12	4.18e-09	-0.57	-0.44	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
SARC	cis	rs12931792	0.712	rs4787495	ENSG00000183604.13	SMG1P5	-7.44	1.94e-12	4.19e-09	-0.4	-0.44	Tonsillectomy;	chr16:30154404	chr16:30267553~30335374:-
SARC	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	7.44	1.94e-12	4.19e-09	0.58	0.44	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
SARC	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-7.44	1.97e-12	4.25e-09	-0.59	-0.44	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
SARC	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-7.44	1.98e-12	4.26e-09	-0.57	-0.44	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
SARC	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	7.44	1.98e-12	4.27e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	7.44	1.98e-12	4.27e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	7.44	1.98e-12	4.27e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	7.44	1.98e-12	4.27e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
SARC	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	7.44	1.98e-12	4.27e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
SARC	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-7.44	1.98e-12	4.27e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
SARC	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	7.43	2e-12	4.29e-09	0.53	0.44	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
SARC	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-7.43	2.02e-12	4.34e-09	-0.55	-0.44	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
SARC	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	7.43	2.03e-12	4.37e-09	0.69	0.44	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
SARC	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	7.43	2.05e-12	4.41e-09	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	7.43	2.05e-12	4.41e-09	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	7.43	2.05e-12	4.41e-09	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
SARC	cis	rs526231	0.543	rs246915	ENSG00000175749.11	EIF3KP1	7.43	2.06e-12	4.42e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103222343	chr5:103032376~103033031:+
SARC	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-7.43	2.06e-12	4.42e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
SARC	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	7.43	2.06e-12	4.43e-09	0.55	0.44	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
SARC	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	7.43	2.07e-12	4.44e-09	0.59	0.44	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
SARC	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-7.43	2.09e-12	4.48e-09	-0.6	-0.44	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
SARC	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-7.43	2.09e-12	4.48e-09	-0.6	-0.44	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
SARC	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-7.43	2.1e-12	4.5e-09	-0.52	-0.44	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
SARC	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	7.42	2.11e-12	4.53e-09	0.58	0.44	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	7.42	2.11e-12	4.53e-09	0.58	0.44	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	7.42	2.12e-12	4.54e-09	0.58	0.44	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	7.42	2.12e-12	4.54e-09	0.58	0.44	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
SARC	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-7.42	2.13e-12	4.56e-09	-0.59	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
SARC	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-7.42	2.16e-12	4.62e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-7.42	2.16e-12	4.62e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
SARC	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-7.42	2.16e-12	4.62e-09	-0.59	-0.44	Depression;	chr6:28205175	chr6:28115628~28116551:+
SARC	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	7.42	2.16e-12	4.62e-09	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
SARC	cis	rs324126	0.78	rs11084150	ENSG00000277977.1	CTD-3018O17.5	-7.42	2.16e-12	4.63e-09	-0.44	-0.44	Colonoscopy-negative controls vs population controls;	chr19:52381851	chr19:52392659~52392755:+
SARC	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	7.42	2.18e-12	4.67e-09	0.62	0.44	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
SARC	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	7.42	2.18e-12	4.67e-09	0.62	0.44	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	7.42	2.18e-12	4.67e-09	0.57	0.44	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
SARC	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	7.42	2.2e-12	4.71e-09	0.53	0.44	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
SARC	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	7.42	2.2e-12	4.71e-09	0.48	0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
SARC	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	7.42	2.2e-12	4.71e-09	0.48	0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
SARC	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	7.42	2.21e-12	4.73e-09	0.6	0.44	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
SARC	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	7.42	2.21e-12	4.73e-09	0.56	0.44	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	7.42	2.21e-12	4.73e-09	0.56	0.44	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
SARC	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	7.42	2.22e-12	4.75e-09	0.49	0.44	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
SARC	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	7.42	2.23e-12	4.77e-09	0.59	0.44	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	7.42	2.24e-12	4.78e-09	0.58	0.44	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
SARC	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-7.42	2.24e-12	4.79e-09	-0.52	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
SARC	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-7.41	2.24e-12	4.79e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
SARC	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	7.41	2.25e-12	4.81e-09	0.59	0.44	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	7.41	2.25e-12	4.81e-09	0.59	0.44	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	7.41	2.26e-12	4.82e-09	0.59	0.44	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
SARC	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-7.41	2.26e-12	4.83e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
SARC	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	7.41	2.26e-12	4.83e-09	0.5	0.44	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	7.41	2.26e-12	4.83e-09	0.5	0.44	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
SARC	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	7.41	2.27e-12	4.85e-09	0.49	0.44	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
SARC	cis	rs1707322	0.752	rs28550303	ENSG00000280836.1	AL355480.1	-7.41	2.3e-12	4.9e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.716	rs28375469	ENSG00000280836.1	AL355480.1	-7.41	2.3e-12	4.9e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs28545085	ENSG00000280836.1	AL355480.1	-7.41	2.3e-12	4.9e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs28719889	ENSG00000280836.1	AL355480.1	-7.41	2.3e-12	4.9e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs28812624	ENSG00000280836.1	AL355480.1	-7.41	2.3e-12	4.9e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45581219~45581321:-
SARC	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	7.41	2.32e-12	4.95e-09	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	7.41	2.32e-12	4.95e-09	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
SARC	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	7.41	2.33e-12	4.96e-09	0.67	0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
SARC	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	7.41	2.33e-12	4.96e-09	0.54	0.44	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
SARC	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	7.41	2.34e-12	4.98e-09	0.59	0.44	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	7.41	2.34e-12	4.98e-09	0.59	0.44	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	7.41	2.34e-12	4.98e-09	0.59	0.44	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	7.41	2.34e-12	4.98e-09	0.59	0.44	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	7.41	2.36e-12	5.02e-09	0.56	0.44	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
SARC	cis	rs1707322	0.752	rs11211168	ENSG00000280836.1	AL355480.1	-7.41	2.36e-12	5.02e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45581219~45581321:-
SARC	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	7.41	2.36e-12	5.03e-09	0.6	0.44	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
SARC	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-7.41	2.37e-12	5.05e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-7.41	2.37e-12	5.05e-09	-0.47	-0.44	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
SARC	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	7.41	2.38e-12	5.05e-09	0.5	0.44	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	7.41	2.38e-12	5.05e-09	0.5	0.44	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
SARC	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	7.4	2.43e-12	5.16e-09	0.77	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
SARC	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	7.4	2.44e-12	5.18e-09	0.58	0.44	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	7.4	2.44e-12	5.18e-09	0.58	0.44	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
SARC	cis	rs1707322	0.721	rs10890336	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs11211151	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs12045096	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs4609469	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs12049027	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs10789467	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs10890337	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs3811435	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs9793568	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs11211157	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs11211158	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs6429575	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.685	rs6690926	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs8179402	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs8179296	ENSG00000280836.1	AL355480.1	-7.4	2.44e-12	5.19e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45581219~45581321:-
SARC	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	7.4	2.47e-12	5.23e-09	0.5	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
SARC	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	7.4	2.47e-12	5.24e-09	0.65	0.44	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
SARC	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	7.4	2.47e-12	5.24e-09	0.65	0.44	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
SARC	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	7.4	2.47e-12	5.24e-09	0.65	0.44	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
SARC	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	7.4	2.48e-12	5.26e-09	0.61	0.44	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	7.4	2.48e-12	5.27e-09	0.59	0.44	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
SARC	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-7.4	2.5e-12	5.29e-09	-0.56	-0.44	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
SARC	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	-7.4	2.5e-12	5.31e-09	-0.42	-0.44	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
SARC	cis	rs1707322	0.721	rs10890341	ENSG00000280836.1	AL355480.1	-7.4	2.52e-12	5.33e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45581219~45581321:-
SARC	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-7.4	2.52e-12	5.33e-09	-0.53	-0.44	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	7.39	2.54e-12	5.38e-09	0.56	0.44	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
SARC	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	7.39	2.55e-12	5.4e-09	0.51	0.44	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
SARC	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	7.39	2.57e-12	5.43e-09	0.58	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
SARC	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	7.39	2.58e-12	5.47e-09	0.51	0.44	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
SARC	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-7.39	2.59e-12	5.47e-09	-0.5	-0.44	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-7.39	2.59e-12	5.47e-09	-0.5	-0.44	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
SARC	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	7.39	2.61e-12	5.53e-09	0.55	0.44	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	7.39	2.63e-12	5.55e-09	0.53	0.44	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	7.39	2.63e-12	5.55e-09	0.53	0.44	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	7.39	2.63e-12	5.55e-09	0.53	0.44	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	7.39	2.63e-12	5.55e-09	0.53	0.44	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	7.39	2.63e-12	5.55e-09	0.53	0.44	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	7.39	2.63e-12	5.55e-09	0.53	0.44	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	7.39	2.63e-12	5.55e-09	0.53	0.44	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
SARC	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	7.39	2.63e-12	5.55e-09	0.53	0.44	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	7.39	2.63e-12	5.55e-09	0.53	0.44	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	7.39	2.63e-12	5.55e-09	0.53	0.44	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	7.39	2.63e-12	5.55e-09	0.53	0.44	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
SARC	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	7.39	2.65e-12	5.59e-09	0.64	0.44	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
SARC	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	7.39	2.65e-12	5.59e-09	0.64	0.44	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
SARC	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	7.39	2.65e-12	5.59e-09	0.64	0.44	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
SARC	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-7.39	2.69e-12	5.67e-09	-0.58	-0.44	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-7.39	2.69e-12	5.67e-09	-0.58	-0.44	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-7.39	2.69e-12	5.67e-09	-0.58	-0.44	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
SARC	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-7.39	2.69e-12	5.67e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-7.39	2.69e-12	5.67e-09	-0.46	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
SARC	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	7.39	2.69e-12	5.67e-09	0.65	0.44	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
SARC	cis	rs6538678	0.824	rs4762633	ENSG00000258343.1	RP11-536G4.2	-7.38	2.7e-12	5.7e-09	-0.59	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95795345~95858839:-
SARC	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-7.38	2.72e-12	5.73e-09	-0.47	-0.44	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
SARC	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	7.38	2.72e-12	5.74e-09	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	7.38	2.72e-12	5.74e-09	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	7.38	2.72e-12	5.74e-09	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
SARC	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-7.38	2.75e-12	5.78e-09	-0.57	-0.44	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
SARC	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-7.38	2.75e-12	5.78e-09	-0.56	-0.44	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
SARC	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	7.38	2.76e-12	5.8e-09	0.47	0.44	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	7.38	2.77e-12	5.82e-09	0.54	0.44	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	7.38	2.77e-12	5.82e-09	0.54	0.44	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
SARC	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	7.38	2.79e-12	5.85e-09	0.45	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
SARC	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	7.38	2.79e-12	5.86e-09	0.58	0.44	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	7.38	2.79e-12	5.86e-09	0.58	0.44	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	7.38	2.79e-12	5.86e-09	0.58	0.44	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	7.38	2.82e-12	5.91e-09	0.56	0.44	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	7.38	2.82e-12	5.91e-09	0.56	0.44	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
SARC	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	7.38	2.82e-12	5.92e-09	0.59	0.44	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
SARC	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	7.38	2.82e-12	5.93e-09	0.48	0.44	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
SARC	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-7.38	2.84e-12	5.95e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-7.38	2.84e-12	5.95e-09	-0.45	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
SARC	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	7.37	2.87e-12	6.02e-09	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	7.37	2.87e-12	6.02e-09	0.49	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
SARC	cis	rs1707322	0.682	rs10890334	ENSG00000280836.1	AL355480.1	-7.37	2.9e-12	6.07e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.682	rs10890335	ENSG00000280836.1	AL355480.1	-7.37	2.9e-12	6.07e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.716	rs6694889	ENSG00000280836.1	AL355480.1	-7.37	2.9e-12	6.07e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.682	rs12041197	ENSG00000280836.1	AL355480.1	-7.37	2.9e-12	6.07e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45581219~45581321:-
SARC	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-7.37	2.9e-12	6.08e-09	-0.6	-0.43	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
SARC	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-7.37	2.92e-12	6.11e-09	-0.53	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
SARC	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-7.37	2.93e-12	6.15e-09	-0.51	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
SARC	cis	rs1707322	0.717	rs11211161	ENSG00000280836.1	AL355480.1	-7.37	3e-12	6.29e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45581219~45581321:-
SARC	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-7.37	3.01e-12	6.3e-09	-0.48	-0.43	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
SARC	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	7.37	3.03e-12	6.35e-09	0.57	0.43	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	7.37	3.03e-12	6.35e-09	0.57	0.43	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	7.37	3.03e-12	6.35e-09	0.57	0.43	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	7.37	3.03e-12	6.35e-09	0.57	0.43	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
SARC	cis	rs1930961	1	rs5996946	ENSG00000272977.1	CTA-390C10.10	-7.37	3.03e-12	6.35e-09	-0.75	-0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25476218~25479971:+
SARC	cis	rs6565180	0.791	rs4247355	ENSG00000183604.13	SMG1P5	7.36	3.05e-12	6.37e-09	0.41	0.43	Tonsillectomy;	chr16:30380778	chr16:30267553~30335374:-
SARC	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	7.36	3.05e-12	6.37e-09	0.59	0.43	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	7.36	3.07e-12	6.41e-09	0.59	0.43	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	7.36	3.09e-12	6.45e-09	0.55	0.43	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
SARC	cis	rs17507216	0.588	rs4778687	ENSG00000278603.1	RP13-608F4.5	7.36	3.09e-12	6.47e-09	0.64	0.43	Excessive daytime sleepiness;	chr15:82649085	chr15:82472203~82472426:+
SARC	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	7.36	3.1e-12	6.47e-09	0.56	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
SARC	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	7.36	3.1e-12	6.48e-09	0.52	0.43	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
SARC	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	7.36	3.12e-12	6.5e-09	0.58	0.43	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
SARC	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-7.36	3.12e-12	6.52e-09	-0.58	-0.43	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
SARC	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	7.36	3.13e-12	6.53e-09	0.42	0.43	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
SARC	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	7.36	3.15e-12	6.56e-09	0.54	0.43	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
SARC	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	7.36	3.15e-12	6.56e-09	0.59	0.43	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	7.36	3.15e-12	6.56e-09	0.59	0.43	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
SARC	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	7.36	3.16e-12	6.59e-09	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	7.36	3.17e-12	6.6e-09	0.51	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
SARC	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	7.36	3.18e-12	6.62e-09	0.59	0.43	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	7.36	3.19e-12	6.63e-09	0.6	0.43	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
SARC	cis	rs1707322	0.752	rs11211146	ENSG00000280836.1	AL355480.1	-7.36	3.19e-12	6.63e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs11211147	ENSG00000280836.1	AL355480.1	-7.36	3.19e-12	6.63e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45581219~45581321:-
SARC	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-7.36	3.2e-12	6.65e-09	-0.52	-0.43	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
SARC	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-7.36	3.2e-12	6.65e-09	-0.4	-0.43	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
SARC	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	7.36	3.2e-12	6.66e-09	0.47	0.43	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	7.36	3.21e-12	6.67e-09	0.55	0.43	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	7.36	3.21e-12	6.67e-09	0.55	0.43	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
SARC	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-7.36	3.21e-12	6.68e-09	-0.48	-0.43	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
SARC	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-7.36	3.21e-12	6.68e-09	-0.48	-0.43	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
SARC	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-7.36	3.23e-12	6.71e-09	-0.47	-0.43	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
SARC	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	7.35	3.24e-12	6.74e-09	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs11211149	ENSG00000280836.1	AL355480.1	-7.35	3.25e-12	6.75e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs11211152	ENSG00000280836.1	AL355480.1	-7.35	3.25e-12	6.75e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs4607935	ENSG00000280836.1	AL355480.1	-7.35	3.25e-12	6.75e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.681	rs12048866	ENSG00000280836.1	AL355480.1	-7.35	3.25e-12	6.75e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs3811436	ENSG00000280836.1	AL355480.1	-7.35	3.25e-12	6.75e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs12024590	ENSG00000280836.1	AL355480.1	-7.35	3.25e-12	6.75e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs12027622	ENSG00000280836.1	AL355480.1	-7.35	3.25e-12	6.75e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs4415615	ENSG00000280836.1	AL355480.1	-7.35	3.25e-12	6.75e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs7529699	ENSG00000280836.1	AL355480.1	-7.35	3.25e-12	6.75e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.716	rs6699444	ENSG00000280836.1	AL355480.1	-7.35	3.25e-12	6.75e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs10430105	ENSG00000280836.1	AL355480.1	-7.35	3.25e-12	6.75e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45581219~45581321:-
SARC	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-7.35	3.26e-12	6.75e-09	-0.49	-0.43	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
SARC	cis	rs6538678	0.777	rs10745736	ENSG00000258343.1	RP11-536G4.2	-7.35	3.27e-12	6.78e-09	-0.57	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95795345~95858839:-
SARC	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-7.35	3.29e-12	6.82e-09	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
SARC	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-7.35	3.3e-12	6.83e-09	-0.52	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
SARC	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-7.35	3.31e-12	6.86e-09	-0.46	-0.43	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
SARC	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	7.35	3.34e-12	6.91e-09	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
SARC	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-7.35	3.34e-12	6.91e-09	-0.52	-0.43	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
SARC	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-7.35	3.34e-12	6.91e-09	-0.52	-0.43	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
SARC	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-7.35	3.34e-12	6.91e-09	-0.52	-0.43	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
SARC	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-7.35	3.36e-12	6.95e-09	-0.48	-0.43	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
SARC	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	7.35	3.36e-12	6.96e-09	0.55	0.43	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
SARC	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	7.35	3.36e-12	6.96e-09	0.59	0.43	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
SARC	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	7.35	3.36e-12	6.96e-09	0.59	0.43	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
SARC	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	7.35	3.37e-12	6.96e-09	0.57	0.43	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
SARC	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-7.35	3.39e-12	7.01e-09	-0.62	-0.43	Depression;	chr6:28096845	chr6:28115628~28116551:+
SARC	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-7.35	3.4e-12	7.03e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
SARC	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	7.35	3.4e-12	7.04e-09	0.4	0.43	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
SARC	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	7.35	3.42e-12	7.08e-09	0.59	0.43	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
SARC	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	7.35	3.43e-12	7.09e-09	0.43	0.43	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
SARC	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	7.34	3.45e-12	7.12e-09	0.69	0.43	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
SARC	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-7.34	3.45e-12	7.14e-09	-0.58	-0.43	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
SARC	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	7.34	3.48e-12	7.2e-09	0.66	0.43	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
SARC	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	7.34	3.51e-12	7.24e-09	0.57	0.43	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
SARC	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	7.34	3.51e-12	7.25e-09	0.47	0.43	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
SARC	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-7.34	3.53e-12	7.29e-09	-0.63	-0.43	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-7.34	3.53e-12	7.29e-09	-0.63	-0.43	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-7.34	3.53e-12	7.29e-09	-0.63	-0.43	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-7.34	3.53e-12	7.29e-09	-0.63	-0.43	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-7.34	3.53e-12	7.29e-09	-0.63	-0.43	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-7.34	3.53e-12	7.29e-09	-0.63	-0.43	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-7.34	3.53e-12	7.29e-09	-0.63	-0.43	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-7.34	3.53e-12	7.29e-09	-0.63	-0.43	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-7.34	3.53e-12	7.29e-09	-0.63	-0.43	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
SARC	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	7.34	3.54e-12	7.29e-09	0.56	0.43	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	7.34	3.54e-12	7.29e-09	0.56	0.43	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
SARC	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	7.34	3.58e-12	7.39e-09	0.52	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
SARC	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	7.34	3.63e-12	7.49e-09	0.59	0.43	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	7.34	3.63e-12	7.49e-09	0.59	0.43	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	7.34	3.63e-12	7.49e-09	0.59	0.43	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
SARC	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	7.34	3.63e-12	7.49e-09	0.59	0.43	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	7.34	3.63e-12	7.49e-09	0.59	0.43	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	7.34	3.64e-12	7.5e-09	0.54	0.43	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
SARC	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	7.33	3.67e-12	7.56e-09	0.51	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
SARC	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-7.33	3.72e-12	7.66e-09	-0.56	-0.43	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
SARC	cis	rs1707322	0.752	rs28507722	ENSG00000280836.1	AL355480.1	-7.33	3.74e-12	7.71e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs28568986	ENSG00000280836.1	AL355480.1	-7.33	3.74e-12	7.71e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.717	rs28396194	ENSG00000280836.1	AL355480.1	-7.33	3.74e-12	7.71e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.717	rs28752166	ENSG00000280836.1	AL355480.1	-7.33	3.74e-12	7.71e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.717	rs10890345	ENSG00000280836.1	AL355480.1	-7.33	3.74e-12	7.71e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs10789471	ENSG00000280836.1	AL355480.1	-7.33	3.74e-12	7.71e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.752	rs11211173	ENSG00000280836.1	AL355480.1	-7.33	3.74e-12	7.71e-09	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45581219~45581321:-
SARC	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-7.33	3.75e-12	7.72e-09	-0.47	-0.43	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
SARC	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-7.33	3.76e-12	7.74e-09	-0.62	-0.43	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
SARC	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-7.33	3.77e-12	7.76e-09	-0.48	-0.43	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
SARC	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	7.33	3.78e-12	7.76e-09	0.57	0.43	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	7.33	3.78e-12	7.76e-09	0.57	0.43	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	7.33	3.78e-12	7.76e-09	0.57	0.43	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
SARC	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	7.33	3.8e-12	7.8e-09	0.57	0.43	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
SARC	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	7.33	3.81e-12	7.82e-09	0.59	0.43	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
SARC	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	7.33	3.82e-12	7.84e-09	0.75	0.43	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
SARC	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-7.33	3.85e-12	7.92e-09	-0.56	-0.43	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
SARC	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	7.33	3.85e-12	7.92e-09	0.54	0.43	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
SARC	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	7.32	3.88e-12	7.96e-09	0.57	0.43	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	7.32	3.88e-12	7.96e-09	0.57	0.43	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	7.32	3.88e-12	7.96e-09	0.57	0.43	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	7.32	3.88e-12	7.96e-09	0.57	0.43	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	7.32	3.88e-12	7.96e-09	0.57	0.43	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
SARC	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	7.32	3.88e-12	7.96e-09	0.57	0.43	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	7.32	3.88e-12	7.96e-09	0.57	0.43	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
SARC	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-7.32	3.89e-12	7.99e-09	-0.54	-0.43	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
SARC	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	7.32	3.9e-12	8e-09	0.46	0.43	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	7.32	3.92e-12	8.04e-09	0.46	0.43	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	7.32	3.92e-12	8.04e-09	0.46	0.43	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	7.32	3.92e-12	8.04e-09	0.46	0.43	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	7.32	3.92e-12	8.04e-09	0.46	0.43	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	7.32	3.92e-12	8.04e-09	0.46	0.43	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	7.32	3.92e-12	8.04e-09	0.46	0.43	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
SARC	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-7.32	4e-12	8.19e-09	-0.58	-0.43	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
SARC	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	7.32	4.01e-12	8.21e-09	0.47	0.43	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	7.32	4.01e-12	8.21e-09	0.47	0.43	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	7.32	4.01e-12	8.21e-09	0.47	0.43	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
SARC	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	7.32	4.05e-12	8.28e-09	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
SARC	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-7.32	4.05e-12	8.28e-09	-0.59	-0.43	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
SARC	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-7.32	4.06e-12	8.29e-09	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
SARC	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-7.32	4.06e-12	8.29e-09	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
SARC	cis	rs6565180	0.926	rs4787643	ENSG00000183604.13	SMG1P5	7.32	4.09e-12	8.35e-09	0.41	0.43	Tonsillectomy;	chr16:30382339	chr16:30267553~30335374:-
SARC	cis	rs6565180	0.926	rs4788409	ENSG00000183604.13	SMG1P5	7.32	4.09e-12	8.35e-09	0.41	0.43	Tonsillectomy;	chr16:30382450	chr16:30267553~30335374:-
SARC	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	7.32	4.09e-12	8.35e-09	0.52	0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
SARC	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	7.31	4.12e-12	8.42e-09	0.58	0.43	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
SARC	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	7.31	4.15e-12	8.47e-09	0.57	0.43	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
SARC	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	7.31	4.15e-12	8.47e-09	0.57	0.43	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	7.31	4.15e-12	8.47e-09	0.57	0.43	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	7.31	4.15e-12	8.47e-09	0.57	0.43	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
SARC	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	7.31	4.15e-12	8.48e-09	0.68	0.43	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
SARC	cis	rs748404	0.578	rs510108	ENSG00000205771.5	CATSPER2P1	-7.31	4.23e-12	8.63e-09	-0.52	-0.43	Lung cancer;	chr15:43313241	chr15:43726918~43747094:-
SARC	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-7.31	4.24e-12	8.64e-09	-0.51	-0.43	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-7.31	4.24e-12	8.64e-09	-0.51	-0.43	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-7.31	4.24e-12	8.64e-09	-0.51	-0.43	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-7.31	4.24e-12	8.64e-09	-0.51	-0.43	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
SARC	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	7.31	4.28e-12	8.73e-09	0.53	0.43	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
SARC	cis	rs4972806	0.814	rs2113560	ENSG00000226363.3	HAGLROS	-7.31	4.29e-12	8.74e-09	-0.55	-0.43	IgG glycosylation;	chr2:176166258	chr2:176177717~176179008:+
SARC	cis	rs4972806	0.849	rs2071581	ENSG00000226363.3	HAGLROS	-7.31	4.3e-12	8.77e-09	-0.55	-0.43	IgG glycosylation;	chr2:176161420	chr2:176177717~176179008:+
SARC	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	7.31	4.33e-12	8.83e-09	0.58	0.43	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
SARC	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	7.31	4.34e-12	8.83e-09	0.48	0.43	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
SARC	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	7.3	4.42e-12	8.99e-09	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	7.3	4.42e-12	8.99e-09	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
SARC	cis	rs748404	0.578	rs576557	ENSG00000205771.5	CATSPER2P1	-7.3	4.42e-12	9e-09	-0.52	-0.43	Lung cancer;	chr15:43305539	chr15:43726918~43747094:-
SARC	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	7.3	4.42e-12	9e-09	0.59	0.43	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
SARC	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	7.3	4.44e-12	9.04e-09	0.51	0.43	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
SARC	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	7.3	4.44e-12	9.04e-09	0.51	0.43	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
SARC	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-7.3	4.45e-12	9.06e-09	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
SARC	cis	rs4972806	0.849	rs2113561	ENSG00000226363.3	HAGLROS	-7.3	4.49e-12	9.13e-09	-0.55	-0.43	IgG glycosylation;	chr2:176166197	chr2:176177717~176179008:+
SARC	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	7.3	4.52e-12	9.19e-09	0.5	0.43	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
SARC	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-7.3	4.52e-12	9.19e-09	-0.56	-0.43	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
SARC	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-7.3	4.56e-12	9.27e-09	-0.53	-0.43	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
SARC	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-7.3	4.59e-12	9.31e-09	-0.62	-0.43	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
SARC	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-7.3	4.6e-12	9.34e-09	-0.43	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
SARC	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-7.3	4.62e-12	9.37e-09	-0.4	-0.43	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
SARC	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-7.3	4.64e-12	9.42e-09	-0.64	-0.43	Depression;	chr6:28135913	chr6:28115628~28116551:+
SARC	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	7.29	4.7e-12	9.54e-09	0.59	0.43	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	7.29	4.7e-12	9.54e-09	0.59	0.43	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	7.29	4.7e-12	9.54e-09	0.59	0.43	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
SARC	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	7.29	4.72e-12	9.57e-09	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
SARC	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	7.29	4.72e-12	9.57e-09	0.6	0.43	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	7.29	4.72e-12	9.57e-09	0.6	0.43	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	7.29	4.72e-12	9.57e-09	0.6	0.43	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	7.29	4.74e-12	9.61e-09	0.58	0.43	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
SARC	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-7.29	4.74e-12	9.61e-09	-0.54	-0.43	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
SARC	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	7.29	4.75e-12	9.62e-09	0.41	0.43	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
SARC	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	7.29	4.76e-12	9.64e-09	0.51	0.43	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
SARC	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	7.29	4.77e-12	9.66e-09	0.58	0.43	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	7.29	4.77e-12	9.67e-09	0.56	0.43	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
SARC	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-7.29	4.78e-12	9.67e-09	-0.5	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
SARC	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	7.29	4.78e-12	9.68e-09	0.73	0.43	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
SARC	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	7.29	4.81e-12	9.74e-09	0.59	0.43	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	7.29	4.81e-12	9.74e-09	0.59	0.43	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	7.29	4.81e-12	9.74e-09	0.59	0.43	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	7.29	4.86e-12	9.83e-09	0.58	0.43	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
SARC	cis	rs6538678	0.818	rs7976294	ENSG00000258343.1	RP11-536G4.2	-7.29	4.86e-12	9.83e-09	-0.58	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95795345~95858839:-
SARC	cis	rs6538678	0.818	rs1036429	ENSG00000258343.1	RP11-536G4.2	-7.29	4.86e-12	9.83e-09	-0.58	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95795345~95858839:-
SARC	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-7.29	4.91e-12	9.93e-09	-0.39	-0.43	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
SARC	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	7.29	4.91e-12	9.93e-09	0.5	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
SARC	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	7.29	4.92e-12	9.93e-09	0.5	0.43	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
SARC	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	7.28	4.95e-12	1e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	7.28	4.95e-12	1e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
SARC	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-7.28	5e-12	1.01e-08	-0.47	-0.43	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
SARC	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	7.28	5e-12	1.01e-08	0.56	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
SARC	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	7.28	5e-12	1.01e-08	0.57	0.43	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
SARC	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	7.28	5.02e-12	1.01e-08	0.42	0.43	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
SARC	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-7.28	5.03e-12	1.01e-08	-0.52	-0.43	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
SARC	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	7.28	5.03e-12	1.01e-08	0.48	0.43	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
SARC	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	7.28	5.04e-12	1.02e-08	0.46	0.43	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
SARC	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	7.28	5.09e-12	1.03e-08	0.49	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
SARC	cis	rs1707322	0.752	rs6662164	ENSG00000280836.1	AL355480.1	-7.28	5.09e-12	1.03e-08	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45581219~45581321:-
SARC	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	7.28	5.11e-12	1.03e-08	0.68	0.43	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
SARC	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-7.28	5.15e-12	1.04e-08	-0.46	-0.43	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
SARC	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	-7.28	5.18e-12	1.04e-08	-0.42	-0.43	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
SARC	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	7.28	5.22e-12	1.05e-08	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
SARC	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-7.28	5.23e-12	1.05e-08	-0.46	-0.43	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-7.28	5.23e-12	1.05e-08	-0.46	-0.43	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
SARC	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	7.28	5.23e-12	1.05e-08	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
SARC	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	7.27	5.28e-12	1.06e-08	0.55	0.43	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
SARC	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-7.27	5.37e-12	1.08e-08	-0.57	-0.43	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
SARC	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	7.27	5.39e-12	1.08e-08	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
SARC	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-7.27	5.42e-12	1.09e-08	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
SARC	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-7.27	5.43e-12	1.09e-08	-0.55	-0.43	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
SARC	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	7.27	5.54e-12	1.11e-08	0.57	0.43	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	7.27	5.54e-12	1.11e-08	0.57	0.43	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	7.27	5.54e-12	1.11e-08	0.57	0.43	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	7.27	5.54e-12	1.11e-08	0.57	0.43	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	7.27	5.54e-12	1.11e-08	0.57	0.43	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	7.27	5.54e-12	1.11e-08	0.57	0.43	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
SARC	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	7.26	5.6e-12	1.12e-08	0.44	0.43	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
SARC	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	7.26	5.6e-12	1.12e-08	0.58	0.43	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	7.26	5.6e-12	1.12e-08	0.58	0.43	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	7.26	5.6e-12	1.12e-08	0.58	0.43	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
SARC	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	7.26	5.65e-12	1.13e-08	0.5	0.43	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
SARC	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	7.26	5.67e-12	1.14e-08	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
SARC	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	7.26	5.67e-12	1.14e-08	0.58	0.43	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	7.26	5.67e-12	1.14e-08	0.58	0.43	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	7.26	5.67e-12	1.14e-08	0.58	0.43	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	7.26	5.67e-12	1.14e-08	0.58	0.43	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	7.26	5.67e-12	1.14e-08	0.58	0.43	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	7.26	5.67e-12	1.14e-08	0.58	0.43	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	7.26	5.67e-12	1.14e-08	0.58	0.43	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
SARC	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-7.26	5.68e-12	1.14e-08	-0.46	-0.43	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-7.26	5.68e-12	1.14e-08	-0.46	-0.43	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
SARC	cis	rs1707322	0.717	rs1972410	ENSG00000280836.1	AL355480.1	-7.26	5.68e-12	1.14e-08	-0.46	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45581219~45581321:-
SARC	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-7.26	5.69e-12	1.14e-08	-0.49	-0.43	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
SARC	cis	rs748404	0.586	rs2584700	ENSG00000205771.5	CATSPER2P1	-7.26	5.71e-12	1.14e-08	-0.52	-0.43	Lung cancer;	chr15:43393134	chr15:43726918~43747094:-
SARC	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-7.26	5.77e-12	1.15e-08	-0.72	-0.43	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
SARC	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-7.26	5.78e-12	1.16e-08	-0.69	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
SARC	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	7.26	5.88e-12	1.17e-08	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	7.26	5.88e-12	1.17e-08	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	7.26	5.88e-12	1.17e-08	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-7.26	5.88e-12	1.17e-08	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
SARC	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-7.26	5.89e-12	1.17e-08	-0.56	-0.43	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
SARC	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-7.26	5.89e-12	1.17e-08	-0.56	-0.43	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
SARC	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-7.26	5.89e-12	1.17e-08	-0.56	-0.43	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
SARC	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	7.25	5.93e-12	1.18e-08	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
SARC	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-7.25	5.93e-12	1.18e-08	-0.53	-0.43	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
SARC	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	7.25	5.96e-12	1.19e-08	0.52	0.43	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
SARC	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	7.25	5.96e-12	1.19e-08	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
SARC	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-7.25	5.97e-12	1.19e-08	-0.56	-0.43	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
SARC	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	7.25	5.97e-12	1.19e-08	0.59	0.43	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
SARC	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	7.25	6.03e-12	1.2e-08	0.41	0.43	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
SARC	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-7.25	6.04e-12	1.2e-08	-0.57	-0.43	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
SARC	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-7.25	6.09e-12	1.21e-08	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
SARC	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-7.25	6.14e-12	1.22e-08	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
SARC	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	7.25	6.17e-12	1.23e-08	0.5	0.43	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
SARC	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	7.25	6.18e-12	1.23e-08	0.5	0.43	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
SARC	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	7.25	6.2e-12	1.23e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
SARC	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-7.25	6.25e-12	1.24e-08	-0.44	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
SARC	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-7.25	6.26e-12	1.24e-08	-0.5	-0.43	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
SARC	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-7.24	6.3e-12	1.25e-08	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
SARC	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-7.24	6.3e-12	1.25e-08	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
SARC	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-7.24	6.3e-12	1.25e-08	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
SARC	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	7.24	6.34e-12	1.26e-08	0.49	0.43	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
SARC	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	7.24	6.36e-12	1.26e-08	0.57	0.43	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
SARC	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-7.24	6.37e-12	1.26e-08	-0.52	-0.43	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
SARC	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-7.24	6.41e-12	1.27e-08	-0.51	-0.43	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
SARC	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	7.24	6.42e-12	1.27e-08	0.44	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	7.24	6.42e-12	1.27e-08	0.44	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	7.24	6.42e-12	1.27e-08	0.44	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
SARC	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-7.24	6.46e-12	1.28e-08	-0.46	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
SARC	cis	rs748404	0.578	rs507178	ENSG00000205771.5	CATSPER2P1	-7.24	6.46e-12	1.28e-08	-0.51	-0.43	Lung cancer;	chr15:43317937	chr15:43726918~43747094:-
SARC	cis	rs748404	0.578	rs478028	ENSG00000205771.5	CATSPER2P1	-7.24	6.46e-12	1.28e-08	-0.51	-0.43	Lung cancer;	chr15:43318574	chr15:43726918~43747094:-
SARC	cis	rs748404	0.578	rs552701	ENSG00000205771.5	CATSPER2P1	-7.24	6.46e-12	1.28e-08	-0.51	-0.43	Lung cancer;	chr15:43321612	chr15:43726918~43747094:-
SARC	cis	rs748404	0.578	rs573615	ENSG00000205771.5	CATSPER2P1	-7.24	6.46e-12	1.28e-08	-0.51	-0.43	Lung cancer;	chr15:43322083	chr15:43726918~43747094:-
SARC	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	7.24	6.48e-12	1.28e-08	0.47	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
SARC	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	7.24	6.48e-12	1.28e-08	0.47	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
SARC	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	7.24	6.5e-12	1.29e-08	0.48	0.43	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
SARC	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-7.24	6.52e-12	1.29e-08	-0.54	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
SARC	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-7.24	6.62e-12	1.31e-08	-0.46	-0.43	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
SARC	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	7.23	6.69e-12	1.32e-08	0.58	0.43	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
SARC	cis	rs34375054	0.525	rs1080910	ENSG00000279233.1	RP11-158L12.4	7.23	6.69e-12	1.32e-08	0.47	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125123946	chr12:125138245~125141711:+
SARC	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-7.23	6.69e-12	1.32e-08	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
SARC	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-7.23	6.75e-12	1.33e-08	-0.7	-0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
SARC	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-7.23	6.75e-12	1.33e-08	-0.54	-0.43	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
SARC	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-7.23	6.78e-12	1.34e-08	-0.62	-0.43	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-7.23	6.78e-12	1.34e-08	-0.62	-0.43	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
SARC	cis	rs1707322	0.752	rs12062535	ENSG00000280836.1	AL355480.1	-7.23	6.82e-12	1.35e-08	-0.44	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	7.23	6.87e-12	1.35e-08	0.44	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	7.23	6.87e-12	1.35e-08	0.44	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	7.23	6.87e-12	1.35e-08	0.44	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
SARC	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	7.23	6.89e-12	1.36e-08	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
SARC	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	7.23	6.9e-12	1.36e-08	0.44	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	7.23	6.9e-12	1.36e-08	0.44	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
SARC	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	7.23	6.9e-12	1.36e-08	0.4	0.43	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
SARC	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	7.23	6.97e-12	1.37e-08	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
SARC	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	7.23	6.97e-12	1.37e-08	0.67	0.43	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
SARC	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	7.23	6.98e-12	1.37e-08	0.57	0.43	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
SARC	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	7.23	7.01e-12	1.38e-08	0.59	0.43	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
SARC	cis	rs6538678	0.895	rs7137751	ENSG00000258343.1	RP11-536G4.2	-7.23	7.02e-12	1.38e-08	-0.55	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95795345~95858839:-
SARC	cis	rs433852	1	rs433852	ENSG00000232871.7	SEC1P	-7.23	7.03e-12	1.38e-08	-0.52	-0.43	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48613847	chr19:48638071~48682245:+
SARC	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	7.22	7.09e-12	1.4e-08	0.55	0.43	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	7.22	7.09e-12	1.4e-08	0.55	0.43	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	7.22	7.1e-12	1.4e-08	0.56	0.43	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	7.22	7.1e-12	1.4e-08	0.59	0.43	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	7.22	7.1e-12	1.4e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	7.22	7.1e-12	1.4e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	7.22	7.11e-12	1.4e-08	0.58	0.43	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	7.22	7.11e-12	1.4e-08	0.58	0.43	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	7.22	7.11e-12	1.4e-08	0.58	0.43	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	7.22	7.11e-12	1.4e-08	0.58	0.43	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	7.22	7.11e-12	1.4e-08	0.58	0.43	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	7.22	7.11e-12	1.4e-08	0.58	0.43	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	7.22	7.11e-12	1.4e-08	0.58	0.43	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	7.22	7.11e-12	1.4e-08	0.58	0.43	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	7.22	7.11e-12	1.4e-08	0.58	0.43	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	7.22	7.11e-12	1.4e-08	0.58	0.43	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	7.22	7.11e-12	1.4e-08	0.58	0.43	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	7.22	7.11e-12	1.4e-08	0.58	0.43	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
SARC	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-7.22	7.12e-12	1.4e-08	-0.58	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
SARC	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	7.22	7.12e-12	1.4e-08	0.4	0.43	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
SARC	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-7.22	7.15e-12	1.4e-08	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
SARC	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-7.22	7.15e-12	1.4e-08	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
SARC	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	7.22	7.17e-12	1.41e-08	0.65	0.43	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
SARC	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-7.22	7.19e-12	1.41e-08	-0.51	-0.43	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
SARC	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	7.22	7.19e-12	1.41e-08	0.45	0.43	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
SARC	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	7.22	7.19e-12	1.41e-08	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
SARC	cis	rs7615952	0.688	rs7624806	ENSG00000248787.1	RP11-666A20.4	-7.22	7.2e-12	1.41e-08	-0.64	-0.43	Blood pressure (smoking interaction);	chr3:125880231	chr3:125908005~125910272:-
SARC	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-7.22	7.26e-12	1.42e-08	-0.54	-0.43	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
SARC	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-7.22	7.27e-12	1.42e-08	-0.48	-0.43	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
SARC	cis	rs1930961	1	rs6004672	ENSG00000272977.1	CTA-390C10.10	-7.22	7.35e-12	1.44e-08	-0.75	-0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25476218~25479971:+
SARC	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	7.22	7.38e-12	1.45e-08	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
SARC	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-7.22	7.43e-12	1.45e-08	-0.52	-0.43	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
SARC	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	7.22	7.47e-12	1.46e-08	0.58	0.43	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	7.22	7.47e-12	1.46e-08	0.58	0.43	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	7.22	7.47e-12	1.46e-08	0.58	0.43	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	7.22	7.47e-12	1.46e-08	0.58	0.43	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
SARC	cis	rs5760092	0.618	rs4461358	ENSG00000225282.1	AP000350.6	-7.22	7.5e-12	1.47e-08	-0.55	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23926900~23929574:+
SARC	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-7.22	7.51e-12	1.47e-08	-0.54	-0.43	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
SARC	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	7.21	7.53e-12	1.47e-08	0.4	0.43	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
SARC	cis	rs113835537	0.529	rs11821155	ENSG00000255517.5	CTD-3074O7.5	7.21	7.58e-12	1.48e-08	0.46	0.43	Airway imaging phenotypes;	chr11:66478866	chr11:66473490~66480233:-
SARC	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-7.21	7.58e-12	1.48e-08	-0.54	-0.43	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
SARC	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	7.21	7.6e-12	1.49e-08	0.56	0.43	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
SARC	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-7.21	7.63e-12	1.49e-08	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
SARC	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	7.21	7.68e-12	1.5e-08	0.6	0.43	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
SARC	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-7.21	7.77e-12	1.52e-08	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
SARC	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-7.21	7.78e-12	1.52e-08	-0.52	-0.43	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
SARC	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-7.21	7.78e-12	1.52e-08	-0.52	-0.43	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
SARC	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	7.21	7.78e-12	1.52e-08	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
SARC	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	7.21	7.79e-12	1.52e-08	0.56	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
SARC	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	7.21	7.81e-12	1.52e-08	0.52	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
SARC	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-7.21	7.82e-12	1.53e-08	-0.55	-0.43	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
SARC	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-7.21	7.91e-12	1.54e-08	-0.47	-0.43	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
SARC	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-7.21	7.93e-12	1.54e-08	-0.54	-0.43	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
SARC	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-7.2	8e-12	1.56e-08	-0.39	-0.43	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
SARC	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	7.2	8.04e-12	1.57e-08	0.5	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
SARC	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-7.2	8.08e-12	1.57e-08	-0.53	-0.43	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
SARC	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	7.2	8.08e-12	1.57e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
SARC	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	7.2	8.11e-12	1.58e-08	0.55	0.43	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
SARC	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	7.2	8.11e-12	1.58e-08	0.55	0.43	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	7.2	8.11e-12	1.58e-08	0.55	0.43	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	7.2	8.11e-12	1.58e-08	0.55	0.43	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	7.2	8.11e-12	1.58e-08	0.55	0.43	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
SARC	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	7.2	8.15e-12	1.59e-08	0.56	0.43	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
SARC	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	7.2	8.16e-12	1.59e-08	0.48	0.43	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
SARC	cis	rs1707322	0.826	rs10890349	ENSG00000280836.1	AL355480.1	-7.2	8.19e-12	1.59e-08	-0.43	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.758	rs10789474	ENSG00000280836.1	AL355480.1	-7.2	8.19e-12	1.59e-08	-0.43	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45581219~45581321:-
SARC	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-7.2	8.28e-12	1.61e-08	-0.54	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
SARC	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	7.2	8.33e-12	1.62e-08	0.46	0.43	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
SARC	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-7.2	8.33e-12	1.62e-08	-0.52	-0.43	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
SARC	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	7.2	8.34e-12	1.62e-08	0.62	0.43	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
SARC	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-7.2	8.36e-12	1.62e-08	-0.55	-0.43	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-7.2	8.36e-12	1.62e-08	-0.55	-0.43	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
SARC	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	7.2	8.37e-12	1.63e-08	0.56	0.43	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	7.2	8.41e-12	1.63e-08	0.58	0.43	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
SARC	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-7.2	8.45e-12	1.64e-08	-0.51	-0.43	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
SARC	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-7.2	8.46e-12	1.64e-08	-0.52	-0.43	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
SARC	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-7.2	8.46e-12	1.64e-08	-0.52	-0.43	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
SARC	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-7.2	8.46e-12	1.64e-08	-0.52	-0.43	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
SARC	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-7.2	8.46e-12	1.64e-08	-0.52	-0.43	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
SARC	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-7.2	8.46e-12	1.64e-08	-0.52	-0.43	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
SARC	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-7.2	8.46e-12	1.64e-08	-0.52	-0.43	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
SARC	cis	rs6565180	0.962	rs6565182	ENSG00000183604.13	SMG1P5	-7.19	8.64e-12	1.67e-08	-0.42	-0.43	Tonsillectomy;	chr16:30363060	chr16:30267553~30335374:-
SARC	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-7.19	8.65e-12	1.68e-08	-0.62	-0.43	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-7.19	8.65e-12	1.68e-08	-0.62	-0.43	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-7.19	8.65e-12	1.68e-08	-0.62	-0.43	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-7.19	8.65e-12	1.68e-08	-0.62	-0.43	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
SARC	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	7.19	8.66e-12	1.68e-08	0.49	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
SARC	cis	rs1707322	0.691	rs61784799	ENSG00000280836.1	AL355480.1	7.19	8.66e-12	1.68e-08	0.45	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45581219~45581321:-
SARC	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	7.19	8.67e-12	1.68e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
SARC	cis	rs6565180	0.962	rs11642676	ENSG00000183604.13	SMG1P5	-7.19	8.72e-12	1.69e-08	-0.42	-0.43	Tonsillectomy;	chr16:30360334	chr16:30267553~30335374:-
SARC	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-7.19	8.75e-12	1.69e-08	-0.53	-0.43	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
SARC	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	7.19	8.76e-12	1.7e-08	0.48	0.43	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	7.19	8.76e-12	1.7e-08	0.48	0.43	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	7.19	8.76e-12	1.7e-08	0.48	0.43	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
SARC	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	7.19	8.8e-12	1.7e-08	0.53	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
SARC	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-7.19	8.81e-12	1.7e-08	-0.54	-0.43	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
SARC	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-7.19	8.92e-12	1.73e-08	-0.55	-0.43	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
SARC	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-7.19	8.93e-12	1.73e-08	-0.55	-0.43	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
SARC	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	7.19	8.94e-12	1.73e-08	0.57	0.43	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
SARC	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	7.19	8.94e-12	1.73e-08	0.57	0.43	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	7.19	8.94e-12	1.73e-08	0.57	0.43	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
SARC	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-7.19	8.98e-12	1.73e-08	-0.52	-0.43	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
SARC	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	7.18	9.05e-12	1.75e-08	0.67	0.43	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
SARC	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-7.18	9.12e-12	1.76e-08	-0.54	-0.43	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
SARC	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-7.18	9.14e-12	1.76e-08	-0.51	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
SARC	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	7.18	9.21e-12	1.77e-08	0.59	0.43	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	7.18	9.21e-12	1.77e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
SARC	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	7.18	9.21e-12	1.77e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	7.18	9.21e-12	1.77e-08	0.59	0.43	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	7.18	9.21e-12	1.77e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
SARC	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	7.18	9.21e-12	1.77e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	7.18	9.21e-12	1.77e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	7.18	9.21e-12	1.77e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	7.18	9.21e-12	1.77e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	7.18	9.21e-12	1.77e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	7.18	9.21e-12	1.77e-08	0.59	0.43	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
SARC	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-7.18	9.25e-12	1.78e-08	-0.57	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
SARC	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-7.18	9.25e-12	1.78e-08	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-7.18	9.25e-12	1.78e-08	-0.45	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
SARC	cis	rs3002131	0.604	rs4400619	ENSG00000225265.1	TAF1A-AS1	-7.18	9.3e-12	1.79e-08	-0.8	-0.43	Interleukin-10 levels;	chr1:222556644	chr1:222589825~222593032:+
SARC	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-7.18	9.32e-12	1.79e-08	-0.51	-0.43	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
SARC	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-7.18	9.36e-12	1.8e-08	-0.46	-0.43	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
SARC	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	7.18	9.48e-12	1.82e-08	0.55	0.43	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
SARC	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	7.17	9.64e-12	1.85e-08	0.58	0.43	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
SARC	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	7.17	9.65e-12	1.85e-08	0.4	0.43	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
SARC	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	7.17	9.65e-12	1.85e-08	0.4	0.43	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
SARC	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	7.17	9.65e-12	1.85e-08	0.4	0.43	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
SARC	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	7.17	9.67e-12	1.86e-08	0.58	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
SARC	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	7.17	9.67e-12	1.86e-08	0.58	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
SARC	cis	rs748404	0.588	rs506120	ENSG00000205771.5	CATSPER2P1	-7.17	9.78e-12	1.88e-08	-0.53	-0.43	Lung cancer;	chr15:43509826	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	7.17	9.78e-12	1.88e-08	0.54	0.43	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
SARC	cis	rs6003958	1	rs6003958	ENSG00000225282.1	AP000350.6	-7.17	9.79e-12	1.88e-08	-0.59	-0.43	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23926900~23929574:+
SARC	cis	rs5760092	0.755	rs6003959	ENSG00000225282.1	AP000350.6	-7.17	9.79e-12	1.88e-08	-0.59	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23926900~23929574:+
SARC	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	7.17	9.8e-12	1.88e-08	0.55	0.43	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
SARC	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	7.17	9.81e-12	1.88e-08	0.48	0.43	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
SARC	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-7.17	9.91e-12	1.9e-08	-0.51	-0.43	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
SARC	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-7.17	9.91e-12	1.9e-08	-0.51	-0.43	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
SARC	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-7.17	9.91e-12	1.9e-08	-0.51	-0.43	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
SARC	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-7.17	9.91e-12	1.9e-08	-0.51	-0.43	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
SARC	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	7.17	9.95e-12	1.9e-08	0.47	0.43	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	7.17	9.95e-12	1.9e-08	0.47	0.43	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	7.17	9.95e-12	1.9e-08	0.47	0.43	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	7.17	9.95e-12	1.9e-08	0.47	0.43	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
SARC	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	7.17	9.98e-12	1.91e-08	0.58	0.43	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	7.17	9.98e-12	1.91e-08	0.58	0.43	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
SARC	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-7.17	1.01e-11	1.93e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
SARC	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-7.17	1.01e-11	1.93e-08	-0.46	-0.42	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
SARC	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	7.16	1.02e-11	1.95e-08	0.56	0.42	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	7.16	1.02e-11	1.95e-08	0.56	0.42	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
SARC	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-7.16	1.02e-11	1.96e-08	-0.57	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
SARC	cis	rs1707322	0.827	rs12125508	ENSG00000280836.1	AL355480.1	-7.16	1.02e-11	1.96e-08	-0.43	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45581219~45581321:-
SARC	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	7.16	1.03e-11	1.96e-08	0.46	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
SARC	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	7.16	1.05e-11	2.01e-08	0.41	0.42	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
SARC	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-7.16	1.06e-11	2.02e-08	-0.55	-0.42	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
SARC	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	7.16	1.06e-11	2.03e-08	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
SARC	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-7.16	1.08e-11	2.05e-08	-0.45	-0.42	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
SARC	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-7.16	1.08e-11	2.05e-08	-0.45	-0.42	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
SARC	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	7.15	1.08e-11	2.06e-08	0.57	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
SARC	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-7.15	1.08e-11	2.06e-08	-0.51	-0.42	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
SARC	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	7.15	1.09e-11	2.08e-08	0.56	0.42	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
SARC	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	7.15	1.09e-11	2.08e-08	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
SARC	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-7.15	1.1e-11	2.09e-08	-0.51	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-7.15	1.1e-11	2.09e-08	-0.51	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-7.15	1.1e-11	2.09e-08	-0.51	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
SARC	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-7.15	1.11e-11	2.11e-08	-0.54	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
SARC	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-7.15	1.11e-11	2.11e-08	-0.67	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
SARC	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-7.15	1.11e-11	2.12e-08	-0.59	-0.42	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
SARC	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-7.15	1.13e-11	2.14e-08	-0.45	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-7.15	1.13e-11	2.14e-08	-0.45	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
SARC	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-7.15	1.14e-11	2.16e-08	-0.51	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
SARC	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-7.14	1.15e-11	2.17e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
SARC	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-7.14	1.15e-11	2.17e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
SARC	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	7.14	1.15e-11	2.18e-08	0.46	0.42	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	7.14	1.15e-11	2.18e-08	0.46	0.42	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	7.14	1.15e-11	2.18e-08	0.46	0.42	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	7.14	1.15e-11	2.18e-08	0.46	0.42	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	7.14	1.15e-11	2.18e-08	0.46	0.42	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	7.14	1.15e-11	2.18e-08	0.46	0.42	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	7.14	1.15e-11	2.18e-08	0.46	0.42	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	7.14	1.15e-11	2.18e-08	0.46	0.42	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	7.14	1.15e-11	2.18e-08	0.46	0.42	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
SARC	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	7.14	1.16e-11	2.2e-08	0.58	0.42	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
SARC	cis	rs5760092	0.627	rs6519489	ENSG00000225282.1	AP000350.6	-7.14	1.16e-11	2.2e-08	-0.6	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23926900~23929574:+
SARC	cis	rs5760092	0.755	rs11090298	ENSG00000225282.1	AP000350.6	-7.14	1.16e-11	2.2e-08	-0.6	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23926900~23929574:+
SARC	cis	rs6538678	0.895	rs1436124	ENSG00000258343.1	RP11-536G4.2	-7.14	1.17e-11	2.21e-08	-0.57	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95795345~95858839:-
SARC	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	7.14	1.17e-11	2.22e-08	0.47	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
SARC	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-7.14	1.19e-11	2.25e-08	-0.54	-0.42	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
SARC	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-7.14	1.19e-11	2.25e-08	-0.54	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
SARC	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	7.14	1.19e-11	2.26e-08	0.59	0.42	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
SARC	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-7.14	1.2e-11	2.26e-08	-0.54	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
SARC	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	7.14	1.2e-11	2.27e-08	0.56	0.42	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	7.14	1.2e-11	2.27e-08	0.56	0.42	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
SARC	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-7.14	1.21e-11	2.28e-08	-0.56	-0.42	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
SARC	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-7.14	1.21e-11	2.29e-08	-0.51	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
SARC	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	7.13	1.22e-11	2.29e-08	0.44	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
SARC	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-7.13	1.24e-11	2.33e-08	-0.5	-0.42	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
SARC	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-7.13	1.24e-11	2.34e-08	-0.5	-0.42	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
SARC	cis	rs12216125	0.801	rs56107510	ENSG00000272462.2	U91328.19	-7.13	1.25e-11	2.35e-08	-0.43	-0.42	Iron status biomarkers;	chr6:25987208	chr6:25992662~26001775:+
SARC	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-7.13	1.25e-11	2.35e-08	-0.43	-0.42	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
SARC	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	7.13	1.25e-11	2.36e-08	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
SARC	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-7.13	1.25e-11	2.36e-08	-0.43	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	7.13	1.25e-11	2.36e-08	0.44	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	7.13	1.26e-11	2.37e-08	0.44	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	7.13	1.26e-11	2.37e-08	0.44	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	7.13	1.26e-11	2.37e-08	0.44	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
SARC	cis	rs6538678	1	rs6538678	ENSG00000258343.1	RP11-536G4.2	-7.13	1.26e-11	2.37e-08	-0.55	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95795345~95858839:-
SARC	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-7.13	1.26e-11	2.37e-08	-0.48	-0.42	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
SARC	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	7.13	1.26e-11	2.38e-08	0.48	0.42	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
SARC	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-7.13	1.27e-11	2.38e-08	-0.38	-0.42	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
SARC	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-7.13	1.27e-11	2.38e-08	-0.5	-0.42	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
SARC	cis	rs12931792	0.712	rs56399904	ENSG00000183604.13	SMG1P5	7.13	1.28e-11	2.41e-08	0.39	0.42	Tonsillectomy;	chr16:30154862	chr16:30267553~30335374:-
SARC	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	7.13	1.28e-11	2.41e-08	0.46	0.42	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
SARC	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	7.13	1.29e-11	2.42e-08	0.44	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
SARC	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	7.13	1.29e-11	2.42e-08	0.54	0.42	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
SARC	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	7.13	1.29e-11	2.42e-08	0.5	0.42	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
SARC	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-7.13	1.29e-11	2.42e-08	-0.43	-0.42	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
SARC	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-7.13	1.29e-11	2.42e-08	-0.43	-0.42	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
SARC	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-7.13	1.29e-11	2.42e-08	-0.43	-0.42	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
SARC	cis	rs433852	0.904	rs8102492	ENSG00000232871.7	SEC1P	7.12	1.29e-11	2.43e-08	0.51	0.42	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48637552	chr19:48638071~48682245:+
SARC	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	7.12	1.3e-11	2.44e-08	0.56	0.42	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
SARC	cis	rs1930961	1	rs9624834	ENSG00000272977.1	CTA-390C10.10	-7.12	1.3e-11	2.45e-08	-0.72	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25476218~25479971:+
SARC	cis	rs1930961	1	rs9624835	ENSG00000272977.1	CTA-390C10.10	-7.12	1.3e-11	2.45e-08	-0.72	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25476218~25479971:+
SARC	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-7.12	1.32e-11	2.47e-08	-0.55	-0.42	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
SARC	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	7.12	1.33e-11	2.49e-08	0.45	0.42	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
SARC	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-7.12	1.33e-11	2.49e-08	-0.59	-0.42	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
SARC	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-7.12	1.33e-11	2.49e-08	-0.53	-0.42	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	7.12	1.34e-11	2.52e-08	0.46	0.42	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
SARC	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	7.12	1.34e-11	2.52e-08	0.56	0.42	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
SARC	cis	rs748404	0.646	rs2253268	ENSG00000205771.5	CATSPER2P1	-7.12	1.34e-11	2.53e-08	-0.52	-0.42	Lung cancer;	chr15:43508770	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.566	rs4870118	ENSG00000268592.3	RAET1E-AS1	-7.12	1.35e-11	2.53e-08	-0.58	-0.42	Lung cancer;	chr6:149923877	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.566	rs4869767	ENSG00000268592.3	RAET1E-AS1	-7.12	1.35e-11	2.53e-08	-0.58	-0.42	Lung cancer;	chr6:149923974	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.566	rs4869768	ENSG00000268592.3	RAET1E-AS1	-7.12	1.35e-11	2.53e-08	-0.58	-0.42	Lung cancer;	chr6:149924067	chr6:149863494~149919507:+
SARC	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-7.12	1.36e-11	2.54e-08	-0.46	-0.42	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
SARC	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	7.12	1.36e-11	2.56e-08	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
SARC	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	7.12	1.36e-11	2.56e-08	0.45	0.42	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
SARC	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	7.11	1.38e-11	2.58e-08	0.48	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
SARC	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	7.11	1.38e-11	2.58e-08	0.47	0.42	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
SARC	cis	rs1707322	0.662	rs11211160	ENSG00000280836.1	AL355480.1	-7.11	1.39e-11	2.6e-08	-0.44	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45581219~45581321:-
SARC	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-7.11	1.39e-11	2.6e-08	-0.66	-0.42	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
SARC	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	7.11	1.39e-11	2.61e-08	0.46	0.42	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
SARC	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-7.11	1.39e-11	2.61e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
SARC	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	7.11	1.39e-11	2.61e-08	0.56	0.42	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
SARC	cis	rs748404	0.56	rs1869258	ENSG00000205771.5	CATSPER2P1	-7.11	1.39e-11	2.61e-08	-0.52	-0.42	Lung cancer;	chr15:43511423	chr15:43726918~43747094:-
SARC	cis	rs765787	0.53	rs12909987	ENSG00000259520.4	CTD-2651B20.3	7.11	1.4e-11	2.61e-08	0.48	0.42	Uric acid levels;	chr15:45220009	chr15:45251580~45279251:-
SARC	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-7.11	1.4e-11	2.62e-08	-0.48	-0.42	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
SARC	cis	rs7615952	0.8	rs2062773	ENSG00000248787.1	RP11-666A20.4	-7.11	1.4e-11	2.63e-08	-0.65	-0.42	Blood pressure (smoking interaction);	chr3:125920805	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.799	rs13315434	ENSG00000248787.1	RP11-666A20.4	-7.11	1.4e-11	2.63e-08	-0.65	-0.42	Blood pressure (smoking interaction);	chr3:125922551	chr3:125908005~125910272:-
SARC	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	7.11	1.41e-11	2.63e-08	0.56	0.42	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
SARC	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-7.11	1.41e-11	2.64e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
SARC	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-7.11	1.41e-11	2.64e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
SARC	cis	rs1707322	0.827	rs6694302	ENSG00000280836.1	AL355480.1	-7.11	1.41e-11	2.64e-08	-0.42	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	7.11	1.42e-11	2.65e-08	0.44	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
SARC	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	7.11	1.43e-11	2.67e-08	0.58	0.42	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
SARC	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-7.11	1.43e-11	2.68e-08	-0.55	-0.42	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
SARC	cis	rs6538678	0.784	rs7297403	ENSG00000258343.1	RP11-536G4.2	-7.11	1.43e-11	2.68e-08	-0.62	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95795345~95858839:-
SARC	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-7.11	1.44e-11	2.69e-08	-0.48	-0.42	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
SARC	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-7.1	1.45e-11	2.72e-08	-0.52	-0.42	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
SARC	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-7.1	1.45e-11	2.72e-08	-0.52	-0.42	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
SARC	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	7.1	1.46e-11	2.72e-08	0.41	0.42	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
SARC	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-7.1	1.47e-11	2.74e-08	-0.57	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
SARC	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	7.1	1.48e-11	2.77e-08	0.56	0.42	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
SARC	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-7.1	1.49e-11	2.78e-08	-0.43	-0.42	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
SARC	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	7.1	1.51e-11	2.82e-08	0.53	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
SARC	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	7.1	1.51e-11	2.82e-08	0.53	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
SARC	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	7.1	1.51e-11	2.82e-08	0.54	0.42	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
SARC	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-7.1	1.52e-11	2.84e-08	-0.41	-0.42	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
SARC	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	7.1	1.53e-11	2.86e-08	0.52	0.42	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
SARC	cis	rs7615952	0.932	rs13321217	ENSG00000248787.1	RP11-666A20.4	-7.09	1.55e-11	2.88e-08	-0.64	-0.42	Blood pressure (smoking interaction);	chr3:125912928	chr3:125908005~125910272:-
SARC	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-7.09	1.55e-11	2.89e-08	-0.56	-0.42	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
SARC	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-7.09	1.55e-11	2.89e-08	-0.47	-0.42	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
SARC	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	7.09	1.56e-11	2.91e-08	0.57	0.42	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
SARC	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	7.09	1.56e-11	2.91e-08	0.57	0.42	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
SARC	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	7.09	1.57e-11	2.92e-08	0.52	0.42	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
SARC	cis	rs9322193	0.923	rs9766037	ENSG00000223701.3	RAET1E-AS1	7.09	1.59e-11	2.95e-08	0.44	0.42	Lung cancer;	chr6:149616921	chr6:149884431~149919508:+
SARC	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	7.09	1.6e-11	2.97e-08	0.48	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
SARC	cis	rs7615952	0.8	rs11915699	ENSG00000248787.1	RP11-666A20.4	-7.09	1.61e-11	2.98e-08	-0.64	-0.42	Blood pressure (smoking interaction);	chr3:125913841	chr3:125908005~125910272:-
SARC	cis	rs1707322	0.789	rs10789473	ENSG00000280836.1	AL355480.1	-7.09	1.62e-11	3e-08	-0.42	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45581219~45581321:-
SARC	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	7.09	1.62e-11	3e-08	0.47	0.42	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
SARC	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	7.09	1.62e-11	3.01e-08	0.51	0.42	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
SARC	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-7.09	1.63e-11	3.02e-08	-0.5	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
SARC	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-7.08	1.64e-11	3.04e-08	-0.49	-0.42	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-7.08	1.64e-11	3.04e-08	-0.49	-0.42	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
SARC	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-7.08	1.64e-11	3.04e-08	-0.49	-0.42	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
SARC	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	7.08	1.65e-11	3.05e-08	0.57	0.42	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
SARC	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	7.08	1.65e-11	3.06e-08	0.49	0.42	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
SARC	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-7.08	1.65e-11	3.06e-08	-0.47	-0.42	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
SARC	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-7.08	1.65e-11	3.07e-08	-0.47	-0.42	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
SARC	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	7.08	1.66e-11	3.07e-08	0.45	0.42	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
SARC	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	7.08	1.66e-11	3.07e-08	0.5	0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
SARC	cis	rs1930961	1	rs6004669	ENSG00000272977.1	CTA-390C10.10	-7.08	1.66e-11	3.08e-08	-0.73	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25476218~25479971:+
SARC	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	7.08	1.67e-11	3.09e-08	0.45	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
SARC	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-7.08	1.69e-11	3.13e-08	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
SARC	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-7.08	1.69e-11	3.13e-08	-0.57	-0.42	Depression;	chr6:28206179	chr6:28115628~28116551:+
SARC	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-7.08	1.7e-11	3.14e-08	-0.47	-0.42	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
SARC	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	7.08	1.71e-11	3.16e-08	0.49	0.42	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
SARC	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-7.08	1.72e-11	3.18e-08	-0.4	-0.42	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
SARC	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	7.08	1.73e-11	3.19e-08	0.44	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
SARC	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	7.08	1.73e-11	3.2e-08	0.41	0.42	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
SARC	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	7.07	1.75e-11	3.23e-08	0.73	0.42	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
SARC	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	7.07	1.75e-11	3.24e-08	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	7.07	1.75e-11	3.24e-08	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
SARC	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-7.07	1.76e-11	3.24e-08	-0.47	-0.42	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
SARC	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-7.07	1.76e-11	3.25e-08	-0.57	-0.42	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
SARC	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	7.07	1.77e-11	3.26e-08	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
SARC	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-7.07	1.78e-11	3.28e-08	-0.39	-0.42	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
SARC	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-7.07	1.78e-11	3.28e-08	-0.44	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
SARC	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-7.07	1.79e-11	3.29e-08	-0.42	-0.42	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
SARC	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	7.07	1.79e-11	3.3e-08	0.45	0.42	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
SARC	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	7.07	1.79e-11	3.3e-08	0.45	0.42	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
SARC	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	7.07	1.79e-11	3.3e-08	0.45	0.42	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
SARC	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	7.07	1.79e-11	3.31e-08	0.47	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
SARC	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-7.07	1.8e-11	3.31e-08	-0.45	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
SARC	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	7.07	1.8e-11	3.32e-08	0.52	0.42	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
SARC	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	7.07	1.8e-11	3.32e-08	0.58	0.42	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	7.07	1.8e-11	3.32e-08	0.58	0.42	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
SARC	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	7.07	1.81e-11	3.33e-08	0.7	0.42	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
SARC	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-7.07	1.82e-11	3.36e-08	-0.54	-0.42	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
SARC	cis	rs3002131	0.604	rs3008644	ENSG00000225265.1	TAF1A-AS1	-7.07	1.83e-11	3.37e-08	-0.8	-0.42	Interleukin-10 levels;	chr1:222577402	chr1:222589825~222593032:+
SARC	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	7.07	1.83e-11	3.37e-08	0.49	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
SARC	cis	rs748404	0.697	rs530683	ENSG00000205771.5	CATSPER2P1	7.07	1.84e-11	3.39e-08	0.5	0.42	Lung cancer;	chr15:43276801	chr15:43726918~43747094:-
SARC	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-7.06	1.89e-11	3.48e-08	-0.48	-0.42	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
SARC	cis	rs1707322	0.752	rs11488313	ENSG00000280836.1	AL355480.1	-7.06	1.91e-11	3.5e-08	-0.44	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.785	rs10890348	ENSG00000280836.1	AL355480.1	-7.06	1.91e-11	3.51e-08	-0.42	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45581219~45581321:-
SARC	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	7.06	1.91e-11	3.51e-08	0.56	0.42	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
SARC	cis	rs1865760	0.623	rs12216125	ENSG00000272810.1	U91328.22	-7.06	1.92e-11	3.53e-08	-0.43	-0.42	Height;	chr6:25997230	chr6:26013241~26013757:+
SARC	cis	rs1707322	0.685	rs11211177	ENSG00000280836.1	AL355480.1	-7.06	1.93e-11	3.55e-08	-0.44	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45581219~45581321:-
SARC	cis	rs1930961	1	rs997873	ENSG00000272977.1	CTA-390C10.10	-7.06	1.94e-11	3.56e-08	-0.73	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25476218~25479971:+
SARC	cis	rs1930961	1	rs6004671	ENSG00000272977.1	CTA-390C10.10	-7.06	1.94e-11	3.56e-08	-0.73	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25476218~25479971:+
SARC	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-7.05	1.96e-11	3.6e-08	-0.47	-0.42	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
SARC	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	7.05	1.97e-11	3.62e-08	0.63	0.42	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
SARC	cis	rs73186030	0.92	rs73186059	ENSG00000272758.4	RP11-299J3.8	7.05	1.98e-11	3.63e-08	0.56	0.42	Serum parathyroid hormone levels;	chr3:122332336	chr3:122416207~122443180:+
SARC	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	7.05	2e-11	3.66e-08	0.76	0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
SARC	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-7.05	2e-11	3.66e-08	-0.39	-0.42	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
SARC	cis	rs6538678	0.895	rs4762637	ENSG00000258343.1	RP11-536G4.2	-7.05	2e-11	3.67e-08	-0.55	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95795345~95858839:-
SARC	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	7.05	2.02e-11	3.7e-08	0.49	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
SARC	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-7.05	2.02e-11	3.7e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
SARC	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-7.05	2.02e-11	3.7e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
SARC	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-7.05	2.03e-11	3.72e-08	-0.43	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
SARC	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-7.05	2.03e-11	3.72e-08	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
SARC	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	7.05	2.03e-11	3.72e-08	0.54	0.42	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	7.05	2.03e-11	3.72e-08	0.54	0.42	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
SARC	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-7.05	2.04e-11	3.74e-08	-0.42	-0.42	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
SARC	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	7.05	2.05e-11	3.75e-08	0.46	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
SARC	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-7.05	2.06e-11	3.77e-08	-0.51	-0.42	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
SARC	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	7.05	2.06e-11	3.77e-08	0.41	0.42	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
SARC	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-7.05	2.07e-11	3.79e-08	-0.47	-0.42	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
SARC	cis	rs748404	0.697	rs471122	ENSG00000205771.5	CATSPER2P1	7.04	2.08e-11	3.79e-08	0.49	0.42	Lung cancer;	chr15:43266376	chr15:43726918~43747094:-
SARC	cis	rs748404	0.697	rs1095389	ENSG00000205771.5	CATSPER2P1	-7.04	2.08e-11	3.81e-08	-0.5	-0.42	Lung cancer;	chr15:43274473	chr15:43726918~43747094:-
SARC	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-7.04	2.09e-11	3.83e-08	-0.37	-0.42	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
SARC	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-7.04	2.09e-11	3.83e-08	-0.37	-0.42	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
SARC	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-7.04	2.09e-11	3.83e-08	-0.37	-0.42	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
SARC	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-7.04	2.09e-11	3.83e-08	-0.37	-0.42	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
SARC	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-7.04	2.09e-11	3.83e-08	-0.37	-0.42	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
SARC	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	7.04	2.11e-11	3.85e-08	0.56	0.42	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
SARC	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-7.04	2.13e-11	3.9e-08	-0.51	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
SARC	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-7.04	2.15e-11	3.93e-08	-0.54	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
SARC	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	7.04	2.16e-11	3.95e-08	0.47	0.42	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	7.04	2.16e-11	3.95e-08	0.47	0.42	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
SARC	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-7.04	2.19e-11	3.99e-08	-0.56	-0.42	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
SARC	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	7.04	2.19e-11	4e-08	0.43	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
SARC	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-7.03	2.22e-11	4.04e-08	-0.39	-0.42	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
SARC	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	7.03	2.23e-11	4.06e-08	0.46	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
SARC	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	7.03	2.23e-11	4.06e-08	0.46	0.42	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
SARC	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-7.03	2.23e-11	4.07e-08	-0.46	-0.42	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
SARC	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	7.03	2.24e-11	4.07e-08	0.55	0.42	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
SARC	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-7.03	2.24e-11	4.08e-08	-0.44	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-7.03	2.24e-11	4.08e-08	-0.44	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-7.03	2.24e-11	4.08e-08	-0.44	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
SARC	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-7.03	2.24e-11	4.08e-08	-0.47	-0.42	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
SARC	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	7.03	2.25e-11	4.09e-08	0.43	0.42	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
SARC	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-7.03	2.26e-11	4.11e-08	-0.51	-0.42	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
SARC	cis	rs1865760	0.686	rs12210098	ENSG00000272462.2	U91328.19	-7.03	2.27e-11	4.12e-08	-0.42	-0.42	Height;	chr6:25963738	chr6:25992662~26001775:+
SARC	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-7.03	2.27e-11	4.13e-08	-0.61	-0.42	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
SARC	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-7.03	2.28e-11	4.15e-08	-0.45	-0.42	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
SARC	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-7.03	2.29e-11	4.15e-08	-0.4	-0.42	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
SARC	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-7.03	2.29e-11	4.16e-08	-0.56	-0.42	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
SARC	cis	rs17270561	0.779	rs1165200	ENSG00000272462.2	U91328.19	7.03	2.29e-11	4.16e-08	0.43	0.42	Iron status biomarkers;	chr6:25874984	chr6:25992662~26001775:+
SARC	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	7.03	2.3e-11	4.18e-08	0.57	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
SARC	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-7.03	2.32e-11	4.21e-08	-0.46	-0.42	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
SARC	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	7.03	2.33e-11	4.22e-08	0.51	0.42	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
SARC	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-7.03	2.33e-11	4.23e-08	-0.45	-0.42	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-7.03	2.33e-11	4.23e-08	-0.45	-0.42	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-7.03	2.33e-11	4.23e-08	-0.45	-0.42	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
SARC	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-7.02	2.35e-11	4.26e-08	-0.44	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
SARC	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-7.02	2.35e-11	4.26e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
SARC	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-7.02	2.35e-11	4.26e-08	-0.46	-0.42	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
SARC	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-7.02	2.35e-11	4.27e-08	-0.47	-0.42	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
SARC	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	7.02	2.37e-11	4.29e-08	0.56	0.42	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
SARC	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	7.02	2.37e-11	4.3e-08	0.54	0.42	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
SARC	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-7.02	2.4e-11	4.36e-08	-0.43	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-7.02	2.4e-11	4.36e-08	-0.43	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
SARC	cis	rs748404	0.697	rs579651	ENSG00000205771.5	CATSPER2P1	-7.02	2.41e-11	4.37e-08	-0.49	-0.42	Lung cancer;	chr15:43266178	chr15:43726918~43747094:-
SARC	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	7.02	2.42e-11	4.38e-08	0.55	0.42	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
SARC	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-7.02	2.43e-11	4.39e-08	-0.6	-0.42	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-7.02	2.44e-11	4.42e-08	-0.61	-0.42	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
SARC	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-7.02	2.44e-11	4.42e-08	-0.49	-0.42	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
SARC	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	7.02	2.45e-11	4.44e-08	0.56	0.42	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
SARC	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	7.02	2.46e-11	4.45e-08	0.45	0.42	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
SARC	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-7.01	2.48e-11	4.49e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
SARC	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-7.01	2.48e-11	4.49e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
SARC	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-7.01	2.49e-11	4.5e-08	-0.58	-0.42	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
SARC	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-7.01	2.49e-11	4.51e-08	-0.47	-0.42	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
SARC	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-7.01	2.49e-11	4.51e-08	-0.47	-0.42	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
SARC	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-7.01	2.49e-11	4.51e-08	-0.47	-0.42	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
SARC	cis	rs2739330	0.752	rs2330634	ENSG00000231271.1	AP000350.8	7.01	2.49e-11	4.51e-08	0.51	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23949918~23954042:+
SARC	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	7.01	2.53e-11	4.56e-08	0.45	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
SARC	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-7.01	2.53e-11	4.58e-08	-0.54	-0.42	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
SARC	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	7.01	2.54e-11	4.59e-08	0.51	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
SARC	cis	rs748404	0.697	rs473554	ENSG00000205771.5	CATSPER2P1	-7.01	2.57e-11	4.63e-08	-0.49	-0.42	Lung cancer;	chr15:43276009	chr15:43726918~43747094:-
SARC	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	7.01	2.57e-11	4.64e-08	0.45	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
SARC	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	7.01	2.58e-11	4.65e-08	0.39	0.42	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
SARC	cis	rs73186030	0.92	rs55784797	ENSG00000272758.4	RP11-299J3.8	7.01	2.6e-11	4.68e-08	0.56	0.42	Serum parathyroid hormone levels;	chr3:122335788	chr3:122416207~122443180:+
SARC	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-7.01	2.62e-11	4.72e-08	-0.55	-0.42	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
SARC	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-7.01	2.62e-11	4.72e-08	-0.55	-0.42	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
SARC	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	7.01	2.63e-11	4.73e-08	0.55	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
SARC	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	7	2.67e-11	4.81e-08	0.49	0.42	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
SARC	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	7	2.68e-11	4.82e-08	0.66	0.42	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
SARC	cis	rs73186030	0.92	rs73186057	ENSG00000272758.4	RP11-299J3.8	7	2.68e-11	4.83e-08	0.56	0.42	Serum parathyroid hormone levels;	chr3:122325058	chr3:122416207~122443180:+
SARC	cis	rs34375054	0.557	rs35620656	ENSG00000279233.1	RP11-158L12.4	7	2.68e-11	4.83e-08	0.45	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125144557	chr12:125138245~125141711:+
SARC	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	7	2.68e-11	4.83e-08	0.39	0.42	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
SARC	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-7	2.69e-11	4.84e-08	-0.48	-0.42	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
SARC	cis	rs6565180	1	rs11863150	ENSG00000183604.13	SMG1P5	7	2.74e-11	4.92e-08	0.38	0.42	Tonsillectomy;	chr16:30374182	chr16:30267553~30335374:-
SARC	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	7	2.76e-11	4.95e-08	0.59	0.42	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	7	2.76e-11	4.97e-08	0.45	0.42	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
SARC	cis	rs73186030	0.841	rs112779893	ENSG00000272758.4	RP11-299J3.8	7	2.76e-11	4.97e-08	0.55	0.42	Serum parathyroid hormone levels;	chr3:122334433	chr3:122416207~122443180:+
SARC	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	6.99	2.79e-11	5.01e-08	0.4	0.42	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
SARC	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-6.99	2.8e-11	5.02e-08	-0.56	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
SARC	cis	rs1930961	1	rs6519611	ENSG00000272977.1	CTA-390C10.10	-6.99	2.8e-11	5.03e-08	-0.72	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25476218~25479971:+
SARC	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-6.99	2.82e-11	5.06e-08	-0.52	-0.42	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
SARC	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	6.99	2.82e-11	5.06e-08	0.51	0.42	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
SARC	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-6.99	2.82e-11	5.06e-08	-0.51	-0.42	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
SARC	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-6.99	2.82e-11	5.06e-08	-0.46	-0.42	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
SARC	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	6.99	2.83e-11	5.08e-08	0.43	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
SARC	cis	rs748404	0.697	rs555001	ENSG00000205771.5	CATSPER2P1	-6.99	2.84e-11	5.09e-08	-0.49	-0.42	Lung cancer;	chr15:43253530	chr15:43726918~43747094:-
SARC	cis	rs748404	0.697	rs475261	ENSG00000205771.5	CATSPER2P1	-6.99	2.84e-11	5.09e-08	-0.49	-0.42	Lung cancer;	chr15:43254258	chr15:43726918~43747094:-
SARC	cis	rs73186030	0.92	rs73186048	ENSG00000272758.4	RP11-299J3.8	6.99	2.84e-11	5.09e-08	0.56	0.42	Serum parathyroid hormone levels;	chr3:122316515	chr3:122416207~122443180:+
SARC	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-6.99	2.87e-11	5.14e-08	-0.45	-0.42	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	6.99	2.88e-11	5.16e-08	0.59	0.42	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
SARC	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-6.99	2.9e-11	5.2e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
SARC	cis	rs10246939	0.511	rs62475469	ENSG00000228775.6	WEE2-AS1	6.99	2.91e-11	5.21e-08	0.51	0.42	Bitter taste perception;	chr7:141864846	chr7:141704338~141738346:-
SARC	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-6.99	2.91e-11	5.21e-08	-0.42	-0.42	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
SARC	cis	rs73186030	0.92	rs73186060	ENSG00000272758.4	RP11-299J3.8	6.99	2.93e-11	5.24e-08	0.56	0.42	Serum parathyroid hormone levels;	chr3:122333507	chr3:122416207~122443180:+
SARC	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	6.99	2.93e-11	5.25e-08	0.46	0.42	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
SARC	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	6.99	2.94e-11	5.26e-08	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
SARC	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-6.98	2.98e-11	5.33e-08	-0.53	-0.42	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
SARC	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	6.98	3.02e-11	5.39e-08	0.59	0.42	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
SARC	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	6.98	3.02e-11	5.39e-08	0.59	0.42	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
SARC	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	6.98	3.02e-11	5.4e-08	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
SARC	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	6.98	3.03e-11	5.4e-08	0.66	0.42	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
SARC	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-6.98	3.06e-11	5.47e-08	-0.57	-0.42	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
SARC	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	6.98	3.07e-11	5.47e-08	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
SARC	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	6.98	3.07e-11	5.48e-08	0.59	0.42	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
SARC	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-6.98	3.08e-11	5.5e-08	-0.48	-0.42	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
SARC	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-6.98	3.11e-11	5.54e-08	-0.44	-0.42	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
SARC	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-6.97	3.16e-11	5.62e-08	-0.54	-0.42	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
SARC	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-6.97	3.18e-11	5.66e-08	-0.5	-0.42	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
SARC	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-6.97	3.18e-11	5.67e-08	-0.61	-0.42	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
SARC	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	6.97	3.2e-11	5.7e-08	0.42	0.42	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
SARC	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	6.97	3.24e-11	5.77e-08	0.46	0.42	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
SARC	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	6.97	3.28e-11	5.82e-08	0.51	0.42	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
SARC	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-6.97	3.28e-11	5.82e-08	-0.47	-0.42	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
SARC	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-6.97	3.31e-11	5.89e-08	-0.57	-0.42	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
SARC	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-6.97	3.32e-11	5.9e-08	-0.45	-0.42	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
SARC	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-6.96	3.33e-11	5.91e-08	-0.49	-0.42	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
SARC	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-6.96	3.37e-11	5.98e-08	-0.54	-0.42	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
SARC	cis	rs8062405	0.756	rs151301	ENSG00000259982.1	CDC37P1	6.96	3.44e-11	6.1e-08	0.48	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28700294~28701540:-
SARC	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	6.96	3.48e-11	6.16e-08	0.59	0.41	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-6.96	3.48e-11	6.17e-08	-0.56	-0.41	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-6.96	3.48e-11	6.17e-08	-0.56	-0.41	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
SARC	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	6.96	3.49e-11	6.18e-08	0.56	0.41	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
SARC	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-6.96	3.51e-11	6.21e-08	-0.53	-0.41	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
SARC	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	6.95	3.58e-11	6.33e-08	0.53	0.41	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
SARC	cis	rs748404	0.723	rs573169	ENSG00000205771.5	CATSPER2P1	-6.95	3.59e-11	6.35e-08	-0.49	-0.41	Lung cancer;	chr15:43258383	chr15:43726918~43747094:-
SARC	cis	rs748404	0.697	rs524547	ENSG00000205771.5	CATSPER2P1	-6.95	3.59e-11	6.35e-08	-0.49	-0.41	Lung cancer;	chr15:43258825	chr15:43726918~43747094:-
SARC	cis	rs748404	0.697	rs564946	ENSG00000205771.5	CATSPER2P1	-6.95	3.59e-11	6.35e-08	-0.49	-0.41	Lung cancer;	chr15:43264074	chr15:43726918~43747094:-
SARC	cis	rs748404	0.723	rs565658	ENSG00000205771.5	CATSPER2P1	-6.95	3.59e-11	6.35e-08	-0.49	-0.41	Lung cancer;	chr15:43264109	chr15:43726918~43747094:-
SARC	cis	rs748404	0.697	rs473016	ENSG00000205771.5	CATSPER2P1	-6.95	3.59e-11	6.35e-08	-0.49	-0.41	Lung cancer;	chr15:43266625	chr15:43726918~43747094:-
SARC	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-6.95	3.61e-11	6.39e-08	-0.55	-0.41	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
SARC	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	6.95	3.61e-11	6.39e-08	0.46	0.41	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
SARC	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-6.95	3.62e-11	6.4e-08	-0.43	-0.41	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
SARC	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-6.95	3.65e-11	6.45e-08	-0.42	-0.41	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
SARC	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-6.95	3.65e-11	6.45e-08	-0.42	-0.41	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
SARC	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-6.95	3.67e-11	6.49e-08	-0.57	-0.41	Depression;	chr6:28184805	chr6:28115628~28116551:+
SARC	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-6.95	3.7e-11	6.53e-08	-0.48	-0.41	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
SARC	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-6.95	3.71e-11	6.55e-08	-0.47	-0.41	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
SARC	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	6.94	3.75e-11	6.62e-08	0.52	0.41	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
SARC	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	6.94	3.75e-11	6.62e-08	0.52	0.41	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
SARC	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	6.94	3.76e-11	6.64e-08	0.53	0.41	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	6.94	3.76e-11	6.64e-08	0.53	0.41	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
SARC	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-6.94	3.77e-11	6.64e-08	-0.58	-0.41	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
SARC	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-6.94	3.78e-11	6.65e-08	-0.57	-0.41	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
SARC	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	6.94	3.84e-11	6.75e-08	0.69	0.41	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	6.94	3.84e-11	6.75e-08	0.69	0.41	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	6.94	3.84e-11	6.75e-08	0.69	0.41	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	6.94	3.84e-11	6.75e-08	0.69	0.41	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
SARC	cis	rs7174755	0.923	rs11634149	ENSG00000260657.2	RP11-315D16.4	6.94	3.86e-11	6.79e-08	0.39	0.41	Major depressive disorder;	chr15:68306072	chr15:68267792~68277994:-
SARC	cis	rs4972806	0.849	rs2857541	ENSG00000226363.3	HAGLROS	-6.94	3.88e-11	6.82e-08	-0.53	-0.41	IgG glycosylation;	chr2:176164358	chr2:176177717~176179008:+
SARC	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	6.94	3.91e-11	6.87e-08	0.53	0.41	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
SARC	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-6.94	3.93e-11	6.9e-08	-0.55	-0.41	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
SARC	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-6.94	3.96e-11	6.95e-08	-0.49	-0.41	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
SARC	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-6.94	3.96e-11	6.95e-08	-0.53	-0.41	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
SARC	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-6.93	3.97e-11	6.96e-08	-0.61	-0.41	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-6.93	3.97e-11	6.96e-08	-0.61	-0.41	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-6.93	3.97e-11	6.96e-08	-0.61	-0.41	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
SARC	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-6.93	3.99e-11	7e-08	-0.39	-0.41	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
SARC	cis	rs73186030	0.92	rs73186050	ENSG00000272758.4	RP11-299J3.8	6.93	3.99e-11	7e-08	0.56	0.41	Serum parathyroid hormone levels;	chr3:122321081	chr3:122416207~122443180:+
SARC	cis	rs73186030	0.92	rs73186053	ENSG00000272758.4	RP11-299J3.8	6.93	3.99e-11	7e-08	0.56	0.41	Serum parathyroid hormone levels;	chr3:122322009	chr3:122416207~122443180:+
SARC	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-6.93	4e-11	7.02e-08	-0.55	-0.41	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
SARC	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-6.93	4e-11	7.02e-08	-0.55	-0.41	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
SARC	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-6.93	4.07e-11	7.13e-08	-0.52	-0.41	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
SARC	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-6.93	4.09e-11	7.17e-08	-0.56	-0.41	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
SARC	cis	rs3002131	0.604	rs2936038	ENSG00000225265.1	TAF1A-AS1	-6.93	4.09e-11	7.17e-08	-0.73	-0.41	Interleukin-10 levels;	chr1:222572449	chr1:222589825~222593032:+
SARC	cis	rs6538678	0.746	rs12820313	ENSG00000258343.1	RP11-536G4.2	-6.93	4.13e-11	7.23e-08	-0.49	-0.41	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95795345~95858839:-
SARC	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-6.93	4.15e-11	7.26e-08	-0.57	-0.41	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
SARC	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-6.93	4.18e-11	7.32e-08	-0.56	-0.41	Depression;	chr6:28206812	chr6:28115628~28116551:+
SARC	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-6.93	4.19e-11	7.33e-08	-0.51	-0.41	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
SARC	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-6.93	4.19e-11	7.33e-08	-0.52	-0.41	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
SARC	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-6.92	4.21e-11	7.35e-08	-0.41	-0.41	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
SARC	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-6.92	4.22e-11	7.37e-08	-0.57	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
SARC	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-6.92	4.22e-11	7.38e-08	-0.47	-0.41	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-6.92	4.22e-11	7.38e-08	-0.47	-0.41	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-6.92	4.22e-11	7.38e-08	-0.47	-0.41	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-6.92	4.22e-11	7.38e-08	-0.47	-0.41	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-6.92	4.22e-11	7.38e-08	-0.47	-0.41	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
SARC	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-6.92	4.24e-11	7.42e-08	-0.57	-0.41	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
SARC	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-6.92	4.24e-11	7.42e-08	-0.57	-0.41	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
SARC	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-6.92	4.24e-11	7.42e-08	-0.57	-0.41	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
SARC	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-6.92	4.26e-11	7.44e-08	-0.37	-0.41	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
SARC	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-6.92	4.28e-11	7.47e-08	-0.44	-0.41	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-6.92	4.28e-11	7.47e-08	-0.44	-0.41	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-6.92	4.3e-11	7.5e-08	-0.44	-0.41	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
SARC	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	6.92	4.31e-11	7.52e-08	0.46	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
SARC	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-6.92	4.31e-11	7.52e-08	-0.55	-0.41	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-6.92	4.31e-11	7.52e-08	-0.55	-0.41	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-6.92	4.31e-11	7.52e-08	-0.55	-0.41	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
SARC	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	6.91	4.48e-11	7.8e-08	0.47	0.41	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
SARC	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	6.91	4.48e-11	7.8e-08	0.47	0.41	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
SARC	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	6.91	4.56e-11	7.94e-08	0.44	0.41	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
SARC	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	6.91	4.58e-11	7.96e-08	0.46	0.41	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
SARC	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	6.91	4.6e-11	8.01e-08	0.47	0.41	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
SARC	cis	rs1707322	0.721	rs6665808	ENSG00000280836.1	AL355480.1	-6.91	4.67e-11	8.11e-08	-0.43	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs61784800	ENSG00000280836.1	AL355480.1	6.91	4.67e-11	8.11e-08	0.43	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45581219~45581321:-
SARC	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-6.91	4.69e-11	8.15e-08	-0.43	-0.41	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
SARC	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-6.91	4.72e-11	8.21e-08	-0.51	-0.41	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	6.9	4.77e-11	8.29e-08	0.44	0.41	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
SARC	cis	rs1707322	0.821	rs10749857	ENSG00000280836.1	AL355480.1	-6.9	4.78e-11	8.3e-08	-0.42	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45581219~45581321:-
SARC	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	6.9	4.79e-11	8.32e-08	0.54	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
SARC	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-6.9	4.84e-11	8.41e-08	-0.49	-0.41	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
SARC	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-6.9	4.87e-11	8.46e-08	-0.55	-0.41	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-6.9	4.87e-11	8.46e-08	-0.55	-0.41	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
SARC	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	6.9	4.88e-11	8.47e-08	0.51	0.41	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
SARC	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-6.9	4.88e-11	8.47e-08	-0.51	-0.41	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
SARC	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-6.9	4.88e-11	8.47e-08	-0.51	-0.41	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
SARC	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-6.9	4.9e-11	8.49e-08	-0.6	-0.41	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	6.9	4.9e-11	8.51e-08	0.61	0.41	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
SARC	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-6.9	4.91e-11	8.51e-08	-0.55	-0.41	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
SARC	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	6.9	4.92e-11	8.53e-08	0.44	0.41	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
SARC	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	6.9	4.94e-11	8.56e-08	0.45	0.41	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
SARC	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-6.9	4.95e-11	8.58e-08	-0.55	-0.41	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
SARC	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-6.9	4.95e-11	8.58e-08	-0.55	-0.41	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
SARC	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-6.9	4.96e-11	8.6e-08	-0.69	-0.41	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
SARC	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-6.9	4.98e-11	8.62e-08	-0.41	-0.41	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
SARC	cis	rs17772222	0.958	rs17798341	ENSG00000258983.2	RP11-507K2.2	6.9	4.99e-11	8.64e-08	0.46	0.41	Coronary artery calcification;	chr14:88548201	chr14:88499334~88515502:+
SARC	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-6.9	5.01e-11	8.67e-08	-0.46	-0.41	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
SARC	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-6.9	5.01e-11	8.67e-08	-0.46	-0.41	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
SARC	cis	rs17772222	0.674	rs112788894	ENSG00000258983.2	RP11-507K2.2	6.9	5.01e-11	8.68e-08	0.46	0.41	Coronary artery calcification;	chr14:88442850	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.876	rs4375590	ENSG00000258983.2	RP11-507K2.2	6.9	5.01e-11	8.68e-08	0.46	0.41	Coronary artery calcification;	chr14:88451334	chr14:88499334~88515502:+
SARC	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-6.89	5.02e-11	8.68e-08	-0.48	-0.41	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
SARC	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-6.89	5.03e-11	8.71e-08	-0.47	-0.41	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
SARC	cis	rs9322193	0.923	rs1572229	ENSG00000223701.3	RAET1E-AS1	6.89	5.03e-11	8.71e-08	0.44	0.41	Lung cancer;	chr6:149743841	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	6.89	5.03e-11	8.71e-08	0.44	0.41	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
SARC	cis	rs2487048	0.905	rs2437812	ENSG00000226334.1	RP11-217B7.2	-6.89	5.06e-11	8.76e-08	-0.56	-0.41	Intraocular pressure;	chr9:104930920	chr9:104927553~104928892:+
SARC	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	6.89	5.09e-11	8.79e-08	0.37	0.41	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
SARC	cis	rs9322193	0.884	rs1125	ENSG00000268592.3	RAET1E-AS1	6.89	5.12e-11	8.85e-08	0.53	0.41	Lung cancer;	chr6:149658280	chr6:149863494~149919507:+
SARC	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	6.89	5.16e-11	8.92e-08	0.38	0.41	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
SARC	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	6.89	5.16e-11	8.92e-08	0.38	0.41	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
SARC	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	6.89	5.16e-11	8.92e-08	0.38	0.41	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
SARC	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	6.89	5.19e-11	8.97e-08	0.51	0.41	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
SARC	cis	rs73186030	0.591	rs56098325	ENSG00000272758.4	RP11-299J3.8	6.89	5.3e-11	9.14e-08	0.57	0.41	Serum parathyroid hormone levels;	chr3:122342362	chr3:122416207~122443180:+
SARC	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-6.89	5.31e-11	9.15e-08	-0.52	-0.41	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
SARC	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-6.89	5.31e-11	9.15e-08	-0.52	-0.41	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
SARC	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-6.88	5.35e-11	9.22e-08	-0.46	-0.41	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
SARC	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	6.88	5.36e-11	9.23e-08	0.56	0.41	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
SARC	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	6.88	5.36e-11	9.24e-08	0.54	0.41	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
SARC	cis	rs12931792	0.712	rs2887799	ENSG00000183604.13	SMG1P5	6.88	5.38e-11	9.27e-08	0.37	0.41	Tonsillectomy;	chr16:30152512	chr16:30267553~30335374:-
SARC	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	6.88	5.41e-11	9.31e-08	0.46	0.41	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
SARC	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	6.88	5.43e-11	9.36e-08	0.39	0.41	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
SARC	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	6.88	5.44e-11	9.37e-08	0.51	0.41	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
SARC	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	6.88	5.44e-11	9.37e-08	0.51	0.41	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
SARC	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	6.88	5.44e-11	9.37e-08	0.51	0.41	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
SARC	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	6.88	5.46e-11	9.39e-08	0.38	0.41	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
SARC	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	6.88	5.5e-11	9.46e-08	0.38	0.41	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
SARC	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	6.88	5.5e-11	9.46e-08	0.38	0.41	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
SARC	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	6.88	5.5e-11	9.46e-08	0.38	0.41	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
SARC	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	6.88	5.5e-11	9.46e-08	0.38	0.41	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
SARC	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	6.88	5.5e-11	9.46e-08	0.38	0.41	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
SARC	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	6.88	5.55e-11	9.54e-08	0.51	0.41	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
SARC	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	6.88	5.58e-11	9.6e-08	0.45	0.41	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
SARC	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-6.87	5.64e-11	9.7e-08	-0.51	-0.41	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
SARC	cis	rs6565180	0.962	rs6565183	ENSG00000183604.13	SMG1P5	-6.87	5.72e-11	9.82e-08	-0.38	-0.41	Tonsillectomy;	chr16:30371434	chr16:30267553~30335374:-
SARC	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	6.87	5.74e-11	9.85e-08	0.69	0.41	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
SARC	cis	rs1707322	0.682	rs28508523	ENSG00000280836.1	AL355480.1	-6.87	5.75e-11	9.87e-08	-0.43	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.691	rs11211175	ENSG00000280836.1	AL355480.1	-6.87	5.75e-11	9.87e-08	-0.43	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45581219~45581321:-
SARC	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-6.87	5.81e-11	9.97e-08	-0.72	-0.41	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
SARC	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-6.87	5.82e-11	9.97e-08	-0.57	-0.41	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-6.87	5.82e-11	9.97e-08	-0.57	-0.41	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
SARC	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-6.87	5.84e-11	1e-07	-0.52	-0.41	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
SARC	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-6.87	5.84e-11	1e-07	-0.52	-0.41	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
SARC	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-6.87	5.84e-11	1e-07	-0.52	-0.41	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
SARC	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-6.87	5.86e-11	1e-07	-0.6	-0.41	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
SARC	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	6.87	5.88e-11	1.01e-07	0.77	0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
SARC	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-6.86	5.99e-11	1.03e-07	-0.41	-0.41	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
SARC	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-6.86	6.02e-11	1.03e-07	-0.45	-0.41	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
SARC	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	6.86	6.03e-11	1.03e-07	0.54	0.41	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
SARC	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	6.86	6.03e-11	1.03e-07	0.54	0.41	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
SARC	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	6.86	6.03e-11	1.03e-07	0.54	0.41	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
SARC	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	6.86	6.03e-11	1.03e-07	0.54	0.41	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	6.86	6.03e-11	1.03e-07	0.54	0.41	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
SARC	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-6.86	6.03e-11	1.03e-07	-0.54	-0.41	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
SARC	cis	rs1707322	0.721	rs10430124	ENSG00000280836.1	AL355480.1	-6.86	6.05e-11	1.03e-07	-0.42	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45581219~45581321:-
SARC	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	6.86	6.05e-11	1.03e-07	0.38	0.41	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
SARC	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-6.86	6.08e-11	1.04e-07	-0.46	-0.41	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
SARC	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-6.86	6.1e-11	1.04e-07	-0.6	-0.41	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
SARC	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-6.86	6.12e-11	1.04e-07	-0.51	-0.41	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
SARC	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	6.86	6.18e-11	1.06e-07	0.46	0.41	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
SARC	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-6.86	6.19e-11	1.06e-07	-0.49	-0.41	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
SARC	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-6.86	6.19e-11	1.06e-07	-0.47	-0.41	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
SARC	cis	rs4972806	0.849	rs1542180	ENSG00000226363.3	HAGLROS	-6.86	6.19e-11	1.06e-07	-0.52	-0.41	IgG glycosylation;	chr2:176164039	chr2:176177717~176179008:+
SARC	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-6.86	6.21e-11	1.06e-07	-0.43	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
SARC	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-6.86	6.22e-11	1.06e-07	-0.56	-0.41	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
SARC	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	6.86	6.27e-11	1.07e-07	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	6.86	6.27e-11	1.07e-07	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
SARC	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-6.86	6.27e-11	1.07e-07	-0.54	-0.41	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
SARC	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	6.86	6.29e-11	1.07e-07	0.46	0.41	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
SARC	cis	rs748404	0.697	rs498227	ENSG00000205771.5	CATSPER2P1	-6.86	6.32e-11	1.08e-07	-0.5	-0.41	Lung cancer;	chr15:43280854	chr15:43726918~43747094:-
SARC	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	6.86	6.33e-11	1.08e-07	0.39	0.41	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
SARC	cis	rs748404	0.697	rs530188	ENSG00000205771.5	CATSPER2P1	-6.85	6.35e-11	1.08e-07	-0.49	-0.41	Lung cancer;	chr15:43253116	chr15:43726918~43747094:-
SARC	cis	rs748404	0.697	rs475227	ENSG00000205771.5	CATSPER2P1	-6.85	6.35e-11	1.08e-07	-0.49	-0.41	Lung cancer;	chr15:43254248	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.923	rs9800871	ENSG00000223701.3	RAET1E-AS1	6.85	6.36e-11	1.08e-07	0.43	0.41	Lung cancer;	chr6:149644540	chr6:149884431~149919508:+
SARC	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-6.85	6.38e-11	1.09e-07	-0.56	-0.41	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
SARC	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-6.85	6.38e-11	1.09e-07	-0.56	-0.41	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
SARC	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-6.85	6.38e-11	1.09e-07	-0.56	-0.41	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
SARC	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-6.85	6.39e-11	1.09e-07	-0.58	-0.41	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
SARC	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	6.85	6.42e-11	1.09e-07	0.51	0.41	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
SARC	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-6.85	6.43e-11	1.09e-07	-0.41	-0.41	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
SARC	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-6.85	6.43e-11	1.09e-07	-0.41	-0.41	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
SARC	cis	rs1930961	1	rs9624836	ENSG00000272977.1	CTA-390C10.10	-6.85	6.46e-11	1.1e-07	-0.71	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25476218~25479971:+
SARC	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-6.85	6.47e-11	1.1e-07	-0.54	-0.41	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
SARC	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-6.85	6.55e-11	1.11e-07	-0.48	-0.41	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
SARC	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	6.85	6.56e-11	1.11e-07	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
SARC	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-6.85	6.56e-11	1.11e-07	-0.39	-0.41	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
SARC	cis	rs9322193	0.923	rs9404048	ENSG00000223701.3	RAET1E-AS1	6.85	6.61e-11	1.12e-07	0.43	0.41	Lung cancer;	chr6:149616188	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9322196	ENSG00000223701.3	RAET1E-AS1	6.85	6.61e-11	1.12e-07	0.43	0.41	Lung cancer;	chr6:149619645	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	6.85	6.61e-11	1.12e-07	0.43	0.41	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	6.85	6.61e-11	1.12e-07	0.43	0.41	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	6.85	6.61e-11	1.12e-07	0.43	0.41	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.847	rs62439808	ENSG00000223701.3	RAET1E-AS1	6.85	6.61e-11	1.12e-07	0.43	0.41	Lung cancer;	chr6:149629690	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9322200	ENSG00000223701.3	RAET1E-AS1	6.85	6.61e-11	1.12e-07	0.43	0.41	Lung cancer;	chr6:149630078	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	6.85	6.61e-11	1.12e-07	0.43	0.41	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	6.85	6.61e-11	1.12e-07	0.43	0.41	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
SARC	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-6.85	6.64e-11	1.12e-07	-0.55	-0.41	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
SARC	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-6.85	6.66e-11	1.13e-07	-0.6	-0.41	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
SARC	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-6.85	6.66e-11	1.13e-07	-0.56	-0.41	Depression;	chr6:28193021	chr6:28115628~28116551:+
SARC	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-6.85	6.67e-11	1.13e-07	-0.41	-0.41	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
SARC	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-6.84	6.72e-11	1.14e-07	-0.54	-0.41	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
SARC	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-6.84	6.72e-11	1.14e-07	-0.54	-0.41	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
SARC	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-6.84	6.77e-11	1.14e-07	-0.52	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
SARC	cis	rs9322193	0.923	rs9689084	ENSG00000223701.3	RAET1E-AS1	6.84	6.77e-11	1.14e-07	0.43	0.41	Lung cancer;	chr6:149639648	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9800614	ENSG00000223701.3	RAET1E-AS1	6.84	6.8e-11	1.15e-07	0.43	0.41	Lung cancer;	chr6:149644604	chr6:149884431~149919508:+
SARC	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-6.84	6.82e-11	1.15e-07	-0.4	-0.41	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
SARC	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-6.84	6.84e-11	1.15e-07	-0.61	-0.41	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
SARC	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	6.84	6.91e-11	1.17e-07	0.54	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
SARC	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-6.84	6.96e-11	1.17e-07	-0.5	-0.41	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
SARC	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-6.84	6.97e-11	1.18e-07	-0.46	-0.41	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
SARC	cis	rs9322193	0.923	rs9505982	ENSG00000223701.3	RAET1E-AS1	6.84	6.99e-11	1.18e-07	0.43	0.41	Lung cancer;	chr6:149618465	chr6:149884431~149919508:+
SARC	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-6.84	7.03e-11	1.19e-07	-0.47	-0.41	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
SARC	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	6.83	7.17e-11	1.21e-07	0.46	0.41	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
SARC	cis	rs748404	0.697	rs531910	ENSG00000205771.5	CATSPER2P1	-6.83	7.18e-11	1.21e-07	-0.48	-0.41	Lung cancer;	chr15:43268409	chr15:43726918~43747094:-
SARC	cis	rs748404	0.697	rs491804	ENSG00000205771.5	CATSPER2P1	-6.83	7.18e-11	1.21e-07	-0.48	-0.41	Lung cancer;	chr15:43268627	chr15:43726918~43747094:-
SARC	cis	rs748404	0.697	rs492743	ENSG00000205771.5	CATSPER2P1	-6.83	7.18e-11	1.21e-07	-0.48	-0.41	Lung cancer;	chr15:43268747	chr15:43726918~43747094:-
SARC	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	6.83	7.19e-11	1.21e-07	0.48	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
SARC	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	6.83	7.22e-11	1.21e-07	0.44	0.41	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
SARC	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	6.83	7.27e-11	1.22e-07	0.51	0.41	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
SARC	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	6.83	7.31e-11	1.23e-07	0.38	0.41	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
SARC	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-6.83	7.35e-11	1.24e-07	-0.46	-0.41	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
SARC	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-6.83	7.35e-11	1.24e-07	-0.46	-0.41	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
SARC	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-6.83	7.39e-11	1.24e-07	-0.56	-0.41	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
SARC	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	6.83	7.39e-11	1.24e-07	0.47	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
SARC	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	6.83	7.49e-11	1.26e-07	0.68	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
SARC	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	6.83	7.5e-11	1.26e-07	0.52	0.41	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
SARC	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	6.83	7.53e-11	1.26e-07	0.51	0.41	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
SARC	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	6.82	7.6e-11	1.27e-07	0.54	0.41	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
SARC	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	6.82	7.65e-11	1.28e-07	0.41	0.41	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
SARC	cis	rs6003958	1	rs6003958	ENSG00000231271.1	AP000350.8	-6.82	7.66e-11	1.28e-07	-0.56	-0.41	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23949918~23954042:+
SARC	cis	rs5760092	0.755	rs6003959	ENSG00000231271.1	AP000350.8	-6.82	7.66e-11	1.28e-07	-0.56	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23949918~23954042:+
SARC	cis	rs1075232	0.826	rs16956738	ENSG00000270055.1	CTD-3092A11.2	6.82	7.67e-11	1.29e-07	0.81	0.41	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30487963~30490313:+
SARC	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	6.82	7.72e-11	1.29e-07	0.44	0.41	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
SARC	cis	rs748404	0.697	rs493444	ENSG00000205771.5	CATSPER2P1	-6.82	7.75e-11	1.3e-07	-0.49	-0.41	Lung cancer;	chr15:43274272	chr15:43726918~43747094:-
SARC	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-6.82	7.85e-11	1.31e-07	-0.55	-0.41	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
SARC	cis	rs748404	0.697	rs546170	ENSG00000205771.5	CATSPER2P1	-6.82	7.85e-11	1.31e-07	-0.49	-0.41	Lung cancer;	chr15:43272651	chr15:43726918~43747094:-
SARC	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-6.82	7.89e-11	1.32e-07	-0.57	-0.41	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-6.82	7.89e-11	1.32e-07	-0.57	-0.41	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
SARC	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	6.82	7.9e-11	1.32e-07	0.41	0.41	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
SARC	cis	rs9322193	0.543	rs9371533	ENSG00000223701.3	RAET1E-AS1	6.81	7.99e-11	1.33e-07	0.44	0.41	Lung cancer;	chr6:149889545	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	6.81	8.01e-11	1.34e-07	0.44	0.41	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	6.81	8.01e-11	1.34e-07	0.44	0.41	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	6.81	8.01e-11	1.34e-07	0.44	0.41	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
SARC	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	6.81	8.08e-11	1.35e-07	0.46	0.41	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
SARC	cis	rs6565180	0.926	rs12446288	ENSG00000183604.13	SMG1P5	6.81	8.13e-11	1.36e-07	0.37	0.41	Tonsillectomy;	chr16:30377388	chr16:30267553~30335374:-
SARC	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	6.81	8.14e-11	1.36e-07	0.38	0.41	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
SARC	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	6.81	8.14e-11	1.36e-07	0.51	0.41	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
SARC	cis	rs9322193	0.923	rs9377230	ENSG00000223701.3	RAET1E-AS1	6.81	8.26e-11	1.38e-07	0.43	0.41	Lung cancer;	chr6:149613607	chr6:149884431~149919508:+
SARC	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	6.81	8.28e-11	1.38e-07	0.44	0.41	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
SARC	cis	rs748404	0.697	rs572959	ENSG00000205771.5	CATSPER2P1	-6.81	8.29e-11	1.38e-07	-0.49	-0.41	Lung cancer;	chr15:43258304	chr15:43726918~43747094:-
SARC	cis	rs748404	0.697	rs554001	ENSG00000205771.5	CATSPER2P1	-6.81	8.29e-11	1.38e-07	-0.49	-0.41	Lung cancer;	chr15:43259721	chr15:43726918~43747094:-
SARC	cis	rs748404	0.697	rs501884	ENSG00000205771.5	CATSPER2P1	-6.81	8.29e-11	1.38e-07	-0.49	-0.41	Lung cancer;	chr15:43261784	chr15:43726918~43747094:-
SARC	cis	rs748404	0.697	rs504417	ENSG00000205771.5	CATSPER2P1	-6.81	8.29e-11	1.38e-07	-0.49	-0.41	Lung cancer;	chr15:43262028	chr15:43726918~43747094:-
SARC	cis	rs748404	0.723	rs560134	ENSG00000205771.5	CATSPER2P1	-6.81	8.29e-11	1.38e-07	-0.49	-0.41	Lung cancer;	chr15:43263501	chr15:43726918~43747094:-
SARC	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-6.81	8.3e-11	1.38e-07	-0.56	-0.41	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
SARC	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	6.81	8.32e-11	1.39e-07	0.39	0.41	Height;	chr3:53073764	chr3:53064283~53065091:-
SARC	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-6.81	8.33e-11	1.39e-07	-0.53	-0.41	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
SARC	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-6.81	8.33e-11	1.39e-07	-0.53	-0.41	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
SARC	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	6.81	8.36e-11	1.39e-07	0.45	0.41	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
SARC	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-6.81	8.46e-11	1.41e-07	-0.57	-0.41	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
SARC	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	6.8	8.49e-11	1.41e-07	0.47	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
SARC	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-6.8	8.51e-11	1.42e-07	-0.41	-0.41	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
SARC	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	6.8	8.59e-11	1.43e-07	0.44	0.41	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
SARC	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-6.8	8.6e-11	1.43e-07	-0.55	-0.41	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
SARC	cis	rs748404	0.697	rs493177	ENSG00000205771.5	CATSPER2P1	-6.8	8.61e-11	1.43e-07	-0.48	-0.41	Lung cancer;	chr15:43251060	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	6.8	8.68e-11	1.44e-07	0.58	0.41	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
SARC	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	6.8	8.69e-11	1.44e-07	0.46	0.41	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.958	rs891750	ENSG00000258983.2	RP11-507K2.2	6.8	8.69e-11	1.44e-07	0.46	0.41	Coronary artery calcification;	chr14:88550856	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.958	rs891749	ENSG00000258983.2	RP11-507K2.2	6.8	8.69e-11	1.44e-07	0.46	0.41	Coronary artery calcification;	chr14:88550893	chr14:88499334~88515502:+
SARC	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-6.8	8.75e-11	1.45e-07	-0.47	-0.41	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
SARC	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-6.8	8.8e-11	1.46e-07	-0.54	-0.41	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
SARC	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	6.8	8.81e-11	1.46e-07	0.53	0.41	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
SARC	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	6.8	8.94e-11	1.48e-07	0.44	0.41	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
SARC	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-6.79	9.03e-11	1.5e-07	-0.44	-0.41	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
SARC	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-6.79	9.1e-11	1.51e-07	-0.55	-0.41	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
SARC	cis	rs9322193	0.923	rs9767554	ENSG00000223701.3	RAET1E-AS1	6.79	9.13e-11	1.51e-07	0.43	0.41	Lung cancer;	chr6:149616860	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.886	rs9485408	ENSG00000223701.3	RAET1E-AS1	6.79	9.13e-11	1.51e-07	0.43	0.41	Lung cancer;	chr6:149618888	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs1080670	ENSG00000223701.3	RAET1E-AS1	6.79	9.13e-11	1.51e-07	0.43	0.41	Lung cancer;	chr6:149620161	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.886	rs9322198	ENSG00000223701.3	RAET1E-AS1	6.79	9.13e-11	1.51e-07	0.43	0.41	Lung cancer;	chr6:149623772	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.847	rs12234128	ENSG00000223701.3	RAET1E-AS1	6.79	9.13e-11	1.51e-07	0.43	0.41	Lung cancer;	chr6:149627553	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs57012784	ENSG00000223701.3	RAET1E-AS1	6.79	9.13e-11	1.51e-07	0.43	0.41	Lung cancer;	chr6:149627691	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9689599	ENSG00000223701.3	RAET1E-AS1	6.79	9.13e-11	1.51e-07	0.43	0.41	Lung cancer;	chr6:149631973	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9800580	ENSG00000223701.3	RAET1E-AS1	6.79	9.13e-11	1.51e-07	0.43	0.41	Lung cancer;	chr6:149632845	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.884	rs11155669	ENSG00000223701.3	RAET1E-AS1	6.79	9.13e-11	1.51e-07	0.43	0.41	Lung cancer;	chr6:149633501	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.887	rs9505824	ENSG00000223701.3	RAET1E-AS1	6.79	9.13e-11	1.51e-07	0.43	0.41	Lung cancer;	chr6:149633663	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9766886	ENSG00000223701.3	RAET1E-AS1	6.79	9.13e-11	1.51e-07	0.43	0.41	Lung cancer;	chr6:149637048	chr6:149884431~149919508:+
SARC	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	6.79	9.19e-11	1.52e-07	0.45	0.41	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
SARC	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	6.79	9.23e-11	1.53e-07	0.9	0.41	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs9688861	ENSG00000223701.3	RAET1E-AS1	6.79	9.35e-11	1.55e-07	0.43	0.41	Lung cancer;	chr6:149637924	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs7740278	ENSG00000223701.3	RAET1E-AS1	6.79	9.35e-11	1.55e-07	0.43	0.41	Lung cancer;	chr6:149640116	chr6:149884431~149919508:+
SARC	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-6.79	9.36e-11	1.55e-07	-0.5	-0.41	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
SARC	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	6.79	9.45e-11	1.56e-07	0.49	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
SARC	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	6.78	9.52e-11	1.57e-07	0.4	0.41	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
SARC	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	6.78	9.56e-11	1.58e-07	0.44	0.41	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
SARC	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	6.78	9.6e-11	1.59e-07	0.45	0.41	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
SARC	cis	rs9322193	0.884	rs10782312	ENSG00000223701.3	RAET1E-AS1	6.78	9.63e-11	1.59e-07	0.43	0.41	Lung cancer;	chr6:149622669	chr6:149884431~149919508:+
SARC	cis	rs1930961	1	rs997872	ENSG00000272977.1	CTA-390C10.10	-6.78	9.65e-11	1.59e-07	-0.72	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25476218~25479971:+
SARC	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-6.78	9.65e-11	1.59e-07	-0.47	-0.41	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
SARC	cis	rs9322193	1	rs9399693	ENSG00000223701.3	RAET1E-AS1	6.78	9.66e-11	1.59e-07	0.42	0.41	Lung cancer;	chr6:149612718	chr6:149884431~149919508:+
SARC	cis	rs11675119	0.517	rs12619851	ENSG00000225234.1	TRAPPC12-AS1	-6.78	9.71e-11	1.6e-07	-0.39	-0.41	Neurofibrillary tangles;	chr2:3488976	chr2:3481242~3482409:-
SARC	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-6.78	9.84e-11	1.62e-07	-0.48	-0.41	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
SARC	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	6.78	9.87e-11	1.63e-07	0.51	0.41	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
SARC	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	6.78	9.98e-11	1.64e-07	0.5	0.41	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
SARC	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	6.78	9.98e-11	1.64e-07	0.5	0.41	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
SARC	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	6.78	9.99e-11	1.65e-07	0.49	0.41	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
SARC	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-6.77	1.01e-10	1.67e-07	-0.37	-0.41	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
SARC	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	6.77	1.02e-10	1.68e-07	0.46	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
SARC	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	6.77	1.03e-10	1.69e-07	0.51	0.41	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	6.77	1.03e-10	1.69e-07	0.51	0.41	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
SARC	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	6.77	1.03e-10	1.69e-07	0.45	0.41	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
SARC	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-6.77	1.03e-10	1.69e-07	-0.54	-0.41	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-6.77	1.03e-10	1.69e-07	-0.54	-0.41	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-6.77	1.03e-10	1.69e-07	-0.54	-0.41	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
SARC	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	6.77	1.04e-10	1.71e-07	0.43	0.41	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
SARC	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-6.77	1.04e-10	1.71e-07	-0.46	-0.41	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
SARC	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-6.77	1.04e-10	1.72e-07	-0.54	-0.41	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
SARC	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-6.77	1.05e-10	1.72e-07	-0.53	-0.41	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
SARC	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-6.77	1.05e-10	1.72e-07	-0.53	-0.41	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
SARC	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-6.77	1.05e-10	1.72e-07	-0.55	-0.41	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
SARC	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-6.77	1.05e-10	1.72e-07	-0.47	-0.41	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
SARC	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	6.77	1.06e-10	1.74e-07	0.43	0.41	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	6.76	1.07e-10	1.75e-07	0.43	0.41	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	6.76	1.07e-10	1.75e-07	0.43	0.41	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
SARC	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-6.76	1.08e-10	1.76e-07	-0.54	-0.41	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
SARC	cis	rs526231	0.575	rs26822	ENSG00000175749.11	EIF3KP1	6.76	1.09e-10	1.79e-07	0.57	0.4	Primary biliary cholangitis;	chr5:103183094	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	6.76	1.1e-10	1.8e-07	0.38	0.4	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs11155671	ENSG00000223701.3	RAET1E-AS1	6.76	1.11e-10	1.81e-07	0.43	0.4	Lung cancer;	chr6:149650996	chr6:149884431~149919508:+
SARC	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-6.76	1.11e-10	1.82e-07	-0.53	-0.4	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
SARC	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	6.76	1.12e-10	1.83e-07	0.44	0.4	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.923	rs9505826	ENSG00000223701.3	RAET1E-AS1	6.76	1.12e-10	1.83e-07	0.43	0.4	Lung cancer;	chr6:149633912	chr6:149884431~149919508:+
SARC	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-6.76	1.12e-10	1.84e-07	-0.56	-0.4	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-6.76	1.12e-10	1.84e-07	-0.56	-0.4	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
SARC	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	6.76	1.13e-10	1.84e-07	0.45	0.4	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
SARC	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-6.75	1.14e-10	1.86e-07	-0.36	-0.4	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
SARC	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	6.75	1.15e-10	1.87e-07	0.45	0.4	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
SARC	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	6.75	1.15e-10	1.88e-07	0.44	0.4	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
SARC	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-6.75	1.16e-10	1.89e-07	-0.5	-0.4	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
SARC	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	6.75	1.16e-10	1.89e-07	0.43	0.4	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
SARC	cis	rs9596270	0.772	rs11842790	ENSG00000274270.1	RP11-34F20.7	6.75	1.16e-10	1.9e-07	0.58	0.4	Multiple sclerosis;	chr13:50350312	chr13:50125816~50128463:+
SARC	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	6.75	1.16e-10	1.9e-07	0.49	0.4	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
SARC	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	6.75	1.16e-10	1.9e-07	0.49	0.4	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
SARC	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	6.75	1.17e-10	1.9e-07	0.47	0.4	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
SARC	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	6.75	1.17e-10	1.91e-07	0.45	0.4	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	6.75	1.17e-10	1.91e-07	0.45	0.4	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
SARC	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	6.75	1.17e-10	1.91e-07	0.5	0.4	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
SARC	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	6.75	1.17e-10	1.91e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
SARC	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	6.75	1.17e-10	1.91e-07	0.43	0.4	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	6.75	1.17e-10	1.91e-07	0.43	0.4	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
SARC	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-6.75	1.18e-10	1.92e-07	-0.53	-0.4	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
SARC	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-6.75	1.18e-10	1.92e-07	-0.5	-0.4	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
SARC	cis	rs9494145	0.531	rs9399136	ENSG00000232876.1	CTA-212D2.2	-6.74	1.2e-10	1.95e-07	-0.53	-0.4	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135081201	chr6:135055033~135060550:+
SARC	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-6.74	1.2e-10	1.95e-07	-0.46	-0.4	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
SARC	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-6.74	1.2e-10	1.96e-07	-0.56	-0.4	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
SARC	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	6.74	1.21e-10	1.97e-07	0.48	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	6.74	1.21e-10	1.97e-07	0.48	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	6.74	1.22e-10	1.98e-07	0.48	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	6.74	1.22e-10	1.98e-07	0.48	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	6.74	1.22e-10	1.98e-07	0.48	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
SARC	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	6.74	1.22e-10	1.98e-07	0.39	0.4	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
SARC	cis	rs748404	0.697	rs505249	ENSG00000205771.5	CATSPER2P1	-6.74	1.22e-10	1.99e-07	-0.48	-0.4	Lung cancer;	chr15:43267762	chr15:43726918~43747094:-
SARC	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-6.74	1.24e-10	2.01e-07	-0.52	-0.4	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
SARC	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-6.74	1.24e-10	2.02e-07	-0.46	-0.4	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
SARC	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	6.74	1.25e-10	2.03e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
SARC	cis	rs748404	0.723	rs512431	ENSG00000205771.5	CATSPER2P1	6.73	1.27e-10	2.06e-07	0.48	0.4	Lung cancer;	chr15:43249741	chr15:43726918~43747094:-
SARC	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	6.73	1.28e-10	2.08e-07	0.47	0.4	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
SARC	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-6.73	1.29e-10	2.08e-07	-0.54	-0.4	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-6.73	1.29e-10	2.08e-07	-0.54	-0.4	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-6.73	1.29e-10	2.08e-07	-0.54	-0.4	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-6.73	1.29e-10	2.08e-07	-0.54	-0.4	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-6.73	1.29e-10	2.08e-07	-0.54	-0.4	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-6.73	1.29e-10	2.08e-07	-0.54	-0.4	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-6.73	1.29e-10	2.08e-07	-0.54	-0.4	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
SARC	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	6.73	1.3e-10	2.1e-07	0.45	0.4	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
SARC	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	6.73	1.32e-10	2.13e-07	0.53	0.4	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
SARC	cis	rs9322193	0.924	rs9498382	ENSG00000223701.3	RAET1E-AS1	6.73	1.32e-10	2.13e-07	0.42	0.4	Lung cancer;	chr6:149610982	chr6:149884431~149919508:+
SARC	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-6.73	1.32e-10	2.13e-07	-0.54	-0.4	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
SARC	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	6.73	1.32e-10	2.13e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
SARC	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-6.73	1.33e-10	2.14e-07	-0.56	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
SARC	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-6.73	1.33e-10	2.14e-07	-0.56	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
SARC	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-6.73	1.33e-10	2.14e-07	-0.44	-0.4	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
SARC	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	6.73	1.33e-10	2.15e-07	0.38	0.4	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
SARC	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-6.72	1.35e-10	2.18e-07	-0.45	-0.4	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
SARC	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-6.72	1.35e-10	2.18e-07	-0.45	-0.4	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
SARC	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	6.72	1.37e-10	2.2e-07	0.53	0.4	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
SARC	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	6.72	1.37e-10	2.2e-07	0.53	0.4	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
SARC	cis	rs17772222	0.958	rs59136503	ENSG00000258983.2	RP11-507K2.2	6.72	1.37e-10	2.2e-07	0.45	0.4	Coronary artery calcification;	chr14:88501921	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs1998670	ENSG00000258983.2	RP11-507K2.2	6.72	1.37e-10	2.2e-07	0.45	0.4	Coronary artery calcification;	chr14:88504581	chr14:88499334~88515502:+
SARC	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-6.72	1.37e-10	2.2e-07	-0.53	-0.4	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
SARC	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-6.72	1.37e-10	2.2e-07	-0.53	-0.4	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
SARC	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-6.72	1.37e-10	2.2e-07	-0.53	-0.4	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
SARC	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	6.72	1.37e-10	2.21e-07	0.44	0.4	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
SARC	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	6.72	1.38e-10	2.22e-07	0.5	0.4	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
SARC	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	6.72	1.38e-10	2.22e-07	0.39	0.4	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
SARC	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-6.72	1.38e-10	2.23e-07	-0.38	-0.4	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
SARC	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	6.72	1.39e-10	2.23e-07	0.5	0.4	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
SARC	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	6.72	1.39e-10	2.23e-07	0.48	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
SARC	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	6.72	1.4e-10	2.24e-07	0.43	0.4	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	6.72	1.4e-10	2.24e-07	0.43	0.4	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	6.72	1.4e-10	2.24e-07	0.43	0.4	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
SARC	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	6.72	1.4e-10	2.25e-07	0.46	0.4	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
SARC	cis	rs73186030	0.841	rs34173813	ENSG00000272758.4	RP11-299J3.8	6.72	1.4e-10	2.25e-07	0.56	0.4	Serum parathyroid hormone levels;	chr3:122341557	chr3:122416207~122443180:+
SARC	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	6.72	1.42e-10	2.27e-07	0.43	0.4	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	6.72	1.42e-10	2.27e-07	0.43	0.4	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	6.72	1.42e-10	2.27e-07	0.43	0.4	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
SARC	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-6.72	1.42e-10	2.28e-07	-0.53	-0.4	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-6.72	1.42e-10	2.28e-07	-0.53	-0.4	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.566	rs9397070	ENSG00000268592.3	RAET1E-AS1	-6.72	1.42e-10	2.28e-07	-0.55	-0.4	Lung cancer;	chr6:149922073	chr6:149863494~149919507:+
SARC	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-6.71	1.43e-10	2.29e-07	-0.39	-0.4	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
SARC	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-6.71	1.43e-10	2.29e-07	-0.53	-0.4	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
SARC	cis	rs7174755	0.884	rs11634026	ENSG00000260657.2	RP11-315D16.4	6.71	1.45e-10	2.32e-07	0.38	0.4	Major depressive disorder;	chr15:68305668	chr15:68267792~68277994:-
SARC	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-6.71	1.47e-10	2.35e-07	-0.53	-0.4	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-6.71	1.47e-10	2.35e-07	-0.53	-0.4	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-6.71	1.47e-10	2.35e-07	-0.53	-0.4	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
SARC	cis	rs1707322	1	rs4660332	ENSG00000280836.1	AL355480.1	-6.71	1.48e-10	2.36e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45581219~45581321:-
SARC	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	6.71	1.49e-10	2.37e-07	0.41	0.4	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
SARC	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-6.71	1.49e-10	2.37e-07	-0.72	-0.4	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
SARC	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-6.71	1.49e-10	2.38e-07	-0.4	-0.4	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
SARC	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	6.71	1.5e-10	2.39e-07	0.45	0.4	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
SARC	cis	rs1707322	1	rs6672115	ENSG00000280836.1	AL355480.1	-6.7	1.51e-10	2.4e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45581219~45581321:-
SARC	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	6.7	1.51e-10	2.4e-07	0.43	0.4	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
SARC	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-6.7	1.51e-10	2.41e-07	-0.5	-0.4	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
SARC	cis	rs7615952	0.8	rs12489350	ENSG00000248787.1	RP11-666A20.4	-6.7	1.52e-10	2.42e-07	-0.62	-0.4	Blood pressure (smoking interaction);	chr3:125925273	chr3:125908005~125910272:-
SARC	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-6.7	1.52e-10	2.42e-07	-0.44	-0.4	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
SARC	cis	rs2303759	0.874	rs10411630	ENSG00000268686.1	AC010524.2	-6.7	1.52e-10	2.42e-07	-0.48	-0.4	Multiple sclerosis;	chr19:49388057	chr19:49368705~49388081:-
SARC	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-6.7	1.54e-10	2.45e-07	-0.42	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
SARC	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-6.7	1.55e-10	2.47e-07	-0.5	-0.4	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
SARC	cis	rs3002131	0.562	rs2173401	ENSG00000225265.1	TAF1A-AS1	-6.7	1.55e-10	2.47e-07	-0.73	-0.4	Interleukin-10 levels;	chr1:222575992	chr1:222589825~222593032:+
SARC	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	6.7	1.56e-10	2.48e-07	0.43	0.4	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	6.7	1.56e-10	2.48e-07	0.43	0.4	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	6.7	1.56e-10	2.48e-07	0.43	0.4	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
SARC	cis	rs12022452	0.822	rs7545012	ENSG00000238287.1	RP11-656D10.3	6.7	1.57e-10	2.5e-07	0.57	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562178	chr1:40493157~40508661:-
SARC	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	6.7	1.58e-10	2.51e-07	0.53	0.4	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
SARC	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	6.7	1.58e-10	2.51e-07	0.53	0.4	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
SARC	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	6.7	1.58e-10	2.51e-07	0.53	0.4	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
SARC	cis	rs6565180	1	rs8049108	ENSG00000183604.13	SMG1P5	-6.7	1.58e-10	2.51e-07	-0.36	-0.4	Tonsillectomy;	chr16:30365165	chr16:30267553~30335374:-
SARC	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	6.69	1.6e-10	2.53e-07	0.42	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
SARC	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	6.69	1.6e-10	2.54e-07	0.43	0.4	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
SARC	cis	rs1707322	0.927	rs6690386	ENSG00000280836.1	AL355480.1	-6.69	1.61e-10	2.55e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45581219~45581321:-
SARC	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-6.69	1.62e-10	2.57e-07	-0.54	-0.4	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
SARC	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	6.69	1.63e-10	2.58e-07	0.43	0.4	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
SARC	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-6.69	1.63e-10	2.59e-07	-0.53	-0.4	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
SARC	cis	rs9494145	0.667	rs1331309	ENSG00000232876.1	CTA-212D2.2	-6.69	1.64e-10	2.59e-07	-0.52	-0.4	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135085040	chr6:135055033~135060550:+
SARC	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-6.69	1.64e-10	2.59e-07	-0.56	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
SARC	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-6.69	1.64e-10	2.6e-07	-0.43	-0.4	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
SARC	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	6.69	1.64e-10	2.6e-07	0.43	0.4	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	6.69	1.64e-10	2.6e-07	0.43	0.4	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
SARC	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-6.69	1.65e-10	2.61e-07	-0.45	-0.4	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
SARC	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	6.69	1.65e-10	2.62e-07	0.53	0.4	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
SARC	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	6.69	1.66e-10	2.63e-07	0.38	0.4	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
SARC	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-6.69	1.66e-10	2.63e-07	-0.47	-0.4	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
SARC	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	6.69	1.69e-10	2.67e-07	0.43	0.4	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	6.69	1.69e-10	2.67e-07	0.43	0.4	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	6.69	1.69e-10	2.67e-07	0.43	0.4	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
SARC	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	6.69	1.69e-10	2.67e-07	0.46	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
SARC	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-6.68	1.7e-10	2.69e-07	-0.53	-0.4	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
SARC	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-6.68	1.7e-10	2.69e-07	-0.93	-0.4	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
SARC	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-6.68	1.7e-10	2.69e-07	-0.55	-0.4	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-6.68	1.7e-10	2.69e-07	-0.55	-0.4	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
SARC	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-6.68	1.72e-10	2.72e-07	-0.45	-0.4	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
SARC	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	6.68	1.72e-10	2.72e-07	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
SARC	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	6.68	1.73e-10	2.74e-07	0.47	0.4	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
SARC	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-6.68	1.74e-10	2.74e-07	-0.51	-0.4	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
SARC	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-6.68	1.74e-10	2.74e-07	-0.53	-0.4	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
SARC	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-6.68	1.74e-10	2.75e-07	-0.47	-0.4	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
SARC	cis	rs17772222	0.917	rs61984683	ENSG00000258983.2	RP11-507K2.2	6.68	1.75e-10	2.75e-07	0.45	0.4	Coronary artery calcification;	chr14:88553162	chr14:88499334~88515502:+
SARC	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	6.68	1.75e-10	2.76e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
SARC	cis	rs12022452	0.822	rs7514623	ENSG00000238287.1	RP11-656D10.3	-6.68	1.75e-10	2.76e-07	-0.56	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40559330	chr1:40493157~40508661:-
SARC	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-6.68	1.76e-10	2.77e-07	-0.51	-0.4	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
SARC	cis	rs748404	0.697	rs1814323	ENSG00000205771.5	CATSPER2P1	6.68	1.76e-10	2.78e-07	0.48	0.4	Lung cancer;	chr15:43271039	chr15:43726918~43747094:-
SARC	cis	rs12022452	0.822	rs11811369	ENSG00000238287.1	RP11-656D10.3	-6.68	1.78e-10	2.8e-07	-0.56	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40560611	chr1:40493157~40508661:-
SARC	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	6.68	1.79e-10	2.81e-07	0.39	0.4	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
SARC	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-6.67	1.8e-10	2.83e-07	-0.56	-0.4	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
SARC	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-6.67	1.81e-10	2.84e-07	-0.48	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
SARC	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-6.67	1.81e-10	2.84e-07	-0.48	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
SARC	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-6.67	1.81e-10	2.85e-07	-0.55	-0.4	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
SARC	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-6.67	1.82e-10	2.86e-07	-0.45	-0.4	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
SARC	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	6.67	1.82e-10	2.86e-07	0.39	0.4	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
SARC	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	6.67	1.82e-10	2.86e-07	0.39	0.4	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
SARC	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	6.67	1.82e-10	2.86e-07	0.66	0.4	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	6.67	1.82e-10	2.86e-07	0.66	0.4	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
SARC	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	6.67	1.84e-10	2.89e-07	0.52	0.4	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
SARC	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-6.67	1.88e-10	2.95e-07	-0.62	-0.4	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
SARC	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-6.67	1.89e-10	2.96e-07	-0.43	-0.4	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-6.67	1.89e-10	2.96e-07	-0.43	-0.4	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-6.67	1.89e-10	2.96e-07	-0.43	-0.4	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
SARC	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	6.66	1.89e-10	2.97e-07	0.51	0.4	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
SARC	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-6.66	1.9e-10	2.98e-07	-0.44	-0.4	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
SARC	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-6.66	1.9e-10	2.98e-07	-0.45	-0.4	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
SARC	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	6.66	1.91e-10	3e-07	0.44	0.4	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
SARC	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	6.66	1.92e-10	3e-07	0.38	0.4	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
SARC	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	6.66	1.92e-10	3.01e-07	0.44	0.4	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
SARC	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	6.66	1.92e-10	3.01e-07	0.44	0.4	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
SARC	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-6.66	1.92e-10	3.01e-07	-0.55	-0.4	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
SARC	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-6.66	1.92e-10	3.01e-07	-0.55	-0.4	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
SARC	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-6.66	1.93e-10	3.02e-07	-0.43	-0.4	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-6.66	1.93e-10	3.02e-07	-0.43	-0.4	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-6.66	1.93e-10	3.02e-07	-0.43	-0.4	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-6.66	1.93e-10	3.02e-07	-0.43	-0.4	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-6.66	1.93e-10	3.02e-07	-0.43	-0.4	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
SARC	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-6.66	1.94e-10	3.04e-07	-0.38	-0.4	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
SARC	cis	rs9322193	0.923	rs12211511	ENSG00000223701.3	RAET1E-AS1	6.66	1.95e-10	3.04e-07	0.42	0.4	Lung cancer;	chr6:149745206	chr6:149884431~149919508:+
SARC	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	6.66	1.95e-10	3.05e-07	0.5	0.4	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	6.66	1.95e-10	3.05e-07	0.5	0.4	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	6.66	1.95e-10	3.05e-07	0.5	0.4	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	6.66	1.95e-10	3.05e-07	0.5	0.4	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	6.66	1.95e-10	3.05e-07	0.5	0.4	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
SARC	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	6.66	1.96e-10	3.06e-07	0.44	0.4	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
SARC	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	6.66	1.96e-10	3.06e-07	0.38	0.4	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
SARC	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	6.66	1.96e-10	3.06e-07	0.38	0.4	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
SARC	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	6.66	1.96e-10	3.06e-07	0.38	0.4	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
SARC	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	6.66	1.96e-10	3.06e-07	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
SARC	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-6.66	1.97e-10	3.07e-07	-0.47	-0.4	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
SARC	cis	rs6003958	1	rs6003958	ENSG00000250470.1	AP000351.3	-6.66	1.97e-10	3.08e-07	-0.55	-0.4	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23976904~23977585:-
SARC	cis	rs5760092	0.755	rs6003959	ENSG00000250470.1	AP000351.3	-6.66	1.97e-10	3.08e-07	-0.55	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23976904~23977585:-
SARC	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	6.66	1.98e-10	3.09e-07	0.54	0.4	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	6.66	1.98e-10	3.09e-07	0.54	0.4	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
SARC	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	6.66	1.99e-10	3.1e-07	0.46	0.4	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
SARC	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	6.65	2.01e-10	3.13e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
SARC	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	6.65	2.01e-10	3.13e-07	0.47	0.4	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	6.65	2.01e-10	3.13e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	6.65	2.01e-10	3.13e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
SARC	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	6.65	2.01e-10	3.13e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	6.65	2.01e-10	3.13e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
SARC	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-6.65	2.01e-10	3.14e-07	-0.43	-0.4	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
SARC	cis	rs9322193	0.923	rs10872645	ENSG00000223701.3	RAET1E-AS1	6.65	2.02e-10	3.14e-07	0.42	0.4	Lung cancer;	chr6:149742840	chr6:149884431~149919508:+
SARC	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	6.65	2.03e-10	3.16e-07	0.47	0.4	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
SARC	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-6.65	2.04e-10	3.17e-07	-0.61	-0.4	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
SARC	cis	rs9322193	0.607	rs12209310	ENSG00000268592.3	RAET1E-AS1	6.65	2.04e-10	3.18e-07	0.54	0.4	Lung cancer;	chr6:149904882	chr6:149863494~149919507:+
SARC	cis	rs748404	0.65	rs556851	ENSG00000205771.5	CATSPER2P1	-6.65	2.05e-10	3.19e-07	-0.48	-0.4	Lung cancer;	chr15:43279021	chr15:43726918~43747094:-
SARC	cis	rs748404	0.697	rs567357	ENSG00000205771.5	CATSPER2P1	-6.65	2.05e-10	3.19e-07	-0.48	-0.4	Lung cancer;	chr15:43279192	chr15:43726918~43747094:-
SARC	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-6.65	2.05e-10	3.19e-07	-0.56	-0.4	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
SARC	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-6.65	2.05e-10	3.19e-07	-0.49	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
SARC	cis	rs73186030	0.92	rs17265703	ENSG00000272758.4	RP11-299J3.8	-6.65	2.06e-10	3.21e-07	-0.5	-0.4	Serum parathyroid hormone levels;	chr3:122329797	chr3:122416207~122443180:+
SARC	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-6.65	2.06e-10	3.21e-07	-0.46	-0.4	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
SARC	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	6.65	2.07e-10	3.21e-07	0.5	0.4	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
SARC	cis	rs5760092	0.627	rs6519489	ENSG00000231271.1	AP000350.8	-6.65	2.07e-10	3.21e-07	-0.55	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23949918~23954042:+
SARC	cis	rs5760092	0.755	rs11090298	ENSG00000231271.1	AP000350.8	-6.65	2.07e-10	3.21e-07	-0.55	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23949918~23954042:+
SARC	cis	rs1707322	1	rs4606257	ENSG00000280836.1	AL355480.1	-6.65	2.08e-10	3.22e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45581219~45581321:-
SARC	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	6.65	2.08e-10	3.23e-07	0.7	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
SARC	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	6.65	2.09e-10	3.24e-07	0.49	0.4	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
SARC	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	6.65	2.09e-10	3.25e-07	0.45	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
SARC	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	6.65	2.11e-10	3.27e-07	0.44	0.4	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
SARC	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-6.64	2.13e-10	3.3e-07	-0.37	-0.4	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
SARC	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	6.64	2.13e-10	3.3e-07	0.44	0.4	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
SARC	cis	rs16828019	0.704	rs35071528	ENSG00000235358.1	RP11-399E6.1	6.64	2.13e-10	3.31e-07	0.81	0.4	Intelligence (multi-trait analysis);	chr1:41146985	chr1:41242373~41284861:+
SARC	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-6.64	2.14e-10	3.31e-07	-0.42	-0.4	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-6.64	2.14e-10	3.32e-07	-0.42	-0.4	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
SARC	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	6.64	2.16e-10	3.34e-07	0.46	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	6.64	2.16e-10	3.34e-07	0.46	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
SARC	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-6.64	2.2e-10	3.4e-07	-0.44	-0.4	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-6.64	2.2e-10	3.4e-07	-0.44	-0.4	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
SARC	cis	rs2946504	0.501	rs2977092	ENSG00000251468.2	RP11-369K16.1	-6.64	2.2e-10	3.41e-07	-0.4	-0.4	Type 2 diabetes;	chr8:12949867	chr8:12958387~12962200:+
SARC	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-6.64	2.21e-10	3.41e-07	-0.37	-0.4	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
SARC	cis	rs9322193	0.566	rs6912330	ENSG00000268592.3	RAET1E-AS1	-6.64	2.21e-10	3.41e-07	-0.54	-0.4	Lung cancer;	chr6:149908811	chr6:149863494~149919507:+
SARC	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-6.64	2.21e-10	3.42e-07	-0.46	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
SARC	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	6.64	2.23e-10	3.44e-07	0.52	0.4	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
SARC	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	6.64	2.23e-10	3.45e-07	0.42	0.4	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
SARC	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-6.64	2.25e-10	3.47e-07	-0.54	-0.4	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
SARC	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	6.63	2.27e-10	3.5e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
SARC	cis	rs7044106	0.578	rs4837788	ENSG00000226752.6	PSMD5-AS1	-6.63	2.28e-10	3.51e-07	-0.67	-0.4	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120824828~120854385:+
SARC	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	6.63	2.28e-10	3.52e-07	0.44	0.4	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
SARC	cis	rs1707322	0.964	rs7512395	ENSG00000280836.1	AL355480.1	-6.63	2.29e-10	3.53e-07	-0.4	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45581219~45581321:-
SARC	cis	rs748404	0.697	rs546722	ENSG00000205771.5	CATSPER2P1	-6.63	2.29e-10	3.54e-07	-0.48	-0.4	Lung cancer;	chr15:43288621	chr15:43726918~43747094:-
SARC	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-6.63	2.3e-10	3.54e-07	-0.46	-0.4	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
SARC	cis	rs7216064	0.953	rs62086044	ENSG00000265055.1	AC145343.2	6.63	2.31e-10	3.56e-07	0.51	0.4	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67974721	chr17:68096046~68101474:-
SARC	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-6.63	2.33e-10	3.59e-07	-0.45	-0.4	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
SARC	cis	rs748404	0.65	rs518234	ENSG00000205771.5	CATSPER2P1	-6.63	2.34e-10	3.6e-07	-0.48	-0.4	Lung cancer;	chr15:43281223	chr15:43726918~43747094:-
SARC	cis	rs748404	0.65	rs518261	ENSG00000205771.5	CATSPER2P1	-6.63	2.34e-10	3.6e-07	-0.48	-0.4	Lung cancer;	chr15:43281231	chr15:43726918~43747094:-
SARC	cis	rs1707322	1	rs12097761	ENSG00000280836.1	AL355480.1	-6.63	2.34e-10	3.6e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45581219~45581321:-
SARC	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-6.63	2.35e-10	3.61e-07	-0.56	-0.4	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
SARC	cis	rs6565180	0.926	rs8046445	ENSG00000183604.13	SMG1P5	-6.63	2.36e-10	3.63e-07	-0.36	-0.4	Tonsillectomy;	chr16:30374941	chr16:30267553~30335374:-
SARC	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-6.62	2.39e-10	3.67e-07	-0.55	-0.4	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
SARC	cis	rs1707322	0.963	rs12145287	ENSG00000280836.1	AL355480.1	-6.62	2.42e-10	3.72e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45581219~45581321:-
SARC	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	6.62	2.42e-10	3.72e-07	0.43	0.4	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
SARC	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-6.62	2.44e-10	3.74e-07	-0.51	-0.4	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
SARC	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-6.62	2.44e-10	3.75e-07	-0.37	-0.4	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
SARC	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	6.62	2.46e-10	3.78e-07	0.43	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
SARC	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-6.62	2.47e-10	3.78e-07	-0.56	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
SARC	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-6.62	2.47e-10	3.78e-07	-0.56	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
SARC	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	6.62	2.5e-10	3.83e-07	0.47	0.4	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	6.62	2.5e-10	3.83e-07	0.47	0.4	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
SARC	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-6.62	2.52e-10	3.86e-07	-0.38	-0.4	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
SARC	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	6.62	2.52e-10	3.86e-07	0.46	0.4	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
SARC	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-6.61	2.53e-10	3.87e-07	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
SARC	cis	rs1707322	1	rs10890382	ENSG00000280836.1	AL355480.1	-6.61	2.53e-10	3.88e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45581219~45581321:-
SARC	cis	rs9322193	0.923	rs62441284	ENSG00000223701.3	RAET1E-AS1	6.61	2.54e-10	3.89e-07	0.43	0.4	Lung cancer;	chr6:149751542	chr6:149884431~149919508:+
SARC	cis	rs748404	0.697	rs513970	ENSG00000205771.5	CATSPER2P1	-6.61	2.55e-10	3.9e-07	-0.48	-0.4	Lung cancer;	chr15:43287368	chr15:43726918~43747094:-
SARC	cis	rs1707322	1	rs4660335	ENSG00000280836.1	AL355480.1	-6.61	2.57e-10	3.93e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45581219~45581321:-
SARC	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-6.61	2.58e-10	3.94e-07	-0.46	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
SARC	cis	rs607541	1	rs607594	ENSG00000259520.4	CTD-2651B20.3	-6.61	2.61e-10	3.99e-07	-0.57	-0.4	Obesity-related traits;	chr15:45642642	chr15:45251580~45279251:-
SARC	cis	rs607541	1	rs607541	ENSG00000259520.4	CTD-2651B20.3	-6.61	2.61e-10	3.99e-07	-0.57	-0.4	Obesity-related traits;	chr15:45642671	chr15:45251580~45279251:-
SARC	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	6.61	2.61e-10	3.99e-07	0.42	0.4	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	6.61	2.61e-10	3.99e-07	0.42	0.4	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	6.61	2.61e-10	3.99e-07	0.42	0.4	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	6.61	2.61e-10	3.99e-07	0.42	0.4	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	6.61	2.61e-10	3.99e-07	0.42	0.4	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	6.61	2.61e-10	3.99e-07	0.42	0.4	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	6.61	2.61e-10	3.99e-07	0.42	0.4	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	6.61	2.61e-10	3.99e-07	0.42	0.4	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
SARC	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-6.61	2.62e-10	3.99e-07	-0.44	-0.4	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
SARC	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	6.61	2.62e-10	4e-07	0.39	0.4	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
SARC	cis	rs113835537	0.529	rs116867234	ENSG00000255517.5	CTD-3074O7.5	-6.61	2.63e-10	4.01e-07	-0.46	-0.4	Airway imaging phenotypes;	chr11:66441553	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs17580784	ENSG00000255517.5	CTD-3074O7.5	-6.61	2.63e-10	4.01e-07	-0.46	-0.4	Airway imaging phenotypes;	chr11:66447388	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs60358007	ENSG00000255517.5	CTD-3074O7.5	-6.61	2.63e-10	4.01e-07	-0.46	-0.4	Airway imaging phenotypes;	chr11:66454882	chr11:66473490~66480233:-
SARC	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	6.61	2.65e-10	4.04e-07	0.38	0.4	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
SARC	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	6.61	2.65e-10	4.05e-07	0.38	0.4	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
SARC	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-6.61	2.66e-10	4.05e-07	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
SARC	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-6.61	2.66e-10	4.05e-07	-0.44	-0.4	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
SARC	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-6.61	2.66e-10	4.06e-07	-0.37	-0.4	Height;	chr3:53074760	chr3:53064283~53065091:-
SARC	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	6.6	2.69e-10	4.09e-07	0.48	0.4	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
SARC	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	6.6	2.69e-10	4.09e-07	0.45	0.4	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
SARC	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-6.6	2.7e-10	4.11e-07	-0.51	-0.4	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-6.6	2.7e-10	4.11e-07	-0.51	-0.4	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-6.6	2.7e-10	4.11e-07	-0.51	-0.4	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
SARC	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-6.6	2.71e-10	4.12e-07	-0.49	-0.4	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
SARC	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-6.6	2.73e-10	4.15e-07	-0.51	-0.4	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
SARC	cis	rs1707322	0.963	rs4630155	ENSG00000280836.1	AL355480.1	-6.6	2.74e-10	4.17e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.963	rs4508055	ENSG00000280836.1	AL355480.1	-6.6	2.74e-10	4.17e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.963	rs12076580	ENSG00000280836.1	AL355480.1	-6.6	2.74e-10	4.17e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45581219~45581321:-
SARC	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-6.6	2.76e-10	4.2e-07	-0.53	-0.4	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
SARC	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-6.6	2.76e-10	4.2e-07	-0.54	-0.4	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
SARC	cis	rs11155671	0.546	rs1999633	ENSG00000268592.3	RAET1E-AS1	6.6	2.76e-10	4.2e-07	0.57	0.4	Testicular germ cell tumor;	chr6:149866576	chr6:149863494~149919507:+
SARC	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	6.6	2.78e-10	4.22e-07	0.4	0.4	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
SARC	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	6.6	2.78e-10	4.23e-07	0.53	0.4	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
SARC	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-6.6	2.8e-10	4.25e-07	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-6.6	2.8e-10	4.25e-07	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-6.6	2.8e-10	4.25e-07	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-6.6	2.8e-10	4.25e-07	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-6.6	2.8e-10	4.25e-07	-0.41	-0.4	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
SARC	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-6.6	2.81e-10	4.27e-07	-0.56	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
SARC	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-6.6	2.81e-10	4.27e-07	-0.56	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
SARC	cis	rs1707322	0.963	rs6429581	ENSG00000280836.1	AL355480.1	-6.6	2.82e-10	4.28e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45581219~45581321:-
SARC	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	6.59	2.83e-10	4.29e-07	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
SARC	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	6.59	2.84e-10	4.3e-07	0.42	0.4	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
SARC	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	6.59	2.84e-10	4.3e-07	0.41	0.4	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
SARC	cis	rs9322193	0.923	rs9505823	ENSG00000223701.3	RAET1E-AS1	6.59	2.84e-10	4.31e-07	0.42	0.4	Lung cancer;	chr6:149628899	chr6:149884431~149919508:+
SARC	cis	rs1707322	1	rs4074225	ENSG00000280836.1	AL355480.1	-6.59	2.86e-10	4.33e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45581219~45581321:-
SARC	cis	rs17772222	1	rs17772064	ENSG00000258983.2	RP11-507K2.2	6.59	2.87e-10	4.34e-07	0.43	0.4	Coronary artery calcification;	chr14:88356527	chr14:88499334~88515502:+
SARC	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-6.59	2.87e-10	4.34e-07	-0.38	-0.4	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
SARC	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-6.59	2.87e-10	4.35e-07	-0.53	-0.4	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
SARC	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-6.59	2.89e-10	4.37e-07	-0.56	-0.4	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-6.59	2.9e-10	4.38e-07	-0.54	-0.4	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
SARC	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-6.59	2.9e-10	4.38e-07	-0.42	-0.4	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
SARC	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-6.59	2.9e-10	4.39e-07	-0.48	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
SARC	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-6.59	2.91e-10	4.39e-07	-0.42	-0.4	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-6.59	2.91e-10	4.39e-07	-0.42	-0.4	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-6.59	2.91e-10	4.39e-07	-0.42	-0.4	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-6.59	2.91e-10	4.39e-07	-0.42	-0.4	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-6.59	2.91e-10	4.39e-07	-0.42	-0.4	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-6.59	2.91e-10	4.39e-07	-0.42	-0.4	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-6.59	2.91e-10	4.39e-07	-0.42	-0.4	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-6.59	2.91e-10	4.39e-07	-0.42	-0.4	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-6.59	2.91e-10	4.39e-07	-0.42	-0.4	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-6.59	2.91e-10	4.39e-07	-0.42	-0.4	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-6.59	2.91e-10	4.39e-07	-0.42	-0.4	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
SARC	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-6.59	2.92e-10	4.42e-07	-0.37	-0.4	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
SARC	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	6.59	2.93e-10	4.42e-07	0.54	0.4	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
SARC	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-6.59	2.93e-10	4.43e-07	-0.45	-0.4	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
SARC	cis	rs17772222	0.917	rs61984684	ENSG00000258983.2	RP11-507K2.2	6.59	2.96e-10	4.47e-07	0.45	0.4	Coronary artery calcification;	chr14:88559104	chr14:88499334~88515502:+
SARC	cis	rs4273100	1	rs868698	ENSG00000228157.4	AC007952.5	6.59	2.96e-10	4.47e-07	0.58	0.4	Schizophrenia;	chr17:19281898	chr17:19092974~19096837:+
SARC	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-6.59	2.97e-10	4.48e-07	-0.37	-0.4	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
SARC	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	6.59	2.97e-10	4.49e-07	0.51	0.4	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
SARC	cis	rs1707322	1	rs10890376	ENSG00000280836.1	AL355480.1	-6.59	2.97e-10	4.49e-07	-0.4	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs10789485	ENSG00000280836.1	AL355480.1	-6.59	2.97e-10	4.49e-07	-0.4	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45581219~45581321:-
SARC	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-6.59	2.98e-10	4.51e-07	-0.52	-0.4	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
SARC	cis	rs7615952	0.736	rs11921945	ENSG00000248787.1	RP11-666A20.4	-6.58	3.01e-10	4.54e-07	-0.61	-0.4	Blood pressure (smoking interaction);	chr3:125924876	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.736	rs13063122	ENSG00000248787.1	RP11-666A20.4	-6.58	3.01e-10	4.54e-07	-0.61	-0.4	Blood pressure (smoking interaction);	chr3:125925017	chr3:125908005~125910272:-
SARC	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	6.58	3.04e-10	4.59e-07	0.51	0.4	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
SARC	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	6.58	3.04e-10	4.59e-07	0.51	0.4	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
SARC	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-6.58	3.05e-10	4.59e-07	-0.42	-0.4	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
SARC	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	6.58	3.05e-10	4.6e-07	0.38	0.4	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
SARC	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	6.58	3.05e-10	4.6e-07	0.38	0.4	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
SARC	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-6.58	3.06e-10	4.61e-07	-0.54	-0.4	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
SARC	cis	rs1707322	0.963	rs10789478	ENSG00000280836.1	AL355480.1	-6.58	3.08e-10	4.64e-07	-0.4	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45581219~45581321:-
SARC	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-6.58	3.11e-10	4.68e-07	-0.49	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
SARC	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	6.58	3.12e-10	4.7e-07	0.46	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
SARC	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-6.58	3.13e-10	4.71e-07	-0.51	-0.4	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
SARC	cis	rs1707322	1	rs11211232	ENSG00000280836.1	AL355480.1	-6.58	3.13e-10	4.71e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45581219~45581321:-
SARC	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	6.58	3.13e-10	4.71e-07	0.39	0.4	Height;	chr11:118758322	chr11:118704607~118750263:+
SARC	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-6.58	3.13e-10	4.71e-07	-0.53	-0.4	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
SARC	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-6.58	3.13e-10	4.72e-07	-0.36	-0.4	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
SARC	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	6.58	3.15e-10	4.73e-07	0.48	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
SARC	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-6.58	3.15e-10	4.74e-07	-0.43	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
SARC	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	6.58	3.15e-10	4.75e-07	0.42	0.4	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
SARC	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	6.58	3.16e-10	4.75e-07	0.46	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
SARC	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	6.57	3.2e-10	4.81e-07	0.42	0.4	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	6.57	3.2e-10	4.81e-07	0.42	0.4	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
SARC	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	6.57	3.21e-10	4.82e-07	0.55	0.4	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
SARC	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	6.57	3.21e-10	4.82e-07	0.44	0.4	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
SARC	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	6.57	3.21e-10	4.82e-07	0.44	0.4	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
SARC	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-6.57	3.21e-10	4.82e-07	-0.5	-0.4	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
SARC	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	6.57	3.21e-10	4.82e-07	0.37	0.4	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
SARC	cis	rs7182621	0.883	rs10468181	ENSG00000259363.4	CTD-2054N24.2	-6.57	3.21e-10	4.83e-07	-0.4	-0.4	Colonoscopy-negative controls vs population controls;	chr15:99885244	chr15:99807023~99877148:+
SARC	cis	rs17265703	0.524	rs12107092	ENSG00000272758.4	RP11-299J3.8	6.57	3.21e-10	4.83e-07	0.49	0.4	Phosphorus levels;	chr3:122405001	chr3:122416207~122443180:+
SARC	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-6.57	3.21e-10	4.83e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-6.57	3.21e-10	4.83e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
SARC	cis	rs2303759	0.918	rs9749416	ENSG00000268686.1	AC010524.2	-6.57	3.25e-10	4.88e-07	-0.48	-0.4	Multiple sclerosis;	chr19:49381748	chr19:49368705~49388081:-
SARC	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-6.57	3.27e-10	4.9e-07	-0.53	-0.4	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-6.57	3.27e-10	4.9e-07	-0.53	-0.4	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-6.57	3.27e-10	4.9e-07	-0.53	-0.4	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
SARC	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-6.57	3.28e-10	4.91e-07	-0.48	-0.4	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
SARC	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	6.57	3.28e-10	4.91e-07	0.52	0.4	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
SARC	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	6.57	3.3e-10	4.93e-07	0.37	0.4	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
SARC	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-6.57	3.32e-10	4.95e-07	-0.42	-0.4	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
SARC	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	6.57	3.33e-10	4.97e-07	0.48	0.4	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
SARC	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-6.57	3.34e-10	4.98e-07	-0.45	-0.4	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
SARC	cis	rs1707322	1	rs4134387	ENSG00000280836.1	AL355480.1	-6.57	3.34e-10	4.98e-07	-0.41	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45581219~45581321:-
SARC	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-6.57	3.34e-10	4.99e-07	-0.42	-0.4	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
SARC	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	6.56	3.35e-10	5e-07	0.63	0.4	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
SARC	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-6.56	3.36e-10	5.01e-07	-0.42	-0.4	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
SARC	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-6.56	3.37e-10	5.02e-07	-0.46	-0.4	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
SARC	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	6.56	3.41e-10	5.08e-07	0.46	0.39	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
SARC	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	6.56	3.42e-10	5.09e-07	0.48	0.39	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
SARC	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	6.56	3.45e-10	5.13e-07	0.48	0.39	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
SARC	cis	rs2303759	0.918	rs7251704	ENSG00000268686.1	AC010524.2	-6.56	3.45e-10	5.13e-07	-0.47	-0.39	Multiple sclerosis;	chr19:49387616	chr19:49368705~49388081:-
SARC	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-6.56	3.46e-10	5.14e-07	-0.42	-0.39	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
SARC	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-6.56	3.48e-10	5.16e-07	-0.52	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
SARC	cis	rs2946504	0.501	rs2946509	ENSG00000251468.2	RP11-369K16.1	-6.56	3.5e-10	5.2e-07	-0.4	-0.39	Type 2 diabetes;	chr8:12950782	chr8:12958387~12962200:+
SARC	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	6.56	3.51e-10	5.21e-07	0.42	0.39	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
SARC	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	6.56	3.51e-10	5.21e-07	0.47	0.39	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
SARC	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	6.56	3.52e-10	5.22e-07	0.42	0.39	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
SARC	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-6.56	3.53e-10	5.24e-07	-0.54	-0.39	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
SARC	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-6.56	3.54e-10	5.25e-07	-0.42	-0.39	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
SARC	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-6.55	3.55e-10	5.26e-07	-0.41	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
SARC	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	6.55	3.55e-10	5.26e-07	0.42	0.39	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
SARC	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	6.55	3.56e-10	5.27e-07	0.44	0.39	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
SARC	cis	rs1707322	1	rs10789479	ENSG00000280836.1	AL355480.1	-6.55	3.57e-10	5.29e-07	-0.4	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45581219~45581321:-
SARC	cis	rs607541	0.764	rs629466	ENSG00000259520.4	CTD-2651B20.3	-6.55	3.58e-10	5.3e-07	-0.55	-0.39	Obesity-related traits;	chr15:45642547	chr15:45251580~45279251:-
SARC	cis	rs607541	0.764	rs629880	ENSG00000259520.4	CTD-2651B20.3	-6.55	3.58e-10	5.3e-07	-0.55	-0.39	Obesity-related traits;	chr15:45642612	chr15:45251580~45279251:-
SARC	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-6.55	3.59e-10	5.32e-07	-0.44	-0.39	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
SARC	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	6.55	3.6e-10	5.33e-07	0.5	0.39	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
SARC	cis	rs4968361	0.892	rs68025251	ENSG00000266992.1	DHX40P1	6.55	3.6e-10	5.33e-07	0.79	0.39	Schizophrenia;	chr17:59442071	chr17:59976009~60002384:-
SARC	cis	rs4968361	0.892	rs67028302	ENSG00000266992.1	DHX40P1	6.55	3.6e-10	5.33e-07	0.79	0.39	Schizophrenia;	chr17:59443342	chr17:59976009~60002384:-
SARC	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	6.55	3.65e-10	5.4e-07	0.42	0.39	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
SARC	cis	rs7615952	0.866	rs13063119	ENSG00000248787.1	RP11-666A20.4	-6.55	3.65e-10	5.4e-07	-0.61	-0.39	Blood pressure (smoking interaction);	chr3:125925004	chr3:125908005~125910272:-
SARC	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	6.55	3.67e-10	5.43e-07	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	6.55	3.67e-10	5.43e-07	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
SARC	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	6.55	3.67e-10	5.43e-07	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
SARC	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	6.55	3.68e-10	5.44e-07	0.48	0.39	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
SARC	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-6.55	3.68e-10	5.44e-07	-0.44	-0.39	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
SARC	cis	rs8081395	0.801	rs2645479	ENSG00000266992.1	DHX40P1	6.55	3.7e-10	5.47e-07	0.42	0.39	White blood cell count;	chr17:59843171	chr17:59976009~60002384:-
SARC	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	6.55	3.72e-10	5.49e-07	0.48	0.39	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
SARC	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	6.55	3.72e-10	5.49e-07	0.48	0.39	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
SARC	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	6.55	3.72e-10	5.5e-07	0.64	0.39	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
SARC	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-6.55	3.75e-10	5.53e-07	-0.54	-0.39	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
SARC	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	6.55	3.75e-10	5.53e-07	0.52	0.39	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
SARC	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-6.54	3.75e-10	5.54e-07	-0.5	-0.39	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
SARC	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	6.54	3.76e-10	5.55e-07	0.44	0.39	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
SARC	cis	rs6538678	0.929	rs10745733	ENSG00000258343.1	RP11-536G4.2	-6.54	3.76e-10	5.55e-07	-0.46	-0.39	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95795345~95858839:-
SARC	cis	rs6538678	0.926	rs10745734	ENSG00000258343.1	RP11-536G4.2	-6.54	3.76e-10	5.55e-07	-0.46	-0.39	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95795345~95858839:-
SARC	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-6.54	3.77e-10	5.57e-07	-0.52	-0.39	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	6.54	3.78e-10	5.57e-07	0.42	0.39	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
SARC	cis	rs17772222	0.958	rs74074098	ENSG00000258983.2	RP11-507K2.2	6.54	3.8e-10	5.59e-07	0.44	0.39	Coronary artery calcification;	chr14:88484213	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	6.54	3.8e-10	5.59e-07	0.44	0.39	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	6.54	3.8e-10	5.59e-07	0.44	0.39	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	6.54	3.8e-10	5.59e-07	0.44	0.39	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
SARC	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	6.54	3.8e-10	5.59e-07	0.45	0.39	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
SARC	cis	rs2303759	0.918	rs2288480	ENSG00000268686.1	AC010524.2	-6.54	3.82e-10	5.63e-07	-0.48	-0.39	Multiple sclerosis;	chr19:49363759	chr19:49368705~49388081:-
SARC	cis	rs2303759	1	rs2303759	ENSG00000268686.1	AC010524.2	-6.54	3.82e-10	5.63e-07	-0.48	-0.39	Multiple sclerosis;	chr19:49365794	chr19:49368705~49388081:-
SARC	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	6.54	3.83e-10	5.64e-07	0.38	0.39	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
SARC	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-6.54	3.83e-10	5.64e-07	-0.47	-0.39	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
SARC	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-6.54	3.85e-10	5.67e-07	-0.58	-0.39	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
SARC	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-6.54	3.86e-10	5.67e-07	-0.36	-0.39	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
SARC	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	6.54	3.88e-10	5.71e-07	0.45	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
SARC	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	6.54	3.88e-10	5.71e-07	0.55	0.39	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
SARC	cis	rs9660180	0.967	rs12040325	ENSG00000231050.1	RP1-140A9.1	6.54	3.9e-10	5.73e-07	0.4	0.39	Body mass index;	chr1:1770997	chr1:1891471~1892658:+
SARC	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	6.54	3.9e-10	5.73e-07	0.4	0.39	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
SARC	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	6.54	3.9e-10	5.73e-07	0.4	0.39	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
SARC	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-6.54	3.9e-10	5.73e-07	-0.54	-0.39	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
SARC	cis	rs6538678	0.833	rs1898178	ENSG00000258343.1	RP11-536G4.2	-6.54	3.9e-10	5.74e-07	-0.47	-0.39	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95795345~95858839:-
SARC	cis	rs6538678	0.833	rs1898177	ENSG00000258343.1	RP11-536G4.2	-6.54	3.9e-10	5.74e-07	-0.47	-0.39	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95795345~95858839:-
SARC	cis	rs9322193	1	rs9377228	ENSG00000223701.3	RAET1E-AS1	6.54	3.91e-10	5.74e-07	0.42	0.39	Lung cancer;	chr6:149600862	chr6:149884431~149919508:+
SARC	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	6.54	3.91e-10	5.75e-07	0.4	0.39	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
SARC	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	6.54	3.91e-10	5.75e-07	0.4	0.39	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
SARC	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	6.54	3.91e-10	5.75e-07	0.46	0.39	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
SARC	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	6.53	3.97e-10	5.82e-07	0.5	0.39	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
SARC	cis	rs1707322	0.964	rs12067716	ENSG00000280836.1	AL355480.1	-6.53	3.97e-10	5.83e-07	-0.4	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45581219~45581321:-
SARC	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-6.53	3.98e-10	5.84e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-6.53	3.98e-10	5.84e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-6.53	3.98e-10	5.84e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-6.53	3.98e-10	5.84e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-6.53	3.98e-10	5.84e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-6.53	3.98e-10	5.84e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-6.53	3.98e-10	5.84e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
SARC	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-6.53	3.98e-10	5.84e-07	-0.44	-0.39	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
SARC	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-6.53	4.01e-10	5.87e-07	-0.42	-0.39	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-6.53	4.01e-10	5.87e-07	-0.42	-0.39	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
SARC	cis	rs6538678	0.929	rs10735336	ENSG00000258343.1	RP11-536G4.2	-6.53	4.01e-10	5.87e-07	-0.46	-0.39	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95795345~95858839:-
SARC	cis	rs2303759	0.83	rs7257053	ENSG00000268686.1	AC010524.2	-6.53	4.03e-10	5.91e-07	-0.47	-0.39	Multiple sclerosis;	chr19:49391199	chr19:49368705~49388081:-
SARC	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	6.53	4.03e-10	5.91e-07	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
SARC	cis	rs113835537	0.529	rs57634456	ENSG00000255517.5	CTD-3074O7.5	-6.53	4.04e-10	5.91e-07	-0.44	-0.39	Airway imaging phenotypes;	chr11:66483367	chr11:66473490~66480233:-
SARC	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-6.53	4.05e-10	5.93e-07	-0.45	-0.39	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
SARC	cis	rs1062177	0.502	rs10463321	ENSG00000253921.1	CTB-113P19.3	-6.53	4.06e-10	5.94e-07	-0.5	-0.39	Preschool internalizing problems;	chr5:151944344	chr5:151753992~151767247:+
SARC	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-6.53	4.08e-10	5.97e-07	-0.44	-0.39	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
SARC	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	6.53	4.09e-10	5.98e-07	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
SARC	cis	rs12022452	0.822	rs11208390	ENSG00000238287.1	RP11-656D10.3	-6.53	4.11e-10	6.02e-07	-0.55	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40556342	chr1:40493157~40508661:-
SARC	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	6.53	4.11e-10	6.02e-07	0.44	0.39	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
SARC	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-6.53	4.12e-10	6.02e-07	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
SARC	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-6.53	4.18e-10	6.12e-07	-0.42	-0.39	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
SARC	cis	rs1707322	1	rs12124847	ENSG00000280836.1	AL355480.1	-6.53	4.18e-10	6.12e-07	-0.4	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45581219~45581321:-
SARC	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-6.53	4.19e-10	6.12e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
SARC	cis	rs1075232	1	rs67634762	ENSG00000270055.1	CTD-3092A11.2	-6.53	4.19e-10	6.12e-07	-0.79	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31455852	chr15:30487963~30490313:+
SARC	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-6.52	4.2e-10	6.14e-07	-0.42	-0.39	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	6.52	4.21e-10	6.15e-07	0.42	0.39	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
SARC	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	6.52	4.23e-10	6.17e-07	0.52	0.39	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
SARC	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	6.52	4.23e-10	6.17e-07	0.52	0.39	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
SARC	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	6.52	4.23e-10	6.17e-07	0.52	0.39	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
SARC	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	6.52	4.23e-10	6.17e-07	0.52	0.39	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
SARC	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	6.52	4.23e-10	6.17e-07	0.52	0.39	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
SARC	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	6.52	4.23e-10	6.17e-07	0.52	0.39	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
SARC	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-6.52	4.24e-10	6.19e-07	-0.6	-0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
SARC	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-6.52	4.26e-10	6.23e-07	-0.52	-0.39	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
SARC	cis	rs113835537	0.529	rs75685325	ENSG00000255517.5	CTD-3074O7.5	-6.52	4.27e-10	6.23e-07	-0.45	-0.39	Airway imaging phenotypes;	chr11:66467771	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs57724777	ENSG00000255517.5	CTD-3074O7.5	-6.52	4.27e-10	6.23e-07	-0.45	-0.39	Airway imaging phenotypes;	chr11:66468960	chr11:66473490~66480233:-
SARC	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	6.52	4.3e-10	6.27e-07	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
SARC	cis	rs9595066	1	rs9595066	ENSG00000227258.4	SMIM2-AS1	6.52	4.31e-10	6.29e-07	0.54	0.39	Schizophrenia;	chr13:44132132	chr13:44110451~44240517:+
SARC	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-6.52	4.33e-10	6.32e-07	-0.53	-0.39	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
SARC	cis	rs113835537	0.529	rs12099041	ENSG00000255517.5	CTD-3074O7.5	-6.52	4.34e-10	6.33e-07	-0.44	-0.39	Airway imaging phenotypes;	chr11:66465302	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs7928882	ENSG00000255517.5	CTD-3074O7.5	-6.52	4.34e-10	6.33e-07	-0.44	-0.39	Airway imaging phenotypes;	chr11:66467294	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs57691879	ENSG00000255517.5	CTD-3074O7.5	-6.52	4.34e-10	6.33e-07	-0.44	-0.39	Airway imaging phenotypes;	chr11:66469133	chr11:66473490~66480233:-
SARC	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	6.52	4.36e-10	6.36e-07	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
SARC	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-6.52	4.37e-10	6.36e-07	-0.53	-0.39	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
SARC	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-6.52	4.37e-10	6.36e-07	-0.53	-0.39	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
SARC	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-6.52	4.37e-10	6.36e-07	-0.53	-0.39	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-6.52	4.37e-10	6.36e-07	-0.53	-0.39	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-6.52	4.37e-10	6.36e-07	-0.53	-0.39	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-6.52	4.37e-10	6.36e-07	-0.53	-0.39	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
SARC	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-6.52	4.42e-10	6.44e-07	-0.36	-0.39	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
SARC	cis	rs7216064	1	rs4791212	ENSG00000265055.1	AC145343.2	6.52	4.43e-10	6.45e-07	0.52	0.39	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67979269	chr17:68096046~68101474:-
SARC	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	6.51	4.48e-10	6.52e-07	0.49	0.39	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
SARC	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	6.51	4.49e-10	6.54e-07	0.43	0.39	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
SARC	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	6.51	4.5e-10	6.54e-07	0.41	0.39	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
SARC	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	6.51	4.5e-10	6.55e-07	0.4	0.39	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
SARC	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-6.51	4.51e-10	6.56e-07	-0.55	-0.39	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
SARC	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	6.51	4.52e-10	6.57e-07	0.41	0.39	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	6.51	4.52e-10	6.57e-07	0.41	0.39	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
SARC	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	6.51	4.55e-10	6.61e-07	0.44	0.39	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
SARC	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	6.51	4.57e-10	6.63e-07	0.43	0.39	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
SARC	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	6.51	4.57e-10	6.63e-07	0.43	0.39	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
SARC	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	6.51	4.57e-10	6.63e-07	0.43	0.39	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
SARC	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-6.51	4.58e-10	6.65e-07	-0.42	-0.39	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
SARC	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	6.51	4.59e-10	6.67e-07	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
SARC	cis	rs1707322	1	rs10890381	ENSG00000280836.1	AL355480.1	-6.51	4.65e-10	6.74e-07	-0.4	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45581219~45581321:-
SARC	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	6.51	4.65e-10	6.75e-07	0.47	0.39	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
SARC	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-6.51	4.65e-10	6.75e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
SARC	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-6.51	4.68e-10	6.79e-07	-0.42	-0.39	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
SARC	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-6.5	4.7e-10	6.81e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
SARC	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	6.5	4.71e-10	6.82e-07	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
SARC	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	6.5	4.71e-10	6.83e-07	0.45	0.39	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
SARC	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-6.5	4.72e-10	6.84e-07	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
SARC	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-6.5	4.73e-10	6.85e-07	-0.42	-0.39	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
SARC	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-6.5	4.75e-10	6.88e-07	-0.41	-0.39	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
SARC	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-6.5	4.75e-10	6.89e-07	-0.5	-0.39	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
SARC	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-6.5	4.75e-10	6.89e-07	-0.5	-0.39	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
SARC	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	6.5	4.79e-10	6.93e-07	0.48	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
SARC	cis	rs526231	0.543	rs34804	ENSG00000175749.11	EIF3KP1	6.5	4.79e-10	6.94e-07	0.55	0.39	Primary biliary cholangitis;	chr5:103092535	chr5:103032376~103033031:+
SARC	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-6.5	4.79e-10	6.94e-07	-0.57	-0.39	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
SARC	cis	rs6538678	0.746	rs703693	ENSG00000258343.1	RP11-536G4.2	-6.5	4.81e-10	6.96e-07	-0.48	-0.39	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95795345~95858839:-
SARC	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	6.5	4.87e-10	7.05e-07	0.46	0.39	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
SARC	cis	rs3002131	0.688	rs3008650	ENSG00000225265.1	TAF1A-AS1	6.5	4.89e-10	7.07e-07	0.61	0.39	Interleukin-10 levels;	chr1:222589873	chr1:222589825~222593032:+
SARC	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-6.5	4.89e-10	7.07e-07	-0.55	-0.39	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	6.5	4.9e-10	7.08e-07	0.41	0.39	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
SARC	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	6.5	4.94e-10	7.14e-07	0.43	0.39	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
SARC	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-6.5	4.95e-10	7.16e-07	-0.36	-0.39	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
SARC	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-6.5	4.95e-10	7.16e-07	-0.36	-0.39	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
SARC	cis	rs9322193	0.884	rs10872646	ENSG00000223701.3	RAET1E-AS1	6.5	4.96e-10	7.17e-07	0.42	0.39	Lung cancer;	chr6:149746539	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.884	rs12528279	ENSG00000223701.3	RAET1E-AS1	6.5	4.96e-10	7.17e-07	0.42	0.39	Lung cancer;	chr6:149750892	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.809	rs9479808	ENSG00000223701.3	RAET1E-AS1	6.5	4.96e-10	7.17e-07	0.42	0.39	Lung cancer;	chr6:149751328	chr6:149884431~149919508:+
SARC	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-6.49	5.04e-10	7.27e-07	-0.39	-0.39	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-6.49	5.04e-10	7.27e-07	-0.39	-0.39	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
SARC	cis	rs748404	0.697	rs574065	ENSG00000205771.5	CATSPER2P1	6.49	5.04e-10	7.27e-07	0.46	0.39	Lung cancer;	chr15:43258457	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	6.49	5.05e-10	7.28e-07	0.41	0.39	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
SARC	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	6.49	5.05e-10	7.29e-07	0.37	0.39	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
SARC	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-6.49	5.06e-10	7.3e-07	-0.44	-0.39	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
SARC	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	6.49	5.06e-10	7.3e-07	0.46	0.39	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
SARC	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-6.49	5.06e-10	7.3e-07	-0.51	-0.39	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
SARC	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	6.49	5.07e-10	7.31e-07	0.37	0.39	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
SARC	cis	rs9322193	0.923	rs10782316	ENSG00000223701.3	RAET1E-AS1	6.49	5.07e-10	7.32e-07	0.42	0.39	Lung cancer;	chr6:149752755	chr6:149884431~149919508:+
SARC	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	6.49	5.1e-10	7.36e-07	0.43	0.39	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
SARC	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	6.49	5.1e-10	7.36e-07	0.43	0.39	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
SARC	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	6.49	5.1e-10	7.36e-07	0.43	0.39	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
SARC	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-6.49	5.11e-10	7.37e-07	-0.46	-0.39	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
SARC	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	6.49	5.11e-10	7.37e-07	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	6.49	5.12e-10	7.37e-07	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
SARC	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	6.49	5.13e-10	7.39e-07	0.39	0.39	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-6.49	5.13e-10	7.39e-07	-0.39	-0.39	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
SARC	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-6.49	5.13e-10	7.39e-07	-0.39	-0.39	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
SARC	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-6.49	5.13e-10	7.39e-07	-0.39	-0.39	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
SARC	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-6.49	5.13e-10	7.39e-07	-0.54	-0.39	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
SARC	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-6.49	5.13e-10	7.39e-07	-0.54	-0.39	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
SARC	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	6.49	5.14e-10	7.4e-07	0.47	0.39	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
SARC	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	6.49	5.2e-10	7.48e-07	0.37	0.39	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
SARC	cis	rs1707322	1	rs1707322	ENSG00000280836.1	AL355480.1	-6.49	5.2e-10	7.49e-07	-0.4	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45581219~45581321:-
SARC	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-6.49	5.21e-10	7.5e-07	-0.52	-0.39	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
SARC	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-6.49	5.22e-10	7.52e-07	-0.38	-0.39	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
SARC	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	6.48	5.27e-10	7.58e-07	0.46	0.39	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	6.48	5.3e-10	7.62e-07	0.46	0.39	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
SARC	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-6.48	5.32e-10	7.64e-07	-0.54	-0.39	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
SARC	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-6.48	5.35e-10	7.69e-07	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
SARC	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-6.48	5.37e-10	7.72e-07	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
SARC	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-6.48	5.38e-10	7.73e-07	-0.54	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
SARC	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-6.48	5.38e-10	7.73e-07	-0.5	-0.39	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
SARC	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	6.48	5.45e-10	7.82e-07	0.52	0.39	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
SARC	cis	rs5760092	0.627	rs6519489	ENSG00000250470.1	AP000351.3	-6.48	5.48e-10	7.86e-07	-0.54	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23976904~23977585:-
SARC	cis	rs5760092	0.755	rs11090298	ENSG00000250470.1	AP000351.3	-6.48	5.48e-10	7.86e-07	-0.54	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23976904~23977585:-
SARC	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-6.48	5.48e-10	7.86e-07	-0.51	-0.39	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
SARC	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-6.48	5.48e-10	7.86e-07	-0.51	-0.39	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
SARC	cis	rs73186030	0.92	rs2001548	ENSG00000272758.4	RP11-299J3.8	6.48	5.48e-10	7.86e-07	0.52	0.39	Serum parathyroid hormone levels;	chr3:122313942	chr3:122416207~122443180:+
SARC	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	6.48	5.52e-10	7.91e-07	0.43	0.39	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
SARC	cis	rs1865760	0.929	rs1816546	ENSG00000272462.2	U91328.19	-6.48	5.53e-10	7.93e-07	-0.37	-0.39	Height;	chr6:25938024	chr6:25992662~26001775:+
SARC	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-6.48	5.54e-10	7.93e-07	-0.54	-0.39	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
SARC	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	6.48	5.55e-10	7.95e-07	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	6.48	5.55e-10	7.95e-07	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
SARC	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-6.47	5.59e-10	8.01e-07	-0.38	-0.39	Height;	chr11:118761813	chr11:118704607~118750263:+
SARC	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	6.47	5.6e-10	8.01e-07	0.46	0.39	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
SARC	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	6.47	5.6e-10	8.01e-07	0.47	0.39	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
SARC	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-6.47	5.64e-10	8.07e-07	-0.52	-0.39	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
SARC	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-6.47	5.69e-10	8.13e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-6.47	5.69e-10	8.13e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-6.47	5.69e-10	8.13e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-6.47	5.69e-10	8.13e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
SARC	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	6.47	5.72e-10	8.17e-07	0.42	0.39	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
SARC	cis	rs6538678	0.864	rs4762249	ENSG00000258343.1	RP11-536G4.2	6.47	5.73e-10	8.18e-07	0.46	0.39	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95795345~95858839:-
SARC	cis	rs9322193	0.923	rs10782317	ENSG00000223701.3	RAET1E-AS1	-6.47	5.73e-10	8.19e-07	-0.42	-0.39	Lung cancer;	chr6:149753911	chr6:149884431~149919508:+
SARC	cis	rs1865760	0.786	rs1436308	ENSG00000272462.2	U91328.19	-6.47	5.74e-10	8.2e-07	-0.37	-0.39	Height;	chr6:25939339	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.929	rs1436307	ENSG00000272462.2	U91328.19	-6.47	5.74e-10	8.2e-07	-0.37	-0.39	Height;	chr6:25939495	chr6:25992662~26001775:+
SARC	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-6.47	5.75e-10	8.2e-07	-0.39	-0.39	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
SARC	cis	rs2019137	0.589	rs7560701	ENSG00000274877.1	RP11-65I12.1	-6.47	5.75e-10	8.21e-07	-0.46	-0.39	Lymphocyte counts;	chr2:113269305	chr2:113237595~113240825:+
SARC	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	6.47	5.76e-10	8.22e-07	0.51	0.39	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
SARC	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-6.47	5.76e-10	8.22e-07	-0.48	-0.39	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
SARC	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	6.47	5.87e-10	8.37e-07	0.37	0.39	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
SARC	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-6.46	5.92e-10	8.43e-07	-0.51	-0.39	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
SARC	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	6.46	5.94e-10	8.46e-07	0.47	0.39	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
SARC	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	6.46	5.97e-10	8.49e-07	0.42	0.39	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	6.46	5.97e-10	8.49e-07	0.42	0.39	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	6.46	5.97e-10	8.49e-07	0.42	0.39	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
SARC	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-6.46	5.98e-10	8.51e-07	-0.42	-0.39	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
SARC	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-6.46	5.98e-10	8.51e-07	-0.42	-0.39	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
SARC	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	6.46	6e-10	8.53e-07	0.39	0.39	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
SARC	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	6.46	6e-10	8.53e-07	0.39	0.39	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
SARC	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-6.46	6e-10	8.54e-07	-0.44	-0.39	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
SARC	cis	rs9322193	0.607	rs7764677	ENSG00000268592.3	RAET1E-AS1	6.46	6.01e-10	8.54e-07	0.53	0.39	Lung cancer;	chr6:149906197	chr6:149863494~149919507:+
SARC	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-6.46	6.05e-10	8.6e-07	-0.42	-0.39	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
SARC	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-6.46	6.07e-10	8.63e-07	-0.42	-0.39	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-6.46	6.07e-10	8.63e-07	-0.42	-0.39	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-6.46	6.07e-10	8.63e-07	-0.42	-0.39	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
SARC	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	6.46	6.08e-10	8.64e-07	0.43	0.39	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
SARC	cis	rs4862750	0.872	rs6811569	ENSG00000249742.1	RP11-217E13.1	6.46	6.13e-10	8.71e-07	0.43	0.39	Lobe attachment (rater-scored or self-reported);	chr4:186976834	chr4:186979490~187021973:-
SARC	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-6.46	6.19e-10	8.78e-07	-0.42	-0.39	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
SARC	cis	rs1707322	0.964	rs796773	ENSG00000280836.1	AL355480.1	6.46	6.19e-10	8.79e-07	0.4	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.896	rs785518	ENSG00000280836.1	AL355480.1	6.46	6.19e-10	8.79e-07	0.4	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs785519	ENSG00000280836.1	AL355480.1	6.46	6.19e-10	8.79e-07	0.4	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45581219~45581321:-
SARC	cis	rs9322193	0.923	rs1934534	ENSG00000223701.3	RAET1E-AS1	6.46	6.19e-10	8.79e-07	0.42	0.39	Lung cancer;	chr6:149711896	chr6:149884431~149919508:+
SARC	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	6.45	6.22e-10	8.82e-07	0.49	0.39	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
SARC	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-6.45	6.23e-10	8.84e-07	-0.39	-0.39	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
SARC	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-6.45	6.27e-10	8.89e-07	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
SARC	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	6.45	6.27e-10	8.89e-07	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
SARC	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-6.45	6.27e-10	8.89e-07	-0.41	-0.39	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
SARC	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-6.45	6.32e-10	8.95e-07	-0.52	-0.39	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
SARC	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-6.45	6.32e-10	8.95e-07	-0.47	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
SARC	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	6.45	6.32e-10	8.95e-07	0.42	0.39	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
SARC	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-6.45	6.35e-10	8.99e-07	-0.54	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
SARC	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	6.45	6.36e-10	9.01e-07	0.51	0.39	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
SARC	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-6.45	6.37e-10	9.02e-07	-0.44	-0.39	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
SARC	cis	rs7216064	0.953	rs62086043	ENSG00000265055.1	AC145343.2	6.45	6.42e-10	9.09e-07	0.5	0.39	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971887	chr17:68096046~68101474:-
SARC	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	6.45	6.42e-10	9.09e-07	0.39	0.39	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
SARC	cis	rs6538678	0.929	rs10777744	ENSG00000258343.1	RP11-536G4.2	-6.45	6.52e-10	9.2e-07	-0.46	-0.39	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95795345~95858839:-
SARC	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-6.44	6.6e-10	9.3e-07	-0.55	-0.39	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
SARC	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	6.44	6.61e-10	9.32e-07	0.37	0.39	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
SARC	cis	rs1865760	0.929	rs9358896	ENSG00000272462.2	U91328.19	-6.44	6.66e-10	9.39e-07	-0.37	-0.39	Height;	chr6:25942969	chr6:25992662~26001775:+
SARC	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	6.44	6.7e-10	9.44e-07	0.42	0.39	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
SARC	cis	rs10463554	1	rs10463554	ENSG00000175749.11	EIF3KP1	6.44	6.7e-10	9.44e-07	0.47	0.39	Parkinson's disease;	chr5:102983270	chr5:103032376~103033031:+
SARC	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	6.44	6.74e-10	9.49e-07	0.5	0.39	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
SARC	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	6.44	6.77e-10	9.52e-07	0.47	0.39	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
SARC	cis	rs1707322	0.896	rs809774	ENSG00000280836.1	AL355480.1	6.44	6.78e-10	9.53e-07	0.4	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45581219~45581321:-
SARC	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	6.44	6.79e-10	9.55e-07	0.48	0.39	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
SARC	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-6.44	6.85e-10	9.63e-07	-0.39	-0.39	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
SARC	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-6.44	6.86e-10	9.64e-07	-0.53	-0.39	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.962	rs9322206	ENSG00000223701.3	RAET1E-AS1	6.44	6.87e-10	9.65e-07	0.4	0.39	Lung cancer;	chr6:149641481	chr6:149884431~149919508:+
SARC	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-6.44	6.88e-10	9.67e-07	-0.42	-0.39	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-6.44	6.88e-10	9.67e-07	-0.42	-0.39	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-6.44	6.88e-10	9.67e-07	-0.42	-0.39	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-6.44	6.88e-10	9.67e-07	-0.42	-0.39	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-6.44	6.88e-10	9.67e-07	-0.42	-0.39	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
SARC	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-6.44	6.9e-10	9.69e-07	-0.53	-0.39	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
SARC	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-6.44	6.9e-10	9.69e-07	-0.53	-0.39	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
SARC	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-6.44	6.9e-10	9.69e-07	-0.39	-0.39	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
SARC	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-6.44	6.93e-10	9.73e-07	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
SARC	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-6.44	6.94e-10	9.74e-07	-0.43	-0.39	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
SARC	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	6.44	6.94e-10	9.74e-07	0.52	0.39	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
SARC	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-6.44	6.95e-10	9.76e-07	-0.4	-0.39	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
SARC	cis	rs6538678	0.712	rs10777748	ENSG00000258343.1	RP11-536G4.2	-6.43	6.96e-10	9.77e-07	-0.48	-0.39	Lupus nephritis in systemic lupus erythematosus;	chr12:95880227	chr12:95795345~95858839:-
SARC	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-6.43	6.97e-10	9.78e-07	-0.51	-0.39	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
SARC	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-6.43	6.97e-10	9.78e-07	-0.51	-0.39	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-6.43	6.97e-10	9.78e-07	-0.51	-0.39	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
SARC	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-6.43	6.97e-10	9.78e-07	-0.44	-0.39	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
SARC	cis	rs1707322	0.964	rs785516	ENSG00000280836.1	AL355480.1	6.43	6.97e-10	9.78e-07	0.4	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs785517	ENSG00000280836.1	AL355480.1	6.43	6.97e-10	9.78e-07	0.4	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs785484	ENSG00000280836.1	AL355480.1	6.43	6.97e-10	9.78e-07	0.4	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45581219~45581321:-
SARC	cis	rs131777	0.575	rs131760	ENSG00000205559.3	CHKB-AS1	-6.43	6.99e-10	9.8e-07	-0.42	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50573507	chr22:50583026~50583877:+
SARC	cis	rs1865760	0.892	rs9379806	ENSG00000272462.2	U91328.19	-6.43	7.01e-10	9.82e-07	-0.37	-0.39	Height;	chr6:25940730	chr6:25992662~26001775:+
SARC	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	6.43	7.02e-10	9.84e-07	0.49	0.39	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
SARC	cis	rs4713118	0.868	rs35069907	ENSG00000219392.1	RP1-265C24.5	-6.43	7.04e-10	9.87e-07	-0.58	-0.39	Parkinson's disease;	chr6:27778913	chr6:28115628~28116551:+
SARC	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	6.43	7.08e-10	9.92e-07	0.44	0.39	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
SARC	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	6.43	7.09e-10	9.93e-07	0.49	0.39	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
SARC	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	6.43	7.15e-10	1e-06	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
SARC	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-6.43	7.26e-10	1.02e-06	-0.39	-0.39	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
SARC	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-6.43	7.31e-10	1.02e-06	-0.53	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
SARC	cis	rs1707322	0.963	rs10890373	ENSG00000280836.1	AL355480.1	-6.43	7.32e-10	1.02e-06	-0.39	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45581219~45581321:-
SARC	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-6.43	7.32e-10	1.02e-06	-0.54	-0.39	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
SARC	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-6.43	7.33e-10	1.02e-06	-0.52	-0.39	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-6.43	7.33e-10	1.02e-06	-0.52	-0.39	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-6.43	7.33e-10	1.02e-06	-0.52	-0.39	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-6.43	7.33e-10	1.02e-06	-0.52	-0.39	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
SARC	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
SARC	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
SARC	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
SARC	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.33e-10	1.02e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
SARC	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-6.43	7.34e-10	1.03e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
SARC	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	6.42	7.45e-10	1.04e-06	0.48	0.39	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
SARC	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-6.42	7.48e-10	1.04e-06	-0.41	-0.39	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
SARC	cis	rs5760092	0.755	rs4585126	ENSG00000250470.1	AP000351.3	-6.42	7.49e-10	1.04e-06	-0.51	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23976904~23977585:-
SARC	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-6.42	7.49e-10	1.05e-06	-0.44	-0.39	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
SARC	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	6.42	7.53e-10	1.05e-06	0.36	0.39	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
SARC	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	6.42	7.55e-10	1.05e-06	0.53	0.39	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
SARC	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-6.42	7.57e-10	1.05e-06	-0.46	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
SARC	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	6.42	7.57e-10	1.05e-06	0.54	0.39	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
SARC	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	6.42	7.57e-10	1.05e-06	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	6.42	7.57e-10	1.05e-06	0.45	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
SARC	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-6.42	7.65e-10	1.07e-06	-0.4	-0.39	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
SARC	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-6.42	7.69e-10	1.07e-06	-0.45	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
SARC	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	6.42	7.73e-10	1.07e-06	0.44	0.39	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
SARC	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	6.42	7.74e-10	1.08e-06	0.45	0.39	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	6.42	7.74e-10	1.08e-06	0.45	0.39	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	6.42	7.74e-10	1.08e-06	0.45	0.39	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
SARC	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	6.42	7.74e-10	1.08e-06	0.54	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
SARC	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-6.42	7.76e-10	1.08e-06	-0.38	-0.39	Height;	chr11:118760944	chr11:118704607~118750263:+
SARC	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-6.42	7.76e-10	1.08e-06	-0.38	-0.39	Height;	chr11:118764443	chr11:118704607~118750263:+
SARC	cis	rs73186030	0.591	rs28630628	ENSG00000272758.4	RP11-299J3.8	6.41	7.83e-10	1.09e-06	0.48	0.39	Serum parathyroid hormone levels;	chr3:122386769	chr3:122416207~122443180:+
SARC	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-6.41	7.84e-10	1.09e-06	-0.48	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
SARC	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-6.41	7.89e-10	1.1e-06	-0.4	-0.39	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
SARC	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-6.41	7.9e-10	1.1e-06	-0.49	-0.39	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
SARC	cis	rs324126	0.752	rs1054612	ENSG00000277977.1	CTD-3018O17.5	-6.41	7.93e-10	1.1e-06	-0.41	-0.39	Colonoscopy-negative controls vs population controls;	chr19:52366799	chr19:52392659~52392755:+
SARC	cis	rs9322193	0.607	rs6925151	ENSG00000268592.3	RAET1E-AS1	6.41	7.95e-10	1.1e-06	0.53	0.39	Lung cancer;	chr6:149889587	chr6:149863494~149919507:+
SARC	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	6.41	7.96e-10	1.1e-06	0.47	0.39	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
SARC	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	6.41	7.96e-10	1.1e-06	0.47	0.39	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
SARC	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-6.41	7.97e-10	1.11e-06	-0.38	-0.39	Height;	chr11:118746590	chr11:118704607~118750263:+
SARC	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	6.41	8.06e-10	1.12e-06	0.35	0.39	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
SARC	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-6.41	8.06e-10	1.12e-06	-0.38	-0.39	Height;	chr11:118749988	chr11:118704607~118750263:+
SARC	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-6.41	8.06e-10	1.12e-06	-0.49	-0.39	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
SARC	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-6.41	8.09e-10	1.12e-06	-0.42	-0.39	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
SARC	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-6.41	8.09e-10	1.12e-06	-0.42	-0.39	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
SARC	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	6.41	8.09e-10	1.12e-06	0.39	0.39	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
SARC	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-6.41	8.15e-10	1.13e-06	-0.45	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
SARC	cis	rs607541	0.85	rs74009656	ENSG00000259520.4	CTD-2651B20.3	-6.41	8.17e-10	1.13e-06	-0.55	-0.39	Obesity-related traits;	chr15:45642809	chr15:45251580~45279251:-
SARC	cis	rs607541	0.85	rs74009657	ENSG00000259520.4	CTD-2651B20.3	-6.41	8.17e-10	1.13e-06	-0.55	-0.39	Obesity-related traits;	chr15:45642823	chr15:45251580~45279251:-
SARC	cis	rs607541	0.85	rs8036651	ENSG00000259520.4	CTD-2651B20.3	-6.41	8.17e-10	1.13e-06	-0.55	-0.39	Obesity-related traits;	chr15:45642826	chr15:45251580~45279251:-
SARC	cis	rs607541	1	rs2099880	ENSG00000259520.4	CTD-2651B20.3	-6.41	8.17e-10	1.13e-06	-0.55	-0.39	Obesity-related traits;	chr15:45642876	chr15:45251580~45279251:-
SARC	cis	rs607541	1	rs2083729	ENSG00000259520.4	CTD-2651B20.3	-6.41	8.17e-10	1.13e-06	-0.55	-0.39	Obesity-related traits;	chr15:45642961	chr15:45251580~45279251:-
SARC	cis	rs607541	0.85	rs642328	ENSG00000259520.4	CTD-2651B20.3	-6.41	8.17e-10	1.13e-06	-0.55	-0.39	Obesity-related traits;	chr15:45643152	chr15:45251580~45279251:-
SARC	cis	rs607541	1	rs593126	ENSG00000259520.4	CTD-2651B20.3	-6.41	8.17e-10	1.13e-06	-0.55	-0.39	Obesity-related traits;	chr15:45643579	chr15:45251580~45279251:-
SARC	cis	rs607541	1	rs644493	ENSG00000259520.4	CTD-2651B20.3	-6.41	8.17e-10	1.13e-06	-0.55	-0.39	Obesity-related traits;	chr15:45643618	chr15:45251580~45279251:-
SARC	cis	rs607541	1	rs688967	ENSG00000259520.4	CTD-2651B20.3	-6.41	8.17e-10	1.13e-06	-0.55	-0.39	Obesity-related traits;	chr15:45643929	chr15:45251580~45279251:-
SARC	cis	rs607541	1	rs4270120	ENSG00000259520.4	CTD-2651B20.3	-6.41	8.17e-10	1.13e-06	-0.55	-0.39	Obesity-related traits;	chr15:45644036	chr15:45251580~45279251:-
SARC	cis	rs607541	1	rs4271550	ENSG00000259520.4	CTD-2651B20.3	-6.41	8.17e-10	1.13e-06	-0.55	-0.39	Obesity-related traits;	chr15:45644068	chr15:45251580~45279251:-
SARC	cis	rs607541	0.85	rs673208	ENSG00000259520.4	CTD-2651B20.3	-6.41	8.17e-10	1.13e-06	-0.55	-0.39	Obesity-related traits;	chr15:45644094	chr15:45251580~45279251:-
SARC	cis	rs2303759	0.881	rs10412811	ENSG00000268686.1	AC010524.2	-6.41	8.17e-10	1.13e-06	-0.48	-0.39	Multiple sclerosis;	chr19:49381238	chr19:49368705~49388081:-
SARC	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-6.41	8.18e-10	1.13e-06	-0.42	-0.39	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
SARC	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-6.41	8.18e-10	1.13e-06	-0.37	-0.39	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
SARC	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	6.41	8.19e-10	1.14e-06	0.37	0.39	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
SARC	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	6.4	8.22e-10	1.14e-06	0.45	0.39	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
SARC	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-6.4	8.24e-10	1.14e-06	-0.41	-0.39	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-6.4	8.24e-10	1.14e-06	-0.41	-0.39	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-6.4	8.24e-10	1.14e-06	-0.41	-0.39	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
SARC	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	6.4	8.25e-10	1.14e-06	0.4	0.39	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
SARC	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	6.4	8.29e-10	1.15e-06	0.47	0.39	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
SARC	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	6.4	8.31e-10	1.15e-06	0.42	0.39	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
SARC	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	6.4	8.34e-10	1.15e-06	0.49	0.39	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
SARC	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	6.4	8.43e-10	1.16e-06	0.43	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
SARC	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-6.4	8.44e-10	1.17e-06	-0.48	-0.39	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
SARC	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-6.4	8.44e-10	1.17e-06	-0.43	-0.39	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
SARC	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-6.4	8.49e-10	1.17e-06	-0.48	-0.39	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
SARC	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	6.4	8.51e-10	1.18e-06	0.47	0.39	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
SARC	cis	rs1865760	0.929	rs12195653	ENSG00000272462.2	U91328.19	-6.4	8.51e-10	1.18e-06	-0.36	-0.39	Height;	chr6:25958393	chr6:25992662~26001775:+
SARC	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	6.4	8.54e-10	1.18e-06	0.43	0.39	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
SARC	cis	rs1707322	1	rs7539800	ENSG00000280836.1	AL355480.1	6.4	8.55e-10	1.18e-06	0.39	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45581219~45581321:-
SARC	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-6.39	8.69e-10	1.2e-06	-0.49	-0.39	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-6.39	8.69e-10	1.2e-06	-0.49	-0.39	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
SARC	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	6.39	8.71e-10	1.2e-06	0.42	0.39	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
SARC	cis	rs1865760	0.929	rs9467646	ENSG00000272462.2	U91328.19	-6.39	8.77e-10	1.21e-06	-0.37	-0.39	Height;	chr6:25957180	chr6:25992662~26001775:+
SARC	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-6.39	8.77e-10	1.21e-06	-0.4	-0.39	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
SARC	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-6.39	8.78e-10	1.21e-06	-0.39	-0.39	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
SARC	cis	rs1865760	0.82	rs9348697	ENSG00000272462.2	U91328.19	-6.39	8.79e-10	1.21e-06	-0.37	-0.39	Height;	chr6:25890606	chr6:25992662~26001775:+
SARC	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	6.39	8.81e-10	1.21e-06	0.35	0.39	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
SARC	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	6.39	8.84e-10	1.22e-06	0.37	0.39	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
SARC	cis	rs9322193	0.961	rs2064520	ENSG00000223701.3	RAET1E-AS1	6.39	8.85e-10	1.22e-06	0.41	0.39	Lung cancer;	chr6:149603650	chr6:149884431~149919508:+
SARC	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-6.39	8.86e-10	1.22e-06	-0.46	-0.39	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
SARC	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	6.39	8.92e-10	1.23e-06	0.41	0.39	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
SARC	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-6.39	8.95e-10	1.23e-06	-0.35	-0.39	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
SARC	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-6.39	8.95e-10	1.23e-06	-0.35	-0.39	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
SARC	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-6.39	8.98e-10	1.24e-06	-0.4	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
SARC	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	6.39	9.01e-10	1.24e-06	0.45	0.39	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	6.39	9.01e-10	1.24e-06	0.45	0.39	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	6.39	9.01e-10	1.24e-06	0.45	0.39	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	6.39	9.01e-10	1.24e-06	0.45	0.39	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	6.39	9.01e-10	1.24e-06	0.45	0.39	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	6.39	9.01e-10	1.24e-06	0.45	0.39	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	6.39	9.01e-10	1.24e-06	0.45	0.39	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	6.39	9.01e-10	1.24e-06	0.45	0.39	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	6.39	9.01e-10	1.24e-06	0.45	0.39	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
SARC	cis	rs113835537	0.529	rs17495838	ENSG00000255517.5	CTD-3074O7.5	-6.39	9.12e-10	1.25e-06	-0.45	-0.39	Airway imaging phenotypes;	chr11:66428794	chr11:66473490~66480233:-
SARC	cis	rs3762637	0.943	rs9289196	ENSG00000272758.4	RP11-299J3.8	-6.39	9.12e-10	1.25e-06	-0.5	-0.39	LDL cholesterol levels;	chr3:122549659	chr3:122416207~122443180:+
SARC	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	6.38	9.22e-10	1.27e-06	0.44	0.39	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
SARC	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	6.38	9.26e-10	1.27e-06	0.42	0.39	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
SARC	cis	rs9322193	0.923	rs9322197	ENSG00000223701.3	RAET1E-AS1	6.38	9.28e-10	1.27e-06	0.4	0.39	Lung cancer;	chr6:149622577	chr6:149884431~149919508:+
SARC	cis	rs2303759	0.918	rs4802597	ENSG00000268686.1	AC010524.2	-6.38	9.29e-10	1.28e-06	-0.46	-0.39	Multiple sclerosis;	chr19:49368828	chr19:49368705~49388081:-
SARC	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	6.38	9.32e-10	1.28e-06	0.45	0.39	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
SARC	cis	rs7216064	1	rs7223813	ENSG00000265055.1	AC145343.2	6.38	9.35e-10	1.28e-06	0.51	0.39	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67949724	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.954	rs4790973	ENSG00000265055.1	AC145343.2	6.38	9.35e-10	1.28e-06	0.51	0.39	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67955017	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.953	rs12601759	ENSG00000265055.1	AC145343.2	6.38	9.35e-10	1.28e-06	0.51	0.39	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67959168	chr17:68096046~68101474:-
SARC	cis	rs9322193	0.884	rs9688858	ENSG00000223701.3	RAET1E-AS1	6.38	9.36e-10	1.28e-06	0.4	0.39	Lung cancer;	chr6:149637911	chr6:149884431~149919508:+
SARC	cis	rs1707322	0.929	rs785513	ENSG00000280836.1	AL355480.1	6.38	9.37e-10	1.29e-06	0.4	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45581219~45581321:-
SARC	cis	rs77204473	0.744	rs2306471	ENSG00000254851.1	RP11-109L13.1	6.38	9.38e-10	1.29e-06	0.86	0.39	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117145734	chr11:117135528~117138582:+
SARC	cis	rs6538678	0.929	rs7962359	ENSG00000258343.1	RP11-536G4.2	-6.38	9.5e-10	1.3e-06	-0.45	-0.39	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95795345~95858839:-
SARC	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-6.38	9.54e-10	1.31e-06	-0.38	-0.39	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
SARC	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-6.38	9.66e-10	1.32e-06	-0.4	-0.39	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
SARC	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	6.38	9.7e-10	1.33e-06	0.44	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
SARC	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-6.37	9.72e-10	1.33e-06	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
SARC	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-6.37	9.72e-10	1.33e-06	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
SARC	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-6.37	9.73e-10	1.33e-06	-0.4	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
SARC	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	6.37	9.74e-10	1.33e-06	0.49	0.39	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
SARC	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	6.37	9.74e-10	1.33e-06	0.51	0.39	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
SARC	cis	rs80285556	1	rs17605685	ENSG00000161643.11	SIGLEC16	6.37	9.78e-10	1.34e-06	0.74	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49983484	chr19:49969673~49975814:+
SARC	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	6.37	9.8e-10	1.34e-06	0.48	0.39	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
SARC	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	6.37	9.85e-10	1.35e-06	0.42	0.39	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
SARC	cis	rs1707322	0.827	rs10890347	ENSG00000280836.1	AL355480.1	6.37	9.86e-10	1.35e-06	0.38	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45581219~45581321:-
SARC	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	6.37	9.9e-10	1.35e-06	0.38	0.39	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
SARC	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	6.37	9.9e-10	1.35e-06	0.38	0.39	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
SARC	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	6.37	9.9e-10	1.35e-06	0.42	0.39	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	6.37	9.9e-10	1.35e-06	0.42	0.39	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
SARC	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-6.37	1e-09	1.37e-06	-0.52	-0.39	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
SARC	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	6.37	1.01e-09	1.37e-06	0.44	0.39	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
SARC	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-6.37	1.01e-09	1.37e-06	-0.57	-0.39	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
SARC	cis	rs3002131	0.604	rs3002151	ENSG00000225265.1	TAF1A-AS1	-6.37	1.01e-09	1.37e-06	-0.62	-0.39	Interleukin-10 levels;	chr1:222573225	chr1:222589825~222593032:+
SARC	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	6.37	1.02e-09	1.39e-06	0.52	0.38	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
SARC	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-6.37	1.02e-09	1.39e-06	-0.43	-0.38	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
SARC	cis	rs7182621	1	rs7182621	ENSG00000259363.4	CTD-2054N24.2	6.37	1.02e-09	1.39e-06	0.38	0.38	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99807023~99877148:+
SARC	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	6.36	1.03e-09	1.4e-06	0.38	0.38	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
SARC	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	6.36	1.03e-09	1.4e-06	0.53	0.38	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	6.36	1.04e-09	1.41e-06	0.46	0.38	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
SARC	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	6.36	1.04e-09	1.41e-06	0.49	0.38	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
SARC	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	6.36	1.04e-09	1.41e-06	0.37	0.38	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
SARC	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-6.36	1.04e-09	1.42e-06	-0.46	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
SARC	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	6.36	1.05e-09	1.43e-06	0.37	0.38	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
SARC	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	6.36	1.05e-09	1.43e-06	0.41	0.38	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
SARC	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	6.36	1.05e-09	1.43e-06	0.54	0.38	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
SARC	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	6.36	1.07e-09	1.45e-06	0.39	0.38	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
SARC	cis	rs9322193	0.962	rs9688750	ENSG00000223701.3	RAET1E-AS1	6.36	1.07e-09	1.45e-06	0.4	0.38	Lung cancer;	chr6:149657633	chr6:149884431~149919508:+
SARC	cis	rs9309473	1	rs56672945	ENSG00000163016.8	ALMS1P	6.36	1.07e-09	1.46e-06	0.49	0.38	Metabolite levels;	chr2:73395535	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs60844734	ENSG00000163016.8	ALMS1P	6.36	1.07e-09	1.46e-06	0.49	0.38	Metabolite levels;	chr2:73396077	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs11899902	ENSG00000163016.8	ALMS1P	6.36	1.07e-09	1.46e-06	0.49	0.38	Metabolite levels;	chr2:73404436	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	6.36	1.07e-09	1.46e-06	0.49	0.38	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
SARC	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	6.36	1.07e-09	1.46e-06	0.45	0.38	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
SARC	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-6.36	1.07e-09	1.46e-06	-0.47	-0.38	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
SARC	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	6.36	1.08e-09	1.46e-06	0.45	0.38	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
SARC	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	6.36	1.08e-09	1.46e-06	0.44	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
SARC	cis	rs17772222	1	rs1955599	ENSG00000258983.2	RP11-507K2.2	6.35	1.09e-09	1.47e-06	0.41	0.38	Coronary artery calcification;	chr14:88358788	chr14:88499334~88515502:+
SARC	cis	rs17772222	1	rs1955600	ENSG00000258983.2	RP11-507K2.2	6.35	1.09e-09	1.47e-06	0.41	0.38	Coronary artery calcification;	chr14:88359040	chr14:88499334~88515502:+
SARC	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-6.35	1.09e-09	1.48e-06	-0.42	-0.38	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
SARC	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-6.35	1.09e-09	1.48e-06	-0.42	-0.38	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
SARC	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	6.35	1.1e-09	1.48e-06	0.37	0.38	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
SARC	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	6.35	1.1e-09	1.48e-06	0.37	0.38	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
SARC	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	6.35	1.1e-09	1.48e-06	0.37	0.38	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
SARC	cis	rs131777	0.575	rs963980	ENSG00000205559.3	CHKB-AS1	-6.35	1.1e-09	1.49e-06	-0.41	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50583688	chr22:50583026~50583877:+
SARC	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	6.35	1.1e-09	1.49e-06	0.53	0.38	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	6.35	1.11e-09	1.51e-06	0.46	0.38	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
SARC	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	6.35	1.12e-09	1.51e-06	0.61	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
SARC	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-6.35	1.12e-09	1.52e-06	-0.37	-0.38	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
SARC	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-6.35	1.12e-09	1.52e-06	-0.37	-0.38	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
SARC	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	6.35	1.13e-09	1.52e-06	0.43	0.38	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
SARC	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-6.35	1.14e-09	1.53e-06	-0.52	-0.38	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
SARC	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	6.35	1.14e-09	1.54e-06	0.61	0.38	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
SARC	cis	rs17772222	1	rs56987357	ENSG00000258983.2	RP11-507K2.2	6.34	1.15e-09	1.55e-06	0.41	0.38	Coronary artery calcification;	chr14:88358019	chr14:88499334~88515502:+
SARC	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-6.34	1.15e-09	1.56e-06	-0.45	-0.38	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
SARC	cis	rs2303759	0.918	rs8107548	ENSG00000268686.1	AC010524.2	-6.34	1.15e-09	1.56e-06	-0.48	-0.38	Multiple sclerosis;	chr19:49367386	chr19:49368705~49388081:-
SARC	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-6.34	1.16e-09	1.56e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
SARC	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	6.34	1.17e-09	1.58e-06	0.52	0.38	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
SARC	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	6.34	1.17e-09	1.58e-06	0.41	0.38	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
SARC	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-6.34	1.18e-09	1.59e-06	-0.4	-0.38	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
SARC	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	6.34	1.18e-09	1.59e-06	0.4	0.38	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
SARC	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-6.34	1.19e-09	1.6e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
SARC	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-6.34	1.19e-09	1.6e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
SARC	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-6.34	1.2e-09	1.61e-06	-0.4	-0.38	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
SARC	cis	rs607541	1	rs675413	ENSG00000259520.4	CTD-2651B20.3	-6.34	1.2e-09	1.61e-06	-0.54	-0.38	Obesity-related traits;	chr15:45644547	chr15:45251580~45279251:-
SARC	cis	rs607541	1	rs675876	ENSG00000259520.4	CTD-2651B20.3	-6.34	1.2e-09	1.61e-06	-0.54	-0.38	Obesity-related traits;	chr15:45644658	chr15:45251580~45279251:-
SARC	cis	rs607541	0.85	rs675890	ENSG00000259520.4	CTD-2651B20.3	-6.34	1.2e-09	1.61e-06	-0.54	-0.38	Obesity-related traits;	chr15:45644666	chr15:45251580~45279251:-
SARC	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-6.33	1.22e-09	1.65e-06	-1	-0.38	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
SARC	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-6.33	1.23e-09	1.65e-06	-0.52	-0.38	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
SARC	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-6.33	1.23e-09	1.65e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-6.33	1.23e-09	1.65e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
SARC	cis	rs113835537	0.529	rs75003264	ENSG00000255517.5	CTD-3074O7.5	-6.33	1.23e-09	1.65e-06	-0.44	-0.38	Airway imaging phenotypes;	chr11:66488628	chr11:66473490~66480233:-
SARC	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	6.33	1.23e-09	1.65e-06	0.58	0.38	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
SARC	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	6.33	1.24e-09	1.67e-06	0.57	0.38	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
SARC	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	6.33	1.24e-09	1.67e-06	0.57	0.38	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
SARC	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	6.33	1.25e-09	1.68e-06	0.42	0.38	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
SARC	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	6.33	1.26e-09	1.7e-06	0.51	0.38	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
SARC	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-6.33	1.26e-09	1.7e-06	-0.48	-0.38	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
SARC	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-6.33	1.26e-09	1.7e-06	-0.4	-0.38	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
SARC	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	6.33	1.27e-09	1.7e-06	0.45	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
SARC	cis	rs5760092	0.618	rs4461358	ENSG00000250470.1	AP000351.3	-6.33	1.27e-09	1.71e-06	-0.48	-0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23976904~23977585:-
SARC	cis	rs2179367	0.959	rs4895789	ENSG00000231760.4	RP11-350J20.5	6.33	1.27e-09	1.71e-06	0.48	0.38	Dupuytren's disease;	chr6:149443518	chr6:149796151~149826294:-
SARC	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	6.32	1.28e-09	1.72e-06	0.48	0.38	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
SARC	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	6.32	1.28e-09	1.72e-06	0.4	0.38	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	6.32	1.28e-09	1.72e-06	0.4	0.38	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	6.32	1.28e-09	1.72e-06	0.4	0.38	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
SARC	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-6.32	1.29e-09	1.73e-06	-0.38	-0.38	Height;	chr11:118791319	chr11:118704607~118750263:+
SARC	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-6.32	1.3e-09	1.74e-06	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
SARC	cis	rs6538678	0.864	rs10777747	ENSG00000258343.1	RP11-536G4.2	-6.32	1.3e-09	1.74e-06	-0.44	-0.38	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95795345~95858839:-
SARC	cis	rs6538678	0.864	rs7308921	ENSG00000258343.1	RP11-536G4.2	6.32	1.3e-09	1.74e-06	0.44	0.38	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95795345~95858839:-
SARC	cis	rs7216064	0.648	rs61676547	ENSG00000278219.1	AC145343.1	-6.32	1.31e-09	1.75e-06	-0.46	-0.38	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896391	chr17:68101538~68101639:+
SARC	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-6.32	1.31e-09	1.76e-06	-0.49	-0.38	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
SARC	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-6.32	1.32e-09	1.76e-06	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
SARC	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	6.32	1.32e-09	1.77e-06	0.46	0.38	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
SARC	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-6.32	1.32e-09	1.77e-06	-0.38	-0.38	Height;	chr11:118742526	chr11:118704607~118750263:+
SARC	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-6.32	1.33e-09	1.78e-06	-0.44	-0.38	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
SARC	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	6.32	1.33e-09	1.78e-06	0.71	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
SARC	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	6.32	1.33e-09	1.78e-06	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
SARC	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	6.32	1.33e-09	1.78e-06	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
SARC	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	6.32	1.34e-09	1.79e-06	0.44	0.38	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
SARC	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-6.32	1.34e-09	1.79e-06	-0.39	-0.38	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
SARC	cis	rs10885396	1	rs10885396	ENSG00000233547.1	RP11-57H14.2	-6.32	1.35e-09	1.8e-06	-0.37	-0.38	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112951996	chr10:112950646~112951875:-
SARC	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	6.32	1.35e-09	1.8e-06	0.42	0.38	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
SARC	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-6.32	1.35e-09	1.81e-06	-0.46	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
SARC	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	6.32	1.35e-09	1.81e-06	0.39	0.38	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
SARC	cis	rs9322193	0.962	rs10452626	ENSG00000223701.3	RAET1E-AS1	6.32	1.35e-09	1.81e-06	0.4	0.38	Lung cancer;	chr6:149767481	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs62441303	ENSG00000223701.3	RAET1E-AS1	6.32	1.35e-09	1.81e-06	0.4	0.38	Lung cancer;	chr6:149767547	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs12175575	ENSG00000223701.3	RAET1E-AS1	6.31	1.36e-09	1.81e-06	0.4	0.38	Lung cancer;	chr6:149763351	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs4869966	ENSG00000223701.3	RAET1E-AS1	6.31	1.36e-09	1.81e-06	0.4	0.38	Lung cancer;	chr6:149763714	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs1112730	ENSG00000223701.3	RAET1E-AS1	6.31	1.36e-09	1.81e-06	0.4	0.38	Lung cancer;	chr6:149766383	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs1112729	ENSG00000223701.3	RAET1E-AS1	6.31	1.36e-09	1.81e-06	0.4	0.38	Lung cancer;	chr6:149766491	chr6:149884431~149919508:+
SARC	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-6.31	1.36e-09	1.82e-06	-0.35	-0.38	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
SARC	cis	rs1707322	0.964	rs1768802	ENSG00000280836.1	AL355480.1	6.31	1.36e-09	1.82e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs1588663	ENSG00000280836.1	AL355480.1	6.31	1.36e-09	1.82e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs1768801	ENSG00000280836.1	AL355480.1	6.31	1.36e-09	1.82e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs1768800	ENSG00000280836.1	AL355480.1	6.31	1.36e-09	1.82e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.964	rs785483	ENSG00000280836.1	AL355480.1	6.31	1.36e-09	1.82e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45581219~45581321:-
SARC	cis	rs73186030	1	rs73186044	ENSG00000272758.4	RP11-299J3.8	6.31	1.37e-09	1.83e-06	0.53	0.38	Serum parathyroid hormone levels;	chr3:122309629	chr3:122416207~122443180:+
SARC	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	6.31	1.37e-09	1.83e-06	0.45	0.38	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
SARC	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	6.31	1.38e-09	1.84e-06	0.49	0.38	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
SARC	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	6.31	1.39e-09	1.85e-06	0.42	0.38	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
SARC	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	6.31	1.4e-09	1.86e-06	0.42	0.38	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
SARC	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	6.31	1.4e-09	1.86e-06	0.46	0.38	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
SARC	cis	rs7182621	0.639	rs36069387	ENSG00000259363.4	CTD-2054N24.2	-6.31	1.4e-09	1.87e-06	-0.38	-0.38	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99807023~99877148:+
SARC	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-6.31	1.41e-09	1.87e-06	-0.52	-0.38	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
SARC	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-6.31	1.41e-09	1.88e-06	-0.47	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
SARC	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-6.31	1.43e-09	1.9e-06	-0.39	-0.38	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
SARC	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	6.31	1.43e-09	1.9e-06	0.44	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
SARC	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-6.3	1.44e-09	1.91e-06	-0.59	-0.38	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
SARC	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	6.3	1.44e-09	1.91e-06	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
SARC	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-6.3	1.44e-09	1.91e-06	-0.39	-0.38	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
SARC	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	6.3	1.45e-09	1.92e-06	0.46	0.38	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
SARC	cis	rs7216064	0.734	rs11653507	ENSG00000278219.1	AC145343.1	-6.3	1.46e-09	1.94e-06	-0.44	-0.38	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67895948	chr17:68101538~68101639:+
SARC	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	6.3	1.47e-09	1.95e-06	0.44	0.38	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	6.3	1.47e-09	1.95e-06	0.44	0.38	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	6.3	1.47e-09	1.95e-06	0.44	0.38	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	6.3	1.47e-09	1.95e-06	0.44	0.38	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	6.3	1.47e-09	1.95e-06	0.44	0.38	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	6.3	1.47e-09	1.95e-06	0.44	0.38	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	6.3	1.47e-09	1.95e-06	0.44	0.38	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
SARC	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	6.3	1.47e-09	1.96e-06	0.44	0.38	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
SARC	cis	rs17772222	1	rs17124700	ENSG00000258983.2	RP11-507K2.2	6.3	1.48e-09	1.96e-06	0.42	0.38	Coronary artery calcification;	chr14:88439285	chr14:88499334~88515502:+
SARC	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-6.3	1.48e-09	1.96e-06	-0.4	-0.38	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
SARC	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	6.3	1.48e-09	1.97e-06	0.5	0.38	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
SARC	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	6.3	1.5e-09	1.99e-06	0.49	0.38	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
SARC	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-6.3	1.5e-09	1.99e-06	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
SARC	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-6.3	1.5e-09	1.99e-06	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
SARC	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-6.3	1.5e-09	1.99e-06	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
SARC	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-6.3	1.5e-09	1.99e-06	-0.48	-0.38	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
SARC	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-6.3	1.51e-09	2e-06	-0.53	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
SARC	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	6.3	1.51e-09	2e-06	0.48	0.38	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
SARC	cis	rs17772222	0.917	rs61986669	ENSG00000258983.2	RP11-507K2.2	6.3	1.51e-09	2e-06	0.42	0.38	Coronary artery calcification;	chr14:88727121	chr14:88499334~88515502:+
SARC	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	6.29	1.52e-09	2.02e-06	0.36	0.38	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
SARC	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	6.29	1.53e-09	2.03e-06	0.58	0.38	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
SARC	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	6.29	1.53e-09	2.03e-06	0.45	0.38	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	6.29	1.53e-09	2.03e-06	0.41	0.38	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
SARC	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-6.29	1.54e-09	2.04e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
SARC	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-6.29	1.54e-09	2.04e-06	-0.51	-0.38	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
SARC	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	6.29	1.54e-09	2.04e-06	0.37	0.38	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	6.29	1.54e-09	2.04e-06	0.39	0.38	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
SARC	cis	rs1707322	1	rs1707317	ENSG00000280836.1	AL355480.1	6.29	1.54e-09	2.04e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45581219~45581321:-
SARC	cis	rs10885396	0.967	rs7094871	ENSG00000233547.1	RP11-57H14.2	-6.29	1.54e-09	2.04e-06	-0.37	-0.38	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952395	chr10:112950646~112951875:-
SARC	cis	rs113835537	0.529	rs3892818	ENSG00000255517.5	CTD-3074O7.5	-6.29	1.56e-09	2.06e-06	-0.42	-0.38	Airway imaging phenotypes;	chr11:66472720	chr11:66473490~66480233:-
SARC	cis	rs607541	1	rs8036075	ENSG00000259520.4	CTD-2651B20.3	-6.29	1.56e-09	2.06e-06	-0.54	-0.38	Obesity-related traits;	chr15:45642723	chr15:45251580~45279251:-
SARC	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-6.29	1.56e-09	2.06e-06	-0.4	-0.38	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
SARC	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	6.29	1.57e-09	2.08e-06	0.45	0.38	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
SARC	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	6.29	1.59e-09	2.1e-06	0.37	0.38	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
SARC	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	6.29	1.6e-09	2.11e-06	0.41	0.38	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
SARC	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-6.28	1.6e-09	2.11e-06	-0.44	-0.38	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
SARC	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	6.28	1.6e-09	2.11e-06	0.49	0.38	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
SARC	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	6.28	1.61e-09	2.12e-06	0.54	0.38	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
SARC	cis	rs1707322	1	rs1612419	ENSG00000280836.1	AL355480.1	6.28	1.61e-09	2.13e-06	0.4	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45581219~45581321:-
SARC	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-6.28	1.65e-09	2.17e-06	-0.46	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
SARC	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-6.28	1.65e-09	2.17e-06	-0.46	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
SARC	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-6.28	1.65e-09	2.17e-06	-0.46	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
SARC	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	6.28	1.65e-09	2.17e-06	0.49	0.38	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
SARC	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	6.28	1.65e-09	2.17e-06	0.45	0.38	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
SARC	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-6.28	1.65e-09	2.18e-06	-0.38	-0.38	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
SARC	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-6.28	1.66e-09	2.18e-06	-0.51	-0.38	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
SARC	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-6.28	1.68e-09	2.21e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-6.28	1.68e-09	2.21e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-6.28	1.68e-09	2.21e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-6.28	1.68e-09	2.21e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-6.28	1.68e-09	2.21e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-6.28	1.68e-09	2.21e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-6.28	1.68e-09	2.21e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-6.28	1.68e-09	2.21e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-6.28	1.68e-09	2.21e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-6.28	1.68e-09	2.21e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-6.28	1.68e-09	2.21e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
SARC	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	6.27	1.69e-09	2.22e-06	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
SARC	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-6.27	1.69e-09	2.22e-06	-0.62	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
SARC	cis	rs9322193	0.923	rs9479810	ENSG00000223701.3	RAET1E-AS1	6.27	1.69e-09	2.22e-06	0.4	0.38	Lung cancer;	chr6:149751359	chr6:149884431~149919508:+
SARC	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-6.27	1.69e-09	2.22e-06	-0.39	-0.38	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-6.27	1.69e-09	2.22e-06	-0.39	-0.38	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-6.27	1.69e-09	2.22e-06	-0.39	-0.38	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-6.27	1.69e-09	2.22e-06	-0.39	-0.38	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-6.27	1.69e-09	2.22e-06	-0.39	-0.38	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-6.27	1.69e-09	2.22e-06	-0.39	-0.38	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
SARC	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	6.27	1.7e-09	2.23e-06	0.47	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
SARC	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	6.27	1.7e-09	2.23e-06	0.44	0.38	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
SARC	cis	rs1707322	1	rs785465	ENSG00000280836.1	AL355480.1	-6.27	1.7e-09	2.23e-06	-0.39	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45581219~45581321:-
SARC	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	6.27	1.71e-09	2.24e-06	0.4	0.38	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
SARC	cis	rs7216064	1	rs11870068	ENSG00000265055.1	AC145343.2	6.27	1.73e-09	2.27e-06	0.5	0.38	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67948399	chr17:68096046~68101474:-
SARC	cis	rs6538678	0.963	rs11108310	ENSG00000258343.1	RP11-536G4.2	-6.27	1.74e-09	2.28e-06	-0.45	-0.38	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95795345~95858839:-
SARC	cis	rs916888	0.687	rs199456	ENSG00000261575.2	RP11-259G18.1	6.27	1.75e-09	2.29e-06	0.57	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46267037~46268694:+
SARC	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-6.27	1.75e-09	2.29e-06	-0.5	-0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
SARC	cis	rs1707322	0.964	rs785508	ENSG00000280836.1	AL355480.1	6.27	1.75e-09	2.3e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.964	rs785509	ENSG00000280836.1	AL355480.1	6.27	1.75e-09	2.3e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs9429186	ENSG00000280836.1	AL355480.1	6.27	1.77e-09	2.31e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs785506	ENSG00000280836.1	AL355480.1	6.27	1.77e-09	2.31e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45581219~45581321:-
SARC	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	6.27	1.78e-09	2.33e-06	0.52	0.38	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
SARC	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-6.27	1.78e-09	2.33e-06	-0.6	-0.38	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
SARC	cis	rs1865760	0.865	rs9467650	ENSG00000272462.2	U91328.19	-6.26	1.79e-09	2.34e-06	-0.36	-0.38	Height;	chr6:25958007	chr6:25992662~26001775:+
SARC	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	6.26	1.8e-09	2.35e-06	0.58	0.38	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
SARC	cis	rs2280018	0.581	rs7404524	ENSG00000260735.1	RP11-72I8.1	-6.26	1.8e-09	2.36e-06	-0.34	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15094411~15109197:+
SARC	cis	rs1707322	1	rs1622208	ENSG00000280836.1	AL355480.1	6.26	1.8e-09	2.36e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45581219~45581321:-
SARC	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	6.26	1.8e-09	2.36e-06	0.44	0.38	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
SARC	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	6.26	1.8e-09	2.36e-06	0.44	0.38	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
SARC	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	6.26	1.81e-09	2.36e-06	0.43	0.38	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.962	rs35443312	ENSG00000223701.3	RAET1E-AS1	6.26	1.83e-09	2.38e-06	0.4	0.38	Lung cancer;	chr6:149670625	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs35031906	ENSG00000223701.3	RAET1E-AS1	6.26	1.83e-09	2.38e-06	0.4	0.38	Lung cancer;	chr6:149677438	chr6:149884431~149919508:+
SARC	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	6.26	1.83e-09	2.39e-06	0.48	0.38	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
SARC	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	6.26	1.83e-09	2.39e-06	0.4	0.38	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
SARC	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-6.26	1.83e-09	2.39e-06	-0.46	-0.38	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
SARC	cis	rs2179367	0.887	rs2143076	ENSG00000231760.4	RP11-350J20.5	6.26	1.84e-09	2.4e-06	0.47	0.38	Dupuytren's disease;	chr6:149425315	chr6:149796151~149826294:-
SARC	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-6.26	1.85e-09	2.41e-06	-0.41	-0.38	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
SARC	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-6.26	1.85e-09	2.41e-06	-0.45	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
SARC	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-6.26	1.85e-09	2.41e-06	-0.45	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
SARC	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-6.26	1.85e-09	2.41e-06	-0.45	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
SARC	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-6.26	1.85e-09	2.41e-06	-0.45	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
SARC	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-6.26	1.85e-09	2.42e-06	-0.48	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
SARC	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-6.26	1.85e-09	2.42e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
SARC	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	6.26	1.86e-09	2.43e-06	0.36	0.38	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
SARC	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	6.26	1.87e-09	2.43e-06	0.37	0.38	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
SARC	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	6.26	1.87e-09	2.44e-06	0.42	0.38	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
SARC	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-6.26	1.88e-09	2.45e-06	-0.49	-0.38	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
SARC	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	6.26	1.88e-09	2.45e-06	0.54	0.38	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
SARC	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	6.25	1.89e-09	2.46e-06	0.44	0.38	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	6.25	1.89e-09	2.46e-06	0.44	0.38	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	6.25	1.89e-09	2.46e-06	0.44	0.38	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	6.25	1.89e-09	2.46e-06	0.44	0.38	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
SARC	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	6.25	1.91e-09	2.48e-06	0.37	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
SARC	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	6.25	1.91e-09	2.48e-06	0.41	0.38	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
SARC	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-6.25	1.91e-09	2.49e-06	-0.43	-0.38	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
SARC	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-6.25	1.91e-09	2.49e-06	-0.43	-0.38	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
SARC	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-6.25	1.92e-09	2.49e-06	-0.51	-0.38	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
SARC	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-6.25	1.92e-09	2.49e-06	-0.51	-0.38	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
SARC	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	6.25	1.92e-09	2.49e-06	0.38	0.38	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
SARC	cis	rs1707322	0.963	rs1768815	ENSG00000280836.1	AL355480.1	6.25	1.92e-09	2.5e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45581219~45581321:-
SARC	cis	rs916888	0.773	rs1378358	ENSG00000261575.2	RP11-259G18.1	6.25	1.92e-09	2.5e-06	0.56	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46267037~46268694:+
SARC	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-6.25	1.92e-09	2.5e-06	-0.54	-0.38	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
SARC	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	6.25	1.93e-09	2.51e-06	0.54	0.38	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
SARC	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	6.25	1.93e-09	2.51e-06	0.63	0.38	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
SARC	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	6.25	1.94e-09	2.52e-06	0.42	0.38	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
SARC	cis	rs1707322	0.964	rs6675259	ENSG00000280836.1	AL355480.1	6.25	1.95e-09	2.53e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45581219~45581321:-
SARC	cis	rs1865760	0.865	rs9467647	ENSG00000272462.2	U91328.19	-6.25	1.95e-09	2.54e-06	-0.36	-0.38	Height;	chr6:25957414	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.865	rs10946800	ENSG00000272462.2	U91328.19	-6.25	1.95e-09	2.54e-06	-0.36	-0.38	Height;	chr6:25957545	chr6:25992662~26001775:+
SARC	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-6.25	1.96e-09	2.54e-06	-0.39	-0.38	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-6.25	1.96e-09	2.54e-06	-0.39	-0.38	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
SARC	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-6.25	1.96e-09	2.54e-06	-0.44	-0.38	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
SARC	cis	rs1865760	0.865	rs9467651	ENSG00000272462.2	U91328.19	-6.25	1.96e-09	2.55e-06	-0.36	-0.38	Height;	chr6:25958029	chr6:25992662~26001775:+
SARC	cis	rs1062177	0.547	rs2915818	ENSG00000253921.1	CTB-113P19.3	6.25	1.96e-09	2.55e-06	0.43	0.38	Preschool internalizing problems;	chr5:151735729	chr5:151753992~151767247:+
SARC	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	6.25	1.96e-09	2.55e-06	0.51	0.38	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
SARC	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	6.25	1.97e-09	2.56e-06	0.48	0.38	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
SARC	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	6.25	1.98e-09	2.57e-06	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
SARC	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	6.25	1.99e-09	2.57e-06	0.4	0.38	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
SARC	cis	rs1707322	1	rs2458400	ENSG00000280836.1	AL355480.1	6.25	1.99e-09	2.58e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45581219~45581321:-
SARC	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	6.24	1.99e-09	2.58e-06	0.57	0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
SARC	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	6.24	2e-09	2.59e-06	0.39	0.38	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
SARC	cis	rs1865760	0.827	rs9295680	ENSG00000272462.2	U91328.19	-6.24	2e-09	2.59e-06	-0.36	-0.38	Height;	chr6:25943875	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.827	rs9295681	ENSG00000272462.2	U91328.19	-6.24	2e-09	2.59e-06	-0.36	-0.38	Height;	chr6:25943889	chr6:25992662~26001775:+
SARC	cis	rs6991838	0.702	rs13274205	ENSG00000272010.1	CTD-3025N20.3	6.24	2e-09	2.59e-06	0.4	0.38	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65591850~65592472:-
SARC	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-6.24	2e-09	2.6e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-6.24	2e-09	2.6e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-6.24	2e-09	2.6e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-6.24	2e-09	2.6e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-6.24	2e-09	2.6e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-6.24	2e-09	2.6e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
SARC	cis	rs1865760	0.865	rs9467648	ENSG00000272462.2	U91328.19	-6.24	2e-09	2.6e-06	-0.36	-0.38	Height;	chr6:25957705	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.865	rs9467652	ENSG00000272462.2	U91328.19	-6.24	2e-09	2.6e-06	-0.36	-0.38	Height;	chr6:25958899	chr6:25992662~26001775:+
SARC	cis	rs1707322	1	rs10789486	ENSG00000280836.1	AL355480.1	-6.24	2.01e-09	2.6e-06	-0.39	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45581219~45581321:-
SARC	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	6.24	2.01e-09	2.61e-06	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
SARC	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	6.24	2.02e-09	2.61e-06	0.55	0.38	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
SARC	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	6.24	2.02e-09	2.62e-06	0.53	0.38	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
SARC	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-6.24	2.03e-09	2.62e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-6.24	2.03e-09	2.62e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-6.24	2.03e-09	2.62e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
SARC	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	6.24	2.03e-09	2.62e-06	0.4	0.38	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	6.24	2.04e-09	2.64e-06	0.4	0.38	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
SARC	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	6.24	2.05e-09	2.65e-06	0.44	0.38	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
SARC	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-6.24	2.06e-09	2.66e-06	-0.34	-0.38	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
SARC	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-6.24	2.09e-09	2.69e-06	-0.38	-0.38	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
SARC	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	6.24	2.09e-09	2.69e-06	0.4	0.38	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
SARC	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-6.24	2.09e-09	2.7e-06	-0.36	-0.38	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
SARC	cis	rs5760092	0.618	rs4461358	ENSG00000231271.1	AP000350.8	-6.24	2.1e-09	2.7e-06	-0.48	-0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23949918~23954042:+
SARC	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	6.24	2.1e-09	2.71e-06	0.45	0.38	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
SARC	cis	rs1707322	1	rs785507	ENSG00000280836.1	AL355480.1	6.24	2.1e-09	2.71e-06	0.4	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45581219~45581321:-
SARC	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-6.23	2.1e-09	2.71e-06	-0.51	-0.38	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
SARC	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	6.23	2.12e-09	2.73e-06	0.39	0.38	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	6.23	2.12e-09	2.73e-06	0.39	0.38	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	6.23	2.12e-09	2.73e-06	0.39	0.38	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
SARC	cis	rs17772222	0.917	rs61986664	ENSG00000258983.2	RP11-507K2.2	6.23	2.12e-09	2.73e-06	0.42	0.38	Coronary artery calcification;	chr14:88711251	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.876	rs61986665	ENSG00000258983.2	RP11-507K2.2	6.23	2.12e-09	2.73e-06	0.42	0.38	Coronary artery calcification;	chr14:88711354	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs8018755	ENSG00000258983.2	RP11-507K2.2	6.23	2.12e-09	2.73e-06	0.42	0.38	Coronary artery calcification;	chr14:88714249	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs8018630	ENSG00000258983.2	RP11-507K2.2	6.23	2.12e-09	2.73e-06	0.42	0.38	Coronary artery calcification;	chr14:88714250	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs8020072	ENSG00000258983.2	RP11-507K2.2	6.23	2.12e-09	2.73e-06	0.42	0.38	Coronary artery calcification;	chr14:88714332	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs17260408	ENSG00000258983.2	RP11-507K2.2	6.23	2.12e-09	2.73e-06	0.42	0.38	Coronary artery calcification;	chr14:88715464	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs12589982	ENSG00000258983.2	RP11-507K2.2	6.23	2.12e-09	2.73e-06	0.42	0.38	Coronary artery calcification;	chr14:88716861	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs8021690	ENSG00000258983.2	RP11-507K2.2	6.23	2.12e-09	2.73e-06	0.42	0.38	Coronary artery calcification;	chr14:88717806	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs61986670	ENSG00000258983.2	RP11-507K2.2	6.23	2.12e-09	2.73e-06	0.42	0.38	Coronary artery calcification;	chr14:88730875	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs61986671	ENSG00000258983.2	RP11-507K2.2	6.23	2.12e-09	2.73e-06	0.42	0.38	Coronary artery calcification;	chr14:88732917	chr14:88499334~88515502:+
SARC	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-6.23	2.12e-09	2.73e-06	-0.43	-0.38	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
SARC	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	6.23	2.13e-09	2.74e-06	0.53	0.38	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	6.23	2.14e-09	2.76e-06	0.41	0.38	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
SARC	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	6.23	2.14e-09	2.76e-06	0.39	0.38	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
SARC	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-6.23	2.14e-09	2.76e-06	-0.41	-0.38	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
SARC	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	6.23	2.15e-09	2.76e-06	0.5	0.38	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
SARC	cis	rs77204473	0.744	rs2239678	ENSG00000254851.1	RP11-109L13.1	6.23	2.15e-09	2.77e-06	0.79	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117199880	chr11:117135528~117138582:+
SARC	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	6.23	2.16e-09	2.78e-06	0.54	0.38	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
SARC	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-6.23	2.16e-09	2.78e-06	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
SARC	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-6.23	2.17e-09	2.79e-06	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
SARC	cis	rs4273100	1	rs16960158	ENSG00000228157.4	AC007952.5	6.23	2.18e-09	2.8e-06	0.57	0.38	Schizophrenia;	chr17:19259739	chr17:19092974~19096837:+
SARC	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-6.23	2.18e-09	2.81e-06	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
SARC	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	6.23	2.19e-09	2.81e-06	0.4	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
SARC	cis	rs8081395	0.651	rs1292067	ENSG00000266992.1	DHX40P1	-6.23	2.19e-09	2.81e-06	-0.42	-0.38	White blood cell count;	chr17:59853285	chr17:59976009~60002384:-
SARC	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-6.23	2.19e-09	2.82e-06	-0.44	-0.38	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
SARC	cis	rs56145559	1	rs56145559	ENSG00000163016.8	ALMS1P	6.23	2.2e-09	2.83e-06	0.49	0.38	Schizophrenia;	chr2:73396311	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	6.23	2.21e-09	2.83e-06	0.47	0.38	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
SARC	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-6.23	2.21e-09	2.83e-06	-0.36	-0.38	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
SARC	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	6.23	2.21e-09	2.83e-06	0.46	0.38	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
SARC	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-6.23	2.22e-09	2.84e-06	-0.45	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
SARC	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	6.22	2.23e-09	2.86e-06	0.55	0.38	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
SARC	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-6.22	2.24e-09	2.87e-06	-0.56	-0.38	Depression;	chr6:28192182	chr6:28115628~28116551:+
SARC	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-6.22	2.24e-09	2.87e-06	-0.44	-0.38	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
SARC	cis	rs2179367	0.959	rs2262617	ENSG00000231760.4	RP11-350J20.5	6.22	2.27e-09	2.91e-06	0.48	0.38	Dupuytren's disease;	chr6:149438590	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs12174035	ENSG00000223701.3	RAET1E-AS1	6.22	2.3e-09	2.94e-06	0.39	0.38	Lung cancer;	chr6:149763311	chr6:149884431~149919508:+
SARC	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	6.22	2.3e-09	2.94e-06	0.44	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
SARC	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	6.22	2.3e-09	2.94e-06	0.36	0.38	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
SARC	cis	rs17772222	1	rs7145588	ENSG00000258983.2	RP11-507K2.2	6.22	2.3e-09	2.95e-06	0.4	0.38	Coronary artery calcification;	chr14:88360452	chr14:88499334~88515502:+
SARC	cis	rs17772222	1	rs61977049	ENSG00000258983.2	RP11-507K2.2	6.22	2.3e-09	2.95e-06	0.4	0.38	Coronary artery calcification;	chr14:88360656	chr14:88499334~88515502:+
SARC	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	6.22	2.31e-09	2.95e-06	0.44	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
SARC	cis	rs17772222	1	rs12433464	ENSG00000258983.2	RP11-507K2.2	6.21	2.35e-09	3e-06	0.41	0.38	Coronary artery calcification;	chr14:88357671	chr14:88499334~88515502:+
SARC	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	6.21	2.35e-09	3e-06	0.38	0.38	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
SARC	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-6.21	2.35e-09	3.01e-06	-0.53	-0.38	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
SARC	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	6.21	2.36e-09	3.01e-06	0.48	0.38	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
SARC	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	6.21	2.37e-09	3.03e-06	0.48	0.38	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
SARC	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	6.21	2.37e-09	3.03e-06	0.67	0.38	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
SARC	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	6.21	2.37e-09	3.03e-06	0.67	0.38	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
SARC	cis	rs1707322	1	rs785510	ENSG00000280836.1	AL355480.1	6.21	2.38e-09	3.03e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45581219~45581321:-
SARC	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	6.21	2.38e-09	3.03e-06	0.53	0.38	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
SARC	cis	rs113835537	0.597	rs2305534	ENSG00000255517.5	CTD-3074O7.5	-6.21	2.39e-09	3.05e-06	-0.42	-0.38	Airway imaging phenotypes;	chr11:66545732	chr11:66473490~66480233:-
SARC	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-6.21	2.39e-09	3.05e-06	-0.41	-0.38	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
SARC	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-6.21	2.39e-09	3.05e-06	-0.41	-0.38	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
SARC	cis	rs17772222	1	rs17772288	ENSG00000258983.2	RP11-507K2.2	6.21	2.4e-09	3.06e-06	0.4	0.38	Coronary artery calcification;	chr14:88361022	chr14:88499334~88515502:+
SARC	cis	rs607541	0.764	rs2470114	ENSG00000259520.4	CTD-2651B20.3	-6.21	2.42e-09	3.09e-06	-0.52	-0.38	Obesity-related traits;	chr15:45638524	chr15:45251580~45279251:-
SARC	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	6.21	2.43e-09	3.1e-06	0.43	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
SARC	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	6.21	2.43e-09	3.1e-06	0.39	0.38	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
SARC	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	6.21	2.46e-09	3.14e-06	0.5	0.38	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
SARC	cis	rs2303759	0.918	rs1054770	ENSG00000268686.1	AC010524.2	-6.21	2.47e-09	3.14e-06	-0.46	-0.38	Multiple sclerosis;	chr19:49374858	chr19:49368705~49388081:-
SARC	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	6.21	2.47e-09	3.15e-06	0.51	0.38	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
SARC	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	6.2	2.48e-09	3.15e-06	0.4	0.38	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
SARC	cis	rs12216125	0.801	rs56107510	ENSG00000272810.1	U91328.22	-6.2	2.48e-09	3.15e-06	-0.4	-0.38	Iron status biomarkers;	chr6:25987208	chr6:26013241~26013757:+
SARC	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-6.2	2.48e-09	3.16e-06	-0.6	-0.38	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
SARC	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-6.2	2.49e-09	3.16e-06	-0.5	-0.38	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
SARC	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	6.2	2.49e-09	3.17e-06	0.43	0.38	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
SARC	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-6.2	2.52e-09	3.21e-06	-0.37	-0.38	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
SARC	cis	rs9376098	0.698	rs7774081	ENSG00000232876.1	CTA-212D2.2	-6.2	2.53e-09	3.21e-06	-0.42	-0.38	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135139861	chr6:135055033~135060550:+
SARC	cis	rs10463554	0.824	rs60588319	ENSG00000175749.11	EIF3KP1	6.2	2.55e-09	3.24e-06	0.47	0.38	Parkinson's disease;	chr5:102988656	chr5:103032376~103033031:+
SARC	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	6.2	2.55e-09	3.24e-06	0.47	0.38	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
SARC	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	6.2	2.55e-09	3.24e-06	0.47	0.38	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
SARC	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-6.2	2.55e-09	3.24e-06	-0.39	-0.38	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
SARC	cis	rs77204473	0.744	rs80351364	ENSG00000254851.1	RP11-109L13.1	6.2	2.56e-09	3.24e-06	0.82	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221678	chr11:117135528~117138582:+
SARC	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	6.2	2.56e-09	3.25e-06	0.54	0.38	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
SARC	cis	rs1707322	1	rs785490	ENSG00000280836.1	AL355480.1	6.2	2.56e-09	3.25e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs785493	ENSG00000280836.1	AL355480.1	6.2	2.56e-09	3.25e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.964	rs785496	ENSG00000280836.1	AL355480.1	6.2	2.56e-09	3.25e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs785497	ENSG00000280836.1	AL355480.1	6.2	2.56e-09	3.25e-06	0.39	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45581219~45581321:-
SARC	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	6.2	2.58e-09	3.27e-06	0.55	0.38	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
SARC	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	6.2	2.58e-09	3.27e-06	0.44	0.38	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	6.2	2.58e-09	3.27e-06	0.44	0.38	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	6.2	2.58e-09	3.27e-06	0.44	0.38	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	6.2	2.58e-09	3.27e-06	0.44	0.38	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
SARC	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-6.2	2.59e-09	3.28e-06	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
SARC	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	6.2	2.6e-09	3.29e-06	0.62	0.38	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	6.2	2.6e-09	3.29e-06	0.62	0.38	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	6.2	2.6e-09	3.29e-06	0.62	0.38	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
SARC	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	6.2	2.6e-09	3.29e-06	0.5	0.38	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
SARC	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	6.2	2.6e-09	3.29e-06	0.58	0.38	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
SARC	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-6.2	2.6e-09	3.29e-06	-0.46	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
SARC	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-6.2	2.61e-09	3.3e-06	-0.51	-0.38	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
SARC	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-6.2	2.61e-09	3.31e-06	-0.39	-0.38	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
SARC	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	6.19	2.62e-09	3.31e-06	0.36	0.38	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	6.19	2.62e-09	3.31e-06	0.36	0.38	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
SARC	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-6.19	2.62e-09	3.31e-06	-0.45	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
SARC	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	6.19	2.62e-09	3.32e-06	0.43	0.38	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
SARC	cis	rs7216064	1	rs3206817	ENSG00000265055.1	AC145343.2	6.19	2.62e-09	3.32e-06	0.5	0.38	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896718	chr17:68096046~68101474:-
SARC	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-6.19	2.62e-09	3.32e-06	-0.39	-0.38	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
SARC	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	6.19	2.63e-09	3.32e-06	0.49	0.38	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
SARC	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	6.19	2.63e-09	3.33e-06	0.49	0.38	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
SARC	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-6.19	2.64e-09	3.34e-06	-0.41	-0.38	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
SARC	cis	rs2070074	0.591	rs3739882	ENSG00000230074.1	RP11-195F19.9	6.19	2.65e-09	3.34e-06	0.62	0.38	CTACK levels;	chr9:34653112	chr9:34665665~34681298:+
SARC	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	6.19	2.65e-09	3.35e-06	0.41	0.38	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
SARC	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	6.19	2.67e-09	3.38e-06	0.6	0.38	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	6.19	2.68e-09	3.38e-06	0.62	0.38	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	6.19	2.68e-09	3.38e-06	0.62	0.38	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
SARC	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	6.19	2.68e-09	3.39e-06	0.41	0.38	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
SARC	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-6.19	2.69e-09	3.4e-06	-0.47	-0.38	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
SARC	cis	rs77204473	0.744	rs2239009	ENSG00000254851.1	RP11-109L13.1	6.19	2.69e-09	3.4e-06	0.82	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117219006	chr11:117135528~117138582:+
SARC	cis	rs77204473	0.744	rs78628783	ENSG00000254851.1	RP11-109L13.1	6.19	2.69e-09	3.4e-06	0.82	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221335	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	6.19	2.7e-09	3.4e-06	0.4	0.38	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	6.19	2.7e-09	3.4e-06	0.4	0.38	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.884	rs62439836	ENSG00000223701.3	RAET1E-AS1	6.19	2.7e-09	3.4e-06	0.4	0.38	Lung cancer;	chr6:149669173	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs4869812	ENSG00000223701.3	RAET1E-AS1	6.19	2.7e-09	3.4e-06	0.4	0.38	Lung cancer;	chr6:149669447	chr6:149884431~149919508:+
SARC	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	6.19	2.7e-09	3.4e-06	0.42	0.38	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
SARC	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	6.19	2.7e-09	3.4e-06	0.42	0.38	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
SARC	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	6.19	2.7e-09	3.41e-06	0.57	0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
SARC	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	6.19	2.7e-09	3.41e-06	0.47	0.38	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
SARC	cis	rs6538678	0.833	rs10859966	ENSG00000258343.1	RP11-536G4.2	6.19	2.7e-09	3.41e-06	0.43	0.38	Lupus nephritis in systemic lupus erythematosus;	chr12:95859597	chr12:95795345~95858839:-
SARC	cis	rs7216064	1	rs7216064	ENSG00000265055.1	AC145343.2	6.19	2.73e-09	3.44e-06	0.49	0.38	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67902693	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs62085993	ENSG00000265055.1	AC145343.2	6.19	2.73e-09	3.44e-06	0.49	0.38	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67927036	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs4271626	ENSG00000265055.1	AC145343.2	6.19	2.73e-09	3.44e-06	0.49	0.38	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934017	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs56393562	ENSG00000265055.1	AC145343.2	6.19	2.73e-09	3.44e-06	0.49	0.38	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67937802	chr17:68096046~68101474:-
SARC	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-6.19	2.74e-09	3.45e-06	-0.62	-0.38	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
SARC	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-6.19	2.74e-09	3.45e-06	-0.37	-0.38	Height;	chr11:118737916	chr11:118704607~118750263:+
SARC	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	6.19	2.75e-09	3.46e-06	0.62	0.38	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
SARC	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-6.19	2.75e-09	3.46e-06	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-6.19	2.75e-09	3.46e-06	-0.37	-0.38	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
SARC	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-6.19	2.75e-09	3.46e-06	-0.37	-0.38	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
SARC	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-6.19	2.75e-09	3.46e-06	-0.37	-0.38	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
SARC	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-6.19	2.75e-09	3.46e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-6.19	2.75e-09	3.46e-06	-0.52	-0.38	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
SARC	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-6.19	2.75e-09	3.46e-06	-0.35	-0.38	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
SARC	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-6.19	2.75e-09	3.46e-06	-0.35	-0.38	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
SARC	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-6.19	2.75e-09	3.46e-06	-0.35	-0.38	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
SARC	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	6.18	2.76e-09	3.48e-06	0.47	0.38	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
SARC	cis	rs77204473	0.744	rs2238005	ENSG00000254851.1	RP11-109L13.1	6.18	2.77e-09	3.48e-06	0.82	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117217366	chr11:117135528~117138582:+
SARC	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	6.18	2.77e-09	3.49e-06	0.43	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
SARC	cis	rs17772222	0.917	rs17188228	ENSG00000258983.2	RP11-507K2.2	6.18	2.78e-09	3.49e-06	0.42	0.38	Coronary artery calcification;	chr14:88738921	chr14:88499334~88515502:+
SARC	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-6.18	2.78e-09	3.49e-06	-0.46	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
SARC	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-6.18	2.78e-09	3.5e-06	-0.5	-0.38	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-6.18	2.78e-09	3.5e-06	-0.5	-0.38	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
SARC	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-6.18	2.78e-09	3.5e-06	-0.5	-0.38	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
SARC	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	6.18	2.79e-09	3.51e-06	0.47	0.38	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
SARC	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	6.18	2.8e-09	3.52e-06	0.47	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
SARC	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-6.18	2.82e-09	3.54e-06	-0.41	-0.38	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-6.18	2.82e-09	3.54e-06	-0.41	-0.38	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-6.18	2.82e-09	3.54e-06	-0.41	-0.38	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-6.18	2.82e-09	3.54e-06	-0.41	-0.38	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-6.18	2.82e-09	3.54e-06	-0.41	-0.38	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
SARC	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-6.18	2.84e-09	3.57e-06	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
SARC	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	6.18	2.85e-09	3.58e-06	0.43	0.38	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	6.18	2.85e-09	3.58e-06	0.43	0.38	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	6.18	2.85e-09	3.58e-06	0.43	0.38	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.962	rs2151912	ENSG00000223701.3	RAET1E-AS1	6.18	2.87e-09	3.6e-06	0.41	0.38	Lung cancer;	chr6:149831772	chr6:149884431~149919508:+
SARC	cis	rs73186030	1	rs55838400	ENSG00000272758.4	RP11-299J3.8	6.18	2.89e-09	3.62e-06	0.51	0.38	Serum parathyroid hormone levels;	chr3:122313446	chr3:122416207~122443180:+
SARC	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	6.18	2.9e-09	3.63e-06	0.62	0.38	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
SARC	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	6.18	2.91e-09	3.64e-06	0.45	0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
SARC	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	6.18	2.91e-09	3.64e-06	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
SARC	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-6.18	2.91e-09	3.64e-06	-0.41	-0.38	Migraine;	chr4:56852087	chr4:56960927~56961373:-
SARC	cis	rs9322193	0.962	rs7745915	ENSG00000223701.3	RAET1E-AS1	6.18	2.91e-09	3.65e-06	0.4	0.38	Lung cancer;	chr6:149834111	chr6:149884431~149919508:+
SARC	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	6.17	2.92e-09	3.65e-06	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
SARC	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	6.17	2.93e-09	3.67e-06	0.44	0.37	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	6.17	2.93e-09	3.67e-06	0.44	0.37	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	6.17	2.93e-09	3.67e-06	0.44	0.37	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	6.17	2.93e-09	3.67e-06	0.44	0.37	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	6.17	2.93e-09	3.67e-06	0.44	0.37	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
SARC	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	6.17	2.93e-09	3.67e-06	0.53	0.37	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
SARC	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	6.17	2.94e-09	3.68e-06	0.37	0.37	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
SARC	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-6.17	2.94e-09	3.68e-06	-0.5	-0.37	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
SARC	cis	rs2836950	0.52	rs59916147	ENSG00000255568.3	BRWD1-AS2	-6.17	2.95e-09	3.69e-06	-0.34	-0.37	Menarche (age at onset);	chr21:39262776	chr21:39313935~39314962:+
SARC	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-6.17	2.95e-09	3.69e-06	-0.51	-0.37	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
SARC	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	6.17	2.96e-09	3.7e-06	0.45	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
SARC	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-6.17	2.97e-09	3.71e-06	-0.35	-0.37	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
SARC	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-6.17	2.97e-09	3.71e-06	-0.35	-0.37	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
SARC	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-6.17	2.97e-09	3.71e-06	-0.35	-0.37	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
SARC	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-6.17	2.97e-09	3.71e-06	-0.35	-0.37	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
SARC	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-6.17	2.97e-09	3.71e-06	-0.35	-0.37	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
SARC	cis	rs7809950	0.798	rs10281535	ENSG00000238832.1	snoU109	6.17	2.97e-09	3.71e-06	0.44	0.37	Coronary artery disease;	chr7:107589173	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.954	rs2189839	ENSG00000238832.1	snoU109	6.17	2.97e-09	3.71e-06	0.44	0.37	Coronary artery disease;	chr7:107589581	chr7:107603363~107603507:+
SARC	cis	rs1865760	0.927	rs6915834	ENSG00000272462.2	U91328.19	-6.17	2.98e-09	3.72e-06	-0.36	-0.37	Height;	chr6:25935199	chr6:25992662~26001775:+
SARC	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-6.17	3e-09	3.74e-06	-0.39	-0.37	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
SARC	cis	rs10463554	1	rs6596529	ENSG00000175749.11	EIF3KP1	6.17	3e-09	3.74e-06	0.46	0.37	Parkinson's disease;	chr5:102981338	chr5:103032376~103033031:+
SARC	cis	rs17772222	1	rs12587386	ENSG00000258983.2	RP11-507K2.2	6.17	3.01e-09	3.75e-06	0.4	0.37	Coronary artery calcification;	chr14:88361420	chr14:88499334~88515502:+
SARC	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-6.17	3.01e-09	3.76e-06	-0.43	-0.37	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
SARC	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-6.17	3.02e-09	3.76e-06	-0.42	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
SARC	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-6.17	3.02e-09	3.76e-06	-0.42	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
SARC	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-6.17	3.03e-09	3.77e-06	-0.4	-0.37	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
SARC	cis	rs1865760	0.892	rs2328903	ENSG00000272462.2	U91328.19	-6.17	3.05e-09	3.8e-06	-0.36	-0.37	Height;	chr6:25935537	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.892	rs6456705	ENSG00000272462.2	U91328.19	-6.17	3.05e-09	3.8e-06	-0.36	-0.37	Height;	chr6:25935828	chr6:25992662~26001775:+
SARC	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-6.17	3.06e-09	3.81e-06	-0.34	-0.37	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
SARC	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-6.17	3.06e-09	3.81e-06	-0.38	-0.37	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
SARC	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-6.17	3.06e-09	3.81e-06	-0.43	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
SARC	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	6.17	3.06e-09	3.82e-06	0.43	0.37	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
SARC	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-6.17	3.07e-09	3.82e-06	-0.35	-0.37	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
SARC	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	6.17	3.08e-09	3.83e-06	0.42	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
SARC	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-6.17	3.08e-09	3.83e-06	-0.51	-0.37	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-6.17	3.08e-09	3.83e-06	-0.51	-0.37	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
SARC	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-6.16	3.08e-09	3.83e-06	-0.41	-0.37	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
SARC	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	6.16	3.09e-09	3.84e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
SARC	cis	rs10463554	0.927	rs62362489	ENSG00000175749.11	EIF3KP1	6.16	3.1e-09	3.85e-06	0.48	0.37	Parkinson's disease;	chr5:102909841	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	6.16	3.1e-09	3.86e-06	0.47	0.37	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
SARC	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-6.16	3.11e-09	3.87e-06	-0.4	-0.37	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
SARC	cis	rs17772222	0.917	rs1956406	ENSG00000258983.2	RP11-507K2.2	6.16	3.11e-09	3.87e-06	0.41	0.37	Coronary artery calcification;	chr14:88749711	chr14:88499334~88515502:+
SARC	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	6.16	3.12e-09	3.87e-06	0.43	0.37	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	6.16	3.12e-09	3.87e-06	0.43	0.37	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	6.16	3.12e-09	3.87e-06	0.43	0.37	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	6.16	3.12e-09	3.87e-06	0.43	0.37	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	6.16	3.12e-09	3.87e-06	0.43	0.37	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
SARC	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	6.16	3.12e-09	3.88e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
SARC	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	6.16	3.12e-09	3.88e-06	0.62	0.37	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
SARC	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	6.16	3.13e-09	3.88e-06	0.38	0.37	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
SARC	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-6.16	3.13e-09	3.89e-06	-0.46	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
SARC	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-6.16	3.13e-09	3.89e-06	-0.46	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
SARC	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-6.16	3.14e-09	3.9e-06	-0.4	-0.37	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
SARC	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-6.16	3.14e-09	3.9e-06	-0.49	-0.37	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
SARC	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	6.16	3.15e-09	3.91e-06	0.36	0.37	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
SARC	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	6.16	3.15e-09	3.91e-06	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
SARC	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	6.16	3.17e-09	3.93e-06	0.43	0.37	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
SARC	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-6.16	3.19e-09	3.95e-06	-0.54	-0.37	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
SARC	cis	rs113835537	0.529	rs2305532	ENSG00000255517.5	CTD-3074O7.5	-6.16	3.2e-09	3.96e-06	-0.41	-0.37	Airway imaging phenotypes;	chr11:66531123	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs2305533	ENSG00000255517.5	CTD-3074O7.5	-6.16	3.2e-09	3.96e-06	-0.41	-0.37	Airway imaging phenotypes;	chr11:66531152	chr11:66473490~66480233:-
SARC	cis	rs2117029	0.767	rs12580349	ENSG00000258017.1	RP11-386G11.10	6.16	3.2e-09	3.96e-06	0.4	0.37	Intelligence (multi-trait analysis);	chr12:49042941	chr12:49127782~49147869:+
SARC	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	6.16	3.2e-09	3.97e-06	0.44	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
SARC	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	6.16	3.21e-09	3.98e-06	0.42	0.37	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
SARC	cis	rs916888	0.773	rs169201	ENSG00000261575.2	RP11-259G18.1	6.16	3.23e-09	3.99e-06	0.56	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46267037~46268694:+
SARC	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	6.16	3.23e-09	4e-06	0.61	0.37	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
SARC	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	6.16	3.23e-09	4e-06	0.37	0.37	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
SARC	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-6.16	3.24e-09	4.01e-06	-0.45	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
SARC	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	6.16	3.25e-09	4.01e-06	0.47	0.37	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
SARC	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-6.16	3.25e-09	4.02e-06	-0.37	-0.37	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
SARC	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-6.16	3.25e-09	4.02e-06	-0.37	-0.37	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
SARC	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-6.16	3.25e-09	4.02e-06	-0.37	-0.37	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
SARC	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-6.16	3.25e-09	4.02e-06	-0.37	-0.37	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
SARC	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	6.15	3.27e-09	4.04e-06	0.43	0.37	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
SARC	cis	rs7615952	0.932	rs1976458	ENSG00000248787.1	RP11-666A20.4	-6.15	3.31e-09	4.09e-06	-0.6	-0.37	Blood pressure (smoking interaction);	chr3:125928669	chr3:125908005~125910272:-
SARC	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	6.15	3.32e-09	4.09e-06	0.48	0.37	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
SARC	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	6.15	3.32e-09	4.09e-06	0.48	0.37	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
SARC	cis	rs1865760	0.786	rs2164487	ENSG00000272462.2	U91328.19	-6.15	3.32e-09	4.1e-06	-0.36	-0.37	Height;	chr6:25950572	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.865	rs6929805	ENSG00000272462.2	U91328.19	-6.15	3.32e-09	4.1e-06	-0.36	-0.37	Height;	chr6:25950606	chr6:25992662~26001775:+
SARC	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-6.15	3.33e-09	4.11e-06	-0.41	-0.37	Migraine;	chr4:56850720	chr4:56960927~56961373:-
SARC	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	6.15	3.34e-09	4.12e-06	0.35	0.37	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	6.15	3.34e-09	4.12e-06	0.35	0.37	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	6.15	3.34e-09	4.12e-06	0.35	0.37	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	6.15	3.34e-09	4.12e-06	0.35	0.37	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	6.15	3.34e-09	4.12e-06	0.35	0.37	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	6.15	3.34e-09	4.12e-06	0.35	0.37	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
SARC	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-6.15	3.35e-09	4.13e-06	-0.48	-0.37	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
SARC	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	6.15	3.35e-09	4.13e-06	0.42	0.37	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
SARC	cis	rs4938303	0.718	rs10892023	ENSG00000254851.1	RP11-109L13.1	-6.15	3.35e-09	4.13e-06	-0.48	-0.37	Triglycerides;	chr11:116727532	chr11:117135528~117138582:+
SARC	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-6.15	3.37e-09	4.15e-06	-0.35	-0.37	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
SARC	cis	rs1707322	1	rs785469	ENSG00000280836.1	AL355480.1	6.15	3.37e-09	4.16e-06	0.38	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs785468	ENSG00000280836.1	AL355480.1	6.15	3.37e-09	4.16e-06	0.38	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45581219~45581321:-
SARC	cis	rs113835537	0.529	rs3816492	ENSG00000255517.5	CTD-3074O7.5	-6.15	3.38e-09	4.16e-06	-0.42	-0.37	Airway imaging phenotypes;	chr11:66529892	chr11:66473490~66480233:-
SARC	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	6.15	3.38e-09	4.17e-06	0.35	0.37	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
SARC	cis	rs1930961	0.702	rs1930966	ENSG00000100058.11	CRYBB2P1	6.15	3.39e-09	4.18e-06	0.77	0.37	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25448105~25520854:+
SARC	cis	rs641862	1	rs641862	ENSG00000229152.2	ANKRD10-IT1	6.15	3.39e-09	4.18e-06	0.46	0.37	Obesity-related traits;	chr13:110137885	chr13:110894639~110899172:-
SARC	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	6.15	3.4e-09	4.19e-06	0.44	0.37	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
SARC	cis	rs1707322	0.964	rs785499	ENSG00000280836.1	AL355480.1	6.15	3.4e-09	4.19e-06	0.39	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45581219~45581321:-
SARC	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	6.15	3.4e-09	4.19e-06	0.68	0.37	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	6.15	3.4e-09	4.19e-06	0.68	0.37	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	6.15	3.4e-09	4.19e-06	0.68	0.37	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
SARC	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-6.15	3.41e-09	4.19e-06	-0.37	-0.37	Height;	chr11:118747911	chr11:118704607~118750263:+
SARC	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-6.15	3.42e-09	4.21e-06	-0.45	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
SARC	cis	rs113835537	0.529	rs11227525	ENSG00000255517.5	CTD-3074O7.5	-6.14	3.43e-09	4.22e-06	-0.42	-0.37	Airway imaging phenotypes;	chr11:66540594	chr11:66473490~66480233:-
SARC	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	6.14	3.45e-09	4.24e-06	0.46	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	6.14	3.45e-09	4.24e-06	0.46	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
SARC	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	6.14	3.47e-09	4.26e-06	0.39	0.37	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
SARC	cis	rs113835537	0.529	rs3179961	ENSG00000255517.5	CTD-3074O7.5	-6.14	3.48e-09	4.28e-06	-0.42	-0.37	Airway imaging phenotypes;	chr11:66476983	chr11:66473490~66480233:-
SARC	cis	rs1862618	0.529	rs978406	ENSG00000271828.1	CTD-2310F14.1	-6.14	3.48e-09	4.28e-06	-0.6	-0.37	Initial pursuit acceleration;	chr5:56963981	chr5:56927874~56929573:+
SARC	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-6.14	3.49e-09	4.28e-06	-0.36	-0.37	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
SARC	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	6.14	3.5e-09	4.29e-06	0.41	0.37	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
SARC	cis	rs7615952	0.866	rs1976459	ENSG00000248787.1	RP11-666A20.4	-6.14	3.52e-09	4.32e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125928643	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.673	rs3811677	ENSG00000248787.1	RP11-666A20.4	-6.14	3.52e-09	4.32e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125929237	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.932	rs3811679	ENSG00000248787.1	RP11-666A20.4	-6.14	3.52e-09	4.32e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125929440	chr3:125908005~125910272:-
SARC	cis	rs9322193	1	rs9322193	ENSG00000223701.3	RAET1E-AS1	6.14	3.52e-09	4.32e-06	0.39	0.37	Lung cancer;	chr6:149598007	chr6:149884431~149919508:+
SARC	cis	rs4713118	0.868	rs10484401	ENSG00000219392.1	RP1-265C24.5	6.14	3.52e-09	4.33e-06	0.58	0.37	Parkinson's disease;	chr6:27778811	chr6:28115628~28116551:+
SARC	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	6.14	3.53e-09	4.33e-06	0.41	0.37	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
SARC	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	6.14	3.53e-09	4.33e-06	0.51	0.37	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
SARC	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-6.14	3.53e-09	4.33e-06	-0.41	-0.37	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
SARC	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	6.14	3.54e-09	4.34e-06	0.42	0.37	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
SARC	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-6.14	3.54e-09	4.34e-06	-0.35	-0.37	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
SARC	cis	rs6538678	0.864	rs10777749	ENSG00000258343.1	RP11-536G4.2	-6.14	3.55e-09	4.35e-06	-0.44	-0.37	Lupus nephritis in systemic lupus erythematosus;	chr12:95883182	chr12:95795345~95858839:-
SARC	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	6.14	3.55e-09	4.35e-06	0.41	0.37	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
SARC	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	6.14	3.55e-09	4.35e-06	0.66	0.37	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
SARC	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	6.14	3.55e-09	4.35e-06	0.44	0.37	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
SARC	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-6.14	3.56e-09	4.36e-06	-0.42	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
SARC	cis	rs77204473	0.744	rs80353869	ENSG00000254851.1	RP11-109L13.1	6.14	3.56e-09	4.37e-06	0.87	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117177406	chr11:117135528~117138582:+
SARC	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	6.14	3.57e-09	4.37e-06	0.43	0.37	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
SARC	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-6.14	3.61e-09	4.42e-06	-0.34	-0.37	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
SARC	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-6.14	3.62e-09	4.42e-06	-0.37	-0.37	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
SARC	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	6.14	3.62e-09	4.42e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-6.14	3.62e-09	4.42e-06	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-6.14	3.62e-09	4.42e-06	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
SARC	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	6.13	3.63e-09	4.43e-06	0.42	0.37	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
SARC	cis	rs641862	1	rs641862	ENSG00000277767.1	RP11-365P13.5	6.13	3.66e-09	4.47e-06	0.56	0.37	Obesity-related traits;	chr13:110137885	chr13:110916004~110917827:+
SARC	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-6.13	3.67e-09	4.47e-06	-0.35	-0.37	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
SARC	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-6.13	3.67e-09	4.47e-06	-0.35	-0.37	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
SARC	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-6.13	3.67e-09	4.47e-06	-0.35	-0.37	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
SARC	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-6.13	3.67e-09	4.47e-06	-0.35	-0.37	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
SARC	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	6.13	3.67e-09	4.48e-06	0.57	0.37	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
SARC	cis	rs4938303	0.718	rs3212282	ENSG00000254851.1	RP11-109L13.1	-6.13	3.68e-09	4.49e-06	-0.49	-0.37	Triglycerides;	chr11:116731229	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.962	rs3763162	ENSG00000223701.3	RAET1E-AS1	-6.13	3.69e-09	4.5e-06	-0.4	-0.37	Lung cancer;	chr6:149819674	chr6:149884431~149919508:+
SARC	cis	rs17772222	0.917	rs12431548	ENSG00000258983.2	RP11-507K2.2	6.13	3.71e-09	4.52e-06	0.42	0.37	Coronary artery calcification;	chr14:88635826	chr14:88499334~88515502:+
SARC	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	6.13	3.72e-09	4.53e-06	0.4	0.37	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
SARC	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	6.13	3.73e-09	4.54e-06	0.35	0.37	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
SARC	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	6.13	3.73e-09	4.54e-06	0.46	0.37	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
SARC	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	6.13	3.74e-09	4.56e-06	0.54	0.37	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
SARC	cis	rs77204473	0.744	rs12418705	ENSG00000254851.1	RP11-109L13.1	6.13	3.75e-09	4.56e-06	0.82	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117213680	chr11:117135528~117138582:+
SARC	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	6.13	3.75e-09	4.56e-06	0.62	0.37	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
SARC	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	6.13	3.76e-09	4.58e-06	0.44	0.37	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	6.13	3.76e-09	4.58e-06	0.44	0.37	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
SARC	cis	rs17772222	0.917	rs2224333	ENSG00000258983.2	RP11-507K2.2	6.13	3.76e-09	4.58e-06	0.42	0.37	Coronary artery calcification;	chr14:88768748	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs12590826	ENSG00000258983.2	RP11-507K2.2	6.13	3.76e-09	4.58e-06	0.42	0.37	Coronary artery calcification;	chr14:88769357	chr14:88499334~88515502:+
SARC	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	6.13	3.77e-09	4.58e-06	0.49	0.37	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
SARC	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	6.13	3.79e-09	4.6e-06	0.42	0.37	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
SARC	cis	rs7615952	0.736	rs11921945	ENSG00000171084.14	FAM86JP	6.13	3.79e-09	4.61e-06	0.6	0.37	Blood pressure (smoking interaction);	chr3:125924876	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	6.13	3.79e-09	4.61e-06	0.6	0.37	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
SARC	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	6.13	3.8e-09	4.62e-06	0.43	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
SARC	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-6.13	3.81e-09	4.63e-06	-0.38	-0.37	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
SARC	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-6.13	3.82e-09	4.64e-06	-0.35	-0.37	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
SARC	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-6.12	3.83e-09	4.65e-06	-0.5	-0.37	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
SARC	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	6.12	3.83e-09	4.66e-06	0.6	0.37	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
SARC	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-6.12	3.85e-09	4.68e-06	-0.42	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
SARC	cis	rs6991838	0.733	rs7822627	ENSG00000272010.1	CTD-3025N20.3	6.12	3.91e-09	4.74e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65591850~65592472:-
SARC	cis	rs6496044	0.507	rs62022863	ENSG00000202081.1	RNU6-1280P	-6.12	3.91e-09	4.74e-06	-0.42	-0.37	Interstitial lung disease;	chr15:85618822	chr15:85651522~85651628:-
SARC	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	6.12	3.92e-09	4.76e-06	0.51	0.37	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
SARC	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-6.12	3.93e-09	4.77e-06	-0.36	-0.37	Height;	chr11:118786602	chr11:118704607~118750263:+
SARC	cis	rs1865760	0.534	rs2032444	ENSG00000272462.2	U91328.19	-6.12	3.96e-09	4.8e-06	-0.38	-0.37	Height;	chr6:26046516	chr6:25992662~26001775:+
SARC	cis	rs17772222	1	rs12589467	ENSG00000258983.2	RP11-507K2.2	6.12	3.96e-09	4.8e-06	0.4	0.37	Coronary artery calcification;	chr14:88357239	chr14:88499334~88515502:+
SARC	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	6.12	3.97e-09	4.81e-06	0.44	0.37	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
SARC	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	6.12	3.97e-09	4.81e-06	0.43	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	6.12	3.97e-09	4.81e-06	0.44	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
SARC	cis	rs17772222	0.793	rs7143853	ENSG00000258983.2	RP11-507K2.2	6.12	3.97e-09	4.81e-06	0.44	0.37	Coronary artery calcification;	chr14:88578477	chr14:88499334~88515502:+
SARC	cis	rs7615952	0.932	rs13086087	ENSG00000248787.1	RP11-666A20.4	-6.12	3.99e-09	4.84e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125927438	chr3:125908005~125910272:-
SARC	cis	rs9376098	0.698	rs6924521	ENSG00000232876.1	CTA-212D2.2	-6.12	4e-09	4.84e-06	-0.41	-0.37	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146277	chr6:135055033~135060550:+
SARC	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	6.12	4.02e-09	4.87e-06	0.41	0.37	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
SARC	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	6.11	4.04e-09	4.89e-06	0.83	0.37	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
SARC	cis	rs1865760	0.865	rs9393677	ENSG00000272462.2	U91328.19	-6.11	4.04e-09	4.89e-06	-0.35	-0.37	Height;	chr6:25945587	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.865	rs9393678	ENSG00000272462.2	U91328.19	-6.11	4.04e-09	4.89e-06	-0.35	-0.37	Height;	chr6:25945591	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.865	rs9467641	ENSG00000272462.2	U91328.19	-6.11	4.04e-09	4.89e-06	-0.35	-0.37	Height;	chr6:25947008	chr6:25992662~26001775:+
SARC	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	6.11	4.05e-09	4.9e-06	0.35	0.37	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
SARC	cis	rs113835537	0.597	rs11227527	ENSG00000255517.5	CTD-3074O7.5	-6.11	4.06e-09	4.91e-06	-0.41	-0.37	Airway imaging phenotypes;	chr11:66545555	chr11:66473490~66480233:-
SARC	cis	rs62103177	0.565	rs473119	ENSG00000261126.6	RP11-795F19.1	-6.11	4.08e-09	4.94e-06	-0.37	-0.37	Opioid sensitivity;	chr18:80091557	chr18:80046900~80095482:+
SARC	cis	rs17772222	0.917	rs61984737	ENSG00000258983.2	RP11-507K2.2	6.11	4.08e-09	4.94e-06	0.42	0.37	Coronary artery calcification;	chr14:88637028	chr14:88499334~88515502:+
SARC	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	6.11	4.1e-09	4.96e-06	0.4	0.37	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	6.11	4.1e-09	4.96e-06	0.4	0.37	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
SARC	cis	rs113835537	0.529	rs117112180	ENSG00000255517.5	CTD-3074O7.5	-6.11	4.11e-09	4.97e-06	-0.42	-0.37	Airway imaging phenotypes;	chr11:66525802	chr11:66473490~66480233:-
SARC	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	6.11	4.11e-09	4.97e-06	0.42	0.37	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
SARC	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-6.11	4.13e-09	4.98e-06	-0.47	-0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
SARC	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	6.11	4.14e-09	5e-06	0.5	0.37	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
SARC	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	6.11	4.14e-09	5e-06	0.5	0.37	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
SARC	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-6.11	4.15e-09	5.01e-06	-0.42	-0.37	QT interval;	chr16:28824579	chr16:28700294~28701540:-
SARC	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-6.11	4.15e-09	5.01e-06	-0.6	-0.37	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
SARC	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-6.11	4.15e-09	5.01e-06	-0.6	-0.37	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
SARC	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-6.11	4.15e-09	5.01e-06	-0.48	-0.37	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
SARC	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	6.11	4.16e-09	5.02e-06	0.43	0.37	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
SARC	cis	rs6496044	0.507	rs410522	ENSG00000202081.1	RNU6-1280P	-6.11	4.17e-09	5.03e-06	-0.41	-0.37	Interstitial lung disease;	chr15:85663813	chr15:85651522~85651628:-
SARC	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-6.11	4.17e-09	5.03e-06	-0.47	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
SARC	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-6.11	4.18e-09	5.04e-06	-0.4	-0.37	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
SARC	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-6.11	4.19e-09	5.05e-06	-0.6	-0.37	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
SARC	cis	rs2729354	0.729	rs2258835	ENSG00000265566.2	RN7SL605P	-6.11	4.19e-09	5.05e-06	-0.51	-0.37	Blood protein levels;	chr11:57476115	chr11:57528085~57528365:-
SARC	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-6.11	4.19e-09	5.05e-06	-0.4	-0.37	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
SARC	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-6.11	4.21e-09	5.07e-06	-0.6	-0.37	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
SARC	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-6.11	4.22e-09	5.08e-06	-0.34	-0.37	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
SARC	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-6.11	4.22e-09	5.08e-06	-0.51	-0.37	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
SARC	cis	rs916888	0.773	rs538628	ENSG00000261575.2	RP11-259G18.1	6.11	4.23e-09	5.09e-06	0.54	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46267037~46268694:+
SARC	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	6.11	4.23e-09	5.09e-06	0.43	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
SARC	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	6.11	4.24e-09	5.1e-06	0.51	0.37	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
SARC	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	6.11	4.25e-09	5.11e-06	0.58	0.37	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
SARC	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-6.1	4.27e-09	5.13e-06	-0.44	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
SARC	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-6.1	4.28e-09	5.15e-06	-0.36	-0.37	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
SARC	cis	rs17772222	0.876	rs58655091	ENSG00000258983.2	RP11-507K2.2	6.1	4.31e-09	5.18e-06	0.41	0.37	Coronary artery calcification;	chr14:88748567	chr14:88499334~88515502:+
SARC	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	6.1	4.31e-09	5.18e-06	0.43	0.37	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	6.1	4.31e-09	5.18e-06	0.43	0.37	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	6.1	4.31e-09	5.18e-06	0.43	0.37	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	6.1	4.31e-09	5.18e-06	0.43	0.37	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	6.1	4.31e-09	5.18e-06	0.43	0.37	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	6.1	4.31e-09	5.18e-06	0.43	0.37	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	6.1	4.31e-09	5.18e-06	0.43	0.37	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
SARC	cis	rs11155671	0.546	rs1999633	ENSG00000223701.3	RAET1E-AS1	6.1	4.32e-09	5.19e-06	0.47	0.37	Testicular germ cell tumor;	chr6:149866576	chr6:149884431~149919508:+
SARC	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	6.1	4.33e-09	5.2e-06	0.54	0.37	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
SARC	cis	rs7216064	0.906	rs78452260	ENSG00000265055.1	AC145343.2	6.1	4.35e-09	5.22e-06	0.5	0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67852406	chr17:68096046~68101474:-
SARC	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	6.1	4.37e-09	5.24e-06	0.54	0.37	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
SARC	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	6.1	4.37e-09	5.24e-06	0.54	0.37	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
SARC	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-6.1	4.37e-09	5.25e-06	-0.47	-0.37	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
SARC	cis	rs1865760	0.827	rs9461227	ENSG00000272462.2	U91328.19	-6.1	4.39e-09	5.27e-06	-0.35	-0.37	Height;	chr6:25960587	chr6:25992662~26001775:+
SARC	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	6.1	4.39e-09	5.27e-06	0.4	0.37	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	6.1	4.4e-09	5.28e-06	0.42	0.37	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
SARC	cis	rs7615952	0.8	rs13086460	ENSG00000248787.1	RP11-666A20.4	-6.1	4.4e-09	5.28e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125927574	chr3:125908005~125910272:-
SARC	cis	rs10463554	0.892	rs10463988	ENSG00000175749.11	EIF3KP1	6.1	4.44e-09	5.32e-06	0.46	0.37	Parkinson's disease;	chr5:102913595	chr5:103032376~103033031:+
SARC	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-6.1	4.45e-09	5.33e-06	-0.44	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
SARC	cis	rs1823913	1	rs13019004	ENSG00000227542.1	AC092614.2	6.1	4.48e-09	5.37e-06	0.42	0.37	Obesity-related traits;	chr2:191245493	chr2:191229165~191246172:-
SARC	cis	rs10463554	0.927	rs6862616	ENSG00000175749.11	EIF3KP1	6.1	4.49e-09	5.38e-06	0.47	0.37	Parkinson's disease;	chr5:102910334	chr5:103032376~103033031:+
SARC	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-6.09	4.51e-09	5.4e-06	-0.46	-0.37	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
SARC	cis	rs7216064	1	rs6504555	ENSG00000278219.1	AC145343.1	6.09	4.53e-09	5.42e-06	0.44	0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67944611	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs56404791	ENSG00000278219.1	AC145343.1	-6.09	4.53e-09	5.42e-06	-0.44	-0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896903	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs55896768	ENSG00000278219.1	AC145343.1	-6.09	4.53e-09	5.42e-06	-0.44	-0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67917242	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.953	rs4791300	ENSG00000278219.1	AC145343.1	-6.09	4.53e-09	5.42e-06	-0.44	-0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934656	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs4791299	ENSG00000278219.1	AC145343.1	-6.09	4.53e-09	5.42e-06	-0.44	-0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934821	chr17:68101538~68101639:+
SARC	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	6.09	4.53e-09	5.42e-06	0.36	0.37	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
SARC	cis	rs1865760	0.929	rs2876693	ENSG00000272462.2	U91328.19	-6.09	4.53e-09	5.42e-06	-0.35	-0.37	Height;	chr6:25954206	chr6:25992662~26001775:+
SARC	cis	rs7615952	0.512	rs34085484	ENSG00000171084.14	FAM86JP	6.09	4.53e-09	5.42e-06	0.54	0.37	Blood pressure (smoking interaction);	chr3:125825343	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.575	rs35949599	ENSG00000171084.14	FAM86JP	6.09	4.53e-09	5.42e-06	0.54	0.37	Blood pressure (smoking interaction);	chr3:125825359	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.608	rs35668111	ENSG00000171084.14	FAM86JP	6.09	4.53e-09	5.42e-06	0.54	0.37	Blood pressure (smoking interaction);	chr3:125825792	chr3:125916620~125930024:+
SARC	cis	rs1707322	0.896	rs785512	ENSG00000280836.1	AL355480.1	6.09	4.54e-09	5.43e-06	0.38	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45581219~45581321:-
SARC	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	6.09	4.58e-09	5.48e-06	0.41	0.37	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
SARC	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	6.09	4.59e-09	5.49e-06	0.54	0.37	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
SARC	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	6.09	4.59e-09	5.49e-06	0.44	0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
SARC	cis	rs7615952	0.932	rs13065725	ENSG00000248787.1	RP11-666A20.4	-6.09	4.59e-09	5.49e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125913446	chr3:125908005~125910272:-
SARC	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	6.09	4.6e-09	5.5e-06	0.42	0.37	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
SARC	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-6.09	4.61e-09	5.5e-06	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-6.09	4.61e-09	5.5e-06	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-6.09	4.61e-09	5.5e-06	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-6.09	4.61e-09	5.5e-06	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-6.09	4.61e-09	5.5e-06	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-6.09	4.61e-09	5.5e-06	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-6.09	4.61e-09	5.5e-06	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-6.09	4.61e-09	5.5e-06	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-6.09	4.61e-09	5.5e-06	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-6.09	4.61e-09	5.5e-06	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
SARC	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	6.09	4.61e-09	5.5e-06	0.55	0.37	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
SARC	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	6.09	4.61e-09	5.51e-06	0.47	0.37	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
SARC	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-6.09	4.62e-09	5.51e-06	-0.38	-0.37	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
SARC	cis	rs77204473	0.744	rs117901629	ENSG00000254851.1	RP11-109L13.1	6.09	4.62e-09	5.51e-06	0.79	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008963	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	6.09	4.62e-09	5.52e-06	0.4	0.37	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
SARC	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-6.09	4.63e-09	5.52e-06	-0.35	-0.37	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
SARC	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	6.09	4.63e-09	5.53e-06	0.42	0.37	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
SARC	cis	rs1707322	1	rs1707337	ENSG00000280836.1	AL355480.1	6.09	4.65e-09	5.55e-06	0.38	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs1768807	ENSG00000280836.1	AL355480.1	6.09	4.65e-09	5.55e-06	0.38	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45581219~45581321:-
SARC	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-6.09	4.66e-09	5.56e-06	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
SARC	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-6.09	4.67e-09	5.57e-06	-0.62	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
SARC	cis	rs916888	0.773	rs199439	ENSG00000261575.2	RP11-259G18.1	6.09	4.69e-09	5.59e-06	0.53	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46267037~46268694:+
SARC	cis	rs1865760	0.865	rs2164485	ENSG00000272462.2	U91328.19	-6.09	4.74e-09	5.65e-06	-0.35	-0.37	Height;	chr6:25951878	chr6:25992662~26001775:+
SARC	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	6.08	4.77e-09	5.69e-06	0.47	0.37	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
SARC	cis	rs1862618	0.573	rs185220	ENSG00000271828.1	CTD-2310F14.1	6.08	4.79e-09	5.7e-06	0.61	0.37	Initial pursuit acceleration;	chr5:56909530	chr5:56927874~56929573:+
SARC	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	6.08	4.81e-09	5.73e-06	0.45	0.37	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
SARC	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	6.08	4.81e-09	5.73e-06	0.45	0.37	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
SARC	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	6.08	4.84e-09	5.75e-06	0.45	0.37	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
SARC	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	6.08	4.84e-09	5.76e-06	0.42	0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
SARC	cis	rs17772222	1	rs60310240	ENSG00000258983.2	RP11-507K2.2	6.08	4.85e-09	5.77e-06	0.4	0.37	Coronary artery calcification;	chr14:88356365	chr14:88499334~88515502:+
SARC	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	6.08	4.86e-09	5.78e-06	0.46	0.37	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
SARC	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	6.08	4.87e-09	5.79e-06	0.43	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
SARC	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-6.08	4.9e-09	5.83e-06	-0.38	-0.37	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
SARC	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-6.08	4.91e-09	5.83e-06	-0.4	-0.37	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
SARC	cis	rs113835537	0.559	rs74933537	ENSG00000255517.5	CTD-3074O7.5	-6.08	4.92e-09	5.85e-06	-0.4	-0.37	Airway imaging phenotypes;	chr11:66507487	chr11:66473490~66480233:-
SARC	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	6.08	4.94e-09	5.86e-06	0.35	0.37	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
SARC	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	6.08	4.94e-09	5.87e-06	0.46	0.37	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
SARC	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-6.08	4.95e-09	5.88e-06	-0.5	-0.37	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
SARC	cis	rs1865760	1	rs2071301	ENSG00000272462.2	U91328.19	-6.08	4.96e-09	5.89e-06	-0.36	-0.37	Height;	chr6:25914035	chr6:25992662~26001775:+
SARC	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-6.08	4.97e-09	5.9e-06	-0.35	-0.37	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
SARC	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	6.08	4.98e-09	5.91e-06	0.45	0.37	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
SARC	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	6.08	4.99e-09	5.93e-06	0.43	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
SARC	cis	rs1865760	0.865	rs1541987	ENSG00000272462.2	U91328.19	6.07	5.02e-09	5.95e-06	0.35	0.37	Height;	chr6:25950169	chr6:25992662~26001775:+
SARC	cis	rs916888	0.773	rs199457	ENSG00000261575.2	RP11-259G18.1	6.07	5.02e-09	5.96e-06	0.55	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46267037~46268694:+
SARC	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	6.07	5.02e-09	5.96e-06	0.44	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
SARC	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-6.07	5.03e-09	5.96e-06	-0.6	-0.37	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
SARC	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-6.07	5.05e-09	5.98e-06	-0.42	-0.37	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
SARC	cis	rs9322193	0.924	rs9322189	ENSG00000223701.3	RAET1E-AS1	6.07	5.05e-09	5.98e-06	0.4	0.37	Lung cancer;	chr6:149588797	chr6:149884431~149919508:+
SARC	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	6.07	5.05e-09	5.98e-06	0.44	0.37	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
SARC	cis	rs3002131	0.604	rs2936037	ENSG00000225265.1	TAF1A-AS1	-6.07	5.06e-09	5.99e-06	-0.61	-0.37	Interleukin-10 levels;	chr1:222575223	chr1:222589825~222593032:+
SARC	cis	rs3002131	0.604	rs2936035	ENSG00000225265.1	TAF1A-AS1	-6.07	5.06e-09	5.99e-06	-0.61	-0.37	Interleukin-10 levels;	chr1:222575582	chr1:222589825~222593032:+
SARC	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-6.07	5.07e-09	6.01e-06	-0.58	-0.37	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
SARC	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	6.07	5.07e-09	6.01e-06	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
SARC	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	6.07	5.07e-09	6.01e-06	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
SARC	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-6.07	5.1e-09	6.05e-06	-0.42	-0.37	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
SARC	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	6.07	5.14e-09	6.09e-06	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
SARC	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	6.07	5.17e-09	6.12e-06	0.44	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
SARC	cis	rs7216064	1	rs12600941	ENSG00000265055.1	AC145343.2	6.07	5.18e-09	6.13e-06	0.49	0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67922691	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs62085992	ENSG00000265055.1	AC145343.2	6.07	5.18e-09	6.13e-06	0.49	0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67926967	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs12451721	ENSG00000265055.1	AC145343.2	6.07	5.18e-09	6.13e-06	0.49	0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67942959	chr17:68096046~68101474:-
SARC	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	6.07	5.18e-09	6.13e-06	0.58	0.37	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
SARC	cis	rs17772222	0.917	rs58550317	ENSG00000258983.2	RP11-507K2.2	6.07	5.18e-09	6.13e-06	0.42	0.37	Coronary artery calcification;	chr14:88775243	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs61982733	ENSG00000258983.2	RP11-507K2.2	6.07	5.18e-09	6.13e-06	0.42	0.37	Coronary artery calcification;	chr14:88776244	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs2145120	ENSG00000258983.2	RP11-507K2.2	6.07	5.18e-09	6.13e-06	0.42	0.37	Coronary artery calcification;	chr14:88777699	chr14:88499334~88515502:+
SARC	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	6.07	5.2e-09	6.14e-06	0.46	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
SARC	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	6.07	5.2e-09	6.14e-06	0.46	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
SARC	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	6.07	5.2e-09	6.14e-06	0.46	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
SARC	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	6.07	5.2e-09	6.14e-06	0.46	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
SARC	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	6.07	5.2e-09	6.14e-06	0.46	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
SARC	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-6.07	5.2e-09	6.15e-06	-0.4	-0.37	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
SARC	cis	rs7216064	1	rs12602655	ENSG00000265055.1	AC145343.2	6.07	5.2e-09	6.15e-06	0.49	0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67913326	chr17:68096046~68101474:-
SARC	cis	rs1707322	1	rs785467	ENSG00000280836.1	AL355480.1	6.07	5.22e-09	6.17e-06	0.38	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45581219~45581321:-
SARC	cis	rs7615952	0.932	rs13325495	ENSG00000248787.1	RP11-666A20.4	-6.07	5.22e-09	6.18e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125918573	chr3:125908005~125910272:-
SARC	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	6.07	5.24e-09	6.19e-06	0.45	0.37	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
SARC	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	6.07	5.24e-09	6.19e-06	0.39	0.37	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
SARC	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	6.07	5.27e-09	6.23e-06	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
SARC	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	6.06	5.29e-09	6.25e-06	0.4	0.37	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	6.06	5.29e-09	6.25e-06	0.4	0.37	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
SARC	cis	rs7216064	1	rs56148300	ENSG00000278219.1	AC145343.1	-6.06	5.3e-09	6.26e-06	-0.44	-0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896636	chr17:68101538~68101639:+
SARC	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	6.06	5.31e-09	6.26e-06	0.35	0.37	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
SARC	cis	rs7216064	1	rs8071463	ENSG00000278219.1	AC145343.1	6.06	5.34e-09	6.29e-06	0.43	0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67942539	chr17:68101538~68101639:+
SARC	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	6.06	5.34e-09	6.3e-06	0.39	0.37	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
SARC	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-6.06	5.35e-09	6.31e-06	-0.47	-0.37	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
SARC	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	6.06	5.35e-09	6.31e-06	0.45	0.37	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
SARC	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	6.06	5.35e-09	6.31e-06	0.57	0.37	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
SARC	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	6.06	5.37e-09	6.33e-06	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
SARC	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	6.06	5.39e-09	6.34e-06	0.47	0.37	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
SARC	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	6.06	5.39e-09	6.34e-06	0.47	0.37	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	6.06	5.39e-09	6.34e-06	0.47	0.37	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	6.06	5.39e-09	6.34e-06	0.47	0.37	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	6.06	5.39e-09	6.34e-06	0.47	0.37	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
SARC	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-6.06	5.43e-09	6.39e-06	-0.44	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
SARC	cis	rs6496044	0.507	rs7175731	ENSG00000202081.1	RNU6-1280P	-6.06	5.43e-09	6.39e-06	-0.41	-0.37	Interstitial lung disease;	chr15:85611115	chr15:85651522~85651628:-
SARC	cis	rs6496044	0.507	rs1471455	ENSG00000202081.1	RNU6-1280P	-6.06	5.43e-09	6.39e-06	-0.41	-0.37	Interstitial lung disease;	chr15:85611496	chr15:85651522~85651628:-
SARC	cis	rs17772222	0.917	rs61984736	ENSG00000258983.2	RP11-507K2.2	6.06	5.45e-09	6.41e-06	0.43	0.37	Coronary artery calcification;	chr14:88626359	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.876	rs61983303	ENSG00000258983.2	RP11-507K2.2	6.06	5.45e-09	6.41e-06	0.42	0.37	Coronary artery calcification;	chr14:88764459	chr14:88499334~88515502:+
SARC	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	6.06	5.46e-09	6.43e-06	0.46	0.37	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.868	rs9468220	ENSG00000219392.1	RP1-265C24.5	6.06	5.47e-09	6.43e-06	0.54	0.37	Parkinson's disease;	chr6:27765197	chr6:28115628~28116551:+
SARC	cis	rs1865760	0.865	rs4478388	ENSG00000272462.2	U91328.19	-6.06	5.47e-09	6.43e-06	-0.35	-0.37	Height;	chr6:25953405	chr6:25992662~26001775:+
SARC	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	6.06	5.48e-09	6.44e-06	0.46	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
SARC	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	6.06	5.48e-09	6.45e-06	0.4	0.37	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
SARC	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	6.06	5.48e-09	6.45e-06	0.39	0.37	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
SARC	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	6.06	5.48e-09	6.45e-06	0.39	0.37	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
SARC	cis	rs7216064	1	rs8072225	ENSG00000278219.1	AC145343.1	-6.06	5.49e-09	6.45e-06	-0.44	-0.37	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67916844	chr17:68101538~68101639:+
SARC	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	6.06	5.52e-09	6.49e-06	0.42	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
SARC	cis	rs4273100	1	rs16960499	ENSG00000228157.4	AC007952.5	6.06	5.53e-09	6.5e-06	0.56	0.37	Schizophrenia;	chr17:19299719	chr17:19092974~19096837:+
SARC	cis	rs1707322	0.89	rs2297883	ENSG00000280836.1	AL355480.1	6.06	5.53e-09	6.5e-06	0.37	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs1707338	ENSG00000280836.1	AL355480.1	6.06	5.53e-09	6.5e-06	0.37	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.964	rs1707339	ENSG00000280836.1	AL355480.1	6.06	5.53e-09	6.5e-06	0.37	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs1768818	ENSG00000280836.1	AL355480.1	6.06	5.53e-09	6.5e-06	0.37	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs1768817	ENSG00000280836.1	AL355480.1	6.06	5.53e-09	6.5e-06	0.37	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45581219~45581321:-
SARC	cis	rs10463554	0.892	rs11952337	ENSG00000175749.11	EIF3KP1	6.06	5.54e-09	6.5e-06	0.47	0.37	Parkinson's disease;	chr5:102928043	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs6871715	ENSG00000175749.11	EIF3KP1	6.06	5.54e-09	6.5e-06	0.47	0.37	Parkinson's disease;	chr5:102930398	chr5:103032376~103033031:+
SARC	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	6.06	5.54e-09	6.5e-06	0.54	0.37	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
SARC	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	6.06	5.55e-09	6.52e-06	0.49	0.37	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
SARC	cis	rs1865760	0.786	rs1436308	ENSG00000272810.1	U91328.22	-6.06	5.56e-09	6.52e-06	-0.37	-0.37	Height;	chr6:25939339	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.929	rs1436307	ENSG00000272810.1	U91328.22	-6.06	5.56e-09	6.52e-06	-0.37	-0.37	Height;	chr6:25939495	chr6:26013241~26013757:+
SARC	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-6.05	5.58e-09	6.55e-06	-0.58	-0.37	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
SARC	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	6.05	5.6e-09	6.57e-06	0.46	0.37	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
SARC	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	6.05	5.6e-09	6.57e-06	0.45	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
SARC	cis	rs7615952	0.551	rs6438945	ENSG00000248787.1	RP11-666A20.4	-6.05	5.61e-09	6.58e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125915630	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.673	rs7632557	ENSG00000248787.1	RP11-666A20.4	-6.05	5.61e-09	6.58e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125916038	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.932	rs9841157	ENSG00000248787.1	RP11-666A20.4	-6.05	5.61e-09	6.58e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125916812	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.551	rs12695470	ENSG00000248787.1	RP11-666A20.4	-6.05	5.61e-09	6.58e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125916875	chr3:125908005~125910272:-
SARC	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-6.05	5.66e-09	6.63e-06	-0.42	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
SARC	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	6.05	5.67e-09	6.64e-06	0.67	0.37	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
SARC	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	6.05	5.67e-09	6.64e-06	0.43	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
SARC	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-6.05	5.67e-09	6.64e-06	-0.36	-0.37	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
SARC	cis	rs1823913	0.892	rs35596292	ENSG00000227542.1	AC092614.2	6.05	5.68e-09	6.65e-06	0.41	0.37	Obesity-related traits;	chr2:191246890	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.927	rs35530564	ENSG00000227542.1	AC092614.2	6.05	5.68e-09	6.65e-06	0.41	0.37	Obesity-related traits;	chr2:191247324	chr2:191229165~191246172:-
SARC	cis	rs7615952	0.932	rs11922218	ENSG00000248787.1	RP11-666A20.4	-6.05	5.69e-09	6.66e-06	-0.58	-0.37	Blood pressure (smoking interaction);	chr3:125912446	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.866	rs11922276	ENSG00000248787.1	RP11-666A20.4	-6.05	5.69e-09	6.66e-06	-0.58	-0.37	Blood pressure (smoking interaction);	chr3:125912483	chr3:125908005~125910272:-
SARC	cis	rs1865760	0.892	rs9379806	ENSG00000272810.1	U91328.22	-6.05	5.71e-09	6.69e-06	-0.37	-0.37	Height;	chr6:25940730	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.622	rs9968910	ENSG00000272810.1	U91328.22	-6.05	5.72e-09	6.69e-06	-0.39	-0.37	Height;	chr6:26071867	chr6:26013241~26013757:+
SARC	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	6.05	5.72e-09	6.69e-06	0.49	0.37	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
SARC	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	6.05	5.72e-09	6.69e-06	0.49	0.37	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
SARC	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	6.05	5.72e-09	6.69e-06	0.49	0.37	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
SARC	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	6.05	5.72e-09	6.69e-06	0.49	0.37	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
SARC	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	6.05	5.73e-09	6.7e-06	0.4	0.37	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
SARC	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	6.05	5.73e-09	6.71e-06	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
SARC	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-6.05	5.75e-09	6.72e-06	-0.39	-0.37	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
SARC	cis	rs7615952	0.866	rs6438949	ENSG00000248787.1	RP11-666A20.4	-6.05	5.76e-09	6.74e-06	-0.57	-0.37	Blood pressure (smoking interaction);	chr3:125931221	chr3:125908005~125910272:-
SARC	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	6.05	5.8e-09	6.78e-06	0.72	0.37	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
SARC	cis	rs748404	0.723	rs11853991	ENSG00000205771.5	CATSPER2P1	-6.05	5.8e-09	6.78e-06	-0.46	-0.37	Lung cancer;	chr15:43265351	chr15:43726918~43747094:-
SARC	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	6.05	5.86e-09	6.85e-06	0.45	0.37	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
SARC	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-6.04	5.89e-09	6.88e-06	-0.4	-0.37	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
SARC	cis	rs17772222	0.837	rs57118463	ENSG00000258983.2	RP11-507K2.2	6.04	5.91e-09	6.9e-06	0.41	0.37	Coronary artery calcification;	chr14:88665822	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.874	rs61984746	ENSG00000258983.2	RP11-507K2.2	6.04	5.91e-09	6.9e-06	0.41	0.37	Coronary artery calcification;	chr14:88668136	chr14:88499334~88515502:+
SARC	cis	rs1865760	0.663	rs9379815	ENSG00000272462.2	U91328.19	-6.04	5.92e-09	6.91e-06	-0.33	-0.37	Height;	chr6:25979888	chr6:25992662~26001775:+
SARC	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-6.04	5.92e-09	6.91e-06	-0.41	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
SARC	cis	rs1865760	0.622	rs9968910	ENSG00000272462.2	U91328.19	-6.04	5.94e-09	6.93e-06	-0.37	-0.37	Height;	chr6:26071867	chr6:25992662~26001775:+
SARC	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	6.04	5.97e-09	6.96e-06	0.54	0.37	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	6.04	5.97e-09	6.96e-06	0.54	0.37	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
SARC	cis	rs1865760	0.865	rs9467645	ENSG00000272462.2	U91328.19	-6.04	6e-09	7e-06	-0.35	-0.37	Height;	chr6:25954948	chr6:25992662~26001775:+
SARC	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-6.04	6e-09	7e-06	-0.35	-0.37	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
SARC	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-6.04	6e-09	7e-06	-0.35	-0.37	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
SARC	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-6.04	6e-09	7e-06	-0.35	-0.37	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
SARC	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-6.04	6e-09	7e-06	-0.35	-0.37	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
SARC	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-6.04	6e-09	7e-06	-0.35	-0.37	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
SARC	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	6.04	6.01e-09	7e-06	0.38	0.37	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	6.04	6.01e-09	7e-06	0.38	0.37	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	6.04	6.01e-09	7e-06	0.38	0.37	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
SARC	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-6.04	6.03e-09	7.02e-06	-0.43	-0.37	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
SARC	cis	rs7615952	0.741	rs13314845	ENSG00000248787.1	RP11-666A20.4	-6.04	6.04e-09	7.04e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125925939	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.733	rs13314847	ENSG00000248787.1	RP11-666A20.4	-6.04	6.04e-09	7.04e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125925945	chr3:125908005~125910272:-
SARC	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	6.04	6.07e-09	7.07e-06	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	6.04	6.07e-09	7.07e-06	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
SARC	cis	rs9322193	0.962	rs9765929	ENSG00000223701.3	RAET1E-AS1	6.04	6.07e-09	7.07e-06	0.39	0.37	Lung cancer;	chr6:149769680	chr6:149884431~149919508:+
SARC	cis	rs3002131	0.525	rs2936034	ENSG00000225265.1	TAF1A-AS1	-6.04	6.08e-09	7.07e-06	-0.61	-0.37	Interleukin-10 levels;	chr1:222575661	chr1:222589825~222593032:+
SARC	cis	rs17772222	0.917	rs17260380	ENSG00000258983.2	RP11-507K2.2	6.04	6.08e-09	7.07e-06	0.41	0.37	Coronary artery calcification;	chr14:88682142	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs58984912	ENSG00000258983.2	RP11-507K2.2	6.04	6.08e-09	7.07e-06	0.41	0.37	Coronary artery calcification;	chr14:88698172	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs17188207	ENSG00000258983.2	RP11-507K2.2	6.04	6.08e-09	7.07e-06	0.41	0.37	Coronary artery calcification;	chr14:88699579	chr14:88499334~88515502:+
SARC	cis	rs1823913	0.927	rs34765012	ENSG00000227542.1	AC092614.2	6.04	6.09e-09	7.09e-06	0.41	0.37	Obesity-related traits;	chr2:191247926	chr2:191229165~191246172:-
SARC	cis	rs4273100	1	rs4924986	ENSG00000228157.4	AC007952.5	-6.04	6.1e-09	7.09e-06	-0.54	-0.37	Schizophrenia;	chr17:19339154	chr17:19092974~19096837:+
SARC	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	6.04	6.13e-09	7.12e-06	0.43	0.37	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
SARC	cis	rs9322193	0.962	rs2275046	ENSG00000223701.3	RAET1E-AS1	6.04	6.13e-09	7.12e-06	0.41	0.37	Lung cancer;	chr6:149835865	chr6:149884431~149919508:+
SARC	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-6.04	6.14e-09	7.14e-06	-0.37	-0.37	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-6.04	6.14e-09	7.14e-06	-0.37	-0.37	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
SARC	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	6.04	6.14e-09	7.14e-06	0.48	0.37	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
SARC	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	6.04	6.15e-09	7.15e-06	0.46	0.37	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
SARC	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	6.04	6.16e-09	7.15e-06	0.45	0.37	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
SARC	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-6.04	6.17e-09	7.17e-06	-0.35	-0.37	Height;	chr11:118703185	chr11:118704607~118750263:+
SARC	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-6.04	6.17e-09	7.17e-06	-0.35	-0.37	Height;	chr11:118703207	chr11:118704607~118750263:+
SARC	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-6.04	6.17e-09	7.17e-06	-0.35	-0.37	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
SARC	cis	rs7615952	0.932	rs13314869	ENSG00000248787.1	RP11-666A20.4	-6.04	6.17e-09	7.17e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125925826	chr3:125908005~125910272:-
SARC	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	6.04	6.2e-09	7.2e-06	0.43	0.37	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
SARC	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-6.04	6.2e-09	7.2e-06	-0.39	-0.37	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
SARC	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-6.03	6.22e-09	7.22e-06	-0.64	-0.37	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
SARC	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-6.03	6.23e-09	7.24e-06	-0.4	-0.37	Migraine;	chr4:56851192	chr4:56960927~56961373:-
SARC	cis	rs2739330	0.752	rs2330634	ENSG00000250470.1	AP000351.3	6.03	6.24e-09	7.24e-06	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23976904~23977585:-
SARC	cis	rs10463554	1	rs6879788	ENSG00000175749.11	EIF3KP1	6.03	6.25e-09	7.26e-06	0.45	0.37	Parkinson's disease;	chr5:102978353	chr5:103032376~103033031:+
SARC	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	6.03	6.25e-09	7.26e-06	0.42	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
SARC	cis	rs17772222	0.917	rs8006652	ENSG00000258983.2	RP11-507K2.2	6.03	6.26e-09	7.27e-06	0.42	0.37	Coronary artery calcification;	chr14:88631290	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs12587200	ENSG00000258983.2	RP11-507K2.2	6.03	6.26e-09	7.27e-06	0.42	0.37	Coronary artery calcification;	chr14:88632060	chr14:88499334~88515502:+
SARC	cis	rs1707322	1	rs7517560	ENSG00000280836.1	AL355480.1	-6.03	6.27e-09	7.27e-06	-0.38	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45581219~45581321:-
SARC	cis	rs17772222	0.917	rs57889459	ENSG00000258983.2	RP11-507K2.2	6.03	6.27e-09	7.28e-06	0.42	0.37	Coronary artery calcification;	chr14:88770820	chr14:88499334~88515502:+
SARC	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-6.03	6.28e-09	7.29e-06	-0.5	-0.37	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
SARC	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	6.03	6.29e-09	7.29e-06	0.37	0.37	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
SARC	cis	rs1865760	0.865	rs1115920	ENSG00000272462.2	U91328.19	-6.03	6.31e-09	7.31e-06	-0.35	-0.37	Height;	chr6:25953799	chr6:25992662~26001775:+
SARC	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	6.03	6.31e-09	7.32e-06	0.43	0.37	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
SARC	cis	rs1865760	0.927	rs6915834	ENSG00000272810.1	U91328.22	-6.03	6.31e-09	7.32e-06	-0.37	-0.37	Height;	chr6:25935199	chr6:26013241~26013757:+
SARC	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	6.03	6.31e-09	7.32e-06	0.43	0.37	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
SARC	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	6.03	6.33e-09	7.34e-06	0.45	0.37	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
SARC	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-6.03	6.34e-09	7.35e-06	-0.48	-0.37	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
SARC	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-6.03	6.36e-09	7.36e-06	-0.46	-0.37	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-6.03	6.36e-09	7.36e-06	-0.46	-0.37	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
SARC	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-6.03	6.36e-09	7.36e-06	-0.46	-0.37	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
SARC	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	6.03	6.39e-09	7.4e-06	0.44	0.37	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
SARC	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-6.03	6.41e-09	7.41e-06	-0.34	-0.37	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
SARC	cis	rs1865760	0.929	rs12195653	ENSG00000272810.1	U91328.22	-6.03	6.41e-09	7.41e-06	-0.37	-0.37	Height;	chr6:25958393	chr6:26013241~26013757:+
SARC	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-6.03	6.43e-09	7.44e-06	-0.48	-0.37	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
SARC	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-6.03	6.43e-09	7.44e-06	-0.4	-0.37	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
SARC	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	6.03	6.45e-09	7.46e-06	0.53	0.37	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
SARC	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	6.03	6.46e-09	7.48e-06	0.33	0.37	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
SARC	cis	rs1865760	0.686	rs12210098	ENSG00000272810.1	U91328.22	-6.03	6.49e-09	7.51e-06	-0.39	-0.37	Height;	chr6:25963738	chr6:26013241~26013757:+
SARC	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	6.02	6.56e-09	7.58e-06	0.42	0.37	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
SARC	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-6.02	6.57e-09	7.59e-06	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
SARC	cis	rs1865760	0.929	rs1816546	ENSG00000272810.1	U91328.22	-6.02	6.58e-09	7.6e-06	-0.37	-0.37	Height;	chr6:25938024	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.892	rs2328903	ENSG00000272810.1	U91328.22	-6.02	6.59e-09	7.62e-06	-0.37	-0.37	Height;	chr6:25935537	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.892	rs6456705	ENSG00000272810.1	U91328.22	-6.02	6.59e-09	7.62e-06	-0.37	-0.37	Height;	chr6:25935828	chr6:26013241~26013757:+
SARC	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	6.02	6.6e-09	7.63e-06	0.43	0.37	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	6.02	6.61e-09	7.63e-06	0.42	0.37	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
SARC	cis	rs113835537	0.597	rs7116921	ENSG00000255517.5	CTD-3074O7.5	-6.02	6.61e-09	7.64e-06	-0.41	-0.37	Airway imaging phenotypes;	chr11:66536383	chr11:66473490~66480233:-
SARC	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	6.02	6.64e-09	7.67e-06	0.47	0.37	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
SARC	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-6.02	6.66e-09	7.69e-06	-0.41	-0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
SARC	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-6.02	6.66e-09	7.69e-06	-0.41	-0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
SARC	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	6.02	6.68e-09	7.71e-06	0.42	0.37	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	6.02	6.72e-09	7.75e-06	0.39	0.37	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
SARC	cis	rs1865760	0.663	rs9467656	ENSG00000272462.2	U91328.19	-6.02	6.76e-09	7.79e-06	-0.33	-0.37	Height;	chr6:25993331	chr6:25992662~26001775:+
SARC	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	6.02	6.78e-09	7.82e-06	0.44	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	6.02	6.78e-09	7.82e-06	0.44	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
SARC	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-6.02	6.79e-09	7.82e-06	-0.45	-0.37	Migraine;	chr4:56881195	chr4:56960927~56961373:-
SARC	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	6.02	6.8e-09	7.83e-06	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
SARC	cis	rs1707322	0.929	rs785500	ENSG00000280836.1	AL355480.1	6.02	6.8e-09	7.83e-06	0.38	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45581219~45581321:-
SARC	cis	rs17772222	0.874	rs78077739	ENSG00000258983.2	RP11-507K2.2	6.02	6.82e-09	7.85e-06	0.41	0.37	Coronary artery calcification;	chr14:88741176	chr14:88499334~88515502:+
SARC	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	6.02	6.84e-09	7.88e-06	0.46	0.37	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
SARC	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	6.02	6.84e-09	7.88e-06	0.46	0.37	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
SARC	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-6.02	6.85e-09	7.89e-06	-0.49	-0.37	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
SARC	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	6.02	6.85e-09	7.89e-06	0.46	0.37	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
SARC	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	6.02	6.85e-09	7.89e-06	0.46	0.37	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
SARC	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	6.02	6.88e-09	7.92e-06	0.43	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
SARC	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-6.02	6.89e-09	7.93e-06	-0.35	-0.37	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
SARC	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-6.02	6.89e-09	7.93e-06	-0.46	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
SARC	cis	rs4713118	0.513	rs200971	ENSG00000216901.1	AL022393.7	6.02	6.9e-09	7.94e-06	0.5	0.37	Parkinson's disease;	chr6:27891126	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.539	rs200967	ENSG00000216901.1	AL022393.7	6.02	6.9e-09	7.94e-06	0.5	0.37	Parkinson's disease;	chr6:27894349	chr6:28176188~28176674:+
SARC	cis	rs1865760	0.827	rs9295680	ENSG00000272810.1	U91328.22	-6.01	6.95e-09	7.99e-06	-0.37	-0.37	Height;	chr6:25943875	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.827	rs9295681	ENSG00000272810.1	U91328.22	-6.01	6.95e-09	7.99e-06	-0.37	-0.37	Height;	chr6:25943889	chr6:26013241~26013757:+
SARC	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-6.01	6.97e-09	8.01e-06	-0.46	-0.37	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
SARC	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-6.01	6.97e-09	8.02e-06	-0.66	-0.37	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
SARC	cis	rs7176527	0.519	rs12148368	ENSG00000230373.7	GOLGA6L5P	6.01	6.98e-09	8.03e-06	0.36	0.37	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84507885~84516814:-
SARC	cis	rs1865760	0.663	rs9348704	ENSG00000272462.2	U91328.19	-6.01	6.99e-09	8.03e-06	-0.33	-0.37	Height;	chr6:26000165	chr6:25992662~26001775:+
SARC	cis	rs17772222	0.876	rs12586348	ENSG00000258983.2	RP11-507K2.2	6.01	6.99e-09	8.03e-06	0.41	0.37	Coronary artery calcification;	chr14:88643523	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs12434935	ENSG00000258983.2	RP11-507K2.2	6.01	6.99e-09	8.03e-06	0.41	0.37	Coronary artery calcification;	chr14:88645449	chr14:88499334~88515502:+
SARC	cis	rs9322193	0.962	rs6899661	ENSG00000223701.3	RAET1E-AS1	6.01	7.03e-09	8.07e-06	0.39	0.37	Lung cancer;	chr6:149818093	chr6:149884431~149919508:+
SARC	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-6.01	7.04e-09	8.08e-06	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
SARC	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	6.01	7.04e-09	8.08e-06	0.41	0.37	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	6.01	7.04e-09	8.08e-06	0.41	0.37	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
SARC	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-6.01	7.07e-09	8.11e-06	-0.41	-0.37	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
SARC	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-6.01	7.07e-09	8.12e-06	-0.36	-0.37	Height;	chr11:118737823	chr11:118704607~118750263:+
SARC	cis	rs17772222	0.917	rs61984708	ENSG00000258983.2	RP11-507K2.2	6.01	7.17e-09	8.22e-06	0.43	0.37	Coronary artery calcification;	chr14:88565523	chr14:88499334~88515502:+
SARC	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	6.01	7.17e-09	8.22e-06	0.39	0.37	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
SARC	cis	rs7181230	0.885	rs3923235	ENSG00000275636.1	RP11-521C20.5	6.01	7.17e-09	8.22e-06	0.45	0.37	Dehydroepiandrosterone sulphate levels;	chr15:40078920	chr15:40078892~40079347:+
SARC	cis	rs1865760	0.865	rs9467650	ENSG00000272810.1	U91328.22	-6.01	7.19e-09	8.24e-06	-0.37	-0.37	Height;	chr6:25958007	chr6:26013241~26013757:+
SARC	cis	rs1707322	1	rs4660331	ENSG00000280836.1	AL355480.1	-6.01	7.26e-09	8.32e-06	-0.37	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45581219~45581321:-
SARC	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	6.01	7.27e-09	8.33e-06	0.42	0.37	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
SARC	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	6.01	7.27e-09	8.33e-06	0.43	0.37	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
SARC	cis	rs4713118	0.513	rs149897	ENSG00000216901.1	AL022393.7	6	7.29e-09	8.35e-06	0.5	0.37	Parkinson's disease;	chr6:28038872	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.513	rs156734	ENSG00000216901.1	AL022393.7	6	7.29e-09	8.35e-06	0.5	0.37	Parkinson's disease;	chr6:28039579	chr6:28176188~28176674:+
SARC	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-6	7.3e-09	8.36e-06	-0.43	-0.37	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
SARC	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	6	7.3e-09	8.36e-06	0.42	0.37	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
SARC	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	6	7.32e-09	8.38e-06	0.4	0.37	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
SARC	cis	rs2946504	0.705	rs1879487	ENSG00000251468.2	RP11-369K16.1	-6	7.33e-09	8.39e-06	-0.37	-0.37	Type 2 diabetes;	chr8:12947413	chr8:12958387~12962200:+
SARC	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	6	7.33e-09	8.39e-06	0.54	0.37	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
SARC	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	6	7.34e-09	8.4e-06	0.46	0.37	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
SARC	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-6	7.35e-09	8.41e-06	-0.46	-0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
SARC	cis	rs2179367	0.959	rs585022	ENSG00000231760.4	RP11-350J20.5	6	7.36e-09	8.42e-06	0.47	0.37	Dupuytren's disease;	chr6:149432168	chr6:149796151~149826294:-
SARC	cis	rs2303759	0.918	rs10405465	ENSG00000268686.1	AC010524.2	-6	7.37e-09	8.44e-06	-0.44	-0.37	Multiple sclerosis;	chr19:49366041	chr19:49368705~49388081:-
SARC	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	6	7.39e-09	8.45e-06	0.45	0.37	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
SARC	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	6	7.45e-09	8.52e-06	0.47	0.37	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
SARC	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-6	7.45e-09	8.52e-06	-0.35	-0.37	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
SARC	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-6	7.46e-09	8.53e-06	-0.39	-0.37	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
SARC	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	6	7.46e-09	8.53e-06	0.48	0.37	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
SARC	cis	rs1865760	0.534	rs72834629	ENSG00000272462.2	U91328.19	-6	7.47e-09	8.54e-06	-0.38	-0.37	Height;	chr6:26022804	chr6:25992662~26001775:+
SARC	cis	rs4968361	0.892	rs4968363	ENSG00000266992.1	DHX40P1	6	7.51e-09	8.59e-06	0.72	0.37	Schizophrenia;	chr17:59433712	chr17:59976009~60002384:-
SARC	cis	rs1865760	0.865	rs1436306	ENSG00000272462.2	U91328.19	-6	7.53e-09	8.61e-06	-0.35	-0.37	Height;	chr6:25948193	chr6:25992662~26001775:+
SARC	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-6	7.58e-09	8.66e-06	-0.42	-0.37	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
SARC	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	6	7.58e-09	8.66e-06	0.44	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
SARC	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	6	7.59e-09	8.67e-06	0.46	0.37	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
SARC	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	6	7.6e-09	8.68e-06	0.41	0.37	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
SARC	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	6	7.63e-09	8.71e-06	0.42	0.37	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
SARC	cis	rs2179367	0.887	rs6570965	ENSG00000231760.4	RP11-350J20.5	6	7.63e-09	8.71e-06	0.45	0.37	Dupuytren's disease;	chr6:149396340	chr6:149796151~149826294:-
SARC	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	6	7.67e-09	8.76e-06	0.43	0.37	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
SARC	cis	rs1865760	0.929	rs9358896	ENSG00000272810.1	U91328.22	-6	7.67e-09	8.76e-06	-0.37	-0.37	Height;	chr6:25942969	chr6:26013241~26013757:+
SARC	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-6	7.68e-09	8.76e-06	-0.63	-0.37	Depression;	chr6:28103220	chr6:28115628~28116551:+
SARC	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-5.99	7.69e-09	8.77e-06	-0.39	-0.37	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
SARC	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-5.99	7.7e-09	8.78e-06	-0.41	-0.37	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
SARC	cis	rs7615952	0.611	rs2971298	ENSG00000248787.1	RP11-666A20.4	-5.99	7.7e-09	8.78e-06	-0.59	-0.37	Blood pressure (smoking interaction);	chr3:125883870	chr3:125908005~125910272:-
SARC	cis	rs77204473	0.744	rs77171490	ENSG00000254851.1	RP11-109L13.1	5.99	7.72e-09	8.8e-06	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117168025	chr11:117135528~117138582:+
SARC	cis	rs77204473	0.744	rs77678768	ENSG00000254851.1	RP11-109L13.1	5.99	7.72e-09	8.8e-06	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117169789	chr11:117135528~117138582:+
SARC	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	5.99	7.73e-09	8.81e-06	0.6	0.37	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.932	rs7630077	ENSG00000171084.14	FAM86JP	5.99	7.73e-09	8.81e-06	0.6	0.37	Blood pressure (smoking interaction);	chr3:125930833	chr3:125916620~125930024:+
SARC	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	5.99	7.8e-09	8.89e-06	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
SARC	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	5.99	7.8e-09	8.89e-06	0.43	0.37	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
SARC	cis	rs9322193	0.962	rs7818	ENSG00000223701.3	RAET1E-AS1	5.99	7.8e-09	8.89e-06	0.39	0.37	Lung cancer;	chr6:149810956	chr6:149884431~149919508:+
SARC	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	5.99	7.81e-09	8.89e-06	0.56	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
SARC	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	5.99	7.83e-09	8.92e-06	0.35	0.37	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
SARC	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	5.99	7.87e-09	8.96e-06	0.43	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
SARC	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	5.99	7.88e-09	8.97e-06	0.45	0.37	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
SARC	cis	rs17772222	0.74	rs7160647	ENSG00000258983.2	RP11-507K2.2	5.99	7.89e-09	8.99e-06	0.36	0.37	Coronary artery calcification;	chr14:88507340	chr14:88499334~88515502:+
SARC	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-5.99	7.92e-09	9.02e-06	-0.52	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
SARC	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-5.99	7.94e-09	9.03e-06	-0.41	-0.37	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
SARC	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	5.99	7.95e-09	9.05e-06	0.43	0.37	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	5.99	7.95e-09	9.05e-06	0.43	0.37	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	5.99	7.95e-09	9.05e-06	0.43	0.37	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	5.99	7.95e-09	9.05e-06	0.43	0.37	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	5.99	7.95e-09	9.05e-06	0.43	0.37	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
SARC	cis	rs1865760	0.713	rs1130000	ENSG00000272462.2	U91328.19	-5.99	7.96e-09	9.05e-06	-0.33	-0.37	Height;	chr6:25985168	chr6:25992662~26001775:+
SARC	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	5.99	7.97e-09	9.05e-06	0.68	0.37	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
SARC	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-5.99	7.98e-09	9.06e-06	-0.41	-0.37	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
SARC	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-5.99	7.98e-09	9.06e-06	-0.49	-0.37	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
SARC	cis	rs1707322	1	rs785486	ENSG00000280836.1	AL355480.1	5.99	8.01e-09	9.09e-06	0.38	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.865	rs785501	ENSG00000280836.1	AL355480.1	5.99	8.01e-09	9.09e-06	0.38	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45581219~45581321:-
SARC	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	5.98	8.12e-09	9.21e-06	0.54	0.37	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
SARC	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	5.98	8.12e-09	9.21e-06	0.54	0.37	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
SARC	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-5.98	8.12e-09	9.21e-06	-0.41	-0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
SARC	cis	rs1707322	1	rs10890350	ENSG00000280836.1	AL355480.1	-5.98	8.13e-09	9.22e-06	-0.37	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45581219~45581321:-
SARC	cis	rs6496044	0.507	rs8034676	ENSG00000202081.1	RNU6-1280P	5.98	8.16e-09	9.25e-06	0.41	0.36	Interstitial lung disease;	chr15:85616031	chr15:85651522~85651628:-
SARC	cis	rs113835537	0.597	rs57288351	ENSG00000255517.5	CTD-3074O7.5	-5.98	8.17e-09	9.25e-06	-0.41	-0.36	Airway imaging phenotypes;	chr11:66540018	chr11:66473490~66480233:-
SARC	cis	rs2836950	0.565	rs3171465	ENSG00000255568.3	BRWD1-AS2	-5.98	8.22e-09	9.31e-06	-0.34	-0.36	Menarche (age at onset);	chr21:39180381	chr21:39313935~39314962:+
SARC	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-5.98	8.22e-09	9.32e-06	-0.48	-0.36	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
SARC	cis	rs11651753	0.613	rs3096	ENSG00000264920.1	RP11-6N17.4	-5.98	8.25e-09	9.34e-06	-0.41	-0.36	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47952066	chr17:47891255~47895812:-
SARC	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	5.98	8.27e-09	9.37e-06	0.56	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
SARC	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	5.98	8.27e-09	9.37e-06	0.41	0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
SARC	cis	rs1707322	1	rs4073847	ENSG00000280836.1	AL355480.1	5.98	8.28e-09	9.37e-06	0.38	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45581219~45581321:-
SARC	cis	rs172166	0.637	rs1233691	ENSG00000219392.1	RP1-265C24.5	-5.98	8.3e-09	9.39e-06	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28186119	chr6:28115628~28116551:+
SARC	cis	rs2117029	0.767	rs3741622	ENSG00000258017.1	RP11-386G11.10	-5.98	8.3e-09	9.4e-06	-0.4	-0.36	Intelligence (multi-trait analysis);	chr12:49032195	chr12:49127782~49147869:+
SARC	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-5.98	8.33e-09	9.43e-06	-0.41	-0.36	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
SARC	cis	rs11651753	0.636	rs4793731	ENSG00000264920.1	RP11-6N17.4	-5.98	8.35e-09	9.45e-06	-0.41	-0.36	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956327	chr17:47891255~47895812:-
SARC	cis	rs11651753	0.636	rs4793733	ENSG00000264920.1	RP11-6N17.4	-5.98	8.35e-09	9.45e-06	-0.41	-0.36	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956616	chr17:47891255~47895812:-
SARC	cis	rs11651753	0.636	rs35280206	ENSG00000264920.1	RP11-6N17.4	-5.98	8.35e-09	9.45e-06	-0.41	-0.36	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47957645	chr17:47891255~47895812:-
SARC	cis	rs131777	0.547	rs131753	ENSG00000205559.3	CHKB-AS1	-5.98	8.36e-09	9.45e-06	-0.39	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50584433	chr22:50583026~50583877:+
SARC	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	5.98	8.39e-09	9.49e-06	0.45	0.36	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
SARC	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	5.98	8.39e-09	9.49e-06	0.45	0.36	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
SARC	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	5.98	8.41e-09	9.51e-06	0.42	0.36	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
SARC	cis	rs6964833	0.554	rs2527380	ENSG00000277053.3	GTF2IP1	5.98	8.45e-09	9.55e-06	0.4	0.36	Menarche (age at onset);	chr7:74690372	chr7:75185385~75237696:-
SARC	cis	rs7216064	1	rs7221651	ENSG00000278219.1	AC145343.1	5.98	8.46e-09	9.56e-06	0.44	0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836274	chr17:68101538~68101639:+
SARC	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-5.98	8.46e-09	9.57e-06	-0.4	-0.36	Migraine;	chr4:56852029	chr4:56960927~56961373:-
SARC	cis	rs2836950	0.561	rs34705151	ENSG00000255568.3	BRWD1-AS2	-5.98	8.47e-09	9.58e-06	-0.34	-0.36	Menarche (age at onset);	chr21:39181418	chr21:39313935~39314962:+
SARC	cis	rs2836950	0.52	rs11911087	ENSG00000255568.3	BRWD1-AS2	-5.98	8.48e-09	9.59e-06	-0.33	-0.36	Menarche (age at onset);	chr21:39293266	chr21:39313935~39314962:+
SARC	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	5.98	8.49e-09	9.6e-06	0.43	0.36	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
SARC	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-5.98	8.49e-09	9.6e-06	-0.36	-0.36	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
SARC	cis	rs7615952	0.673	rs16834637	ENSG00000248787.1	RP11-666A20.4	-5.98	8.5e-09	9.6e-06	-0.6	-0.36	Blood pressure (smoking interaction);	chr3:125886628	chr3:125908005~125910272:-
SARC	cis	rs6964833	0.554	rs2527366	ENSG00000277053.3	GTF2IP1	5.98	8.5e-09	9.6e-06	0.4	0.36	Menarche (age at onset);	chr7:74684615	chr7:75185385~75237696:-
SARC	cis	rs6964833	0.554	rs2527367	ENSG00000277053.3	GTF2IP1	5.98	8.5e-09	9.6e-06	0.4	0.36	Menarche (age at onset);	chr7:74684804	chr7:75185385~75237696:-
SARC	cis	rs9376098	0.698	rs6908307	ENSG00000232876.1	CTA-212D2.2	-5.98	8.52e-09	9.62e-06	-0.41	-0.36	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135141542	chr6:135055033~135060550:+
SARC	cis	rs9376098	0.698	rs2050020	ENSG00000232876.1	CTA-212D2.2	-5.98	8.52e-09	9.62e-06	-0.41	-0.36	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135142915	chr6:135055033~135060550:+
SARC	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-5.97	8.56e-09	9.67e-06	-0.47	-0.36	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
SARC	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	5.97	8.57e-09	9.67e-06	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	5.97	8.57e-09	9.67e-06	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
SARC	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	5.97	8.63e-09	9.74e-06	0.34	0.36	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
SARC	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-5.97	8.64e-09	9.74e-06	-0.39	-0.36	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
SARC	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-5.97	8.66e-09	9.77e-06	-0.34	-0.36	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
SARC	cis	rs1865760	0.865	rs9467648	ENSG00000272810.1	U91328.22	-5.97	8.69e-09	9.8e-06	-0.36	-0.36	Height;	chr6:25957705	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.865	rs9467652	ENSG00000272810.1	U91328.22	-5.97	8.69e-09	9.8e-06	-0.36	-0.36	Height;	chr6:25958899	chr6:26013241~26013757:+
SARC	cis	rs17767294	0.612	rs9461424	ENSG00000219392.1	RP1-265C24.5	-5.97	8.71e-09	9.82e-06	-0.66	-0.36	Parkinson's disease;	chr6:27951623	chr6:28115628~28116551:+
SARC	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	5.97	8.73e-09	9.85e-06	0.45	0.36	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
SARC	cis	rs2303759	0.551	rs7249040	ENSG00000268686.1	AC010524.2	-5.97	8.74e-09	9.85e-06	-0.47	-0.36	Multiple sclerosis;	chr19:49287345	chr19:49368705~49388081:-
SARC	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	5.97	8.75e-09	9.86e-06	0.38	0.36	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	5.97	8.75e-09	9.86e-06	0.38	0.36	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	5.97	8.75e-09	9.86e-06	0.38	0.36	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	5.97	8.75e-09	9.86e-06	0.38	0.36	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
SARC	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	5.97	8.75e-09	9.86e-06	0.73	0.36	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
SARC	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	5.97	8.75e-09	9.86e-06	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	5.97	8.75e-09	9.86e-06	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
SARC	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	5.97	8.79e-09	9.9e-06	0.41	0.36	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	5.97	8.79e-09	9.9e-06	0.41	0.36	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
SARC	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	5.97	8.79e-09	9.9e-06	0.39	0.36	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	5.97	8.79e-09	9.9e-06	0.39	0.36	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	5.97	8.79e-09	9.9e-06	0.39	0.36	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
SARC	cis	rs9376098	0.698	rs9494155	ENSG00000232876.1	CTA-212D2.2	-5.97	8.79e-09	9.9e-06	-0.4	-0.36	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135147753	chr6:135055033~135060550:+
SARC	cis	rs9376098	0.698	rs7756303	ENSG00000232876.1	CTA-212D2.2	-5.97	8.79e-09	9.9e-06	-0.4	-0.36	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135148846	chr6:135055033~135060550:+
SARC	cis	rs1865760	0.865	rs9467647	ENSG00000272810.1	U91328.22	-5.97	8.8e-09	9.91e-06	-0.36	-0.36	Height;	chr6:25957414	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.865	rs10946800	ENSG00000272810.1	U91328.22	-5.97	8.8e-09	9.91e-06	-0.36	-0.36	Height;	chr6:25957545	chr6:26013241~26013757:+
SARC	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	5.97	8.8e-09	9.91e-06	0.55	0.36	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
SARC	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-5.97	8.81e-09	9.92e-06	-0.4	-0.36	Migraine;	chr4:56853383	chr4:56960927~56961373:-
SARC	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-5.97	8.81e-09	9.92e-06	-0.35	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
SARC	cis	rs9322193	0.651	rs9322188	ENSG00000223701.3	RAET1E-AS1	-5.97	8.81e-09	9.92e-06	-0.4	-0.36	Lung cancer;	chr6:149588355	chr6:149884431~149919508:+
SARC	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	5.97	8.82e-09	9.93e-06	0.39	0.36	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
SARC	cis	rs9322193	0.884	rs9371201	ENSG00000268592.3	RAET1E-AS1	5.97	8.83e-09	9.94e-06	0.47	0.36	Lung cancer;	chr6:149823865	chr6:149863494~149919507:+
SARC	cis	rs7615952	0.673	rs34209763	ENSG00000248787.1	RP11-666A20.4	-5.97	8.83e-09	9.94e-06	-0.59	-0.36	Blood pressure (smoking interaction);	chr3:125880752	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.8	rs35390120	ENSG00000248787.1	RP11-666A20.4	-5.97	8.83e-09	9.94e-06	-0.59	-0.36	Blood pressure (smoking interaction);	chr3:125880966	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.611	rs35321002	ENSG00000248787.1	RP11-666A20.4	-5.97	8.83e-09	9.94e-06	-0.59	-0.36	Blood pressure (smoking interaction);	chr3:125893222	chr3:125908005~125910272:-
SARC	cis	rs17772222	0.917	rs11159868	ENSG00000258983.2	RP11-507K2.2	5.97	8.85e-09	9.95e-06	0.42	0.36	Coronary artery calcification;	chr14:88760528	chr14:88499334~88515502:+
SARC	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	5.97	8.87e-09	9.97e-06	0.35	0.36	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
SARC	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-5.97	8.87e-09	9.97e-06	-0.46	-0.36	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-5.97	8.87e-09	9.97e-06	-0.46	-0.36	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-5.97	8.87e-09	9.97e-06	-0.46	-0.36	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
SARC	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	5.97	8.87e-09	9.97e-06	0.41	0.36	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
SARC	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	5.97	8.87e-09	9.98e-06	0.67	0.36	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
SARC	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	5.97	8.87e-09	9.98e-06	0.67	0.36	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
SARC	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	5.97	8.88e-09	9.98e-06	0.46	0.36	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
SARC	cis	rs17772222	0.917	rs61983300	ENSG00000258983.2	RP11-507K2.2	5.97	8.88e-09	9.99e-06	0.41	0.36	Coronary artery calcification;	chr14:88754047	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.876	rs78068036	ENSG00000258983.2	RP11-507K2.2	5.97	8.88e-09	9.99e-06	0.41	0.36	Coronary artery calcification;	chr14:88754817	chr14:88499334~88515502:+
SARC	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-5.97	8.89e-09	9.99e-06	-0.51	-0.36	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-5.97	8.89e-09	9.99e-06	-0.51	-0.36	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-5.97	8.89e-09	9.99e-06	-0.51	-0.36	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
SARC	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	5.97	8.9e-09	1e-05	0.45	0.36	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	5.97	8.9e-09	1e-05	0.45	0.36	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
SARC	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-5.97	8.92e-09	1e-05	-0.68	-0.36	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
SARC	cis	rs77204473	1	rs12287768	ENSG00000254851.1	RP11-109L13.1	5.97	8.98e-09	1.01e-05	0.76	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985606	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs12274771	ENSG00000254851.1	RP11-109L13.1	5.97	8.98e-09	1.01e-05	0.76	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985982	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs12274773	ENSG00000254851.1	RP11-109L13.1	5.97	8.98e-09	1.01e-05	0.76	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985993	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs75212922	ENSG00000254851.1	RP11-109L13.1	5.97	8.98e-09	1.01e-05	0.76	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986276	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs11216217	ENSG00000254851.1	RP11-109L13.1	5.97	8.98e-09	1.01e-05	0.76	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986936	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs11216218	ENSG00000254851.1	RP11-109L13.1	5.97	8.98e-09	1.01e-05	0.76	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116991945	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs11216219	ENSG00000254851.1	RP11-109L13.1	5.97	8.98e-09	1.01e-05	0.76	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992039	chr11:117135528~117138582:+
SARC	cis	rs75920871	1	rs11216221	ENSG00000254851.1	RP11-109L13.1	5.97	8.98e-09	1.01e-05	0.76	0.36	Subjective well-being;	chr11:116997421	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs12278943	ENSG00000254851.1	RP11-109L13.1	5.97	8.98e-09	1.01e-05	0.76	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117003642	chr11:117135528~117138582:+
SARC	cis	rs7615952	0.688	rs9754526	ENSG00000171084.14	FAM86JP	5.97	8.99e-09	1.01e-05	0.53	0.36	Blood pressure (smoking interaction);	chr3:125824023	chr3:125916620~125930024:+
SARC	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	5.97	9e-09	1.01e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	5.97	9e-09	1.01e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	5.97	9e-09	1.01e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	5.97	9e-09	1.01e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	5.97	9e-09	1.01e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	5.97	9e-09	1.01e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
SARC	cis	rs1707322	0.963	rs34907901	ENSG00000280836.1	AL355480.1	-5.97	9.02e-09	1.01e-05	-0.38	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45581219~45581321:-
SARC	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	5.96	9.03e-09	1.01e-05	0.39	0.36	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
SARC	cis	rs1865760	0.568	rs2032450	ENSG00000272462.2	U91328.19	-5.96	9.06e-09	1.02e-05	-0.33	-0.36	Height;	chr6:25992886	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.713	rs2013063	ENSG00000272462.2	U91328.19	-5.96	9.06e-09	1.02e-05	-0.33	-0.36	Height;	chr6:25993870	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.713	rs6928951	ENSG00000272462.2	U91328.19	-5.96	9.06e-09	1.02e-05	-0.33	-0.36	Height;	chr6:25995326	chr6:25992662~26001775:+
SARC	cis	rs5769707	0.632	rs135872	ENSG00000235111.1	RP1-29C18.8	-5.96	9.09e-09	1.02e-05	-0.46	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49612657~49615716:-
SARC	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-5.96	9.1e-09	1.02e-05	-0.34	-0.36	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
SARC	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	5.96	9.14e-09	1.02e-05	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
SARC	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	5.96	9.16e-09	1.02e-05	0.46	0.36	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
SARC	cis	rs1707322	1	rs6429588	ENSG00000280836.1	AL355480.1	-5.96	9.16e-09	1.02e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211243	ENSG00000280836.1	AL355480.1	-5.96	9.16e-09	1.02e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211244	ENSG00000280836.1	AL355480.1	-5.96	9.16e-09	1.02e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs4660903	ENSG00000280836.1	AL355480.1	-5.96	9.16e-09	1.02e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs12097799	ENSG00000280836.1	AL355480.1	-5.96	9.16e-09	1.02e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45581219~45581321:-
SARC	cis	rs1865760	0.865	rs9467651	ENSG00000272810.1	U91328.22	-5.96	9.18e-09	1.03e-05	-0.36	-0.36	Height;	chr6:25958029	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.713	rs7766342	ENSG00000272462.2	U91328.19	-5.96	9.18e-09	1.03e-05	-0.33	-0.36	Height;	chr6:25990446	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.713	rs9461229	ENSG00000272462.2	U91328.19	-5.96	9.18e-09	1.03e-05	-0.33	-0.36	Height;	chr6:25992051	chr6:25992662~26001775:+
SARC	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-5.96	9.19e-09	1.03e-05	-0.44	-0.36	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
SARC	cis	rs113835537	0.529	rs11227495	ENSG00000255517.5	CTD-3074O7.5	-5.96	9.2e-09	1.03e-05	-0.4	-0.36	Airway imaging phenotypes;	chr11:66495772	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.559	rs11227498	ENSG00000255517.5	CTD-3074O7.5	-5.96	9.2e-09	1.03e-05	-0.4	-0.36	Airway imaging phenotypes;	chr11:66502243	chr11:66473490~66480233:-
SARC	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-5.96	9.2e-09	1.03e-05	-0.4	-0.36	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
SARC	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-5.96	9.22e-09	1.03e-05	-0.48	-0.36	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
SARC	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-5.96	9.22e-09	1.03e-05	-0.48	-0.36	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
SARC	cis	rs2729354	0.768	rs2848635	ENSG00000265566.2	RN7SL605P	-5.96	9.22e-09	1.03e-05	-0.48	-0.36	Blood protein levels;	chr11:57486458	chr11:57528085~57528365:-
SARC	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-5.96	9.22e-09	1.03e-05	-0.34	-0.36	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
SARC	cis	rs2729354	0.52	rs2729377	ENSG00000265566.2	RN7SL605P	-5.96	9.23e-09	1.03e-05	-0.49	-0.36	Blood protein levels;	chr11:57482611	chr11:57528085~57528365:-
SARC	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	5.96	9.24e-09	1.03e-05	0.39	0.36	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
SARC	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-5.96	9.24e-09	1.03e-05	-0.49	-0.36	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
SARC	cis	rs7216064	1	rs58551145	ENSG00000265055.1	AC145343.2	5.96	9.26e-09	1.04e-05	0.5	0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841119	chr17:68096046~68101474:-
SARC	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	5.96	9.26e-09	1.04e-05	0.42	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
SARC	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-5.96	9.27e-09	1.04e-05	-0.43	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
SARC	cis	rs17772222	0.876	rs12587598	ENSG00000258983.2	RP11-507K2.2	5.96	9.27e-09	1.04e-05	0.4	0.36	Coronary artery calcification;	chr14:88729474	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.917	rs17188046	ENSG00000258983.2	RP11-507K2.2	5.96	9.29e-09	1.04e-05	0.41	0.36	Coronary artery calcification;	chr14:88624417	chr14:88499334~88515502:+
SARC	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	5.96	9.31e-09	1.04e-05	0.43	0.36	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
SARC	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-5.96	9.32e-09	1.04e-05	-0.47	-0.36	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-5.96	9.32e-09	1.04e-05	-0.47	-0.36	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
SARC	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	5.96	9.39e-09	1.05e-05	0.41	0.36	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	5.96	9.39e-09	1.05e-05	0.41	0.36	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	5.96	9.39e-09	1.05e-05	0.41	0.36	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
SARC	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-5.96	9.41e-09	1.05e-05	-0.41	-0.36	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
SARC	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-5.96	9.41e-09	1.05e-05	-0.41	-0.36	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
SARC	cis	rs113835537	0.529	rs75683511	ENSG00000255517.5	CTD-3074O7.5	-5.96	9.45e-09	1.05e-05	-0.41	-0.36	Airway imaging phenotypes;	chr11:66507555	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs17065	ENSG00000255517.5	CTD-3074O7.5	-5.96	9.45e-09	1.05e-05	-0.41	-0.36	Airway imaging phenotypes;	chr11:66509564	chr11:66473490~66480233:-
SARC	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-5.96	9.45e-09	1.05e-05	-0.44	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
SARC	cis	rs11018904	0.861	rs4589254	ENSG00000280385.1	AP000648.5	5.96	9.47e-09	1.06e-05	0.4	0.36	Intelligence (multi-trait analysis);	chr11:90230187	chr11:90193614~90198120:+
SARC	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	5.96	9.47e-09	1.06e-05	0.43	0.36	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
SARC	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	5.96	9.49e-09	1.06e-05	0.53	0.36	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
SARC	cis	rs1061377	0.965	rs12511857	ENSG00000249207.1	RP11-360F5.1	-5.95	9.51e-09	1.06e-05	-0.4	-0.36	Uric acid levels;	chr4:39143252	chr4:39112677~39126818:-
SARC	cis	rs112721625	1	rs112721625	ENSG00000266992.1	DHX40P1	5.95	9.52e-09	1.06e-05	0.41	0.36	Monocyte count;	chr17:59850066	chr17:59976009~60002384:-
SARC	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	5.95	9.53e-09	1.06e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	5.95	9.53e-09	1.06e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	5.95	9.53e-09	1.06e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	5.95	9.53e-09	1.06e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	5.95	9.53e-09	1.06e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
SARC	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-5.95	9.58e-09	1.07e-05	-0.41	-0.36	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
SARC	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	5.95	9.61e-09	1.07e-05	0.41	0.36	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
SARC	cis	rs1707322	1	rs6677777	ENSG00000280836.1	AL355480.1	-5.95	9.62e-09	1.07e-05	-0.39	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45581219~45581321:-
SARC	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-5.95	9.65e-09	1.08e-05	-0.4	-0.36	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
SARC	cis	rs1431005	0.893	rs12501227	ENSG00000250620.1	RP11-91J3.3	5.95	9.67e-09	1.08e-05	0.4	0.36	Response to statin therapy;	chr4:187401223	chr4:187413564~187415697:+
SARC	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	5.95	9.69e-09	1.08e-05	0.4	0.36	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
SARC	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-5.95	9.69e-09	1.08e-05	-0.41	-0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
SARC	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	5.95	9.7e-09	1.08e-05	0.45	0.36	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
SARC	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-5.95	9.71e-09	1.08e-05	-0.57	-0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
SARC	cis	rs62103177	0.525	rs4799117	ENSG00000261126.6	RP11-795F19.1	-5.95	9.73e-09	1.08e-05	-0.35	-0.36	Opioid sensitivity;	chr18:79996604	chr18:80046900~80095482:+
SARC	cis	rs62103177	0.525	rs4283293	ENSG00000261126.6	RP11-795F19.1	-5.95	9.73e-09	1.08e-05	-0.35	-0.36	Opioid sensitivity;	chr18:79999582	chr18:80046900~80095482:+
SARC	cis	rs62103177	0.608	rs4799115	ENSG00000261126.6	RP11-795F19.1	-5.95	9.74e-09	1.08e-05	-0.38	-0.36	Opioid sensitivity;	chr18:79976365	chr18:80046900~80095482:+
SARC	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-5.95	9.76e-09	1.09e-05	-0.5	-0.36	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
SARC	cis	rs526231	0.543	rs246901	ENSG00000175749.11	EIF3KP1	5.95	9.77e-09	1.09e-05	0.52	0.36	Primary biliary cholangitis;	chr5:103248477	chr5:103032376~103033031:+
SARC	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	5.95	9.79e-09	1.09e-05	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
SARC	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	5.95	9.83e-09	1.09e-05	0.44	0.36	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
SARC	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-5.95	9.84e-09	1.09e-05	-0.45	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
SARC	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	5.95	9.84e-09	1.09e-05	0.42	0.36	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
SARC	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-5.95	9.9e-09	1.1e-05	-0.35	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
SARC	cis	rs1707322	1	rs785504	ENSG00000280836.1	AL355480.1	5.95	9.95e-09	1.11e-05	0.38	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45581219~45581321:-
SARC	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	5.95	9.95e-09	1.11e-05	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
SARC	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	5.95	9.97e-09	1.11e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
SARC	cis	rs9494145	0.68	rs35959442	ENSG00000232876.1	CTA-212D2.2	-5.95	9.97e-09	1.11e-05	-0.46	-0.36	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135103041	chr6:135055033~135060550:+
SARC	cis	rs11673344	0.808	rs57916401	ENSG00000226686.6	LINC01535	5.95	9.99e-09	1.11e-05	0.43	0.36	Obesity-related traits;	chr19:37153149	chr19:37251912~37265535:+
SARC	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	5.95	1e-08	1.11e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
SARC	cis	rs2117029	0.767	rs11614738	ENSG00000258017.1	RP11-386G11.10	-5.95	1e-08	1.11e-05	-0.4	-0.36	Intelligence (multi-trait analysis);	chr12:49030833	chr12:49127782~49147869:+
SARC	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-5.94	1.01e-08	1.12e-05	-0.39	-0.36	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
SARC	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	5.94	1.01e-08	1.12e-05	0.42	0.36	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
SARC	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-5.94	1.02e-08	1.13e-05	-0.61	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
SARC	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	5.94	1.02e-08	1.13e-05	0.42	0.36	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
SARC	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	5.94	1.02e-08	1.13e-05	0.42	0.36	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
SARC	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-5.94	1.02e-08	1.13e-05	-0.46	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
SARC	cis	rs7216064	1	rs62084240	ENSG00000265055.1	AC145343.2	5.94	1.02e-08	1.13e-05	0.49	0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67863117	chr17:68096046~68101474:-
SARC	cis	rs17772222	0.74	rs7143642	ENSG00000258983.2	RP11-507K2.2	5.94	1.02e-08	1.14e-05	0.36	0.36	Coronary artery calcification;	chr14:88507616	chr14:88499334~88515502:+
SARC	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-5.94	1.03e-08	1.14e-05	-0.35	-0.36	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
SARC	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	5.94	1.03e-08	1.14e-05	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
SARC	cis	rs2729354	0.729	rs2729353	ENSG00000265566.2	RN7SL605P	-5.94	1.03e-08	1.15e-05	-0.48	-0.36	Blood protein levels;	chr11:57480530	chr11:57528085~57528365:-
SARC	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	5.94	1.04e-08	1.15e-05	0.46	0.36	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
SARC	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	5.94	1.04e-08	1.15e-05	0.46	0.36	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
SARC	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	5.94	1.04e-08	1.15e-05	0.4	0.36	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
SARC	cis	rs7181230	0.885	rs4924413	ENSG00000275636.1	RP11-521C20.5	5.94	1.04e-08	1.15e-05	0.44	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40056496	chr15:40078892~40079347:+
SARC	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-5.94	1.05e-08	1.16e-05	-0.46	-0.36	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
SARC	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-5.94	1.05e-08	1.16e-05	-0.42	-0.36	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
SARC	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	5.94	1.05e-08	1.16e-05	0.39	0.36	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
SARC	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	5.94	1.05e-08	1.16e-05	0.53	0.36	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
SARC	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	5.94	1.05e-08	1.16e-05	0.45	0.36	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
SARC	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	5.94	1.05e-08	1.17e-05	0.45	0.36	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
SARC	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-5.94	1.06e-08	1.17e-05	-0.41	-0.36	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
SARC	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	5.93	1.06e-08	1.17e-05	0.41	0.36	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	5.93	1.06e-08	1.17e-05	0.41	0.36	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
SARC	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-5.93	1.06e-08	1.18e-05	-0.45	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
SARC	cis	rs2836950	0.545	rs11700813	ENSG00000255568.3	BRWD1-AS2	-5.93	1.07e-08	1.18e-05	-0.34	-0.36	Menarche (age at onset);	chr21:39145543	chr21:39313935~39314962:+
SARC	cis	rs7615952	1	rs7616044	ENSG00000248787.1	RP11-666A20.4	-5.93	1.07e-08	1.18e-05	-0.57	-0.36	Blood pressure (smoking interaction);	chr3:125930511	chr3:125908005~125910272:-
SARC	cis	rs1707322	1	rs34694458	ENSG00000280836.1	AL355480.1	-5.93	1.08e-08	1.19e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs10158032	ENSG00000280836.1	AL355480.1	-5.93	1.08e-08	1.19e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45581219~45581321:-
SARC	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-5.93	1.08e-08	1.19e-05	-0.49	-0.36	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
SARC	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-5.93	1.08e-08	1.19e-05	-0.57	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
SARC	cis	rs9494145	0.68	rs9376092	ENSG00000232876.1	CTA-212D2.2	5.93	1.08e-08	1.19e-05	0.46	0.36	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106006	chr6:135055033~135060550:+
SARC	cis	rs77683187	1	rs77683187	ENSG00000254851.1	RP11-109L13.1	5.93	1.09e-08	1.21e-05	0.78	0.36	Breast cancer;	chr11:117214494	chr11:117135528~117138582:+
SARC	cis	rs2836950	0.501	rs35994303	ENSG00000255568.3	BRWD1-AS2	-5.93	1.1e-08	1.21e-05	-0.33	-0.36	Menarche (age at onset);	chr21:39314094	chr21:39313935~39314962:+
SARC	cis	rs5769707	0.521	rs5769719	ENSG00000188511.11	C22orf34	5.93	1.1e-08	1.21e-05	0.45	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49414524~49657542:-
SARC	cis	rs5769707	0.521	rs5769720	ENSG00000188511.11	C22orf34	5.93	1.1e-08	1.21e-05	0.45	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49414524~49657542:-
SARC	cis	rs5769707	0.521	rs5770633	ENSG00000188511.11	C22orf34	5.93	1.1e-08	1.21e-05	0.45	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49414524~49657542:-
SARC	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	5.93	1.11e-08	1.22e-05	0.42	0.36	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
SARC	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-5.93	1.11e-08	1.22e-05	-0.45	-0.36	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
SARC	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-5.93	1.11e-08	1.23e-05	-0.39	-0.36	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
SARC	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	5.92	1.12e-08	1.23e-05	0.46	0.36	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
SARC	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	5.92	1.12e-08	1.23e-05	0.46	0.36	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
SARC	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	5.92	1.12e-08	1.23e-05	0.46	0.36	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
SARC	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	5.92	1.13e-08	1.24e-05	0.5	0.36	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
SARC	cis	rs77204473	0.744	rs74955808	ENSG00000254851.1	RP11-109L13.1	5.92	1.13e-08	1.24e-05	0.89	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117121969	chr11:117135528~117138582:+
SARC	cis	rs80285556	1	rs79633979	ENSG00000161643.11	SIGLEC16	5.92	1.13e-08	1.24e-05	0.67	0.36	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49985355	chr19:49969673~49975814:+
SARC	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	5.92	1.13e-08	1.24e-05	0.67	0.36	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
SARC	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	5.92	1.13e-08	1.24e-05	0.67	0.36	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
SARC	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-5.92	1.13e-08	1.24e-05	-0.44	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
SARC	cis	rs7216064	0.953	rs4790981	ENSG00000278219.1	AC145343.1	-5.92	1.13e-08	1.24e-05	-0.43	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67925718	chr17:68101538~68101639:+
SARC	cis	rs113835537	0.597	rs3737525	ENSG00000255517.5	CTD-3074O7.5	-5.92	1.13e-08	1.25e-05	-0.41	-0.36	Airway imaging phenotypes;	chr11:66538884	chr11:66473490~66480233:-
SARC	cis	rs1707322	1	rs6661500	ENSG00000280836.1	AL355480.1	-5.92	1.14e-08	1.25e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45581219~45581321:-
SARC	cis	rs17772222	0.74	rs11847417	ENSG00000258983.2	RP11-507K2.2	-5.92	1.14e-08	1.25e-05	-0.36	-0.36	Coronary artery calcification;	chr14:88510606	chr14:88499334~88515502:+
SARC	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-5.92	1.14e-08	1.25e-05	-0.39	-0.36	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
SARC	cis	rs7246657	0.943	rs1559229	ENSG00000276846.1	CTD-3220F14.3	5.92	1.14e-08	1.26e-05	0.46	0.36	Coronary artery calcification;	chr19:37385295	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.882	rs6508719	ENSG00000276846.1	CTD-3220F14.3	5.92	1.14e-08	1.26e-05	0.46	0.36	Coronary artery calcification;	chr19:37386517	chr19:37314868~37315620:-
SARC	cis	rs1707322	1	rs785498	ENSG00000280836.1	AL355480.1	5.92	1.15e-08	1.26e-05	0.38	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45581219~45581321:-
SARC	cis	rs7809950	1	rs7809950	ENSG00000238832.1	snoU109	5.92	1.15e-08	1.26e-05	0.43	0.36	Coronary artery disease;	chr7:107597362	chr7:107603363~107603507:+
SARC	cis	rs80285556	1	rs111902838	ENSG00000161643.11	SIGLEC16	5.92	1.15e-08	1.26e-05	0.68	0.36	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49993357	chr19:49969673~49975814:+
SARC	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-5.92	1.15e-08	1.27e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
SARC	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-5.92	1.16e-08	1.27e-05	-0.49	-0.36	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-5.92	1.16e-08	1.27e-05	-0.49	-0.36	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-5.92	1.16e-08	1.27e-05	-0.49	-0.36	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-5.92	1.16e-08	1.27e-05	-0.49	-0.36	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
SARC	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-5.92	1.16e-08	1.27e-05	-0.4	-0.36	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
SARC	cis	rs113835537	0.529	rs57207756	ENSG00000255517.5	CTD-3074O7.5	-5.92	1.16e-08	1.27e-05	-0.41	-0.36	Airway imaging phenotypes;	chr11:66502889	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs17496250	ENSG00000255517.5	CTD-3074O7.5	-5.92	1.16e-08	1.27e-05	-0.41	-0.36	Airway imaging phenotypes;	chr11:66503303	chr11:66473490~66480233:-
SARC	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	5.92	1.16e-08	1.27e-05	0.45	0.36	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
SARC	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	5.92	1.16e-08	1.27e-05	0.45	0.36	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
SARC	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	5.92	1.16e-08	1.28e-05	0.4	0.36	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
SARC	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	5.92	1.17e-08	1.28e-05	0.4	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
SARC	cis	rs34375054	0.623	rs2297478	ENSG00000279233.1	RP11-158L12.4	5.92	1.17e-08	1.28e-05	0.43	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125107298	chr12:125138245~125141711:+
SARC	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	5.91	1.18e-08	1.29e-05	0.4	0.36	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
SARC	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-5.91	1.18e-08	1.29e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
SARC	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	5.91	1.18e-08	1.29e-05	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
SARC	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	5.91	1.18e-08	1.29e-05	0.7	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
SARC	cis	rs1865760	0.588	rs9467658	ENSG00000272462.2	U91328.19	-5.91	1.18e-08	1.3e-05	-0.33	-0.36	Height;	chr6:26010653	chr6:25992662~26001775:+
SARC	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	5.91	1.18e-08	1.3e-05	0.42	0.36	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	5.91	1.18e-08	1.3e-05	0.42	0.36	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
SARC	cis	rs1062177	0.502	rs10463321	ENSG00000213433.5	RPLP1P6	-5.91	1.19e-08	1.3e-05	-0.48	-0.36	Preschool internalizing problems;	chr5:151944344	chr5:151765859~151766378:-
SARC	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-5.91	1.21e-08	1.32e-05	-0.57	-0.36	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
SARC	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	5.91	1.21e-08	1.32e-05	0.51	0.36	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	5.91	1.21e-08	1.32e-05	0.51	0.36	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	5.91	1.21e-08	1.32e-05	0.51	0.36	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
SARC	cis	rs2303759	0.874	rs8108669	ENSG00000268686.1	AC010524.2	-5.91	1.21e-08	1.32e-05	-0.44	-0.36	Multiple sclerosis;	chr19:49342638	chr19:49368705~49388081:-
SARC	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-5.91	1.21e-08	1.32e-05	-0.41	-0.36	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
SARC	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-5.91	1.22e-08	1.33e-05	-0.44	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
SARC	cis	rs77204473	1	rs12272973	ENSG00000254851.1	RP11-109L13.1	5.91	1.22e-08	1.33e-05	0.74	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992331	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs10128682	ENSG00000254851.1	RP11-109L13.1	5.91	1.22e-08	1.33e-05	0.74	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992742	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs75826529	ENSG00000254851.1	RP11-109L13.1	5.91	1.22e-08	1.33e-05	0.74	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994384	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs74460214	ENSG00000254851.1	RP11-109L13.1	5.91	1.22e-08	1.33e-05	0.74	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994491	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs79349393	ENSG00000254851.1	RP11-109L13.1	5.91	1.22e-08	1.33e-05	0.74	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994651	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs10892056	ENSG00000254851.1	RP11-109L13.1	5.91	1.22e-08	1.33e-05	0.74	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116999695	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs12276805	ENSG00000254851.1	RP11-109L13.1	5.91	1.22e-08	1.33e-05	0.74	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008043	chr11:117135528~117138582:+
SARC	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-5.91	1.22e-08	1.33e-05	-0.36	-0.36	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
SARC	cis	rs1865760	0.533	rs1408270	ENSG00000272462.2	U91328.19	-5.91	1.22e-08	1.33e-05	-0.35	-0.36	Height;	chr6:25872956	chr6:25992662~26001775:+
SARC	cis	rs7246657	0.943	rs8106839	ENSG00000276846.1	CTD-3220F14.3	5.91	1.22e-08	1.33e-05	0.46	0.36	Coronary artery calcification;	chr19:37467573	chr19:37314868~37315620:-
SARC	cis	rs7216064	0.953	rs10445361	ENSG00000265055.1	AC145343.2	-5.91	1.23e-08	1.34e-05	-0.45	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67966122	chr17:68096046~68101474:-
SARC	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-5.91	1.23e-08	1.35e-05	-0.39	-0.36	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
SARC	cis	rs7809950	0.954	rs2894466	ENSG00000238832.1	snoU109	5.91	1.24e-08	1.35e-05	0.43	0.36	Coronary artery disease;	chr7:107602464	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.834	rs3801946	ENSG00000238832.1	snoU109	5.91	1.24e-08	1.35e-05	0.43	0.36	Coronary artery disease;	chr7:107602550	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs10258385	ENSG00000238832.1	snoU109	5.91	1.24e-08	1.35e-05	0.43	0.36	Coronary artery disease;	chr7:107602905	chr7:107603363~107603507:+
SARC	cis	rs6991838	0.67	rs869151	ENSG00000272010.1	CTD-3025N20.3	5.91	1.24e-08	1.35e-05	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65591850~65592472:-
SARC	cis	rs2946504	0.628	rs2946510	ENSG00000251468.2	RP11-369K16.1	-5.9	1.24e-08	1.35e-05	-0.37	-0.36	Type 2 diabetes;	chr8:12950371	chr8:12958387~12962200:+
SARC	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-5.9	1.24e-08	1.35e-05	-0.46	-0.36	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
SARC	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	5.9	1.24e-08	1.35e-05	0.45	0.36	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
SARC	cis	rs7809950	1	rs4727684	ENSG00000238832.1	snoU109	-5.9	1.24e-08	1.35e-05	-0.41	-0.36	Coronary artery disease;	chr7:107586025	chr7:107603363~107603507:+
SARC	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-5.9	1.24e-08	1.36e-05	-0.34	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
SARC	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	5.9	1.25e-08	1.36e-05	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
SARC	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	5.9	1.25e-08	1.36e-05	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
SARC	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	5.9	1.26e-08	1.37e-05	0.7	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
SARC	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	5.9	1.26e-08	1.37e-05	0.45	0.36	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
SARC	cis	rs4713118	0.513	rs156739	ENSG00000216901.1	AL022393.7	5.9	1.26e-08	1.37e-05	0.49	0.36	Parkinson's disease;	chr6:28045632	chr6:28176188~28176674:+
SARC	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	5.9	1.26e-08	1.37e-05	0.58	0.36	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
SARC	cis	rs2117029	0.727	rs10875910	ENSG00000258017.1	RP11-386G11.10	-5.9	1.26e-08	1.37e-05	-0.4	-0.36	Intelligence (multi-trait analysis);	chr12:49008610	chr12:49127782~49147869:+
SARC	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-5.9	1.26e-08	1.37e-05	-0.48	-0.36	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
SARC	cis	rs7216064	0.911	rs12449442	ENSG00000265055.1	AC145343.2	5.9	1.26e-08	1.37e-05	0.49	0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67951524	chr17:68096046~68101474:-
SARC	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-5.9	1.26e-08	1.38e-05	-0.44	-0.36	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
SARC	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-5.9	1.27e-08	1.38e-05	-0.5	-0.36	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-5.9	1.27e-08	1.38e-05	-0.5	-0.36	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
SARC	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	5.9	1.27e-08	1.38e-05	0.57	0.36	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
SARC	cis	rs17772222	0.917	rs7157149	ENSG00000258983.2	RP11-507K2.2	5.9	1.27e-08	1.38e-05	0.41	0.36	Coronary artery calcification;	chr14:88765501	chr14:88499334~88515502:+
SARC	cis	rs17270561	1	rs17270561	ENSG00000272462.2	U91328.19	5.9	1.27e-08	1.39e-05	0.4	0.36	Iron status biomarkers;	chr6:25820211	chr6:25992662~26001775:+
SARC	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	5.9	1.28e-08	1.39e-05	0.44	0.36	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
SARC	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-5.9	1.28e-08	1.39e-05	-0.35	-0.36	Height;	chr11:118809363	chr11:118704607~118750263:+
SARC	cis	rs2288884	0.515	rs8112458	ENSG00000275055.1	CTC-471J1.11	-5.9	1.28e-08	1.4e-05	-0.38	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52030052	chr19:52049007~52049754:+
SARC	cis	rs7181230	0.885	rs28736699	ENSG00000275636.1	RP11-521C20.5	5.9	1.29e-08	1.4e-05	0.44	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40055234	chr15:40078892~40079347:+
SARC	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	5.9	1.29e-08	1.4e-05	0.41	0.36	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	5.9	1.29e-08	1.4e-05	0.41	0.36	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	5.9	1.29e-08	1.4e-05	0.41	0.36	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	5.9	1.29e-08	1.4e-05	0.41	0.36	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	5.9	1.29e-08	1.4e-05	0.41	0.36	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
SARC	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	5.9	1.29e-08	1.4e-05	0.52	0.36	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
SARC	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	5.9	1.29e-08	1.41e-05	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
SARC	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	5.9	1.3e-08	1.41e-05	0.41	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
SARC	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-5.89	1.31e-08	1.42e-05	-0.37	-0.36	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
SARC	cis	rs7181230	0.885	rs2412478	ENSG00000275636.1	RP11-521C20.5	5.89	1.31e-08	1.42e-05	0.43	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40068971	chr15:40078892~40079347:+
SARC	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	5.89	1.31e-08	1.42e-05	0.33	0.36	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
SARC	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	5.89	1.31e-08	1.42e-05	0.45	0.36	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
SARC	cis	rs113835537	0.529	rs74869459	ENSG00000255517.5	CTD-3074O7.5	-5.89	1.32e-08	1.43e-05	-0.39	-0.36	Airway imaging phenotypes;	chr11:66529098	chr11:66473490~66480233:-
SARC	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-5.89	1.32e-08	1.43e-05	-0.36	-0.36	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
SARC	cis	rs1707322	1	rs785470	ENSG00000280836.1	AL355480.1	5.89	1.32e-08	1.43e-05	0.37	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211190	ENSG00000280836.1	AL355480.1	-5.89	1.32e-08	1.43e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs4390216	ENSG00000280836.1	AL355480.1	-5.89	1.32e-08	1.43e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.964	rs10437063	ENSG00000280836.1	AL355480.1	-5.89	1.32e-08	1.43e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs6676982	ENSG00000280836.1	AL355480.1	-5.89	1.32e-08	1.43e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs6429580	ENSG00000280836.1	AL355480.1	-5.89	1.32e-08	1.43e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.927	rs11211194	ENSG00000280836.1	AL355480.1	-5.89	1.32e-08	1.43e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.964	rs7546237	ENSG00000280836.1	AL355480.1	-5.89	1.32e-08	1.43e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.964	rs6697830	ENSG00000280836.1	AL355480.1	-5.89	1.32e-08	1.43e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs12060274	ENSG00000280836.1	AL355480.1	-5.89	1.32e-08	1.43e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211217	ENSG00000280836.1	AL355480.1	-5.89	1.32e-08	1.43e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45581219~45581321:-
SARC	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-5.89	1.32e-08	1.43e-05	-0.42	-0.36	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
SARC	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	5.89	1.33e-08	1.44e-05	0.34	0.36	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	5.89	1.33e-08	1.44e-05	0.34	0.36	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	5.89	1.33e-08	1.44e-05	0.34	0.36	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
SARC	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-5.89	1.33e-08	1.44e-05	-0.44	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
SARC	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-5.89	1.34e-08	1.44e-05	-0.37	-0.36	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
SARC	cis	rs80285556	1	rs80285556	ENSG00000161643.11	SIGLEC16	5.89	1.34e-08	1.45e-05	0.66	0.36	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50036913	chr19:49969673~49975814:+
SARC	cis	rs7743045	0.652	rs9387621	ENSG00000253194.1	RP11-351A11.1	5.89	1.34e-08	1.45e-05	0.44	0.36	Mean platelet volume;	chr6:118973412	chr6:118934785~119031541:+
SARC	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	5.89	1.35e-08	1.45e-05	0.39	0.36	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	5.89	1.35e-08	1.45e-05	0.39	0.36	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	5.89	1.35e-08	1.45e-05	0.39	0.36	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
SARC	cis	rs1707322	0.963	rs11211202	ENSG00000280836.1	AL355480.1	-5.89	1.35e-08	1.46e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs4660889	ENSG00000280836.1	AL355480.1	-5.89	1.35e-08	1.46e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs10890353	ENSG00000280836.1	AL355480.1	-5.89	1.35e-08	1.46e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs10890355	ENSG00000280836.1	AL355480.1	-5.89	1.35e-08	1.46e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211204	ENSG00000280836.1	AL355480.1	-5.89	1.35e-08	1.46e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45581219~45581321:-
SARC	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	5.89	1.35e-08	1.46e-05	0.35	0.36	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
SARC	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	5.89	1.35e-08	1.46e-05	0.66	0.36	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	5.89	1.35e-08	1.46e-05	0.66	0.36	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	5.89	1.35e-08	1.46e-05	0.66	0.36	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
SARC	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	5.89	1.35e-08	1.46e-05	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	5.89	1.35e-08	1.46e-05	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
SARC	cis	rs1707322	1	rs4660906	ENSG00000280836.1	AL355480.1	-5.89	1.36e-08	1.46e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs3922887	ENSG00000280836.1	AL355480.1	-5.89	1.36e-08	1.46e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs3922886	ENSG00000280836.1	AL355480.1	-5.89	1.36e-08	1.46e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45581219~45581321:-
SARC	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	5.89	1.36e-08	1.46e-05	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	5.89	1.36e-08	1.46e-05	0.42	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
SARC	cis	rs2029362	0.684	rs11030096	ENSG00000245573.6	BDNF-AS	-5.89	1.36e-08	1.47e-05	-0.31	-0.36	Total body bone mineral density;	chr11:27643996	chr11:27506838~27698174:+
SARC	cis	rs1865760	0.827	rs9461227	ENSG00000272810.1	U91328.22	-5.89	1.36e-08	1.47e-05	-0.36	-0.36	Height;	chr6:25960587	chr6:26013241~26013757:+
SARC	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	5.89	1.37e-08	1.47e-05	0.52	0.36	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
SARC	cis	rs1707322	1	rs4539075	ENSG00000280836.1	AL355480.1	-5.89	1.37e-08	1.48e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs34444543	ENSG00000280836.1	AL355480.1	-5.89	1.37e-08	1.48e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211219	ENSG00000280836.1	AL355480.1	-5.89	1.37e-08	1.48e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211222	ENSG00000280836.1	AL355480.1	-5.89	1.37e-08	1.48e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.928	rs7527244	ENSG00000280836.1	AL355480.1	-5.89	1.37e-08	1.48e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45581219~45581321:-
SARC	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	5.89	1.37e-08	1.48e-05	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	5.89	1.37e-08	1.48e-05	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
SARC	cis	rs2303759	0.709	rs2278405	ENSG00000268686.1	AC010524.2	5.89	1.37e-08	1.48e-05	0.45	0.36	Multiple sclerosis;	chr19:49309146	chr19:49368705~49388081:-
SARC	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-5.88	1.38e-08	1.48e-05	-0.44	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
SARC	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	5.88	1.38e-08	1.48e-05	0.34	0.36	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	5.88	1.38e-08	1.48e-05	0.34	0.36	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	5.88	1.38e-08	1.48e-05	0.34	0.36	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	5.88	1.38e-08	1.48e-05	0.34	0.36	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	5.88	1.38e-08	1.48e-05	0.34	0.36	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	5.88	1.38e-08	1.48e-05	0.34	0.36	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	5.88	1.38e-08	1.48e-05	0.34	0.36	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	5.88	1.38e-08	1.48e-05	0.34	0.36	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
SARC	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	5.88	1.38e-08	1.48e-05	0.34	0.36	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
SARC	cis	rs77204473	1	rs12294657	ENSG00000254851.1	RP11-109L13.1	5.88	1.38e-08	1.48e-05	0.78	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117135528~117138582:+
SARC	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-5.88	1.38e-08	1.48e-05	-0.36	-0.36	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
SARC	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	5.88	1.39e-08	1.49e-05	0.42	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
SARC	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-5.88	1.39e-08	1.5e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
SARC	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	5.88	1.4e-08	1.51e-05	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
SARC	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	5.88	1.41e-08	1.51e-05	0.42	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
SARC	cis	rs1707322	1	rs11211248	ENSG00000280836.1	AL355480.1	-5.88	1.41e-08	1.51e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45581219~45581321:-
SARC	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-5.88	1.41e-08	1.51e-05	-0.42	-0.36	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
SARC	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	5.88	1.41e-08	1.51e-05	0.7	0.36	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
SARC	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-5.88	1.41e-08	1.52e-05	-0.36	-0.36	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-5.88	1.41e-08	1.52e-05	-0.36	-0.36	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-5.88	1.41e-08	1.52e-05	-0.36	-0.36	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
SARC	cis	rs7246657	0.943	rs4803229	ENSG00000276846.1	CTD-3220F14.3	5.88	1.43e-08	1.53e-05	0.46	0.36	Coronary artery calcification;	chr19:37373780	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs4452075	ENSG00000276846.1	CTD-3220F14.3	5.88	1.43e-08	1.53e-05	0.46	0.36	Coronary artery calcification;	chr19:37388687	chr19:37314868~37315620:-
SARC	cis	rs9399135	0.517	rs1883354	ENSG00000232876.1	CTA-212D2.2	5.88	1.43e-08	1.53e-05	0.39	0.36	Red blood cell count;	chr6:135136403	chr6:135055033~135060550:+
SARC	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-5.88	1.43e-08	1.53e-05	-0.45	-0.36	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
SARC	cis	rs2836950	0.565	rs2836930	ENSG00000255568.3	BRWD1-AS2	-5.88	1.43e-08	1.53e-05	-0.33	-0.36	Menarche (age at onset);	chr21:39173730	chr21:39313935~39314962:+
SARC	cis	rs2836950	0.565	rs2836931	ENSG00000255568.3	BRWD1-AS2	-5.88	1.43e-08	1.53e-05	-0.33	-0.36	Menarche (age at onset);	chr21:39174643	chr21:39313935~39314962:+
SARC	cis	rs77204473	0.744	rs76942203	ENSG00000254851.1	RP11-109L13.1	5.88	1.43e-08	1.54e-05	0.77	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117102531	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.962	rs3805748	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149772542	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.736	rs10457851	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149775216	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.886	rs10872652	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149775303	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.886	rs12525871	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149775882	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.886	rs17672976	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149776207	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs2184369	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149776681	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs2342861	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149777561	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.926	rs2342860	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149777641	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs10872653	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149778907	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.736	rs3828701	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149791063	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.736	rs3805750	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149791065	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.926	rs3805751	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149791193	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs10872656	ENSG00000223701.3	RAET1E-AS1	5.88	1.44e-08	1.54e-05	0.38	0.36	Lung cancer;	chr6:149799444	chr6:149884431~149919508:+
SARC	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	5.88	1.44e-08	1.54e-05	0.39	0.36	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
SARC	cis	rs200986	1	rs200986	ENSG00000216901.1	AL022393.7	5.87	1.45e-08	1.55e-05	0.48	0.36	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28176188~28176674:+
SARC	cis	rs7615952	0.932	rs6438948	ENSG00000248787.1	RP11-666A20.4	5.87	1.46e-08	1.56e-05	0.55	0.36	Blood pressure (smoking interaction);	chr3:125931202	chr3:125908005~125910272:-
SARC	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	5.87	1.46e-08	1.56e-05	0.49	0.36	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
SARC	cis	rs916888	0.773	rs199447	ENSG00000261575.2	RP11-259G18.1	5.87	1.46e-08	1.56e-05	0.53	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46267037~46268694:+
SARC	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	5.87	1.46e-08	1.56e-05	0.46	0.36	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
SARC	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-5.87	1.46e-08	1.57e-05	-0.4	-0.36	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
SARC	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	5.87	1.47e-08	1.57e-05	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
SARC	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	5.87	1.47e-08	1.57e-05	0.44	0.36	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
SARC	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	5.87	1.47e-08	1.57e-05	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
SARC	cis	rs7181230	0.885	rs749748	ENSG00000275636.1	RP11-521C20.5	5.87	1.48e-08	1.58e-05	0.43	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40057708	chr15:40078892~40079347:+
SARC	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	5.87	1.49e-08	1.59e-05	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
SARC	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	5.87	1.5e-08	1.6e-05	0.42	0.36	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	5.87	1.5e-08	1.6e-05	0.42	0.36	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
SARC	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-5.87	1.5e-08	1.6e-05	-0.45	-0.36	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
SARC	cis	rs172166	0.637	rs1225597	ENSG00000216901.1	AL022393.7	5.87	1.5e-08	1.6e-05	0.47	0.36	Cardiac Troponin-T levels;	chr6:28194309	chr6:28176188~28176674:+
SARC	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-5.87	1.51e-08	1.61e-05	-0.46	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
SARC	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	5.87	1.51e-08	1.61e-05	0.41	0.36	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
SARC	cis	rs899997	0.814	rs28661610	ENSG00000261143.1	ADAMTS7P3	-5.87	1.52e-08	1.62e-05	-0.55	-0.36	Coronary artery disease or large artery stroke;	chr15:78692975	chr15:77976042~77993057:+
SARC	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-5.86	1.53e-08	1.63e-05	-0.41	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
SARC	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-5.86	1.53e-08	1.63e-05	-0.46	-0.36	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
SARC	cis	rs1707322	0.964	rs10890358	ENSG00000280836.1	AL355480.1	-5.86	1.53e-08	1.63e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs7547189	ENSG00000280836.1	AL355480.1	-5.86	1.53e-08	1.63e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs7547284	ENSG00000280836.1	AL355480.1	-5.86	1.53e-08	1.63e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211205	ENSG00000280836.1	AL355480.1	-5.86	1.53e-08	1.63e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs6675222	ENSG00000280836.1	AL355480.1	-5.86	1.53e-08	1.63e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs4660895	ENSG00000280836.1	AL355480.1	-5.86	1.53e-08	1.63e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs7531911	ENSG00000280836.1	AL355480.1	-5.86	1.53e-08	1.63e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs4660318	ENSG00000280836.1	AL355480.1	-5.86	1.53e-08	1.63e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs10890359	ENSG00000280836.1	AL355480.1	-5.86	1.53e-08	1.63e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs10890360	ENSG00000280836.1	AL355480.1	-5.86	1.53e-08	1.63e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45581219~45581321:-
SARC	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	5.86	1.53e-08	1.63e-05	0.64	0.36	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
SARC	cis	rs1865760	0.534	rs2032444	ENSG00000272810.1	U91328.22	-5.86	1.53e-08	1.63e-05	-0.39	-0.36	Height;	chr6:26046516	chr6:26013241~26013757:+
SARC	cis	rs17772222	0.74	rs10143744	ENSG00000258983.2	RP11-507K2.2	5.86	1.54e-08	1.64e-05	0.36	0.36	Coronary artery calcification;	chr14:88508073	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs1999177	ENSG00000258983.2	RP11-507K2.2	5.86	1.54e-08	1.64e-05	0.36	0.36	Coronary artery calcification;	chr14:88508298	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs1999176	ENSG00000258983.2	RP11-507K2.2	5.86	1.54e-08	1.64e-05	0.36	0.36	Coronary artery calcification;	chr14:88508371	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs1864746	ENSG00000258983.2	RP11-507K2.2	5.86	1.54e-08	1.64e-05	0.36	0.36	Coronary artery calcification;	chr14:88508455	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs1864747	ENSG00000258983.2	RP11-507K2.2	5.86	1.54e-08	1.64e-05	0.36	0.36	Coronary artery calcification;	chr14:88508523	chr14:88499334~88515502:+
SARC	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	5.86	1.55e-08	1.64e-05	0.52	0.36	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	5.86	1.55e-08	1.64e-05	0.52	0.36	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	5.86	1.55e-08	1.64e-05	0.52	0.36	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	5.86	1.55e-08	1.64e-05	0.52	0.36	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	5.86	1.55e-08	1.64e-05	0.52	0.36	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	5.86	1.55e-08	1.64e-05	0.52	0.36	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	5.86	1.55e-08	1.64e-05	0.52	0.36	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	5.86	1.55e-08	1.64e-05	0.52	0.36	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
SARC	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-5.86	1.55e-08	1.65e-05	-0.36	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
SARC	cis	rs6509701	0.813	rs8111139	ENSG00000268225.1	CTD-2331H12.5	5.86	1.56e-08	1.65e-05	0.35	0.36	Psychosis in Alzheimer's disease;	chr19:52871309	chr19:52861807~52862866:-
SARC	cis	rs1075232	0.579	rs58156651	ENSG00000270055.1	CTD-3092A11.2	-5.86	1.56e-08	1.65e-05	-0.71	-0.36	Survival in colorectal cancer (non-distant metastatic);	chr15:31456864	chr15:30487963~30490313:+
SARC	cis	rs113835537	0.529	rs3819247	ENSG00000255517.5	CTD-3074O7.5	-5.86	1.56e-08	1.66e-05	-0.39	-0.36	Airway imaging phenotypes;	chr11:66526308	chr11:66473490~66480233:-
SARC	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	5.86	1.56e-08	1.66e-05	0.39	0.36	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
SARC	cis	rs113835537	0.597	rs11227523	ENSG00000255517.5	CTD-3074O7.5	-5.86	1.56e-08	1.66e-05	-0.4	-0.36	Airway imaging phenotypes;	chr11:66538467	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.597	rs3825065	ENSG00000255517.5	CTD-3074O7.5	-5.86	1.56e-08	1.66e-05	-0.4	-0.36	Airway imaging phenotypes;	chr11:66543540	chr11:66473490~66480233:-
SARC	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	5.86	1.56e-08	1.66e-05	0.44	0.36	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
SARC	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	5.86	1.57e-08	1.66e-05	0.45	0.36	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
SARC	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	5.86	1.57e-08	1.66e-05	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
SARC	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	5.86	1.57e-08	1.66e-05	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
SARC	cis	rs113835537	0.529	rs11227515	ENSG00000255517.5	CTD-3074O7.5	-5.86	1.57e-08	1.67e-05	-0.39	-0.36	Airway imaging phenotypes;	chr11:66519912	chr11:66473490~66480233:-
SARC	cis	rs7743045	0.624	rs12527363	ENSG00000253194.1	RP11-351A11.1	5.86	1.57e-08	1.67e-05	0.45	0.36	Mean platelet volume;	chr6:119008222	chr6:118934785~119031541:+
SARC	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	5.86	1.58e-08	1.67e-05	0.43	0.36	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	5.86	1.58e-08	1.67e-05	0.43	0.36	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	5.86	1.58e-08	1.67e-05	0.43	0.36	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	5.86	1.58e-08	1.67e-05	0.43	0.36	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
SARC	cis	rs1707322	1	rs7527079	ENSG00000280836.1	AL355480.1	-5.86	1.58e-08	1.67e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45581219~45581321:-
SARC	cis	rs17767294	0.612	rs9461425	ENSG00000219392.1	RP1-265C24.5	-5.86	1.58e-08	1.67e-05	-0.65	-0.36	Parkinson's disease;	chr6:27951910	chr6:28115628~28116551:+
SARC	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-5.86	1.58e-08	1.68e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
SARC	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	5.86	1.58e-08	1.68e-05	0.42	0.36	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
SARC	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	5.86	1.59e-08	1.68e-05	0.46	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
SARC	cis	rs4713118	0.868	rs7756968	ENSG00000219392.1	RP1-265C24.5	-5.86	1.6e-08	1.69e-05	-0.53	-0.36	Parkinson's disease;	chr6:27767175	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.826	rs2893929	ENSG00000219392.1	RP1-265C24.5	-5.86	1.6e-08	1.69e-05	-0.53	-0.36	Parkinson's disease;	chr6:27770953	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.666	rs4140646	ENSG00000219392.1	RP1-265C24.5	-5.86	1.6e-08	1.69e-05	-0.53	-0.36	Parkinson's disease;	chr6:27771022	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.666	rs2893930	ENSG00000219392.1	RP1-265C24.5	-5.86	1.6e-08	1.69e-05	-0.53	-0.36	Parkinson's disease;	chr6:27771027	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.868	rs742047	ENSG00000219392.1	RP1-265C24.5	-5.86	1.6e-08	1.69e-05	-0.53	-0.36	Parkinson's disease;	chr6:27771601	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.868	rs760587	ENSG00000219392.1	RP1-265C24.5	-5.86	1.6e-08	1.69e-05	-0.53	-0.36	Parkinson's disease;	chr6:27772521	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	5.86	1.6e-08	1.69e-05	0.39	0.36	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
SARC	cis	rs3762637	0.941	rs75344200	ENSG00000272758.4	RP11-299J3.8	-5.86	1.6e-08	1.7e-05	-0.5	-0.36	LDL cholesterol levels;	chr3:122354574	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.941	rs9810996	ENSG00000272758.4	RP11-299J3.8	-5.86	1.6e-08	1.7e-05	-0.5	-0.36	LDL cholesterol levels;	chr3:122355540	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.941	rs9810999	ENSG00000272758.4	RP11-299J3.8	-5.86	1.6e-08	1.7e-05	-0.5	-0.36	LDL cholesterol levels;	chr3:122355544	chr3:122416207~122443180:+
SARC	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	5.86	1.6e-08	1.7e-05	0.35	0.36	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
SARC	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-5.86	1.6e-08	1.7e-05	-0.56	-0.36	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
SARC	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	5.86	1.6e-08	1.7e-05	0.46	0.36	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
SARC	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-5.86	1.61e-08	1.7e-05	-0.81	-0.36	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
SARC	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	5.86	1.61e-08	1.7e-05	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	5.85	1.61e-08	1.7e-05	0.37	0.36	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
SARC	cis	rs80285556	1	rs10500303	ENSG00000161643.11	SIGLEC16	5.85	1.61e-08	1.71e-05	0.68	0.36	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50008776	chr19:49969673~49975814:+
SARC	cis	rs1707322	1	rs946527	ENSG00000280836.1	AL355480.1	-5.85	1.62e-08	1.72e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45581219~45581321:-
SARC	cis	rs4968361	0.892	rs58003080	ENSG00000266992.1	DHX40P1	5.85	1.62e-08	1.72e-05	0.71	0.36	Schizophrenia;	chr17:59437596	chr17:59976009~60002384:-
SARC	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-5.85	1.63e-08	1.72e-05	-0.44	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
SARC	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-5.85	1.63e-08	1.72e-05	-0.44	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
SARC	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	5.85	1.63e-08	1.72e-05	0.42	0.36	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
SARC	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	5.85	1.64e-08	1.73e-05	0.39	0.36	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	5.85	1.64e-08	1.73e-05	0.39	0.36	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
SARC	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	5.85	1.64e-08	1.73e-05	0.52	0.36	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
SARC	cis	rs1707322	0.928	rs925524	ENSG00000280836.1	AL355480.1	5.85	1.64e-08	1.73e-05	0.37	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46031037	chr1:45581219~45581321:-
SARC	cis	rs4713118	0.868	rs2893928	ENSG00000219392.1	RP1-265C24.5	-5.85	1.64e-08	1.73e-05	-0.53	-0.36	Parkinson's disease;	chr6:27770651	chr6:28115628~28116551:+
SARC	cis	rs10895987	0.531	rs11227118	ENSG00000254614.2	AP003068.23	5.85	1.64e-08	1.73e-05	0.42	0.36	Blood protein levels;	chr11:65093183	chr11:65177606~65181834:-
SARC	cis	rs10895987	0.531	rs11227120	ENSG00000254614.2	AP003068.23	5.85	1.64e-08	1.73e-05	0.42	0.36	Blood protein levels;	chr11:65097387	chr11:65177606~65181834:-
SARC	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	5.85	1.64e-08	1.73e-05	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
SARC	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	5.85	1.64e-08	1.73e-05	0.34	0.36	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
SARC	cis	rs2836950	0.545	rs2297256	ENSG00000255568.3	BRWD1-AS2	-5.85	1.64e-08	1.73e-05	-0.32	-0.36	Menarche (age at onset);	chr21:39186495	chr21:39313935~39314962:+
SARC	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-5.85	1.64e-08	1.73e-05	-0.42	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
SARC	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-5.85	1.64e-08	1.73e-05	-0.35	-0.36	Height;	chr11:118808920	chr11:118704607~118750263:+
SARC	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-5.85	1.65e-08	1.74e-05	-0.41	-0.36	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
SARC	cis	rs17772222	0.917	rs1950806	ENSG00000258983.2	RP11-507K2.2	5.85	1.65e-08	1.74e-05	0.42	0.36	Coronary artery calcification;	chr14:88774412	chr14:88499334~88515502:+
SARC	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	5.85	1.66e-08	1.75e-05	0.42	0.36	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
SARC	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-5.85	1.66e-08	1.75e-05	-0.4	-0.36	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
SARC	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	5.85	1.67e-08	1.76e-05	0.35	0.36	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
SARC	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	5.85	1.67e-08	1.76e-05	0.45	0.36	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	5.85	1.67e-08	1.76e-05	0.45	0.36	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	5.85	1.67e-08	1.76e-05	0.45	0.36	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	5.85	1.67e-08	1.76e-05	0.45	0.36	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
SARC	cis	rs2288884	0.537	rs7254254	ENSG00000275055.1	CTC-471J1.11	-5.85	1.67e-08	1.76e-05	-0.37	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035824	chr19:52049007~52049754:+
SARC	cis	rs6991838	0.701	rs7829434	ENSG00000272010.1	CTD-3025N20.3	5.85	1.68e-08	1.77e-05	0.37	0.36	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65591850~65592472:-
SARC	cis	rs1075265	0.54	rs2542587	ENSG00000233266.1	HMGB1P31	5.85	1.68e-08	1.77e-05	0.42	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.563	rs2692537	ENSG00000233266.1	HMGB1P31	5.85	1.68e-08	1.77e-05	0.42	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54051334~54051760:+
SARC	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	5.85	1.68e-08	1.77e-05	0.68	0.36	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
SARC	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-5.85	1.68e-08	1.77e-05	-0.47	-0.36	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
SARC	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	5.85	1.68e-08	1.77e-05	0.44	0.36	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
SARC	cis	rs1707322	1	rs6682683	ENSG00000280836.1	AL355480.1	-5.85	1.69e-08	1.78e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45581219~45581321:-
SARC	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	5.85	1.69e-08	1.78e-05	0.44	0.36	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
SARC	cis	rs9322193	0.962	rs9322220	ENSG00000223701.3	RAET1E-AS1	5.85	1.69e-08	1.78e-05	0.38	0.36	Lung cancer;	chr6:149782897	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs10214845	ENSG00000223701.3	RAET1E-AS1	5.85	1.69e-08	1.78e-05	0.38	0.36	Lung cancer;	chr6:149783124	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs9767122	ENSG00000223701.3	RAET1E-AS1	5.85	1.69e-08	1.78e-05	0.38	0.36	Lung cancer;	chr6:149783553	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs1413654	ENSG00000223701.3	RAET1E-AS1	5.85	1.69e-08	1.78e-05	0.38	0.36	Lung cancer;	chr6:149783956	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.683	rs113281309	ENSG00000223701.3	RAET1E-AS1	5.85	1.69e-08	1.78e-05	0.38	0.36	Lung cancer;	chr6:149787289	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs9688809	ENSG00000223701.3	RAET1E-AS1	5.85	1.69e-08	1.78e-05	0.38	0.36	Lung cancer;	chr6:149787920	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs9689242	ENSG00000223701.3	RAET1E-AS1	5.85	1.69e-08	1.78e-05	0.38	0.36	Lung cancer;	chr6:149787970	chr6:149884431~149919508:+
SARC	cis	rs9322193	1	rs9767077	ENSG00000223701.3	RAET1E-AS1	5.85	1.69e-08	1.78e-05	0.38	0.36	Lung cancer;	chr6:149788479	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.926	rs9766562	ENSG00000223701.3	RAET1E-AS1	5.85	1.69e-08	1.78e-05	0.38	0.36	Lung cancer;	chr6:149788709	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9688938	ENSG00000223701.3	RAET1E-AS1	5.85	1.69e-08	1.78e-05	0.38	0.36	Lung cancer;	chr6:149788941	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs9688940	ENSG00000223701.3	RAET1E-AS1	5.85	1.69e-08	1.78e-05	0.38	0.36	Lung cancer;	chr6:149788977	chr6:149884431~149919508:+
SARC	cis	rs17772222	0.74	rs3783885	ENSG00000258983.2	RP11-507K2.2	5.85	1.69e-08	1.78e-05	0.36	0.36	Coronary artery calcification;	chr14:88510714	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs11159857	ENSG00000258983.2	RP11-507K2.2	5.85	1.69e-08	1.78e-05	0.36	0.36	Coronary artery calcification;	chr14:88510796	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs4390529	ENSG00000258983.2	RP11-507K2.2	5.85	1.69e-08	1.78e-05	0.36	0.36	Coronary artery calcification;	chr14:88510853	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.771	rs4516145	ENSG00000258983.2	RP11-507K2.2	5.85	1.69e-08	1.78e-05	0.36	0.36	Coronary artery calcification;	chr14:88510953	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs4594187	ENSG00000258983.2	RP11-507K2.2	5.85	1.69e-08	1.78e-05	0.36	0.36	Coronary artery calcification;	chr14:88511071	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs4514599	ENSG00000258983.2	RP11-507K2.2	5.85	1.69e-08	1.78e-05	0.36	0.36	Coronary artery calcification;	chr14:88511083	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs73317739	ENSG00000258983.2	RP11-507K2.2	5.85	1.69e-08	1.78e-05	0.36	0.36	Coronary artery calcification;	chr14:88511400	chr14:88499334~88515502:+
SARC	cis	rs1865760	0.622	rs10946807	ENSG00000272462.2	U91328.19	-5.84	1.7e-08	1.79e-05	-0.36	-0.36	Height;	chr6:26079410	chr6:25992662~26001775:+
SARC	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-5.84	1.71e-08	1.8e-05	-0.35	-0.36	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
SARC	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	5.84	1.71e-08	1.8e-05	0.44	0.36	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
SARC	cis	rs2303759	0.67	rs45549132	ENSG00000268686.1	AC010524.2	-5.84	1.71e-08	1.8e-05	-0.45	-0.36	Multiple sclerosis;	chr19:49290771	chr19:49368705~49388081:-
SARC	cis	rs7809950	1	rs3801948	ENSG00000238832.1	snoU109	-5.84	1.71e-08	1.8e-05	-0.41	-0.36	Coronary artery disease;	chr7:107598002	chr7:107603363~107603507:+
SARC	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
SARC	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-5.84	1.72e-08	1.8e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
SARC	cis	rs1865760	0.929	rs9467646	ENSG00000272810.1	U91328.22	-5.84	1.72e-08	1.8e-05	-0.36	-0.36	Height;	chr6:25957180	chr6:26013241~26013757:+
SARC	cis	rs7181230	0.885	rs28826672	ENSG00000275636.1	RP11-521C20.5	5.84	1.72e-08	1.8e-05	0.43	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40068165	chr15:40078892~40079347:+
SARC	cis	rs9494145	0.68	rs4895441	ENSG00000232876.1	CTA-212D2.2	5.84	1.72e-08	1.81e-05	0.46	0.36	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105435	chr6:135055033~135060550:+
SARC	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	5.84	1.73e-08	1.81e-05	0.5	0.36	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	5.84	1.73e-08	1.81e-05	0.5	0.36	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
SARC	cis	rs62103177	0.564	rs1715230	ENSG00000261126.6	RP11-795F19.1	5.84	1.73e-08	1.81e-05	0.34	0.36	Opioid sensitivity;	chr18:80090098	chr18:80046900~80095482:+
SARC	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	5.84	1.73e-08	1.82e-05	0.34	0.36	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
SARC	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-5.84	1.73e-08	1.82e-05	-0.41	-0.36	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
SARC	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	5.84	1.74e-08	1.83e-05	0.44	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
SARC	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-5.84	1.74e-08	1.83e-05	-0.35	-0.36	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
SARC	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-5.84	1.74e-08	1.83e-05	-0.35	-0.36	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
SARC	cis	rs172166	0.637	rs1225595	ENSG00000219392.1	RP1-265C24.5	-5.84	1.74e-08	1.83e-05	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28183562	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.962	rs9688412	ENSG00000223701.3	RAET1E-AS1	-5.84	1.75e-08	1.83e-05	-0.38	-0.36	Lung cancer;	chr6:149803147	chr6:149884431~149919508:+
SARC	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-5.84	1.75e-08	1.84e-05	-0.34	-0.36	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
SARC	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	5.84	1.75e-08	1.84e-05	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
SARC	cis	rs1865760	0.865	rs4478388	ENSG00000272810.1	U91328.22	-5.84	1.76e-08	1.85e-05	-0.36	-0.36	Height;	chr6:25953405	chr6:26013241~26013757:+
SARC	cis	rs2179367	0.887	rs2789488	ENSG00000231760.4	RP11-350J20.5	-5.84	1.77e-08	1.85e-05	-0.43	-0.36	Dupuytren's disease;	chr6:149404154	chr6:149796151~149826294:-
SARC	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	5.84	1.78e-08	1.86e-05	0.43	0.36	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
SARC	cis	rs1707322	1	rs6657720	ENSG00000280836.1	AL355480.1	-5.84	1.79e-08	1.87e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs7519181	ENSG00000280836.1	AL355480.1	-5.84	1.79e-08	1.87e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs7526369	ENSG00000280836.1	AL355480.1	-5.84	1.79e-08	1.87e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.963	rs10890371	ENSG00000280836.1	AL355480.1	-5.84	1.79e-08	1.87e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs10890372	ENSG00000280836.1	AL355480.1	-5.84	1.79e-08	1.87e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45581219~45581321:-
SARC	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-5.83	1.79e-08	1.88e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
SARC	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	5.83	1.79e-08	1.88e-05	0.46	0.36	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
SARC	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	5.83	1.79e-08	1.88e-05	0.41	0.36	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
SARC	cis	rs916888	0.773	rs199445	ENSG00000261575.2	RP11-259G18.1	5.83	1.8e-08	1.88e-05	0.51	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46267037~46268694:+
SARC	cis	rs916888	0.773	rs199443	ENSG00000261575.2	RP11-259G18.1	5.83	1.8e-08	1.88e-05	0.51	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46267037~46268694:+
SARC	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-5.83	1.8e-08	1.88e-05	-0.36	-0.36	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
SARC	cis	rs1707322	1	rs7553924	ENSG00000280836.1	AL355480.1	-5.83	1.8e-08	1.88e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs4641257	ENSG00000280836.1	AL355480.1	-5.83	1.8e-08	1.88e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs6693336	ENSG00000280836.1	AL355480.1	-5.83	1.8e-08	1.88e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45581219~45581321:-
SARC	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-5.83	1.8e-08	1.88e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-5.83	1.8e-08	1.88e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
SARC	cis	rs1707322	1	rs34446427	ENSG00000280836.1	AL355480.1	-5.83	1.8e-08	1.88e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.963	rs4660900	ENSG00000280836.1	AL355480.1	-5.83	1.8e-08	1.88e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs4454479	ENSG00000280836.1	AL355480.1	-5.83	1.8e-08	1.88e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs12403666	ENSG00000280836.1	AL355480.1	-5.83	1.8e-08	1.88e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs12077546	ENSG00000280836.1	AL355480.1	-5.83	1.8e-08	1.88e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs12124291	ENSG00000280836.1	AL355480.1	-5.83	1.8e-08	1.88e-05	-0.37	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45581219~45581321:-
SARC	cis	rs17772222	0.74	rs11845147	ENSG00000258983.2	RP11-507K2.2	5.83	1.8e-08	1.89e-05	0.36	0.36	Coronary artery calcification;	chr14:88502804	chr14:88499334~88515502:+
SARC	cis	rs1431005	0.893	rs9684748	ENSG00000250620.1	RP11-91J3.3	5.83	1.81e-08	1.89e-05	0.4	0.36	Response to statin therapy;	chr4:187398070	chr4:187413564~187415697:+
SARC	cis	rs607541	0.85	rs1017518	ENSG00000259520.4	CTD-2651B20.3	-5.83	1.81e-08	1.89e-05	-0.7	-0.36	Obesity-related traits;	chr15:45641109	chr15:45251580~45279251:-
SARC	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	5.83	1.82e-08	1.9e-05	0.41	0.36	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	5.83	1.82e-08	1.9e-05	0.41	0.36	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
SARC	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	5.83	1.82e-08	1.9e-05	0.47	0.36	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
SARC	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-5.83	1.82e-08	1.9e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-5.83	1.82e-08	1.9e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
SARC	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	5.83	1.82e-08	1.9e-05	0.38	0.36	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
SARC	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-5.83	1.82e-08	1.9e-05	-0.59	-0.36	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
SARC	cis	rs7809950	0.954	rs3779494	ENSG00000238832.1	snoU109	5.83	1.82e-08	1.9e-05	0.42	0.36	Coronary artery disease;	chr7:107609910	chr7:107603363~107603507:+
SARC	cis	rs607541	1	rs674568	ENSG00000259520.4	CTD-2651B20.3	-5.83	1.83e-08	1.91e-05	-0.51	-0.36	Obesity-related traits;	chr15:45644389	chr15:45251580~45279251:-
SARC	cis	rs2836950	0.52	rs2836966	ENSG00000255568.3	BRWD1-AS2	-5.83	1.83e-08	1.91e-05	-0.33	-0.36	Menarche (age at onset);	chr21:39265595	chr21:39313935~39314962:+
SARC	cis	rs1707322	0.928	rs6681068	ENSG00000280836.1	AL355480.1	-5.83	1.84e-08	1.91e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211228	ENSG00000280836.1	AL355480.1	-5.83	1.84e-08	1.91e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.963	rs11211229	ENSG00000280836.1	AL355480.1	-5.83	1.84e-08	1.91e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs9803784	ENSG00000280836.1	AL355480.1	-5.83	1.84e-08	1.91e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.963	rs12022335	ENSG00000280836.1	AL355480.1	-5.83	1.84e-08	1.91e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs10890375	ENSG00000280836.1	AL355480.1	-5.83	1.84e-08	1.91e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs10890377	ENSG00000280836.1	AL355480.1	-5.83	1.84e-08	1.91e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.963	rs10789484	ENSG00000280836.1	AL355480.1	-5.83	1.84e-08	1.91e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45581219~45581321:-
SARC	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-5.83	1.84e-08	1.92e-05	-0.36	-0.36	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
SARC	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-5.83	1.84e-08	1.92e-05	-0.36	-0.36	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
SARC	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-5.83	1.84e-08	1.92e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
SARC	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	5.83	1.85e-08	1.92e-05	0.44	0.36	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
SARC	cis	rs1865760	0.865	rs9467645	ENSG00000272810.1	U91328.22	-5.83	1.86e-08	1.94e-05	-0.36	-0.36	Height;	chr6:25954948	chr6:26013241~26013757:+
SARC	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	5.83	1.86e-08	1.94e-05	0.44	0.36	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
SARC	cis	rs4713118	0.539	rs200951	ENSG00000216901.1	AL022393.7	5.83	1.86e-08	1.94e-05	0.48	0.36	Parkinson's disease;	chr6:27868152	chr6:28176188~28176674:+
SARC	cis	rs2836950	0.565	rs4816617	ENSG00000255568.3	BRWD1-AS2	-5.83	1.87e-08	1.95e-05	-0.33	-0.36	Menarche (age at onset);	chr21:39168764	chr21:39313935~39314962:+
SARC	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	5.83	1.88e-08	1.95e-05	0.44	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
SARC	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	5.83	1.88e-08	1.96e-05	0.54	0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
SARC	cis	rs2288884	0.515	rs11084133	ENSG00000275055.1	CTC-471J1.11	-5.83	1.88e-08	1.96e-05	-0.37	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52041125	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.515	rs3752118	ENSG00000275055.1	CTC-471J1.11	-5.83	1.88e-08	1.96e-05	-0.37	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048233	chr19:52049007~52049754:+
SARC	cis	rs1431005	0.893	rs67136716	ENSG00000250620.1	RP11-91J3.3	5.82	1.9e-08	1.97e-05	0.39	0.36	Response to statin therapy;	chr4:187414928	chr4:187413564~187415697:+
SARC	cis	rs17772222	0.653	rs1346996	ENSG00000258983.2	RP11-507K2.2	5.82	1.9e-08	1.98e-05	0.35	0.36	Coronary artery calcification;	chr14:88507174	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs7160471	ENSG00000258983.2	RP11-507K2.2	5.82	1.9e-08	1.98e-05	0.35	0.36	Coronary artery calcification;	chr14:88507241	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs9323830	ENSG00000258983.2	RP11-507K2.2	5.82	1.9e-08	1.98e-05	0.35	0.36	Coronary artery calcification;	chr14:88507260	chr14:88499334~88515502:+
SARC	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	5.82	1.9e-08	1.98e-05	0.42	0.36	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
SARC	cis	rs1865760	0.865	rs1436306	ENSG00000272810.1	U91328.22	-5.82	1.9e-08	1.98e-05	-0.36	-0.36	Height;	chr6:25948193	chr6:26013241~26013757:+
SARC	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-5.82	1.91e-08	1.99e-05	-0.41	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
SARC	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	5.82	1.91e-08	1.99e-05	0.41	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
SARC	cis	rs7615952	0.866	rs6438949	ENSG00000171084.14	FAM86JP	5.82	1.92e-08	2e-05	0.57	0.36	Blood pressure (smoking interaction);	chr3:125931221	chr3:125916620~125930024:+
SARC	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	5.82	1.93e-08	2e-05	0.41	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
SARC	cis	rs172166	0.637	rs1225592	ENSG00000219392.1	RP1-265C24.5	-5.82	1.93e-08	2.01e-05	-0.47	-0.36	Cardiac Troponin-T levels;	chr6:28182464	chr6:28115628~28116551:+
SARC	cis	rs113835537	0.529	rs10896125	ENSG00000255517.5	CTD-3074O7.5	-5.82	1.93e-08	2.01e-05	-0.39	-0.36	Airway imaging phenotypes;	chr11:66521262	chr11:66473490~66480233:-
SARC	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	5.82	1.94e-08	2.01e-05	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
SARC	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	5.82	1.95e-08	2.02e-05	0.39	0.36	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
SARC	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-5.82	1.95e-08	2.02e-05	-0.36	-0.36	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
SARC	cis	rs9322193	0.962	rs9689447	ENSG00000223701.3	RAET1E-AS1	5.82	1.95e-08	2.03e-05	0.38	0.36	Lung cancer;	chr6:149789350	chr6:149884431~149919508:+
SARC	cis	rs4968361	0.892	rs11653976	ENSG00000266992.1	DHX40P1	-5.82	1.96e-08	2.03e-05	-0.68	-0.36	Schizophrenia;	chr17:59439633	chr17:59976009~60002384:-
SARC	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	5.82	1.96e-08	2.03e-05	0.4	0.36	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	5.82	1.96e-08	2.03e-05	0.4	0.36	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
SARC	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-5.82	1.97e-08	2.04e-05	-0.41	-0.36	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
SARC	cis	rs7216064	1	rs1976053	ENSG00000278219.1	AC145343.1	-5.82	1.97e-08	2.04e-05	-0.42	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836886	chr17:68101538~68101639:+
SARC	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	5.82	1.97e-08	2.04e-05	0.5	0.36	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	5.82	1.97e-08	2.04e-05	0.5	0.36	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
SARC	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-5.82	1.97e-08	2.04e-05	-0.33	-0.36	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
SARC	cis	rs1865760	0.865	rs1115920	ENSG00000272810.1	U91328.22	-5.82	1.97e-08	2.05e-05	-0.36	-0.36	Height;	chr6:25953799	chr6:26013241~26013757:+
SARC	cis	rs113835537	0.529	rs3741360	ENSG00000255517.5	CTD-3074O7.5	-5.82	1.97e-08	2.05e-05	-0.39	-0.36	Airway imaging phenotypes;	chr11:66532877	chr11:66473490~66480233:-
SARC	cis	rs17772222	0.545	rs1758846	ENSG00000258983.2	RP11-507K2.2	-5.82	1.97e-08	2.05e-05	-0.36	-0.36	Coronary artery calcification;	chr14:88449288	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.675	rs845769	ENSG00000258983.2	RP11-507K2.2	-5.82	1.97e-08	2.05e-05	-0.36	-0.36	Coronary artery calcification;	chr14:88461455	chr14:88499334~88515502:+
SARC	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	5.82	1.98e-08	2.05e-05	0.44	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
SARC	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-5.82	1.98e-08	2.05e-05	-0.35	-0.36	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
SARC	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	5.81	1.99e-08	2.06e-05	0.51	0.36	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
SARC	cis	rs2283792	0.792	rs151680	ENSG00000224086.5	LL22NC03-86G7.1	-5.81	2e-08	2.07e-05	-0.35	-0.36	Multiple sclerosis;	chr22:21918869	chr22:21938293~21977632:+
SARC	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-5.81	2e-08	2.07e-05	-0.4	-0.36	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
SARC	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-5.81	2e-08	2.07e-05	-0.4	-0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
SARC	cis	rs7216064	0.531	rs62084683	ENSG00000265055.1	AC145343.2	-5.81	2e-08	2.07e-05	-0.43	-0.36	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68035609	chr17:68096046~68101474:-
SARC	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	5.81	2e-08	2.07e-05	0.39	0.36	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	5.81	2e-08	2.07e-05	0.39	0.36	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
SARC	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	5.81	2e-08	2.07e-05	0.39	0.36	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	5.81	2e-08	2.07e-05	0.39	0.36	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	5.81	2e-08	2.07e-05	0.39	0.36	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	5.81	2.01e-08	2.08e-05	0.39	0.36	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
SARC	cis	rs113835537	0.529	rs11227511	ENSG00000255517.5	CTD-3074O7.5	-5.81	2.02e-08	2.08e-05	-0.39	-0.36	Airway imaging phenotypes;	chr11:66513773	chr11:66473490~66480233:-
SARC	cis	rs9494145	0.526	rs6924687	ENSG00000232876.1	CTA-212D2.2	-5.81	2.02e-08	2.09e-05	-0.53	-0.36	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135146383	chr6:135055033~135060550:+
SARC	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	5.81	2.02e-08	2.09e-05	0.38	0.36	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
SARC	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	5.81	2.02e-08	2.09e-05	0.56	0.36	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
SARC	cis	rs2562456	0.876	rs11085465	ENSG00000268081.1	RP11-678G14.2	-5.81	2.02e-08	2.09e-05	-0.54	-0.36	Pain;	chr19:21568988	chr19:21554640~21569237:-
SARC	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	5.81	2.03e-08	2.1e-05	0.44	0.36	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
SARC	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	5.81	2.04e-08	2.11e-05	0.4	0.36	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
SARC	cis	rs113835537	0.529	rs11227500	ENSG00000255517.5	CTD-3074O7.5	-5.81	2.05e-08	2.12e-05	-0.38	-0.36	Airway imaging phenotypes;	chr11:66505762	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs11227502	ENSG00000255517.5	CTD-3074O7.5	-5.81	2.05e-08	2.12e-05	-0.38	-0.36	Airway imaging phenotypes;	chr11:66506677	chr11:66473490~66480233:-
SARC	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	5.81	2.05e-08	2.12e-05	0.34	0.36	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
SARC	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	5.81	2.05e-08	2.12e-05	0.39	0.36	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
SARC	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	5.81	2.06e-08	2.12e-05	0.38	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
SARC	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-5.81	2.06e-08	2.12e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
SARC	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	5.81	2.07e-08	2.14e-05	0.42	0.36	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	5.81	2.07e-08	2.14e-05	0.42	0.36	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
SARC	cis	rs2280018	0.538	rs7404526	ENSG00000260735.1	RP11-72I8.1	-5.81	2.07e-08	2.14e-05	-0.33	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15094411~15109197:+
SARC	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-5.81	2.07e-08	2.14e-05	-0.51	-0.36	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-5.81	2.07e-08	2.14e-05	-0.51	-0.36	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
SARC	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-5.81	2.07e-08	2.14e-05	-0.51	-0.36	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-5.81	2.07e-08	2.14e-05	-0.51	-0.36	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
SARC	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-5.81	2.07e-08	2.14e-05	-0.51	-0.36	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-5.81	2.07e-08	2.14e-05	-0.51	-0.36	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
SARC	cis	rs1707322	1	rs4298677	ENSG00000280836.1	AL355480.1	-5.81	2.08e-08	2.14e-05	-0.36	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45581219~45581321:-
SARC	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	5.81	2.08e-08	2.14e-05	0.34	0.36	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
SARC	cis	rs9322193	0.923	rs7769101	ENSG00000223701.3	RAET1E-AS1	5.81	2.08e-08	2.14e-05	0.4	0.36	Lung cancer;	chr6:149848768	chr6:149884431~149919508:+
SARC	cis	rs6496044	0.507	rs2467096	ENSG00000202081.1	RNU6-1280P	-5.81	2.08e-08	2.15e-05	-0.4	-0.36	Interstitial lung disease;	chr15:85667447	chr15:85651522~85651628:-
SARC	cis	rs7246657	0.943	rs28373708	ENSG00000276846.1	CTD-3220F14.3	5.81	2.08e-08	2.15e-05	0.46	0.36	Coronary artery calcification;	chr19:37485757	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs1382357	ENSG00000276846.1	CTD-3220F14.3	5.81	2.08e-08	2.15e-05	0.46	0.36	Coronary artery calcification;	chr19:37486707	chr19:37314868~37315620:-
SARC	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	5.81	2.09e-08	2.15e-05	0.35	0.36	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
SARC	cis	rs1865760	0.534	rs72834629	ENSG00000272810.1	U91328.22	-5.81	2.09e-08	2.15e-05	-0.39	-0.36	Height;	chr6:26022804	chr6:26013241~26013757:+
SARC	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	5.81	2.09e-08	2.15e-05	0.44	0.36	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
SARC	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	5.8	2.09e-08	2.16e-05	0.43	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
SARC	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-5.8	2.09e-08	2.16e-05	-0.52	-0.36	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
SARC	cis	rs7181230	0.885	rs35781999	ENSG00000275636.1	RP11-521C20.5	5.8	2.1e-08	2.16e-05	0.43	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40063205	chr15:40078892~40079347:+
SARC	cis	rs7181230	0.885	rs28444847	ENSG00000275636.1	RP11-521C20.5	5.8	2.1e-08	2.16e-05	0.43	0.36	Dehydroepiandrosterone sulphate levels;	chr15:40064403	chr15:40078892~40079347:+
SARC	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-5.8	2.1e-08	2.17e-05	-0.35	-0.36	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
SARC	cis	rs9322193	0.923	rs11155683	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149779341	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9372044	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149780867	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs11155685	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149781649	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.632	rs3828700	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149791033	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs9689269	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149791861	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs62441335	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149792658	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs4816	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149793609	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.926	rs952166	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149798774	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs952165	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149798900	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.926	rs9285525	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149801253	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.884	rs2342858	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149805967	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs6914319	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149806304	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.884	rs2095375	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149807037	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs4869730	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149808187	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.884	rs11155689	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149808470	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs2151913	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149809506	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs2342857	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149809537	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.884	rs933055	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149809701	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs4869731	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149810072	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs4552	ENSG00000223701.3	RAET1E-AS1	5.8	2.1e-08	2.17e-05	0.38	0.36	Lung cancer;	chr6:149811183	chr6:149884431~149919508:+
SARC	cis	rs9309473	0.95	rs6756885	ENSG00000163016.8	ALMS1P	5.8	2.11e-08	2.17e-05	0.44	0.36	Metabolite levels;	chr2:73578045	chr2:73644919~73685576:+
SARC	cis	rs9322193	0.962	rs17673294	ENSG00000223701.3	RAET1E-AS1	5.8	2.12e-08	2.18e-05	0.38	0.36	Lung cancer;	chr6:149813857	chr6:149884431~149919508:+
SARC	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	5.8	2.12e-08	2.18e-05	0.54	0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
SARC	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-5.8	2.12e-08	2.18e-05	-0.43	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
SARC	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	5.8	2.13e-08	2.19e-05	0.35	0.36	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
SARC	cis	rs4713118	0.911	rs9461406	ENSG00000219392.1	RP1-265C24.5	5.8	2.13e-08	2.19e-05	0.51	0.36	Parkinson's disease;	chr6:27751985	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.866	rs9468217	ENSG00000219392.1	RP1-265C24.5	-5.8	2.13e-08	2.19e-05	-0.51	-0.36	Parkinson's disease;	chr6:27758688	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.911	rs9295746	ENSG00000219392.1	RP1-265C24.5	-5.8	2.13e-08	2.19e-05	-0.51	-0.36	Parkinson's disease;	chr6:27762285	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	5.8	2.13e-08	2.19e-05	0.41	0.36	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
SARC	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-5.8	2.14e-08	2.2e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-5.8	2.14e-08	2.2e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-5.8	2.14e-08	2.2e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-5.8	2.14e-08	2.2e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-5.8	2.14e-08	2.2e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-5.8	2.14e-08	2.2e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-5.8	2.14e-08	2.2e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-5.8	2.14e-08	2.2e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-5.8	2.14e-08	2.2e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-5.8	2.14e-08	2.2e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-5.8	2.14e-08	2.2e-05	-0.41	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
SARC	cis	rs80285556	0.85	rs55975323	ENSG00000161643.11	SIGLEC16	5.8	2.15e-08	2.2e-05	0.64	0.36	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50071686	chr19:49969673~49975814:+
SARC	cis	rs172166	0.637	rs1225595	ENSG00000216901.1	AL022393.7	5.8	2.15e-08	2.21e-05	0.46	0.36	Cardiac Troponin-T levels;	chr6:28183562	chr6:28176188~28176674:+
SARC	cis	rs1431005	1	rs12650667	ENSG00000250620.1	RP11-91J3.3	5.8	2.15e-08	2.21e-05	0.39	0.36	Response to statin therapy;	chr4:187424873	chr4:187413564~187415697:+
SARC	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-5.8	2.16e-08	2.21e-05	-0.48	-0.36	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
SARC	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-5.8	2.16e-08	2.22e-05	-0.51	-0.36	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
SARC	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-5.8	2.16e-08	2.22e-05	-0.41	-0.36	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
SARC	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	5.8	2.16e-08	2.22e-05	0.34	0.36	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
SARC	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-5.8	2.17e-08	2.23e-05	-0.4	-0.36	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
SARC	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	5.8	2.18e-08	2.23e-05	0.43	0.36	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	5.8	2.18e-08	2.23e-05	0.43	0.36	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
SARC	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	5.8	2.18e-08	2.23e-05	0.34	0.36	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
SARC	cis	rs7181230	0.885	rs4497657	ENSG00000275636.1	RP11-521C20.5	5.8	2.19e-08	2.25e-05	0.43	0.35	Dehydroepiandrosterone sulphate levels;	chr15:40067232	chr15:40078892~40079347:+
SARC	cis	rs9376098	0.698	rs6929368	ENSG00000232876.1	CTA-212D2.2	5.8	2.2e-08	2.26e-05	0.38	0.35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146587	chr6:135055033~135060550:+
SARC	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-5.8	2.2e-08	2.26e-05	-0.38	-0.35	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
SARC	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-5.8	2.2e-08	2.26e-05	-0.36	-0.35	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-5.8	2.2e-08	2.26e-05	-0.36	-0.35	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-5.8	2.2e-08	2.26e-05	-0.36	-0.35	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-5.8	2.2e-08	2.26e-05	-0.36	-0.35	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-5.8	2.2e-08	2.26e-05	-0.36	-0.35	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-5.8	2.2e-08	2.26e-05	-0.36	-0.35	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-5.8	2.2e-08	2.26e-05	-0.36	-0.35	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-5.8	2.2e-08	2.26e-05	-0.36	-0.35	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-5.8	2.2e-08	2.26e-05	-0.36	-0.35	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-5.8	2.2e-08	2.26e-05	-0.36	-0.35	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-5.8	2.2e-08	2.26e-05	-0.36	-0.35	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
SARC	cis	rs17270561	0.609	rs1408271	ENSG00000272462.2	U91328.19	-5.8	2.2e-08	2.26e-05	-0.32	-0.35	Iron status biomarkers;	chr6:25859393	chr6:25992662~26001775:+
SARC	cis	rs9309473	0.66	rs62151564	ENSG00000163016.8	ALMS1P	5.79	2.21e-08	2.26e-05	0.52	0.35	Metabolite levels;	chr2:73388321	chr2:73644919~73685576:+
SARC	cis	rs7246657	0.943	rs7252325	ENSG00000276846.1	CTD-3220F14.3	5.79	2.21e-08	2.26e-05	0.46	0.35	Coronary artery calcification;	chr19:37439743	chr19:37314868~37315620:-
SARC	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	5.79	2.21e-08	2.26e-05	0.41	0.35	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	5.79	2.21e-08	2.26e-05	0.41	0.35	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
SARC	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-5.79	2.22e-08	2.27e-05	-0.35	-0.35	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
SARC	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	5.79	2.22e-08	2.27e-05	0.35	0.35	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
SARC	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-5.79	2.22e-08	2.27e-05	-0.38	-0.35	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
SARC	cis	rs1431005	0.892	rs72725289	ENSG00000250620.1	RP11-91J3.3	5.79	2.23e-08	2.29e-05	0.38	0.35	Response to statin therapy;	chr4:187477579	chr4:187413564~187415697:+
SARC	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	5.79	2.24e-08	2.29e-05	0.39	0.35	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
SARC	cis	rs2179367	0.959	rs652807	ENSG00000231760.4	RP11-350J20.5	-5.79	2.25e-08	2.3e-05	-0.44	-0.35	Dupuytren's disease;	chr6:149416359	chr6:149796151~149826294:-
SARC	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-5.79	2.25e-08	2.3e-05	-0.37	-0.35	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
SARC	cis	rs113835537	0.66	rs7116940	ENSG00000255517.5	CTD-3074O7.5	-5.79	2.25e-08	2.3e-05	-0.39	-0.35	Airway imaging phenotypes;	chr11:66536424	chr11:66473490~66480233:-
SARC	cis	rs1707322	1	rs7532204	ENSG00000280836.1	AL355480.1	5.79	2.25e-08	2.3e-05	0.36	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.835	rs946525	ENSG00000280836.1	AL355480.1	5.79	2.25e-08	2.3e-05	0.36	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs946524	ENSG00000280836.1	AL355480.1	5.79	2.25e-08	2.3e-05	0.36	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs4660336	ENSG00000280836.1	AL355480.1	5.79	2.25e-08	2.3e-05	0.36	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45581219~45581321:-
SARC	cis	rs1865760	0.865	rs9393677	ENSG00000272810.1	U91328.22	-5.79	2.25e-08	2.3e-05	-0.36	-0.35	Height;	chr6:25945587	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.865	rs9393678	ENSG00000272810.1	U91328.22	-5.79	2.25e-08	2.3e-05	-0.36	-0.35	Height;	chr6:25945591	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.865	rs9467641	ENSG00000272810.1	U91328.22	-5.79	2.25e-08	2.3e-05	-0.36	-0.35	Height;	chr6:25947008	chr6:26013241~26013757:+
SARC	cis	rs6991838	0.671	rs13251307	ENSG00000272010.1	CTD-3025N20.3	5.79	2.26e-08	2.31e-05	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.733	rs10111844	ENSG00000272010.1	CTD-3025N20.3	5.79	2.26e-08	2.31e-05	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65591850~65592472:-
SARC	cis	rs3779195	0.929	rs10953260	ENSG00000272950.1	RP11-307C18.1	5.79	2.27e-08	2.32e-05	0.56	0.35	Sex hormone-binding globulin levels;	chr7:98404180	chr7:98322853~98323430:+
SARC	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-5.79	2.28e-08	2.33e-05	-0.51	-0.35	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
SARC	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-5.79	2.28e-08	2.33e-05	-0.51	-0.35	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-5.79	2.28e-08	2.33e-05	-0.51	-0.35	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-5.79	2.28e-08	2.33e-05	-0.51	-0.35	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-5.79	2.28e-08	2.33e-05	-0.51	-0.35	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
SARC	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-5.79	2.28e-08	2.33e-05	-0.51	-0.35	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
SARC	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-5.79	2.28e-08	2.33e-05	-0.51	-0.35	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-5.79	2.28e-08	2.33e-05	-0.51	-0.35	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
SARC	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-5.79	2.28e-08	2.33e-05	-0.51	-0.35	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
SARC	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	5.79	2.28e-08	2.33e-05	0.4	0.35	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
SARC	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	5.79	2.29e-08	2.33e-05	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
SARC	cis	rs7246657	0.943	rs7255785	ENSG00000276846.1	CTD-3220F14.3	5.79	2.29e-08	2.33e-05	0.47	0.35	Coronary artery calcification;	chr19:37480781	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs7255996	ENSG00000276846.1	CTD-3220F14.3	5.79	2.29e-08	2.33e-05	0.47	0.35	Coronary artery calcification;	chr19:37480797	chr19:37314868~37315620:-
SARC	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	5.79	2.29e-08	2.34e-05	0.4	0.35	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	5.79	2.29e-08	2.34e-05	0.4	0.35	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
SARC	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-5.79	2.29e-08	2.34e-05	-0.45	-0.35	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
SARC	cis	rs1865760	1	rs6905887	ENSG00000272462.2	U91328.19	-5.79	2.29e-08	2.34e-05	-0.34	-0.35	Height;	chr6:25911875	chr6:25992662~26001775:+
SARC	cis	rs1707322	1	rs6671754	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.963	rs6666763	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs4489497	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211235	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.893	rs9919275	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211236	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs4660328	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.928	rs61785614	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs9793167	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211237	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.963	rs11211238	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs10890380	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs4460583	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.963	rs4459051	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211239	ENSG00000280836.1	AL355480.1	-5.79	2.29e-08	2.34e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45581219~45581321:-
SARC	cis	rs8081395	0.805	rs1295927	ENSG00000266992.1	DHX40P1	5.79	2.3e-08	2.34e-05	0.38	0.35	White blood cell count;	chr17:59852174	chr17:59976009~60002384:-
SARC	cis	rs172166	0.769	rs149965	ENSG00000216901.1	AL022393.7	5.79	2.3e-08	2.34e-05	0.5	0.35	Cardiac Troponin-T levels;	chr6:28050911	chr6:28176188~28176674:+
SARC	cis	rs17772222	0.74	rs10138139	ENSG00000258983.2	RP11-507K2.2	5.79	2.32e-08	2.36e-05	0.35	0.35	Coronary artery calcification;	chr14:88510027	chr14:88499334~88515502:+
SARC	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	5.78	2.33e-08	2.37e-05	0.44	0.35	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
SARC	cis	rs17772222	0.74	rs7151164	ENSG00000258983.2	RP11-507K2.2	5.78	2.33e-08	2.37e-05	0.35	0.35	Coronary artery calcification;	chr14:88509329	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs12433026	ENSG00000258983.2	RP11-507K2.2	5.78	2.33e-08	2.37e-05	0.35	0.35	Coronary artery calcification;	chr14:88509495	chr14:88499334~88515502:+
SARC	cis	rs1865760	1	rs3799371	ENSG00000272462.2	U91328.19	5.78	2.33e-08	2.37e-05	0.33	0.35	Height;	chr6:25912588	chr6:25992662~26001775:+
SARC	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-5.78	2.33e-08	2.37e-05	-0.41	-0.35	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
SARC	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	5.78	2.33e-08	2.37e-05	0.41	0.35	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	5.78	2.33e-08	2.38e-05	0.41	0.35	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.962	rs3805753	ENSG00000223701.3	RAET1E-AS1	5.78	2.34e-08	2.38e-05	0.38	0.35	Lung cancer;	chr6:149795662	chr6:149884431~149919508:+
SARC	cis	rs6991838	0.702	rs34496943	ENSG00000272010.1	CTD-3025N20.3	5.78	2.34e-08	2.38e-05	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.733	rs13281090	ENSG00000272010.1	CTD-3025N20.3	5.78	2.34e-08	2.38e-05	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65591850~65592472:-
SARC	cis	rs17772222	0.876	rs12436982	ENSG00000258983.2	RP11-507K2.2	5.78	2.34e-08	2.38e-05	0.4	0.35	Coronary artery calcification;	chr14:88689862	chr14:88499334~88515502:+
SARC	cis	rs77204473	0.744	rs116861530	ENSG00000254851.1	RP11-109L13.1	5.78	2.34e-08	2.38e-05	0.79	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117091945	chr11:117135528~117138582:+
SARC	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-5.78	2.34e-08	2.38e-05	-0.45	-0.35	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
SARC	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-5.78	2.35e-08	2.39e-05	-0.35	-0.35	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
SARC	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	5.78	2.35e-08	2.39e-05	0.37	0.35	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
SARC	cis	rs1865760	0.929	rs2876693	ENSG00000272810.1	U91328.22	-5.78	2.35e-08	2.39e-05	-0.36	-0.35	Height;	chr6:25954206	chr6:26013241~26013757:+
SARC	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	5.78	2.35e-08	2.39e-05	0.44	0.35	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	5.78	2.35e-08	2.39e-05	0.44	0.35	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	5.78	2.35e-08	2.39e-05	0.44	0.35	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	5.78	2.35e-08	2.39e-05	0.44	0.35	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
SARC	cis	rs2836950	0.565	rs8134214	ENSG00000255568.3	BRWD1-AS2	-5.78	2.37e-08	2.41e-05	-0.32	-0.35	Menarche (age at onset);	chr21:39170441	chr21:39313935~39314962:+
SARC	cis	rs2836950	0.52	rs1980407	ENSG00000255568.3	BRWD1-AS2	-5.78	2.37e-08	2.41e-05	-0.32	-0.35	Menarche (age at onset);	chr21:39172035	chr21:39313935~39314962:+
SARC	cis	rs4713118	0.539	rs200988	ENSG00000216901.1	AL022393.7	5.78	2.37e-08	2.41e-05	0.47	0.35	Parkinson's disease;	chr6:27851575	chr6:28176188~28176674:+
SARC	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	5.78	2.37e-08	2.41e-05	0.44	0.35	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
SARC	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	5.78	2.37e-08	2.41e-05	0.45	0.35	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
SARC	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	5.78	2.37e-08	2.41e-05	0.45	0.35	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
SARC	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	5.78	2.37e-08	2.41e-05	0.45	0.35	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
SARC	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	5.78	2.37e-08	2.41e-05	0.45	0.35	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
SARC	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	5.78	2.37e-08	2.41e-05	0.45	0.35	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
SARC	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	5.78	2.37e-08	2.41e-05	0.41	0.35	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
SARC	cis	rs2739330	0.752	rs2330634	ENSG00000099984.9	GSTT2	-5.78	2.39e-08	2.43e-05	-0.42	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23980123~23983911:+
SARC	cis	rs916888	0.773	rs199448	ENSG00000261575.2	RP11-259G18.1	5.78	2.39e-08	2.43e-05	0.51	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46267037~46268694:+
SARC	cis	rs7246657	0.943	rs7253091	ENSG00000276846.1	CTD-3220F14.3	5.78	2.4e-08	2.43e-05	0.46	0.35	Coronary artery calcification;	chr19:37476312	chr19:37314868~37315620:-
SARC	cis	rs10885396	0.967	rs7094463	ENSG00000233547.1	RP11-57H14.2	5.78	2.4e-08	2.44e-05	0.34	0.35	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952224	chr10:112950646~112951875:-
SARC	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	5.78	2.4e-08	2.44e-05	0.4	0.35	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
SARC	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	5.78	2.42e-08	2.46e-05	0.42	0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
SARC	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-5.78	2.42e-08	2.46e-05	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
SARC	cis	rs1707322	1	rs11211200	ENSG00000280836.1	AL355480.1	-5.78	2.42e-08	2.46e-05	-0.37	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45581219~45581321:-
SARC	cis	rs4713118	0.513	rs149959	ENSG00000216901.1	AL022393.7	5.78	2.42e-08	2.46e-05	0.49	0.35	Parkinson's disease;	chr6:28046076	chr6:28176188~28176674:+
SARC	cis	rs172166	0.637	rs1225597	ENSG00000219392.1	RP1-265C24.5	-5.78	2.43e-08	2.46e-05	-0.46	-0.35	Cardiac Troponin-T levels;	chr6:28194309	chr6:28115628~28116551:+
SARC	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	5.78	2.43e-08	2.46e-05	0.44	0.35	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
SARC	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-5.78	2.44e-08	2.47e-05	-0.39	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
SARC	cis	rs77204473	1	rs77204473	ENSG00000254851.1	RP11-109L13.1	5.78	2.44e-08	2.47e-05	0.88	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934348	chr11:117135528~117138582:+
SARC	cis	rs1707322	0.963	rs9787412	ENSG00000280836.1	AL355480.1	-5.78	2.44e-08	2.47e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs4660896	ENSG00000280836.1	AL355480.1	-5.78	2.44e-08	2.47e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.928	rs10732844	ENSG00000280836.1	AL355480.1	-5.78	2.44e-08	2.47e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs12133129	ENSG00000280836.1	AL355480.1	-5.78	2.44e-08	2.47e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.963	rs4553121	ENSG00000280836.1	AL355480.1	-5.78	2.44e-08	2.47e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45581219~45581321:-
SARC	cis	rs1707322	0.963	rs6690652	ENSG00000280836.1	AL355480.1	-5.78	2.44e-08	2.47e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs6695421	ENSG00000280836.1	AL355480.1	-5.78	2.44e-08	2.47e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs11211223	ENSG00000280836.1	AL355480.1	-5.78	2.44e-08	2.47e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs6687301	ENSG00000280836.1	AL355480.1	-5.78	2.44e-08	2.47e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45581219~45581321:-
SARC	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	5.78	2.44e-08	2.47e-05	0.31	0.35	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
SARC	cis	rs7216064	0.7	rs4791295	ENSG00000265055.1	AC145343.2	5.77	2.45e-08	2.48e-05	0.46	0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68001201	chr17:68096046~68101474:-
SARC	cis	rs172166	0.637	rs1225592	ENSG00000216901.1	AL022393.7	5.77	2.47e-08	2.5e-05	0.46	0.35	Cardiac Troponin-T levels;	chr6:28182464	chr6:28176188~28176674:+
SARC	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	5.77	2.47e-08	2.5e-05	0.35	0.35	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	5.77	2.47e-08	2.5e-05	0.35	0.35	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	5.77	2.47e-08	2.5e-05	0.35	0.35	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
SARC	cis	rs7216064	0.7	rs4791295	ENSG00000278219.1	AC145343.1	-5.77	2.48e-08	2.5e-05	-0.44	-0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68001201	chr17:68101538~68101639:+
SARC	cis	rs113835537	0.559	rs11227497	ENSG00000255517.5	CTD-3074O7.5	-5.77	2.49e-08	2.52e-05	-0.38	-0.35	Airway imaging phenotypes;	chr11:66501993	chr11:66473490~66480233:-
SARC	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	5.77	2.5e-08	2.53e-05	0.42	0.35	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	5.77	2.5e-08	2.53e-05	0.42	0.35	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
SARC	cis	rs62103177	0.525	rs10438902	ENSG00000261126.6	RP11-795F19.1	-5.77	2.51e-08	2.53e-05	-0.35	-0.35	Opioid sensitivity;	chr18:79985640	chr18:80046900~80095482:+
SARC	cis	rs4273100	0.834	rs59415593	ENSG00000228157.4	AC007952.5	5.77	2.52e-08	2.54e-05	0.54	0.35	Schizophrenia;	chr17:19319911	chr17:19092974~19096837:+
SARC	cis	rs1865760	0.622	rs10946807	ENSG00000272810.1	U91328.22	-5.77	2.53e-08	2.55e-05	-0.37	-0.35	Height;	chr6:26079410	chr6:26013241~26013757:+
SARC	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-5.77	2.53e-08	2.56e-05	-0.39	-0.35	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-5.77	2.53e-08	2.56e-05	-0.39	-0.35	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	5.77	2.53e-08	2.56e-05	0.45	0.35	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
SARC	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	5.77	2.55e-08	2.57e-05	0.43	0.35	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
SARC	cis	rs1431005	0.893	rs68010462	ENSG00000250620.1	RP11-91J3.3	5.77	2.55e-08	2.57e-05	0.39	0.35	Response to statin therapy;	chr4:187418181	chr4:187413564~187415697:+
SARC	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	5.77	2.55e-08	2.57e-05	0.36	0.35	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
SARC	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-5.77	2.55e-08	2.57e-05	-0.35	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
SARC	cis	rs1865760	0.786	rs2164487	ENSG00000272810.1	U91328.22	-5.77	2.55e-08	2.57e-05	-0.36	-0.35	Height;	chr6:25950572	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.865	rs6929805	ENSG00000272810.1	U91328.22	-5.77	2.55e-08	2.57e-05	-0.36	-0.35	Height;	chr6:25950606	chr6:26013241~26013757:+
SARC	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	5.77	2.57e-08	2.59e-05	0.44	0.35	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
SARC	cis	rs17767294	0.612	rs12332927	ENSG00000219392.1	RP1-265C24.5	-5.77	2.57e-08	2.59e-05	-0.64	-0.35	Parkinson's disease;	chr6:27987337	chr6:28115628~28116551:+
SARC	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	5.77	2.57e-08	2.59e-05	0.33	0.35	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
SARC	cis	rs34375054	0.687	rs12303572	ENSG00000279233.1	RP11-158L12.4	5.77	2.57e-08	2.59e-05	0.42	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125126725	chr12:125138245~125141711:+
SARC	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-5.77	2.58e-08	2.59e-05	-0.43	-0.35	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
SARC	cis	rs7216064	1	rs7212293	ENSG00000278219.1	AC145343.1	-5.77	2.58e-08	2.59e-05	-0.42	-0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67851209	chr17:68101538~68101639:+
SARC	cis	rs7181230	0.885	rs17723133	ENSG00000275636.1	RP11-521C20.5	-5.76	2.58e-08	2.6e-05	-0.42	-0.35	Dehydroepiandrosterone sulphate levels;	chr15:40073217	chr15:40078892~40079347:+
SARC	cis	rs5769707	0.632	rs135871	ENSG00000235111.1	RP1-29C18.8	-5.76	2.59e-08	2.61e-05	-0.45	-0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49612657~49615716:-
SARC	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-5.76	2.6e-08	2.61e-05	-0.34	-0.35	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
SARC	cis	rs7615952	0.932	rs7629977	ENSG00000248787.1	RP11-666A20.4	-5.76	2.6e-08	2.61e-05	-0.56	-0.35	Blood pressure (smoking interaction);	chr3:125930730	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.932	rs7630077	ENSG00000248787.1	RP11-666A20.4	-5.76	2.6e-08	2.61e-05	-0.56	-0.35	Blood pressure (smoking interaction);	chr3:125930833	chr3:125908005~125910272:-
SARC	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	5.76	2.6e-08	2.61e-05	0.72	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
SARC	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	5.76	2.6e-08	2.62e-05	0.41	0.35	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
SARC	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-5.76	2.61e-08	2.62e-05	-0.39	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
SARC	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-5.76	2.61e-08	2.62e-05	-0.35	-0.35	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
SARC	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-5.76	2.61e-08	2.63e-05	-0.51	-0.35	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
SARC	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-5.76	2.61e-08	2.63e-05	-0.35	-0.35	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
SARC	cis	rs2288884	0.537	rs12151130	ENSG00000275055.1	CTC-471J1.11	-5.76	2.62e-08	2.63e-05	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060531	chr19:52049007~52049754:+
SARC	cis	rs4938330	0.681	rs12271169	ENSG00000254851.1	RP11-109L13.1	5.76	2.62e-08	2.63e-05	0.48	0.35	Blood protein levels;	chr11:117109305	chr11:117135528~117138582:+
SARC	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	5.76	2.63e-08	2.64e-05	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
SARC	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	5.76	2.63e-08	2.64e-05	0.45	0.35	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
SARC	cis	rs1865760	0.865	rs2164485	ENSG00000272810.1	U91328.22	-5.76	2.63e-08	2.65e-05	-0.35	-0.35	Height;	chr6:25951878	chr6:26013241~26013757:+
SARC	cis	rs7809950	0.784	rs7803102	ENSG00000238832.1	snoU109	5.76	2.64e-08	2.65e-05	0.41	0.35	Coronary artery disease;	chr7:107608484	chr7:107603363~107603507:+
SARC	cis	rs2946504	0.553	rs2977078	ENSG00000251468.2	RP11-369K16.1	-5.76	2.64e-08	2.65e-05	-0.37	-0.35	Type 2 diabetes;	chr8:12959997	chr8:12958387~12962200:+
SARC	cis	rs17772222	0.682	rs28371093	ENSG00000258983.2	RP11-507K2.2	5.76	2.65e-08	2.66e-05	0.36	0.35	Coronary artery calcification;	chr14:88486112	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.655	rs10150594	ENSG00000258983.2	RP11-507K2.2	5.76	2.65e-08	2.66e-05	0.36	0.35	Coronary artery calcification;	chr14:88489613	chr14:88499334~88515502:+
SARC	cis	rs1431005	0.892	rs72725288	ENSG00000250620.1	RP11-91J3.3	5.76	2.65e-08	2.66e-05	0.37	0.35	Response to statin therapy;	chr4:187477411	chr4:187413564~187415697:+
SARC	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	5.76	2.65e-08	2.66e-05	0.39	0.35	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
SARC	cis	rs2288884	0.515	rs2869602	ENSG00000275055.1	CTC-471J1.11	-5.76	2.66e-08	2.67e-05	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52072324	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.515	rs17779341	ENSG00000275055.1	CTC-471J1.11	-5.76	2.66e-08	2.67e-05	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047148	chr19:52049007~52049754:+
SARC	cis	rs4862750	0.872	rs7679956	ENSG00000249742.1	RP11-217E13.1	-5.76	2.66e-08	2.67e-05	-0.37	-0.35	Lobe attachment (rater-scored or self-reported);	chr4:186979075	chr4:186979490~187021973:-
SARC	cis	rs1823913	0.599	rs1378156	ENSG00000227542.1	AC092614.2	-5.76	2.67e-08	2.67e-05	-0.41	-0.35	Obesity-related traits;	chr2:191272466	chr2:191229165~191246172:-
SARC	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	5.76	2.67e-08	2.68e-05	0.44	0.35	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	5.76	2.67e-08	2.68e-05	0.44	0.35	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	5.76	2.67e-08	2.68e-05	0.44	0.35	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
SARC	cis	rs7216064	0.684	rs62084675	ENSG00000265055.1	AC145343.2	-5.76	2.67e-08	2.68e-05	-0.43	-0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68030909	chr17:68096046~68101474:-
SARC	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-5.76	2.69e-08	2.69e-05	-0.32	-0.35	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
SARC	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-5.76	2.69e-08	2.69e-05	-0.39	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
SARC	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	5.76	2.69e-08	2.69e-05	0.5	0.35	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
SARC	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	5.76	2.69e-08	2.7e-05	0.43	0.35	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
SARC	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	5.76	2.7e-08	2.71e-05	0.39	0.35	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
SARC	cis	rs4713118	0.513	rs149962	ENSG00000216901.1	AL022393.7	5.76	2.7e-08	2.71e-05	0.49	0.35	Parkinson's disease;	chr6:28048140	chr6:28176188~28176674:+
SARC	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	5.76	2.7e-08	2.71e-05	0.4	0.35	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
SARC	cis	rs6964833	0.554	rs112506907	ENSG00000277053.3	GTF2IP1	-5.76	2.7e-08	2.71e-05	-0.38	-0.35	Menarche (age at onset);	chr7:74654407	chr7:75185385~75237696:-
SARC	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	5.75	2.71e-08	2.72e-05	0.39	0.35	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
SARC	cis	rs2946504	0.607	rs2977080	ENSG00000251468.2	RP11-369K16.1	-5.75	2.72e-08	2.72e-05	-0.37	-0.35	Type 2 diabetes;	chr8:12959492	chr8:12958387~12962200:+
SARC	cis	rs2946504	0.553	rs2977079	ENSG00000251468.2	RP11-369K16.1	-5.75	2.72e-08	2.72e-05	-0.37	-0.35	Type 2 diabetes;	chr8:12959500	chr8:12958387~12962200:+
SARC	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	5.75	2.72e-08	2.72e-05	0.41	0.35	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	5.75	2.72e-08	2.72e-05	0.41	0.35	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	5.75	2.72e-08	2.72e-05	0.41	0.35	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	5.75	2.72e-08	2.72e-05	0.41	0.35	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	5.75	2.72e-08	2.72e-05	0.41	0.35	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	5.75	2.72e-08	2.72e-05	0.41	0.35	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	5.75	2.72e-08	2.72e-05	0.41	0.35	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
SARC	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	5.75	2.72e-08	2.72e-05	0.43	0.35	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
SARC	cis	rs2836950	0.565	rs2836926	ENSG00000255568.3	BRWD1-AS2	-5.75	2.74e-08	2.74e-05	-0.32	-0.35	Menarche (age at onset);	chr21:39164864	chr21:39313935~39314962:+
SARC	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-5.75	2.75e-08	2.75e-05	-0.34	-0.35	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
SARC	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-5.75	2.76e-08	2.76e-05	-0.43	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
SARC	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	5.75	2.76e-08	2.76e-05	0.39	0.35	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
SARC	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	5.75	2.76e-08	2.76e-05	0.35	0.35	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
SARC	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	5.75	2.77e-08	2.77e-05	0.37	0.35	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	5.75	2.77e-08	2.77e-05	0.37	0.35	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
SARC	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-5.75	2.77e-08	2.77e-05	-0.41	-0.35	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
SARC	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	5.75	2.81e-08	2.8e-05	0.38	0.35	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
SARC	cis	rs2303759	0.709	rs10411679	ENSG00000268686.1	AC010524.2	-5.75	2.81e-08	2.81e-05	-0.45	-0.35	Multiple sclerosis;	chr19:49323223	chr19:49368705~49388081:-
SARC	cis	rs34375054	0.641	rs34624329	ENSG00000279233.1	RP11-158L12.4	5.75	2.82e-08	2.81e-05	0.37	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125123482	chr12:125138245~125141711:+
SARC	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	5.75	2.82e-08	2.81e-05	0.4	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
SARC	cis	rs17772222	0.727	rs3179969	ENSG00000258983.2	RP11-507K2.2	5.75	2.82e-08	2.82e-05	0.35	0.35	Coronary artery calcification;	chr14:88396185	chr14:88499334~88515502:+
SARC	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-5.75	2.83e-08	2.82e-05	-0.43	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
SARC	cis	rs3822625	0.541	rs10042998	ENSG00000271828.1	CTD-2310F14.1	5.75	2.83e-08	2.82e-05	0.55	0.35	Breast cancer (early onset);	chr5:56909472	chr5:56927874~56929573:+
SARC	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	5.75	2.84e-08	2.83e-05	0.39	0.35	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
SARC	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	5.75	2.85e-08	2.84e-05	0.44	0.35	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	5.75	2.85e-08	2.84e-05	0.44	0.35	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
SARC	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	5.75	2.85e-08	2.84e-05	0.33	0.35	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
SARC	cis	rs7216064	1	rs7209675	ENSG00000278219.1	AC145343.1	-5.75	2.85e-08	2.84e-05	-0.41	-0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67835142	chr17:68101538~68101639:+
SARC	cis	rs113835537	0.529	rs11227514	ENSG00000255517.5	CTD-3074O7.5	-5.75	2.85e-08	2.84e-05	-0.38	-0.35	Airway imaging phenotypes;	chr11:66519156	chr11:66473490~66480233:-
SARC	cis	rs2836950	0.545	rs2836922	ENSG00000255568.3	BRWD1-AS2	-5.75	2.86e-08	2.84e-05	-0.33	-0.35	Menarche (age at onset);	chr21:39144382	chr21:39313935~39314962:+
SARC	cis	rs77204473	0.744	rs79955870	ENSG00000254851.1	RP11-109L13.1	5.75	2.86e-08	2.84e-05	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117066645	chr11:117135528~117138582:+
SARC	cis	rs77204473	0.744	rs11216261	ENSG00000254851.1	RP11-109L13.1	5.75	2.86e-08	2.84e-05	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069494	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.623	rs7928320	ENSG00000254851.1	RP11-109L13.1	5.75	2.86e-08	2.84e-05	0.75	0.35	Subjective well-being;	chr11:117072037	chr11:117135528~117138582:+
SARC	cis	rs2303759	0.709	rs10414921	ENSG00000268686.1	AC010524.2	-5.74	2.86e-08	2.85e-05	-0.45	-0.35	Multiple sclerosis;	chr19:49319790	chr19:49368705~49388081:-
SARC	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	5.74	2.87e-08	2.85e-05	0.37	0.35	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
SARC	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-5.74	2.87e-08	2.86e-05	-0.4	-0.35	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
SARC	cis	rs17772222	0.74	rs10138002	ENSG00000258983.2	RP11-507K2.2	-5.74	2.87e-08	2.86e-05	-0.35	-0.35	Coronary artery calcification;	chr14:88510071	chr14:88499334~88515502:+
SARC	cis	rs2836950	0.565	rs8130320	ENSG00000255568.3	BRWD1-AS2	-5.74	2.88e-08	2.87e-05	-0.32	-0.35	Menarche (age at onset);	chr21:39208332	chr21:39313935~39314962:+
SARC	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	5.74	2.9e-08	2.88e-05	0.4	0.35	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
SARC	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-5.74	2.9e-08	2.88e-05	-0.56	-0.35	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
SARC	cis	rs7216064	0.954	rs9907491	ENSG00000278219.1	AC145343.1	5.74	2.92e-08	2.9e-05	0.42	0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67953877	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.954	rs4790974	ENSG00000278219.1	AC145343.1	5.74	2.92e-08	2.9e-05	0.42	0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67954991	chr17:68101538~68101639:+
SARC	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	5.74	2.92e-08	2.91e-05	0.35	0.35	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
SARC	cis	rs7246657	0.882	rs59224125	ENSG00000276846.1	CTD-3220F14.3	5.74	2.93e-08	2.91e-05	0.46	0.35	Coronary artery calcification;	chr19:37472303	chr19:37314868~37315620:-
SARC	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	5.74	2.94e-08	2.92e-05	0.44	0.35	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
SARC	cis	rs1075265	0.563	rs2692536	ENSG00000233266.1	HMGB1P31	5.74	2.94e-08	2.92e-05	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54051334~54051760:+
SARC	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	5.74	2.95e-08	2.93e-05	0.46	0.35	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	5.74	2.95e-08	2.93e-05	0.46	0.35	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
SARC	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-5.74	2.95e-08	2.93e-05	-0.41	-0.35	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
SARC	cis	rs62103177	0.608	rs613847	ENSG00000261126.6	RP11-795F19.1	-5.74	2.97e-08	2.95e-05	-0.35	-0.35	Opioid sensitivity;	chr18:80087736	chr18:80046900~80095482:+
SARC	cis	rs62103177	0.525	rs612913	ENSG00000261126.6	RP11-795F19.1	-5.74	2.97e-08	2.95e-05	-0.35	-0.35	Opioid sensitivity;	chr18:80087974	chr18:80046900~80095482:+
SARC	cis	rs17772222	0.701	rs1627444	ENSG00000258983.2	RP11-507K2.2	-5.74	2.97e-08	2.95e-05	-0.36	-0.35	Coronary artery calcification;	chr14:88413784	chr14:88499334~88515502:+
SARC	cis	rs524281	0.731	rs7931167	ENSG00000255320.1	RP11-755F10.1	-5.74	2.98e-08	2.96e-05	-0.56	-0.35	Electroencephalogram traits;	chr11:66036279	chr11:66244840~66246239:-
SARC	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	5.74	2.98e-08	2.96e-05	0.45	0.35	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
SARC	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-5.74	2.98e-08	2.96e-05	-0.49	-0.35	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-5.74	2.98e-08	2.96e-05	-0.49	-0.35	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
SARC	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	5.74	2.99e-08	2.96e-05	0.51	0.35	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
SARC	cis	rs75920871	0.588	rs7112111	ENSG00000254851.1	RP11-109L13.1	5.74	2.99e-08	2.96e-05	0.48	0.35	Subjective well-being;	chr11:117110142	chr11:117135528~117138582:+
SARC	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	5.74	3e-08	2.97e-05	0.53	0.35	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
SARC	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	5.74	3.01e-08	2.98e-05	0.36	0.35	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
SARC	cis	rs2288884	0.515	rs73053909	ENSG00000275055.1	CTC-471J1.11	-5.74	3.01e-08	2.98e-05	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032864	chr19:52049007~52049754:+
SARC	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	5.74	3.01e-08	2.98e-05	0.53	0.35	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	5.74	3.01e-08	2.98e-05	0.53	0.35	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	5.74	3.01e-08	2.98e-05	0.53	0.35	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
SARC	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	5.73	3.01e-08	2.98e-05	0.43	0.35	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
SARC	cis	rs2303759	0.709	rs10422677	ENSG00000268686.1	AC010524.2	-5.73	3.02e-08	2.99e-05	-0.45	-0.35	Multiple sclerosis;	chr19:49321033	chr19:49368705~49388081:-
SARC	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	5.73	3.02e-08	2.99e-05	0.49	0.35	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
SARC	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	5.73	3.03e-08	3e-05	0.4	0.35	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
SARC	cis	rs4972806	0.739	rs10834	ENSG00000226363.3	HAGLROS	-5.73	3.04e-08	3e-05	-0.48	-0.35	IgG glycosylation;	chr2:176177359	chr2:176177717~176179008:+
SARC	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	5.73	3.04e-08	3.01e-05	0.44	0.35	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	5.73	3.04e-08	3.01e-05	0.44	0.35	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
SARC	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	5.73	3.05e-08	3.01e-05	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
SARC	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-5.73	3.05e-08	3.02e-05	-0.4	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
SARC	cis	rs2303759	0.709	rs8102658	ENSG00000268686.1	AC010524.2	-5.73	3.05e-08	3.02e-05	-0.45	-0.35	Multiple sclerosis;	chr19:49325598	chr19:49368705~49388081:-
SARC	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	5.73	3.06e-08	3.02e-05	0.4	0.35	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	5.73	3.06e-08	3.02e-05	0.4	0.35	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	5.73	3.06e-08	3.02e-05	0.4	0.35	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	5.73	3.06e-08	3.02e-05	0.4	0.35	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
SARC	cis	rs77204473	0.744	rs74420345	ENSG00000254851.1	RP11-109L13.1	5.73	3.07e-08	3.03e-05	0.79	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117092561	chr11:117135528~117138582:+
SARC	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	5.73	3.07e-08	3.03e-05	0.55	0.35	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
SARC	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	5.73	3.07e-08	3.03e-05	0.55	0.35	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
SARC	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	5.73	3.08e-08	3.04e-05	0.53	0.35	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
SARC	cis	rs7246657	0.943	rs10420754	ENSG00000276846.1	CTD-3220F14.3	5.73	3.08e-08	3.04e-05	0.45	0.35	Coronary artery calcification;	chr19:37468470	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10415937	ENSG00000276846.1	CTD-3220F14.3	5.73	3.08e-08	3.04e-05	0.45	0.35	Coronary artery calcification;	chr19:37339162	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10414904	ENSG00000276846.1	CTD-3220F14.3	5.73	3.08e-08	3.04e-05	0.45	0.35	Coronary artery calcification;	chr19:37339186	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10417844	ENSG00000276846.1	CTD-3220F14.3	5.73	3.08e-08	3.04e-05	0.45	0.35	Coronary artery calcification;	chr19:37346685	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs1373991	ENSG00000276846.1	CTD-3220F14.3	5.73	3.08e-08	3.04e-05	0.45	0.35	Coronary artery calcification;	chr19:37348009	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10405407	ENSG00000276846.1	CTD-3220F14.3	5.73	3.08e-08	3.04e-05	0.45	0.35	Coronary artery calcification;	chr19:37348262	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs12709813	ENSG00000276846.1	CTD-3220F14.3	5.73	3.08e-08	3.04e-05	0.45	0.35	Coronary artery calcification;	chr19:37354081	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs13345116	ENSG00000276846.1	CTD-3220F14.3	5.73	3.08e-08	3.04e-05	0.45	0.35	Coronary artery calcification;	chr19:37356196	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.765	rs7247259	ENSG00000276846.1	CTD-3220F14.3	5.73	3.08e-08	3.04e-05	0.45	0.35	Coronary artery calcification;	chr19:37360188	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs3745765	ENSG00000276846.1	CTD-3220F14.3	5.73	3.08e-08	3.04e-05	0.45	0.35	Coronary artery calcification;	chr19:37363333	chr19:37314868~37315620:-
SARC	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	5.73	3.08e-08	3.04e-05	0.44	0.35	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
SARC	cis	rs899997	1	rs11072793	ENSG00000261143.1	ADAMTS7P3	5.73	3.08e-08	3.05e-05	0.53	0.35	Coronary artery disease or large artery stroke;	chr15:78714100	chr15:77976042~77993057:+
SARC	cis	rs113835537	0.529	rs11227501	ENSG00000255517.5	CTD-3074O7.5	-5.73	3.08e-08	3.05e-05	-0.38	-0.35	Airway imaging phenotypes;	chr11:66506601	chr11:66473490~66480233:-
SARC	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-5.73	3.11e-08	3.07e-05	-0.32	-0.35	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
SARC	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-5.73	3.11e-08	3.07e-05	-0.35	-0.35	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
SARC	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-5.73	3.12e-08	3.08e-05	-0.45	-0.35	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
SARC	cis	rs2303759	0.709	rs3760667	ENSG00000268686.1	AC010524.2	-5.73	3.12e-08	3.08e-05	-0.44	-0.35	Multiple sclerosis;	chr19:49311575	chr19:49368705~49388081:-
SARC	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	5.73	3.12e-08	3.08e-05	0.33	0.35	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
SARC	cis	rs13129231	1	rs13129231	ENSG00000206820.1	RNU1-138P	-5.73	3.13e-08	3.08e-05	-0.35	-0.35	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113431725	chr4:113420323~113420486:+
SARC	cis	rs7246657	0.943	rs4803460	ENSG00000276846.1	CTD-3220F14.3	5.73	3.13e-08	3.08e-05	0.46	0.35	Coronary artery calcification;	chr19:37394326	chr19:37314868~37315620:-
SARC	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	5.73	3.13e-08	3.08e-05	0.39	0.35	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
SARC	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-5.73	3.13e-08	3.09e-05	-0.48	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
SARC	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	5.73	3.13e-08	3.09e-05	0.42	0.35	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
SARC	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-5.73	3.15e-08	3.11e-05	-0.43	-0.35	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
SARC	cis	rs11651753	0.636	rs12602494	ENSG00000264920.1	RP11-6N17.4	-5.73	3.15e-08	3.11e-05	-0.39	-0.35	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47960241	chr17:47891255~47895812:-
SARC	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	5.73	3.17e-08	3.12e-05	0.39	0.35	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs7259968	ENSG00000276846.1	CTD-3220F14.3	5.72	3.17e-08	3.12e-05	0.45	0.35	Coronary artery calcification;	chr19:37320952	chr19:37314868~37315620:-
SARC	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	5.72	3.19e-08	3.14e-05	0.51	0.35	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
SARC	cis	rs1707322	1	rs4524994	ENSG00000280836.1	AL355480.1	-5.72	3.2e-08	3.15e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45581219~45581321:-
SARC	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-5.72	3.21e-08	3.16e-05	-0.48	-0.35	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-5.72	3.21e-08	3.16e-05	-0.48	-0.35	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-5.72	3.21e-08	3.16e-05	-0.48	-0.35	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-5.72	3.21e-08	3.16e-05	-0.48	-0.35	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-5.72	3.21e-08	3.16e-05	-0.48	-0.35	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
SARC	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	5.72	3.21e-08	3.16e-05	0.49	0.35	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
SARC	cis	rs2288884	0.537	rs12151270	ENSG00000275055.1	CTC-471J1.11	-5.72	3.21e-08	3.16e-05	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058984	chr19:52049007~52049754:+
SARC	cis	rs2303759	0.709	rs8102574	ENSG00000268686.1	AC010524.2	-5.72	3.22e-08	3.17e-05	-0.45	-0.35	Multiple sclerosis;	chr19:49325640	chr19:49368705~49388081:-
SARC	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	5.72	3.23e-08	3.17e-05	0.49	0.35	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	5.72	3.23e-08	3.17e-05	0.49	0.35	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
SARC	cis	rs875971	0.651	rs313829	ENSG00000237310.1	GS1-124K5.4	-5.72	3.23e-08	3.18e-05	-0.4	-0.35	Aortic root size;	chr7:66087510	chr7:66493706~66495474:+
SARC	cis	rs17772222	0.917	rs12588535	ENSG00000258983.2	RP11-507K2.2	5.72	3.23e-08	3.18e-05	0.41	0.35	Coronary artery calcification;	chr14:88781900	chr14:88499334~88515502:+
SARC	cis	rs1823874	0.72	rs1993296	ENSG00000182397.13	DNM1P46	-5.72	3.23e-08	3.18e-05	-0.39	-0.35	IgG glycosylation;	chr15:99823383	chr15:99790156~99806927:-
SARC	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-5.72	3.24e-08	3.19e-05	-0.44	-0.35	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
SARC	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	5.72	3.26e-08	3.21e-05	0.54	0.35	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
SARC	cis	rs1799949	0.931	rs34474989	ENSG00000267681.1	CTD-3199J23.6	-5.72	3.26e-08	3.21e-05	-0.39	-0.35	Menopause (age at onset);	chr17:43368042	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.931	rs9912203	ENSG00000267681.1	CTD-3199J23.6	5.72	3.26e-08	3.21e-05	0.39	0.35	Menopause (age at onset);	chr17:43367777	chr17:43144956~43145255:+
SARC	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	5.72	3.27e-08	3.22e-05	0.38	0.35	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
SARC	cis	rs17772222	0.696	rs28666030	ENSG00000258983.2	RP11-507K2.2	5.72	3.27e-08	3.22e-05	0.35	0.35	Coronary artery calcification;	chr14:88511463	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs28493481	ENSG00000258983.2	RP11-507K2.2	5.72	3.27e-08	3.22e-05	0.35	0.35	Coronary artery calcification;	chr14:88511491	chr14:88499334~88515502:+
SARC	cis	rs113835537	0.529	rs11824771	ENSG00000255517.5	CTD-3074O7.5	-5.72	3.28e-08	3.22e-05	-0.38	-0.35	Airway imaging phenotypes;	chr11:66495079	chr11:66473490~66480233:-
SARC	cis	rs4862750	0.915	rs6835681	ENSG00000249742.1	RP11-217E13.1	-5.72	3.28e-08	3.22e-05	-0.39	-0.35	Lobe attachment (rater-scored or self-reported);	chr4:186982322	chr4:186979490~187021973:-
SARC	cis	rs7246657	0.943	rs2081096	ENSG00000276846.1	CTD-3220F14.3	5.72	3.29e-08	3.22e-05	0.45	0.35	Coronary artery calcification;	chr19:37473798	chr19:37314868~37315620:-
SARC	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	5.72	3.29e-08	3.22e-05	0.33	0.35	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
SARC	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	5.72	3.29e-08	3.22e-05	0.33	0.35	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
SARC	cis	rs113835537	0.529	rs10501397	ENSG00000255517.5	CTD-3074O7.5	-5.72	3.29e-08	3.22e-05	-0.39	-0.35	Airway imaging phenotypes;	chr11:66505505	chr11:66473490~66480233:-
SARC	cis	rs2288884	0.537	rs7254131	ENSG00000275055.1	CTC-471J1.11	-5.72	3.29e-08	3.22e-05	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035774	chr19:52049007~52049754:+
SARC	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-5.72	3.3e-08	3.22e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
SARC	cis	rs2029362	0.684	rs2203877	ENSG00000245573.6	BDNF-AS	5.72	3.3e-08	3.22e-05	0.3	0.35	Total body bone mineral density;	chr11:27649363	chr11:27506838~27698174:+
SARC	cis	rs2946504	0.553	rs2946498	ENSG00000251468.2	RP11-369K16.1	-5.72	3.31e-08	3.22e-05	-0.37	-0.35	Type 2 diabetes;	chr8:12960578	chr8:12958387~12962200:+
SARC	cis	rs2946504	0.506	rs9644017	ENSG00000251468.2	RP11-369K16.1	-5.72	3.31e-08	3.22e-05	-0.37	-0.35	Type 2 diabetes;	chr8:12961375	chr8:12958387~12962200:+
SARC	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	5.72	3.31e-08	3.23e-05	0.36	0.35	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
SARC	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	5.72	3.31e-08	3.23e-05	0.45	0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
SARC	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	5.72	3.31e-08	3.23e-05	0.39	0.35	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	5.72	3.31e-08	3.23e-05	0.39	0.35	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	5.72	3.31e-08	3.23e-05	0.39	0.35	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	5.72	3.31e-08	3.23e-05	0.39	0.35	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	5.72	3.31e-08	3.23e-05	0.39	0.35	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	5.72	3.31e-08	3.23e-05	0.39	0.35	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	5.72	3.31e-08	3.23e-05	0.39	0.35	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	5.72	3.31e-08	3.23e-05	0.39	0.35	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	5.72	3.31e-08	3.23e-05	0.39	0.35	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	5.72	3.31e-08	3.23e-05	0.39	0.35	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	5.72	3.31e-08	3.23e-05	0.39	0.35	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	5.72	3.31e-08	3.23e-05	0.39	0.35	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
SARC	cis	rs7615952	0.688	rs4422259	ENSG00000171084.14	FAM86JP	5.72	3.33e-08	3.24e-05	0.5	0.35	Blood pressure (smoking interaction);	chr3:125826988	chr3:125916620~125930024:+
SARC	cis	rs2836950	0.52	rs8130240	ENSG00000255568.3	BRWD1-AS2	-5.72	3.33e-08	3.24e-05	-0.32	-0.35	Menarche (age at onset);	chr21:39166182	chr21:39313935~39314962:+
SARC	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-5.72	3.33e-08	3.24e-05	-0.35	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-5.72	3.33e-08	3.24e-05	-0.35	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
SARC	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	5.72	3.34e-08	3.25e-05	0.36	0.35	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
SARC	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-5.71	3.34e-08	3.25e-05	-0.43	-0.35	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
SARC	cis	rs1799949	0.859	rs11657004	ENSG00000267681.1	CTD-3199J23.6	-5.71	3.34e-08	3.25e-05	-0.39	-0.35	Menopause (age at onset);	chr17:43365383	chr17:43144956~43145255:+
SARC	cis	rs7216064	0.954	rs9907491	ENSG00000265055.1	AC145343.2	-5.71	3.35e-08	3.26e-05	-0.44	-0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67953877	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.954	rs4790974	ENSG00000265055.1	AC145343.2	-5.71	3.35e-08	3.26e-05	-0.44	-0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67954991	chr17:68096046~68101474:-
SARC	cis	rs77204473	0.744	rs76883864	ENSG00000254851.1	RP11-109L13.1	5.71	3.36e-08	3.26e-05	0.86	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117181009	chr11:117135528~117138582:+
SARC	cis	rs113835537	0.529	rs7950790	ENSG00000255517.5	CTD-3074O7.5	-5.71	3.36e-08	3.26e-05	-0.38	-0.35	Airway imaging phenotypes;	chr11:66490582	chr11:66473490~66480233:-
SARC	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-5.71	3.37e-08	3.27e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-5.71	3.37e-08	3.27e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
SARC	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-5.71	3.37e-08	3.28e-05	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
SARC	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	5.71	3.38e-08	3.28e-05	0.39	0.35	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
SARC	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	5.71	3.38e-08	3.28e-05	0.39	0.35	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
SARC	cis	rs7181230	0.813	rs4924417	ENSG00000275636.1	RP11-521C20.5	5.71	3.38e-08	3.29e-05	0.42	0.35	Dehydroepiandrosterone sulphate levels;	chr15:40074738	chr15:40078892~40079347:+
SARC	cis	rs1431005	0.893	rs7663709	ENSG00000250620.1	RP11-91J3.3	5.71	3.39e-08	3.29e-05	0.39	0.35	Response to statin therapy;	chr4:187414777	chr4:187413564~187415697:+
SARC	cis	rs2179367	0.887	rs2789492	ENSG00000231760.4	RP11-350J20.5	-5.71	3.39e-08	3.29e-05	-0.44	-0.35	Dupuytren's disease;	chr6:149426243	chr6:149796151~149826294:-
SARC	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	5.71	3.4e-08	3.3e-05	0.44	0.35	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
SARC	cis	rs4865169	0.934	rs12650737	ENSG00000269949.1	RP11-738E22.3	-5.71	3.4e-08	3.3e-05	-0.4	-0.35	Breast cancer;	chr4:57026309	chr4:56960927~56961373:-
SARC	cis	rs17772222	0.682	rs1864744	ENSG00000258983.2	RP11-507K2.2	-5.71	3.42e-08	3.32e-05	-0.35	-0.35	Coronary artery calcification;	chr14:88484662	chr14:88499334~88515502:+
SARC	cis	rs160451	0.966	rs160447	ENSG00000251136.7	RP11-37B2.1	5.71	3.42e-08	3.32e-05	0.4	0.35	Leprosy;	chr8:89647432	chr8:89609409~89757727:-
SARC	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	5.71	3.44e-08	3.34e-05	0.43	0.35	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
SARC	cis	rs7246657	0.943	rs6508711	ENSG00000276846.1	CTD-3220F14.3	5.71	3.44e-08	3.34e-05	0.45	0.35	Coronary artery calcification;	chr19:37324232	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.882	rs6508716	ENSG00000276846.1	CTD-3220F14.3	5.71	3.44e-08	3.34e-05	0.45	0.35	Coronary artery calcification;	chr19:37328108	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.882	rs13345148	ENSG00000276846.1	CTD-3220F14.3	5.71	3.44e-08	3.34e-05	0.45	0.35	Coronary artery calcification;	chr19:37328729	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs7257672	ENSG00000276846.1	CTD-3220F14.3	5.71	3.44e-08	3.34e-05	0.45	0.35	Coronary artery calcification;	chr19:37332957	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.891	rs7257495	ENSG00000276846.1	CTD-3220F14.3	5.71	3.44e-08	3.34e-05	0.45	0.35	Coronary artery calcification;	chr19:37332974	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.882	rs10412043	ENSG00000276846.1	CTD-3220F14.3	5.71	3.44e-08	3.34e-05	0.45	0.35	Coronary artery calcification;	chr19:37335724	chr19:37314868~37315620:-
SARC	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	5.71	3.44e-08	3.34e-05	0.33	0.35	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
SARC	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	5.71	3.44e-08	3.34e-05	0.39	0.35	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
SARC	cis	rs6991838	0.701	rs17395275	ENSG00000272010.1	CTD-3025N20.3	5.71	3.45e-08	3.34e-05	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65591850~65592472:-
SARC	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-5.71	3.46e-08	3.35e-05	-0.35	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-5.71	3.46e-08	3.35e-05	-0.35	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-5.71	3.46e-08	3.35e-05	-0.35	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
SARC	cis	rs2303759	0.626	rs12982246	ENSG00000268686.1	AC010524.2	-5.71	3.47e-08	3.36e-05	-0.43	-0.35	Multiple sclerosis;	chr19:49297912	chr19:49368705~49388081:-
SARC	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-5.71	3.48e-08	3.37e-05	-0.66	-0.35	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
SARC	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-5.71	3.48e-08	3.37e-05	-0.35	-0.35	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
SARC	cis	rs4713118	0.869	rs4713121	ENSG00000219392.1	RP1-265C24.5	-5.71	3.51e-08	3.4e-05	-0.49	-0.35	Parkinson's disease;	chr6:27754285	chr6:28115628~28116551:+
SARC	cis	rs2404602	0.569	rs2469249	ENSG00000259422.1	RP11-593F23.1	-5.71	3.51e-08	3.4e-05	-0.45	-0.35	Blood metabolite levels;	chr15:76479721	chr15:76174891~76181486:-
SARC	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-5.7	3.51e-08	3.4e-05	-0.42	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
SARC	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	5.7	3.52e-08	3.41e-05	0.43	0.35	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
SARC	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-5.7	3.53e-08	3.42e-05	-0.32	-0.35	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
SARC	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	5.7	3.56e-08	3.44e-05	0.43	0.35	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
SARC	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	5.7	3.56e-08	3.44e-05	0.44	0.35	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	5.7	3.56e-08	3.44e-05	0.44	0.35	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	5.7	3.56e-08	3.44e-05	0.44	0.35	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	5.7	3.56e-08	3.44e-05	0.44	0.35	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
SARC	cis	rs1431005	0.793	rs7695310	ENSG00000250620.1	RP11-91J3.3	5.7	3.57e-08	3.45e-05	0.39	0.35	Response to statin therapy;	chr4:187415987	chr4:187413564~187415697:+
SARC	cis	rs7216064	1	rs6504549	ENSG00000278219.1	AC145343.1	-5.7	3.59e-08	3.46e-05	-0.41	-0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67892668	chr17:68101538~68101639:+
SARC	cis	rs7246657	0.943	rs7408563	ENSG00000276846.1	CTD-3220F14.3	5.7	3.59e-08	3.47e-05	0.46	0.35	Coronary artery calcification;	chr19:37317683	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs7258692	ENSG00000276846.1	CTD-3220F14.3	5.7	3.59e-08	3.47e-05	0.46	0.35	Coronary artery calcification;	chr19:37327927	chr19:37314868~37315620:-
SARC	cis	rs2283792	0.566	rs1005579	ENSG00000224086.5	LL22NC03-86G7.1	-5.7	3.59e-08	3.47e-05	-0.35	-0.35	Multiple sclerosis;	chr22:21946569	chr22:21938293~21977632:+
SARC	cis	rs6569992	0.5	rs75623964	ENSG00000232876.1	CTA-212D2.2	-5.7	3.6e-08	3.47e-05	-0.52	-0.35	Red blood cell traits;	chr6:135147172	chr6:135055033~135060550:+
SARC	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	5.7	3.6e-08	3.47e-05	0.45	0.35	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
SARC	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	5.7	3.6e-08	3.48e-05	0.41	0.35	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
SARC	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	5.7	3.63e-08	3.5e-05	0.43	0.35	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
SARC	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	5.7	3.64e-08	3.51e-05	0.41	0.35	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
SARC	cis	rs17772222	0.839	rs2274735	ENSG00000258983.2	RP11-507K2.2	5.7	3.67e-08	3.53e-05	0.34	0.35	Coronary artery calcification;	chr14:88505414	chr14:88499334~88515502:+
SARC	cis	rs1707322	1	rs10890365	ENSG00000280836.1	AL355480.1	-5.7	3.67e-08	3.54e-05	-0.35	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45581219~45581321:-
SARC	cis	rs56751865	1	rs56751865	ENSG00000254851.1	RP11-109L13.1	5.7	3.67e-08	3.54e-05	0.73	0.35	Lobe attachment (rater scored);	chr11:117066155	chr11:117135528~117138582:+
SARC	cis	rs5821446	1	rs5821446	ENSG00000265055.1	AC145343.2	-5.7	3.68e-08	3.55e-05	-0.43	-0.35	Eosinophil percentage of granulocytes;	chr17:67966422	chr17:68096046~68101474:-
SARC	cis	rs4934494	0.911	rs7098233	ENSG00000240996.1	RP11-80H5.7	5.7	3.69e-08	3.55e-05	0.36	0.35	Red blood cell count;	chr10:89663111	chr10:89694295~89697928:-
SARC	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-5.7	3.69e-08	3.56e-05	-0.4	-0.35	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
SARC	cis	rs858239	0.665	rs858305	ENSG00000226816.2	AC005082.12	-5.69	3.7e-08	3.57e-05	-0.42	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23206013~23208045:+
SARC	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-5.69	3.71e-08	3.58e-05	-0.38	-0.35	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
SARC	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	5.69	3.72e-08	3.58e-05	0.41	0.35	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
SARC	cis	rs1431005	0.893	rs7676864	ENSG00000250620.1	RP11-91J3.3	5.69	3.72e-08	3.58e-05	0.38	0.35	Response to statin therapy;	chr4:187400331	chr4:187413564~187415697:+
SARC	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	5.69	3.73e-08	3.59e-05	0.39	0.35	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
SARC	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	5.69	3.74e-08	3.6e-05	0.36	0.35	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
SARC	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	5.69	3.74e-08	3.6e-05	0.36	0.35	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
SARC	cis	rs1865760	0.663	rs9348704	ENSG00000272810.1	U91328.22	-5.69	3.74e-08	3.6e-05	-0.33	-0.35	Height;	chr6:26000165	chr6:26013241~26013757:+
SARC	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	5.69	3.75e-08	3.6e-05	0.43	0.35	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
SARC	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	5.69	3.75e-08	3.6e-05	0.43	0.35	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
SARC	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	5.69	3.77e-08	3.62e-05	0.34	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
SARC	cis	rs17772222	1	rs17698817	ENSG00000258983.2	RP11-507K2.2	5.69	3.77e-08	3.62e-05	0.39	0.35	Coronary artery calcification;	chr14:88356632	chr14:88499334~88515502:+
SARC	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	5.69	3.8e-08	3.65e-05	0.4	0.35	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
SARC	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	5.69	3.81e-08	3.66e-05	0.53	0.35	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
SARC	cis	rs1707322	1	rs4660905	ENSG00000280836.1	AL355480.1	5.69	3.82e-08	3.67e-05	0.36	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45581219~45581321:-
SARC	cis	rs4862750	0.872	rs4862747	ENSG00000249742.1	RP11-217E13.1	5.69	3.82e-08	3.67e-05	0.38	0.35	Lobe attachment (rater-scored or self-reported);	chr4:186956082	chr4:186979490~187021973:-
SARC	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	5.69	3.82e-08	3.67e-05	0.39	0.35	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
SARC	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-5.69	3.83e-08	3.67e-05	-0.42	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
SARC	cis	rs2303759	0.709	rs7256363	ENSG00000268686.1	AC010524.2	-5.69	3.84e-08	3.68e-05	-0.44	-0.35	Multiple sclerosis;	chr19:49324547	chr19:49368705~49388081:-
SARC	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-5.69	3.84e-08	3.68e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
SARC	cis	rs2288884	0.515	rs9676397	ENSG00000275055.1	CTC-471J1.11	-5.69	3.84e-08	3.69e-05	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52076750	chr19:52049007~52049754:+
SARC	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	5.69	3.85e-08	3.69e-05	0.44	0.35	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
SARC	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	5.69	3.86e-08	3.7e-05	0.38	0.35	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	5.69	3.86e-08	3.7e-05	0.38	0.35	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
SARC	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	5.69	3.86e-08	3.7e-05	0.48	0.35	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
SARC	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	5.69	3.86e-08	3.7e-05	0.48	0.35	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
SARC	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	5.69	3.87e-08	3.71e-05	0.53	0.35	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
SARC	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	5.69	3.87e-08	3.71e-05	0.5	0.35	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
SARC	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-5.69	3.88e-08	3.71e-05	-0.44	-0.35	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
SARC	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	5.69	3.88e-08	3.72e-05	0.39	0.35	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
SARC	cis	rs62103177	0.608	rs8088089	ENSG00000261126.6	RP11-795F19.1	-5.69	3.89e-08	3.73e-05	-0.35	-0.35	Opioid sensitivity;	chr18:80073851	chr18:80046900~80095482:+
SARC	cis	rs17772222	0.701	rs845757	ENSG00000258983.2	RP11-507K2.2	-5.69	3.89e-08	3.73e-05	-0.35	-0.35	Coronary artery calcification;	chr14:88455372	chr14:88499334~88515502:+
SARC	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	5.68	3.9e-08	3.73e-05	0.41	0.35	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
SARC	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	5.68	3.92e-08	3.76e-05	0.56	0.35	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
SARC	cis	rs113835537	0.529	rs61561111	ENSG00000255517.5	CTD-3074O7.5	-5.68	3.93e-08	3.76e-05	-0.38	-0.35	Airway imaging phenotypes;	chr11:66508452	chr11:66473490~66480233:-
SARC	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-5.68	3.93e-08	3.76e-05	-0.55	-0.35	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
SARC	cis	rs77204473	1	rs12421902	ENSG00000254851.1	RP11-109L13.1	5.68	3.93e-08	3.76e-05	0.72	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116943930	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs11216193	ENSG00000254851.1	RP11-109L13.1	5.68	3.93e-08	3.76e-05	0.72	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116944883	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs11216197	ENSG00000254851.1	RP11-109L13.1	5.68	3.93e-08	3.76e-05	0.72	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116946062	chr11:117135528~117138582:+
SARC	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-5.68	3.94e-08	3.77e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
SARC	cis	rs1865760	0.663	rs9467656	ENSG00000272810.1	U91328.22	-5.68	3.95e-08	3.78e-05	-0.33	-0.35	Height;	chr6:25993331	chr6:26013241~26013757:+
SARC	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-5.68	3.95e-08	3.78e-05	-0.54	-0.35	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
SARC	cis	rs524281	0.861	rs12049852	ENSG00000255320.1	RP11-755F10.1	5.68	3.95e-08	3.78e-05	0.49	0.35	Electroencephalogram traits;	chr11:66117231	chr11:66244840~66246239:-
SARC	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	5.68	3.97e-08	3.8e-05	0.37	0.35	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	5.68	3.97e-08	3.8e-05	0.37	0.35	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
SARC	cis	rs17772222	0.63	rs816069	ENSG00000258983.2	RP11-507K2.2	-5.68	3.98e-08	3.81e-05	-0.35	-0.35	Coronary artery calcification;	chr14:88500992	chr14:88499334~88515502:+
SARC	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	5.68	3.99e-08	3.81e-05	0.38	0.35	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
SARC	cis	rs77204473	1	rs12420857	ENSG00000254851.1	RP11-109L13.1	5.68	3.99e-08	3.81e-05	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958726	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	5.68	3.99e-08	3.82e-05	0.38	0.35	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
SARC	cis	rs9309473	0.653	rs6718843	ENSG00000163016.8	ALMS1P	5.68	4e-08	3.82e-05	0.43	0.35	Metabolite levels;	chr2:73625378	chr2:73644919~73685576:+
SARC	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	5.68	4e-08	3.82e-05	0.36	0.35	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
SARC	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	5.68	4e-08	3.82e-05	0.41	0.35	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
SARC	cis	rs7712401	0.601	rs34126945	ENSG00000263432.2	RN7SL689P	-5.68	4.02e-08	3.84e-05	-0.43	-0.35	Mean platelet volume;	chr5:122994034	chr5:123022487~123022783:-
SARC	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-5.68	4.02e-08	3.84e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
SARC	cis	rs858239	0.665	rs858306	ENSG00000226816.2	AC005082.12	5.68	4.03e-08	3.85e-05	0.42	0.35	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23206013~23208045:+
SARC	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	5.68	4.03e-08	3.85e-05	0.43	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
SARC	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-5.68	4.04e-08	3.85e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
SARC	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	5.68	4.06e-08	3.87e-05	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
SARC	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-5.68	4.06e-08	3.87e-05	-0.38	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
SARC	cis	rs77204473	1	rs77136879	ENSG00000254851.1	RP11-109L13.1	5.68	4.07e-08	3.88e-05	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs7480278	ENSG00000254851.1	RP11-109L13.1	5.68	4.07e-08	3.88e-05	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs80015203	ENSG00000254851.1	RP11-109L13.1	5.68	4.07e-08	3.88e-05	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs117877581	ENSG00000254851.1	RP11-109L13.1	5.68	4.07e-08	3.88e-05	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs116597701	ENSG00000254851.1	RP11-109L13.1	5.68	4.07e-08	3.88e-05	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs78066444	ENSG00000254851.1	RP11-109L13.1	5.68	4.07e-08	3.88e-05	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117135528~117138582:+
SARC	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-5.68	4.07e-08	3.88e-05	-0.41	-0.35	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
SARC	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-5.68	4.08e-08	3.89e-05	-0.49	-0.35	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
SARC	cis	rs7615952	1	rs7615952	ENSG00000248787.1	RP11-666A20.4	5.68	4.1e-08	3.91e-05	0.53	0.35	Blood pressure (smoking interaction);	chr3:125930560	chr3:125908005~125910272:-
SARC	cis	rs2836950	0.545	rs2836940	ENSG00000255568.3	BRWD1-AS2	-5.67	4.11e-08	3.91e-05	-0.32	-0.35	Menarche (age at onset);	chr21:39216770	chr21:39313935~39314962:+
SARC	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-5.67	4.11e-08	3.92e-05	-0.41	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
SARC	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-5.67	4.12e-08	3.93e-05	-0.4	-0.35	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
SARC	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-5.67	4.12e-08	3.93e-05	-0.4	-0.35	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
SARC	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-5.67	4.13e-08	3.94e-05	-0.44	-0.35	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-5.67	4.13e-08	3.94e-05	-0.44	-0.35	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-5.67	4.13e-08	3.94e-05	-0.44	-0.35	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
SARC	cis	rs7216064	0.532	rs8065296	ENSG00000278219.1	AC145343.1	5.67	4.13e-08	3.94e-05	0.4	0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68022446	chr17:68101538~68101639:+
SARC	cis	rs1431005	0.893	rs998344	ENSG00000250620.1	RP11-91J3.3	5.67	4.13e-08	3.94e-05	0.38	0.35	Response to statin therapy;	chr4:187413335	chr4:187413564~187415697:+
SARC	cis	rs728478	0.845	rs9747559	ENSG00000266992.1	DHX40P1	-5.67	4.14e-08	3.95e-05	-0.37	-0.35	QT interval;	chr17:59403334	chr17:59976009~60002384:-
SARC	cis	rs11651753	0.561	rs17616603	ENSG00000264920.1	RP11-6N17.4	-5.67	4.14e-08	3.95e-05	-0.37	-0.35	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47882254	chr17:47891255~47895812:-
SARC	cis	rs1707322	1	rs10890378	ENSG00000280836.1	AL355480.1	5.67	4.15e-08	3.96e-05	0.36	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45581219~45581321:-
SARC	cis	rs2117029	0.767	rs10875912	ENSG00000258017.1	RP11-386G11.10	-5.67	4.16e-08	3.96e-05	-0.38	-0.35	Intelligence (multi-trait analysis);	chr12:49023161	chr12:49127782~49147869:+
SARC	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	5.67	4.16e-08	3.96e-05	0.43	0.35	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
SARC	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	5.67	4.17e-08	3.97e-05	0.33	0.35	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
SARC	cis	rs11651753	0.561	rs35336840	ENSG00000264920.1	RP11-6N17.4	-5.67	4.2e-08	4e-05	-0.37	-0.35	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47888742	chr17:47891255~47895812:-
SARC	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-5.67	4.2e-08	4e-05	-0.42	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
SARC	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	5.67	4.21e-08	4e-05	0.42	0.35	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
SARC	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-5.67	4.22e-08	4.01e-05	-0.41	-0.35	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
SARC	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-5.67	4.22e-08	4.01e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
SARC	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	5.67	4.23e-08	4.02e-05	0.43	0.35	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
SARC	cis	rs526231	0.543	rs72785717	ENSG00000175749.11	EIF3KP1	5.67	4.23e-08	4.02e-05	0.46	0.35	Primary biliary cholangitis;	chr5:102997401	chr5:103032376~103033031:+
SARC	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-5.67	4.23e-08	4.02e-05	-0.32	-0.35	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
SARC	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	5.67	4.23e-08	4.02e-05	0.48	0.35	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
SARC	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-5.67	4.24e-08	4.03e-05	-0.38	-0.35	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
SARC	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	5.67	4.26e-08	4.05e-05	0.41	0.35	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
SARC	cis	rs1431005	0.784	rs67451289	ENSG00000250620.1	RP11-91J3.3	5.67	4.29e-08	4.08e-05	0.38	0.35	Response to statin therapy;	chr4:187415295	chr4:187413564~187415697:+
SARC	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-5.67	4.3e-08	4.08e-05	-0.48	-0.35	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
SARC	cis	rs1865760	0.964	rs6932113	ENSG00000272462.2	U91328.19	-5.67	4.31e-08	4.1e-05	-0.33	-0.35	Height;	chr6:25912870	chr6:25992662~26001775:+
SARC	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	5.66	4.32e-08	4.1e-05	0.45	0.35	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
SARC	cis	rs7246657	0.943	rs1035479	ENSG00000276846.1	CTD-3220F14.3	-5.66	4.32e-08	4.1e-05	-0.44	-0.35	Coronary artery calcification;	chr19:37402398	chr19:37314868~37315620:-
SARC	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	5.66	4.33e-08	4.11e-05	0.37	0.35	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
SARC	cis	rs4865169	0.871	rs9918067	ENSG00000269949.1	RP11-738E22.3	-5.66	4.33e-08	4.11e-05	-0.4	-0.35	Breast cancer;	chr4:57004378	chr4:56960927~56961373:-
SARC	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	5.66	4.34e-08	4.12e-05	0.39	0.35	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
SARC	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-5.66	4.35e-08	4.13e-05	-0.43	-0.35	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
SARC	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	5.66	4.35e-08	4.13e-05	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
SARC	cis	rs7216064	0.906	rs7223643	ENSG00000278219.1	AC145343.1	-5.66	4.36e-08	4.14e-05	-0.43	-0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67834166	chr17:68101538~68101639:+
SARC	cis	rs17772222	0.682	rs3783889	ENSG00000258983.2	RP11-507K2.2	5.66	4.37e-08	4.14e-05	0.35	0.35	Coronary artery calcification;	chr14:88475637	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.637	rs879932	ENSG00000258983.2	RP11-507K2.2	5.66	4.37e-08	4.14e-05	0.35	0.35	Coronary artery calcification;	chr14:88479247	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.682	rs8017689	ENSG00000258983.2	RP11-507K2.2	5.66	4.37e-08	4.14e-05	0.35	0.35	Coronary artery calcification;	chr14:88483442	chr14:88499334~88515502:+
SARC	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	5.66	4.37e-08	4.15e-05	0.42	0.35	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
SARC	cis	rs4865169	1	rs4865169	ENSG00000269949.1	RP11-738E22.3	-5.66	4.39e-08	4.16e-05	-0.4	-0.35	Breast cancer;	chr4:57013626	chr4:56960927~56961373:-
SARC	cis	rs2836950	0.545	rs1888489	ENSG00000255568.3	BRWD1-AS2	-5.66	4.39e-08	4.16e-05	-0.32	-0.35	Menarche (age at onset);	chr21:39161238	chr21:39313935~39314962:+
SARC	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	5.66	4.39e-08	4.16e-05	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
SARC	cis	rs7216064	1	rs2365468	ENSG00000278219.1	AC145343.1	-5.66	4.41e-08	4.18e-05	-0.42	-0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67845202	chr17:68101538~68101639:+
SARC	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-5.66	4.42e-08	4.18e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-5.66	4.42e-08	4.18e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
SARC	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	5.66	4.44e-08	4.2e-05	0.34	0.35	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
SARC	cis	rs7216064	0.684	rs62084675	ENSG00000278219.1	AC145343.1	5.66	4.45e-08	4.21e-05	0.4	0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68030909	chr17:68101538~68101639:+
SARC	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	5.66	4.46e-08	4.22e-05	0.43	0.35	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
SARC	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	5.66	4.47e-08	4.23e-05	0.53	0.35	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	5.66	4.47e-08	4.23e-05	0.53	0.35	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	5.66	4.47e-08	4.23e-05	0.53	0.35	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	5.66	4.47e-08	4.23e-05	0.53	0.35	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
SARC	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	5.66	4.49e-08	4.24e-05	0.42	0.35	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
SARC	cis	rs5821446	1	rs5821446	ENSG00000278219.1	AC145343.1	5.66	4.52e-08	4.27e-05	0.41	0.35	Eosinophil percentage of granulocytes;	chr17:67966422	chr17:68101538~68101639:+
SARC	cis	rs7181230	0.848	rs1010879	ENSG00000275636.1	RP11-521C20.5	5.66	4.53e-08	4.28e-05	0.42	0.35	Dehydroepiandrosterone sulphate levels;	chr15:40041714	chr15:40078892~40079347:+
SARC	cis	rs10895987	0.531	rs7943007	ENSG00000254614.2	AP003068.23	-5.66	4.53e-08	4.28e-05	-0.42	-0.35	Blood protein levels;	chr11:65089626	chr11:65177606~65181834:-
SARC	cis	rs1865760	0.865	rs1541987	ENSG00000272810.1	U91328.22	5.66	4.54e-08	4.29e-05	0.35	0.35	Height;	chr6:25950169	chr6:26013241~26013757:+
SARC	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-5.66	4.54e-08	4.29e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-5.66	4.54e-08	4.29e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-5.66	4.54e-08	4.29e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
SARC	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	5.65	4.55e-08	4.29e-05	0.32	0.35	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
SARC	cis	rs1865760	0.613	rs9379805	ENSG00000272462.2	U91328.19	-5.65	4.56e-08	4.31e-05	-0.33	-0.35	Height;	chr6:25938536	chr6:25992662~26001775:+
SARC	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	5.65	4.56e-08	4.31e-05	0.51	0.35	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
SARC	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-5.65	4.57e-08	4.31e-05	-0.5	-0.35	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
SARC	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	5.65	4.58e-08	4.32e-05	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
SARC	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	5.65	4.58e-08	4.32e-05	0.41	0.35	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
SARC	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	5.65	4.58e-08	4.32e-05	0.4	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
SARC	cis	rs62103177	0.608	rs34383580	ENSG00000261126.6	RP11-795F19.1	-5.65	4.6e-08	4.33e-05	-0.34	-0.35	Opioid sensitivity;	chr18:80074960	chr18:80046900~80095482:+
SARC	cis	rs62103177	0.608	rs551643	ENSG00000261126.6	RP11-795F19.1	-5.65	4.6e-08	4.33e-05	-0.34	-0.35	Opioid sensitivity;	chr18:80081068	chr18:80046900~80095482:+
SARC	cis	rs113835537	0.529	rs11227503	ENSG00000255517.5	CTD-3074O7.5	-5.65	4.61e-08	4.35e-05	-0.38	-0.35	Airway imaging phenotypes;	chr11:66507771	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.529	rs4542420	ENSG00000255517.5	CTD-3074O7.5	-5.65	4.61e-08	4.35e-05	-0.38	-0.35	Airway imaging phenotypes;	chr11:66510139	chr11:66473490~66480233:-
SARC	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-5.65	4.63e-08	4.36e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-5.65	4.63e-08	4.36e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-5.65	4.63e-08	4.36e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-5.65	4.63e-08	4.36e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-5.65	4.63e-08	4.36e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
SARC	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-5.65	4.63e-08	4.36e-05	-0.4	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
SARC	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	5.65	4.65e-08	4.38e-05	0.32	0.35	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
SARC	cis	rs11651753	0.613	rs4793732	ENSG00000264920.1	RP11-6N17.4	-5.65	4.65e-08	4.38e-05	-0.39	-0.35	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956488	chr17:47891255~47895812:-
SARC	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	5.65	4.65e-08	4.38e-05	0.44	0.35	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	5.65	4.65e-08	4.38e-05	0.44	0.35	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	5.65	4.65e-08	4.38e-05	0.44	0.35	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	5.65	4.65e-08	4.38e-05	0.44	0.35	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
SARC	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	5.65	4.65e-08	4.38e-05	0.52	0.35	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
SARC	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-5.65	4.66e-08	4.39e-05	-0.38	-0.35	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
SARC	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-5.65	4.66e-08	4.39e-05	-0.38	-0.35	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
SARC	cis	rs7216064	1	rs6504548	ENSG00000278219.1	AC145343.1	-5.65	4.67e-08	4.39e-05	-0.41	-0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889932	chr17:68101538~68101639:+
SARC	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-5.65	4.67e-08	4.4e-05	-0.51	-0.35	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
SARC	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	5.65	4.69e-08	4.41e-05	0.42	0.35	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
SARC	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-5.65	4.69e-08	4.41e-05	-0.39	-0.35	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
SARC	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-5.65	4.69e-08	4.41e-05	-0.39	-0.35	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
SARC	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	5.65	4.7e-08	4.42e-05	0.43	0.35	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
SARC	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	5.65	4.71e-08	4.43e-05	0.43	0.35	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
SARC	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	5.65	4.72e-08	4.43e-05	0.44	0.35	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	5.65	4.72e-08	4.43e-05	0.44	0.35	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
SARC	cis	rs1865760	1	rs7757666	ENSG00000272462.2	U91328.19	-5.65	4.72e-08	4.44e-05	-0.33	-0.35	Height;	chr6:25902398	chr6:25992662~26001775:+
SARC	cis	rs1865760	1	rs6910138	ENSG00000272462.2	U91328.19	-5.65	4.72e-08	4.44e-05	-0.33	-0.35	Height;	chr6:25904124	chr6:25992662~26001775:+
SARC	cis	rs1865760	1	rs6910174	ENSG00000272462.2	U91328.19	-5.65	4.72e-08	4.44e-05	-0.33	-0.35	Height;	chr6:25904186	chr6:25992662~26001775:+
SARC	cis	rs1707322	0.896	rs946528	ENSG00000280836.1	AL355480.1	5.65	4.73e-08	4.45e-05	0.35	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45581219~45581321:-
SARC	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-5.65	4.74e-08	4.45e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
SARC	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-5.65	4.74e-08	4.45e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
SARC	cis	rs7246657	0.943	rs10406177	ENSG00000276846.1	CTD-3220F14.3	5.65	4.78e-08	4.48e-05	0.45	0.35	Coronary artery calcification;	chr19:37417045	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.882	rs28623164	ENSG00000276846.1	CTD-3220F14.3	5.65	4.78e-08	4.48e-05	0.45	0.35	Coronary artery calcification;	chr19:37422551	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs7252346	ENSG00000276846.1	CTD-3220F14.3	5.65	4.78e-08	4.48e-05	0.45	0.35	Coronary artery calcification;	chr19:37423780	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs2891699	ENSG00000276846.1	CTD-3220F14.3	5.65	4.78e-08	4.48e-05	0.45	0.35	Coronary artery calcification;	chr19:37429335	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs9676967	ENSG00000276846.1	CTD-3220F14.3	5.65	4.78e-08	4.48e-05	0.45	0.35	Coronary artery calcification;	chr19:37437187	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.882	rs8112610	ENSG00000276846.1	CTD-3220F14.3	5.65	4.78e-08	4.48e-05	0.45	0.35	Coronary artery calcification;	chr19:37437828	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs8109632	ENSG00000276846.1	CTD-3220F14.3	5.65	4.78e-08	4.48e-05	0.45	0.35	Coronary artery calcification;	chr19:37440223	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs7255407	ENSG00000276846.1	CTD-3220F14.3	5.65	4.78e-08	4.48e-05	0.45	0.35	Coronary artery calcification;	chr19:37443034	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.941	rs7256130	ENSG00000276846.1	CTD-3220F14.3	5.65	4.78e-08	4.48e-05	0.45	0.35	Coronary artery calcification;	chr19:37443079	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs2112923	ENSG00000276846.1	CTD-3220F14.3	5.65	4.78e-08	4.48e-05	0.45	0.35	Coronary artery calcification;	chr19:37449425	chr19:37314868~37315620:-
SARC	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	5.64	4.79e-08	4.49e-05	0.29	0.35	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
SARC	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	5.64	4.79e-08	4.49e-05	0.43	0.35	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	5.64	4.79e-08	4.49e-05	0.43	0.35	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
SARC	cis	rs4713118	0.513	rs149942	ENSG00000216901.1	AL022393.7	5.64	4.79e-08	4.49e-05	0.46	0.35	Parkinson's disease;	chr6:28033832	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.513	rs149944	ENSG00000216901.1	AL022393.7	5.64	4.79e-08	4.49e-05	0.46	0.35	Parkinson's disease;	chr6:28035040	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.513	rs149945	ENSG00000216901.1	AL022393.7	5.64	4.79e-08	4.49e-05	0.46	0.35	Parkinson's disease;	chr6:28035075	chr6:28176188~28176674:+
SARC	cis	rs3096299	0.586	rs4572400	ENSG00000274627.1	RP11-104N10.2	5.64	4.82e-08	4.52e-05	0.33	0.35	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89516797~89522217:+
SARC	cis	rs2836950	0.565	rs2836934	ENSG00000255568.3	BRWD1-AS2	-5.64	4.82e-08	4.52e-05	-0.32	-0.35	Menarche (age at onset);	chr21:39192959	chr21:39313935~39314962:+
SARC	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	5.64	4.84e-08	4.53e-05	0.44	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
SARC	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	5.64	4.86e-08	4.55e-05	0.37	0.35	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
SARC	cis	rs1707322	1	rs10890370	ENSG00000280836.1	AL355480.1	-5.64	4.86e-08	4.55e-05	-0.36	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45581219~45581321:-
SARC	cis	rs890448	0.796	rs2471683	ENSG00000254531.1	FLJ20021	5.64	4.86e-08	4.55e-05	0.37	0.35	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101436777	chr4:101347780~101348883:+
SARC	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	5.64	4.87e-08	4.56e-05	0.44	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	5.64	4.87e-08	4.56e-05	0.44	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
SARC	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	5.64	4.88e-08	4.57e-05	0.41	0.35	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
SARC	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-5.64	4.88e-08	4.57e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
SARC	cis	rs916888	0.773	rs199534	ENSG00000261575.2	RP11-259G18.1	5.64	4.88e-08	4.57e-05	0.51	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46267037~46268694:+
SARC	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-5.64	4.88e-08	4.57e-05	-0.32	-0.35	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
SARC	cis	rs2029362	0.612	rs1519479	ENSG00000245573.6	BDNF-AS	5.64	4.88e-08	4.57e-05	0.3	0.35	Total body bone mineral density;	chr11:27645984	chr11:27506838~27698174:+
SARC	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-5.64	4.9e-08	4.58e-05	-0.39	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
SARC	cis	rs7216064	0.636	rs62084696	ENSG00000278219.1	AC145343.1	5.64	4.9e-08	4.58e-05	0.39	0.35	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68042065	chr17:68101538~68101639:+
SARC	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-5.64	4.92e-08	4.6e-05	-0.48	-0.35	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-5.64	4.92e-08	4.6e-05	-0.48	-0.35	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
SARC	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-5.64	4.92e-08	4.6e-05	-0.48	-0.35	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
SARC	cis	rs17772222	0.682	rs2297129	ENSG00000258983.2	RP11-507K2.2	5.64	4.93e-08	4.61e-05	0.35	0.35	Coronary artery calcification;	chr14:88469581	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.682	rs61542857	ENSG00000258983.2	RP11-507K2.2	5.64	4.93e-08	4.61e-05	0.35	0.35	Coronary artery calcification;	chr14:88470358	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.637	rs7161660	ENSG00000258983.2	RP11-507K2.2	5.64	4.93e-08	4.61e-05	0.35	0.35	Coronary artery calcification;	chr14:88471832	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.682	rs7141363	ENSG00000258983.2	RP11-507K2.2	5.64	4.93e-08	4.61e-05	0.35	0.35	Coronary artery calcification;	chr14:88471879	chr14:88499334~88515502:+
SARC	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	5.64	4.93e-08	4.61e-05	0.4	0.35	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
SARC	cis	rs9309473	0.615	rs62151562	ENSG00000163016.8	ALMS1P	5.64	4.95e-08	4.63e-05	0.53	0.35	Metabolite levels;	chr2:73376412	chr2:73644919~73685576:+
SARC	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	5.64	4.96e-08	4.63e-05	0.39	0.35	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
SARC	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-5.64	4.96e-08	4.63e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-5.64	4.96e-08	4.63e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-5.64	4.96e-08	4.63e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
SARC	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-5.64	4.96e-08	4.63e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
SARC	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-5.64	4.96e-08	4.63e-05	-0.42	-0.35	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
SARC	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-5.64	4.96e-08	4.63e-05	-0.44	-0.35	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
SARC	cis	rs916888	0.773	rs199451	ENSG00000261575.2	RP11-259G18.1	5.64	4.96e-08	4.63e-05	0.51	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46267037~46268694:+
SARC	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-5.64	4.97e-08	4.64e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-5.64	4.97e-08	4.64e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
SARC	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-5.64	4.97e-08	4.64e-05	-0.34	-0.35	Height;	chr11:118773873	chr11:118704607~118750263:+
SARC	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	5.64	4.98e-08	4.64e-05	0.43	0.35	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
SARC	cis	rs1823913	0.561	rs60479498	ENSG00000227542.1	AC092614.2	5.64	5e-08	4.67e-05	0.38	0.35	Obesity-related traits;	chr2:191275197	chr2:191229165~191246172:-
SARC	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	5.64	5e-08	4.67e-05	0.4	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
SARC	cis	rs77204473	1	rs79207844	ENSG00000254851.1	RP11-109L13.1	5.64	5.01e-08	4.67e-05	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934725	chr11:117135528~117138582:+
SARC	cis	rs1799949	0.965	rs7223952	ENSG00000267681.1	CTD-3199J23.6	-5.64	5.01e-08	4.67e-05	-0.39	-0.35	Menopause (age at onset);	chr17:43042868	chr17:43144956~43145255:+
SARC	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-5.64	5.02e-08	4.68e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
SARC	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	5.63	5.03e-08	4.7e-05	0.34	0.35	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
SARC	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	5.63	5.04e-08	4.7e-05	0.38	0.35	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
SARC	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-5.63	5.05e-08	4.7e-05	-0.35	-0.35	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
SARC	cis	rs77204473	1	rs12281729	ENSG00000254851.1	RP11-109L13.1	5.63	5.05e-08	4.71e-05	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116967414	chr11:117135528~117138582:+
SARC	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-5.63	5.05e-08	4.71e-05	-0.35	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
SARC	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-5.63	5.06e-08	4.71e-05	-0.38	-0.35	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
SARC	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	5.63	5.07e-08	4.72e-05	0.4	0.35	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
SARC	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-5.63	5.07e-08	4.72e-05	-0.43	-0.35	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
SARC	cis	rs710913	0.618	rs6587	ENSG00000182109.6	RP11-69E11.4	5.63	5.09e-08	4.74e-05	0.33	0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39522280~39546187:-
SARC	cis	rs7246657	0.882	rs4803539	ENSG00000276846.1	CTD-3220F14.3	5.63	5.09e-08	4.74e-05	0.45	0.35	Coronary artery calcification;	chr19:37406620	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs3803895	ENSG00000276846.1	CTD-3220F14.3	5.63	5.09e-08	4.74e-05	0.45	0.35	Coronary artery calcification;	chr19:37407767	chr19:37314868~37315620:-
SARC	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-5.63	5.11e-08	4.75e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
SARC	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-5.63	5.12e-08	4.76e-05	-0.44	-0.35	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
SARC	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	5.63	5.13e-08	4.77e-05	0.42	0.35	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
SARC	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	5.63	5.13e-08	4.77e-05	0.42	0.35	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
SARC	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	5.63	5.13e-08	4.77e-05	0.42	0.35	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
SARC	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-5.63	5.15e-08	4.79e-05	-0.51	-0.35	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
SARC	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	5.63	5.15e-08	4.79e-05	0.48	0.35	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	5.63	5.15e-08	4.79e-05	0.48	0.35	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
SARC	cis	rs17772222	0.74	rs61975276	ENSG00000258983.2	RP11-507K2.2	5.63	5.16e-08	4.79e-05	0.35	0.35	Coronary artery calcification;	chr14:88511193	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.74	rs61975277	ENSG00000258983.2	RP11-507K2.2	5.63	5.16e-08	4.79e-05	0.35	0.35	Coronary artery calcification;	chr14:88511202	chr14:88499334~88515502:+
SARC	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-5.63	5.16e-08	4.79e-05	-0.33	-0.35	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
SARC	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-5.63	5.16e-08	4.8e-05	-0.41	-0.35	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
SARC	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-5.63	5.17e-08	4.8e-05	-0.39	-0.35	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
SARC	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	5.63	5.18e-08	4.81e-05	0.32	0.35	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
SARC	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	5.63	5.19e-08	4.82e-05	0.4	0.35	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
SARC	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	5.63	5.2e-08	4.83e-05	0.43	0.35	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
SARC	cis	rs11118620	0.622	rs11118618	ENSG00000257551.1	HLX-AS1	5.63	5.2e-08	4.83e-05	0.43	0.35	Heart failure;	chr1:220838204	chr1:220832763~220880140:-
SARC	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	5.63	5.21e-08	4.83e-05	0.34	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
SARC	cis	rs7615952	1	rs9289275	ENSG00000248787.1	RP11-666A20.4	-5.63	5.23e-08	4.85e-05	-0.56	-0.35	Blood pressure (smoking interaction);	chr3:125929816	chr3:125908005~125910272:-
SARC	cis	rs1823913	0.599	rs1378155	ENSG00000227542.1	AC092614.2	5.63	5.24e-08	4.86e-05	0.39	0.35	Obesity-related traits;	chr2:191266610	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.576	rs13011608	ENSG00000227542.1	AC092614.2	5.63	5.24e-08	4.86e-05	0.39	0.35	Obesity-related traits;	chr2:191267097	chr2:191229165~191246172:-
SARC	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-5.63	5.24e-08	4.86e-05	-0.41	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
SARC	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-5.63	5.25e-08	4.87e-05	-0.39	-0.35	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
SARC	cis	rs7246657	0.943	rs3760825	ENSG00000276846.1	CTD-3220F14.3	5.63	5.27e-08	4.88e-05	0.45	0.35	Coronary artery calcification;	chr19:37454699	chr19:37314868~37315620:-
SARC	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-5.63	5.28e-08	4.89e-05	-0.35	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
SARC	cis	rs73186030	1	rs5008830	ENSG00000272758.4	RP11-299J3.8	5.63	5.29e-08	4.9e-05	0.49	0.35	Serum parathyroid hormone levels;	chr3:122311615	chr3:122416207~122443180:+
SARC	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	5.62	5.3e-08	4.91e-05	0.53	0.35	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
SARC	cis	rs1823913	0.599	rs13035132	ENSG00000227542.1	AC092614.2	5.62	5.38e-08	4.98e-05	0.39	0.35	Obesity-related traits;	chr2:191265275	chr2:191229165~191246172:-
SARC	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-5.62	5.38e-08	4.98e-05	-0.41	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
SARC	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-5.62	5.38e-08	4.98e-05	-0.41	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
SARC	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-5.62	5.38e-08	4.98e-05	-0.41	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
SARC	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-5.62	5.38e-08	4.98e-05	-0.41	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
SARC	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-5.62	5.39e-08	4.99e-05	-0.35	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-5.62	5.39e-08	4.99e-05	-0.35	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-5.62	5.39e-08	4.99e-05	-0.35	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
SARC	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	5.62	5.4e-08	4.99e-05	0.34	0.35	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
SARC	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	5.62	5.41e-08	5e-05	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
SARC	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	5.62	5.42e-08	5.01e-05	0.39	0.35	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
SARC	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	5.62	5.42e-08	5.01e-05	0.43	0.35	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
SARC	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	5.62	5.44e-08	5.03e-05	0.56	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
SARC	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	5.62	5.46e-08	5.05e-05	0.32	0.35	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
SARC	cis	rs17772222	0.917	rs17260415	ENSG00000258983.2	RP11-507K2.2	5.62	5.47e-08	5.05e-05	0.39	0.35	Coronary artery calcification;	chr14:88745629	chr14:88499334~88515502:+
SARC	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-5.62	5.47e-08	5.05e-05	-0.4	-0.35	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
SARC	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	5.62	5.47e-08	5.05e-05	0.34	0.35	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
SARC	cis	rs2562456	0.876	rs2681395	ENSG00000268081.1	RP11-678G14.2	5.62	5.48e-08	5.06e-05	0.52	0.35	Pain;	chr19:21555338	chr19:21554640~21569237:-
SARC	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	5.62	5.48e-08	5.06e-05	0.47	0.35	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
SARC	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	5.62	5.48e-08	5.06e-05	0.47	0.35	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
SARC	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	5.62	5.48e-08	5.06e-05	0.47	0.35	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
SARC	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	5.62	5.51e-08	5.08e-05	0.42	0.35	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
SARC	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-5.62	5.52e-08	5.1e-05	-0.35	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
SARC	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	5.62	5.54e-08	5.11e-05	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
SARC	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	5.62	5.54e-08	5.12e-05	0.32	0.35	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
SARC	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	5.62	5.56e-08	5.13e-05	0.47	0.35	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
SARC	cis	rs17772222	0.675	rs1099698	ENSG00000258983.2	RP11-507K2.2	-5.62	5.56e-08	5.13e-05	-0.35	-0.35	Coronary artery calcification;	chr14:88414904	chr14:88499334~88515502:+
SARC	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-5.62	5.57e-08	5.13e-05	-0.41	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
SARC	cis	rs7181230	0.885	rs9919974	ENSG00000275636.1	RP11-521C20.5	5.61	5.59e-08	5.15e-05	0.42	0.35	Dehydroepiandrosterone sulphate levels;	chr15:40045261	chr15:40078892~40079347:+
SARC	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-5.61	5.62e-08	5.18e-05	-0.56	-0.35	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
SARC	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-5.61	5.63e-08	5.19e-05	-0.47	-0.35	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
SARC	cis	rs77204473	0.744	rs6589606	ENSG00000254851.1	RP11-109L13.1	5.61	5.63e-08	5.19e-05	0.69	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117222170	chr11:117135528~117138582:+
SARC	cis	rs77204473	0.744	rs12277910	ENSG00000254851.1	RP11-109L13.1	-5.61	5.65e-08	5.21e-05	-0.72	-0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117087817	chr11:117135528~117138582:+
SARC	cis	rs5769707	0.616	rs135869	ENSG00000235111.1	RP1-29C18.8	-5.61	5.66e-08	5.21e-05	-0.44	-0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49612657~49615716:-
SARC	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	5.61	5.66e-08	5.21e-05	0.47	0.35	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
SARC	cis	rs524281	0.638	rs4261293	ENSG00000255320.1	RP11-755F10.1	-5.61	5.66e-08	5.21e-05	-0.54	-0.35	Electroencephalogram traits;	chr11:66037664	chr11:66244840~66246239:-
SARC	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	5.61	5.67e-08	5.22e-05	0.52	0.35	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
SARC	cis	rs5769707	0.632	rs135876	ENSG00000235111.1	RP1-29C18.8	-5.61	5.68e-08	5.23e-05	-0.44	-0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49612657~49615716:-
SARC	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-5.61	5.69e-08	5.23e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-5.61	5.69e-08	5.23e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-5.61	5.69e-08	5.23e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-5.61	5.69e-08	5.23e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-5.61	5.69e-08	5.23e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-5.61	5.69e-08	5.23e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-5.61	5.69e-08	5.23e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-5.61	5.69e-08	5.23e-05	-0.5	-0.35	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
SARC	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	5.61	5.7e-08	5.24e-05	0.41	0.34	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
SARC	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	5.61	5.7e-08	5.24e-05	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
SARC	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-5.61	5.71e-08	5.25e-05	-0.54	-0.34	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
SARC	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-5.61	5.71e-08	5.25e-05	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
SARC	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	5.61	5.75e-08	5.28e-05	0.44	0.34	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
SARC	cis	rs17772222	0.565	rs845759	ENSG00000258983.2	RP11-507K2.2	-5.61	5.77e-08	5.3e-05	-0.35	-0.34	Coronary artery calcification;	chr14:88415538	chr14:88499334~88515502:+
SARC	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	5.61	5.77e-08	5.3e-05	0.55	0.34	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	5.61	5.77e-08	5.3e-05	0.55	0.34	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
SARC	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-5.61	5.79e-08	5.31e-05	-0.35	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-5.61	5.79e-08	5.31e-05	-0.35	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-5.61	5.79e-08	5.31e-05	-0.35	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
SARC	cis	rs6991838	0.701	rs7829434	ENSG00000200714.1	Y_RNA	5.61	5.8e-08	5.32e-05	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65592731~65592820:+
SARC	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	5.61	5.8e-08	5.33e-05	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
SARC	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	5.61	5.81e-08	5.33e-05	0.51	0.34	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
SARC	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	5.61	5.81e-08	5.33e-05	0.51	0.34	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
SARC	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	5.61	5.81e-08	5.33e-05	0.51	0.34	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
SARC	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	5.61	5.81e-08	5.33e-05	0.51	0.34	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
SARC	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	5.61	5.81e-08	5.33e-05	0.51	0.34	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
SARC	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	5.61	5.81e-08	5.33e-05	0.51	0.34	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
SARC	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	5.61	5.81e-08	5.33e-05	0.51	0.34	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
SARC	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	5.61	5.81e-08	5.33e-05	0.51	0.34	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
SARC	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-5.61	5.81e-08	5.33e-05	-0.4	-0.34	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
SARC	cis	rs34375054	0.687	rs4559740	ENSG00000279233.1	RP11-158L12.4	5.61	5.82e-08	5.33e-05	0.44	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125148450	chr12:125138245~125141711:+
SARC	cis	rs2562456	0.561	rs12610883	ENSG00000268081.1	RP11-678G14.2	5.61	5.83e-08	5.35e-05	0.52	0.34	Pain;	chr19:21567257	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.837	rs11085462	ENSG00000268081.1	RP11-678G14.2	5.61	5.83e-08	5.35e-05	0.52	0.34	Pain;	chr19:21567449	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.793	rs7259708	ENSG00000268081.1	RP11-678G14.2	5.61	5.83e-08	5.35e-05	0.52	0.34	Pain;	chr19:21567846	chr19:21554640~21569237:-
SARC	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-5.61	5.85e-08	5.36e-05	-0.34	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
SARC	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	5.61	5.85e-08	5.36e-05	0.42	0.34	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
SARC	cis	rs4713118	0.539	rs510987	ENSG00000216901.1	AL022393.7	5.61	5.85e-08	5.36e-05	0.46	0.34	Parkinson's disease;	chr6:27879739	chr6:28176188~28176674:+
SARC	cis	rs11018904	0.636	rs61903695	ENSG00000280385.1	AP000648.5	-5.61	5.86e-08	5.37e-05	-0.35	-0.34	Intelligence (multi-trait analysis);	chr11:90189249	chr11:90193614~90198120:+
SARC	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-5.6	5.87e-08	5.38e-05	-0.39	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
SARC	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-5.6	5.89e-08	5.39e-05	-0.47	-0.34	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
SARC	cis	rs62103177	0.564	rs7228971	ENSG00000261126.6	RP11-795F19.1	-5.6	5.94e-08	5.43e-05	-0.37	-0.34	Opioid sensitivity;	chr18:79978025	chr18:80046900~80095482:+
SARC	cis	rs7587476	0.643	rs6714373	ENSG00000229267.2	AC072062.1	-5.6	5.97e-08	5.46e-05	-0.34	-0.34	Neuroblastoma;	chr2:214854290	chr2:214810229~214963274:+
SARC	cis	rs4273100	1	rs12602286	ENSG00000228157.4	AC007952.5	-5.6	5.97e-08	5.46e-05	-0.48	-0.34	Schizophrenia;	chr17:19333641	chr17:19092974~19096837:+
SARC	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-5.6	6e-08	5.48e-05	-0.49	-0.34	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
SARC	cis	rs7216064	1	rs8079754	ENSG00000278219.1	AC145343.1	-5.6	6e-08	5.48e-05	-0.41	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67891780	chr17:68101538~68101639:+
SARC	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-5.6	6.01e-08	5.49e-05	-0.35	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
SARC	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	5.6	6.03e-08	5.5e-05	0.48	0.34	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
SARC	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	5.6	6.03e-08	5.51e-05	0.52	0.34	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
SARC	cis	rs77204473	0.744	rs11216265	ENSG00000254851.1	RP11-109L13.1	5.6	6.04e-08	5.51e-05	0.76	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117076464	chr11:117135528~117138582:+
SARC	cis	rs77204473	0.744	rs11216270	ENSG00000254851.1	RP11-109L13.1	5.6	6.04e-08	5.51e-05	0.76	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117082928	chr11:117135528~117138582:+
SARC	cis	rs77204473	0.744	rs2368149	ENSG00000254851.1	RP11-109L13.1	5.6	6.04e-08	5.51e-05	0.76	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117085218	chr11:117135528~117138582:+
SARC	cis	rs11651753	0.561	rs60580012	ENSG00000264920.1	RP11-6N17.4	-5.6	6.04e-08	5.51e-05	-0.37	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892442	chr17:47891255~47895812:-
SARC	cis	rs11651753	0.561	rs61422354	ENSG00000264920.1	RP11-6N17.4	-5.6	6.04e-08	5.51e-05	-0.37	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892443	chr17:47891255~47895812:-
SARC	cis	rs2836950	0.545	rs2836959	ENSG00000255568.3	BRWD1-AS2	-5.6	6.04e-08	5.51e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39251742	chr21:39313935~39314962:+
SARC	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	5.6	6.05e-08	5.52e-05	0.35	0.34	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
SARC	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	5.6	6.06e-08	5.53e-05	0.44	0.34	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
SARC	cis	rs2562456	0.917	rs2650825	ENSG00000268081.1	RP11-678G14.2	5.6	6.09e-08	5.56e-05	0.53	0.34	Pain;	chr19:21516423	chr19:21554640~21569237:-
SARC	cis	rs1865760	1	rs6938233	ENSG00000272462.2	U91328.19	-5.6	6.09e-08	5.56e-05	-0.33	-0.34	Height;	chr6:25913849	chr6:25992662~26001775:+
SARC	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	5.6	6.1e-08	5.56e-05	0.29	0.34	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	5.6	6.1e-08	5.56e-05	0.29	0.34	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	5.6	6.1e-08	5.56e-05	0.29	0.34	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	5.6	6.1e-08	5.56e-05	0.29	0.34	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	5.6	6.1e-08	5.56e-05	0.29	0.34	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
SARC	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	5.6	6.1e-08	5.56e-05	0.36	0.34	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
SARC	cis	rs2562456	0.876	rs11085468	ENSG00000268081.1	RP11-678G14.2	5.6	6.1e-08	5.57e-05	0.51	0.34	Pain;	chr19:21569087	chr19:21554640~21569237:-
SARC	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	5.6	6.13e-08	5.59e-05	0.31	0.34	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
SARC	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	5.6	6.13e-08	5.59e-05	0.32	0.34	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
SARC	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-5.6	6.14e-08	5.59e-05	-0.52	-0.34	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-5.6	6.14e-08	5.59e-05	-0.52	-0.34	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-5.6	6.14e-08	5.59e-05	-0.52	-0.34	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
SARC	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-5.6	6.16e-08	5.61e-05	-0.35	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
SARC	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-5.6	6.16e-08	5.61e-05	-0.48	-0.34	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
SARC	cis	rs17270561	1	rs17270561	ENSG00000272810.1	U91328.22	5.59	6.17e-08	5.63e-05	0.4	0.34	Iron status biomarkers;	chr6:25820211	chr6:26013241~26013757:+
SARC	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	5.59	6.18e-08	5.63e-05	0.45	0.34	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
SARC	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-5.59	6.2e-08	5.64e-05	-0.42	-0.34	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
SARC	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-5.59	6.2e-08	5.64e-05	-0.35	-0.34	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
SARC	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	5.59	6.23e-08	5.67e-05	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
SARC	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-5.59	6.23e-08	5.67e-05	-0.41	-0.34	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
SARC	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-5.59	6.24e-08	5.68e-05	-0.35	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-5.59	6.24e-08	5.68e-05	-0.35	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
SARC	cis	rs1865760	0.588	rs9467658	ENSG00000272810.1	U91328.22	-5.59	6.25e-08	5.68e-05	-0.33	-0.34	Height;	chr6:26010653	chr6:26013241~26013757:+
SARC	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-5.59	6.25e-08	5.68e-05	-0.4	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
SARC	cis	rs2562456	0.724	rs58001930	ENSG00000268081.1	RP11-678G14.2	5.59	6.27e-08	5.7e-05	0.52	0.34	Pain;	chr19:21560061	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.754	rs55771551	ENSG00000268081.1	RP11-678G14.2	5.59	6.27e-08	5.7e-05	0.52	0.34	Pain;	chr19:21563578	chr19:21554640~21569237:-
SARC	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	5.59	6.27e-08	5.7e-05	0.39	0.34	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
SARC	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-5.59	6.28e-08	5.7e-05	-0.42	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
SARC	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-5.59	6.28e-08	5.7e-05	-0.49	-0.34	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
SARC	cis	rs916888	0.821	rs199506	ENSG00000261575.2	RP11-259G18.1	-5.59	6.28e-08	5.71e-05	-0.49	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46267037~46268694:+
SARC	cis	rs2836950	0.565	rs2836945	ENSG00000255568.3	BRWD1-AS2	-5.59	6.29e-08	5.72e-05	-0.32	-0.34	Menarche (age at onset);	chr21:39224831	chr21:39313935~39314962:+
SARC	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	5.59	6.3e-08	5.72e-05	0.42	0.34	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
SARC	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	5.59	6.32e-08	5.74e-05	0.43	0.34	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
SARC	cis	rs2303759	0.666	rs66967196	ENSG00000268686.1	AC010524.2	-5.59	6.33e-08	5.74e-05	-0.43	-0.34	Multiple sclerosis;	chr19:49305637	chr19:49368705~49388081:-
SARC	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	5.59	6.35e-08	5.76e-05	0.5	0.34	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	5.59	6.35e-08	5.76e-05	0.5	0.34	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
SARC	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-5.59	6.36e-08	5.76e-05	-0.42	-0.34	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
SARC	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	5.59	6.37e-08	5.77e-05	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
SARC	cis	rs7216064	0.531	rs62084683	ENSG00000278219.1	AC145343.1	5.59	6.38e-08	5.79e-05	0.39	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68035609	chr17:68101538~68101639:+
SARC	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-5.59	6.41e-08	5.81e-05	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
SARC	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-5.59	6.42e-08	5.82e-05	-0.33	-0.34	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
SARC	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-5.59	6.42e-08	5.82e-05	-0.33	-0.34	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
SARC	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-5.59	6.43e-08	5.83e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
SARC	cis	rs7216064	1	rs2052187	ENSG00000278219.1	AC145343.1	-5.59	6.48e-08	5.87e-05	-0.41	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67838621	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs6504543	ENSG00000278219.1	AC145343.1	-5.59	6.48e-08	5.87e-05	-0.41	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841543	chr17:68101538~68101639:+
SARC	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-5.58	6.5e-08	5.89e-05	-0.33	-0.34	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
SARC	cis	rs7809950	1	rs3801944	ENSG00000238832.1	snoU109	5.58	6.5e-08	5.89e-05	0.4	0.34	Coronary artery disease;	chr7:107615103	chr7:107603363~107603507:+
SARC	cis	rs2836950	0.545	rs8132424	ENSG00000255568.3	BRWD1-AS2	5.58	6.51e-08	5.9e-05	0.31	0.34	Menarche (age at onset);	chr21:39212486	chr21:39313935~39314962:+
SARC	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-5.58	6.53e-08	5.91e-05	-0.52	-0.34	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-5.58	6.54e-08	5.92e-05	-0.54	-0.34	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-5.58	6.54e-08	5.92e-05	-0.54	-0.34	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-5.58	6.54e-08	5.92e-05	-0.54	-0.34	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-5.58	6.54e-08	5.92e-05	-0.54	-0.34	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-5.58	6.54e-08	5.92e-05	-0.54	-0.34	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-5.58	6.57e-08	5.94e-05	-0.51	-0.34	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
SARC	cis	rs899997	1	rs9888691	ENSG00000261143.1	ADAMTS7P3	5.58	6.57e-08	5.95e-05	0.51	0.34	Coronary artery disease or large artery stroke;	chr15:78717704	chr15:77976042~77993057:+
SARC	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	5.58	6.58e-08	5.95e-05	0.32	0.34	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
SARC	cis	rs113835537	0.529	rs11227499	ENSG00000255517.5	CTD-3074O7.5	-5.58	6.62e-08	5.99e-05	-0.38	-0.34	Airway imaging phenotypes;	chr11:66505353	chr11:66473490~66480233:-
SARC	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-5.58	6.62e-08	5.99e-05	-0.34	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
SARC	cis	rs1707322	1	rs785480	ENSG00000280836.1	AL355480.1	-5.58	6.62e-08	5.99e-05	-0.36	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45581219~45581321:-
SARC	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-5.58	6.63e-08	5.99e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
SARC	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-5.58	6.64e-08	6e-05	-0.56	-0.34	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
SARC	cis	rs916888	0.773	rs199535	ENSG00000261575.2	RP11-259G18.1	5.58	6.66e-08	6.01e-05	0.49	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46267037~46268694:+
SARC	cis	rs7216064	0.636	rs62084696	ENSG00000265055.1	AC145343.2	-5.58	6.66e-08	6.02e-05	-0.41	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68042065	chr17:68096046~68101474:-
SARC	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-5.58	6.69e-08	6.04e-05	-0.35	-0.34	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
SARC	cis	rs7246657	0.943	rs2045908	ENSG00000276846.1	CTD-3220F14.3	5.58	6.69e-08	6.04e-05	0.45	0.34	Coronary artery calcification;	chr19:37488866	chr19:37314868~37315620:-
SARC	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-5.58	6.69e-08	6.04e-05	-0.35	-0.34	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
SARC	cis	rs4713118	0.513	rs149989	ENSG00000216901.1	AL022393.7	5.58	6.71e-08	6.05e-05	0.46	0.34	Parkinson's disease;	chr6:28030406	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.513	rs149941	ENSG00000216901.1	AL022393.7	5.58	6.71e-08	6.05e-05	0.46	0.34	Parkinson's disease;	chr6:28033255	chr6:28176188~28176674:+
SARC	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	5.58	6.71e-08	6.06e-05	0.52	0.34	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
SARC	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	5.58	6.72e-08	6.07e-05	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	5.58	6.72e-08	6.07e-05	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
SARC	cis	rs11651753	0.636	rs4793737	ENSG00000264920.1	RP11-6N17.4	-5.58	6.73e-08	6.07e-05	-0.38	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964891	chr17:47891255~47895812:-
SARC	cis	rs4862750	0.794	rs1030382	ENSG00000250971.1	RP11-696F12.1	5.58	6.73e-08	6.08e-05	0.41	0.34	Lobe attachment (rater-scored or self-reported);	chr4:186982628	chr4:187060099~187060930:+
SARC	cis	rs7587476	0.862	rs13001462	ENSG00000229267.2	AC072062.1	-5.58	6.74e-08	6.08e-05	-0.33	-0.34	Neuroblastoma;	chr2:214813622	chr2:214810229~214963274:+
SARC	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-5.58	6.74e-08	6.08e-05	-0.34	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-5.58	6.76e-08	6.09e-05	-0.34	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
SARC	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	5.58	6.76e-08	6.1e-05	0.36	0.34	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
SARC	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	5.58	6.79e-08	6.12e-05	0.42	0.34	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	5.58	6.79e-08	6.12e-05	0.42	0.34	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	5.58	6.79e-08	6.12e-05	0.42	0.34	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
SARC	cis	rs7181230	0.885	rs8026641	ENSG00000275636.1	RP11-521C20.5	-5.58	6.79e-08	6.12e-05	-0.39	-0.34	Dehydroepiandrosterone sulphate levels;	chr15:40046660	chr15:40078892~40079347:+
SARC	cis	rs172166	0.637	rs1233708	ENSG00000216901.1	AL022393.7	5.58	6.79e-08	6.12e-05	0.43	0.34	Cardiac Troponin-T levels;	chr6:28205441	chr6:28176188~28176674:+
SARC	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-5.58	6.8e-08	6.13e-05	-0.37	-0.34	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-5.58	6.8e-08	6.13e-05	-0.37	-0.34	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-5.58	6.8e-08	6.13e-05	-0.37	-0.34	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
SARC	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-5.58	6.81e-08	6.13e-05	-0.47	-0.34	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
SARC	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-5.57	6.83e-08	6.15e-05	-0.34	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-5.57	6.83e-08	6.15e-05	-0.34	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
SARC	cis	rs2179367	0.959	rs4895788	ENSG00000231760.4	RP11-350J20.5	5.57	6.88e-08	6.19e-05	0.43	0.34	Dupuytren's disease;	chr6:149426955	chr6:149796151~149826294:-
SARC	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	5.57	6.89e-08	6.2e-05	0.52	0.34	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
SARC	cis	rs172166	0.637	rs1233708	ENSG00000219392.1	RP1-265C24.5	-5.57	6.9e-08	6.21e-05	-0.43	-0.34	Cardiac Troponin-T levels;	chr6:28205441	chr6:28115628~28116551:+
SARC	cis	rs7216064	0.636	rs4638	ENSG00000265055.1	AC145343.2	-5.57	6.94e-08	6.24e-05	-0.41	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043234	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.601	rs35453056	ENSG00000265055.1	AC145343.2	-5.57	6.94e-08	6.24e-05	-0.41	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043552	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.628	rs62084702	ENSG00000265055.1	AC145343.2	-5.57	6.94e-08	6.24e-05	-0.41	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68047041	chr17:68096046~68101474:-
SARC	cis	rs131777	0.708	rs131749	ENSG00000205559.3	CHKB-AS1	5.57	6.94e-08	6.24e-05	0.38	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50583026~50583877:+
SARC	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-5.57	6.97e-08	6.27e-05	-0.5	-0.34	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
SARC	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-5.57	6.97e-08	6.27e-05	-0.41	-0.34	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
SARC	cis	rs2562456	0.761	rs35008138	ENSG00000268081.1	RP11-678G14.2	5.57	6.98e-08	6.27e-05	0.52	0.34	Pain;	chr19:21548822	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs2681388	ENSG00000268081.1	RP11-678G14.2	5.57	6.98e-08	6.27e-05	0.52	0.34	Pain;	chr19:21549451	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.876	rs2681370	ENSG00000268081.1	RP11-678G14.2	5.57	6.98e-08	6.27e-05	0.52	0.34	Pain;	chr19:21554036	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.876	rs11668606	ENSG00000268081.1	RP11-678G14.2	5.57	6.98e-08	6.27e-05	0.52	0.34	Pain;	chr19:21554618	chr19:21554640~21569237:-
SARC	cis	rs1075265	0.587	rs2949812	ENSG00000233266.1	HMGB1P31	5.57	6.99e-08	6.28e-05	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54051334~54051760:+
SARC	cis	rs4862750	0.872	rs6553029	ENSG00000249742.1	RP11-217E13.1	5.57	7.01e-08	6.3e-05	0.37	0.34	Lobe attachment (rater-scored or self-reported);	chr4:186955316	chr4:186979490~187021973:-
SARC	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-5.57	7.02e-08	6.31e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-5.57	7.02e-08	6.31e-05	-0.34	-0.34	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
SARC	cis	rs17270561	0.609	rs1892246	ENSG00000272810.1	U91328.22	-5.57	7.02e-08	6.31e-05	-0.34	-0.34	Iron status biomarkers;	chr6:25764180	chr6:26013241~26013757:+
SARC	cis	rs11018904	0.906	rs61903722	ENSG00000280385.1	AP000648.5	-5.57	7.02e-08	6.31e-05	-0.4	-0.34	Intelligence (multi-trait analysis);	chr11:90233874	chr11:90193614~90198120:+
SARC	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	5.57	7.03e-08	6.32e-05	0.43	0.34	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
SARC	cis	rs7216064	0.684	rs7406031	ENSG00000278219.1	AC145343.1	5.57	7.06e-08	6.34e-05	0.39	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68025637	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs9897982	ENSG00000278219.1	AC145343.1	-5.57	7.07e-08	6.35e-05	-0.41	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67883476	chr17:68101538~68101639:+
SARC	cis	rs1075265	0.621	rs2542593	ENSG00000233266.1	HMGB1P31	5.57	7.08e-08	6.36e-05	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-5.57	7.09e-08	6.36e-05	-0.4	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	5.57	7.09e-08	6.36e-05	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
SARC	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-5.57	7.1e-08	6.37e-05	-0.51	-0.34	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
SARC	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-5.57	7.1e-08	6.37e-05	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
SARC	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	5.57	7.1e-08	6.37e-05	0.38	0.34	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	5.57	7.1e-08	6.37e-05	0.38	0.34	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	5.57	7.1e-08	6.37e-05	0.38	0.34	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	5.57	7.1e-08	6.37e-05	0.38	0.34	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	5.57	7.1e-08	6.37e-05	0.38	0.34	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
SARC	cis	rs7250849	0.529	rs73052877	ENSG00000273837.1	LLNLR-470E3.1	-5.57	7.13e-08	6.39e-05	-0.36	-0.34	Blood protein levels;	chr19:51662744	chr19:51639478~51639931:-
SARC	cis	rs1707322	1	rs4660334	ENSG00000280836.1	AL355480.1	-5.57	7.13e-08	6.39e-05	-0.35	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45581219~45581321:-
SARC	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	5.57	7.14e-08	6.4e-05	0.46	0.34	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
SARC	cis	rs1075265	0.87	rs10207537	ENSG00000233266.1	HMGB1P31	5.57	7.15e-08	6.41e-05	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54051334~54051760:+
SARC	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	5.57	7.16e-08	6.42e-05	0.43	0.34	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	5.57	7.16e-08	6.42e-05	0.43	0.34	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
SARC	cis	rs6565180	0.632	rs8050812	ENSG00000183604.13	SMG1P5	-5.57	7.16e-08	6.42e-05	-0.36	-0.34	Tonsillectomy;	chr16:30374516	chr16:30267553~30335374:-
SARC	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	5.57	7.16e-08	6.42e-05	0.41	0.34	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
SARC	cis	rs7712401	0.601	rs448505	ENSG00000263432.2	RN7SL689P	-5.57	7.17e-08	6.43e-05	-0.43	-0.34	Mean platelet volume;	chr5:123000995	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs2164773	ENSG00000263432.2	RN7SL689P	-5.57	7.17e-08	6.43e-05	-0.43	-0.34	Mean platelet volume;	chr5:123003222	chr5:123022487~123022783:-
SARC	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	5.57	7.17e-08	6.43e-05	0.42	0.34	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
SARC	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-5.57	7.18e-08	6.43e-05	-0.32	-0.34	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
SARC	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-5.57	7.18e-08	6.43e-05	-0.32	-0.34	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
SARC	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-5.57	7.18e-08	6.43e-05	-0.32	-0.34	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
SARC	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-5.57	7.18e-08	6.43e-05	-0.32	-0.34	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
SARC	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	5.56	7.22e-08	6.46e-05	0.5	0.34	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
SARC	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	5.56	7.22e-08	6.46e-05	0.5	0.34	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
SARC	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-5.56	7.24e-08	6.48e-05	-0.37	-0.34	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
SARC	cis	rs1075232	1	rs12437749	ENSG00000270055.1	CTD-3092A11.2	-5.56	7.24e-08	6.48e-05	-0.69	-0.34	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30487963~30490313:+
SARC	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	5.56	7.24e-08	6.48e-05	0.44	0.34	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	5.56	7.24e-08	6.48e-05	0.44	0.34	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	5.56	7.24e-08	6.48e-05	0.44	0.34	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
SARC	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	5.56	7.25e-08	6.48e-05	0.42	0.34	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	5.56	7.25e-08	6.48e-05	0.42	0.34	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	5.56	7.25e-08	6.48e-05	0.42	0.34	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	5.56	7.25e-08	6.48e-05	0.42	0.34	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	5.56	7.25e-08	6.48e-05	0.42	0.34	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	5.56	7.25e-08	6.48e-05	0.42	0.34	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	5.56	7.25e-08	6.48e-05	0.42	0.34	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	5.56	7.25e-08	6.48e-05	0.42	0.34	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	5.56	7.25e-08	6.48e-05	0.42	0.34	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	5.56	7.25e-08	6.48e-05	0.42	0.34	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
SARC	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	5.56	7.25e-08	6.49e-05	0.43	0.34	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
SARC	cis	rs7712401	0.601	rs154502	ENSG00000263432.2	RN7SL689P	5.56	7.27e-08	6.5e-05	0.43	0.34	Mean platelet volume;	chr5:122871351	chr5:123022487~123022783:-
SARC	cis	rs1707322	1	rs785478	ENSG00000280836.1	AL355480.1	5.56	7.27e-08	6.5e-05	0.35	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45581219~45581321:-
SARC	cis	rs1707322	1	rs7538978	ENSG00000280836.1	AL355480.1	5.56	7.28e-08	6.51e-05	0.35	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45581219~45581321:-
SARC	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-5.56	7.28e-08	6.51e-05	-0.43	-0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
SARC	cis	rs524281	0.682	rs34274349	ENSG00000255320.1	RP11-755F10.1	-5.56	7.3e-08	6.52e-05	-0.54	-0.34	Electroencephalogram traits;	chr11:66030595	chr11:66244840~66246239:-
SARC	cis	rs524281	0.731	rs730787	ENSG00000255320.1	RP11-755F10.1	-5.56	7.3e-08	6.52e-05	-0.54	-0.34	Electroencephalogram traits;	chr11:66031488	chr11:66244840~66246239:-
SARC	cis	rs4862750	0.957	rs6858853	ENSG00000249742.1	RP11-217E13.1	5.56	7.34e-08	6.55e-05	0.36	0.34	Lobe attachment (rater-scored or self-reported);	chr4:186982258	chr4:186979490~187021973:-
SARC	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	5.56	7.36e-08	6.57e-05	0.51	0.34	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
SARC	cis	rs7809950	0.911	rs7778250	ENSG00000238832.1	snoU109	5.56	7.36e-08	6.57e-05	0.4	0.34	Coronary artery disease;	chr7:107584120	chr7:107603363~107603507:+
SARC	cis	rs8031584	0.678	rs4779790	ENSG00000260382.1	RP11-540B6.2	5.56	7.36e-08	6.57e-05	0.41	0.34	Huntington's disease progression;	chr15:30872392	chr15:30882267~30883231:-
SARC	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	5.56	7.37e-08	6.58e-05	0.44	0.34	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
SARC	cis	rs6991838	0.751	rs35553155	ENSG00000272010.1	CTD-3025N20.3	5.56	7.39e-08	6.59e-05	0.37	0.34	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.806	rs35024820	ENSG00000272010.1	CTD-3025N20.3	5.56	7.39e-08	6.59e-05	0.37	0.34	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65591850~65592472:-
SARC	cis	rs17772222	0.74	rs61975278	ENSG00000258983.2	RP11-507K2.2	5.56	7.39e-08	6.59e-05	0.34	0.34	Coronary artery calcification;	chr14:88511223	chr14:88499334~88515502:+
SARC	cis	rs2836950	0.565	rs2836943	ENSG00000255568.3	BRWD1-AS2	-5.56	7.39e-08	6.6e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39220685	chr21:39313935~39314962:+
SARC	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-5.56	7.4e-08	6.6e-05	-0.5	-0.34	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
SARC	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	5.56	7.4e-08	6.6e-05	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
SARC	cis	rs1865760	0.663	rs9379815	ENSG00000272810.1	U91328.22	-5.56	7.43e-08	6.62e-05	-0.32	-0.34	Height;	chr6:25979888	chr6:26013241~26013757:+
SARC	cis	rs77204473	0.744	rs11216252	ENSG00000254851.1	RP11-109L13.1	5.56	7.45e-08	6.64e-05	0.77	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057507	chr11:117135528~117138582:+
SARC	cis	rs77204473	0.744	rs11216253	ENSG00000254851.1	RP11-109L13.1	5.56	7.45e-08	6.64e-05	0.77	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057509	chr11:117135528~117138582:+
SARC	cis	rs6782228	1	rs6782228	ENSG00000242551.2	POU5F1P6	5.56	7.46e-08	6.65e-05	0.39	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128604581	chr3:128674735~128677005:-
SARC	cis	rs4862750	0.794	rs7692427	ENSG00000249742.1	RP11-217E13.1	-5.56	7.48e-08	6.66e-05	-0.37	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186980573	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.832	rs9995958	ENSG00000249742.1	RP11-217E13.1	-5.56	7.48e-08	6.66e-05	-0.37	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186980610	chr4:186979490~187021973:-
SARC	cis	rs1865760	0.713	rs7766342	ENSG00000272810.1	U91328.22	-5.56	7.48e-08	6.66e-05	-0.32	-0.34	Height;	chr6:25990446	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.713	rs9461229	ENSG00000272810.1	U91328.22	-5.56	7.48e-08	6.66e-05	-0.32	-0.34	Height;	chr6:25992051	chr6:26013241~26013757:+
SARC	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-5.56	7.49e-08	6.67e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
SARC	cis	rs763567	0.565	rs546258	ENSG00000271811.1	RP1-79C4.4	-5.56	7.49e-08	6.67e-05	-0.41	-0.34	Tonsillectomy;	chr1:170610453	chr1:170667381~170669425:+
SARC	cis	rs763567	0.585	rs553905	ENSG00000271811.1	RP1-79C4.4	-5.56	7.49e-08	6.67e-05	-0.41	-0.34	Tonsillectomy;	chr1:170611336	chr1:170667381~170669425:+
SARC	cis	rs763567	0.585	rs476810	ENSG00000271811.1	RP1-79C4.4	-5.56	7.5e-08	6.68e-05	-0.41	-0.34	Tonsillectomy;	chr1:170604673	chr1:170667381~170669425:+
SARC	cis	rs763567	0.585	rs1234233	ENSG00000271811.1	RP1-79C4.4	-5.56	7.5e-08	6.68e-05	-0.41	-0.34	Tonsillectomy;	chr1:170605787	chr1:170667381~170669425:+
SARC	cis	rs763567	0.546	rs566850	ENSG00000271811.1	RP1-79C4.4	-5.56	7.5e-08	6.68e-05	-0.41	-0.34	Tonsillectomy;	chr1:170607597	chr1:170667381~170669425:+
SARC	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	5.56	7.51e-08	6.68e-05	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	5.56	7.51e-08	6.68e-05	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
SARC	cis	rs11651753	0.636	rs4794332	ENSG00000264920.1	RP11-6N17.4	-5.56	7.53e-08	6.7e-05	-0.38	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47963201	chr17:47891255~47895812:-
SARC	cis	rs34375054	0.66	rs57491100	ENSG00000279233.1	RP11-158L12.4	5.56	7.54e-08	6.7e-05	0.41	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125108464	chr12:125138245~125141711:+
SARC	cis	rs34375054	0.66	rs57031290	ENSG00000279233.1	RP11-158L12.4	5.56	7.54e-08	6.7e-05	0.41	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125108507	chr12:125138245~125141711:+
SARC	cis	rs34375054	0.66	rs58624919	ENSG00000279233.1	RP11-158L12.4	5.56	7.54e-08	6.7e-05	0.41	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125111912	chr12:125138245~125141711:+
SARC	cis	rs2836950	0.585	rs1029004	ENSG00000255568.3	BRWD1-AS2	-5.56	7.54e-08	6.7e-05	-0.32	-0.34	Menarche (age at onset);	chr21:39243417	chr21:39313935~39314962:+
SARC	cis	rs1823913	0.599	rs17511410	ENSG00000227542.1	AC092614.2	5.56	7.55e-08	6.71e-05	0.38	0.34	Obesity-related traits;	chr2:191278043	chr2:191229165~191246172:-
SARC	cis	rs8031584	0.958	rs34909055	ENSG00000260382.1	RP11-540B6.2	5.56	7.55e-08	6.71e-05	0.41	0.34	Huntington's disease progression;	chr15:30991967	chr15:30882267~30883231:-
SARC	cis	rs172166	0.637	rs1233691	ENSG00000216901.1	AL022393.7	5.55	7.56e-08	6.72e-05	0.44	0.34	Cardiac Troponin-T levels;	chr6:28186119	chr6:28176188~28176674:+
SARC	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-5.55	7.57e-08	6.73e-05	-0.53	-0.34	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
SARC	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-5.55	7.57e-08	6.73e-05	-0.53	-0.34	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
SARC	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	5.55	7.59e-08	6.75e-05	0.38	0.34	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
SARC	cis	rs4862750	0.794	rs1030382	ENSG00000249742.1	RP11-217E13.1	-5.55	7.61e-08	6.76e-05	-0.37	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186982628	chr4:186979490~187021973:-
SARC	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	5.55	7.62e-08	6.77e-05	0.43	0.34	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
SARC	cis	rs7181230	0.848	rs62004114	ENSG00000275636.1	RP11-521C20.5	5.55	7.63e-08	6.77e-05	0.42	0.34	Dehydroepiandrosterone sulphate levels;	chr15:40041154	chr15:40078892~40079347:+
SARC	cis	rs7181230	0.848	rs75509561	ENSG00000275636.1	RP11-521C20.5	5.55	7.63e-08	6.77e-05	0.42	0.34	Dehydroepiandrosterone sulphate levels;	chr15:40041268	chr15:40078892~40079347:+
SARC	cis	rs7181230	0.848	rs7497289	ENSG00000275636.1	RP11-521C20.5	5.55	7.63e-08	6.77e-05	0.42	0.34	Dehydroepiandrosterone sulphate levels;	chr15:40041456	chr15:40078892~40079347:+
SARC	cis	rs899997	1	rs11629824	ENSG00000261143.1	ADAMTS7P3	5.55	7.66e-08	6.8e-05	0.5	0.34	Coronary artery disease or large artery stroke;	chr15:78713182	chr15:77976042~77993057:+
SARC	cis	rs899997	1	rs11634628	ENSG00000261143.1	ADAMTS7P3	5.55	7.66e-08	6.8e-05	0.5	0.34	Coronary artery disease or large artery stroke;	chr15:78713237	chr15:77976042~77993057:+
SARC	cis	rs1799949	0.965	rs8176198	ENSG00000267681.1	CTD-3199J23.6	-5.55	7.66e-08	6.8e-05	-0.37	-0.34	Menopause (age at onset);	chr17:43078520	chr17:43144956~43145255:+
SARC	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-5.55	7.67e-08	6.81e-05	-0.4	-0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
SARC	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-5.55	7.68e-08	6.82e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-5.55	7.68e-08	6.82e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-5.55	7.68e-08	6.82e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-5.55	7.68e-08	6.82e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
SARC	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-5.55	7.7e-08	6.83e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
SARC	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-5.55	7.72e-08	6.85e-05	-0.43	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
SARC	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	5.55	7.72e-08	6.85e-05	0.42	0.34	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	5.55	7.72e-08	6.85e-05	0.42	0.34	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
SARC	cis	rs11651753	0.561	rs11654010	ENSG00000264920.1	RP11-6N17.4	5.55	7.73e-08	6.86e-05	0.36	0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47883499	chr17:47891255~47895812:-
SARC	cis	rs7809950	1	rs6976607	ENSG00000238832.1	snoU109	5.55	7.74e-08	6.86e-05	0.4	0.34	Coronary artery disease;	chr7:107582956	chr7:107603363~107603507:+
SARC	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-5.55	7.74e-08	6.86e-05	-0.37	-0.34	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
SARC	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-5.55	7.74e-08	6.86e-05	-0.37	-0.34	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
SARC	cis	rs34375054	0.715	rs35933435	ENSG00000279233.1	RP11-158L12.4	5.55	7.74e-08	6.87e-05	0.43	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125147570	chr12:125138245~125141711:+
SARC	cis	rs1865760	0.568	rs2032450	ENSG00000272810.1	U91328.22	-5.55	7.75e-08	6.88e-05	-0.32	-0.34	Height;	chr6:25992886	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.713	rs2013063	ENSG00000272810.1	U91328.22	-5.55	7.75e-08	6.88e-05	-0.32	-0.34	Height;	chr6:25993870	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.713	rs6928951	ENSG00000272810.1	U91328.22	-5.55	7.75e-08	6.88e-05	-0.32	-0.34	Height;	chr6:25995326	chr6:26013241~26013757:+
SARC	cis	rs11651753	0.561	rs4794261	ENSG00000264920.1	RP11-6N17.4	-5.55	7.76e-08	6.88e-05	-0.37	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47904980	chr17:47891255~47895812:-
SARC	cis	rs11651753	0.561	rs7211859	ENSG00000264920.1	RP11-6N17.4	-5.55	7.76e-08	6.88e-05	-0.37	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47908916	chr17:47891255~47895812:-
SARC	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	5.55	7.76e-08	6.88e-05	0.42	0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
SARC	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-5.55	7.77e-08	6.89e-05	-0.4	-0.34	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
SARC	cis	rs2562456	0.837	rs62110205	ENSG00000268081.1	RP11-678G14.2	5.55	7.79e-08	6.9e-05	0.52	0.34	Pain;	chr19:21577269	chr19:21554640~21569237:-
SARC	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	5.55	7.8e-08	6.91e-05	0.43	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
SARC	cis	rs75920871	0.588	rs7101763	ENSG00000254851.1	RP11-109L13.1	5.55	7.81e-08	6.92e-05	0.47	0.34	Subjective well-being;	chr11:117071269	chr11:117135528~117138582:+
SARC	cis	rs7216064	1	rs7216064	ENSG00000278219.1	AC145343.1	-5.55	7.82e-08	6.92e-05	-0.42	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67902693	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs62085993	ENSG00000278219.1	AC145343.1	-5.55	7.82e-08	6.92e-05	-0.42	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67927036	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs4271626	ENSG00000278219.1	AC145343.1	-5.55	7.82e-08	6.92e-05	-0.42	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934017	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs56393562	ENSG00000278219.1	AC145343.1	-5.55	7.82e-08	6.92e-05	-0.42	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67937802	chr17:68101538~68101639:+
SARC	cis	rs4273100	0.85	rs11204306	ENSG00000228157.4	AC007952.5	5.55	7.84e-08	6.93e-05	0.5	0.34	Schizophrenia;	chr17:19364058	chr17:19092974~19096837:+
SARC	cis	rs4713118	0.699	rs200978	ENSG00000219392.1	RP1-265C24.5	-5.55	7.84e-08	6.94e-05	-0.52	-0.34	Parkinson's disease;	chr6:27885390	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	5.55	7.84e-08	6.94e-05	0.37	0.34	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
SARC	cis	rs7587476	0.784	rs13026390	ENSG00000229267.2	AC072062.1	5.55	7.89e-08	6.98e-05	0.33	0.34	Neuroblastoma;	chr2:214822351	chr2:214810229~214963274:+
SARC	cis	rs17772222	0.682	rs1152377	ENSG00000258983.2	RP11-507K2.2	-5.55	7.89e-08	6.98e-05	-0.35	-0.34	Coronary artery calcification;	chr14:88496243	chr14:88499334~88515502:+
SARC	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	5.55	7.9e-08	6.99e-05	0.52	0.34	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
SARC	cis	rs6991838	0.702	rs13274205	ENSG00000200714.1	Y_RNA	5.55	7.93e-08	7.01e-05	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65592731~65592820:+
SARC	cis	rs4865169	0.967	rs10023088	ENSG00000269949.1	RP11-738E22.3	5.55	7.94e-08	7.02e-05	0.39	0.34	Breast cancer;	chr4:57018269	chr4:56960927~56961373:-
SARC	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	5.54	7.96e-08	7.04e-05	0.43	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
SARC	cis	rs5769707	0.667	rs4824069	ENSG00000188511.11	C22orf34	5.54	7.96e-08	7.04e-05	0.43	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49414524~49657542:-
SARC	cis	rs7772486	0.754	rs9386133	ENSG00000270638.1	RP3-466P17.1	5.54	7.98e-08	7.05e-05	0.28	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145735570~145737218:+
SARC	cis	rs8031584	0.678	rs8035703	ENSG00000260382.1	RP11-540B6.2	5.54	8.01e-08	7.07e-05	0.4	0.34	Huntington's disease progression;	chr15:30876269	chr15:30882267~30883231:-
SARC	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	5.54	8.03e-08	7.08e-05	0.47	0.34	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
SARC	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	5.54	8.06e-08	7.11e-05	0.47	0.34	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
SARC	cis	rs8031584	0.678	rs798125	ENSG00000260382.1	RP11-540B6.2	-5.54	8.11e-08	7.15e-05	-0.41	-0.34	Huntington's disease progression;	chr15:30824597	chr15:30882267~30883231:-
SARC	cis	rs2836950	0.545	rs2836952	ENSG00000255568.3	BRWD1-AS2	-5.54	8.12e-08	7.15e-05	-0.32	-0.34	Menarche (age at onset);	chr21:39244725	chr21:39313935~39314962:+
SARC	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	5.54	8.13e-08	7.16e-05	0.47	0.34	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
SARC	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	5.54	8.13e-08	7.16e-05	0.47	0.34	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
SARC	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	5.54	8.13e-08	7.16e-05	0.47	0.34	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
SARC	cis	rs6570726	0.846	rs7773939	ENSG00000270638.1	RP3-466P17.1	-5.54	8.17e-08	7.19e-05	-0.28	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145735570~145737218:+
SARC	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	5.54	8.17e-08	7.2e-05	0.49	0.34	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	5.54	8.17e-08	7.2e-05	0.49	0.34	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
SARC	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-5.54	8.18e-08	7.2e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-5.54	8.18e-08	7.2e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-5.54	8.18e-08	7.2e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-5.54	8.18e-08	7.2e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-5.54	8.18e-08	7.2e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-5.54	8.18e-08	7.2e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-5.54	8.18e-08	7.2e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-5.54	8.18e-08	7.2e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
SARC	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-5.54	8.18e-08	7.2e-05	-0.5	-0.34	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-5.54	8.18e-08	7.2e-05	-0.5	-0.34	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
SARC	cis	rs2836950	0.527	rs2836958	ENSG00000255568.3	BRWD1-AS2	-5.54	8.2e-08	7.22e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39251600	chr21:39313935~39314962:+
SARC	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-5.54	8.22e-08	7.23e-05	-0.39	-0.34	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
SARC	cis	rs77204473	1	rs75410648	ENSG00000254851.1	RP11-109L13.1	5.54	8.22e-08	7.23e-05	0.74	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116942722	chr11:117135528~117138582:+
SARC	cis	rs7247513	0.964	rs35235213	ENSG00000213290.4	PGK1P2	-5.54	8.24e-08	7.25e-05	-0.41	-0.34	Bipolar disorder;	chr19:12602342	chr19:12559571~12561105:+
SARC	cis	rs2562456	0.792	rs2562398	ENSG00000268081.1	RP11-678G14.2	-5.54	8.27e-08	7.27e-05	-0.51	-0.34	Pain;	chr19:21540147	chr19:21554640~21569237:-
SARC	cis	rs8031584	0.578	rs1088473	ENSG00000260382.1	RP11-540B6.2	-5.54	8.28e-08	7.27e-05	-0.41	-0.34	Huntington's disease progression;	chr15:30847095	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.678	rs4779496	ENSG00000260382.1	RP11-540B6.2	5.54	8.28e-08	7.27e-05	0.41	0.34	Huntington's disease progression;	chr15:30858851	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.678	rs4779497	ENSG00000260382.1	RP11-540B6.2	5.54	8.28e-08	7.27e-05	0.41	0.34	Huntington's disease progression;	chr15:30859162	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.678	rs8028173	ENSG00000260382.1	RP11-540B6.2	5.54	8.28e-08	7.27e-05	0.41	0.34	Huntington's disease progression;	chr15:30863546	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.706	rs2177670	ENSG00000260382.1	RP11-540B6.2	5.54	8.28e-08	7.27e-05	0.41	0.34	Huntington's disease progression;	chr15:30865548	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.678	rs36047941	ENSG00000260382.1	RP11-540B6.2	5.54	8.28e-08	7.27e-05	0.41	0.34	Huntington's disease progression;	chr15:30867032	chr15:30882267~30883231:-
SARC	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-5.54	8.28e-08	7.27e-05	-0.38	-0.34	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
SARC	cis	rs755249	0.565	rs3768320	ENSG00000182109.6	RP11-69E11.4	-5.54	8.29e-08	7.28e-05	-0.34	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39566567	chr1:39522280~39546187:-
SARC	cis	rs4713118	0.513	rs149958	ENSG00000216901.1	AL022393.7	5.54	8.3e-08	7.3e-05	0.48	0.34	Parkinson's disease;	chr6:28045839	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.513	rs156738	ENSG00000216901.1	AL022393.7	5.54	8.3e-08	7.3e-05	0.48	0.34	Parkinson's disease;	chr6:28046247	chr6:28176188~28176674:+
SARC	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-5.54	8.32e-08	7.31e-05	-0.33	-0.34	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-5.54	8.32e-08	7.31e-05	-0.33	-0.34	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-5.54	8.32e-08	7.31e-05	-0.33	-0.34	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
SARC	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-5.54	8.32e-08	7.31e-05	-0.34	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
SARC	cis	rs858239	0.636	rs7808488	ENSG00000226816.2	AC005082.12	5.54	8.32e-08	7.31e-05	0.42	0.34	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23206013~23208045:+
SARC	cis	rs2836950	0.545	rs11700449	ENSG00000255568.3	BRWD1-AS2	-5.54	8.33e-08	7.32e-05	-0.32	-0.34	Menarche (age at onset);	chr21:39150493	chr21:39313935~39314962:+
SARC	cis	rs4862750	0.832	rs6836076	ENSG00000249742.1	RP11-217E13.1	-5.54	8.35e-08	7.33e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186978506	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.872	rs6836781	ENSG00000249742.1	RP11-217E13.1	-5.54	8.35e-08	7.33e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186978547	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.872	rs11947595	ENSG00000249742.1	RP11-217E13.1	-5.54	8.35e-08	7.33e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186978673	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.872	rs7658314	ENSG00000249742.1	RP11-217E13.1	-5.54	8.35e-08	7.33e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186979202	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.832	rs6419953	ENSG00000249742.1	RP11-217E13.1	-5.54	8.35e-08	7.33e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186979355	chr4:186979490~187021973:-
SARC	cis	rs9494145	0.68	rs9402686	ENSG00000232876.1	CTA-212D2.2	-5.53	8.38e-08	7.36e-05	-0.44	-0.34	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106679	chr6:135055033~135060550:+
SARC	cis	rs4862750	0.872	rs6811837	ENSG00000249742.1	RP11-217E13.1	-5.53	8.39e-08	7.36e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186977008	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.872	rs6553030	ENSG00000249742.1	RP11-217E13.1	-5.53	8.39e-08	7.36e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186978080	chr4:186979490~187021973:-
SARC	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	5.53	8.39e-08	7.36e-05	0.41	0.34	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
SARC	cis	rs2562456	0.917	rs2681377	ENSG00000268081.1	RP11-678G14.2	-5.53	8.39e-08	7.36e-05	-0.51	-0.34	Pain;	chr19:21533718	chr19:21554640~21569237:-
SARC	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	5.53	8.39e-08	7.37e-05	0.51	0.34	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
SARC	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	5.53	8.44e-08	7.41e-05	0.49	0.34	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
SARC	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-5.53	8.46e-08	7.42e-05	-0.33	-0.34	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
SARC	cis	rs77204473	0.744	rs12279266	ENSG00000254851.1	RP11-109L13.1	5.53	8.46e-08	7.42e-05	0.74	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116969317	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs74927399	ENSG00000254851.1	RP11-109L13.1	5.53	8.46e-08	7.42e-05	0.74	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975550	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs76949321	ENSG00000254851.1	RP11-109L13.1	5.53	8.46e-08	7.42e-05	0.74	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975627	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs11216209	ENSG00000254851.1	RP11-109L13.1	5.53	8.46e-08	7.42e-05	0.74	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116977470	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs11216215	ENSG00000254851.1	RP11-109L13.1	5.53	8.46e-08	7.42e-05	0.74	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116981971	chr11:117135528~117138582:+
SARC	cis	rs2276314	0.857	rs28540805	ENSG00000278986.1	RP11-723J4.3	-5.53	8.48e-08	7.43e-05	-0.42	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36062012	chr18:35972151~35973916:+
SARC	cis	rs9637599	0.967	rs7656367	ENSG00000246375.2	RP11-10L7.1	5.53	8.49e-08	7.44e-05	0.42	0.34	Metabolite levels (small molecules and protein measures);	chr4:88275669	chr4:88284942~88331421:+
SARC	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-5.53	8.49e-08	7.44e-05	-0.43	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
SARC	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-5.53	8.51e-08	7.46e-05	-0.33	-0.34	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
SARC	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	5.53	8.54e-08	7.47e-05	0.42	0.34	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
SARC	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	5.53	8.54e-08	7.47e-05	0.42	0.34	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
SARC	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	5.53	8.54e-08	7.47e-05	0.42	0.34	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
SARC	cis	rs7809950	1	rs2057837	ENSG00000238832.1	snoU109	5.53	8.54e-08	7.48e-05	0.4	0.34	Coronary artery disease;	chr7:107582280	chr7:107603363~107603507:+
SARC	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-5.53	8.57e-08	7.5e-05	-0.57	-0.34	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
SARC	cis	rs2562456	0.874	rs2562408	ENSG00000268081.1	RP11-678G14.2	-5.53	8.59e-08	7.51e-05	-0.51	-0.34	Pain;	chr19:21527079	chr19:21554640~21569237:-
SARC	cis	rs8031584	0.697	rs798080	ENSG00000260382.1	RP11-540B6.2	-5.53	8.59e-08	7.52e-05	-0.41	-0.34	Huntington's disease progression;	chr15:30829966	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.723	rs711224	ENSG00000260382.1	RP11-540B6.2	-5.53	8.59e-08	7.52e-05	-0.41	-0.34	Huntington's disease progression;	chr15:30835718	chr15:30882267~30883231:-
SARC	cis	rs1823913	0.599	rs2124093	ENSG00000227542.1	AC092614.2	5.53	8.6e-08	7.52e-05	0.38	0.34	Obesity-related traits;	chr2:191288280	chr2:191229165~191246172:-
SARC	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-5.53	8.62e-08	7.54e-05	-0.52	-0.34	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
SARC	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	5.53	8.63e-08	7.55e-05	0.49	0.34	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
SARC	cis	rs7216064	0.684	rs7406031	ENSG00000265055.1	AC145343.2	-5.53	8.64e-08	7.56e-05	-0.41	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68025637	chr17:68096046~68101474:-
SARC	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	5.53	8.67e-08	7.58e-05	0.54	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
SARC	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	5.53	8.7e-08	7.61e-05	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
SARC	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	5.53	8.72e-08	7.62e-05	0.42	0.34	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
SARC	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	5.53	8.72e-08	7.62e-05	0.42	0.34	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
SARC	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-5.53	8.73e-08	7.63e-05	-0.33	-0.34	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
SARC	cis	rs75920871	0.66	rs12271161	ENSG00000254851.1	RP11-109L13.1	5.53	8.74e-08	7.63e-05	0.45	0.34	Subjective well-being;	chr11:117109195	chr11:117135528~117138582:+
SARC	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-5.53	8.77e-08	7.66e-05	-0.4	-0.34	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
SARC	cis	rs2179367	0.887	rs506268	ENSG00000231760.4	RP11-350J20.5	5.53	8.78e-08	7.66e-05	0.42	0.34	Dupuytren's disease;	chr6:149364481	chr6:149796151~149826294:-
SARC	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-5.52	8.8e-08	7.69e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
SARC	cis	rs77204473	0.744	rs79870586	ENSG00000254851.1	RP11-109L13.1	5.52	8.81e-08	7.69e-05	0.73	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117016005	chr11:117135528~117138582:+
SARC	cis	rs77204473	0.744	rs80054374	ENSG00000254851.1	RP11-109L13.1	5.52	8.81e-08	7.69e-05	0.73	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117019951	chr11:117135528~117138582:+
SARC	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-5.52	8.81e-08	7.69e-05	-0.39	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-5.52	8.81e-08	7.69e-05	-0.39	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-5.52	8.81e-08	7.69e-05	-0.39	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-5.52	8.81e-08	7.69e-05	-0.39	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-5.52	8.81e-08	7.69e-05	-0.39	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-5.52	8.81e-08	7.69e-05	-0.39	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
SARC	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-5.52	8.82e-08	7.69e-05	-0.42	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
SARC	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	5.52	8.83e-08	7.7e-05	0.47	0.34	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
SARC	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	5.52	8.84e-08	7.71e-05	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
SARC	cis	rs9818758	0.545	rs9853352	ENSG00000225399.4	RP11-3B7.1	5.52	8.84e-08	7.71e-05	0.61	0.34	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49775825	chr3:49260085~49261316:+
SARC	cis	rs7250849	0.529	rs16982912	ENSG00000273837.1	LLNLR-470E3.1	-5.52	8.85e-08	7.73e-05	-0.36	-0.34	Blood protein levels;	chr19:51661874	chr19:51639478~51639931:-
SARC	cis	rs1865760	1	rs7770139	ENSG00000272462.2	U91328.19	-5.52	8.86e-08	7.73e-05	-0.32	-0.34	Height;	chr6:25925595	chr6:25992662~26001775:+
SARC	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	5.52	8.87e-08	7.74e-05	0.42	0.34	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.95	rs7566364	ENSG00000163016.8	ALMS1P	5.52	8.87e-08	7.74e-05	0.42	0.34	Metabolite levels;	chr2:73615762	chr2:73644919~73685576:+
SARC	cis	rs4862750	0.872	rs9998172	ENSG00000249742.1	RP11-217E13.1	-5.52	8.9e-08	7.76e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186977619	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.872	rs9998173	ENSG00000249742.1	RP11-217E13.1	-5.52	8.9e-08	7.76e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186977624	chr4:186979490~187021973:-
SARC	cis	rs9494145	0.526	rs17064262	ENSG00000232876.1	CTA-212D2.2	-5.52	8.91e-08	7.77e-05	-0.54	-0.34	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135144336	chr6:135055033~135060550:+
SARC	cis	rs1865760	0.963	rs9356991	ENSG00000272462.2	U91328.19	-5.52	8.92e-08	7.78e-05	-0.33	-0.34	Height;	chr6:25901530	chr6:25992662~26001775:+
SARC	cis	rs2836950	0.502	rs12627205	ENSG00000255568.3	BRWD1-AS2	-5.52	8.93e-08	7.79e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39258101	chr21:39313935~39314962:+
SARC	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-5.52	8.93e-08	7.79e-05	-0.38	-0.34	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
SARC	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-5.52	8.94e-08	7.79e-05	-0.33	-0.34	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-5.52	8.94e-08	7.79e-05	-0.33	-0.34	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
SARC	cis	rs12922317	0.681	rs2869492	ENSG00000260488.1	RP11-166B2.7	5.52	8.95e-08	7.8e-05	0.36	0.34	Schizophrenia;	chr16:11977484	chr16:11976851~11977850:-
SARC	cis	rs4862750	0.957	rs1030381	ENSG00000249742.1	RP11-217E13.1	-5.52	8.98e-08	7.82e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186982414	chr4:186979490~187021973:-
SARC	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-5.52	8.98e-08	7.83e-05	-0.33	-0.34	Height;	chr11:118781100	chr11:118704607~118750263:+
SARC	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	5.52	8.98e-08	7.83e-05	0.41	0.34	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
SARC	cis	rs17772222	0.682	rs2274736	ENSG00000258983.2	RP11-507K2.2	5.52	8.98e-08	7.83e-05	0.35	0.34	Coronary artery calcification;	chr14:88472308	chr14:88499334~88515502:+
SARC	cis	rs7216064	0.953	rs4790981	ENSG00000265055.1	AC145343.2	5.52	8.99e-08	7.83e-05	0.43	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67925718	chr17:68096046~68101474:-
SARC	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-5.52	8.99e-08	7.83e-05	-0.54	-0.34	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
SARC	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	5.52	9e-08	7.84e-05	0.49	0.34	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
SARC	cis	rs2836950	0.509	rs4816618	ENSG00000255568.3	BRWD1-AS2	-5.52	9.01e-08	7.85e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39227603	chr21:39313935~39314962:+
SARC	cis	rs2836950	0.527	rs2836948	ENSG00000255568.3	BRWD1-AS2	-5.52	9.01e-08	7.85e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39227751	chr21:39313935~39314962:+
SARC	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-5.52	9.02e-08	7.86e-05	-0.41	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
SARC	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-5.52	9.02e-08	7.86e-05	-0.41	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
SARC	cis	rs7216064	0.953	rs2086744	ENSG00000265055.1	AC145343.2	5.52	9.03e-08	7.87e-05	0.44	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67853159	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs2046323	ENSG00000265055.1	AC145343.2	5.52	9.03e-08	7.87e-05	0.44	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67853811	chr17:68096046~68101474:-
SARC	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	5.52	9.07e-08	7.89e-05	0.37	0.34	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
SARC	cis	rs7216064	1	rs6504555	ENSG00000265055.1	AC145343.2	-5.52	9.08e-08	7.9e-05	-0.43	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67944611	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs56404791	ENSG00000265055.1	AC145343.2	5.52	9.08e-08	7.9e-05	0.43	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896903	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs55896768	ENSG00000265055.1	AC145343.2	5.52	9.08e-08	7.9e-05	0.43	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67917242	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.953	rs4791300	ENSG00000265055.1	AC145343.2	5.52	9.08e-08	7.9e-05	0.43	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934656	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs4791299	ENSG00000265055.1	AC145343.2	5.52	9.08e-08	7.9e-05	0.43	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934821	chr17:68096046~68101474:-
SARC	cis	rs9818758	0.607	rs5030795	ENSG00000225399.4	RP11-3B7.1	-5.52	9.11e-08	7.93e-05	-0.6	-0.34	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49103683	chr3:49260085~49261316:+
SARC	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	5.52	9.11e-08	7.93e-05	0.48	0.34	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
SARC	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	5.52	9.12e-08	7.94e-05	0.37	0.34	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
SARC	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	5.52	9.12e-08	7.94e-05	0.37	0.34	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
SARC	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	5.52	9.12e-08	7.94e-05	0.37	0.34	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
SARC	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	5.52	9.13e-08	7.94e-05	0.36	0.34	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
SARC	cis	rs7216064	1	rs56148300	ENSG00000265055.1	AC145343.2	5.52	9.13e-08	7.94e-05	0.43	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896636	chr17:68096046~68101474:-
SARC	cis	rs7809950	1	rs7778270	ENSG00000238832.1	snoU109	5.52	9.13e-08	7.94e-05	0.4	0.34	Coronary artery disease;	chr7:107584222	chr7:107603363~107603507:+
SARC	cis	rs7216064	0.636	rs4638	ENSG00000278219.1	AC145343.1	5.52	9.14e-08	7.95e-05	0.39	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043234	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.601	rs35453056	ENSG00000278219.1	AC145343.1	5.52	9.14e-08	7.95e-05	0.39	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043552	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.628	rs62084702	ENSG00000278219.1	AC145343.1	5.52	9.14e-08	7.95e-05	0.39	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68047041	chr17:68101538~68101639:+
SARC	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	5.52	9.17e-08	7.97e-05	0.4	0.34	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
SARC	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-5.52	9.18e-08	7.99e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
SARC	cis	rs9494145	0.526	rs55875437	ENSG00000232876.1	CTA-212D2.2	-5.52	9.19e-08	7.99e-05	-0.48	-0.34	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135146050	chr6:135055033~135060550:+
SARC	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-5.52	9.2e-08	8e-05	-0.68	-0.34	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
SARC	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-5.52	9.2e-08	8e-05	-0.68	-0.34	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
SARC	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	5.52	9.22e-08	8.02e-05	0.38	0.34	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
SARC	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	5.51	9.26e-08	8.04e-05	0.69	0.34	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
SARC	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	5.51	9.26e-08	8.05e-05	0.41	0.34	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
SARC	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	5.51	9.26e-08	8.05e-05	0.41	0.34	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
SARC	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-5.51	9.33e-08	8.11e-05	-0.44	-0.34	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
SARC	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-5.51	9.34e-08	8.11e-05	-0.56	-0.34	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
SARC	cis	rs17772222	0.74	rs61984675	ENSG00000258983.2	RP11-507K2.2	5.51	9.34e-08	8.11e-05	0.34	0.34	Coronary artery calcification;	chr14:88511236	chr14:88499334~88515502:+
SARC	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	5.51	9.37e-08	8.14e-05	0.54	0.34	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
SARC	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	5.51	9.38e-08	8.14e-05	0.42	0.34	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
SARC	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	5.51	9.38e-08	8.14e-05	0.41	0.34	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	5.51	9.38e-08	8.14e-05	0.41	0.34	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
SARC	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	5.51	9.38e-08	8.14e-05	0.42	0.34	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
SARC	cis	rs6991838	0.725	rs6995134	ENSG00000272010.1	CTD-3025N20.3	5.51	9.39e-08	8.15e-05	0.37	0.34	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65591850~65592472:-
SARC	cis	rs11018904	0.906	rs55685917	ENSG00000280385.1	AP000648.5	-5.51	9.41e-08	8.17e-05	-0.39	-0.34	Intelligence (multi-trait analysis);	chr11:90231197	chr11:90193614~90198120:+
SARC	cis	rs11018904	0.906	rs35286339	ENSG00000280385.1	AP000648.5	-5.51	9.41e-08	8.17e-05	-0.39	-0.34	Intelligence (multi-trait analysis);	chr11:90232511	chr11:90193614~90198120:+
SARC	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-5.51	9.42e-08	8.17e-05	-0.42	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
SARC	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-5.51	9.42e-08	8.17e-05	-0.42	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
SARC	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-5.51	9.42e-08	8.17e-05	-0.42	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
SARC	cis	rs4862750	0.872	rs7672831	ENSG00000249742.1	RP11-217E13.1	-5.51	9.46e-08	8.21e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186977728	chr4:186979490~187021973:-
SARC	cis	rs2562456	0.876	rs62110163	ENSG00000268081.1	RP11-678G14.2	5.51	9.47e-08	8.21e-05	0.51	0.34	Pain;	chr19:21546020	chr19:21554640~21569237:-
SARC	cis	rs1865760	1	rs2071297	ENSG00000272462.2	U91328.19	5.51	9.48e-08	8.22e-05	0.32	0.34	Height;	chr6:25924285	chr6:25992662~26001775:+
SARC	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-5.51	9.48e-08	8.22e-05	-0.42	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
SARC	cis	rs11651753	0.598	rs4794286	ENSG00000264920.1	RP11-6N17.4	-5.51	9.51e-08	8.24e-05	-0.37	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47913231	chr17:47891255~47895812:-
SARC	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	5.51	9.54e-08	8.27e-05	0.48	0.34	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
SARC	cis	rs6991838	0.733	rs7822627	ENSG00000200714.1	Y_RNA	5.51	9.54e-08	8.27e-05	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65592731~65592820:+
SARC	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	5.51	9.56e-08	8.28e-05	0.42	0.34	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
SARC	cis	rs899997	1	rs12899940	ENSG00000261143.1	ADAMTS7P3	-5.51	9.56e-08	8.28e-05	-0.5	-0.34	Coronary artery disease or large artery stroke;	chr15:78709357	chr15:77976042~77993057:+
SARC	cis	rs7809950	1	rs7793613	ENSG00000238832.1	snoU109	-5.51	9.56e-08	8.28e-05	-0.39	-0.34	Coronary artery disease;	chr7:107610039	chr7:107603363~107603507:+
SARC	cis	rs6991838	0.806	rs35284121	ENSG00000272010.1	CTD-3025N20.3	5.51	9.58e-08	8.29e-05	0.37	0.34	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65591850~65592472:-
SARC	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-5.51	9.59e-08	8.31e-05	-0.35	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
SARC	cis	rs4938303	0.718	rs10892020	ENSG00000254851.1	RP11-109L13.1	-5.51	9.6e-08	8.31e-05	-0.42	-0.34	Triglycerides;	chr11:116718936	chr11:117135528~117138582:+
SARC	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	5.51	9.6e-08	8.31e-05	0.43	0.34	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
SARC	cis	rs2836950	0.501	rs2836980	ENSG00000255568.3	BRWD1-AS2	-5.51	9.63e-08	8.33e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39315692	chr21:39313935~39314962:+
SARC	cis	rs2836950	0.501	rs11088470	ENSG00000255568.3	BRWD1-AS2	-5.51	9.63e-08	8.33e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39317236	chr21:39313935~39314962:+
SARC	cis	rs2836950	0.501	rs2836983	ENSG00000255568.3	BRWD1-AS2	-5.51	9.63e-08	8.33e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39317410	chr21:39313935~39314962:+
SARC	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-5.51	9.63e-08	8.33e-05	-0.37	-0.34	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
SARC	cis	rs1823913	0.599	rs56328712	ENSG00000227542.1	AC092614.2	5.51	9.66e-08	8.36e-05	0.38	0.34	Obesity-related traits;	chr2:191273807	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.599	rs55862924	ENSG00000227542.1	AC092614.2	5.51	9.66e-08	8.36e-05	0.38	0.34	Obesity-related traits;	chr2:191273809	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.599	rs12989203	ENSG00000227542.1	AC092614.2	5.51	9.66e-08	8.36e-05	0.38	0.34	Obesity-related traits;	chr2:191276617	chr2:191229165~191246172:-
SARC	cis	rs899997	0.953	rs11633519	ENSG00000261143.1	ADAMTS7P3	5.51	9.67e-08	8.36e-05	0.52	0.34	Coronary artery disease or large artery stroke;	chr15:78707210	chr15:77976042~77993057:+
SARC	cis	rs2836950	0.52	rs8133927	ENSG00000255568.3	BRWD1-AS2	-5.51	9.68e-08	8.37e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39318035	chr21:39313935~39314962:+
SARC	cis	rs2836950	0.52	rs8133928	ENSG00000255568.3	BRWD1-AS2	-5.51	9.68e-08	8.37e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39318037	chr21:39313935~39314962:+
SARC	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-5.51	9.69e-08	8.38e-05	-0.5	-0.34	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
SARC	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-5.51	9.69e-08	8.38e-05	-0.5	-0.34	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-5.51	9.69e-08	8.38e-05	-0.5	-0.34	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
SARC	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	5.51	9.7e-08	8.38e-05	0.42	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
SARC	cis	rs4862750	0.872	rs13101380	ENSG00000249742.1	RP11-217E13.1	-5.51	9.7e-08	8.38e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186973590	chr4:186979490~187021973:-
SARC	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-5.5	9.72e-08	8.4e-05	-0.43	-0.34	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
SARC	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	5.5	9.72e-08	8.4e-05	0.36	0.34	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
SARC	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	5.5	9.76e-08	8.43e-05	0.33	0.34	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
SARC	cis	rs17270561	0.609	rs1317817	ENSG00000272810.1	U91328.22	-5.5	9.76e-08	8.43e-05	-0.34	-0.34	Iron status biomarkers;	chr6:25765149	chr6:26013241~26013757:+
SARC	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	5.5	9.76e-08	8.44e-05	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
SARC	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-5.5	9.77e-08	8.44e-05	-0.39	-0.34	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
SARC	cis	rs1865760	1	rs9358895	ENSG00000272462.2	U91328.19	-5.5	9.78e-08	8.45e-05	-0.32	-0.34	Height;	chr6:25924427	chr6:25992662~26001775:+
SARC	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	5.5	9.79e-08	8.45e-05	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	5.5	9.79e-08	8.45e-05	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	5.5	9.79e-08	8.45e-05	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	5.5	9.79e-08	8.45e-05	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	5.5	9.79e-08	8.45e-05	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	5.5	9.79e-08	8.45e-05	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	5.5	9.79e-08	8.45e-05	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	5.5	9.79e-08	8.45e-05	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	5.5	9.79e-08	8.45e-05	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	5.5	9.79e-08	8.45e-05	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	5.5	9.79e-08	8.45e-05	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
SARC	cis	rs2836950	0.565	rs2150413	ENSG00000255568.3	BRWD1-AS2	-5.5	9.79e-08	8.46e-05	-0.31	-0.34	Menarche (age at onset);	chr21:39242952	chr21:39313935~39314962:+
SARC	cis	rs77204473	0.744	rs10892067	ENSG00000254851.1	RP11-109L13.1	5.5	9.8e-08	8.46e-05	0.74	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057046	chr11:117135528~117138582:+
SARC	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-5.5	9.82e-08	8.48e-05	-0.37	-0.34	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
SARC	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-5.5	9.82e-08	8.48e-05	-0.37	-0.34	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
SARC	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-5.5	9.82e-08	8.48e-05	-0.37	-0.34	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
SARC	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-5.5	9.82e-08	8.48e-05	-0.37	-0.34	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
SARC	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	5.5	9.82e-08	8.48e-05	0.39	0.34	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
SARC	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-5.5	9.84e-08	8.49e-05	-0.43	-0.34	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
SARC	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-5.5	9.84e-08	8.49e-05	-0.44	-0.34	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
SARC	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-5.5	9.84e-08	8.49e-05	-0.44	-0.34	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
SARC	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	5.5	9.87e-08	8.51e-05	0.43	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
SARC	cis	rs4862750	0.872	rs13110072	ENSG00000250971.1	RP11-696F12.1	5.5	9.89e-08	8.53e-05	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr4:186957370	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.872	rs6825289	ENSG00000250971.1	RP11-696F12.1	5.5	9.89e-08	8.53e-05	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr4:186957955	chr4:187060099~187060930:+
SARC	cis	rs1707322	1	rs12077974	ENSG00000280836.1	AL355480.1	-5.5	9.95e-08	8.58e-05	-0.37	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45581219~45581321:-
SARC	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	5.5	9.97e-08	8.59e-05	0.43	0.34	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	5.5	9.97e-08	8.59e-05	0.43	0.34	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	5.5	9.97e-08	8.59e-05	0.43	0.34	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
SARC	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-5.5	1e-07	8.62e-05	-0.36	-0.34	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
SARC	cis	rs1865760	1	rs3799372	ENSG00000272462.2	U91328.19	-5.5	1e-07	8.62e-05	-0.32	-0.34	Height;	chr6:25922083	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.963	rs1540273	ENSG00000272462.2	U91328.19	-5.5	1e-07	8.62e-05	-0.32	-0.34	Height;	chr6:25923930	chr6:25992662~26001775:+
SARC	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-5.5	1.01e-07	8.66e-05	-0.32	-0.34	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
SARC	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-5.5	1.01e-07	8.68e-05	-0.49	-0.34	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-5.5	1.01e-07	8.68e-05	-0.49	-0.34	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-5.5	1.01e-07	8.68e-05	-0.49	-0.34	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-5.5	1.01e-07	8.68e-05	-0.49	-0.34	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
SARC	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-5.5	1.01e-07	8.68e-05	-0.49	-0.34	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-5.5	1.01e-07	8.68e-05	-0.49	-0.34	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-5.5	1.01e-07	8.68e-05	-0.49	-0.34	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-5.5	1.01e-07	8.68e-05	-0.49	-0.34	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-5.5	1.01e-07	8.68e-05	-0.49	-0.34	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
SARC	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-5.5	1.01e-07	8.68e-05	-0.49	-0.34	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	5.5	1.01e-07	8.68e-05	0.49	0.34	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
SARC	cis	rs2179367	0.959	rs9377212	ENSG00000231760.4	RP11-350J20.5	5.5	1.01e-07	8.72e-05	0.41	0.34	Dupuytren's disease;	chr6:149383765	chr6:149796151~149826294:-
SARC	cis	rs17772222	0.655	rs816072	ENSG00000258983.2	RP11-507K2.2	-5.5	1.01e-07	8.72e-05	-0.35	-0.34	Coronary artery calcification;	chr14:88484335	chr14:88499334~88515502:+
SARC	cis	rs2933343	1	rs789213	ENSG00000231305.3	RP11-723O4.2	-5.5	1.02e-07	8.75e-05	-0.37	-0.34	IgG glycosylation;	chr3:128897516	chr3:128861313~128871540:-
SARC	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	5.5	1.02e-07	8.75e-05	0.4	0.34	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
SARC	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	5.5	1.02e-07	8.75e-05	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
SARC	cis	rs4713118	0.662	rs4713120	ENSG00000216901.1	AL022393.7	5.5	1.02e-07	8.75e-05	0.42	0.34	Parkinson's disease;	chr6:27754056	chr6:28176188~28176674:+
SARC	cis	rs7216064	0.861	rs62084252	ENSG00000278219.1	AC145343.1	-5.5	1.02e-07	8.77e-05	-0.4	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67883462	chr17:68101538~68101639:+
SARC	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-5.49	1.02e-07	8.79e-05	-0.37	-0.34	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
SARC	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	5.49	1.02e-07	8.79e-05	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
SARC	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-5.49	1.03e-07	8.82e-05	-0.44	-0.34	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
SARC	cis	rs10800713	0.826	rs6427834	ENSG00000260088.1	RP11-92G12.3	-5.49	1.03e-07	8.82e-05	-0.42	-0.34	Tandem gait;	chr1:200561936	chr1:200669507~200694250:+
SARC	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-5.49	1.03e-07	8.83e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
SARC	cis	rs13129231	0.92	rs17676840	ENSG00000206820.1	RNU1-138P	5.49	1.03e-07	8.83e-05	0.34	0.34	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113439469	chr4:113420323~113420486:+
SARC	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-5.49	1.03e-07	8.84e-05	-0.34	-0.34	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
SARC	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	5.49	1.03e-07	8.85e-05	0.43	0.34	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
SARC	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	5.49	1.03e-07	8.85e-05	0.43	0.34	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
SARC	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	5.49	1.03e-07	8.88e-05	0.38	0.34	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
SARC	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-5.49	1.04e-07	8.89e-05	-0.33	-0.34	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-5.49	1.04e-07	8.89e-05	-0.33	-0.34	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
SARC	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	5.49	1.04e-07	8.91e-05	0.35	0.34	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
SARC	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	5.49	1.04e-07	8.91e-05	0.35	0.34	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
SARC	cis	rs1823913	0.599	rs35892286	ENSG00000227542.1	AC092614.2	5.49	1.04e-07	8.91e-05	0.38	0.34	Obesity-related traits;	chr2:191269010	chr2:191229165~191246172:-
SARC	cis	rs890448	0.796	rs2471673	ENSG00000254531.1	FLJ20021	5.49	1.04e-07	8.92e-05	0.36	0.34	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101432430	chr4:101347780~101348883:+
SARC	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-5.49	1.04e-07	8.96e-05	-0.42	-0.34	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
SARC	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-5.49	1.05e-07	8.97e-05	-0.31	-0.34	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
SARC	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-5.49	1.05e-07	8.97e-05	-0.31	-0.34	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
SARC	cis	rs77204473	0.744	rs75890305	ENSG00000254851.1	RP11-109L13.1	5.49	1.05e-07	8.97e-05	0.77	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117049253	chr11:117135528~117138582:+
SARC	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-5.49	1.05e-07	8.98e-05	-0.36	-0.34	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
SARC	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-5.49	1.05e-07	8.99e-05	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
SARC	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-5.49	1.05e-07	9e-05	-0.37	-0.34	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
SARC	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	5.49	1.05e-07	9e-05	0.4	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
SARC	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-5.49	1.05e-07	9.02e-05	-0.44	-0.34	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
SARC	cis	rs7587476	0.784	rs36086595	ENSG00000229267.2	AC072062.1	-5.49	1.05e-07	9.02e-05	-0.33	-0.34	Neuroblastoma;	chr2:214815569	chr2:214810229~214963274:+
SARC	cis	rs858239	0.965	rs156429	ENSG00000226816.2	AC005082.12	5.49	1.05e-07	9.03e-05	0.41	0.34	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23206013~23208045:+
SARC	cis	rs17772222	0.682	rs28482235	ENSG00000258983.2	RP11-507K2.2	5.49	1.05e-07	9.03e-05	0.34	0.34	Coronary artery calcification;	chr14:88472857	chr14:88499334~88515502:+
SARC	cis	rs858239	0.699	rs955187	ENSG00000226816.2	AC005082.12	-5.49	1.06e-07	9.04e-05	-0.41	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23206013~23208045:+
SARC	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	5.49	1.06e-07	9.06e-05	0.36	0.34	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
SARC	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-5.49	1.06e-07	9.06e-05	-0.33	-0.34	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
SARC	cis	rs77204473	1	rs11216199	ENSG00000254851.1	RP11-109L13.1	5.49	1.06e-07	9.07e-05	0.73	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116960300	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs10892051	ENSG00000254851.1	RP11-109L13.1	5.49	1.06e-07	9.07e-05	0.73	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116962002	chr11:117135528~117138582:+
SARC	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	5.49	1.06e-07	9.08e-05	0.48	0.34	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
SARC	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	5.49	1.06e-07	9.09e-05	0.39	0.34	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
SARC	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-5.49	1.06e-07	9.09e-05	-0.31	-0.34	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
SARC	cis	rs2404602	0.569	rs283793	ENSG00000259422.1	RP11-593F23.1	5.49	1.06e-07	9.09e-05	0.41	0.34	Blood metabolite levels;	chr15:76482411	chr15:76174891~76181486:-
SARC	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-5.49	1.06e-07	9.11e-05	-0.38	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
SARC	cis	rs1075232	1	rs72722861	ENSG00000270055.1	CTD-3092A11.2	-5.49	1.06e-07	9.11e-05	-0.68	-0.34	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30487963~30490313:+
SARC	cis	rs1075232	0.826	rs12438813	ENSG00000270055.1	CTD-3092A11.2	-5.49	1.06e-07	9.11e-05	-0.68	-0.34	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30487963~30490313:+
SARC	cis	rs1075232	1	rs34959140	ENSG00000270055.1	CTD-3092A11.2	-5.49	1.06e-07	9.11e-05	-0.68	-0.34	Survival in colorectal cancer (non-distant metastatic);	chr15:31433020	chr15:30487963~30490313:+
SARC	cis	rs1865760	0.625	rs9393681	ENSG00000272462.2	U91328.19	-5.49	1.07e-07	9.15e-05	-0.3	-0.34	Height;	chr6:26008032	chr6:25992662~26001775:+
SARC	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	5.49	1.07e-07	9.16e-05	0.34	0.34	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
SARC	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-5.49	1.07e-07	9.18e-05	-0.42	-0.34	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
SARC	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-5.49	1.07e-07	9.18e-05	-0.42	-0.34	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
SARC	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-5.49	1.07e-07	9.18e-05	-0.42	-0.34	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
SARC	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-5.49	1.07e-07	9.18e-05	-0.42	-0.34	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
SARC	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-5.49	1.07e-07	9.18e-05	-0.42	-0.34	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
SARC	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-5.49	1.07e-07	9.18e-05	-0.42	-0.34	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
SARC	cis	rs2562456	0.793	rs279807	ENSG00000268081.1	RP11-678G14.2	5.48	1.08e-07	9.2e-05	0.54	0.34	Pain;	chr19:21283020	chr19:21554640~21569237:-
SARC	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-5.48	1.08e-07	9.23e-05	-0.41	-0.34	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
SARC	cis	rs77204473	1	rs2186844	ENSG00000254851.1	RP11-109L13.1	-5.48	1.08e-07	9.24e-05	-0.7	-0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117135528~117138582:+
SARC	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	5.48	1.08e-07	9.24e-05	0.37	0.34	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
SARC	cis	rs4862750	1	rs4862750	ENSG00000249742.1	RP11-217E13.1	-5.48	1.08e-07	9.25e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186982889	chr4:186979490~187021973:-
SARC	cis	rs4862750	1	rs4862751	ENSG00000249742.1	RP11-217E13.1	-5.48	1.08e-07	9.25e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186982896	chr4:186979490~187021973:-
SARC	cis	rs11651753	0.561	rs1108833	ENSG00000264920.1	RP11-6N17.4	-5.48	1.08e-07	9.25e-05	-0.37	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47905431	chr17:47891255~47895812:-
SARC	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-5.48	1.08e-07	9.25e-05	-0.32	-0.34	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
SARC	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	5.48	1.09e-07	9.28e-05	0.48	0.34	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
SARC	cis	rs9494145	0.68	rs4895440	ENSG00000232876.1	CTA-212D2.2	-5.48	1.09e-07	9.3e-05	-0.42	-0.34	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105420	chr6:135055033~135060550:+
SARC	cis	rs8031584	0.652	rs2691683	ENSG00000260382.1	RP11-540B6.2	-5.48	1.09e-07	9.3e-05	-0.4	-0.34	Huntington's disease progression;	chr15:30842857	chr15:30882267~30883231:-
SARC	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	5.48	1.09e-07	9.3e-05	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
SARC	cis	rs1823913	0.599	rs17511445	ENSG00000227542.1	AC092614.2	-5.48	1.09e-07	9.31e-05	-0.37	-0.34	Obesity-related traits;	chr2:191279831	chr2:191229165~191246172:-
SARC	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	5.48	1.09e-07	9.31e-05	0.4	0.34	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
SARC	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-5.48	1.09e-07	9.32e-05	-0.41	-0.34	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
SARC	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	5.48	1.09e-07	9.33e-05	0.33	0.34	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
SARC	cis	rs710913	0.738	rs755247	ENSG00000182109.6	RP11-69E11.4	-5.48	1.09e-07	9.33e-05	-0.32	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39522280~39546187:-
SARC	cis	rs9494145	0.526	rs9494154	ENSG00000232876.1	CTA-212D2.2	5.48	1.1e-07	9.36e-05	0.47	0.34	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135146867	chr6:135055033~135060550:+
SARC	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	5.48	1.1e-07	9.36e-05	0.36	0.34	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
SARC	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	5.48	1.1e-07	9.36e-05	0.36	0.34	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
SARC	cis	rs62103177	0.525	rs9949598	ENSG00000261126.6	RP11-795F19.1	-5.48	1.1e-07	9.38e-05	-0.33	-0.34	Opioid sensitivity;	chr18:79993037	chr18:80046900~80095482:+
SARC	cis	rs1865760	1	rs3799371	ENSG00000272810.1	U91328.22	5.48	1.1e-07	9.38e-05	0.33	0.34	Height;	chr6:25912588	chr6:26013241~26013757:+
SARC	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	5.48	1.1e-07	9.39e-05	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
SARC	cis	rs4862750	0.872	rs13143414	ENSG00000249742.1	RP11-217E13.1	-5.48	1.1e-07	9.4e-05	-0.36	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186957059	chr4:186979490~187021973:-
SARC	cis	rs6991838	0.67	rs869151	ENSG00000200714.1	Y_RNA	5.48	1.11e-07	9.42e-05	0.34	0.34	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65592731~65592820:+
SARC	cis	rs10055631	0.518	rs2662226	ENSG00000229666.1	MAST4-AS1	-5.48	1.11e-07	9.42e-05	-0.35	-0.34	Coronary artery disease;	chr5:67017390	chr5:67001383~67003953:-
SARC	cis	rs7216064	1	rs7210027	ENSG00000278219.1	AC145343.1	5.48	1.11e-07	9.43e-05	0.4	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67980937	chr17:68101538~68101639:+
SARC	cis	rs524281	0.861	rs3862386	ENSG00000255320.1	RP11-755F10.1	5.48	1.11e-07	9.44e-05	0.49	0.34	Electroencephalogram traits;	chr11:66126953	chr11:66244840~66246239:-
SARC	cis	rs5769707	0.632	rs135877	ENSG00000235111.1	RP1-29C18.8	-5.48	1.11e-07	9.47e-05	-0.43	-0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49612657~49615716:-
SARC	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-5.48	1.11e-07	9.47e-05	-0.56	-0.34	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
SARC	cis	rs1823913	0.599	rs35098152	ENSG00000227542.1	AC092614.2	5.48	1.11e-07	9.5e-05	0.37	0.34	Obesity-related traits;	chr2:191286658	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.599	rs35150635	ENSG00000227542.1	AC092614.2	5.48	1.11e-07	9.5e-05	0.37	0.34	Obesity-related traits;	chr2:191287303	chr2:191229165~191246172:-
SARC	cis	rs7216064	0.532	rs8065296	ENSG00000265055.1	AC145343.2	-5.48	1.11e-07	9.5e-05	-0.41	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68022446	chr17:68096046~68101474:-
SARC	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	5.48	1.12e-07	9.53e-05	0.32	0.34	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
SARC	cis	rs8031584	0.872	rs11634761	ENSG00000260382.1	RP11-540B6.2	5.48	1.12e-07	9.55e-05	0.42	0.34	Huntington's disease progression;	chr15:30950970	chr15:30882267~30883231:-
SARC	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	5.48	1.12e-07	9.56e-05	0.4	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
SARC	cis	rs1823913	0.599	rs2168166	ENSG00000227542.1	AC092614.2	5.48	1.13e-07	9.57e-05	0.37	0.34	Obesity-related traits;	chr2:191288063	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.622	rs55787447	ENSG00000227542.1	AC092614.2	5.48	1.13e-07	9.57e-05	0.37	0.34	Obesity-related traits;	chr2:191288596	chr2:191229165~191246172:-
SARC	cis	rs4862750	0.914	rs7658351	ENSG00000249742.1	RP11-217E13.1	-5.48	1.13e-07	9.57e-05	-0.37	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186954526	chr4:186979490~187021973:-
SARC	cis	rs2562456	0.754	rs11673234	ENSG00000268081.1	RP11-678G14.2	5.48	1.13e-07	9.6e-05	0.55	0.34	Pain;	chr19:21324800	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.754	rs11673320	ENSG00000268081.1	RP11-678G14.2	5.48	1.13e-07	9.6e-05	0.55	0.34	Pain;	chr19:21324801	chr19:21554640~21569237:-
SARC	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	5.47	1.13e-07	9.61e-05	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
SARC	cis	rs7809950	1	rs10276604	ENSG00000238832.1	snoU109	5.47	1.13e-07	9.62e-05	0.4	0.34	Coronary artery disease;	chr7:107576293	chr7:107603363~107603507:+
SARC	cis	rs1865760	0.593	rs9295678	ENSG00000272810.1	U91328.22	-5.47	1.13e-07	9.62e-05	-0.34	-0.34	Height;	chr6:25936805	chr6:26013241~26013757:+
SARC	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-5.47	1.14e-07	9.66e-05	-0.43	-0.34	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
SARC	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-5.47	1.14e-07	9.71e-05	-0.41	-0.34	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
SARC	cis	rs7216064	0.953	rs1599859	ENSG00000278219.1	AC145343.1	-5.47	1.14e-07	9.71e-05	-0.4	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841077	chr17:68101538~68101639:+
SARC	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-5.47	1.15e-07	9.72e-05	-0.33	-0.34	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
SARC	cis	rs9309473	0.514	rs62149630	ENSG00000163016.8	ALMS1P	5.47	1.15e-07	9.75e-05	0.51	0.34	Metabolite levels;	chr2:73354627	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.514	rs62149659	ENSG00000163016.8	ALMS1P	5.47	1.15e-07	9.75e-05	0.51	0.34	Metabolite levels;	chr2:73358068	chr2:73644919~73685576:+
SARC	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	5.47	1.15e-07	9.75e-05	0.38	0.34	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
SARC	cis	rs17772222	0.638	rs11159859	ENSG00000258983.2	RP11-507K2.2	5.47	1.15e-07	9.75e-05	0.35	0.34	Coronary artery calcification;	chr14:88561547	chr14:88499334~88515502:+
SARC	cis	rs7216064	1	rs8072225	ENSG00000265055.1	AC145343.2	5.47	1.15e-07	9.76e-05	0.43	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67916844	chr17:68096046~68101474:-
SARC	cis	rs5769707	0.656	rs135878	ENSG00000235111.1	RP1-29C18.8	-5.47	1.16e-07	9.8e-05	-0.43	-0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49612657~49615716:-
SARC	cis	rs7712401	0.623	rs426877	ENSG00000263432.2	RN7SL689P	-5.47	1.16e-07	9.81e-05	-0.43	-0.34	Mean platelet volume;	chr5:122978940	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs34233716	ENSG00000263432.2	RN7SL689P	-5.47	1.16e-07	9.81e-05	-0.43	-0.34	Mean platelet volume;	chr5:122980670	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.54	rs416763	ENSG00000263432.2	RN7SL689P	-5.47	1.16e-07	9.81e-05	-0.43	-0.34	Mean platelet volume;	chr5:122981546	chr5:123022487~123022783:-
SARC	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-5.47	1.16e-07	9.82e-05	-0.48	-0.34	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-5.47	1.16e-07	9.82e-05	-0.48	-0.34	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
SARC	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-5.47	1.16e-07	9.82e-05	-0.48	-0.34	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-5.47	1.16e-07	9.82e-05	-0.48	-0.34	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-5.47	1.16e-07	9.82e-05	-0.48	-0.34	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-5.47	1.16e-07	9.82e-05	-0.48	-0.34	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-5.47	1.16e-07	9.82e-05	-0.48	-0.34	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
SARC	cis	rs4862750	0.872	rs13101408	ENSG00000250971.1	RP11-696F12.1	5.47	1.16e-07	9.82e-05	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr4:186973623	chr4:187060099~187060930:+
SARC	cis	rs17772222	0.582	rs1288122	ENSG00000258983.2	RP11-507K2.2	-5.47	1.16e-07	9.83e-05	-0.35	-0.34	Coronary artery calcification;	chr14:88472736	chr14:88499334~88515502:+
SARC	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	5.47	1.16e-07	9.84e-05	0.32	0.34	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
SARC	cis	rs7587476	0.784	rs13008641	ENSG00000229267.2	AC072062.1	-5.47	1.16e-07	9.84e-05	-0.33	-0.34	Neuroblastoma;	chr2:214833309	chr2:214810229~214963274:+
SARC	cis	rs7587476	0.784	rs13032278	ENSG00000229267.2	AC072062.1	-5.47	1.16e-07	9.84e-05	-0.33	-0.34	Neuroblastoma;	chr2:214833310	chr2:214810229~214963274:+
SARC	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-5.47	1.17e-07	9.89e-05	-0.55	-0.34	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
SARC	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-5.47	1.17e-07	9.89e-05	-0.33	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
SARC	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-5.47	1.17e-07	9.89e-05	-0.34	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
SARC	cis	rs9494145	0.68	rs9389269	ENSG00000232876.1	CTA-212D2.2	-5.47	1.17e-07	9.9e-05	-0.44	-0.34	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106021	chr6:135055033~135060550:+
SARC	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-5.47	1.17e-07	9.91e-05	-0.42	-0.34	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
SARC	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-5.47	1.17e-07	9.91e-05	-0.42	-0.34	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
SARC	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-5.47	1.17e-07	9.91e-05	-0.42	-0.34	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
SARC	cis	rs4713118	0.699	rs573179	ENSG00000219392.1	RP1-265C24.5	-5.47	1.17e-07	9.92e-05	-0.51	-0.34	Parkinson's disease;	chr6:27881898	chr6:28115628~28116551:+
SARC	cis	rs3762637	0.941	rs9289192	ENSG00000272758.4	RP11-299J3.8	-5.47	1.18e-07	9.95e-05	-0.48	-0.34	LDL cholesterol levels;	chr3:122357268	chr3:122416207~122443180:+
SARC	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-5.47	1.18e-07	9.95e-05	-0.36	-0.34	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
SARC	cis	rs2562456	0.874	rs9304986	ENSG00000268081.1	RP11-678G14.2	-5.47	1.18e-07	9.98e-05	-0.5	-0.34	Pain;	chr19:21499260	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.917	rs2650805	ENSG00000268081.1	RP11-678G14.2	-5.47	1.18e-07	9.98e-05	-0.5	-0.34	Pain;	chr19:21505137	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.917	rs10420016	ENSG00000268081.1	RP11-678G14.2	-5.47	1.18e-07	9.98e-05	-0.5	-0.34	Pain;	chr19:21505800	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.917	rs2681389	ENSG00000268081.1	RP11-678G14.2	-5.47	1.18e-07	9.98e-05	-0.5	-0.34	Pain;	chr19:21509773	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.917	rs6511256	ENSG00000268081.1	RP11-678G14.2	-5.47	1.18e-07	9.98e-05	-0.5	-0.34	Pain;	chr19:21510513	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.917	rs2681392	ENSG00000268081.1	RP11-678G14.2	-5.47	1.18e-07	9.98e-05	-0.5	-0.34	Pain;	chr19:21513185	chr19:21554640~21569237:-
SARC	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	5.47	1.18e-07	1e-04	0.39	0.34	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
SARC	cis	rs2562456	0.682	rs11085464	ENSG00000268081.1	RP11-678G14.2	5.46	1.19e-07	1e-04	0.5	0.34	Pain;	chr19:21568976	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.876	rs11085467	ENSG00000268081.1	RP11-678G14.2	5.46	1.19e-07	1e-04	0.5	0.34	Pain;	chr19:21569041	chr19:21554640~21569237:-
SARC	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-5.46	1.19e-07	1e-04	-0.42	-0.34	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
SARC	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-5.46	1.19e-07	1e-04	-0.42	-0.34	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
SARC	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	5.46	1.19e-07	1e-04	0.42	0.34	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
SARC	cis	rs73186030	0.748	rs16832956	ENSG00000272758.4	RP11-299J3.8	5.46	1.19e-07	0.000101	0.41	0.34	Serum parathyroid hormone levels;	chr3:122298661	chr3:122416207~122443180:+
SARC	cis	rs4862750	0.794	rs7672272	ENSG00000250971.1	RP11-696F12.1	5.46	1.2e-07	0.000101	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr4:186975620	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.872	rs6852907	ENSG00000250971.1	RP11-696F12.1	5.46	1.2e-07	0.000101	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr4:186975940	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.872	rs6830426	ENSG00000250971.1	RP11-696F12.1	5.46	1.2e-07	0.000101	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr4:186976116	chr4:187060099~187060930:+
SARC	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	5.46	1.2e-07	0.000101	0.43	0.34	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
SARC	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	5.46	1.2e-07	0.000101	0.48	0.34	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
SARC	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	5.46	1.2e-07	0.000101	0.48	0.34	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	5.46	1.2e-07	0.000101	0.48	0.34	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
SARC	cis	rs2836950	0.565	rs2836942	ENSG00000255568.3	BRWD1-AS2	-5.46	1.2e-07	0.000101	-0.31	-0.34	Menarche (age at onset);	chr21:39219455	chr21:39313935~39314962:+
SARC	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-5.46	1.2e-07	0.000101	-0.32	-0.34	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
SARC	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-5.46	1.2e-07	0.000101	-0.36	-0.34	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
SARC	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-5.46	1.2e-07	0.000102	-0.41	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
SARC	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	5.46	1.21e-07	0.000102	0.49	0.34	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
SARC	cis	rs34787248	1	rs34787248	ENSG00000219392.1	RP1-265C24.5	-5.46	1.21e-07	0.000102	-0.52	-0.34	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28115628~28116551:+
SARC	cis	rs853679	0.76	rs2299029	ENSG00000219392.1	RP1-265C24.5	-5.46	1.21e-07	0.000102	-0.52	-0.34	Depression;	chr6:28231053	chr6:28115628~28116551:+
SARC	cis	rs2562456	0.755	rs1879234	ENSG00000268081.1	RP11-678G14.2	-5.46	1.21e-07	0.000102	-0.5	-0.34	Pain;	chr19:21521677	chr19:21554640~21569237:-
SARC	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	5.46	1.21e-07	0.000102	0.52	0.34	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
SARC	cis	rs17772222	0.682	rs28711639	ENSG00000258983.2	RP11-507K2.2	5.46	1.21e-07	0.000102	0.34	0.34	Coronary artery calcification;	chr14:88482277	chr14:88499334~88515502:+
SARC	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-5.46	1.22e-07	0.000103	-0.4	-0.34	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
SARC	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	5.46	1.22e-07	0.000103	0.49	0.34	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
SARC	cis	rs4862750	0.872	rs1991254	ENSG00000249742.1	RP11-217E13.1	-5.46	1.22e-07	0.000103	-0.38	-0.34	Lobe attachment (rater-scored or self-reported);	chr4:186954221	chr4:186979490~187021973:-
SARC	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	5.46	1.22e-07	0.000103	0.43	0.34	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
SARC	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	5.46	1.22e-07	0.000103	0.46	0.34	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
SARC	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	5.46	1.22e-07	0.000103	0.34	0.34	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
SARC	cis	rs899997	1	rs11072794	ENSG00000261143.1	ADAMTS7P3	5.46	1.23e-07	0.000103	0.49	0.34	Coronary artery disease or large artery stroke;	chr15:78714240	chr15:77976042~77993057:+
SARC	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	5.46	1.23e-07	0.000103	0.37	0.34	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
SARC	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	5.46	1.23e-07	0.000103	0.38	0.34	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	5.46	1.23e-07	0.000103	0.38	0.34	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
SARC	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-5.46	1.23e-07	0.000103	-0.43	-0.34	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
SARC	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-5.46	1.23e-07	0.000103	-0.32	-0.34	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-5.46	1.23e-07	0.000103	-0.32	-0.34	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
SARC	cis	rs1865760	0.964	rs3799373	ENSG00000272462.2	U91328.19	-5.46	1.23e-07	0.000104	-0.32	-0.34	Height;	chr6:25928945	chr6:25992662~26001775:+
SARC	cis	rs1865760	1	rs9348698	ENSG00000272462.2	U91328.19	-5.46	1.23e-07	0.000104	-0.32	-0.34	Height;	chr6:25929461	chr6:25992662~26001775:+
SARC	cis	rs7430456	1	rs7430456	ENSG00000225790.1	RP11-2L8.1	5.46	1.24e-07	0.000105	0.34	0.34	Breast cancer;	chr3:177768082	chr3:177934823~177937662:+
SARC	cis	rs7712401	0.601	rs442427	ENSG00000263432.2	RN7SL689P	-5.46	1.25e-07	0.000105	-0.42	-0.34	Mean platelet volume;	chr5:122986570	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs418562	ENSG00000263432.2	RN7SL689P	-5.45	1.25e-07	0.000105	-0.43	-0.34	Mean platelet volume;	chr5:123004567	chr5:123022487~123022783:-
SARC	cis	rs7587476	0.689	rs78989396	ENSG00000229267.2	AC072062.1	-5.45	1.25e-07	0.000105	-0.33	-0.34	Neuroblastoma;	chr2:214850092	chr2:214810229~214963274:+
SARC	cis	rs607541	0.85	rs2218309	ENSG00000259520.4	CTD-2651B20.3	-5.45	1.25e-07	0.000105	-0.63	-0.34	Obesity-related traits;	chr15:45646463	chr15:45251580~45279251:-
SARC	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	5.45	1.25e-07	0.000105	0.41	0.34	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
SARC	cis	rs916888	0.773	rs199533	ENSG00000261575.2	RP11-259G18.1	5.45	1.25e-07	0.000105	0.5	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46267037~46268694:+
SARC	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-5.45	1.25e-07	0.000105	-0.39	-0.34	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
SARC	cis	rs4862750	0.874	rs6822062	ENSG00000250971.1	RP11-696F12.1	5.45	1.26e-07	0.000106	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr4:186974399	chr4:187060099~187060930:+
SARC	cis	rs2946504	0.861	rs2946494	ENSG00000251468.2	RP11-369K16.1	-5.45	1.26e-07	0.000106	-0.37	-0.34	Type 2 diabetes;	chr8:12962601	chr8:12958387~12962200:+
SARC	cis	rs201779	1	rs200221	ENSG00000274270.1	RP11-34F20.7	5.45	1.26e-07	0.000106	0.66	0.34	Left atrial antero-posterior diameter;	chr13:50386041	chr13:50125816~50128463:+
SARC	cis	rs10461617	0.531	rs2662033	ENSG00000271828.1	CTD-2310F14.1	5.45	1.26e-07	0.000106	0.53	0.34	Type 2 diabetes;	chr5:56917583	chr5:56927874~56929573:+
SARC	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	5.45	1.26e-07	0.000106	0.4	0.34	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
SARC	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-5.45	1.26e-07	0.000106	-0.49	-0.34	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
SARC	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	5.45	1.27e-07	0.000106	0.56	0.34	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
SARC	cis	rs9309473	0.95	rs13391258	ENSG00000163016.8	ALMS1P	5.45	1.27e-07	0.000106	0.41	0.34	Metabolite levels;	chr2:73621806	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.898	rs6546861	ENSG00000163016.8	ALMS1P	5.45	1.27e-07	0.000106	0.41	0.34	Metabolite levels;	chr2:73622734	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.95	rs6711001	ENSG00000163016.8	ALMS1P	5.45	1.27e-07	0.000106	0.41	0.34	Metabolite levels;	chr2:73623693	chr2:73644919~73685576:+
SARC	cis	rs7216064	1	rs7210027	ENSG00000265055.1	AC145343.2	-5.45	1.27e-07	0.000106	-0.42	-0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67980937	chr17:68096046~68101474:-
SARC	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-5.45	1.27e-07	0.000106	-0.37	-0.34	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
SARC	cis	rs4654783	0.627	rs2092322	ENSG00000228397.1	RP1-224A6.3	-5.45	1.27e-07	0.000106	-0.38	-0.34	Endometriosis;	chr1:22109230	chr1:22023994~22024968:-
SARC	cis	rs7809950	0.862	rs62482502	ENSG00000238832.1	snoU109	-5.45	1.27e-07	0.000107	-0.39	-0.34	Coronary artery disease;	chr7:107347365	chr7:107603363~107603507:+
SARC	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	5.45	1.27e-07	0.000107	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	5.45	1.27e-07	0.000107	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
SARC	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	5.45	1.27e-07	0.000107	0.41	0.34	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
SARC	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	5.45	1.28e-07	0.000107	0.34	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
SARC	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-5.45	1.28e-07	0.000107	-0.32	-0.34	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
SARC	cis	rs7216064	0.655	rs8078543	ENSG00000278219.1	AC145343.1	5.45	1.28e-07	0.000107	0.38	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68041135	chr17:68101538~68101639:+
SARC	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-5.45	1.28e-07	0.000108	-0.36	-0.34	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
SARC	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-5.45	1.29e-07	0.000108	-0.48	-0.34	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
SARC	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	5.45	1.29e-07	0.000108	0.57	0.34	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	5.45	1.29e-07	0.000108	0.57	0.34	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	5.45	1.29e-07	0.000108	0.57	0.34	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
SARC	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-5.45	1.29e-07	0.000108	-0.4	-0.34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
SARC	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	5.45	1.29e-07	0.000108	0.37	0.34	Migraine;	chr4:56861145	chr4:56960927~56961373:-
SARC	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	5.45	1.29e-07	0.000108	0.42	0.34	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
SARC	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	5.45	1.29e-07	0.000108	0.33	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-5.45	1.3e-07	0.000109	-0.34	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
SARC	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-5.45	1.3e-07	0.000109	-0.37	-0.34	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
SARC	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	5.45	1.3e-07	0.000109	0.67	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
SARC	cis	rs1865760	0.515	rs2003208	ENSG00000272810.1	U91328.22	-5.45	1.3e-07	0.000109	-0.34	-0.34	Height;	chr6:25940491	chr6:26013241~26013757:+
SARC	cis	rs12022452	0.818	rs11810978	ENSG00000238287.1	RP11-656D10.3	-5.45	1.3e-07	0.000109	-0.53	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40493157~40508661:-
SARC	cis	rs12022452	0.908	rs11811487	ENSG00000238287.1	RP11-656D10.3	-5.45	1.3e-07	0.000109	-0.53	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40493157~40508661:-
SARC	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-5.45	1.3e-07	0.000109	-0.32	-0.34	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
SARC	cis	rs7772486	0.754	rs702324	ENSG00000270638.1	RP3-466P17.1	-5.45	1.31e-07	0.00011	-0.28	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145687657	chr6:145735570~145737218:+
SARC	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-5.44	1.32e-07	0.00011	-0.47	-0.34	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
SARC	cis	rs4862750	0.872	rs56389997	ENSG00000250971.1	RP11-696F12.1	5.44	1.32e-07	0.000111	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr4:186973642	chr4:187060099~187060930:+
SARC	cis	rs1865760	1	rs9393675	ENSG00000272462.2	U91328.19	-5.44	1.32e-07	0.000111	-0.32	-0.34	Height;	chr6:25929888	chr6:25992662~26001775:+
SARC	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-5.44	1.33e-07	0.000111	-0.48	-0.34	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
SARC	cis	rs1865760	1	rs7739966	ENSG00000272462.2	U91328.19	-5.44	1.33e-07	0.000111	-0.32	-0.34	Height;	chr6:25905812	chr6:25992662~26001775:+
SARC	cis	rs1865760	1	rs56118523	ENSG00000272462.2	U91328.19	-5.44	1.33e-07	0.000111	-0.32	-0.34	Height;	chr6:25908747	chr6:25992662~26001775:+
SARC	cis	rs1865760	1	rs12209482	ENSG00000272462.2	U91328.19	-5.44	1.33e-07	0.000111	-0.32	-0.34	Height;	chr6:25909001	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.963	rs3846838	ENSG00000272462.2	U91328.19	-5.44	1.33e-07	0.000111	-0.32	-0.34	Height;	chr6:25911547	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.928	rs9295673	ENSG00000272462.2	U91328.19	-5.44	1.33e-07	0.000111	-0.32	-0.34	Height;	chr6:25911866	chr6:25992662~26001775:+
SARC	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-5.44	1.33e-07	0.000111	-0.42	-0.34	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
SARC	cis	rs2562456	0.876	rs62110202	ENSG00000268081.1	RP11-678G14.2	5.44	1.33e-07	0.000111	0.51	0.34	Pain;	chr19:21571799	chr19:21554640~21569237:-
SARC	cis	rs9532669	0.926	rs4942014	ENSG00000176268.5	CYCSP34	5.44	1.33e-07	0.000111	0.33	0.34	Cervical cancer;	chr13:40966366	chr13:40863599~40863902:-
SARC	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-5.44	1.33e-07	0.000111	-0.34	-0.34	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
SARC	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	5.44	1.34e-07	0.000112	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
SARC	cis	rs7181230	0.922	rs4924410	ENSG00000275636.1	RP11-521C20.5	-5.44	1.34e-07	0.000112	-0.4	-0.34	Dehydroepiandrosterone sulphate levels;	chr15:40047293	chr15:40078892~40079347:+
SARC	cis	rs739310	0.556	rs9625074	ENSG00000206028.1	CTA-373H7.7	-5.44	1.34e-07	0.000112	-0.53	-0.34	Obesity-related traits;	chr22:26703325	chr22:26667693~26672654:-
SARC	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-5.44	1.34e-07	0.000112	-0.41	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
SARC	cis	rs6991838	0.806	rs11777025	ENSG00000272010.1	CTD-3025N20.3	-5.44	1.35e-07	0.000112	-0.36	-0.34	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65591850~65592472:-
SARC	cis	rs7712401	0.601	rs436546	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122987095	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs397731	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122987264	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.58	rs35902490	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122987703	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.562	rs383638	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122988983	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.562	rs62377399	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122988984	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs415534	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122989606	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs442911	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122989856	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs425573	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122990313	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.562	rs364723	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122990769	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs35847506	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122991413	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs390234	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122995828	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs4555798	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122996419	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs62377424	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122996627	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs35699701	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122998061	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs35256179	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122998560	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs35858098	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122998670	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs13155907	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122998938	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs62377430	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122998993	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs34348084	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122999419	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs35334805	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:122999566	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs13164134	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:123002246	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs13185741	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:123002315	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs418229	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:123005969	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs374403	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:123006018	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs446782	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:123006173	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs417268	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:123009317	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs398142	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:123009881	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.58	rs383262	ENSG00000263432.2	RN7SL689P	-5.44	1.35e-07	0.000112	-0.42	-0.34	Mean platelet volume;	chr5:123009989	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs154506	ENSG00000263432.2	RN7SL689P	5.44	1.35e-07	0.000112	0.42	0.34	Mean platelet volume;	chr5:122867086	chr5:123022487~123022783:-
SARC	cis	rs2562456	0.833	rs2562416	ENSG00000268081.1	RP11-678G14.2	5.44	1.35e-07	0.000112	0.57	0.34	Pain;	chr19:21430609	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62110429	ENSG00000268081.1	RP11-678G14.2	5.44	1.35e-07	0.000112	0.57	0.34	Pain;	chr19:21430984	chr19:21554640~21569237:-
SARC	cis	rs10800713	0.954	rs4504918	ENSG00000260088.1	RP11-92G12.3	5.44	1.35e-07	0.000112	0.43	0.34	Tandem gait;	chr1:200588639	chr1:200669507~200694250:+
SARC	cis	rs3805389	1	rs3805389	ENSG00000273257.1	RP11-177J6.1	-5.44	1.35e-07	0.000112	-0.46	-0.34	Waist-to-hip ratio adjusted for body mass index;	chr4:55616583	chr4:55387949~55388271:+
SARC	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	5.44	1.35e-07	0.000112	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
SARC	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-5.44	1.36e-07	0.000113	-0.33	-0.34	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
SARC	cis	rs7587476	0.822	rs13018304	ENSG00000229267.2	AC072062.1	-5.44	1.37e-07	0.000114	-0.32	-0.34	Neuroblastoma;	chr2:214817494	chr2:214810229~214963274:+
SARC	cis	rs7712401	0.601	rs404442	ENSG00000263432.2	RN7SL689P	-5.44	1.38e-07	0.000114	-0.43	-0.34	Mean platelet volume;	chr5:123009236	chr5:123022487~123022783:-
SARC	cis	rs10895987	0.531	rs2282498	ENSG00000254614.2	AP003068.23	5.44	1.38e-07	0.000114	0.4	0.34	Blood protein levels;	chr11:65088514	chr11:65177606~65181834:-
SARC	cis	rs2562456	0.833	rs2650776	ENSG00000268081.1	RP11-678G14.2	5.43	1.38e-07	0.000115	0.56	0.34	Pain;	chr19:21430595	chr19:21554640~21569237:-
SARC	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	5.43	1.38e-07	0.000115	0.36	0.34	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
SARC	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	5.43	1.38e-07	0.000115	0.36	0.34	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
SARC	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	5.43	1.38e-07	0.000115	0.36	0.34	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
SARC	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	5.43	1.38e-07	0.000115	0.36	0.34	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
SARC	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	5.43	1.38e-07	0.000115	0.36	0.34	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
SARC	cis	rs7587476	0.822	rs6726763	ENSG00000229267.2	AC072062.1	-5.43	1.39e-07	0.000115	-0.32	-0.34	Neuroblastoma;	chr2:214816856	chr2:214810229~214963274:+
SARC	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	5.43	1.39e-07	0.000115	0.39	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
SARC	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	5.43	1.39e-07	0.000115	0.37	0.34	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	5.43	1.39e-07	0.000115	0.37	0.34	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
SARC	cis	rs853679	0.517	rs6932109	ENSG00000272009.1	RP1-313I6.12	5.43	1.4e-07	0.000116	0.38	0.34	Depression;	chr6:28110525	chr6:28078792~28081130:-
SARC	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	5.43	1.4e-07	0.000116	0.38	0.34	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
SARC	cis	rs2562456	0.833	rs1626404	ENSG00000268081.1	RP11-678G14.2	5.43	1.4e-07	0.000116	0.53	0.34	Pain;	chr19:21300986	chr19:21554640~21569237:-
SARC	cis	rs881375	0.967	rs3761849	ENSG00000226752.6	PSMD5-AS1	-5.43	1.4e-07	0.000116	-0.41	-0.34	Rheumatoid arthritis;	chr9:120928679	chr9:120824828~120854385:+
SARC	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-5.43	1.41e-07	0.000116	-0.47	-0.34	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
SARC	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-5.43	1.41e-07	0.000117	-0.35	-0.34	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
SARC	cis	rs7246657	1	rs12709812	ENSG00000276846.1	CTD-3220F14.3	-5.43	1.41e-07	0.000117	-0.45	-0.34	Coronary artery calcification;	chr19:37303948	chr19:37314868~37315620:-
SARC	cis	rs1823913	0.599	rs17346412	ENSG00000227542.1	AC092614.2	5.43	1.41e-07	0.000117	0.37	0.34	Obesity-related traits;	chr2:191285902	chr2:191229165~191246172:-
SARC	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-5.43	1.41e-07	0.000117	-0.48	-0.34	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
SARC	cis	rs7216064	0.553	rs62084690	ENSG00000278219.1	AC145343.1	5.43	1.42e-07	0.000117	0.37	0.34	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68039295	chr17:68101538~68101639:+
SARC	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	5.43	1.42e-07	0.000118	0.44	0.34	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
SARC	cis	rs77204473	1	rs11216186	ENSG00000254851.1	RP11-109L13.1	5.43	1.43e-07	0.000118	0.73	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117135528~117138582:+
SARC	cis	rs4862750	0.872	rs7671914	ENSG00000250971.1	RP11-696F12.1	5.43	1.43e-07	0.000118	0.39	0.34	Lobe attachment (rater-scored or self-reported);	chr4:186957011	chr4:187060099~187060930:+
SARC	cis	rs17772222	0.682	rs10132554	ENSG00000258983.2	RP11-507K2.2	5.43	1.43e-07	0.000118	0.34	0.34	Coronary artery calcification;	chr14:88473090	chr14:88499334~88515502:+
SARC	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-5.43	1.43e-07	0.000119	-0.34	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
SARC	cis	rs7712401	0.601	rs35479600	ENSG00000263432.2	RN7SL689P	-5.43	1.43e-07	0.000119	-0.43	-0.33	Mean platelet volume;	chr5:122988775	chr5:123022487~123022783:-
SARC	cis	rs1865760	0.713	rs1130000	ENSG00000272810.1	U91328.22	-5.43	1.44e-07	0.000119	-0.32	-0.33	Height;	chr6:25985168	chr6:26013241~26013757:+
SARC	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-5.43	1.44e-07	0.000119	-0.4	-0.33	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
SARC	cis	rs17772222	0.655	rs1152376	ENSG00000258983.2	RP11-507K2.2	-5.43	1.44e-07	0.000119	-0.34	-0.33	Coronary artery calcification;	chr14:88495121	chr14:88499334~88515502:+
SARC	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-5.43	1.44e-07	0.000119	-0.32	-0.33	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-5.43	1.44e-07	0.000119	-0.32	-0.33	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-5.43	1.44e-07	0.000119	-0.32	-0.33	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-5.43	1.44e-07	0.000119	-0.32	-0.33	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
SARC	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	5.43	1.45e-07	0.00012	0.43	0.33	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
SARC	cis	rs6991838	0.702	rs34496943	ENSG00000200714.1	Y_RNA	5.42	1.45e-07	0.00012	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.733	rs13281090	ENSG00000200714.1	Y_RNA	5.42	1.45e-07	0.00012	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65592731~65592820:+
SARC	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-5.42	1.46e-07	0.00012	-0.37	-0.33	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
SARC	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-5.42	1.46e-07	0.00012	-0.4	-0.33	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
SARC	cis	rs1823913	1	rs12623832	ENSG00000227542.1	AC092614.2	-5.42	1.46e-07	0.00012	-0.37	-0.33	Obesity-related traits;	chr2:191260918	chr2:191229165~191246172:-
SARC	cis	rs160451	0.966	rs160427	ENSG00000251136.7	RP11-37B2.1	5.42	1.46e-07	0.00012	0.37	0.33	Leprosy;	chr8:89659156	chr8:89609409~89757727:-
SARC	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	5.42	1.46e-07	0.000121	0.36	0.33	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
SARC	cis	rs7809950	0.862	rs58391518	ENSG00000238832.1	snoU109	-5.42	1.47e-07	0.000121	-0.39	-0.33	Coronary artery disease;	chr7:107390342	chr7:107603363~107603507:+
SARC	cis	rs2946504	0.861	rs2977081	ENSG00000251468.2	RP11-369K16.1	-5.42	1.47e-07	0.000121	-0.36	-0.33	Type 2 diabetes;	chr8:12958272	chr8:12958387~12962200:+
SARC	cis	rs2946504	0.861	rs6986271	ENSG00000251468.2	RP11-369K16.1	-5.42	1.47e-07	0.000121	-0.36	-0.33	Type 2 diabetes;	chr8:12959345	chr8:12958387~12962200:+
SARC	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	5.42	1.47e-07	0.000122	0.36	0.33	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
SARC	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	5.42	1.48e-07	0.000122	0.41	0.33	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
SARC	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-5.42	1.48e-07	0.000122	-0.41	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
SARC	cis	rs2946504	0.861	rs2946497	ENSG00000251468.2	RP11-369K16.1	-5.42	1.49e-07	0.000123	-0.36	-0.33	Type 2 diabetes;	chr8:12960804	chr8:12958387~12962200:+
SARC	cis	rs77204473	1	rs12279433	ENSG00000254851.1	RP11-109L13.1	5.42	1.5e-07	0.000124	0.74	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877505	chr11:117135528~117138582:+
SARC	cis	rs7809950	0.906	rs2395907	ENSG00000238832.1	snoU109	5.42	1.51e-07	0.000124	0.4	0.33	Coronary artery disease;	chr7:107612859	chr7:107603363~107603507:+
SARC	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	5.42	1.51e-07	0.000124	0.32	0.33	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
SARC	cis	rs4862750	0.872	rs6830828	ENSG00000249742.1	RP11-217E13.1	-5.42	1.51e-07	0.000124	-0.36	-0.33	Lobe attachment (rater-scored or self-reported);	chr4:186976318	chr4:186979490~187021973:-
SARC	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-5.42	1.51e-07	0.000125	-0.3	-0.33	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
SARC	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-5.42	1.51e-07	0.000125	-0.3	-0.33	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
SARC	cis	rs2562456	0.833	rs2562507	ENSG00000268081.1	RP11-678G14.2	-5.42	1.52e-07	0.000125	-0.49	-0.33	Pain;	chr19:21543535	chr19:21554640~21569237:-
SARC	cis	rs1799949	0.965	rs9911630	ENSG00000267681.1	CTD-3199J23.6	-5.42	1.52e-07	0.000125	-0.37	-0.33	Menopause (age at onset);	chr17:43036325	chr17:43144956~43145255:+
SARC	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-5.42	1.52e-07	0.000125	-0.31	-0.33	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
SARC	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-5.42	1.52e-07	0.000125	-0.36	-0.33	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
SARC	cis	rs5769707	0.632	rs6009782	ENSG00000235111.1	RP1-29C18.8	-5.41	1.53e-07	0.000126	-0.42	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49612657~49615716:-
SARC	cis	rs5769707	0.592	rs6009783	ENSG00000235111.1	RP1-29C18.8	-5.41	1.53e-07	0.000126	-0.42	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49612657~49615716:-
SARC	cis	rs710913	0.738	rs1180347	ENSG00000182109.6	RP11-69E11.4	-5.41	1.53e-07	0.000126	-0.32	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39531044	chr1:39522280~39546187:-
SARC	cis	rs7216064	0.953	rs4791048	ENSG00000278219.1	AC145343.1	-5.41	1.53e-07	0.000126	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67852878	chr17:68101538~68101639:+
SARC	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	5.41	1.54e-07	0.000126	0.37	0.33	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
SARC	cis	rs2562456	0.833	rs1781867	ENSG00000268081.1	RP11-678G14.2	5.41	1.54e-07	0.000126	0.53	0.33	Pain;	chr19:21304368	chr19:21554640~21569237:-
SARC	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	5.41	1.54e-07	0.000126	0.4	0.33	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
SARC	cis	rs1865760	0.613	rs9379805	ENSG00000272810.1	U91328.22	-5.41	1.54e-07	0.000126	-0.34	-0.33	Height;	chr6:25938536	chr6:26013241~26013757:+
SARC	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-5.41	1.54e-07	0.000127	-0.47	-0.33	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
SARC	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	5.41	1.55e-07	0.000127	0.42	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
SARC	cis	rs7216064	1	rs62084214	ENSG00000265055.1	AC145343.2	5.41	1.55e-07	0.000127	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67847209	chr17:68096046~68101474:-
SARC	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-5.41	1.55e-07	0.000127	-0.43	-0.33	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
SARC	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-5.41	1.55e-07	0.000127	-0.5	-0.33	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
SARC	cis	rs710913	0.816	rs1727098	ENSG00000182109.6	RP11-69E11.4	-5.41	1.55e-07	0.000127	-0.32	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39522280~39546187:-
SARC	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-5.41	1.55e-07	0.000128	-0.38	-0.33	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
SARC	cis	rs2562456	0.833	rs62110428	ENSG00000268081.1	RP11-678G14.2	5.41	1.55e-07	0.000128	0.56	0.33	Pain;	chr19:21430854	chr19:21554640~21569237:-
SARC	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-5.41	1.56e-07	0.000128	-0.37	-0.33	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
SARC	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	5.41	1.56e-07	0.000128	0.42	0.33	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
SARC	cis	rs853679	0.517	rs16893666	ENSG00000272009.1	RP1-313I6.12	5.41	1.56e-07	0.000128	0.38	0.33	Depression;	chr6:28086929	chr6:28078792~28081130:-
SARC	cis	rs1799949	1	rs4793229	ENSG00000267681.1	CTD-3199J23.6	5.41	1.56e-07	0.000128	0.38	0.33	Menopause (age at onset);	chr17:43340966	chr17:43144956~43145255:+
SARC	cis	rs7626444	0.625	rs843530	ENSG00000272359.1	U4	-5.41	1.57e-07	0.000129	-0.34	-0.33	Monocyte count;	chr3:196754153	chr3:196747192~196747324:-
SARC	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	5.41	1.58e-07	0.000129	0.42	0.33	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
SARC	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-5.41	1.58e-07	0.00013	-0.42	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
SARC	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-5.41	1.59e-07	0.00013	-0.43	-0.33	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
SARC	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-5.41	1.59e-07	0.00013	-0.36	-0.33	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
SARC	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-5.41	1.59e-07	0.000131	-0.59	-0.33	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
SARC	cis	rs34375054	0.672	rs10400509	ENSG00000279233.1	RP11-158L12.4	5.41	1.59e-07	0.000131	0.36	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125107627	chr12:125138245~125141711:+
SARC	cis	rs77204473	0.744	rs77999164	ENSG00000254851.1	RP11-109L13.1	5.41	1.6e-07	0.000131	0.79	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117041401	chr11:117135528~117138582:+
SARC	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-5.41	1.6e-07	0.000131	-0.33	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
SARC	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-5.41	1.6e-07	0.000131	-0.33	-0.33	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-5.41	1.6e-07	0.000131	-0.33	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-5.41	1.6e-07	0.000131	-0.33	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-5.41	1.6e-07	0.000131	-0.33	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-5.41	1.6e-07	0.000131	-0.33	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
SARC	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-5.4	1.6e-07	0.000131	-0.35	-0.33	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
SARC	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-5.4	1.61e-07	0.000132	-0.42	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
SARC	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-5.4	1.61e-07	0.000132	-0.37	-0.33	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
SARC	cis	rs4862750	0.872	rs6811837	ENSG00000250971.1	RP11-696F12.1	5.4	1.61e-07	0.000132	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186977008	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.872	rs6553030	ENSG00000250971.1	RP11-696F12.1	5.4	1.61e-07	0.000132	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186978080	chr4:187060099~187060930:+
SARC	cis	rs8031584	0.736	rs11635775	ENSG00000260382.1	RP11-540B6.2	5.4	1.62e-07	0.000132	0.42	0.33	Huntington's disease progression;	chr15:30868437	chr15:30882267~30883231:-
SARC	cis	rs7712401	0.601	rs35339188	ENSG00000263432.2	RN7SL689P	-5.4	1.62e-07	0.000132	-0.42	-0.33	Mean platelet volume;	chr5:122981990	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs36099390	ENSG00000263432.2	RN7SL689P	-5.4	1.62e-07	0.000132	-0.42	-0.33	Mean platelet volume;	chr5:122982024	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs35157167	ENSG00000263432.2	RN7SL689P	-5.4	1.62e-07	0.000132	-0.42	-0.33	Mean platelet volume;	chr5:122982506	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs396941	ENSG00000263432.2	RN7SL689P	-5.4	1.62e-07	0.000132	-0.42	-0.33	Mean platelet volume;	chr5:122982570	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.58	rs439739	ENSG00000263432.2	RN7SL689P	-5.4	1.62e-07	0.000132	-0.42	-0.33	Mean platelet volume;	chr5:122982726	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs371604	ENSG00000263432.2	RN7SL689P	-5.4	1.62e-07	0.000132	-0.42	-0.33	Mean platelet volume;	chr5:122982737	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs34707663	ENSG00000263432.2	RN7SL689P	-5.4	1.62e-07	0.000132	-0.42	-0.33	Mean platelet volume;	chr5:122984768	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs385547	ENSG00000263432.2	RN7SL689P	-5.4	1.62e-07	0.000132	-0.42	-0.33	Mean platelet volume;	chr5:122986138	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs454617	ENSG00000263432.2	RN7SL689P	-5.4	1.62e-07	0.000132	-0.42	-0.33	Mean platelet volume;	chr5:122986232	chr5:123022487~123022783:-
SARC	cis	rs763121	0.962	rs138711	ENSG00000273076.1	RP3-508I15.22	5.4	1.62e-07	0.000133	0.38	0.33	Menopause (age at onset);	chr22:38743908	chr22:38743495~38743910:+
SARC	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	5.4	1.62e-07	0.000133	0.69	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
SARC	cis	rs9309473	1	rs2421555	ENSG00000163016.8	ALMS1P	5.4	1.63e-07	0.000133	0.42	0.33	Metabolite levels;	chr2:73589828	chr2:73644919~73685576:+
SARC	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-5.4	1.63e-07	0.000133	-0.31	-0.33	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
SARC	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	5.4	1.63e-07	0.000133	0.35	0.33	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
SARC	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	5.4	1.64e-07	0.000133	0.48	0.33	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
SARC	cis	rs4372836	1	rs2169748	ENSG00000226833.4	AC097724.3	-5.4	1.64e-07	0.000134	-0.31	-0.33	Body mass index;	chr2:28734887	chr2:28708953~28736205:-
SARC	cis	rs131805	1	rs3091397	ENSG00000205559.3	CHKB-AS1	-5.4	1.64e-07	0.000134	-0.4	-0.33	Granulocyte percentage of myeloid white cells;	chr22:50519091	chr22:50583026~50583877:+
SARC	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	5.4	1.64e-07	0.000134	0.5	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
SARC	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-5.4	1.64e-07	0.000134	-0.43	-0.33	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
SARC	cis	rs4273100	0.79	rs2048230	ENSG00000228157.4	AC007952.5	5.4	1.64e-07	0.000134	0.49	0.33	Schizophrenia;	chr17:19372886	chr17:19092974~19096837:+
SARC	cis	rs4862750	0.872	rs9998172	ENSG00000250971.1	RP11-696F12.1	5.4	1.65e-07	0.000134	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186977619	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.872	rs9998173	ENSG00000250971.1	RP11-696F12.1	5.4	1.65e-07	0.000134	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186977624	chr4:187060099~187060930:+
SARC	cis	rs77204473	1	rs12289032	ENSG00000254851.1	RP11-109L13.1	5.4	1.65e-07	0.000134	0.76	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117028864	chr11:117135528~117138582:+
SARC	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-5.4	1.65e-07	0.000135	-0.36	-0.33	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
SARC	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-5.4	1.65e-07	0.000135	-0.32	-0.33	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-5.4	1.65e-07	0.000135	-0.32	-0.33	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
SARC	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	5.4	1.66e-07	0.000135	0.42	0.33	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
SARC	cis	rs858239	0.932	rs1728313	ENSG00000226816.2	AC005082.12	5.4	1.66e-07	0.000135	0.41	0.33	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23206013~23208045:+
SARC	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	5.4	1.66e-07	0.000135	0.36	0.33	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
SARC	cis	rs1865760	0.593	rs2097273	ENSG00000272810.1	U91328.22	-5.4	1.67e-07	0.000136	-0.33	-0.33	Height;	chr6:25941082	chr6:26013241~26013757:+
SARC	cis	rs7216064	1	rs1976054	ENSG00000278219.1	AC145343.1	-5.4	1.67e-07	0.000136	-0.4	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67837108	chr17:68101538~68101639:+
SARC	cis	rs673078	0.562	rs61944668	ENSG00000275759.1	RP11-131L12.3	-5.4	1.67e-07	0.000136	-0.5	-0.33	Glucose homeostasis traits;	chr12:118448446	chr12:118428281~118428870:+
SARC	cis	rs710913	0.691	rs1180351	ENSG00000182109.6	RP11-69E11.4	-5.4	1.67e-07	0.000136	-0.32	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39522280~39546187:-
SARC	cis	rs710913	0.717	rs1180352	ENSG00000182109.6	RP11-69E11.4	-5.4	1.67e-07	0.000136	-0.32	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39542157	chr1:39522280~39546187:-
SARC	cis	rs710913	0.745	rs1180334	ENSG00000182109.6	RP11-69E11.4	-5.4	1.67e-07	0.000136	-0.32	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39522280~39546187:-
SARC	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-5.4	1.67e-07	0.000136	-0.37	-0.33	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
SARC	cis	rs7216064	1	rs6504542	ENSG00000278219.1	AC145343.1	-5.4	1.68e-07	0.000136	-0.4	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67840526	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.953	rs1966410	ENSG00000278219.1	AC145343.1	-5.4	1.68e-07	0.000136	-0.4	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841099	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs8067892	ENSG00000278219.1	AC145343.1	-5.4	1.68e-07	0.000136	-0.4	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841867	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs7223930	ENSG00000278219.1	AC145343.1	-5.4	1.68e-07	0.000136	-0.4	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67846070	chr17:68101538~68101639:+
SARC	cis	rs4713118	0.786	rs200503	ENSG00000219392.1	RP1-265C24.5	-5.4	1.68e-07	0.000137	-0.47	-0.33	Parkinson's disease;	chr6:27818104	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.786	rs200502	ENSG00000219392.1	RP1-265C24.5	-5.4	1.68e-07	0.000137	-0.47	-0.33	Parkinson's disease;	chr6:27820284	chr6:28115628~28116551:+
SARC	cis	rs1865760	0.593	rs2097273	ENSG00000272462.2	U91328.19	-5.39	1.68e-07	0.000137	-0.31	-0.33	Height;	chr6:25941082	chr6:25992662~26001775:+
SARC	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-5.39	1.68e-07	0.000137	-0.34	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
SARC	cis	rs7216064	0.734	rs12942774	ENSG00000265055.1	AC145343.2	-5.39	1.69e-07	0.000137	-0.4	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971446	chr17:68096046~68101474:-
SARC	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-5.39	1.69e-07	0.000137	-0.36	-0.33	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
SARC	cis	rs1799949	0.864	rs60309406	ENSG00000267681.1	CTD-3199J23.6	-5.39	1.69e-07	0.000137	-0.38	-0.33	Menopause (age at onset);	chr17:43358297	chr17:43144956~43145255:+
SARC	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-5.39	1.69e-07	0.000138	-0.33	-0.33	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
SARC	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-5.39	1.69e-07	0.000138	-0.37	-0.33	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
SARC	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-5.39	1.69e-07	0.000138	-0.42	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
SARC	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-5.39	1.7e-07	0.000138	-0.37	-0.33	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
SARC	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-5.39	1.7e-07	0.000138	-0.37	-0.33	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
SARC	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	5.39	1.7e-07	0.000138	0.41	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
SARC	cis	rs1823874	0.653	rs12902823	ENSG00000182397.13	DNM1P46	-5.39	1.71e-07	0.000138	-0.36	-0.33	IgG glycosylation;	chr15:99812013	chr15:99790156~99806927:-
SARC	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	5.39	1.71e-07	0.000139	0.42	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
SARC	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-5.39	1.71e-07	0.000139	-0.5	-0.33	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
SARC	cis	rs1823913	0.599	rs17412239	ENSG00000227542.1	AC092614.2	5.39	1.71e-07	0.000139	0.37	0.33	Obesity-related traits;	chr2:191285937	chr2:191229165~191246172:-
SARC	cis	rs9322193	0.566	rs4870118	ENSG00000223701.3	RAET1E-AS1	-5.39	1.71e-07	0.000139	-0.4	-0.33	Lung cancer;	chr6:149923877	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.566	rs4869767	ENSG00000223701.3	RAET1E-AS1	-5.39	1.71e-07	0.000139	-0.4	-0.33	Lung cancer;	chr6:149923974	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.566	rs4869768	ENSG00000223701.3	RAET1E-AS1	-5.39	1.71e-07	0.000139	-0.4	-0.33	Lung cancer;	chr6:149924067	chr6:149884431~149919508:+
SARC	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-5.39	1.72e-07	0.000139	-0.4	-0.33	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
SARC	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	5.39	1.72e-07	0.000139	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	5.39	1.73e-07	0.00014	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	5.39	1.73e-07	0.00014	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	5.39	1.73e-07	0.00014	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
SARC	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	5.39	1.73e-07	0.00014	0.46	0.33	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
SARC	cis	rs899997	1	rs4887078	ENSG00000261143.1	ADAMTS7P3	5.39	1.73e-07	0.000141	0.5	0.33	Coronary artery disease or large artery stroke;	chr15:78718731	chr15:77976042~77993057:+
SARC	cis	rs17772222	0.63	rs12437422	ENSG00000258983.2	RP11-507K2.2	-5.39	1.73e-07	0.000141	-0.33	-0.33	Coronary artery calcification;	chr14:88529621	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.605	rs4899955	ENSG00000258983.2	RP11-507K2.2	-5.39	1.73e-07	0.000141	-0.33	-0.33	Coronary artery calcification;	chr14:88530381	chr14:88499334~88515502:+
SARC	cis	rs2836950	0.502	rs2150411	ENSG00000255568.3	BRWD1-AS2	-5.39	1.74e-07	0.000141	-0.3	-0.33	Menarche (age at onset);	chr21:39202626	chr21:39313935~39314962:+
SARC	cis	rs2836950	0.545	rs4818001	ENSG00000255568.3	BRWD1-AS2	-5.39	1.74e-07	0.000141	-0.3	-0.33	Menarche (age at onset);	chr21:39203162	chr21:39313935~39314962:+
SARC	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-5.39	1.74e-07	0.000141	-0.42	-0.33	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
SARC	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-5.39	1.74e-07	0.000141	-0.31	-0.33	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
SARC	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	5.39	1.75e-07	0.000141	0.37	0.33	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
SARC	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	5.39	1.75e-07	0.000142	0.45	0.33	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
SARC	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-5.39	1.75e-07	0.000142	-0.36	-0.33	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
SARC	cis	rs4862750	0.832	rs6836426	ENSG00000249742.1	RP11-217E13.1	-5.39	1.75e-07	0.000142	-0.36	-0.33	Lobe attachment (rater-scored or self-reported);	chr4:186976683	chr4:186979490~187021973:-
SARC	cis	rs7809950	1	rs986994	ENSG00000238832.1	snoU109	-5.39	1.75e-07	0.000142	-0.38	-0.33	Coronary artery disease;	chr7:107463670	chr7:107603363~107603507:+
SARC	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-5.39	1.75e-07	0.000142	-0.42	-0.33	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
SARC	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-5.39	1.75e-07	0.000142	-0.34	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-5.39	1.75e-07	0.000142	-0.34	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
SARC	cis	rs17772222	0.682	rs4904452	ENSG00000258983.2	RP11-507K2.2	-5.39	1.76e-07	0.000142	-0.33	-0.33	Coronary artery calcification;	chr14:88517329	chr14:88499334~88515502:+
SARC	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-5.39	1.76e-07	0.000143	-0.32	-0.33	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-5.39	1.76e-07	0.000143	-0.32	-0.33	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-5.39	1.76e-07	0.000143	-0.32	-0.33	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-5.39	1.76e-07	0.000143	-0.32	-0.33	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-5.39	1.76e-07	0.000143	-0.32	-0.33	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
SARC	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	5.38	1.77e-07	0.000143	0.39	0.33	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
SARC	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-5.38	1.78e-07	0.000144	-0.37	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
SARC	cis	rs7216064	1	rs8074078	ENSG00000278219.1	AC145343.1	-5.38	1.78e-07	0.000144	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67842627	chr17:68101538~68101639:+
SARC	cis	rs75920871	0.545	rs7939934	ENSG00000254851.1	RP11-109L13.1	5.38	1.78e-07	0.000144	0.45	0.33	Subjective well-being;	chr11:116990552	chr11:117135528~117138582:+
SARC	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	5.38	1.78e-07	0.000144	0.34	0.33	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
SARC	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	5.38	1.78e-07	0.000144	0.33	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
SARC	cis	rs710913	0.717	rs1180349	ENSG00000182109.6	RP11-69E11.4	-5.38	1.78e-07	0.000144	-0.32	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39522280~39546187:-
SARC	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	5.38	1.79e-07	0.000145	0.36	0.33	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
SARC	cis	rs2562456	0.752	rs279809	ENSG00000268081.1	RP11-678G14.2	5.38	1.79e-07	0.000145	0.53	0.33	Pain;	chr19:21284729	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62110071	ENSG00000268081.1	RP11-678G14.2	5.38	1.79e-07	0.000145	0.53	0.33	Pain;	chr19:21288101	chr19:21554640~21569237:-
SARC	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	5.38	1.79e-07	0.000145	0.37	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
SARC	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	5.38	1.79e-07	0.000145	0.49	0.33	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
SARC	cis	rs1823913	0.599	rs55786000	ENSG00000227542.1	AC092614.2	5.38	1.8e-07	0.000145	0.37	0.33	Obesity-related traits;	chr2:191284500	chr2:191229165~191246172:-
SARC	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	5.38	1.8e-07	0.000146	0.39	0.33	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
SARC	cis	rs7196129	0.932	rs11574938	ENSG00000183604.13	SMG1P5	5.38	1.81e-07	0.000146	0.3	0.33	Monocyte count;	chr16:30474072	chr16:30267553~30335374:-
SARC	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	5.38	1.81e-07	0.000146	0.38	0.33	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
SARC	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	5.38	1.81e-07	0.000146	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
SARC	cis	rs1865760	0.593	rs9393676	ENSG00000272810.1	U91328.22	-5.38	1.81e-07	0.000146	-0.34	-0.33	Height;	chr6:25936716	chr6:26013241~26013757:+
SARC	cis	rs858239	0.699	rs1881200	ENSG00000226816.2	AC005082.12	-5.38	1.82e-07	0.000147	-0.41	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23206013~23208045:+
SARC	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-5.38	1.82e-07	0.000147	-0.31	-0.33	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
SARC	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-5.38	1.82e-07	0.000147	-0.31	-0.33	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
SARC	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-5.38	1.82e-07	0.000147	-0.36	-0.33	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
SARC	cis	rs113835537	0.569	rs17496586	ENSG00000255517.5	CTD-3074O7.5	-5.38	1.83e-07	0.000147	-0.37	-0.33	Airway imaging phenotypes;	chr11:66548041	chr11:66473490~66480233:-
SARC	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	5.38	1.83e-07	0.000147	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
SARC	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	5.38	1.83e-07	0.000148	0.67	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
SARC	cis	rs2562456	0.833	rs1781872	ENSG00000268081.1	RP11-678G14.2	5.38	1.83e-07	0.000148	0.53	0.33	Pain;	chr19:21294601	chr19:21554640~21569237:-
SARC	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	5.38	1.83e-07	0.000148	0.4	0.33	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
SARC	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	5.38	1.83e-07	0.000148	0.4	0.33	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
SARC	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	5.38	1.84e-07	0.000148	0.32	0.33	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
SARC	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-5.38	1.84e-07	0.000148	-0.36	-0.33	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
SARC	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-5.38	1.84e-07	0.000148	-0.36	-0.33	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
SARC	cis	rs1865760	1	rs6905887	ENSG00000272810.1	U91328.22	-5.38	1.84e-07	0.000149	-0.33	-0.33	Height;	chr6:25911875	chr6:26013241~26013757:+
SARC	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	5.38	1.84e-07	0.000149	0.27	0.33	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
SARC	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-5.38	1.84e-07	0.000149	-0.33	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
SARC	cis	rs1799949	0.773	rs2137990	ENSG00000267681.1	CTD-3199J23.6	5.38	1.85e-07	0.000149	0.37	0.33	Menopause (age at onset);	chr17:43165879	chr17:43144956~43145255:+
SARC	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	5.38	1.85e-07	0.000149	0.42	0.33	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
SARC	cis	rs1823874	0.72	rs7162911	ENSG00000182397.13	DNM1P46	-5.38	1.85e-07	0.000149	-0.36	-0.33	IgG glycosylation;	chr15:99814845	chr15:99790156~99806927:-
SARC	cis	rs7196129	0.966	rs12598978	ENSG00000183604.13	SMG1P5	5.38	1.85e-07	0.000149	0.3	0.33	Monocyte count;	chr16:30471219	chr16:30267553~30335374:-
SARC	cis	rs13129231	0.806	rs17676882	ENSG00000206820.1	RNU1-138P	-5.38	1.86e-07	0.00015	-0.34	-0.33	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113451912	chr4:113420323~113420486:+
SARC	cis	rs7772486	0.727	rs12190966	ENSG00000270638.1	RP3-466P17.1	5.37	1.86e-07	0.00015	0.27	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145735570~145737218:+
SARC	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-5.37	1.86e-07	0.00015	-0.41	-0.33	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
SARC	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-5.37	1.86e-07	0.00015	-0.37	-0.33	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
SARC	cis	rs9309473	0.861	rs6546856	ENSG00000163016.8	ALMS1P	5.37	1.86e-07	0.00015	0.42	0.33	Metabolite levels;	chr2:73610624	chr2:73644919~73685576:+
SARC	cis	rs7216064	0.531	rs6504573	ENSG00000278219.1	AC145343.1	-5.37	1.86e-07	0.00015	-0.38	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68019847	chr17:68101538~68101639:+
SARC	cis	rs9309473	0.898	rs11126403	ENSG00000163016.8	ALMS1P	5.37	1.86e-07	0.00015	0.41	0.33	Metabolite levels;	chr2:73569796	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.898	rs11126404	ENSG00000163016.8	ALMS1P	5.37	1.86e-07	0.00015	0.41	0.33	Metabolite levels;	chr2:73569797	chr2:73644919~73685576:+
SARC	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	5.37	1.87e-07	0.000151	0.33	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
SARC	cis	rs2739330	0.732	rs5760175	ENSG00000099984.9	GSTT2	-5.37	1.87e-07	0.000151	-0.39	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23980123~23983911:+
SARC	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-5.37	1.87e-07	0.000151	-0.35	-0.33	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
SARC	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-5.37	1.87e-07	0.000151	-0.35	-0.33	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
SARC	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	5.37	1.87e-07	0.000151	0.44	0.33	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
SARC	cis	rs2562456	0.754	rs11666213	ENSG00000268081.1	RP11-678G14.2	5.37	1.88e-07	0.000151	0.56	0.33	Pain;	chr19:21422843	chr19:21554640~21569237:-
SARC	cis	rs2836950	0.565	rs7276046	ENSG00000255568.3	BRWD1-AS2	-5.37	1.88e-07	0.000151	-0.3	-0.33	Menarche (age at onset);	chr21:39209367	chr21:39313935~39314962:+
SARC	cis	rs2836950	0.545	rs8132143	ENSG00000255568.3	BRWD1-AS2	-5.37	1.88e-07	0.000151	-0.3	-0.33	Menarche (age at onset);	chr21:39212332	chr21:39313935~39314962:+
SARC	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-5.37	1.88e-07	0.000151	-0.31	-0.33	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
SARC	cis	rs113835537	0.597	rs2075792	ENSG00000255517.5	CTD-3074O7.5	-5.37	1.88e-07	0.000152	-0.37	-0.33	Airway imaging phenotypes;	chr11:66567085	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.597	rs7939759	ENSG00000255517.5	CTD-3074O7.5	-5.37	1.88e-07	0.000152	-0.37	-0.33	Airway imaging phenotypes;	chr11:66570493	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.597	rs10896129	ENSG00000255517.5	CTD-3074O7.5	-5.37	1.88e-07	0.000152	-0.37	-0.33	Airway imaging phenotypes;	chr11:66570829	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.559	rs57045447	ENSG00000255517.5	CTD-3074O7.5	-5.37	1.88e-07	0.000152	-0.37	-0.33	Airway imaging phenotypes;	chr11:66572212	chr11:66473490~66480233:-
SARC	cis	rs7216064	0.953	rs11079705	ENSG00000265055.1	AC145343.2	5.37	1.88e-07	0.000152	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839336	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs11079706	ENSG00000265055.1	AC145343.2	5.37	1.88e-07	0.000152	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839354	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.953	rs80135947	ENSG00000265055.1	AC145343.2	5.37	1.88e-07	0.000152	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839885	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs8082512	ENSG00000265055.1	AC145343.2	5.37	1.88e-07	0.000152	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67840943	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.953	rs8073510	ENSG00000265055.1	AC145343.2	5.37	1.88e-07	0.000152	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67843094	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.953	rs11871285	ENSG00000265055.1	AC145343.2	5.37	1.88e-07	0.000152	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67844693	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs62084213	ENSG00000265055.1	AC145343.2	5.37	1.88e-07	0.000152	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67845900	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs7224923	ENSG00000265055.1	AC145343.2	5.37	1.88e-07	0.000152	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67846149	chr17:68096046~68101474:-
SARC	cis	rs1823913	0.599	rs34262638	ENSG00000227542.1	AC092614.2	5.37	1.89e-07	0.000152	0.37	0.33	Obesity-related traits;	chr2:191279442	chr2:191229165~191246172:-
SARC	cis	rs7301826	1	rs10773819	ENSG00000256299.1	RP11-989F5.3	-5.37	1.89e-07	0.000152	-0.34	-0.33	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810821~130812622:-
SARC	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	5.37	1.89e-07	0.000152	0.49	0.33	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
SARC	cis	rs763567	0.626	rs1234230	ENSG00000271811.1	RP1-79C4.4	-5.37	1.9e-07	0.000152	-0.39	-0.33	Tonsillectomy;	chr1:170602702	chr1:170667381~170669425:+
SARC	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-5.37	1.9e-07	0.000153	-0.32	-0.33	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
SARC	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	5.37	1.9e-07	0.000153	0.4	0.33	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
SARC	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-5.37	1.91e-07	0.000154	-0.41	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
SARC	cis	rs7250849	0.688	rs78019331	ENSG00000273837.1	LLNLR-470E3.1	-5.37	1.91e-07	0.000154	-0.38	-0.33	Blood protein levels;	chr19:51658484	chr19:51639478~51639931:-
SARC	cis	rs4862750	0.872	rs6830828	ENSG00000250971.1	RP11-696F12.1	5.37	1.92e-07	0.000154	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186976318	chr4:187060099~187060930:+
SARC	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	5.37	1.92e-07	0.000154	0.47	0.33	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
SARC	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-5.37	1.93e-07	0.000155	-0.32	-0.33	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-5.37	1.93e-07	0.000155	-0.32	-0.33	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-5.37	1.93e-07	0.000155	-0.32	-0.33	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-5.37	1.93e-07	0.000155	-0.32	-0.33	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
SARC	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	5.37	1.94e-07	0.000156	0.4	0.33	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
SARC	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	5.37	1.94e-07	0.000156	0.4	0.33	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
SARC	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-5.37	1.95e-07	0.000156	-0.41	-0.33	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
SARC	cis	rs7772486	0.686	rs1292336	ENSG00000270638.1	RP3-466P17.1	-5.36	1.95e-07	0.000156	-0.27	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs2179323	ENSG00000270638.1	RP3-466P17.1	-5.36	1.95e-07	0.000157	-0.27	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145735570~145737218:+
SARC	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-5.36	1.96e-07	0.000157	-0.36	-0.33	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
SARC	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-5.36	1.96e-07	0.000157	-0.36	-0.33	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
SARC	cis	rs2562456	0.793	rs73537884	ENSG00000268081.1	RP11-678G14.2	5.36	1.96e-07	0.000157	0.52	0.33	Pain;	chr19:21321908	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.793	rs78467454	ENSG00000268081.1	RP11-678G14.2	5.36	1.96e-07	0.000157	0.52	0.33	Pain;	chr19:21321930	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs55790393	ENSG00000268081.1	RP11-678G14.2	5.36	1.96e-07	0.000157	0.52	0.33	Pain;	chr19:21323382	chr19:21554640~21569237:-
SARC	cis	rs7216064	0.773	rs74541577	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67857535	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs2128792	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67861061	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs2365764	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67861598	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs59950564	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67864743	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs34872586	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67867350	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.953	rs58141639	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67868786	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs62084246	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67871795	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs11869819	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67872553	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs55939964	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67873181	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs12602912	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67873957	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.953	rs12450907	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67874528	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs4569324	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67876634	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs62084248	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878425	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs12451511	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878745	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs62084249	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878882	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs35243555	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67880361	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs62084251	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67882620	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs4318247	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67886056	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.953	rs75231441	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889369	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.954	rs8079291	ENSG00000265055.1	AC145343.2	5.36	1.96e-07	0.000157	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67891506	chr17:68096046~68101474:-
SARC	cis	rs9309473	0.898	rs10170786	ENSG00000163016.8	ALMS1P	5.36	1.97e-07	0.000157	0.42	0.33	Metabolite levels;	chr2:73585861	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.95	rs6546847	ENSG00000163016.8	ALMS1P	5.36	1.97e-07	0.000158	0.41	0.33	Metabolite levels;	chr2:73558231	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs7604682	ENSG00000163016.8	ALMS1P	5.36	1.97e-07	0.000158	0.41	0.33	Metabolite levels;	chr2:73560899	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.898	rs7580750	ENSG00000163016.8	ALMS1P	5.36	1.97e-07	0.000158	0.41	0.33	Metabolite levels;	chr2:73560999	chr2:73644919~73685576:+
SARC	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	5.36	1.97e-07	0.000158	0.42	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
SARC	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-5.36	1.97e-07	0.000158	-0.36	-0.33	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
SARC	cis	rs2179367	0.959	rs237034	ENSG00000231760.4	RP11-350J20.5	5.36	1.97e-07	0.000158	0.41	0.33	Dupuytren's disease;	chr6:149390726	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.959	rs628488	ENSG00000231760.4	RP11-350J20.5	5.36	1.97e-07	0.000158	0.41	0.33	Dupuytren's disease;	chr6:149398264	chr6:149796151~149826294:-
SARC	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	5.36	1.98e-07	0.000158	0.42	0.33	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
SARC	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-5.36	1.98e-07	0.000158	-0.36	-0.33	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-5.36	1.98e-07	0.000158	-0.36	-0.33	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-5.36	1.98e-07	0.000158	-0.36	-0.33	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-5.36	1.98e-07	0.000158	-0.36	-0.33	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-5.36	1.98e-07	0.000158	-0.36	-0.33	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
SARC	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	5.36	1.98e-07	0.000158	0.41	0.33	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
SARC	cis	rs7216064	1	rs12451707	ENSG00000265055.1	AC145343.2	5.36	1.98e-07	0.000158	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67875482	chr17:68096046~68101474:-
SARC	cis	rs1431005	0.963	rs72725287	ENSG00000250620.1	RP11-91J3.3	5.36	1.98e-07	0.000159	0.35	0.33	Response to statin therapy;	chr4:187477151	chr4:187413564~187415697:+
SARC	cis	rs9494145	0.648	rs7758845	ENSG00000232876.1	CTA-212D2.2	-5.36	1.98e-07	0.000159	-0.41	-0.33	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135107399	chr6:135055033~135060550:+
SARC	cis	rs1799949	0.794	rs116409325	ENSG00000267681.1	CTD-3199J23.6	-5.36	1.99e-07	0.000159	-0.37	-0.33	Menopause (age at onset);	chr17:43368092	chr17:43144956~43145255:+
SARC	cis	rs9309473	1	rs11903916	ENSG00000163016.8	ALMS1P	5.36	1.99e-07	0.000159	0.41	0.33	Metabolite levels;	chr2:73588201	chr2:73644919~73685576:+
SARC	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	5.36	2e-07	0.000159	0.37	0.33	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
SARC	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	5.36	2e-07	0.000159	0.37	0.33	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
SARC	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	5.36	2e-07	0.000159	0.37	0.33	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
SARC	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	5.36	2e-07	0.000159	0.37	0.33	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
SARC	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-5.36	2e-07	0.00016	-0.6	-0.33	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
SARC	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-5.36	2.01e-07	0.00016	-0.36	-0.33	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
SARC	cis	rs7712401	0.601	rs386602	ENSG00000263432.2	RN7SL689P	-5.36	2.01e-07	0.00016	-0.42	-0.33	Mean platelet volume;	chr5:122986262	chr5:123022487~123022783:-
SARC	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	5.36	2.02e-07	0.000161	0.45	0.33	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
SARC	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-5.36	2.02e-07	0.000161	-0.32	-0.33	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
SARC	cis	rs853679	0.517	rs868987	ENSG00000272009.1	RP1-313I6.12	5.36	2.03e-07	0.000162	0.37	0.33	Depression;	chr6:28142370	chr6:28078792~28081130:-
SARC	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	5.36	2.03e-07	0.000162	0.4	0.33	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
SARC	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	5.36	2.03e-07	0.000162	0.4	0.33	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
SARC	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	5.36	2.03e-07	0.000162	0.4	0.33	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
SARC	cis	rs1823874	0.72	rs2003037	ENSG00000182397.13	DNM1P46	-5.36	2.03e-07	0.000162	-0.36	-0.33	IgG glycosylation;	chr15:99821757	chr15:99790156~99806927:-
SARC	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-5.36	2.03e-07	0.000162	-0.31	-0.33	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
SARC	cis	rs77204473	1	rs2044426	ENSG00000254851.1	RP11-109L13.1	5.36	2.03e-07	0.000162	0.68	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116885467	chr11:117135528~117138582:+
SARC	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	5.36	2.03e-07	0.000162	0.48	0.33	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
SARC	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-5.36	2.03e-07	0.000162	-0.33	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
SARC	cis	rs17772222	0.63	rs1344747	ENSG00000258983.2	RP11-507K2.2	-5.36	2.04e-07	0.000163	-0.33	-0.33	Coronary artery calcification;	chr14:88548091	chr14:88499334~88515502:+
SARC	cis	rs77204473	1	rs12416987	ENSG00000254851.1	RP11-109L13.1	5.36	2.05e-07	0.000163	0.69	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.588	rs6589587	ENSG00000254851.1	RP11-109L13.1	5.35	2.05e-07	0.000163	0.44	0.33	Subjective well-being;	chr11:117004622	chr11:117135528~117138582:+
SARC	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	5.35	2.05e-07	0.000163	0.5	0.33	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
SARC	cis	rs7216064	0.655	rs8078543	ENSG00000265055.1	AC145343.2	-5.35	2.05e-07	0.000163	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68041135	chr17:68096046~68101474:-
SARC	cis	rs160451	0.899	rs218918	ENSG00000251136.7	RP11-37B2.1	-5.35	2.05e-07	0.000164	-0.39	-0.33	Leprosy;	chr8:89690153	chr8:89609409~89757727:-
SARC	cis	rs1823913	0.599	rs34100174	ENSG00000227542.1	AC092614.2	5.35	2.06e-07	0.000164	0.36	0.33	Obesity-related traits;	chr2:191283579	chr2:191229165~191246172:-
SARC	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-5.35	2.06e-07	0.000164	-0.32	-0.33	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-5.35	2.06e-07	0.000164	-0.32	-0.33	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-5.35	2.06e-07	0.000164	-0.32	-0.33	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-5.35	2.06e-07	0.000164	-0.32	-0.33	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-5.35	2.06e-07	0.000164	-0.32	-0.33	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
SARC	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	5.35	2.07e-07	0.000165	0.41	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
SARC	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	5.35	2.07e-07	0.000165	0.56	0.33	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
SARC	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	5.35	2.08e-07	0.000165	0.35	0.33	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
SARC	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-5.35	2.08e-07	0.000166	-0.36	-0.33	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
SARC	cis	rs75920871	0.588	rs4620758	ENSG00000254851.1	RP11-109L13.1	5.35	2.08e-07	0.000166	0.46	0.33	Subjective well-being;	chr11:117075002	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.588	rs1871756	ENSG00000254851.1	RP11-109L13.1	5.35	2.08e-07	0.000166	0.46	0.33	Subjective well-being;	chr11:117082929	chr11:117135528~117138582:+
SARC	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	5.35	2.09e-07	0.000166	0.41	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
SARC	cis	rs198389	0.589	rs198391	ENSG00000242349.4	NPPA-AS1	5.35	2.09e-07	0.000166	0.33	0.33	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11816360	chr1:11841017~11848079:+
SARC	cis	rs7712401	0.715	rs6862366	ENSG00000263432.2	RN7SL689P	-5.35	2.1e-07	0.000167	-0.42	-0.33	Mean platelet volume;	chr5:123024463	chr5:123022487~123022783:-
SARC	cis	rs7587476	0.784	rs17424051	ENSG00000229267.2	AC072062.1	-5.35	2.1e-07	0.000167	-0.32	-0.33	Neuroblastoma;	chr2:214824268	chr2:214810229~214963274:+
SARC	cis	rs7587476	0.784	rs62202001	ENSG00000229267.2	AC072062.1	-5.35	2.1e-07	0.000167	-0.32	-0.33	Neuroblastoma;	chr2:214825635	chr2:214810229~214963274:+
SARC	cis	rs7587476	0.736	rs62202002	ENSG00000229267.2	AC072062.1	-5.35	2.1e-07	0.000167	-0.32	-0.33	Neuroblastoma;	chr2:214825876	chr2:214810229~214963274:+
SARC	cis	rs7587476	0.682	rs13009646	ENSG00000229267.2	AC072062.1	-5.35	2.1e-07	0.000167	-0.32	-0.33	Neuroblastoma;	chr2:214826535	chr2:214810229~214963274:+
SARC	cis	rs7772486	0.686	rs9390357	ENSG00000270638.1	RP3-466P17.1	5.35	2.11e-07	0.000167	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145735570~145737218:+
SARC	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-5.35	2.11e-07	0.000167	-0.53	-0.33	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
SARC	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-5.35	2.11e-07	0.000168	-0.54	-0.33	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
SARC	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-5.35	2.11e-07	0.000168	-0.54	-0.33	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
SARC	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-5.35	2.11e-07	0.000168	-0.54	-0.33	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
SARC	cis	rs113835537	0.597	rs4576	ENSG00000255517.5	CTD-3074O7.5	-5.35	2.11e-07	0.000168	-0.37	-0.33	Airway imaging phenotypes;	chr11:66563529	chr11:66473490~66480233:-
SARC	cis	rs6969780	0.915	rs4722659	ENSG00000233429.8	HOTAIRM1	-5.35	2.11e-07	0.000168	-0.46	-0.33	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127131	chr7:27095647~27100265:+
SARC	cis	rs6969780	0.915	rs3801320	ENSG00000233429.8	HOTAIRM1	5.35	2.11e-07	0.000168	0.46	0.33	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27124745	chr7:27095647~27100265:+
SARC	cis	rs12655019	0.92	rs6882657	ENSG00000271828.1	CTD-2310F14.1	5.35	2.11e-07	0.000168	0.54	0.33	Breast cancer (early onset);	chr5:56926912	chr5:56927874~56929573:+
SARC	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-5.35	2.11e-07	0.000168	-0.47	-0.33	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
SARC	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-5.35	2.12e-07	0.000168	-0.46	-0.33	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
SARC	cis	rs7772486	0.686	rs4895684	ENSG00000270638.1	RP3-466P17.1	-5.35	2.12e-07	0.000168	-0.26	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs9386131	ENSG00000270638.1	RP3-466P17.1	5.35	2.12e-07	0.000168	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs7739735	ENSG00000270638.1	RP3-466P17.1	5.35	2.12e-07	0.000168	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs7744014	ENSG00000270638.1	RP3-466P17.1	5.35	2.12e-07	0.000168	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145735570~145737218:+
SARC	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	5.35	2.12e-07	0.000168	0.41	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
SARC	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	5.35	2.12e-07	0.000169	0.4	0.33	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
SARC	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	5.35	2.12e-07	0.000169	0.47	0.33	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	5.35	2.12e-07	0.000169	0.47	0.33	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
SARC	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	5.35	2.12e-07	0.000169	0.47	0.33	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
SARC	cis	rs1865760	1	rs9393675	ENSG00000272810.1	U91328.22	-5.35	2.13e-07	0.000169	-0.34	-0.33	Height;	chr6:25929888	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.625	rs9393681	ENSG00000272810.1	U91328.22	-5.35	2.13e-07	0.000169	-0.31	-0.33	Height;	chr6:26008032	chr6:26013241~26013757:+
SARC	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-5.35	2.14e-07	0.00017	-0.37	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
SARC	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-5.35	2.14e-07	0.00017	-0.36	-0.33	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-5.35	2.14e-07	0.00017	-0.36	-0.33	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-5.35	2.14e-07	0.00017	-0.36	-0.33	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-5.35	2.14e-07	0.00017	-0.36	-0.33	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-5.35	2.14e-07	0.00017	-0.36	-0.33	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-5.35	2.14e-07	0.00017	-0.36	-0.33	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-5.35	2.14e-07	0.00017	-0.36	-0.33	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
SARC	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	5.35	2.14e-07	0.00017	0.37	0.33	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
SARC	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	5.35	2.14e-07	0.00017	0.37	0.33	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
SARC	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	5.35	2.14e-07	0.00017	0.37	0.33	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
SARC	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	5.35	2.14e-07	0.00017	0.39	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
SARC	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	5.35	2.15e-07	0.00017	0.39	0.33	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
SARC	cis	rs1823913	0.599	rs10497713	ENSG00000227542.1	AC092614.2	5.35	2.15e-07	0.00017	0.37	0.33	Obesity-related traits;	chr2:191279312	chr2:191229165~191246172:-
SARC	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	5.34	2.15e-07	0.00017	0.39	0.33	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
SARC	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	5.34	2.15e-07	0.00017	0.39	0.33	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
SARC	cis	rs7772486	0.686	rs10872579	ENSG00000270638.1	RP3-466P17.1	5.34	2.15e-07	0.000171	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145735570~145737218:+
SARC	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-5.34	2.17e-07	0.000171	-0.37	-0.33	QT interval;	chr16:28857143	chr16:28700294~28701540:-
SARC	cis	rs7216064	1	rs4790908	ENSG00000278219.1	AC145343.1	-5.34	2.18e-07	0.000172	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67856791	chr17:68101538~68101639:+
SARC	cis	rs7615952	0.576	rs17523380	ENSG00000250012.1	RP11-124N2.1	-5.34	2.18e-07	0.000172	-0.3	-0.33	Blood pressure (smoking interaction);	chr3:126084031	chr3:126084220~126095349:+
SARC	cis	rs1865760	1	rs2071299	ENSG00000272462.2	U91328.19	-5.34	2.18e-07	0.000172	-0.32	-0.33	Height;	chr6:25914573	chr6:25992662~26001775:+
SARC	cis	rs1865760	1	rs2071298	ENSG00000272462.2	U91328.19	-5.34	2.18e-07	0.000172	-0.32	-0.33	Height;	chr6:25914673	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.964	rs1324084	ENSG00000272462.2	U91328.19	-5.34	2.18e-07	0.000172	-0.32	-0.33	Height;	chr6:25914906	chr6:25992662~26001775:+
SARC	cis	rs1865760	1	rs1865760	ENSG00000272462.2	U91328.19	-5.34	2.18e-07	0.000172	-0.32	-0.33	Height;	chr6:25916751	chr6:25992662~26001775:+
SARC	cis	rs7587476	0.601	rs13021937	ENSG00000229267.2	AC072062.1	5.34	2.18e-07	0.000172	0.32	0.33	Neuroblastoma;	chr2:214809213	chr2:214810229~214963274:+
SARC	cis	rs7587476	0.531	rs35933323	ENSG00000229267.2	AC072062.1	5.34	2.18e-07	0.000172	0.32	0.33	Neuroblastoma;	chr2:214809366	chr2:214810229~214963274:+
SARC	cis	rs2562456	0.833	rs55920089	ENSG00000268081.1	RP11-678G14.2	5.34	2.18e-07	0.000172	0.53	0.33	Pain;	chr19:21337891	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs4334427	ENSG00000268081.1	RP11-678G14.2	5.34	2.18e-07	0.000172	0.53	0.33	Pain;	chr19:21338090	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs4644962	ENSG00000268081.1	RP11-678G14.2	5.34	2.18e-07	0.000172	0.53	0.33	Pain;	chr19:21338125	chr19:21554640~21569237:-
SARC	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	5.34	2.18e-07	0.000172	0.33	0.33	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
SARC	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	5.34	2.18e-07	0.000172	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
SARC	cis	rs890448	0.796	rs2471682	ENSG00000254531.1	FLJ20021	5.34	2.19e-07	0.000173	0.34	0.33	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101428822	chr4:101347780~101348883:+
SARC	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-5.34	2.19e-07	0.000173	-0.4	-0.33	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
SARC	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	5.34	2.2e-07	0.000173	0.36	0.33	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
SARC	cis	rs1707322	0.686	rs2991986	ENSG00000281133.1	AL355480.3	5.34	2.2e-07	0.000173	0.38	0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45580892~45580996:-
SARC	cis	rs7216064	0.953	rs11868959	ENSG00000265055.1	AC145343.2	5.34	2.2e-07	0.000173	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67844694	chr17:68096046~68101474:-
SARC	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-5.34	2.2e-07	0.000174	-0.43	-0.33	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
SARC	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-5.34	2.2e-07	0.000174	-0.33	-0.33	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
SARC	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-5.34	2.2e-07	0.000174	-0.33	-0.33	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
SARC	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-5.34	2.2e-07	0.000174	-0.33	-0.33	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
SARC	cis	rs4862750	0.914	rs11945845	ENSG00000249742.1	RP11-217E13.1	-5.34	2.21e-07	0.000174	-0.36	-0.33	Lobe attachment (rater-scored or self-reported);	chr4:186952982	chr4:186979490~187021973:-
SARC	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-5.34	2.21e-07	0.000175	-0.36	-0.33	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
SARC	cis	rs7587476	0.601	rs1129804	ENSG00000229267.2	AC072062.1	5.34	2.21e-07	0.000175	0.32	0.33	Neuroblastoma;	chr2:214809599	chr2:214810229~214963274:+
SARC	cis	rs7587476	0.601	rs17489363	ENSG00000229267.2	AC072062.1	5.34	2.21e-07	0.000175	0.32	0.33	Neuroblastoma;	chr2:214809617	chr2:214810229~214963274:+
SARC	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	5.34	2.21e-07	0.000175	0.39	0.33	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
SARC	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-5.34	2.22e-07	0.000175	-0.36	-0.33	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
SARC	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-5.34	2.22e-07	0.000175	-0.46	-0.33	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
SARC	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	5.34	2.22e-07	0.000175	0.37	0.33	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
SARC	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	5.34	2.22e-07	0.000175	0.37	0.33	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
SARC	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	5.34	2.23e-07	0.000176	0.48	0.33	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	5.34	2.23e-07	0.000176	0.48	0.33	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
SARC	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-5.34	2.23e-07	0.000176	-0.32	-0.33	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
SARC	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-5.34	2.23e-07	0.000176	-0.39	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
SARC	cis	rs4372836	0.929	rs11675572	ENSG00000226833.4	AC097724.3	-5.34	2.24e-07	0.000176	-0.32	-0.33	Body mass index;	chr2:28708510	chr2:28708953~28736205:-
SARC	cis	rs4862750	0.872	rs7671914	ENSG00000249742.1	RP11-217E13.1	-5.34	2.24e-07	0.000177	-0.35	-0.33	Lobe attachment (rater-scored or self-reported);	chr4:186957011	chr4:186979490~187021973:-
SARC	cis	rs7712401	0.715	rs6859163	ENSG00000263432.2	RN7SL689P	-5.34	2.24e-07	0.000177	-0.42	-0.33	Mean platelet volume;	chr5:123019225	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs385996	ENSG00000263432.2	RN7SL689P	-5.34	2.24e-07	0.000177	-0.42	-0.33	Mean platelet volume;	chr5:123019533	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs436160	ENSG00000263432.2	RN7SL689P	-5.34	2.24e-07	0.000177	-0.42	-0.33	Mean platelet volume;	chr5:123020258	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs434789	ENSG00000263432.2	RN7SL689P	-5.34	2.24e-07	0.000177	-0.42	-0.33	Mean platelet volume;	chr5:123021615	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs1139334	ENSG00000263432.2	RN7SL689P	-5.34	2.24e-07	0.000177	-0.42	-0.33	Mean platelet volume;	chr5:123022724	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs1062350	ENSG00000263432.2	RN7SL689P	-5.34	2.24e-07	0.000177	-0.42	-0.33	Mean platelet volume;	chr5:123022811	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.678	rs401535	ENSG00000263432.2	RN7SL689P	-5.34	2.24e-07	0.000177	-0.42	-0.33	Mean platelet volume;	chr5:123022990	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs15577	ENSG00000263432.2	RN7SL689P	-5.34	2.24e-07	0.000177	-0.42	-0.33	Mean platelet volume;	chr5:123023495	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs451195	ENSG00000263432.2	RN7SL689P	-5.34	2.24e-07	0.000177	-0.42	-0.33	Mean platelet volume;	chr5:123023945	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs407392	ENSG00000263432.2	RN7SL689P	-5.34	2.24e-07	0.000177	-0.42	-0.33	Mean platelet volume;	chr5:123025299	chr5:123022487~123022783:-
SARC	cis	rs2439831	0.867	rs2278860	ENSG00000205771.5	CATSPER2P1	5.34	2.25e-07	0.000177	0.48	0.33	Lung cancer in ever smokers;	chr15:43366848	chr15:43726918~43747094:-
SARC	cis	rs4372836	0.964	rs2293553	ENSG00000226833.4	AC097724.3	-5.34	2.25e-07	0.000177	-0.32	-0.33	Body mass index;	chr2:28709418	chr2:28708953~28736205:-
SARC	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	5.34	2.26e-07	0.000177	0.37	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
SARC	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-5.34	2.26e-07	0.000178	-0.36	-0.33	QT interval;	chr16:28877088	chr16:28700294~28701540:-
SARC	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-5.33	2.28e-07	0.000179	-0.32	-0.33	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-5.33	2.28e-07	0.000179	-0.32	-0.33	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-5.33	2.28e-07	0.000179	-0.32	-0.33	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
SARC	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	5.33	2.29e-07	0.00018	0.35	0.33	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
SARC	cis	rs7712401	0.601	rs30029	ENSG00000263432.2	RN7SL689P	-5.33	2.29e-07	0.00018	-0.42	-0.33	Mean platelet volume;	chr5:122947475	chr5:123022487~123022783:-
SARC	cis	rs7615952	0.688	rs4422259	ENSG00000248787.1	RP11-666A20.4	-5.33	2.31e-07	0.000181	-0.45	-0.33	Blood pressure (smoking interaction);	chr3:125826988	chr3:125908005~125910272:-
SARC	cis	rs7772486	0.686	rs9497380	ENSG00000270638.1	RP3-466P17.1	5.33	2.31e-07	0.000181	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145735570~145737218:+
SARC	cis	rs7246657	0.943	rs10420722	ENSG00000276846.1	CTD-3220F14.3	5.33	2.31e-07	0.000181	0.45	0.33	Coronary artery calcification;	chr19:37482872	chr19:37314868~37315620:-
SARC	cis	rs2562456	0.958	rs2562508	ENSG00000268081.1	RP11-678G14.2	-5.33	2.31e-07	0.000182	-0.49	-0.33	Pain;	chr19:21543479	chr19:21554640~21569237:-
SARC	cis	rs77204473	0.744	rs12281009	ENSG00000254851.1	RP11-109L13.1	5.33	2.32e-07	0.000182	0.71	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117162243	chr11:117135528~117138582:+
SARC	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-5.33	2.32e-07	0.000182	-0.37	-0.33	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-5.33	2.32e-07	0.000182	-0.37	-0.33	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-5.33	2.32e-07	0.000182	-0.37	-0.33	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
SARC	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-5.33	2.32e-07	0.000182	-0.31	-0.33	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
SARC	cis	rs77204473	0.744	rs12419178	ENSG00000254851.1	RP11-109L13.1	5.33	2.33e-07	0.000182	0.74	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117180202	chr11:117135528~117138582:+
SARC	cis	rs4862750	0.872	rs7672831	ENSG00000250971.1	RP11-696F12.1	5.33	2.33e-07	0.000183	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186977728	chr4:187060099~187060930:+
SARC	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-5.33	2.34e-07	0.000183	-0.38	-0.33	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
SARC	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-5.33	2.34e-07	0.000183	-0.49	-0.33	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
SARC	cis	rs2836950	0.565	rs7278297	ENSG00000255568.3	BRWD1-AS2	-5.33	2.34e-07	0.000184	-0.3	-0.33	Menarche (age at onset);	chr21:39253826	chr21:39313935~39314962:+
SARC	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	5.33	2.34e-07	0.000184	0.38	0.33	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
SARC	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	5.33	2.35e-07	0.000184	0.38	0.33	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
SARC	cis	rs2562456	0.834	rs2650848	ENSG00000268081.1	RP11-678G14.2	5.33	2.35e-07	0.000184	0.54	0.33	Pain;	chr19:21403835	chr19:21554640~21569237:-
SARC	cis	rs5769707	0.656	rs135875	ENSG00000235111.1	RP1-29C18.8	-5.33	2.36e-07	0.000185	-0.41	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49612657~49615716:-
SARC	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	5.33	2.36e-07	0.000185	0.38	0.33	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
SARC	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-5.33	2.36e-07	0.000185	-0.31	-0.33	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
SARC	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-5.33	2.36e-07	0.000185	-0.34	-0.33	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
SARC	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-5.33	2.36e-07	0.000185	-0.33	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-5.33	2.36e-07	0.000185	-0.33	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-5.33	2.36e-07	0.000185	-0.33	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
SARC	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-5.33	2.37e-07	0.000185	-0.34	-0.33	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
SARC	cis	rs11118620	0.853	rs11118622	ENSG00000257551.1	HLX-AS1	5.33	2.37e-07	0.000185	0.39	0.33	Heart failure;	chr1:220868833	chr1:220832763~220880140:-
SARC	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-5.33	2.37e-07	0.000186	-0.42	-0.33	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
SARC	cis	rs7587476	0.784	rs34112702	ENSG00000229267.2	AC072062.1	-5.32	2.37e-07	0.000186	-0.32	-0.33	Neuroblastoma;	chr2:214831278	chr2:214810229~214963274:+
SARC	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-5.32	2.38e-07	0.000186	-0.32	-0.33	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
SARC	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	5.32	2.38e-07	0.000186	0.36	0.33	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
SARC	cis	rs17772222	0.63	rs7146241	ENSG00000258983.2	RP11-507K2.2	-5.32	2.38e-07	0.000187	-0.33	-0.33	Coronary artery calcification;	chr14:88551622	chr14:88499334~88515502:+
SARC	cis	rs7712401	0.601	rs246322	ENSG00000263432.2	RN7SL689P	-5.32	2.38e-07	0.000187	-0.41	-0.33	Mean platelet volume;	chr5:122971574	chr5:123022487~123022783:-
SARC	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-5.32	2.39e-07	0.000187	-0.41	-0.33	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
SARC	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-5.32	2.39e-07	0.000187	-0.32	-0.33	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
SARC	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-5.32	2.41e-07	0.000188	-0.42	-0.33	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
SARC	cis	rs2946504	0.861	rs2977085	ENSG00000251468.2	RP11-369K16.1	-5.32	2.41e-07	0.000189	-0.35	-0.33	Type 2 diabetes;	chr8:12956237	chr8:12958387~12962200:+
SARC	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	5.32	2.42e-07	0.000189	0.4	0.33	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
SARC	cis	rs7772486	0.686	rs4896833	ENSG00000270638.1	RP3-466P17.1	5.32	2.42e-07	0.000189	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145735570~145737218:+
SARC	cis	rs1865760	0.515	rs2003208	ENSG00000272462.2	U91328.19	-5.32	2.42e-07	0.000189	-0.31	-0.33	Height;	chr6:25940491	chr6:25992662~26001775:+
SARC	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-5.32	2.42e-07	0.000189	-0.36	-0.33	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
SARC	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	5.32	2.43e-07	0.00019	0.39	0.33	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
SARC	cis	rs728478	0.809	rs1451507	ENSG00000266992.1	DHX40P1	5.32	2.43e-07	0.00019	0.35	0.33	QT interval;	chr17:59399912	chr17:59976009~60002384:-
SARC	cis	rs728478	0.845	rs758379	ENSG00000266992.1	DHX40P1	5.32	2.43e-07	0.00019	0.35	0.33	QT interval;	chr17:59400255	chr17:59976009~60002384:-
SARC	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	5.32	2.43e-07	0.00019	0.38	0.33	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
SARC	cis	rs2562456	0.833	rs7246339	ENSG00000268081.1	RP11-678G14.2	5.32	2.43e-07	0.00019	0.52	0.33	Pain;	chr19:21292495	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs55899865	ENSG00000268081.1	RP11-678G14.2	5.32	2.43e-07	0.00019	0.52	0.33	Pain;	chr19:21298933	chr19:21554640~21569237:-
SARC	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-5.32	2.43e-07	0.00019	-0.35	-0.33	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
SARC	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-5.32	2.43e-07	0.00019	-0.35	-0.33	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
SARC	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-5.32	2.43e-07	0.00019	-0.35	-0.33	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
SARC	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-5.32	2.43e-07	0.00019	-0.35	-0.33	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
SARC	cis	rs8031584	1	rs1474380	ENSG00000260382.1	RP11-540B6.2	5.32	2.45e-07	0.000191	0.39	0.33	Huntington's disease progression;	chr15:30977032	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.918	rs34095794	ENSG00000260382.1	RP11-540B6.2	5.32	2.45e-07	0.000191	0.39	0.33	Huntington's disease progression;	chr15:30977488	chr15:30882267~30883231:-
SARC	cis	rs899997	0.862	rs8043123	ENSG00000261143.1	ADAMTS7P3	-5.32	2.45e-07	0.000191	-0.47	-0.33	Coronary artery disease or large artery stroke;	chr15:78681051	chr15:77976042~77993057:+
SARC	cis	rs4372836	0.964	rs17007191	ENSG00000226833.4	AC097724.3	-5.32	2.45e-07	0.000192	-0.31	-0.33	Body mass index;	chr2:28709636	chr2:28708953~28736205:-
SARC	cis	rs7246657	0.891	rs7253114	ENSG00000276846.1	CTD-3220F14.3	5.32	2.46e-07	0.000192	0.43	0.33	Coronary artery calcification;	chr19:37497823	chr19:37314868~37315620:-
SARC	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-5.32	2.46e-07	0.000192	-0.36	-0.33	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
SARC	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-5.32	2.46e-07	0.000192	-0.38	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
SARC	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-5.32	2.46e-07	0.000192	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
SARC	cis	rs2179367	0.959	rs544947	ENSG00000231760.4	RP11-350J20.5	5.32	2.46e-07	0.000192	0.4	0.33	Dupuytren's disease;	chr6:149402412	chr6:149796151~149826294:-
SARC	cis	rs79349575	0.716	rs46522	ENSG00000270781.1	RP11-501C14.9	-5.32	2.47e-07	0.000192	-0.4	-0.33	Type 2 diabetes;	chr17:48911235	chr17:48899131~48899748:+
SARC	cis	rs453301	0.624	rs6987558	ENSG00000253893.2	FAM85B	-5.32	2.47e-07	0.000193	-0.29	-0.33	Joint mobility (Beighton score);	chr8:9005011	chr8:8167819~8226614:-
SARC	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-5.32	2.47e-07	0.000193	-0.34	-0.33	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
SARC	cis	rs6991838	0.701	rs17395275	ENSG00000200714.1	Y_RNA	5.32	2.48e-07	0.000194	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65592731~65592820:+
SARC	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	5.31	2.5e-07	0.000195	0.41	0.33	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
SARC	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-5.31	2.5e-07	0.000195	-0.35	-0.33	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
SARC	cis	rs7772486	0.754	rs9390358	ENSG00000270638.1	RP3-466P17.1	5.31	2.5e-07	0.000195	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145735570~145737218:+
SARC	cis	rs75920871	0.588	rs10892054	ENSG00000254851.1	RP11-109L13.1	5.31	2.51e-07	0.000195	0.44	0.33	Subjective well-being;	chr11:116997505	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.588	rs10892055	ENSG00000254851.1	RP11-109L13.1	5.31	2.51e-07	0.000195	0.44	0.33	Subjective well-being;	chr11:116997655	chr11:117135528~117138582:+
SARC	cis	rs4713118	0.869	rs9461405	ENSG00000219392.1	RP1-265C24.5	-5.31	2.51e-07	0.000195	-0.46	-0.33	Parkinson's disease;	chr6:27751596	chr6:28115628~28116551:+
SARC	cis	rs8031584	0.678	rs798086	ENSG00000260382.1	RP11-540B6.2	-5.31	2.51e-07	0.000195	-0.41	-0.33	Huntington's disease progression;	chr15:30837008	chr15:30882267~30883231:-
SARC	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-5.31	2.51e-07	0.000195	-0.33	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
SARC	cis	rs2933343	1	rs1680795	ENSG00000231305.3	RP11-723O4.2	5.31	2.52e-07	0.000196	0.36	0.33	IgG glycosylation;	chr3:128901545	chr3:128861313~128871540:-
SARC	cis	rs2933343	1	rs1683776	ENSG00000231305.3	RP11-723O4.2	5.31	2.52e-07	0.000196	0.36	0.33	IgG glycosylation;	chr3:128903917	chr3:128861313~128871540:-
SARC	cis	rs2933343	1	rs2630252	ENSG00000231305.3	RP11-723O4.2	5.31	2.52e-07	0.000196	0.36	0.33	IgG glycosylation;	chr3:128905929	chr3:128861313~128871540:-
SARC	cis	rs2562456	0.874	rs2562417	ENSG00000268081.1	RP11-678G14.2	-5.31	2.53e-07	0.000197	-0.49	-0.33	Pain;	chr19:21528400	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.917	rs2562468	ENSG00000268081.1	RP11-678G14.2	-5.31	2.53e-07	0.000197	-0.49	-0.33	Pain;	chr19:21532048	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.917	rs2562471	ENSG00000268081.1	RP11-678G14.2	-5.31	2.53e-07	0.000197	-0.49	-0.33	Pain;	chr19:21533017	chr19:21554640~21569237:-
SARC	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	5.31	2.53e-07	0.000197	0.41	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
SARC	cis	rs62103177	0.535	rs34299914	ENSG00000261126.6	RP11-795F19.1	5.31	2.53e-07	0.000197	0.36	0.33	Opioid sensitivity;	chr18:80191353	chr18:80046900~80095482:+
SARC	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	5.31	2.53e-07	0.000197	0.26	0.33	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
SARC	cis	rs1799949	0.965	rs7212284	ENSG00000267681.1	CTD-3199J23.6	-5.31	2.54e-07	0.000198	-0.36	-0.33	Menopause (age at onset);	chr17:43053924	chr17:43144956~43145255:+
SARC	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	5.31	2.55e-07	0.000198	0.41	0.33	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
SARC	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-5.31	2.55e-07	0.000198	-0.31	-0.33	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
SARC	cis	rs6570726	0.791	rs952406	ENSG00000270638.1	RP3-466P17.1	5.31	2.55e-07	0.000198	0.27	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145735570~145737218:+
SARC	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-5.31	2.56e-07	0.000199	-0.34	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
SARC	cis	rs7809950	0.862	rs12112877	ENSG00000238832.1	snoU109	-5.31	2.56e-07	0.000199	-0.38	-0.33	Coronary artery disease;	chr7:107300879	chr7:107603363~107603507:+
SARC	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-5.31	2.56e-07	0.000199	-0.41	-0.33	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
SARC	cis	rs7216064	1	rs60432293	ENSG00000278219.1	AC145343.1	-5.31	2.56e-07	0.000199	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67864291	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.953	rs4790905	ENSG00000278219.1	AC145343.1	-5.31	2.56e-07	0.000199	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67867234	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs9912084	ENSG00000278219.1	AC145343.1	-5.31	2.56e-07	0.000199	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67871919	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs9912770	ENSG00000278219.1	AC145343.1	-5.31	2.56e-07	0.000199	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67872117	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs9915108	ENSG00000278219.1	AC145343.1	-5.31	2.56e-07	0.000199	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878347	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs9913471	ENSG00000278219.1	AC145343.1	-5.31	2.56e-07	0.000199	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878379	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.861	rs73352810	ENSG00000278219.1	AC145343.1	-5.31	2.56e-07	0.000199	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67879068	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.906	rs8074644	ENSG00000278219.1	AC145343.1	-5.31	2.56e-07	0.000199	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67882101	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs3935969	ENSG00000278219.1	AC145343.1	-5.31	2.56e-07	0.000199	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67885843	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs7208663	ENSG00000278219.1	AC145343.1	-5.31	2.56e-07	0.000199	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889055	chr17:68101538~68101639:+
SARC	cis	rs2562456	0.917	rs2681376	ENSG00000268081.1	RP11-678G14.2	-5.31	2.57e-07	2e-04	-0.49	-0.33	Pain;	chr19:21532723	chr19:21554640~21569237:-
SARC	cis	rs4862750	0.832	rs10007858	ENSG00000250971.1	RP11-696F12.1	5.31	2.57e-07	2e-04	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186956338	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.872	rs9997374	ENSG00000250971.1	RP11-696F12.1	5.31	2.57e-07	2e-04	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186956395	chr4:187060099~187060930:+
SARC	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	5.31	2.58e-07	0.000201	0.35	0.33	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
SARC	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	5.31	2.59e-07	0.000201	0.51	0.33	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	5.31	2.59e-07	0.000201	0.51	0.33	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
SARC	cis	rs7216064	0.817	rs28609796	ENSG00000265055.1	AC145343.2	5.31	2.59e-07	0.000201	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67858988	chr17:68096046~68101474:-
SARC	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-5.31	2.6e-07	0.000201	-0.36	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
SARC	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	5.31	2.6e-07	0.000201	0.26	0.33	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	5.31	2.6e-07	0.000201	0.26	0.33	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	5.31	2.6e-07	0.000201	0.26	0.33	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
SARC	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	5.31	2.61e-07	0.000202	0.4	0.33	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	5.31	2.61e-07	0.000202	0.4	0.33	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
SARC	cis	rs6969780	0.915	rs4722657	ENSG00000233429.8	HOTAIRM1	-5.31	2.61e-07	0.000202	-0.46	-0.33	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27118137	chr7:27095647~27100265:+
SARC	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	5.31	2.61e-07	0.000203	0.42	0.33	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
SARC	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-5.31	2.62e-07	0.000203	-0.34	-0.33	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
SARC	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-5.31	2.62e-07	0.000203	-0.3	-0.33	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
SARC	cis	rs710913	0.717	rs2068473	ENSG00000182109.6	RP11-69E11.4	-5.3	2.63e-07	0.000203	-0.31	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39522280~39546187:-
SARC	cis	rs17772222	0.63	rs12436642	ENSG00000258983.2	RP11-507K2.2	-5.3	2.63e-07	0.000203	-0.33	-0.33	Coronary artery calcification;	chr14:88559032	chr14:88499334~88515502:+
SARC	cis	rs7216064	1	rs58122682	ENSG00000265055.1	AC145343.2	5.3	2.63e-07	0.000203	0.43	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67880799	chr17:68096046~68101474:-
SARC	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-5.3	2.63e-07	0.000203	-0.32	-0.33	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
SARC	cis	rs8031584	0.958	rs7168641	ENSG00000260382.1	RP11-540B6.2	5.3	2.63e-07	0.000204	0.4	0.33	Huntington's disease progression;	chr15:30943249	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.958	rs35256769	ENSG00000260382.1	RP11-540B6.2	5.3	2.63e-07	0.000204	0.4	0.33	Huntington's disease progression;	chr15:30945573	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.958	rs11629793	ENSG00000260382.1	RP11-540B6.2	5.3	2.63e-07	0.000204	0.4	0.33	Huntington's disease progression;	chr15:30946220	chr15:30882267~30883231:-
SARC	cis	rs17772222	0.63	rs930181	ENSG00000258983.2	RP11-507K2.2	-5.3	2.63e-07	0.000204	-0.33	-0.33	Coronary artery calcification;	chr14:88552364	chr14:88499334~88515502:+
SARC	cis	rs2562456	0.793	rs61445561	ENSG00000268081.1	RP11-678G14.2	5.3	2.63e-07	0.000204	0.53	0.33	Pain;	chr19:21321230	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.793	rs57299552	ENSG00000268081.1	RP11-678G14.2	5.3	2.63e-07	0.000204	0.53	0.33	Pain;	chr19:21321326	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.754	rs76688173	ENSG00000268081.1	RP11-678G14.2	5.3	2.63e-07	0.000204	0.53	0.33	Pain;	chr19:21321856	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs74711277	ENSG00000268081.1	RP11-678G14.2	5.3	2.63e-07	0.000204	0.53	0.33	Pain;	chr19:21322641	chr19:21554640~21569237:-
SARC	cis	rs7712401	0.601	rs154500	ENSG00000263432.2	RN7SL689P	5.3	2.64e-07	0.000204	0.41	0.33	Mean platelet volume;	chr5:122876296	chr5:123022487~123022783:-
SARC	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-5.3	2.64e-07	0.000204	-0.34	-0.33	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
SARC	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-5.3	2.64e-07	0.000204	-0.36	-0.33	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-5.3	2.64e-07	0.000204	-0.36	-0.33	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-5.3	2.64e-07	0.000204	-0.36	-0.33	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-5.3	2.64e-07	0.000204	-0.36	-0.33	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-5.3	2.64e-07	0.000204	-0.36	-0.33	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
SARC	cis	rs5769707	0.616	rs6009786	ENSG00000235111.1	RP1-29C18.8	-5.3	2.65e-07	0.000205	-0.41	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49612657~49615716:-
SARC	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-5.3	2.65e-07	0.000205	-0.26	-0.33	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
SARC	cis	rs2562456	0.833	rs7260065	ENSG00000268081.1	RP11-678G14.2	5.3	2.65e-07	0.000205	0.53	0.33	Pain;	chr19:21334175	chr19:21554640~21569237:-
SARC	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	5.3	2.65e-07	0.000205	0.38	0.33	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
SARC	cis	rs7430456	0.839	rs9824506	ENSG00000225790.1	RP11-2L8.1	5.3	2.65e-07	0.000205	0.34	0.33	Breast cancer;	chr3:177751431	chr3:177934823~177937662:+
SARC	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-5.3	2.66e-07	0.000205	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-5.3	2.66e-07	0.000205	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-5.3	2.66e-07	0.000205	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-5.3	2.66e-07	0.000205	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-5.3	2.66e-07	0.000205	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-5.3	2.66e-07	0.000205	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-5.3	2.66e-07	0.000205	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-5.3	2.66e-07	0.000205	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-5.3	2.66e-07	0.000205	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-5.3	2.66e-07	0.000205	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
SARC	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	5.3	2.66e-07	0.000205	0.42	0.33	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
SARC	cis	rs17270561	0.609	rs1892246	ENSG00000272462.2	U91328.19	-5.3	2.66e-07	0.000205	-0.31	-0.33	Iron status biomarkers;	chr6:25764180	chr6:25992662~26001775:+
SARC	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	5.3	2.66e-07	0.000205	0.42	0.33	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	5.3	2.66e-07	0.000205	0.42	0.33	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
SARC	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	5.3	2.66e-07	0.000206	0.52	0.33	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
SARC	cis	rs2562456	0.793	rs11672341	ENSG00000268081.1	RP11-678G14.2	5.3	2.66e-07	0.000206	0.53	0.33	Pain;	chr19:21324502	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs61035285	ENSG00000268081.1	RP11-678G14.2	5.3	2.66e-07	0.000206	0.53	0.33	Pain;	chr19:21329475	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.641	rs62107468	ENSG00000268081.1	RP11-678G14.2	5.3	2.66e-07	0.000206	0.52	0.33	Pain;	chr19:21307177	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs2154302	ENSG00000268081.1	RP11-678G14.2	5.3	2.66e-07	0.000206	0.52	0.33	Pain;	chr19:21307609	chr19:21554640~21569237:-
SARC	cis	rs5769707	0.554	rs10854876	ENSG00000235111.1	RP1-29C18.8	-5.3	2.66e-07	0.000206	-0.42	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49612657~49615716:-
SARC	cis	rs2562456	0.793	rs11667103	ENSG00000268081.1	RP11-678G14.2	5.3	2.66e-07	0.000206	0.52	0.33	Pain;	chr19:21303839	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.754	rs62107469	ENSG00000268081.1	RP11-678G14.2	5.3	2.66e-07	0.000206	0.52	0.33	Pain;	chr19:21312699	chr19:21554640~21569237:-
SARC	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-5.3	2.67e-07	0.000206	-0.37	-0.33	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
SARC	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	5.3	2.67e-07	0.000206	0.48	0.33	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
SARC	cis	rs7712401	0.601	rs1990890	ENSG00000263432.2	RN7SL689P	5.3	2.67e-07	0.000206	0.41	0.33	Mean platelet volume;	chr5:122847275	chr5:123022487~123022783:-
SARC	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-5.3	2.67e-07	0.000206	-0.37	-0.33	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
SARC	cis	rs7712401	0.642	rs17388251	ENSG00000263432.2	RN7SL689P	5.3	2.67e-07	0.000206	0.4	0.33	Mean platelet volume;	chr5:123024708	chr5:123022487~123022783:-
SARC	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	5.3	2.68e-07	0.000207	0.42	0.33	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
SARC	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-5.3	2.68e-07	0.000207	-0.44	-0.33	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
SARC	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-5.3	2.68e-07	0.000207	-0.42	-0.33	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
SARC	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-5.3	2.68e-07	0.000207	-0.41	-0.33	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
SARC	cis	rs1865760	1	rs9467636	ENSG00000272462.2	U91328.19	-5.3	2.68e-07	0.000207	-0.31	-0.33	Height;	chr6:25919321	chr6:25992662~26001775:+
SARC	cis	rs1865760	1	rs9358893	ENSG00000272462.2	U91328.19	-5.3	2.68e-07	0.000207	-0.31	-0.33	Height;	chr6:25921533	chr6:25992662~26001775:+
SARC	cis	rs8031584	0.918	rs34331396	ENSG00000260382.1	RP11-540B6.2	5.3	2.68e-07	0.000207	0.41	0.33	Huntington's disease progression;	chr15:30956533	chr15:30882267~30883231:-
SARC	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-5.3	2.69e-07	0.000207	-0.37	-0.33	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
SARC	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	5.3	2.7e-07	0.000208	0.32	0.33	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
SARC	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-5.3	2.71e-07	0.000209	-0.34	-0.33	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
SARC	cis	rs763121	0.925	rs9835	ENSG00000273076.1	RP3-508I15.22	5.3	2.71e-07	0.000209	0.35	0.33	Menopause (age at onset);	chr22:38734966	chr22:38743495~38743910:+
SARC	cis	rs4862750	0.758	rs2375915	ENSG00000250971.1	RP11-696F12.1	5.3	2.71e-07	0.000209	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186975101	chr4:187060099~187060930:+
SARC	cis	rs853679	0.76	rs11967137	ENSG00000219392.1	RP1-265C24.5	-5.3	2.71e-07	0.000209	-0.52	-0.33	Depression;	chr6:28231986	chr6:28115628~28116551:+
SARC	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-5.3	2.72e-07	0.00021	-0.41	-0.33	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
SARC	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	5.3	2.72e-07	0.00021	0.51	0.33	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
SARC	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	5.3	2.72e-07	0.00021	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
SARC	cis	rs7216064	1	rs11079707	ENSG00000278219.1	AC145343.1	5.3	2.72e-07	0.00021	0.39	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839501	chr17:68101538~68101639:+
SARC	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	5.3	2.72e-07	0.00021	0.47	0.33	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
SARC	cis	rs4862750	0.957	rs2375916	ENSG00000250971.1	RP11-696F12.1	5.3	2.73e-07	0.00021	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186982769	chr4:187060099~187060930:+
SARC	cis	rs7216064	0.953	rs9890629	ENSG00000278219.1	AC145343.1	-5.3	2.73e-07	0.00021	-0.39	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67875443	chr17:68101538~68101639:+
SARC	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-5.3	2.73e-07	0.00021	-0.42	-0.33	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
SARC	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-5.3	2.73e-07	0.00021	-0.42	-0.33	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
SARC	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-5.3	2.73e-07	0.00021	-0.42	-0.33	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
SARC	cis	rs2562456	0.834	rs13346641	ENSG00000268081.1	RP11-678G14.2	5.3	2.74e-07	0.000211	0.53	0.33	Pain;	chr19:21409481	chr19:21554640~21569237:-
SARC	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-5.3	2.75e-07	0.000211	-0.32	-0.33	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
SARC	cis	rs1865760	0.964	rs3799373	ENSG00000272810.1	U91328.22	-5.3	2.75e-07	0.000211	-0.33	-0.33	Height;	chr6:25928945	chr6:26013241~26013757:+
SARC	cis	rs1865760	1	rs9348698	ENSG00000272810.1	U91328.22	-5.3	2.75e-07	0.000211	-0.33	-0.33	Height;	chr6:25929461	chr6:26013241~26013757:+
SARC	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	5.29	2.75e-07	0.000211	0.36	0.33	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
SARC	cis	rs8005677	1	rs4982709	ENSG00000257285.4	RP11-298I3.1	5.29	2.75e-07	0.000212	0.3	0.33	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:22929609~22955562:+
SARC	cis	rs17270561	0.636	rs9348696	ENSG00000272810.1	U91328.22	-5.29	2.75e-07	0.000212	-0.32	-0.33	Iron status biomarkers;	chr6:25781710	chr6:26013241~26013757:+
SARC	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	5.29	2.76e-07	0.000212	0.5	0.33	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
SARC	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-5.29	2.76e-07	0.000212	-0.31	-0.33	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
SARC	cis	rs7216064	1	rs12452511	ENSG00000265055.1	AC145343.2	5.29	2.77e-07	0.000213	0.44	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836460	chr17:68096046~68101474:-
SARC	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-5.29	2.77e-07	0.000213	-0.31	-0.33	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-5.29	2.77e-07	0.000213	-0.31	-0.33	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
SARC	cis	rs728478	0.845	rs9905500	ENSG00000266992.1	DHX40P1	5.29	2.77e-07	0.000213	0.35	0.33	QT interval;	chr17:59398535	chr17:59976009~60002384:-
SARC	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	5.29	2.77e-07	0.000213	0.38	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
SARC	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	5.29	2.78e-07	0.000213	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
SARC	cis	rs7809950	1	rs2808	ENSG00000238832.1	snoU109	5.29	2.78e-07	0.000214	0.38	0.33	Coronary artery disease;	chr7:107620411	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs10274041	ENSG00000238832.1	snoU109	5.29	2.78e-07	0.000214	0.38	0.33	Coronary artery disease;	chr7:107621111	chr7:107603363~107603507:+
SARC	cis	rs2562456	0.793	rs11667392	ENSG00000268081.1	RP11-678G14.2	5.29	2.79e-07	0.000214	0.52	0.33	Pain;	chr19:21289806	chr19:21554640~21569237:-
SARC	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-5.29	2.79e-07	0.000214	-0.38	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
SARC	cis	rs17772222	0.682	rs7142053	ENSG00000258983.2	RP11-507K2.2	5.29	2.79e-07	0.000214	0.32	0.33	Coronary artery calcification;	chr14:88511594	chr14:88499334~88515502:+
SARC	cis	rs2562456	0.833	rs62107540	ENSG00000268081.1	RP11-678G14.2	5.29	2.79e-07	0.000214	0.53	0.33	Pain;	chr19:21335693	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62107541	ENSG00000268081.1	RP11-678G14.2	5.29	2.79e-07	0.000214	0.53	0.33	Pain;	chr19:21335733	chr19:21554640~21569237:-
SARC	cis	rs2404602	0.684	rs2454451	ENSG00000259422.1	RP11-593F23.1	5.29	2.8e-07	0.000215	0.39	0.33	Blood metabolite levels;	chr15:76569120	chr15:76174891~76181486:-
SARC	cis	rs8031584	0.678	rs798127	ENSG00000260382.1	RP11-540B6.2	-5.29	2.8e-07	0.000215	-0.4	-0.33	Huntington's disease progression;	chr15:30825200	chr15:30882267~30883231:-
SARC	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-5.29	2.8e-07	0.000215	-0.32	-0.33	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
SARC	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	5.29	2.8e-07	0.000215	0.42	0.33	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
SARC	cis	rs2439831	0.867	rs933941	ENSG00000205771.5	CATSPER2P1	-5.29	2.81e-07	0.000215	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43340028	chr15:43726918~43747094:-
SARC	cis	rs4273100	0.79	rs60606605	ENSG00000228157.4	AC007952.5	5.29	2.81e-07	0.000215	0.47	0.33	Schizophrenia;	chr17:19373831	chr17:19092974~19096837:+
SARC	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-5.29	2.81e-07	0.000216	-0.32	-0.33	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
SARC	cis	rs755249	0.545	rs12037073	ENSG00000182109.6	RP11-69E11.4	-5.29	2.83e-07	0.000216	-0.33	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39522280~39546187:-
SARC	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	5.29	2.83e-07	0.000217	0.47	0.33	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
SARC	cis	rs2179367	0.959	rs9390677	ENSG00000231760.4	RP11-350J20.5	5.29	2.84e-07	0.000217	0.4	0.33	Dupuytren's disease;	chr6:149389361	chr6:149796151~149826294:-
SARC	cis	rs7712401	0.601	rs154501	ENSG00000263432.2	RN7SL689P	5.29	2.84e-07	0.000217	0.41	0.33	Mean platelet volume;	chr5:122875899	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs246271	ENSG00000263432.2	RN7SL689P	5.29	2.84e-07	0.000217	0.41	0.33	Mean platelet volume;	chr5:122877127	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs257813	ENSG00000263432.2	RN7SL689P	5.29	2.84e-07	0.000217	0.41	0.33	Mean platelet volume;	chr5:122881473	chr5:123022487~123022783:-
SARC	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	5.29	2.84e-07	0.000218	0.59	0.33	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
SARC	cis	rs7216064	0.648	rs61676547	ENSG00000265055.1	AC145343.2	5.29	2.85e-07	0.000218	0.42	0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896391	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs3206817	ENSG00000278219.1	AC145343.1	-5.29	2.86e-07	0.000219	-0.41	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896718	chr17:68101538~68101639:+
SARC	cis	rs9309473	0.95	rs6726694	ENSG00000163016.8	ALMS1P	5.29	2.86e-07	0.000219	0.4	0.33	Metabolite levels;	chr2:73620103	chr2:73644919~73685576:+
SARC	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	5.29	2.87e-07	0.000219	0.37	0.33	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
SARC	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	5.29	2.87e-07	0.00022	0.34	0.33	Height;	chr3:53085313	chr3:53064283~53065091:-
SARC	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	5.29	2.87e-07	0.00022	0.38	0.33	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
SARC	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-5.29	2.89e-07	0.000221	-0.34	-0.33	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
SARC	cis	rs7587476	0.689	rs10498025	ENSG00000229267.2	AC072062.1	-5.28	2.89e-07	0.000221	-0.32	-0.33	Neuroblastoma;	chr2:214884532	chr2:214810229~214963274:+
SARC	cis	rs4713118	0.539	rs200988	ENSG00000219392.1	RP1-265C24.5	-5.28	2.9e-07	0.000222	-0.44	-0.33	Parkinson's disease;	chr6:27851575	chr6:28115628~28116551:+
SARC	cis	rs7246657	0.943	rs6508732	ENSG00000276846.1	CTD-3220F14.3	5.28	2.92e-07	0.000223	0.42	0.33	Coronary artery calcification;	chr19:37509566	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	5.28	2.92e-07	0.000223	0.42	0.33	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
SARC	cis	rs10463554	0.716	rs152136	ENSG00000175749.11	EIF3KP1	5.28	2.92e-07	0.000223	0.44	0.33	Parkinson's disease;	chr5:103248167	chr5:103032376~103033031:+
SARC	cis	rs2179367	0.92	rs638407	ENSG00000231760.4	RP11-350J20.5	5.28	2.92e-07	0.000223	0.4	0.33	Dupuytren's disease;	chr6:149417214	chr6:149796151~149826294:-
SARC	cis	rs9309473	0.66	rs17349321	ENSG00000163016.8	ALMS1P	5.28	2.92e-07	0.000223	0.46	0.33	Metabolite levels;	chr2:73416625	chr2:73644919~73685576:+
SARC	cis	rs7246657	0.943	rs10424574	ENSG00000276846.1	CTD-3220F14.3	5.28	2.93e-07	0.000223	0.44	0.33	Coronary artery calcification;	chr19:37347491	chr19:37314868~37315620:-
SARC	cis	rs710913	0.717	rs11206377	ENSG00000182109.6	RP11-69E11.4	5.28	2.93e-07	0.000223	0.3	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39522280~39546187:-
SARC	cis	rs7772486	0.651	rs1292338	ENSG00000270638.1	RP3-466P17.1	-5.28	2.93e-07	0.000224	-0.26	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145735570~145737218:+
SARC	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.93e-07	0.000224	-0.38	-0.33	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs36036395	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.93e-07	0.000224	-0.38	-0.33	Menopause (age at onset);	chr17:43029280	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.93e-07	0.000224	-0.38	-0.33	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.93e-07	0.000224	-0.38	-0.33	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.93e-07	0.000224	-0.38	-0.33	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.93e-07	0.000224	-0.38	-0.33	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
SARC	cis	rs7772486	0.686	rs1292337	ENSG00000270638.1	RP3-466P17.1	-5.28	2.94e-07	0.000224	-0.26	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs857879	ENSG00000270638.1	RP3-466P17.1	-5.28	2.94e-07	0.000224	-0.26	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145735570~145737218:+
SARC	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	5.28	2.95e-07	0.000225	0.42	0.33	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
SARC	cis	rs7216064	1	rs11870068	ENSG00000278219.1	AC145343.1	-5.28	2.95e-07	0.000225	-0.41	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67948399	chr17:68101538~68101639:+
SARC	cis	rs2562456	0.833	rs56179986	ENSG00000268081.1	RP11-678G14.2	5.28	2.95e-07	0.000225	0.53	0.33	Pain;	chr19:21337882	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs4429400	ENSG00000268081.1	RP11-678G14.2	5.28	2.95e-07	0.000225	0.53	0.33	Pain;	chr19:21338163	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs1932087	ENSG00000268081.1	RP11-678G14.2	5.28	2.95e-07	0.000225	0.53	0.33	Pain;	chr19:21338625	chr19:21554640~21569237:-
SARC	cis	rs673078	1	rs673078	ENSG00000275759.1	RP11-131L12.3	5.28	2.95e-07	0.000225	0.42	0.33	Glucose homeostasis traits;	chr12:118353636	chr12:118428281~118428870:+
SARC	cis	rs1799949	1	rs2298862	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.95e-07	0.000225	-0.38	-0.33	Menopause (age at onset);	chr17:43024671	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.93	rs2298861	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.95e-07	0.000225	-0.38	-0.33	Menopause (age at onset);	chr17:43024814	chr17:43144956~43145255:+
SARC	cis	rs77204473	1	rs79711490	ENSG00000254851.1	RP11-109L13.1	5.28	2.96e-07	0.000225	0.71	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117135528~117138582:+
SARC	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.96e-07	0.000225	-0.37	-0.33	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.96e-07	0.000225	-0.37	-0.33	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.96e-07	0.000225	-0.37	-0.33	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
SARC	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-5.28	2.96e-07	0.000225	-0.32	-0.33	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
SARC	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.96e-07	0.000226	-0.38	-0.33	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
SARC	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-5.28	2.96e-07	0.000226	-0.33	-0.33	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
SARC	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.96e-07	0.000226	-0.37	-0.33	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-5.28	2.96e-07	0.000226	-0.37	-0.33	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
SARC	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-5.28	2.97e-07	0.000226	-0.4	-0.33	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs10496191	ENSG00000163016.8	ALMS1P	5.28	2.97e-07	0.000226	0.41	0.33	Metabolite levels;	chr2:73446670	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	5.28	2.97e-07	0.000226	0.4	0.33	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
SARC	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	5.28	2.97e-07	0.000226	0.38	0.33	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
SARC	cis	rs899997	0.862	rs8032552	ENSG00000261143.1	ADAMTS7P3	-5.28	2.98e-07	0.000227	-0.46	-0.33	Coronary artery disease or large artery stroke;	chr15:78678794	chr15:77976042~77993057:+
SARC	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-5.28	2.98e-07	0.000227	-0.3	-0.33	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
SARC	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-5.28	2.98e-07	0.000227	-0.34	-0.33	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
SARC	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-5.28	2.99e-07	0.000228	-0.33	-0.33	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
SARC	cis	rs7246657	0.943	rs10407084	ENSG00000276846.1	CTD-3220F14.3	5.28	3e-07	0.000228	0.44	0.33	Coronary artery calcification;	chr19:37416890	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.823	rs4802236	ENSG00000276846.1	CTD-3220F14.3	5.28	3e-07	0.000228	0.44	0.33	Coronary artery calcification;	chr19:37428344	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs7252099	ENSG00000276846.1	CTD-3220F14.3	5.28	3e-07	0.000228	0.44	0.33	Coronary artery calcification;	chr19:37442878	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs7255972	ENSG00000276846.1	CTD-3220F14.3	5.28	3e-07	0.000228	0.44	0.33	Coronary artery calcification;	chr19:37442939	chr19:37314868~37315620:-
SARC	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	5.28	3e-07	0.000228	0.45	0.33	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
SARC	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-5.28	3e-07	0.000229	-0.46	-0.33	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
SARC	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	5.28	3.01e-07	0.000229	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
SARC	cis	rs6991838	0.751	rs35553155	ENSG00000200714.1	Y_RNA	5.28	3.01e-07	0.000229	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.806	rs35024820	ENSG00000200714.1	Y_RNA	5.28	3.01e-07	0.000229	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65592731~65592820:+
SARC	cis	rs1865760	0.566	rs2032445	ENSG00000272810.1	U91328.22	-5.28	3.01e-07	0.000229	-0.31	-0.33	Height;	chr6:26044584	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs2032443	ENSG00000272810.1	U91328.22	-5.28	3.01e-07	0.000229	-0.31	-0.33	Height;	chr6:26046574	chr6:26013241~26013757:+
SARC	cis	rs17772222	0.63	rs10873392	ENSG00000258983.2	RP11-507K2.2	-5.28	3.01e-07	0.000229	-0.33	-0.33	Coronary artery calcification;	chr14:88545124	chr14:88499334~88515502:+
SARC	cis	rs9309473	1	rs10175180	ENSG00000163016.8	ALMS1P	5.28	3.01e-07	0.000229	0.41	0.33	Metabolite levels;	chr2:73445995	chr2:73644919~73685576:+
SARC	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-5.28	3.02e-07	0.000229	-0.32	-0.33	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-5.28	3.02e-07	0.000229	-0.32	-0.33	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-5.28	3.02e-07	0.000229	-0.32	-0.33	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
SARC	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-5.28	3.02e-07	0.00023	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
SARC	cis	rs4713118	0.513	rs149878	ENSG00000219392.1	RP1-265C24.5	-5.27	3.03e-07	0.00023	-0.45	-0.33	Parkinson's disease;	chr6:27910960	chr6:28115628~28116551:+
SARC	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	5.27	3.04e-07	0.000231	0.3	0.33	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
SARC	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-5.27	3.04e-07	0.000231	-0.33	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-5.27	3.04e-07	0.000231	-0.33	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
SARC	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	5.27	3.04e-07	0.000231	0.34	0.33	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
SARC	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-5.27	3.04e-07	0.000231	-0.41	-0.33	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
SARC	cis	rs4862750	0.832	rs6836076	ENSG00000250971.1	RP11-696F12.1	5.27	3.04e-07	0.000231	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186978506	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.872	rs6836781	ENSG00000250971.1	RP11-696F12.1	5.27	3.04e-07	0.000231	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186978547	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.872	rs11947595	ENSG00000250971.1	RP11-696F12.1	5.27	3.04e-07	0.000231	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186978673	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.872	rs7658314	ENSG00000250971.1	RP11-696F12.1	5.27	3.04e-07	0.000231	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186979202	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.832	rs6419953	ENSG00000250971.1	RP11-696F12.1	5.27	3.04e-07	0.000231	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186979355	chr4:187060099~187060930:+
SARC	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	5.27	3.04e-07	0.000231	0.38	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
SARC	cis	rs77204473	1	rs12292614	ENSG00000254851.1	RP11-109L13.1	5.27	3.05e-07	0.000232	0.73	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117135528~117138582:+
SARC	cis	rs853679	0.76	rs11962305	ENSG00000219392.1	RP1-265C24.5	-5.27	3.06e-07	0.000232	-0.52	-0.33	Depression;	chr6:28232159	chr6:28115628~28116551:+
SARC	cis	rs4372836	0.964	rs34627117	ENSG00000226833.4	AC097724.3	-5.27	3.06e-07	0.000232	-0.32	-0.33	Body mass index;	chr2:28707610	chr2:28708953~28736205:-
SARC	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	5.27	3.07e-07	0.000233	0.36	0.33	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
SARC	cis	rs7712401	0.601	rs30045	ENSG00000263432.2	RN7SL689P	5.27	3.08e-07	0.000233	0.4	0.33	Mean platelet volume;	chr5:122935924	chr5:123022487~123022783:-
SARC	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-5.27	3.09e-07	0.000234	-0.34	-0.33	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
SARC	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-5.27	3.09e-07	0.000234	-0.42	-0.33	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
SARC	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-5.27	3.1e-07	0.000234	-0.37	-0.33	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
SARC	cis	rs1865760	0.551	rs9461230	ENSG00000272810.1	U91328.22	-5.27	3.11e-07	0.000235	-0.31	-0.33	Height;	chr6:26019012	chr6:26013241~26013757:+
SARC	cis	rs17772222	0.56	rs3742681	ENSG00000258983.2	RP11-507K2.2	-5.27	3.12e-07	0.000236	-0.33	-0.33	Coronary artery calcification;	chr14:88554903	chr14:88499334~88515502:+
SARC	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-5.27	3.13e-07	0.000237	-0.4	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
SARC	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-5.27	3.13e-07	0.000237	-0.4	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
SARC	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-5.27	3.13e-07	0.000237	-0.4	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
SARC	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	5.27	3.14e-07	0.000237	0.42	0.33	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
SARC	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-5.27	3.14e-07	0.000238	-0.42	-0.33	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
SARC	cis	rs2562456	0.917	rs9304987	ENSG00000268081.1	RP11-678G14.2	-5.27	3.15e-07	0.000238	-0.48	-0.33	Pain;	chr19:21499472	chr19:21554640~21569237:-
SARC	cis	rs6570726	0.846	rs7762536	ENSG00000270638.1	RP3-466P17.1	5.27	3.15e-07	0.000238	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145735570~145737218:+
SARC	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-5.27	3.15e-07	0.000238	-0.31	-0.33	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
SARC	cis	rs2562456	0.917	rs6511253	ENSG00000268081.1	RP11-678G14.2	-5.27	3.16e-07	0.000239	-0.48	-0.33	Pain;	chr19:21495996	chr19:21554640~21569237:-
SARC	cis	rs890448	0.796	rs2433298	ENSG00000254531.1	FLJ20021	5.27	3.16e-07	0.000239	0.34	0.33	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101421169	chr4:101347780~101348883:+
SARC	cis	rs10754283	0.967	rs4658308	ENSG00000231613.1	RP5-943J3.1	5.27	3.16e-07	0.000239	0.33	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89657372	chr1:89788914~89790492:+
SARC	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	5.27	3.17e-07	0.000239	0.49	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
SARC	cis	rs9543976	0.544	rs73223950	ENSG00000261553.4	RP11-29G8.3	-5.27	3.17e-07	0.000239	-0.64	-0.33	Diabetic retinopathy;	chr13:75524901	chr13:75549773~75807120:+
SARC	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	5.27	3.17e-07	0.000239	0.4	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
SARC	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-5.27	3.17e-07	0.000239	-0.36	-0.33	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
SARC	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-5.27	3.17e-07	0.000239	-0.36	-0.33	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
SARC	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-5.27	3.17e-07	0.000239	-0.36	-0.33	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
SARC	cis	rs763567	0.585	rs577827	ENSG00000271811.1	RP1-79C4.4	5.27	3.18e-07	0.00024	0.38	0.33	Tonsillectomy;	chr1:170593942	chr1:170667381~170669425:+
SARC	cis	rs17270561	0.609	rs4712963	ENSG00000272810.1	U91328.22	-5.27	3.18e-07	0.00024	-0.33	-0.33	Iron status biomarkers;	chr6:25740274	chr6:26013241~26013757:+
SARC	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-5.26	3.18e-07	0.00024	-0.4	-0.33	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
SARC	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-5.26	3.19e-07	0.00024	-0.35	-0.33	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
SARC	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-5.26	3.19e-07	0.00024	-0.35	-0.33	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
SARC	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-5.26	3.19e-07	0.00024	-0.35	-0.33	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
SARC	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-5.26	3.19e-07	0.00024	-0.35	-0.33	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
SARC	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-5.26	3.19e-07	0.000241	-0.35	-0.33	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
SARC	cis	rs17772222	0.63	rs4904454	ENSG00000258983.2	RP11-507K2.2	-5.26	3.19e-07	0.000241	-0.33	-0.33	Coronary artery calcification;	chr14:88537777	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.63	rs2033418	ENSG00000258983.2	RP11-507K2.2	-5.26	3.19e-07	0.000241	-0.33	-0.33	Coronary artery calcification;	chr14:88539331	chr14:88499334~88515502:+
SARC	cis	rs2562456	0.834	rs2173727	ENSG00000268081.1	RP11-678G14.2	-5.26	3.2e-07	0.000241	-0.49	-0.33	Pain;	chr19:21491155	chr19:21554640~21569237:-
SARC	cis	rs160451	1	rs160448	ENSG00000251136.7	RP11-37B2.1	5.26	3.2e-07	0.000241	0.36	0.33	Leprosy;	chr8:89647622	chr8:89609409~89757727:-
SARC	cis	rs2439831	0.85	rs7163245	ENSG00000205771.5	CATSPER2P1	-5.26	3.2e-07	0.000241	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43379096	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs28729853	ENSG00000205771.5	CATSPER2P1	-5.26	3.2e-07	0.000241	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43381482	chr15:43726918~43747094:-
SARC	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-5.26	3.2e-07	0.000241	-0.39	-0.33	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
SARC	cis	rs7772486	0.686	rs1045820	ENSG00000270638.1	RP3-466P17.1	5.26	3.2e-07	0.000241	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs6570703	ENSG00000270638.1	RP3-466P17.1	5.26	3.2e-07	0.000241	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs6570705	ENSG00000270638.1	RP3-466P17.1	5.26	3.2e-07	0.000241	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145735570~145737218:+
SARC	cis	rs2404602	0.552	rs11630185	ENSG00000259422.1	RP11-593F23.1	-5.26	3.21e-07	0.000242	-0.43	-0.33	Blood metabolite levels;	chr15:76667442	chr15:76174891~76181486:-
SARC	cis	rs7196129	0.966	rs11150589	ENSG00000183604.13	SMG1P5	5.26	3.21e-07	0.000242	0.29	0.33	Monocyte count;	chr16:30471173	chr16:30267553~30335374:-
SARC	cis	rs12716977	1	rs12716977	ENSG00000183604.13	SMG1P5	5.26	3.21e-07	0.000242	0.29	0.33	Lymphocyte percentage of white cells;Lymphocyte counts;	chr16:30471482	chr16:30267553~30335374:-
SARC	cis	rs6782228	1	rs12635488	ENSG00000242551.2	POU5F1P6	5.26	3.21e-07	0.000242	0.4	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128674735~128677005:-
SARC	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-5.26	3.22e-07	0.000242	-0.39	-0.33	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
SARC	cis	rs17270561	0.609	rs2000351	ENSG00000272810.1	U91328.22	-5.26	3.22e-07	0.000243	-0.32	-0.33	Iron status biomarkers;	chr6:25759555	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4712968	ENSG00000272810.1	U91328.22	-5.26	3.22e-07	0.000243	-0.32	-0.33	Iron status biomarkers;	chr6:25760116	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs7769908	ENSG00000272810.1	U91328.22	-5.26	3.22e-07	0.000243	-0.32	-0.33	Iron status biomarkers;	chr6:25760311	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs7770037	ENSG00000272810.1	U91328.22	-5.26	3.22e-07	0.000243	-0.32	-0.33	Iron status biomarkers;	chr6:25760363	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9348695	ENSG00000272810.1	U91328.22	-5.26	3.22e-07	0.000243	-0.32	-0.33	Iron status biomarkers;	chr6:25762782	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs2000350	ENSG00000272810.1	U91328.22	-5.26	3.22e-07	0.000243	-0.32	-0.33	Iron status biomarkers;	chr6:25762926	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs1318016	ENSG00000272810.1	U91328.22	-5.26	3.22e-07	0.000243	-0.32	-0.33	Iron status biomarkers;	chr6:25764476	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs1892245	ENSG00000272810.1	U91328.22	-5.26	3.22e-07	0.000243	-0.32	-0.33	Iron status biomarkers;	chr6:25764605	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs1317816	ENSG00000272810.1	U91328.22	-5.26	3.22e-07	0.000243	-0.32	-0.33	Iron status biomarkers;	chr6:25765162	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.583	rs6937800	ENSG00000272810.1	U91328.22	-5.26	3.22e-07	0.000243	-0.32	-0.33	Iron status biomarkers;	chr6:25765715	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs3778272	ENSG00000272810.1	U91328.22	-5.26	3.22e-07	0.000243	-0.32	-0.33	Iron status biomarkers;	chr6:25767433	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs2275905	ENSG00000272810.1	U91328.22	-5.26	3.22e-07	0.000243	-0.32	-0.33	Iron status biomarkers;	chr6:25767878	chr6:26013241~26013757:+
SARC	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-5.26	3.23e-07	0.000243	-0.42	-0.33	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
SARC	cis	rs1865760	0.566	rs10807006	ENSG00000272810.1	U91328.22	-5.26	3.23e-07	0.000243	-0.31	-0.33	Height;	chr6:26048524	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs7772312	ENSG00000272810.1	U91328.22	-5.26	3.23e-07	0.000243	-0.31	-0.33	Height;	chr6:26049388	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs9379821	ENSG00000272810.1	U91328.22	-5.26	3.23e-07	0.000243	-0.31	-0.33	Height;	chr6:26054040	chr6:26013241~26013757:+
SARC	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	5.26	3.23e-07	0.000243	0.41	0.33	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	5.26	3.23e-07	0.000243	0.41	0.33	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
SARC	cis	rs75422866	0.541	rs61918136	ENSG00000257433.4	RP1-197B17.3	5.26	3.24e-07	0.000244	0.58	0.33	Pneumonia;	chr12:47566798	chr12:47706085~47742294:+
SARC	cis	rs7246657	0.943	rs1015849	ENSG00000276846.1	CTD-3220F14.3	5.26	3.24e-07	0.000244	0.44	0.33	Coronary artery calcification;	chr19:37455278	chr19:37314868~37315620:-
SARC	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	5.26	3.25e-07	0.000245	0.42	0.33	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
SARC	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-5.26	3.26e-07	0.000245	-0.35	-0.33	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-5.26	3.26e-07	0.000245	-0.35	-0.33	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
SARC	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-5.26	3.26e-07	0.000245	-0.36	-0.33	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
SARC	cis	rs6991838	0.806	rs11781358	ENSG00000272010.1	CTD-3025N20.3	5.26	3.26e-07	0.000245	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65591850~65592472:-
SARC	cis	rs4713118	0.955	rs9468206	ENSG00000219392.1	RP1-265C24.5	-5.26	3.28e-07	0.000246	-0.47	-0.33	Parkinson's disease;	chr6:27722674	chr6:28115628~28116551:+
SARC	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	5.26	3.28e-07	0.000246	0.49	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
SARC	cis	rs193541	0.545	rs112390044	ENSG00000263432.2	RN7SL689P	-5.26	3.28e-07	0.000247	-0.42	-0.33	Glucose homeostasis traits;	chr5:122976307	chr5:123022487~123022783:-
SARC	cis	rs4372836	1	rs7562170	ENSG00000226833.4	AC097724.3	-5.26	3.28e-07	0.000247	-0.31	-0.33	Body mass index;	chr2:28720650	chr2:28708953~28736205:-
SARC	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-5.26	3.3e-07	0.000248	-0.31	-0.33	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
SARC	cis	rs4862750	0.832	rs6836426	ENSG00000250971.1	RP11-696F12.1	5.26	3.3e-07	0.000248	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr4:186976683	chr4:187060099~187060930:+
SARC	cis	rs9494145	0.526	rs9389272	ENSG00000232876.1	CTA-212D2.2	-5.26	3.3e-07	0.000248	-0.51	-0.33	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135138699	chr6:135055033~135060550:+
SARC	cis	rs6570726	0.846	rs446031	ENSG00000270638.1	RP3-466P17.1	5.26	3.3e-07	0.000248	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145564456	chr6:145735570~145737218:+
SARC	cis	rs198389	0.568	rs12406667	ENSG00000242349.4	NPPA-AS1	5.26	3.31e-07	0.000249	0.33	0.33	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813794	chr1:11841017~11848079:+
SARC	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-5.26	3.32e-07	0.000249	-0.4	-0.33	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
SARC	cis	rs77204473	1	rs12293755	ENSG00000254851.1	RP11-109L13.1	5.26	3.33e-07	0.00025	0.7	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116948548	chr11:117135528~117138582:+
SARC	cis	rs2439831	0.867	rs8039638	ENSG00000205771.5	CATSPER2P1	-5.26	3.33e-07	0.00025	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43342207	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs28415933	ENSG00000205771.5	CATSPER2P1	-5.26	3.33e-07	0.00025	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43343602	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs12324572	ENSG00000205771.5	CATSPER2P1	-5.26	3.33e-07	0.00025	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43344002	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs2412780	ENSG00000205771.5	CATSPER2P1	-5.26	3.33e-07	0.00025	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43363596	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs2412779	ENSG00000205771.5	CATSPER2P1	-5.26	3.33e-07	0.00025	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43363729	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs2899082	ENSG00000205771.5	CATSPER2P1	-5.26	3.33e-07	0.00025	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43363845	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs3213991	ENSG00000205771.5	CATSPER2P1	-5.26	3.33e-07	0.00025	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43378082	chr15:43726918~43747094:-
SARC	cis	rs7246657	0.943	rs7248733	ENSG00000276846.1	CTD-3220F14.3	5.26	3.34e-07	0.00025	0.43	0.33	Coronary artery calcification;	chr19:37505459	chr19:37314868~37315620:-
SARC	cis	rs2562456	0.917	rs11085463	ENSG00000268081.1	RP11-678G14.2	5.26	3.34e-07	0.00025	0.48	0.33	Pain;	chr19:21568500	chr19:21554640~21569237:-
SARC	cis	rs11822910	0.815	rs11229028	ENSG00000265566.2	RN7SL605P	5.26	3.34e-07	0.00025	0.44	0.33	Platelet distribution width;	chr11:57426445	chr11:57528085~57528365:-
SARC	cis	rs7216064	1	rs7223813	ENSG00000278219.1	AC145343.1	-5.25	3.35e-07	0.000251	-0.41	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67949724	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.954	rs4790973	ENSG00000278219.1	AC145343.1	-5.25	3.35e-07	0.000251	-0.41	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67955017	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.953	rs12601759	ENSG00000278219.1	AC145343.1	-5.25	3.35e-07	0.000251	-0.41	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67959168	chr17:68101538~68101639:+
SARC	cis	rs6570726	0.846	rs9399559	ENSG00000270638.1	RP3-466P17.1	5.25	3.36e-07	0.000251	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs9376956	ENSG00000270638.1	RP3-466P17.1	5.25	3.36e-07	0.000251	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.658	rs6570706	ENSG00000270638.1	RP3-466P17.1	5.25	3.36e-07	0.000251	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145735570~145737218:+
SARC	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-5.25	3.36e-07	0.000252	-0.36	-0.33	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
SARC	cis	rs77204473	0.744	rs12273545	ENSG00000254851.1	RP11-109L13.1	5.25	3.36e-07	0.000252	0.79	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040296	chr11:117135528~117138582:+
SARC	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	5.25	3.37e-07	0.000253	0.49	0.33	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	5.25	3.37e-07	0.000253	0.49	0.33	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	5.25	3.37e-07	0.000253	0.49	0.33	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
SARC	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	5.25	3.37e-07	0.000253	0.36	0.33	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	5.25	3.37e-07	0.000253	0.36	0.33	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
SARC	cis	rs7430456	0.967	rs6780021	ENSG00000225790.1	RP11-2L8.1	-5.25	3.37e-07	0.000253	-0.33	-0.33	Breast cancer;	chr3:177739677	chr3:177934823~177937662:+
SARC	cis	rs1865760	0.508	rs9379820	ENSG00000272810.1	U91328.22	-5.25	3.38e-07	0.000253	-0.31	-0.33	Height;	chr6:26049696	chr6:26013241~26013757:+
SARC	cis	rs6991838	0.806	rs35284121	ENSG00000200714.1	Y_RNA	5.25	3.38e-07	0.000253	0.34	0.33	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65592731~65592820:+
SARC	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-5.25	3.39e-07	0.000253	-0.31	-0.33	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
SARC	cis	rs7809950	0.953	rs1468336	ENSG00000238832.1	snoU109	5.25	3.39e-07	0.000254	0.39	0.33	Coronary artery disease;	chr7:107567805	chr7:107603363~107603507:+
SARC	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-5.25	3.4e-07	0.000254	-0.52	-0.33	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
SARC	cis	rs2439831	0.681	rs498837	ENSG00000205771.5	CATSPER2P1	-5.25	3.41e-07	0.000254	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43315826	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.681	rs540031	ENSG00000205771.5	CATSPER2P1	-5.25	3.41e-07	0.000254	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43316657	chr15:43726918~43747094:-
SARC	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-5.25	3.41e-07	0.000255	-0.36	-0.33	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
SARC	cis	rs4372836	0.828	rs6728459	ENSG00000226833.4	AC097724.3	5.25	3.43e-07	0.000256	0.32	0.33	Body mass index;	chr2:28776470	chr2:28708953~28736205:-
SARC	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	5.25	3.43e-07	0.000256	0.41	0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
SARC	cis	rs7246657	0.943	rs10415358	ENSG00000276846.1	CTD-3220F14.3	5.25	3.43e-07	0.000256	0.43	0.33	Coronary artery calcification;	chr19:37317961	chr19:37314868~37315620:-
SARC	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	5.25	3.43e-07	0.000256	0.37	0.33	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
SARC	cis	rs7246657	0.943	rs13343502	ENSG00000276846.1	CTD-3220F14.3	5.25	3.44e-07	0.000256	0.44	0.33	Coronary artery calcification;	chr19:37471390	chr19:37314868~37315620:-
SARC	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-5.25	3.44e-07	0.000256	-0.32	-0.33	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
SARC	cis	rs7216064	0.953	rs62086044	ENSG00000278219.1	AC145343.1	-5.25	3.44e-07	0.000257	-0.4	-0.33	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67974721	chr17:68101538~68101639:+
SARC	cis	rs2179367	0.959	rs9373592	ENSG00000231760.4	RP11-350J20.5	5.25	3.44e-07	0.000257	0.4	0.33	Dupuytren's disease;	chr6:149412119	chr6:149796151~149826294:-
SARC	cis	rs1865760	0.964	rs6932113	ENSG00000272810.1	U91328.22	-5.25	3.45e-07	0.000257	-0.33	-0.33	Height;	chr6:25912870	chr6:26013241~26013757:+
SARC	cis	rs9890032	0.532	rs1808257	ENSG00000263531.1	RP13-753N3.1	5.25	3.45e-07	0.000257	0.43	0.33	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30863921~30864940:-
SARC	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-5.25	3.45e-07	0.000258	-0.42	-0.33	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
SARC	cis	rs1823874	0.886	rs2123933	ENSG00000182397.13	DNM1P46	-5.25	3.45e-07	0.000258	-0.38	-0.33	IgG glycosylation;	chr15:99824131	chr15:99790156~99806927:-
SARC	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-5.25	3.46e-07	0.000258	-0.44	-0.33	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
SARC	cis	rs6570726	0.846	rs1935616	ENSG00000270638.1	RP3-466P17.1	5.25	3.46e-07	0.000258	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.846	rs9376954	ENSG00000270638.1	RP3-466P17.1	5.25	3.46e-07	0.000258	0.26	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145735570~145737218:+
SARC	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-5.25	3.46e-07	0.000258	-0.5	-0.33	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
SARC	cis	rs1823913	1	rs1454749	ENSG00000227542.1	AC092614.2	5.25	3.47e-07	0.000258	0.36	0.33	Obesity-related traits;	chr2:191240909	chr2:191229165~191246172:-
SARC	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	5.25	3.47e-07	0.000259	0.42	0.33	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
SARC	cis	rs77204473	0.744	rs75216569	ENSG00000254851.1	RP11-109L13.1	5.25	3.47e-07	0.000259	0.79	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117036999	chr11:117135528~117138582:+
SARC	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	5.25	3.47e-07	0.000259	0.49	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
SARC	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	5.25	3.47e-07	0.000259	0.49	0.33	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
SARC	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	5.25	3.47e-07	0.000259	0.49	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
SARC	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-5.25	3.47e-07	0.000259	-0.32	-0.33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
SARC	cis	rs9890032	1	rs28539246	ENSG00000263531.1	RP13-753N3.1	5.25	3.48e-07	0.000259	0.39	0.33	Hip circumference adjusted for BMI;	chr17:30899612	chr17:30863921~30864940:-
SARC	cis	rs9890032	0.967	rs9897628	ENSG00000263531.1	RP13-753N3.1	5.25	3.48e-07	0.000259	0.39	0.33	Hip circumference adjusted for BMI;	chr17:30899634	chr17:30863921~30864940:-
SARC	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-5.25	3.48e-07	0.00026	-0.35	-0.33	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
SARC	cis	rs193541	0.545	rs12518979	ENSG00000263432.2	RN7SL689P	-5.25	3.49e-07	0.00026	-0.4	-0.33	Glucose homeostasis traits;	chr5:122846092	chr5:123022487~123022783:-
SARC	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-5.25	3.49e-07	0.00026	-0.34	-0.33	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-5.25	3.49e-07	0.00026	-0.34	-0.33	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-5.25	3.49e-07	0.00026	-0.34	-0.33	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-5.25	3.49e-07	0.00026	-0.34	-0.33	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-5.25	3.49e-07	0.00026	-0.34	-0.33	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-5.25	3.49e-07	0.00026	-0.34	-0.33	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
SARC	cis	rs8005677	1	rs1956880	ENSG00000257285.4	RP11-298I3.1	5.25	3.5e-07	0.000261	0.3	0.32	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:22929609~22955562:+
SARC	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-5.24	3.51e-07	0.000262	-0.43	-0.32	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
SARC	cis	rs710913	0.745	rs67563067	ENSG00000182109.6	RP11-69E11.4	-5.24	3.51e-07	0.000262	-0.31	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581323	chr1:39522280~39546187:-
SARC	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-5.24	3.52e-07	0.000262	-0.37	-0.32	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-5.24	3.52e-07	0.000262	-0.37	-0.32	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
SARC	cis	rs9309473	1	rs7585004	ENSG00000163016.8	ALMS1P	5.24	3.53e-07	0.000262	0.43	0.32	Metabolite levels;	chr2:73439517	chr2:73644919~73685576:+
SARC	cis	rs4862750	0.794	rs7692427	ENSG00000250971.1	RP11-696F12.1	5.24	3.53e-07	0.000262	0.39	0.32	Lobe attachment (rater-scored or self-reported);	chr4:186980573	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.832	rs9995958	ENSG00000250971.1	RP11-696F12.1	5.24	3.53e-07	0.000262	0.39	0.32	Lobe attachment (rater-scored or self-reported);	chr4:186980610	chr4:187060099~187060930:+
SARC	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-5.24	3.53e-07	0.000263	-0.33	-0.32	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
SARC	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-5.24	3.53e-07	0.000263	-0.33	-0.32	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
SARC	cis	rs4968361	1	rs4968361	ENSG00000266992.1	DHX40P1	5.24	3.54e-07	0.000263	0.59	0.32	Schizophrenia;	chr17:59425467	chr17:59976009~60002384:-
SARC	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-5.24	3.54e-07	0.000263	-0.35	-0.32	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
SARC	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-5.24	3.54e-07	0.000263	-0.39	-0.32	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
SARC	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	5.24	3.55e-07	0.000264	0.42	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
SARC	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-5.24	3.56e-07	0.000264	-0.38	-0.32	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
SARC	cis	rs2946504	0.861	rs2954171	ENSG00000251468.2	RP11-369K16.1	-5.24	3.56e-07	0.000265	-0.35	-0.32	Type 2 diabetes;	chr8:12956087	chr8:12958387~12962200:+
SARC	cis	rs4713118	0.869	rs7776351	ENSG00000219392.1	RP1-265C24.5	5.24	3.56e-07	0.000265	0.46	0.32	Parkinson's disease;	chr6:27758952	chr6:28115628~28116551:+
SARC	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	5.24	3.56e-07	0.000265	0.35	0.32	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
SARC	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	5.24	3.56e-07	0.000265	0.35	0.32	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
SARC	cis	rs7587476	0.906	rs3768713	ENSG00000229267.2	AC072062.1	-5.24	3.57e-07	0.000265	-0.33	-0.32	Neuroblastoma;	chr2:214772781	chr2:214810229~214963274:+
SARC	cis	rs2562456	0.833	rs62107479	ENSG00000268081.1	RP11-678G14.2	5.24	3.57e-07	0.000265	0.53	0.32	Pain;	chr19:21323962	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62107531	ENSG00000268081.1	RP11-678G14.2	5.24	3.57e-07	0.000265	0.53	0.32	Pain;	chr19:21326263	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs55756795	ENSG00000268081.1	RP11-678G14.2	5.24	3.57e-07	0.000265	0.53	0.32	Pain;	chr19:21327257	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs11669790	ENSG00000268081.1	RP11-678G14.2	5.24	3.57e-07	0.000265	0.53	0.32	Pain;	chr19:21328980	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62107534	ENSG00000268081.1	RP11-678G14.2	5.24	3.57e-07	0.000265	0.53	0.32	Pain;	chr19:21329389	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.793	rs7258473	ENSG00000268081.1	RP11-678G14.2	5.24	3.57e-07	0.000265	0.53	0.32	Pain;	chr19:21331795	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.793	rs2219839	ENSG00000268081.1	RP11-678G14.2	5.24	3.57e-07	0.000265	0.53	0.32	Pain;	chr19:21333520	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62107539	ENSG00000268081.1	RP11-678G14.2	5.24	3.57e-07	0.000265	0.53	0.32	Pain;	chr19:21334910	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs76646508	ENSG00000268081.1	RP11-678G14.2	5.24	3.57e-07	0.000265	0.53	0.32	Pain;	chr19:21335247	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs77576302	ENSG00000268081.1	RP11-678G14.2	5.24	3.57e-07	0.000265	0.53	0.32	Pain;	chr19:21335385	chr19:21554640~21569237:-
SARC	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	5.24	3.58e-07	0.000266	0.48	0.32	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
SARC	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-5.24	3.58e-07	0.000266	-0.33	-0.32	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-5.24	3.58e-07	0.000266	-0.33	-0.32	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
SARC	cis	rs448720	0.532	rs8033140	ENSG00000259410.4	RP11-34F13.3	5.24	3.6e-07	0.000267	0.39	0.32	Cognitive performance;	chr15:67906403	chr15:67832725~67873866:+
SARC	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	5.24	3.61e-07	0.000268	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
SARC	cis	rs4862750	0.874	rs6822062	ENSG00000249742.1	RP11-217E13.1	-5.24	3.61e-07	0.000268	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186974399	chr4:186979490~187021973:-
SARC	cis	rs2117029	0.862	rs10875915	ENSG00000258017.1	RP11-386G11.10	-5.24	3.61e-07	0.000268	-0.34	-0.32	Intelligence (multi-trait analysis);	chr12:49036311	chr12:49127782~49147869:+
SARC	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	5.24	3.61e-07	0.000268	0.42	0.32	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
SARC	cis	rs710913	0.618	rs11206437	ENSG00000182109.6	RP11-69E11.4	5.24	3.61e-07	0.000268	0.32	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613039	chr1:39522280~39546187:-
SARC	cis	rs7772486	0.625	rs9390355	ENSG00000270638.1	RP3-466P17.1	-5.24	3.62e-07	0.000268	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.658	rs4895683	ENSG00000270638.1	RP3-466P17.1	-5.24	3.62e-07	0.000268	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.625	rs2050027	ENSG00000270638.1	RP3-466P17.1	-5.24	3.62e-07	0.000268	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145735570~145737218:+
SARC	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-5.24	3.62e-07	0.000269	-0.42	-0.32	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
SARC	cis	rs4794202	0.523	rs11871969	ENSG00000264920.1	RP11-6N17.4	-5.24	3.62e-07	0.000269	-0.44	-0.32	Alzheimer's disease (cognitive decline);	chr17:47915256	chr17:47891255~47895812:-
SARC	cis	rs7712401	0.645	rs154497	ENSG00000263432.2	RN7SL689P	5.24	3.62e-07	0.000269	0.41	0.32	Mean platelet volume;	chr5:122885725	chr5:123022487~123022783:-
SARC	cis	rs9322193	0.566	rs9397070	ENSG00000223701.3	RAET1E-AS1	-5.24	3.63e-07	0.000269	-0.39	-0.32	Lung cancer;	chr6:149922073	chr6:149884431~149919508:+
SARC	cis	rs4372836	0.894	rs55877710	ENSG00000226833.4	AC097724.3	-5.24	3.63e-07	0.000269	-0.32	-0.32	Body mass index;	chr2:28706442	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.929	rs55883854	ENSG00000226833.4	AC097724.3	-5.24	3.63e-07	0.000269	-0.32	-0.32	Body mass index;	chr2:28706675	chr2:28708953~28736205:-
SARC	cis	rs4862750	0.872	rs13101408	ENSG00000249742.1	RP11-217E13.1	-5.24	3.64e-07	0.00027	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186973623	chr4:186979490~187021973:-
SARC	cis	rs7246657	0.943	rs4803347	ENSG00000276846.1	CTD-3220F14.3	5.24	3.65e-07	0.000271	0.42	0.32	Coronary artery calcification;	chr19:37357115	chr19:37314868~37315620:-
SARC	cis	rs1799949	1	rs11659028	ENSG00000267681.1	CTD-3199J23.6	-5.24	3.66e-07	0.000271	-0.38	-0.32	Menopause (age at onset);	chr17:43043008	chr17:43144956~43145255:+
SARC	cis	rs2117029	0.898	rs10875914	ENSG00000258017.1	RP11-386G11.10	-5.24	3.66e-07	0.000271	-0.34	-0.32	Intelligence (multi-trait analysis);	chr12:49028311	chr12:49127782~49147869:+
SARC	cis	rs4372836	1	rs6710959	ENSG00000226833.4	AC097724.3	5.24	3.67e-07	0.000272	0.31	0.32	Body mass index;	chr2:28735737	chr2:28708953~28736205:-
SARC	cis	rs4372836	1	rs4640348	ENSG00000226833.4	AC097724.3	5.24	3.67e-07	0.000272	0.31	0.32	Body mass index;	chr2:28742613	chr2:28708953~28736205:-
SARC	cis	rs4372836	1	rs2169751	ENSG00000226833.4	AC097724.3	5.24	3.67e-07	0.000272	0.31	0.32	Body mass index;	chr2:28743892	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.93	rs7589860	ENSG00000226833.4	AC097724.3	5.24	3.67e-07	0.000272	0.31	0.32	Body mass index;	chr2:28744782	chr2:28708953~28736205:-
SARC	cis	rs2946504	0.861	rs2946501	ENSG00000251468.2	RP11-369K16.1	5.23	3.69e-07	0.000273	0.34	0.32	Type 2 diabetes;	chr8:12955922	chr8:12958387~12962200:+
SARC	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	5.23	3.69e-07	0.000273	0.36	0.32	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
SARC	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	5.23	3.69e-07	0.000273	0.36	0.32	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
SARC	cis	rs9828933	0.678	rs704366	ENSG00000280620.1	SCAANT1	-5.23	3.7e-07	0.000274	-0.46	-0.32	Type 2 diabetes;	chr3:63885972	chr3:63911518~63911772:-
SARC	cis	rs5769707	0.609	rs2071890	ENSG00000235111.1	RP1-29C18.8	-5.23	3.7e-07	0.000274	-0.4	-0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49612657~49615716:-
SARC	cis	rs62103177	0.525	rs8086024	ENSG00000261126.6	RP11-795F19.1	-5.23	3.7e-07	0.000274	-0.3	-0.32	Opioid sensitivity;	chr18:79986623	chr18:80046900~80095482:+
SARC	cis	rs4372836	1	rs34409160	ENSG00000226833.4	AC097724.3	-5.23	3.71e-07	0.000274	-0.31	-0.32	Body mass index;	chr2:28720999	chr2:28708953~28736205:-
SARC	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-5.23	3.71e-07	0.000274	-0.41	-0.32	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
SARC	cis	rs2404602	0.735	rs4886798	ENSG00000259422.1	RP11-593F23.1	5.23	3.71e-07	0.000274	0.4	0.32	Blood metabolite levels;	chr15:76380885	chr15:76174891~76181486:-
SARC	cis	rs587080	0.624	rs512715	ENSG00000245532.5	NEAT1	-5.23	3.72e-07	0.000275	-0.27	-0.32	Plateletcrit;	chr11:65423737	chr11:65422774~65445540:+
SARC	cis	rs8031584	0.918	rs61997139	ENSG00000260382.1	RP11-540B6.2	5.23	3.72e-07	0.000275	0.39	0.32	Huntington's disease progression;	chr15:30981399	chr15:30882267~30883231:-
SARC	cis	rs2439831	0.867	rs4583210	ENSG00000205771.5	CATSPER2P1	-5.23	3.73e-07	0.000276	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43368727	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs28461955	ENSG00000205771.5	CATSPER2P1	-5.23	3.73e-07	0.000276	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43369261	chr15:43726918~43747094:-
SARC	cis	rs7772486	0.622	rs1292333	ENSG00000270638.1	RP3-466P17.1	-5.23	3.73e-07	0.000276	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145735570~145737218:+
SARC	cis	rs1823913	1	rs6749232	ENSG00000227542.1	AC092614.2	-5.23	3.75e-07	0.000277	-0.35	-0.32	Obesity-related traits;	chr2:191250326	chr2:191229165~191246172:-
SARC	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-5.23	3.75e-07	0.000277	-0.33	-0.32	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
SARC	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	5.23	3.75e-07	0.000277	0.46	0.32	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
SARC	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-5.23	3.75e-07	0.000277	-0.35	-0.32	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
SARC	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-5.23	3.77e-07	0.000278	-0.33	-0.32	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-5.23	3.77e-07	0.000278	-0.33	-0.32	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
SARC	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-5.23	3.77e-07	0.000278	-0.4	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
SARC	cis	rs763567	0.605	rs619456	ENSG00000271811.1	RP1-79C4.4	-5.23	3.77e-07	0.000278	-0.39	-0.32	Tonsillectomy;	chr1:170616691	chr1:170667381~170669425:+
SARC	cis	rs4934494	1	rs4934494	ENSG00000240996.1	RP11-80H5.7	-5.23	3.77e-07	0.000279	-0.33	-0.32	Red blood cell count;	chr10:89687662	chr10:89694295~89697928:-
SARC	cis	rs1865760	1	rs7757666	ENSG00000272810.1	U91328.22	-5.23	3.77e-07	0.000279	-0.32	-0.32	Height;	chr6:25902398	chr6:26013241~26013757:+
SARC	cis	rs1865760	1	rs6910138	ENSG00000272810.1	U91328.22	-5.23	3.77e-07	0.000279	-0.32	-0.32	Height;	chr6:25904124	chr6:26013241~26013757:+
SARC	cis	rs1865760	1	rs6910174	ENSG00000272810.1	U91328.22	-5.23	3.77e-07	0.000279	-0.32	-0.32	Height;	chr6:25904186	chr6:26013241~26013757:+
SARC	cis	rs710913	0.717	rs2243761	ENSG00000182109.6	RP11-69E11.4	-5.23	3.78e-07	0.000279	-0.3	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39522280~39546187:-
SARC	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-5.23	3.78e-07	0.000279	-0.43	-0.32	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
SARC	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	5.23	3.78e-07	0.000279	0.35	0.32	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
SARC	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-5.23	3.79e-07	0.000279	-0.4	-0.32	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
SARC	cis	rs1823913	0.599	rs6732976	ENSG00000227542.1	AC092614.2	-5.23	3.8e-07	0.00028	-0.36	-0.32	Obesity-related traits;	chr2:191281004	chr2:191229165~191246172:-
SARC	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	5.23	3.8e-07	0.00028	0.33	0.32	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
SARC	cis	rs7809950	1	rs2107713	ENSG00000238832.1	snoU109	-5.23	3.8e-07	0.00028	-0.38	-0.32	Coronary artery disease;	chr7:107591924	chr7:107603363~107603507:+
SARC	cis	rs7216064	1	rs8081517	ENSG00000278219.1	AC145343.1	-5.23	3.8e-07	0.00028	-0.38	-0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67849581	chr17:68101538~68101639:+
SARC	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-5.23	3.81e-07	0.000281	-0.39	-0.32	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
SARC	cis	rs198389	0.589	rs535107	ENSG00000242349.4	NPPA-AS1	5.23	3.82e-07	0.000281	0.33	0.32	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11829411	chr1:11841017~11848079:+
SARC	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-5.23	3.82e-07	0.000281	-0.35	-0.32	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
SARC	cis	rs9494145	0.526	rs7738935	ENSG00000232876.1	CTA-212D2.2	-5.23	3.83e-07	0.000282	-0.49	-0.32	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135152677	chr6:135055033~135060550:+
SARC	cis	rs2439831	0.681	rs526450	ENSG00000205771.5	CATSPER2P1	-5.23	3.83e-07	0.000282	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43307127	chr15:43726918~43747094:-
SARC	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	5.23	3.83e-07	0.000282	0.38	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
SARC	cis	rs12022452	0.73	rs2297755	ENSG00000238287.1	RP11-656D10.3	-5.23	3.84e-07	0.000282	-0.53	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40493157~40508661:-
SARC	cis	rs2404602	0.552	rs11636612	ENSG00000259422.1	RP11-593F23.1	-5.23	3.84e-07	0.000282	-0.43	-0.32	Blood metabolite levels;	chr15:76667189	chr15:76174891~76181486:-
SARC	cis	rs2946504	0.861	rs2946502	ENSG00000251468.2	RP11-369K16.1	-5.23	3.84e-07	0.000283	-0.34	-0.32	Type 2 diabetes;	chr8:12955445	chr8:12958387~12962200:+
SARC	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	5.23	3.85e-07	0.000283	0.45	0.32	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
SARC	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-5.23	3.85e-07	0.000283	-0.37	-0.32	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
SARC	cis	rs8062405	1	rs8061590	ENSG00000251417.2	RP11-1348G14.4	-5.23	3.86e-07	0.000284	-0.32	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28802743~28817828:+
SARC	cis	rs1075232	1	rs67634762	ENSG00000215302.7	CTD-3092A11.1	-5.22	3.87e-07	0.000284	-0.68	-0.32	Survival in colorectal cancer (non-distant metastatic);	chr15:31455852	chr15:30470779~30507623:+
SARC	cis	rs13631	0.965	rs7853589	ENSG00000268996.3	MAN1B1-AS1	-5.22	3.88e-07	0.000285	-0.33	-0.32	Cerebrospinal fluid biomarker levels;	chr9:137109392	chr9:137084946~137086817:-
SARC	cis	rs9309473	0.95	rs6546849	ENSG00000163016.8	ALMS1P	5.22	3.9e-07	0.000287	0.4	0.32	Metabolite levels;	chr2:73603910	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.851	rs6546850	ENSG00000163016.8	ALMS1P	5.22	3.9e-07	0.000287	0.4	0.32	Metabolite levels;	chr2:73604020	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.898	rs6546852	ENSG00000163016.8	ALMS1P	5.22	3.9e-07	0.000287	0.4	0.32	Metabolite levels;	chr2:73606304	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.95	rs6546853	ENSG00000163016.8	ALMS1P	5.22	3.9e-07	0.000287	0.4	0.32	Metabolite levels;	chr2:73606612	chr2:73644919~73685576:+
SARC	cis	rs2439831	0.681	rs511673	ENSG00000205771.5	CATSPER2P1	-5.22	3.92e-07	0.000288	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43326665	chr15:43726918~43747094:-
SARC	cis	rs9399135	0.517	rs1041478	ENSG00000232876.1	CTA-212D2.2	-5.22	3.93e-07	0.000288	-0.36	-0.32	Red blood cell count;	chr6:135130059	chr6:135055033~135060550:+
SARC	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	5.22	3.93e-07	0.000289	0.37	0.32	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
SARC	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-5.22	3.93e-07	0.000289	-0.35	-0.32	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
SARC	cis	rs1823913	0.895	rs10931491	ENSG00000227542.1	AC092614.2	-5.22	3.93e-07	0.000289	-0.35	-0.32	Obesity-related traits;	chr2:191256087	chr2:191229165~191246172:-
SARC	cis	rs1823913	1	rs11681777	ENSG00000227542.1	AC092614.2	-5.22	3.93e-07	0.000289	-0.35	-0.32	Obesity-related traits;	chr2:191256741	chr2:191229165~191246172:-
SARC	cis	rs1823913	1	rs1840377	ENSG00000227542.1	AC092614.2	-5.22	3.93e-07	0.000289	-0.35	-0.32	Obesity-related traits;	chr2:191257992	chr2:191229165~191246172:-
SARC	cis	rs1823913	1	rs4853564	ENSG00000227542.1	AC092614.2	-5.22	3.93e-07	0.000289	-0.35	-0.32	Obesity-related traits;	chr2:191258939	chr2:191229165~191246172:-
SARC	cis	rs1823913	1	rs4853565	ENSG00000227542.1	AC092614.2	-5.22	3.93e-07	0.000289	-0.35	-0.32	Obesity-related traits;	chr2:191259020	chr2:191229165~191246172:-
SARC	cis	rs1823913	1	rs4853462	ENSG00000227542.1	AC092614.2	-5.22	3.93e-07	0.000289	-0.35	-0.32	Obesity-related traits;	chr2:191259078	chr2:191229165~191246172:-
SARC	cis	rs2562456	0.876	rs10424079	ENSG00000268081.1	RP11-678G14.2	5.22	3.95e-07	0.00029	0.53	0.32	Pain;	chr19:21406377	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.876	rs2359144	ENSG00000268081.1	RP11-678G14.2	5.22	3.95e-07	0.00029	0.53	0.32	Pain;	chr19:21407834	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.876	rs4638726	ENSG00000268081.1	RP11-678G14.2	5.22	3.95e-07	0.00029	0.53	0.32	Pain;	chr19:21409710	chr19:21554640~21569237:-
SARC	cis	rs8031584	0.958	rs11293	ENSG00000260382.1	RP11-540B6.2	5.22	3.96e-07	0.00029	0.4	0.32	Huntington's disease progression;	chr15:30942778	chr15:30882267~30883231:-
SARC	cis	rs1865760	0.534	rs1541988	ENSG00000272462.2	U91328.19	-5.22	3.97e-07	0.000291	-0.3	-0.32	Height;	chr6:25950576	chr6:25992662~26001775:+
SARC	cis	rs4862750	0.872	rs56389997	ENSG00000249742.1	RP11-217E13.1	-5.22	3.98e-07	0.000292	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186973642	chr4:186979490~187021973:-
SARC	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-5.22	3.98e-07	0.000292	-0.38	-0.32	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
SARC	cis	rs7772486	0.79	rs9485024	ENSG00000270638.1	RP3-466P17.1	-5.22	3.99e-07	0.000292	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145735570~145737218:+
SARC	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-5.22	3.99e-07	0.000292	-0.31	-0.32	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
SARC	cis	rs77204473	1	rs12278117	ENSG00000254851.1	RP11-109L13.1	5.22	3.99e-07	0.000292	0.73	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117135528~117138582:+
SARC	cis	rs2029362	0.636	rs11030101	ENSG00000245573.6	BDNF-AS	5.22	4e-07	0.000293	0.29	0.32	Total body bone mineral density;	chr11:27659197	chr11:27506838~27698174:+
SARC	cis	rs7809950	1	rs2894475	ENSG00000238832.1	snoU109	-5.22	4.01e-07	0.000294	-0.38	-0.32	Coronary artery disease;	chr7:107622113	chr7:107603363~107603507:+
SARC	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-5.22	4.03e-07	0.000295	-0.35	-0.32	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
SARC	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-5.22	4.03e-07	0.000295	-0.34	-0.32	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
SARC	cis	rs1134634	0.52	rs11932730	ENSG00000273133.1	RP11-799M12.2	5.22	4.03e-07	0.000295	0.41	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15564135	chr4:15563698~15564253:-
SARC	cis	rs890448	0.828	rs2471680	ENSG00000254531.1	FLJ20021	5.22	4.03e-07	0.000295	0.33	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426586	chr4:101347780~101348883:+
SARC	cis	rs739310	0.556	rs2051652	ENSG00000206028.1	CTA-373H7.7	-5.22	4.04e-07	0.000296	-0.49	-0.32	Obesity-related traits;	chr22:26686016	chr22:26667693~26672654:-
SARC	cis	rs890448	0.796	rs7698946	ENSG00000254531.1	FLJ20021	5.22	4.04e-07	0.000296	0.34	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101436919	chr4:101347780~101348883:+
SARC	cis	rs9818758	0.607	rs34326553	ENSG00000225399.4	RP11-3B7.1	-5.22	4.05e-07	0.000297	-0.61	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49096996	chr3:49260085~49261316:+
SARC	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-5.22	4.05e-07	0.000297	-0.33	-0.32	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
SARC	cis	rs2562456	0.752	rs7258562	ENSG00000268081.1	RP11-678G14.2	5.21	4.06e-07	0.000297	0.51	0.32	Pain;	chr19:21331762	chr19:21554640~21569237:-
SARC	cis	rs783540	0.521	rs1259176	ENSG00000275695.1	UBE2Q2P6	-5.21	4.08e-07	0.000298	-0.35	-0.32	Schizophrenia;	chr15:82602149	chr15:82445719~82454837:+
SARC	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	5.21	4.08e-07	0.000298	0.39	0.32	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
SARC	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-5.21	4.08e-07	0.000298	-0.4	-0.32	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
SARC	cis	rs2179367	0.959	rs521845	ENSG00000231760.4	RP11-350J20.5	-5.21	4.08e-07	0.000298	-0.39	-0.32	Dupuytren's disease;	chr6:149350562	chr6:149796151~149826294:-
SARC	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	5.21	4.09e-07	0.000299	0.45	0.32	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
SARC	cis	rs4372836	0.897	rs6707130	ENSG00000226833.4	AC097724.3	5.21	4.09e-07	0.000299	0.31	0.32	Body mass index;	chr2:28750410	chr2:28708953~28736205:-
SARC	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-5.21	4.09e-07	0.000299	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
SARC	cis	rs9309473	0.95	rs10207264	ENSG00000163016.8	ALMS1P	5.21	4.09e-07	0.000299	0.41	0.32	Metabolite levels;	chr2:73486970	chr2:73644919~73685576:+
SARC	cis	rs1707322	0.752	rs4660880	ENSG00000281133.1	AL355480.3	-5.21	4.09e-07	0.000299	-0.38	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45580892~45580996:-
SARC	cis	rs12049351	0.943	rs6687883	ENSG00000229367.1	HMGN2P19	-5.21	4.1e-07	0.000299	-0.28	-0.32	Circulating myeloperoxidase levels (plasma);	chr1:229582109	chr1:229570532~229570796:+
SARC	cis	rs9890032	0.52	rs2321926	ENSG00000263531.1	RP13-753N3.1	5.21	4.1e-07	3e-04	0.43	0.32	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30863921~30864940:-
SARC	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-5.21	4.11e-07	3e-04	-0.35	-0.32	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
SARC	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-5.21	4.11e-07	3e-04	-0.39	-0.32	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
SARC	cis	rs12216125	0.554	rs6942196	ENSG00000272810.1	U91328.22	-5.21	4.11e-07	3e-04	-0.31	-0.32	Iron status biomarkers;	chr6:26072576	chr6:26013241~26013757:+
SARC	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-5.21	4.13e-07	0.000301	-0.37	-0.32	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-5.21	4.13e-07	0.000301	-0.37	-0.32	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
SARC	cis	rs2562456	0.833	rs4321312	ENSG00000268081.1	RP11-678G14.2	5.21	4.13e-07	0.000302	0.52	0.32	Pain;	chr19:21336614	chr19:21554640~21569237:-
SARC	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-5.21	4.13e-07	0.000302	-0.4	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
SARC	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	5.21	4.13e-07	0.000302	0.37	0.32	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
SARC	cis	rs17772222	0.63	rs8017811	ENSG00000258983.2	RP11-507K2.2	-5.21	4.14e-07	0.000302	-0.32	-0.32	Coronary artery calcification;	chr14:88534559	chr14:88499334~88515502:+
SARC	cis	rs7246657	0.943	rs9917081	ENSG00000276846.1	CTD-3220F14.3	5.21	4.14e-07	0.000302	0.43	0.32	Coronary artery calcification;	chr19:37385714	chr19:37314868~37315620:-
SARC	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-5.21	4.14e-07	0.000302	-0.36	-0.32	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
SARC	cis	rs8031584	0.678	rs3122	ENSG00000260382.1	RP11-540B6.2	-5.21	4.15e-07	0.000303	-0.4	-0.32	Huntington's disease progression;	chr15:30878087	chr15:30882267~30883231:-
SARC	cis	rs7247513	0.866	rs2861405	ENSG00000213290.4	PGK1P2	-5.21	4.15e-07	0.000303	-0.39	-0.32	Bipolar disorder;	chr19:12611518	chr19:12559571~12561105:+
SARC	cis	rs708547	0.581	rs10020462	ENSG00000269949.1	RP11-738E22.3	-5.21	4.15e-07	0.000303	-0.4	-0.32	Response to bleomycin (chromatid breaks);	chr4:56959427	chr4:56960927~56961373:-
SARC	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	5.21	4.15e-07	0.000303	0.3	0.32	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
SARC	cis	rs4845875	0.513	rs198397	ENSG00000242349.4	NPPA-AS1	-5.21	4.15e-07	0.000303	-0.33	-0.32	Midregional pro atrial natriuretic peptide levels;	chr1:11823275	chr1:11841017~11848079:+
SARC	cis	rs113835537	0.627	rs11227534	ENSG00000255517.5	CTD-3074O7.5	-5.21	4.16e-07	0.000304	-0.37	-0.32	Airway imaging phenotypes;	chr11:66568700	chr11:66473490~66480233:-
SARC	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	5.21	4.16e-07	0.000304	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
SARC	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	5.21	4.16e-07	0.000304	0.45	0.32	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
SARC	cis	rs4372836	1	rs11690423	ENSG00000226833.4	AC097724.3	-5.21	4.16e-07	0.000304	-0.31	-0.32	Body mass index;	chr2:28728671	chr2:28708953~28736205:-
SARC	cis	rs4372836	1	rs72782294	ENSG00000226833.4	AC097724.3	-5.21	4.16e-07	0.000304	-0.31	-0.32	Body mass index;	chr2:28730524	chr2:28708953~28736205:-
SARC	cis	rs17772222	0.63	rs2778936	ENSG00000258983.2	RP11-507K2.2	-5.21	4.16e-07	0.000304	-0.32	-0.32	Coronary artery calcification;	chr14:88505959	chr14:88499334~88515502:+
SARC	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	5.21	4.18e-07	0.000304	0.34	0.32	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
SARC	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	5.21	4.19e-07	0.000305	0.41	0.32	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
SARC	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	5.21	4.19e-07	0.000305	0.46	0.32	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	5.21	4.19e-07	0.000305	0.46	0.32	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
SARC	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-5.21	4.19e-07	0.000305	-0.34	-0.32	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
SARC	cis	rs899997	0.862	rs11072787	ENSG00000261143.1	ADAMTS7P3	-5.21	4.2e-07	0.000306	-0.46	-0.32	Coronary artery disease or large artery stroke;	chr15:78680635	chr15:77976042~77993057:+
SARC	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-5.21	4.21e-07	0.000307	-0.34	-0.32	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
SARC	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-5.21	4.22e-07	0.000307	-0.5	-0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
SARC	cis	rs890448	0.792	rs1372242	ENSG00000254531.1	FLJ20021	5.21	4.22e-07	0.000307	0.33	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101369371	chr4:101347780~101348883:+
SARC	cis	rs4372836	1	rs11127188	ENSG00000226833.4	AC097724.3	5.21	4.23e-07	0.000308	0.3	0.32	Body mass index;	chr2:28749986	chr2:28708953~28736205:-
SARC	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-5.21	4.24e-07	0.000308	-0.4	-0.32	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
SARC	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-5.21	4.24e-07	0.000308	-0.4	-0.32	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
SARC	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-5.21	4.24e-07	0.000308	-0.4	-0.32	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
SARC	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-5.21	4.24e-07	0.000308	-0.4	-0.32	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
SARC	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-5.21	4.24e-07	0.000308	-0.4	-0.32	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
SARC	cis	rs62432291	0.681	rs397476	ENSG00000235086.1	FNDC1-IT1	-5.21	4.24e-07	0.000309	-0.53	-0.32	Joint mobility (Beighton score);	chr6:159218252	chr6:159240786~159243329:+
SARC	cis	rs4925166	1	rs4925166	ENSG00000273018.4	CTD-2303H24.2	-5.21	4.25e-07	0.000309	-0.35	-0.32	Multiple sclerosis;	chr17:18307496	chr17:18511221~18551705:-
SARC	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-5.21	4.26e-07	0.000309	-0.32	-0.32	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-5.21	4.26e-07	0.000309	-0.32	-0.32	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
SARC	cis	rs7712401	0.601	rs154496	ENSG00000263432.2	RN7SL689P	5.2	4.26e-07	0.00031	0.41	0.32	Mean platelet volume;	chr5:122886036	chr5:123022487~123022783:-
SARC	cis	rs853679	0.542	rs6934769	ENSG00000272009.1	RP1-313I6.12	-5.2	4.26e-07	0.00031	-0.37	-0.32	Depression;	chr6:28123153	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs17711801	ENSG00000272009.1	RP1-313I6.12	-5.2	4.26e-07	0.00031	-0.37	-0.32	Depression;	chr6:28124529	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs6922063	ENSG00000272009.1	RP1-313I6.12	-5.2	4.26e-07	0.00031	-0.37	-0.32	Depression;	chr6:28126588	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs2275508	ENSG00000272009.1	RP1-313I6.12	-5.2	4.26e-07	0.00031	-0.37	-0.32	Depression;	chr6:28126953	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.527	rs9461433	ENSG00000272009.1	RP1-313I6.12	-5.2	4.26e-07	0.00031	-0.37	-0.32	Parkinson's disease;	chr6:28127394	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9468292	ENSG00000272009.1	RP1-313I6.12	-5.2	4.26e-07	0.00031	-0.37	-0.32	Depression;	chr6:28127577	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs1947863	ENSG00000272009.1	RP1-313I6.12	-5.2	4.26e-07	0.00031	-0.37	-0.32	Depression;	chr6:28131566	chr6:28078792~28081130:-
SARC	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	5.2	4.26e-07	0.00031	0.54	0.32	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
SARC	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-5.2	4.28e-07	0.000311	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
SARC	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-5.2	4.28e-07	0.000311	-0.33	-0.32	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
SARC	cis	rs7615952	0.641	rs61048217	ENSG00000250012.1	RP11-124N2.1	-5.2	4.28e-07	0.000311	-0.32	-0.32	Blood pressure (smoking interaction);	chr3:126089062	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.641	rs60839048	ENSG00000250012.1	RP11-124N2.1	-5.2	4.28e-07	0.000311	-0.32	-0.32	Blood pressure (smoking interaction);	chr3:126089095	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.641	rs7640158	ENSG00000250012.1	RP11-124N2.1	-5.2	4.28e-07	0.000311	-0.32	-0.32	Blood pressure (smoking interaction);	chr3:126089168	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.641	rs2365019	ENSG00000250012.1	RP11-124N2.1	-5.2	4.28e-07	0.000311	-0.32	-0.32	Blood pressure (smoking interaction);	chr3:126089292	chr3:126084220~126095349:+
SARC	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-5.2	4.29e-07	0.000311	-0.4	-0.32	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-5.2	4.29e-07	0.000311	-0.4	-0.32	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
SARC	cis	rs4713118	0.869	rs2056925	ENSG00000219392.1	RP1-265C24.5	-5.2	4.29e-07	0.000312	-0.46	-0.32	Parkinson's disease;	chr6:27723126	chr6:28115628~28116551:+
SARC	cis	rs4372836	0.964	rs4665432	ENSG00000226833.4	AC097724.3	-5.2	4.3e-07	0.000312	-0.3	-0.32	Body mass index;	chr2:28729160	chr2:28708953~28736205:-
SARC	cis	rs4372836	1	rs11688129	ENSG00000226833.4	AC097724.3	-5.2	4.3e-07	0.000312	-0.3	-0.32	Body mass index;	chr2:28729715	chr2:28708953~28736205:-
SARC	cis	rs4372836	1	rs4549034	ENSG00000226833.4	AC097724.3	5.2	4.3e-07	0.000312	0.3	0.32	Body mass index;	chr2:28749713	chr2:28708953~28736205:-
SARC	cis	rs4372836	1	rs4372836	ENSG00000226833.4	AC097724.3	5.2	4.3e-07	0.000312	0.3	0.32	Body mass index;	chr2:28751017	chr2:28708953~28736205:-
SARC	cis	rs4372836	1	rs7598876	ENSG00000226833.4	AC097724.3	5.2	4.3e-07	0.000312	0.3	0.32	Body mass index;	chr2:28751600	chr2:28708953~28736205:-
SARC	cis	rs890448	0.796	rs2433308	ENSG00000254531.1	FLJ20021	5.2	4.3e-07	0.000312	0.33	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426421	chr4:101347780~101348883:+
SARC	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-5.2	4.3e-07	0.000312	-0.39	-0.32	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
SARC	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-5.2	4.3e-07	0.000312	-0.39	-0.32	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
SARC	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-5.2	4.3e-07	0.000313	-0.36	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
SARC	cis	rs12022452	0.908	rs4660423	ENSG00000238287.1	RP11-656D10.3	-5.2	4.31e-07	0.000313	-0.52	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40493157~40508661:-
SARC	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	5.2	4.33e-07	0.000314	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
SARC	cis	rs2562456	1	rs2359155	ENSG00000268081.1	RP11-678G14.2	-5.2	4.33e-07	0.000314	-0.48	-0.32	Pain;	chr19:21489067	chr19:21554640~21569237:-
SARC	cis	rs4862750	0.872	rs13110072	ENSG00000249742.1	RP11-217E13.1	-5.2	4.35e-07	0.000315	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186957370	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.872	rs6825289	ENSG00000249742.1	RP11-217E13.1	-5.2	4.35e-07	0.000315	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186957955	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.794	rs7672272	ENSG00000249742.1	RP11-217E13.1	-5.2	4.35e-07	0.000315	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186975620	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.872	rs6852907	ENSG00000249742.1	RP11-217E13.1	-5.2	4.35e-07	0.000315	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186975940	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.872	rs6830426	ENSG00000249742.1	RP11-217E13.1	-5.2	4.35e-07	0.000315	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186976116	chr4:186979490~187021973:-
SARC	cis	rs1823913	1	rs4853561	ENSG00000227542.1	AC092614.2	-5.2	4.36e-07	0.000316	-0.35	-0.32	Obesity-related traits;	chr2:191242980	chr2:191229165~191246172:-
SARC	cis	rs1823913	1	rs6704784	ENSG00000227542.1	AC092614.2	-5.2	4.36e-07	0.000316	-0.35	-0.32	Obesity-related traits;	chr2:191244832	chr2:191229165~191246172:-
SARC	cis	rs7712401	0.584	rs30037	ENSG00000263432.2	RN7SL689P	5.2	4.36e-07	0.000316	0.4	0.32	Mean platelet volume;	chr5:122942295	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs30035	ENSG00000263432.2	RN7SL689P	5.2	4.36e-07	0.000316	0.4	0.32	Mean platelet volume;	chr5:122942850	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs246306	ENSG00000263432.2	RN7SL689P	5.2	4.36e-07	0.000316	0.4	0.32	Mean platelet volume;	chr5:122943523	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.562	rs2927639	ENSG00000263432.2	RN7SL689P	5.2	4.36e-07	0.000316	0.4	0.32	Mean platelet volume;	chr5:122943971	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs246274	ENSG00000263432.2	RN7SL689P	5.2	4.36e-07	0.000316	0.4	0.32	Mean platelet volume;	chr5:122945108	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs246273	ENSG00000263432.2	RN7SL689P	5.2	4.36e-07	0.000316	0.4	0.32	Mean platelet volume;	chr5:122945280	chr5:123022487~123022783:-
SARC	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	5.2	4.37e-07	0.000317	0.52	0.32	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
SARC	cis	rs77204473	0.744	rs80273401	ENSG00000254851.1	RP11-109L13.1	5.2	4.37e-07	0.000317	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117037990	chr11:117135528~117138582:+
SARC	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	5.2	4.38e-07	0.000317	0.37	0.32	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
SARC	cis	rs7246657	0.943	rs2303131	ENSG00000276846.1	CTD-3220F14.3	5.2	4.38e-07	0.000317	0.43	0.32	Coronary artery calcification;	chr19:37445123	chr19:37314868~37315620:-
SARC	cis	rs2562456	0.754	rs58338799	ENSG00000268081.1	RP11-678G14.2	5.2	4.38e-07	0.000317	0.52	0.32	Pain;	chr19:21339009	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.793	rs7259396	ENSG00000268081.1	RP11-678G14.2	5.2	4.38e-07	0.000317	0.52	0.32	Pain;	chr19:21340661	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.678	rs7260140	ENSG00000268081.1	RP11-678G14.2	5.2	4.38e-07	0.000317	0.52	0.32	Pain;	chr19:21340723	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs11880624	ENSG00000268081.1	RP11-678G14.2	5.2	4.38e-07	0.000317	0.52	0.32	Pain;	chr19:21341028	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62107547	ENSG00000268081.1	RP11-678G14.2	5.2	4.38e-07	0.000317	0.52	0.32	Pain;	chr19:21341245	chr19:21554640~21569237:-
SARC	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	5.2	4.38e-07	0.000317	0.4	0.32	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
SARC	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	5.2	4.39e-07	0.000318	0.37	0.32	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
SARC	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-5.2	4.4e-07	0.000318	-0.33	-0.32	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
SARC	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-5.2	4.4e-07	0.000319	-0.44	-0.32	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
SARC	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-5.2	4.42e-07	0.00032	-0.39	-0.32	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
SARC	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-5.2	4.42e-07	0.00032	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
SARC	cis	rs9818758	0.607	rs3923475	ENSG00000225399.4	RP11-3B7.1	-5.2	4.42e-07	0.00032	-0.6	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49018355	chr3:49260085~49261316:+
SARC	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-5.2	4.42e-07	0.00032	-0.43	-0.32	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
SARC	cis	rs2562456	0.833	rs2359145	ENSG00000268081.1	RP11-678G14.2	5.2	4.42e-07	0.00032	0.53	0.32	Pain;	chr19:21409791	chr19:21554640~21569237:-
SARC	cis	rs9890032	1	rs3764419	ENSG00000263531.1	RP13-753N3.1	5.2	4.42e-07	0.00032	0.39	0.32	Hip circumference adjusted for BMI;	chr17:30837005	chr17:30863921~30864940:-
SARC	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-5.2	4.43e-07	0.000321	-0.37	-0.32	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
SARC	cis	rs1823913	0.599	rs17412094	ENSG00000227542.1	AC092614.2	5.2	4.43e-07	0.000321	0.36	0.32	Obesity-related traits;	chr2:191284202	chr2:191229165~191246172:-
SARC	cis	rs17270561	0.609	rs4712970	ENSG00000272810.1	U91328.22	-5.2	4.44e-07	0.000321	-0.32	-0.32	Iron status biomarkers;	chr6:25770479	chr6:26013241~26013757:+
SARC	cis	rs867371	0.717	rs3858954	ENSG00000259429.4	UBE2Q2P2	-5.2	4.46e-07	0.000322	-0.3	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82355142~82420075:+
SARC	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-5.2	4.46e-07	0.000322	-0.39	-0.32	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
SARC	cis	rs8031584	0.958	rs1043742	ENSG00000260382.1	RP11-540B6.2	5.2	4.46e-07	0.000323	0.39	0.32	Huntington's disease progression;	chr15:30940378	chr15:30882267~30883231:-
SARC	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.562	rs30073	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122954814	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs30072	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122956525	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs30069	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122957331	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs30067	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122957973	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs187405	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122959300	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs40818	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122959378	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.562	rs30062	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122960681	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs30060	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122961005	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.525	rs2910150	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122961050	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs30059	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122961814	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs30058	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122962008	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.623	rs30057	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122962423	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.584	rs39820	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122964226	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs30055	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122965384	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs39819	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122965981	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs30054	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122966304	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.562	rs30053	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122967948	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.562	rs30052	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122969314	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs30049	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122970402	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs246321	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122972604	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs246320	ENSG00000263432.2	RN7SL689P	5.19	4.47e-07	0.000323	0.4	0.32	Mean platelet volume;	chr5:122972886	chr5:123022487~123022783:-
SARC	cis	rs1134634	0.52	rs28528670	ENSG00000273133.1	RP11-799M12.2	-5.19	4.47e-07	0.000323	-0.41	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15591295	chr4:15563698~15564253:-
SARC	cis	rs1134634	0.52	rs10034328	ENSG00000273133.1	RP11-799M12.2	-5.19	4.47e-07	0.000323	-0.41	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15616764	chr4:15563698~15564253:-
SARC	cis	rs6991838	0.806	rs11777025	ENSG00000200714.1	Y_RNA	-5.19	4.48e-07	0.000323	-0.33	-0.32	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65592731~65592820:+
SARC	cis	rs77204473	1	rs12286581	ENSG00000254851.1	RP11-109L13.1	5.19	4.48e-07	0.000324	0.73	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs75294699	ENSG00000254851.1	RP11-109L13.1	5.19	4.48e-07	0.000324	0.73	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117135528~117138582:+
SARC	cis	rs17270561	0.609	rs9358878	ENSG00000272810.1	U91328.22	-5.19	4.48e-07	0.000324	-0.33	-0.32	Iron status biomarkers;	chr6:25740045	chr6:26013241~26013757:+
SARC	cis	rs8031584	0.958	rs61997079	ENSG00000260382.1	RP11-540B6.2	5.19	4.49e-07	0.000324	0.39	0.32	Huntington's disease progression;	chr15:30946068	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.958	rs11637469	ENSG00000260382.1	RP11-540B6.2	5.19	4.49e-07	0.000324	0.39	0.32	Huntington's disease progression;	chr15:30946580	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.958	rs8034856	ENSG00000260382.1	RP11-540B6.2	5.19	4.49e-07	0.000324	0.39	0.32	Huntington's disease progression;	chr15:30948754	chr15:30882267~30883231:-
SARC	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	5.19	4.5e-07	0.000325	0.26	0.32	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
SARC	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	5.19	4.51e-07	0.000326	0.38	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
SARC	cis	rs75920871	0.588	rs7118591	ENSG00000254851.1	RP11-109L13.1	-5.19	4.53e-07	0.000327	-0.42	-0.32	Subjective well-being;	chr11:117037741	chr11:117135528~117138582:+
SARC	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-5.19	4.53e-07	0.000327	-0.32	-0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
SARC	cis	rs1800562	1	rs1800562	ENSG00000272462.2	U91328.19	-5.19	4.54e-07	0.000327	-0.63	-0.32	Hematology traits;Iron status biomarkers (transferrin levels);Iron status biomarkers;Red blood cell count;Red blood cell traits;Mean corpuscular volume;Iron status biomarkers (ferritin levels);Iron status biomarkers (transferrin saturation);Diastolic blood pressure;Cholesterol, total;Cardiovascular disease risk factors;Hematocrit;Alcohol consumption (transferrin glycosylation);Hemoglobin;Iron status biomarkers (iron levels);Hematological parameters;LDL cholesterol;Mean corpuscular hemoglobin;Iron status biomarkers (total iron binding capacity);Glycated hemoglobin levels;Hepcidin levels;	chr6:26092913	chr6:25992662~26001775:+
SARC	cis	rs6991838	0.806	rs4285523	ENSG00000200714.1	Y_RNA	5.19	4.55e-07	0.000328	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65592731~65592820:+
SARC	cis	rs9309473	1	rs2901438	ENSG00000163016.8	ALMS1P	5.19	4.55e-07	0.000328	0.4	0.32	Metabolite levels;	chr2:73438528	chr2:73644919~73685576:+
SARC	cis	rs7216064	0.953	rs62086043	ENSG00000278219.1	AC145343.1	-5.19	4.55e-07	0.000328	-0.39	-0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971887	chr17:68101538~68101639:+
SARC	cis	rs9309473	1	rs7576245	ENSG00000163016.8	ALMS1P	5.19	4.56e-07	0.000329	0.4	0.32	Metabolite levels;	chr2:73602551	chr2:73644919~73685576:+
SARC	cis	rs858239	0.932	rs1637190	ENSG00000226816.2	AC005082.12	5.19	4.56e-07	0.000329	0.39	0.32	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23206013~23208045:+
SARC	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-5.19	4.56e-07	0.000329	-0.38	-0.32	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
SARC	cis	rs9309473	0.95	rs6546858	ENSG00000163016.8	ALMS1P	5.19	4.56e-07	0.000329	0.4	0.32	Metabolite levels;	chr2:73611486	chr2:73644919~73685576:+
SARC	cis	rs367615	0.679	rs11241021	ENSG00000249476.1	CTD-2587M2.1	5.19	4.57e-07	0.000329	0.41	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109476389	chr5:109237120~109326369:-
SARC	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	5.19	4.57e-07	0.000329	0.34	0.32	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
SARC	cis	rs2439831	1	rs690263	ENSG00000205771.5	CATSPER2P1	-5.19	4.57e-07	0.000329	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43412267	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs2254321	ENSG00000205771.5	CATSPER2P1	-5.19	4.57e-07	0.000329	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43415344	chr15:43726918~43747094:-
SARC	cis	rs4372836	0.964	rs56240884	ENSG00000226833.4	AC097724.3	-5.19	4.58e-07	0.00033	-0.31	-0.32	Body mass index;	chr2:28717288	chr2:28708953~28736205:-
SARC	cis	rs875971	0.638	rs6960778	ENSG00000236529.1	RP13-254B10.1	-5.19	4.58e-07	0.00033	-0.34	-0.32	Aortic root size;	chr7:66606610	chr7:65840212~65840596:+
SARC	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-5.19	4.58e-07	0.00033	-0.44	-0.32	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
SARC	cis	rs7712401	0.601	rs144597	ENSG00000263432.2	RN7SL689P	5.19	4.59e-07	0.000331	0.41	0.32	Mean platelet volume;	chr5:122887537	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs246282	ENSG00000263432.2	RN7SL689P	5.19	4.59e-07	0.000331	0.41	0.32	Mean platelet volume;	chr5:122889910	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.623	rs538424	ENSG00000263432.2	RN7SL689P	5.19	4.59e-07	0.000331	0.41	0.32	Mean platelet volume;	chr5:122893068	chr5:123022487~123022783:-
SARC	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	5.19	4.6e-07	0.000331	0.37	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
SARC	cis	rs172166	0.694	rs9295760	ENSG00000216901.1	AL022393.7	5.19	4.61e-07	0.000332	0.45	0.32	Cardiac Troponin-T levels;	chr6:28179607	chr6:28176188~28176674:+
SARC	cis	rs77204473	0.744	rs80143284	ENSG00000254851.1	RP11-109L13.1	5.19	4.61e-07	0.000332	0.73	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117042854	chr11:117135528~117138582:+
SARC	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	5.19	4.62e-07	0.000332	0.38	0.32	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
SARC	cis	rs4713118	0.539	rs200951	ENSG00000219392.1	RP1-265C24.5	-5.19	4.62e-07	0.000333	-0.43	-0.32	Parkinson's disease;	chr6:27868152	chr6:28115628~28116551:+
SARC	cis	rs1823913	1	rs4853563	ENSG00000227542.1	AC092614.2	-5.19	4.63e-07	0.000333	-0.35	-0.32	Obesity-related traits;	chr2:191254808	chr2:191229165~191246172:-
SARC	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-5.19	4.63e-07	0.000333	-0.35	-0.32	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
SARC	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-5.19	4.63e-07	0.000333	-0.35	-0.32	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
SARC	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-5.19	4.63e-07	0.000333	-0.35	-0.32	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
SARC	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-5.19	4.63e-07	0.000333	-0.35	-0.32	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
SARC	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-5.19	4.63e-07	0.000333	-0.35	-0.32	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
SARC	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-5.19	4.63e-07	0.000333	-0.35	-0.32	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
SARC	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-5.19	4.63e-07	0.000333	-0.35	-0.32	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
SARC	cis	rs8031584	0.958	rs3512	ENSG00000260382.1	RP11-540B6.2	5.19	4.64e-07	0.000334	0.39	0.32	Huntington's disease progression;	chr15:30942802	chr15:30882267~30883231:-
SARC	cis	rs17270561	0.639	rs9356989	ENSG00000272810.1	U91328.22	-5.19	4.64e-07	0.000334	-0.32	-0.32	Iron status biomarkers;	chr6:25781722	chr6:26013241~26013757:+
SARC	cis	rs10262624	0.967	rs2188845	ENSG00000234286.1	AC006026.13	-5.19	4.68e-07	0.000336	-0.35	-0.32	Schizophrenia;	chr7:23882391	chr7:23680195~23680786:-
SARC	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	5.19	4.68e-07	0.000336	0.36	0.32	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
SARC	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	5.19	4.68e-07	0.000336	0.34	0.32	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
SARC	cis	rs1865760	0.534	rs1541988	ENSG00000272810.1	U91328.22	-5.18	4.69e-07	0.000337	-0.32	-0.32	Height;	chr6:25950576	chr6:26013241~26013757:+
SARC	cis	rs11651753	0.689	rs2525107	ENSG00000264920.1	RP11-6N17.4	5.18	4.69e-07	0.000337	0.35	0.32	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964038	chr17:47891255~47895812:-
SARC	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-5.18	4.7e-07	0.000338	-0.35	-0.32	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
SARC	cis	rs4372836	0.681	rs6547875	ENSG00000226833.4	AC097724.3	5.18	4.7e-07	0.000338	0.28	0.32	Body mass index;	chr2:28774274	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.658	rs10178852	ENSG00000226833.4	AC097724.3	5.18	4.7e-07	0.000338	0.28	0.32	Body mass index;	chr2:28774969	chr2:28708953~28736205:-
SARC	cis	rs710913	0.618	rs12030495	ENSG00000182109.6	RP11-69E11.4	5.18	4.71e-07	0.000338	0.32	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39623923	chr1:39522280~39546187:-
SARC	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-5.18	4.71e-07	0.000338	-0.44	-0.32	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
SARC	cis	rs6570726	0.818	rs952405	ENSG00000270638.1	RP3-466P17.1	5.18	4.71e-07	0.000339	0.26	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145735570~145737218:+
SARC	cis	rs7246657	0.943	rs1015848	ENSG00000276846.1	CTD-3220F14.3	5.18	4.72e-07	0.000339	0.43	0.32	Coronary artery calcification;	chr19:37454372	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs4801759	ENSG00000276846.1	CTD-3220F14.3	5.18	4.72e-07	0.000339	0.43	0.32	Coronary artery calcification;	chr19:37464083	chr19:37314868~37315620:-
SARC	cis	rs17270561	0.779	rs1165200	ENSG00000272810.1	U91328.22	5.18	4.72e-07	0.000339	0.35	0.32	Iron status biomarkers;	chr6:25874984	chr6:26013241~26013757:+
SARC	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-5.18	4.72e-07	0.000339	-0.4	-0.32	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
SARC	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-5.18	4.73e-07	0.00034	-0.31	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
SARC	cis	rs2404602	0.532	rs206205	ENSG00000259422.1	RP11-593F23.1	5.18	4.75e-07	0.000341	0.36	0.32	Blood metabolite levels;	chr15:76443750	chr15:76174891~76181486:-
SARC	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	5.18	4.77e-07	0.000342	0.3	0.32	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
SARC	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-5.18	4.77e-07	0.000342	-0.4	-0.32	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
SARC	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	5.18	4.77e-07	0.000342	0.39	0.32	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
SARC	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	5.18	4.77e-07	0.000342	0.7	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
SARC	cis	rs6570726	0.846	rs6570698	ENSG00000270638.1	RP3-466P17.1	5.18	4.78e-07	0.000343	0.26	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.846	rs6914304	ENSG00000270638.1	RP3-466P17.1	5.18	4.78e-07	0.000343	0.26	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145735570~145737218:+
SARC	cis	rs8031584	0.918	rs1425292	ENSG00000260382.1	RP11-540B6.2	5.18	4.78e-07	0.000343	0.4	0.32	Huntington's disease progression;	chr15:30993219	chr15:30882267~30883231:-
SARC	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-5.18	4.78e-07	0.000343	-0.48	-0.32	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
SARC	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	5.18	4.79e-07	0.000343	0.25	0.32	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
SARC	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-5.18	4.79e-07	0.000343	-0.34	-0.32	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
SARC	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-5.18	4.81e-07	0.000344	-0.36	-0.32	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-5.18	4.81e-07	0.000344	-0.36	-0.32	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
SARC	cis	rs1865760	0.516	rs9379818	ENSG00000272810.1	U91328.22	-5.18	4.82e-07	0.000345	-0.31	-0.32	Height;	chr6:26022978	chr6:26013241~26013757:+
SARC	cis	rs9818758	0.556	rs9813813	ENSG00000225399.4	RP11-3B7.1	-5.18	4.84e-07	0.000346	-0.59	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49169660	chr3:49260085~49261316:+
SARC	cis	rs9309473	0.948	rs7607892	ENSG00000163016.8	ALMS1P	5.18	4.84e-07	0.000346	0.4	0.32	Metabolite levels;	chr2:73591580	chr2:73644919~73685576:+
SARC	cis	rs10800713	0.866	rs6703783	ENSG00000260088.1	RP11-92G12.3	-5.18	4.84e-07	0.000347	-0.4	-0.32	Tandem gait;	chr1:200544290	chr1:200669507~200694250:+
SARC	cis	rs7246657	0.943	rs8111782	ENSG00000276846.1	CTD-3220F14.3	5.18	4.84e-07	0.000347	0.43	0.32	Coronary artery calcification;	chr19:37377002	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10404920	ENSG00000276846.1	CTD-3220F14.3	5.18	4.84e-07	0.000347	0.43	0.32	Coronary artery calcification;	chr19:37390654	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10405325	ENSG00000276846.1	CTD-3220F14.3	5.18	4.84e-07	0.000347	0.43	0.32	Coronary artery calcification;	chr19:37392575	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs12981532	ENSG00000276846.1	CTD-3220F14.3	5.18	4.84e-07	0.000347	0.43	0.32	Coronary artery calcification;	chr19:37398378	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs7246993	ENSG00000276846.1	CTD-3220F14.3	5.18	4.84e-07	0.000347	0.43	0.32	Coronary artery calcification;	chr19:37399252	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10413602	ENSG00000276846.1	CTD-3220F14.3	5.18	4.84e-07	0.000347	0.43	0.32	Coronary artery calcification;	chr19:37400590	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10422074	ENSG00000276846.1	CTD-3220F14.3	5.18	4.84e-07	0.000347	0.43	0.32	Coronary artery calcification;	chr19:37403334	chr19:37314868~37315620:-
SARC	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-5.18	4.85e-07	0.000347	-0.37	-0.32	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
SARC	cis	rs7712401	0.601	rs30027	ENSG00000263432.2	RN7SL689P	5.18	4.86e-07	0.000347	0.41	0.32	Mean platelet volume;	chr5:122947695	chr5:123022487~123022783:-
SARC	cis	rs17270561	0.609	rs1937131	ENSG00000272810.1	U91328.22	5.18	4.87e-07	0.000348	0.33	0.32	Iron status biomarkers;	chr6:25744603	chr6:26013241~26013757:+
SARC	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	5.18	4.87e-07	0.000348	0.41	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	5.18	4.87e-07	0.000348	0.41	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
SARC	cis	rs739310	0.556	rs9625070	ENSG00000206028.1	CTA-373H7.7	-5.18	4.88e-07	0.000349	-0.49	-0.32	Obesity-related traits;	chr22:26687029	chr22:26667693~26672654:-
SARC	cis	rs62103177	0.568	rs2365388	ENSG00000261126.6	RP11-795F19.1	5.18	4.9e-07	0.00035	0.33	0.32	Opioid sensitivity;	chr18:80215819	chr18:80046900~80095482:+
SARC	cis	rs9309473	0.898	rs10209517	ENSG00000163016.8	ALMS1P	5.18	4.91e-07	0.000351	0.39	0.32	Metabolite levels;	chr2:73618265	chr2:73644919~73685576:+
SARC	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	5.17	4.92e-07	0.000351	0.25	0.32	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
SARC	cis	rs34375054	0.735	rs34961756	ENSG00000279233.1	RP11-158L12.4	5.17	4.93e-07	0.000352	0.33	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125144052	chr12:125138245~125141711:+
SARC	cis	rs10483853	0.525	rs7158272	ENSG00000258695.2	RP3-414A15.2	5.17	4.93e-07	0.000352	0.43	0.32	Coronary artery calcification;	chr14:73476486	chr14:73522878~73530610:+
SARC	cis	rs1865760	0.593	rs9295678	ENSG00000272462.2	U91328.19	-5.17	4.93e-07	0.000352	-0.31	-0.32	Height;	chr6:25936805	chr6:25992662~26001775:+
SARC	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	5.17	4.94e-07	0.000353	0.34	0.32	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
SARC	cis	rs867371	0.762	rs12905578	ENSG00000259429.4	UBE2Q2P2	5.17	4.95e-07	0.000353	0.31	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82355142~82420075:+
SARC	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-5.17	4.96e-07	0.000353	-0.38	-0.32	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
SARC	cis	rs1707322	0.686	rs3014251	ENSG00000281133.1	AL355480.3	5.17	4.96e-07	0.000353	0.37	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45580892~45580996:-
SARC	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-5.17	4.96e-07	0.000354	-0.32	-0.32	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
SARC	cis	rs7567389	0.51	rs6755028	ENSG00000236682.1	AC068282.3	5.17	4.96e-07	0.000354	0.35	0.32	Self-rated health;	chr2:127437866	chr2:127389130~127400580:+
SARC	cis	rs2179367	0.959	rs9285519	ENSG00000231760.4	RP11-350J20.5	5.17	4.96e-07	0.000354	0.39	0.32	Dupuytren's disease;	chr6:149371799	chr6:149796151~149826294:-
SARC	cis	rs9309473	0.797	rs6723247	ENSG00000163016.8	ALMS1P	5.17	4.97e-07	0.000354	0.39	0.32	Metabolite levels;	chr2:73619622	chr2:73644919~73685576:+
SARC	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-5.17	4.97e-07	0.000354	-0.26	-0.32	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
SARC	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-5.17	4.97e-07	0.000355	-0.31	-0.32	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
SARC	cis	rs9637599	0.967	rs7661312	ENSG00000246375.2	RP11-10L7.1	5.17	4.98e-07	0.000355	0.39	0.32	Metabolite levels (small molecules and protein measures);	chr4:88279855	chr4:88284942~88331421:+
SARC	cis	rs4934494	0.911	rs7081788	ENSG00000240996.1	RP11-80H5.7	-5.17	4.99e-07	0.000356	-0.32	-0.32	Red blood cell count;	chr10:89648999	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.911	rs34486602	ENSG00000240996.1	RP11-80H5.7	-5.17	4.99e-07	0.000356	-0.32	-0.32	Red blood cell count;	chr10:89655895	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.911	rs6586213	ENSG00000240996.1	RP11-80H5.7	-5.17	4.99e-07	0.000356	-0.32	-0.32	Red blood cell count;	chr10:89656327	chr10:89694295~89697928:-
SARC	cis	rs7809950	1	rs2237677	ENSG00000238832.1	snoU109	-5.17	5e-07	0.000356	-0.38	-0.32	Coronary artery disease;	chr7:107562057	chr7:107603363~107603507:+
SARC	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	5.17	5e-07	0.000356	0.32	0.32	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
SARC	cis	rs2439831	0.681	rs1095386	ENSG00000205771.5	CATSPER2P1	-5.17	5.01e-07	0.000357	-0.45	-0.32	Lung cancer in ever smokers;	chr15:43317311	chr15:43726918~43747094:-
SARC	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-5.17	5.01e-07	0.000357	-0.39	-0.32	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
SARC	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-5.17	5.02e-07	0.000357	-0.3	-0.32	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-5.17	5.02e-07	0.000357	-0.3	-0.32	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
SARC	cis	rs6570726	0.846	rs409553	ENSG00000270638.1	RP3-466P17.1	5.17	5.03e-07	0.000358	0.26	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145565827	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.846	rs371186	ENSG00000270638.1	RP3-466P17.1	5.17	5.03e-07	0.000358	0.26	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145565835	chr6:145735570~145737218:+
SARC	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-5.17	5.03e-07	0.000359	-0.31	-0.32	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
SARC	cis	rs9818758	0.607	rs35673421	ENSG00000225399.4	RP11-3B7.1	-5.17	5.03e-07	0.000359	-0.6	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49101973	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs11552724	ENSG00000225399.4	RP11-3B7.1	-5.17	5.03e-07	0.000359	-0.6	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49119040	chr3:49260085~49261316:+
SARC	cis	rs1823913	0.599	rs13001899	ENSG00000227542.1	AC092614.2	5.17	5.03e-07	0.000359	0.36	0.32	Obesity-related traits;	chr2:191285442	chr2:191229165~191246172:-
SARC	cis	rs7772486	0.632	rs9386128	ENSG00000270638.1	RP3-466P17.1	-5.17	5.04e-07	0.000359	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145735570~145737218:+
SARC	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-5.17	5.04e-07	0.000359	-0.48	-0.32	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
SARC	cis	rs853679	0.517	rs4713141	ENSG00000272009.1	RP1-313I6.12	-5.17	5.04e-07	0.000359	-0.36	-0.32	Depression;	chr6:28133900	chr6:28078792~28081130:-
SARC	cis	rs4865169	0.934	rs3796531	ENSG00000269949.1	RP11-738E22.3	-5.17	5.05e-07	0.000359	-0.36	-0.32	Breast cancer;	chr4:56984680	chr4:56960927~56961373:-
SARC	cis	rs867371	0.762	rs1846910	ENSG00000259429.4	UBE2Q2P2	-5.17	5.05e-07	0.00036	-0.3	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82355142~82420075:+
SARC	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-5.17	5.06e-07	0.00036	-0.39	-0.32	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
SARC	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-5.17	5.06e-07	0.00036	-0.39	-0.32	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
SARC	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	5.17	5.06e-07	0.00036	0.35	0.32	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
SARC	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	5.17	5.06e-07	0.00036	0.35	0.32	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
SARC	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	5.17	5.06e-07	0.00036	0.35	0.32	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
SARC	cis	rs7246657	0.943	rs10404602	ENSG00000276846.1	CTD-3220F14.3	5.17	5.07e-07	0.00036	0.43	0.32	Coronary artery calcification;	chr19:37334731	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10426666	ENSG00000276846.1	CTD-3220F14.3	5.17	5.07e-07	0.00036	0.43	0.32	Coronary artery calcification;	chr19:37337612	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs4969487	ENSG00000276846.1	CTD-3220F14.3	5.17	5.07e-07	0.00036	0.43	0.32	Coronary artery calcification;	chr19:37340137	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs28402338	ENSG00000276846.1	CTD-3220F14.3	5.17	5.07e-07	0.00036	0.43	0.32	Coronary artery calcification;	chr19:37343021	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10417503	ENSG00000276846.1	CTD-3220F14.3	5.17	5.07e-07	0.00036	0.43	0.32	Coronary artery calcification;	chr19:37351833	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10403613	ENSG00000276846.1	CTD-3220F14.3	5.17	5.07e-07	0.00036	0.43	0.32	Coronary artery calcification;	chr19:37353404	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs9304566	ENSG00000276846.1	CTD-3220F14.3	5.17	5.07e-07	0.00036	0.43	0.32	Coronary artery calcification;	chr19:37354602	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10422967	ENSG00000276846.1	CTD-3220F14.3	5.17	5.07e-07	0.00036	0.43	0.32	Coronary artery calcification;	chr19:37359235	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs4417644	ENSG00000276846.1	CTD-3220F14.3	5.17	5.07e-07	0.00036	0.43	0.32	Coronary artery calcification;	chr19:37361570	chr19:37314868~37315620:-
SARC	cis	rs7246657	0.943	rs10405064	ENSG00000276846.1	CTD-3220F14.3	5.17	5.07e-07	0.00036	0.43	0.32	Coronary artery calcification;	chr19:37370959	chr19:37314868~37315620:-
SARC	cis	rs1134634	0.52	rs4393989	ENSG00000273133.1	RP11-799M12.2	-5.17	5.08e-07	0.000362	-0.41	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15614276	chr4:15563698~15564253:-
SARC	cis	rs1134634	0.52	rs10003739	ENSG00000273133.1	RP11-799M12.2	-5.17	5.08e-07	0.000362	-0.41	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15617063	chr4:15563698~15564253:-
SARC	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-5.17	5.08e-07	0.000362	-0.3	-0.32	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
SARC	cis	rs7587476	0.861	rs3768716	ENSG00000229267.2	AC072062.1	-5.17	5.09e-07	0.000362	-0.34	-0.32	Neuroblastoma;	chr2:214771070	chr2:214810229~214963274:+
SARC	cis	rs8031584	0.958	rs34294266	ENSG00000260382.1	RP11-540B6.2	5.17	5.1e-07	0.000363	0.39	0.32	Huntington's disease progression;	chr15:30954637	chr15:30882267~30883231:-
SARC	cis	rs7772486	0.686	rs9485019	ENSG00000270638.1	RP3-466P17.1	-5.17	5.1e-07	0.000363	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145735570~145737218:+
SARC	cis	rs2562456	0.917	rs2650804	ENSG00000268081.1	RP11-678G14.2	5.17	5.11e-07	0.000364	0.47	0.32	Pain;	chr19:21497382	chr19:21554640~21569237:-
SARC	cis	rs160451	0.966	rs160423	ENSG00000251136.7	RP11-37B2.1	5.17	5.12e-07	0.000364	0.36	0.32	Leprosy;	chr8:89658395	chr8:89609409~89757727:-
SARC	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	5.17	5.13e-07	0.000364	0.34	0.32	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
SARC	cis	rs198389	0.589	rs198401	ENSG00000242349.4	NPPA-AS1	-5.17	5.14e-07	0.000365	-0.33	-0.32	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11828327	chr1:11841017~11848079:+
SARC	cis	rs1707322	0.685	rs11211177	ENSG00000281133.1	AL355480.3	-5.17	5.14e-07	0.000365	-0.37	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45580892~45580996:-
SARC	cis	rs890448	0.796	rs1426541	ENSG00000254531.1	FLJ20021	5.17	5.14e-07	0.000365	0.34	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101435702	chr4:101347780~101348883:+
SARC	cis	rs7772486	0.754	rs9399567	ENSG00000270638.1	RP3-466P17.1	5.17	5.16e-07	0.000366	0.26	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs9403741	ENSG00000270638.1	RP3-466P17.1	-5.16	5.16e-07	0.000367	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145735570~145737218:+
SARC	cis	rs7246657	0.943	rs713256	ENSG00000276846.1	CTD-3220F14.3	5.16	5.16e-07	0.000367	0.43	0.32	Coronary artery calcification;	chr19:37374463	chr19:37314868~37315620:-
SARC	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	5.16	5.17e-07	0.000367	0.36	0.32	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
SARC	cis	rs890448	0.796	rs10012024	ENSG00000254531.1	FLJ20021	5.16	5.17e-07	0.000367	0.34	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101431868	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs990960	ENSG00000254531.1	FLJ20021	5.16	5.17e-07	0.000367	0.34	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101432777	chr4:101347780~101348883:+
SARC	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-5.16	5.18e-07	0.000368	-0.33	-0.32	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
SARC	cis	rs4654783	0.521	rs59709264	ENSG00000228397.1	RP1-224A6.3	5.16	5.18e-07	0.000368	0.36	0.32	Endometriosis;	chr1:22122832	chr1:22023994~22024968:-
SARC	cis	rs899997	0.862	rs57260218	ENSG00000261143.1	ADAMTS7P3	-5.16	5.18e-07	0.000368	-0.46	-0.32	Coronary artery disease or large artery stroke;	chr15:78681430	chr15:77976042~77993057:+
SARC	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-5.16	5.19e-07	0.000369	-0.4	-0.32	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
SARC	cis	rs2439831	0.867	rs6493082	ENSG00000205771.5	CATSPER2P1	-5.16	5.2e-07	0.000369	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43342610	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs8041132	ENSG00000205771.5	CATSPER2P1	-5.16	5.2e-07	0.000369	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43342938	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs7170489	ENSG00000205771.5	CATSPER2P1	-5.16	5.2e-07	0.000369	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43344453	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs16957627	ENSG00000205771.5	CATSPER2P1	-5.16	5.2e-07	0.000369	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43350459	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs16957630	ENSG00000205771.5	CATSPER2P1	-5.16	5.2e-07	0.000369	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43350582	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs16957632	ENSG00000205771.5	CATSPER2P1	-5.16	5.2e-07	0.000369	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43350699	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs6493085	ENSG00000205771.5	CATSPER2P1	-5.16	5.2e-07	0.000369	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43361984	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs3213990	ENSG00000205771.5	CATSPER2P1	-5.16	5.2e-07	0.000369	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43378028	chr15:43726918~43747094:-
SARC	cis	rs7247513	0.964	rs1007352	ENSG00000213290.4	PGK1P2	-5.16	5.22e-07	0.00037	-0.39	-0.32	Bipolar disorder;	chr19:12611731	chr19:12559571~12561105:+
SARC	cis	rs17270561	0.609	rs1317510	ENSG00000272810.1	U91328.22	-5.16	5.25e-07	0.000372	-0.32	-0.32	Iron status biomarkers;	chr6:25778696	chr6:26013241~26013757:+
SARC	cis	rs9818758	0.607	rs35283189	ENSG00000225399.4	RP11-3B7.1	-5.16	5.26e-07	0.000373	-0.6	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076235	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs34580506	ENSG00000225399.4	RP11-3B7.1	-5.16	5.26e-07	0.000373	-0.6	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076280	chr3:49260085~49261316:+
SARC	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-5.16	5.28e-07	0.000374	-0.37	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
SARC	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-5.16	5.28e-07	0.000374	-0.42	-0.32	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
SARC	cis	rs1799949	0.86	rs8176279	ENSG00000267681.1	CTD-3199J23.6	-5.16	5.28e-07	0.000374	-0.34	-0.32	Menopause (age at onset);	chr17:43058379	chr17:43144956~43145255:+
SARC	cis	rs4862750	0.914	rs1346126	ENSG00000249742.1	RP11-217E13.1	-5.16	5.28e-07	0.000374	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186955250	chr4:186979490~187021973:-
SARC	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-5.16	5.28e-07	0.000374	-0.35	-0.32	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
SARC	cis	rs1075232	0.826	rs16956738	ENSG00000215302.7	CTD-3092A11.1	5.16	5.29e-07	0.000375	0.67	0.32	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30470779~30507623:+
SARC	cis	rs7809950	0.911	rs1015411	ENSG00000238832.1	snoU109	-5.16	5.29e-07	0.000375	-0.37	-0.32	Coronary artery disease;	chr7:107495167	chr7:107603363~107603507:+
SARC	cis	rs4654783	0.627	rs66766977	ENSG00000228397.1	RP1-224A6.3	5.16	5.3e-07	0.000375	0.36	0.32	Endometriosis;	chr1:22104599	chr1:22023994~22024968:-
SARC	cis	rs77204473	1	rs12275565	ENSG00000254851.1	RP11-109L13.1	5.16	5.33e-07	0.000377	0.66	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116882836	chr11:117135528~117138582:+
SARC	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-5.16	5.33e-07	0.000377	-0.36	-0.32	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
SARC	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-5.16	5.34e-07	0.000378	-0.39	-0.32	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
SARC	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-5.16	5.34e-07	0.000378	-0.33	-0.32	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
SARC	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	5.16	5.35e-07	0.000378	0.25	0.32	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
SARC	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-5.16	5.35e-07	0.000379	-0.42	-0.32	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
SARC	cis	rs7567389	0.51	rs1473623	ENSG00000236682.1	AC068282.3	5.16	5.36e-07	0.000379	0.35	0.32	Self-rated health;	chr2:127438644	chr2:127389130~127400580:+
SARC	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-5.16	5.36e-07	0.000379	-0.4	-0.32	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
SARC	cis	rs198389	0.617	rs503040	ENSG00000242349.4	NPPA-AS1	-5.16	5.37e-07	0.000379	-0.32	-0.32	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11830638	chr1:11841017~11848079:+
SARC	cis	rs3822625	0.541	rs12655019	ENSG00000271828.1	CTD-2310F14.1	5.16	5.37e-07	0.000379	0.55	0.32	Breast cancer (early onset);	chr5:56899963	chr5:56927874~56929573:+
SARC	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	5.16	5.37e-07	0.00038	0.45	0.32	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
SARC	cis	rs1823913	0.599	rs55685315	ENSG00000227542.1	AC092614.2	5.16	5.4e-07	0.000381	0.35	0.32	Obesity-related traits;	chr2:191306451	chr2:191229165~191246172:-
SARC	cis	rs193541	0.586	rs11241662	ENSG00000263432.2	RN7SL689P	-5.16	5.41e-07	0.000382	-0.4	-0.32	Glucose homeostasis traits;	chr5:122846280	chr5:123022487~123022783:-
SARC	cis	rs7772486	0.686	rs1004752	ENSG00000270638.1	RP3-466P17.1	-5.15	5.42e-07	0.000382	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs9390347	ENSG00000270638.1	RP3-466P17.1	-5.15	5.42e-07	0.000382	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs9390348	ENSG00000270638.1	RP3-466P17.1	-5.15	5.42e-07	0.000382	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145735570~145737218:+
SARC	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-5.15	5.42e-07	0.000382	-0.34	-0.32	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
SARC	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-5.15	5.42e-07	0.000383	-0.33	-0.32	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
SARC	cis	rs7809950	1	rs10243340	ENSG00000238832.1	snoU109	-5.15	5.44e-07	0.000384	-0.37	-0.32	Coronary artery disease;	chr7:107450510	chr7:107603363~107603507:+
SARC	cis	rs7772486	0.727	rs10447449	ENSG00000270638.1	RP3-466P17.1	5.15	5.44e-07	0.000384	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145735570~145737218:+
SARC	cis	rs783540	0.5	rs1313494	ENSG00000275695.1	UBE2Q2P6	-5.15	5.44e-07	0.000384	-0.35	-0.32	Schizophrenia;	chr15:82605530	chr15:82445719~82454837:+
SARC	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	5.15	5.44e-07	0.000384	0.68	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
SARC	cis	rs160451	0.933	rs2088198	ENSG00000251136.7	RP11-37B2.1	5.15	5.46e-07	0.000385	0.37	0.32	Leprosy;	chr8:89678693	chr8:89609409~89757727:-
SARC	cis	rs77204473	0.744	rs12273536	ENSG00000254851.1	RP11-109L13.1	5.15	5.46e-07	0.000385	0.79	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040255	chr11:117135528~117138582:+
SARC	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-5.15	5.46e-07	0.000385	-0.44	-0.32	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
SARC	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-5.15	5.46e-07	0.000385	-0.44	-0.32	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
SARC	cis	rs7772486	0.686	rs4896827	ENSG00000270638.1	RP3-466P17.1	5.15	5.47e-07	0.000385	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs4896828	ENSG00000270638.1	RP3-466P17.1	5.15	5.47e-07	0.000385	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs6570701	ENSG00000270638.1	RP3-466P17.1	5.15	5.47e-07	0.000385	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs702305	ENSG00000270638.1	RP3-466P17.1	-5.15	5.47e-07	0.000385	-0.25	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs857875	ENSG00000270638.1	RP3-466P17.1	-5.15	5.47e-07	0.000385	-0.25	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145735570~145737218:+
SARC	cis	rs858239	1	rs156421	ENSG00000226816.2	AC005082.12	5.15	5.47e-07	0.000385	0.4	0.32	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23206013~23208045:+
SARC	cis	rs2439831	0.681	rs540388	ENSG00000205771.5	CATSPER2P1	-5.15	5.48e-07	0.000386	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43314296	chr15:43726918~43747094:-
SARC	cis	rs7772486	0.686	rs2092263	ENSG00000270638.1	RP3-466P17.1	-5.15	5.48e-07	0.000386	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145735570~145737218:+
SARC	cis	rs2836950	0.501	rs4818018	ENSG00000255568.3	BRWD1-AS2	-5.15	5.48e-07	0.000386	-0.29	-0.32	Menarche (age at onset);	chr21:39322146	chr21:39313935~39314962:+
SARC	cis	rs2836950	0.501	rs4818019	ENSG00000255568.3	BRWD1-AS2	-5.15	5.48e-07	0.000386	-0.29	-0.32	Menarche (age at onset);	chr21:39322530	chr21:39313935~39314962:+
SARC	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-5.15	5.48e-07	0.000387	-0.59	-0.32	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
SARC	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	5.15	5.5e-07	0.000388	0.35	0.32	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
SARC	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	5.15	5.52e-07	0.000389	0.39	0.32	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
SARC	cis	rs7772486	0.754	rs6570708	ENSG00000270638.1	RP3-466P17.1	-5.15	5.52e-07	0.000389	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145735570~145737218:+
SARC	cis	rs7809950	1	rs2520271	ENSG00000238832.1	snoU109	-5.15	5.53e-07	0.000389	-0.38	-0.32	Coronary artery disease;	chr7:107554504	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs2237676	ENSG00000238832.1	snoU109	-5.15	5.53e-07	0.000389	-0.38	-0.32	Coronary artery disease;	chr7:107557634	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs2253146	ENSG00000238832.1	snoU109	-5.15	5.53e-07	0.000389	-0.38	-0.32	Coronary artery disease;	chr7:107559874	chr7:107603363~107603507:+
SARC	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	5.15	5.54e-07	0.00039	0.37	0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
SARC	cis	rs7809950	1	rs2395883	ENSG00000238832.1	snoU109	-5.15	5.54e-07	0.00039	-0.37	-0.32	Coronary artery disease;	chr7:107449225	chr7:107603363~107603507:+
SARC	cis	rs890448	0.796	rs4452435	ENSG00000254531.1	FLJ20021	-5.15	5.54e-07	0.00039	-0.33	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101416549	chr4:101347780~101348883:+
SARC	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-5.15	5.55e-07	0.000391	-0.38	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
SARC	cis	rs7216064	0.953	rs10445361	ENSG00000278219.1	AC145343.1	5.15	5.56e-07	0.000391	0.38	0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67966122	chr17:68101538~68101639:+
SARC	cis	rs890448	0.519	rs10027194	ENSG00000254531.1	FLJ20021	5.15	5.57e-07	0.000392	0.33	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101371280	chr4:101347780~101348883:+
SARC	cis	rs890448	0.76	rs12642424	ENSG00000254531.1	FLJ20021	5.15	5.57e-07	0.000392	0.33	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101382629	chr4:101347780~101348883:+
SARC	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	5.15	5.57e-07	0.000392	0.37	0.32	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
SARC	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	5.15	5.58e-07	0.000393	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
SARC	cis	rs853679	0.517	rs9393891	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Depression;	chr6:28111382	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9468286	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Depression;	chr6:28111650	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.516	rs7739216	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Parkinson's disease;	chr6:28112168	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs35512245	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Depression;	chr6:28112175	chr6:28078792~28081130:-
SARC	cis	rs853679	0.542	rs9393892	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Depression;	chr6:28113616	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9380055	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Depression;	chr6:28113851	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9368553	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Depression;	chr6:28114487	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9368554	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Depression;	chr6:28114933	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs4713137	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Depression;	chr6:28115743	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9348793	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Depression;	chr6:28116411	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.586	rs6905516	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Parkinson's disease;	chr6:28118700	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.586	rs6905522	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Parkinson's disease;	chr6:28118701	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.586	rs9468290	ENSG00000272009.1	RP1-313I6.12	-5.15	5.58e-07	0.000393	-0.36	-0.32	Parkinson's disease;	chr6:28119896	chr6:28078792~28081130:-
SARC	cis	rs7626444	0.625	rs1798634	ENSG00000272359.1	U4	-5.15	5.58e-07	0.000393	-0.32	-0.32	Monocyte count;	chr3:196747416	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.625	rs1798635	ENSG00000272359.1	U4	-5.15	5.58e-07	0.000393	-0.32	-0.32	Monocyte count;	chr3:196747418	chr3:196747192~196747324:-
SARC	cis	rs1865760	1	rs3830057	ENSG00000272462.2	U91328.19	-5.15	5.59e-07	0.000393	-0.3	-0.32	Height;	chr6:25918282	chr6:25992662~26001775:+
SARC	cis	rs1865760	1	rs3752421	ENSG00000272462.2	U91328.19	-5.15	5.59e-07	0.000393	-0.3	-0.32	Height;	chr6:25918460	chr6:25992662~26001775:+
SARC	cis	rs1823913	0.599	rs12988037	ENSG00000227542.1	AC092614.2	5.15	5.59e-07	0.000393	0.35	0.32	Obesity-related traits;	chr2:191306419	chr2:191229165~191246172:-
SARC	cis	rs2562456	0.755	rs11670868	ENSG00000268081.1	RP11-678G14.2	5.15	5.61e-07	0.000394	0.53	0.32	Pain;	chr19:21373613	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs55961038	ENSG00000268081.1	RP11-678G14.2	5.15	5.61e-07	0.000394	0.53	0.32	Pain;	chr19:21375205	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs2358993	ENSG00000268081.1	RP11-678G14.2	5.15	5.61e-07	0.000394	0.53	0.32	Pain;	chr19:21375367	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs11672583	ENSG00000268081.1	RP11-678G14.2	5.15	5.61e-07	0.000394	0.53	0.32	Pain;	chr19:21379363	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs17680605	ENSG00000268081.1	RP11-678G14.2	5.15	5.61e-07	0.000394	0.53	0.32	Pain;	chr19:21379646	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62110416	ENSG00000268081.1	RP11-678G14.2	5.15	5.61e-07	0.000394	0.53	0.32	Pain;	chr19:21401924	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.754	rs112195516	ENSG00000268081.1	RP11-678G14.2	5.15	5.61e-07	0.000394	0.53	0.32	Pain;	chr19:21410849	chr19:21554640~21569237:-
SARC	cis	rs200986	1	rs200986	ENSG00000219392.1	RP1-265C24.5	-5.15	5.62e-07	0.000395	-0.43	-0.32	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28115628~28116551:+
SARC	cis	rs916888	0.779	rs199528	ENSG00000261575.2	RP11-259G18.1	5.15	5.62e-07	0.000395	0.47	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46267037~46268694:+
SARC	cis	rs916888	0.821	rs199525	ENSG00000261575.2	RP11-259G18.1	5.15	5.62e-07	0.000395	0.47	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46267037~46268694:+
SARC	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-5.15	5.62e-07	0.000395	-0.39	-0.32	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
SARC	cis	rs875971	0.66	rs6460308	ENSG00000236529.1	RP13-254B10.1	-5.15	5.62e-07	0.000395	-0.33	-0.32	Aortic root size;	chr7:66619753	chr7:65840212~65840596:+
SARC	cis	rs2239557	1	rs11628710	ENSG00000259065.1	RP5-1021I20.1	-5.15	5.62e-07	0.000395	-0.37	-0.32	Common traits (Other);	chr14:74182577	chr14:73787360~73803270:+
SARC	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-5.15	5.63e-07	0.000395	-0.36	-0.32	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
SARC	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-5.15	5.63e-07	0.000395	-0.36	-0.32	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
SARC	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-5.15	5.63e-07	0.000396	-0.3	-0.32	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
SARC	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	5.15	5.64e-07	0.000396	0.49	0.32	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
SARC	cis	rs7712401	0.601	rs27976	ENSG00000263432.2	RN7SL689P	-5.15	5.64e-07	0.000396	-0.4	-0.32	Mean platelet volume;	chr5:122870765	chr5:123022487~123022783:-
SARC	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-5.15	5.64e-07	0.000396	-0.39	-0.32	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
SARC	cis	rs198389	0.589	rs12404124	ENSG00000242349.4	NPPA-AS1	-5.15	5.65e-07	0.000397	-0.33	-0.32	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813812	chr1:11841017~11848079:+
SARC	cis	rs7772486	0.686	rs9497395	ENSG00000270638.1	RP3-466P17.1	-5.15	5.66e-07	0.000397	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145735570~145737218:+
SARC	cis	rs1134634	0.52	rs7661102	ENSG00000273133.1	RP11-799M12.2	-5.15	5.68e-07	0.000398	-0.41	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15596914	chr4:15563698~15564253:-
SARC	cis	rs1134634	0.52	rs56041141	ENSG00000273133.1	RP11-799M12.2	-5.15	5.68e-07	0.000398	-0.41	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15598222	chr4:15563698~15564253:-
SARC	cis	rs7246657	0.882	rs10422667	ENSG00000276846.1	CTD-3220F14.3	5.14	5.68e-07	0.000399	0.43	0.32	Coronary artery calcification;	chr19:37446974	chr19:37314868~37315620:-
SARC	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-5.14	5.69e-07	0.000399	-0.36	-0.32	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
SARC	cis	rs2439831	0.681	rs478104	ENSG00000205771.5	CATSPER2P1	-5.14	5.7e-07	4e-04	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43302702	chr15:43726918~43747094:-
SARC	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-5.14	5.7e-07	4e-04	-0.39	-0.32	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
SARC	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-5.14	5.7e-07	4e-04	-0.39	-0.32	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
SARC	cis	rs890448	0.796	rs6845368	ENSG00000254531.1	FLJ20021	-5.14	5.7e-07	4e-04	-0.34	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101364742	chr4:101347780~101348883:+
SARC	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	5.14	5.71e-07	4e-04	0.3	0.32	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
SARC	cis	rs1865760	0.82	rs9348697	ENSG00000272810.1	U91328.22	-5.14	5.71e-07	4e-04	-0.32	-0.32	Height;	chr6:25890606	chr6:26013241~26013757:+
SARC	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	5.14	5.71e-07	4e-04	0.34	0.32	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
SARC	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-5.14	5.71e-07	0.000401	-0.31	-0.32	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
SARC	cis	rs7246657	0.943	rs10420430	ENSG00000276846.1	CTD-3220F14.3	5.14	5.72e-07	0.000401	0.43	0.32	Coronary artery calcification;	chr19:37403292	chr19:37314868~37315620:-
SARC	cis	rs9309473	0.95	rs6546860	ENSG00000163016.8	ALMS1P	5.14	5.72e-07	0.000401	0.39	0.32	Metabolite levels;	chr2:73617122	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.95	rs13427832	ENSG00000163016.8	ALMS1P	5.14	5.72e-07	0.000401	0.39	0.32	Metabolite levels;	chr2:73617691	chr2:73644919~73685576:+
SARC	cis	rs890448	0.796	rs1365381	ENSG00000254531.1	FLJ20021	-5.14	5.72e-07	0.000401	-0.33	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422718	chr4:101347780~101348883:+
SARC	cis	rs17270561	0.609	rs1892248	ENSG00000272810.1	U91328.22	-5.14	5.73e-07	0.000401	-0.32	-0.32	Iron status biomarkers;	chr6:25768686	chr6:26013241~26013757:+
SARC	cis	rs3822625	0.541	rs76679228	ENSG00000271828.1	CTD-2310F14.1	5.14	5.73e-07	0.000402	0.53	0.32	Breast cancer (early onset);	chr5:56903684	chr5:56927874~56929573:+
SARC	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	5.14	5.74e-07	0.000402	0.42	0.32	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
SARC	cis	rs4862750	0.957	rs4861733	ENSG00000250971.1	RP11-696F12.1	5.14	5.74e-07	0.000402	0.38	0.32	Lobe attachment (rater-scored or self-reported);	chr4:186982779	chr4:187060099~187060930:+
SARC	cis	rs7809950	1	rs28714607	ENSG00000238832.1	snoU109	-5.14	5.74e-07	0.000402	-0.36	-0.32	Coronary artery disease;	chr7:107465808	chr7:107603363~107603507:+
SARC	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-5.14	5.75e-07	0.000403	-0.32	-0.32	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
SARC	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-5.14	5.75e-07	0.000403	-0.32	-0.32	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
SARC	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-5.14	5.75e-07	0.000403	-0.32	-0.32	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
SARC	cis	rs7301826	0.504	rs11061164	ENSG00000256250.1	RP11-989F5.1	-5.14	5.75e-07	0.000403	-0.32	-0.32	Plasma plasminogen activator levels;	chr12:130839724	chr12:130810606~130812438:+
SARC	cis	rs2562456	0.833	rs11666447	ENSG00000268081.1	RP11-678G14.2	5.14	5.75e-07	0.000403	0.53	0.32	Pain;	chr19:21416270	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs11666525	ENSG00000268081.1	RP11-678G14.2	5.14	5.75e-07	0.000403	0.53	0.32	Pain;	chr19:21416503	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.793	rs62110424	ENSG00000268081.1	RP11-678G14.2	5.14	5.75e-07	0.000403	0.53	0.32	Pain;	chr19:21416835	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.793	rs3853838	ENSG00000268081.1	RP11-678G14.2	5.14	5.75e-07	0.000403	0.53	0.32	Pain;	chr19:21419192	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62110426	ENSG00000268081.1	RP11-678G14.2	5.14	5.75e-07	0.000403	0.53	0.32	Pain;	chr19:21420124	chr19:21554640~21569237:-
SARC	cis	rs1823913	1	rs4853562	ENSG00000227542.1	AC092614.2	-5.14	5.75e-07	0.000403	-0.35	-0.32	Obesity-related traits;	chr2:191253696	chr2:191229165~191246172:-
SARC	cis	rs1823913	1	rs4853461	ENSG00000227542.1	AC092614.2	-5.14	5.75e-07	0.000403	-0.35	-0.32	Obesity-related traits;	chr2:191254572	chr2:191229165~191246172:-
SARC	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	5.14	5.75e-07	0.000403	0.31	0.32	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	5.14	5.75e-07	0.000403	0.31	0.32	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	5.14	5.75e-07	0.000403	0.31	0.32	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
SARC	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-5.14	5.77e-07	0.000404	-0.32	-0.32	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
SARC	cis	rs6969780	0.915	rs2107063	ENSG00000233429.8	HOTAIRM1	-5.14	5.78e-07	0.000404	-0.44	-0.32	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127727	chr7:27095647~27100265:+
SARC	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-5.14	5.78e-07	0.000404	-0.31	-0.32	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
SARC	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-5.14	5.78e-07	0.000404	-0.32	-0.32	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
SARC	cis	rs4713118	0.955	rs9393848	ENSG00000219392.1	RP1-265C24.5	-5.14	5.8e-07	0.000406	-0.46	-0.32	Parkinson's disease;	chr6:27720590	chr6:28115628~28116551:+
SARC	cis	rs2439831	0.681	rs825739	ENSG00000205771.5	CATSPER2P1	-5.14	5.8e-07	0.000406	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43300230	chr15:43726918~43747094:-
SARC	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	5.14	5.8e-07	0.000406	0.3	0.32	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
SARC	cis	rs2562456	0.876	rs2562413	ENSG00000268081.1	RP11-678G14.2	5.14	5.81e-07	0.000406	0.51	0.32	Pain;	chr19:21420084	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.916	rs1967182	ENSG00000268081.1	RP11-678G14.2	5.14	5.81e-07	0.000406	0.51	0.32	Pain;	chr19:21420337	chr19:21554640~21569237:-
SARC	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	5.14	5.81e-07	0.000407	0.37	0.32	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
SARC	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-5.14	5.82e-07	0.000407	-0.34	-0.32	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
SARC	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-5.14	5.82e-07	0.000407	-0.34	-0.32	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
SARC	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-5.14	5.82e-07	0.000407	-0.32	-0.32	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
SARC	cis	rs11719291	0.504	rs34571182	ENSG00000225399.4	RP11-3B7.1	-5.14	5.82e-07	0.000407	-0.58	-0.32	Cognitive function;	chr3:49171624	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs11706189	ENSG00000225399.4	RP11-3B7.1	-5.14	5.82e-07	0.000407	-0.58	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49173400	chr3:49260085~49261316:+
SARC	cis	rs1799949	1	rs8077486	ENSG00000267681.1	CTD-3199J23.6	-5.14	5.83e-07	0.000407	-0.35	-0.32	Menopause (age at onset);	chr17:43060788	chr17:43144956~43145255:+
SARC	cis	rs7809950	0.906	rs2253269	ENSG00000238832.1	snoU109	-5.14	5.83e-07	0.000408	-0.38	-0.32	Coronary artery disease;	chr7:107560669	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.953	rs2253271	ENSG00000238832.1	snoU109	-5.14	5.83e-07	0.000408	-0.38	-0.32	Coronary artery disease;	chr7:107560807	chr7:107603363~107603507:+
SARC	cis	rs77204473	0.744	rs2046150	ENSG00000254851.1	RP11-109L13.1	5.14	5.83e-07	0.000408	0.72	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117182717	chr11:117135528~117138582:+
SARC	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	5.14	5.84e-07	0.000408	0.43	0.32	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
SARC	cis	rs9596270	0.772	rs11842790	ENSG00000231607.7	DLEU2	5.14	5.84e-07	0.000408	0.44	0.32	Multiple sclerosis;	chr13:50350312	chr13:49982552~50125720:-
SARC	cis	rs1865760	1	rs6938233	ENSG00000272810.1	U91328.22	-5.14	5.84e-07	0.000408	-0.32	-0.32	Height;	chr6:25913849	chr6:26013241~26013757:+
SARC	cis	rs9818758	0.607	rs11706052	ENSG00000225399.4	RP11-3B7.1	-5.14	5.84e-07	0.000408	-0.6	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49026677	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs61729488	ENSG00000225399.4	RP11-3B7.1	-5.14	5.84e-07	0.000408	-0.6	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49030471	chr3:49260085~49261316:+
SARC	cis	rs11719291	0.584	rs13080725	ENSG00000225399.4	RP11-3B7.1	-5.14	5.84e-07	0.000408	-0.6	-0.32	Cognitive function;	chr3:49038659	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs35108630	ENSG00000225399.4	RP11-3B7.1	-5.14	5.84e-07	0.000408	-0.6	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49050923	chr3:49260085~49261316:+
SARC	cis	rs9532669	0.927	rs9532670	ENSG00000176268.5	CYCSP34	-5.14	5.85e-07	0.000408	-0.3	-0.32	Cervical cancer;	chr13:40927691	chr13:40863599~40863902:-
SARC	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	5.14	5.85e-07	0.000409	0.41	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
SARC	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	5.14	5.85e-07	0.000409	0.33	0.32	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
SARC	cis	rs2439831	0.867	rs2412778	ENSG00000205771.5	CATSPER2P1	-5.14	5.86e-07	0.000409	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43368784	chr15:43726918~43747094:-
SARC	cis	rs2179367	0.959	rs514839	ENSG00000231760.4	RP11-350J20.5	5.14	5.87e-07	0.00041	0.39	0.32	Dupuytren's disease;	chr6:149327304	chr6:149796151~149826294:-
SARC	cis	rs5769707	0.656	rs135875	ENSG00000188511.11	C22orf34	5.14	5.87e-07	0.00041	0.4	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49414524~49657542:-
SARC	cis	rs524281	0.861	rs580891	ENSG00000255320.1	RP11-755F10.1	5.14	5.88e-07	0.00041	0.46	0.32	Electroencephalogram traits;	chr11:66187210	chr11:66244840~66246239:-
SARC	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	5.14	5.88e-07	0.00041	0.32	0.32	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
SARC	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	5.14	5.88e-07	0.00041	0.38	0.32	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
SARC	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	5.14	5.88e-07	0.00041	0.38	0.32	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
SARC	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	5.14	5.88e-07	0.00041	0.38	0.32	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
SARC	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	5.14	5.88e-07	0.00041	0.38	0.32	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
SARC	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	5.14	5.88e-07	0.00041	0.38	0.32	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
SARC	cis	rs4713118	0.869	rs9283883	ENSG00000219392.1	RP1-265C24.5	-5.14	5.88e-07	0.000411	-0.44	-0.32	Parkinson's disease;	chr6:27747691	chr6:28115628~28116551:+
SARC	cis	rs1865760	1	rs7739966	ENSG00000272810.1	U91328.22	-5.14	5.89e-07	0.000411	-0.32	-0.32	Height;	chr6:25905812	chr6:26013241~26013757:+
SARC	cis	rs1865760	1	rs56118523	ENSG00000272810.1	U91328.22	-5.14	5.89e-07	0.000411	-0.32	-0.32	Height;	chr6:25908747	chr6:26013241~26013757:+
SARC	cis	rs1865760	1	rs12209482	ENSG00000272810.1	U91328.22	-5.14	5.89e-07	0.000411	-0.32	-0.32	Height;	chr6:25909001	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.963	rs3846838	ENSG00000272810.1	U91328.22	-5.14	5.89e-07	0.000411	-0.32	-0.32	Height;	chr6:25911547	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.928	rs9295673	ENSG00000272810.1	U91328.22	-5.14	5.89e-07	0.000411	-0.32	-0.32	Height;	chr6:25911866	chr6:26013241~26013757:+
SARC	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	5.14	5.89e-07	0.000411	0.36	0.32	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
SARC	cis	rs6964833	0.554	rs2527380	ENSG00000123965.13	PMS2P5	-5.14	5.89e-07	0.000411	-0.46	-0.32	Menarche (age at onset);	chr7:74690372	chr7:74894116~74897835:+
SARC	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-5.14	5.9e-07	0.000412	-0.36	-0.32	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
SARC	cis	rs8005677	1	rs8014936	ENSG00000257285.4	RP11-298I3.1	5.14	5.9e-07	0.000412	0.29	0.32	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:22929609~22955562:+
SARC	cis	rs8005677	1	rs8016061	ENSG00000257285.4	RP11-298I3.1	5.14	5.9e-07	0.000412	0.29	0.32	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:22929609~22955562:+
SARC	cis	rs8005677	1	rs8005677	ENSG00000257285.4	RP11-298I3.1	5.14	5.9e-07	0.000412	0.29	0.32	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:22929609~22955562:+
SARC	cis	rs11118620	1	rs11118620	ENSG00000257551.1	HLX-AS1	5.14	5.91e-07	0.000412	0.39	0.32	Heart failure;	chr1:220855166	chr1:220832763~220880140:-
SARC	cis	rs3822625	0.541	rs12657353	ENSG00000271828.1	CTD-2310F14.1	5.14	5.91e-07	0.000412	0.55	0.32	Breast cancer (early onset);	chr5:56900449	chr5:56927874~56929573:+
SARC	cis	rs1865760	0.566	rs9366634	ENSG00000272810.1	U91328.22	-5.14	5.91e-07	0.000412	-0.31	-0.32	Height;	chr6:26072168	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.585	rs9393663	ENSG00000272810.1	U91328.22	-5.14	5.91e-07	0.000412	-0.33	-0.32	Iron status biomarkers;	chr6:25740805	chr6:26013241~26013757:+
SARC	cis	rs6452524	0.618	rs1871203	ENSG00000248112.1	RP11-78C3.1	5.14	5.93e-07	0.000413	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:82919376~82921119:-
SARC	cis	rs7615952	0.688	rs4422259	ENSG00000241288.6	RP11-379B18.5	-5.14	5.94e-07	0.000414	-0.36	-0.32	Blood pressure (smoking interaction);	chr3:125826988	chr3:125827238~125916384:-
SARC	cis	rs12022452	1	rs3738471	ENSG00000238287.1	RP11-656D10.3	-5.14	5.94e-07	0.000414	-0.52	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40493157~40508661:-
SARC	cis	rs4713118	0.513	rs1225591	ENSG00000216901.1	AL022393.7	5.14	5.95e-07	0.000415	0.45	0.32	Parkinson's disease;	chr6:28180974	chr6:28176188~28176674:+
SARC	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-5.14	5.95e-07	0.000415	-0.4	-0.32	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
SARC	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-5.13	5.96e-07	0.000415	-0.48	-0.32	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
SARC	cis	rs1799949	1	rs915945	ENSG00000267681.1	CTD-3199J23.6	-5.13	5.96e-07	0.000415	-0.37	-0.32	Menopause (age at onset);	chr17:43027847	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs12944597	ENSG00000267681.1	CTD-3199J23.6	-5.13	5.96e-07	0.000415	-0.37	-0.32	Menopause (age at onset);	chr17:43035667	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs12942277	ENSG00000267681.1	CTD-3199J23.6	-5.13	5.96e-07	0.000415	-0.37	-0.32	Menopause (age at onset);	chr17:43035957	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs34616041	ENSG00000267681.1	CTD-3199J23.6	-5.13	5.96e-07	0.000415	-0.37	-0.32	Menopause (age at onset);	chr17:43036769	chr17:43144956~43145255:+
SARC	cis	rs867371	0.722	rs8033050	ENSG00000259429.4	UBE2Q2P2	-5.13	5.96e-07	0.000415	-0.3	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82355142~82420075:+
SARC	cis	rs27434	0.66	rs27043	ENSG00000272109.1	CTD-2260A17.3	5.13	5.96e-07	0.000415	0.46	0.32	Ankylosing spondylitis;	chr5:96781596	chr5:96804353~96806105:+
SARC	cis	rs1865760	0.519	rs4360119	ENSG00000272810.1	U91328.22	-5.13	5.96e-07	0.000416	-0.32	-0.32	Height;	chr6:25814846	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.516	rs10807007	ENSG00000272810.1	U91328.22	-5.13	5.97e-07	0.000416	-0.3	-0.32	Height;	chr6:26048703	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.516	rs9379819	ENSG00000272810.1	U91328.22	-5.13	5.97e-07	0.000416	-0.3	-0.32	Height;	chr6:26049591	chr6:26013241~26013757:+
SARC	cis	rs2562456	0.876	rs2650844	ENSG00000268081.1	RP11-678G14.2	5.13	5.97e-07	0.000416	0.53	0.32	Pain;	chr19:21419288	chr19:21554640~21569237:-
SARC	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-5.13	5.97e-07	0.000416	-0.36	-0.32	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-5.13	5.97e-07	0.000416	-0.36	-0.32	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
SARC	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-5.13	5.98e-07	0.000416	-0.4	-0.32	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-5.13	5.98e-07	0.000416	-0.42	-0.32	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
SARC	cis	rs7615952	0.576	rs6780025	ENSG00000250012.1	RP11-124N2.1	-5.13	5.99e-07	0.000417	-0.31	-0.32	Blood pressure (smoking interaction);	chr3:126096781	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.576	rs6804482	ENSG00000250012.1	RP11-124N2.1	-5.13	5.99e-07	0.000417	-0.31	-0.32	Blood pressure (smoking interaction);	chr3:126096919	chr3:126084220~126095349:+
SARC	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-5.13	5.99e-07	0.000417	-0.39	-0.32	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
SARC	cis	rs916888	0.821	rs70600	ENSG00000261575.2	RP11-259G18.1	5.13	6e-07	0.000418	0.45	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46267037~46268694:+
SARC	cis	rs524281	0.861	rs535395	ENSG00000255320.1	RP11-755F10.1	-5.13	6.01e-07	0.000418	-0.45	-0.32	Electroencephalogram traits;	chr11:66139063	chr11:66244840~66246239:-
SARC	cis	rs6538678	0.824	rs7307510	ENSG00000258343.1	RP11-536G4.2	-5.13	6.01e-07	0.000418	-0.43	-0.32	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95795345~95858839:-
SARC	cis	rs3822625	0.541	rs112793966	ENSG00000271828.1	CTD-2310F14.1	5.13	6.03e-07	0.000419	0.53	0.32	Breast cancer (early onset);	chr5:56908291	chr5:56927874~56929573:+
SARC	cis	rs1707322	0.506	rs2991983	ENSG00000281133.1	AL355480.3	5.13	6.03e-07	0.000419	0.37	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.717	rs3014249	ENSG00000281133.1	AL355480.3	5.13	6.03e-07	0.000419	0.37	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.686	rs2991987	ENSG00000281133.1	AL355480.3	5.13	6.03e-07	0.000419	0.37	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45580892~45580996:-
SARC	cis	rs6452524	0.648	rs27364	ENSG00000248112.1	RP11-78C3.1	5.13	6.05e-07	0.00042	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:82919376~82921119:-
SARC	cis	rs10483853	0.525	rs10138789	ENSG00000258695.2	RP3-414A15.2	-5.13	6.05e-07	0.000421	-0.39	-0.32	Coronary artery calcification;	chr14:73497574	chr14:73522878~73530610:+
SARC	cis	rs7809950	1	rs2520268	ENSG00000238832.1	snoU109	-5.13	6.05e-07	0.000421	-0.38	-0.32	Coronary artery disease;	chr7:107550716	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs2520269	ENSG00000238832.1	snoU109	-5.13	6.05e-07	0.000421	-0.38	-0.32	Coronary artery disease;	chr7:107550882	chr7:107603363~107603507:+
SARC	cis	rs8031584	0.706	rs798084	ENSG00000260382.1	RP11-540B6.2	5.13	6.06e-07	0.000421	0.39	0.32	Huntington's disease progression;	chr15:30834732	chr15:30882267~30883231:-
SARC	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-5.13	6.06e-07	0.000421	-0.39	-0.32	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
SARC	cis	rs4862750	0.914	rs1991255	ENSG00000249742.1	RP11-217E13.1	-5.13	6.07e-07	0.000422	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186954186	chr4:186979490~187021973:-
SARC	cis	rs4713118	0.516	rs6931858	ENSG00000272009.1	RP1-313I6.12	-5.13	6.07e-07	0.000422	-0.38	-0.32	Parkinson's disease;	chr6:28110633	chr6:28078792~28081130:-
SARC	cis	rs2836950	0.545	rs2836956	ENSG00000255568.3	BRWD1-AS2	5.13	6.07e-07	0.000422	0.29	0.32	Menarche (age at onset);	chr21:39251092	chr21:39313935~39314962:+
SARC	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-5.13	6.08e-07	0.000423	-0.35	-0.32	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
SARC	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-5.13	6.08e-07	0.000423	-0.35	-0.32	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
SARC	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-5.13	6.08e-07	0.000423	-0.35	-0.32	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-5.13	6.08e-07	0.000423	-0.35	-0.32	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-5.13	6.08e-07	0.000423	-0.35	-0.32	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
SARC	cis	rs2439831	0.717	rs9806227	ENSG00000205771.5	CATSPER2P1	-5.13	6.08e-07	0.000423	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43387917	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs2584702	ENSG00000205771.5	CATSPER2P1	-5.13	6.08e-07	0.000423	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43392716	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs2243434	ENSG00000205771.5	CATSPER2P1	-5.13	6.08e-07	0.000423	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43397669	chr15:43726918~43747094:-
SARC	cis	rs7615952	0.576	rs2276727	ENSG00000250012.1	RP11-124N2.1	-5.13	6.09e-07	0.000423	-0.31	-0.32	Blood pressure (smoking interaction);	chr3:126107400	chr3:126084220~126095349:+
SARC	cis	rs2836974	0.563	rs6517522	ENSG00000255568.3	BRWD1-AS2	5.13	6.12e-07	0.000425	0.29	0.32	Cognitive function;	chr21:39181919	chr21:39313935~39314962:+
SARC	cis	rs783540	0.521	rs28719490	ENSG00000275695.1	UBE2Q2P6	5.13	6.13e-07	0.000426	0.34	0.32	Schizophrenia;	chr15:82720688	chr15:82445719~82454837:+
SARC	cis	rs783540	0.5	rs7178459	ENSG00000275695.1	UBE2Q2P6	5.13	6.13e-07	0.000426	0.34	0.32	Schizophrenia;	chr15:82729632	chr15:82445719~82454837:+
SARC	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	5.13	6.14e-07	0.000426	0.31	0.32	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
SARC	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	5.13	6.14e-07	0.000426	0.41	0.32	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
SARC	cis	rs9818758	0.607	rs9880088	ENSG00000225399.4	RP11-3B7.1	-5.13	6.15e-07	0.000427	-0.59	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49141557	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs9862483	ENSG00000225399.4	RP11-3B7.1	-5.13	6.15e-07	0.000427	-0.59	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49158008	chr3:49260085~49261316:+
SARC	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-5.13	6.16e-07	0.000427	-0.32	-0.32	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
SARC	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	5.13	6.18e-07	0.000429	0.39	0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
SARC	cis	rs6452524	0.618	rs6452501	ENSG00000248112.1	RP11-78C3.1	5.13	6.18e-07	0.000429	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:82919376~82921119:-
SARC	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	5.13	6.19e-07	0.00043	0.34	0.32	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
SARC	cis	rs2439831	0.681	rs999047	ENSG00000205771.5	CATSPER2P1	-5.13	6.2e-07	0.00043	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43396718	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.614	rs2467733	ENSG00000205771.5	CATSPER2P1	-5.13	6.2e-07	0.00043	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43401130	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.681	rs2444036	ENSG00000205771.5	CATSPER2P1	-5.13	6.2e-07	0.00043	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43401910	chr15:43726918~43747094:-
SARC	cis	rs6570726	0.846	rs453834	ENSG00000270638.1	RP3-466P17.1	5.13	6.2e-07	0.00043	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145565125	chr6:145735570~145737218:+
SARC	cis	rs11719291	0.833	rs13074318	ENSG00000225399.4	RP11-3B7.1	-5.13	6.22e-07	0.000431	-0.59	-0.32	Cognitive function;	chr3:48779292	chr3:49260085~49261316:+
SARC	cis	rs12655019	0.92	rs2271202	ENSG00000271828.1	CTD-2310F14.1	5.13	6.22e-07	0.000431	0.53	0.32	Breast cancer (early onset);	chr5:56912714	chr5:56927874~56929573:+
SARC	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-5.13	6.22e-07	0.000432	-0.3	-0.32	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
SARC	cis	rs77204473	1	rs11216185	ENSG00000254851.1	RP11-109L13.1	5.13	6.23e-07	0.000432	0.69	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117135528~117138582:+
SARC	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-5.13	6.23e-07	0.000432	-0.3	-0.32	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
SARC	cis	rs4713118	0.588	rs200994	ENSG00000219392.1	RP1-265C24.5	5.13	6.23e-07	0.000432	0.45	0.32	Parkinson's disease;	chr6:27846035	chr6:28115628~28116551:+
SARC	cis	rs890448	0.796	rs10433980	ENSG00000254531.1	FLJ20021	5.13	6.24e-07	0.000433	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101362429	chr4:101347780~101348883:+
SARC	cis	rs890448	0.694	rs13108283	ENSG00000254531.1	FLJ20021	5.13	6.24e-07	0.000433	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101371711	chr4:101347780~101348883:+
SARC	cis	rs2439831	0.681	rs528517	ENSG00000205771.5	CATSPER2P1	-5.12	6.26e-07	0.000434	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43320727	chr15:43726918~43747094:-
SARC	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	5.12	6.27e-07	0.000434	0.36	0.32	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
SARC	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-5.12	6.27e-07	0.000435	-0.36	-0.32	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
SARC	cis	rs7809950	0.954	rs2520242	ENSG00000238832.1	snoU109	5.12	6.28e-07	0.000435	0.36	0.32	Coronary artery disease;	chr7:107495875	chr7:107603363~107603507:+
SARC	cis	rs2439831	0.717	rs7165471	ENSG00000205771.5	CATSPER2P1	-5.12	6.29e-07	0.000436	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43352590	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs4075674	ENSG00000205771.5	CATSPER2P1	-5.12	6.29e-07	0.000436	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43358032	chr15:43726918~43747094:-
SARC	cis	rs1707322	0.686	rs2050376	ENSG00000281133.1	AL355480.3	-5.12	6.3e-07	0.000436	-0.37	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45580892~45580996:-
SARC	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-5.12	6.31e-07	0.000437	-0.33	-0.32	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
SARC	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-5.12	6.33e-07	0.000438	-0.35	-0.32	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
SARC	cis	rs6991838	0.806	rs4285523	ENSG00000272010.1	CTD-3025N20.3	5.12	6.34e-07	0.000439	0.35	0.32	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65591850~65592472:-
SARC	cis	rs2562456	0.917	rs2562466	ENSG00000268081.1	RP11-678G14.2	-5.12	6.34e-07	0.000439	-0.47	-0.32	Pain;	chr19:21531402	chr19:21554640~21569237:-
SARC	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	5.12	6.34e-07	0.000439	0.38	0.32	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
SARC	cis	rs875971	0.66	rs79009421	ENSG00000236529.1	RP13-254B10.1	-5.12	6.35e-07	0.000439	-0.33	-0.32	Aortic root size;	chr7:66603522	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs7807930	ENSG00000236529.1	RP13-254B10.1	-5.12	6.35e-07	0.000439	-0.33	-0.32	Aortic root size;	chr7:66622178	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs7807944	ENSG00000236529.1	RP13-254B10.1	-5.12	6.35e-07	0.000439	-0.33	-0.32	Aortic root size;	chr7:66622208	chr7:65840212~65840596:+
SARC	cis	rs7772486	0.754	rs9497419	ENSG00000270638.1	RP3-466P17.1	5.12	6.35e-07	0.000439	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs6921073	ENSG00000270638.1	RP3-466P17.1	5.12	6.35e-07	0.000439	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145735570~145737218:+
SARC	cis	rs1865760	0.533	rs1408270	ENSG00000272810.1	U91328.22	-5.12	6.35e-07	0.000439	-0.32	-0.32	Height;	chr6:25872956	chr6:26013241~26013757:+
SARC	cis	rs9309473	1	rs6546835	ENSG00000163016.8	ALMS1P	5.12	6.36e-07	0.00044	0.4	0.32	Metabolite levels;	chr2:73437587	chr2:73644919~73685576:+
SARC	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	5.12	6.36e-07	0.00044	0.39	0.32	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
SARC	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	5.12	6.36e-07	0.00044	0.41	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
SARC	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-5.12	6.37e-07	0.00044	-0.32	-0.32	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
SARC	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	5.12	6.37e-07	0.00044	0.31	0.32	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
SARC	cis	rs4862750	0.914	rs1863405	ENSG00000249742.1	RP11-217E13.1	5.12	6.38e-07	0.000441	0.34	0.32	Lobe attachment (rater-scored or self-reported);	chr4:186953374	chr4:186979490~187021973:-
SARC	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	5.12	6.38e-07	0.000441	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
SARC	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	5.12	6.38e-07	0.000441	0.37	0.32	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
SARC	cis	rs6964833	0.554	rs2527366	ENSG00000123965.13	PMS2P5	-5.12	6.41e-07	0.000443	-0.46	-0.32	Menarche (age at onset);	chr7:74684615	chr7:74894116~74897835:+
SARC	cis	rs6964833	0.554	rs2527367	ENSG00000123965.13	PMS2P5	-5.12	6.41e-07	0.000443	-0.46	-0.32	Menarche (age at onset);	chr7:74684804	chr7:74894116~74897835:+
SARC	cis	rs4372836	1	rs55835850	ENSG00000226833.4	AC097724.3	-5.12	6.41e-07	0.000443	-0.3	-0.32	Body mass index;	chr2:28726430	chr2:28708953~28736205:-
SARC	cis	rs1134634	0.52	rs11943107	ENSG00000273133.1	RP11-799M12.2	-5.12	6.43e-07	0.000444	-0.41	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15573042	chr4:15563698~15564253:-
SARC	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-5.12	6.43e-07	0.000444	-0.36	-0.32	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
SARC	cis	rs4372836	0.796	rs7580078	ENSG00000226833.4	AC097724.3	5.12	6.43e-07	0.000444	0.32	0.32	Body mass index;	chr2:28774135	chr2:28708953~28736205:-
SARC	cis	rs8081395	0.741	rs1292055	ENSG00000266992.1	DHX40P1	5.12	6.44e-07	0.000444	0.35	0.32	White blood cell count;	chr17:59881707	chr17:59976009~60002384:-
SARC	cis	rs7216064	1	rs12600941	ENSG00000278219.1	AC145343.1	-5.12	6.44e-07	0.000445	-0.4	-0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67922691	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs62085992	ENSG00000278219.1	AC145343.1	-5.12	6.44e-07	0.000445	-0.4	-0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67926967	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs12451721	ENSG00000278219.1	AC145343.1	-5.12	6.44e-07	0.000445	-0.4	-0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67942959	chr17:68101538~68101639:+
SARC	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-5.12	6.45e-07	0.000445	-0.35	-0.32	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
SARC	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-5.12	6.45e-07	0.000445	-0.4	-0.32	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
SARC	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	5.12	6.45e-07	0.000445	0.39	0.32	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
SARC	cis	rs4713118	0.512	rs2622319	ENSG00000216901.1	AL022393.7	5.12	6.46e-07	0.000446	0.45	0.32	Parkinson's disease;	chr6:28152623	chr6:28176188~28176674:+
SARC	cis	rs7809950	0.954	rs12673675	ENSG00000238832.1	snoU109	-5.12	6.47e-07	0.000446	-0.36	-0.32	Coronary artery disease;	chr7:107472775	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs3801954	ENSG00000238832.1	snoU109	-5.12	6.47e-07	0.000446	-0.36	-0.32	Coronary artery disease;	chr7:107476603	chr7:107603363~107603507:+
SARC	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	5.12	6.5e-07	0.000448	0.37	0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
SARC	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	5.12	6.5e-07	0.000448	0.32	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
SARC	cis	rs2404602	0.735	rs62028423	ENSG00000259422.1	RP11-593F23.1	-5.12	6.51e-07	0.000449	-0.38	-0.32	Blood metabolite levels;	chr15:76462173	chr15:76174891~76181486:-
SARC	cis	rs1707322	0.686	rs2230658	ENSG00000281133.1	AL355480.3	5.12	6.51e-07	0.000449	0.37	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.686	rs2230659	ENSG00000281133.1	AL355480.3	5.12	6.51e-07	0.000449	0.37	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45580892~45580996:-
SARC	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	5.12	6.52e-07	0.000449	0.39	0.32	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
SARC	cis	rs7712401	0.645	rs246316	ENSG00000263432.2	RN7SL689P	5.12	6.52e-07	0.000449	0.4	0.32	Mean platelet volume;	chr5:122930502	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs246315	ENSG00000263432.2	RN7SL689P	5.12	6.52e-07	0.000449	0.4	0.32	Mean platelet volume;	chr5:122930743	chr5:123022487~123022783:-
SARC	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	5.12	6.52e-07	0.000449	0.32	0.32	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
SARC	cis	rs7809950	0.953	rs28687365	ENSG00000238832.1	snoU109	-5.12	6.53e-07	0.00045	-0.36	-0.32	Coronary artery disease;	chr7:107466267	chr7:107603363~107603507:+
SARC	cis	rs9818758	0.607	rs80170003	ENSG00000225399.4	RP11-3B7.1	-5.12	6.53e-07	0.00045	-0.6	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48914207	chr3:49260085~49261316:+
SARC	cis	rs2179367	0.6	rs11155654	ENSG00000231760.4	RP11-350J20.5	5.11	6.55e-07	0.000451	0.46	0.32	Dupuytren's disease;	chr6:149442001	chr6:149796151~149826294:-
SARC	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	5.11	6.56e-07	0.000452	0.27	0.32	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
SARC	cis	rs6570726	0.846	rs4896824	ENSG00000270638.1	RP3-466P17.1	5.11	6.56e-07	0.000452	0.26	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145735570~145737218:+
SARC	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	5.11	6.57e-07	0.000452	0.25	0.32	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	5.11	6.57e-07	0.000452	0.25	0.32	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	5.11	6.57e-07	0.000452	0.25	0.32	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
SARC	cis	rs10911902	0.643	rs3766702	ENSG00000229739.2	RP11-295K2.3	-5.11	6.57e-07	0.000452	-0.46	-0.32	Schizophrenia;	chr1:186346832	chr1:186435161~186470291:+
SARC	cis	rs875971	0.638	rs35986979	ENSG00000236529.1	RP13-254B10.1	-5.11	6.59e-07	0.000453	-0.33	-0.32	Aortic root size;	chr7:66624003	chr7:65840212~65840596:+
SARC	cis	rs77204473	1	rs17120119	ENSG00000254851.1	RP11-109L13.1	5.11	6.59e-07	0.000453	0.63	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116876566	chr11:117135528~117138582:+
SARC	cis	rs172166	0.694	rs1150666	ENSG00000216901.1	AL022393.7	5.11	6.6e-07	0.000454	0.44	0.32	Cardiac Troponin-T levels;	chr6:28156150	chr6:28176188~28176674:+
SARC	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	5.11	6.6e-07	0.000454	0.33	0.32	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	5.11	6.6e-07	0.000454	0.33	0.32	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	5.11	6.6e-07	0.000454	0.33	0.32	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	5.11	6.6e-07	0.000454	0.33	0.32	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	5.11	6.6e-07	0.000454	0.33	0.32	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	5.11	6.6e-07	0.000454	0.33	0.32	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
SARC	cis	rs7216064	0.532	rs3890640	ENSG00000265055.1	AC145343.2	-5.11	6.61e-07	0.000455	-0.38	-0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68056912	chr17:68096046~68101474:-
SARC	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-5.11	6.62e-07	0.000455	-0.41	-0.32	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
SARC	cis	rs2933343	0.649	rs728839	ENSG00000261159.1	RP11-723O4.9	5.11	6.64e-07	0.000456	0.34	0.32	IgG glycosylation;	chr3:128870516	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.649	rs789219	ENSG00000261159.1	RP11-723O4.9	5.11	6.64e-07	0.000456	0.34	0.32	IgG glycosylation;	chr3:128873677	chr3:128859716~128860526:-
SARC	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-5.11	6.65e-07	0.000457	-0.39	-0.32	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
SARC	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-5.11	6.65e-07	0.000457	-0.39	-0.32	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
SARC	cis	rs2179367	0.553	rs7762222	ENSG00000231760.4	RP11-350J20.5	5.11	6.68e-07	0.000459	0.45	0.32	Dupuytren's disease;	chr6:149444846	chr6:149796151~149826294:-
SARC	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-5.11	6.68e-07	0.000459	-0.35	-0.32	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
SARC	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-5.11	6.68e-07	0.000459	-0.35	-0.32	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
SARC	cis	rs890448	0.796	rs1365382	ENSG00000254531.1	FLJ20021	5.11	6.69e-07	0.000459	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422729	chr4:101347780~101348883:+
SARC	cis	rs1799949	0.965	rs9897425	ENSG00000267681.1	CTD-3199J23.6	-5.11	6.71e-07	0.000461	-0.36	-0.32	Menopause (age at onset);	chr17:43352811	chr17:43144956~43145255:+
SARC	cis	rs9309473	1	rs6546837	ENSG00000163016.8	ALMS1P	5.11	6.71e-07	0.000461	0.4	0.32	Metabolite levels;	chr2:73450771	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs6546838	ENSG00000163016.8	ALMS1P	5.11	6.71e-07	0.000461	0.4	0.32	Metabolite levels;	chr2:73452153	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs6724782	ENSG00000163016.8	ALMS1P	5.11	6.71e-07	0.000461	0.4	0.32	Metabolite levels;	chr2:73452863	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs6546839	ENSG00000163016.8	ALMS1P	5.11	6.71e-07	0.000461	0.4	0.32	Metabolite levels;	chr2:73453381	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs6756987	ENSG00000163016.8	ALMS1P	5.11	6.71e-07	0.000461	0.4	0.32	Metabolite levels;	chr2:73459950	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs10186501	ENSG00000163016.8	ALMS1P	5.11	6.71e-07	0.000461	0.4	0.32	Metabolite levels;	chr2:73470717	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs10189574	ENSG00000163016.8	ALMS1P	5.11	6.71e-07	0.000461	0.4	0.32	Metabolite levels;	chr2:73471391	chr2:73644919~73685576:+
SARC	cis	rs2439831	0.681	rs484846	ENSG00000205771.5	CATSPER2P1	-5.11	6.72e-07	0.000461	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43308605	chr15:43726918~43747094:-
SARC	cis	rs1823913	0.599	rs1823912	ENSG00000227542.1	AC092614.2	5.11	6.72e-07	0.000461	0.35	0.32	Obesity-related traits;	chr2:191266388	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.599	rs7598639	ENSG00000227542.1	AC092614.2	5.11	6.72e-07	0.000461	0.35	0.32	Obesity-related traits;	chr2:191267958	chr2:191229165~191246172:-
SARC	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	5.11	6.73e-07	0.000462	0.35	0.32	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
SARC	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-5.11	6.73e-07	0.000462	-0.35	-0.32	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-5.11	6.73e-07	0.000462	-0.35	-0.32	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
SARC	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-5.11	6.74e-07	0.000462	-0.3	-0.32	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
SARC	cis	rs1823913	0.599	rs13399251	ENSG00000227542.1	AC092614.2	5.11	6.74e-07	0.000463	0.35	0.32	Obesity-related traits;	chr2:191268758	chr2:191229165~191246172:-
SARC	cis	rs12554020	0.892	rs59483310	ENSG00000227603.1	RP11-165J3.6	5.11	6.76e-07	0.000464	0.44	0.32	Schizophrenia;	chr9:93503318	chr9:93435332~93437121:-
SARC	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-5.11	6.76e-07	0.000464	-0.33	-0.32	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
SARC	cis	rs7216064	0.531	rs6504573	ENSG00000265055.1	AC145343.2	5.11	6.78e-07	0.000465	0.38	0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68019847	chr17:68096046~68101474:-
SARC	cis	rs7809950	1	rs2237672	ENSG00000238832.1	snoU109	-5.11	6.79e-07	0.000465	-0.36	-0.32	Coronary artery disease;	chr7:107491118	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs2237673	ENSG00000238832.1	snoU109	-5.11	6.79e-07	0.000465	-0.36	-0.32	Coronary artery disease;	chr7:107491135	chr7:107603363~107603507:+
SARC	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	5.11	6.8e-07	0.000466	0.49	0.32	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
SARC	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	5.11	6.8e-07	0.000466	0.49	0.32	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
SARC	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	5.11	6.8e-07	0.000466	0.49	0.32	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
SARC	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	5.11	6.8e-07	0.000466	0.49	0.32	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
SARC	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	5.11	6.8e-07	0.000466	0.49	0.32	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
SARC	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	5.11	6.8e-07	0.000466	0.49	0.32	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
SARC	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	5.11	6.8e-07	0.000466	0.49	0.32	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
SARC	cis	rs4862750	0.758	rs2375915	ENSG00000249742.1	RP11-217E13.1	-5.11	6.81e-07	0.000467	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186975101	chr4:186979490~187021973:-
SARC	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	5.11	6.82e-07	0.000467	0.37	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
SARC	cis	rs684603	1	rs684603	ENSG00000246174.6	KCTD21-AS1	-5.11	6.84e-07	0.000469	-0.44	-0.32	Number of common colds;	chr11:78102803	chr11:78139771~78175323:+
SARC	cis	rs160451	1	rs160424	ENSG00000251136.7	RP11-37B2.1	5.11	6.85e-07	0.000469	0.35	0.32	Leprosy;	chr8:89658452	chr8:89609409~89757727:-
SARC	cis	rs4713118	0.955	rs9468203	ENSG00000219392.1	RP1-265C24.5	-5.11	6.85e-07	0.000469	-0.45	-0.32	Parkinson's disease;	chr6:27720888	chr6:28115628~28116551:+
SARC	cis	rs739310	0.556	rs5761685	ENSG00000206028.1	CTA-373H7.7	-5.11	6.86e-07	0.00047	-0.48	-0.32	Obesity-related traits;	chr22:26691422	chr22:26667693~26672654:-
SARC	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-5.11	6.86e-07	0.00047	-0.39	-0.32	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
SARC	cis	rs8031584	0.918	rs35396566	ENSG00000260382.1	RP11-540B6.2	5.11	6.87e-07	0.000471	0.42	0.32	Huntington's disease progression;	chr15:30970854	chr15:30882267~30883231:-
SARC	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	5.1	6.87e-07	0.000471	0.35	0.32	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
SARC	cis	rs4372836	0.964	rs2045884	ENSG00000226833.4	AC097724.3	5.1	6.87e-07	0.000471	0.3	0.32	Body mass index;	chr2:28741489	chr2:28708953~28736205:-
SARC	cis	rs11118620	0.81	rs4587570	ENSG00000257551.1	HLX-AS1	5.1	6.87e-07	0.000471	0.38	0.32	Heart failure;	chr1:220860693	chr1:220832763~220880140:-
SARC	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-5.1	6.88e-07	0.000471	-0.33	-0.32	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-5.1	6.88e-07	0.000471	-0.33	-0.32	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-5.1	6.88e-07	0.000471	-0.33	-0.32	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
SARC	cis	rs27434	0.66	rs42398	ENSG00000272109.1	CTD-2260A17.3	-5.1	6.91e-07	0.000473	-0.45	-0.32	Ankylosing spondylitis;	chr5:96784751	chr5:96804353~96806105:+
SARC	cis	rs6991838	0.806	rs17302392	ENSG00000272010.1	CTD-3025N20.3	5.1	6.91e-07	0.000473	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65591850~65592472:-
SARC	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	5.1	6.92e-07	0.000473	0.31	0.32	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
SARC	cis	rs7250849	0.565	rs11883221	ENSG00000273837.1	LLNLR-470E3.1	-5.1	6.92e-07	0.000474	-0.33	-0.32	Blood protein levels;	chr19:51665579	chr19:51639478~51639931:-
SARC	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	5.1	6.95e-07	0.000476	0.3	0.32	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
SARC	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-5.1	6.97e-07	0.000476	-0.33	-0.32	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-5.1	6.97e-07	0.000476	-0.33	-0.32	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-5.1	6.97e-07	0.000476	-0.33	-0.32	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-5.1	6.97e-07	0.000476	-0.33	-0.32	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
SARC	cis	rs1823913	0.599	rs67342262	ENSG00000227542.1	AC092614.2	5.1	6.98e-07	0.000477	0.36	0.32	Obesity-related traits;	chr2:191295612	chr2:191229165~191246172:-
SARC	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-5.1	6.98e-07	0.000477	-0.39	-0.32	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-5.1	6.98e-07	0.000477	-0.39	-0.32	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-5.1	6.98e-07	0.000477	-0.39	-0.32	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
SARC	cis	rs890448	0.726	rs2850371	ENSG00000254531.1	FLJ20021	-5.1	6.98e-07	0.000477	-0.32	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101319590	chr4:101347780~101348883:+
SARC	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-5.1	6.99e-07	0.000478	-0.48	-0.32	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
SARC	cis	rs1865760	0.593	rs9393676	ENSG00000272462.2	U91328.19	-5.1	7e-07	0.000478	-0.3	-0.32	Height;	chr6:25936716	chr6:25992662~26001775:+
SARC	cis	rs4862750	0.914	rs1991256	ENSG00000249742.1	RP11-217E13.1	-5.1	7.02e-07	0.00048	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186954176	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.914	rs6553026	ENSG00000249742.1	RP11-217E13.1	-5.1	7.02e-07	0.00048	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186954494	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.874	rs6553027	ENSG00000249742.1	RP11-217E13.1	-5.1	7.02e-07	0.00048	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186954623	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.914	rs6553028	ENSG00000249742.1	RP11-217E13.1	-5.1	7.02e-07	0.00048	-0.35	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186954892	chr4:186979490~187021973:-
SARC	cis	rs1823913	1	rs11691372	ENSG00000227542.1	AC092614.2	-5.1	7.03e-07	0.00048	-0.35	-0.32	Obesity-related traits;	chr2:191249952	chr2:191229165~191246172:-
SARC	cis	rs4713118	0.669	rs200997	ENSG00000219392.1	RP1-265C24.5	-5.1	7.03e-07	0.00048	-0.42	-0.32	Parkinson's disease;	chr6:27844037	chr6:28115628~28116551:+
SARC	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-5.1	7.06e-07	0.000482	-0.42	-0.32	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-5.1	7.06e-07	0.000482	-0.42	-0.32	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
SARC	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-5.1	7.06e-07	0.000482	-0.34	-0.32	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
SARC	cis	rs2439831	0.681	rs825740	ENSG00000205771.5	CATSPER2P1	-5.1	7.07e-07	0.000482	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43300210	chr15:43726918~43747094:-
SARC	cis	rs4372836	0.93	rs4233727	ENSG00000226833.4	AC097724.3	5.1	7.08e-07	0.000483	0.3	0.32	Body mass index;	chr2:28754378	chr2:28708953~28736205:-
SARC	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-5.1	7.08e-07	0.000483	-0.35	-0.32	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
SARC	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	5.1	7.08e-07	0.000483	0.37	0.32	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
SARC	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	5.1	7.09e-07	0.000483	0.34	0.32	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
SARC	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-5.1	7.1e-07	0.000484	-0.36	-0.32	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
SARC	cis	rs7587476	0.906	rs2070096	ENSG00000229267.2	AC072062.1	-5.1	7.13e-07	0.000486	-0.33	-0.32	Neuroblastoma;	chr2:214780821	chr2:214810229~214963274:+
SARC	cis	rs1707322	0.686	rs1541131	ENSG00000281133.1	AL355480.3	5.1	7.13e-07	0.000486	0.36	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45580892~45580996:-
SARC	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	5.1	7.15e-07	0.000487	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	5.1	7.16e-07	0.000488	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	5.1	7.16e-07	0.000488	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	5.1	7.16e-07	0.000488	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
SARC	cis	rs12655019	0.92	rs7731829	ENSG00000271828.1	CTD-2310F14.1	5.1	7.16e-07	0.000488	0.53	0.32	Breast cancer (early onset);	chr5:56911884	chr5:56927874~56929573:+
SARC	cis	rs9818758	0.556	rs9814987	ENSG00000225399.4	RP11-3B7.1	-5.1	7.16e-07	0.000488	-0.56	-0.32	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49170416	chr3:49260085~49261316:+
SARC	cis	rs2274273	0.588	rs7154831	ENSG00000258413.1	RP11-665C16.6	-5.1	7.16e-07	0.000488	-0.4	-0.32	Protein biomarker;	chr14:55357247	chr14:55262767~55272075:-
SARC	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-5.1	7.17e-07	0.000488	-0.34	-0.32	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
SARC	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-5.1	7.17e-07	0.000489	-0.4	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
SARC	cis	rs1823913	0.599	rs13427761	ENSG00000227542.1	AC092614.2	-5.1	7.2e-07	0.00049	-0.35	-0.32	Obesity-related traits;	chr2:191269256	chr2:191229165~191246172:-
SARC	cis	rs7216064	0.906	rs1976052	ENSG00000278219.1	AC145343.1	-5.1	7.2e-07	0.00049	-0.4	-0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67834462	chr17:68101538~68101639:+
SARC	cis	rs193541	0.632	rs154512	ENSG00000263432.2	RN7SL689P	5.09	7.21e-07	0.00049	0.4	0.32	Glucose homeostasis traits;	chr5:122859345	chr5:123022487~123022783:-
SARC	cis	rs193541	0.555	rs2438151	ENSG00000263432.2	RN7SL689P	5.09	7.21e-07	0.00049	0.4	0.32	Glucose homeostasis traits;	chr5:122863502	chr5:123022487~123022783:-
SARC	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-5.09	7.21e-07	0.000491	-0.39	-0.32	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
SARC	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-5.09	7.21e-07	0.000491	-0.39	-0.32	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
SARC	cis	rs7712401	0.601	rs30039	ENSG00000263432.2	RN7SL689P	-5.09	7.22e-07	0.000491	-0.4	-0.32	Mean platelet volume;	chr5:122941484	chr5:123022487~123022783:-
SARC	cis	rs890448	0.796	rs2433306	ENSG00000254531.1	FLJ20021	5.09	7.23e-07	0.000492	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101425843	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs2433307	ENSG00000254531.1	FLJ20021	5.09	7.23e-07	0.000492	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426059	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs2471679	ENSG00000254531.1	FLJ20021	5.09	7.23e-07	0.000492	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426354	chr4:101347780~101348883:+
SARC	cis	rs17270561	0.609	rs9358887	ENSG00000272810.1	U91328.22	-5.09	7.24e-07	0.000493	-0.32	-0.32	Iron status biomarkers;	chr6:25759178	chr6:26013241~26013757:+
SARC	cis	rs6991838	0.778	rs13261559	ENSG00000272010.1	CTD-3025N20.3	5.09	7.25e-07	0.000493	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.778	rs7843697	ENSG00000272010.1	CTD-3025N20.3	5.09	7.25e-07	0.000493	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65591850~65592472:-
SARC	cis	rs6991838	0.778	rs7843724	ENSG00000272010.1	CTD-3025N20.3	5.09	7.25e-07	0.000493	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65591850~65592472:-
SARC	cis	rs890448	0.76	rs7699920	ENSG00000254531.1	FLJ20021	-5.09	7.26e-07	0.000494	-0.32	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422302	chr4:101347780~101348883:+
SARC	cis	rs2562456	0.833	rs55875743	ENSG00000268081.1	RP11-678G14.2	5.09	7.26e-07	0.000494	0.53	0.32	Pain;	chr19:21383393	chr19:21554640~21569237:-
SARC	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-5.09	7.28e-07	0.000495	-0.33	-0.32	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-5.09	7.28e-07	0.000495	-0.33	-0.32	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
SARC	cis	rs1823913	0.599	rs67781530	ENSG00000227542.1	AC092614.2	5.09	7.29e-07	0.000496	0.36	0.32	Obesity-related traits;	chr2:191295608	chr2:191229165~191246172:-
SARC	cis	rs4703855	0.538	rs4703536	ENSG00000244061.1	RP11-389C8.1	5.09	7.29e-07	0.000496	0.32	0.32	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72423021	chr5:72381794~72382393:+
SARC	cis	rs2404602	0.503	rs284909	ENSG00000259422.1	RP11-593F23.1	5.09	7.3e-07	0.000496	0.35	0.32	Blood metabolite levels;	chr15:76444287	chr15:76174891~76181486:-
SARC	cis	rs7809950	1	rs17154077	ENSG00000238832.1	snoU109	5.09	7.3e-07	0.000496	0.37	0.32	Coronary artery disease;	chr7:107437496	chr7:107603363~107603507:+
SARC	cis	rs1865760	0.566	rs9358904	ENSG00000272810.1	U91328.22	-5.09	7.3e-07	0.000496	-0.3	-0.32	Height;	chr6:26068338	chr6:26013241~26013757:+
SARC	cis	rs7712401	0.715	rs13163098	ENSG00000263432.2	RN7SL689P	-5.09	7.3e-07	0.000496	-0.4	-0.32	Mean platelet volume;	chr5:123010841	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs13164161	ENSG00000263432.2	RN7SL689P	-5.09	7.3e-07	0.000496	-0.4	-0.32	Mean platelet volume;	chr5:123011202	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs401226	ENSG00000263432.2	RN7SL689P	-5.09	7.3e-07	0.000496	-0.4	-0.32	Mean platelet volume;	chr5:123012031	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs395981	ENSG00000263432.2	RN7SL689P	-5.09	7.3e-07	0.000496	-0.4	-0.32	Mean platelet volume;	chr5:123012216	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs424247	ENSG00000263432.2	RN7SL689P	-5.09	7.3e-07	0.000496	-0.4	-0.32	Mean platelet volume;	chr5:123012298	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.715	rs424262	ENSG00000263432.2	RN7SL689P	-5.09	7.3e-07	0.000496	-0.4	-0.32	Mean platelet volume;	chr5:123012317	chr5:123022487~123022783:-
SARC	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-5.09	7.32e-07	0.000498	-0.41	-0.32	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
SARC	cis	rs2439831	0.867	rs12323999	ENSG00000205771.5	CATSPER2P1	-5.09	7.34e-07	0.000499	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43390917	chr15:43726918~43747094:-
SARC	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	5.09	7.34e-07	0.000499	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	5.09	7.34e-07	0.000499	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
SARC	cis	rs17270561	0.609	rs2154218	ENSG00000272810.1	U91328.22	-5.09	7.35e-07	0.000499	-0.32	-0.32	Iron status biomarkers;	chr6:25776062	chr6:26013241~26013757:+
SARC	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	5.09	7.35e-07	0.000499	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	5.09	7.35e-07	0.000499	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
SARC	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	5.09	7.36e-07	5e-04	0.25	0.32	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	5.09	7.36e-07	5e-04	0.25	0.32	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	5.09	7.36e-07	5e-04	0.25	0.32	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	5.09	7.36e-07	5e-04	0.25	0.32	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
SARC	cis	rs890448	0.796	rs1365383	ENSG00000254531.1	FLJ20021	5.09	7.38e-07	0.000501	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422850	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs1365384	ENSG00000254531.1	FLJ20021	5.09	7.38e-07	0.000501	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101423238	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs13102837	ENSG00000254531.1	FLJ20021	5.09	7.38e-07	0.000501	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101423377	chr4:101347780~101348883:+
SARC	cis	rs890448	0.76	rs10003315	ENSG00000254531.1	FLJ20021	5.09	7.38e-07	0.000501	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101423887	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs2162338	ENSG00000254531.1	FLJ20021	5.09	7.38e-07	0.000501	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101424411	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs2433304	ENSG00000254531.1	FLJ20021	5.09	7.38e-07	0.000501	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101425309	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs2433305	ENSG00000254531.1	FLJ20021	5.09	7.38e-07	0.000501	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101425472	chr4:101347780~101348883:+
SARC	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-5.09	7.38e-07	0.000501	-0.34	-0.32	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
SARC	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	5.09	7.39e-07	0.000502	0.35	0.32	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
SARC	cis	rs7216064	0.589	rs8072723	ENSG00000278219.1	AC145343.1	5.09	7.39e-07	0.000502	0.36	0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68060854	chr17:68101538~68101639:+
SARC	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-5.09	7.41e-07	0.000503	-0.36	-0.32	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
SARC	cis	rs4862750	0.832	rs10007858	ENSG00000249742.1	RP11-217E13.1	-5.09	7.41e-07	0.000503	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186956338	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.872	rs9997374	ENSG00000249742.1	RP11-217E13.1	-5.09	7.41e-07	0.000503	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr4:186956395	chr4:186979490~187021973:-
SARC	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	5.09	7.42e-07	0.000503	0.25	0.32	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	5.09	7.42e-07	0.000503	0.25	0.32	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	5.09	7.42e-07	0.000503	0.25	0.32	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
SARC	cis	rs4372836	1	rs7579277	ENSG00000226833.4	AC097724.3	5.09	7.42e-07	0.000503	0.3	0.32	Body mass index;	chr2:28773429	chr2:28708953~28736205:-
SARC	cis	rs11118620	0.853	rs12037861	ENSG00000257551.1	HLX-AS1	5.09	7.42e-07	0.000504	0.38	0.32	Heart failure;	chr1:220864835	chr1:220832763~220880140:-
SARC	cis	rs7216064	0.953	rs4791046	ENSG00000278219.1	AC145343.1	-5.09	7.45e-07	0.000505	-0.37	-0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67855857	chr17:68101538~68101639:+
SARC	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-5.09	7.46e-07	0.000506	-0.35	-0.32	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
SARC	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	5.09	7.47e-07	0.000506	0.37	0.32	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
SARC	cis	rs7772486	0.754	rs9373476	ENSG00000270638.1	RP3-466P17.1	5.09	7.47e-07	0.000506	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.727	rs11155442	ENSG00000270638.1	RP3-466P17.1	5.09	7.47e-07	0.000506	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145735570~145737218:+
SARC	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-5.09	7.49e-07	0.000507	-0.38	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-5.09	7.49e-07	0.000507	-0.38	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
SARC	cis	rs1823913	0.599	rs17346475	ENSG00000227542.1	AC092614.2	-5.09	7.49e-07	0.000508	-0.35	-0.32	Obesity-related traits;	chr2:191288488	chr2:191229165~191246172:-
SARC	cis	rs2117029	1	rs11168827	ENSG00000258017.1	RP11-386G11.10	5.09	7.5e-07	0.000508	0.34	0.32	Intelligence (multi-trait analysis);	chr12:49025894	chr12:49127782~49147869:+
SARC	cis	rs75920871	0.588	rs1940626	ENSG00000254851.1	RP11-109L13.1	5.09	7.51e-07	0.000509	0.42	0.32	Subjective well-being;	chr11:116957405	chr11:117135528~117138582:+
SARC	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	5.09	7.51e-07	0.000509	0.4	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
SARC	cis	rs10800713	0.529	rs10919966	ENSG00000260088.1	RP11-92G12.3	5.09	7.51e-07	0.000509	0.47	0.32	Tandem gait;	chr1:200533441	chr1:200669507~200694250:+
SARC	cis	rs7216064	1	rs62084238	ENSG00000265055.1	AC145343.2	5.09	7.52e-07	0.000509	0.42	0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67860457	chr17:68096046~68101474:-
SARC	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	5.09	7.52e-07	0.00051	0.35	0.32	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
SARC	cis	rs13392177	0.647	rs10932761	ENSG00000261338.2	RP11-378A13.1	-5.09	7.53e-07	0.00051	-0.31	-0.32	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218199668	chr2:218255319~218257366:+
SARC	cis	rs7246657	0.943	rs10415024	ENSG00000276846.1	CTD-3220F14.3	5.09	7.53e-07	0.00051	0.42	0.32	Coronary artery calcification;	chr19:37323822	chr19:37314868~37315620:-
SARC	cis	rs1865760	0.532	rs2794719	ENSG00000272810.1	U91328.22	-5.09	7.54e-07	0.00051	-0.31	-0.32	Height;	chr6:26088662	chr6:26013241~26013757:+
SARC	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	5.09	7.54e-07	0.00051	0.35	0.32	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
SARC	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	5.09	7.54e-07	0.000511	0.35	0.32	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
SARC	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	5.09	7.54e-07	0.000511	0.35	0.32	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
SARC	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-5.09	7.55e-07	0.000511	-0.41	-0.32	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
SARC	cis	rs2404602	0.646	rs3764245	ENSG00000259422.1	RP11-593F23.1	5.08	7.57e-07	0.000512	0.38	0.32	Blood metabolite levels;	chr15:76930835	chr15:76174891~76181486:-
SARC	cis	rs2933343	0.621	rs728838	ENSG00000261159.1	RP11-723O4.9	5.08	7.57e-07	0.000512	0.34	0.32	IgG glycosylation;	chr3:128870170	chr3:128859716~128860526:-
SARC	cis	rs9322193	0.884	rs1125	ENSG00000223701.3	RAET1E-AS1	5.08	7.57e-07	0.000512	0.35	0.32	Lung cancer;	chr6:149658280	chr6:149884431~149919508:+
SARC	cis	rs7250849	0.565	rs73052857	ENSG00000273837.1	LLNLR-470E3.1	-5.08	7.58e-07	0.000513	-0.35	-0.32	Blood protein levels;	chr19:51661182	chr19:51639478~51639931:-
SARC	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	5.08	7.58e-07	0.000513	0.34	0.32	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
SARC	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	5.08	7.59e-07	0.000514	0.36	0.32	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
SARC	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	5.08	7.6e-07	0.000514	0.41	0.32	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	5.08	7.6e-07	0.000514	0.41	0.32	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
SARC	cis	rs2439831	0.618	rs8023508	ENSG00000205771.5	CATSPER2P1	5.08	7.6e-07	0.000514	0.48	0.32	Lung cancer in ever smokers;	chr15:43883905	chr15:43726918~43747094:-
SARC	cis	rs7520050	0.645	rs1768809	ENSG00000280836.1	AL355480.1	5.08	7.6e-07	0.000514	0.3	0.32	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45581219~45581321:-
SARC	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-5.08	7.61e-07	0.000514	-0.42	-0.32	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
SARC	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-5.08	7.61e-07	0.000514	-0.41	-0.32	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
SARC	cis	rs7772486	0.686	rs857880	ENSG00000270638.1	RP3-466P17.1	-5.08	7.61e-07	0.000514	-0.26	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145735570~145737218:+
SARC	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	5.08	7.61e-07	0.000515	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
SARC	cis	rs7809950	0.954	rs2712193	ENSG00000238832.1	snoU109	-5.08	7.63e-07	0.000515	-0.36	-0.32	Coronary artery disease;	chr7:107485440	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs2520277	ENSG00000238832.1	snoU109	-5.08	7.63e-07	0.000515	-0.36	-0.32	Coronary artery disease;	chr7:107489789	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.953	rs2237670	ENSG00000238832.1	snoU109	-5.08	7.63e-07	0.000515	-0.36	-0.32	Coronary artery disease;	chr7:107491040	chr7:107603363~107603507:+
SARC	cis	rs916888	0.738	rs199515	ENSG00000261575.2	RP11-259G18.1	-5.08	7.64e-07	0.000516	-0.44	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46267037~46268694:+
SARC	cis	rs7712401	0.562	rs246267	ENSG00000263432.2	RN7SL689P	5.08	7.64e-07	0.000516	0.39	0.32	Mean platelet volume;	chr5:122920409	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs246269	ENSG00000263432.2	RN7SL689P	5.08	7.64e-07	0.000516	0.39	0.32	Mean platelet volume;	chr5:122921046	chr5:123022487~123022783:-
SARC	cis	rs6570726	0.846	rs6570700	ENSG00000270638.1	RP3-466P17.1	5.08	7.66e-07	0.000517	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.846	rs870491	ENSG00000270638.1	RP3-466P17.1	5.08	7.66e-07	0.000517	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs4332001	ENSG00000270638.1	RP3-466P17.1	5.08	7.66e-07	0.000517	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145735570~145737218:+
SARC	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-5.08	7.68e-07	0.000518	-0.37	-0.32	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
SARC	cis	rs6570726	0.791	rs4896820	ENSG00000270638.1	RP3-466P17.1	5.08	7.68e-07	0.000519	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145573821	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.764	rs4896821	ENSG00000270638.1	RP3-466P17.1	5.08	7.68e-07	0.000519	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145575045	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs6902404	ENSG00000270638.1	RP3-466P17.1	5.08	7.68e-07	0.000519	0.25	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145584118	chr6:145735570~145737218:+
SARC	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-5.08	7.68e-07	0.000519	-0.41	-0.32	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
SARC	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-5.08	7.68e-07	0.000519	-0.41	-0.32	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
SARC	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-5.08	7.68e-07	0.000519	-0.41	-0.32	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
SARC	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-5.08	7.69e-07	0.000519	-0.38	-0.32	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
SARC	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-5.08	7.69e-07	0.000519	-0.38	-0.32	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
SARC	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-5.08	7.69e-07	0.000519	-0.38	-0.32	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
SARC	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-5.08	7.69e-07	0.000519	-0.38	-0.32	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
SARC	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-5.08	7.7e-07	0.00052	-0.34	-0.32	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-5.08	7.7e-07	0.00052	-0.34	-0.32	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
SARC	cis	rs12655019	0.92	rs12654125	ENSG00000271828.1	CTD-2310F14.1	5.08	7.7e-07	0.00052	0.52	0.32	Breast cancer (early onset);	chr5:56919926	chr5:56927874~56929573:+
SARC	cis	rs6452524	0.618	rs7722924	ENSG00000248112.1	RP11-78C3.1	5.08	7.7e-07	0.00052	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:82919376~82921119:-
SARC	cis	rs6452524	0.618	rs10051445	ENSG00000248112.1	RP11-78C3.1	5.08	7.7e-07	0.00052	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:82919376~82921119:-
SARC	cis	rs6452524	0.618	rs6867727	ENSG00000248112.1	RP11-78C3.1	5.08	7.7e-07	0.00052	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:82919376~82921119:-
SARC	cis	rs6452524	0.618	rs7723639	ENSG00000248112.1	RP11-78C3.1	5.08	7.7e-07	0.00052	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:82919376~82921119:-
SARC	cis	rs6452524	0.618	rs2306336	ENSG00000248112.1	RP11-78C3.1	5.08	7.7e-07	0.00052	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:82919376~82921119:-
SARC	cis	rs6452524	0.589	rs6882386	ENSG00000248112.1	RP11-78C3.1	5.08	7.7e-07	0.00052	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:82919376~82921119:-
SARC	cis	rs6452524	0.618	rs6860752	ENSG00000248112.1	RP11-78C3.1	5.08	7.7e-07	0.00052	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:82919376~82921119:-
SARC	cis	rs6452524	0.618	rs3899556	ENSG00000248112.1	RP11-78C3.1	5.08	7.7e-07	0.00052	0.34	0.32	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:82919376~82921119:-
SARC	cis	rs8081395	0.805	rs2645485	ENSG00000266992.1	DHX40P1	5.08	7.7e-07	0.00052	0.35	0.32	White blood cell count;	chr17:59866920	chr17:59976009~60002384:-
SARC	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	5.08	7.71e-07	0.00052	0.35	0.32	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
SARC	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-5.08	7.71e-07	0.000521	-0.34	-0.32	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
SARC	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	5.08	7.72e-07	0.000521	0.34	0.32	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
SARC	cis	rs7772486	0.754	rs10872580	ENSG00000270638.1	RP3-466P17.1	-5.08	7.75e-07	0.000523	-0.25	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145735570~145737218:+
SARC	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	5.08	7.76e-07	0.000523	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	5.08	7.76e-07	0.000523	0.37	0.32	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
SARC	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-5.08	7.77e-07	0.000524	-0.41	-0.32	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
SARC	cis	rs2933343	1	rs789237	ENSG00000231305.3	RP11-723O4.2	5.08	7.77e-07	0.000524	0.34	0.32	IgG glycosylation;	chr3:128918118	chr3:128861313~128871540:-
SARC	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-5.08	7.79e-07	0.000525	-0.31	-0.32	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
SARC	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	5.08	7.79e-07	0.000525	0.37	0.32	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
SARC	cis	rs9309473	1	rs6546836	ENSG00000163016.8	ALMS1P	5.08	7.79e-07	0.000525	0.4	0.32	Metabolite levels;	chr2:73450706	chr2:73644919~73685576:+
SARC	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	5.08	7.8e-07	0.000525	0.48	0.32	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
SARC	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-5.08	7.84e-07	0.000528	-0.37	-0.32	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
SARC	cis	rs7772486	0.686	rs2328708	ENSG00000270638.1	RP3-466P17.1	-5.08	7.85e-07	0.000529	-0.25	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145735570~145737218:+
SARC	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	5.08	7.85e-07	0.000529	0.34	0.32	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
SARC	cis	rs12655019	0.92	rs6450410	ENSG00000271828.1	CTD-2310F14.1	5.08	7.86e-07	0.000529	0.53	0.32	Breast cancer (early onset);	chr5:56910874	chr5:56927874~56929573:+
SARC	cis	rs11018904	0.861	rs61903723	ENSG00000280385.1	AP000648.5	-5.08	7.87e-07	0.00053	-0.39	-0.32	Intelligence (multi-trait analysis);	chr11:90235078	chr11:90193614~90198120:+
SARC	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-5.08	7.87e-07	0.00053	-0.38	-0.32	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	5.08	7.91e-07	0.000532	0.35	0.32	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
SARC	cis	rs1865760	0.963	rs9356991	ENSG00000272810.1	U91328.22	-5.07	7.92e-07	0.000533	-0.32	-0.32	Height;	chr6:25901530	chr6:26013241~26013757:+
SARC	cis	rs9890032	0.967	rs7342976	ENSG00000263531.1	RP13-753N3.1	5.07	7.93e-07	0.000533	0.38	0.32	Hip circumference adjusted for BMI;	chr17:30863001	chr17:30863921~30864940:-
SARC	cis	rs5769707	0.616	rs6009786	ENSG00000188511.11	C22orf34	5.07	7.93e-07	0.000533	0.4	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49414524~49657542:-
SARC	cis	rs115344852	0.598	rs2191035	ENSG00000216901.1	AL022393.7	5.07	7.95e-07	0.000534	0.41	0.32	Epithelial ovarian cancer;	chr6:28467166	chr6:28176188~28176674:+
SARC	cis	rs115344852	0.598	rs2531815	ENSG00000216901.1	AL022393.7	5.07	7.95e-07	0.000534	0.41	0.32	Epithelial ovarian cancer;	chr6:28468283	chr6:28176188~28176674:+
SARC	cis	rs1865760	0.566	rs2858993	ENSG00000272810.1	U91328.22	-5.07	7.97e-07	0.000536	-0.31	-0.32	Height;	chr6:26087628	chr6:26013241~26013757:+
SARC	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-5.07	7.98e-07	0.000536	-0.31	-0.32	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
SARC	cis	rs7809950	1	rs17154104	ENSG00000238832.1	snoU109	-5.07	7.98e-07	0.000536	-0.36	-0.32	Coronary artery disease;	chr7:107450253	chr7:107603363~107603507:+
SARC	cis	rs1865760	0.566	rs9295686	ENSG00000272810.1	U91328.22	-5.07	7.98e-07	0.000536	-0.31	-0.32	Height;	chr6:26081755	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.532	rs9295687	ENSG00000272810.1	U91328.22	-5.07	7.98e-07	0.000536	-0.31	-0.32	Height;	chr6:26082482	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs4529296	ENSG00000272810.1	U91328.22	-5.07	7.98e-07	0.000536	-0.31	-0.32	Height;	chr6:26082907	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs9379825	ENSG00000272810.1	U91328.22	-5.07	7.98e-07	0.000536	-0.31	-0.32	Height;	chr6:26083643	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs9467672	ENSG00000272810.1	U91328.22	-5.07	7.98e-07	0.000536	-0.31	-0.32	Height;	chr6:26083676	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs9295688	ENSG00000272810.1	U91328.22	-5.07	7.98e-07	0.000536	-0.31	-0.32	Height;	chr6:26083989	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs1971509	ENSG00000272810.1	U91328.22	-5.07	7.98e-07	0.000536	-0.31	-0.32	Height;	chr6:26085549	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.532	rs2006736	ENSG00000272810.1	U91328.22	-5.07	7.98e-07	0.000536	-0.31	-0.32	Height;	chr6:26085789	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs1800702	ENSG00000272810.1	U91328.22	-5.07	7.98e-07	0.000536	-0.31	-0.32	Height;	chr6:26086235	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs2794720	ENSG00000272810.1	U91328.22	-5.07	7.98e-07	0.000536	-0.31	-0.32	Height;	chr6:26086974	chr6:26013241~26013757:+
SARC	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-5.07	7.99e-07	0.000537	-0.35	-0.32	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
SARC	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-5.07	7.99e-07	0.000537	-0.35	-0.32	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
SARC	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-5.07	7.99e-07	0.000537	-0.35	-0.32	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
SARC	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-5.07	7.99e-07	0.000537	-0.35	-0.32	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-5.07	7.99e-07	0.000537	-0.35	-0.32	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
SARC	cis	rs13631	0.894	rs7856589	ENSG00000268996.3	MAN1B1-AS1	-5.07	8e-07	0.000537	-0.32	-0.32	Cerebrospinal fluid biomarker levels;	chr9:137109469	chr9:137084946~137086817:-
SARC	cis	rs42490	1	rs218929	ENSG00000251136.7	RP11-37B2.1	-5.07	8.01e-07	0.000538	-0.35	-0.32	Leprosy;	chr8:89739091	chr8:89609409~89757727:-
SARC	cis	rs8005677	1	rs8006396	ENSG00000257285.4	RP11-298I3.1	5.07	8.01e-07	0.000538	0.29	0.32	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:22929609~22955562:+
SARC	cis	rs8005677	1	rs4982706	ENSG00000257285.4	RP11-298I3.1	5.07	8.01e-07	0.000538	0.29	0.32	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:22929609~22955562:+
SARC	cis	rs8005677	0.926	rs34344888	ENSG00000257285.4	RP11-298I3.1	5.07	8.01e-07	0.000538	0.29	0.32	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:22929609~22955562:+
SARC	cis	rs8005677	0.962	rs34917191	ENSG00000257285.4	RP11-298I3.1	5.07	8.01e-07	0.000538	0.29	0.32	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:22929609~22955562:+
SARC	cis	rs8005677	1	rs1951119	ENSG00000257285.4	RP11-298I3.1	5.07	8.01e-07	0.000538	0.29	0.32	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:22929609~22955562:+
SARC	cis	rs8005677	1	rs2295683	ENSG00000257285.4	RP11-298I3.1	5.07	8.01e-07	0.000538	0.29	0.32	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:22929609~22955562:+
SARC	cis	rs8005677	1	rs4981449	ENSG00000257285.4	RP11-298I3.1	5.07	8.01e-07	0.000538	0.29	0.32	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:22929609~22955562:+
SARC	cis	rs4654783	0.505	rs7544210	ENSG00000228397.1	RP1-224A6.3	-5.07	8.02e-07	0.000538	-0.35	-0.32	Endometriosis;	chr1:22128649	chr1:22023994~22024968:-
SARC	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-5.07	8.02e-07	0.000538	-0.35	-0.32	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
SARC	cis	rs17270561	0.609	rs9366629	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25740988	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.553	rs6456696	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25741180	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.636	rs6456697	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25741206	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.636	rs6456698	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25741436	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.666	rs4711099	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25741581	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4711100	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25741726	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4711101	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25741742	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4712965	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25741794	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.608	rs4711102	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25741847	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4711103	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25741996	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9379788	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25742531	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9358879	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25742690	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.636	rs9358880	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25742933	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4145216	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25743331	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4145217	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25743769	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9393665	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25744056	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs7754733	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25744821	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.636	rs7754814	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25745015	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.636	rs7775354	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25745038	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9379789	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25745351	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs6941933	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25745474	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.636	rs6923367	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25745624	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.636	rs6923839	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25745625	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.636	rs4145218	ENSG00000272810.1	U91328.22	-5.07	8.03e-07	0.000538	-0.32	-0.32	Iron status biomarkers;	chr6:25745855	chr6:26013241~26013757:+
SARC	cis	rs8005677	0.962	rs10130756	ENSG00000257285.4	RP11-298I3.1	5.07	8.03e-07	0.000538	0.3	0.32	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:22929609~22955562:+
SARC	cis	rs1865760	1	rs7770139	ENSG00000272810.1	U91328.22	-5.07	8.04e-07	0.000539	-0.32	-0.32	Height;	chr6:25925595	chr6:26013241~26013757:+
SARC	cis	rs710913	0.816	rs1180341	ENSG00000182109.6	RP11-69E11.4	-5.07	8.05e-07	0.000539	-0.31	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39522280~39546187:-
SARC	cis	rs890448	0.796	rs2433302	ENSG00000254531.1	FLJ20021	5.07	8.05e-07	0.00054	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101425038	chr4:101347780~101348883:+
SARC	cis	rs916888	0.773	rs9896243	ENSG00000261575.2	RP11-259G18.1	5.07	8.05e-07	0.00054	0.45	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46267037~46268694:+
SARC	cis	rs17270561	0.583	rs7749149	ENSG00000272810.1	U91328.22	-5.07	8.08e-07	0.000541	-0.31	-0.32	Iron status biomarkers;	chr6:25780911	chr6:26013241~26013757:+
SARC	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	5.07	8.08e-07	0.000541	0.33	0.32	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
SARC	cis	rs394563	0.69	rs237009	ENSG00000231760.4	RP11-350J20.5	5.07	8.08e-07	0.000542	0.4	0.32	Dupuytren's disease;	chr6:149438416	chr6:149796151~149826294:-
SARC	cis	rs6991838	0.806	rs13262793	ENSG00000272010.1	CTD-3025N20.3	5.07	8.12e-07	0.000544	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65591850~65592472:-
SARC	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-5.07	8.12e-07	0.000544	-0.4	-0.32	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
SARC	cis	rs2029362	0.591	rs10835210	ENSG00000245573.6	BDNF-AS	5.07	8.15e-07	0.000546	0.28	0.32	Total body bone mineral density;	chr11:27674363	chr11:27506838~27698174:+
SARC	cis	rs7246657	0.943	rs10409204	ENSG00000276846.1	CTD-3220F14.3	5.07	8.15e-07	0.000546	0.42	0.32	Coronary artery calcification;	chr19:37426790	chr19:37314868~37315620:-
SARC	cis	rs2274273	0.588	rs58296156	ENSG00000258413.1	RP11-665C16.6	-5.07	8.16e-07	0.000546	-0.4	-0.32	Protein biomarker;	chr14:55361609	chr14:55262767~55272075:-
SARC	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	5.07	8.17e-07	0.000546	0.29	0.32	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
SARC	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-5.07	8.18e-07	0.000548	-0.33	-0.32	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
SARC	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	5.07	8.19e-07	0.000548	0.3	0.32	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
SARC	cis	rs2933343	0.621	rs789241	ENSG00000261159.1	RP11-723O4.9	5.07	8.19e-07	0.000548	0.34	0.32	IgG glycosylation;	chr3:128866909	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.649	rs2638845	ENSG00000261159.1	RP11-723O4.9	5.07	8.19e-07	0.000548	0.34	0.32	IgG glycosylation;	chr3:128868526	chr3:128859716~128860526:-
SARC	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	5.07	8.2e-07	0.000548	0.26	0.32	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
SARC	cis	rs1799949	0.965	rs2236762	ENSG00000267681.1	CTD-3199J23.6	-5.07	8.2e-07	0.000549	-0.35	-0.32	Menopause (age at onset);	chr17:43074658	chr17:43144956~43145255:+
SARC	cis	rs1865760	0.566	rs9358904	ENSG00000272462.2	U91328.19	-5.07	8.21e-07	0.000549	-0.29	-0.32	Height;	chr6:26068338	chr6:25992662~26001775:+
SARC	cis	rs890448	0.796	rs10009249	ENSG00000254531.1	FLJ20021	5.07	8.21e-07	0.000549	0.32	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101369460	chr4:101347780~101348883:+
SARC	cis	rs7615952	0.576	rs12497295	ENSG00000250012.1	RP11-124N2.1	-5.07	8.21e-07	0.000549	-0.31	-0.32	Blood pressure (smoking interaction);	chr3:126099807	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.512	rs1077621	ENSG00000250012.1	RP11-124N2.1	-5.07	8.21e-07	0.000549	-0.31	-0.32	Blood pressure (smoking interaction);	chr3:126100956	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.512	rs4646765	ENSG00000250012.1	RP11-124N2.1	-5.07	8.21e-07	0.000549	-0.31	-0.32	Blood pressure (smoking interaction);	chr3:126101864	chr3:126084220~126095349:+
SARC	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	5.07	8.22e-07	0.00055	0.36	0.32	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
SARC	cis	rs9309473	0.606	rs6759452	ENSG00000163016.8	ALMS1P	5.07	8.22e-07	0.00055	0.45	0.32	Metabolite levels;	chr2:73651225	chr2:73644919~73685576:+
SARC	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-5.07	8.22e-07	0.00055	-0.3	-0.32	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
SARC	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	5.07	8.23e-07	0.00055	0.39	0.32	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
SARC	cis	rs1823874	0.71	rs58572174	ENSG00000182397.13	DNM1P46	-5.07	8.24e-07	0.000551	-0.36	-0.32	IgG glycosylation;	chr15:99822635	chr15:99790156~99806927:-
SARC	cis	rs1823874	0.677	rs1993295	ENSG00000182397.13	DNM1P46	-5.07	8.24e-07	0.000551	-0.36	-0.32	IgG glycosylation;	chr15:99823332	chr15:99790156~99806927:-
SARC	cis	rs1823874	0.71	rs1993297	ENSG00000182397.13	DNM1P46	-5.07	8.24e-07	0.000551	-0.36	-0.32	IgG glycosylation;	chr15:99823423	chr15:99790156~99806927:-
SARC	cis	rs7216064	1	rs58551145	ENSG00000278219.1	AC145343.1	-5.07	8.25e-07	0.000551	-0.41	-0.32	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841119	chr17:68101538~68101639:+
SARC	cis	rs7615952	0.641	rs7632497	ENSG00000250012.1	RP11-124N2.1	-5.07	8.27e-07	0.000552	-0.31	-0.31	Blood pressure (smoking interaction);	chr3:126064243	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.641	rs12487875	ENSG00000250012.1	RP11-124N2.1	-5.07	8.27e-07	0.000552	-0.31	-0.31	Blood pressure (smoking interaction);	chr3:126068381	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.641	rs7618515	ENSG00000250012.1	RP11-124N2.1	-5.07	8.27e-07	0.000552	-0.31	-0.31	Blood pressure (smoking interaction);	chr3:126071735	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.576	rs66671308	ENSG00000250012.1	RP11-124N2.1	-5.07	8.27e-07	0.000552	-0.31	-0.31	Blood pressure (smoking interaction);	chr3:126074683	chr3:126084220~126095349:+
SARC	cis	rs7216064	1	rs12602655	ENSG00000278219.1	AC145343.1	-5.07	8.27e-07	0.000552	-0.39	-0.31	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67913326	chr17:68101538~68101639:+
SARC	cis	rs12554020	1	rs59582399	ENSG00000227603.1	RP11-165J3.6	5.07	8.28e-07	0.000553	0.43	0.31	Schizophrenia;	chr9:93523881	chr9:93435332~93437121:-
SARC	cis	rs17270561	0.609	rs7772382	ENSG00000272810.1	U91328.22	-5.07	8.3e-07	0.000554	-0.32	-0.31	Iron status biomarkers;	chr6:25707888	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs3752420	ENSG00000272810.1	U91328.22	-5.07	8.3e-07	0.000554	-0.3	-0.31	Height;	chr6:26026907	chr6:26013241~26013757:+
SARC	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-5.06	8.31e-07	0.000555	-0.36	-0.31	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
SARC	cis	rs4372836	0.964	rs4531886	ENSG00000226833.4	AC097724.3	-5.06	8.32e-07	0.000555	-0.3	-0.31	Body mass index;	chr2:28695098	chr2:28708953~28736205:-
SARC	cis	rs890448	0.76	rs293210	ENSG00000254531.1	FLJ20021	5.06	8.33e-07	0.000556	0.33	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395248	chr4:101347780~101348883:+
SARC	cis	rs1823913	0.599	rs13002286	ENSG00000227542.1	AC092614.2	-5.06	8.33e-07	0.000556	-0.35	-0.31	Obesity-related traits;	chr2:191285626	chr2:191229165~191246172:-
SARC	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-5.06	8.33e-07	0.000556	-0.57	-0.31	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
SARC	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	5.06	8.33e-07	0.000556	0.47	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
SARC	cis	rs17270561	0.609	rs1937127	ENSG00000272810.1	U91328.22	5.06	8.34e-07	0.000557	0.33	0.31	Iron status biomarkers;	chr6:25769644	chr6:26013241~26013757:+
SARC	cis	rs7250849	0.688	rs16982907	ENSG00000273837.1	LLNLR-470E3.1	-5.06	8.37e-07	0.000558	-0.35	-0.31	Blood protein levels;	chr19:51659782	chr19:51639478~51639931:-
SARC	cis	rs12655019	0.92	rs75167082	ENSG00000271828.1	CTD-2310F14.1	5.06	8.38e-07	0.000559	0.52	0.31	Breast cancer (early onset);	chr5:56915577	chr5:56927874~56929573:+
SARC	cis	rs4372836	1	rs4666118	ENSG00000226833.4	AC097724.3	5.06	8.39e-07	0.000559	0.3	0.31	Body mass index;	chr2:28728832	chr2:28708953~28736205:-
SARC	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-5.06	8.39e-07	0.000559	-0.39	-0.31	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
SARC	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-5.06	8.43e-07	0.000562	-0.31	-0.31	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
SARC	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-5.06	8.43e-07	0.000562	-0.31	-0.31	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
SARC	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-5.06	8.43e-07	0.000562	-0.31	-0.31	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
SARC	cis	rs2179367	0.613	rs62426122	ENSG00000231760.4	RP11-350J20.5	5.06	8.44e-07	0.000562	0.43	0.31	Dupuytren's disease;	chr6:149427449	chr6:149796151~149826294:-
SARC	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-5.06	8.44e-07	0.000563	-0.37	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
SARC	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	5.06	8.45e-07	0.000563	0.44	0.31	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
SARC	cis	rs1707322	0.721	rs10890333	ENSG00000281133.1	AL355480.3	-5.06	8.45e-07	0.000563	-0.37	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45580892~45580996:-
SARC	cis	rs1865760	1	rs9358895	ENSG00000272810.1	U91328.22	-5.06	8.45e-07	0.000563	-0.31	-0.31	Height;	chr6:25924427	chr6:26013241~26013757:+
SARC	cis	rs890448	0.796	rs2114365	ENSG00000254531.1	FLJ20021	5.06	8.47e-07	0.000564	0.32	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101424489	chr4:101347780~101348883:+
SARC	cis	rs7216064	0.589	rs8072723	ENSG00000265055.1	AC145343.2	-5.06	8.48e-07	0.000565	-0.38	-0.31	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68060854	chr17:68096046~68101474:-
SARC	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-5.06	8.51e-07	0.000567	-0.32	-0.31	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
SARC	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	5.06	8.52e-07	0.000567	0.36	0.31	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
SARC	cis	rs1707322	0.686	rs1084086	ENSG00000281133.1	AL355480.3	5.06	8.53e-07	0.000568	0.37	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45580892~45580996:-
SARC	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-5.06	8.53e-07	0.000568	-0.31	-0.31	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
SARC	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	5.06	8.55e-07	0.000569	0.4	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
SARC	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	5.06	8.55e-07	0.000569	0.4	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
SARC	cis	rs1823913	0.599	rs4146103	ENSG00000227542.1	AC092614.2	5.06	8.56e-07	0.000569	0.35	0.31	Obesity-related traits;	chr2:191272000	chr2:191229165~191246172:-
SARC	cis	rs9601248	0.627	rs2146593	ENSG00000227354.5	RBM26-AS1	5.06	8.57e-07	0.00057	0.33	0.31	Major depressive disorder;	chr13:79605977	chr13:79406309~79424328:+
SARC	cis	rs4713118	0.824	rs742046	ENSG00000219392.1	RP1-265C24.5	-5.06	8.58e-07	0.00057	-0.44	-0.31	Parkinson's disease;	chr6:27771475	chr6:28115628~28116551:+
SARC	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-5.06	8.58e-07	0.000571	-0.3	-0.31	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
SARC	cis	rs2439831	0.867	rs2242068	ENSG00000205771.5	CATSPER2P1	-5.06	8.6e-07	0.000572	-0.5	-0.31	Lung cancer in ever smokers;	chr15:43407106	chr15:43726918~43747094:-
SARC	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-5.06	8.62e-07	0.000573	-0.34	-0.31	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
SARC	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-5.06	8.62e-07	0.000573	-0.26	-0.31	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
SARC	cis	rs2836974	0.583	rs9981884	ENSG00000255568.3	BRWD1-AS2	5.06	8.63e-07	0.000573	0.3	0.31	Cognitive function;	chr21:39213707	chr21:39313935~39314962:+
SARC	cis	rs858239	0.669	rs1618339	ENSG00000226816.2	AC005082.12	5.06	8.63e-07	0.000574	0.38	0.31	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23206013~23208045:+
SARC	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-5.06	8.63e-07	0.000574	-0.3	-0.31	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
SARC	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-5.06	8.65e-07	0.000575	-0.39	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
SARC	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-5.06	8.66e-07	0.000575	-0.35	-0.31	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
SARC	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-5.06	8.67e-07	0.000576	-0.36	-0.31	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
SARC	cis	rs4862750	0.957	rs4861733	ENSG00000249742.1	RP11-217E13.1	-5.06	8.67e-07	0.000576	-0.34	-0.31	Lobe attachment (rater-scored or self-reported);	chr4:186982779	chr4:186979490~187021973:-
SARC	cis	rs4660456	0.827	rs617413	ENSG00000237899.1	RP4-739H11.3	5.06	8.68e-07	0.000576	0.37	0.31	Platelet count;	chr1:40669846	chr1:40669089~40687588:-
SARC	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-5.06	8.68e-07	0.000577	-0.3	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
SARC	cis	rs9376098	0.825	rs6922541	ENSG00000232876.1	CTA-212D2.2	-5.06	8.7e-07	0.000578	-0.35	-0.31	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161681	chr6:135055033~135060550:+
SARC	cis	rs12655019	0.92	rs113772507	ENSG00000271828.1	CTD-2310F14.1	5.06	8.7e-07	0.000578	0.53	0.31	Breast cancer (early onset);	chr5:56929449	chr5:56927874~56929573:+
SARC	cis	rs1865760	0.566	rs9366634	ENSG00000272462.2	U91328.19	-5.06	8.7e-07	0.000578	-0.29	-0.31	Height;	chr6:26072168	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.566	rs1539183	ENSG00000272810.1	U91328.22	-5.05	8.73e-07	0.00058	-0.31	-0.31	Height;	chr6:26074823	chr6:26013241~26013757:+
SARC	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-5.05	8.74e-07	0.00058	-0.4	-0.31	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
SARC	cis	rs5769707	0.632	rs135876	ENSG00000188511.11	C22orf34	5.05	8.74e-07	0.00058	0.4	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49414524~49657542:-
SARC	cis	rs12655019	0.92	rs1466007	ENSG00000271828.1	CTD-2310F14.1	5.05	8.76e-07	0.000581	0.52	0.31	Breast cancer (early onset);	chr5:56917812	chr5:56927874~56929573:+
SARC	cis	rs2439831	0.85	rs694985	ENSG00000205771.5	CATSPER2P1	-5.05	8.77e-07	0.000582	-0.49	-0.31	Lung cancer in ever smokers;	chr15:43521189	chr15:43726918~43747094:-
SARC	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-5.05	8.78e-07	0.000583	-0.35	-0.31	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
SARC	cis	rs7772486	0.686	rs9399565	ENSG00000270638.1	RP3-466P17.1	-5.05	8.78e-07	0.000583	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145735570~145737218:+
SARC	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-5.05	8.78e-07	0.000583	-0.41	-0.31	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
SARC	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-5.05	8.8e-07	0.000584	-0.34	-0.31	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
SARC	cis	rs11719291	0.833	rs11715835	ENSG00000225399.4	RP11-3B7.1	-5.05	8.81e-07	0.000584	-0.61	-0.31	Cognitive function;	chr3:48733299	chr3:49260085~49261316:+
SARC	cis	rs8031584	0.918	rs34693097	ENSG00000260382.1	RP11-540B6.2	5.05	8.81e-07	0.000585	0.38	0.31	Huntington's disease progression;	chr15:30961781	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.918	rs35784593	ENSG00000260382.1	RP11-540B6.2	5.05	8.81e-07	0.000585	0.38	0.31	Huntington's disease progression;	chr15:30962385	chr15:30882267~30883231:-
SARC	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	5.05	8.82e-07	0.000585	0.49	0.31	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
SARC	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	5.05	8.82e-07	0.000585	0.49	0.31	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
SARC	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-5.05	8.82e-07	0.000585	-0.37	-0.31	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
SARC	cis	rs1865760	1	rs3799372	ENSG00000272810.1	U91328.22	-5.05	8.83e-07	0.000585	-0.31	-0.31	Height;	chr6:25922083	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.963	rs1540273	ENSG00000272810.1	U91328.22	-5.05	8.83e-07	0.000585	-0.31	-0.31	Height;	chr6:25923930	chr6:26013241~26013757:+
SARC	cis	rs524281	0.731	rs6591201	ENSG00000255320.1	RP11-755F10.1	-5.05	8.83e-07	0.000585	-0.47	-0.31	Electroencephalogram traits;	chr11:66038499	chr11:66244840~66246239:-
SARC	cis	rs4372836	0.964	rs55721532	ENSG00000226833.4	AC097724.3	-5.05	8.83e-07	0.000585	-0.3	-0.31	Body mass index;	chr2:28716102	chr2:28708953~28736205:-
SARC	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	5.05	8.85e-07	0.000587	0.34	0.31	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
SARC	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-5.05	8.85e-07	0.000587	-0.34	-0.31	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-5.05	8.85e-07	0.000587	-0.34	-0.31	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
SARC	cis	rs2018683	0.624	rs2286219	ENSG00000228421.2	AC005013.5	5.05	8.86e-07	0.000587	0.33	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28957667~28959345:+
SARC	cis	rs2439831	0.557	rs13329084	ENSG00000205771.5	CATSPER2P1	5.05	8.87e-07	0.000588	0.52	0.31	Lung cancer in ever smokers;	chr15:43858865	chr15:43726918~43747094:-
SARC	cis	rs875971	0.577	rs35072105	ENSG00000236529.1	RP13-254B10.1	-5.05	8.9e-07	0.00059	-0.32	-0.31	Aortic root size;	chr7:66144830	chr7:65840212~65840596:+
SARC	cis	rs9309473	1	rs2056486	ENSG00000163016.8	ALMS1P	5.05	8.9e-07	0.00059	0.4	0.31	Metabolite levels;	chr2:73490440	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs10193972	ENSG00000163016.8	ALMS1P	5.05	8.9e-07	0.00059	0.4	0.31	Metabolite levels;	chr2:73490529	chr2:73644919~73685576:+
SARC	cis	rs4713118	0.621	rs9295756	ENSG00000272009.1	RP1-313I6.12	-5.05	8.93e-07	0.000592	-0.36	-0.31	Parkinson's disease;	chr6:28065618	chr6:28078792~28081130:-
SARC	cis	rs2274273	0.588	rs11158037	ENSG00000258413.1	RP11-665C16.6	-5.05	8.93e-07	0.000592	-0.4	-0.31	Protein biomarker;	chr14:55365434	chr14:55262767~55272075:-
SARC	cis	rs193541	0.632	rs152038	ENSG00000263432.2	RN7SL689P	5.05	8.94e-07	0.000592	0.4	0.31	Glucose homeostasis traits;	chr5:122860151	chr5:123022487~123022783:-
SARC	cis	rs7615952	0.576	rs4646763	ENSG00000250012.1	RP11-124N2.1	-5.05	8.96e-07	0.000593	-0.31	-0.31	Blood pressure (smoking interaction);	chr3:126103286	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.576	rs4646759	ENSG00000250012.1	RP11-124N2.1	-5.05	8.96e-07	0.000593	-0.31	-0.31	Blood pressure (smoking interaction);	chr3:126104103	chr3:126084220~126095349:+
SARC	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	5.05	8.96e-07	0.000593	0.35	0.31	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
SARC	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-5.05	8.96e-07	0.000593	-0.38	-0.31	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
SARC	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	5.05	8.96e-07	0.000594	0.39	0.31	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
SARC	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	5.05	8.97e-07	0.000594	0.4	0.31	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
SARC	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-5.05	8.97e-07	0.000594	-0.39	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
SARC	cis	rs5769707	0.632	rs135877	ENSG00000188511.11	C22orf34	5.05	8.98e-07	0.000595	0.4	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49414524~49657542:-
SARC	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	5.05	8.99e-07	0.000595	0.33	0.31	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
SARC	cis	rs75920871	0.588	rs7119185	ENSG00000254851.1	RP11-109L13.1	5.05	9e-07	0.000595	0.43	0.31	Subjective well-being;	chr11:117015380	chr11:117135528~117138582:+
SARC	cis	rs2439831	1	rs690002	ENSG00000205771.5	CATSPER2P1	-5.05	9e-07	0.000595	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43437151	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs537115	ENSG00000205771.5	CATSPER2P1	-5.05	9e-07	0.000595	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43437750	chr15:43726918~43747094:-
SARC	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	5.05	9e-07	0.000596	0.38	0.31	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
SARC	cis	rs9890032	1	rs9890032	ENSG00000263531.1	RP13-753N3.1	-5.05	9.03e-07	0.000597	-0.38	-0.31	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30863921~30864940:-
SARC	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	5.05	9.03e-07	0.000598	0.36	0.31	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.869	rs616954	ENSG00000237899.1	RP4-739H11.3	5.05	9.04e-07	0.000598	0.37	0.31	Platelet count;	chr1:40669947	chr1:40669089~40687588:-
SARC	cis	rs7772486	0.686	rs6933161	ENSG00000270638.1	RP3-466P17.1	-5.05	9.05e-07	0.000599	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145735570~145737218:+
SARC	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-5.05	9.06e-07	0.000599	-0.36	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
SARC	cis	rs7772486	0.686	rs702314	ENSG00000270638.1	RP3-466P17.1	-5.05	9.06e-07	0.000599	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145735570~145737218:+
SARC	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	5.05	9.07e-07	6e-04	0.29	0.31	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
SARC	cis	rs4862750	0.914	rs1346127	ENSG00000249742.1	RP11-217E13.1	5.05	9.08e-07	6e-04	0.36	0.31	Lobe attachment (rater-scored or self-reported);	chr4:186955235	chr4:186979490~187021973:-
SARC	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-5.05	9.09e-07	0.000601	-0.4	-0.31	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
SARC	cis	rs453301	0.624	rs2288671	ENSG00000253893.2	FAM85B	-5.05	9.1e-07	0.000601	-0.27	-0.31	Joint mobility (Beighton score);	chr8:9003384	chr8:8167819~8226614:-
SARC	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-5.05	9.1e-07	0.000602	-0.36	-0.31	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
SARC	cis	rs728478	0.845	rs7207830	ENSG00000266992.1	DHX40P1	5.05	9.1e-07	0.000602	0.33	0.31	QT interval;	chr17:59402382	chr17:59976009~60002384:-
SARC	cis	rs1707322	0.627	rs3014213	ENSG00000281133.1	AL355480.3	5.05	9.12e-07	0.000603	0.36	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.686	rs2152078	ENSG00000281133.1	AL355480.3	5.05	9.12e-07	0.000603	0.36	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.686	rs2991979	ENSG00000281133.1	AL355480.3	5.05	9.12e-07	0.000603	0.36	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45580892~45580996:-
SARC	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-5.04	9.13e-07	0.000603	-0.3	-0.31	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
SARC	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-5.04	9.13e-07	0.000603	-0.33	-0.31	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
SARC	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-5.04	9.13e-07	0.000603	-0.33	-0.31	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
SARC	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	5.04	9.14e-07	0.000604	0.29	0.31	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
SARC	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-5.04	9.15e-07	0.000604	-0.3	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
SARC	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-5.04	9.15e-07	0.000604	-0.3	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
SARC	cis	rs916888	0.821	rs199513	ENSG00000261575.2	RP11-259G18.1	-5.04	9.16e-07	0.000605	-0.42	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46267037~46268694:+
SARC	cis	rs2404602	0.684	rs11854850	ENSG00000259422.1	RP11-593F23.1	-5.04	9.16e-07	0.000605	-0.38	-0.31	Blood metabolite levels;	chr15:76552230	chr15:76174891~76181486:-
SARC	cis	rs79349575	0.749	rs1057902	ENSG00000270781.1	RP11-501C14.9	-5.04	9.16e-07	0.000605	-0.37	-0.31	Type 2 diabetes;	chr17:48928226	chr17:48899131~48899748:+
SARC	cis	rs2274273	0.84	rs6573014	ENSG00000258413.1	RP11-665C16.6	5.04	9.17e-07	0.000605	0.37	0.31	Protein biomarker;	chr14:55269174	chr14:55262767~55272075:-
SARC	cis	rs7809950	0.954	rs62482543	ENSG00000238832.1	snoU109	-5.04	9.17e-07	0.000606	-0.36	-0.31	Coronary artery disease;	chr7:107440211	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs1544336	ENSG00000238832.1	snoU109	-5.04	9.17e-07	0.000606	-0.36	-0.31	Coronary artery disease;	chr7:107441970	chr7:107603363~107603507:+
SARC	cis	rs2524005	1	rs2524005	ENSG00000235821.1	IFITM4P	-5.04	9.19e-07	0.000607	-0.39	-0.31	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29750729~29751148:-
SARC	cis	rs2439831	0.764	rs12324584	ENSG00000205771.5	CATSPER2P1	-5.04	9.19e-07	0.000607	-0.47	-0.31	Lung cancer in ever smokers;	chr15:43391248	chr15:43726918~43747094:-
SARC	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-5.04	9.2e-07	0.000608	-0.38	-0.31	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
SARC	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-5.04	9.2e-07	0.000608	-0.38	-0.31	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
SARC	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-5.04	9.22e-07	0.000608	-0.37	-0.31	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
SARC	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-5.04	9.22e-07	0.000608	-0.41	-0.31	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
SARC	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	5.04	9.22e-07	0.000609	0.34	0.31	QT interval;	chr16:28860645	chr16:28700294~28701540:-
SARC	cis	rs7216064	1	rs73352808	ENSG00000278219.1	AC145343.1	-5.04	9.25e-07	0.00061	-0.38	-0.31	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67879041	chr17:68101538~68101639:+
SARC	cis	rs7712401	0.601	rs30038	ENSG00000263432.2	RN7SL689P	5.04	9.26e-07	0.000611	0.4	0.31	Mean platelet volume;	chr5:122941667	chr5:123022487~123022783:-
SARC	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-5.04	9.27e-07	0.000612	-0.34	-0.31	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
SARC	cis	rs6993244	1	rs6993244	ENSG00000253893.2	FAM85B	-5.04	9.29e-07	0.000613	-0.28	-0.31	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8167819~8226614:-
SARC	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	5.04	9.29e-07	0.000613	0.48	0.31	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
SARC	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-5.04	9.29e-07	0.000613	-0.33	-0.31	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-5.04	9.29e-07	0.000613	-0.33	-0.31	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
SARC	cis	rs2117029	0.965	rs2293446	ENSG00000258017.1	RP11-386G11.10	-5.04	9.3e-07	0.000613	-0.33	-0.31	Intelligence (multi-trait analysis);	chr12:49018926	chr12:49127782~49147869:+
SARC	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	5.04	9.3e-07	0.000613	0.34	0.31	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
SARC	cis	rs6509701	1	rs6509701	ENSG00000268225.1	CTD-2331H12.5	-5.04	9.3e-07	0.000613	-0.3	-0.31	Psychosis in Alzheimer's disease;	chr19:52880932	chr19:52861807~52862866:-
SARC	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	5.04	9.31e-07	0.000614	0.37	0.31	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
SARC	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-5.04	9.32e-07	0.000614	-0.35	-0.31	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
SARC	cis	rs524281	0.682	rs6591202	ENSG00000255320.1	RP11-755F10.1	-5.04	9.34e-07	0.000616	-0.47	-0.31	Electroencephalogram traits;	chr11:66038622	chr11:66244840~66246239:-
SARC	cis	rs524281	0.731	rs6591203	ENSG00000255320.1	RP11-755F10.1	-5.04	9.34e-07	0.000616	-0.47	-0.31	Electroencephalogram traits;	chr11:66038758	chr11:66244840~66246239:-
SARC	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-5.04	9.35e-07	0.000616	-0.36	-0.31	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
SARC	cis	rs2439831	0.681	rs484029	ENSG00000205771.5	CATSPER2P1	-5.04	9.36e-07	0.000617	-0.46	-0.31	Lung cancer in ever smokers;	chr15:43327362	chr15:43726918~43747094:-
SARC	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-5.04	9.39e-07	0.000619	-0.32	-0.31	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
SARC	cis	rs12554020	0.786	rs6479495	ENSG00000227603.1	RP11-165J3.6	5.04	9.39e-07	0.000619	0.43	0.31	Schizophrenia;	chr9:93572320	chr9:93435332~93437121:-
SARC	cis	rs394563	0.69	rs237010	ENSG00000231760.4	RP11-350J20.5	5.04	9.39e-07	0.000619	0.4	0.31	Dupuytren's disease;	chr6:149437614	chr6:149796151~149826294:-
SARC	cis	rs7809950	1	rs10251808	ENSG00000238832.1	snoU109	-5.04	9.4e-07	0.000619	-0.36	-0.31	Coronary artery disease;	chr7:107480008	chr7:107603363~107603507:+
SARC	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	5.04	9.42e-07	0.000621	0.31	0.31	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
SARC	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	5.04	9.42e-07	0.000621	0.47	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
SARC	cis	rs8005677	1	rs4981446	ENSG00000257285.4	RP11-298I3.1	5.04	9.44e-07	0.000622	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:22929609~22955562:+
SARC	cis	rs2562456	0.833	rs56187954	ENSG00000268081.1	RP11-678G14.2	5.04	9.44e-07	0.000622	0.5	0.31	Pain;	chr19:21345258	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs7258099	ENSG00000268081.1	RP11-678G14.2	5.04	9.44e-07	0.000622	0.5	0.31	Pain;	chr19:21352941	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62109229	ENSG00000268081.1	RP11-678G14.2	5.04	9.44e-07	0.000622	0.5	0.31	Pain;	chr19:21354380	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs11670815	ENSG00000268081.1	RP11-678G14.2	5.04	9.44e-07	0.000622	0.5	0.31	Pain;	chr19:21356515	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs11666540	ENSG00000268081.1	RP11-678G14.2	5.04	9.44e-07	0.000622	0.5	0.31	Pain;	chr19:21356550	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs11667361	ENSG00000268081.1	RP11-678G14.2	5.04	9.44e-07	0.000622	0.5	0.31	Pain;	chr19:21356580	chr19:21554640~21569237:-
SARC	cis	rs17270561	0.609	rs9393655	ENSG00000272810.1	U91328.22	-5.04	9.47e-07	0.000623	-0.31	-0.31	Iron status biomarkers;	chr6:25711110	chr6:26013241~26013757:+
SARC	cis	rs9309473	0.95	rs73947808	ENSG00000163016.8	ALMS1P	5.04	9.51e-07	0.000625	0.42	0.31	Metabolite levels;	chr2:73494123	chr2:73644919~73685576:+
SARC	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-5.04	9.51e-07	0.000626	-0.37	-0.31	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
SARC	cis	rs12554020	0.892	rs6479494	ENSG00000227603.1	RP11-165J3.6	-5.04	9.52e-07	0.000626	-0.42	-0.31	Schizophrenia;	chr9:93568217	chr9:93435332~93437121:-
SARC	cis	rs858239	0.932	rs1624451	ENSG00000226816.2	AC005082.12	-5.04	9.52e-07	0.000626	-0.38	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23206013~23208045:+
SARC	cis	rs11719291	0.833	rs11713694	ENSG00000225399.4	RP11-3B7.1	-5.04	9.52e-07	0.000626	-0.57	-0.31	Cognitive function;	chr3:48796182	chr3:49260085~49261316:+
SARC	cis	rs11719291	0.833	rs11709246	ENSG00000225399.4	RP11-3B7.1	-5.04	9.52e-07	0.000626	-0.57	-0.31	Cognitive function;	chr3:48822065	chr3:49260085~49261316:+
SARC	cis	rs11719291	0.504	rs71324924	ENSG00000225399.4	RP11-3B7.1	-5.04	9.52e-07	0.000626	-0.57	-0.31	Cognitive function;	chr3:48828011	chr3:49260085~49261316:+
SARC	cis	rs8031584	0.918	rs61997138	ENSG00000260382.1	RP11-540B6.2	5.04	9.52e-07	0.000626	0.38	0.31	Huntington's disease progression;	chr15:30978573	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.918	rs61997140	ENSG00000260382.1	RP11-540B6.2	5.04	9.52e-07	0.000626	0.38	0.31	Huntington's disease progression;	chr15:30985109	chr15:30882267~30883231:-
SARC	cis	rs12655019	0.92	rs74865790	ENSG00000271828.1	CTD-2310F14.1	5.04	9.53e-07	0.000627	0.51	0.31	Breast cancer (early onset);	chr5:56923871	chr5:56927874~56929573:+
SARC	cis	rs12655019	0.92	rs12657064	ENSG00000271828.1	CTD-2310F14.1	5.04	9.53e-07	0.000627	0.51	0.31	Breast cancer (early onset);	chr5:56925172	chr5:56927874~56929573:+
SARC	cis	rs12530	0.715	rs5749416	ENSG00000230736.2	RP1-149A16.3	5.04	9.54e-07	0.000627	0.35	0.31	IgG glycosylation;	chr22:32381136	chr22:32376664~32384343:+
SARC	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	5.04	9.54e-07	0.000627	0.35	0.31	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
SARC	cis	rs9376098	0.825	rs6569999	ENSG00000232876.1	CTA-212D2.2	5.04	9.55e-07	0.000628	0.35	0.31	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161428	chr6:135055033~135060550:+
SARC	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-5.04	9.56e-07	0.000628	-0.52	-0.31	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
SARC	cis	rs7712401	0.601	rs30028	ENSG00000263432.2	RN7SL689P	5.04	9.56e-07	0.000628	0.38	0.31	Mean platelet volume;	chr5:122947574	chr5:123022487~123022783:-
SARC	cis	rs7246657	0.941	rs12982333	ENSG00000276846.1	CTD-3220F14.3	5.03	9.61e-07	0.000631	0.43	0.31	Coronary artery calcification;	chr19:37303822	chr19:37314868~37315620:-
SARC	cis	rs7246657	1	rs10426297	ENSG00000276846.1	CTD-3220F14.3	5.03	9.61e-07	0.000631	0.43	0.31	Coronary artery calcification;	chr19:37307471	chr19:37314868~37315620:-
SARC	cis	rs7246657	1	rs1823061	ENSG00000276846.1	CTD-3220F14.3	5.03	9.61e-07	0.000631	0.43	0.31	Coronary artery calcification;	chr19:37309724	chr19:37314868~37315620:-
SARC	cis	rs1865760	0.551	rs9461230	ENSG00000272462.2	U91328.19	-5.03	9.61e-07	0.000631	-0.29	-0.31	Height;	chr6:26019012	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs2070642	ENSG00000272462.2	U91328.19	-5.03	9.62e-07	0.000632	-0.28	-0.31	Iron status biomarkers;	chr6:25830984	chr6:25992662~26001775:+
SARC	cis	rs4862750	0.872	rs6553029	ENSG00000250971.1	RP11-696F12.1	-5.03	9.63e-07	0.000632	-0.38	-0.31	Lobe attachment (rater-scored or self-reported);	chr4:186955316	chr4:187060099~187060930:+
SARC	cis	rs1865760	0.566	rs2032449	ENSG00000272810.1	U91328.22	-5.03	9.63e-07	0.000632	-0.3	-0.31	Height;	chr6:26026371	chr6:26013241~26013757:+
SARC	cis	rs4372836	1	rs2276547	ENSG00000226833.4	AC097724.3	5.03	9.64e-07	0.000633	0.29	0.31	Body mass index;	chr2:28752241	chr2:28708953~28736205:-
SARC	cis	rs6570726	0.846	rs6899900	ENSG00000270638.1	RP3-466P17.1	5.03	9.65e-07	0.000633	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145735570~145737218:+
SARC	cis	rs7615952	0.576	rs4646748	ENSG00000250012.1	RP11-124N2.1	-5.03	9.65e-07	0.000633	-0.3	-0.31	Blood pressure (smoking interaction);	chr3:126107486	chr3:126084220~126095349:+
SARC	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	5.03	9.65e-07	0.000633	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	5.03	9.65e-07	0.000633	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
SARC	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-5.03	9.65e-07	0.000634	-0.32	-0.31	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
SARC	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-5.03	9.65e-07	0.000634	-0.32	-0.31	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
SARC	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	5.03	9.67e-07	0.000634	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
SARC	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-5.03	9.68e-07	0.000635	-0.44	-0.31	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
SARC	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-5.03	9.69e-07	0.000636	-0.41	-0.31	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
SARC	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-5.03	9.71e-07	0.000637	-0.32	-0.31	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
SARC	cis	rs1823874	0.613	rs4608318	ENSG00000182397.13	DNM1P46	-5.03	9.72e-07	0.000638	-0.36	-0.31	IgG glycosylation;	chr15:99823621	chr15:99790156~99806927:-
SARC	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	5.03	9.73e-07	0.000638	0.34	0.31	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
SARC	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	5.03	9.73e-07	0.000638	0.34	0.31	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
SARC	cis	rs7772486	0.658	rs9403737	ENSG00000270638.1	RP3-466P17.1	5.03	9.74e-07	0.000639	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs4896832	ENSG00000270638.1	RP3-466P17.1	5.03	9.74e-07	0.000639	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs857883	ENSG00000270638.1	RP3-466P17.1	-5.03	9.74e-07	0.000639	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs857882	ENSG00000270638.1	RP3-466P17.1	-5.03	9.74e-07	0.000639	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs857877	ENSG00000270638.1	RP3-466P17.1	-5.03	9.74e-07	0.000639	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145735570~145737218:+
SARC	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	5.03	9.74e-07	0.000639	0.27	0.31	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	5.03	9.74e-07	0.000639	0.27	0.31	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	5.03	9.74e-07	0.000639	0.27	0.31	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
SARC	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	5.03	9.75e-07	0.000639	0.34	0.31	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
SARC	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	5.03	9.75e-07	0.000639	0.34	0.31	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
SARC	cis	rs1865760	0.566	rs2051544	ENSG00000272810.1	U91328.22	-5.03	9.76e-07	0.00064	-0.3	-0.31	Height;	chr6:26070865	chr6:26013241~26013757:+
SARC	cis	rs2288884	0.559	rs11084130	ENSG00000275055.1	CTC-471J1.11	-5.03	9.78e-07	0.000641	-0.34	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:52049007~52049754:+
SARC	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-5.03	9.79e-07	0.000641	-0.38	-0.31	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
SARC	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-5.03	9.79e-07	0.000642	-0.32	-0.31	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
SARC	cis	rs4862750	0.915	rs6835681	ENSG00000250971.1	RP11-696F12.1	5.03	9.8e-07	0.000642	0.39	0.31	Lobe attachment (rater-scored or self-reported);	chr4:186982322	chr4:187060099~187060930:+
SARC	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-5.03	9.83e-07	0.000644	-0.38	-0.31	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
SARC	cis	rs2288884	0.559	rs61287503	ENSG00000275055.1	CTC-471J1.11	-5.03	9.84e-07	0.000644	-0.35	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017939	chr19:52049007~52049754:+
SARC	cis	rs9309473	0.898	rs6546851	ENSG00000163016.8	ALMS1P	5.03	9.85e-07	0.000645	0.39	0.31	Metabolite levels;	chr2:73606156	chr2:73644919~73685576:+
SARC	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-5.03	9.86e-07	0.000646	-0.34	-0.31	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
SARC	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	5.03	9.86e-07	0.000646	0.33	0.31	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
SARC	cis	rs12655019	0.92	rs16886510	ENSG00000271828.1	CTD-2310F14.1	5.03	9.89e-07	0.000647	0.52	0.31	Breast cancer (early onset);	chr5:56932618	chr5:56927874~56929573:+
SARC	cis	rs12655019	0.92	rs78075120	ENSG00000271828.1	CTD-2310F14.1	5.03	9.89e-07	0.000647	0.52	0.31	Breast cancer (early onset);	chr5:56932640	chr5:56927874~56929573:+
SARC	cis	rs12655019	0.92	rs76869724	ENSG00000271828.1	CTD-2310F14.1	5.03	9.89e-07	0.000647	0.52	0.31	Breast cancer (early onset);	chr5:56932668	chr5:56927874~56929573:+
SARC	cis	rs17270561	0.666	rs1937129	ENSG00000272810.1	U91328.22	-5.03	9.9e-07	0.000648	-0.31	-0.31	Iron status biomarkers;	chr6:25788904	chr6:26013241~26013757:+
SARC	cis	rs6509701	1	rs2162919	ENSG00000268225.1	CTD-2331H12.5	5.03	9.93e-07	0.000649	0.3	0.31	Psychosis in Alzheimer's disease;	chr19:52878176	chr19:52861807~52862866:-
SARC	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	5.03	9.95e-07	0.00065	0.35	0.31	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
SARC	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	5.03	9.95e-07	0.00065	0.32	0.31	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
SARC	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-5.03	9.95e-07	0.000651	-0.35	-0.31	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
SARC	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-5.03	9.95e-07	0.000651	-0.35	-0.31	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-5.03	9.95e-07	0.000651	-0.35	-0.31	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-5.03	9.95e-07	0.000651	-0.35	-0.31	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
SARC	cis	rs7567389	0.504	rs2069895	ENSG00000236682.1	AC068282.3	-5.03	9.96e-07	0.000651	-0.35	-0.31	Self-rated health;	chr2:127416492	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.504	rs2069898	ENSG00000236682.1	AC068282.3	-5.03	9.96e-07	0.000651	-0.35	-0.31	Self-rated health;	chr2:127416651	chr2:127389130~127400580:+
SARC	cis	rs4372836	0.636	rs4665434	ENSG00000226833.4	AC097724.3	5.03	9.97e-07	0.000651	0.27	0.31	Body mass index;	chr2:28753537	chr2:28708953~28736205:-
SARC	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-5.03	9.99e-07	0.000652	-0.29	-0.31	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
SARC	cis	rs7772486	0.624	rs6930154	ENSG00000270638.1	RP3-466P17.1	-5.03	9.99e-07	0.000652	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145735570~145737218:+
SARC	cis	rs2274273	0.806	rs7146752	ENSG00000258413.1	RP11-665C16.6	-5.03	9.99e-07	0.000652	-0.37	-0.31	Protein biomarker;	chr14:55272189	chr14:55262767~55272075:-
SARC	cis	rs6570726	0.846	rs439035	ENSG00000270638.1	RP3-466P17.1	5.03	9.99e-07	0.000653	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145566854	chr6:145735570~145737218:+
SARC	cis	rs2288884	0.559	rs7257830	ENSG00000275055.1	CTC-471J1.11	-5.03	9.99e-07	0.000653	-0.34	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005392	chr19:52049007~52049754:+
SARC	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	5.03	1e-06	0.000654	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	5.03	1e-06	0.000654	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	5.03	1e-06	0.000654	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	5.03	1e-06	0.000654	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
SARC	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-5.02	1e-06	0.000655	-0.4	-0.31	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
SARC	cis	rs17270561	0.609	rs1185976	ENSG00000272462.2	U91328.19	5.02	1e-06	0.000655	0.28	0.31	Iron status biomarkers;	chr6:25822135	chr6:25992662~26001775:+
SARC	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	5.02	1e-06	0.000656	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	5.02	1e-06	0.000656	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
SARC	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	5.02	1.01e-06	0.000656	0.38	0.31	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	5.02	1.01e-06	0.000656	0.38	0.31	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
SARC	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	5.02	1.01e-06	0.000656	0.36	0.31	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
SARC	cis	rs7712401	0.601	rs152039	ENSG00000263432.2	RN7SL689P	5.02	1.01e-06	0.000656	0.4	0.31	Mean platelet volume;	chr5:122884970	chr5:123022487~123022783:-
SARC	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-5.02	1.01e-06	0.000657	-0.35	-0.31	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-5.02	1.01e-06	0.000657	-0.35	-0.31	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-5.02	1.01e-06	0.000657	-0.35	-0.31	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
SARC	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	5.02	1.01e-06	0.000657	0.38	0.31	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
SARC	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-5.02	1.01e-06	0.000658	-0.35	-0.31	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-5.02	1.01e-06	0.000658	-0.35	-0.31	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-5.02	1.01e-06	0.000658	-0.35	-0.31	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-5.02	1.01e-06	0.000658	-0.35	-0.31	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
SARC	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-5.02	1.01e-06	0.000658	-0.32	-0.31	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
SARC	cis	rs7626444	0.625	rs843539	ENSG00000272359.1	U4	-5.02	1.01e-06	0.000658	-0.32	-0.31	Monocyte count;	chr3:196747985	chr3:196747192~196747324:-
SARC	cis	rs1134634	0.52	rs10008889	ENSG00000273133.1	RP11-799M12.2	-5.02	1.01e-06	0.000658	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15622896	chr4:15563698~15564253:-
SARC	cis	rs1134634	0.52	rs75099653	ENSG00000273133.1	RP11-799M12.2	-5.02	1.01e-06	0.000658	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15626397	chr4:15563698~15564253:-
SARC	cis	rs1134634	0.52	rs872678	ENSG00000273133.1	RP11-799M12.2	-5.02	1.01e-06	0.000658	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15654075	chr4:15563698~15564253:-
SARC	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	5.02	1.01e-06	0.000659	0.34	0.31	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
SARC	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-5.02	1.01e-06	0.000659	-0.39	-0.31	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.735	rs12906143	ENSG00000259422.1	RP11-593F23.1	-5.02	1.01e-06	0.000659	-0.39	-0.31	Blood metabolite levels;	chr15:76417182	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.735	rs11632222	ENSG00000259422.1	RP11-593F23.1	-5.02	1.01e-06	0.000659	-0.39	-0.31	Blood metabolite levels;	chr15:76420586	chr15:76174891~76181486:-
SARC	cis	rs8005677	1	rs2295685	ENSG00000257285.4	RP11-298I3.1	5.02	1.01e-06	0.000659	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:22929609~22955562:+
SARC	cis	rs8005677	1	rs4982710	ENSG00000257285.4	RP11-298I3.1	5.02	1.01e-06	0.000659	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:22929609~22955562:+
SARC	cis	rs8005677	1	rs7145494	ENSG00000257285.4	RP11-298I3.1	5.02	1.01e-06	0.000659	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:22929609~22955562:+
SARC	cis	rs8005677	1	rs7155857	ENSG00000257285.4	RP11-298I3.1	5.02	1.01e-06	0.000659	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:22929609~22955562:+
SARC	cis	rs8005677	0.962	rs8003934	ENSG00000257285.4	RP11-298I3.1	5.02	1.01e-06	0.000659	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:22929609~22955562:+
SARC	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-5.02	1.01e-06	0.00066	-0.32	-0.31	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
SARC	cis	rs8005677	1	rs8006409	ENSG00000257285.4	RP11-298I3.1	5.02	1.01e-06	0.000661	0.3	0.31	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:22929609~22955562:+
SARC	cis	rs2439831	1	rs2245908	ENSG00000205771.5	CATSPER2P1	-5.02	1.01e-06	0.000661	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43439256	chr15:43726918~43747094:-
SARC	cis	rs7809950	1	rs12667527	ENSG00000238832.1	snoU109	-5.02	1.01e-06	0.000661	-0.36	-0.31	Coronary artery disease;	chr7:107446524	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs4727680	ENSG00000238832.1	snoU109	-5.02	1.01e-06	0.000661	-0.36	-0.31	Coronary artery disease;	chr7:107446962	chr7:107603363~107603507:+
SARC	cis	rs2404602	0.735	rs1607017	ENSG00000259422.1	RP11-593F23.1	-5.02	1.01e-06	0.000661	-0.39	-0.31	Blood metabolite levels;	chr15:76434124	chr15:76174891~76181486:-
SARC	cis	rs1707322	0.686	rs1250	ENSG00000281133.1	AL355480.3	-5.02	1.02e-06	0.000662	-0.37	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45580892~45580996:-
SARC	cis	rs2803122	0.846	rs7851656	ENSG00000273226.1	RP11-513M16.8	-5.02	1.02e-06	0.000663	-0.29	-0.31	Pulse pressure;	chr9:19213962	chr9:19375451~19375996:+
SARC	cis	rs9309473	1	rs11901272	ENSG00000163016.8	ALMS1P	5.02	1.02e-06	0.000663	0.39	0.31	Metabolite levels;	chr2:73493317	chr2:73644919~73685576:+
SARC	cis	rs2803122	0.745	rs10123714	ENSG00000273226.1	RP11-513M16.8	-5.02	1.02e-06	0.000664	-0.29	-0.31	Pulse pressure;	chr9:19231645	chr9:19375451~19375996:+
SARC	cis	rs12554020	1	rs7048853	ENSG00000227603.1	RP11-165J3.6	5.02	1.02e-06	0.000664	0.43	0.31	Schizophrenia;	chr9:93490896	chr9:93435332~93437121:-
SARC	cis	rs890448	0.796	rs2583387	ENSG00000254531.1	FLJ20021	5.02	1.02e-06	0.000664	0.32	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101359241	chr4:101347780~101348883:+
SARC	cis	rs7567389	0.677	rs10850	ENSG00000236682.1	AC068282.3	5.02	1.02e-06	0.000665	0.36	0.31	Self-rated health;	chr2:127306369	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	5.02	1.02e-06	0.000665	0.36	0.31	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
SARC	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-5.02	1.02e-06	0.000666	-0.38	-0.31	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
SARC	cis	rs2303759	0.914	rs2288481	ENSG00000268686.1	AC010524.2	-5.02	1.02e-06	0.000666	-0.43	-0.31	Multiple sclerosis;	chr19:49374939	chr19:49368705~49388081:-
SARC	cis	rs7809950	1	rs2712189	ENSG00000238832.1	snoU109	-5.02	1.02e-06	0.000666	-0.38	-0.31	Coronary artery disease;	chr7:107555302	chr7:107603363~107603507:+
SARC	cis	rs524281	0.861	rs485857	ENSG00000255320.1	RP11-755F10.1	5.02	1.02e-06	0.000667	0.44	0.31	Electroencephalogram traits;	chr11:66192048	chr11:66244840~66246239:-
SARC	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	5.02	1.02e-06	0.000667	0.29	0.31	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
SARC	cis	rs2117029	1	rs2117029	ENSG00000258017.1	RP11-386G11.10	-5.02	1.03e-06	0.000668	-0.33	-0.31	Intelligence (multi-trait analysis);	chr12:49014657	chr12:49127782~49147869:+
SARC	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	5.02	1.03e-06	0.000668	0.28	0.31	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
SARC	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	5.02	1.03e-06	0.000671	0.31	0.31	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
SARC	cis	rs11118620	0.535	rs1389750	ENSG00000257551.1	HLX-AS1	5.02	1.03e-06	0.000671	0.34	0.31	Heart failure;	chr1:220866829	chr1:220832763~220880140:-
SARC	cis	rs6991838	0.725	rs6995134	ENSG00000200714.1	Y_RNA	5.02	1.03e-06	0.000672	0.33	0.31	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65592731~65592820:+
SARC	cis	rs2933343	0.951	rs7648327	ENSG00000231305.3	RP11-723O4.2	5.02	1.03e-06	0.000673	0.34	0.31	IgG glycosylation;	chr3:128851865	chr3:128861313~128871540:-
SARC	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-5.02	1.03e-06	0.000673	-0.38	-0.31	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
SARC	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	5.02	1.04e-06	0.000675	0.33	0.31	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
SARC	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	5.02	1.04e-06	0.000675	0.33	0.31	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
SARC	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-5.02	1.04e-06	0.000676	-0.38	-0.31	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
SARC	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	5.02	1.04e-06	0.000677	0.36	0.31	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
SARC	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-5.02	1.04e-06	0.000677	-0.34	-0.31	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
SARC	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	5.02	1.04e-06	0.000679	0.25	0.31	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	5.02	1.04e-06	0.000679	0.25	0.31	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
SARC	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-5.02	1.05e-06	0.000681	-0.35	-0.31	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-5.02	1.05e-06	0.000681	-0.35	-0.31	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-5.02	1.05e-06	0.000681	-0.35	-0.31	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-5.02	1.05e-06	0.000681	-0.35	-0.31	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
SARC	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-5.02	1.05e-06	0.000682	-0.39	-0.31	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
SARC	cis	rs2562456	0.833	rs11666828	ENSG00000268081.1	RP11-678G14.2	5.01	1.05e-06	0.000682	0.51	0.31	Pain;	chr19:21342218	chr19:21554640~21569237:-
SARC	cis	rs6452524	0.618	rs255561	ENSG00000248112.1	RP11-78C3.1	5.01	1.05e-06	0.000682	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:82919376~82921119:-
SARC	cis	rs1823874	0.677	rs2168069	ENSG00000182397.13	DNM1P46	-5.01	1.05e-06	0.000683	-0.36	-0.31	IgG glycosylation;	chr15:99823798	chr15:99790156~99806927:-
SARC	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	5.01	1.05e-06	0.000683	0.46	0.31	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
SARC	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	5.01	1.05e-06	0.000683	0.29	0.31	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
SARC	cis	rs2274273	0.84	rs2341622	ENSG00000258413.1	RP11-665C16.6	-5.01	1.06e-06	0.000685	-0.37	-0.31	Protein biomarker;	chr14:55270525	chr14:55262767~55272075:-
SARC	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-5.01	1.06e-06	0.000685	-0.34	-0.31	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
SARC	cis	rs7772486	0.623	rs735535	ENSG00000270638.1	RP3-466P17.1	-5.01	1.06e-06	0.000686	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.566	rs735536	ENSG00000270638.1	RP3-466P17.1	-5.01	1.06e-06	0.000686	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145735570~145737218:+
SARC	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-5.01	1.06e-06	0.000686	-0.36	-0.31	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
SARC	cis	rs2439831	0.681	rs11858152	ENSG00000205771.5	CATSPER2P1	-5.01	1.06e-06	0.000687	-0.46	-0.31	Lung cancer in ever smokers;	chr15:43341998	chr15:43726918~43747094:-
SARC	cis	rs4862750	0.837	rs1863404	ENSG00000250971.1	RP11-696F12.1	5.01	1.06e-06	0.00069	0.38	0.31	Lobe attachment (rater-scored or self-reported);	chr4:186953500	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.914	rs9998558	ENSG00000250971.1	RP11-696F12.1	5.01	1.06e-06	0.00069	0.38	0.31	Lobe attachment (rater-scored or self-reported);	chr4:186953537	chr4:187060099~187060930:+
SARC	cis	rs7809950	0.954	rs2520241	ENSG00000238832.1	snoU109	-5.01	1.06e-06	0.00069	-0.36	-0.31	Coronary artery disease;	chr7:107494998	chr7:107603363~107603507:+
SARC	cis	rs1061377	0.748	rs6816202	ENSG00000249207.1	RP11-360F5.1	-5.01	1.07e-06	0.00069	-0.35	-0.31	Uric acid levels;	chr4:39106868	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.748	rs6842561	ENSG00000249207.1	RP11-360F5.1	-5.01	1.07e-06	0.00069	-0.35	-0.31	Uric acid levels;	chr4:39106873	chr4:39112677~39126818:-
SARC	cis	rs2933343	0.679	rs789221	ENSG00000261159.1	RP11-723O4.9	5.01	1.07e-06	0.000692	0.33	0.31	IgG glycosylation;	chr3:128872782	chr3:128859716~128860526:-
SARC	cis	rs1823913	0.599	rs13027086	ENSG00000227542.1	AC092614.2	5.01	1.07e-06	0.000692	0.35	0.31	Obesity-related traits;	chr2:191294058	chr2:191229165~191246172:-
SARC	cis	rs1707322	0.721	rs12043945	ENSG00000281133.1	AL355480.3	-5.01	1.07e-06	0.000692	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs12091503	ENSG00000281133.1	AL355480.3	-5.01	1.07e-06	0.000692	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45580892~45580996:-
SARC	cis	rs12655019	0.92	rs1466010	ENSG00000271828.1	CTD-2310F14.1	5.01	1.07e-06	0.000692	0.52	0.31	Breast cancer (early onset);	chr5:56917329	chr5:56927874~56929573:+
SARC	cis	rs4273100	0.79	rs60166680	ENSG00000228157.4	AC007952.5	5.01	1.07e-06	0.000693	0.45	0.31	Schizophrenia;	chr17:19374231	chr17:19092974~19096837:+
SARC	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-5.01	1.07e-06	0.000693	-0.26	-0.31	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
SARC	cis	rs75920871	0.528	rs7950093	ENSG00000254851.1	RP11-109L13.1	5.01	1.07e-06	0.000693	0.42	0.31	Subjective well-being;	chr11:117092803	chr11:117135528~117138582:+
SARC	cis	rs4862750	0.837	rs1863404	ENSG00000249742.1	RP11-217E13.1	-5.01	1.07e-06	0.000694	-0.34	-0.31	Lobe attachment (rater-scored or self-reported);	chr4:186953500	chr4:186979490~187021973:-
SARC	cis	rs4862750	0.914	rs9998558	ENSG00000249742.1	RP11-217E13.1	-5.01	1.07e-06	0.000694	-0.34	-0.31	Lobe attachment (rater-scored or self-reported);	chr4:186953537	chr4:186979490~187021973:-
SARC	cis	rs7772486	0.686	rs1292334	ENSG00000270638.1	RP3-466P17.1	5.01	1.07e-06	0.000694	0.26	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145735570~145737218:+
SARC	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-5.01	1.07e-06	0.000695	-0.36	-0.31	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-5.01	1.07e-06	0.000695	-0.36	-0.31	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
SARC	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-5.01	1.07e-06	0.000695	-0.35	-0.31	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
SARC	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-5.01	1.08e-06	0.000696	-0.36	-0.31	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
SARC	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	5.01	1.08e-06	0.000697	0.39	0.31	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
SARC	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-5.01	1.08e-06	0.000698	-0.36	-0.31	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-5.01	1.08e-06	0.000698	-0.36	-0.31	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
SARC	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-5.01	1.08e-06	0.000698	-0.31	-0.31	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
SARC	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-5.01	1.08e-06	0.000698	-0.37	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
SARC	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-5.01	1.08e-06	0.000699	-0.38	-0.31	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
SARC	cis	rs524281	0.731	rs3814744	ENSG00000255320.1	RP11-755F10.1	5.01	1.08e-06	0.000701	0.51	0.31	Electroencephalogram traits;	chr11:66042292	chr11:66244840~66246239:-
SARC	cis	rs524281	0.648	rs4565902	ENSG00000255320.1	RP11-755F10.1	5.01	1.08e-06	0.000701	0.51	0.31	Electroencephalogram traits;	chr11:66042574	chr11:66244840~66246239:-
SARC	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	5.01	1.08e-06	0.000701	0.34	0.31	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
SARC	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	5.01	1.08e-06	0.000701	0.51	0.31	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
SARC	cis	rs12216125	0.554	rs6942196	ENSG00000272462.2	U91328.19	-5.01	1.09e-06	0.000702	-0.29	-0.31	Iron status biomarkers;	chr6:26072576	chr6:25992662~26001775:+
SARC	cis	rs7809950	1	rs2178497	ENSG00000238832.1	snoU109	5.01	1.09e-06	0.000702	0.37	0.31	Coronary artery disease;	chr7:107638456	chr7:107603363~107603507:+
SARC	cis	rs890448	0.796	rs182393	ENSG00000254531.1	FLJ20021	5.01	1.09e-06	0.000703	0.32	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101403811	chr4:101347780~101348883:+
SARC	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-5.01	1.09e-06	0.000704	-0.3	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
SARC	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-5.01	1.09e-06	0.000704	-0.41	-0.31	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
SARC	cis	rs7772486	0.754	rs9386134	ENSG00000270638.1	RP3-466P17.1	5.01	1.09e-06	0.000706	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145735570~145737218:+
SARC	cis	rs7567389	0.719	rs4150499	ENSG00000236682.1	AC068282.3	5.01	1.09e-06	0.000706	0.37	0.31	Self-rated health;	chr2:127271216	chr2:127389130~127400580:+
SARC	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-5.01	1.09e-06	0.000706	-0.51	-0.31	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
SARC	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-5.01	1.09e-06	0.000706	-0.36	-0.31	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
SARC	cis	rs7772486	0.624	rs9485018	ENSG00000270638.1	RP3-466P17.1	-5.01	1.1e-06	0.000708	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145735570~145737218:+
SARC	cis	rs12468226	0.873	rs2350358	ENSG00000272966.1	RP11-686O6.1	-5.01	1.1e-06	0.000709	-0.47	-0.31	Urate levels;	chr2:202199771	chr2:202336739~202337200:+
SARC	cis	rs2933343	0.601	rs1680759	ENSG00000261159.1	RP11-723O4.9	5.01	1.1e-06	0.000709	0.33	0.31	IgG glycosylation;	chr3:128876053	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.601	rs1680758	ENSG00000261159.1	RP11-723O4.9	5.01	1.1e-06	0.000709	0.33	0.31	IgG glycosylation;	chr3:128876054	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.649	rs789214	ENSG00000261159.1	RP11-723O4.9	5.01	1.1e-06	0.000709	0.33	0.31	IgG glycosylation;	chr3:128876152	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.729	rs789224	ENSG00000261159.1	RP11-723O4.9	5.01	1.1e-06	0.000709	0.33	0.31	IgG glycosylation;	chr3:128879388	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.761	rs789225	ENSG00000261159.1	RP11-723O4.9	5.01	1.1e-06	0.000709	0.33	0.31	IgG glycosylation;	chr3:128881386	chr3:128859716~128860526:-
SARC	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	5.01	1.1e-06	0.00071	0.33	0.31	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
SARC	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	5.01	1.1e-06	0.00071	0.4	0.31	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
SARC	cis	rs7772486	0.754	rs697055	ENSG00000270638.1	RP3-466P17.1	5.01	1.1e-06	0.00071	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145735570~145737218:+
SARC	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	5	1.1e-06	0.000711	0.29	0.31	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
SARC	cis	rs1707322	0.717	rs2253862	ENSG00000281133.1	AL355480.3	5	1.1e-06	0.000711	0.36	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.717	rs2991988	ENSG00000281133.1	AL355480.3	5	1.1e-06	0.000711	0.36	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.717	rs2991989	ENSG00000281133.1	AL355480.3	5	1.1e-06	0.000711	0.36	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45580892~45580996:-
SARC	cis	rs2933343	0.951	rs789220	ENSG00000261159.1	RP11-723O4.9	-5	1.1e-06	0.000712	-0.36	-0.31	IgG glycosylation;	chr3:128873292	chr3:128859716~128860526:-
SARC	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-5	1.1e-06	0.000712	-0.54	-0.31	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
SARC	cis	rs27434	0.51	rs27038	ENSG00000272109.1	CTD-2260A17.3	-5	1.11e-06	0.000715	-0.45	-0.31	Ankylosing spondylitis;	chr5:96777250	chr5:96804353~96806105:+
SARC	cis	rs62432291	0.681	rs2932987	ENSG00000235086.1	FNDC1-IT1	5	1.11e-06	0.000715	0.5	0.31	Joint mobility (Beighton score);	chr6:159234641	chr6:159240786~159243329:+
SARC	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	5	1.11e-06	0.000716	0.3	0.31	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
SARC	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-5	1.11e-06	0.000717	-0.31	-0.31	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
SARC	cis	rs453301	0.624	rs4841083	ENSG00000253893.2	FAM85B	-5	1.11e-06	0.000717	-0.28	-0.31	Joint mobility (Beighton score);	chr8:9012918	chr8:8167819~8226614:-
SARC	cis	rs524281	0.731	rs2452682	ENSG00000255320.1	RP11-755F10.1	5	1.11e-06	0.000717	0.47	0.31	Electroencephalogram traits;	chr11:66045138	chr11:66244840~66246239:-
SARC	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	5	1.11e-06	0.000717	0.35	0.31	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
SARC	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-5	1.11e-06	0.000717	-0.36	-0.31	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
SARC	cis	rs6452524	0.618	rs6452506	ENSG00000248112.1	RP11-78C3.1	5	1.11e-06	0.000717	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:82919376~82921119:-
SARC	cis	rs6452524	0.618	rs1993948	ENSG00000248112.1	RP11-78C3.1	5	1.11e-06	0.000717	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:82919376~82921119:-
SARC	cis	rs9818758	0.545	rs55921200	ENSG00000225399.4	RP11-3B7.1	-5	1.11e-06	0.000717	-0.63	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49151883	chr3:49260085~49261316:+
SARC	cis	rs17270561	0.639	rs9356989	ENSG00000272462.2	U91328.19	-5	1.11e-06	0.000718	-0.3	-0.31	Iron status biomarkers;	chr6:25781722	chr6:25992662~26001775:+
SARC	cis	rs9818758	0.607	rs35060561	ENSG00000225399.4	RP11-3B7.1	-5	1.11e-06	0.000718	-0.58	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49218070	chr3:49260085~49261316:+
SARC	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	5	1.11e-06	0.000718	0.35	0.31	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
SARC	cis	rs9868809	0.505	rs73080312	ENSG00000225399.4	RP11-3B7.1	-5	1.12e-06	0.000722	-0.66	-0.31	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48700414	chr3:49260085~49261316:+
SARC	cis	rs7587476	0.906	rs16852750	ENSG00000229267.2	AC072062.1	-5	1.12e-06	0.000723	-0.32	-0.31	Neuroblastoma;	chr2:214781959	chr2:214810229~214963274:+
SARC	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	5	1.12e-06	0.000724	0.4	0.31	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
SARC	cis	rs890448	0.726	rs1530259	ENSG00000254531.1	FLJ20021	-5	1.12e-06	0.000724	-0.32	-0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101303753	chr4:101347780~101348883:+
SARC	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-5	1.13e-06	0.000725	-0.4	-0.31	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
SARC	cis	rs7216064	0.532	rs3890640	ENSG00000278219.1	AC145343.1	5	1.13e-06	0.000725	0.35	0.31	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68056912	chr17:68101538~68101639:+
SARC	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	5	1.13e-06	0.000726	0.29	0.31	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
SARC	cis	rs7216064	0.911	rs12449442	ENSG00000278219.1	AC145343.1	-5	1.13e-06	0.000727	-0.4	-0.31	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67951524	chr17:68101538~68101639:+
SARC	cis	rs9309473	1	rs1403284	ENSG00000163016.8	ALMS1P	-5	1.13e-06	0.000727	-0.39	-0.31	Metabolite levels;	chr2:73499535	chr2:73644919~73685576:+
SARC	cis	rs3805389	0.962	rs28708716	ENSG00000273257.1	RP11-177J6.1	-5	1.13e-06	0.000728	-0.42	-0.31	Waist-to-hip ratio adjusted for body mass index;	chr4:55596308	chr4:55387949~55388271:+
SARC	cis	rs11098499	0.566	rs17051356	ENSG00000245958.5	RP11-33B1.1	-5	1.13e-06	0.000728	-0.29	-0.31	Corneal astigmatism;	chr4:119664153	chr4:119454791~119552025:+
SARC	cis	rs7772486	0.754	rs1415747	ENSG00000270638.1	RP3-466P17.1	5	1.13e-06	0.000728	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145735570~145737218:+
SARC	cis	rs853679	0.517	rs36078605	ENSG00000272009.1	RP1-313I6.12	-5	1.13e-06	0.000728	-0.35	-0.31	Depression;	chr6:28110254	chr6:28078792~28081130:-
SARC	cis	rs6452524	0.618	rs2075685	ENSG00000248112.1	RP11-78C3.1	5	1.13e-06	0.000729	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:82919376~82921119:-
SARC	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-5	1.13e-06	0.000729	-0.39	-0.31	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
SARC	cis	rs79349575	0.721	rs9904645	ENSG00000270781.1	RP11-501C14.9	-5	1.13e-06	0.000729	-0.36	-0.31	Type 2 diabetes;	chr17:48892303	chr17:48899131~48899748:+
SARC	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	5	1.14e-06	0.00073	0.33	0.31	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
SARC	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	5	1.14e-06	0.00073	0.33	0.31	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
SARC	cis	rs453301	0.624	rs2979256	ENSG00000253893.2	FAM85B	-5	1.14e-06	0.000731	-0.28	-0.31	Joint mobility (Beighton score);	chr8:9014200	chr8:8167819~8226614:-
SARC	cis	rs7809950	1	rs4727681	ENSG00000238832.1	snoU109	-5	1.14e-06	0.000733	-0.36	-0.31	Coronary artery disease;	chr7:107455699	chr7:107603363~107603507:+
SARC	cis	rs17270561	0.609	rs4712964	ENSG00000272810.1	U91328.22	-5	1.14e-06	0.000733	-0.32	-0.31	Iron status biomarkers;	chr6:25740594	chr6:26013241~26013757:+
SARC	cis	rs2117029	0.965	rs1138908	ENSG00000258017.1	RP11-386G11.10	-5	1.14e-06	0.000734	-0.33	-0.31	Intelligence (multi-trait analysis);	chr12:49008516	chr12:49127782~49147869:+
SARC	cis	rs6991838	1	rs6991838	ENSG00000200714.1	Y_RNA	-5	1.14e-06	0.000734	-0.32	-0.31	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65592731~65592820:+
SARC	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-5	1.14e-06	0.000734	-0.36	-0.31	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
SARC	cis	rs11719291	0.833	rs73080361	ENSG00000225399.4	RP11-3B7.1	-5	1.14e-06	0.000735	-0.62	-0.31	Cognitive function;	chr3:48794713	chr3:49260085~49261316:+
SARC	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-5	1.14e-06	0.000735	-0.39	-0.31	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
SARC	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-5	1.14e-06	0.000735	-0.38	-0.31	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
SARC	cis	rs17270561	0.636	rs2070642	ENSG00000272810.1	U91328.22	-5	1.15e-06	0.000735	-0.3	-0.31	Iron status biomarkers;	chr6:25830984	chr6:26013241~26013757:+
SARC	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-5	1.15e-06	0.000736	-0.35	-0.31	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-5	1.15e-06	0.000736	-0.35	-0.31	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-5	1.15e-06	0.000736	-0.35	-0.31	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-5	1.15e-06	0.000736	-0.35	-0.31	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-5	1.15e-06	0.000736	-0.35	-0.31	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-5	1.15e-06	0.000736	-0.35	-0.31	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
SARC	cis	rs9309473	0.948	rs2421577	ENSG00000163016.8	ALMS1P	5	1.15e-06	0.000736	0.39	0.31	Metabolite levels;	chr2:73613871	chr2:73644919~73685576:+
SARC	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-5	1.15e-06	0.000737	-0.34	-0.31	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-5	1.15e-06	0.000737	-0.34	-0.31	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
SARC	cis	rs1930961	0.702	rs1930966	ENSG00000272977.1	CTA-390C10.10	-5	1.15e-06	0.000737	-0.59	-0.31	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25476218~25479971:+
SARC	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	5	1.15e-06	0.000739	0.49	0.31	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
SARC	cis	rs17270561	0.609	rs9358885	ENSG00000272810.1	U91328.22	-5	1.15e-06	0.00074	-0.32	-0.31	Iron status biomarkers;	chr6:25757796	chr6:26013241~26013757:+
SARC	cis	rs7430456	0.87	rs9864169	ENSG00000225790.1	RP11-2L8.1	-4.99	1.16e-06	0.000741	-0.32	-0.31	Breast cancer;	chr3:177746841	chr3:177934823~177937662:+
SARC	cis	rs7430456	0.901	rs12696448	ENSG00000225790.1	RP11-2L8.1	-4.99	1.16e-06	0.000741	-0.32	-0.31	Breast cancer;	chr3:177746860	chr3:177934823~177937662:+
SARC	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	4.99	1.16e-06	0.000741	0.38	0.31	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
SARC	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-4.99	1.16e-06	0.000745	-0.35	-0.31	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-4.99	1.16e-06	0.000745	-0.35	-0.31	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	4.99	1.16e-06	0.000745	0.36	0.31	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
SARC	cis	rs875971	0.825	rs59466412	ENSG00000237310.1	GS1-124K5.4	-4.99	1.16e-06	0.000746	-0.34	-0.31	Aortic root size;	chr7:66100371	chr7:66493706~66495474:+
SARC	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	4.99	1.17e-06	0.000747	0.38	0.31	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
SARC	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-4.99	1.17e-06	0.000748	-0.37	-0.31	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
SARC	cis	rs7246657	0.943	rs7255952	ENSG00000276846.1	CTD-3220F14.3	4.99	1.17e-06	0.000748	0.41	0.31	Coronary artery calcification;	chr19:37497895	chr19:37314868~37315620:-
SARC	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	4.99	1.17e-06	0.000749	0.35	0.31	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
SARC	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-4.99	1.17e-06	0.000749	-0.34	-0.31	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
SARC	cis	rs7567389	0.599	rs6430938	ENSG00000236682.1	AC068282.3	4.99	1.17e-06	0.000749	0.35	0.31	Self-rated health;	chr2:127405047	chr2:127389130~127400580:+
SARC	cis	rs6969780	0.673	rs2301721	ENSG00000233429.8	HOTAIRM1	-4.99	1.17e-06	0.00075	-0.41	-0.31	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27156494	chr7:27095647~27100265:+
SARC	cis	rs6969780	0.722	rs4722666	ENSG00000233429.8	HOTAIRM1	-4.99	1.17e-06	0.00075	-0.41	-0.31	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27157982	chr7:27095647~27100265:+
SARC	cis	rs1799949	0.965	rs8176323	ENSG00000267681.1	CTD-3199J23.6	-4.99	1.17e-06	0.00075	-0.35	-0.31	Menopause (age at onset);	chr17:43043694	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs8176322	ENSG00000267681.1	CTD-3199J23.6	-4.99	1.17e-06	0.00075	-0.35	-0.31	Menopause (age at onset);	chr17:43043756	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs12516	ENSG00000267681.1	CTD-3199J23.6	-4.99	1.17e-06	0.00075	-0.35	-0.31	Menopause (age at onset);	chr17:43044391	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs4793190	ENSG00000267681.1	CTD-3199J23.6	-4.99	1.17e-06	0.00075	-0.35	-0.31	Menopause (age at onset);	chr17:43048092	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs8176297	ENSG00000267681.1	CTD-3199J23.6	-4.99	1.17e-06	0.00075	-0.35	-0.31	Menopause (age at onset);	chr17:43051308	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs8176296	ENSG00000267681.1	CTD-3199J23.6	-4.99	1.17e-06	0.00075	-0.35	-0.31	Menopause (age at onset);	chr17:43051574	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs4793191	ENSG00000267681.1	CTD-3199J23.6	-4.99	1.17e-06	0.00075	-0.35	-0.31	Menopause (age at onset);	chr17:43052360	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs4793192	ENSG00000267681.1	CTD-3199J23.6	-4.99	1.17e-06	0.00075	-0.35	-0.31	Menopause (age at onset);	chr17:43052373	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs8176289	ENSG00000267681.1	CTD-3199J23.6	-4.99	1.17e-06	0.00075	-0.35	-0.31	Menopause (age at onset);	chr17:43054039	chr17:43144956~43145255:+
SARC	cis	rs6969780	0.63	rs3735530	ENSG00000233429.8	HOTAIRM1	-4.99	1.17e-06	0.00075	-0.4	-0.31	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27150363	chr7:27095647~27100265:+
SARC	cis	rs890448	0.726	rs2850329	ENSG00000254531.1	FLJ20021	4.99	1.17e-06	0.000752	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101354107	chr4:101347780~101348883:+
SARC	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-4.99	1.17e-06	0.000752	-0.31	-0.31	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
SARC	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-4.99	1.18e-06	0.000752	-0.31	-0.31	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
SARC	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-4.99	1.18e-06	0.000753	-0.43	-0.31	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
SARC	cis	rs875971	1	rs1544549	ENSG00000232559.3	GS1-124K5.12	-4.99	1.18e-06	0.000753	-0.35	-0.31	Aortic root size;	chr7:66625676	chr7:66554588~66576923:-
SARC	cis	rs875971	1	rs2420820	ENSG00000232559.3	GS1-124K5.12	-4.99	1.18e-06	0.000753	-0.35	-0.31	Aortic root size;	chr7:66626920	chr7:66554588~66576923:-
SARC	cis	rs2933343	0.953	rs2933344	ENSG00000231305.3	RP11-723O4.2	4.99	1.18e-06	0.000754	0.33	0.31	IgG glycosylation;	chr3:128939872	chr3:128861313~128871540:-
SARC	cis	rs929843	1	rs929843	ENSG00000196696.11	PDXDC2P	-4.99	1.18e-06	0.000754	-0.33	-0.31	Menarche (age at onset);	chr16:70011845	chr16:69976297~70065948:-
SARC	cis	rs12655019	0.92	rs16886497	ENSG00000271828.1	CTD-2310F14.1	4.99	1.18e-06	0.000756	0.51	0.31	Breast cancer (early onset);	chr5:56924887	chr5:56927874~56929573:+
SARC	cis	rs12655019	0.92	rs79354983	ENSG00000271828.1	CTD-2310F14.1	4.99	1.18e-06	0.000756	0.51	0.31	Breast cancer (early onset);	chr5:56925710	chr5:56927874~56929573:+
SARC	cis	rs4372836	0.964	rs4408686	ENSG00000226833.4	AC097724.3	-4.99	1.18e-06	0.000756	-0.3	-0.31	Body mass index;	chr2:28717660	chr2:28708953~28736205:-
SARC	cis	rs7246657	0.714	rs12972195	ENSG00000276846.1	CTD-3220F14.3	4.99	1.19e-06	0.000758	0.42	0.31	Coronary artery calcification;	chr19:37261603	chr19:37314868~37315620:-
SARC	cis	rs890448	0.796	rs4235418	ENSG00000254531.1	FLJ20021	4.99	1.19e-06	0.000758	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101420762	chr4:101347780~101348883:+
SARC	cis	rs7567389	0.719	rs4150476	ENSG00000236682.1	AC068282.3	4.99	1.19e-06	0.000758	0.36	0.31	Self-rated health;	chr2:127275246	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.719	rs4150471	ENSG00000236682.1	AC068282.3	4.99	1.19e-06	0.000758	0.36	0.31	Self-rated health;	chr2:127276963	chr2:127389130~127400580:+
SARC	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-4.99	1.19e-06	0.000758	-0.38	-0.31	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
SARC	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	4.99	1.19e-06	0.00076	0.38	0.31	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
SARC	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-4.99	1.19e-06	0.000761	-0.37	-0.31	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
SARC	cis	rs160451	0.966	rs183363	ENSG00000251136.7	RP11-37B2.1	4.99	1.19e-06	0.000762	0.36	0.31	Leprosy;	chr8:89665951	chr8:89609409~89757727:-
SARC	cis	rs875971	0.862	rs6460307	ENSG00000232559.3	GS1-124K5.12	4.99	1.19e-06	0.000762	0.35	0.31	Aortic root size;	chr7:66595884	chr7:66554588~66576923:-
SARC	cis	rs9890032	0.532	rs1808257	ENSG00000266490.1	CTD-2349P21.9	4.99	1.19e-06	0.000763	0.3	0.31	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30792372~30792833:+
SARC	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	4.99	1.19e-06	0.000763	0.4	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
SARC	cis	rs2274273	0.588	rs7158791	ENSG00000258413.1	RP11-665C16.6	-4.99	1.2e-06	0.000763	-0.39	-0.31	Protein biomarker;	chr14:55361889	chr14:55262767~55272075:-
SARC	cis	rs6570726	0.818	rs9399555	ENSG00000270638.1	RP3-466P17.1	4.99	1.2e-06	0.000763	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs441290	ENSG00000270638.1	RP3-466P17.1	4.99	1.2e-06	0.000763	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145735570~145737218:+
SARC	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-4.99	1.2e-06	0.000763	-0.31	-0.31	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-4.99	1.2e-06	0.000763	-0.31	-0.31	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-4.99	1.2e-06	0.000763	-0.31	-0.31	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-4.99	1.2e-06	0.000763	-0.31	-0.31	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
SARC	cis	rs7772486	0.654	rs702321	ENSG00000270638.1	RP3-466P17.1	-4.99	1.2e-06	0.000764	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145735570~145737218:+
SARC	cis	rs1865760	0.532	rs2794719	ENSG00000272462.2	U91328.19	-4.99	1.2e-06	0.000764	-0.29	-0.31	Height;	chr6:26088662	chr6:25992662~26001775:+
SARC	cis	rs7615952	0.599	rs67566088	ENSG00000250012.1	RP11-124N2.1	-4.99	1.2e-06	0.000765	-0.3	-0.31	Blood pressure (smoking interaction);	chr3:126050130	chr3:126084220~126095349:+
SARC	cis	rs9494145	0.838	rs9483788	ENSG00000232876.1	CTA-212D2.2	-4.99	1.2e-06	0.000766	-0.41	-0.31	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135114363	chr6:135055033~135060550:+
SARC	cis	rs75920871	0.588	rs3181	ENSG00000254851.1	RP11-109L13.1	4.99	1.2e-06	0.000766	0.43	0.31	Subjective well-being;	chr11:117036327	chr11:117135528~117138582:+
SARC	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-4.99	1.21e-06	0.000769	-0.31	-0.31	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-4.99	1.21e-06	0.000769	-0.31	-0.31	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
SARC	cis	rs1707322	0.691	rs61784799	ENSG00000281133.1	AL355480.3	4.99	1.21e-06	0.000769	0.36	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45580892~45580996:-
SARC	cis	rs1865760	1	rs2071299	ENSG00000272810.1	U91328.22	-4.99	1.21e-06	0.000769	-0.31	-0.31	Height;	chr6:25914573	chr6:26013241~26013757:+
SARC	cis	rs1865760	1	rs2071298	ENSG00000272810.1	U91328.22	-4.99	1.21e-06	0.000769	-0.31	-0.31	Height;	chr6:25914673	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.964	rs1324084	ENSG00000272810.1	U91328.22	-4.99	1.21e-06	0.000769	-0.31	-0.31	Height;	chr6:25914906	chr6:26013241~26013757:+
SARC	cis	rs1865760	1	rs1865760	ENSG00000272810.1	U91328.22	-4.99	1.21e-06	0.000769	-0.31	-0.31	Height;	chr6:25916751	chr6:26013241~26013757:+
SARC	cis	rs2836950	0.545	rs2836949	ENSG00000255568.3	BRWD1-AS2	-4.99	1.21e-06	0.00077	-0.29	-0.31	Menarche (age at onset);	chr21:39230530	chr21:39313935~39314962:+
SARC	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	4.99	1.21e-06	0.00077	0.35	0.31	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
SARC	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	4.99	1.21e-06	0.00077	0.4	0.31	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
SARC	cis	rs17772222	0.606	rs449338	ENSG00000258983.2	RP11-507K2.2	-4.99	1.21e-06	0.00077	-0.31	-0.31	Coronary artery calcification;	chr14:88411690	chr14:88499334~88515502:+
SARC	cis	rs838147	0.563	rs281379	ENSG00000232871.7	SEC1P	4.99	1.21e-06	0.00077	0.33	0.31	Dietary macronutrient intake;	chr19:48711017	chr19:48638071~48682245:+
SARC	cis	rs453301	0.624	rs2288673	ENSG00000253893.2	FAM85B	-4.99	1.21e-06	0.00077	-0.28	-0.31	Joint mobility (Beighton score);	chr8:9002766	chr8:8167819~8226614:-
SARC	cis	rs8081395	0.741	rs2645462	ENSG00000266992.1	DHX40P1	4.98	1.21e-06	0.000771	0.34	0.31	White blood cell count;	chr17:59906198	chr17:59976009~60002384:-
SARC	cis	rs8081395	0.711	rs1292034	ENSG00000266992.1	DHX40P1	4.98	1.21e-06	0.000771	0.34	0.31	White blood cell count;	chr17:59912499	chr17:59976009~60002384:-
SARC	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	4.98	1.21e-06	0.000771	0.34	0.31	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	4.98	1.21e-06	0.000771	0.34	0.31	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	4.98	1.21e-06	0.000771	0.34	0.31	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
SARC	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	4.98	1.21e-06	0.000771	0.34	0.31	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
SARC	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	4.98	1.21e-06	0.000771	0.34	0.31	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	4.98	1.21e-06	0.000771	0.34	0.31	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	4.98	1.21e-06	0.000771	0.34	0.31	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	4.98	1.21e-06	0.000771	0.34	0.31	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
SARC	cis	rs2562456	0.833	rs57250002	ENSG00000268081.1	RP11-678G14.2	4.98	1.21e-06	0.000771	0.51	0.31	Pain;	chr19:21344048	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62109218	ENSG00000268081.1	RP11-678G14.2	4.98	1.21e-06	0.000771	0.51	0.31	Pain;	chr19:21346059	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62109223	ENSG00000268081.1	RP11-678G14.2	4.98	1.21e-06	0.000771	0.51	0.31	Pain;	chr19:21349591	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs62109225	ENSG00000268081.1	RP11-678G14.2	4.98	1.21e-06	0.000771	0.51	0.31	Pain;	chr19:21353861	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.754	rs62109226	ENSG00000268081.1	RP11-678G14.2	4.98	1.21e-06	0.000771	0.51	0.31	Pain;	chr19:21354111	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.754	rs62109227	ENSG00000268081.1	RP11-678G14.2	4.98	1.21e-06	0.000771	0.51	0.31	Pain;	chr19:21354128	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.754	rs62109228	ENSG00000268081.1	RP11-678G14.2	4.98	1.21e-06	0.000771	0.51	0.31	Pain;	chr19:21354129	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs8102783	ENSG00000268081.1	RP11-678G14.2	4.98	1.21e-06	0.000771	0.51	0.31	Pain;	chr19:21355751	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs2061916	ENSG00000268081.1	RP11-678G14.2	4.98	1.21e-06	0.000771	0.51	0.31	Pain;	chr19:21358906	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs4359573	ENSG00000268081.1	RP11-678G14.2	4.98	1.21e-06	0.000771	0.51	0.31	Pain;	chr19:21359494	chr19:21554640~21569237:-
SARC	cis	rs801193	1	rs2659915	ENSG00000236529.1	RP13-254B10.1	4.98	1.21e-06	0.000771	0.32	0.31	Aortic root size;	chr7:66688114	chr7:65840212~65840596:+
SARC	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-4.98	1.21e-06	0.000771	-0.38	-0.31	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
SARC	cis	rs8005677	1	rs1956881	ENSG00000257285.4	RP11-298I3.1	4.98	1.21e-06	0.000772	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:22929609~22955562:+
SARC	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-4.98	1.21e-06	0.000772	-0.31	-0.31	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
SARC	cis	rs7662987	0.793	rs28730602	ENSG00000272777.1	RP11-571L19.8	4.98	1.21e-06	0.000773	0.37	0.31	Smoking initiation;	chr4:99080531	chr4:99067256~99068125:-
SARC	cis	rs4713118	0.869	rs7773070	ENSG00000219392.1	RP1-265C24.5	-4.98	1.21e-06	0.000773	-0.43	-0.31	Parkinson's disease;	chr6:27761048	chr6:28115628~28116551:+
SARC	cis	rs2933343	0.909	rs1683817	ENSG00000231305.3	RP11-723O4.2	4.98	1.22e-06	0.000774	0.34	0.31	IgG glycosylation;	chr3:128932693	chr3:128861313~128871540:-
SARC	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	4.98	1.22e-06	0.000775	0.34	0.31	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
SARC	cis	rs17772222	0.675	rs845758	ENSG00000258983.2	RP11-507K2.2	-4.98	1.22e-06	0.000775	-0.31	-0.31	Coronary artery calcification;	chr14:88433746	chr14:88499334~88515502:+
SARC	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	4.98	1.22e-06	0.000775	0.37	0.31	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
SARC	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-4.98	1.22e-06	0.000776	-0.37	-0.31	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
SARC	cis	rs9309473	1	rs10496193	ENSG00000163016.8	ALMS1P	4.98	1.22e-06	0.000778	0.4	0.31	Metabolite levels;	chr2:73546376	chr2:73644919~73685576:+
SARC	cis	rs193541	0.593	rs154517	ENSG00000263432.2	RN7SL689P	4.98	1.22e-06	0.000778	0.39	0.31	Glucose homeostasis traits;	chr5:122854130	chr5:123022487~123022783:-
SARC	cis	rs10788972	0.873	rs11206283	ENSG00000225183.1	RP4-758J24.4	4.98	1.22e-06	0.000778	0.35	0.31	Parkinson disease and lewy body pathology;	chr1:54110966	chr1:54089856~54090093:+
SARC	cis	rs17270561	0.609	rs1317817	ENSG00000272462.2	U91328.19	-4.98	1.22e-06	0.000779	-0.29	-0.31	Iron status biomarkers;	chr6:25765149	chr6:25992662~26001775:+
SARC	cis	rs1823913	0.637	rs12992372	ENSG00000227542.1	AC092614.2	4.98	1.23e-06	0.00078	0.36	0.31	Obesity-related traits;	chr2:191289251	chr2:191229165~191246172:-
SARC	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-4.98	1.23e-06	0.00078	-0.39	-0.31	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
SARC	cis	rs2933343	0.621	rs789249	ENSG00000261159.1	RP11-723O4.9	4.98	1.23e-06	0.00078	0.33	0.31	IgG glycosylation;	chr3:128859610	chr3:128859716~128860526:-
SARC	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-4.98	1.23e-06	0.00078	-0.39	-0.31	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-4.98	1.23e-06	0.00078	-0.39	-0.31	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-4.98	1.23e-06	0.00078	-0.39	-0.31	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
SARC	cis	rs7247513	0.897	rs12972944	ENSG00000213290.4	PGK1P2	-4.98	1.23e-06	0.000781	-0.37	-0.31	Bipolar disorder;	chr19:12602994	chr19:12559571~12561105:+
SARC	cis	rs1865760	0.566	rs2858993	ENSG00000272462.2	U91328.19	-4.98	1.23e-06	0.000783	-0.29	-0.31	Height;	chr6:26087628	chr6:25992662~26001775:+
SARC	cis	rs3805389	0.961	rs62308665	ENSG00000273257.1	RP11-177J6.1	-4.98	1.23e-06	0.000783	-0.43	-0.31	Waist-to-hip ratio adjusted for body mass index;	chr4:55611630	chr4:55387949~55388271:+
SARC	cis	rs17270561	0.609	rs4712970	ENSG00000272462.2	U91328.19	-4.98	1.23e-06	0.000784	-0.29	-0.31	Iron status biomarkers;	chr6:25770479	chr6:25992662~26001775:+
SARC	cis	rs597539	0.652	rs611046	ENSG00000250508.1	RP11-757G1.6	-4.98	1.23e-06	0.000784	-0.39	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68864236	chr11:68870664~68874542:+
SARC	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-4.98	1.23e-06	0.000784	-0.4	-0.31	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-4.98	1.23e-06	0.000784	-0.4	-0.31	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
SARC	cis	rs2439831	1	rs565007	ENSG00000205771.5	CATSPER2P1	-4.98	1.23e-06	0.000784	-0.47	-0.31	Lung cancer in ever smokers;	chr15:43424443	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs550239	ENSG00000205771.5	CATSPER2P1	-4.98	1.23e-06	0.000784	-0.47	-0.31	Lung cancer in ever smokers;	chr15:43427999	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs558656	ENSG00000205771.5	CATSPER2P1	-4.98	1.23e-06	0.000784	-0.47	-0.31	Lung cancer in ever smokers;	chr15:43431316	chr15:43726918~43747094:-
SARC	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	4.98	1.24e-06	0.000785	0.33	0.31	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
SARC	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	4.98	1.24e-06	0.000785	0.33	0.31	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
SARC	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	4.98	1.24e-06	0.000785	0.35	0.31	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	4.98	1.24e-06	0.000785	0.35	0.31	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	4.98	1.24e-06	0.000785	0.35	0.31	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	4.98	1.24e-06	0.000785	0.35	0.31	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
SARC	cis	rs7772486	0.686	rs1337839	ENSG00000270638.1	RP3-466P17.1	-4.98	1.24e-06	0.000786	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145735570~145737218:+
SARC	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	4.98	1.24e-06	0.000786	0.36	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
SARC	cis	rs7216064	1	rs62084240	ENSG00000278219.1	AC145343.1	-4.98	1.24e-06	0.000786	-0.4	-0.31	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67863117	chr17:68101538~68101639:+
SARC	cis	rs1823913	0.599	rs58106487	ENSG00000227542.1	AC092614.2	4.98	1.24e-06	0.000787	0.35	0.31	Obesity-related traits;	chr2:191292404	chr2:191229165~191246172:-
SARC	cis	rs7216064	0.734	rs12942774	ENSG00000278219.1	AC145343.1	4.98	1.24e-06	0.000787	0.35	0.31	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971446	chr17:68101538~68101639:+
SARC	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-4.98	1.24e-06	0.000788	-0.42	-0.31	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
SARC	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	4.98	1.24e-06	0.000788	0.31	0.31	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
SARC	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-4.98	1.24e-06	0.000789	-0.39	-0.31	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-4.98	1.24e-06	0.000789	-0.39	-0.31	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
SARC	cis	rs875971	0.638	rs6460305	ENSG00000236529.1	RP13-254B10.1	-4.98	1.25e-06	0.00079	-0.32	-0.31	Aortic root size;	chr7:66595421	chr7:65840212~65840596:+
SARC	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-4.98	1.25e-06	0.00079	-0.26	-0.31	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
SARC	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-4.98	1.25e-06	0.000791	-0.34	-0.31	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
SARC	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-4.98	1.25e-06	0.000791	-0.34	-0.31	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-4.98	1.25e-06	0.000791	-0.34	-0.31	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-4.98	1.25e-06	0.000791	-0.34	-0.31	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-4.98	1.25e-06	0.000791	-0.34	-0.31	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
SARC	cis	rs17772222	0.682	rs2401751	ENSG00000258983.2	RP11-507K2.2	-4.98	1.25e-06	0.000792	-0.32	-0.31	Coronary artery calcification;	chr14:88480278	chr14:88499334~88515502:+
SARC	cis	rs2179367	0.959	rs480034	ENSG00000231760.4	RP11-350J20.5	-4.98	1.25e-06	0.000792	-0.38	-0.31	Dupuytren's disease;	chr6:149414294	chr6:149796151~149826294:-
SARC	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-4.98	1.25e-06	0.000792	-0.31	-0.31	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
SARC	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	4.98	1.25e-06	0.000792	0.33	0.31	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
SARC	cis	rs1707322	0.721	rs10890336	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs11211151	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs12045096	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs4609469	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs12049027	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs10789467	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs10890337	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs3811435	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs9793568	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs11211157	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs11211158	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs6429575	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.685	rs6690926	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs8179402	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs8179296	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000792	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.691	rs11211174	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000793	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.682	rs10890334	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000793	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.682	rs10890335	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000793	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.716	rs6694889	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000793	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.682	rs12041197	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000793	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs11211146	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000793	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs11211147	ENSG00000281133.1	AL355480.3	-4.98	1.25e-06	0.000793	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45580892~45580996:-
SARC	cis	rs77204473	0.744	rs10892068	ENSG00000254851.1	RP11-109L13.1	-4.98	1.25e-06	0.000794	-0.63	-0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117135528~117138582:+
SARC	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-4.98	1.25e-06	0.000794	-0.34	-0.31	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
SARC	cis	rs10911902	0.643	rs111828305	ENSG00000229739.2	RP11-295K2.3	-4.98	1.25e-06	0.000795	-0.45	-0.31	Schizophrenia;	chr1:186393069	chr1:186435161~186470291:+
SARC	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000796	-0.35	-0.31	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000796	-0.35	-0.31	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000796	-0.35	-0.31	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000796	-0.35	-0.31	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000796	-0.35	-0.31	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000796	-0.35	-0.31	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
SARC	cis	rs6509701	0.922	rs8109094	ENSG00000268225.1	CTD-2331H12.5	-4.98	1.26e-06	0.000797	-0.3	-0.31	Psychosis in Alzheimer's disease;	chr19:52892050	chr19:52861807~52862866:-
SARC	cis	rs12655019	0.92	rs12514633	ENSG00000271828.1	CTD-2310F14.1	4.98	1.26e-06	0.000798	0.52	0.31	Breast cancer (early onset);	chr5:56940186	chr5:56927874~56929573:+
SARC	cis	rs12655019	0.92	rs16886525	ENSG00000271828.1	CTD-2310F14.1	4.98	1.26e-06	0.000798	0.52	0.31	Breast cancer (early onset);	chr5:56941838	chr5:56927874~56929573:+
SARC	cis	rs12655019	0.92	rs75713680	ENSG00000271828.1	CTD-2310F14.1	4.98	1.26e-06	0.000798	0.52	0.31	Breast cancer (early onset);	chr5:56942377	chr5:56927874~56929573:+
SARC	cis	rs12655019	0.92	rs76797434	ENSG00000271828.1	CTD-2310F14.1	4.98	1.26e-06	0.000798	0.52	0.31	Breast cancer (early onset);	chr5:56945862	chr5:56927874~56929573:+
SARC	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000798	-0.35	-0.31	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000798	-0.35	-0.31	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000798	-0.35	-0.31	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000798	-0.35	-0.31	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000798	-0.35	-0.31	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000798	-0.35	-0.31	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-4.98	1.26e-06	0.000798	-0.35	-0.31	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
SARC	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-4.98	1.26e-06	0.000798	-0.35	-0.31	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-4.98	1.26e-06	0.000798	-0.35	-0.31	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-4.98	1.26e-06	0.000798	-0.35	-0.31	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
SARC	cis	rs9494145	0.638	rs6934903	ENSG00000232876.1	CTA-212D2.2	4.98	1.26e-06	0.000798	0.49	0.31	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135130426	chr6:135055033~135060550:+
SARC	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	4.98	1.27e-06	0.000801	0.32	0.31	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
SARC	cis	rs7809950	1	rs2250414	ENSG00000238832.1	snoU109	-4.97	1.27e-06	0.000801	-0.36	-0.31	Coronary artery disease;	chr7:107500542	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs2712200	ENSG00000238832.1	snoU109	-4.97	1.27e-06	0.000801	-0.36	-0.31	Coronary artery disease;	chr7:107501990	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.953	rs3094383	ENSG00000238832.1	snoU109	-4.97	1.27e-06	0.000801	-0.36	-0.31	Coronary artery disease;	chr7:107502719	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.954	rs2520247	ENSG00000238832.1	snoU109	-4.97	1.27e-06	0.000801	-0.36	-0.31	Coronary artery disease;	chr7:107503501	chr7:107603363~107603507:+
SARC	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-4.97	1.27e-06	0.000802	-0.39	-0.31	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
SARC	cis	rs8031584	0.541	rs2959037	ENSG00000260382.1	RP11-540B6.2	-4.97	1.27e-06	0.000802	-0.35	-0.31	Huntington's disease progression;	chr15:30925961	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.505	rs2959036	ENSG00000260382.1	RP11-540B6.2	-4.97	1.27e-06	0.000802	-0.35	-0.31	Huntington's disease progression;	chr15:30927539	chr15:30882267~30883231:-
SARC	cis	rs8031584	0.541	rs2955777	ENSG00000260382.1	RP11-540B6.2	-4.97	1.27e-06	0.000802	-0.35	-0.31	Huntington's disease progression;	chr15:30927585	chr15:30882267~30883231:-
SARC	cis	rs7772486	0.659	rs9376957	ENSG00000270638.1	RP3-466P17.1	-4.97	1.27e-06	0.000802	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs9497396	ENSG00000270638.1	RP3-466P17.1	-4.97	1.27e-06	0.000802	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145735570~145737218:+
SARC	cis	rs1865760	0.566	rs9348706	ENSG00000272810.1	U91328.22	-4.97	1.27e-06	0.000803	-0.3	-0.31	Height;	chr6:26065253	chr6:26013241~26013757:+
SARC	cis	rs1707322	0.752	rs12062535	ENSG00000281133.1	AL355480.3	-4.97	1.27e-06	0.000803	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45580892~45580996:-
SARC	cis	rs2439831	1	rs2444029	ENSG00000205771.5	CATSPER2P1	-4.97	1.28e-06	0.000805	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43445286	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs690316	ENSG00000205771.5	CATSPER2P1	-4.97	1.28e-06	0.000805	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43445682	chr15:43726918~43747094:-
SARC	cis	rs4654783	0.505	rs4655025	ENSG00000228397.1	RP1-224A6.3	4.97	1.28e-06	0.000807	0.36	0.31	Endometriosis;	chr1:22133261	chr1:22023994~22024968:-
SARC	cis	rs10800713	0.779	rs2815289	ENSG00000260088.1	RP11-92G12.3	4.97	1.28e-06	0.000808	0.39	0.31	Tandem gait;	chr1:200610628	chr1:200669507~200694250:+
SARC	cis	rs875971	0.66	rs10272357	ENSG00000236529.1	RP13-254B10.1	-4.97	1.28e-06	0.000809	-0.32	-0.31	Aortic root size;	chr7:66598087	chr7:65840212~65840596:+
SARC	cis	rs8005677	1	rs1043209	ENSG00000257285.4	RP11-298I3.1	-4.97	1.28e-06	0.00081	-0.28	-0.31	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:22929609~22955562:+
SARC	cis	rs916888	0.821	rs199512	ENSG00000261575.2	RP11-259G18.1	-4.97	1.28e-06	0.00081	-0.43	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46267037~46268694:+
SARC	cis	rs916888	0.821	rs199509	ENSG00000261575.2	RP11-259G18.1	-4.97	1.28e-06	0.00081	-0.43	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46267037~46268694:+
SARC	cis	rs916888	0.821	rs199507	ENSG00000261575.2	RP11-259G18.1	-4.97	1.28e-06	0.00081	-0.43	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46267037~46268694:+
SARC	cis	rs916888	0.821	rs415430	ENSG00000261575.2	RP11-259G18.1	-4.97	1.28e-06	0.00081	-0.43	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46267037~46268694:+
SARC	cis	rs916888	0.779	rs430685	ENSG00000261575.2	RP11-259G18.1	-4.97	1.28e-06	0.00081	-0.43	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46267037~46268694:+
SARC	cis	rs916888	0.821	rs199505	ENSG00000261575.2	RP11-259G18.1	-4.97	1.28e-06	0.00081	-0.43	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46267037~46268694:+
SARC	cis	rs916888	0.821	rs70602	ENSG00000261575.2	RP11-259G18.1	-4.97	1.28e-06	0.00081	-0.43	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46267037~46268694:+
SARC	cis	rs1865760	0.622	rs9295685	ENSG00000272810.1	U91328.22	-4.97	1.29e-06	0.000811	-0.3	-0.31	Height;	chr6:26071497	chr6:26013241~26013757:+
SARC	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-4.97	1.29e-06	0.000812	-0.38	-0.31	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
SARC	cis	rs4862750	0.914	rs1863405	ENSG00000250971.1	RP11-696F12.1	-4.97	1.29e-06	0.000813	-0.37	-0.31	Lobe attachment (rater-scored or self-reported);	chr4:186953374	chr4:187060099~187060930:+
SARC	cis	rs5769707	0.632	rs135872	ENSG00000188511.11	C22orf34	4.97	1.29e-06	0.000813	0.4	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49414524~49657542:-
SARC	cis	rs6969780	0.722	rs985652	ENSG00000233429.8	HOTAIRM1	-4.97	1.29e-06	0.000813	-0.4	-0.31	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27158464	chr7:27095647~27100265:+
SARC	cis	rs17270561	0.636	rs9393656	ENSG00000272810.1	U91328.22	-4.97	1.29e-06	0.000813	-0.31	-0.31	Iron status biomarkers;	chr6:25721831	chr6:26013241~26013757:+
SARC	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	4.97	1.29e-06	0.000814	0.33	0.31	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
SARC	cis	rs17270561	0.609	rs1408271	ENSG00000272810.1	U91328.22	-4.97	1.29e-06	0.000815	-0.3	-0.31	Iron status biomarkers;	chr6:25859393	chr6:26013241~26013757:+
SARC	cis	rs113835537	0.735	rs519380	ENSG00000255517.5	CTD-3074O7.5	-4.97	1.29e-06	0.000816	-0.36	-0.31	Airway imaging phenotypes;	chr11:66641938	chr11:66473490~66480233:-
SARC	cis	rs2117029	1	rs10783299	ENSG00000258017.1	RP11-386G11.10	-4.97	1.29e-06	0.000816	-0.33	-0.31	Intelligence (multi-trait analysis);	chr12:48996894	chr12:49127782~49147869:+
SARC	cis	rs4862750	0.872	rs6821507	ENSG00000249742.1	RP11-217E13.1	4.97	1.29e-06	0.000816	0.33	0.31	Lobe attachment (rater-scored or self-reported);	chr4:186955675	chr4:186979490~187021973:-
SARC	cis	rs763121	0.925	rs5757251	ENSG00000273076.1	RP3-508I15.22	4.97	1.3e-06	0.000818	0.33	0.31	Menopause (age at onset);	chr22:38704123	chr22:38743495~38743910:+
SARC	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	4.97	1.3e-06	0.000818	0.35	0.31	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	4.97	1.3e-06	0.000818	0.35	0.31	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
SARC	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	4.97	1.3e-06	0.000818	0.28	0.31	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
SARC	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-4.97	1.3e-06	0.000819	-0.31	-0.31	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
SARC	cis	rs2439831	1	rs2584726	ENSG00000205771.5	CATSPER2P1	-4.97	1.3e-06	0.000819	-0.47	-0.31	Lung cancer in ever smokers;	chr15:43423184	chr15:43726918~43747094:-
SARC	cis	rs890448	0.693	rs2433309	ENSG00000254531.1	FLJ20021	4.97	1.3e-06	0.00082	0.33	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101436381	chr4:101347780~101348883:+
SARC	cis	rs79349575	0.594	rs1985785	ENSG00000270781.1	RP11-501C14.9	-4.97	1.3e-06	0.00082	-0.36	-0.31	Type 2 diabetes;	chr17:48890426	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.685	rs1124829	ENSG00000270781.1	RP11-501C14.9	-4.97	1.3e-06	0.00082	-0.36	-0.31	Type 2 diabetes;	chr17:48890435	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.721	rs1008834	ENSG00000270781.1	RP11-501C14.9	-4.97	1.3e-06	0.00082	-0.36	-0.31	Type 2 diabetes;	chr17:48890646	chr17:48899131~48899748:+
SARC	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-4.97	1.3e-06	0.00082	-0.3	-0.31	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-4.97	1.3e-06	0.00082	-0.3	-0.31	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-4.97	1.3e-06	0.00082	-0.3	-0.31	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
SARC	cis	rs2564921	0.693	rs2336721	ENSG00000242142.1	SERBP1P3	-4.97	1.3e-06	0.000821	-0.3	-0.31	Height;	chr3:52994359	chr3:53064283~53065091:-
SARC	cis	rs6964833	0.554	rs112506907	ENSG00000123965.13	PMS2P5	4.97	1.3e-06	0.000821	0.44	0.31	Menarche (age at onset);	chr7:74654407	chr7:74894116~74897835:+
SARC	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	4.97	1.3e-06	0.000821	0.25	0.31	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
SARC	cis	rs853679	0.723	rs9366718	ENSG00000219392.1	RP1-265C24.5	-4.97	1.31e-06	0.000823	-0.5	-0.31	Depression;	chr6:28237724	chr6:28115628~28116551:+
SARC	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-4.97	1.31e-06	0.000823	-0.31	-0.31	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
SARC	cis	rs7772486	0.686	rs9403746	ENSG00000270638.1	RP3-466P17.1	-4.97	1.31e-06	0.000824	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145735570~145737218:+
SARC	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	4.97	1.31e-06	0.000824	0.36	0.31	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
SARC	cis	rs1075265	0.933	rs918357	ENSG00000233266.1	HMGB1P31	4.97	1.31e-06	0.000824	0.4	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54108826	chr2:54051334~54051760:+
SARC	cis	rs1134634	0.52	rs28522268	ENSG00000273133.1	RP11-799M12.2	-4.97	1.31e-06	0.000825	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601844	chr4:15563698~15564253:-
SARC	cis	rs2274273	0.84	rs6573013	ENSG00000258413.1	RP11-665C16.6	-4.97	1.31e-06	0.000825	-0.36	-0.31	Protein biomarker;	chr14:55269155	chr14:55262767~55272075:-
SARC	cis	rs7772486	0.754	rs702323	ENSG00000270638.1	RP3-466P17.1	-4.97	1.31e-06	0.000826	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145735570~145737218:+
SARC	cis	rs6452524	0.618	rs10462394	ENSG00000248112.1	RP11-78C3.1	4.97	1.31e-06	0.000826	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:82919376~82921119:-
SARC	cis	rs62103177	0.535	rs62101568	ENSG00000261126.6	RP11-795F19.1	4.97	1.31e-06	0.000827	0.32	0.31	Opioid sensitivity;	chr18:80176788	chr18:80046900~80095482:+
SARC	cis	rs2439831	1	rs2245790	ENSG00000205771.5	CATSPER2P1	-4.97	1.31e-06	0.000827	-0.47	-0.31	Lung cancer in ever smokers;	chr15:43452259	chr15:43726918~43747094:-
SARC	cis	rs755249	0.565	rs7539279	ENSG00000182109.6	RP11-69E11.4	-4.97	1.32e-06	0.000828	-0.3	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39522280~39546187:-
SARC	cis	rs10911902	0.643	rs76991105	ENSG00000229739.2	RP11-295K2.3	-4.97	1.32e-06	0.000829	-0.45	-0.31	Schizophrenia;	chr1:186376920	chr1:186435161~186470291:+
SARC	cis	rs1134634	0.52	rs28419165	ENSG00000273133.1	RP11-799M12.2	-4.97	1.32e-06	0.000829	-0.41	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15587722	chr4:15563698~15564253:-
SARC	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-4.97	1.32e-06	0.000829	-0.33	-0.31	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
SARC	cis	rs2933343	0.621	rs789242	ENSG00000261159.1	RP11-723O4.9	4.97	1.32e-06	0.000829	0.33	0.31	IgG glycosylation;	chr3:128866864	chr3:128859716~128860526:-
SARC	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	4.97	1.32e-06	0.00083	0.33	0.31	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
SARC	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	4.97	1.32e-06	0.00083	0.33	0.31	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	4.97	1.32e-06	0.00083	0.33	0.31	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
SARC	cis	rs7587476	0.906	rs17487827	ENSG00000229267.2	AC072062.1	-4.97	1.32e-06	0.00083	-0.32	-0.31	Neuroblastoma;	chr2:214779611	chr2:214810229~214963274:+
SARC	cis	rs10483853	0.525	rs2302041	ENSG00000258695.2	RP3-414A15.2	-4.97	1.32e-06	0.00083	-0.4	-0.31	Coronary artery calcification;	chr14:73494166	chr14:73522878~73530610:+
SARC	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	4.97	1.32e-06	0.000831	0.28	0.31	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
SARC	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	4.97	1.32e-06	0.000832	0.31	0.31	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
SARC	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-4.97	1.32e-06	0.000832	-0.31	-0.31	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
SARC	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-4.97	1.32e-06	0.000832	-0.31	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
SARC	cis	rs12554020	0.892	rs12551084	ENSG00000227603.1	RP11-165J3.6	4.97	1.33e-06	0.000833	0.53	0.31	Schizophrenia;	chr9:93538013	chr9:93435332~93437121:-
SARC	cis	rs12554020	1	rs35540150	ENSG00000227603.1	RP11-165J3.6	4.97	1.33e-06	0.000833	0.53	0.31	Schizophrenia;	chr9:93538572	chr9:93435332~93437121:-
SARC	cis	rs2562456	0.833	rs11671609	ENSG00000268081.1	RP11-678G14.2	4.97	1.33e-06	0.000833	0.51	0.31	Pain;	chr19:21342769	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.793	rs62109212	ENSG00000268081.1	RP11-678G14.2	4.97	1.33e-06	0.000833	0.51	0.31	Pain;	chr19:21343716	chr19:21554640~21569237:-
SARC	cis	rs763121	0.925	rs1043312	ENSG00000273076.1	RP3-508I15.22	4.97	1.33e-06	0.000833	0.32	0.31	Menopause (age at onset);	chr22:38735722	chr22:38743495~38743910:+
SARC	cis	rs708547	0.581	rs781661	ENSG00000269949.1	RP11-738E22.3	-4.97	1.33e-06	0.000834	-0.39	-0.31	Response to bleomycin (chromatid breaks);	chr4:56914141	chr4:56960927~56961373:-
SARC	cis	rs6452524	0.618	rs6452502	ENSG00000248112.1	RP11-78C3.1	4.96	1.33e-06	0.000835	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:82919376~82921119:-
SARC	cis	rs6452524	0.618	rs6452503	ENSG00000248112.1	RP11-78C3.1	4.96	1.33e-06	0.000835	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:82919376~82921119:-
SARC	cis	rs6452524	0.618	rs6452504	ENSG00000248112.1	RP11-78C3.1	4.96	1.33e-06	0.000835	0.34	0.31	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:82919376~82921119:-
SARC	cis	rs79349575	0.87	rs12941262	ENSG00000270781.1	RP11-501C14.9	-4.96	1.33e-06	0.000835	-0.36	-0.31	Type 2 diabetes;	chr17:48889675	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.778	rs12950328	ENSG00000270781.1	RP11-501C14.9	-4.96	1.33e-06	0.000835	-0.36	-0.31	Type 2 diabetes;	chr17:48889699	chr17:48899131~48899748:+
SARC	cis	rs1865760	1	rs9467636	ENSG00000272810.1	U91328.22	-4.96	1.33e-06	0.000836	-0.31	-0.31	Height;	chr6:25919321	chr6:26013241~26013757:+
SARC	cis	rs1865760	1	rs9358893	ENSG00000272810.1	U91328.22	-4.96	1.33e-06	0.000836	-0.31	-0.31	Height;	chr6:25921533	chr6:26013241~26013757:+
SARC	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-4.96	1.33e-06	0.000836	-0.35	-0.31	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
SARC	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-4.96	1.33e-06	0.000837	-0.4	-0.31	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
SARC	cis	rs3805389	1	rs10026676	ENSG00000273257.1	RP11-177J6.1	-4.96	1.33e-06	0.000838	-0.43	-0.31	Waist-to-hip ratio adjusted for body mass index;	chr4:55612585	chr4:55387949~55388271:+
SARC	cis	rs3805389	0.924	rs10029142	ENSG00000273257.1	RP11-177J6.1	-4.96	1.33e-06	0.000838	-0.43	-0.31	Waist-to-hip ratio adjusted for body mass index;	chr4:55612967	chr4:55387949~55388271:+
SARC	cis	rs3805389	1	rs28564902	ENSG00000273257.1	RP11-177J6.1	-4.96	1.33e-06	0.000838	-0.43	-0.31	Waist-to-hip ratio adjusted for body mass index;	chr4:55613324	chr4:55387949~55388271:+
SARC	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-4.96	1.34e-06	0.000838	-0.31	-0.31	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
SARC	cis	rs1823913	0.599	rs34840299	ENSG00000227542.1	AC092614.2	4.96	1.34e-06	0.000839	0.34	0.31	Obesity-related traits;	chr2:191280379	chr2:191229165~191246172:-
SARC	cis	rs7615952	0.611	rs9681518	ENSG00000248787.1	RP11-666A20.4	-4.96	1.34e-06	0.00084	-0.53	-0.31	Blood pressure (smoking interaction);	chr3:125896287	chr3:125908005~125910272:-
SARC	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-4.96	1.34e-06	0.00084	-0.29	-0.31	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
SARC	cis	rs755249	0.509	rs710913	ENSG00000182109.6	RP11-69E11.4	-4.96	1.34e-06	0.000842	-0.3	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39522280~39546187:-
SARC	cis	rs2933343	0.7	rs789233	ENSG00000261159.1	RP11-723O4.9	4.96	1.34e-06	0.000843	0.33	0.31	IgG glycosylation;	chr3:128884307	chr3:128859716~128860526:-
SARC	cis	rs11634944	0.738	rs34091931	ENSG00000274307.1	RP11-345J18.2	-4.96	1.34e-06	0.000843	-0.4	-0.31	Interleukin-8 levels;	chr15:25006466	chr15:25708470~25710869:-
SARC	cis	rs1707322	0.752	rs28507722	ENSG00000281133.1	AL355480.3	-4.96	1.35e-06	0.000844	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs28568986	ENSG00000281133.1	AL355480.3	-4.96	1.35e-06	0.000844	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.717	rs28396194	ENSG00000281133.1	AL355480.3	-4.96	1.35e-06	0.000844	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.717	rs28752166	ENSG00000281133.1	AL355480.3	-4.96	1.35e-06	0.000844	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.717	rs10890345	ENSG00000281133.1	AL355480.3	-4.96	1.35e-06	0.000844	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs10789471	ENSG00000281133.1	AL355480.3	-4.96	1.35e-06	0.000844	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs11211173	ENSG00000281133.1	AL355480.3	-4.96	1.35e-06	0.000844	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45580892~45580996:-
SARC	cis	rs9818758	0.607	rs67060340	ENSG00000225399.4	RP11-3B7.1	-4.96	1.35e-06	0.000844	-0.57	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48877888	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.556	rs116432667	ENSG00000225399.4	RP11-3B7.1	-4.96	1.35e-06	0.000844	-0.57	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48910156	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs13087930	ENSG00000225399.4	RP11-3B7.1	-4.96	1.35e-06	0.000844	-0.57	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48924293	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.545	rs11717978	ENSG00000225399.4	RP11-3B7.1	-4.96	1.35e-06	0.000844	-0.57	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48931603	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.556	rs13086240	ENSG00000225399.4	RP11-3B7.1	-4.96	1.35e-06	0.000844	-0.57	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48963976	chr3:49260085~49261316:+
SARC	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	4.96	1.35e-06	0.000844	0.3	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
SARC	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	4.96	1.35e-06	0.000845	0.32	0.31	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
SARC	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-4.96	1.35e-06	0.000845	-0.37	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
SARC	cis	rs7809950	1	rs7782057	ENSG00000238832.1	snoU109	-4.96	1.35e-06	0.000845	-0.35	-0.31	Coronary artery disease;	chr7:107458432	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs67982599	ENSG00000238832.1	snoU109	-4.96	1.35e-06	0.000845	-0.35	-0.31	Coronary artery disease;	chr7:107459659	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs987391	ENSG00000238832.1	snoU109	-4.96	1.35e-06	0.000845	-0.35	-0.31	Coronary artery disease;	chr7:107460349	chr7:107603363~107603507:+
SARC	cis	rs4713118	0.869	rs6901520	ENSG00000219392.1	RP1-265C24.5	-4.96	1.35e-06	0.000845	-0.43	-0.31	Parkinson's disease;	chr6:27746796	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.869	rs9295743	ENSG00000219392.1	RP1-265C24.5	-4.96	1.35e-06	0.000845	-0.43	-0.31	Parkinson's disease;	chr6:27747323	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.869	rs9283880	ENSG00000219392.1	RP1-265C24.5	-4.96	1.35e-06	0.000845	-0.43	-0.31	Parkinson's disease;	chr6:27747464	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.869	rs9283881	ENSG00000219392.1	RP1-265C24.5	-4.96	1.35e-06	0.000845	-0.43	-0.31	Parkinson's disease;	chr6:27747476	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.869	rs9283882	ENSG00000219392.1	RP1-265C24.5	-4.96	1.35e-06	0.000845	-0.43	-0.31	Parkinson's disease;	chr6:27747479	chr6:28115628~28116551:+
SARC	cis	rs910316	0.935	rs2268620	ENSG00000279594.1	RP11-950C14.10	-4.96	1.35e-06	0.000846	-0.34	-0.31	Height;	chr14:75173700	chr14:75011269~75012851:-
SARC	cis	rs13631	0.928	rs9411308	ENSG00000268996.3	MAN1B1-AS1	4.96	1.35e-06	0.000846	0.31	0.31	Cerebrospinal fluid biomarker levels;	chr9:137105663	chr9:137084946~137086817:-
SARC	cis	rs14027	0.883	rs35449013	ENSG00000279347.1	RP11-85I17.2	-4.96	1.35e-06	0.000847	-0.27	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729239	chr8:119838736~119840385:-
SARC	cis	rs14027	0.705	rs13265683	ENSG00000279347.1	RP11-85I17.2	-4.96	1.35e-06	0.000847	-0.27	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729926	chr8:119838736~119840385:-
SARC	cis	rs2274273	0.624	rs7152390	ENSG00000258413.1	RP11-665C16.6	-4.96	1.36e-06	0.000849	-0.39	-0.31	Protein biomarker;	chr14:55344983	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.588	rs9919923	ENSG00000258413.1	RP11-665C16.6	-4.96	1.36e-06	0.000849	-0.39	-0.31	Protein biomarker;	chr14:55347181	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.588	rs9919932	ENSG00000258413.1	RP11-665C16.6	-4.96	1.36e-06	0.000849	-0.39	-0.31	Protein biomarker;	chr14:55347362	chr14:55262767~55272075:-
SARC	cis	rs2803122	0.774	rs10757034	ENSG00000273226.1	RP11-513M16.8	-4.96	1.36e-06	0.000852	-0.3	-0.31	Pulse pressure;	chr9:19227805	chr9:19375451~19375996:+
SARC	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-4.96	1.36e-06	0.000853	-0.35	-0.31	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
SARC	cis	rs2288884	0.559	rs9636139	ENSG00000275055.1	CTC-471J1.11	-4.96	1.36e-06	0.000853	-0.34	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018043	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.559	rs12610953	ENSG00000275055.1	CTC-471J1.11	-4.96	1.36e-06	0.000853	-0.34	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018675	chr19:52049007~52049754:+
SARC	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	4.96	1.36e-06	0.000853	0.47	0.31	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
SARC	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	4.96	1.36e-06	0.000854	0.37	0.31	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
SARC	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	4.96	1.37e-06	0.000855	0.34	0.31	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
SARC	cis	rs2179367	0.959	rs579789	ENSG00000231760.4	RP11-350J20.5	4.96	1.37e-06	0.000856	0.37	0.31	Dupuytren's disease;	chr6:149358235	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.959	rs489551	ENSG00000231760.4	RP11-350J20.5	4.96	1.37e-06	0.000856	0.37	0.31	Dupuytren's disease;	chr6:149368321	chr6:149796151~149826294:-
SARC	cis	rs7712401	0.601	rs246268	ENSG00000263432.2	RN7SL689P	4.96	1.37e-06	0.000857	0.38	0.31	Mean platelet volume;	chr5:122920647	chr5:123022487~123022783:-
SARC	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-4.96	1.37e-06	0.000857	-0.32	-0.31	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
SARC	cis	rs10754283	0.871	rs72712569	ENSG00000231613.1	RP5-943J3.1	-4.96	1.37e-06	0.000859	-0.31	-0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89660098	chr1:89788914~89790492:+
SARC	cis	rs4372836	1	rs4666119	ENSG00000226833.4	AC097724.3	4.96	1.37e-06	0.000859	0.29	0.31	Body mass index;	chr2:28752824	chr2:28708953~28736205:-
SARC	cis	rs890448	0.796	rs293212	ENSG00000254531.1	FLJ20021	4.96	1.37e-06	0.000859	0.32	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395077	chr4:101347780~101348883:+
SARC	cis	rs2179367	0.959	rs9322178	ENSG00000231760.4	RP11-350J20.5	4.96	1.37e-06	0.000859	0.38	0.31	Dupuytren's disease;	chr6:149372131	chr6:149796151~149826294:-
SARC	cis	rs890448	0.796	rs10433984	ENSG00000254531.1	FLJ20021	4.96	1.37e-06	0.000859	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101419152	chr4:101347780~101348883:+
SARC	cis	rs8031584	1	rs35607976	ENSG00000260382.1	RP11-540B6.2	4.96	1.37e-06	0.000859	0.4	0.31	Huntington's disease progression;	chr15:30985585	chr15:30882267~30883231:-
SARC	cis	rs9818758	0.607	rs56004653	ENSG00000225399.4	RP11-3B7.1	-4.96	1.38e-06	0.000861	-0.62	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49034795	chr3:49260085~49261316:+
SARC	cis	rs4794202	0.717	rs6503897	ENSG00000264920.1	RP11-6N17.4	4.96	1.38e-06	0.000862	0.4	0.31	Alzheimer's disease (cognitive decline);	chr17:47879683	chr17:47891255~47895812:-
SARC	cis	rs7712401	0.623	rs30043	ENSG00000263432.2	RN7SL689P	4.96	1.38e-06	0.000863	0.38	0.31	Mean platelet volume;	chr5:122936598	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs185009	ENSG00000263432.2	RN7SL689P	4.96	1.38e-06	0.000863	0.38	0.31	Mean platelet volume;	chr5:122938072	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.541	rs42537	ENSG00000263432.2	RN7SL689P	4.96	1.38e-06	0.000863	0.38	0.31	Mean platelet volume;	chr5:122938993	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.58	rs185008	ENSG00000263432.2	RN7SL689P	4.96	1.38e-06	0.000863	0.38	0.31	Mean platelet volume;	chr5:122939039	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.58	rs30041	ENSG00000263432.2	RN7SL689P	4.96	1.38e-06	0.000863	0.38	0.31	Mean platelet volume;	chr5:122939658	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.58	rs42536	ENSG00000263432.2	RN7SL689P	4.96	1.38e-06	0.000863	0.38	0.31	Mean platelet volume;	chr5:122940728	chr5:123022487~123022783:-
SARC	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-4.96	1.38e-06	0.000864	-0.51	-0.31	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
SARC	cis	rs7216064	1	rs8071463	ENSG00000265055.1	AC145343.2	-4.96	1.38e-06	0.000865	-0.38	-0.31	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67942539	chr17:68096046~68101474:-
SARC	cis	rs4713118	0.621	rs10484403	ENSG00000272009.1	RP1-313I6.12	-4.96	1.38e-06	0.000865	-0.37	-0.31	Parkinson's disease;	chr6:28065745	chr6:28078792~28081130:-
SARC	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-4.96	1.39e-06	0.000866	-0.3	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
SARC	cis	rs7567389	0.677	rs61422716	ENSG00000236682.1	AC068282.3	-4.96	1.39e-06	0.000866	-0.36	-0.31	Self-rated health;	chr2:127330075	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.677	rs10496661	ENSG00000236682.1	AC068282.3	-4.96	1.39e-06	0.000866	-0.36	-0.31	Self-rated health;	chr2:127332568	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.677	rs11680877	ENSG00000236682.1	AC068282.3	-4.96	1.39e-06	0.000866	-0.36	-0.31	Self-rated health;	chr2:127332874	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.677	rs72846002	ENSG00000236682.1	AC068282.3	-4.96	1.39e-06	0.000866	-0.36	-0.31	Self-rated health;	chr2:127360571	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.677	rs72848604	ENSG00000236682.1	AC068282.3	-4.96	1.39e-06	0.000866	-0.36	-0.31	Self-rated health;	chr2:127362542	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-4.96	1.39e-06	0.000866	-0.36	-0.31	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.71	rs72848615	ENSG00000236682.1	AC068282.3	-4.96	1.39e-06	0.000866	-0.36	-0.31	Self-rated health;	chr2:127376022	chr2:127389130~127400580:+
SARC	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-4.96	1.39e-06	0.000866	-0.34	-0.31	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
SARC	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-4.96	1.39e-06	0.000867	-0.35	-0.31	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
SARC	cis	rs5769707	0.656	rs135878	ENSG00000188511.11	C22orf34	4.96	1.39e-06	0.000867	0.4	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49414524~49657542:-
SARC	cis	rs2179367	0.509	rs9485390	ENSG00000231760.4	RP11-350J20.5	4.96	1.39e-06	0.000868	0.41	0.31	Dupuytren's disease;	chr6:149421004	chr6:149796151~149826294:-
SARC	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-4.96	1.39e-06	0.000868	-0.3	-0.31	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
SARC	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	4.96	1.39e-06	0.000868	0.29	0.31	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	4.96	1.39e-06	0.000868	0.29	0.31	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
SARC	cis	rs13129231	0.847	rs12499647	ENSG00000206820.1	RNU1-138P	-4.95	1.39e-06	0.00087	-0.3	-0.31	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113447561	chr4:113420323~113420486:+
SARC	cis	rs6570726	0.846	rs6919684	ENSG00000270638.1	RP3-466P17.1	4.95	1.4e-06	0.000871	0.24	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145735570~145737218:+
SARC	cis	rs1865760	0.602	rs9467662	ENSG00000272810.1	U91328.22	-4.95	1.4e-06	0.000871	-0.3	-0.31	Height;	chr6:26021099	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs9358902	ENSG00000272810.1	U91328.22	-4.95	1.4e-06	0.000871	-0.3	-0.31	Height;	chr6:26058342	chr6:26013241~26013757:+
SARC	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-4.95	1.4e-06	0.000872	-0.35	-0.31	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-4.95	1.4e-06	0.000872	-0.35	-0.31	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
SARC	cis	rs1865760	1	rs2071301	ENSG00000272810.1	U91328.22	-4.95	1.4e-06	0.000872	-0.31	-0.31	Height;	chr6:25914035	chr6:26013241~26013757:+
SARC	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	4.95	1.4e-06	0.000872	0.29	0.31	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
SARC	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-4.95	1.4e-06	0.000872	-0.51	-0.31	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
SARC	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-4.95	1.4e-06	0.000873	-0.55	-0.31	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
SARC	cis	rs3805389	0.961	rs9996936	ENSG00000273257.1	RP11-177J6.1	-4.95	1.4e-06	0.000873	-0.42	-0.31	Waist-to-hip ratio adjusted for body mass index;	chr4:55601472	chr4:55387949~55388271:+
SARC	cis	rs7512898	0.9	rs6427851	ENSG00000260088.1	RP11-92G12.3	-4.95	1.4e-06	0.000874	-0.31	-0.31	Electrocardiographic conduction measures;	chr1:200704177	chr1:200669507~200694250:+
SARC	cis	rs1707322	0.717	rs3014237	ENSG00000281133.1	AL355480.3	4.95	1.41e-06	0.000876	0.36	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45580892~45580996:-
SARC	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-4.95	1.41e-06	0.000876	-0.29	-0.31	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
SARC	cis	rs875971	0.66	rs3764903	ENSG00000236529.1	RP13-254B10.1	-4.95	1.41e-06	0.000877	-0.32	-0.31	Aortic root size;	chr7:66633495	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs1860470	ENSG00000236529.1	RP13-254B10.1	-4.95	1.41e-06	0.000877	-0.32	-0.31	Aortic root size;	chr7:66638707	chr7:65840212~65840596:+
SARC	cis	rs2412819	0.571	rs28410121	ENSG00000205771.5	CATSPER2P1	4.95	1.41e-06	0.000878	0.44	0.31	Lung cancer;	chr15:43777831	chr15:43726918~43747094:-
SARC	cis	rs1707322	0.721	rs28501477	ENSG00000281133.1	AL355480.3	-4.95	1.41e-06	0.000878	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45580892~45580996:-
SARC	cis	rs27434	0.605	rs39840	ENSG00000272109.1	CTD-2260A17.3	-4.95	1.41e-06	0.000879	-0.45	-0.31	Ankylosing spondylitis;	chr5:96784350	chr5:96804353~96806105:+
SARC	cis	rs7772486	0.754	rs864148	ENSG00000270638.1	RP3-466P17.1	-4.95	1.41e-06	0.000879	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145735570~145737218:+
SARC	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-4.95	1.41e-06	0.00088	-0.39	-0.31	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
SARC	cis	rs7615952	0.599	rs12486459	ENSG00000250012.1	RP11-124N2.1	-4.95	1.41e-06	0.00088	-0.3	-0.31	Blood pressure (smoking interaction);	chr3:126022622	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.599	rs67575510	ENSG00000250012.1	RP11-124N2.1	-4.95	1.41e-06	0.00088	-0.3	-0.31	Blood pressure (smoking interaction);	chr3:126023512	chr3:126084220~126095349:+
SARC	cis	rs77204473	1	rs35184536	ENSG00000254851.1	RP11-109L13.1	4.95	1.41e-06	0.000881	0.69	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117135528~117138582:+
SARC	cis	rs12554020	0.892	rs16909273	ENSG00000227603.1	RP11-165J3.6	4.95	1.41e-06	0.000881	0.53	0.31	Schizophrenia;	chr9:93532820	chr9:93435332~93437121:-
SARC	cis	rs4862750	0.914	rs1346126	ENSG00000250971.1	RP11-696F12.1	4.95	1.41e-06	0.000881	0.38	0.31	Lobe attachment (rater-scored or self-reported);	chr4:186955250	chr4:187060099~187060930:+
SARC	cis	rs1865760	0.566	rs9467663	ENSG00000272810.1	U91328.22	-4.95	1.42e-06	0.000881	-0.3	-0.31	Height;	chr6:26021228	chr6:26013241~26013757:+
SARC	cis	rs755249	0.565	rs4660846	ENSG00000182109.6	RP11-69E11.4	-4.95	1.42e-06	0.000882	-0.3	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39522280~39546187:-
SARC	cis	rs7246657	0.943	rs4801803	ENSG00000276846.1	CTD-3220F14.3	-4.95	1.42e-06	0.000883	-0.41	-0.31	Coronary artery calcification;	chr19:37476021	chr19:37314868~37315620:-
SARC	cis	rs7250849	0.736	rs12459542	ENSG00000273837.1	LLNLR-470E3.1	-4.95	1.42e-06	0.000883	-0.34	-0.31	Blood protein levels;	chr19:51660025	chr19:51639478~51639931:-
SARC	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	4.95	1.42e-06	0.000884	0.31	0.31	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
SARC	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-4.95	1.42e-06	0.000886	-0.34	-0.31	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
SARC	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	4.95	1.43e-06	0.000887	0.36	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
SARC	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-4.95	1.43e-06	0.000887	-0.3	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
SARC	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.43e-06	0.000888	-0.35	-0.31	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.43e-06	0.000888	-0.35	-0.31	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.43e-06	0.000888	-0.35	-0.31	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.43e-06	0.000888	-0.35	-0.31	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.43e-06	0.000888	-0.35	-0.31	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.43e-06	0.000888	-0.35	-0.31	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.43e-06	0.000888	-0.35	-0.31	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.43e-06	0.000888	-0.35	-0.31	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.43e-06	0.000888	-0.35	-0.31	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
SARC	cis	rs899997	0.906	rs62010552	ENSG00000261143.1	ADAMTS7P3	-4.95	1.43e-06	0.000889	-0.46	-0.31	Coronary artery disease or large artery stroke;	chr15:78695344	chr15:77976042~77993057:+
SARC	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	4.95	1.43e-06	0.00089	0.43	0.31	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
SARC	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-4.95	1.43e-06	0.00089	-0.39	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
SARC	cis	rs394563	0.663	rs415434	ENSG00000231760.4	RP11-350J20.5	4.95	1.43e-06	0.00089	0.4	0.31	Dupuytren's disease;	chr6:149451509	chr6:149796151~149826294:-
SARC	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	4.95	1.43e-06	0.00089	0.28	0.31	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
SARC	cis	rs160451	1	rs160449	ENSG00000251136.7	RP11-37B2.1	4.95	1.43e-06	0.000891	0.34	0.31	Leprosy;	chr8:89648287	chr8:89609409~89757727:-
SARC	cis	rs2404602	0.709	rs11072591	ENSG00000259422.1	RP11-593F23.1	4.95	1.43e-06	0.000891	0.37	0.31	Blood metabolite levels;	chr15:76357221	chr15:76174891~76181486:-
SARC	cis	rs7615952	0.576	rs1127717	ENSG00000250012.1	RP11-124N2.1	-4.95	1.44e-06	0.000892	-0.3	-0.31	Blood pressure (smoking interaction);	chr3:126107216	chr3:126084220~126095349:+
SARC	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-4.95	1.44e-06	0.000892	-0.37	-0.31	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
SARC	cis	rs7712401	0.546	rs10044921	ENSG00000263432.2	RN7SL689P	4.95	1.44e-06	0.000892	0.39	0.31	Mean platelet volume;	chr5:122843662	chr5:123022487~123022783:-
SARC	cis	rs1865760	0.508	rs9379820	ENSG00000272462.2	U91328.19	-4.95	1.44e-06	0.000896	-0.28	-0.31	Height;	chr6:26049696	chr6:25992662~26001775:+
SARC	cis	rs6762	0.748	rs5030780	ENSG00000279672.1	CMB9-55F22.1	4.95	1.44e-06	0.000896	0.27	0.31	Mean platelet volume;	chr11:838110	chr11:779617~780755:+
SARC	cis	rs17270561	0.609	rs9358887	ENSG00000272462.2	U91328.19	-4.95	1.44e-06	0.000897	-0.29	-0.31	Iron status biomarkers;	chr6:25759178	chr6:25992662~26001775:+
SARC	cis	rs875971	0.965	rs697968	ENSG00000237310.1	GS1-124K5.4	-4.95	1.45e-06	0.000898	-0.32	-0.31	Aortic root size;	chr7:66070046	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs1183245	ENSG00000237310.1	GS1-124K5.4	-4.95	1.45e-06	0.000898	-0.32	-0.31	Aortic root size;	chr7:66076198	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs1144895	ENSG00000237310.1	GS1-124K5.4	-4.95	1.45e-06	0.000898	-0.32	-0.31	Aortic root size;	chr7:66076320	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs1144894	ENSG00000237310.1	GS1-124K5.4	-4.95	1.45e-06	0.000898	-0.32	-0.31	Aortic root size;	chr7:66077907	chr7:66493706~66495474:+
SARC	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	4.95	1.45e-06	0.000898	0.29	0.31	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	4.95	1.45e-06	0.000898	0.29	0.31	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	4.95	1.45e-06	0.000898	0.29	0.31	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	4.95	1.45e-06	0.000898	0.29	0.31	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	4.95	1.45e-06	0.000898	0.29	0.31	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	4.95	1.45e-06	0.000898	0.29	0.31	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	4.95	1.45e-06	0.000898	0.29	0.31	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	4.95	1.45e-06	0.000898	0.29	0.31	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	4.95	1.45e-06	0.000898	0.29	0.31	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	4.95	1.45e-06	0.000898	0.29	0.31	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	4.95	1.45e-06	0.000898	0.29	0.31	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
SARC	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-4.95	1.45e-06	0.000898	-0.4	-0.31	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-4.95	1.45e-06	0.000899	-0.4	-0.31	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
SARC	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	4.95	1.45e-06	9e-04	0.36	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
SARC	cis	rs4372836	1	rs6547872	ENSG00000226833.4	AC097724.3	4.95	1.45e-06	0.000901	0.29	0.31	Body mass index;	chr2:28755208	chr2:28708953~28736205:-
SARC	cis	rs2933343	0.679	rs789254	ENSG00000261159.1	RP11-723O4.9	4.95	1.45e-06	0.000902	0.33	0.31	IgG glycosylation;	chr3:128855750	chr3:128859716~128860526:-
SARC	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-4.95	1.46e-06	0.000902	-0.37	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
SARC	cis	rs1134634	0.52	rs2041671	ENSG00000273133.1	RP11-799M12.2	-4.95	1.46e-06	0.000902	-0.39	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15550575	chr4:15563698~15564253:-
SARC	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	4.95	1.46e-06	0.000902	0.37	0.31	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
SARC	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.46e-06	0.000902	-0.35	-0.31	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.46e-06	0.000902	-0.35	-0.31	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.46e-06	0.000902	-0.35	-0.31	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.46e-06	0.000902	-0.35	-0.31	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.46e-06	0.000902	-0.35	-0.31	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.46e-06	0.000902	-0.35	-0.31	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.46e-06	0.000902	-0.35	-0.31	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.46e-06	0.000902	-0.35	-0.31	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-4.95	1.46e-06	0.000902	-0.35	-0.31	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
SARC	cis	rs1061377	0.748	rs1964345	ENSG00000249207.1	RP11-360F5.1	-4.95	1.46e-06	0.000903	-0.34	-0.31	Uric acid levels;	chr4:39104793	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.748	rs1964347	ENSG00000249207.1	RP11-360F5.1	-4.95	1.46e-06	0.000903	-0.34	-0.31	Uric acid levels;	chr4:39104956	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.748	rs1036033	ENSG00000249207.1	RP11-360F5.1	-4.95	1.46e-06	0.000903	-0.34	-0.31	Uric acid levels;	chr4:39105295	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.748	rs4974933	ENSG00000249207.1	RP11-360F5.1	-4.95	1.46e-06	0.000903	-0.34	-0.31	Uric acid levels;	chr4:39105636	chr4:39112677~39126818:-
SARC	cis	rs1707322	0.721	rs11211149	ENSG00000281133.1	AL355480.3	-4.94	1.46e-06	0.000903	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs11211152	ENSG00000281133.1	AL355480.3	-4.94	1.46e-06	0.000903	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs4607935	ENSG00000281133.1	AL355480.3	-4.94	1.46e-06	0.000903	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.681	rs12048866	ENSG00000281133.1	AL355480.3	-4.94	1.46e-06	0.000903	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs3811436	ENSG00000281133.1	AL355480.3	-4.94	1.46e-06	0.000903	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs12024590	ENSG00000281133.1	AL355480.3	-4.94	1.46e-06	0.000903	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs12027622	ENSG00000281133.1	AL355480.3	-4.94	1.46e-06	0.000903	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs4415615	ENSG00000281133.1	AL355480.3	-4.94	1.46e-06	0.000903	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs7529699	ENSG00000281133.1	AL355480.3	-4.94	1.46e-06	0.000903	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.716	rs6699444	ENSG00000281133.1	AL355480.3	-4.94	1.46e-06	0.000903	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs10430105	ENSG00000281133.1	AL355480.3	-4.94	1.46e-06	0.000903	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45580892~45580996:-
SARC	cis	rs7615952	0.641	rs12495947	ENSG00000250012.1	RP11-124N2.1	-4.94	1.46e-06	0.000903	-0.3	-0.31	Blood pressure (smoking interaction);	chr3:126052855	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.641	rs6805074	ENSG00000250012.1	RP11-124N2.1	-4.94	1.46e-06	0.000903	-0.3	-0.31	Blood pressure (smoking interaction);	chr3:126053431	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.641	rs66520539	ENSG00000250012.1	RP11-124N2.1	-4.94	1.46e-06	0.000903	-0.3	-0.31	Blood pressure (smoking interaction);	chr3:126061531	chr3:126084220~126095349:+
SARC	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-4.94	1.46e-06	0.000904	-0.35	-0.31	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
SARC	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	4.94	1.46e-06	0.000906	0.31	0.31	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
SARC	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	4.94	1.46e-06	0.000906	0.31	0.31	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
SARC	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-4.94	1.46e-06	0.000906	-0.29	-0.31	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
SARC	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	4.94	1.47e-06	0.000908	0.35	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
SARC	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	4.94	1.47e-06	0.000908	0.35	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
SARC	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	4.94	1.47e-06	0.000908	0.35	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
SARC	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	4.94	1.47e-06	0.000908	0.35	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
SARC	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	4.94	1.47e-06	0.000908	0.35	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
SARC	cis	rs8081395	0.741	rs180519	ENSG00000266992.1	DHX40P1	4.94	1.47e-06	0.000911	0.34	0.31	White blood cell count;	chr17:59938910	chr17:59976009~60002384:-
SARC	cis	rs193541	0.593	rs154499	ENSG00000263432.2	RN7SL689P	4.94	1.47e-06	0.000912	0.39	0.31	Glucose homeostasis traits;	chr5:122883971	chr5:123022487~123022783:-
SARC	cis	rs916888	0.697	rs199516	ENSG00000261575.2	RP11-259G18.1	-4.94	1.47e-06	0.000912	-0.43	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46267037~46268694:+
SARC	cis	rs916888	0.821	rs199514	ENSG00000261575.2	RP11-259G18.1	-4.94	1.47e-06	0.000912	-0.43	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46267037~46268694:+
SARC	cis	rs683250	0.629	rs681259	ENSG00000254551.1	RP11-727A23.7	4.94	1.47e-06	0.000912	0.35	0.31	Subcortical brain region volumes;	chr11:83222984	chr11:83209431~83213379:-
SARC	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	4.94	1.48e-06	0.000913	0.34	0.31	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	4.94	1.48e-06	0.000913	0.34	0.31	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
SARC	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	4.94	1.48e-06	0.000913	0.34	0.31	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
SARC	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	4.94	1.48e-06	0.000913	0.34	0.31	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	4.94	1.48e-06	0.000913	0.34	0.31	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
SARC	cis	rs8005677	1	rs10148215	ENSG00000257285.4	RP11-298I3.1	4.94	1.48e-06	0.000914	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:22929609~22955562:+
SARC	cis	rs73186030	1	rs73186030	ENSG00000272758.4	RP11-299J3.8	4.94	1.48e-06	0.000915	0.45	0.31	Serum parathyroid hormone levels;	chr3:122294618	chr3:122416207~122443180:+
SARC	cis	rs6991838	0.806	rs11781358	ENSG00000200714.1	Y_RNA	4.94	1.48e-06	0.000915	0.31	0.31	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65592731~65592820:+
SARC	cis	rs7162943	0.734	rs420017	ENSG00000260123.1	RP11-326A19.4	4.94	1.48e-06	0.000917	0.28	0.31	Mean platelet volume;	chr15:89073850	chr15:89041223~89082819:+
SARC	cis	rs9818758	0.556	rs11716614	ENSG00000225399.4	RP11-3B7.1	-4.94	1.49e-06	0.000918	-0.62	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48979775	chr3:49260085~49261316:+
SARC	cis	rs890448	0.793	rs2433297	ENSG00000254531.1	FLJ20021	4.94	1.49e-06	0.000918	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101421153	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs2433299	ENSG00000254531.1	FLJ20021	4.94	1.49e-06	0.000918	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101421313	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs10213549	ENSG00000254531.1	FLJ20021	4.94	1.49e-06	0.000918	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422041	chr4:101347780~101348883:+
SARC	cis	rs4372836	0.893	rs745645	ENSG00000226833.4	AC097724.3	-4.94	1.49e-06	0.000919	-0.3	-0.31	Body mass index;	chr2:28708705	chr2:28708953~28736205:-
SARC	cis	rs7809950	0.954	rs11977187	ENSG00000238832.1	snoU109	4.94	1.49e-06	0.000921	0.37	0.31	Coronary artery disease;	chr7:107569938	chr7:107603363~107603507:+
SARC	cis	rs7567389	0.719	rs1011019	ENSG00000236682.1	AC068282.3	4.94	1.49e-06	0.000923	0.36	0.31	Self-rated health;	chr2:127279984	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.534	rs2069904	ENSG00000236682.1	AC068282.3	-4.94	1.49e-06	0.000923	-0.35	-0.31	Self-rated health;	chr2:127418203	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.504	rs41280570	ENSG00000236682.1	AC068282.3	-4.94	1.49e-06	0.000923	-0.35	-0.31	Self-rated health;	chr2:127418654	chr2:127389130~127400580:+
SARC	cis	rs12655019	0.92	rs3756586	ENSG00000271828.1	CTD-2310F14.1	4.94	1.49e-06	0.000923	0.5	0.31	Breast cancer (early onset);	chr5:56921369	chr5:56927874~56929573:+
SARC	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-4.94	1.5e-06	0.000924	-0.4	-0.31	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
SARC	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	4.94	1.5e-06	0.000924	0.34	0.31	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
SARC	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	4.94	1.5e-06	0.000924	0.34	0.31	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
SARC	cis	rs7772486	0.686	rs9399564	ENSG00000270638.1	RP3-466P17.1	-4.94	1.5e-06	0.000925	-0.24	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145735570~145737218:+
SARC	cis	rs17270561	0.609	rs1892255	ENSG00000272810.1	U91328.22	-4.94	1.5e-06	0.000926	-0.31	-0.31	Iron status biomarkers;	chr6:25750126	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs1892254	ENSG00000272810.1	U91328.22	-4.94	1.5e-06	0.000926	-0.31	-0.31	Iron status biomarkers;	chr6:25750302	chr6:26013241~26013757:+
SARC	cis	rs3779195	0.584	rs1688605	ENSG00000272950.1	RP11-307C18.1	-4.94	1.5e-06	0.000926	-0.56	-0.31	Sex hormone-binding globulin levels;	chr7:98410534	chr7:98322853~98323430:+
SARC	cis	rs1707322	0.752	rs11488313	ENSG00000281133.1	AL355480.3	-4.94	1.5e-06	0.000926	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45580892~45580996:-
SARC	cis	rs890448	0.796	rs12649313	ENSG00000254531.1	FLJ20021	4.94	1.5e-06	0.000927	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101420352	chr4:101347780~101348883:+
SARC	cis	rs8062405	0.755	rs4788076	ENSG00000251417.2	RP11-1348G14.4	-4.94	1.5e-06	0.000927	-0.31	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28802743~28817828:+
SARC	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	4.94	1.5e-06	0.000928	0.44	0.31	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
SARC	cis	rs79349575	0.749	rs46521	ENSG00000270781.1	RP11-501C14.9	-4.94	1.5e-06	0.000928	-0.35	-0.31	Type 2 diabetes;	chr17:48911167	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.749	rs318093	ENSG00000270781.1	RP11-501C14.9	-4.94	1.5e-06	0.000928	-0.35	-0.31	Type 2 diabetes;	chr17:48911992	chr17:48899131~48899748:+
SARC	cis	rs7587476	0.599	rs61073893	ENSG00000229267.2	AC072062.1	-4.94	1.51e-06	0.000929	-0.32	-0.31	Neuroblastoma;	chr2:214880090	chr2:214810229~214963274:+
SARC	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	4.94	1.51e-06	0.000929	0.39	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
SARC	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	4.94	1.51e-06	0.000929	0.3	0.31	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
SARC	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	4.94	1.51e-06	0.00093	0.24	0.31	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
SARC	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	4.94	1.51e-06	0.00093	0.35	0.31	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
SARC	cis	rs2179367	0.6	rs9498355	ENSG00000231760.4	RP11-350J20.5	-4.94	1.51e-06	0.000932	-0.43	-0.31	Dupuytren's disease;	chr6:149442274	chr6:149796151~149826294:-
SARC	cis	rs8081395	0.711	rs11368	ENSG00000266992.1	DHX40P1	4.94	1.51e-06	0.000933	0.34	0.31	White blood cell count;	chr17:59954051	chr17:59976009~60002384:-
SARC	cis	rs14027	0.883	rs1469755	ENSG00000279347.1	RP11-85I17.2	-4.94	1.51e-06	0.000933	-0.27	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119728107	chr8:119838736~119840385:-
SARC	cis	rs2117029	1	rs3782357	ENSG00000258017.1	RP11-386G11.10	-4.94	1.51e-06	0.000933	-0.33	-0.31	Intelligence (multi-trait analysis);	chr12:49033869	chr12:49127782~49147869:+
SARC	cis	rs7567389	0.677	rs7556675	ENSG00000236682.1	AC068282.3	4.94	1.51e-06	0.000933	0.36	0.31	Self-rated health;	chr2:127296171	chr2:127389130~127400580:+
SARC	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-4.94	1.51e-06	0.000934	-0.51	-0.31	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-4.94	1.51e-06	0.000934	-0.51	-0.31	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
SARC	cis	rs2274273	0.624	rs10143136	ENSG00000258413.1	RP11-665C16.6	-4.94	1.51e-06	0.000934	-0.39	-0.31	Protein biomarker;	chr14:55276810	chr14:55262767~55272075:-
SARC	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	4.94	1.52e-06	0.000935	0.29	0.31	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
SARC	cis	rs1865760	0.519	rs4360119	ENSG00000272462.2	U91328.19	-4.94	1.52e-06	0.000936	-0.3	-0.31	Height;	chr6:25814846	chr6:25992662~26001775:+
SARC	cis	rs193541	0.632	rs154504	ENSG00000263432.2	RN7SL689P	4.94	1.52e-06	0.000936	0.38	0.31	Glucose homeostasis traits;	chr5:122868391	chr5:123022487~123022783:-
SARC	cis	rs2562456	0.833	rs62110367	ENSG00000268081.1	RP11-678G14.2	4.94	1.52e-06	0.000937	0.5	0.31	Pain;	chr19:21365829	chr19:21554640~21569237:-
SARC	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	4.94	1.52e-06	0.000937	0.45	0.31	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
SARC	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	4.94	1.52e-06	0.000938	0.32	0.31	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	4.94	1.52e-06	0.000938	0.32	0.31	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	4.94	1.52e-06	0.000938	0.32	0.31	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	4.94	1.52e-06	0.000938	0.32	0.31	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
SARC	cis	rs7216064	1	rs8079754	ENSG00000265055.1	AC145343.2	4.94	1.52e-06	0.000938	0.39	0.31	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67891780	chr17:68096046~68101474:-
SARC	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-4.94	1.52e-06	0.000939	-0.34	-0.31	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-4.94	1.52e-06	0.000939	-0.34	-0.31	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-4.94	1.52e-06	0.000939	-0.34	-0.31	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-4.94	1.52e-06	0.000939	-0.34	-0.31	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-4.94	1.52e-06	0.000939	-0.34	-0.31	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-4.94	1.52e-06	0.000939	-0.34	-0.31	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-4.94	1.52e-06	0.000939	-0.34	-0.31	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-4.94	1.52e-06	0.000939	-0.34	-0.31	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
SARC	cis	rs853679	0.76	rs9295768	ENSG00000219392.1	RP1-265C24.5	-4.94	1.52e-06	0.000939	-0.5	-0.31	Depression;	chr6:28241324	chr6:28115628~28116551:+
SARC	cis	rs853679	0.699	rs9468318	ENSG00000219392.1	RP1-265C24.5	-4.94	1.52e-06	0.000939	-0.5	-0.31	Depression;	chr6:28241753	chr6:28115628~28116551:+
SARC	cis	rs853679	0.76	rs9357067	ENSG00000219392.1	RP1-265C24.5	-4.94	1.52e-06	0.000939	-0.5	-0.31	Depression;	chr6:28242515	chr6:28115628~28116551:+
SARC	cis	rs853679	0.76	rs967005	ENSG00000219392.1	RP1-265C24.5	-4.94	1.52e-06	0.000939	-0.5	-0.31	Depression;	chr6:28242910	chr6:28115628~28116551:+
SARC	cis	rs1707322	0.717	rs11211161	ENSG00000281133.1	AL355480.3	-4.94	1.52e-06	0.000939	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45580892~45580996:-
SARC	cis	rs4688759	0.764	rs2023953	ENSG00000225399.4	RP11-3B7.1	-4.93	1.53e-06	0.000941	-0.61	-0.31	Blood protein levels;	chr3:50066484	chr3:49260085~49261316:+
SARC	cis	rs6452524	0.618	rs4266384	ENSG00000248112.1	RP11-78C3.1	4.93	1.53e-06	0.000941	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:82919376~82921119:-
SARC	cis	rs1865760	0.602	rs2157050	ENSG00000272810.1	U91328.22	-4.93	1.53e-06	0.000942	-0.3	-0.31	Height;	chr6:26020203	chr6:26013241~26013757:+
SARC	cis	rs4273100	1	rs12602286	ENSG00000265185.4	SNORD3B-1	-4.93	1.53e-06	0.000943	-0.41	-0.31	Schizophrenia;	chr17:19333641	chr17:19061912~19062669:+
SARC	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-4.93	1.53e-06	0.000945	-0.3	-0.31	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
SARC	cis	rs10911902	0.643	rs3753565	ENSG00000229739.2	RP11-295K2.3	4.93	1.54e-06	0.000947	0.44	0.31	Schizophrenia;	chr1:186347356	chr1:186435161~186470291:+
SARC	cis	rs7809950	1	rs10234355	ENSG00000238832.1	snoU109	-4.93	1.55e-06	0.000952	-0.35	-0.31	Coronary artery disease;	chr7:107446072	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs4730245	ENSG00000238832.1	snoU109	-4.93	1.55e-06	0.000952	-0.35	-0.31	Coronary artery disease;	chr7:107446849	chr7:107603363~107603507:+
SARC	cis	rs7567389	0.677	rs72848616	ENSG00000236682.1	AC068282.3	-4.93	1.55e-06	0.000952	-0.36	-0.31	Self-rated health;	chr2:127377521	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.71	rs72848618	ENSG00000236682.1	AC068282.3	-4.93	1.55e-06	0.000952	-0.36	-0.31	Self-rated health;	chr2:127377749	chr2:127389130~127400580:+
SARC	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-4.93	1.55e-06	0.000952	-0.33	-0.31	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
SARC	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	4.93	1.55e-06	0.000953	0.39	0.31	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
SARC	cis	rs9818758	0.505	rs67286839	ENSG00000225399.4	RP11-3B7.1	-4.93	1.55e-06	0.000954	-0.57	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49228311	chr3:49260085~49261316:+
SARC	cis	rs4713118	0.955	rs9380010	ENSG00000219392.1	RP1-265C24.5	-4.93	1.55e-06	0.000955	-0.46	-0.31	Parkinson's disease;	chr6:27715793	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.955	rs9368528	ENSG00000219392.1	RP1-265C24.5	-4.93	1.55e-06	0.000955	-0.46	-0.31	Parkinson's disease;	chr6:27716019	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.955	rs9380011	ENSG00000219392.1	RP1-265C24.5	-4.93	1.55e-06	0.000955	-0.46	-0.31	Parkinson's disease;	chr6:27716145	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.955	rs9368529	ENSG00000219392.1	RP1-265C24.5	-4.93	1.55e-06	0.000955	-0.46	-0.31	Parkinson's disease;	chr6:27716852	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.955	rs9380012	ENSG00000219392.1	RP1-265C24.5	-4.93	1.55e-06	0.000955	-0.46	-0.31	Parkinson's disease;	chr6:27716875	chr6:28115628~28116551:+
SARC	cis	rs1823874	0.71	rs1840298	ENSG00000182397.13	DNM1P46	-4.93	1.55e-06	0.000955	-0.35	-0.31	IgG glycosylation;	chr15:99821889	chr15:99790156~99806927:-
SARC	cis	rs1823874	0.71	rs67068917	ENSG00000182397.13	DNM1P46	-4.93	1.55e-06	0.000955	-0.35	-0.31	IgG glycosylation;	chr15:99822310	chr15:99790156~99806927:-
SARC	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	4.93	1.56e-06	0.000957	0.39	0.31	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
SARC	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-4.93	1.56e-06	0.000957	-0.34	-0.31	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-4.93	1.56e-06	0.000957	-0.34	-0.31	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
SARC	cis	rs7662987	0.793	rs4699700	ENSG00000272777.1	RP11-571L19.8	4.93	1.56e-06	0.000959	0.36	0.31	Smoking initiation;	chr4:99077184	chr4:99067256~99068125:-
SARC	cis	rs1707322	0.721	rs10890346	ENSG00000281133.1	AL355480.3	4.93	1.56e-06	0.000959	0.36	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45580892~45580996:-
SARC	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	4.93	1.56e-06	0.000959	0.35	0.31	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
SARC	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	4.93	1.56e-06	0.000959	0.35	0.31	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
SARC	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	4.93	1.56e-06	0.000959	0.35	0.31	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
SARC	cis	rs7712401	0.623	rs30044	ENSG00000263432.2	RN7SL689P	4.93	1.56e-06	0.000961	0.38	0.31	Mean platelet volume;	chr5:122936385	chr5:123022487~123022783:-
SARC	cis	rs4713118	0.955	rs9468200	ENSG00000219392.1	RP1-265C24.5	-4.93	1.57e-06	0.000961	-0.46	-0.31	Parkinson's disease;	chr6:27715284	chr6:28115628~28116551:+
SARC	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-4.93	1.57e-06	0.000962	-0.35	-0.31	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-4.93	1.57e-06	0.000962	-0.35	-0.31	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-4.93	1.57e-06	0.000962	-0.35	-0.31	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-4.93	1.57e-06	0.000962	-0.35	-0.31	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
SARC	cis	rs193541	0.632	rs7735618	ENSG00000263432.2	RN7SL689P	4.93	1.57e-06	0.000963	0.39	0.31	Glucose homeostasis traits;	chr5:122840550	chr5:123022487~123022783:-
SARC	cis	rs7772486	0.79	rs7742333	ENSG00000270638.1	RP3-466P17.1	-4.93	1.57e-06	0.000963	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145735570~145737218:+
SARC	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-4.93	1.57e-06	0.000965	-0.36	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
SARC	cis	rs8062405	0.721	rs151181	ENSG00000251417.2	RP11-1348G14.4	-4.93	1.57e-06	0.000966	-0.29	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28802743~28817828:+
SARC	cis	rs7216064	0.765	rs6504550	ENSG00000265055.1	AC145343.2	4.93	1.57e-06	0.000966	0.36	0.31	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67898426	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.911	rs6504551	ENSG00000265055.1	AC145343.2	4.93	1.57e-06	0.000966	0.36	0.31	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67907210	chr17:68096046~68101474:-
SARC	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-4.93	1.57e-06	0.000966	-0.31	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
SARC	cis	rs4713118	0.869	rs9366700	ENSG00000219392.1	RP1-265C24.5	-4.93	1.57e-06	0.000966	-0.43	-0.31	Parkinson's disease;	chr6:27729172	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.869	rs6456802	ENSG00000219392.1	RP1-265C24.5	-4.93	1.57e-06	0.000966	-0.43	-0.31	Parkinson's disease;	chr6:27730576	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.869	rs9393851	ENSG00000219392.1	RP1-265C24.5	-4.93	1.57e-06	0.000966	-0.43	-0.31	Parkinson's disease;	chr6:27731802	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.869	rs9461400	ENSG00000219392.1	RP1-265C24.5	-4.93	1.57e-06	0.000966	-0.43	-0.31	Parkinson's disease;	chr6:27732780	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.869	rs9295742	ENSG00000219392.1	RP1-265C24.5	-4.93	1.57e-06	0.000966	-0.43	-0.31	Parkinson's disease;	chr6:27735053	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.869	rs9461401	ENSG00000219392.1	RP1-265C24.5	-4.93	1.57e-06	0.000966	-0.43	-0.31	Parkinson's disease;	chr6:27735512	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.869	rs6914924	ENSG00000219392.1	RP1-265C24.5	-4.93	1.57e-06	0.000966	-0.43	-0.31	Parkinson's disease;	chr6:27743751	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.869	rs6930992	ENSG00000219392.1	RP1-265C24.5	-4.93	1.57e-06	0.000966	-0.43	-0.31	Parkinson's disease;	chr6:27744341	chr6:28115628~28116551:+
SARC	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	4.93	1.58e-06	0.000966	0.37	0.31	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	4.93	1.58e-06	0.000966	0.37	0.31	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	4.93	1.58e-06	0.000966	0.37	0.31	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
SARC	cis	rs7587476	0.906	rs62201985	ENSG00000229267.2	AC072062.1	-4.93	1.58e-06	0.000967	-0.32	-0.31	Neuroblastoma;	chr2:214793914	chr2:214810229~214963274:+
SARC	cis	rs12655019	0.92	rs74455703	ENSG00000271828.1	CTD-2310F14.1	4.93	1.58e-06	0.000968	0.52	0.31	Breast cancer (early onset);	chr5:56949442	chr5:56927874~56929573:+
SARC	cis	rs75920871	0.588	rs4938321	ENSG00000254851.1	RP11-109L13.1	4.93	1.58e-06	0.000968	0.41	0.31	Subjective well-being;	chr11:116981791	chr11:117135528~117138582:+
SARC	cis	rs4372836	1	rs6707848	ENSG00000226833.4	AC097724.3	4.93	1.58e-06	0.000968	0.29	0.31	Body mass index;	chr2:28765217	chr2:28708953~28736205:-
SARC	cis	rs875971	1	rs2220626	ENSG00000237310.1	GS1-124K5.4	-4.93	1.58e-06	0.000968	-0.32	-0.31	Aortic root size;	chr7:66081075	chr7:66493706~66495474:+
SARC	cis	rs9818758	0.607	rs9990153	ENSG00000225399.4	RP11-3B7.1	-4.93	1.58e-06	0.00097	-0.57	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49254450	chr3:49260085~49261316:+
SARC	cis	rs6570726	0.791	rs11759979	ENSG00000270638.1	RP3-466P17.1	4.93	1.58e-06	0.000971	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145735570~145737218:+
SARC	cis	rs72945132	0.882	rs17160762	ENSG00000254604.1	AP000487.6	4.93	1.59e-06	0.000971	0.42	0.31	Coronary artery disease;	chr11:70288660	chr11:70282367~70363368:-
SARC	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-4.93	1.59e-06	0.000972	-0.35	-0.31	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
SARC	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-4.93	1.59e-06	0.000972	-0.3	-0.31	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
SARC	cis	rs2288884	0.559	rs8111873	ENSG00000275055.1	CTC-471J1.11	-4.93	1.59e-06	0.000972	-0.34	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014267	chr19:52049007~52049754:+
SARC	cis	rs1707322	0.647	rs6686944	ENSG00000281133.1	AL355480.3	-4.93	1.59e-06	0.000972	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45580892~45580996:-
SARC	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	4.93	1.59e-06	0.000972	0.32	0.31	Height;	chr3:53073584	chr3:53064283~53065091:-
SARC	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-4.93	1.59e-06	0.000973	-0.38	-0.31	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
SARC	cis	rs4919687	0.55	rs7904252	ENSG00000213061.2	PFN1P11	-4.93	1.59e-06	0.000973	-0.4	-0.31	Colorectal cancer;	chr10:102696968	chr10:102838011~102845473:-
SARC	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-4.93	1.59e-06	0.000974	-0.32	-0.31	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
SARC	cis	rs4845875	0.534	rs6541003	ENSG00000242349.4	NPPA-AS1	4.93	1.59e-06	0.000974	0.32	0.31	Midregional pro atrial natriuretic peptide levels;	chr1:11795810	chr1:11841017~11848079:+
SARC	cis	rs7772486	0.754	rs9399561	ENSG00000270638.1	RP3-466P17.1	4.93	1.59e-06	0.000975	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145735570~145737218:+
SARC	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-4.93	1.59e-06	0.000975	-0.3	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
SARC	cis	rs2274273	0.624	rs11158034	ENSG00000258413.1	RP11-665C16.6	-4.93	1.59e-06	0.000975	-0.39	-0.31	Protein biomarker;	chr14:55286842	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs11848456	ENSG00000258413.1	RP11-665C16.6	-4.93	1.59e-06	0.000975	-0.39	-0.31	Protein biomarker;	chr14:55288674	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs11848575	ENSG00000258413.1	RP11-665C16.6	-4.93	1.59e-06	0.000975	-0.39	-0.31	Protein biomarker;	chr14:55289070	chr14:55262767~55272075:-
SARC	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-4.93	1.59e-06	0.000976	-0.39	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
SARC	cis	rs899997	1	rs11632672	ENSG00000261143.1	ADAMTS7P3	4.93	1.6e-06	0.000976	0.46	0.31	Coronary artery disease or large artery stroke;	chr15:78751988	chr15:77976042~77993057:+
SARC	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-4.93	1.6e-06	0.000977	-0.37	-0.31	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
SARC	cis	rs17270561	0.609	rs2000351	ENSG00000272462.2	U91328.19	-4.92	1.6e-06	0.000979	-0.29	-0.31	Iron status biomarkers;	chr6:25759555	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4712968	ENSG00000272462.2	U91328.19	-4.92	1.6e-06	0.000979	-0.29	-0.31	Iron status biomarkers;	chr6:25760116	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs7769908	ENSG00000272462.2	U91328.19	-4.92	1.6e-06	0.000979	-0.29	-0.31	Iron status biomarkers;	chr6:25760311	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs7770037	ENSG00000272462.2	U91328.19	-4.92	1.6e-06	0.000979	-0.29	-0.31	Iron status biomarkers;	chr6:25760363	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9348695	ENSG00000272462.2	U91328.19	-4.92	1.6e-06	0.000979	-0.29	-0.31	Iron status biomarkers;	chr6:25762782	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs2000350	ENSG00000272462.2	U91328.19	-4.92	1.6e-06	0.000979	-0.29	-0.31	Iron status biomarkers;	chr6:25762926	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs1318016	ENSG00000272462.2	U91328.19	-4.92	1.6e-06	0.000979	-0.29	-0.31	Iron status biomarkers;	chr6:25764476	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs1892245	ENSG00000272462.2	U91328.19	-4.92	1.6e-06	0.000979	-0.29	-0.31	Iron status biomarkers;	chr6:25764605	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs1317816	ENSG00000272462.2	U91328.19	-4.92	1.6e-06	0.000979	-0.29	-0.31	Iron status biomarkers;	chr6:25765162	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.583	rs6937800	ENSG00000272462.2	U91328.19	-4.92	1.6e-06	0.000979	-0.29	-0.31	Iron status biomarkers;	chr6:25765715	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs3778272	ENSG00000272462.2	U91328.19	-4.92	1.6e-06	0.000979	-0.29	-0.31	Iron status biomarkers;	chr6:25767433	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs2275905	ENSG00000272462.2	U91328.19	-4.92	1.6e-06	0.000979	-0.29	-0.31	Iron status biomarkers;	chr6:25767878	chr6:25992662~26001775:+
SARC	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-4.92	1.6e-06	0.000981	-0.35	-0.31	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
SARC	cis	rs1799949	0.827	rs74252763	ENSG00000267681.1	CTD-3199J23.6	-4.92	1.6e-06	0.000981	-0.37	-0.31	Menopause (age at onset);	chr17:43324652	chr17:43144956~43145255:+
SARC	cis	rs2179367	0.6	rs1001305	ENSG00000231760.4	RP11-350J20.5	4.92	1.6e-06	0.000981	0.45	0.31	Dupuytren's disease;	chr6:149436808	chr6:149796151~149826294:-
SARC	cis	rs526231	0.926	rs35805	ENSG00000175749.11	EIF3KP1	4.92	1.61e-06	0.000983	0.38	0.31	Primary biliary cholangitis;	chr5:103337432	chr5:103032376~103033031:+
SARC	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	4.92	1.61e-06	0.000983	0.37	0.31	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
SARC	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	4.92	1.61e-06	0.000984	0.27	0.31	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
SARC	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-4.92	1.61e-06	0.000984	-0.38	-0.31	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
SARC	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-4.92	1.61e-06	0.000984	-0.32	-0.31	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-4.92	1.61e-06	0.000984	-0.32	-0.31	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
SARC	cis	rs2933343	0.953	rs2933344	ENSG00000261159.1	RP11-723O4.9	4.92	1.61e-06	0.000986	0.35	0.31	IgG glycosylation;	chr3:128939872	chr3:128859716~128860526:-
SARC	cis	rs1823874	0.71	rs3919790	ENSG00000182397.13	DNM1P46	-4.92	1.61e-06	0.000986	-0.35	-0.31	IgG glycosylation;	chr15:99821130	chr15:99790156~99806927:-
SARC	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	4.92	1.61e-06	0.000986	0.31	0.31	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
SARC	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	4.92	1.62e-06	0.000987	0.25	0.31	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
SARC	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-4.92	1.62e-06	0.000987	-0.25	-0.31	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
SARC	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-4.92	1.62e-06	0.000987	-0.33	-0.31	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-4.92	1.62e-06	0.000987	-0.33	-0.31	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
SARC	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	4.92	1.62e-06	0.000988	0.35	0.31	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
SARC	cis	rs2439831	0.681	rs2278859	ENSG00000205771.5	CATSPER2P1	-4.92	1.62e-06	0.000988	-0.45	-0.31	Lung cancer in ever smokers;	chr15:43340762	chr15:43726918~43747094:-
SARC	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-4.92	1.62e-06	0.000989	-0.36	-0.31	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
SARC	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-4.92	1.62e-06	0.000989	-0.29	-0.31	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
SARC	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	4.92	1.62e-06	0.00099	0.42	0.31	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
SARC	cis	rs7567389	0.573	rs11541137	ENSG00000236682.1	AC068282.3	-4.92	1.62e-06	0.000991	-0.36	-0.31	Self-rated health;	chr2:127388195	chr2:127389130~127400580:+
SARC	cis	rs17270561	0.609	rs9358883	ENSG00000272810.1	U91328.22	-4.92	1.62e-06	0.000991	-0.31	-0.31	Iron status biomarkers;	chr6:25755287	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs1937132	ENSG00000272810.1	U91328.22	-4.92	1.62e-06	0.000991	-0.31	-0.31	Iron status biomarkers;	chr6:25756789	chr6:26013241~26013757:+
SARC	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	4.92	1.62e-06	0.000991	0.34	0.31	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
SARC	cis	rs890448	0.726	rs2583395	ENSG00000254531.1	FLJ20021	-4.92	1.62e-06	0.000991	-0.31	-0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101320584	chr4:101347780~101348883:+
SARC	cis	rs77204473	1	rs77349713	ENSG00000254851.1	RP11-109L13.1	4.92	1.63e-06	0.000992	0.67	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116894760	chr11:117135528~117138582:+
SARC	cis	rs4660456	0.913	rs12040422	ENSG00000237899.1	RP4-739H11.3	4.92	1.63e-06	0.000992	0.36	0.31	Platelet count;	chr1:40669239	chr1:40669089~40687588:-
SARC	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	4.92	1.63e-06	0.000993	0.28	0.31	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
SARC	cis	rs2439831	0.681	rs7168940	ENSG00000205771.5	CATSPER2P1	-4.92	1.63e-06	0.000993	-0.45	-0.31	Lung cancer in ever smokers;	chr15:43341136	chr15:43726918~43747094:-
SARC	cis	rs7772486	0.79	rs2249147	ENSG00000270638.1	RP3-466P17.1	4.92	1.63e-06	0.000993	0.24	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145735570~145737218:+
SARC	cis	rs8081395	0.603	rs1292047	ENSG00000266992.1	DHX40P1	4.92	1.63e-06	0.000996	0.35	0.31	White blood cell count;	chr17:59877805	chr17:59976009~60002384:-
SARC	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-4.92	1.64e-06	0.000997	-0.3	-0.31	Height;	chr2:231516587	chr2:231508426~231514339:-
SARC	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	4.92	1.64e-06	0.000998	0.37	0.31	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
SARC	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-4.92	1.64e-06	0.000999	-0.37	-0.31	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
SARC	cis	rs2933343	0.7	rs2624910	ENSG00000261159.1	RP11-723O4.9	4.92	1.64e-06	0.001	0.33	0.31	IgG glycosylation;	chr3:128931432	chr3:128859716~128860526:-
SARC	cis	rs7430456	0.901	rs9824206	ENSG00000225790.1	RP11-2L8.1	-4.92	1.64e-06	0.001	-0.31	-0.31	Breast cancer;	chr3:177742093	chr3:177934823~177937662:+
SARC	cis	rs7246657	0.943	rs4802766	ENSG00000276846.1	CTD-3220F14.3	4.92	1.64e-06	0.001	0.42	0.31	Coronary artery calcification;	chr19:37491031	chr19:37314868~37315620:-
SARC	cis	rs6570726	0.818	rs9390338	ENSG00000270638.1	RP3-466P17.1	4.92	1.64e-06	0.001	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs6570693	ENSG00000270638.1	RP3-466P17.1	4.92	1.64e-06	0.001	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs6570694	ENSG00000270638.1	RP3-466P17.1	4.92	1.64e-06	0.001	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs6570695	ENSG00000270638.1	RP3-466P17.1	4.92	1.64e-06	0.001	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.764	rs9386125	ENSG00000270638.1	RP3-466P17.1	4.92	1.64e-06	0.001	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs9373466	ENSG00000270638.1	RP3-466P17.1	4.92	1.64e-06	0.001	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145735570~145737218:+
SARC	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-4.92	1.64e-06	0.001	-0.35	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
SARC	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-4.92	1.64e-06	0.001	-0.35	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
SARC	cis	rs4372836	0.681	rs13025377	ENSG00000226833.4	AC097724.3	4.92	1.64e-06	0.001	0.26	0.31	Body mass index;	chr2:28730690	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.681	rs13394863	ENSG00000226833.4	AC097724.3	4.92	1.64e-06	0.001	0.26	0.31	Body mass index;	chr2:28733818	chr2:28708953~28736205:-
SARC	cis	rs6496044	0.963	rs11853972	ENSG00000202081.1	RNU6-1280P	4.92	1.64e-06	0.001	0.35	0.31	Interstitial lung disease;	chr15:85519209	chr15:85651522~85651628:-
SARC	cis	rs763567	0.605	rs647438	ENSG00000271811.1	RP1-79C4.4	-4.92	1.64e-06	0.001	-0.35	-0.31	Tonsillectomy;	chr1:170608094	chr1:170667381~170669425:+
SARC	cis	rs75422866	0.85	rs73111210	ENSG00000257433.4	RP1-197B17.3	4.92	1.65e-06	0.001	0.59	0.31	Pneumonia;	chr12:47576949	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.85	rs73111212	ENSG00000257433.4	RP1-197B17.3	4.92	1.65e-06	0.001	0.59	0.31	Pneumonia;	chr12:47577638	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.85	rs73111216	ENSG00000257433.4	RP1-197B17.3	4.92	1.65e-06	0.001	0.59	0.31	Pneumonia;	chr12:47577671	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.85	rs73111217	ENSG00000257433.4	RP1-197B17.3	4.92	1.65e-06	0.001	0.59	0.31	Pneumonia;	chr12:47577693	chr12:47706085~47742294:+
SARC	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	4.92	1.65e-06	0.001	0.32	0.31	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	4.92	1.65e-06	0.001	0.32	0.31	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
SARC	cis	rs890448	0.726	rs1549515	ENSG00000254531.1	FLJ20021	4.92	1.65e-06	0.00101	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417750	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs1549514	ENSG00000254531.1	FLJ20021	4.92	1.65e-06	0.00101	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417870	chr4:101347780~101348883:+
SARC	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-4.92	1.65e-06	0.00101	-0.25	-0.31	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
SARC	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-4.92	1.65e-06	0.00101	-0.25	-0.31	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
SARC	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-4.92	1.65e-06	0.00101	-0.25	-0.31	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
SARC	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	4.92	1.66e-06	0.00101	0.25	0.31	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	4.92	1.66e-06	0.00101	0.25	0.31	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	4.92	1.66e-06	0.00101	0.25	0.31	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
SARC	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	4.92	1.66e-06	0.00101	0.38	0.31	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	4.92	1.66e-06	0.00101	0.38	0.31	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs193539	ENSG00000263432.2	RN7SL689P	4.92	1.66e-06	0.00101	0.38	0.31	Mean platelet volume;	chr5:122921922	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.607	rs246270	ENSG00000263432.2	RN7SL689P	4.92	1.66e-06	0.00101	0.38	0.31	Mean platelet volume;	chr5:122922954	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.562	rs377316	ENSG00000263432.2	RN7SL689P	4.92	1.66e-06	0.00101	0.38	0.31	Mean platelet volume;	chr5:122924180	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs438196	ENSG00000263432.2	RN7SL689P	4.92	1.66e-06	0.00101	0.38	0.31	Mean platelet volume;	chr5:122927368	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.562	rs401729	ENSG00000263432.2	RN7SL689P	4.92	1.66e-06	0.00101	0.38	0.31	Mean platelet volume;	chr5:122928590	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs2910140	ENSG00000263432.2	RN7SL689P	4.92	1.66e-06	0.00101	0.38	0.31	Mean platelet volume;	chr5:122928700	chr5:123022487~123022783:-
SARC	cis	rs4703855	0.538	rs4428386	ENSG00000244061.1	RP11-389C8.1	4.92	1.66e-06	0.00101	0.31	0.31	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72411447	chr5:72381794~72382393:+
SARC	cis	rs4703855	0.538	rs7730838	ENSG00000244061.1	RP11-389C8.1	4.92	1.66e-06	0.00101	0.31	0.31	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72412871	chr5:72381794~72382393:+
SARC	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-4.92	1.66e-06	0.00101	-0.38	-0.31	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
SARC	cis	rs9818758	0.607	rs11710247	ENSG00000225399.4	RP11-3B7.1	-4.92	1.66e-06	0.00101	-0.56	-0.31	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49212367	chr3:49260085~49261316:+
SARC	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	4.92	1.66e-06	0.00101	0.39	0.31	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
SARC	cis	rs2933343	0.649	rs1683786	ENSG00000261159.1	RP11-723O4.9	4.92	1.67e-06	0.00101	0.33	0.31	IgG glycosylation;	chr3:128908109	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.7	rs876754	ENSG00000261159.1	RP11-723O4.9	4.92	1.67e-06	0.00101	0.33	0.31	IgG glycosylation;	chr3:128908910	chr3:128859716~128860526:-
SARC	cis	rs1865760	0.566	rs2032445	ENSG00000272462.2	U91328.19	-4.92	1.67e-06	0.00101	-0.28	-0.31	Height;	chr6:26044584	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.566	rs2032443	ENSG00000272462.2	U91328.19	-4.92	1.67e-06	0.00101	-0.28	-0.31	Height;	chr6:26046574	chr6:25992662~26001775:+
SARC	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-4.92	1.67e-06	0.00102	-0.36	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
SARC	cis	rs2274273	0.87	rs7158768	ENSG00000258413.1	RP11-665C16.6	-4.92	1.67e-06	0.00102	-0.36	-0.31	Protein biomarker;	chr14:55296894	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.87	rs10142547	ENSG00000258413.1	RP11-665C16.6	-4.92	1.67e-06	0.00102	-0.36	-0.31	Protein biomarker;	chr14:55297245	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.87	rs61210954	ENSG00000258413.1	RP11-665C16.6	-4.92	1.67e-06	0.00102	-0.36	-0.31	Protein biomarker;	chr14:55298684	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.87	rs8023197	ENSG00000258413.1	RP11-665C16.6	-4.92	1.67e-06	0.00102	-0.36	-0.31	Protein biomarker;	chr14:55300677	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.837	rs7148171	ENSG00000258413.1	RP11-665C16.6	-4.92	1.67e-06	0.00102	-0.36	-0.31	Protein biomarker;	chr14:55304026	chr14:55262767~55272075:-
SARC	cis	rs7772486	0.79	rs2253764	ENSG00000270638.1	RP3-466P17.1	4.91	1.68e-06	0.00102	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs2253880	ENSG00000270638.1	RP3-466P17.1	4.91	1.68e-06	0.00102	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs2814879	ENSG00000270638.1	RP3-466P17.1	4.91	1.68e-06	0.00102	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145735570~145737218:+
SARC	cis	rs4372836	0.504	rs6737027	ENSG00000226833.4	AC097724.3	-4.91	1.68e-06	0.00102	-0.26	-0.31	Body mass index;	chr2:28847939	chr2:28708953~28736205:-
SARC	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	4.91	1.68e-06	0.00102	0.37	0.31	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
SARC	cis	rs1431005	0.858	rs11132461	ENSG00000250620.1	RP11-91J3.3	-4.91	1.68e-06	0.00102	-0.32	-0.31	Response to statin therapy;	chr4:187509161	chr4:187413564~187415697:+
SARC	cis	rs1865760	0.566	rs9295686	ENSG00000272462.2	U91328.19	-4.91	1.68e-06	0.00102	-0.28	-0.31	Height;	chr6:26081755	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.532	rs9295687	ENSG00000272462.2	U91328.19	-4.91	1.68e-06	0.00102	-0.28	-0.31	Height;	chr6:26082482	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.566	rs4529296	ENSG00000272462.2	U91328.19	-4.91	1.68e-06	0.00102	-0.28	-0.31	Height;	chr6:26082907	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.566	rs9379825	ENSG00000272462.2	U91328.19	-4.91	1.68e-06	0.00102	-0.28	-0.31	Height;	chr6:26083643	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.566	rs9467672	ENSG00000272462.2	U91328.19	-4.91	1.68e-06	0.00102	-0.28	-0.31	Height;	chr6:26083676	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.566	rs9295688	ENSG00000272462.2	U91328.19	-4.91	1.68e-06	0.00102	-0.28	-0.31	Height;	chr6:26083989	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.566	rs1971509	ENSG00000272462.2	U91328.19	-4.91	1.68e-06	0.00102	-0.28	-0.31	Height;	chr6:26085549	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.532	rs2006736	ENSG00000272462.2	U91328.19	-4.91	1.68e-06	0.00102	-0.28	-0.31	Height;	chr6:26085789	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.566	rs1800702	ENSG00000272462.2	U91328.19	-4.91	1.68e-06	0.00102	-0.28	-0.31	Height;	chr6:26086235	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.566	rs2794720	ENSG00000272462.2	U91328.19	-4.91	1.68e-06	0.00102	-0.28	-0.31	Height;	chr6:26086974	chr6:25992662~26001775:+
SARC	cis	rs8031584	0.781	rs4779498	ENSG00000260382.1	RP11-540B6.2	4.91	1.68e-06	0.00102	0.37	0.31	Huntington's disease progression;	chr15:30885273	chr15:30882267~30883231:-
SARC	cis	rs7567389	0.719	rs4150404	ENSG00000236682.1	AC068282.3	4.91	1.68e-06	0.00102	0.36	0.31	Self-rated health;	chr2:127292424	chr2:127389130~127400580:+
SARC	cis	rs34375054	0.752	rs12582808	ENSG00000279233.1	RP11-158L12.4	4.91	1.68e-06	0.00102	0.38	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125176913	chr12:125138245~125141711:+
SARC	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-4.91	1.69e-06	0.00102	-0.34	-0.31	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
SARC	cis	rs1707322	0.752	rs28550303	ENSG00000281133.1	AL355480.3	-4.91	1.69e-06	0.00102	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.716	rs28375469	ENSG00000281133.1	AL355480.3	-4.91	1.69e-06	0.00102	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs28545085	ENSG00000281133.1	AL355480.3	-4.91	1.69e-06	0.00102	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs28719889	ENSG00000281133.1	AL355480.3	-4.91	1.69e-06	0.00102	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs28812624	ENSG00000281133.1	AL355480.3	-4.91	1.69e-06	0.00102	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45580892~45580996:-
SARC	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-4.91	1.69e-06	0.00103	-0.31	-0.31	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
SARC	cis	rs8031584	0.958	rs7176569	ENSG00000260382.1	RP11-540B6.2	-4.91	1.69e-06	0.00103	-0.37	-0.31	Huntington's disease progression;	chr15:30952292	chr15:30882267~30883231:-
SARC	cis	rs7712401	0.623	rs30032	ENSG00000263432.2	RN7SL689P	4.91	1.69e-06	0.00103	0.39	0.31	Mean platelet volume;	chr5:122902692	chr5:123022487~123022783:-
SARC	cis	rs7772486	0.79	rs1832362	ENSG00000270638.1	RP3-466P17.1	4.91	1.69e-06	0.00103	0.24	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs9376968	ENSG00000270638.1	RP3-466P17.1	4.91	1.69e-06	0.00103	0.24	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145735570~145737218:+
SARC	cis	rs6952407	1	rs6952407	ENSG00000236529.1	RP13-254B10.1	-4.91	1.7e-06	0.00103	-0.32	-0.31	Cotinine glucuronidation;	chr7:66580525	chr7:65840212~65840596:+
SARC	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-4.91	1.7e-06	0.00103	-0.39	-0.31	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
SARC	cis	rs17772222	0.63	rs7141608	ENSG00000258983.2	RP11-507K2.2	-4.91	1.7e-06	0.00103	-0.3	-0.31	Coronary artery calcification;	chr14:88514045	chr14:88499334~88515502:+
SARC	cis	rs7246657	1	rs1529957	ENSG00000276846.1	CTD-3220F14.3	4.91	1.7e-06	0.00103	0.41	0.31	Coronary artery calcification;	chr19:37248899	chr19:37314868~37315620:-
SARC	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	4.91	1.7e-06	0.00103	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
SARC	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	4.91	1.71e-06	0.00103	0.29	0.31	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
SARC	cis	rs4865169	0.691	rs1056364	ENSG00000269949.1	RP11-738E22.3	-4.91	1.71e-06	0.00103	-0.35	-0.31	Breast cancer;	chr4:57023511	chr4:56960927~56961373:-
SARC	cis	rs1799949	1	rs3092988	ENSG00000267681.1	CTD-3199J23.6	-4.91	1.71e-06	0.00103	-0.35	-0.31	Menopause (age at onset);	chr17:43049685	chr17:43144956~43145255:+
SARC	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-4.91	1.71e-06	0.00103	-0.39	-0.31	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
SARC	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	4.91	1.71e-06	0.00104	0.45	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
SARC	cis	rs17270561	0.636	rs7453371	ENSG00000272810.1	U91328.22	-4.91	1.71e-06	0.00104	-0.31	-0.31	Iron status biomarkers;	chr6:25719028	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs7450798	ENSG00000272810.1	U91328.22	-4.91	1.71e-06	0.00104	-0.31	-0.31	Iron status biomarkers;	chr6:25719052	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4712957	ENSG00000272810.1	U91328.22	-4.91	1.71e-06	0.00104	-0.31	-0.31	Iron status biomarkers;	chr6:25719586	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.666	rs17320090	ENSG00000272810.1	U91328.22	-4.91	1.71e-06	0.00104	-0.31	-0.31	Iron status biomarkers;	chr6:25719987	chr6:26013241~26013757:+
SARC	cis	rs7626444	0.625	rs2686596	ENSG00000272359.1	U4	-4.91	1.71e-06	0.00104	-0.31	-0.31	Monocyte count;	chr3:196748248	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.625	rs2686595	ENSG00000272359.1	U4	-4.91	1.71e-06	0.00104	-0.31	-0.31	Monocyte count;	chr3:196748271	chr3:196747192~196747324:-
SARC	cis	rs5769707	0.681	rs2319346	ENSG00000188511.11	C22orf34	4.91	1.71e-06	0.00104	0.4	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49414524~49657542:-
SARC	cis	rs1707322	0.717	rs3014245	ENSG00000281133.1	AL355480.3	4.91	1.71e-06	0.00104	0.36	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.717	rs12023439	ENSG00000281133.1	AL355480.3	-4.91	1.72e-06	0.00104	-0.36	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45580892~45580996:-
SARC	cis	rs890448	0.796	rs833945	ENSG00000254531.1	FLJ20021	4.91	1.72e-06	0.00104	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101396936	chr4:101347780~101348883:+
SARC	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-4.91	1.72e-06	0.00104	-0.38	-0.31	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
SARC	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	4.91	1.72e-06	0.00104	0.37	0.31	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	4.91	1.72e-06	0.00104	0.37	0.31	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
SARC	cis	rs6570726	0.791	rs1509214	ENSG00000270638.1	RP3-466P17.1	-4.91	1.73e-06	0.00104	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145735570~145737218:+
SARC	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-4.91	1.73e-06	0.00105	-0.35	-0.31	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
SARC	cis	rs1865760	1	rs2071297	ENSG00000272810.1	U91328.22	4.91	1.73e-06	0.00105	0.3	0.31	Height;	chr6:25924285	chr6:26013241~26013757:+
SARC	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	4.91	1.74e-06	0.00105	0.38	0.31	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
SARC	cis	rs2562456	0.917	rs2650793	ENSG00000268081.1	RP11-678G14.2	-4.91	1.74e-06	0.00105	-0.46	-0.31	Pain;	chr19:21493313	chr19:21554640~21569237:-
SARC	cis	rs17270561	0.609	rs9358886	ENSG00000272810.1	U91328.22	-4.91	1.74e-06	0.00105	-0.31	-0.31	Iron status biomarkers;	chr6:25758025	chr6:26013241~26013757:+
SARC	cis	rs7615952	0.673	rs9821905	ENSG00000248787.1	RP11-666A20.4	4.91	1.74e-06	0.00105	0.55	0.31	Blood pressure (smoking interaction);	chr3:125902007	chr3:125908005~125910272:-
SARC	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-4.91	1.74e-06	0.00105	-0.31	-0.31	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-4.91	1.74e-06	0.00105	-0.31	-0.31	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-4.91	1.74e-06	0.00105	-0.31	-0.31	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
SARC	cis	rs1134634	0.52	rs28661857	ENSG00000273133.1	RP11-799M12.2	-4.91	1.74e-06	0.00105	-0.4	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15589842	chr4:15563698~15564253:-
SARC	cis	rs6570726	0.846	rs426874	ENSG00000270638.1	RP3-466P17.1	4.91	1.75e-06	0.00105	0.24	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145735570~145737218:+
SARC	cis	rs17772222	0.638	rs11629164	ENSG00000258983.2	RP11-507K2.2	-4.91	1.75e-06	0.00105	-0.32	-0.31	Coronary artery calcification;	chr14:88564740	chr14:88499334~88515502:+
SARC	cis	rs6991838	0.806	rs13262793	ENSG00000200714.1	Y_RNA	4.91	1.75e-06	0.00106	0.32	0.31	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65592731~65592820:+
SARC	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-4.91	1.75e-06	0.00106	-0.31	-0.31	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
SARC	cis	rs2933343	0.649	rs789216	ENSG00000261159.1	RP11-723O4.9	4.91	1.75e-06	0.00106	0.33	0.31	IgG glycosylation;	chr3:128875660	chr3:128859716~128860526:-
SARC	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	4.91	1.75e-06	0.00106	0.24	0.31	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
SARC	cis	rs1823913	0.637	rs10931493	ENSG00000227542.1	AC092614.2	4.91	1.75e-06	0.00106	0.34	0.31	Obesity-related traits;	chr2:191288142	chr2:191229165~191246172:-
SARC	cis	rs7772486	0.79	rs9403750	ENSG00000270638.1	RP3-466P17.1	4.91	1.75e-06	0.00106	0.24	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145735570~145737218:+
SARC	cis	rs890448	0.726	rs2583399	ENSG00000254531.1	FLJ20021	-4.91	1.75e-06	0.00106	-0.32	-0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101315757	chr4:101347780~101348883:+
SARC	cis	rs2179367	0.92	rs560051	ENSG00000231760.4	RP11-350J20.5	4.9	1.75e-06	0.00106	0.38	0.31	Dupuytren's disease;	chr6:149345841	chr6:149796151~149826294:-
SARC	cis	rs193541	0.632	rs6878609	ENSG00000263432.2	RN7SL689P	4.9	1.75e-06	0.00106	0.38	0.31	Glucose homeostasis traits;	chr5:122759854	chr5:123022487~123022783:-
SARC	cis	rs2404602	0.735	rs11637490	ENSG00000259422.1	RP11-593F23.1	-4.9	1.75e-06	0.00106	-0.36	-0.31	Blood metabolite levels;	chr15:76467224	chr15:76174891~76181486:-
SARC	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	4.9	1.76e-06	0.00106	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
SARC	cis	rs4713118	0.869	rs6922574	ENSG00000219392.1	RP1-265C24.5	-4.9	1.76e-06	0.00106	-0.43	-0.31	Parkinson's disease;	chr6:27725224	chr6:28115628~28116551:+
SARC	cis	rs7615952	0.736	rs9866347	ENSG00000171084.14	FAM86JP	4.9	1.76e-06	0.00106	0.57	0.31	Blood pressure (smoking interaction);	chr3:125951082	chr3:125916620~125930024:+
SARC	cis	rs10788972	0.787	rs6674720	ENSG00000225183.1	RP4-758J24.4	-4.9	1.76e-06	0.00106	-0.36	-0.31	Parkinson disease and lewy body pathology;	chr1:54073666	chr1:54089856~54090093:+
SARC	cis	rs10788972	0.779	rs7516791	ENSG00000225183.1	RP4-758J24.4	-4.9	1.76e-06	0.00106	-0.36	-0.31	Parkinson disease and lewy body pathology;	chr1:54086202	chr1:54089856~54090093:+
SARC	cis	rs9309473	1	rs58603761	ENSG00000163016.8	ALMS1P	4.9	1.76e-06	0.00106	0.38	0.31	Metabolite levels;	chr2:73499478	chr2:73644919~73685576:+
SARC	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	4.9	1.76e-06	0.00106	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	4.9	1.76e-06	0.00106	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	4.9	1.76e-06	0.00106	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	4.9	1.76e-06	0.00106	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
SARC	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	4.9	1.77e-06	0.00107	0.36	0.31	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-4.9	1.77e-06	0.00107	-0.39	-0.31	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
SARC	cis	rs1865760	1	rs3830057	ENSG00000272810.1	U91328.22	-4.9	1.77e-06	0.00107	-0.31	-0.31	Height;	chr6:25918282	chr6:26013241~26013757:+
SARC	cis	rs1865760	1	rs3752421	ENSG00000272810.1	U91328.22	-4.9	1.77e-06	0.00107	-0.31	-0.31	Height;	chr6:25918460	chr6:26013241~26013757:+
SARC	cis	rs7567389	0.719	rs4662718	ENSG00000236682.1	AC068282.3	4.9	1.78e-06	0.00107	0.36	0.31	Self-rated health;	chr2:127257791	chr2:127389130~127400580:+
SARC	cis	rs853679	0.517	rs9380056	ENSG00000272009.1	RP1-313I6.12	-4.9	1.78e-06	0.00107	-0.35	-0.31	Depression;	chr6:28136698	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9380057	ENSG00000272009.1	RP1-313I6.12	-4.9	1.78e-06	0.00107	-0.35	-0.31	Depression;	chr6:28136856	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs6941992	ENSG00000272009.1	RP1-313I6.12	-4.9	1.78e-06	0.00107	-0.35	-0.31	Depression;	chr6:28138363	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.516	rs4713142	ENSG00000272009.1	RP1-313I6.12	-4.9	1.78e-06	0.00107	-0.35	-0.31	Parkinson's disease;	chr6:28138569	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs4713143	ENSG00000272009.1	RP1-313I6.12	-4.9	1.78e-06	0.00107	-0.35	-0.31	Depression;	chr6:28138981	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs4713144	ENSG00000272009.1	RP1-313I6.12	-4.9	1.78e-06	0.00107	-0.35	-0.31	Depression;	chr6:28139012	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs4713145	ENSG00000272009.1	RP1-313I6.12	-4.9	1.78e-06	0.00107	-0.35	-0.31	Depression;	chr6:28139049	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs3757187	ENSG00000272009.1	RP1-313I6.12	-4.9	1.78e-06	0.00107	-0.35	-0.31	Depression;	chr6:28139876	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs3757185	ENSG00000272009.1	RP1-313I6.12	-4.9	1.78e-06	0.00107	-0.35	-0.31	Depression;	chr6:28139998	chr6:28078792~28081130:-
SARC	cis	rs7772486	0.754	rs2328709	ENSG00000270638.1	RP3-466P17.1	-4.9	1.78e-06	0.00107	-0.25	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145735570~145737218:+
SARC	cis	rs1823874	0.677	rs56096943	ENSG00000182397.13	DNM1P46	-4.9	1.78e-06	0.00107	-0.35	-0.31	IgG glycosylation;	chr15:99820513	chr15:99790156~99806927:-
SARC	cis	rs7712401	0.601	rs246275	ENSG00000263432.2	RN7SL689P	4.9	1.78e-06	0.00107	0.39	0.31	Mean platelet volume;	chr5:122895718	chr5:123022487~123022783:-
SARC	cis	rs7567389	0.502	rs2069919	ENSG00000236682.1	AC068282.3	-4.9	1.78e-06	0.00107	-0.34	-0.31	Self-rated health;	chr2:127421977	chr2:127389130~127400580:+
SARC	cis	rs2439831	0.867	rs2255051	ENSG00000205771.5	CATSPER2P1	-4.9	1.78e-06	0.00107	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43553963	chr15:43726918~43747094:-
SARC	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	4.9	1.79e-06	0.00108	0.31	0.31	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
SARC	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	4.9	1.79e-06	0.00108	0.5	0.31	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
SARC	cis	rs524281	0.731	rs78578425	ENSG00000255320.1	RP11-755F10.1	4.9	1.79e-06	0.00108	0.5	0.31	Electroencephalogram traits;	chr11:66042768	chr11:66244840~66246239:-
SARC	cis	rs4703855	0.538	rs17312595	ENSG00000244061.1	RP11-389C8.1	4.9	1.79e-06	0.00108	0.31	0.31	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72418030	chr5:72381794~72382393:+
SARC	cis	rs4703855	0.538	rs6886010	ENSG00000244061.1	RP11-389C8.1	4.9	1.79e-06	0.00108	0.31	0.31	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72418500	chr5:72381794~72382393:+
SARC	cis	rs875971	0.508	rs10950045	ENSG00000236529.1	RP13-254B10.1	-4.9	1.79e-06	0.00108	-0.31	-0.31	Aortic root size;	chr7:66601386	chr7:65840212~65840596:+
SARC	cis	rs10754283	0.935	rs1934046	ENSG00000231613.1	RP5-943J3.1	-4.9	1.79e-06	0.00108	-0.3	-0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89653731	chr1:89788914~89790492:+
SARC	cis	rs801193	0.839	rs6968619	ENSG00000236529.1	RP13-254B10.1	-4.9	1.79e-06	0.00108	-0.31	-0.31	Aortic root size;	chr7:66603880	chr7:65840212~65840596:+
SARC	cis	rs801193	0.839	rs12534943	ENSG00000236529.1	RP13-254B10.1	-4.9	1.79e-06	0.00108	-0.31	-0.31	Aortic root size;	chr7:66605533	chr7:65840212~65840596:+
SARC	cis	rs801193	0.805	rs12532355	ENSG00000236529.1	RP13-254B10.1	-4.9	1.79e-06	0.00108	-0.31	-0.31	Aortic root size;	chr7:66605597	chr7:65840212~65840596:+
SARC	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	4.9	1.79e-06	0.00108	0.29	0.31	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
SARC	cis	rs4862750	0.957	rs2375916	ENSG00000249742.1	RP11-217E13.1	-4.9	1.79e-06	0.00108	-0.33	-0.31	Lobe attachment (rater-scored or self-reported);	chr4:186982769	chr4:186979490~187021973:-
SARC	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-4.9	1.79e-06	0.00108	-0.34	-0.31	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
SARC	cis	rs2280018	0.526	rs2941257	ENSG00000188599.16	NPIPP1	-4.9	1.79e-06	0.00108	-0.3	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15104312~15123498:-
SARC	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-4.9	1.8e-06	0.00108	-0.34	-0.31	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
SARC	cis	rs7772486	0.701	rs11155438	ENSG00000270638.1	RP3-466P17.1	4.9	1.8e-06	0.00108	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.701	rs7772717	ENSG00000270638.1	RP3-466P17.1	4.9	1.8e-06	0.00108	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145735570~145737218:+
SARC	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-4.9	1.8e-06	0.00108	-0.31	-0.31	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
SARC	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-4.9	1.8e-06	0.00108	-0.33	-0.31	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
SARC	cis	rs1134634	0.52	rs4698408	ENSG00000273133.1	RP11-799M12.2	-4.9	1.8e-06	0.00108	-0.39	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15657425	chr4:15563698~15564253:-
SARC	cis	rs2179367	0.6	rs9498354	ENSG00000231760.4	RP11-350J20.5	-4.9	1.8e-06	0.00108	-0.44	-0.31	Dupuytren's disease;	chr6:149441715	chr6:149796151~149826294:-
SARC	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-4.9	1.8e-06	0.00108	-0.35	-0.31	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
SARC	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	4.9	1.8e-06	0.00108	0.25	0.31	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
SARC	cis	rs858239	0.896	rs1637193	ENSG00000226816.2	AC005082.12	4.9	1.8e-06	0.00108	0.37	0.31	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23206013~23208045:+
SARC	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	4.9	1.8e-06	0.00108	0.33	0.31	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
SARC	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	4.9	1.81e-06	0.00109	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
SARC	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	4.9	1.81e-06	0.00109	0.36	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
SARC	cis	rs2274273	0.563	rs79163357	ENSG00000258413.1	RP11-665C16.6	-4.9	1.81e-06	0.00109	-0.4	-0.31	Protein biomarker;	chr14:55271731	chr14:55262767~55272075:-
SARC	cis	rs890448	0.726	rs2044043	ENSG00000254531.1	FLJ20021	-4.9	1.81e-06	0.00109	-0.31	-0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101314983	chr4:101347780~101348883:+
SARC	cis	rs7247513	0.964	rs8100964	ENSG00000213290.4	PGK1P2	-4.9	1.81e-06	0.00109	-0.36	-0.31	Bipolar disorder;	chr19:12609817	chr19:12559571~12561105:+
SARC	cis	rs2564921	0.73	rs56026870	ENSG00000242142.1	SERBP1P3	-4.9	1.81e-06	0.00109	-0.3	-0.31	Height;	chr3:52998472	chr3:53064283~53065091:-
SARC	cis	rs1707322	0.685	rs28617418	ENSG00000281133.1	AL355480.3	-4.9	1.81e-06	0.00109	-0.35	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.682	rs28490344	ENSG00000281133.1	AL355480.3	-4.9	1.81e-06	0.00109	-0.35	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs28641748	ENSG00000281133.1	AL355480.3	-4.9	1.81e-06	0.00109	-0.35	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs6697821	ENSG00000281133.1	AL355480.3	-4.9	1.81e-06	0.00109	-0.35	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs4330955	ENSG00000281133.1	AL355480.3	-4.9	1.81e-06	0.00109	-0.35	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.691	rs12031182	ENSG00000281133.1	AL355480.3	-4.9	1.81e-06	0.00109	-0.35	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs10430123	ENSG00000281133.1	AL355480.3	-4.9	1.81e-06	0.00109	-0.35	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45580892~45580996:-
SARC	cis	rs17270561	0.609	rs9348694	ENSG00000272810.1	U91328.22	-4.9	1.81e-06	0.00109	-0.31	-0.31	Iron status biomarkers;	chr6:25753412	chr6:26013241~26013757:+
SARC	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	4.9	1.81e-06	0.00109	0.35	0.31	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	4.9	1.81e-06	0.00109	0.35	0.31	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	4.9	1.81e-06	0.00109	0.35	0.31	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	4.9	1.81e-06	0.00109	0.35	0.31	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	4.9	1.81e-06	0.00109	0.35	0.31	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	4.9	1.81e-06	0.00109	0.35	0.31	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
SARC	cis	rs11719291	0.833	rs34037363	ENSG00000225399.4	RP11-3B7.1	-4.9	1.82e-06	0.00109	-0.56	-0.31	Cognitive function;	chr3:48783603	chr3:49260085~49261316:+
SARC	cis	rs7809950	0.954	rs2520243	ENSG00000238832.1	snoU109	-4.9	1.82e-06	0.00109	-0.35	-0.31	Coronary artery disease;	chr7:107496528	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.954	rs2520245	ENSG00000238832.1	snoU109	-4.9	1.82e-06	0.00109	-0.35	-0.31	Coronary artery disease;	chr7:107496983	chr7:107603363~107603507:+
SARC	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-4.9	1.82e-06	0.00109	-0.39	-0.31	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
SARC	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-4.9	1.82e-06	0.00109	-0.33	-0.31	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
SARC	cis	rs77204473	0.744	rs11606672	ENSG00000254851.1	RP11-109L13.1	4.9	1.82e-06	0.00109	0.67	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117185343	chr11:117135528~117138582:+
SARC	cis	rs17270561	0.609	rs4711096	ENSG00000272810.1	U91328.22	-4.9	1.82e-06	0.00109	-0.31	-0.31	Iron status biomarkers;	chr6:25726826	chr6:26013241~26013757:+
SARC	cis	rs7772486	0.686	rs9376961	ENSG00000270638.1	RP3-466P17.1	4.9	1.82e-06	0.0011	0.25	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145735570~145737218:+
SARC	cis	rs890448	0.796	rs13143896	ENSG00000254531.1	FLJ20021	4.9	1.83e-06	0.0011	0.33	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101440045	chr4:101347780~101348883:+
SARC	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	4.9	1.83e-06	0.0011	0.32	0.31	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
SARC	cis	rs890448	0.796	rs293200	ENSG00000254531.1	FLJ20021	4.9	1.83e-06	0.0011	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101403113	chr4:101347780~101348883:+
SARC	cis	rs1823913	0.599	rs17412635	ENSG00000227542.1	AC092614.2	-4.9	1.83e-06	0.0011	-0.34	-0.31	Obesity-related traits;	chr2:191294834	chr2:191229165~191246172:-
SARC	cis	rs1707322	0.721	rs10890341	ENSG00000281133.1	AL355480.3	-4.9	1.83e-06	0.0011	-0.35	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45580892~45580996:-
SARC	cis	rs9309473	1	rs10187416	ENSG00000163016.8	ALMS1P	4.9	1.83e-06	0.0011	0.38	0.31	Metabolite levels;	chr2:73486614	chr2:73644919~73685576:+
SARC	cis	rs7712401	0.601	rs2126935	ENSG00000263432.2	RN7SL689P	-4.9	1.83e-06	0.0011	-0.39	-0.31	Mean platelet volume;	chr5:122977876	chr5:123022487~123022783:-
SARC	cis	rs890448	0.726	rs2850369	ENSG00000254531.1	FLJ20021	-4.9	1.83e-06	0.0011	-0.32	-0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101311828	chr4:101347780~101348883:+
SARC	cis	rs1134634	0.52	rs16892140	ENSG00000273133.1	RP11-799M12.2	-4.9	1.83e-06	0.0011	-0.39	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15546927	chr4:15563698~15564253:-
SARC	cis	rs6762	0.748	rs1130663	ENSG00000279672.1	CMB9-55F22.1	4.89	1.84e-06	0.0011	0.27	0.31	Mean platelet volume;	chr11:837582	chr11:779617~780755:+
SARC	cis	rs9309473	0.898	rs9807961	ENSG00000163016.8	ALMS1P	4.89	1.84e-06	0.0011	0.38	0.31	Metabolite levels;	chr2:73466916	chr2:73644919~73685576:+
SARC	cis	rs9309473	1	rs2140195	ENSG00000163016.8	ALMS1P	4.89	1.84e-06	0.0011	0.38	0.31	Metabolite levels;	chr2:73475217	chr2:73644919~73685576:+
SARC	cis	rs801193	0.761	rs2659888	ENSG00000236529.1	RP13-254B10.1	4.89	1.84e-06	0.0011	0.32	0.31	Aortic root size;	chr7:66765184	chr7:65840212~65840596:+
SARC	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-4.89	1.84e-06	0.0011	-0.49	-0.31	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
SARC	cis	rs5769707	0.609	rs739247	ENSG00000235111.1	RP1-29C18.8	-4.89	1.84e-06	0.0011	-0.38	-0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49612657~49615716:-
SARC	cis	rs1134634	0.52	rs3822298	ENSG00000273133.1	RP11-799M12.2	-4.89	1.84e-06	0.00111	-0.39	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15554780	chr4:15563698~15564253:-
SARC	cis	rs2117029	1	rs10875913	ENSG00000258017.1	RP11-386G11.10	-4.89	1.84e-06	0.00111	-0.32	-0.31	Intelligence (multi-trait analysis);	chr12:49025525	chr12:49127782~49147869:+
SARC	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	4.89	1.85e-06	0.00111	0.42	0.31	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
SARC	cis	rs890448	0.726	rs2850367	ENSG00000254531.1	FLJ20021	-4.89	1.85e-06	0.00111	-0.31	-0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101310306	chr4:101347780~101348883:+
SARC	cis	rs2933343	0.729	rs1680794	ENSG00000261159.1	RP11-723O4.9	4.89	1.85e-06	0.00111	0.33	0.31	IgG glycosylation;	chr3:128901547	chr3:128859716~128860526:-
SARC	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-4.89	1.85e-06	0.00111	-0.34	-0.31	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
SARC	cis	rs2439831	0.681	rs3742969	ENSG00000205771.5	CATSPER2P1	-4.89	1.86e-06	0.00111	-0.43	-0.31	Lung cancer in ever smokers;	chr15:43329749	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.681	rs1549523	ENSG00000205771.5	CATSPER2P1	-4.89	1.86e-06	0.00111	-0.43	-0.31	Lung cancer in ever smokers;	chr15:43331991	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.681	rs1549525	ENSG00000205771.5	CATSPER2P1	-4.89	1.86e-06	0.00111	-0.43	-0.31	Lung cancer in ever smokers;	chr15:43335657	chr15:43726918~43747094:-
SARC	cis	rs7567389	0.637	rs4150421	ENSG00000236682.1	AC068282.3	4.89	1.86e-06	0.00112	0.36	0.31	Self-rated health;	chr2:127287354	chr2:127389130~127400580:+
SARC	cis	rs14027	0.883	rs4871642	ENSG00000279347.1	RP11-85I17.2	-4.89	1.86e-06	0.00112	-0.27	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119818813	chr8:119838736~119840385:-
SARC	cis	rs7587476	0.906	rs17487792	ENSG00000229267.2	AC072062.1	4.89	1.86e-06	0.00112	0.33	0.31	Neuroblastoma;	chr2:214778776	chr2:214810229~214963274:+
SARC	cis	rs4713118	0.869	rs6902689	ENSG00000219392.1	RP1-265C24.5	-4.89	1.87e-06	0.00112	-0.42	-0.31	Parkinson's disease;	chr6:27741662	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.869	rs9468214	ENSG00000219392.1	RP1-265C24.5	-4.89	1.87e-06	0.00112	-0.42	-0.31	Parkinson's disease;	chr6:27745520	chr6:28115628~28116551:+
SARC	cis	rs9527	0.662	rs4919686	ENSG00000213061.2	PFN1P11	4.89	1.87e-06	0.00112	0.4	0.31	Arsenic metabolism;	chr10:102832492	chr10:102838011~102845473:-
SARC	cis	rs7809950	1	rs2293658	ENSG00000238832.1	snoU109	-4.89	1.87e-06	0.00112	-0.34	-0.31	Coronary artery disease;	chr7:107630122	chr7:107603363~107603507:+
SARC	cis	rs2803122	0.838	rs10757033	ENSG00000273226.1	RP11-513M16.8	-4.89	1.88e-06	0.00112	-0.29	-0.31	Pulse pressure;	chr9:19223306	chr9:19375451~19375996:+
SARC	cis	rs1799949	1	rs35070007	ENSG00000267681.1	CTD-3199J23.6	4.89	1.88e-06	0.00112	0.34	0.31	Menopause (age at onset);	chr17:43164730	chr17:43144956~43145255:+
SARC	cis	rs708547	0.533	rs3806746	ENSG00000269949.1	RP11-738E22.3	-4.89	1.88e-06	0.00113	-0.38	-0.31	Response to bleomycin (chromatid breaks);	chr4:56907164	chr4:56960927~56961373:-
SARC	cis	rs890448	0.726	rs293214	ENSG00000254531.1	FLJ20021	4.89	1.88e-06	0.00113	0.32	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101393116	chr4:101347780~101348883:+
SARC	cis	rs6452524	0.618	rs1478487	ENSG00000248112.1	RP11-78C3.1	4.89	1.89e-06	0.00113	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:82919376~82921119:-
SARC	cis	rs2803122	0.846	rs10757032	ENSG00000273226.1	RP11-513M16.8	-4.89	1.89e-06	0.00113	-0.29	-0.31	Pulse pressure;	chr9:19213350	chr9:19375451~19375996:+
SARC	cis	rs910316	0.737	rs108622	ENSG00000279594.1	RP11-950C14.10	-4.89	1.89e-06	0.00113	-0.34	-0.3	Height;	chr14:75015205	chr14:75011269~75012851:-
SARC	cis	rs2562456	0.839	rs2562411	ENSG00000268081.1	RP11-678G14.2	4.89	1.89e-06	0.00113	0.49	0.3	Pain;	chr19:21419181	chr19:21554640~21569237:-
SARC	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-4.89	1.89e-06	0.00113	-0.31	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
SARC	cis	rs2018683	0.624	rs1006521	ENSG00000228421.2	AC005013.5	4.89	1.89e-06	0.00113	0.32	0.3	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28956604	chr7:28957667~28959345:+
SARC	cis	rs17270561	0.609	rs4464787	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25733330	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4711098	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25734111	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.636	rs4360128	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25734330	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs3922699	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25734741	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs6924782	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25735588	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs6924794	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25735646	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs3922842	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25736336	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.608	rs9358875	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25737780	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9358876	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25738728	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.583	rs9393661	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25738852	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9356986	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25738891	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.666	rs9356987	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25738959	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9358877	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25739000	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs12663099	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25739290	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9393662	ENSG00000272810.1	U91328.22	-4.89	1.9e-06	0.00113	-0.31	-0.3	Iron status biomarkers;	chr6:25739442	chr6:26013241~26013757:+
SARC	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	4.89	1.9e-06	0.00113	0.31	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
SARC	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	4.89	1.9e-06	0.00113	0.33	0.3	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
SARC	cis	rs875971	0.793	rs460678	ENSG00000237310.1	GS1-124K5.4	4.89	1.9e-06	0.00113	0.31	0.3	Aortic root size;	chr7:66062213	chr7:66493706~66495474:+
SARC	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	4.89	1.9e-06	0.00113	0.29	0.3	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
SARC	cis	rs2933343	0.951	rs789217	ENSG00000261159.1	RP11-723O4.9	4.89	1.9e-06	0.00114	0.35	0.3	IgG glycosylation;	chr3:128874358	chr3:128859716~128860526:-
SARC	cis	rs910316	0.737	rs424120	ENSG00000279594.1	RP11-950C14.10	-4.89	1.91e-06	0.00114	-0.34	-0.3	Height;	chr14:75016125	chr14:75011269~75012851:-
SARC	cis	rs6570726	0.791	rs7765687	ENSG00000270638.1	RP3-466P17.1	4.89	1.91e-06	0.00114	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145735570~145737218:+
SARC	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	4.89	1.91e-06	0.00114	0.37	0.3	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
SARC	cis	rs7615952	0.611	rs78137633	ENSG00000171084.14	FAM86JP	4.89	1.91e-06	0.00114	0.62	0.3	Blood pressure (smoking interaction);	chr3:126056218	chr3:125916620~125930024:+
SARC	cis	rs4713118	0.955	rs34752872	ENSG00000219392.1	RP1-265C24.5	-4.89	1.91e-06	0.00114	-0.46	-0.3	Parkinson's disease;	chr6:27715465	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.911	rs2394000	ENSG00000219392.1	RP1-265C24.5	-4.89	1.91e-06	0.00114	-0.46	-0.3	Parkinson's disease;	chr6:27719212	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.955	rs9393847	ENSG00000219392.1	RP1-265C24.5	-4.89	1.91e-06	0.00114	-0.46	-0.3	Parkinson's disease;	chr6:27720194	chr6:28115628~28116551:+
SARC	cis	rs17270561	0.609	rs9379785	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25725985	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9358871	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25726447	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4711095	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25726546	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4712959	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25726829	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4712960	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25727037	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4712961	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25727106	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9358872	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25727289	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9356985	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25727870	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.636	rs12194699	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25729001	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9379786	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25730027	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9393658	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25730210	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs4711097	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25732086	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs12203927	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25732462	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs12192077	ENSG00000272810.1	U91328.22	-4.89	1.91e-06	0.00114	-0.31	-0.3	Iron status biomarkers;	chr6:25732566	chr6:26013241~26013757:+
SARC	cis	rs2562456	0.793	rs3853837	ENSG00000268081.1	RP11-678G14.2	4.89	1.91e-06	0.00114	0.5	0.3	Pain;	chr19:21419172	chr19:21554640~21569237:-
SARC	cis	rs853679	0.517	rs1947862	ENSG00000272009.1	RP1-313I6.12	-4.89	1.92e-06	0.00114	-0.36	-0.3	Depression;	chr6:28137418	chr6:28078792~28081130:-
SARC	cis	rs160451	0.934	rs160453	ENSG00000251136.7	RP11-37B2.1	4.89	1.92e-06	0.00114	0.34	0.3	Leprosy;	chr8:89652326	chr8:89609409~89757727:-
SARC	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-4.89	1.92e-06	0.00114	-0.41	-0.3	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
SARC	cis	rs2239557	1	rs7157566	ENSG00000259065.1	RP5-1021I20.1	4.88	1.92e-06	0.00115	0.35	0.3	Common traits (Other);	chr14:74182426	chr14:73787360~73803270:+
SARC	cis	rs524281	0.731	rs1125078	ENSG00000255320.1	RP11-755F10.1	-4.88	1.92e-06	0.00115	-0.46	-0.3	Electroencephalogram traits;	chr11:66042404	chr11:66244840~66246239:-
SARC	cis	rs1823913	1	rs4853563	ENSG00000280083.1	RP11-317J9.1	4.88	1.93e-06	0.00115	0.34	0.3	Obesity-related traits;	chr2:191254808	chr2:191154118~191156070:-
SARC	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-4.88	1.93e-06	0.00115	-0.28	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
SARC	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-4.88	1.93e-06	0.00115	-0.39	-0.3	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
SARC	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-4.88	1.93e-06	0.00115	-0.3	-0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
SARC	cis	rs4713118	0.621	rs9295755	ENSG00000272009.1	RP1-313I6.12	4.88	1.93e-06	0.00115	0.35	0.3	Parkinson's disease;	chr6:28065396	chr6:28078792~28081130:-
SARC	cis	rs75920871	0.588	rs1815789	ENSG00000254851.1	RP11-109L13.1	4.88	1.94e-06	0.00115	0.4	0.3	Subjective well-being;	chr11:116964237	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.588	rs1815788	ENSG00000254851.1	RP11-109L13.1	4.88	1.94e-06	0.00115	0.4	0.3	Subjective well-being;	chr11:116964255	chr11:117135528~117138582:+
SARC	cis	rs910316	0.763	rs1548807	ENSG00000279594.1	RP11-950C14.10	4.88	1.95e-06	0.00116	0.33	0.3	Height;	chr14:75012879	chr14:75011269~75012851:-
SARC	cis	rs8081395	0.627	rs12952730	ENSG00000266992.1	DHX40P1	4.88	1.95e-06	0.00116	0.35	0.3	White blood cell count;	chr17:59901475	chr17:59976009~60002384:-
SARC	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	4.88	1.95e-06	0.00116	0.34	0.3	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	4.88	1.95e-06	0.00116	0.34	0.3	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	4.88	1.95e-06	0.00116	0.34	0.3	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	4.88	1.95e-06	0.00116	0.34	0.3	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	4.88	1.95e-06	0.00116	0.34	0.3	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
SARC	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	4.88	1.95e-06	0.00116	0.34	0.3	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	4.88	1.95e-06	0.00116	0.34	0.3	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	4.88	1.95e-06	0.00116	0.34	0.3	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
SARC	cis	rs2439831	1	rs2467739	ENSG00000205771.5	CATSPER2P1	-4.88	1.96e-06	0.00116	-0.46	-0.3	Lung cancer in ever smokers;	chr15:43447998	chr15:43726918~43747094:-
SARC	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-4.88	1.96e-06	0.00116	-0.36	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
SARC	cis	rs160451	1	rs160446	ENSG00000251136.7	RP11-37B2.1	4.88	1.96e-06	0.00117	0.34	0.3	Leprosy;	chr8:89647035	chr8:89609409~89757727:-
SARC	cis	rs160451	0.966	rs160450	ENSG00000251136.7	RP11-37B2.1	4.88	1.96e-06	0.00117	0.34	0.3	Leprosy;	chr8:89650354	chr8:89609409~89757727:-
SARC	cis	rs160451	1	rs160451	ENSG00000251136.7	RP11-37B2.1	4.88	1.96e-06	0.00117	0.34	0.3	Leprosy;	chr8:89650713	chr8:89609409~89757727:-
SARC	cis	rs1707322	0.752	rs61784793	ENSG00000281133.1	AL355480.3	-4.88	1.96e-06	0.00117	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs4586014	ENSG00000281133.1	AL355480.3	-4.88	1.96e-06	0.00117	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.648	rs4439382	ENSG00000281133.1	AL355480.3	-4.88	1.96e-06	0.00117	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45580892~45580996:-
SARC	cis	rs9309473	0.948	rs10170849	ENSG00000163016.8	ALMS1P	4.88	1.96e-06	0.00117	0.38	0.3	Metabolite levels;	chr2:73520805	chr2:73644919~73685576:+
SARC	cis	rs1707322	0.686	rs3014242	ENSG00000281133.1	AL355480.3	4.88	1.97e-06	0.00117	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.686	rs3014236	ENSG00000281133.1	AL355480.3	4.88	1.97e-06	0.00117	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45580892~45580996:-
SARC	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-4.88	1.97e-06	0.00117	-0.32	-0.3	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
SARC	cis	rs1865760	0.566	rs1539183	ENSG00000272462.2	U91328.19	-4.88	1.97e-06	0.00117	-0.28	-0.3	Height;	chr6:26074823	chr6:25992662~26001775:+
SARC	cis	rs10911902	0.643	rs75158977	ENSG00000229739.2	RP11-295K2.3	-4.88	1.97e-06	0.00117	-0.43	-0.3	Schizophrenia;	chr1:186324597	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.602	rs3736595	ENSG00000229739.2	RP11-295K2.3	-4.88	1.97e-06	0.00117	-0.43	-0.3	Schizophrenia;	chr1:186331745	chr1:186435161~186470291:+
SARC	cis	rs7216064	0.906	rs78452260	ENSG00000278219.1	AC145343.1	-4.88	1.97e-06	0.00117	-0.39	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67852406	chr17:68101538~68101639:+
SARC	cis	rs2018683	0.624	rs2286220	ENSG00000228421.2	AC005013.5	4.88	1.97e-06	0.00117	0.32	0.3	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28957667~28959345:+
SARC	cis	rs2018683	0.584	rs4722880	ENSG00000228421.2	AC005013.5	4.88	1.97e-06	0.00117	0.32	0.3	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28957667~28959345:+
SARC	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	4.88	1.97e-06	0.00117	0.39	0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
SARC	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	4.88	1.97e-06	0.00117	0.31	0.3	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
SARC	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-4.88	1.97e-06	0.00117	-0.38	-0.3	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
SARC	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-4.88	1.97e-06	0.00117	-0.29	-0.3	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
SARC	cis	rs2933343	0.729	rs1680785	ENSG00000261159.1	RP11-723O4.9	4.88	1.97e-06	0.00117	0.33	0.3	IgG glycosylation;	chr3:128925973	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.729	rs1680786	ENSG00000261159.1	RP11-723O4.9	4.88	1.97e-06	0.00117	0.33	0.3	IgG glycosylation;	chr3:128925997	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.672	rs1872545	ENSG00000261159.1	RP11-723O4.9	4.88	1.97e-06	0.00117	0.33	0.3	IgG glycosylation;	chr3:128926196	chr3:128859716~128860526:-
SARC	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-4.88	1.98e-06	0.00118	-0.37	-0.3	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
SARC	cis	rs6969780	0.841	rs10246712	ENSG00000233429.8	HOTAIRM1	4.88	1.98e-06	0.00118	0.43	0.3	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27159241	chr7:27095647~27100265:+
SARC	cis	rs2803122	0.807	rs10757035	ENSG00000273226.1	RP11-513M16.8	-4.88	1.98e-06	0.00118	-0.29	-0.3	Pulse pressure;	chr9:19230274	chr9:19375451~19375996:+
SARC	cis	rs2933343	0.7	rs883602	ENSG00000261159.1	RP11-723O4.9	4.88	1.99e-06	0.00118	0.33	0.3	IgG glycosylation;	chr3:128935109	chr3:128859716~128860526:-
SARC	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-4.88	1.99e-06	0.00118	-0.38	-0.3	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-4.88	1.99e-06	0.00118	-0.38	-0.3	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
SARC	cis	rs7567389	0.719	rs4150402	ENSG00000236682.1	AC068282.3	-4.88	1.99e-06	0.00118	-0.36	-0.3	Self-rated health;	chr2:127292558	chr2:127389130~127400580:+
SARC	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	4.88	1.99e-06	0.00118	0.45	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
SARC	cis	rs7772486	0.686	rs9390349	ENSG00000270638.1	RP3-466P17.1	-4.88	1.99e-06	0.00118	-0.25	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145735570~145737218:+
SARC	cis	rs1865760	0.566	rs10807006	ENSG00000272462.2	U91328.19	-4.88	1.99e-06	0.00118	-0.28	-0.3	Height;	chr6:26048524	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.566	rs7772312	ENSG00000272462.2	U91328.19	-4.88	1.99e-06	0.00118	-0.28	-0.3	Height;	chr6:26049388	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.566	rs9379821	ENSG00000272462.2	U91328.19	-4.88	1.99e-06	0.00118	-0.28	-0.3	Height;	chr6:26054040	chr6:25992662~26001775:+
SARC	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	4.88	2e-06	0.00118	0.31	0.3	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
SARC	cis	rs6496044	1	rs6496044	ENSG00000202081.1	RNU6-1280P	4.88	2e-06	0.00118	0.34	0.3	Interstitial lung disease;	chr15:85524075	chr15:85651522~85651628:-
SARC	cis	rs12554020	1	rs12554020	ENSG00000227603.1	RP11-165J3.6	4.88	2e-06	0.00119	0.41	0.3	Schizophrenia;	chr9:93507955	chr9:93435332~93437121:-
SARC	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	4.88	2e-06	0.00119	0.34	0.3	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
SARC	cis	rs7250849	0.565	rs7255319	ENSG00000273837.1	LLNLR-470E3.1	4.88	2e-06	0.00119	0.31	0.3	Blood protein levels;	chr19:51664653	chr19:51639478~51639931:-
SARC	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-4.88	2e-06	0.00119	-0.34	-0.3	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
SARC	cis	rs890448	0.796	rs4699215	ENSG00000254531.1	FLJ20021	-4.88	2e-06	0.00119	-0.3	-0.3	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422414	chr4:101347780~101348883:+
SARC	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-4.88	2.01e-06	0.00119	-0.31	-0.3	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
SARC	cis	rs2179367	0.959	rs562428	ENSG00000231760.4	RP11-350J20.5	4.88	2.01e-06	0.00119	0.37	0.3	Dupuytren's disease;	chr6:149326389	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.959	rs540538	ENSG00000231760.4	RP11-350J20.5	4.88	2.01e-06	0.00119	0.37	0.3	Dupuytren's disease;	chr6:149326808	chr6:149796151~149826294:-
SARC	cis	rs2404602	0.735	rs11629888	ENSG00000259422.1	RP11-593F23.1	-4.88	2.01e-06	0.00119	-0.39	-0.3	Blood metabolite levels;	chr15:76427539	chr15:76174891~76181486:-
SARC	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	4.88	2.01e-06	0.00119	0.31	0.3	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
SARC	cis	rs8031584	0.958	rs61997076	ENSG00000260382.1	RP11-540B6.2	4.88	2.01e-06	0.00119	0.4	0.3	Huntington's disease progression;	chr15:30924022	chr15:30882267~30883231:-
SARC	cis	rs77204473	0.744	rs17120344	ENSG00000254851.1	RP11-109L13.1	-4.87	2.01e-06	0.00119	-0.73	-0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117125629	chr11:117135528~117138582:+
SARC	cis	rs1707322	0.752	rs4660313	ENSG00000281133.1	AL355480.3	4.87	2.01e-06	0.00119	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45580892~45580996:-
SARC	cis	rs7772486	0.875	rs56181683	ENSG00000270638.1	RP3-466P17.1	-4.87	2.02e-06	0.0012	-0.25	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145965484	chr6:145735570~145737218:+
SARC	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	4.87	2.02e-06	0.0012	0.26	0.3	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
SARC	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	4.87	2.02e-06	0.0012	0.3	0.3	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
SARC	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-4.87	2.02e-06	0.0012	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
SARC	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-4.87	2.02e-06	0.0012	-0.37	-0.3	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-4.87	2.02e-06	0.0012	-0.37	-0.3	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-4.87	2.02e-06	0.0012	-0.37	-0.3	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
SARC	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	4.87	2.02e-06	0.0012	0.45	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
SARC	cis	rs79349575	0.749	rs12601672	ENSG00000270781.1	RP11-501C14.9	-4.87	2.02e-06	0.0012	-0.35	-0.3	Type 2 diabetes;	chr17:48929131	chr17:48899131~48899748:+
SARC	cis	rs193541	0.53	rs1466371	ENSG00000263432.2	RN7SL689P	4.87	2.03e-06	0.0012	0.38	0.3	Glucose homeostasis traits;	chr5:122748093	chr5:123022487~123022783:-
SARC	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	4.87	2.03e-06	0.0012	0.32	0.3	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
SARC	cis	rs1707322	0.821	rs11211182	ENSG00000281133.1	AL355480.3	-4.87	2.03e-06	0.0012	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45580892~45580996:-
SARC	cis	rs9818758	0.607	rs11719220	ENSG00000225399.4	RP11-3B7.1	-4.87	2.03e-06	0.0012	-0.56	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49207768	chr3:49260085~49261316:+
SARC	cis	rs1881744	0.588	rs78808618	ENSG00000257433.4	RP1-197B17.3	4.87	2.03e-06	0.0012	0.52	0.3	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47706085~47742294:+
SARC	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-4.87	2.03e-06	0.0012	-0.5	-0.3	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-4.87	2.03e-06	0.0012	-0.5	-0.3	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
SARC	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-4.87	2.03e-06	0.0012	-0.31	-0.3	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
SARC	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-4.87	2.03e-06	0.0012	-0.42	-0.3	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-4.87	2.03e-06	0.0012	-0.37	-0.3	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
SARC	cis	rs6762	0.719	rs28655651	ENSG00000279672.1	CMB9-55F22.1	4.87	2.04e-06	0.00121	0.27	0.3	Mean platelet volume;	chr11:837121	chr11:779617~780755:+
SARC	cis	rs56080343	0.748	rs2893771	ENSG00000275759.1	RP11-131L12.3	-4.87	2.04e-06	0.00121	-0.52	-0.3	Neuroticism;	chr12:118440051	chr12:118428281~118428870:+
SARC	cis	rs2274273	0.773	rs8012380	ENSG00000258413.1	RP11-665C16.6	-4.87	2.04e-06	0.00121	-0.36	-0.3	Protein biomarker;	chr14:55268292	chr14:55262767~55272075:-
SARC	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-4.87	2.04e-06	0.00121	-0.29	-0.3	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-4.87	2.04e-06	0.00121	-0.29	-0.3	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
SARC	cis	rs4713118	0.955	rs9468201	ENSG00000219392.1	RP1-265C24.5	-4.87	2.04e-06	0.00121	-0.46	-0.3	Parkinson's disease;	chr6:27719256	chr6:28115628~28116551:+
SARC	cis	rs10911902	0.643	rs75906210	ENSG00000229739.2	RP11-295K2.3	-4.87	2.04e-06	0.00121	-0.44	-0.3	Schizophrenia;	chr1:186365092	chr1:186435161~186470291:+
SARC	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-4.87	2.05e-06	0.00121	-0.37	-0.3	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
SARC	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	4.87	2.05e-06	0.00121	0.28	0.3	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
SARC	cis	rs7662987	0.793	rs12697	ENSG00000272777.1	RP11-571L19.8	-4.87	2.05e-06	0.00121	-0.37	-0.3	Smoking initiation;	chr4:99072225	chr4:99067256~99068125:-
SARC	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-4.87	2.05e-06	0.00121	-0.34	-0.3	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-4.87	2.05e-06	0.00121	-0.34	-0.3	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
SARC	cis	rs7247513	0.964	rs8105902	ENSG00000213290.4	PGK1P2	-4.87	2.05e-06	0.00121	-0.36	-0.3	Bipolar disorder;	chr19:12607537	chr19:12559571~12561105:+
SARC	cis	rs62103177	0.525	rs62101233	ENSG00000261126.6	RP11-795F19.1	4.87	2.05e-06	0.00122	0.33	0.3	Opioid sensitivity;	chr18:79964288	chr18:80046900~80095482:+
SARC	cis	rs7250849	0.565	rs73052859	ENSG00000273837.1	LLNLR-470E3.1	-4.87	2.05e-06	0.00122	-0.33	-0.3	Blood protein levels;	chr19:51661210	chr19:51639478~51639931:-
SARC	cis	rs7250849	0.565	rs73052861	ENSG00000273837.1	LLNLR-470E3.1	-4.87	2.05e-06	0.00122	-0.33	-0.3	Blood protein levels;	chr19:51661217	chr19:51639478~51639931:-
SARC	cis	rs1707322	0.686	rs3014239	ENSG00000281133.1	AL355480.3	4.87	2.06e-06	0.00122	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45580892~45580996:-
SARC	cis	rs42490	0.546	rs160437	ENSG00000251136.7	RP11-37B2.1	4.87	2.06e-06	0.00122	0.34	0.3	Leprosy;	chr8:89669656	chr8:89609409~89757727:-
SARC	cis	rs7811142	1	rs1000215	ENSG00000078319.8	PMS2P1	-4.87	2.06e-06	0.00122	-0.42	-0.3	Platelet count;	chr7:100406920	chr7:100320992~100341908:-
SARC	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-4.87	2.06e-06	0.00122	-0.31	-0.3	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
SARC	cis	rs2292342	0.85	rs7255644	ENSG00000232871.7	SEC1P	-4.87	2.06e-06	0.00122	-0.7	-0.3	Elevated serum carcinoembryonic antigen levels;	chr19:48644237	chr19:48638071~48682245:+
SARC	cis	rs9818758	0.607	rs113186424	ENSG00000225399.4	RP11-3B7.1	-4.87	2.07e-06	0.00122	-0.56	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49235293	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs34784192	ENSG00000225399.4	RP11-3B7.1	-4.87	2.07e-06	0.00122	-0.56	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49237390	chr3:49260085~49261316:+
SARC	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	4.87	2.07e-06	0.00122	0.68	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
SARC	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	4.87	2.07e-06	0.00122	0.31	0.3	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	4.87	2.07e-06	0.00122	0.31	0.3	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	4.87	2.07e-06	0.00122	0.31	0.3	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	4.87	2.07e-06	0.00122	0.31	0.3	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	4.87	2.07e-06	0.00122	0.31	0.3	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	4.87	2.07e-06	0.00122	0.31	0.3	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
SARC	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-4.87	2.07e-06	0.00122	-0.37	-0.3	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
SARC	cis	rs4713118	0.869	rs9348775	ENSG00000219392.1	RP1-265C24.5	-4.87	2.08e-06	0.00123	-0.42	-0.3	Parkinson's disease;	chr6:27727550	chr6:28115628~28116551:+
SARC	cis	rs6570726	0.791	rs9399558	ENSG00000270638.1	RP3-466P17.1	4.87	2.08e-06	0.00123	0.25	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs9376953	ENSG00000270638.1	RP3-466P17.1	4.87	2.08e-06	0.00123	0.25	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.764	rs9403733	ENSG00000270638.1	RP3-466P17.1	4.87	2.08e-06	0.00123	0.25	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs13202312	ENSG00000270638.1	RP3-466P17.1	4.87	2.08e-06	0.00123	0.25	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs7765675	ENSG00000270638.1	RP3-466P17.1	4.87	2.08e-06	0.00123	0.25	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.738	rs6917199	ENSG00000270638.1	RP3-466P17.1	4.87	2.08e-06	0.00123	0.25	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145735570~145737218:+
SARC	cis	rs11634944	0.689	rs2732040	ENSG00000274307.1	RP11-345J18.2	-4.87	2.08e-06	0.00123	-0.38	-0.3	Interleukin-8 levels;	chr15:25024203	chr15:25708470~25710869:-
SARC	cis	rs10256972	0.626	rs62433138	ENSG00000229043.2	AC091729.9	-4.87	2.08e-06	0.00123	-0.36	-0.3	Endometriosis;Longevity;	chr7:1011241	chr7:1160374~1165267:+
SARC	cis	rs2439831	0.681	rs825739	ENSG00000275601.1	AC011330.13	-4.87	2.08e-06	0.00123	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43300230	chr15:43642389~43643023:-
SARC	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	4.87	2.09e-06	0.00123	0.34	0.3	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
SARC	cis	rs7512898	0.9	rs7535122	ENSG00000260088.1	RP11-92G12.3	4.87	2.09e-06	0.00123	0.31	0.3	Electrocardiographic conduction measures;	chr1:200703571	chr1:200669507~200694250:+
SARC	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-4.87	2.09e-06	0.00123	-0.31	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
SARC	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-4.87	2.09e-06	0.00123	-0.36	-0.3	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
SARC	cis	rs11822910	0.815	rs12422015	ENSG00000265566.2	RN7SL605P	4.87	2.09e-06	0.00123	0.41	0.3	Platelet distribution width;	chr11:57426180	chr11:57528085~57528365:-
SARC	cis	rs9818758	0.607	rs9850917	ENSG00000225399.4	RP11-3B7.1	-4.87	2.1e-06	0.00124	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49249550	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs9847839	ENSG00000225399.4	RP11-3B7.1	-4.87	2.1e-06	0.00124	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49251570	chr3:49260085~49261316:+
SARC	cis	rs890448	0.796	rs293201	ENSG00000254531.1	FLJ20021	4.87	2.1e-06	0.00124	0.31	0.3	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101402425	chr4:101347780~101348883:+
SARC	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	4.87	2.1e-06	0.00124	0.28	0.3	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
SARC	cis	rs42490	0.727	rs42481	ENSG00000251136.7	RP11-37B2.1	4.87	2.1e-06	0.00124	0.35	0.3	Leprosy;	chr8:89825486	chr8:89609409~89757727:-
SARC	cis	rs2933343	0.7	rs789240	ENSG00000261159.1	RP11-723O4.9	4.87	2.1e-06	0.00124	0.32	0.3	IgG glycosylation;	chr3:128911792	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.7	rs789239	ENSG00000261159.1	RP11-723O4.9	4.87	2.1e-06	0.00124	0.32	0.3	IgG glycosylation;	chr3:128914965	chr3:128859716~128860526:-
SARC	cis	rs7809950	0.678	rs62482499	ENSG00000238832.1	snoU109	-4.87	2.11e-06	0.00124	-0.36	-0.3	Coronary artery disease;	chr7:107334614	chr7:107603363~107603507:+
SARC	cis	rs2665103	0.632	rs3902959	ENSG00000278603.1	RP13-608F4.5	4.87	2.11e-06	0.00124	0.35	0.3	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472203~82472426:+
SARC	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	4.87	2.11e-06	0.00124	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	4.87	2.11e-06	0.00124	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs17120132	ENSG00000254851.1	RP11-109L13.1	4.87	2.11e-06	0.00124	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs17120136	ENSG00000254851.1	RP11-109L13.1	4.87	2.11e-06	0.00124	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs78694306	ENSG00000254851.1	RP11-109L13.1	4.87	2.11e-06	0.00124	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs115971514	ENSG00000254851.1	RP11-109L13.1	4.87	2.11e-06	0.00124	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs12280030	ENSG00000254851.1	RP11-109L13.1	4.87	2.11e-06	0.00124	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs12273762	ENSG00000254851.1	RP11-109L13.1	4.87	2.11e-06	0.00124	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs9651681	ENSG00000254851.1	RP11-109L13.1	4.87	2.11e-06	0.00124	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117135528~117138582:+
SARC	cis	rs6452524	0.56	rs6895174	ENSG00000248112.1	RP11-78C3.1	4.86	2.11e-06	0.00124	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:82919376~82921119:-
SARC	cis	rs801193	1	rs4279493	ENSG00000236529.1	RP13-254B10.1	4.86	2.11e-06	0.00124	0.32	0.3	Aortic root size;	chr7:66761633	chr7:65840212~65840596:+
SARC	cis	rs1707322	0.65	rs4553239	ENSG00000281133.1	AL355480.3	-4.86	2.11e-06	0.00124	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45580892~45580996:-
SARC	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	4.86	2.11e-06	0.00125	0.34	0.3	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
SARC	cis	rs2933343	0.7	rs789238	ENSG00000261159.1	RP11-723O4.9	4.86	2.11e-06	0.00125	0.32	0.3	IgG glycosylation;	chr3:128917872	chr3:128859716~128860526:-
SARC	cis	rs2274273	0.87	rs13379169	ENSG00000258413.1	RP11-665C16.6	-4.86	2.11e-06	0.00125	-0.36	-0.3	Protein biomarker;	chr14:55274569	chr14:55262767~55272075:-
SARC	cis	rs1707322	0.716	rs10890342	ENSG00000281133.1	AL355480.3	-4.86	2.12e-06	0.00125	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs6658700	ENSG00000281133.1	AL355480.3	-4.86	2.12e-06	0.00125	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs12047629	ENSG00000281133.1	AL355480.3	-4.86	2.12e-06	0.00125	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs11211169	ENSG00000281133.1	AL355480.3	-4.86	2.12e-06	0.00125	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs11211171	ENSG00000281133.1	AL355480.3	-4.86	2.12e-06	0.00125	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs28623463	ENSG00000281133.1	AL355480.3	-4.86	2.12e-06	0.00125	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.716	rs28370457	ENSG00000281133.1	AL355480.3	-4.86	2.12e-06	0.00125	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs28890893	ENSG00000281133.1	AL355480.3	-4.86	2.12e-06	0.00125	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45580892~45580996:-
SARC	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	4.86	2.12e-06	0.00125	0.28	0.3	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
SARC	cis	rs7246657	1	rs6508710	ENSG00000276846.1	CTD-3220F14.3	4.86	2.12e-06	0.00125	0.41	0.3	Coronary artery calcification;	chr19:37258984	chr19:37314868~37315620:-
SARC	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-4.86	2.12e-06	0.00125	-0.4	-0.3	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
SARC	cis	rs1799949	0.894	rs71367985	ENSG00000267681.1	CTD-3199J23.6	-4.86	2.12e-06	0.00125	-0.34	-0.3	Menopause (age at onset);	chr17:43222443	chr17:43144956~43145255:+
SARC	cis	rs79349575	0.783	rs318095	ENSG00000270781.1	RP11-501C14.9	-4.86	2.13e-06	0.00125	-0.35	-0.3	Type 2 diabetes;	chr17:48897372	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs318096	ENSG00000270781.1	RP11-501C14.9	-4.86	2.13e-06	0.00125	-0.35	-0.3	Type 2 diabetes;	chr17:48898008	chr17:48899131~48899748:+
SARC	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	4.86	2.14e-06	0.00126	0.34	0.3	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
SARC	cis	rs7811142	1	rs6953107	ENSG00000242294.5	STAG3L5P	4.86	2.15e-06	0.00126	0.24	0.3	Platelet count;	chr7:100498041	chr7:100336079~100351900:+
SARC	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-4.86	2.15e-06	0.00126	-0.32	-0.3	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
SARC	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-4.86	2.15e-06	0.00126	-0.32	-0.3	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
SARC	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-4.86	2.15e-06	0.00127	-0.29	-0.3	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
SARC	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	4.86	2.16e-06	0.00127	0.35	0.3	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
SARC	cis	rs2153535	0.562	rs10458225	ENSG00000230939.1	RP11-314C16.1	4.86	2.16e-06	0.00127	0.34	0.3	Motion sickness;	chr6:8385771	chr6:8784178~8785445:+
SARC	cis	rs2439831	0.717	rs2470132	ENSG00000205771.5	CATSPER2P1	-4.86	2.16e-06	0.00127	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43543283	chr15:43726918~43747094:-
SARC	cis	rs10895987	0.531	rs7943007	ENSG00000255200.1	AP003068.18	-4.86	2.16e-06	0.00127	-0.34	-0.3	Blood protein levels;	chr11:65089626	chr11:65174117~65176470:-
SARC	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	4.86	2.16e-06	0.00127	0.28	0.3	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
SARC	cis	rs7216064	0.953	rs11868959	ENSG00000278219.1	AC145343.1	-4.86	2.17e-06	0.00127	-0.38	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67844694	chr17:68101538~68101639:+
SARC	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-4.86	2.17e-06	0.00127	-0.37	-0.3	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
SARC	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-4.86	2.17e-06	0.00127	-0.37	-0.3	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
SARC	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	4.86	2.17e-06	0.00127	0.28	0.3	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
SARC	cis	rs79349575	0.749	rs519537	ENSG00000270781.1	RP11-501C14.9	-4.86	2.17e-06	0.00127	-0.35	-0.3	Type 2 diabetes;	chr17:48893778	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs832410	ENSG00000270781.1	RP11-501C14.9	-4.86	2.17e-06	0.00127	-0.35	-0.3	Type 2 diabetes;	chr17:48895503	chr17:48899131~48899748:+
SARC	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-4.86	2.18e-06	0.00128	-0.31	-0.3	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
SARC	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	4.86	2.18e-06	0.00128	0.37	0.3	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
SARC	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-4.86	2.18e-06	0.00128	-0.31	-0.3	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
SARC	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-4.86	2.18e-06	0.00128	-0.31	-0.3	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
SARC	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	4.86	2.18e-06	0.00128	0.39	0.3	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
SARC	cis	rs2439831	0.867	rs2255042	ENSG00000205771.5	CATSPER2P1	4.86	2.18e-06	0.00128	0.47	0.3	Lung cancer in ever smokers;	chr15:43542120	chr15:43726918~43747094:-
SARC	cis	rs79349575	0.783	rs4793991	ENSG00000270781.1	RP11-501C14.9	-4.86	2.19e-06	0.00128	-0.35	-0.3	Type 2 diabetes;	chr17:48924439	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.715	rs62075844	ENSG00000270781.1	RP11-501C14.9	-4.86	2.19e-06	0.00128	-0.35	-0.3	Type 2 diabetes;	chr17:48925027	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.749	rs957557	ENSG00000270781.1	RP11-501C14.9	-4.86	2.19e-06	0.00128	-0.35	-0.3	Type 2 diabetes;	chr17:48925859	chr17:48899131~48899748:+
SARC	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-4.86	2.19e-06	0.00128	-0.51	-0.3	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
SARC	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-4.86	2.19e-06	0.00128	-0.34	-0.3	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-4.86	2.19e-06	0.00128	-0.34	-0.3	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
SARC	cis	rs10911902	0.643	rs74842753	ENSG00000229739.2	RP11-295K2.3	-4.86	2.19e-06	0.00129	-0.44	-0.3	Schizophrenia;	chr1:186390059	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs17491733	ENSG00000229739.2	RP11-295K2.3	-4.86	2.19e-06	0.00129	-0.44	-0.3	Schizophrenia;	chr1:186402168	chr1:186435161~186470291:+
SARC	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	4.86	2.19e-06	0.00129	0.28	0.3	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	4.86	2.19e-06	0.00129	0.28	0.3	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	4.86	2.19e-06	0.00129	0.28	0.3	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
SARC	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	4.86	2.2e-06	0.00129	0.33	0.3	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
SARC	cis	rs1707322	0.656	rs2991981	ENSG00000281133.1	AL355480.3	4.86	2.2e-06	0.00129	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45580892~45580996:-
SARC	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-4.86	2.2e-06	0.00129	-0.31	-0.3	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
SARC	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	4.86	2.2e-06	0.00129	0.33	0.3	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
SARC	cis	rs2933343	1	rs789213	ENSG00000261159.1	RP11-723O4.9	-4.86	2.21e-06	0.00129	-0.36	-0.3	IgG glycosylation;	chr3:128897516	chr3:128859716~128860526:-
SARC	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-4.86	2.21e-06	0.00129	-0.34	-0.3	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
SARC	cis	rs10911902	0.643	rs3766699	ENSG00000229739.2	RP11-295K2.3	-4.85	2.21e-06	0.0013	-0.44	-0.3	Schizophrenia;	chr1:186381179	chr1:186435161~186470291:+
SARC	cis	rs4654783	0.627	rs1046310	ENSG00000228397.1	RP1-224A6.3	4.85	2.22e-06	0.0013	0.34	0.3	Endometriosis;	chr1:22117394	chr1:22023994~22024968:-
SARC	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-4.85	2.22e-06	0.0013	-0.27	-0.3	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
SARC	cis	rs7772486	0.727	rs6941429	ENSG00000270638.1	RP3-466P17.1	4.85	2.22e-06	0.0013	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs857881	ENSG00000270638.1	RP3-466P17.1	-4.85	2.22e-06	0.0013	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145735570~145737218:+
SARC	cis	rs2274273	0.87	rs1109170	ENSG00000258413.1	RP11-665C16.6	-4.85	2.22e-06	0.0013	-0.35	-0.3	Protein biomarker;	chr14:55319070	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.837	rs10141483	ENSG00000258413.1	RP11-665C16.6	-4.85	2.22e-06	0.0013	-0.35	-0.3	Protein biomarker;	chr14:55320153	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.837	rs10131913	ENSG00000258413.1	RP11-665C16.6	-4.85	2.22e-06	0.0013	-0.35	-0.3	Protein biomarker;	chr14:55320702	chr14:55262767~55272075:-
SARC	cis	rs6991838	0.778	rs13261559	ENSG00000200714.1	Y_RNA	4.85	2.22e-06	0.0013	0.32	0.3	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.778	rs7843697	ENSG00000200714.1	Y_RNA	4.85	2.22e-06	0.0013	0.32	0.3	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65592731~65592820:+
SARC	cis	rs6991838	0.778	rs7843724	ENSG00000200714.1	Y_RNA	4.85	2.22e-06	0.0013	0.32	0.3	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65592731~65592820:+
SARC	cis	rs2803122	0.871	rs10733360	ENSG00000273226.1	RP11-513M16.8	-4.85	2.22e-06	0.0013	-0.29	-0.3	Pulse pressure;	chr9:19221580	chr9:19375451~19375996:+
SARC	cis	rs2933343	0.7	rs1683777	ENSG00000261159.1	RP11-723O4.9	4.85	2.23e-06	0.0013	0.32	0.3	IgG glycosylation;	chr3:128906037	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.7	rs1680788	ENSG00000261159.1	RP11-723O4.9	4.85	2.23e-06	0.0013	0.32	0.3	IgG glycosylation;	chr3:128906475	chr3:128859716~128860526:-
SARC	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-4.85	2.23e-06	0.0013	-0.34	-0.3	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
SARC	cis	rs526231	0.726	rs2288789	ENSG00000175749.11	EIF3KP1	4.85	2.23e-06	0.0013	0.4	0.3	Primary biliary cholangitis;	chr5:103264823	chr5:103032376~103033031:+
SARC	cis	rs394563	0.602	rs409111	ENSG00000231760.4	RP11-350J20.5	4.85	2.23e-06	0.0013	0.39	0.3	Dupuytren's disease;	chr6:149445724	chr6:149796151~149826294:-
SARC	cis	rs394563	0.602	rs409099	ENSG00000231760.4	RP11-350J20.5	4.85	2.23e-06	0.0013	0.39	0.3	Dupuytren's disease;	chr6:149445727	chr6:149796151~149826294:-
SARC	cis	rs4372836	0.504	rs13382966	ENSG00000226833.4	AC097724.3	4.85	2.23e-06	0.0013	0.25	0.3	Body mass index;	chr2:28846016	chr2:28708953~28736205:-
SARC	cis	rs7338174	0.655	rs9316535	ENSG00000236778.6	INTS6-AS1	4.85	2.23e-06	0.00131	0.57	0.3	Mitochondrial DNA levels;	chr13:51329329	chr13:51452367~51552364:+
SARC	cis	rs10911902	0.643	rs75856021	ENSG00000229739.2	RP11-295K2.3	-4.85	2.23e-06	0.00131	-0.44	-0.3	Schizophrenia;	chr1:186405853	chr1:186435161~186470291:+
SARC	cis	rs41369048	0.669	rs111238725	ENSG00000238078.1	LINC01352	-4.85	2.24e-06	0.00131	-0.46	-0.3	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220860320	chr1:220829255~220832429:+
SARC	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	4.85	2.24e-06	0.00131	0.31	0.3	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
SARC	cis	rs4862750	0.872	rs1991254	ENSG00000250971.1	RP11-696F12.1	4.85	2.24e-06	0.00131	0.38	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186954221	chr4:187060099~187060930:+
SARC	cis	rs1865760	0.516	rs9393683	ENSG00000272810.1	U91328.22	-4.85	2.24e-06	0.00131	-0.29	-0.3	Height;	chr6:26065970	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.516	rs9295684	ENSG00000272810.1	U91328.22	-4.85	2.24e-06	0.00131	-0.29	-0.3	Height;	chr6:26069441	chr6:26013241~26013757:+
SARC	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	4.85	2.24e-06	0.00131	0.32	0.3	Height;	chr3:53072864	chr3:53064283~53065091:-
SARC	cis	rs2404602	0.598	rs11855999	ENSG00000259422.1	RP11-593F23.1	-4.85	2.25e-06	0.00131	-0.39	-0.3	Blood metabolite levels;	chr15:76334992	chr15:76174891~76181486:-
SARC	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-4.85	2.25e-06	0.00131	-0.34	-0.3	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
SARC	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	4.85	2.25e-06	0.00131	0.36	0.3	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
SARC	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-4.85	2.25e-06	0.00132	-0.31	-0.3	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
SARC	cis	rs2179367	0.881	rs2744432	ENSG00000231760.4	RP11-350J20.5	-4.85	2.25e-06	0.00132	-0.39	-0.3	Dupuytren's disease;	chr6:149422735	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	4.85	2.25e-06	0.00132	0.28	0.3	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	4.85	2.25e-06	0.00132	0.28	0.3	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	4.85	2.25e-06	0.00132	0.28	0.3	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	4.85	2.25e-06	0.00132	0.28	0.3	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	4.85	2.25e-06	0.00132	0.28	0.3	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	4.85	2.25e-06	0.00132	0.28	0.3	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	4.85	2.25e-06	0.00132	0.28	0.3	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	4.85	2.25e-06	0.00132	0.28	0.3	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	4.85	2.25e-06	0.00132	0.28	0.3	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
SARC	cis	rs1707322	0.717	rs1135812	ENSG00000281133.1	AL355480.3	-4.85	2.26e-06	0.00132	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs6703748	ENSG00000281133.1	AL355480.3	-4.85	2.26e-06	0.00132	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45580892~45580996:-
SARC	cis	rs4713118	0.824	rs7759217	ENSG00000219392.1	RP1-265C24.5	-4.85	2.26e-06	0.00132	-0.42	-0.3	Parkinson's disease;	chr6:27762684	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.784	rs9468219	ENSG00000219392.1	RP1-265C24.5	-4.85	2.26e-06	0.00132	-0.42	-0.3	Parkinson's disease;	chr6:27763976	chr6:28115628~28116551:+
SARC	cis	rs2239557	1	rs2358633	ENSG00000259065.1	RP5-1021I20.1	4.85	2.26e-06	0.00132	0.35	0.3	Common traits (Other);	chr14:74180715	chr14:73787360~73803270:+
SARC	cis	rs42490	0.506	rs160429	ENSG00000251136.7	RP11-37B2.1	4.85	2.26e-06	0.00132	0.33	0.3	Leprosy;	chr8:89661255	chr8:89609409~89757727:-
SARC	cis	rs7809950	1	rs2520260	ENSG00000238832.1	snoU109	-4.85	2.27e-06	0.00132	-0.35	-0.3	Coronary artery disease;	chr7:107532349	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs12668402	ENSG00000238832.1	snoU109	-4.85	2.27e-06	0.00132	-0.35	-0.3	Coronary artery disease;	chr7:107532575	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.953	rs2520263	ENSG00000238832.1	snoU109	-4.85	2.27e-06	0.00132	-0.35	-0.3	Coronary artery disease;	chr7:107538674	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs2520264	ENSG00000238832.1	snoU109	-4.85	2.27e-06	0.00132	-0.35	-0.3	Coronary artery disease;	chr7:107538899	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.773	rs62483722	ENSG00000238832.1	snoU109	-4.85	2.27e-06	0.00132	-0.35	-0.3	Coronary artery disease;	chr7:107545904	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.906	rs62483723	ENSG00000238832.1	snoU109	-4.85	2.27e-06	0.00132	-0.35	-0.3	Coronary artery disease;	chr7:107545913	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.953	rs2520267	ENSG00000238832.1	snoU109	-4.85	2.27e-06	0.00132	-0.35	-0.3	Coronary artery disease;	chr7:107547052	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs2712214	ENSG00000238832.1	snoU109	-4.85	2.27e-06	0.00132	-0.35	-0.3	Coronary artery disease;	chr7:107547586	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs2712215	ENSG00000238832.1	snoU109	-4.85	2.27e-06	0.00132	-0.35	-0.3	Coronary artery disease;	chr7:107547762	chr7:107603363~107603507:+
SARC	cis	rs7216064	0.953	rs11079705	ENSG00000278219.1	AC145343.1	-4.85	2.27e-06	0.00132	-0.38	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839336	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs11079706	ENSG00000278219.1	AC145343.1	-4.85	2.27e-06	0.00132	-0.38	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839354	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.953	rs80135947	ENSG00000278219.1	AC145343.1	-4.85	2.27e-06	0.00132	-0.38	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839885	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs8082512	ENSG00000278219.1	AC145343.1	-4.85	2.27e-06	0.00132	-0.38	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67840943	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.953	rs8073510	ENSG00000278219.1	AC145343.1	-4.85	2.27e-06	0.00132	-0.38	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67843094	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.953	rs11871285	ENSG00000278219.1	AC145343.1	-4.85	2.27e-06	0.00132	-0.38	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67844693	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs62084213	ENSG00000278219.1	AC145343.1	-4.85	2.27e-06	0.00132	-0.38	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67845900	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs7224923	ENSG00000278219.1	AC145343.1	-4.85	2.27e-06	0.00132	-0.38	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67846149	chr17:68101538~68101639:+
SARC	cis	rs79349575	0.783	rs62075818	ENSG00000270781.1	RP11-501C14.9	-4.85	2.27e-06	0.00132	-0.35	-0.3	Type 2 diabetes;	chr17:48904965	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs9912829	ENSG00000270781.1	RP11-501C14.9	-4.85	2.27e-06	0.00132	-0.35	-0.3	Type 2 diabetes;	chr17:48905387	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs62075820	ENSG00000270781.1	RP11-501C14.9	-4.85	2.27e-06	0.00132	-0.35	-0.3	Type 2 diabetes;	chr17:48905809	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs4294857	ENSG00000270781.1	RP11-501C14.9	-4.85	2.27e-06	0.00132	-0.35	-0.3	Type 2 diabetes;	chr17:48906029	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs61576918	ENSG00000270781.1	RP11-501C14.9	-4.85	2.27e-06	0.00132	-0.35	-0.3	Type 2 diabetes;	chr17:48908231	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.729	rs62075824	ENSG00000270781.1	RP11-501C14.9	-4.85	2.27e-06	0.00132	-0.35	-0.3	Type 2 diabetes;	chr17:48909317	chr17:48899131~48899748:+
SARC	cis	rs4372836	0.504	rs13030945	ENSG00000226833.4	AC097724.3	4.85	2.27e-06	0.00132	0.25	0.3	Body mass index;	chr2:28864933	chr2:28708953~28736205:-
SARC	cis	rs11118620	0.81	rs1603047	ENSG00000257551.1	HLX-AS1	4.85	2.27e-06	0.00132	0.36	0.3	Heart failure;	chr1:220849953	chr1:220832763~220880140:-
SARC	cis	rs890448	0.796	rs2433310	ENSG00000254531.1	FLJ20021	4.85	2.27e-06	0.00132	0.33	0.3	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101431756	chr4:101347780~101348883:+
SARC	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	4.85	2.27e-06	0.00133	0.28	0.3	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
SARC	cis	rs1707322	0.691	rs61784803	ENSG00000281133.1	AL355480.3	4.85	2.28e-06	0.00133	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.663	rs3935296	ENSG00000281133.1	AL355480.3	4.85	2.28e-06	0.00133	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs11211163	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs12037803	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs11211165	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs11211166	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs10789470	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs61784796	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs10749856	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs10890344	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs4564187	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.752	rs28438704	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs28442079	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs28817701	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.691	rs28495425	ENSG00000281133.1	AL355480.3	-4.85	2.28e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45580892~45580996:-
SARC	cis	rs899997	0.906	rs1994018	ENSG00000261143.1	ADAMTS7P3	-4.85	2.28e-06	0.00133	-0.53	-0.3	Coronary artery disease or large artery stroke;	chr15:78733242	chr15:77976042~77993057:+
SARC	cis	rs7216064	1	rs11079707	ENSG00000265055.1	AC145343.2	-4.85	2.28e-06	0.00133	-0.38	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839501	chr17:68096046~68101474:-
SARC	cis	rs79349575	0.783	rs55771415	ENSG00000270781.1	RP11-501C14.9	-4.85	2.29e-06	0.00133	-0.35	-0.3	Type 2 diabetes;	chr17:48922575	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs2088139	ENSG00000270781.1	RP11-501C14.9	-4.85	2.29e-06	0.00133	-0.35	-0.3	Type 2 diabetes;	chr17:48922748	chr17:48899131~48899748:+
SARC	cis	rs10911902	0.643	rs79080293	ENSG00000229739.2	RP11-295K2.3	-4.85	2.29e-06	0.00133	-0.44	-0.3	Schizophrenia;	chr1:186379546	chr1:186435161~186470291:+
SARC	cis	rs1707322	0.655	rs3014240	ENSG00000281133.1	AL355480.3	4.85	2.29e-06	0.00133	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.686	rs3014235	ENSG00000281133.1	AL355480.3	4.85	2.29e-06	0.00133	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.656	rs9429172	ENSG00000281133.1	AL355480.3	4.85	2.29e-06	0.00133	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.717	rs1135850	ENSG00000281133.1	AL355480.3	-4.85	2.29e-06	0.00133	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45580892~45580996:-
SARC	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	4.85	2.29e-06	0.00133	0.38	0.3	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
SARC	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	4.85	2.29e-06	0.00133	0.38	0.3	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
SARC	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	4.85	2.29e-06	0.00134	0.28	0.3	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
SARC	cis	rs7246657	1	rs7246657	ENSG00000276846.1	CTD-3220F14.3	-4.85	2.29e-06	0.00134	-0.41	-0.3	Coronary artery calcification;	chr19:37256206	chr19:37314868~37315620:-
SARC	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-4.85	2.29e-06	0.00134	-0.34	-0.3	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
SARC	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-4.85	2.29e-06	0.00134	-0.27	-0.3	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
SARC	cis	rs79349575	0.756	rs2643361	ENSG00000270781.1	RP11-501C14.9	-4.85	2.3e-06	0.00134	-0.35	-0.3	Type 2 diabetes;	chr17:48900100	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.749	rs2546491	ENSG00000270781.1	RP11-501C14.9	-4.85	2.3e-06	0.00134	-0.35	-0.3	Type 2 diabetes;	chr17:48900554	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs962272	ENSG00000270781.1	RP11-501C14.9	-4.85	2.3e-06	0.00134	-0.35	-0.3	Type 2 diabetes;	chr17:48900921	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs903567	ENSG00000270781.1	RP11-501C14.9	-4.85	2.3e-06	0.00134	-0.35	-0.3	Type 2 diabetes;	chr17:48902956	chr17:48899131~48899748:+
SARC	cis	rs526231	0.963	rs12187443	ENSG00000175749.11	EIF3KP1	4.85	2.3e-06	0.00134	0.38	0.3	Primary biliary cholangitis;	chr5:103324699	chr5:103032376~103033031:+
SARC	cis	rs4862750	0.914	rs1346127	ENSG00000250971.1	RP11-696F12.1	-4.85	2.3e-06	0.00134	-0.38	-0.3	Lobe attachment (rater-scored or self-reported);	chr4:186955235	chr4:187060099~187060930:+
SARC	cis	rs4372836	0.928	rs55836936	ENSG00000226833.4	AC097724.3	-4.85	2.3e-06	0.00134	-0.29	-0.3	Body mass index;	chr2:28699967	chr2:28708953~28736205:-
SARC	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	4.85	2.3e-06	0.00134	0.31	0.3	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
SARC	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-4.85	2.3e-06	0.00134	-0.31	-0.3	Height;	chr3:53084188	chr3:53064283~53065091:-
SARC	cis	rs17270561	0.609	rs1937127	ENSG00000272462.2	U91328.19	4.85	2.3e-06	0.00134	0.3	0.3	Iron status biomarkers;	chr6:25769644	chr6:25992662~26001775:+
SARC	cis	rs7772486	0.686	rs2072911	ENSG00000270638.1	RP3-466P17.1	-4.85	2.3e-06	0.00134	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145735570~145737218:+
SARC	cis	rs4713118	0.539	rs510987	ENSG00000219392.1	RP1-265C24.5	-4.85	2.31e-06	0.00134	-0.41	-0.3	Parkinson's disease;	chr6:27879739	chr6:28115628~28116551:+
SARC	cis	rs17270561	0.609	rs1165181	ENSG00000272462.2	U91328.19	-4.85	2.31e-06	0.00134	-0.27	-0.3	Iron status biomarkers;	chr6:25825162	chr6:25992662~26001775:+
SARC	cis	rs853679	0.513	rs9468296	ENSG00000272009.1	RP1-313I6.12	-4.85	2.31e-06	0.00134	-0.35	-0.3	Depression;	chr6:28145952	chr6:28078792~28081130:-
SARC	cis	rs9828933	0.766	rs704372	ENSG00000280620.1	SCAANT1	-4.84	2.31e-06	0.00135	-0.42	-0.3	Type 2 diabetes;	chr3:63881777	chr3:63911518~63911772:-
SARC	cis	rs8062405	0.823	rs7202948	ENSG00000251417.2	RP11-1348G14.4	-4.84	2.31e-06	0.00135	-0.28	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28802743~28817828:+
SARC	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	4.84	2.31e-06	0.00135	0.34	0.3	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
SARC	cis	rs524281	0.861	rs471484	ENSG00000255320.1	RP11-755F10.1	4.84	2.31e-06	0.00135	0.42	0.3	Electroencephalogram traits;	chr11:66187673	chr11:66244840~66246239:-
SARC	cis	rs10788972	0.815	rs9651202	ENSG00000225183.1	RP4-758J24.4	-4.84	2.32e-06	0.00135	-0.36	-0.3	Parkinson disease and lewy body pathology;	chr1:54087534	chr1:54089856~54090093:+
SARC	cis	rs10788972	0.815	rs1981039	ENSG00000225183.1	RP4-758J24.4	-4.84	2.32e-06	0.00135	-0.36	-0.3	Parkinson disease and lewy body pathology;	chr1:54089732	chr1:54089856~54090093:+
SARC	cis	rs7430456	0.81	rs6443489	ENSG00000225790.1	RP11-2L8.1	-4.84	2.32e-06	0.00135	-0.31	-0.3	Breast cancer;	chr3:177737489	chr3:177934823~177937662:+
SARC	cis	rs7430456	0.874	rs7428501	ENSG00000225790.1	RP11-2L8.1	-4.84	2.32e-06	0.00135	-0.31	-0.3	Breast cancer;	chr3:177751974	chr3:177934823~177937662:+
SARC	cis	rs1823874	0.71	rs2085087	ENSG00000182397.13	DNM1P46	-4.84	2.32e-06	0.00135	-0.34	-0.3	IgG glycosylation;	chr15:99819938	chr15:99790156~99806927:-
SARC	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	4.84	2.32e-06	0.00135	0.38	0.3	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
SARC	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	4.84	2.32e-06	0.00135	0.31	0.3	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
SARC	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	4.84	2.32e-06	0.00135	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	4.84	2.32e-06	0.00135	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	4.84	2.32e-06	0.00135	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	4.84	2.32e-06	0.00135	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	4.84	2.32e-06	0.00135	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	4.84	2.32e-06	0.00135	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
SARC	cis	rs607541	0.85	rs12594997	ENSG00000259520.4	CTD-2651B20.3	-4.84	2.33e-06	0.00135	-0.6	-0.3	Obesity-related traits;	chr15:45637226	chr15:45251580~45279251:-
SARC	cis	rs2239557	1	rs10150201	ENSG00000259065.1	RP5-1021I20.1	4.84	2.33e-06	0.00135	0.35	0.3	Common traits (Other);	chr14:74182454	chr14:73787360~73803270:+
SARC	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-4.84	2.33e-06	0.00135	-0.36	-0.3	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
SARC	cis	rs1799949	0.965	rs9646413	ENSG00000267681.1	CTD-3199J23.6	-4.84	2.33e-06	0.00135	-0.35	-0.3	Menopause (age at onset);	chr17:43348789	chr17:43144956~43145255:+
SARC	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	4.84	2.33e-06	0.00135	0.27	0.3	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
SARC	cis	rs7712401	0.525	rs246312	ENSG00000263432.2	RN7SL689P	4.84	2.33e-06	0.00135	0.38	0.3	Mean platelet volume;	chr5:122933760	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs246308	ENSG00000263432.2	RN7SL689P	4.84	2.33e-06	0.00135	0.38	0.3	Mean platelet volume;	chr5:122934395	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.601	rs30047	ENSG00000263432.2	RN7SL689P	4.84	2.33e-06	0.00135	0.38	0.3	Mean platelet volume;	chr5:122934829	chr5:123022487~123022783:-
SARC	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-4.84	2.33e-06	0.00135	-0.37	-0.3	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
SARC	cis	rs1134634	0.52	rs7682586	ENSG00000273133.1	RP11-799M12.2	-4.84	2.34e-06	0.00136	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15624620	chr4:15563698~15564253:-
SARC	cis	rs1134634	0.52	rs12645849	ENSG00000273133.1	RP11-799M12.2	-4.84	2.34e-06	0.00136	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15627457	chr4:15563698~15564253:-
SARC	cis	rs1134634	0.52	rs4698403	ENSG00000273133.1	RP11-799M12.2	-4.84	2.34e-06	0.00136	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15628204	chr4:15563698~15564253:-
SARC	cis	rs1134634	0.52	rs10022610	ENSG00000273133.1	RP11-799M12.2	-4.84	2.34e-06	0.00136	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15635864	chr4:15563698~15564253:-
SARC	cis	rs1134634	0.52	rs73127647	ENSG00000273133.1	RP11-799M12.2	-4.84	2.34e-06	0.00136	-0.39	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15639969	chr4:15563698~15564253:-
SARC	cis	rs1075232	1	rs72722829	ENSG00000215302.7	CTD-3092A11.1	-4.84	2.34e-06	0.00136	-0.63	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30470779~30507623:+
SARC	cis	rs1075232	1	rs16956707	ENSG00000215302.7	CTD-3092A11.1	-4.84	2.34e-06	0.00136	-0.63	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30470779~30507623:+
SARC	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-4.84	2.34e-06	0.00136	-0.31	-0.3	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
SARC	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	4.84	2.34e-06	0.00136	0.31	0.3	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
SARC	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	4.84	2.34e-06	0.00136	0.31	0.3	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
SARC	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	4.84	2.34e-06	0.00136	0.34	0.3	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
SARC	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	4.84	2.34e-06	0.00136	0.44	0.3	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
SARC	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	4.84	2.34e-06	0.00136	0.44	0.3	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
SARC	cis	rs2280018	0.526	rs1510148	ENSG00000188599.16	NPIPP1	-4.84	2.35e-06	0.00136	-0.3	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15104312~15123498:-
SARC	cis	rs7615952	0.611	rs72979452	ENSG00000171084.14	FAM86JP	4.84	2.35e-06	0.00136	0.63	0.3	Blood pressure (smoking interaction);	chr3:126037335	chr3:125916620~125930024:+
SARC	cis	rs2836950	0.565	rs2150414	ENSG00000255568.3	BRWD1-AS2	-4.84	2.35e-06	0.00136	-0.28	-0.3	Menarche (age at onset);	chr21:39243062	chr21:39313935~39314962:+
SARC	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	4.84	2.35e-06	0.00137	0.36	0.3	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
SARC	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-4.84	2.36e-06	0.00137	-0.3	-0.3	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
SARC	cis	rs6991838	0.806	rs17302392	ENSG00000200714.1	Y_RNA	4.84	2.36e-06	0.00137	0.31	0.3	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65592731~65592820:+
SARC	cis	rs1823874	0.677	rs2100446	ENSG00000182397.13	DNM1P46	-4.84	2.36e-06	0.00137	-0.34	-0.3	IgG glycosylation;	chr15:99820169	chr15:99790156~99806927:-
SARC	cis	rs1823874	0.677	rs2100447	ENSG00000182397.13	DNM1P46	-4.84	2.36e-06	0.00137	-0.34	-0.3	IgG glycosylation;	chr15:99820188	chr15:99790156~99806927:-
SARC	cis	rs1823874	0.71	rs56160817	ENSG00000182397.13	DNM1P46	-4.84	2.36e-06	0.00137	-0.34	-0.3	IgG glycosylation;	chr15:99820472	chr15:99790156~99806927:-
SARC	cis	rs1823874	0.71	rs56186545	ENSG00000182397.13	DNM1P46	-4.84	2.36e-06	0.00137	-0.34	-0.3	IgG glycosylation;	chr15:99820554	chr15:99790156~99806927:-
SARC	cis	rs1823874	0.71	rs55947799	ENSG00000182397.13	DNM1P46	-4.84	2.36e-06	0.00137	-0.34	-0.3	IgG glycosylation;	chr15:99820700	chr15:99790156~99806927:-
SARC	cis	rs1823874	0.71	rs4965543	ENSG00000182397.13	DNM1P46	-4.84	2.36e-06	0.00137	-0.34	-0.3	IgG glycosylation;	chr15:99821050	chr15:99790156~99806927:-
SARC	cis	rs4713118	0.513	rs200971	ENSG00000219392.1	RP1-265C24.5	-4.84	2.36e-06	0.00137	-0.41	-0.3	Parkinson's disease;	chr6:27891126	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.539	rs200967	ENSG00000219392.1	RP1-265C24.5	-4.84	2.36e-06	0.00137	-0.41	-0.3	Parkinson's disease;	chr6:27894349	chr6:28115628~28116551:+
SARC	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-4.84	2.36e-06	0.00137	-0.37	-0.3	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
SARC	cis	rs1061377	0.748	rs1036034	ENSG00000249207.1	RP11-360F5.1	-4.84	2.36e-06	0.00137	-0.33	-0.3	Uric acid levels;	chr4:39105299	chr4:39112677~39126818:-
SARC	cis	rs899997	0.906	rs6495317	ENSG00000261143.1	ADAMTS7P3	-4.84	2.36e-06	0.00137	-0.46	-0.3	Coronary artery disease or large artery stroke;	chr15:78699374	chr15:77976042~77993057:+
SARC	cis	rs7809950	1	rs7786801	ENSG00000238832.1	snoU109	-4.84	2.36e-06	0.00137	-0.35	-0.3	Coronary artery disease;	chr7:107445444	chr7:107603363~107603507:+
SARC	cis	rs4713118	0.669	rs200997	ENSG00000216901.1	AL022393.7	4.84	2.37e-06	0.00137	0.4	0.3	Parkinson's disease;	chr6:27844037	chr6:28176188~28176674:+
SARC	cis	rs17270561	0.609	rs12529272	ENSG00000272810.1	U91328.22	-4.84	2.37e-06	0.00137	-0.31	-0.3	Iron status biomarkers;	chr6:25731114	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs9393659	ENSG00000272810.1	U91328.22	-4.84	2.37e-06	0.00137	-0.31	-0.3	Iron status biomarkers;	chr6:25731130	chr6:26013241~26013757:+
SARC	cis	rs1075265	0.508	rs12621225	ENSG00000233266.1	HMGB1P31	4.84	2.37e-06	0.00137	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54051334~54051760:+
SARC	cis	rs1707322	0.685	rs56177313	ENSG00000281133.1	AL355480.3	-4.84	2.37e-06	0.00137	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs11211178	ENSG00000281133.1	AL355480.3	-4.84	2.37e-06	0.00137	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45580892~45580996:-
SARC	cis	rs875971	0.619	rs10278371	ENSG00000236529.1	RP13-254B10.1	-4.84	2.37e-06	0.00137	-0.31	-0.3	Aortic root size;	chr7:66586553	chr7:65840212~65840596:+
SARC	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-4.84	2.37e-06	0.00137	-0.31	-0.3	Height;	chr3:53093751	chr3:53064283~53065091:-
SARC	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-4.84	2.37e-06	0.00138	-0.48	-0.3	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
SARC	cis	rs6570726	0.791	rs6570692	ENSG00000270638.1	RP3-466P17.1	4.84	2.38e-06	0.00138	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs6902410	ENSG00000270638.1	RP3-466P17.1	4.84	2.38e-06	0.00138	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs9322029	ENSG00000270638.1	RP3-466P17.1	4.84	2.38e-06	0.00138	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs9403730	ENSG00000270638.1	RP3-466P17.1	4.84	2.38e-06	0.00138	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145735570~145737218:+
SARC	cis	rs1707322	0.752	rs11211168	ENSG00000281133.1	AL355480.3	-4.84	2.38e-06	0.00138	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45580892~45580996:-
SARC	cis	rs801193	0.967	rs2707853	ENSG00000236529.1	RP13-254B10.1	4.84	2.38e-06	0.00138	0.32	0.3	Aortic root size;	chr7:66749023	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs2659889	ENSG00000236529.1	RP13-254B10.1	4.84	2.38e-06	0.00138	0.32	0.3	Aortic root size;	chr7:66752125	chr7:65840212~65840596:+
SARC	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	4.84	2.38e-06	0.00138	0.38	0.3	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
SARC	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	4.84	2.38e-06	0.00138	0.38	0.3	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
SARC	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	4.84	2.38e-06	0.00138	0.38	0.3	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
SARC	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-4.84	2.38e-06	0.00138	-0.34	-0.3	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
SARC	cis	rs10754283	0.967	rs10801764	ENSG00000231613.1	RP5-943J3.1	4.84	2.38e-06	0.00138	0.3	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89656192	chr1:89788914~89790492:+
SARC	cis	rs853679	0.723	rs1736904	ENSG00000219392.1	RP1-265C24.5	-4.84	2.38e-06	0.00138	-0.41	-0.3	Depression;	chr6:28251492	chr6:28115628~28116551:+
SARC	cis	rs2933343	1	rs1683782	ENSG00000261159.1	RP11-723O4.9	4.84	2.38e-06	0.00138	0.36	0.3	IgG glycosylation;	chr3:128921434	chr3:128859716~128860526:-
SARC	cis	rs9818758	0.607	rs73084135	ENSG00000225399.4	RP11-3B7.1	-4.84	2.38e-06	0.00138	-0.57	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49234785	chr3:49260085~49261316:+
SARC	cis	rs875971	0.642	rs35526611	ENSG00000236529.1	RP13-254B10.1	-4.84	2.38e-06	0.00138	-0.31	-0.3	Aortic root size;	chr7:66629021	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs3800812	ENSG00000236529.1	RP13-254B10.1	4.84	2.39e-06	0.00138	0.32	0.3	Aortic root size;	chr7:66758474	chr7:65840212~65840596:+
SARC	cis	rs2404602	0.622	rs2003344	ENSG00000259422.1	RP11-593F23.1	-4.84	2.39e-06	0.00138	-0.4	-0.3	Blood metabolite levels;	chr15:76339960	chr15:76174891~76181486:-
SARC	cis	rs160451	0.934	rs160422	ENSG00000251136.7	RP11-37B2.1	4.84	2.39e-06	0.00138	0.33	0.3	Leprosy;	chr8:89657610	chr8:89609409~89757727:-
SARC	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-4.84	2.39e-06	0.00138	-0.33	-0.3	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-4.84	2.39e-06	0.00138	-0.33	-0.3	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
SARC	cis	rs755249	0.565	rs9729677	ENSG00000182109.6	RP11-69E11.4	-4.84	2.39e-06	0.00138	-0.3	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39522280~39546187:-
SARC	cis	rs9868809	0.772	rs73078349	ENSG00000225399.4	RP11-3B7.1	-4.84	2.39e-06	0.00139	-0.64	-0.3	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48650681	chr3:49260085~49261316:+
SARC	cis	rs10911902	0.643	rs3766705	ENSG00000229739.2	RP11-295K2.3	-4.84	2.39e-06	0.00139	-0.44	-0.3	Schizophrenia;	chr1:186342680	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs16825201	ENSG00000229739.2	RP11-295K2.3	-4.84	2.39e-06	0.00139	-0.44	-0.3	Schizophrenia;	chr1:186344698	chr1:186435161~186470291:+
SARC	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-4.84	2.39e-06	0.00139	-0.38	-0.3	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
SARC	cis	rs1823874	0.71	rs2085086	ENSG00000182397.13	DNM1P46	-4.84	2.4e-06	0.00139	-0.34	-0.3	IgG glycosylation;	chr15:99819887	chr15:99790156~99806927:-
SARC	cis	rs1707322	0.752	rs6678444	ENSG00000281133.1	AL355480.3	-4.84	2.4e-06	0.00139	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45580892~45580996:-
SARC	cis	rs6570726	0.791	rs9497357	ENSG00000270638.1	RP3-466P17.1	4.84	2.4e-06	0.00139	0.25	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.764	rs4263604	ENSG00000270638.1	RP3-466P17.1	4.84	2.4e-06	0.00139	0.25	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145735570~145737218:+
SARC	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	4.84	2.4e-06	0.00139	0.5	0.3	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
SARC	cis	rs1799949	0.965	rs8071278	ENSG00000267681.1	CTD-3199J23.6	-4.84	2.41e-06	0.00139	-0.33	-0.3	Menopause (age at onset);	chr17:43041893	chr17:43144956~43145255:+
SARC	cis	rs7246657	1	rs35398388	ENSG00000276846.1	CTD-3220F14.3	4.84	2.41e-06	0.00139	0.42	0.3	Coronary artery calcification;	chr19:37249456	chr19:37314868~37315620:-
SARC	cis	rs7246657	1	rs7247672	ENSG00000276846.1	CTD-3220F14.3	4.84	2.41e-06	0.00139	0.42	0.3	Coronary artery calcification;	chr19:37253026	chr19:37314868~37315620:-
SARC	cis	rs7246657	1	rs8110011	ENSG00000276846.1	CTD-3220F14.3	4.84	2.41e-06	0.00139	0.42	0.3	Coronary artery calcification;	chr19:37254911	chr19:37314868~37315620:-
SARC	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	4.84	2.41e-06	0.00139	0.35	0.3	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
SARC	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-4.84	2.41e-06	0.00139	-0.31	-0.3	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
SARC	cis	rs910316	0.789	rs12894419	ENSG00000279594.1	RP11-950C14.10	4.84	2.42e-06	0.0014	0.33	0.3	Height;	chr14:75005099	chr14:75011269~75012851:-
SARC	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	4.84	2.42e-06	0.0014	0.32	0.3	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
SARC	cis	rs1799949	0.894	rs36062488	ENSG00000267681.1	CTD-3199J23.6	4.83	2.42e-06	0.0014	0.33	0.3	Menopause (age at onset);	chr17:43185455	chr17:43144956~43145255:+
SARC	cis	rs73186030	0.925	rs1801725	ENSG00000272758.4	RP11-299J3.8	4.83	2.42e-06	0.0014	0.43	0.3	Serum parathyroid hormone levels;	chr3:122284910	chr3:122416207~122443180:+
SARC	cis	rs79349575	0.745	rs170319	ENSG00000270781.1	RP11-501C14.9	-4.83	2.42e-06	0.0014	-0.35	-0.3	Type 2 diabetes;	chr17:48914169	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs318090	ENSG00000270781.1	RP11-501C14.9	-4.83	2.42e-06	0.0014	-0.35	-0.3	Type 2 diabetes;	chr17:48914390	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.721	rs3744608	ENSG00000270781.1	RP11-501C14.9	-4.83	2.42e-06	0.0014	-0.35	-0.3	Type 2 diabetes;	chr17:48915871	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.651	rs4378658	ENSG00000270781.1	RP11-501C14.9	-4.83	2.42e-06	0.0014	-0.35	-0.3	Type 2 diabetes;	chr17:48916008	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs12453374	ENSG00000270781.1	RP11-501C14.9	-4.83	2.42e-06	0.0014	-0.35	-0.3	Type 2 diabetes;	chr17:48917484	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs12453394	ENSG00000270781.1	RP11-501C14.9	-4.83	2.42e-06	0.0014	-0.35	-0.3	Type 2 diabetes;	chr17:48917608	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs62075838	ENSG00000270781.1	RP11-501C14.9	-4.83	2.42e-06	0.0014	-0.35	-0.3	Type 2 diabetes;	chr17:48919070	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs62075839	ENSG00000270781.1	RP11-501C14.9	-4.83	2.42e-06	0.0014	-0.35	-0.3	Type 2 diabetes;	chr17:48919072	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs4255820	ENSG00000270781.1	RP11-501C14.9	-4.83	2.42e-06	0.0014	-0.35	-0.3	Type 2 diabetes;	chr17:48919221	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.811	rs12601072	ENSG00000270781.1	RP11-501C14.9	-4.83	2.42e-06	0.0014	-0.35	-0.3	Type 2 diabetes;	chr17:48920636	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.749	rs58838744	ENSG00000270781.1	RP11-501C14.9	-4.83	2.42e-06	0.0014	-0.35	-0.3	Type 2 diabetes;	chr17:48921540	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.811	rs60708039	ENSG00000270781.1	RP11-501C14.9	-4.83	2.42e-06	0.0014	-0.35	-0.3	Type 2 diabetes;	chr17:48922011	chr17:48899131~48899748:+
SARC	cis	rs755249	0.565	rs7539261	ENSG00000182109.6	RP11-69E11.4	-4.83	2.42e-06	0.0014	-0.3	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39522280~39546187:-
SARC	cis	rs3002142	0.658	rs1053316	ENSG00000272750.1	RP11-378J18.8	4.83	2.42e-06	0.0014	0.46	0.3	LDL peak particle diameter (total fat intake interaction);	chr1:222666496	chr1:222658867~222661512:-
SARC	cis	rs7615952	0.611	rs7632305	ENSG00000248787.1	RP11-666A20.4	-4.83	2.42e-06	0.0014	-0.53	-0.3	Blood pressure (smoking interaction);	chr3:125915924	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.673	rs9841194	ENSG00000248787.1	RP11-666A20.4	-4.83	2.42e-06	0.0014	-0.53	-0.3	Blood pressure (smoking interaction);	chr3:125916896	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.673	rs9289270	ENSG00000248787.1	RP11-666A20.4	-4.83	2.42e-06	0.0014	-0.53	-0.3	Blood pressure (smoking interaction);	chr3:125918136	chr3:125908005~125910272:-
SARC	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	4.83	2.42e-06	0.0014	0.28	0.3	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
SARC	cis	rs7246657	0.943	rs13343471	ENSG00000276846.1	CTD-3220F14.3	4.83	2.43e-06	0.0014	0.42	0.3	Coronary artery calcification;	chr19:37441228	chr19:37314868~37315620:-
SARC	cis	rs7615952	0.534	rs1503072	ENSG00000250012.1	RP11-124N2.1	-4.83	2.43e-06	0.0014	-0.3	-0.3	Blood pressure (smoking interaction);	chr3:126035848	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.599	rs7631268	ENSG00000250012.1	RP11-124N2.1	-4.83	2.43e-06	0.0014	-0.3	-0.3	Blood pressure (smoking interaction);	chr3:126036821	chr3:126084220~126095349:+
SARC	cis	rs6969780	0.915	rs10085570	ENSG00000233429.8	HOTAIRM1	-4.83	2.43e-06	0.0014	-0.41	-0.3	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111569	chr7:27095647~27100265:+
SARC	cis	rs763121	0.889	rs4820335	ENSG00000273076.1	RP3-508I15.22	-4.83	2.43e-06	0.0014	-0.32	-0.3	Menopause (age at onset);	chr22:38539922	chr22:38743495~38743910:+
SARC	cis	rs1799949	0.536	rs4793227	ENSG00000267681.1	CTD-3199J23.6	-4.83	2.44e-06	0.00141	-0.34	-0.3	Menopause (age at onset);	chr17:43334882	chr17:43144956~43145255:+
SARC	cis	rs7216064	0.589	rs7213585	ENSG00000278219.1	AC145343.1	-4.83	2.44e-06	0.00141	-0.34	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68066200	chr17:68101538~68101639:+
SARC	cis	rs7809950	0.678	rs7777950	ENSG00000238832.1	snoU109	-4.83	2.44e-06	0.00141	-0.36	-0.3	Coronary artery disease;	chr7:107364227	chr7:107603363~107603507:+
SARC	cis	rs8081395	0.775	rs2645482	ENSG00000266992.1	DHX40P1	4.83	2.44e-06	0.00141	0.33	0.3	White blood cell count;	chr17:59865754	chr17:59976009~60002384:-
SARC	cis	rs7216064	0.651	rs12947658	ENSG00000278219.1	AC145343.1	4.83	2.44e-06	0.00141	0.33	0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67906890	chr17:68101538~68101639:+
SARC	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	4.83	2.45e-06	0.00141	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	4.83	2.45e-06	0.00141	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
SARC	cis	rs8031584	1	rs35811129	ENSG00000260382.1	RP11-540B6.2	4.83	2.45e-06	0.00141	0.4	0.3	Huntington's disease progression;	chr15:30949143	chr15:30882267~30883231:-
SARC	cis	rs593531	0.513	rs7947911	ENSG00000280269.1	AP000577.2	4.83	2.45e-06	0.00141	0.39	0.3	Neuroticism;	chr11:74312706	chr11:74204869~74205746:+
SARC	cis	rs6600671	0.764	rs6600673	ENSG00000270231.3	NBPF8P	4.83	2.45e-06	0.00141	0.25	0.3	Hip geometry;	chr1:121426988	chr1:120436353~120467739:+
SARC	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	4.83	2.45e-06	0.00141	0.25	0.3	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
SARC	cis	rs875971	0.964	rs160635	ENSG00000237310.1	GS1-124K5.4	4.83	2.45e-06	0.00141	0.31	0.3	Aortic root size;	chr7:66063931	chr7:66493706~66495474:+
SARC	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-4.83	2.46e-06	0.00142	-0.29	-0.3	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
SARC	cis	rs2283792	0.765	rs8139376	ENSG00000224086.5	LL22NC03-86G7.1	-4.83	2.46e-06	0.00142	-0.31	-0.3	Multiple sclerosis;	chr22:21755307	chr22:21938293~21977632:+
SARC	cis	rs1707322	0.717	rs3014246	ENSG00000281133.1	AL355480.3	4.83	2.46e-06	0.00142	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45580892~45580996:-
SARC	cis	rs7615952	0.599	rs60847438	ENSG00000250012.1	RP11-124N2.1	-4.83	2.46e-06	0.00142	-0.3	-0.3	Blood pressure (smoking interaction);	chr3:126027162	chr3:126084220~126095349:+
SARC	cis	rs2562456	0.516	rs56072098	ENSG00000268081.1	RP11-678G14.2	-4.83	2.46e-06	0.00142	-0.44	-0.3	Pain;	chr19:21469158	chr19:21554640~21569237:-
SARC	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-4.83	2.46e-06	0.00142	-0.37	-0.3	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
SARC	cis	rs899997	0.731	rs58717592	ENSG00000261143.1	ADAMTS7P3	-4.83	2.47e-06	0.00142	-0.53	-0.3	Coronary artery disease or large artery stroke;	chr15:78738075	chr15:77976042~77993057:+
SARC	cis	rs2933343	0.951	rs796862	ENSG00000261159.1	RP11-723O4.9	4.83	2.47e-06	0.00142	0.35	0.3	IgG glycosylation;	chr3:128874197	chr3:128859716~128860526:-
SARC	cis	rs2933343	1	rs789227	ENSG00000261159.1	RP11-723O4.9	4.83	2.47e-06	0.00142	0.35	0.3	IgG glycosylation;	chr3:128881742	chr3:128859716~128860526:-
SARC	cis	rs2933343	1	rs789232	ENSG00000261159.1	RP11-723O4.9	4.83	2.47e-06	0.00142	0.35	0.3	IgG glycosylation;	chr3:128884237	chr3:128859716~128860526:-
SARC	cis	rs2933343	1	rs2929859	ENSG00000261159.1	RP11-723O4.9	4.83	2.47e-06	0.00142	0.35	0.3	IgG glycosylation;	chr3:128889498	chr3:128859716~128860526:-
SARC	cis	rs2933343	1	rs1683811	ENSG00000261159.1	RP11-723O4.9	4.83	2.47e-06	0.00142	0.35	0.3	IgG glycosylation;	chr3:128893270	chr3:128859716~128860526:-
SARC	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-4.83	2.47e-06	0.00142	-0.36	-0.3	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
SARC	cis	rs9868809	0.764	rs2633958	ENSG00000225399.4	RP11-3B7.1	4.83	2.48e-06	0.00143	0.61	0.3	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48597999	chr3:49260085~49261316:+
SARC	cis	rs4372836	0.93	rs7607844	ENSG00000226833.4	AC097724.3	4.83	2.48e-06	0.00143	0.3	0.3	Body mass index;	chr2:28748872	chr2:28708953~28736205:-
SARC	cis	rs79349575	0.777	rs28517720	ENSG00000270781.1	RP11-501C14.9	-4.83	2.48e-06	0.00143	-0.35	-0.3	Type 2 diabetes;	chr17:48899394	chr17:48899131~48899748:+
SARC	cis	rs17270561	0.609	rs9348692	ENSG00000272810.1	U91328.22	-4.83	2.49e-06	0.00143	-0.31	-0.3	Iron status biomarkers;	chr6:25720584	chr6:26013241~26013757:+
SARC	cis	rs2274273	0.588	rs2880103	ENSG00000258413.1	RP11-665C16.6	-4.83	2.49e-06	0.00143	-0.39	-0.3	Protein biomarker;	chr14:55271114	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.553	rs56166765	ENSG00000258413.1	RP11-665C16.6	-4.83	2.49e-06	0.00143	-0.39	-0.3	Protein biomarker;	chr14:55271300	chr14:55262767~55272075:-
SARC	cis	rs17270561	0.609	rs1185976	ENSG00000272810.1	U91328.22	4.83	2.49e-06	0.00143	0.28	0.3	Iron status biomarkers;	chr6:25822135	chr6:26013241~26013757:+
SARC	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-4.83	2.49e-06	0.00143	-0.4	-0.3	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-4.83	2.49e-06	0.00143	-0.4	-0.3	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
SARC	cis	rs7615952	0.611	rs12488771	ENSG00000171084.14	FAM86JP	4.83	2.5e-06	0.00144	0.63	0.3	Blood pressure (smoking interaction);	chr3:125981683	chr3:125916620~125930024:+
SARC	cis	rs77204473	1	rs10892040	ENSG00000254851.1	RP11-109L13.1	4.83	2.5e-06	0.00144	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs11216174	ENSG00000254851.1	RP11-109L13.1	4.83	2.5e-06	0.00144	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117135528~117138582:+
SARC	cis	rs77204473	1	rs11216175	ENSG00000254851.1	RP11-109L13.1	4.83	2.5e-06	0.00144	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117135528~117138582:+
SARC	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	4.83	2.5e-06	0.00144	0.37	0.3	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
SARC	cis	rs41369048	0.669	rs6660867	ENSG00000238078.1	LINC01352	-4.83	2.5e-06	0.00144	-0.46	-0.3	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220864097	chr1:220829255~220832429:+
SARC	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	4.83	2.5e-06	0.00144	0.28	0.3	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
SARC	cis	rs7615952	0.611	rs114419739	ENSG00000171084.14	FAM86JP	4.83	2.51e-06	0.00144	0.62	0.3	Blood pressure (smoking interaction);	chr3:126003647	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.611	rs79405914	ENSG00000171084.14	FAM86JP	4.83	2.51e-06	0.00144	0.62	0.3	Blood pressure (smoking interaction);	chr3:126004780	chr3:125916620~125930024:+
SARC	cis	rs4713118	0.955	rs9468204	ENSG00000219392.1	RP1-265C24.5	-4.83	2.51e-06	0.00144	-0.44	-0.3	Parkinson's disease;	chr6:27721030	chr6:28115628~28116551:+
SARC	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-4.83	2.51e-06	0.00144	-0.32	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
SARC	cis	rs17270561	0.609	rs17267614	ENSG00000272810.1	U91328.22	-4.83	2.51e-06	0.00144	-0.3	-0.3	Iron status biomarkers;	chr6:25729799	chr6:26013241~26013757:+
SARC	cis	rs6570726	0.791	rs9390336	ENSG00000270638.1	RP3-466P17.1	4.83	2.51e-06	0.00144	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.738	rs6925594	ENSG00000270638.1	RP3-466P17.1	4.83	2.51e-06	0.00144	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs11155432	ENSG00000270638.1	RP3-466P17.1	4.83	2.51e-06	0.00144	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs6913727	ENSG00000270638.1	RP3-466P17.1	4.83	2.51e-06	0.00144	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs10872577	ENSG00000270638.1	RP3-466P17.1	4.83	2.51e-06	0.00144	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145735570~145737218:+
SARC	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-4.83	2.51e-06	0.00144	-0.39	-0.3	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
SARC	cis	rs916888	0.821	rs199504	ENSG00000261575.2	RP11-259G18.1	-4.83	2.51e-06	0.00144	-0.42	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46267037~46268694:+
SARC	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	4.83	2.51e-06	0.00144	0.3	0.3	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
SARC	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	4.83	2.51e-06	0.00144	0.3	0.3	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
SARC	cis	rs899997	1	rs7182993	ENSG00000261143.1	ADAMTS7P3	4.83	2.51e-06	0.00145	0.45	0.3	Coronary artery disease or large artery stroke;	chr15:78752672	chr15:77976042~77993057:+
SARC	cis	rs899997	1	rs7182694	ENSG00000261143.1	ADAMTS7P3	4.83	2.51e-06	0.00145	0.45	0.3	Coronary artery disease or large artery stroke;	chr15:78752688	chr15:77976042~77993057:+
SARC	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-4.83	2.52e-06	0.00145	-0.3	-0.3	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
SARC	cis	rs1823913	1	rs4853562	ENSG00000280083.1	RP11-317J9.1	4.83	2.52e-06	0.00145	0.33	0.3	Obesity-related traits;	chr2:191253696	chr2:191154118~191156070:-
SARC	cis	rs1823913	1	rs4853461	ENSG00000280083.1	RP11-317J9.1	4.83	2.52e-06	0.00145	0.33	0.3	Obesity-related traits;	chr2:191254572	chr2:191154118~191156070:-
SARC	cis	rs12554020	0.792	rs79419498	ENSG00000227603.1	RP11-165J3.6	4.83	2.52e-06	0.00145	0.51	0.3	Schizophrenia;	chr9:93504701	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.892	rs78046549	ENSG00000227603.1	RP11-165J3.6	4.83	2.52e-06	0.00145	0.51	0.3	Schizophrenia;	chr9:93506196	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.892	rs76977206	ENSG00000227603.1	RP11-165J3.6	4.83	2.52e-06	0.00145	0.51	0.3	Schizophrenia;	chr9:93518181	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.786	rs883785	ENSG00000227603.1	RP11-165J3.6	4.83	2.52e-06	0.00145	0.51	0.3	Schizophrenia;	chr9:93519841	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.681	rs883783	ENSG00000227603.1	RP11-165J3.6	4.83	2.52e-06	0.00145	0.51	0.3	Schizophrenia;	chr9:93519987	chr9:93435332~93437121:-
SARC	cis	rs7181230	0.961	rs7183977	ENSG00000275636.1	RP11-521C20.5	-4.82	2.54e-06	0.00146	-0.35	-0.3	Dehydroepiandrosterone sulphate levels;	chr15:40084891	chr15:40078892~40079347:+
SARC	cis	rs4713118	0.869	rs10214440	ENSG00000219392.1	RP1-265C24.5	-4.82	2.54e-06	0.00146	-0.42	-0.3	Parkinson's disease;	chr6:27734661	chr6:28115628~28116551:+
SARC	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-4.82	2.54e-06	0.00146	-0.3	-0.3	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
SARC	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	4.82	2.54e-06	0.00146	0.26	0.3	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
SARC	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	4.82	2.55e-06	0.00146	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	4.82	2.55e-06	0.00146	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
SARC	cis	rs853679	0.76	rs9393910	ENSG00000219392.1	RP1-265C24.5	-4.82	2.55e-06	0.00146	-0.48	-0.3	Depression;	chr6:28240414	chr6:28115628~28116551:+
SARC	cis	rs853679	0.76	rs9368563	ENSG00000219392.1	RP1-265C24.5	-4.82	2.55e-06	0.00146	-0.48	-0.3	Depression;	chr6:28240780	chr6:28115628~28116551:+
SARC	cis	rs6570726	0.764	rs9403731	ENSG00000270638.1	RP3-466P17.1	4.82	2.55e-06	0.00146	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145735570~145737218:+
SARC	cis	rs12655019	0.92	rs16886496	ENSG00000271828.1	CTD-2310F14.1	-4.82	2.55e-06	0.00146	-0.49	-0.3	Breast cancer (early onset);	chr5:56921702	chr5:56927874~56929573:+
SARC	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	4.82	2.55e-06	0.00146	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
SARC	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-4.82	2.55e-06	0.00146	-0.38	-0.3	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
SARC	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	4.82	2.56e-06	0.00147	0.28	0.3	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
SARC	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-4.82	2.56e-06	0.00147	-0.38	-0.3	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-4.82	2.56e-06	0.00147	-0.38	-0.3	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
SARC	cis	rs853679	0.517	rs1904841	ENSG00000272009.1	RP1-313I6.12	-4.82	2.57e-06	0.00147	-0.35	-0.3	Depression;	chr6:28140307	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs1904840	ENSG00000272009.1	RP1-313I6.12	-4.82	2.57e-06	0.00147	-0.35	-0.3	Depression;	chr6:28140454	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9368555	ENSG00000272009.1	RP1-313I6.12	-4.82	2.57e-06	0.00147	-0.35	-0.3	Depression;	chr6:28141189	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9393893	ENSG00000272009.1	RP1-313I6.12	-4.82	2.57e-06	0.00147	-0.35	-0.3	Depression;	chr6:28141484	chr6:28078792~28081130:-
SARC	cis	rs890448	0.693	rs4312760	ENSG00000254531.1	FLJ20021	4.82	2.57e-06	0.00147	0.3	0.3	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417443	chr4:101347780~101348883:+
SARC	cis	rs6570726	0.791	rs10457788	ENSG00000270638.1	RP3-466P17.1	4.82	2.58e-06	0.00148	0.25	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145735570~145737218:+
SARC	cis	rs11098499	0.532	rs4833624	ENSG00000245958.5	RP11-33B1.1	-4.82	2.58e-06	0.00148	-0.27	-0.3	Corneal astigmatism;	chr4:119664342	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.532	rs12512646	ENSG00000245958.5	RP11-33B1.1	-4.82	2.58e-06	0.00148	-0.27	-0.3	Corneal astigmatism;	chr4:119664578	chr4:119454791~119552025:+
SARC	cis	rs9818758	0.607	rs34566463	ENSG00000225399.4	RP11-3B7.1	-4.82	2.58e-06	0.00148	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49207644	chr3:49260085~49261316:+
SARC	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-4.82	2.58e-06	0.00148	-0.44	-0.3	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
SARC	cis	rs193541	0.617	rs2045628	ENSG00000263432.2	RN7SL689P	4.82	2.58e-06	0.00148	0.38	0.3	Glucose homeostasis traits;	chr5:122759459	chr5:123022487~123022783:-
SARC	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-4.82	2.58e-06	0.00148	-0.36	-0.3	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
SARC	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-4.82	2.58e-06	0.00148	-0.37	-0.3	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
SARC	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	4.82	2.58e-06	0.00148	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
SARC	cis	rs2153535	0.606	rs11243253	ENSG00000230939.1	RP11-314C16.1	4.82	2.59e-06	0.00148	0.34	0.3	Motion sickness;	chr6:8379960	chr6:8784178~8785445:+
SARC	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	4.82	2.6e-06	0.00149	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
SARC	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-4.82	2.6e-06	0.00149	-0.31	-0.3	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
SARC	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-4.82	2.6e-06	0.00149	-0.34	-0.3	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
SARC	cis	rs858239	1	rs156407	ENSG00000226816.2	AC005082.12	4.82	2.6e-06	0.00149	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23206013~23208045:+
SARC	cis	rs8081395	0.741	rs1292051	ENSG00000266992.1	DHX40P1	4.82	2.61e-06	0.00149	0.33	0.3	White blood cell count;	chr17:59886562	chr17:59976009~60002384:-
SARC	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-4.82	2.61e-06	0.00149	-0.33	-0.3	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-4.82	2.61e-06	0.00149	-0.33	-0.3	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
SARC	cis	rs1707322	0.686	rs2991977	ENSG00000281133.1	AL355480.3	4.82	2.61e-06	0.00149	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45580892~45580996:-
SARC	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	4.82	2.61e-06	0.00149	0.38	0.3	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
SARC	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-4.82	2.61e-06	0.0015	-0.31	-0.3	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
SARC	cis	rs739310	0.556	rs9680723	ENSG00000206028.1	CTA-373H7.7	-4.82	2.61e-06	0.0015	-0.47	-0.3	Obesity-related traits;	chr22:26712697	chr22:26667693~26672654:-
SARC	cis	rs739310	0.556	rs5761700	ENSG00000206028.1	CTA-373H7.7	-4.82	2.61e-06	0.0015	-0.47	-0.3	Obesity-related traits;	chr22:26716806	chr22:26667693~26672654:-
SARC	cis	rs858239	0.896	rs1637192	ENSG00000226816.2	AC005082.12	4.82	2.62e-06	0.0015	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23206013~23208045:+
SARC	cis	rs11822910	0.654	rs2439450	ENSG00000265566.2	RN7SL605P	4.82	2.62e-06	0.0015	0.4	0.3	Platelet distribution width;	chr11:57445588	chr11:57528085~57528365:-
SARC	cis	rs9467603	0.8	rs1892252	ENSG00000228223.2	HCG11	-4.82	2.62e-06	0.0015	-0.44	-0.3	Intelligence (multi-trait analysis);	chr6:25772411	chr6:26523450~26526579:+
SARC	cis	rs12554020	0.786	rs79469056	ENSG00000227603.1	RP11-165J3.6	4.82	2.63e-06	0.0015	0.5	0.3	Schizophrenia;	chr9:93453807	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.786	rs16909150	ENSG00000227603.1	RP11-165J3.6	-4.82	2.63e-06	0.0015	-0.5	-0.3	Schizophrenia;	chr9:93454464	chr9:93435332~93437121:-
SARC	cis	rs910316	1	rs910316	ENSG00000279594.1	RP11-950C14.10	4.82	2.63e-06	0.0015	0.33	0.3	Height;	chr14:75159339	chr14:75011269~75012851:-
SARC	cis	rs910316	0.874	rs61980828	ENSG00000279594.1	RP11-950C14.10	-4.82	2.63e-06	0.0015	-0.33	-0.3	Height;	chr14:75163675	chr14:75011269~75012851:-
SARC	cis	rs6762	0.748	rs7929032	ENSG00000279672.1	CMB9-55F22.1	4.82	2.63e-06	0.0015	0.27	0.3	Mean platelet volume;	chr11:839078	chr11:779617~780755:+
SARC	cis	rs6762	0.748	rs7936838	ENSG00000279672.1	CMB9-55F22.1	4.82	2.63e-06	0.0015	0.27	0.3	Mean platelet volume;	chr11:839093	chr11:779617~780755:+
SARC	cis	rs77204473	1	rs12292278	ENSG00000254851.1	RP11-109L13.1	-4.82	2.63e-06	0.0015	-0.63	-0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887977	chr11:117135528~117138582:+
SARC	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-4.82	2.63e-06	0.00151	-0.34	-0.3	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
SARC	cis	rs7216064	0.651	rs12947658	ENSG00000265055.1	AC145343.2	-4.82	2.64e-06	0.00151	-0.35	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67906890	chr17:68096046~68101474:-
SARC	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-4.82	2.64e-06	0.00151	-0.28	-0.3	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
SARC	cis	rs7615952	0.576	rs2276729	ENSG00000250012.1	RP11-124N2.1	-4.82	2.64e-06	0.00151	-0.29	-0.3	Blood pressure (smoking interaction);	chr3:126107371	chr3:126084220~126095349:+
SARC	cis	rs7216064	0.906	rs1976052	ENSG00000265055.1	AC145343.2	4.82	2.64e-06	0.00151	0.4	0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67834462	chr17:68096046~68101474:-
SARC	cis	rs1707322	0.721	rs4660883	ENSG00000281133.1	AL355480.3	-4.82	2.64e-06	0.00151	-0.34	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45580892~45580996:-
SARC	cis	rs2933343	1	rs1680790	ENSG00000261159.1	RP11-723O4.9	4.82	2.64e-06	0.00151	0.36	0.3	IgG glycosylation;	chr3:128907010	chr3:128859716~128860526:-
SARC	cis	rs2933343	1	rs876756	ENSG00000261159.1	RP11-723O4.9	4.82	2.64e-06	0.00151	0.36	0.3	IgG glycosylation;	chr3:128908780	chr3:128859716~128860526:-
SARC	cis	rs2933343	1	rs876755	ENSG00000261159.1	RP11-723O4.9	4.82	2.64e-06	0.00151	0.36	0.3	IgG glycosylation;	chr3:128909090	chr3:128859716~128860526:-
SARC	cis	rs858239	0.862	rs1728292	ENSG00000226816.2	AC005082.12	4.82	2.65e-06	0.00151	0.36	0.3	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23206013~23208045:+
SARC	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-4.82	2.65e-06	0.00151	-0.37	-0.3	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
SARC	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-4.82	2.65e-06	0.00151	-0.37	-0.3	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
SARC	cis	rs4919687	0.55	rs7904396	ENSG00000213061.2	PFN1P11	4.82	2.65e-06	0.00151	0.38	0.3	Colorectal cancer;	chr10:102697081	chr10:102838011~102845473:-
SARC	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	4.81	2.65e-06	0.00151	0.28	0.3	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	4.81	2.65e-06	0.00151	0.28	0.3	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	4.81	2.65e-06	0.00151	0.28	0.3	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	4.81	2.65e-06	0.00151	0.28	0.3	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	4.81	2.65e-06	0.00151	0.28	0.3	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	4.81	2.65e-06	0.00151	0.28	0.3	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	4.81	2.65e-06	0.00151	0.28	0.3	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	4.81	2.65e-06	0.00151	0.28	0.3	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
SARC	cis	rs9818758	0.607	rs55873331	ENSG00000225399.4	RP11-3B7.1	-4.81	2.65e-06	0.00151	-0.59	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49559622	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs73074866	ENSG00000225399.4	RP11-3B7.1	-4.81	2.65e-06	0.00151	-0.59	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49589233	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.505	rs11716159	ENSG00000225399.4	RP11-3B7.1	-4.81	2.65e-06	0.00151	-0.59	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49594152	chr3:49260085~49261316:+
SARC	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	4.81	2.66e-06	0.00152	0.28	0.3	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
SARC	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-4.81	2.66e-06	0.00152	-0.33	-0.3	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-4.81	2.66e-06	0.00152	-0.33	-0.3	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-4.81	2.66e-06	0.00152	-0.33	-0.3	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-4.81	2.66e-06	0.00152	-0.33	-0.3	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-4.81	2.66e-06	0.00152	-0.33	-0.3	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-4.81	2.66e-06	0.00152	-0.33	-0.3	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
SARC	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	4.81	2.66e-06	0.00152	0.32	0.3	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	4.81	2.66e-06	0.00152	0.32	0.3	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	4.81	2.66e-06	0.00152	0.32	0.3	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	4.81	2.66e-06	0.00152	0.32	0.3	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
SARC	cis	rs7615952	0.599	rs66532274	ENSG00000248787.1	RP11-666A20.4	-4.81	2.66e-06	0.00152	-0.41	-0.3	Blood pressure (smoking interaction);	chr3:126013002	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.599	rs2333408	ENSG00000248787.1	RP11-666A20.4	-4.81	2.66e-06	0.00152	-0.41	-0.3	Blood pressure (smoking interaction);	chr3:126013255	chr3:125908005~125910272:-
SARC	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-4.81	2.66e-06	0.00152	-0.37	-0.3	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
SARC	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-4.81	2.66e-06	0.00152	-0.34	-0.3	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-4.81	2.66e-06	0.00152	-0.34	-0.3	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-4.81	2.66e-06	0.00152	-0.34	-0.3	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
SARC	cis	rs2404602	0.575	rs11072611	ENSG00000259422.1	RP11-593F23.1	4.81	2.66e-06	0.00152	0.4	0.3	Blood metabolite levels;	chr15:76655642	chr15:76174891~76181486:-
SARC	cis	rs12594515	0.625	rs2176866	ENSG00000273972.1	CTD-2306A12.1	-4.81	2.67e-06	0.00152	-0.32	-0.3	Weight;Waist circumference;	chr15:45704620	chr15:45702640~45703183:+
SARC	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	4.81	2.67e-06	0.00152	0.34	0.3	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
SARC	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	4.81	2.67e-06	0.00152	0.35	0.3	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
SARC	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-4.81	2.68e-06	0.00152	-0.34	-0.3	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-4.81	2.68e-06	0.00152	-0.34	-0.3	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-4.81	2.68e-06	0.00152	-0.34	-0.3	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-4.81	2.68e-06	0.00152	-0.34	-0.3	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-4.81	2.68e-06	0.00152	-0.34	-0.3	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
SARC	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-4.81	2.68e-06	0.00152	-0.34	-0.3	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-4.81	2.68e-06	0.00152	-0.34	-0.3	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
SARC	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	4.81	2.68e-06	0.00153	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	4.81	2.68e-06	0.00153	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
SARC	cis	rs79349575	0.783	rs1994970	ENSG00000270781.1	RP11-501C14.9	4.81	2.68e-06	0.00153	0.36	0.3	Type 2 diabetes;	chr17:48936765	chr17:48899131~48899748:+
SARC	cis	rs7615952	0.599	rs6438953	ENSG00000248787.1	RP11-666A20.4	-4.81	2.68e-06	0.00153	-0.41	-0.3	Blood pressure (smoking interaction);	chr3:126006108	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.599	rs1044215	ENSG00000248787.1	RP11-666A20.4	-4.81	2.68e-06	0.00153	-0.41	-0.3	Blood pressure (smoking interaction);	chr3:126006716	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.599	rs6438955	ENSG00000248787.1	RP11-666A20.4	-4.81	2.68e-06	0.00153	-0.41	-0.3	Blood pressure (smoking interaction);	chr3:126011490	chr3:125908005~125910272:-
SARC	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	4.81	2.68e-06	0.00153	0.32	0.3	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
SARC	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	4.81	2.68e-06	0.00153	0.33	0.3	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
SARC	cis	rs8081395	0.741	rs1292056	ENSG00000266992.1	DHX40P1	4.81	2.69e-06	0.00153	0.32	0.3	White blood cell count;	chr17:59881686	chr17:59976009~60002384:-
SARC	cis	rs708547	0.581	rs13121027	ENSG00000269949.1	RP11-738E22.3	-4.81	2.69e-06	0.00153	-0.38	-0.3	Response to bleomycin (chromatid breaks);	chr4:56947203	chr4:56960927~56961373:-
SARC	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-4.81	2.69e-06	0.00153	-0.36	-0.3	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
SARC	cis	rs4794202	0.618	rs4794224	ENSG00000264920.1	RP11-6N17.4	-4.81	2.69e-06	0.00153	-0.38	-0.3	Alzheimer's disease (cognitive decline);	chr17:47880097	chr17:47891255~47895812:-
SARC	cis	rs2562456	0.72	rs6511250	ENSG00000268081.1	RP11-678G14.2	-4.81	2.7e-06	0.00153	-0.44	-0.3	Pain;	chr19:21473244	chr19:21554640~21569237:-
SARC	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	4.81	2.7e-06	0.00153	0.32	0.3	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
SARC	cis	rs2179367	0.6	rs9498356	ENSG00000231760.4	RP11-350J20.5	4.81	2.7e-06	0.00153	0.43	0.3	Dupuytren's disease;	chr6:149443337	chr6:149796151~149826294:-
SARC	cis	rs1865760	0.566	rs3752419	ENSG00000272810.1	U91328.22	-4.81	2.7e-06	0.00154	-0.29	-0.3	Height;	chr6:26027205	chr6:26013241~26013757:+
SARC	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-4.81	2.7e-06	0.00154	-0.31	-0.3	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
SARC	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	4.81	2.7e-06	0.00154	0.36	0.3	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
SARC	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	4.81	2.7e-06	0.00154	0.43	0.3	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
SARC	cis	rs5769707	0.609	rs135861	ENSG00000235111.1	RP1-29C18.8	-4.81	2.71e-06	0.00154	-0.38	-0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49612657~49615716:-
SARC	cis	rs11018904	0.861	rs12786959	ENSG00000280385.1	AP000648.5	-4.81	2.71e-06	0.00154	-0.35	-0.3	Intelligence (multi-trait analysis);	chr11:90210508	chr11:90193614~90198120:+
SARC	cis	rs11018904	0.861	rs12787117	ENSG00000280385.1	AP000648.5	-4.81	2.71e-06	0.00154	-0.35	-0.3	Intelligence (multi-trait analysis);	chr11:90210513	chr11:90193614~90198120:+
SARC	cis	rs11018904	0.817	rs11601793	ENSG00000280385.1	AP000648.5	-4.81	2.71e-06	0.00154	-0.35	-0.3	Intelligence (multi-trait analysis);	chr11:90213186	chr11:90193614~90198120:+
SARC	cis	rs11018904	0.906	rs35129016	ENSG00000280385.1	AP000648.5	-4.81	2.71e-06	0.00154	-0.35	-0.3	Intelligence (multi-trait analysis);	chr11:90215521	chr11:90193614~90198120:+
SARC	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	4.81	2.71e-06	0.00154	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	4.81	2.71e-06	0.00154	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	4.81	2.71e-06	0.00154	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	4.81	2.71e-06	0.00154	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	4.81	2.71e-06	0.00154	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	4.81	2.71e-06	0.00154	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	4.81	2.71e-06	0.00154	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	4.81	2.71e-06	0.00154	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	4.81	2.71e-06	0.00154	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	4.81	2.71e-06	0.00154	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	4.81	2.71e-06	0.00154	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
SARC	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-4.81	2.71e-06	0.00154	-0.36	-0.3	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
SARC	cis	rs12554020	0.786	rs12554164	ENSG00000227603.1	RP11-165J3.6	4.81	2.71e-06	0.00154	0.5	0.3	Schizophrenia;	chr9:93456677	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.786	rs16909158	ENSG00000227603.1	RP11-165J3.6	4.81	2.71e-06	0.00154	0.5	0.3	Schizophrenia;	chr9:93457882	chr9:93435332~93437121:-
SARC	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	4.81	2.72e-06	0.00154	0.34	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	4.81	2.72e-06	0.00154	0.34	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	4.81	2.72e-06	0.00154	0.34	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
SARC	cis	rs35160687	0.644	rs10204589	ENSG00000273080.1	RP11-301O19.1	4.81	2.72e-06	0.00154	0.32	0.3	Night sleep phenotypes;	chr2:86266100	chr2:86195590~86196049:+
SARC	cis	rs17270561	0.609	rs1165181	ENSG00000272810.1	U91328.22	-4.81	2.72e-06	0.00154	-0.28	-0.3	Iron status biomarkers;	chr6:25825162	chr6:26013241~26013757:+
SARC	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-4.81	2.72e-06	0.00154	-0.34	-0.3	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
SARC	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-4.81	2.72e-06	0.00154	-0.37	-0.3	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
SARC	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-4.81	2.72e-06	0.00154	-0.31	-0.3	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
SARC	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-4.81	2.72e-06	0.00154	-0.31	-0.3	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
SARC	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-4.81	2.73e-06	0.00155	-0.37	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
SARC	cis	rs899997	1	rs7182567	ENSG00000261143.1	ADAMTS7P3	4.81	2.73e-06	0.00155	0.44	0.3	Coronary artery disease or large artery stroke;	chr15:78752712	chr15:77976042~77993057:+
SARC	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-4.81	2.73e-06	0.00155	-0.29	-0.3	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
SARC	cis	rs2274273	0.564	rs3783649	ENSG00000258413.1	RP11-665C16.6	-4.81	2.73e-06	0.00155	-0.38	-0.3	Protein biomarker;	chr14:55367692	chr14:55262767~55272075:-
SARC	cis	rs1707322	0.686	rs1547924	ENSG00000281133.1	AL355480.3	-4.81	2.74e-06	0.00155	-0.34	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45580892~45580996:-
SARC	cis	rs783540	0.5	rs7163840	ENSG00000275695.1	UBE2Q2P6	-4.81	2.74e-06	0.00156	-0.32	-0.3	Schizophrenia;	chr15:82729551	chr15:82445719~82454837:+
SARC	cis	rs2274273	0.905	rs2147961	ENSG00000258413.1	RP11-665C16.6	-4.81	2.75e-06	0.00156	-0.35	-0.3	Protein biomarker;	chr14:55118663	chr14:55262767~55272075:-
SARC	cis	rs1865760	0.555	rs2051541	ENSG00000272810.1	U91328.22	4.81	2.75e-06	0.00156	0.32	0.3	Height;	chr6:25944983	chr6:26013241~26013757:+
SARC	cis	rs858239	0.932	rs858275	ENSG00000226816.2	AC005082.12	4.81	2.75e-06	0.00156	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23206013~23208045:+
SARC	cis	rs2933343	0.7	rs6787833	ENSG00000261159.1	RP11-723O4.9	4.81	2.76e-06	0.00156	0.32	0.3	IgG glycosylation;	chr3:128937341	chr3:128859716~128860526:-
SARC	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-4.81	2.76e-06	0.00156	-0.31	-0.3	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
SARC	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-4.81	2.76e-06	0.00156	-0.48	-0.3	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-4.81	2.76e-06	0.00156	-0.48	-0.3	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-4.81	2.76e-06	0.00156	-0.48	-0.3	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
SARC	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-4.81	2.76e-06	0.00156	-0.36	-0.3	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
SARC	cis	rs4713118	0.866	rs2179094	ENSG00000219392.1	RP1-265C24.5	-4.81	2.77e-06	0.00157	-0.42	-0.3	Parkinson's disease;	chr6:27774046	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	4.8	2.78e-06	0.00157	0.28	0.3	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
SARC	cis	rs910316	0.737	rs108621	ENSG00000279594.1	RP11-950C14.10	-4.8	2.78e-06	0.00157	-0.34	-0.3	Height;	chr14:75013934	chr14:75011269~75012851:-
SARC	cis	rs1862618	0.525	rs2662019	ENSG00000271828.1	CTD-2310F14.1	-4.8	2.78e-06	0.00158	-0.46	-0.3	Initial pursuit acceleration;	chr5:56967277	chr5:56927874~56929573:+
SARC	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-4.8	2.78e-06	0.00158	-0.36	-0.3	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
SARC	cis	rs4664293	0.647	rs1863686	ENSG00000226266.5	AC009961.3	-4.8	2.79e-06	0.00158	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159647538	chr2:159670708~159712435:-
SARC	cis	rs17270561	0.636	rs9348696	ENSG00000272462.2	U91328.19	-4.8	2.79e-06	0.00158	-0.28	-0.3	Iron status biomarkers;	chr6:25781710	chr6:25992662~26001775:+
SARC	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-4.8	2.79e-06	0.00158	-0.34	-0.3	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-4.8	2.79e-06	0.00158	-0.34	-0.3	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
SARC	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-4.8	2.79e-06	0.00158	-0.31	-0.3	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
SARC	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	4.8	2.8e-06	0.00158	0.44	0.3	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
SARC	cis	rs11676348	0.703	rs6737563	ENSG00000261338.2	RP11-378A13.1	-4.8	2.8e-06	0.00158	-0.29	-0.3	Ulcerative colitis;	chr2:218080951	chr2:218255319~218257366:+
SARC	cis	rs4703855	0.538	rs7445013	ENSG00000244061.1	RP11-389C8.1	4.8	2.8e-06	0.00158	0.31	0.3	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72402150	chr5:72381794~72382393:+
SARC	cis	rs5769707	0.706	rs763128	ENSG00000235111.1	RP1-29C18.8	-4.8	2.8e-06	0.00158	-0.37	-0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49612657~49615716:-
SARC	cis	rs1865760	0.516	rs9379818	ENSG00000272462.2	U91328.19	-4.8	2.8e-06	0.00158	-0.27	-0.3	Height;	chr6:26022978	chr6:25992662~26001775:+
SARC	cis	rs1707322	0.662	rs11211160	ENSG00000281133.1	AL355480.3	-4.8	2.81e-06	0.00159	-0.34	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45580892~45580996:-
SARC	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-4.8	2.81e-06	0.00159	-0.34	-0.3	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
SARC	cis	rs4372836	0.964	rs4665431	ENSG00000226833.4	AC097724.3	-4.8	2.81e-06	0.00159	-0.29	-0.3	Body mass index;	chr2:28715302	chr2:28708953~28736205:-
SARC	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	4.8	2.81e-06	0.00159	0.33	0.3	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
SARC	cis	rs1823913	0.599	rs17414109	ENSG00000227542.1	AC092614.2	4.8	2.81e-06	0.00159	0.34	0.3	Obesity-related traits;	chr2:191310675	chr2:191229165~191246172:-
SARC	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-4.8	2.82e-06	0.00159	-0.25	-0.3	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
SARC	cis	rs2274273	0.624	rs7150234	ENSG00000258413.1	RP11-665C16.6	-4.8	2.82e-06	0.00159	-0.37	-0.3	Protein biomarker;	chr14:55335463	chr14:55262767~55272075:-
SARC	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	4.8	2.82e-06	0.00159	0.59	0.3	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	4.8	2.82e-06	0.00159	0.59	0.3	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
SARC	cis	rs899997	1	rs11072800	ENSG00000261143.1	ADAMTS7P3	-4.8	2.82e-06	0.00159	-0.42	-0.3	Coronary artery disease or large artery stroke;	chr15:78753515	chr15:77976042~77993057:+
SARC	cis	rs890448	0.93	rs57302549	ENSG00000254531.1	FLJ20021	-4.8	2.82e-06	0.00159	-0.3	-0.3	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101450675	chr4:101347780~101348883:+
SARC	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	4.8	2.83e-06	0.0016	0.24	0.3	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
SARC	cis	rs2439831	0.867	rs2260160	ENSG00000275601.1	AC011330.13	-4.8	2.83e-06	0.0016	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43603445	chr15:43642389~43643023:-
SARC	cis	rs7772486	0.79	rs6570723	ENSG00000270638.1	RP3-466P17.1	4.8	2.83e-06	0.0016	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs6570724	ENSG00000270638.1	RP3-466P17.1	4.8	2.83e-06	0.0016	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs6917135	ENSG00000270638.1	RP3-466P17.1	4.8	2.83e-06	0.0016	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145735570~145737218:+
SARC	cis	rs12554020	0.786	rs56073019	ENSG00000227603.1	RP11-165J3.6	4.8	2.83e-06	0.0016	0.51	0.3	Schizophrenia;	chr9:93491169	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.786	rs75576302	ENSG00000227603.1	RP11-165J3.6	4.8	2.83e-06	0.0016	0.51	0.3	Schizophrenia;	chr9:93492940	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.786	rs76703294	ENSG00000227603.1	RP11-165J3.6	4.8	2.83e-06	0.0016	0.51	0.3	Schizophrenia;	chr9:93493884	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.786	rs12553389	ENSG00000227603.1	RP11-165J3.6	4.8	2.83e-06	0.0016	0.51	0.3	Schizophrenia;	chr9:93500979	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.786	rs78865387	ENSG00000227603.1	RP11-165J3.6	4.8	2.83e-06	0.0016	0.51	0.3	Schizophrenia;	chr9:93501827	chr9:93435332~93437121:-
SARC	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-4.8	2.83e-06	0.0016	-0.41	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
SARC	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-4.8	2.83e-06	0.0016	-0.41	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
SARC	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	4.8	2.83e-06	0.0016	0.28	0.3	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
SARC	cis	rs2404602	0.552	rs11634428	ENSG00000259422.1	RP11-593F23.1	-4.8	2.83e-06	0.0016	-0.4	-0.3	Blood metabolite levels;	chr15:76792241	chr15:76174891~76181486:-
SARC	cis	rs4703855	0.538	rs10942294	ENSG00000244061.1	RP11-389C8.1	-4.8	2.84e-06	0.0016	-0.31	-0.3	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72415442	chr5:72381794~72382393:+
SARC	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-4.8	2.84e-06	0.0016	-0.48	-0.3	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
SARC	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-4.8	2.84e-06	0.0016	-0.48	-0.3	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
SARC	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-4.8	2.84e-06	0.0016	-0.35	-0.3	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
SARC	cis	rs11634944	0.643	rs975699	ENSG00000274307.1	RP11-345J18.2	-4.8	2.85e-06	0.00161	-0.38	-0.3	Interleukin-8 levels;	chr15:25015378	chr15:25708470~25710869:-
SARC	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-4.8	2.85e-06	0.00161	-0.44	-0.3	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
SARC	cis	rs9309473	0.606	rs77962988	ENSG00000163016.8	ALMS1P	4.8	2.85e-06	0.00161	0.42	0.3	Metabolite levels;	chr2:73658963	chr2:73644919~73685576:+
SARC	cis	rs6570726	0.791	rs6914203	ENSG00000270638.1	RP3-466P17.1	4.8	2.85e-06	0.00161	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.764	rs9403726	ENSG00000270638.1	RP3-466P17.1	4.8	2.85e-06	0.00161	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs1935612	ENSG00000270638.1	RP3-466P17.1	4.8	2.85e-06	0.00161	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145735570~145737218:+
SARC	cis	rs910316	0.591	rs7157158	ENSG00000279594.1	RP11-950C14.10	4.8	2.85e-06	0.00161	0.33	0.3	Height;	chr14:74990535	chr14:75011269~75012851:-
SARC	cis	rs12049351	0.774	rs36021190	ENSG00000229367.1	HMGN2P19	4.8	2.85e-06	0.00161	0.25	0.3	Circulating myeloperoxidase levels (plasma);	chr1:229562116	chr1:229570532~229570796:+
SARC	cis	rs17270561	0.666	rs12209856	ENSG00000272810.1	U91328.22	-4.8	2.85e-06	0.00161	-0.3	-0.3	Iron status biomarkers;	chr6:25793445	chr6:26013241~26013757:+
SARC	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-4.8	2.85e-06	0.00161	-0.31	-0.3	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
SARC	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	4.8	2.86e-06	0.00161	0.28	0.3	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
SARC	cis	rs7216064	1	rs12452511	ENSG00000278219.1	AC145343.1	-4.8	2.86e-06	0.00161	-0.38	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836460	chr17:68101538~68101639:+
SARC	cis	rs7567389	0.677	rs7607907	ENSG00000236682.1	AC068282.3	4.8	2.86e-06	0.00161	0.35	0.3	Self-rated health;	chr2:127386710	chr2:127389130~127400580:+
SARC	cis	rs7615952	0.641	rs12488180	ENSG00000250012.1	RP11-124N2.1	-4.8	2.86e-06	0.00161	-0.29	-0.3	Blood pressure (smoking interaction);	chr3:126063393	chr3:126084220~126095349:+
SARC	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	4.8	2.86e-06	0.00161	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
SARC	cis	rs77204473	1	rs12284346	ENSG00000254851.1	RP11-109L13.1	4.8	2.86e-06	0.00161	0.66	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887077	chr11:117135528~117138582:+
SARC	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-4.8	2.87e-06	0.00161	-0.49	-0.3	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
SARC	cis	rs193541	0.632	rs154503	ENSG00000263432.2	RN7SL689P	4.8	2.87e-06	0.00162	0.38	0.3	Glucose homeostasis traits;	chr5:122868804	chr5:123022487~123022783:-
SARC	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-4.8	2.87e-06	0.00162	-0.34	-0.3	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-4.8	2.87e-06	0.00162	-0.34	-0.3	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
SARC	cis	rs9494145	0.526	rs7751525	ENSG00000232876.1	CTA-212D2.2	-4.8	2.87e-06	0.00162	-0.45	-0.3	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135142570	chr6:135055033~135060550:+
SARC	cis	rs1823913	0.895	rs10931491	ENSG00000280083.1	RP11-317J9.1	4.8	2.87e-06	0.00162	0.33	0.3	Obesity-related traits;	chr2:191256087	chr2:191154118~191156070:-
SARC	cis	rs1823913	1	rs11681777	ENSG00000280083.1	RP11-317J9.1	4.8	2.87e-06	0.00162	0.33	0.3	Obesity-related traits;	chr2:191256741	chr2:191154118~191156070:-
SARC	cis	rs1823913	1	rs1840377	ENSG00000280083.1	RP11-317J9.1	4.8	2.87e-06	0.00162	0.33	0.3	Obesity-related traits;	chr2:191257992	chr2:191154118~191156070:-
SARC	cis	rs1823913	1	rs4853564	ENSG00000280083.1	RP11-317J9.1	4.8	2.87e-06	0.00162	0.33	0.3	Obesity-related traits;	chr2:191258939	chr2:191154118~191156070:-
SARC	cis	rs1823913	1	rs4853565	ENSG00000280083.1	RP11-317J9.1	4.8	2.87e-06	0.00162	0.33	0.3	Obesity-related traits;	chr2:191259020	chr2:191154118~191156070:-
SARC	cis	rs1823913	1	rs4853462	ENSG00000280083.1	RP11-317J9.1	4.8	2.87e-06	0.00162	0.33	0.3	Obesity-related traits;	chr2:191259078	chr2:191154118~191156070:-
SARC	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	4.8	2.88e-06	0.00162	0.45	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
SARC	cis	rs4862750	0.914	rs1991256	ENSG00000250971.1	RP11-696F12.1	4.8	2.88e-06	0.00162	0.37	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186954176	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.914	rs6553026	ENSG00000250971.1	RP11-696F12.1	4.8	2.88e-06	0.00162	0.37	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186954494	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.874	rs6553027	ENSG00000250971.1	RP11-696F12.1	4.8	2.88e-06	0.00162	0.37	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186954623	chr4:187060099~187060930:+
SARC	cis	rs4862750	0.914	rs6553028	ENSG00000250971.1	RP11-696F12.1	4.8	2.88e-06	0.00162	0.37	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186954892	chr4:187060099~187060930:+
SARC	cis	rs8005677	1	rs4982712	ENSG00000257285.4	RP11-298I3.1	4.8	2.88e-06	0.00162	0.28	0.3	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:22929609~22955562:+
SARC	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	4.8	2.88e-06	0.00162	0.33	0.3	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
SARC	cis	rs12049351	0.774	rs1020353	ENSG00000229367.1	HMGN2P19	4.8	2.88e-06	0.00162	0.26	0.3	Circulating myeloperoxidase levels (plasma);	chr1:229561571	chr1:229570532~229570796:+
SARC	cis	rs7809950	0.678	rs7788330	ENSG00000238832.1	snoU109	-4.8	2.89e-06	0.00162	-0.36	-0.3	Coronary artery disease;	chr7:107345203	chr7:107603363~107603507:+
SARC	cis	rs2239557	1	rs7153587	ENSG00000259065.1	RP5-1021I20.1	-4.8	2.89e-06	0.00162	-0.35	-0.3	Common traits (Other);	chr14:74042957	chr14:73787360~73803270:+
SARC	cis	rs2239557	1	rs75824542	ENSG00000259065.1	RP5-1021I20.1	-4.8	2.89e-06	0.00162	-0.35	-0.3	Common traits (Other);	chr14:74056344	chr14:73787360~73803270:+
SARC	cis	rs2239557	1	rs2072293	ENSG00000259065.1	RP5-1021I20.1	-4.8	2.89e-06	0.00162	-0.35	-0.3	Common traits (Other);	chr14:74071182	chr14:73787360~73803270:+
SARC	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-4.8	2.89e-06	0.00162	-0.36	-0.3	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-4.8	2.89e-06	0.00162	-0.36	-0.3	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-4.8	2.89e-06	0.00162	-0.36	-0.3	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
SARC	cis	rs2274273	0.624	rs7150763	ENSG00000258413.1	RP11-665C16.6	-4.8	2.89e-06	0.00163	-0.37	-0.3	Protein biomarker;	chr14:55373083	chr14:55262767~55272075:-
SARC	cis	rs875971	1	rs1167411	ENSG00000237310.1	GS1-124K5.4	-4.8	2.89e-06	0.00163	-0.31	-0.3	Aortic root size;	chr7:66074277	chr7:66493706~66495474:+
SARC	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	4.8	2.9e-06	0.00163	0.41	0.3	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
SARC	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-4.8	2.9e-06	0.00163	-0.33	-0.3	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-4.8	2.9e-06	0.00163	-0.33	-0.3	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-4.8	2.9e-06	0.00163	-0.33	-0.3	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
SARC	cis	rs4862750	0.914	rs11945845	ENSG00000250971.1	RP11-696F12.1	4.8	2.9e-06	0.00163	0.37	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186952982	chr4:187060099~187060930:+
SARC	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-4.8	2.9e-06	0.00163	-0.36	-0.3	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
SARC	cis	rs10754283	0.967	rs1320563	ENSG00000231613.1	RP5-943J3.1	4.8	2.9e-06	0.00163	0.3	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89655473	chr1:89788914~89790492:+
SARC	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-4.79	2.9e-06	0.00163	-0.37	-0.3	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
SARC	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-4.79	2.9e-06	0.00163	-0.37	-0.3	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
SARC	cis	rs1865760	0.516	rs9358903	ENSG00000272810.1	U91328.22	-4.79	2.9e-06	0.00163	-0.29	-0.3	Height;	chr6:26061721	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.566	rs9467663	ENSG00000272462.2	U91328.19	-4.79	2.91e-06	0.00164	-0.28	-0.3	Height;	chr6:26021228	chr6:25992662~26001775:+
SARC	cis	rs1707322	0.638	rs1416706	ENSG00000280836.1	AL355480.1	4.79	2.92e-06	0.00164	0.32	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45581219~45581321:-
SARC	cis	rs7809950	1	rs2066735	ENSG00000238832.1	snoU109	-4.79	2.92e-06	0.00164	-0.35	-0.3	Coronary artery disease;	chr7:107548274	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.678	rs62483641	ENSG00000238832.1	snoU109	-4.79	2.92e-06	0.00164	-0.35	-0.3	Coronary artery disease;	chr7:107261296	chr7:107603363~107603507:+
SARC	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-4.79	2.92e-06	0.00164	-0.44	-0.3	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
SARC	cis	rs72627509	0.629	rs1277313	ENSG00000269949.1	RP11-738E22.3	-4.79	2.92e-06	0.00164	-0.39	-0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037782	chr4:56960927~56961373:-
SARC	cis	rs7772486	0.754	rs6937661	ENSG00000270638.1	RP3-466P17.1	-4.79	2.92e-06	0.00164	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145735570~145737218:+
SARC	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-4.79	2.92e-06	0.00164	-0.33	-0.3	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
SARC	cis	rs2439831	0.681	rs7175434	ENSG00000205771.5	CATSPER2P1	-4.79	2.93e-06	0.00164	-0.42	-0.3	Lung cancer in ever smokers;	chr15:43336344	chr15:43726918~43747094:-
SARC	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	4.79	2.93e-06	0.00165	0.26	0.3	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
SARC	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-4.79	2.93e-06	0.00165	-0.49	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
SARC	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-4.79	2.94e-06	0.00165	-0.31	-0.3	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-4.79	2.94e-06	0.00165	-0.31	-0.3	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-4.79	2.94e-06	0.00165	-0.31	-0.3	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
SARC	cis	rs13161895	1	rs17079966	ENSG00000250999.1	RP11-1379J22.5	-4.79	2.94e-06	0.00165	-0.51	-0.3	LDL cholesterol;	chr5:180016190	chr5:179657762~179664432:+
SARC	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	4.79	2.94e-06	0.00165	0.36	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
SARC	cis	rs62432291	0.681	rs431205	ENSG00000235086.1	FNDC1-IT1	-4.79	2.94e-06	0.00165	-0.48	-0.3	Joint mobility (Beighton score);	chr6:159241467	chr6:159240786~159243329:+
SARC	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-4.79	2.94e-06	0.00165	-0.33	-0.3	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
SARC	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-4.79	2.94e-06	0.00165	-0.33	-0.3	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
SARC	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-4.79	2.94e-06	0.00165	-0.33	-0.3	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
SARC	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-4.79	2.94e-06	0.00165	-0.33	-0.3	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-4.79	2.94e-06	0.00165	-0.33	-0.3	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
SARC	cis	rs6570726	0.738	rs7746330	ENSG00000270638.1	RP3-466P17.1	4.79	2.94e-06	0.00165	0.25	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs12208812	ENSG00000270638.1	RP3-466P17.1	4.79	2.94e-06	0.00165	0.25	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs4335004	ENSG00000270638.1	RP3-466P17.1	4.79	2.94e-06	0.00165	0.25	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145735570~145737218:+
SARC	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	4.79	2.94e-06	0.00165	0.61	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
SARC	cis	rs7772486	0.714	rs1883365	ENSG00000270638.1	RP3-466P17.1	-4.79	2.94e-06	0.00165	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145735570~145737218:+
SARC	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-4.79	2.94e-06	0.00165	-0.3	-0.3	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
SARC	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-4.79	2.94e-06	0.00165	-0.48	-0.3	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
SARC	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-4.79	2.94e-06	0.00165	-0.38	-0.3	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
SARC	cis	rs1799949	1	rs35330014	ENSG00000267681.1	CTD-3199J23.6	-4.79	2.95e-06	0.00165	-0.34	-0.3	Menopause (age at onset);	chr17:43060530	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-4.79	2.95e-06	0.00165	-0.34	-0.3	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
SARC	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	4.79	2.95e-06	0.00165	0.58	0.3	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	4.79	2.95e-06	0.00165	0.58	0.3	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
SARC	cis	rs7809950	1	rs2712201	ENSG00000238832.1	snoU109	-4.79	2.95e-06	0.00165	-0.35	-0.3	Coronary artery disease;	chr7:107505119	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs2520249	ENSG00000238832.1	snoU109	-4.79	2.95e-06	0.00165	-0.35	-0.3	Coronary artery disease;	chr7:107506303	chr7:107603363~107603507:+
SARC	cis	rs7772486	0.738	rs2246334	ENSG00000270638.1	RP3-466P17.1	4.79	2.95e-06	0.00166	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145735570~145737218:+
SARC	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-4.79	2.96e-06	0.00166	-0.32	-0.3	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
SARC	cis	rs4713118	0.824	rs9366702	ENSG00000219392.1	RP1-265C24.5	-4.79	2.96e-06	0.00166	-0.42	-0.3	Parkinson's disease;	chr6:27766691	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.824	rs9468223	ENSG00000219392.1	RP1-265C24.5	-4.79	2.96e-06	0.00166	-0.42	-0.3	Parkinson's disease;	chr6:27772887	chr6:28115628~28116551:+
SARC	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	4.79	2.96e-06	0.00166	0.33	0.3	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
SARC	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	4.79	2.96e-06	0.00166	0.37	0.3	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
SARC	cis	rs193541	0.632	rs400207	ENSG00000263432.2	RN7SL689P	-4.79	2.96e-06	0.00166	-0.39	-0.3	Glucose homeostasis traits;	chr5:122982802	chr5:123022487~123022783:-
SARC	cis	rs13161895	1	rs248320	ENSG00000250999.1	RP11-1379J22.5	-4.79	2.96e-06	0.00166	-0.51	-0.3	LDL cholesterol;	chr5:180005096	chr5:179657762~179664432:+
SARC	cis	rs2179367	0.919	rs577001	ENSG00000231760.4	RP11-350J20.5	4.79	2.96e-06	0.00166	0.36	0.3	Dupuytren's disease;	chr6:149325172	chr6:149796151~149826294:-
SARC	cis	rs394563	0.775	rs412894	ENSG00000231760.4	RP11-350J20.5	4.79	2.97e-06	0.00166	0.39	0.3	Dupuytren's disease;	chr6:149460039	chr6:149796151~149826294:-
SARC	cis	rs394563	0.717	rs548848	ENSG00000231760.4	RP11-350J20.5	4.79	2.97e-06	0.00166	0.39	0.3	Dupuytren's disease;	chr6:149460873	chr6:149796151~149826294:-
SARC	cis	rs394563	0.775	rs399673	ENSG00000231760.4	RP11-350J20.5	4.79	2.97e-06	0.00166	0.39	0.3	Dupuytren's disease;	chr6:149462085	chr6:149796151~149826294:-
SARC	cis	rs394563	0.775	rs420430	ENSG00000231760.4	RP11-350J20.5	4.79	2.97e-06	0.00166	0.39	0.3	Dupuytren's disease;	chr6:149464403	chr6:149796151~149826294:-
SARC	cis	rs394563	0.775	rs448420	ENSG00000231760.4	RP11-350J20.5	4.79	2.97e-06	0.00166	0.39	0.3	Dupuytren's disease;	chr6:149464666	chr6:149796151~149826294:-
SARC	cis	rs7512898	0.545	rs12047681	ENSG00000260088.1	RP11-92G12.3	-4.79	2.97e-06	0.00167	-0.3	-0.3	Electrocardiographic conduction measures;	chr1:200727731	chr1:200669507~200694250:+
SARC	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-4.79	2.97e-06	0.00167	-0.34	-0.3	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-4.79	2.97e-06	0.00167	-0.34	-0.3	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
SARC	cis	rs7809950	0.678	rs2301801	ENSG00000238832.1	snoU109	-4.79	2.98e-06	0.00167	-0.36	-0.3	Coronary artery disease;	chr7:107230301	chr7:107603363~107603507:+
SARC	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-4.79	2.98e-06	0.00167	-0.4	-0.3	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
SARC	cis	rs10986311	0.889	rs1107342	ENSG00000235204.1	RP11-121A14.2	4.79	2.98e-06	0.00167	0.34	0.3	Vitiligo;	chr9:124311033	chr9:124259250~124261156:-
SARC	cis	rs1823913	1	rs1823913	ENSG00000280083.1	RP11-317J9.1	-4.79	2.98e-06	0.00167	-0.33	-0.3	Obesity-related traits;	chr2:191253321	chr2:191154118~191156070:-
SARC	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-4.79	2.98e-06	0.00167	-0.34	-0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
SARC	cis	rs1823874	0.677	rs4381582	ENSG00000182397.13	DNM1P46	-4.79	2.99e-06	0.00167	-0.35	-0.3	IgG glycosylation;	chr15:99820308	chr15:99790156~99806927:-
SARC	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-4.79	2.99e-06	0.00167	-0.36	-0.3	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
SARC	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	4.79	2.99e-06	0.00168	0.31	0.3	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
SARC	cis	rs7772486	0.686	rs1337841	ENSG00000270638.1	RP3-466P17.1	-4.79	2.99e-06	0.00168	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145735570~145737218:+
SARC	cis	rs1865760	0.602	rs9467662	ENSG00000272462.2	U91328.19	-4.79	2.99e-06	0.00168	-0.28	-0.3	Height;	chr6:26021099	chr6:25992662~26001775:+
SARC	cis	rs2803122	0.871	rs10481512	ENSG00000273226.1	RP11-513M16.8	-4.79	3e-06	0.00168	-0.29	-0.3	Pulse pressure;	chr9:19230741	chr9:19375451~19375996:+
SARC	cis	rs10895987	0.531	rs11227118	ENSG00000255200.1	AP003068.18	4.79	3e-06	0.00168	0.33	0.3	Blood protein levels;	chr11:65093183	chr11:65174117~65176470:-
SARC	cis	rs10895987	0.531	rs11227120	ENSG00000255200.1	AP003068.18	4.79	3e-06	0.00168	0.33	0.3	Blood protein levels;	chr11:65097387	chr11:65174117~65176470:-
SARC	cis	rs240993	0.715	rs7752418	ENSG00000230177.1	RP5-1112D6.4	4.79	3e-06	0.00168	0.33	0.3	Inflammatory skin disease;Psoriasis;	chr6:111466682	chr6:111277932~111278742:+
SARC	cis	rs7772486	0.79	rs7753833	ENSG00000270638.1	RP3-466P17.1	4.79	3e-06	0.00168	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145735570~145737218:+
SARC	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-4.79	3.01e-06	0.00168	-0.33	-0.3	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
SARC	cis	rs14027	0.921	rs1567359	ENSG00000279347.1	RP11-85I17.2	-4.79	3.01e-06	0.00168	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119778378	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs2043430	ENSG00000279347.1	RP11-85I17.2	-4.79	3.01e-06	0.00168	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119779741	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs12543087	ENSG00000279347.1	RP11-85I17.2	-4.79	3.01e-06	0.00168	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784207	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs10101278	ENSG00000279347.1	RP11-85I17.2	-4.79	3.01e-06	0.00168	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784799	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs1976575	ENSG00000279347.1	RP11-85I17.2	-4.79	3.01e-06	0.00168	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119788618	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs7837589	ENSG00000279347.1	RP11-85I17.2	-4.79	3.01e-06	0.00168	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119789401	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs67905698	ENSG00000279347.1	RP11-85I17.2	-4.79	3.01e-06	0.00168	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119792186	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs28756749	ENSG00000279347.1	RP11-85I17.2	-4.79	3.01e-06	0.00168	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119803164	chr8:119838736~119840385:-
SARC	cis	rs8062405	0.754	rs149299	ENSG00000251417.2	RP11-1348G14.4	-4.79	3.01e-06	0.00168	-0.29	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28802743~28817828:+
SARC	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-4.79	3.01e-06	0.00169	-0.38	-0.3	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
SARC	cis	rs6969780	0.545	rs983184	ENSG00000233429.8	HOTAIRM1	-4.79	3.02e-06	0.00169	-0.39	-0.3	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27148760	chr7:27095647~27100265:+
SARC	cis	rs801193	1	rs3778909	ENSG00000236529.1	RP13-254B10.1	4.79	3.02e-06	0.00169	0.32	0.3	Aortic root size;	chr7:66790659	chr7:65840212~65840596:+
SARC	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-4.79	3.03e-06	0.00169	-0.38	-0.3	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
SARC	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	4.79	3.03e-06	0.00169	0.32	0.3	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
SARC	cis	rs10911902	0.643	rs3820181	ENSG00000229739.2	RP11-295K2.3	-4.79	3.03e-06	0.0017	-0.43	-0.3	Schizophrenia;	chr1:186347067	chr1:186435161~186470291:+
SARC	cis	rs160451	1	rs160441	ENSG00000251136.7	RP11-37B2.1	4.79	3.04e-06	0.0017	0.33	0.3	Leprosy;	chr8:89644760	chr8:89609409~89757727:-
SARC	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-4.79	3.04e-06	0.0017	-0.49	-0.3	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
SARC	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-4.78	3.04e-06	0.0017	-0.31	-0.3	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
SARC	cis	rs7772486	0.764	rs7762562	ENSG00000270638.1	RP3-466P17.1	4.78	3.04e-06	0.0017	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145735570~145737218:+
SARC	cis	rs4862750	0.914	rs1991255	ENSG00000250971.1	RP11-696F12.1	4.78	3.04e-06	0.0017	0.37	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186954186	chr4:187060099~187060930:+
SARC	cis	rs853679	0.517	rs4711164	ENSG00000272009.1	RP1-313I6.12	-4.78	3.04e-06	0.0017	-0.35	-0.3	Depression;	chr6:28147378	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs4711165	ENSG00000272009.1	RP1-313I6.12	-4.78	3.04e-06	0.0017	-0.35	-0.3	Depression;	chr6:28147406	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs4713148	ENSG00000272009.1	RP1-313I6.12	-4.78	3.04e-06	0.0017	-0.35	-0.3	Depression;	chr6:28148143	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9348794	ENSG00000272009.1	RP1-313I6.12	-4.78	3.04e-06	0.0017	-0.35	-0.3	Depression;	chr6:28149979	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9468297	ENSG00000272009.1	RP1-313I6.12	-4.78	3.04e-06	0.0017	-0.35	-0.3	Depression;	chr6:28151096	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9295758	ENSG00000272009.1	RP1-313I6.12	-4.78	3.04e-06	0.0017	-0.35	-0.3	Depression;	chr6:28152885	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs17774663	ENSG00000272009.1	RP1-313I6.12	-4.78	3.04e-06	0.0017	-0.35	-0.3	Depression;	chr6:28153120	chr6:28078792~28081130:-
SARC	cis	rs10911902	0.643	rs16825224	ENSG00000229739.2	RP11-295K2.3	-4.78	3.04e-06	0.0017	-0.43	-0.3	Schizophrenia;	chr1:186349723	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs75008037	ENSG00000229739.2	RP11-295K2.3	-4.78	3.04e-06	0.0017	-0.43	-0.3	Schizophrenia;	chr1:186371380	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs76554103	ENSG00000229739.2	RP11-295K2.3	-4.78	3.04e-06	0.0017	-0.43	-0.3	Schizophrenia;	chr1:186371402	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs7514615	ENSG00000229739.2	RP11-295K2.3	-4.78	3.04e-06	0.0017	-0.43	-0.3	Schizophrenia;	chr1:186373191	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs6425027	ENSG00000229739.2	RP11-295K2.3	-4.78	3.04e-06	0.0017	-0.43	-0.3	Schizophrenia;	chr1:186376034	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs6425028	ENSG00000229739.2	RP11-295K2.3	-4.78	3.04e-06	0.0017	-0.43	-0.3	Schizophrenia;	chr1:186376149	chr1:186435161~186470291:+
SARC	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-4.78	3.05e-06	0.0017	-0.3	-0.3	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
SARC	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-4.78	3.05e-06	0.0017	-0.3	-0.3	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
SARC	cis	rs1865760	0.566	rs2051544	ENSG00000272462.2	U91328.19	-4.78	3.06e-06	0.00171	-0.27	-0.3	Height;	chr6:26070865	chr6:25992662~26001775:+
SARC	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-4.78	3.06e-06	0.00171	-0.36	-0.3	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
SARC	cis	rs7567389	0.785	rs4150474	ENSG00000236682.1	AC068282.3	4.78	3.06e-06	0.00171	0.35	0.3	Self-rated health;	chr2:127275751	chr2:127389130~127400580:+
SARC	cis	rs14027	0.883	rs10087723	ENSG00000279347.1	RP11-85I17.2	-4.78	3.06e-06	0.00171	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119711014	chr8:119838736~119840385:-
SARC	cis	rs14027	0.883	rs13272852	ENSG00000279347.1	RP11-85I17.2	-4.78	3.06e-06	0.00171	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712921	chr8:119838736~119840385:-
SARC	cis	rs4372836	0.964	rs11683296	ENSG00000226833.4	AC097724.3	-4.78	3.06e-06	0.00171	-0.29	-0.3	Body mass index;	chr2:28702538	chr2:28708953~28736205:-
SARC	cis	rs1865760	0.516	rs9393684	ENSG00000272810.1	U91328.22	-4.78	3.06e-06	0.00171	-0.29	-0.3	Height;	chr6:26075303	chr6:26013241~26013757:+
SARC	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	4.78	3.06e-06	0.00171	0.33	0.3	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
SARC	cis	rs2280018	0.963	rs4985147	ENSG00000260735.1	RP11-72I8.1	-4.78	3.06e-06	0.00171	-0.24	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15094411~15109197:+
SARC	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-4.78	3.07e-06	0.00171	-0.37	-0.3	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
SARC	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-4.78	3.07e-06	0.00171	-0.37	-0.3	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
SARC	cis	rs12554020	0.892	rs75775593	ENSG00000227603.1	RP11-165J3.6	4.78	3.07e-06	0.00171	0.52	0.3	Schizophrenia;	chr9:93568611	chr9:93435332~93437121:-
SARC	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-4.78	3.07e-06	0.00171	-0.28	-0.3	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
SARC	cis	rs2404602	0.532	rs744336	ENSG00000259422.1	RP11-593F23.1	4.78	3.07e-06	0.00171	0.34	0.3	Blood metabolite levels;	chr15:76382283	chr15:76174891~76181486:-
SARC	cis	rs7246657	0.941	rs7259618	ENSG00000276846.1	CTD-3220F14.3	4.78	3.07e-06	0.00171	0.42	0.3	Coronary artery calcification;	chr19:37259817	chr19:37314868~37315620:-
SARC	cis	rs4919687	0.55	rs7907503	ENSG00000213061.2	PFN1P11	4.78	3.08e-06	0.00172	0.37	0.3	Colorectal cancer;	chr10:102680293	chr10:102838011~102845473:-
SARC	cis	rs1823913	1	rs1823913	ENSG00000227542.1	AC092614.2	4.78	3.08e-06	0.00172	0.32	0.3	Obesity-related traits;	chr2:191253321	chr2:191229165~191246172:-
SARC	cis	rs524281	0.731	rs10791840	ENSG00000255320.1	RP11-755F10.1	4.78	3.08e-06	0.00172	0.5	0.3	Electroencephalogram traits;	chr11:66035912	chr11:66244840~66246239:-
SARC	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	4.78	3.09e-06	0.00172	0.31	0.3	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
SARC	cis	rs7772486	0.654	rs6928007	ENSG00000270638.1	RP3-466P17.1	-4.78	3.09e-06	0.00172	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145735570~145737218:+
SARC	cis	rs853679	0.882	rs9461432	ENSG00000219392.1	RP1-265C24.5	-4.78	3.09e-06	0.00172	-0.57	-0.3	Depression;	chr6:28119105	chr6:28115628~28116551:+
SARC	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-4.78	3.11e-06	0.00173	-0.35	-0.3	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
SARC	cis	rs7615952	0.599	rs2279821	ENSG00000250012.1	RP11-124N2.1	-4.78	3.11e-06	0.00173	-0.29	-0.3	Blood pressure (smoking interaction);	chr3:126015465	chr3:126084220~126095349:+
SARC	cis	rs910316	0.737	rs398896	ENSG00000279594.1	RP11-950C14.10	-4.78	3.11e-06	0.00173	-0.34	-0.3	Height;	chr14:75016124	chr14:75011269~75012851:-
SARC	cis	rs890448	0.796	rs4478190	ENSG00000254531.1	FLJ20021	4.78	3.11e-06	0.00173	0.3	0.3	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417304	chr4:101347780~101348883:+
SARC	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	4.78	3.12e-06	0.00173	0.24	0.3	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	4.78	3.12e-06	0.00173	0.24	0.3	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	4.78	3.12e-06	0.00173	0.24	0.3	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	4.78	3.12e-06	0.00173	0.24	0.3	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	4.78	3.12e-06	0.00173	0.24	0.3	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
SARC	cis	rs7809950	0.678	rs982447	ENSG00000238832.1	snoU109	-4.78	3.12e-06	0.00174	-0.35	-0.3	Coronary artery disease;	chr7:107333089	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.593	rs62482503	ENSG00000238832.1	snoU109	-4.78	3.12e-06	0.00174	-0.35	-0.3	Coronary artery disease;	chr7:107347543	chr7:107603363~107603507:+
SARC	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-4.78	3.13e-06	0.00174	-0.33	-0.3	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-4.78	3.13e-06	0.00174	-0.33	-0.3	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-4.78	3.13e-06	0.00174	-0.33	-0.3	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-4.78	3.13e-06	0.00174	-0.33	-0.3	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-4.78	3.13e-06	0.00174	-0.33	-0.3	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-4.78	3.13e-06	0.00174	-0.33	-0.3	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-4.78	3.13e-06	0.00174	-0.33	-0.3	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-4.78	3.13e-06	0.00174	-0.33	-0.3	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
SARC	cis	rs8062405	0.824	rs7191618	ENSG00000251417.2	RP11-1348G14.4	-4.78	3.13e-06	0.00174	-0.28	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.754	rs3859172	ENSG00000251417.2	RP11-1348G14.4	-4.78	3.13e-06	0.00174	-0.28	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28802743~28817828:+
SARC	cis	rs9309473	0.687	rs12465867	ENSG00000163016.8	ALMS1P	4.78	3.13e-06	0.00174	0.36	0.3	Metabolite levels;	chr2:73384974	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.583	rs35885918	ENSG00000163016.8	ALMS1P	4.78	3.13e-06	0.00174	0.36	0.3	Metabolite levels;	chr2:73385106	chr2:73644919~73685576:+
SARC	cis	rs7267979	0.966	rs2500433	ENSG00000276952.1	RP5-965G21.6	-4.78	3.14e-06	0.00175	-0.3	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2482948	ENSG00000276952.1	RP5-965G21.6	-4.78	3.14e-06	0.00175	-0.3	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:25284915~25285588:-
SARC	cis	rs2439831	0.681	rs478104	ENSG00000275601.1	AC011330.13	-4.78	3.14e-06	0.00175	-0.44	-0.3	Lung cancer in ever smokers;	chr15:43302702	chr15:43642389~43643023:-
SARC	cis	rs7772486	0.79	rs1133832	ENSG00000270638.1	RP3-466P17.1	-4.78	3.14e-06	0.00175	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145735570~145737218:+
SARC	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-4.78	3.14e-06	0.00175	-0.55	-0.3	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
SARC	cis	rs13161895	1	rs17079968	ENSG00000250999.1	RP11-1379J22.5	-4.78	3.14e-06	0.00175	-0.51	-0.3	LDL cholesterol;	chr5:180016423	chr5:179657762~179664432:+
SARC	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-4.78	3.14e-06	0.00175	-0.32	-0.3	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
SARC	cis	rs17270561	0.583	rs6926425	ENSG00000272810.1	U91328.22	-4.78	3.14e-06	0.00175	-0.29	-0.3	Iron status biomarkers;	chr6:25785076	chr6:26013241~26013757:+
SARC	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-4.78	3.15e-06	0.00175	-0.34	-0.3	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
SARC	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-4.78	3.15e-06	0.00175	-0.33	-0.3	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-4.78	3.15e-06	0.00175	-0.33	-0.3	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-4.78	3.15e-06	0.00175	-0.33	-0.3	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
SARC	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	4.78	3.15e-06	0.00175	0.36	0.3	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
SARC	cis	rs394563	0.967	rs420099	ENSG00000231760.4	RP11-350J20.5	4.78	3.15e-06	0.00175	0.38	0.3	Dupuytren's disease;	chr6:149473154	chr6:149796151~149826294:-
SARC	cis	rs10986311	0.962	rs10818943	ENSG00000235204.1	RP11-121A14.2	4.78	3.16e-06	0.00175	0.35	0.3	Vitiligo;	chr9:124325461	chr9:124259250~124261156:-
SARC	cis	rs910316	0.737	rs175049	ENSG00000279594.1	RP11-950C14.10	-4.78	3.16e-06	0.00176	-0.34	-0.3	Height;	chr14:75014665	chr14:75011269~75012851:-
SARC	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	4.78	3.16e-06	0.00176	0.35	0.3	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
SARC	cis	rs2404602	0.532	rs12591100	ENSG00000259422.1	RP11-593F23.1	-4.78	3.16e-06	0.00176	-0.33	-0.3	Blood metabolite levels;	chr15:76408460	chr15:76174891~76181486:-
SARC	cis	rs10506328	0.689	rs4759348	ENSG00000248265.1	FLJ12825	4.78	3.16e-06	0.00176	0.41	0.3	Mean platelet volume;	chr12:54236733	chr12:54058254~54122234:+
SARC	cis	rs2179367	0.6	rs9498353	ENSG00000231760.4	RP11-350J20.5	4.78	3.16e-06	0.00176	0.43	0.3	Dupuytren's disease;	chr6:149439860	chr6:149796151~149826294:-
SARC	cis	rs12554020	0.892	rs6479483	ENSG00000227603.1	RP11-165J3.6	4.78	3.16e-06	0.00176	0.41	0.3	Schizophrenia;	chr9:93441746	chr9:93435332~93437121:-
SARC	cis	rs875971	0.558	rs4433015	ENSG00000236529.1	RP13-254B10.1	-4.78	3.16e-06	0.00176	-0.31	-0.3	Aortic root size;	chr7:66174736	chr7:65840212~65840596:+
SARC	cis	rs1707322	0.827	rs6683274	ENSG00000281133.1	AL355480.3	-4.78	3.17e-06	0.00176	-0.34	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45580892~45580996:-
SARC	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	4.78	3.17e-06	0.00176	0.38	0.3	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
SARC	cis	rs7809950	0.678	rs7788271	ENSG00000238832.1	snoU109	-4.78	3.17e-06	0.00176	-0.35	-0.3	Coronary artery disease;	chr7:107345428	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.678	rs77395658	ENSG00000238832.1	snoU109	-4.78	3.17e-06	0.00176	-0.35	-0.3	Coronary artery disease;	chr7:107360206	chr7:107603363~107603507:+
SARC	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-4.78	3.17e-06	0.00176	-0.31	-0.3	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
SARC	cis	rs739310	0.556	rs72617273	ENSG00000206028.1	CTA-373H7.7	-4.78	3.18e-06	0.00176	-0.47	-0.3	Obesity-related traits;	chr22:26712084	chr22:26667693~26672654:-
SARC	cis	rs858239	0.863	rs274054	ENSG00000226816.2	AC005082.12	4.77	3.18e-06	0.00177	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23206013~23208045:+
SARC	cis	rs1823913	0.538	rs35311234	ENSG00000227542.1	AC092614.2	4.77	3.19e-06	0.00177	0.34	0.3	Obesity-related traits;	chr2:191316952	chr2:191229165~191246172:-
SARC	cis	rs858239	1	rs199351	ENSG00000226816.2	AC005082.12	4.77	3.19e-06	0.00177	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23206013~23208045:+
SARC	cis	rs2933343	0.7	rs2249514	ENSG00000261159.1	RP11-723O4.9	4.77	3.19e-06	0.00177	0.32	0.3	IgG glycosylation;	chr3:128924969	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.7	rs2630257	ENSG00000261159.1	RP11-723O4.9	4.77	3.19e-06	0.00177	0.32	0.3	IgG glycosylation;	chr3:128925172	chr3:128859716~128860526:-
SARC	cis	rs1075232	1	rs72722861	ENSG00000215302.7	CTD-3092A11.1	-4.77	3.19e-06	0.00177	-0.63	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30470779~30507623:+
SARC	cis	rs1075232	0.826	rs12438813	ENSG00000215302.7	CTD-3092A11.1	-4.77	3.19e-06	0.00177	-0.63	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30470779~30507623:+
SARC	cis	rs1075232	1	rs34959140	ENSG00000215302.7	CTD-3092A11.1	-4.77	3.19e-06	0.00177	-0.63	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31433020	chr15:30470779~30507623:+
SARC	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-4.77	3.19e-06	0.00177	-0.26	-0.3	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
SARC	cis	rs890448	0.796	rs1125180	ENSG00000254531.1	FLJ20021	4.77	3.2e-06	0.00177	0.31	0.3	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101400473	chr4:101347780~101348883:+
SARC	cis	rs7615952	0.599	rs16834938	ENSG00000250012.1	RP11-124N2.1	-4.77	3.2e-06	0.00177	-0.29	-0.3	Blood pressure (smoking interaction);	chr3:125987203	chr3:126084220~126095349:+
SARC	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-4.77	3.2e-06	0.00178	-0.29	-0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
SARC	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-4.77	3.2e-06	0.00178	-0.29	-0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
SARC	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-4.77	3.2e-06	0.00178	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
SARC	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-4.77	3.2e-06	0.00178	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
SARC	cis	rs7216064	1	rs4791212	ENSG00000237854.3	LINC00674	4.77	3.2e-06	0.00178	0.37	0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67979269	chr17:68101908~68115518:+
SARC	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-4.77	3.21e-06	0.00178	-0.44	-0.3	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-4.77	3.21e-06	0.00178	-0.44	-0.3	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
SARC	cis	rs394563	0.81	rs480870	ENSG00000231760.4	RP11-350J20.5	4.77	3.21e-06	0.00178	0.38	0.3	Dupuytren's disease;	chr6:149463682	chr6:149796151~149826294:-
SARC	cis	rs858239	0.932	rs858272	ENSG00000226816.2	AC005082.12	4.77	3.21e-06	0.00178	0.37	0.3	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23206013~23208045:+
SARC	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-4.77	3.21e-06	0.00178	-0.3	-0.3	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
SARC	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-4.77	3.21e-06	0.00178	-0.49	-0.3	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
SARC	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	4.77	3.22e-06	0.00178	0.36	0.3	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
SARC	cis	rs7615952	0.604	rs9837847	ENSG00000248787.1	RP11-666A20.4	-4.77	3.22e-06	0.00179	-0.52	-0.3	Blood pressure (smoking interaction);	chr3:125905076	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.673	rs35955861	ENSG00000248787.1	RP11-666A20.4	-4.77	3.22e-06	0.00179	-0.52	-0.3	Blood pressure (smoking interaction);	chr3:125907358	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.673	rs35001498	ENSG00000248787.1	RP11-666A20.4	-4.77	3.22e-06	0.00179	-0.52	-0.3	Blood pressure (smoking interaction);	chr3:125909801	chr3:125908005~125910272:-
SARC	cis	rs597539	0.616	rs72945243	ENSG00000250508.1	RP11-757G1.6	-4.77	3.22e-06	0.00179	-0.35	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:68870664~68874542:+
SARC	cis	rs17270561	0.609	rs4711094	ENSG00000272810.1	U91328.22	-4.77	3.22e-06	0.00179	-0.3	-0.3	Iron status biomarkers;	chr6:25705946	chr6:26013241~26013757:+
SARC	cis	rs7216064	0.773	rs74541577	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67857535	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs2128792	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67861061	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs2365764	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67861598	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs59950564	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67864743	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs34872586	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67867350	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.953	rs58141639	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67868786	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs62084246	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67871795	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs11869819	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67872553	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs55939964	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67873181	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs12602912	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67873957	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.953	rs12450907	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67874528	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs4569324	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67876634	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs62084248	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878425	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs12451511	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878745	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs62084249	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878882	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs35243555	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67880361	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs62084251	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67882620	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs4318247	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67886056	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.953	rs75231441	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889369	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.954	rs8079291	ENSG00000278219.1	AC145343.1	-4.77	3.22e-06	0.00179	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67891506	chr17:68101538~68101639:+
SARC	cis	rs801193	1	rs4717319	ENSG00000236529.1	RP13-254B10.1	4.77	3.23e-06	0.00179	0.32	0.3	Aortic root size;	chr7:66777606	chr7:65840212~65840596:+
SARC	cis	rs2274273	0.624	rs10141396	ENSG00000258413.1	RP11-665C16.6	-4.77	3.23e-06	0.00179	-0.38	-0.3	Protein biomarker;	chr14:55350207	chr14:55262767~55272075:-
SARC	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	4.77	3.23e-06	0.00179	0.34	0.3	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
SARC	cis	rs11018904	0.906	rs7925507	ENSG00000280385.1	AP000648.5	-4.77	3.23e-06	0.00179	-0.35	-0.3	Intelligence (multi-trait analysis);	chr11:90206978	chr11:90193614~90198120:+
SARC	cis	rs801193	0.904	rs4718403	ENSG00000236529.1	RP13-254B10.1	4.77	3.23e-06	0.00179	0.31	0.3	Aortic root size;	chr7:66777742	chr7:65840212~65840596:+
SARC	cis	rs7267979	0.549	rs6138537	ENSG00000276952.1	RP5-965G21.6	4.77	3.24e-06	0.00179	0.29	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25203830	chr20:25284915~25285588:-
SARC	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-4.77	3.24e-06	0.00179	-0.31	-0.3	Height;	chr3:53080524	chr3:53064283~53065091:-
SARC	cis	rs890448	0.726	rs2583396	ENSG00000254531.1	FLJ20021	-4.77	3.24e-06	0.00179	-0.31	-0.3	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101308621	chr4:101347780~101348883:+
SARC	cis	rs7615952	0.641	rs4490307	ENSG00000248787.1	RP11-666A20.4	-4.77	3.24e-06	0.0018	-0.4	-0.3	Blood pressure (smoking interaction);	chr3:125993833	chr3:125908005~125910272:-
SARC	cis	rs2439831	0.702	rs2467402	ENSG00000275601.1	AC011330.13	4.77	3.24e-06	0.0018	0.47	0.3	Lung cancer in ever smokers;	chr15:43732292	chr15:43642389~43643023:-
SARC	cis	rs7587476	0.505	rs777323	ENSG00000229267.2	AC072062.1	4.77	3.25e-06	0.0018	0.28	0.3	Neuroblastoma;	chr2:214873761	chr2:214810229~214963274:+
SARC	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-4.77	3.25e-06	0.0018	-0.31	-0.3	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
SARC	cis	rs12893668	0.703	rs8017993	ENSG00000269940.1	RP11-73M18.7	4.77	3.25e-06	0.0018	0.29	0.3	Reticulocyte count;	chr14:103581397	chr14:103694560~103695170:+
SARC	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-4.77	3.25e-06	0.0018	-0.35	-0.3	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
SARC	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-4.77	3.25e-06	0.0018	-0.33	-0.3	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
SARC	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-4.77	3.25e-06	0.0018	-0.36	-0.3	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
SARC	cis	rs7772486	0.686	rs9403739	ENSG00000270638.1	RP3-466P17.1	-4.77	3.25e-06	0.0018	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145735570~145737218:+
SARC	cis	rs10800713	0.56	rs10800706	ENSG00000260088.1	RP11-92G12.3	-4.77	3.26e-06	0.0018	-0.42	-0.3	Tandem gait;	chr1:200526967	chr1:200669507~200694250:+
SARC	cis	rs858239	0.669	rs10950940	ENSG00000226816.2	AC005082.12	-4.77	3.27e-06	0.00181	-0.37	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23206013~23208045:+
SARC	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	4.77	3.27e-06	0.00181	0.26	0.3	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	4.77	3.27e-06	0.00181	0.26	0.3	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
SARC	cis	rs2179367	0.537	rs12192159	ENSG00000231760.4	RP11-350J20.5	4.77	3.27e-06	0.00181	0.42	0.3	Dupuytren's disease;	chr6:149445969	chr6:149796151~149826294:-
SARC	cis	rs2018683	0.6	rs6948880	ENSG00000228421.2	AC005013.5	4.77	3.27e-06	0.00181	0.31	0.3	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28957667~28959345:+
SARC	cis	rs2018683	0.624	rs6462119	ENSG00000228421.2	AC005013.5	4.77	3.27e-06	0.00181	0.31	0.3	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28957667~28959345:+
SARC	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	4.77	3.27e-06	0.00181	0.48	0.3	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	4.77	3.27e-06	0.00181	0.48	0.3	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
SARC	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	4.77	3.27e-06	0.00181	0.48	0.3	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
SARC	cis	rs890448	0.93	rs2471677	ENSG00000254531.1	FLJ20021	-4.77	3.27e-06	0.00181	-0.29	-0.3	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101458438	chr4:101347780~101348883:+
SARC	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-4.77	3.27e-06	0.00181	-0.32	-0.3	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
SARC	cis	rs7267979	1	rs6050555	ENSG00000276952.1	RP5-965G21.6	-4.77	3.28e-06	0.00181	-0.29	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25284915~25285588:-
SARC	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	4.77	3.28e-06	0.00181	0.37	0.3	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
SARC	cis	rs75422866	0.541	rs61918136	ENSG00000274902.1	RP1-197B17.4	4.77	3.28e-06	0.00182	0.61	0.3	Pneumonia;	chr12:47566798	chr12:47731908~47732351:+
SARC	cis	rs9494145	0.638	rs6569992	ENSG00000232876.1	CTA-212D2.2	-4.77	3.29e-06	0.00182	-0.45	-0.3	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135131014	chr6:135055033~135060550:+
SARC	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-4.77	3.29e-06	0.00182	-0.4	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
SARC	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-4.77	3.29e-06	0.00182	-0.36	-0.3	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
SARC	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	4.77	3.29e-06	0.00182	0.35	0.3	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
SARC	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	4.77	3.29e-06	0.00182	0.32	0.3	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
SARC	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	4.77	3.29e-06	0.00182	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	4.77	3.29e-06	0.00182	0.34	0.3	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
SARC	cis	rs8005677	1	rs11157930	ENSG00000257285.4	RP11-298I3.1	4.77	3.29e-06	0.00182	0.28	0.3	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:22929609~22955562:+
SARC	cis	rs8005677	0.962	rs11157931	ENSG00000257285.4	RP11-298I3.1	4.77	3.29e-06	0.00182	0.28	0.3	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:22929609~22955562:+
SARC	cis	rs8031584	0.56	rs7171208	ENSG00000260382.1	RP11-540B6.2	-4.77	3.29e-06	0.00182	-0.34	-0.3	Huntington's disease progression;	chr15:30906726	chr15:30882267~30883231:-
SARC	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-4.77	3.29e-06	0.00182	-0.37	-0.3	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
SARC	cis	rs1865760	0.566	rs3752420	ENSG00000272462.2	U91328.19	-4.77	3.29e-06	0.00182	-0.27	-0.3	Height;	chr6:26026907	chr6:25992662~26001775:+
SARC	cis	rs2439831	1	rs28666488	ENSG00000205771.5	CATSPER2P1	-4.77	3.29e-06	0.00182	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43448892	chr15:43726918~43747094:-
SARC	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-4.77	3.29e-06	0.00182	-0.31	-0.3	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
SARC	cis	rs910316	0.967	rs4899545	ENSG00000279594.1	RP11-950C14.10	4.77	3.3e-06	0.00182	0.32	0.3	Height;	chr14:75101435	chr14:75011269~75012851:-
SARC	cis	rs7246657	0.943	rs8109038	ENSG00000276846.1	CTD-3220F14.3	-4.77	3.3e-06	0.00182	-0.39	-0.3	Coronary artery calcification;	chr19:37524807	chr19:37314868~37315620:-
SARC	cis	rs8031584	0.541	rs1983459	ENSG00000260382.1	RP11-540B6.2	4.77	3.3e-06	0.00182	0.34	0.3	Huntington's disease progression;	chr15:30916546	chr15:30882267~30883231:-
SARC	cis	rs7216064	0.553	rs62084690	ENSG00000265055.1	AC145343.2	-4.77	3.3e-06	0.00182	-0.35	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68039295	chr17:68096046~68101474:-
SARC	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-4.77	3.3e-06	0.00182	-0.3	-0.3	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
SARC	cis	rs10911902	0.643	rs76057663	ENSG00000229739.2	RP11-295K2.3	-4.77	3.3e-06	0.00182	-0.43	-0.3	Schizophrenia;	chr1:186325889	chr1:186435161~186470291:+
SARC	cis	rs853679	0.517	rs4713146	ENSG00000272009.1	RP1-313I6.12	-4.77	3.3e-06	0.00182	-0.35	-0.3	Depression;	chr6:28143758	chr6:28078792~28081130:-
SARC	cis	rs12216125	0.549	rs9358905	ENSG00000272810.1	U91328.22	-4.77	3.3e-06	0.00182	-0.29	-0.3	Iron status biomarkers;	chr6:26077611	chr6:26013241~26013757:+
SARC	cis	rs6969780	0.841	rs2301720	ENSG00000233429.8	HOTAIRM1	-4.77	3.3e-06	0.00182	-0.43	-0.3	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27156450	chr7:27095647~27100265:+
SARC	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-4.77	3.3e-06	0.00182	-0.45	-0.3	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
SARC	cis	rs2179367	0.537	rs6911411	ENSG00000231760.4	RP11-350J20.5	4.77	3.31e-06	0.00183	0.44	0.3	Dupuytren's disease;	chr6:149366954	chr6:149796151~149826294:-
SARC	cis	rs910316	0.737	rs175043	ENSG00000279594.1	RP11-950C14.10	-4.77	3.31e-06	0.00183	-0.34	-0.3	Height;	chr14:75005100	chr14:75011269~75012851:-
SARC	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-4.77	3.31e-06	0.00183	-0.3	-0.3	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
SARC	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	4.77	3.31e-06	0.00183	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	4.77	3.31e-06	0.00183	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	4.77	3.31e-06	0.00183	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
SARC	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-4.77	3.31e-06	0.00183	-0.31	-0.3	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
SARC	cis	rs7772486	0.727	rs10223508	ENSG00000270638.1	RP3-466P17.1	-4.77	3.32e-06	0.00183	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145735570~145737218:+
SARC	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-4.77	3.32e-06	0.00183	-0.3	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
SARC	cis	rs10754283	0.967	rs12058749	ENSG00000231613.1	RP5-943J3.1	4.77	3.32e-06	0.00183	0.29	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89640045	chr1:89788914~89790492:+
SARC	cis	rs7216064	0.817	rs28609796	ENSG00000278219.1	AC145343.1	-4.77	3.32e-06	0.00183	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67858988	chr17:68101538~68101639:+
SARC	cis	rs2708377	0.656	rs73066852	ENSG00000247157.5	LINC01252	4.77	3.32e-06	0.00183	0.5	0.3	Bitter taste perception;	chr12:11123942	chr12:11548030~11590369:+
SARC	cis	rs2708377	0.858	rs117212341	ENSG00000247157.5	LINC01252	4.77	3.32e-06	0.00183	0.5	0.3	Bitter taste perception;	chr12:11129957	chr12:11548030~11590369:+
SARC	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	4.76	3.32e-06	0.00183	0.33	0.3	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
SARC	cis	rs1707322	0.717	rs1547925	ENSG00000281133.1	AL355480.3	4.76	3.33e-06	0.00183	0.35	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45580892~45580996:-
SARC	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-4.76	3.33e-06	0.00184	-0.56	-0.3	Gout;	chr7:66721259	chr7:66654538~66669855:+
SARC	cis	rs2404602	0.552	rs4886823	ENSG00000259422.1	RP11-593F23.1	-4.76	3.33e-06	0.00184	-0.37	-0.3	Blood metabolite levels;	chr15:76673061	chr15:76174891~76181486:-
SARC	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-4.76	3.34e-06	0.00184	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
SARC	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-4.76	3.34e-06	0.00184	-0.44	-0.3	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
SARC	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	4.76	3.34e-06	0.00184	0.48	0.3	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
SARC	cis	rs7772486	0.72	rs6931553	ENSG00000270638.1	RP3-466P17.1	-4.76	3.34e-06	0.00184	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs9373475	ENSG00000270638.1	RP3-466P17.1	4.76	3.34e-06	0.00184	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145735570~145737218:+
SARC	cis	rs17270561	0.609	rs1317510	ENSG00000272462.2	U91328.19	-4.76	3.35e-06	0.00184	-0.28	-0.3	Iron status biomarkers;	chr6:25778696	chr6:25992662~26001775:+
SARC	cis	rs1707322	0.682	rs12037459	ENSG00000281133.1	AL355480.3	-4.76	3.35e-06	0.00185	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45580892~45580996:-
SARC	cis	rs875971	0.619	rs12533585	ENSG00000236529.1	RP13-254B10.1	4.76	3.35e-06	0.00185	0.31	0.3	Aortic root size;	chr7:66519618	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs12698534	ENSG00000236529.1	RP13-254B10.1	4.76	3.35e-06	0.00185	0.31	0.3	Aortic root size;	chr7:66521858	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs28698552	ENSG00000236529.1	RP13-254B10.1	4.76	3.35e-06	0.00185	0.31	0.3	Aortic root size;	chr7:66540031	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs62465434	ENSG00000236529.1	RP13-254B10.1	4.76	3.35e-06	0.00185	0.31	0.3	Aortic root size;	chr7:66540165	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs13224319	ENSG00000236529.1	RP13-254B10.1	4.76	3.35e-06	0.00185	0.31	0.3	Aortic root size;	chr7:66542376	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs801217	ENSG00000236529.1	RP13-254B10.1	-4.76	3.35e-06	0.00185	-0.31	-0.3	Aortic root size;	chr7:66545590	chr7:65840212~65840596:+
SARC	cis	rs875971	0.638	rs801216	ENSG00000236529.1	RP13-254B10.1	-4.76	3.35e-06	0.00185	-0.31	-0.3	Aortic root size;	chr7:66546680	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs801211	ENSG00000236529.1	RP13-254B10.1	-4.76	3.35e-06	0.00185	-0.31	-0.3	Aortic root size;	chr7:66550702	chr7:65840212~65840596:+
SARC	cis	rs875971	0.638	rs801205	ENSG00000236529.1	RP13-254B10.1	-4.76	3.35e-06	0.00185	-0.31	-0.3	Aortic root size;	chr7:66557157	chr7:65840212~65840596:+
SARC	cis	rs875971	0.617	rs810400	ENSG00000236529.1	RP13-254B10.1	-4.76	3.35e-06	0.00185	-0.31	-0.3	Aortic root size;	chr7:66557902	chr7:65840212~65840596:+
SARC	cis	rs4713118	0.824	rs9468225	ENSG00000219392.1	RP1-265C24.5	-4.76	3.35e-06	0.00185	-0.41	-0.3	Parkinson's disease;	chr6:27777940	chr6:28115628~28116551:+
SARC	cis	rs2274273	0.588	rs17675223	ENSG00000258413.1	RP11-665C16.6	-4.76	3.35e-06	0.00185	-0.39	-0.3	Protein biomarker;	chr14:55395518	chr14:55262767~55272075:-
SARC	cis	rs4862750	0.872	rs4862747	ENSG00000250971.1	RP11-696F12.1	-4.76	3.36e-06	0.00185	-0.36	-0.3	Lobe attachment (rater-scored or self-reported);	chr4:186956082	chr4:187060099~187060930:+
SARC	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-4.76	3.36e-06	0.00185	-0.35	-0.3	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
SARC	cis	rs875971	0.66	rs801192	ENSG00000236529.1	RP13-254B10.1	-4.76	3.36e-06	0.00185	-0.31	-0.3	Aortic root size;	chr7:66566965	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs801190	ENSG00000236529.1	RP13-254B10.1	-4.76	3.36e-06	0.00185	-0.31	-0.3	Aortic root size;	chr7:66568046	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs3857686	ENSG00000236529.1	RP13-254B10.1	-4.76	3.36e-06	0.00185	-0.31	-0.3	Aortic root size;	chr7:66571204	chr7:65840212~65840596:+
SARC	cis	rs875971	0.638	rs3898855	ENSG00000236529.1	RP13-254B10.1	-4.76	3.36e-06	0.00185	-0.31	-0.3	Aortic root size;	chr7:66571411	chr7:65840212~65840596:+
SARC	cis	rs875971	0.638	rs10278816	ENSG00000236529.1	RP13-254B10.1	-4.76	3.36e-06	0.00185	-0.31	-0.3	Aortic root size;	chr7:66572000	chr7:65840212~65840596:+
SARC	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-4.76	3.36e-06	0.00185	-0.28	-0.3	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
SARC	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-4.76	3.36e-06	0.00185	-0.32	-0.3	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-4.76	3.36e-06	0.00185	-0.32	-0.3	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-4.76	3.36e-06	0.00185	-0.32	-0.3	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
SARC	cis	rs910316	0.967	rs4384542	ENSG00000279594.1	RP11-950C14.10	-4.76	3.37e-06	0.00185	-0.32	-0.3	Height;	chr14:75191310	chr14:75011269~75012851:-
SARC	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-4.76	3.37e-06	0.00185	-0.34	-0.3	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
SARC	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-4.76	3.37e-06	0.00185	-0.34	-0.3	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
SARC	cis	rs6570726	0.738	rs4495284	ENSG00000270638.1	RP3-466P17.1	4.76	3.37e-06	0.00185	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145735570~145737218:+
SARC	cis	rs7208859	0.778	rs6505219	ENSG00000263531.1	RP13-753N3.1	4.76	3.37e-06	0.00185	0.43	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30863921~30864940:-
SARC	cis	rs2439831	0.85	rs68079546	ENSG00000205771.5	CATSPER2P1	-4.76	3.37e-06	0.00185	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43844759	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs56909447	ENSG00000205771.5	CATSPER2P1	-4.76	3.37e-06	0.00185	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43845420	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs28476182	ENSG00000205771.5	CATSPER2P1	-4.76	3.37e-06	0.00185	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43847445	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs28696802	ENSG00000205771.5	CATSPER2P1	-4.76	3.37e-06	0.00185	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43848197	chr15:43726918~43747094:-
SARC	cis	rs910316	0.934	rs7141705	ENSG00000279594.1	RP11-950C14.10	-4.76	3.37e-06	0.00186	-0.32	-0.3	Height;	chr14:75188649	chr14:75011269~75012851:-
SARC	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	4.76	3.38e-06	0.00186	0.45	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
SARC	cis	rs7772486	0.686	rs1569540	ENSG00000270638.1	RP3-466P17.1	-4.76	3.38e-06	0.00186	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.686	rs2142983	ENSG00000270638.1	RP3-466P17.1	-4.76	3.38e-06	0.00186	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145735570~145737218:+
SARC	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-4.76	3.39e-06	0.00186	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
SARC	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-4.76	3.39e-06	0.00186	-0.39	-0.3	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
SARC	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	4.76	3.39e-06	0.00187	0.29	0.3	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
SARC	cis	rs2179367	0.568	rs9498358	ENSG00000231760.4	RP11-350J20.5	4.76	3.39e-06	0.00187	0.44	0.3	Dupuytren's disease;	chr6:149458529	chr6:149796151~149826294:-
SARC	cis	rs193541	0.632	rs415417	ENSG00000263432.2	RN7SL689P	-4.76	3.39e-06	0.00187	-0.38	-0.3	Glucose homeostasis traits;	chr5:122987189	chr5:123022487~123022783:-
SARC	cis	rs193541	0.632	rs62377425	ENSG00000263432.2	RN7SL689P	-4.76	3.39e-06	0.00187	-0.38	-0.3	Glucose homeostasis traits;	chr5:122996930	chr5:123022487~123022783:-
SARC	cis	rs193541	0.632	rs34714850	ENSG00000263432.2	RN7SL689P	-4.76	3.39e-06	0.00187	-0.38	-0.3	Glucose homeostasis traits;	chr5:122997000	chr5:123022487~123022783:-
SARC	cis	rs4703855	0.538	rs4703869	ENSG00000244061.1	RP11-389C8.1	4.76	3.39e-06	0.00187	0.3	0.3	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72423202	chr5:72381794~72382393:+
SARC	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-4.76	3.4e-06	0.00187	-0.39	-0.3	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
SARC	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-4.76	3.4e-06	0.00187	-0.45	-0.3	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
SARC	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	4.76	3.4e-06	0.00187	0.29	0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
SARC	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-4.76	3.4e-06	0.00187	-0.33	-0.3	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
SARC	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	4.76	3.4e-06	0.00187	0.33	0.3	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	4.76	3.4e-06	0.00187	0.33	0.3	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	4.76	3.4e-06	0.00187	0.33	0.3	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	4.76	3.4e-06	0.00187	0.33	0.3	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	4.76	3.4e-06	0.00187	0.33	0.3	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	4.76	3.4e-06	0.00187	0.33	0.3	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
SARC	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	4.76	3.4e-06	0.00187	0.33	0.3	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
SARC	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-4.76	3.4e-06	0.00187	-0.48	-0.3	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
SARC	cis	rs2487048	0.519	rs2487032	ENSG00000226334.1	RP11-217B7.2	-4.76	3.4e-06	0.00187	-0.4	-0.3	Intraocular pressure;	chr9:104941653	chr9:104927553~104928892:+
SARC	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	4.76	3.41e-06	0.00187	0.43	0.3	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
SARC	cis	rs1707322	0.752	rs7541962	ENSG00000281133.1	AL355480.3	-4.76	3.41e-06	0.00187	-0.34	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45580892~45580996:-
SARC	cis	rs7216064	0.734	rs11653507	ENSG00000265055.1	AC145343.2	4.76	3.41e-06	0.00187	0.36	0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67895948	chr17:68096046~68101474:-
SARC	cis	rs11123170	0.65	rs2289897	ENSG00000274877.1	RP11-65I12.1	-4.76	3.41e-06	0.00187	-0.38	-0.3	Renal function-related traits (BUN);	chr2:113219877	chr2:113237595~113240825:+
SARC	cis	rs2179367	0.6	rs9498352	ENSG00000231760.4	RP11-350J20.5	4.76	3.41e-06	0.00187	0.43	0.3	Dupuytren's disease;	chr6:149439108	chr6:149796151~149826294:-
SARC	cis	rs7512898	0.9	rs6427847	ENSG00000260088.1	RP11-92G12.3	-4.76	3.41e-06	0.00187	-0.29	-0.3	Electrocardiographic conduction measures;	chr1:200700052	chr1:200669507~200694250:+
SARC	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	4.76	3.41e-06	0.00188	0.33	0.3	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
SARC	cis	rs7811142	1	rs6972167	ENSG00000242294.5	STAG3L5P	4.76	3.42e-06	0.00188	0.24	0.3	Platelet count;	chr7:100482390	chr7:100336079~100351900:+
SARC	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-4.76	3.42e-06	0.00188	-0.33	-0.3	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
SARC	cis	rs17270561	0.636	rs9393671	ENSG00000272810.1	U91328.22	4.76	3.42e-06	0.00188	0.29	0.3	Iron status biomarkers;	chr6:25788961	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs1179086	ENSG00000272810.1	U91328.22	-4.76	3.42e-06	0.00188	-0.29	-0.3	Iron status biomarkers;	chr6:25791517	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.636	rs1165157	ENSG00000272810.1	U91328.22	-4.76	3.42e-06	0.00188	-0.29	-0.3	Iron status biomarkers;	chr6:25792022	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs1165156	ENSG00000272810.1	U91328.22	-4.76	3.42e-06	0.00188	-0.29	-0.3	Iron status biomarkers;	chr6:25792750	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.609	rs1165155	ENSG00000272810.1	U91328.22	-4.76	3.42e-06	0.00188	-0.29	-0.3	Iron status biomarkers;	chr6:25795349	chr6:26013241~26013757:+
SARC	cis	rs17270561	0.636	rs1165216	ENSG00000272810.1	U91328.22	-4.76	3.42e-06	0.00188	-0.29	-0.3	Iron status biomarkers;	chr6:25797743	chr6:26013241~26013757:+
SARC	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-4.76	3.42e-06	0.00188	-0.34	-0.3	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-4.76	3.42e-06	0.00188	-0.34	-0.3	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-4.76	3.42e-06	0.00188	-0.34	-0.3	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
SARC	cis	rs875971	0.638	rs7793569	ENSG00000236529.1	RP13-254B10.1	-4.76	3.42e-06	0.00188	-0.31	-0.3	Aortic root size;	chr7:66651646	chr7:65840212~65840596:+
SARC	cis	rs17270561	0.609	rs4132072	ENSG00000272810.1	U91328.22	-4.76	3.42e-06	0.00188	-0.3	-0.3	Iron status biomarkers;	chr6:25717615	chr6:26013241~26013757:+
SARC	cis	rs7216064	1	rs12451707	ENSG00000278219.1	AC145343.1	-4.76	3.42e-06	0.00188	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67875482	chr17:68101538~68101639:+
SARC	cis	rs62103177	0.564	rs1864529	ENSG00000261126.6	RP11-795F19.1	-4.76	3.43e-06	0.00188	-0.3	-0.3	Opioid sensitivity;	chr18:79988975	chr18:80046900~80095482:+
SARC	cis	rs4862750	0.914	rs9995391	ENSG00000249742.1	RP11-217E13.1	4.76	3.43e-06	0.00188	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186952595	chr4:186979490~187021973:-
SARC	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	4.76	3.43e-06	0.00188	0.28	0.3	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
SARC	cis	rs9438901	0.592	rs1293259	ENSG00000261349.1	RP3-465N24.5	4.76	3.43e-06	0.00189	0.47	0.3	Red cell distribution width;	chr1:25369344	chr1:25266102~25267136:-
SARC	cis	rs7430456	0.837	rs7651130	ENSG00000225790.1	RP11-2L8.1	-4.76	3.44e-06	0.00189	-0.29	-0.3	Breast cancer;	chr3:177719720	chr3:177934823~177937662:+
SARC	cis	rs2439831	1	rs1814538	ENSG00000205771.5	CATSPER2P1	4.76	3.44e-06	0.00189	0.43	0.3	Lung cancer in ever smokers;	chr15:43467576	chr15:43726918~43747094:-
SARC	cis	rs8062405	0.72	rs9926245	ENSG00000251417.2	RP11-1348G14.4	-4.76	3.44e-06	0.00189	-0.28	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28802743~28817828:+
SARC	cis	rs14027	0.883	rs28486074	ENSG00000279347.1	RP11-85I17.2	-4.76	3.44e-06	0.00189	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720762	chr8:119838736~119840385:-
SARC	cis	rs14027	0.842	rs28634937	ENSG00000279347.1	RP11-85I17.2	-4.76	3.44e-06	0.00189	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720877	chr8:119838736~119840385:-
SARC	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-4.76	3.45e-06	0.00189	-0.33	-0.3	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-4.76	3.45e-06	0.00189	-0.33	-0.3	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
SARC	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-4.76	3.45e-06	0.00189	-0.32	-0.3	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
SARC	cis	rs858239	0.863	rs274058	ENSG00000226816.2	AC005082.12	4.76	3.45e-06	0.00189	0.36	0.3	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23206013~23208045:+
SARC	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-4.76	3.46e-06	0.0019	-0.33	-0.3	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-4.76	3.46e-06	0.0019	-0.33	-0.3	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
SARC	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-4.76	3.46e-06	0.0019	-0.34	-0.3	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-4.76	3.46e-06	0.0019	-0.34	-0.3	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
SARC	cis	rs2933343	0.7	rs1683779	ENSG00000261159.1	RP11-723O4.9	4.76	3.46e-06	0.0019	0.32	0.3	IgG glycosylation;	chr3:128923205	chr3:128859716~128860526:-
SARC	cis	rs13161895	0.941	rs6876648	ENSG00000250999.1	RP11-1379J22.5	4.76	3.47e-06	0.0019	0.51	0.3	LDL cholesterol;	chr5:180014842	chr5:179657762~179664432:+
SARC	cis	rs17270561	0.609	rs1165211	ENSG00000272810.1	U91328.22	-4.76	3.47e-06	0.0019	-0.29	-0.3	Iron status biomarkers;	chr6:25800694	chr6:26013241~26013757:+
SARC	cis	rs2288884	0.559	rs73052102	ENSG00000275055.1	CTC-471J1.11	-4.76	3.47e-06	0.0019	-0.34	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:52049007~52049754:+
SARC	cis	rs7772486	0.686	rs1011596	ENSG00000270638.1	RP3-466P17.1	4.76	3.47e-06	0.0019	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145735570~145737218:+
SARC	cis	rs2404602	0.735	rs2461870	ENSG00000259422.1	RP11-593F23.1	-4.76	3.47e-06	0.0019	-0.35	-0.3	Blood metabolite levels;	chr15:76521579	chr15:76174891~76181486:-
SARC	cis	rs4845875	0.514	rs198406	ENSG00000242349.4	NPPA-AS1	-4.76	3.47e-06	0.0019	-0.31	-0.3	Midregional pro atrial natriuretic peptide levels;	chr1:11837535	chr1:11841017~11848079:+
SARC	cis	rs4845875	0.535	rs198408	ENSG00000242349.4	NPPA-AS1	-4.76	3.47e-06	0.0019	-0.31	-0.3	Midregional pro atrial natriuretic peptide levels;	chr1:11838073	chr1:11841017~11848079:+
SARC	cis	rs1823913	0.637	rs2067610	ENSG00000227542.1	AC092614.2	4.75	3.49e-06	0.00191	0.33	0.3	Obesity-related traits;	chr2:191299251	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.599	rs1454754	ENSG00000227542.1	AC092614.2	4.75	3.49e-06	0.00191	0.33	0.3	Obesity-related traits;	chr2:191303562	chr2:191229165~191246172:-
SARC	cis	rs1865760	0.602	rs2157050	ENSG00000272462.2	U91328.19	-4.75	3.49e-06	0.00191	-0.27	-0.3	Height;	chr6:26020203	chr6:25992662~26001775:+
SARC	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	4.75	3.49e-06	0.00191	0.36	0.3	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
SARC	cis	rs910316	0.935	rs11159119	ENSG00000279594.1	RP11-950C14.10	-4.75	3.49e-06	0.00191	-0.33	-0.3	Height;	chr14:75170264	chr14:75011269~75012851:-
SARC	cis	rs62432291	0.681	rs400477	ENSG00000235086.1	FNDC1-IT1	4.75	3.49e-06	0.00191	0.49	0.3	Joint mobility (Beighton score);	chr6:159214911	chr6:159240786~159243329:+
SARC	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-4.75	3.5e-06	0.00192	-0.35	-0.3	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
SARC	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	4.75	3.5e-06	0.00192	0.35	0.3	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
SARC	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-4.75	3.5e-06	0.00192	-0.36	-0.3	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
SARC	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-4.75	3.5e-06	0.00192	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-4.75	3.5e-06	0.00192	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-4.75	3.5e-06	0.00192	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
SARC	cis	rs1823913	0.637	rs13010441	ENSG00000227542.1	AC092614.2	4.75	3.51e-06	0.00192	0.33	0.3	Obesity-related traits;	chr2:191303903	chr2:191229165~191246172:-
SARC	cis	rs2179367	0.6	rs58747890	ENSG00000231760.4	RP11-350J20.5	4.75	3.51e-06	0.00192	0.44	0.3	Dupuytren's disease;	chr6:149459369	chr6:149796151~149826294:-
SARC	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	4.75	3.52e-06	0.00193	0.25	0.3	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
SARC	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-4.75	3.52e-06	0.00193	-0.31	-0.3	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-4.75	3.52e-06	0.00193	-0.31	-0.3	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
SARC	cis	rs2283792	0.73	rs56398890	ENSG00000224086.5	LL22NC03-86G7.1	-4.75	3.52e-06	0.00193	-0.31	-0.3	Multiple sclerosis;	chr22:21836496	chr22:21938293~21977632:+
SARC	cis	rs10754283	0.967	rs1934044	ENSG00000231613.1	RP5-943J3.1	-4.75	3.52e-06	0.00193	-0.3	-0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89641942	chr1:89788914~89790492:+
SARC	cis	rs875971	0.577	rs34888281	ENSG00000236529.1	RP13-254B10.1	-4.75	3.52e-06	0.00193	-0.31	-0.3	Aortic root size;	chr7:66120784	chr7:65840212~65840596:+
SARC	cis	rs2803122	0.807	rs4977289	ENSG00000273226.1	RP11-513M16.8	-4.75	3.52e-06	0.00193	-0.29	-0.3	Pulse pressure;	chr9:19225190	chr9:19375451~19375996:+
SARC	cis	rs7615952	0.599	rs2270986	ENSG00000250012.1	RP11-124N2.1	-4.75	3.53e-06	0.00193	-0.29	-0.3	Blood pressure (smoking interaction);	chr3:125982256	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.599	rs12496921	ENSG00000250012.1	RP11-124N2.1	-4.75	3.53e-06	0.00193	-0.29	-0.3	Blood pressure (smoking interaction);	chr3:125983105	chr3:126084220~126095349:+
SARC	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	4.75	3.53e-06	0.00193	0.3	0.3	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
SARC	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-4.75	3.53e-06	0.00193	-0.29	-0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
SARC	cis	rs964184	0.63	rs2075290	ENSG00000254851.1	RP11-109L13.1	-4.75	3.53e-06	0.00193	-0.57	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116782580	chr11:117135528~117138582:+
SARC	cis	rs964184	0.63	rs10750096	ENSG00000254851.1	RP11-109L13.1	-4.75	3.53e-06	0.00193	-0.57	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116786072	chr11:117135528~117138582:+
SARC	cis	rs4372836	0.504	rs10177006	ENSG00000226833.4	AC097724.3	4.75	3.53e-06	0.00193	0.25	0.3	Body mass index;	chr2:28865390	chr2:28708953~28736205:-
SARC	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	4.75	3.53e-06	0.00193	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
SARC	cis	rs7772486	0.623	rs9485021	ENSG00000270638.1	RP3-466P17.1	-4.75	3.54e-06	0.00193	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145735570~145737218:+
SARC	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-4.75	3.54e-06	0.00193	-0.36	-0.3	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
SARC	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-4.75	3.54e-06	0.00194	-0.35	-0.3	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
SARC	cis	rs875971	0.66	rs10281080	ENSG00000236529.1	RP13-254B10.1	-4.75	3.54e-06	0.00194	-0.31	-0.3	Aortic root size;	chr7:66577454	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs10950044	ENSG00000236529.1	RP13-254B10.1	-4.75	3.54e-06	0.00194	-0.31	-0.3	Aortic root size;	chr7:66577989	chr7:65840212~65840596:+
SARC	cis	rs8081395	0.741	rs1292053	ENSG00000266992.1	DHX40P1	-4.75	3.55e-06	0.00194	-0.31	-0.3	White blood cell count;	chr17:59886176	chr17:59976009~60002384:-
SARC	cis	rs2562456	0.876	rs7252585	ENSG00000268081.1	RP11-678G14.2	-4.75	3.56e-06	0.00194	-0.43	-0.3	Pain;	chr19:21475141	chr19:21554640~21569237:-
SARC	cis	rs367615	0.679	rs10070786	ENSG00000249476.1	CTD-2587M2.1	4.75	3.56e-06	0.00194	0.38	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109479380	chr5:109237120~109326369:-
SARC	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-4.75	3.56e-06	0.00194	-0.36	-0.3	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
SARC	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-4.75	3.56e-06	0.00194	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
SARC	cis	rs2404602	0.598	rs71405204	ENSG00000259422.1	RP11-593F23.1	-4.75	3.56e-06	0.00195	-0.38	-0.3	Blood metabolite levels;	chr15:76342964	chr15:76174891~76181486:-
SARC	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-4.75	3.56e-06	0.00195	-0.34	-0.3	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
SARC	cis	rs7743045	0.625	rs12664251	ENSG00000253194.1	RP11-351A11.1	4.75	3.57e-06	0.00195	0.35	0.3	Mean platelet volume;	chr6:119023381	chr6:118934785~119031541:+
SARC	cis	rs801193	0.967	rs34356500	ENSG00000236529.1	RP13-254B10.1	4.75	3.58e-06	0.00195	0.3	0.3	Aortic root size;	chr7:66771620	chr7:65840212~65840596:+
SARC	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-4.75	3.58e-06	0.00195	-0.34	-0.3	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
SARC	cis	rs62432291	0.681	rs1699442	ENSG00000235086.1	FNDC1-IT1	4.75	3.58e-06	0.00195	0.48	0.3	Joint mobility (Beighton score);	chr6:159234886	chr6:159240786~159243329:+
SARC	cis	rs1431005	1	rs1431005	ENSG00000250620.1	RP11-91J3.3	-4.75	3.59e-06	0.00196	-0.33	-0.3	Response to statin therapy;	chr4:187424214	chr4:187413564~187415697:+
SARC	cis	rs7216064	1	rs8081517	ENSG00000265055.1	AC145343.2	4.75	3.59e-06	0.00196	0.37	0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67849581	chr17:68096046~68101474:-
SARC	cis	rs853679	0.517	rs9283884	ENSG00000272009.1	RP1-313I6.12	4.75	3.6e-06	0.00196	0.34	0.3	Depression;	chr6:28167882	chr6:28078792~28081130:-
SARC	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	4.75	3.6e-06	0.00196	0.27	0.3	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
SARC	cis	rs763121	1	rs138457	ENSG00000273076.1	RP3-508I15.22	-4.75	3.6e-06	0.00196	-0.31	-0.3	Menopause (age at onset);	chr22:38502046	chr22:38743495~38743910:+
SARC	cis	rs1993293	1	rs1993293	ENSG00000259363.4	CTD-2054N24.2	4.75	3.6e-06	0.00196	0.29	0.3	Coronary artery calcification;	chr15:99757458	chr15:99807023~99877148:+
SARC	cis	rs7712401	0.58	rs4288111	ENSG00000263432.2	RN7SL689P	-4.75	3.6e-06	0.00196	-0.36	-0.3	Mean platelet volume;	chr5:123052487	chr5:123022487~123022783:-
SARC	cis	rs14027	0.921	rs4871634	ENSG00000279347.1	RP11-85I17.2	-4.75	3.6e-06	0.00196	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119806243	chr8:119838736~119840385:-
SARC	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	4.75	3.61e-06	0.00197	0.31	0.3	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	4.75	3.61e-06	0.00197	0.31	0.3	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
SARC	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	4.75	3.61e-06	0.00197	0.57	0.3	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	4.75	3.61e-06	0.00197	0.57	0.3	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	4.75	3.61e-06	0.00197	0.57	0.3	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	4.75	3.61e-06	0.00197	0.57	0.3	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
SARC	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	4.75	3.61e-06	0.00197	0.57	0.3	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	4.75	3.61e-06	0.00197	0.57	0.3	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	4.75	3.61e-06	0.00197	0.57	0.3	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	4.75	3.61e-06	0.00197	0.57	0.3	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	4.75	3.61e-06	0.00197	0.57	0.3	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	4.75	3.61e-06	0.00197	0.57	0.3	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
SARC	cis	rs41369048	0.669	rs11589654	ENSG00000238078.1	LINC01352	-4.75	3.62e-06	0.00197	-0.46	-0.3	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220866646	chr1:220829255~220832429:+
SARC	cis	rs6570726	0.791	rs9403729	ENSG00000270638.1	RP3-466P17.1	4.75	3.62e-06	0.00197	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145735570~145737218:+
SARC	cis	rs607541	0.85	rs9672672	ENSG00000259520.4	CTD-2651B20.3	-4.75	3.63e-06	0.00198	-0.58	-0.3	Obesity-related traits;	chr15:45636853	chr15:45251580~45279251:-
SARC	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-4.75	3.63e-06	0.00198	-0.3	-0.3	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
SARC	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-4.75	3.63e-06	0.00198	-0.33	-0.3	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-4.75	3.63e-06	0.00198	-0.33	-0.3	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
SARC	cis	rs1823913	0.614	rs4853463	ENSG00000227542.1	AC092614.2	-4.75	3.63e-06	0.00198	-0.33	-0.3	Obesity-related traits;	chr2:191278699	chr2:191229165~191246172:-
SARC	cis	rs17270561	0.609	rs7754296	ENSG00000272810.1	U91328.22	-4.74	3.64e-06	0.00198	-0.3	-0.3	Iron status biomarkers;	chr6:25744650	chr6:26013241~26013757:+
SARC	cis	rs910316	0.763	rs12588981	ENSG00000279594.1	RP11-950C14.10	4.74	3.65e-06	0.00198	0.33	0.3	Height;	chr14:74993858	chr14:75011269~75012851:-
SARC	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	4.74	3.65e-06	0.00198	0.3	0.3	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
SARC	cis	rs42490	0.716	rs40636	ENSG00000251136.7	RP11-37B2.1	-4.74	3.65e-06	0.00199	-0.32	-0.3	Leprosy;	chr8:89809079	chr8:89609409~89757727:-
SARC	cis	rs890448	0.726	rs2583394	ENSG00000254531.1	FLJ20021	4.74	3.65e-06	0.00199	0.31	0.3	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101330625	chr4:101347780~101348883:+
SARC	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-4.74	3.65e-06	0.00199	-0.34	-0.3	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
SARC	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	4.74	3.65e-06	0.00199	0.32	0.3	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
SARC	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-4.74	3.67e-06	0.00199	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
SARC	cis	rs7772486	0.79	rs2485632	ENSG00000270638.1	RP3-466P17.1	4.74	3.67e-06	0.002	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs2253307	ENSG00000270638.1	RP3-466P17.1	4.74	3.67e-06	0.002	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145735570~145737218:+
SARC	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	4.74	3.67e-06	0.002	0.34	0.3	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
SARC	cis	rs10800713	0.56	rs10919965	ENSG00000260088.1	RP11-92G12.3	-4.74	3.68e-06	0.002	-0.4	-0.3	Tandem gait;	chr1:200532134	chr1:200669507~200694250:+
SARC	cis	rs2933343	0.729	rs789231	ENSG00000231305.3	RP11-723O4.2	4.74	3.68e-06	0.002	0.3	0.3	IgG glycosylation;	chr3:128884004	chr3:128861313~128871540:-
SARC	cis	rs597539	0.617	rs669659	ENSG00000250508.1	RP11-757G1.6	-4.74	3.69e-06	0.002	-0.35	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868155	chr11:68870664~68874542:+
SARC	cis	rs597539	0.617	rs598353	ENSG00000250508.1	RP11-757G1.6	-4.74	3.69e-06	0.002	-0.35	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:68870664~68874542:+
SARC	cis	rs597539	0.617	rs686348	ENSG00000250508.1	RP11-757G1.6	-4.74	3.69e-06	0.002	-0.35	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:68870664~68874542:+
SARC	cis	rs597539	0.652	rs686877	ENSG00000250508.1	RP11-757G1.6	-4.74	3.69e-06	0.002	-0.35	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:68870664~68874542:+
SARC	cis	rs597539	0.652	rs579136	ENSG00000250508.1	RP11-757G1.6	-4.74	3.69e-06	0.002	-0.35	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68870664~68874542:+
SARC	cis	rs597539	0.652	rs10792001	ENSG00000250508.1	RP11-757G1.6	-4.74	3.69e-06	0.002	-0.35	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68870664~68874542:+
SARC	cis	rs597539	0.652	rs613128	ENSG00000250508.1	RP11-757G1.6	-4.74	3.69e-06	0.002	-0.35	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68870664~68874542:+
SARC	cis	rs792448	0.501	rs11119880	ENSG00000229983.1	RP11-15I11.2	4.74	3.69e-06	0.00201	0.31	0.3	White blood cell count (basophil);	chr1:212205143	chr1:212168207~212190259:+
SARC	cis	rs75920871	0.512	rs6589583	ENSG00000254851.1	RP11-109L13.1	4.74	3.69e-06	0.00201	0.39	0.3	Subjective well-being;	chr11:116993050	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.528	rs7930264	ENSG00000254851.1	RP11-109L13.1	4.74	3.69e-06	0.00201	0.39	0.3	Subjective well-being;	chr11:117000050	chr11:117135528~117138582:+
SARC	cis	rs7162943	0.887	rs293366	ENSG00000260123.1	RP11-326A19.4	4.74	3.69e-06	0.00201	0.27	0.3	Mean platelet volume;	chr15:89072556	chr15:89041223~89082819:+
SARC	cis	rs10911902	0.602	rs74370445	ENSG00000229739.2	RP11-295K2.3	-4.74	3.69e-06	0.00201	-0.43	-0.3	Schizophrenia;	chr1:186380327	chr1:186435161~186470291:+
SARC	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	4.74	3.7e-06	0.00201	0.31	0.3	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
SARC	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	4.74	3.7e-06	0.00201	0.31	0.3	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
SARC	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	4.74	3.7e-06	0.00201	0.3	0.3	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
SARC	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-4.74	3.7e-06	0.00201	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-4.74	3.7e-06	0.00201	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
SARC	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-4.74	3.7e-06	0.00201	-0.31	-0.3	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
SARC	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	4.74	3.7e-06	0.00201	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	4.74	3.7e-06	0.00201	0.35	0.3	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
SARC	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-4.74	3.71e-06	0.00201	-0.24	-0.3	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
SARC	cis	rs2239557	1	rs7153160	ENSG00000259065.1	RP5-1021I20.1	-4.74	3.71e-06	0.00201	-0.35	-0.3	Common traits (Other);	chr14:74042674	chr14:73787360~73803270:+
SARC	cis	rs4845875	0.514	rs198392	ENSG00000242349.4	NPPA-AS1	-4.74	3.71e-06	0.00201	-0.31	-0.3	Midregional pro atrial natriuretic peptide levels;	chr1:11819105	chr1:11841017~11848079:+
SARC	cis	rs7772486	0.754	rs4896841	ENSG00000270638.1	RP3-466P17.1	-4.74	3.71e-06	0.00201	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145735570~145737218:+
SARC	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-4.74	3.71e-06	0.00202	-0.28	-0.3	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
SARC	cis	rs2933343	0.729	rs1680780	ENSG00000231305.3	RP11-723O4.2	4.74	3.72e-06	0.00202	0.3	0.3	IgG glycosylation;	chr3:128893816	chr3:128861313~128871540:-
SARC	cis	rs62432291	0.681	rs404461	ENSG00000235086.1	FNDC1-IT1	4.74	3.72e-06	0.00202	0.49	0.3	Joint mobility (Beighton score);	chr6:159219677	chr6:159240786~159243329:+
SARC	cis	rs9487605	1	rs9487605	ENSG00000230177.1	RP5-1112D6.4	-4.74	3.73e-06	0.00202	-0.32	-0.3	Inflammatory skin disease;	chr6:111261682	chr6:111277932~111278742:+
SARC	cis	rs875971	0.638	rs10249404	ENSG00000236529.1	RP13-254B10.1	-4.74	3.73e-06	0.00202	-0.31	-0.3	Aortic root size;	chr7:66581737	chr7:65840212~65840596:+
SARC	cis	rs875971	0.66	rs10215132	ENSG00000236529.1	RP13-254B10.1	-4.74	3.73e-06	0.00202	-0.31	-0.3	Aortic root size;	chr7:66589419	chr7:65840212~65840596:+
SARC	cis	rs875971	0.522	rs1968127	ENSG00000236529.1	RP13-254B10.1	-4.74	3.73e-06	0.00202	-0.31	-0.3	Aortic root size;	chr7:66591816	chr7:65840212~65840596:+
SARC	cis	rs1823913	0.637	rs12624271	ENSG00000227542.1	AC092614.2	-4.74	3.73e-06	0.00202	-0.33	-0.3	Obesity-related traits;	chr2:191288586	chr2:191229165~191246172:-
SARC	cis	rs1707322	0.721	rs4660314	ENSG00000281133.1	AL355480.3	-4.74	3.73e-06	0.00202	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs12069121	ENSG00000281133.1	AL355480.3	-4.74	3.73e-06	0.00202	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45580892~45580996:-
SARC	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-4.74	3.73e-06	0.00202	-0.34	-0.3	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
SARC	cis	rs6969780	0.63	rs10238095	ENSG00000233429.8	HOTAIRM1	-4.74	3.73e-06	0.00202	-0.4	-0.3	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27157024	chr7:27095647~27100265:+
SARC	cis	rs910316	1	rs12590452	ENSG00000279594.1	RP11-950C14.10	4.74	3.73e-06	0.00202	0.32	0.3	Height;	chr14:75082053	chr14:75011269~75012851:-
SARC	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-4.74	3.73e-06	0.00202	-0.36	-0.3	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
SARC	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	4.74	3.73e-06	0.00202	0.3	0.3	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
SARC	cis	rs6570726	0.791	rs9373464	ENSG00000270638.1	RP3-466P17.1	4.74	3.74e-06	0.00202	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145735570~145737218:+
SARC	cis	rs79349575	0.783	rs17635252	ENSG00000270781.1	RP11-501C14.9	-4.74	3.74e-06	0.00203	-0.34	-0.3	Type 2 diabetes;	chr17:48929588	chr17:48899131~48899748:+
SARC	cis	rs7772486	0.686	rs1415744	ENSG00000270638.1	RP3-466P17.1	4.74	3.74e-06	0.00203	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145735570~145737218:+
SARC	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	4.74	3.74e-06	0.00203	0.32	0.3	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
SARC	cis	rs7809950	0.723	rs2237662	ENSG00000238832.1	snoU109	-4.74	3.74e-06	0.00203	-0.35	-0.3	Coronary artery disease;	chr7:107233620	chr7:107603363~107603507:+
SARC	cis	rs9309473	0.95	rs6745480	ENSG00000163016.8	ALMS1P	4.74	3.74e-06	0.00203	0.37	0.3	Metabolite levels;	chr2:73612928	chr2:73644919~73685576:+
SARC	cis	rs875971	0.508	rs10242423	ENSG00000236529.1	RP13-254B10.1	-4.74	3.74e-06	0.00203	-0.3	-0.3	Aortic root size;	chr7:66594188	chr7:65840212~65840596:+
SARC	cis	rs875971	0.508	rs10253883	ENSG00000236529.1	RP13-254B10.1	-4.74	3.74e-06	0.00203	-0.3	-0.3	Aortic root size;	chr7:66596151	chr7:65840212~65840596:+
SARC	cis	rs2933343	0.7	rs1683787	ENSG00000261159.1	RP11-723O4.9	-4.74	3.74e-06	0.00203	-0.32	-0.3	IgG glycosylation;	chr3:128908178	chr3:128859716~128860526:-
SARC	cis	rs1707322	0.638	rs9429095	ENSG00000280836.1	AL355480.1	4.74	3.74e-06	0.00203	0.3	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr1:45581219~45581321:-
SARC	cis	rs910316	0.967	rs2010678	ENSG00000279594.1	RP11-950C14.10	4.74	3.74e-06	0.00203	0.32	0.3	Height;	chr14:75100475	chr14:75011269~75012851:-
SARC	cis	rs1134634	0.52	rs4280723	ENSG00000273133.1	RP11-799M12.2	4.74	3.74e-06	0.00203	0.38	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574095	chr4:15563698~15564253:-
SARC	cis	rs9309473	0.687	rs6748040	ENSG00000163016.8	ALMS1P	-4.74	3.74e-06	0.00203	-0.35	-0.3	Metabolite levels;	chr2:73382800	chr2:73644919~73685576:+
SARC	cis	rs910316	1	rs1043674	ENSG00000279594.1	RP11-950C14.10	4.74	3.75e-06	0.00203	0.32	0.3	Height;	chr14:75082667	chr14:75011269~75012851:-
SARC	cis	rs910316	1	rs10142865	ENSG00000279594.1	RP11-950C14.10	4.74	3.75e-06	0.00203	0.32	0.3	Height;	chr14:75088921	chr14:75011269~75012851:-
SARC	cis	rs910316	1	rs10142626	ENSG00000279594.1	RP11-950C14.10	4.74	3.75e-06	0.00203	0.32	0.3	Height;	chr14:75088933	chr14:75011269~75012851:-
SARC	cis	rs910316	1	rs7142235	ENSG00000279594.1	RP11-950C14.10	4.74	3.75e-06	0.00203	0.32	0.3	Height;	chr14:75093260	chr14:75011269~75012851:-
SARC	cis	rs7216064	1	rs6504548	ENSG00000265055.1	AC145343.2	4.74	3.75e-06	0.00203	0.37	0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889932	chr17:68096046~68101474:-
SARC	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	4.74	3.75e-06	0.00203	0.32	0.3	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
SARC	cis	rs7712401	0.562	rs2407403	ENSG00000263432.2	RN7SL689P	4.74	3.75e-06	0.00203	0.37	0.3	Mean platelet volume;	chr5:122838336	chr5:123022487~123022783:-
SARC	cis	rs6570726	0.967	rs6903252	ENSG00000270638.1	RP3-466P17.1	4.74	3.75e-06	0.00203	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145601641	chr6:145735570~145737218:+
SARC	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	4.74	3.76e-06	0.00203	0.31	0.3	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	4.74	3.76e-06	0.00203	0.31	0.3	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	4.74	3.76e-06	0.00203	0.31	0.3	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	4.74	3.76e-06	0.00203	0.31	0.3	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
SARC	cis	rs7216064	0.589	rs7213585	ENSG00000265055.1	AC145343.2	4.74	3.76e-06	0.00203	0.35	0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68066200	chr17:68096046~68101474:-
SARC	cis	rs10911902	0.643	rs16825248	ENSG00000229739.2	RP11-295K2.3	-4.74	3.76e-06	0.00203	-0.43	-0.3	Schizophrenia;	chr1:186358057	chr1:186435161~186470291:+
SARC	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-4.74	3.76e-06	0.00204	-0.38	-0.3	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
SARC	cis	rs673078	0.66	rs61943365	ENSG00000275759.1	RP11-131L12.3	-4.74	3.76e-06	0.00204	-0.4	-0.3	Glucose homeostasis traits;	chr12:118339166	chr12:118428281~118428870:+
SARC	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-4.74	3.77e-06	0.00204	-0.33	-0.3	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-4.74	3.77e-06	0.00204	-0.33	-0.3	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
SARC	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-4.74	3.77e-06	0.00204	-0.34	-0.3	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
SARC	cis	rs875971	0.66	rs2191268	ENSG00000226824.5	RP4-756H11.3	-4.74	3.77e-06	0.00204	-0.34	-0.3	Aortic root size;	chr7:66645237	chr7:66654538~66669855:+
SARC	cis	rs728478	0.967	rs12600623	ENSG00000266992.1	DHX40P1	4.74	3.77e-06	0.00204	0.32	0.3	QT interval;	chr17:59378931	chr17:59976009~60002384:-
SARC	cis	rs7250849	0.79	rs73052830	ENSG00000273837.1	LLNLR-470E3.1	-4.74	3.77e-06	0.00204	-0.42	-0.3	Blood protein levels;	chr19:51657512	chr19:51639478~51639931:-
SARC	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-4.74	3.77e-06	0.00204	-0.37	-0.3	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
SARC	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-4.74	3.77e-06	0.00204	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
SARC	cis	rs7772486	0.72	rs6901888	ENSG00000270638.1	RP3-466P17.1	-4.74	3.78e-06	0.00204	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145735570~145737218:+
SARC	cis	rs875971	0.508	rs10258739	ENSG00000236529.1	RP13-254B10.1	-4.74	3.78e-06	0.00204	-0.3	-0.3	Aortic root size;	chr7:66597948	chr7:65840212~65840596:+
SARC	cis	rs7216064	1	rs7221651	ENSG00000265055.1	AC145343.2	-4.74	3.79e-06	0.00205	-0.38	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836274	chr17:68096046~68101474:-
SARC	cis	rs4862750	0.872	rs6821507	ENSG00000250971.1	RP11-696F12.1	-4.74	3.79e-06	0.00205	-0.35	-0.3	Lobe attachment (rater-scored or self-reported);	chr4:186955675	chr4:187060099~187060930:+
SARC	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	4.74	3.79e-06	0.00205	0.31	0.3	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	4.74	3.79e-06	0.00205	0.31	0.3	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
SARC	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-4.74	3.79e-06	0.00205	-0.36	-0.3	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
SARC	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-4.74	3.79e-06	0.00205	-0.4	-0.3	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
SARC	cis	rs2274273	0.6	rs10131730	ENSG00000258413.1	RP11-665C16.6	-4.74	3.79e-06	0.00205	-0.37	-0.3	Protein biomarker;	chr14:55373374	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs12050123	ENSG00000258413.1	RP11-665C16.6	-4.74	3.79e-06	0.00205	-0.37	-0.3	Protein biomarker;	chr14:55373668	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs10132453	ENSG00000258413.1	RP11-665C16.6	-4.74	3.79e-06	0.00205	-0.37	-0.3	Protein biomarker;	chr14:55374133	chr14:55262767~55272075:-
SARC	cis	rs4835473	0.932	rs4260486	ENSG00000251600.4	RP11-673E1.1	4.74	3.8e-06	0.00205	0.29	0.3	Immature fraction of reticulocytes;	chr4:143987556	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4287958	ENSG00000251600.4	RP11-673E1.1	4.74	3.8e-06	0.00205	0.29	0.3	Immature fraction of reticulocytes;	chr4:143987719	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4125545	ENSG00000251600.4	RP11-673E1.1	4.74	3.8e-06	0.00205	0.29	0.3	Immature fraction of reticulocytes;	chr4:143988650	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs12649594	ENSG00000251600.4	RP11-673E1.1	4.74	3.8e-06	0.00205	0.29	0.3	Immature fraction of reticulocytes;	chr4:143989307	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.864	rs13101482	ENSG00000251600.4	RP11-673E1.1	4.74	3.8e-06	0.00205	0.29	0.3	Immature fraction of reticulocytes;	chr4:143989463	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.864	rs13135472	ENSG00000251600.4	RP11-673E1.1	4.74	3.8e-06	0.00205	0.29	0.3	Immature fraction of reticulocytes;	chr4:143989465	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.8	rs1849117	ENSG00000251600.4	RP11-673E1.1	4.74	3.8e-06	0.00205	0.29	0.3	Immature fraction of reticulocytes;	chr4:143989791	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1849118	ENSG00000251600.4	RP11-673E1.1	4.74	3.8e-06	0.00205	0.29	0.3	Immature fraction of reticulocytes;	chr4:143989822	chr4:143912331~143982454:+
SARC	cis	rs1707322	0.721	rs4559551	ENSG00000281133.1	AL355480.3	-4.74	3.8e-06	0.00205	-0.35	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45580892~45580996:-
SARC	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	4.74	3.8e-06	0.00206	0.28	0.3	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
SARC	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-4.74	3.8e-06	0.00206	-0.35	-0.3	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
SARC	cis	rs10911902	0.643	rs16825185	ENSG00000229739.2	RP11-295K2.3	-4.74	3.8e-06	0.00206	-0.42	-0.3	Schizophrenia;	chr1:186337932	chr1:186435161~186470291:+
SARC	cis	rs2905347	0.964	rs2961270	ENSG00000179428.2	AC073072.5	4.73	3.81e-06	0.00206	0.31	0.3	Major depression and alcohol dependence;	chr7:22582519	chr7:22725395~22727620:-
SARC	cis	rs2933343	0.729	rs813732	ENSG00000231305.3	RP11-723O4.2	4.73	3.81e-06	0.00206	0.3	0.3	IgG glycosylation;	chr3:128900514	chr3:128861313~128871540:-
SARC	cis	rs1823913	0.637	rs4853569	ENSG00000227542.1	AC092614.2	-4.73	3.81e-06	0.00206	-0.33	-0.3	Obesity-related traits;	chr2:191266970	chr2:191229165~191246172:-
SARC	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-4.73	3.82e-06	0.00206	-0.34	-0.3	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
SARC	cis	rs17772222	0.582	rs12050316	ENSG00000258983.2	RP11-507K2.2	4.73	3.82e-06	0.00206	0.29	0.3	Coronary artery calcification;	chr14:88522097	chr14:88499334~88515502:+
SARC	cis	rs9309473	0.606	rs79234109	ENSG00000163016.8	ALMS1P	4.73	3.82e-06	0.00206	0.42	0.3	Metabolite levels;	chr2:73621227	chr2:73644919~73685576:+
SARC	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-4.73	3.82e-06	0.00206	-0.3	-0.3	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
SARC	cis	rs7216064	1	rs62084238	ENSG00000278219.1	AC145343.1	-4.73	3.82e-06	0.00206	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67860457	chr17:68101538~68101639:+
SARC	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-4.73	3.82e-06	0.00207	-0.4	-0.3	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
SARC	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	4.73	3.82e-06	0.00207	0.3	0.3	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
SARC	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-4.73	3.83e-06	0.00207	-0.4	-0.3	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
SARC	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-4.73	3.83e-06	0.00207	-0.29	-0.3	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
SARC	cis	rs9532669	0.963	rs2324739	ENSG00000176268.5	CYCSP34	4.73	3.83e-06	0.00207	0.28	0.3	Cervical cancer;	chr13:40925479	chr13:40863599~40863902:-
SARC	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-4.73	3.83e-06	0.00207	-0.43	-0.3	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
SARC	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	4.73	3.83e-06	0.00207	0.36	0.3	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
SARC	cis	rs4703855	0.538	rs7733862	ENSG00000244061.1	RP11-389C8.1	4.73	3.83e-06	0.00207	0.3	0.3	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72425637	chr5:72381794~72382393:+
SARC	cis	rs728478	1	rs11079377	ENSG00000266992.1	DHX40P1	4.73	3.84e-06	0.00207	0.32	0.3	QT interval;	chr17:59376150	chr17:59976009~60002384:-
SARC	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	4.73	3.84e-06	0.00207	0.31	0.3	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	4.73	3.84e-06	0.00207	0.31	0.3	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
SARC	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-4.73	3.85e-06	0.00208	-0.3	-0.3	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
SARC	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-4.73	3.85e-06	0.00208	-0.34	-0.3	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
SARC	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-4.73	3.85e-06	0.00208	-0.34	-0.3	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-4.73	3.85e-06	0.00208	-0.34	-0.3	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
SARC	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	4.73	3.85e-06	0.00208	0.34	0.3	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
SARC	cis	rs1707322	0.686	rs2275085	ENSG00000281133.1	AL355480.3	4.73	3.86e-06	0.00208	0.34	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45580892~45580996:-
SARC	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	4.73	3.86e-06	0.00208	0.31	0.3	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	4.73	3.86e-06	0.00208	0.31	0.3	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	4.73	3.86e-06	0.00208	0.31	0.3	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	4.73	3.86e-06	0.00208	0.31	0.3	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	4.73	3.86e-06	0.00208	0.31	0.3	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	4.73	3.86e-06	0.00208	0.31	0.3	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	4.73	3.86e-06	0.00208	0.31	0.3	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	4.73	3.86e-06	0.00208	0.31	0.3	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	4.73	3.86e-06	0.00208	0.31	0.3	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
SARC	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-4.73	3.86e-06	0.00208	-0.44	-0.3	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-4.73	3.86e-06	0.00208	-0.44	-0.3	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-4.73	3.86e-06	0.00208	-0.44	-0.3	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-4.73	3.86e-06	0.00208	-0.44	-0.3	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	4.73	3.86e-06	0.00208	0.28	0.3	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
SARC	cis	rs2179367	0.632	rs7349921	ENSG00000231760.4	RP11-350J20.5	4.73	3.87e-06	0.00208	0.4	0.3	Dupuytren's disease;	chr6:149392727	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs60153446	ENSG00000231760.4	RP11-350J20.5	4.73	3.87e-06	0.00208	0.4	0.3	Dupuytren's disease;	chr6:149393186	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs61259243	ENSG00000231760.4	RP11-350J20.5	4.73	3.87e-06	0.00208	0.4	0.3	Dupuytren's disease;	chr6:149393457	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs62426115	ENSG00000231760.4	RP11-350J20.5	4.73	3.87e-06	0.00208	0.4	0.3	Dupuytren's disease;	chr6:149393718	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs68080376	ENSG00000231760.4	RP11-350J20.5	4.73	3.87e-06	0.00208	0.4	0.3	Dupuytren's disease;	chr6:149393873	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs763590	ENSG00000231760.4	RP11-350J20.5	4.73	3.87e-06	0.00208	0.4	0.3	Dupuytren's disease;	chr6:149398831	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs17506789	ENSG00000231760.4	RP11-350J20.5	4.73	3.87e-06	0.00208	0.4	0.3	Dupuytren's disease;	chr6:149399710	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.586	rs34097428	ENSG00000231760.4	RP11-350J20.5	4.73	3.87e-06	0.00208	0.4	0.3	Dupuytren's disease;	chr6:149399822	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498344	ENSG00000231760.4	RP11-350J20.5	4.73	3.87e-06	0.00208	0.4	0.3	Dupuytren's disease;	chr6:149401053	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs12154153	ENSG00000231760.4	RP11-350J20.5	4.73	3.87e-06	0.00208	0.4	0.3	Dupuytren's disease;	chr6:149401686	chr6:149796151~149826294:-
SARC	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	4.73	3.87e-06	0.00209	0.3	0.3	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
SARC	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-4.73	3.88e-06	0.00209	-0.31	-0.3	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
SARC	cis	rs910316	0.737	rs2098251	ENSG00000279594.1	RP11-950C14.10	4.73	3.88e-06	0.00209	0.33	0.3	Height;	chr14:75025993	chr14:75011269~75012851:-
SARC	cis	rs910316	0.664	rs2098252	ENSG00000279594.1	RP11-950C14.10	4.73	3.88e-06	0.00209	0.33	0.3	Height;	chr14:75026029	chr14:75011269~75012851:-
SARC	cis	rs910316	0.737	rs28687415	ENSG00000279594.1	RP11-950C14.10	4.73	3.88e-06	0.00209	0.33	0.3	Height;	chr14:75028779	chr14:75011269~75012851:-
SARC	cis	rs7809950	0.678	rs17153981	ENSG00000238832.1	snoU109	-4.73	3.88e-06	0.00209	-0.35	-0.3	Coronary artery disease;	chr7:107281661	chr7:107603363~107603507:+
SARC	cis	rs7772486	0.754	rs702306	ENSG00000270638.1	RP3-466P17.1	-4.73	3.89e-06	0.00209	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145735570~145737218:+
SARC	cis	rs7567389	0.677	rs72845991	ENSG00000236682.1	AC068282.3	-4.73	3.89e-06	0.00209	-0.35	-0.3	Self-rated health;	chr2:127350331	chr2:127389130~127400580:+
SARC	cis	rs7567389	0.671	rs11692990	ENSG00000236682.1	AC068282.3	-4.73	3.89e-06	0.00209	-0.35	-0.3	Self-rated health;	chr2:127354614	chr2:127389130~127400580:+
SARC	cis	rs4639966	0.569	rs603486	ENSG00000255422.1	AP002954.4	-4.73	3.89e-06	0.0021	-0.29	-0.3	Systemic lupus erythematosus;	chr11:118716638	chr11:118704607~118750263:+
SARC	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-4.73	3.89e-06	0.0021	-0.32	-0.3	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
SARC	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-4.73	3.89e-06	0.0021	-0.49	-0.3	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
SARC	cis	rs17270561	0.609	rs2154218	ENSG00000272462.2	U91328.19	-4.73	3.89e-06	0.0021	-0.28	-0.3	Iron status biomarkers;	chr6:25776062	chr6:25992662~26001775:+
SARC	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	4.73	3.9e-06	0.0021	0.28	0.3	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	4.73	3.9e-06	0.0021	0.28	0.3	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	4.73	3.9e-06	0.0021	0.28	0.3	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
SARC	cis	rs4664293	0.867	rs7579206	ENSG00000226266.5	AC009961.3	-4.73	3.9e-06	0.0021	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159715992	chr2:159670708~159712435:-
SARC	cis	rs9818758	0.607	rs13068038	ENSG00000225399.4	RP11-3B7.1	-4.73	3.9e-06	0.0021	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49256817	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs12715434	ENSG00000225399.4	RP11-3B7.1	-4.73	3.9e-06	0.0021	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49257592	chr3:49260085~49261316:+
SARC	cis	rs1823913	0.599	rs13020656	ENSG00000227542.1	AC092614.2	4.73	3.9e-06	0.0021	0.33	0.3	Obesity-related traits;	chr2:191314197	chr2:191229165~191246172:-
SARC	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-4.73	3.91e-06	0.0021	-0.31	-0.3	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
SARC	cis	rs1865760	0.566	rs2032449	ENSG00000272462.2	U91328.19	-4.73	3.91e-06	0.0021	-0.27	-0.3	Height;	chr6:26026371	chr6:25992662~26001775:+
SARC	cis	rs7809950	0.678	rs2237665	ENSG00000238832.1	snoU109	-4.73	3.91e-06	0.0021	-0.35	-0.3	Coronary artery disease;	chr7:107266553	chr7:107603363~107603507:+
SARC	cis	rs17270561	0.609	rs1892248	ENSG00000272462.2	U91328.19	-4.73	3.91e-06	0.00211	-0.28	-0.3	Iron status biomarkers;	chr6:25768686	chr6:25992662~26001775:+
SARC	cis	rs6969780	0.632	rs11762730	ENSG00000233429.8	HOTAIRM1	-4.73	3.92e-06	0.00211	-0.39	-0.3	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27150779	chr7:27095647~27100265:+
SARC	cis	rs526231	0.782	rs434816	ENSG00000175749.11	EIF3KP1	4.73	3.92e-06	0.00211	0.4	0.3	Primary biliary cholangitis;	chr5:103263627	chr5:103032376~103033031:+
SARC	cis	rs13161895	1	rs3719	ENSG00000250999.1	RP11-1379J22.5	4.73	3.92e-06	0.00211	0.5	0.3	LDL cholesterol;	chr5:180008118	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs6873994	ENSG00000250999.1	RP11-1379J22.5	4.73	3.92e-06	0.00211	0.5	0.3	LDL cholesterol;	chr5:180009696	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs6873781	ENSG00000250999.1	RP11-1379J22.5	4.73	3.92e-06	0.00211	0.5	0.3	LDL cholesterol;	chr5:180009734	chr5:179657762~179664432:+
SARC	cis	rs13161895	0.941	rs12519642	ENSG00000250999.1	RP11-1379J22.5	4.73	3.92e-06	0.00211	0.5	0.3	LDL cholesterol;	chr5:180011626	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs12654148	ENSG00000250999.1	RP11-1379J22.5	4.73	3.92e-06	0.00211	0.5	0.3	LDL cholesterol;	chr5:180011920	chr5:179657762~179664432:+
SARC	cis	rs13161895	0.941	rs3797764	ENSG00000250999.1	RP11-1379J22.5	4.73	3.92e-06	0.00211	0.5	0.3	LDL cholesterol;	chr5:180012345	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs3797763	ENSG00000250999.1	RP11-1379J22.5	4.73	3.92e-06	0.00211	0.5	0.3	LDL cholesterol;	chr5:180012516	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs864482	ENSG00000250999.1	RP11-1379J22.5	-4.73	3.92e-06	0.00211	-0.5	-0.3	LDL cholesterol;	chr5:180000873	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs248318	ENSG00000250999.1	RP11-1379J22.5	-4.73	3.92e-06	0.00211	-0.5	-0.3	LDL cholesterol;	chr5:180003530	chr5:179657762~179664432:+
SARC	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	4.73	3.92e-06	0.00211	0.32	0.3	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
SARC	cis	rs2439831	0.85	rs12440573	ENSG00000275601.1	AC011330.13	-4.73	3.92e-06	0.00211	-0.51	-0.3	Lung cancer in ever smokers;	chr15:43816799	chr15:43642389~43643023:-
SARC	cis	rs8081395	0.737	rs4968401	ENSG00000266992.1	DHX40P1	-4.73	3.93e-06	0.00211	-0.33	-0.3	White blood cell count;	chr17:59963369	chr17:59976009~60002384:-
SARC	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-4.73	3.93e-06	0.00211	-0.33	-0.3	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
SARC	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	4.73	3.94e-06	0.00212	0.31	0.3	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	4.73	3.94e-06	0.00212	0.31	0.3	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	4.73	3.94e-06	0.00212	0.31	0.3	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
SARC	cis	rs1799949	0.965	rs8070179	ENSG00000267681.1	CTD-3199J23.6	-4.73	3.94e-06	0.00212	-0.32	-0.3	Menopause (age at onset);	chr17:43050671	chr17:43144956~43145255:+
SARC	cis	rs910316	0.712	rs175037	ENSG00000279594.1	RP11-950C14.10	-4.73	3.95e-06	0.00212	-0.33	-0.3	Height;	chr14:74998335	chr14:75011269~75012851:-
SARC	cis	rs910316	0.726	rs175040	ENSG00000279594.1	RP11-950C14.10	-4.73	3.95e-06	0.00212	-0.33	-0.3	Height;	chr14:75002852	chr14:75011269~75012851:-
SARC	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	4.73	3.95e-06	0.00212	0.36	0.3	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
SARC	cis	rs7772486	0.79	rs2253768	ENSG00000270638.1	RP3-466P17.1	4.73	3.95e-06	0.00212	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145735570~145737218:+
SARC	cis	rs7809950	1	rs2712191	ENSG00000238832.1	snoU109	-4.73	3.95e-06	0.00212	-0.34	-0.3	Coronary artery disease;	chr7:107542279	chr7:107603363~107603507:+
SARC	cis	rs7809950	1	rs10267907	ENSG00000238832.1	snoU109	-4.73	3.95e-06	0.00212	-0.34	-0.3	Coronary artery disease;	chr7:107544021	chr7:107603363~107603507:+
SARC	cis	rs55726902	0.506	rs1006476	ENSG00000276691.1	RP5-1057I20.5	4.73	3.95e-06	0.00212	0.41	0.3	Allergic disease (asthma, hay fever or eczema);	chr12:47785564	chr12:47788426~47788971:+
SARC	cis	rs801193	1	rs6975195	ENSG00000236529.1	RP13-254B10.1	-4.73	3.95e-06	0.00212	-0.31	-0.3	Aortic root size;	chr7:66659787	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs3857688	ENSG00000236529.1	RP13-254B10.1	-4.73	3.95e-06	0.00212	-0.31	-0.3	Aortic root size;	chr7:66662819	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs2286684	ENSG00000236529.1	RP13-254B10.1	-4.73	3.95e-06	0.00212	-0.31	-0.3	Aortic root size;	chr7:66664843	chr7:65840212~65840596:+
SARC	cis	rs801193	0.935	rs2286683	ENSG00000236529.1	RP13-254B10.1	-4.73	3.95e-06	0.00212	-0.31	-0.3	Aortic root size;	chr7:66664856	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs10274773	ENSG00000236529.1	RP13-254B10.1	-4.73	3.95e-06	0.00212	-0.31	-0.3	Aortic root size;	chr7:66668591	chr7:65840212~65840596:+
SARC	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	4.73	3.96e-06	0.00213	0.25	0.3	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	4.73	3.96e-06	0.00213	0.25	0.3	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	4.73	3.96e-06	0.00213	0.25	0.3	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	4.73	3.96e-06	0.00213	0.25	0.3	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	4.73	3.96e-06	0.00213	0.25	0.3	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	4.73	3.96e-06	0.00213	0.25	0.3	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
SARC	cis	rs17508449	0.819	rs76726048	ENSG00000232450.1	RP4-730K3.3	-4.73	3.97e-06	0.00213	-0.38	-0.3	Leprosy;	chr1:113664077	chr1:113698884~113699631:-
SARC	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	4.73	3.97e-06	0.00213	0.42	0.3	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
SARC	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-4.73	3.98e-06	0.00213	-0.37	-0.3	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
SARC	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-4.73	3.98e-06	0.00214	-0.32	-0.3	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
SARC	cis	rs7216064	1	rs62084214	ENSG00000278219.1	AC145343.1	-4.72	3.98e-06	0.00214	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67847209	chr17:68101538~68101639:+
SARC	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-4.72	3.99e-06	0.00214	-0.39	-0.3	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
SARC	cis	rs7772486	0.754	rs12199362	ENSG00000270638.1	RP3-466P17.1	4.72	3.99e-06	0.00214	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs13214277	ENSG00000270638.1	RP3-466P17.1	4.72	3.99e-06	0.00214	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs9386132	ENSG00000270638.1	RP3-466P17.1	4.72	3.99e-06	0.00214	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145735570~145737218:+
SARC	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-4.72	3.99e-06	0.00214	-0.25	-0.3	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
SARC	cis	rs321358	0.895	rs17457430	ENSG00000271584.1	RP11-89C3.4	4.72	3.99e-06	0.00214	0.51	0.3	Body mass index;	chr11:111085279	chr11:111091932~111097357:-
SARC	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	4.72	3.99e-06	0.00214	0.37	0.3	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
SARC	cis	rs6991838	0.778	rs11779602	ENSG00000200714.1	Y_RNA	4.72	3.99e-06	0.00214	0.31	0.3	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65592731~65592820:+
SARC	cis	rs12554020	0.892	rs78816659	ENSG00000227603.1	RP11-165J3.6	4.72	3.99e-06	0.00214	0.52	0.3	Schizophrenia;	chr9:93575141	chr9:93435332~93437121:-
SARC	cis	rs453301	0.624	rs2915251	ENSG00000253893.2	FAM85B	-4.72	3.99e-06	0.00214	-0.25	-0.3	Joint mobility (Beighton score);	chr8:9009901	chr8:8167819~8226614:-
SARC	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-4.72	4e-06	0.00214	-0.34	-0.3	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
SARC	cis	rs6969780	0.915	rs7341470	ENSG00000233429.8	HOTAIRM1	-4.72	4e-06	0.00215	-0.4	-0.3	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27145223	chr7:27095647~27100265:+
SARC	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	4.72	4e-06	0.00215	0.31	0.3	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
SARC	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-4.72	4e-06	0.00215	-0.38	-0.3	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
SARC	cis	rs17270561	0.583	rs12662869	ENSG00000272810.1	U91328.22	4.72	4e-06	0.00215	0.28	0.3	Iron status biomarkers;	chr6:25784253	chr6:26013241~26013757:+
SARC	cis	rs7772486	0.743	rs9376955	ENSG00000270638.1	RP3-466P17.1	4.72	4e-06	0.00215	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145628268	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.805	rs4896831	ENSG00000270638.1	RP3-466P17.1	4.72	4e-06	0.00215	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145638345	chr6:145735570~145737218:+
SARC	cis	rs910316	0.763	rs4556	ENSG00000279594.1	RP11-950C14.10	4.72	4.01e-06	0.00215	0.33	0.3	Height;	chr14:75009368	chr14:75011269~75012851:-
SARC	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	4.72	4.01e-06	0.00215	0.31	0.3	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	4.72	4.01e-06	0.00215	0.31	0.3	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
SARC	cis	rs1707322	0.827	rs10890347	ENSG00000281133.1	AL355480.3	4.72	4.01e-06	0.00215	0.33	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45580892~45580996:-
SARC	cis	rs2239557	0.961	rs10133356	ENSG00000259065.1	RP5-1021I20.1	4.72	4.01e-06	0.00215	0.34	0.3	Common traits (Other);	chr14:74181056	chr14:73787360~73803270:+
SARC	cis	rs2239557	1	rs10144220	ENSG00000259065.1	RP5-1021I20.1	4.72	4.01e-06	0.00215	0.34	0.3	Common traits (Other);	chr14:74181201	chr14:73787360~73803270:+
SARC	cis	rs2239557	0.961	rs10135858	ENSG00000259065.1	RP5-1021I20.1	4.72	4.01e-06	0.00215	0.34	0.3	Common traits (Other);	chr14:74181259	chr14:73787360~73803270:+
SARC	cis	rs8062405	0.755	rs7193402	ENSG00000251417.2	RP11-1348G14.4	-4.72	4.01e-06	0.00215	-0.29	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28802743~28817828:+
SARC	cis	rs4688759	0.719	rs73079018	ENSG00000225399.4	RP11-3B7.1	-4.72	4.02e-06	0.00215	-0.56	-0.3	Blood protein levels;	chr3:49837894	chr3:49260085~49261316:+
SARC	cis	rs8031584	0.541	rs2955797	ENSG00000260382.1	RP11-540B6.2	-4.72	4.02e-06	0.00215	-0.33	-0.3	Huntington's disease progression;	chr15:30918778	chr15:30882267~30883231:-
SARC	cis	rs853679	0.517	rs1853097	ENSG00000272009.1	RP1-313I6.12	-4.72	4.03e-06	0.00216	-0.34	-0.3	Depression;	chr6:28090857	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9393887	ENSG00000272009.1	RP1-313I6.12	-4.72	4.03e-06	0.00216	-0.34	-0.3	Depression;	chr6:28091242	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9393888	ENSG00000272009.1	RP1-313I6.12	-4.72	4.03e-06	0.00216	-0.34	-0.3	Depression;	chr6:28091439	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs3734573	ENSG00000272009.1	RP1-313I6.12	-4.72	4.03e-06	0.00216	-0.34	-0.3	Depression;	chr6:28091659	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9357063	ENSG00000272009.1	RP1-313I6.12	-4.72	4.03e-06	0.00216	-0.34	-0.3	Depression;	chr6:28092227	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs3823180	ENSG00000272009.1	RP1-313I6.12	-4.72	4.03e-06	0.00216	-0.34	-0.3	Depression;	chr6:28093966	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9368551	ENSG00000272009.1	RP1-313I6.12	-4.72	4.03e-06	0.00216	-0.34	-0.3	Depression;	chr6:28094014	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9393890	ENSG00000272009.1	RP1-313I6.12	-4.72	4.03e-06	0.00216	-0.34	-0.3	Depression;	chr6:28096077	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9366715	ENSG00000272009.1	RP1-313I6.12	-4.72	4.03e-06	0.00216	-0.34	-0.3	Depression;	chr6:28096855	chr6:28078792~28081130:-
SARC	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	4.72	4.03e-06	0.00216	0.28	0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
SARC	cis	rs1823913	0.526	rs36028476	ENSG00000227542.1	AC092614.2	4.72	4.03e-06	0.00216	0.33	0.3	Obesity-related traits;	chr2:191300595	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.599	rs2124095	ENSG00000227542.1	AC092614.2	4.72	4.03e-06	0.00216	0.33	0.3	Obesity-related traits;	chr2:191301728	chr2:191229165~191246172:-
SARC	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	4.72	4.03e-06	0.00216	0.32	0.3	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
SARC	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-4.72	4.03e-06	0.00216	-0.35	-0.3	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-4.72	4.03e-06	0.00216	-0.35	-0.3	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-4.72	4.03e-06	0.00216	-0.35	-0.3	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
SARC	cis	rs853679	0.882	rs9380069	ENSG00000219392.1	RP1-265C24.5	-4.72	4.03e-06	0.00216	-0.57	-0.3	Depression;	chr6:28235522	chr6:28115628~28116551:+
SARC	cis	rs17270561	0.636	rs1575535	ENSG00000272462.2	U91328.19	-4.72	4.03e-06	0.00216	-0.27	-0.3	Iron status biomarkers;	chr6:25809681	chr6:25992662~26001775:+
SARC	cis	rs7615952	0.599	rs6803160	ENSG00000250012.1	RP11-124N2.1	-4.72	4.04e-06	0.00216	-0.29	-0.3	Blood pressure (smoking interaction);	chr3:125990711	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.599	rs6779141	ENSG00000250012.1	RP11-124N2.1	-4.72	4.04e-06	0.00216	-0.29	-0.3	Blood pressure (smoking interaction);	chr3:125991152	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.688	rs12485622	ENSG00000250012.1	RP11-124N2.1	-4.72	4.04e-06	0.00216	-0.29	-0.3	Blood pressure (smoking interaction);	chr3:125991896	chr3:126084220~126095349:+
SARC	cis	rs801193	1	rs11773829	ENSG00000236529.1	RP13-254B10.1	-4.72	4.04e-06	0.00216	-0.3	-0.3	Aortic root size;	chr7:66676087	chr7:65840212~65840596:+
SARC	cis	rs7512898	0.545	rs7512279	ENSG00000260088.1	RP11-92G12.3	-4.72	4.04e-06	0.00216	-0.3	-0.3	Electrocardiographic conduction measures;	chr1:200733210	chr1:200669507~200694250:+
SARC	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-4.72	4.05e-06	0.00217	-0.4	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
SARC	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-4.72	4.05e-06	0.00217	-0.42	-0.3	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
SARC	cis	rs7615952	0.599	rs6766327	ENSG00000250012.1	RP11-124N2.1	-4.72	4.05e-06	0.00217	-0.28	-0.3	Blood pressure (smoking interaction);	chr3:126004834	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.641	rs12491577	ENSG00000250012.1	RP11-124N2.1	-4.72	4.05e-06	0.00217	-0.28	-0.3	Blood pressure (smoking interaction);	chr3:126012288	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.599	rs1875683	ENSG00000250012.1	RP11-124N2.1	-4.72	4.05e-06	0.00217	-0.28	-0.3	Blood pressure (smoking interaction);	chr3:126013638	chr3:126084220~126095349:+
SARC	cis	rs2404602	0.698	rs12909656	ENSG00000259422.1	RP11-593F23.1	-4.72	4.06e-06	0.00217	-0.36	-0.3	Blood metabolite levels;	chr15:76372037	chr15:76174891~76181486:-
SARC	cis	rs7216064	1	rs58122682	ENSG00000278219.1	AC145343.1	-4.72	4.06e-06	0.00217	-0.37	-0.3	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67880799	chr17:68101538~68101639:+
SARC	cis	rs6845263	0.536	rs9991697	ENSG00000254531.1	FLJ20021	-4.72	4.06e-06	0.00218	-0.29	-0.3	Superior crus of antihelix expression;	chr4:101555781	chr4:101347780~101348883:+
SARC	cis	rs6845263	0.511	rs10024842	ENSG00000254531.1	FLJ20021	-4.72	4.06e-06	0.00218	-0.29	-0.3	Superior crus of antihelix expression;	chr4:101555787	chr4:101347780~101348883:+
SARC	cis	rs2274273	0.84	rs10467798	ENSG00000258413.1	RP11-665C16.6	-4.72	4.07e-06	0.00218	-0.34	-0.3	Protein biomarker;	chr14:55258209	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-4.72	4.07e-06	0.00218	-0.34	-0.3	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
SARC	cis	rs7772486	0.875	rs2748483	ENSG00000270638.1	RP3-466P17.1	-4.72	4.08e-06	0.00218	-0.24	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145735570~145737218:+
SARC	cis	rs17270561	0.609	rs1165208	ENSG00000272810.1	U91328.22	-4.72	4.08e-06	0.00218	-0.28	-0.3	Iron status biomarkers;	chr6:25803676	chr6:26013241~26013757:+
SARC	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-4.72	4.09e-06	0.00219	-0.32	-0.3	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
SARC	cis	rs11719291	0.915	rs1048940	ENSG00000225399.4	RP11-3B7.1	-4.72	4.09e-06	0.00219	-0.63	-0.3	Cognitive function;	chr3:48688274	chr3:49260085~49261316:+
SARC	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-4.72	4.09e-06	0.00219	-0.29	-0.3	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
SARC	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-4.72	4.09e-06	0.00219	-0.29	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
SARC	cis	rs9828933	0.701	rs7621544	ENSG00000280620.1	SCAANT1	4.72	4.1e-06	0.00219	0.41	0.3	Type 2 diabetes;	chr3:63943005	chr3:63911518~63911772:-
SARC	cis	rs2404602	0.532	rs284892	ENSG00000259422.1	RP11-593F23.1	4.72	4.11e-06	0.0022	0.33	0.3	Blood metabolite levels;	chr15:76428696	chr15:76174891~76181486:-
SARC	cis	rs4835473	0.932	rs4585249	ENSG00000251600.4	RP11-673E1.1	-4.72	4.11e-06	0.0022	-0.29	-0.3	Immature fraction of reticulocytes;	chr4:143981173	chr4:143912331~143982454:+
SARC	cis	rs6991838	0.778	rs11779602	ENSG00000272010.1	CTD-3025N20.3	4.72	4.11e-06	0.0022	0.32	0.3	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65591850~65592472:-
SARC	cis	rs7809950	0.678	rs17154040	ENSG00000238832.1	snoU109	4.72	4.11e-06	0.0022	0.35	0.3	Coronary artery disease;	chr7:107364801	chr7:107603363~107603507:+
SARC	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-4.72	4.11e-06	0.0022	-0.32	-0.3	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
SARC	cis	rs2404602	0.735	rs2454454	ENSG00000259422.1	RP11-593F23.1	-4.72	4.11e-06	0.0022	-0.34	-0.3	Blood metabolite levels;	chr15:76531306	chr15:76174891~76181486:-
SARC	cis	rs2274273	0.805	rs60972460	ENSG00000258413.1	RP11-665C16.6	-4.72	4.12e-06	0.0022	-0.35	-0.3	Protein biomarker;	chr14:55105055	chr14:55262767~55272075:-
SARC	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	4.72	4.12e-06	0.0022	0.38	0.3	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
SARC	cis	rs875971	0.66	rs2013222	ENSG00000236529.1	RP13-254B10.1	-4.72	4.12e-06	0.0022	-0.31	-0.3	Aortic root size;	chr7:66570949	chr7:65840212~65840596:+
SARC	cis	rs2274273	0.624	rs10146637	ENSG00000258413.1	RP11-665C16.6	-4.72	4.12e-06	0.0022	-0.38	-0.3	Protein biomarker;	chr14:55278092	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs7155954	ENSG00000258413.1	RP11-665C16.6	-4.72	4.12e-06	0.0022	-0.38	-0.3	Protein biomarker;	chr14:55284225	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs7159824	ENSG00000258413.1	RP11-665C16.6	-4.72	4.12e-06	0.0022	-0.38	-0.3	Protein biomarker;	chr14:55305818	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs10129505	ENSG00000258413.1	RP11-665C16.6	-4.72	4.12e-06	0.0022	-0.38	-0.3	Protein biomarker;	chr14:55309657	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.6	rs35112084	ENSG00000258413.1	RP11-665C16.6	-4.72	4.12e-06	0.0022	-0.38	-0.3	Protein biomarker;	chr14:55314382	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs1972221	ENSG00000258413.1	RP11-665C16.6	-4.72	4.12e-06	0.0022	-0.38	-0.3	Protein biomarker;	chr14:55318663	chr14:55262767~55272075:-
SARC	cis	rs11673344	0.528	rs578655	ENSG00000226686.6	LINC01535	4.72	4.12e-06	0.0022	0.32	0.3	Obesity-related traits;	chr19:36919855	chr19:37251912~37265535:+
SARC	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-4.72	4.13e-06	0.00221	-0.34	-0.3	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
SARC	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-4.72	4.13e-06	0.00221	-0.43	-0.3	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
SARC	cis	rs728478	0.967	rs7221245	ENSG00000266992.1	DHX40P1	4.72	4.13e-06	0.00221	0.32	0.3	QT interval;	chr17:59378241	chr17:59976009~60002384:-
SARC	cis	rs14027	0.921	rs10109901	ENSG00000279347.1	RP11-85I17.2	-4.72	4.14e-06	0.00221	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817287	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs10109951	ENSG00000279347.1	RP11-85I17.2	-4.72	4.14e-06	0.00221	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817519	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs2634	ENSG00000279347.1	RP11-85I17.2	-4.72	4.14e-06	0.00221	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119819869	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs4870955	ENSG00000279347.1	RP11-85I17.2	-4.72	4.14e-06	0.00221	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119821929	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs34718068	ENSG00000279347.1	RP11-85I17.2	-4.72	4.14e-06	0.00221	-0.26	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119822368	chr8:119838736~119840385:-
SARC	cis	rs910316	1	rs12589376	ENSG00000279594.1	RP11-950C14.10	4.72	4.14e-06	0.00221	0.32	0.3	Height;	chr14:75094449	chr14:75011269~75012851:-
SARC	cis	rs910316	0.967	rs1071989	ENSG00000279594.1	RP11-950C14.10	4.72	4.14e-06	0.00221	0.32	0.3	Height;	chr14:75097956	chr14:75011269~75012851:-
SARC	cis	rs910316	1	rs9805979	ENSG00000279594.1	RP11-950C14.10	4.72	4.14e-06	0.00221	0.32	0.3	Height;	chr14:75099506	chr14:75011269~75012851:-
SARC	cis	rs7131987	0.65	rs10843382	ENSG00000257176.2	RP11-996F15.2	-4.72	4.15e-06	0.00222	-0.34	-0.3	QT interval;	chr12:29298788	chr12:29280418~29317848:-
SARC	cis	rs193541	0.632	rs30036	ENSG00000263432.2	RN7SL689P	4.72	4.16e-06	0.00222	0.38	0.3	Glucose homeostasis traits;	chr5:122942565	chr5:123022487~123022783:-
SARC	cis	rs7772486	0.654	rs4896829	ENSG00000270638.1	RP3-466P17.1	4.72	4.16e-06	0.00222	0.24	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145632539	chr6:145735570~145737218:+
SARC	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-4.71	4.16e-06	0.00222	-0.34	-0.3	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-4.71	4.16e-06	0.00222	-0.34	-0.3	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-4.71	4.16e-06	0.00222	-0.34	-0.3	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
SARC	cis	rs910316	1	rs4899544	ENSG00000279594.1	RP11-950C14.10	4.71	4.16e-06	0.00222	0.32	0.3	Height;	chr14:75079853	chr14:75011269~75012851:-
SARC	cis	rs910316	1	rs4903279	ENSG00000279594.1	RP11-950C14.10	4.71	4.16e-06	0.00222	0.32	0.3	Height;	chr14:75079880	chr14:75011269~75012851:-
SARC	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-4.71	4.17e-06	0.00222	-0.28	-0.3	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
SARC	cis	rs7809950	0.678	rs6949634	ENSG00000238832.1	snoU109	-4.71	4.17e-06	0.00222	-0.35	-0.3	Coronary artery disease;	chr7:107344239	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.815	rs62482495	ENSG00000238832.1	snoU109	-4.71	4.17e-06	0.00223	-0.35	-0.3	Coronary artery disease;	chr7:107324564	chr7:107603363~107603507:+
SARC	cis	rs8081395	0.741	rs180532	ENSG00000266992.1	DHX40P1	4.71	4.17e-06	0.00223	0.32	0.3	White blood cell count;	chr17:59925936	chr17:59976009~60002384:-
SARC	cis	rs8081395	0.741	rs180530	ENSG00000266992.1	DHX40P1	4.71	4.17e-06	0.00223	0.32	0.3	White blood cell count;	chr17:59926233	chr17:59976009~60002384:-
SARC	cis	rs1993293	1	rs1993293	ENSG00000254744.3	CTD-3076O17.1	4.71	4.17e-06	0.00223	0.32	0.3	Coronary artery calcification;	chr15:99757458	chr15:99970215~99974010:+
SARC	cis	rs321358	0.895	rs17457375	ENSG00000271584.1	RP11-89C3.4	4.71	4.18e-06	0.00223	0.51	0.3	Body mass index;	chr11:111085100	chr11:111091932~111097357:-
SARC	cis	rs321358	0.895	rs17535942	ENSG00000271584.1	RP11-89C3.4	4.71	4.18e-06	0.00223	0.51	0.3	Body mass index;	chr11:111085233	chr11:111091932~111097357:-
SARC	cis	rs321358	0.895	rs7101466	ENSG00000271584.1	RP11-89C3.4	4.71	4.18e-06	0.00223	0.51	0.3	Body mass index;	chr11:111085729	chr11:111091932~111097357:-
SARC	cis	rs321358	0.895	rs7101576	ENSG00000271584.1	RP11-89C3.4	4.71	4.18e-06	0.00223	0.51	0.3	Body mass index;	chr11:111085795	chr11:111091932~111097357:-
SARC	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	4.71	4.19e-06	0.00223	0.36	0.3	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
SARC	cis	rs1823913	0.637	rs1378162	ENSG00000227542.1	AC092614.2	4.71	4.19e-06	0.00223	0.33	0.3	Obesity-related traits;	chr2:191298523	chr2:191229165~191246172:-
SARC	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	4.71	4.19e-06	0.00224	0.28	0.3	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
SARC	cis	rs9818758	0.556	rs9880309	ENSG00000225399.4	RP11-3B7.1	-4.71	4.2e-06	0.00224	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49266896	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs34343820	ENSG00000225399.4	RP11-3B7.1	-4.71	4.2e-06	0.00224	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272101	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs10049462	ENSG00000225399.4	RP11-3B7.1	-4.71	4.2e-06	0.00224	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272251	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs9311439	ENSG00000225399.4	RP11-3B7.1	-4.71	4.2e-06	0.00224	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272975	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs67831908	ENSG00000225399.4	RP11-3B7.1	-4.71	4.2e-06	0.00224	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49276080	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs13077498	ENSG00000225399.4	RP11-3B7.1	-4.71	4.2e-06	0.00224	-0.55	-0.3	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49276545	chr3:49260085~49261316:+
SARC	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	4.71	4.2e-06	0.00224	0.28	0.3	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	4.71	4.2e-06	0.00224	0.28	0.3	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	4.71	4.2e-06	0.00224	0.28	0.3	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
SARC	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-4.71	4.2e-06	0.00224	-0.33	-0.3	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
SARC	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-4.71	4.2e-06	0.00224	-0.39	-0.3	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
SARC	cis	rs853679	0.517	rs9393894	ENSG00000272009.1	RP1-313I6.12	-4.71	4.2e-06	0.00224	-0.34	-0.3	Depression;	chr6:28144784	chr6:28078792~28081130:-
SARC	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	4.71	4.2e-06	0.00224	0.29	0.3	Height;	chr3:53091453	chr3:53064283~53065091:-
SARC	cis	rs7615952	0.558	rs17334039	ENSG00000241288.6	RP11-379B18.5	-4.71	4.2e-06	0.00224	-0.35	-0.3	Blood pressure (smoking interaction);	chr3:125821465	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.688	rs12638240	ENSG00000241288.6	RP11-379B18.5	-4.71	4.2e-06	0.00224	-0.35	-0.3	Blood pressure (smoking interaction);	chr3:125822395	chr3:125827238~125916384:-
SARC	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	4.71	4.2e-06	0.00224	0.31	0.3	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
SARC	cis	rs77204473	0.744	rs78832854	ENSG00000254851.1	RP11-109L13.1	4.71	4.21e-06	0.00224	0.62	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903759	chr11:117135528~117138582:+
SARC	cis	rs910316	0.967	rs7146523	ENSG00000279594.1	RP11-950C14.10	-4.71	4.21e-06	0.00224	-0.32	-0.29	Height;	chr14:75193177	chr14:75011269~75012851:-
SARC	cis	rs910316	1	rs12588240	ENSG00000279594.1	RP11-950C14.10	4.71	4.21e-06	0.00224	0.32	0.29	Height;	chr14:75145380	chr14:75011269~75012851:-
SARC	cis	rs6991838	0.778	rs11779601	ENSG00000200714.1	Y_RNA	4.71	4.21e-06	0.00224	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65592731~65592820:+
SARC	cis	rs763121	0.853	rs2072794	ENSG00000273076.1	RP3-508I15.22	4.71	4.21e-06	0.00224	0.33	0.29	Menopause (age at onset);	chr22:38754538	chr22:38743495~38743910:+
SARC	cis	rs1865760	0.622	rs9295685	ENSG00000272462.2	U91328.19	-4.71	4.22e-06	0.00225	-0.27	-0.29	Height;	chr6:26071497	chr6:25992662~26001775:+
SARC	cis	rs2018683	0.899	rs10479816	ENSG00000228421.2	AC005013.5	4.71	4.22e-06	0.00225	0.3	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938404	chr7:28957667~28959345:+
SARC	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-4.71	4.23e-06	0.00225	-0.37	-0.29	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
SARC	cis	rs7772486	0.743	rs62433835	ENSG00000270638.1	RP3-466P17.1	-4.71	4.23e-06	0.00225	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.743	rs2092262	ENSG00000270638.1	RP3-466P17.1	-4.71	4.23e-06	0.00225	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.682	rs1337840	ENSG00000270638.1	RP3-466P17.1	-4.71	4.23e-06	0.00225	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145735570~145737218:+
SARC	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-4.71	4.23e-06	0.00225	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
SARC	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-4.71	4.23e-06	0.00225	-0.35	-0.29	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
SARC	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
SARC	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
SARC	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
SARC	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
SARC	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
SARC	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
SARC	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
SARC	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
SARC	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
SARC	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
SARC	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
SARC	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
SARC	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
SARC	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	4.71	4.24e-06	0.00225	0.31	0.29	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
SARC	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-4.71	4.24e-06	0.00225	-0.33	-0.29	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-4.71	4.24e-06	0.00225	-0.33	-0.29	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-4.71	4.24e-06	0.00225	-0.33	-0.29	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-4.71	4.24e-06	0.00225	-0.33	-0.29	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-4.71	4.24e-06	0.00225	-0.33	-0.29	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-4.71	4.24e-06	0.00225	-0.33	-0.29	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-4.71	4.24e-06	0.00225	-0.33	-0.29	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-4.71	4.24e-06	0.00225	-0.33	-0.29	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
SARC	cis	rs1134634	0.52	rs1473166	ENSG00000273133.1	RP11-799M12.2	-4.71	4.24e-06	0.00225	-0.38	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15555868	chr4:15563698~15564253:-
SARC	cis	rs1134634	0.52	rs73125606	ENSG00000273133.1	RP11-799M12.2	-4.71	4.24e-06	0.00225	-0.38	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15545691	chr4:15563698~15564253:-
SARC	cis	rs890448	0.93	rs2433313	ENSG00000254531.1	FLJ20021	-4.71	4.25e-06	0.00226	-0.29	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101467784	chr4:101347780~101348883:+
SARC	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-4.71	4.25e-06	0.00226	-0.37	-0.29	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
SARC	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-4.71	4.25e-06	0.00226	-0.34	-0.29	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
SARC	cis	rs1799949	1	rs8176273	ENSG00000267681.1	CTD-3199J23.6	-4.71	4.26e-06	0.00226	-0.34	-0.29	Menopause (age at onset);	chr17:43059636	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs8176269	ENSG00000267681.1	CTD-3199J23.6	-4.71	4.26e-06	0.00226	-0.34	-0.29	Menopause (age at onset);	chr17:43061609	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs8176265	ENSG00000267681.1	CTD-3199J23.6	-4.71	4.26e-06	0.00226	-0.34	-0.29	Menopause (age at onset);	chr17:43061979	chr17:43144956~43145255:+
SARC	cis	rs6762	0.55	rs8672	ENSG00000279672.1	CMB9-55F22.1	4.71	4.26e-06	0.00226	0.26	0.29	Mean platelet volume;	chr11:838634	chr11:779617~780755:+
SARC	cis	rs1823913	0.562	rs17347499	ENSG00000227542.1	AC092614.2	4.71	4.27e-06	0.00227	0.34	0.29	Obesity-related traits;	chr2:191301116	chr2:191229165~191246172:-
SARC	cis	rs9868809	0.505	rs28793701	ENSG00000225399.4	RP11-3B7.1	-4.71	4.28e-06	0.00227	-0.51	-0.29	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48725250	chr3:49260085~49261316:+
SARC	cis	rs6496044	0.963	rs7165300	ENSG00000202081.1	RNU6-1280P	4.71	4.28e-06	0.00227	0.33	0.29	Interstitial lung disease;	chr15:85526838	chr15:85651522~85651628:-
SARC	cis	rs1823913	0.637	rs6741454	ENSG00000227542.1	AC092614.2	-4.71	4.28e-06	0.00227	-0.33	-0.29	Obesity-related traits;	chr2:191269520	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.614	rs6755243	ENSG00000227542.1	AC092614.2	-4.71	4.28e-06	0.00227	-0.33	-0.29	Obesity-related traits;	chr2:191269810	chr2:191229165~191246172:-
SARC	cis	rs7267979	1	rs1888998	ENSG00000276952.1	RP5-965G21.6	-4.71	4.28e-06	0.00228	-0.29	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:25284915~25285588:-
SARC	cis	rs7772486	0.764	rs7745696	ENSG00000270638.1	RP3-466P17.1	4.71	4.29e-06	0.00228	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145735570~145737218:+
SARC	cis	rs12893668	0.703	rs34026011	ENSG00000269940.1	RP11-73M18.7	4.71	4.29e-06	0.00228	0.29	0.29	Reticulocyte count;	chr14:103584546	chr14:103694560~103695170:+
SARC	cis	rs2933343	0.951	rs789251	ENSG00000261159.1	RP11-723O4.9	4.71	4.29e-06	0.00228	0.35	0.29	IgG glycosylation;	chr3:128857927	chr3:128859716~128860526:-
SARC	cis	rs7772486	0.79	rs9497425	ENSG00000270638.1	RP3-466P17.1	-4.71	4.29e-06	0.00228	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145913061	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs9497427	ENSG00000270638.1	RP3-466P17.1	-4.71	4.29e-06	0.00228	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145917166	chr6:145735570~145737218:+
SARC	cis	rs12893668	0.645	rs35229468	ENSG00000269940.1	RP11-73M18.7	4.71	4.29e-06	0.00228	0.29	0.29	Reticulocyte count;	chr14:103585720	chr14:103694560~103695170:+
SARC	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	4.71	4.3e-06	0.00228	0.36	0.29	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
SARC	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	4.71	4.3e-06	0.00228	0.28	0.29	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
SARC	cis	rs1823913	0.599	rs13015653	ENSG00000227542.1	AC092614.2	4.71	4.31e-06	0.00228	0.33	0.29	Obesity-related traits;	chr2:191306813	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.599	rs12994212	ENSG00000227542.1	AC092614.2	4.71	4.31e-06	0.00228	0.33	0.29	Obesity-related traits;	chr2:191306910	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.599	rs12994236	ENSG00000227542.1	AC092614.2	4.71	4.31e-06	0.00228	0.33	0.29	Obesity-related traits;	chr2:191306991	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.599	rs35495506	ENSG00000227542.1	AC092614.2	4.71	4.31e-06	0.00228	0.33	0.29	Obesity-related traits;	chr2:191307551	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.599	rs34691559	ENSG00000227542.1	AC092614.2	4.71	4.31e-06	0.00228	0.33	0.29	Obesity-related traits;	chr2:191307688	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.561	rs55790432	ENSG00000227542.1	AC092614.2	4.71	4.31e-06	0.00228	0.33	0.29	Obesity-related traits;	chr2:191307722	chr2:191229165~191246172:-
SARC	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-4.71	4.31e-06	0.00228	-0.33	-0.29	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-4.71	4.31e-06	0.00228	-0.33	-0.29	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
SARC	cis	rs7567389	0.671	rs72845993	ENSG00000236682.1	AC068282.3	-4.71	4.31e-06	0.00229	-0.34	-0.29	Self-rated health;	chr2:127351025	chr2:127389130~127400580:+
SARC	cis	rs853679	0.882	rs4713139	ENSG00000219392.1	RP1-265C24.5	-4.71	4.31e-06	0.00229	-0.56	-0.29	Depression;	chr6:28124907	chr6:28115628~28116551:+
SARC	cis	rs2933343	0.729	rs1680781	ENSG00000231305.3	RP11-723O4.2	4.71	4.31e-06	0.00229	0.3	0.29	IgG glycosylation;	chr3:128893987	chr3:128861313~128871540:-
SARC	cis	rs79349575	0.783	rs2112617	ENSG00000270781.1	RP11-501C14.9	-4.71	4.31e-06	0.00229	-0.34	-0.29	Type 2 diabetes;	chr17:48899763	chr17:48899131~48899748:+
SARC	cis	rs910316	0.763	rs175036	ENSG00000279594.1	RP11-950C14.10	-4.71	4.32e-06	0.00229	-0.32	-0.29	Height;	chr14:74997592	chr14:75011269~75012851:-
SARC	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	4.71	4.32e-06	0.00229	0.34	0.29	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
SARC	cis	rs17508449	0.819	rs3761934	ENSG00000232450.1	RP4-730K3.3	-4.71	4.32e-06	0.00229	-0.37	-0.29	Leprosy;	chr1:113646445	chr1:113698884~113699631:-
SARC	cis	rs2933343	0.729	rs789228	ENSG00000231305.3	RP11-723O4.2	4.71	4.32e-06	0.00229	0.3	0.29	IgG glycosylation;	chr3:128882207	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.679	rs789229	ENSG00000231305.3	RP11-723O4.2	4.71	4.32e-06	0.00229	0.3	0.29	IgG glycosylation;	chr3:128883683	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.729	rs789230	ENSG00000231305.3	RP11-723O4.2	4.71	4.32e-06	0.00229	0.3	0.29	IgG glycosylation;	chr3:128883715	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.661	rs2630259	ENSG00000231305.3	RP11-723O4.2	4.71	4.32e-06	0.00229	0.3	0.29	IgG glycosylation;	chr3:128887479	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.729	rs6790091	ENSG00000231305.3	RP11-723O4.2	4.71	4.32e-06	0.00229	0.3	0.29	IgG glycosylation;	chr3:128889908	chr3:128861313~128871540:-
SARC	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-4.71	4.32e-06	0.00229	-0.35	-0.29	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
SARC	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-4.71	4.32e-06	0.00229	-0.43	-0.29	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
SARC	cis	rs763121	0.853	rs138713	ENSG00000273076.1	RP3-508I15.22	4.71	4.32e-06	0.00229	0.31	0.29	Menopause (age at onset);	chr22:38746610	chr22:38743495~38743910:+
SARC	cis	rs14027	0.883	rs16893025	ENSG00000279347.1	RP11-85I17.2	-4.71	4.32e-06	0.00229	-0.25	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701440	chr8:119838736~119840385:-
SARC	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	4.71	4.33e-06	0.00229	0.3	0.29	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
SARC	cis	rs2274273	0.84	rs28568813	ENSG00000258413.1	RP11-665C16.6	-4.71	4.33e-06	0.00229	-0.34	-0.29	Protein biomarker;	chr14:55327396	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.837	rs6573017	ENSG00000258413.1	RP11-665C16.6	-4.71	4.33e-06	0.00229	-0.34	-0.29	Protein biomarker;	chr14:55335525	chr14:55262767~55272075:-
SARC	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	4.71	4.33e-06	0.00229	0.32	0.29	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
SARC	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	4.71	4.33e-06	0.00229	0.34	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
SARC	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-4.71	4.34e-06	0.0023	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-4.71	4.34e-06	0.0023	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
SARC	cis	rs7267979	0.816	rs3746337	ENSG00000276952.1	RP5-965G21.6	4.71	4.34e-06	0.0023	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25227636	chr20:25284915~25285588:-
SARC	cis	rs7216064	1	rs2052187	ENSG00000265055.1	AC145343.2	4.71	4.34e-06	0.0023	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67838621	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs6504543	ENSG00000265055.1	AC145343.2	4.71	4.34e-06	0.0023	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841543	chr17:68096046~68101474:-
SARC	cis	rs11673344	0.528	rs573294	ENSG00000226686.6	LINC01535	4.71	4.35e-06	0.0023	0.32	0.29	Obesity-related traits;	chr19:36919260	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.528	rs476194	ENSG00000226686.6	LINC01535	4.71	4.35e-06	0.0023	0.32	0.29	Obesity-related traits;	chr19:36919831	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.528	rs579452	ENSG00000226686.6	LINC01535	4.71	4.35e-06	0.0023	0.32	0.29	Obesity-related traits;	chr19:36919936	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.528	rs491326	ENSG00000226686.6	LINC01535	4.71	4.35e-06	0.0023	0.32	0.29	Obesity-related traits;	chr19:36920037	chr19:37251912~37265535:+
SARC	cis	rs11673344	0.528	rs563786	ENSG00000226686.6	LINC01535	4.71	4.35e-06	0.0023	0.32	0.29	Obesity-related traits;	chr19:36922012	chr19:37251912~37265535:+
SARC	cis	rs7809950	0.723	rs62483634	ENSG00000238832.1	snoU109	-4.71	4.35e-06	0.0023	-0.35	-0.29	Coronary artery disease;	chr7:107238071	chr7:107603363~107603507:+
SARC	cis	rs7267979	1	rs884613	ENSG00000276952.1	RP5-965G21.6	-4.71	4.35e-06	0.0023	-0.29	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:25284915~25285588:-
SARC	cis	rs597539	0.689	rs596874	ENSG00000250508.1	RP11-757G1.6	4.71	4.35e-06	0.0023	0.35	0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68870664~68874542:+
SARC	cis	rs890448	0.895	rs55962826	ENSG00000254531.1	FLJ20021	-4.71	4.35e-06	0.0023	-0.29	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101450988	chr4:101347780~101348883:+
SARC	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-4.7	4.36e-06	0.00231	-0.35	-0.29	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
SARC	cis	rs4703855	0.557	rs10515147	ENSG00000244061.1	RP11-389C8.1	4.7	4.36e-06	0.00231	0.3	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72404555	chr5:72381794~72382393:+
SARC	cis	rs4703855	0.538	rs9293294	ENSG00000244061.1	RP11-389C8.1	4.7	4.36e-06	0.00231	0.3	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72404701	chr5:72381794~72382393:+
SARC	cis	rs4703855	0.538	rs9293295	ENSG00000244061.1	RP11-389C8.1	4.7	4.36e-06	0.00231	0.3	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72404764	chr5:72381794~72382393:+
SARC	cis	rs4703855	0.538	rs2338215	ENSG00000244061.1	RP11-389C8.1	4.7	4.36e-06	0.00231	0.3	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72405893	chr5:72381794~72382393:+
SARC	cis	rs4703855	0.538	rs2338216	ENSG00000244061.1	RP11-389C8.1	4.7	4.36e-06	0.00231	0.3	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72405987	chr5:72381794~72382393:+
SARC	cis	rs6570726	0.643	rs9403735	ENSG00000270638.1	RP3-466P17.1	4.7	4.36e-06	0.00231	0.24	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145735570~145737218:+
SARC	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	4.7	4.36e-06	0.00231	0.27	0.29	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	4.7	4.36e-06	0.00231	0.27	0.29	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
SARC	cis	rs8062405	0.723	rs4788077	ENSG00000251417.2	RP11-1348G14.4	-4.7	4.36e-06	0.00231	-0.3	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28802743~28817828:+
SARC	cis	rs12049351	0.774	rs4148755	ENSG00000229367.1	HMGN2P19	4.7	4.37e-06	0.00231	0.26	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229559119	chr1:229570532~229570796:+
SARC	cis	rs17292804	0.527	rs12887734	ENSG00000269940.1	RP11-73M18.7	4.7	4.38e-06	0.00232	0.29	0.29	Autism spectrum disorder or schizophrenia;	chr14:103580497	chr14:103694560~103695170:+
SARC	cis	rs890448	0.897	rs2953534	ENSG00000254531.1	FLJ20021	-4.7	4.39e-06	0.00232	-0.29	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101454897	chr4:101347780~101348883:+
SARC	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-4.7	4.39e-06	0.00232	-0.28	-0.29	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
SARC	cis	rs4845875	0.514	rs198393	ENSG00000242349.4	NPPA-AS1	-4.7	4.39e-06	0.00232	-0.31	-0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11819628	chr1:11841017~11848079:+
SARC	cis	rs9494145	1	rs9494145	ENSG00000232876.1	CTA-212D2.2	-4.7	4.39e-06	0.00232	-0.43	-0.29	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135111414	chr6:135055033~135060550:+
SARC	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	4.7	4.39e-06	0.00232	0.28	0.29	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	4.7	4.39e-06	0.00232	0.28	0.29	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	4.7	4.39e-06	0.00232	0.28	0.29	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
SARC	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-4.7	4.39e-06	0.00232	-0.33	-0.29	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-4.7	4.39e-06	0.00232	-0.33	-0.29	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
SARC	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-4.7	4.39e-06	0.00232	-0.33	-0.29	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
SARC	cis	rs526231	0.819	rs2288788	ENSG00000175749.11	EIF3KP1	4.7	4.4e-06	0.00232	0.4	0.29	Primary biliary cholangitis;	chr5:103264868	chr5:103032376~103033031:+
SARC	cis	rs763121	0.853	rs6001214	ENSG00000273076.1	RP3-508I15.22	4.7	4.41e-06	0.00233	0.32	0.29	Menopause (age at onset);	chr22:38753150	chr22:38743495~38743910:+
SARC	cis	rs6570726	0.791	rs9403734	ENSG00000270638.1	RP3-466P17.1	4.7	4.42e-06	0.00233	0.24	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs2096201	ENSG00000270638.1	RP3-466P17.1	4.7	4.42e-06	0.00233	0.24	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145735570~145737218:+
SARC	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.42e-06	0.00233	-0.34	-0.29	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
SARC	cis	rs193541	0.621	rs898391	ENSG00000263432.2	RN7SL689P	4.7	4.42e-06	0.00233	0.37	0.29	Glucose homeostasis traits;	chr5:122746471	chr5:123022487~123022783:-
SARC	cis	rs4703855	0.538	rs12520894	ENSG00000244061.1	RP11-389C8.1	4.7	4.42e-06	0.00233	0.3	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72419964	chr5:72381794~72382393:+
SARC	cis	rs4703855	0.538	rs7722907	ENSG00000244061.1	RP11-389C8.1	4.7	4.42e-06	0.00233	0.3	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72421337	chr5:72381794~72382393:+
SARC	cis	rs4703855	0.538	rs2338218	ENSG00000244061.1	RP11-389C8.1	4.7	4.42e-06	0.00233	0.3	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72422105	chr5:72381794~72382393:+
SARC	cis	rs4703855	0.538	rs2338220	ENSG00000244061.1	RP11-389C8.1	4.7	4.42e-06	0.00233	0.3	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72422275	chr5:72381794~72382393:+
SARC	cis	rs890448	0.93	rs11937097	ENSG00000254531.1	FLJ20021	-4.7	4.42e-06	0.00233	-0.29	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101460780	chr4:101347780~101348883:+
SARC	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	4.7	4.42e-06	0.00233	0.28	0.29	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	4.7	4.42e-06	0.00233	0.28	0.29	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
SARC	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	4.7	4.43e-06	0.00233	0.25	0.29	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
SARC	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-4.7	4.43e-06	0.00233	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-4.7	4.43e-06	0.00233	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-4.7	4.43e-06	0.00233	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-4.7	4.43e-06	0.00233	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-4.7	4.43e-06	0.00233	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
SARC	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-4.7	4.43e-06	0.00233	-0.24	-0.29	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
SARC	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-4.7	4.43e-06	0.00233	-0.32	-0.29	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
SARC	cis	rs17508449	0.819	rs79220465	ENSG00000232450.1	RP4-730K3.3	-4.7	4.43e-06	0.00233	-0.38	-0.29	Leprosy;	chr1:113628719	chr1:113698884~113699631:-
SARC	cis	rs4703855	0.538	rs10462378	ENSG00000244061.1	RP11-389C8.1	4.7	4.44e-06	0.00234	0.3	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72403258	chr5:72381794~72382393:+
SARC	cis	rs4703855	0.513	rs12654408	ENSG00000244061.1	RP11-389C8.1	4.7	4.44e-06	0.00234	0.3	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72403842	chr5:72381794~72382393:+
SARC	cis	rs1707322	0.682	rs3014241	ENSG00000281133.1	AL355480.3	4.7	4.44e-06	0.00234	0.34	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45580892~45580996:-
SARC	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	4.7	4.44e-06	0.00234	0.25	0.29	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	4.7	4.44e-06	0.00234	0.25	0.29	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
SARC	cis	rs7772486	0.764	rs9399569	ENSG00000270638.1	RP3-466P17.1	-4.7	4.44e-06	0.00234	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145921806	chr6:145735570~145737218:+
SARC	cis	rs7181230	1	rs7181230	ENSG00000275636.1	RP11-521C20.5	4.7	4.45e-06	0.00234	0.34	0.29	Dehydroepiandrosterone sulphate levels;	chr15:40068540	chr15:40078892~40079347:+
SARC	cis	rs7216064	0.861	rs62084252	ENSG00000265055.1	AC145343.2	4.7	4.45e-06	0.00234	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67883462	chr17:68096046~68101474:-
SARC	cis	rs17772222	0.651	rs1950280	ENSG00000258983.2	RP11-507K2.2	-4.7	4.45e-06	0.00234	-0.29	-0.29	Coronary artery calcification;	chr14:88366259	chr14:88499334~88515502:+
SARC	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-4.7	4.45e-06	0.00235	-0.34	-0.29	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
SARC	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-4.7	4.45e-06	0.00235	-0.31	-0.29	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
SARC	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	4.7	4.46e-06	0.00235	0.47	0.29	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
SARC	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	4.7	4.46e-06	0.00235	0.31	0.29	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
SARC	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-4.7	4.47e-06	0.00235	-0.36	-0.29	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
SARC	cis	rs1865760	0.532	rs1061482	ENSG00000272462.2	U91328.19	-4.7	4.47e-06	0.00236	-0.27	-0.29	Height;	chr6:26086471	chr6:25992662~26001775:+
SARC	cis	rs2439831	1	rs2467740	ENSG00000205771.5	CATSPER2P1	-4.7	4.48e-06	0.00236	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43454594	chr15:43726918~43747094:-
SARC	cis	rs193541	0.501	rs3943379	ENSG00000263432.2	RN7SL689P	4.7	4.48e-06	0.00236	0.38	0.29	Glucose homeostasis traits;	chr5:122720442	chr5:123022487~123022783:-
SARC	cis	rs193541	0.502	rs2061511	ENSG00000263432.2	RN7SL689P	4.7	4.48e-06	0.00236	0.38	0.29	Glucose homeostasis traits;	chr5:122721032	chr5:123022487~123022783:-
SARC	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-4.7	4.48e-06	0.00236	-0.31	-0.29	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
SARC	cis	rs2274273	0.624	rs8014477	ENSG00000258413.1	RP11-665C16.6	4.7	4.48e-06	0.00236	0.37	0.29	Protein biomarker;	chr14:55374759	chr14:55262767~55272075:-
SARC	cis	rs7772486	0.72	rs991507	ENSG00000270638.1	RP3-466P17.1	-4.7	4.49e-06	0.00236	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145735570~145737218:+
SARC	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.49e-06	0.00236	-0.34	-0.29	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
SARC	cis	rs35160687	0.623	rs2276625	ENSG00000273080.1	RP11-301O19.1	4.7	4.5e-06	0.00237	0.31	0.29	Night sleep phenotypes;	chr2:86254712	chr2:86195590~86196049:+
SARC	cis	rs2274273	0.714	rs7154889	ENSG00000258413.1	RP11-665C16.6	-4.7	4.5e-06	0.00237	-0.34	-0.29	Protein biomarker;	chr14:55340167	chr14:55262767~55272075:-
SARC	cis	rs321358	0.895	rs6589210	ENSG00000271584.1	RP11-89C3.4	4.7	4.5e-06	0.00237	0.47	0.29	Body mass index;	chr11:111088408	chr11:111091932~111097357:-
SARC	cis	rs8031584	1	rs12906054	ENSG00000260382.1	RP11-540B6.2	4.7	4.51e-06	0.00237	0.4	0.29	Huntington's disease progression;	chr15:30999820	chr15:30882267~30883231:-
SARC	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-4.7	4.51e-06	0.00237	-0.29	-0.29	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
SARC	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-4.7	4.51e-06	0.00237	-0.38	-0.29	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
SARC	cis	rs2439831	0.85	rs16950562	ENSG00000275601.1	AC011330.13	-4.7	4.51e-06	0.00237	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43744166	chr15:43642389~43643023:-
SARC	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	4.7	4.51e-06	0.00237	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
SARC	cis	rs2555155	0.602	rs2555143	ENSG00000254595.1	CTD-2010I16.1	-4.7	4.51e-06	0.00237	-0.28	-0.29	DNA methylation (variation);	chr11:6520350	chr11:6488186~6489377:-
SARC	cis	rs910316	1	rs8003506	ENSG00000279594.1	RP11-950C14.10	-4.7	4.51e-06	0.00237	-0.33	-0.29	Height;	chr14:75119585	chr14:75011269~75012851:-
SARC	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-4.7	4.52e-06	0.00238	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
SARC	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	4.7	4.52e-06	0.00238	0.27	0.29	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	4.7	4.52e-06	0.00238	0.27	0.29	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	4.7	4.52e-06	0.00238	0.27	0.29	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	4.7	4.52e-06	0.00238	0.27	0.29	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
SARC	cis	rs6762	0.719	rs28620453	ENSG00000279672.1	CMB9-55F22.1	4.7	4.52e-06	0.00238	0.26	0.29	Mean platelet volume;	chr11:836971	chr11:779617~780755:+
SARC	cis	rs8081395	0.775	rs2526355	ENSG00000266992.1	DHX40P1	4.7	4.52e-06	0.00238	0.31	0.29	White blood cell count;	chr17:59875872	chr17:59976009~60002384:-
SARC	cis	rs1292048	1	rs1292048	ENSG00000266992.1	DHX40P1	4.7	4.52e-06	0.00238	0.31	0.29	Red cell distribution width;	chr17:59877710	chr17:59976009~60002384:-
SARC	cis	rs1134634	0.52	rs4280724	ENSG00000273133.1	RP11-799M12.2	-4.7	4.53e-06	0.00238	-0.38	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574128	chr4:15563698~15564253:-
SARC	cis	rs1134634	0.52	rs7665390	ENSG00000273133.1	RP11-799M12.2	-4.7	4.53e-06	0.00238	-0.38	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15576115	chr4:15563698~15564253:-
SARC	cis	rs4664293	0.867	rs7565297	ENSG00000226266.5	AC009961.3	-4.7	4.53e-06	0.00238	-0.35	-0.29	Monocyte percentage of white cells;	chr2:159716008	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs7594329	ENSG00000226266.5	AC009961.3	-4.7	4.53e-06	0.00238	-0.35	-0.29	Monocyte percentage of white cells;	chr2:159716207	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs7582124	ENSG00000226266.5	AC009961.3	-4.7	4.53e-06	0.00238	-0.35	-0.29	Monocyte percentage of white cells;	chr2:159716326	chr2:159670708~159712435:-
SARC	cis	rs17508449	0.819	rs79667495	ENSG00000232450.1	RP4-730K3.3	-4.7	4.53e-06	0.00238	-0.37	-0.29	Leprosy;	chr1:113648707	chr1:113698884~113699631:-
SARC	cis	rs2274273	0.624	rs7151754	ENSG00000258413.1	RP11-665C16.6	-4.7	4.54e-06	0.00238	-0.37	-0.29	Protein biomarker;	chr14:55321783	chr14:55262767~55272075:-
SARC	cis	rs12893668	0.703	rs2403197	ENSG00000269940.1	RP11-73M18.7	4.7	4.54e-06	0.00238	0.29	0.29	Reticulocyte count;	chr14:103587427	chr14:103694560~103695170:+
SARC	cis	rs728478	1	rs11079376	ENSG00000266992.1	DHX40P1	4.7	4.54e-06	0.00238	0.31	0.29	QT interval;	chr17:59376128	chr17:59976009~60002384:-
SARC	cis	rs1799949	0.929	rs799906	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.54e-06	0.00238	-0.33	-0.29	Menopause (age at onset);	chr17:43126099	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs799908	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.54e-06	0.00238	-0.33	-0.29	Menopause (age at onset);	chr17:43126899	chr17:43144956~43145255:+
SARC	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-4.7	4.54e-06	0.00238	-0.36	-0.29	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
SARC	cis	rs12049351	0.774	rs10916516	ENSG00000229367.1	HMGN2P19	4.7	4.54e-06	0.00238	0.26	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229564427	chr1:229570532~229570796:+
SARC	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-4.7	4.54e-06	0.00239	-0.3	-0.29	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
SARC	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-4.7	4.54e-06	0.00239	-0.46	-0.29	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
SARC	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.55e-06	0.00239	-0.34	-0.29	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.55e-06	0.00239	-0.34	-0.29	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.55e-06	0.00239	-0.34	-0.29	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.55e-06	0.00239	-0.34	-0.29	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-4.7	4.55e-06	0.00239	-0.34	-0.29	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
SARC	cis	rs2708377	0.858	rs68045377	ENSG00000247157.5	LINC01252	4.7	4.55e-06	0.00239	0.5	0.29	Bitter taste perception;	chr12:11141853	chr12:11548030~11590369:+
SARC	cis	rs193541	0.642	rs42538	ENSG00000263432.2	RN7SL689P	4.69	4.55e-06	0.00239	0.38	0.29	Glucose homeostasis traits;	chr5:122956657	chr5:123022487~123022783:-
SARC	cis	rs193541	0.632	rs39821	ENSG00000263432.2	RN7SL689P	4.69	4.55e-06	0.00239	0.38	0.29	Glucose homeostasis traits;	chr5:122959777	chr5:123022487~123022783:-
SARC	cis	rs72945132	0.882	rs7123602	ENSG00000254604.1	AP000487.6	-4.69	4.56e-06	0.00239	-0.41	-0.29	Coronary artery disease;	chr11:70335383	chr11:70282367~70363368:-
SARC	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-4.69	4.56e-06	0.00239	-0.35	-0.29	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
SARC	cis	rs12980942	0.872	rs3816052	ENSG00000206674.1	RNU6-945P	-4.69	4.56e-06	0.00239	-0.42	-0.29	Coronary artery disease;	chr19:41267892	chr19:40299478~40299584:-
SARC	cis	rs1865760	0.566	rs9348706	ENSG00000272462.2	U91328.19	-4.69	4.56e-06	0.00239	-0.27	-0.29	Height;	chr6:26065253	chr6:25992662~26001775:+
SARC	cis	rs1707322	0.717	rs1972410	ENSG00000281133.1	AL355480.3	-4.69	4.57e-06	0.0024	-0.35	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45580892~45580996:-
SARC	cis	rs7255436	0.965	rs11666233	ENSG00000269386.4	RAB11B-AS1	4.69	4.57e-06	0.0024	0.29	0.29	HDL cholesterol;	chr19:8387161	chr19:8374373~8390685:-
SARC	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	4.69	4.57e-06	0.0024	0.25	0.29	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
SARC	cis	rs62432291	0.681	rs365045	ENSG00000235086.1	FNDC1-IT1	4.69	4.58e-06	0.0024	0.47	0.29	Joint mobility (Beighton score);	chr6:159211218	chr6:159240786~159243329:+
SARC	cis	rs8062405	0.755	rs56272201	ENSG00000251417.2	RP11-1348G14.4	-4.69	4.58e-06	0.0024	-0.3	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.755	rs62034355	ENSG00000251417.2	RP11-1348G14.4	-4.69	4.58e-06	0.0024	-0.3	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28802743~28817828:+
SARC	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	4.69	4.58e-06	0.0024	0.32	0.29	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
SARC	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-4.69	4.59e-06	0.0024	-0.55	-0.29	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-4.69	4.59e-06	0.0024	-0.55	-0.29	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-4.69	4.59e-06	0.0024	-0.55	-0.29	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-4.69	4.59e-06	0.0024	-0.55	-0.29	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-4.69	4.59e-06	0.0024	-0.55	-0.29	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-4.69	4.59e-06	0.0024	-0.55	-0.29	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-4.69	4.59e-06	0.0024	-0.55	-0.29	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs2707856	ENSG00000236529.1	RP13-254B10.1	4.69	4.59e-06	0.00241	0.3	0.29	Aortic root size;	chr7:66746023	chr7:65840212~65840596:+
SARC	cis	rs131805	1	rs131816	ENSG00000205559.3	CHKB-AS1	-4.69	4.59e-06	0.00241	-0.35	-0.29	Granulocyte percentage of myeloid white cells;	chr22:50519033	chr22:50583026~50583877:+
SARC	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-4.69	4.6e-06	0.00241	-0.37	-0.29	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
SARC	cis	rs7615952	0.641	rs4422257	ENSG00000250012.1	RP11-124N2.1	-4.69	4.6e-06	0.00241	-0.29	-0.29	Blood pressure (smoking interaction);	chr3:126055520	chr3:126084220~126095349:+
SARC	cis	rs193541	0.632	rs119449	ENSG00000263432.2	RN7SL689P	4.69	4.6e-06	0.00241	0.38	0.29	Glucose homeostasis traits;	chr5:122948046	chr5:123022487~123022783:-
SARC	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	4.69	4.61e-06	0.00241	0.25	0.29	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
SARC	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	4.69	4.61e-06	0.00242	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	4.69	4.61e-06	0.00242	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
SARC	cis	rs2404602	0.735	rs2280306	ENSG00000259422.1	RP11-593F23.1	-4.69	4.62e-06	0.00242	-0.35	-0.29	Blood metabolite levels;	chr15:76359917	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.735	rs11638767	ENSG00000259422.1	RP11-593F23.1	-4.69	4.62e-06	0.00242	-0.35	-0.29	Blood metabolite levels;	chr15:76363597	chr15:76174891~76181486:-
SARC	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-4.69	4.62e-06	0.00242	-0.36	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
SARC	cis	rs73186030	0.764	rs17251221	ENSG00000272758.4	RP11-299J3.8	4.69	4.62e-06	0.00242	0.42	0.29	Serum parathyroid hormone levels;	chr3:122274400	chr3:122416207~122443180:+
SARC	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	4.69	4.63e-06	0.00243	0.34	0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
SARC	cis	rs2933343	0.729	rs1683780	ENSG00000231305.3	RP11-723O4.2	4.69	4.63e-06	0.00243	0.3	0.29	IgG glycosylation;	chr3:128921396	chr3:128861313~128871540:-
SARC	cis	rs10911902	0.643	rs10494584	ENSG00000229739.2	RP11-295K2.3	-4.69	4.63e-06	0.00243	-0.42	-0.29	Schizophrenia;	chr1:186321389	chr1:186435161~186470291:+
SARC	cis	rs1799949	0.93	rs1554063	ENSG00000267681.1	CTD-3199J23.6	-4.69	4.63e-06	0.00243	-0.33	-0.29	Menopause (age at onset);	chr17:43135128	chr17:43144956~43145255:+
SARC	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-4.69	4.64e-06	0.00243	-0.36	-0.29	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
SARC	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	4.69	4.64e-06	0.00243	0.42	0.29	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
SARC	cis	rs42490	0.868	rs4961155	ENSG00000251136.7	RP11-37B2.1	4.69	4.64e-06	0.00243	0.32	0.29	Leprosy;	chr8:89666035	chr8:89609409~89757727:-
SARC	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-4.69	4.65e-06	0.00243	-0.37	-0.29	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
SARC	cis	rs2274273	0.624	rs7154796	ENSG00000258413.1	RP11-665C16.6	-4.69	4.65e-06	0.00244	-0.38	-0.29	Protein biomarker;	chr14:55304740	chr14:55262767~55272075:-
SARC	cis	rs2439831	0.681	rs825740	ENSG00000275601.1	AC011330.13	-4.69	4.65e-06	0.00244	-0.44	-0.29	Lung cancer in ever smokers;	chr15:43300210	chr15:43642389~43643023:-
SARC	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-4.69	4.66e-06	0.00244	-0.44	-0.29	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-4.69	4.66e-06	0.00244	-0.44	-0.29	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
SARC	cis	rs4835473	0.932	rs2323200	ENSG00000251600.4	RP11-673E1.1	4.69	4.66e-06	0.00244	0.29	0.29	Immature fraction of reticulocytes;	chr4:143765448	chr4:143912331~143982454:+
SARC	cis	rs6570726	0.967	rs7772286	ENSG00000270638.1	RP3-466P17.1	-4.69	4.66e-06	0.00244	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145735570~145737218:+
SARC	cis	rs2836950	0.84	rs12482317	ENSG00000255568.3	BRWD1-AS2	-4.69	4.66e-06	0.00244	-0.28	-0.29	Menarche (age at onset);	chr21:39216315	chr21:39313935~39314962:+
SARC	cis	rs7809950	0.723	rs62483633	ENSG00000238832.1	snoU109	-4.69	4.66e-06	0.00244	-0.35	-0.29	Coronary artery disease;	chr7:107236199	chr7:107603363~107603507:+
SARC	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-4.69	4.67e-06	0.00244	-0.32	-0.29	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
SARC	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-4.69	4.67e-06	0.00244	-0.3	-0.29	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
SARC	cis	rs890448	0.796	rs4594730	ENSG00000254531.1	FLJ20021	4.69	4.68e-06	0.00245	0.3	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417303	chr4:101347780~101348883:+
SARC	cis	rs7216064	1	rs6504549	ENSG00000265055.1	AC145343.2	4.69	4.68e-06	0.00245	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67892668	chr17:68096046~68101474:-
SARC	cis	rs17270561	0.553	rs9379784	ENSG00000272810.1	U91328.22	-4.69	4.68e-06	0.00245	-0.3	-0.29	Iron status biomarkers;	chr6:25725278	chr6:26013241~26013757:+
SARC	cis	rs12468226	1	rs74766638	ENSG00000272966.1	RP11-686O6.1	4.69	4.68e-06	0.00245	0.47	0.29	Urate levels;	chr2:202445168	chr2:202336739~202337200:+
SARC	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-4.69	4.69e-06	0.00245	-0.33	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
SARC	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-4.69	4.69e-06	0.00245	-0.37	-0.29	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
SARC	cis	rs7178375	1	rs4779797	ENSG00000215302.7	CTD-3092A11.1	4.69	4.69e-06	0.00245	0.36	0.29	Hypertriglyceridemia;	chr15:30916222	chr15:30470779~30507623:+
SARC	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	4.69	4.7e-06	0.00246	0.27	0.29	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	4.69	4.7e-06	0.00246	0.27	0.29	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
SARC	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-4.69	4.7e-06	0.00246	-0.38	-0.29	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
SARC	cis	rs2412819	0.597	rs2412821	ENSG00000205771.5	CATSPER2P1	-4.69	4.7e-06	0.00246	-0.43	-0.29	Lung cancer;	chr15:43864966	chr15:43726918~43747094:-
SARC	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	4.69	4.71e-06	0.00246	0.32	0.29	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
SARC	cis	rs1799949	0.965	rs8176310	ENSG00000267681.1	CTD-3199J23.6	-4.69	4.71e-06	0.00246	-0.32	-0.29	Menopause (age at onset);	chr17:43047896	chr17:43144956~43145255:+
SARC	cis	rs4372836	0.504	rs13025081	ENSG00000226833.4	AC097724.3	4.69	4.71e-06	0.00246	0.25	0.29	Body mass index;	chr2:28860984	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.504	rs6760186	ENSG00000226833.4	AC097724.3	4.69	4.71e-06	0.00246	0.25	0.29	Body mass index;	chr2:28864408	chr2:28708953~28736205:-
SARC	cis	rs910316	0.687	rs175059	ENSG00000279594.1	RP11-950C14.10	-4.69	4.72e-06	0.00246	-0.33	-0.29	Height;	chr14:75023964	chr14:75011269~75012851:-
SARC	cis	rs1707322	0.721	rs10430124	ENSG00000281133.1	AL355480.3	-4.69	4.72e-06	0.00246	-0.34	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45580892~45580996:-
SARC	cis	rs2439831	0.681	rs540388	ENSG00000275601.1	AC011330.13	-4.69	4.72e-06	0.00247	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43314296	chr15:43642389~43643023:-
SARC	cis	rs853679	0.882	rs3757188	ENSG00000219392.1	RP1-265C24.5	-4.69	4.72e-06	0.00247	-0.57	-0.29	Depression;	chr6:28139579	chr6:28115628~28116551:+
SARC	cis	rs7216064	1	rs2365468	ENSG00000265055.1	AC145343.2	4.69	4.72e-06	0.00247	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67845202	chr17:68096046~68101474:-
SARC	cis	rs7772486	0.654	rs1011597	ENSG00000270638.1	RP3-466P17.1	-4.69	4.72e-06	0.00247	-0.23	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145735570~145737218:+
SARC	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-4.69	4.73e-06	0.00247	-0.34	-0.29	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
SARC	cis	rs7615952	0.641	rs6438951	ENSG00000250012.1	RP11-124N2.1	-4.69	4.73e-06	0.00247	-0.28	-0.29	Blood pressure (smoking interaction);	chr3:125978156	chr3:126084220~126095349:+
SARC	cis	rs2274273	0.901	rs112870553	ENSG00000258413.1	RP11-665C16.6	-4.69	4.73e-06	0.00247	-0.34	-0.29	Protein biomarker;	chr14:55323344	chr14:55262767~55272075:-
SARC	cis	rs2933343	0.679	rs1091938	ENSG00000231305.3	RP11-723O4.2	4.69	4.74e-06	0.00247	0.3	0.29	IgG glycosylation;	chr3:128918182	chr3:128861313~128871540:-
SARC	cis	rs2708377	0.656	rs116607079	ENSG00000247157.5	LINC01252	4.69	4.74e-06	0.00248	0.5	0.29	Bitter taste perception;	chr12:11109445	chr12:11548030~11590369:+
SARC	cis	rs2708377	0.929	rs73066828	ENSG00000247157.5	LINC01252	4.69	4.74e-06	0.00248	0.5	0.29	Bitter taste perception;	chr12:11118055	chr12:11548030~11590369:+
SARC	cis	rs2708377	0.858	rs115781584	ENSG00000247157.5	LINC01252	4.69	4.74e-06	0.00248	0.5	0.29	Bitter taste perception;	chr12:11151961	chr12:11548030~11590369:+
SARC	cis	rs7216064	1	rs4791212	ENSG00000278740.1	RP11-147L13.14	4.69	4.75e-06	0.00248	0.34	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67979269	chr17:68188547~68189165:+
SARC	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	4.69	4.75e-06	0.00248	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
SARC	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-4.69	4.76e-06	0.00248	-0.29	-0.29	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
SARC	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	4.68	4.76e-06	0.00248	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
SARC	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	4.68	4.76e-06	0.00248	0.3	0.29	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
SARC	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-4.68	4.76e-06	0.00248	-0.34	-0.29	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
SARC	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	4.68	4.76e-06	0.00248	0.28	0.29	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	4.68	4.76e-06	0.00248	0.28	0.29	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	4.68	4.76e-06	0.00248	0.28	0.29	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
SARC	cis	rs792448	0.545	rs7519168	ENSG00000229983.1	RP11-15I11.2	-4.68	4.76e-06	0.00249	-0.31	-0.29	White blood cell count (basophil);	chr1:212220043	chr1:212168207~212190259:+
SARC	cis	rs8062405	0.824	rs4788083	ENSG00000251417.2	RP11-1348G14.4	-4.68	4.77e-06	0.00249	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28802743~28817828:+
SARC	cis	rs2179367	0.613	rs12207047	ENSG00000231760.4	RP11-350J20.5	4.68	4.77e-06	0.00249	0.4	0.29	Dupuytren's disease;	chr6:149423496	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.613	rs12207261	ENSG00000231760.4	RP11-350J20.5	4.68	4.77e-06	0.00249	0.4	0.29	Dupuytren's disease;	chr6:149423722	chr6:149796151~149826294:-
SARC	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-4.68	4.77e-06	0.00249	-0.48	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
SARC	cis	rs853679	0.546	rs483143	ENSG00000216901.1	AL022393.7	4.68	4.77e-06	0.00249	0.67	0.29	Depression;	chr6:27878966	chr6:28176188~28176674:+
SARC	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	4.68	4.77e-06	0.00249	0.35	0.29	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	4.68	4.77e-06	0.00249	0.35	0.29	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
SARC	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	4.68	4.77e-06	0.00249	0.35	0.29	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
SARC	cis	rs193541	0.632	rs34486978	ENSG00000263432.2	RN7SL689P	-4.68	4.78e-06	0.00249	-0.38	-0.29	Glucose homeostasis traits;	chr5:122976848	chr5:123022487~123022783:-
SARC	cis	rs9868809	0.505	rs56735597	ENSG00000225399.4	RP11-3B7.1	-4.68	4.78e-06	0.00249	-0.54	-0.29	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48727735	chr3:49260085~49261316:+
SARC	cis	rs763121	0.853	rs5750677	ENSG00000273076.1	RP3-508I15.22	4.68	4.78e-06	0.00249	0.32	0.29	Menopause (age at onset);	chr22:38751710	chr22:38743495~38743910:+
SARC	cis	rs763121	0.853	rs2072798	ENSG00000273076.1	RP3-508I15.22	4.68	4.78e-06	0.00249	0.32	0.29	Menopause (age at onset);	chr22:38752478	chr22:38743495~38743910:+
SARC	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	4.68	4.78e-06	0.00249	0.38	0.29	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
SARC	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-4.68	4.78e-06	0.00249	-0.39	-0.29	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
SARC	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.79e-06	0.0025	-0.33	-0.29	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.79e-06	0.0025	-0.33	-0.29	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.79e-06	0.0025	-0.33	-0.29	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.79e-06	0.0025	-0.33	-0.29	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
SARC	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-4.68	4.79e-06	0.0025	-0.36	-0.29	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
SARC	cis	rs2439831	1	rs690002	ENSG00000275601.1	AC011330.13	-4.68	4.79e-06	0.0025	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43437151	chr15:43642389~43643023:-
SARC	cis	rs2439831	1	rs537115	ENSG00000275601.1	AC011330.13	-4.68	4.79e-06	0.0025	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43437750	chr15:43642389~43643023:-
SARC	cis	rs2803122	0.811	rs7871640	ENSG00000273226.1	RP11-513M16.8	-4.68	4.8e-06	0.0025	-0.28	-0.29	Pulse pressure;	chr9:19218365	chr9:19375451~19375996:+
SARC	cis	rs193541	0.632	rs6595413	ENSG00000263432.2	RN7SL689P	4.68	4.8e-06	0.0025	0.37	0.29	Glucose homeostasis traits;	chr5:122821254	chr5:123022487~123022783:-
SARC	cis	rs2274273	0.934	rs17740741	ENSG00000258413.1	RP11-665C16.6	-4.68	4.81e-06	0.0025	-0.35	-0.29	Protein biomarker;	chr14:55295994	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.901	rs68046603	ENSG00000258413.1	RP11-665C16.6	-4.68	4.81e-06	0.0025	-0.35	-0.29	Protein biomarker;	chr14:55296085	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.901	rs12050099	ENSG00000258413.1	RP11-665C16.6	-4.68	4.81e-06	0.0025	-0.35	-0.29	Protein biomarker;	chr14:55297613	chr14:55262767~55272075:-
SARC	cis	rs7216064	1	rs1976054	ENSG00000265055.1	AC145343.2	4.68	4.81e-06	0.0025	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67837108	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs4790908	ENSG00000265055.1	AC145343.2	4.68	4.81e-06	0.00251	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67856791	chr17:68096046~68101474:-
SARC	cis	rs4654783	0.627	rs4655024	ENSG00000228397.1	RP1-224A6.3	4.68	4.82e-06	0.00251	0.33	0.29	Endometriosis;	chr1:22126221	chr1:22023994~22024968:-
SARC	cis	rs910316	0.967	rs4903293	ENSG00000279594.1	RP11-950C14.10	-4.68	4.82e-06	0.00251	-0.32	-0.29	Height;	chr14:75189865	chr14:75011269~75012851:-
SARC	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-4.68	4.82e-06	0.00251	-0.34	-0.29	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
SARC	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.82e-06	0.00251	-0.34	-0.29	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
SARC	cis	rs2439831	0.867	rs486301	ENSG00000205771.5	CATSPER2P1	-4.68	4.82e-06	0.00251	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43544751	chr15:43726918~43747094:-
SARC	cis	rs638893	0.673	rs538645	ENSG00000278376.1	RP11-158I9.8	4.68	4.83e-06	0.00251	0.25	0.29	Vitiligo;	chr11:118840360	chr11:118791254~118793137:+
SARC	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-4.68	4.83e-06	0.00251	-0.29	-0.29	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
SARC	cis	rs2179367	0.959	rs537354	ENSG00000231760.4	RP11-350J20.5	4.68	4.83e-06	0.00251	0.36	0.29	Dupuytren's disease;	chr6:149344801	chr6:149796151~149826294:-
SARC	cis	rs2018683	0.899	rs10479817	ENSG00000228421.2	AC005013.5	4.68	4.83e-06	0.00251	0.29	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938531	chr7:28957667~28959345:+
SARC	cis	rs7216064	1	rs9897982	ENSG00000265055.1	AC145343.2	4.68	4.83e-06	0.00251	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67883476	chr17:68096046~68101474:-
SARC	cis	rs367615	0.704	rs55956735	ENSG00000249476.1	CTD-2587M2.1	4.68	4.83e-06	0.00252	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109509341	chr5:109237120~109326369:-
SARC	cis	rs193541	0.556	rs30024	ENSG00000263432.2	RN7SL689P	4.68	4.83e-06	0.00252	0.38	0.29	Glucose homeostasis traits;	chr5:122949465	chr5:123022487~123022783:-
SARC	cis	rs193541	0.632	rs30023	ENSG00000263432.2	RN7SL689P	4.68	4.83e-06	0.00252	0.38	0.29	Glucose homeostasis traits;	chr5:122949604	chr5:123022487~123022783:-
SARC	cis	rs7216064	0.953	rs2086744	ENSG00000278219.1	AC145343.1	-4.68	4.83e-06	0.00252	-0.36	-0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67853159	chr17:68101538~68101639:+
SARC	cis	rs7216064	1	rs2046323	ENSG00000278219.1	AC145343.1	-4.68	4.83e-06	0.00252	-0.36	-0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67853811	chr17:68101538~68101639:+
SARC	cis	rs890448	0.726	rs1348161	ENSG00000254531.1	FLJ20021	4.68	4.84e-06	0.00252	0.3	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101331539	chr4:101347780~101348883:+
SARC	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	4.68	4.84e-06	0.00252	0.32	0.29	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
SARC	cis	rs72627509	0.629	rs1718824	ENSG00000269949.1	RP11-738E22.3	-4.68	4.84e-06	0.00252	-0.38	-0.29	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037581	chr4:56960927~56961373:-
SARC	cis	rs2179367	0.632	rs55836833	ENSG00000231760.4	RP11-350J20.5	4.68	4.84e-06	0.00252	0.4	0.29	Dupuytren's disease;	chr6:149403736	chr6:149796151~149826294:-
SARC	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	4.68	4.84e-06	0.00252	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
SARC	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	4.68	4.84e-06	0.00252	0.36	0.29	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
SARC	cis	rs6762	0.692	rs5030778	ENSG00000279672.1	CMB9-55F22.1	4.68	4.84e-06	0.00252	0.26	0.29	Mean platelet volume;	chr11:836008	chr11:779617~780755:+
SARC	cis	rs7267979	1	rs2482931	ENSG00000276952.1	RP5-965G21.6	-4.68	4.84e-06	0.00252	-0.29	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25284915~25285588:-
SARC	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.85e-06	0.00252	-0.34	-0.29	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.85e-06	0.00252	-0.34	-0.29	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
SARC	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-4.68	4.85e-06	0.00253	-0.36	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
SARC	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	4.68	4.85e-06	0.00253	0.32	0.29	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
SARC	cis	rs8081395	0.58	rs180515	ENSG00000266992.1	DHX40P1	4.68	4.86e-06	0.00253	0.34	0.29	White blood cell count;	chr17:59946914	chr17:59976009~60002384:-
SARC	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-4.68	4.86e-06	0.00253	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
SARC	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-4.68	4.86e-06	0.00253	-0.32	-0.29	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-4.68	4.86e-06	0.00253	-0.32	-0.29	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-4.68	4.86e-06	0.00253	-0.32	-0.29	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
SARC	cis	rs1799949	1	rs8176202	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.87e-06	0.00253	-0.34	-0.29	Menopause (age at onset);	chr17:43078211	chr17:43144956~43145255:+
SARC	cis	rs7772486	0.719	rs702307	ENSG00000270638.1	RP3-466P17.1	-4.68	4.87e-06	0.00253	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145735570~145737218:+
SARC	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-4.68	4.87e-06	0.00253	-0.33	-0.29	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
SARC	cis	rs8062405	0.756	rs151301	ENSG00000251417.2	RP11-1348G14.4	-4.68	4.87e-06	0.00253	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28802743~28817828:+
SARC	cis	rs2933343	0.729	rs789228	ENSG00000261159.1	RP11-723O4.9	4.68	4.88e-06	0.00253	0.32	0.29	IgG glycosylation;	chr3:128882207	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.679	rs789229	ENSG00000261159.1	RP11-723O4.9	4.68	4.88e-06	0.00253	0.32	0.29	IgG glycosylation;	chr3:128883683	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.729	rs789230	ENSG00000261159.1	RP11-723O4.9	4.68	4.88e-06	0.00253	0.32	0.29	IgG glycosylation;	chr3:128883715	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.661	rs2630259	ENSG00000261159.1	RP11-723O4.9	4.68	4.88e-06	0.00253	0.32	0.29	IgG glycosylation;	chr3:128887479	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.729	rs6790091	ENSG00000261159.1	RP11-723O4.9	4.68	4.88e-06	0.00253	0.32	0.29	IgG glycosylation;	chr3:128889908	chr3:128859716~128860526:-
SARC	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	4.68	4.88e-06	0.00254	0.3	0.29	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	4.68	4.88e-06	0.00254	0.3	0.29	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
SARC	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-4.68	4.88e-06	0.00254	-0.32	-0.29	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
SARC	cis	rs1865760	0.532	rs1061482	ENSG00000272810.1	U91328.22	-4.68	4.88e-06	0.00254	-0.29	-0.29	Height;	chr6:26086471	chr6:26013241~26013757:+
SARC	cis	rs2287838	0.686	rs730554	ENSG00000267289.1	CTD-2623N2.11	-4.68	4.88e-06	0.00254	-0.29	-0.29	Sleep duration;	chr19:9850870	chr19:9834079~9835013:-
SARC	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	4.68	4.89e-06	0.00254	0.3	0.29	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
SARC	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	4.68	4.89e-06	0.00254	0.3	0.29	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
SARC	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.89e-06	0.00254	-0.34	-0.29	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
SARC	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	4.68	4.89e-06	0.00254	0.32	0.29	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	4.68	4.89e-06	0.00254	0.32	0.29	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	4.68	4.89e-06	0.00254	0.32	0.29	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	4.68	4.89e-06	0.00254	0.32	0.29	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	4.68	4.89e-06	0.00254	0.32	0.29	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	4.68	4.89e-06	0.00254	0.32	0.29	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
SARC	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	4.68	4.89e-06	0.00254	0.3	0.29	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
SARC	cis	rs7255436	1	rs7255436	ENSG00000269386.4	RAB11B-AS1	4.68	4.89e-06	0.00254	0.29	0.29	HDL cholesterol;	chr19:8368312	chr19:8374373~8390685:-
SARC	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.89e-06	0.00254	-0.33	-0.29	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.89e-06	0.00254	-0.33	-0.29	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.89e-06	0.00254	-0.33	-0.29	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.89e-06	0.00254	-0.33	-0.29	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.89e-06	0.00254	-0.33	-0.29	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.89e-06	0.00254	-0.33	-0.29	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.89e-06	0.00254	-0.33	-0.29	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-4.68	4.89e-06	0.00254	-0.33	-0.29	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
SARC	cis	rs4372836	0.504	rs12185717	ENSG00000226833.4	AC097724.3	4.68	4.89e-06	0.00254	0.25	0.29	Body mass index;	chr2:28846685	chr2:28708953~28736205:-
SARC	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	4.68	4.9e-06	0.00255	0.32	0.29	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
SARC	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-4.68	4.9e-06	0.00255	-0.32	-0.29	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
SARC	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-4.68	4.92e-06	0.00255	-0.29	-0.29	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
SARC	cis	rs7512898	0.9	rs6427848	ENSG00000260088.1	RP11-92G12.3	-4.68	4.93e-06	0.00256	-0.29	-0.29	Electrocardiographic conduction measures;	chr1:200701253	chr1:200669507~200694250:+
SARC	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-4.68	4.93e-06	0.00256	-0.28	-0.29	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
SARC	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	4.68	4.94e-06	0.00256	0.36	0.29	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
SARC	cis	rs7216064	1	rs4791212	ENSG00000278219.1	AC145343.1	-4.68	4.94e-06	0.00256	-0.37	-0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67979269	chr17:68101538~68101639:+
SARC	cis	rs8031584	0.56	rs1056118	ENSG00000260382.1	RP11-540B6.2	-4.68	4.94e-06	0.00256	-0.33	-0.29	Huntington's disease progression;	chr15:30911583	chr15:30882267~30883231:-
SARC	cis	rs853679	0.517	rs17711344	ENSG00000272009.1	RP1-313I6.12	4.68	4.94e-06	0.00256	0.35	0.29	Depression;	chr6:28109824	chr6:28078792~28081130:-
SARC	cis	rs4845875	0.53	rs4846048	ENSG00000242349.4	NPPA-AS1	-4.68	4.94e-06	0.00256	-0.32	-0.29	Midregional pro atrial natriuretic peptide levels;	chr1:11786195	chr1:11841017~11848079:+
SARC	cis	rs9890032	0.934	rs7225461	ENSG00000263531.1	RP13-753N3.1	4.68	4.94e-06	0.00256	0.35	0.29	Hip circumference adjusted for BMI;	chr17:30932881	chr17:30863921~30864940:-
SARC	cis	rs950027	0.516	rs12916762	ENSG00000259520.4	CTD-2651B20.3	-4.68	4.94e-06	0.00256	-0.37	-0.29	Response to fenofibrate (adiponectin levels);	chr15:45656104	chr15:45251580~45279251:-
SARC	cis	rs801193	0.935	rs3800820	ENSG00000236529.1	RP13-254B10.1	-4.68	4.95e-06	0.00257	-0.3	-0.29	Aortic root size;	chr7:66682191	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs2003301	ENSG00000236529.1	RP13-254B10.1	-4.68	4.95e-06	0.00257	-0.3	-0.29	Aortic root size;	chr7:66682669	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs7788576	ENSG00000236529.1	RP13-254B10.1	-4.68	4.95e-06	0.00257	-0.3	-0.29	Aortic root size;	chr7:66683315	chr7:65840212~65840596:+
SARC	cis	rs801193	0.935	rs2659916	ENSG00000236529.1	RP13-254B10.1	4.68	4.95e-06	0.00257	0.3	0.29	Aortic root size;	chr7:66686365	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs6958520	ENSG00000236529.1	RP13-254B10.1	4.68	4.95e-06	0.00257	0.3	0.29	Aortic root size;	chr7:66686466	chr7:65840212~65840596:+
SARC	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	4.68	4.95e-06	0.00257	0.32	0.29	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
SARC	cis	rs5769707	0.568	rs2011097	ENSG00000235111.1	RP1-29C18.8	-4.68	4.96e-06	0.00257	-0.36	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49612657~49615716:-
SARC	cis	rs2179367	0.959	rs536203	ENSG00000231760.4	RP11-350J20.5	4.68	4.96e-06	0.00257	0.36	0.29	Dupuytren's disease;	chr6:149330128	chr6:149796151~149826294:-
SARC	cis	rs193541	0.564	rs407230	ENSG00000263432.2	RN7SL689P	-4.68	4.96e-06	0.00257	-0.38	-0.29	Glucose homeostasis traits;	chr5:123010032	chr5:123022487~123022783:-
SARC	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	4.68	4.97e-06	0.00258	0.3	0.29	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
SARC	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	4.68	4.97e-06	0.00258	0.33	0.29	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
SARC	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	4.68	4.97e-06	0.00258	0.33	0.29	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	4.68	4.97e-06	0.00258	0.33	0.29	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	4.67	4.98e-06	0.00258	0.31	0.29	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
SARC	cis	rs12554020	0.892	rs12341488	ENSG00000227603.1	RP11-165J3.6	4.67	4.98e-06	0.00258	0.4	0.29	Schizophrenia;	chr9:93568889	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.786	rs7857183	ENSG00000227603.1	RP11-165J3.6	4.67	4.98e-06	0.00258	0.4	0.29	Schizophrenia;	chr9:93569762	chr9:93435332~93437121:-
SARC	cis	rs7512898	0.545	rs10800729	ENSG00000260088.1	RP11-92G12.3	-4.67	4.99e-06	0.00258	-0.3	-0.29	Electrocardiographic conduction measures;	chr1:200732620	chr1:200669507~200694250:+
SARC	cis	rs10911902	0.643	rs6678193	ENSG00000229739.2	RP11-295K2.3	-4.67	5e-06	0.00259	-0.43	-0.29	Schizophrenia;	chr1:186413607	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.602	rs79668124	ENSG00000229739.2	RP11-295K2.3	-4.67	5e-06	0.00259	-0.43	-0.29	Schizophrenia;	chr1:186415103	chr1:186435161~186470291:+
SARC	cis	rs4835473	0.932	rs35164917	ENSG00000251600.4	RP11-673E1.1	4.67	5e-06	0.00259	0.28	0.29	Immature fraction of reticulocytes;	chr4:143748891	chr4:143912331~143982454:+
SARC	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-4.67	5e-06	0.00259	-0.32	-0.29	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-4.67	5e-06	0.00259	-0.32	-0.29	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-4.67	5e-06	0.00259	-0.32	-0.29	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
SARC	cis	rs17270561	0.583	rs7749149	ENSG00000272462.2	U91328.19	-4.67	5e-06	0.00259	-0.27	-0.29	Iron status biomarkers;	chr6:25780911	chr6:25992662~26001775:+
SARC	cis	rs853679	1	rs2799079	ENSG00000219392.1	RP1-265C24.5	-4.67	5.01e-06	0.00259	-0.47	-0.29	Depression;	chr6:28267398	chr6:28115628~28116551:+
SARC	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	4.67	5.01e-06	0.00259	0.32	0.29	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
SARC	cis	rs2439831	0.85	rs12441861	ENSG00000275601.1	AC011330.13	-4.67	5.01e-06	0.00259	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43768685	chr15:43642389~43643023:-
SARC	cis	rs7772486	0.79	rs2247206	ENSG00000270638.1	RP3-466P17.1	4.67	5.02e-06	0.0026	0.24	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145895048	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.764	rs2247211	ENSG00000270638.1	RP3-466P17.1	4.67	5.02e-06	0.0026	0.24	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145895243	chr6:145735570~145737218:+
SARC	cis	rs526231	0.853	rs2561477	ENSG00000175749.11	EIF3KP1	4.67	5.02e-06	0.0026	0.39	0.29	Primary biliary cholangitis;	chr5:103273223	chr5:103032376~103033031:+
SARC	cis	rs11018904	0.906	rs17227345	ENSG00000280385.1	AP000648.5	4.67	5.02e-06	0.0026	0.32	0.29	Intelligence (multi-trait analysis);	chr11:90221517	chr11:90193614~90198120:+
SARC	cis	rs13161895	1	rs35592104	ENSG00000250999.1	RP11-1379J22.5	-4.67	5.04e-06	0.00261	-0.5	-0.29	LDL cholesterol;	chr5:180020661	chr5:179657762~179664432:+
SARC	cis	rs4664293	0.769	rs10171236	ENSG00000226266.5	AC009961.3	-4.67	5.05e-06	0.00261	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159729752	chr2:159670708~159712435:-
SARC	cis	rs2933343	0.729	rs813945	ENSG00000261159.1	RP11-723O4.9	4.67	5.05e-06	0.00261	0.32	0.29	IgG glycosylation;	chr3:128942094	chr3:128859716~128860526:-
SARC	cis	rs1707322	0.656	rs3014210	ENSG00000281133.1	AL355480.3	4.67	5.05e-06	0.00261	0.35	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45580892~45580996:-
SARC	cis	rs1865760	0.516	rs10807007	ENSG00000272462.2	U91328.19	-4.67	5.05e-06	0.00261	-0.26	-0.29	Height;	chr6:26048703	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.516	rs9379819	ENSG00000272462.2	U91328.19	-4.67	5.05e-06	0.00261	-0.26	-0.29	Height;	chr6:26049591	chr6:25992662~26001775:+
SARC	cis	rs7615952	0.688	rs12638224	ENSG00000241288.6	RP11-379B18.5	-4.67	5.06e-06	0.00261	-0.35	-0.29	Blood pressure (smoking interaction);	chr3:125822477	chr3:125827238~125916384:-
SARC	cis	rs858239	1	rs166663	ENSG00000226816.2	AC005082.12	4.67	5.06e-06	0.00262	0.36	0.29	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23206013~23208045:+
SARC	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	4.67	5.07e-06	0.00262	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
SARC	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	4.67	5.07e-06	0.00262	0.29	0.29	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
SARC	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	4.67	5.07e-06	0.00262	0.29	0.29	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
SARC	cis	rs12554020	0.686	rs77734990	ENSG00000227603.1	RP11-165J3.6	4.67	5.07e-06	0.00262	0.52	0.29	Schizophrenia;	chr9:93561870	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.686	rs56275034	ENSG00000227603.1	RP11-165J3.6	4.67	5.07e-06	0.00262	0.52	0.29	Schizophrenia;	chr9:93563474	chr9:93435332~93437121:-
SARC	cis	rs890448	0.796	rs10433982	ENSG00000254531.1	FLJ20021	4.67	5.08e-06	0.00262	0.31	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101362741	chr4:101347780~101348883:+
SARC	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	4.67	5.08e-06	0.00262	0.29	0.29	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
SARC	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	4.67	5.08e-06	0.00262	0.29	0.29	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
SARC	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	4.67	5.08e-06	0.00262	0.29	0.29	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
SARC	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	4.67	5.08e-06	0.00262	0.29	0.29	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
SARC	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	4.67	5.08e-06	0.00262	0.29	0.29	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
SARC	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-4.67	5.08e-06	0.00263	-0.35	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
SARC	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-4.67	5.08e-06	0.00263	-0.36	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
SARC	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	4.67	5.09e-06	0.00263	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
SARC	cis	rs2439831	0.867	rs2260160	ENSG00000205771.5	CATSPER2P1	-4.67	5.09e-06	0.00263	-0.45	-0.29	Lung cancer in ever smokers;	chr15:43603445	chr15:43726918~43747094:-
SARC	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-4.67	5.09e-06	0.00263	-0.27	-0.29	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
SARC	cis	rs2933343	0.729	rs789231	ENSG00000261159.1	RP11-723O4.9	4.67	5.1e-06	0.00263	0.32	0.29	IgG glycosylation;	chr3:128884004	chr3:128859716~128860526:-
SARC	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-4.67	5.1e-06	0.00263	-0.55	-0.29	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-4.67	5.1e-06	0.00263	-0.55	-0.29	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-4.67	5.1e-06	0.00263	-0.55	-0.29	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-4.67	5.1e-06	0.00263	-0.55	-0.29	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-4.67	5.1e-06	0.00263	-0.55	-0.29	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-4.67	5.1e-06	0.00263	-0.55	-0.29	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
SARC	cis	rs79349575	0.783	rs28409394	ENSG00000270781.1	RP11-501C14.9	-4.67	5.11e-06	0.00264	-0.34	-0.29	Type 2 diabetes;	chr17:48920756	chr17:48899131~48899748:+
SARC	cis	rs75920871	0.528	rs682048	ENSG00000254851.1	RP11-109L13.1	4.67	5.11e-06	0.00264	0.39	0.29	Subjective well-being;	chr11:116957604	chr11:117135528~117138582:+
SARC	cis	rs7181230	1	rs28620926	ENSG00000275636.1	RP11-521C20.5	4.67	5.11e-06	0.00264	0.35	0.29	Dehydroepiandrosterone sulphate levels;	chr15:40064970	chr15:40078892~40079347:+
SARC	cis	rs2439831	0.571	rs689883	ENSG00000205771.5	CATSPER2P1	-4.67	5.11e-06	0.00264	-0.45	-0.29	Lung cancer in ever smokers;	chr15:43520398	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-4.67	5.11e-06	0.00264	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
SARC	cis	rs2274273	0.624	rs8014540	ENSG00000258413.1	RP11-665C16.6	-4.67	5.12e-06	0.00264	-0.37	-0.29	Protein biomarker;	chr14:55374970	chr14:55262767~55272075:-
SARC	cis	rs17508449	0.819	rs41352847	ENSG00000232450.1	RP4-730K3.3	-4.67	5.13e-06	0.00265	-0.37	-0.29	Leprosy;	chr1:113647258	chr1:113698884~113699631:-
SARC	cis	rs17508449	0.819	rs2146018	ENSG00000232450.1	RP4-730K3.3	-4.67	5.13e-06	0.00265	-0.37	-0.29	Leprosy;	chr1:113652708	chr1:113698884~113699631:-
SARC	cis	rs890448	0.662	rs2850372	ENSG00000254531.1	FLJ20021	-4.67	5.13e-06	0.00265	-0.3	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101326034	chr4:101347780~101348883:+
SARC	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	4.67	5.13e-06	0.00265	0.37	0.29	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
SARC	cis	rs7772486	0.701	rs2244308	ENSG00000270638.1	RP3-466P17.1	4.67	5.13e-06	0.00265	0.24	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145892570	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs9497424	ENSG00000270638.1	RP3-466P17.1	-4.67	5.13e-06	0.00265	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145735570~145737218:+
SARC	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	4.67	5.13e-06	0.00265	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
SARC	cis	rs4654783	0.671	rs3765351	ENSG00000228397.1	RP1-224A6.3	4.67	5.14e-06	0.00265	0.32	0.29	Endometriosis;	chr1:22119498	chr1:22023994~22024968:-
SARC	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	4.67	5.14e-06	0.00265	0.33	0.29	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
SARC	cis	rs7216064	0.953	rs1599859	ENSG00000265055.1	AC145343.2	4.67	5.14e-06	0.00265	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841077	chr17:68096046~68101474:-
SARC	cis	rs1799949	0.965	rs8067269	ENSG00000267681.1	CTD-3199J23.6	-4.67	5.14e-06	0.00265	-0.32	-0.29	Menopause (age at onset);	chr17:43083782	chr17:43144956~43145255:+
SARC	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-4.67	5.15e-06	0.00265	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-4.67	5.15e-06	0.00265	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
SARC	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-4.67	5.15e-06	0.00265	-0.38	-0.29	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
SARC	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	4.67	5.15e-06	0.00266	0.34	0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
SARC	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-4.67	5.16e-06	0.00266	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
SARC	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	4.67	5.17e-06	0.00266	0.34	0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
SARC	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-4.67	5.17e-06	0.00267	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
SARC	cis	rs7267979	0.565	rs6107060	ENSG00000125804.12	FAM182A	-4.67	5.18e-06	0.00267	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:26054655~26086917:+
SARC	cis	rs1707322	0.686	rs61784833	ENSG00000281133.1	AL355480.3	-4.67	5.18e-06	0.00267	-0.34	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs7519900	ENSG00000281133.1	AL355480.3	-4.67	5.18e-06	0.00267	-0.34	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45580892~45580996:-
SARC	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	4.67	5.18e-06	0.00267	0.34	0.29	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
SARC	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	4.67	5.18e-06	0.00267	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
SARC	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-4.67	5.19e-06	0.00267	-0.3	-0.29	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
SARC	cis	rs3768716	0.5	rs777329	ENSG00000229267.2	AC072062.1	4.67	5.19e-06	0.00267	0.28	0.29	Neuroblastoma;	chr2:214877871	chr2:214810229~214963274:+
SARC	cis	rs1134634	0.52	rs10025837	ENSG00000273133.1	RP11-799M12.2	-4.67	5.19e-06	0.00268	-0.38	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15548362	chr4:15563698~15564253:-
SARC	cis	rs12893668	0.543	rs12147645	ENSG00000269940.1	RP11-73M18.7	4.67	5.19e-06	0.00268	0.29	0.29	Reticulocyte count;	chr14:103633871	chr14:103694560~103695170:+
SARC	cis	rs1823913	0.637	rs4853573	ENSG00000227542.1	AC092614.2	-4.67	5.2e-06	0.00268	-0.33	-0.29	Obesity-related traits;	chr2:191295866	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.614	rs4853466	ENSG00000227542.1	AC092614.2	-4.67	5.2e-06	0.00268	-0.33	-0.29	Obesity-related traits;	chr2:191295943	chr2:191229165~191246172:-
SARC	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	4.67	5.2e-06	0.00268	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	4.67	5.2e-06	0.00268	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	4.67	5.2e-06	0.00268	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	4.67	5.2e-06	0.00268	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	4.67	5.2e-06	0.00268	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	4.67	5.2e-06	0.00268	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	4.67	5.2e-06	0.00268	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	4.67	5.2e-06	0.00268	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	4.67	5.2e-06	0.00268	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	4.67	5.2e-06	0.00268	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	4.67	5.2e-06	0.00268	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	4.67	5.2e-06	0.00268	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
SARC	cis	rs7301826	0.504	rs11061164	ENSG00000256299.1	RP11-989F5.3	-4.67	5.2e-06	0.00268	-0.29	-0.29	Plasma plasminogen activator levels;	chr12:130839724	chr12:130810821~130812622:-
SARC	cis	rs9595908	0.865	rs743760	ENSG00000212293.1	SNORA16	-4.67	5.2e-06	0.00268	-0.33	-0.29	Body mass index;	chr13:32496990	chr13:32420390~32420516:-
SARC	cis	rs2117029	1	rs11168839	ENSG00000258017.1	RP11-386G11.10	4.67	5.2e-06	0.00268	0.34	0.29	Intelligence (multi-trait analysis);	chr12:49063852	chr12:49127782~49147869:+
SARC	cis	rs6991838	0.778	rs11782837	ENSG00000272010.1	CTD-3025N20.3	4.66	5.2e-06	0.00268	0.32	0.29	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65591850~65592472:-
SARC	cis	rs2933343	0.621	rs728838	ENSG00000231305.3	RP11-723O4.2	4.66	5.21e-06	0.00268	0.29	0.29	IgG glycosylation;	chr3:128870170	chr3:128861313~128871540:-
SARC	cis	rs2179367	0.959	rs564961	ENSG00000231760.4	RP11-350J20.5	4.66	5.21e-06	0.00268	0.36	0.29	Dupuytren's disease;	chr6:149336091	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.959	rs504985	ENSG00000231760.4	RP11-350J20.5	4.66	5.21e-06	0.00268	0.36	0.29	Dupuytren's disease;	chr6:149337842	chr6:149796151~149826294:-
SARC	cis	rs8059260	0.604	rs12102345	ENSG00000274038.1	RP11-66H6.4	-4.66	5.21e-06	0.00268	-0.42	-0.29	Alcohol consumption over the past year;	chr16:11053863	chr16:11056556~11057034:+
SARC	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-4.66	5.21e-06	0.00268	-0.29	-0.29	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
SARC	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-4.66	5.22e-06	0.00269	-0.3	-0.29	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
SARC	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	4.66	5.22e-06	0.00269	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
SARC	cis	rs7772486	0.754	rs6906258	ENSG00000270638.1	RP3-466P17.1	-4.66	5.23e-06	0.00269	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs6915718	ENSG00000270638.1	RP3-466P17.1	-4.66	5.23e-06	0.00269	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145735570~145737218:+
SARC	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	4.66	5.23e-06	0.00269	0.35	0.29	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
SARC	cis	rs7712401	0.601	rs246303	ENSG00000263432.2	RN7SL689P	4.66	5.23e-06	0.00269	0.36	0.29	Mean platelet volume;	chr5:122916022	chr5:123022487~123022783:-
SARC	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	4.66	5.24e-06	0.00269	0.32	0.29	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
SARC	cis	rs910316	1	rs3742778	ENSG00000279594.1	RP11-950C14.10	-4.66	5.24e-06	0.0027	-0.31	-0.29	Height;	chr14:75071514	chr14:75011269~75012851:-
SARC	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	4.66	5.25e-06	0.0027	0.27	0.29	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	4.66	5.25e-06	0.0027	0.27	0.29	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
SARC	cis	rs4919687	0.55	rs10437480	ENSG00000213061.2	PFN1P11	4.66	5.26e-06	0.0027	0.37	0.29	Colorectal cancer;	chr10:102693267	chr10:102838011~102845473:-
SARC	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-4.66	5.26e-06	0.00271	-0.28	-0.29	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
SARC	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-4.66	5.26e-06	0.00271	-0.28	-0.29	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
SARC	cis	rs4919687	0.55	rs4264100	ENSG00000213061.2	PFN1P11	4.66	5.27e-06	0.00271	0.37	0.29	Colorectal cancer;	chr10:102694356	chr10:102838011~102845473:-
SARC	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-4.66	5.27e-06	0.00271	-0.3	-0.29	Height;	chr3:52971094	chr3:53064283~53065091:-
SARC	cis	rs448720	0.595	rs8032153	ENSG00000259410.4	RP11-34F13.3	4.66	5.28e-06	0.00271	0.35	0.29	Cognitive performance;	chr15:67902697	chr15:67832725~67873866:+
SARC	cis	rs2933343	0.951	rs789218	ENSG00000261159.1	RP11-723O4.9	4.66	5.28e-06	0.00271	0.34	0.29	IgG glycosylation;	chr3:128873827	chr3:128859716~128860526:-
SARC	cis	rs1930961	0.702	rs8141065	ENSG00000100058.11	CRYBB2P1	-4.66	5.28e-06	0.00272	-0.59	-0.29	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25448105~25520854:+
SARC	cis	rs910316	0.839	rs35977276	ENSG00000279594.1	RP11-950C14.10	-4.66	5.29e-06	0.00272	-0.33	-0.29	Height;	chr14:75170656	chr14:75011269~75012851:-
SARC	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-4.66	5.29e-06	0.00272	-0.31	-0.29	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
SARC	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-4.66	5.29e-06	0.00272	-0.36	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
SARC	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-4.66	5.29e-06	0.00272	-0.3	-0.29	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
SARC	cis	rs7216064	1	rs7209675	ENSG00000265055.1	AC145343.2	4.66	5.29e-06	0.00272	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67835142	chr17:68096046~68101474:-
SARC	cis	rs7567389	0.677	rs72845997	ENSG00000236682.1	AC068282.3	-4.66	5.29e-06	0.00272	-0.34	-0.29	Self-rated health;	chr2:127352506	chr2:127389130~127400580:+
SARC	cis	rs7615952	0.599	rs7652883	ENSG00000250012.1	RP11-124N2.1	-4.66	5.29e-06	0.00272	-0.28	-0.29	Blood pressure (smoking interaction);	chr3:125989134	chr3:126084220~126095349:+
SARC	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-4.66	5.3e-06	0.00272	-0.32	-0.29	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
SARC	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-4.66	5.3e-06	0.00272	-0.26	-0.29	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
SARC	cis	rs792448	0.501	rs2307128	ENSG00000229983.1	RP11-15I11.2	4.66	5.3e-06	0.00272	0.31	0.29	White blood cell count (basophil);	chr1:212226474	chr1:212168207~212190259:+
SARC	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-4.66	5.3e-06	0.00272	-0.28	-0.29	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
SARC	cis	rs1075232	0.579	rs58156651	ENSG00000215302.7	CTD-3092A11.1	-4.66	5.3e-06	0.00272	-0.6	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31456864	chr15:30470779~30507623:+
SARC	cis	rs4938330	0.723	rs7931398	ENSG00000254851.1	RP11-109L13.1	4.66	5.3e-06	0.00272	0.37	0.29	Blood protein levels;	chr11:117008960	chr11:117135528~117138582:+
SARC	cis	rs2404602	0.622	rs11632365	ENSG00000259422.1	RP11-593F23.1	-4.66	5.31e-06	0.00273	-0.39	-0.29	Blood metabolite levels;	chr15:76846739	chr15:76174891~76181486:-
SARC	cis	rs17270561	0.583	rs6926425	ENSG00000272462.2	U91328.19	-4.66	5.32e-06	0.00273	-0.27	-0.29	Iron status biomarkers;	chr6:25785076	chr6:25992662~26001775:+
SARC	cis	rs7615952	0.8	rs12489350	ENSG00000241288.6	RP11-379B18.5	-4.66	5.32e-06	0.00273	-0.38	-0.29	Blood pressure (smoking interaction);	chr3:125925273	chr3:125827238~125916384:-
SARC	cis	rs1823913	0.637	rs4853465	ENSG00000227542.1	AC092614.2	-4.66	5.33e-06	0.00274	-0.32	-0.29	Obesity-related traits;	chr2:191294768	chr2:191229165~191246172:-
SARC	cis	rs10754283	0.967	rs7523046	ENSG00000231613.1	RP5-943J3.1	4.66	5.33e-06	0.00274	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89643940	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs7523518	ENSG00000231613.1	RP5-943J3.1	4.66	5.33e-06	0.00274	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89644451	chr1:89788914~89790492:+
SARC	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-4.66	5.33e-06	0.00274	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-4.66	5.33e-06	0.00274	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-4.66	5.33e-06	0.00274	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-4.66	5.33e-06	0.00274	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
SARC	cis	rs8062405	0.723	rs12445744	ENSG00000251417.2	RP11-1348G14.4	-4.66	5.34e-06	0.00274	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.755	rs4787455	ENSG00000251417.2	RP11-1348G14.4	-4.66	5.34e-06	0.00274	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28802743~28817828:+
SARC	cis	rs7976269	0.559	rs10843313	ENSG00000257176.2	RP11-996F15.2	-4.66	5.34e-06	0.00274	-0.33	-0.29	Male-pattern baldness;	chr12:29078317	chr12:29280418~29317848:-
SARC	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	4.66	5.35e-06	0.00274	0.34	0.29	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
SARC	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-4.66	5.35e-06	0.00274	-0.3	-0.29	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
SARC	cis	rs17508449	0.819	rs4839332	ENSG00000232450.1	RP4-730K3.3	-4.66	5.35e-06	0.00275	-0.38	-0.29	Leprosy;	chr1:113619569	chr1:113698884~113699631:-
SARC	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-4.66	5.35e-06	0.00275	-0.33	-0.29	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-4.66	5.36e-06	0.00275	-0.33	-0.29	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
SARC	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-4.66	5.36e-06	0.00275	-0.3	-0.29	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
SARC	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-4.66	5.36e-06	0.00275	-0.34	-0.29	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
SARC	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-4.66	5.37e-06	0.00275	-0.34	-0.29	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
SARC	cis	rs193541	0.632	rs1903260	ENSG00000263432.2	RN7SL689P	4.66	5.37e-06	0.00275	0.37	0.29	Glucose homeostasis traits;	chr5:122799493	chr5:123022487~123022783:-
SARC	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	4.66	5.38e-06	0.00276	0.34	0.29	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
SARC	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	4.66	5.38e-06	0.00276	0.34	0.29	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	4.66	5.38e-06	0.00276	0.34	0.29	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
SARC	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	4.66	5.38e-06	0.00276	0.35	0.29	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
SARC	cis	rs11018904	0.817	rs11606060	ENSG00000280385.1	AP000648.5	-4.66	5.38e-06	0.00276	-0.34	-0.29	Intelligence (multi-trait analysis);	chr11:90195429	chr11:90193614~90198120:+
SARC	cis	rs11018904	0.906	rs11603498	ENSG00000280385.1	AP000648.5	-4.66	5.38e-06	0.00276	-0.34	-0.29	Intelligence (multi-trait analysis);	chr11:90195615	chr11:90193614~90198120:+
SARC	cis	rs8062405	0.69	rs62034351	ENSG00000251417.2	RP11-1348G14.4	-4.66	5.38e-06	0.00276	-0.3	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28802743~28817828:+
SARC	cis	rs853679	0.517	rs1340004	ENSG00000272009.1	RP1-313I6.12	-4.66	5.39e-06	0.00276	-0.35	-0.29	Depression;	chr6:28135913	chr6:28078792~28081130:-
SARC	cis	rs6570726	0.791	rs12208019	ENSG00000270638.1	RP3-466P17.1	4.66	5.39e-06	0.00276	0.24	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs11155435	ENSG00000270638.1	RP3-466P17.1	4.66	5.39e-06	0.00276	0.24	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145735570~145737218:+
SARC	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-4.66	5.39e-06	0.00276	-0.28	-0.29	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
SARC	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-4.66	5.39e-06	0.00276	-0.28	-0.29	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
SARC	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-4.66	5.4e-06	0.00277	-0.39	-0.29	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
SARC	cis	rs524281	0.861	rs7941469	ENSG00000255320.1	RP11-755F10.1	-4.66	5.4e-06	0.00277	-0.4	-0.29	Electroencephalogram traits;	chr11:66132681	chr11:66244840~66246239:-
SARC	cis	rs8062405	0.69	rs4787458	ENSG00000251417.2	RP11-1348G14.4	-4.66	5.4e-06	0.00277	-0.3	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28802743~28817828:+
SARC	cis	rs2439831	1	rs2245908	ENSG00000275601.1	AC011330.13	-4.66	5.4e-06	0.00277	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43439256	chr15:43642389~43643023:-
SARC	cis	rs62432291	0.681	rs423533	ENSG00000235086.1	FNDC1-IT1	-4.66	5.41e-06	0.00277	-0.47	-0.29	Joint mobility (Beighton score);	chr6:159243484	chr6:159240786~159243329:+
SARC	cis	rs890448	0.796	rs293217	ENSG00000254531.1	FLJ20021	4.66	5.41e-06	0.00277	0.3	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101391036	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs293216	ENSG00000254531.1	FLJ20021	4.66	5.41e-06	0.00277	0.3	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101391116	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs833949	ENSG00000254531.1	FLJ20021	4.66	5.41e-06	0.00277	0.3	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101391363	chr4:101347780~101348883:+
SARC	cis	rs42490	0.837	rs218916	ENSG00000251136.7	RP11-37B2.1	-4.66	5.41e-06	0.00277	-0.33	-0.29	Leprosy;	chr8:89688709	chr8:89609409~89757727:-
SARC	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-4.66	5.41e-06	0.00277	-0.33	-0.29	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
SARC	cis	rs6991838	0.778	rs11782837	ENSG00000200714.1	Y_RNA	4.66	5.42e-06	0.00278	0.31	0.29	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65592731~65592820:+
SARC	cis	rs7615952	0.688	rs9754526	ENSG00000241288.6	RP11-379B18.5	-4.66	5.42e-06	0.00278	-0.34	-0.29	Blood pressure (smoking interaction);	chr3:125824023	chr3:125827238~125916384:-
SARC	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-4.66	5.43e-06	0.00278	-0.51	-0.29	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
SARC	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	4.66	5.43e-06	0.00278	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
SARC	cis	rs2274273	0.624	rs78205412	ENSG00000258413.1	RP11-665C16.6	-4.66	5.43e-06	0.00278	-0.37	-0.29	Protein biomarker;	chr14:55314532	chr14:55262767~55272075:-
SARC	cis	rs7712401	0.601	rs36180885	ENSG00000263432.2	RN7SL689P	-4.66	5.43e-06	0.00278	-0.37	-0.29	Mean platelet volume;	chr5:123020708	chr5:123022487~123022783:-
SARC	cis	rs7567389	0.504	rs5937	ENSG00000236682.1	AC068282.3	-4.66	5.44e-06	0.00278	-0.34	-0.29	Self-rated health;	chr2:127427194	chr2:127389130~127400580:+
SARC	cis	rs7615952	0.8	rs2062773	ENSG00000241288.6	RP11-379B18.5	-4.66	5.44e-06	0.00278	-0.37	-0.29	Blood pressure (smoking interaction);	chr3:125920805	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.799	rs13315434	ENSG00000241288.6	RP11-379B18.5	-4.66	5.44e-06	0.00278	-0.37	-0.29	Blood pressure (smoking interaction);	chr3:125922551	chr3:125827238~125916384:-
SARC	cis	rs853679	0.723	rs1736904	ENSG00000216901.1	AL022393.7	4.66	5.44e-06	0.00278	0.4	0.29	Depression;	chr6:28251492	chr6:28176188~28176674:+
SARC	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-4.65	5.44e-06	0.00278	-0.27	-0.29	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
SARC	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	4.65	5.45e-06	0.00279	0.23	0.29	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
SARC	cis	rs801193	0.904	rs4718405	ENSG00000236529.1	RP13-254B10.1	4.65	5.46e-06	0.00279	0.3	0.29	Aortic root size;	chr7:66789659	chr7:65840212~65840596:+
SARC	cis	rs2439831	0.867	rs3809481	ENSG00000205771.5	CATSPER2P1	-4.65	5.47e-06	0.0028	-0.45	-0.29	Lung cancer in ever smokers;	chr15:43370631	chr15:43726918~43747094:-
SARC	cis	rs67180937	0.778	rs3002126	ENSG00000272750.1	RP11-378J18.8	-4.65	5.47e-06	0.0028	-0.43	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222676939	chr1:222658867~222661512:-
SARC	cis	rs7809950	0.678	rs2107317	ENSG00000238832.1	snoU109	-4.65	5.48e-06	0.0028	-0.34	-0.29	Coronary artery disease;	chr7:107259240	chr7:107603363~107603507:+
SARC	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	4.65	5.49e-06	0.00281	0.27	0.29	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
SARC	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-4.65	5.49e-06	0.00281	-0.32	-0.29	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-4.65	5.49e-06	0.00281	-0.32	-0.29	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
SARC	cis	rs2933343	0.679	rs789221	ENSG00000231305.3	RP11-723O4.2	4.65	5.49e-06	0.00281	0.29	0.29	IgG glycosylation;	chr3:128872782	chr3:128861313~128871540:-
SARC	cis	rs14027	0.921	rs13261032	ENSG00000279347.1	RP11-85I17.2	-4.65	5.5e-06	0.00281	-0.26	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733117	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs2048239	ENSG00000279347.1	RP11-85I17.2	-4.65	5.5e-06	0.00281	-0.26	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119735701	chr8:119838736~119840385:-
SARC	cis	rs10754283	0.967	rs7546518	ENSG00000231613.1	RP5-943J3.1	4.65	5.5e-06	0.00281	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89644397	chr1:89788914~89790492:+
SARC	cis	rs7216064	0.953	rs4791048	ENSG00000265055.1	AC145343.2	4.65	5.51e-06	0.00281	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67852878	chr17:68096046~68101474:-
SARC	cis	rs11719291	0.831	rs11715177	ENSG00000225399.4	RP11-3B7.1	-4.65	5.51e-06	0.00282	-0.51	-0.29	Cognitive function;	chr3:48726461	chr3:49260085~49261316:+
SARC	cis	rs853679	0.882	rs9468287	ENSG00000272009.1	RP1-313I6.12	-4.65	5.52e-06	0.00282	-0.43	-0.29	Depression;	chr6:28111963	chr6:28078792~28081130:-
SARC	cis	rs17270561	0.636	rs1185977	ENSG00000272810.1	U91328.22	-4.65	5.52e-06	0.00282	-0.27	-0.29	Iron status biomarkers;	chr6:25828826	chr6:26013241~26013757:+
SARC	cis	rs7512898	0.5	rs7516036	ENSG00000260088.1	RP11-92G12.3	-4.65	5.52e-06	0.00282	-0.33	-0.29	Electrocardiographic conduction measures;	chr1:200727825	chr1:200669507~200694250:+
SARC	cis	rs2239557	0.961	rs8003212	ENSG00000259065.1	RP5-1021I20.1	4.65	5.53e-06	0.00282	0.35	0.29	Common traits (Other);	chr14:74158260	chr14:73787360~73803270:+
SARC	cis	rs2274273	0.624	rs3783651	ENSG00000258413.1	RP11-665C16.6	-4.65	5.53e-06	0.00282	-0.37	-0.29	Protein biomarker;	chr14:55384255	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs7151581	ENSG00000258413.1	RP11-665C16.6	4.65	5.53e-06	0.00282	0.37	0.29	Protein biomarker;	chr14:55321727	chr14:55262767~55272075:-
SARC	cis	rs2836950	0.772	rs62222988	ENSG00000255568.3	BRWD1-AS2	-4.65	5.53e-06	0.00283	-0.27	-0.29	Menarche (age at onset);	chr21:39197582	chr21:39313935~39314962:+
SARC	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-4.65	5.53e-06	0.00283	-0.33	-0.29	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
SARC	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-4.65	5.54e-06	0.00283	-0.34	-0.29	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
SARC	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-4.65	5.55e-06	0.00283	-0.43	-0.29	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
SARC	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-4.65	5.55e-06	0.00284	-0.35	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
SARC	cis	rs2933343	0.951	rs1055128	ENSG00000261159.1	RP11-723O4.9	4.65	5.56e-06	0.00284	0.34	0.29	IgG glycosylation;	chr3:128872205	chr3:128859716~128860526:-
SARC	cis	rs7712401	0.541	rs6867714	ENSG00000263432.2	RN7SL689P	4.65	5.57e-06	0.00284	0.37	0.29	Mean platelet volume;	chr5:123046364	chr5:123022487~123022783:-
SARC	cis	rs14027	0.921	rs10505374	ENSG00000279347.1	RP11-85I17.2	-4.65	5.58e-06	0.00285	-0.26	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119832350	chr8:119838736~119840385:-
SARC	cis	rs853679	0.517	rs12174753	ENSG00000272009.1	RP1-313I6.12	-4.65	5.58e-06	0.00285	-0.33	-0.29	Depression;	chr6:28074687	chr6:28078792~28081130:-
SARC	cis	rs193541	0.632	rs2910135	ENSG00000263432.2	RN7SL689P	4.65	5.58e-06	0.00285	0.37	0.29	Glucose homeostasis traits;	chr5:122894095	chr5:123022487~123022783:-
SARC	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-4.65	5.58e-06	0.00285	-0.32	-0.29	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-4.65	5.58e-06	0.00285	-0.32	-0.29	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-4.65	5.58e-06	0.00285	-0.32	-0.29	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
SARC	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-4.65	5.58e-06	0.00285	-0.3	-0.29	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-4.65	5.58e-06	0.00285	-0.3	-0.29	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-4.65	5.58e-06	0.00285	-0.3	-0.29	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
SARC	cis	rs4950322	0.57	rs4950315	ENSG00000278811.3	LINC00624	-4.65	5.58e-06	0.00285	-0.3	-0.29	Protein quantitative trait loci;	chr1:147264433	chr1:147258885~147517875:-
SARC	cis	rs12554020	0.792	rs11975	ENSG00000227603.1	RP11-165J3.6	4.65	5.59e-06	0.00285	0.4	0.29	Schizophrenia;	chr9:93565409	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.892	rs7870210	ENSG00000227603.1	RP11-165J3.6	4.65	5.59e-06	0.00285	0.4	0.29	Schizophrenia;	chr9:93569534	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.892	rs7860098	ENSG00000227603.1	RP11-165J3.6	4.65	5.59e-06	0.00285	0.4	0.29	Schizophrenia;	chr9:93569562	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.786	rs60076242	ENSG00000227603.1	RP11-165J3.6	4.65	5.59e-06	0.00285	0.4	0.29	Schizophrenia;	chr9:93571634	chr9:93435332~93437121:-
SARC	cis	rs7267979	1	rs2027003	ENSG00000276952.1	RP5-965G21.6	-4.65	5.6e-06	0.00285	-0.29	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2027004	ENSG00000276952.1	RP5-965G21.6	-4.65	5.6e-06	0.00285	-0.29	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.934	rs2500399	ENSG00000276952.1	RP5-965G21.6	-4.65	5.6e-06	0.00285	-0.29	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2500404	ENSG00000276952.1	RP5-965G21.6	-4.65	5.6e-06	0.00285	-0.29	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2500405	ENSG00000276952.1	RP5-965G21.6	-4.65	5.6e-06	0.00285	-0.29	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2482941	ENSG00000276952.1	RP5-965G21.6	-4.65	5.6e-06	0.00285	-0.29	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25284915~25285588:-
SARC	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	4.65	5.6e-06	0.00286	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	4.65	5.6e-06	0.00286	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	4.65	5.6e-06	0.00286	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
SARC	cis	rs8031584	1	rs11634216	ENSG00000260382.1	RP11-540B6.2	4.65	5.61e-06	0.00286	0.38	0.29	Huntington's disease progression;	chr15:30996467	chr15:30882267~30883231:-
SARC	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-4.65	5.62e-06	0.00286	-0.43	-0.29	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
SARC	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	4.65	5.62e-06	0.00286	0.29	0.29	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
SARC	cis	rs763121	0.853	rs138716	ENSG00000273076.1	RP3-508I15.22	4.65	5.62e-06	0.00286	0.32	0.29	Menopause (age at onset);	chr22:38750522	chr22:38743495~38743910:+
SARC	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	4.65	5.62e-06	0.00287	0.3	0.29	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
SARC	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-4.65	5.62e-06	0.00287	-0.27	-0.29	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
SARC	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-4.65	5.63e-06	0.00287	-0.34	-0.29	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-4.65	5.63e-06	0.00287	-0.34	-0.29	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
SARC	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	4.65	5.63e-06	0.00287	0.55	0.29	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	4.65	5.63e-06	0.00287	0.55	0.29	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	4.65	5.63e-06	0.00287	0.55	0.29	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	4.65	5.63e-06	0.00287	0.55	0.29	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
SARC	cis	rs910316	0.763	rs175044	ENSG00000279594.1	RP11-950C14.10	-4.65	5.64e-06	0.00287	-0.34	-0.29	Height;	chr14:75005406	chr14:75011269~75012851:-
SARC	cis	rs8081395	0.741	rs180520	ENSG00000266992.1	DHX40P1	4.65	5.64e-06	0.00287	0.32	0.29	White blood cell count;	chr17:59937788	chr17:59976009~60002384:-
SARC	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-4.65	5.65e-06	0.00288	-0.36	-0.29	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
SARC	cis	rs7430456	0.638	rs13071694	ENSG00000225790.1	RP11-2L8.1	4.65	5.65e-06	0.00288	0.31	0.29	Breast cancer;	chr3:177775198	chr3:177934823~177937662:+
SARC	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-4.65	5.65e-06	0.00288	-0.33	-0.29	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
SARC	cis	rs7918232	0.574	rs10458708	ENSG00000262412.1	RP11-85G18.6	4.65	5.65e-06	0.00288	0.29	0.29	Breast cancer;	chr10:27166676	chr10:27243130~27250804:+
SARC	cis	rs17270561	0.609	rs7746502	ENSG00000272810.1	U91328.22	4.65	5.65e-06	0.00288	0.28	0.29	Iron status biomarkers;	chr6:25718534	chr6:26013241~26013757:+
SARC	cis	rs763121	0.962	rs2071887	ENSG00000273076.1	RP3-508I15.22	4.65	5.66e-06	0.00288	0.31	0.29	Menopause (age at onset);	chr22:38483005	chr22:38743495~38743910:+
SARC	cis	rs2179367	0.552	rs11155652	ENSG00000231760.4	RP11-350J20.5	4.65	5.67e-06	0.00289	0.39	0.29	Dupuytren's disease;	chr6:149417849	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs12209364	ENSG00000231760.4	RP11-350J20.5	4.65	5.67e-06	0.00289	0.39	0.29	Dupuytren's disease;	chr6:149418062	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498348	ENSG00000231760.4	RP11-350J20.5	4.65	5.67e-06	0.00289	0.39	0.29	Dupuytren's disease;	chr6:149418352	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9322179	ENSG00000231760.4	RP11-350J20.5	4.65	5.67e-06	0.00289	0.39	0.29	Dupuytren's disease;	chr6:149418664	chr6:149796151~149826294:-
SARC	cis	rs910316	0.763	rs175016	ENSG00000279594.1	RP11-950C14.10	-4.65	5.67e-06	0.00289	-0.32	-0.29	Height;	chr14:74992930	chr14:75011269~75012851:-
SARC	cis	rs2439831	0.557	rs13329084	ENSG00000275601.1	AC011330.13	4.65	5.67e-06	0.00289	0.5	0.29	Lung cancer in ever smokers;	chr15:43858865	chr15:43642389~43643023:-
SARC	cis	rs2933343	0.649	rs728839	ENSG00000231305.3	RP11-723O4.2	4.65	5.68e-06	0.00289	0.29	0.29	IgG glycosylation;	chr3:128870516	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.649	rs789219	ENSG00000231305.3	RP11-723O4.2	4.65	5.68e-06	0.00289	0.29	0.29	IgG glycosylation;	chr3:128873677	chr3:128861313~128871540:-
SARC	cis	rs198389	0.589	rs198399	ENSG00000242349.4	NPPA-AS1	-4.65	5.68e-06	0.00289	-0.3	-0.29	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11823572	chr1:11841017~11848079:+
SARC	cis	rs7976269	0.583	rs2117997	ENSG00000257176.2	RP11-996F15.2	4.65	5.68e-06	0.00289	0.33	0.29	Male-pattern baldness;	chr12:29143428	chr12:29280418~29317848:-
SARC	cis	rs13161895	1	rs4235504	ENSG00000250999.1	RP11-1379J22.5	-4.65	5.68e-06	0.00289	-0.51	-0.29	LDL cholesterol;	chr5:180026680	chr5:179657762~179664432:+
SARC	cis	rs728478	1	rs728478	ENSG00000266992.1	DHX40P1	4.65	5.68e-06	0.00289	0.31	0.29	QT interval;	chr17:59389143	chr17:59976009~60002384:-
SARC	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-4.64	5.69e-06	0.00289	-0.35	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
SARC	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-4.64	5.7e-06	0.0029	-0.38	-0.29	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-4.64	5.7e-06	0.0029	-0.38	-0.29	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
SARC	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-4.64	5.7e-06	0.0029	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
SARC	cis	rs17174870	1	rs7568632	ENSG00000228251.1	AC012442.6	4.64	5.7e-06	0.0029	0.37	0.29	Multiple sclerosis;	chr2:111912373	chr2:112590796~112591939:+
SARC	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-4.64	5.72e-06	0.00291	-0.35	-0.29	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
SARC	cis	rs801193	0.66	rs2659914	ENSG00000232559.3	GS1-124K5.12	4.64	5.72e-06	0.00291	0.33	0.29	Aortic root size;	chr7:66691927	chr7:66554588~66576923:-
SARC	cis	rs30380	0.632	rs27045	ENSG00000272109.1	CTD-2260A17.3	-4.64	5.73e-06	0.00291	-0.37	-0.29	Cerebrospinal fluid biomarker levels;	chr5:96803158	chr5:96804353~96806105:+
SARC	cis	rs5769707	0.967	rs2051626	ENSG00000235111.1	RP1-29C18.8	-4.64	5.73e-06	0.00291	-0.32	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49612657~49615716:-
SARC	cis	rs5769707	0.967	rs1018812	ENSG00000235111.1	RP1-29C18.8	-4.64	5.73e-06	0.00291	-0.32	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49612657~49615716:-
SARC	cis	rs193541	0.632	rs7729834	ENSG00000263432.2	RN7SL689P	4.64	5.73e-06	0.00291	0.37	0.29	Glucose homeostasis traits;	chr5:122786464	chr5:123022487~123022783:-
SARC	cis	rs193541	0.632	rs10037044	ENSG00000263432.2	RN7SL689P	-4.64	5.73e-06	0.00291	-0.37	-0.29	Glucose homeostasis traits;	chr5:122787604	chr5:123022487~123022783:-
SARC	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-4.64	5.73e-06	0.00291	-0.36	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
SARC	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-4.64	5.73e-06	0.00291	-0.35	-0.29	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
SARC	cis	rs9902453	0.765	rs2874505	ENSG00000264538.5	SUZ12P1	4.64	5.74e-06	0.00291	0.2	0.29	Coffee consumption (cups per day);	chr17:29710905	chr17:30709299~30790908:+
SARC	cis	rs2439831	0.85	rs3097773	ENSG00000205771.5	CATSPER2P1	4.64	5.74e-06	0.00291	0.42	0.29	Lung cancer in ever smokers;	chr15:43600874	chr15:43726918~43747094:-
SARC	cis	rs4664293	0.967	rs1006192	ENSG00000226266.5	AC009961.3	-4.64	5.75e-06	0.00292	-0.35	-0.29	Monocyte percentage of white cells;	chr2:159711078	chr2:159670708~159712435:-
SARC	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	4.64	5.75e-06	0.00292	0.31	0.29	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
SARC	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	4.64	5.75e-06	0.00292	0.33	0.29	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
SARC	cis	rs12893668	0.663	rs12889731	ENSG00000269940.1	RP11-73M18.7	4.64	5.75e-06	0.00292	0.29	0.29	Reticulocyte count;	chr14:103621145	chr14:103694560~103695170:+
SARC	cis	rs7712401	0.511	rs30068	ENSG00000263432.2	RN7SL689P	4.64	5.75e-06	0.00292	0.35	0.29	Mean platelet volume;	chr5:122957914	chr5:123022487~123022783:-
SARC	cis	rs8062405	0.756	rs151182	ENSG00000251417.2	RP11-1348G14.4	-4.64	5.75e-06	0.00292	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28802743~28817828:+
SARC	cis	rs4664293	0.967	rs2357526	ENSG00000226266.5	AC009961.3	4.64	5.76e-06	0.00292	0.35	0.29	Monocyte percentage of white cells;	chr2:159668085	chr2:159670708~159712435:-
SARC	cis	rs875971	0.54	rs35510581	ENSG00000236529.1	RP13-254B10.1	-4.64	5.76e-06	0.00292	-0.31	-0.29	Aortic root size;	chr7:66113790	chr7:65840212~65840596:+
SARC	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	4.64	5.76e-06	0.00292	0.36	0.29	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
SARC	cis	rs1707322	0.717	rs2275086	ENSG00000281133.1	AL355480.3	4.64	5.76e-06	0.00292	0.34	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45580892~45580996:-
SARC	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-4.64	5.77e-06	0.00293	-0.28	-0.29	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
SARC	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-4.64	5.78e-06	0.00293	-0.25	-0.29	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
SARC	cis	rs7726354	0.546	rs77982563	ENSG00000271828.1	CTD-2310F14.1	4.64	5.78e-06	0.00293	0.58	0.29	Breast cancer (early onset);	chr5:56897840	chr5:56927874~56929573:+
SARC	cis	rs4372836	0.504	rs13009357	ENSG00000226833.4	AC097724.3	4.64	5.79e-06	0.00294	0.24	0.29	Body mass index;	chr2:28819011	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.504	rs62131973	ENSG00000226833.4	AC097724.3	4.64	5.79e-06	0.00294	0.24	0.29	Body mass index;	chr2:28821571	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.504	rs12714249	ENSG00000226833.4	AC097724.3	4.64	5.79e-06	0.00294	0.24	0.29	Body mass index;	chr2:28833050	chr2:28708953~28736205:-
SARC	cis	rs7615952	0.512	rs34085484	ENSG00000241288.6	RP11-379B18.5	-4.64	5.8e-06	0.00294	-0.34	-0.29	Blood pressure (smoking interaction);	chr3:125825343	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.575	rs35949599	ENSG00000241288.6	RP11-379B18.5	-4.64	5.8e-06	0.00294	-0.34	-0.29	Blood pressure (smoking interaction);	chr3:125825359	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.608	rs35668111	ENSG00000241288.6	RP11-379B18.5	-4.64	5.8e-06	0.00294	-0.34	-0.29	Blood pressure (smoking interaction);	chr3:125825792	chr3:125827238~125916384:-
SARC	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-4.64	5.8e-06	0.00294	-0.3	-0.29	Height;	chr3:53007328	chr3:53064283~53065091:-
SARC	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-4.64	5.8e-06	0.00294	-0.3	-0.29	Height;	chr3:53009621	chr3:53064283~53065091:-
SARC	cis	rs10911902	0.643	rs7525634	ENSG00000229739.2	RP11-295K2.3	-4.64	5.81e-06	0.00294	-0.43	-0.29	Schizophrenia;	chr1:186411333	chr1:186435161~186470291:+
SARC	cis	rs801193	1	rs7785213	ENSG00000236529.1	RP13-254B10.1	-4.64	5.81e-06	0.00294	-0.3	-0.29	Aortic root size;	chr7:66673991	chr7:65840212~65840596:+
SARC	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	4.64	5.81e-06	0.00294	0.37	0.29	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
SARC	cis	rs526231	0.819	rs2569018	ENSG00000175749.11	EIF3KP1	4.64	5.81e-06	0.00294	0.39	0.29	Primary biliary cholangitis;	chr5:103262042	chr5:103032376~103033031:+
SARC	cis	rs526231	0.747	rs434830	ENSG00000175749.11	EIF3KP1	4.64	5.81e-06	0.00294	0.39	0.29	Primary biliary cholangitis;	chr5:103263605	chr5:103032376~103033031:+
SARC	cis	rs593531	0.513	rs7930193	ENSG00000280269.1	AP000577.2	4.64	5.82e-06	0.00295	0.37	0.29	Neuroticism;	chr11:74320512	chr11:74204869~74205746:+
SARC	cis	rs7615952	0.8	rs11915699	ENSG00000241288.6	RP11-379B18.5	-4.64	5.83e-06	0.00295	-0.37	-0.29	Blood pressure (smoking interaction);	chr3:125913841	chr3:125827238~125916384:-
SARC	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-4.64	5.83e-06	0.00295	-0.3	-0.29	Height;	chr3:52967831	chr3:53064283~53065091:-
SARC	cis	rs240993	0.81	rs466765	ENSG00000230177.1	RP5-1112D6.4	-4.64	5.83e-06	0.00295	-0.34	-0.29	Inflammatory skin disease;Psoriasis;	chr6:111347291	chr6:111277932~111278742:+
SARC	cis	rs2439831	0.681	rs524527	ENSG00000205771.5	CATSPER2P1	4.64	5.83e-06	0.00295	0.42	0.29	Lung cancer in ever smokers;	chr15:43306918	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-4.64	5.83e-06	0.00295	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
SARC	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-4.64	5.85e-06	0.00296	-0.32	-0.29	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
SARC	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-4.64	5.85e-06	0.00296	-0.28	-0.29	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
SARC	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	4.64	5.85e-06	0.00296	0.44	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
SARC	cis	rs240993	0.715	rs6920798	ENSG00000230177.1	RP5-1112D6.4	4.64	5.85e-06	0.00296	0.33	0.29	Inflammatory skin disease;Psoriasis;	chr6:111526074	chr6:111277932~111278742:+
SARC	cis	rs964184	0.63	rs2160669	ENSG00000254851.1	RP11-109L13.1	-4.64	5.85e-06	0.00296	-0.56	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116776891	chr11:117135528~117138582:+
SARC	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-4.64	5.85e-06	0.00296	-0.55	-0.29	Gout;	chr7:66732812	chr7:66654538~66669855:+
SARC	cis	rs4372836	0.675	rs72782280	ENSG00000226833.4	AC097724.3	-4.64	5.86e-06	0.00296	-0.3	-0.29	Body mass index;	chr2:28688483	chr2:28708953~28736205:-
SARC	cis	rs42490	0.8	rs56291556	ENSG00000251136.7	RP11-37B2.1	4.64	5.86e-06	0.00296	0.32	0.29	Leprosy;	chr8:89662546	chr8:89609409~89757727:-
SARC	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-4.64	5.87e-06	0.00297	-0.28	-0.29	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
SARC	cis	rs1799949	0.93	rs8176194	ENSG00000267681.1	CTD-3199J23.6	-4.64	5.88e-06	0.00297	-0.34	-0.29	Menopause (age at onset);	chr17:43079204	chr17:43144956~43145255:+
SARC	cis	rs9309473	0.632	rs11885217	ENSG00000163016.8	ALMS1P	4.64	5.88e-06	0.00297	0.38	0.29	Metabolite levels;	chr2:73326080	chr2:73644919~73685576:+
SARC	cis	rs7267979	1	rs2482919	ENSG00000276952.1	RP5-965G21.6	-4.64	5.9e-06	0.00298	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6037086	ENSG00000276952.1	RP5-965G21.6	-4.64	5.9e-06	0.00298	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25284915~25285588:-
SARC	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-4.64	5.9e-06	0.00298	-0.29	-0.29	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
SARC	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	4.64	5.9e-06	0.00298	0.33	0.29	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
SARC	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-4.64	5.91e-06	0.00299	-0.27	-0.29	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
SARC	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-4.64	5.91e-06	0.00299	-0.5	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
SARC	cis	rs801193	1	rs2707845	ENSG00000236529.1	RP13-254B10.1	4.64	5.92e-06	0.00299	0.3	0.29	Aortic root size;	chr7:66733811	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs2707850	ENSG00000236529.1	RP13-254B10.1	4.64	5.92e-06	0.00299	0.3	0.29	Aortic root size;	chr7:66738883	chr7:65840212~65840596:+
SARC	cis	rs801193	0.967	rs1110414	ENSG00000236529.1	RP13-254B10.1	4.64	5.92e-06	0.00299	0.3	0.29	Aortic root size;	chr7:66740595	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs7783924	ENSG00000236529.1	RP13-254B10.1	4.64	5.92e-06	0.00299	0.3	0.29	Aortic root size;	chr7:66744070	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs7789184	ENSG00000236529.1	RP13-254B10.1	4.64	5.92e-06	0.00299	0.3	0.29	Aortic root size;	chr7:66745208	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs2707854	ENSG00000236529.1	RP13-254B10.1	4.64	5.92e-06	0.00299	0.3	0.29	Aortic root size;	chr7:66747610	chr7:65840212~65840596:+
SARC	cis	rs12893668	0.637	rs12892038	ENSG00000269940.1	RP11-73M18.7	4.64	5.93e-06	0.00299	0.29	0.29	Reticulocyte count;	chr14:103602292	chr14:103694560~103695170:+
SARC	cis	rs12893668	0.637	rs4525427	ENSG00000269940.1	RP11-73M18.7	4.64	5.93e-06	0.00299	0.29	0.29	Reticulocyte count;	chr14:103606456	chr14:103694560~103695170:+
SARC	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-4.64	5.93e-06	0.00299	-0.38	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
SARC	cis	rs62432291	0.681	rs436277	ENSG00000235086.1	FNDC1-IT1	4.64	5.93e-06	0.00299	0.48	0.29	Joint mobility (Beighton score);	chr6:159213110	chr6:159240786~159243329:+
SARC	cis	rs4835473	0.932	rs1839448	ENSG00000251600.4	RP11-673E1.1	4.64	5.93e-06	0.003	0.28	0.29	Immature fraction of reticulocytes;	chr4:143752113	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs10021860	ENSG00000251600.4	RP11-673E1.1	4.64	5.93e-06	0.003	0.28	0.29	Immature fraction of reticulocytes;	chr4:143754593	chr4:143912331~143982454:+
SARC	cis	rs853679	0.517	rs9468298	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28154567	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9295759	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28156691	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9348796	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28158424	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs11552219	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28159056	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9393895	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28159843	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9393896	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28159925	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9393897	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28159932	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9357065	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28161802	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9357066	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28162053	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9393898	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28162598	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9368556	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28163375	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9368557	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28163759	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9380059	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28164580	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9380060	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28164825	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs35227624	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28164948	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9380061	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28165025	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9368558	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28165528	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.587	rs9393899	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Parkinson's disease;	chr6:28165750	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs4713150	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28168434	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.527	rs4713151	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Parkinson's disease;	chr6:28168578	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9393901	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28169019	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs3173443	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28169249	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs4713152	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28169676	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9348797	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28169755	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9380062	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28169791	chr6:28078792~28081130:-
SARC	cis	rs853679	0.542	rs9380063	ENSG00000272009.1	RP1-313I6.12	-4.64	5.94e-06	0.003	-0.33	-0.29	Depression;	chr6:28170075	chr6:28078792~28081130:-
SARC	cis	rs7255436	0.931	rs7249520	ENSG00000269386.4	RAB11B-AS1	4.63	5.95e-06	0.003	0.29	0.29	HDL cholesterol;	chr19:8381172	chr19:8374373~8390685:-
SARC	cis	rs7255436	0.965	rs7249624	ENSG00000269386.4	RAB11B-AS1	4.63	5.95e-06	0.003	0.29	0.29	HDL cholesterol;	chr19:8381251	chr19:8374373~8390685:-
SARC	cis	rs7255436	0.83	rs4350678	ENSG00000269386.4	RAB11B-AS1	4.63	5.95e-06	0.003	0.29	0.29	HDL cholesterol;	chr19:8382482	chr19:8374373~8390685:-
SARC	cis	rs12200782	0.858	rs72836448	ENSG00000272810.1	U91328.22	-4.63	5.96e-06	0.00301	-0.5	-0.29	Small cell lung carcinoma;	chr6:26342842	chr6:26013241~26013757:+
SARC	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-4.63	5.97e-06	0.00301	-0.34	-0.29	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-4.63	5.97e-06	0.00301	-0.34	-0.29	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
SARC	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-4.63	5.97e-06	0.00301	-0.37	-0.29	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
SARC	cis	rs763121	0.888	rs2235229	ENSG00000273076.1	RP3-508I15.22	4.63	5.97e-06	0.00301	0.3	0.29	Menopause (age at onset);	chr22:38728907	chr22:38743495~38743910:+
SARC	cis	rs14027	0.883	rs13255850	ENSG00000279347.1	RP11-85I17.2	-4.63	5.97e-06	0.00301	-0.25	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119705923	chr8:119838736~119840385:-
SARC	cis	rs7267979	0.714	rs6132825	ENSG00000276952.1	RP5-965G21.6	4.63	5.98e-06	0.00301	0.27	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25257673	chr20:25284915~25285588:-
SARC	cis	rs9828933	0.882	rs3733127	ENSG00000280620.1	SCAANT1	4.63	5.98e-06	0.00301	0.47	0.29	Type 2 diabetes;	chr3:64002498	chr3:63911518~63911772:-
SARC	cis	rs6907340	0.513	rs6938418	ENSG00000228412.5	RP4-625H18.2	-4.63	5.98e-06	0.00301	-0.33	-0.29	Endometriosis;	chr6:19808802	chr6:19802164~19804752:-
SARC	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-4.63	5.98e-06	0.00302	-0.37	-0.29	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
SARC	cis	rs910316	1	rs4903281	ENSG00000279594.1	RP11-950C14.10	4.63	5.99e-06	0.00302	0.32	0.29	Height;	chr14:75087658	chr14:75011269~75012851:-
SARC	cis	rs526231	0.783	rs28158	ENSG00000175749.11	EIF3KP1	4.63	5.99e-06	0.00302	0.39	0.29	Primary biliary cholangitis;	chr5:103260191	chr5:103032376~103033031:+
SARC	cis	rs526231	0.819	rs26232	ENSG00000175749.11	EIF3KP1	4.63	5.99e-06	0.00302	0.39	0.29	Primary biliary cholangitis;	chr5:103261019	chr5:103032376~103033031:+
SARC	cis	rs526231	0.819	rs26234	ENSG00000175749.11	EIF3KP1	4.63	5.99e-06	0.00302	0.39	0.29	Primary biliary cholangitis;	chr5:103261455	chr5:103032376~103033031:+
SARC	cis	rs526231	0.747	rs39984	ENSG00000175749.11	EIF3KP1	4.63	5.99e-06	0.00302	0.39	0.29	Primary biliary cholangitis;	chr5:103261591	chr5:103032376~103033031:+
SARC	cis	rs526231	0.819	rs2561482	ENSG00000175749.11	EIF3KP1	4.63	5.99e-06	0.00302	0.39	0.29	Primary biliary cholangitis;	chr5:103262097	chr5:103032376~103033031:+
SARC	cis	rs526231	0.747	rs375637	ENSG00000175749.11	EIF3KP1	4.63	5.99e-06	0.00302	0.39	0.29	Primary biliary cholangitis;	chr5:103263877	chr5:103032376~103033031:+
SARC	cis	rs526231	0.747	rs434294	ENSG00000175749.11	EIF3KP1	4.63	5.99e-06	0.00302	0.39	0.29	Primary biliary cholangitis;	chr5:103263925	chr5:103032376~103033031:+
SARC	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	4.63	5.99e-06	0.00302	0.33	0.29	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
SARC	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	4.63	6e-06	0.00302	0.34	0.29	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
SARC	cis	rs9309473	0.718	rs6546829	ENSG00000163016.8	ALMS1P	4.63	6.01e-06	0.00303	0.35	0.29	Metabolite levels;	chr2:73386661	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.5	rs2421668	ENSG00000163016.8	ALMS1P	-4.63	6.01e-06	0.00303	-0.33	-0.29	Metabolite levels;	chr2:73657969	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.519	rs2421670	ENSG00000163016.8	ALMS1P	-4.63	6.01e-06	0.00303	-0.33	-0.29	Metabolite levels;	chr2:73659534	chr2:73644919~73685576:+
SARC	cis	rs7809950	0.637	rs3801964	ENSG00000238832.1	snoU109	-4.63	6.01e-06	0.00303	-0.38	-0.29	Coronary artery disease;	chr7:107195797	chr7:107603363~107603507:+
SARC	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-4.63	6.01e-06	0.00303	-0.28	-0.29	Height;	chr3:52994045	chr3:53064283~53065091:-
SARC	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-4.63	6.01e-06	0.00303	-0.28	-0.29	Height;	chr3:52994990	chr3:53064283~53065091:-
SARC	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-4.63	6.01e-06	0.00303	-0.26	-0.29	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
SARC	cis	rs1799949	1	rs4793236	ENSG00000267681.1	CTD-3199J23.6	-4.63	6.02e-06	0.00303	-0.33	-0.29	Menopause (age at onset);	chr17:43359072	chr17:43144956~43145255:+
SARC	cis	rs6751744	0.513	rs10173538	ENSG00000226266.5	AC009961.3	-4.63	6.02e-06	0.00303	-0.35	-0.29	Dysphagia;	chr2:159712765	chr2:159670708~159712435:-
SARC	cis	rs240993	0.715	rs7742724	ENSG00000230177.1	RP5-1112D6.4	4.63	6.02e-06	0.00303	0.33	0.29	Inflammatory skin disease;Psoriasis;	chr6:111517816	chr6:111277932~111278742:+
SARC	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	4.63	6.03e-06	0.00303	0.45	0.29	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
SARC	cis	rs11264213	0.901	rs581459	ENSG00000271554.1	RP4-665N4.8	-4.63	6.03e-06	0.00304	-0.39	-0.29	Schizophrenia;	chr1:35909509	chr1:35992109~36013630:-
SARC	cis	rs526231	0.819	rs2288787	ENSG00000175749.11	EIF3KP1	4.63	6.04e-06	0.00304	0.38	0.29	Primary biliary cholangitis;	chr5:103265005	chr5:103032376~103033031:+
SARC	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-4.63	6.04e-06	0.00304	-0.35	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
SARC	cis	rs17270561	0.636	rs1575535	ENSG00000272810.1	U91328.22	-4.63	6.04e-06	0.00304	-0.28	-0.29	Iron status biomarkers;	chr6:25809681	chr6:26013241~26013757:+
SARC	cis	rs1134634	0.52	rs2160044	ENSG00000273133.1	RP11-799M12.2	-4.63	6.05e-06	0.00304	-0.37	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15556720	chr4:15563698~15564253:-
SARC	cis	rs910316	0.737	rs175071	ENSG00000279594.1	RP11-950C14.10	-4.63	6.06e-06	0.00305	-0.32	-0.29	Height;	chr14:75031474	chr14:75011269~75012851:-
SARC	cis	rs910316	0.967	rs11159116	ENSG00000279594.1	RP11-950C14.10	4.63	6.07e-06	0.00305	0.31	0.29	Height;	chr14:75083881	chr14:75011269~75012851:-
SARC	cis	rs42490	0.868	rs4961158	ENSG00000251136.7	RP11-37B2.1	4.63	6.08e-06	0.00306	0.32	0.29	Leprosy;	chr8:89685607	chr8:89609409~89757727:-
SARC	cis	rs11634944	0.716	rs1030389	ENSG00000274307.1	RP11-345J18.2	4.63	6.08e-06	0.00306	0.36	0.29	Interleukin-8 levels;	chr15:25032641	chr15:25708470~25710869:-
SARC	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	4.63	6.08e-06	0.00306	0.3	0.29	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	4.63	6.08e-06	0.00306	0.3	0.29	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	4.63	6.08e-06	0.00306	0.3	0.29	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
SARC	cis	rs3813579	0.606	rs3813583	ENSG00000261390.4	RP11-345M22.2	-4.63	6.09e-06	0.00306	-0.3	-0.29	Thyroid volume;	chr16:79721183	chr16:79715232~79770563:-
SARC	cis	rs7809950	0.678	rs62483640	ENSG00000238832.1	snoU109	-4.63	6.09e-06	0.00306	-0.35	-0.29	Coronary artery disease;	chr7:107259769	chr7:107603363~107603507:+
SARC	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-4.63	6.09e-06	0.00306	-0.3	-0.29	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
SARC	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	4.63	6.1e-06	0.00307	0.29	0.29	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
SARC	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-4.63	6.11e-06	0.00307	-0.33	-0.29	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-4.63	6.11e-06	0.00307	-0.33	-0.29	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
SARC	cis	rs2280018	1	rs2280018	ENSG00000260735.1	RP11-72I8.1	-4.63	6.11e-06	0.00307	-0.24	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15094411~15109197:+
SARC	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-4.63	6.12e-06	0.00308	-0.33	-0.29	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
SARC	cis	rs2412819	0.571	rs12443084	ENSG00000205771.5	CATSPER2P1	4.63	6.12e-06	0.00308	0.41	0.29	Lung cancer;	chr15:43748767	chr15:43726918~43747094:-
SARC	cis	rs2412819	0.571	rs10163069	ENSG00000205771.5	CATSPER2P1	4.63	6.12e-06	0.00308	0.41	0.29	Lung cancer;	chr15:43755372	chr15:43726918~43747094:-
SARC	cis	rs2929278	0.617	rs3986209	ENSG00000205771.5	CATSPER2P1	4.63	6.12e-06	0.00308	0.41	0.29	Schizophrenia;	chr15:43758675	chr15:43726918~43747094:-
SARC	cis	rs7976269	0.559	rs10771473	ENSG00000257176.2	RP11-996F15.2	-4.63	6.12e-06	0.00308	-0.31	-0.29	Male-pattern baldness;	chr12:29068729	chr12:29280418~29317848:-
SARC	cis	rs8062405	0.723	rs4788079	ENSG00000251417.2	RP11-1348G14.4	-4.63	6.12e-06	0.00308	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28802743~28817828:+
SARC	cis	rs3824347	0.967	rs10869462	ENSG00000203321.2	C9orf41-AS1	-4.63	6.13e-06	0.00308	-0.32	-0.29	Urinary magnesium-to-creatinine ratio;	chr9:74960777	chr9:74952968~74996293:+
SARC	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-4.63	6.13e-06	0.00308	-0.37	-0.29	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
SARC	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-4.63	6.14e-06	0.00308	-0.31	-0.29	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
SARC	cis	rs8062405	0.755	rs4788080	ENSG00000251417.2	RP11-1348G14.4	-4.63	6.14e-06	0.00308	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.755	rs4787456	ENSG00000251417.2	RP11-1348G14.4	-4.63	6.14e-06	0.00308	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.755	rs4788078	ENSG00000251417.2	RP11-1348G14.4	-4.63	6.14e-06	0.00308	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28802743~28817828:+
SARC	cis	rs1134634	0.52	rs13121363	ENSG00000273133.1	RP11-799M12.2	4.63	6.14e-06	0.00308	0.38	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567369	chr4:15563698~15564253:-
SARC	cis	rs1134634	0.52	rs13116304	ENSG00000273133.1	RP11-799M12.2	4.63	6.14e-06	0.00308	0.38	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567523	chr4:15563698~15564253:-
SARC	cis	rs2933343	0.729	rs1683780	ENSG00000261159.1	RP11-723O4.9	4.63	6.14e-06	0.00309	0.32	0.29	IgG glycosylation;	chr3:128921396	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.859	rs789247	ENSG00000261159.1	RP11-723O4.9	4.63	6.15e-06	0.00309	0.34	0.29	IgG glycosylation;	chr3:128861742	chr3:128859716~128860526:-
SARC	cis	rs2933343	0.903	rs2638846	ENSG00000261159.1	RP11-723O4.9	4.63	6.15e-06	0.00309	0.34	0.29	IgG glycosylation;	chr3:128868320	chr3:128859716~128860526:-
SARC	cis	rs75422866	0.867	rs73111258	ENSG00000257433.4	RP1-197B17.3	4.63	6.15e-06	0.00309	0.57	0.29	Pneumonia;	chr12:47597313	chr12:47706085~47742294:+
SARC	cis	rs597539	0.652	rs501799	ENSG00000250508.1	RP11-757G1.6	-4.63	6.15e-06	0.00309	-0.34	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:68870664~68874542:+
SARC	cis	rs2933343	1	rs6785869	ENSG00000261159.1	RP11-723O4.9	4.63	6.16e-06	0.00309	0.34	0.29	IgG glycosylation;	chr3:128924301	chr3:128859716~128860526:-
SARC	cis	rs2933343	1	rs1680784	ENSG00000261159.1	RP11-723O4.9	4.63	6.16e-06	0.00309	0.34	0.29	IgG glycosylation;	chr3:128925615	chr3:128859716~128860526:-
SARC	cis	rs2933343	1	rs1683778	ENSG00000261159.1	RP11-723O4.9	4.63	6.16e-06	0.00309	0.34	0.29	IgG glycosylation;	chr3:128925752	chr3:128859716~128860526:-
SARC	cis	rs2292342	0.85	rs2301139	ENSG00000232871.7	SEC1P	-4.63	6.16e-06	0.00309	-0.65	-0.29	Elevated serum carcinoembryonic antigen levels;	chr19:48630504	chr19:48638071~48682245:+
SARC	cis	rs763121	1	rs86796	ENSG00000273076.1	RP3-508I15.22	-4.63	6.16e-06	0.00309	-0.3	-0.29	Menopause (age at onset);	chr22:38485449	chr22:38743495~38743910:+
SARC	cis	rs193541	0.53	rs2125857	ENSG00000263432.2	RN7SL689P	4.63	6.16e-06	0.00309	0.36	0.29	Glucose homeostasis traits;	chr5:122747461	chr5:123022487~123022783:-
SARC	cis	rs193541	0.53	rs6595405	ENSG00000263432.2	RN7SL689P	4.63	6.16e-06	0.00309	0.36	0.29	Glucose homeostasis traits;	chr5:122749050	chr5:123022487~123022783:-
SARC	cis	rs8062405	0.789	rs1968752	ENSG00000251417.2	RP11-1348G14.4	-4.63	6.17e-06	0.0031	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.721	rs151303	ENSG00000251417.2	RP11-1348G14.4	-4.63	6.18e-06	0.0031	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28802743~28817828:+
SARC	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-4.63	6.18e-06	0.0031	-0.3	-0.29	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
SARC	cis	rs2439831	1	rs2467743	ENSG00000205771.5	CATSPER2P1	-4.63	6.19e-06	0.00311	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43458148	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs2245176	ENSG00000205771.5	CATSPER2P1	-4.63	6.19e-06	0.00311	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43458564	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs2245054	ENSG00000205771.5	CATSPER2P1	-4.63	6.19e-06	0.00311	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43459711	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs2264876	ENSG00000205771.5	CATSPER2P1	-4.63	6.19e-06	0.00311	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43465221	chr15:43726918~43747094:-
SARC	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	4.63	6.2e-06	0.00311	0.39	0.29	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
SARC	cis	rs890448	0.93	rs2433312	ENSG00000254531.1	FLJ20021	-4.63	6.2e-06	0.00311	-0.29	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101464975	chr4:101347780~101348883:+
SARC	cis	rs7772486	0.719	rs2206141	ENSG00000270638.1	RP3-466P17.1	-4.63	6.21e-06	0.00312	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs6570718	ENSG00000270638.1	RP3-466P17.1	-4.63	6.21e-06	0.00312	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.654	rs6906402	ENSG00000270638.1	RP3-466P17.1	-4.63	6.21e-06	0.00312	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145735570~145737218:+
SARC	cis	rs7246657	0.943	rs35540940	ENSG00000276846.1	CTD-3220F14.3	4.62	6.21e-06	0.00312	0.39	0.29	Coronary artery calcification;	chr19:37517333	chr19:37314868~37315620:-
SARC	cis	rs7178375	1	rs9806159	ENSG00000215302.7	CTD-3092A11.1	-4.62	6.22e-06	0.00312	-0.36	-0.29	Hypertriglyceridemia;	chr15:30917451	chr15:30470779~30507623:+
SARC	cis	rs11018904	0.906	rs12793836	ENSG00000280385.1	AP000648.5	-4.62	6.22e-06	0.00312	-0.34	-0.29	Intelligence (multi-trait analysis);	chr11:90220325	chr11:90193614~90198120:+
SARC	cis	rs14027	0.883	rs10102038	ENSG00000279347.1	RP11-85I17.2	-4.62	6.23e-06	0.00312	-0.25	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119702544	chr8:119838736~119840385:-
SARC	cis	rs14027	0.883	rs35660840	ENSG00000279347.1	RP11-85I17.2	-4.62	6.23e-06	0.00312	-0.25	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704351	chr8:119838736~119840385:-
SARC	cis	rs14027	0.883	rs1433953	ENSG00000279347.1	RP11-85I17.2	-4.62	6.23e-06	0.00312	-0.25	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704754	chr8:119838736~119840385:-
SARC	cis	rs12049351	0.719	rs12129135	ENSG00000229367.1	HMGN2P19	4.62	6.24e-06	0.00313	0.24	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229559940	chr1:229570532~229570796:+
SARC	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-4.62	6.25e-06	0.00313	-0.3	-0.29	Height;	chr3:53015087	chr3:53064283~53065091:-
SARC	cis	rs2274273	0.624	rs67386901	ENSG00000258413.1	RP11-665C16.6	-4.62	6.25e-06	0.00313	-0.36	-0.29	Protein biomarker;	chr14:55290646	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs7140628	ENSG00000258413.1	RP11-665C16.6	-4.62	6.25e-06	0.00313	-0.36	-0.29	Protein biomarker;	chr14:55293963	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs68138420	ENSG00000258413.1	RP11-665C16.6	-4.62	6.25e-06	0.00313	-0.36	-0.29	Protein biomarker;	chr14:55311249	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs4580079	ENSG00000258413.1	RP11-665C16.6	-4.62	6.25e-06	0.00313	-0.36	-0.29	Protein biomarker;	chr14:55313648	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs7157308	ENSG00000258413.1	RP11-665C16.6	-4.62	6.25e-06	0.00313	-0.36	-0.29	Protein biomarker;	chr14:55315325	chr14:55262767~55272075:-
SARC	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-4.62	6.25e-06	0.00313	-0.29	-0.29	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
SARC	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-4.62	6.25e-06	0.00313	-0.29	-0.29	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
SARC	cis	rs763121	0.853	rs2076028	ENSG00000273076.1	RP3-508I15.22	4.62	6.26e-06	0.00314	0.32	0.29	Menopause (age at onset);	chr22:38754445	chr22:38743495~38743910:+
SARC	cis	rs12022452	1	rs12022452	ENSG00000238287.1	RP11-656D10.3	-4.62	6.27e-06	0.00314	-0.5	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40493157~40508661:-
SARC	cis	rs7181230	1	rs11638521	ENSG00000275636.1	RP11-521C20.5	-4.62	6.27e-06	0.00314	-0.34	-0.29	Dehydroepiandrosterone sulphate levels;	chr15:40068113	chr15:40078892~40079347:+
SARC	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-4.62	6.28e-06	0.00314	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
SARC	cis	rs801193	1	rs2659906	ENSG00000236529.1	RP13-254B10.1	4.62	6.28e-06	0.00314	0.3	0.29	Aortic root size;	chr7:66700323	chr7:65840212~65840596:+
SARC	cis	rs801193	0.935	rs2659899	ENSG00000236529.1	RP13-254B10.1	4.62	6.28e-06	0.00314	0.3	0.29	Aortic root size;	chr7:66721734	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs62466793	ENSG00000236529.1	RP13-254B10.1	4.62	6.28e-06	0.00314	0.3	0.29	Aortic root size;	chr7:66726530	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs62466794	ENSG00000236529.1	RP13-254B10.1	4.62	6.28e-06	0.00314	0.3	0.29	Aortic root size;	chr7:66726592	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs1553609	ENSG00000236529.1	RP13-254B10.1	4.62	6.28e-06	0.00314	0.3	0.29	Aortic root size;	chr7:66732152	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs1553610	ENSG00000236529.1	RP13-254B10.1	4.62	6.28e-06	0.00314	0.3	0.29	Aortic root size;	chr7:66732246	chr7:65840212~65840596:+
SARC	cis	rs8062405	0.755	rs62034350	ENSG00000251417.2	RP11-1348G14.4	-4.62	6.28e-06	0.00315	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28802743~28817828:+
SARC	cis	rs62432291	0.681	rs445957	ENSG00000235086.1	FNDC1-IT1	-4.62	6.28e-06	0.00315	-0.46	-0.29	Joint mobility (Beighton score);	chr6:159241032	chr6:159240786~159243329:+
SARC	cis	rs4835473	0.932	rs1877235	ENSG00000251600.4	RP11-673E1.1	-4.62	6.29e-06	0.00315	-0.28	-0.29	Immature fraction of reticulocytes;	chr4:143986961	chr4:143912331~143982454:+
SARC	cis	rs792448	0.527	rs11119887	ENSG00000229983.1	RP11-15I11.2	4.62	6.29e-06	0.00315	0.3	0.29	White blood cell count (basophil);	chr1:212234220	chr1:212168207~212190259:+
SARC	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	4.62	6.29e-06	0.00315	0.27	0.29	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	4.62	6.29e-06	0.00315	0.27	0.29	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
SARC	cis	rs7976269	0.537	rs10843303	ENSG00000257176.2	RP11-996F15.2	-4.62	6.29e-06	0.00315	-0.31	-0.29	Male-pattern baldness;	chr12:29069435	chr12:29280418~29317848:-
SARC	cis	rs2933343	1	rs1680795	ENSG00000261159.1	RP11-723O4.9	4.62	6.29e-06	0.00315	0.34	0.29	IgG glycosylation;	chr3:128901545	chr3:128859716~128860526:-
SARC	cis	rs2933343	1	rs1683776	ENSG00000261159.1	RP11-723O4.9	4.62	6.29e-06	0.00315	0.34	0.29	IgG glycosylation;	chr3:128903917	chr3:128859716~128860526:-
SARC	cis	rs2933343	1	rs2630252	ENSG00000261159.1	RP11-723O4.9	4.62	6.29e-06	0.00315	0.34	0.29	IgG glycosylation;	chr3:128905929	chr3:128859716~128860526:-
SARC	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-4.62	6.29e-06	0.00315	-0.32	-0.29	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
SARC	cis	rs8031584	1	rs890159	ENSG00000260382.1	RP11-540B6.2	4.62	6.3e-06	0.00315	0.39	0.29	Huntington's disease progression;	chr15:30999431	chr15:30882267~30883231:-
SARC	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-4.62	6.3e-06	0.00315	-0.34	-0.29	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-4.62	6.3e-06	0.00315	-0.34	-0.29	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-4.62	6.3e-06	0.00315	-0.34	-0.29	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
SARC	cis	rs10754283	0.901	rs10047070	ENSG00000231613.1	RP5-943J3.1	4.62	6.31e-06	0.00316	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89633156	chr1:89788914~89790492:+
SARC	cis	rs853679	1	rs11965538	ENSG00000219392.1	RP1-265C24.5	-4.62	6.31e-06	0.00316	-0.5	-0.29	Depression;	chr6:28272137	chr6:28115628~28116551:+
SARC	cis	rs853679	0.882	rs2743555	ENSG00000219392.1	RP1-265C24.5	-4.62	6.31e-06	0.00316	-0.5	-0.29	Depression;	chr6:28273304	chr6:28115628~28116551:+
SARC	cis	rs853679	1	rs1419183	ENSG00000219392.1	RP1-265C24.5	-4.62	6.31e-06	0.00316	-0.5	-0.29	Depression;	chr6:28275017	chr6:28115628~28116551:+
SARC	cis	rs801193	0.967	rs2707849	ENSG00000236529.1	RP13-254B10.1	4.62	6.32e-06	0.00316	0.3	0.29	Aortic root size;	chr7:66687725	chr7:65840212~65840596:+
SARC	cis	rs801193	0.967	rs2707841	ENSG00000236529.1	RP13-254B10.1	4.62	6.32e-06	0.00316	0.3	0.29	Aortic root size;	chr7:66692033	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs2659912	ENSG00000236529.1	RP13-254B10.1	4.62	6.32e-06	0.00316	0.3	0.29	Aortic root size;	chr7:66693012	chr7:65840212~65840596:+
SARC	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-4.62	6.32e-06	0.00316	-0.55	-0.29	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
SARC	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	4.62	6.32e-06	0.00316	0.27	0.29	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
SARC	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-4.62	6.33e-06	0.00316	-0.33	-0.29	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
SARC	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	4.62	6.33e-06	0.00316	0.3	0.29	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
SARC	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	4.62	6.33e-06	0.00316	0.42	0.29	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
SARC	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-4.62	6.34e-06	0.00317	-0.28	-0.29	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
SARC	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-4.62	6.34e-06	0.00317	-0.28	-0.29	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
SARC	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-4.62	6.34e-06	0.00317	-0.28	-0.29	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
SARC	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-4.62	6.34e-06	0.00317	-0.28	-0.29	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
SARC	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-4.62	6.34e-06	0.00317	-0.28	-0.29	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
SARC	cis	rs1865760	0.566	rs9358902	ENSG00000272462.2	U91328.19	-4.62	6.34e-06	0.00317	-0.27	-0.29	Height;	chr6:26058342	chr6:25992662~26001775:+
SARC	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	4.62	6.34e-06	0.00317	0.3	0.29	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
SARC	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-4.62	6.34e-06	0.00317	-0.27	-0.29	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-4.62	6.34e-06	0.00317	-0.27	-0.29	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
SARC	cis	rs755249	0.509	rs11206378	ENSG00000182109.6	RP11-69E11.4	-4.62	6.34e-06	0.00317	-0.28	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39522280~39546187:-
SARC	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-4.62	6.35e-06	0.00317	-0.3	-0.29	Height;	chr3:53070344	chr3:53064283~53065091:-
SARC	cis	rs6991838	0.778	rs11779601	ENSG00000272010.1	CTD-3025N20.3	4.62	6.35e-06	0.00317	0.32	0.29	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65591850~65592472:-
SARC	cis	rs2439831	1	rs471229	ENSG00000205771.5	CATSPER2P1	-4.62	6.35e-06	0.00317	-0.45	-0.29	Lung cancer in ever smokers;	chr15:43441796	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs2439841	ENSG00000205771.5	CATSPER2P1	-4.62	6.35e-06	0.00317	-0.45	-0.29	Lung cancer in ever smokers;	chr15:43442551	chr15:43726918~43747094:-
SARC	cis	rs79349575	0.783	rs4399576	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48932473	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.687	rs12602179	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48932672	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs17708633	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48934258	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs9747646	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48939520	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs62075852	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48939814	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs12601858	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48940115	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.715	rs55724082	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48940517	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.749	rs8182364	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48940663	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.681	rs56080003	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48941687	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs4793995	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48942037	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs4793996	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48942235	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.715	rs4793997	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48942310	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs4793998	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48942537	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.749	rs2270574	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48944908	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs4794000	ENSG00000270781.1	RP11-501C14.9	-4.62	6.35e-06	0.00317	-0.34	-0.29	Type 2 diabetes;	chr17:48945393	chr17:48899131~48899748:+
SARC	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	4.62	6.35e-06	0.00317	0.31	0.29	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
SARC	cis	rs2439831	0.681	rs498837	ENSG00000275601.1	AC011330.13	-4.62	6.35e-06	0.00317	-0.42	-0.29	Lung cancer in ever smokers;	chr15:43315826	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.681	rs540031	ENSG00000275601.1	AC011330.13	-4.62	6.35e-06	0.00317	-0.42	-0.29	Lung cancer in ever smokers;	chr15:43316657	chr15:43642389~43643023:-
SARC	cis	rs9309473	0.5	rs6546862	ENSG00000163016.8	ALMS1P	-4.62	6.36e-06	0.00318	-0.33	-0.29	Metabolite levels;	chr2:73633221	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.519	rs12618600	ENSG00000163016.8	ALMS1P	-4.62	6.36e-06	0.00318	-0.33	-0.29	Metabolite levels;	chr2:73663555	chr2:73644919~73685576:+
SARC	cis	rs75920871	0.528	rs12279066	ENSG00000254851.1	RP11-109L13.1	4.62	6.36e-06	0.00318	0.39	0.29	Subjective well-being;	chr11:117043193	chr11:117135528~117138582:+
SARC	cis	rs7267979	1	rs2500432	ENSG00000276952.1	RP5-965G21.6	4.62	6.37e-06	0.00318	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:25284915~25285588:-
SARC	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-4.62	6.37e-06	0.00318	-0.33	-0.29	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
SARC	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-4.62	6.37e-06	0.00318	-0.33	-0.29	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
SARC	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-4.62	6.37e-06	0.00318	-0.33	-0.29	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
SARC	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-4.62	6.37e-06	0.00318	-0.33	-0.29	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
SARC	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-4.62	6.37e-06	0.00318	-0.36	-0.29	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-4.62	6.37e-06	0.00318	-0.36	-0.29	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
SARC	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-4.62	6.37e-06	0.00318	-0.3	-0.29	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-4.62	6.37e-06	0.00318	-0.3	-0.29	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
SARC	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-4.62	6.38e-06	0.00318	-0.37	-0.29	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
SARC	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	4.62	6.39e-06	0.00319	0.27	0.29	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
SARC	cis	rs597539	0.652	rs604524	ENSG00000250508.1	RP11-757G1.6	-4.62	6.39e-06	0.00319	-0.34	-0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:68870664~68874542:+
SARC	cis	rs7772486	0.686	rs9373473	ENSG00000270638.1	RP3-466P17.1	4.62	6.4e-06	0.00319	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145735570~145737218:+
SARC	cis	rs75422866	0.51	rs73105803	ENSG00000257433.4	RP1-197B17.3	4.62	6.4e-06	0.00319	0.5	0.29	Pneumonia;	chr12:47722135	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.51	rs73105812	ENSG00000257433.4	RP1-197B17.3	4.62	6.4e-06	0.00319	0.5	0.29	Pneumonia;	chr12:47724404	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.51	rs74733564	ENSG00000257433.4	RP1-197B17.3	4.62	6.4e-06	0.00319	0.5	0.29	Pneumonia;	chr12:47724644	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.51	rs73105814	ENSG00000257433.4	RP1-197B17.3	4.62	6.4e-06	0.00319	0.5	0.29	Pneumonia;	chr12:47725817	chr12:47706085~47742294:+
SARC	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	4.62	6.4e-06	0.00319	0.32	0.29	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
SARC	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-4.62	6.4e-06	0.00319	-0.37	-0.29	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
SARC	cis	rs7267979	1	rs2482927	ENSG00000276952.1	RP5-965G21.6	-4.62	6.41e-06	0.0032	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25284915~25285588:-
SARC	cis	rs9425766	0.927	rs5878	ENSG00000270084.1	GAS5-AS1	-4.62	6.42e-06	0.0032	-0.32	-0.29	Life satisfaction;	chr1:173909694	chr1:173863248~173863941:+
SARC	cis	rs910316	0.737	rs175065	ENSG00000279594.1	RP11-950C14.10	-4.62	6.42e-06	0.0032	-0.33	-0.29	Height;	chr14:75028280	chr14:75011269~75012851:-
SARC	cis	rs9876781	0.56	rs2362451	ENSG00000229759.1	MRPS18AP1	-4.62	6.42e-06	0.0032	-0.31	-0.29	Longevity;	chr3:48358338	chr3:48256350~48256938:-
SARC	cis	rs520525	0.927	rs583006	ENSG00000271811.1	RP1-79C4.4	4.62	6.42e-06	0.0032	0.41	0.29	Atrial fibrillation;	chr1:170659247	chr1:170667381~170669425:+
SARC	cis	rs910316	0.699	rs175039	ENSG00000279594.1	RP11-950C14.10	-4.62	6.43e-06	0.0032	-0.33	-0.29	Height;	chr14:75002247	chr14:75011269~75012851:-
SARC	cis	rs910316	0.763	rs175042	ENSG00000279594.1	RP11-950C14.10	-4.62	6.43e-06	0.0032	-0.33	-0.29	Height;	chr14:75004130	chr14:75011269~75012851:-
SARC	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-4.62	6.43e-06	0.00321	-0.32	-0.29	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-4.62	6.43e-06	0.00321	-0.32	-0.29	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-4.62	6.43e-06	0.00321	-0.32	-0.29	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-4.62	6.43e-06	0.00321	-0.32	-0.29	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-4.62	6.43e-06	0.00321	-0.32	-0.29	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-4.62	6.43e-06	0.00321	-0.32	-0.29	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
SARC	cis	rs10986311	1	rs748741	ENSG00000235204.1	RP11-121A14.2	-4.62	6.44e-06	0.00321	-0.33	-0.29	Vitiligo;	chr9:124327496	chr9:124259250~124261156:-
SARC	cis	rs193541	0.632	rs1363200	ENSG00000263432.2	RN7SL689P	4.62	6.45e-06	0.00322	0.36	0.29	Glucose homeostasis traits;	chr5:122828107	chr5:123022487~123022783:-
SARC	cis	rs875971	0.619	rs2302918	ENSG00000236529.1	RP13-254B10.1	4.62	6.46e-06	0.00322	0.3	0.29	Aortic root size;	chr7:66535945	chr7:65840212~65840596:+
SARC	cis	rs9818758	0.607	rs56306491	ENSG00000225399.4	RP11-3B7.1	-4.62	6.46e-06	0.00322	-0.55	-0.29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49277527	chr3:49260085~49261316:+
SARC	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-4.62	6.48e-06	0.00323	-0.32	-0.29	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-4.62	6.48e-06	0.00323	-0.32	-0.29	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-4.62	6.48e-06	0.00323	-0.32	-0.29	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
SARC	cis	rs12893668	0.581	rs34843146	ENSG00000269940.1	RP11-73M18.7	4.62	6.48e-06	0.00323	0.28	0.29	Reticulocyte count;	chr14:103613527	chr14:103694560~103695170:+
SARC	cis	rs9818758	0.607	rs9837237	ENSG00000225399.4	RP11-3B7.1	-4.62	6.48e-06	0.00323	-0.54	-0.29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49178150	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs9837625	ENSG00000225399.4	RP11-3B7.1	-4.62	6.48e-06	0.00323	-0.54	-0.29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49178533	chr3:49260085~49261316:+
SARC	cis	rs9818758	0.607	rs9855123	ENSG00000225399.4	RP11-3B7.1	-4.62	6.48e-06	0.00323	-0.54	-0.29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49192024	chr3:49260085~49261316:+
SARC	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-4.62	6.49e-06	0.00323	-0.3	-0.29	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
SARC	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	4.62	6.49e-06	0.00323	0.31	0.29	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
SARC	cis	rs890448	0.796	rs13135111	ENSG00000254531.1	FLJ20021	4.61	6.5e-06	0.00323	0.31	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101380662	chr4:101347780~101348883:+
SARC	cis	rs890448	0.694	rs2119593	ENSG00000254531.1	FLJ20021	4.61	6.5e-06	0.00323	0.31	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101381407	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs13148622	ENSG00000254531.1	FLJ20021	4.61	6.5e-06	0.00323	0.31	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101382421	chr4:101347780~101348883:+
SARC	cis	rs17270561	0.636	rs9379782	ENSG00000272810.1	U91328.22	-4.61	6.5e-06	0.00323	-0.29	-0.29	Iron status biomarkers;	chr6:25714795	chr6:26013241~26013757:+
SARC	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-4.61	6.5e-06	0.00324	-0.33	-0.29	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
SARC	cis	rs858239	1	rs858240	ENSG00000226816.2	AC005082.12	4.61	6.52e-06	0.00324	0.36	0.29	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23206013~23208045:+
SARC	cis	rs1799949	1	rs8176242	ENSG00000267681.1	CTD-3199J23.6	-4.61	6.52e-06	0.00325	-0.33	-0.29	Menopause (age at onset);	chr17:43065857	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.93	rs3092987	ENSG00000267681.1	CTD-3199J23.6	-4.61	6.52e-06	0.00325	-0.33	-0.29	Menopause (age at onset);	chr17:43070706	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs9646418	ENSG00000267681.1	CTD-3199J23.6	-4.61	6.52e-06	0.00325	-0.32	-0.29	Menopause (age at onset);	chr17:43348533	chr17:43144956~43145255:+
SARC	cis	rs6570726	0.791	rs383841	ENSG00000270638.1	RP3-466P17.1	-4.61	6.52e-06	0.00325	-0.24	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145735570~145737218:+
SARC	cis	rs7216064	0.953	rs4791046	ENSG00000265055.1	AC145343.2	4.61	6.53e-06	0.00325	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67855857	chr17:68096046~68101474:-
SARC	cis	rs4862750	0.957	rs1030381	ENSG00000250971.1	RP11-696F12.1	4.61	6.53e-06	0.00325	0.34	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186982414	chr4:187060099~187060930:+
SARC	cis	rs801193	1	rs10234018	ENSG00000236529.1	RP13-254B10.1	-4.61	6.53e-06	0.00325	-0.29	-0.29	Aortic root size;	chr7:66681297	chr7:65840212~65840596:+
SARC	cis	rs1061377	0.748	rs12506723	ENSG00000249207.1	RP11-360F5.1	-4.61	6.53e-06	0.00325	-0.32	-0.29	Uric acid levels;	chr4:39103152	chr4:39112677~39126818:-
SARC	cis	rs7976269	0.609	rs10771475	ENSG00000257176.2	RP11-996F15.2	-4.61	6.53e-06	0.00325	-0.31	-0.29	Male-pattern baldness;	chr12:29071077	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.609	rs10843305	ENSG00000257176.2	RP11-996F15.2	-4.61	6.53e-06	0.00325	-0.31	-0.29	Male-pattern baldness;	chr12:29073147	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.609	rs10843306	ENSG00000257176.2	RP11-996F15.2	-4.61	6.53e-06	0.00325	-0.31	-0.29	Male-pattern baldness;	chr12:29073417	chr12:29280418~29317848:-
SARC	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	4.61	6.54e-06	0.00325	0.32	0.29	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	4.61	6.54e-06	0.00325	0.32	0.29	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	4.61	6.54e-06	0.00325	0.32	0.29	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	4.61	6.54e-06	0.00325	0.32	0.29	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	4.61	6.54e-06	0.00325	0.32	0.29	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
SARC	cis	rs4713118	0.824	rs2179095	ENSG00000219392.1	RP1-265C24.5	4.61	6.55e-06	0.00326	0.41	0.29	Parkinson's disease;	chr6:27783079	chr6:28115628~28116551:+
SARC	cis	rs7772486	0.79	rs2254288	ENSG00000270638.1	RP3-466P17.1	4.61	6.55e-06	0.00326	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145735570~145737218:+
SARC	cis	rs1707322	0.752	rs6662164	ENSG00000281133.1	AL355480.3	-4.61	6.55e-06	0.00326	-0.33	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45580892~45580996:-
SARC	cis	rs4934494	0.822	rs3962370	ENSG00000240996.1	RP11-80H5.7	-4.61	6.55e-06	0.00326	-0.29	-0.29	Red blood cell count;	chr10:89777763	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.727	rs1590566	ENSG00000240996.1	RP11-80H5.7	-4.61	6.55e-06	0.00326	-0.29	-0.29	Red blood cell count;	chr10:89778781	chr10:89694295~89697928:-
SARC	cis	rs7615952	0.611	rs78137633	ENSG00000250012.1	RP11-124N2.1	-4.61	6.55e-06	0.00326	-0.38	-0.29	Blood pressure (smoking interaction);	chr3:126056218	chr3:126084220~126095349:+
SARC	cis	rs7216064	1	rs6504542	ENSG00000265055.1	AC145343.2	4.61	6.56e-06	0.00326	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67840526	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.953	rs1966410	ENSG00000265055.1	AC145343.2	4.61	6.56e-06	0.00326	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841099	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs8067892	ENSG00000265055.1	AC145343.2	4.61	6.56e-06	0.00326	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67841867	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs7223930	ENSG00000265055.1	AC145343.2	4.61	6.56e-06	0.00326	0.37	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67846070	chr17:68096046~68101474:-
SARC	cis	rs6969780	0.915	rs12666919	ENSG00000233429.8	HOTAIRM1	-4.61	6.56e-06	0.00326	-0.41	-0.29	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149879	chr7:27095647~27100265:+
SARC	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-4.61	6.57e-06	0.00327	-0.35	-0.29	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
SARC	cis	rs75422866	0.702	rs12426387	ENSG00000257433.4	RP1-197B17.3	4.61	6.57e-06	0.00327	0.59	0.29	Pneumonia;	chr12:47582915	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.85	rs12423789	ENSG00000257433.4	RP1-197B17.3	4.61	6.57e-06	0.00327	0.59	0.29	Pneumonia;	chr12:47583112	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.702	rs73111229	ENSG00000257433.4	RP1-197B17.3	4.61	6.57e-06	0.00327	0.59	0.29	Pneumonia;	chr12:47583333	chr12:47706085~47742294:+
SARC	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-4.61	6.58e-06	0.00327	-0.32	-0.29	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
SARC	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	4.61	6.58e-06	0.00327	0.34	0.29	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
SARC	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	4.61	6.58e-06	0.00327	0.34	0.29	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
SARC	cis	rs2562456	0.92	rs2650784	ENSG00000268081.1	RP11-678G14.2	-4.61	6.58e-06	0.00327	-0.42	-0.29	Pain;	chr19:21483795	chr19:21554640~21569237:-
SARC	cis	rs7712401	0.502	rs30066	ENSG00000263432.2	RN7SL689P	4.61	6.59e-06	0.00328	0.37	0.29	Mean platelet volume;	chr5:122958007	chr5:123022487~123022783:-
SARC	cis	rs193541	0.632	rs30063	ENSG00000263432.2	RN7SL689P	4.61	6.59e-06	0.00328	0.37	0.29	Glucose homeostasis traits;	chr5:122959998	chr5:123022487~123022783:-
SARC	cis	rs62432291	0.681	rs435521	ENSG00000235086.1	FNDC1-IT1	4.61	6.59e-06	0.00328	0.47	0.29	Joint mobility (Beighton score);	chr6:159241606	chr6:159240786~159243329:+
SARC	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-4.61	6.6e-06	0.00328	-0.4	-0.29	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
SARC	cis	rs2439831	0.85	rs7181039	ENSG00000205771.5	CATSPER2P1	-4.61	6.61e-06	0.00328	-0.51	-0.29	Lung cancer in ever smokers;	chr15:43886914	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.702	rs495175	ENSG00000205771.5	CATSPER2P1	-4.61	6.61e-06	0.00328	-0.45	-0.29	Lung cancer in ever smokers;	chr15:43506486	chr15:43726918~43747094:-
SARC	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-4.61	6.61e-06	0.00329	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
SARC	cis	rs453301	0.592	rs4841084	ENSG00000253893.2	FAM85B	-4.61	6.62e-06	0.00329	-0.25	-0.29	Joint mobility (Beighton score);	chr8:9026395	chr8:8167819~8226614:-
SARC	cis	rs453301	0.653	rs2956244	ENSG00000253893.2	FAM85B	-4.61	6.62e-06	0.00329	-0.25	-0.29	Joint mobility (Beighton score);	chr8:9027656	chr8:8167819~8226614:-
SARC	cis	rs7615952	0.932	rs13321217	ENSG00000241288.6	RP11-379B18.5	-4.61	6.62e-06	0.00329	-0.36	-0.29	Blood pressure (smoking interaction);	chr3:125912928	chr3:125827238~125916384:-
SARC	cis	rs7772486	0.806	rs2253648	ENSG00000270638.1	RP3-466P17.1	4.61	6.62e-06	0.00329	0.24	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145735570~145737218:+
SARC	cis	rs858239	0.899	rs858271	ENSG00000226816.2	AC005082.12	4.61	6.62e-06	0.00329	0.36	0.29	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23206013~23208045:+
SARC	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-4.61	6.62e-06	0.00329	-0.31	-0.29	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-4.61	6.62e-06	0.00329	-0.31	-0.29	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-4.61	6.62e-06	0.00329	-0.31	-0.29	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-4.61	6.62e-06	0.00329	-0.31	-0.29	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-4.61	6.62e-06	0.00329	-0.31	-0.29	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-4.61	6.62e-06	0.00329	-0.31	-0.29	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
SARC	cis	rs4372836	0.681	rs9309664	ENSG00000226833.4	AC097724.3	-4.61	6.62e-06	0.00329	-0.25	-0.29	Body mass index;	chr2:28716760	chr2:28708953~28736205:-
SARC	cis	rs3864261	0.515	rs57149385	ENSG00000272081.1	CTD-2376I4.2	4.61	6.62e-06	0.00329	0.37	0.29	Discordance in emotional problems in monozygotic twins;	chr5:73060354	chr5:72955206~72955699:-
SARC	cis	rs3864261	0.515	rs10942539	ENSG00000272081.1	CTD-2376I4.2	4.61	6.62e-06	0.00329	0.37	0.29	Discordance in emotional problems in monozygotic twins;	chr5:73061259	chr5:72955206~72955699:-
SARC	cis	rs890448	0.694	rs2583392	ENSG00000254531.1	FLJ20021	-4.61	6.62e-06	0.00329	-0.29	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101338208	chr4:101347780~101348883:+
SARC	cis	rs890448	0.726	rs2850326	ENSG00000254531.1	FLJ20021	-4.61	6.62e-06	0.00329	-0.29	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101343418	chr4:101347780~101348883:+
SARC	cis	rs17270561	0.583	rs7765833	ENSG00000272810.1	U91328.22	-4.61	6.63e-06	0.00329	-0.28	-0.29	Iron status biomarkers;	chr6:25712205	chr6:26013241~26013757:+
SARC	cis	rs7615952	0.576	rs2276726	ENSG00000250012.1	RP11-124N2.1	-4.61	6.63e-06	0.00329	-0.27	-0.29	Blood pressure (smoking interaction);	chr3:126107444	chr3:126084220~126095349:+
SARC	cis	rs801193	0.844	rs732465	ENSG00000236529.1	RP13-254B10.1	4.61	6.63e-06	0.00329	0.3	0.29	Aortic root size;	chr7:66533463	chr7:65840212~65840596:+
SARC	cis	rs2439831	0.85	rs7183809	ENSG00000275601.1	AC011330.13	-4.61	6.63e-06	0.00329	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43828670	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs3759790	ENSG00000275601.1	AC011330.13	-4.61	6.63e-06	0.00329	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43828832	chr15:43642389~43643023:-
SARC	cis	rs858239	0.796	rs433395	ENSG00000226816.2	AC005082.12	4.61	6.63e-06	0.00329	0.35	0.29	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23206013~23208045:+
SARC	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-4.61	6.64e-06	0.00329	-0.4	-0.29	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
SARC	cis	rs948562	0.74	rs12361770	ENSG00000280010.1	AP001350.4	4.61	6.64e-06	0.0033	0.42	0.29	Lymphoma;	chr11:58666759	chr11:58627435~58628528:+
SARC	cis	rs890448	0.93	rs2471675	ENSG00000254531.1	FLJ20021	-4.61	6.65e-06	0.0033	-0.29	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101467385	chr4:101347780~101348883:+
SARC	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-4.61	6.65e-06	0.0033	-0.29	-0.29	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
SARC	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	4.61	6.66e-06	0.0033	0.32	0.29	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
SARC	cis	rs12554020	0.786	rs10429558	ENSG00000227603.1	RP11-165J3.6	4.61	6.66e-06	0.0033	0.4	0.29	Schizophrenia;	chr9:93574508	chr9:93435332~93437121:-
SARC	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-4.61	6.66e-06	0.0033	-0.34	-0.29	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
SARC	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	4.61	6.67e-06	0.00331	0.31	0.29	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
SARC	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	4.61	6.67e-06	0.00331	0.31	0.29	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
SARC	cis	rs2439831	0.85	rs694985	ENSG00000275601.1	AC011330.13	-4.61	6.67e-06	0.00331	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43521189	chr15:43642389~43643023:-
SARC	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-4.61	6.67e-06	0.00331	-0.36	-0.29	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
SARC	cis	rs8062405	0.69	rs7187604	ENSG00000251417.2	RP11-1348G14.4	-4.61	6.68e-06	0.00331	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28802743~28817828:+
SARC	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-4.61	6.68e-06	0.00331	-0.32	-0.29	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-4.61	6.68e-06	0.00331	-0.32	-0.29	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-4.61	6.68e-06	0.00331	-0.32	-0.29	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
SARC	cis	rs7216064	1	rs60432293	ENSG00000265055.1	AC145343.2	4.61	6.68e-06	0.00331	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67864291	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.953	rs4790905	ENSG00000265055.1	AC145343.2	4.61	6.68e-06	0.00331	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67867234	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs9912084	ENSG00000265055.1	AC145343.2	4.61	6.68e-06	0.00331	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67871919	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs9912770	ENSG00000265055.1	AC145343.2	4.61	6.68e-06	0.00331	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67872117	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs9915108	ENSG00000265055.1	AC145343.2	4.61	6.68e-06	0.00331	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878347	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs9913471	ENSG00000265055.1	AC145343.2	4.61	6.68e-06	0.00331	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878379	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.861	rs73352810	ENSG00000265055.1	AC145343.2	4.61	6.68e-06	0.00331	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67879068	chr17:68096046~68101474:-
SARC	cis	rs7216064	0.906	rs8074644	ENSG00000265055.1	AC145343.2	4.61	6.68e-06	0.00331	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67882101	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs3935969	ENSG00000265055.1	AC145343.2	4.61	6.68e-06	0.00331	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67885843	chr17:68096046~68101474:-
SARC	cis	rs7216064	1	rs7208663	ENSG00000265055.1	AC145343.2	4.61	6.68e-06	0.00331	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889055	chr17:68096046~68101474:-
SARC	cis	rs526231	0.857	rs415657	ENSG00000175749.11	EIF3KP1	-4.61	6.68e-06	0.00331	-0.35	-0.29	Primary biliary cholangitis;	chr5:103329295	chr5:103032376~103033031:+
SARC	cis	rs2439831	0.702	rs28699233	ENSG00000205771.5	CATSPER2P1	-4.61	6.7e-06	0.00332	-0.5	-0.29	Lung cancer in ever smokers;	chr15:43830668	chr15:43726918~43747094:-
SARC	cis	rs17270561	0.609	rs9379783	ENSG00000272810.1	U91328.22	-4.61	6.7e-06	0.00332	-0.29	-0.29	Iron status biomarkers;	chr6:25724979	chr6:26013241~26013757:+
SARC	cis	rs7216064	0.953	rs9890629	ENSG00000265055.1	AC145343.2	4.61	6.7e-06	0.00332	0.36	0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67875443	chr17:68096046~68101474:-
SARC	cis	rs739310	0.556	rs2051654	ENSG00000206028.1	CTA-373H7.7	-4.61	6.71e-06	0.00332	-0.44	-0.29	Obesity-related traits;	chr22:26686190	chr22:26667693~26672654:-
SARC	cis	rs4703855	0.538	rs3891932	ENSG00000244061.1	RP11-389C8.1	-4.61	6.74e-06	0.00334	-0.29	-0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72402277	chr5:72381794~72382393:+
SARC	cis	rs853679	0.517	rs9380047	ENSG00000272009.1	RP1-313I6.12	-4.61	6.74e-06	0.00334	-0.33	-0.29	Depression;	chr6:28070115	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs7755442	ENSG00000272009.1	RP1-313I6.12	-4.61	6.74e-06	0.00334	-0.33	-0.29	Depression;	chr6:28071237	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs55747925	ENSG00000272009.1	RP1-313I6.12	-4.61	6.74e-06	0.00334	-0.33	-0.29	Depression;	chr6:28076559	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs56310871	ENSG00000272009.1	RP1-313I6.12	-4.61	6.74e-06	0.00334	-0.33	-0.29	Depression;	chr6:28076704	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs34716816	ENSG00000272009.1	RP1-313I6.12	-4.61	6.74e-06	0.00334	-0.33	-0.29	Depression;	chr6:28078391	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9393884	ENSG00000272009.1	RP1-313I6.12	-4.61	6.74e-06	0.00334	-0.33	-0.29	Depression;	chr6:28079011	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9380049	ENSG00000272009.1	RP1-313I6.12	-4.61	6.74e-06	0.00334	-0.33	-0.29	Depression;	chr6:28080757	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9380050	ENSG00000272009.1	RP1-313I6.12	-4.61	6.74e-06	0.00334	-0.33	-0.29	Depression;	chr6:28080760	chr6:28078792~28081130:-
SARC	cis	rs7809950	0.862	rs2299421	ENSG00000238832.1	snoU109	-4.61	6.74e-06	0.00334	-0.33	-0.29	Coronary artery disease;	chr7:107305750	chr7:107603363~107603507:+
SARC	cis	rs79349575	0.783	rs56046215	ENSG00000270781.1	RP11-501C14.9	-4.61	6.74e-06	0.00334	-0.34	-0.29	Type 2 diabetes;	chr17:48931395	chr17:48899131~48899748:+
SARC	cis	rs17270561	0.666	rs12209856	ENSG00000272462.2	U91328.19	-4.61	6.75e-06	0.00334	-0.27	-0.29	Iron status biomarkers;	chr6:25793445	chr6:25992662~26001775:+
SARC	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-4.61	6.75e-06	0.00334	-0.32	-0.29	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
SARC	cis	rs6842047	1	rs1511800	ENSG00000272218.1	RP11-11N5.3	4.61	6.75e-06	0.00334	0.43	0.29	Blood protein levels;	chr4:186214402	chr4:186892552~186892983:+
SARC	cis	rs6842047	0.706	rs4862666	ENSG00000272218.1	RP11-11N5.3	4.61	6.75e-06	0.00334	0.43	0.29	Blood protein levels;	chr4:186215153	chr4:186892552~186892983:+
SARC	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	4.61	6.76e-06	0.00335	0.33	0.29	QT interval;	chr12:29379056	chr12:29280418~29317848:-
SARC	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	4.61	6.76e-06	0.00335	0.24	0.29	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
SARC	cis	rs4372836	0.504	rs13024443	ENSG00000226833.4	AC097724.3	4.61	6.76e-06	0.00335	0.24	0.29	Body mass index;	chr2:28823319	chr2:28708953~28736205:-
SARC	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-4.61	6.78e-06	0.00335	-0.29	-0.29	Height;	chr3:52972039	chr3:53064283~53065091:-
SARC	cis	rs8062405	0.755	rs62034358	ENSG00000251417.2	RP11-1348G14.4	-4.61	6.78e-06	0.00336	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.755	rs12445823	ENSG00000251417.2	RP11-1348G14.4	-4.61	6.78e-06	0.00336	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28802743~28817828:+
SARC	cis	rs5769707	0.681	rs4824068	ENSG00000235111.1	RP1-29C18.8	-4.6	6.79e-06	0.00336	-0.36	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49612657~49615716:-
SARC	cis	rs763121	0.853	rs138706	ENSG00000273076.1	RP3-508I15.22	4.6	6.79e-06	0.00336	0.31	0.29	Menopause (age at onset);	chr22:38741829	chr22:38743495~38743910:+
SARC	cis	rs2179367	0.632	rs11155649	ENSG00000231760.4	RP11-350J20.5	4.6	6.79e-06	0.00336	0.39	0.29	Dupuytren's disease;	chr6:149405830	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs11155650	ENSG00000231760.4	RP11-350J20.5	4.6	6.79e-06	0.00336	0.39	0.29	Dupuytren's disease;	chr6:149407613	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs11155651	ENSG00000231760.4	RP11-350J20.5	4.6	6.79e-06	0.00336	0.39	0.29	Dupuytren's disease;	chr6:149408146	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs7896	ENSG00000231760.4	RP11-350J20.5	4.6	6.79e-06	0.00336	0.39	0.29	Dupuytren's disease;	chr6:149410340	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs12196750	ENSG00000231760.4	RP11-350J20.5	4.6	6.79e-06	0.00336	0.39	0.29	Dupuytren's disease;	chr6:149413335	chr6:149796151~149826294:-
SARC	cis	rs7255436	0.928	rs7250870	ENSG00000269386.4	RAB11B-AS1	4.6	6.79e-06	0.00336	0.29	0.29	HDL cholesterol;	chr19:8388798	chr19:8374373~8390685:-
SARC	cis	rs10754283	0.967	rs7552896	ENSG00000231613.1	RP5-943J3.1	4.6	6.79e-06	0.00336	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89637635	chr1:89788914~89790492:+
SARC	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-4.6	6.8e-06	0.00336	-0.34	-0.29	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
SARC	cis	rs2404602	0.735	rs2461871	ENSG00000259422.1	RP11-593F23.1	-4.6	6.8e-06	0.00336	-0.35	-0.29	Blood metabolite levels;	chr15:76530077	chr15:76174891~76181486:-
SARC	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-4.6	6.82e-06	0.00337	-0.46	-0.29	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
SARC	cis	rs7267979	0.932	rs446649	ENSG00000276952.1	RP5-965G21.6	4.6	6.82e-06	0.00337	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25284915~25285588:-
SARC	cis	rs7809950	0.954	rs2712229	ENSG00000238832.1	snoU109	4.6	6.82e-06	0.00337	0.35	0.29	Coronary artery disease;	chr7:107654881	chr7:107603363~107603507:+
SARC	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-4.6	6.82e-06	0.00337	-0.33	-0.29	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
SARC	cis	rs6496044	0.963	rs6496050	ENSG00000202081.1	RNU6-1280P	4.6	6.82e-06	0.00337	0.32	0.29	Interstitial lung disease;	chr15:85526019	chr15:85651522~85651628:-
SARC	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	4.6	6.83e-06	0.00338	0.44	0.29	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
SARC	cis	rs1799949	1	rs1060915	ENSG00000267681.1	CTD-3199J23.6	-4.6	6.83e-06	0.00338	-0.33	-0.29	Menopause (age at onset);	chr17:43082453	chr17:43144956~43145255:+
SARC	cis	rs123509	0.863	rs339662	ENSG00000230970.3	HHATL-AS1	-4.6	6.84e-06	0.00338	-0.34	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42710601	chr3:42702653~42706776:+
SARC	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-4.6	6.84e-06	0.00338	-0.32	-0.29	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
SARC	cis	rs13434995	0.842	rs9790448	ENSG00000273257.1	RP11-177J6.1	-4.6	6.84e-06	0.00338	-0.43	-0.29	Adiponectin levels;	chr4:55592918	chr4:55387949~55388271:+
SARC	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-4.6	6.84e-06	0.00338	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
SARC	cis	rs524281	1	rs472518	ENSG00000255320.1	RP11-755F10.1	-4.6	6.85e-06	0.00338	-0.4	-0.29	Electroencephalogram traits;	chr11:66084431	chr11:66244840~66246239:-
SARC	cis	rs8081395	0.627	rs180536	ENSG00000266992.1	DHX40P1	4.6	6.85e-06	0.00339	0.33	0.29	White blood cell count;	chr17:59919445	chr17:59976009~60002384:-
SARC	cis	rs1865760	0.555	rs2051541	ENSG00000272462.2	U91328.19	4.6	6.85e-06	0.00339	0.29	0.29	Height;	chr6:25944983	chr6:25992662~26001775:+
SARC	cis	rs12554020	0.786	rs79804179	ENSG00000227603.1	RP11-165J3.6	4.6	6.87e-06	0.0034	0.49	0.29	Schizophrenia;	chr9:93486200	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.681	rs74816254	ENSG00000227603.1	RP11-165J3.6	4.6	6.87e-06	0.0034	0.49	0.29	Schizophrenia;	chr9:93486661	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.786	rs79068125	ENSG00000227603.1	RP11-165J3.6	4.6	6.87e-06	0.0034	0.49	0.29	Schizophrenia;	chr9:93486957	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.786	rs79330192	ENSG00000227603.1	RP11-165J3.6	4.6	6.87e-06	0.0034	0.49	0.29	Schizophrenia;	chr9:93487542	chr9:93435332~93437121:-
SARC	cis	rs160451	0.811	rs2735886	ENSG00000251136.7	RP11-37B2.1	4.6	6.88e-06	0.0034	0.35	0.29	Leprosy;	chr8:89639406	chr8:89609409~89757727:-
SARC	cis	rs8062405	0.754	rs151179	ENSG00000251417.2	RP11-1348G14.4	-4.6	6.89e-06	0.0034	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28802743~28817828:+
SARC	cis	rs2708377	0.79	rs73051387	ENSG00000247157.5	LINC01252	4.6	6.91e-06	0.00341	0.5	0.29	Bitter taste perception;	chr12:11161864	chr12:11548030~11590369:+
SARC	cis	rs4664293	0.707	rs7563956	ENSG00000226266.5	AC009961.3	4.6	6.91e-06	0.00341	0.33	0.29	Monocyte percentage of white cells;	chr2:159815943	chr2:159670708~159712435:-
SARC	cis	rs4273100	0.646	rs1472932	ENSG00000265185.4	SNORD3B-1	-4.6	6.92e-06	0.00341	-0.34	-0.29	Schizophrenia;	chr17:19317353	chr17:19061912~19062669:+
SARC	cis	rs2439831	1	rs2444029	ENSG00000275601.1	AC011330.13	-4.6	6.92e-06	0.00341	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43445286	chr15:43642389~43643023:-
SARC	cis	rs2439831	1	rs690316	ENSG00000275601.1	AC011330.13	-4.6	6.92e-06	0.00341	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43445682	chr15:43642389~43643023:-
SARC	cis	rs1546924	0.57	rs197419	ENSG00000260948.1	RP11-552M11.8	-4.6	6.92e-06	0.00342	-0.32	-0.29	Body mass index;	chr1:111772828	chr1:111431046~111433068:-
SARC	cis	rs7829975	0.51	rs2921073	ENSG00000253893.2	FAM85B	-4.6	6.93e-06	0.00342	-0.26	-0.29	Mood instability;	chr8:8450133	chr8:8167819~8226614:-
SARC	cis	rs7829975	0.51	rs2979160	ENSG00000253893.2	FAM85B	-4.6	6.93e-06	0.00342	-0.26	-0.29	Mood instability;	chr8:8450156	chr8:8167819~8226614:-
SARC	cis	rs910316	1	rs7145159	ENSG00000279594.1	RP11-950C14.10	4.6	6.94e-06	0.00342	0.31	0.29	Height;	chr14:75116565	chr14:75011269~75012851:-
SARC	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-4.6	6.94e-06	0.00343	-0.27	-0.29	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-4.6	6.94e-06	0.00343	-0.27	-0.29	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
SARC	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	4.6	6.95e-06	0.00343	0.27	0.29	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
SARC	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	4.6	6.95e-06	0.00343	0.32	0.29	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
SARC	cis	rs367615	0.704	rs7705399	ENSG00000249476.1	CTD-2587M2.1	4.6	6.98e-06	0.00344	0.36	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109514650	chr5:109237120~109326369:-
SARC	cis	rs115344852	0.585	rs1016069	ENSG00000216901.1	AL022393.7	4.6	6.99e-06	0.00344	0.38	0.29	Epithelial ovarian cancer;	chr6:28472641	chr6:28176188~28176674:+
SARC	cis	rs7772486	0.754	rs697054	ENSG00000270638.1	RP3-466P17.1	4.6	6.99e-06	0.00344	0.24	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145735570~145737218:+
SARC	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-4.6	6.99e-06	0.00345	-0.27	-0.29	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
SARC	cis	rs1823874	0.71	rs4246297	ENSG00000182397.13	DNM1P46	-4.6	6.99e-06	0.00345	-0.32	-0.29	IgG glycosylation;	chr15:99826723	chr15:99790156~99806927:-
SARC	cis	rs72945132	0.882	rs7122057	ENSG00000254604.1	AP000487.6	-4.6	7e-06	0.00345	-0.4	-0.29	Coronary artery disease;	chr11:70355324	chr11:70282367~70363368:-
SARC	cis	rs2412819	0.571	rs495880	ENSG00000205771.5	CATSPER2P1	4.6	7e-06	0.00345	0.43	0.29	Lung cancer;	chr15:43855067	chr15:43726918~43747094:-
SARC	cis	rs7208859	0.614	rs216412	ENSG00000264538.5	SUZ12P1	4.6	7e-06	0.00345	0.26	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30709299~30790908:+
SARC	cis	rs7567389	0.504	rs1568278	ENSG00000236682.1	AC068282.3	-4.6	7.01e-06	0.00345	-0.32	-0.29	Self-rated health;	chr2:127432619	chr2:127389130~127400580:+
SARC	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-4.6	7.01e-06	0.00345	-0.27	-0.29	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
SARC	cis	rs7267979	0.933	rs2424708	ENSG00000276952.1	RP5-965G21.6	4.6	7.01e-06	0.00346	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:25284915~25285588:-
SARC	cis	rs14027	0.921	rs12707880	ENSG00000279347.1	RP11-85I17.2	-4.6	7.01e-06	0.00346	-0.26	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119829051	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs12542706	ENSG00000279347.1	RP11-85I17.2	-4.6	7.01e-06	0.00346	-0.26	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119831539	chr8:119838736~119840385:-
SARC	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-4.6	7.02e-06	0.00346	-0.32	-0.29	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-4.6	7.02e-06	0.00346	-0.32	-0.29	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-4.6	7.02e-06	0.00346	-0.32	-0.29	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-4.6	7.02e-06	0.00346	-0.32	-0.29	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
SARC	cis	rs2439831	1	rs2444032	ENSG00000205771.5	CATSPER2P1	-4.6	7.02e-06	0.00346	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43463148	chr15:43726918~43747094:-
SARC	cis	rs2933343	0.729	rs1683816	ENSG00000261159.1	RP11-723O4.9	-4.6	7.02e-06	0.00346	-0.31	-0.29	IgG glycosylation;	chr3:128932352	chr3:128859716~128860526:-
SARC	cis	rs2439831	0.85	rs7183809	ENSG00000205771.5	CATSPER2P1	-4.6	7.02e-06	0.00346	-0.45	-0.29	Lung cancer in ever smokers;	chr15:43828670	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs3759790	ENSG00000205771.5	CATSPER2P1	-4.6	7.02e-06	0.00346	-0.45	-0.29	Lung cancer in ever smokers;	chr15:43828832	chr15:43726918~43747094:-
SARC	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	4.6	7.02e-06	0.00346	0.34	0.29	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
SARC	cis	rs910316	0.763	rs175047	ENSG00000279594.1	RP11-950C14.10	-4.6	7.03e-06	0.00346	-0.32	-0.29	Height;	chr14:75012336	chr14:75011269~75012851:-
SARC	cis	rs2018683	0.899	rs10269454	ENSG00000228421.2	AC005013.5	4.6	7.03e-06	0.00346	0.29	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938783	chr7:28957667~28959345:+
SARC	cis	rs193541	0.632	rs168913	ENSG00000263432.2	RN7SL689P	4.6	7.03e-06	0.00346	0.37	0.29	Glucose homeostasis traits;	chr5:122890098	chr5:123022487~123022783:-
SARC	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	4.6	7.03e-06	0.00346	0.32	0.29	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
SARC	cis	rs8062405	0.755	rs1074631	ENSG00000251417.2	RP11-1348G14.4	4.6	7.04e-06	0.00347	0.29	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28802743~28817828:+
SARC	cis	rs12022452	1	rs12048678	ENSG00000238287.1	RP11-656D10.3	-4.6	7.05e-06	0.00347	-0.5	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:40493157~40508661:-
SARC	cis	rs2303759	0.676	rs7248378	ENSG00000268686.1	AC010524.2	-4.6	7.05e-06	0.00347	-0.33	-0.29	Multiple sclerosis;	chr19:49404887	chr19:49368705~49388081:-
SARC	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	4.6	7.05e-06	0.00347	0.36	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
SARC	cis	rs853679	0.517	rs9393885	ENSG00000272009.1	RP1-313I6.12	-4.6	7.06e-06	0.00348	-0.33	-0.29	Depression;	chr6:28082231	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9393886	ENSG00000272009.1	RP1-313I6.12	-4.6	7.06e-06	0.00348	-0.33	-0.29	Depression;	chr6:28082261	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.515	rs9368549	ENSG00000272009.1	RP1-313I6.12	-4.6	7.06e-06	0.00348	-0.33	-0.29	Parkinson's disease;	chr6:28082269	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs56364346	ENSG00000272009.1	RP1-313I6.12	-4.6	7.06e-06	0.00348	-0.33	-0.29	Depression;	chr6:28082984	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9357061	ENSG00000272009.1	RP1-313I6.12	-4.6	7.06e-06	0.00348	-0.33	-0.29	Depression;	chr6:28083994	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9368550	ENSG00000272009.1	RP1-313I6.12	-4.6	7.06e-06	0.00348	-0.33	-0.29	Depression;	chr6:28084025	chr6:28078792~28081130:-
SARC	cis	rs853679	0.542	rs2295594	ENSG00000272009.1	RP1-313I6.12	-4.6	7.06e-06	0.00348	-0.33	-0.29	Depression;	chr6:28085319	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs2273564	ENSG00000272009.1	RP1-313I6.12	-4.6	7.06e-06	0.00348	-0.33	-0.29	Depression;	chr6:28089816	chr6:28078792~28081130:-
SARC	cis	rs59104589	0.617	rs60178325	ENSG00000266621.1	AC104841.1	4.6	7.07e-06	0.00348	0.4	0.29	Fibrinogen levels;	chr2:241361236	chr2:241245202~241245299:-
SARC	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-4.6	7.07e-06	0.00348	-0.35	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
SARC	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-4.6	7.07e-06	0.00348	-0.35	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
SARC	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	4.6	7.07e-06	0.00348	0.37	0.29	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
SARC	cis	rs394563	0.591	rs237026	ENSG00000231760.4	RP11-350J20.5	4.6	7.08e-06	0.00348	0.37	0.29	Dupuytren's disease;	chr6:149399545	chr6:149796151~149826294:-
SARC	cis	rs394563	0.622	rs237024	ENSG00000231760.4	RP11-350J20.5	4.6	7.08e-06	0.00348	0.37	0.29	Dupuytren's disease;	chr6:149400829	chr6:149796151~149826294:-
SARC	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-4.6	7.09e-06	0.00349	-0.32	-0.29	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-4.6	7.09e-06	0.00349	-0.32	-0.29	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
SARC	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-4.59	7.09e-06	0.00349	-0.34	-0.29	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
SARC	cis	rs12554020	0.786	rs78271342	ENSG00000227603.1	RP11-165J3.6	4.59	7.1e-06	0.00349	0.47	0.29	Schizophrenia;	chr9:93468959	chr9:93435332~93437121:-
SARC	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-4.59	7.11e-06	0.0035	-0.28	-0.29	Height;	chr3:53085518	chr3:53064283~53065091:-
SARC	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-4.59	7.12e-06	0.0035	-0.33	-0.29	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
SARC	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-4.59	7.12e-06	0.0035	-0.33	-0.29	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
SARC	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-4.59	7.12e-06	0.0035	-0.33	-0.29	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
SARC	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	4.59	7.12e-06	0.0035	0.42	0.29	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
SARC	cis	rs2412819	0.571	rs528764	ENSG00000205771.5	CATSPER2P1	4.59	7.12e-06	0.0035	0.42	0.29	Lung cancer;	chr15:43838650	chr15:43726918~43747094:-
SARC	cis	rs2562456	0.55	rs4809143	ENSG00000268081.1	RP11-678G14.2	4.59	7.12e-06	0.0035	0.45	0.29	Pain;	chr19:21589926	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.583	rs4809144	ENSG00000268081.1	RP11-678G14.2	4.59	7.12e-06	0.0035	0.45	0.29	Pain;	chr19:21589928	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.652	rs62110214	ENSG00000268081.1	RP11-678G14.2	4.59	7.12e-06	0.0035	0.45	0.29	Pain;	chr19:21592406	chr19:21554640~21569237:-
SARC	cis	rs10911902	0.561	rs78701198	ENSG00000229739.2	RP11-295K2.3	-4.59	7.13e-06	0.00351	-0.41	-0.29	Schizophrenia;	chr1:186380240	chr1:186435161~186470291:+
SARC	cis	rs524281	1	rs475805	ENSG00000255320.1	RP11-755F10.1	-4.59	7.14e-06	0.00351	-0.39	-0.29	Electroencephalogram traits;	chr11:66081267	chr11:66244840~66246239:-
SARC	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-4.59	7.15e-06	0.00351	-0.33	-0.29	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
SARC	cis	rs11822910	1	rs2439448	ENSG00000265566.2	RN7SL605P	4.59	7.15e-06	0.00352	0.38	0.29	Platelet distribution width;	chr11:57431738	chr11:57528085~57528365:-
SARC	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	4.59	7.15e-06	0.00352	0.32	0.29	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
SARC	cis	rs6918586	0.658	rs198826	ENSG00000272462.2	U91328.19	4.59	7.16e-06	0.00352	0.27	0.29	Schizophrenia;	chr6:26120925	chr6:25992662~26001775:+
SARC	cis	rs2274273	0.588	rs7155054	ENSG00000258413.1	RP11-665C16.6	-4.59	7.17e-06	0.00352	-0.36	-0.29	Protein biomarker;	chr14:55283944	chr14:55262767~55272075:-
SARC	cis	rs8062405	0.755	rs12447461	ENSG00000251417.2	RP11-1348G14.4	-4.59	7.17e-06	0.00352	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28802743~28817828:+
SARC	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-4.59	7.18e-06	0.00353	-0.25	-0.29	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
SARC	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-4.59	7.18e-06	0.00353	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-4.59	7.18e-06	0.00353	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-4.59	7.18e-06	0.00353	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-4.59	7.18e-06	0.00353	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
SARC	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-4.59	7.18e-06	0.00353	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
SARC	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-4.59	7.19e-06	0.00353	-0.35	-0.29	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
SARC	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-4.59	7.19e-06	0.00353	-0.35	-0.29	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
SARC	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	4.59	7.19e-06	0.00353	0.32	0.29	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	4.59	7.19e-06	0.00353	0.32	0.29	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	4.59	7.19e-06	0.00353	0.32	0.29	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
SARC	cis	rs910316	0.967	rs4903292	ENSG00000279594.1	RP11-950C14.10	4.59	7.2e-06	0.00353	0.32	0.29	Height;	chr14:75189542	chr14:75011269~75012851:-
SARC	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-4.59	7.21e-06	0.00354	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-4.59	7.21e-06	0.00354	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
SARC	cis	rs853679	0.598	rs9380054	ENSG00000272009.1	RP1-313I6.12	-4.59	7.21e-06	0.00354	-0.33	-0.29	Depression;	chr6:28099759	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.547	rs2116981	ENSG00000272009.1	RP1-313I6.12	-4.59	7.21e-06	0.00354	-0.33	-0.29	Parkinson's disease;	chr6:28100173	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9368552	ENSG00000272009.1	RP1-313I6.12	-4.59	7.21e-06	0.00354	-0.33	-0.29	Depression;	chr6:28100648	chr6:28078792~28081130:-
SARC	cis	rs853679	0.542	rs34131763	ENSG00000272009.1	RP1-313I6.12	-4.59	7.21e-06	0.00354	-0.33	-0.29	Depression;	chr6:28107222	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs35193936	ENSG00000272009.1	RP1-313I6.12	-4.59	7.21e-06	0.00354	-0.33	-0.29	Depression;	chr6:28108492	chr6:28078792~28081130:-
SARC	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	4.59	7.21e-06	0.00354	0.24	0.29	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
SARC	cis	rs11018904	0.906	rs10501713	ENSG00000280385.1	AP000648.5	-4.59	7.22e-06	0.00354	-0.33	-0.29	Intelligence (multi-trait analysis);	chr11:90219845	chr11:90193614~90198120:+
SARC	cis	rs2070074	0.591	rs12352811	ENSG00000230074.1	RP11-195F19.9	4.59	7.23e-06	0.00355	0.44	0.29	CTACK levels;	chr9:34614684	chr9:34665665~34681298:+
SARC	cis	rs1823913	0.637	rs921737	ENSG00000227542.1	AC092614.2	-4.59	7.24e-06	0.00355	-0.32	-0.29	Obesity-related traits;	chr2:191286097	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.599	rs6736071	ENSG00000227542.1	AC092614.2	-4.59	7.24e-06	0.00355	-0.32	-0.29	Obesity-related traits;	chr2:191287265	chr2:191229165~191246172:-
SARC	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	4.59	7.24e-06	0.00355	0.41	0.29	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
SARC	cis	rs2439831	0.85	rs9944216	ENSG00000275601.1	AC011330.13	4.59	7.25e-06	0.00356	0.48	0.29	Lung cancer in ever smokers;	chr15:43868575	chr15:43642389~43643023:-
SARC	cis	rs910316	0.737	rs175499	ENSG00000279594.1	RP11-950C14.10	-4.59	7.25e-06	0.00356	-0.32	-0.29	Height;	chr14:75069224	chr14:75011269~75012851:-
SARC	cis	rs7772486	0.713	rs2328704	ENSG00000270638.1	RP3-466P17.1	-4.59	7.26e-06	0.00356	-0.23	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145735570~145737218:+
SARC	cis	rs11634944	0.772	rs2732029	ENSG00000274307.1	RP11-345J18.2	-4.59	7.27e-06	0.00356	-0.36	-0.29	Interleukin-8 levels;	chr15:24990569	chr15:25708470~25710869:-
SARC	cis	rs73186030	0.764	rs34408666	ENSG00000272758.4	RP11-299J3.8	4.59	7.27e-06	0.00357	0.42	0.29	Serum parathyroid hormone levels;	chr3:122262762	chr3:122416207~122443180:+
SARC	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	4.59	7.28e-06	0.00357	0.35	0.29	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
SARC	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-4.59	7.28e-06	0.00357	-0.32	-0.29	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
SARC	cis	rs13126694	0.778	rs10000610	ENSG00000248429.4	RP11-597D13.9	4.59	7.28e-06	0.00357	0.27	0.29	Blood osmolality (transformed sodium);	chr4:158112023	chr4:158170752~158202877:+
SARC	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	4.59	7.28e-06	0.00357	0.52	0.29	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
SARC	cis	rs4713118	0.621	rs4713132	ENSG00000272009.1	RP1-313I6.12	-4.59	7.28e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:28066257	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.621	rs4713133	ENSG00000272009.1	RP1-313I6.12	-4.59	7.28e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:28066263	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.621	rs4713134	ENSG00000272009.1	RP1-313I6.12	-4.59	7.28e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:28066343	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.621	rs9368548	ENSG00000272009.1	RP1-313I6.12	-4.59	7.28e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:28066959	chr6:28078792~28081130:-
SARC	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	4.59	7.28e-06	0.00357	0.32	0.29	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
SARC	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	4.59	7.28e-06	0.00357	0.32	0.29	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
SARC	cis	rs520525	0.963	rs663887	ENSG00000271811.1	RP1-79C4.4	4.59	7.28e-06	0.00357	0.39	0.29	Atrial fibrillation;	chr1:170657812	chr1:170667381~170669425:+
SARC	cis	rs2933343	0.729	rs1680780	ENSG00000261159.1	RP11-723O4.9	4.59	7.29e-06	0.00357	0.32	0.29	IgG glycosylation;	chr3:128893816	chr3:128859716~128860526:-
SARC	cis	rs7267979	1	rs2474777	ENSG00000276952.1	RP5-965G21.6	4.59	7.29e-06	0.00357	0.31	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:25284915~25285588:-
SARC	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-4.59	7.31e-06	0.00358	-0.31	-0.29	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
SARC	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	4.59	7.31e-06	0.00358	0.33	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
SARC	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-4.59	7.31e-06	0.00358	-0.32	-0.29	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-4.59	7.31e-06	0.00358	-0.32	-0.29	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-4.59	7.31e-06	0.00358	-0.32	-0.29	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-4.59	7.31e-06	0.00358	-0.32	-0.29	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
SARC	cis	rs8081395	0.576	rs1292032	ENSG00000266992.1	DHX40P1	4.59	7.32e-06	0.00359	0.31	0.29	White blood cell count;	chr17:59914982	chr17:59976009~60002384:-
SARC	cis	rs7772486	0.754	rs697053	ENSG00000270638.1	RP3-466P17.1	-4.59	7.32e-06	0.00359	-0.23	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145735570~145737218:+
SARC	cis	rs7829975	0.871	rs7829826	ENSG00000253893.2	FAM85B	4.59	7.33e-06	0.00359	0.26	0.29	Mood instability;	chr8:8720610	chr8:8167819~8226614:-
SARC	cis	rs7226408	0.857	rs3747896	ENSG00000267707.2	RP11-95O2.5	-4.59	7.33e-06	0.00359	-0.38	-0.29	Obesity-related traits;	chr18:37067360	chr18:37243776~37247506:+
SARC	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-4.59	7.33e-06	0.00359	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
SARC	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	4.59	7.33e-06	0.00359	0.27	0.29	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
SARC	cis	rs2439831	0.867	rs2255440	ENSG00000205771.5	CATSPER2P1	-4.59	7.34e-06	0.00359	-0.45	-0.29	Lung cancer in ever smokers;	chr15:43538269	chr15:43726918~43747094:-
SARC	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	4.59	7.34e-06	0.00359	0.31	0.29	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
SARC	cis	rs7809950	0.678	rs13230144	ENSG00000238832.1	snoU109	-4.59	7.35e-06	0.0036	-0.34	-0.29	Coronary artery disease;	chr7:107268727	chr7:107603363~107603507:+
SARC	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-4.59	7.36e-06	0.0036	-0.32	-0.29	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-4.59	7.36e-06	0.0036	-0.32	-0.29	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
SARC	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	4.59	7.36e-06	0.0036	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
SARC	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	4.59	7.36e-06	0.0036	0.38	0.29	Height;	chr4:55415153	chr4:55363971~55395847:-
SARC	cis	rs4835473	0.897	rs4835095	ENSG00000251600.4	RP11-673E1.1	4.59	7.36e-06	0.0036	0.28	0.29	Immature fraction of reticulocytes;	chr4:143960431	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.831	rs2667353	ENSG00000251600.4	RP11-673E1.1	4.59	7.36e-06	0.0036	0.28	0.29	Immature fraction of reticulocytes;	chr4:143960462	chr4:143912331~143982454:+
SARC	cis	rs2439831	0.702	rs3784275	ENSG00000205771.5	CATSPER2P1	-4.59	7.38e-06	0.00361	-0.5	-0.29	Lung cancer in ever smokers;	chr15:43799188	chr15:43726918~43747094:-
SARC	cis	rs6570726	0.764	rs451108	ENSG00000270638.1	RP3-466P17.1	4.59	7.38e-06	0.00361	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145735570~145737218:+
SARC	cis	rs12893668	0.697	rs67899457	ENSG00000269940.1	RP11-73M18.7	4.59	7.38e-06	0.00361	0.28	0.29	Reticulocyte count;	chr14:103593729	chr14:103694560~103695170:+
SARC	cis	rs6762	0.748	rs28735718	ENSG00000279672.1	CMB9-55F22.1	4.59	7.39e-06	0.00361	0.26	0.29	Mean platelet volume;	chr11:839629	chr11:779617~780755:+
SARC	cis	rs6762	0.642	rs28692469	ENSG00000279672.1	CMB9-55F22.1	4.59	7.39e-06	0.00361	0.26	0.29	Mean platelet volume;	chr11:839675	chr11:779617~780755:+
SARC	cis	rs853679	0.517	rs9380058	ENSG00000272009.1	RP1-313I6.12	-4.59	7.4e-06	0.00362	-0.33	-0.29	Depression;	chr6:28159666	chr6:28078792~28081130:-
SARC	cis	rs4664293	0.51	rs6731277	ENSG00000226266.5	AC009961.3	4.59	7.4e-06	0.00362	0.36	0.29	Monocyte percentage of white cells;	chr2:159610606	chr2:159670708~159712435:-
SARC	cis	rs2404602	0.735	rs2436994	ENSG00000259422.1	RP11-593F23.1	-4.59	7.41e-06	0.00362	-0.33	-0.29	Blood metabolite levels;	chr15:76508722	chr15:76174891~76181486:-
SARC	cis	rs4938330	0.739	rs11216266	ENSG00000254851.1	RP11-109L13.1	4.58	7.41e-06	0.00362	0.38	0.29	Blood protein levels;	chr11:117079434	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.748	rs7106662	ENSG00000254851.1	RP11-109L13.1	4.58	7.41e-06	0.00362	0.38	0.29	Subjective well-being;	chr11:117080669	chr11:117135528~117138582:+
SARC	cis	rs2562456	1	rs2562456	ENSG00000268081.1	RP11-678G14.2	4.58	7.41e-06	0.00362	0.41	0.29	Pain;	chr19:21483408	chr19:21554640~21569237:-
SARC	cis	rs1962636	1	rs1962636	ENSG00000260306.1	RP11-645C24.5	-4.58	7.43e-06	0.00363	-0.29	-0.29	Schizophrenia;	chr16:22053074	chr16:21794095~21795759:-
SARC	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	4.58	7.44e-06	0.00363	0.31	0.29	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
SARC	cis	rs6570726	0.791	rs1280275	ENSG00000270638.1	RP3-466P17.1	4.58	7.44e-06	0.00363	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145735570~145737218:+
SARC	cis	rs12893668	0.703	rs4906338	ENSG00000269940.1	RP11-73M18.7	4.58	7.44e-06	0.00363	0.29	0.29	Reticulocyte count;	chr14:103584020	chr14:103694560~103695170:+
SARC	cis	rs3805389	0.504	rs10026315	ENSG00000273257.1	RP11-177J6.1	-4.58	7.45e-06	0.00364	-0.44	-0.29	Waist-to-hip ratio adjusted for body mass index;	chr4:55612195	chr4:55387949~55388271:+
SARC	cis	rs17270561	0.666	rs1937129	ENSG00000272462.2	U91328.19	-4.58	7.46e-06	0.00364	-0.27	-0.29	Iron status biomarkers;	chr6:25788904	chr6:25992662~26001775:+
SARC	cis	rs7512898	0.545	rs7518347	ENSG00000260088.1	RP11-92G12.3	-4.58	7.46e-06	0.00364	-0.28	-0.29	Electrocardiographic conduction measures;	chr1:200704899	chr1:200669507~200694250:+
SARC	cis	rs79349575	0.811	rs1057897	ENSG00000270781.1	RP11-501C14.9	-4.58	7.46e-06	0.00364	-0.33	-0.29	Type 2 diabetes;	chr17:48928147	chr17:48899131~48899748:+
SARC	cis	rs8062405	0.755	rs111693583	ENSG00000251417.2	RP11-1348G14.4	-4.58	7.46e-06	0.00364	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28802743~28817828:+
SARC	cis	rs17508449	0.819	rs17359378	ENSG00000232450.1	RP4-730K3.3	-4.58	7.47e-06	0.00365	-0.37	-0.29	Leprosy;	chr1:113674087	chr1:113698884~113699631:-
SARC	cis	rs17508449	0.819	rs17274627	ENSG00000232450.1	RP4-730K3.3	-4.58	7.47e-06	0.00365	-0.37	-0.29	Leprosy;	chr1:113674773	chr1:113698884~113699631:-
SARC	cis	rs890448	0.76	rs293215	ENSG00000254531.1	FLJ20021	4.58	7.47e-06	0.00365	0.3	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101392717	chr4:101347780~101348883:+
SARC	cis	rs890448	0.726	rs293211	ENSG00000254531.1	FLJ20021	4.58	7.47e-06	0.00365	0.3	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395224	chr4:101347780~101348883:+
SARC	cis	rs890448	0.76	rs293209	ENSG00000254531.1	FLJ20021	4.58	7.47e-06	0.00365	0.3	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395285	chr4:101347780~101348883:+
SARC	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	4.58	7.47e-06	0.00365	0.31	0.29	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
SARC	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	4.58	7.47e-06	0.00365	0.35	0.29	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
SARC	cis	rs2439831	0.702	rs3759791	ENSG00000205771.5	CATSPER2P1	-4.58	7.48e-06	0.00365	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43798600	chr15:43726918~43747094:-
SARC	cis	rs10754283	0.967	rs7513928	ENSG00000231613.1	RP5-943J3.1	4.58	7.49e-06	0.00365	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89639275	chr1:89788914~89790492:+
SARC	cis	rs2412819	0.597	rs541871	ENSG00000205771.5	CATSPER2P1	-4.58	7.49e-06	0.00365	-0.43	-0.29	Lung cancer;	chr15:43868656	chr15:43726918~43747094:-
SARC	cis	rs2412819	0.597	rs514311	ENSG00000205771.5	CATSPER2P1	-4.58	7.49e-06	0.00365	-0.43	-0.29	Lung cancer;	chr15:43869376	chr15:43726918~43747094:-
SARC	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-4.58	7.49e-06	0.00366	-0.32	-0.29	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
SARC	cis	rs2404602	0.552	rs11072613	ENSG00000259422.1	RP11-593F23.1	-4.58	7.5e-06	0.00366	-0.36	-0.29	Blood metabolite levels;	chr15:76669185	chr15:76174891~76181486:-
SARC	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-4.58	7.5e-06	0.00366	-0.32	-0.29	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
SARC	cis	rs7512898	0.5	rs10753880	ENSG00000260088.1	RP11-92G12.3	-4.58	7.5e-06	0.00366	-0.33	-0.29	Electrocardiographic conduction measures;	chr1:200731246	chr1:200669507~200694250:+
SARC	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	4.58	7.5e-06	0.00366	0.3	0.29	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
SARC	cis	rs2933343	0.679	rs789254	ENSG00000231305.3	RP11-723O4.2	4.58	7.51e-06	0.00366	0.28	0.29	IgG glycosylation;	chr3:128855750	chr3:128861313~128871540:-
SARC	cis	rs9527	0.641	rs4919684	ENSG00000213061.2	PFN1P11	4.58	7.52e-06	0.00367	0.37	0.29	Arsenic metabolism;	chr10:102827267	chr10:102838011~102845473:-
SARC	cis	rs7829975	0.54	rs2976909	ENSG00000253981.4	ALG1L13P	-4.58	7.53e-06	0.00367	-0.27	-0.29	Mood instability;	chr8:8489180	chr8:8236003~8244667:-
SARC	cis	rs3805389	0.504	rs59571323	ENSG00000273257.1	RP11-177J6.1	-4.58	7.53e-06	0.00367	-0.43	-0.29	Waist-to-hip ratio adjusted for body mass index;	chr4:55611187	chr4:55387949~55388271:+
SARC	cis	rs13434995	0.838	rs57178140	ENSG00000273257.1	RP11-177J6.1	-4.58	7.53e-06	0.00367	-0.43	-0.29	Adiponectin levels;	chr4:55611361	chr4:55387949~55388271:+
SARC	cis	rs10754283	0.934	rs6428563	ENSG00000231613.1	RP5-943J3.1	4.58	7.53e-06	0.00367	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89788914~89790492:+
SARC	cis	rs2439831	0.867	rs2251844	ENSG00000205771.5	CATSPER2P1	-4.58	7.53e-06	0.00367	-0.45	-0.29	Lung cancer in ever smokers;	chr15:43544280	chr15:43726918~43747094:-
SARC	cis	rs7216064	0.765	rs6504550	ENSG00000278219.1	AC145343.1	-4.58	7.55e-06	0.00368	-0.32	-0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67898426	chr17:68101538~68101639:+
SARC	cis	rs7216064	0.911	rs6504551	ENSG00000278219.1	AC145343.1	-4.58	7.55e-06	0.00368	-0.32	-0.29	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67907210	chr17:68101538~68101639:+
SARC	cis	rs4938330	0.512	rs4938327	ENSG00000254851.1	RP11-109L13.1	4.58	7.55e-06	0.00368	0.4	0.29	Blood protein levels;	chr11:117036012	chr11:117135528~117138582:+
SARC	cis	rs801193	0.935	rs11772264	ENSG00000236529.1	RP13-254B10.1	4.58	7.56e-06	0.00368	0.3	0.29	Aortic root size;	chr7:66711400	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs7782320	ENSG00000236529.1	RP13-254B10.1	4.58	7.56e-06	0.00368	0.3	0.29	Aortic root size;	chr7:66712111	chr7:65840212~65840596:+
SARC	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	4.58	7.56e-06	0.00368	0.35	0.29	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
SARC	cis	rs858239	1	rs858239	ENSG00000226816.2	AC005082.12	4.58	7.56e-06	0.00369	0.35	0.29	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23206013~23208045:+
SARC	cis	rs853679	0.517	rs4713135	ENSG00000272009.1	RP1-313I6.12	-4.58	7.56e-06	0.00369	-0.33	-0.29	Depression;	chr6:28071808	chr6:28078792~28081130:-
SARC	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-4.58	7.56e-06	0.00369	-0.29	-0.29	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
SARC	cis	rs10788972	0.903	rs7537946	ENSG00000225183.1	RP4-758J24.4	-4.58	7.56e-06	0.00369	-0.34	-0.29	Parkinson disease and lewy body pathology;	chr1:54073027	chr1:54089856~54090093:+
SARC	cis	rs12893668	0.542	rs12884809	ENSG00000269940.1	RP11-73M18.7	4.58	7.57e-06	0.00369	0.28	0.29	Reticulocyte count;	chr14:103628983	chr14:103694560~103695170:+
SARC	cis	rs910316	1	rs10873275	ENSG00000279594.1	RP11-950C14.10	4.58	7.58e-06	0.00369	0.31	0.29	Height;	chr14:75064757	chr14:75011269~75012851:-
SARC	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	4.58	7.58e-06	0.00369	0.27	0.29	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
SARC	cis	rs7246657	0.941	rs67293224	ENSG00000276846.1	CTD-3220F14.3	4.58	7.58e-06	0.0037	0.41	0.29	Coronary artery calcification;	chr19:37312346	chr19:37314868~37315620:-
SARC	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	4.58	7.63e-06	0.00371	0.28	0.29	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
SARC	cis	rs783540	0.934	rs4779053	ENSG00000275695.1	UBE2Q2P6	4.58	7.64e-06	0.00372	0.29	0.29	Schizophrenia;	chr15:82702846	chr15:82445719~82454837:+
SARC	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-4.58	7.64e-06	0.00372	-0.35	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
SARC	cis	rs858239	1	rs199347	ENSG00000226816.2	AC005082.12	4.58	7.64e-06	0.00372	0.35	0.29	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23206013~23208045:+
SARC	cis	rs4664293	0.967	rs7597482	ENSG00000226266.5	AC009961.3	-4.58	7.66e-06	0.00373	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159690580	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.967	rs7597488	ENSG00000226266.5	AC009961.3	-4.58	7.66e-06	0.00373	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159690585	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.967	rs10803758	ENSG00000226266.5	AC009961.3	-4.58	7.66e-06	0.00373	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159691708	chr2:159670708~159712435:-
SARC	cis	rs16846053	0.71	rs13006199	ENSG00000227403.1	AC009299.3	4.58	7.67e-06	0.00373	0.34	0.29	Blood osmolality (transformed sodium);	chr2:161770258	chr2:161244739~161249050:+
SARC	cis	rs75920871	0.528	rs11216244	ENSG00000254851.1	RP11-109L13.1	4.58	7.67e-06	0.00373	0.39	0.29	Subjective well-being;	chr11:117042014	chr11:117135528~117138582:+
SARC	cis	rs1823913	0.637	rs2356354	ENSG00000227542.1	AC092614.2	-4.58	7.68e-06	0.00374	-0.32	-0.29	Obesity-related traits;	chr2:191270970	chr2:191229165~191246172:-
SARC	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-4.58	7.69e-06	0.00374	-0.36	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
SARC	cis	rs7267979	1	rs2258719	ENSG00000276952.1	RP5-965G21.6	4.58	7.69e-06	0.00374	0.29	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:25284915~25285588:-
SARC	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-4.58	7.7e-06	0.00374	-0.32	-0.29	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-4.58	7.7e-06	0.00374	-0.32	-0.29	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-4.58	7.7e-06	0.00374	-0.32	-0.29	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-4.58	7.7e-06	0.00374	-0.32	-0.29	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-4.58	7.7e-06	0.00374	-0.32	-0.29	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-4.58	7.7e-06	0.00374	-0.32	-0.29	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-4.58	7.7e-06	0.00374	-0.32	-0.29	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
SARC	cis	rs321358	0.895	rs7131434	ENSG00000271584.1	RP11-89C3.4	4.58	7.7e-06	0.00375	0.5	0.29	Body mass index;	chr11:111085693	chr11:111091932~111097357:-
SARC	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-4.58	7.71e-06	0.00375	-0.37	-0.29	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
SARC	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-4.58	7.71e-06	0.00375	-0.29	-0.29	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
SARC	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	4.58	7.72e-06	0.00375	0.3	0.29	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
SARC	cis	rs910316	1	rs7156105	ENSG00000279594.1	RP11-950C14.10	4.58	7.73e-06	0.00376	0.31	0.29	Height;	chr14:75075251	chr14:75011269~75012851:-
SARC	cis	rs853679	0.517	rs12332979	ENSG00000272009.1	RP1-313I6.12	-4.58	7.73e-06	0.00376	-0.33	-0.29	Depression;	chr6:28173770	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs67878650	ENSG00000272009.1	RP1-313I6.12	-4.58	7.73e-06	0.00376	-0.33	-0.29	Depression;	chr6:28174809	chr6:28078792~28081130:-
SARC	cis	rs853679	0.569	rs9348798	ENSG00000272009.1	RP1-313I6.12	-4.58	7.73e-06	0.00376	-0.33	-0.29	Depression;	chr6:28175233	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9380065	ENSG00000272009.1	RP1-313I6.12	-4.58	7.73e-06	0.00376	-0.33	-0.29	Depression;	chr6:28176973	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9295761	ENSG00000272009.1	RP1-313I6.12	-4.58	7.73e-06	0.00376	-0.33	-0.29	Depression;	chr6:28180209	chr6:28078792~28081130:-
SARC	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
SARC	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
SARC	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
SARC	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
SARC	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
SARC	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
SARC	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
SARC	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
SARC	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	4.58	7.73e-06	0.00376	0.3	0.29	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
SARC	cis	rs2439831	0.85	rs68079546	ENSG00000275601.1	AC011330.13	-4.58	7.74e-06	0.00376	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43844759	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs56909447	ENSG00000275601.1	AC011330.13	-4.58	7.74e-06	0.00376	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43845420	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs28476182	ENSG00000275601.1	AC011330.13	-4.58	7.74e-06	0.00376	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43847445	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs28696802	ENSG00000275601.1	AC011330.13	-4.58	7.74e-06	0.00376	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43848197	chr15:43642389~43643023:-
SARC	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-4.58	7.74e-06	0.00376	-0.32	-0.29	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-4.58	7.74e-06	0.00376	-0.32	-0.29	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
SARC	cis	rs1823874	0.71	rs2902472	ENSG00000182397.13	DNM1P46	-4.57	7.75e-06	0.00376	-0.32	-0.29	IgG glycosylation;	chr15:99824257	chr15:99790156~99806927:-
SARC	cis	rs10754283	0.967	rs1317864	ENSG00000231613.1	RP5-943J3.1	4.57	7.75e-06	0.00376	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89639889	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs2390763	ENSG00000231613.1	RP5-943J3.1	4.57	7.75e-06	0.00376	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs2002883	ENSG00000231613.1	RP5-943J3.1	4.57	7.75e-06	0.00376	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89640279	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.934	rs1934043	ENSG00000231613.1	RP5-943J3.1	4.57	7.75e-06	0.00376	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89641086	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.934	rs10493829	ENSG00000231613.1	RP5-943J3.1	4.57	7.75e-06	0.00376	0.28	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89652274	chr1:89788914~89790492:+
SARC	cis	rs853679	0.513	rs13437444	ENSG00000272009.1	RP1-313I6.12	-4.57	7.76e-06	0.00377	-0.4	-0.29	Depression;	chr6:28103220	chr6:28078792~28081130:-
SARC	cis	rs7615952	0.611	rs2947646	ENSG00000248787.1	RP11-666A20.4	4.57	7.76e-06	0.00377	0.5	0.29	Blood pressure (smoking interaction);	chr3:125874759	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.688	rs7624806	ENSG00000241288.6	RP11-379B18.5	-4.57	7.76e-06	0.00377	-0.36	-0.29	Blood pressure (smoking interaction);	chr3:125880231	chr3:125827238~125916384:-
SARC	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-4.57	7.77e-06	0.00377	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
SARC	cis	rs763121	0.962	rs5757135	ENSG00000273076.1	RP3-508I15.22	4.57	7.77e-06	0.00377	0.3	0.29	Menopause (age at onset);	chr22:38556568	chr22:38743495~38743910:+
SARC	cis	rs910316	1	rs10149880	ENSG00000279594.1	RP11-950C14.10	-4.57	7.78e-06	0.00378	-0.32	-0.29	Height;	chr14:75166305	chr14:75011269~75012851:-
SARC	cis	rs1134634	0.52	rs741180	ENSG00000273133.1	RP11-799M12.2	-4.57	7.78e-06	0.00378	-0.37	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15561787	chr4:15563698~15564253:-
SARC	cis	rs10754283	0.967	rs2185195	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89641138	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs6657988	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89641186	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs6698273	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89641232	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.905	rs7519969	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs7519971	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs7546410	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs7515375	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.901	rs6663526	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.934	rs7529653	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.87	rs2390764	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.901	rs4520403	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs4658130	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.934	rs10754284	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs10801759	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs10801760	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs7528433	ENSG00000231613.1	RP5-943J3.1	4.57	7.79e-06	0.00378	0.29	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89788914~89790492:+
SARC	cis	rs2933343	0.729	rs1680781	ENSG00000261159.1	RP11-723O4.9	4.57	7.79e-06	0.00378	0.32	0.29	IgG glycosylation;	chr3:128893987	chr3:128859716~128860526:-
SARC	cis	rs4862750	1	rs4862750	ENSG00000250971.1	RP11-696F12.1	4.57	7.79e-06	0.00378	0.34	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186982889	chr4:187060099~187060930:+
SARC	cis	rs4862750	1	rs4862751	ENSG00000250971.1	RP11-696F12.1	4.57	7.79e-06	0.00378	0.34	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186982896	chr4:187060099~187060930:+
SARC	cis	rs5769707	0.632	rs1476037	ENSG00000235111.1	RP1-29C18.8	-4.57	7.79e-06	0.00378	-0.36	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49612657~49615716:-
SARC	cis	rs2179367	0.959	rs652807	ENSG00000216906.2	RP11-350J20.9	-4.57	7.79e-06	0.00378	-0.27	-0.29	Dupuytren's disease;	chr6:149416359	chr6:149904243~149906418:+
SARC	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-4.57	7.8e-06	0.00378	-0.54	-0.29	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
SARC	cis	rs2803122	0.775	rs10118150	ENSG00000273226.1	RP11-513M16.8	-4.57	7.82e-06	0.00379	-0.27	-0.29	Pulse pressure;	chr9:19235482	chr9:19375451~19375996:+
SARC	cis	rs524281	1	rs547087	ENSG00000255320.1	RP11-755F10.1	-4.57	7.82e-06	0.00379	-0.4	-0.29	Electroencephalogram traits;	chr11:66078793	chr11:66244840~66246239:-
SARC	cis	rs4865169	0.811	rs6841086	ENSG00000269949.1	RP11-738E22.3	4.57	7.82e-06	0.00379	0.33	0.29	Breast cancer;	chr4:57037102	chr4:56960927~56961373:-
SARC	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-4.57	7.82e-06	0.00379	-0.34	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
SARC	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-4.57	7.83e-06	0.00379	-0.27	-0.29	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-4.57	7.83e-06	0.00379	-0.27	-0.29	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
SARC	cis	rs4664293	0.934	rs4380179	ENSG00000226266.5	AC009961.3	-4.57	7.83e-06	0.0038	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159685064	chr2:159670708~159712435:-
SARC	cis	rs910316	0.967	rs4903285	ENSG00000279594.1	RP11-950C14.10	4.57	7.84e-06	0.0038	0.31	0.29	Height;	chr14:75142565	chr14:75011269~75012851:-
SARC	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	4.57	7.84e-06	0.0038	0.27	0.29	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
SARC	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-4.57	7.84e-06	0.0038	-0.34	-0.29	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
SARC	cis	rs14027	0.921	rs7813651	ENSG00000279347.1	RP11-85I17.2	-4.57	7.84e-06	0.0038	-0.25	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839119	chr8:119838736~119840385:-
SARC	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-4.57	7.85e-06	0.0038	-0.33	-0.29	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
SARC	cis	rs1009647	0.592	rs1045004	ENSG00000258413.1	RP11-665C16.6	-4.57	7.85e-06	0.00381	-0.45	-0.29	Testicular germ cell tumor;	chr14:55353073	chr14:55262767~55272075:-
SARC	cis	rs728478	1	rs7213014	ENSG00000266992.1	DHX40P1	4.57	7.86e-06	0.00381	0.31	0.29	QT interval;	chr17:59351739	chr17:59976009~60002384:-
SARC	cis	rs4919687	0.55	rs10748828	ENSG00000213061.2	PFN1P11	-4.57	7.86e-06	0.00381	-0.36	-0.29	Colorectal cancer;	chr10:102697037	chr10:102838011~102845473:-
SARC	cis	rs7809950	0.773	rs9791733	ENSG00000238832.1	snoU109	-4.57	7.86e-06	0.00381	-0.35	-0.29	Coronary artery disease;	chr7:107401285	chr7:107603363~107603507:+
SARC	cis	rs853679	0.517	rs2281588	ENSG00000272009.1	RP1-313I6.12	-4.57	7.86e-06	0.00381	-0.34	-0.29	Depression;	chr6:28104824	chr6:28078792~28081130:-
SARC	cis	rs2280018	0.963	rs11075255	ENSG00000260735.1	RP11-72I8.1	-4.57	7.88e-06	0.00382	-0.24	-0.29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15094411~15109197:+
SARC	cis	rs8062405	0.824	rs4788085	ENSG00000251417.2	RP11-1348G14.4	-4.57	7.89e-06	0.00382	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.824	rs28772958	ENSG00000251417.2	RP11-1348G14.4	-4.57	7.89e-06	0.00382	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.789	rs2106480	ENSG00000251417.2	RP11-1348G14.4	-4.57	7.89e-06	0.00382	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28802743~28817828:+
SARC	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-4.57	7.9e-06	0.00383	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
SARC	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-4.57	7.92e-06	0.00383	-0.41	-0.29	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
SARC	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-4.57	7.92e-06	0.00384	-0.27	-0.29	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
SARC	cis	rs10800713	0.56	rs10919967	ENSG00000260088.1	RP11-92G12.3	4.57	7.92e-06	0.00384	0.38	0.29	Tandem gait;	chr1:200533543	chr1:200669507~200694250:+
SARC	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-4.57	7.92e-06	0.00384	-0.28	-0.29	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
SARC	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-4.57	7.94e-06	0.00384	-0.41	-0.29	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
SARC	cis	rs4835473	0.932	rs4092718	ENSG00000251600.4	RP11-673E1.1	-4.57	7.94e-06	0.00384	-0.28	-0.29	Immature fraction of reticulocytes;	chr4:143799637	chr4:143912331~143982454:+
SARC	cis	rs910316	0.663	rs175034	ENSG00000279594.1	RP11-950C14.10	-4.57	7.94e-06	0.00384	-0.33	-0.29	Height;	chr14:74996984	chr14:75011269~75012851:-
SARC	cis	rs9309473	0.687	rs6706235	ENSG00000163016.8	ALMS1P	4.57	7.95e-06	0.00385	0.34	0.29	Metabolite levels;	chr2:73386430	chr2:73644919~73685576:+
SARC	cis	rs4664293	0.867	rs7566802	ENSG00000226266.5	AC009961.3	-4.57	7.96e-06	0.00385	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159728480	chr2:159670708~159712435:-
SARC	cis	rs4372836	0.504	rs7601413	ENSG00000226833.4	AC097724.3	4.57	7.97e-06	0.00386	0.24	0.29	Body mass index;	chr2:28809372	chr2:28708953~28736205:-
SARC	cis	rs14027	0.921	rs3812463	ENSG00000279347.1	RP11-85I17.2	-4.57	7.98e-06	0.00386	-0.25	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839860	chr8:119838736~119840385:-
SARC	cis	rs30380	0.632	rs30186	ENSG00000272109.1	CTD-2260A17.3	-4.57	7.98e-06	0.00386	-0.37	-0.29	Cerebrospinal fluid biomarker levels;	chr5:96788744	chr5:96804353~96806105:+
SARC	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-4.57	7.98e-06	0.00386	-0.29	-0.29	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
SARC	cis	rs75422866	0.51	rs73105818	ENSG00000257433.4	RP1-197B17.3	4.57	7.98e-06	0.00386	0.49	0.29	Pneumonia;	chr12:47726538	chr12:47706085~47742294:+
SARC	cis	rs7772486	0.754	rs9390356	ENSG00000270638.1	RP3-466P17.1	-4.57	7.98e-06	0.00386	-0.23	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145735570~145737218:+
SARC	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	4.57	7.99e-06	0.00386	0.28	0.29	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
SARC	cis	rs890448	0.796	rs4699209	ENSG00000254531.1	FLJ20021	4.57	7.99e-06	0.00386	0.3	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101363783	chr4:101347780~101348883:+
SARC	cis	rs2274273	0.934	rs8021940	ENSG00000258413.1	RP11-665C16.6	-4.57	7.99e-06	0.00387	-0.33	-0.29	Protein biomarker;	chr14:55252997	chr14:55262767~55272075:-
SARC	cis	rs2933343	0.729	rs813732	ENSG00000261159.1	RP11-723O4.9	4.57	7.99e-06	0.00387	0.32	0.29	IgG glycosylation;	chr3:128900514	chr3:128859716~128860526:-
SARC	cis	rs9818758	0.607	rs66991555	ENSG00000225399.4	RP11-3B7.1	-4.57	7.99e-06	0.00387	-0.53	-0.29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49191210	chr3:49260085~49261316:+
SARC	cis	rs412050	0.594	rs113463481	ENSG00000224086.5	LL22NC03-86G7.1	-4.57	8.02e-06	0.00387	-0.41	-0.29	Attention deficit hyperactivity disorder;	chr22:21742941	chr22:21938293~21977632:+
SARC	cis	rs890448	0.796	rs2960588	ENSG00000254531.1	FLJ20021	4.57	8.02e-06	0.00388	0.31	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101429307	chr4:101347780~101348883:+
SARC	cis	rs77204473	1	rs17120157	ENSG00000254851.1	RP11-109L13.1	-4.57	8.02e-06	0.00388	-0.6	-0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941912	chr11:117135528~117138582:+
SARC	cis	rs7267979	1	rs2482940	ENSG00000276952.1	RP5-965G21.6	-4.57	8.02e-06	0.00388	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25284915~25285588:-
SARC	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	4.57	8.03e-06	0.00388	0.27	0.29	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
SARC	cis	rs4713118	0.587	rs61471148	ENSG00000272009.1	RP1-313I6.12	-4.57	8.03e-06	0.00388	-0.33	-0.29	Parkinson's disease;	chr6:28069254	chr6:28078792~28081130:-
SARC	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-4.57	8.03e-06	0.00388	-0.34	-0.29	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-4.57	8.03e-06	0.00388	-0.34	-0.29	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
SARC	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-4.57	8.04e-06	0.00388	-0.39	-0.29	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
SARC	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	4.57	8.04e-06	0.00388	0.3	0.29	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	4.57	8.04e-06	0.00388	0.3	0.29	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	4.57	8.04e-06	0.00388	0.3	0.29	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	4.57	8.04e-06	0.00388	0.3	0.29	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	4.57	8.04e-06	0.00388	0.3	0.29	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	4.57	8.04e-06	0.00388	0.3	0.29	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	4.57	8.04e-06	0.00388	0.3	0.29	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	4.57	8.04e-06	0.00388	0.3	0.29	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
SARC	cis	rs17508449	0.819	rs4839331	ENSG00000232450.1	RP4-730K3.3	-4.57	8.04e-06	0.00389	-0.36	-0.29	Leprosy;	chr1:113619009	chr1:113698884~113699631:-
SARC	cis	rs2933343	0.7	rs1680778	ENSG00000261159.1	RP11-723O4.9	4.57	8.05e-06	0.00389	0.31	0.29	IgG glycosylation;	chr3:128895342	chr3:128859716~128860526:-
SARC	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-4.57	8.05e-06	0.00389	-0.3	-0.29	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
SARC	cis	rs10911902	0.643	rs6664763	ENSG00000229739.2	RP11-295K2.3	-4.57	8.06e-06	0.00389	-0.41	-0.29	Schizophrenia;	chr1:186357043	chr1:186435161~186470291:+
SARC	cis	rs123509	0.913	rs339661	ENSG00000230970.3	HHATL-AS1	-4.57	8.06e-06	0.00389	-0.33	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42712412	chr3:42702653~42706776:+
SARC	cis	rs7246657	0.943	rs34603719	ENSG00000276846.1	CTD-3220F14.3	4.57	8.07e-06	0.00389	0.41	0.29	Coronary artery calcification;	chr19:37303626	chr19:37314868~37315620:-
SARC	cis	rs9309711	0.772	rs9309715	ENSG00000225234.1	TRAPPC12-AS1	4.57	8.07e-06	0.00389	0.31	0.29	Neurofibrillary tangles;	chr2:3488547	chr2:3481242~3482409:-
SARC	cis	rs4820294	0.669	rs12628135	ENSG00000233360.4	Z83844.1	4.57	8.07e-06	0.0039	0.33	0.29	Fat distribution (HIV);	chr22:37669648	chr22:37641832~37658377:-
SARC	cis	rs2018683	0.711	rs2158788	ENSG00000228421.2	AC005013.5	4.57	8.07e-06	0.0039	0.28	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932341	chr7:28957667~28959345:+
SARC	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-4.57	8.08e-06	0.0039	-0.26	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
SARC	cis	rs2439831	0.85	rs28413881	ENSG00000205771.5	CATSPER2P1	-4.57	8.08e-06	0.0039	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43881901	chr15:43726918~43747094:-
SARC	cis	rs2239557	1	rs2239557	ENSG00000259065.1	RP5-1021I20.1	-4.56	8.09e-06	0.0039	-0.34	-0.29	Common traits (Other);	chr14:74085267	chr14:73787360~73803270:+
SARC	cis	rs2239557	0.961	rs11159061	ENSG00000259065.1	RP5-1021I20.1	-4.56	8.09e-06	0.0039	-0.34	-0.29	Common traits (Other);	chr14:74089560	chr14:73787360~73803270:+
SARC	cis	rs2239557	1	rs17096228	ENSG00000259065.1	RP5-1021I20.1	-4.56	8.09e-06	0.0039	-0.34	-0.29	Common traits (Other);	chr14:74091966	chr14:73787360~73803270:+
SARC	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-4.56	8.1e-06	0.00391	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
SARC	cis	rs448720	0.595	rs11856862	ENSG00000259410.4	RP11-34F13.3	4.56	8.1e-06	0.00391	0.34	0.29	Cognitive performance;	chr15:67898923	chr15:67832725~67873866:+
SARC	cis	rs6570726	0.791	rs407887	ENSG00000270638.1	RP3-466P17.1	4.56	8.1e-06	0.00391	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145735570~145737218:+
SARC	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-4.56	8.1e-06	0.00391	-0.3	-0.29	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
SARC	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-4.56	8.11e-06	0.00391	-0.35	-0.29	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
SARC	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-4.56	8.11e-06	0.00391	-0.35	-0.29	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
SARC	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-4.56	8.11e-06	0.00391	-0.35	-0.29	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
SARC	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-4.56	8.11e-06	0.00391	-0.35	-0.29	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
SARC	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-4.56	8.11e-06	0.00391	-0.33	-0.29	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
SARC	cis	rs13434995	0.838	rs73236165	ENSG00000273257.1	RP11-177J6.1	-4.56	8.12e-06	0.00392	-0.43	-0.29	Adiponectin levels;	chr4:55617617	chr4:55387949~55388271:+
SARC	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-4.56	8.12e-06	0.00392	-0.31	-0.29	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
SARC	cis	rs6844153	1	rs6844153	ENSG00000240005.4	RP11-293A21.1	-4.56	8.12e-06	0.00392	-0.4	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26942692	chr4:26859806~26860599:-
SARC	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-4.56	8.13e-06	0.00392	-0.3	-0.29	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
SARC	cis	rs2404602	0.735	rs2468130	ENSG00000259422.1	RP11-593F23.1	-4.56	8.14e-06	0.00392	-0.35	-0.29	Blood metabolite levels;	chr15:76504155	chr15:76174891~76181486:-
SARC	cis	rs13217239	0.574	rs9366680	ENSG00000241549.7	GUSBP2	4.56	8.14e-06	0.00393	0.27	0.29	Schizophrenia;	chr6:27038344	chr6:26871484~26956554:-
SARC	cis	rs1799949	0.683	rs55737636	ENSG00000267681.1	CTD-3199J23.6	-4.56	8.15e-06	0.00393	-0.32	-0.29	Menopause (age at onset);	chr17:43112722	chr17:43144956~43145255:+
SARC	cis	rs7181230	1	rs28587891	ENSG00000275636.1	RP11-521C20.5	4.56	8.15e-06	0.00393	0.33	0.29	Dehydroepiandrosterone sulphate levels;	chr15:40072905	chr15:40078892~40079347:+
SARC	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	4.56	8.15e-06	0.00393	0.29	0.29	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
SARC	cis	rs1823913	0.637	rs897197	ENSG00000227542.1	AC092614.2	-4.56	8.15e-06	0.00393	-0.32	-0.29	Obesity-related traits;	chr2:191281456	chr2:191229165~191246172:-
SARC	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-4.56	8.15e-06	0.00393	-0.33	-0.29	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
SARC	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-4.56	8.17e-06	0.00394	-0.32	-0.29	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-4.56	8.17e-06	0.00394	-0.32	-0.29	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-4.56	8.17e-06	0.00394	-0.32	-0.29	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-4.56	8.17e-06	0.00394	-0.32	-0.29	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-4.56	8.17e-06	0.00394	-0.32	-0.29	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
SARC	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-4.56	8.17e-06	0.00394	-0.3	-0.29	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-4.56	8.17e-06	0.00394	-0.3	-0.29	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-4.56	8.17e-06	0.00394	-0.3	-0.29	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-4.56	8.17e-06	0.00394	-0.3	-0.29	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
SARC	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-4.56	8.17e-06	0.00394	-0.3	-0.29	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
SARC	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	4.56	8.17e-06	0.00394	0.32	0.29	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
SARC	cis	rs2274273	0.837	rs6573010	ENSG00000258413.1	RP11-665C16.6	-4.56	8.17e-06	0.00394	-0.33	-0.29	Protein biomarker;	chr14:55254874	chr14:55262767~55272075:-
SARC	cis	rs8062405	0.69	rs762634	ENSG00000251417.2	RP11-1348G14.4	-4.56	8.18e-06	0.00394	-0.29	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28802743~28817828:+
SARC	cis	rs9309473	0.687	rs11126399	ENSG00000163016.8	ALMS1P	4.56	8.2e-06	0.00395	0.35	0.29	Metabolite levels;	chr2:73386213	chr2:73644919~73685576:+
SARC	cis	rs890448	0.93	rs4699220	ENSG00000254531.1	FLJ20021	-4.56	8.2e-06	0.00395	-0.28	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101495282	chr4:101347780~101348883:+
SARC	cis	rs1707322	1	rs1707322	ENSG00000281133.1	AL355480.3	-4.56	8.21e-06	0.00395	-0.32	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45580892~45580996:-
SARC	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-4.56	8.21e-06	0.00395	-0.51	-0.29	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-4.56	8.21e-06	0.00395	-0.51	-0.29	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
SARC	cis	rs2439831	0.85	rs8023458	ENSG00000205771.5	CATSPER2P1	-4.56	8.22e-06	0.00396	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43788741	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs16963953	ENSG00000205771.5	CATSPER2P1	-4.56	8.22e-06	0.00396	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43789521	chr15:43726918~43747094:-
SARC	cis	rs72945132	0.882	rs55758686	ENSG00000254604.1	AP000487.6	-4.56	8.22e-06	0.00396	-0.41	-0.29	Coronary artery disease;	chr11:70326098	chr11:70282367~70363368:-
SARC	cis	rs17270561	0.583	rs12662869	ENSG00000272462.2	U91328.19	4.56	8.22e-06	0.00396	0.26	0.29	Iron status biomarkers;	chr6:25784253	chr6:25992662~26001775:+
SARC	cis	rs7255436	0.965	rs11668346	ENSG00000269386.4	RAB11B-AS1	4.56	8.23e-06	0.00396	0.28	0.29	HDL cholesterol;	chr19:8385970	chr19:8374373~8390685:-
SARC	cis	rs7255436	0.965	rs12981318	ENSG00000269386.4	RAB11B-AS1	4.56	8.23e-06	0.00396	0.28	0.29	HDL cholesterol;	chr19:8386546	chr19:8374373~8390685:-
SARC	cis	rs7255436	0.965	rs7351098	ENSG00000269386.4	RAB11B-AS1	4.56	8.23e-06	0.00396	0.28	0.29	HDL cholesterol;	chr19:8386787	chr19:8374373~8390685:-
SARC	cis	rs7255436	0.965	rs11666003	ENSG00000269386.4	RAB11B-AS1	4.56	8.23e-06	0.00396	0.28	0.29	HDL cholesterol;	chr19:8387218	chr19:8374373~8390685:-
SARC	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-4.56	8.23e-06	0.00396	-0.29	-0.29	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
SARC	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-4.56	8.23e-06	0.00396	-0.35	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
SARC	cis	rs42490	0.664	rs43227	ENSG00000251136.7	RP11-37B2.1	-4.56	8.24e-06	0.00396	-0.32	-0.29	Leprosy;	chr8:89809351	chr8:89609409~89757727:-
SARC	cis	rs42490	0.638	rs28144	ENSG00000251136.7	RP11-37B2.1	-4.56	8.24e-06	0.00396	-0.32	-0.29	Leprosy;	chr8:89810531	chr8:89609409~89757727:-
SARC	cis	rs7809950	0.817	rs17154091	ENSG00000238832.1	snoU109	-4.56	8.24e-06	0.00397	-0.35	-0.29	Coronary artery disease;	chr7:107444345	chr7:107603363~107603507:+
SARC	cis	rs910316	0.673	rs2012627	ENSG00000279594.1	RP11-950C14.10	4.56	8.24e-06	0.00397	0.32	0.29	Height;	chr14:74976400	chr14:75011269~75012851:-
SARC	cis	rs8005677	0.798	rs4982711	ENSG00000257285.4	RP11-298I3.1	4.56	8.25e-06	0.00397	0.28	0.29	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:22929609~22955562:+
SARC	cis	rs4372836	0.681	rs4477866	ENSG00000226833.4	AC097724.3	4.56	8.25e-06	0.00397	0.24	0.29	Body mass index;	chr2:28786223	chr2:28708953~28736205:-
SARC	cis	rs1823874	0.677	rs8042705	ENSG00000182397.13	DNM1P46	-4.56	8.26e-06	0.00397	-0.32	-0.29	IgG glycosylation;	chr15:99824501	chr15:99790156~99806927:-
SARC	cis	rs2281636	0.723	rs11190195	ENSG00000233690.1	EBAG9P1	-4.56	8.26e-06	0.00397	-0.28	-0.29	Obesity-related traits;	chr10:99626710	chr10:99697407~99697949:-
SARC	cis	rs11018904	0.906	rs36177012	ENSG00000280385.1	AP000648.5	-4.56	8.26e-06	0.00397	-0.33	-0.29	Intelligence (multi-trait analysis);	chr11:90200151	chr11:90193614~90198120:+
SARC	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	4.56	8.27e-06	0.00398	0.26	0.29	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
SARC	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-4.56	8.27e-06	0.00398	-0.37	-0.29	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
SARC	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-4.56	8.28e-06	0.00398	-0.29	-0.29	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
SARC	cis	rs9573567	0.881	rs1570539	ENSG00000261553.4	RP11-29G8.3	4.56	8.28e-06	0.00398	0.54	0.29	Red blood cell count;Mean corpuscular volume;	chr13:75500498	chr13:75549773~75807120:+
SARC	cis	rs2439831	0.717	rs2447198	ENSG00000275601.1	AC011330.13	-4.56	8.28e-06	0.00398	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43602920	chr15:43642389~43643023:-
SARC	cis	rs75422866	0.51	rs73105819	ENSG00000257433.4	RP1-197B17.3	4.56	8.28e-06	0.00398	0.49	0.29	Pneumonia;	chr12:47727190	chr12:47706085~47742294:+
SARC	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-4.56	8.29e-06	0.00399	-0.29	-0.29	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
SARC	cis	rs6570726	0.791	rs6900040	ENSG00000270638.1	RP3-466P17.1	4.56	8.3e-06	0.00399	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs6923074	ENSG00000270638.1	RP3-466P17.1	4.56	8.3e-06	0.00399	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.755	rs2092296	ENSG00000270638.1	RP3-466P17.1	4.56	8.3e-06	0.00399	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.755	rs2092297	ENSG00000270638.1	RP3-466P17.1	4.56	8.3e-06	0.00399	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.755	rs2103633	ENSG00000270638.1	RP3-466P17.1	4.56	8.3e-06	0.00399	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs9373463	ENSG00000270638.1	RP3-466P17.1	4.56	8.3e-06	0.00399	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.764	rs9322028	ENSG00000270638.1	RP3-466P17.1	4.56	8.3e-06	0.00399	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs12205752	ENSG00000270638.1	RP3-466P17.1	4.56	8.3e-06	0.00399	0.23	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145735570~145737218:+
SARC	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-4.56	8.3e-06	0.00399	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
SARC	cis	rs7267979	0.565	rs958075	ENSG00000125804.12	FAM182A	4.56	8.3e-06	0.00399	0.33	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:26054655~26086917:+
SARC	cis	rs4664293	0.528	rs12477092	ENSG00000226266.5	AC009961.3	4.56	8.31e-06	0.004	0.36	0.29	Monocyte percentage of white cells;	chr2:159577170	chr2:159670708~159712435:-
SARC	cis	rs6751744	0.514	rs12386214	ENSG00000226266.5	AC009961.3	-4.56	8.32e-06	0.004	-0.34	-0.29	Dysphagia;	chr2:159675012	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.967	rs13032135	ENSG00000226266.5	AC009961.3	-4.56	8.32e-06	0.004	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159675588	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.932	rs4665104	ENSG00000226266.5	AC009961.3	-4.56	8.32e-06	0.004	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159675847	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.967	rs7595639	ENSG00000226266.5	AC009961.3	-4.56	8.32e-06	0.004	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159676533	chr2:159670708~159712435:-
SARC	cis	rs12893668	0.572	rs34000399	ENSG00000269940.1	RP11-73M18.7	4.56	8.32e-06	0.004	0.28	0.29	Reticulocyte count;	chr14:103635080	chr14:103694560~103695170:+
SARC	cis	rs2933343	0.621	rs789242	ENSG00000231305.3	RP11-723O4.2	4.56	8.32e-06	0.004	0.29	0.29	IgG glycosylation;	chr3:128866864	chr3:128861313~128871540:-
SARC	cis	rs4639966	0.589	rs480958	ENSG00000255422.1	AP002954.4	-4.56	8.33e-06	0.004	-0.3	-0.29	Systemic lupus erythematosus;	chr11:118707281	chr11:118704607~118750263:+
SARC	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-4.56	8.33e-06	0.004	-0.3	-0.29	Height;	chr3:52949886	chr3:53064283~53065091:-
SARC	cis	rs910316	1	rs7303	ENSG00000279594.1	RP11-950C14.10	4.56	8.34e-06	0.00401	0.31	0.29	Height;	chr14:75053362	chr14:75011269~75012851:-
SARC	cis	rs910316	1	rs10143132	ENSG00000279594.1	RP11-950C14.10	4.56	8.34e-06	0.00401	0.31	0.29	Height;	chr14:75059147	chr14:75011269~75012851:-
SARC	cis	rs2439831	0.717	rs10518820	ENSG00000205771.5	CATSPER2P1	-4.56	8.35e-06	0.00401	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43596778	chr15:43726918~43747094:-
SARC	cis	rs1075232	1	rs12437749	ENSG00000215302.7	CTD-3092A11.1	-4.56	8.35e-06	0.00401	-0.61	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30470779~30507623:+
SARC	cis	rs10906115	1	rs10906115	ENSG00000228302.2	RP11-186N15.3	4.56	8.36e-06	0.00401	0.21	0.29	Type 2 diabetes;	chr10:12272998	chr10:12244751~12247845:-
SARC	cis	rs10911902	0.601	rs16825279	ENSG00000229739.2	RP11-295K2.3	-4.56	8.36e-06	0.00401	-0.42	-0.29	Schizophrenia;	chr1:186385523	chr1:186435161~186470291:+
SARC	cis	rs4919687	0.55	rs11191371	ENSG00000213061.2	PFN1P11	4.56	8.36e-06	0.00402	0.36	0.29	Colorectal cancer;	chr10:102700140	chr10:102838011~102845473:-
SARC	cis	rs5769707	0.542	rs739242	ENSG00000235111.1	RP1-29C18.8	-4.56	8.36e-06	0.00402	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49612657~49615716:-
SARC	cis	rs5769707	0.521	rs7285764	ENSG00000235111.1	RP1-29C18.8	-4.56	8.36e-06	0.00402	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49612657~49615716:-
SARC	cis	rs5769707	0.521	rs9616715	ENSG00000235111.1	RP1-29C18.8	-4.56	8.36e-06	0.00402	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49612657~49615716:-
SARC	cis	rs5769707	0.521	rs6009805	ENSG00000235111.1	RP1-29C18.8	-4.56	8.36e-06	0.00402	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49612657~49615716:-
SARC	cis	rs5769707	0.521	rs6009807	ENSG00000235111.1	RP1-29C18.8	-4.56	8.36e-06	0.00402	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49612657~49615716:-
SARC	cis	rs56116382	0.604	rs9858428	ENSG00000225399.4	RP11-3B7.1	-4.56	8.38e-06	0.00402	-0.59	-0.29	High light scatter reticulocyte count;Intelligence (multi-trait analysis);	chr3:49840152	chr3:49260085~49261316:+
SARC	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	4.56	8.39e-06	0.00403	0.51	0.29	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
SARC	cis	rs520525	0.963	rs552277	ENSG00000271811.1	RP1-79C4.4	4.56	8.39e-06	0.00403	0.39	0.29	Atrial fibrillation;	chr1:170658653	chr1:170667381~170669425:+
SARC	cis	rs8062405	0.824	rs4788084	ENSG00000251417.2	RP11-1348G14.4	-4.56	8.4e-06	0.00403	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28802743~28817828:+
SARC	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-4.56	8.41e-06	0.00404	-0.35	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
SARC	cis	rs2933343	0.621	rs789241	ENSG00000231305.3	RP11-723O4.2	4.56	8.41e-06	0.00404	0.28	0.29	IgG glycosylation;	chr3:128866909	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.649	rs2638845	ENSG00000231305.3	RP11-723O4.2	4.56	8.41e-06	0.00404	0.28	0.29	IgG glycosylation;	chr3:128868526	chr3:128861313~128871540:-
SARC	cis	rs910316	1	rs12897094	ENSG00000279594.1	RP11-950C14.10	4.56	8.41e-06	0.00404	0.31	0.29	Height;	chr14:75112713	chr14:75011269~75012851:-
SARC	cis	rs964184	0.554	rs7118999	ENSG00000254851.1	RP11-109L13.1	-4.56	8.41e-06	0.00404	-0.35	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116774559	chr11:117135528~117138582:+
SARC	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-4.56	8.42e-06	0.00404	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
SARC	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	4.56	8.42e-06	0.00404	0.22	0.29	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
SARC	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-4.56	8.42e-06	0.00404	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-4.56	8.42e-06	0.00404	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-4.56	8.42e-06	0.00404	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-4.56	8.42e-06	0.00404	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
SARC	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	4.56	8.43e-06	0.00405	0.37	0.29	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
SARC	cis	rs4664293	0.51	rs66537229	ENSG00000226266.5	AC009961.3	4.56	8.43e-06	0.00405	0.36	0.29	Monocyte percentage of white cells;	chr2:159624095	chr2:159670708~159712435:-
SARC	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	4.56	8.44e-06	0.00405	0.27	0.29	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
SARC	cis	rs253959	0.502	rs10478275	ENSG00000272265.1	CTD-2287O16.4	4.56	8.44e-06	0.00405	0.33	0.29	Bipolar disorder and schizophrenia;	chr5:116092399	chr5:116078110~116078570:-
SARC	cis	rs12550612	0.614	rs11135696	ENSG00000253616.4	RP11-875O11.3	4.56	8.45e-06	0.00405	0.37	0.29	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084410	chr8:23071377~23074488:-
SARC	cis	rs12049351	0.774	rs12117468	ENSG00000229367.1	HMGN2P19	4.55	8.45e-06	0.00405	0.24	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229535614	chr1:229570532~229570796:+
SARC	cis	rs17508449	0.819	rs6678422	ENSG00000232450.1	RP4-730K3.3	-4.55	8.45e-06	0.00405	-0.36	-0.29	Leprosy;	chr1:113662078	chr1:113698884~113699631:-
SARC	cis	rs7772486	0.625	rs9390355	ENSG00000235652.6	RP11-545I5.3	-4.55	8.46e-06	0.00406	-0.26	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.658	rs4895683	ENSG00000235652.6	RP11-545I5.3	-4.55	8.46e-06	0.00406	-0.26	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.625	rs2050027	ENSG00000235652.6	RP11-545I5.3	-4.55	8.46e-06	0.00406	-0.26	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145799409~145886585:+
SARC	cis	rs79349575	0.783	rs58591767	ENSG00000270781.1	RP11-501C14.9	-4.55	8.47e-06	0.00406	-0.33	-0.29	Type 2 diabetes;	chr17:48948714	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs59270107	ENSG00000270781.1	RP11-501C14.9	-4.55	8.47e-06	0.00406	-0.33	-0.29	Type 2 diabetes;	chr17:48948823	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs62078370	ENSG00000270781.1	RP11-501C14.9	-4.55	8.47e-06	0.00406	-0.33	-0.29	Type 2 diabetes;	chr17:48949474	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs11079844	ENSG00000270781.1	RP11-501C14.9	-4.55	8.47e-06	0.00406	-0.33	-0.29	Type 2 diabetes;	chr17:48950972	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs62078372	ENSG00000270781.1	RP11-501C14.9	-4.55	8.47e-06	0.00406	-0.33	-0.29	Type 2 diabetes;	chr17:48951627	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs12602933	ENSG00000270781.1	RP11-501C14.9	-4.55	8.47e-06	0.00406	-0.33	-0.29	Type 2 diabetes;	chr17:48951918	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs4794003	ENSG00000270781.1	RP11-501C14.9	-4.55	8.47e-06	0.00406	-0.33	-0.29	Type 2 diabetes;	chr17:48952542	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.783	rs12602746	ENSG00000270781.1	RP11-501C14.9	-4.55	8.47e-06	0.00406	-0.33	-0.29	Type 2 diabetes;	chr17:48954379	chr17:48899131~48899748:+
SARC	cis	rs890448	0.93	rs6532938	ENSG00000254531.1	FLJ20021	4.55	8.48e-06	0.00406	0.28	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101468422	chr4:101347780~101348883:+
SARC	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	4.55	8.48e-06	0.00406	0.34	0.29	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
SARC	cis	rs2439831	0.85	rs2957637	ENSG00000205771.5	CATSPER2P1	-4.55	8.5e-06	0.00407	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43658920	chr15:43726918~43747094:-
SARC	cis	rs2404602	0.735	rs2048856	ENSG00000259422.1	RP11-593F23.1	-4.55	8.5e-06	0.00407	-0.35	-0.29	Blood metabolite levels;	chr15:76507742	chr15:76174891~76181486:-
SARC	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	4.55	8.51e-06	0.00408	0.35	0.29	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
SARC	cis	rs14027	0.921	rs35496588	ENSG00000279347.1	RP11-85I17.2	4.55	8.52e-06	0.00408	0.26	0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119842461	chr8:119838736~119840385:-
SARC	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	4.55	8.52e-06	0.00408	0.33	0.29	QT interval;	chr12:29284120	chr12:29280418~29317848:-
SARC	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-4.55	8.52e-06	0.00408	-0.39	-0.29	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
SARC	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-4.55	8.53e-06	0.00408	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
SARC	cis	rs7131987	0.65	rs67146951	ENSG00000257176.2	RP11-996F15.2	-4.55	8.54e-06	0.00409	-0.33	-0.29	QT interval;	chr12:29297620	chr12:29280418~29317848:-
SARC	cis	rs910316	0.967	rs8013444	ENSG00000279594.1	RP11-950C14.10	-4.55	8.56e-06	0.00409	-0.31	-0.29	Height;	chr14:75195278	chr14:75011269~75012851:-
SARC	cis	rs910316	0.737	rs175084	ENSG00000279594.1	RP11-950C14.10	-4.55	8.56e-06	0.0041	-0.32	-0.29	Height;	chr14:75052472	chr14:75011269~75012851:-
SARC	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-4.55	8.57e-06	0.0041	-0.41	-0.29	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
SARC	cis	rs4664293	0.546	rs12469866	ENSG00000226266.5	AC009961.3	4.55	8.58e-06	0.0041	0.33	0.29	Monocyte percentage of white cells;	chr2:159766119	chr2:159670708~159712435:-
SARC	cis	rs7772486	0.719	rs702317	ENSG00000270638.1	RP3-466P17.1	-4.55	8.58e-06	0.00411	-0.23	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.72	rs702320	ENSG00000270638.1	RP3-466P17.1	-4.55	8.58e-06	0.00411	-0.23	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.72	rs4896837	ENSG00000270638.1	RP3-466P17.1	-4.55	8.58e-06	0.00411	-0.23	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145735570~145737218:+
SARC	cis	rs853679	0.766	rs9368561	ENSG00000219392.1	RP1-265C24.5	-4.55	8.59e-06	0.00411	-0.56	-0.29	Depression;	chr6:28200565	chr6:28115628~28116551:+
SARC	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-4.55	8.6e-06	0.00411	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
SARC	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-4.55	8.62e-06	0.00412	-0.25	-0.29	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
SARC	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-4.55	8.62e-06	0.00412	-0.43	-0.29	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
SARC	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	4.55	8.63e-06	0.00413	0.31	0.29	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	4.55	8.63e-06	0.00413	0.31	0.29	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
SARC	cis	rs4703855	0.538	rs4446432	ENSG00000244061.1	RP11-389C8.1	4.55	8.63e-06	0.00413	0.29	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72429229	chr5:72381794~72382393:+
SARC	cis	rs8062405	0.824	rs62034319	ENSG00000251417.2	RP11-1348G14.4	-4.55	8.63e-06	0.00413	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.824	rs28698667	ENSG00000251417.2	RP11-1348G14.4	-4.55	8.63e-06	0.00413	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28802743~28817828:+
SARC	cis	rs890448	0.826	rs6532939	ENSG00000254531.1	FLJ20021	-4.55	8.64e-06	0.00413	-0.28	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101478052	chr4:101347780~101348883:+
SARC	cis	rs4703855	0.538	rs10462377	ENSG00000244061.1	RP11-389C8.1	-4.55	8.65e-06	0.00413	-0.29	-0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72403237	chr5:72381794~72382393:+
SARC	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	4.55	8.65e-06	0.00413	0.23	0.29	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	4.55	8.65e-06	0.00413	0.23	0.29	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
SARC	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	4.55	8.65e-06	0.00413	0.35	0.29	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
SARC	cis	rs2803122	0.871	rs3802333	ENSG00000273226.1	RP11-513M16.8	-4.55	8.66e-06	0.00414	-0.27	-0.29	Pulse pressure;	chr9:19232137	chr9:19375451~19375996:+
SARC	cis	rs2239557	1	rs4903201	ENSG00000259065.1	RP5-1021I20.1	4.55	8.68e-06	0.00415	0.33	0.29	Common traits (Other);	chr14:74192987	chr14:73787360~73803270:+
SARC	cis	rs2239557	1	rs10140433	ENSG00000259065.1	RP5-1021I20.1	4.55	8.68e-06	0.00415	0.33	0.29	Common traits (Other);	chr14:74193286	chr14:73787360~73803270:+
SARC	cis	rs2239557	1	rs4903202	ENSG00000259065.1	RP5-1021I20.1	4.55	8.68e-06	0.00415	0.33	0.29	Common traits (Other);	chr14:74193599	chr14:73787360~73803270:+
SARC	cis	rs2239557	1	rs4903203	ENSG00000259065.1	RP5-1021I20.1	4.55	8.68e-06	0.00415	0.33	0.29	Common traits (Other);	chr14:74193805	chr14:73787360~73803270:+
SARC	cis	rs321358	1	rs321357	ENSG00000271584.1	RP11-89C3.4	4.55	8.69e-06	0.00415	0.52	0.29	Body mass index;	chr11:111125002	chr11:111091932~111097357:-
SARC	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	4.55	8.7e-06	0.00415	0.24	0.29	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
SARC	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	4.55	8.72e-06	0.00416	0.49	0.29	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
SARC	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-4.55	8.73e-06	0.00417	-0.32	-0.29	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs16940	ENSG00000267681.1	CTD-3199J23.6	-4.55	8.73e-06	0.00417	-0.32	-0.29	Menopause (age at onset);	chr17:43093220	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.93	rs66499067	ENSG00000267681.1	CTD-3199J23.6	-4.55	8.73e-06	0.00417	-0.32	-0.29	Menopause (age at onset);	chr17:43096467	chr17:43144956~43145255:+
SARC	cis	rs9818758	0.607	rs73082362	ENSG00000225399.4	RP11-3B7.1	-4.55	8.73e-06	0.00417	-0.59	-0.29	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076296	chr3:49260085~49261316:+
SARC	cis	rs9309473	0.583	rs6705203	ENSG00000163016.8	ALMS1P	4.55	8.74e-06	0.00417	0.35	0.29	Metabolite levels;	chr2:73347472	chr2:73644919~73685576:+
SARC	cis	rs6969780	0.915	rs3807597	ENSG00000233429.8	HOTAIRM1	-4.55	8.74e-06	0.00417	-0.41	-0.29	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149576	chr7:27095647~27100265:+
SARC	cis	rs6969780	0.915	rs12666926	ENSG00000233429.8	HOTAIRM1	-4.55	8.74e-06	0.00417	-0.41	-0.29	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149942	chr7:27095647~27100265:+
SARC	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-4.55	8.75e-06	0.00418	-0.3	-0.29	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
SARC	cis	rs2439831	1	rs561863	ENSG00000205771.5	CATSPER2P1	-4.55	8.75e-06	0.00418	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43469154	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs689596	ENSG00000205771.5	CATSPER2P1	-4.55	8.75e-06	0.00418	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43469519	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs689616	ENSG00000205771.5	CATSPER2P1	-4.55	8.75e-06	0.00418	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43469703	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs689647	ENSG00000205771.5	CATSPER2P1	-4.55	8.75e-06	0.00418	-0.43	-0.29	Lung cancer in ever smokers;	chr15:43469998	chr15:43726918~43747094:-
SARC	cis	rs1823913	1	rs12623832	ENSG00000280083.1	RP11-317J9.1	4.55	8.75e-06	0.00418	0.32	0.29	Obesity-related traits;	chr2:191260918	chr2:191154118~191156070:-
SARC	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	4.55	8.75e-06	0.00418	0.34	0.29	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
SARC	cis	rs9828933	0.752	rs12633353	ENSG00000280620.1	SCAANT1	4.55	8.76e-06	0.00418	0.53	0.29	Type 2 diabetes;	chr3:63984604	chr3:63911518~63911772:-
SARC	cis	rs4835473	0.932	rs17018238	ENSG00000251600.4	RP11-673E1.1	-4.55	8.76e-06	0.00418	-0.28	-0.29	Immature fraction of reticulocytes;	chr4:143782737	chr4:143912331~143982454:+
SARC	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-4.55	8.77e-06	0.00419	-0.32	-0.29	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
SARC	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	4.55	8.77e-06	0.00419	0.29	0.29	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
SARC	cis	rs4703855	0.538	rs2338217	ENSG00000244061.1	RP11-389C8.1	4.55	8.78e-06	0.00419	0.29	0.29	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72410136	chr5:72381794~72382393:+
SARC	cis	rs7267979	1	rs1888999	ENSG00000276952.1	RP5-965G21.6	4.55	8.78e-06	0.00419	0.28	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:25284915~25285588:-
SARC	cis	rs1635	0.574	rs7757215	ENSG00000219392.1	RP1-265C24.5	4.55	8.78e-06	0.00419	0.72	0.29	Schizophrenia;	chr6:28244711	chr6:28115628~28116551:+
SARC	cis	rs882252	0.749	rs725033	ENSG00000232480.1	TGFB2-AS1	-4.55	8.79e-06	0.00419	-0.37	-0.29	Post bronchodilator FEV1/FVC ratio;	chr1:218470598	chr1:218344196~218345678:-
SARC	cis	rs11634944	0.716	rs2732045	ENSG00000274307.1	RP11-345J18.2	-4.55	8.81e-06	0.0042	-0.36	-0.29	Interleukin-8 levels;	chr15:25036707	chr15:25708470~25710869:-
SARC	cis	rs910316	0.737	rs175055	ENSG00000279594.1	RP11-950C14.10	-4.55	8.82e-06	0.0042	-0.32	-0.29	Height;	chr14:75022243	chr14:75011269~75012851:-
SARC	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-4.55	8.82e-06	0.00421	-0.34	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
SARC	cis	rs7267979	1	rs2500443	ENSG00000276952.1	RP5-965G21.6	-4.54	8.83e-06	0.00421	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2482928	ENSG00000276952.1	RP5-965G21.6	-4.54	8.83e-06	0.00421	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2482930	ENSG00000276952.1	RP5-965G21.6	-4.54	8.83e-06	0.00421	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2500446	ENSG00000276952.1	RP5-965G21.6	-4.54	8.83e-06	0.00421	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25284915~25285588:-
SARC	cis	rs12200782	0.79	rs72840194	ENSG00000272810.1	U91328.22	-4.54	8.84e-06	0.00421	-0.48	-0.29	Small cell lung carcinoma;	chr6:26361141	chr6:26013241~26013757:+
SARC	cis	rs2933343	0.679	rs1091938	ENSG00000261159.1	RP11-723O4.9	4.54	8.84e-06	0.00421	0.31	0.29	IgG glycosylation;	chr3:128918182	chr3:128859716~128860526:-
SARC	cis	rs57561814	1	rs57561814	ENSG00000179428.2	AC073072.5	-4.54	8.85e-06	0.00422	-0.53	-0.29	Tonsillectomy;	chr7:22714056	chr7:22725395~22727620:-
SARC	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	4.54	8.88e-06	0.00423	0.33	0.29	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
SARC	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	4.54	8.89e-06	0.00424	0.24	0.29	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	4.54	8.89e-06	0.00424	0.24	0.29	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
SARC	cis	rs62034325	0.697	rs710410	ENSG00000251417.2	RP11-1348G14.4	-4.54	8.89e-06	0.00424	-0.29	-0.29	Body mass index;	chr16:28592021	chr16:28802743~28817828:+
SARC	cis	rs10986311	1	rs3758212	ENSG00000235204.1	RP11-121A14.2	4.54	8.89e-06	0.00424	0.33	0.29	Vitiligo;	chr9:124307474	chr9:124259250~124261156:-
SARC	cis	rs9309473	0.687	rs10165862	ENSG00000163016.8	ALMS1P	4.54	8.9e-06	0.00424	0.34	0.29	Metabolite levels;	chr2:73383615	chr2:73644919~73685576:+
SARC	cis	rs8064029	0.803	rs11861487	ENSG00000267077.1	RP11-127I20.5	-4.54	8.91e-06	0.00424	-0.5	-0.29	Cancer;	chr16:4822759	chr16:4795265~4796532:-
SARC	cis	rs2274273	0.967	rs2340931	ENSG00000258413.1	RP11-665C16.6	-4.54	8.93e-06	0.00425	-0.34	-0.29	Protein biomarker;	chr14:55150219	chr14:55262767~55272075:-
SARC	cis	rs9318086	0.776	rs1326130	ENSG00000205861.10	C1QTNF9B-AS1	-4.54	8.93e-06	0.00425	-0.32	-0.29	Myopia (pathological);	chr13:23873525	chr13:23888889~23897263:+
SARC	cis	rs2288884	0.581	rs9636144	ENSG00000275055.1	CTC-471J1.11	-4.54	8.95e-06	0.00426	-0.31	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:52049007~52049754:+
SARC	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	4.54	8.96e-06	0.00427	0.31	0.29	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
SARC	cis	rs890448	0.895	rs2465896	ENSG00000254531.1	FLJ20021	-4.54	8.97e-06	0.00427	-0.28	-0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101463875	chr4:101347780~101348883:+
SARC	cis	rs12049351	0.83	rs12042088	ENSG00000229367.1	HMGN2P19	4.54	8.97e-06	0.00427	0.26	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229582388	chr1:229570532~229570796:+
SARC	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	4.54	8.98e-06	0.00427	0.25	0.29	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
SARC	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	4.54	8.98e-06	0.00428	0.31	0.29	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
SARC	cis	rs7811142	1	rs6953107	ENSG00000078319.8	PMS2P1	-4.54	8.99e-06	0.00428	-0.41	-0.29	Platelet count;	chr7:100498041	chr7:100320992~100341908:-
SARC	cis	rs9309473	0.519	rs2421586	ENSG00000163016.8	ALMS1P	-4.54	9.01e-06	0.00429	-0.32	-0.29	Metabolite levels;	chr2:73672592	chr2:73644919~73685576:+
SARC	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-4.54	9.02e-06	0.00429	-0.42	-0.29	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
SARC	cis	rs524281	1	rs527897	ENSG00000255320.1	RP11-755F10.1	4.54	9.02e-06	0.00429	0.39	0.29	Electroencephalogram traits;	chr11:66133306	chr11:66244840~66246239:-
SARC	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-4.54	9.02e-06	0.00429	-0.33	-0.29	QT interval;	chr12:29306357	chr12:29280418~29317848:-
SARC	cis	rs2439831	0.85	rs28590651	ENSG00000275601.1	AC011330.13	-4.54	9.03e-06	0.00429	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43820818	chr15:43642389~43643023:-
SARC	cis	rs4794202	0.609	rs4794318	ENSG00000264920.1	RP11-6N17.4	-4.54	9.03e-06	0.00429	-0.44	-0.29	Alzheimer's disease (cognitive decline);	chr17:47950705	chr17:47891255~47895812:-
SARC	cis	rs732716	0.785	rs7769	ENSG00000267980.1	AC007292.6	-4.54	9.03e-06	0.00429	-0.4	-0.29	Mean corpuscular volume;	chr19:4360546	chr19:4363789~4364640:+
SARC	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-4.54	9.03e-06	0.0043	-0.39	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
SARC	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-4.54	9.04e-06	0.0043	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
SARC	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-4.54	9.04e-06	0.0043	-0.34	-0.29	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
SARC	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-4.54	9.05e-06	0.0043	-0.29	-0.29	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
SARC	cis	rs2303759	0.676	rs10426452	ENSG00000268686.1	AC010524.2	-4.54	9.05e-06	0.0043	-0.33	-0.29	Multiple sclerosis;	chr19:49404433	chr19:49368705~49388081:-
SARC	cis	rs7615952	0.611	rs72979452	ENSG00000250012.1	RP11-124N2.1	-4.54	9.05e-06	0.0043	-0.39	-0.29	Blood pressure (smoking interaction);	chr3:126037335	chr3:126084220~126095349:+
SARC	cis	rs12893668	0.703	rs4906337	ENSG00000269940.1	RP11-73M18.7	4.54	9.06e-06	0.00431	0.28	0.29	Reticulocyte count;	chr14:103574077	chr14:103694560~103695170:+
SARC	cis	rs12893668	0.703	rs7140568	ENSG00000269940.1	RP11-73M18.7	4.54	9.06e-06	0.00431	0.28	0.29	Reticulocyte count;	chr14:103575037	chr14:103694560~103695170:+
SARC	cis	rs12893668	0.703	rs35026580	ENSG00000269940.1	RP11-73M18.7	4.54	9.06e-06	0.00431	0.28	0.29	Reticulocyte count;	chr14:103576416	chr14:103694560~103695170:+
SARC	cis	rs9527	0.545	rs35756290	ENSG00000213061.2	PFN1P11	4.54	9.06e-06	0.00431	0.37	0.29	Arsenic metabolism;	chr10:102825815	chr10:102838011~102845473:-
SARC	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-4.54	9.06e-06	0.00431	-0.31	-0.29	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
SARC	cis	rs71327718	1	rs71327718	ENSG00000248787.1	RP11-666A20.4	-4.54	9.06e-06	0.00431	-0.49	-0.29	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125908005~125910272:-
SARC	cis	rs9625935	0.748	rs1468177	ENSG00000227201.2	CNN2P1	4.54	9.06e-06	0.00431	0.29	0.29	Tonsillectomy;	chr22:30148570	chr22:30046276~30047193:-
SARC	cis	rs4835473	0.8	rs1849134	ENSG00000251600.4	RP11-673E1.1	4.54	9.07e-06	0.00431	0.28	0.29	Immature fraction of reticulocytes;	chr4:143958260	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.8	rs1849133	ENSG00000251600.4	RP11-673E1.1	4.54	9.07e-06	0.00431	0.28	0.29	Immature fraction of reticulocytes;	chr4:143958262	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.864	rs1849132	ENSG00000251600.4	RP11-673E1.1	4.54	9.07e-06	0.00431	0.28	0.29	Immature fraction of reticulocytes;	chr4:143958309	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs13123407	ENSG00000251600.4	RP11-673E1.1	4.54	9.07e-06	0.00431	0.28	0.29	Immature fraction of reticulocytes;	chr4:143958713	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs61611095	ENSG00000251600.4	RP11-673E1.1	4.54	9.07e-06	0.00431	0.28	0.29	Immature fraction of reticulocytes;	chr4:143958802	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs4835449	ENSG00000251600.4	RP11-673E1.1	4.54	9.07e-06	0.00431	0.28	0.29	Immature fraction of reticulocytes;	chr4:143958830	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1838516	ENSG00000251600.4	RP11-673E1.1	4.54	9.07e-06	0.00431	0.28	0.29	Immature fraction of reticulocytes;	chr4:143962082	chr4:143912331~143982454:+
SARC	cis	rs75920871	0.588	rs721783	ENSG00000254851.1	RP11-109L13.1	4.54	9.07e-06	0.00431	0.4	0.29	Subjective well-being;	chr11:117036733	chr11:117135528~117138582:+
SARC	cis	rs8062405	0.755	rs17640009	ENSG00000251417.2	RP11-1348G14.4	-4.54	9.09e-06	0.00432	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28802743~28817828:+
SARC	cis	rs7267979	1	rs6107033	ENSG00000276952.1	RP5-965G21.6	-4.54	9.09e-06	0.00432	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25284915~25285588:-
SARC	cis	rs1823913	0.525	rs7424440	ENSG00000227542.1	AC092614.2	4.54	9.09e-06	0.00432	0.33	0.28	Obesity-related traits;	chr2:191337919	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.526	rs35340557	ENSG00000227542.1	AC092614.2	4.54	9.09e-06	0.00432	0.33	0.28	Obesity-related traits;	chr2:191338688	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.503	rs35562914	ENSG00000227542.1	AC092614.2	4.54	9.09e-06	0.00432	0.33	0.28	Obesity-related traits;	chr2:191338969	chr2:191229165~191246172:-
SARC	cis	rs7031325	0.962	rs2578283	ENSG00000229611.1	RP11-390F4.10	-4.54	9.09e-06	0.00432	-0.32	-0.28	Systemic lupus erythematosus;	chr9:6652997	chr9:6704471~6707780:+
SARC	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	4.54	9.09e-06	0.00432	0.44	0.28	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
SARC	cis	rs792448	0.545	rs6679796	ENSG00000229983.1	RP11-15I11.2	4.54	9.1e-06	0.00432	0.3	0.28	White blood cell count (basophil);	chr1:212229182	chr1:212168207~212190259:+
SARC	cis	rs9309473	0.632	rs6546825	ENSG00000163016.8	ALMS1P	4.54	9.11e-06	0.00433	0.35	0.28	Metabolite levels;	chr2:73365125	chr2:73644919~73685576:+
SARC	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-4.54	9.11e-06	0.00433	-0.42	-0.28	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
SARC	cis	rs595244	0.706	rs4775770	ENSG00000259705.1	RP11-227D13.1	-4.54	9.11e-06	0.00433	-0.47	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48652366	chr15:48645951~48652016:+
SARC	cis	rs6570726	0.791	rs443628	ENSG00000270638.1	RP3-466P17.1	4.54	9.11e-06	0.00433	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145735570~145737218:+
SARC	cis	rs7809950	0.817	rs34325395	ENSG00000238832.1	snoU109	-4.54	9.12e-06	0.00433	-0.34	-0.28	Coronary artery disease;	chr7:107473363	chr7:107603363~107603507:+
SARC	cis	rs17508449	0.819	rs77892281	ENSG00000232450.1	RP4-730K3.3	-4.54	9.12e-06	0.00433	-0.36	-0.28	Leprosy;	chr1:113620995	chr1:113698884~113699631:-
SARC	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-4.54	9.12e-06	0.00433	-0.29	-0.28	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
SARC	cis	rs1707322	0.789	rs7540578	ENSG00000281133.1	AL355480.3	-4.54	9.13e-06	0.00433	-0.32	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45580892~45580996:-
SARC	cis	rs10754283	0.967	rs10922679	ENSG00000231613.1	RP5-943J3.1	4.54	9.14e-06	0.00434	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89635366	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.935	rs10801756	ENSG00000231613.1	RP5-943J3.1	4.54	9.14e-06	0.00434	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89636273	chr1:89788914~89790492:+
SARC	cis	rs763121	1	rs138464	ENSG00000273076.1	RP3-508I15.22	-4.54	9.14e-06	0.00434	-0.3	-0.28	Menopause (age at onset);	chr22:38510427	chr22:38743495~38743910:+
SARC	cis	rs17767294	1	rs17767294	ENSG00000219392.1	RP1-265C24.5	-4.54	9.15e-06	0.00434	-0.61	-0.28	Parkinson's disease;	chr6:28086420	chr6:28115628~28116551:+
SARC	cis	rs1707322	0.752	rs11211145	ENSG00000281133.1	AL355480.3	-4.54	9.18e-06	0.00435	-0.35	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45580892~45580996:-
SARC	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-4.54	9.18e-06	0.00435	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
SARC	cis	rs2274273	0.588	rs2297816	ENSG00000258413.1	RP11-665C16.6	-4.54	9.18e-06	0.00435	-0.34	-0.28	Protein biomarker;	chr14:55366320	chr14:55262767~55272075:-
SARC	cis	rs7216064	0.531	rs62084683	ENSG00000278740.1	RP11-147L13.14	-4.54	9.19e-06	0.00436	-0.3	-0.28	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68035609	chr17:68188547~68189165:+
SARC	cis	rs7772486	0.806	rs7740785	ENSG00000270638.1	RP3-466P17.1	4.54	9.19e-06	0.00436	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145735570~145737218:+
SARC	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	4.54	9.2e-06	0.00436	0.24	0.28	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	4.54	9.2e-06	0.00436	0.24	0.28	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
SARC	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-4.54	9.21e-06	0.00437	-0.31	-0.28	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
SARC	cis	rs7181230	1	rs9972424	ENSG00000275636.1	RP11-521C20.5	4.53	9.22e-06	0.00437	0.33	0.28	Dehydroepiandrosterone sulphate levels;	chr15:40073650	chr15:40078892~40079347:+
SARC	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-4.53	9.23e-06	0.00437	-0.27	-0.28	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
SARC	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-4.53	9.23e-06	0.00437	-0.33	-0.28	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
SARC	cis	rs4835473	0.932	rs10016223	ENSG00000251600.4	RP11-673E1.1	4.53	9.24e-06	0.00438	0.28	0.28	Immature fraction of reticulocytes;	chr4:143777429	chr4:143912331~143982454:+
SARC	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-4.53	9.24e-06	0.00438	-0.31	-0.28	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
SARC	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-4.53	9.24e-06	0.00438	-0.31	-0.28	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
SARC	cis	rs73186030	0.844	rs73186015	ENSG00000272758.4	RP11-299J3.8	4.53	9.24e-06	0.00438	0.42	0.28	Serum parathyroid hormone levels;	chr3:122272236	chr3:122416207~122443180:+
SARC	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	4.53	9.24e-06	0.00438	0.23	0.28	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
SARC	cis	rs7216064	0.906	rs7223643	ENSG00000265055.1	AC145343.2	4.53	9.25e-06	0.00438	0.37	0.28	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67834166	chr17:68096046~68101474:-
SARC	cis	rs801193	1	rs2707836	ENSG00000236529.1	RP13-254B10.1	4.53	9.25e-06	0.00438	0.29	0.28	Aortic root size;	chr7:66695448	chr7:65840212~65840596:+
SARC	cis	rs801193	1	rs4717310	ENSG00000236529.1	RP13-254B10.1	4.53	9.25e-06	0.00438	0.29	0.28	Aortic root size;	chr7:66696020	chr7:65840212~65840596:+
SARC	cis	rs27434	0.821	rs28337	ENSG00000272109.1	CTD-2260A17.3	-4.53	9.26e-06	0.00439	-0.37	-0.28	Ankylosing spondylitis;	chr5:96789611	chr5:96804353~96806105:+
SARC	cis	rs853679	1	rs7740487	ENSG00000219392.1	RP1-265C24.5	-4.53	9.27e-06	0.00439	-0.51	-0.28	Depression;	chr6:28248708	chr6:28115628~28116551:+
SARC	cis	rs853679	1	rs68141011	ENSG00000219392.1	RP1-265C24.5	-4.53	9.27e-06	0.00439	-0.51	-0.28	Depression;	chr6:28250019	chr6:28115628~28116551:+
SARC	cis	rs853679	1	rs13200462	ENSG00000219392.1	RP1-265C24.5	-4.53	9.27e-06	0.00439	-0.51	-0.28	Depression;	chr6:28250421	chr6:28115628~28116551:+
SARC	cis	rs7255436	0.965	rs62117510	ENSG00000269386.4	RAB11B-AS1	4.53	9.27e-06	0.00439	0.28	0.28	HDL cholesterol;	chr19:8387729	chr19:8374373~8390685:-
SARC	cis	rs7255436	0.965	rs28729307	ENSG00000269386.4	RAB11B-AS1	4.53	9.27e-06	0.00439	0.28	0.28	HDL cholesterol;	chr19:8387858	chr19:8374373~8390685:-
SARC	cis	rs7255436	0.894	rs10413136	ENSG00000269386.4	RAB11B-AS1	4.53	9.27e-06	0.00439	0.28	0.28	HDL cholesterol;	chr19:8387995	chr19:8374373~8390685:-
SARC	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	4.53	9.28e-06	0.00439	0.35	0.28	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
SARC	cis	rs801193	0.844	rs7779971	ENSG00000236529.1	RP13-254B10.1	4.53	9.28e-06	0.0044	0.3	0.28	Aortic root size;	chr7:66696803	chr7:65840212~65840596:+
SARC	cis	rs7772486	0.79	rs2243665	ENSG00000270638.1	RP3-466P17.1	4.53	9.28e-06	0.0044	0.24	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145886984	chr6:145735570~145737218:+
SARC	cis	rs8005677	0.828	rs2295682	ENSG00000257285.4	RP11-298I3.1	4.53	9.29e-06	0.0044	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:22929609~22955562:+
SARC	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	4.53	9.29e-06	0.0044	0.24	0.28	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
SARC	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	4.53	9.31e-06	0.00441	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	4.53	9.31e-06	0.00441	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
SARC	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-4.53	9.32e-06	0.00441	-0.36	-0.28	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
SARC	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-4.53	9.32e-06	0.00441	-0.33	-0.28	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-4.53	9.32e-06	0.00441	-0.33	-0.28	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
SARC	cis	rs890448	0.796	rs2912483	ENSG00000254531.1	FLJ20021	4.53	9.32e-06	0.00441	0.31	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101428540	chr4:101347780~101348883:+
SARC	cis	rs526231	0.819	rs568999	ENSG00000175749.11	EIF3KP1	4.53	9.33e-06	0.00441	0.37	0.28	Primary biliary cholangitis;	chr5:103265657	chr5:103032376~103033031:+
SARC	cis	rs526231	0.819	rs411648	ENSG00000175749.11	EIF3KP1	4.53	9.33e-06	0.00441	0.37	0.28	Primary biliary cholangitis;	chr5:103267201	chr5:103032376~103033031:+
SARC	cis	rs526231	0.819	rs2569016	ENSG00000175749.11	EIF3KP1	4.53	9.33e-06	0.00441	0.37	0.28	Primary biliary cholangitis;	chr5:103267431	chr5:103032376~103033031:+
SARC	cis	rs526231	0.853	rs377192	ENSG00000175749.11	EIF3KP1	4.53	9.33e-06	0.00441	0.37	0.28	Primary biliary cholangitis;	chr5:103267853	chr5:103032376~103033031:+
SARC	cis	rs8062405	0.722	rs3785354	ENSG00000251417.2	RP11-1348G14.4	-4.53	9.34e-06	0.00442	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.755	rs4787457	ENSG00000251417.2	RP11-1348G14.4	-4.53	9.34e-06	0.00442	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28802743~28817828:+
SARC	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-4.53	9.34e-06	0.00442	-0.28	-0.28	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
SARC	cis	rs42490	0.868	rs12675281	ENSG00000251136.7	RP11-37B2.1	4.53	9.34e-06	0.00442	0.32	0.28	Leprosy;	chr8:89681561	chr8:89609409~89757727:-
SARC	cis	rs10986311	0.851	rs10760345	ENSG00000235204.1	RP11-121A14.2	4.53	9.36e-06	0.00443	0.33	0.28	Vitiligo;	chr9:124275517	chr9:124259250~124261156:-
SARC	cis	rs910316	1	rs10146482	ENSG00000279594.1	RP11-950C14.10	4.53	9.37e-06	0.00443	0.3	0.28	Height;	chr14:75107384	chr14:75011269~75012851:-
SARC	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-4.53	9.37e-06	0.00443	-0.37	-0.28	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
SARC	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	4.53	9.37e-06	0.00443	0.49	0.28	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
SARC	cis	rs8062405	0.754	rs62034323	ENSG00000251417.2	RP11-1348G14.4	-4.53	9.38e-06	0.00443	-0.27	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.824	rs62034324	ENSG00000251417.2	RP11-1348G14.4	-4.53	9.38e-06	0.00443	-0.27	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.824	rs62034326	ENSG00000251417.2	RP11-1348G14.4	-4.53	9.38e-06	0.00443	-0.27	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28802743~28817828:+
SARC	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	4.53	9.38e-06	0.00444	0.27	0.28	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
SARC	cis	rs2933343	1	rs2933343	ENSG00000261159.1	RP11-723O4.9	4.53	9.39e-06	0.00444	0.34	0.28	IgG glycosylation;	chr3:128939649	chr3:128859716~128860526:-
SARC	cis	rs910316	1	rs7156328	ENSG00000279594.1	RP11-950C14.10	4.53	9.41e-06	0.00445	0.31	0.28	Height;	chr14:75066238	chr14:75011269~75012851:-
SARC	cis	rs7662987	0.793	rs12106	ENSG00000272777.1	RP11-571L19.8	4.53	9.41e-06	0.00445	0.33	0.28	Smoking initiation;	chr4:99072199	chr4:99067256~99068125:-
SARC	cis	rs7662987	0.793	rs28730632	ENSG00000272777.1	RP11-571L19.8	4.53	9.41e-06	0.00445	0.33	0.28	Smoking initiation;	chr4:99074552	chr4:99067256~99068125:-
SARC	cis	rs2933343	0.729	rs1683816	ENSG00000231305.3	RP11-723O4.2	-4.53	9.41e-06	0.00445	-0.29	-0.28	IgG glycosylation;	chr3:128932352	chr3:128861313~128871540:-
SARC	cis	rs875971	0.862	rs1860469	ENSG00000232559.3	GS1-124K5.12	-4.53	9.41e-06	0.00445	-0.35	-0.28	Aortic root size;	chr7:66641888	chr7:66554588~66576923:-
SARC	cis	rs875971	0.862	rs4718383	ENSG00000232559.3	GS1-124K5.12	-4.53	9.41e-06	0.00445	-0.35	-0.28	Aortic root size;	chr7:66643422	chr7:66554588~66576923:-
SARC	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-4.53	9.42e-06	0.00445	-0.32	-0.28	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
SARC	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-4.53	9.42e-06	0.00445	-0.32	-0.28	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
SARC	cis	rs4835473	0.897	rs11100812	ENSG00000251600.4	RP11-673E1.1	4.53	9.43e-06	0.00445	0.28	0.28	Immature fraction of reticulocytes;	chr4:143790400	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.545	rs10022856	ENSG00000251600.4	RP11-673E1.1	4.53	9.43e-06	0.00445	0.28	0.28	Immature fraction of reticulocytes;	chr4:143793157	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1842484	ENSG00000251600.4	RP11-673E1.1	4.53	9.43e-06	0.00445	0.28	0.28	Immature fraction of reticulocytes;	chr4:143793829	chr4:143912331~143982454:+
SARC	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	4.53	9.43e-06	0.00446	0.38	0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
SARC	cis	rs34375054	0.526	rs2343638	ENSG00000279233.1	RP11-158L12.4	4.53	9.44e-06	0.00446	0.32	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125192576	chr12:125138245~125141711:+
SARC	cis	rs2179367	0.959	rs9373589	ENSG00000231760.4	RP11-350J20.5	4.53	9.45e-06	0.00446	0.35	0.28	Dupuytren's disease;	chr6:149386152	chr6:149796151~149826294:-
SARC	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	4.53	9.45e-06	0.00446	0.47	0.28	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
SARC	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	4.53	9.45e-06	0.00446	0.47	0.28	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
SARC	cis	rs875971	1	rs10244498	ENSG00000232559.3	GS1-124K5.12	4.53	9.45e-06	0.00446	0.32	0.28	Aortic root size;	chr7:66651069	chr7:66554588~66576923:-
SARC	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-4.53	9.46e-06	0.00447	-0.39	-0.28	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-4.53	9.46e-06	0.00447	-0.39	-0.28	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
SARC	cis	rs4835473	0.771	rs4835097	ENSG00000251600.4	RP11-673E1.1	4.53	9.46e-06	0.00447	0.28	0.28	Immature fraction of reticulocytes;	chr4:143960687	chr4:143912331~143982454:+
SARC	cis	rs7772486	0.743	rs9390344	ENSG00000270638.1	RP3-466P17.1	-4.53	9.48e-06	0.00448	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145735570~145737218:+
SARC	cis	rs10754283	0.967	rs6428561	ENSG00000231613.1	RP5-943J3.1	4.53	9.48e-06	0.00448	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89637060	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs6428562	ENSG00000231613.1	RP5-943J3.1	4.53	9.48e-06	0.00448	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89637106	chr1:89788914~89790492:+
SARC	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	4.53	9.48e-06	0.00448	0.25	0.28	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
SARC	cis	rs4835473	0.932	rs13152209	ENSG00000251600.4	RP11-673E1.1	4.53	9.48e-06	0.00448	0.28	0.28	Immature fraction of reticulocytes;	chr4:143776088	chr4:143912331~143982454:+
SARC	cis	rs7267979	1	rs2297496	ENSG00000276952.1	RP5-965G21.6	-4.53	9.48e-06	0.00448	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25284915~25285588:-
SARC	cis	rs193541	0.53	rs2045626	ENSG00000263432.2	RN7SL689P	4.53	9.49e-06	0.00448	0.35	0.28	Glucose homeostasis traits;	chr5:122745558	chr5:123022487~123022783:-
SARC	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	4.53	9.49e-06	0.00448	0.31	0.28	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
SARC	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	4.53	9.49e-06	0.00448	0.28	0.28	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
SARC	cis	rs13434995	0.945	rs28473211	ENSG00000273257.1	RP11-177J6.1	-4.53	9.5e-06	0.00448	-0.43	-0.28	Adiponectin levels;	chr4:55615808	chr4:55387949~55388271:+
SARC	cis	rs526231	0.784	rs28157	ENSG00000175749.11	EIF3KP1	4.53	9.51e-06	0.00449	0.4	0.28	Primary biliary cholangitis;	chr5:103260136	chr5:103032376~103033031:+
SARC	cis	rs7267979	0.844	rs8184820	ENSG00000276952.1	RP5-965G21.6	-4.53	9.51e-06	0.00449	-0.26	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:25284915~25285588:-
SARC	cis	rs910316	0.967	rs4899551	ENSG00000279594.1	RP11-950C14.10	-4.53	9.52e-06	0.00449	-0.31	-0.28	Height;	chr14:75193543	chr14:75011269~75012851:-
SARC	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	4.53	9.52e-06	0.00449	0.3	0.28	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	4.53	9.52e-06	0.00449	0.3	0.28	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
SARC	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-4.53	9.52e-06	0.00449	-0.34	-0.28	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
SARC	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-4.53	9.52e-06	0.00449	-0.34	-0.28	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
SARC	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-4.53	9.52e-06	0.00449	-0.34	-0.28	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
SARC	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-4.53	9.52e-06	0.00449	-0.34	-0.28	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
SARC	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-4.53	9.52e-06	0.00449	-0.34	-0.28	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
SARC	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-4.53	9.52e-06	0.00449	-0.34	-0.28	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
SARC	cis	rs7216064	1	rs8074078	ENSG00000265055.1	AC145343.2	4.53	9.53e-06	0.0045	0.36	0.28	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67842627	chr17:68096046~68101474:-
SARC	cis	rs35160687	0.712	rs4832261	ENSG00000273080.1	RP11-301O19.1	4.53	9.54e-06	0.0045	0.3	0.28	Night sleep phenotypes;	chr2:86257375	chr2:86195590~86196049:+
SARC	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	4.53	9.54e-06	0.0045	0.24	0.28	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
SARC	cis	rs9527	0.59	rs1475642	ENSG00000213061.2	PFN1P11	-4.53	9.54e-06	0.0045	-0.37	-0.28	Arsenic metabolism;	chr10:102786426	chr10:102838011~102845473:-
SARC	cis	rs6570726	0.791	rs418701	ENSG00000270638.1	RP3-466P17.1	4.53	9.54e-06	0.0045	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145735570~145737218:+
SARC	cis	rs708547	0.581	rs6554400	ENSG00000269949.1	RP11-738E22.3	-4.53	9.55e-06	0.0045	-0.36	-0.28	Response to bleomycin (chromatid breaks);	chr4:56939140	chr4:56960927~56961373:-
SARC	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	4.53	9.57e-06	0.00451	0.35	0.28	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
SARC	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	4.53	9.57e-06	0.00451	0.35	0.28	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
SARC	cis	rs7615952	0.576	rs2276726	ENSG00000171084.14	FAM86JP	4.53	9.57e-06	0.00451	0.41	0.28	Blood pressure (smoking interaction);	chr3:126107444	chr3:125916620~125930024:+
SARC	cis	rs11651000	0.625	rs4794067	ENSG00000239291.1	RP5-867C24.1	4.53	9.58e-06	0.00452	0.35	0.28	IgG glycosylation;	chr17:47731462	chr17:47159191~47159993:-
SARC	cis	rs2288884	0.636	rs73066154	ENSG00000275055.1	CTC-471J1.11	-4.53	9.58e-06	0.00452	-0.31	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:52049007~52049754:+
SARC	cis	rs8081395	0.707	rs1024637	ENSG00000266992.1	DHX40P1	-4.53	9.6e-06	0.00452	-0.31	-0.28	White blood cell count;	chr17:59961532	chr17:59976009~60002384:-
SARC	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-4.53	9.61e-06	0.00453	-0.28	-0.28	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
SARC	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	4.53	9.62e-06	0.00453	0.31	0.28	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
SARC	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-4.53	9.62e-06	0.00453	-0.35	-0.28	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
SARC	cis	rs4664293	0.585	rs13019325	ENSG00000226266.5	AC009961.3	4.53	9.62e-06	0.00453	0.33	0.28	Monocyte percentage of white cells;	chr2:159772479	chr2:159670708~159712435:-
SARC	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-4.53	9.63e-06	0.00454	-0.35	-0.28	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-4.53	9.63e-06	0.00454	-0.35	-0.28	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-4.53	9.63e-06	0.00454	-0.35	-0.28	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
SARC	cis	rs30380	0.587	rs30185	ENSG00000272109.1	CTD-2260A17.3	-4.52	9.63e-06	0.00454	-0.37	-0.28	Cerebrospinal fluid biomarker levels;	chr5:96789762	chr5:96804353~96806105:+
SARC	cis	rs3864261	0.515	rs12186995	ENSG00000272081.1	CTD-2376I4.2	4.52	9.65e-06	0.00454	0.36	0.28	Discordance in emotional problems in monozygotic twins;	chr5:73039500	chr5:72955206~72955699:-
SARC	cis	rs2179367	0.632	rs11155642	ENSG00000231760.4	RP11-350J20.5	4.52	9.66e-06	0.00455	0.39	0.28	Dupuytren's disease;	chr6:149332984	chr6:149796151~149826294:-
SARC	cis	rs875971	0.825	rs1860472	ENSG00000232559.3	GS1-124K5.12	-4.52	9.66e-06	0.00455	-0.34	-0.28	Aortic root size;	chr7:66617736	chr7:66554588~66576923:-
SARC	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	4.52	9.68e-06	0.00456	0.34	0.28	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
SARC	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	4.52	9.68e-06	0.00456	0.34	0.28	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
SARC	cis	rs6570726	0.791	rs370654	ENSG00000270638.1	RP3-466P17.1	4.52	9.68e-06	0.00456	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs400329	ENSG00000270638.1	RP3-466P17.1	4.52	9.68e-06	0.00456	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs435671	ENSG00000270638.1	RP3-466P17.1	4.52	9.68e-06	0.00456	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.764	rs367065	ENSG00000270638.1	RP3-466P17.1	4.52	9.68e-06	0.00456	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145735570~145737218:+
SARC	cis	rs948562	0.947	rs75708979	ENSG00000280010.1	AP001350.4	4.52	9.68e-06	0.00456	0.43	0.28	Lymphoma;	chr11:58662312	chr11:58627435~58628528:+
SARC	cis	rs948562	0.947	rs78629620	ENSG00000280010.1	AP001350.4	4.52	9.68e-06	0.00456	0.43	0.28	Lymphoma;	chr11:58662329	chr11:58627435~58628528:+
SARC	cis	rs520525	0.963	rs524877	ENSG00000271811.1	RP1-79C4.4	4.52	9.69e-06	0.00456	0.39	0.28	Atrial fibrillation;	chr1:170659294	chr1:170667381~170669425:+
SARC	cis	rs62432291	0.681	rs438853	ENSG00000235086.1	FNDC1-IT1	-4.52	9.69e-06	0.00456	-0.45	-0.28	Joint mobility (Beighton score);	chr6:159209320	chr6:159240786~159243329:+
SARC	cis	rs7772486	0.681	rs9390343	ENSG00000270638.1	RP3-466P17.1	-4.52	9.69e-06	0.00456	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145689391	chr6:145735570~145737218:+
SARC	cis	rs2439831	0.85	rs3736180	ENSG00000275601.1	AC011330.13	-4.52	9.7e-06	0.00457	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43814426	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs28684672	ENSG00000275601.1	AC011330.13	-4.52	9.7e-06	0.00457	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43815464	chr15:43642389~43643023:-
SARC	cis	rs4862750	0.914	rs9995391	ENSG00000250971.1	RP11-696F12.1	-4.52	9.7e-06	0.00457	-0.34	-0.28	Lobe attachment (rater-scored or self-reported);	chr4:186952595	chr4:187060099~187060930:+
SARC	cis	rs910316	0.737	rs175077	ENSG00000279594.1	RP11-950C14.10	-4.52	9.7e-06	0.00457	-0.32	-0.28	Height;	chr14:75040172	chr14:75011269~75012851:-
SARC	cis	rs367615	0.513	rs11741087	ENSG00000249476.1	CTD-2587M2.1	4.52	9.7e-06	0.00457	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109472059	chr5:109237120~109326369:-
SARC	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-4.52	9.71e-06	0.00457	-0.45	-0.28	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
SARC	cis	rs972578	0.501	rs5759126	ENSG00000230319.1	AL022476.2	4.52	9.71e-06	0.00457	0.34	0.28	Mean platelet volume;	chr22:43059659	chr22:43038585~43052366:+
SARC	cis	rs2439831	1	rs689826	ENSG00000205771.5	CATSPER2P1	-4.52	9.71e-06	0.00457	-0.43	-0.28	Lung cancer in ever smokers;	chr15:43457718	chr15:43726918~43747094:-
SARC	cis	rs12049351	0.774	rs3738187	ENSG00000229367.1	HMGN2P19	4.52	9.71e-06	0.00457	0.23	0.28	Circulating myeloperoxidase levels (plasma);	chr1:229547517	chr1:229570532~229570796:+
SARC	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-4.52	9.71e-06	0.00457	-0.37	-0.28	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
SARC	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-4.52	9.72e-06	0.00458	-0.37	-0.28	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-4.52	9.72e-06	0.00458	-0.37	-0.28	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
SARC	cis	rs2762353	0.562	rs1165206	ENSG00000272462.2	U91328.19	-4.52	9.73e-06	0.00458	-0.26	-0.28	Blood metabolite levels;	chr6:25867338	chr6:25992662~26001775:+
SARC	cis	rs948562	0.744	rs60998298	ENSG00000280010.1	AP001350.4	4.52	9.75e-06	0.00458	0.43	0.28	Lymphoma;	chr11:58534382	chr11:58627435~58628528:+
SARC	cis	rs6845263	0.512	rs2723047	ENSG00000254531.1	FLJ20021	4.52	9.76e-06	0.00459	0.27	0.28	Superior crus of antihelix expression;	chr4:101592863	chr4:101347780~101348883:+
SARC	cis	rs6845263	0.512	rs2717847	ENSG00000254531.1	FLJ20021	4.52	9.76e-06	0.00459	0.27	0.28	Superior crus of antihelix expression;	chr4:101592886	chr4:101347780~101348883:+
SARC	cis	rs7267979	0.966	rs6037083	ENSG00000276952.1	RP5-965G21.6	-4.52	9.77e-06	0.00459	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25284915~25285588:-
SARC	cis	rs910316	1	rs11845639	ENSG00000279594.1	RP11-950C14.10	4.52	9.78e-06	0.0046	0.31	0.28	Height;	chr14:75103590	chr14:75011269~75012851:-
SARC	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-4.52	9.78e-06	0.0046	-0.35	-0.28	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
SARC	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-4.52	9.78e-06	0.0046	-0.33	-0.28	QT interval;	chr12:29309811	chr12:29280418~29317848:-
SARC	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-4.52	9.78e-06	0.0046	-0.33	-0.28	QT interval;	chr12:29310155	chr12:29280418~29317848:-
SARC	cis	rs73186030	0.623	rs16832958	ENSG00000272758.4	RP11-299J3.8	4.52	9.78e-06	0.0046	0.33	0.28	Serum parathyroid hormone levels;	chr3:122299646	chr3:122416207~122443180:+
SARC	cis	rs7162943	0.708	rs293365	ENSG00000260123.1	RP11-326A19.4	-4.52	9.78e-06	0.0046	-0.26	-0.28	Mean platelet volume;	chr15:89070777	chr15:89041223~89082819:+
SARC	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-4.52	9.79e-06	0.0046	-0.31	-0.28	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
SARC	cis	rs7772486	0.622	rs1292333	ENSG00000235652.6	RP11-545I5.3	-4.52	9.79e-06	0.0046	-0.25	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145799409~145886585:+
SARC	cis	rs801193	0.773	rs801207	ENSG00000236529.1	RP13-254B10.1	-4.52	9.8e-06	0.0046	-0.29	-0.28	Aortic root size;	chr7:66555603	chr7:65840212~65840596:+
SARC	cis	rs7615952	0.576	rs2276729	ENSG00000171084.14	FAM86JP	4.52	9.8e-06	0.00461	0.42	0.28	Blood pressure (smoking interaction);	chr3:126107371	chr3:125916620~125930024:+
SARC	cis	rs7587476	1	rs3768707	ENSG00000229267.2	AC072062.1	-4.52	9.8e-06	0.00461	-0.27	-0.28	Neuroblastoma;	chr2:214780411	chr2:214810229~214963274:+
SARC	cis	rs3790268	0.527	rs6112466	ENSG00000273148.1	RP5-1068E13.7	4.52	9.81e-06	0.00461	0.32	0.28	Matrix metalloproteinase levels;	chr20:19574059	chr20:18794529~18796067:+
SARC	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-4.52	9.82e-06	0.00462	-0.32	-0.28	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
SARC	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-4.52	9.83e-06	0.00462	-0.54	-0.28	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-4.52	9.83e-06	0.00462	-0.54	-0.28	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-4.52	9.83e-06	0.00462	-0.54	-0.28	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-4.52	9.83e-06	0.00462	-0.54	-0.28	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-4.52	9.83e-06	0.00462	-0.54	-0.28	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
SARC	cis	rs1707322	0.721	rs6699418	ENSG00000281133.1	AL355480.3	-4.52	9.84e-06	0.00462	-0.33	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs4431884	ENSG00000281133.1	AL355480.3	-4.52	9.84e-06	0.00462	-0.33	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.65	rs4660879	ENSG00000281133.1	AL355480.3	-4.52	9.84e-06	0.00462	-0.33	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45580892~45580996:-
SARC	cis	rs1823913	0.503	rs34716486	ENSG00000227542.1	AC092614.2	4.52	9.85e-06	0.00463	0.33	0.28	Obesity-related traits;	chr2:191343335	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.503	rs35868016	ENSG00000227542.1	AC092614.2	4.52	9.85e-06	0.00463	0.33	0.28	Obesity-related traits;	chr2:191344082	chr2:191229165~191246172:-
SARC	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-4.52	9.85e-06	0.00463	-0.36	-0.28	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
SARC	cis	rs7772486	0.79	rs2265474	ENSG00000270638.1	RP3-466P17.1	4.52	9.86e-06	0.00463	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145735570~145737218:+
SARC	cis	rs7809950	1	rs2520265	ENSG00000238832.1	snoU109	-4.52	9.86e-06	0.00463	-0.33	-0.28	Coronary artery disease;	chr7:107540786	chr7:107603363~107603507:+
SARC	cis	rs910316	1	rs7147118	ENSG00000279594.1	RP11-950C14.10	4.52	9.86e-06	0.00463	0.3	0.28	Height;	chr14:75143467	chr14:75011269~75012851:-
SARC	cis	rs14027	0.921	rs2136374	ENSG00000279347.1	RP11-85I17.2	-4.52	9.86e-06	0.00463	-0.25	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119765046	chr8:119838736~119840385:-
SARC	cis	rs14027	0.881	rs4871578	ENSG00000279347.1	RP11-85I17.2	-4.52	9.86e-06	0.00463	-0.25	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767615	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs10110601	ENSG00000279347.1	RP11-85I17.2	-4.52	9.86e-06	0.00463	-0.25	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119774866	chr8:119838736~119840385:-
SARC	cis	rs6969780	0.722	rs983185	ENSG00000233429.8	HOTAIRM1	-4.52	9.87e-06	0.00463	-0.38	-0.28	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27148988	chr7:27095647~27100265:+
SARC	cis	rs7246657	0.943	rs2291004	ENSG00000276846.1	CTD-3220F14.3	4.52	9.87e-06	0.00463	0.38	0.28	Coronary artery calcification;	chr19:37507050	chr19:37314868~37315620:-
SARC	cis	rs1823913	0.637	rs2883912	ENSG00000227542.1	AC092614.2	-4.52	9.87e-06	0.00463	-0.31	-0.28	Obesity-related traits;	chr2:191284290	chr2:191229165~191246172:-
SARC	cis	rs9876781	0.507	rs1824362	ENSG00000229759.1	MRPS18AP1	-4.52	9.87e-06	0.00463	-0.3	-0.28	Longevity;	chr3:48360459	chr3:48256350~48256938:-
SARC	cis	rs10911902	0.643	rs3766703	ENSG00000229739.2	RP11-295K2.3	-4.52	9.88e-06	0.00464	-0.4	-0.28	Schizophrenia;	chr1:186346575	chr1:186435161~186470291:+
SARC	cis	rs17508449	0.819	rs4839000	ENSG00000232450.1	RP4-730K3.3	-4.52	9.88e-06	0.00464	-0.36	-0.28	Leprosy;	chr1:113737513	chr1:113698884~113699631:-
SARC	cis	rs319598	1	rs319598	ENSG00000224186.7	C5orf66	4.52	9.89e-06	0.00464	0.25	0.28	Type 2 diabetes;	chr5:134904545	chr5:135033280~135358219:+
SARC	cis	rs6570726	0.791	rs1280276	ENSG00000270638.1	RP3-466P17.1	4.52	9.89e-06	0.00464	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145735570~145737218:+
SARC	cis	rs7267979	0.903	rs2500400	ENSG00000276952.1	RP5-965G21.6	-4.52	9.89e-06	0.00464	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25284915~25285588:-
SARC	cis	rs2905347	0.965	rs2961272	ENSG00000179428.2	AC073072.5	4.52	9.9e-06	0.00465	0.3	0.28	Major depression and alcohol dependence;	chr7:22585117	chr7:22725395~22727620:-
SARC	cis	rs6969780	0.915	rs886339	ENSG00000233429.8	HOTAIRM1	-4.52	9.9e-06	0.00465	-0.42	-0.28	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27151051	chr7:27095647~27100265:+
SARC	cis	rs2439831	1	rs2253708	ENSG00000205771.5	CATSPER2P1	-4.52	9.91e-06	0.00465	-0.45	-0.28	Lung cancer in ever smokers;	chr15:43505075	chr15:43726918~43747094:-
SARC	cis	rs11634944	0.643	rs2732044	ENSG00000274307.1	RP11-345J18.2	-4.52	9.91e-06	0.00465	-0.36	-0.28	Interleukin-8 levels;	chr15:25032169	chr15:25708470~25710869:-
SARC	cis	rs367615	0.66	rs10061221	ENSG00000249476.1	CTD-2587M2.1	4.52	9.91e-06	0.00465	0.36	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109503337	chr5:109237120~109326369:-
SARC	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	4.52	9.92e-06	0.00465	0.45	0.28	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
SARC	cis	rs7267979	1	rs7020	ENSG00000276952.1	RP5-965G21.6	4.52	9.93e-06	0.00466	0.28	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25284915~25285588:-
SARC	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	4.52	9.93e-06	0.00466	0.34	0.28	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
SARC	cis	rs2836950	0.501	rs2836984	ENSG00000255568.3	BRWD1-AS2	-4.52	9.93e-06	0.00466	-0.26	-0.28	Menarche (age at onset);	chr21:39329023	chr21:39313935~39314962:+
SARC	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-4.52	9.94e-06	0.00466	-0.33	-0.28	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
SARC	cis	rs3805389	0.504	rs28756087	ENSG00000273257.1	RP11-177J6.1	-4.52	9.94e-06	0.00466	-0.42	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr4:55601940	chr4:55387949~55388271:+
SARC	cis	rs3805389	0.504	rs28713371	ENSG00000273257.1	RP11-177J6.1	-4.52	9.94e-06	0.00466	-0.42	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr4:55602255	chr4:55387949~55388271:+
SARC	cis	rs3805389	0.504	rs10011801	ENSG00000273257.1	RP11-177J6.1	-4.52	9.94e-06	0.00466	-0.42	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr4:55602567	chr4:55387949~55388271:+
SARC	cis	rs3805389	0.504	rs10000512	ENSG00000273257.1	RP11-177J6.1	-4.52	9.94e-06	0.00466	-0.42	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr4:55602855	chr4:55387949~55388271:+
SARC	cis	rs4372836	0.677	rs4632298	ENSG00000226833.4	AC097724.3	-4.52	9.97e-06	0.00467	-0.24	-0.28	Body mass index;	chr2:28853416	chr2:28708953~28736205:-
SARC	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-4.52	9.97e-06	0.00468	-0.35	-0.28	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
SARC	cis	rs12554020	0.786	rs76640831	ENSG00000227603.1	RP11-165J3.6	4.52	9.99e-06	0.00468	0.47	0.28	Schizophrenia;	chr9:93474133	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.579	rs74740549	ENSG00000227603.1	RP11-165J3.6	4.52	9.99e-06	0.00468	0.47	0.28	Schizophrenia;	chr9:93480399	chr9:93435332~93437121:-
SARC	cis	rs9309473	0.5	rs12472502	ENSG00000163016.8	ALMS1P	-4.52	1e-05	0.00468	-0.32	-0.28	Metabolite levels;	chr2:73632057	chr2:73644919~73685576:+
SARC	cis	rs123509	0.913	rs339682	ENSG00000230970.3	HHATL-AS1	-4.52	1e-05	0.00468	-0.33	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42749631	chr3:42702653~42706776:+
SARC	cis	rs7267979	0.966	rs4813557	ENSG00000276952.1	RP5-965G21.6	-4.52	1e-05	0.00469	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25284915~25285588:-
SARC	cis	rs4794202	0.755	rs11651698	ENSG00000264920.1	RP11-6N17.4	-4.52	1e-05	0.00469	-0.41	-0.28	Alzheimer's disease (cognitive decline);	chr17:47854937	chr17:47891255~47895812:-
SARC	cis	rs2933343	1	rs789237	ENSG00000261159.1	RP11-723O4.9	4.52	1e-05	0.00469	0.33	0.28	IgG glycosylation;	chr3:128918118	chr3:128859716~128860526:-
SARC	cis	rs9818758	0.607	rs71324929	ENSG00000225399.4	RP11-3B7.1	-4.52	1e-05	0.00469	-0.55	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49007280	chr3:49260085~49261316:+
SARC	cis	rs890448	0.726	rs2850328	ENSG00000254531.1	FLJ20021	-4.52	1e-05	0.00469	-0.29	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101347783	chr4:101347780~101348883:+
SARC	cis	rs7299940	0.967	rs10848243	ENSG00000256250.1	RP11-989F5.1	-4.52	1e-05	0.0047	-0.28	-0.28	Panic disorder;	chr12:130894769	chr12:130810606~130812438:+
SARC	cis	rs6570726	0.689	rs411785	ENSG00000270638.1	RP3-466P17.1	4.52	1e-05	0.0047	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145735570~145737218:+
SARC	cis	rs35160687	0.644	rs56394965	ENSG00000273080.1	RP11-301O19.1	-4.51	1.01e-05	0.00471	-0.3	-0.28	Night sleep phenotypes;	chr2:86271226	chr2:86195590~86196049:+
SARC	cis	rs7255436	0.965	rs7254882	ENSG00000269386.4	RAB11B-AS1	4.51	1.01e-05	0.00471	0.28	0.28	HDL cholesterol;	chr19:8388938	chr19:8374373~8390685:-
SARC	cis	rs3824347	0.872	rs11144182	ENSG00000203321.2	C9orf41-AS1	-4.51	1.01e-05	0.00472	-0.32	-0.28	Urinary magnesium-to-creatinine ratio;	chr9:75000123	chr9:74952968~74996293:+
SARC	cis	rs42490	0.664	rs40457	ENSG00000251136.7	RP11-37B2.1	-4.51	1.01e-05	0.00473	-0.31	-0.28	Leprosy;	chr8:89811459	chr8:89609409~89757727:-
SARC	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-4.51	1.01e-05	0.00473	-0.3	-0.28	Height;	chr3:53094335	chr3:53064283~53065091:-
SARC	cis	rs853679	0.882	rs9468300	ENSG00000219392.1	RP1-265C24.5	-4.51	1.01e-05	0.00473	-0.55	-0.28	Depression;	chr6:28159062	chr6:28115628~28116551:+
SARC	cis	rs4664293	0.51	rs3903306	ENSG00000226266.5	AC009961.3	4.51	1.01e-05	0.00474	0.36	0.28	Monocyte percentage of white cells;	chr2:159592171	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.528	rs56027129	ENSG00000226266.5	AC009961.3	4.51	1.01e-05	0.00474	0.36	0.28	Monocyte percentage of white cells;	chr2:159600091	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.51	rs890096	ENSG00000226266.5	AC009961.3	4.51	1.01e-05	0.00474	0.36	0.28	Monocyte percentage of white cells;	chr2:159604849	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.51	rs747707	ENSG00000226266.5	AC009961.3	4.51	1.01e-05	0.00474	0.36	0.28	Monocyte percentage of white cells;	chr2:159609003	chr2:159670708~159712435:-
SARC	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-4.51	1.01e-05	0.00474	-0.29	-0.28	Height;	chr3:52975027	chr3:53064283~53065091:-
SARC	cis	rs948562	0.793	rs79869893	ENSG00000280010.1	AP001350.4	4.51	1.01e-05	0.00474	0.43	0.28	Lymphoma;	chr11:58514409	chr11:58627435~58628528:+
SARC	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-4.51	1.01e-05	0.00474	-0.3	-0.28	Height;	chr3:53027969	chr3:53064283~53065091:-
SARC	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	4.51	1.01e-05	0.00474	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
SARC	cis	rs890448	0.93	rs28863533	ENSG00000254531.1	FLJ20021	-4.51	1.02e-05	0.00475	-0.28	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101488397	chr4:101347780~101348883:+
SARC	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	4.51	1.02e-05	0.00475	0.31	0.28	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
SARC	cis	rs8031584	1	rs35239376	ENSG00000260382.1	RP11-540B6.2	4.51	1.02e-05	0.00475	0.38	0.28	Huntington's disease progression;	chr15:30998335	chr15:30882267~30883231:-
SARC	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-4.51	1.02e-05	0.00475	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
SARC	cis	rs1823913	0.503	rs35672076	ENSG00000227542.1	AC092614.2	4.51	1.02e-05	0.00475	0.33	0.28	Obesity-related traits;	chr2:191343907	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.503	rs35282329	ENSG00000227542.1	AC092614.2	4.51	1.02e-05	0.00475	0.33	0.28	Obesity-related traits;	chr2:191343925	chr2:191229165~191246172:-
SARC	cis	rs79349575	0.783	rs4793992	ENSG00000270781.1	RP11-501C14.9	-4.51	1.02e-05	0.00476	-0.33	-0.28	Type 2 diabetes;	chr17:48930845	chr17:48899131~48899748:+
SARC	cis	rs875971	0.543	rs801191	ENSG00000236529.1	RP13-254B10.1	-4.51	1.02e-05	0.00476	-0.29	-0.28	Aortic root size;	chr7:66567968	chr7:65840212~65840596:+
SARC	cis	rs875971	0.508	rs6947808	ENSG00000236529.1	RP13-254B10.1	-4.51	1.02e-05	0.00476	-0.29	-0.28	Aortic root size;	chr7:66580095	chr7:65840212~65840596:+
SARC	cis	rs2288884	0.559	rs2903710	ENSG00000275055.1	CTC-471J1.11	-4.51	1.02e-05	0.00476	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004285	chr19:52049007~52049754:+
SARC	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	4.51	1.02e-05	0.00477	0.34	0.28	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
SARC	cis	rs61160187	0.582	rs4700402	ENSG00000215032.2	GNL3LP1	4.51	1.02e-05	0.00477	0.28	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60966220	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.549	rs61017995	ENSG00000215032.2	GNL3LP1	4.51	1.02e-05	0.00477	0.28	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60968176	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.556	rs62367862	ENSG00000215032.2	GNL3LP1	4.51	1.02e-05	0.00477	0.28	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60973134	chr5:60891935~60893577:-
SARC	cis	rs12049351	0.832	rs28798529	ENSG00000229367.1	HMGN2P19	4.51	1.02e-05	0.00477	0.24	0.28	Circulating myeloperoxidase levels (plasma);	chr1:229535867	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs4148760	ENSG00000229367.1	HMGN2P19	4.51	1.02e-05	0.00477	0.24	0.28	Circulating myeloperoxidase levels (plasma);	chr1:229538187	chr1:229570532~229570796:+
SARC	cis	rs7567389	0.504	rs13030463	ENSG00000236682.1	AC068282.3	-4.51	1.02e-05	0.00477	-0.32	-0.28	Self-rated health;	chr2:127431295	chr2:127389130~127400580:+
SARC	cis	rs7267979	0.966	rs2482923	ENSG00000276952.1	RP5-965G21.6	-4.51	1.02e-05	0.00477	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25284915~25285588:-
SARC	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	4.51	1.02e-05	0.00478	0.27	0.28	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
SARC	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-4.51	1.02e-05	0.00478	-0.33	-0.28	QT interval;	chr12:29314736	chr12:29280418~29317848:-
SARC	cis	rs12980942	0.872	rs7257583	ENSG00000206674.1	RNU6-945P	-4.51	1.02e-05	0.00478	-0.4	-0.28	Coronary artery disease;	chr19:41282212	chr19:40299478~40299584:-
SARC	cis	rs12980942	0.872	rs10421990	ENSG00000206674.1	RNU6-945P	-4.51	1.02e-05	0.00478	-0.4	-0.28	Coronary artery disease;	chr19:41291194	chr19:40299478~40299584:-
SARC	cis	rs2439831	0.85	rs3097773	ENSG00000275601.1	AC011330.13	4.51	1.02e-05	0.00478	0.42	0.28	Lung cancer in ever smokers;	chr15:43600874	chr15:43642389~43643023:-
SARC	cis	rs4664293	0.867	rs1427329	ENSG00000226266.5	AC009961.3	-4.51	1.02e-05	0.00478	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159748301	chr2:159670708~159712435:-
SARC	cis	rs7178375	1	rs35162264	ENSG00000215302.7	CTD-3092A11.1	-4.51	1.02e-05	0.00478	-0.36	-0.28	Hypertriglyceridemia;	chr15:30908480	chr15:30470779~30507623:+
SARC	cis	rs1865760	0.516	rs9393684	ENSG00000272462.2	U91328.19	-4.51	1.02e-05	0.00478	-0.26	-0.28	Height;	chr6:26075303	chr6:25992662~26001775:+
SARC	cis	rs4713118	0.662	rs175954	ENSG00000216901.1	AL022393.7	4.51	1.02e-05	0.00479	0.41	0.28	Parkinson's disease;	chr6:28043807	chr6:28176188~28176674:+
SARC	cis	rs4664293	0.546	rs72956113	ENSG00000226266.5	AC009961.3	4.51	1.03e-05	0.00479	0.35	0.28	Monocyte percentage of white cells;	chr2:159631132	chr2:159670708~159712435:-
SARC	cis	rs2439831	0.85	rs28513374	ENSG00000275601.1	AC011330.13	-4.51	1.03e-05	0.00479	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43833297	chr15:43642389~43643023:-
SARC	cis	rs867371	1	rs13380317	ENSG00000259429.4	UBE2Q2P2	4.51	1.03e-05	0.00479	0.26	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82355142~82420075:+
SARC	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-4.51	1.03e-05	0.00479	-0.33	-0.28	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
SARC	cis	rs4835473	0.897	rs7662736	ENSG00000251600.4	RP11-673E1.1	4.51	1.03e-05	0.00479	0.28	0.28	Immature fraction of reticulocytes;	chr4:143958036	chr4:143912331~143982454:+
SARC	cis	rs2439831	0.681	rs3742971	ENSG00000205771.5	CATSPER2P1	4.51	1.03e-05	0.0048	0.39	0.28	Lung cancer in ever smokers;	chr15:43330718	chr15:43726918~43747094:-
SARC	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	4.51	1.03e-05	0.0048	0.31	0.28	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
SARC	cis	rs6845263	0.511	rs1365386	ENSG00000254531.1	FLJ20021	-4.51	1.03e-05	0.0048	-0.27	-0.28	Superior crus of antihelix expression;	chr4:101563119	chr4:101347780~101348883:+
SARC	cis	rs2439831	0.681	rs484846	ENSG00000275601.1	AC011330.13	-4.51	1.03e-05	0.0048	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43308605	chr15:43642389~43643023:-
SARC	cis	rs910316	1	rs12589815	ENSG00000279594.1	RP11-950C14.10	4.51	1.03e-05	0.0048	0.31	0.28	Height;	chr14:75077398	chr14:75011269~75012851:-
SARC	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-4.51	1.03e-05	0.0048	-0.29	-0.28	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
SARC	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	4.51	1.03e-05	0.0048	0.31	0.28	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
SARC	cis	rs2274273	0.624	rs7147247	ENSG00000258413.1	RP11-665C16.6	-4.51	1.03e-05	0.00481	-0.36	-0.28	Protein biomarker;	chr14:55310995	chr14:55262767~55272075:-
SARC	cis	rs853679	0.76	rs11962305	ENSG00000216901.1	AL022393.7	4.51	1.03e-05	0.00481	0.45	0.28	Depression;	chr6:28232159	chr6:28176188~28176674:+
SARC	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	4.51	1.03e-05	0.00481	0.51	0.28	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
SARC	cis	rs11264213	0.591	rs4653158	ENSG00000271554.1	RP4-665N4.8	4.51	1.03e-05	0.00482	0.39	0.28	Schizophrenia;	chr1:36090586	chr1:35992109~36013630:-
SARC	cis	rs6570726	0.791	rs6915094	ENSG00000270638.1	RP3-466P17.1	4.51	1.03e-05	0.00482	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs365869	ENSG00000270638.1	RP3-466P17.1	4.51	1.03e-05	0.00482	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145735570~145737218:+
SARC	cis	rs916888	0.61	rs199454	ENSG00000261575.2	RP11-259G18.1	-4.51	1.03e-05	0.00482	-0.37	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46267037~46268694:+
SARC	cis	rs2280018	1	rs2280017	ENSG00000260735.1	RP11-72I8.1	4.51	1.03e-05	0.00482	0.23	0.28	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15094411~15109197:+
SARC	cis	rs75920871	0.528	rs7128772	ENSG00000254851.1	RP11-109L13.1	4.51	1.03e-05	0.00482	0.38	0.28	Subjective well-being;	chr11:117018695	chr11:117135528~117138582:+
SARC	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-4.51	1.03e-05	0.00482	-0.28	-0.28	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
SARC	cis	rs453301	0.653	rs11784393	ENSG00000253893.2	FAM85B	-4.51	1.04e-05	0.00483	-0.25	-0.28	Joint mobility (Beighton score);	chr8:9045624	chr8:8167819~8226614:-
SARC	cis	rs10754283	0.967	rs10922680	ENSG00000231613.1	RP5-943J3.1	-4.51	1.04e-05	0.00483	-0.28	-0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89635767	chr1:89788914~89790492:+
SARC	cis	rs7267979	0.549	rs11698185	ENSG00000276952.1	RP5-965G21.6	4.51	1.04e-05	0.00483	0.29	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25201362	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.549	rs6138536	ENSG00000276952.1	RP5-965G21.6	4.51	1.04e-05	0.00483	0.29	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25202012	chr20:25284915~25285588:-
SARC	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	4.51	1.04e-05	0.00483	0.29	0.28	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
SARC	cis	rs6061231	0.624	rs8668	ENSG00000275437.1	RP5-908M14.10	-4.51	1.04e-05	0.00484	-0.25	-0.28	Colorectal cancer;	chr20:62389008	chr20:62402236~62405935:-
SARC	cis	rs17508449	0.819	rs79198040	ENSG00000232450.1	RP4-730K3.3	-4.51	1.04e-05	0.00484	-0.36	-0.28	Leprosy;	chr1:113746069	chr1:113698884~113699631:-
SARC	cis	rs6679677	0.543	rs1230680	ENSG00000232450.1	RP4-730K3.3	-4.51	1.04e-05	0.00484	-0.36	-0.28	Rheumatoid arthritis;Monokine induced by gamma interferon levels;Type 1 diabetes;Hypothyroidism;Systemic lupus erythematosus;Pediatric autoimmune diseases;Crohn's disease;Antineutrophil cytoplasmic antibody-associated vasculitis;	chr1:113754148	chr1:113698884~113699631:-
SARC	cis	rs597539	0.616	rs473997	ENSG00000250508.1	RP11-757G1.6	-4.51	1.04e-05	0.00484	-0.34	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68870664~68874542:+
SARC	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-4.51	1.04e-05	0.00484	-0.54	-0.28	Gout;	chr7:66679692	chr7:66654538~66669855:+
SARC	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-4.51	1.04e-05	0.00484	-0.54	-0.28	Gout;	chr7:66692349	chr7:66654538~66669855:+
SARC	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-4.51	1.04e-05	0.00484	-0.54	-0.28	Gout;	chr7:66693028	chr7:66654538~66669855:+
SARC	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-4.51	1.04e-05	0.00484	-0.54	-0.28	Gout;	chr7:66693433	chr7:66654538~66669855:+
SARC	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-4.51	1.04e-05	0.00484	-0.54	-0.28	Gout;	chr7:66694214	chr7:66654538~66669855:+
SARC	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-4.51	1.04e-05	0.00484	-0.54	-0.28	Gout;	chr7:66701371	chr7:66654538~66669855:+
SARC	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-4.51	1.04e-05	0.00484	-0.54	-0.28	Gout;	chr7:66702658	chr7:66654538~66669855:+
SARC	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-4.51	1.04e-05	0.00484	-0.54	-0.28	Gout;	chr7:66706390	chr7:66654538~66669855:+
SARC	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-4.51	1.04e-05	0.00484	-0.54	-0.28	Gout;	chr7:66710076	chr7:66654538~66669855:+
SARC	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	4.51	1.04e-05	0.00484	0.54	0.28	Gout;	chr7:66682070	chr7:66654538~66669855:+
SARC	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	4.51	1.04e-05	0.00484	0.54	0.28	Gout;	chr7:66682162	chr7:66654538~66669855:+
SARC	cis	rs801193	1	rs2420824	ENSG00000236529.1	RP13-254B10.1	-4.51	1.04e-05	0.00484	-0.29	-0.28	Aortic root size;	chr7:66666129	chr7:65840212~65840596:+
SARC	cis	rs62432291	0.681	rs385438	ENSG00000235086.1	FNDC1-IT1	-4.51	1.04e-05	0.00484	-0.47	-0.28	Joint mobility (Beighton score);	chr6:159235181	chr6:159240786~159243329:+
SARC	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-4.51	1.04e-05	0.00484	-0.35	-0.28	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
SARC	cis	rs7772486	0.727	rs4896843	ENSG00000270638.1	RP3-466P17.1	-4.51	1.04e-05	0.00485	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145735570~145737218:+
SARC	cis	rs12554020	0.786	rs7035657	ENSG00000227603.1	RP11-165J3.6	-4.51	1.04e-05	0.00485	-0.38	-0.28	Schizophrenia;	chr9:93434769	chr9:93435332~93437121:-
SARC	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	4.51	1.04e-05	0.00485	0.32	0.28	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
SARC	cis	rs253959	0.545	rs7734133	ENSG00000272265.1	CTD-2287O16.4	4.51	1.04e-05	0.00485	0.33	0.28	Bipolar disorder and schizophrenia;	chr5:116096418	chr5:116078110~116078570:-
SARC	cis	rs253959	0.545	rs10072417	ENSG00000272265.1	CTD-2287O16.4	4.51	1.04e-05	0.00485	0.33	0.28	Bipolar disorder and schizophrenia;	chr5:116097906	chr5:116078110~116078570:-
SARC	cis	rs253959	0.595	rs11241361	ENSG00000272265.1	CTD-2287O16.4	4.51	1.04e-05	0.00485	0.33	0.28	Bipolar disorder and schizophrenia;	chr5:116112611	chr5:116078110~116078570:-
SARC	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	4.51	1.04e-05	0.00485	0.34	0.28	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
SARC	cis	rs4664293	0.934	rs7604482	ENSG00000226266.5	AC009961.3	-4.51	1.04e-05	0.00485	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159657315	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.967	rs10176436	ENSG00000226266.5	AC009961.3	-4.51	1.04e-05	0.00485	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159658883	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.967	rs7559127	ENSG00000226266.5	AC009961.3	-4.51	1.04e-05	0.00485	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159659424	chr2:159670708~159712435:-
SARC	cis	rs14027	0.921	rs7833112	ENSG00000279347.1	RP11-85I17.2	-4.51	1.04e-05	0.00486	-0.25	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119835842	chr8:119838736~119840385:-
SARC	cis	rs7267979	0.903	rs2500423	ENSG00000276952.1	RP5-965G21.6	-4.51	1.04e-05	0.00486	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25284915~25285588:-
SARC	cis	rs2439831	0.85	rs11070408	ENSG00000275601.1	AC011330.13	-4.51	1.04e-05	0.00486	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43742590	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-4.51	1.04e-05	0.00486	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs28595038	ENSG00000275601.1	AC011330.13	-4.51	1.04e-05	0.00486	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43752661	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs10163054	ENSG00000275601.1	AC011330.13	-4.51	1.04e-05	0.00486	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43755440	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-4.51	1.04e-05	0.00486	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-4.51	1.04e-05	0.00486	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-4.51	1.04e-05	0.00486	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-4.51	1.04e-05	0.00486	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
SARC	cis	rs7267979	0.773	rs6132821	ENSG00000276952.1	RP5-965G21.6	4.51	1.04e-05	0.00486	0.26	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25245556	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.873	rs6132822	ENSG00000276952.1	RP5-965G21.6	4.51	1.04e-05	0.00486	0.26	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25248059	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.844	rs1555330	ENSG00000276952.1	RP5-965G21.6	4.51	1.04e-05	0.00486	0.26	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25251461	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.844	rs6107017	ENSG00000276952.1	RP5-965G21.6	4.51	1.04e-05	0.00486	0.26	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25251664	chr20:25284915~25285588:-
SARC	cis	rs8062405	0.755	rs7186573	ENSG00000251417.2	RP11-1348G14.4	-4.51	1.04e-05	0.00486	-0.27	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28802743~28817828:+
SARC	cis	rs7267979	1	rs6076339	ENSG00000276952.1	RP5-965G21.6	-4.51	1.05e-05	0.00486	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25284915~25285588:-
SARC	cis	rs12049351	0.774	rs4148757	ENSG00000229367.1	HMGN2P19	4.51	1.05e-05	0.00487	0.23	0.28	Circulating myeloperoxidase levels (plasma);	chr1:229558099	chr1:229570532~229570796:+
SARC	cis	rs7772486	0.79	rs9403749	ENSG00000270638.1	RP3-466P17.1	4.51	1.05e-05	0.00488	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145735570~145737218:+
SARC	cis	rs7587476	0.954	rs3768708	ENSG00000229267.2	AC072062.1	4.51	1.05e-05	0.00488	0.27	0.28	Neuroblastoma;	chr2:214780322	chr2:214810229~214963274:+
SARC	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-4.5	1.05e-05	0.00489	-0.35	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
SARC	cis	rs10515750	0.643	rs10063413	ENSG00000251405.2	CTB-109A12.1	-4.5	1.05e-05	0.00489	-0.36	-0.28	Lung function (FEV1/FVC);	chr5:157384435	chr5:157362615~157460078:-
SARC	cis	rs8062405	0.755	rs4788074	ENSG00000251417.2	RP11-1348G14.4	4.5	1.05e-05	0.00489	0.28	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28802743~28817828:+
SARC	cis	rs10986311	0.747	rs2026190	ENSG00000235204.1	RP11-121A14.2	4.5	1.05e-05	0.00489	0.33	0.28	Vitiligo;	chr9:124260984	chr9:124259250~124261156:-
SARC	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	4.5	1.05e-05	0.00489	0.31	0.28	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
SARC	cis	rs10911902	0.602	rs10494583	ENSG00000229739.2	RP11-295K2.3	-4.5	1.05e-05	0.00489	-0.4	-0.28	Schizophrenia;	chr1:186321363	chr1:186435161~186470291:+
SARC	cis	rs7178375	1	rs12907055	ENSG00000215302.7	CTD-3092A11.1	-4.5	1.05e-05	0.00489	-0.36	-0.28	Hypertriglyceridemia;	chr15:30912091	chr15:30470779~30507623:+
SARC	cis	rs3824347	0.967	rs10869459	ENSG00000203321.2	C9orf41-AS1	-4.5	1.05e-05	0.00489	-0.31	-0.28	Urinary magnesium-to-creatinine ratio;	chr9:74956225	chr9:74952968~74996293:+
SARC	cis	rs948562	0.793	rs79170562	ENSG00000280010.1	AP001350.4	4.5	1.05e-05	0.00489	0.42	0.28	Lymphoma;	chr11:58604081	chr11:58627435~58628528:+
SARC	cis	rs948562	0.793	rs1944051	ENSG00000280010.1	AP001350.4	4.5	1.05e-05	0.00489	0.42	0.28	Lymphoma;	chr11:58607820	chr11:58627435~58628528:+
SARC	cis	rs948562	0.793	rs1800169	ENSG00000280010.1	AP001350.4	4.5	1.05e-05	0.00489	0.42	0.28	Lymphoma;	chr11:58624028	chr11:58627435~58628528:+
SARC	cis	rs948562	0.696	rs17568220	ENSG00000280010.1	AP001350.4	4.5	1.05e-05	0.00489	0.42	0.28	Lymphoma;	chr11:58627550	chr11:58627435~58628528:+
SARC	cis	rs1823913	0.637	rs11686185	ENSG00000227542.1	AC092614.2	-4.5	1.05e-05	0.0049	-0.31	-0.28	Obesity-related traits;	chr2:191289282	chr2:191229165~191246172:-
SARC	cis	rs4713118	0.696	rs2394002	ENSG00000219392.1	RP1-265C24.5	-4.5	1.05e-05	0.0049	-0.4	-0.28	Parkinson's disease;	chr6:27780236	chr6:28115628~28116551:+
SARC	cis	rs7772486	0.701	rs697056	ENSG00000270638.1	RP3-466P17.1	-4.5	1.06e-05	0.0049	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs4896839	ENSG00000270638.1	RP3-466P17.1	-4.5	1.06e-05	0.0049	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145735570~145737218:+
SARC	cis	rs526231	0.819	rs366437	ENSG00000175749.11	EIF3KP1	4.5	1.06e-05	0.00491	0.37	0.28	Primary biliary cholangitis;	chr5:103269900	chr5:103032376~103033031:+
SARC	cis	rs8062405	0.755	rs56209193	ENSG00000251417.2	RP11-1348G14.4	-4.5	1.06e-05	0.00491	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28802743~28817828:+
SARC	cis	rs7615952	0.611	rs114419739	ENSG00000250012.1	RP11-124N2.1	-4.5	1.06e-05	0.00491	-0.38	-0.28	Blood pressure (smoking interaction);	chr3:126003647	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.611	rs79405914	ENSG00000250012.1	RP11-124N2.1	-4.5	1.06e-05	0.00491	-0.38	-0.28	Blood pressure (smoking interaction);	chr3:126004780	chr3:126084220~126095349:+
SARC	cis	rs593531	0.513	rs7944333	ENSG00000280269.1	AP000577.2	4.5	1.06e-05	0.00491	0.36	0.28	Neuroticism;	chr11:74311384	chr11:74204869~74205746:+
SARC	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-4.5	1.06e-05	0.00491	-0.34	-0.28	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
SARC	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	4.5	1.06e-05	0.00491	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
SARC	cis	rs12655019	0.92	rs7725377	ENSG00000271828.1	CTD-2310F14.1	-4.5	1.06e-05	0.00492	-0.47	-0.28	Breast cancer (early onset);	chr5:56960769	chr5:56927874~56929573:+
SARC	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	4.5	1.06e-05	0.00492	0.41	0.28	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
SARC	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	4.5	1.06e-05	0.00492	0.41	0.28	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
SARC	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	4.5	1.06e-05	0.00492	0.41	0.28	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
SARC	cis	rs7772486	0.754	rs6932863	ENSG00000270638.1	RP3-466P17.1	-4.5	1.06e-05	0.00492	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145735570~145737218:+
SARC	cis	rs42490	0.51	rs7003919	ENSG00000251136.7	RP11-37B2.1	4.5	1.06e-05	0.00492	0.32	0.28	Leprosy;	chr8:89688185	chr8:89609409~89757727:-
SARC	cis	rs42490	0.51	rs218917	ENSG00000251136.7	RP11-37B2.1	-4.5	1.06e-05	0.00492	-0.32	-0.28	Leprosy;	chr8:89688902	chr8:89609409~89757727:-
SARC	cis	rs193541	0.593	rs1035372	ENSG00000263432.2	RN7SL689P	4.5	1.06e-05	0.00492	0.36	0.28	Glucose homeostasis traits;	chr5:122833753	chr5:123022487~123022783:-
SARC	cis	rs2404602	0.583	rs2176623	ENSG00000259422.1	RP11-593F23.1	4.5	1.06e-05	0.00492	0.31	0.28	Blood metabolite levels;	chr15:76276238	chr15:76174891~76181486:-
SARC	cis	rs2412819	0.571	rs4923964	ENSG00000205771.5	CATSPER2P1	4.5	1.06e-05	0.00492	0.42	0.28	Lung cancer;	chr15:43722882	chr15:43726918~43747094:-
SARC	cis	rs4273100	0.646	rs1472932	ENSG00000228157.4	AC007952.5	-4.5	1.06e-05	0.00493	-0.35	-0.28	Schizophrenia;	chr17:19317353	chr17:19092974~19096837:+
SARC	cis	rs7772486	0.754	rs10872580	ENSG00000235652.6	RP11-545I5.3	-4.5	1.06e-05	0.00493	-0.25	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145799409~145886585:+
SARC	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-4.5	1.06e-05	0.00493	-0.3	-0.28	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
SARC	cis	rs14027	0.921	rs13270831	ENSG00000279347.1	RP11-85I17.2	-4.5	1.06e-05	0.00493	-0.25	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119755071	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs16893113	ENSG00000279347.1	RP11-85I17.2	-4.5	1.06e-05	0.00493	-0.25	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756447	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs2326377	ENSG00000279347.1	RP11-85I17.2	-4.5	1.06e-05	0.00493	-0.25	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756696	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs13257002	ENSG00000279347.1	RP11-85I17.2	-4.5	1.06e-05	0.00493	-0.25	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119757489	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs62526565	ENSG00000279347.1	RP11-85I17.2	-4.5	1.06e-05	0.00493	-0.25	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759301	chr8:119838736~119840385:-
SARC	cis	rs7267979	1	rs2500418	ENSG00000276952.1	RP5-965G21.6	-4.5	1.06e-05	0.00493	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:25284915~25285588:-
SARC	cis	rs4654783	0.671	rs1474647	ENSG00000228397.1	RP1-224A6.3	4.5	1.06e-05	0.00494	0.32	0.28	Endometriosis;	chr1:22115372	chr1:22023994~22024968:-
SARC	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	4.5	1.06e-05	0.00494	0.26	0.28	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
SARC	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	4.5	1.06e-05	0.00494	0.26	0.28	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
SARC	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	4.5	1.06e-05	0.00494	0.26	0.28	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
SARC	cis	rs848486	0.686	rs58329075	ENSG00000214293.7	APTR	-4.5	1.07e-05	0.00494	-0.3	-0.28	Glomerular filtration rate;	chr7:77640626	chr7:77657660~77696265:-
SARC	cis	rs4938330	0.68	rs4938329	ENSG00000254851.1	RP11-109L13.1	4.5	1.07e-05	0.00495	0.37	0.28	Blood protein levels;	chr11:117057396	chr11:117135528~117138582:+
SARC	cis	rs2439831	0.85	rs28564774	ENSG00000275601.1	AC011330.13	-4.5	1.07e-05	0.00495	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43833277	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs12441984	ENSG00000275601.1	AC011330.13	-4.5	1.07e-05	0.00495	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43834087	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs7169322	ENSG00000275601.1	AC011330.13	-4.5	1.07e-05	0.00495	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43838816	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs28707214	ENSG00000275601.1	AC011330.13	-4.5	1.07e-05	0.00495	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43839425	chr15:43642389~43643023:-
SARC	cis	rs8062405	0.792	rs12446550	ENSG00000251417.2	RP11-1348G14.4	-4.5	1.07e-05	0.00495	-0.27	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28802743~28817828:+
SARC	cis	rs783540	0.934	rs803747	ENSG00000275695.1	UBE2Q2P6	-4.5	1.07e-05	0.00496	-0.28	-0.28	Schizophrenia;	chr15:82589345	chr15:82445719~82454837:+
SARC	cis	rs783540	0.967	rs55972423	ENSG00000275695.1	UBE2Q2P6	-4.5	1.07e-05	0.00496	-0.28	-0.28	Schizophrenia;	chr15:82590203	chr15:82445719~82454837:+
SARC	cis	rs193541	0.632	rs1460040	ENSG00000263432.2	RN7SL689P	4.5	1.07e-05	0.00496	0.35	0.28	Glucose homeostasis traits;	chr5:122769537	chr5:123022487~123022783:-
SARC	cis	rs46522	0.585	rs79049364	ENSG00000270781.1	RP11-501C14.9	-4.5	1.07e-05	0.00496	-0.33	-0.28	Coronary heart disease;	chr17:48937629	chr17:48899131~48899748:+
SARC	cis	rs79349575	0.811	rs80032154	ENSG00000270781.1	RP11-501C14.9	-4.5	1.07e-05	0.00496	-0.33	-0.28	Type 2 diabetes;	chr17:48937630	chr17:48899131~48899748:+
SARC	cis	rs7267979	1	rs6050561	ENSG00000276952.1	RP5-965G21.6	-4.5	1.07e-05	0.00496	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6083813	ENSG00000276952.1	RP5-965G21.6	-4.5	1.07e-05	0.00496	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25284915~25285588:-
SARC	cis	rs2179367	0.632	rs2341774	ENSG00000231760.4	RP11-350J20.5	4.5	1.07e-05	0.00496	0.39	0.28	Dupuytren's disease;	chr6:149425014	chr6:149796151~149826294:-
SARC	cis	rs2018683	0.711	rs917213	ENSG00000228421.2	AC005013.5	4.5	1.07e-05	0.00497	0.28	0.28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928587	chr7:28957667~28959345:+
SARC	cis	rs2018683	0.711	rs917214	ENSG00000228421.2	AC005013.5	4.5	1.07e-05	0.00497	0.28	0.28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928676	chr7:28957667~28959345:+
SARC	cis	rs7131987	0.65	rs3782509	ENSG00000257176.2	RP11-996F15.2	-4.5	1.07e-05	0.00497	-0.33	-0.28	QT interval;	chr12:29300845	chr12:29280418~29317848:-
SARC	cis	rs763121	0.853	rs138709	ENSG00000273076.1	RP3-508I15.22	4.5	1.07e-05	0.00497	0.3	0.28	Menopause (age at onset);	chr22:38743211	chr22:38743495~38743910:+
SARC	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	4.5	1.07e-05	0.00497	0.29	0.28	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
SARC	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	4.5	1.07e-05	0.00497	0.29	0.28	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
SARC	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-4.5	1.07e-05	0.00498	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-4.5	1.07e-05	0.00498	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
SARC	cis	rs12432203	1	rs4566067	ENSG00000273888.1	FRMD6-AS1	-4.5	1.07e-05	0.00498	-0.4	-0.28	Cancer;	chr14:51262769	chr14:51649516~51651744:-
SARC	cis	rs7772486	0.743	rs9403742	ENSG00000270638.1	RP3-466P17.1	4.5	1.07e-05	0.00498	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145735570~145737218:+
SARC	cis	rs7615952	1	rs7615952	ENSG00000241288.6	RP11-379B18.5	4.5	1.08e-05	0.00499	0.36	0.28	Blood pressure (smoking interaction);	chr3:125930560	chr3:125827238~125916384:-
SARC	cis	rs13161895	1	rs34603792	ENSG00000250999.1	RP11-1379J22.5	-4.5	1.08e-05	0.00499	-0.49	-0.28	LDL cholesterol;	chr5:180032287	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs4389651	ENSG00000250999.1	RP11-1379J22.5	-4.5	1.08e-05	0.00499	-0.49	-0.28	LDL cholesterol;	chr5:180033968	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs34882290	ENSG00000250999.1	RP11-1379J22.5	-4.5	1.08e-05	0.00499	-0.49	-0.28	LDL cholesterol;	chr5:180036836	chr5:179657762~179664432:+
SARC	cis	rs11123170	0.542	rs28522253	ENSG00000189223.12	PAX8-AS1	-4.5	1.08e-05	0.00499	-0.41	-0.28	Renal function-related traits (BUN);	chr2:113209810	chr2:113211522~113276581:+
SARC	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-4.5	1.08e-05	0.00499	-0.53	-0.28	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
SARC	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	4.5	1.08e-05	0.00499	0.26	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
SARC	cis	rs2018683	0.711	rs1874977	ENSG00000228421.2	AC005013.5	4.5	1.08e-05	0.005	0.28	0.28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928466	chr7:28957667~28959345:+
SARC	cis	rs7267979	1	rs1888997	ENSG00000276952.1	RP5-965G21.6	-4.5	1.08e-05	0.005	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs3002698	ENSG00000276952.1	RP5-965G21.6	-4.5	1.08e-05	0.005	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25284915~25285588:-
SARC	cis	rs858239	1	rs156425	ENSG00000226816.2	AC005082.12	-4.5	1.08e-05	0.005	-0.35	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23206013~23208045:+
SARC	cis	rs8018967	0.622	rs2041073	ENSG00000258695.2	RP3-414A15.2	4.5	1.08e-05	0.005	0.3	0.28	Blood metabolite ratios;	chr14:73505831	chr14:73522878~73530610:+
SARC	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-4.5	1.08e-05	0.005	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs7169988	ENSG00000275601.1	AC011330.13	-4.5	1.08e-05	0.005	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43768237	chr15:43642389~43643023:-
SARC	cis	rs853679	0.546	rs200981	ENSG00000216901.1	AL022393.7	4.5	1.08e-05	0.005	0.63	0.28	Depression;	chr6:27865396	chr6:28176188~28176674:+
SARC	cis	rs853679	0.546	rs200953	ENSG00000216901.1	AL022393.7	4.5	1.08e-05	0.005	0.63	0.28	Depression;	chr6:27869489	chr6:28176188~28176674:+
SARC	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-4.5	1.08e-05	0.005	-0.29	-0.28	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
SARC	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-4.5	1.08e-05	0.005	-0.53	-0.28	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
SARC	cis	rs4664293	0.836	rs13016015	ENSG00000226266.5	AC009961.3	-4.5	1.08e-05	0.005	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159790018	chr2:159670708~159712435:-
SARC	cis	rs12950390	0.893	rs72831644	ENSG00000239291.1	RP5-867C24.1	4.5	1.08e-05	0.005	0.34	0.28	IgG glycosylation;	chr17:47747025	chr17:47159191~47159993:-
SARC	cis	rs4835473	0.932	rs13129702	ENSG00000251600.4	RP11-673E1.1	4.5	1.08e-05	0.005	0.27	0.28	Immature fraction of reticulocytes;	chr4:143785132	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4383567	ENSG00000251600.4	RP11-673E1.1	4.5	1.08e-05	0.005	0.27	0.28	Immature fraction of reticulocytes;	chr4:143788873	chr4:143912331~143982454:+
SARC	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-4.5	1.08e-05	0.00501	-0.53	-0.28	Gout;	chr7:66671562	chr7:66654538~66669855:+
SARC	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-4.5	1.08e-05	0.00501	-0.32	-0.28	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
SARC	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	4.5	1.08e-05	0.00501	0.31	0.28	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	4.5	1.08e-05	0.00501	0.31	0.28	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
SARC	cis	rs853679	0.882	rs9468287	ENSG00000219392.1	RP1-265C24.5	-4.5	1.08e-05	0.00501	-0.51	-0.28	Depression;	chr6:28111963	chr6:28115628~28116551:+
SARC	cis	rs7267979	0.844	rs6132824	ENSG00000276952.1	RP5-965G21.6	4.5	1.08e-05	0.00502	0.26	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25257537	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.739	rs6138555	ENSG00000276952.1	RP5-965G21.6	4.5	1.08e-05	0.00502	0.26	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25262274	chr20:25284915~25285588:-
SARC	cis	rs1799949	0.965	rs11080034	ENSG00000267681.1	CTD-3199J23.6	-4.5	1.08e-05	0.00502	-0.31	-0.28	Menopause (age at onset);	chr17:43365646	chr17:43144956~43145255:+
SARC	cis	rs6570726	0.791	rs379040	ENSG00000270638.1	RP3-466P17.1	4.5	1.09e-05	0.00502	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145735570~145737218:+
SARC	cis	rs1707322	0.721	rs10890343	ENSG00000281133.1	AL355480.3	-4.5	1.09e-05	0.00502	-0.33	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45580892~45580996:-
SARC	cis	rs910316	1	rs12879542	ENSG00000279594.1	RP11-950C14.10	4.5	1.09e-05	0.00502	0.31	0.28	Height;	chr14:75040822	chr14:75011269~75012851:-
SARC	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	4.5	1.09e-05	0.00503	0.41	0.28	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
SARC	cis	rs75422866	0.51	rs73105829	ENSG00000257433.4	RP1-197B17.3	4.5	1.09e-05	0.00503	0.5	0.28	Pneumonia;	chr12:47734162	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.51	rs75424057	ENSG00000257433.4	RP1-197B17.3	4.5	1.09e-05	0.00503	0.5	0.28	Pneumonia;	chr12:47737294	chr12:47706085~47742294:+
SARC	cis	rs2412819	0.571	rs678084	ENSG00000205771.5	CATSPER2P1	4.5	1.09e-05	0.00503	0.42	0.28	Lung cancer;	chr15:43828361	chr15:43726918~43747094:-
SARC	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-4.5	1.09e-05	0.00503	-0.34	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
SARC	cis	rs4835473	0.897	rs2089835	ENSG00000251600.4	RP11-673E1.1	4.5	1.09e-05	0.00504	0.27	0.28	Immature fraction of reticulocytes;	chr4:143965127	chr4:143912331~143982454:+
SARC	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	4.5	1.09e-05	0.00504	0.32	0.28	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
SARC	cis	rs4664293	0.625	rs4665102	ENSG00000226266.5	AC009961.3	4.5	1.09e-05	0.00504	0.33	0.28	Monocyte percentage of white cells;	chr2:159666076	chr2:159670708~159712435:-
SARC	cis	rs7662987	0.793	rs7669660	ENSG00000272777.1	RP11-571L19.8	4.5	1.09e-05	0.00504	0.33	0.28	Smoking initiation;	chr4:99071451	chr4:99067256~99068125:-
SARC	cis	rs34375054	0.526	rs883315	ENSG00000279233.1	RP11-158L12.4	4.5	1.09e-05	0.00505	0.32	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125192343	chr12:125138245~125141711:+
SARC	cis	rs910316	1	rs12889472	ENSG00000279594.1	RP11-950C14.10	4.5	1.09e-05	0.00505	0.31	0.28	Height;	chr14:75077276	chr14:75011269~75012851:-
SARC	cis	rs57561814	0.655	rs58879058	ENSG00000179428.2	AC073072.5	-4.5	1.09e-05	0.00505	-0.52	-0.28	Tonsillectomy;	chr7:22702203	chr7:22725395~22727620:-
SARC	cis	rs4664293	0.836	rs13403371	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159736603	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs13428679	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159736687	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs12623283	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159736959	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs2098976	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159737264	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs2081723	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159737649	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs2081722	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159737697	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs10166694	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159738380	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.836	rs10190704	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159738451	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs2357529	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159738922	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs12692562	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159739199	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs12998291	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159739392	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs10194483	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159739883	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs2357531	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159740907	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs16844269	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159742569	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.836	rs4664300	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159743927	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs16822556	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159744392	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs16822558	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159744496	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs1834761	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159745278	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs6432558	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159745397	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.836	rs7567818	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159746186	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs12692563	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159746300	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs12620924	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159746452	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs12617546	ENSG00000226266.5	AC009961.3	-4.5	1.09e-05	0.00505	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159767079	chr2:159670708~159712435:-
SARC	cis	rs7772486	0.754	rs702319	ENSG00000270638.1	RP3-466P17.1	-4.5	1.1e-05	0.00506	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145735570~145737218:+
SARC	cis	rs9818758	0.607	rs34823813	ENSG00000225399.4	RP11-3B7.1	-4.5	1.1e-05	0.00506	-0.53	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49712543	chr3:49260085~49261316:+
SARC	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-4.49	1.1e-05	0.00507	-0.53	-0.28	Gout;	chr7:66715944	chr7:66654538~66669855:+
SARC	cis	rs123509	0.913	rs339686	ENSG00000230970.3	HHATL-AS1	-4.49	1.1e-05	0.00507	-0.33	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42728196	chr3:42702653~42706776:+
SARC	cis	rs123509	0.913	rs121993	ENSG00000230970.3	HHATL-AS1	-4.49	1.1e-05	0.00507	-0.33	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42735109	chr3:42702653~42706776:+
SARC	cis	rs123509	0.913	rs339685	ENSG00000230970.3	HHATL-AS1	-4.49	1.1e-05	0.00507	-0.33	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42741460	chr3:42702653~42706776:+
SARC	cis	rs7587476	1	rs7587476	ENSG00000229267.2	AC072062.1	4.49	1.1e-05	0.00507	0.27	0.28	Neuroblastoma;	chr2:214789163	chr2:214810229~214963274:+
SARC	cis	rs6540731	1	rs6540733	ENSG00000229983.1	RP11-15I11.2	4.49	1.1e-05	0.00508	0.29	0.28	Intelligence (childhood);	chr1:212219611	chr1:212168207~212190259:+
SARC	cis	rs2288884	0.636	rs11669439	ENSG00000275055.1	CTC-471J1.11	-4.49	1.1e-05	0.00508	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.636	rs8101936	ENSG00000275055.1	CTC-471J1.11	-4.49	1.1e-05	0.00508	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.636	rs8105801	ENSG00000275055.1	CTC-471J1.11	-4.49	1.1e-05	0.00508	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.636	rs1560690	ENSG00000275055.1	CTC-471J1.11	-4.49	1.1e-05	0.00508	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:52049007~52049754:+
SARC	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	4.49	1.1e-05	0.00508	0.53	0.28	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
SARC	cis	rs324126	0.78	rs60935857	ENSG00000269834.4	ZNF528-AS1	4.49	1.1e-05	0.00508	0.3	0.28	Colonoscopy-negative controls vs population controls;	chr19:52382606	chr19:52388842~52397766:-
SARC	cis	rs9309473	0.519	rs2421545	ENSG00000163016.8	ALMS1P	-4.49	1.1e-05	0.00509	-0.32	-0.28	Metabolite levels;	chr2:73412348	chr2:73644919~73685576:+
SARC	cis	rs7560272	0.723	rs2421548	ENSG00000163016.8	ALMS1P	-4.49	1.1e-05	0.00509	-0.32	-0.28	Schizophrenia;	chr2:73414112	chr2:73644919~73685576:+
SARC	cis	rs7560272	0.723	rs12995433	ENSG00000163016.8	ALMS1P	-4.49	1.1e-05	0.00509	-0.32	-0.28	Schizophrenia;	chr2:73414198	chr2:73644919~73685576:+
SARC	cis	rs7560272	0.723	rs4852927	ENSG00000163016.8	ALMS1P	-4.49	1.1e-05	0.00509	-0.32	-0.28	Schizophrenia;	chr2:73414429	chr2:73644919~73685576:+
SARC	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	4.49	1.1e-05	0.00509	0.33	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
SARC	cis	rs3805389	0.504	rs13434995	ENSG00000273257.1	RP11-177J6.1	-4.49	1.1e-05	0.00509	-0.42	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr4:55601047	chr4:55387949~55388271:+
SARC	cis	rs890448	0.726	rs2583391	ENSG00000254531.1	FLJ20021	-4.49	1.1e-05	0.00509	-0.29	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101346296	chr4:101347780~101348883:+
SARC	cis	rs1707322	0.721	rs10789468	ENSG00000281133.1	AL355480.3	-4.49	1.1e-05	0.00509	-0.33	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs6429574	ENSG00000281133.1	AL355480.3	-4.49	1.1e-05	0.00509	-0.33	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45580892~45580996:-
SARC	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	4.49	1.1e-05	0.0051	0.27	0.28	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
SARC	cis	rs910316	1	rs2300601	ENSG00000279594.1	RP11-950C14.10	4.49	1.11e-05	0.0051	0.33	0.28	Height;	chr14:75172868	chr14:75011269~75012851:-
SARC	cis	rs7216064	1	rs73352808	ENSG00000265055.1	AC145343.2	4.49	1.11e-05	0.00511	0.36	0.28	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67879041	chr17:68096046~68101474:-
SARC	cis	rs7267979	0.816	rs6037158	ENSG00000125804.12	FAM182A	-4.49	1.11e-05	0.00511	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:26054655~26086917:+
SARC	cis	rs7976269	0.609	rs10771478	ENSG00000257176.2	RP11-996F15.2	4.49	1.11e-05	0.00511	0.31	0.28	Male-pattern baldness;	chr12:29075351	chr12:29280418~29317848:-
SARC	cis	rs520525	0.963	rs600093	ENSG00000271811.1	RP1-79C4.4	4.49	1.11e-05	0.00512	0.39	0.28	Atrial fibrillation;	chr1:170660697	chr1:170667381~170669425:+
SARC	cis	rs7772486	0.754	rs702318	ENSG00000270638.1	RP3-466P17.1	-4.49	1.11e-05	0.00512	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs4896838	ENSG00000270638.1	RP3-466P17.1	-4.49	1.11e-05	0.00512	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145735570~145737218:+
SARC	cis	rs6844153	0.823	rs12642922	ENSG00000240005.4	RP11-293A21.1	-4.49	1.11e-05	0.00512	-0.38	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:27025996	chr4:26859806~26860599:-
SARC	cis	rs2439831	0.681	rs2242067	ENSG00000205771.5	CATSPER2P1	-4.49	1.11e-05	0.00512	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43407105	chr15:43726918~43747094:-
SARC	cis	rs7267979	1	rs6050598	ENSG00000276952.1	RP5-965G21.6	4.49	1.11e-05	0.00512	0.28	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25284915~25285588:-
SARC	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	4.49	1.11e-05	0.00513	0.28	0.28	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
SARC	cis	rs17508449	0.819	rs77042378	ENSG00000232450.1	RP4-730K3.3	-4.49	1.11e-05	0.00513	-0.36	-0.28	Leprosy;	chr1:113666479	chr1:113698884~113699631:-
SARC	cis	rs77204473	0.744	rs12420200	ENSG00000254851.1	RP11-109L13.1	-4.49	1.11e-05	0.00513	-0.53	-0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117127590	chr11:117135528~117138582:+
SARC	cis	rs2439831	0.85	rs28413704	ENSG00000275601.1	AC011330.13	-4.49	1.11e-05	0.00513	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43856229	chr15:43642389~43643023:-
SARC	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-4.49	1.11e-05	0.00514	-0.29	-0.28	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
SARC	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-4.49	1.11e-05	0.00514	-0.29	-0.28	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
SARC	cis	rs910316	0.737	rs175510	ENSG00000279594.1	RP11-950C14.10	-4.49	1.12e-05	0.00515	-0.32	-0.28	Height;	chr14:75058136	chr14:75011269~75012851:-
SARC	cis	rs8005677	0.798	rs61977741	ENSG00000257285.4	RP11-298I3.1	4.49	1.12e-05	0.00515	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:22929609~22955562:+
SARC	cis	rs7617773	0.817	rs9830016	ENSG00000228638.1	FCF1P2	-4.49	1.12e-05	0.00515	-0.32	-0.28	Coronary artery disease;	chr3:48241004	chr3:48290793~48291375:-
SARC	cis	rs1865760	0.516	rs9393683	ENSG00000272462.2	U91328.19	-4.49	1.12e-05	0.00515	-0.25	-0.28	Height;	chr6:26065970	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.516	rs9295684	ENSG00000272462.2	U91328.19	-4.49	1.12e-05	0.00515	-0.25	-0.28	Height;	chr6:26069441	chr6:25992662~26001775:+
SARC	cis	rs1707322	0.682	rs28508523	ENSG00000281133.1	AL355480.3	-4.49	1.12e-05	0.00515	-0.33	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.691	rs11211175	ENSG00000281133.1	AL355480.3	-4.49	1.12e-05	0.00515	-0.33	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45580892~45580996:-
SARC	cis	rs75920871	0.528	rs2513097	ENSG00000254851.1	RP11-109L13.1	4.49	1.12e-05	0.00516	0.38	0.28	Subjective well-being;	chr11:116965496	chr11:117135528~117138582:+
SARC	cis	rs7809950	0.678	rs75617662	ENSG00000238832.1	snoU109	-4.49	1.12e-05	0.00516	-0.34	-0.28	Coronary artery disease;	chr7:107389994	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.678	rs7790080	ENSG00000238832.1	snoU109	-4.49	1.12e-05	0.00516	-0.34	-0.28	Coronary artery disease;	chr7:107390877	chr7:107603363~107603507:+
SARC	cis	rs910316	1	rs4903275	ENSG00000279594.1	RP11-950C14.10	4.49	1.12e-05	0.00516	0.31	0.28	Height;	chr14:75045806	chr14:75011269~75012851:-
SARC	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	4.49	1.12e-05	0.00516	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
SARC	cis	rs1707322	0.827	rs6694302	ENSG00000281133.1	AL355480.3	-4.49	1.12e-05	0.00517	-0.31	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45580892~45580996:-
SARC	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	4.49	1.12e-05	0.00517	0.33	0.28	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
SARC	cis	rs7267979	0.844	rs2474780	ENSG00000125804.12	FAM182A	-4.49	1.13e-05	0.00518	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:26054655~26086917:+
SARC	cis	rs7178375	0.941	rs4779796	ENSG00000215302.7	CTD-3092A11.1	-4.49	1.13e-05	0.00519	-0.36	-0.28	Hypertriglyceridemia;	chr15:30915847	chr15:30470779~30507623:+
SARC	cis	rs2288884	0.559	rs6509611	ENSG00000275055.1	CTC-471J1.11	-4.49	1.13e-05	0.00519	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006953	chr19:52049007~52049754:+
SARC	cis	rs2404602	0.71	rs2469541	ENSG00000259422.1	RP11-593F23.1	-4.49	1.13e-05	0.00519	-0.32	-0.28	Blood metabolite levels;	chr15:76269777	chr15:76174891~76181486:-
SARC	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	4.49	1.13e-05	0.00519	0.31	0.28	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
SARC	cis	rs253959	0.545	rs10072350	ENSG00000272265.1	CTD-2287O16.4	4.49	1.13e-05	0.00519	0.33	0.28	Bipolar disorder and schizophrenia;	chr5:116097829	chr5:116078110~116078570:-
SARC	cis	rs783540	0.967	rs2567635	ENSG00000275695.1	UBE2Q2P6	-4.49	1.13e-05	0.00519	-0.28	-0.28	Schizophrenia;	chr15:82593431	chr15:82445719~82454837:+
SARC	cis	rs783540	0.933	rs2567636	ENSG00000275695.1	UBE2Q2P6	-4.49	1.13e-05	0.00519	-0.28	-0.28	Schizophrenia;	chr15:82594678	chr15:82445719~82454837:+
SARC	cis	rs783540	0.934	rs783530	ENSG00000275695.1	UBE2Q2P6	-4.49	1.13e-05	0.00519	-0.28	-0.28	Schizophrenia;	chr15:82597799	chr15:82445719~82454837:+
SARC	cis	rs13217239	0.646	rs62401067	ENSG00000241549.7	GUSBP2	4.49	1.13e-05	0.00519	0.27	0.28	Schizophrenia;	chr6:27050322	chr6:26871484~26956554:-
SARC	cis	rs324126	0.743	rs34221182	ENSG00000269834.4	ZNF528-AS1	4.49	1.13e-05	0.0052	0.3	0.28	Colonoscopy-negative controls vs population controls;	chr19:52378107	chr19:52388842~52397766:-
SARC	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-4.49	1.13e-05	0.0052	-0.31	-0.28	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
SARC	cis	rs8062405	0.755	rs4788073	ENSG00000251417.2	RP11-1348G14.4	-4.49	1.13e-05	0.0052	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28802743~28817828:+
SARC	cis	rs1707322	0.826	rs10890349	ENSG00000281133.1	AL355480.3	-4.49	1.13e-05	0.0052	-0.32	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.758	rs10789474	ENSG00000281133.1	AL355480.3	-4.49	1.13e-05	0.0052	-0.32	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45580892~45580996:-
SARC	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-4.49	1.13e-05	0.0052	-0.36	-0.28	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
SARC	cis	rs4664293	0.764	rs10195287	ENSG00000226266.5	AC009961.3	-4.49	1.13e-05	0.0052	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159604967	chr2:159670708~159712435:-
SARC	cis	rs783540	0.835	rs8030185	ENSG00000275695.1	UBE2Q2P6	4.49	1.13e-05	0.0052	0.29	0.28	Schizophrenia;	chr15:82722785	chr15:82445719~82454837:+
SARC	cis	rs2439831	0.85	rs3825783	ENSG00000275601.1	AC011330.13	-4.49	1.13e-05	0.0052	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43810111	chr15:43642389~43643023:-
SARC	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	4.49	1.13e-05	0.0052	0.35	0.28	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
SARC	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00522	-0.53	-0.28	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	4.49	1.14e-05	0.00522	0.53	0.28	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
SARC	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-4.49	1.14e-05	0.00522	-0.31	-0.28	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-4.49	1.14e-05	0.00522	-0.31	-0.28	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
SARC	cis	rs8059260	0.542	rs7184915	ENSG00000274038.1	RP11-66H6.4	-4.49	1.14e-05	0.00523	-0.39	-0.28	Alcohol consumption over the past year;	chr16:11034509	chr16:11056556~11057034:+
SARC	cis	rs72945132	0.882	rs7129843	ENSG00000254604.1	AP000487.6	-4.49	1.14e-05	0.00523	-0.39	-0.28	Coronary artery disease;	chr11:70334275	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs58039907	ENSG00000254604.1	AP000487.6	-4.49	1.14e-05	0.00523	-0.39	-0.28	Coronary artery disease;	chr11:70337230	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs11235953	ENSG00000254604.1	AP000487.6	-4.49	1.14e-05	0.00523	-0.39	-0.28	Coronary artery disease;	chr11:70338831	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs1061328	ENSG00000254604.1	AP000487.6	-4.49	1.14e-05	0.00523	-0.39	-0.28	Coronary artery disease;	chr11:70339219	chr11:70282367~70363368:-
SARC	cis	rs5769707	0.967	rs9616327	ENSG00000235111.1	RP1-29C18.8	-4.49	1.14e-05	0.00524	-0.31	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49612657~49615716:-
SARC	cis	rs910316	0.712	rs175015	ENSG00000279594.1	RP11-950C14.10	-4.49	1.14e-05	0.00524	-0.32	-0.28	Height;	chr14:74990372	chr14:75011269~75012851:-
SARC	cis	rs2905347	1	rs2905347	ENSG00000179428.2	AC073072.5	-4.49	1.14e-05	0.00524	-0.3	-0.28	Major depression and alcohol dependence;	chr7:22580700	chr7:22725395~22727620:-
SARC	cis	rs7160336	0.555	rs7147523	ENSG00000259065.1	RP5-1021I20.1	4.49	1.14e-05	0.00524	0.38	0.28	Blood protein levels;	chr14:74034747	chr14:73787360~73803270:+
SARC	cis	rs4664293	0.867	rs7566584	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159728284	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs3732289	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159728887	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs3821299	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159729229	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs13415100	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159729716	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs13389662	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159729926	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs7562060	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159730618	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs4665110	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159731014	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs34893664	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159732266	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs34795915	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159732420	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs10204867	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159732674	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs35196716	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159733266	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs6432557	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159735699	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs7603274	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159736179	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs1126842	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159770806	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs3771721	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159771644	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs11681245	ENSG00000226266.5	AC009961.3	-4.49	1.14e-05	0.00524	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159772882	chr2:159670708~159712435:-
SARC	cis	rs1823913	0.637	rs4853583	ENSG00000227542.1	AC092614.2	-4.48	1.15e-05	0.00525	-0.32	-0.28	Obesity-related traits;	chr2:191304648	chr2:191229165~191246172:-
SARC	cis	rs2439831	0.85	rs16965120	ENSG00000205771.5	CATSPER2P1	-4.48	1.15e-05	0.00526	-0.45	-0.28	Lung cancer in ever smokers;	chr15:43808144	chr15:43726918~43747094:-
SARC	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-4.48	1.15e-05	0.00526	-0.33	-0.28	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
SARC	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	4.48	1.15e-05	0.00526	0.33	0.28	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
SARC	cis	rs910316	0.763	rs13712	ENSG00000279594.1	RP11-950C14.10	4.48	1.15e-05	0.00527	0.31	0.28	Height;	chr14:75017109	chr14:75011269~75012851:-
SARC	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-4.48	1.15e-05	0.00527	-0.53	-0.28	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
SARC	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-4.48	1.15e-05	0.00527	-0.31	-0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
SARC	cis	rs4664293	0.51	rs66571608	ENSG00000226266.5	AC009961.3	4.48	1.15e-05	0.00527	0.35	0.28	Monocyte percentage of white cells;	chr2:159635851	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.51	rs66589863	ENSG00000226266.5	AC009961.3	4.48	1.15e-05	0.00527	0.35	0.28	Monocyte percentage of white cells;	chr2:159649684	chr2:159670708~159712435:-
SARC	cis	rs2288884	0.559	rs12459268	ENSG00000275055.1	CTC-471J1.11	-4.48	1.15e-05	0.00528	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52002719	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.559	rs8109948	ENSG00000275055.1	CTC-471J1.11	-4.48	1.15e-05	0.00528	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004796	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.559	rs8109964	ENSG00000275055.1	CTC-471J1.11	-4.48	1.15e-05	0.00528	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004835	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.559	rs8109854	ENSG00000275055.1	CTC-471J1.11	-4.48	1.15e-05	0.00528	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004866	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.559	rs12461141	ENSG00000275055.1	CTC-471J1.11	-4.48	1.15e-05	0.00528	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005712	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.559	rs12459079	ENSG00000275055.1	CTC-471J1.11	-4.48	1.15e-05	0.00528	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005741	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.559	rs12461226	ENSG00000275055.1	CTC-471J1.11	-4.48	1.15e-05	0.00528	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005996	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.559	rs12461230	ENSG00000275055.1	CTC-471J1.11	-4.48	1.15e-05	0.00528	-0.3	-0.28	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006051	chr19:52049007~52049754:+
SARC	cis	rs7712401	0.691	rs62377436	ENSG00000263432.2	RN7SL689P	-4.48	1.15e-05	0.00528	-0.35	-0.28	Mean platelet volume;	chr5:123018007	chr5:123022487~123022783:-
SARC	cis	rs860818	1	rs858249	ENSG00000226816.2	AC005082.12	-4.48	1.15e-05	0.00528	-0.69	-0.28	Initial pursuit acceleration;	chr7:23181020	chr7:23206013~23208045:+
SARC	cis	rs62184315	0.938	rs17806132	ENSG00000273240.1	RP11-455J20.3	4.48	1.15e-05	0.00529	0.4	0.28	Alcohol dependence (age at onset);	chr2:189843561	chr2:189763859~189764456:-
SARC	cis	rs524281	0.954	rs549187	ENSG00000255320.1	RP11-755F10.1	4.48	1.15e-05	0.00529	0.38	0.28	Electroencephalogram traits;	chr11:66131160	chr11:66244840~66246239:-
SARC	cis	rs4664293	0.967	rs35975814	ENSG00000226266.5	AC009961.3	-4.48	1.15e-05	0.00529	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159691280	chr2:159670708~159712435:-
SARC	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	4.48	1.16e-05	0.00529	0.29	0.28	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
SARC	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-4.48	1.16e-05	0.00529	-0.3	-0.28	Height;	chr3:53034139	chr3:53064283~53065091:-
SARC	cis	rs17772222	0.636	rs3850390	ENSG00000258983.2	RP11-507K2.2	4.48	1.16e-05	0.0053	0.32	0.28	Coronary artery calcification;	chr14:88829185	chr14:88499334~88515502:+
SARC	cis	rs17772222	0.597	rs17700296	ENSG00000258983.2	RP11-507K2.2	4.48	1.16e-05	0.0053	0.32	0.28	Coronary artery calcification;	chr14:88840976	chr14:88499334~88515502:+
SARC	cis	rs7267979	1	rs2500448	ENSG00000276952.1	RP5-965G21.6	-4.48	1.16e-05	0.0053	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25284915~25285588:-
SARC	cis	rs526231	0.819	rs26233	ENSG00000175749.11	EIF3KP1	4.48	1.16e-05	0.00531	0.38	0.28	Primary biliary cholangitis;	chr5:103261115	chr5:103032376~103033031:+
SARC	cis	rs526231	0.853	rs376286	ENSG00000175749.11	EIF3KP1	4.48	1.16e-05	0.00531	0.38	0.28	Primary biliary cholangitis;	chr5:103263689	chr5:103032376~103033031:+
SARC	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-4.48	1.16e-05	0.00531	-0.36	-0.28	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
SARC	cis	rs732716	0.719	rs56088814	ENSG00000267769.1	CTB-50L17.9	-4.48	1.16e-05	0.00531	-0.34	-0.28	Mean corpuscular volume;	chr19:4422181	chr19:4454014~4455286:+
SARC	cis	rs7267979	0.873	rs6083853	ENSG00000276952.1	RP5-965G21.6	-4.48	1.16e-05	0.00531	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.934	rs2482913	ENSG00000276952.1	RP5-965G21.6	-4.48	1.16e-05	0.00531	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25284915~25285588:-
SARC	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	4.48	1.16e-05	0.00531	0.23	0.28	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	4.48	1.16e-05	0.00531	0.23	0.28	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
SARC	cis	rs1001021	1	rs5752249	ENSG00000230637.2	CTA-246H3.8	-4.48	1.16e-05	0.00532	-0.58	-0.28	Schizophrenia, bipolar disorder and depression (combined);	chr22:25992740	chr22:25327252~25339975:+
SARC	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	4.48	1.16e-05	0.00532	0.27	0.28	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
SARC	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-4.48	1.16e-05	0.00532	-0.32	-0.28	QT interval;	chr12:29303562	chr12:29280418~29317848:-
SARC	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-4.48	1.16e-05	0.00532	-0.32	-0.28	QT interval;	chr12:29306799	chr12:29280418~29317848:-
SARC	cis	rs4835473	0.932	rs11100824	ENSG00000251600.4	RP11-673E1.1	4.48	1.16e-05	0.00532	0.28	0.28	Immature fraction of reticulocytes;	chr4:143964845	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.592	rs11100825	ENSG00000251600.4	RP11-673E1.1	4.48	1.16e-05	0.00532	0.28	0.28	Immature fraction of reticulocytes;	chr4:143964903	chr4:143912331~143982454:+
SARC	cis	rs4372836	0.504	rs6547881	ENSG00000226833.4	AC097724.3	-4.48	1.16e-05	0.00533	-0.23	-0.28	Body mass index;	chr2:28809880	chr2:28708953~28736205:-
SARC	cis	rs72945132	0.882	rs3900797	ENSG00000254604.1	AP000487.6	-4.48	1.16e-05	0.00533	-0.39	-0.28	Coronary artery disease;	chr11:70340508	chr11:70282367~70363368:-
SARC	cis	rs12216125	0.549	rs9358905	ENSG00000272462.2	U91328.19	-4.48	1.16e-05	0.00533	-0.26	-0.28	Iron status biomarkers;	chr6:26077611	chr6:25992662~26001775:+
SARC	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	4.48	1.16e-05	0.00533	0.23	0.28	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	4.48	1.16e-05	0.00533	0.23	0.28	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
SARC	cis	rs7809950	0.678	rs7803151	ENSG00000238832.1	snoU109	-4.48	1.16e-05	0.00533	-0.34	-0.28	Coronary artery disease;	chr7:107293801	chr7:107603363~107603507:+
SARC	cis	rs5769707	0.605	rs6009791	ENSG00000235111.1	RP1-29C18.8	-4.48	1.16e-05	0.00533	-0.35	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49612657~49615716:-
SARC	cis	rs5769707	0.667	rs4824069	ENSG00000235111.1	RP1-29C18.8	-4.48	1.16e-05	0.00533	-0.35	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49612657~49615716:-
SARC	cis	rs6842047	1	rs4862665	ENSG00000272218.1	RP11-11N5.3	-4.48	1.17e-05	0.00534	-0.4	-0.28	Blood protein levels;	chr4:186214988	chr4:186892552~186892983:+
SARC	cis	rs42490	0.903	rs218900	ENSG00000251136.7	RP11-37B2.1	-4.48	1.17e-05	0.00535	-0.31	-0.28	Leprosy;	chr8:89718678	chr8:89609409~89757727:-
SARC	cis	rs42490	0.903	rs218901	ENSG00000251136.7	RP11-37B2.1	-4.48	1.17e-05	0.00535	-0.31	-0.28	Leprosy;	chr8:89719089	chr8:89609409~89757727:-
SARC	cis	rs4835473	0.864	rs2089837	ENSG00000251600.4	RP11-673E1.1	4.48	1.17e-05	0.00535	0.28	0.28	Immature fraction of reticulocytes;	chr4:143965038	chr4:143912331~143982454:+
SARC	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-4.48	1.17e-05	0.00535	-0.27	-0.28	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-4.48	1.17e-05	0.00535	-0.27	-0.28	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-4.48	1.17e-05	0.00535	-0.27	-0.28	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
SARC	cis	rs5752326	0.867	rs713900	ENSG00000261188.1	CTA-445C9.14	4.48	1.17e-05	0.00535	0.51	0.28	Ischemic stroke;	chr22:26502276	chr22:26512537~26514568:+
SARC	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-4.48	1.17e-05	0.00536	-0.31	-0.28	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
SARC	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	4.48	1.17e-05	0.00536	0.38	0.28	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
SARC	cis	rs75920871	0.502	rs7124996	ENSG00000254851.1	RP11-109L13.1	4.48	1.17e-05	0.00537	0.37	0.28	Subjective well-being;	chr11:117057290	chr11:117135528~117138582:+
SARC	cis	rs9527	0.615	rs10883781	ENSG00000213061.2	PFN1P11	4.48	1.17e-05	0.00537	0.37	0.28	Arsenic metabolism;	chr10:102821373	chr10:102838011~102845473:-
SARC	cis	rs67478160	0.643	rs2887282	ENSG00000269958.1	RP11-73M18.8	4.48	1.17e-05	0.00537	0.28	0.28	Schizophrenia;	chr14:103814397	chr14:103696353~103697163:+
SARC	cis	rs7976269	0.559	rs4930848	ENSG00000257176.2	RP11-996F15.2	-4.48	1.17e-05	0.00537	-0.3	-0.28	Male-pattern baldness;	chr12:29068441	chr12:29280418~29317848:-
SARC	cis	rs17772222	0.651	rs12586714	ENSG00000258983.2	RP11-507K2.2	4.48	1.17e-05	0.00537	0.28	0.28	Coronary artery calcification;	chr14:88360497	chr14:88499334~88515502:+
SARC	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-4.48	1.18e-05	0.00537	-0.42	-0.28	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
SARC	cis	rs11634944	0.615	rs2732035	ENSG00000274307.1	RP11-345J18.2	-4.48	1.18e-05	0.00537	-0.36	-0.28	Interleukin-8 levels;	chr15:25008346	chr15:25708470~25710869:-
SARC	cis	rs7662987	0.793	rs7684735	ENSG00000272777.1	RP11-571L19.8	4.48	1.18e-05	0.00538	0.33	0.28	Smoking initiation;	chr4:99070355	chr4:99067256~99068125:-
SARC	cis	rs2933343	0.909	rs1683817	ENSG00000261159.1	RP11-723O4.9	4.48	1.18e-05	0.00538	0.33	0.28	IgG glycosylation;	chr3:128932693	chr3:128859716~128860526:-
SARC	cis	rs4950322	0.57	rs72692979	ENSG00000278811.3	LINC00624	4.48	1.18e-05	0.00539	0.3	0.28	Protein quantitative trait loci;	chr1:147336094	chr1:147258885~147517875:-
SARC	cis	rs2179367	0.632	rs12197598	ENSG00000231760.4	RP11-350J20.5	4.48	1.18e-05	0.00539	0.38	0.28	Dupuytren's disease;	chr6:149385418	chr6:149796151~149826294:-
SARC	cis	rs4372836	0.504	rs6730321	ENSG00000226833.4	AC097724.3	4.48	1.18e-05	0.00539	0.24	0.28	Body mass index;	chr2:28781433	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.504	rs2045886	ENSG00000226833.4	AC097724.3	4.48	1.18e-05	0.00539	0.24	0.28	Body mass index;	chr2:28787651	chr2:28708953~28736205:-
SARC	cis	rs61160187	0.582	rs12652830	ENSG00000215032.2	GNL3LP1	4.48	1.18e-05	0.00539	0.27	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956655	chr5:60891935~60893577:-
SARC	cis	rs4713118	0.662	rs149901	ENSG00000272009.1	RP1-313I6.12	-4.48	1.18e-05	0.0054	-0.33	-0.28	Parkinson's disease;	chr6:27997725	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.662	rs464312	ENSG00000272009.1	RP1-313I6.12	-4.48	1.18e-05	0.0054	-0.33	-0.28	Parkinson's disease;	chr6:27999813	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.662	rs469228	ENSG00000272009.1	RP1-313I6.12	-4.48	1.18e-05	0.0054	-0.33	-0.28	Parkinson's disease;	chr6:28002926	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.54	rs469227	ENSG00000272009.1	RP1-313I6.12	-4.48	1.18e-05	0.0054	-0.33	-0.28	Parkinson's disease;	chr6:28002927	chr6:28078792~28081130:-
SARC	cis	rs4950322	0.57	rs4950392	ENSG00000278811.3	LINC00624	4.48	1.18e-05	0.00541	0.3	0.28	Protein quantitative trait loci;	chr1:147264889	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs17356219	ENSG00000278811.3	LINC00624	4.48	1.18e-05	0.00541	0.3	0.28	Protein quantitative trait loci;	chr1:147265684	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72691041	ENSG00000278811.3	LINC00624	4.48	1.18e-05	0.00541	0.3	0.28	Protein quantitative trait loci;	chr1:147267084	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs17356233	ENSG00000278811.3	LINC00624	4.48	1.18e-05	0.00541	0.3	0.28	Protein quantitative trait loci;	chr1:147268843	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs17356240	ENSG00000278811.3	LINC00624	4.48	1.18e-05	0.00541	0.3	0.28	Protein quantitative trait loci;	chr1:147269877	chr1:147258885~147517875:-
SARC	cis	rs12200782	0.929	rs10456328	ENSG00000272810.1	U91328.22	-4.48	1.18e-05	0.00541	-0.47	-0.28	Small cell lung carcinoma;	chr6:26347769	chr6:26013241~26013757:+
SARC	cis	rs12422267	0.623	rs11246919	ENSG00000256576.2	RP13-977J11.2	4.48	1.18e-05	0.00541	0.54	0.28	Plasma amyloid beta peptide concentrations (ABx-40);	chr12:132084948	chr12:132186735~132189695:-
SARC	cis	rs8062405	0.755	rs4149398	ENSG00000251417.2	RP11-1348G14.4	-4.48	1.18e-05	0.00541	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28802743~28817828:+
SARC	cis	rs7520050	0.751	rs2230657	ENSG00000280836.1	AL355480.1	4.48	1.18e-05	0.00541	0.26	0.28	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45581219~45581321:-
SARC	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-4.48	1.18e-05	0.00541	-0.33	-0.28	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
SARC	cis	rs7267979	0.74	rs2259961	ENSG00000125804.12	FAM182A	-4.48	1.18e-05	0.00541	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:26054655~26086917:+
SARC	cis	rs1865760	0.566	rs3752419	ENSG00000272462.2	U91328.19	-4.48	1.19e-05	0.00541	-0.26	-0.28	Height;	chr6:26027205	chr6:25992662~26001775:+
SARC	cis	rs6570726	0.818	rs437147	ENSG00000270638.1	RP3-466P17.1	4.48	1.19e-05	0.00542	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145735570~145737218:+
SARC	cis	rs12285276	0.636	rs7120031	ENSG00000205106.4	DKFZp779M0652	4.48	1.19e-05	0.00542	0.4	0.28	Visceral fat;	chr11:45794469	chr11:45771432~45772358:+
SARC	cis	rs2439831	0.85	rs28509275	ENSG00000205771.5	CATSPER2P1	-4.48	1.19e-05	0.00542	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43805907	chr15:43726918~43747094:-
SARC	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	4.48	1.19e-05	0.00542	0.29	0.28	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
SARC	cis	rs7267979	0.844	rs35735333	ENSG00000125804.12	FAM182A	4.48	1.19e-05	0.00542	0.31	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:26054655~26086917:+
SARC	cis	rs910316	0.967	rs10142770	ENSG00000279594.1	RP11-950C14.10	4.48	1.19e-05	0.00543	0.31	0.28	Height;	chr14:75058746	chr14:75011269~75012851:-
SARC	cis	rs2439831	0.681	rs526450	ENSG00000275601.1	AC011330.13	-4.48	1.19e-05	0.00543	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43307127	chr15:43642389~43643023:-
SARC	cis	rs7615952	0.736	rs11921945	ENSG00000241288.6	RP11-379B18.5	-4.48	1.19e-05	0.00543	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125924876	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.736	rs13063122	ENSG00000241288.6	RP11-379B18.5	-4.48	1.19e-05	0.00543	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125925017	chr3:125827238~125916384:-
SARC	cis	rs4664293	0.747	rs7600347	ENSG00000226266.5	AC009961.3	-4.48	1.19e-05	0.00543	-0.36	-0.28	Monocyte percentage of white cells;	chr2:159800981	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.967	rs12999124	ENSG00000226266.5	AC009961.3	-4.48	1.19e-05	0.00543	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159674817	chr2:159670708~159712435:-
SARC	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	4.48	1.19e-05	0.00543	0.31	0.28	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
SARC	cis	rs7615952	0.611	rs12488771	ENSG00000250012.1	RP11-124N2.1	-4.48	1.19e-05	0.00543	-0.38	-0.28	Blood pressure (smoking interaction);	chr3:125981683	chr3:126084220~126095349:+
SARC	cis	rs2179367	0.632	rs9485389	ENSG00000231760.4	RP11-350J20.5	-4.48	1.19e-05	0.00544	-0.38	-0.28	Dupuytren's disease;	chr6:149420078	chr6:149796151~149826294:-
SARC	cis	rs324126	0.78	rs3170100	ENSG00000269834.4	ZNF528-AS1	4.48	1.19e-05	0.00544	0.3	0.28	Colonoscopy-negative controls vs population controls;	chr19:52385367	chr19:52388842~52397766:-
SARC	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	4.48	1.19e-05	0.00545	0.37	0.28	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
SARC	cis	rs11719291	0.915	rs9834996	ENSG00000225399.4	RP11-3B7.1	-4.48	1.2e-05	0.00545	-0.48	-0.28	Cognitive function;	chr3:48717444	chr3:49260085~49261316:+
SARC	cis	rs520525	1	rs520525	ENSG00000271811.1	RP1-79C4.4	4.47	1.2e-05	0.00545	0.39	0.28	Atrial fibrillation;	chr1:170669192	chr1:170667381~170669425:+
SARC	cis	rs2274273	0.624	rs67412516	ENSG00000258413.1	RP11-665C16.6	-4.47	1.2e-05	0.00546	-0.36	-0.28	Protein biomarker;	chr14:55386519	chr14:55262767~55272075:-
SARC	cis	rs17270561	0.636	rs1185977	ENSG00000272462.2	U91328.19	-4.47	1.2e-05	0.00546	-0.25	-0.28	Iron status biomarkers;	chr6:25828826	chr6:25992662~26001775:+
SARC	cis	rs910316	1	rs4903289	ENSG00000279594.1	RP11-950C14.10	-4.47	1.2e-05	0.00547	-0.3	-0.28	Height;	chr14:75157285	chr14:75011269~75012851:-
SARC	cis	rs2274273	0.744	rs8011808	ENSG00000258413.1	RP11-665C16.6	-4.47	1.2e-05	0.00547	-0.32	-0.28	Protein biomarker;	chr14:55356626	chr14:55262767~55272075:-
SARC	cis	rs17508449	0.819	rs78394484	ENSG00000232450.1	RP4-730K3.3	-4.47	1.2e-05	0.00547	-0.36	-0.28	Leprosy;	chr1:113740136	chr1:113698884~113699631:-
SARC	cis	rs783540	0.869	rs783521	ENSG00000275695.1	UBE2Q2P6	-4.47	1.2e-05	0.00548	-0.28	-0.28	Schizophrenia;	chr15:82611694	chr15:82445719~82454837:+
SARC	cis	rs783540	0.835	rs783522	ENSG00000275695.1	UBE2Q2P6	-4.47	1.2e-05	0.00548	-0.28	-0.28	Schizophrenia;	chr15:82611862	chr15:82445719~82454837:+
SARC	cis	rs853679	1	rs9986596	ENSG00000219392.1	RP1-265C24.5	-4.47	1.2e-05	0.00548	-0.5	-0.28	Depression;	chr6:28251883	chr6:28115628~28116551:+
SARC	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-4.47	1.2e-05	0.00548	-0.42	-0.28	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-4.47	1.2e-05	0.00548	-0.42	-0.28	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-4.47	1.2e-05	0.00548	-0.42	-0.28	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
SARC	cis	rs9818758	0.556	rs9835439	ENSG00000225399.4	RP11-3B7.1	-4.47	1.2e-05	0.00548	-0.53	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49182897	chr3:49260085~49261316:+
SARC	cis	rs875971	0.862	rs9791712	ENSG00000232559.3	GS1-124K5.12	-4.47	1.21e-05	0.00549	-0.34	-0.28	Aortic root size;	chr7:66640176	chr7:66554588~66576923:-
SARC	cis	rs875971	0.862	rs9791713	ENSG00000232559.3	GS1-124K5.12	-4.47	1.21e-05	0.00549	-0.34	-0.28	Aortic root size;	chr7:66640211	chr7:66554588~66576923:-
SARC	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-4.47	1.21e-05	0.00549	-0.37	-0.28	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
SARC	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-4.47	1.21e-05	0.00549	-0.37	-0.28	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
SARC	cis	rs12594515	0.548	rs12912226	ENSG00000273972.1	CTD-2306A12.1	-4.47	1.21e-05	0.0055	-0.31	-0.28	Weight;Waist circumference;	chr15:45693510	chr15:45702640~45703183:+
SARC	cis	rs6570726	0.791	rs446362	ENSG00000270638.1	RP3-466P17.1	4.47	1.21e-05	0.0055	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs414600	ENSG00000270638.1	RP3-466P17.1	4.47	1.21e-05	0.0055	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145735570~145737218:+
SARC	cis	rs2274273	0.624	rs8015211	ENSG00000258413.1	RP11-665C16.6	-4.47	1.21e-05	0.0055	-0.35	-0.28	Protein biomarker;	chr14:55374729	chr14:55262767~55272075:-
SARC	cis	rs34375054	0.526	rs7302475	ENSG00000279233.1	RP11-158L12.4	4.47	1.21e-05	0.0055	0.32	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125193340	chr12:125138245~125141711:+
SARC	cis	rs5769707	0.967	rs763127	ENSG00000235111.1	RP1-29C18.8	-4.47	1.21e-05	0.00551	-0.3	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49612657~49615716:-
SARC	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-4.47	1.21e-05	0.00552	-0.33	-0.28	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
SARC	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-4.47	1.21e-05	0.00552	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-4.47	1.21e-05	0.00552	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-4.47	1.21e-05	0.00552	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-4.47	1.21e-05	0.00552	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-4.47	1.21e-05	0.00552	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-4.47	1.21e-05	0.00552	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-4.47	1.21e-05	0.00552	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-4.47	1.21e-05	0.00552	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
SARC	cis	rs910316	0.934	rs4903278	ENSG00000279594.1	RP11-950C14.10	4.47	1.21e-05	0.00552	0.3	0.28	Height;	chr14:75068316	chr14:75011269~75012851:-
SARC	cis	rs2281636	0.63	rs12355655	ENSG00000233690.1	EBAG9P1	4.47	1.21e-05	0.00552	0.28	0.28	Obesity-related traits;	chr10:99616982	chr10:99697407~99697949:-
SARC	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-4.47	1.21e-05	0.00552	-0.35	-0.28	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
SARC	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-4.47	1.21e-05	0.00552	-0.29	-0.28	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
SARC	cis	rs14027	0.921	rs16893101	ENSG00000279347.1	RP11-85I17.2	-4.47	1.21e-05	0.00552	-0.25	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119750669	chr8:119838736~119840385:-
SARC	cis	rs4761974	1	rs2135829	ENSG00000258279.2	LINC00592	4.47	1.21e-05	0.00552	0.69	0.28	White matter lesion progression;White matter lesion progression (adjusted for white matter lesion burden at baseline);	chr12:51420611	chr12:52210930~52223804:+
SARC	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-4.47	1.22e-05	0.00553	-0.33	-0.28	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
SARC	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-4.47	1.22e-05	0.00553	-0.34	-0.28	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
SARC	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-4.47	1.22e-05	0.00553	-0.24	-0.28	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
SARC	cis	rs4950322	0.57	rs72691012	ENSG00000278811.3	LINC00624	4.47	1.22e-05	0.00553	0.3	0.28	Protein quantitative trait loci;	chr1:147239751	chr1:147258885~147517875:-
SARC	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	4.47	1.22e-05	0.00553	0.27	0.28	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
SARC	cis	rs17270561	0.609	rs7746609	ENSG00000272810.1	U91328.22	4.47	1.22e-05	0.00553	0.27	0.28	Iron status biomarkers;	chr6:25727768	chr6:26013241~26013757:+
SARC	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-4.47	1.22e-05	0.00554	-0.29	-0.28	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
SARC	cis	rs10754283	0.934	rs6661282	ENSG00000231613.1	RP5-943J3.1	4.47	1.22e-05	0.00554	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89654433	chr1:89788914~89790492:+
SARC	cis	rs899997	1	rs11633170	ENSG00000261143.1	ADAMTS7P3	-4.47	1.22e-05	0.00555	-0.44	-0.28	Coronary artery disease or large artery stroke;	chr15:78712300	chr15:77976042~77993057:+
SARC	cis	rs9487605	1	rs9487605	ENSG00000271789.1	RP5-1112D6.7	-4.47	1.22e-05	0.00555	-0.32	-0.28	Inflammatory skin disease;	chr6:111261682	chr6:111297126~111298510:+
SARC	cis	rs2439831	0.681	rs956391	ENSG00000205771.5	CATSPER2P1	4.47	1.22e-05	0.00555	0.42	0.28	Lung cancer in ever smokers;	chr15:43325295	chr15:43726918~43747094:-
SARC	cis	rs7772486	0.754	rs4895682	ENSG00000270638.1	RP3-466P17.1	-4.47	1.22e-05	0.00555	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145735570~145737218:+
SARC	cis	rs910316	1	rs3742773	ENSG00000279594.1	RP11-950C14.10	4.47	1.22e-05	0.00555	0.31	0.28	Height;	chr14:75112940	chr14:75011269~75012851:-
SARC	cis	rs910316	1	rs8017642	ENSG00000279594.1	RP11-950C14.10	4.47	1.22e-05	0.00556	0.31	0.28	Height;	chr14:75124119	chr14:75011269~75012851:-
SARC	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	4.47	1.22e-05	0.00556	0.32	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
SARC	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	4.47	1.22e-05	0.00556	0.32	0.28	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
SARC	cis	rs4664293	0.836	rs13032500	ENSG00000226266.5	AC009961.3	-4.47	1.22e-05	0.00556	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159749740	chr2:159670708~159712435:-
SARC	cis	rs9894429	0.789	rs7213849	ENSG00000229848.1	RP13-766D20.2	-4.47	1.22e-05	0.00556	-0.28	-0.28	Eye color traits;	chr17:81600584	chr17:81514047~81527776:+
SARC	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	4.47	1.23e-05	0.00557	0.3	0.28	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
SARC	cis	rs524281	1	rs489337	ENSG00000255320.1	RP11-755F10.1	-4.47	1.23e-05	0.00557	-0.39	-0.28	Electroencephalogram traits;	chr11:66087090	chr11:66244840~66246239:-
SARC	cis	rs1167827	0.805	rs809439	ENSG00000278416.1	PMS2L2	-4.47	1.23e-05	0.00558	-0.33	-0.28	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75344015~75359550:-
SARC	cis	rs2933343	0.729	rs1680794	ENSG00000231305.3	RP11-723O4.2	4.47	1.23e-05	0.00558	0.28	0.28	IgG glycosylation;	chr3:128901547	chr3:128861313~128871540:-
SARC	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-4.47	1.23e-05	0.00558	-0.32	-0.28	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
SARC	cis	rs75422866	0.51	rs35784744	ENSG00000257433.4	RP1-197B17.3	4.47	1.23e-05	0.00558	0.48	0.28	Pneumonia;	chr12:47729646	chr12:47706085~47742294:+
SARC	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	4.47	1.23e-05	0.00558	0.27	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
SARC	cis	rs42490	1	rs2735873	ENSG00000251136.7	RP11-37B2.1	4.47	1.23e-05	0.00558	0.31	0.28	Leprosy;	chr8:89737748	chr8:89609409~89757727:-
SARC	cis	rs42490	0.966	rs2644033	ENSG00000251136.7	RP11-37B2.1	4.47	1.23e-05	0.00558	0.31	0.28	Leprosy;	chr8:89739196	chr8:89609409~89757727:-
SARC	cis	rs7216064	0.684	rs62084675	ENSG00000278740.1	RP11-147L13.14	-4.47	1.23e-05	0.00559	-0.3	-0.28	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68030909	chr17:68188547~68189165:+
SARC	cis	rs4372836	0.729	rs67410623	ENSG00000226833.4	AC097724.3	-4.47	1.23e-05	0.0056	-0.24	-0.28	Body mass index;	chr2:28834574	chr2:28708953~28736205:-
SARC	cis	rs890448	0.796	rs10007902	ENSG00000254531.1	FLJ20021	4.47	1.23e-05	0.0056	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101414961	chr4:101347780~101348883:+
SARC	cis	rs792448	0.545	rs6668866	ENSG00000229983.1	RP11-15I11.2	-4.47	1.23e-05	0.0056	-0.29	-0.28	White blood cell count (basophil);	chr1:212231605	chr1:212168207~212190259:+
SARC	cis	rs75920871	0.528	rs1241655	ENSG00000254851.1	RP11-109L13.1	4.47	1.23e-05	0.0056	0.38	0.28	Subjective well-being;	chr11:116967092	chr11:117135528~117138582:+
SARC	cis	rs1823913	1	rs6749232	ENSG00000280083.1	RP11-317J9.1	4.47	1.24e-05	0.00561	0.31	0.28	Obesity-related traits;	chr2:191250326	chr2:191154118~191156070:-
SARC	cis	rs9309473	0.519	rs4852951	ENSG00000163016.8	ALMS1P	-4.47	1.24e-05	0.00561	-0.32	-0.28	Metabolite levels;	chr2:73642669	chr2:73644919~73685576:+
SARC	cis	rs13217239	0.646	rs4269366	ENSG00000241549.7	GUSBP2	4.47	1.24e-05	0.00561	0.27	0.28	Schizophrenia;	chr6:27048634	chr6:26871484~26956554:-
SARC	cis	rs75920871	0.588	rs4548653	ENSG00000254851.1	RP11-109L13.1	4.47	1.24e-05	0.00561	0.39	0.28	Subjective well-being;	chr11:117032600	chr11:117135528~117138582:+
SARC	cis	rs367615	0.704	rs72802966	ENSG00000249476.1	CTD-2587M2.1	4.47	1.24e-05	0.00562	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109511053	chr5:109237120~109326369:-
SARC	cis	rs367615	0.704	rs7726991	ENSG00000249476.1	CTD-2587M2.1	4.47	1.24e-05	0.00562	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109511733	chr5:109237120~109326369:-
SARC	cis	rs367615	0.704	rs72804385	ENSG00000249476.1	CTD-2587M2.1	4.47	1.24e-05	0.00562	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109512442	chr5:109237120~109326369:-
SARC	cis	rs577676	0.524	rs601938	ENSG00000271811.1	RP1-79C4.4	4.47	1.24e-05	0.00562	0.39	0.28	Prevalent atrial fibrillation;	chr1:170661118	chr1:170667381~170669425:+
SARC	cis	rs7811142	1	rs60478351	ENSG00000078319.8	PMS2P1	-4.47	1.24e-05	0.00562	-0.4	-0.28	Platelet count;	chr7:100491394	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs7787620	ENSG00000078319.8	PMS2P1	-4.47	1.24e-05	0.00562	-0.4	-0.28	Platelet count;	chr7:100491611	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs11769700	ENSG00000078319.8	PMS2P1	-4.47	1.24e-05	0.00562	-0.4	-0.28	Platelet count;	chr7:100492426	chr7:100320992~100341908:-
SARC	cis	rs7560272	0.549	rs2421554	ENSG00000163016.8	ALMS1P	4.47	1.24e-05	0.00562	0.32	0.28	Schizophrenia;	chr2:73579075	chr2:73644919~73685576:+
SARC	cis	rs763121	0.889	rs9607557	ENSG00000273076.1	RP3-508I15.22	4.47	1.24e-05	0.00563	0.3	0.28	Menopause (age at onset);	chr22:38644274	chr22:38743495~38743910:+
SARC	cis	rs763121	0.925	rs5750654	ENSG00000273076.1	RP3-508I15.22	4.47	1.24e-05	0.00563	0.3	0.28	Menopause (age at onset);	chr22:38655423	chr22:38743495~38743910:+
SARC	cis	rs597539	0.652	rs478647	ENSG00000250508.1	RP11-757G1.6	-4.47	1.24e-05	0.00563	-0.34	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68870664~68874542:+
SARC	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-4.47	1.24e-05	0.00563	-0.33	-0.28	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-4.47	1.24e-05	0.00563	-0.33	-0.28	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-4.47	1.24e-05	0.00563	-0.33	-0.28	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
SARC	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-4.47	1.24e-05	0.00564	-0.26	-0.28	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
SARC	cis	rs2439831	0.85	rs16965120	ENSG00000275601.1	AC011330.13	-4.47	1.24e-05	0.00564	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43808144	chr15:43642389~43643023:-
SARC	cis	rs7772486	0.686	rs702305	ENSG00000235652.6	RP11-545I5.3	-4.47	1.24e-05	0.00564	-0.25	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs857875	ENSG00000235652.6	RP11-545I5.3	-4.47	1.24e-05	0.00564	-0.25	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs4896827	ENSG00000235652.6	RP11-545I5.3	4.47	1.24e-05	0.00564	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs4896828	ENSG00000235652.6	RP11-545I5.3	4.47	1.24e-05	0.00564	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs6570701	ENSG00000235652.6	RP11-545I5.3	4.47	1.24e-05	0.00564	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145799409~145886585:+
SARC	cis	rs253959	0.564	rs4921064	ENSG00000272265.1	CTD-2287O16.4	4.47	1.24e-05	0.00564	0.33	0.28	Bipolar disorder and schizophrenia;	chr5:116111637	chr5:116078110~116078570:-
SARC	cis	rs193541	0.632	rs2407402	ENSG00000263432.2	RN7SL689P	4.47	1.24e-05	0.00564	0.35	0.28	Glucose homeostasis traits;	chr5:122771410	chr5:123022487~123022783:-
SARC	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	4.47	1.25e-05	0.00565	0.33	0.28	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
SARC	cis	rs253959	0.545	rs2416425	ENSG00000272265.1	CTD-2287O16.4	4.47	1.25e-05	0.00565	0.32	0.28	Bipolar disorder and schizophrenia;	chr5:116101727	chr5:116078110~116078570:-
SARC	cis	rs253959	0.545	rs11241362	ENSG00000272265.1	CTD-2287O16.4	4.47	1.25e-05	0.00565	0.32	0.28	Bipolar disorder and schizophrenia;	chr5:116112630	chr5:116078110~116078570:-
SARC	cis	rs7976269	0.537	rs2117992	ENSG00000257176.2	RP11-996F15.2	-4.47	1.25e-05	0.00565	-0.3	-0.28	Male-pattern baldness;	chr12:29070611	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.559	rs10843304	ENSG00000257176.2	RP11-996F15.2	-4.47	1.25e-05	0.00565	-0.3	-0.28	Male-pattern baldness;	chr12:29071226	chr12:29280418~29317848:-
SARC	cis	rs8062405	0.723	rs762633	ENSG00000251417.2	RP11-1348G14.4	-4.47	1.25e-05	0.00565	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.723	rs35175818	ENSG00000251417.2	RP11-1348G14.4	-4.47	1.25e-05	0.00565	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28802743~28817828:+
SARC	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-4.46	1.25e-05	0.00566	-0.26	-0.28	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
SARC	cis	rs453301	0.506	rs476845	ENSG00000253893.2	FAM85B	4.46	1.25e-05	0.00566	0.24	0.28	Joint mobility (Beighton score);	chr8:8765367	chr8:8167819~8226614:-
SARC	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	4.46	1.25e-05	0.00566	0.26	0.28	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	4.46	1.25e-05	0.00566	0.26	0.28	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
SARC	cis	rs4835473	0.77	rs4835096	ENSG00000251600.4	RP11-673E1.1	4.46	1.25e-05	0.00566	0.28	0.28	Immature fraction of reticulocytes;	chr4:143960685	chr4:143912331~143982454:+
SARC	cis	rs10754283	0.967	rs4658302	ENSG00000231613.1	RP5-943J3.1	4.46	1.25e-05	0.00566	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89637777	chr1:89788914~89790492:+
SARC	cis	rs910316	1	rs10140851	ENSG00000279594.1	RP11-950C14.10	4.46	1.25e-05	0.00566	0.31	0.28	Height;	chr14:75045909	chr14:75011269~75012851:-
SARC	cis	rs2439831	0.85	rs28524541	ENSG00000275601.1	AC011330.13	-4.46	1.25e-05	0.00566	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43832633	chr15:43642389~43643023:-
SARC	cis	rs890448	0.896	rs1016127	ENSG00000254531.1	FLJ20021	-4.46	1.25e-05	0.00566	-0.28	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101484796	chr4:101347780~101348883:+
SARC	cis	rs890448	0.86	rs1863575	ENSG00000254531.1	FLJ20021	-4.46	1.25e-05	0.00566	-0.28	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101485952	chr4:101347780~101348883:+
SARC	cis	rs890448	0.93	rs6532941	ENSG00000254531.1	FLJ20021	-4.46	1.25e-05	0.00566	-0.28	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101492469	chr4:101347780~101348883:+
SARC	cis	rs890448	0.93	rs10012311	ENSG00000254531.1	FLJ20021	-4.46	1.25e-05	0.00566	-0.28	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101493140	chr4:101347780~101348883:+
SARC	cis	rs2562456	0.617	rs34203148	ENSG00000268081.1	RP11-678G14.2	4.46	1.25e-05	0.00566	0.43	0.28	Pain;	chr19:21590743	chr19:21554640~21569237:-
SARC	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-4.46	1.25e-05	0.00567	-0.41	-0.28	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
SARC	cis	rs4664293	0.625	rs13006088	ENSG00000226266.5	AC009961.3	4.46	1.25e-05	0.00567	0.32	0.28	Monocyte percentage of white cells;	chr2:159652915	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.605	rs2042774	ENSG00000226266.5	AC009961.3	4.46	1.25e-05	0.00567	0.32	0.28	Monocyte percentage of white cells;	chr2:159653496	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs2042775	ENSG00000226266.5	AC009961.3	4.46	1.25e-05	0.00567	0.32	0.28	Monocyte percentage of white cells;	chr2:159653581	chr2:159670708~159712435:-
SARC	cis	rs1538970	0.504	rs3790585	ENSG00000280836.1	AL355480.1	-4.46	1.25e-05	0.00567	-0.39	-0.28	Platelet count;	chr1:45557684	chr1:45581219~45581321:-
SARC	cis	rs30380	0.632	rs26489	ENSG00000272109.1	CTD-2260A17.3	-4.46	1.25e-05	0.00567	-0.36	-0.28	Cerebrospinal fluid biomarker levels;	chr5:96797724	chr5:96804353~96806105:+
SARC	cis	rs30380	0.632	rs26496	ENSG00000272109.1	CTD-2260A17.3	-4.46	1.25e-05	0.00567	-0.36	-0.28	Cerebrospinal fluid biomarker levels;	chr5:96802179	chr5:96804353~96806105:+
SARC	cis	rs79349575	0.783	rs15563	ENSG00000270781.1	RP11-501C14.9	-4.46	1.25e-05	0.00567	-0.33	-0.28	Type 2 diabetes;	chr17:48927831	chr17:48899131~48899748:+
SARC	cis	rs910316	1	rs876402	ENSG00000279594.1	RP11-950C14.10	-4.46	1.25e-05	0.00567	-0.3	-0.28	Height;	chr14:75135159	chr14:75011269~75012851:-
SARC	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	4.46	1.25e-05	0.00567	0.28	0.28	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
SARC	cis	rs4934494	0.636	rs34408087	ENSG00000240996.1	RP11-80H5.7	-4.46	1.25e-05	0.00567	-0.31	-0.28	Red blood cell count;	chr10:89783794	chr10:89694295~89697928:-
SARC	cis	rs910316	0.967	rs8007539	ENSG00000279594.1	RP11-950C14.10	-4.46	1.25e-05	0.00568	-0.3	-0.28	Height;	chr14:75198250	chr14:75011269~75012851:-
SARC	cis	rs10911902	0.643	rs3766704	ENSG00000229739.2	RP11-295K2.3	-4.46	1.26e-05	0.00568	-0.4	-0.28	Schizophrenia;	chr1:186342710	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.567	rs76557279	ENSG00000229739.2	RP11-295K2.3	-4.46	1.26e-05	0.00568	-0.4	-0.28	Schizophrenia;	chr1:186344161	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs2272412	ENSG00000229739.2	RP11-295K2.3	-4.46	1.26e-05	0.00568	-0.4	-0.28	Schizophrenia;	chr1:186345817	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs6667940	ENSG00000229739.2	RP11-295K2.3	-4.46	1.26e-05	0.00568	-0.4	-0.28	Schizophrenia;	chr1:186350448	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs76748438	ENSG00000229739.2	RP11-295K2.3	-4.46	1.26e-05	0.00568	-0.4	-0.28	Schizophrenia;	chr1:186367379	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs2297226	ENSG00000229739.2	RP11-295K2.3	-4.46	1.26e-05	0.00568	-0.4	-0.28	Schizophrenia;	chr1:186374627	chr1:186435161~186470291:+
SARC	cis	rs7809950	0.773	rs2237668	ENSG00000238832.1	snoU109	-4.46	1.26e-05	0.00569	-0.34	-0.28	Coronary artery disease;	chr7:107409764	chr7:107603363~107603507:+
SARC	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-4.46	1.26e-05	0.00569	-0.33	-0.28	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-4.46	1.26e-05	0.00569	-0.33	-0.28	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
SARC	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-4.46	1.26e-05	0.00569	-0.37	-0.28	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
SARC	cis	rs7216064	0.684	rs62084675	ENSG00000237854.3	LINC00674	-4.46	1.26e-05	0.0057	-0.32	-0.28	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68030909	chr17:68101908~68115518:+
SARC	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-4.46	1.26e-05	0.0057	-0.33	-0.28	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-4.46	1.26e-05	0.0057	-0.33	-0.28	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
SARC	cis	rs34435647	1	rs34435647	ENSG00000226266.5	AC009961.3	-4.46	1.26e-05	0.0057	-0.34	-0.28	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;	chr2:159661779	chr2:159670708~159712435:-
SARC	cis	rs1823913	0.637	rs1470962	ENSG00000227542.1	AC092614.2	-4.46	1.26e-05	0.00571	-0.31	-0.28	Obesity-related traits;	chr2:191270271	chr2:191229165~191246172:-
SARC	cis	rs2274273	0.87	rs59629906	ENSG00000258413.1	RP11-665C16.6	-4.46	1.26e-05	0.00571	-0.33	-0.28	Protein biomarker;	chr14:55314471	chr14:55262767~55272075:-
SARC	cis	rs910316	1	rs2268617	ENSG00000279594.1	RP11-950C14.10	4.46	1.26e-05	0.00571	0.31	0.28	Height;	chr14:75142025	chr14:75011269~75012851:-
SARC	cis	rs14027	0.921	rs1433951	ENSG00000279347.1	RP11-85I17.2	-4.46	1.26e-05	0.00571	-0.25	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119777362	chr8:119838736~119840385:-
SARC	cis	rs4664293	0.647	rs4144512	ENSG00000226266.5	AC009961.3	4.46	1.26e-05	0.00571	0.32	0.28	Monocyte percentage of white cells;	chr2:159651008	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs35241460	ENSG00000226266.5	AC009961.3	4.46	1.26e-05	0.00571	0.32	0.28	Monocyte percentage of white cells;	chr2:159651689	chr2:159670708~159712435:-
SARC	cis	rs2933343	0.729	rs813945	ENSG00000231305.3	RP11-723O4.2	4.46	1.26e-05	0.00571	0.29	0.28	IgG glycosylation;	chr3:128942094	chr3:128861313~128871540:-
SARC	cis	rs7267979	1	rs2424710	ENSG00000276952.1	RP5-965G21.6	4.46	1.26e-05	0.00571	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6115140	ENSG00000276952.1	RP5-965G21.6	4.46	1.26e-05	0.00571	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25284915~25285588:-
SARC	cis	rs2836950	0.501	rs11702505	ENSG00000255568.3	BRWD1-AS2	-4.46	1.26e-05	0.00571	-0.25	-0.28	Menarche (age at onset);	chr21:39328688	chr21:39313935~39314962:+
SARC	cis	rs2836950	0.501	rs2836985	ENSG00000255568.3	BRWD1-AS2	-4.46	1.26e-05	0.00571	-0.25	-0.28	Menarche (age at onset);	chr21:39329243	chr21:39313935~39314962:+
SARC	cis	rs7772486	0.79	rs9497435	ENSG00000270638.1	RP3-466P17.1	-4.46	1.27e-05	0.00572	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145944204	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs9791313	ENSG00000270638.1	RP3-466P17.1	-4.46	1.27e-05	0.00572	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145945036	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs9386141	ENSG00000270638.1	RP3-466P17.1	-4.46	1.27e-05	0.00572	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145947487	chr6:145735570~145737218:+
SARC	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-4.46	1.27e-05	0.00572	-0.33	-0.28	QT interval;	chr12:29302457	chr12:29280418~29317848:-
SARC	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-4.46	1.27e-05	0.00572	-0.33	-0.28	QT interval;	chr12:29302458	chr12:29280418~29317848:-
SARC	cis	rs7809950	0.768	rs62482493	ENSG00000238832.1	snoU109	-4.46	1.27e-05	0.00572	-0.35	-0.28	Coronary artery disease;	chr7:107311134	chr7:107603363~107603507:+
SARC	cis	rs17508449	0.819	rs4839329	ENSG00000232450.1	RP4-730K3.3	-4.46	1.27e-05	0.00572	-0.36	-0.28	Leprosy;	chr1:113593083	chr1:113698884~113699631:-
SARC	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-4.46	1.27e-05	0.00572	-0.33	-0.28	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
SARC	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-4.46	1.27e-05	0.00573	-0.44	-0.28	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
SARC	cis	rs2439831	0.717	rs690170	ENSG00000205771.5	CATSPER2P1	-4.46	1.27e-05	0.00573	-0.5	-0.28	Lung cancer in ever smokers;	chr15:43518224	chr15:43726918~43747094:-
SARC	cis	rs8040855	0.542	rs2342122	ENSG00000259774.1	RP11-182J1.13	-4.46	1.27e-05	0.00574	-0.25	-0.28	Bulimia nervosa;	chr15:85185304	chr15:84422618~84425882:+
SARC	cis	rs8040855	0.644	rs2342120	ENSG00000259774.1	RP11-182J1.13	-4.46	1.27e-05	0.00574	-0.25	-0.28	Bulimia nervosa;	chr15:85185589	chr15:84422618~84425882:+
SARC	cis	rs853679	0.882	rs4713140	ENSG00000219392.1	RP1-265C24.5	-4.46	1.27e-05	0.00574	-0.55	-0.28	Depression;	chr6:28129415	chr6:28115628~28116551:+
SARC	cis	rs7615952	0.546	rs2976733	ENSG00000171084.14	FAM86JP	4.46	1.27e-05	0.00574	0.4	0.28	Blood pressure (smoking interaction);	chr3:125695294	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.543	rs4645102	ENSG00000171084.14	FAM86JP	4.46	1.27e-05	0.00574	0.4	0.28	Blood pressure (smoking interaction);	chr3:125705597	chr3:125916620~125930024:+
SARC	cis	rs17508449	1	rs17461918	ENSG00000232450.1	RP4-730K3.3	-4.46	1.27e-05	0.00574	-0.36	-0.28	Leprosy;	chr1:113538822	chr1:113698884~113699631:-
SARC	cis	rs9818758	0.607	rs11716445	ENSG00000225399.4	RP11-3B7.1	-4.46	1.27e-05	0.00574	-0.59	-0.28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49368662	chr3:49260085~49261316:+
SARC	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-4.46	1.27e-05	0.00574	-0.33	-0.28	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
SARC	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-4.46	1.27e-05	0.00574	-0.33	-0.28	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
SARC	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	4.46	1.27e-05	0.00575	0.26	0.28	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	4.46	1.27e-05	0.00575	0.26	0.28	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
SARC	cis	rs11634944	0.673	rs1549474	ENSG00000274307.1	RP11-345J18.2	-4.46	1.27e-05	0.00575	-0.37	-0.28	Interleukin-8 levels;	chr15:25000886	chr15:25708470~25710869:-
SARC	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-4.46	1.27e-05	0.00575	-0.33	-0.28	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
SARC	cis	rs4950322	0.57	rs72691032	ENSG00000278811.3	LINC00624	4.46	1.28e-05	0.00575	0.3	0.28	Protein quantitative trait loci;	chr1:147261120	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72691033	ENSG00000278811.3	LINC00624	4.46	1.28e-05	0.00575	0.3	0.28	Protein quantitative trait loci;	chr1:147261267	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs111370771	ENSG00000278811.3	LINC00624	4.46	1.28e-05	0.00575	0.3	0.28	Protein quantitative trait loci;	chr1:147261420	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs4301678	ENSG00000278811.3	LINC00624	4.46	1.28e-05	0.00575	0.3	0.28	Protein quantitative trait loci;	chr1:147261907	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs17356184	ENSG00000278811.3	LINC00624	4.46	1.28e-05	0.00575	0.3	0.28	Protein quantitative trait loci;	chr1:147262943	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs80270233	ENSG00000278811.3	LINC00624	4.46	1.28e-05	0.00575	0.3	0.28	Protein quantitative trait loci;	chr1:147263320	chr1:147258885~147517875:-
SARC	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-4.46	1.28e-05	0.00576	-0.36	-0.28	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-4.46	1.28e-05	0.00576	-0.36	-0.28	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
SARC	cis	rs8005677	0.77	rs56180741	ENSG00000257285.4	RP11-298I3.1	4.46	1.28e-05	0.00576	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:22929609~22955562:+
SARC	cis	rs8005677	0.828	rs3794452	ENSG00000257285.4	RP11-298I3.1	4.46	1.28e-05	0.00576	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:22929609~22955562:+
SARC	cis	rs8005677	0.828	rs4981450	ENSG00000257285.4	RP11-298I3.1	4.46	1.28e-05	0.00576	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:22929609~22955562:+
SARC	cis	rs597539	0.617	rs672853	ENSG00000250508.1	RP11-757G1.6	-4.46	1.28e-05	0.00576	-0.34	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68870664~68874542:+
SARC	cis	rs597539	0.616	rs631001	ENSG00000250508.1	RP11-757G1.6	-4.46	1.28e-05	0.00576	-0.34	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68870664~68874542:+
SARC	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	4.46	1.28e-05	0.00576	0.28	0.28	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
SARC	cis	rs76693355	0.512	rs12270397	ENSG00000232460.4	BMPR1APS2	4.46	1.28e-05	0.00576	0.35	0.28	Intraocular pressure;	chr11:120377633	chr11:121361854~121362865:-
SARC	cis	rs2439831	1	rs690436	ENSG00000205771.5	CATSPER2P1	-4.46	1.28e-05	0.00577	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43469007	chr15:43726918~43747094:-
SARC	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	4.46	1.28e-05	0.00577	0.45	0.28	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
SARC	cis	rs28386778	0.897	rs6504177	ENSG00000240280.5	TCAM1P	-4.46	1.28e-05	0.00577	-0.34	-0.28	Prudent dietary pattern;	chr17:63735295	chr17:63849292~63864379:+
SARC	cis	rs2439831	1	rs565007	ENSG00000275601.1	AC011330.13	-4.46	1.28e-05	0.00577	-0.44	-0.28	Lung cancer in ever smokers;	chr15:43424443	chr15:43642389~43643023:-
SARC	cis	rs2439831	1	rs550239	ENSG00000275601.1	AC011330.13	-4.46	1.28e-05	0.00577	-0.44	-0.28	Lung cancer in ever smokers;	chr15:43427999	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs558656	ENSG00000275601.1	AC011330.13	-4.46	1.28e-05	0.00577	-0.44	-0.28	Lung cancer in ever smokers;	chr15:43431316	chr15:43642389~43643023:-
SARC	cis	rs4664293	0.902	rs13391919	ENSG00000226266.5	AC009961.3	-4.46	1.28e-05	0.00578	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159703649	chr2:159670708~159712435:-
SARC	cis	rs253959	0.607	rs1396497	ENSG00000272265.1	CTD-2287O16.4	4.46	1.28e-05	0.00578	0.32	0.28	Bipolar disorder and schizophrenia;	chr5:116091719	chr5:116078110~116078570:-
SARC	cis	rs12554020	0.892	rs7028729	ENSG00000227603.1	RP11-165J3.6	4.46	1.28e-05	0.00578	0.37	0.28	Schizophrenia;	chr9:93443206	chr9:93435332~93437121:-
SARC	cis	rs4664293	0.625	rs6432543	ENSG00000226266.5	AC009961.3	4.46	1.28e-05	0.00578	0.32	0.28	Monocyte percentage of white cells;	chr2:159638820	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs4665099	ENSG00000226266.5	AC009961.3	4.46	1.28e-05	0.00578	0.32	0.28	Monocyte percentage of white cells;	chr2:159639027	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs6724151	ENSG00000226266.5	AC009961.3	4.46	1.28e-05	0.00578	0.32	0.28	Monocyte percentage of white cells;	chr2:159642788	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs34573069	ENSG00000226266.5	AC009961.3	4.46	1.28e-05	0.00578	0.32	0.28	Monocyte percentage of white cells;	chr2:159643561	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.567	rs6711125	ENSG00000226266.5	AC009961.3	4.46	1.28e-05	0.00578	0.32	0.28	Monocyte percentage of white cells;	chr2:159645040	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.609	rs357033	ENSG00000226266.5	AC009961.3	-4.46	1.28e-05	0.00578	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159637962	chr2:159670708~159712435:-
SARC	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	4.46	1.28e-05	0.00578	0.3	0.28	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
SARC	cis	rs72945132	0.882	rs7121012	ENSG00000254604.1	AP000487.6	-4.46	1.28e-05	0.00578	-0.38	-0.28	Coronary artery disease;	chr11:70368315	chr11:70282367~70363368:-
SARC	cis	rs4835473	0.897	rs11727223	ENSG00000251600.4	RP11-673E1.1	4.46	1.28e-05	0.00579	0.28	0.28	Immature fraction of reticulocytes;	chr4:143707090	chr4:143912331~143982454:+
SARC	cis	rs853679	1	rs2799077	ENSG00000219392.1	RP1-265C24.5	-4.46	1.29e-05	0.00579	-0.49	-0.28	Depression;	chr6:28266819	chr6:28115628~28116551:+
SARC	cis	rs9309473	0.687	rs11693531	ENSG00000163016.8	ALMS1P	4.46	1.29e-05	0.00579	0.34	0.28	Metabolite levels;	chr2:73381486	chr2:73644919~73685576:+
SARC	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-4.46	1.29e-05	0.0058	-0.31	-0.28	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-4.46	1.29e-05	0.0058	-0.31	-0.28	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
SARC	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	4.46	1.29e-05	0.0058	0.23	0.28	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
SARC	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-4.46	1.29e-05	0.00581	-0.25	-0.28	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
SARC	cis	rs72945132	0.66	rs12292191	ENSG00000254604.1	AP000487.6	-4.46	1.29e-05	0.00581	-0.39	-0.28	Coronary artery disease;	chr11:70276320	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs61177215	ENSG00000254604.1	AP000487.6	-4.46	1.29e-05	0.00581	-0.39	-0.28	Coronary artery disease;	chr11:70283428	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs12279046	ENSG00000254604.1	AP000487.6	-4.46	1.29e-05	0.00581	-0.39	-0.28	Coronary artery disease;	chr11:70284282	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs17160753	ENSG00000254604.1	AP000487.6	-4.46	1.29e-05	0.00581	-0.39	-0.28	Coronary artery disease;	chr11:70285356	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs12274436	ENSG00000254604.1	AP000487.6	-4.46	1.29e-05	0.00581	-0.39	-0.28	Coronary artery disease;	chr11:70286098	chr11:70282367~70363368:-
SARC	cis	rs4664293	0.802	rs13025347	ENSG00000226266.5	AC009961.3	-4.46	1.29e-05	0.00581	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159721056	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs6432554	ENSG00000226266.5	AC009961.3	-4.46	1.29e-05	0.00581	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159722573	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs6760485	ENSG00000226266.5	AC009961.3	-4.46	1.29e-05	0.00581	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159723179	chr2:159670708~159712435:-
SARC	cis	rs9309473	0.607	rs2421489	ENSG00000163016.8	ALMS1P	4.46	1.29e-05	0.00582	0.35	0.28	Metabolite levels;	chr2:73366320	chr2:73644919~73685576:+
SARC	cis	rs10986311	0.962	rs2068165	ENSG00000235204.1	RP11-121A14.2	4.46	1.29e-05	0.00582	0.33	0.28	Vitiligo;	chr9:124326071	chr9:124259250~124261156:-
SARC	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-4.46	1.29e-05	0.00582	-0.31	-0.28	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
SARC	cis	rs2933343	0.859	rs789245	ENSG00000261159.1	RP11-723O4.9	4.46	1.3e-05	0.00583	0.33	0.28	IgG glycosylation;	chr3:128864737	chr3:128859716~128860526:-
SARC	cis	rs2562456	0.833	rs516519	ENSG00000268081.1	RP11-678G14.2	-4.46	1.3e-05	0.00583	-0.41	-0.28	Pain;	chr19:21298730	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.833	rs552800	ENSG00000268081.1	RP11-678G14.2	-4.46	1.3e-05	0.00583	-0.41	-0.28	Pain;	chr19:21301840	chr19:21554640~21569237:-
SARC	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-4.46	1.3e-05	0.00583	-0.32	-0.28	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
SARC	cis	rs7772486	0.686	rs1292336	ENSG00000235652.6	RP11-545I5.3	-4.46	1.3e-05	0.00583	-0.25	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145799409~145886585:+
SARC	cis	rs10911902	0.643	rs74537283	ENSG00000229739.2	RP11-295K2.3	-4.46	1.3e-05	0.00583	-0.39	-0.28	Schizophrenia;	chr1:186328038	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs3736597	ENSG00000229739.2	RP11-295K2.3	-4.46	1.3e-05	0.00583	-0.39	-0.28	Schizophrenia;	chr1:186331918	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs16825183	ENSG00000229739.2	RP11-295K2.3	-4.46	1.3e-05	0.00583	-0.39	-0.28	Schizophrenia;	chr1:186336861	chr1:186435161~186470291:+
SARC	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-4.46	1.3e-05	0.00585	-0.26	-0.28	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
SARC	cis	rs27434	0.51	rs27041	ENSG00000272109.1	CTD-2260A17.3	-4.46	1.3e-05	0.00585	-0.41	-0.28	Ankylosing spondylitis;	chr5:96780017	chr5:96804353~96806105:+
SARC	cis	rs9309473	0.607	rs6716776	ENSG00000163016.8	ALMS1P	4.46	1.3e-05	0.00585	0.35	0.28	Metabolite levels;	chr2:73360585	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.607	rs2421488	ENSG00000163016.8	ALMS1P	4.46	1.3e-05	0.00585	0.35	0.28	Metabolite levels;	chr2:73363497	chr2:73644919~73685576:+
SARC	cis	rs2933343	0.63	rs75824035	ENSG00000261159.1	RP11-723O4.9	4.46	1.3e-05	0.00585	0.31	0.28	IgG glycosylation;	chr3:128934142	chr3:128859716~128860526:-
SARC	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-4.46	1.3e-05	0.00585	-0.31	-0.28	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-4.46	1.3e-05	0.00585	-0.31	-0.28	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-4.46	1.3e-05	0.00585	-0.31	-0.28	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-4.46	1.3e-05	0.00585	-0.31	-0.28	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-4.46	1.3e-05	0.00585	-0.31	-0.28	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
SARC	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	4.45	1.31e-05	0.00587	0.27	0.28	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
SARC	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	4.45	1.31e-05	0.00588	0.25	0.28	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
SARC	cis	rs2562456	0.755	rs2914646	ENSG00000268081.1	RP11-678G14.2	-4.45	1.31e-05	0.00588	-0.43	-0.28	Pain;	chr19:21454359	chr19:21554640~21569237:-
SARC	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-4.45	1.31e-05	0.00588	-0.29	-0.28	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
SARC	cis	rs9309473	0.519	rs13027816	ENSG00000163016.8	ALMS1P	-4.45	1.31e-05	0.00589	-0.32	-0.28	Metabolite levels;	chr2:73670564	chr2:73644919~73685576:+
SARC	cis	rs1823913	0.637	rs4853584	ENSG00000227542.1	AC092614.2	-4.45	1.31e-05	0.00589	-0.31	-0.28	Obesity-related traits;	chr2:191310596	chr2:191229165~191246172:-
SARC	cis	rs890448	0.796	rs1596061	ENSG00000254531.1	FLJ20021	4.45	1.31e-05	0.00589	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101379218	chr4:101347780~101348883:+
SARC	cis	rs853679	0.546	rs200977	ENSG00000216901.1	AL022393.7	4.45	1.31e-05	0.00589	0.65	0.28	Depression;	chr6:27886523	chr6:28176188~28176674:+
SARC	cis	rs9309473	0.519	rs12991161	ENSG00000163016.8	ALMS1P	-4.45	1.31e-05	0.00589	-0.32	-0.28	Metabolite levels;	chr2:73644244	chr2:73644919~73685576:+
SARC	cis	rs123509	0.913	rs123506	ENSG00000230970.3	HHATL-AS1	-4.45	1.31e-05	0.00589	-0.33	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42734484	chr3:42702653~42706776:+
SARC	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-4.45	1.31e-05	0.0059	-0.32	-0.28	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
SARC	cis	rs728478	1	rs9912732	ENSG00000266992.1	DHX40P1	4.45	1.31e-05	0.0059	0.3	0.28	QT interval;	chr17:59370604	chr17:59976009~60002384:-
SARC	cis	rs1865760	0.613	rs9379801	ENSG00000272810.1	U91328.22	-4.45	1.31e-05	0.0059	-0.27	-0.28	Height;	chr6:25901483	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.613	rs9295674	ENSG00000272810.1	U91328.22	-4.45	1.31e-05	0.0059	-0.27	-0.28	Height;	chr6:25912114	chr6:26013241~26013757:+
SARC	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-4.45	1.31e-05	0.0059	-0.34	-0.28	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
SARC	cis	rs4950322	0.57	rs17356492	ENSG00000278811.3	LINC00624	4.45	1.32e-05	0.00591	0.29	0.28	Protein quantitative trait loci;	chr1:147296089	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72691093	ENSG00000278811.3	LINC00624	4.45	1.32e-05	0.00591	0.29	0.28	Protein quantitative trait loci;	chr1:147297977	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs76236344	ENSG00000278811.3	LINC00624	4.45	1.32e-05	0.00591	0.29	0.28	Protein quantitative trait loci;	chr1:147297989	chr1:147258885~147517875:-
SARC	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-4.45	1.32e-05	0.00592	-0.29	-0.28	Height;	chr3:53064759	chr3:53064283~53065091:-
SARC	cis	rs597539	0.652	rs544370	ENSG00000250508.1	RP11-757G1.6	-4.45	1.32e-05	0.00592	-0.32	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:68870664~68874542:+
SARC	cis	rs2274273	0.868	rs6573007	ENSG00000258413.1	RP11-665C16.6	-4.45	1.32e-05	0.00592	-0.32	-0.28	Protein biomarker;	chr14:55159220	chr14:55262767~55272075:-
SARC	cis	rs7267979	1	rs6050565	ENSG00000276952.1	RP5-965G21.6	-4.45	1.32e-05	0.00592	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:25284915~25285588:-
SARC	cis	rs2933343	0.649	rs789216	ENSG00000231305.3	RP11-723O4.2	4.45	1.32e-05	0.00593	0.28	0.28	IgG glycosylation;	chr3:128875660	chr3:128861313~128871540:-
SARC	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	4.45	1.32e-05	0.00593	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
SARC	cis	rs7772486	0.72	rs7752286	ENSG00000270638.1	RP3-466P17.1	-4.45	1.32e-05	0.00593	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145735570~145737218:+
SARC	cis	rs10986311	0.649	rs10818936	ENSG00000235204.1	RP11-121A14.2	4.45	1.32e-05	0.00593	0.33	0.28	Vitiligo;	chr9:124244067	chr9:124259250~124261156:-
SARC	cis	rs526231	0.819	rs35803	ENSG00000175749.11	EIF3KP1	4.45	1.32e-05	0.00594	0.37	0.28	Primary biliary cholangitis;	chr5:103271241	chr5:103032376~103033031:+
SARC	cis	rs526231	0.853	rs35802	ENSG00000175749.11	EIF3KP1	4.45	1.32e-05	0.00594	0.37	0.28	Primary biliary cholangitis;	chr5:103271884	chr5:103032376~103033031:+
SARC	cis	rs526231	0.819	rs35801	ENSG00000175749.11	EIF3KP1	4.45	1.32e-05	0.00594	0.37	0.28	Primary biliary cholangitis;	chr5:103272512	chr5:103032376~103033031:+
SARC	cis	rs526231	0.819	rs2561476	ENSG00000175749.11	EIF3KP1	4.45	1.32e-05	0.00594	0.37	0.28	Primary biliary cholangitis;	chr5:103273133	chr5:103032376~103033031:+
SARC	cis	rs526231	0.781	rs2569015	ENSG00000175749.11	EIF3KP1	4.45	1.32e-05	0.00594	0.37	0.28	Primary biliary cholangitis;	chr5:103273146	chr5:103032376~103033031:+
SARC	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-4.45	1.32e-05	0.00594	-0.29	-0.28	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
SARC	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-4.45	1.32e-05	0.00594	-0.32	-0.28	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
SARC	cis	rs7615952	0.866	rs13063119	ENSG00000241288.6	RP11-379B18.5	-4.45	1.32e-05	0.00594	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125925004	chr3:125827238~125916384:-
SARC	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	4.45	1.32e-05	0.00594	0.29	0.28	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
SARC	cis	rs7772486	0.754	rs9497401	ENSG00000270638.1	RP3-466P17.1	-4.45	1.32e-05	0.00594	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs1055212	ENSG00000270638.1	RP3-466P17.1	-4.45	1.32e-05	0.00594	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145735570~145737218:+
SARC	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	4.45	1.33e-05	0.00594	0.26	0.28	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
SARC	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	4.45	1.33e-05	0.00594	0.51	0.28	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
SARC	cis	rs12220777	0.748	rs11201641	ENSG00000230091.5	TMEM254-AS1	4.45	1.33e-05	0.00595	0.39	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80091975	chr10:80046860~80078912:-
SARC	cis	rs7772486	0.719	rs4391282	ENSG00000270638.1	RP3-466P17.1	-4.45	1.33e-05	0.00595	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145955644	chr6:145735570~145737218:+
SARC	cis	rs853679	1	rs6901575	ENSG00000219392.1	RP1-265C24.5	-4.45	1.33e-05	0.00595	-0.48	-0.28	Depression;	chr6:28283207	chr6:28115628~28116551:+
SARC	cis	rs1799949	0.93	rs34210004	ENSG00000267681.1	CTD-3199J23.6	-4.45	1.33e-05	0.00596	-0.31	-0.28	Menopause (age at onset);	chr17:43218318	chr17:43144956~43145255:+
SARC	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-4.45	1.33e-05	0.00596	-0.25	-0.28	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
SARC	cis	rs4835473	0.571	rs1992656	ENSG00000251600.4	RP11-673E1.1	4.45	1.33e-05	0.00596	0.27	0.28	Immature fraction of reticulocytes;	chr4:143855286	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.571	rs1992655	ENSG00000251600.4	RP11-673E1.1	4.45	1.33e-05	0.00596	0.27	0.28	Immature fraction of reticulocytes;	chr4:143855290	chr4:143912331~143982454:+
SARC	cis	rs2439831	0.867	rs3101443	ENSG00000205771.5	CATSPER2P1	-4.45	1.33e-05	0.00598	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43620174	chr15:43726918~43747094:-
SARC	cis	rs2933343	0.601	rs1680759	ENSG00000231305.3	RP11-723O4.2	4.45	1.34e-05	0.00598	0.28	0.28	IgG glycosylation;	chr3:128876053	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.601	rs1680758	ENSG00000231305.3	RP11-723O4.2	4.45	1.34e-05	0.00598	0.28	0.28	IgG glycosylation;	chr3:128876054	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.649	rs789214	ENSG00000231305.3	RP11-723O4.2	4.45	1.34e-05	0.00598	0.28	0.28	IgG glycosylation;	chr3:128876152	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.729	rs789224	ENSG00000231305.3	RP11-723O4.2	4.45	1.34e-05	0.00598	0.28	0.28	IgG glycosylation;	chr3:128879388	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.761	rs789225	ENSG00000231305.3	RP11-723O4.2	4.45	1.34e-05	0.00598	0.28	0.28	IgG glycosylation;	chr3:128881386	chr3:128861313~128871540:-
SARC	cis	rs9894429	0.69	rs11869779	ENSG00000229848.1	RP13-766D20.2	-4.45	1.34e-05	0.00598	-0.27	-0.28	Eye color traits;	chr17:81603041	chr17:81514047~81527776:+
SARC	cis	rs7131987	0.65	rs16934135	ENSG00000257176.2	RP11-996F15.2	-4.45	1.34e-05	0.00598	-0.32	-0.28	QT interval;	chr12:29331030	chr12:29280418~29317848:-
SARC	cis	rs12554020	0.786	rs17532098	ENSG00000227603.1	RP11-165J3.6	4.45	1.34e-05	0.00599	0.52	0.28	Schizophrenia;	chr9:93500443	chr9:93435332~93437121:-
SARC	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-4.45	1.34e-05	0.00599	-0.25	-0.28	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
SARC	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-4.45	1.34e-05	0.00599	-0.32	-0.28	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-4.45	1.34e-05	0.00599	-0.32	-0.28	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
SARC	cis	rs2412819	0.571	rs2930529	ENSG00000205771.5	CATSPER2P1	4.45	1.34e-05	0.00599	0.41	0.28	Lung cancer;	chr15:43819467	chr15:43726918~43747094:-
SARC	cis	rs2412819	0.571	rs2930530	ENSG00000205771.5	CATSPER2P1	4.45	1.34e-05	0.00599	0.41	0.28	Lung cancer;	chr15:43823268	chr15:43726918~43747094:-
SARC	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-4.45	1.34e-05	0.006	-0.31	-0.28	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
SARC	cis	rs11634944	0.643	rs975698	ENSG00000274307.1	RP11-345J18.2	-4.45	1.34e-05	0.006	-0.36	-0.28	Interleukin-8 levels;	chr15:25015360	chr15:25708470~25710869:-
SARC	cis	rs6844153	0.877	rs10939146	ENSG00000240005.4	RP11-293A21.1	-4.45	1.34e-05	0.006	-0.38	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26978399	chr4:26859806~26860599:-
SARC	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	4.45	1.34e-05	0.00601	0.27	0.28	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
SARC	cis	rs4835473	0.868	rs1822841	ENSG00000251600.4	RP11-673E1.1	4.45	1.34e-05	0.00601	0.28	0.28	Immature fraction of reticulocytes;	chr4:143921485	chr4:143912331~143982454:+
SARC	cis	rs6570726	0.791	rs6912079	ENSG00000270638.1	RP3-466P17.1	4.45	1.34e-05	0.00601	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145735570~145737218:+
SARC	cis	rs72945132	0.882	rs2276001	ENSG00000254604.1	AP000487.6	-4.45	1.34e-05	0.00601	-0.39	-0.28	Coronary artery disease;	chr11:70335454	chr11:70282367~70363368:-
SARC	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	4.45	1.35e-05	0.00602	0.53	0.28	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	4.45	1.35e-05	0.00602	0.53	0.28	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	4.45	1.35e-05	0.00602	0.53	0.28	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	4.45	1.35e-05	0.00602	0.53	0.28	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
SARC	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	4.45	1.35e-05	0.00602	0.3	0.28	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
SARC	cis	rs4835473	0.932	rs6858195	ENSG00000251600.4	RP11-673E1.1	-4.45	1.35e-05	0.00602	-0.28	-0.28	Immature fraction of reticulocytes;	chr4:143768444	chr4:143912331~143982454:+
SARC	cis	rs10754283	0.967	rs10801757	ENSG00000231613.1	RP5-943J3.1	4.45	1.35e-05	0.00602	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89637521	chr1:89788914~89790492:+
SARC	cis	rs4664293	0.967	rs1346325	ENSG00000226266.5	AC009961.3	-4.45	1.35e-05	0.00603	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159685995	chr2:159670708~159712435:-
SARC	cis	rs526231	0.819	rs403214	ENSG00000175749.11	EIF3KP1	4.45	1.35e-05	0.00603	0.37	0.28	Primary biliary cholangitis;	chr5:103268000	chr5:103032376~103033031:+
SARC	cis	rs4372836	0.504	rs3768666	ENSG00000226833.4	AC097724.3	4.45	1.35e-05	0.00604	0.23	0.28	Body mass index;	chr2:28783004	chr2:28708953~28736205:-
SARC	cis	rs1823913	0.927	rs13013390	ENSG00000227542.1	AC092614.2	4.45	1.35e-05	0.00604	0.3	0.28	Obesity-related traits;	chr2:191262001	chr2:191229165~191246172:-
SARC	cis	rs4862750	0.957	rs6858853	ENSG00000250971.1	RP11-696F12.1	-4.45	1.35e-05	0.00604	-0.32	-0.28	Lobe attachment (rater-scored or self-reported);	chr4:186982258	chr4:187060099~187060930:+
SARC	cis	rs7512898	0.545	rs6427850	ENSG00000260088.1	RP11-92G12.3	-4.45	1.35e-05	0.00605	-0.27	-0.28	Electrocardiographic conduction measures;	chr1:200703282	chr1:200669507~200694250:+
SARC	cis	rs12893668	0.572	rs11846404	ENSG00000269940.1	RP11-73M18.7	4.45	1.35e-05	0.00605	0.27	0.28	Reticulocyte count;	chr14:103689771	chr14:103694560~103695170:+
SARC	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	4.45	1.36e-05	0.00606	0.46	0.28	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
SARC	cis	rs7267979	1	rs6083825	ENSG00000276952.1	RP5-965G21.6	-4.45	1.36e-05	0.00606	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs34645895	ENSG00000276952.1	RP5-965G21.6	-4.45	1.36e-05	0.00606	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6115168	ENSG00000276952.1	RP5-965G21.6	-4.45	1.36e-05	0.00606	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6037105	ENSG00000276952.1	RP5-965G21.6	-4.45	1.36e-05	0.00606	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25284915~25285588:-
SARC	cis	rs4865169	0.783	rs7668814	ENSG00000269949.1	RP11-738E22.3	4.45	1.36e-05	0.00606	0.31	0.28	Breast cancer;	chr4:56959024	chr4:56960927~56961373:-
SARC	cis	rs1707322	0.721	rs6665808	ENSG00000281133.1	AL355480.3	-4.45	1.36e-05	0.00606	-0.32	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs61784800	ENSG00000281133.1	AL355480.3	4.45	1.36e-05	0.00606	0.32	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45580892~45580996:-
SARC	cis	rs4372836	0.715	rs66904522	ENSG00000226833.4	AC097724.3	-4.45	1.36e-05	0.00607	-0.24	-0.28	Body mass index;	chr2:28858026	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.729	rs11684695	ENSG00000226833.4	AC097724.3	-4.45	1.36e-05	0.00607	-0.24	-0.28	Body mass index;	chr2:28865584	chr2:28708953~28736205:-
SARC	cis	rs2292342	1	rs11880333	ENSG00000232871.7	SEC1P	-4.45	1.36e-05	0.00607	-0.51	-0.28	Elevated serum carcinoembryonic antigen levels;	chr19:48641533	chr19:48638071~48682245:+
SARC	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-4.45	1.36e-05	0.00607	-0.31	-0.28	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
SARC	cis	rs12893668	0.542	rs12884809	ENSG00000269958.1	RP11-73M18.8	4.44	1.36e-05	0.00608	0.3	0.28	Reticulocyte count;	chr14:103628983	chr14:103696353~103697163:+
SARC	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-4.44	1.36e-05	0.00608	-0.32	-0.28	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
SARC	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-4.44	1.36e-05	0.00609	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-4.44	1.36e-05	0.00609	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-4.44	1.36e-05	0.00609	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-4.44	1.36e-05	0.00609	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
SARC	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	4.44	1.36e-05	0.00609	0.27	0.28	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
SARC	cis	rs14027	0.843	rs1828238	ENSG00000279347.1	RP11-85I17.2	4.44	1.36e-05	0.00609	0.25	0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848105	chr8:119838736~119840385:-
SARC	cis	rs14027	0.921	rs1960438	ENSG00000279347.1	RP11-85I17.2	4.44	1.36e-05	0.00609	0.25	0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848193	chr8:119838736~119840385:-
SARC	cis	rs61160187	0.582	rs2898309	ENSG00000215032.2	GNL3LP1	4.44	1.37e-05	0.00611	0.27	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60981546	chr5:60891935~60893577:-
SARC	cis	rs2933343	0.729	rs6767104	ENSG00000261159.1	RP11-723O4.9	-4.44	1.37e-05	0.00613	-0.31	-0.28	IgG glycosylation;	chr3:128929274	chr3:128859716~128860526:-
SARC	cis	rs10986311	1	rs10986311	ENSG00000235204.1	RP11-121A14.2	4.44	1.37e-05	0.00613	0.32	0.28	Vitiligo;	chr9:124309214	chr9:124259250~124261156:-
SARC	cis	rs72945132	0.769	rs680571	ENSG00000254604.1	AP000487.6	-4.44	1.37e-05	0.00613	-0.39	-0.28	Coronary artery disease;	chr11:70341335	chr11:70282367~70363368:-
SARC	cis	rs8059260	0.668	rs7199305	ENSG00000274038.1	RP11-66H6.4	4.44	1.38e-05	0.00614	0.4	0.28	Alcohol consumption over the past year;	chr16:11006476	chr16:11056556~11057034:+
SARC	cis	rs42490	0.638	rs40637	ENSG00000251136.7	RP11-37B2.1	-4.44	1.38e-05	0.00614	-0.31	-0.28	Leprosy;	chr8:89811082	chr8:89609409~89757727:-
SARC	cis	rs6570726	0.791	rs621382	ENSG00000270638.1	RP3-466P17.1	4.44	1.38e-05	0.00615	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs1509213	ENSG00000270638.1	RP3-466P17.1	-4.44	1.38e-05	0.00615	-0.22	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145735570~145737218:+
SARC	cis	rs7267979	1	rs6037095	ENSG00000276952.1	RP5-965G21.6	-4.44	1.38e-05	0.00615	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6050562	ENSG00000276952.1	RP5-965G21.6	-4.44	1.38e-05	0.00615	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25284915~25285588:-
SARC	cis	rs12200782	0.929	rs72836467	ENSG00000272810.1	U91328.22	-4.44	1.38e-05	0.00615	-0.43	-0.28	Small cell lung carcinoma;	chr6:26353699	chr6:26013241~26013757:+
SARC	cis	rs12200782	0.929	rs116018523	ENSG00000272810.1	U91328.22	-4.44	1.38e-05	0.00615	-0.43	-0.28	Small cell lung carcinoma;	chr6:26357006	chr6:26013241~26013757:+
SARC	cis	rs4703855	0.538	rs4346752	ENSG00000244061.1	RP11-389C8.1	4.44	1.38e-05	0.00616	0.29	0.28	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72429489	chr5:72381794~72382393:+
SARC	cis	rs7267979	1	rs2482937	ENSG00000276952.1	RP5-965G21.6	-4.44	1.38e-05	0.00616	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25284915~25285588:-
SARC	cis	rs853679	0.517	rs9380052	ENSG00000272009.1	RP1-313I6.12	-4.44	1.38e-05	0.00616	-0.32	-0.28	Depression;	chr6:28096845	chr6:28078792~28081130:-
SARC	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-4.44	1.38e-05	0.00617	-0.32	-0.28	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
SARC	cis	rs1865760	0.516	rs9358903	ENSG00000272462.2	U91328.19	-4.44	1.38e-05	0.00617	-0.25	-0.28	Height;	chr6:26061721	chr6:25992662~26001775:+
SARC	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-4.44	1.39e-05	0.00618	-0.31	-0.28	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
SARC	cis	rs910316	0.763	rs735452	ENSG00000279594.1	RP11-950C14.10	-4.44	1.39e-05	0.00618	-0.31	-0.28	Height;	chr14:75031281	chr14:75011269~75012851:-
SARC	cis	rs9309473	0.66	rs11679594	ENSG00000163016.8	ALMS1P	4.44	1.39e-05	0.00618	0.41	0.28	Metabolite levels;	chr2:73552380	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.528	rs79799178	ENSG00000163016.8	ALMS1P	4.44	1.39e-05	0.00618	0.41	0.28	Metabolite levels;	chr2:73564108	chr2:73644919~73685576:+
SARC	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	4.44	1.39e-05	0.00618	0.52	0.28	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	4.44	1.39e-05	0.00618	0.52	0.28	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	4.44	1.39e-05	0.00618	0.52	0.28	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	4.44	1.39e-05	0.00618	0.52	0.28	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	4.44	1.39e-05	0.00618	0.52	0.28	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	4.44	1.39e-05	0.00618	0.52	0.28	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	4.44	1.39e-05	0.00618	0.52	0.28	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	4.44	1.39e-05	0.00618	0.52	0.28	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	4.44	1.39e-05	0.00618	0.52	0.28	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
SARC	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	4.44	1.39e-05	0.00619	0.29	0.28	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
SARC	cis	rs12285276	0.636	rs7114337	ENSG00000205106.4	DKFZp779M0652	4.44	1.39e-05	0.0062	0.39	0.28	Visceral fat;	chr11:45779608	chr11:45771432~45772358:+
SARC	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	4.44	1.39e-05	0.0062	0.32	0.28	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
SARC	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	4.44	1.39e-05	0.0062	0.32	0.28	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
SARC	cis	rs4835473	0.838	rs56033497	ENSG00000251600.4	RP11-673E1.1	-4.44	1.39e-05	0.0062	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143792341	chr4:143912331~143982454:+
SARC	cis	rs1823913	1	rs11691372	ENSG00000280083.1	RP11-317J9.1	4.44	1.39e-05	0.0062	0.31	0.28	Obesity-related traits;	chr2:191249952	chr2:191154118~191156070:-
SARC	cis	rs14027	0.921	rs12542794	ENSG00000279347.1	RP11-85I17.2	-4.44	1.39e-05	0.0062	-0.24	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119826153	chr8:119838736~119840385:-
SARC	cis	rs4664293	0.867	rs13415025	ENSG00000226266.5	AC009961.3	-4.44	1.39e-05	0.0062	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159729799	chr2:159670708~159712435:-
SARC	cis	rs12893668	0.543	rs1799796	ENSG00000269940.1	RP11-73M18.7	4.44	1.39e-05	0.0062	0.28	0.28	Reticulocyte count;	chr14:103699590	chr14:103694560~103695170:+
SARC	cis	rs12893668	0.514	rs3212090	ENSG00000269940.1	RP11-73M18.7	4.44	1.39e-05	0.0062	0.28	0.28	Reticulocyte count;	chr14:103702526	chr14:103694560~103695170:+
SARC	cis	rs1823913	0.637	rs4853574	ENSG00000227542.1	AC092614.2	-4.44	1.39e-05	0.0062	-0.31	-0.28	Obesity-related traits;	chr2:191296113	chr2:191229165~191246172:-
SARC	cis	rs324126	0.78	rs2059817	ENSG00000269834.4	ZNF528-AS1	4.44	1.4e-05	0.00621	0.3	0.28	Colonoscopy-negative controls vs population controls;	chr19:52379032	chr19:52388842~52397766:-
SARC	cis	rs860818	1	rs860817	ENSG00000226816.2	AC005082.12	4.44	1.4e-05	0.00621	0.74	0.28	Initial pursuit acceleration;	chr7:23211850	chr7:23206013~23208045:+
SARC	cis	rs253959	0.576	rs1588268	ENSG00000272265.1	CTD-2287O16.4	4.44	1.4e-05	0.00622	0.32	0.28	Bipolar disorder and schizophrenia;	chr5:116101091	chr5:116078110~116078570:-
SARC	cis	rs2274273	0.588	rs9323285	ENSG00000258413.1	RP11-665C16.6	4.44	1.4e-05	0.00622	0.36	0.28	Protein biomarker;	chr14:55397111	chr14:55262767~55272075:-
SARC	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	4.44	1.4e-05	0.00622	0.23	0.28	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
SARC	cis	rs890448	0.965	rs11944753	ENSG00000254531.1	FLJ20021	-4.44	1.4e-05	0.00622	-0.28	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101503451	chr4:101347780~101348883:+
SARC	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	4.44	1.4e-05	0.00622	0.31	0.28	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
SARC	cis	rs367615	0.704	rs4286723	ENSG00000249476.1	CTD-2587M2.1	4.44	1.4e-05	0.00622	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109500258	chr5:109237120~109326369:-
SARC	cis	rs35160687	0.712	rs4832262	ENSG00000273080.1	RP11-301O19.1	-4.44	1.4e-05	0.00622	-0.29	-0.28	Night sleep phenotypes;	chr2:86258011	chr2:86195590~86196049:+
SARC	cis	rs867371	1	rs1392976	ENSG00000259429.4	UBE2Q2P2	4.44	1.4e-05	0.00623	0.26	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82355142~82420075:+
SARC	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	4.44	1.4e-05	0.00623	0.4	0.28	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
SARC	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	4.44	1.4e-05	0.00623	0.35	0.28	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
SARC	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	4.44	1.4e-05	0.00623	0.35	0.28	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
SARC	cis	rs7772486	0.641	rs9390374	ENSG00000270638.1	RP3-466P17.1	4.44	1.4e-05	0.00623	0.24	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146047039	chr6:145735570~145737218:+
SARC	cis	rs4664293	1	rs11676412	ENSG00000226266.5	AC009961.3	-4.44	1.4e-05	0.00624	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159651560	chr2:159670708~159712435:-
SARC	cis	rs7267979	1	rs6115153	ENSG00000276952.1	RP5-965G21.6	-4.44	1.41e-05	0.00625	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs7268053	ENSG00000276952.1	RP5-965G21.6	-4.44	1.41e-05	0.00625	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6083809	ENSG00000276952.1	RP5-965G21.6	-4.44	1.41e-05	0.00625	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25284915~25285588:-
SARC	cis	rs4835473	0.897	rs6835827	ENSG00000251600.4	RP11-673E1.1	4.44	1.41e-05	0.00625	0.27	0.28	Immature fraction of reticulocytes;	chr4:143712803	chr4:143912331~143982454:+
SARC	cis	rs2274273	0.967	rs8013027	ENSG00000258413.1	RP11-665C16.6	-4.44	1.41e-05	0.00625	-0.35	-0.28	Protein biomarker;	chr14:55144222	chr14:55262767~55272075:-
SARC	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-4.44	1.41e-05	0.00625	-0.42	-0.28	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
SARC	cis	rs61160187	0.549	rs62367879	ENSG00000215032.2	GNL3LP1	4.44	1.41e-05	0.00626	0.27	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996384	chr5:60891935~60893577:-
SARC	cis	rs8059260	0.542	rs11860777	ENSG00000274038.1	RP11-66H6.4	-4.44	1.41e-05	0.00626	-0.39	-0.28	Alcohol consumption over the past year;	chr16:11033718	chr16:11056556~11057034:+
SARC	cis	rs123509	0.874	rs339683	ENSG00000230970.3	HHATL-AS1	-4.44	1.41e-05	0.00627	-0.32	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42747019	chr3:42702653~42706776:+
SARC	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-4.44	1.41e-05	0.00627	-0.29	-0.28	Height;	chr3:53029908	chr3:53064283~53065091:-
SARC	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	4.44	1.41e-05	0.00627	0.23	0.28	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
SARC	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-4.44	1.41e-05	0.00627	-0.3	-0.28	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-4.44	1.41e-05	0.00627	-0.3	-0.28	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
SARC	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	4.44	1.41e-05	0.00628	0.33	0.28	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
SARC	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	4.44	1.41e-05	0.00628	0.52	0.28	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	4.44	1.41e-05	0.00628	0.52	0.28	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	4.44	1.41e-05	0.00628	0.52	0.28	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
SARC	cis	rs739310	1	rs739310	ENSG00000206028.1	CTA-373H7.7	-4.44	1.41e-05	0.00628	-0.35	-0.28	Obesity-related traits;	chr22:26655335	chr22:26667693~26672654:-
SARC	cis	rs9309473	0.687	rs7576824	ENSG00000163016.8	ALMS1P	-4.44	1.41e-05	0.00628	-0.34	-0.28	Metabolite levels;	chr2:73384153	chr2:73644919~73685576:+
SARC	cis	rs75920871	0.528	rs3886960	ENSG00000254851.1	RP11-109L13.1	4.44	1.41e-05	0.00628	0.37	0.28	Subjective well-being;	chr11:117054274	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.528	rs723955	ENSG00000254851.1	RP11-109L13.1	4.44	1.41e-05	0.00628	0.37	0.28	Subjective well-being;	chr11:117054326	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.528	rs7108912	ENSG00000254851.1	RP11-109L13.1	4.44	1.41e-05	0.00628	0.37	0.28	Subjective well-being;	chr11:117055280	chr11:117135528~117138582:+
SARC	cis	rs7267979	0.866	rs2424699	ENSG00000276952.1	RP5-965G21.6	4.44	1.42e-05	0.00629	0.28	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25276826	chr20:25284915~25285588:-
SARC	cis	rs6845263	0.538	rs2717846	ENSG00000254531.1	FLJ20021	4.44	1.42e-05	0.00629	0.27	0.28	Superior crus of antihelix expression;	chr4:101592323	chr4:101347780~101348883:+
SARC	cis	rs6845263	0.512	rs2615972	ENSG00000254531.1	FLJ20021	4.44	1.42e-05	0.00629	0.27	0.28	Superior crus of antihelix expression;	chr4:101592350	chr4:101347780~101348883:+
SARC	cis	rs6845263	0.511	rs62321926	ENSG00000254531.1	FLJ20021	4.44	1.42e-05	0.00629	0.27	0.28	Superior crus of antihelix expression;	chr4:101592388	chr4:101347780~101348883:+
SARC	cis	rs2179367	0.632	rs62426068	ENSG00000231760.4	RP11-350J20.5	4.44	1.42e-05	0.00629	0.38	0.28	Dupuytren's disease;	chr6:149325795	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs62426069	ENSG00000231760.4	RP11-350J20.5	4.44	1.42e-05	0.00629	0.38	0.28	Dupuytren's disease;	chr6:149325804	chr6:149796151~149826294:-
SARC	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-4.44	1.42e-05	0.00629	-0.25	-0.28	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
SARC	cis	rs6570726	0.791	rs398408	ENSG00000270638.1	RP3-466P17.1	4.44	1.42e-05	0.00629	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145735570~145737218:+
SARC	cis	rs526231	0.853	rs187579	ENSG00000175749.11	EIF3KP1	4.44	1.42e-05	0.0063	0.37	0.28	Primary biliary cholangitis;	chr5:103269232	chr5:103032376~103033031:+
SARC	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-4.44	1.42e-05	0.0063	-0.39	-0.28	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
SARC	cis	rs520525	0.963	rs627848	ENSG00000271811.1	RP1-79C4.4	4.44	1.42e-05	0.0063	0.39	0.28	Atrial fibrillation;	chr1:170662279	chr1:170667381~170669425:+
SARC	cis	rs12893668	0.603	rs61637848	ENSG00000269940.1	RP11-73M18.7	4.43	1.42e-05	0.0063	0.27	0.28	Reticulocyte count;	chr14:103629694	chr14:103694560~103695170:+
SARC	cis	rs2933343	0.7	rs1683777	ENSG00000231305.3	RP11-723O4.2	4.43	1.42e-05	0.0063	0.28	0.28	IgG glycosylation;	chr3:128906037	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.7	rs1680788	ENSG00000231305.3	RP11-723O4.2	4.43	1.42e-05	0.0063	0.28	0.28	IgG glycosylation;	chr3:128906475	chr3:128861313~128871540:-
SARC	cis	rs2439831	0.702	rs9989313	ENSG00000275601.1	AC011330.13	-4.43	1.42e-05	0.00631	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43860619	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs61390361	ENSG00000275601.1	AC011330.13	-4.43	1.42e-05	0.00631	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43867644	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs11856795	ENSG00000275601.1	AC011330.13	-4.43	1.42e-05	0.00631	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43868384	chr15:43642389~43643023:-
SARC	cis	rs9309473	0.539	rs7574268	ENSG00000163016.8	ALMS1P	-4.43	1.42e-05	0.00632	-0.32	-0.28	Metabolite levels;	chr2:73677745	chr2:73644919~73685576:+
SARC	cis	rs7512898	1	rs7512898	ENSG00000260088.1	RP11-92G12.3	4.43	1.43e-05	0.00633	0.27	0.28	Electrocardiographic conduction measures;	chr1:200703778	chr1:200669507~200694250:+
SARC	cis	rs11634944	0.705	rs2554441	ENSG00000274307.1	RP11-345J18.2	-4.43	1.43e-05	0.00633	-0.36	-0.28	Interleukin-8 levels;	chr15:25031500	chr15:25708470~25710869:-
SARC	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-4.43	1.43e-05	0.00633	-0.43	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
SARC	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-4.43	1.43e-05	0.00634	-0.41	-0.28	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
SARC	cis	rs1823913	0.614	rs4853576	ENSG00000227542.1	AC092614.2	-4.43	1.43e-05	0.00634	-0.31	-0.28	Obesity-related traits;	chr2:191296618	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs4853577	ENSG00000227542.1	AC092614.2	-4.43	1.43e-05	0.00634	-0.31	-0.28	Obesity-related traits;	chr2:191297118	chr2:191229165~191246172:-
SARC	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-4.43	1.43e-05	0.00634	-0.29	-0.28	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
SARC	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-4.43	1.43e-05	0.00634	-0.29	-0.28	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
SARC	cis	rs2933343	0.649	rs1683786	ENSG00000231305.3	RP11-723O4.2	4.43	1.43e-05	0.00634	0.28	0.28	IgG glycosylation;	chr3:128908109	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.7	rs876754	ENSG00000231305.3	RP11-723O4.2	4.43	1.43e-05	0.00634	0.28	0.28	IgG glycosylation;	chr3:128908910	chr3:128861313~128871540:-
SARC	cis	rs7267979	0.966	rs3827014	ENSG00000276952.1	RP5-965G21.6	-4.43	1.43e-05	0.00634	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25284915~25285588:-
SARC	cis	rs2239557	0.961	rs4903200	ENSG00000259065.1	RP5-1021I20.1	4.43	1.43e-05	0.00634	0.32	0.28	Common traits (Other);	chr14:74192934	chr14:73787360~73803270:+
SARC	cis	rs2274273	0.905	rs4652	ENSG00000258413.1	RP11-665C16.6	-4.43	1.43e-05	0.00635	-0.32	-0.28	Protein biomarker;	chr14:55138318	chr14:55262767~55272075:-
SARC	cis	rs1823913	0.637	rs4853578	ENSG00000227542.1	AC092614.2	4.43	1.43e-05	0.00635	0.31	0.28	Obesity-related traits;	chr2:191297215	chr2:191229165~191246172:-
SARC	cis	rs12200782	0.929	rs72836460	ENSG00000272810.1	U91328.22	-4.43	1.43e-05	0.00635	-0.46	-0.28	Small cell lung carcinoma;	chr6:26351662	chr6:26013241~26013757:+
SARC	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-4.43	1.43e-05	0.00636	-0.51	-0.28	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
SARC	cis	rs7267979	0.932	rs6138588	ENSG00000276952.1	RP5-965G21.6	4.43	1.43e-05	0.00636	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:25284915~25285588:-
SARC	cis	rs9868809	0.656	rs73078362	ENSG00000225399.4	RP11-3B7.1	-4.43	1.43e-05	0.00636	-0.61	-0.28	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48666484	chr3:49260085~49261316:+
SARC	cis	rs7829975	0.774	rs1703982	ENSG00000253893.2	FAM85B	4.43	1.44e-05	0.00636	0.25	0.28	Mood instability;	chr8:8740878	chr8:8167819~8226614:-
SARC	cis	rs8062405	0.691	rs743590	ENSG00000251417.2	RP11-1348G14.4	-4.43	1.44e-05	0.00637	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28802743~28817828:+
SARC	cis	rs4845875	0.559	rs4846047	ENSG00000242349.4	NPPA-AS1	4.43	1.44e-05	0.00638	0.32	0.28	Midregional pro atrial natriuretic peptide levels;	chr1:11783575	chr1:11841017~11848079:+
SARC	cis	rs6908034	0.66	rs7746588	ENSG00000228412.5	RP4-625H18.2	4.43	1.44e-05	0.00639	0.45	0.28	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804409	chr6:19802164~19804752:-
SARC	cis	rs6908034	0.556	rs7750703	ENSG00000228412.5	RP4-625H18.2	4.43	1.44e-05	0.00639	0.45	0.28	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804583	chr6:19802164~19804752:-
SARC	cis	rs6908034	0.66	rs7750716	ENSG00000228412.5	RP4-625H18.2	4.43	1.44e-05	0.00639	0.45	0.28	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804608	chr6:19802164~19804752:-
SARC	cis	rs12893668	0.572	rs4900591	ENSG00000269940.1	RP11-73M18.7	4.43	1.44e-05	0.00639	0.27	0.28	Reticulocyte count;	chr14:103688541	chr14:103694560~103695170:+
SARC	cis	rs7567389	0.719	rs1504135	ENSG00000236682.1	AC068282.3	4.43	1.44e-05	0.00639	0.35	0.28	Self-rated health;	chr2:127245675	chr2:127389130~127400580:+
SARC	cis	rs12817211	0.502	rs12369049	ENSG00000272368.2	RP4-605O3.4	-4.43	1.44e-05	0.0064	-0.27	-0.28	Colorectal or endometrial cancer;	chr12:50116679	chr12:50112197~50165618:+
SARC	cis	rs12893668	0.543	rs12147645	ENSG00000269910.1	RP11-73M18.10	4.43	1.44e-05	0.0064	0.25	0.28	Reticulocyte count;	chr14:103633871	chr14:103694516~103695050:-
SARC	cis	rs440932	1	rs378974	ENSG00000253893.2	FAM85B	-4.43	1.45e-05	0.0064	-0.26	-0.28	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8167819~8226614:-
SARC	cis	rs193541	0.632	rs4835896	ENSG00000263432.2	RN7SL689P	-4.43	1.45e-05	0.0064	-0.36	-0.28	Glucose homeostasis traits;	chr5:122785545	chr5:123022487~123022783:-
SARC	cis	rs150992	0.688	rs161947	ENSG00000248489.1	CTD-2007H13.3	4.43	1.45e-05	0.00641	0.33	0.28	Body mass index;	chr5:98932868	chr5:98929171~98995013:+
SARC	cis	rs853679	0.546	rs493161	ENSG00000216901.1	AL022393.7	4.43	1.45e-05	0.00641	0.65	0.28	Depression;	chr6:27882936	chr6:28176188~28176674:+
SARC	cis	rs910316	1	rs175492	ENSG00000279594.1	RP11-950C14.10	4.43	1.45e-05	0.00641	0.29	0.28	Height;	chr14:75078517	chr14:75011269~75012851:-
SARC	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-4.43	1.45e-05	0.00641	-0.25	-0.28	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
SARC	cis	rs910316	0.737	rs175072	ENSG00000279594.1	RP11-950C14.10	-4.43	1.45e-05	0.00641	-0.31	-0.28	Height;	chr14:75036124	chr14:75011269~75012851:-
SARC	cis	rs910316	0.712	rs175074	ENSG00000279594.1	RP11-950C14.10	-4.43	1.45e-05	0.00641	-0.31	-0.28	Height;	chr14:75037751	chr14:75011269~75012851:-
SARC	cis	rs10754283	0.967	rs10737707	ENSG00000231613.1	RP5-943J3.1	4.43	1.45e-05	0.00641	0.27	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89653745	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs10737708	ENSG00000231613.1	RP5-943J3.1	4.43	1.45e-05	0.00641	0.27	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89654245	chr1:89788914~89790492:+
SARC	cis	rs10754283	0.967	rs10801763	ENSG00000231613.1	RP5-943J3.1	4.43	1.45e-05	0.00641	0.27	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89655263	chr1:89788914~89790492:+
SARC	cis	rs4664293	0.51	rs2042781	ENSG00000226266.5	AC009961.3	4.43	1.45e-05	0.00641	0.34	0.28	Monocyte percentage of white cells;	chr2:159789899	chr2:159670708~159712435:-
SARC	cis	rs2179367	0.632	rs2143075	ENSG00000231760.4	RP11-350J20.5	4.43	1.45e-05	0.00642	0.39	0.28	Dupuytren's disease;	chr6:149425507	chr6:149796151~149826294:-
SARC	cis	rs801193	0.66	rs974239	ENSG00000232559.3	GS1-124K5.12	4.43	1.45e-05	0.00642	0.32	0.28	Aortic root size;	chr7:66748504	chr7:66554588~66576923:-
SARC	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-4.43	1.45e-05	0.00642	-0.32	-0.28	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
SARC	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-4.43	1.45e-05	0.00642	-0.32	-0.28	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-4.43	1.45e-05	0.00642	-0.32	-0.28	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-4.43	1.45e-05	0.00642	-0.32	-0.28	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
SARC	cis	rs853679	1	rs853685	ENSG00000216901.1	AL022393.7	4.43	1.45e-05	0.00642	0.47	0.28	Depression;	chr6:28321008	chr6:28176188~28176674:+
SARC	cis	rs853679	1	rs853679	ENSG00000216901.1	AL022393.7	4.43	1.45e-05	0.00642	0.47	0.28	Depression;	chr6:28329086	chr6:28176188~28176674:+
SARC	cis	rs853679	1	rs853678	ENSG00000216901.1	AL022393.7	4.43	1.45e-05	0.00642	0.47	0.28	Depression;	chr6:28329536	chr6:28176188~28176674:+
SARC	cis	rs2179367	0.568	rs6932778	ENSG00000231760.4	RP11-350J20.5	4.43	1.45e-05	0.00643	0.41	0.28	Dupuytren's disease;	chr6:149328293	chr6:149796151~149826294:-
SARC	cis	rs2562456	0.833	rs2562487	ENSG00000268081.1	RP11-678G14.2	4.43	1.45e-05	0.00643	0.41	0.28	Pain;	chr19:21468580	chr19:21554640~21569237:-
SARC	cis	rs4372836	0.602	rs11685682	ENSG00000226833.4	AC097724.3	-4.43	1.45e-05	0.00643	-0.24	-0.28	Body mass index;	chr2:28833935	chr2:28708953~28736205:-
SARC	cis	rs2933343	0.621	rs789249	ENSG00000231305.3	RP11-723O4.2	4.43	1.46e-05	0.00644	0.28	0.28	IgG glycosylation;	chr3:128859610	chr3:128861313~128871540:-
SARC	cis	rs4372836	0.504	rs10183665	ENSG00000226833.4	AC097724.3	4.43	1.46e-05	0.00644	0.23	0.28	Body mass index;	chr2:28772360	chr2:28708953~28736205:-
SARC	cis	rs17772222	0.636	rs77528165	ENSG00000258983.2	RP11-507K2.2	4.43	1.46e-05	0.00645	0.33	0.28	Coronary artery calcification;	chr14:88794249	chr14:88499334~88515502:+
SARC	cis	rs739310	0.516	rs2301524	ENSG00000206028.1	CTA-373H7.7	-4.43	1.46e-05	0.00645	-0.41	-0.28	Obesity-related traits;	chr22:26666832	chr22:26667693~26672654:-
SARC	cis	rs6763768	0.705	rs312483	ENSG00000280417.1	RP11-5O17.1	4.43	1.46e-05	0.00645	0.33	0.28	Bacterial meningitis;	chr3:53490024	chr3:53046166~53048122:+
SARC	cis	rs2179367	0.586	rs9498341	ENSG00000231760.4	RP11-350J20.5	4.43	1.46e-05	0.00645	0.37	0.28	Dupuytren's disease;	chr6:149379737	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498342	ENSG00000231760.4	RP11-350J20.5	4.43	1.46e-05	0.00645	0.37	0.28	Dupuytren's disease;	chr6:149379806	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs12191079	ENSG00000231760.4	RP11-350J20.5	4.43	1.46e-05	0.00645	0.37	0.28	Dupuytren's disease;	chr6:149380333	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs12204461	ENSG00000231760.4	RP11-350J20.5	4.43	1.46e-05	0.00645	0.37	0.28	Dupuytren's disease;	chr6:149380399	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs12196656	ENSG00000231760.4	RP11-350J20.5	4.43	1.46e-05	0.00645	0.37	0.28	Dupuytren's disease;	chr6:149383104	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs12211570	ENSG00000231760.4	RP11-350J20.5	4.43	1.46e-05	0.00645	0.37	0.28	Dupuytren's disease;	chr6:149383616	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.568	rs11155647	ENSG00000231760.4	RP11-350J20.5	4.43	1.46e-05	0.00645	0.37	0.28	Dupuytren's disease;	chr6:149384499	chr6:149796151~149826294:-
SARC	cis	rs890448	0.796	rs13148645	ENSG00000254531.1	FLJ20021	4.43	1.46e-05	0.00645	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101385675	chr4:101347780~101348883:+
SARC	cis	rs2836950	0.501	rs62223052	ENSG00000255568.3	BRWD1-AS2	-4.43	1.46e-05	0.00645	-0.26	-0.28	Menarche (age at onset);	chr21:39336776	chr21:39313935~39314962:+
SARC	cis	rs14027	0.921	rs2289011	ENSG00000279347.1	RP11-85I17.2	4.43	1.46e-05	0.00646	0.24	0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119744768	chr8:119838736~119840385:-
SARC	cis	rs597539	0.654	rs655816	ENSG00000250508.1	RP11-757G1.6	-4.43	1.46e-05	0.00646	-0.33	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68870664~68874542:+
SARC	cis	rs597539	0.69	rs497149	ENSG00000250508.1	RP11-757G1.6	-4.43	1.46e-05	0.00646	-0.33	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68870664~68874542:+
SARC	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-4.43	1.46e-05	0.00646	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
SARC	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	4.43	1.46e-05	0.00647	0.26	0.28	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
SARC	cis	rs1707322	0.721	rs56255771	ENSG00000281133.1	AL355480.3	-4.43	1.46e-05	0.00647	-0.32	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45580892~45580996:-
SARC	cis	rs910316	1	rs12589876	ENSG00000279594.1	RP11-950C14.10	4.43	1.46e-05	0.00647	0.31	0.28	Height;	chr14:75077486	chr14:75011269~75012851:-
SARC	cis	rs910316	0.967	rs10246	ENSG00000279594.1	RP11-950C14.10	4.43	1.46e-05	0.00647	0.31	0.28	Height;	chr14:75077767	chr14:75011269~75012851:-
SARC	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	4.43	1.47e-05	0.00648	0.5	0.28	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
SARC	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	4.43	1.47e-05	0.00648	0.5	0.28	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
SARC	cis	rs520525	0.963	rs501680	ENSG00000271811.1	RP1-79C4.4	4.43	1.47e-05	0.00648	0.38	0.28	Atrial fibrillation;	chr1:170656726	chr1:170667381~170669425:+
SARC	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-4.43	1.47e-05	0.00649	-0.3	-0.28	Height;	chr3:53097932	chr3:53064283~53065091:-
SARC	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-4.43	1.47e-05	0.00649	-0.35	-0.28	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
SARC	cis	rs62432291	0.681	rs378547	ENSG00000235086.1	FNDC1-IT1	4.43	1.47e-05	0.00649	0.45	0.28	Joint mobility (Beighton score);	chr6:159241493	chr6:159240786~159243329:+
SARC	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-4.43	1.47e-05	0.00649	-0.38	-0.28	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
SARC	cis	rs59104589	0.583	rs62186377	ENSG00000266621.1	AC104841.1	4.43	1.47e-05	0.00649	0.4	0.28	Fibrinogen levels;	chr2:241272035	chr2:241245202~241245299:-
SARC	cis	rs42490	1	rs218907	ENSG00000251136.7	RP11-37B2.1	-4.43	1.47e-05	0.00649	-0.31	-0.28	Leprosy;	chr8:89728164	chr8:89609409~89757727:-
SARC	cis	rs42490	0.966	rs218908	ENSG00000251136.7	RP11-37B2.1	-4.43	1.47e-05	0.00649	-0.31	-0.28	Leprosy;	chr8:89728886	chr8:89609409~89757727:-
SARC	cis	rs42490	1	rs218913	ENSG00000251136.7	RP11-37B2.1	-4.43	1.47e-05	0.00649	-0.31	-0.28	Leprosy;	chr8:89732206	chr8:89609409~89757727:-
SARC	cis	rs42490	0.966	rs218914	ENSG00000251136.7	RP11-37B2.1	-4.43	1.47e-05	0.00649	-0.31	-0.28	Leprosy;	chr8:89733130	chr8:89609409~89757727:-
SARC	cis	rs42490	0.934	rs218925	ENSG00000251136.7	RP11-37B2.1	-4.43	1.47e-05	0.00649	-0.31	-0.28	Leprosy;	chr8:89737352	chr8:89609409~89757727:-
SARC	cis	rs42490	1	rs2735870	ENSG00000251136.7	RP11-37B2.1	4.43	1.47e-05	0.00649	0.31	0.28	Leprosy;	chr8:89730456	chr8:89609409~89757727:-
SARC	cis	rs42490	0.966	rs2735871	ENSG00000251136.7	RP11-37B2.1	4.43	1.47e-05	0.00649	0.31	0.28	Leprosy;	chr8:89731154	chr8:89609409~89757727:-
SARC	cis	rs7247513	0.93	rs35275129	ENSG00000213290.4	PGK1P2	-4.43	1.47e-05	0.00649	-0.32	-0.28	Bipolar disorder;	chr19:12605679	chr19:12559571~12561105:+
SARC	cis	rs7247513	0.897	rs12979146	ENSG00000213290.4	PGK1P2	-4.43	1.47e-05	0.00649	-0.32	-0.28	Bipolar disorder;	chr19:12607090	chr19:12559571~12561105:+
SARC	cis	rs2933343	0.7	rs789240	ENSG00000231305.3	RP11-723O4.2	4.43	1.47e-05	0.0065	0.28	0.28	IgG glycosylation;	chr3:128911792	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.7	rs789239	ENSG00000231305.3	RP11-723O4.2	4.43	1.47e-05	0.0065	0.28	0.28	IgG glycosylation;	chr3:128914965	chr3:128861313~128871540:-
SARC	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	4.43	1.47e-05	0.0065	0.39	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
SARC	cis	rs8031584	0.723	rs11632229	ENSG00000260382.1	RP11-540B6.2	-4.43	1.47e-05	0.00651	-0.32	-0.28	Huntington's disease progression;	chr15:30887331	chr15:30882267~30883231:-
SARC	cis	rs4664293	0.836	rs13397597	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159747084	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.805	rs7593273	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159749349	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs34392518	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159749367	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.805	rs6432559	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159750649	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs6432560	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159750758	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs3863924	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159758247	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs11681565	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159760362	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.836	rs11687502	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159760464	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.836	rs13401087	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159760957	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs12692564	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159761326	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs1427328	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159762064	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.613	rs9784044	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159765854	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs4664301	ENSG00000226266.5	AC009961.3	-4.43	1.47e-05	0.00651	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159766855	chr2:159670708~159712435:-
SARC	cis	rs7772486	0.754	rs4360151	ENSG00000270638.1	RP3-466P17.1	-4.43	1.47e-05	0.00651	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145933943	chr6:145735570~145737218:+
SARC	cis	rs763121	0.962	rs5757130	ENSG00000273076.1	RP3-508I15.22	4.43	1.48e-05	0.00651	0.29	0.28	Menopause (age at onset);	chr22:38541789	chr22:38743495~38743910:+
SARC	cis	rs7712401	0.623	rs26372	ENSG00000263432.2	RN7SL689P	-4.43	1.48e-05	0.00651	-0.35	-0.28	Mean platelet volume;	chr5:122870752	chr5:123022487~123022783:-
SARC	cis	rs858239	0.932	rs199355	ENSG00000226816.2	AC005082.12	4.43	1.48e-05	0.00651	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23206013~23208045:+
SARC	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	4.43	1.48e-05	0.00651	0.32	0.28	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
SARC	cis	rs2292342	0.85	rs11878449	ENSG00000232871.7	SEC1P	-4.43	1.48e-05	0.00652	-0.51	-0.28	Elevated serum carcinoembryonic antigen levels;	chr19:48641677	chr19:48638071~48682245:+
SARC	cis	rs9902453	0.578	rs8073217	ENSG00000264538.5	SUZ12P1	4.43	1.48e-05	0.00652	0.2	0.28	Coffee consumption (cups per day);	chr17:29837245	chr17:30709299~30790908:+
SARC	cis	rs453301	0.686	rs6601280	ENSG00000253893.2	FAM85B	-4.43	1.48e-05	0.00653	-0.25	-0.28	Joint mobility (Beighton score);	chr8:9051726	chr8:8167819~8226614:-
SARC	cis	rs8062405	0.755	rs2077031	ENSG00000251417.2	RP11-1348G14.4	-4.43	1.48e-05	0.00653	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28802743~28817828:+
SARC	cis	rs7772486	0.79	rs9403755	ENSG00000270638.1	RP3-466P17.1	-4.43	1.48e-05	0.00653	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145735570~145737218:+
SARC	cis	rs6496932	0.563	rs2344083	ENSG00000202081.1	RNU6-1280P	-4.43	1.48e-05	0.00653	-0.3	-0.28	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85651522~85651628:-
SARC	cis	rs4664293	0.631	rs13019272	ENSG00000226266.5	AC009961.3	-4.43	1.48e-05	0.00653	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159802352	chr2:159670708~159712435:-
SARC	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-4.43	1.48e-05	0.00653	-0.45	-0.28	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
SARC	cis	rs12530	0.715	rs2294311	ENSG00000230736.2	RP1-149A16.3	-4.43	1.48e-05	0.00653	-0.32	-0.28	IgG glycosylation;	chr22:32397282	chr22:32376664~32384343:+
SARC	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-4.42	1.48e-05	0.00654	-0.29	-0.28	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
SARC	cis	rs6540731	1	rs7518329	ENSG00000229983.1	RP11-15I11.2	4.42	1.48e-05	0.00654	0.28	0.28	Intelligence (childhood);	chr1:212225191	chr1:212168207~212190259:+
SARC	cis	rs7712401	0.562	rs384483	ENSG00000263432.2	RN7SL689P	-4.42	1.48e-05	0.00654	-0.33	-0.28	Mean platelet volume;	chr5:122925878	chr5:123022487~123022783:-
SARC	cis	rs7267979	0.528	rs2387976	ENSG00000125804.12	FAM182A	4.42	1.48e-05	0.00655	0.33	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:26054655~26086917:+
SARC	cis	rs160451	0.966	rs218886	ENSG00000251136.7	RP11-37B2.1	-4.42	1.48e-05	0.00655	-0.31	-0.28	Leprosy;	chr8:89678365	chr8:89609409~89757727:-
SARC	cis	rs160451	0.933	rs218888	ENSG00000251136.7	RP11-37B2.1	-4.42	1.48e-05	0.00655	-0.31	-0.28	Leprosy;	chr8:89679693	chr8:89609409~89757727:-
SARC	cis	rs160451	0.933	rs218889	ENSG00000251136.7	RP11-37B2.1	-4.42	1.48e-05	0.00655	-0.31	-0.28	Leprosy;	chr8:89679935	chr8:89609409~89757727:-
SARC	cis	rs875971	0.522	rs9530	ENSG00000236529.1	RP13-254B10.1	4.42	1.49e-05	0.00656	0.29	0.28	Aortic root size;	chr7:65960907	chr7:65840212~65840596:+
SARC	cis	rs1823913	0.637	rs10931497	ENSG00000227542.1	AC092614.2	-4.42	1.49e-05	0.00656	-0.31	-0.28	Obesity-related traits;	chr2:191306254	chr2:191229165~191246172:-
SARC	cis	rs7267979	1	rs6050631	ENSG00000276952.1	RP5-965G21.6	4.42	1.49e-05	0.00656	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25284915~25285588:-
SARC	cis	rs7560272	0.723	rs1052161	ENSG00000163016.8	ALMS1P	4.42	1.49e-05	0.00657	0.32	0.28	Schizophrenia;	chr2:73601411	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.607	rs7560272	ENSG00000163016.8	ALMS1P	4.42	1.49e-05	0.00657	0.36	0.28	Metabolite levels;	chr2:73334357	chr2:73644919~73685576:+
SARC	cis	rs41369048	0.669	rs6660867	ENSG00000272823.1	RP11-295M18.6	-4.42	1.49e-05	0.00657	-0.42	-0.28	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220864097	chr1:220828676~220829211:-
SARC	cis	rs4664293	0.605	rs6745815	ENSG00000226266.5	AC009961.3	4.42	1.49e-05	0.00658	0.32	0.28	Monocyte percentage of white cells;	chr2:159693558	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.551	rs11898293	ENSG00000226266.5	AC009961.3	4.42	1.49e-05	0.00658	0.32	0.28	Monocyte percentage of white cells;	chr2:159696082	chr2:159670708~159712435:-
SARC	cis	rs2239557	0.5	rs7157723	ENSG00000259065.1	RP5-1021I20.1	4.42	1.49e-05	0.00658	0.33	0.28	Common traits (Other);	chr14:73999497	chr14:73787360~73803270:+
SARC	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	4.42	1.49e-05	0.00658	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
SARC	cis	rs7772486	0.79	rs10223507	ENSG00000270638.1	RP3-466P17.1	-4.42	1.49e-05	0.00658	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145735570~145737218:+
SARC	cis	rs9309473	0.583	rs6713196	ENSG00000163016.8	ALMS1P	4.42	1.49e-05	0.00658	0.34	0.28	Metabolite levels;	chr2:73349277	chr2:73644919~73685576:+
SARC	cis	rs75920871	0.528	rs2513094	ENSG00000254851.1	RP11-109L13.1	4.42	1.5e-05	0.00658	0.37	0.28	Subjective well-being;	chr11:116935696	chr11:117135528~117138582:+
SARC	cis	rs160451	0.84	rs216990	ENSG00000251136.7	RP11-37B2.1	4.42	1.5e-05	0.00659	0.34	0.28	Leprosy;	chr8:89664572	chr8:89609409~89757727:-
SARC	cis	rs1707322	0.686	rs11211179	ENSG00000281133.1	AL355480.3	-4.42	1.5e-05	0.00659	-0.32	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.721	rs10157795	ENSG00000281133.1	AL355480.3	-4.42	1.5e-05	0.00659	-0.32	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45580892~45580996:-
SARC	cis	rs9902453	0.904	rs9900112	ENSG00000264538.5	SUZ12P1	4.42	1.5e-05	0.00659	0.2	0.28	Coffee consumption (cups per day);	chr17:29955892	chr17:30709299~30790908:+
SARC	cis	rs61160187	0.582	rs12655209	ENSG00000215032.2	GNL3LP1	-4.42	1.5e-05	0.00659	-0.27	-0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:61010225	chr5:60891935~60893577:-
SARC	cis	rs72945132	0.66	rs7121703	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70294190	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs7118156	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70296816	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs7937984	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70298148	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs17160039	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70299383	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs12282678	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70306351	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.823	rs12292240	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70306506	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs7945389	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70312770	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs7116059	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70313584	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs7116191	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70313675	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.714	rs57320340	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70313904	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.556	rs57172967	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70313954	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs67529561	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70315949	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs61260732	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70316039	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs60780459	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70316362	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs56176527	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70316407	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs17160777	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70317617	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs7929271	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70319643	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs7932431	ENSG00000254604.1	AP000487.6	-4.42	1.5e-05	0.00659	-0.39	-0.28	Coronary artery disease;	chr11:70319953	chr11:70282367~70363368:-
SARC	cis	rs4372836	0.504	rs13011935	ENSG00000226833.4	AC097724.3	4.42	1.5e-05	0.0066	0.23	0.28	Body mass index;	chr2:28791880	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.504	rs7601720	ENSG00000226833.4	AC097724.3	4.42	1.5e-05	0.0066	0.23	0.28	Body mass index;	chr2:28809612	chr2:28708953~28736205:-
SARC	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	4.42	1.5e-05	0.0066	0.27	0.28	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
SARC	cis	rs890448	0.796	rs2471681	ENSG00000254531.1	FLJ20021	4.42	1.5e-05	0.0066	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426910	chr4:101347780~101348883:+
SARC	cis	rs7772486	0.754	rs702304	ENSG00000270638.1	RP3-466P17.1	-4.42	1.5e-05	0.0066	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145735570~145737218:+
SARC	cis	rs11822910	0.911	rs2250887	ENSG00000265566.2	RN7SL605P	4.42	1.5e-05	0.00661	0.37	0.28	Platelet distribution width;	chr11:57434711	chr11:57528085~57528365:-
SARC	cis	rs9309711	0.698	rs9750503	ENSG00000225234.1	TRAPPC12-AS1	4.42	1.5e-05	0.00661	0.3	0.28	Neurofibrillary tangles;	chr2:3488001	chr2:3481242~3482409:-
SARC	cis	rs9309473	0.632	rs6706179	ENSG00000163016.8	ALMS1P	4.42	1.5e-05	0.00661	0.34	0.28	Metabolite levels;	chr2:73351449	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.607	rs11686504	ENSG00000163016.8	ALMS1P	4.42	1.5e-05	0.00661	0.34	0.28	Metabolite levels;	chr2:73352684	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.607	rs10198301	ENSG00000163016.8	ALMS1P	4.42	1.5e-05	0.00661	0.34	0.28	Metabolite levels;	chr2:73354472	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.607	rs7573719	ENSG00000163016.8	ALMS1P	4.42	1.5e-05	0.00661	0.34	0.28	Metabolite levels;	chr2:73355858	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.607	rs6546824	ENSG00000163016.8	ALMS1P	4.42	1.5e-05	0.00661	0.34	0.28	Metabolite levels;	chr2:73360203	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.607	rs4641966	ENSG00000163016.8	ALMS1P	4.42	1.5e-05	0.00661	0.34	0.28	Metabolite levels;	chr2:73363678	chr2:73644919~73685576:+
SARC	cis	rs10788972	0.508	rs6691549	ENSG00000225183.1	RP4-758J24.4	-4.42	1.5e-05	0.00661	-0.31	-0.28	Parkinson disease and lewy body pathology;	chr1:54015230	chr1:54089856~54090093:+
SARC	cis	rs7267979	0.903	rs6107015	ENSG00000276952.1	RP5-965G21.6	4.42	1.5e-05	0.00662	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25284915~25285588:-
SARC	cis	rs1823913	0.637	rs13382985	ENSG00000227542.1	AC092614.2	-4.42	1.51e-05	0.00662	-0.31	-0.28	Obesity-related traits;	chr2:191306335	chr2:191229165~191246172:-
SARC	cis	rs11641365	1	rs11641365	ENSG00000278341.1	RP5-1142A6.10	-4.42	1.51e-05	0.00662	-0.35	-0.28	Autism spectrum disorder-related traits;	chr16:88707485	chr16:88708956~88710437:-
SARC	cis	rs27434	0.66	rs26493	ENSG00000272109.1	CTD-2260A17.3	-4.42	1.51e-05	0.00662	-0.43	-0.28	Ankylosing spondylitis;	chr5:96819615	chr5:96804353~96806105:+
SARC	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-4.42	1.51e-05	0.00662	-0.24	-0.28	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
SARC	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-4.42	1.51e-05	0.00662	-0.3	-0.28	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
SARC	cis	rs6570726	0.791	rs392612	ENSG00000270638.1	RP3-466P17.1	-4.42	1.51e-05	0.00663	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145735570~145737218:+
SARC	cis	rs889122	0.68	rs4804459	ENSG00000267289.1	CTD-2623N2.11	-4.42	1.51e-05	0.00663	-0.33	-0.28	Menarche (age at onset);	chr19:9834111	chr19:9834079~9835013:-
SARC	cis	rs9880192	0.516	rs2713575	ENSG00000242551.2	POU5F1P6	-4.42	1.51e-05	0.00663	-0.28	-0.28	White blood cell count;Eosinophil percentage of white cells;Monocyte count;Neutrophil percentage of granulocytes;Monocyte-lymphocyte ratio;Eosinophil percentage of granulocytes;Eosinophil counts;	chr3:128575512	chr3:128674735~128677005:-
SARC	cis	rs3002142	0.658	rs2291833	ENSG00000272750.1	RP11-378J18.8	-4.42	1.51e-05	0.00664	-0.43	-0.28	LDL peak particle diameter (total fat intake interaction);	chr1:222653505	chr1:222658867~222661512:-
SARC	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	4.42	1.51e-05	0.00664	0.28	0.28	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
SARC	cis	rs4713118	0.739	rs2893931	ENSG00000219392.1	RP1-265C24.5	-4.42	1.51e-05	0.00665	-0.39	-0.28	Parkinson's disease;	chr6:27780231	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.824	rs2092075	ENSG00000219392.1	RP1-265C24.5	-4.42	1.51e-05	0.00665	-0.39	-0.28	Parkinson's disease;	chr6:27781551	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.824	rs13211701	ENSG00000219392.1	RP1-265C24.5	-4.42	1.51e-05	0.00665	-0.39	-0.28	Parkinson's disease;	chr6:27782300	chr6:28115628~28116551:+
SARC	cis	rs4713118	0.824	rs9468229	ENSG00000219392.1	RP1-265C24.5	-4.42	1.51e-05	0.00665	-0.39	-0.28	Parkinson's disease;	chr6:27782307	chr6:28115628~28116551:+
SARC	cis	rs9573567	0.881	rs1570541	ENSG00000261553.4	RP11-29G8.3	4.42	1.51e-05	0.00665	0.55	0.28	Red blood cell count;Mean corpuscular volume;	chr13:75500729	chr13:75549773~75807120:+
SARC	cis	rs890448	0.796	rs6846097	ENSG00000254531.1	FLJ20021	-4.42	1.51e-05	0.00665	-0.3	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101364893	chr4:101347780~101348883:+
SARC	cis	rs61160187	0.517	rs7709522	ENSG00000215032.2	GNL3LP1	4.42	1.51e-05	0.00665	0.27	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60891935~60893577:-
SARC	cis	rs4664293	0.625	rs2114625	ENSG00000226266.5	AC009961.3	-4.42	1.51e-05	0.00665	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159687297	chr2:159670708~159712435:-
SARC	cis	rs6969780	1	rs1801085	ENSG00000233429.8	HOTAIRM1	4.42	1.51e-05	0.00665	0.44	0.28	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27128971	chr7:27095647~27100265:+
SARC	cis	rs8062405	0.723	rs62031562	ENSG00000251417.2	RP11-1348G14.4	-4.42	1.52e-05	0.00666	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28802743~28817828:+
SARC	cis	rs7267979	1	rs4815408	ENSG00000276952.1	RP5-965G21.6	-4.42	1.52e-05	0.00666	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25284915~25285588:-
SARC	cis	rs7772486	0.79	rs4435956	ENSG00000270638.1	RP3-466P17.1	-4.42	1.52e-05	0.00666	-0.22	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs6926076	ENSG00000270638.1	RP3-466P17.1	-4.42	1.52e-05	0.00666	-0.22	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145735570~145737218:+
SARC	cis	rs2439831	1	rs2251538	ENSG00000205771.5	CATSPER2P1	-4.42	1.52e-05	0.00666	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43475011	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs2439850	ENSG00000205771.5	CATSPER2P1	-4.42	1.52e-05	0.00666	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43492656	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs2467736	ENSG00000205771.5	CATSPER2P1	-4.42	1.52e-05	0.00666	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43492719	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs2444250	ENSG00000205771.5	CATSPER2P1	-4.42	1.52e-05	0.00666	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43492853	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs101094	ENSG00000205771.5	CATSPER2P1	-4.42	1.52e-05	0.00666	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43495124	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs689781	ENSG00000205771.5	CATSPER2P1	-4.42	1.52e-05	0.00666	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43499899	chr15:43726918~43747094:-
SARC	cis	rs2439831	1	rs2584725	ENSG00000205771.5	CATSPER2P1	-4.42	1.52e-05	0.00666	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43500937	chr15:43726918~43747094:-
SARC	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-4.42	1.52e-05	0.00666	-0.33	-0.28	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-4.42	1.52e-05	0.00666	-0.33	-0.28	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-4.42	1.52e-05	0.00666	-0.33	-0.28	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-4.42	1.52e-05	0.00666	-0.33	-0.28	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
SARC	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-4.42	1.52e-05	0.00667	-0.41	-0.28	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
SARC	cis	rs10754283	0.967	rs10922685	ENSG00000231613.1	RP5-943J3.1	4.42	1.52e-05	0.00667	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89652761	chr1:89788914~89790492:+
SARC	cis	rs12049351	1	rs12049351	ENSG00000229367.1	HMGN2P19	4.42	1.52e-05	0.00667	0.23	0.28	Circulating myeloperoxidase levels (plasma);	chr1:229582254	chr1:229570532~229570796:+
SARC	cis	rs2439831	0.85	rs3816792	ENSG00000275601.1	AC011330.13	4.42	1.52e-05	0.00667	0.48	0.28	Lung cancer in ever smokers;	chr15:43824788	chr15:43642389~43643023:-
SARC	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-4.42	1.52e-05	0.00667	-0.25	-0.28	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
SARC	cis	rs3805389	0.504	rs28416150	ENSG00000273257.1	RP11-177J6.1	-4.42	1.52e-05	0.00667	-0.42	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr4:55608211	chr4:55387949~55388271:+
SARC	cis	rs2933343	0.7	rs789238	ENSG00000231305.3	RP11-723O4.2	4.42	1.52e-05	0.00667	0.28	0.28	IgG glycosylation;	chr3:128917872	chr3:128861313~128871540:-
SARC	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	4.42	1.52e-05	0.00669	0.4	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	4.42	1.52e-05	0.00669	0.4	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	4.42	1.52e-05	0.00669	0.4	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
SARC	cis	rs526231	0.853	rs1991797	ENSG00000175749.11	EIF3KP1	4.42	1.52e-05	0.00669	0.37	0.28	Primary biliary cholangitis;	chr5:103286752	chr5:103032376~103033031:+
SARC	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	4.42	1.53e-05	0.00669	0.3	0.28	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
SARC	cis	rs7615952	0.576	rs1127717	ENSG00000171084.14	FAM86JP	4.42	1.53e-05	0.0067	0.42	0.28	Blood pressure (smoking interaction);	chr3:126107216	chr3:125916620~125930024:+
SARC	cis	rs12049351	0.943	rs6678454	ENSG00000229367.1	HMGN2P19	-4.42	1.53e-05	0.0067	-0.24	-0.28	Circulating myeloperoxidase levels (plasma);	chr1:229582232	chr1:229570532~229570796:+
SARC	cis	rs4820294	0.646	rs9622675	ENSG00000233360.4	Z83844.1	4.42	1.53e-05	0.00671	0.32	0.28	Fat distribution (HIV);	chr22:37657658	chr22:37641832~37658377:-
SARC	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-4.42	1.53e-05	0.00671	-0.33	-0.28	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
SARC	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	4.42	1.53e-05	0.00671	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
SARC	cis	rs2179367	0.632	rs9498336	ENSG00000231760.4	RP11-350J20.5	4.42	1.53e-05	0.00671	0.37	0.28	Dupuytren's disease;	chr6:149374208	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs1980774	ENSG00000231760.4	RP11-350J20.5	4.42	1.53e-05	0.00671	0.37	0.28	Dupuytren's disease;	chr6:149375030	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498337	ENSG00000231760.4	RP11-350J20.5	4.42	1.53e-05	0.00671	0.37	0.28	Dupuytren's disease;	chr6:149375970	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498338	ENSG00000231760.4	RP11-350J20.5	4.42	1.53e-05	0.00671	0.37	0.28	Dupuytren's disease;	chr6:149376428	chr6:149796151~149826294:-
SARC	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	4.42	1.53e-05	0.00671	0.23	0.28	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	4.42	1.53e-05	0.00671	0.23	0.28	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
SARC	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	4.42	1.53e-05	0.00672	0.51	0.28	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
SARC	cis	rs4713118	0.715	rs200480	ENSG00000219392.1	RP1-265C24.5	-4.42	1.53e-05	0.00672	-0.35	-0.28	Parkinson's disease;	chr6:27805886	chr6:28115628~28116551:+
SARC	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	4.42	1.53e-05	0.00672	0.27	0.28	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	4.42	1.53e-05	0.00672	0.27	0.28	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	4.42	1.53e-05	0.00672	0.27	0.28	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	4.42	1.53e-05	0.00672	0.27	0.28	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
SARC	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	4.42	1.53e-05	0.00672	0.27	0.28	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
SARC	cis	rs11654699	0.806	rs62068381	ENSG00000266718.1	RP11-466A19.1	-4.42	1.54e-05	0.00673	-0.24	-0.28	Neurofibrillary tangles;	chr17:32592731	chr17:32495536~32499333:+
SARC	cis	rs11654699	0.773	rs62068382	ENSG00000266718.1	RP11-466A19.1	-4.42	1.54e-05	0.00673	-0.24	-0.28	Neurofibrillary tangles;	chr17:32592865	chr17:32495536~32499333:+
SARC	cis	rs728478	1	rs9913367	ENSG00000266992.1	DHX40P1	4.42	1.54e-05	0.00673	0.29	0.28	QT interval;	chr17:59370661	chr17:59976009~60002384:-
SARC	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-4.42	1.54e-05	0.00674	-0.31	-0.28	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
SARC	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-4.42	1.54e-05	0.00674	-0.31	-0.28	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
SARC	cis	rs7927592	0.513	rs556442	ENSG00000212093.1	AP000807.1	-4.42	1.54e-05	0.00674	-0.26	-0.28	Total body bone mineral density;	chr11:68425222	chr11:68506083~68506166:-
SARC	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-4.42	1.54e-05	0.00675	-0.44	-0.28	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
SARC	cis	rs8062405	0.789	rs240704	ENSG00000251417.2	RP11-1348G14.4	-4.42	1.54e-05	0.00675	-0.26	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28802743~28817828:+
SARC	cis	rs193541	0.632	rs246276	ENSG00000263432.2	RN7SL689P	4.42	1.54e-05	0.00675	0.36	0.28	Glucose homeostasis traits;	chr5:122904262	chr5:123022487~123022783:-
SARC	cis	rs1823913	0.66	rs1454752	ENSG00000227542.1	AC092614.2	-4.42	1.54e-05	0.00676	-0.31	-0.28	Obesity-related traits;	chr2:191298668	chr2:191229165~191246172:-
SARC	cis	rs7560272	0.723	rs13386124	ENSG00000163016.8	ALMS1P	4.42	1.54e-05	0.00676	0.33	0.28	Schizophrenia;	chr2:73544568	chr2:73644919~73685576:+
SARC	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-4.42	1.54e-05	0.00676	-0.41	-0.28	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
SARC	cis	rs11634944	0.506	rs765438	ENSG00000274307.1	RP11-345J18.2	-4.42	1.54e-05	0.00676	-0.34	-0.28	Interleukin-8 levels;	chr15:24990981	chr15:25708470~25710869:-
SARC	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-4.42	1.55e-05	0.00677	-0.33	-0.28	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
SARC	cis	rs12554020	0.786	rs7036984	ENSG00000227603.1	RP11-165J3.6	4.41	1.55e-05	0.00679	0.38	0.28	Schizophrenia;	chr9:93438258	chr9:93435332~93437121:-
SARC	cis	rs910316	0.763	rs175435	ENSG00000279594.1	RP11-950C14.10	4.41	1.55e-05	0.00679	0.31	0.28	Height;	chr14:75145322	chr14:75011269~75012851:-
SARC	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	4.41	1.55e-05	0.00679	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	4.41	1.55e-05	0.00679	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	4.41	1.55e-05	0.00679	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
SARC	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	4.41	1.55e-05	0.00679	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
SARC	cis	rs14027	0.883	rs16893027	ENSG00000279347.1	RP11-85I17.2	-4.41	1.55e-05	0.00679	-0.24	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701534	chr8:119838736~119840385:-
SARC	cis	rs763121	0.815	rs4821799	ENSG00000273076.1	RP3-508I15.22	4.41	1.55e-05	0.0068	0.29	0.28	Menopause (age at onset);	chr22:38625321	chr22:38743495~38743910:+
SARC	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	4.41	1.55e-05	0.0068	0.32	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
SARC	cis	rs7560272	0.669	rs13008860	ENSG00000163016.8	ALMS1P	4.41	1.55e-05	0.0068	0.32	0.28	Schizophrenia;	chr2:73546892	chr2:73644919~73685576:+
SARC	cis	rs7267979	1	rs4813562	ENSG00000276952.1	RP5-965G21.6	-4.41	1.55e-05	0.0068	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs6050567	ENSG00000276952.1	RP5-965G21.6	-4.41	1.55e-05	0.0068	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6037099	ENSG00000276952.1	RP5-965G21.6	-4.41	1.55e-05	0.0068	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs4815414	ENSG00000276952.1	RP5-965G21.6	-4.41	1.55e-05	0.0068	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25284915~25285588:-
SARC	cis	rs7772486	0.754	rs2328707	ENSG00000270638.1	RP3-466P17.1	-4.41	1.55e-05	0.0068	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145735570~145737218:+
SARC	cis	rs10911902	0.643	rs16825335	ENSG00000229739.2	RP11-295K2.3	-4.41	1.55e-05	0.0068	-0.41	-0.28	Schizophrenia;	chr1:186418612	chr1:186435161~186470291:+
SARC	cis	rs2836950	0.501	rs13047518	ENSG00000255568.3	BRWD1-AS2	-4.41	1.56e-05	0.00681	-0.25	-0.28	Menarche (age at onset);	chr21:39335381	chr21:39313935~39314962:+
SARC	cis	rs910316	0.935	rs175076	ENSG00000279594.1	RP11-950C14.10	-4.41	1.56e-05	0.00682	-0.31	-0.28	Height;	chr14:75038783	chr14:75011269~75012851:-
SARC	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-4.41	1.56e-05	0.00682	-0.34	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
SARC	cis	rs599083	0.793	rs314750	ENSG00000212093.1	AP000807.1	-4.41	1.56e-05	0.00682	-0.26	-0.28	Bone mineral density (spine);	chr11:68414560	chr11:68506083~68506166:-
SARC	cis	rs7267979	1	rs7019	ENSG00000276952.1	RP5-965G21.6	4.41	1.56e-05	0.00683	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25284915~25285588:-
SARC	cis	rs9902453	0.78	rs3115093	ENSG00000264538.5	SUZ12P1	4.41	1.56e-05	0.00683	0.19	0.28	Coffee consumption (cups per day);	chr17:29712737	chr17:30709299~30790908:+
SARC	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-4.41	1.56e-05	0.00683	-0.38	-0.28	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
SARC	cis	rs367615	0.704	rs11747622	ENSG00000249476.1	CTD-2587M2.1	4.41	1.56e-05	0.00684	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109509019	chr5:109237120~109326369:-
SARC	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	4.41	1.56e-05	0.00684	0.32	0.28	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
SARC	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-4.41	1.57e-05	0.00684	-0.25	-0.28	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
SARC	cis	rs4664293	0.867	rs6761145	ENSG00000226266.5	AC009961.3	-4.41	1.57e-05	0.00685	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159725673	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs6732987	ENSG00000226266.5	AC009961.3	-4.41	1.57e-05	0.00685	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159725918	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs7589941	ENSG00000226266.5	AC009961.3	-4.41	1.57e-05	0.00685	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159727589	chr2:159670708~159712435:-
SARC	cis	rs9309473	0.5	rs4286298	ENSG00000163016.8	ALMS1P	-4.41	1.57e-05	0.00685	-0.31	-0.28	Metabolite levels;	chr2:73654981	chr2:73644919~73685576:+
SARC	cis	rs12893668	0.572	rs4906356	ENSG00000269940.1	RP11-73M18.7	4.41	1.57e-05	0.00685	0.27	0.28	Reticulocyte count;	chr14:103672364	chr14:103694560~103695170:+
SARC	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-4.41	1.57e-05	0.00686	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
SARC	cis	rs1707322	0.821	rs10749857	ENSG00000281133.1	AL355480.3	-4.41	1.57e-05	0.00687	-0.31	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45580892~45580996:-
SARC	cis	rs11123170	0.503	rs28679654	ENSG00000189223.12	PAX8-AS1	-4.41	1.57e-05	0.00687	-0.38	-0.28	Renal function-related traits (BUN);	chr2:113210040	chr2:113211522~113276581:+
SARC	cis	rs17508449	0.865	rs4839330	ENSG00000232450.1	RP4-730K3.3	-4.41	1.57e-05	0.00687	-0.36	-0.28	Leprosy;	chr1:113594960	chr1:113698884~113699631:-
SARC	cis	rs17508449	0.865	rs75296543	ENSG00000232450.1	RP4-730K3.3	-4.41	1.57e-05	0.00687	-0.36	-0.28	Leprosy;	chr1:113595664	chr1:113698884~113699631:-
SARC	cis	rs11264213	0.901	rs7542179	ENSG00000271554.1	RP4-665N4.8	4.41	1.57e-05	0.00687	0.37	0.28	Schizophrenia;	chr1:35995521	chr1:35992109~36013630:-
SARC	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	4.41	1.57e-05	0.00687	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	4.41	1.57e-05	0.00687	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
SARC	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	4.41	1.57e-05	0.00688	0.26	0.28	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	4.41	1.57e-05	0.00688	0.26	0.28	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
SARC	cis	rs783540	0.934	rs36109438	ENSG00000275695.1	UBE2Q2P6	-4.41	1.58e-05	0.00688	-0.28	-0.28	Schizophrenia;	chr15:82595709	chr15:82445719~82454837:+
SARC	cis	rs7615952	0.576	rs6780025	ENSG00000171084.14	FAM86JP	4.41	1.58e-05	0.00688	0.42	0.28	Blood pressure (smoking interaction);	chr3:126096781	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.576	rs6804482	ENSG00000171084.14	FAM86JP	4.41	1.58e-05	0.00688	0.42	0.28	Blood pressure (smoking interaction);	chr3:126096919	chr3:125916620~125930024:+
SARC	cis	rs61160187	0.582	rs7723901	ENSG00000215032.2	GNL3LP1	4.41	1.58e-05	0.00688	0.27	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977163	chr5:60891935~60893577:-
SARC	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-4.41	1.58e-05	0.00688	-0.44	-0.28	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
SARC	cis	rs783540	0.656	rs783524	ENSG00000275695.1	UBE2Q2P6	-4.41	1.58e-05	0.00689	-0.29	-0.28	Schizophrenia;	chr15:82615393	chr15:82445719~82454837:+
SARC	cis	rs783540	0.592	rs2567632	ENSG00000275695.1	UBE2Q2P6	-4.41	1.58e-05	0.00689	-0.29	-0.28	Schizophrenia;	chr15:82616053	chr15:82445719~82454837:+
SARC	cis	rs4664293	0.867	rs2357532	ENSG00000226266.5	AC009961.3	-4.41	1.58e-05	0.00689	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159740916	chr2:159670708~159712435:-
SARC	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-4.41	1.58e-05	0.00689	-0.52	-0.28	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
SARC	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-4.41	1.58e-05	0.00689	-0.32	-0.28	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-4.41	1.58e-05	0.00689	-0.32	-0.28	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
SARC	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-4.41	1.58e-05	0.00689	-0.32	-0.28	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
SARC	cis	rs324126	0.78	rs4802926	ENSG00000269834.4	ZNF528-AS1	-4.41	1.58e-05	0.0069	-0.29	-0.28	Colonoscopy-negative controls vs population controls;	chr19:52377012	chr19:52388842~52397766:-
SARC	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-4.41	1.58e-05	0.0069	-0.39	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
SARC	cis	rs2836950	0.805	rs2836961	ENSG00000255568.3	BRWD1-AS2	-4.41	1.58e-05	0.00691	-0.26	-0.28	Menarche (age at onset);	chr21:39255094	chr21:39313935~39314962:+
SARC	cis	rs763121	0.853	rs2235230	ENSG00000273076.1	RP3-508I15.22	-4.41	1.59e-05	0.00691	-0.33	-0.28	Menopause (age at onset);	chr22:38728462	chr22:38743495~38743910:+
SARC	cis	rs4835473	0.932	rs10030428	ENSG00000251600.4	RP11-673E1.1	4.41	1.59e-05	0.00691	0.27	0.28	Immature fraction of reticulocytes;	chr4:143762699	chr4:143912331~143982454:+
SARC	cis	rs9595908	0.931	rs9315167	ENSG00000212293.1	SNORA16	4.41	1.59e-05	0.00692	0.28	0.28	Body mass index;	chr13:32495051	chr13:32420390~32420516:-
SARC	cis	rs11634944	0.676	rs2732031	ENSG00000274307.1	RP11-345J18.2	-4.41	1.59e-05	0.00692	-0.35	-0.28	Interleukin-8 levels;	chr15:24997789	chr15:25708470~25710869:-
SARC	cis	rs7267979	1	rs6050566	ENSG00000276952.1	RP5-965G21.6	-4.41	1.59e-05	0.00692	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs4813563	ENSG00000276952.1	RP5-965G21.6	-4.41	1.59e-05	0.00692	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs6037103	ENSG00000276952.1	RP5-965G21.6	-4.41	1.59e-05	0.00692	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25284915~25285588:-
SARC	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-4.41	1.59e-05	0.00692	-0.33	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
SARC	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-4.41	1.59e-05	0.00692	-0.32	-0.28	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
SARC	cis	rs72945132	0.882	rs11235755	ENSG00000254604.1	AP000487.6	-4.41	1.59e-05	0.00692	-0.39	-0.28	Coronary artery disease;	chr11:70290217	chr11:70282367~70363368:-
SARC	cis	rs4835473	0.897	rs7695328	ENSG00000251600.4	RP11-673E1.1	4.41	1.59e-05	0.00693	0.27	0.28	Immature fraction of reticulocytes;	chr4:143703768	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.864	rs57137521	ENSG00000251600.4	RP11-673E1.1	-4.41	1.59e-05	0.00693	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143704045	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs55945293	ENSG00000251600.4	RP11-673E1.1	-4.41	1.59e-05	0.00693	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143704766	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs924234	ENSG00000251600.4	RP11-673E1.1	4.41	1.59e-05	0.00693	0.27	0.28	Immature fraction of reticulocytes;	chr4:143706799	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs2219912	ENSG00000251600.4	RP11-673E1.1	4.41	1.59e-05	0.00693	0.27	0.28	Immature fraction of reticulocytes;	chr4:143707909	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs6537172	ENSG00000251600.4	RP11-673E1.1	4.41	1.59e-05	0.00693	0.27	0.28	Immature fraction of reticulocytes;	chr4:143710612	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.714	rs10013005	ENSG00000251600.4	RP11-673E1.1	4.41	1.59e-05	0.00693	0.27	0.28	Immature fraction of reticulocytes;	chr4:143711351	chr4:143912331~143982454:+
SARC	cis	rs2404602	0.536	rs12915248	ENSG00000259422.1	RP11-593F23.1	4.41	1.59e-05	0.00693	0.3	0.28	Blood metabolite levels;	chr15:76473274	chr15:76174891~76181486:-
SARC	cis	rs4664293	0.625	rs11899419	ENSG00000226266.5	AC009961.3	4.41	1.59e-05	0.00694	0.32	0.28	Monocyte percentage of white cells;	chr2:159688858	chr2:159670708~159712435:-
SARC	cis	rs890448	0.86	rs6826588	ENSG00000254531.1	FLJ20021	-4.41	1.59e-05	0.00694	-0.27	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101481713	chr4:101347780~101348883:+
SARC	cis	rs890448	0.896	rs3974654	ENSG00000254531.1	FLJ20021	-4.41	1.59e-05	0.00694	-0.27	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101482523	chr4:101347780~101348883:+
SARC	cis	rs890448	0.86	rs6833608	ENSG00000254531.1	FLJ20021	-4.41	1.59e-05	0.00694	-0.27	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101482978	chr4:101347780~101348883:+
SARC	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-4.41	1.59e-05	0.00694	-0.28	-0.28	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
SARC	cis	rs9309473	0.607	rs10196402	ENSG00000163016.8	ALMS1P	4.41	1.59e-05	0.00695	0.34	0.28	Metabolite levels;	chr2:73344953	chr2:73644919~73685576:+
SARC	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	4.41	1.59e-05	0.00695	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
SARC	cis	rs7615952	0.736	rs9866347	ENSG00000248787.1	RP11-666A20.4	-4.41	1.6e-05	0.00695	-0.5	-0.28	Blood pressure (smoking interaction);	chr3:125951082	chr3:125908005~125910272:-
SARC	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	4.41	1.6e-05	0.00696	0.29	0.28	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
SARC	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	4.41	1.6e-05	0.00696	0.29	0.28	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
SARC	cis	rs783540	0.967	rs1269134	ENSG00000275695.1	UBE2Q2P6	-4.41	1.6e-05	0.00696	-0.28	-0.28	Schizophrenia;	chr15:82613877	chr15:82445719~82454837:+
SARC	cis	rs11123170	0.529	rs112692022	ENSG00000189223.12	PAX8-AS1	-4.41	1.6e-05	0.00696	-0.38	-0.28	Renal function-related traits (BUN);	chr2:113212605	chr2:113211522~113276581:+
SARC	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-4.41	1.6e-05	0.00696	-0.32	-0.28	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
SARC	cis	rs8062405	0.824	rs153106	ENSG00000251417.2	RP11-1348G14.4	-4.41	1.6e-05	0.00697	-0.26	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28802743~28817828:+
SARC	cis	rs8062405	0.824	rs240702	ENSG00000251417.2	RP11-1348G14.4	-4.41	1.6e-05	0.00697	-0.26	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28802743~28817828:+
SARC	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	4.41	1.6e-05	0.00697	0.3	0.28	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
SARC	cis	rs7247513	0.964	rs4804202	ENSG00000213290.4	PGK1P2	-4.41	1.6e-05	0.00698	-0.32	-0.28	Bipolar disorder;	chr19:12607805	chr19:12559571~12561105:+
SARC	cis	rs801193	0.613	rs2659900	ENSG00000232559.3	GS1-124K5.12	4.41	1.6e-05	0.00699	0.31	0.28	Aortic root size;	chr7:66719456	chr7:66554588~66576923:-
SARC	cis	rs7772486	0.79	rs2265917	ENSG00000270638.1	RP3-466P17.1	4.41	1.61e-05	0.00699	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs2265469	ENSG00000270638.1	RP3-466P17.1	4.41	1.61e-05	0.00699	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs2265918	ENSG00000270638.1	RP3-466P17.1	4.41	1.61e-05	0.00699	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs2265472	ENSG00000270638.1	RP3-466P17.1	4.41	1.61e-05	0.00699	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs2265919	ENSG00000270638.1	RP3-466P17.1	4.41	1.61e-05	0.00699	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145735570~145737218:+
SARC	cis	rs1167827	1	rs1167827	ENSG00000278416.1	PMS2L2	4.41	1.61e-05	0.00699	0.31	0.28	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75344015~75359550:-
SARC	cis	rs7560272	0.564	rs10496190	ENSG00000163016.8	ALMS1P	-4.41	1.61e-05	0.00699	-0.31	-0.28	Schizophrenia;	chr2:73411695	chr2:73644919~73685576:+
SARC	cis	rs4664293	0.647	rs357022	ENSG00000226266.5	AC009961.3	-4.41	1.61e-05	0.00699	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159632933	chr2:159670708~159712435:-
SARC	cis	rs10754283	0.934	rs6684676	ENSG00000231613.1	RP5-943J3.1	4.41	1.61e-05	0.00699	0.28	0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89636614	chr1:89788914~89790492:+
SARC	cis	rs11822910	0.645	rs7122734	ENSG00000265566.2	RN7SL605P	-4.41	1.61e-05	0.007	-0.37	-0.28	Platelet distribution width;	chr11:57422947	chr11:57528085~57528365:-
SARC	cis	rs61160187	0.582	rs1471488	ENSG00000215032.2	GNL3LP1	4.41	1.61e-05	0.007	0.27	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60990270	chr5:60891935~60893577:-
SARC	cis	rs599083	0.829	rs314751	ENSG00000212093.1	AP000807.1	-4.41	1.61e-05	0.007	-0.26	-0.28	Bone mineral density (spine);	chr11:68412092	chr11:68506083~68506166:-
SARC	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	4.41	1.61e-05	0.00701	0.32	0.28	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
SARC	cis	rs910316	0.763	rs175490	ENSG00000279594.1	RP11-950C14.10	4.41	1.61e-05	0.00701	0.31	0.28	Height;	chr14:75078982	chr14:75011269~75012851:-
SARC	cis	rs42490	0.664	rs43226	ENSG00000251136.7	RP11-37B2.1	-4.41	1.61e-05	0.00701	-0.3	-0.28	Leprosy;	chr8:89809048	chr8:89609409~89757727:-
SARC	cis	rs42490	0.664	rs422559	ENSG00000251136.7	RP11-37B2.1	-4.41	1.61e-05	0.00701	-0.3	-0.28	Leprosy;	chr8:89809121	chr8:89609409~89757727:-
SARC	cis	rs763121	0.815	rs9306328	ENSG00000273076.1	RP3-508I15.22	4.41	1.61e-05	0.00701	0.3	0.28	Menopause (age at onset);	chr22:38632908	chr22:38743495~38743910:+
SARC	cis	rs9902453	0.808	rs8069669	ENSG00000264538.5	SUZ12P1	4.41	1.61e-05	0.00701	0.2	0.28	Coffee consumption (cups per day);	chr17:29912484	chr17:30709299~30790908:+
SARC	cis	rs4835473	0.932	rs1597445	ENSG00000251600.4	RP11-673E1.1	-4.4	1.61e-05	0.00702	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143768543	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs1450246	ENSG00000251600.4	RP11-673E1.1	4.4	1.61e-05	0.00702	0.27	0.28	Immature fraction of reticulocytes;	chr4:143702954	chr4:143912331~143982454:+
SARC	cis	rs7809950	0.822	rs2712228	ENSG00000238832.1	snoU109	4.4	1.62e-05	0.00703	0.33	0.28	Coronary artery disease;	chr7:107659895	chr7:107603363~107603507:+
SARC	cis	rs890448	0.796	rs2433303	ENSG00000254531.1	FLJ20021	4.4	1.62e-05	0.00703	0.29	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101425155	chr4:101347780~101348883:+
SARC	cis	rs6570726	0.791	rs378937	ENSG00000270638.1	RP3-466P17.1	4.4	1.62e-05	0.00704	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145735570~145737218:+
SARC	cis	rs13217239	0.646	rs10946898	ENSG00000241549.7	GUSBP2	4.4	1.62e-05	0.00704	0.26	0.28	Schizophrenia;	chr6:27036105	chr6:26871484~26956554:-
SARC	cis	rs10911902	0.643	rs28715477	ENSG00000229739.2	RP11-295K2.3	-4.4	1.62e-05	0.00704	-0.39	-0.28	Schizophrenia;	chr1:186326392	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs3766707	ENSG00000229739.2	RP11-295K2.3	-4.4	1.62e-05	0.00704	-0.39	-0.28	Schizophrenia;	chr1:186335955	chr1:186435161~186470291:+
SARC	cis	rs7772486	0.655	rs2142981	ENSG00000270638.1	RP3-466P17.1	-4.4	1.62e-05	0.00704	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.72	rs6570713	ENSG00000270638.1	RP3-466P17.1	-4.4	1.62e-05	0.00704	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145735570~145737218:+
SARC	cis	rs30380	0.632	rs26500	ENSG00000272109.1	CTD-2260A17.3	-4.4	1.62e-05	0.00704	-0.35	-0.28	Cerebrospinal fluid biomarker levels;	chr5:96798009	chr5:96804353~96806105:+
SARC	cis	rs30380	0.632	rs149189	ENSG00000272109.1	CTD-2260A17.3	-4.4	1.62e-05	0.00704	-0.35	-0.28	Cerebrospinal fluid biomarker levels;	chr5:96802101	chr5:96804353~96806105:+
SARC	cis	rs30380	0.632	rs26495	ENSG00000272109.1	CTD-2260A17.3	-4.4	1.62e-05	0.00704	-0.35	-0.28	Cerebrospinal fluid biomarker levels;	chr5:96802137	chr5:96804353~96806105:+
SARC	cis	rs2708377	0.789	rs3911150	ENSG00000247157.5	LINC01252	-4.4	1.62e-05	0.00704	-0.45	-0.28	Bitter taste perception;	chr12:11049649	chr12:11548030~11590369:+
SARC	cis	rs1799949	0.965	rs4793237	ENSG00000267681.1	CTD-3199J23.6	-4.4	1.62e-05	0.00705	-0.31	-0.28	Menopause (age at onset);	chr17:43359227	chr17:43144956~43145255:+
SARC	cis	rs599083	0.829	rs23691	ENSG00000212093.1	AP000807.1	-4.4	1.62e-05	0.00705	-0.26	-0.28	Bone mineral density (spine);	chr11:68411200	chr11:68506083~68506166:-
SARC	cis	rs853679	0.882	rs9393908	ENSG00000219392.1	RP1-265C24.5	-4.4	1.62e-05	0.00705	-0.55	-0.28	Depression;	chr6:28223052	chr6:28115628~28116551:+
SARC	cis	rs853679	0.882	rs9366717	ENSG00000219392.1	RP1-265C24.5	-4.4	1.62e-05	0.00705	-0.55	-0.28	Depression;	chr6:28223279	chr6:28115628~28116551:+
SARC	cis	rs4664293	0.585	rs10460301	ENSG00000226266.5	AC009961.3	4.4	1.62e-05	0.00705	0.32	0.28	Monocyte percentage of white cells;	chr2:159778566	chr2:159670708~159712435:-
SARC	cis	rs7772486	0.692	rs1577916	ENSG00000270638.1	RP3-466P17.1	-4.4	1.62e-05	0.00705	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145735570~145737218:+
SARC	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	4.4	1.62e-05	0.00706	0.3	0.28	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
SARC	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	4.4	1.63e-05	0.00707	0.29	0.28	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
SARC	cis	rs4273100	0.688	rs4924980	ENSG00000228157.4	AC007952.5	-4.4	1.63e-05	0.00707	-0.34	-0.28	Schizophrenia;	chr17:19301550	chr17:19092974~19096837:+
SARC	cis	rs7267979	1	rs4815412	ENSG00000276952.1	RP5-965G21.6	4.4	1.63e-05	0.00708	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs6107031	ENSG00000276952.1	RP5-965G21.6	-4.4	1.63e-05	0.00708	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6115159	ENSG00000276952.1	RP5-965G21.6	-4.4	1.63e-05	0.00708	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25284915~25285588:-
SARC	cis	rs8040855	0.559	rs6496801	ENSG00000259774.1	RP11-182J1.13	-4.4	1.63e-05	0.00708	-0.25	-0.28	Bulimia nervosa;	chr15:85185168	chr15:84422618~84425882:+
SARC	cis	rs6570726	0.791	rs11155433	ENSG00000270638.1	RP3-466P17.1	-4.4	1.63e-05	0.00708	-0.23	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145735570~145737218:+
SARC	cis	rs2274273	0.624	rs66551709	ENSG00000258413.1	RP11-665C16.6	-4.4	1.63e-05	0.00708	-0.35	-0.28	Protein biomarker;	chr14:55324304	chr14:55262767~55272075:-
SARC	cis	rs853679	0.766	rs9368561	ENSG00000272009.1	RP1-313I6.12	-4.4	1.63e-05	0.00709	-0.44	-0.28	Depression;	chr6:28200565	chr6:28078792~28081130:-
SARC	cis	rs6540731	1	rs12402397	ENSG00000229983.1	RP11-15I11.2	4.4	1.63e-05	0.00709	0.28	0.28	Intelligence (childhood);	chr1:212222602	chr1:212168207~212190259:+
SARC	cis	rs75920871	0.528	rs10466590	ENSG00000254851.1	RP11-109L13.1	4.4	1.64e-05	0.00711	0.37	0.28	Subjective well-being;	chr11:117023697	chr11:117135528~117138582:+
SARC	cis	rs6424115	0.618	rs10917420	ENSG00000230228.2	RP11-4M23.4	-4.4	1.64e-05	0.00711	-0.29	-0.28	Immature fraction of reticulocytes;	chr1:23736497	chr1:23949016~23949383:-
SARC	cis	rs4950322	0.57	rs113498894	ENSG00000278811.3	LINC00624	4.4	1.64e-05	0.00711	0.29	0.28	Protein quantitative trait loci;	chr1:147318880	chr1:147258885~147517875:-
SARC	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-4.4	1.64e-05	0.00712	-0.41	-0.28	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
SARC	cis	rs4664293	0.605	rs12474082	ENSG00000226266.5	AC009961.3	4.4	1.64e-05	0.00712	0.32	0.28	Monocyte percentage of white cells;	chr2:159657403	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.585	rs1991372	ENSG00000226266.5	AC009961.3	4.4	1.64e-05	0.00712	0.32	0.28	Monocyte percentage of white cells;	chr2:159659556	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.546	rs1991373	ENSG00000226266.5	AC009961.3	4.4	1.64e-05	0.00712	0.32	0.28	Monocyte percentage of white cells;	chr2:159659714	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs6707985	ENSG00000226266.5	AC009961.3	4.4	1.64e-05	0.00712	0.32	0.28	Monocyte percentage of white cells;	chr2:159659877	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs62171641	ENSG00000226266.5	AC009961.3	4.4	1.64e-05	0.00712	0.32	0.28	Monocyte percentage of white cells;	chr2:159659994	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.585	rs35293435	ENSG00000226266.5	AC009961.3	4.4	1.64e-05	0.00712	0.32	0.28	Monocyte percentage of white cells;	chr2:159662396	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs62171646	ENSG00000226266.5	AC009961.3	4.4	1.64e-05	0.00712	0.32	0.28	Monocyte percentage of white cells;	chr2:159662563	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs4664295	ENSG00000226266.5	AC009961.3	4.4	1.64e-05	0.00712	0.32	0.28	Monocyte percentage of white cells;	chr2:159663807	chr2:159670708~159712435:-
SARC	cis	rs2439831	0.85	rs28858500	ENSG00000275601.1	AC011330.13	-4.4	1.64e-05	0.00713	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43864744	chr15:43642389~43643023:-
SARC	cis	rs7131987	0.65	rs11050187	ENSG00000257176.2	RP11-996F15.2	-4.4	1.65e-05	0.00714	-0.32	-0.28	QT interval;	chr12:29319943	chr12:29280418~29317848:-
SARC	cis	rs253959	0.545	rs4920905	ENSG00000272265.1	CTD-2287O16.4	4.4	1.65e-05	0.00714	0.32	0.28	Bipolar disorder and schizophrenia;	chr5:116090771	chr5:116078110~116078570:-
SARC	cis	rs2276314	0.512	rs17562898	ENSG00000278986.1	RP11-723J4.3	4.4	1.65e-05	0.00714	0.52	0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:35997212	chr18:35972151~35973916:+
SARC	cis	rs7772486	0.623	rs735535	ENSG00000235652.6	RP11-545I5.3	-4.4	1.65e-05	0.00715	-0.25	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.566	rs735536	ENSG00000235652.6	RP11-545I5.3	-4.4	1.65e-05	0.00715	-0.25	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145799409~145886585:+
SARC	cis	rs9868809	0.772	rs13070798	ENSG00000225399.4	RP11-3B7.1	4.4	1.65e-05	0.00715	0.43	0.28	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48668501	chr3:49260085~49261316:+
SARC	cis	rs7267979	0.816	rs443009	ENSG00000274414.1	RP5-965G21.4	4.4	1.65e-05	0.00715	0.29	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:25239007~25245229:-
SARC	cis	rs7772486	0.624	rs6930154	ENSG00000235652.6	RP11-545I5.3	-4.4	1.65e-05	0.00715	-0.25	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145799409~145886585:+
SARC	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-4.4	1.65e-05	0.00716	-0.26	-0.28	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
SARC	cis	rs875971	0.825	rs28480509	ENSG00000232559.3	GS1-124K5.12	-4.4	1.65e-05	0.00716	-0.33	-0.28	Aortic root size;	chr7:66634237	chr7:66554588~66576923:-
SARC	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	4.4	1.65e-05	0.00717	0.29	0.28	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
SARC	cis	rs72945132	0.882	rs6592522	ENSG00000254604.1	AP000487.6	-4.4	1.66e-05	0.00718	-0.4	-0.28	Coronary artery disease;	chr11:70282165	chr11:70282367~70363368:-
SARC	cis	rs453301	0.506	rs686189	ENSG00000253893.2	FAM85B	4.4	1.66e-05	0.00718	0.24	0.28	Joint mobility (Beighton score);	chr8:8766127	chr8:8167819~8226614:-
SARC	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-4.4	1.66e-05	0.00718	-0.32	-0.28	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
SARC	cis	rs3805389	0.504	rs10017749	ENSG00000273257.1	RP11-177J6.1	-4.4	1.66e-05	0.00718	-0.42	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr4:55613007	chr4:55387949~55388271:+
SARC	cis	rs9473147	0.516	rs9369695	ENSG00000270761.1	RP11-385F7.1	-4.4	1.66e-05	0.00719	-0.34	-0.28	Platelet distribution width;Mean platelet volume;	chr6:47472829	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs7754282	ENSG00000270761.1	RP11-385F7.1	4.4	1.66e-05	0.00719	0.33	0.28	Platelet distribution width;Mean platelet volume;	chr6:47534288	chr6:47477243~47477572:-
SARC	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-4.4	1.66e-05	0.00719	-0.45	-0.28	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-4.4	1.66e-05	0.00719	-0.45	-0.28	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-4.4	1.66e-05	0.00719	-0.45	-0.28	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
SARC	cis	rs61160187	0.582	rs72757187	ENSG00000215032.2	GNL3LP1	4.4	1.66e-05	0.00719	0.27	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967939	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.582	rs67490467	ENSG00000215032.2	GNL3LP1	4.4	1.66e-05	0.00719	0.27	0.28	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967991	chr5:60891935~60893577:-
SARC	cis	rs4664293	0.51	rs57575372	ENSG00000226266.5	AC009961.3	4.4	1.66e-05	0.00719	0.35	0.28	Monocyte percentage of white cells;	chr2:159569253	chr2:159670708~159712435:-
SARC	cis	rs4835473	0.643	rs34680080	ENSG00000251600.4	RP11-673E1.1	-4.4	1.66e-05	0.00719	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143797290	chr4:143912331~143982454:+
SARC	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	4.4	1.66e-05	0.00719	0.4	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
SARC	cis	rs3824347	1	rs12379215	ENSG00000203321.2	C9orf41-AS1	-4.4	1.66e-05	0.0072	-0.31	-0.28	Urinary magnesium-to-creatinine ratio;	chr9:74940794	chr9:74952968~74996293:+
SARC	cis	rs12817211	0.502	rs7961065	ENSG00000272368.2	RP4-605O3.4	-4.4	1.66e-05	0.0072	-0.26	-0.28	Colorectal or endometrial cancer;	chr12:50119904	chr12:50112197~50165618:+
SARC	cis	rs1865760	0.573	rs7450342	ENSG00000272810.1	U91328.22	-4.4	1.66e-05	0.0072	-0.27	-0.28	Height;	chr6:25919252	chr6:26013241~26013757:+
SARC	cis	rs1865760	0.613	rs7749342	ENSG00000272810.1	U91328.22	-4.4	1.66e-05	0.0072	-0.27	-0.28	Height;	chr6:25920037	chr6:26013241~26013757:+
SARC	cis	rs4664293	0.647	rs7580816	ENSG00000226266.5	AC009961.3	-4.4	1.66e-05	0.0072	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159619370	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs1966530	ENSG00000226266.5	AC009961.3	-4.4	1.66e-05	0.0072	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159620897	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.669	rs357021	ENSG00000226266.5	AC009961.3	-4.4	1.66e-05	0.0072	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159632572	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs357030	ENSG00000226266.5	AC009961.3	-4.4	1.66e-05	0.0072	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159636515	chr2:159670708~159712435:-
SARC	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	4.4	1.66e-05	0.0072	0.24	0.28	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
SARC	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-4.4	1.66e-05	0.0072	-0.26	-0.28	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
SARC	cis	rs739310	0.597	rs4274	ENSG00000206028.1	CTA-373H7.7	-4.4	1.67e-05	0.00721	-0.4	-0.28	Obesity-related traits;	chr22:26668324	chr22:26667693~26672654:-
SARC	cis	rs741951	0.832	rs8127770	ENSG00000235374.2	SSR4P1	4.4	1.67e-05	0.00721	0.46	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr21:44835383	chr21:45070952~45074165:-
SARC	cis	rs324126	0.78	rs1993531	ENSG00000269834.4	ZNF528-AS1	4.4	1.67e-05	0.00722	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52381633	chr19:52388842~52397766:-
SARC	cis	rs10788972	0.933	rs4492560	ENSG00000225183.1	RP4-758J24.4	-4.4	1.67e-05	0.00722	-0.33	-0.28	Parkinson disease and lewy body pathology;	chr1:54102815	chr1:54089856~54090093:+
SARC	cis	rs321358	0.945	rs7112932	ENSG00000271584.1	RP11-89C3.4	4.4	1.67e-05	0.00722	0.52	0.28	Body mass index;	chr11:111101099	chr11:111091932~111097357:-
SARC	cis	rs10986311	0.708	rs34011920	ENSG00000235204.1	RP11-121A14.2	4.4	1.67e-05	0.00722	0.33	0.28	Vitiligo;	chr9:124265133	chr9:124259250~124261156:-
SARC	cis	rs55894132	1	rs55894132	ENSG00000257285.4	RP11-298I3.1	4.4	1.67e-05	0.00722	0.27	0.28	Intelligence (multi-trait analysis);	chr14:22939628	chr14:22929609~22955562:+
SARC	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-4.4	1.67e-05	0.00722	-0.52	-0.28	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-4.4	1.67e-05	0.00722	-0.52	-0.28	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-4.4	1.67e-05	0.00722	-0.52	-0.28	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-4.4	1.67e-05	0.00722	-0.52	-0.28	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-4.4	1.67e-05	0.00722	-0.52	-0.28	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
SARC	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-4.4	1.67e-05	0.00722	-0.34	-0.28	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
SARC	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	4.4	1.67e-05	0.00722	0.27	0.28	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
SARC	cis	rs7267979	1	rs4815404	ENSG00000276952.1	RP5-965G21.6	-4.4	1.67e-05	0.00723	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25284915~25285588:-
SARC	cis	rs2439831	0.85	rs7179388	ENSG00000275601.1	AC011330.13	-4.4	1.67e-05	0.00724	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43831747	chr15:43642389~43643023:-
SARC	cis	rs10936632	0.565	rs9865021	ENSG00000242578.1	RP11-469J4.3	-4.4	1.67e-05	0.00724	-0.28	-0.28	Prostate cancer;	chr3:170429093	chr3:170410512~170418615:+
SARC	cis	rs4372836	0.729	rs4611608	ENSG00000226833.4	AC097724.3	-4.4	1.68e-05	0.00725	-0.24	-0.28	Body mass index;	chr2:28841670	chr2:28708953~28736205:-
SARC	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-4.4	1.68e-05	0.00725	-0.32	-0.28	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
SARC	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	4.4	1.68e-05	0.00725	0.25	0.28	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
SARC	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	4.4	1.68e-05	0.00726	0.37	0.28	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
SARC	cis	rs7512898	0.5	rs10800724	ENSG00000260088.1	RP11-92G12.3	-4.4	1.68e-05	0.00727	-0.3	-0.28	Electrocardiographic conduction measures;	chr1:200709285	chr1:200669507~200694250:+
SARC	cis	rs853679	0.546	rs34295134	ENSG00000216901.1	AL022393.7	4.39	1.68e-05	0.00728	0.62	0.28	Depression;	chr6:27860373	chr6:28176188~28176674:+
SARC	cis	rs853679	0.546	rs200948	ENSG00000216901.1	AL022393.7	4.39	1.68e-05	0.00728	0.62	0.28	Depression;	chr6:27867494	chr6:28176188~28176674:+
SARC	cis	rs853679	0.546	rs200950	ENSG00000216901.1	AL022393.7	4.39	1.68e-05	0.00728	0.62	0.28	Depression;	chr6:27867994	chr6:28176188~28176674:+
SARC	cis	rs853679	0.546	rs200952	ENSG00000216901.1	AL022393.7	4.39	1.68e-05	0.00728	0.62	0.28	Depression;	chr6:27869198	chr6:28176188~28176674:+
SARC	cis	rs853679	0.546	rs200954	ENSG00000216901.1	AL022393.7	4.39	1.68e-05	0.00728	0.62	0.28	Depression;	chr6:27870986	chr6:28176188~28176674:+
SARC	cis	rs3805389	0.504	rs10018932	ENSG00000273257.1	RP11-177J6.1	-4.39	1.68e-05	0.00728	-0.41	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr4:55601699	chr4:55387949~55388271:+
SARC	cis	rs7216064	0.532	rs3890640	ENSG00000237854.3	LINC00674	-4.39	1.69e-05	0.00728	-0.31	-0.28	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68056912	chr17:68101908~68115518:+
SARC	cis	rs7615952	0.932	rs1976458	ENSG00000241288.6	RP11-379B18.5	-4.39	1.69e-05	0.00728	-0.37	-0.28	Blood pressure (smoking interaction);	chr3:125928669	chr3:125827238~125916384:-
SARC	cis	rs7772486	0.686	rs9403746	ENSG00000235652.6	RP11-545I5.3	-4.39	1.69e-05	0.00729	-0.25	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145799409~145886585:+
SARC	cis	rs7267979	1	rs4815406	ENSG00000276952.1	RP5-965G21.6	-4.39	1.69e-05	0.00729	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs6083817	ENSG00000276952.1	RP5-965G21.6	-4.39	1.69e-05	0.00729	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6050564	ENSG00000276952.1	RP5-965G21.6	-4.39	1.69e-05	0.00729	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6138572	ENSG00000276952.1	RP5-965G21.6	4.39	1.69e-05	0.0073	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6138575	ENSG00000276952.1	RP5-965G21.6	4.39	1.69e-05	0.0073	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs11087521	ENSG00000276952.1	RP5-965G21.6	4.39	1.69e-05	0.0073	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs13038834	ENSG00000276952.1	RP5-965G21.6	4.39	1.69e-05	0.0073	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25284915~25285588:-
SARC	cis	rs9309473	0.632	rs7599076	ENSG00000163016.8	ALMS1P	4.39	1.69e-05	0.0073	0.33	0.28	Metabolite levels;	chr2:73358391	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.583	rs11126397	ENSG00000163016.8	ALMS1P	4.39	1.69e-05	0.0073	0.33	0.28	Metabolite levels;	chr2:73361605	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.5	rs2421582	ENSG00000163016.8	ALMS1P	-4.39	1.69e-05	0.0073	-0.31	-0.28	Metabolite levels;	chr2:73671293	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.519	rs2421584	ENSG00000163016.8	ALMS1P	-4.39	1.69e-05	0.0073	-0.31	-0.28	Metabolite levels;	chr2:73671725	chr2:73644919~73685576:+
SARC	cis	rs597539	0.652	rs496616	ENSG00000250508.1	RP11-757G1.6	-4.39	1.69e-05	0.00731	-0.32	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68870664~68874542:+
SARC	cis	rs4950322	0.542	rs72692942	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147318467	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs4950399	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147319302	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs4950401	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147319571	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs4950402	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147319684	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs4950403	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147319723	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs4950404	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147319834	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692946	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147319966	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692948	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147320298	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692951	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147320551	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs77118461	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147320718	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.517	rs116479391	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147320940	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs78681047	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147321013	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692953	ENSG00000278811.3	LINC00624	4.39	1.69e-05	0.00731	0.29	0.28	Protein quantitative trait loci;	chr1:147321416	chr1:147258885~147517875:-
SARC	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-4.39	1.69e-05	0.00731	-0.52	-0.28	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-4.39	1.69e-05	0.00731	-0.52	-0.28	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-4.39	1.69e-05	0.00731	-0.52	-0.28	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-4.39	1.69e-05	0.00731	-0.52	-0.28	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
SARC	cis	rs4664293	0.605	rs6741498	ENSG00000226266.5	AC009961.3	4.39	1.69e-05	0.00731	0.32	0.28	Monocyte percentage of white cells;	chr2:159698111	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs6760931	ENSG00000226266.5	AC009961.3	4.39	1.69e-05	0.00731	0.32	0.28	Monocyte percentage of white cells;	chr2:159702600	chr2:159670708~159712435:-
SARC	cis	rs4950322	0.57	rs1999820	ENSG00000278811.3	LINC00624	4.39	1.7e-05	0.00731	0.3	0.28	Protein quantitative trait loci;	chr1:147270329	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs3737855	ENSG00000278811.3	LINC00624	4.39	1.7e-05	0.00731	0.3	0.28	Protein quantitative trait loci;	chr1:147271257	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs4950316	ENSG00000278811.3	LINC00624	4.39	1.7e-05	0.00731	0.3	0.28	Protein quantitative trait loci;	chr1:147273712	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs2354428	ENSG00000278811.3	LINC00624	4.39	1.7e-05	0.00731	0.3	0.28	Protein quantitative trait loci;	chr1:147277512	chr1:147258885~147517875:-
SARC	cis	rs7772486	0.79	rs2814880	ENSG00000270638.1	RP3-466P17.1	4.39	1.7e-05	0.00731	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs11760	ENSG00000270638.1	RP3-466P17.1	4.39	1.7e-05	0.00731	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs1062067	ENSG00000270638.1	RP3-466P17.1	4.39	1.7e-05	0.00731	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs2256998	ENSG00000270638.1	RP3-466P17.1	4.39	1.7e-05	0.00731	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145735570~145737218:+
SARC	cis	rs5751614	0.62	rs1811017	ENSG00000230701.2	FBXW4P1	4.39	1.7e-05	0.00732	0.35	0.28	Height;	chr22:23264771	chr22:23262767~23265005:+
SARC	cis	rs5751614	0.62	rs5759669	ENSG00000230701.2	FBXW4P1	4.39	1.7e-05	0.00732	0.35	0.28	Height;	chr22:23267313	chr22:23262767~23265005:+
SARC	cis	rs5751614	0.56	rs9612269	ENSG00000230701.2	FBXW4P1	4.39	1.7e-05	0.00732	0.35	0.28	Height;	chr22:23269170	chr22:23262767~23265005:+
SARC	cis	rs2274273	0.6	rs10134317	ENSG00000258413.1	RP11-665C16.6	-4.39	1.7e-05	0.00733	-0.35	-0.28	Protein biomarker;	chr14:55326730	chr14:55262767~55272075:-
SARC	cis	rs12893668	0.572	rs1606	ENSG00000269940.1	RP11-73M18.7	4.39	1.7e-05	0.00733	0.27	0.28	Reticulocyte count;	chr14:103694944	chr14:103694560~103695170:+
SARC	cis	rs2032447	0.613	rs6456708	ENSG00000272810.1	U91328.22	-4.39	1.7e-05	0.00733	-0.27	-0.28	Intelligence (multi-trait analysis);	chr6:26032619	chr6:26013241~26013757:+
SARC	cis	rs7567389	0.719	rs6738690	ENSG00000236682.1	AC068282.3	4.39	1.7e-05	0.00734	0.34	0.28	Self-rated health;	chr2:127235149	chr2:127389130~127400580:+
SARC	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-4.39	1.7e-05	0.00734	-0.36	-0.28	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-4.39	1.7e-05	0.00734	-0.36	-0.28	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-4.39	1.7e-05	0.00734	-0.36	-0.28	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-4.39	1.7e-05	0.00734	-0.36	-0.28	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-4.39	1.7e-05	0.00734	-0.36	-0.28	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-4.39	1.7e-05	0.00734	-0.36	-0.28	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-4.39	1.7e-05	0.00734	-0.36	-0.28	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-4.39	1.7e-05	0.00734	-0.36	-0.28	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-4.39	1.7e-05	0.00734	-0.36	-0.28	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
SARC	cis	rs8062405	0.723	rs113208333	ENSG00000251417.2	RP11-1348G14.4	-4.39	1.7e-05	0.00734	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28802743~28817828:+
SARC	cis	rs9309473	0.607	rs7574291	ENSG00000163016.8	ALMS1P	4.39	1.7e-05	0.00734	0.35	0.28	Metabolite levels;	chr2:73367813	chr2:73644919~73685576:+
SARC	cis	rs950776	0.518	rs12910978	ENSG00000261762.1	RP11-650L12.2	4.39	1.7e-05	0.00734	0.3	0.28	Sudden cardiac arrest;	chr15:78517675	chr15:78589123~78591276:-
SARC	cis	rs950776	0.518	rs12591557	ENSG00000261762.1	RP11-650L12.2	4.39	1.7e-05	0.00734	0.3	0.28	Sudden cardiac arrest;	chr15:78519390	chr15:78589123~78591276:-
SARC	cis	rs7809950	0.817	rs2237678	ENSG00000238832.1	snoU109	-4.39	1.7e-05	0.00734	-0.34	-0.28	Coronary artery disease;	chr7:107562820	chr7:107603363~107603507:+
SARC	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-4.39	1.7e-05	0.00734	-0.35	-0.28	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
SARC	cis	rs2303759	0.515	rs2334867	ENSG00000268686.1	AC010524.2	4.39	1.7e-05	0.00734	0.37	0.28	Multiple sclerosis;	chr19:49284948	chr19:49368705~49388081:-
SARC	cis	rs9309473	0.554	rs4330127	ENSG00000163016.8	ALMS1P	4.39	1.71e-05	0.00735	0.34	0.28	Metabolite levels;	chr2:73354192	chr2:73644919~73685576:+
SARC	cis	rs10986311	0.747	rs10760344	ENSG00000235204.1	RP11-121A14.2	4.39	1.71e-05	0.00735	0.32	0.28	Vitiligo;	chr9:124264003	chr9:124259250~124261156:-
SARC	cis	rs728478	0.566	rs7221185	ENSG00000266992.1	DHX40P1	4.39	1.71e-05	0.00735	0.29	0.28	QT interval;	chr17:59399292	chr17:59976009~60002384:-
SARC	cis	rs728478	0.566	rs1451508	ENSG00000266992.1	DHX40P1	4.39	1.71e-05	0.00735	0.29	0.28	QT interval;	chr17:59399874	chr17:59976009~60002384:-
SARC	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-4.39	1.71e-05	0.00735	-0.32	-0.28	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
SARC	cis	rs17508449	0.865	rs4838993	ENSG00000232450.1	RP4-730K3.3	-4.39	1.71e-05	0.00735	-0.35	-0.28	Leprosy;	chr1:113592511	chr1:113698884~113699631:-
SARC	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-4.39	1.71e-05	0.00736	-0.25	-0.28	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
SARC	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-4.39	1.71e-05	0.00736	-0.33	-0.28	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
SARC	cis	rs193541	0.53	rs9327272	ENSG00000263432.2	RN7SL689P	4.39	1.71e-05	0.00736	0.34	0.28	Glucose homeostasis traits;	chr5:122737853	chr5:123022487~123022783:-
SARC	cis	rs4835473	0.9	rs35670120	ENSG00000251600.4	RP11-673E1.1	-4.39	1.71e-05	0.00737	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143787041	chr4:143912331~143982454:+
SARC	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-4.39	1.71e-05	0.00737	-0.27	-0.28	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
SARC	cis	rs72945132	0.714	rs66542029	ENSG00000254604.1	AP000487.6	-4.39	1.71e-05	0.00737	-0.39	-0.28	Coronary artery disease;	chr11:70350196	chr11:70282367~70363368:-
SARC	cis	rs4273100	0.688	rs1467028	ENSG00000228157.4	AC007952.5	4.39	1.71e-05	0.00737	0.35	0.28	Schizophrenia;	chr17:19271561	chr17:19092974~19096837:+
SARC	cis	rs10986311	0.814	rs7861040	ENSG00000235204.1	RP11-121A14.2	4.39	1.71e-05	0.00738	0.33	0.28	Vitiligo;	chr9:124281856	chr9:124259250~124261156:-
SARC	cis	rs6740322	0.895	rs6744746	ENSG00000234936.1	AC010883.5	-4.39	1.71e-05	0.00738	-0.31	-0.28	Coronary artery disease;	chr2:43328666	chr2:43229573~43233394:+
SARC	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-4.39	1.71e-05	0.00738	-0.5	-0.28	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
SARC	cis	rs2439831	0.571	rs689883	ENSG00000275601.1	AC011330.13	-4.39	1.71e-05	0.00738	-0.44	-0.28	Lung cancer in ever smokers;	chr15:43520398	chr15:43642389~43643023:-
SARC	cis	rs41369048	0.669	rs111238725	ENSG00000272823.1	RP11-295M18.6	-4.39	1.72e-05	0.00738	-0.41	-0.28	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220860320	chr1:220828676~220829211:-
SARC	cis	rs7772486	0.79	rs9485024	ENSG00000235652.6	RP11-545I5.3	-4.39	1.72e-05	0.00739	-0.25	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145799409~145886585:+
SARC	cis	rs4820294	0.669	rs1894532	ENSG00000233360.4	Z83844.1	4.39	1.72e-05	0.00739	0.32	0.28	Fat distribution (HIV);	chr22:37663743	chr22:37641832~37658377:-
SARC	cis	rs7267979	0.932	rs1541061	ENSG00000276952.1	RP5-965G21.6	4.39	1.72e-05	0.0074	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.932	rs6138600	ENSG00000276952.1	RP5-965G21.6	4.39	1.72e-05	0.0074	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25284915~25285588:-
SARC	cis	rs7299940	1	rs7299940	ENSG00000256250.1	RP11-989F5.1	-4.39	1.72e-05	0.0074	-0.27	-0.28	Panic disorder;	chr12:130906209	chr12:130810606~130812438:+
SARC	cis	rs2439831	0.702	rs28699233	ENSG00000275601.1	AC011330.13	-4.39	1.72e-05	0.00741	-0.49	-0.28	Lung cancer in ever smokers;	chr15:43830668	chr15:43642389~43643023:-
SARC	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	4.39	1.72e-05	0.00741	0.26	0.28	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
SARC	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	4.39	1.72e-05	0.00741	0.29	0.28	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
SARC	cis	rs4664293	0.625	rs6722715	ENSG00000226266.5	AC009961.3	4.39	1.72e-05	0.00741	0.32	0.28	Monocyte percentage of white cells;	chr2:159668515	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.669	rs2042778	ENSG00000226266.5	AC009961.3	4.39	1.72e-05	0.00741	0.32	0.28	Monocyte percentage of white cells;	chr2:159672119	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs62171654	ENSG00000226266.5	AC009961.3	4.39	1.72e-05	0.00741	0.32	0.28	Monocyte percentage of white cells;	chr2:159675107	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs11903816	ENSG00000226266.5	AC009961.3	4.39	1.72e-05	0.00741	0.32	0.28	Monocyte percentage of white cells;	chr2:159675347	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs6738523	ENSG00000226266.5	AC009961.3	4.39	1.72e-05	0.00741	0.32	0.28	Monocyte percentage of white cells;	chr2:159681203	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.585	rs11893106	ENSG00000226266.5	AC009961.3	4.39	1.72e-05	0.00741	0.32	0.28	Monocyte percentage of white cells;	chr2:159684294	chr2:159670708~159712435:-
SARC	cis	rs7267979	1	rs6083862	ENSG00000276952.1	RP5-965G21.6	-4.39	1.72e-05	0.00741	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:25284915~25285588:-
SARC	cis	rs5769707	0.521	rs5769719	ENSG00000235111.1	RP1-29C18.8	-4.39	1.72e-05	0.00742	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49612657~49615716:-
SARC	cis	rs5769707	0.521	rs5769720	ENSG00000235111.1	RP1-29C18.8	-4.39	1.72e-05	0.00742	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49612657~49615716:-
SARC	cis	rs5769707	0.521	rs5770633	ENSG00000235111.1	RP1-29C18.8	-4.39	1.72e-05	0.00742	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49612657~49615716:-
SARC	cis	rs741951	0.832	rs73372549	ENSG00000235374.2	SSR4P1	4.39	1.73e-05	0.00742	0.46	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr21:44835864	chr21:45070952~45074165:-
SARC	cis	rs7216064	0.953	rs62086044	ENSG00000237854.3	LINC00674	4.39	1.73e-05	0.00742	0.34	0.28	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67974721	chr17:68101908~68115518:+
SARC	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-4.39	1.73e-05	0.00742	-0.26	-0.28	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
SARC	cis	rs7267979	0.873	rs6115093	ENSG00000276952.1	RP5-965G21.6	4.39	1.73e-05	0.00742	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs7343481	ENSG00000276952.1	RP5-965G21.6	-4.39	1.73e-05	0.00742	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6115146	ENSG00000276952.1	RP5-965G21.6	-4.39	1.73e-05	0.00742	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.934	rs6037085	ENSG00000276952.1	RP5-965G21.6	-4.39	1.73e-05	0.00742	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs6050532	ENSG00000276952.1	RP5-965G21.6	-4.39	1.73e-05	0.00742	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25284915~25285588:-
SARC	cis	rs324126	0.78	rs62108320	ENSG00000269834.4	ZNF528-AS1	4.39	1.73e-05	0.00742	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52380770	chr19:52388842~52397766:-
SARC	cis	rs324126	0.752	rs62108321	ENSG00000269834.4	ZNF528-AS1	4.39	1.73e-05	0.00742	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52380825	chr19:52388842~52397766:-
SARC	cis	rs1707322	0.785	rs10890348	ENSG00000281133.1	AL355480.3	-4.39	1.73e-05	0.00742	-0.31	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45580892~45580996:-
SARC	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	4.39	1.73e-05	0.00742	0.26	0.28	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	4.39	1.73e-05	0.00742	0.26	0.28	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	4.39	1.73e-05	0.00742	0.26	0.28	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
SARC	cis	rs75920871	0.528	rs7109649	ENSG00000254851.1	RP11-109L13.1	4.39	1.73e-05	0.00743	0.37	0.28	Subjective well-being;	chr11:117072828	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.528	rs1531706	ENSG00000254851.1	RP11-109L13.1	4.39	1.73e-05	0.00743	0.37	0.28	Subjective well-being;	chr11:117073236	chr11:117135528~117138582:+
SARC	cis	rs4664293	0.585	rs34385495	ENSG00000226266.5	AC009961.3	4.39	1.73e-05	0.00743	0.32	0.28	Monocyte percentage of white cells;	chr2:159656372	chr2:159670708~159712435:-
SARC	cis	rs5769707	0.967	rs5770585	ENSG00000235111.1	RP1-29C18.8	-4.39	1.73e-05	0.00743	-0.3	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49612657~49615716:-
SARC	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	4.39	1.73e-05	0.00744	0.3	0.28	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
SARC	cis	rs7208859	0.673	rs9889755	ENSG00000263603.1	CTD-2349P21.5	4.39	1.73e-05	0.00744	0.35	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30729469~30731202:+
SARC	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-4.39	1.73e-05	0.00744	-0.45	-0.28	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
SARC	cis	rs4950322	0.57	rs72691095	ENSG00000278811.3	LINC00624	4.39	1.73e-05	0.00745	0.29	0.28	Protein quantitative trait loci;	chr1:147298305	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72691097	ENSG00000278811.3	LINC00624	4.39	1.73e-05	0.00745	0.29	0.28	Protein quantitative trait loci;	chr1:147299711	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72691098	ENSG00000278811.3	LINC00624	4.39	1.73e-05	0.00745	0.29	0.28	Protein quantitative trait loci;	chr1:147300142	chr1:147258885~147517875:-
SARC	cis	rs17270561	0.609	rs9356984	ENSG00000272810.1	U91328.22	4.39	1.73e-05	0.00745	0.28	0.28	Iron status biomarkers;	chr6:25725253	chr6:26013241~26013757:+
SARC	cis	rs2404602	0.563	rs12914005	ENSG00000259422.1	RP11-593F23.1	4.39	1.73e-05	0.00745	0.3	0.28	Blood metabolite levels;	chr15:76473326	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.536	rs7163946	ENSG00000259422.1	RP11-593F23.1	4.39	1.73e-05	0.00745	0.3	0.28	Blood metabolite levels;	chr15:76473708	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.536	rs7165025	ENSG00000259422.1	RP11-593F23.1	4.39	1.73e-05	0.00745	0.3	0.28	Blood metabolite levels;	chr15:76474093	chr15:76174891~76181486:-
SARC	cis	rs17508449	0.865	rs76308249	ENSG00000232450.1	RP4-730K3.3	-4.39	1.73e-05	0.00745	-0.36	-0.28	Leprosy;	chr1:113605059	chr1:113698884~113699631:-
SARC	cis	rs17508449	0.779	rs78703286	ENSG00000232450.1	RP4-730K3.3	-4.39	1.73e-05	0.00745	-0.36	-0.28	Leprosy;	chr1:113605493	chr1:113698884~113699631:-
SARC	cis	rs526231	0.857	rs2569013	ENSG00000175749.11	EIF3KP1	4.39	1.74e-05	0.00745	0.34	0.28	Primary biliary cholangitis;	chr5:103305870	chr5:103032376~103033031:+
SARC	cis	rs7267979	0.966	rs6083818	ENSG00000276952.1	RP5-965G21.6	-4.39	1.74e-05	0.00745	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs4815409	ENSG00000276952.1	RP5-965G21.6	-4.39	1.74e-05	0.00745	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25284915~25285588:-
SARC	cis	rs4835473	0.932	rs12512649	ENSG00000251600.4	RP11-673E1.1	-4.39	1.74e-05	0.00745	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143736745	chr4:143912331~143982454:+
SARC	cis	rs76693355	0.512	rs11217857	ENSG00000232460.4	BMPR1APS2	4.39	1.74e-05	0.00745	0.34	0.28	Intraocular pressure;	chr11:120399461	chr11:121361854~121362865:-
SARC	cis	rs3805389	0.504	rs3805385	ENSG00000273257.1	RP11-177J6.1	-4.39	1.74e-05	0.00746	-0.41	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr4:55613821	chr4:55387949~55388271:+
SARC	cis	rs3805389	0.504	rs3805388	ENSG00000273257.1	RP11-177J6.1	-4.39	1.74e-05	0.00746	-0.41	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr4:55614754	chr4:55387949~55388271:+
SARC	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-4.39	1.74e-05	0.00746	-0.33	-0.28	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
SARC	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	4.39	1.74e-05	0.00746	0.28	0.28	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
SARC	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-4.39	1.74e-05	0.00746	-0.31	-0.28	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
SARC	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-4.39	1.74e-05	0.00747	-0.31	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
SARC	cis	rs7216064	1	rs7212293	ENSG00000265055.1	AC145343.2	4.39	1.74e-05	0.00747	0.35	0.28	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67851209	chr17:68096046~68101474:-
SARC	cis	rs890448	0.796	rs2433311	ENSG00000254531.1	FLJ20021	4.39	1.74e-05	0.00747	0.29	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101434778	chr4:101347780~101348883:+
SARC	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
SARC	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-4.39	1.74e-05	0.00747	-0.25	-0.28	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
SARC	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-4.39	1.74e-05	0.00747	-0.52	-0.28	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
SARC	cis	rs193541	0.632	rs246279	ENSG00000263432.2	RN7SL689P	-4.39	1.74e-05	0.00748	-0.43	-0.28	Glucose homeostasis traits;	chr5:122905568	chr5:123022487~123022783:-
SARC	cis	rs7712401	0.58	rs10066632	ENSG00000263432.2	RN7SL689P	4.39	1.75e-05	0.00748	0.36	0.28	Mean platelet volume;	chr5:123028988	chr5:123022487~123022783:-
SARC	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-4.39	1.75e-05	0.00749	-0.41	-0.28	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
SARC	cis	rs763121	0.962	rs1980455	ENSG00000273076.1	RP3-508I15.22	4.39	1.75e-05	0.00749	0.28	0.28	Menopause (age at onset);	chr22:38529714	chr22:38743495~38743910:+
SARC	cis	rs4835473	0.9	rs4054634	ENSG00000251600.4	RP11-673E1.1	-4.39	1.75e-05	0.00749	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143787045	chr4:143912331~143982454:+
SARC	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	4.39	1.75e-05	0.0075	0.35	0.28	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
SARC	cis	rs72945132	0.882	rs17425511	ENSG00000254604.1	AP000487.6	-4.39	1.75e-05	0.00751	-0.39	-0.28	Coronary artery disease;	chr11:70337631	chr11:70282367~70363368:-
SARC	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-4.39	1.75e-05	0.00751	-0.25	-0.28	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
SARC	cis	rs597539	0.652	rs636049	ENSG00000250508.1	RP11-757G1.6	-4.39	1.75e-05	0.00752	-0.32	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:68870664~68874542:+
SARC	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	4.39	1.75e-05	0.00752	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
SARC	cis	rs2179367	0.632	rs6920383	ENSG00000231760.4	RP11-350J20.5	4.39	1.75e-05	0.00752	0.37	0.28	Dupuytren's disease;	chr6:149356361	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs11155645	ENSG00000231760.4	RP11-350J20.5	4.39	1.75e-05	0.00752	0.37	0.28	Dupuytren's disease;	chr6:149360056	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs10155766	ENSG00000231760.4	RP11-350J20.5	4.39	1.75e-05	0.00752	0.37	0.28	Dupuytren's disease;	chr6:149364577	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498332	ENSG00000231760.4	RP11-350J20.5	4.39	1.75e-05	0.00752	0.37	0.28	Dupuytren's disease;	chr6:149367490	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498333	ENSG00000231760.4	RP11-350J20.5	4.39	1.75e-05	0.00752	0.37	0.28	Dupuytren's disease;	chr6:149368196	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498334	ENSG00000231760.4	RP11-350J20.5	4.39	1.75e-05	0.00752	0.37	0.28	Dupuytren's disease;	chr6:149370902	chr6:149796151~149826294:-
SARC	cis	rs253959	0.545	rs6896147	ENSG00000272265.1	CTD-2287O16.4	-4.39	1.76e-05	0.00752	-0.32	-0.28	Bipolar disorder and schizophrenia;	chr5:116089699	chr5:116078110~116078570:-
SARC	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	4.38	1.76e-05	0.00753	0.33	0.28	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
SARC	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-4.38	1.76e-05	0.00753	-0.26	-0.28	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-4.38	1.76e-05	0.00753	-0.26	-0.28	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
SARC	cis	rs3805389	0.504	rs3805386	ENSG00000273257.1	RP11-177J6.1	-4.38	1.76e-05	0.00754	-0.41	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr4:55613838	chr4:55387949~55388271:+
SARC	cis	rs3805389	0.504	rs3805387	ENSG00000273257.1	RP11-177J6.1	-4.38	1.76e-05	0.00754	-0.41	-0.28	Waist-to-hip ratio adjusted for body mass index;	chr4:55613841	chr4:55387949~55388271:+
SARC	cis	rs2408955	0.515	rs10875742	ENSG00000240399.1	RP1-228P16.1	-4.38	1.76e-05	0.00754	-0.3	-0.28	Glycated hemoglobin levels;	chr12:48099591	chr12:48054813~48055591:-
SARC	cis	rs10906115	0.899	rs10906116	ENSG00000228302.2	RP11-186N15.3	4.38	1.76e-05	0.00754	0.21	0.28	Type 2 diabetes;	chr10:12275719	chr10:12244751~12247845:-
SARC	cis	rs11822910	0.737	rs2584858	ENSG00000265566.2	RN7SL605P	4.38	1.76e-05	0.00754	0.33	0.28	Platelet distribution width;	chr11:57439604	chr11:57528085~57528365:-
SARC	cis	rs11098499	0.874	rs28452522	ENSG00000245958.5	RP11-33B1.1	-4.38	1.76e-05	0.00755	-0.26	-0.28	Corneal astigmatism;	chr4:119189629	chr4:119454791~119552025:+
SARC	cis	rs12893668	0.572	rs7148857	ENSG00000269940.1	RP11-73M18.7	4.38	1.77e-05	0.00755	0.27	0.28	Reticulocyte count;	chr14:103676900	chr14:103694560~103695170:+
SARC	cis	rs12893668	0.572	rs11540512	ENSG00000269940.1	RP11-73M18.7	4.38	1.77e-05	0.00755	0.27	0.28	Reticulocyte count;	chr14:103681040	chr14:103694560~103695170:+
SARC	cis	rs12893668	0.572	rs35011804	ENSG00000269940.1	RP11-73M18.7	4.38	1.77e-05	0.00755	0.27	0.28	Reticulocyte count;	chr14:103685063	chr14:103694560~103695170:+
SARC	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-4.38	1.77e-05	0.00756	-0.32	-0.28	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
SARC	cis	rs4372836	0.729	rs55785599	ENSG00000226833.4	AC097724.3	-4.38	1.77e-05	0.00756	-0.24	-0.28	Body mass index;	chr2:28864948	chr2:28708953~28736205:-
SARC	cis	rs718433	0.594	rs10146835	ENSG00000199436.1	SNORD9	-4.38	1.77e-05	0.00756	-0.28	-0.28	Intraocular pressure;	chr14:21854869	chr14:21392150~21392253:-
SARC	cis	rs1707322	0.827	rs12125508	ENSG00000281133.1	AL355480.3	-4.38	1.77e-05	0.00757	-0.31	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45580892~45580996:-
SARC	cis	rs755249	0.614	rs10888798	ENSG00000182109.6	RP11-69E11.4	-4.38	1.77e-05	0.00757	-0.26	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39492408	chr1:39522280~39546187:-
SARC	cis	rs7726354	1	rs79565352	ENSG00000271828.1	CTD-2310F14.1	4.38	1.77e-05	0.00758	0.58	0.28	Breast cancer (early onset);	chr5:56955926	chr5:56927874~56929573:+
SARC	cis	rs4372836	0.504	rs7475	ENSG00000226833.4	AC097724.3	4.38	1.77e-05	0.00759	0.23	0.28	Body mass index;	chr2:28800883	chr2:28708953~28736205:-
SARC	cis	rs28386778	0.863	rs6919	ENSG00000240280.5	TCAM1P	4.38	1.78e-05	0.0076	0.34	0.28	Prudent dietary pattern;	chr17:63832125	chr17:63849292~63864379:+
SARC	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-4.38	1.78e-05	0.0076	-0.29	-0.28	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
SARC	cis	rs910316	0.875	rs12588099	ENSG00000279594.1	RP11-950C14.10	4.38	1.78e-05	0.00761	0.3	0.28	Height;	chr14:75127759	chr14:75011269~75012851:-
SARC	cis	rs4835473	0.932	rs17694797	ENSG00000251600.4	RP11-673E1.1	-4.38	1.78e-05	0.00761	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143778812	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs35947975	ENSG00000251600.4	RP11-673E1.1	-4.38	1.78e-05	0.00761	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143778969	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.778	rs75562808	ENSG00000251600.4	RP11-673E1.1	-4.38	1.78e-05	0.00761	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143779065	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1375987	ENSG00000251600.4	RP11-673E1.1	-4.38	1.78e-05	0.00761	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143779622	chr4:143912331~143982454:+
SARC	cis	rs2179367	0.568	rs62426092	ENSG00000231760.4	RP11-350J20.5	4.38	1.78e-05	0.00761	0.37	0.28	Dupuytren's disease;	chr6:149352720	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs10872636	ENSG00000231760.4	RP11-350J20.5	4.38	1.78e-05	0.00761	0.37	0.28	Dupuytren's disease;	chr6:149353678	chr6:149796151~149826294:-
SARC	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-4.38	1.78e-05	0.00761	-0.41	-0.28	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
SARC	cis	rs77633900	0.73	rs17456573	ENSG00000196274.5	Metazoa_SRP	4.38	1.78e-05	0.00761	0.61	0.28	Glioma;Non-glioblastoma glioma;	chr15:76184020	chr15:76230048~76230390:-
SARC	cis	rs4664293	1	rs10184034	ENSG00000226266.5	AC009961.3	-4.38	1.78e-05	0.00762	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159648916	chr2:159670708~159712435:-
SARC	cis	rs4664293	1	rs4664293	ENSG00000226266.5	AC009961.3	-4.38	1.78e-05	0.00762	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159649241	chr2:159670708~159712435:-
SARC	cis	rs4664293	1	rs10193402	ENSG00000226266.5	AC009961.3	-4.38	1.78e-05	0.00762	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159651271	chr2:159670708~159712435:-
SARC	cis	rs3761847	0.593	rs1468673	ENSG00000226752.6	PSMD5-AS1	-4.38	1.78e-05	0.00763	-0.32	-0.28	Rheumatoid arthritis;	chr9:121047612	chr9:120824828~120854385:+
SARC	cis	rs1865760	0.573	rs7450342	ENSG00000272462.2	U91328.19	-4.38	1.78e-05	0.00763	-0.26	-0.28	Height;	chr6:25919252	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.613	rs7749342	ENSG00000272462.2	U91328.19	-4.38	1.78e-05	0.00763	-0.26	-0.28	Height;	chr6:25920037	chr6:25992662~26001775:+
SARC	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	4.38	1.78e-05	0.00763	0.23	0.28	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
SARC	cis	rs61378614	1	rs61378614	ENSG00000270344.2	RP11-734K2.4	-4.38	1.78e-05	0.00763	-0.33	-0.28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89509877	chr12:89525654~89548005:+
SARC	cis	rs2933343	0.7	rs2624910	ENSG00000231305.3	RP11-723O4.2	4.38	1.79e-05	0.00764	0.27	0.28	IgG glycosylation;	chr3:128931432	chr3:128861313~128871540:-
SARC	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-4.38	1.79e-05	0.00764	-0.25	-0.28	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
SARC	cis	rs72945132	0.882	rs7942613	ENSG00000254604.1	AP000487.6	-4.38	1.79e-05	0.00765	-0.39	-0.28	Coronary artery disease;	chr11:70364569	chr11:70282367~70363368:-
SARC	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-4.38	1.79e-05	0.00765	-0.39	-0.28	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
SARC	cis	rs8062405	0.755	rs55792032	ENSG00000251417.2	RP11-1348G14.4	-4.38	1.79e-05	0.00765	-0.27	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28802743~28817828:+
SARC	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-4.38	1.79e-05	0.00765	-0.43	-0.28	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
SARC	cis	rs4713118	0.662	rs149946	ENSG00000272009.1	RP1-313I6.12	4.38	1.8e-05	0.00767	0.32	0.28	Parkinson's disease;	chr6:28002253	chr6:28078792~28081130:-
SARC	cis	rs7809950	0.678	rs12670688	ENSG00000238832.1	snoU109	4.38	1.8e-05	0.00767	0.38	0.28	Coronary artery disease;	chr7:107180571	chr7:107603363~107603507:+
SARC	cis	rs394563	0.591	rs237018	ENSG00000231760.4	RP11-350J20.5	4.38	1.8e-05	0.00769	0.34	0.28	Dupuytren's disease;	chr6:149422794	chr6:149796151~149826294:-
SARC	cis	rs2933343	0.63	rs75824035	ENSG00000231305.3	RP11-723O4.2	4.38	1.8e-05	0.00769	0.28	0.28	IgG glycosylation;	chr3:128934142	chr3:128861313~128871540:-
SARC	cis	rs12210905	0.764	rs72835248	ENSG00000272810.1	U91328.22	-4.38	1.8e-05	0.00769	-0.53	-0.28	Hip circumference adjusted for BMI;	chr6:26964038	chr6:26013241~26013757:+
SARC	cis	rs12210905	1	rs115268625	ENSG00000272810.1	U91328.22	-4.38	1.8e-05	0.00769	-0.53	-0.28	Hip circumference adjusted for BMI;	chr6:26980450	chr6:26013241~26013757:+
SARC	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	4.38	1.81e-05	0.0077	0.29	0.28	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
SARC	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	4.38	1.81e-05	0.0077	0.29	0.28	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
SARC	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	4.38	1.81e-05	0.0077	0.34	0.28	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
SARC	cis	rs783540	0.632	rs17356528	ENSG00000275695.1	UBE2Q2P6	-4.38	1.81e-05	0.00771	-0.29	-0.28	Schizophrenia;	chr15:82636799	chr15:82445719~82454837:+
SARC	cis	rs17508449	0.819	rs17359281	ENSG00000232450.1	RP4-730K3.3	4.38	1.81e-05	0.00771	0.35	0.28	Leprosy;	chr1:113643337	chr1:113698884~113699631:-
SARC	cis	rs7267979	1	rs6083805	ENSG00000276952.1	RP5-965G21.6	-4.38	1.81e-05	0.00771	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6050544	ENSG00000276952.1	RP5-965G21.6	-4.38	1.81e-05	0.00771	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs8125868	ENSG00000276952.1	RP5-965G21.6	-4.38	1.81e-05	0.00771	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25284915~25285588:-
SARC	cis	rs4835473	0.808	rs62339607	ENSG00000251600.4	RP11-673E1.1	-4.38	1.81e-05	0.00771	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143791474	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-4.38	1.81e-05	0.00771	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-4.38	1.81e-05	0.00771	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
SARC	cis	rs2933343	0.729	rs1680785	ENSG00000231305.3	RP11-723O4.2	4.38	1.81e-05	0.00771	0.27	0.28	IgG glycosylation;	chr3:128925973	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.729	rs1680786	ENSG00000231305.3	RP11-723O4.2	4.38	1.81e-05	0.00771	0.27	0.28	IgG glycosylation;	chr3:128925997	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.672	rs1872545	ENSG00000231305.3	RP11-723O4.2	4.38	1.81e-05	0.00771	0.27	0.28	IgG glycosylation;	chr3:128926196	chr3:128861313~128871540:-
SARC	cis	rs4664293	0.833	rs3764969	ENSG00000226266.5	AC009961.3	-4.38	1.81e-05	0.00771	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159764337	chr2:159670708~159712435:-
SARC	cis	rs72945132	0.825	rs7941965	ENSG00000254604.1	AP000487.6	-4.38	1.81e-05	0.00772	-0.39	-0.28	Coronary artery disease;	chr11:70367076	chr11:70282367~70363368:-
SARC	cis	rs12893668	0.572	rs4906350	ENSG00000269940.1	RP11-73M18.7	4.38	1.81e-05	0.00772	0.27	0.28	Reticulocyte count;	chr14:103645457	chr14:103694560~103695170:+
SARC	cis	rs4763555	1	rs4763555	ENSG00000256667.5	KLRAP1	4.38	1.81e-05	0.00772	0.26	0.28	Cognitive function;	chr12:10568857	chr12:10588063~10599669:-
SARC	cis	rs12468226	1	rs16839090	ENSG00000272966.1	RP11-686O6.1	4.38	1.81e-05	0.00772	0.44	0.28	Urate levels;	chr2:202348338	chr2:202336739~202337200:+
SARC	cis	rs7615952	0.866	rs6438949	ENSG00000241288.6	RP11-379B18.5	-4.38	1.81e-05	0.00772	-0.36	-0.28	Blood pressure (smoking interaction);	chr3:125931221	chr3:125827238~125916384:-
SARC	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
SARC	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-4.38	1.81e-05	0.00772	-0.26	-0.28	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
SARC	cis	rs890448	0.796	rs6840099	ENSG00000254531.1	FLJ20021	4.38	1.82e-05	0.00773	0.29	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101423356	chr4:101347780~101348883:+
SARC	cis	rs577676	0.586	rs10489231	ENSG00000271811.1	RP1-79C4.4	-4.38	1.82e-05	0.00774	-0.38	-0.28	Prevalent atrial fibrillation;	chr1:170620296	chr1:170667381~170669425:+
SARC	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-4.38	1.82e-05	0.00775	-0.49	-0.28	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
SARC	cis	rs916888	0.61	rs199436	ENSG00000261575.2	RP11-259G18.1	-4.38	1.82e-05	0.00775	-0.35	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46267037~46268694:+
SARC	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	4.38	1.82e-05	0.00776	0.25	0.28	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	4.38	1.82e-05	0.00776	0.25	0.28	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
SARC	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-4.38	1.82e-05	0.00776	-0.34	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
SARC	cis	rs113835537	0.877	rs3867132	ENSG00000255517.5	CTD-3074O7.5	-4.38	1.82e-05	0.00776	-0.36	-0.28	Airway imaging phenotypes;	chr11:66541798	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.877	rs57127845	ENSG00000255517.5	CTD-3074O7.5	-4.38	1.82e-05	0.00776	-0.36	-0.28	Airway imaging phenotypes;	chr11:66550854	chr11:66473490~66480233:-
SARC	cis	rs14027	0.921	rs6469852	ENSG00000279347.1	RP11-85I17.2	4.38	1.82e-05	0.00777	0.24	0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848495	chr8:119838736~119840385:-
SARC	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	4.38	1.82e-05	0.00777	0.39	0.28	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
SARC	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-4.38	1.82e-05	0.00777	-0.25	-0.28	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
SARC	cis	rs12922317	0.538	rs446289	ENSG00000260488.1	RP11-166B2.7	-4.38	1.83e-05	0.00777	-0.28	-0.28	Schizophrenia;	chr16:11976629	chr16:11976851~11977850:-
SARC	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	4.38	1.83e-05	0.00778	0.4	0.28	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
SARC	cis	rs9596270	0.555	rs17363566	ENSG00000274270.1	RP11-34F20.7	4.38	1.83e-05	0.00778	0.64	0.28	Multiple sclerosis;	chr13:50360756	chr13:50125816~50128463:+
SARC	cis	rs4835473	0.669	rs75704080	ENSG00000251600.4	RP11-673E1.1	-4.38	1.83e-05	0.00778	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143779066	chr4:143912331~143982454:+
SARC	cis	rs7267979	1	rs6050547	ENSG00000276952.1	RP5-965G21.6	-4.38	1.83e-05	0.00778	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25284915~25285588:-
SARC	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	4.38	1.83e-05	0.00779	0.23	0.28	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
SARC	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-4.38	1.83e-05	0.00779	-0.31	-0.28	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
SARC	cis	rs890448	0.796	rs10433981	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101362432	chr4:101347780~101348883:+
SARC	cis	rs890448	0.76	rs7687487	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101362824	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs7668224	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101363270	chr4:101347780~101348883:+
SARC	cis	rs890448	0.76	rs4699210	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101363829	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs4699211	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101363878	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs13109704	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101365056	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs6852377	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101365552	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs4698957	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101367762	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs4699213	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101367950	chr4:101347780~101348883:+
SARC	cis	rs890448	0.792	rs6824603	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101368745	chr4:101347780~101348883:+
SARC	cis	rs890448	0.76	rs6856370	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101369529	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs1946946	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101370420	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs4699214	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101371077	chr4:101347780~101348883:+
SARC	cis	rs890448	0.726	rs13135441	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101371727	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs1822169	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101372107	chr4:101347780~101348883:+
SARC	cis	rs890448	0.76	rs1822168	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101372387	chr4:101347780~101348883:+
SARC	cis	rs890448	0.726	rs6532928	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101373080	chr4:101347780~101348883:+
SARC	cis	rs890448	0.661	rs1583911	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101374542	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs11097747	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101376639	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs6532929	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101377307	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs7670594	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101378105	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs12499349	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101380198	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs13135270	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101380602	chr4:101347780~101348883:+
SARC	cis	rs890448	0.76	rs7677595	ENSG00000254531.1	FLJ20021	4.38	1.83e-05	0.00779	0.3	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101382570	chr4:101347780~101348883:+
SARC	cis	rs875971	0.867	rs13227219	ENSG00000237310.1	GS1-124K5.4	4.38	1.83e-05	0.00779	0.29	0.28	Aortic root size;	chr7:66379075	chr7:66493706~66495474:+
SARC	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-4.38	1.83e-05	0.00779	-0.3	-0.28	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-4.38	1.83e-05	0.00779	-0.3	-0.28	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-4.38	1.83e-05	0.00779	-0.3	-0.28	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
SARC	cis	rs4934494	0.768	rs17126269	ENSG00000240996.1	RP11-80H5.7	-4.38	1.83e-05	0.00779	-0.3	-0.28	Red blood cell count;	chr10:89694974	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.768	rs768805	ENSG00000240996.1	RP11-80H5.7	-4.38	1.83e-05	0.00779	-0.3	-0.28	Red blood cell count;	chr10:89695448	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.768	rs12571268	ENSG00000240996.1	RP11-80H5.7	-4.38	1.83e-05	0.00779	-0.3	-0.28	Red blood cell count;	chr10:89698830	chr10:89694295~89697928:-
SARC	cis	rs4835473	0.9	rs7689374	ENSG00000251600.4	RP11-673E1.1	-4.37	1.83e-05	0.0078	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143769567	chr4:143912331~143982454:+
SARC	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-4.37	1.83e-05	0.0078	-0.44	-0.28	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
SARC	cis	rs10911902	0.643	rs75235608	ENSG00000229739.2	RP11-295K2.3	-4.37	1.83e-05	0.0078	-0.4	-0.28	Schizophrenia;	chr1:186303471	chr1:186435161~186470291:+
SARC	cis	rs597539	0.615	rs583182	ENSG00000250508.1	RP11-757G1.6	-4.37	1.83e-05	0.0078	-0.32	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68870664~68874542:+
SARC	cis	rs7809950	0.598	rs2283038	ENSG00000238832.1	snoU109	-4.37	1.83e-05	0.0078	-0.36	-0.28	Coronary artery disease;	chr7:107194965	chr7:107603363~107603507:+
SARC	cis	rs8005677	0.798	rs4982711	ENSG00000279656.1	RP11-298I3.6	4.37	1.84e-05	0.00781	0.36	0.28	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:23023083~23024217:-
SARC	cis	rs783540	0.809	rs3970696	ENSG00000275695.1	UBE2Q2P6	4.37	1.84e-05	0.00781	0.27	0.28	Schizophrenia;	chr15:82595006	chr15:82445719~82454837:+
SARC	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-4.37	1.84e-05	0.00781	-0.33	-0.28	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
SARC	cis	rs7772486	0.754	rs1415746	ENSG00000270638.1	RP3-466P17.1	-4.37	1.84e-05	0.00781	-0.22	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145735570~145737218:+
SARC	cis	rs4664293	1	rs6432542	ENSG00000226266.5	AC009961.3	-4.37	1.84e-05	0.00781	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159624025	chr2:159670708~159712435:-
SARC	cis	rs4664293	1	rs2357382	ENSG00000226266.5	AC009961.3	-4.37	1.84e-05	0.00781	-0.34	-0.28	Monocyte percentage of white cells;	chr2:159636614	chr2:159670708~159712435:-
SARC	cis	rs1823913	0.637	rs4853575	ENSG00000227542.1	AC092614.2	-4.37	1.84e-05	0.00781	-0.31	-0.28	Obesity-related traits;	chr2:191296149	chr2:191229165~191246172:-
SARC	cis	rs4664293	0.967	rs9646765	ENSG00000226266.5	AC009961.3	-4.37	1.84e-05	0.00782	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159709137	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.528	rs72960224	ENSG00000226266.5	AC009961.3	4.37	1.84e-05	0.00782	0.35	0.28	Monocyte percentage of white cells;	chr2:159563993	chr2:159670708~159712435:-
SARC	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-4.37	1.84e-05	0.00782	-0.3	-0.28	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
SARC	cis	rs7811142	0.943	rs67196635	ENSG00000078319.8	PMS2P1	-4.37	1.84e-05	0.00782	-0.39	-0.28	Platelet count;	chr7:100427941	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs6962151	ENSG00000078319.8	PMS2P1	-4.37	1.84e-05	0.00782	-0.39	-0.28	Platelet count;	chr7:100430861	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs67239991	ENSG00000078319.8	PMS2P1	-4.37	1.84e-05	0.00782	-0.39	-0.28	Platelet count;	chr7:100448881	chr7:100320992~100341908:-
SARC	cis	rs7811142	0.943	rs111493473	ENSG00000078319.8	PMS2P1	-4.37	1.84e-05	0.00782	-0.39	-0.28	Platelet count;	chr7:100452119	chr7:100320992~100341908:-
SARC	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-4.37	1.84e-05	0.00783	-0.42	-0.28	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
SARC	cis	rs75422866	0.541	rs12425816	ENSG00000257433.4	RP1-197B17.3	4.37	1.84e-05	0.00783	0.48	0.28	Pneumonia;	chr12:47731419	chr12:47706085~47742294:+
SARC	cis	rs324126	0.78	rs11084153	ENSG00000269834.4	ZNF528-AS1	4.37	1.84e-05	0.00783	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52382142	chr19:52388842~52397766:-
SARC	cis	rs324126	0.78	rs11084154	ENSG00000269834.4	ZNF528-AS1	4.37	1.84e-05	0.00783	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52382168	chr19:52388842~52397766:-
SARC	cis	rs324126	0.78	rs11084155	ENSG00000269834.4	ZNF528-AS1	4.37	1.84e-05	0.00783	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52383613	chr19:52388842~52397766:-
SARC	cis	rs324126	0.752	rs11084156	ENSG00000269834.4	ZNF528-AS1	4.37	1.84e-05	0.00783	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52383634	chr19:52388842~52397766:-
SARC	cis	rs324126	0.78	rs11084157	ENSG00000269834.4	ZNF528-AS1	4.37	1.84e-05	0.00783	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52383652	chr19:52388842~52397766:-
SARC	cis	rs324126	0.78	rs8104808	ENSG00000269834.4	ZNF528-AS1	4.37	1.84e-05	0.00783	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52384174	chr19:52388842~52397766:-
SARC	cis	rs324126	0.78	rs8104812	ENSG00000269834.4	ZNF528-AS1	4.37	1.84e-05	0.00783	0.29	0.28	Colonoscopy-negative controls vs population controls;	chr19:52384184	chr19:52388842~52397766:-
SARC	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	4.37	1.84e-05	0.00784	0.26	0.28	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
SARC	cis	rs6570726	0.764	rs9399553	ENSG00000270638.1	RP3-466P17.1	4.37	1.85e-05	0.00784	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs408443	ENSG00000270638.1	RP3-466P17.1	4.37	1.85e-05	0.00784	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145735570~145737218:+
SARC	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-4.37	1.85e-05	0.00784	-0.25	-0.28	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
SARC	cis	rs42490	0.51	rs13278061	ENSG00000251136.7	RP11-37B2.1	-4.37	1.85e-05	0.00784	-0.3	-0.28	Leprosy;	chr8:89686032	chr8:89609409~89757727:-
SARC	cis	rs7811142	0.943	rs28578163	ENSG00000078319.8	PMS2P1	-4.37	1.85e-05	0.00784	-0.39	-0.28	Platelet count;	chr7:100447131	chr7:100320992~100341908:-
SARC	cis	rs2933343	0.7	rs789233	ENSG00000231305.3	RP11-723O4.2	4.37	1.85e-05	0.00785	0.27	0.28	IgG glycosylation;	chr3:128884307	chr3:128861313~128871540:-
SARC	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	4.37	1.85e-05	0.00785	0.34	0.28	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
SARC	cis	rs7811142	1	rs4472444	ENSG00000078319.8	PMS2P1	-4.37	1.85e-05	0.00785	-0.39	-0.28	Platelet count;	chr7:100473135	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs7809801	ENSG00000078319.8	PMS2P1	-4.37	1.85e-05	0.00785	-0.39	-0.28	Platelet count;	chr7:100474408	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs11766752	ENSG00000078319.8	PMS2P1	-4.37	1.85e-05	0.00785	-0.39	-0.28	Platelet count;	chr7:100475669	chr7:100320992~100341908:-
SARC	cis	rs12594515	0.587	rs8033024	ENSG00000273972.1	CTD-2306A12.1	-4.37	1.85e-05	0.00785	-0.29	-0.28	Weight;Waist circumference;	chr15:45705898	chr15:45702640~45703183:+
SARC	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	4.37	1.85e-05	0.00787	0.26	0.28	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	4.37	1.85e-05	0.00787	0.26	0.28	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	4.37	1.85e-05	0.00787	0.26	0.28	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	4.37	1.85e-05	0.00787	0.26	0.28	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
SARC	cis	rs783540	0.967	rs34186444	ENSG00000275695.1	UBE2Q2P6	-4.37	1.85e-05	0.00787	-0.28	-0.28	Schizophrenia;	chr15:82618749	chr15:82445719~82454837:+
SARC	cis	rs2029362	0.611	rs2883187	ENSG00000245573.6	BDNF-AS	4.37	1.85e-05	0.00787	0.24	0.28	Total body bone mineral density;	chr11:27719545	chr11:27506838~27698174:+
SARC	cis	rs7247513	0.79	rs17476839	ENSG00000213290.4	PGK1P2	4.37	1.85e-05	0.00787	0.33	0.28	Bipolar disorder;	chr19:12651969	chr19:12559571~12561105:+
SARC	cis	rs2540552	0.965	rs2192803	ENSG00000278819.1	RP5-1099C19.2	-4.37	1.85e-05	0.00787	-0.33	-0.28	IgG glycosylation;	chr7:91609809	chr7:92540268~92557877:-
SARC	cis	rs4950322	0.57	rs80070044	ENSG00000278811.3	LINC00624	4.37	1.85e-05	0.00787	0.29	0.28	Protein quantitative trait loci;	chr1:147330238	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692963	ENSG00000278811.3	LINC00624	4.37	1.85e-05	0.00787	0.29	0.28	Protein quantitative trait loci;	chr1:147331090	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.518	rs72692965	ENSG00000278811.3	LINC00624	4.37	1.85e-05	0.00787	0.29	0.28	Protein quantitative trait loci;	chr1:147332085	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.518	rs72692968	ENSG00000278811.3	LINC00624	4.37	1.85e-05	0.00787	0.29	0.28	Protein quantitative trait loci;	chr1:147332884	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.518	rs72692970	ENSG00000278811.3	LINC00624	4.37	1.85e-05	0.00787	0.29	0.28	Protein quantitative trait loci;	chr1:147332887	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692971	ENSG00000278811.3	LINC00624	4.37	1.85e-05	0.00787	0.29	0.28	Protein quantitative trait loci;	chr1:147333088	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692973	ENSG00000278811.3	LINC00624	4.37	1.85e-05	0.00787	0.29	0.28	Protein quantitative trait loci;	chr1:147333281	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692975	ENSG00000278811.3	LINC00624	4.37	1.85e-05	0.00787	0.29	0.28	Protein quantitative trait loci;	chr1:147333506	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs4950409	ENSG00000278811.3	LINC00624	4.37	1.85e-05	0.00787	0.29	0.28	Protein quantitative trait loci;	chr1:147335879	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692980	ENSG00000278811.3	LINC00624	4.37	1.85e-05	0.00787	0.29	0.28	Protein quantitative trait loci;	chr1:147337830	chr1:147258885~147517875:-
SARC	cis	rs801193	0.66	rs1016265	ENSG00000232559.3	GS1-124K5.12	4.37	1.86e-05	0.00787	0.31	0.28	Aortic root size;	chr7:66749580	chr7:66554588~66576923:-
SARC	cis	rs7772486	0.764	rs2265471	ENSG00000270638.1	RP3-466P17.1	4.37	1.86e-05	0.00787	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145735570~145737218:+
SARC	cis	rs801193	1	rs2659909	ENSG00000236529.1	RP13-254B10.1	4.37	1.86e-05	0.00787	0.28	0.28	Aortic root size;	chr7:66695292	chr7:65840212~65840596:+
SARC	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-4.37	1.86e-05	0.00788	-0.43	-0.28	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
SARC	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	4.37	1.86e-05	0.00788	0.37	0.28	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
SARC	cis	rs172166	0.694	rs536704	ENSG00000272009.1	RP1-313I6.12	-4.37	1.86e-05	0.00788	-0.31	-0.28	Cardiac Troponin-T levels;	chr6:28124825	chr6:28078792~28081130:-
SARC	cis	rs603446	0.583	rs180377	ENSG00000254851.1	RP11-109L13.1	-4.37	1.86e-05	0.00788	-0.3	-0.28	Triglycerides;	chr11:116718411	chr11:117135528~117138582:+
SARC	cis	rs7267979	1	rs6083804	ENSG00000276952.1	RP5-965G21.6	-4.37	1.86e-05	0.00788	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6076336	ENSG00000276952.1	RP5-965G21.6	-4.37	1.86e-05	0.00788	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25284915~25285588:-
SARC	cis	rs7615952	0.932	rs6438948	ENSG00000241288.6	RP11-379B18.5	4.37	1.86e-05	0.00788	0.35	0.28	Blood pressure (smoking interaction);	chr3:125931202	chr3:125827238~125916384:-
SARC	cis	rs5769707	0.681	rs2319346	ENSG00000235111.1	RP1-29C18.8	-4.37	1.86e-05	0.00789	-0.36	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49612657~49615716:-
SARC	cis	rs7299940	0.967	rs9738957	ENSG00000256250.1	RP11-989F5.1	4.37	1.86e-05	0.00789	0.28	0.28	Panic disorder;	chr12:130904256	chr12:130810606~130812438:+
SARC	cis	rs1881744	0.588	rs78808618	ENSG00000274902.1	RP1-197B17.4	4.37	1.86e-05	0.0079	0.54	0.28	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47731908~47732351:+
SARC	cis	rs7809950	0.678	rs2395869	ENSG00000238832.1	snoU109	-4.37	1.86e-05	0.0079	-0.33	-0.28	Coronary artery disease;	chr7:107299653	chr7:107603363~107603507:+
SARC	cis	rs853679	0.599	rs188015	ENSG00000216901.1	AL022393.7	4.37	1.86e-05	0.00791	0.59	0.28	Depression;	chr6:27909668	chr6:28176188~28176674:+
SARC	cis	rs7267979	1	rs2482911	ENSG00000276952.1	RP5-965G21.6	-4.37	1.87e-05	0.00792	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25284915~25285588:-
SARC	cis	rs172166	0.611	rs203883	ENSG00000272009.1	RP1-313I6.12	-4.37	1.87e-05	0.00792	-0.31	-0.28	Cardiac Troponin-T levels;	chr6:28110578	chr6:28078792~28081130:-
SARC	cis	rs172166	0.611	rs203882	ENSG00000272009.1	RP1-313I6.12	-4.37	1.87e-05	0.00792	-0.31	-0.28	Cardiac Troponin-T levels;	chr6:28110724	chr6:28078792~28081130:-
SARC	cis	rs172166	0.694	rs1770131	ENSG00000272009.1	RP1-313I6.12	-4.37	1.87e-05	0.00792	-0.31	-0.28	Cardiac Troponin-T levels;	chr6:28118635	chr6:28078792~28081130:-
SARC	cis	rs7267979	0.966	rs2263204	ENSG00000276952.1	RP5-965G21.6	-4.37	1.87e-05	0.00792	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25284915~25285588:-
SARC	cis	rs72945132	0.882	rs6592537	ENSG00000254604.1	AP000487.6	-4.37	1.87e-05	0.00792	-0.39	-0.28	Coronary artery disease;	chr11:70326869	chr11:70282367~70363368:-
SARC	cis	rs7662987	0.793	rs78790289	ENSG00000272777.1	RP11-571L19.8	4.37	1.87e-05	0.00793	0.33	0.28	Smoking initiation;	chr4:99066736	chr4:99067256~99068125:-
SARC	cis	rs4664293	0.51	rs12469374	ENSG00000226266.5	AC009961.3	4.37	1.87e-05	0.00793	0.34	0.28	Monocyte percentage of white cells;	chr2:159720393	chr2:159670708~159712435:-
SARC	cis	rs6570726	0.791	rs436156	ENSG00000270638.1	RP3-466P17.1	4.37	1.87e-05	0.00794	0.22	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145735570~145737218:+
SARC	cis	rs9902453	0.868	rs7212162	ENSG00000264538.5	SUZ12P1	4.37	1.87e-05	0.00794	0.19	0.28	Coffee consumption (cups per day);	chr17:29994310	chr17:30709299~30790908:+
SARC	cis	rs9309473	0.687	rs6706409	ENSG00000163016.8	ALMS1P	-4.37	1.88e-05	0.00795	-0.33	-0.28	Metabolite levels;	chr2:73379380	chr2:73644919~73685576:+
SARC	cis	rs783540	0.774	rs28415133	ENSG00000275695.1	UBE2Q2P6	-4.37	1.88e-05	0.00795	-0.27	-0.28	Schizophrenia;	chr15:82595963	chr15:82445719~82454837:+
SARC	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-4.37	1.88e-05	0.00795	-0.27	-0.28	Height;	chr3:53069965	chr3:53064283~53065091:-
SARC	cis	rs910316	1	rs10136948	ENSG00000279594.1	RP11-950C14.10	4.37	1.88e-05	0.00796	0.3	0.28	Height;	chr14:75044372	chr14:75011269~75012851:-
SARC	cis	rs6570726	0.791	rs952406	ENSG00000235652.6	RP11-545I5.3	4.37	1.88e-05	0.00796	0.25	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145799409~145886585:+
SARC	cis	rs72945132	0.882	rs72945194	ENSG00000254604.1	AP000487.6	-4.37	1.88e-05	0.00796	-0.39	-0.28	Coronary artery disease;	chr11:70292515	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs72947012	ENSG00000254604.1	AP000487.6	-4.37	1.88e-05	0.00796	-0.39	-0.28	Coronary artery disease;	chr11:70303366	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.714	rs115143889	ENSG00000254604.1	AP000487.6	-4.37	1.88e-05	0.00796	-0.39	-0.28	Coronary artery disease;	chr11:70304016	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs56368270	ENSG00000254604.1	AP000487.6	-4.37	1.88e-05	0.00796	-0.39	-0.28	Coronary artery disease;	chr11:70316484	chr11:70282367~70363368:-
SARC	cis	rs380904	0.519	rs10102146	ENSG00000254859.1	RP11-661A12.5	4.37	1.88e-05	0.00796	0.43	0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr8:143541973~143549729:-
SARC	cis	rs7267979	1	rs7018	ENSG00000276952.1	RP5-965G21.6	4.37	1.88e-05	0.00797	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25284915~25285588:-
SARC	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	4.37	1.89e-05	0.00797	0.3	0.28	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
SARC	cis	rs7811142	1	rs2897358	ENSG00000078319.8	PMS2P1	-4.37	1.89e-05	0.00797	-0.39	-0.28	Platelet count;	chr7:100491017	chr7:100320992~100341908:-
SARC	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-4.37	1.89e-05	0.00797	-0.29	-0.28	Height;	chr3:52977358	chr3:53064283~53065091:-
SARC	cis	rs7267979	1	rs2258879	ENSG00000276952.1	RP5-965G21.6	4.37	1.89e-05	0.00797	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2257496	ENSG00000276952.1	RP5-965G21.6	4.37	1.89e-05	0.00797	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2258884	ENSG00000276952.1	RP5-965G21.6	4.37	1.89e-05	0.00797	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2259837	ENSG00000276952.1	RP5-965G21.6	4.37	1.89e-05	0.00797	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2259873	ENSG00000276952.1	RP5-965G21.6	4.37	1.89e-05	0.00797	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs11100	ENSG00000276952.1	RP5-965G21.6	4.37	1.89e-05	0.00797	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs1046073	ENSG00000276952.1	RP5-965G21.6	4.37	1.89e-05	0.00797	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2259926	ENSG00000276952.1	RP5-965G21.6	4.37	1.89e-05	0.00797	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2259928	ENSG00000276952.1	RP5-965G21.6	4.37	1.89e-05	0.00797	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2259956	ENSG00000276952.1	RP5-965G21.6	4.37	1.89e-05	0.00797	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25284915~25285588:-
SARC	cis	rs17508449	0.865	rs75419513	ENSG00000232450.1	RP4-730K3.3	-4.37	1.89e-05	0.00798	-0.35	-0.28	Leprosy;	chr1:113590174	chr1:113698884~113699631:-
SARC	cis	rs910316	0.737	rs175080	ENSG00000279594.1	RP11-950C14.10	-4.37	1.89e-05	0.00798	-0.31	-0.28	Height;	chr14:75047125	chr14:75011269~75012851:-
SARC	cis	rs13126694	0.778	rs6814979	ENSG00000248429.4	RP11-597D13.9	-4.37	1.89e-05	0.00798	-0.26	-0.28	Blood osmolality (transformed sodium);	chr4:158135798	chr4:158170752~158202877:+
SARC	cis	rs2179367	0.632	rs9498321	ENSG00000231760.4	RP11-350J20.5	4.37	1.89e-05	0.00798	0.37	0.28	Dupuytren's disease;	chr6:149322573	chr6:149796151~149826294:-
SARC	cis	rs7772486	0.72	rs1890171	ENSG00000270638.1	RP3-466P17.1	-4.37	1.89e-05	0.00799	-0.22	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.72	rs4896844	ENSG00000270638.1	RP3-466P17.1	-4.37	1.89e-05	0.00799	-0.22	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145735570~145737218:+
SARC	cis	rs12220777	0.748	rs7920814	ENSG00000230091.5	TMEM254-AS1	4.37	1.89e-05	0.008	0.39	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80095713	chr10:80046860~80078912:-
SARC	cis	rs4835473	0.9	rs935732	ENSG00000251600.4	RP11-673E1.1	-4.37	1.89e-05	0.008	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143759164	chr4:143912331~143982454:+
SARC	cis	rs2439831	0.867	rs12323999	ENSG00000275601.1	AC011330.13	-4.37	1.89e-05	0.008	-0.42	-0.28	Lung cancer in ever smokers;	chr15:43390917	chr15:43642389~43643023:-
SARC	cis	rs526231	0.726	rs35800	ENSG00000175749.11	EIF3KP1	4.37	1.89e-05	0.008	0.35	0.28	Primary biliary cholangitis;	chr5:103272980	chr5:103032376~103033031:+
SARC	cis	rs4835473	0.932	rs6537183	ENSG00000251600.4	RP11-673E1.1	-4.37	1.89e-05	0.008	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143770441	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs12512202	ENSG00000251600.4	RP11-673E1.1	-4.37	1.89e-05	0.008	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143771248	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs6843671	ENSG00000251600.4	RP11-673E1.1	-4.37	1.89e-05	0.008	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143772041	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs35395070	ENSG00000251600.4	RP11-673E1.1	-4.37	1.89e-05	0.008	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143772283	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs34614750	ENSG00000251600.4	RP11-673E1.1	-4.37	1.89e-05	0.008	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143772369	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs35002497	ENSG00000251600.4	RP11-673E1.1	-4.37	1.89e-05	0.008	-0.27	-0.28	Immature fraction of reticulocytes;	chr4:143772952	chr4:143912331~143982454:+
SARC	cis	rs7615952	0.609	rs13088451	ENSG00000241288.6	RP11-379B18.5	-4.37	1.9e-05	0.00801	-0.33	-0.28	Blood pressure (smoking interaction);	chr3:125834656	chr3:125827238~125916384:-
SARC	cis	rs7772486	0.776	rs2265467	ENSG00000270638.1	RP3-466P17.1	4.37	1.9e-05	0.00802	0.23	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145897203	chr6:145735570~145737218:+
SARC	cis	rs9309473	0.607	rs1851546	ENSG00000163016.8	ALMS1P	4.37	1.9e-05	0.00803	0.34	0.28	Metabolite levels;	chr2:73363999	chr2:73644919~73685576:+
SARC	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	4.37	1.9e-05	0.00803	0.34	0.28	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
SARC	cis	rs7267979	0.966	rs2500417	ENSG00000276952.1	RP5-965G21.6	-4.37	1.9e-05	0.00803	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25284915~25285588:-
SARC	cis	rs9473147	0.516	rs4715018	ENSG00000270761.1	RP11-385F7.1	-4.37	1.9e-05	0.00803	-0.34	-0.28	Platelet distribution width;Mean platelet volume;	chr6:47474135	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs1931837	ENSG00000270761.1	RP11-385F7.1	-4.37	1.9e-05	0.00803	-0.34	-0.28	Platelet distribution width;Mean platelet volume;	chr6:47474641	chr6:47477243~47477572:-
SARC	cis	rs9902453	0.765	rs34585141	ENSG00000264538.5	SUZ12P1	-4.37	1.9e-05	0.00804	-0.19	-0.27	Coffee consumption (cups per day);	chr17:30009414	chr17:30709299~30790908:+
SARC	cis	rs6570726	0.791	rs436498	ENSG00000270638.1	RP3-466P17.1	4.37	1.9e-05	0.00804	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145735570~145737218:+
SARC	cis	rs853679	0.825	rs8180562	ENSG00000219392.1	RP1-265C24.5	-4.37	1.9e-05	0.00804	-0.53	-0.27	Depression;	chr6:28173682	chr6:28115628~28116551:+
SARC	cis	rs853679	0.882	rs9380064	ENSG00000219392.1	RP1-265C24.5	-4.37	1.9e-05	0.00804	-0.53	-0.27	Depression;	chr6:28175340	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	4.37	1.91e-05	0.00805	0.26	0.27	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
SARC	cis	rs2033711	0.84	rs3764533	ENSG00000269473.1	CTD-2619J13.19	4.37	1.91e-05	0.00805	0.31	0.27	Uric acid clearance;	chr19:58417827	chr19:58440448~58445849:+
SARC	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	4.37	1.91e-05	0.00806	0.32	0.27	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
SARC	cis	rs240993	0.715	rs4947122	ENSG00000230177.1	RP5-1112D6.4	-4.36	1.91e-05	0.00807	-0.31	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111548887	chr6:111277932~111278742:+
SARC	cis	rs783540	0.967	rs783529	ENSG00000275695.1	UBE2Q2P6	-4.36	1.92e-05	0.00808	-0.28	-0.27	Schizophrenia;	chr15:82599231	chr15:82445719~82454837:+
SARC	cis	rs7267979	1	rs6050542	ENSG00000276952.1	RP5-965G21.6	-4.36	1.92e-05	0.00808	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25284915~25285588:-
SARC	cis	rs4934494	0.727	rs55823491	ENSG00000240996.1	RP11-80H5.7	-4.36	1.92e-05	0.00808	-0.3	-0.27	Red blood cell count;	chr10:89757598	chr10:89694295~89697928:-
SARC	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	4.36	1.92e-05	0.00808	0.29	0.27	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
SARC	cis	rs62388641	0.547	rs2317966	ENSG00000272279.1	RP11-157J24.2	-4.36	1.92e-05	0.00809	-0.35	-0.27	Daytime sleep phenotypes;	chr6:1550651	chr6:1528364~1528911:-
SARC	cis	rs7809950	0.731	rs4730238	ENSG00000238832.1	snoU109	-4.36	1.92e-05	0.00809	-0.33	-0.27	Coronary artery disease;	chr7:107414342	chr7:107603363~107603507:+
SARC	cis	rs12549025	0.836	rs11778179	ENSG00000253390.1	CTC-756D1.2	4.36	1.92e-05	0.0081	0.45	0.27	Reticulocyte fraction of red cells;	chr8:23558142	chr8:23458601~23484971:+
SARC	cis	rs61160187	0.582	rs1382917	ENSG00000215032.2	GNL3LP1	4.36	1.92e-05	0.0081	0.27	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956668	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.549	rs56031340	ENSG00000215032.2	GNL3LP1	4.36	1.92e-05	0.0081	0.27	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60958043	chr5:60891935~60893577:-
SARC	cis	rs910316	1	rs3742780	ENSG00000279594.1	RP11-950C14.10	4.36	1.92e-05	0.0081	0.31	0.27	Height;	chr14:75038305	chr14:75011269~75012851:-
SARC	cis	rs6842047	1	rs4862668	ENSG00000272218.1	RP11-11N5.3	4.36	1.92e-05	0.0081	0.41	0.27	Blood protein levels;	chr4:186215289	chr4:186892552~186892983:+
SARC	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	4.36	1.92e-05	0.00811	0.27	0.27	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
SARC	cis	rs7615952	0.512	rs4234285	ENSG00000171084.14	FAM86JP	4.36	1.92e-05	0.00811	0.4	0.27	Blood pressure (smoking interaction);	chr3:125685633	chr3:125916620~125930024:+
SARC	cis	rs2803122	0.84	rs10757036	ENSG00000273226.1	RP11-513M16.8	-4.36	1.92e-05	0.00811	-0.26	-0.27	Pulse pressure;	chr9:19236127	chr9:19375451~19375996:+
SARC	cis	rs2404602	0.583	rs35707798	ENSG00000259422.1	RP11-593F23.1	4.36	1.92e-05	0.00811	0.3	0.27	Blood metabolite levels;	chr15:76272685	chr15:76174891~76181486:-
SARC	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-4.36	1.92e-05	0.00811	-0.31	-0.27	QT interval;	chr16:28845498	chr16:28700294~28701540:-
SARC	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-4.36	1.93e-05	0.00812	-0.52	-0.27	Gout;	chr7:66654674	chr7:66654538~66669855:+
SARC	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-4.36	1.93e-05	0.00812	-0.52	-0.27	Gout;	chr7:66661502	chr7:66654538~66669855:+
SARC	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-4.36	1.93e-05	0.00812	-0.32	-0.27	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
SARC	cis	rs2439831	1	rs471229	ENSG00000275601.1	AC011330.13	-4.36	1.93e-05	0.00812	-0.43	-0.27	Lung cancer in ever smokers;	chr15:43441796	chr15:43642389~43643023:-
SARC	cis	rs2439831	1	rs2439841	ENSG00000275601.1	AC011330.13	-4.36	1.93e-05	0.00812	-0.43	-0.27	Lung cancer in ever smokers;	chr15:43442551	chr15:43642389~43643023:-
SARC	cis	rs10515750	0.643	rs10054755	ENSG00000251405.2	CTB-109A12.1	4.36	1.93e-05	0.00813	0.35	0.27	Lung function (FEV1/FVC);	chr5:157384037	chr5:157362615~157460078:-
SARC	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-4.36	1.93e-05	0.00813	-0.3	-0.27	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
SARC	cis	rs7267979	0.899	rs2104734	ENSG00000276952.1	RP5-965G21.6	4.36	1.93e-05	0.00813	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25284915~25285588:-
SARC	cis	rs910316	0.81	rs77939209	ENSG00000279594.1	RP11-950C14.10	-4.36	1.93e-05	0.00813	-0.3	-0.27	Height;	chr14:75203367	chr14:75011269~75012851:-
SARC	cis	rs6570726	0.599	rs9403725	ENSG00000235652.6	RP11-545I5.3	-4.36	1.93e-05	0.00813	-0.28	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145799409~145886585:+
SARC	cis	rs1707322	0.789	rs10789473	ENSG00000281133.1	AL355480.3	-4.36	1.93e-05	0.00814	-0.31	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45580892~45580996:-
SARC	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-4.36	1.93e-05	0.00814	-0.32	-0.27	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
SARC	cis	rs524281	0.731	rs2430979	ENSG00000255320.1	RP11-755F10.1	-4.36	1.93e-05	0.00814	-0.42	-0.27	Electroencephalogram traits;	chr11:66045912	chr11:66244840~66246239:-
SARC	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	4.36	1.93e-05	0.00815	0.37	0.27	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
SARC	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	4.36	1.94e-05	0.00815	0.29	0.27	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	4.36	1.94e-05	0.00815	0.29	0.27	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
SARC	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-4.36	1.94e-05	0.00815	-0.29	-0.27	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
SARC	cis	rs2280018	0.963	rs12928424	ENSG00000260735.1	RP11-72I8.1	-4.36	1.94e-05	0.00816	-0.23	-0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15094411~15109197:+
SARC	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-4.36	1.94e-05	0.00816	-0.26	-0.27	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
SARC	cis	rs7829975	0.511	rs2955578	ENSG00000253893.2	FAM85B	-4.36	1.94e-05	0.00816	-0.25	-0.27	Mood instability;	chr8:8279561	chr8:8167819~8226614:-
SARC	cis	rs7826238	0.653	rs2979202	ENSG00000253981.4	ALG1L13P	4.36	1.94e-05	0.00816	0.26	0.27	Systolic blood pressure;	chr8:8486617	chr8:8236003~8244667:-
SARC	cis	rs7267979	1	rs7267979	ENSG00000276952.1	RP5-965G21.6	4.36	1.94e-05	0.00817	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25284915~25285588:-
SARC	cis	rs131805	0.794	rs131813	ENSG00000205559.3	CHKB-AS1	-4.36	1.94e-05	0.00817	-0.34	-0.27	Granulocyte percentage of myeloid white cells;	chr22:50522740	chr22:50583026~50583877:+
SARC	cis	rs72945132	0.825	rs58532402	ENSG00000254604.1	AP000487.6	-4.36	1.94e-05	0.00817	-0.38	-0.27	Coronary artery disease;	chr11:70343385	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs3781648	ENSG00000254604.1	AP000487.6	-4.36	1.94e-05	0.00817	-0.38	-0.27	Coronary artery disease;	chr11:70343952	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.769	rs3781644	ENSG00000254604.1	AP000487.6	-4.36	1.94e-05	0.00817	-0.38	-0.27	Coronary artery disease;	chr11:70344269	chr11:70282367~70363368:-
SARC	cis	rs801193	1	rs10252765	ENSG00000236529.1	RP13-254B10.1	4.36	1.94e-05	0.00817	0.29	0.27	Aortic root size;	chr7:66763745	chr7:65840212~65840596:+
SARC	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	4.36	1.94e-05	0.00817	0.23	0.27	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
SARC	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	4.36	1.94e-05	0.00817	0.26	0.27	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
SARC	cis	rs7615952	0.866	rs1976459	ENSG00000241288.6	RP11-379B18.5	-4.36	1.94e-05	0.00817	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125928643	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.673	rs3811677	ENSG00000241288.6	RP11-379B18.5	-4.36	1.94e-05	0.00817	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125929237	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.932	rs3811679	ENSG00000241288.6	RP11-379B18.5	-4.36	1.94e-05	0.00817	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125929440	chr3:125827238~125916384:-
SARC	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-4.36	1.94e-05	0.00818	-0.4	-0.27	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-4.36	1.94e-05	0.00818	-0.4	-0.27	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-4.36	1.94e-05	0.00818	-0.4	-0.27	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-4.36	1.94e-05	0.00818	-0.4	-0.27	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
SARC	cis	rs7131987	0.65	rs10843384	ENSG00000257176.2	RP11-996F15.2	-4.36	1.94e-05	0.00818	-0.32	-0.27	QT interval;	chr12:29319476	chr12:29280418~29317848:-
SARC	cis	rs7131987	0.65	rs11050188	ENSG00000257176.2	RP11-996F15.2	-4.36	1.94e-05	0.00818	-0.32	-0.27	QT interval;	chr12:29320175	chr12:29280418~29317848:-
SARC	cis	rs7131987	0.683	rs12366505	ENSG00000257176.2	RP11-996F15.2	-4.36	1.94e-05	0.00818	-0.32	-0.27	QT interval;	chr12:29321177	chr12:29280418~29317848:-
SARC	cis	rs7131987	0.65	rs12366527	ENSG00000257176.2	RP11-996F15.2	-4.36	1.94e-05	0.00818	-0.32	-0.27	QT interval;	chr12:29321323	chr12:29280418~29317848:-
SARC	cis	rs7131987	0.65	rs7311912	ENSG00000257176.2	RP11-996F15.2	-4.36	1.94e-05	0.00818	-0.32	-0.27	QT interval;	chr12:29322770	chr12:29280418~29317848:-
SARC	cis	rs12049351	0.774	rs1053512	ENSG00000229367.1	HMGN2P19	4.36	1.94e-05	0.00818	0.24	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229516951	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs12138176	ENSG00000229367.1	HMGN2P19	4.36	1.94e-05	0.00818	0.24	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229522155	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs12022203	ENSG00000229367.1	HMGN2P19	4.36	1.94e-05	0.00818	0.24	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229523050	chr1:229570532~229570796:+
SARC	cis	rs30380	0.586	rs28119	ENSG00000272109.1	CTD-2260A17.3	-4.36	1.94e-05	0.00818	-0.35	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96796030	chr5:96804353~96806105:+
SARC	cis	rs30380	0.632	rs26491	ENSG00000272109.1	CTD-2260A17.3	-4.36	1.94e-05	0.00818	-0.35	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96798410	chr5:96804353~96806105:+
SARC	cis	rs7615952	0.599	rs6438953	ENSG00000250012.1	RP11-124N2.1	-4.36	1.95e-05	0.00818	-0.25	-0.27	Blood pressure (smoking interaction);	chr3:126006108	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.599	rs1044215	ENSG00000250012.1	RP11-124N2.1	-4.36	1.95e-05	0.00818	-0.25	-0.27	Blood pressure (smoking interaction);	chr3:126006716	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.599	rs6438955	ENSG00000250012.1	RP11-124N2.1	-4.36	1.95e-05	0.00818	-0.25	-0.27	Blood pressure (smoking interaction);	chr3:126011490	chr3:126084220~126095349:+
SARC	cis	rs9902453	0.933	rs9303628	ENSG00000264538.5	SUZ12P1	4.36	1.95e-05	0.00818	0.19	0.27	Coffee consumption (cups per day);	chr17:30200210	chr17:30709299~30790908:+
SARC	cis	rs6425521	0.66	rs9425824	ENSG00000213060.4	RP4-612B18.3	4.36	1.95e-05	0.00819	0.5	0.27	Platelet count;	chr1:171915030	chr1:171803517~171803939:+
SARC	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	4.36	1.95e-05	0.00819	0.25	0.27	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
SARC	cis	rs7216064	0.684	rs7406031	ENSG00000237854.3	LINC00674	-4.36	1.95e-05	0.00819	-0.32	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68025637	chr17:68101908~68115518:+
SARC	cis	rs2933343	0.729	rs6767104	ENSG00000231305.3	RP11-723O4.2	-4.36	1.95e-05	0.0082	-0.28	-0.27	IgG glycosylation;	chr3:128929274	chr3:128861313~128871540:-
SARC	cis	rs17508449	0.865	rs80348557	ENSG00000232450.1	RP4-730K3.3	-4.36	1.95e-05	0.0082	-0.35	-0.27	Leprosy;	chr1:113608494	chr1:113698884~113699631:-
SARC	cis	rs3805389	0.504	rs1873090	ENSG00000273257.1	RP11-177J6.1	-4.36	1.95e-05	0.0082	-0.41	-0.27	Waist-to-hip ratio adjusted for body mass index;	chr4:55605237	chr4:55387949~55388271:+
SARC	cis	rs4950322	0.57	rs17160051	ENSG00000278811.3	LINC00624	4.36	1.95e-05	0.0082	0.29	0.27	Protein quantitative trait loci;	chr1:147255733	chr1:147258885~147517875:-
SARC	cis	rs7809950	0.678	rs4730235	ENSG00000238832.1	snoU109	-4.36	1.95e-05	0.0082	-0.33	-0.27	Coronary artery disease;	chr7:107382061	chr7:107603363~107603507:+
SARC	cis	rs801193	0.636	rs10233806	ENSG00000232559.3	GS1-124K5.12	-4.36	1.95e-05	0.0082	-0.31	-0.27	Aortic root size;	chr7:66653261	chr7:66554588~66576923:-
SARC	cis	rs524281	1	rs524281	ENSG00000255320.1	RP11-755F10.1	-4.36	1.95e-05	0.00821	-0.37	-0.27	Electroencephalogram traits;	chr11:66119191	chr11:66244840~66246239:-
SARC	cis	rs9902453	0.904	rs9905638	ENSG00000264538.5	SUZ12P1	4.36	1.95e-05	0.00821	0.19	0.27	Coffee consumption (cups per day);	chr17:29934004	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs7208579	ENSG00000264538.5	SUZ12P1	4.36	1.95e-05	0.00821	0.19	0.27	Coffee consumption (cups per day);	chr17:29936049	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.874	rs62070271	ENSG00000264538.5	SUZ12P1	4.36	1.95e-05	0.00821	0.19	0.27	Coffee consumption (cups per day);	chr17:29941340	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs4567782	ENSG00000264538.5	SUZ12P1	4.36	1.95e-05	0.00821	0.19	0.27	Coffee consumption (cups per day);	chr17:29941782	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs9894893	ENSG00000264538.5	SUZ12P1	4.36	1.95e-05	0.00821	0.19	0.27	Coffee consumption (cups per day);	chr17:29943332	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.935	rs9909093	ENSG00000264538.5	SUZ12P1	4.36	1.95e-05	0.00821	0.19	0.27	Coffee consumption (cups per day);	chr17:29944189	chr17:30709299~30790908:+
SARC	cis	rs875971	0.666	rs13242072	ENSG00000236529.1	RP13-254B10.1	-4.36	1.95e-05	0.00821	-0.29	-0.27	Aortic root size;	chr7:66301001	chr7:65840212~65840596:+
SARC	cis	rs2179367	0.887	rs506268	ENSG00000216906.2	RP11-350J20.9	4.36	1.95e-05	0.00821	0.25	0.27	Dupuytren's disease;	chr6:149364481	chr6:149904243~149906418:+
SARC	cis	rs7216064	0.531	rs62084683	ENSG00000237854.3	LINC00674	-4.36	1.95e-05	0.00821	-0.31	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68035609	chr17:68101908~68115518:+
SARC	cis	rs875971	0.54	rs781152	ENSG00000236529.1	RP13-254B10.1	4.36	1.95e-05	0.00821	0.28	0.27	Aortic root size;	chr7:66014585	chr7:65840212~65840596:+
SARC	cis	rs17711722	0.727	rs781151	ENSG00000236529.1	RP13-254B10.1	4.36	1.95e-05	0.00821	0.28	0.27	Calcium levels;	chr7:66014891	chr7:65840212~65840596:+
SARC	cis	rs72945132	0.882	rs12294540	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70272867	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.66	rs67433166	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70275498	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.607	rs67767222	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70275504	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs67244582	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70275903	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.825	rs12287883	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70276263	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs55905028	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70281644	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs67927691	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70282680	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs56770826	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70282768	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs72945168	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70285365	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs12295111	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70285776	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs12289915	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70285850	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs4261311	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70286796	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs7943547	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70287176	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs12278125	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70287910	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs7928686	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70288422	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs59398290	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70288713	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs12278741	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70289636	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.769	rs11235754	ENSG00000254604.1	AP000487.6	-4.36	1.96e-05	0.00821	-0.38	-0.27	Coronary artery disease;	chr11:70289986	chr11:70282367~70363368:-
SARC	cis	rs577676	0.564	rs619699	ENSG00000271811.1	RP1-79C4.4	4.36	1.96e-05	0.00822	0.39	0.27	Prevalent atrial fibrillation;	chr1:170648238	chr1:170667381~170669425:+
SARC	cis	rs7560272	0.564	rs4852939	ENSG00000163016.8	ALMS1P	4.36	1.96e-05	0.00822	0.31	0.27	Schizophrenia;	chr2:73629642	chr2:73644919~73685576:+
SARC	cis	rs853679	0.55	rs1233701	ENSG00000272009.1	RP1-313I6.12	4.36	1.96e-05	0.00822	0.3	0.27	Depression;	chr6:28200948	chr6:28078792~28081130:-
SARC	cis	rs4835473	0.9	rs10003922	ENSG00000251600.4	RP11-673E1.1	-4.36	1.96e-05	0.00822	-0.28	-0.27	Immature fraction of reticulocytes;	chr4:143921235	chr4:143912331~143982454:+
SARC	cis	rs597539	0.615	rs629426	ENSG00000250508.1	RP11-757G1.6	-4.36	1.96e-05	0.00822	-0.32	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68870664~68874542:+
SARC	cis	rs324126	0.78	rs62108319	ENSG00000269834.4	ZNF528-AS1	4.36	1.96e-05	0.00822	0.29	0.27	Colonoscopy-negative controls vs population controls;	chr19:52380577	chr19:52388842~52397766:-
SARC	cis	rs4934494	0.768	rs1926139	ENSG00000240996.1	RP11-80H5.7	-4.36	1.96e-05	0.00822	-0.3	-0.27	Red blood cell count;	chr10:89753395	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.727	rs12570750	ENSG00000240996.1	RP11-80H5.7	-4.36	1.96e-05	0.00822	-0.3	-0.27	Red blood cell count;	chr10:89761273	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.723	rs17127001	ENSG00000240996.1	RP11-80H5.7	-4.36	1.96e-05	0.00822	-0.3	-0.27	Red blood cell count;	chr10:89762932	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.727	rs36019294	ENSG00000240996.1	RP11-80H5.7	-4.36	1.96e-05	0.00822	-0.3	-0.27	Red blood cell count;	chr10:89777822	chr10:89694295~89697928:-
SARC	cis	rs42490	0.868	rs1605996	ENSG00000251136.7	RP11-37B2.1	4.36	1.96e-05	0.00822	0.3	0.27	Leprosy;	chr8:89655674	chr8:89609409~89757727:-
SARC	cis	rs11123170	0.529	rs35606997	ENSG00000189223.12	PAX8-AS1	-4.36	1.96e-05	0.00823	-0.38	-0.27	Renal function-related traits (BUN);	chr2:113215773	chr2:113211522~113276581:+
SARC	cis	rs783540	0.967	rs17158390	ENSG00000275695.1	UBE2Q2P6	-4.36	1.96e-05	0.00823	-0.27	-0.27	Schizophrenia;	chr15:82624277	chr15:82445719~82454837:+
SARC	cis	rs783540	0.967	rs2870966	ENSG00000275695.1	UBE2Q2P6	-4.36	1.96e-05	0.00823	-0.27	-0.27	Schizophrenia;	chr15:82626493	chr15:82445719~82454837:+
SARC	cis	rs193541	0.632	rs173481	ENSG00000263432.2	RN7SL689P	4.36	1.96e-05	0.00824	0.35	0.27	Glucose homeostasis traits;	chr5:122918857	chr5:123022487~123022783:-
SARC	cis	rs193541	0.632	rs430069	ENSG00000263432.2	RN7SL689P	4.36	1.96e-05	0.00824	0.35	0.27	Glucose homeostasis traits;	chr5:122927656	chr5:123022487~123022783:-
SARC	cis	rs7216064	0.636	rs62084696	ENSG00000278740.1	RP11-147L13.14	-4.36	1.96e-05	0.00825	-0.29	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68042065	chr17:68188547~68189165:+
SARC	cis	rs2439831	1	rs2467426	ENSG00000275601.1	AC011330.13	-4.36	1.96e-05	0.00825	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43697320	chr15:43642389~43643023:-
SARC	cis	rs8005677	0.798	rs61977741	ENSG00000279656.1	RP11-298I3.6	4.36	1.97e-05	0.00825	0.36	0.27	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:23023083~23024217:-
SARC	cis	rs72945132	0.882	rs67283107	ENSG00000254604.1	AP000487.6	-4.36	1.97e-05	0.00825	-0.38	-0.27	Coronary artery disease;	chr11:70375098	chr11:70282367~70363368:-
SARC	cis	rs7267979	1	rs10966	ENSG00000276952.1	RP5-965G21.6	4.36	1.97e-05	0.00825	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25284915~25285588:-
SARC	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	4.36	1.97e-05	0.00826	0.22	0.27	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
SARC	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-4.36	1.97e-05	0.00826	-0.38	-0.27	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
SARC	cis	rs4713118	0.614	rs9380007	ENSG00000216901.1	AL022393.7	4.36	1.97e-05	0.00826	0.34	0.27	Parkinson's disease;	chr6:27692729	chr6:28176188~28176674:+
SARC	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	4.36	1.97e-05	0.00826	0.29	0.27	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
SARC	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	4.36	1.97e-05	0.00826	0.32	0.27	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
SARC	cis	rs4835473	0.864	rs2323418	ENSG00000251600.4	RP11-673E1.1	4.36	1.97e-05	0.00827	0.27	0.27	Immature fraction of reticulocytes;	chr4:143969141	chr4:143912331~143982454:+
SARC	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-4.36	1.97e-05	0.00827	-0.35	-0.27	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
SARC	cis	rs7267979	0.966	rs6037097	ENSG00000276952.1	RP5-965G21.6	4.36	1.97e-05	0.00828	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25284915~25285588:-
SARC	cis	rs12049351	0.774	rs12024146	ENSG00000229367.1	HMGN2P19	4.36	1.97e-05	0.00828	0.24	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229525144	chr1:229570532~229570796:+
SARC	cis	rs4713118	0.662	rs149900	ENSG00000216901.1	AL022393.7	4.36	1.98e-05	0.00828	0.4	0.27	Parkinson's disease;	chr6:28046819	chr6:28176188~28176674:+
SARC	cis	rs11159086	0.938	rs11623040	ENSG00000270000.1	RP3-449M8.9	4.36	1.98e-05	0.00829	0.45	0.27	Advanced glycation end-product levels;	chr14:74496743	chr14:74471930~74472360:-
SARC	cis	rs42490	0.664	rs421411	ENSG00000251136.7	RP11-37B2.1	-4.36	1.98e-05	0.00829	-0.3	-0.27	Leprosy;	chr8:89808665	chr8:89609409~89757727:-
SARC	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-4.36	1.98e-05	0.00829	-0.31	-0.27	QT interval;	chr12:29287150	chr12:29280418~29317848:-
SARC	cis	rs57561814	0.51	rs1524107	ENSG00000179428.2	AC073072.5	-4.36	1.98e-05	0.00829	-0.49	-0.27	Tonsillectomy;	chr7:22728600	chr7:22725395~22727620:-
SARC	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-4.36	1.98e-05	0.00829	-0.25	-0.27	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-4.36	1.98e-05	0.00829	-0.25	-0.27	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
SARC	cis	rs4664293	0.647	rs6756502	ENSG00000226266.5	AC009961.3	4.36	1.98e-05	0.00829	0.31	0.27	Monocyte percentage of white cells;	chr2:159698072	chr2:159670708~159712435:-
SARC	cis	rs875971	0.66	rs10229345	ENSG00000236529.1	RP13-254B10.1	4.36	1.98e-05	0.00829	0.29	0.27	Aortic root size;	chr7:66517181	chr7:65840212~65840596:+
SARC	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	4.36	1.98e-05	0.0083	0.41	0.27	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
SARC	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-4.36	1.98e-05	0.00831	-0.28	-0.27	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
SARC	cis	rs6844153	1	rs74642474	ENSG00000240005.4	RP11-293A21.1	-4.36	1.98e-05	0.00831	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26854979	chr4:26859806~26860599:-
SARC	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	4.36	1.98e-05	0.00832	0.39	0.27	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
SARC	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	4.36	1.99e-05	0.00832	0.4	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
SARC	cis	rs2562456	0.793	rs2562474	ENSG00000268081.1	RP11-678G14.2	-4.36	1.99e-05	0.00832	-0.42	-0.27	Pain;	chr19:21463480	chr19:21554640~21569237:-
SARC	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	4.36	1.99e-05	0.00833	0.32	0.27	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
SARC	cis	rs853679	0.824	rs34712084	ENSG00000219392.1	RP1-265C24.5	-4.36	1.99e-05	0.00833	-0.54	-0.27	Depression;	chr6:28076050	chr6:28115628~28116551:+
SARC	cis	rs853679	0.824	rs1321505	ENSG00000219392.1	RP1-265C24.5	-4.36	1.99e-05	0.00833	-0.54	-0.27	Depression;	chr6:28085045	chr6:28115628~28116551:+
SARC	cis	rs2803122	0.934	rs10119618	ENSG00000273226.1	RP11-513M16.8	-4.36	1.99e-05	0.00833	-0.26	-0.27	Pulse pressure;	chr9:19251643	chr9:19375451~19375996:+
SARC	cis	rs7247513	0.964	rs12979795	ENSG00000213290.4	PGK1P2	4.36	1.99e-05	0.00834	0.32	0.27	Bipolar disorder;	chr19:12607033	chr19:12559571~12561105:+
SARC	cis	rs12922317	0.535	rs8051349	ENSG00000260488.1	RP11-166B2.7	-4.36	1.99e-05	0.00834	-0.3	-0.27	Schizophrenia;	chr16:12011666	chr16:11976851~11977850:-
SARC	cis	rs2562456	0.793	rs627522	ENSG00000268081.1	RP11-678G14.2	4.36	1.99e-05	0.00835	0.41	0.27	Pain;	chr19:21313002	chr19:21554640~21569237:-
SARC	cis	rs890448	0.93	rs10011201	ENSG00000254531.1	FLJ20021	-4.36	1.99e-05	0.00835	-0.27	-0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101470298	chr4:101347780~101348883:+
SARC	cis	rs4835473	0.932	rs17018200	ENSG00000251600.4	RP11-673E1.1	-4.36	1.99e-05	0.00835	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143760866	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs11100805	ENSG00000251600.4	RP11-673E1.1	-4.36	1.99e-05	0.00835	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143760979	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.868	rs56115009	ENSG00000251600.4	RP11-673E1.1	-4.36	1.99e-05	0.00835	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143761073	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs10857406	ENSG00000251600.4	RP11-673E1.1	-4.36	1.99e-05	0.00835	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143761216	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs10857407	ENSG00000251600.4	RP11-673E1.1	-4.36	1.99e-05	0.00835	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143761226	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs10857408	ENSG00000251600.4	RP11-673E1.1	-4.36	1.99e-05	0.00835	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143761333	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs10857409	ENSG00000251600.4	RP11-673E1.1	-4.36	1.99e-05	0.00835	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143761461	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs10857410	ENSG00000251600.4	RP11-673E1.1	-4.36	1.99e-05	0.00835	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143761566	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs10857411	ENSG00000251600.4	RP11-673E1.1	-4.36	1.99e-05	0.00835	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143761599	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1006406	ENSG00000251600.4	RP11-673E1.1	-4.36	1.99e-05	0.00835	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143761710	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1562776	ENSG00000251600.4	RP11-673E1.1	-4.36	1.99e-05	0.00835	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143761999	chr4:143912331~143982454:+
SARC	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-4.35	1.99e-05	0.00835	-0.3	-0.27	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-4.35	1.99e-05	0.00835	-0.3	-0.27	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-4.35	1.99e-05	0.00835	-0.3	-0.27	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
SARC	cis	rs10770857	0.53	rs10841876	ENSG00000164845.15	FAM86FP	-4.35	2e-05	0.00835	-0.32	-0.27	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8546384	chr12:8232512~8242948:-
SARC	cis	rs7216064	0.636	rs4638	ENSG00000237854.3	LINC00674	-4.35	2e-05	0.00835	-0.31	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043234	chr17:68101908~68115518:+
SARC	cis	rs7216064	0.601	rs35453056	ENSG00000237854.3	LINC00674	-4.35	2e-05	0.00835	-0.31	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043552	chr17:68101908~68115518:+
SARC	cis	rs7216064	0.628	rs62084702	ENSG00000237854.3	LINC00674	-4.35	2e-05	0.00835	-0.31	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68047041	chr17:68101908~68115518:+
SARC	cis	rs7809950	0.817	rs2807	ENSG00000238832.1	snoU109	4.35	2e-05	0.00836	0.33	0.27	Coronary artery disease;	chr7:107620333	chr7:107603363~107603507:+
SARC	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	4.35	2e-05	0.00836	0.51	0.27	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
SARC	cis	rs7772486	0.719	rs7753770	ENSG00000270638.1	RP3-466P17.1	-4.35	2e-05	0.00836	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145735570~145737218:+
SARC	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	4.35	2e-05	0.00836	0.26	0.27	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	4.35	2e-05	0.00836	0.26	0.27	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
SARC	cis	rs12893668	0.673	rs2296482	ENSG00000269940.1	RP11-73M18.7	4.35	2e-05	0.00837	0.28	0.27	Reticulocyte count;	chr14:103563482	chr14:103694560~103695170:+
SARC	cis	rs12893668	0.616	rs58033365	ENSG00000269940.1	RP11-73M18.7	4.35	2e-05	0.00837	0.28	0.27	Reticulocyte count;	chr14:103564564	chr14:103694560~103695170:+
SARC	cis	rs12893668	0.703	rs4906336	ENSG00000269940.1	RP11-73M18.7	4.35	2e-05	0.00837	0.28	0.27	Reticulocyte count;	chr14:103566928	chr14:103694560~103695170:+
SARC	cis	rs12893668	0.645	rs12889403	ENSG00000269940.1	RP11-73M18.7	4.35	2e-05	0.00837	0.28	0.27	Reticulocyte count;	chr14:103568409	chr14:103694560~103695170:+
SARC	cis	rs12893668	0.703	rs12894729	ENSG00000269940.1	RP11-73M18.7	4.35	2e-05	0.00837	0.28	0.27	Reticulocyte count;	chr14:103568955	chr14:103694560~103695170:+
SARC	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-4.35	2e-05	0.00838	-0.28	-0.27	Height;	chr3:52989619	chr3:53064283~53065091:-
SARC	cis	rs9902453	0.765	rs3102562	ENSG00000264538.5	SUZ12P1	4.35	2e-05	0.00838	0.19	0.27	Coffee consumption (cups per day);	chr17:29713385	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.765	rs3102555	ENSG00000264538.5	SUZ12P1	4.35	2e-05	0.00838	0.19	0.27	Coffee consumption (cups per day);	chr17:29717083	chr17:30709299~30790908:+
SARC	cis	rs319598	1	rs319601	ENSG00000224186.7	C5orf66	4.35	2e-05	0.00838	0.24	0.27	Type 2 diabetes;	chr5:134887477	chr5:135033280~135358219:+
SARC	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-4.35	2e-05	0.00839	-0.31	-0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
SARC	cis	rs9527	0.615	rs4919685	ENSG00000213061.2	PFN1P11	4.35	2.01e-05	0.00841	0.35	0.27	Arsenic metabolism;	chr10:102827605	chr10:102838011~102845473:-
SARC	cis	rs7726354	0.793	rs75433101	ENSG00000271828.1	CTD-2310F14.1	4.35	2.02e-05	0.00843	0.56	0.27	Breast cancer (early onset);	chr5:56706243	chr5:56927874~56929573:+
SARC	cis	rs858239	0.831	rs7796541	ENSG00000226816.2	AC005082.12	4.35	2.02e-05	0.00843	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23206013~23208045:+
SARC	cis	rs922692	0.696	rs1809420	ENSG00000261143.1	ADAMTS7P3	4.35	2.02e-05	0.00843	0.39	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78764427	chr15:77976042~77993057:+
SARC	cis	rs6560039	1	rs6560039	ENSG00000214888.2	XXyac-YM21GA2.7	-4.35	2.02e-05	0.00843	-0.34	-0.27	Gait variability;	chr9:87860031	chr9:87857015~87859399:-
SARC	cis	rs755249	0.517	rs56809193	ENSG00000182109.6	RP11-69E11.4	4.35	2.02e-05	0.00844	0.33	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39143626	chr1:39522280~39546187:-
SARC	cis	rs2933343	0.7	rs883602	ENSG00000231305.3	RP11-723O4.2	4.35	2.02e-05	0.00844	0.27	0.27	IgG glycosylation;	chr3:128935109	chr3:128861313~128871540:-
SARC	cis	rs4835473	0.932	rs1450236	ENSG00000251600.4	RP11-673E1.1	-4.35	2.02e-05	0.00844	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143783069	chr4:143912331~143982454:+
SARC	cis	rs7267979	1	rs6083828	ENSG00000276952.1	RP5-965G21.6	-4.35	2.02e-05	0.00844	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25284915~25285588:-
SARC	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	4.35	2.02e-05	0.00845	0.32	0.27	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
SARC	cis	rs783540	0.843	rs28374463	ENSG00000275695.1	UBE2Q2P6	-4.35	2.02e-05	0.00845	-0.28	-0.27	Schizophrenia;	chr15:82630613	chr15:82445719~82454837:+
SARC	cis	rs9902453	0.904	rs6505148	ENSG00000264538.5	SUZ12P1	4.35	2.02e-05	0.00845	0.19	0.27	Coffee consumption (cups per day);	chr17:29962800	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs4077465	ENSG00000264538.5	SUZ12P1	4.35	2.02e-05	0.00845	0.19	0.27	Coffee consumption (cups per day);	chr17:29973126	chr17:30709299~30790908:+
SARC	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-4.35	2.02e-05	0.00845	-0.26	-0.27	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
SARC	cis	rs1823913	0.637	rs1947456	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191298759	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.614	rs11693878	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191299399	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs10931494	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191299442	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs10931495	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191299447	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs12623156	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191299661	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs1349938	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191299970	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.592	rs1349939	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191300079	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.614	rs6434459	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191300886	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.592	rs7588555	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191300912	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs4853581	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191301533	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.614	rs7565987	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191301815	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.614	rs1973067	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191302021	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs1973068	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191302227	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs7569231	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191302373	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs6434461	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191302661	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.614	rs6434462	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191302705	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs6750360	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191303089	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs11677694	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191303203	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.571	rs6737307	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191303247	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs4853582	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191303483	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs35200176	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191303534	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs17348013	ENSG00000227542.1	AC092614.2	-4.35	2.02e-05	0.00845	-0.31	-0.27	Obesity-related traits;	chr2:191303726	chr2:191229165~191246172:-
SARC	cis	rs7615952	0.641	rs4490307	ENSG00000250012.1	RP11-124N2.1	-4.35	2.02e-05	0.00845	-0.25	-0.27	Blood pressure (smoking interaction);	chr3:125993833	chr3:126084220~126095349:+
SARC	cis	rs9506514	0.509	rs9509294	ENSG00000238286.1	SLC35E1P1	-4.35	2.02e-05	0.00845	-0.24	-0.27	Coronary artery calcification;	chr13:20600506	chr13:20607268~20608131:+
SARC	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-4.35	2.03e-05	0.00846	-0.26	-0.27	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
SARC	cis	rs8040855	0.644	rs4635318	ENSG00000259774.1	RP11-182J1.13	-4.35	2.03e-05	0.00847	-0.24	-0.27	Bulimia nervosa;	chr15:85183506	chr15:84422618~84425882:+
SARC	cis	rs7520050	0.898	rs4660885	ENSG00000280836.1	AL355480.1	4.35	2.03e-05	0.00848	0.25	0.27	Reticulocyte count;Red blood cell count;	chr1:45778084	chr1:45581219~45581321:-
SARC	cis	rs2404602	0.536	rs1587381	ENSG00000259422.1	RP11-593F23.1	4.35	2.03e-05	0.00848	0.3	0.27	Blood metabolite levels;	chr15:76477279	chr15:76174891~76181486:-
SARC	cis	rs12049351	0.665	rs4148761	ENSG00000229367.1	HMGN2P19	4.35	2.03e-05	0.00848	0.24	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229526597	chr1:229570532~229570796:+
SARC	cis	rs150992	0.504	rs152036	ENSG00000248489.1	CTD-2007H13.3	4.35	2.03e-05	0.00849	0.34	0.27	Body mass index;	chr5:98981729	chr5:98929171~98995013:+
SARC	cis	rs76693355	0.512	rs10892569	ENSG00000232460.4	BMPR1APS2	4.35	2.03e-05	0.00849	0.34	0.27	Intraocular pressure;	chr11:120399540	chr11:121361854~121362865:-
SARC	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	4.35	2.03e-05	0.00849	0.25	0.27	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
SARC	cis	rs875971	0.577	rs35072105	ENSG00000224316.1	RP11-479O9.2	-4.35	2.04e-05	0.0085	-0.25	-0.27	Aortic root size;	chr7:66144830	chr7:65773620~65802067:+
SARC	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-4.35	2.04e-05	0.0085	-0.32	-0.27	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
SARC	cis	rs2179367	0.632	rs9498335	ENSG00000231760.4	RP11-350J20.5	4.35	2.04e-05	0.00851	0.36	0.27	Dupuytren's disease;	chr6:149372648	chr6:149796151~149826294:-
SARC	cis	rs4950322	0.515	rs72691016	ENSG00000278811.3	LINC00624	4.35	2.04e-05	0.00851	0.29	0.27	Protein quantitative trait loci;	chr1:147245375	chr1:147258885~147517875:-
SARC	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	4.35	2.04e-05	0.00851	0.29	0.27	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
SARC	cis	rs1823913	0.637	rs4853579	ENSG00000227542.1	AC092614.2	-4.35	2.04e-05	0.00852	-0.31	-0.27	Obesity-related traits;	chr2:191297413	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs12622194	ENSG00000227542.1	AC092614.2	-4.35	2.04e-05	0.00852	-0.31	-0.27	Obesity-related traits;	chr2:191298680	chr2:191229165~191246172:-
SARC	cis	rs1823913	0.637	rs13019567	ENSG00000227542.1	AC092614.2	-4.35	2.04e-05	0.00852	-0.31	-0.27	Obesity-related traits;	chr2:191298736	chr2:191229165~191246172:-
SARC	cis	rs763121	0.962	rs6001159	ENSG00000273076.1	RP3-508I15.22	4.35	2.04e-05	0.00852	0.28	0.27	Menopause (age at onset);	chr22:38570482	chr22:38743495~38743910:+
SARC	cis	rs9309473	0.519	rs2421583	ENSG00000163016.8	ALMS1P	-4.35	2.04e-05	0.00852	-0.31	-0.27	Metabolite levels;	chr2:73671658	chr2:73644919~73685576:+
SARC	cis	rs7216064	0.589	rs8072723	ENSG00000278740.1	RP11-147L13.14	-4.35	2.04e-05	0.00852	-0.29	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68060854	chr17:68188547~68189165:+
SARC	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-4.35	2.04e-05	0.00853	-0.31	-0.27	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
SARC	cis	rs6570726	0.791	rs370112	ENSG00000270638.1	RP3-466P17.1	4.35	2.05e-05	0.00853	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs427128	ENSG00000270638.1	RP3-466P17.1	4.35	2.05e-05	0.00853	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145735570~145737218:+
SARC	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	4.35	2.05e-05	0.00854	0.23	0.27	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	4.35	2.05e-05	0.00854	0.23	0.27	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	4.35	2.05e-05	0.00854	0.23	0.27	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	4.35	2.05e-05	0.00854	0.23	0.27	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	4.35	2.05e-05	0.00854	0.23	0.27	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	4.35	2.05e-05	0.00854	0.23	0.27	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	4.35	2.05e-05	0.00854	0.23	0.27	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
SARC	cis	rs7267979	1	rs2500436	ENSG00000276952.1	RP5-965G21.6	-4.35	2.05e-05	0.00854	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6083856	ENSG00000276952.1	RP5-965G21.6	-4.35	2.05e-05	0.00854	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25284915~25285588:-
SARC	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-4.35	2.05e-05	0.00854	-0.31	-0.27	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
SARC	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-4.35	2.05e-05	0.00854	-0.25	-0.27	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
SARC	cis	rs7772486	0.79	rs2254283	ENSG00000270638.1	RP3-466P17.1	4.35	2.05e-05	0.00854	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145735570~145737218:+
SARC	cis	rs10770857	0.552	rs10841875	ENSG00000164845.15	FAM86FP	-4.35	2.05e-05	0.00855	-0.32	-0.27	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8546358	chr12:8232512~8242948:-
SARC	cis	rs4835473	0.932	rs62339580	ENSG00000251600.4	RP11-673E1.1	-4.35	2.05e-05	0.00855	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143785090	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs62339581	ENSG00000251600.4	RP11-673E1.1	-4.35	2.05e-05	0.00855	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143785172	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs7666368	ENSG00000251600.4	RP11-673E1.1	-4.35	2.05e-05	0.00855	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143785372	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs7690428	ENSG00000251600.4	RP11-673E1.1	-4.35	2.05e-05	0.00855	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143785400	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs34781605	ENSG00000251600.4	RP11-673E1.1	-4.35	2.05e-05	0.00855	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143785486	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs11100810	ENSG00000251600.4	RP11-673E1.1	-4.35	2.05e-05	0.00855	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143787518	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.838	rs6832094	ENSG00000251600.4	RP11-673E1.1	-4.35	2.05e-05	0.00855	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143795388	chr4:143912331~143982454:+
SARC	cis	rs2243480	0.666	rs1880311	ENSG00000226824.5	RP4-756H11.3	4.35	2.05e-05	0.00855	0.54	0.27	Diabetic kidney disease;	chr7:65811765	chr7:66654538~66669855:+
SARC	cis	rs13161895	1	rs34027780	ENSG00000250999.1	RP11-1379J22.5	-4.35	2.05e-05	0.00856	-0.48	-0.27	LDL cholesterol;	chr5:180051891	chr5:179657762~179664432:+
SARC	cis	rs14027	0.961	rs7017279	ENSG00000279347.1	RP11-85I17.2	4.35	2.06e-05	0.00857	0.24	0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119847580	chr8:119838736~119840385:-
SARC	cis	rs12049351	0.774	rs12066463	ENSG00000229367.1	HMGN2P19	4.35	2.06e-05	0.00857	0.24	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229533540	chr1:229570532~229570796:+
SARC	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-4.35	2.06e-05	0.00858	-0.3	-0.27	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-4.35	2.06e-05	0.00858	-0.3	-0.27	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
SARC	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-4.35	2.06e-05	0.00858	-0.24	-0.27	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
SARC	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	4.35	2.06e-05	0.00858	0.37	0.27	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
SARC	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	4.35	2.06e-05	0.00858	0.23	0.27	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
SARC	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	4.35	2.06e-05	0.00858	0.23	0.27	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
SARC	cis	rs4835473	0.9	rs4285038	ENSG00000251600.4	RP11-673E1.1	-4.35	2.06e-05	0.00859	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143763637	chr4:143912331~143982454:+
SARC	cis	rs4664293	0.625	rs3821300	ENSG00000226266.5	AC009961.3	4.35	2.06e-05	0.00859	0.31	0.27	Monocyte percentage of white cells;	chr2:159710719	chr2:159670708~159712435:-
SARC	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-4.35	2.06e-05	0.00859	-0.3	-0.27	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
SARC	cis	rs28386778	0.897	rs2665797	ENSG00000240280.5	TCAM1P	4.35	2.06e-05	0.00859	0.34	0.27	Prudent dietary pattern;	chr17:63845125	chr17:63849292~63864379:+
SARC	cis	rs7772486	0.79	rs9390365	ENSG00000270638.1	RP3-466P17.1	-4.35	2.06e-05	0.0086	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145735570~145737218:+
SARC	cis	rs801193	0.844	rs2244022	ENSG00000236529.1	RP13-254B10.1	4.35	2.07e-05	0.0086	0.28	0.27	Aortic root size;	chr7:66737443	chr7:65840212~65840596:+
SARC	cis	rs9309473	0.687	rs6710659	ENSG00000163016.8	ALMS1P	4.35	2.07e-05	0.0086	0.33	0.27	Metabolite levels;	chr2:73380382	chr2:73644919~73685576:+
SARC	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-4.35	2.07e-05	0.0086	-0.27	-0.27	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
SARC	cis	rs12200782	0.929	rs72841519	ENSG00000272810.1	U91328.22	-4.35	2.07e-05	0.0086	-0.42	-0.27	Small cell lung carcinoma;	chr6:26371673	chr6:26013241~26013757:+
SARC	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-4.35	2.07e-05	0.0086	-0.37	-0.27	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
SARC	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	4.35	2.07e-05	0.00861	0.25	0.27	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
SARC	cis	rs889122	0.659	rs62106799	ENSG00000267289.1	CTD-2623N2.11	4.35	2.07e-05	0.00861	0.33	0.27	Menarche (age at onset);	chr19:9874359	chr19:9834079~9835013:-
SARC	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	4.35	2.07e-05	0.00861	0.23	0.27	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
SARC	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	4.35	2.07e-05	0.00861	0.23	0.27	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
SARC	cis	rs1713985	0.508	rs1277286	ENSG00000269949.1	RP11-738E22.3	-4.35	2.07e-05	0.00862	-0.49	-0.27	Age-related macular degeneration;	chr4:56988132	chr4:56960927~56961373:-
SARC	cis	rs72945132	0.882	rs7114200	ENSG00000254604.1	AP000487.6	-4.35	2.07e-05	0.00862	-0.39	-0.27	Coronary artery disease;	chr11:70339993	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs55738915	ENSG00000254604.1	AP000487.6	-4.35	2.07e-05	0.00862	-0.39	-0.27	Coronary artery disease;	chr11:70343913	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs4567496	ENSG00000254604.1	AP000487.6	-4.35	2.07e-05	0.00862	-0.39	-0.27	Coronary artery disease;	chr11:70347102	chr11:70282367~70363368:-
SARC	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	4.35	2.07e-05	0.00862	0.25	0.27	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
SARC	cis	rs7267979	1	rs2482943	ENSG00000276952.1	RP5-965G21.6	-4.35	2.07e-05	0.00863	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:25284915~25285588:-
SARC	cis	rs12554020	0.786	rs78619366	ENSG00000227603.1	RP11-165J3.6	4.35	2.08e-05	0.00864	0.49	0.27	Schizophrenia;	chr9:93590541	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.579	rs78814851	ENSG00000227603.1	RP11-165J3.6	4.35	2.08e-05	0.00864	0.49	0.27	Schizophrenia;	chr9:93590652	chr9:93435332~93437121:-
SARC	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-4.35	2.08e-05	0.00864	-0.51	-0.27	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-4.35	2.08e-05	0.00864	-0.51	-0.27	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
SARC	cis	rs17695224	0.545	rs10500309	ENSG00000275055.1	CTC-471J1.11	-4.34	2.08e-05	0.00865	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51829123	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.545	rs8111469	ENSG00000275055.1	CTC-471J1.11	-4.34	2.08e-05	0.00865	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51829272	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.565	rs61681419	ENSG00000275055.1	CTC-471J1.11	-4.34	2.08e-05	0.00865	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51830726	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.545	rs13346095	ENSG00000275055.1	CTC-471J1.11	-4.34	2.08e-05	0.00865	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51831092	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.5	rs13346104	ENSG00000275055.1	CTC-471J1.11	-4.34	2.08e-05	0.00865	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51831173	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.5	rs4801897	ENSG00000275055.1	CTC-471J1.11	-4.34	2.08e-05	0.00865	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51831942	chr19:52049007~52049754:+
SARC	cis	rs448720	0.508	rs2414978	ENSG00000259410.4	RP11-34F13.3	4.34	2.08e-05	0.00865	0.3	0.27	Cognitive performance;	chr15:67928227	chr15:67832725~67873866:+
SARC	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-4.34	2.08e-05	0.00866	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
SARC	cis	rs9364687	0.664	rs2294709	ENSG00000228692.2	RP5-826L7.1	-4.34	2.09e-05	0.00867	-0.32	-0.27	Body mass index;	chr6:163486209	chr6:163586583~163588165:-
SARC	cis	rs4273100	0.688	rs12938803	ENSG00000228157.4	AC007952.5	-4.34	2.09e-05	0.00867	-0.33	-0.27	Schizophrenia;	chr17:19301119	chr17:19092974~19096837:+
SARC	cis	rs948562	0.593	rs74556128	ENSG00000280010.1	AP001350.4	4.34	2.09e-05	0.00867	0.45	0.27	Lymphoma;	chr11:58559704	chr11:58627435~58628528:+
SARC	cis	rs6570726	0.791	rs422099	ENSG00000270638.1	RP3-466P17.1	4.34	2.09e-05	0.00867	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145735570~145737218:+
SARC	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	4.34	2.09e-05	0.00867	0.26	0.27	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	4.34	2.09e-05	0.00867	0.26	0.27	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
SARC	cis	rs10936632	0.565	rs6794467	ENSG00000242578.1	RP11-469J4.3	-4.34	2.09e-05	0.00868	-0.28	-0.27	Prostate cancer;	chr3:170430203	chr3:170410512~170418615:+
SARC	cis	rs2404602	0.536	rs11072599	ENSG00000259422.1	RP11-593F23.1	4.34	2.09e-05	0.00868	0.3	0.27	Blood metabolite levels;	chr15:76482167	chr15:76174891~76181486:-
SARC	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-4.34	2.09e-05	0.00868	-0.39	-0.27	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
SARC	cis	rs7267979	0.844	rs869358	ENSG00000276952.1	RP5-965G21.6	-4.34	2.09e-05	0.00868	-0.26	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.789	rs4815400	ENSG00000125804.12	FAM182A	4.34	2.09e-05	0.00869	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:26054655~26086917:+
SARC	cis	rs9473147	0.543	rs9369716	ENSG00000270761.1	RP11-385F7.1	-4.34	2.09e-05	0.00869	-0.34	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47584444	chr6:47477243~47477572:-
SARC	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	4.34	2.1e-05	0.00871	0.3	0.27	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
SARC	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-4.34	2.1e-05	0.00871	-0.3	-0.27	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
SARC	cis	rs6570726	0.791	rs440477	ENSG00000270638.1	RP3-466P17.1	4.34	2.1e-05	0.00871	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs385729	ENSG00000270638.1	RP3-466P17.1	4.34	2.1e-05	0.00871	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs7755253	ENSG00000270638.1	RP3-466P17.1	4.34	2.1e-05	0.00871	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.764	rs376257	ENSG00000270638.1	RP3-466P17.1	4.34	2.1e-05	0.00871	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.693	rs450921	ENSG00000270638.1	RP3-466P17.1	4.34	2.1e-05	0.00871	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs365747	ENSG00000270638.1	RP3-466P17.1	4.34	2.1e-05	0.00871	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.764	rs448258	ENSG00000270638.1	RP3-466P17.1	4.34	2.1e-05	0.00871	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145735570~145737218:+
SARC	cis	rs12530	0.715	rs5749428	ENSG00000230736.2	RP1-149A16.3	-4.34	2.1e-05	0.00872	-0.31	-0.27	IgG glycosylation;	chr22:32403709	chr22:32376664~32384343:+
SARC	cis	rs12530	0.715	rs5998475	ENSG00000230736.2	RP1-149A16.3	-4.34	2.1e-05	0.00872	-0.31	-0.27	IgG glycosylation;	chr22:32405345	chr22:32376664~32384343:+
SARC	cis	rs890448	0.726	rs2583397	ENSG00000254531.1	FLJ20021	-4.34	2.1e-05	0.00872	-0.29	-0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101308565	chr4:101347780~101348883:+
SARC	cis	rs10788972	1	rs10788972	ENSG00000225183.1	RP4-758J24.4	-4.34	2.1e-05	0.00873	-0.33	-0.27	Parkinson disease and lewy body pathology;	chr1:54106570	chr1:54089856~54090093:+
SARC	cis	rs597539	0.652	rs584108	ENSG00000250508.1	RP11-757G1.6	4.34	2.1e-05	0.00873	0.32	0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68870664~68874542:+
SARC	cis	rs2439831	1	rs28628574	ENSG00000205771.5	CATSPER2P1	-4.34	2.1e-05	0.00873	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43509840	chr15:43726918~43747094:-
SARC	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-4.34	2.11e-05	0.00874	-0.51	-0.27	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-4.34	2.11e-05	0.00874	-0.51	-0.27	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-4.34	2.11e-05	0.00874	-0.51	-0.27	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-4.34	2.11e-05	0.00874	-0.51	-0.27	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-4.34	2.11e-05	0.00874	-0.51	-0.27	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-4.34	2.11e-05	0.00874	-0.51	-0.27	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-4.34	2.11e-05	0.00874	-0.51	-0.27	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-4.34	2.11e-05	0.00874	-0.51	-0.27	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-4.34	2.11e-05	0.00874	-0.51	-0.27	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
SARC	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-4.34	2.11e-05	0.00875	-0.35	-0.27	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
SARC	cis	rs7267979	1	rs2258563	ENSG00000276952.1	RP5-965G21.6	4.34	2.11e-05	0.00875	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2258617	ENSG00000276952.1	RP5-965G21.6	4.34	2.11e-05	0.00875	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2257420	ENSG00000276952.1	RP5-965G21.6	4.34	2.11e-05	0.00875	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2258769	ENSG00000276952.1	RP5-965G21.6	4.34	2.11e-05	0.00875	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25284915~25285588:-
SARC	cis	rs4938303	0.549	rs12785772	ENSG00000254851.1	RP11-109L13.1	4.34	2.11e-05	0.00875	0.35	0.27	Triglycerides;	chr11:116692892	chr11:117135528~117138582:+
SARC	cis	rs10751647	0.804	rs3809112	ENSG00000251661.3	RP11-326C3.11	-4.34	2.11e-05	0.00875	-0.26	-0.27	Monocyte count;	chr11:307036	chr11:318640~325631:+
SARC	cis	rs9473147	0.543	rs4715019	ENSG00000270761.1	RP11-385F7.1	-4.34	2.11e-05	0.00875	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47479305	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.543	rs9367279	ENSG00000270761.1	RP11-385F7.1	-4.34	2.11e-05	0.00875	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47480600	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.543	rs9473119	ENSG00000270761.1	RP11-385F7.1	-4.34	2.11e-05	0.00875	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47482882	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.543	rs9296559	ENSG00000270761.1	RP11-385F7.1	-4.34	2.11e-05	0.00875	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47484534	chr6:47477243~47477572:-
SARC	cis	rs4835473	0.932	rs13130345	ENSG00000251600.4	RP11-673E1.1	4.34	2.11e-05	0.00876	0.28	0.27	Immature fraction of reticulocytes;	chr4:143920939	chr4:143912331~143982454:+
SARC	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-4.34	2.12e-05	0.00877	-0.29	-0.27	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
SARC	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	4.34	2.12e-05	0.00877	0.25	0.27	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	4.34	2.12e-05	0.00877	0.25	0.27	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	4.34	2.12e-05	0.00877	0.25	0.27	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
SARC	cis	rs783540	0.967	rs783526	ENSG00000275695.1	UBE2Q2P6	-4.34	2.12e-05	0.00877	-0.28	-0.27	Schizophrenia;	chr15:82617044	chr15:82445719~82454837:+
SARC	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	4.34	2.12e-05	0.00878	0.27	0.27	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
SARC	cis	rs9309473	0.5	rs12996463	ENSG00000163016.8	ALMS1P	-4.34	2.12e-05	0.00878	-0.31	-0.27	Metabolite levels;	chr2:73428368	chr2:73644919~73685576:+
SARC	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-4.34	2.12e-05	0.00879	-0.29	-0.27	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
SARC	cis	rs3096644	0.544	rs112734318	ENSG00000270781.1	RP11-501C14.9	-4.34	2.12e-05	0.00879	-0.3	-0.27	Metabolite levels (Dihydroxy docosatrienoic acid);	chr17:48687101	chr17:48899131~48899748:+
SARC	cis	rs72945132	0.825	rs7950280	ENSG00000254604.1	AP000487.6	-4.34	2.12e-05	0.00879	-0.38	-0.27	Coronary artery disease;	chr11:70367349	chr11:70282367~70363368:-
SARC	cis	rs7772486	0.743	rs1292339	ENSG00000270638.1	RP3-466P17.1	-4.34	2.12e-05	0.0088	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145645950	chr6:145735570~145737218:+
SARC	cis	rs12200782	1	rs3927423	ENSG00000272810.1	U91328.22	-4.34	2.13e-05	0.00881	-0.48	-0.27	Small cell lung carcinoma;	chr6:26393259	chr6:26013241~26013757:+
SARC	cis	rs12200782	1	rs12201802	ENSG00000272810.1	U91328.22	-4.34	2.13e-05	0.00881	-0.48	-0.27	Small cell lung carcinoma;	chr6:26398436	chr6:26013241~26013757:+
SARC	cis	rs2281558	0.583	rs11087526	ENSG00000125804.12	FAM182A	-4.34	2.13e-05	0.00881	-0.44	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25667380	chr20:26054655~26086917:+
SARC	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-4.34	2.13e-05	0.00882	-0.4	-0.27	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
SARC	cis	rs17508449	0.821	rs1419231	ENSG00000232450.1	RP4-730K3.3	-4.34	2.13e-05	0.00882	-0.35	-0.27	Leprosy;	chr1:113583596	chr1:113698884~113699631:-
SARC	cis	rs2274273	0.529	rs10131562	ENSG00000258413.1	RP11-665C16.6	-4.34	2.13e-05	0.00883	-0.34	-0.27	Protein biomarker;	chr14:55380297	chr14:55262767~55272075:-
SARC	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	4.34	2.13e-05	0.00883	0.34	0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
SARC	cis	rs13217239	0.646	rs12527111	ENSG00000241549.7	GUSBP2	4.34	2.13e-05	0.00883	0.26	0.27	Schizophrenia;	chr6:27038696	chr6:26871484~26956554:-
SARC	cis	rs7216064	0.589	rs8072723	ENSG00000237854.3	LINC00674	-4.34	2.13e-05	0.00884	-0.31	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68060854	chr17:68101908~68115518:+
SARC	cis	rs30380	0.506	rs469735	ENSG00000272109.1	CTD-2260A17.3	-4.34	2.14e-05	0.00885	-0.35	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96794311	chr5:96804353~96806105:+
SARC	cis	rs9902453	0.74	rs2617867	ENSG00000264538.5	SUZ12P1	-4.34	2.14e-05	0.00886	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29722381	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.765	rs2628191	ENSG00000264538.5	SUZ12P1	-4.34	2.14e-05	0.00886	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29724122	chr17:30709299~30790908:+
SARC	cis	rs7267979	1	rs4815407	ENSG00000276952.1	RP5-965G21.6	-4.34	2.14e-05	0.00887	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25284915~25285588:-
SARC	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-4.34	2.14e-05	0.00887	-0.25	-0.27	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
SARC	cis	rs72945132	0.882	rs72947078	ENSG00000254604.1	AP000487.6	-4.34	2.15e-05	0.00888	-0.39	-0.27	Coronary artery disease;	chr11:70351436	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs17853270	ENSG00000254604.1	AP000487.6	-4.34	2.15e-05	0.00888	-0.39	-0.27	Coronary artery disease;	chr11:70354423	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs947812	ENSG00000254604.1	AP000487.6	-4.34	2.15e-05	0.00888	-0.39	-0.27	Coronary artery disease;	chr11:70363063	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs55915603	ENSG00000254604.1	AP000487.6	-4.34	2.15e-05	0.00888	-0.39	-0.27	Coronary artery disease;	chr11:70363961	chr11:70282367~70363368:-
SARC	cis	rs5751614	0.577	rs2330369	ENSG00000230701.2	FBXW4P1	4.34	2.15e-05	0.00889	0.34	0.27	Height;	chr22:23265255	chr22:23262767~23265005:+
SARC	cis	rs6540731	1	rs951623	ENSG00000229983.1	RP11-15I11.2	4.34	2.15e-05	0.00889	0.28	0.27	Intelligence (childhood);	chr1:212225720	chr1:212168207~212190259:+
SARC	cis	rs7246657	1	rs34544865	ENSG00000276846.1	CTD-3220F14.3	4.34	2.15e-05	0.00889	0.41	0.27	Coronary artery calcification;	chr19:37310340	chr19:37314868~37315620:-
SARC	cis	rs7560272	0.723	rs4346412	ENSG00000163016.8	ALMS1P	4.34	2.15e-05	0.0089	0.31	0.27	Schizophrenia;	chr2:73616444	chr2:73644919~73685576:+
SARC	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-4.34	2.15e-05	0.00891	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
SARC	cis	rs12049351	0.774	rs2145395	ENSG00000229367.1	HMGN2P19	4.34	2.16e-05	0.00891	0.23	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229535234	chr1:229570532~229570796:+
SARC	cis	rs75920871	0.528	rs10892071	ENSG00000254851.1	RP11-109L13.1	4.34	2.16e-05	0.00891	0.37	0.27	Subjective well-being;	chr11:117083849	chr11:117135528~117138582:+
SARC	cis	rs2404602	0.536	rs17364330	ENSG00000259422.1	RP11-593F23.1	4.34	2.16e-05	0.00892	0.3	0.27	Blood metabolite levels;	chr15:76473044	chr15:76174891~76181486:-
SARC	cis	rs7267979	1	rs4815420	ENSG00000276952.1	RP5-965G21.6	-4.34	2.16e-05	0.00892	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25284915~25285588:-
SARC	cis	rs7811142	0.775	rs1059129	ENSG00000078319.8	PMS2P1	-4.34	2.16e-05	0.00892	-0.38	-0.27	Platelet count;	chr7:100328899	chr7:100320992~100341908:-
SARC	cis	rs7811142	0.562	rs7786844	ENSG00000078319.8	PMS2P1	-4.34	2.16e-05	0.00892	-0.38	-0.27	Platelet count;	chr7:100336385	chr7:100320992~100341908:-
SARC	cis	rs7811142	0.667	rs3873746	ENSG00000078319.8	PMS2P1	-4.34	2.16e-05	0.00892	-0.38	-0.27	Platelet count;	chr7:100337474	chr7:100320992~100341908:-
SARC	cis	rs12554020	1	rs3933797	ENSG00000227603.1	RP11-165J3.6	4.34	2.16e-05	0.00893	0.36	0.27	Schizophrenia;	chr9:93423049	chr9:93435332~93437121:-
SARC	cis	rs12554020	1	rs3933796	ENSG00000227603.1	RP11-165J3.6	4.34	2.16e-05	0.00893	0.36	0.27	Schizophrenia;	chr9:93423123	chr9:93435332~93437121:-
SARC	cis	rs12554020	1	rs7859267	ENSG00000227603.1	RP11-165J3.6	4.34	2.16e-05	0.00893	0.36	0.27	Schizophrenia;	chr9:93426827	chr9:93435332~93437121:-
SARC	cis	rs13217239	0.572	rs9379958	ENSG00000241549.7	GUSBP2	-4.34	2.16e-05	0.00893	-0.26	-0.27	Schizophrenia;	chr6:27098384	chr6:26871484~26956554:-
SARC	cis	rs13217239	0.646	rs9393789	ENSG00000241549.7	GUSBP2	-4.34	2.16e-05	0.00893	-0.26	-0.27	Schizophrenia;	chr6:27099249	chr6:26871484~26956554:-
SARC	cis	rs13217239	0.646	rs6456767	ENSG00000241549.7	GUSBP2	-4.34	2.16e-05	0.00893	-0.26	-0.27	Schizophrenia;	chr6:27102764	chr6:26871484~26956554:-
SARC	cis	rs867371	1	rs9944197	ENSG00000259429.4	UBE2Q2P2	-4.34	2.16e-05	0.00893	-0.26	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82355142~82420075:+
SARC	cis	rs599083	0.744	rs603129	ENSG00000212093.1	AP000807.1	-4.34	2.16e-05	0.00893	-0.26	-0.27	Bone mineral density (spine);	chr11:68419201	chr11:68506083~68506166:-
SARC	cis	rs755249	1	rs755249	ENSG00000182109.6	RP11-69E11.4	4.34	2.16e-05	0.00894	0.3	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39522280~39546187:-
SARC	cis	rs1799949	1	rs8176318	ENSG00000267681.1	CTD-3199J23.6	-4.34	2.17e-05	0.00895	-0.3	-0.27	Menopause (age at onset);	chr17:43045257	chr17:43144956~43145255:+
SARC	cis	rs4835473	0.932	rs34697602	ENSG00000251600.4	RP11-673E1.1	-4.34	2.17e-05	0.00895	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143762499	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs34618381	ENSG00000251600.4	RP11-673E1.1	-4.34	2.17e-05	0.00895	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143762612	chr4:143912331~143982454:+
SARC	cis	rs143626010	1	rs143626010	ENSG00000251417.2	RP11-1348G14.4	-4.34	2.17e-05	0.00896	-0.27	-0.27	Mosquito bite size;	chr16:28528081	chr16:28802743~28817828:+
SARC	cis	rs910316	1	rs10138183	ENSG00000279594.1	RP11-950C14.10	4.34	2.17e-05	0.00896	0.3	0.27	Height;	chr14:75148524	chr14:75011269~75012851:-
SARC	cis	rs367615	0.679	rs4259216	ENSG00000249476.1	CTD-2587M2.1	4.33	2.17e-05	0.00896	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109506116	chr5:109237120~109326369:-
SARC	cis	rs867371	1	rs11855089	ENSG00000259429.4	UBE2Q2P2	-4.33	2.17e-05	0.00896	-0.26	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82355142~82420075:+
SARC	cis	rs867371	1	rs1174543	ENSG00000259429.4	UBE2Q2P2	4.33	2.17e-05	0.00896	0.26	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82355142~82420075:+
SARC	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-4.33	2.17e-05	0.00897	-0.26	-0.27	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
SARC	cis	rs755249	0.53	rs1472662	ENSG00000182109.6	RP11-69E11.4	4.33	2.17e-05	0.00897	0.3	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39124737	chr1:39522280~39546187:-
SARC	cis	rs9902453	0.904	rs55866125	ENSG00000264538.5	SUZ12P1	4.33	2.17e-05	0.00897	0.19	0.27	Coffee consumption (cups per day);	chr17:29985975	chr17:30709299~30790908:+
SARC	cis	rs7216064	0.953	rs62086043	ENSG00000237854.3	LINC00674	4.33	2.18e-05	0.00899	0.33	0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971887	chr17:68101908~68115518:+
SARC	cis	rs9318086	0.537	rs7993131	ENSG00000205861.10	C1QTNF9B-AS1	4.33	2.18e-05	0.00899	0.33	0.27	Myopia (pathological);	chr13:23723014	chr13:23888889~23897263:+
SARC	cis	rs6425521	0.848	rs10914053	ENSG00000213060.4	RP4-612B18.3	4.33	2.18e-05	0.00899	0.42	0.27	Platelet count;	chr1:171946041	chr1:171803517~171803939:+
SARC	cis	rs67478160	0.643	rs2887282	ENSG00000269910.1	RP11-73M18.10	4.33	2.18e-05	0.00899	0.23	0.27	Schizophrenia;	chr14:103814397	chr14:103694516~103695050:-
SARC	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-4.33	2.18e-05	0.00899	-0.35	-0.27	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-4.33	2.18e-05	0.00899	-0.35	-0.27	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
SARC	cis	rs875971	0.862	rs6971059	ENSG00000232559.3	GS1-124K5.12	-4.33	2.18e-05	0.00899	-0.32	-0.27	Aortic root size;	chr7:66602045	chr7:66554588~66576923:-
SARC	cis	rs875971	0.789	rs7808013	ENSG00000232559.3	GS1-124K5.12	-4.33	2.18e-05	0.00899	-0.32	-0.27	Aortic root size;	chr7:66606209	chr7:66554588~66576923:-
SARC	cis	rs875971	0.825	rs7384021	ENSG00000232559.3	GS1-124K5.12	-4.33	2.18e-05	0.00899	-0.32	-0.27	Aortic root size;	chr7:66612917	chr7:66554588~66576923:-
SARC	cis	rs875971	0.825	rs66981195	ENSG00000232559.3	GS1-124K5.12	-4.33	2.18e-05	0.00899	-0.32	-0.27	Aortic root size;	chr7:66614048	chr7:66554588~66576923:-
SARC	cis	rs875971	0.862	rs3926380	ENSG00000232559.3	GS1-124K5.12	-4.33	2.18e-05	0.00899	-0.32	-0.27	Aortic root size;	chr7:66615658	chr7:66554588~66576923:-
SARC	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-4.33	2.18e-05	0.009	-0.35	-0.27	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
SARC	cis	rs4703855	0.538	rs4464671	ENSG00000244061.1	RP11-389C8.1	4.33	2.18e-05	0.009	0.28	0.27	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72429473	chr5:72381794~72382393:+
SARC	cis	rs7267979	0.932	rs6115200	ENSG00000276952.1	RP5-965G21.6	4.33	2.18e-05	0.009	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:25284915~25285588:-
SARC	cis	rs7247513	0.658	rs4804728	ENSG00000213290.4	PGK1P2	-4.33	2.18e-05	0.009	-0.33	-0.27	Bipolar disorder;	chr19:12642114	chr19:12559571~12561105:+
SARC	cis	rs9902453	0.933	rs7225462	ENSG00000264538.5	SUZ12P1	4.33	2.19e-05	0.00902	0.19	0.27	Coffee consumption (cups per day);	chr17:29994208	chr17:30709299~30790908:+
SARC	cis	rs61160187	0.582	rs62367872	ENSG00000215032.2	GNL3LP1	4.33	2.19e-05	0.00902	0.27	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60976943	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.556	rs55738840	ENSG00000215032.2	GNL3LP1	4.33	2.19e-05	0.00902	0.27	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977587	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.582	rs58646987	ENSG00000215032.2	GNL3LP1	4.33	2.19e-05	0.00902	0.27	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60979867	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.582	rs11739952	ENSG00000215032.2	GNL3LP1	4.33	2.19e-05	0.00902	0.27	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60980150	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.582	rs4642318	ENSG00000215032.2	GNL3LP1	4.33	2.19e-05	0.00902	0.27	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996931	chr5:60891935~60893577:-
SARC	cis	rs11064768	0.633	rs12370095	ENSG00000255857.4	PXN-AS1	-4.33	2.19e-05	0.00902	-0.41	-0.27	Schizophrenia;	chr12:119415333	chr12:120201291~120213138:+
SARC	cis	rs6964833	1	rs4717907	ENSG00000184616.8	AC004166.6	4.33	2.19e-05	0.00902	0.38	0.27	Menarche (age at onset);	chr7:74672169	chr7:74906673~74913256:-
SARC	cis	rs1001021	0.85	rs75397903	ENSG00000230637.2	CTA-246H3.8	4.33	2.19e-05	0.00903	0.58	0.27	Schizophrenia, bipolar disorder and depression (combined);	chr22:25991798	chr22:25327252~25339975:+
SARC	cis	rs12893668	0.603	rs12896171	ENSG00000269940.1	RP11-73M18.7	4.33	2.19e-05	0.00903	0.27	0.27	Reticulocyte count;	chr14:103669629	chr14:103694560~103695170:+
SARC	cis	rs12893668	0.572	rs12590968	ENSG00000269940.1	RP11-73M18.7	4.33	2.19e-05	0.00903	0.27	0.27	Reticulocyte count;	chr14:103670296	chr14:103694560~103695170:+
SARC	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	4.33	2.19e-05	0.00903	0.24	0.27	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
SARC	cis	rs7712401	0.56	rs13168225	ENSG00000263432.2	RN7SL689P	-4.33	2.19e-05	0.00903	-0.35	-0.27	Mean platelet volume;	chr5:123011569	chr5:123022487~123022783:-
SARC	cis	rs9902453	0.868	rs12944395	ENSG00000264538.5	SUZ12P1	-4.33	2.19e-05	0.00904	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29996481	chr17:30709299~30790908:+
SARC	cis	rs10911902	0.643	rs1406294	ENSG00000229739.2	RP11-295K2.3	-4.33	2.2e-05	0.00905	-0.39	-0.27	Schizophrenia;	chr1:186314293	chr1:186435161~186470291:+
SARC	cis	rs9902453	0.791	rs3115100	ENSG00000264538.5	SUZ12P1	4.33	2.2e-05	0.00905	0.19	0.27	Coffee consumption (cups per day);	chr17:29718726	chr17:30709299~30790908:+
SARC	cis	rs4862750	0.872	rs13143414	ENSG00000250971.1	RP11-696F12.1	4.33	2.2e-05	0.00905	0.32	0.27	Lobe attachment (rater-scored or self-reported);	chr4:186957059	chr4:187060099~187060930:+
SARC	cis	rs7615952	0.641	rs61048217	ENSG00000171084.14	FAM86JP	4.33	2.2e-05	0.00905	0.41	0.27	Blood pressure (smoking interaction);	chr3:126089062	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.641	rs60839048	ENSG00000171084.14	FAM86JP	4.33	2.2e-05	0.00905	0.41	0.27	Blood pressure (smoking interaction);	chr3:126089095	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.641	rs7640158	ENSG00000171084.14	FAM86JP	4.33	2.2e-05	0.00905	0.41	0.27	Blood pressure (smoking interaction);	chr3:126089168	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.641	rs2365019	ENSG00000171084.14	FAM86JP	4.33	2.2e-05	0.00905	0.41	0.27	Blood pressure (smoking interaction);	chr3:126089292	chr3:125916620~125930024:+
SARC	cis	rs7267979	0.745	rs6132845	ENSG00000276952.1	RP5-965G21.6	4.33	2.2e-05	0.00906	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:25284915~25285588:-
SARC	cis	rs2439831	0.681	rs11858152	ENSG00000275601.1	AC011330.13	-4.33	2.2e-05	0.00908	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43341998	chr15:43642389~43643023:-
SARC	cis	rs2274273	0.554	rs3742564	ENSG00000258413.1	RP11-665C16.6	4.33	2.2e-05	0.00908	0.31	0.27	Protein biomarker;	chr14:55063402	chr14:55262767~55272075:-
SARC	cis	rs853679	0.76	rs11967137	ENSG00000216901.1	AL022393.7	4.33	2.2e-05	0.00908	0.43	0.27	Depression;	chr6:28231986	chr6:28176188~28176674:+
SARC	cis	rs2439831	0.702	rs16977724	ENSG00000275601.1	AC011330.13	-4.33	2.2e-05	0.00908	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43859101	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs11856184	ENSG00000205771.5	CATSPER2P1	-4.33	2.2e-05	0.00908	-0.44	-0.27	Lung cancer in ever smokers;	chr15:43626964	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs2927072	ENSG00000205771.5	CATSPER2P1	-4.33	2.2e-05	0.00908	-0.44	-0.27	Lung cancer in ever smokers;	chr15:43630200	chr15:43726918~43747094:-
SARC	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-4.33	2.2e-05	0.00908	-0.44	-0.27	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
SARC	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	4.33	2.21e-05	0.00908	0.25	0.27	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
SARC	cis	rs7255436	0.965	rs4044435	ENSG00000269386.4	RAB11B-AS1	4.33	2.21e-05	0.00908	0.27	0.27	HDL cholesterol;	chr19:8383293	chr19:8374373~8390685:-
SARC	cis	rs11123170	0.529	rs1015753	ENSG00000189223.12	PAX8-AS1	-4.33	2.21e-05	0.00909	-0.37	-0.27	Renal function-related traits (BUN);	chr2:113211226	chr2:113211522~113276581:+
SARC	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	4.33	2.21e-05	0.00909	0.27	0.27	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
SARC	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-4.33	2.21e-05	0.0091	-0.3	-0.27	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-4.33	2.21e-05	0.0091	-0.3	-0.27	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
SARC	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	4.33	2.21e-05	0.0091	0.33	0.27	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
SARC	cis	rs6570726	0.846	rs7762536	ENSG00000235652.6	RP11-545I5.3	4.33	2.21e-05	0.0091	0.25	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145799409~145886585:+
SARC	cis	rs7811142	0.943	rs111757992	ENSG00000078319.8	PMS2P1	-4.33	2.21e-05	0.0091	-0.38	-0.27	Platelet count;	chr7:100418731	chr7:100320992~100341908:-
SARC	cis	rs2439831	0.867	rs2470134	ENSG00000205771.5	CATSPER2P1	4.33	2.21e-05	0.00911	0.45	0.27	Lung cancer in ever smokers;	chr15:43557688	chr15:43726918~43747094:-
SARC	cis	rs7267979	1	rs2500424	ENSG00000276952.1	RP5-965G21.6	-4.33	2.21e-05	0.00912	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25284915~25285588:-
SARC	cis	rs599083	0.793	rs471966	ENSG00000212093.1	AP000807.1	-4.33	2.21e-05	0.00912	-0.26	-0.27	Bone mineral density (spine);	chr11:68406393	chr11:68506083~68506166:-
SARC	cis	rs4835473	0.932	rs4835278	ENSG00000251600.4	RP11-673E1.1	-4.33	2.22e-05	0.00912	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143788433	chr4:143912331~143982454:+
SARC	cis	rs755249	0.567	rs4660214	ENSG00000182109.6	RP11-69E11.4	4.33	2.22e-05	0.00912	0.3	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39522280~39546187:-
SARC	cis	rs27434	0.605	rs12659825	ENSG00000272109.1	CTD-2260A17.3	4.33	2.22e-05	0.00912	0.41	0.27	Ankylosing spondylitis;	chr5:96852380	chr5:96804353~96806105:+
SARC	cis	rs4950322	0.57	rs72691090	ENSG00000278811.3	LINC00624	4.33	2.22e-05	0.00912	0.29	0.27	Protein quantitative trait loci;	chr1:147297884	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.543	rs4950318	ENSG00000278811.3	LINC00624	4.33	2.22e-05	0.00912	0.29	0.27	Protein quantitative trait loci;	chr1:147316240	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.543	rs4950319	ENSG00000278811.3	LINC00624	4.33	2.22e-05	0.00912	0.29	0.27	Protein quantitative trait loci;	chr1:147316250	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.543	rs4453096	ENSG00000278811.3	LINC00624	4.33	2.22e-05	0.00912	0.29	0.27	Protein quantitative trait loci;	chr1:147316574	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.571	rs4373796	ENSG00000278811.3	LINC00624	4.33	2.22e-05	0.00912	0.29	0.27	Protein quantitative trait loci;	chr1:147316747	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.543	rs4568882	ENSG00000278811.3	LINC00624	4.33	2.22e-05	0.00912	0.29	0.27	Protein quantitative trait loci;	chr1:147316885	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.543	rs2883323	ENSG00000278811.3	LINC00624	4.33	2.22e-05	0.00912	0.29	0.27	Protein quantitative trait loci;	chr1:147316995	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.543	rs2883324	ENSG00000278811.3	LINC00624	4.33	2.22e-05	0.00912	0.29	0.27	Protein quantitative trait loci;	chr1:147317157	chr1:147258885~147517875:-
SARC	cis	rs2439831	1	rs2264239	ENSG00000205771.5	CATSPER2P1	-4.33	2.22e-05	0.00912	-0.42	-0.27	Lung cancer in ever smokers;	chr15:43473335	chr15:43726918~43747094:-
SARC	cis	rs72945132	0.882	rs7941933	ENSG00000254604.1	AP000487.6	-4.33	2.22e-05	0.00914	-0.39	-0.27	Coronary artery disease;	chr11:70277245	chr11:70282367~70363368:-
SARC	cis	rs4950322	0.634	rs7542951	ENSG00000278811.3	LINC00624	4.33	2.22e-05	0.00914	0.28	0.27	Protein quantitative trait loci;	chr1:147340308	chr1:147258885~147517875:-
SARC	cis	rs9309473	0.66	rs11686541	ENSG00000163016.8	ALMS1P	4.33	2.22e-05	0.00915	0.41	0.27	Metabolite levels;	chr2:73477348	chr2:73644919~73685576:+
SARC	cis	rs7267979	0.934	rs4815423	ENSG00000276952.1	RP5-965G21.6	-4.33	2.23e-05	0.00915	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2482918	ENSG00000276952.1	RP5-965G21.6	-4.33	2.23e-05	0.00915	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25284915~25285588:-
SARC	cis	rs4835473	0.932	rs7356157	ENSG00000251600.4	RP11-673E1.1	4.33	2.23e-05	0.00915	0.26	0.27	Immature fraction of reticulocytes;	chr4:143739233	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs2127788	ENSG00000251600.4	RP11-673E1.1	4.33	2.23e-05	0.00915	0.26	0.27	Immature fraction of reticulocytes;	chr4:143741996	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs6851999	ENSG00000251600.4	RP11-673E1.1	4.33	2.23e-05	0.00915	0.26	0.27	Immature fraction of reticulocytes;	chr4:143742567	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs6852195	ENSG00000251600.4	RP11-673E1.1	4.33	2.23e-05	0.00915	0.26	0.27	Immature fraction of reticulocytes;	chr4:143742584	chr4:143912331~143982454:+
SARC	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-4.33	2.23e-05	0.00916	-0.4	-0.27	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
SARC	cis	rs4703855	0.538	rs4703872	ENSG00000244061.1	RP11-389C8.1	4.33	2.23e-05	0.00916	0.28	0.27	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72427817	chr5:72381794~72382393:+
SARC	cis	rs801193	0.66	rs4610622	ENSG00000232559.3	GS1-124K5.12	4.33	2.23e-05	0.00917	0.31	0.27	Aortic root size;	chr7:66759510	chr7:66554588~66576923:-
SARC	cis	rs948562	0.793	rs11229552	ENSG00000280010.1	AP001350.4	4.33	2.23e-05	0.00917	0.4	0.27	Lymphoma;	chr11:58633441	chr11:58627435~58628528:+
SARC	cis	rs9473147	0.516	rs6931478	ENSG00000270761.1	RP11-385F7.1	-4.33	2.23e-05	0.00917	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47494177	chr6:47477243~47477572:-
SARC	cis	rs7216064	0.7	rs4791295	ENSG00000278740.1	RP11-147L13.14	4.33	2.23e-05	0.00917	0.31	0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68001201	chr17:68188547~68189165:+
SARC	cis	rs1799949	0.965	rs799916	ENSG00000267681.1	CTD-3199J23.6	4.33	2.23e-05	0.00918	0.29	0.27	Menopause (age at onset);	chr17:43091173	chr17:43144956~43145255:+
SARC	cis	rs7615952	0.688	rs12638224	ENSG00000248787.1	RP11-666A20.4	-4.33	2.23e-05	0.00918	-0.39	-0.27	Blood pressure (smoking interaction);	chr3:125822477	chr3:125908005~125910272:-
SARC	cis	rs4835473	0.897	rs6537170	ENSG00000251600.4	RP11-673E1.1	4.33	2.23e-05	0.00918	0.26	0.27	Immature fraction of reticulocytes;	chr4:143691747	chr4:143912331~143982454:+
SARC	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-4.33	2.24e-05	0.00919	-0.33	-0.27	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
SARC	cis	rs8059260	0.542	rs16957948	ENSG00000274038.1	RP11-66H6.4	-4.33	2.24e-05	0.00919	-0.37	-0.27	Alcohol consumption over the past year;	chr16:11034208	chr16:11056556~11057034:+
SARC	cis	rs4679904	0.96	rs76358731	ENSG00000243116.1	RP11-564C24.1	4.33	2.24e-05	0.00919	0.28	0.27	Primary biliary cholangitis;	chr3:160639897	chr3:159721524~159722401:-
SARC	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-4.33	2.24e-05	0.00919	-0.45	-0.27	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
SARC	cis	rs7216064	0.636	rs62084696	ENSG00000237854.3	LINC00674	-4.33	2.24e-05	0.0092	-0.31	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68042065	chr17:68101908~68115518:+
SARC	cis	rs367615	0.918	rs4270746	ENSG00000249476.1	CTD-2587M2.1	4.33	2.24e-05	0.0092	0.36	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109541138	chr5:109237120~109326369:-
SARC	cis	rs367615	0.918	rs72797472	ENSG00000249476.1	CTD-2587M2.1	4.33	2.24e-05	0.0092	0.36	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109545642	chr5:109237120~109326369:-
SARC	cis	rs8005677	0.798	rs4982713	ENSG00000279656.1	RP11-298I3.6	4.33	2.24e-05	0.00921	0.36	0.27	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:23023083~23024217:-
SARC	cis	rs8005677	0.798	rs35615180	ENSG00000279656.1	RP11-298I3.6	4.33	2.24e-05	0.00921	0.36	0.27	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:23023083~23024217:-
SARC	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	4.33	2.24e-05	0.00921	0.31	0.27	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
SARC	cis	rs12554020	0.786	rs6479482	ENSG00000227603.1	RP11-165J3.6	4.33	2.24e-05	0.00921	0.37	0.27	Schizophrenia;	chr9:93435814	chr9:93435332~93437121:-
SARC	cis	rs4835473	0.932	rs7696106	ENSG00000251600.4	RP11-673E1.1	-4.33	2.25e-05	0.00922	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143765454	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs7680045	ENSG00000251600.4	RP11-673E1.1	-4.33	2.25e-05	0.00922	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143765470	chr4:143912331~143982454:+
SARC	cis	rs10911902	0.643	rs78088787	ENSG00000229739.2	RP11-295K2.3	-4.33	2.25e-05	0.00923	-0.39	-0.27	Schizophrenia;	chr1:186364550	chr1:186435161~186470291:+
SARC	cis	rs30380	0.632	rs26497	ENSG00000272109.1	CTD-2260A17.3	-4.33	2.25e-05	0.00923	-0.35	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96803064	chr5:96804353~96806105:+
SARC	cis	rs11634944	0.615	rs1549475	ENSG00000274307.1	RP11-345J18.2	-4.33	2.25e-05	0.00923	-0.35	-0.27	Interleukin-8 levels;	chr15:25001297	chr15:25708470~25710869:-
SARC	cis	rs7772486	0.79	rs3924498	ENSG00000270638.1	RP3-466P17.1	-4.33	2.25e-05	0.00924	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145735570~145737218:+
SARC	cis	rs55894132	1	rs55894132	ENSG00000279656.1	RP11-298I3.6	4.33	2.25e-05	0.00925	0.36	0.27	Intelligence (multi-trait analysis);	chr14:22939628	chr14:23023083~23024217:-
SARC	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-4.33	2.25e-05	0.00925	-0.25	-0.27	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
SARC	cis	rs7267979	1	rs4815411	ENSG00000276952.1	RP5-965G21.6	-4.33	2.25e-05	0.00925	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25284915~25285588:-
SARC	cis	rs755249	0.529	rs3768299	ENSG00000182109.6	RP11-69E11.4	4.33	2.25e-05	0.00925	0.31	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39522280~39546187:-
SARC	cis	rs889122	0.729	rs16996141	ENSG00000267289.1	CTD-2623N2.11	4.33	2.25e-05	0.00926	0.34	0.27	Menarche (age at onset);	chr19:9855016	chr19:9834079~9835013:-
SARC	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-4.33	2.26e-05	0.00926	-0.42	-0.27	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
SARC	cis	rs4713118	0.662	rs149961	ENSG00000216901.1	AL022393.7	4.33	2.26e-05	0.00926	0.4	0.27	Parkinson's disease;	chr6:28047791	chr6:28176188~28176674:+
SARC	cis	rs7811142	1	rs11559117	ENSG00000078319.8	PMS2P1	-4.33	2.26e-05	0.00926	-0.39	-0.27	Platelet count;	chr7:100478991	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs4463351	ENSG00000078319.8	PMS2P1	-4.33	2.26e-05	0.00926	-0.39	-0.27	Platelet count;	chr7:100480603	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs60844404	ENSG00000078319.8	PMS2P1	-4.33	2.26e-05	0.00926	-0.39	-0.27	Platelet count;	chr7:100482851	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs113738841	ENSG00000078319.8	PMS2P1	-4.33	2.26e-05	0.00926	-0.39	-0.27	Platelet count;	chr7:100483683	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs11763511	ENSG00000078319.8	PMS2P1	-4.33	2.26e-05	0.00926	-0.39	-0.27	Platelet count;	chr7:100484321	chr7:100320992~100341908:-
SARC	cis	rs4835473	0.932	rs7687151	ENSG00000251600.4	RP11-673E1.1	-4.33	2.26e-05	0.00927	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143781681	chr4:143912331~143982454:+
SARC	cis	rs783540	0.967	rs783523	ENSG00000275695.1	UBE2Q2P6	4.33	2.26e-05	0.00928	0.27	0.27	Schizophrenia;	chr15:82614804	chr15:82445719~82454837:+
SARC	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-4.33	2.26e-05	0.00928	-0.3	-0.27	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
SARC	cis	rs4862750	0.914	rs11943333	ENSG00000250971.1	RP11-696F12.1	4.32	2.27e-05	0.00929	0.35	0.27	Lobe attachment (rater-scored or self-reported);	chr4:186951301	chr4:187060099~187060930:+
SARC	cis	rs853679	0.769	rs17720293	ENSG00000219392.1	RP1-265C24.5	-4.32	2.27e-05	0.0093	-0.59	-0.27	Depression;	chr6:28246920	chr6:28115628~28116551:+
SARC	cis	rs10515750	0.643	rs10063539	ENSG00000251405.2	CTB-109A12.1	4.32	2.27e-05	0.0093	0.35	0.27	Lung function (FEV1/FVC);	chr5:157384666	chr5:157362615~157460078:-
SARC	cis	rs4820294	0.669	rs9622678	ENSG00000233360.4	Z83844.1	4.32	2.27e-05	0.0093	0.31	0.27	Fat distribution (HIV);	chr22:37661331	chr22:37641832~37658377:-
SARC	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	4.32	2.27e-05	0.0093	0.35	0.27	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
SARC	cis	rs7615952	0.688	rs9754526	ENSG00000248787.1	RP11-666A20.4	-4.32	2.27e-05	0.00931	-0.38	-0.27	Blood pressure (smoking interaction);	chr3:125824023	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.599	rs66532274	ENSG00000250012.1	RP11-124N2.1	-4.32	2.27e-05	0.00931	-0.25	-0.27	Blood pressure (smoking interaction);	chr3:126013002	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.599	rs2333408	ENSG00000250012.1	RP11-124N2.1	-4.32	2.27e-05	0.00931	-0.25	-0.27	Blood pressure (smoking interaction);	chr3:126013255	chr3:126084220~126095349:+
SARC	cis	rs597539	0.654	rs619727	ENSG00000250508.1	RP11-757G1.6	-4.32	2.28e-05	0.00933	-0.32	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:68870664~68874542:+
SARC	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	4.32	2.28e-05	0.00934	0.28	0.27	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
SARC	cis	rs13217239	0.646	rs7451149	ENSG00000241549.7	GUSBP2	-4.32	2.28e-05	0.00934	-0.26	-0.27	Schizophrenia;	chr6:27089739	chr6:26871484~26956554:-
SARC	cis	rs72634501	0.716	rs67062906	ENSG00000182109.6	RP11-69E11.4	4.32	2.28e-05	0.00934	0.3	0.27	HDL cholesterol;	chr1:39151018	chr1:39522280~39546187:-
SARC	cis	rs7216064	0.532	rs3890640	ENSG00000278740.1	RP11-147L13.14	-4.32	2.28e-05	0.00935	-0.29	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68056912	chr17:68188547~68189165:+
SARC	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-4.32	2.28e-05	0.00935	-0.4	-0.27	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
SARC	cis	rs755249	1	rs61779359	ENSG00000182109.6	RP11-69E11.4	4.32	2.28e-05	0.00935	0.31	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39522280~39546187:-
SARC	cis	rs755249	0.959	rs61781363	ENSG00000182109.6	RP11-69E11.4	4.32	2.28e-05	0.00935	0.31	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39522280~39546187:-
SARC	cis	rs755249	1	rs4660808	ENSG00000182109.6	RP11-69E11.4	4.32	2.28e-05	0.00935	0.31	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39522280~39546187:-
SARC	cis	rs755249	1	rs61781364	ENSG00000182109.6	RP11-69E11.4	4.32	2.28e-05	0.00935	0.31	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39522280~39546187:-
SARC	cis	rs890448	0.796	rs4699212	ENSG00000254531.1	FLJ20021	-4.32	2.29e-05	0.00936	-0.3	-0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101367620	chr4:101347780~101348883:+
SARC	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-4.32	2.29e-05	0.00936	-0.5	-0.27	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-4.32	2.29e-05	0.00936	-0.5	-0.27	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-4.32	2.29e-05	0.00936	-0.5	-0.27	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-4.32	2.29e-05	0.00936	-0.5	-0.27	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-4.32	2.29e-05	0.00936	-0.5	-0.27	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-4.32	2.29e-05	0.00936	-0.5	-0.27	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
SARC	cis	rs4934494	0.768	rs1409357	ENSG00000240996.1	RP11-80H5.7	-4.32	2.29e-05	0.00937	-0.3	-0.27	Red blood cell count;	chr10:89669719	chr10:89694295~89697928:-
SARC	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	4.32	2.29e-05	0.00937	0.31	0.27	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
SARC	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	4.32	2.29e-05	0.00937	0.31	0.27	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
SARC	cis	rs7772486	0.875	rs2492855	ENSG00000270638.1	RP3-466P17.1	4.32	2.29e-05	0.00937	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145975790	chr6:145735570~145737218:+
SARC	cis	rs1930961	1	rs59226697	ENSG00000100058.11	CRYBB2P1	4.32	2.29e-05	0.00938	0.64	0.27	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25448105~25520854:+
SARC	cis	rs12922317	0.538	rs442234	ENSG00000260488.1	RP11-166B2.7	4.32	2.29e-05	0.00938	0.27	0.27	Schizophrenia;	chr16:11978304	chr16:11976851~11977850:-
SARC	cis	rs910316	1	rs28626045	ENSG00000279594.1	RP11-950C14.10	4.32	2.3e-05	0.0094	0.29	0.27	Height;	chr14:75122492	chr14:75011269~75012851:-
SARC	cis	rs910316	0.967	rs12890371	ENSG00000279594.1	RP11-950C14.10	4.32	2.3e-05	0.0094	0.29	0.27	Height;	chr14:75127136	chr14:75011269~75012851:-
SARC	cis	rs910316	1	rs12889309	ENSG00000279594.1	RP11-950C14.10	4.32	2.3e-05	0.0094	0.29	0.27	Height;	chr14:75127199	chr14:75011269~75012851:-
SARC	cis	rs910316	1	rs4322591	ENSG00000279594.1	RP11-950C14.10	4.32	2.3e-05	0.0094	0.29	0.27	Height;	chr14:75133994	chr14:75011269~75012851:-
SARC	cis	rs910316	1	rs876403	ENSG00000279594.1	RP11-950C14.10	4.32	2.3e-05	0.0094	0.29	0.27	Height;	chr14:75136131	chr14:75011269~75012851:-
SARC	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-4.32	2.3e-05	0.0094	-0.25	-0.27	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
SARC	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-4.32	2.3e-05	0.0094	-0.4	-0.27	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
SARC	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-4.32	2.3e-05	0.00941	-0.37	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
SARC	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-4.32	2.31e-05	0.00944	-0.4	-0.27	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
SARC	cis	rs4664293	0.625	rs7595852	ENSG00000226266.5	AC009961.3	4.32	2.31e-05	0.00944	0.31	0.27	Monocyte percentage of white cells;	chr2:159683656	chr2:159670708~159712435:-
SARC	cis	rs4835473	0.932	rs1849112	ENSG00000251600.4	RP11-673E1.1	4.32	2.31e-05	0.00945	0.27	0.27	Immature fraction of reticulocytes;	chr4:143962502	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.831	rs4125544	ENSG00000251600.4	RP11-673E1.1	4.32	2.31e-05	0.00945	0.27	0.27	Immature fraction of reticulocytes;	chr4:143962542	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.864	rs12507633	ENSG00000251600.4	RP11-673E1.1	4.32	2.31e-05	0.00945	0.27	0.27	Immature fraction of reticulocytes;	chr4:143962730	chr4:143912331~143982454:+
SARC	cis	rs2439831	0.85	rs8023458	ENSG00000275601.1	AC011330.13	-4.32	2.31e-05	0.00945	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43788741	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs16963953	ENSG00000275601.1	AC011330.13	-4.32	2.31e-05	0.00945	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43789521	chr15:43642389~43643023:-
SARC	cis	rs75920871	0.528	rs11216245	ENSG00000254851.1	RP11-109L13.1	4.32	2.31e-05	0.00945	0.36	0.27	Subjective well-being;	chr11:117042486	chr11:117135528~117138582:+
SARC	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	4.32	2.31e-05	0.00946	0.33	0.27	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
SARC	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	4.32	2.31e-05	0.00946	0.33	0.27	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
SARC	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	4.32	2.31e-05	0.00946	0.33	0.27	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
SARC	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	4.32	2.31e-05	0.00946	0.33	0.27	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
SARC	cis	rs7772486	0.776	rs4316025	ENSG00000270638.1	RP3-466P17.1	-4.32	2.31e-05	0.00946	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145916896	chr6:145735570~145737218:+
SARC	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	4.32	2.32e-05	0.00946	0.32	0.27	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
SARC	cis	rs801193	0.66	rs10950049	ENSG00000232559.3	GS1-124K5.12	4.32	2.32e-05	0.00947	0.31	0.27	Aortic root size;	chr7:66765873	chr7:66554588~66576923:-
SARC	cis	rs2412819	0.571	rs12900924	ENSG00000205771.5	CATSPER2P1	-4.32	2.32e-05	0.00948	-0.42	-0.27	Lung cancer;	chr15:43737329	chr15:43726918~43747094:-
SARC	cis	rs12554020	0.892	rs3815563	ENSG00000227603.1	RP11-165J3.6	4.32	2.32e-05	0.00948	0.36	0.27	Schizophrenia;	chr9:93450864	chr9:93435332~93437121:-
SARC	cis	rs12554020	1	rs7853605	ENSG00000227603.1	RP11-165J3.6	4.32	2.32e-05	0.00948	0.36	0.27	Schizophrenia;	chr9:93451247	chr9:93435332~93437121:-
SARC	cis	rs12468226	1	rs76528043	ENSG00000272966.1	RP11-686O6.1	4.32	2.32e-05	0.00948	0.43	0.27	Urate levels;	chr2:202466116	chr2:202336739~202337200:+
SARC	cis	rs12468226	1	rs12468226	ENSG00000272966.1	RP11-686O6.1	4.32	2.32e-05	0.00948	0.43	0.27	Urate levels;	chr2:202472278	chr2:202336739~202337200:+
SARC	cis	rs12468226	1	rs75040639	ENSG00000272966.1	RP11-686O6.1	4.32	2.32e-05	0.00948	0.43	0.27	Urate levels;	chr2:202486973	chr2:202336739~202337200:+
SARC	cis	rs12468226	0.872	rs115187557	ENSG00000272966.1	RP11-686O6.1	4.32	2.32e-05	0.00948	0.43	0.27	Urate levels;	chr2:202495351	chr2:202336739~202337200:+
SARC	cis	rs867371	0.519	rs1566560	ENSG00000278603.1	RP13-608F4.5	4.32	2.32e-05	0.00948	0.32	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472203~82472426:+
SARC	cis	rs867371	0.519	rs1566559	ENSG00000278603.1	RP13-608F4.5	4.32	2.32e-05	0.00948	0.32	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472203~82472426:+
SARC	cis	rs17695224	0.545	rs4802875	ENSG00000275055.1	CTC-471J1.11	-4.32	2.32e-05	0.00948	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51827056	chr19:52049007~52049754:+
SARC	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-4.32	2.32e-05	0.00948	-0.24	-0.27	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
SARC	cis	rs10986311	0.713	rs944337	ENSG00000235204.1	RP11-121A14.2	4.32	2.32e-05	0.00949	0.32	0.27	Vitiligo;	chr9:124259987	chr9:124259250~124261156:-
SARC	cis	rs10986311	0.747	rs944338	ENSG00000235204.1	RP11-121A14.2	4.32	2.32e-05	0.00949	0.32	0.27	Vitiligo;	chr9:124259988	chr9:124259250~124261156:-
SARC	cis	rs7181230	0.845	rs4923852	ENSG00000275636.1	RP11-521C20.5	-4.32	2.32e-05	0.00949	-0.3	-0.27	Dehydroepiandrosterone sulphate levels;	chr15:40085664	chr15:40078892~40079347:+
SARC	cis	rs394563	0.591	rs805026	ENSG00000231760.4	RP11-350J20.5	4.32	2.33e-05	0.00951	0.34	0.27	Dupuytren's disease;	chr6:149407118	chr6:149796151~149826294:-
SARC	cis	rs910316	1	rs175512	ENSG00000279594.1	RP11-950C14.10	-4.32	2.33e-05	0.00951	-0.3	-0.27	Height;	chr14:75056679	chr14:75011269~75012851:-
SARC	cis	rs11264213	0.901	rs10796876	ENSG00000271554.1	RP4-665N4.8	-4.32	2.33e-05	0.00951	-0.37	-0.27	Schizophrenia;	chr1:35959384	chr1:35992109~36013630:-
SARC	cis	rs11264213	0.901	rs649152	ENSG00000271554.1	RP4-665N4.8	-4.32	2.33e-05	0.00951	-0.37	-0.27	Schizophrenia;	chr1:35973048	chr1:35992109~36013630:-
SARC	cis	rs11264213	0.901	rs682686	ENSG00000271554.1	RP4-665N4.8	-4.32	2.33e-05	0.00951	-0.37	-0.27	Schizophrenia;	chr1:35978177	chr1:35992109~36013630:-
SARC	cis	rs11264213	0.901	rs665521	ENSG00000271554.1	RP4-665N4.8	-4.32	2.33e-05	0.00951	-0.37	-0.27	Schizophrenia;	chr1:35980236	chr1:35992109~36013630:-
SARC	cis	rs8062405	0.691	rs11646653	ENSG00000251417.2	RP11-1348G14.4	4.32	2.33e-05	0.00952	0.27	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28802743~28817828:+
SARC	cis	rs7772486	0.686	rs9399564	ENSG00000235652.6	RP11-545I5.3	-4.32	2.33e-05	0.00952	-0.24	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145799409~145886585:+
SARC	cis	rs7726354	1	rs74571895	ENSG00000271828.1	CTD-2310F14.1	4.32	2.33e-05	0.00952	0.57	0.27	Breast cancer (early onset);	chr5:56958945	chr5:56927874~56929573:+
SARC	cis	rs7726354	1	rs78743305	ENSG00000271828.1	CTD-2310F14.1	4.32	2.33e-05	0.00952	0.57	0.27	Breast cancer (early onset);	chr5:56960390	chr5:56927874~56929573:+
SARC	cis	rs7772486	0.754	rs2064185	ENSG00000270638.1	RP3-466P17.1	-4.32	2.33e-05	0.00953	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145735570~145737218:+
SARC	cis	rs172166	0.694	rs1631552	ENSG00000272009.1	RP1-313I6.12	-4.32	2.33e-05	0.00953	-0.3	-0.27	Cardiac Troponin-T levels;	chr6:28121921	chr6:28078792~28081130:-
SARC	cis	rs2288884	0.649	rs11667001	ENSG00000275055.1	CTC-471J1.11	-4.32	2.33e-05	0.00953	-0.42	-0.27	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049416	chr19:52049007~52049754:+
SARC	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-4.32	2.33e-05	0.00953	-0.3	-0.27	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-4.32	2.33e-05	0.00953	-0.3	-0.27	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
SARC	cis	rs2439831	1	rs2467426	ENSG00000205771.5	CATSPER2P1	-4.32	2.34e-05	0.00954	-0.43	-0.27	Lung cancer in ever smokers;	chr15:43697320	chr15:43726918~43747094:-
SARC	cis	rs10911902	0.688	rs113019508	ENSG00000229739.2	RP11-295K2.3	-4.32	2.34e-05	0.00955	-0.39	-0.27	Schizophrenia;	chr1:186349685	chr1:186435161~186470291:+
SARC	cis	rs7712401	0.58	rs10076327	ENSG00000263432.2	RN7SL689P	4.32	2.34e-05	0.00956	0.35	0.27	Mean platelet volume;	chr5:123031652	chr5:123022487~123022783:-
SARC	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	4.32	2.34e-05	0.00956	0.25	0.27	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
SARC	cis	rs2412819	0.571	rs4923965	ENSG00000205771.5	CATSPER2P1	4.32	2.34e-05	0.00956	0.4	0.27	Lung cancer;	chr15:43790232	chr15:43726918~43747094:-
SARC	cis	rs2412819	0.571	rs6493090	ENSG00000205771.5	CATSPER2P1	4.32	2.34e-05	0.00956	0.4	0.27	Lung cancer;	chr15:43792084	chr15:43726918~43747094:-
SARC	cis	rs2412819	0.571	rs4644832	ENSG00000205771.5	CATSPER2P1	4.32	2.34e-05	0.00956	0.4	0.27	Lung cancer;	chr15:43792507	chr15:43726918~43747094:-
SARC	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	4.32	2.34e-05	0.00956	0.34	0.27	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
SARC	cis	rs10911902	0.643	rs6689129	ENSG00000229739.2	RP11-295K2.3	-4.32	2.34e-05	0.00957	-0.39	-0.27	Schizophrenia;	chr1:186357078	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs16825243	ENSG00000229739.2	RP11-295K2.3	-4.32	2.34e-05	0.00957	-0.39	-0.27	Schizophrenia;	chr1:186357769	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs76469621	ENSG00000229739.2	RP11-295K2.3	-4.32	2.34e-05	0.00957	-0.39	-0.27	Schizophrenia;	chr1:186363848	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs79081972	ENSG00000229739.2	RP11-295K2.3	-4.32	2.34e-05	0.00957	-0.39	-0.27	Schizophrenia;	chr1:186364669	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs75490185	ENSG00000229739.2	RP11-295K2.3	-4.32	2.34e-05	0.00957	-0.39	-0.27	Schizophrenia;	chr1:186366319	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs112738913	ENSG00000229739.2	RP11-295K2.3	-4.32	2.34e-05	0.00957	-0.39	-0.27	Schizophrenia;	chr1:186367231	chr1:186435161~186470291:+
SARC	cis	rs9595908	0.931	rs9595617	ENSG00000212293.1	SNORA16	4.32	2.35e-05	0.00957	0.28	0.27	Body mass index;	chr13:32483208	chr13:32420390~32420516:-
SARC	cis	rs2562456	0.755	rs2650773	ENSG00000268081.1	RP11-678G14.2	-4.32	2.35e-05	0.00957	-0.41	-0.27	Pain;	chr19:21461286	chr19:21554640~21569237:-
SARC	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	4.32	2.35e-05	0.00957	0.32	0.27	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
SARC	cis	rs10055631	0.5	rs706702	ENSG00000229666.1	MAST4-AS1	4.32	2.35e-05	0.00957	0.28	0.27	Coronary artery disease;	chr5:67009622	chr5:67001383~67003953:-
SARC	cis	rs6657613	0.503	rs9435739	ENSG00000186715.9	MST1L	4.32	2.35e-05	0.00958	0.28	0.27	Hip circumference adjusted for BMI;	chr1:17016429	chr1:16754910~16770237:-
SARC	cis	rs3136516	0.935	rs4506602	ENSG00000270060.1	RP11-390K5.6	4.32	2.35e-05	0.00958	0.18	0.27	Venous thromboembolism;	chr11:46794083	chr11:47168281~47169563:-
SARC	cis	rs9364687	0.628	rs4709720	ENSG00000228692.2	RP5-826L7.1	-4.32	2.35e-05	0.00958	-0.32	-0.27	Body mass index;	chr6:163503273	chr6:163586583~163588165:-
SARC	cis	rs9364687	0.689	rs9364689	ENSG00000228692.2	RP5-826L7.1	-4.32	2.35e-05	0.00958	-0.32	-0.27	Body mass index;	chr6:163508308	chr6:163586583~163588165:-
SARC	cis	rs367615	0.704	rs6889301	ENSG00000249476.1	CTD-2587M2.1	4.32	2.35e-05	0.00958	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109499480	chr5:109237120~109326369:-
SARC	cis	rs367615	0.661	rs9326775	ENSG00000249476.1	CTD-2587M2.1	4.32	2.35e-05	0.00958	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109501224	chr5:109237120~109326369:-
SARC	cis	rs1880529	0.83	rs3796929	ENSG00000206820.1	RNU1-138P	-4.32	2.35e-05	0.00958	-0.26	-0.27	White matter integrity (bipolar disorder risk interaction);	chr4:113446824	chr4:113420323~113420486:+
SARC	cis	rs7267979	0.789	rs4815429	ENSG00000274414.1	RP5-965G21.4	4.32	2.35e-05	0.00959	0.28	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:25239007~25245229:-
SARC	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	4.32	2.35e-05	0.0096	0.27	0.27	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
SARC	cis	rs253959	0.545	rs4921057	ENSG00000272265.1	CTD-2287O16.4	4.32	2.35e-05	0.0096	0.31	0.27	Bipolar disorder and schizophrenia;	chr5:116090723	chr5:116078110~116078570:-
SARC	cis	rs853679	0.628	rs9368560	ENSG00000272009.1	RP1-313I6.12	-4.32	2.36e-05	0.00962	-0.33	-0.27	Depression;	chr6:28192182	chr6:28078792~28081130:-
SARC	cis	rs9573567	1	rs74239773	ENSG00000261553.4	RP11-29G8.3	-4.31	2.36e-05	0.00962	-0.53	-0.27	Red blood cell count;Mean corpuscular volume;	chr13:75493858	chr13:75549773~75807120:+
SARC	cis	rs9573567	1	rs77775668	ENSG00000261553.4	RP11-29G8.3	-4.31	2.36e-05	0.00962	-0.53	-0.27	Red blood cell count;Mean corpuscular volume;	chr13:75494142	chr13:75549773~75807120:+
SARC	cis	rs9573567	1	rs961631	ENSG00000261553.4	RP11-29G8.3	-4.31	2.36e-05	0.00962	-0.53	-0.27	Red blood cell count;Mean corpuscular volume;	chr13:75494340	chr13:75549773~75807120:+
SARC	cis	rs9573567	1	rs4142591	ENSG00000261553.4	RP11-29G8.3	-4.31	2.36e-05	0.00962	-0.53	-0.27	Red blood cell count;Mean corpuscular volume;	chr13:75494789	chr13:75549773~75807120:+
SARC	cis	rs9573567	1	rs78772197	ENSG00000261553.4	RP11-29G8.3	-4.31	2.36e-05	0.00962	-0.53	-0.27	Red blood cell count;Mean corpuscular volume;	chr13:75494856	chr13:75549773~75807120:+
SARC	cis	rs9573567	1	rs76947676	ENSG00000261553.4	RP11-29G8.3	-4.31	2.36e-05	0.00962	-0.53	-0.27	Red blood cell count;Mean corpuscular volume;	chr13:75495484	chr13:75549773~75807120:+
SARC	cis	rs9573567	1	rs74906504	ENSG00000261553.4	RP11-29G8.3	-4.31	2.36e-05	0.00962	-0.53	-0.27	Red blood cell count;Mean corpuscular volume;	chr13:75495672	chr13:75549773~75807120:+
SARC	cis	rs9573567	1	rs75965116	ENSG00000261553.4	RP11-29G8.3	-4.31	2.36e-05	0.00962	-0.53	-0.27	Red blood cell count;Mean corpuscular volume;	chr13:75496211	chr13:75549773~75807120:+
SARC	cis	rs9573567	1	rs79011584	ENSG00000261553.4	RP11-29G8.3	-4.31	2.36e-05	0.00962	-0.53	-0.27	Red blood cell count;Mean corpuscular volume;	chr13:75496506	chr13:75549773~75807120:+
SARC	cis	rs9573567	1	rs76498606	ENSG00000261553.4	RP11-29G8.3	-4.31	2.36e-05	0.00962	-0.53	-0.27	Red blood cell count;Mean corpuscular volume;	chr13:75496510	chr13:75549773~75807120:+
SARC	cis	rs9573567	0.881	rs9573571	ENSG00000261553.4	RP11-29G8.3	-4.31	2.36e-05	0.00962	-0.53	-0.27	Red blood cell count;Mean corpuscular volume;	chr13:75498684	chr13:75549773~75807120:+
SARC	cis	rs7267979	0.844	rs4815413	ENSG00000276952.1	RP5-965G21.6	-4.31	2.36e-05	0.00962	-0.26	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.844	rs6083824	ENSG00000276952.1	RP5-965G21.6	-4.31	2.36e-05	0.00962	-0.26	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:25284915~25285588:-
SARC	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-4.31	2.36e-05	0.00962	-0.28	-0.27	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
SARC	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	4.31	2.36e-05	0.00963	0.31	0.27	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
SARC	cis	rs910316	0.87	rs7147712	ENSG00000279594.1	RP11-950C14.10	-4.31	2.36e-05	0.00963	-0.3	-0.27	Height;	chr14:75204004	chr14:75011269~75012851:-
SARC	cis	rs4835473	0.897	rs4835333	ENSG00000251600.4	RP11-673E1.1	-4.31	2.36e-05	0.00963	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143703174	chr4:143912331~143982454:+
SARC	cis	rs12049351	0.774	rs12079612	ENSG00000229367.1	HMGN2P19	4.31	2.37e-05	0.00964	0.23	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229513625	chr1:229570532~229570796:+
SARC	cis	rs9364687	0.664	rs9364691	ENSG00000228692.2	RP5-826L7.1	-4.31	2.37e-05	0.00965	-0.32	-0.27	Body mass index;	chr6:163526392	chr6:163586583~163588165:-
SARC	cis	rs75920871	0.528	rs11216255	ENSG00000254851.1	RP11-109L13.1	4.31	2.37e-05	0.00965	0.35	0.27	Subjective well-being;	chr11:117059279	chr11:117135528~117138582:+
SARC	cis	rs7615952	0.932	rs7629977	ENSG00000241288.6	RP11-379B18.5	-4.31	2.37e-05	0.00965	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125930730	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.932	rs7630077	ENSG00000241288.6	RP11-379B18.5	-4.31	2.37e-05	0.00965	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125930833	chr3:125827238~125916384:-
SARC	cis	rs12285276	0.504	rs7120278	ENSG00000205106.4	DKFZp779M0652	4.31	2.37e-05	0.00965	0.38	0.27	Visceral fat;	chr11:45796560	chr11:45771432~45772358:+
SARC	cis	rs6844153	0.752	rs7681462	ENSG00000240005.4	RP11-293A21.1	-4.31	2.37e-05	0.00965	-0.34	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26894272	chr4:26859806~26860599:-
SARC	cis	rs324126	0.78	rs2059818	ENSG00000269834.4	ZNF528-AS1	4.31	2.37e-05	0.00966	0.3	0.27	Colonoscopy-negative controls vs population controls;	chr19:52379267	chr19:52388842~52397766:-
SARC	cis	rs1062177	1	rs12653926	ENSG00000254226.4	CTB-12O2.1	4.31	2.37e-05	0.00966	0.37	0.27	Preschool internalizing problems;	chr5:151870687	chr5:151949571~152270448:+
SARC	cis	rs875971	1	rs7792762	ENSG00000232559.3	GS1-124K5.12	4.31	2.37e-05	0.00966	0.31	0.27	Aortic root size;	chr7:66539151	chr7:66554588~66576923:-
SARC	cis	rs7267979	0.932	rs6115215	ENSG00000276952.1	RP5-965G21.6	4.31	2.38e-05	0.00967	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25284915~25285588:-
SARC	cis	rs948562	0.535	rs11229439	ENSG00000280010.1	AP001350.4	4.31	2.38e-05	0.00968	0.41	0.27	Lymphoma;	chr11:58425138	chr11:58627435~58628528:+
SARC	cis	rs7772486	0.79	rs3923579	ENSG00000270638.1	RP3-466P17.1	-4.31	2.38e-05	0.00969	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs2247429	ENSG00000270638.1	RP3-466P17.1	4.31	2.38e-05	0.00969	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs2247666	ENSG00000270638.1	RP3-466P17.1	4.31	2.38e-05	0.00969	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145735570~145737218:+
SARC	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-4.31	2.38e-05	0.00969	-0.5	-0.27	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-4.31	2.38e-05	0.00969	-0.5	-0.27	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-4.31	2.38e-05	0.00969	-0.5	-0.27	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-4.31	2.38e-05	0.00969	-0.5	-0.27	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-4.31	2.38e-05	0.00969	-0.5	-0.27	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-4.31	2.38e-05	0.00969	-0.5	-0.27	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-4.31	2.38e-05	0.00969	-0.5	-0.27	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
SARC	cis	rs2439831	0.764	rs2447193	ENSG00000275601.1	AC011330.13	-4.31	2.38e-05	0.00969	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43637535	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs2447211	ENSG00000275601.1	AC011330.13	-4.31	2.38e-05	0.00969	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43644153	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.571	rs2470121	ENSG00000275601.1	AC011330.13	-4.31	2.38e-05	0.00969	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43645420	chr15:43642389~43643023:-
SARC	cis	rs13217239	0.646	rs7768407	ENSG00000241549.7	GUSBP2	4.31	2.38e-05	0.0097	0.26	0.27	Schizophrenia;	chr6:27049016	chr6:26871484~26956554:-
SARC	cis	rs7267979	0.899	rs6115213	ENSG00000276952.1	RP5-965G21.6	4.31	2.39e-05	0.0097	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25284915~25285588:-
SARC	cis	rs7247513	0.797	rs3815914	ENSG00000213290.4	PGK1P2	-4.31	2.39e-05	0.0097	-0.32	-0.27	Bipolar disorder;	chr19:12649850	chr19:12559571~12561105:+
SARC	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	4.31	2.39e-05	0.0097	0.33	0.27	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
SARC	cis	rs7615952	0.512	rs34085484	ENSG00000248787.1	RP11-666A20.4	-4.31	2.39e-05	0.00971	-0.38	-0.27	Blood pressure (smoking interaction);	chr3:125825343	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.575	rs35949599	ENSG00000248787.1	RP11-666A20.4	-4.31	2.39e-05	0.00971	-0.38	-0.27	Blood pressure (smoking interaction);	chr3:125825359	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.608	rs35668111	ENSG00000248787.1	RP11-666A20.4	-4.31	2.39e-05	0.00971	-0.38	-0.27	Blood pressure (smoking interaction);	chr3:125825792	chr3:125908005~125910272:-
SARC	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	4.31	2.39e-05	0.00971	0.32	0.27	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
SARC	cis	rs890448	0.796	rs4574415	ENSG00000254531.1	FLJ20021	4.31	2.39e-05	0.00971	0.29	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101361276	chr4:101347780~101348883:+
SARC	cis	rs7615952	0.932	rs13086087	ENSG00000241288.6	RP11-379B18.5	-4.31	2.39e-05	0.00971	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125927438	chr3:125827238~125916384:-
SARC	cis	rs4862750	0.872	rs13101380	ENSG00000250971.1	RP11-696F12.1	4.31	2.39e-05	0.00972	0.32	0.27	Lobe attachment (rater-scored or self-reported);	chr4:186973590	chr4:187060099~187060930:+
SARC	cis	rs42490	0.966	rs218932	ENSG00000251136.7	RP11-37B2.1	-4.31	2.39e-05	0.00972	-0.3	-0.27	Leprosy;	chr8:89740725	chr8:89609409~89757727:-
SARC	cis	rs42490	0.966	rs2735878	ENSG00000251136.7	RP11-37B2.1	-4.31	2.39e-05	0.00972	-0.3	-0.27	Leprosy;	chr8:89742720	chr8:89609409~89757727:-
SARC	cis	rs42490	0.966	rs218936	ENSG00000251136.7	RP11-37B2.1	4.31	2.39e-05	0.00972	0.3	0.27	Leprosy;	chr8:89743186	chr8:89609409~89757727:-
SARC	cis	rs9309473	0.607	rs12478346	ENSG00000163016.8	ALMS1P	4.31	2.39e-05	0.00972	0.35	0.27	Metabolite levels;	chr2:73357232	chr2:73644919~73685576:+
SARC	cis	rs4372836	0.729	rs11127190	ENSG00000226833.4	AC097724.3	-4.31	2.39e-05	0.00973	-0.23	-0.27	Body mass index;	chr2:28820346	chr2:28708953~28736205:-
SARC	cis	rs9364687	0.639	rs13202282	ENSG00000228692.2	RP5-826L7.1	-4.31	2.4e-05	0.00973	-0.32	-0.27	Body mass index;	chr6:163509211	chr6:163586583~163588165:-
SARC	cis	rs763121	0.925	rs5757165	ENSG00000273076.1	RP3-508I15.22	4.31	2.4e-05	0.00974	0.29	0.27	Menopause (age at onset);	chr22:38598572	chr22:38743495~38743910:+
SARC	cis	rs10895987	0.531	rs2282498	ENSG00000255200.1	AP003068.18	4.31	2.4e-05	0.00974	0.3	0.27	Blood protein levels;	chr11:65088514	chr11:65174117~65176470:-
SARC	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-4.31	2.4e-05	0.00974	-0.36	-0.27	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-4.31	2.4e-05	0.00974	-0.36	-0.27	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-4.31	2.4e-05	0.00974	-0.36	-0.27	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-4.31	2.4e-05	0.00974	-0.36	-0.27	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-4.31	2.4e-05	0.00974	-0.36	-0.27	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-4.31	2.4e-05	0.00974	-0.36	-0.27	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-4.31	2.4e-05	0.00974	-0.36	-0.27	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-4.31	2.4e-05	0.00974	-0.36	-0.27	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
SARC	cis	rs8005677	0.828	rs35085068	ENSG00000279656.1	RP11-298I3.6	4.31	2.4e-05	0.00975	0.36	0.27	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:23023083~23024217:-
SARC	cis	rs8005677	0.828	rs57822749	ENSG00000279656.1	RP11-298I3.6	4.31	2.4e-05	0.00975	0.36	0.27	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:23023083~23024217:-
SARC	cis	rs8005677	0.828	rs4981451	ENSG00000279656.1	RP11-298I3.6	4.31	2.4e-05	0.00975	0.36	0.27	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:23023083~23024217:-
SARC	cis	rs8005677	0.798	rs4536383	ENSG00000279656.1	RP11-298I3.6	4.31	2.4e-05	0.00975	0.36	0.27	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:23023083~23024217:-
SARC	cis	rs8005677	0.828	rs34584578	ENSG00000279656.1	RP11-298I3.6	4.31	2.4e-05	0.00975	0.36	0.27	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:23023083~23024217:-
SARC	cis	rs7976269	0.609	rs6487744	ENSG00000257176.2	RP11-996F15.2	-4.31	2.4e-05	0.00975	-0.3	-0.27	Male-pattern baldness;	chr12:29030756	chr12:29280418~29317848:-
SARC	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-4.31	2.4e-05	0.00976	-0.33	-0.27	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
SARC	cis	rs17508449	0.865	rs76112502	ENSG00000232450.1	RP4-730K3.3	-4.31	2.4e-05	0.00976	-0.35	-0.27	Leprosy;	chr1:113607074	chr1:113698884~113699631:-
SARC	cis	rs728478	0.935	rs8073731	ENSG00000266992.1	DHX40P1	4.31	2.41e-05	0.00976	0.29	0.27	QT interval;	chr17:59386621	chr17:59976009~60002384:-
SARC	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-4.31	2.41e-05	0.00977	-0.39	-0.27	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
SARC	cis	rs7216064	0.636	rs4638	ENSG00000278740.1	RP11-147L13.14	-4.31	2.41e-05	0.00978	-0.29	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043234	chr17:68188547~68189165:+
SARC	cis	rs7216064	0.601	rs35453056	ENSG00000278740.1	RP11-147L13.14	-4.31	2.41e-05	0.00978	-0.29	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043552	chr17:68188547~68189165:+
SARC	cis	rs7216064	0.628	rs62084702	ENSG00000278740.1	RP11-147L13.14	-4.31	2.41e-05	0.00978	-0.29	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68047041	chr17:68188547~68189165:+
SARC	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	4.31	2.41e-05	0.00978	0.37	0.27	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
SARC	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-4.31	2.41e-05	0.00978	-0.4	-0.27	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
SARC	cis	rs745109	0.504	rs76654460	ENSG00000273080.1	RP11-301O19.1	4.31	2.41e-05	0.00979	0.43	0.27	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86378757	chr2:86195590~86196049:+
SARC	cis	rs7267979	1	rs3761117	ENSG00000276952.1	RP5-965G21.6	-4.31	2.41e-05	0.00979	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25284915~25285588:-
SARC	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-4.31	2.42e-05	0.0098	-0.32	-0.27	QT interval;	chr12:29344573	chr12:29280418~29317848:-
SARC	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-4.31	2.42e-05	0.0098	-0.32	-0.27	QT interval;	chr12:29349303	chr12:29280418~29317848:-
SARC	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-4.31	2.42e-05	0.0098	-0.33	-0.27	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
SARC	cis	rs9894429	0.646	rs8080391	ENSG00000229848.1	RP13-766D20.2	-4.31	2.42e-05	0.0098	-0.27	-0.27	Eye color traits;	chr17:81599293	chr17:81514047~81527776:+
SARC	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-4.31	2.42e-05	0.0098	-0.25	-0.27	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-4.31	2.42e-05	0.0098	-0.25	-0.27	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-4.31	2.42e-05	0.0098	-0.25	-0.27	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-4.31	2.42e-05	0.0098	-0.25	-0.27	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-4.31	2.42e-05	0.0098	-0.25	-0.27	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
SARC	cis	rs10754283	0.967	rs1953821	ENSG00000231613.1	RP5-943J3.1	4.31	2.42e-05	0.00981	0.27	0.27	Amyotrophic lateral sclerosis (sporadic);	chr1:89641539	chr1:89788914~89790492:+
SARC	cis	rs28386778	0.897	rs968719	ENSG00000240280.5	TCAM1P	-4.31	2.42e-05	0.00981	-0.34	-0.27	Prudent dietary pattern;	chr17:63830911	chr17:63849292~63864379:+
SARC	cis	rs5751614	0.62	rs1811018	ENSG00000230701.2	FBXW4P1	4.31	2.42e-05	0.00981	0.34	0.27	Height;	chr22:23264778	chr22:23262767~23265005:+
SARC	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	4.31	2.42e-05	0.00982	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
SARC	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-4.31	2.42e-05	0.00982	-0.27	-0.27	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
SARC	cis	rs7615952	0.599	rs12485717	ENSG00000250012.1	RP11-124N2.1	4.31	2.42e-05	0.00982	0.26	0.27	Blood pressure (smoking interaction);	chr3:125988232	chr3:126084220~126095349:+
SARC	cis	rs728616	0.614	rs1998374	ENSG00000225484.5	NUTM2B-AS1	-4.31	2.43e-05	0.00983	-0.46	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79942966	chr10:79663088~79826594:-
SARC	cis	rs728616	0.614	rs10887199	ENSG00000225484.5	NUTM2B-AS1	-4.31	2.43e-05	0.00983	-0.46	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79943078	chr10:79663088~79826594:-
SARC	cis	rs11064768	0.633	rs11064789	ENSG00000255857.4	PXN-AS1	-4.31	2.43e-05	0.00983	-0.4	-0.27	Schizophrenia;	chr12:119415871	chr12:120201291~120213138:+
SARC	cis	rs12893668	0.667	rs8017628	ENSG00000269940.1	RP11-73M18.7	4.31	2.43e-05	0.00983	0.26	0.27	Reticulocyte count;	chr14:103581091	chr14:103694560~103695170:+
SARC	cis	rs4938303	0.549	rs12785990	ENSG00000254851.1	RP11-109L13.1	4.31	2.43e-05	0.00984	0.34	0.27	Triglycerides;	chr11:116692990	chr11:117135528~117138582:+
SARC	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-4.31	2.43e-05	0.00984	-0.25	-0.27	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-4.31	2.43e-05	0.00984	-0.25	-0.27	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-4.31	2.43e-05	0.00984	-0.25	-0.27	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
SARC	cis	rs4763879	1	rs4763879	ENSG00000214776.8	RP11-726G1.1	4.31	2.43e-05	0.00985	0.32	0.27	Type 1 diabetes;	chr12:9757568	chr12:9467552~9576275:+
SARC	cis	rs2281558	0.517	rs16987966	ENSG00000125804.12	FAM182A	-4.31	2.44e-05	0.00985	-0.44	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25662778	chr20:26054655~26086917:+
SARC	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-4.31	2.44e-05	0.00986	-0.28	-0.27	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
SARC	cis	rs11064768	0.633	rs4471499	ENSG00000255857.4	PXN-AS1	-4.31	2.44e-05	0.00986	-0.41	-0.27	Schizophrenia;	chr12:119403883	chr12:120201291~120213138:+
SARC	cis	rs11064768	0.633	rs11064778	ENSG00000255857.4	PXN-AS1	-4.31	2.44e-05	0.00986	-0.41	-0.27	Schizophrenia;	chr12:119404346	chr12:120201291~120213138:+
SARC	cis	rs11064768	0.633	rs7312409	ENSG00000255857.4	PXN-AS1	-4.31	2.44e-05	0.00986	-0.41	-0.27	Schizophrenia;	chr12:119405222	chr12:120201291~120213138:+
SARC	cis	rs11064768	0.633	rs11064782	ENSG00000255857.4	PXN-AS1	-4.31	2.44e-05	0.00986	-0.41	-0.27	Schizophrenia;	chr12:119407783	chr12:120201291~120213138:+
SARC	cis	rs11064768	0.633	rs80158076	ENSG00000255857.4	PXN-AS1	-4.31	2.44e-05	0.00986	-0.41	-0.27	Schizophrenia;	chr12:119414741	chr12:120201291~120213138:+
SARC	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-4.31	2.44e-05	0.00987	-0.31	-0.27	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
SARC	cis	rs763121	0.819	rs5757161	ENSG00000273076.1	RP3-508I15.22	4.31	2.44e-05	0.00987	0.29	0.27	Menopause (age at onset);	chr22:38594657	chr22:38743495~38743910:+
SARC	cis	rs4835473	0.897	rs6537167	ENSG00000251600.4	RP11-673E1.1	4.31	2.44e-05	0.00987	0.26	0.27	Immature fraction of reticulocytes;	chr4:143691323	chr4:143912331~143982454:+
SARC	cis	rs9309473	0.687	rs6747145	ENSG00000163016.8	ALMS1P	4.31	2.44e-05	0.00988	0.32	0.27	Metabolite levels;	chr2:73382049	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.615	rs11680965	ENSG00000163016.8	ALMS1P	4.31	2.45e-05	0.00989	0.41	0.27	Metabolite levels;	chr2:73498789	chr2:73644919~73685576:+
SARC	cis	rs7809950	0.817	rs3779495	ENSG00000238832.1	snoU109	4.31	2.45e-05	0.00989	0.32	0.27	Coronary artery disease;	chr7:107609815	chr7:107603363~107603507:+
SARC	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	4.31	2.45e-05	0.0099	0.51	0.27	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	4.31	2.45e-05	0.0099	0.51	0.27	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	4.31	2.45e-05	0.0099	0.51	0.27	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	4.31	2.45e-05	0.0099	0.51	0.27	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	4.31	2.45e-05	0.0099	0.51	0.27	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	4.31	2.45e-05	0.0099	0.51	0.27	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	4.31	2.45e-05	0.0099	0.51	0.27	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	4.31	2.45e-05	0.0099	0.51	0.27	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	4.31	2.45e-05	0.0099	0.51	0.27	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	4.31	2.45e-05	0.0099	0.51	0.27	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	4.31	2.45e-05	0.0099	0.51	0.27	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-4.31	2.45e-05	0.0099	-0.51	-0.27	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
SARC	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	4.31	2.45e-05	0.0099	0.27	0.27	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
SARC	cis	rs72945132	0.882	rs60917762	ENSG00000254604.1	AP000487.6	-4.31	2.45e-05	0.0099	-0.38	-0.27	Coronary artery disease;	chr11:70365278	chr11:70282367~70363368:-
SARC	cis	rs9890032	1	rs3764419	ENSG00000266490.1	CTD-2349P21.9	4.31	2.45e-05	0.0099	0.24	0.27	Hip circumference adjusted for BMI;	chr17:30837005	chr17:30792372~30792833:+
SARC	cis	rs890448	0.896	rs1863573	ENSG00000254531.1	FLJ20021	-4.31	2.45e-05	0.00991	-0.27	-0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101480630	chr4:101347780~101348883:+
SARC	cis	rs394563	0.901	rs448874	ENSG00000231760.4	RP11-350J20.5	4.31	2.45e-05	0.00992	0.35	0.27	Dupuytren's disease;	chr6:149475831	chr6:149796151~149826294:-
SARC	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-4.31	2.45e-05	0.00992	-0.28	-0.27	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
SARC	cis	rs7615952	0.8	rs13086460	ENSG00000241288.6	RP11-379B18.5	-4.31	2.46e-05	0.00992	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125927574	chr3:125827238~125916384:-
SARC	cis	rs4372836	0.729	rs10865508	ENSG00000226833.4	AC097724.3	-4.31	2.46e-05	0.00993	-0.23	-0.27	Body mass index;	chr2:28830838	chr2:28708953~28736205:-
SARC	cis	rs72945132	0.882	rs67093918	ENSG00000254604.1	AP000487.6	-4.31	2.46e-05	0.00993	-0.38	-0.27	Coronary artery disease;	chr11:70352893	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs66627443	ENSG00000254604.1	AP000487.6	-4.31	2.46e-05	0.00993	-0.38	-0.27	Coronary artery disease;	chr11:70352930	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs7128969	ENSG00000254604.1	AP000487.6	-4.31	2.46e-05	0.00993	-0.38	-0.27	Coronary artery disease;	chr11:70358911	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.825	rs947811	ENSG00000254604.1	AP000487.6	-4.31	2.46e-05	0.00993	-0.38	-0.27	Coronary artery disease;	chr11:70363036	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs7950916	ENSG00000254604.1	AP000487.6	-4.31	2.46e-05	0.00993	-0.38	-0.27	Coronary artery disease;	chr11:70363895	chr11:70282367~70363368:-
SARC	cis	rs2274273	0.638	rs3825614	ENSG00000258413.1	RP11-665C16.6	-4.31	2.46e-05	0.00993	-0.36	-0.27	Protein biomarker;	chr14:55262669	chr14:55262767~55272075:-
SARC	cis	rs7267979	1	rs2387880	ENSG00000276952.1	RP5-965G21.6	-4.31	2.46e-05	0.00993	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2387882	ENSG00000276952.1	RP5-965G21.6	-4.31	2.46e-05	0.00993	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2387884	ENSG00000276952.1	RP5-965G21.6	-4.31	2.46e-05	0.00993	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25284915~25285588:-
SARC	cis	rs7512898	0.522	rs7534184	ENSG00000260088.1	RP11-92G12.3	-4.3	2.46e-05	0.00994	-0.3	-0.27	Electrocardiographic conduction measures;	chr1:200708502	chr1:200669507~200694250:+
SARC	cis	rs4794202	0.618	rs11079799	ENSG00000264920.1	RP11-6N17.4	4.3	2.46e-05	0.00994	0.34	0.27	Alzheimer's disease (cognitive decline);	chr17:47878707	chr17:47891255~47895812:-
SARC	cis	rs7267979	0.966	rs8123949	ENSG00000276952.1	RP5-965G21.6	-4.3	2.46e-05	0.00995	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2184000	ENSG00000276952.1	RP5-965G21.6	-4.3	2.46e-05	0.00995	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs4815425	ENSG00000276952.1	RP5-965G21.6	-4.3	2.46e-05	0.00995	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6050599	ENSG00000276952.1	RP5-965G21.6	-4.3	2.46e-05	0.00995	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6050602	ENSG00000276952.1	RP5-965G21.6	-4.3	2.46e-05	0.00995	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs6083855	ENSG00000276952.1	RP5-965G21.6	-4.3	2.46e-05	0.00995	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs4815426	ENSG00000276952.1	RP5-965G21.6	-4.3	2.46e-05	0.00995	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6115182	ENSG00000276952.1	RP5-965G21.6	-4.3	2.46e-05	0.00995	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25284915~25285588:-
SARC	cis	rs1799949	0.965	rs6503727	ENSG00000267681.1	CTD-3199J23.6	-4.3	2.47e-05	0.00995	-0.3	-0.27	Menopause (age at onset);	chr17:43160842	chr17:43144956~43145255:+
SARC	cis	rs10986311	0.851	rs35956754	ENSG00000235204.1	RP11-121A14.2	4.3	2.47e-05	0.00995	0.31	0.27	Vitiligo;	chr9:124272079	chr9:124259250~124261156:-
SARC	cis	rs890448	0.796	rs10007821	ENSG00000254531.1	FLJ20021	4.3	2.47e-05	0.00997	0.29	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101414887	chr4:101347780~101348883:+
SARC	cis	rs4950322	0.57	rs72691054	ENSG00000278811.3	LINC00624	4.3	2.47e-05	0.00997	0.29	0.27	Protein quantitative trait loci;	chr1:147277942	chr1:147258885~147517875:-
SARC	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	4.3	2.47e-05	0.00998	0.33	0.27	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
SARC	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	4.3	2.47e-05	0.00998	0.33	0.27	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
SARC	cis	rs2274273	0.624	rs67795323	ENSG00000258413.1	RP11-665C16.6	-4.3	2.47e-05	0.00998	-0.34	-0.27	Protein biomarker;	chr14:55331115	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.624	rs8005450	ENSG00000258413.1	RP11-665C16.6	-4.3	2.47e-05	0.00998	-0.34	-0.27	Protein biomarker;	chr14:55332447	chr14:55262767~55272075:-
SARC	cis	rs42490	1	rs218905	ENSG00000251136.7	RP11-37B2.1	-4.3	2.47e-05	0.00998	-0.3	-0.27	Leprosy;	chr8:89723661	chr8:89609409~89757727:-
SARC	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-4.3	2.47e-05	0.00998	-0.31	-0.27	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
SARC	cis	rs324126	0.78	rs1993530	ENSG00000269834.4	ZNF528-AS1	-4.3	2.47e-05	0.00998	-0.29	-0.27	Colonoscopy-negative controls vs population controls;	chr19:52381756	chr19:52388842~52397766:-
SARC	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-4.3	2.48e-05	0.00999	-0.37	-0.27	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
SARC	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-4.3	2.48e-05	0.01	-0.4	-0.27	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
SARC	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-4.3	2.48e-05	0.01	-0.4	-0.27	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-4.3	2.48e-05	0.01	-0.4	-0.27	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-4.3	2.48e-05	0.01	-0.4	-0.27	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-4.3	2.48e-05	0.01	-0.4	-0.27	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
SARC	cis	rs3136516	0.935	rs11038993	ENSG00000270060.1	RP11-390K5.6	-4.3	2.48e-05	0.01	-0.18	-0.27	Venous thromboembolism;	chr11:46789366	chr11:47168281~47169563:-
SARC	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	4.3	2.48e-05	0.01	0.33	0.27	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
SARC	cis	rs1880529	0.764	rs13129893	ENSG00000206820.1	RNU1-138P	-4.3	2.48e-05	0.01	-0.26	-0.27	White matter integrity (bipolar disorder risk interaction);	chr4:113432016	chr4:113420323~113420486:+
SARC	cis	rs28386778	0.897	rs2727287	ENSG00000240280.5	TCAM1P	-4.3	2.48e-05	0.01	-0.34	-0.27	Prudent dietary pattern;	chr17:63827368	chr17:63849292~63864379:+
SARC	cis	rs4372836	0.664	rs4233729	ENSG00000226833.4	AC097724.3	-4.3	2.48e-05	0.01	-0.23	-0.27	Body mass index;	chr2:28869813	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.729	rs4666122	ENSG00000226833.4	AC097724.3	-4.3	2.48e-05	0.01	-0.23	-0.27	Body mass index;	chr2:28869984	chr2:28708953~28736205:-
SARC	cis	rs7267979	0.565	rs3752273	ENSG00000125804.12	FAM182A	4.3	2.48e-05	0.01	0.32	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:26054655~26086917:+
SARC	cis	rs7615952	0.558	rs17334039	ENSG00000248787.1	RP11-666A20.4	-4.3	2.48e-05	0.01	-0.38	-0.27	Blood pressure (smoking interaction);	chr3:125821465	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.688	rs12638240	ENSG00000248787.1	RP11-666A20.4	-4.3	2.48e-05	0.01	-0.38	-0.27	Blood pressure (smoking interaction);	chr3:125822395	chr3:125908005~125910272:-
SARC	cis	rs7267979	1	rs2387881	ENSG00000276952.1	RP5-965G21.6	-4.3	2.49e-05	0.01	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25284915~25285588:-
SARC	cis	rs4664293	0.737	rs1549579	ENSG00000226266.5	AC009961.3	-4.3	2.49e-05	0.01	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159812150	chr2:159670708~159712435:-
SARC	cis	rs34929064	0.846	rs2905340	ENSG00000225541.1	AC002480.5	4.3	2.49e-05	0.01	0.29	0.27	Major depression and alcohol dependence;	chr7:22687579	chr7:22571607~22661792:-
SARC	cis	rs34929064	0.881	rs2961311	ENSG00000225541.1	AC002480.5	4.3	2.49e-05	0.01	0.29	0.27	Major depression and alcohol dependence;	chr7:22687919	chr7:22571607~22661792:-
SARC	cis	rs6845263	0.511	rs13122215	ENSG00000254531.1	FLJ20021	-4.3	2.49e-05	0.01	-0.26	-0.27	Superior crus of antihelix expression;	chr4:101549281	chr4:101347780~101348883:+
SARC	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-4.3	2.49e-05	0.01	-0.33	-0.27	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-4.3	2.49e-05	0.01	-0.33	-0.27	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
SARC	cis	rs4372836	0.504	rs7597048	ENSG00000226833.4	AC097724.3	-4.3	2.49e-05	0.01	-0.23	-0.27	Body mass index;	chr2:28843890	chr2:28708953~28736205:-
SARC	cis	rs7267979	0.744	rs6050464	ENSG00000276952.1	RP5-965G21.6	4.3	2.49e-05	0.01	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25228663	chr20:25284915~25285588:-
SARC	cis	rs2898681	0.519	rs76606067	ENSG00000248375.1	RP11-177B4.1	-4.3	2.49e-05	0.01	-0.42	-0.27	Optic nerve measurement (cup area);	chr4:52862054	chr4:52720081~52720831:-
SARC	cis	rs12893668	0.703	rs34896432	ENSG00000269940.1	RP11-73M18.7	4.3	2.49e-05	0.0101	0.27	0.27	Reticulocyte count;	chr14:103561658	chr14:103694560~103695170:+
SARC	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	4.3	2.49e-05	0.0101	0.33	0.27	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
SARC	cis	rs7267979	1	rs6076345	ENSG00000276952.1	RP5-965G21.6	-4.3	2.5e-05	0.0101	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs4815418	ENSG00000276952.1	RP5-965G21.6	-4.3	2.5e-05	0.0101	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6050590	ENSG00000276952.1	RP5-965G21.6	-4.3	2.5e-05	0.0101	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs4813566	ENSG00000276952.1	RP5-965G21.6	-4.3	2.5e-05	0.0101	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs4815421	ENSG00000276952.1	RP5-965G21.6	-4.3	2.5e-05	0.0101	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25284915~25285588:-
SARC	cis	rs950027	0.538	rs635205	ENSG00000259520.4	CTD-2651B20.3	-4.3	2.5e-05	0.0101	-0.33	-0.27	Response to fenofibrate (adiponectin levels);	chr15:45656186	chr15:45251580~45279251:-
SARC	cis	rs28498283	0.792	rs10199639	ENSG00000279873.2	LINC01126	4.3	2.5e-05	0.0101	0.25	0.27	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:43119988	chr2:43227210~43228855:+
SARC	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-4.3	2.5e-05	0.0101	-0.25	-0.27	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
SARC	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	4.3	2.5e-05	0.0101	0.31	0.27	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
SARC	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	4.3	2.5e-05	0.0101	0.31	0.27	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
SARC	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	4.3	2.5e-05	0.0101	0.31	0.27	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
SARC	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	4.3	2.5e-05	0.0101	0.31	0.27	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
SARC	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	4.3	2.5e-05	0.0101	0.31	0.27	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
SARC	cis	rs2439831	0.717	rs9806227	ENSG00000275601.1	AC011330.13	-4.3	2.51e-05	0.0101	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43387917	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs2584702	ENSG00000275601.1	AC011330.13	-4.3	2.51e-05	0.0101	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43392716	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs2243434	ENSG00000275601.1	AC011330.13	-4.3	2.51e-05	0.0101	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43397669	chr15:43642389~43643023:-
SARC	cis	rs853679	0.769	rs17720293	ENSG00000272009.1	RP1-313I6.12	-4.3	2.51e-05	0.0101	-0.48	-0.27	Depression;	chr6:28246920	chr6:28078792~28081130:-
SARC	cis	rs853679	1	rs2799079	ENSG00000272009.1	RP1-313I6.12	-4.3	2.51e-05	0.0101	-0.35	-0.27	Depression;	chr6:28267398	chr6:28078792~28081130:-
SARC	cis	rs4835473	0.932	rs1597442	ENSG00000251600.4	RP11-673E1.1	-4.3	2.51e-05	0.0101	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143764359	chr4:143912331~143982454:+
SARC	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-4.3	2.51e-05	0.0101	-0.3	-0.27	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
SARC	cis	rs1223397	0.938	rs3817741	ENSG00000215022.6	RP1-257A7.4	4.3	2.51e-05	0.0101	0.34	0.27	Blood pressure;	chr6:13279275	chr6:13264861~13295586:-
SARC	cis	rs394563	1	rs394563	ENSG00000231760.4	RP11-350J20.5	4.3	2.51e-05	0.0101	0.35	0.27	Dupuytren's disease;	chr6:149475878	chr6:149796151~149826294:-
SARC	cis	rs394563	0.967	rs444784	ENSG00000231760.4	RP11-350J20.5	4.3	2.51e-05	0.0101	0.35	0.27	Dupuytren's disease;	chr6:149477230	chr6:149796151~149826294:-
SARC	cis	rs593531	0.571	rs10898981	ENSG00000280269.1	AP000577.2	-4.3	2.51e-05	0.0101	-0.35	-0.27	Neuroticism;	chr11:74381420	chr11:74204869~74205746:+
SARC	cis	rs2412819	0.571	rs2930531	ENSG00000205771.5	CATSPER2P1	4.3	2.51e-05	0.0101	0.38	0.27	Lung cancer;	chr15:43829372	chr15:43726918~43747094:-
SARC	cis	rs7615952	0.576	rs12497295	ENSG00000171084.14	FAM86JP	4.3	2.51e-05	0.0101	0.41	0.27	Blood pressure (smoking interaction);	chr3:126099807	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.512	rs1077621	ENSG00000171084.14	FAM86JP	4.3	2.51e-05	0.0101	0.41	0.27	Blood pressure (smoking interaction);	chr3:126100956	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.512	rs4646765	ENSG00000171084.14	FAM86JP	4.3	2.51e-05	0.0101	0.41	0.27	Blood pressure (smoking interaction);	chr3:126101864	chr3:125916620~125930024:+
SARC	cis	rs8005677	0.828	rs12589539	ENSG00000257285.4	RP11-298I3.1	4.3	2.51e-05	0.0101	0.26	0.27	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:22929609~22955562:+
SARC	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-4.3	2.51e-05	0.0101	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-4.3	2.51e-05	0.0101	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
SARC	cis	rs11634944	0.673	rs1541759	ENSG00000274307.1	RP11-345J18.2	-4.3	2.52e-05	0.0101	-0.35	-0.27	Interleukin-8 levels;	chr15:25030210	chr15:25708470~25710869:-
SARC	cis	rs9902453	0.868	rs8066602	ENSG00000264538.5	SUZ12P1	4.3	2.52e-05	0.0101	0.19	0.27	Coffee consumption (cups per day);	chr17:30196067	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.868	rs8066731	ENSG00000264538.5	SUZ12P1	4.3	2.52e-05	0.0101	0.19	0.27	Coffee consumption (cups per day);	chr17:30196103	chr17:30709299~30790908:+
SARC	cis	rs7772486	0.79	rs1062068	ENSG00000270638.1	RP3-466P17.1	4.3	2.52e-05	0.0102	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145735570~145737218:+
SARC	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-4.3	2.52e-05	0.0102	-0.3	-0.27	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-4.3	2.52e-05	0.0102	-0.3	-0.27	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-4.3	2.52e-05	0.0102	-0.3	-0.27	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-4.3	2.52e-05	0.0102	-0.3	-0.27	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-4.3	2.52e-05	0.0102	-0.3	-0.27	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-4.3	2.52e-05	0.0102	-0.3	-0.27	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
SARC	cis	rs34787248	1	rs34787248	ENSG00000216901.1	AL022393.7	4.3	2.52e-05	0.0102	0.41	0.27	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28176188~28176674:+
SARC	cis	rs853679	0.76	rs2299029	ENSG00000216901.1	AL022393.7	4.3	2.52e-05	0.0102	0.41	0.27	Depression;	chr6:28231053	chr6:28176188~28176674:+
SARC	cis	rs4820294	0.669	rs732857	ENSG00000233360.4	Z83844.1	4.3	2.52e-05	0.0102	0.32	0.27	Fat distribution (HIV);	chr22:37664843	chr22:37641832~37658377:-
SARC	cis	rs9868809	0.881	rs2276852	ENSG00000225399.4	RP11-3B7.1	-4.3	2.53e-05	0.0102	-0.46	-0.27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48629490	chr3:49260085~49261316:+
SARC	cis	rs7267979	0.866	rs6138609	ENSG00000276952.1	RP5-965G21.6	4.3	2.53e-05	0.0102	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25284915~25285588:-
SARC	cis	rs2439831	0.681	rs511673	ENSG00000275601.1	AC011330.13	-4.3	2.53e-05	0.0102	-0.4	-0.27	Lung cancer in ever smokers;	chr15:43326665	chr15:43642389~43643023:-
SARC	cis	rs526231	0.764	rs365975	ENSG00000175749.11	EIF3KP1	4.3	2.53e-05	0.0102	0.32	0.27	Primary biliary cholangitis;	chr5:103297657	chr5:103032376~103033031:+
SARC	cis	rs9309473	0.579	rs6728128	ENSG00000163016.8	ALMS1P	4.3	2.53e-05	0.0102	0.33	0.27	Metabolite levels;	chr2:73368854	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.607	rs7567343	ENSG00000163016.8	ALMS1P	4.3	2.53e-05	0.0102	0.33	0.27	Metabolite levels;	chr2:73369477	chr2:73644919~73685576:+
SARC	cis	rs10788972	0.873	rs4926619	ENSG00000225183.1	RP4-758J24.4	-4.3	2.53e-05	0.0102	-0.33	-0.27	Parkinson disease and lewy body pathology;	chr1:54092428	chr1:54089856~54090093:+
SARC	cis	rs4835473	0.9	rs13119630	ENSG00000251600.4	RP11-673E1.1	-4.3	2.53e-05	0.0102	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143773901	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1450233	ENSG00000251600.4	RP11-673E1.1	-4.3	2.53e-05	0.0102	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143774710	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4308330	ENSG00000251600.4	RP11-673E1.1	-4.3	2.53e-05	0.0102	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143774761	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs11725708	ENSG00000251600.4	RP11-673E1.1	-4.3	2.53e-05	0.0102	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143775683	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs17762299	ENSG00000251600.4	RP11-673E1.1	-4.3	2.53e-05	0.0102	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143777196	chr4:143912331~143982454:+
SARC	cis	rs916888	0.61	rs199529	ENSG00000261575.2	RP11-259G18.1	4.3	2.53e-05	0.0102	0.37	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46267037~46268694:+
SARC	cis	rs11651000	0.625	rs2074190	ENSG00000239291.1	RP5-867C24.1	4.3	2.53e-05	0.0102	0.33	0.27	IgG glycosylation;	chr17:47733844	chr17:47159191~47159993:-
SARC	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-4.3	2.53e-05	0.0102	-0.32	-0.27	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
SARC	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-4.3	2.53e-05	0.0102	-0.29	-0.27	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-4.3	2.53e-05	0.0102	-0.29	-0.27	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-4.3	2.53e-05	0.0102	-0.29	-0.27	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
SARC	cis	rs5758511	0.68	rs5758699	ENSG00000227370.1	RP4-669P10.19	4.3	2.53e-05	0.0102	0.31	0.27	Birth weight;	chr22:42292028	chr22:42132543~42132998:+
SARC	cis	rs4938303	0.549	rs11216096	ENSG00000254851.1	RP11-109L13.1	4.3	2.53e-05	0.0102	0.34	0.27	Triglycerides;	chr11:116691864	chr11:117135528~117138582:+
SARC	cis	rs6844153	0.752	rs28520489	ENSG00000240005.4	RP11-293A21.1	-4.3	2.54e-05	0.0102	-0.33	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26896082	chr4:26859806~26860599:-
SARC	cis	rs4664293	0.625	rs6713600	ENSG00000226266.5	AC009961.3	4.3	2.54e-05	0.0102	0.31	0.27	Monocyte percentage of white cells;	chr2:159706559	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs7607394	ENSG00000226266.5	AC009961.3	4.3	2.54e-05	0.0102	0.31	0.27	Monocyte percentage of white cells;	chr2:159707286	chr2:159670708~159712435:-
SARC	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	4.3	2.54e-05	0.0102	0.4	0.27	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
SARC	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	4.3	2.54e-05	0.0102	0.25	0.27	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
SARC	cis	rs4713118	0.738	rs200465	ENSG00000219392.1	RP1-265C24.5	-4.3	2.54e-05	0.0102	-0.38	-0.27	Parkinson's disease;	chr6:27789875	chr6:28115628~28116551:+
SARC	cis	rs2439831	0.85	rs7163245	ENSG00000275601.1	AC011330.13	-4.3	2.54e-05	0.0102	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43379096	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs28729853	ENSG00000275601.1	AC011330.13	-4.3	2.54e-05	0.0102	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43381482	chr15:43642389~43643023:-
SARC	cis	rs9473147	0.516	rs9381564	ENSG00000270761.1	RP11-385F7.1	-4.3	2.54e-05	0.0102	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47476070	chr6:47477243~47477572:-
SARC	cis	rs1823913	0.637	rs6722183	ENSG00000227542.1	AC092614.2	-4.3	2.54e-05	0.0102	-0.3	-0.27	Obesity-related traits;	chr2:191333203	chr2:191229165~191246172:-
SARC	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	4.3	2.54e-05	0.0102	0.26	0.27	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
SARC	cis	rs910316	1	rs4903284	ENSG00000279594.1	RP11-950C14.10	4.3	2.54e-05	0.0102	0.29	0.27	Height;	chr14:75125780	chr14:75011269~75012851:-
SARC	cis	rs910316	0.967	rs2024653	ENSG00000279594.1	RP11-950C14.10	4.3	2.54e-05	0.0102	0.29	0.27	Height;	chr14:75128451	chr14:75011269~75012851:-
SARC	cis	rs2898681	0.521	rs115874483	ENSG00000248375.1	RP11-177B4.1	-4.3	2.54e-05	0.0102	-0.42	-0.27	Optic nerve measurement (cup area);	chr4:52862105	chr4:52720081~52720831:-
SARC	cis	rs7772486	0.686	rs2179323	ENSG00000235652.6	RP11-545I5.3	-4.3	2.55e-05	0.0102	-0.24	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145799409~145886585:+
SARC	cis	rs14027	0.921	rs13262434	ENSG00000279347.1	RP11-85I17.2	-4.3	2.55e-05	0.0102	-0.24	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733423	chr8:119838736~119840385:-
SARC	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	4.3	2.55e-05	0.0102	0.32	0.27	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
SARC	cis	rs910316	1	rs1047418	ENSG00000279594.1	RP11-950C14.10	4.3	2.55e-05	0.0102	0.29	0.27	Height;	chr14:75139089	chr14:75011269~75012851:-
SARC	cis	rs853679	0.546	rs200990	ENSG00000216901.1	AL022393.7	4.3	2.55e-05	0.0102	0.6	0.27	Depression;	chr6:27848045	chr6:28176188~28176674:+
SARC	cis	rs11886999	0.812	rs4826	ENSG00000237510.6	AC008268.2	-4.3	2.55e-05	0.0102	-0.42	-0.27	Cardiac Troponin-T levels;	chr2:96185147	chr2:95789654~95800166:+
SARC	cis	rs1707322	0.964	rs7512395	ENSG00000281133.1	AL355480.3	-4.3	2.55e-05	0.0102	-0.31	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45580892~45580996:-
SARC	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	4.3	2.55e-05	0.0103	0.25	0.27	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
SARC	cis	rs4664293	0.528	rs1549386	ENSG00000226266.5	AC009961.3	4.3	2.56e-05	0.0103	0.35	0.27	Monocyte percentage of white cells;	chr2:159558015	chr2:159670708~159712435:-
SARC	cis	rs12049351	0.774	rs4148758	ENSG00000229367.1	HMGN2P19	4.3	2.56e-05	0.0103	0.23	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229557919	chr1:229570532~229570796:+
SARC	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	4.3	2.56e-05	0.0103	0.26	0.27	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
SARC	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	4.3	2.56e-05	0.0103	0.26	0.27	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
SARC	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	4.3	2.56e-05	0.0103	0.26	0.27	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
SARC	cis	rs6763768	0.668	rs312475	ENSG00000280417.1	RP11-5O17.1	-4.3	2.56e-05	0.0103	-0.31	-0.27	Bacterial meningitis;	chr3:53479327	chr3:53046166~53048122:+
SARC	cis	rs4664293	0.867	rs3771718	ENSG00000226266.5	AC009961.3	-4.3	2.56e-05	0.0103	-0.32	-0.27	Monocyte percentage of white cells;	chr2:159780397	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.867	rs2303550	ENSG00000226266.5	AC009961.3	-4.3	2.56e-05	0.0103	-0.32	-0.27	Monocyte percentage of white cells;	chr2:159781110	chr2:159670708~159712435:-
SARC	cis	rs61160187	0.582	rs12516995	ENSG00000215032.2	GNL3LP1	4.3	2.56e-05	0.0103	0.26	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60891935~60893577:-
SARC	cis	rs7216064	0.655	rs8078543	ENSG00000278740.1	RP11-147L13.14	-4.3	2.57e-05	0.0103	-0.28	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68041135	chr17:68188547~68189165:+
SARC	cis	rs910316	0.763	rs175057	ENSG00000279594.1	RP11-950C14.10	-4.29	2.57e-05	0.0103	-0.3	-0.27	Height;	chr14:75022929	chr14:75011269~75012851:-
SARC	cis	rs950776	0.593	rs481134	ENSG00000261762.1	RP11-650L12.2	4.29	2.57e-05	0.0103	0.28	0.27	Sudden cardiac arrest;	chr15:78585221	chr15:78589123~78591276:-
SARC	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-4.29	2.57e-05	0.0103	-0.39	-0.27	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
SARC	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-4.29	2.57e-05	0.0103	-0.25	-0.27	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
SARC	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-4.29	2.57e-05	0.0103	-0.47	-0.27	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
SARC	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-4.29	2.57e-05	0.0103	-0.31	-0.27	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-4.29	2.57e-05	0.0103	-0.31	-0.27	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
SARC	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-4.29	2.57e-05	0.0103	-0.33	-0.27	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
SARC	cis	rs4372836	0.615	rs61407258	ENSG00000226833.4	AC097724.3	4.29	2.57e-05	0.0103	0.23	0.27	Body mass index;	chr2:28824043	chr2:28708953~28736205:-
SARC	cis	rs9828933	0.766	rs704361	ENSG00000280620.1	SCAANT1	-4.29	2.57e-05	0.0103	-0.44	-0.27	Type 2 diabetes;	chr3:63897995	chr3:63911518~63911772:-
SARC	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-4.29	2.58e-05	0.0103	-0.29	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-4.29	2.58e-05	0.0103	-0.29	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-4.29	2.58e-05	0.0103	-0.29	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-4.29	2.58e-05	0.0103	-0.29	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-4.29	2.58e-05	0.0103	-0.29	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-4.29	2.58e-05	0.0103	-0.29	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-4.29	2.58e-05	0.0103	-0.29	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-4.29	2.58e-05	0.0103	-0.29	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-4.29	2.58e-05	0.0103	-0.29	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-4.29	2.58e-05	0.0103	-0.29	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-4.29	2.58e-05	0.0103	-0.29	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-4.29	2.58e-05	0.0103	-0.29	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
SARC	cis	rs8005677	0.828	rs8016027	ENSG00000279656.1	RP11-298I3.6	4.29	2.58e-05	0.0103	0.36	0.27	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:23023083~23024217:-
SARC	cis	rs27434	0.602	rs2927620	ENSG00000272109.1	CTD-2260A17.3	-4.29	2.58e-05	0.0103	-0.4	-0.27	Ankylosing spondylitis;	chr5:96845594	chr5:96804353~96806105:+
SARC	cis	rs495337	0.76	rs4810994	ENSG00000229222.1	KRT18P4	-4.29	2.58e-05	0.0103	-0.34	-0.27	Psoriasis;	chr20:49955136	chr20:49956745~49958032:+
SARC	cis	rs7615952	0.932	rs13065725	ENSG00000241288.6	RP11-379B18.5	-4.29	2.58e-05	0.0103	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125913446	chr3:125827238~125916384:-
SARC	cis	rs950776	0.518	rs62008174	ENSG00000261762.1	RP11-650L12.2	4.29	2.58e-05	0.0103	0.29	0.27	Sudden cardiac arrest;	chr15:78516605	chr15:78589123~78591276:-
SARC	cis	rs7615952	0.932	rs13325495	ENSG00000241288.6	RP11-379B18.5	-4.29	2.58e-05	0.0103	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125918573	chr3:125827238~125916384:-
SARC	cis	rs2404602	0.583	rs12898415	ENSG00000259422.1	RP11-593F23.1	4.29	2.58e-05	0.0104	0.3	0.27	Blood metabolite levels;	chr15:76281891	chr15:76174891~76181486:-
SARC	cis	rs394563	0.591	rs237035	ENSG00000231760.4	RP11-350J20.5	4.29	2.58e-05	0.0104	0.34	0.27	Dupuytren's disease;	chr6:149389712	chr6:149796151~149826294:-
SARC	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	4.29	2.58e-05	0.0104	0.25	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
SARC	cis	rs11822910	0.911	rs61886978	ENSG00000265566.2	RN7SL605P	4.29	2.58e-05	0.0104	0.35	0.27	Platelet distribution width;	chr11:57427375	chr11:57528085~57528365:-
SARC	cis	rs853679	0.546	rs200996	ENSG00000216901.1	AL022393.7	4.29	2.59e-05	0.0104	0.6	0.27	Depression;	chr6:27844050	chr6:28176188~28176674:+
SARC	cis	rs6540731	1	rs11119884	ENSG00000229983.1	RP11-15I11.2	4.29	2.59e-05	0.0104	0.28	0.27	Intelligence (childhood);	chr1:212226804	chr1:212168207~212190259:+
SARC	cis	rs2439831	0.867	rs3101443	ENSG00000275601.1	AC011330.13	-4.29	2.59e-05	0.0104	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43620174	chr15:43642389~43643023:-
SARC	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	4.29	2.59e-05	0.0104	0.36	0.27	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
SARC	cis	rs2243480	1	rs709607	ENSG00000273142.1	RP11-458F8.4	4.29	2.59e-05	0.0104	0.39	0.27	Diabetic kidney disease;	chr7:65984554	chr7:66902857~66906297:+
SARC	cis	rs12950390	0.853	rs8071192	ENSG00000239291.1	RP5-867C24.1	4.29	2.59e-05	0.0104	0.32	0.27	IgG glycosylation;	chr17:47778775	chr17:47159191~47159993:-
SARC	cis	rs9902453	0.904	rs4598962	ENSG00000264538.5	SUZ12P1	4.29	2.59e-05	0.0104	0.19	0.27	Coffee consumption (cups per day);	chr17:29966930	chr17:30709299~30790908:+
SARC	cis	rs4273100	0.646	rs2296981	ENSG00000228157.4	AC007952.5	-4.29	2.59e-05	0.0104	-0.33	-0.27	Schizophrenia;	chr17:19310022	chr17:19092974~19096837:+
SARC	cis	rs7560272	0.723	rs7566315	ENSG00000163016.8	ALMS1P	4.29	2.59e-05	0.0104	0.3	0.27	Schizophrenia;	chr2:73564681	chr2:73644919~73685576:+
SARC	cis	rs2412819	0.571	rs7174260	ENSG00000205771.5	CATSPER2P1	-4.29	2.6e-05	0.0104	-0.41	-0.27	Lung cancer;	chr15:43751988	chr15:43726918~43747094:-
SARC	cis	rs783540	0.967	rs783527	ENSG00000275695.1	UBE2Q2P6	-4.29	2.6e-05	0.0104	-0.28	-0.27	Schizophrenia;	chr15:82617096	chr15:82445719~82454837:+
SARC	cis	rs9595908	0.931	rs35555940	ENSG00000212293.1	SNORA16	4.29	2.6e-05	0.0104	0.28	0.27	Body mass index;	chr13:32492975	chr13:32420390~32420516:-
SARC	cis	rs9902453	0.874	rs3936006	ENSG00000264538.5	SUZ12P1	4.29	2.6e-05	0.0104	0.2	0.27	Coffee consumption (cups per day);	chr17:29930642	chr17:30709299~30790908:+
SARC	cis	rs453301	0.653	rs7853	ENSG00000253893.2	FAM85B	-4.29	2.6e-05	0.0104	-0.24	-0.27	Joint mobility (Beighton score);	chr8:9033304	chr8:8167819~8226614:-
SARC	cis	rs319598	1	rs319602	ENSG00000224186.7	C5orf66	-4.29	2.6e-05	0.0104	-0.24	-0.27	Type 2 diabetes;	chr5:134886474	chr5:135033280~135358219:+
SARC	cis	rs59104589	0.55	rs62193172	ENSG00000266621.1	AC104841.1	4.29	2.6e-05	0.0104	0.38	0.27	Fibrinogen levels;	chr2:241338300	chr2:241245202~241245299:-
SARC	cis	rs1799949	0.965	rs4793230	ENSG00000267681.1	CTD-3199J23.6	-4.29	2.6e-05	0.0104	-0.31	-0.27	Menopause (age at onset);	chr17:43350035	chr17:43144956~43145255:+
SARC	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-4.29	2.6e-05	0.0104	-0.29	-0.27	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
SARC	cis	rs11064768	0.633	rs11064773	ENSG00000255857.4	PXN-AS1	-4.29	2.6e-05	0.0104	-0.41	-0.27	Schizophrenia;	chr12:119395200	chr12:120201291~120213138:+
SARC	cis	rs4664293	0.867	rs7606046	ENSG00000226266.5	AC009961.3	-4.29	2.6e-05	0.0104	-0.32	-0.27	Monocyte percentage of white cells;	chr2:159719647	chr2:159670708~159712435:-
SARC	cis	rs72945132	0.714	rs117232799	ENSG00000254604.1	AP000487.6	-4.29	2.6e-05	0.0104	-0.4	-0.27	Coronary artery disease;	chr11:70311076	chr11:70282367~70363368:-
SARC	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-4.29	2.61e-05	0.0104	-0.34	-0.27	Height;	chr6:109432968	chr6:109382795~109383666:+
SARC	cis	rs319598	1	rs319589	ENSG00000224186.7	C5orf66	4.29	2.61e-05	0.0104	0.24	0.27	Type 2 diabetes;	chr5:134919643	chr5:135033280~135358219:+
SARC	cis	rs2018683	0.803	rs12700920	ENSG00000228421.2	AC005013.5	4.29	2.61e-05	0.0104	0.28	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945307	chr7:28957667~28959345:+
SARC	cis	rs2018683	0.933	rs12536127	ENSG00000228421.2	AC005013.5	4.29	2.61e-05	0.0104	0.28	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28946350	chr7:28957667~28959345:+
SARC	cis	rs8064029	0.892	rs2660226	ENSG00000267077.1	RP11-127I20.5	-4.29	2.61e-05	0.0104	-0.43	-0.27	Cancer;	chr16:4876725	chr16:4795265~4796532:-
SARC	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-4.29	2.62e-05	0.0105	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
SARC	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	4.29	2.62e-05	0.0105	0.33	0.27	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
SARC	cis	rs7162943	0.887	rs11858077	ENSG00000260123.1	RP11-326A19.4	-4.29	2.62e-05	0.0105	-0.26	-0.27	Mean platelet volume;	chr15:89068326	chr15:89041223~89082819:+
SARC	cis	rs207954	0.922	rs17597602	ENSG00000258922.1	CTD-2313J17.1	4.29	2.62e-05	0.0105	0.29	0.27	Acute lymphoblastic leukemia (childhood);	chr15:92117474	chr15:92805770~92808567:-
SARC	cis	rs7267979	1	rs2297497	ENSG00000276952.1	RP5-965G21.6	-4.29	2.62e-05	0.0105	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:25284915~25285588:-
SARC	cis	rs12893668	0.572	rs4900590	ENSG00000269940.1	RP11-73M18.7	4.29	2.62e-05	0.0105	0.27	0.27	Reticulocyte count;	chr14:103680084	chr14:103694560~103695170:+
SARC	cis	rs2289583	0.642	rs8034281	ENSG00000260269.4	CTD-2323K18.1	-4.29	2.62e-05	0.0105	-0.39	-0.27	Systemic lupus erythematosus;	chr15:75091886	chr15:75527150~75601205:-
SARC	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	4.29	2.62e-05	0.0105	0.25	0.27	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
SARC	cis	rs11064768	0.633	rs11064776	ENSG00000255857.4	PXN-AS1	-4.29	2.62e-05	0.0105	-0.41	-0.27	Schizophrenia;	chr12:119402895	chr12:120201291~120213138:+
SARC	cis	rs11064768	0.633	rs12371440	ENSG00000255857.4	PXN-AS1	-4.29	2.62e-05	0.0105	-0.41	-0.27	Schizophrenia;	chr12:119408865	chr12:120201291~120213138:+
SARC	cis	rs11064768	0.633	rs11064785	ENSG00000255857.4	PXN-AS1	-4.29	2.62e-05	0.0105	-0.41	-0.27	Schizophrenia;	chr12:119412143	chr12:120201291~120213138:+
SARC	cis	rs7976269	0.537	rs10843308	ENSG00000257176.2	RP11-996F15.2	-4.29	2.62e-05	0.0105	-0.3	-0.27	Male-pattern baldness;	chr12:29075172	chr12:29280418~29317848:-
SARC	cis	rs62432291	0.681	rs439126	ENSG00000235086.1	FNDC1-IT1	-4.29	2.62e-05	0.0105	-0.45	-0.27	Joint mobility (Beighton score);	chr6:159235600	chr6:159240786~159243329:+
SARC	cis	rs4664293	0.967	rs13020365	ENSG00000226266.5	AC009961.3	-4.29	2.63e-05	0.0105	-0.33	-0.27	Monocyte percentage of white cells;	chr2:159619893	chr2:159670708~159712435:-
SARC	cis	rs4664293	1	rs13014418	ENSG00000226266.5	AC009961.3	-4.29	2.63e-05	0.0105	-0.33	-0.27	Monocyte percentage of white cells;	chr2:159627174	chr2:159670708~159712435:-
SARC	cis	rs7267979	1	rs6050559	ENSG00000276952.1	RP5-965G21.6	4.29	2.63e-05	0.0105	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25284915~25285588:-
SARC	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-4.29	2.63e-05	0.0105	-0.31	-0.27	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
SARC	cis	rs7772486	0.806	rs2265477	ENSG00000270638.1	RP3-466P17.1	4.29	2.63e-05	0.0105	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145735570~145737218:+
SARC	cis	rs2439831	0.85	rs3742982	ENSG00000275601.1	AC011330.13	-4.29	2.63e-05	0.0105	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43884483	chr15:43642389~43643023:-
SARC	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-4.29	2.63e-05	0.0105	-0.4	-0.27	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-4.29	2.63e-05	0.0105	-0.4	-0.27	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
SARC	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-4.29	2.63e-05	0.0105	-0.35	-0.27	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
SARC	cis	rs7615952	0.576	rs2276727	ENSG00000171084.14	FAM86JP	4.29	2.63e-05	0.0105	0.4	0.27	Blood pressure (smoking interaction);	chr3:126107400	chr3:125916620~125930024:+
SARC	cis	rs240993	0.715	rs240995	ENSG00000230177.1	RP5-1112D6.4	-4.29	2.64e-05	0.0105	-0.31	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111355310	chr6:111277932~111278742:+
SARC	cis	rs783540	0.656	rs783538	ENSG00000275695.1	UBE2Q2P6	-4.29	2.64e-05	0.0105	-0.28	-0.27	Schizophrenia;	chr15:82584394	chr15:82445719~82454837:+
SARC	cis	rs7160336	0.555	rs8021337	ENSG00000259065.1	RP5-1021I20.1	-4.29	2.64e-05	0.0105	-0.37	-0.27	Blood protein levels;	chr14:74184738	chr14:73787360~73803270:+
SARC	cis	rs7772486	0.806	rs2247317	ENSG00000270638.1	RP3-466P17.1	4.29	2.64e-05	0.0105	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145896434	chr6:145735570~145737218:+
SARC	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	4.29	2.64e-05	0.0106	0.39	0.27	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
SARC	cis	rs8062405	0.755	rs62034325	ENSG00000251417.2	RP11-1348G14.4	-4.29	2.64e-05	0.0106	-0.27	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28802743~28817828:+
SARC	cis	rs7267979	0.78	rs6050679	ENSG00000276952.1	RP5-965G21.6	4.29	2.65e-05	0.0106	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:25284915~25285588:-
SARC	cis	rs9364687	0.664	rs2294706	ENSG00000228692.2	RP5-826L7.1	4.29	2.65e-05	0.0106	0.32	0.27	Body mass index;	chr6:163521130	chr6:163586583~163588165:-
SARC	cis	rs783540	0.967	rs1259183	ENSG00000275695.1	UBE2Q2P6	-4.29	2.65e-05	0.0106	-0.28	-0.27	Schizophrenia;	chr15:82610683	chr15:82445719~82454837:+
SARC	cis	rs4713118	0.662	rs149901	ENSG00000216901.1	AL022393.7	4.29	2.65e-05	0.0106	0.39	0.27	Parkinson's disease;	chr6:27997725	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.662	rs464312	ENSG00000216901.1	AL022393.7	4.29	2.65e-05	0.0106	0.39	0.27	Parkinson's disease;	chr6:27999813	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.662	rs469228	ENSG00000216901.1	AL022393.7	4.29	2.65e-05	0.0106	0.39	0.27	Parkinson's disease;	chr6:28002926	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.54	rs469227	ENSG00000216901.1	AL022393.7	4.29	2.65e-05	0.0106	0.39	0.27	Parkinson's disease;	chr6:28002927	chr6:28176188~28176674:+
SARC	cis	rs7267979	1	rs6050609	ENSG00000276952.1	RP5-965G21.6	-4.29	2.65e-05	0.0106	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25284915~25285588:-
SARC	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-4.29	2.65e-05	0.0106	-0.3	-0.27	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-4.29	2.65e-05	0.0106	-0.3	-0.27	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
SARC	cis	rs755249	0.53	rs112205225	ENSG00000182109.6	RP11-69E11.4	4.29	2.65e-05	0.0106	0.3	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39121716	chr1:39522280~39546187:-
SARC	cis	rs755249	0.53	rs4660443	ENSG00000182109.6	RP11-69E11.4	4.29	2.65e-05	0.0106	0.3	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39126107	chr1:39522280~39546187:-
SARC	cis	rs8005677	0.828	rs712486	ENSG00000279656.1	RP11-298I3.6	4.29	2.65e-05	0.0106	0.35	0.27	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:23023083~23024217:-
SARC	cis	rs193541	0.632	rs26370	ENSG00000263432.2	RN7SL689P	4.29	2.65e-05	0.0106	0.35	0.27	Glucose homeostasis traits;	chr5:122899497	chr5:123022487~123022783:-
SARC	cis	rs7267979	0.789	rs4815400	ENSG00000276952.1	RP5-965G21.6	-4.29	2.65e-05	0.0106	-0.26	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:25284915~25285588:-
SARC	cis	rs7615952	0.932	rs11922218	ENSG00000241288.6	RP11-379B18.5	-4.29	2.65e-05	0.0106	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125912446	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.866	rs11922276	ENSG00000241288.6	RP11-379B18.5	-4.29	2.65e-05	0.0106	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125912483	chr3:125827238~125916384:-
SARC	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-4.29	2.66e-05	0.0106	-0.5	-0.27	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
SARC	cis	rs7267979	0.933	rs2258728	ENSG00000276952.1	RP5-965G21.6	4.29	2.66e-05	0.0106	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25284915~25285588:-
SARC	cis	rs2439831	0.681	rs528517	ENSG00000275601.1	AC011330.13	-4.29	2.66e-05	0.0106	-0.4	-0.27	Lung cancer in ever smokers;	chr15:43320727	chr15:43642389~43643023:-
SARC	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	4.29	2.66e-05	0.0106	0.27	0.27	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
SARC	cis	rs7520050	0.807	rs28844317	ENSG00000280836.1	AL355480.1	-4.29	2.66e-05	0.0106	-0.25	-0.27	Reticulocyte count;Red blood cell count;	chr1:45743535	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.807	rs6429576	ENSG00000280836.1	AL355480.1	-4.29	2.66e-05	0.0106	-0.25	-0.27	Reticulocyte count;Red blood cell count;	chr1:45750903	chr1:45581219~45581321:-
SARC	cis	rs2439831	0.717	rs2447198	ENSG00000205771.5	CATSPER2P1	-4.29	2.66e-05	0.0106	-0.42	-0.27	Lung cancer in ever smokers;	chr15:43602920	chr15:43726918~43747094:-
SARC	cis	rs520525	0.927	rs1234282	ENSG00000271811.1	RP1-79C4.4	4.29	2.67e-05	0.0106	0.37	0.27	Atrial fibrillation;	chr1:170650183	chr1:170667381~170669425:+
SARC	cis	rs2933343	0.7	rs6787833	ENSG00000231305.3	RP11-723O4.2	4.29	2.67e-05	0.0106	0.27	0.27	IgG glycosylation;	chr3:128937341	chr3:128861313~128871540:-
SARC	cis	rs7267979	0.933	rs1130694	ENSG00000276952.1	RP5-965G21.6	4.29	2.67e-05	0.0106	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25284915~25285588:-
SARC	cis	rs4950322	0.517	rs114823926	ENSG00000278811.3	LINC00624	4.29	2.67e-05	0.0106	0.29	0.27	Protein quantitative trait loci;	chr1:147281805	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs6703892	ENSG00000278811.3	LINC00624	4.29	2.67e-05	0.0106	0.29	0.27	Protein quantitative trait loci;	chr1:147287627	chr1:147258885~147517875:-
SARC	cis	rs12468226	1	rs16839149	ENSG00000272966.1	RP11-686O6.1	4.29	2.67e-05	0.0106	0.42	0.27	Urate levels;	chr2:202427621	chr2:202336739~202337200:+
SARC	cis	rs890448	0.796	rs1549513	ENSG00000254531.1	FLJ20021	4.29	2.67e-05	0.0106	0.29	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101419773	chr4:101347780~101348883:+
SARC	cis	rs4664293	0.51	rs72961751	ENSG00000226266.5	AC009961.3	4.29	2.67e-05	0.0106	0.34	0.27	Monocyte percentage of white cells;	chr2:159738067	chr2:159670708~159712435:-
SARC	cis	rs8098244	0.597	rs72877804	ENSG00000265752.2	RP11-403A21.1	-4.29	2.67e-05	0.0106	-0.34	-0.27	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23991782	chr18:23957754~23982556:-
SARC	cis	rs4835473	0.637	rs1825040	ENSG00000251600.4	RP11-673E1.1	-4.29	2.67e-05	0.0106	-0.25	-0.27	Immature fraction of reticulocytes;	chr4:143794417	chr4:143912331~143982454:+
SARC	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	4.29	2.67e-05	0.0107	0.26	0.27	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
SARC	cis	rs755249	0.567	rs67408364	ENSG00000182109.6	RP11-69E11.4	4.29	2.67e-05	0.0107	0.3	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39152884	chr1:39522280~39546187:-
SARC	cis	rs7208859	0.623	rs7214570	ENSG00000263603.1	CTD-2349P21.5	-4.28	2.68e-05	0.0107	-0.36	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30729469~30731202:+
SARC	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	4.28	2.68e-05	0.0107	0.26	0.27	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
SARC	cis	rs867371	0.896	rs6495647	ENSG00000259429.4	UBE2Q2P2	-4.28	2.68e-05	0.0107	-0.25	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82355142~82420075:+
SARC	cis	rs890448	0.796	rs7690316	ENSG00000254531.1	FLJ20021	4.28	2.68e-05	0.0107	0.28	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417949	chr4:101347780~101348883:+
SARC	cis	rs75920871	0.528	rs10082609	ENSG00000254851.1	RP11-109L13.1	4.28	2.68e-05	0.0107	0.36	0.27	Subjective well-being;	chr11:117078358	chr11:117135528~117138582:+
SARC	cis	rs253959	0.532	rs10045890	ENSG00000272265.1	CTD-2287O16.4	4.28	2.69e-05	0.0107	0.32	0.27	Bipolar disorder and schizophrenia;	chr5:116112188	chr5:116078110~116078570:-
SARC	cis	rs8028182	0.636	rs62027209	ENSG00000260206.1	CTD-2026K11.2	-4.28	2.69e-05	0.0107	-0.32	-0.27	Sudden cardiac arrest;	chr15:75579285	chr15:75636139~75639239:+
SARC	cis	rs30380	0.632	rs27640	ENSG00000272109.1	CTD-2260A17.3	-4.28	2.69e-05	0.0107	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96792202	chr5:96804353~96806105:+
SARC	cis	rs30380	0.666	rs26512	ENSG00000272109.1	CTD-2260A17.3	-4.28	2.69e-05	0.0107	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96792697	chr5:96804353~96806105:+
SARC	cis	rs30380	0.632	rs27434	ENSG00000272109.1	CTD-2260A17.3	-4.28	2.69e-05	0.0107	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96793809	chr5:96804353~96806105:+
SARC	cis	rs9364687	0.554	rs35442073	ENSG00000228692.2	RP5-826L7.1	-4.28	2.69e-05	0.0107	-0.32	-0.27	Body mass index;	chr6:163509149	chr6:163586583~163588165:-
SARC	cis	rs14027	0.843	rs6469849	ENSG00000279347.1	RP11-85I17.2	-4.28	2.69e-05	0.0107	-0.23	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119844929	chr8:119838736~119840385:-
SARC	cis	rs910316	0.763	rs175450	ENSG00000279594.1	RP11-950C14.10	-4.28	2.69e-05	0.0107	-0.3	-0.27	Height;	chr14:75123637	chr14:75011269~75012851:-
SARC	cis	rs1707322	0.963	rs10789478	ENSG00000281133.1	AL355480.3	-4.28	2.69e-05	0.0107	-0.31	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45580892~45580996:-
SARC	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-4.28	2.69e-05	0.0107	-0.39	-0.27	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
SARC	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	4.28	2.69e-05	0.0107	0.29	0.27	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
SARC	cis	rs1009647	0.656	rs10147254	ENSG00000258413.1	RP11-665C16.6	-4.28	2.69e-05	0.0107	-0.34	-0.27	Testicular germ cell tumor;	chr14:55383597	chr14:55262767~55272075:-
SARC	cis	rs7809950	1	rs10273733	ENSG00000238832.1	snoU109	4.28	2.69e-05	0.0107	0.33	0.27	Coronary artery disease;	chr7:107617676	chr7:107603363~107603507:+
SARC	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-4.28	2.7e-05	0.0107	-0.28	-0.27	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
SARC	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	4.28	2.7e-05	0.0107	0.26	0.27	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
SARC	cis	rs9625935	0.748	rs2412974	ENSG00000227201.2	CNN2P1	-4.28	2.7e-05	0.0107	-0.27	-0.27	Tonsillectomy;	chr22:30143832	chr22:30046276~30047193:-
SARC	cis	rs7811142	0.943	rs67483801	ENSG00000078319.8	PMS2P1	-4.28	2.7e-05	0.0107	-0.38	-0.27	Platelet count;	chr7:100434135	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs11761784	ENSG00000078319.8	PMS2P1	-4.28	2.7e-05	0.0107	-0.38	-0.27	Platelet count;	chr7:100442347	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs112317829	ENSG00000078319.8	PMS2P1	-4.28	2.7e-05	0.0107	-0.38	-0.27	Platelet count;	chr7:100445550	chr7:100320992~100341908:-
SARC	cis	rs4835473	0.712	rs2198000	ENSG00000251600.4	RP11-673E1.1	-4.28	2.7e-05	0.0107	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143750005	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs2198002	ENSG00000251600.4	RP11-673E1.1	-4.28	2.7e-05	0.0107	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143750028	chr4:143912331~143982454:+
SARC	cis	rs763121	0.853	rs1043441	ENSG00000273076.1	RP3-508I15.22	4.28	2.7e-05	0.0108	0.29	0.27	Menopause (age at onset);	chr22:38734959	chr22:38743495~38743910:+
SARC	cis	rs12430683	0.818	rs874732	ENSG00000280734.1	LINC01232	4.28	2.7e-05	0.0108	0.39	0.27	QRS interval (sulfonylurea treatment interaction);	chr13:98770161	chr13:99486962~99499306:-
SARC	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-4.28	2.7e-05	0.0108	-0.32	-0.27	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
SARC	cis	rs9595908	0.931	rs9595628	ENSG00000212293.1	SNORA16	4.28	2.71e-05	0.0108	0.27	0.27	Body mass index;	chr13:32491021	chr13:32420390~32420516:-
SARC	cis	rs763121	0.925	rs17032	ENSG00000273076.1	RP3-508I15.22	4.28	2.71e-05	0.0108	0.28	0.27	Menopause (age at onset);	chr22:38734838	chr22:38743495~38743910:+
SARC	cis	rs12049351	0.774	rs10799533	ENSG00000229367.1	HMGN2P19	4.28	2.71e-05	0.0108	0.23	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229520815	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.613	rs10799535	ENSG00000229367.1	HMGN2P19	4.28	2.71e-05	0.0108	0.23	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229522047	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs3767327	ENSG00000229367.1	HMGN2P19	4.28	2.71e-05	0.0108	0.23	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229523563	chr1:229570532~229570796:+
SARC	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	4.28	2.71e-05	0.0108	0.25	0.27	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
SARC	cis	rs2898681	0.528	rs73814883	ENSG00000248375.1	RP11-177B4.1	-4.28	2.71e-05	0.0108	-0.46	-0.27	Optic nerve measurement (cup area);	chr4:52861887	chr4:52720081~52720831:-
SARC	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	4.28	2.71e-05	0.0108	0.35	0.27	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
SARC	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-4.28	2.71e-05	0.0108	-0.3	-0.27	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
SARC	cis	rs2439831	1	rs690263	ENSG00000275601.1	AC011330.13	-4.28	2.71e-05	0.0108	-0.42	-0.27	Lung cancer in ever smokers;	chr15:43412267	chr15:43642389~43643023:-
SARC	cis	rs2439831	1	rs2254321	ENSG00000275601.1	AC011330.13	-4.28	2.71e-05	0.0108	-0.42	-0.27	Lung cancer in ever smokers;	chr15:43415344	chr15:43642389~43643023:-
SARC	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	4.28	2.72e-05	0.0108	0.4	0.27	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
SARC	cis	rs7267979	0.966	rs2387885	ENSG00000276952.1	RP5-965G21.6	-4.28	2.72e-05	0.0108	-0.27	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2424713	ENSG00000276952.1	RP5-965G21.6	4.28	2.72e-05	0.0108	0.27	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25284915~25285588:-
SARC	cis	rs10986311	0.814	rs12379417	ENSG00000235204.1	RP11-121A14.2	-4.28	2.72e-05	0.0108	-0.32	-0.27	Vitiligo;	chr9:124267457	chr9:124259250~124261156:-
SARC	cis	rs4835473	0.932	rs1849113	ENSG00000251600.4	RP11-673E1.1	-4.28	2.72e-05	0.0108	-0.28	-0.27	Immature fraction of reticulocytes;	chr4:143962512	chr4:143912331~143982454:+
SARC	cis	rs4849845	0.637	rs2028147	ENSG00000236878.1	AC012363.7	-4.28	2.72e-05	0.0108	-0.27	-0.27	Mean platelet volume;	chr2:120300836	chr2:120211054~120211715:+
SARC	cis	rs526231	0.764	rs183707	ENSG00000175749.11	EIF3KP1	4.28	2.73e-05	0.0108	0.32	0.27	Primary biliary cholangitis;	chr5:103305081	chr5:103032376~103033031:+
SARC	cis	rs858239	1	rs199348	ENSG00000226816.2	AC005082.12	4.28	2.73e-05	0.0108	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23206013~23208045:+
SARC	cis	rs1823913	1	rs1454749	ENSG00000280083.1	RP11-317J9.1	-4.28	2.73e-05	0.0108	-0.3	-0.27	Obesity-related traits;	chr2:191240909	chr2:191154118~191156070:-
SARC	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	4.28	2.73e-05	0.0108	0.39	0.27	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
SARC	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-4.28	2.73e-05	0.0108	-0.25	-0.27	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-4.28	2.73e-05	0.0108	-0.25	-0.27	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-4.28	2.73e-05	0.0108	-0.25	-0.27	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-4.28	2.73e-05	0.0108	-0.25	-0.27	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-4.28	2.73e-05	0.0108	-0.25	-0.27	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-4.28	2.73e-05	0.0108	-0.25	-0.27	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-4.28	2.73e-05	0.0108	-0.25	-0.27	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-4.28	2.73e-05	0.0108	-0.25	-0.27	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-4.28	2.73e-05	0.0108	-0.25	-0.27	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-4.28	2.73e-05	0.0108	-0.25	-0.27	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
SARC	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-4.28	2.73e-05	0.0109	-0.5	-0.27	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
SARC	cis	rs9858542	0.537	rs9863142	ENSG00000225399.4	RP11-3B7.1	-4.28	2.74e-05	0.0109	-0.41	-0.27	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49329308	chr3:49260085~49261316:+
SARC	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	4.28	2.74e-05	0.0109	0.24	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
SARC	cis	rs11651000	0.625	rs4794063	ENSG00000239291.1	RP5-867C24.1	4.28	2.74e-05	0.0109	0.33	0.27	IgG glycosylation;	chr17:47727128	chr17:47159191~47159993:-
SARC	cis	rs11886999	0.723	rs72825854	ENSG00000237510.6	AC008268.2	-4.28	2.74e-05	0.0109	-0.42	-0.27	Cardiac Troponin-T levels;	chr2:96189312	chr2:95789654~95800166:+
SARC	cis	rs11886999	0.812	rs72825856	ENSG00000237510.6	AC008268.2	-4.28	2.74e-05	0.0109	-0.42	-0.27	Cardiac Troponin-T levels;	chr2:96190389	chr2:95789654~95800166:+
SARC	cis	rs2439831	1	rs2256764	ENSG00000205771.5	CATSPER2P1	-4.28	2.74e-05	0.0109	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43443565	chr15:43726918~43747094:-
SARC	cis	rs860818	1	rs858247	ENSG00000226816.2	AC005082.12	4.28	2.75e-05	0.0109	0.71	0.27	Initial pursuit acceleration;	chr7:23181664	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858245	ENSG00000226816.2	AC005082.12	4.28	2.75e-05	0.0109	0.71	0.27	Initial pursuit acceleration;	chr7:23183108	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858243	ENSG00000226816.2	AC005082.12	4.28	2.75e-05	0.0109	0.71	0.27	Initial pursuit acceleration;	chr7:23184738	chr7:23206013~23208045:+
SARC	cis	rs7688540	0.771	rs11248013	ENSG00000275426.1	CH17-262A2.1	4.28	2.75e-05	0.0109	0.4	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:149738~150317:+
SARC	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	4.28	2.75e-05	0.0109	0.25	0.27	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
SARC	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-4.28	2.75e-05	0.0109	-0.5	-0.27	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
SARC	cis	rs9309473	0.66	rs10496192	ENSG00000163016.8	ALMS1P	4.28	2.75e-05	0.0109	0.41	0.27	Metabolite levels;	chr2:73452739	chr2:73644919~73685576:+
SARC	cis	rs597539	0.58	rs7935851	ENSG00000250508.1	RP11-757G1.6	-4.28	2.75e-05	0.0109	-0.33	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68870664~68874542:+
SARC	cis	rs1823913	0.892	rs35596292	ENSG00000280083.1	RP11-317J9.1	-4.28	2.76e-05	0.0109	-0.3	-0.27	Obesity-related traits;	chr2:191246890	chr2:191154118~191156070:-
SARC	cis	rs1823913	0.927	rs35530564	ENSG00000280083.1	RP11-317J9.1	-4.28	2.76e-05	0.0109	-0.3	-0.27	Obesity-related traits;	chr2:191247324	chr2:191154118~191156070:-
SARC	cis	rs6570726	0.791	rs401331	ENSG00000270638.1	RP3-466P17.1	4.28	2.76e-05	0.0109	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145735570~145737218:+
SARC	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-4.28	2.76e-05	0.0109	-0.25	-0.27	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
SARC	cis	rs7216064	0.684	rs7406031	ENSG00000278740.1	RP11-147L13.14	-4.28	2.76e-05	0.0109	-0.29	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68025637	chr17:68188547~68189165:+
SARC	cis	rs4820294	0.669	rs7287340	ENSG00000233360.4	Z83844.1	4.28	2.76e-05	0.0109	0.31	0.27	Fat distribution (HIV);	chr22:37658318	chr22:37641832~37658377:-
SARC	cis	rs4820294	0.669	rs7287358	ENSG00000233360.4	Z83844.1	4.28	2.76e-05	0.0109	0.31	0.27	Fat distribution (HIV);	chr22:37658396	chr22:37641832~37658377:-
SARC	cis	rs7246657	0.943	rs7255952	ENSG00000226686.6	LINC01535	-4.28	2.76e-05	0.011	-0.38	-0.27	Coronary artery calcification;	chr19:37497895	chr19:37251912~37265535:+
SARC	cis	rs2439831	0.867	rs2245715	ENSG00000205771.5	CATSPER2P1	-4.28	2.76e-05	0.011	-0.43	-0.27	Lung cancer in ever smokers;	chr15:43525854	chr15:43726918~43747094:-
SARC	cis	rs783540	0.869	rs783533	ENSG00000275695.1	UBE2Q2P6	-4.28	2.77e-05	0.011	-0.27	-0.27	Schizophrenia;	chr15:82581437	chr15:82445719~82454837:+
SARC	cis	rs4835473	0.932	rs11100808	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143762728	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs7661407	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143762982	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1562777	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143763676	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1562778	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143763816	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1562779	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143763999	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1597441	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143764158	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1597443	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143764406	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1597444	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143764547	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs60038202	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143764662	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1450230	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143765118	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs34683160	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143765227	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs72946226	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143765238	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs34230433	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143765253	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs7696869	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143765855	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs7698287	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143765859	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs11721495	ENSG00000251600.4	RP11-673E1.1	-4.28	2.77e-05	0.011	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143767216	chr4:143912331~143982454:+
SARC	cis	rs12893668	0.572	rs34000399	ENSG00000269958.1	RP11-73M18.8	4.28	2.77e-05	0.011	0.29	0.27	Reticulocyte count;	chr14:103635080	chr14:103696353~103697163:+
SARC	cis	rs2439831	0.867	rs11856184	ENSG00000275601.1	AC011330.13	-4.28	2.77e-05	0.011	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43626964	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs2927072	ENSG00000275601.1	AC011330.13	-4.28	2.77e-05	0.011	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43630200	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs2920781	ENSG00000275601.1	AC011330.13	-4.28	2.77e-05	0.011	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43632484	chr15:43642389~43643023:-
SARC	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	4.28	2.77e-05	0.011	0.31	0.27	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
SARC	cis	rs75920871	0.528	rs12274465	ENSG00000254851.1	RP11-109L13.1	4.28	2.77e-05	0.011	0.36	0.27	Subjective well-being;	chr11:117086473	chr11:117135528~117138582:+
SARC	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	4.28	2.77e-05	0.011	0.25	0.27	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	4.28	2.77e-05	0.011	0.25	0.27	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	4.28	2.77e-05	0.011	0.25	0.27	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	4.28	2.77e-05	0.011	0.25	0.27	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
SARC	cis	rs950776	0.507	rs12912673	ENSG00000261762.1	RP11-650L12.2	4.28	2.77e-05	0.011	0.29	0.27	Sudden cardiac arrest;	chr15:78517874	chr15:78589123~78591276:-
SARC	cis	rs9902453	0.765	rs2169810	ENSG00000264538.5	SUZ12P1	4.28	2.77e-05	0.011	0.19	0.27	Coffee consumption (cups per day);	chr17:29840923	chr17:30709299~30790908:+
SARC	cis	rs7615952	0.932	rs13314869	ENSG00000241288.6	RP11-379B18.5	-4.28	2.78e-05	0.011	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125925826	chr3:125827238~125916384:-
SARC	cis	rs6163	0.54	rs11191385	ENSG00000213061.2	PFN1P11	4.28	2.78e-05	0.011	0.35	0.27	Waist circumference;Hip circumference;	chr10:102753292	chr10:102838011~102845473:-
SARC	cis	rs57561814	1	rs6949149	ENSG00000179428.2	AC073072.5	-4.28	2.78e-05	0.011	-0.49	-0.27	Tonsillectomy;	chr7:22709538	chr7:22725395~22727620:-
SARC	cis	rs57561814	0.655	rs8180726	ENSG00000179428.2	AC073072.5	-4.28	2.78e-05	0.011	-0.49	-0.27	Tonsillectomy;	chr7:22709687	chr7:22725395~22727620:-
SARC	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-4.28	2.78e-05	0.011	-0.3	-0.27	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-4.28	2.78e-05	0.011	-0.3	-0.27	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-4.28	2.78e-05	0.011	-0.3	-0.27	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-4.28	2.78e-05	0.011	-0.3	-0.27	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
SARC	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-4.28	2.78e-05	0.011	-0.3	-0.27	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
SARC	cis	rs853679	0.76	rs9393910	ENSG00000216901.1	AL022393.7	4.28	2.78e-05	0.011	0.43	0.27	Depression;	chr6:28240414	chr6:28176188~28176674:+
SARC	cis	rs853679	0.76	rs9368563	ENSG00000216901.1	AL022393.7	4.28	2.78e-05	0.011	0.43	0.27	Depression;	chr6:28240780	chr6:28176188~28176674:+
SARC	cis	rs2274273	0.662	rs2147970	ENSG00000258413.1	RP11-665C16.6	-4.27	2.79e-05	0.011	-0.37	-0.27	Protein biomarker;	chr14:55193499	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.662	rs2094436	ENSG00000258413.1	RP11-665C16.6	-4.27	2.79e-05	0.011	-0.37	-0.27	Protein biomarker;	chr14:55194777	chr14:55262767~55272075:-
SARC	cis	rs319598	1	rs2548966	ENSG00000224186.7	C5orf66	4.27	2.79e-05	0.011	0.24	0.27	Type 2 diabetes;	chr5:134879437	chr5:135033280~135358219:+
SARC	cis	rs2412819	0.597	rs7181912	ENSG00000205771.5	CATSPER2P1	4.27	2.79e-05	0.011	0.39	0.27	Lung cancer;	chr15:43770676	chr15:43726918~43747094:-
SARC	cis	rs2412819	0.545	rs3862143	ENSG00000205771.5	CATSPER2P1	4.27	2.79e-05	0.011	0.39	0.27	Lung cancer;	chr15:43779282	chr15:43726918~43747094:-
SARC	cis	rs7809950	0.678	rs62482507	ENSG00000238832.1	snoU109	-4.27	2.8e-05	0.0111	-0.32	-0.27	Coronary artery disease;	chr7:107384043	chr7:107603363~107603507:+
SARC	cis	rs12608544	1	rs12608544	ENSG00000232871.7	SEC1P	-4.27	2.8e-05	0.0111	-0.53	-0.27	Elevated serum carcinoembryonic antigen levels;	chr19:48633394	chr19:48638071~48682245:+
SARC	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	4.27	2.8e-05	0.0111	0.28	0.27	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
SARC	cis	rs1865760	0.593	rs3903852	ENSG00000272810.1	U91328.22	-4.27	2.8e-05	0.0111	-0.27	-0.27	Height;	chr6:25914919	chr6:26013241~26013757:+
SARC	cis	rs3110496	0.819	rs3115097	ENSG00000264608.1	RP11-192H23.8	4.27	2.8e-05	0.0111	0.27	0.27	Height;	chr17:29580295	chr17:28601827~28602284:-
SARC	cis	rs11634944	0.508	rs10451029	ENSG00000274307.1	RP11-345J18.2	-4.27	2.8e-05	0.0111	-0.33	-0.27	Interleukin-8 levels;	chr15:24992196	chr15:25708470~25710869:-
SARC	cis	rs7918232	0.574	rs10458708	ENSG00000230445.4	LRRC37A6P	4.27	2.8e-05	0.0111	0.31	0.27	Breast cancer;	chr10:27166676	chr10:27246350~27259455:-
SARC	cis	rs240993	0.672	rs6922226	ENSG00000230177.1	RP5-1112D6.4	-4.27	2.8e-05	0.0111	-0.31	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111403281	chr6:111277932~111278742:+
SARC	cis	rs240993	0.812	rs7764543	ENSG00000230177.1	RP5-1112D6.4	-4.27	2.8e-05	0.0111	-0.31	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111423116	chr6:111277932~111278742:+
SARC	cis	rs9283706	0.593	rs10077634	ENSG00000229666.1	MAST4-AS1	-4.27	2.8e-05	0.0111	-0.33	-0.27	Coronary artery disease;	chr5:67007518	chr5:67001383~67003953:-
SARC	cis	rs17270561	0.609	rs4712963	ENSG00000272462.2	U91328.19	-4.27	2.8e-05	0.0111	-0.26	-0.27	Iron status biomarkers;	chr6:25740274	chr6:25992662~26001775:+
SARC	cis	rs875971	0.628	rs6974355	ENSG00000236529.1	RP13-254B10.1	4.27	2.8e-05	0.0111	0.28	0.27	Aortic root size;	chr7:66376994	chr7:65840212~65840596:+
SARC	cis	rs494459	0.536	rs34561290	ENSG00000255422.1	AP002954.4	-4.27	2.8e-05	0.0111	-0.27	-0.27	Height;	chr11:118860890	chr11:118704607~118750263:+
SARC	cis	rs494459	0.536	rs11217072	ENSG00000255422.1	AP002954.4	-4.27	2.8e-05	0.0111	-0.27	-0.27	Height;	chr11:118861053	chr11:118704607~118750263:+
SARC	cis	rs7615952	0.688	rs17334074	ENSG00000241288.6	RP11-379B18.5	4.27	2.8e-05	0.0111	0.31	0.27	Blood pressure (smoking interaction);	chr3:125821617	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.673	rs115942855	ENSG00000248787.1	RP11-666A20.4	-4.27	2.8e-05	0.0111	-0.49	-0.27	Blood pressure (smoking interaction);	chr3:125883117	chr3:125908005~125910272:-
SARC	cis	rs240993	0.812	rs118203	ENSG00000230177.1	RP5-1112D6.4	-4.27	2.81e-05	0.0111	-0.31	-0.27	Inflammatory skin disease;Psoriasis;	chr6:111337017	chr6:111277932~111278742:+
SARC	cis	rs7267979	0.932	rs6132848	ENSG00000276952.1	RP5-965G21.6	4.27	2.81e-05	0.0111	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25284915~25285588:-
SARC	cis	rs4703855	0.538	rs2338223	ENSG00000244061.1	RP11-389C8.1	4.27	2.81e-05	0.0111	0.27	0.27	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72432587	chr5:72381794~72382393:+
SARC	cis	rs4703855	0.538	rs12054750	ENSG00000244061.1	RP11-389C8.1	4.27	2.81e-05	0.0111	0.27	0.27	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:72433394	chr5:72381794~72382393:+
SARC	cis	rs867371	1	rs867370	ENSG00000259429.4	UBE2Q2P2	4.27	2.81e-05	0.0111	0.26	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82145921	chr15:82355142~82420075:+
SARC	cis	rs867371	1	rs867371	ENSG00000259429.4	UBE2Q2P2	4.27	2.81e-05	0.0111	0.26	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82146005	chr15:82355142~82420075:+
SARC	cis	rs7809950	0.817	rs2253833	ENSG00000238832.1	snoU109	4.27	2.81e-05	0.0111	0.33	0.27	Coronary artery disease;	chr7:107565224	chr7:107603363~107603507:+
SARC	cis	rs4713118	0.662	rs156744	ENSG00000272009.1	RP1-313I6.12	-4.27	2.81e-05	0.0111	-0.31	-0.27	Parkinson's disease;	chr6:27999496	chr6:28078792~28081130:-
SARC	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	4.27	2.81e-05	0.0111	0.4	0.27	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
SARC	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-4.27	2.82e-05	0.0111	-0.24	-0.27	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
SARC	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-4.27	2.82e-05	0.0111	-0.29	-0.27	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
SARC	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	4.27	2.82e-05	0.0111	0.28	0.27	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
SARC	cis	rs11064768	0.687	rs12367044	ENSG00000255857.4	PXN-AS1	-4.27	2.82e-05	0.0111	-0.41	-0.27	Schizophrenia;	chr12:119398259	chr12:120201291~120213138:+
SARC	cis	rs11064768	0.687	rs12368799	ENSG00000255857.4	PXN-AS1	-4.27	2.82e-05	0.0111	-0.41	-0.27	Schizophrenia;	chr12:119398398	chr12:120201291~120213138:+
SARC	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-4.27	2.82e-05	0.0111	-0.5	-0.27	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-4.27	2.82e-05	0.0111	-0.5	-0.27	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.623	rs9898084	ENSG00000264538.5	SUZ12P1	-4.27	2.82e-05	0.0111	-0.29	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30709299~30790908:+
SARC	cis	rs9890032	1	rs9890032	ENSG00000266490.1	CTD-2349P21.9	-4.27	2.82e-05	0.0112	-0.24	-0.27	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30792372~30792833:+
SARC	cis	rs9473147	0.543	rs4711880	ENSG00000270761.1	RP11-385F7.1	-4.27	2.83e-05	0.0112	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47512940	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.543	rs9473126	ENSG00000270761.1	RP11-385F7.1	-4.27	2.83e-05	0.0112	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47514097	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.543	rs4715025	ENSG00000270761.1	RP11-385F7.1	-4.27	2.83e-05	0.0112	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47515917	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs7767350	ENSG00000270761.1	RP11-385F7.1	-4.27	2.83e-05	0.0112	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47517390	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs10948363	ENSG00000270761.1	RP11-385F7.1	-4.27	2.83e-05	0.0112	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47520026	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs2171089	ENSG00000270761.1	RP11-385F7.1	-4.27	2.83e-05	0.0112	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47548075	chr6:47477243~47477572:-
SARC	cis	rs7615952	0.576	rs4646763	ENSG00000171084.14	FAM86JP	4.27	2.83e-05	0.0112	0.41	0.27	Blood pressure (smoking interaction);	chr3:126103286	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.576	rs4646759	ENSG00000171084.14	FAM86JP	4.27	2.83e-05	0.0112	0.41	0.27	Blood pressure (smoking interaction);	chr3:126104103	chr3:125916620~125930024:+
SARC	cis	rs42490	0.528	rs1040327	ENSG00000251136.7	RP11-37B2.1	4.27	2.83e-05	0.0112	0.29	0.27	Leprosy;	chr8:89669585	chr8:89609409~89757727:-
SARC	cis	rs42490	0.528	rs2840206	ENSG00000251136.7	RP11-37B2.1	4.27	2.83e-05	0.0112	0.29	0.27	Leprosy;	chr8:89670184	chr8:89609409~89757727:-
SARC	cis	rs2274273	0.662	rs66476033	ENSG00000258413.1	RP11-665C16.6	-4.27	2.83e-05	0.0112	-0.37	-0.27	Protein biomarker;	chr14:55194145	chr14:55262767~55272075:-
SARC	cis	rs12049351	0.774	rs12138965	ENSG00000229367.1	HMGN2P19	4.27	2.83e-05	0.0112	0.23	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229519973	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs10916504	ENSG00000229367.1	HMGN2P19	4.27	2.83e-05	0.0112	0.23	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229520145	chr1:229570532~229570796:+
SARC	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-4.27	2.83e-05	0.0112	-0.5	-0.27	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
SARC	cis	rs1707322	0.721	rs11211181	ENSG00000281133.1	AL355480.3	-4.27	2.83e-05	0.0112	-0.31	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45580892~45580996:-
SARC	cis	rs910316	0.967	rs11159121	ENSG00000279594.1	RP11-950C14.10	-4.27	2.83e-05	0.0112	-0.28	-0.27	Height;	chr14:75199326	chr14:75011269~75012851:-
SARC	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	4.27	2.84e-05	0.0112	0.25	0.27	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
SARC	cis	rs12468226	1	rs79919139	ENSG00000272966.1	RP11-686O6.1	4.27	2.84e-05	0.0112	0.42	0.27	Urate levels;	chr2:202382786	chr2:202336739~202337200:+
SARC	cis	rs12468226	0.935	rs75597391	ENSG00000272966.1	RP11-686O6.1	4.27	2.84e-05	0.0112	0.42	0.27	Urate levels;	chr2:202398850	chr2:202336739~202337200:+
SARC	cis	rs12468226	1	rs115170232	ENSG00000272966.1	RP11-686O6.1	4.27	2.84e-05	0.0112	0.42	0.27	Urate levels;	chr2:202416790	chr2:202336739~202337200:+
SARC	cis	rs7712401	0.584	rs4836382	ENSG00000263432.2	RN7SL689P	4.27	2.84e-05	0.0112	0.34	0.27	Mean platelet volume;	chr5:123040946	chr5:123022487~123022783:-
SARC	cis	rs12468226	0.938	rs10931993	ENSG00000272966.1	RP11-686O6.1	4.27	2.84e-05	0.0112	0.43	0.27	Urate levels;	chr2:202243017	chr2:202336739~202337200:+
SARC	cis	rs910316	0.737	rs175048	ENSG00000279594.1	RP11-950C14.10	-4.27	2.84e-05	0.0112	-0.3	-0.27	Height;	chr14:75013191	chr14:75011269~75012851:-
SARC	cis	rs17695224	0.5	rs4802876	ENSG00000275055.1	CTC-471J1.11	-4.27	2.84e-05	0.0112	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51831964	chr19:52049007~52049754:+
SARC	cis	rs9868809	0.772	rs9812200	ENSG00000225399.4	RP11-3B7.1	4.27	2.84e-05	0.0112	0.46	0.27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48658234	chr3:49260085~49261316:+
SARC	cis	rs755249	0.583	rs61779328	ENSG00000182109.6	RP11-69E11.4	4.27	2.84e-05	0.0112	0.32	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39487795	chr1:39522280~39546187:-
SARC	cis	rs763121	0.925	rs4821797	ENSG00000273076.1	RP3-508I15.22	4.27	2.84e-05	0.0112	0.29	0.27	Menopause (age at onset);	chr22:38620177	chr22:38743495~38743910:+
SARC	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-4.27	2.84e-05	0.0112	-0.5	-0.27	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-4.27	2.84e-05	0.0112	-0.5	-0.27	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-4.27	2.84e-05	0.0112	-0.5	-0.27	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-4.27	2.84e-05	0.0112	-0.5	-0.27	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-4.27	2.84e-05	0.0112	-0.5	-0.27	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-4.27	2.84e-05	0.0112	-0.5	-0.27	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-4.27	2.84e-05	0.0112	-0.5	-0.27	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-4.27	2.84e-05	0.0112	-0.5	-0.27	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-4.27	2.84e-05	0.0112	-0.5	-0.27	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-4.27	2.84e-05	0.0112	-0.5	-0.27	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
SARC	cis	rs5752326	1	rs2157586	ENSG00000261188.1	CTA-445C9.14	-4.27	2.84e-05	0.0112	-0.42	-0.27	Ischemic stroke;	chr22:26499095	chr22:26512537~26514568:+
SARC	cis	rs853679	1	rs1778508	ENSG00000219392.1	RP1-265C24.5	4.27	2.84e-05	0.0112	0.47	0.27	Depression;	chr6:28262103	chr6:28115628~28116551:+
SARC	cis	rs745109	0.504	rs75610186	ENSG00000273080.1	RP11-301O19.1	4.27	2.84e-05	0.0112	0.42	0.27	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86372933	chr2:86195590~86196049:+
SARC	cis	rs7976269	0.559	rs10771477	ENSG00000257176.2	RP11-996F15.2	-4.27	2.84e-05	0.0112	-0.29	-0.27	Male-pattern baldness;	chr12:29074137	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.559	rs10843307	ENSG00000257176.2	RP11-996F15.2	-4.27	2.84e-05	0.0112	-0.29	-0.27	Male-pattern baldness;	chr12:29074710	chr12:29280418~29317848:-
SARC	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	4.27	2.84e-05	0.0112	0.24	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
SARC	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	4.27	2.85e-05	0.0112	0.27	0.27	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
SARC	cis	rs72945132	0.882	rs7935969	ENSG00000254604.1	AP000487.6	-4.27	2.85e-05	0.0112	-0.38	-0.27	Coronary artery disease;	chr11:70348069	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs113472486	ENSG00000254604.1	AP000487.6	-4.27	2.85e-05	0.0112	-0.38	-0.27	Coronary artery disease;	chr11:70348839	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs12099016	ENSG00000254604.1	AP000487.6	-4.27	2.85e-05	0.0112	-0.38	-0.27	Coronary artery disease;	chr11:70349055	chr11:70282367~70363368:-
SARC	cis	rs7537765	1	rs17037452	ENSG00000242349.4	NPPA-AS1	-4.27	2.85e-05	0.0113	-0.35	-0.27	QRS complex (12-leadsum);	chr1:11835618	chr1:11841017~11848079:+
SARC	cis	rs2307449	0.892	rs2238301	ENSG00000261441.1	RP11-217B1.2	-4.27	2.85e-05	0.0113	-0.34	-0.27	Menopause (age at onset);	chr15:89308207	chr15:89335053~89336161:+
SARC	cis	rs17270561	0.609	rs1165211	ENSG00000272462.2	U91328.19	-4.27	2.86e-05	0.0113	-0.25	-0.27	Iron status biomarkers;	chr6:25800694	chr6:25992662~26001775:+
SARC	cis	rs7809950	0.817	rs10224503	ENSG00000238832.1	snoU109	-4.27	2.86e-05	0.0113	-0.32	-0.27	Coronary artery disease;	chr7:107435124	chr7:107603363~107603507:+
SARC	cis	rs7811142	0.83	rs6979910	ENSG00000078319.8	PMS2P1	-4.27	2.86e-05	0.0113	-0.38	-0.27	Platelet count;	chr7:100343007	chr7:100320992~100341908:-
SARC	cis	rs4713118	0.662	rs156744	ENSG00000216901.1	AL022393.7	4.27	2.86e-05	0.0113	0.39	0.27	Parkinson's disease;	chr6:27999496	chr6:28176188~28176674:+
SARC	cis	rs324126	0.78	rs10445583	ENSG00000269834.4	ZNF528-AS1	4.27	2.86e-05	0.0113	0.28	0.27	Colonoscopy-negative controls vs population controls;	chr19:52379480	chr19:52388842~52397766:-
SARC	cis	rs324126	0.752	rs10445584	ENSG00000269834.4	ZNF528-AS1	4.27	2.86e-05	0.0113	0.28	0.27	Colonoscopy-negative controls vs population controls;	chr19:52379552	chr19:52388842~52397766:-
SARC	cis	rs324126	0.78	rs10445585	ENSG00000269834.4	ZNF528-AS1	4.27	2.86e-05	0.0113	0.28	0.27	Colonoscopy-negative controls vs population controls;	chr19:52379571	chr19:52388842~52397766:-
SARC	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-4.27	2.86e-05	0.0113	-0.31	-0.27	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
SARC	cis	rs916888	0.61	rs199452	ENSG00000261575.2	RP11-259G18.1	4.27	2.86e-05	0.0113	0.34	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46267037~46268694:+
SARC	cis	rs10911902	0.643	rs3820182	ENSG00000229739.2	RP11-295K2.3	4.27	2.86e-05	0.0113	0.38	0.27	Schizophrenia;	chr1:186321201	chr1:186435161~186470291:+
SARC	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-4.27	2.87e-05	0.0113	-0.32	-0.27	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
SARC	cis	rs7267979	1	rs4815424	ENSG00000276952.1	RP5-965G21.6	-4.27	2.87e-05	0.0113	-0.26	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25284915~25285588:-
SARC	cis	rs1707322	0.721	rs7520123	ENSG00000281133.1	AL355480.3	-4.27	2.87e-05	0.0113	-0.31	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45580892~45580996:-
SARC	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-4.27	2.87e-05	0.0113	-0.25	-0.27	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
SARC	cis	rs4713118	0.513	rs1225591	ENSG00000272009.1	RP1-313I6.12	-4.27	2.87e-05	0.0113	-0.31	-0.27	Parkinson's disease;	chr6:28180974	chr6:28078792~28081130:-
SARC	cis	rs792448	1	rs518793	ENSG00000229983.1	RP11-15I11.2	4.27	2.88e-05	0.0113	0.28	0.27	White blood cell count (basophil);	chr1:212414864	chr1:212168207~212190259:+
SARC	cis	rs8031584	0.918	rs11639169	ENSG00000260382.1	RP11-540B6.2	4.27	2.88e-05	0.0113	0.34	0.27	Huntington's disease progression;	chr15:30963235	chr15:30882267~30883231:-
SARC	cis	rs4972806	0.814	rs1446575	ENSG00000226363.3	HAGLROS	-4.27	2.88e-05	0.0113	-0.35	-0.27	IgG glycosylation;	chr2:176183073	chr2:176177717~176179008:+
SARC	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-4.27	2.88e-05	0.0114	-0.3	-0.27	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
SARC	cis	rs7512898	0.583	rs6427852	ENSG00000260088.1	RP11-92G12.3	-4.27	2.88e-05	0.0114	-0.27	-0.27	Electrocardiographic conduction measures;	chr1:200707080	chr1:200669507~200694250:+
SARC	cis	rs910316	1	rs2098297	ENSG00000279594.1	RP11-950C14.10	-4.27	2.88e-05	0.0114	-0.29	-0.27	Height;	chr14:75152415	chr14:75011269~75012851:-
SARC	cis	rs7809950	0.724	rs1858888	ENSG00000238832.1	snoU109	-4.27	2.88e-05	0.0114	-0.32	-0.27	Coronary artery disease;	chr7:107405617	chr7:107603363~107603507:+
SARC	cis	rs853679	0.723	rs9366718	ENSG00000216901.1	AL022393.7	4.27	2.88e-05	0.0114	0.43	0.27	Depression;	chr6:28237724	chr6:28176188~28176674:+
SARC	cis	rs17597773	0.527	rs2484699	ENSG00000238078.1	LINC01352	-4.27	2.88e-05	0.0114	-0.28	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220910410	chr1:220829255~220832429:+
SARC	cis	rs792448	0.798	rs612414	ENSG00000229983.1	RP11-15I11.2	4.27	2.89e-05	0.0114	0.28	0.27	White blood cell count (basophil);	chr1:212428834	chr1:212168207~212190259:+
SARC	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-4.27	2.89e-05	0.0114	-0.24	-0.27	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
SARC	cis	rs7537765	0.895	rs2236796	ENSG00000242349.4	NPPA-AS1	-4.27	2.89e-05	0.0114	-0.35	-0.27	QRS complex (12-leadsum);	chr1:11832558	chr1:11841017~11848079:+
SARC	cis	rs7267979	1	rs4815405	ENSG00000276952.1	RP5-965G21.6	-4.27	2.89e-05	0.0114	-0.26	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25284915~25285588:-
SARC	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-4.27	2.89e-05	0.0114	-0.4	-0.27	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
SARC	cis	rs72945132	0.825	rs72947052	ENSG00000254604.1	AP000487.6	-4.27	2.89e-05	0.0114	-0.4	-0.27	Coronary artery disease;	chr11:70342469	chr11:70282367~70363368:-
SARC	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	4.27	2.89e-05	0.0114	0.33	0.27	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
SARC	cis	rs7267979	0.706	rs6138542	ENSG00000276952.1	RP5-965G21.6	4.27	2.89e-05	0.0114	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:25284915~25285588:-
SARC	cis	rs4950322	0.57	rs72691102	ENSG00000278811.3	LINC00624	4.27	2.89e-05	0.0114	0.28	0.27	Protein quantitative trait loci;	chr1:147301189	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692904	ENSG00000278811.3	LINC00624	4.27	2.89e-05	0.0114	0.28	0.27	Protein quantitative trait loci;	chr1:147301437	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692905	ENSG00000278811.3	LINC00624	4.27	2.89e-05	0.0114	0.28	0.27	Protein quantitative trait loci;	chr1:147301560	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692907	ENSG00000278811.3	LINC00624	4.27	2.89e-05	0.0114	0.28	0.27	Protein quantitative trait loci;	chr1:147301921	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692914	ENSG00000278811.3	LINC00624	4.27	2.89e-05	0.0114	0.28	0.27	Protein quantitative trait loci;	chr1:147302946	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692917	ENSG00000278811.3	LINC00624	4.27	2.89e-05	0.0114	0.28	0.27	Protein quantitative trait loci;	chr1:147304389	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72692920	ENSG00000278811.3	LINC00624	4.27	2.89e-05	0.0114	0.28	0.27	Protein quantitative trait loci;	chr1:147308501	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs66580541	ENSG00000278811.3	LINC00624	4.27	2.89e-05	0.0114	0.28	0.27	Protein quantitative trait loci;	chr1:147308828	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs945742	ENSG00000278811.3	LINC00624	4.27	2.89e-05	0.0114	0.28	0.27	Protein quantitative trait loci;	chr1:147313437	chr1:147258885~147517875:-
SARC	cis	rs1075265	0.518	rs13414393	ENSG00000233266.1	HMGB1P31	4.27	2.9e-05	0.0114	0.31	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54051334~54051760:+
SARC	cis	rs2562456	0.833	rs2968076	ENSG00000268081.1	RP11-678G14.2	-4.27	2.9e-05	0.0114	-0.41	-0.27	Pain;	chr19:21454299	chr19:21554640~21569237:-
SARC	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	4.27	2.9e-05	0.0114	0.28	0.27	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
SARC	cis	rs367615	0.661	rs9326773	ENSG00000249476.1	CTD-2587M2.1	4.27	2.9e-05	0.0114	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109497822	chr5:109237120~109326369:-
SARC	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	4.27	2.9e-05	0.0114	0.39	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	4.27	2.9e-05	0.0114	0.39	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
SARC	cis	rs2439831	0.867	rs8039638	ENSG00000275601.1	AC011330.13	-4.27	2.9e-05	0.0114	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43342207	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs28415933	ENSG00000275601.1	AC011330.13	-4.27	2.9e-05	0.0114	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43343602	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs12324572	ENSG00000275601.1	AC011330.13	-4.27	2.9e-05	0.0114	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43344002	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs2412780	ENSG00000275601.1	AC011330.13	-4.27	2.9e-05	0.0114	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43363596	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs2412779	ENSG00000275601.1	AC011330.13	-4.27	2.9e-05	0.0114	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43363729	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs2899082	ENSG00000275601.1	AC011330.13	-4.27	2.9e-05	0.0114	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43363845	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs3213991	ENSG00000275601.1	AC011330.13	-4.27	2.9e-05	0.0114	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43378082	chr15:43642389~43643023:-
SARC	cis	rs7250849	0.79	rs7259861	ENSG00000273837.1	LLNLR-470E3.1	-4.27	2.9e-05	0.0114	-0.35	-0.27	Blood protein levels;	chr19:51657490	chr19:51639478~51639931:-
SARC	cis	rs2803122	0.756	rs1129101	ENSG00000273226.1	RP11-513M16.8	4.27	2.9e-05	0.0114	0.26	0.27	Pulse pressure;	chr9:19372992	chr9:19375451~19375996:+
SARC	cis	rs7819412	0.668	rs4841507	ENSG00000255310.2	AF131215.2	-4.27	2.9e-05	0.0114	-0.3	-0.27	Triglycerides;	chr8:11188885	chr8:11107788~11109726:-
SARC	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	4.27	2.9e-05	0.0114	0.25	0.27	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
SARC	cis	rs7216064	0.532	rs8065296	ENSG00000278740.1	RP11-147L13.14	-4.26	2.91e-05	0.0114	-0.29	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68022446	chr17:68188547~68189165:+
SARC	cis	rs7647973	0.621	rs3774800	ENSG00000225399.4	RP11-3B7.1	-4.26	2.91e-05	0.0114	-0.33	-0.27	Menarche (age at onset);	chr3:49297335	chr3:49260085~49261316:+
SARC	cis	rs72627509	0.904	rs3796529	ENSG00000269949.1	RP11-738E22.3	4.26	2.91e-05	0.0114	0.39	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56931248	chr4:56960927~56961373:-
SARC	cis	rs758129	0.722	rs149234	ENSG00000261441.1	RP11-217B1.2	4.26	2.91e-05	0.0114	0.35	0.27	Schizophrenia;	chr15:89386376	chr15:89335053~89336161:+
SARC	cis	rs7615952	0.741	rs13314845	ENSG00000241288.6	RP11-379B18.5	-4.26	2.91e-05	0.0114	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125925939	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.733	rs13314847	ENSG00000241288.6	RP11-379B18.5	-4.26	2.91e-05	0.0114	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125925945	chr3:125827238~125916384:-
SARC	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-4.26	2.91e-05	0.0114	-0.25	-0.27	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
SARC	cis	rs9595908	0.895	rs9591012	ENSG00000212293.1	SNORA16	4.26	2.92e-05	0.0115	0.28	0.27	Body mass index;	chr13:32484196	chr13:32420390~32420516:-
SARC	cis	rs367615	0.918	rs17161889	ENSG00000249476.1	CTD-2587M2.1	-4.26	2.92e-05	0.0115	-0.35	-0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109519550	chr5:109237120~109326369:-
SARC	cis	rs35160687	0.712	rs11691807	ENSG00000273080.1	RP11-301O19.1	-4.26	2.92e-05	0.0115	-0.28	-0.27	Night sleep phenotypes;	chr2:86255898	chr2:86195590~86196049:+
SARC	cis	rs319598	1	rs319593	ENSG00000224186.7	C5orf66	-4.26	2.92e-05	0.0115	-0.24	-0.27	Type 2 diabetes;	chr5:134915993	chr5:135033280~135358219:+
SARC	cis	rs4820294	0.669	rs9622677	ENSG00000233360.4	Z83844.1	4.26	2.92e-05	0.0115	0.31	0.27	Fat distribution (HIV);	chr22:37658255	chr22:37641832~37658377:-
SARC	cis	rs11822910	0.871	rs2581928	ENSG00000265566.2	RN7SL605P	-4.26	2.92e-05	0.0115	-0.35	-0.27	Platelet distribution width;	chr11:57435317	chr11:57528085~57528365:-
SARC	cis	rs41369048	0.669	rs11589654	ENSG00000272823.1	RP11-295M18.6	-4.26	2.93e-05	0.0115	-0.41	-0.27	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220866646	chr1:220828676~220829211:-
SARC	cis	rs61160187	0.582	rs12653132	ENSG00000272308.1	RP11-231G3.1	-4.26	2.93e-05	0.0115	-0.24	-0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61062881	chr5:60866457~60866935:-
SARC	cis	rs61160187	0.582	rs56284222	ENSG00000272308.1	RP11-231G3.1	-4.26	2.93e-05	0.0115	-0.24	-0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61065723	chr5:60866457~60866935:-
SARC	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	4.26	2.93e-05	0.0115	0.3	0.27	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
SARC	cis	rs7246657	1	rs35398388	ENSG00000226686.6	LINC01535	-4.26	2.93e-05	0.0115	-0.39	-0.27	Coronary artery calcification;	chr19:37249456	chr19:37251912~37265535:+
SARC	cis	rs7246657	1	rs7247672	ENSG00000226686.6	LINC01535	-4.26	2.93e-05	0.0115	-0.39	-0.27	Coronary artery calcification;	chr19:37253026	chr19:37251912~37265535:+
SARC	cis	rs7246657	1	rs8110011	ENSG00000226686.6	LINC01535	-4.26	2.93e-05	0.0115	-0.39	-0.27	Coronary artery calcification;	chr19:37254911	chr19:37251912~37265535:+
SARC	cis	rs394563	0.591	rs237029	ENSG00000231760.4	RP11-350J20.5	4.26	2.93e-05	0.0115	0.34	0.27	Dupuytren's disease;	chr6:149396289	chr6:149796151~149826294:-
SARC	cis	rs394563	0.591	rs237028	ENSG00000231760.4	RP11-350J20.5	4.26	2.93e-05	0.0115	0.34	0.27	Dupuytren's disease;	chr6:149397514	chr6:149796151~149826294:-
SARC	cis	rs910316	0.967	rs175502	ENSG00000279594.1	RP11-950C14.10	-4.26	2.93e-05	0.0115	-0.29	-0.27	Height;	chr14:75066976	chr14:75011269~75012851:-
SARC	cis	rs7772486	0.79	rs3924499	ENSG00000270638.1	RP3-466P17.1	-4.26	2.93e-05	0.0115	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145735570~145737218:+
SARC	cis	rs7615952	0.576	rs4646748	ENSG00000171084.14	FAM86JP	4.26	2.93e-05	0.0115	0.4	0.27	Blood pressure (smoking interaction);	chr3:126107486	chr3:125916620~125930024:+
SARC	cis	rs9902453	0.817	rs9909128	ENSG00000264538.5	SUZ12P1	4.26	2.93e-05	0.0115	0.19	0.27	Coffee consumption (cups per day);	chr17:29834464	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.765	rs12601647	ENSG00000264538.5	SUZ12P1	4.26	2.93e-05	0.0115	0.19	0.27	Coffee consumption (cups per day);	chr17:29837935	chr17:30709299~30790908:+
SARC	cis	rs30380	0.587	rs469674	ENSG00000272109.1	CTD-2260A17.3	-4.26	2.93e-05	0.0115	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96794312	chr5:96804353~96806105:+
SARC	cis	rs9473147	0.516	rs9357546	ENSG00000270761.1	RP11-385F7.1	-4.26	2.94e-05	0.0115	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47581759	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs9395283	ENSG00000270761.1	RP11-385F7.1	-4.26	2.94e-05	0.0115	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47583708	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs9349415	ENSG00000270761.1	RP11-385F7.1	-4.26	2.94e-05	0.0115	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47584125	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs9349416	ENSG00000270761.1	RP11-385F7.1	-4.26	2.94e-05	0.0115	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47584202	chr6:47477243~47477572:-
SARC	cis	rs853679	0.599	rs149990	ENSG00000216901.1	AL022393.7	4.26	2.94e-05	0.0115	0.52	0.27	Depression;	chr6:28030480	chr6:28176188~28176674:+
SARC	cis	rs853679	0.599	rs149943	ENSG00000216901.1	AL022393.7	4.26	2.94e-05	0.0115	0.52	0.27	Depression;	chr6:28034610	chr6:28176188~28176674:+
SARC	cis	rs7246657	0.943	rs4801803	ENSG00000226686.6	LINC01535	4.26	2.94e-05	0.0116	0.38	0.27	Coronary artery calcification;	chr19:37476021	chr19:37251912~37265535:+
SARC	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	4.26	2.94e-05	0.0116	0.24	0.27	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
SARC	cis	rs4372836	0.729	rs4665436	ENSG00000226833.4	AC097724.3	-4.26	2.95e-05	0.0116	-0.23	-0.27	Body mass index;	chr2:28867361	chr2:28708953~28736205:-
SARC	cis	rs4835473	0.932	rs12513087	ENSG00000251600.4	RP11-673E1.1	-4.26	2.95e-05	0.0116	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143758551	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs12513119	ENSG00000251600.4	RP11-673E1.1	-4.26	2.95e-05	0.0116	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143758619	chr4:143912331~143982454:+
SARC	cis	rs638893	0.617	rs7103314	ENSG00000278376.1	RP11-158I9.8	-4.26	2.96e-05	0.0116	-0.24	-0.27	Vitiligo;	chr11:118852828	chr11:118791254~118793137:+
SARC	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-4.26	2.96e-05	0.0116	-0.25	-0.27	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-4.26	2.96e-05	0.0116	-0.25	-0.27	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
SARC	cis	rs1167832	0.645	rs1167828	ENSG00000127957.15	PMS2P3	-4.26	2.96e-05	0.0116	-0.37	-0.27	Ankle injury;	chr7:75534076	chr7:75502930~75528148:-
SARC	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	4.26	2.96e-05	0.0116	0.25	0.27	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
SARC	cis	rs10911902	0.56	rs76317001	ENSG00000229739.2	RP11-295K2.3	-4.26	2.96e-05	0.0116	-0.39	-0.27	Schizophrenia;	chr1:186303357	chr1:186435161~186470291:+
SARC	cis	rs6842047	1	rs9995366	ENSG00000272218.1	RP11-11N5.3	4.26	2.96e-05	0.0116	0.41	0.27	Blood protein levels;	chr4:186210230	chr4:186892552~186892983:+
SARC	cis	rs9473147	0.543	rs7738044	ENSG00000270761.1	RP11-385F7.1	-4.26	2.97e-05	0.0116	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47501537	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.543	rs9473122	ENSG00000270761.1	RP11-385F7.1	-4.26	2.97e-05	0.0116	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47507226	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.503	rs9473123	ENSG00000270761.1	RP11-385F7.1	-4.26	2.97e-05	0.0116	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47507603	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.543	rs13211285	ENSG00000270761.1	RP11-385F7.1	-4.26	2.97e-05	0.0116	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47511882	chr6:47477243~47477572:-
SARC	cis	rs367615	0.959	rs4957830	ENSG00000249476.1	CTD-2587M2.1	4.26	2.97e-05	0.0116	0.35	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109576057	chr5:109237120~109326369:-
SARC	cis	rs9473147	0.516	rs1485780	ENSG00000270761.1	RP11-385F7.1	-4.26	2.97e-05	0.0116	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47588894	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.543	rs9381578	ENSG00000270761.1	RP11-385F7.1	-4.26	2.97e-05	0.0116	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47588898	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs9381579	ENSG00000270761.1	RP11-385F7.1	-4.26	2.97e-05	0.0116	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47588944	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs10456570	ENSG00000270761.1	RP11-385F7.1	-4.26	2.97e-05	0.0116	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47591715	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs6903331	ENSG00000270761.1	RP11-385F7.1	-4.26	2.97e-05	0.0116	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47595179	chr6:47477243~47477572:-
SARC	cis	rs9369695	0.842	rs2396825	ENSG00000270761.1	RP11-385F7.1	-4.26	2.97e-05	0.0116	-0.33	-0.27	Reticulocyte count;	chr6:47600960	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs9395286	ENSG00000270761.1	RP11-385F7.1	-4.26	2.97e-05	0.0116	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47607596	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs13212790	ENSG00000270761.1	RP11-385F7.1	-4.26	2.97e-05	0.0116	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47608631	chr6:47477243~47477572:-
SARC	cis	rs448720	0.508	rs17247210	ENSG00000259410.4	RP11-34F13.3	4.26	2.97e-05	0.0117	0.3	0.27	Cognitive performance;	chr15:67927734	chr15:67832725~67873866:+
SARC	cis	rs4835473	0.838	rs4271960	ENSG00000251600.4	RP11-673E1.1	-4.26	2.98e-05	0.0117	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143763591	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.808	rs2323198	ENSG00000251600.4	RP11-673E1.1	-4.26	2.98e-05	0.0117	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143763595	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs2323199	ENSG00000251600.4	RP11-673E1.1	-4.26	2.98e-05	0.0117	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143763606	chr4:143912331~143982454:+
SARC	cis	rs324126	0.78	rs55748277	ENSG00000269834.4	ZNF528-AS1	4.26	2.98e-05	0.0117	0.29	0.27	Colonoscopy-negative controls vs population controls;	chr19:52384992	chr19:52388842~52397766:-
SARC	cis	rs4835473	0.897	rs7681903	ENSG00000251600.4	RP11-673E1.1	-4.26	2.98e-05	0.0117	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143759326	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs7656753	ENSG00000251600.4	RP11-673E1.1	-4.26	2.98e-05	0.0117	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143759414	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs7656786	ENSG00000251600.4	RP11-673E1.1	-4.26	2.98e-05	0.0117	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143759455	chr4:143912331~143982454:+
SARC	cis	rs9309473	0.519	rs6746971	ENSG00000163016.8	ALMS1P	4.26	2.99e-05	0.0117	0.31	0.27	Metabolite levels;	chr2:73442334	chr2:73644919~73685576:+
SARC	cis	rs910316	1	rs12435391	ENSG00000279594.1	RP11-950C14.10	4.26	2.99e-05	0.0117	0.3	0.27	Height;	chr14:75135034	chr14:75011269~75012851:-
SARC	cis	rs17270561	0.609	rs1165208	ENSG00000272462.2	U91328.19	-4.26	2.99e-05	0.0117	-0.25	-0.27	Iron status biomarkers;	chr6:25803676	chr6:25992662~26001775:+
SARC	cis	rs4372836	0.729	rs10166861	ENSG00000226833.4	AC097724.3	4.26	2.99e-05	0.0117	0.23	0.27	Body mass index;	chr2:28838245	chr2:28708953~28736205:-
SARC	cis	rs4660456	0.504	rs2744805	ENSG00000237899.1	RP4-739H11.3	4.26	2.99e-05	0.0117	0.33	0.27	Platelet count;	chr1:40654827	chr1:40669089~40687588:-
SARC	cis	rs7615952	0.551	rs6438945	ENSG00000241288.6	RP11-379B18.5	-4.26	2.99e-05	0.0117	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125915630	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.673	rs7632557	ENSG00000241288.6	RP11-379B18.5	-4.26	2.99e-05	0.0117	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125916038	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.932	rs9841157	ENSG00000241288.6	RP11-379B18.5	-4.26	2.99e-05	0.0117	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125916812	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.551	rs12695470	ENSG00000241288.6	RP11-379B18.5	-4.26	2.99e-05	0.0117	-0.36	-0.27	Blood pressure (smoking interaction);	chr3:125916875	chr3:125827238~125916384:-
SARC	cis	rs5752326	0.717	rs5761545	ENSG00000261188.1	CTA-445C9.14	4.26	2.99e-05	0.0117	0.49	0.27	Ischemic stroke;	chr22:26466806	chr22:26512537~26514568:+
SARC	cis	rs1880529	0.732	rs9307390	ENSG00000206820.1	RNU1-138P	-4.26	3e-05	0.0117	-0.25	-0.27	White matter integrity (bipolar disorder risk interaction);	chr4:113435007	chr4:113420323~113420486:+
SARC	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	4.26	3e-05	0.0117	0.4	0.27	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
SARC	cis	rs9473147	0.602	rs9296567	ENSG00000270761.1	RP11-385F7.1	-4.26	3e-05	0.0117	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47585666	chr6:47477243~47477572:-
SARC	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	4.26	3e-05	0.0118	0.39	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	4.26	3e-05	0.0118	0.39	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	4.26	3e-05	0.0118	0.39	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
SARC	cis	rs10946940	0.965	rs9393830	ENSG00000219392.1	RP1-265C24.5	-4.26	3.01e-05	0.0118	-0.33	-0.27	Systemic lupus erythematosus;	chr6:27619248	chr6:28115628~28116551:+
SARC	cis	rs9473147	0.543	rs9349417	ENSG00000270761.1	RP11-385F7.1	-4.26	3.01e-05	0.0118	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47612921	chr6:47477243~47477572:-
SARC	cis	rs9369695	0.883	rs9381581	ENSG00000270761.1	RP11-385F7.1	-4.26	3.01e-05	0.0118	-0.33	-0.27	Reticulocyte count;	chr6:47612959	chr6:47477243~47477572:-
SARC	cis	rs7772486	0.651	rs1292338	ENSG00000235652.6	RP11-545I5.3	-4.26	3.01e-05	0.0118	-0.24	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145799409~145886585:+
SARC	cis	rs72945132	0.882	rs3133179	ENSG00000254604.1	AP000487.6	-4.26	3.01e-05	0.0118	-0.38	-0.27	Coronary artery disease;	chr11:70341468	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.769	rs3781645	ENSG00000254604.1	AP000487.6	-4.26	3.01e-05	0.0118	-0.38	-0.27	Coronary artery disease;	chr11:70344268	chr11:70282367~70363368:-
SARC	cis	rs3823536	0.583	rs6973975	ENSG00000275106.1	RP11-309L24.10	-4.26	3.01e-05	0.0118	-0.35	-0.27	Sjögren's syndrome;	chr7:129035495	chr7:128952527~128953316:-
SARC	cis	rs7429990	0.965	rs11709289	ENSG00000229759.1	MRPS18AP1	4.26	3.01e-05	0.0118	0.38	0.27	Educational attainment (years of education);	chr3:47765159	chr3:48256350~48256938:-
SARC	cis	rs6570726	0.791	rs11155426	ENSG00000270638.1	RP3-466P17.1	4.26	3.01e-05	0.0118	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145735570~145737218:+
SARC	cis	rs2235544	0.565	rs928444	ENSG00000225183.1	RP4-758J24.4	4.26	3.02e-05	0.0118	0.3	0.27	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54007875	chr1:54089856~54090093:+
SARC	cis	rs7772486	0.79	rs2254257	ENSG00000270638.1	RP3-466P17.1	4.26	3.02e-05	0.0118	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145735570~145737218:+
SARC	cis	rs2439831	1	rs2584726	ENSG00000275601.1	AC011330.13	-4.26	3.02e-05	0.0118	-0.42	-0.27	Lung cancer in ever smokers;	chr15:43423184	chr15:43642389~43643023:-
SARC	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	4.26	3.02e-05	0.0118	0.27	0.27	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
SARC	cis	rs2439831	0.717	rs28495368	ENSG00000275601.1	AC011330.13	-4.26	3.03e-05	0.0118	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43603444	chr15:43642389~43643023:-
SARC	cis	rs459482	0.508	rs467558	ENSG00000228318.3	AP001610.5	4.26	3.03e-05	0.0118	0.3	0.27	IgG glycosylation;	chr21:41439468	chr21:41441056~41445708:-
SARC	cis	rs1001021	0.678	rs16986621	ENSG00000230637.2	CTA-246H3.8	4.26	3.03e-05	0.0118	0.59	0.27	Schizophrenia, bipolar disorder and depression (combined);	chr22:25999336	chr22:25327252~25339975:+
SARC	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	4.26	3.03e-05	0.0118	0.29	0.27	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
SARC	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-4.26	3.03e-05	0.0118	-0.51	-0.27	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-4.26	3.03e-05	0.0118	-0.51	-0.27	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-4.26	3.03e-05	0.0118	-0.51	-0.27	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
SARC	cis	rs910316	1	rs11159117	ENSG00000279594.1	RP11-950C14.10	4.26	3.03e-05	0.0118	0.29	0.27	Height;	chr14:75118164	chr14:75011269~75012851:-
SARC	cis	rs394563	0.591	rs237016	ENSG00000231760.4	RP11-350J20.5	4.25	3.04e-05	0.0119	0.34	0.27	Dupuytren's disease;	chr6:149423723	chr6:149796151~149826294:-
SARC	cis	rs367615	0.704	rs17161885	ENSG00000249476.1	CTD-2587M2.1	4.25	3.04e-05	0.0119	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109516941	chr5:109237120~109326369:-
SARC	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-4.25	3.04e-05	0.0119	-0.44	-0.27	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
SARC	cis	rs11264213	0.792	rs709309	ENSG00000271554.1	RP4-665N4.8	-4.25	3.04e-05	0.0119	-0.38	-0.27	Schizophrenia;	chr1:35975547	chr1:35992109~36013630:-
SARC	cis	rs9326248	1	rs7107152	ENSG00000280143.1	AP000892.6	-4.25	3.04e-05	0.0119	-0.26	-0.27	Blood protein levels;	chr11:117185364	chr11:117204967~117210292:+
SARC	cis	rs860818	1	rs78100089	ENSG00000226816.2	AC005082.12	4.25	3.04e-05	0.0119	0.77	0.27	Initial pursuit acceleration;	chr7:23184220	chr7:23206013~23208045:+
SARC	cis	rs1799810	0.523	rs11683986	ENSG00000236682.1	AC068282.3	4.25	3.05e-05	0.0119	0.3	0.27	Self-rated health;	chr2:127438822	chr2:127389130~127400580:+
SARC	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-4.25	3.05e-05	0.0119	-0.25	-0.27	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
SARC	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-4.25	3.05e-05	0.0119	-0.31	-0.27	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
SARC	cis	rs2439831	0.85	rs8032649	ENSG00000275601.1	AC011330.13	4.25	3.05e-05	0.0119	0.46	0.27	Lung cancer in ever smokers;	chr15:43842724	chr15:43642389~43643023:-
SARC	cis	rs394563	0.591	rs237012	ENSG00000231760.4	RP11-350J20.5	4.25	3.05e-05	0.0119	0.34	0.27	Dupuytren's disease;	chr6:149408062	chr6:149796151~149826294:-
SARC	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	4.25	3.05e-05	0.0119	0.36	0.27	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
SARC	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	4.25	3.05e-05	0.0119	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
SARC	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-4.25	3.05e-05	0.0119	-0.25	-0.27	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
SARC	cis	rs1062177	1	rs62394155	ENSG00000254226.4	CTB-12O2.1	4.25	3.05e-05	0.0119	0.37	0.27	Preschool internalizing problems;	chr5:151868508	chr5:151949571~152270448:+
SARC	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-4.25	3.05e-05	0.0119	-0.33	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
SARC	cis	rs17270561	0.636	rs9393671	ENSG00000272462.2	U91328.19	4.25	3.05e-05	0.0119	0.25	0.27	Iron status biomarkers;	chr6:25788961	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs1179086	ENSG00000272462.2	U91328.19	-4.25	3.05e-05	0.0119	-0.25	-0.27	Iron status biomarkers;	chr6:25791517	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs1165157	ENSG00000272462.2	U91328.19	-4.25	3.05e-05	0.0119	-0.25	-0.27	Iron status biomarkers;	chr6:25792022	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs1165156	ENSG00000272462.2	U91328.19	-4.25	3.05e-05	0.0119	-0.25	-0.27	Iron status biomarkers;	chr6:25792750	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs1165155	ENSG00000272462.2	U91328.19	-4.25	3.05e-05	0.0119	-0.25	-0.27	Iron status biomarkers;	chr6:25795349	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs1165216	ENSG00000272462.2	U91328.19	-4.25	3.05e-05	0.0119	-0.25	-0.27	Iron status biomarkers;	chr6:25797743	chr6:25992662~26001775:+
SARC	cis	rs11654699	0.84	rs8067122	ENSG00000266718.1	RP11-466A19.1	-4.25	3.06e-05	0.0119	-0.24	-0.27	Neurofibrillary tangles;	chr17:32592530	chr17:32495536~32499333:+
SARC	cis	rs526231	0.764	rs599447	ENSG00000175749.11	EIF3KP1	4.25	3.06e-05	0.0119	0.32	0.27	Primary biliary cholangitis;	chr5:103302154	chr5:103032376~103033031:+
SARC	cis	rs6433895	1	rs59395276	ENSG00000236153.1	AC104076.3	-4.25	3.06e-05	0.012	-0.26	-0.27	Lymphocyte counts;	chr2:181155969	chr2:180979427~180980090:-
SARC	cis	rs9473147	0.543	rs4711878	ENSG00000270761.1	RP11-385F7.1	-4.25	3.07e-05	0.012	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47488382	chr6:47477243~47477572:-
SARC	cis	rs9369695	0.881	rs9349409	ENSG00000270761.1	RP11-385F7.1	-4.25	3.07e-05	0.012	-0.32	-0.27	Reticulocyte count;	chr6:47495390	chr6:47477243~47477572:-
SARC	cis	rs9369695	0.842	rs9395262	ENSG00000270761.1	RP11-385F7.1	-4.25	3.07e-05	0.012	-0.32	-0.27	Reticulocyte count;	chr6:47497531	chr6:47477243~47477572:-
SARC	cis	rs9376098	0.79	rs6903653	ENSG00000232876.1	CTA-212D2.2	-4.25	3.07e-05	0.012	-0.31	-0.27	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135171396	chr6:135055033~135060550:+
SARC	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-4.25	3.07e-05	0.012	-0.31	-0.27	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-4.25	3.07e-05	0.012	-0.31	-0.27	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
SARC	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	4.25	3.07e-05	0.012	0.25	0.27	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	4.25	3.07e-05	0.012	0.25	0.27	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	4.25	3.07e-05	0.012	0.25	0.27	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
SARC	cis	rs319598	0.933	rs2546712	ENSG00000224186.7	C5orf66	4.25	3.07e-05	0.012	0.24	0.27	Type 2 diabetes;	chr5:134880578	chr5:135033280~135358219:+
SARC	cis	rs889122	0.765	rs16996255	ENSG00000267289.1	CTD-2623N2.11	4.25	3.07e-05	0.012	0.31	0.27	Menarche (age at onset);	chr19:9872134	chr19:9834079~9835013:-
SARC	cis	rs11018904	0.575	rs12797899	ENSG00000280385.1	AP000648.5	-4.25	3.07e-05	0.012	-0.28	-0.27	Intelligence (multi-trait analysis);	chr11:90242309	chr11:90193614~90198120:+
SARC	cis	rs324126	0.78	rs10445586	ENSG00000269834.4	ZNF528-AS1	4.25	3.07e-05	0.012	0.28	0.27	Colonoscopy-negative controls vs population controls;	chr19:52379870	chr19:52388842~52397766:-
SARC	cis	rs324126	0.78	rs62108317	ENSG00000269834.4	ZNF528-AS1	4.25	3.07e-05	0.012	0.28	0.27	Colonoscopy-negative controls vs population controls;	chr19:52380230	chr19:52388842~52397766:-
SARC	cis	rs7267979	1	rs2258201	ENSG00000276952.1	RP5-965G21.6	4.25	3.08e-05	0.012	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.844	rs35735333	ENSG00000276952.1	RP5-965G21.6	-4.25	3.08e-05	0.012	-0.26	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:25284915~25285588:-
SARC	cis	rs4950322	0.57	rs79810882	ENSG00000278811.3	LINC00624	4.25	3.08e-05	0.012	0.29	0.27	Protein quantitative trait loci;	chr1:147235575	chr1:147258885~147517875:-
SARC	cis	rs4907240	0.658	rs4907319	ENSG00000237510.6	AC008268.2	-4.25	3.08e-05	0.012	-0.35	-0.27	Event-related brain oscillations;	chr2:96472788	chr2:95789654~95800166:+
SARC	cis	rs9473147	0.516	rs9395279	ENSG00000270761.1	RP11-385F7.1	-4.25	3.08e-05	0.012	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47575128	chr6:47477243~47477572:-
SARC	cis	rs7772486	0.686	rs9485019	ENSG00000235652.6	RP11-545I5.3	-4.25	3.08e-05	0.012	-0.24	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145799409~145886585:+
SARC	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	4.25	3.08e-05	0.012	0.26	0.27	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
SARC	cis	rs4835473	0.9	rs10032963	ENSG00000251600.4	RP11-673E1.1	4.25	3.08e-05	0.012	0.26	0.27	Immature fraction of reticulocytes;	chr4:143733068	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs28796049	ENSG00000251600.4	RP11-673E1.1	4.25	3.08e-05	0.012	0.26	0.27	Immature fraction of reticulocytes;	chr4:143733990	chr4:143912331~143982454:+
SARC	cis	rs7216064	0.734	rs12942774	ENSG00000237854.3	LINC00674	-4.25	3.09e-05	0.012	-0.3	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67971446	chr17:68101908~68115518:+
SARC	cis	rs9473147	0.516	rs2151974	ENSG00000270761.1	RP11-385F7.1	-4.25	3.09e-05	0.012	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47547894	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs2151975	ENSG00000270761.1	RP11-385F7.1	-4.25	3.09e-05	0.012	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47547927	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs9367284	ENSG00000270761.1	RP11-385F7.1	-4.25	3.09e-05	0.012	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47548633	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs9381575	ENSG00000270761.1	RP11-385F7.1	-4.25	3.09e-05	0.012	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47561028	chr6:47477243~47477572:-
SARC	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	4.25	3.09e-05	0.012	0.32	0.27	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
SARC	cis	rs7520050	0.807	rs72688483	ENSG00000280836.1	AL355480.1	-4.25	3.09e-05	0.012	-0.25	-0.27	Reticulocyte count;Red blood cell count;	chr1:45683537	chr1:45581219~45581321:-
SARC	cis	rs6570726	0.764	rs366673	ENSG00000270638.1	RP3-466P17.1	4.25	3.09e-05	0.012	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs447992	ENSG00000270638.1	RP3-466P17.1	4.25	3.09e-05	0.012	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs425999	ENSG00000270638.1	RP3-466P17.1	4.25	3.09e-05	0.012	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs387376	ENSG00000270638.1	RP3-466P17.1	4.25	3.09e-05	0.012	0.22	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145735570~145737218:+
SARC	cis	rs2803122	0.967	rs10964066	ENSG00000273226.1	RP11-513M16.8	-4.25	3.09e-05	0.012	-0.25	-0.27	Pulse pressure;	chr9:19250780	chr9:19375451~19375996:+
SARC	cis	rs2179367	0.959	rs9285519	ENSG00000216906.2	RP11-350J20.9	4.25	3.09e-05	0.0121	0.24	0.27	Dupuytren's disease;	chr6:149371799	chr6:149904243~149906418:+
SARC	cis	rs453301	0.686	rs7814328	ENSG00000253893.2	FAM85B	4.25	3.1e-05	0.0121	0.24	0.27	Joint mobility (Beighton score);	chr8:9018719	chr8:8167819~8226614:-
SARC	cis	rs4862750	0.872	rs7679956	ENSG00000250971.1	RP11-696F12.1	4.25	3.1e-05	0.0121	0.31	0.27	Lobe attachment (rater-scored or self-reported);	chr4:186979075	chr4:187060099~187060930:+
SARC	cis	rs4664293	0.867	rs6432553	ENSG00000226266.5	AC009961.3	-4.25	3.1e-05	0.0121	-0.32	-0.27	Monocyte percentage of white cells;	chr2:159720499	chr2:159670708~159712435:-
SARC	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	4.25	3.1e-05	0.0121	0.29	0.27	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
SARC	cis	rs7772486	0.686	rs9403741	ENSG00000235652.6	RP11-545I5.3	-4.25	3.1e-05	0.0121	-0.24	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145799409~145886585:+
SARC	cis	rs7267979	0.78	rs6050679	ENSG00000125804.12	FAM182A	-4.25	3.1e-05	0.0121	-0.3	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:26054655~26086917:+
SARC	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-4.25	3.1e-05	0.0121	-0.31	-0.27	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
SARC	cis	rs9902453	0.689	rs7216948	ENSG00000264538.5	SUZ12P1	4.25	3.1e-05	0.0121	0.19	0.27	Coffee consumption (cups per day);	chr17:29876155	chr17:30709299~30790908:+
SARC	cis	rs17826219	0.568	rs11658027	ENSG00000263603.1	CTD-2349P21.5	4.25	3.11e-05	0.0121	0.36	0.27	Body mass index;	chr17:30767864	chr17:30729469~30731202:+
SARC	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-4.25	3.11e-05	0.0121	-0.5	-0.27	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
SARC	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-4.25	3.11e-05	0.0121	-0.27	-0.27	Height;	chr3:52992698	chr3:53064283~53065091:-
SARC	cis	rs948562	0.569	rs74810062	ENSG00000280010.1	AP001350.4	4.25	3.11e-05	0.0121	0.41	0.27	Lymphoma;	chr11:58446218	chr11:58627435~58628528:+
SARC	cis	rs7216064	0.532	rs8065296	ENSG00000237854.3	LINC00674	-4.25	3.12e-05	0.0121	-0.31	-0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68022446	chr17:68101908~68115518:+
SARC	cis	rs4372836	0.58	rs6718662	ENSG00000226833.4	AC097724.3	4.25	3.12e-05	0.0121	0.23	0.27	Body mass index;	chr2:28825892	chr2:28708953~28736205:-
SARC	cis	rs412050	0.502	rs75034650	ENSG00000224086.5	LL22NC03-86G7.1	-4.25	3.12e-05	0.0121	-0.4	-0.27	Attention deficit hyperactivity disorder;	chr22:21823660	chr22:21938293~21977632:+
SARC	cis	rs7598759	0.527	rs7571691	ENSG00000223198.1	RNU2-22P	-4.25	3.12e-05	0.0121	-0.27	-0.27	Noise-induced hearing loss;	chr2:231504690	chr2:231501990~231502201:-
SARC	cis	rs4713118	0.629	rs149899	ENSG00000216901.1	AL022393.7	4.25	3.12e-05	0.0121	0.39	0.27	Parkinson's disease;	chr6:28052201	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.629	rs172165	ENSG00000216901.1	AL022393.7	4.25	3.12e-05	0.0121	0.39	0.27	Parkinson's disease;	chr6:28053036	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.597	rs172166	ENSG00000216901.1	AL022393.7	4.25	3.12e-05	0.0121	0.39	0.27	Parkinson's disease;	chr6:28053042	chr6:28176188~28176674:+
SARC	cis	rs526231	0.853	rs2288786	ENSG00000175749.11	EIF3KP1	4.25	3.12e-05	0.0121	0.35	0.27	Primary biliary cholangitis;	chr5:103265053	chr5:103032376~103033031:+
SARC	cis	rs17508449	0.909	rs7514649	ENSG00000232450.1	RP4-730K3.3	-4.25	3.12e-05	0.0122	-0.34	-0.27	Leprosy;	chr1:113537200	chr1:113698884~113699631:-
SARC	cis	rs4713118	0.662	rs149948	ENSG00000216901.1	AL022393.7	4.25	3.13e-05	0.0122	0.39	0.27	Parkinson's disease;	chr6:28007039	chr6:28176188~28176674:+
SARC	cis	rs61160187	0.582	rs55814394	ENSG00000215032.2	GNL3LP1	4.25	3.13e-05	0.0122	0.26	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.582	rs10939879	ENSG00000215032.2	GNL3LP1	4.25	3.13e-05	0.0122	0.26	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60891935~60893577:-
SARC	cis	rs7772486	0.686	rs9386131	ENSG00000235652.6	RP11-545I5.3	4.25	3.13e-05	0.0122	0.24	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs7739735	ENSG00000235652.6	RP11-545I5.3	4.25	3.13e-05	0.0122	0.24	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs7744014	ENSG00000235652.6	RP11-545I5.3	4.25	3.13e-05	0.0122	0.24	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs4895684	ENSG00000235652.6	RP11-545I5.3	-4.25	3.13e-05	0.0122	-0.24	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145799409~145886585:+
SARC	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-4.25	3.13e-05	0.0122	-0.24	-0.27	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-4.25	3.13e-05	0.0122	-0.24	-0.27	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-4.25	3.13e-05	0.0122	-0.24	-0.27	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-4.25	3.13e-05	0.0122	-0.24	-0.27	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
SARC	cis	rs910316	1	rs4899546	ENSG00000279594.1	RP11-950C14.10	4.25	3.13e-05	0.0122	0.29	0.27	Height;	chr14:75128243	chr14:75011269~75012851:-
SARC	cis	rs1707322	1	rs4660332	ENSG00000281133.1	AL355480.3	-4.25	3.14e-05	0.0122	-0.3	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45580892~45580996:-
SARC	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	4.25	3.14e-05	0.0122	0.4	0.27	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	4.25	3.14e-05	0.0122	0.4	0.27	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	4.25	3.14e-05	0.0122	0.4	0.27	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
SARC	cis	rs10986311	0.775	rs13300918	ENSG00000235204.1	RP11-121A14.2	-4.25	3.14e-05	0.0122	-0.31	-0.27	Vitiligo;	chr9:124383011	chr9:124259250~124261156:-
SARC	cis	rs9473147	0.516	rs6904764	ENSG00000270761.1	RP11-385F7.1	-4.25	3.14e-05	0.0122	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47535761	chr6:47477243~47477572:-
SARC	cis	rs9369695	0.883	rs9473128	ENSG00000270761.1	RP11-385F7.1	-4.25	3.14e-05	0.0122	-0.32	-0.27	Reticulocyte count;	chr6:47537274	chr6:47477243~47477572:-
SARC	cis	rs4835473	0.932	rs7356305	ENSG00000251600.4	RP11-673E1.1	4.25	3.15e-05	0.0122	0.26	0.27	Immature fraction of reticulocytes;	chr4:143737850	chr4:143912331~143982454:+
SARC	cis	rs9364687	0.664	rs724826	ENSG00000228692.2	RP5-826L7.1	-4.25	3.15e-05	0.0122	-0.31	-0.27	Body mass index;	chr6:163517562	chr6:163586583~163588165:-
SARC	cis	rs34375054	0.526	rs34764657	ENSG00000279233.1	RP11-158L12.4	4.25	3.15e-05	0.0122	0.3	0.27	Post bronchodilator FEV1/FVC ratio;	chr12:125195093	chr12:125138245~125141711:+
SARC	cis	rs7809950	0.678	rs2395868	ENSG00000238832.1	snoU109	4.25	3.15e-05	0.0123	0.31	0.27	Coronary artery disease;	chr7:107257055	chr7:107603363~107603507:+
SARC	cis	rs4664293	0.528	rs12466650	ENSG00000226266.5	AC009961.3	4.25	3.16e-05	0.0123	0.34	0.27	Monocyte percentage of white cells;	chr2:159552252	chr2:159670708~159712435:-
SARC	cis	rs638893	0.588	rs2156755	ENSG00000278376.1	RP11-158I9.8	-4.25	3.16e-05	0.0123	-0.24	-0.27	Vitiligo;	chr11:118855521	chr11:118791254~118793137:+
SARC	cis	rs75920871	0.528	rs7935913	ENSG00000254851.1	RP11-109L13.1	-4.25	3.16e-05	0.0123	-0.35	-0.27	Subjective well-being;	chr11:117073632	chr11:117135528~117138582:+
SARC	cis	rs2179367	0.632	rs9485384	ENSG00000231760.4	RP11-350J20.5	4.25	3.16e-05	0.0123	0.36	0.27	Dupuytren's disease;	chr6:149328808	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs12211357	ENSG00000231760.4	RP11-350J20.5	4.25	3.16e-05	0.0123	0.36	0.27	Dupuytren's disease;	chr6:149331148	chr6:149796151~149826294:-
SARC	cis	rs853679	0.882	rs9461432	ENSG00000272009.1	RP1-313I6.12	-4.24	3.16e-05	0.0123	-0.41	-0.27	Depression;	chr6:28119105	chr6:28078792~28081130:-
SARC	cis	rs2018683	0.621	rs10261556	ENSG00000228421.2	AC005013.5	4.24	3.16e-05	0.0123	0.27	0.27	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28937019	chr7:28957667~28959345:+
SARC	cis	rs783540	0.681	rs1259178	ENSG00000275695.1	UBE2Q2P6	-4.24	3.16e-05	0.0123	-0.28	-0.27	Schizophrenia;	chr15:82603127	chr15:82445719~82454837:+
SARC	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-4.24	3.16e-05	0.0123	-0.5	-0.27	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
SARC	cis	rs7772486	0.686	rs4896833	ENSG00000235652.6	RP11-545I5.3	4.24	3.16e-05	0.0123	0.24	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145799409~145886585:+
SARC	cis	rs853679	0.55	rs1233699	ENSG00000272009.1	RP1-313I6.12	-4.24	3.17e-05	0.0123	-0.29	-0.27	Depression;	chr6:28201380	chr6:28078792~28081130:-
SARC	cis	rs853679	0.55	rs1233704	ENSG00000272009.1	RP1-313I6.12	4.24	3.17e-05	0.0123	0.29	0.27	Depression;	chr6:28199145	chr6:28078792~28081130:-
SARC	cis	rs910316	0.934	rs8016330	ENSG00000279594.1	RP11-950C14.10	-4.24	3.17e-05	0.0123	-0.3	-0.27	Height;	chr14:75190804	chr14:75011269~75012851:-
SARC	cis	rs4938303	0.633	rs35681250	ENSG00000254851.1	RP11-109L13.1	4.24	3.17e-05	0.0123	0.37	0.27	Triglycerides;	chr11:116684670	chr11:117135528~117138582:+
SARC	cis	rs6750795	0.569	rs1667313	ENSG00000223198.1	RNU2-22P	-4.24	3.18e-05	0.0123	-0.27	-0.27	Height;	chr2:231543307	chr2:231501990~231502201:-
SARC	cis	rs7809950	0.678	rs3801966	ENSG00000238832.1	snoU109	-4.24	3.18e-05	0.0123	-0.36	-0.27	Coronary artery disease;	chr7:107184135	chr7:107603363~107603507:+
SARC	cis	rs72627509	0.904	rs17081933	ENSG00000269949.1	RP11-738E22.3	4.24	3.18e-05	0.0123	0.4	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56956703	chr4:56960927~56961373:-
SARC	cis	rs910316	0.789	rs175444	ENSG00000279594.1	RP11-950C14.10	-4.24	3.18e-05	0.0123	-0.3	-0.27	Height;	chr14:75135079	chr14:75011269~75012851:-
SARC	cis	rs61160187	0.576	rs10805374	ENSG00000215032.2	GNL3LP1	4.24	3.18e-05	0.0124	0.26	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:61004078	chr5:60891935~60893577:-
SARC	cis	rs860818	1	rs858255	ENSG00000226816.2	AC005082.12	4.24	3.19e-05	0.0124	0.77	0.27	Initial pursuit acceleration;	chr7:23177086	chr7:23206013~23208045:+
SARC	cis	rs3823536	0.583	rs1072767	ENSG00000275106.1	RP11-309L24.10	-4.24	3.2e-05	0.0124	-0.35	-0.27	Sjögren's syndrome;	chr7:129033151	chr7:128952527~128953316:-
SARC	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-4.24	3.2e-05	0.0124	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
SARC	cis	rs6969780	1	rs929249	ENSG00000233429.8	HOTAIRM1	4.24	3.21e-05	0.0124	0.42	0.27	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127918	chr7:27095647~27100265:+
SARC	cis	rs2898681	0.519	rs3811781	ENSG00000248375.1	RP11-177B4.1	-4.24	3.21e-05	0.0124	-0.42	-0.27	Optic nerve measurement (cup area);	chr4:52862999	chr4:52720081~52720831:-
SARC	cis	rs9473147	0.571	rs9395285	ENSG00000270761.1	RP11-385F7.1	-4.24	3.21e-05	0.0124	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47586441	chr6:47477243~47477572:-
SARC	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	4.24	3.21e-05	0.0124	0.25	0.27	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
SARC	cis	rs4713118	0.629	rs203890	ENSG00000216901.1	AL022393.7	4.24	3.21e-05	0.0124	0.39	0.27	Parkinson's disease;	chr6:28054470	chr6:28176188~28176674:+
SARC	cis	rs7772486	0.686	rs1292337	ENSG00000235652.6	RP11-545I5.3	-4.24	3.21e-05	0.0125	-0.24	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs857879	ENSG00000235652.6	RP11-545I5.3	-4.24	3.21e-05	0.0125	-0.24	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145799409~145886585:+
SARC	cis	rs577676	0.586	rs2022373	ENSG00000271811.1	RP1-79C4.4	4.24	3.21e-05	0.0125	0.38	0.27	Prevalent atrial fibrillation;	chr1:170619453	chr1:170667381~170669425:+
SARC	cis	rs890448	0.76	rs1476159	ENSG00000254531.1	FLJ20021	4.24	3.21e-05	0.0125	0.29	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101359938	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs2850334	ENSG00000254531.1	FLJ20021	4.24	3.21e-05	0.0125	0.29	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101360231	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs2583386	ENSG00000254531.1	FLJ20021	4.24	3.21e-05	0.0125	0.29	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101360294	chr4:101347780~101348883:+
SARC	cis	rs890448	0.76	rs2583385	ENSG00000254531.1	FLJ20021	4.24	3.21e-05	0.0125	0.29	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101360655	chr4:101347780~101348883:+
SARC	cis	rs890448	0.764	rs2850333	ENSG00000254531.1	FLJ20021	-4.24	3.21e-05	0.0125	-0.29	-0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101358736	chr4:101347780~101348883:+
SARC	cis	rs10911902	0.643	rs16825150	ENSG00000229739.2	RP11-295K2.3	-4.24	3.22e-05	0.0125	-0.38	-0.27	Schizophrenia;	chr1:186306628	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs76559138	ENSG00000229739.2	RP11-295K2.3	-4.24	3.22e-05	0.0125	-0.38	-0.27	Schizophrenia;	chr1:186314891	chr1:186435161~186470291:+
SARC	cis	rs30380	0.632	rs26498	ENSG00000272109.1	CTD-2260A17.3	4.24	3.22e-05	0.0125	0.34	0.27	Cerebrospinal fluid biomarker levels;	chr5:96803109	chr5:96804353~96806105:+
SARC	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	4.24	3.22e-05	0.0125	0.32	0.27	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
SARC	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	4.24	3.22e-05	0.0125	0.32	0.27	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
SARC	cis	rs7772486	0.79	rs9399571	ENSG00000270638.1	RP3-466P17.1	-4.24	3.22e-05	0.0125	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145735570~145737218:+
SARC	cis	rs7811142	1	rs28490152	ENSG00000078319.8	PMS2P1	-4.24	3.22e-05	0.0125	-0.37	-0.27	Platelet count;	chr7:100423359	chr7:100320992~100341908:-
SARC	cis	rs7772486	0.686	rs9390357	ENSG00000235652.6	RP11-545I5.3	4.24	3.22e-05	0.0125	0.24	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145799409~145886585:+
SARC	cis	rs42490	1	rs1003843	ENSG00000251136.7	RP11-37B2.1	-4.24	3.22e-05	0.0125	-0.3	-0.27	Leprosy;	chr8:89727252	chr8:89609409~89757727:-
SARC	cis	rs9309473	0.615	rs62149774	ENSG00000163016.8	ALMS1P	4.24	3.22e-05	0.0125	0.39	0.27	Metabolite levels;	chr2:73560525	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.606	rs62149777	ENSG00000163016.8	ALMS1P	4.24	3.22e-05	0.0125	0.39	0.27	Metabolite levels;	chr2:73568237	chr2:73644919~73685576:+
SARC	cis	rs4934494	0.768	rs17125834	ENSG00000240996.1	RP11-80H5.7	-4.24	3.22e-05	0.0125	-0.3	-0.27	Red blood cell count;	chr10:89673405	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.768	rs12571918	ENSG00000240996.1	RP11-80H5.7	-4.24	3.22e-05	0.0125	-0.3	-0.27	Red blood cell count;	chr10:89674920	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.768	rs12776306	ENSG00000240996.1	RP11-80H5.7	-4.24	3.22e-05	0.0125	-0.3	-0.27	Red blood cell count;	chr10:89676300	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.768	rs7078321	ENSG00000240996.1	RP11-80H5.7	-4.24	3.22e-05	0.0125	-0.3	-0.27	Red blood cell count;	chr10:89678341	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.768	rs34379399	ENSG00000240996.1	RP11-80H5.7	-4.24	3.22e-05	0.0125	-0.3	-0.27	Red blood cell count;	chr10:89683526	chr10:89694295~89697928:-
SARC	cis	rs2708377	0.929	rs73053785	ENSG00000247157.5	LINC01252	4.24	3.22e-05	0.0125	0.47	0.27	Bitter taste perception;	chr12:11009812	chr12:11548030~11590369:+
SARC	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-4.24	3.23e-05	0.0125	-0.25	-0.27	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-4.24	3.23e-05	0.0125	-0.25	-0.27	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
SARC	cis	rs12950390	0.853	rs11079791	ENSG00000239291.1	RP5-867C24.1	4.24	3.23e-05	0.0125	0.32	0.27	IgG glycosylation;	chr17:47781733	chr17:47159191~47159993:-
SARC	cis	rs9473147	0.543	rs1004173	ENSG00000270761.1	RP11-385F7.1	-4.24	3.23e-05	0.0125	-0.33	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47477281	chr6:47477243~47477572:-
SARC	cis	rs7688540	0.771	rs2353605	ENSG00000275426.1	CH17-262A2.1	4.24	3.23e-05	0.0125	0.39	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:225749	chr4:149738~150317:+
SARC	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-4.24	3.23e-05	0.0125	-0.31	-0.27	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-4.24	3.23e-05	0.0125	-0.31	-0.27	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-4.24	3.23e-05	0.0125	-0.31	-0.27	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
SARC	cis	rs12073837	0.5	rs11118610	ENSG00000238078.1	LINC01352	-4.24	3.23e-05	0.0125	-0.28	-0.27	F-cell distribution;	chr1:220816744	chr1:220829255~220832429:+
SARC	cis	rs2439831	0.867	rs4583210	ENSG00000275601.1	AC011330.13	-4.24	3.23e-05	0.0125	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43368727	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs28461955	ENSG00000275601.1	AC011330.13	-4.24	3.23e-05	0.0125	-0.41	-0.27	Lung cancer in ever smokers;	chr15:43369261	chr15:43642389~43643023:-
SARC	cis	rs897984	0.645	rs58726213	ENSG00000260911.2	RP11-196G11.2	4.24	3.23e-05	0.0125	0.26	0.27	Dementia with Lewy bodies;	chr16:31033362	chr16:31043150~31049868:+
SARC	cis	rs9473147	0.543	rs9296558	ENSG00000270761.1	RP11-385F7.1	-4.24	3.24e-05	0.0125	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47484147	chr6:47477243~47477572:-
SARC	cis	rs7726354	1	rs59536253	ENSG00000271828.1	CTD-2310F14.1	4.24	3.24e-05	0.0125	0.53	0.27	Breast cancer (early onset);	chr5:56973685	chr5:56927874~56929573:+
SARC	cis	rs72945132	0.882	rs11235967	ENSG00000254604.1	AP000487.6	-4.24	3.24e-05	0.0125	-0.37	-0.27	Coronary artery disease;	chr11:70345585	chr11:70282367~70363368:-
SARC	cis	rs3823536	0.583	rs921403	ENSG00000275106.1	RP11-309L24.10	-4.24	3.24e-05	0.0125	-0.34	-0.27	Sjögren's syndrome;	chr7:129036670	chr7:128952527~128953316:-
SARC	cis	rs10144321	0.644	rs11160580	ENSG00000271417.2	SNHG24	-4.24	3.24e-05	0.0125	-0.24	-0.27	Menarche (age at onset);	chr14:100327977	chr14:100967652~100987280:+
SARC	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-4.24	3.24e-05	0.0125	-0.44	-0.27	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
SARC	cis	rs9828933	0.577	rs832193	ENSG00000280620.1	SCAANT1	-4.24	3.24e-05	0.0125	-0.42	-0.27	Type 2 diabetes;	chr3:63868769	chr3:63911518~63911772:-
SARC	cis	rs890448	0.796	rs2119591	ENSG00000254531.1	FLJ20021	4.24	3.24e-05	0.0126	0.29	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101398487	chr4:101347780~101348883:+
SARC	cis	rs7809950	0.817	rs11535285	ENSG00000238832.1	snoU109	-4.24	3.24e-05	0.0126	-0.32	-0.27	Coronary artery disease;	chr7:107503421	chr7:107603363~107603507:+
SARC	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-4.24	3.25e-05	0.0126	-0.25	-0.27	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-4.24	3.25e-05	0.0126	-0.25	-0.27	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
SARC	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	4.24	3.25e-05	0.0126	0.25	0.27	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
SARC	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	4.24	3.26e-05	0.0126	0.39	0.27	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
SARC	cis	rs1823913	0.927	rs34765012	ENSG00000280083.1	RP11-317J9.1	-4.24	3.26e-05	0.0126	-0.3	-0.27	Obesity-related traits;	chr2:191247926	chr2:191154118~191156070:-
SARC	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	4.24	3.26e-05	0.0126	0.39	0.27	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
SARC	cis	rs7829975	0.511	rs2921028	ENSG00000253981.4	ALG1L13P	4.24	3.27e-05	0.0126	0.25	0.27	Mood instability;	chr8:8482967	chr8:8236003~8244667:-
SARC	cis	rs4835473	0.932	rs6853460	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143750392	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs6853676	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143750495	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs6848393	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143750537	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.868	rs971391	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143751324	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs971392	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143751384	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.838	rs35978782	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143751713	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs34060266	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143751766	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs35300159	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143751768	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs13139419	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143751862	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.868	rs13106052	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143751995	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs13134401	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143752008	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs13106287	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143752091	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs13134679	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143752187	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs13108134	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143752213	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs34406317	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143752237	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs35863996	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143752260	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs6836896	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143752404	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs2874983	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143752589	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs2874984	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143752622	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs2323192	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143752646	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs2323193	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143752812	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs34152627	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143753205	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs35670108	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143753280	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs6832005	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143754284	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.838	rs55963933	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143755048	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.868	rs35243309	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143755116	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs34790336	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143755284	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs35740243	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143755395	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4395452	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143755678	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.741	rs6537180	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143755984	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.741	rs6537181	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143755995	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs6814065	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143756233	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs6816347	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143756674	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.808	rs6847256	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143757032	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.868	rs57413073	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143757852	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs34732468	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143758009	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs12510395	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143758107	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs12513130	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143758666	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.868	rs7681891	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143759289	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.771	rs34069296	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143759656	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs7687915	ENSG00000251600.4	RP11-673E1.1	-4.24	3.27e-05	0.0126	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143759801	chr4:143912331~143982454:+
SARC	cis	rs4664293	0.609	rs10167143	ENSG00000226266.5	AC009961.3	-4.24	3.27e-05	0.0126	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159606885	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.669	rs13389096	ENSG00000226266.5	AC009961.3	-4.24	3.27e-05	0.0126	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159611246	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.609	rs12470879	ENSG00000226266.5	AC009961.3	-4.24	3.27e-05	0.0126	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159612116	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.55	rs13388082	ENSG00000226266.5	AC009961.3	-4.24	3.27e-05	0.0126	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159616439	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.582	rs1046496	ENSG00000226266.5	AC009961.3	-4.24	3.27e-05	0.0126	-0.31	-0.27	Monocyte percentage of white cells;	chr2:159616888	chr2:159670708~159712435:-
SARC	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-4.24	3.28e-05	0.0127	-0.31	-0.27	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
SARC	cis	rs13217239	0.646	rs11756275	ENSG00000241549.7	GUSBP2	-4.24	3.29e-05	0.0127	-0.26	-0.27	Schizophrenia;	chr6:27039334	chr6:26871484~26956554:-
SARC	cis	rs7267979	1	rs2257432	ENSG00000276952.1	RP5-965G21.6	4.24	3.29e-05	0.0127	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2258066	ENSG00000276952.1	RP5-965G21.6	4.24	3.29e-05	0.0127	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2258135	ENSG00000276952.1	RP5-965G21.6	4.24	3.29e-05	0.0127	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25284915~25285588:-
SARC	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-4.23	3.29e-05	0.0127	-0.24	-0.27	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
SARC	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	4.23	3.3e-05	0.0127	0.29	0.27	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
SARC	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	4.23	3.3e-05	0.0127	0.29	0.27	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
SARC	cis	rs9902453	0.904	rs8078638	ENSG00000264538.5	SUZ12P1	4.23	3.3e-05	0.0127	0.19	0.27	Coffee consumption (cups per day);	chr17:29963340	chr17:30709299~30790908:+
SARC	cis	rs755249	0.833	rs61779313	ENSG00000182109.6	RP11-69E11.4	4.23	3.3e-05	0.0127	0.29	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39522280~39546187:-
SARC	cis	rs6452524	0.711	rs1478486	ENSG00000248112.1	RP11-78C3.1	4.23	3.31e-05	0.0127	0.29	0.27	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:82919376~82921119:-
SARC	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	4.23	3.31e-05	0.0128	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
SARC	cis	rs763121	0.925	rs4821815	ENSG00000273076.1	RP3-508I15.22	4.23	3.31e-05	0.0128	0.28	0.27	Menopause (age at onset);	chr22:38709702	chr22:38743495~38743910:+
SARC	cis	rs4664293	0.51	rs72961735	ENSG00000226266.5	AC009961.3	4.23	3.31e-05	0.0128	0.33	0.27	Monocyte percentage of white cells;	chr2:159708009	chr2:159670708~159712435:-
SARC	cis	rs42490	0.528	rs10956209	ENSG00000251136.7	RP11-37B2.1	4.23	3.32e-05	0.0128	0.29	0.27	Leprosy;	chr8:89670923	chr8:89609409~89757727:-
SARC	cis	rs41271951	0.512	rs77306500	ENSG00000237781.3	RP11-54A4.2	4.23	3.32e-05	0.0128	0.47	0.27	Blood protein levels;	chr1:151107620	chr1:150548562~150557724:-
SARC	cis	rs41271951	0.512	rs114222784	ENSG00000237781.3	RP11-54A4.2	4.23	3.32e-05	0.0128	0.47	0.27	Blood protein levels;	chr1:151112305	chr1:150548562~150557724:-
SARC	cis	rs41271951	0.512	rs12074309	ENSG00000237781.3	RP11-54A4.2	4.23	3.32e-05	0.0128	0.47	0.27	Blood protein levels;	chr1:151115351	chr1:150548562~150557724:-
SARC	cis	rs7430456	0.674	rs13079337	ENSG00000225790.1	RP11-2L8.1	-4.23	3.32e-05	0.0128	-0.3	-0.27	Breast cancer;	chr3:177776996	chr3:177934823~177937662:+
SARC	cis	rs875971	0.706	rs1643374	ENSG00000236529.1	RP13-254B10.1	4.23	3.32e-05	0.0128	0.28	0.27	Aortic root size;	chr7:66407695	chr7:65840212~65840596:+
SARC	cis	rs12554020	0.579	rs79056932	ENSG00000227603.1	RP11-165J3.6	4.23	3.32e-05	0.0128	0.47	0.27	Schizophrenia;	chr9:93585431	chr9:93435332~93437121:-
SARC	cis	rs783540	0.746	rs7165125	ENSG00000275695.1	UBE2Q2P6	-4.23	3.32e-05	0.0128	-0.27	-0.27	Schizophrenia;	chr15:82629185	chr15:82445719~82454837:+
SARC	cis	rs59104589	0.617	rs59487360	ENSG00000266621.1	AC104841.1	4.23	3.33e-05	0.0128	0.37	0.27	Fibrinogen levels;	chr2:241331018	chr2:241245202~241245299:-
SARC	cis	rs59104589	0.617	rs60614486	ENSG00000266621.1	AC104841.1	4.23	3.33e-05	0.0128	0.37	0.27	Fibrinogen levels;	chr2:241335583	chr2:241245202~241245299:-
SARC	cis	rs113835537	0.866	rs59320108	ENSG00000255517.5	CTD-3074O7.5	-4.23	3.33e-05	0.0128	-0.36	-0.27	Airway imaging phenotypes;	chr11:66598525	chr11:66473490~66480233:-
SARC	cis	rs6570726	0.818	rs412350	ENSG00000270638.1	RP3-466P17.1	4.23	3.33e-05	0.0128	0.21	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145735570~145737218:+
SARC	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-4.23	3.33e-05	0.0128	-0.24	-0.27	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
SARC	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	4.23	3.33e-05	0.0128	0.25	0.27	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
SARC	cis	rs12049351	0.719	rs2145394	ENSG00000229367.1	HMGN2P19	4.23	3.34e-05	0.0129	0.23	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229535217	chr1:229570532~229570796:+
SARC	cis	rs950776	0.593	rs588765	ENSG00000261762.1	RP11-650L12.2	-4.23	3.34e-05	0.0129	-0.28	-0.27	Sudden cardiac arrest;	chr15:78573083	chr15:78589123~78591276:-
SARC	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	4.23	3.35e-05	0.0129	0.25	0.27	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
SARC	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-4.23	3.35e-05	0.0129	-0.25	-0.27	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
SARC	cis	rs72615157	0.613	rs56089143	ENSG00000242294.5	STAG3L5P	4.23	3.35e-05	0.0129	0.22	0.27	Lung function (FEV1/FVC);	chr7:100222221	chr7:100336079~100351900:+
SARC	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	4.23	3.35e-05	0.0129	0.39	0.27	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
SARC	cis	rs394563	0.591	rs237019	ENSG00000231760.4	RP11-350J20.5	4.23	3.35e-05	0.0129	0.34	0.27	Dupuytren's disease;	chr6:149405928	chr6:149796151~149826294:-
SARC	cis	rs659580	1	rs659580	ENSG00000271811.1	RP1-79C4.4	-4.23	3.36e-05	0.0129	-0.36	-0.27	Response to angiotensin II receptor blocker therapy;Lobe attachment (rater-scored or self-reported);	chr1:170664755	chr1:170667381~170669425:+
SARC	cis	rs12554020	0.786	rs75395683	ENSG00000227603.1	RP11-165J3.6	4.23	3.36e-05	0.0129	0.45	0.27	Schizophrenia;	chr9:93415128	chr9:93435332~93437121:-
SARC	cis	rs12554020	1	rs55846141	ENSG00000227603.1	RP11-165J3.6	4.23	3.36e-05	0.0129	0.45	0.27	Schizophrenia;	chr9:93427679	chr9:93435332~93437121:-
SARC	cis	rs7772486	0.79	rs9376970	ENSG00000270638.1	RP3-466P17.1	-4.23	3.36e-05	0.0129	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145735570~145737218:+
SARC	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-4.23	3.36e-05	0.0129	-0.28	-0.27	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
SARC	cis	rs783540	1	rs783531	ENSG00000275695.1	UBE2Q2P6	-4.23	3.37e-05	0.013	-0.27	-0.27	Schizophrenia;	chr15:82580370	chr15:82445719~82454837:+
SARC	cis	rs783540	0.934	rs783532	ENSG00000275695.1	UBE2Q2P6	-4.23	3.37e-05	0.013	-0.27	-0.27	Schizophrenia;	chr15:82580618	chr15:82445719~82454837:+
SARC	cis	rs7811142	1	rs2406253	ENSG00000078319.8	PMS2P1	-4.23	3.37e-05	0.013	-0.38	-0.27	Platelet count;	chr7:100479650	chr7:100320992~100341908:-
SARC	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	4.23	3.37e-05	0.013	0.39	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	4.23	3.37e-05	0.013	0.39	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
SARC	cis	rs1880529	0.797	rs13129686	ENSG00000206820.1	RNU1-138P	4.23	3.37e-05	0.013	0.26	0.27	White matter integrity (bipolar disorder risk interaction);	chr4:113431993	chr4:113420323~113420486:+
SARC	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	4.23	3.37e-05	0.013	0.36	0.27	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
SARC	cis	rs6964833	0.554	rs2527380	ENSG00000184616.8	AC004166.6	-4.23	3.38e-05	0.013	-0.36	-0.27	Menarche (age at onset);	chr7:74690372	chr7:74906673~74913256:-
SARC	cis	rs4713118	0.662	rs149947	ENSG00000216901.1	AL022393.7	4.23	3.38e-05	0.013	0.39	0.27	Parkinson's disease;	chr6:28004655	chr6:28176188~28176674:+
SARC	cis	rs1707322	1	rs12124847	ENSG00000281133.1	AL355480.3	-4.23	3.39e-05	0.013	-0.3	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45580892~45580996:-
SARC	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	4.23	3.39e-05	0.013	0.2	0.27	Height;	chr11:118758322	chr11:118791254~118793137:+
SARC	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-4.23	3.39e-05	0.013	-0.25	-0.27	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
SARC	cis	rs4372836	0.741	rs4563180	ENSG00000226833.4	AC097724.3	-4.23	3.39e-05	0.013	-0.23	-0.27	Body mass index;	chr2:28870829	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.729	rs4638745	ENSG00000226833.4	AC097724.3	-4.23	3.39e-05	0.013	-0.23	-0.27	Body mass index;	chr2:28870937	chr2:28708953~28736205:-
SARC	cis	rs4950322	0.57	rs4950400	ENSG00000278811.3	LINC00624	-4.23	3.39e-05	0.013	-0.28	-0.27	Protein quantitative trait loci;	chr1:147319383	chr1:147258885~147517875:-
SARC	cis	rs2179367	0.959	rs9377212	ENSG00000216906.2	RP11-350J20.9	4.23	3.4e-05	0.013	0.24	0.27	Dupuytren's disease;	chr6:149383765	chr6:149904243~149906418:+
SARC	cis	rs4835473	0.932	rs5015760	ENSG00000251600.4	RP11-673E1.1	-4.23	3.4e-05	0.0131	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143737955	chr4:143912331~143982454:+
SARC	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-4.23	3.4e-05	0.0131	-0.5	-0.27	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
SARC	cis	rs11264213	0.901	rs2765013	ENSG00000271554.1	RP4-665N4.8	-4.23	3.4e-05	0.0131	-0.36	-0.27	Schizophrenia;	chr1:35908500	chr1:35992109~36013630:-
SARC	cis	rs7811142	0.943	rs28660238	ENSG00000078319.8	PMS2P1	-4.23	3.4e-05	0.0131	-0.37	-0.27	Platelet count;	chr7:100425685	chr7:100320992~100341908:-
SARC	cis	rs8059260	0.604	rs8052325	ENSG00000274038.1	RP11-66H6.4	-4.23	3.4e-05	0.0131	-0.37	-0.27	Alcohol consumption over the past year;	chr16:11044121	chr16:11056556~11057034:+
SARC	cis	rs62432291	0.614	rs370434	ENSG00000235086.1	FNDC1-IT1	-4.23	3.41e-05	0.0131	-0.45	-0.27	Joint mobility (Beighton score);	chr6:159233519	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs402388	ENSG00000235086.1	FNDC1-IT1	-4.23	3.41e-05	0.0131	-0.45	-0.27	Joint mobility (Beighton score);	chr6:159233962	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.764	rs436743	ENSG00000235086.1	FNDC1-IT1	-4.23	3.41e-05	0.0131	-0.45	-0.27	Joint mobility (Beighton score);	chr6:159234070	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs3003174	ENSG00000235086.1	FNDC1-IT1	-4.23	3.41e-05	0.0131	-0.45	-0.27	Joint mobility (Beighton score);	chr6:159234294	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs2501176	ENSG00000235086.1	FNDC1-IT1	-4.23	3.41e-05	0.0131	-0.45	-0.27	Joint mobility (Beighton score);	chr6:159234351	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs2932988	ENSG00000235086.1	FNDC1-IT1	-4.23	3.41e-05	0.0131	-0.45	-0.27	Joint mobility (Beighton score);	chr6:159234370	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs2501177	ENSG00000235086.1	FNDC1-IT1	-4.23	3.41e-05	0.0131	-0.45	-0.27	Joint mobility (Beighton score);	chr6:159234561	chr6:159240786~159243329:+
SARC	cis	rs7512898	0.5	rs7519783	ENSG00000260088.1	RP11-92G12.3	-4.23	3.41e-05	0.0131	-0.29	-0.27	Electrocardiographic conduction measures;	chr1:200715929	chr1:200669507~200694250:+
SARC	cis	rs17270561	0.609	rs9358878	ENSG00000272462.2	U91328.19	-4.23	3.41e-05	0.0131	-0.26	-0.27	Iron status biomarkers;	chr6:25740045	chr6:25992662~26001775:+
SARC	cis	rs6669008	1	rs55912359	ENSG00000232450.1	RP4-730K3.3	-4.23	3.41e-05	0.0131	-0.24	-0.27	Bacteremia;	chr1:113624477	chr1:113698884~113699631:-
SARC	cis	rs17508449	1	rs79381435	ENSG00000232450.1	RP4-730K3.3	-4.23	3.41e-05	0.0131	-0.34	-0.27	Leprosy;	chr1:113543054	chr1:113698884~113699631:-
SARC	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	4.23	3.41e-05	0.0131	0.26	0.27	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
SARC	cis	rs2235544	0.579	rs1537321	ENSG00000225183.1	RP4-758J24.4	-4.23	3.41e-05	0.0131	-0.3	-0.27	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54016563	chr1:54089856~54090093:+
SARC	cis	rs2898681	0.58	rs41279517	ENSG00000248375.1	RP11-177B4.1	-4.23	3.41e-05	0.0131	-0.45	-0.27	Optic nerve measurement (cup area);	chr4:52863604	chr4:52720081~52720831:-
SARC	cis	rs2898681	0.567	rs77657787	ENSG00000248375.1	RP11-177B4.1	-4.23	3.41e-05	0.0131	-0.45	-0.27	Optic nerve measurement (cup area);	chr4:52863814	chr4:52720081~52720831:-
SARC	cis	rs7985	1	rs5761672	ENSG00000206028.1	CTA-373H7.7	4.23	3.41e-05	0.0131	0.3	0.27	Electroencephalogram traits;	chr22:26673476	chr22:26667693~26672654:-
SARC	cis	rs2404602	0.716	rs3866543	ENSG00000259422.1	RP11-593F23.1	4.23	3.42e-05	0.0131	0.3	0.27	Blood metabolite levels;	chr15:76337268	chr15:76174891~76181486:-
SARC	cis	rs12893668	0.703	rs2274267	ENSG00000269940.1	RP11-73M18.7	4.23	3.42e-05	0.0131	0.27	0.27	Reticulocyte count;	chr14:103563112	chr14:103694560~103695170:+
SARC	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-4.23	3.42e-05	0.0131	-0.25	-0.27	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
SARC	cis	rs9309473	0.607	rs6720094	ENSG00000163016.8	ALMS1P	4.23	3.42e-05	0.0131	0.31	0.27	Metabolite levels;	chr2:73360948	chr2:73644919~73685576:+
SARC	cis	rs7772486	0.806	rs4243478	ENSG00000270638.1	RP3-466P17.1	-4.23	3.42e-05	0.0131	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145963424	chr6:145735570~145737218:+
SARC	cis	rs4934494	0.768	rs58163515	ENSG00000240996.1	RP11-80H5.7	-4.23	3.42e-05	0.0131	-0.29	-0.27	Red blood cell count;	chr10:89637807	chr10:89694295~89697928:-
SARC	cis	rs75920871	0.528	rs1531707	ENSG00000254851.1	RP11-109L13.1	4.23	3.42e-05	0.0131	0.36	0.27	Subjective well-being;	chr11:117073996	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.528	rs7484045	ENSG00000254851.1	RP11-109L13.1	4.23	3.42e-05	0.0131	0.36	0.27	Subjective well-being;	chr11:117076174	chr11:117135528~117138582:+
SARC	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-4.23	3.42e-05	0.0131	-0.3	-0.27	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
SARC	cis	rs2179367	0.959	rs9322178	ENSG00000216906.2	RP11-350J20.9	4.23	3.42e-05	0.0131	0.24	0.27	Dupuytren's disease;	chr6:149372131	chr6:149904243~149906418:+
SARC	cis	rs42490	0.903	rs7824932	ENSG00000251136.7	RP11-37B2.1	4.23	3.43e-05	0.0131	0.3	0.27	Leprosy;	chr8:89703848	chr8:89609409~89757727:-
SARC	cis	rs2179367	0.632	rs66672129	ENSG00000231760.4	RP11-350J20.5	4.23	3.43e-05	0.0131	0.36	0.27	Dupuytren's disease;	chr6:149334387	chr6:149796151~149826294:-
SARC	cis	rs916888	0.531	rs183211	ENSG00000261575.2	RP11-259G18.1	4.23	3.43e-05	0.0131	0.34	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46267037~46268694:+
SARC	cis	rs7726354	0.793	rs76482628	ENSG00000271828.1	CTD-2310F14.1	4.23	3.43e-05	0.0131	0.57	0.27	Breast cancer (early onset);	chr5:56729855	chr5:56927874~56929573:+
SARC	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	4.23	3.43e-05	0.0131	0.35	0.27	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
SARC	cis	rs4835473	0.932	rs971390	ENSG00000251600.4	RP11-673E1.1	-4.23	3.43e-05	0.0131	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143751264	chr4:143912331~143982454:+
SARC	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	4.22	3.43e-05	0.0131	0.39	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
SARC	cis	rs9902453	0.765	rs2729440	ENSG00000264538.5	SUZ12P1	-4.22	3.43e-05	0.0132	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29779856	chr17:30709299~30790908:+
SARC	cis	rs890448	0.796	rs2044044	ENSG00000254531.1	FLJ20021	4.22	3.44e-05	0.0132	0.28	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101412708	chr4:101347780~101348883:+
SARC	cis	rs8028182	0.636	rs11636199	ENSG00000260206.1	CTD-2026K11.2	-4.22	3.44e-05	0.0132	-0.32	-0.27	Sudden cardiac arrest;	chr15:75532996	chr15:75636139~75639239:+
SARC	cis	rs12893668	0.572	rs11846404	ENSG00000269958.1	RP11-73M18.8	4.22	3.44e-05	0.0132	0.29	0.27	Reticulocyte count;	chr14:103689771	chr14:103696353~103697163:+
SARC	cis	rs4664293	0.867	rs3764968	ENSG00000226266.5	AC009961.3	-4.22	3.44e-05	0.0132	-0.33	-0.27	Monocyte percentage of white cells;	chr2:159790579	chr2:159670708~159712435:-
SARC	cis	rs9868809	0.881	rs7631574	ENSG00000225399.4	RP11-3B7.1	4.22	3.44e-05	0.0132	0.44	0.27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48625613	chr3:49260085~49261316:+
SARC	cis	rs11719291	0.667	rs9877542	ENSG00000225399.4	RP11-3B7.1	-4.22	3.45e-05	0.0132	-0.45	-0.27	Cognitive function;	chr3:48711112	chr3:49260085~49261316:+
SARC	cis	rs1823913	0.637	rs11688994	ENSG00000227542.1	AC092614.2	4.22	3.45e-05	0.0132	0.31	0.27	Obesity-related traits;	chr2:191266242	chr2:191229165~191246172:-
SARC	cis	rs4835473	0.9	rs1375983	ENSG00000251600.4	RP11-673E1.1	-4.22	3.45e-05	0.0132	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143760423	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1375984	ENSG00000251600.4	RP11-673E1.1	-4.22	3.45e-05	0.0132	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143760510	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1375985	ENSG00000251600.4	RP11-673E1.1	-4.22	3.45e-05	0.0132	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143760556	chr4:143912331~143982454:+
SARC	cis	rs4938303	0.549	rs12291024	ENSG00000254851.1	RP11-109L13.1	4.22	3.45e-05	0.0132	0.33	0.27	Triglycerides;	chr11:116689951	chr11:117135528~117138582:+
SARC	cis	rs17695224	0.545	rs10853846	ENSG00000275055.1	CTC-471J1.11	-4.22	3.45e-05	0.0132	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51826595	chr19:52049007~52049754:+
SARC	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	4.22	3.46e-05	0.0132	0.28	0.27	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
SARC	cis	rs9309473	0.519	rs13017182	ENSG00000163016.8	ALMS1P	-4.22	3.46e-05	0.0132	-0.3	-0.27	Metabolite levels;	chr2:73663877	chr2:73644919~73685576:+
SARC	cis	rs2404602	0.583	rs12908334	ENSG00000259422.1	RP11-593F23.1	4.22	3.46e-05	0.0132	0.29	0.27	Blood metabolite levels;	chr15:76289251	chr15:76174891~76181486:-
SARC	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	4.22	3.46e-05	0.0133	0.26	0.27	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
SARC	cis	rs7246657	0.941	rs10418729	ENSG00000226686.6	LINC01535	-4.22	3.46e-05	0.0133	-0.39	-0.27	Coronary artery calcification;	chr19:37246163	chr19:37251912~37265535:+
SARC	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-4.22	3.46e-05	0.0133	-0.3	-0.27	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
SARC	cis	rs7628338	0.62	rs11128270	ENSG00000243083.4	LINC00870	4.22	3.47e-05	0.0133	0.28	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr3:72459745	chr3:72151257~72174332:+
SARC	cis	rs9894429	0.624	rs9910935	ENSG00000229848.1	RP13-766D20.2	4.22	3.47e-05	0.0133	0.27	0.27	Eye color traits;	chr17:81646923	chr17:81514047~81527776:+
SARC	cis	rs72627509	0.857	rs2227901	ENSG00000269949.1	RP11-738E22.3	-4.22	3.47e-05	0.0133	-0.39	-0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56932023	chr4:56960927~56961373:-
SARC	cis	rs113835537	0.877	rs77239910	ENSG00000255517.5	CTD-3074O7.5	-4.22	3.47e-05	0.0133	-0.35	-0.27	Airway imaging phenotypes;	chr11:66562168	chr11:66473490~66480233:-
SARC	cis	rs2803122	0.967	rs4977297	ENSG00000273226.1	RP11-513M16.8	-4.22	3.47e-05	0.0133	-0.26	-0.27	Pulse pressure;	chr9:19312326	chr9:19375451~19375996:+
SARC	cis	rs1823913	1	rs4853561	ENSG00000280083.1	RP11-317J9.1	4.22	3.47e-05	0.0133	0.29	0.27	Obesity-related traits;	chr2:191242980	chr2:191154118~191156070:-
SARC	cis	rs1823913	1	rs6704784	ENSG00000280083.1	RP11-317J9.1	4.22	3.47e-05	0.0133	0.29	0.27	Obesity-related traits;	chr2:191244832	chr2:191154118~191156070:-
SARC	cis	rs17695224	0.5	rs4802877	ENSG00000275055.1	CTC-471J1.11	-4.22	3.48e-05	0.0133	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51831991	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.52	rs4801898	ENSG00000275055.1	CTC-471J1.11	-4.22	3.48e-05	0.0133	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51832064	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.545	rs17761960	ENSG00000275055.1	CTC-471J1.11	-4.22	3.48e-05	0.0133	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51832275	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.565	rs7248523	ENSG00000275055.1	CTC-471J1.11	-4.22	3.48e-05	0.0133	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51833888	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.585	rs10406893	ENSG00000275055.1	CTC-471J1.11	-4.22	3.48e-05	0.0133	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51833901	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.545	rs10406732	ENSG00000275055.1	CTC-471J1.11	-4.22	3.48e-05	0.0133	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51833974	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.527	rs2903546	ENSG00000275055.1	CTC-471J1.11	-4.22	3.48e-05	0.0133	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51834082	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.527	rs7250063	ENSG00000275055.1	CTC-471J1.11	-4.22	3.48e-05	0.0133	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51834447	chr19:52049007~52049754:+
SARC	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-4.22	3.48e-05	0.0133	-0.39	-0.27	Gout;	chr7:66671562	chr7:66902857~66906297:+
SARC	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-4.22	3.48e-05	0.0133	-0.28	-0.27	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
SARC	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-4.22	3.48e-05	0.0133	-0.28	-0.27	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
SARC	cis	rs1865760	0.613	rs9379801	ENSG00000272462.2	U91328.19	-4.22	3.48e-05	0.0133	-0.25	-0.27	Height;	chr6:25901483	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.613	rs9295674	ENSG00000272462.2	U91328.19	-4.22	3.48e-05	0.0133	-0.25	-0.27	Height;	chr6:25912114	chr6:25992662~26001775:+
SARC	cis	rs1707322	1	rs10789479	ENSG00000281133.1	AL355480.3	-4.22	3.48e-05	0.0133	-0.3	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45580892~45580996:-
SARC	cis	rs2898681	0.618	rs116241740	ENSG00000248375.1	RP11-177B4.1	-4.22	3.48e-05	0.0133	-0.45	-0.27	Optic nerve measurement (cup area);	chr4:52867356	chr4:52720081~52720831:-
SARC	cis	rs597539	0.652	rs646586	ENSG00000250508.1	RP11-757G1.6	4.22	3.48e-05	0.0133	0.31	0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68870664~68874542:+
SARC	cis	rs16949788	1	rs11071894	ENSG00000261351.2	CTD-3185P2.1	4.22	3.49e-05	0.0133	0.5	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66481395	chr15:66488658~66492109:-
SARC	cis	rs2933343	0.7	rs1683779	ENSG00000231305.3	RP11-723O4.2	4.22	3.49e-05	0.0133	0.27	0.27	IgG glycosylation;	chr3:128923205	chr3:128861313~128871540:-
SARC	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-4.22	3.49e-05	0.0133	-0.31	-0.27	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
SARC	cis	rs11264213	0.901	rs2791962	ENSG00000271554.1	RP4-665N4.8	-4.22	3.49e-05	0.0133	-0.37	-0.27	Schizophrenia;	chr1:35905567	chr1:35992109~36013630:-
SARC	cis	rs7951911	1	rs7952511	ENSG00000254427.1	RP11-430H10.1	-4.22	3.49e-05	0.0133	-0.4	-0.27	IgG glycosylation;	chr11:45063430	chr11:45355371~45366121:+
SARC	cis	rs3934047	0.904	rs4448893	ENSG00000274376.3	ADAMTS7P1	-4.22	3.5e-05	0.0134	-0.3	-0.27	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81719014	chr15:82298553~82334609:+
SARC	cis	rs17695224	0.606	rs10411054	ENSG00000275055.1	CTC-471J1.11	-4.22	3.5e-05	0.0134	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51831208	chr19:52049007~52049754:+
SARC	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	4.22	3.51e-05	0.0134	0.39	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
SARC	cis	rs7267979	1	rs4815417	ENSG00000276952.1	RP5-965G21.6	-4.22	3.51e-05	0.0134	-0.26	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:25284915~25285588:-
SARC	cis	rs26949	0.935	rs26950	ENSG00000215032.2	GNL3LP1	4.22	3.51e-05	0.0134	0.29	0.27	Intelligence (multi-trait analysis);	chr5:60527291	chr5:60891935~60893577:-
SARC	cis	rs1546924	0.692	rs197379	ENSG00000260948.1	RP11-552M11.8	4.22	3.51e-05	0.0134	0.29	0.27	Body mass index;	chr1:111749681	chr1:111431046~111433068:-
SARC	cis	rs2933343	0.951	rs7648327	ENSG00000261159.1	RP11-723O4.9	4.22	3.52e-05	0.0134	0.31	0.27	IgG glycosylation;	chr3:128851865	chr3:128859716~128860526:-
SARC	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	4.22	3.52e-05	0.0134	0.25	0.27	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
SARC	cis	rs6964833	0.554	rs112506907	ENSG00000184616.8	AC004166.6	4.22	3.52e-05	0.0134	0.36	0.27	Menarche (age at onset);	chr7:74654407	chr7:74906673~74913256:-
SARC	cis	rs12049351	0.774	rs1053513	ENSG00000229367.1	HMGN2P19	4.22	3.53e-05	0.0135	0.22	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229516840	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.722	rs4148763	ENSG00000229367.1	HMGN2P19	4.22	3.53e-05	0.0135	0.22	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229519213	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.665	rs10799534	ENSG00000229367.1	HMGN2P19	4.22	3.53e-05	0.0135	0.22	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229521466	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.665	rs3738186	ENSG00000229367.1	HMGN2P19	4.22	3.53e-05	0.0135	0.22	0.27	Circulating myeloperoxidase levels (plasma);	chr1:229521483	chr1:229570532~229570796:+
SARC	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-4.22	3.53e-05	0.0135	-0.32	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
SARC	cis	rs155076	0.711	rs4770131	ENSG00000233325.3	MIPEPP3	-4.22	3.53e-05	0.0135	-0.34	-0.27	White matter hyperintensity burden;	chr13:21323329	chr13:21298139~21306373:+
SARC	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	4.22	3.54e-05	0.0135	0.32	0.27	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
SARC	cis	rs7829975	0.502	rs7820738	ENSG00000254340.1	RP11-10A14.3	-4.22	3.54e-05	0.0135	-0.29	-0.27	Mood instability;	chr8:8845097	chr8:9141424~9145435:+
SARC	cis	rs7267979	0.844	rs6083845	ENSG00000276952.1	RP5-965G21.6	-4.22	3.54e-05	0.0135	-0.26	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.844	rs6083851	ENSG00000276952.1	RP5-965G21.6	-4.22	3.54e-05	0.0135	-0.26	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.844	rs4423675	ENSG00000276952.1	RP5-965G21.6	-4.22	3.54e-05	0.0135	-0.26	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:25284915~25285588:-
SARC	cis	rs948562	0.585	rs11229477	ENSG00000280010.1	AP001350.4	4.22	3.54e-05	0.0135	0.41	0.27	Lymphoma;	chr11:58461125	chr11:58627435~58628528:+
SARC	cis	rs4664293	0.867	rs13022404	ENSG00000226266.5	AC009961.3	-4.22	3.54e-05	0.0135	-0.32	-0.27	Monocyte percentage of white cells;	chr2:159732981	chr2:159670708~159712435:-
SARC	cis	rs62229266	1	rs62229266	ENSG00000231106.2	LINC01436	4.22	3.54e-05	0.0135	0.35	0.27	Mitral valve prolapse;	chr21:36087973	chr21:36005338~36007838:+
SARC	cis	rs3761847	0.622	rs10435888	ENSG00000226752.6	PSMD5-AS1	-4.22	3.54e-05	0.0135	-0.31	-0.27	Rheumatoid arthritis;	chr9:121057325	chr9:120824828~120854385:+
SARC	cis	rs3761847	0.593	rs10985140	ENSG00000226752.6	PSMD5-AS1	-4.22	3.54e-05	0.0135	-0.31	-0.27	Rheumatoid arthritis;	chr9:121060559	chr9:120824828~120854385:+
SARC	cis	rs3761847	0.622	rs1323471	ENSG00000226752.6	PSMD5-AS1	-4.22	3.54e-05	0.0135	-0.31	-0.27	Rheumatoid arthritis;	chr9:121064037	chr9:120824828~120854385:+
SARC	cis	rs17695224	0.519	rs2159654	ENSG00000275055.1	CTC-471J1.11	-4.22	3.55e-05	0.0135	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51834004	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.5	rs2159655	ENSG00000275055.1	CTC-471J1.11	-4.22	3.55e-05	0.0135	-0.27	-0.27	HDL cholesterol;HDL cholesterol levels;	chr19:51834006	chr19:52049007~52049754:+
SARC	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	4.22	3.55e-05	0.0135	0.24	0.27	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
SARC	cis	rs890448	0.796	rs6816400	ENSG00000254531.1	FLJ20021	4.22	3.55e-05	0.0135	0.29	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101367295	chr4:101347780~101348883:+
SARC	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-4.22	3.55e-05	0.0135	-0.36	-0.27	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
SARC	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	4.22	3.56e-05	0.0135	0.24	0.27	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
SARC	cis	rs4664293	0.903	rs10185155	ENSG00000226266.5	AC009961.3	-4.22	3.56e-05	0.0135	-0.33	-0.27	Monocyte percentage of white cells;	chr2:159696717	chr2:159670708~159712435:-
SARC	cis	rs755249	0.917	rs61779330	ENSG00000182109.6	RP11-69E11.4	4.22	3.56e-05	0.0135	0.29	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501551	chr1:39522280~39546187:-
SARC	cis	rs755249	0.876	rs72662001	ENSG00000182109.6	RP11-69E11.4	4.22	3.56e-05	0.0135	0.29	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501608	chr1:39522280~39546187:-
SARC	cis	rs755249	0.917	rs72663503	ENSG00000182109.6	RP11-69E11.4	4.22	3.56e-05	0.0135	0.29	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39503387	chr1:39522280~39546187:-
SARC	cis	rs755249	0.917	rs61779331	ENSG00000182109.6	RP11-69E11.4	4.22	3.56e-05	0.0135	0.29	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39505256	chr1:39522280~39546187:-
SARC	cis	rs964184	0.63	rs7930786	ENSG00000254851.1	RP11-109L13.1	-4.22	3.56e-05	0.0135	-0.51	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116754011	chr11:117135528~117138582:+
SARC	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-4.22	3.56e-05	0.0135	-0.32	-0.27	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
SARC	cis	rs17508449	0.732	rs74610368	ENSG00000232450.1	RP4-730K3.3	-4.22	3.56e-05	0.0135	-0.34	-0.27	Leprosy;	chr1:113742681	chr1:113698884~113699631:-
SARC	cis	rs2029362	0.611	rs10835215	ENSG00000245573.6	BDNF-AS	4.22	3.56e-05	0.0136	0.23	0.27	Total body bone mineral density;	chr11:27718402	chr11:27506838~27698174:+
SARC	cis	rs846178	1	rs846178	ENSG00000251229.1	RP11-503N18.5	4.22	3.57e-05	0.0136	0.35	0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr4:2483888	chr4:2505081~2506279:-
SARC	cis	rs853679	1	rs1679732	ENSG00000219392.1	RP1-265C24.5	4.22	3.57e-05	0.0136	0.47	0.27	Depression;	chr6:28253486	chr6:28115628~28116551:+
SARC	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	4.22	3.57e-05	0.0136	0.25	0.27	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	4.22	3.57e-05	0.0136	0.25	0.27	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
SARC	cis	rs11634944	0.716	rs2052723	ENSG00000274307.1	RP11-345J18.2	-4.22	3.57e-05	0.0136	-0.34	-0.27	Interleukin-8 levels;	chr15:24992745	chr15:25708470~25710869:-
SARC	cis	rs4664293	0.967	rs3940435	ENSG00000226266.5	AC009961.3	-4.22	3.57e-05	0.0136	-0.33	-0.27	Monocyte percentage of white cells;	chr2:159638272	chr2:159670708~159712435:-
SARC	cis	rs7246657	0.943	rs10409204	ENSG00000226686.6	LINC01535	-4.22	3.57e-05	0.0136	-0.37	-0.27	Coronary artery calcification;	chr19:37426790	chr19:37251912~37265535:+
SARC	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	4.21	3.58e-05	0.0136	0.22	0.27	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
SARC	cis	rs526231	0.725	rs487937	ENSG00000175749.11	EIF3KP1	4.21	3.58e-05	0.0136	0.31	0.27	Primary biliary cholangitis;	chr5:103302541	chr5:103032376~103033031:+
SARC	cis	rs11723261	0.621	rs6599307	ENSG00000211553.1	AC253576.2	-4.21	3.58e-05	0.0136	-0.33	-0.27	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:136461~136568:+
SARC	cis	rs11886999	0.812	rs62153022	ENSG00000237510.6	AC008268.2	-4.21	3.58e-05	0.0136	-0.41	-0.27	Cardiac Troponin-T levels;	chr2:96222426	chr2:95789654~95800166:+
SARC	cis	rs11886999	0.762	rs72825864	ENSG00000237510.6	AC008268.2	-4.21	3.58e-05	0.0136	-0.41	-0.27	Cardiac Troponin-T levels;	chr2:96222870	chr2:95789654~95800166:+
SARC	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	4.21	3.58e-05	0.0136	0.5	0.27	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	4.21	3.58e-05	0.0136	0.5	0.27	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	4.21	3.58e-05	0.0136	0.5	0.27	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	4.21	3.58e-05	0.0136	0.5	0.27	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	4.21	3.58e-05	0.0136	0.5	0.27	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
SARC	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	4.21	3.58e-05	0.0136	0.24	0.27	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
SARC	cis	rs1538970	0.504	rs3790585	ENSG00000281133.1	AL355480.3	-4.21	3.58e-05	0.0136	-0.41	-0.27	Platelet count;	chr1:45557684	chr1:45580892~45580996:-
SARC	cis	rs2439831	0.702	rs3784275	ENSG00000275601.1	AC011330.13	-4.21	3.58e-05	0.0136	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43799188	chr15:43642389~43643023:-
SARC	cis	rs882252	0.749	rs2001552	ENSG00000232480.1	TGFB2-AS1	4.21	3.58e-05	0.0136	0.37	0.27	Post bronchodilator FEV1/FVC ratio;	chr1:218466919	chr1:218344196~218345678:-
SARC	cis	rs4664293	0.769	rs2729726	ENSG00000226266.5	AC009961.3	-4.21	3.59e-05	0.0136	-0.32	-0.27	Monocyte percentage of white cells;	chr2:159811597	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.738	rs1549580	ENSG00000226266.5	AC009961.3	-4.21	3.59e-05	0.0136	-0.32	-0.27	Monocyte percentage of white cells;	chr2:159812177	chr2:159670708~159712435:-
SARC	cis	rs11264213	0.901	rs794222	ENSG00000271554.1	RP4-665N4.8	-4.21	3.59e-05	0.0136	-0.37	-0.27	Schizophrenia;	chr1:35903423	chr1:35992109~36013630:-
SARC	cis	rs7429990	0.965	rs5016900	ENSG00000229759.1	MRPS18AP1	4.21	3.59e-05	0.0136	0.37	0.27	Educational attainment (years of education);	chr3:47781387	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.896	rs34448818	ENSG00000229759.1	MRPS18AP1	4.21	3.59e-05	0.0136	0.37	0.27	Educational attainment (years of education);	chr3:47799822	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.93	rs13072132	ENSG00000229759.1	MRPS18AP1	4.21	3.59e-05	0.0136	0.37	0.27	Educational attainment (years of education);	chr3:47824671	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.965	rs34507589	ENSG00000229759.1	MRPS18AP1	4.21	3.59e-05	0.0136	0.37	0.27	Educational attainment (years of education);	chr3:47832552	chr3:48256350~48256938:-
SARC	cis	rs7246657	0.941	rs10418729	ENSG00000276846.1	CTD-3220F14.3	4.21	3.6e-05	0.0137	0.37	0.27	Coronary artery calcification;	chr19:37246163	chr19:37314868~37315620:-
SARC	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-4.21	3.6e-05	0.0137	-0.28	-0.27	Height;	chr3:53047596	chr3:53064283~53065091:-
SARC	cis	rs4934494	0.727	rs12764076	ENSG00000240996.1	RP11-80H5.7	-4.21	3.6e-05	0.0137	-0.29	-0.27	Red blood cell count;	chr10:89630443	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.634	rs12762448	ENSG00000240996.1	RP11-80H5.7	-4.21	3.6e-05	0.0137	-0.29	-0.27	Red blood cell count;	chr10:89630483	chr10:89694295~89697928:-
SARC	cis	rs5751614	0.577	rs11090227	ENSG00000230701.2	FBXW4P1	4.21	3.6e-05	0.0137	0.33	0.27	Height;	chr22:23285436	chr22:23262767~23265005:+
SARC	cis	rs763121	1	rs1946990	ENSG00000273076.1	RP3-508I15.22	-4.21	3.6e-05	0.0137	-0.27	-0.27	Menopause (age at onset);	chr22:38516766	chr22:38743495~38743910:+
SARC	cis	rs4835473	0.932	rs1993015	ENSG00000251600.4	RP11-673E1.1	-4.21	3.6e-05	0.0137	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143760202	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs1993016	ENSG00000251600.4	RP11-673E1.1	-4.21	3.6e-05	0.0137	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143760217	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1993017	ENSG00000251600.4	RP11-673E1.1	-4.21	3.6e-05	0.0137	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143760285	chr4:143912331~143982454:+
SARC	cis	rs10540	1	rs117339389	ENSG00000277290.1	RP11-326C3.16	4.21	3.6e-05	0.0137	0.32	0.27	Body mass index;	chr11:505025	chr11:243099~243483:-
SARC	cis	rs17508449	0.732	rs74533448	ENSG00000232450.1	RP4-730K3.3	-4.21	3.61e-05	0.0137	-0.34	-0.27	Leprosy;	chr1:113750266	chr1:113698884~113699631:-
SARC	cis	rs1150668	0.796	rs2531825	ENSG00000219392.1	RP1-265C24.5	-4.21	3.61e-05	0.0137	-0.3	-0.27	Pubertal anthropometrics;	chr6:28381487	chr6:28115628~28116551:+
SARC	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-4.21	3.61e-05	0.0137	-0.25	-0.27	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
SARC	cis	rs4835473	0.838	rs6838981	ENSG00000251600.4	RP11-673E1.1	-4.21	3.61e-05	0.0137	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143826484	chr4:143912331~143982454:+
SARC	cis	rs7216064	1	rs7223813	ENSG00000237854.3	LINC00674	4.21	3.61e-05	0.0137	0.33	0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67949724	chr17:68101908~68115518:+
SARC	cis	rs7216064	0.954	rs4790973	ENSG00000237854.3	LINC00674	4.21	3.61e-05	0.0137	0.33	0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67955017	chr17:68101908~68115518:+
SARC	cis	rs7216064	0.953	rs12601759	ENSG00000237854.3	LINC00674	4.21	3.61e-05	0.0137	0.33	0.27	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67959168	chr17:68101908~68115518:+
SARC	cis	rs7829975	0.742	rs882462	ENSG00000253893.2	FAM85B	-4.21	3.61e-05	0.0137	-0.24	-0.27	Mood instability;	chr8:8821020	chr8:8167819~8226614:-
SARC	cis	rs6918586	0.616	rs198836	ENSG00000272462.2	U91328.19	-4.21	3.61e-05	0.0137	-0.24	-0.27	Schizophrenia;	chr6:26113388	chr6:25992662~26001775:+
SARC	cis	rs10911902	0.643	rs77583019	ENSG00000229739.2	RP11-295K2.3	-4.21	3.62e-05	0.0137	-0.38	-0.27	Schizophrenia;	chr1:186302136	chr1:186435161~186470291:+
SARC	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-4.21	3.62e-05	0.0137	-0.25	-0.27	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
SARC	cis	rs2307449	0.929	rs1013445	ENSG00000261441.1	RP11-217B1.2	4.21	3.62e-05	0.0137	0.34	0.27	Menopause (age at onset);	chr15:89309413	chr15:89335053~89336161:+
SARC	cis	rs7267979	0.966	rs454723	ENSG00000276952.1	RP5-965G21.6	4.21	3.62e-05	0.0137	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25284915~25285588:-
SARC	cis	rs7726354	0.793	rs6883200	ENSG00000271828.1	CTD-2310F14.1	4.21	3.62e-05	0.0137	0.57	0.27	Breast cancer (early onset);	chr5:56714198	chr5:56927874~56929573:+
SARC	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-4.21	3.62e-05	0.0137	-0.33	-0.27	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
SARC	cis	rs1707322	1	rs10890376	ENSG00000281133.1	AL355480.3	-4.21	3.62e-05	0.0137	-0.3	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs10789485	ENSG00000281133.1	AL355480.3	-4.21	3.62e-05	0.0137	-0.3	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45580892~45580996:-
SARC	cis	rs9894429	0.716	rs7405578	ENSG00000229848.1	RP13-766D20.2	4.21	3.62e-05	0.0137	0.26	0.27	Eye color traits;	chr17:81621280	chr17:81514047~81527776:+
SARC	cis	rs11264213	0.901	rs716926	ENSG00000271554.1	RP4-665N4.8	-4.21	3.63e-05	0.0137	-0.36	-0.27	Schizophrenia;	chr1:35958875	chr1:35992109~36013630:-
SARC	cis	rs2033711	0.837	rs3764535	ENSG00000269473.1	CTD-2619J13.19	4.21	3.63e-05	0.0137	0.3	0.27	Uric acid clearance;	chr19:58417685	chr19:58440448~58445849:+
SARC	cis	rs9902453	0.765	rs2628180	ENSG00000264538.5	SUZ12P1	-4.21	3.63e-05	0.0138	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29774705	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.74	rs2729446	ENSG00000264538.5	SUZ12P1	-4.21	3.63e-05	0.0138	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29775481	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.74	rs2244247	ENSG00000264538.5	SUZ12P1	-4.21	3.63e-05	0.0138	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29783156	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.74	rs1382391	ENSG00000264538.5	SUZ12P1	-4.21	3.63e-05	0.0138	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29784968	chr17:30709299~30790908:+
SARC	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	4.21	3.63e-05	0.0138	0.36	0.27	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
SARC	cis	rs6570726	0.764	rs1912023	ENSG00000270638.1	RP3-466P17.1	4.21	3.64e-05	0.0138	0.21	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs9376945	ENSG00000270638.1	RP3-466P17.1	4.21	3.64e-05	0.0138	0.21	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.755	rs451699	ENSG00000270638.1	RP3-466P17.1	4.21	3.64e-05	0.0138	0.21	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs401561	ENSG00000270638.1	RP3-466P17.1	4.21	3.64e-05	0.0138	0.21	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs405206	ENSG00000270638.1	RP3-466P17.1	4.21	3.64e-05	0.0138	0.21	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.791	rs374478	ENSG00000270638.1	RP3-466P17.1	4.21	3.64e-05	0.0138	0.21	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145735570~145737218:+
SARC	cis	rs600231	0.665	rs1616810	ENSG00000245532.5	NEAT1	4.21	3.65e-05	0.0138	0.2	0.27	Bone mineral density;	chr11:65452634	chr11:65422774~65445540:+
SARC	cis	rs2274273	0.662	rs4525413	ENSG00000258413.1	RP11-665C16.6	-4.21	3.65e-05	0.0138	-0.36	-0.27	Protein biomarker;	chr14:55194420	chr14:55262767~55272075:-
SARC	cis	rs7772486	0.632	rs9386128	ENSG00000235652.6	RP11-545I5.3	-4.21	3.65e-05	0.0138	-0.24	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145799409~145886585:+
SARC	cis	rs12893668	0.703	rs55751606	ENSG00000269940.1	RP11-73M18.7	4.21	3.65e-05	0.0138	0.27	0.27	Reticulocyte count;	chr14:103562469	chr14:103694560~103695170:+
SARC	cis	rs755249	0.874	rs61779310	ENSG00000182109.6	RP11-69E11.4	4.21	3.65e-05	0.0138	0.29	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39476625	chr1:39522280~39546187:-
SARC	cis	rs4835473	0.932	rs4835279	ENSG00000251600.4	RP11-673E1.1	-4.21	3.66e-05	0.0138	-0.27	-0.27	Immature fraction of reticulocytes;	chr4:143788917	chr4:143912331~143982454:+
SARC	cis	rs2439831	0.85	rs28413881	ENSG00000275601.1	AC011330.13	-4.21	3.66e-05	0.0139	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43881901	chr15:43642389~43643023:-
SARC	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	4.21	3.66e-05	0.0139	0.37	0.27	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
SARC	cis	rs11105298	0.891	rs10858864	ENSG00000258302.2	RP11-981P6.1	4.21	3.66e-05	0.0139	0.31	0.27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs10858865	ENSG00000258302.2	RP11-981P6.1	4.21	3.66e-05	0.0139	0.31	0.27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89561129~89594878:+
SARC	cis	rs9309473	0.607	rs7604588	ENSG00000163016.8	ALMS1P	4.21	3.66e-05	0.0139	0.32	0.27	Metabolite levels;	chr2:73344289	chr2:73644919~73685576:+
SARC	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	4.21	3.66e-05	0.0139	0.25	0.27	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	4.21	3.66e-05	0.0139	0.25	0.27	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	4.21	3.66e-05	0.0139	0.25	0.27	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	4.21	3.66e-05	0.0139	0.25	0.27	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	4.21	3.66e-05	0.0139	0.25	0.27	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	4.21	3.66e-05	0.0139	0.25	0.27	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	4.21	3.66e-05	0.0139	0.25	0.27	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	4.21	3.66e-05	0.0139	0.25	0.27	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	4.21	3.66e-05	0.0139	0.25	0.27	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
SARC	cis	rs41271951	0.512	rs34761930	ENSG00000237781.3	RP11-54A4.2	4.21	3.67e-05	0.0139	0.47	0.27	Blood protein levels;	chr1:151117047	chr1:150548562~150557724:-
SARC	cis	rs9902453	0.845	rs7209622	ENSG00000264538.5	SUZ12P1	4.21	3.67e-05	0.0139	0.19	0.27	Coffee consumption (cups per day);	chr17:29929789	chr17:30709299~30790908:+
SARC	cis	rs9907295	1	rs9904675	ENSG00000270240.2	AC015849.2	4.21	3.67e-05	0.0139	0.47	0.27	Fibroblast growth factor basic levels;	chr17:35921435	chr17:35868967~35885863:+
SARC	cis	rs755249	1	rs17513135	ENSG00000182109.6	RP11-69E11.4	4.21	3.67e-05	0.0139	0.3	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570014	chr1:39522280~39546187:-
SARC	cis	rs1707322	1	rs4660331	ENSG00000281133.1	AL355480.3	-4.21	3.67e-05	0.0139	-0.3	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45580892~45580996:-
SARC	cis	rs253959	0.739	rs712573	ENSG00000272265.1	CTD-2287O16.4	-4.21	3.68e-05	0.0139	-0.31	-0.27	Bipolar disorder and schizophrenia;	chr5:116302121	chr5:116078110~116078570:-
SARC	cis	rs950776	0.684	rs692780	ENSG00000261762.1	RP11-650L12.2	-4.21	3.68e-05	0.0139	-0.3	-0.27	Sudden cardiac arrest;	chr15:78584163	chr15:78589123~78591276:-
SARC	cis	rs17507216	0.56	rs28493687	ENSG00000278603.1	RP13-608F4.5	4.21	3.68e-05	0.0139	0.31	0.27	Excessive daytime sleepiness;	chr15:82560062	chr15:82472203~82472426:+
SARC	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-4.21	3.68e-05	0.0139	-0.44	-0.27	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
SARC	cis	rs9309473	0.66	rs79370894	ENSG00000163016.8	ALMS1P	4.21	3.69e-05	0.0139	0.4	0.27	Metabolite levels;	chr2:73456388	chr2:73644919~73685576:+
SARC	cis	rs524281	1	rs565198	ENSG00000255320.1	RP11-755F10.1	-4.21	3.69e-05	0.0139	-0.35	-0.27	Electroencephalogram traits;	chr11:66146037	chr11:66244840~66246239:-
SARC	cis	rs367615	0.879	rs4351197	ENSG00000249476.1	CTD-2587M2.1	4.21	3.69e-05	0.0139	0.36	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109530966	chr5:109237120~109326369:-
SARC	cis	rs367615	0.918	rs4576198	ENSG00000249476.1	CTD-2587M2.1	4.21	3.69e-05	0.0139	0.36	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109531649	chr5:109237120~109326369:-
SARC	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-4.21	3.69e-05	0.0139	-0.35	-0.27	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
SARC	cis	rs9473147	0.543	rs1872505	ENSG00000270761.1	RP11-385F7.1	-4.21	3.69e-05	0.0139	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47513239	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs7749271	ENSG00000270761.1	RP11-385F7.1	-4.21	3.69e-05	0.0139	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47517266	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs9296561	ENSG00000270761.1	RP11-385F7.1	-4.21	3.69e-05	0.0139	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47521202	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs7749167	ENSG00000270761.1	RP11-385F7.1	-4.21	3.69e-05	0.0139	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47526204	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs9296564	ENSG00000270761.1	RP11-385F7.1	-4.21	3.69e-05	0.0139	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47527023	chr6:47477243~47477572:-
SARC	cis	rs9902453	0.765	rs2617883	ENSG00000264538.5	SUZ12P1	-4.21	3.69e-05	0.0139	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29793470	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.765	rs2729436	ENSG00000264538.5	SUZ12P1	-4.21	3.69e-05	0.0139	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29793652	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.765	rs2250320	ENSG00000264538.5	SUZ12P1	-4.21	3.69e-05	0.0139	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29801639	chr17:30709299~30790908:+
SARC	cis	rs7560272	0.723	rs7609249	ENSG00000163016.8	ALMS1P	4.21	3.69e-05	0.0139	0.3	0.27	Schizophrenia;	chr2:73586693	chr2:73644919~73685576:+
SARC	cis	rs2439831	1	rs2601014	ENSG00000205771.5	CATSPER2P1	-4.21	3.69e-05	0.014	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43463815	chr15:43726918~43747094:-
SARC	cis	rs9902453	0.765	rs2628167	ENSG00000264538.5	SUZ12P1	-4.21	3.7e-05	0.014	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29737480	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.765	rs1531553	ENSG00000264538.5	SUZ12P1	-4.21	3.7e-05	0.014	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29739734	chr17:30709299~30790908:+
SARC	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-4.21	3.7e-05	0.014	-0.24	-0.27	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
SARC	cis	rs17772222	0.597	rs17700521	ENSG00000258983.2	RP11-507K2.2	4.21	3.7e-05	0.014	0.3	0.27	Coronary artery calcification;	chr14:88849531	chr14:88499334~88515502:+
SARC	cis	rs9309473	0.607	rs1522927	ENSG00000163016.8	ALMS1P	4.21	3.7e-05	0.014	0.34	0.27	Metabolite levels;	chr2:73329027	chr2:73644919~73685576:+
SARC	cis	rs1741464	0.614	rs229670	ENSG00000258824.2	CTD-2555O16.2	-4.21	3.7e-05	0.014	-0.28	-0.27	Reticulocyte count;Reticulocyte fraction of red cells;	chr14:64816783	chr14:64422935~64448557:-
SARC	cis	rs867371	1	rs7173339	ENSG00000259429.4	UBE2Q2P2	-4.21	3.7e-05	0.014	-0.25	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82355142~82420075:+
SARC	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	4.21	3.7e-05	0.014	0.4	0.27	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
SARC	cis	rs9309473	0.519	rs2178154	ENSG00000163016.8	ALMS1P	-4.21	3.7e-05	0.014	-0.3	-0.27	Metabolite levels;	chr2:73434610	chr2:73644919~73685576:+
SARC	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-4.21	3.71e-05	0.014	-0.26	-0.27	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
SARC	cis	rs755249	0.958	rs2068663	ENSG00000182109.6	RP11-69E11.4	4.21	3.71e-05	0.014	0.3	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39522280~39546187:-
SARC	cis	rs875971	1	rs697970	ENSG00000232559.3	GS1-124K5.12	-4.21	3.71e-05	0.014	-0.3	-0.27	Aortic root size;	chr7:66095065	chr7:66554588~66576923:-
SARC	cis	rs7512898	0.966	rs6427846	ENSG00000260088.1	RP11-92G12.3	-4.21	3.71e-05	0.014	-0.26	-0.27	Electrocardiographic conduction measures;	chr1:200699170	chr1:200669507~200694250:+
SARC	cis	rs875971	0.965	rs6971509	ENSG00000232559.3	GS1-124K5.12	-4.21	3.71e-05	0.014	-0.3	-0.27	Aortic root size;	chr7:66249983	chr7:66554588~66576923:-
SARC	cis	rs9364687	0.664	rs9346960	ENSG00000228692.2	RP5-826L7.1	-4.21	3.71e-05	0.014	-0.31	-0.27	Body mass index;	chr6:163464258	chr6:163586583~163588165:-
SARC	cis	rs13126694	0.682	rs9991381	ENSG00000248429.4	RP11-597D13.9	4.21	3.71e-05	0.014	0.27	0.27	Blood osmolality (transformed sodium);	chr4:157982239	chr4:158170752~158202877:+
SARC	cis	rs4664293	0.836	rs73967923	ENSG00000226266.5	AC009961.3	-4.21	3.72e-05	0.014	-0.33	-0.27	Monocyte percentage of white cells;	chr2:159801754	chr2:159670708~159712435:-
SARC	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-4.21	3.72e-05	0.014	-0.25	-0.27	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
SARC	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-4.21	3.72e-05	0.014	-0.34	-0.27	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
SARC	cis	rs9902453	0.904	rs4528633	ENSG00000264538.5	SUZ12P1	-4.21	3.72e-05	0.014	-0.19	-0.27	Coffee consumption (cups per day);	chr17:30029118	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs7225686	ENSG00000264538.5	SUZ12P1	-4.21	3.72e-05	0.014	-0.19	-0.27	Coffee consumption (cups per day);	chr17:30029726	chr17:30709299~30790908:+
SARC	cis	rs17772222	0.636	rs10484010	ENSG00000258983.2	RP11-507K2.2	4.21	3.72e-05	0.014	0.3	0.27	Coronary artery calcification;	chr14:88831944	chr14:88499334~88515502:+
SARC	cis	rs6732426	0.55	rs6544647	ENSG00000279873.2	LINC01126	4.21	3.72e-05	0.014	0.21	0.27	Hair morphology;	chr2:43351280	chr2:43227210~43228855:+
SARC	cis	rs4664293	0.867	rs13432	ENSG00000226266.5	AC009961.3	-4.21	3.72e-05	0.014	-0.32	-0.27	Monocyte percentage of white cells;	chr2:159769216	chr2:159670708~159712435:-
SARC	cis	rs12542260	0.774	rs10956189	ENSG00000253106.1	RP11-158K1.3	4.2	3.72e-05	0.014	0.31	0.27	Colonoscopy-negative controls vs population controls;	chr8:124554778	chr8:124488510~124491643:+
SARC	cis	rs57561814	0.51	rs2066992	ENSG00000179428.2	AC073072.5	-4.2	3.72e-05	0.014	-0.45	-0.27	Tonsillectomy;	chr7:22728630	chr7:22725395~22727620:-
SARC	cis	rs9902453	0.765	rs2467334	ENSG00000264538.5	SUZ12P1	-4.2	3.73e-05	0.0141	-0.19	-0.27	Coffee consumption (cups per day);	chr17:29808490	chr17:30709299~30790908:+
SARC	cis	rs9481169	0.85	rs60962769	ENSG00000231889.6	TRAF3IP2-AS1	4.2	3.73e-05	0.0141	0.49	0.27	Inflammatory skin disease;	chr6:111598221	chr6:111483511~111598302:+
SARC	cis	rs853679	0.76	rs9295768	ENSG00000216901.1	AL022393.7	4.2	3.73e-05	0.0141	0.43	0.27	Depression;	chr6:28241324	chr6:28176188~28176674:+
SARC	cis	rs853679	0.699	rs9468318	ENSG00000216901.1	AL022393.7	4.2	3.73e-05	0.0141	0.43	0.27	Depression;	chr6:28241753	chr6:28176188~28176674:+
SARC	cis	rs853679	0.76	rs9357067	ENSG00000216901.1	AL022393.7	4.2	3.73e-05	0.0141	0.43	0.27	Depression;	chr6:28242515	chr6:28176188~28176674:+
SARC	cis	rs853679	0.76	rs967005	ENSG00000216901.1	AL022393.7	4.2	3.73e-05	0.0141	0.43	0.27	Depression;	chr6:28242910	chr6:28176188~28176674:+
SARC	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	4.2	3.73e-05	0.0141	0.32	0.27	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
SARC	cis	rs7976269	0.609	rs7979788	ENSG00000257176.2	RP11-996F15.2	-4.2	3.73e-05	0.0141	-0.29	-0.27	Male-pattern baldness;	chr12:29064827	chr12:29280418~29317848:-
SARC	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	4.2	3.73e-05	0.0141	0.4	0.27	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	4.2	3.73e-05	0.0141	0.4	0.27	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	4.2	3.73e-05	0.0141	0.4	0.27	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.576	rs66671308	ENSG00000171084.14	FAM86JP	4.2	3.73e-05	0.0141	0.4	0.27	Blood pressure (smoking interaction);	chr3:126074683	chr3:125916620~125930024:+
SARC	cis	rs12220777	0.748	rs6584955	ENSG00000230091.5	TMEM254-AS1	4.2	3.73e-05	0.0141	0.37	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80100568	chr10:80046860~80078912:-
SARC	cis	rs113835537	0.808	rs10896128	ENSG00000255517.5	CTD-3074O7.5	-4.2	3.73e-05	0.0141	-0.35	-0.27	Airway imaging phenotypes;	chr11:66557058	chr11:66473490~66480233:-
SARC	cis	rs4934494	0.813	rs12775783	ENSG00000240996.1	RP11-80H5.7	-4.2	3.74e-05	0.0141	-0.29	-0.27	Red blood cell count;	chr10:89646494	chr10:89694295~89697928:-
SARC	cis	rs12980942	0.872	rs12327659	ENSG00000206674.1	RNU6-945P	-4.2	3.74e-05	0.0141	-0.4	-0.27	Coronary artery disease;	chr19:41290567	chr19:40299478~40299584:-
SARC	cis	rs910316	0.967	rs175498	ENSG00000279594.1	RP11-950C14.10	-4.2	3.74e-05	0.0141	-0.29	-0.27	Height;	chr14:75069666	chr14:75011269~75012851:-
SARC	cis	rs72615157	0.612	rs7786505	ENSG00000242294.5	STAG3L5P	4.2	3.74e-05	0.0141	0.22	0.27	Lung function (FEV1/FVC);	chr7:100219962	chr7:100336079~100351900:+
SARC	cis	rs17292804	0.506	rs71417868	ENSG00000269940.1	RP11-73M18.7	4.2	3.74e-05	0.0141	0.26	0.27	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103694560~103695170:+
SARC	cis	rs2029362	0.611	rs10219241	ENSG00000245573.6	BDNF-AS	-4.2	3.74e-05	0.0141	-0.23	-0.27	Total body bone mineral density;	chr11:27715576	chr11:27506838~27698174:+
SARC	cis	rs7567389	0.719	rs6733478	ENSG00000236682.1	AC068282.3	4.2	3.74e-05	0.0141	0.33	0.27	Self-rated health;	chr2:127238413	chr2:127389130~127400580:+
SARC	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	4.2	3.75e-05	0.0141	0.49	0.27	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
SARC	cis	rs7615952	1	rs7616044	ENSG00000241288.6	RP11-379B18.5	-4.2	3.75e-05	0.0141	-0.35	-0.27	Blood pressure (smoking interaction);	chr3:125930511	chr3:125827238~125916384:-
SARC	cis	rs9364687	0.664	rs4709717	ENSG00000228692.2	RP5-826L7.1	-4.2	3.75e-05	0.0141	-0.31	-0.27	Body mass index;	chr6:163473632	chr6:163586583~163588165:-
SARC	cis	rs9364687	0.664	rs4709718	ENSG00000228692.2	RP5-826L7.1	-4.2	3.75e-05	0.0141	-0.31	-0.27	Body mass index;	chr6:163474756	chr6:163586583~163588165:-
SARC	cis	rs9364687	0.664	rs9364688	ENSG00000228692.2	RP5-826L7.1	-4.2	3.75e-05	0.0141	-0.31	-0.27	Body mass index;	chr6:163480359	chr6:163586583~163588165:-
SARC	cis	rs972578	0.561	rs5759113	ENSG00000230319.1	AL022476.2	4.2	3.75e-05	0.0141	0.32	0.27	Mean platelet volume;	chr22:43047946	chr22:43038585~43052366:+
SARC	cis	rs7772486	0.686	rs1337841	ENSG00000235652.6	RP11-545I5.3	-4.2	3.75e-05	0.0141	-0.24	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145799409~145886585:+
SARC	cis	rs11955398	0.502	rs295559	ENSG00000272308.1	RP11-231G3.1	4.2	3.76e-05	0.0141	0.24	0.27	Intelligence (multi-trait analysis);	chr5:61105395	chr5:60866457~60866935:-
SARC	cis	rs875971	0.66	rs10263935	ENSG00000236529.1	RP13-254B10.1	4.2	3.76e-05	0.0142	0.25	0.27	Aortic root size;	chr7:66631041	chr7:65840212~65840596:+
SARC	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-4.2	3.76e-05	0.0142	-0.31	-0.27	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
SARC	cis	rs7646881	1	rs59313096	ENSG00000240207.5	RP11-379F4.4	-4.2	3.76e-05	0.0142	-0.38	-0.27	Tetralogy of Fallot;	chr3:158734453	chr3:158732263~158784070:+
SARC	cis	rs7646881	1	rs59217052	ENSG00000240207.5	RP11-379F4.4	-4.2	3.76e-05	0.0142	-0.38	-0.27	Tetralogy of Fallot;	chr3:158734667	chr3:158732263~158784070:+
SARC	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-4.2	3.76e-05	0.0142	-0.32	-0.27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
SARC	cis	rs7267979	0.966	rs2261795	ENSG00000276952.1	RP5-965G21.6	4.2	3.77e-05	0.0142	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25284915~25285588:-
SARC	cis	rs4835473	0.932	rs17018500	ENSG00000251600.4	RP11-673E1.1	-4.2	3.77e-05	0.0142	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143824849	chr4:143912331~143982454:+
SARC	cis	rs4938303	0.549	rs12420888	ENSG00000254851.1	RP11-109L13.1	4.2	3.77e-05	0.0142	0.34	0.27	Triglycerides;	chr11:116693106	chr11:117135528~117138582:+
SARC	cis	rs9473147	0.516	rs9463342	ENSG00000270761.1	RP11-385F7.1	-4.2	3.77e-05	0.0142	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47617370	chr6:47477243~47477572:-
SARC	cis	rs9473147	0.516	rs7754971	ENSG00000270761.1	RP11-385F7.1	-4.2	3.77e-05	0.0142	-0.32	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47622740	chr6:47477243~47477572:-
SARC	cis	rs72945132	0.882	rs10466703	ENSG00000254604.1	AP000487.6	-4.2	3.77e-05	0.0142	-0.37	-0.27	Coronary artery disease;	chr11:70372442	chr11:70282367~70363368:-
SARC	cis	rs10911902	0.913	rs61810323	ENSG00000229739.2	RP11-295K2.3	-4.2	3.78e-05	0.0142	-0.37	-0.27	Schizophrenia;	chr1:186525919	chr1:186435161~186470291:+
SARC	cis	rs17826219	0.568	rs11658027	ENSG00000264538.5	SUZ12P1	4.2	3.78e-05	0.0142	0.27	0.27	Body mass index;	chr17:30767864	chr17:30709299~30790908:+
SARC	cis	rs193541	0.593	rs30042	ENSG00000263432.2	RN7SL689P	4.2	3.78e-05	0.0142	0.34	0.27	Glucose homeostasis traits;	chr5:122936946	chr5:123022487~123022783:-
SARC	cis	rs7267979	0.966	rs7270835	ENSG00000276952.1	RP5-965G21.6	4.2	3.78e-05	0.0142	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6115191	ENSG00000276952.1	RP5-965G21.6	4.2	3.78e-05	0.0142	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6107046	ENSG00000276952.1	RP5-965G21.6	4.2	3.78e-05	0.0142	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6107047	ENSG00000276952.1	RP5-965G21.6	4.2	3.78e-05	0.0142	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25284915~25285588:-
SARC	cis	rs4713118	0.621	rs9295756	ENSG00000280107.1	AL022393.9	-4.2	3.78e-05	0.0142	-0.34	-0.27	Parkinson's disease;	chr6:28065618	chr6:28170845~28172521:+
SARC	cis	rs12817211	0.502	rs1554844	ENSG00000272368.2	RP4-605O3.4	-4.2	3.78e-05	0.0142	-0.25	-0.27	Colorectal or endometrial cancer;	chr12:50120582	chr12:50112197~50165618:+
SARC	cis	rs2235544	0.565	rs928441	ENSG00000225183.1	RP4-758J24.4	-4.2	3.79e-05	0.0142	-0.3	-0.27	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54007695	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.541	rs928442	ENSG00000225183.1	RP4-758J24.4	-4.2	3.79e-05	0.0142	-0.3	-0.27	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54007815	chr1:54089856~54090093:+
SARC	cis	rs7772486	0.79	rs7753696	ENSG00000270638.1	RP3-466P17.1	-4.2	3.79e-05	0.0142	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145735570~145737218:+
SARC	cis	rs910316	0.967	rs11624893	ENSG00000279594.1	RP11-950C14.10	-4.2	3.79e-05	0.0143	-0.29	-0.27	Height;	chr14:75193421	chr14:75011269~75012851:-
SARC	cis	rs1468333	0.537	rs13184188	ENSG00000206989.1	SNORD63	-4.2	3.79e-05	0.0143	-0.27	-0.27	Resting heart rate;	chr5:138453830	chr5:138561043~138561110:-
SARC	cis	rs113835537	1	rs113835537	ENSG00000255517.5	CTD-3074O7.5	-4.2	3.79e-05	0.0143	-0.36	-0.27	Airway imaging phenotypes;	chr11:66572168	chr11:66473490~66480233:-
SARC	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	4.2	3.79e-05	0.0143	0.25	0.27	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
SARC	cis	rs9828933	0.752	rs832192	ENSG00000280620.1	SCAANT1	-4.2	3.79e-05	0.0143	-0.45	-0.27	Type 2 diabetes;	chr3:63867747	chr3:63911518~63911772:-
SARC	cis	rs4835473	0.932	rs34886773	ENSG00000251600.4	RP11-673E1.1	-4.2	3.8e-05	0.0143	-0.26	-0.27	Immature fraction of reticulocytes;	chr4:143764678	chr4:143912331~143982454:+
SARC	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-4.2	3.8e-05	0.0143	-0.27	-0.27	Height;	chr3:52989412	chr3:53064283~53065091:-
SARC	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-4.2	3.8e-05	0.0143	-0.27	-0.27	Height;	chr3:52991821	chr3:53064283~53065091:-
SARC	cis	rs10911902	0.913	rs3131554	ENSG00000229739.2	RP11-295K2.3	-4.2	3.8e-05	0.0143	-0.36	-0.27	Schizophrenia;	chr1:186482939	chr1:186435161~186470291:+
SARC	cis	rs448720	0.806	rs11071966	ENSG00000259410.4	RP11-34F13.3	4.2	3.8e-05	0.0143	0.29	0.27	Cognitive performance;	chr15:67871436	chr15:67832725~67873866:+
SARC	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-4.2	3.8e-05	0.0143	-0.28	-0.27	Height;	chr3:53052712	chr3:53064283~53065091:-
SARC	cis	rs13434995	0.635	rs1818461	ENSG00000273257.1	RP11-177J6.1	-4.2	3.8e-05	0.0143	-0.37	-0.27	Adiponectin levels;	chr4:55379156	chr4:55387949~55388271:+
SARC	cis	rs13434995	0.589	rs861029	ENSG00000273257.1	RP11-177J6.1	-4.2	3.8e-05	0.0143	-0.37	-0.27	Adiponectin levels;	chr4:55379470	chr4:55387949~55388271:+
SARC	cis	rs1823913	0.614	rs12616167	ENSG00000227542.1	AC092614.2	-4.2	3.8e-05	0.0143	-0.3	-0.27	Obesity-related traits;	chr2:191311274	chr2:191229165~191246172:-
SARC	cis	rs4950322	0.57	rs11800580	ENSG00000278811.3	LINC00624	-4.2	3.8e-05	0.0143	-0.28	-0.27	Protein quantitative trait loci;	chr1:147261053	chr1:147258885~147517875:-
SARC	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	4.2	3.81e-05	0.0143	0.39	0.27	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	4.2	3.81e-05	0.0143	0.39	0.27	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
SARC	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	4.2	3.81e-05	0.0143	0.39	0.27	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
SARC	cis	rs2029362	0.513	rs10767667	ENSG00000245573.6	BDNF-AS	4.2	3.81e-05	0.0143	0.23	0.27	Total body bone mineral density;	chr11:27725002	chr11:27506838~27698174:+
SARC	cis	rs2029362	0.513	rs7931247	ENSG00000245573.6	BDNF-AS	4.2	3.81e-05	0.0143	0.23	0.27	Total body bone mineral density;	chr11:27725444	chr11:27506838~27698174:+
SARC	cis	rs7615952	0.609	rs13088451	ENSG00000248787.1	RP11-666A20.4	-4.2	3.81e-05	0.0143	-0.38	-0.27	Blood pressure (smoking interaction);	chr3:125834656	chr3:125908005~125910272:-
SARC	cis	rs890448	0.693	rs4276280	ENSG00000254531.1	FLJ20021	4.2	3.81e-05	0.0143	0.28	0.27	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417442	chr4:101347780~101348883:+
SARC	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	4.2	3.82e-05	0.0143	0.25	0.27	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
SARC	cis	rs61160187	0.667	rs7722373	ENSG00000215032.2	GNL3LP1	4.2	3.82e-05	0.0143	0.26	0.27	Educational attainment (years of education);Educational attainment (college completion);	chr5:60951988	chr5:60891935~60893577:-
SARC	cis	rs7976269	0.609	rs2196482	ENSG00000257176.2	RP11-996F15.2	-4.2	3.82e-05	0.0143	-0.29	-0.27	Male-pattern baldness;	chr12:29052559	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.609	rs2217906	ENSG00000257176.2	RP11-996F15.2	-4.2	3.82e-05	0.0143	-0.29	-0.27	Male-pattern baldness;	chr12:29052626	chr12:29280418~29317848:-
SARC	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-4.2	3.82e-05	0.0143	-0.28	-0.27	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
SARC	cis	rs2281636	0.723	rs2150916	ENSG00000233690.1	EBAG9P1	4.2	3.82e-05	0.0143	0.26	0.27	Obesity-related traits;	chr10:99692737	chr10:99697407~99697949:-
SARC	cis	rs7267979	1	rs2424712	ENSG00000276952.1	RP5-965G21.6	4.2	3.82e-05	0.0143	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2424714	ENSG00000276952.1	RP5-965G21.6	4.2	3.82e-05	0.0143	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2424715	ENSG00000276952.1	RP5-965G21.6	4.2	3.82e-05	0.0143	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6050617	ENSG00000276952.1	RP5-965G21.6	4.2	3.82e-05	0.0143	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.933	rs2387887	ENSG00000276952.1	RP5-965G21.6	4.2	3.82e-05	0.0143	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6050626	ENSG00000276952.1	RP5-965G21.6	4.2	3.82e-05	0.0143	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6037121	ENSG00000276952.1	RP5-965G21.6	4.2	3.82e-05	0.0143	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs1047171	ENSG00000276952.1	RP5-965G21.6	4.2	3.82e-05	0.0143	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6050629	ENSG00000276952.1	RP5-965G21.6	4.2	3.82e-05	0.0143	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6050630	ENSG00000276952.1	RP5-965G21.6	4.2	3.82e-05	0.0143	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6050632	ENSG00000276952.1	RP5-965G21.6	4.2	3.82e-05	0.0143	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25284915~25285588:-
SARC	cis	rs8005677	0.828	rs12437151	ENSG00000279656.1	RP11-298I3.6	4.2	3.82e-05	0.0144	0.34	0.27	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:23023083~23024217:-
SARC	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-4.2	3.83e-05	0.0144	-0.36	-0.27	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
SARC	cis	rs13217239	0.646	rs10456352	ENSG00000241549.7	GUSBP2	4.2	3.83e-05	0.0144	0.25	0.27	Schizophrenia;	chr6:27022579	chr6:26871484~26956554:-
SARC	cis	rs1707322	1	rs9429186	ENSG00000281133.1	AL355480.3	4.2	3.83e-05	0.0144	0.31	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs785506	ENSG00000281133.1	AL355480.3	4.2	3.83e-05	0.0144	0.31	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45580892~45580996:-
SARC	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	4.2	3.83e-05	0.0144	0.25	0.27	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
SARC	cis	rs950776	0.648	rs57945453	ENSG00000261762.1	RP11-650L12.2	4.2	3.83e-05	0.0144	0.29	0.27	Sudden cardiac arrest;	chr15:78570503	chr15:78589123~78591276:-
SARC	cis	rs7772486	0.79	rs9376971	ENSG00000270638.1	RP3-466P17.1	-4.2	3.84e-05	0.0144	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs4314514	ENSG00000270638.1	RP3-466P17.1	-4.2	3.84e-05	0.0144	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.72	rs9403757	ENSG00000270638.1	RP3-466P17.1	-4.2	3.84e-05	0.0144	-0.22	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145735570~145737218:+
SARC	cis	rs380904	0.519	rs12541790	ENSG00000254859.1	RP11-661A12.5	-4.2	3.84e-05	0.0144	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:143561151	chr8:143541973~143549729:-
SARC	cis	rs380904	0.519	rs1377663	ENSG00000254859.1	RP11-661A12.5	-4.2	3.84e-05	0.0144	-0.39	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr8:143541973~143549729:-
SARC	cis	rs7267979	0.816	rs1044573	ENSG00000276952.1	RP5-965G21.6	4.2	3.84e-05	0.0144	0.25	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25226018	chr20:25284915~25285588:-
SARC	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-4.2	3.85e-05	0.0144	-0.33	-0.27	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
SARC	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-4.2	3.85e-05	0.0144	-0.38	-0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
SARC	cis	rs763121	0.853	rs138712	ENSG00000273076.1	RP3-508I15.22	4.2	3.85e-05	0.0144	0.28	0.27	Menopause (age at onset);	chr22:38745595	chr22:38743495~38743910:+
SARC	cis	rs1707322	0.896	rs785512	ENSG00000281133.1	AL355480.3	4.2	3.85e-05	0.0144	0.31	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45580892~45580996:-
SARC	cis	rs853679	1	rs853676	ENSG00000219392.1	RP1-265C24.5	-4.2	3.85e-05	0.0145	-0.46	-0.27	Depression;	chr6:28331910	chr6:28115628~28116551:+
SARC	cis	rs7267979	0.844	rs6107027	ENSG00000276952.1	RP5-965G21.6	4.2	3.86e-05	0.0145	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:25284915~25285588:-
SARC	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-4.2	3.86e-05	0.0145	-0.25	-0.27	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
SARC	cis	rs7267979	1	rs6132835	ENSG00000276952.1	RP5-965G21.6	4.2	3.87e-05	0.0145	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.933	rs11699203	ENSG00000276952.1	RP5-965G21.6	4.2	3.87e-05	0.0145	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.933	rs6138571	ENSG00000276952.1	RP5-965G21.6	4.2	3.87e-05	0.0145	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs416745	ENSG00000276952.1	RP5-965G21.6	4.2	3.87e-05	0.0145	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs448396	ENSG00000276952.1	RP5-965G21.6	4.2	3.87e-05	0.0145	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs447722	ENSG00000276952.1	RP5-965G21.6	4.2	3.87e-05	0.0145	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs422424	ENSG00000276952.1	RP5-965G21.6	4.2	3.87e-05	0.0145	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs422844	ENSG00000276952.1	RP5-965G21.6	4.2	3.87e-05	0.0145	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs401166	ENSG00000276952.1	RP5-965G21.6	4.2	3.87e-05	0.0145	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs404394	ENSG00000276952.1	RP5-965G21.6	4.2	3.87e-05	0.0145	0.26	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25284915~25285588:-
SARC	cis	rs732716	0.853	rs62129349	ENSG00000267980.1	AC007292.6	-4.2	3.87e-05	0.0145	-0.34	-0.27	Mean corpuscular volume;	chr19:4385662	chr19:4363789~4364640:+
SARC	cis	rs4950322	0.58	rs972368	ENSG00000278811.3	LINC00624	4.2	3.87e-05	0.0145	0.27	0.27	Protein quantitative trait loci;	chr1:147111142	chr1:147258885~147517875:-
SARC	cis	rs1707322	1	rs4073847	ENSG00000281133.1	AL355480.3	4.2	3.87e-05	0.0145	0.31	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45580892~45580996:-
SARC	cis	rs4273100	0.688	rs4924980	ENSG00000265185.4	SNORD3B-1	-4.2	3.88e-05	0.0145	-0.31	-0.27	Schizophrenia;	chr17:19301550	chr17:19061912~19062669:+
SARC	cis	rs9902453	0.765	rs2259857	ENSG00000264538.5	SUZ12P1	-4.19	3.88e-05	0.0145	-0.19	-0.26	Coffee consumption (cups per day);	chr17:29770762	chr17:30709299~30790908:+
SARC	cis	rs713477	1	rs8014526	ENSG00000258413.1	RP11-665C16.6	4.19	3.88e-05	0.0145	0.3	0.26	Pediatric bone mineral content (femoral neck);	chr14:55418336	chr14:55262767~55272075:-
SARC	cis	rs9309473	0.607	rs7567017	ENSG00000163016.8	ALMS1P	4.19	3.89e-05	0.0146	0.32	0.26	Metabolite levels;	chr2:73369142	chr2:73644919~73685576:+
SARC	cis	rs1707322	1	rs2458400	ENSG00000281133.1	AL355480.3	4.19	3.89e-05	0.0146	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45580892~45580996:-
SARC	cis	rs7267979	0.816	rs390123	ENSG00000125804.12	FAM182A	-4.19	3.89e-05	0.0146	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:26054655~26086917:+
SARC	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	4.19	3.89e-05	0.0146	0.25	0.26	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
SARC	cis	rs1707322	0.927	rs6690386	ENSG00000281133.1	AL355480.3	-4.19	3.89e-05	0.0146	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45580892~45580996:-
SARC	cis	rs10911902	0.602	rs6425025	ENSG00000229739.2	RP11-295K2.3	-4.19	3.89e-05	0.0146	-0.39	-0.26	Schizophrenia;	chr1:186305025	chr1:186435161~186470291:+
SARC	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	4.19	3.89e-05	0.0146	0.39	0.26	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	4.19	3.89e-05	0.0146	0.39	0.26	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
SARC	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	4.19	3.89e-05	0.0146	0.33	0.26	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
SARC	cis	rs7520050	0.807	rs28378621	ENSG00000280836.1	AL355480.1	-4.19	3.9e-05	0.0146	-0.25	-0.26	Reticulocyte count;Red blood cell count;	chr1:45723882	chr1:45581219~45581321:-
SARC	cis	rs56046484	0.956	rs2174218	ENSG00000259295.5	CSPG4P12	-4.19	3.9e-05	0.0146	-0.39	-0.26	Testicular germ cell tumor;	chr15:85081425	chr15:85191438~85213905:+
SARC	cis	rs13126694	0.778	rs7692254	ENSG00000248429.4	RP11-597D13.9	4.19	3.9e-05	0.0146	0.26	0.26	Blood osmolality (transformed sodium);	chr4:158134140	chr4:158170752~158202877:+
SARC	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	4.19	3.91e-05	0.0146	0.24	0.26	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
SARC	cis	rs453301	0.658	rs6986044	ENSG00000253893.2	FAM85B	4.19	3.91e-05	0.0146	0.24	0.26	Joint mobility (Beighton score);	chr8:9017276	chr8:8167819~8226614:-
SARC	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	4.19	3.91e-05	0.0146	0.25	0.26	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
SARC	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-4.19	3.91e-05	0.0146	-0.36	-0.26	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
SARC	cis	rs11886999	0.812	rs12617019	ENSG00000237510.6	AC008268.2	-4.19	3.92e-05	0.0146	-0.39	-0.26	Cardiac Troponin-T levels;	chr2:96239830	chr2:95789654~95800166:+
SARC	cis	rs4664293	0.967	rs4665103	ENSG00000226266.5	AC009961.3	-4.19	3.92e-05	0.0146	-0.32	-0.26	Monocyte percentage of white cells;	chr2:159675801	chr2:159670708~159712435:-
SARC	cis	rs758129	0.722	rs150295	ENSG00000261441.1	RP11-217B1.2	4.19	3.92e-05	0.0147	0.34	0.26	Schizophrenia;	chr15:89386703	chr15:89335053~89336161:+
SARC	cis	rs6988985	0.678	rs7831617	ENSG00000247317.3	RP11-273G15.2	-4.19	3.92e-05	0.0147	-0.29	-0.26	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142920867	chr8:142981738~143018437:-
SARC	cis	rs6988985	0.678	rs4072020	ENSG00000247317.3	RP11-273G15.2	-4.19	3.92e-05	0.0147	-0.29	-0.26	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142915999	chr8:142981738~143018437:-
SARC	cis	rs948562	0.696	rs11229532	ENSG00000280010.1	AP001350.4	4.19	3.92e-05	0.0147	0.44	0.26	Lymphoma;	chr11:58574877	chr11:58627435~58628528:+
SARC	cis	rs755249	0.53	rs4660475	ENSG00000182109.6	RP11-69E11.4	4.19	3.93e-05	0.0147	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146568	chr1:39522280~39546187:-
SARC	cis	rs755249	0.53	rs66848709	ENSG00000182109.6	RP11-69E11.4	4.19	3.93e-05	0.0147	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146885	chr1:39522280~39546187:-
SARC	cis	rs2283792	0.646	rs9610317	ENSG00000224086.5	LL22NC03-86G7.1	-4.19	3.93e-05	0.0147	-0.28	-0.26	Multiple sclerosis;	chr22:21785601	chr22:21938293~21977632:+
SARC	cis	rs7267979	0.932	rs2260997	ENSG00000276952.1	RP5-965G21.6	-4.19	3.93e-05	0.0147	-0.27	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:25284915~25285588:-
SARC	cis	rs9894429	0.789	rs9747336	ENSG00000229848.1	RP13-766D20.2	4.19	3.93e-05	0.0147	0.26	0.26	Eye color traits;	chr17:81617163	chr17:81514047~81527776:+
SARC	cis	rs597539	0.518	rs35093305	ENSG00000250508.1	RP11-757G1.6	-4.19	3.93e-05	0.0147	-0.32	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68870664~68874542:+
SARC	cis	rs801193	0.66	rs2659897	ENSG00000232559.3	GS1-124K5.12	-4.19	3.93e-05	0.0147	-0.3	-0.26	Aortic root size;	chr7:66722728	chr7:66554588~66576923:-
SARC	cis	rs9828933	0.577	rs704374	ENSG00000280620.1	SCAANT1	-4.19	3.93e-05	0.0147	-0.4	-0.26	Type 2 diabetes;	chr3:63880271	chr3:63911518~63911772:-
SARC	cis	rs62432291	0.614	rs420339	ENSG00000235086.1	FNDC1-IT1	-4.19	3.93e-05	0.0147	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159236163	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs425906	ENSG00000235086.1	FNDC1-IT1	-4.19	3.93e-05	0.0147	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159236543	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs388001	ENSG00000235086.1	FNDC1-IT1	-4.19	3.93e-05	0.0147	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159237427	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs447637	ENSG00000235086.1	FNDC1-IT1	-4.19	3.93e-05	0.0147	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159237694	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs378339	ENSG00000235086.1	FNDC1-IT1	-4.19	3.93e-05	0.0147	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159237820	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs419836	ENSG00000235086.1	FNDC1-IT1	-4.19	3.93e-05	0.0147	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159238449	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs450538	ENSG00000235086.1	FNDC1-IT1	-4.19	3.93e-05	0.0147	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159238491	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.764	rs433256	ENSG00000235086.1	FNDC1-IT1	-4.19	3.93e-05	0.0147	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159239073	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs429339	ENSG00000235086.1	FNDC1-IT1	-4.19	3.93e-05	0.0147	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159239116	chr6:159240786~159243329:+
SARC	cis	rs783540	0.934	rs10400906	ENSG00000275695.1	UBE2Q2P6	4.19	3.93e-05	0.0147	0.26	0.26	Schizophrenia;	chr15:82628387	chr15:82445719~82454837:+
SARC	cis	rs9868809	0.772	rs12107252	ENSG00000225399.4	RP11-3B7.1	-4.19	3.94e-05	0.0147	-0.46	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48653883	chr3:49260085~49261316:+
SARC	cis	rs5758511	0.68	rs5758681	ENSG00000227370.1	RP4-669P10.19	4.19	3.94e-05	0.0147	0.3	0.26	Birth weight;	chr22:42249085	chr22:42132543~42132998:+
SARC	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-4.19	3.94e-05	0.0147	-0.3	-0.26	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-4.19	3.94e-05	0.0147	-0.3	-0.26	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-4.19	3.94e-05	0.0147	-0.3	-0.26	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
SARC	cis	rs12200782	1	rs12204145	ENSG00000272810.1	U91328.22	-4.19	3.95e-05	0.0147	-0.44	-0.26	Small cell lung carcinoma;	chr6:26599928	chr6:26013241~26013757:+
SARC	cis	rs10911902	0.643	rs78468398	ENSG00000229739.2	RP11-295K2.3	-4.19	3.95e-05	0.0147	-0.38	-0.26	Schizophrenia;	chr1:186315149	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.643	rs34585917	ENSG00000229739.2	RP11-295K2.3	-4.19	3.95e-05	0.0147	-0.38	-0.26	Schizophrenia;	chr1:186317650	chr1:186435161~186470291:+
SARC	cis	rs4950322	0.57	rs4593887	ENSG00000278811.3	LINC00624	4.19	3.95e-05	0.0148	0.28	0.26	Protein quantitative trait loci;	chr1:147234246	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.57	rs72691004	ENSG00000278811.3	LINC00624	4.19	3.95e-05	0.0148	0.28	0.26	Protein quantitative trait loci;	chr1:147234309	chr1:147258885~147517875:-
SARC	cis	rs62432291	0.681	rs420054	ENSG00000235086.1	FNDC1-IT1	-4.19	3.95e-05	0.0148	-0.45	-0.26	Joint mobility (Beighton score);	chr6:159234052	chr6:159240786~159243329:+
SARC	cis	rs595244	0.706	rs2289136	ENSG00000259705.1	RP11-227D13.1	-4.19	3.96e-05	0.0148	-0.43	-0.26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48652075	chr15:48645951~48652016:+
SARC	cis	rs10986311	0.889	rs3780204	ENSG00000235204.1	RP11-121A14.2	-4.19	3.96e-05	0.0148	-0.31	-0.26	Vitiligo;	chr9:124330608	chr9:124259250~124261156:-
SARC	cis	rs4664293	1	rs6753181	ENSG00000226266.5	AC009961.3	-4.19	3.96e-05	0.0148	-0.32	-0.26	Monocyte percentage of white cells;	chr2:159635927	chr2:159670708~159712435:-
SARC	cis	rs867371	1	rs1501372	ENSG00000259429.4	UBE2Q2P2	-4.19	3.96e-05	0.0148	-0.25	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82355142~82420075:+
SARC	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	4.19	3.97e-05	0.0148	0.36	0.26	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
SARC	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	4.19	3.97e-05	0.0148	0.32	0.26	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
SARC	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-4.19	3.97e-05	0.0148	-0.24	-0.26	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
SARC	cis	rs495337	0.76	rs6125830	ENSG00000229222.1	KRT18P4	-4.19	3.97e-05	0.0148	-0.34	-0.26	Psoriasis;	chr20:49955125	chr20:49956745~49958032:+
SARC	cis	rs4664293	0.647	rs7587700	ENSG00000226266.5	AC009961.3	-4.19	3.97e-05	0.0148	-0.31	-0.26	Monocyte percentage of white cells;	chr2:159587809	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs7595044	ENSG00000226266.5	AC009961.3	-4.19	3.97e-05	0.0148	-0.31	-0.26	Monocyte percentage of white cells;	chr2:159589694	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs12623149	ENSG00000226266.5	AC009961.3	-4.19	3.97e-05	0.0148	-0.31	-0.26	Monocyte percentage of white cells;	chr2:159590835	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.609	rs10209829	ENSG00000226266.5	AC009961.3	-4.19	3.97e-05	0.0148	-0.31	-0.26	Monocyte percentage of white cells;	chr2:159591113	chr2:159670708~159712435:-
SARC	cis	rs9894429	0.738	rs8077038	ENSG00000229848.1	RP13-766D20.2	-4.19	3.97e-05	0.0148	-0.26	-0.26	Eye color traits;	chr17:81610101	chr17:81514047~81527776:+
SARC	cis	rs755249	1	rs2293476	ENSG00000182109.6	RP11-69E11.4	-4.19	3.97e-05	0.0148	-0.3	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39522280~39546187:-
SARC	cis	rs4664293	0.647	rs10198053	ENSG00000226266.5	AC009961.3	-4.19	3.97e-05	0.0148	-0.31	-0.26	Monocyte percentage of white cells;	chr2:159605169	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.669	rs10174515	ENSG00000226266.5	AC009961.3	-4.19	3.97e-05	0.0148	-0.31	-0.26	Monocyte percentage of white cells;	chr2:159605524	chr2:159670708~159712435:-
SARC	cis	rs2179367	0.586	rs62426088	ENSG00000231760.4	RP11-350J20.5	4.19	3.97e-05	0.0148	0.36	0.26	Dupuytren's disease;	chr6:149339301	chr6:149796151~149826294:-
SARC	cis	rs708547	0.541	rs6554392	ENSG00000269949.1	RP11-738E22.3	-4.19	3.98e-05	0.0148	-0.33	-0.26	Response to bleomycin (chromatid breaks);	chr4:56873782	chr4:56960927~56961373:-
SARC	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	4.19	3.98e-05	0.0148	0.35	0.26	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
SARC	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	4.19	3.98e-05	0.0148	0.35	0.26	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
SARC	cis	rs253959	0.739	rs1421842	ENSG00000272265.1	CTD-2287O16.4	-4.19	3.98e-05	0.0148	-0.31	-0.26	Bipolar disorder and schizophrenia;	chr5:116298593	chr5:116078110~116078570:-
SARC	cis	rs9309473	0.718	rs10175529	ENSG00000163016.8	ALMS1P	4.19	3.98e-05	0.0149	0.31	0.26	Metabolite levels;	chr2:73378965	chr2:73644919~73685576:+
SARC	cis	rs7216064	0.953	rs10445361	ENSG00000237854.3	LINC00674	-4.19	3.99e-05	0.0149	-0.31	-0.26	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67966122	chr17:68101908~68115518:+
SARC	cis	rs2404602	0.716	rs67418609	ENSG00000259422.1	RP11-593F23.1	4.19	3.99e-05	0.0149	0.3	0.26	Blood metabolite levels;	chr15:76334748	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.716	rs12440815	ENSG00000259422.1	RP11-593F23.1	4.19	3.99e-05	0.0149	0.3	0.26	Blood metabolite levels;	chr15:76334987	chr15:76174891~76181486:-
SARC	cis	rs1707322	1	rs4074225	ENSG00000281133.1	AL355480.3	-4.19	3.99e-05	0.0149	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45580892~45580996:-
SARC	cis	rs11694172	0.826	rs56712316	ENSG00000273456.1	RP11-686O6.2	4.19	3.99e-05	0.0149	0.24	0.26	Cholesterol, total;	chr2:202766724	chr2:202374932~202375604:-
SARC	cis	rs11694172	0.826	rs16839311	ENSG00000273456.1	RP11-686O6.2	4.19	3.99e-05	0.0149	0.24	0.26	Cholesterol, total;	chr2:202766833	chr2:202374932~202375604:-
SARC	cis	rs858239	0.601	rs6971002	ENSG00000226816.2	AC005082.12	4.19	3.99e-05	0.0149	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23206013~23208045:+
SARC	cis	rs1062177	0.756	rs2964591	ENSG00000254226.4	CTB-12O2.1	-4.19	3.99e-05	0.0149	-0.34	-0.26	Preschool internalizing problems;	chr5:151737836	chr5:151949571~152270448:+
SARC	cis	rs11264213	0.901	rs716925	ENSG00000271554.1	RP4-665N4.8	-4.19	3.99e-05	0.0149	-0.36	-0.26	Schizophrenia;	chr1:35958916	chr1:35992109~36013630:-
SARC	cis	rs2072438	0.503	rs10739590	ENSG00000226752.6	PSMD5-AS1	-4.19	3.99e-05	0.0149	-0.31	-0.26	Rheumatoid arthritis;	chr9:121109203	chr9:120824828~120854385:+
SARC	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	4.19	4e-05	0.0149	0.39	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
SARC	cis	rs13217239	0.646	rs6937880	ENSG00000241549.7	GUSBP2	4.19	4e-05	0.0149	0.25	0.26	Schizophrenia;	chr6:27032457	chr6:26871484~26956554:-
SARC	cis	rs13217239	0.621	rs12527231	ENSG00000241549.7	GUSBP2	4.19	4e-05	0.0149	0.25	0.26	Schizophrenia;	chr6:27033509	chr6:26871484~26956554:-
SARC	cis	rs13217239	0.646	rs12523820	ENSG00000241549.7	GUSBP2	4.19	4e-05	0.0149	0.25	0.26	Schizophrenia;	chr6:27033723	chr6:26871484~26956554:-
SARC	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-4.19	4e-05	0.0149	-0.34	-0.26	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
SARC	cis	rs853679	0.546	rs200989	ENSG00000216901.1	AL022393.7	4.19	4.01e-05	0.0149	0.59	0.26	Depression;	chr6:27848664	chr6:28176188~28176674:+
SARC	cis	rs11651000	0.625	rs58067360	ENSG00000239291.1	RP5-867C24.1	4.19	4.01e-05	0.0149	0.31	0.26	IgG glycosylation;	chr17:47742221	chr17:47159191~47159993:-
SARC	cis	rs875971	0.755	rs76288834	ENSG00000232559.3	GS1-124K5.12	-4.19	4.01e-05	0.0149	-0.32	-0.26	Aortic root size;	chr7:66604815	chr7:66554588~66576923:-
SARC	cis	rs10895987	1	rs72932837	ENSG00000254614.2	AP003068.23	4.19	4.01e-05	0.0149	0.38	0.26	Blood protein levels;	chr11:65109268	chr11:65177606~65181834:-
SARC	cis	rs59104589	0.535	rs73002160	ENSG00000266621.1	AC104841.1	4.19	4.01e-05	0.0149	0.36	0.26	Fibrinogen levels;	chr2:241382292	chr2:241245202~241245299:-
SARC	cis	rs2439831	0.867	rs12443102	ENSG00000275601.1	AC011330.13	-4.19	4.02e-05	0.0149	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43639905	chr15:43642389~43643023:-
SARC	cis	rs853679	1	rs10456362	ENSG00000219392.1	RP1-265C24.5	4.19	4.02e-05	0.0149	0.44	0.26	Depression;	chr6:28254038	chr6:28115628~28116551:+
SARC	cis	rs61160187	0.698	rs72755157	ENSG00000272308.1	RP11-231G3.1	-4.19	4.02e-05	0.015	-0.23	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60651559	chr5:60866457~60866935:-
SARC	cis	rs61160187	0.673	rs2198865	ENSG00000272308.1	RP11-231G3.1	-4.19	4.02e-05	0.015	-0.23	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60658230	chr5:60866457~60866935:-
SARC	cis	rs61160187	0.698	rs17387940	ENSG00000272308.1	RP11-231G3.1	-4.19	4.02e-05	0.015	-0.23	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60671889	chr5:60866457~60866935:-
SARC	cis	rs61160187	0.698	rs56726435	ENSG00000272308.1	RP11-231G3.1	-4.19	4.02e-05	0.015	-0.23	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60679237	chr5:60866457~60866935:-
SARC	cis	rs910316	0.783	rs11850751	ENSG00000279594.1	RP11-950C14.10	4.19	4.02e-05	0.015	0.29	0.26	Height;	chr14:75123410	chr14:75011269~75012851:-
SARC	cis	rs367615	0.68	rs253247	ENSG00000249476.1	CTD-2587M2.1	4.19	4.02e-05	0.015	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109648265	chr5:109237120~109326369:-
SARC	cis	rs2179367	0.632	rs11155640	ENSG00000231760.4	RP11-350J20.5	4.19	4.02e-05	0.015	0.36	0.26	Dupuytren's disease;	chr6:149323648	chr6:149796151~149826294:-
SARC	cis	rs7712401	0.584	rs28373879	ENSG00000263432.2	RN7SL689P	4.19	4.02e-05	0.015	0.34	0.26	Mean platelet volume;	chr5:123036707	chr5:123022487~123022783:-
SARC	cis	rs72945132	0.825	rs2298411	ENSG00000254604.1	AP000487.6	-4.19	4.02e-05	0.015	-0.37	-0.26	Coronary artery disease;	chr11:70359940	chr11:70282367~70363368:-
SARC	cis	rs61160187	0.582	rs1479645	ENSG00000215032.2	GNL3LP1	4.19	4.02e-05	0.015	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60891935~60893577:-
SARC	cis	rs9473147	0.571	rs9463335	ENSG00000270761.1	RP11-385F7.1	-4.19	4.02e-05	0.015	-0.32	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47511400	chr6:47477243~47477572:-
SARC	cis	rs755249	0.567	rs66531516	ENSG00000182109.6	RP11-69E11.4	4.19	4.02e-05	0.015	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39522280~39546187:-
SARC	cis	rs897984	0.609	rs57576577	ENSG00000260911.2	RP11-196G11.2	4.19	4.03e-05	0.015	0.26	0.26	Dementia with Lewy bodies;	chr16:31025046	chr16:31043150~31049868:+
SARC	cis	rs2562456	0.833	rs2968078	ENSG00000268081.1	RP11-678G14.2	-4.19	4.03e-05	0.015	-0.4	-0.26	Pain;	chr19:21458942	chr19:21554640~21569237:-
SARC	cis	rs597539	0.652	rs514296	ENSG00000250508.1	RP11-757G1.6	-4.19	4.03e-05	0.015	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:68870664~68874542:+
SARC	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	4.19	4.03e-05	0.015	0.24	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
SARC	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	4.19	4.03e-05	0.015	0.29	0.26	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
SARC	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-4.19	4.03e-05	0.015	-0.4	-0.26	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
SARC	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-4.19	4.03e-05	0.015	-0.4	-0.26	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
SARC	cis	rs916888	0.61	rs199453	ENSG00000261575.2	RP11-259G18.1	4.19	4.03e-05	0.015	0.33	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46267037~46268694:+
SARC	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-4.19	4.03e-05	0.015	-0.3	-0.26	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
SARC	cis	rs4664293	0.867	rs6720304	ENSG00000226266.5	AC009961.3	-4.19	4.03e-05	0.015	-0.33	-0.26	Monocyte percentage of white cells;	chr2:159787321	chr2:159670708~159712435:-
SARC	cis	rs890448	0.796	rs6532934	ENSG00000254531.1	FLJ20021	4.19	4.04e-05	0.015	0.29	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101386461	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs6847376	ENSG00000254531.1	FLJ20021	4.19	4.04e-05	0.015	0.29	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101387340	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs6825658	ENSG00000254531.1	FLJ20021	4.19	4.04e-05	0.015	0.29	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101387944	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs2119592	ENSG00000254531.1	FLJ20021	4.19	4.04e-05	0.015	0.29	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101387981	chr4:101347780~101348883:+
SARC	cis	rs2933343	0.7	rs1683787	ENSG00000231305.3	RP11-723O4.2	-4.19	4.04e-05	0.015	-0.26	-0.26	IgG glycosylation;	chr3:128908178	chr3:128861313~128871540:-
SARC	cis	rs9739682	1	rs1373456	ENSG00000139239.7	RPL14P1	-4.19	4.04e-05	0.015	-0.24	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62127219	chr12:62965325~62965969:+
SARC	cis	rs42490	0.903	rs218902	ENSG00000251136.7	RP11-37B2.1	4.19	4.04e-05	0.015	0.3	0.26	Leprosy;	chr8:89719986	chr8:89609409~89757727:-
SARC	cis	rs801193	0.591	rs2707839	ENSG00000232559.3	GS1-124K5.12	4.18	4.05e-05	0.0151	0.3	0.26	Aortic root size;	chr7:66728097	chr7:66554588~66576923:-
SARC	cis	rs853679	0.546	rs175597	ENSG00000216901.1	AL022393.7	4.18	4.06e-05	0.0151	0.59	0.26	Depression;	chr6:27842848	chr6:28176188~28176674:+
SARC	cis	rs597539	0.69	rs635529	ENSG00000250508.1	RP11-757G1.6	-4.18	4.06e-05	0.0151	-0.32	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68870664~68874542:+
SARC	cis	rs14027	0.921	rs16893077	ENSG00000279347.1	RP11-85I17.2	-4.18	4.06e-05	0.0151	-0.23	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119740332	chr8:119838736~119840385:-
SARC	cis	rs745109	0.504	rs17027169	ENSG00000273080.1	RP11-301O19.1	4.18	4.06e-05	0.0151	0.41	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86368710	chr2:86195590~86196049:+
SARC	cis	rs783540	0.9	rs783525	ENSG00000275695.1	UBE2Q2P6	-4.18	4.06e-05	0.0151	-0.26	-0.26	Schizophrenia;	chr15:82615878	chr15:82445719~82454837:+
SARC	cis	rs2933343	0.7	rs2249514	ENSG00000231305.3	RP11-723O4.2	4.18	4.06e-05	0.0151	0.26	0.26	IgG glycosylation;	chr3:128924969	chr3:128861313~128871540:-
SARC	cis	rs2933343	0.7	rs2630257	ENSG00000231305.3	RP11-723O4.2	4.18	4.06e-05	0.0151	0.26	0.26	IgG glycosylation;	chr3:128925172	chr3:128861313~128871540:-
SARC	cis	rs3110496	1	rs3110496	ENSG00000264608.1	RP11-192H23.8	4.18	4.06e-05	0.0151	0.26	0.26	Height;	chr17:29590753	chr17:28601827~28602284:-
SARC	cis	rs160451	0.782	rs160410	ENSG00000251136.7	RP11-37B2.1	-4.18	4.06e-05	0.0151	-0.31	-0.26	Leprosy;	chr8:89636500	chr8:89609409~89757727:-
SARC	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
SARC	cis	rs11086243	0.935	rs1133029	ENSG00000276923.1	RP11-321P16.1	4.18	4.07e-05	0.0151	0.33	0.26	Nephrotic syndrome (acquired);	chr20:48135884	chr20:48073869~48074188:+
SARC	cis	rs755249	0.567	rs61783378	ENSG00000182109.6	RP11-69E11.4	4.18	4.07e-05	0.0151	0.3	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39311487	chr1:39522280~39546187:-
SARC	cis	rs4664293	0.647	rs7580539	ENSG00000226266.5	AC009961.3	-4.18	4.07e-05	0.0151	-0.31	-0.26	Monocyte percentage of white cells;	chr2:159589238	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.539	rs7580661	ENSG00000226266.5	AC009961.3	-4.18	4.07e-05	0.0151	-0.31	-0.26	Monocyte percentage of white cells;	chr2:159589326	chr2:159670708~159712435:-
SARC	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	4.18	4.07e-05	0.0151	0.25	0.26	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
SARC	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	4.18	4.07e-05	0.0151	0.32	0.26	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	4.18	4.07e-05	0.0151	0.32	0.26	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
SARC	cis	rs853679	0.506	rs1150693	ENSG00000216901.1	AL022393.7	4.18	4.07e-05	0.0151	0.36	0.26	Depression;	chr6:28206812	chr6:28176188~28176674:+
SARC	cis	rs160451	0.782	rs10956226	ENSG00000251136.7	RP11-37B2.1	4.18	4.07e-05	0.0151	0.33	0.26	Leprosy;	chr8:89687131	chr8:89609409~89757727:-
SARC	cis	rs72627509	0.951	rs6554401	ENSG00000269949.1	RP11-738E22.3	4.18	4.08e-05	0.0151	0.39	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56959170	chr4:56960927~56961373:-
SARC	cis	rs72945132	0.882	rs7940090	ENSG00000254604.1	AP000487.6	-4.18	4.08e-05	0.0151	-0.36	-0.26	Coronary artery disease;	chr11:70381718	chr11:70282367~70363368:-
SARC	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	4.18	4.09e-05	0.0152	0.32	0.26	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
SARC	cis	rs7772486	0.782	rs7747576	ENSG00000270638.1	RP3-466P17.1	-4.18	4.09e-05	0.0152	-0.22	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145735570~145737218:+
SARC	cis	rs2439831	0.867	rs2447208	ENSG00000275601.1	AC011330.13	-4.18	4.09e-05	0.0152	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43641697	chr15:43642389~43643023:-
SARC	cis	rs713477	1	rs8010013	ENSG00000258413.1	RP11-665C16.6	4.18	4.09e-05	0.0152	0.3	0.26	Pediatric bone mineral content (femoral neck);	chr14:55418110	chr14:55262767~55272075:-
SARC	cis	rs7267979	1	rs2424704	ENSG00000276952.1	RP5-965G21.6	4.18	4.1e-05	0.0152	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25284915~25285588:-
SARC	cis	rs4713118	0.662	rs149970	ENSG00000272009.1	RP1-313I6.12	-4.18	4.1e-05	0.0152	-0.32	-0.26	Parkinson's disease;	chr6:28012442	chr6:28078792~28081130:-
SARC	cis	rs4835473	0.808	rs4054643	ENSG00000251600.4	RP11-673E1.1	-4.18	4.1e-05	0.0152	-0.26	-0.26	Immature fraction of reticulocytes;	chr4:143787329	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.838	rs34819068	ENSG00000251600.4	RP11-673E1.1	-4.18	4.1e-05	0.0152	-0.26	-0.26	Immature fraction of reticulocytes;	chr4:143787330	chr4:143912331~143982454:+
SARC	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	4.18	4.1e-05	0.0152	0.23	0.26	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
SARC	cis	rs8005677	0.798	rs4982713	ENSG00000257285.4	RP11-298I3.1	4.18	4.1e-05	0.0152	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:22929609~22955562:+
SARC	cis	rs8005677	0.798	rs35615180	ENSG00000257285.4	RP11-298I3.1	4.18	4.1e-05	0.0152	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:22929609~22955562:+
SARC	cis	rs8005677	0.828	rs8016027	ENSG00000257285.4	RP11-298I3.1	4.18	4.11e-05	0.0152	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:22929609~22955562:+
SARC	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-4.18	4.11e-05	0.0152	-0.5	-0.26	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
SARC	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-4.18	4.11e-05	0.0152	-0.32	-0.26	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
SARC	cis	rs76693355	0.512	rs4938803	ENSG00000232460.4	BMPR1APS2	4.18	4.11e-05	0.0152	0.33	0.26	Intraocular pressure;	chr11:120397313	chr11:121361854~121362865:-
SARC	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-4.18	4.11e-05	0.0152	-0.47	-0.26	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
SARC	cis	rs62432291	0.614	rs452112	ENSG00000235086.1	FNDC1-IT1	-4.18	4.12e-05	0.0152	-0.45	-0.26	Joint mobility (Beighton score);	chr6:159236996	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs417719	ENSG00000235086.1	FNDC1-IT1	-4.18	4.12e-05	0.0152	-0.45	-0.26	Joint mobility (Beighton score);	chr6:159237010	chr6:159240786~159243329:+
SARC	cis	rs75920871	0.528	rs12274388	ENSG00000254851.1	RP11-109L13.1	4.18	4.12e-05	0.0153	0.35	0.26	Subjective well-being;	chr11:117075522	chr11:117135528~117138582:+
SARC	cis	rs4372836	0.729	rs6547882	ENSG00000226833.4	AC097724.3	4.18	4.12e-05	0.0153	0.23	0.26	Body mass index;	chr2:28814135	chr2:28708953~28736205:-
SARC	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-4.18	4.12e-05	0.0153	-0.5	-0.26	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
SARC	cis	rs9473147	0.516	rs10948367	ENSG00000270761.1	RP11-385F7.1	-4.18	4.12e-05	0.0153	-0.32	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47617879	chr6:47477243~47477572:-
SARC	cis	rs28498283	0.792	rs10199788	ENSG00000279873.2	LINC01126	-4.18	4.12e-05	0.0153	-0.24	-0.26	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:43119950	chr2:43227210~43228855:+
SARC	cis	rs12530	0.715	rs2294313	ENSG00000230736.2	RP1-149A16.3	-4.18	4.12e-05	0.0153	-0.31	-0.26	IgG glycosylation;	chr22:32398452	chr22:32376664~32384343:+
SARC	cis	rs9828933	0.938	rs3816157	ENSG00000280620.1	SCAANT1	4.18	4.13e-05	0.0153	0.41	0.26	Type 2 diabetes;	chr3:64013646	chr3:63911518~63911772:-
SARC	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	4.18	4.13e-05	0.0153	0.33	0.26	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
SARC	cis	rs9926296	0.508	rs1558184	ENSG00000260279.2	AC137932.5	4.18	4.13e-05	0.0153	0.25	0.26	Vitiligo;	chr16:89775966	chr16:89297508~89298317:+
SARC	cis	rs853679	1	rs853694	ENSG00000216901.1	AL022393.7	4.18	4.13e-05	0.0153	0.45	0.26	Depression;	chr6:28311323	chr6:28176188~28176674:+
SARC	cis	rs7772486	0.79	rs7753833	ENSG00000235652.6	RP11-545I5.3	4.18	4.14e-05	0.0153	0.24	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145799409~145886585:+
SARC	cis	rs7267979	0.844	rs6076343	ENSG00000276952.1	RP5-965G21.6	-4.18	4.14e-05	0.0153	-0.26	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:25284915~25285588:-
SARC	cis	rs910316	0.967	rs175479	ENSG00000279594.1	RP11-950C14.10	-4.18	4.14e-05	0.0153	-0.29	-0.26	Height;	chr14:75095168	chr14:75011269~75012851:-
SARC	cis	rs59104589	0.521	rs2240482	ENSG00000266621.1	AC104841.1	4.18	4.14e-05	0.0153	0.33	0.26	Fibrinogen levels;	chr2:241465606	chr2:241245202~241245299:-
SARC	cis	rs12049351	0.665	rs10799532	ENSG00000229367.1	HMGN2P19	4.18	4.14e-05	0.0153	0.22	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229448873	chr1:229570532~229570796:+
SARC	cis	rs2179367	0.632	rs56924465	ENSG00000231760.4	RP11-350J20.5	4.18	4.15e-05	0.0153	0.36	0.26	Dupuytren's disease;	chr6:149350270	chr6:149796151~149826294:-
SARC	cis	rs7044106	0.578	rs4837788	ENSG00000238181.2	AHCYP2	-4.18	4.15e-05	0.0154	-0.29	-0.26	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120720673~120721972:+
SARC	cis	rs11955398	0.62	rs6449512	ENSG00000215032.2	GNL3LP1	4.18	4.16e-05	0.0154	0.25	0.26	Intelligence (multi-trait analysis);	chr5:60938415	chr5:60891935~60893577:-
SARC	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	4.18	4.16e-05	0.0154	0.28	0.26	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
SARC	cis	rs862687	0.584	rs2594113	ENSG00000270562.1	RP11-154H23.3	4.18	4.16e-05	0.0154	0.25	0.26	Intelligence (multi-trait analysis);	chr3:71614097	chr3:71584943~71587409:+
SARC	cis	rs6969780	1	rs73071550	ENSG00000233429.8	HOTAIRM1	4.18	4.17e-05	0.0154	0.43	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109480	chr7:27095647~27100265:+
SARC	cis	rs6969780	1	rs6461985	ENSG00000233429.8	HOTAIRM1	4.18	4.17e-05	0.0154	0.43	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111015	chr7:27095647~27100265:+
SARC	cis	rs7267979	0.932	rs928121	ENSG00000276952.1	RP5-965G21.6	4.18	4.17e-05	0.0154	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25284915~25285588:-
SARC	cis	rs77204473	1	rs12294191	ENSG00000254851.1	RP11-109L13.1	4.18	4.17e-05	0.0154	0.58	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116889108	chr11:117135528~117138582:+
SARC	cis	rs6964833	1	rs4717906	ENSG00000184616.8	AC004166.6	4.18	4.17e-05	0.0154	0.39	0.26	Menarche (age at onset);	chr7:74671923	chr7:74906673~74913256:-
SARC	cis	rs4865169	0.623	rs6838975	ENSG00000269949.1	RP11-738E22.3	-4.18	4.18e-05	0.0154	-0.33	-0.26	Breast cancer;	chr4:56873650	chr4:56960927~56961373:-
SARC	cis	rs7772486	0.686	rs1004752	ENSG00000235652.6	RP11-545I5.3	-4.18	4.18e-05	0.0155	-0.24	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs9390347	ENSG00000235652.6	RP11-545I5.3	-4.18	4.18e-05	0.0155	-0.24	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs9390348	ENSG00000235652.6	RP11-545I5.3	-4.18	4.18e-05	0.0155	-0.24	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145799409~145886585:+
SARC	cis	rs597539	0.616	rs10896386	ENSG00000250508.1	RP11-757G1.6	-4.18	4.19e-05	0.0155	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68870664~68874542:+
SARC	cis	rs14027	0.921	rs16893140	ENSG00000279347.1	RP11-85I17.2	-4.18	4.19e-05	0.0155	-0.23	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767007	chr8:119838736~119840385:-
SARC	cis	rs1865760	0.613	rs9358894	ENSG00000272810.1	U91328.22	-4.18	4.19e-05	0.0155	-0.26	-0.26	Height;	chr6:25923087	chr6:26013241~26013757:+
SARC	cis	rs11264213	0.901	rs2791961	ENSG00000271554.1	RP4-665N4.8	4.18	4.2e-05	0.0155	0.35	0.26	Schizophrenia;	chr1:35905818	chr1:35992109~36013630:-
SARC	cis	rs10845170	1	rs10845170	ENSG00000256667.5	KLRAP1	-4.18	4.2e-05	0.0155	-0.23	-0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:10571818	chr12:10588063~10599669:-
SARC	cis	rs61160187	0.582	rs17419290	ENSG00000215032.2	GNL3LP1	-4.18	4.2e-05	0.0155	-0.27	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:60891935~60893577:-
SARC	cis	rs7267979	1	rs6107045	ENSG00000276952.1	RP5-965G21.6	4.18	4.2e-05	0.0155	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.844	rs6107027	ENSG00000125804.12	FAM182A	-4.18	4.2e-05	0.0155	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:26054655~26086917:+
SARC	cis	rs597539	0.69	rs578791	ENSG00000250508.1	RP11-757G1.6	-4.18	4.2e-05	0.0155	-0.32	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68870664~68874542:+
SARC	cis	rs1707322	1	rs10789486	ENSG00000281133.1	AL355480.3	-4.18	4.2e-05	0.0155	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45580892~45580996:-
SARC	cis	rs7772486	0.686	rs2092263	ENSG00000235652.6	RP11-545I5.3	-4.18	4.21e-05	0.0155	-0.24	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145799409~145886585:+
SARC	cis	rs2117029	0.638	rs7296288	ENSG00000258017.1	RP11-386G11.10	-4.18	4.21e-05	0.0155	-0.27	-0.26	Intelligence (multi-trait analysis);	chr12:49086185	chr12:49127782~49147869:+
SARC	cis	rs9928842	0.54	rs8051363	ENSG00000280152.1	RP11-331F4.5	4.18	4.21e-05	0.0155	0.27	0.26	Alcoholic chronic pancreatitis;	chr16:75221319	chr16:75245994~75250077:-
SARC	cis	rs11723261	0.664	rs4627799	ENSG00000211553.1	AC253576.2	-4.18	4.21e-05	0.0155	-0.32	-0.26	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:136461~136568:+
SARC	cis	rs7267979	0.816	rs404775	ENSG00000125804.12	FAM182A	-4.18	4.21e-05	0.0155	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:26054655~26086917:+
SARC	cis	rs9573567	0.541	rs2328945	ENSG00000261553.4	RP11-29G8.3	4.17	4.21e-05	0.0155	0.51	0.26	Red blood cell count;Mean corpuscular volume;	chr13:75501017	chr13:75549773~75807120:+
SARC	cis	rs9573567	0.881	rs2328946	ENSG00000261553.4	RP11-29G8.3	4.17	4.21e-05	0.0155	0.51	0.26	Red blood cell count;Mean corpuscular volume;	chr13:75501096	chr13:75549773~75807120:+
SARC	cis	rs9573567	0.881	rs2328947	ENSG00000261553.4	RP11-29G8.3	4.17	4.21e-05	0.0155	0.51	0.26	Red blood cell count;Mean corpuscular volume;	chr13:75501191	chr13:75549773~75807120:+
SARC	cis	rs9573567	0.881	rs7318786	ENSG00000261553.4	RP11-29G8.3	4.17	4.21e-05	0.0155	0.51	0.26	Red blood cell count;Mean corpuscular volume;	chr13:75501461	chr13:75549773~75807120:+
SARC	cis	rs9573567	0.881	rs6562896	ENSG00000261553.4	RP11-29G8.3	4.17	4.21e-05	0.0155	0.51	0.26	Red blood cell count;Mean corpuscular volume;	chr13:75501794	chr13:75549773~75807120:+
SARC	cis	rs9573567	0.881	rs6562897	ENSG00000261553.4	RP11-29G8.3	4.17	4.21e-05	0.0155	0.51	0.26	Red blood cell count;Mean corpuscular volume;	chr13:75502157	chr13:75549773~75807120:+
SARC	cis	rs9573567	1	rs4242961	ENSG00000261553.4	RP11-29G8.3	4.17	4.21e-05	0.0155	0.51	0.26	Red blood cell count;Mean corpuscular volume;	chr13:75503772	chr13:75549773~75807120:+
SARC	cis	rs7267979	0.932	rs6107052	ENSG00000276952.1	RP5-965G21.6	4.17	4.22e-05	0.0156	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25284915~25285588:-
SARC	cis	rs5751614	0.62	rs6003598	ENSG00000230701.2	FBXW4P1	4.17	4.22e-05	0.0156	0.33	0.26	Height;	chr22:23274529	chr22:23262767~23265005:+
SARC	cis	rs5751614	0.577	rs6003600	ENSG00000230701.2	FBXW4P1	4.17	4.22e-05	0.0156	0.33	0.26	Height;	chr22:23275893	chr22:23262767~23265005:+
SARC	cis	rs5751614	0.577	rs5759675	ENSG00000230701.2	FBXW4P1	4.17	4.22e-05	0.0156	0.33	0.26	Height;	chr22:23278154	chr22:23262767~23265005:+
SARC	cis	rs997295	1	rs35395156	ENSG00000259410.4	RP11-34F13.3	4.17	4.22e-05	0.0156	0.29	0.26	Motion sickness;	chr15:67670425	chr15:67832725~67873866:+
SARC	cis	rs997295	1	rs8035675	ENSG00000259410.4	RP11-34F13.3	4.17	4.22e-05	0.0156	0.29	0.26	Motion sickness;	chr15:67673243	chr15:67832725~67873866:+
SARC	cis	rs2404602	0.716	rs12441247	ENSG00000259422.1	RP11-593F23.1	4.17	4.22e-05	0.0156	0.29	0.26	Blood metabolite levels;	chr15:76519975	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.716	rs56351018	ENSG00000259422.1	RP11-593F23.1	4.17	4.22e-05	0.0156	0.29	0.26	Blood metabolite levels;	chr15:76532250	chr15:76174891~76181486:-
SARC	cis	rs6603134	0.502	rs10405588	ENSG00000267939.1	CTD-2325M2.1	-4.17	4.22e-05	0.0156	-0.28	-0.26	Blood protein levels;	chr19:8038663	chr19:8008729~8016025:+
SARC	cis	rs890448	0.796	rs7663913	ENSG00000254531.1	FLJ20021	4.17	4.22e-05	0.0156	0.28	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101411954	chr4:101347780~101348883:+
SARC	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-4.17	4.23e-05	0.0156	-0.33	-0.26	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
SARC	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-4.17	4.23e-05	0.0156	-0.33	-0.26	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
SARC	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-4.17	4.23e-05	0.0156	-0.29	-0.26	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
SARC	cis	rs12893668	0.543	rs1799796	ENSG00000269958.1	RP11-73M18.8	4.17	4.23e-05	0.0156	0.29	0.26	Reticulocyte count;	chr14:103699590	chr14:103696353~103697163:+
SARC	cis	rs12893668	0.514	rs3212090	ENSG00000269958.1	RP11-73M18.8	4.17	4.23e-05	0.0156	0.29	0.26	Reticulocyte count;	chr14:103702526	chr14:103696353~103697163:+
SARC	cis	rs2439831	0.85	rs3097773	ENSG00000166763.7	STRCP1	-4.17	4.23e-05	0.0156	-0.32	-0.26	Lung cancer in ever smokers;	chr15:43600874	chr15:43699488~43718184:-
SARC	cis	rs9858542	0.537	rs2304442	ENSG00000225399.4	RP11-3B7.1	4.17	4.24e-05	0.0156	0.41	0.26	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49284594	chr3:49260085~49261316:+
SARC	cis	rs910316	0.789	rs175457	ENSG00000279594.1	RP11-950C14.10	-4.17	4.24e-05	0.0156	-0.29	-0.26	Height;	chr14:75117804	chr14:75011269~75012851:-
SARC	cis	rs7267979	0.866	rs2424698	ENSG00000276952.1	RP5-965G21.6	4.17	4.24e-05	0.0156	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25284915~25285588:-
SARC	cis	rs2239557	1	rs11159067	ENSG00000259065.1	RP5-1021I20.1	-4.17	4.24e-05	0.0156	-0.31	-0.26	Common traits (Other);	chr14:74170741	chr14:73787360~73803270:+
SARC	cis	rs755249	0.567	rs41270799	ENSG00000182109.6	RP11-69E11.4	4.17	4.25e-05	0.0156	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs16826038	ENSG00000182109.6	RP11-69E11.4	4.17	4.25e-05	0.0156	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs61782157	ENSG00000182109.6	RP11-69E11.4	4.17	4.25e-05	0.0156	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs4660636	ENSG00000182109.6	RP11-69E11.4	4.17	4.25e-05	0.0156	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39522280~39546187:-
SARC	cis	rs2179367	0.543	rs9498328	ENSG00000231760.4	RP11-350J20.5	4.17	4.25e-05	0.0156	0.36	0.26	Dupuytren's disease;	chr6:149348715	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498329	ENSG00000231760.4	RP11-350J20.5	4.17	4.25e-05	0.0156	0.36	0.26	Dupuytren's disease;	chr6:149349941	chr6:149796151~149826294:-
SARC	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
SARC	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
SARC	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
SARC	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
SARC	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
SARC	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
SARC	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
SARC	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
SARC	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	4.17	4.25e-05	0.0156	0.28	0.26	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
SARC	cis	rs11886999	0.812	rs997548	ENSG00000237510.6	AC008268.2	-4.17	4.25e-05	0.0157	-0.4	-0.26	Cardiac Troponin-T levels;	chr2:96193176	chr2:95789654~95800166:+
SARC	cis	rs11886999	0.812	rs62153014	ENSG00000237510.6	AC008268.2	-4.17	4.25e-05	0.0157	-0.4	-0.26	Cardiac Troponin-T levels;	chr2:96200079	chr2:95789654~95800166:+
SARC	cis	rs11886999	0.812	rs59664047	ENSG00000237510.6	AC008268.2	-4.17	4.25e-05	0.0157	-0.4	-0.26	Cardiac Troponin-T levels;	chr2:96203553	chr2:95789654~95800166:+
SARC	cis	rs72945132	0.882	rs72949076	ENSG00000254604.1	AP000487.6	-4.17	4.25e-05	0.0157	-0.37	-0.26	Coronary artery disease;	chr11:70371589	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs72949078	ENSG00000254604.1	AP000487.6	-4.17	4.25e-05	0.0157	-0.37	-0.26	Coronary artery disease;	chr11:70371602	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs72949081	ENSG00000254604.1	AP000487.6	-4.17	4.25e-05	0.0157	-0.37	-0.26	Coronary artery disease;	chr11:70372964	chr11:70282367~70363368:-
SARC	cis	rs4835473	0.932	rs7693772	ENSG00000251600.4	RP11-673E1.1	4.17	4.25e-05	0.0157	0.25	0.26	Immature fraction of reticulocytes;	chr4:143965614	chr4:143912331~143982454:+
SARC	cis	rs61160187	0.556	rs10939881	ENSG00000272308.1	RP11-231G3.1	-4.17	4.26e-05	0.0157	-0.23	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61087146	chr5:60866457~60866935:-
SARC	cis	rs12893668	0.543	rs12147645	ENSG00000269958.1	RP11-73M18.8	4.17	4.26e-05	0.0157	0.29	0.26	Reticulocyte count;	chr14:103633871	chr14:103696353~103697163:+
SARC	cis	rs12922317	0.556	rs8062691	ENSG00000260488.1	RP11-166B2.7	-4.17	4.26e-05	0.0157	-0.29	-0.26	Schizophrenia;	chr16:11997972	chr16:11976851~11977850:-
SARC	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-4.17	4.26e-05	0.0157	-0.25	-0.26	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
SARC	cis	rs6477918	0.544	rs10981382	ENSG00000250068.1	RP11-576C12.1	-4.17	4.26e-05	0.0157	-0.28	-0.26	Obstetric antiphospholipid syndrome;	chr9:112392218	chr9:112581779~112582590:-
SARC	cis	rs897984	0.572	rs112906665	ENSG00000260911.2	RP11-196G11.2	4.17	4.26e-05	0.0157	0.26	0.26	Dementia with Lewy bodies;	chr16:31028818	chr16:31043150~31049868:+
SARC	cis	rs897984	0.609	rs12445650	ENSG00000260911.2	RP11-196G11.2	4.17	4.26e-05	0.0157	0.26	0.26	Dementia with Lewy bodies;	chr16:31033576	chr16:31043150~31049868:+
SARC	cis	rs890448	0.796	rs1549516	ENSG00000254531.1	FLJ20021	4.17	4.27e-05	0.0157	0.27	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417585	chr4:101347780~101348883:+
SARC	cis	rs9890032	1	rs28539246	ENSG00000266490.1	CTD-2349P21.9	4.17	4.27e-05	0.0157	0.23	0.26	Hip circumference adjusted for BMI;	chr17:30899612	chr17:30792372~30792833:+
SARC	cis	rs9890032	0.967	rs9897628	ENSG00000266490.1	CTD-2349P21.9	4.17	4.27e-05	0.0157	0.23	0.26	Hip circumference adjusted for BMI;	chr17:30899634	chr17:30792372~30792833:+
SARC	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	4.17	4.27e-05	0.0157	0.27	0.26	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
SARC	cis	rs367615	0.704	rs60538082	ENSG00000249476.1	CTD-2587M2.1	4.17	4.27e-05	0.0157	0.34	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109493400	chr5:109237120~109326369:-
SARC	cis	rs651386	0.506	rs12027180	ENSG00000271811.1	RP1-79C4.4	4.17	4.28e-05	0.0157	0.37	0.26	Atrial fibrillation;	chr1:170594064	chr1:170667381~170669425:+
SARC	cis	rs853679	0.55	rs1150692	ENSG00000216901.1	AL022393.7	4.17	4.28e-05	0.0157	0.36	0.26	Depression;	chr6:28206179	chr6:28176188~28176674:+
SARC	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	4.17	4.28e-05	0.0157	0.29	0.26	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
SARC	cis	rs7811142	1	rs6972167	ENSG00000078319.8	PMS2P1	-4.17	4.28e-05	0.0158	-0.38	-0.26	Platelet count;	chr7:100482390	chr7:100320992~100341908:-
SARC	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	4.17	4.28e-05	0.0158	0.35	0.26	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
SARC	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	4.17	4.28e-05	0.0158	0.35	0.26	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
SARC	cis	rs4273100	1	rs868698	ENSG00000265185.4	SNORD3B-1	4.17	4.29e-05	0.0158	0.37	0.26	Schizophrenia;	chr17:19281898	chr17:19061912~19062669:+
SARC	cis	rs595244	0.764	rs6493333	ENSG00000259705.1	RP11-227D13.1	-4.17	4.29e-05	0.0158	-0.41	-0.26	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48646849	chr15:48645951~48652016:+
SARC	cis	rs8005677	0.828	rs35085068	ENSG00000257285.4	RP11-298I3.1	4.17	4.29e-05	0.0158	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:22929609~22955562:+
SARC	cis	rs8005677	0.828	rs57822749	ENSG00000257285.4	RP11-298I3.1	4.17	4.29e-05	0.0158	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:22929609~22955562:+
SARC	cis	rs8005677	0.828	rs4981451	ENSG00000257285.4	RP11-298I3.1	4.17	4.29e-05	0.0158	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:22929609~22955562:+
SARC	cis	rs8005677	0.798	rs4536383	ENSG00000257285.4	RP11-298I3.1	4.17	4.29e-05	0.0158	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:22929609~22955562:+
SARC	cis	rs8005677	0.828	rs34584578	ENSG00000257285.4	RP11-298I3.1	4.17	4.29e-05	0.0158	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:22929609~22955562:+
SARC	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-4.17	4.29e-05	0.0158	-0.25	-0.26	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
SARC	cis	rs9894429	0.789	rs7502346	ENSG00000229848.1	RP13-766D20.2	4.17	4.29e-05	0.0158	0.26	0.26	Eye color traits;	chr17:81636715	chr17:81514047~81527776:+
SARC	cis	rs2179367	0.92	rs638407	ENSG00000216906.2	RP11-350J20.9	4.17	4.3e-05	0.0158	0.24	0.26	Dupuytren's disease;	chr6:149417214	chr6:149904243~149906418:+
SARC	cis	rs6142102	0.602	rs1054534	ENSG00000275784.1	RP5-1125A11.6	-4.17	4.3e-05	0.0158	-0.3	-0.26	Skin pigmentation;	chr20:34017521	chr20:33989480~33991818:-
SARC	cis	rs2439831	0.85	rs2957637	ENSG00000275601.1	AC011330.13	-4.17	4.3e-05	0.0158	-0.45	-0.26	Lung cancer in ever smokers;	chr15:43658920	chr15:43642389~43643023:-
SARC	cis	rs7178375	1	rs1474382	ENSG00000215302.7	CTD-3092A11.1	-4.17	4.3e-05	0.0158	-0.34	-0.26	Hypertriglyceridemia;	chr15:30922446	chr15:30470779~30507623:+
SARC	cis	rs12422267	0.623	rs11246919	ENSG00000256312.1	RP13-977J11.8	4.17	4.3e-05	0.0158	0.51	0.26	Plasma amyloid beta peptide concentrations (ABx-40);	chr12:132084948	chr12:132190213~132190997:+
SARC	cis	rs1134634	0.52	rs16892152	ENSG00000273133.1	RP11-799M12.2	-4.17	4.31e-05	0.0158	-0.36	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15559630	chr4:15563698~15564253:-
SARC	cis	rs2292342	1	rs3745734	ENSG00000232871.7	SEC1P	-4.17	4.31e-05	0.0158	-0.49	-0.26	Elevated serum carcinoembryonic antigen levels;	chr19:48631131	chr19:48638071~48682245:+
SARC	cis	rs2292342	1	rs28540190	ENSG00000232871.7	SEC1P	-4.17	4.31e-05	0.0158	-0.49	-0.26	Elevated serum carcinoembryonic antigen levels;	chr19:48631786	chr19:48638071~48682245:+
SARC	cis	rs673078	0.66	rs11068910	ENSG00000275759.1	RP11-131L12.3	-4.17	4.31e-05	0.0158	-0.34	-0.26	Glucose homeostasis traits;	chr12:118336076	chr12:118428281~118428870:+
SARC	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	4.17	4.31e-05	0.0158	0.39	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
SARC	cis	rs1707322	1	rs7539800	ENSG00000281133.1	AL355480.3	4.17	4.32e-05	0.0159	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45580892~45580996:-
SARC	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	4.17	4.32e-05	0.0159	0.49	0.26	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	4.17	4.32e-05	0.0159	0.49	0.26	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	4.17	4.32e-05	0.0159	0.49	0.26	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	4.17	4.32e-05	0.0159	0.49	0.26	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
SARC	cis	rs7267979	1	rs3002702	ENSG00000276952.1	RP5-965G21.6	4.17	4.32e-05	0.0159	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25284915~25285588:-
SARC	cis	rs783540	0.867	rs7167880	ENSG00000275695.1	UBE2Q2P6	-4.17	4.32e-05	0.0159	-0.26	-0.26	Schizophrenia;	chr15:82625685	chr15:82445719~82454837:+
SARC	cis	rs453301	0.598	rs2921383	ENSG00000253893.2	FAM85B	-4.17	4.33e-05	0.0159	-0.23	-0.26	Joint mobility (Beighton score);	chr8:9034711	chr8:8167819~8226614:-
SARC	cis	rs28386778	0.897	rs11654841	ENSG00000240280.5	TCAM1P	-4.17	4.33e-05	0.0159	-0.32	-0.26	Prudent dietary pattern;	chr17:63760899	chr17:63849292~63864379:+
SARC	cis	rs889122	0.531	rs8113425	ENSG00000267289.1	CTD-2623N2.11	-4.17	4.33e-05	0.0159	-0.25	-0.26	Menarche (age at onset);	chr19:9889630	chr19:9834079~9835013:-
SARC	cis	rs4845875	0.54	rs10864543	ENSG00000242349.4	NPPA-AS1	4.17	4.33e-05	0.0159	0.29	0.26	Midregional pro atrial natriuretic peptide levels;	chr1:11784273	chr1:11841017~11848079:+
SARC	cis	rs890448	0.796	rs6532930	ENSG00000254531.1	FLJ20021	4.17	4.33e-05	0.0159	0.28	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101383758	chr4:101347780~101348883:+
SARC	cis	rs9309473	0.519	rs2421667	ENSG00000163016.8	ALMS1P	-4.17	4.33e-05	0.0159	-0.3	-0.26	Metabolite levels;	chr2:73605332	chr2:73644919~73685576:+
SARC	cis	rs1707322	1	rs4660335	ENSG00000281133.1	AL355480.3	-4.17	4.34e-05	0.0159	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45580892~45580996:-
SARC	cis	rs1729407	0.706	rs1268354	ENSG00000254851.1	RP11-109L13.1	-4.17	4.34e-05	0.0159	-0.31	-0.26	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117135528~117138582:+
SARC	cis	rs12468226	0.689	rs60584169	ENSG00000273456.1	RP11-686O6.2	4.17	4.34e-05	0.0159	0.31	0.26	Urate levels;	chr2:202111695	chr2:202374932~202375604:-
SARC	cis	rs1823913	0.637	rs979967	ENSG00000227542.1	AC092614.2	4.17	4.34e-05	0.0159	0.3	0.26	Obesity-related traits;	chr2:191304695	chr2:191229165~191246172:-
SARC	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	4.17	4.34e-05	0.0159	0.3	0.26	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
SARC	cis	rs12893668	0.703	rs729438	ENSG00000269940.1	RP11-73M18.7	-4.17	4.34e-05	0.0159	-0.25	-0.26	Reticulocyte count;	chr14:103626452	chr14:103694560~103695170:+
SARC	cis	rs4713118	0.629	rs203889	ENSG00000216901.1	AL022393.7	4.17	4.34e-05	0.0159	0.38	0.26	Parkinson's disease;	chr6:28053997	chr6:28176188~28176674:+
SARC	cis	rs9625935	0.7	rs9625921	ENSG00000227201.2	CNN2P1	-4.17	4.34e-05	0.0159	-0.27	-0.26	Tonsillectomy;	chr22:30112286	chr22:30046276~30047193:-
SARC	cis	rs853679	0.882	rs4713139	ENSG00000272009.1	RP1-313I6.12	-4.17	4.34e-05	0.0159	-0.41	-0.26	Depression;	chr6:28124907	chr6:28078792~28081130:-
SARC	cis	rs860818	1	rs858278	ENSG00000226816.2	AC005082.12	4.17	4.34e-05	0.0159	0.71	0.26	Initial pursuit acceleration;	chr7:23212583	chr7:23206013~23208045:+
SARC	cis	rs8005677	0.77	rs56180741	ENSG00000279656.1	RP11-298I3.6	4.17	4.34e-05	0.0159	0.34	0.26	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:23023083~23024217:-
SARC	cis	rs8005677	0.828	rs3794452	ENSG00000279656.1	RP11-298I3.6	4.17	4.34e-05	0.0159	0.34	0.26	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:23023083~23024217:-
SARC	cis	rs8005677	0.828	rs4981450	ENSG00000279656.1	RP11-298I3.6	4.17	4.34e-05	0.0159	0.34	0.26	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:23023083~23024217:-
SARC	cis	rs2274273	0.648	rs58553156	ENSG00000258413.1	RP11-665C16.6	-4.17	4.34e-05	0.0159	-0.34	-0.26	Protein biomarker;	chr14:55115976	chr14:55262767~55272075:-
SARC	cis	rs5758511	0.633	rs5758690	ENSG00000227370.1	RP4-669P10.19	4.17	4.35e-05	0.0159	0.3	0.26	Birth weight;	chr22:42272289	chr22:42132543~42132998:+
SARC	cis	rs801193	0.636	rs2659895	ENSG00000232559.3	GS1-124K5.12	4.17	4.35e-05	0.0159	0.3	0.26	Aortic root size;	chr7:66731484	chr7:66554588~66576923:-
SARC	cis	rs984222	0.501	rs1361906	ENSG00000231365.4	RP11-418J17.1	-4.17	4.35e-05	0.0159	-0.27	-0.26	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118942021	chr1:119140396~119275973:+
SARC	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-4.17	4.35e-05	0.016	-0.31	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
SARC	cis	rs9309473	0.687	rs6546827	ENSG00000163016.8	ALMS1P	4.17	4.35e-05	0.016	0.31	0.26	Metabolite levels;	chr2:73379365	chr2:73644919~73685576:+
SARC	cis	rs13190036	0.901	rs4631	ENSG00000249129.1	SUDS3P1	-4.17	4.36e-05	0.016	-0.43	-0.26	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr5:177971316~177972281:+
SARC	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-4.17	4.36e-05	0.016	-0.29	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
SARC	cis	rs950776	0.684	rs61012457	ENSG00000261762.1	RP11-650L12.2	4.17	4.36e-05	0.016	0.29	0.26	Sudden cardiac arrest;	chr15:78573352	chr15:78589123~78591276:-
SARC	cis	rs253959	0.739	rs37181	ENSG00000272265.1	CTD-2287O16.4	-4.17	4.36e-05	0.016	-0.3	-0.26	Bipolar disorder and schizophrenia;	chr5:116294307	chr5:116078110~116078570:-
SARC	cis	rs9868809	0.505	rs11708786	ENSG00000225399.4	RP11-3B7.1	-4.17	4.36e-05	0.016	-0.44	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48715221	chr3:49260085~49261316:+
SARC	cis	rs2439831	0.702	rs8033995	ENSG00000275601.1	AC011330.13	-4.17	4.37e-05	0.016	-0.46	-0.26	Lung cancer in ever smokers;	chr15:43721311	chr15:43642389~43643023:-
SARC	cis	rs9868809	0.772	rs12107418	ENSG00000225399.4	RP11-3B7.1	-4.17	4.37e-05	0.016	-0.46	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48652354	chr3:49260085~49261316:+
SARC	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-4.17	4.37e-05	0.016	-0.28	-0.26	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
SARC	cis	rs6969780	0.915	rs17471520	ENSG00000233429.8	HOTAIRM1	4.17	4.37e-05	0.016	0.4	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27139171	chr7:27095647~27100265:+
SARC	cis	rs2117029	0.782	rs6580699	ENSG00000258017.1	RP11-386G11.10	4.17	4.37e-05	0.016	0.27	0.26	Intelligence (multi-trait analysis);	chr12:49085029	chr12:49127782~49147869:+
SARC	cis	rs11886999	0.723	rs62153018	ENSG00000237510.6	AC008268.2	-4.17	4.37e-05	0.016	-0.4	-0.26	Cardiac Troponin-T levels;	chr2:96210717	chr2:95789654~95800166:+
SARC	cis	rs11886999	0.812	rs7579709	ENSG00000237510.6	AC008268.2	-4.17	4.37e-05	0.016	-0.4	-0.26	Cardiac Troponin-T levels;	chr2:96215858	chr2:95789654~95800166:+
SARC	cis	rs11886999	0.723	rs62153020	ENSG00000237510.6	AC008268.2	-4.17	4.37e-05	0.016	-0.4	-0.26	Cardiac Troponin-T levels;	chr2:96216390	chr2:95789654~95800166:+
SARC	cis	rs526231	0.764	rs2569014	ENSG00000175749.11	EIF3KP1	4.17	4.37e-05	0.016	0.31	0.26	Primary biliary cholangitis;	chr5:103302398	chr5:103032376~103033031:+
SARC	cis	rs12817211	0.502	rs3741562	ENSG00000272368.2	RP4-605O3.4	-4.17	4.38e-05	0.016	-0.25	-0.26	Colorectal or endometrial cancer;	chr12:50135953	chr12:50112197~50165618:+
SARC	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	4.17	4.38e-05	0.016	0.25	0.26	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
SARC	cis	rs7267979	0.753	rs400357	ENSG00000125804.12	FAM182A	-4.17	4.38e-05	0.016	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:26054655~26086917:+
SARC	cis	rs1707322	1	rs785470	ENSG00000281133.1	AL355480.3	4.17	4.38e-05	0.016	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45580892~45580996:-
SARC	cis	rs8059260	0.542	rs80000109	ENSG00000274038.1	RP11-66H6.4	-4.17	4.39e-05	0.0161	-0.37	-0.26	Alcohol consumption over the past year;	chr16:11031457	chr16:11056556~11057034:+
SARC	cis	rs4713118	0.513	rs149972	ENSG00000272009.1	RP1-313I6.12	-4.17	4.39e-05	0.0161	-0.28	-0.26	Parkinson's disease;	chr6:28015449	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.513	rs149975	ENSG00000272009.1	RP1-313I6.12	-4.17	4.39e-05	0.0161	-0.28	-0.26	Parkinson's disease;	chr6:28018562	chr6:28078792~28081130:-
SARC	cis	rs12554020	1	rs12335532	ENSG00000227603.1	RP11-165J3.6	4.16	4.39e-05	0.0161	0.34	0.26	Schizophrenia;	chr9:93431673	chr9:93435332~93437121:-
SARC	cis	rs1707322	1	rs4660905	ENSG00000281133.1	AL355480.3	4.16	4.4e-05	0.0161	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45580892~45580996:-
SARC	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	4.16	4.4e-05	0.0161	0.28	0.26	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
SARC	cis	rs728478	0.967	rs12452950	ENSG00000266992.1	DHX40P1	4.16	4.4e-05	0.0161	0.28	0.26	QT interval;	chr17:59362992	chr17:59976009~60002384:-
SARC	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	4.16	4.4e-05	0.0161	0.25	0.26	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
SARC	cis	rs13113518	0.729	rs13120134	ENSG00000273257.1	RP11-177J6.1	4.16	4.41e-05	0.0161	0.35	0.26	Height;	chr4:55415153	chr4:55387949~55388271:+
SARC	cis	rs7267979	0.844	rs2424703	ENSG00000125804.12	FAM182A	-4.16	4.41e-05	0.0161	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:26054655~26086917:+
SARC	cis	rs2708377	0.858	rs73051630	ENSG00000247157.5	LINC01252	4.16	4.41e-05	0.0161	0.46	0.26	Bitter taste perception;	chr12:10994589	chr12:11548030~11590369:+
SARC	cis	rs2708377	0.929	rs73053768	ENSG00000247157.5	LINC01252	4.16	4.41e-05	0.0161	0.46	0.26	Bitter taste perception;	chr12:11003148	chr12:11548030~11590369:+
SARC	cis	rs897984	0.609	rs17839567	ENSG00000260911.2	RP11-196G11.2	4.16	4.41e-05	0.0161	0.26	0.26	Dementia with Lewy bodies;	chr16:31046624	chr16:31043150~31049868:+
SARC	cis	rs59104589	0.583	rs57576464	ENSG00000266621.1	AC104841.1	4.16	4.41e-05	0.0161	0.37	0.26	Fibrinogen levels;	chr2:241301282	chr2:241245202~241245299:-
SARC	cis	rs59104589	0.583	rs61689231	ENSG00000266621.1	AC104841.1	4.16	4.41e-05	0.0161	0.37	0.26	Fibrinogen levels;	chr2:241305168	chr2:241245202~241245299:-
SARC	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-4.16	4.42e-05	0.0161	-0.4	-0.26	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
SARC	cis	rs35607894	0.607	rs764625	ENSG00000259146.3	RP1-261D10.2	-4.16	4.42e-05	0.0162	-0.4	-0.26	Schizophrenia;	chr14:71993801	chr14:71292729~71321814:-
SARC	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-4.16	4.42e-05	0.0162	-0.35	-0.26	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
SARC	cis	rs6964833	0.554	rs2527366	ENSG00000184616.8	AC004166.6	-4.16	4.42e-05	0.0162	-0.36	-0.26	Menarche (age at onset);	chr7:74684615	chr7:74906673~74913256:-
SARC	cis	rs6964833	0.554	rs2527367	ENSG00000184616.8	AC004166.6	-4.16	4.42e-05	0.0162	-0.36	-0.26	Menarche (age at onset);	chr7:74684804	chr7:74906673~74913256:-
SARC	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-4.16	4.42e-05	0.0162	-0.3	-0.26	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
SARC	cis	rs494459	0.536	rs10790267	ENSG00000255422.1	AP002954.4	-4.16	4.42e-05	0.0162	-0.27	-0.26	Height;	chr11:118856460	chr11:118704607~118750263:+
SARC	cis	rs494459	0.536	rs11217067	ENSG00000255422.1	AP002954.4	-4.16	4.42e-05	0.0162	-0.27	-0.26	Height;	chr11:118856623	chr11:118704607~118750263:+
SARC	cis	rs2510897	0.675	rs4936442	ENSG00000255422.1	AP002954.4	-4.16	4.42e-05	0.0162	-0.27	-0.26	Height;	chr11:118857611	chr11:118704607~118750263:+
SARC	cis	rs9894429	0.789	rs7219915	ENSG00000229848.1	RP13-766D20.2	4.16	4.42e-05	0.0162	0.26	0.26	Eye color traits;	chr17:81624787	chr17:81514047~81527776:+
SARC	cis	rs9894429	0.752	rs6565610	ENSG00000229848.1	RP13-766D20.2	4.16	4.42e-05	0.0162	0.26	0.26	Eye color traits;	chr17:81625626	chr17:81514047~81527776:+
SARC	cis	rs9894429	0.816	rs7406040	ENSG00000229848.1	RP13-766D20.2	4.16	4.42e-05	0.0162	0.26	0.26	Eye color traits;	chr17:81630557	chr17:81514047~81527776:+
SARC	cis	rs9894429	0.789	rs6565611	ENSG00000229848.1	RP13-766D20.2	4.16	4.42e-05	0.0162	0.26	0.26	Eye color traits;	chr17:81631293	chr17:81514047~81527776:+
SARC	cis	rs9894429	0.789	rs8074989	ENSG00000229848.1	RP13-766D20.2	4.16	4.42e-05	0.0162	0.26	0.26	Eye color traits;	chr17:81631702	chr17:81514047~81527776:+
SARC	cis	rs12073837	0.5	rs2807845	ENSG00000238078.1	LINC01352	-4.16	4.43e-05	0.0162	-0.27	-0.26	F-cell distribution;	chr1:220822945	chr1:220829255~220832429:+
SARC	cis	rs12285276	0.673	rs12283175	ENSG00000205106.4	DKFZp779M0652	4.16	4.43e-05	0.0162	0.37	0.26	Visceral fat;	chr11:45781619	chr11:45771432~45772358:+
SARC	cis	rs12285276	0.75	rs7116816	ENSG00000205106.4	DKFZp779M0652	4.16	4.43e-05	0.0162	0.37	0.26	Visceral fat;	chr11:45783444	chr11:45771432~45772358:+
SARC	cis	rs12285276	0.711	rs12274152	ENSG00000205106.4	DKFZp779M0652	4.16	4.43e-05	0.0162	0.37	0.26	Visceral fat;	chr11:45786272	chr11:45771432~45772358:+
SARC	cis	rs12285276	0.75	rs4756024	ENSG00000205106.4	DKFZp779M0652	4.16	4.43e-05	0.0162	0.37	0.26	Visceral fat;	chr11:45789727	chr11:45771432~45772358:+
SARC	cis	rs72627123	0.881	rs28548133	ENSG00000259065.1	RP5-1021I20.1	4.16	4.43e-05	0.0162	0.43	0.26	Morning vs. evening chronotype;	chr14:73842451	chr14:73787360~73803270:+
SARC	cis	rs2132683	1	rs4839740	ENSG00000219755.1	RP1-199J3.5	-4.16	4.43e-05	0.0162	-0.35	-0.26	Brain structure;	chr6:99222748	chr6:99575712~99576456:+
SARC	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-4.16	4.43e-05	0.0162	-0.3	-0.26	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
SARC	cis	rs7809950	0.635	rs62483629	ENSG00000238832.1	snoU109	-4.16	4.43e-05	0.0162	-0.34	-0.26	Coronary artery disease;	chr7:107225733	chr7:107603363~107603507:+
SARC	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	4.16	4.43e-05	0.0162	0.27	0.26	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
SARC	cis	rs853679	0.882	rs3757188	ENSG00000272009.1	RP1-313I6.12	-4.16	4.43e-05	0.0162	-0.41	-0.26	Depression;	chr6:28139579	chr6:28078792~28081130:-
SARC	cis	rs853679	0.882	rs4713140	ENSG00000272009.1	RP1-313I6.12	-4.16	4.43e-05	0.0162	-0.42	-0.26	Depression;	chr6:28129415	chr6:28078792~28081130:-
SARC	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	4.16	4.44e-05	0.0162	0.28	0.26	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
SARC	cis	rs641862	1	rs641862	ENSG00000255874.2	LINC00346	4.16	4.44e-05	0.0162	0.53	0.26	Obesity-related traits;	chr13:110137885	chr13:110863987~110870251:-
SARC	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-4.16	4.44e-05	0.0162	-0.34	-0.26	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
SARC	cis	rs28386778	0.897	rs1062791	ENSG00000240280.5	TCAM1P	-4.16	4.44e-05	0.0162	-0.33	-0.26	Prudent dietary pattern;	chr17:63819127	chr17:63849292~63864379:+
SARC	cis	rs6964833	1	rs36044436	ENSG00000184616.8	AC004166.6	4.16	4.44e-05	0.0162	0.39	0.26	Menarche (age at onset);	chr7:74675495	chr7:74906673~74913256:-
SARC	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	4.16	4.44e-05	0.0162	0.41	0.26	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
SARC	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	4.16	4.44e-05	0.0162	0.41	0.26	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
SARC	cis	rs7560272	0.695	rs13022149	ENSG00000163016.8	ALMS1P	-4.16	4.44e-05	0.0162	-0.3	-0.26	Schizophrenia;	chr2:73414387	chr2:73644919~73685576:+
SARC	cis	rs2018683	0.745	rs917217	ENSG00000228421.2	AC005013.5	-4.16	4.45e-05	0.0162	-0.25	-0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935408	chr7:28957667~28959345:+
SARC	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	4.16	4.45e-05	0.0162	0.24	0.26	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
SARC	cis	rs1449572	1	rs17072467	ENSG00000275202.1	RP11-156K23.3	4.16	4.45e-05	0.0162	0.34	0.26	Multiple myeloma (IgH translocation);	chr13:48898640	chr13:48974967~48976867:-
SARC	cis	rs11088226	0.681	rs2833926	ENSG00000186842.4	LINC00846	-4.16	4.45e-05	0.0162	-0.36	-0.26	Gastritis;	chr21:32602969	chr21:32572238~32575881:-
SARC	cis	rs160451	0.782	rs160409	ENSG00000251136.7	RP11-37B2.1	4.16	4.45e-05	0.0162	0.31	0.26	Leprosy;	chr8:89636342	chr8:89609409~89757727:-
SARC	cis	rs11886999	0.812	rs72825868	ENSG00000237510.6	AC008268.2	-4.16	4.45e-05	0.0162	-0.41	-0.26	Cardiac Troponin-T levels;	chr2:96231921	chr2:95789654~95800166:+
SARC	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-4.16	4.45e-05	0.0163	-0.3	-0.26	QT interval;	chr12:29343291	chr12:29280418~29317848:-
SARC	cis	rs752590	0.566	rs6542126	ENSG00000240356.5	RP11-395L14.11	-4.16	4.45e-05	0.0163	-0.44	-0.26	Mucinous ovarian carcinoma;	chr2:113264992	chr2:113610502~113627090:-
SARC	cis	rs5769707	0.609	rs2007024	ENSG00000235111.1	RP1-29C18.8	-4.16	4.45e-05	0.0163	-0.32	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49612657~49615716:-
SARC	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	4.16	4.45e-05	0.0163	0.26	0.26	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
SARC	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	4.16	4.46e-05	0.0163	0.24	0.26	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
SARC	cis	rs7247513	1	rs2042947	ENSG00000213290.4	PGK1P2	-4.16	4.46e-05	0.0163	-0.3	-0.26	Bipolar disorder;	chr19:12582289	chr19:12559571~12561105:+
SARC	cis	rs6540731	1	rs4362041	ENSG00000229983.1	RP11-15I11.2	4.16	4.46e-05	0.0163	0.26	0.26	Intelligence (childhood);	chr1:212227127	chr1:212168207~212190259:+
SARC	cis	rs755249	0.959	rs72663520	ENSG00000182109.6	RP11-69E11.4	4.16	4.46e-05	0.0163	0.3	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39537738	chr1:39522280~39546187:-
SARC	cis	rs160451	0.782	rs2132348	ENSG00000251136.7	RP11-37B2.1	4.16	4.46e-05	0.0163	0.32	0.26	Leprosy;	chr8:89694545	chr8:89609409~89757727:-
SARC	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	4.16	4.47e-05	0.0163	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
SARC	cis	rs889398	1	rs889398	ENSG00000226232.7	RP11-419C5.2	4.16	4.47e-05	0.0163	0.25	0.26	Body mass index;	chr16:69522812	chr16:69976388~69996188:-
SARC	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	4.16	4.47e-05	0.0163	0.34	0.26	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
SARC	cis	rs28386778	0.897	rs2854214	ENSG00000240280.5	TCAM1P	4.16	4.48e-05	0.0163	0.32	0.26	Prudent dietary pattern;	chr17:63868089	chr17:63849292~63864379:+
SARC	cis	rs1823913	0.637	rs4613316	ENSG00000227542.1	AC092614.2	4.16	4.48e-05	0.0163	0.29	0.26	Obesity-related traits;	chr2:191326074	chr2:191229165~191246172:-
SARC	cis	rs6908034	0.769	rs6916589	ENSG00000228412.5	RP4-625H18.2	4.16	4.48e-05	0.0164	0.42	0.26	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19761132	chr6:19802164~19804752:-
SARC	cis	rs7267979	0.833	rs4619688	ENSG00000276952.1	RP5-965G21.6	4.16	4.48e-05	0.0164	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.903	rs6115118	ENSG00000276952.1	RP5-965G21.6	4.16	4.48e-05	0.0164	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.903	rs1118963	ENSG00000276952.1	RP5-965G21.6	4.16	4.48e-05	0.0164	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:25284915~25285588:-
SARC	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-4.16	4.49e-05	0.0164	-0.24	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	4.16	4.49e-05	0.0164	0.24	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
SARC	cis	rs2404602	0.583	rs2469542	ENSG00000259422.1	RP11-593F23.1	-4.16	4.49e-05	0.0164	-0.29	-0.26	Blood metabolite levels;	chr15:76265135	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.583	rs2456076	ENSG00000259422.1	RP11-593F23.1	-4.16	4.49e-05	0.0164	-0.29	-0.26	Blood metabolite levels;	chr15:76265212	chr15:76174891~76181486:-
SARC	cis	rs4660214	0.671	rs16826068	ENSG00000182109.6	RP11-69E11.4	4.16	4.49e-05	0.0164	0.32	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39326204	chr1:39522280~39546187:-
SARC	cis	rs10510217	0.688	rs7621478	ENSG00000214073.2	RPL21P17	4.16	4.49e-05	0.0164	0.38	0.26	Total ventricular volume;	chr3:1841274	chr3:1905651~1906125:+
SARC	cis	rs11955398	0.502	rs3101879	ENSG00000215032.2	GNL3LP1	4.16	4.49e-05	0.0164	0.28	0.26	Intelligence (multi-trait analysis);	chr5:60971048	chr5:60891935~60893577:-
SARC	cis	rs9894429	0.789	rs35887231	ENSG00000229848.1	RP13-766D20.2	4.16	4.49e-05	0.0164	0.26	0.26	Eye color traits;	chr17:81620100	chr17:81514047~81527776:+
SARC	cis	rs1707322	0.963	rs12145287	ENSG00000281133.1	AL355480.3	-4.16	4.49e-05	0.0164	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45580892~45580996:-
SARC	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-4.16	4.49e-05	0.0164	-0.32	-0.26	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
SARC	cis	rs9595908	0.931	rs9591001	ENSG00000212293.1	SNORA16	-4.16	4.5e-05	0.0164	-0.26	-0.26	Body mass index;	chr13:32468733	chr13:32420390~32420516:-
SARC	cis	rs7267979	0.966	rs2261784	ENSG00000276952.1	RP5-965G21.6	4.16	4.5e-05	0.0164	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2261785	ENSG00000276952.1	RP5-965G21.6	4.16	4.5e-05	0.0164	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25284915~25285588:-
SARC	cis	rs2540552	1	rs2540552	ENSG00000278819.1	RP5-1099C19.2	-4.16	4.5e-05	0.0164	-0.31	-0.26	IgG glycosylation;	chr7:91610982	chr7:92540268~92557877:-
SARC	cis	rs12049351	0.613	rs3738185	ENSG00000229367.1	HMGN2P19	4.16	4.51e-05	0.0164	0.23	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229499520	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs12033713	ENSG00000229367.1	HMGN2P19	4.16	4.51e-05	0.0164	0.23	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229502693	chr1:229570532~229570796:+
SARC	cis	rs2439831	0.867	rs935901	ENSG00000205771.5	CATSPER2P1	-4.16	4.51e-05	0.0164	-0.45	-0.26	Lung cancer in ever smokers;	chr15:43359058	chr15:43726918~43747094:-
SARC	cis	rs12049351	0.774	rs35464914	ENSG00000229367.1	HMGN2P19	4.16	4.51e-05	0.0164	0.23	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229554485	chr1:229570532~229570796:+
SARC	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-4.16	4.51e-05	0.0164	-0.36	-0.26	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
SARC	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-4.16	4.51e-05	0.0164	-0.36	-0.26	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
SARC	cis	rs2898681	0.519	rs73814886	ENSG00000248375.1	RP11-177B4.1	-4.16	4.51e-05	0.0164	-0.41	-0.26	Optic nerve measurement (cup area);	chr4:52867084	chr4:52720081~52720831:-
SARC	cis	rs2898681	0.519	rs7670068	ENSG00000248375.1	RP11-177B4.1	-4.16	4.51e-05	0.0164	-0.41	-0.26	Optic nerve measurement (cup area);	chr4:52867817	chr4:52720081~52720831:-
SARC	cis	rs2898681	0.561	rs58577680	ENSG00000248375.1	RP11-177B4.1	-4.16	4.51e-05	0.0164	-0.41	-0.26	Optic nerve measurement (cup area);	chr4:52868127	chr4:52720081~52720831:-
SARC	cis	rs2898681	0.561	rs7699960	ENSG00000248375.1	RP11-177B4.1	-4.16	4.51e-05	0.0164	-0.41	-0.26	Optic nerve measurement (cup area);	chr4:52869494	chr4:52720081~52720831:-
SARC	cis	rs67478160	0.643	rs2887282	ENSG00000269940.1	RP11-73M18.7	4.16	4.51e-05	0.0164	0.24	0.26	Schizophrenia;	chr14:103814397	chr14:103694560~103695170:+
SARC	cis	rs7267979	0.844	rs6083845	ENSG00000125804.12	FAM182A	4.16	4.51e-05	0.0164	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:26054655~26086917:+
SARC	cis	rs7267979	0.844	rs6083851	ENSG00000125804.12	FAM182A	4.16	4.51e-05	0.0164	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:26054655~26086917:+
SARC	cis	rs7267979	0.844	rs4423675	ENSG00000125804.12	FAM182A	4.16	4.51e-05	0.0164	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:26054655~26086917:+
SARC	cis	rs597539	0.69	rs647661	ENSG00000250508.1	RP11-757G1.6	-4.16	4.52e-05	0.0164	-0.32	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68870664~68874542:+
SARC	cis	rs34929064	0.846	rs2905342	ENSG00000225541.1	AC002480.5	4.16	4.52e-05	0.0165	0.28	0.26	Major depression and alcohol dependence;	chr7:22691425	chr7:22571607~22661792:-
SARC	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-4.16	4.52e-05	0.0165	-0.31	-0.26	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
SARC	cis	rs2708377	0.858	rs55748583	ENSG00000247157.5	LINC01252	4.16	4.52e-05	0.0165	0.48	0.26	Bitter taste perception;	chr12:10987113	chr12:11548030~11590369:+
SARC	cis	rs7520050	0.807	rs3013595	ENSG00000280836.1	AL355480.1	-4.16	4.52e-05	0.0165	-0.25	-0.26	Reticulocyte count;Red blood cell count;	chr1:45687531	chr1:45581219~45581321:-
SARC	cis	rs2307449	0.929	rs1013444	ENSG00000261441.1	RP11-217B1.2	4.16	4.52e-05	0.0165	0.33	0.26	Menopause (age at onset);	chr15:89309397	chr15:89335053~89336161:+
SARC	cis	rs4845875	0.564	rs2151655	ENSG00000242349.4	NPPA-AS1	4.16	4.52e-05	0.0165	0.3	0.26	Midregional pro atrial natriuretic peptide levels;	chr1:11785461	chr1:11841017~11848079:+
SARC	cis	rs75920871	0.528	rs11216240	ENSG00000254851.1	RP11-109L13.1	4.16	4.53e-05	0.0165	0.36	0.26	Subjective well-being;	chr11:117028532	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.528	rs11216241	ENSG00000254851.1	RP11-109L13.1	4.16	4.53e-05	0.0165	0.36	0.26	Subjective well-being;	chr11:117028533	chr11:117135528~117138582:+
SARC	cis	rs75920871	0.528	rs11600552	ENSG00000254851.1	RP11-109L13.1	4.16	4.53e-05	0.0165	0.36	0.26	Subjective well-being;	chr11:117030231	chr11:117135528~117138582:+
SARC	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	4.16	4.53e-05	0.0165	0.39	0.26	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
SARC	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	4.16	4.53e-05	0.0165	0.25	0.26	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
SARC	cis	rs1943345	0.556	rs606381	ENSG00000254551.1	RP11-727A23.7	4.16	4.53e-05	0.0165	0.28	0.26	Obesity-related traits;	chr11:83196207	chr11:83209431~83213379:-
SARC	cis	rs7520050	0.778	rs3013597	ENSG00000280836.1	AL355480.1	-4.16	4.53e-05	0.0165	-0.25	-0.26	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45581219~45581321:-
SARC	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	4.16	4.53e-05	0.0165	0.24	0.26	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
SARC	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-4.16	4.54e-05	0.0165	-0.35	-0.26	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
SARC	cis	rs763121	0.819	rs138700	ENSG00000273076.1	RP3-508I15.22	4.16	4.54e-05	0.0165	0.28	0.26	Menopause (age at onset);	chr22:38733994	chr22:38743495~38743910:+
SARC	cis	rs7726354	0.793	rs77961606	ENSG00000271828.1	CTD-2310F14.1	4.16	4.54e-05	0.0165	0.58	0.26	Breast cancer (early onset);	chr5:56744816	chr5:56927874~56929573:+
SARC	cis	rs7726354	0.793	rs78591923	ENSG00000271828.1	CTD-2310F14.1	4.16	4.54e-05	0.0165	0.58	0.26	Breast cancer (early onset);	chr5:56748680	chr5:56927874~56929573:+
SARC	cis	rs7726354	0.793	rs73131777	ENSG00000271828.1	CTD-2310F14.1	4.16	4.54e-05	0.0165	0.58	0.26	Breast cancer (early onset);	chr5:56749076	chr5:56927874~56929573:+
SARC	cis	rs7726354	0.793	rs73131786	ENSG00000271828.1	CTD-2310F14.1	4.16	4.54e-05	0.0165	0.58	0.26	Breast cancer (early onset);	chr5:56750429	chr5:56927874~56929573:+
SARC	cis	rs7726354	0.793	rs56793118	ENSG00000271828.1	CTD-2310F14.1	4.16	4.54e-05	0.0165	0.58	0.26	Breast cancer (early onset);	chr5:56750572	chr5:56927874~56929573:+
SARC	cis	rs7726354	0.793	rs79957360	ENSG00000271828.1	CTD-2310F14.1	4.16	4.54e-05	0.0165	0.58	0.26	Breast cancer (early onset);	chr5:56750634	chr5:56927874~56929573:+
SARC	cis	rs7726354	0.793	rs80146798	ENSG00000271828.1	CTD-2310F14.1	4.16	4.54e-05	0.0165	0.58	0.26	Breast cancer (early onset);	chr5:56750824	chr5:56927874~56929573:+
SARC	cis	rs7726354	0.793	rs75499227	ENSG00000271828.1	CTD-2310F14.1	4.16	4.54e-05	0.0165	0.58	0.26	Breast cancer (early onset);	chr5:56752808	chr5:56927874~56929573:+
SARC	cis	rs7726354	0.793	rs79160707	ENSG00000271828.1	CTD-2310F14.1	4.16	4.54e-05	0.0165	0.58	0.26	Breast cancer (early onset);	chr5:56757111	chr5:56927874~56929573:+
SARC	cis	rs12554020	0.892	rs6479487	ENSG00000227603.1	RP11-165J3.6	4.16	4.54e-05	0.0165	0.34	0.26	Schizophrenia;	chr9:93475091	chr9:93435332~93437121:-
SARC	cis	rs7520050	0.807	rs28647556	ENSG00000280836.1	AL355480.1	-4.16	4.54e-05	0.0165	-0.25	-0.26	Reticulocyte count;Red blood cell count;	chr1:45740727	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.807	rs4274104	ENSG00000280836.1	AL355480.1	-4.16	4.54e-05	0.0165	-0.25	-0.26	Reticulocyte count;Red blood cell count;	chr1:45752269	chr1:45581219~45581321:-
SARC	cis	rs867371	1	rs13380319	ENSG00000259429.4	UBE2Q2P2	-4.16	4.55e-05	0.0165	-0.24	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82355142~82420075:+
SARC	cis	rs2404602	0.618	rs12442266	ENSG00000259422.1	RP11-593F23.1	4.16	4.55e-05	0.0165	0.29	0.26	Blood metabolite levels;	chr15:76274801	chr15:76174891~76181486:-
SARC	cis	rs5751614	0.537	rs3788358	ENSG00000230701.2	FBXW4P1	4.16	4.55e-05	0.0165	0.33	0.26	Height;	chr22:23274168	chr22:23262767~23265005:+
SARC	cis	rs7772486	0.686	rs9497380	ENSG00000235652.6	RP11-545I5.3	4.16	4.55e-05	0.0165	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145799409~145886585:+
SARC	cis	rs4664293	0.647	rs6714917	ENSG00000226266.5	AC009961.3	-4.16	4.55e-05	0.0165	-0.3	-0.26	Monocyte percentage of white cells;	chr2:159592942	chr2:159670708~159712435:-
SARC	cis	rs2439831	1	rs2439831	ENSG00000205771.5	CATSPER2P1	-4.16	4.55e-05	0.0165	-0.41	-0.26	Lung cancer in ever smokers;	chr15:43492277	chr15:43726918~43747094:-
SARC	cis	rs4713118	0.621	rs9295755	ENSG00000280107.1	AL022393.9	4.16	4.55e-05	0.0165	0.34	0.26	Parkinson's disease;	chr6:28065396	chr6:28170845~28172521:+
SARC	cis	rs7520050	0.807	rs3013594	ENSG00000280836.1	AL355480.1	-4.16	4.55e-05	0.0166	-0.25	-0.26	Reticulocyte count;Red blood cell count;	chr1:45672328	chr1:45581219~45581321:-
SARC	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	4.16	4.55e-05	0.0166	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	4.16	4.55e-05	0.0166	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
SARC	cis	rs6603134	0.502	rs6603133	ENSG00000267939.1	CTD-2325M2.1	-4.16	4.56e-05	0.0166	-0.29	-0.26	Blood protein levels;	chr19:8038352	chr19:8008729~8016025:+
SARC	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	4.16	4.56e-05	0.0166	0.33	0.26	Height;	chr6:109382188	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	4.16	4.56e-05	0.0166	0.33	0.26	Height;	chr6:109383239	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	4.16	4.56e-05	0.0166	0.33	0.26	Height;	chr6:109383248	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	4.16	4.56e-05	0.0166	0.33	0.26	Height;	chr6:109383848	chr6:109382795~109383666:+
SARC	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-4.16	4.56e-05	0.0166	-0.29	-0.26	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
SARC	cis	rs72945132	0.825	rs57871058	ENSG00000254604.1	AP000487.6	-4.16	4.56e-05	0.0166	-0.37	-0.26	Coronary artery disease;	chr11:70346238	chr11:70282367~70363368:-
SARC	cis	rs783540	0.867	rs10906984	ENSG00000275695.1	UBE2Q2P6	4.16	4.56e-05	0.0166	0.26	0.26	Schizophrenia;	chr15:82697544	chr15:82445719~82454837:+
SARC	cis	rs7772486	0.686	rs1045820	ENSG00000235652.6	RP11-545I5.3	4.16	4.56e-05	0.0166	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.754	rs6570703	ENSG00000235652.6	RP11-545I5.3	4.16	4.56e-05	0.0166	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs6570705	ENSG00000235652.6	RP11-545I5.3	4.16	4.56e-05	0.0166	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145799409~145886585:+
SARC	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	4.16	4.57e-05	0.0166	0.25	0.26	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
SARC	cis	rs62229266	0.618	rs11088334	ENSG00000231106.2	LINC01436	4.15	4.57e-05	0.0166	0.34	0.26	Mitral valve prolapse;	chr21:36094531	chr21:36005338~36007838:+
SARC	cis	rs1707322	0.964	rs785508	ENSG00000281133.1	AL355480.3	4.15	4.58e-05	0.0166	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.964	rs785509	ENSG00000281133.1	AL355480.3	4.15	4.58e-05	0.0166	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45580892~45580996:-
SARC	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	4.15	4.58e-05	0.0166	0.41	0.26	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
SARC	cis	rs13161895	0.887	rs863231	ENSG00000250999.1	RP11-1379J22.5	-4.15	4.58e-05	0.0166	-0.42	-0.26	LDL cholesterol;	chr5:179982613	chr5:179657762~179664432:+
SARC	cis	rs13161895	0.887	rs1103811	ENSG00000250999.1	RP11-1379J22.5	-4.15	4.58e-05	0.0166	-0.42	-0.26	LDL cholesterol;	chr5:179986168	chr5:179657762~179664432:+
SARC	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-4.15	4.58e-05	0.0166	-0.25	-0.26	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
SARC	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	4.15	4.59e-05	0.0167	0.24	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	4.15	4.59e-05	0.0167	0.24	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	4.15	4.59e-05	0.0167	0.24	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
SARC	cis	rs7246657	0.943	rs2045908	ENSG00000226686.6	LINC01535	-4.15	4.59e-05	0.0167	-0.36	-0.26	Coronary artery calcification;	chr19:37488866	chr19:37251912~37265535:+
SARC	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	4.15	4.59e-05	0.0167	0.28	0.26	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
SARC	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	4.15	4.59e-05	0.0167	0.28	0.26	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
SARC	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	4.15	4.59e-05	0.0167	0.28	0.26	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	4.15	4.59e-05	0.0167	0.28	0.26	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
SARC	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	4.15	4.59e-05	0.0167	0.28	0.26	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	4.15	4.59e-05	0.0167	0.28	0.26	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
SARC	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-4.15	4.59e-05	0.0167	-0.32	-0.26	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
SARC	cis	rs495337	0.76	rs1056200	ENSG00000229222.1	KRT18P4	-4.15	4.59e-05	0.0167	-0.34	-0.26	Psoriasis;	chr20:49939711	chr20:49956745~49958032:+
SARC	cis	rs72945132	0.825	rs2277273	ENSG00000254604.1	AP000487.6	-4.15	4.6e-05	0.0167	-0.36	-0.26	Coronary artery disease;	chr11:70377886	chr11:70282367~70363368:-
SARC	cis	rs6433895	1	rs6433895	ENSG00000236153.1	AC104076.3	-4.15	4.6e-05	0.0167	-0.25	-0.26	Lymphocyte counts;	chr2:181147287	chr2:180979427~180980090:-
SARC	cis	rs6433895	1	rs56169464	ENSG00000236153.1	AC104076.3	-4.15	4.6e-05	0.0167	-0.25	-0.26	Lymphocyte counts;	chr2:181148101	chr2:180979427~180980090:-
SARC	cis	rs4835473	0.932	rs11100806	ENSG00000251600.4	RP11-673E1.1	4.15	4.6e-05	0.0167	0.27	0.26	Immature fraction of reticulocytes;	chr4:143761006	chr4:143912331~143982454:+
SARC	cis	rs9329221	0.527	rs34259385	ENSG00000261451.1	RP11-981G7.1	-4.15	4.6e-05	0.0167	-0.25	-0.26	Neuroticism;	chr8:10467946	chr8:10433672~10438312:+
SARC	cis	rs2404602	1	rs2120107	ENSG00000259422.1	RP11-593F23.1	4.15	4.6e-05	0.0167	0.3	0.26	Blood metabolite levels;	chr15:76577448	chr15:76174891~76181486:-
SARC	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	4.15	4.6e-05	0.0167	0.32	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
SARC	cis	rs755249	0.567	rs1537817	ENSG00000182109.6	RP11-69E11.4	-4.15	4.6e-05	0.0167	-0.29	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39522280~39546187:-
SARC	cis	rs9527	0.59	rs7894959	ENSG00000213061.2	PFN1P11	4.15	4.61e-05	0.0167	0.34	0.26	Arsenic metabolism;	chr10:102996425	chr10:102838011~102845473:-
SARC	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	4.15	4.61e-05	0.0167	0.24	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
SARC	cis	rs1823913	0.503	rs6434464	ENSG00000227542.1	AC092614.2	-4.15	4.61e-05	0.0167	-0.3	-0.26	Obesity-related traits;	chr2:191341120	chr2:191229165~191246172:-
SARC	cis	rs7646881	1	rs7646881	ENSG00000240207.5	RP11-379F4.4	-4.15	4.61e-05	0.0167	-0.37	-0.26	Tetralogy of Fallot;	chr3:158735490	chr3:158732263~158784070:+
SARC	cis	rs897984	0.609	rs35468353	ENSG00000260911.2	RP11-196G11.2	4.15	4.61e-05	0.0167	0.26	0.26	Dementia with Lewy bodies;	chr16:31045112	chr16:31043150~31049868:+
SARC	cis	rs897984	0.609	rs11862744	ENSG00000260911.2	RP11-196G11.2	4.15	4.61e-05	0.0167	0.26	0.26	Dementia with Lewy bodies;	chr16:31046479	chr16:31043150~31049868:+
SARC	cis	rs3761847	0.651	rs1323472	ENSG00000226752.6	PSMD5-AS1	-4.15	4.62e-05	0.0167	-0.3	-0.26	Rheumatoid arthritis;	chr9:121064057	chr9:120824828~120854385:+
SARC	cis	rs1707322	0.89	rs2297883	ENSG00000281133.1	AL355480.3	4.15	4.62e-05	0.0168	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs1707338	ENSG00000281133.1	AL355480.3	4.15	4.62e-05	0.0168	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.964	rs1707339	ENSG00000281133.1	AL355480.3	4.15	4.62e-05	0.0168	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs1768818	ENSG00000281133.1	AL355480.3	4.15	4.62e-05	0.0168	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs1768817	ENSG00000281133.1	AL355480.3	4.15	4.62e-05	0.0168	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45580892~45580996:-
SARC	cis	rs922692	0.967	rs11633351	ENSG00000261143.1	ADAMTS7P3	4.15	4.62e-05	0.0168	0.38	0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78764473	chr15:77976042~77993057:+
SARC	cis	rs7829975	0.511	rs2976902	ENSG00000253981.4	ALG1L13P	4.15	4.62e-05	0.0168	0.25	0.26	Mood instability;	chr8:8483595	chr8:8236003~8244667:-
SARC	cis	rs10911902	0.866	rs3131556	ENSG00000229739.2	RP11-295K2.3	-4.15	4.62e-05	0.0168	-0.36	-0.26	Schizophrenia;	chr1:186477195	chr1:186435161~186470291:+
SARC	cis	rs853679	0.599	rs156743	ENSG00000216901.1	AL022393.7	4.15	4.62e-05	0.0168	0.54	0.26	Depression;	chr6:27999311	chr6:28176188~28176674:+
SARC	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-4.15	4.62e-05	0.0168	-0.24	-0.26	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-4.15	4.62e-05	0.0168	-0.24	-0.26	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
SARC	cis	rs61160187	0.582	rs62372134	ENSG00000215032.2	GNL3LP1	4.15	4.62e-05	0.0168	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:60891935~60893577:-
SARC	cis	rs12468226	1	rs12472408	ENSG00000272966.1	RP11-686O6.1	4.15	4.62e-05	0.0168	0.42	0.26	Urate levels;	chr2:202413973	chr2:202336739~202337200:+
SARC	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	4.15	4.63e-05	0.0168	0.3	0.26	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
SARC	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	4.15	4.63e-05	0.0168	0.3	0.26	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
SARC	cis	rs17360053	0.859	rs35849962	ENSG00000218510.5	LINC00339	-4.15	4.63e-05	0.0168	-0.28	-0.26	Obesity-related traits;	chr1:22177156	chr1:22025188~22031223:+
SARC	cis	rs755249	0.565	rs722357	ENSG00000182109.6	RP11-69E11.4	-4.15	4.63e-05	0.0168	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39522280~39546187:-
SARC	cis	rs2072438	0.503	rs2146838	ENSG00000226752.6	PSMD5-AS1	4.15	4.63e-05	0.0168	0.31	0.26	Rheumatoid arthritis;	chr9:121114027	chr9:120824828~120854385:+
SARC	cis	rs10911902	0.602	rs1919200	ENSG00000229739.2	RP11-295K2.3	-4.15	4.63e-05	0.0168	-0.38	-0.26	Schizophrenia;	chr1:186300848	chr1:186435161~186470291:+
SARC	cis	rs4273100	0.688	rs1467028	ENSG00000265185.4	SNORD3B-1	4.15	4.63e-05	0.0168	0.31	0.26	Schizophrenia;	chr17:19271561	chr17:19061912~19062669:+
SARC	cis	rs7267979	0.833	rs6138556	ENSG00000276952.1	RP5-965G21.6	4.15	4.63e-05	0.0168	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25284915~25285588:-
SARC	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	4.15	4.63e-05	0.0168	0.34	0.26	Height;	chr6:109476101	chr6:109382795~109383666:+
SARC	cis	rs2179367	0.632	rs9498322	ENSG00000231760.4	RP11-350J20.5	4.15	4.63e-05	0.0168	0.36	0.26	Dupuytren's disease;	chr6:149335950	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498323	ENSG00000231760.4	RP11-350J20.5	4.15	4.63e-05	0.0168	0.36	0.26	Dupuytren's disease;	chr6:149336077	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498324	ENSG00000231760.4	RP11-350J20.5	4.15	4.63e-05	0.0168	0.36	0.26	Dupuytren's disease;	chr6:149338973	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs12204793	ENSG00000231760.4	RP11-350J20.5	4.15	4.63e-05	0.0168	0.36	0.26	Dupuytren's disease;	chr6:149340102	chr6:149796151~149826294:-
SARC	cis	rs7246657	0.943	rs2291004	ENSG00000226686.6	LINC01535	-4.15	4.64e-05	0.0168	-0.37	-0.26	Coronary artery calcification;	chr19:37507050	chr19:37251912~37265535:+
SARC	cis	rs61160187	0.698	rs11741754	ENSG00000272308.1	RP11-231G3.1	-4.15	4.64e-05	0.0168	-0.23	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60681231	chr5:60866457~60866935:-
SARC	cis	rs61160187	0.66	rs12517207	ENSG00000272308.1	RP11-231G3.1	-4.15	4.64e-05	0.0168	-0.23	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60697441	chr5:60866457~60866935:-
SARC	cis	rs12893668	0.572	rs1606	ENSG00000269958.1	RP11-73M18.8	4.15	4.64e-05	0.0168	0.28	0.26	Reticulocyte count;	chr14:103694944	chr14:103696353~103697163:+
SARC	cis	rs1823913	0.927	rs13013390	ENSG00000280083.1	RP11-317J9.1	-4.15	4.64e-05	0.0168	-0.29	-0.26	Obesity-related traits;	chr2:191262001	chr2:191154118~191156070:-
SARC	cis	rs7537765	1	rs55857306	ENSG00000242349.4	NPPA-AS1	-4.15	4.64e-05	0.0168	-0.37	-0.26	QRS complex (12-leadsum);	chr1:11835738	chr1:11841017~11848079:+
SARC	cis	rs7267979	0.565	rs6107059	ENSG00000125804.12	FAM182A	4.15	4.64e-05	0.0168	0.31	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:26054655~26086917:+
SARC	cis	rs9309711	0.772	rs9309714	ENSG00000225234.1	TRAPPC12-AS1	-4.15	4.65e-05	0.0168	-0.28	-0.26	Neurofibrillary tangles;	chr2:3488059	chr2:3481242~3482409:-
SARC	cis	rs72615157	0.561	rs113844570	ENSG00000242294.5	STAG3L5P	4.15	4.65e-05	0.0168	0.22	0.26	Lung function (FEV1/FVC);	chr7:100276155	chr7:100336079~100351900:+
SARC	cis	rs7512898	0.5	rs10753881	ENSG00000260088.1	RP11-92G12.3	-4.15	4.65e-05	0.0168	-0.29	-0.26	Electrocardiographic conduction measures;	chr1:200796185	chr1:200669507~200694250:+
SARC	cis	rs2235544	0.565	rs7513522	ENSG00000225183.1	RP4-758J24.4	4.15	4.65e-05	0.0168	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54000032	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.565	rs12758219	ENSG00000225183.1	RP4-758J24.4	4.15	4.65e-05	0.0168	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54000472	chr1:54089856~54090093:+
SARC	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	4.15	4.65e-05	0.0168	0.37	0.26	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
SARC	cis	rs1707322	1	rs10890382	ENSG00000281133.1	AL355480.3	-4.15	4.65e-05	0.0169	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45580892~45580996:-
SARC	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-4.15	4.65e-05	0.0169	-0.5	-0.26	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
SARC	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	4.15	4.66e-05	0.0169	0.4	0.26	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
SARC	cis	rs4820294	0.77	rs7285699	ENSG00000233360.4	Z83844.1	4.15	4.66e-05	0.0169	0.31	0.26	Fat distribution (HIV);	chr22:37670549	chr22:37641832~37658377:-
SARC	cis	rs597539	0.652	rs668576	ENSG00000250508.1	RP11-757G1.6	-4.15	4.66e-05	0.0169	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68870664~68874542:+
SARC	cis	rs59104589	0.617	rs16843642	ENSG00000266621.1	AC104841.1	4.15	4.66e-05	0.0169	0.36	0.26	Fibrinogen levels;	chr2:241411964	chr2:241245202~241245299:-
SARC	cis	rs2562456	0.833	rs8106025	ENSG00000268081.1	RP11-678G14.2	-4.15	4.67e-05	0.0169	-0.4	-0.26	Pain;	chr19:21451922	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.793	rs2650819	ENSG00000268081.1	RP11-678G14.2	-4.15	4.67e-05	0.0169	-0.4	-0.26	Pain;	chr19:21456071	chr19:21554640~21569237:-
SARC	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	4.15	4.67e-05	0.0169	0.33	0.26	Height;	chr6:109370741	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	4.15	4.67e-05	0.0169	0.33	0.26	Height;	chr6:109371524	chr6:109382795~109383666:+
SARC	cis	rs7615952	0.641	rs4422257	ENSG00000248787.1	RP11-666A20.4	-4.15	4.67e-05	0.0169	-0.38	-0.26	Blood pressure (smoking interaction);	chr3:126055520	chr3:125908005~125910272:-
SARC	cis	rs11654699	0.806	rs8067382	ENSG00000266718.1	RP11-466A19.1	-4.15	4.67e-05	0.0169	-0.23	-0.26	Neurofibrillary tangles;	chr17:32600945	chr17:32495536~32499333:+
SARC	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	4.15	4.67e-05	0.0169	0.3	0.26	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
SARC	cis	rs4713118	0.662	rs149946	ENSG00000216901.1	AL022393.7	-4.15	4.67e-05	0.0169	-0.38	-0.26	Parkinson's disease;	chr6:28002253	chr6:28176188~28176674:+
SARC	cis	rs7267979	0.966	rs910996	ENSG00000276952.1	RP5-965G21.6	4.15	4.67e-05	0.0169	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25284915~25285588:-
SARC	cis	rs13096357	0.52	rs17080319	ENSG00000225399.4	RP11-3B7.1	-4.15	4.67e-05	0.0169	-0.44	-0.26	Cognitive ability (multi-trait analysis);	chr3:48695047	chr3:49260085~49261316:+
SARC	cis	rs9868809	0.505	rs13434258	ENSG00000225399.4	RP11-3B7.1	-4.15	4.67e-05	0.0169	-0.44	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48701058	chr3:49260085~49261316:+
SARC	cis	rs9868809	0.505	rs35064573	ENSG00000225399.4	RP11-3B7.1	-4.15	4.67e-05	0.0169	-0.44	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48702847	chr3:49260085~49261316:+
SARC	cis	rs9868809	0.505	rs9877685	ENSG00000225399.4	RP11-3B7.1	-4.15	4.67e-05	0.0169	-0.44	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48711155	chr3:49260085~49261316:+
SARC	cis	rs9868809	0.505	rs13063223	ENSG00000225399.4	RP11-3B7.1	-4.15	4.67e-05	0.0169	-0.44	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48712907	chr3:49260085~49261316:+
SARC	cis	rs9890032	0.967	rs7342976	ENSG00000266490.1	CTD-2349P21.9	4.15	4.67e-05	0.0169	0.23	0.26	Hip circumference adjusted for BMI;	chr17:30863001	chr17:30792372~30792833:+
SARC	cis	rs12893668	0.703	rs34186780	ENSG00000269940.1	RP11-73M18.7	4.15	4.67e-05	0.0169	0.27	0.26	Reticulocyte count;	chr14:103561258	chr14:103694560~103695170:+
SARC	cis	rs4664293	0.647	rs357028	ENSG00000226266.5	AC009961.3	-4.15	4.67e-05	0.0169	-0.3	-0.26	Monocyte percentage of white cells;	chr2:159635331	chr2:159670708~159712435:-
SARC	cis	rs2239557	1	rs2358628	ENSG00000259065.1	RP5-1021I20.1	4.15	4.67e-05	0.0169	0.32	0.26	Common traits (Other);	chr14:74165054	chr14:73787360~73803270:+
SARC	cis	rs7772486	0.79	rs6917482	ENSG00000270638.1	RP3-466P17.1	-4.15	4.68e-05	0.0169	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs4566902	ENSG00000270638.1	RP3-466P17.1	-4.15	4.68e-05	0.0169	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs6926657	ENSG00000270638.1	RP3-466P17.1	-4.15	4.68e-05	0.0169	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145735570~145737218:+
SARC	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	4.15	4.68e-05	0.0169	0.29	0.26	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
SARC	cis	rs7267979	0.74	rs2259961	ENSG00000276952.1	RP5-965G21.6	4.15	4.68e-05	0.0169	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:25284915~25285588:-
SARC	cis	rs11123170	0.569	rs1049137	ENSG00000189223.12	PAX8-AS1	-4.15	4.68e-05	0.0169	-0.36	-0.26	Renal function-related traits (BUN);	chr2:113217533	chr2:113211522~113276581:+
SARC	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	4.15	4.69e-05	0.017	0.3	0.26	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
SARC	cis	rs12050794	0.636	rs4506844	ENSG00000260037.4	CTD-2524L6.3	4.15	4.69e-05	0.017	0.34	0.26	Metabolite levels (HVA/MHPG ratio);	chr15:72216797	chr15:71818396~71823384:+
SARC	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	4.15	4.69e-05	0.017	0.38	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
SARC	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	4.15	4.69e-05	0.017	0.33	0.26	Height;	chr6:109360263	chr6:109382795~109383666:+
SARC	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	4.15	4.69e-05	0.017	0.33	0.26	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
SARC	cis	rs758129	0.501	rs12899409	ENSG00000261441.1	RP11-217B1.2	4.15	4.69e-05	0.017	0.33	0.26	Schizophrenia;	chr15:89325025	chr15:89335053~89336161:+
SARC	cis	rs6918586	0.658	rs13161	ENSG00000272462.2	U91328.19	-4.15	4.7e-05	0.017	-0.24	-0.26	Schizophrenia;	chr6:26114474	chr6:25992662~26001775:+
SARC	cis	rs6918586	0.616	rs1056314	ENSG00000272462.2	U91328.19	4.15	4.7e-05	0.017	0.24	0.26	Schizophrenia;	chr6:26114425	chr6:25992662~26001775:+
SARC	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-4.15	4.7e-05	0.017	-0.29	-0.26	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
SARC	cis	rs2018683	0.835	rs7782264	ENSG00000228421.2	AC005013.5	-4.15	4.7e-05	0.017	-0.26	-0.26	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28939369	chr7:28957667~28959345:+
SARC	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	4.15	4.7e-05	0.017	0.24	0.26	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
SARC	cis	rs3114020	0.517	rs3114018	ENSG00000246375.2	RP11-10L7.1	4.15	4.71e-05	0.017	0.3	0.26	Gout;	chr4:88143429	chr4:88284942~88331421:+
SARC	cis	rs12049351	0.774	rs12039754	ENSG00000229367.1	HMGN2P19	4.15	4.71e-05	0.017	0.23	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229509149	chr1:229570532~229570796:+
SARC	cis	rs2439831	0.702	rs3759791	ENSG00000275601.1	AC011330.13	-4.15	4.71e-05	0.017	-0.45	-0.26	Lung cancer in ever smokers;	chr15:43798600	chr15:43642389~43643023:-
SARC	cis	rs4713118	0.629	rs203888	ENSG00000216901.1	AL022393.7	4.15	4.72e-05	0.0171	0.39	0.26	Parkinson's disease;	chr6:28053811	chr6:28176188~28176674:+
SARC	cis	rs4372836	0.729	rs7567861	ENSG00000226833.4	AC097724.3	4.15	4.72e-05	0.0171	0.22	0.26	Body mass index;	chr2:28812983	chr2:28708953~28736205:-
SARC	cis	rs8005677	0.828	rs2295682	ENSG00000279656.1	RP11-298I3.6	4.15	4.72e-05	0.0171	0.34	0.26	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:23023083~23024217:-
SARC	cis	rs1707322	1	rs6429588	ENSG00000281133.1	AL355480.3	-4.15	4.72e-05	0.0171	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs11211243	ENSG00000281133.1	AL355480.3	-4.15	4.72e-05	0.0171	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs11211244	ENSG00000281133.1	AL355480.3	-4.15	4.72e-05	0.0171	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4660903	ENSG00000281133.1	AL355480.3	-4.15	4.72e-05	0.0171	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs12097799	ENSG00000281133.1	AL355480.3	-4.15	4.72e-05	0.0171	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45580892~45580996:-
SARC	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	4.15	4.73e-05	0.0171	0.3	0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
SARC	cis	rs783540	0.846	rs783539	ENSG00000275695.1	UBE2Q2P6	-4.15	4.73e-05	0.0171	-0.26	-0.26	Schizophrenia;	chr15:82585320	chr15:82445719~82454837:+
SARC	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-4.15	4.73e-05	0.0171	-0.26	-0.26	Height;	chr2:231543307	chr2:231508426~231514339:-
SARC	cis	rs853679	1	rs6905391	ENSG00000219392.1	RP1-265C24.5	-4.15	4.73e-05	0.0171	-0.45	-0.26	Depression;	chr6:28294909	chr6:28115628~28116551:+
SARC	cis	rs7267979	0.932	rs2387891	ENSG00000276952.1	RP5-965G21.6	4.15	4.73e-05	0.0171	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25284915~25285588:-
SARC	cis	rs2071303	0.836	rs198835	ENSG00000272462.2	U91328.19	-4.15	4.74e-05	0.0171	-0.24	-0.26	Intelligence (multi-trait analysis);	chr6:26113766	chr6:25992662~26001775:+
SARC	cis	rs717662	0.507	rs619191	ENSG00000248027.1	CTD-2383M3.1	4.15	4.74e-05	0.0171	0.47	0.26	Red cell distribution width;	chr11:100851407	chr11:100684162~100687955:-
SARC	cis	rs860818	0.793	rs1728312	ENSG00000226816.2	AC005082.12	4.15	4.74e-05	0.0171	0.74	0.26	Initial pursuit acceleration;	chr7:23231308	chr7:23206013~23208045:+
SARC	cis	rs783540	0.934	rs7182403	ENSG00000275695.1	UBE2Q2P6	-4.15	4.74e-05	0.0171	-0.26	-0.26	Schizophrenia;	chr15:82628862	chr15:82445719~82454837:+
SARC	cis	rs4845875	0.557	rs4846054	ENSG00000242349.4	NPPA-AS1	4.15	4.75e-05	0.0171	0.27	0.26	Midregional pro atrial natriuretic peptide levels;	chr1:11809173	chr1:11841017~11848079:+
SARC	cis	rs7772486	0.79	rs2250387	ENSG00000270638.1	RP3-466P17.1	4.15	4.75e-05	0.0171	0.21	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145735570~145737218:+
SARC	cis	rs2404602	0.583	rs3759853	ENSG00000259422.1	RP11-593F23.1	4.15	4.75e-05	0.0171	0.29	0.26	Blood metabolite levels;	chr15:76295436	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.583	rs4381566	ENSG00000259422.1	RP11-593F23.1	4.15	4.75e-05	0.0171	0.29	0.26	Blood metabolite levels;	chr15:76296921	chr15:76174891~76181486:-
SARC	cis	rs4713118	0.662	rs9393881	ENSG00000272009.1	RP1-313I6.12	-4.15	4.75e-05	0.0171	-0.31	-0.26	Parkinson's disease;	chr6:28055973	chr6:28078792~28081130:-
SARC	cis	rs6603134	0.502	rs10405582	ENSG00000267939.1	CTD-2325M2.1	-4.15	4.75e-05	0.0171	-0.28	-0.26	Blood protein levels;	chr19:8038654	chr19:8008729~8016025:+
SARC	cis	rs6603134	0.502	rs10406511	ENSG00000267939.1	CTD-2325M2.1	-4.15	4.75e-05	0.0171	-0.28	-0.26	Blood protein levels;	chr19:8039061	chr19:8008729~8016025:+
SARC	cis	rs6603134	0.502	rs10406540	ENSG00000267939.1	CTD-2325M2.1	-4.15	4.75e-05	0.0171	-0.28	-0.26	Blood protein levels;	chr19:8039113	chr19:8008729~8016025:+
SARC	cis	rs4664293	0.769	rs1365798	ENSG00000226266.5	AC009961.3	4.15	4.75e-05	0.0171	0.32	0.26	Monocyte percentage of white cells;	chr2:159795853	chr2:159670708~159712435:-
SARC	cis	rs1707322	0.929	rs785513	ENSG00000281133.1	AL355480.3	4.15	4.75e-05	0.0171	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45580892~45580996:-
SARC	cis	rs7267979	1	rs2257985	ENSG00000276952.1	RP5-965G21.6	4.15	4.75e-05	0.0171	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2257988	ENSG00000276952.1	RP5-965G21.6	4.15	4.75e-05	0.0171	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25284915~25285588:-
SARC	cis	rs755249	0.567	rs3818806	ENSG00000182109.6	RP11-69E11.4	4.15	4.75e-05	0.0171	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39522280~39546187:-
SARC	cis	rs72634501	0.54	rs16826036	ENSG00000182109.6	RP11-69E11.4	4.15	4.75e-05	0.0171	0.29	0.26	HDL cholesterol;	chr1:39292127	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs41270803	ENSG00000182109.6	RP11-69E11.4	4.15	4.75e-05	0.0171	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs61783376	ENSG00000182109.6	RP11-69E11.4	4.15	4.75e-05	0.0171	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39522280~39546187:-
SARC	cis	rs6477918	0.598	rs7041981	ENSG00000250068.1	RP11-576C12.1	-4.15	4.75e-05	0.0171	-0.28	-0.26	Obstetric antiphospholipid syndrome;	chr9:112420435	chr9:112581779~112582590:-
SARC	cis	rs6477918	0.598	rs949904	ENSG00000250068.1	RP11-576C12.1	-4.15	4.75e-05	0.0171	-0.28	-0.26	Obstetric antiphospholipid syndrome;	chr9:112421656	chr9:112581779~112582590:-
SARC	cis	rs12554020	1	rs55766809	ENSG00000227603.1	RP11-165J3.6	4.15	4.75e-05	0.0172	0.34	0.26	Schizophrenia;	chr9:93428436	chr9:93435332~93437121:-
SARC	cis	rs2179367	0.959	rs2262617	ENSG00000216906.2	RP11-350J20.9	4.15	4.75e-05	0.0172	0.25	0.26	Dupuytren's disease;	chr6:149438590	chr6:149904243~149906418:+
SARC	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-4.15	4.76e-05	0.0172	-0.24	-0.26	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-4.15	4.76e-05	0.0172	-0.24	-0.26	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-4.15	4.76e-05	0.0172	-0.24	-0.26	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-4.15	4.76e-05	0.0172	-0.24	-0.26	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-4.15	4.76e-05	0.0172	-0.24	-0.26	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-4.15	4.76e-05	0.0172	-0.24	-0.26	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
SARC	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-4.15	4.76e-05	0.0172	-0.24	-0.26	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
SARC	cis	rs6964833	0.935	rs13238996	ENSG00000184616.8	AC004166.6	4.14	4.76e-05	0.0172	0.39	0.26	Menarche (age at onset);	chr7:74655318	chr7:74906673~74913256:-
SARC	cis	rs10986311	0.928	rs12349571	ENSG00000235204.1	RP11-121A14.2	-4.14	4.76e-05	0.0172	-0.3	-0.26	Vitiligo;	chr9:124331464	chr9:124259250~124261156:-
SARC	cis	rs10986311	0.928	rs10986319	ENSG00000235204.1	RP11-121A14.2	-4.14	4.76e-05	0.0172	-0.3	-0.26	Vitiligo;	chr9:124331544	chr9:124259250~124261156:-
SARC	cis	rs10986311	0.894	rs10986320	ENSG00000235204.1	RP11-121A14.2	-4.14	4.76e-05	0.0172	-0.3	-0.26	Vitiligo;	chr9:124331623	chr9:124259250~124261156:-
SARC	cis	rs7267979	0.903	rs6115101	ENSG00000276952.1	RP5-965G21.6	4.14	4.76e-05	0.0172	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.868	rs6107019	ENSG00000276952.1	RP5-965G21.6	4.14	4.76e-05	0.0172	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:25284915~25285588:-
SARC	cis	rs6142102	0.517	rs8119076	ENSG00000275784.1	RP5-1125A11.6	-4.14	4.76e-05	0.0172	-0.31	-0.26	Skin pigmentation;	chr20:33937909	chr20:33989480~33991818:-
SARC	cis	rs875971	1	rs11971949	ENSG00000232559.3	GS1-124K5.12	-4.14	4.77e-05	0.0172	-0.29	-0.26	Aortic root size;	chr7:66161027	chr7:66554588~66576923:-
SARC	cis	rs9894429	0.682	rs7406360	ENSG00000229848.1	RP13-766D20.2	4.14	4.77e-05	0.0172	0.26	0.26	Eye color traits;	chr17:81624519	chr17:81514047~81527776:+
SARC	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	4.14	4.77e-05	0.0172	0.3	0.26	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
SARC	cis	rs72627509	0.857	rs56155140	ENSG00000269949.1	RP11-738E22.3	4.14	4.77e-05	0.0172	0.39	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958285	chr4:56960927~56961373:-
SARC	cis	rs12554020	0.681	rs78792144	ENSG00000227603.1	RP11-165J3.6	4.14	4.77e-05	0.0172	0.46	0.26	Schizophrenia;	chr9:93583725	chr9:93435332~93437121:-
SARC	cis	rs7246657	1	rs34544865	ENSG00000226686.6	LINC01535	-4.14	4.77e-05	0.0172	-0.41	-0.26	Coronary artery calcification;	chr19:37310340	chr19:37251912~37265535:+
SARC	cis	rs9473147	0.543	rs9349407	ENSG00000270761.1	RP11-385F7.1	-4.14	4.78e-05	0.0172	-0.31	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47485642	chr6:47477243~47477572:-
SARC	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	4.14	4.78e-05	0.0172	0.3	0.26	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
SARC	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	4.14	4.78e-05	0.0172	0.25	0.26	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
SARC	cis	rs853679	1	rs853694	ENSG00000219392.1	RP1-265C24.5	-4.14	4.78e-05	0.0172	-0.45	-0.26	Depression;	chr6:28311323	chr6:28115628~28116551:+
SARC	cis	rs2439831	0.681	rs3742969	ENSG00000275601.1	AC011330.13	-4.14	4.79e-05	0.0172	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43329749	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.681	rs1549523	ENSG00000275601.1	AC011330.13	-4.14	4.79e-05	0.0172	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43331991	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.681	rs1549525	ENSG00000275601.1	AC011330.13	-4.14	4.79e-05	0.0172	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43335657	chr15:43642389~43643023:-
SARC	cis	rs1707322	0.964	rs1768802	ENSG00000281133.1	AL355480.3	4.14	4.79e-05	0.0173	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs1588663	ENSG00000281133.1	AL355480.3	4.14	4.79e-05	0.0173	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs1768801	ENSG00000281133.1	AL355480.3	4.14	4.79e-05	0.0173	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs1768800	ENSG00000281133.1	AL355480.3	4.14	4.79e-05	0.0173	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.964	rs785483	ENSG00000281133.1	AL355480.3	4.14	4.79e-05	0.0173	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45580892~45580996:-
SARC	cis	rs12980942	0.81	rs3745295	ENSG00000206674.1	RNU6-945P	-4.14	4.8e-05	0.0173	-0.39	-0.26	Coronary artery disease;	chr19:41279377	chr19:40299478~40299584:-
SARC	cis	rs7267979	0.933	rs2261109	ENSG00000276952.1	RP5-965G21.6	4.14	4.8e-05	0.0173	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2261720	ENSG00000276952.1	RP5-965G21.6	4.14	4.8e-05	0.0173	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2227890	ENSG00000276952.1	RP5-965G21.6	4.14	4.8e-05	0.0173	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.934	rs2261753	ENSG00000276952.1	RP5-965G21.6	4.14	4.8e-05	0.0173	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2261790	ENSG00000276952.1	RP5-965G21.6	4.14	4.8e-05	0.0173	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2261794	ENSG00000276952.1	RP5-965G21.6	4.14	4.8e-05	0.0173	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2145126	ENSG00000276952.1	RP5-965G21.6	4.14	4.8e-05	0.0173	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2257705	ENSG00000276952.1	RP5-965G21.6	4.14	4.8e-05	0.0173	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2227892	ENSG00000276952.1	RP5-965G21.6	4.14	4.8e-05	0.0173	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2257712	ENSG00000276952.1	RP5-965G21.6	4.14	4.8e-05	0.0173	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2257461	ENSG00000276952.1	RP5-965G21.6	4.14	4.8e-05	0.0173	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs2257809	ENSG00000276952.1	RP5-965G21.6	4.14	4.8e-05	0.0173	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25284915~25285588:-
SARC	cis	rs4664293	0.647	rs6432539	ENSG00000226266.5	AC009961.3	-4.14	4.8e-05	0.0173	-0.3	-0.26	Monocyte percentage of white cells;	chr2:159592209	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.631	rs6714899	ENSG00000226266.5	AC009961.3	-4.14	4.8e-05	0.0173	-0.3	-0.26	Monocyte percentage of white cells;	chr2:159592895	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs4665090	ENSG00000226266.5	AC009961.3	-4.14	4.8e-05	0.0173	-0.3	-0.26	Monocyte percentage of white cells;	chr2:159597396	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs4635484	ENSG00000226266.5	AC009961.3	-4.14	4.8e-05	0.0173	-0.3	-0.26	Monocyte percentage of white cells;	chr2:159597619	chr2:159670708~159712435:-
SARC	cis	rs495337	0.76	rs515686	ENSG00000229222.1	KRT18P4	-4.14	4.8e-05	0.0173	-0.35	-0.26	Psoriasis;	chr20:49899252	chr20:49956745~49958032:+
SARC	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	4.14	4.8e-05	0.0173	0.29	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
SARC	cis	rs6477918	0.544	rs6477927	ENSG00000250068.1	RP11-576C12.1	-4.14	4.8e-05	0.0173	-0.27	-0.26	Obstetric antiphospholipid syndrome;	chr9:112393041	chr9:112581779~112582590:-
SARC	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-4.14	4.8e-05	0.0173	-0.29	-0.26	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
SARC	cis	rs2029362	0.66	rs2049046	ENSG00000245573.6	BDNF-AS	4.14	4.81e-05	0.0173	0.22	0.26	Total body bone mineral density;	chr11:27702228	chr11:27506838~27698174:+
SARC	cis	rs7267979	0.816	rs376742	ENSG00000276952.1	RP5-965G21.6	4.14	4.81e-05	0.0173	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:25284915~25285588:-
SARC	cis	rs58873874	0.522	rs6875379	ENSG00000251405.2	CTB-109A12.1	4.14	4.81e-05	0.0173	0.35	0.26	Bipolar disorder (body mass index interaction);	chr5:157391295	chr5:157362615~157460078:-
SARC	cis	rs9473147	0.503	rs2171086	ENSG00000270761.1	RP11-385F7.1	-4.14	4.81e-05	0.0173	-0.32	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47622368	chr6:47477243~47477572:-
SARC	cis	rs755249	0.567	rs4660603	ENSG00000182109.6	RP11-69E11.4	-4.14	4.82e-05	0.0173	-0.29	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39522280~39546187:-
SARC	cis	rs6500602	0.702	rs9929475	ENSG00000280063.1	RP11-295D4.3	-4.14	4.82e-05	0.0174	-0.15	-0.26	Schizophrenia;	chr16:4490884	chr16:4346694~4348648:-
SARC	cis	rs7267979	0.934	rs2257464	ENSG00000276952.1	RP5-965G21.6	4.14	4.82e-05	0.0174	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25284915~25285588:-
SARC	cis	rs11955398	0.502	rs158922	ENSG00000215032.2	GNL3LP1	4.14	4.83e-05	0.0174	0.28	0.26	Intelligence (multi-trait analysis);	chr5:60945159	chr5:60891935~60893577:-
SARC	cis	rs12554020	0.892	rs10117236	ENSG00000227603.1	RP11-165J3.6	4.14	4.83e-05	0.0174	0.42	0.26	Schizophrenia;	chr9:93419731	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.892	rs7863760	ENSG00000227603.1	RP11-165J3.6	4.14	4.83e-05	0.0174	0.42	0.26	Schizophrenia;	chr9:93420287	chr9:93435332~93437121:-
SARC	cis	rs860818	1	rs10634	ENSG00000226816.2	AC005082.12	-4.14	4.83e-05	0.0174	-0.67	-0.26	Initial pursuit acceleration;	chr7:23200977	chr7:23206013~23208045:+
SARC	cis	rs4886920	0.536	rs11857840	ENSG00000214646.7	RP11-114H24.4	-4.14	4.83e-05	0.0174	-0.31	-0.26	Neuroticism;	chr15:77864411	chr15:77941442~77944582:-
SARC	cis	rs9894429	0.752	rs7502883	ENSG00000229848.1	RP13-766D20.2	4.14	4.83e-05	0.0174	0.26	0.26	Eye color traits;	chr17:81621531	chr17:81514047~81527776:+
SARC	cis	rs1707322	0.963	rs1768815	ENSG00000281133.1	AL355480.3	4.14	4.83e-05	0.0174	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45580892~45580996:-
SARC	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	4.14	4.84e-05	0.0174	0.35	0.26	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
SARC	cis	rs12702271	0.865	rs4330601	ENSG00000229628.1	AC073115.7	4.14	4.84e-05	0.0174	0.36	0.26	Male-pattern baldness;	chr7:46856729	chr7:45990905~46000898:+
SARC	cis	rs453301	0.653	rs1045529	ENSG00000253893.2	FAM85B	4.14	4.85e-05	0.0174	0.23	0.26	Joint mobility (Beighton score);	chr8:9032588	chr8:8167819~8226614:-
SARC	cis	rs763121	0.853	rs1062687	ENSG00000273076.1	RP3-508I15.22	4.14	4.85e-05	0.0174	0.28	0.26	Menopause (age at onset);	chr22:38738710	chr22:38743495~38743910:+
SARC	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	4.14	4.85e-05	0.0174	0.28	0.26	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
SARC	cis	rs2179367	0.632	rs55826712	ENSG00000231760.4	RP11-350J20.5	4.14	4.85e-05	0.0174	0.36	0.26	Dupuytren's disease;	chr6:149344716	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498325	ENSG00000231760.4	RP11-350J20.5	4.14	4.85e-05	0.0174	0.36	0.26	Dupuytren's disease;	chr6:149345993	chr6:149796151~149826294:-
SARC	cis	rs2179367	0.632	rs9498326	ENSG00000231760.4	RP11-350J20.5	4.14	4.85e-05	0.0174	0.36	0.26	Dupuytren's disease;	chr6:149346112	chr6:149796151~149826294:-
SARC	cis	rs494459	0.504	rs7929520	ENSG00000255422.1	AP002954.4	-4.14	4.85e-05	0.0174	-0.26	-0.26	Height;	chr11:118859432	chr11:118704607~118750263:+
SARC	cis	rs9902453	0.74	rs2617884	ENSG00000264538.5	SUZ12P1	-4.14	4.85e-05	0.0174	-0.19	-0.26	Coffee consumption (cups per day);	chr17:29793412	chr17:30709299~30790908:+
SARC	cis	rs783540	0.846	rs783534	ENSG00000275695.1	UBE2Q2P6	-4.14	4.86e-05	0.0175	-0.26	-0.26	Schizophrenia;	chr15:82581494	chr15:82445719~82454837:+
SARC	cis	rs4372836	0.729	rs12475612	ENSG00000226833.4	AC097724.3	-4.14	4.86e-05	0.0175	-0.22	-0.26	Body mass index;	chr2:28807140	chr2:28708953~28736205:-
SARC	cis	rs950776	0.684	rs11637635	ENSG00000261762.1	RP11-650L12.2	-4.14	4.86e-05	0.0175	-0.29	-0.26	Sudden cardiac arrest;	chr15:78584808	chr15:78589123~78591276:-
SARC	cis	rs745109	0.504	rs80252327	ENSG00000273080.1	RP11-301O19.1	4.14	4.86e-05	0.0175	0.41	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86385089	chr2:86195590~86196049:+
SARC	cis	rs7246657	0.941	rs7259618	ENSG00000226686.6	LINC01535	-4.14	4.87e-05	0.0175	-0.38	-0.26	Coronary artery calcification;	chr19:37259817	chr19:37251912~37265535:+
SARC	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-4.14	4.87e-05	0.0175	-0.48	-0.26	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-4.14	4.87e-05	0.0175	-0.48	-0.26	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-4.14	4.87e-05	0.0175	-0.48	-0.26	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-4.14	4.87e-05	0.0175	-0.48	-0.26	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
SARC	cis	rs4835473	0.932	rs6827971	ENSG00000251600.4	RP11-673E1.1	-4.14	4.87e-05	0.0175	-0.26	-0.26	Immature fraction of reticulocytes;	chr4:143822126	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs11721700	ENSG00000251600.4	RP11-673E1.1	-4.14	4.87e-05	0.0175	-0.26	-0.26	Immature fraction of reticulocytes;	chr4:143824264	chr4:143912331~143982454:+
SARC	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	4.14	4.87e-05	0.0175	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
SARC	cis	rs61160187	0.582	rs62367903	ENSG00000215032.2	GNL3LP1	4.14	4.87e-05	0.0175	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:60891935~60893577:-
SARC	cis	rs367615	0.918	rs17161895	ENSG00000249476.1	CTD-2587M2.1	4.14	4.87e-05	0.0175	0.34	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109520130	chr5:109237120~109326369:-
SARC	cis	rs10770857	0.829	rs10841879	ENSG00000164845.15	FAM86FP	-4.14	4.88e-05	0.0175	-0.32	-0.26	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8548421	chr12:8232512~8242948:-
SARC	cis	rs7267979	0.816	rs405822	ENSG00000276952.1	RP5-965G21.6	4.14	4.88e-05	0.0175	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.816	rs6138593	ENSG00000276952.1	RP5-965G21.6	4.14	4.88e-05	0.0175	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.816	rs409853	ENSG00000276952.1	RP5-965G21.6	4.14	4.88e-05	0.0175	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:25284915~25285588:-
SARC	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	4.14	4.88e-05	0.0175	0.3	0.26	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
SARC	cis	rs9868809	0.505	rs11706983	ENSG00000225399.4	RP11-3B7.1	-4.14	4.88e-05	0.0175	-0.44	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48701245	chr3:49260085~49261316:+
SARC	cis	rs7772486	0.597	rs2485631	ENSG00000270638.1	RP3-466P17.1	4.14	4.88e-05	0.0175	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.641	rs2253757	ENSG00000270638.1	RP3-466P17.1	4.14	4.88e-05	0.0175	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145735570~145737218:+
SARC	cis	rs651386	0.529	rs2206063	ENSG00000271811.1	RP1-79C4.4	-4.14	4.88e-05	0.0175	-0.36	-0.26	Atrial fibrillation;	chr1:170615956	chr1:170667381~170669425:+
SARC	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	4.14	4.89e-05	0.0175	0.33	0.26	Height;	chr6:109375548	chr6:109382795~109383666:+
SARC	cis	rs59104589	0.617	rs3755400	ENSG00000266621.1	AC104841.1	-4.14	4.89e-05	0.0176	-0.4	-0.26	Fibrinogen levels;	chr2:241440380	chr2:241245202~241245299:-
SARC	cis	rs42490	0.844	rs444078	ENSG00000251136.7	RP11-37B2.1	-4.14	4.89e-05	0.0176	-0.29	-0.26	Leprosy;	chr8:89701558	chr8:89609409~89757727:-
SARC	cis	rs42490	0.903	rs218944	ENSG00000251136.7	RP11-37B2.1	-4.14	4.89e-05	0.0176	-0.29	-0.26	Leprosy;	chr8:89701839	chr8:89609409~89757727:-
SARC	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	4.14	4.89e-05	0.0176	0.27	0.26	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
SARC	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	4.14	4.89e-05	0.0176	0.27	0.26	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
SARC	cis	rs4927850	1	rs10881563	ENSG00000242086.7	LINC00969	4.14	4.89e-05	0.0176	0.25	0.26	Pancreatic cancer;	chr3:196023354	chr3:195658062~195739964:+
SARC	cis	rs7247513	1	rs7247513	ENSG00000213290.4	PGK1P2	-4.14	4.89e-05	0.0176	-0.3	-0.26	Bipolar disorder;	chr19:12580371	chr19:12559571~12561105:+
SARC	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-4.14	4.89e-05	0.0176	-0.25	-0.26	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
SARC	cis	rs13161895	0.938	rs594202	ENSG00000250999.1	RP11-1379J22.5	-4.14	4.9e-05	0.0176	-0.46	-0.26	LDL cholesterol;	chr5:179990335	chr5:179657762~179664432:+
SARC	cis	rs8098244	0.597	rs57266464	ENSG00000265752.2	RP11-403A21.1	-4.14	4.9e-05	0.0176	-0.29	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23989811	chr18:23957754~23982556:-
SARC	cis	rs7246657	0.943	rs2126977	ENSG00000226686.6	LINC01535	4.14	4.9e-05	0.0176	0.36	0.26	Coronary artery calcification;	chr19:37504845	chr19:37251912~37265535:+
SARC	cis	rs66887589	0.616	rs10032299	ENSG00000245958.5	RP11-33B1.1	-4.14	4.9e-05	0.0176	-0.23	-0.26	Diastolic blood pressure;	chr4:119285264	chr4:119454791~119552025:+
SARC	cis	rs889122	0.68	rs1077220	ENSG00000267289.1	CTD-2623N2.11	-4.14	4.91e-05	0.0176	-0.29	-0.26	Menarche (age at onset);	chr19:9836241	chr19:9834079~9835013:-
SARC	cis	rs6988985	0.678	rs9643358	ENSG00000247317.3	RP11-273G15.2	-4.14	4.91e-05	0.0176	-0.29	-0.26	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142921722	chr8:142981738~143018437:-
SARC	cis	rs11886999	0.812	rs72825865	ENSG00000237510.6	AC008268.2	-4.14	4.91e-05	0.0176	-0.4	-0.26	Cardiac Troponin-T levels;	chr2:96224162	chr2:95789654~95800166:+
SARC	cis	rs11886999	0.812	rs12618133	ENSG00000237510.6	AC008268.2	-4.14	4.91e-05	0.0176	-0.4	-0.26	Cardiac Troponin-T levels;	chr2:96226396	chr2:95789654~95800166:+
SARC	cis	rs11886999	0.812	rs57476471	ENSG00000237510.6	AC008268.2	-4.14	4.91e-05	0.0176	-0.4	-0.26	Cardiac Troponin-T levels;	chr2:96236582	chr2:95789654~95800166:+
SARC	cis	rs11886999	0.812	rs4371393	ENSG00000237510.6	AC008268.2	-4.14	4.91e-05	0.0176	-0.4	-0.26	Cardiac Troponin-T levels;	chr2:96237622	chr2:95789654~95800166:+
SARC	cis	rs4938303	0.633	rs77835865	ENSG00000254851.1	RP11-109L13.1	4.14	4.91e-05	0.0176	0.36	0.26	Triglycerides;	chr11:116684713	chr11:117135528~117138582:+
SARC	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	4.14	4.91e-05	0.0176	0.34	0.26	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
SARC	cis	rs4148883	0.651	rs4147547	ENSG00000263923.1	RP11-571L19.7	-4.14	4.92e-05	0.0176	-0.27	-0.26	Alcohol dependence;	chr4:99206154	chr4:98928897~98994994:+
SARC	cis	rs2836974	0.604	rs2854727	ENSG00000255568.3	BRWD1-AS2	4.14	4.92e-05	0.0176	0.23	0.26	Cognitive function;	chr21:39341861	chr21:39313935~39314962:+
SARC	cis	rs2898681	0.519	rs6554057	ENSG00000248375.1	RP11-177B4.1	-4.14	4.92e-05	0.0176	-0.41	-0.26	Optic nerve measurement (cup area);	chr4:52863980	chr4:52720081~52720831:-
SARC	cis	rs2898681	0.519	rs6848200	ENSG00000248375.1	RP11-177B4.1	-4.14	4.92e-05	0.0176	-0.41	-0.26	Optic nerve measurement (cup area);	chr4:52864014	chr4:52720081~52720831:-
SARC	cis	rs4927850	1	rs6799572	ENSG00000242086.7	LINC00969	4.14	4.92e-05	0.0176	0.25	0.26	Pancreatic cancer;	chr3:196013537	chr3:195658062~195739964:+
SARC	cis	rs1707322	1	rs11211232	ENSG00000281133.1	AL355480.3	-4.14	4.92e-05	0.0176	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4524994	ENSG00000281133.1	AL355480.3	-4.14	4.92e-05	0.0176	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45580892~45580996:-
SARC	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	4.14	4.93e-05	0.0177	0.3	0.26	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
SARC	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-4.14	4.93e-05	0.0177	-0.24	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
SARC	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	4.14	4.93e-05	0.0177	0.34	0.26	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
SARC	cis	rs35740288	0.694	rs17618909	ENSG00000202081.1	RNU6-1280P	4.14	4.93e-05	0.0177	0.31	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85552231	chr15:85651522~85651628:-
SARC	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-4.14	4.93e-05	0.0177	-0.48	-0.26	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-4.14	4.93e-05	0.0177	-0.48	-0.26	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-4.14	4.93e-05	0.0177	-0.48	-0.26	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-4.14	4.93e-05	0.0177	-0.48	-0.26	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-4.14	4.93e-05	0.0177	-0.48	-0.26	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-4.14	4.93e-05	0.0177	-0.48	-0.26	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-4.14	4.93e-05	0.0177	-0.48	-0.26	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-4.14	4.93e-05	0.0177	-0.48	-0.26	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-4.14	4.93e-05	0.0177	-0.48	-0.26	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-4.14	4.93e-05	0.0177	-0.48	-0.26	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-4.14	4.93e-05	0.0177	-0.48	-0.26	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-4.14	4.93e-05	0.0177	-0.48	-0.26	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
SARC	cis	rs253959	0.739	rs153613	ENSG00000272265.1	CTD-2287O16.4	-4.14	4.93e-05	0.0177	-0.3	-0.26	Bipolar disorder and schizophrenia;	chr5:116297777	chr5:116078110~116078570:-
SARC	cis	rs72945132	0.882	rs6592554	ENSG00000254604.1	AP000487.6	-4.14	4.94e-05	0.0177	-0.36	-0.26	Coronary artery disease;	chr11:70379934	chr11:70282367~70363368:-
SARC	cis	rs2836950	0.762	rs8134638	ENSG00000255568.3	BRWD1-AS2	-4.14	4.94e-05	0.0177	-0.24	-0.26	Menarche (age at onset);	chr21:39272244	chr21:39313935~39314962:+
SARC	cis	rs367615	0.66	rs10477972	ENSG00000249476.1	CTD-2587M2.1	4.14	4.94e-05	0.0177	0.33	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109496250	chr5:109237120~109326369:-
SARC	cis	rs367615	0.66	rs4632850	ENSG00000249476.1	CTD-2587M2.1	4.14	4.94e-05	0.0177	0.33	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109497182	chr5:109237120~109326369:-
SARC	cis	rs916888	0.61	rs199438	ENSG00000261575.2	RP11-259G18.1	4.14	4.94e-05	0.0177	0.33	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46267037~46268694:+
SARC	cis	rs6163	0.508	rs11191381	ENSG00000213061.2	PFN1P11	4.14	4.94e-05	0.0177	0.34	0.26	Waist circumference;Hip circumference;	chr10:102733687	chr10:102838011~102845473:-
SARC	cis	rs12049351	0.774	rs2295624	ENSG00000229367.1	HMGN2P19	4.14	4.94e-05	0.0177	0.22	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229508410	chr1:229570532~229570796:+
SARC	cis	rs7267979	0.745	rs6132845	ENSG00000125804.12	FAM182A	-4.14	4.94e-05	0.0177	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:26054655~26086917:+
SARC	cis	rs7267979	1	rs2257808	ENSG00000276952.1	RP5-965G21.6	4.14	4.95e-05	0.0177	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25284915~25285588:-
SARC	cis	rs1499614	0.522	rs13247442	ENSG00000273142.1	RP11-458F8.4	-4.14	4.95e-05	0.0177	-0.46	-0.26	Gout;	chr7:66723871	chr7:66902857~66906297:+
SARC	cis	rs72615157	0.561	rs113401658	ENSG00000242294.5	STAG3L5P	4.14	4.95e-05	0.0177	0.22	0.26	Lung function (FEV1/FVC);	chr7:100260882	chr7:100336079~100351900:+
SARC	cis	rs7646881	1	rs7646987	ENSG00000240207.5	RP11-379F4.4	4.14	4.95e-05	0.0177	0.37	0.26	Tetralogy of Fallot;	chr3:158735653	chr3:158732263~158784070:+
SARC	cis	rs7267979	1	rs910997	ENSG00000276952.1	RP5-965G21.6	4.14	4.95e-05	0.0177	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25284915~25285588:-
SARC	cis	rs6969780	1	rs6948297	ENSG00000233429.8	HOTAIRM1	4.14	4.95e-05	0.0177	0.42	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109785	chr7:27095647~27100265:+
SARC	cis	rs11159086	0.793	rs1029703	ENSG00000270000.1	RP3-449M8.9	4.13	4.96e-05	0.0177	0.39	0.26	Advanced glycation end-product levels;	chr14:74473899	chr14:74471930~74472360:-
SARC	cis	rs755249	0.701	rs1180342	ENSG00000182109.6	RP11-69E11.4	-4.13	4.96e-05	0.0177	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39522280~39546187:-
SARC	cis	rs1880529	0.83	rs6818968	ENSG00000206820.1	RNU1-138P	-4.13	4.96e-05	0.0178	-0.26	-0.26	White matter integrity (bipolar disorder risk interaction);	chr4:113449960	chr4:113420323~113420486:+
SARC	cis	rs755249	0.567	rs16826069	ENSG00000182109.6	RP11-69E11.4	4.13	4.96e-05	0.0178	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39331383	chr1:39522280~39546187:-
SARC	cis	rs1707322	0.964	rs12067716	ENSG00000281133.1	AL355480.3	-4.13	4.96e-05	0.0178	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45580892~45580996:-
SARC	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-4.13	4.96e-05	0.0178	-0.39	-0.26	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
SARC	cis	rs28498283	0.751	rs10176003	ENSG00000279873.2	LINC01126	-4.13	4.96e-05	0.0178	-0.24	-0.26	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:43119957	chr2:43227210~43228855:+
SARC	cis	rs6570726	0.599	rs9403725	ENSG00000270638.1	RP3-466P17.1	-4.13	4.96e-05	0.0178	-0.23	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145735570~145737218:+
SARC	cis	rs2439831	0.85	rs28509275	ENSG00000275601.1	AC011330.13	-4.13	4.96e-05	0.0178	-0.47	-0.26	Lung cancer in ever smokers;	chr15:43805907	chr15:43642389~43643023:-
SARC	cis	rs28386778	0.897	rs8073515	ENSG00000240280.5	TCAM1P	-4.13	4.96e-05	0.0178	-0.32	-0.26	Prudent dietary pattern;	chr17:63717968	chr17:63849292~63864379:+
SARC	cis	rs12817211	0.502	rs12369104	ENSG00000272368.2	RP4-605O3.4	-4.13	4.97e-05	0.0178	-0.25	-0.26	Colorectal or endometrial cancer;	chr12:50141207	chr12:50112197~50165618:+
SARC	cis	rs495337	0.76	rs4810995	ENSG00000229222.1	KRT18P4	-4.13	4.97e-05	0.0178	-0.34	-0.26	Psoriasis;	chr20:49955265	chr20:49956745~49958032:+
SARC	cis	rs9902453	0.765	rs2729447	ENSG00000264538.5	SUZ12P1	-4.13	4.97e-05	0.0178	-0.18	-0.26	Coffee consumption (cups per day);	chr17:29771984	chr17:30709299~30790908:+
SARC	cis	rs4664293	0.934	rs1365800	ENSG00000226266.5	AC009961.3	-4.13	4.98e-05	0.0178	-0.32	-0.26	Monocyte percentage of white cells;	chr2:159699112	chr2:159670708~159712435:-
SARC	cis	rs8026198	0.929	rs1678986	ENSG00000260571.1	BNIP3P5	-4.13	4.98e-05	0.0178	-0.4	-0.26	Fibrinogen levels;	chr15:42228990	chr15:42313687~42314386:+
SARC	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	4.13	4.98e-05	0.0178	0.3	0.26	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
SARC	cis	rs4664293	0.802	rs7563417	ENSG00000226266.5	AC009961.3	-4.13	4.98e-05	0.0178	-0.32	-0.26	Monocyte percentage of white cells;	chr2:159727762	chr2:159670708~159712435:-
SARC	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	4.13	4.99e-05	0.0178	0.37	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
SARC	cis	rs7246657	0.943	rs7248733	ENSG00000226686.6	LINC01535	-4.13	4.99e-05	0.0178	-0.36	-0.26	Coronary artery calcification;	chr19:37505459	chr19:37251912~37265535:+
SARC	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-4.13	4.99e-05	0.0178	-0.34	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
SARC	cis	rs253959	0.705	rs153590	ENSG00000272265.1	CTD-2287O16.4	-4.13	4.99e-05	0.0178	-0.3	-0.26	Bipolar disorder and schizophrenia;	chr5:116304341	chr5:116078110~116078570:-
SARC	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	4.13	5e-05	0.0179	0.38	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
SARC	cis	rs739310	0.597	rs12166567	ENSG00000206028.1	CTA-373H7.7	-4.13	5e-05	0.0179	-0.39	-0.26	Obesity-related traits;	chr22:26666158	chr22:26667693~26672654:-
SARC	cis	rs4934494	0.768	rs11330	ENSG00000240996.1	RP11-80H5.7	4.13	5e-05	0.0179	0.27	0.26	Red blood cell count;	chr10:89634322	chr10:89694295~89697928:-
SARC	cis	rs7408868	1	rs10422818	ENSG00000266913.1	CTC-548K16.2	-4.13	5e-05	0.0179	-0.39	-0.26	Pulse pressure;	chr19:15174461	chr19:14305458~14370196:-
SARC	cis	rs61160187	0.582	rs12654306	ENSG00000215032.2	GNL3LP1	4.13	5e-05	0.0179	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60889029	chr5:60891935~60893577:-
SARC	cis	rs7267979	1	rs12428	ENSG00000276952.1	RP5-965G21.6	-4.13	5e-05	0.0179	-0.26	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.868	rs6138553	ENSG00000276952.1	RP5-965G21.6	4.13	5.01e-05	0.0179	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.903	rs6115109	ENSG00000276952.1	RP5-965G21.6	4.13	5.01e-05	0.0179	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25284915~25285588:-
SARC	cis	rs7208859	0.614	rs216412	ENSG00000276250.1	CTD-2349P21.12	4.13	5.01e-05	0.0179	0.27	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30803654~30804077:+
SARC	cis	rs875971	0.838	rs2173570	ENSG00000232559.3	GS1-124K5.12	-4.13	5.01e-05	0.0179	-0.29	-0.26	Aortic root size;	chr7:66297976	chr7:66554588~66576923:-
SARC	cis	rs801193	0.569	rs10950050	ENSG00000232559.3	GS1-124K5.12	4.13	5.01e-05	0.0179	0.31	0.26	Aortic root size;	chr7:66774601	chr7:66554588~66576923:-
SARC	cis	rs9868809	0.542	rs9873726	ENSG00000225399.4	RP11-3B7.1	-4.13	5.01e-05	0.0179	-0.46	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48674934	chr3:49260085~49261316:+
SARC	cis	rs61160187	0.582	rs1526896	ENSG00000272308.1	RP11-231G3.1	-4.13	5.01e-05	0.0179	-0.23	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61063883	chr5:60866457~60866935:-
SARC	cis	rs1880529	0.864	rs13111762	ENSG00000206820.1	RNU1-138P	-4.13	5.01e-05	0.0179	-0.25	-0.26	White matter integrity (bipolar disorder risk interaction);	chr4:113447474	chr4:113420323~113420486:+
SARC	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	4.13	5.01e-05	0.0179	0.35	0.26	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
SARC	cis	rs910316	1	rs175425	ENSG00000279594.1	RP11-950C14.10	-4.13	5.02e-05	0.0179	-0.29	-0.26	Height;	chr14:75159428	chr14:75011269~75012851:-
SARC	cis	rs910316	0.935	rs175422	ENSG00000279594.1	RP11-950C14.10	-4.13	5.02e-05	0.0179	-0.29	-0.26	Height;	chr14:75160616	chr14:75011269~75012851:-
SARC	cis	rs910316	0.967	rs35446981	ENSG00000279594.1	RP11-950C14.10	-4.13	5.02e-05	0.0179	-0.29	-0.26	Height;	chr14:75170648	chr14:75011269~75012851:-
SARC	cis	rs7829975	0.711	rs1039916	ENSG00000253893.2	FAM85B	-4.13	5.02e-05	0.0179	-0.23	-0.26	Mood instability;	chr8:8828344	chr8:8167819~8226614:-
SARC	cis	rs7216064	0.589	rs7213585	ENSG00000237854.3	LINC00674	4.13	5.02e-05	0.0179	0.3	0.26	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68066200	chr17:68101908~68115518:+
SARC	cis	rs9926296	0.605	rs12599180	ENSG00000260279.2	AC137932.5	-4.13	5.02e-05	0.0179	-0.27	-0.26	Vitiligo;	chr16:89772898	chr16:89297508~89298317:+
SARC	cis	rs42490	0.903	rs184302	ENSG00000251136.7	RP11-37B2.1	-4.13	5.02e-05	0.0179	-0.29	-0.26	Leprosy;	chr8:89704396	chr8:89609409~89757727:-
SARC	cis	rs42490	0.934	rs218946	ENSG00000251136.7	RP11-37B2.1	-4.13	5.02e-05	0.0179	-0.29	-0.26	Leprosy;	chr8:89704478	chr8:89609409~89757727:-
SARC	cis	rs11064768	0.633	rs11064779	ENSG00000255857.4	PXN-AS1	-4.13	5.02e-05	0.0179	-0.39	-0.26	Schizophrenia;	chr12:119404889	chr12:120201291~120213138:+
SARC	cis	rs11064768	0.633	rs7308840	ENSG00000255857.4	PXN-AS1	-4.13	5.02e-05	0.0179	-0.39	-0.26	Schizophrenia;	chr12:119405629	chr12:120201291~120213138:+
SARC	cis	rs11064768	0.633	rs7959781	ENSG00000255857.4	PXN-AS1	-4.13	5.02e-05	0.0179	-0.39	-0.26	Schizophrenia;	chr12:119406253	chr12:120201291~120213138:+
SARC	cis	rs11064768	0.633	rs7980254	ENSG00000255857.4	PXN-AS1	-4.13	5.02e-05	0.0179	-0.39	-0.26	Schizophrenia;	chr12:119406318	chr12:120201291~120213138:+
SARC	cis	rs1707322	1	rs785480	ENSG00000281133.1	AL355480.3	-4.13	5.02e-05	0.0179	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45580892~45580996:-
SARC	cis	rs17508449	1	rs17508449	ENSG00000232450.1	RP4-730K3.3	-4.13	5.02e-05	0.0179	-0.33	-0.26	Leprosy;	chr1:113542523	chr1:113698884~113699631:-
SARC	cis	rs7246657	0.891	rs7253114	ENSG00000226686.6	LINC01535	-4.13	5.03e-05	0.018	-0.36	-0.26	Coronary artery calcification;	chr19:37497823	chr19:37251912~37265535:+
SARC	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-4.13	5.04e-05	0.018	-0.28	-0.26	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
SARC	cis	rs11159086	0.793	rs1029702	ENSG00000270000.1	RP3-449M8.9	4.13	5.04e-05	0.018	0.39	0.26	Advanced glycation end-product levels;	chr14:74473909	chr14:74471930~74472360:-
SARC	cis	rs1707322	1	rs4539075	ENSG00000281133.1	AL355480.3	-4.13	5.04e-05	0.018	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs34444543	ENSG00000281133.1	AL355480.3	-4.13	5.04e-05	0.018	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs11211219	ENSG00000281133.1	AL355480.3	-4.13	5.04e-05	0.018	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs11211222	ENSG00000281133.1	AL355480.3	-4.13	5.04e-05	0.018	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.928	rs7527244	ENSG00000281133.1	AL355480.3	-4.13	5.04e-05	0.018	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45580892~45580996:-
SARC	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-4.13	5.04e-05	0.018	-0.35	-0.26	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
SARC	cis	rs7208859	0.673	rs216410	ENSG00000276250.1	CTD-2349P21.12	4.13	5.04e-05	0.018	0.29	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30803654~30804077:+
SARC	cis	rs6763768	0.962	rs3774414	ENSG00000280417.1	RP11-5O17.1	4.13	5.04e-05	0.018	0.29	0.26	Bacterial meningitis;	chr3:53498728	chr3:53046166~53048122:+
SARC	cis	rs7267979	0.816	rs422148	ENSG00000276952.1	RP5-965G21.6	4.13	5.04e-05	0.018	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:25284915~25285588:-
SARC	cis	rs4372836	0.681	rs6419696	ENSG00000226833.4	AC097724.3	4.13	5.05e-05	0.018	0.22	0.26	Body mass index;	chr2:28787473	chr2:28708953~28736205:-
SARC	cis	rs755249	0.567	rs4660543	ENSG00000182109.6	RP11-69E11.4	4.13	5.05e-05	0.018	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39522280~39546187:-
SARC	cis	rs324126	0.752	rs1054612	ENSG00000269834.4	ZNF528-AS1	-4.13	5.06e-05	0.018	-0.29	-0.26	Colonoscopy-negative controls vs population controls;	chr19:52366799	chr19:52388842~52397766:-
SARC	cis	rs853679	0.824	rs34712084	ENSG00000272009.1	RP1-313I6.12	-4.13	5.06e-05	0.018	-0.42	-0.26	Depression;	chr6:28076050	chr6:28078792~28081130:-
SARC	cis	rs853679	0.824	rs1321505	ENSG00000272009.1	RP1-313I6.12	-4.13	5.06e-05	0.018	-0.42	-0.26	Depression;	chr6:28085045	chr6:28078792~28081130:-
SARC	cis	rs76693355	0.512	rs11217874	ENSG00000232460.4	BMPR1APS2	4.13	5.06e-05	0.0181	0.33	0.26	Intraocular pressure;	chr11:120454839	chr11:121361854~121362865:-
SARC	cis	rs76693355	0.512	rs11217875	ENSG00000232460.4	BMPR1APS2	4.13	5.06e-05	0.0181	0.33	0.26	Intraocular pressure;	chr11:120454850	chr11:121361854~121362865:-
SARC	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	4.13	5.06e-05	0.0181	0.38	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	4.13	5.06e-05	0.0181	0.38	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
SARC	cis	rs853679	0.55	rs1150689	ENSG00000272009.1	RP1-313I6.12	-4.13	5.07e-05	0.0181	-0.28	-0.26	Depression;	chr6:28197321	chr6:28078792~28081130:-
SARC	cis	rs853679	0.55	rs1225599	ENSG00000272009.1	RP1-313I6.12	-4.13	5.07e-05	0.0181	-0.28	-0.26	Depression;	chr6:28197412	chr6:28078792~28081130:-
SARC	cis	rs853679	0.574	rs1233705	ENSG00000272009.1	RP1-313I6.12	-4.13	5.07e-05	0.0181	-0.28	-0.26	Depression;	chr6:28198669	chr6:28078792~28081130:-
SARC	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-4.13	5.07e-05	0.0181	-0.28	-0.26	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
SARC	cis	rs12980942	0.872	rs3752705	ENSG00000206674.1	RNU6-945P	-4.13	5.07e-05	0.0181	-0.38	-0.26	Coronary artery disease;	chr19:41292206	chr19:40299478~40299584:-
SARC	cis	rs9283706	0.689	rs12517976	ENSG00000229666.1	MAST4-AS1	-4.13	5.07e-05	0.0181	-0.34	-0.26	Coronary artery disease;	chr5:67025751	chr5:67001383~67003953:-
SARC	cis	rs1707322	1	rs785469	ENSG00000281133.1	AL355480.3	4.13	5.08e-05	0.0181	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs785468	ENSG00000281133.1	AL355480.3	4.13	5.08e-05	0.0181	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45580892~45580996:-
SARC	cis	rs7520050	0.807	rs6656279	ENSG00000280836.1	AL355480.1	-4.13	5.08e-05	0.0181	-0.24	-0.26	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.807	rs6671802	ENSG00000280836.1	AL355480.1	-4.13	5.08e-05	0.0181	-0.24	-0.26	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45581219~45581321:-
SARC	cis	rs597539	0.652	rs553875	ENSG00000250508.1	RP11-757G1.6	-4.13	5.08e-05	0.0181	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68870664~68874542:+
SARC	cis	rs11955398	0.502	rs169700	ENSG00000215032.2	GNL3LP1	4.13	5.08e-05	0.0181	0.28	0.26	Intelligence (multi-trait analysis);	chr5:60969281	chr5:60891935~60893577:-
SARC	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	4.13	5.09e-05	0.0181	0.33	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
SARC	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-4.13	5.09e-05	0.0181	-0.24	-0.26	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
SARC	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-4.13	5.09e-05	0.0181	-0.28	-0.26	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
SARC	cis	rs7267979	1	rs2424700	ENSG00000276952.1	RP5-965G21.6	4.13	5.09e-05	0.0182	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25284915~25285588:-
SARC	cis	rs1707322	1	rs946527	ENSG00000281133.1	AL355480.3	-4.13	5.1e-05	0.0182	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45580892~45580996:-
SARC	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-4.13	5.1e-05	0.0182	-0.27	-0.26	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
SARC	cis	rs9473147	0.516	rs9349413	ENSG00000270761.1	RP11-385F7.1	-4.13	5.1e-05	0.0182	-0.32	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47543755	chr6:47477243~47477572:-
SARC	cis	rs6142102	0.602	rs11696338	ENSG00000275784.1	RP5-1125A11.6	-4.13	5.1e-05	0.0182	-0.31	-0.26	Skin pigmentation;	chr20:34099805	chr20:33989480~33991818:-
SARC	cis	rs4664293	0.647	rs7576644	ENSG00000226266.5	AC009961.3	-4.13	5.1e-05	0.0182	-0.3	-0.26	Monocyte percentage of white cells;	chr2:159584947	chr2:159670708~159712435:-
SARC	cis	rs7267979	0.545	rs6050426	ENSG00000276952.1	RP5-965G21.6	4.13	5.11e-05	0.0182	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25197629	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.789	rs1983974	ENSG00000274414.1	RP5-965G21.4	4.13	5.11e-05	0.0182	0.27	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:25239007~25245229:-
SARC	cis	rs4664293	1	rs10204535	ENSG00000226266.5	AC009961.3	-4.13	5.11e-05	0.0182	-0.32	-0.26	Monocyte percentage of white cells;	chr2:159607181	chr2:159670708~159712435:-
SARC	cis	rs2439831	0.702	rs7171750	ENSG00000275601.1	AC011330.13	-4.13	5.12e-05	0.0182	-0.45	-0.26	Lung cancer in ever smokers;	chr15:43733660	chr15:43642389~43643023:-
SARC	cis	rs9506514	0.509	rs9509294	ENSG00000222726.1	RNU2-7P	-4.13	5.12e-05	0.0182	-0.25	-0.26	Coronary artery calcification;	chr13:20600506	chr13:20612161~20612338:+
SARC	cis	rs34375054	0.624	rs73233307	ENSG00000279233.1	RP11-158L12.4	4.13	5.12e-05	0.0182	0.32	0.26	Post bronchodilator FEV1/FVC ratio;	chr12:125191327	chr12:125138245~125141711:+
SARC	cis	rs34375054	0.624	rs12580033	ENSG00000279233.1	RP11-158L12.4	4.13	5.12e-05	0.0182	0.32	0.26	Post bronchodilator FEV1/FVC ratio;	chr12:125191537	chr12:125138245~125141711:+
SARC	cis	rs1223397	0.938	rs20500	ENSG00000215022.6	RP1-257A7.4	4.13	5.12e-05	0.0182	0.32	0.26	Blood pressure;	chr6:13294744	chr6:13264861~13295586:-
SARC	cis	rs755249	0.565	rs12138051	ENSG00000182109.6	RP11-69E11.4	-4.13	5.12e-05	0.0182	-0.24	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39522280~39546187:-
SARC	cis	rs755249	0.564	rs6691194	ENSG00000182109.6	RP11-69E11.4	-4.13	5.12e-05	0.0182	-0.24	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39522280~39546187:-
SARC	cis	rs2905347	0.757	rs2961295	ENSG00000179428.2	AC073072.5	-4.13	5.12e-05	0.0182	-0.28	-0.26	Major depression and alcohol dependence;	chr7:22656653	chr7:22725395~22727620:-
SARC	cis	rs13161895	0.941	rs438050	ENSG00000250999.1	RP11-1379J22.5	-4.13	5.12e-05	0.0182	-0.46	-0.26	LDL cholesterol;	chr5:179987645	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs1102191	ENSG00000250999.1	RP11-1379J22.5	-4.13	5.12e-05	0.0182	-0.46	-0.26	LDL cholesterol;	chr5:179989210	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs394616	ENSG00000250999.1	RP11-1379J22.5	-4.13	5.12e-05	0.0182	-0.46	-0.26	LDL cholesterol;	chr5:179991134	chr5:179657762~179664432:+
SARC	cis	rs62432291	0.681	rs7757530	ENSG00000235086.1	FNDC1-IT1	4.13	5.12e-05	0.0182	0.44	0.26	Joint mobility (Beighton score);	chr6:159226897	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs418859	ENSG00000235086.1	FNDC1-IT1	4.13	5.12e-05	0.0182	0.44	0.26	Joint mobility (Beighton score);	chr6:159228663	chr6:159240786~159243329:+
SARC	cis	rs62432291	0.681	rs404435	ENSG00000235086.1	FNDC1-IT1	-4.13	5.12e-05	0.0182	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159233455	chr6:159240786~159243329:+
SARC	cis	rs2235544	0.55	rs12075159	ENSG00000225183.1	RP4-758J24.4	4.13	5.13e-05	0.0183	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54004561	chr1:54089856~54090093:+
SARC	cis	rs7267979	0.873	rs6037062	ENSG00000274414.1	RP5-965G21.4	-4.13	5.13e-05	0.0183	-0.27	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:25239007~25245229:-
SARC	cis	rs9902453	0.765	rs2264302	ENSG00000264538.5	SUZ12P1	-4.13	5.13e-05	0.0183	-0.18	-0.26	Coffee consumption (cups per day);	chr17:29730077	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.765	rs2447935	ENSG00000264538.5	SUZ12P1	-4.13	5.13e-05	0.0183	-0.18	-0.26	Coffee consumption (cups per day);	chr17:29730506	chr17:30709299~30790908:+
SARC	cis	rs853679	0.546	rs200949	ENSG00000216901.1	AL022393.7	4.13	5.13e-05	0.0183	0.52	0.26	Depression;	chr6:27867657	chr6:28176188~28176674:+
SARC	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	4.13	5.13e-05	0.0183	0.31	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
SARC	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-4.13	5.13e-05	0.0183	-0.48	-0.26	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
SARC	cis	rs2803122	0.967	rs10811148	ENSG00000273226.1	RP11-513M16.8	-4.13	5.14e-05	0.0183	-0.25	-0.26	Pulse pressure;	chr9:19246469	chr9:19375451~19375996:+
SARC	cis	rs61160187	0.698	rs12517174	ENSG00000272308.1	RP11-231G3.1	4.13	5.14e-05	0.0183	0.22	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60673188	chr5:60866457~60866935:-
SARC	cis	rs17360053	0.826	rs34026022	ENSG00000218510.5	LINC00339	-4.13	5.14e-05	0.0183	-0.28	-0.26	Obesity-related traits;	chr1:22177411	chr1:22025188~22031223:+
SARC	cis	rs4835473	0.932	rs4835305	ENSG00000251600.4	RP11-673E1.1	-4.13	5.15e-05	0.0183	-0.26	-0.26	Immature fraction of reticulocytes;	chr4:143823646	chr4:143912331~143982454:+
SARC	cis	rs10986311	0.963	rs10986318	ENSG00000235204.1	RP11-121A14.2	-4.13	5.15e-05	0.0183	-0.3	-0.26	Vitiligo;	chr9:124331210	chr9:124259250~124261156:-
SARC	cis	rs17695224	0.585	rs7252487	ENSG00000275055.1	CTC-471J1.11	-4.13	5.15e-05	0.0183	-0.27	-0.26	HDL cholesterol;HDL cholesterol levels;	chr19:51821490	chr19:52049007~52049754:+
SARC	cis	rs1707322	1	rs4134387	ENSG00000281133.1	AL355480.3	-4.13	5.15e-05	0.0183	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45580892~45580996:-
SARC	cis	rs7120173	1	rs7120173	ENSG00000254851.1	RP11-109L13.1	4.13	5.16e-05	0.0183	0.34	0.26	Visceral adipose tissue adjusted for BMI;	chr11:116958937	chr11:117135528~117138582:+
SARC	cis	rs6540731	1	rs1389369	ENSG00000229983.1	RP11-15I11.2	4.13	5.16e-05	0.0183	0.26	0.26	Intelligence (childhood);	chr1:212227194	chr1:212168207~212190259:+
SARC	cis	rs12530	0.715	rs2294314	ENSG00000230736.2	RP1-149A16.3	-4.13	5.16e-05	0.0184	-0.3	-0.26	IgG glycosylation;	chr22:32398616	chr22:32376664~32384343:+
SARC	cis	rs7772486	0.738	rs2246334	ENSG00000235652.6	RP11-545I5.3	4.13	5.16e-05	0.0184	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145799409~145886585:+
SARC	cis	rs597539	0.652	rs514833	ENSG00000250508.1	RP11-757G1.6	-4.13	5.16e-05	0.0184	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68870664~68874542:+
SARC	cis	rs597539	0.652	rs488363	ENSG00000250508.1	RP11-757G1.6	-4.13	5.16e-05	0.0184	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68870664~68874542:+
SARC	cis	rs9868809	0.505	rs28567949	ENSG00000225399.4	RP11-3B7.1	-4.12	5.16e-05	0.0184	-0.44	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48707127	chr3:49260085~49261316:+
SARC	cis	rs9868809	0.505	rs13316551	ENSG00000225399.4	RP11-3B7.1	-4.12	5.16e-05	0.0184	-0.44	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48707734	chr3:49260085~49261316:+
SARC	cis	rs9868809	0.505	rs11706203	ENSG00000225399.4	RP11-3B7.1	-4.12	5.16e-05	0.0184	-0.44	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48708806	chr3:49260085~49261316:+
SARC	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	4.12	5.16e-05	0.0184	0.23	0.26	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
SARC	cis	rs172166	0.694	rs188105	ENSG00000272009.1	RP1-313I6.12	-4.12	5.16e-05	0.0184	-0.29	-0.26	Cardiac Troponin-T levels;	chr6:28103615	chr6:28078792~28081130:-
SARC	cis	rs763121	0.853	rs138705	ENSG00000273076.1	RP3-508I15.22	4.12	5.16e-05	0.0184	0.29	0.26	Menopause (age at onset);	chr22:38737798	chr22:38743495~38743910:+
SARC	cis	rs61160187	0.582	rs4647132	ENSG00000215032.2	GNL3LP1	4.12	5.17e-05	0.0184	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60886893	chr5:60891935~60893577:-
SARC	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-4.12	5.17e-05	0.0184	-0.33	-0.26	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
SARC	cis	rs6918586	0.658	rs198838	ENSG00000272462.2	U91328.19	4.12	5.17e-05	0.0184	0.24	0.26	Schizophrenia;	chr6:26113112	chr6:25992662~26001775:+
SARC	cis	rs858267	0.661	rs7786708	ENSG00000230658.1	KLHL7-AS1	-4.12	5.17e-05	0.0184	-0.57	-0.26	Blood protein levels;	chr7:23075797	chr7:23101228~23105703:-
SARC	cis	rs4679904	0.96	rs12630956	ENSG00000243116.1	RP11-564C24.1	4.12	5.17e-05	0.0184	0.27	0.26	Primary biliary cholangitis;	chr3:160489597	chr3:159721524~159722401:-
SARC	cis	rs4763879	1	rs917911	ENSG00000214776.8	RP11-726G1.1	-4.12	5.18e-05	0.0184	-0.32	-0.26	Type 1 diabetes;	chr12:9753255	chr12:9467552~9576275:+
SARC	cis	rs867371	1	rs7166570	ENSG00000259429.4	UBE2Q2P2	-4.12	5.18e-05	0.0184	-0.25	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82355142~82420075:+
SARC	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	4.12	5.18e-05	0.0184	0.48	0.26	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
SARC	cis	rs1546924	0.692	rs197374	ENSG00000260948.1	RP11-552M11.8	4.12	5.18e-05	0.0184	0.29	0.26	Body mass index;	chr1:111747361	chr1:111431046~111433068:-
SARC	cis	rs2032447	0.53	rs9356996	ENSG00000272462.2	U91328.19	-4.12	5.19e-05	0.0184	-0.24	-0.26	Intelligence (multi-trait analysis);	chr6:26008259	chr6:25992662~26001775:+
SARC	cis	rs7829975	0.572	rs28446104	ENSG00000253893.2	FAM85B	4.12	5.19e-05	0.0184	0.24	0.26	Mood instability;	chr8:8938391	chr8:8167819~8226614:-
SARC	cis	rs8059260	0.736	rs16957835	ENSG00000274038.1	RP11-66H6.4	-4.12	5.19e-05	0.0184	-0.36	-0.26	Alcohol consumption over the past year;	chr16:10958198	chr16:11056556~11057034:+
SARC	cis	rs597539	0.652	rs627731	ENSG00000250508.1	RP11-757G1.6	-4.12	5.19e-05	0.0185	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68870664~68874542:+
SARC	cis	rs597539	0.652	rs674654	ENSG00000250508.1	RP11-757G1.6	-4.12	5.19e-05	0.0185	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68870664~68874542:+
SARC	cis	rs597539	0.616	rs513476	ENSG00000250508.1	RP11-757G1.6	-4.12	5.19e-05	0.0185	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68870664~68874542:+
SARC	cis	rs2132683	0.959	rs9483633	ENSG00000219755.1	RP1-199J3.5	4.12	5.19e-05	0.0185	0.34	0.26	Brain structure;	chr6:99220744	chr6:99575712~99576456:+
SARC	cis	rs27434	0.605	rs152468	ENSG00000272109.1	CTD-2260A17.3	-4.12	5.19e-05	0.0185	-0.39	-0.26	Ankylosing spondylitis;	chr5:96831833	chr5:96804353~96806105:+
SARC	cis	rs27434	0.615	rs61112531	ENSG00000272109.1	CTD-2260A17.3	4.12	5.19e-05	0.0185	0.39	0.26	Ankylosing spondylitis;	chr5:96856117	chr5:96804353~96806105:+
SARC	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-4.12	5.2e-05	0.0185	-0.35	-0.26	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
SARC	cis	rs6844153	0.938	rs16878655	ENSG00000240005.4	RP11-293A21.1	4.12	5.21e-05	0.0185	0.35	0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26964655	chr4:26859806~26860599:-
SARC	cis	rs7267979	0.844	rs2474780	ENSG00000276952.1	RP5-965G21.6	4.12	5.21e-05	0.0185	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:25284915~25285588:-
SARC	cis	rs6477918	0.598	rs10981381	ENSG00000250068.1	RP11-576C12.1	-4.12	5.21e-05	0.0185	-0.27	-0.26	Obstetric antiphospholipid syndrome;	chr9:112390704	chr9:112581779~112582590:-
SARC	cis	rs853679	0.55	rs1237875	ENSG00000272009.1	RP1-313I6.12	4.12	5.21e-05	0.0185	0.29	0.26	Depression;	chr6:28205232	chr6:28078792~28081130:-
SARC	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	4.12	5.21e-05	0.0185	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
SARC	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-4.12	5.21e-05	0.0185	-0.32	-0.26	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
SARC	cis	rs3805389	0.504	rs17781708	ENSG00000273257.1	RP11-177J6.1	4.12	5.21e-05	0.0185	0.39	0.26	Waist-to-hip ratio adjusted for body mass index;	chr4:55614902	chr4:55387949~55388271:+
SARC	cis	rs597539	0.652	rs592697	ENSG00000250508.1	RP11-757G1.6	-4.12	5.22e-05	0.0185	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68870664~68874542:+
SARC	cis	rs597539	0.652	rs654071	ENSG00000250508.1	RP11-757G1.6	-4.12	5.22e-05	0.0185	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68870664~68874542:+
SARC	cis	rs783540	0.934	rs1594511	ENSG00000275695.1	UBE2Q2P6	-4.12	5.22e-05	0.0185	-0.27	-0.26	Schizophrenia;	chr15:82638312	chr15:82445719~82454837:+
SARC	cis	rs860818	1	rs858316	ENSG00000226816.2	AC005082.12	4.12	5.22e-05	0.0185	0.73	0.26	Initial pursuit acceleration;	chr7:23163511	chr7:23206013~23208045:+
SARC	cis	rs12893668	0.603	rs61637848	ENSG00000269958.1	RP11-73M18.8	4.12	5.22e-05	0.0185	0.28	0.26	Reticulocyte count;	chr14:103629694	chr14:103696353~103697163:+
SARC	cis	rs12950390	0.776	rs4793646	ENSG00000239291.1	RP5-867C24.1	4.12	5.23e-05	0.0185	0.31	0.26	IgG glycosylation;	chr17:47776600	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.853	rs4793647	ENSG00000239291.1	RP5-867C24.1	4.12	5.23e-05	0.0185	0.31	0.26	IgG glycosylation;	chr17:47776724	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.853	rs67441169	ENSG00000239291.1	RP5-867C24.1	4.12	5.23e-05	0.0185	0.31	0.26	IgG glycosylation;	chr17:47777096	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.853	rs12450729	ENSG00000239291.1	RP5-867C24.1	4.12	5.23e-05	0.0185	0.31	0.26	IgG glycosylation;	chr17:47777997	chr17:47159191~47159993:-
SARC	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	4.12	5.23e-05	0.0185	0.3	0.26	QT interval;	chr12:29304617	chr12:29280418~29317848:-
SARC	cis	rs113835537	0.866	rs59566349	ENSG00000255517.5	CTD-3074O7.5	-4.12	5.23e-05	0.0186	-0.35	-0.26	Airway imaging phenotypes;	chr11:66598523	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.935	rs1127145	ENSG00000255517.5	CTD-3074O7.5	-4.12	5.23e-05	0.0186	-0.35	-0.26	Airway imaging phenotypes;	chr11:66605834	chr11:66473490~66480233:-
SARC	cis	rs2179367	0.959	rs4895788	ENSG00000216906.2	RP11-350J20.9	4.12	5.24e-05	0.0186	0.25	0.26	Dupuytren's disease;	chr6:149426955	chr6:149904243~149906418:+
SARC	cis	rs7923609	0.756	rs7090758	ENSG00000232075.1	MRPL35P2	4.12	5.24e-05	0.0186	0.23	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63575555	chr10:63634317~63634827:-
SARC	cis	rs4950322	0.634	rs4950415	ENSG00000278811.3	LINC00624	4.12	5.24e-05	0.0186	0.26	0.26	Protein quantitative trait loci;	chr1:147350951	chr1:147258885~147517875:-
SARC	cis	rs7267979	0.932	rs449370	ENSG00000276952.1	RP5-965G21.6	-4.12	5.24e-05	0.0186	-0.26	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:25284915~25285588:-
SARC	cis	rs1150668	0.796	rs213236	ENSG00000219392.1	RP1-265C24.5	-4.12	5.24e-05	0.0186	-0.3	-0.26	Pubertal anthropometrics;	chr6:28356620	chr6:28115628~28116551:+
SARC	cis	rs6844153	0.752	rs6815719	ENSG00000240005.4	RP11-293A21.1	-4.12	5.24e-05	0.0186	-0.32	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26880232	chr4:26859806~26860599:-
SARC	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-4.12	5.24e-05	0.0186	-0.3	-0.26	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
SARC	cis	rs1914816	0.941	rs2456027	ENSG00000196274.5	Metazoa_SRP	4.12	5.24e-05	0.0186	0.35	0.26	Response to tocilizumab in rheumatoid arthritis;	chr15:76275868	chr15:76230048~76230390:-
SARC	cis	rs7267979	0.816	rs6076358	ENSG00000276952.1	RP5-965G21.6	-4.12	5.25e-05	0.0186	-0.25	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:25284915~25285588:-
SARC	cis	rs7216064	1	rs11870068	ENSG00000237854.3	LINC00674	4.12	5.25e-05	0.0186	0.33	0.26	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67948399	chr17:68101908~68115518:+
SARC	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	4.12	5.25e-05	0.0186	0.31	0.26	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
SARC	cis	rs1964356	0.967	rs2953802	ENSG00000253893.2	FAM85B	-4.12	5.26e-05	0.0186	-0.24	-0.26	Mean corpuscular volume;	chr8:8994371	chr8:8167819~8226614:-
SARC	cis	rs11955398	0.502	rs248683	ENSG00000272308.1	RP11-231G3.1	-4.12	5.26e-05	0.0186	-0.24	-0.26	Intelligence (multi-trait analysis);	chr5:61064331	chr5:60866457~60866935:-
SARC	cis	rs2029362	0.611	rs7934165	ENSG00000245573.6	BDNF-AS	4.12	5.26e-05	0.0186	0.22	0.26	Total body bone mineral density;	chr11:27710436	chr11:27506838~27698174:+
SARC	cis	rs745109	0.882	rs72930315	ENSG00000273080.1	RP11-301O19.1	4.12	5.26e-05	0.0186	0.4	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86427428	chr2:86195590~86196049:+
SARC	cis	rs2439831	0.681	rs1095386	ENSG00000275601.1	AC011330.13	-4.12	5.26e-05	0.0187	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43317311	chr15:43642389~43643023:-
SARC	cis	rs4664293	0.867	rs6740910	ENSG00000226266.5	AC009961.3	-4.12	5.27e-05	0.0187	-0.32	-0.26	Monocyte percentage of white cells;	chr2:159792709	chr2:159670708~159712435:-
SARC	cis	rs597539	0.652	rs482172	ENSG00000250508.1	RP11-757G1.6	-4.12	5.27e-05	0.0187	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68870664~68874542:+
SARC	cis	rs9902453	0.765	rs2628185	ENSG00000264538.5	SUZ12P1	-4.12	5.27e-05	0.0187	-0.18	-0.26	Coffee consumption (cups per day);	chr17:29743089	chr17:30709299~30790908:+
SARC	cis	rs7246657	0.943	rs6508732	ENSG00000226686.6	LINC01535	-4.12	5.27e-05	0.0187	-0.36	-0.26	Coronary artery calcification;	chr19:37509566	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs6508733	ENSG00000226686.6	LINC01535	-4.12	5.27e-05	0.0187	-0.36	-0.26	Coronary artery calcification;	chr19:37509646	chr19:37251912~37265535:+
SARC	cis	rs858239	0.665	rs6964665	ENSG00000226816.2	AC005082.12	4.12	5.27e-05	0.0187	0.33	0.26	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23206013~23208045:+
SARC	cis	rs7267979	0.816	rs374701	ENSG00000276952.1	RP5-965G21.6	4.12	5.28e-05	0.0187	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:25284915~25285588:-
SARC	cis	rs875971	0.862	rs1968126	ENSG00000232559.3	GS1-124K5.12	-4.12	5.28e-05	0.0187	-0.3	-0.26	Aortic root size;	chr7:66592017	chr7:66554588~66576923:-
SARC	cis	rs875971	0.862	rs6460306	ENSG00000232559.3	GS1-124K5.12	-4.12	5.28e-05	0.0187	-0.3	-0.26	Aortic root size;	chr7:66595806	chr7:66554588~66576923:-
SARC	cis	rs7267979	1	rs1077889	ENSG00000276952.1	RP5-965G21.6	4.12	5.28e-05	0.0187	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25284915~25285588:-
SARC	cis	rs755249	0.958	rs17264866	ENSG00000182109.6	RP11-69E11.4	4.12	5.28e-05	0.0187	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557105	chr1:39522280~39546187:-
SARC	cis	rs717662	0.507	rs633021	ENSG00000248027.1	CTD-2383M3.1	4.12	5.28e-05	0.0187	0.49	0.26	Red cell distribution width;	chr11:100852256	chr11:100684162~100687955:-
SARC	cis	rs8005677	0.828	rs12437151	ENSG00000257285.4	RP11-298I3.1	4.12	5.29e-05	0.0187	0.25	0.26	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:22929609~22955562:+
SARC	cis	rs7809615	0.748	rs10240199	ENSG00000237640.1	RP4-604G5.1	-4.12	5.29e-05	0.0187	-0.47	-0.26	Blood metabolite ratios;	chr7:99599555	chr7:99929392~99948620:+
SARC	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-4.12	5.29e-05	0.0187	-0.48	-0.26	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-4.12	5.29e-05	0.0187	-0.48	-0.26	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-4.12	5.29e-05	0.0187	-0.48	-0.26	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-4.12	5.29e-05	0.0187	-0.48	-0.26	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-4.12	5.29e-05	0.0187	-0.48	-0.26	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
SARC	cis	rs7267979	0.899	rs2179459	ENSG00000276952.1	RP5-965G21.6	4.12	5.29e-05	0.0187	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25284915~25285588:-
SARC	cis	rs7772486	0.846	rs6908063	ENSG00000270638.1	RP3-466P17.1	4.12	5.3e-05	0.0187	0.21	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146082482	chr6:145735570~145737218:+
SARC	cis	rs6477918	0.55	rs10981402	ENSG00000250068.1	RP11-576C12.1	-4.12	5.3e-05	0.0187	-0.29	-0.26	Obstetric antiphospholipid syndrome;	chr9:112428367	chr9:112581779~112582590:-
SARC	cis	rs5751614	0.62	rs5759670	ENSG00000230701.2	FBXW4P1	4.12	5.3e-05	0.0187	0.32	0.26	Height;	chr22:23272239	chr22:23262767~23265005:+
SARC	cis	rs6570726	0.791	rs6918814	ENSG00000270638.1	RP3-466P17.1	4.12	5.3e-05	0.0187	0.21	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145735570~145737218:+
SARC	cis	rs3824347	0.839	rs10869471	ENSG00000203321.2	C9orf41-AS1	-4.12	5.3e-05	0.0188	-0.28	-0.26	Urinary magnesium-to-creatinine ratio;	chr9:75014556	chr9:74952968~74996293:+
SARC	cis	rs72627509	0.904	rs7687767	ENSG00000269949.1	RP11-738E22.3	-4.12	5.3e-05	0.0188	-0.38	-0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958766	chr4:56960927~56961373:-
SARC	cis	rs11264213	0.901	rs644095	ENSG00000271554.1	RP4-665N4.8	-4.12	5.31e-05	0.0188	-0.37	-0.26	Schizophrenia;	chr1:35897571	chr1:35992109~36013630:-
SARC	cis	rs1707322	1	rs7553924	ENSG00000281133.1	AL355480.3	-4.12	5.31e-05	0.0188	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4641257	ENSG00000281133.1	AL355480.3	-4.12	5.31e-05	0.0188	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs6693336	ENSG00000281133.1	AL355480.3	-4.12	5.31e-05	0.0188	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45580892~45580996:-
SARC	cis	rs34929064	0.672	rs2961298	ENSG00000179428.2	AC073072.5	4.12	5.31e-05	0.0188	0.28	0.26	Major depression and alcohol dependence;	chr7:22668472	chr7:22725395~22727620:-
SARC	cis	rs11264213	0.818	rs2765012	ENSG00000271554.1	RP4-665N4.8	-4.12	5.31e-05	0.0188	-0.36	-0.26	Schizophrenia;	chr1:35890856	chr1:35992109~36013630:-
SARC	cis	rs11264213	0.901	rs653417	ENSG00000271554.1	RP4-665N4.8	-4.12	5.31e-05	0.0188	-0.36	-0.26	Schizophrenia;	chr1:35891241	chr1:35992109~36013630:-
SARC	cis	rs11264213	0.901	rs620956	ENSG00000271554.1	RP4-665N4.8	-4.12	5.31e-05	0.0188	-0.36	-0.26	Schizophrenia;	chr1:35896561	chr1:35992109~36013630:-
SARC	cis	rs11264213	0.901	rs636832	ENSG00000271554.1	RP4-665N4.8	-4.12	5.31e-05	0.0188	-0.36	-0.26	Schizophrenia;	chr1:35897874	chr1:35992109~36013630:-
SARC	cis	rs11264213	0.901	rs661233	ENSG00000271554.1	RP4-665N4.8	-4.12	5.31e-05	0.0188	-0.36	-0.26	Schizophrenia;	chr1:35899115	chr1:35992109~36013630:-
SARC	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-4.12	5.31e-05	0.0188	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
SARC	cis	rs72945132	0.882	rs7943840	ENSG00000254604.1	AP000487.6	-4.12	5.31e-05	0.0188	-0.36	-0.26	Coronary artery disease;	chr11:70382509	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs57810426	ENSG00000254604.1	AP000487.6	-4.12	5.31e-05	0.0188	-0.36	-0.26	Coronary artery disease;	chr11:70383924	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs67822447	ENSG00000254604.1	AP000487.6	-4.12	5.31e-05	0.0188	-0.36	-0.26	Coronary artery disease;	chr11:70384866	chr11:70282367~70363368:-
SARC	cis	rs7085104	0.591	rs4919683	ENSG00000213061.2	PFN1P11	4.12	5.32e-05	0.0188	0.31	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825368	chr10:102838011~102845473:-
SARC	cis	rs67478160	0.643	rs8004408	ENSG00000269940.1	RP11-73M18.7	4.12	5.32e-05	0.0188	0.22	0.26	Schizophrenia;	chr14:103737601	chr14:103694560~103695170:+
SARC	cis	rs6540731	0.967	rs2884512	ENSG00000229983.1	RP11-15I11.2	4.12	5.32e-05	0.0188	0.27	0.26	Intelligence (childhood);	chr1:212229848	chr1:212168207~212190259:+
SARC	cis	rs4950322	0.515	rs17160050	ENSG00000278811.3	LINC00624	4.12	5.32e-05	0.0188	0.26	0.26	Protein quantitative trait loci;	chr1:147255558	chr1:147258885~147517875:-
SARC	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	4.12	5.32e-05	0.0188	0.31	0.26	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
SARC	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	4.12	5.32e-05	0.0188	0.31	0.26	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
SARC	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	4.12	5.32e-05	0.0188	0.33	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
SARC	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	4.12	5.32e-05	0.0188	0.33	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
SARC	cis	rs1376877	0.901	rs57235969	ENSG00000213925.3	NPM1P33	4.12	5.33e-05	0.0188	0.24	0.26	Subclinical atherosclerosis traits (other);	chr2:203240680	chr2:203772631~203773502:-
SARC	cis	rs7927592	0.546	rs497261	ENSG00000212093.1	AP000807.1	4.12	5.33e-05	0.0188	0.25	0.26	Total body bone mineral density;	chr11:68424776	chr11:68506083~68506166:-
SARC	cis	rs7927592	0.546	rs599083	ENSG00000212093.1	AP000807.1	4.12	5.33e-05	0.0188	0.25	0.26	Total body bone mineral density;	chr11:68424878	chr11:68506083~68506166:-
SARC	cis	rs7927592	0.546	rs683978	ENSG00000212093.1	AP000807.1	4.12	5.33e-05	0.0188	0.25	0.26	Total body bone mineral density;	chr11:68424953	chr11:68506083~68506166:-
SARC	cis	rs7927592	0.546	rs554734	ENSG00000212093.1	AP000807.1	4.12	5.33e-05	0.0188	0.25	0.26	Total body bone mineral density;	chr11:68425050	chr11:68506083~68506166:-
SARC	cis	rs75920871	0.528	rs7935834	ENSG00000254851.1	RP11-109L13.1	4.12	5.33e-05	0.0188	0.35	0.26	Subjective well-being;	chr11:117073721	chr11:117135528~117138582:+
SARC	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	4.12	5.34e-05	0.0189	0.37	0.26	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
SARC	cis	rs4664293	0.647	rs1425042	ENSG00000226266.5	AC009961.3	-4.12	5.34e-05	0.0189	-0.3	-0.26	Monocyte percentage of white cells;	chr2:159584004	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs6711049	ENSG00000226266.5	AC009961.3	-4.12	5.34e-05	0.0189	-0.3	-0.26	Monocyte percentage of white cells;	chr2:159584634	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs7562850	ENSG00000226266.5	AC009961.3	-4.12	5.34e-05	0.0189	-0.3	-0.26	Monocyte percentage of white cells;	chr2:159585023	chr2:159670708~159712435:-
SARC	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-4.12	5.34e-05	0.0189	-0.3	-0.26	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
SARC	cis	rs2439831	0.867	rs496584	ENSG00000275601.1	AC011330.13	-4.12	5.36e-05	0.0189	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43539725	chr15:43642389~43643023:-
SARC	cis	rs9473147	0.571	rs9369717	ENSG00000270761.1	RP11-385F7.1	-4.12	5.36e-05	0.0189	-0.32	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47586732	chr6:47477243~47477572:-
SARC	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-4.12	5.36e-05	0.0189	-0.25	-0.26	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
SARC	cis	rs853679	0.599	rs149949	ENSG00000216901.1	AL022393.7	4.12	5.36e-05	0.0189	0.51	0.26	Depression;	chr6:28043738	chr6:28176188~28176674:+
SARC	cis	rs12049351	0.665	rs7534252	ENSG00000229367.1	HMGN2P19	4.12	5.37e-05	0.019	0.23	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229433845	chr1:229570532~229570796:+
SARC	cis	rs17270561	0.609	rs1937131	ENSG00000272462.2	U91328.19	4.12	5.37e-05	0.019	0.25	0.26	Iron status biomarkers;	chr6:25744603	chr6:25992662~26001775:+
SARC	cis	rs910316	1	rs175426	ENSG00000279594.1	RP11-950C14.10	-4.12	5.37e-05	0.019	-0.29	-0.26	Height;	chr14:75157431	chr14:75011269~75012851:-
SARC	cis	rs9828933	0.882	rs3816156	ENSG00000280620.1	SCAANT1	4.12	5.37e-05	0.019	0.37	0.26	Type 2 diabetes;	chr3:64014036	chr3:63911518~63911772:-
SARC	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	4.12	5.37e-05	0.019	0.33	0.26	Height;	chr6:109361200	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	4.12	5.37e-05	0.019	0.33	0.26	Height;	chr6:109367335	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	4.12	5.37e-05	0.019	0.33	0.26	Height;	chr6:109368228	chr6:109382795~109383666:+
SARC	cis	rs763121	0.853	rs138704	ENSG00000273076.1	RP3-508I15.22	4.12	5.37e-05	0.019	0.27	0.26	Menopause (age at onset);	chr22:38737405	chr22:38743495~38743910:+
SARC	cis	rs1707322	1	rs785478	ENSG00000281133.1	AL355480.3	4.11	5.38e-05	0.019	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45580892~45580996:-
SARC	cis	rs7163013	0.933	rs4283201	ENSG00000259792.1	RP11-114H24.6	-4.11	5.38e-05	0.019	-0.27	-0.26	Obesity-related traits;	chr15:78389023	chr15:77993405~77995289:+
SARC	cis	rs9739682	1	rs1025935	ENSG00000139239.7	RPL14P1	-4.11	5.38e-05	0.019	-0.24	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62126384	chr12:62965325~62965969:+
SARC	cis	rs9902453	0.817	rs2321333	ENSG00000264538.5	SUZ12P1	4.11	5.38e-05	0.019	0.18	0.26	Coffee consumption (cups per day);	chr17:29813839	chr17:30709299~30790908:+
SARC	cis	rs1707322	1	rs4660334	ENSG00000281133.1	AL355480.3	-4.11	5.38e-05	0.019	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45580892~45580996:-
SARC	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	4.11	5.39e-05	0.019	0.3	0.26	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
SARC	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	4.11	5.39e-05	0.019	0.34	0.26	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
SARC	cis	rs6969780	1	rs6973182	ENSG00000233429.8	HOTAIRM1	4.11	5.39e-05	0.019	0.4	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27132702	chr7:27095647~27100265:+
SARC	cis	rs4679904	1	rs35008770	ENSG00000243116.1	RP11-564C24.1	4.11	5.4e-05	0.019	0.27	0.26	Primary biliary cholangitis;	chr3:160616529	chr3:159721524~159722401:-
SARC	cis	rs4679904	1	rs2178451	ENSG00000243116.1	RP11-564C24.1	4.11	5.4e-05	0.019	0.27	0.26	Primary biliary cholangitis;	chr3:160618048	chr3:159721524~159722401:-
SARC	cis	rs4679904	1	rs2141668	ENSG00000243116.1	RP11-564C24.1	4.11	5.4e-05	0.019	0.27	0.26	Primary biliary cholangitis;	chr3:160618244	chr3:159721524~159722401:-
SARC	cis	rs7178375	1	rs28693590	ENSG00000215302.7	CTD-3092A11.1	-4.11	5.4e-05	0.019	-0.34	-0.26	Hypertriglyceridemia;	chr15:30902818	chr15:30470779~30507623:+
SARC	cis	rs151234	0.741	rs151227	ENSG00000259982.1	CDC37P1	-4.11	5.4e-05	0.019	-0.37	-0.26	Platelet distribution width;	chr16:28538187	chr16:28700294~28701540:-
SARC	cis	rs113835537	0.935	rs11550057	ENSG00000255517.5	CTD-3074O7.5	-4.11	5.4e-05	0.0191	-0.35	-0.26	Airway imaging phenotypes;	chr11:66625409	chr11:66473490~66480233:-
SARC	cis	rs113835537	0.935	rs15969	ENSG00000255517.5	CTD-3074O7.5	-4.11	5.4e-05	0.0191	-0.35	-0.26	Airway imaging phenotypes;	chr11:66626916	chr11:66473490~66480233:-
SARC	cis	rs7267979	0.844	rs6115188	ENSG00000276952.1	RP5-965G21.6	4.11	5.4e-05	0.0191	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:25284915~25285588:-
SARC	cis	rs17270561	0.609	rs9348692	ENSG00000272462.2	U91328.19	-4.11	5.41e-05	0.0191	-0.25	-0.26	Iron status biomarkers;	chr6:25720584	chr6:25992662~26001775:+
SARC	cis	rs12950390	0.853	rs11655336	ENSG00000239291.1	RP5-867C24.1	-4.11	5.41e-05	0.0191	-0.3	-0.26	IgG glycosylation;	chr17:47781470	chr17:47159191~47159993:-
SARC	cis	rs5742933	0.597	rs6756913	ENSG00000273240.1	RP11-455J20.3	4.11	5.41e-05	0.0191	0.3	0.26	Ferritin levels;	chr2:189641040	chr2:189763859~189764456:-
SARC	cis	rs728478	0.935	rs8071771	ENSG00000266992.1	DHX40P1	4.11	5.42e-05	0.0191	0.28	0.26	QT interval;	chr17:59376906	chr17:59976009~60002384:-
SARC	cis	rs12554020	0.892	rs10217595	ENSG00000227603.1	RP11-165J3.6	4.11	5.44e-05	0.0192	0.41	0.26	Schizophrenia;	chr9:93418609	chr9:93435332~93437121:-
SARC	cis	rs9739682	0.564	rs34330649	ENSG00000139239.7	RPL14P1	-4.11	5.44e-05	0.0192	-0.26	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62088930	chr12:62965325~62965969:+
SARC	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	4.11	5.44e-05	0.0192	0.49	0.26	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
SARC	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-4.11	5.44e-05	0.0192	-0.35	-0.26	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
SARC	cis	rs72945132	0.714	rs72947077	ENSG00000254604.1	AP000487.6	-4.11	5.44e-05	0.0192	-0.38	-0.26	Coronary artery disease;	chr11:70351325	chr11:70282367~70363368:-
SARC	cis	rs2235544	0.565	rs605182	ENSG00000225183.1	RP4-758J24.4	4.11	5.44e-05	0.0192	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54001283	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.554	rs605272	ENSG00000225183.1	RP4-758J24.4	4.11	5.44e-05	0.0192	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54001353	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.565	rs650134	ENSG00000225183.1	RP4-758J24.4	4.11	5.44e-05	0.0192	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54001669	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.588	rs662603	ENSG00000225183.1	RP4-758J24.4	4.11	5.44e-05	0.0192	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54002094	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.565	rs620907	ENSG00000225183.1	RP4-758J24.4	4.11	5.44e-05	0.0192	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54002493	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.565	rs664848	ENSG00000225183.1	RP4-758J24.4	4.11	5.44e-05	0.0192	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54002648	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.565	rs633315	ENSG00000225183.1	RP4-758J24.4	4.11	5.44e-05	0.0192	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54003016	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.565	rs633697	ENSG00000225183.1	RP4-758J24.4	4.11	5.44e-05	0.0192	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54003087	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.565	rs677481	ENSG00000225183.1	RP4-758J24.4	4.11	5.44e-05	0.0192	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54003164	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.565	rs635059	ENSG00000225183.1	RP4-758J24.4	4.11	5.44e-05	0.0192	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54003447	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.565	rs635509	ENSG00000225183.1	RP4-758J24.4	4.11	5.44e-05	0.0192	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54003554	chr1:54089856~54090093:+
SARC	cis	rs61160187	0.582	rs7713481	ENSG00000272308.1	RP11-231G3.1	-4.11	5.44e-05	0.0192	-0.22	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60866457~60866935:-
SARC	cis	rs61160187	0.582	rs7737276	ENSG00000272308.1	RP11-231G3.1	-4.11	5.44e-05	0.0192	-0.22	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60866457~60866935:-
SARC	cis	rs1823913	1	rs13019004	ENSG00000280083.1	RP11-317J9.1	-4.11	5.44e-05	0.0192	-0.29	-0.26	Obesity-related traits;	chr2:191245493	chr2:191154118~191156070:-
SARC	cis	rs1499614	0.522	rs13247442	ENSG00000226824.5	RP4-756H11.3	-4.11	5.44e-05	0.0192	-0.58	-0.26	Gout;	chr7:66723871	chr7:66654538~66669855:+
SARC	cis	rs2731006	0.64	rs2731002	ENSG00000257114.2	RP11-25I15.3	-4.11	5.44e-05	0.0192	-0.41	-0.26	Panic disorder;	chr12:42790472	chr12:42692216~42717119:+
SARC	cis	rs7267979	0.714	rs3787082	ENSG00000276952.1	RP5-965G21.6	4.11	5.44e-05	0.0192	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.714	rs6115107	ENSG00000276952.1	RP5-965G21.6	4.11	5.44e-05	0.0192	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.78	rs2500413	ENSG00000276952.1	RP5-965G21.6	4.11	5.44e-05	0.0192	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.714	rs2474763	ENSG00000276952.1	RP5-965G21.6	4.11	5.44e-05	0.0192	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:25284915~25285588:-
SARC	cis	rs14027	1	rs14027	ENSG00000279347.1	RP11-85I17.2	-4.11	5.45e-05	0.0192	-0.23	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119834349	chr8:119838736~119840385:-
SARC	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-4.11	5.45e-05	0.0192	-0.27	-0.26	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
SARC	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-4.11	5.45e-05	0.0192	-0.35	-0.26	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
SARC	cis	rs2239557	0.529	rs2041185	ENSG00000259065.1	RP5-1021I20.1	4.11	5.45e-05	0.0192	0.31	0.26	Common traits (Other);	chr14:73815387	chr14:73787360~73803270:+
SARC	cis	rs12468226	0.689	rs17656903	ENSG00000273456.1	RP11-686O6.2	-4.11	5.45e-05	0.0192	-0.3	-0.26	Urate levels;	chr2:202106312	chr2:202374932~202375604:-
SARC	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	4.11	5.46e-05	0.0192	0.26	0.26	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
SARC	cis	rs7826238	0.601	rs2979206	ENSG00000253981.4	ALG1L13P	4.11	5.46e-05	0.0192	0.25	0.26	Systolic blood pressure;	chr8:8488071	chr8:8236003~8244667:-
SARC	cis	rs6570726	1	rs951143	ENSG00000270638.1	RP3-466P17.1	4.11	5.46e-05	0.0192	0.21	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145735570~145737218:+
SARC	cis	rs1707322	0.964	rs796773	ENSG00000281133.1	AL355480.3	4.11	5.47e-05	0.0193	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.896	rs785518	ENSG00000281133.1	AL355480.3	4.11	5.47e-05	0.0193	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs785519	ENSG00000281133.1	AL355480.3	4.11	5.47e-05	0.0193	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45580892~45580996:-
SARC	cis	rs7267979	0.714	rs1555329	ENSG00000276952.1	RP5-965G21.6	4.11	5.47e-05	0.0193	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:25284915~25285588:-
SARC	cis	rs9902453	0.765	rs8071576	ENSG00000264538.5	SUZ12P1	4.11	5.47e-05	0.0193	0.19	0.26	Coffee consumption (cups per day);	chr17:29861536	chr17:30709299~30790908:+
SARC	cis	rs10895987	0.83	rs12292693	ENSG00000254614.2	AP003068.23	-4.11	5.47e-05	0.0193	-0.37	-0.26	Blood protein levels;	chr11:65169248	chr11:65177606~65181834:-
SARC	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-4.11	5.48e-05	0.0193	-0.5	-0.26	Gout;	chr7:66642037	chr7:66654538~66669855:+
SARC	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-4.11	5.48e-05	0.0193	-0.5	-0.26	Gout;	chr7:66645053	chr7:66654538~66669855:+
SARC	cis	rs1799949	0.965	rs799917	ENSG00000267681.1	CTD-3199J23.6	-4.11	5.48e-05	0.0193	-0.29	-0.26	Menopause (age at onset);	chr17:43092919	chr17:43144956~43145255:+
SARC	cis	rs4713118	0.699	rs200969	ENSG00000216901.1	AL022393.7	4.11	5.48e-05	0.0193	0.4	0.26	Parkinson's disease;	chr6:27891675	chr6:28176188~28176674:+
SARC	cis	rs28386778	0.562	rs721575	ENSG00000240280.5	TCAM1P	4.11	5.48e-05	0.0193	0.31	0.26	Prudent dietary pattern;	chr17:63705560	chr17:63849292~63864379:+
SARC	cis	rs1976403	0.51	rs1697421	ENSG00000227001.3	NBPF2P	4.11	5.49e-05	0.0193	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr1:21496799	chr1:21424625~21427967:-
SARC	cis	rs9902453	0.612	rs2617868	ENSG00000264538.5	SUZ12P1	-4.11	5.49e-05	0.0193	-0.18	-0.26	Coffee consumption (cups per day);	chr17:29746229	chr17:30709299~30790908:+
SARC	cis	rs453301	0.658	rs9650616	ENSG00000253893.2	FAM85B	4.11	5.49e-05	0.0193	0.24	0.26	Joint mobility (Beighton score);	chr8:9011689	chr8:8167819~8226614:-
SARC	cis	rs9902453	0.765	rs2127001	ENSG00000264538.5	SUZ12P1	-4.11	5.49e-05	0.0193	-0.18	-0.26	Coffee consumption (cups per day);	chr17:29771201	chr17:30709299~30790908:+
SARC	cis	rs28386778	0.797	rs4968664	ENSG00000240280.5	TCAM1P	-4.11	5.49e-05	0.0193	-0.32	-0.26	Prudent dietary pattern;	chr17:63774006	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs9913323	ENSG00000240280.5	TCAM1P	-4.11	5.49e-05	0.0193	-0.32	-0.26	Prudent dietary pattern;	chr17:63774125	chr17:63849292~63864379:+
SARC	cis	rs2439831	0.867	rs45585139	ENSG00000205771.5	CATSPER2P1	-4.11	5.49e-05	0.0193	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43408229	chr15:43726918~43747094:-
SARC	cis	rs11079159	0.637	rs4147524	ENSG00000262052.1	RP11-763E3.1	-4.11	5.49e-05	0.0193	-0.35	-0.26	QRS duration;	chr17:55274249	chr17:55842677~55872939:-
SARC	cis	rs8064029	0.655	rs77468976	ENSG00000267077.1	RP11-127I20.5	4.11	5.49e-05	0.0193	0.47	0.26	Cancer;	chr16:4819249	chr16:4795265~4796532:-
SARC	cis	rs12893668	0.572	rs2273175	ENSG00000269940.1	RP11-73M18.7	4.11	5.49e-05	0.0193	0.25	0.26	Reticulocyte count;	chr14:103693804	chr14:103694560~103695170:+
SARC	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-4.11	5.5e-05	0.0193	-0.33	-0.26	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
SARC	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-4.11	5.5e-05	0.0193	-0.33	-0.26	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
SARC	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-4.11	5.5e-05	0.0193	-0.33	-0.26	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
SARC	cis	rs1707322	0.896	rs809774	ENSG00000281133.1	AL355480.3	4.11	5.5e-05	0.0193	0.29	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45580892~45580996:-
SARC	cis	rs2439831	0.681	rs7175434	ENSG00000275601.1	AC011330.13	-4.11	5.5e-05	0.0193	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43336344	chr15:43642389~43643023:-
SARC	cis	rs7688540	0.771	rs61792114	ENSG00000275426.1	CH17-262A2.1	4.11	5.5e-05	0.0194	0.37	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:295350	chr4:149738~150317:+
SARC	cis	rs2905347	0.895	rs2961280	ENSG00000179428.2	AC073072.5	4.11	5.51e-05	0.0194	0.27	0.26	Major depression and alcohol dependence;	chr7:22600098	chr7:22725395~22727620:-
SARC	cis	rs2905347	0.895	rs2961282	ENSG00000179428.2	AC073072.5	4.11	5.51e-05	0.0194	0.27	0.26	Major depression and alcohol dependence;	chr7:22600770	chr7:22725395~22727620:-
SARC	cis	rs7615952	0.641	rs6438951	ENSG00000248787.1	RP11-666A20.4	-4.11	5.52e-05	0.0194	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:125978156	chr3:125908005~125910272:-
SARC	cis	rs321358	0.79	rs10502128	ENSG00000271584.1	RP11-89C3.4	4.11	5.52e-05	0.0194	0.44	0.26	Body mass index;	chr11:111076827	chr11:111091932~111097357:-
SARC	cis	rs321358	0.848	rs57168185	ENSG00000271584.1	RP11-89C3.4	4.11	5.52e-05	0.0194	0.44	0.26	Body mass index;	chr11:111078120	chr11:111091932~111097357:-
SARC	cis	rs26528	0.584	rs153103	ENSG00000251417.2	RP11-1348G14.4	4.11	5.52e-05	0.0194	0.23	0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28802743~28817828:+
SARC	cis	rs593531	0.504	rs4944041	ENSG00000280269.1	AP000577.2	4.11	5.52e-05	0.0194	0.33	0.26	Neuroticism;	chr11:74318814	chr11:74204869~74205746:+
SARC	cis	rs593531	0.513	rs4944887	ENSG00000280269.1	AP000577.2	4.11	5.52e-05	0.0194	0.33	0.26	Neuroticism;	chr11:74318838	chr11:74204869~74205746:+
SARC	cis	rs17767294	0.612	rs12332927	ENSG00000280107.1	AL022393.9	-4.11	5.52e-05	0.0194	-0.42	-0.26	Parkinson's disease;	chr6:27987337	chr6:28170845~28172521:+
SARC	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-4.11	5.53e-05	0.0194	-0.34	-0.26	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
SARC	cis	rs12950390	0.853	rs11079790	ENSG00000239291.1	RP5-867C24.1	4.11	5.53e-05	0.0194	0.31	0.26	IgG glycosylation;	chr17:47776260	chr17:47159191~47159993:-
SARC	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	4.11	5.54e-05	0.0195	0.49	0.26	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
SARC	cis	rs2562456	0.755	rs2562421	ENSG00000268081.1	RP11-678G14.2	-4.11	5.54e-05	0.0195	-0.39	-0.26	Pain;	chr19:21448502	chr19:21554640~21569237:-
SARC	cis	rs2562456	0.793	rs2562420	ENSG00000268081.1	RP11-678G14.2	-4.11	5.54e-05	0.0195	-0.39	-0.26	Pain;	chr19:21448503	chr19:21554640~21569237:-
SARC	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-4.11	5.54e-05	0.0195	-0.24	-0.26	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
SARC	cis	rs2179367	0.632	rs59820585	ENSG00000231760.4	RP11-350J20.5	4.11	5.54e-05	0.0195	0.35	0.26	Dupuytren's disease;	chr6:149350249	chr6:149796151~149826294:-
SARC	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-4.11	5.54e-05	0.0195	-0.3	-0.26	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
SARC	cis	rs6877440	0.555	rs59962048	ENSG00000271849.1	CTC-332L22.1	-4.11	5.54e-05	0.0195	-0.54	-0.26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr5:109662997	chr5:109687802~109688329:-
SARC	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-4.11	5.55e-05	0.0195	-0.24	-0.26	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-4.11	5.55e-05	0.0195	-0.24	-0.26	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
SARC	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-4.11	5.55e-05	0.0195	-0.31	-0.26	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
SARC	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-4.11	5.55e-05	0.0195	-0.31	-0.26	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
SARC	cis	rs889122	0.765	rs62105756	ENSG00000267289.1	CTD-2623N2.11	4.11	5.55e-05	0.0195	0.31	0.26	Menarche (age at onset);	chr19:9863257	chr19:9834079~9835013:-
SARC	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	4.11	5.56e-05	0.0195	0.33	0.26	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
SARC	cis	rs763121	0.785	rs5750646	ENSG00000273076.1	RP3-508I15.22	4.11	5.56e-05	0.0195	0.28	0.26	Menopause (age at onset);	chr22:38617825	chr22:38743495~38743910:+
SARC	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-4.11	5.56e-05	0.0195	-0.48	-0.26	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-4.11	5.56e-05	0.0195	-0.48	-0.26	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-4.11	5.56e-05	0.0195	-0.48	-0.26	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-4.11	5.56e-05	0.0195	-0.48	-0.26	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-4.11	5.56e-05	0.0195	-0.48	-0.26	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-4.11	5.56e-05	0.0195	-0.48	-0.26	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-4.11	5.56e-05	0.0195	-0.49	-0.26	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-4.11	5.56e-05	0.0195	-0.49	-0.26	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-4.11	5.56e-05	0.0195	-0.49	-0.26	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-4.11	5.56e-05	0.0195	-0.49	-0.26	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-4.11	5.56e-05	0.0195	-0.49	-0.26	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
SARC	cis	rs27434	0.605	rs2351012	ENSG00000272109.1	CTD-2260A17.3	-4.11	5.56e-05	0.0195	-0.39	-0.26	Ankylosing spondylitis;	chr5:96856044	chr5:96804353~96806105:+
SARC	cis	rs56046484	0.703	rs12439802	ENSG00000259295.5	CSPG4P12	4.11	5.56e-05	0.0195	0.4	0.26	Testicular germ cell tumor;	chr15:84977098	chr15:85191438~85213905:+
SARC	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	4.11	5.56e-05	0.0195	0.24	0.26	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
SARC	cis	rs4862750	0.872	rs6811569	ENSG00000250971.1	RP11-696F12.1	-4.11	5.56e-05	0.0195	-0.32	-0.26	Lobe attachment (rater-scored or self-reported);	chr4:186976834	chr4:187060099~187060930:+
SARC	cis	rs4273100	0.646	rs6587216	ENSG00000228157.4	AC007952.5	-4.11	5.57e-05	0.0195	-0.34	-0.26	Schizophrenia;	chr17:19321084	chr17:19092974~19096837:+
SARC	cis	rs783540	0.9	rs55924160	ENSG00000275695.1	UBE2Q2P6	-4.11	5.57e-05	0.0195	-0.26	-0.26	Schizophrenia;	chr15:82613445	chr15:82445719~82454837:+
SARC	cis	rs6477918	0.598	rs7019216	ENSG00000250068.1	RP11-576C12.1	4.11	5.57e-05	0.0195	0.27	0.26	Obstetric antiphospholipid syndrome;	chr9:112399568	chr9:112581779~112582590:-
SARC	cis	rs7216064	1	rs1976053	ENSG00000265055.1	AC145343.2	4.11	5.58e-05	0.0196	0.32	0.26	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836886	chr17:68096046~68101474:-
SARC	cis	rs61160187	0.582	rs1021005	ENSG00000215032.2	GNL3LP1	4.11	5.58e-05	0.0196	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60895633	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.517	rs6884966	ENSG00000215032.2	GNL3LP1	4.11	5.58e-05	0.0196	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60897512	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.518	rs62372133	ENSG00000215032.2	GNL3LP1	4.11	5.58e-05	0.0196	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906350	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.582	rs12655603	ENSG00000215032.2	GNL3LP1	4.11	5.58e-05	0.0196	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60908769	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.582	rs976630	ENSG00000215032.2	GNL3LP1	4.11	5.58e-05	0.0196	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60919654	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.582	rs3797559	ENSG00000215032.2	GNL3LP1	4.11	5.58e-05	0.0196	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60927914	chr5:60891935~60893577:-
SARC	cis	rs42490	0.664	rs394108	ENSG00000251136.7	RP11-37B2.1	-4.11	5.58e-05	0.0196	-0.29	-0.26	Leprosy;	chr8:89812991	chr8:89609409~89757727:-
SARC	cis	rs9309473	0.607	rs6546826	ENSG00000163016.8	ALMS1P	-4.11	5.58e-05	0.0196	-0.31	-0.26	Metabolite levels;	chr2:73372680	chr2:73644919~73685576:+
SARC	cis	rs10911902	0.561	rs1919199	ENSG00000229739.2	RP11-295K2.3	-4.11	5.58e-05	0.0196	-0.38	-0.26	Schizophrenia;	chr1:186300752	chr1:186435161~186470291:+
SARC	cis	rs2439831	0.867	rs2251844	ENSG00000275601.1	AC011330.13	-4.11	5.58e-05	0.0196	-0.41	-0.26	Lung cancer in ever smokers;	chr15:43544280	chr15:43642389~43643023:-
SARC	cis	rs11673344	0.563	rs55825113	ENSG00000226686.6	LINC01535	4.11	5.58e-05	0.0196	0.29	0.26	Obesity-related traits;	chr19:37191523	chr19:37251912~37265535:+
SARC	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-4.11	5.59e-05	0.0196	-0.3	-0.26	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
SARC	cis	rs367615	0.659	rs13435970	ENSG00000249476.1	CTD-2587M2.1	4.11	5.59e-05	0.0196	0.34	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109548959	chr5:109237120~109326369:-
SARC	cis	rs7208859	0.623	rs7214570	ENSG00000264538.5	SUZ12P1	-4.11	5.59e-05	0.0196	-0.27	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30709299~30790908:+
SARC	cis	rs17270561	0.609	rs4711094	ENSG00000272462.2	U91328.19	-4.11	5.59e-05	0.0196	-0.25	-0.26	Iron status biomarkers;	chr6:25705946	chr6:25992662~26001775:+
SARC	cis	rs858239	0.6	rs9691762	ENSG00000226816.2	AC005082.12	4.11	5.59e-05	0.0196	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23206013~23208045:+
SARC	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-4.1	5.6e-05	0.0196	-0.39	-0.26	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
SARC	cis	rs7246657	0.943	rs28373708	ENSG00000226686.6	LINC01535	-4.1	5.6e-05	0.0196	-0.36	-0.26	Coronary artery calcification;	chr19:37485757	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs1382357	ENSG00000226686.6	LINC01535	-4.1	5.6e-05	0.0196	-0.36	-0.26	Coronary artery calcification;	chr19:37486707	chr19:37251912~37265535:+
SARC	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	4.1	5.6e-05	0.0196	0.33	0.26	Height;	chr6:109384807	chr6:109382795~109383666:+
SARC	cis	rs4950322	0.515	rs76327075	ENSG00000278811.3	LINC00624	4.1	5.6e-05	0.0196	0.26	0.26	Protein quantitative trait loci;	chr1:147246319	chr1:147258885~147517875:-
SARC	cis	rs7772486	0.754	rs9497434	ENSG00000270638.1	RP3-466P17.1	-4.1	5.6e-05	0.0196	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs6924159	ENSG00000270638.1	RP3-466P17.1	-4.1	5.6e-05	0.0196	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145735570~145737218:+
SARC	cis	rs755249	0.761	rs3768321	ENSG00000182109.6	RP11-69E11.4	4.1	5.6e-05	0.0196	0.31	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570256	chr1:39522280~39546187:-
SARC	cis	rs853679	0.546	rs200995	ENSG00000216901.1	AL022393.7	-4.1	5.61e-05	0.0196	-0.57	-0.26	Depression;	chr6:27845916	chr6:28176188~28176674:+
SARC	cis	rs7267979	0.932	rs431579	ENSG00000276952.1	RP5-965G21.6	4.1	5.61e-05	0.0197	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:25284915~25285588:-
SARC	cis	rs12893668	0.667	rs71417869	ENSG00000269940.1	RP11-73M18.7	4.1	5.61e-05	0.0197	0.25	0.26	Reticulocyte count;	chr14:103611097	chr14:103694560~103695170:+
SARC	cis	rs910316	0.687	rs11627442	ENSG00000279594.1	RP11-950C14.10	-4.1	5.61e-05	0.0197	-0.29	-0.26	Height;	chr14:75202946	chr14:75011269~75012851:-
SARC	cis	rs61160187	0.698	rs11955398	ENSG00000272308.1	RP11-231G3.1	-4.1	5.61e-05	0.0197	-0.22	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60685258	chr5:60866457~60866935:-
SARC	cis	rs6844153	0.752	rs12650172	ENSG00000240005.4	RP11-293A21.1	-4.1	5.61e-05	0.0197	-0.32	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872784	chr4:26859806~26860599:-
SARC	cis	rs6844153	0.752	rs12641261	ENSG00000240005.4	RP11-293A21.1	-4.1	5.61e-05	0.0197	-0.32	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872814	chr4:26859806~26860599:-
SARC	cis	rs10986311	0.862	rs753788	ENSG00000235204.1	RP11-121A14.2	-4.1	5.62e-05	0.0197	-0.3	-0.26	Vitiligo;	chr9:124332760	chr9:124259250~124261156:-
SARC	cis	rs860818	1	rs858259	ENSG00000226816.2	AC005082.12	4.1	5.62e-05	0.0197	0.75	0.26	Initial pursuit acceleration;	chr7:23175885	chr7:23206013~23208045:+
SARC	cis	rs13126694	0.682	rs4504305	ENSG00000248429.4	RP11-597D13.9	4.1	5.62e-05	0.0197	0.25	0.26	Blood osmolality (transformed sodium);	chr4:157982801	chr4:158170752~158202877:+
SARC	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-4.1	5.62e-05	0.0197	-0.39	-0.26	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
SARC	cis	rs860818	0.793	rs4722233	ENSG00000226816.2	AC005082.12	-4.1	5.62e-05	0.0197	-0.73	-0.26	Initial pursuit acceleration;	chr7:23157792	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs6960118	ENSG00000226816.2	AC005082.12	-4.1	5.62e-05	0.0197	-0.73	-0.26	Initial pursuit acceleration;	chr7:23160709	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs6964671	ENSG00000226816.2	AC005082.12	-4.1	5.62e-05	0.0197	-0.73	-0.26	Initial pursuit acceleration;	chr7:23161183	chr7:23206013~23208045:+
SARC	cis	rs6570726	0.599	rs9376951	ENSG00000270638.1	RP3-466P17.1	4.1	5.62e-05	0.0197	0.22	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145735570~145737218:+
SARC	cis	rs7267979	1	rs11087520	ENSG00000276952.1	RP5-965G21.6	4.1	5.62e-05	0.0197	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs398036	ENSG00000276952.1	RP5-965G21.6	4.1	5.62e-05	0.0197	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs397119	ENSG00000276952.1	RP5-965G21.6	4.1	5.62e-05	0.0197	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs453329	ENSG00000276952.1	RP5-965G21.6	4.1	5.62e-05	0.0197	0.26	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25284915~25285588:-
SARC	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-4.1	5.62e-05	0.0197	-0.24	-0.26	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
SARC	cis	rs11264213	0.901	rs630364	ENSG00000271554.1	RP4-665N4.8	-4.1	5.62e-05	0.0197	-0.36	-0.26	Schizophrenia;	chr1:35983703	chr1:35992109~36013630:-
SARC	cis	rs4713118	0.699	rs200978	ENSG00000216901.1	AL022393.7	4.1	5.62e-05	0.0197	0.4	0.26	Parkinson's disease;	chr6:27885390	chr6:28176188~28176674:+
SARC	cis	rs551585	1	rs17099445	ENSG00000226084.5	RP4-706A16.3	4.1	5.63e-05	0.0197	0.53	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:76682137	chr1:77129114~77129668:+
SARC	cis	rs4664293	0.51	rs2113861	ENSG00000226266.5	AC009961.3	4.1	5.63e-05	0.0197	0.33	0.26	Monocyte percentage of white cells;	chr2:159585233	chr2:159670708~159712435:-
SARC	cis	rs1707322	1	rs1707337	ENSG00000281133.1	AL355480.3	4.1	5.64e-05	0.0197	0.29	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs1768807	ENSG00000281133.1	AL355480.3	4.1	5.64e-05	0.0197	0.29	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45580892~45580996:-
SARC	cis	rs5751614	0.537	rs5759679	ENSG00000230701.2	FBXW4P1	4.1	5.64e-05	0.0197	0.34	0.26	Height;	chr22:23286826	chr22:23262767~23265005:+
SARC	cis	rs4664293	0.967	rs13000070	ENSG00000226266.5	AC009961.3	-4.1	5.64e-05	0.0197	-0.32	-0.26	Monocyte percentage of white cells;	chr2:159669263	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.899	rs7588710	ENSG00000226266.5	AC009961.3	-4.1	5.64e-05	0.0197	-0.32	-0.26	Monocyte percentage of white cells;	chr2:159673011	chr2:159670708~159712435:-
SARC	cis	rs755249	0.588	rs2275767	ENSG00000182109.6	RP11-69E11.4	-4.1	5.64e-05	0.0197	-0.24	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39522280~39546187:-
SARC	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	4.1	5.64e-05	0.0197	0.38	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
SARC	cis	rs597539	0.652	rs602805	ENSG00000250508.1	RP11-757G1.6	-4.1	5.64e-05	0.0198	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68870664~68874542:+
SARC	cis	rs597539	0.652	rs602364	ENSG00000250508.1	RP11-757G1.6	-4.1	5.64e-05	0.0198	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68870664~68874542:+
SARC	cis	rs4660456	0.504	rs587963	ENSG00000237899.1	RP4-739H11.3	4.1	5.64e-05	0.0198	0.31	0.26	Platelet count;	chr1:40640045	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.504	rs587064	ENSG00000237899.1	RP4-739H11.3	4.1	5.64e-05	0.0198	0.31	0.26	Platelet count;	chr1:40640238	chr1:40669089~40687588:-
SARC	cis	rs7772486	0.654	rs4896829	ENSG00000235652.6	RP11-545I5.3	4.1	5.64e-05	0.0198	0.24	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145632539	chr6:145799409~145886585:+
SARC	cis	rs75920871	0.528	rs7124872	ENSG00000254851.1	RP11-109L13.1	-4.1	5.65e-05	0.0198	-0.35	-0.26	Subjective well-being;	chr11:117057235	chr11:117135528~117138582:+
SARC	cis	rs16958440	1	rs62096471	ENSG00000280212.1	RP11-49K24.3	4.1	5.65e-05	0.0198	0.63	0.26	Sitting height ratio;	chr18:47117443	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs4609941	ENSG00000280212.1	RP11-49K24.3	4.1	5.65e-05	0.0198	0.63	0.26	Sitting height ratio;	chr18:47119120	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs57928699	ENSG00000280212.1	RP11-49K24.3	4.1	5.65e-05	0.0198	0.63	0.26	Sitting height ratio;	chr18:47119222	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs60854219	ENSG00000280212.1	RP11-49K24.3	4.1	5.65e-05	0.0198	0.63	0.26	Sitting height ratio;	chr18:47120293	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs62096474	ENSG00000280212.1	RP11-49K24.3	4.1	5.65e-05	0.0198	0.63	0.26	Sitting height ratio;	chr18:47121133	chr18:47076117~47076594:+
SARC	cis	rs16958440	0.737	rs16958699	ENSG00000280212.1	RP11-49K24.3	4.1	5.65e-05	0.0198	0.63	0.26	Sitting height ratio;	chr18:47128475	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs16958701	ENSG00000280212.1	RP11-49K24.3	4.1	5.65e-05	0.0198	0.63	0.26	Sitting height ratio;	chr18:47128870	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs62096478	ENSG00000280212.1	RP11-49K24.3	4.1	5.65e-05	0.0198	0.63	0.26	Sitting height ratio;	chr18:47136038	chr18:47076117~47076594:+
SARC	cis	rs1707322	1	rs10890378	ENSG00000281133.1	AL355480.3	4.1	5.65e-05	0.0198	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45580892~45580996:-
SARC	cis	rs860818	1	rs858253	ENSG00000226816.2	AC005082.12	4.1	5.65e-05	0.0198	0.69	0.26	Initial pursuit acceleration;	chr7:23178101	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858252	ENSG00000226816.2	AC005082.12	4.1	5.65e-05	0.0198	0.69	0.26	Initial pursuit acceleration;	chr7:23178253	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858250	ENSG00000226816.2	AC005082.12	4.1	5.65e-05	0.0198	0.69	0.26	Initial pursuit acceleration;	chr7:23178941	chr7:23206013~23208045:+
SARC	cis	rs867371	1	rs8037224	ENSG00000259429.4	UBE2Q2P2	-4.1	5.66e-05	0.0198	-0.25	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82355142~82420075:+
SARC	cis	rs7923609	0.729	rs7902616	ENSG00000232075.1	MRPL35P2	4.1	5.66e-05	0.0198	0.23	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576613	chr10:63634317~63634827:-
SARC	cis	rs7923609	0.756	rs10822183	ENSG00000232075.1	MRPL35P2	4.1	5.66e-05	0.0198	0.23	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577381	chr10:63634317~63634827:-
SARC	cis	rs28386778	0.863	rs3760256	ENSG00000240280.5	TCAM1P	-4.1	5.66e-05	0.0198	-0.32	-0.26	Prudent dietary pattern;	chr17:63743801	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs8069969	ENSG00000240280.5	TCAM1P	-4.1	5.66e-05	0.0198	-0.32	-0.26	Prudent dietary pattern;	chr17:63744863	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.863	rs9207	ENSG00000240280.5	TCAM1P	-4.1	5.66e-05	0.0198	-0.32	-0.26	Prudent dietary pattern;	chr17:63746539	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs3785572	ENSG00000240280.5	TCAM1P	-4.1	5.66e-05	0.0198	-0.32	-0.26	Prudent dietary pattern;	chr17:63752629	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs4968662	ENSG00000240280.5	TCAM1P	-4.1	5.66e-05	0.0198	-0.32	-0.26	Prudent dietary pattern;	chr17:63757177	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs4968598	ENSG00000240280.5	TCAM1P	-4.1	5.66e-05	0.0198	-0.32	-0.26	Prudent dietary pattern;	chr17:63758219	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs4968663	ENSG00000240280.5	TCAM1P	-4.1	5.66e-05	0.0198	-0.32	-0.26	Prudent dietary pattern;	chr17:63758243	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs7222189	ENSG00000240280.5	TCAM1P	-4.1	5.66e-05	0.0198	-0.32	-0.26	Prudent dietary pattern;	chr17:63759012	chr17:63849292~63864379:+
SARC	cis	rs2235544	0.565	rs928443	ENSG00000225183.1	RP4-758J24.4	4.1	5.66e-05	0.0198	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54007843	chr1:54089856~54090093:+
SARC	cis	rs853679	1	rs1936365	ENSG00000216901.1	AL022393.7	-4.1	5.67e-05	0.0198	-0.44	-0.26	Depression;	chr6:28300675	chr6:28176188~28176674:+
SARC	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	4.1	5.67e-05	0.0198	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	4.1	5.67e-05	0.0198	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	4.1	5.67e-05	0.0198	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
SARC	cis	rs7985	1	rs1894720	ENSG00000206028.1	CTA-373H7.7	4.1	5.67e-05	0.0198	0.29	0.26	Electroencephalogram traits;	chr22:26671261	chr22:26667693~26672654:-
SARC	cis	rs7985	0.967	rs73163299	ENSG00000206028.1	CTA-373H7.7	4.1	5.67e-05	0.0198	0.29	0.26	Electroencephalogram traits;	chr22:26671680	chr22:26667693~26672654:-
SARC	cis	rs755249	0.532	rs2296173	ENSG00000182109.6	RP11-69E11.4	4.1	5.67e-05	0.0198	0.28	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs3118014	ENSG00000182109.6	RP11-69E11.4	4.1	5.67e-05	0.0198	0.28	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39522280~39546187:-
SARC	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-4.1	5.68e-05	0.0199	-0.46	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
SARC	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-4.1	5.68e-05	0.0199	-0.46	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
SARC	cis	rs2274273	0.615	rs17672058	ENSG00000258413.1	RP11-665C16.6	-4.1	5.68e-05	0.0199	-0.35	-0.26	Protein biomarker;	chr14:55206676	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.662	rs67215571	ENSG00000258413.1	RP11-665C16.6	-4.1	5.68e-05	0.0199	-0.35	-0.26	Protein biomarker;	chr14:55207005	chr14:55262767~55272075:-
SARC	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-4.1	5.68e-05	0.0199	-0.24	-0.26	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
SARC	cis	rs495337	0.735	rs528075	ENSG00000229222.1	KRT18P4	-4.1	5.68e-05	0.0199	-0.34	-0.26	Psoriasis;	chr20:49895107	chr20:49956745~49958032:+
SARC	cis	rs1707322	1	rs4606257	ENSG00000281133.1	AL355480.3	-4.1	5.69e-05	0.0199	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45580892~45580996:-
SARC	cis	rs61160187	0.582	rs976631	ENSG00000215032.2	GNL3LP1	4.1	5.69e-05	0.0199	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60920216	chr5:60891935~60893577:-
SARC	cis	rs11955398	0.522	rs329624	ENSG00000215032.2	GNL3LP1	4.1	5.69e-05	0.0199	0.28	0.26	Intelligence (multi-trait analysis);	chr5:60989310	chr5:60891935~60893577:-
SARC	cis	rs11955398	0.502	rs162251	ENSG00000215032.2	GNL3LP1	4.1	5.69e-05	0.0199	0.28	0.26	Intelligence (multi-trait analysis);	chr5:60996457	chr5:60891935~60893577:-
SARC	cis	rs12950390	0.853	rs66471233	ENSG00000239291.1	RP5-867C24.1	4.1	5.69e-05	0.0199	0.3	0.26	IgG glycosylation;	chr17:47789720	chr17:47159191~47159993:-
SARC	cis	rs7937612	1	rs2305010	ENSG00000232460.4	BMPR1APS2	-4.1	5.69e-05	0.0199	-0.26	-0.26	Intraocular pressure;	chr11:120459440	chr11:121361854~121362865:-
SARC	cis	rs2803122	0.745	rs10811143	ENSG00000273226.1	RP11-513M16.8	-4.1	5.7e-05	0.0199	-0.25	-0.26	Pulse pressure;	chr9:19240221	chr9:19375451~19375996:+
SARC	cis	rs12893668	0.572	rs4900591	ENSG00000269958.1	RP11-73M18.8	4.1	5.7e-05	0.0199	0.28	0.26	Reticulocyte count;	chr14:103688541	chr14:103696353~103697163:+
SARC	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	4.1	5.7e-05	0.0199	0.27	0.26	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
SARC	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	4.1	5.7e-05	0.0199	0.49	0.26	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	4.1	5.7e-05	0.0199	0.49	0.26	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	4.1	5.7e-05	0.0199	0.49	0.26	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	4.1	5.7e-05	0.0199	0.49	0.26	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	4.1	5.7e-05	0.0199	0.49	0.26	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	4.1	5.7e-05	0.0199	0.49	0.26	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
SARC	cis	rs13217239	0.646	rs4583981	ENSG00000241549.7	GUSBP2	4.1	5.7e-05	0.0199	0.24	0.26	Schizophrenia;	chr6:27024244	chr6:26871484~26956554:-
SARC	cis	rs13217239	0.646	rs10946897	ENSG00000241549.7	GUSBP2	4.1	5.7e-05	0.0199	0.24	0.26	Schizophrenia;	chr6:27027472	chr6:26871484~26956554:-
SARC	cis	rs4950322	0.515	rs11239958	ENSG00000278811.3	LINC00624	4.1	5.71e-05	0.0199	0.26	0.26	Protein quantitative trait loci;	chr1:147247454	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.515	rs12060046	ENSG00000278811.3	LINC00624	4.1	5.71e-05	0.0199	0.26	0.26	Protein quantitative trait loci;	chr1:147249278	chr1:147258885~147517875:-
SARC	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	4.1	5.71e-05	0.0199	0.23	0.26	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
SARC	cis	rs12817211	0.502	rs12819883	ENSG00000272368.2	RP4-605O3.4	-4.1	5.71e-05	0.0199	-0.25	-0.26	Colorectal or endometrial cancer;	chr12:50140005	chr12:50112197~50165618:+
SARC	cis	rs1707322	1	rs785507	ENSG00000281133.1	AL355480.3	4.1	5.71e-05	0.0199	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45580892~45580996:-
SARC	cis	rs7267979	0.966	rs2261698	ENSG00000276952.1	RP5-965G21.6	4.1	5.72e-05	0.02	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25284915~25285588:-
SARC	cis	rs6142102	0.625	rs6141431	ENSG00000275784.1	RP5-1125A11.6	-4.1	5.72e-05	0.02	-0.3	-0.26	Skin pigmentation;	chr20:33952508	chr20:33989480~33991818:-
SARC	cis	rs7976269	0.609	rs10771474	ENSG00000257176.2	RP11-996F15.2	4.1	5.72e-05	0.02	0.28	0.26	Male-pattern baldness;	chr12:29068776	chr12:29280418~29317848:-
SARC	cis	rs3796352	1	rs7622420	ENSG00000242142.1	SERBP1P3	-4.1	5.72e-05	0.02	-0.44	-0.26	Immune reponse to smallpox (secreted IL-2);	chr3:53077053	chr3:53064283~53065091:-
SARC	cis	rs801193	0.844	rs732465	ENSG00000224316.1	RP11-479O9.2	4.1	5.72e-05	0.02	0.24	0.26	Aortic root size;	chr7:66533463	chr7:65773620~65802067:+
SARC	cis	rs75920871	0.66	rs4938330	ENSG00000254851.1	RP11-109L13.1	4.1	5.72e-05	0.02	0.33	0.26	Subjective well-being;	chr11:117057798	chr11:117135528~117138582:+
SARC	cis	rs890448	0.76	rs833948	ENSG00000254531.1	FLJ20021	4.1	5.72e-05	0.02	0.28	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101391529	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs293213	ENSG00000254531.1	FLJ20021	4.1	5.72e-05	0.02	0.28	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101393716	chr4:101347780~101348883:+
SARC	cis	rs890448	0.76	rs833946	ENSG00000254531.1	FLJ20021	4.1	5.72e-05	0.02	0.28	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395742	chr4:101347780~101348883:+
SARC	cis	rs890448	0.796	rs210811	ENSG00000254531.1	FLJ20021	4.1	5.72e-05	0.02	0.28	0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395833	chr4:101347780~101348883:+
SARC	cis	rs651386	0.505	rs10919441	ENSG00000271811.1	RP1-79C4.4	4.1	5.72e-05	0.02	0.36	0.26	Atrial fibrillation;	chr1:170609948	chr1:170667381~170669425:+
SARC	cis	rs72634501	0.716	rs67637163	ENSG00000182109.6	RP11-69E11.4	4.1	5.73e-05	0.02	0.3	0.26	HDL cholesterol;	chr1:39110949	chr1:39522280~39546187:-
SARC	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-4.1	5.74e-05	0.02	-0.23	-0.26	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
SARC	cis	rs860818	1	rs858251	ENSG00000226816.2	AC005082.12	4.1	5.74e-05	0.02	0.75	0.26	Initial pursuit acceleration;	chr7:23178732	chr7:23206013~23208045:+
SARC	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-4.1	5.75e-05	0.02	-0.19	-0.26	Height;	chr11:118773873	chr11:118791254~118793137:+
SARC	cis	rs1150668	0.796	rs213237	ENSG00000219392.1	RP1-265C24.5	-4.1	5.75e-05	0.02	-0.3	-0.26	Pubertal anthropometrics;	chr6:28356161	chr6:28115628~28116551:+
SARC	cis	rs42490	0.789	rs383592	ENSG00000251136.7	RP11-37B2.1	-4.1	5.75e-05	0.0201	-0.28	-0.26	Leprosy;	chr8:89792100	chr8:89609409~89757727:-
SARC	cis	rs2274273	0.661	rs8019978	ENSG00000258413.1	RP11-665C16.6	4.1	5.76e-05	0.0201	0.29	0.26	Protein biomarker;	chr14:55090566	chr14:55262767~55272075:-
SARC	cis	rs367615	0.918	rs10051855	ENSG00000249476.1	CTD-2587M2.1	4.1	5.76e-05	0.0201	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109524257	chr5:109237120~109326369:-
SARC	cis	rs367615	0.918	rs10055528	ENSG00000249476.1	CTD-2587M2.1	4.1	5.76e-05	0.0201	0.35	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109525428	chr5:109237120~109326369:-
SARC	cis	rs6477918	0.598	rs34120702	ENSG00000250068.1	RP11-576C12.1	-4.1	5.76e-05	0.0201	-0.26	-0.26	Obstetric antiphospholipid syndrome;	chr9:112397239	chr9:112581779~112582590:-
SARC	cis	rs6477918	0.598	rs7046534	ENSG00000250068.1	RP11-576C12.1	-4.1	5.76e-05	0.0201	-0.26	-0.26	Obstetric antiphospholipid syndrome;	chr9:112399269	chr9:112581779~112582590:-
SARC	cis	rs16958440	1	rs60422392	ENSG00000280212.1	RP11-49K24.3	4.1	5.76e-05	0.0201	0.62	0.26	Sitting height ratio;	chr18:47095102	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs62096466	ENSG00000280212.1	RP11-49K24.3	4.1	5.76e-05	0.0201	0.62	0.26	Sitting height ratio;	chr18:47109800	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs76594057	ENSG00000280212.1	RP11-49K24.3	4.1	5.76e-05	0.0201	0.62	0.26	Sitting height ratio;	chr18:47110901	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs62096469	ENSG00000280212.1	RP11-49K24.3	4.1	5.76e-05	0.0201	0.62	0.26	Sitting height ratio;	chr18:47111927	chr18:47076117~47076594:+
SARC	cis	rs6988985	0.678	rs28659182	ENSG00000247317.3	RP11-273G15.2	-4.1	5.76e-05	0.0201	-0.28	-0.26	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142918503	chr8:142981738~143018437:-
SARC	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-4.1	5.77e-05	0.0201	-0.4	-0.26	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
SARC	cis	rs13217239	0.646	rs35691005	ENSG00000241549.7	GUSBP2	4.1	5.77e-05	0.0201	0.24	0.26	Schizophrenia;	chr6:27004291	chr6:26871484~26956554:-
SARC	cis	rs13217239	0.646	rs10946891	ENSG00000241549.7	GUSBP2	4.1	5.77e-05	0.0201	0.24	0.26	Schizophrenia;	chr6:27005436	chr6:26871484~26956554:-
SARC	cis	rs13217239	0.646	rs12201393	ENSG00000241549.7	GUSBP2	4.1	5.77e-05	0.0201	0.24	0.26	Schizophrenia;	chr6:27007911	chr6:26871484~26956554:-
SARC	cis	rs13217239	0.646	rs12209886	ENSG00000241549.7	GUSBP2	4.1	5.77e-05	0.0201	0.24	0.26	Schizophrenia;	chr6:27016978	chr6:26871484~26956554:-
SARC	cis	rs6940638	0.531	rs12211984	ENSG00000241549.7	GUSBP2	4.1	5.77e-05	0.0201	0.24	0.26	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26871484~26956554:-
SARC	cis	rs13217239	0.646	rs10456351	ENSG00000241549.7	GUSBP2	4.1	5.77e-05	0.0201	0.24	0.26	Schizophrenia;	chr6:27019013	chr6:26871484~26956554:-
SARC	cis	rs526231	0.67	rs421946	ENSG00000175749.11	EIF3KP1	4.1	5.77e-05	0.0201	0.31	0.26	Primary biliary cholangitis;	chr5:103286340	chr5:103032376~103033031:+
SARC	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-4.1	5.77e-05	0.0201	-0.35	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
SARC	cis	rs1707322	1	rs6661500	ENSG00000281133.1	AL355480.3	-4.1	5.77e-05	0.0201	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45580892~45580996:-
SARC	cis	rs42490	0.614	rs445172	ENSG00000251136.7	RP11-37B2.1	-4.1	5.77e-05	0.0201	-0.28	-0.26	Leprosy;	chr8:89808322	chr8:89609409~89757727:-
SARC	cis	rs6061231	0.724	rs1570027	ENSG00000275437.1	RP5-908M14.10	4.1	5.77e-05	0.0201	0.26	0.26	Colorectal cancer;	chr20:62393540	chr20:62402236~62405935:-
SARC	cis	rs6061231	0.798	rs2427308	ENSG00000275437.1	RP5-908M14.10	4.1	5.77e-05	0.0201	0.26	0.26	Colorectal cancer;	chr20:62394395	chr20:62402236~62405935:-
SARC	cis	rs2288884	0.708	rs11665783	ENSG00000275055.1	CTC-471J1.11	-4.1	5.78e-05	0.0201	-0.33	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014641	chr19:52049007~52049754:+
SARC	cis	rs9902453	0.904	rs12939344	ENSG00000264538.5	SUZ12P1	-4.1	5.78e-05	0.0201	-0.19	-0.26	Coffee consumption (cups per day);	chr17:30001801	chr17:30709299~30790908:+
SARC	cis	rs12950390	0.853	rs11655112	ENSG00000239291.1	RP5-867C24.1	4.1	5.78e-05	0.0201	0.31	0.26	IgG glycosylation;	chr17:47779197	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.853	rs11658511	ENSG00000239291.1	RP5-867C24.1	4.1	5.78e-05	0.0201	0.31	0.26	IgG glycosylation;	chr17:47779552	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.853	rs17773010	ENSG00000239291.1	RP5-867C24.1	4.1	5.78e-05	0.0201	0.31	0.26	IgG glycosylation;	chr17:47780931	chr17:47159191~47159993:-
SARC	cis	rs11123170	0.529	rs1015755	ENSG00000189223.12	PAX8-AS1	-4.1	5.78e-05	0.0201	-0.36	-0.26	Renal function-related traits (BUN);	chr2:113210730	chr2:113211522~113276581:+
SARC	cis	rs853679	1	rs1936365	ENSG00000219392.1	RP1-265C24.5	4.1	5.78e-05	0.0201	0.44	0.26	Depression;	chr6:28300675	chr6:28115628~28116551:+
SARC	cis	rs718433	0.621	rs10131946	ENSG00000199436.1	SNORD9	4.1	5.78e-05	0.0201	0.26	0.26	Intraocular pressure;	chr14:21858683	chr14:21392150~21392253:-
SARC	cis	rs10911902	0.866	rs3119331	ENSG00000229739.2	RP11-295K2.3	4.1	5.79e-05	0.0202	0.36	0.26	Schizophrenia;	chr1:186465386	chr1:186435161~186470291:+
SARC	cis	rs1862618	0.853	rs2113078	ENSG00000271828.1	CTD-2310F14.1	4.1	5.79e-05	0.0202	0.39	0.26	Initial pursuit acceleration;	chr5:56791363	chr5:56927874~56929573:+
SARC	cis	rs1707322	0.963	rs6429581	ENSG00000281133.1	AL355480.3	-4.1	5.79e-05	0.0202	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45580892~45580996:-
SARC	cis	rs6540731	1	rs1389370	ENSG00000229983.1	RP11-15I11.2	4.1	5.79e-05	0.0202	0.26	0.26	Intelligence (childhood);	chr1:212227275	chr1:212168207~212190259:+
SARC	cis	rs6540731	1	rs6540735	ENSG00000229983.1	RP11-15I11.2	4.1	5.79e-05	0.0202	0.26	0.26	Intelligence (childhood);	chr1:212227418	chr1:212168207~212190259:+
SARC	cis	rs6540731	1	rs6657900	ENSG00000229983.1	RP11-15I11.2	4.1	5.79e-05	0.0202	0.26	0.26	Intelligence (childhood);	chr1:212227524	chr1:212168207~212190259:+
SARC	cis	rs240993	0.715	rs6920798	ENSG00000271789.1	RP5-1112D6.7	4.1	5.79e-05	0.0202	0.3	0.26	Inflammatory skin disease;Psoriasis;	chr6:111526074	chr6:111297126~111298510:+
SARC	cis	rs2712431	0.554	rs2010054	ENSG00000242551.2	POU5F1P6	-4.1	5.81e-05	0.0202	-0.27	-0.26	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128674735~128677005:-
SARC	cis	rs72945132	0.882	rs66989619	ENSG00000254604.1	AP000487.6	-4.1	5.81e-05	0.0202	-0.37	-0.26	Coronary artery disease;	chr11:70356021	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.882	rs56368190	ENSG00000254604.1	AP000487.6	-4.1	5.81e-05	0.0202	-0.37	-0.26	Coronary artery disease;	chr11:70358222	chr11:70282367~70363368:-
SARC	cis	rs13434995	0.513	rs6851971	ENSG00000273257.1	RP11-177J6.1	4.1	5.81e-05	0.0202	0.35	0.26	Adiponectin levels;	chr4:55561897	chr4:55387949~55388271:+
SARC	cis	rs7246657	0.943	rs13343502	ENSG00000226686.6	LINC01535	-4.1	5.81e-05	0.0202	-0.37	-0.26	Coronary artery calcification;	chr19:37471390	chr19:37251912~37265535:+
SARC	cis	rs783540	1	rs11637433	ENSG00000275695.1	UBE2Q2P6	4.1	5.81e-05	0.0202	0.26	0.26	Schizophrenia;	chr15:82652585	chr15:82445719~82454837:+
SARC	cis	rs7267979	1	rs6083844	ENSG00000276952.1	RP5-965G21.6	-4.1	5.82e-05	0.0202	-0.26	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25284915~25285588:-
SARC	cis	rs42490	0.903	rs218948	ENSG00000251136.7	RP11-37B2.1	-4.1	5.82e-05	0.0202	-0.29	-0.26	Leprosy;	chr8:89705617	chr8:89609409~89757727:-
SARC	cis	rs7208859	0.623	rs7220999	ENSG00000264538.5	SUZ12P1	-4.1	5.82e-05	0.0203	-0.29	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs55638872	ENSG00000264538.5	SUZ12P1	-4.1	5.82e-05	0.0203	-0.29	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9899268	ENSG00000264538.5	SUZ12P1	-4.1	5.82e-05	0.0203	-0.29	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30709299~30790908:+
SARC	cis	rs593531	0.513	rs3867268	ENSG00000280269.1	AP000577.2	4.1	5.82e-05	0.0203	0.33	0.26	Neuroticism;	chr11:74322332	chr11:74204869~74205746:+
SARC	cis	rs6540731	1	rs6540731	ENSG00000229983.1	RP11-15I11.2	-4.1	5.82e-05	0.0203	-0.26	-0.26	Intelligence (childhood);	chr1:212218821	chr1:212168207~212190259:+
SARC	cis	rs2904804	0.756	rs7100824	ENSG00000215267.7	AKR1C7P	4.1	5.82e-05	0.0203	0.24	0.26	Economic and political preferences (immigration/crime);	chr10:4943618	chr10:5275173~5288470:-
SARC	cis	rs4660456	0.504	rs491619	ENSG00000237899.1	RP4-739H11.3	4.1	5.82e-05	0.0203	0.31	0.26	Platelet count;	chr1:40641688	chr1:40669089~40687588:-
SARC	cis	rs4660456	0.542	rs850009	ENSG00000237899.1	RP4-739H11.3	4.1	5.82e-05	0.0203	0.31	0.26	Platelet count;	chr1:40643593	chr1:40669089~40687588:-
SARC	cis	rs1023500	0.505	rs2143139	ENSG00000205702.9	CYP2D7	4.1	5.83e-05	0.0203	0.21	0.26	Schizophrenia;	chr22:42218395	chr22:42140203~42144577:-
SARC	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-4.1	5.83e-05	0.0203	-0.28	-0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
SARC	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-4.1	5.83e-05	0.0203	-0.28	-0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
SARC	cis	rs1707322	0.963	rs4630155	ENSG00000281133.1	AL355480.3	-4.09	5.83e-05	0.0203	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.963	rs4508055	ENSG00000281133.1	AL355480.3	-4.09	5.83e-05	0.0203	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.963	rs12076580	ENSG00000281133.1	AL355480.3	-4.09	5.83e-05	0.0203	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45580892~45580996:-
SARC	cis	rs2274273	0.662	rs67958555	ENSG00000258413.1	RP11-665C16.6	-4.09	5.83e-05	0.0203	-0.35	-0.26	Protein biomarker;	chr14:55204148	chr14:55262767~55272075:-
SARC	cis	rs67340775	0.541	rs200965	ENSG00000216901.1	AL022393.7	4.09	5.83e-05	0.0203	0.47	0.26	Lung cancer in ever smokers;	chr6:27898606	chr6:28176188~28176674:+
SARC	cis	rs67340775	0.541	rs200964	ENSG00000216901.1	AL022393.7	4.09	5.83e-05	0.0203	0.47	0.26	Lung cancer in ever smokers;	chr6:27899165	chr6:28176188~28176674:+
SARC	cis	rs16949788	1	rs78288367	ENSG00000261351.2	CTD-3185P2.1	-4.09	5.83e-05	0.0203	-0.5	-0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66480383	chr15:66488658~66492109:-
SARC	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-4.09	5.84e-05	0.0203	-0.49	-0.26	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
SARC	cis	rs448720	0.811	rs694267	ENSG00000259410.4	RP11-34F13.3	-4.09	5.84e-05	0.0203	-0.28	-0.26	Cognitive performance;	chr15:67891039	chr15:67832725~67873866:+
SARC	cis	rs448720	0.811	rs399408	ENSG00000259410.4	RP11-34F13.3	-4.09	5.84e-05	0.0203	-0.28	-0.26	Cognitive performance;	chr15:67891513	chr15:67832725~67873866:+
SARC	cis	rs28386778	0.897	rs9912557	ENSG00000240280.5	TCAM1P	-4.09	5.84e-05	0.0203	-0.32	-0.26	Prudent dietary pattern;	chr17:63707603	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs7210443	ENSG00000240280.5	TCAM1P	-4.09	5.84e-05	0.0203	-0.32	-0.26	Prudent dietary pattern;	chr17:63708014	chr17:63849292~63864379:+
SARC	cis	rs11264213	0.901	rs811114	ENSG00000271554.1	RP4-665N4.8	-4.09	5.84e-05	0.0203	-0.36	-0.26	Schizophrenia;	chr1:35880157	chr1:35992109~36013630:-
SARC	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	4.09	5.84e-05	0.0203	0.39	0.26	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	4.09	5.84e-05	0.0203	0.39	0.26	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	4.09	5.84e-05	0.0203	0.39	0.26	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
SARC	cis	rs890448	0.726	rs2850370	ENSG00000254531.1	FLJ20021	-4.09	5.84e-05	0.0203	-0.27	-0.26	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101315584	chr4:101347780~101348883:+
SARC	cis	rs6477918	0.598	rs7866567	ENSG00000250068.1	RP11-576C12.1	-4.09	5.84e-05	0.0203	-0.28	-0.26	Obstetric antiphospholipid syndrome;	chr9:112437545	chr9:112581779~112582590:-
SARC	cis	rs11955398	0.502	rs6869073	ENSG00000272308.1	RP11-231G3.1	-4.09	5.85e-05	0.0203	-0.24	-0.26	Intelligence (multi-trait analysis);	chr5:61117301	chr5:60866457~60866935:-
SARC	cis	rs11955398	0.542	rs295578	ENSG00000272308.1	RP11-231G3.1	-4.09	5.85e-05	0.0203	-0.24	-0.26	Intelligence (multi-trait analysis);	chr5:61124955	chr5:60866457~60866935:-
SARC	cis	rs11955398	0.502	rs159375	ENSG00000272308.1	RP11-231G3.1	-4.09	5.85e-05	0.0203	-0.24	-0.26	Intelligence (multi-trait analysis);	chr5:61137440	chr5:60866457~60866935:-
SARC	cis	rs11955398	0.502	rs159374	ENSG00000272308.1	RP11-231G3.1	-4.09	5.85e-05	0.0203	-0.24	-0.26	Intelligence (multi-trait analysis);	chr5:61139117	chr5:60866457~60866935:-
SARC	cis	rs11955398	0.502	rs159371	ENSG00000272308.1	RP11-231G3.1	-4.09	5.85e-05	0.0203	-0.24	-0.26	Intelligence (multi-trait analysis);	chr5:61148449	chr5:60866457~60866935:-
SARC	cis	rs11955398	0.502	rs810884	ENSG00000272308.1	RP11-231G3.1	-4.09	5.85e-05	0.0203	-0.24	-0.26	Intelligence (multi-trait analysis);	chr5:61152449	chr5:60866457~60866935:-
SARC	cis	rs11955398	0.502	rs34623	ENSG00000272308.1	RP11-231G3.1	-4.09	5.85e-05	0.0203	-0.24	-0.26	Intelligence (multi-trait analysis);	chr5:61166012	chr5:60866457~60866935:-
SARC	cis	rs11955398	0.502	rs159357	ENSG00000272308.1	RP11-231G3.1	-4.09	5.85e-05	0.0203	-0.24	-0.26	Intelligence (multi-trait analysis);	chr5:61174363	chr5:60866457~60866935:-
SARC	cis	rs7537765	1	rs2050265	ENSG00000242349.4	NPPA-AS1	-4.09	5.85e-05	0.0203	-0.34	-0.26	QRS complex (12-leadsum);	chr1:11819642	chr1:11841017~11848079:+
SARC	cis	rs367615	0.918	rs10054960	ENSG00000249476.1	CTD-2587M2.1	4.09	5.85e-05	0.0203	0.34	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109530747	chr5:109237120~109326369:-
SARC	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	4.09	5.85e-05	0.0203	0.34	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
SARC	cis	rs367615	0.84	rs113540823	ENSG00000249476.1	CTD-2587M2.1	4.09	5.85e-05	0.0203	0.34	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109543383	chr5:109237120~109326369:-
SARC	cis	rs367615	0.879	rs56689485	ENSG00000249476.1	CTD-2587M2.1	4.09	5.85e-05	0.0203	0.34	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109544127	chr5:109237120~109326369:-
SARC	cis	rs111321694	1	rs111321694	ENSG00000271584.1	RP11-89C3.4	4.09	5.85e-05	0.0203	0.44	0.26	Educational attainment (years of education);	chr11:111079662	chr11:111091932~111097357:-
SARC	cis	rs321358	0.895	rs17457076	ENSG00000271584.1	RP11-89C3.4	4.09	5.85e-05	0.0203	0.44	0.26	Body mass index;	chr11:111081030	chr11:111091932~111097357:-
SARC	cis	rs9902453	0.619	rs2617866	ENSG00000264538.5	SUZ12P1	-4.09	5.85e-05	0.0203	-0.18	-0.26	Coffee consumption (cups per day);	chr17:29749199	chr17:30709299~30790908:+
SARC	cis	rs910316	0.935	rs3742771	ENSG00000279594.1	RP11-950C14.10	4.09	5.86e-05	0.0204	0.28	0.26	Height;	chr14:75132944	chr14:75011269~75012851:-
SARC	cis	rs745109	0.751	rs1518808	ENSG00000273080.1	RP11-301O19.1	4.09	5.86e-05	0.0204	0.39	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86419070	chr2:86195590~86196049:+
SARC	cis	rs28386778	0.897	rs2727295	ENSG00000240280.5	TCAM1P	-4.09	5.86e-05	0.0204	-0.32	-0.26	Prudent dietary pattern;	chr17:63810333	chr17:63849292~63864379:+
SARC	cis	rs4835473	0.932	rs4835455	ENSG00000251600.4	RP11-673E1.1	4.09	5.86e-05	0.0204	0.26	0.26	Immature fraction of reticulocytes;	chr4:143962290	chr4:143912331~143982454:+
SARC	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-4.09	5.86e-05	0.0204	-0.26	-0.26	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
SARC	cis	rs7560272	0.682	rs2421546	ENSG00000163016.8	ALMS1P	-4.09	5.86e-05	0.0204	-0.3	-0.26	Schizophrenia;	chr2:73413949	chr2:73644919~73685576:+
SARC	cis	rs253959	0.739	rs712572	ENSG00000272265.1	CTD-2287O16.4	-4.09	5.87e-05	0.0204	-0.3	-0.26	Bipolar disorder and schizophrenia;	chr5:116298430	chr5:116078110~116078570:-
SARC	cis	rs4835473	0.778	rs6856553	ENSG00000251600.4	RP11-673E1.1	-4.09	5.87e-05	0.0204	-0.26	-0.26	Immature fraction of reticulocytes;	chr4:143825973	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.868	rs11737787	ENSG00000251600.4	RP11-673E1.1	-4.09	5.87e-05	0.0204	-0.26	-0.26	Immature fraction of reticulocytes;	chr4:143826498	chr4:143912331~143982454:+
SARC	cis	rs10200159	1	rs7594497	ENSG00000272606.1	RP11-554J4.1	4.09	5.87e-05	0.0204	0.47	0.26	Vitiligo;	chr2:55645403	chr2:55617909~55618373:+
SARC	cis	rs6603134	0.502	rs10411185	ENSG00000267939.1	CTD-2325M2.1	-4.09	5.87e-05	0.0204	-0.28	-0.26	Blood protein levels;	chr19:8038997	chr19:8008729~8016025:+
SARC	cis	rs597539	0.652	rs507520	ENSG00000250508.1	RP11-757G1.6	-4.09	5.87e-05	0.0204	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68870664~68874542:+
SARC	cis	rs7267979	1	rs2856	ENSG00000276952.1	RP5-965G21.6	4.09	5.88e-05	0.0204	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25284915~25285588:-
SARC	cis	rs1823874	0.71	rs8042933	ENSG00000182397.13	DNM1P46	4.09	5.89e-05	0.0204	0.29	0.26	IgG glycosylation;	chr15:99824641	chr15:99790156~99806927:-
SARC	cis	rs1713985	0.508	rs1277283	ENSG00000269949.1	RP11-738E22.3	-4.09	5.89e-05	0.0204	-0.46	-0.26	Age-related macular degeneration;	chr4:56989475	chr4:56960927~56961373:-
SARC	cis	rs7246657	0.943	rs7408563	ENSG00000226686.6	LINC01535	-4.09	5.89e-05	0.0204	-0.36	-0.26	Coronary artery calcification;	chr19:37317683	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs7258692	ENSG00000226686.6	LINC01535	-4.09	5.89e-05	0.0204	-0.36	-0.26	Coronary artery calcification;	chr19:37327927	chr19:37251912~37265535:+
SARC	cis	rs7216064	0.7	rs4791295	ENSG00000237854.3	LINC00674	4.09	5.89e-05	0.0205	0.32	0.26	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68001201	chr17:68101908~68115518:+
SARC	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-4.09	5.89e-05	0.0205	-0.24	-0.26	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
SARC	cis	rs7615952	0.551	rs6438945	ENSG00000250012.1	RP11-124N2.1	-4.09	5.89e-05	0.0205	-0.28	-0.26	Blood pressure (smoking interaction);	chr3:125915630	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.673	rs7632557	ENSG00000250012.1	RP11-124N2.1	-4.09	5.89e-05	0.0205	-0.28	-0.26	Blood pressure (smoking interaction);	chr3:125916038	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.932	rs9841157	ENSG00000250012.1	RP11-124N2.1	-4.09	5.89e-05	0.0205	-0.28	-0.26	Blood pressure (smoking interaction);	chr3:125916812	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.551	rs12695470	ENSG00000250012.1	RP11-124N2.1	-4.09	5.89e-05	0.0205	-0.28	-0.26	Blood pressure (smoking interaction);	chr3:125916875	chr3:126084220~126095349:+
SARC	cis	rs8031584	0.723	rs11632229	ENSG00000270015.1	RP11-540B6.6	4.09	5.9e-05	0.0205	0.23	0.26	Huntington's disease progression;	chr15:30887331	chr15:30926514~30928407:+
SARC	cis	rs9928842	0.823	rs2870472	ENSG00000280152.1	RP11-331F4.5	4.09	5.9e-05	0.0205	0.29	0.26	Alcoholic chronic pancreatitis;	chr16:75244943	chr16:75245994~75250077:-
SARC	cis	rs7520050	0.778	rs3014218	ENSG00000280836.1	AL355480.1	4.09	5.91e-05	0.0205	0.25	0.26	Reticulocyte count;Red blood cell count;	chr1:45560656	chr1:45581219~45581321:-
SARC	cis	rs367615	1	rs58931051	ENSG00000249476.1	CTD-2587M2.1	4.09	5.91e-05	0.0205	0.34	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109572031	chr5:109237120~109326369:-
SARC	cis	rs28386778	0.83	rs67905415	ENSG00000240280.5	TCAM1P	-4.09	5.92e-05	0.0205	-0.32	-0.26	Prudent dietary pattern;	chr17:63763876	chr17:63849292~63864379:+
SARC	cis	rs964184	0.63	rs6589566	ENSG00000254851.1	RP11-109L13.1	-4.09	5.92e-05	0.0205	-0.51	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116781707	chr11:117135528~117138582:+
SARC	cis	rs4934494	0.768	rs34663515	ENSG00000240996.1	RP11-80H5.7	-4.09	5.93e-05	0.0206	-0.28	-0.26	Red blood cell count;	chr10:89632786	chr10:89694295~89697928:-
SARC	cis	rs151234	0.676	rs231970	ENSG00000259982.1	CDC37P1	-4.09	5.93e-05	0.0206	-0.39	-0.26	Platelet distribution width;	chr16:28555683	chr16:28700294~28701540:-
SARC	cis	rs12049351	0.665	rs66521073	ENSG00000229367.1	HMGN2P19	4.09	5.93e-05	0.0206	0.22	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229434771	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.665	rs10753458	ENSG00000229367.1	HMGN2P19	4.09	5.93e-05	0.0206	0.22	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229439962	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.612	rs10753459	ENSG00000229367.1	HMGN2P19	4.09	5.93e-05	0.0206	0.22	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229440017	chr1:229570532~229570796:+
SARC	cis	rs7267979	0.934	rs2261115	ENSG00000276952.1	RP5-965G21.6	4.09	5.93e-05	0.0206	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.966	rs2261747	ENSG00000276952.1	RP5-965G21.6	4.09	5.93e-05	0.0206	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25284915~25285588:-
SARC	cis	rs7772486	0.79	rs4896852	ENSG00000270638.1	RP3-466P17.1	-4.09	5.93e-05	0.0206	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145735570~145737218:+
SARC	cis	rs9902453	0.904	rs12936302	ENSG00000264538.5	SUZ12P1	-4.09	5.93e-05	0.0206	-0.18	-0.26	Coffee consumption (cups per day);	chr17:30022458	chr17:30709299~30790908:+
SARC	cis	rs308403	0.6	rs376131	ENSG00000224786.1	CETN4P	4.09	5.94e-05	0.0206	0.34	0.26	Blood protein levels;	chr4:122708070	chr4:122730548~122732193:-
SARC	cis	rs4372836	0.704	rs966250	ENSG00000226833.4	AC097724.3	4.09	5.94e-05	0.0206	0.23	0.26	Body mass index;	chr2:28751273	chr2:28708953~28736205:-
SARC	cis	rs1865760	0.613	rs9358894	ENSG00000272462.2	U91328.19	-4.09	5.94e-05	0.0206	-0.24	-0.26	Height;	chr6:25923087	chr6:25992662~26001775:+
SARC	cis	rs10751667	0.6	rs1128419	ENSG00000255026.1	RP11-326C3.2	4.09	5.94e-05	0.0206	0.25	0.26	Alzheimer's disease (late onset);	chr11:1010750	chr11:287305~288987:+
SARC	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-4.09	5.95e-05	0.0206	-0.5	-0.26	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
SARC	cis	rs755249	0.567	rs41270807	ENSG00000182109.6	RP11-69E11.4	4.09	5.95e-05	0.0206	0.28	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39522280~39546187:-
SARC	cis	rs792448	1	rs1086893	ENSG00000229983.1	RP11-15I11.2	4.09	5.95e-05	0.0206	0.27	0.26	White blood cell count (basophil);	chr1:212389772	chr1:212168207~212190259:+
SARC	cis	rs6142102	0.58	rs6142101	ENSG00000275784.1	RP5-1125A11.6	-4.09	5.95e-05	0.0206	-0.3	-0.26	Skin pigmentation;	chr20:34110039	chr20:33989480~33991818:-
SARC	cis	rs11955398	0.502	rs34610	ENSG00000272308.1	RP11-231G3.1	-4.09	5.95e-05	0.0206	-0.24	-0.26	Intelligence (multi-trait analysis);	chr5:61183854	chr5:60866457~60866935:-
SARC	cis	rs732716	0.889	rs11085074	ENSG00000267980.1	AC007292.6	-4.09	5.95e-05	0.0206	-0.33	-0.26	Mean corpuscular volume;	chr19:4386355	chr19:4363789~4364640:+
SARC	cis	rs732716	0.889	rs55637375	ENSG00000267980.1	AC007292.6	-4.09	5.95e-05	0.0206	-0.33	-0.26	Mean corpuscular volume;	chr19:4386848	chr19:4363789~4364640:+
SARC	cis	rs2179367	0.887	rs6570965	ENSG00000216906.2	RP11-350J20.9	4.09	5.96e-05	0.0206	0.24	0.26	Dupuytren's disease;	chr6:149396340	chr6:149904243~149906418:+
SARC	cis	rs7772486	0.686	rs2328708	ENSG00000235652.6	RP11-545I5.3	-4.09	5.96e-05	0.0206	-0.23	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145799409~145886585:+
SARC	cis	rs2179367	0.632	rs9285520	ENSG00000231760.4	RP11-350J20.5	-4.09	5.96e-05	0.0206	-0.34	-0.26	Dupuytren's disease;	chr6:149372001	chr6:149796151~149826294:-
SARC	cis	rs160451	0.811	rs160418	ENSG00000251136.7	RP11-37B2.1	4.09	5.96e-05	0.0207	0.3	0.26	Leprosy;	chr8:89631300	chr8:89609409~89757727:-
SARC	cis	rs35740288	0.731	rs11638407	ENSG00000202081.1	RNU6-1280P	4.09	5.96e-05	0.0207	0.31	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85551424	chr15:85651522~85651628:-
SARC	cis	rs763121	1	rs763121	ENSG00000273076.1	RP3-508I15.22	-4.09	5.96e-05	0.0207	-0.28	-0.26	Menopause (age at onset);	chr22:38483935	chr22:38743495~38743910:+
SARC	cis	rs4664293	0.867	rs2114626	ENSG00000226266.5	AC009961.3	4.09	5.96e-05	0.0207	0.31	0.26	Monocyte percentage of white cells;	chr2:159783459	chr2:159670708~159712435:-
SARC	cis	rs2439831	0.85	rs524417	ENSG00000205771.5	CATSPER2P1	-4.09	5.97e-05	0.0207	-0.41	-0.26	Lung cancer in ever smokers;	chr15:43480176	chr15:43726918~43747094:-
SARC	cis	rs11086243	0.935	rs6090807	ENSG00000276923.1	RP11-321P16.1	4.09	5.97e-05	0.0207	0.32	0.26	Nephrotic syndrome (acquired);	chr20:48134671	chr20:48073869~48074188:+
SARC	cis	rs6877440	0.555	rs17162024	ENSG00000271849.1	CTC-332L22.1	-4.09	5.97e-05	0.0207	-0.53	-0.26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr5:109658979	chr5:109687802~109688329:-
SARC	cis	rs17695224	0.545	rs7253924	ENSG00000275055.1	CTC-471J1.11	-4.09	5.97e-05	0.0207	-0.26	-0.26	HDL cholesterol;HDL cholesterol levels;	chr19:51824960	chr19:52049007~52049754:+
SARC	cis	rs17695224	0.545	rs8109098	ENSG00000275055.1	CTC-471J1.11	-4.09	5.97e-05	0.0207	-0.26	-0.26	HDL cholesterol;HDL cholesterol levels;	chr19:51825363	chr19:52049007~52049754:+
SARC	cis	rs4372836	0.729	rs10198789	ENSG00000226833.4	AC097724.3	4.09	5.97e-05	0.0207	0.22	0.26	Body mass index;	chr2:28745945	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.729	rs10174533	ENSG00000226833.4	AC097724.3	4.09	5.97e-05	0.0207	0.22	0.26	Body mass index;	chr2:28746062	chr2:28708953~28736205:-
SARC	cis	rs4773330	0.66	rs1557247	ENSG00000277767.1	RP11-365P13.5	4.09	5.98e-05	0.0207	0.26	0.26	Bilirubin levels;	chr13:111155301	chr13:110916004~110917827:+
SARC	cis	rs1707322	1	rs1613296	ENSG00000280836.1	AL355480.1	4.09	5.98e-05	0.0207	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45581219~45581321:-
SARC	cis	rs9928842	0.882	rs3169330	ENSG00000280152.1	RP11-331F4.5	4.09	5.98e-05	0.0207	0.32	0.26	Alcoholic chronic pancreatitis;	chr16:75235369	chr16:75245994~75250077:-
SARC	cis	rs8028182	0.636	rs4564532	ENSG00000260206.1	CTD-2026K11.2	-4.09	5.98e-05	0.0207	-0.31	-0.26	Sudden cardiac arrest;	chr15:75413955	chr15:75636139~75639239:+
SARC	cis	rs889122	0.55	rs8108431	ENSG00000267289.1	CTD-2623N2.11	4.09	5.98e-05	0.0207	0.25	0.26	Menarche (age at onset);	chr19:9886011	chr19:9834079~9835013:-
SARC	cis	rs2288884	0.708	rs12460617	ENSG00000275055.1	CTC-471J1.11	-4.09	5.98e-05	0.0207	-0.32	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032581	chr19:52049007~52049754:+
SARC	cis	rs12468226	0.873	rs1474267	ENSG00000272966.1	RP11-686O6.1	-4.09	5.99e-05	0.0207	-0.47	-0.26	Urate levels;	chr2:202178596	chr2:202336739~202337200:+
SARC	cis	rs2404602	0.716	rs12594577	ENSG00000259422.1	RP11-593F23.1	4.09	5.99e-05	0.0207	0.28	0.26	Blood metabolite levels;	chr15:76536452	chr15:76174891~76181486:-
SARC	cis	rs12893668	0.572	rs4906356	ENSG00000269958.1	RP11-73M18.8	4.09	5.99e-05	0.0207	0.28	0.26	Reticulocyte count;	chr14:103672364	chr14:103696353~103697163:+
SARC	cis	rs72480748	0.509	rs3865457	ENSG00000256612.6	CYP2B7P	-4.09	5.99e-05	0.0207	-0.32	-0.26	Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);Post bronchodilator FEV1;	chr19:40893064	chr19:40924219~40950660:+
SARC	cis	rs6477918	0.598	rs58653211	ENSG00000250068.1	RP11-576C12.1	-4.09	6e-05	0.0207	-0.27	-0.26	Obstetric antiphospholipid syndrome;	chr9:112406179	chr9:112581779~112582590:-
SARC	cis	rs9601248	0.627	rs2146593	ENSG00000227676.3	LINC01068	4.09	6e-05	0.0207	0.28	0.26	Major depressive disorder;	chr13:79605977	chr13:79566727~79571436:+
SARC	cis	rs160451	0.966	rs28374917	ENSG00000251136.7	RP11-37B2.1	4.09	6e-05	0.0207	0.28	0.26	Leprosy;	chr8:89666525	chr8:89609409~89757727:-
SARC	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-4.09	6e-05	0.0207	-0.23	-0.26	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-4.09	6e-05	0.0207	-0.23	-0.26	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-4.09	6e-05	0.0207	-0.23	-0.26	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
SARC	cis	rs7429990	0.932	rs13085054	ENSG00000229759.1	MRPS18AP1	-4.09	6e-05	0.0207	-0.3	-0.26	Educational attainment (years of education);	chr3:48092647	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.87	rs13089844	ENSG00000229759.1	MRPS18AP1	-4.09	6e-05	0.0207	-0.3	-0.26	Educational attainment (years of education);	chr3:48098741	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-4.09	6e-05	0.0207	-0.3	-0.26	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.932	rs12486714	ENSG00000229759.1	MRPS18AP1	-4.09	6e-05	0.0207	-0.3	-0.26	Educational attainment (years of education);	chr3:48107210	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-4.09	6e-05	0.0207	-0.3	-0.26	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.896	rs7427648	ENSG00000229759.1	MRPS18AP1	-4.09	6e-05	0.0207	-0.3	-0.26	Educational attainment (years of education);	chr3:48116749	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-4.09	6e-05	0.0207	-0.3	-0.26	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
SARC	cis	rs72627509	0.904	rs781663	ENSG00000269949.1	RP11-738E22.3	4.09	6e-05	0.0208	0.38	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915588	chr4:56960927~56961373:-
SARC	cis	rs755249	0.588	rs6665948	ENSG00000182109.6	RP11-69E11.4	-4.09	6e-05	0.0208	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478508	chr1:39522280~39546187:-
SARC	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	4.09	6e-05	0.0208	0.38	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
SARC	cis	rs367615	0.879	rs2201015	ENSG00000249476.1	CTD-2587M2.1	4.09	6e-05	0.0208	0.32	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109611749	chr5:109237120~109326369:-
SARC	cis	rs6570726	0.967	rs7772286	ENSG00000235652.6	RP11-545I5.3	-4.09	6e-05	0.0208	-0.23	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145799409~145886585:+
SARC	cis	rs7208859	0.573	rs8064686	ENSG00000264538.5	SUZ12P1	-4.09	6.01e-05	0.0208	-0.27	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30709299~30790908:+
SARC	cis	rs28386778	0.863	rs7221573	ENSG00000240280.5	TCAM1P	-4.09	6.01e-05	0.0208	-0.32	-0.26	Prudent dietary pattern;	chr17:63782030	chr17:63849292~63864379:+
SARC	cis	rs9527	0.615	rs11191401	ENSG00000213061.2	PFN1P11	4.09	6.01e-05	0.0208	0.32	0.26	Arsenic metabolism;	chr10:102813646	chr10:102838011~102845473:-
SARC	cis	rs763121	0.925	rs9611008	ENSG00000273076.1	RP3-508I15.22	4.09	6.01e-05	0.0208	0.27	0.26	Menopause (age at onset);	chr22:38702782	chr22:38743495~38743910:+
SARC	cis	rs875971	0.558	rs4433015	ENSG00000224316.1	RP11-479O9.2	-4.09	6.01e-05	0.0208	-0.24	-0.26	Aortic root size;	chr7:66174736	chr7:65773620~65802067:+
SARC	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-4.09	6.01e-05	0.0208	-0.48	-0.26	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-4.09	6.01e-05	0.0208	-0.48	-0.26	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-4.09	6.01e-05	0.0208	-0.48	-0.26	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-4.09	6.01e-05	0.0208	-0.48	-0.26	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
SARC	cis	rs11634944	0.644	rs2554419	ENSG00000274307.1	RP11-345J18.2	-4.09	6.02e-05	0.0208	-0.33	-0.26	Interleukin-8 levels;	chr15:24995018	chr15:25708470~25710869:-
SARC	cis	rs4372836	0.576	rs6547880	ENSG00000226833.4	AC097724.3	4.09	6.02e-05	0.0208	0.22	0.26	Body mass index;	chr2:28796023	chr2:28708953~28736205:-
SARC	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	4.09	6.02e-05	0.0208	0.31	0.26	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
SARC	cis	rs2933343	0.516	rs11926639	ENSG00000231305.3	RP11-723O4.2	4.09	6.02e-05	0.0208	0.37	0.26	IgG glycosylation;	chr3:128872320	chr3:128861313~128871540:-
SARC	cis	rs745109	0.504	rs76526816	ENSG00000273080.1	RP11-301O19.1	4.09	6.03e-05	0.0208	0.39	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86370509	chr2:86195590~86196049:+
SARC	cis	rs7772486	0.654	rs1011597	ENSG00000235652.6	RP11-545I5.3	-4.09	6.03e-05	0.0208	-0.23	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145799409~145886585:+
SARC	cis	rs2412819	0.545	rs654276	ENSG00000205771.5	CATSPER2P1	4.09	6.04e-05	0.0209	0.4	0.26	Lung cancer;	chr15:43798656	chr15:43726918~43747094:-
SARC	cis	rs12893668	0.542	rs12884809	ENSG00000269910.1	RP11-73M18.10	4.09	6.04e-05	0.0209	0.23	0.26	Reticulocyte count;	chr14:103628983	chr14:103694516~103695050:-
SARC	cis	rs12980942	0.872	rs7256416	ENSG00000206674.1	RNU6-945P	-4.09	6.04e-05	0.0209	-0.38	-0.26	Coronary artery disease;	chr19:41282026	chr19:40299478~40299584:-
SARC	cis	rs12980942	0.63	rs7257825	ENSG00000206674.1	RNU6-945P	-4.09	6.04e-05	0.0209	-0.38	-0.26	Coronary artery disease;	chr19:41282439	chr19:40299478~40299584:-
SARC	cis	rs12980942	0.63	rs7256856	ENSG00000206674.1	RNU6-945P	-4.09	6.04e-05	0.0209	-0.38	-0.26	Coronary artery disease;	chr19:41282447	chr19:40299478~40299584:-
SARC	cis	rs12950390	0.853	rs56363619	ENSG00000239291.1	RP5-867C24.1	4.09	6.05e-05	0.0209	0.3	0.26	IgG glycosylation;	chr17:47777255	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.853	rs28589850	ENSG00000239291.1	RP5-867C24.1	4.09	6.05e-05	0.0209	0.3	0.26	IgG glycosylation;	chr17:47778347	chr17:47159191~47159993:-
SARC	cis	rs8028182	0.636	rs4486847	ENSG00000260206.1	CTD-2026K11.2	-4.09	6.05e-05	0.0209	-0.31	-0.26	Sudden cardiac arrest;	chr15:75436190	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs4886703	ENSG00000260206.1	CTD-2026K11.2	-4.09	6.05e-05	0.0209	-0.31	-0.26	Sudden cardiac arrest;	chr15:75438025	chr15:75636139~75639239:+
SARC	cis	rs755249	0.567	rs61779309	ENSG00000182109.6	RP11-69E11.4	4.09	6.05e-05	0.0209	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39522280~39546187:-
SARC	cis	rs577676	0.586	rs12068805	ENSG00000271811.1	RP1-79C4.4	4.09	6.05e-05	0.0209	0.37	0.26	Prevalent atrial fibrillation;	chr1:170632172	chr1:170667381~170669425:+
SARC	cis	rs577676	0.586	rs12566725	ENSG00000271811.1	RP1-79C4.4	4.09	6.05e-05	0.0209	0.37	0.26	Prevalent atrial fibrillation;	chr1:170632794	chr1:170667381~170669425:+
SARC	cis	rs577676	0.564	rs644784	ENSG00000271811.1	RP1-79C4.4	4.09	6.05e-05	0.0209	0.37	0.26	Prevalent atrial fibrillation;	chr1:170636945	chr1:170667381~170669425:+
SARC	cis	rs160451	0.739	rs218904	ENSG00000251136.7	RP11-37B2.1	-4.09	6.06e-05	0.0209	-0.3	-0.26	Leprosy;	chr8:89722278	chr8:89609409~89757727:-
SARC	cis	rs2274273	0.688	rs6573001	ENSG00000258413.1	RP11-665C16.6	-4.09	6.06e-05	0.0209	-0.29	-0.26	Protein biomarker;	chr14:55089784	chr14:55262767~55272075:-
SARC	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-4.08	6.07e-05	0.0209	-0.4	-0.26	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
SARC	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-4.08	6.07e-05	0.021	-0.19	-0.26	Height;	chr11:118761813	chr11:118791254~118793137:+
SARC	cis	rs2288884	0.708	rs61574510	ENSG00000275055.1	CTC-471J1.11	-4.08	6.07e-05	0.021	-0.33	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017354	chr19:52049007~52049754:+
SARC	cis	rs2439831	0.85	rs2228368	ENSG00000275601.1	AC011330.13	-4.08	6.07e-05	0.021	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43809812	chr15:43642389~43643023:-
SARC	cis	rs638893	0.617	rs4938558	ENSG00000278376.1	RP11-158I9.8	-4.08	6.08e-05	0.021	-0.22	-0.26	Vitiligo;	chr11:118847220	chr11:118791254~118793137:+
SARC	cis	rs61160187	0.556	rs4647052	ENSG00000215032.2	GNL3LP1	4.08	6.08e-05	0.021	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60939656	chr5:60891935~60893577:-
SARC	cis	rs28386778	0.897	rs2584640	ENSG00000240280.5	TCAM1P	-4.08	6.08e-05	0.021	-0.32	-0.26	Prudent dietary pattern;	chr17:63786128	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2584639	ENSG00000240280.5	TCAM1P	-4.08	6.08e-05	0.021	-0.32	-0.26	Prudent dietary pattern;	chr17:63786372	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.863	rs2597633	ENSG00000240280.5	TCAM1P	-4.08	6.08e-05	0.021	-0.32	-0.26	Prudent dietary pattern;	chr17:63795511	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2727333	ENSG00000240280.5	TCAM1P	-4.08	6.08e-05	0.021	-0.32	-0.26	Prudent dietary pattern;	chr17:63798663	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.863	rs2251164	ENSG00000240280.5	TCAM1P	-4.08	6.08e-05	0.021	-0.32	-0.26	Prudent dietary pattern;	chr17:63806760	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2727290	ENSG00000240280.5	TCAM1P	-4.08	6.08e-05	0.021	-0.32	-0.26	Prudent dietary pattern;	chr17:63817368	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs1062788	ENSG00000240280.5	TCAM1P	-4.08	6.08e-05	0.021	-0.32	-0.26	Prudent dietary pattern;	chr17:63818767	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs1062790	ENSG00000240280.5	TCAM1P	-4.08	6.08e-05	0.021	-0.32	-0.26	Prudent dietary pattern;	chr17:63819095	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs894408	ENSG00000240280.5	TCAM1P	-4.08	6.08e-05	0.021	-0.32	-0.26	Prudent dietary pattern;	chr17:63819454	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.863	rs2727288	ENSG00000240280.5	TCAM1P	-4.08	6.08e-05	0.021	-0.32	-0.26	Prudent dietary pattern;	chr17:63823837	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs894407	ENSG00000240280.5	TCAM1P	-4.08	6.08e-05	0.021	-0.32	-0.26	Prudent dietary pattern;	chr17:63824281	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs894406	ENSG00000240280.5	TCAM1P	-4.08	6.08e-05	0.021	-0.32	-0.26	Prudent dietary pattern;	chr17:63824297	chr17:63849292~63864379:+
SARC	cis	rs2235544	0.565	rs676562	ENSG00000225183.1	RP4-758J24.4	4.08	6.08e-05	0.021	0.29	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54002965	chr1:54089856~54090093:+
SARC	cis	rs10895987	1	rs10895987	ENSG00000254614.2	AP003068.23	-4.08	6.08e-05	0.021	-0.37	-0.26	Blood protein levels;	chr11:65137437	chr11:65177606~65181834:-
SARC	cis	rs9283706	0.594	rs10515036	ENSG00000229666.1	MAST4-AS1	4.08	6.08e-05	0.021	0.32	0.26	Coronary artery disease;	chr5:67047959	chr5:67001383~67003953:-
SARC	cis	rs4934494	0.768	rs2094214	ENSG00000240996.1	RP11-80H5.7	-4.08	6.09e-05	0.021	-0.28	-0.26	Red blood cell count;	chr10:89649624	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.635	rs12572869	ENSG00000240996.1	RP11-80H5.7	-4.08	6.09e-05	0.021	-0.28	-0.26	Red blood cell count;	chr10:89653611	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.768	rs67111731	ENSG00000240996.1	RP11-80H5.7	-4.08	6.09e-05	0.021	-0.28	-0.26	Red blood cell count;	chr10:89659528	chr10:89694295~89697928:-
SARC	cis	rs193541	0.593	rs246309	ENSG00000263432.2	RN7SL689P	4.08	6.09e-05	0.021	0.33	0.26	Glucose homeostasis traits;	chr5:122934024	chr5:123022487~123022783:-
SARC	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	4.08	6.09e-05	0.021	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
SARC	cis	rs755249	0.567	rs61779308	ENSG00000182109.6	RP11-69E11.4	4.08	6.09e-05	0.021	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39522280~39546187:-
SARC	cis	rs11098499	0.863	rs1155576	ENSG00000250950.1	RP11-33B1.3	-4.08	6.09e-05	0.021	-0.28	-0.26	Corneal astigmatism;	chr4:119529004	chr4:119456350~119457277:+
SARC	cis	rs11098499	0.863	rs6858592	ENSG00000250950.1	RP11-33B1.3	-4.08	6.09e-05	0.021	-0.28	-0.26	Corneal astigmatism;	chr4:119537537	chr4:119456350~119457277:+
SARC	cis	rs6570726	0.846	rs9399559	ENSG00000235652.6	RP11-545I5.3	4.08	6.1e-05	0.021	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs9376956	ENSG00000235652.6	RP11-545I5.3	4.08	6.1e-05	0.021	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.658	rs6570706	ENSG00000235652.6	RP11-545I5.3	4.08	6.1e-05	0.021	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145799409~145886585:+
SARC	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-4.08	6.1e-05	0.021	-0.3	-0.26	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
SARC	cis	rs597539	0.652	rs660614	ENSG00000250508.1	RP11-757G1.6	-4.08	6.1e-05	0.021	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68870664~68874542:+
SARC	cis	rs3821902	0.646	rs17344570	ENSG00000271843.1	RP11-245J9.5	4.08	6.1e-05	0.021	0.36	0.26	Breast cancer;	chr3:64028563	chr3:64008082~64008692:-
SARC	cis	rs12893668	0.663	rs12889731	ENSG00000269910.1	RP11-73M18.10	4.08	6.1e-05	0.021	0.24	0.26	Reticulocyte count;	chr14:103621145	chr14:103694516~103695050:-
SARC	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	4.08	6.11e-05	0.021	0.33	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
SARC	cis	rs8098244	0.571	rs72876000	ENSG00000265752.2	RP11-403A21.1	-4.08	6.11e-05	0.0211	-0.31	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23989446	chr18:23957754~23982556:-
SARC	cis	rs13434995	0.589	rs62305201	ENSG00000273257.1	RP11-177J6.1	-4.08	6.11e-05	0.0211	-0.35	-0.26	Adiponectin levels;	chr4:55386778	chr4:55387949~55388271:+
SARC	cis	rs13434995	0.589	rs62305202	ENSG00000273257.1	RP11-177J6.1	-4.08	6.11e-05	0.0211	-0.35	-0.26	Adiponectin levels;	chr4:55386861	chr4:55387949~55388271:+
SARC	cis	rs7772486	0.686	rs9497395	ENSG00000235652.6	RP11-545I5.3	-4.08	6.11e-05	0.0211	-0.23	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145799409~145886585:+
SARC	cis	rs727479	0.502	rs12591172	ENSG00000244879.4	GABPB1-AS1	-4.08	6.12e-05	0.0211	-0.21	-0.26	Estradiol levels;	chr15:51211530	chr15:50354959~50372202:+
SARC	cis	rs2439831	0.681	rs2278858	ENSG00000205771.5	CATSPER2P1	-4.08	6.12e-05	0.0211	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43340557	chr15:43726918~43747094:-
SARC	cis	rs7246657	0.943	rs34603719	ENSG00000226686.6	LINC01535	-4.08	6.12e-05	0.0211	-0.39	-0.26	Coronary artery calcification;	chr19:37303626	chr19:37251912~37265535:+
SARC	cis	rs4660214	0.666	rs4660550	ENSG00000182109.6	RP11-69E11.4	-4.08	6.13e-05	0.0211	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222787	chr1:39522280~39546187:-
SARC	cis	rs950776	0.518	rs12914694	ENSG00000261762.1	RP11-650L12.2	4.08	6.13e-05	0.0211	0.27	0.26	Sudden cardiac arrest;	chr15:78522102	chr15:78589123~78591276:-
SARC	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	4.08	6.13e-05	0.0211	0.24	0.26	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
SARC	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-4.08	6.13e-05	0.0211	-0.24	-0.26	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
SARC	cis	rs11955398	0.502	rs295524	ENSG00000272308.1	RP11-231G3.1	-4.08	6.14e-05	0.0211	-0.24	-0.26	Intelligence (multi-trait analysis);	chr5:61177224	chr5:60866457~60866935:-
SARC	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-4.08	6.14e-05	0.0211	-0.27	-0.26	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
SARC	cis	rs11159086	1	rs4899514	ENSG00000270000.1	RP3-449M8.9	-4.08	6.14e-05	0.0211	-0.4	-0.26	Advanced glycation end-product levels;	chr14:74473467	chr14:74471930~74472360:-
SARC	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-4.08	6.14e-05	0.0211	-0.49	-0.26	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
SARC	cis	rs12817211	0.549	rs6580728	ENSG00000272368.2	RP4-605O3.4	-4.08	6.14e-05	0.0211	-0.25	-0.26	Colorectal or endometrial cancer;	chr12:50147344	chr12:50112197~50165618:+
SARC	cis	rs12049351	0.774	rs6681212	ENSG00000229367.1	HMGN2P19	4.08	6.14e-05	0.0211	0.21	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229503337	chr1:229570532~229570796:+
SARC	cis	rs7267979	0.727	rs4815431	ENSG00000276952.1	RP5-965G21.6	-4.08	6.14e-05	0.0211	-0.25	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25284915~25285588:-
SARC	cis	rs1707322	1	rs11211217	ENSG00000281133.1	AL355480.3	-4.08	6.14e-05	0.0211	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45580892~45580996:-
SARC	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	4.08	6.14e-05	0.0211	0.35	0.26	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
SARC	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	4.08	6.14e-05	0.0211	0.35	0.26	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
SARC	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	4.08	6.14e-05	0.0211	0.35	0.26	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
SARC	cis	rs867371	0.892	rs4344697	ENSG00000259429.4	UBE2Q2P2	-4.08	6.15e-05	0.0212	-0.24	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82355142~82420075:+
SARC	cis	rs6845263	0.571	rs1593545	ENSG00000254531.1	FLJ20021	-4.08	6.15e-05	0.0212	-0.25	-0.26	Superior crus of antihelix expression;	chr4:101536850	chr4:101347780~101348883:+
SARC	cis	rs11105298	0.891	rs10858854	ENSG00000258302.2	RP11-981P6.1	4.08	6.15e-05	0.0212	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89441951	chr12:89561129~89594878:+
SARC	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-4.08	6.16e-05	0.0212	-0.26	-0.26	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
SARC	cis	rs853679	1	rs853685	ENSG00000219392.1	RP1-265C24.5	-4.08	6.16e-05	0.0212	-0.44	-0.26	Depression;	chr6:28321008	chr6:28115628~28116551:+
SARC	cis	rs853679	1	rs853679	ENSG00000219392.1	RP1-265C24.5	-4.08	6.16e-05	0.0212	-0.44	-0.26	Depression;	chr6:28329086	chr6:28115628~28116551:+
SARC	cis	rs853679	1	rs853678	ENSG00000219392.1	RP1-265C24.5	-4.08	6.16e-05	0.0212	-0.44	-0.26	Depression;	chr6:28329536	chr6:28115628~28116551:+
SARC	cis	rs12950390	0.853	rs8078052	ENSG00000239291.1	RP5-867C24.1	4.08	6.16e-05	0.0212	0.3	0.26	IgG glycosylation;	chr17:47782068	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.853	rs56387656	ENSG00000239291.1	RP5-867C24.1	4.08	6.16e-05	0.0212	0.3	0.26	IgG glycosylation;	chr17:47782823	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.853	rs56137679	ENSG00000239291.1	RP5-867C24.1	4.08	6.16e-05	0.0212	0.3	0.26	IgG glycosylation;	chr17:47784746	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.853	rs11079792	ENSG00000239291.1	RP5-867C24.1	4.08	6.16e-05	0.0212	0.3	0.26	IgG glycosylation;	chr17:47785945	chr17:47159191~47159993:-
SARC	cis	rs4372836	0.729	rs4132617	ENSG00000226833.4	AC097724.3	4.08	6.16e-05	0.0212	0.22	0.26	Body mass index;	chr2:28808446	chr2:28708953~28736205:-
SARC	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-4.08	6.16e-05	0.0212	-0.49	-0.26	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-4.08	6.16e-05	0.0212	-0.49	-0.26	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
SARC	cis	rs4372836	0.658	rs11127189	ENSG00000226833.4	AC097724.3	4.08	6.17e-05	0.0212	0.23	0.26	Body mass index;	chr2:28769154	chr2:28708953~28736205:-
SARC	cis	rs72945132	0.882	rs6592552	ENSG00000254604.1	AP000487.6	-4.08	6.17e-05	0.0212	-0.37	-0.26	Coronary artery disease;	chr11:70377725	chr11:70282367~70363368:-
SARC	cis	rs72615157	0.664	rs6953580	ENSG00000242294.5	STAG3L5P	4.08	6.17e-05	0.0212	0.21	0.26	Lung function (FEV1/FVC);	chr7:100227652	chr7:100336079~100351900:+
SARC	cis	rs4713118	0.662	rs149948	ENSG00000272009.1	RP1-313I6.12	-4.08	6.17e-05	0.0212	-0.31	-0.26	Parkinson's disease;	chr6:28007039	chr6:28078792~28081130:-
SARC	cis	rs2274273	0.87	rs1952087	ENSG00000258413.1	RP11-665C16.6	-4.08	6.17e-05	0.0212	-0.29	-0.26	Protein biomarker;	chr14:55216493	chr14:55262767~55272075:-
SARC	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-4.08	6.18e-05	0.0212	-0.19	-0.26	Height;	chr11:118760944	chr11:118791254~118793137:+
SARC	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-4.08	6.18e-05	0.0212	-0.19	-0.26	Height;	chr11:118764443	chr11:118791254~118793137:+
SARC	cis	rs875971	0.577	rs34888281	ENSG00000224316.1	RP11-479O9.2	-4.08	6.18e-05	0.0213	-0.25	-0.26	Aortic root size;	chr7:66120784	chr7:65773620~65802067:+
SARC	cis	rs867371	0.964	rs7169961	ENSG00000259429.4	UBE2Q2P2	-4.08	6.18e-05	0.0213	-0.25	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82355142~82420075:+
SARC	cis	rs867371	1	rs6495643	ENSG00000259429.4	UBE2Q2P2	-4.08	6.18e-05	0.0213	-0.25	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82355142~82420075:+
SARC	cis	rs59104589	0.583	rs62186399	ENSG00000266621.1	AC104841.1	4.08	6.19e-05	0.0213	0.36	0.26	Fibrinogen levels;	chr2:241285910	chr2:241245202~241245299:-
SARC	cis	rs4835473	0.932	rs6838887	ENSG00000251600.4	RP11-673E1.1	-4.08	6.19e-05	0.0213	-0.25	-0.26	Immature fraction of reticulocytes;	chr4:143748130	chr4:143912331~143982454:+
SARC	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	4.08	6.2e-05	0.0213	0.24	0.26	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
SARC	cis	rs1823913	0.637	rs11688994	ENSG00000280083.1	RP11-317J9.1	-4.08	6.21e-05	0.0213	-0.3	-0.26	Obesity-related traits;	chr2:191266242	chr2:191154118~191156070:-
SARC	cis	rs728616	0.614	rs2181204	ENSG00000225484.5	NUTM2B-AS1	-4.08	6.21e-05	0.0213	-0.42	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944756	chr10:79663088~79826594:-
SARC	cis	rs67340775	0.541	rs200968	ENSG00000216901.1	AL022393.7	4.08	6.21e-05	0.0213	0.47	0.26	Lung cancer in ever smokers;	chr6:27891790	chr6:28176188~28176674:+
SARC	cis	rs67340775	0.541	rs200966	ENSG00000216901.1	AL022393.7	4.08	6.21e-05	0.0213	0.47	0.26	Lung cancer in ever smokers;	chr6:27894374	chr6:28176188~28176674:+
SARC	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	4.08	6.21e-05	0.0213	0.24	0.26	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
SARC	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	4.08	6.22e-05	0.0213	0.3	0.26	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
SARC	cis	rs9902453	0.868	rs11080118	ENSG00000264538.5	SUZ12P1	-4.08	6.22e-05	0.0213	-0.18	-0.26	Coffee consumption (cups per day);	chr17:30148361	chr17:30709299~30790908:+
SARC	cis	rs7772486	0.686	rs9403739	ENSG00000235652.6	RP11-545I5.3	-4.08	6.22e-05	0.0213	-0.23	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145799409~145886585:+
SARC	cis	rs577676	0.586	rs549449	ENSG00000271811.1	RP1-79C4.4	4.08	6.22e-05	0.0214	0.37	0.26	Prevalent atrial fibrillation;	chr1:170641569	chr1:170667381~170669425:+
SARC	cis	rs2439831	0.85	rs2439832	ENSG00000205771.5	CATSPER2P1	-4.08	6.22e-05	0.0214	-0.41	-0.26	Lung cancer in ever smokers;	chr15:43487488	chr15:43726918~43747094:-
SARC	cis	rs7085104	0.632	rs6162	ENSG00000213061.2	PFN1P11	4.08	6.22e-05	0.0214	0.3	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837224	chr10:102838011~102845473:-
SARC	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	4.08	6.22e-05	0.0214	0.24	0.26	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
SARC	cis	rs6570726	0.846	rs1935616	ENSG00000235652.6	RP11-545I5.3	4.08	6.22e-05	0.0214	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.846	rs9376954	ENSG00000235652.6	RP11-545I5.3	4.08	6.22e-05	0.0214	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145799409~145886585:+
SARC	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-4.08	6.22e-05	0.0214	-0.29	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-4.08	6.22e-05	0.0214	-0.29	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
SARC	cis	rs2029362	0.611	rs2030324	ENSG00000245573.6	BDNF-AS	4.08	6.22e-05	0.0214	0.22	0.26	Total body bone mineral density;	chr11:27705368	chr11:27506838~27698174:+
SARC	cis	rs9828933	1	rs9828933	ENSG00000280620.1	SCAANT1	4.08	6.23e-05	0.0214	0.38	0.26	Type 2 diabetes;	chr3:64017221	chr3:63911518~63911772:-
SARC	cis	rs9828933	0.938	rs7617036	ENSG00000280620.1	SCAANT1	4.08	6.23e-05	0.0214	0.38	0.26	Type 2 diabetes;	chr3:64017319	chr3:63911518~63911772:-
SARC	cis	rs2274273	0.905	rs8007620	ENSG00000258413.1	RP11-665C16.6	-4.08	6.23e-05	0.0214	-0.31	-0.26	Protein biomarker;	chr14:55119869	chr14:55262767~55272075:-
SARC	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	4.08	6.23e-05	0.0214	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	4.08	6.23e-05	0.0214	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
SARC	cis	rs7246657	0.943	rs4802766	ENSG00000226686.6	LINC01535	-4.08	6.23e-05	0.0214	-0.37	-0.26	Coronary artery calcification;	chr19:37491031	chr19:37251912~37265535:+
SARC	cis	rs7772486	0.875	rs1331639	ENSG00000270638.1	RP3-466P17.1	-4.08	6.24e-05	0.0214	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:146110733	chr6:145735570~145737218:+
SARC	cis	rs4835265	0.852	rs4835023	ENSG00000272727.1	RP11-142A22.4	-4.08	6.24e-05	0.0214	-0.37	-0.26	Gamma glutamyl transpeptidase;	chr4:145848840	chr4:145335263~145340421:-
SARC	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-4.08	6.24e-05	0.0214	-0.24	-0.26	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
SARC	cis	rs494459	0.536	rs11217063	ENSG00000255422.1	AP002954.4	-4.08	6.24e-05	0.0214	-0.26	-0.26	Height;	chr11:118855233	chr11:118704607~118750263:+
SARC	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-4.08	6.24e-05	0.0214	-0.48	-0.26	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	4.08	6.24e-05	0.0214	0.48	0.26	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	4.08	6.24e-05	0.0214	0.48	0.26	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-4.08	6.24e-05	0.0214	-0.48	-0.26	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
SARC	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	4.08	6.25e-05	0.0214	0.29	0.26	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
SARC	cis	rs9926296	0.744	rs164746	ENSG00000260259.1	RP11-368I7.4	4.08	6.25e-05	0.0214	0.29	0.26	Vitiligo;	chr16:89642611	chr16:89682620~89686569:-
SARC	cis	rs783540	1	rs698500	ENSG00000275695.1	UBE2Q2P6	-4.08	6.25e-05	0.0214	-0.27	-0.26	Schizophrenia;	chr15:82569019	chr15:82445719~82454837:+
SARC	cis	rs12049351	0.665	rs12140368	ENSG00000229367.1	HMGN2P19	4.08	6.25e-05	0.0215	0.22	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229435823	chr1:229570532~229570796:+
SARC	cis	rs62432291	0.681	rs420137	ENSG00000235086.1	FNDC1-IT1	-4.08	6.25e-05	0.0215	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159231899	chr6:159240786~159243329:+
SARC	cis	rs755249	0.546	rs7533743	ENSG00000182109.6	RP11-69E11.4	-4.08	6.25e-05	0.0215	-0.24	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491497	chr1:39522280~39546187:-
SARC	cis	rs755249	0.565	rs7555699	ENSG00000182109.6	RP11-69E11.4	-4.08	6.25e-05	0.0215	-0.24	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491629	chr1:39522280~39546187:-
SARC	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	4.08	6.26e-05	0.0215	0.28	0.26	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	4.08	6.26e-05	0.0215	0.28	0.26	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
SARC	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	4.08	6.26e-05	0.0215	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	4.08	6.26e-05	0.0215	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
SARC	cis	rs6969780	1	rs1548497	ENSG00000233429.8	HOTAIRM1	-4.08	6.26e-05	0.0215	-0.4	-0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27134697	chr7:27095647~27100265:+
SARC	cis	rs72634501	0.716	rs2036465	ENSG00000182109.6	RP11-69E11.4	-4.08	6.26e-05	0.0215	-0.29	-0.26	HDL cholesterol;	chr1:39110310	chr1:39522280~39546187:-
SARC	cis	rs2179367	0.959	rs9373592	ENSG00000216906.2	RP11-350J20.9	4.08	6.26e-05	0.0215	0.24	0.26	Dupuytren's disease;	chr6:149412119	chr6:149904243~149906418:+
SARC	cis	rs2404602	0.716	rs12907805	ENSG00000259422.1	RP11-593F23.1	4.08	6.26e-05	0.0215	0.29	0.26	Blood metabolite levels;	chr15:76398265	chr15:76174891~76181486:-
SARC	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	4.08	6.27e-05	0.0215	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
SARC	cis	rs7772486	0.686	rs1292334	ENSG00000235652.6	RP11-545I5.3	4.08	6.27e-05	0.0215	0.24	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145799409~145886585:+
SARC	cis	rs6082278	0.563	rs6035756	ENSG00000225127.2	LINC00237	-4.08	6.27e-05	0.0215	-0.29	-0.26	Colonoscopy-negative controls vs population controls;	chr20:20997786	chr20:21087604~21106358:-
SARC	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-4.08	6.28e-05	0.0215	-0.3	-0.26	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
SARC	cis	rs2412819	0.571	rs8038068	ENSG00000205771.5	CATSPER2P1	-4.08	6.28e-05	0.0215	-0.41	-0.26	Lung cancer;	chr15:43622175	chr15:43726918~43747094:-
SARC	cis	rs2315504	0.509	rs3760335	ENSG00000234477.1	AC004231.2	-4.08	6.28e-05	0.0215	-0.31	-0.26	Height;	chr17:40869809	chr17:40921430~40975926:+
SARC	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-4.08	6.28e-05	0.0215	-0.26	-0.26	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
SARC	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	4.08	6.28e-05	0.0215	0.25	0.26	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
SARC	cis	rs7267979	0.844	rs6076343	ENSG00000125804.12	FAM182A	4.08	6.28e-05	0.0215	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:26054655~26086917:+
SARC	cis	rs7162943	0.887	rs11858280	ENSG00000260123.1	RP11-326A19.4	-4.08	6.28e-05	0.0215	-0.25	-0.26	Mean platelet volume;	chr15:89069059	chr15:89041223~89082819:+
SARC	cis	rs157198	1	rs157198	ENSG00000237934.1	RP11-467D18.2	4.08	6.29e-05	0.0215	0.44	0.26	Mean platelet volume;	chr1:28877395	chr1:29223933~29224816:+
SARC	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	4.08	6.29e-05	0.0216	0.27	0.26	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
SARC	cis	rs8042680	0.522	rs12595616	ENSG00000214432.8	AC068831.10	4.08	6.29e-05	0.0216	0.28	0.26	Type 2 diabetes;	chr15:91020283	chr15:91022619~91036611:+
SARC	cis	rs494459	0.536	rs7103067	ENSG00000255422.1	AP002954.4	-4.08	6.29e-05	0.0216	-0.26	-0.26	Height;	chr11:118852670	chr11:118704607~118750263:+
SARC	cis	rs6540731	0.967	rs1472226	ENSG00000229983.1	RP11-15I11.2	4.08	6.3e-05	0.0216	0.26	0.26	Intelligence (childhood);	chr1:212229238	chr1:212168207~212190259:+
SARC	cis	rs11264213	0.901	rs12031138	ENSG00000271554.1	RP4-665N4.8	4.08	6.3e-05	0.0216	0.35	0.26	Schizophrenia;	chr1:35942205	chr1:35992109~36013630:-
SARC	cis	rs783540	1	rs1259180	ENSG00000275695.1	UBE2Q2P6	-4.08	6.31e-05	0.0216	-0.26	-0.26	Schizophrenia;	chr15:82575930	chr15:82445719~82454837:+
SARC	cis	rs59104589	0.583	rs12618809	ENSG00000266621.1	AC104841.1	4.08	6.31e-05	0.0216	0.36	0.26	Fibrinogen levels;	chr2:241309707	chr2:241245202~241245299:-
SARC	cis	rs7560272	0.723	rs6743576	ENSG00000163016.8	ALMS1P	4.07	6.31e-05	0.0216	0.3	0.26	Schizophrenia;	chr2:73587206	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.607	rs1522926	ENSG00000163016.8	ALMS1P	4.07	6.32e-05	0.0216	0.31	0.26	Metabolite levels;	chr2:73364113	chr2:73644919~73685576:+
SARC	cis	rs6570726	0.599	rs4398765	ENSG00000270638.1	RP3-466P17.1	4.07	6.32e-05	0.0216	0.22	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145735570~145737218:+
SARC	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-4.07	6.32e-05	0.0216	-0.48	-0.26	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	4.07	6.32e-05	0.0216	0.48	0.26	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	4.07	6.32e-05	0.0216	0.48	0.26	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	4.07	6.32e-05	0.0216	0.48	0.26	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	4.07	6.32e-05	0.0216	0.48	0.26	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	4.07	6.32e-05	0.0216	0.48	0.26	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	4.07	6.32e-05	0.0216	0.48	0.26	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
SARC	cis	rs5758511	0.68	rs56111723	ENSG00000227370.1	RP4-669P10.19	4.07	6.32e-05	0.0216	0.29	0.26	Birth weight;	chr22:42268877	chr22:42132543~42132998:+
SARC	cis	rs12049351	0.719	rs10916499	ENSG00000229367.1	HMGN2P19	4.07	6.32e-05	0.0216	0.22	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229505331	chr1:229570532~229570796:+
SARC	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	4.07	6.32e-05	0.0216	0.37	0.26	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
SARC	cis	rs755249	0.701	rs4660823	ENSG00000182109.6	RP11-69E11.4	4.07	6.32e-05	0.0216	0.25	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39532851	chr1:39522280~39546187:-
SARC	cis	rs2933343	0.818	rs6764681	ENSG00000231305.3	RP11-723O4.2	-4.07	6.32e-05	0.0216	-0.29	-0.26	IgG glycosylation;	chr3:128849537	chr3:128861313~128871540:-
SARC	cis	rs5758659	1	rs5758659	ENSG00000270083.1	RP1-257I20.14	4.07	6.33e-05	0.0216	0.26	0.26	Cognitive function;	chr22:42225997	chr22:42089630~42090028:-
SARC	cis	rs6142102	0.625	rs6142051	ENSG00000275784.1	RP5-1125A11.6	-4.07	6.33e-05	0.0216	-0.3	-0.26	Skin pigmentation;	chr20:33945212	chr20:33989480~33991818:-
SARC	cis	rs1707322	1	rs4660906	ENSG00000281133.1	AL355480.3	-4.07	6.33e-05	0.0216	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs3922887	ENSG00000281133.1	AL355480.3	-4.07	6.33e-05	0.0216	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs3922886	ENSG00000281133.1	AL355480.3	-4.07	6.33e-05	0.0216	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45580892~45580996:-
SARC	cis	rs875971	0.508	rs10258739	ENSG00000224316.1	RP11-479O9.2	-4.07	6.33e-05	0.0217	-0.24	-0.26	Aortic root size;	chr7:66597948	chr7:65773620~65802067:+
SARC	cis	rs67340775	0.541	rs200979	ENSG00000216901.1	AL022393.7	4.07	6.33e-05	0.0217	0.47	0.26	Lung cancer in ever smokers;	chr6:27884579	chr6:28176188~28176674:+
SARC	cis	rs67340775	0.541	rs169287	ENSG00000216901.1	AL022393.7	4.07	6.33e-05	0.0217	0.47	0.26	Lung cancer in ever smokers;	chr6:27886982	chr6:28176188~28176674:+
SARC	cis	rs67340775	0.541	rs200975	ENSG00000216901.1	AL022393.7	4.07	6.33e-05	0.0217	0.47	0.26	Lung cancer in ever smokers;	chr6:27887847	chr6:28176188~28176674:+
SARC	cis	rs67340775	0.541	rs200974	ENSG00000216901.1	AL022393.7	4.07	6.33e-05	0.0217	0.47	0.26	Lung cancer in ever smokers;	chr6:27888067	chr6:28176188~28176674:+
SARC	cis	rs2404602	0.716	rs12437627	ENSG00000259422.1	RP11-593F23.1	4.07	6.33e-05	0.0217	0.28	0.26	Blood metabolite levels;	chr15:76552709	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.716	rs1946650	ENSG00000259422.1	RP11-593F23.1	4.07	6.33e-05	0.0217	0.28	0.26	Blood metabolite levels;	chr15:76556122	chr15:76174891~76181486:-
SARC	cis	rs9925964	0.933	rs8050894	ENSG00000183604.13	SMG1P5	4.07	6.34e-05	0.0217	0.24	0.26	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093188	chr16:30267553~30335374:-
SARC	cis	rs526231	0.764	rs2116755	ENSG00000175749.11	EIF3KP1	4.07	6.34e-05	0.0217	0.31	0.26	Primary biliary cholangitis;	chr5:103314187	chr5:103032376~103033031:+
SARC	cis	rs6142102	0.517	rs6142046	ENSG00000275784.1	RP5-1125A11.6	-4.07	6.34e-05	0.0217	-0.3	-0.26	Skin pigmentation;	chr20:33926255	chr20:33989480~33991818:-
SARC	cis	rs12530	0.651	rs2072816	ENSG00000230736.2	RP1-149A16.3	-4.07	6.34e-05	0.0217	-0.3	-0.26	IgG glycosylation;	chr22:32394411	chr22:32376664~32384343:+
SARC	cis	rs860818	0.793	rs1881202	ENSG00000226816.2	AC005082.12	-4.07	6.35e-05	0.0217	-0.65	-0.26	Initial pursuit acceleration;	chr7:23153889	chr7:23206013~23208045:+
SARC	cis	rs7246657	0.941	rs67293224	ENSG00000226686.6	LINC01535	-4.07	6.35e-05	0.0217	-0.39	-0.26	Coronary artery calcification;	chr19:37312346	chr19:37251912~37265535:+
SARC	cis	rs3824347	0.934	rs1176815	ENSG00000203321.2	C9orf41-AS1	4.07	6.35e-05	0.0217	0.29	0.26	Urinary magnesium-to-creatinine ratio;	chr9:74937279	chr9:74952968~74996293:+
SARC	cis	rs1062177	1	rs62377945	ENSG00000254226.4	CTB-12O2.1	4.07	6.36e-05	0.0217	0.35	0.26	Preschool internalizing problems;	chr5:151828443	chr5:151949571~152270448:+
SARC	cis	rs12542260	1	rs12548836	ENSG00000253106.1	RP11-158K1.3	-4.07	6.36e-05	0.0217	-0.3	-0.26	Colonoscopy-negative controls vs population controls;	chr8:124517114	chr8:124488510~124491643:+
SARC	cis	rs12542260	0.953	rs62527910	ENSG00000253106.1	RP11-158K1.3	-4.07	6.36e-05	0.0217	-0.3	-0.26	Colonoscopy-negative controls vs population controls;	chr8:124519198	chr8:124488510~124491643:+
SARC	cis	rs9595908	0.931	rs9595595	ENSG00000212293.1	SNORA16	4.07	6.36e-05	0.0217	0.26	0.26	Body mass index;	chr13:32473678	chr13:32420390~32420516:-
SARC	cis	rs9595908	0.931	rs11839309	ENSG00000212293.1	SNORA16	4.07	6.36e-05	0.0217	0.26	0.26	Body mass index;	chr13:32473853	chr13:32420390~32420516:-
SARC	cis	rs3824347	0.571	rs773141	ENSG00000203321.2	C9orf41-AS1	4.07	6.36e-05	0.0217	0.26	0.26	Urinary magnesium-to-creatinine ratio;	chr9:75049679	chr9:74952968~74996293:+
SARC	cis	rs2307449	0.892	rs8040654	ENSG00000261441.1	RP11-217B1.2	4.07	6.36e-05	0.0217	0.32	0.26	Menopause (age at onset);	chr15:89262401	chr15:89335053~89336161:+
SARC	cis	rs6988985	0.678	rs1799998	ENSG00000247317.3	RP11-273G15.2	-4.07	6.37e-05	0.0218	-0.28	-0.26	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142918184	chr8:142981738~143018437:-
SARC	cis	rs4934494	0.681	rs12572928	ENSG00000240996.1	RP11-80H5.7	-4.07	6.37e-05	0.0218	-0.28	-0.26	Red blood cell count;	chr10:89793792	chr10:89694295~89697928:-
SARC	cis	rs745109	0.504	rs77013753	ENSG00000273080.1	RP11-301O19.1	4.07	6.38e-05	0.0218	0.39	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86371654	chr2:86195590~86196049:+
SARC	cis	rs10911902	0.874	rs7515126	ENSG00000229739.2	RP11-295K2.3	-4.07	6.38e-05	0.0218	-0.36	-0.26	Schizophrenia;	chr1:186543283	chr1:186435161~186470291:+
SARC	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-4.07	6.38e-05	0.0218	-0.27	-0.26	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
SARC	cis	rs11955398	0.502	rs6868884	ENSG00000272308.1	RP11-231G3.1	-4.07	6.38e-05	0.0218	-0.24	-0.26	Intelligence (multi-trait analysis);	chr5:61087133	chr5:60866457~60866935:-
SARC	cis	rs4835473	0.932	rs13119602	ENSG00000251600.4	RP11-673E1.1	-4.07	6.38e-05	0.0218	-0.25	-0.26	Immature fraction of reticulocytes;	chr4:143736621	chr4:143912331~143982454:+
SARC	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	4.07	6.39e-05	0.0218	0.41	0.26	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
SARC	cis	rs279910	0.604	rs279888	ENSG00000281769.1	LINC01230	-4.07	6.39e-05	0.0218	-0.24	-0.26	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr9:978833	chr9:1045625~1048641:+
SARC	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-4.07	6.39e-05	0.0218	-0.24	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
SARC	cis	rs5758511	0.68	rs739146	ENSG00000227370.1	RP4-669P10.19	4.07	6.4e-05	0.0218	0.29	0.26	Birth weight;	chr22:42264408	chr22:42132543~42132998:+
SARC	cis	rs5758511	0.596	rs55644935	ENSG00000227370.1	RP4-669P10.19	4.07	6.4e-05	0.0218	0.29	0.26	Birth weight;	chr22:42270063	chr22:42132543~42132998:+
SARC	cis	rs755249	1	rs4660293	ENSG00000182109.6	RP11-69E11.4	-4.07	6.4e-05	0.0218	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39522280~39546187:-
SARC	cis	rs577676	0.586	rs533603	ENSG00000271811.1	RP1-79C4.4	4.07	6.4e-05	0.0218	0.37	0.26	Prevalent atrial fibrillation;	chr1:170639527	chr1:170667381~170669425:+
SARC	cis	rs577676	0.586	rs578928	ENSG00000271811.1	RP1-79C4.4	4.07	6.4e-05	0.0218	0.37	0.26	Prevalent atrial fibrillation;	chr1:170640602	chr1:170667381~170669425:+
SARC	cis	rs1707322	1	rs10890381	ENSG00000281133.1	AL355480.3	-4.07	6.4e-05	0.0218	-0.3	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45580892~45580996:-
SARC	cis	rs860818	1	rs6461699	ENSG00000226816.2	AC005082.12	-4.07	6.4e-05	0.0218	-0.73	-0.26	Initial pursuit acceleration;	chr7:23162679	chr7:23206013~23208045:+
SARC	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-4.07	6.4e-05	0.0218	-0.41	-0.26	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
SARC	cis	rs61160187	0.582	rs13359074	ENSG00000215032.2	GNL3LP1	4.07	6.41e-05	0.0219	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906758	chr5:60891935~60893577:-
SARC	cis	rs72647484	0.555	rs2982288	ENSG00000228397.1	RP1-224A6.3	-4.07	6.41e-05	0.0219	-0.55	-0.26	Colorectal cancer;	chr1:22195077	chr1:22023994~22024968:-
SARC	cis	rs72647484	0.555	rs2998271	ENSG00000228397.1	RP1-224A6.3	-4.07	6.41e-05	0.0219	-0.55	-0.26	Colorectal cancer;	chr1:22195110	chr1:22023994~22024968:-
SARC	cis	rs72647484	0.555	rs2807313	ENSG00000228397.1	RP1-224A6.3	-4.07	6.41e-05	0.0219	-0.55	-0.26	Colorectal cancer;	chr1:22195707	chr1:22023994~22024968:-
SARC	cis	rs1943345	0.556	rs665714	ENSG00000254551.1	RP11-727A23.7	4.07	6.41e-05	0.0219	0.27	0.26	Obesity-related traits;	chr11:83200219	chr11:83209431~83213379:-
SARC	cis	rs593531	0.571	rs10793081	ENSG00000280269.1	AP000577.2	-4.07	6.42e-05	0.0219	-0.32	-0.26	Neuroticism;	chr11:74381358	chr11:74204869~74205746:+
SARC	cis	rs13161895	1	rs27018	ENSG00000250999.1	RP11-1379J22.5	-4.07	6.43e-05	0.0219	-0.45	-0.26	LDL cholesterol;	chr5:179978144	chr5:179657762~179664432:+
SARC	cis	rs853679	1	rs1679709	ENSG00000219392.1	RP1-265C24.5	4.07	6.43e-05	0.0219	0.48	0.26	Depression;	chr6:28260564	chr6:28115628~28116551:+
SARC	cis	rs7617773	0.78	rs35411187	ENSG00000228638.1	FCF1P2	-4.07	6.43e-05	0.0219	-0.3	-0.26	Coronary artery disease;	chr3:48318527	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs11714176	ENSG00000228638.1	FCF1P2	-4.07	6.43e-05	0.0219	-0.3	-0.26	Coronary artery disease;	chr3:48319372	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs11718350	ENSG00000228638.1	FCF1P2	-4.07	6.43e-05	0.0219	-0.3	-0.26	Coronary artery disease;	chr3:48319502	chr3:48290793~48291375:-
SARC	cis	rs10540	1	rs35068485	ENSG00000277290.1	RP11-326C3.16	4.07	6.43e-05	0.0219	0.31	0.26	Body mass index;	chr11:466032	chr11:243099~243483:-
SARC	cis	rs10540	1	rs61876326	ENSG00000277290.1	RP11-326C3.16	4.07	6.43e-05	0.0219	0.31	0.26	Body mass index;	chr11:467368	chr11:243099~243483:-
SARC	cis	rs2079515	0.585	rs11077529	ENSG00000267365.1	KCNJ2-AS1	-4.07	6.43e-05	0.0219	-0.3	-0.26	Childhood and early adolescence aggressive behavior;	chr17:70906410	chr17:70166961~70169402:-
SARC	cis	rs12893668	0.572	rs4906350	ENSG00000269958.1	RP11-73M18.8	4.07	6.43e-05	0.0219	0.28	0.26	Reticulocyte count;	chr14:103645457	chr14:103696353~103697163:+
SARC	cis	rs72817562	0.688	rs17074187	ENSG00000254252.1	RPL7P20	4.07	6.44e-05	0.0219	0.34	0.26	Neuroticism;	chr5:165244550	chr5:166028567~166029311:-
SARC	cis	rs2762353	0.505	rs2096386	ENSG00000272462.2	U91328.19	4.07	6.44e-05	0.0219	0.23	0.26	Blood metabolite levels;	chr6:25787589	chr6:25992662~26001775:+
SARC	cis	rs867371	1	rs1846911	ENSG00000259429.4	UBE2Q2P2	-4.07	6.45e-05	0.022	-0.24	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82355142~82420075:+
SARC	cis	rs867371	0.929	rs7176075	ENSG00000259429.4	UBE2Q2P2	-4.07	6.45e-05	0.022	-0.24	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82355142~82420075:+
SARC	cis	rs867371	1	rs8041868	ENSG00000259429.4	UBE2Q2P2	-4.07	6.45e-05	0.022	-0.24	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82355142~82420075:+
SARC	cis	rs253959	0.739	rs168826	ENSG00000272265.1	CTD-2287O16.4	-4.07	6.45e-05	0.022	-0.3	-0.26	Bipolar disorder and schizophrenia;	chr5:116299083	chr5:116078110~116078570:-
SARC	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	4.07	6.45e-05	0.022	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
SARC	cis	rs12542260	0.906	rs62527886	ENSG00000253106.1	RP11-158K1.3	-4.07	6.46e-05	0.022	-0.3	-0.26	Colonoscopy-negative controls vs population controls;	chr8:124481298	chr8:124488510~124491643:+
SARC	cis	rs12542260	1	rs12542260	ENSG00000253106.1	RP11-158K1.3	-4.07	6.46e-05	0.022	-0.3	-0.26	Colonoscopy-negative controls vs population controls;	chr8:124490199	chr8:124488510~124491643:+
SARC	cis	rs12542260	0.906	rs7830325	ENSG00000253106.1	RP11-158K1.3	-4.07	6.46e-05	0.022	-0.3	-0.26	Colonoscopy-negative controls vs population controls;	chr8:124491175	chr8:124488510~124491643:+
SARC	cis	rs4761974	1	rs10783445	ENSG00000260473.1	RP11-923I11.4	4.07	6.46e-05	0.022	0.56	0.26	White matter lesion progression;White matter lesion progression (adjusted for white matter lesion burden at baseline);	chr12:51486042	chr12:51823503~51835496:+
SARC	cis	rs7308116	0.676	rs10861832	ENSG00000240441.1	RP11-864J10.2	-4.07	6.46e-05	0.022	-0.29	-0.26	Pelvic organ prolapse (moderate/severe);	chr12:107901658	chr12:107719599~107720133:+
SARC	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-4.07	6.47e-05	0.022	-0.3	-0.26	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
SARC	cis	rs783540	0.5	rs783541	ENSG00000275695.1	UBE2Q2P6	-4.07	6.47e-05	0.022	-0.28	-0.26	Schizophrenia;	chr15:82586310	chr15:82445719~82454837:+
SARC	cis	rs853679	0.55	rs1150689	ENSG00000216901.1	AL022393.7	4.07	6.47e-05	0.022	0.34	0.26	Depression;	chr6:28197321	chr6:28176188~28176674:+
SARC	cis	rs853679	0.55	rs1225599	ENSG00000216901.1	AL022393.7	4.07	6.47e-05	0.022	0.34	0.26	Depression;	chr6:28197412	chr6:28176188~28176674:+
SARC	cis	rs853679	0.574	rs1233705	ENSG00000216901.1	AL022393.7	4.07	6.47e-05	0.022	0.34	0.26	Depression;	chr6:28198669	chr6:28176188~28176674:+
SARC	cis	rs9890032	0.934	rs7225461	ENSG00000266490.1	CTD-2349P21.9	4.07	6.47e-05	0.022	0.22	0.26	Hip circumference adjusted for BMI;	chr17:30932881	chr17:30792372~30792833:+
SARC	cis	rs17270561	0.636	rs9393656	ENSG00000272462.2	U91328.19	-4.07	6.47e-05	0.022	-0.25	-0.26	Iron status biomarkers;	chr6:25721831	chr6:25992662~26001775:+
SARC	cis	rs2179367	0.959	rs579789	ENSG00000216906.2	RP11-350J20.9	4.07	6.48e-05	0.022	0.23	0.26	Dupuytren's disease;	chr6:149358235	chr6:149904243~149906418:+
SARC	cis	rs2179367	0.959	rs489551	ENSG00000216906.2	RP11-350J20.9	4.07	6.48e-05	0.022	0.23	0.26	Dupuytren's disease;	chr6:149368321	chr6:149904243~149906418:+
SARC	cis	rs4934494	0.727	rs12572012	ENSG00000240996.1	RP11-80H5.7	-4.07	6.48e-05	0.022	-0.28	-0.26	Red blood cell count;	chr10:89727892	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.727	rs3758388	ENSG00000240996.1	RP11-80H5.7	-4.07	6.48e-05	0.022	-0.28	-0.26	Red blood cell count;	chr10:89729222	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.727	rs12783582	ENSG00000240996.1	RP11-80H5.7	-4.07	6.48e-05	0.022	-0.28	-0.26	Red blood cell count;	chr10:89735210	chr10:89694295~89697928:-
SARC	cis	rs13217239	0.646	rs4403259	ENSG00000241549.7	GUSBP2	4.07	6.48e-05	0.022	0.24	0.26	Schizophrenia;	chr6:27029838	chr6:26871484~26956554:-
SARC	cis	rs12950390	0.814	rs11659069	ENSG00000239291.1	RP5-867C24.1	4.07	6.48e-05	0.0221	0.3	0.26	IgG glycosylation;	chr17:47756909	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.814	rs4794099	ENSG00000239291.1	RP5-867C24.1	4.07	6.48e-05	0.0221	0.3	0.26	IgG glycosylation;	chr17:47760992	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.893	rs12325760	ENSG00000239291.1	RP5-867C24.1	4.07	6.48e-05	0.0221	0.3	0.26	IgG glycosylation;	chr17:47763520	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.853	rs4794107	ENSG00000239291.1	RP5-867C24.1	4.07	6.48e-05	0.0221	0.3	0.26	IgG glycosylation;	chr17:47765793	chr17:47159191~47159993:-
SARC	cis	rs151234	0.676	rs151320	ENSG00000259982.1	CDC37P1	4.07	6.48e-05	0.0221	0.38	0.26	Platelet distribution width;	chr16:28557357	chr16:28700294~28701540:-
SARC	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	4.07	6.49e-05	0.0221	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
SARC	cis	rs7267979	0.844	rs4815413	ENSG00000125804.12	FAM182A	4.07	6.49e-05	0.0221	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:26054655~26086917:+
SARC	cis	rs7267979	0.844	rs6083824	ENSG00000125804.12	FAM182A	4.07	6.49e-05	0.0221	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:26054655~26086917:+
SARC	cis	rs11264213	0.686	rs12041193	ENSG00000271554.1	RP4-665N4.8	-4.07	6.49e-05	0.0221	-0.35	-0.26	Schizophrenia;	chr1:35947159	chr1:35992109~36013630:-
SARC	cis	rs11264213	0.901	rs67641270	ENSG00000271554.1	RP4-665N4.8	-4.07	6.49e-05	0.0221	-0.35	-0.26	Schizophrenia;	chr1:35947728	chr1:35992109~36013630:-
SARC	cis	rs2404602	0.583	rs11072580	ENSG00000259422.1	RP11-593F23.1	4.07	6.49e-05	0.0221	0.28	0.26	Blood metabolite levels;	chr15:76247890	chr15:76174891~76181486:-
SARC	cis	rs72627123	0.749	rs72627104	ENSG00000259065.1	RP5-1021I20.1	-4.07	6.49e-05	0.0221	-0.42	-0.26	Morning vs. evening chronotype;	chr14:73839245	chr14:73787360~73803270:+
SARC	cis	rs2032314	0.73	rs2834289	ENSG00000272657.1	AP000320.7	4.07	6.5e-05	0.0221	0.6	0.26	Red blood cell traits;	chr21:33892844	chr21:34073592~34360033:+
SARC	cis	rs853679	0.55	rs6901017	ENSG00000216901.1	AL022393.7	4.07	6.5e-05	0.0221	0.35	0.26	Depression;	chr6:28184805	chr6:28176188~28176674:+
SARC	cis	rs172166	0.694	rs203893	ENSG00000272009.1	RP1-313I6.12	-4.07	6.5e-05	0.0221	-0.29	-0.26	Cardiac Troponin-T levels;	chr6:28094288	chr6:28078792~28081130:-
SARC	cis	rs172166	0.652	rs476167	ENSG00000272009.1	RP1-313I6.12	-4.07	6.5e-05	0.0221	-0.29	-0.26	Cardiac Troponin-T levels;	chr6:28098110	chr6:28078792~28081130:-
SARC	cis	rs172166	0.694	rs203892	ENSG00000272009.1	RP1-313I6.12	-4.07	6.5e-05	0.0221	-0.29	-0.26	Cardiac Troponin-T levels;	chr6:28099418	chr6:28078792~28081130:-
SARC	cis	rs7726354	0.793	rs60590641	ENSG00000271828.1	CTD-2310F14.1	4.07	6.51e-05	0.0221	0.55	0.26	Breast cancer (early onset);	chr5:56845328	chr5:56927874~56929573:+
SARC	cis	rs9341808	0.556	rs10455370	ENSG00000272129.1	RP11-250B2.6	-4.07	6.51e-05	0.0221	-0.33	-0.26	Sitting height ratio;	chr6:80331150	chr6:80355424~80356859:+
SARC	cis	rs7614311	0.681	rs6776209	ENSG00000280620.1	SCAANT1	-4.07	6.51e-05	0.0221	-0.37	-0.26	Lung function (FVC);Lung function (FEV1);	chr3:63872957	chr3:63911518~63911772:-
SARC	cis	rs2274273	0.905	rs8007614	ENSG00000258413.1	RP11-665C16.6	-4.07	6.52e-05	0.0222	-0.31	-0.26	Protein biomarker;	chr14:55119857	chr14:55262767~55272075:-
SARC	cis	rs7809950	0.678	rs12672451	ENSG00000238832.1	snoU109	-4.07	6.52e-05	0.0222	-0.33	-0.26	Coronary artery disease;	chr7:107213372	chr7:107603363~107603507:+
SARC	cis	rs2243480	0.522	rs778717	ENSG00000273142.1	RP11-458F8.4	-4.07	6.52e-05	0.0222	-0.45	-0.26	Diabetic kidney disease;	chr7:66383164	chr7:66902857~66906297:+
SARC	cis	rs597539	0.652	rs686390	ENSG00000250508.1	RP11-757G1.6	-4.07	6.52e-05	0.0222	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68870664~68874542:+
SARC	cis	rs910316	0.789	rs4899552	ENSG00000279594.1	RP11-950C14.10	-4.07	6.53e-05	0.0222	-0.29	-0.26	Height;	chr14:75201218	chr14:75011269~75012851:-
SARC	cis	rs6570726	0.818	rs9390338	ENSG00000235652.6	RP11-545I5.3	4.07	6.53e-05	0.0222	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.791	rs6570693	ENSG00000235652.6	RP11-545I5.3	4.07	6.53e-05	0.0222	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.791	rs6570694	ENSG00000235652.6	RP11-545I5.3	4.07	6.53e-05	0.0222	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.791	rs6570695	ENSG00000235652.6	RP11-545I5.3	4.07	6.53e-05	0.0222	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.764	rs9386125	ENSG00000235652.6	RP11-545I5.3	4.07	6.53e-05	0.0222	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.791	rs9373466	ENSG00000235652.6	RP11-545I5.3	4.07	6.53e-05	0.0222	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145799409~145886585:+
SARC	cis	rs4938303	0.671	rs35352977	ENSG00000254851.1	RP11-109L13.1	4.07	6.53e-05	0.0222	0.36	0.26	Triglycerides;	chr11:116681756	chr11:117135528~117138582:+
SARC	cis	rs593531	0.571	rs35170680	ENSG00000280269.1	AP000577.2	-4.07	6.53e-05	0.0222	-0.32	-0.26	Neuroticism;	chr11:74374375	chr11:74204869~74205746:+
SARC	cis	rs593531	0.571	rs6592557	ENSG00000280269.1	AP000577.2	-4.07	6.53e-05	0.0222	-0.32	-0.26	Neuroticism;	chr11:74375597	chr11:74204869~74205746:+
SARC	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-4.07	6.54e-05	0.0222	-0.48	-0.26	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-4.07	6.54e-05	0.0222	-0.48	-0.26	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-4.07	6.54e-05	0.0222	-0.48	-0.26	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-4.07	6.54e-05	0.0222	-0.48	-0.26	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
SARC	cis	rs526231	0.824	rs253753	ENSG00000175749.11	EIF3KP1	4.07	6.54e-05	0.0222	0.31	0.26	Primary biliary cholangitis;	chr5:103322120	chr5:103032376~103033031:+
SARC	cis	rs7267979	0.816	rs6037158	ENSG00000276952.1	RP5-965G21.6	4.07	6.54e-05	0.0222	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:25284915~25285588:-
SARC	cis	rs9902453	0.619	rs2244585	ENSG00000264538.5	SUZ12P1	-4.07	6.54e-05	0.0222	-0.18	-0.26	Coffee consumption (cups per day);	chr17:29745158	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.619	rs1038088	ENSG00000264538.5	SUZ12P1	-4.07	6.54e-05	0.0222	-0.18	-0.26	Coffee consumption (cups per day);	chr17:29747545	chr17:30709299~30790908:+
SARC	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	4.07	6.54e-05	0.0222	0.35	0.26	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
SARC	cis	rs1707322	1	rs7517560	ENSG00000281133.1	AL355480.3	-4.07	6.54e-05	0.0222	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs6682683	ENSG00000281133.1	AL355480.3	-4.07	6.55e-05	0.0222	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45580892~45580996:-
SARC	cis	rs12744310	0.887	rs12040046	ENSG00000235358.1	RP11-399E6.1	-4.07	6.55e-05	0.0222	-0.35	-0.26	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41331911	chr1:41242373~41284861:+
SARC	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-4.07	6.55e-05	0.0222	-0.31	-0.26	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
SARC	cis	rs3824347	0.678	rs773162	ENSG00000203321.2	C9orf41-AS1	4.07	6.55e-05	0.0223	0.26	0.26	Urinary magnesium-to-creatinine ratio;	chr9:75032053	chr9:74952968~74996293:+
SARC	cis	rs12049351	0.613	rs12037690	ENSG00000229367.1	HMGN2P19	4.07	6.56e-05	0.0223	0.22	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229506638	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs6661924	ENSG00000229367.1	HMGN2P19	4.07	6.56e-05	0.0223	0.22	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229506993	chr1:229570532~229570796:+
SARC	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	4.07	6.56e-05	0.0223	0.24	0.26	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
SARC	cis	rs6477918	0.55	rs10981399	ENSG00000250068.1	RP11-576C12.1	-4.07	6.56e-05	0.0223	-0.27	-0.26	Obstetric antiphospholipid syndrome;	chr9:112413295	chr9:112581779~112582590:-
SARC	cis	rs12922317	0.964	rs12930612	ENSG00000260488.1	RP11-166B2.7	4.07	6.56e-05	0.0223	0.28	0.26	Schizophrenia;	chr16:11978346	chr16:11976851~11977850:-
SARC	cis	rs6477918	0.598	rs4978489	ENSG00000250068.1	RP11-576C12.1	-4.06	6.57e-05	0.0223	-0.27	-0.26	Obstetric antiphospholipid syndrome;	chr9:112404866	chr9:112581779~112582590:-
SARC	cis	rs6477918	0.598	rs1571638	ENSG00000250068.1	RP11-576C12.1	-4.06	6.57e-05	0.0223	-0.27	-0.26	Obstetric antiphospholipid syndrome;	chr9:112407124	chr9:112581779~112582590:-
SARC	cis	rs597539	0.652	rs11603827	ENSG00000250508.1	RP11-757G1.6	-4.06	6.57e-05	0.0223	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68870664~68874542:+
SARC	cis	rs732716	0.889	rs62129355	ENSG00000267980.1	AC007292.6	-4.06	6.57e-05	0.0223	-0.33	-0.26	Mean corpuscular volume;	chr19:4397037	chr19:4363789~4364640:+
SARC	cis	rs4664293	0.51	rs2042776	ENSG00000226266.5	AC009961.3	4.06	6.57e-05	0.0223	0.39	0.26	Monocyte percentage of white cells;	chr2:159653793	chr2:159670708~159712435:-
SARC	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	4.06	6.58e-05	0.0223	0.23	0.26	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
SARC	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	4.06	6.58e-05	0.0223	0.37	0.26	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
SARC	cis	rs111226991	0.505	rs77207476	ENSG00000273080.1	RP11-301O19.1	4.06	6.58e-05	0.0223	0.39	0.26	Glomerular filtration rate in chronic kidney disease;	chr2:86371847	chr2:86195590~86196049:+
SARC	cis	rs950776	0.714	rs3743074	ENSG00000261762.1	RP11-650L12.2	-4.06	6.58e-05	0.0223	-0.28	-0.26	Sudden cardiac arrest;	chr15:78617138	chr15:78589123~78591276:-
SARC	cis	rs9625935	0.748	rs12537	ENSG00000227201.2	CNN2P1	-4.06	6.59e-05	0.0223	-0.27	-0.26	Tonsillectomy;	chr22:30027471	chr22:30046276~30047193:-
SARC	cis	rs891378	0.837	rs11120688	ENSG00000274245.1	RP11-357P18.2	4.06	6.59e-05	0.0223	0.31	0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207312770	chr1:207372559~207373252:+
SARC	cis	rs12542260	1	rs62527883	ENSG00000253106.1	RP11-158K1.3	-4.06	6.59e-05	0.0223	-0.31	-0.26	Colonoscopy-negative controls vs population controls;	chr8:124470672	chr8:124488510~124491643:+
SARC	cis	rs972578	0.535	rs3091364	ENSG00000172250.13	SERHL	-4.06	6.59e-05	0.0223	-0.28	-0.26	Mean platelet volume;	chr22:43018324	chr22:42500579~42512560:+
SARC	cis	rs7429990	0.965	rs17785248	ENSG00000229759.1	MRPS18AP1	4.06	6.59e-05	0.0223	0.35	0.26	Educational attainment (years of education);	chr3:47631425	chr3:48256350~48256938:-
SARC	cis	rs2439831	0.681	rs484029	ENSG00000275601.1	AC011330.13	-4.06	6.59e-05	0.0223	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43327362	chr15:43642389~43643023:-
SARC	cis	rs12664251	0.809	rs6931074	ENSG00000253194.1	RP11-351A11.1	4.06	6.59e-05	0.0224	0.3	0.26	Schizophrenia;	chr6:119020840	chr6:118934785~119031541:+
SARC	cis	rs7615952	0.534	rs1503072	ENSG00000248787.1	RP11-666A20.4	-4.06	6.6e-05	0.0224	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126035848	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.599	rs7631268	ENSG00000248787.1	RP11-666A20.4	-4.06	6.6e-05	0.0224	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126036821	chr3:125908005~125910272:-
SARC	cis	rs4372836	0.754	rs6709674	ENSG00000226833.4	AC097724.3	4.06	6.61e-05	0.0224	0.22	0.26	Body mass index;	chr2:28766801	chr2:28708953~28736205:-
SARC	cis	rs2179367	0.959	rs480034	ENSG00000216906.2	RP11-350J20.9	-4.06	6.61e-05	0.0224	-0.24	-0.26	Dupuytren's disease;	chr6:149414294	chr6:149904243~149906418:+
SARC	cis	rs2404602	0.631	rs9646213	ENSG00000259422.1	RP11-593F23.1	4.06	6.62e-05	0.0224	0.28	0.26	Blood metabolite levels;	chr15:76515331	chr15:76174891~76181486:-
SARC	cis	rs783540	0.9	rs12916980	ENSG00000275695.1	UBE2Q2P6	-4.06	6.62e-05	0.0224	-0.26	-0.26	Schizophrenia;	chr15:82637696	chr15:82445719~82454837:+
SARC	cis	rs997295	1	rs4363822	ENSG00000259410.4	RP11-34F13.3	4.06	6.62e-05	0.0224	0.28	0.26	Motion sickness;	chr15:67700245	chr15:67832725~67873866:+
SARC	cis	rs997295	1	rs938878	ENSG00000259410.4	RP11-34F13.3	4.06	6.62e-05	0.0224	0.28	0.26	Motion sickness;	chr15:67701028	chr15:67832725~67873866:+
SARC	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-4.06	6.62e-05	0.0224	-0.38	-0.26	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
SARC	cis	rs9739682	1	rs9739682	ENSG00000139239.7	RPL14P1	-4.06	6.62e-05	0.0224	-0.24	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62122868	chr12:62965325~62965969:+
SARC	cis	rs748404	0.723	rs512431	ENSG00000275601.1	AC011330.13	4.06	6.63e-05	0.0224	0.31	0.26	Lung cancer;	chr15:43249741	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs16977798	ENSG00000275601.1	AC011330.13	-4.06	6.63e-05	0.0225	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43859750	chr15:43642389~43643023:-
SARC	cis	rs8005677	0.611	rs11624528	ENSG00000279656.1	RP11-298I3.6	4.06	6.63e-05	0.0225	0.34	0.26	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:23023083~23024217:-
SARC	cis	rs597539	0.69	rs608810	ENSG00000250508.1	RP11-757G1.6	-4.06	6.63e-05	0.0225	-0.31	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68870664~68874542:+
SARC	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	4.06	6.64e-05	0.0225	0.37	0.26	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
SARC	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	4.06	6.64e-05	0.0225	0.4	0.26	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	4.06	6.64e-05	0.0225	0.4	0.26	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
SARC	cis	rs853679	0.55	rs1225598	ENSG00000216901.1	AL022393.7	4.06	6.64e-05	0.0225	0.35	0.26	Depression;	chr6:28193021	chr6:28176188~28176674:+
SARC	cis	rs1376877	0.934	rs4625888	ENSG00000213925.3	NPM1P33	4.06	6.65e-05	0.0225	0.24	0.26	Subclinical atherosclerosis traits (other);	chr2:203236434	chr2:203772631~203773502:-
SARC	cis	rs10895987	0.955	rs12365171	ENSG00000254614.2	AP003068.23	4.06	6.65e-05	0.0225	0.38	0.26	Blood protein levels;	chr11:65161417	chr11:65177606~65181834:-
SARC	cis	rs1150668	0.796	rs2247002	ENSG00000219392.1	RP1-265C24.5	-4.06	6.65e-05	0.0225	-0.29	-0.26	Pubertal anthropometrics;	chr6:28430174	chr6:28115628~28116551:+
SARC	cis	rs1150668	0.796	rs728122	ENSG00000219392.1	RP1-265C24.5	-4.06	6.65e-05	0.0225	-0.29	-0.26	Pubertal anthropometrics;	chr6:28431347	chr6:28115628~28116551:+
SARC	cis	rs41369048	0.858	rs10495155	ENSG00000238078.1	LINC01352	-4.06	6.65e-05	0.0225	-0.35	-0.26	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220902527	chr1:220829255~220832429:+
SARC	cis	rs755249	0.567	rs61779306	ENSG00000182109.6	RP11-69E11.4	4.06	6.65e-05	0.0225	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39522280~39546187:-
SARC	cis	rs495337	0.76	rs492702	ENSG00000229222.1	KRT18P4	-4.06	6.65e-05	0.0225	-0.34	-0.26	Psoriasis;	chr20:49906048	chr20:49956745~49958032:+
SARC	cis	rs1930961	0.85	rs5996945	ENSG00000100058.11	CRYBB2P1	-4.06	6.65e-05	0.0225	-0.42	-0.26	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25448105~25520854:+
SARC	cis	rs9858542	0.537	rs35869135	ENSG00000225399.4	RP11-3B7.1	-4.06	6.65e-05	0.0225	-0.4	-0.26	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49321669	chr3:49260085~49261316:+
SARC	cis	rs28386778	0.863	rs11649912	ENSG00000240280.5	TCAM1P	-4.06	6.66e-05	0.0225	-0.32	-0.26	Prudent dietary pattern;	chr17:63720155	chr17:63849292~63864379:+
SARC	cis	rs853679	0.666	rs200956	ENSG00000219392.1	RP1-265C24.5	-4.06	6.66e-05	0.0225	-0.42	-0.26	Depression;	chr6:27871968	chr6:28115628~28116551:+
SARC	cis	rs495337	0.965	rs6122848	ENSG00000229222.1	KRT18P4	-4.06	6.66e-05	0.0225	-0.33	-0.26	Psoriasis;	chr20:49930020	chr20:49956745~49958032:+
SARC	cis	rs3934047	0.904	rs1567897	ENSG00000274376.3	ADAMTS7P1	-4.06	6.66e-05	0.0225	-0.29	-0.26	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81729288	chr15:82298553~82334609:+
SARC	cis	rs7178375	1	rs7178533	ENSG00000215302.7	CTD-3092A11.1	-4.06	6.66e-05	0.0225	-0.33	-0.26	Hypertriglyceridemia;	chr15:30923773	chr15:30470779~30507623:+
SARC	cis	rs6845263	0.546	rs9917976	ENSG00000254531.1	FLJ20021	-4.06	6.66e-05	0.0225	-0.24	-0.26	Superior crus of antihelix expression;	chr4:101534624	chr4:101347780~101348883:+
SARC	cis	rs4849845	0.637	rs4849851	ENSG00000236878.1	AC012363.7	4.06	6.67e-05	0.0226	0.26	0.26	Mean platelet volume;	chr2:120298334	chr2:120211054~120211715:+
SARC	cis	rs896655	0.631	rs1345024	ENSG00000266446.1	RP11-149I2.4	4.06	6.67e-05	0.0226	0.23	0.26	Coronary artery disease;	chr9:21785019	chr9:21995482~21996013:+
SARC	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	4.06	6.68e-05	0.0226	0.24	0.26	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	4.06	6.68e-05	0.0226	0.24	0.26	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	4.06	6.68e-05	0.0226	0.24	0.26	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	4.06	6.68e-05	0.0226	0.24	0.26	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	4.06	6.68e-05	0.0226	0.24	0.26	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	4.06	6.68e-05	0.0226	0.24	0.26	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	4.06	6.68e-05	0.0226	0.24	0.26	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
SARC	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	4.06	6.68e-05	0.0226	0.24	0.26	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	4.06	6.68e-05	0.0226	0.24	0.26	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	4.06	6.68e-05	0.0226	0.24	0.26	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	4.06	6.68e-05	0.0226	0.24	0.26	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
SARC	cis	rs7267979	0.844	rs869358	ENSG00000125804.12	FAM182A	4.06	6.68e-05	0.0226	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:26054655~26086917:+
SARC	cis	rs6964833	1	rs2301907	ENSG00000184616.8	AC004166.6	4.06	6.68e-05	0.0226	0.37	0.26	Menarche (age at onset);	chr7:74700517	chr7:74906673~74913256:-
SARC	cis	rs6964833	0.935	rs7795282	ENSG00000184616.8	AC004166.6	4.06	6.68e-05	0.0226	0.37	0.26	Menarche (age at onset);	chr7:74708526	chr7:74906673~74913256:-
SARC	cis	rs7772486	0.686	rs702314	ENSG00000235652.6	RP11-545I5.3	-4.06	6.68e-05	0.0226	-0.23	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145799409~145886585:+
SARC	cis	rs13217239	0.608	rs6930508	ENSG00000241549.7	GUSBP2	-4.06	6.68e-05	0.0226	-0.24	-0.26	Schizophrenia;	chr6:27085363	chr6:26871484~26956554:-
SARC	cis	rs13217239	0.646	rs2142685	ENSG00000241549.7	GUSBP2	-4.06	6.68e-05	0.0226	-0.24	-0.26	Schizophrenia;	chr6:27086718	chr6:26871484~26956554:-
SARC	cis	rs801193	0.591	rs9986881	ENSG00000224316.1	RP11-479O9.2	4.06	6.69e-05	0.0226	0.24	0.26	Aortic root size;	chr7:66708053	chr7:65773620~65802067:+
SARC	cis	rs1546924	0.669	rs6687953	ENSG00000260948.1	RP11-552M11.8	4.06	6.7e-05	0.0226	0.28	0.26	Body mass index;	chr1:111750890	chr1:111431046~111433068:-
SARC	cis	rs858239	0.6	rs4409314	ENSG00000226816.2	AC005082.12	4.06	6.7e-05	0.0226	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23206013~23208045:+
SARC	cis	rs9739682	0.516	rs12827315	ENSG00000139239.7	RPL14P1	-4.06	6.7e-05	0.0227	-0.26	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62086573	chr12:62965325~62965969:+
SARC	cis	rs4148883	0.615	rs2187483	ENSG00000263923.1	RP11-571L19.7	4.06	6.7e-05	0.0227	0.27	0.26	Alcohol dependence;	chr4:99212946	chr4:98928897~98994994:+
SARC	cis	rs9309473	0.519	rs6730785	ENSG00000163016.8	ALMS1P	-4.06	6.71e-05	0.0227	-0.29	-0.26	Metabolite levels;	chr2:73415275	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.519	rs1881246	ENSG00000163016.8	ALMS1P	-4.06	6.71e-05	0.0227	-0.29	-0.26	Metabolite levels;	chr2:73422994	chr2:73644919~73685576:+
SARC	cis	rs4927850	0.958	rs2044599	ENSG00000242086.7	LINC00969	4.06	6.71e-05	0.0227	0.25	0.26	Pancreatic cancer;	chr3:196009869	chr3:195658062~195739964:+
SARC	cis	rs4927850	1	rs4927704	ENSG00000242086.7	LINC00969	4.06	6.71e-05	0.0227	0.25	0.26	Pancreatic cancer;	chr3:196011357	chr3:195658062~195739964:+
SARC	cis	rs4927850	1	rs4927848	ENSG00000242086.7	LINC00969	4.06	6.71e-05	0.0227	0.25	0.26	Pancreatic cancer;	chr3:196011535	chr3:195658062~195739964:+
SARC	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	4.06	6.71e-05	0.0227	0.32	0.26	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
SARC	cis	rs5769707	0.521	rs6009810	ENSG00000235111.1	RP1-29C18.8	-4.06	6.71e-05	0.0227	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49612657~49615716:-
SARC	cis	rs172166	0.694	rs1225716	ENSG00000272009.1	RP1-313I6.12	-4.06	6.71e-05	0.0227	-0.29	-0.26	Cardiac Troponin-T levels;	chr6:28145968	chr6:28078792~28081130:-
SARC	cis	rs28386778	0.897	rs894413	ENSG00000240280.5	TCAM1P	-4.06	6.71e-05	0.0227	-0.32	-0.26	Prudent dietary pattern;	chr17:63838987	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.863	rs894414	ENSG00000240280.5	TCAM1P	-4.06	6.71e-05	0.0227	-0.32	-0.26	Prudent dietary pattern;	chr17:63839024	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.863	rs8076760	ENSG00000240280.5	TCAM1P	-4.06	6.71e-05	0.0227	-0.32	-0.26	Prudent dietary pattern;	chr17:63843137	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.83	rs2665798	ENSG00000240280.5	TCAM1P	-4.06	6.71e-05	0.0227	-0.32	-0.26	Prudent dietary pattern;	chr17:63844037	chr17:63849292~63864379:+
SARC	cis	rs61160187	0.582	rs888799	ENSG00000272308.1	RP11-231G3.1	-4.06	6.72e-05	0.0227	-0.22	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61049363	chr5:60866457~60866935:-
SARC	cis	rs61160187	0.548	rs1983484	ENSG00000272308.1	RP11-231G3.1	-4.06	6.72e-05	0.0227	-0.22	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61050998	chr5:60866457~60866935:-
SARC	cis	rs61160187	0.582	rs56025209	ENSG00000272308.1	RP11-231G3.1	-4.06	6.72e-05	0.0227	-0.22	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61053793	chr5:60866457~60866935:-
SARC	cis	rs7512898	0.5	rs7520984	ENSG00000260088.1	RP11-92G12.3	-4.06	6.72e-05	0.0227	-0.28	-0.26	Electrocardiographic conduction measures;	chr1:200741190	chr1:200669507~200694250:+
SARC	cis	rs1707322	0.963	rs9787412	ENSG00000281133.1	AL355480.3	-4.06	6.72e-05	0.0227	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4660896	ENSG00000281133.1	AL355480.3	-4.06	6.72e-05	0.0227	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.928	rs10732844	ENSG00000281133.1	AL355480.3	-4.06	6.72e-05	0.0227	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs12133129	ENSG00000281133.1	AL355480.3	-4.06	6.72e-05	0.0227	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.963	rs4553121	ENSG00000281133.1	AL355480.3	-4.06	6.72e-05	0.0227	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.963	rs6690652	ENSG00000281133.1	AL355480.3	-4.06	6.72e-05	0.0227	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs6695421	ENSG00000281133.1	AL355480.3	-4.06	6.72e-05	0.0227	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs11211223	ENSG00000281133.1	AL355480.3	-4.06	6.72e-05	0.0227	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs6687301	ENSG00000281133.1	AL355480.3	-4.06	6.72e-05	0.0227	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45580892~45580996:-
SARC	cis	rs4849845	0.584	rs3896630	ENSG00000236878.1	AC012363.7	4.06	6.72e-05	0.0227	0.26	0.26	Mean platelet volume;	chr2:120279442	chr2:120211054~120211715:+
SARC	cis	rs1799949	0.965	rs799912	ENSG00000267681.1	CTD-3199J23.6	-4.06	6.72e-05	0.0227	-0.28	-0.26	Menopause (age at onset);	chr17:43105117	chr17:43144956~43145255:+
SARC	cis	rs412050	0.502	rs8136405	ENSG00000224086.5	LL22NC03-86G7.1	-4.06	6.73e-05	0.0227	-0.38	-0.26	Attention deficit hyperactivity disorder;	chr22:21793732	chr22:21938293~21977632:+
SARC	cis	rs755249	0.567	rs72661927	ENSG00000182109.6	RP11-69E11.4	4.06	6.73e-05	0.0227	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39522280~39546187:-
SARC	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-4.06	6.74e-05	0.0227	-0.28	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
SARC	cis	rs875971	0.898	rs6977501	ENSG00000232559.3	GS1-124K5.12	-4.06	6.74e-05	0.0227	-0.29	-0.26	Aortic root size;	chr7:66228355	chr7:66554588~66576923:-
SARC	cis	rs11955398	0.502	rs295531	ENSG00000272308.1	RP11-231G3.1	-4.06	6.74e-05	0.0227	-0.23	-0.26	Intelligence (multi-trait analysis);	chr5:61099916	chr5:60866457~60866935:-
SARC	cis	rs7162943	0.887	rs12438271	ENSG00000260123.1	RP11-326A19.4	-4.06	6.75e-05	0.0228	-0.24	-0.26	Mean platelet volume;	chr15:89069996	chr15:89041223~89082819:+
SARC	cis	rs3824347	0.839	rs4744733	ENSG00000203321.2	C9orf41-AS1	4.06	6.75e-05	0.0228	0.27	0.26	Urinary magnesium-to-creatinine ratio;	chr9:74979628	chr9:74952968~74996293:+
SARC	cis	rs4713118	0.662	rs149969	ENSG00000272009.1	RP1-313I6.12	-4.06	6.75e-05	0.0228	-0.3	-0.26	Parkinson's disease;	chr6:28009959	chr6:28078792~28081130:-
SARC	cis	rs755249	0.958	rs61781370	ENSG00000182109.6	RP11-69E11.4	4.06	6.76e-05	0.0228	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39522280~39546187:-
SARC	cis	rs5771242	0.845	rs4838859	ENSG00000273253.2	RP3-402G11.26	-4.06	6.76e-05	0.0228	-0.35	-0.26	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50174773	chr22:50199090~50200837:-
SARC	cis	rs2731006	0.64	rs2678141	ENSG00000257114.2	RP11-25I15.3	4.06	6.77e-05	0.0228	0.38	0.26	Panic disorder;	chr12:42807005	chr12:42692216~42717119:+
SARC	cis	rs2731006	0.64	rs2056192	ENSG00000257114.2	RP11-25I15.3	4.06	6.77e-05	0.0228	0.38	0.26	Panic disorder;	chr12:42808192	chr12:42692216~42717119:+
SARC	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	4.06	6.77e-05	0.0228	0.23	0.26	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
SARC	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-4.06	6.77e-05	0.0228	-0.36	-0.26	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
SARC	cis	rs495337	0.76	rs615868	ENSG00000229222.1	KRT18P4	-4.06	6.78e-05	0.0228	-0.34	-0.26	Psoriasis;	chr20:49902687	chr20:49956745~49958032:+
SARC	cis	rs728478	1	rs9903669	ENSG00000266992.1	DHX40P1	-4.06	6.78e-05	0.0229	-0.28	-0.26	QT interval;	chr17:59354405	chr17:59976009~60002384:-
SARC	cis	rs4664293	0.967	rs12611922	ENSG00000226266.5	AC009961.3	-4.06	6.78e-05	0.0229	-0.31	-0.26	Monocyte percentage of white cells;	chr2:159606238	chr2:159670708~159712435:-
SARC	cis	rs10200159	0.793	rs13383352	ENSG00000272606.1	RP11-554J4.1	4.06	6.78e-05	0.0229	0.45	0.26	Vitiligo;	chr2:55643692	chr2:55617909~55618373:+
SARC	cis	rs6969780	0.908	rs6461987	ENSG00000233429.8	HOTAIRM1	4.06	6.79e-05	0.0229	0.4	0.26	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127337	chr7:27095647~27100265:+
SARC	cis	rs997295	0.966	rs3784692	ENSG00000259410.4	RP11-34F13.3	4.06	6.79e-05	0.0229	0.28	0.26	Motion sickness;	chr15:67695795	chr15:67832725~67873866:+
SARC	cis	rs4664293	0.625	rs7590617	ENSG00000226266.5	AC009961.3	4.06	6.79e-05	0.0229	0.29	0.26	Monocyte percentage of white cells;	chr2:159775437	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs7564585	ENSG00000226266.5	AC009961.3	4.06	6.79e-05	0.0229	0.29	0.26	Monocyte percentage of white cells;	chr2:159775582	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.546	rs7564399	ENSG00000226266.5	AC009961.3	4.06	6.79e-05	0.0229	0.29	0.26	Monocyte percentage of white cells;	chr2:159775608	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs35481084	ENSG00000226266.5	AC009961.3	4.06	6.79e-05	0.0229	0.29	0.26	Monocyte percentage of white cells;	chr2:159777729	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs10460300	ENSG00000226266.5	AC009961.3	4.06	6.79e-05	0.0229	0.29	0.26	Monocyte percentage of white cells;	chr2:159778210	chr2:159670708~159712435:-
SARC	cis	rs7615952	0.599	rs60847438	ENSG00000248787.1	RP11-666A20.4	-4.06	6.8e-05	0.0229	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126027162	chr3:125908005~125910272:-
SARC	cis	rs28498283	0.792	rs10173378	ENSG00000279873.2	LINC01126	-4.06	6.8e-05	0.0229	-0.23	-0.26	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:43119650	chr2:43227210~43228855:+
SARC	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-4.06	6.8e-05	0.0229	-0.23	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
SARC	cis	rs4938303	0.633	rs12799441	ENSG00000254851.1	RP11-109L13.1	4.06	6.8e-05	0.0229	0.36	0.26	Triglycerides;	chr11:116687799	chr11:117135528~117138582:+
SARC	cis	rs858239	0.699	rs858260	ENSG00000226816.2	AC005082.12	4.06	6.8e-05	0.0229	0.32	0.26	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23206013~23208045:+
SARC	cis	rs807029	0.533	rs3740485	ENSG00000272572.1	RP11-179B2.2	-4.06	6.8e-05	0.0229	-0.27	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990864	chr10:100911103~100912739:-
SARC	cis	rs807029	0.533	rs3740486	ENSG00000272572.1	RP11-179B2.2	-4.06	6.8e-05	0.0229	-0.27	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990866	chr10:100911103~100912739:-
SARC	cis	rs807029	0.533	rs3740487	ENSG00000272572.1	RP11-179B2.2	-4.06	6.8e-05	0.0229	-0.27	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991026	chr10:100911103~100912739:-
SARC	cis	rs7772486	0.686	rs1415744	ENSG00000235652.6	RP11-545I5.3	4.06	6.8e-05	0.0229	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145799409~145886585:+
SARC	cis	rs1707322	1	rs7538978	ENSG00000281133.1	AL355480.3	4.06	6.81e-05	0.0229	0.29	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45580892~45580996:-
SARC	cis	rs495337	0.76	rs2745078	ENSG00000229222.1	KRT18P4	-4.06	6.81e-05	0.0229	-0.33	-0.26	Psoriasis;	chr20:49908923	chr20:49956745~49958032:+
SARC	cis	rs6142102	0.625	rs9753690	ENSG00000275784.1	RP5-1125A11.6	-4.06	6.81e-05	0.0229	-0.3	-0.26	Skin pigmentation;	chr20:33952995	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.58	rs9753679	ENSG00000275784.1	RP5-1125A11.6	-4.06	6.81e-05	0.0229	-0.3	-0.26	Skin pigmentation;	chr20:33953054	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.625	rs7263727	ENSG00000275784.1	RP5-1125A11.6	-4.06	6.81e-05	0.0229	-0.3	-0.26	Skin pigmentation;	chr20:33953133	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.625	rs6142056	ENSG00000275784.1	RP5-1125A11.6	-4.06	6.81e-05	0.0229	-0.3	-0.26	Skin pigmentation;	chr20:33953349	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.538	rs6142058	ENSG00000275784.1	RP5-1125A11.6	-4.06	6.81e-05	0.0229	-0.3	-0.26	Skin pigmentation;	chr20:33954995	chr20:33989480~33991818:-
SARC	cis	rs111315781	1	rs111315781	ENSG00000183308.6	AC005037.3	4.06	6.81e-05	0.0229	0.44	0.26	Triptolide cytotoxicity;	chr2:200874001	chr2:200963263~201009102:+
SARC	cis	rs27434	0.605	rs1230366	ENSG00000272109.1	CTD-2260A17.3	-4.06	6.82e-05	0.023	-0.38	-0.26	Ankylosing spondylitis;	chr5:96859577	chr5:96804353~96806105:+
SARC	cis	rs11264213	0.901	rs11263830	ENSG00000271554.1	RP4-665N4.8	-4.06	6.82e-05	0.023	-0.34	-0.26	Schizophrenia;	chr1:35880197	chr1:35992109~36013630:-
SARC	cis	rs4938303	0.633	rs17092638	ENSG00000254851.1	RP11-109L13.1	4.06	6.82e-05	0.023	0.35	0.26	Triglycerides;	chr11:116685520	chr11:117135528~117138582:+
SARC	cis	rs2412819	0.571	rs56226333	ENSG00000205771.5	CATSPER2P1	-4.06	6.83e-05	0.023	-0.38	-0.26	Lung cancer;	chr15:43632410	chr15:43726918~43747094:-
SARC	cis	rs61160187	0.582	rs12652878	ENSG00000215032.2	GNL3LP1	4.06	6.83e-05	0.023	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.548	rs17392014	ENSG00000215032.2	GNL3LP1	4.06	6.83e-05	0.023	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60869373	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.582	rs4647150	ENSG00000215032.2	GNL3LP1	4.06	6.83e-05	0.023	0.26	0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60874778	chr5:60891935~60893577:-
SARC	cis	rs11976180	0.517	rs6949375	ENSG00000170356.8	OR2A20P	-4.06	6.83e-05	0.023	-0.46	-0.26	Obesity-related traits;	chr7:144076758	chr7:144250045~144252957:-
SARC	cis	rs840616	0.547	rs7586854	ENSG00000231739.2	GAPDHP59	4.06	6.83e-05	0.023	0.28	0.26	Coronary heart disease;Coronary artery disease;	chr2:187211110	chr2:187415552~187415818:+
SARC	cis	rs4372836	0.729	rs12714241	ENSG00000226833.4	AC097724.3	4.06	6.84e-05	0.023	0.22	0.26	Body mass index;	chr2:28746547	chr2:28708953~28736205:-
SARC	cis	rs41271951	0.512	rs79122717	ENSG00000237781.3	RP11-54A4.2	4.06	6.84e-05	0.023	0.46	0.26	Blood protein levels;	chr1:151121050	chr1:150548562~150557724:-
SARC	cis	rs495337	0.76	rs2254930	ENSG00000229222.1	KRT18P4	-4.06	6.84e-05	0.023	-0.33	-0.26	Psoriasis;	chr20:49910570	chr20:49956745~49958032:+
SARC	cis	rs495337	0.76	rs2769977	ENSG00000229222.1	KRT18P4	-4.06	6.84e-05	0.023	-0.33	-0.26	Psoriasis;	chr20:49910927	chr20:49956745~49958032:+
SARC	cis	rs495337	0.646	rs6067267	ENSG00000229222.1	KRT18P4	-4.06	6.84e-05	0.023	-0.33	-0.26	Psoriasis;	chr20:49911700	chr20:49956745~49958032:+
SARC	cis	rs495337	0.76	rs13040201	ENSG00000229222.1	KRT18P4	-4.06	6.84e-05	0.023	-0.33	-0.26	Psoriasis;	chr20:49919812	chr20:49956745~49958032:+
SARC	cis	rs495337	0.72	rs2869937	ENSG00000229222.1	KRT18P4	-4.06	6.84e-05	0.023	-0.33	-0.26	Psoriasis;	chr20:49920081	chr20:49956745~49958032:+
SARC	cis	rs495337	0.76	rs6067270	ENSG00000229222.1	KRT18P4	-4.06	6.84e-05	0.023	-0.33	-0.26	Psoriasis;	chr20:49920717	chr20:49956745~49958032:+
SARC	cis	rs9739682	0.529	rs35758278	ENSG00000139239.7	RPL14P1	-4.05	6.84e-05	0.023	-0.26	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62088927	chr12:62965325~62965969:+
SARC	cis	rs7520050	0.966	rs1707340	ENSG00000280836.1	AL355480.1	4.05	6.85e-05	0.023	0.24	0.26	Reticulocyte count;Red blood cell count;	chr1:46049270	chr1:45581219~45581321:-
SARC	cis	rs7520050	1	rs785473	ENSG00000280836.1	AL355480.1	4.05	6.85e-05	0.023	0.24	0.26	Reticulocyte count;Red blood cell count;	chr1:46051191	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.931	rs785472	ENSG00000280836.1	AL355480.1	4.05	6.85e-05	0.023	0.24	0.26	Reticulocyte count;Red blood cell count;	chr1:46052616	chr1:45581219~45581321:-
SARC	cis	rs2274273	0.624	rs8003279	ENSG00000258413.1	RP11-665C16.6	-4.05	6.85e-05	0.023	-0.35	-0.26	Protein biomarker;	chr14:55397412	chr14:55262767~55272075:-
SARC	cis	rs6142102	0.625	rs4911137	ENSG00000275784.1	RP5-1125A11.6	-4.05	6.85e-05	0.023	-0.3	-0.26	Skin pigmentation;	chr20:33947657	chr20:33989480~33991818:-
SARC	cis	rs7429990	0.965	rs35012836	ENSG00000229759.1	MRPS18AP1	4.05	6.85e-05	0.023	0.35	0.26	Educational attainment (years of education);	chr3:47670000	chr3:48256350~48256938:-
SARC	cis	rs3824347	0.805	rs2376382	ENSG00000203321.2	C9orf41-AS1	-4.05	6.85e-05	0.0231	-0.28	-0.26	Urinary magnesium-to-creatinine ratio;	chr9:75020051	chr9:74952968~74996293:+
SARC	cis	rs7772486	0.686	rs10872579	ENSG00000235652.6	RP11-545I5.3	4.05	6.85e-05	0.0231	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145799409~145886585:+
SARC	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	4.05	6.86e-05	0.0231	0.28	0.26	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
SARC	cis	rs17270561	0.585	rs9393663	ENSG00000272462.2	U91328.19	-4.05	6.86e-05	0.0231	-0.25	-0.26	Iron status biomarkers;	chr6:25740805	chr6:25992662~26001775:+
SARC	cis	rs7772486	0.79	rs6923545	ENSG00000270638.1	RP3-466P17.1	-4.05	6.86e-05	0.0231	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.754	rs6922507	ENSG00000270638.1	RP3-466P17.1	-4.05	6.86e-05	0.0231	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs4075694	ENSG00000270638.1	RP3-466P17.1	-4.05	6.86e-05	0.0231	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145735570~145737218:+
SARC	cis	rs875971	0.66	rs801193	ENSG00000236529.1	RP13-254B10.1	-4.05	6.86e-05	0.0231	-0.26	-0.26	Aortic root size;	chr7:66565625	chr7:65840212~65840596:+
SARC	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-4.05	6.87e-05	0.0231	-0.35	-0.26	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
SARC	cis	rs7772486	0.79	rs4280983	ENSG00000270638.1	RP3-466P17.1	-4.05	6.87e-05	0.0231	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145735570~145737218:+
SARC	cis	rs755249	0.565	rs1809697	ENSG00000182109.6	RP11-69E11.4	-4.05	6.87e-05	0.0231	-0.24	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39493413	chr1:39522280~39546187:-
SARC	cis	rs755249	0.762	rs1775654	ENSG00000182109.6	RP11-69E11.4	4.05	6.88e-05	0.0231	0.26	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39522280~39546187:-
SARC	cis	rs448720	0.811	rs2458506	ENSG00000259410.4	RP11-34F13.3	-4.05	6.88e-05	0.0231	-0.28	-0.26	Cognitive performance;	chr15:67890272	chr15:67832725~67873866:+
SARC	cis	rs7829975	0.514	rs2979151	ENSG00000253981.4	ALG1L13P	-4.05	6.88e-05	0.0231	-0.28	-0.26	Mood instability;	chr8:8400509	chr8:8236003~8244667:-
SARC	cis	rs846111	1	rs846111	ENSG00000225077.2	LINC00337	-4.05	6.88e-05	0.0231	-0.31	-0.26	QT interval;	chr1:6219310	chr1:6236240~6239444:+
SARC	cis	rs9902453	0.726	rs4795523	ENSG00000264538.5	SUZ12P1	4.05	6.89e-05	0.0232	0.18	0.26	Coffee consumption (cups per day);	chr17:29849296	chr17:30709299~30790908:+
SARC	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	4.05	6.89e-05	0.0232	0.26	0.26	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
SARC	cis	rs526231	0.736	rs6886092	ENSG00000175749.11	EIF3KP1	4.05	6.89e-05	0.0232	0.29	0.26	Primary biliary cholangitis;	chr5:103298328	chr5:103032376~103033031:+
SARC	cis	rs7615952	0.576	rs4646763	ENSG00000248787.1	RP11-666A20.4	-4.05	6.89e-05	0.0232	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126103286	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.576	rs4646759	ENSG00000248787.1	RP11-666A20.4	-4.05	6.89e-05	0.0232	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126104103	chr3:125908005~125910272:-
SARC	cis	rs7614311	1	rs7646324	ENSG00000271843.1	RP11-245J9.5	-4.05	6.89e-05	0.0232	-0.34	-0.26	Lung function (FVC);Lung function (FEV1);	chr3:63822442	chr3:64008082~64008692:-
SARC	cis	rs7580658	0.864	rs10928761	ENSG00000236682.1	AC068282.3	-4.05	6.89e-05	0.0232	-0.3	-0.26	Protein C levels;	chr2:127245671	chr2:127389130~127400580:+
SARC	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-4.05	6.9e-05	0.0232	-0.34	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
SARC	cis	rs7726354	1	rs7726354	ENSG00000271828.1	CTD-2310F14.1	-4.05	6.9e-05	0.0232	-0.53	-0.26	Breast cancer (early onset);	chr5:56960656	chr5:56927874~56929573:+
SARC	cis	rs4934494	0.727	rs67827533	ENSG00000240996.1	RP11-80H5.7	-4.05	6.9e-05	0.0232	-0.28	-0.26	Red blood cell count;	chr10:89745626	chr10:89694295~89697928:-
SARC	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-4.05	6.91e-05	0.0232	-0.25	-0.26	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-4.05	6.91e-05	0.0232	-0.25	-0.26	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
SARC	cis	rs28386778	0.897	rs8079818	ENSG00000240280.5	TCAM1P	-4.05	6.91e-05	0.0232	-0.32	-0.26	Prudent dietary pattern;	chr17:63747307	chr17:63849292~63864379:+
SARC	cis	rs526231	0.644	rs386352	ENSG00000175749.11	EIF3KP1	4.05	6.91e-05	0.0232	0.32	0.26	Primary biliary cholangitis;	chr5:103280006	chr5:103032376~103033031:+
SARC	cis	rs35740288	0.731	rs11634651	ENSG00000202081.1	RNU6-1280P	4.05	6.91e-05	0.0232	0.31	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85550695	chr15:85651522~85651628:-
SARC	cis	rs9739682	0.957	rs10877791	ENSG00000139239.7	RPL14P1	-4.05	6.91e-05	0.0232	-0.23	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62098256	chr12:62965325~62965969:+
SARC	cis	rs13217239	0.646	rs9379956	ENSG00000241549.7	GUSBP2	-4.05	6.91e-05	0.0232	-0.24	-0.26	Schizophrenia;	chr6:27065956	chr6:26871484~26956554:-
SARC	cis	rs13217239	0.646	rs7747454	ENSG00000241549.7	GUSBP2	-4.05	6.91e-05	0.0232	-0.24	-0.26	Schizophrenia;	chr6:27066474	chr6:26871484~26956554:-
SARC	cis	rs7246657	0.943	rs2081096	ENSG00000226686.6	LINC01535	-4.05	6.91e-05	0.0232	-0.35	-0.26	Coronary artery calcification;	chr19:37473798	chr19:37251912~37265535:+
SARC	cis	rs495337	0.72	rs6067274	ENSG00000229222.1	KRT18P4	-4.05	6.92e-05	0.0232	-0.33	-0.26	Psoriasis;	chr20:49927849	chr20:49956745~49958032:+
SARC	cis	rs495337	0.72	rs6125819	ENSG00000229222.1	KRT18P4	-4.05	6.92e-05	0.0232	-0.33	-0.26	Psoriasis;	chr20:49929173	chr20:49956745~49958032:+
SARC	cis	rs495337	0.786	rs6125820	ENSG00000229222.1	KRT18P4	-4.05	6.92e-05	0.0232	-0.33	-0.26	Psoriasis;	chr20:49929294	chr20:49956745~49958032:+
SARC	cis	rs495337	0.76	rs6067275	ENSG00000229222.1	KRT18P4	-4.05	6.92e-05	0.0232	-0.33	-0.26	Psoriasis;	chr20:49929336	chr20:49956745~49958032:+
SARC	cis	rs495337	0.76	rs6122845	ENSG00000229222.1	KRT18P4	-4.05	6.92e-05	0.0232	-0.33	-0.26	Psoriasis;	chr20:49929737	chr20:49956745~49958032:+
SARC	cis	rs495337	0.721	rs11696404	ENSG00000229222.1	KRT18P4	-4.05	6.92e-05	0.0232	-0.33	-0.26	Psoriasis;	chr20:49931743	chr20:49956745~49958032:+
SARC	cis	rs495337	0.76	rs11696437	ENSG00000229222.1	KRT18P4	-4.05	6.92e-05	0.0232	-0.33	-0.26	Psoriasis;	chr20:49931781	chr20:49956745~49958032:+
SARC	cis	rs495337	0.721	rs6125822	ENSG00000229222.1	KRT18P4	-4.05	6.92e-05	0.0232	-0.33	-0.26	Psoriasis;	chr20:49932229	chr20:49956745~49958032:+
SARC	cis	rs6142102	0.581	rs4911148	ENSG00000275784.1	RP5-1125A11.6	-4.05	6.92e-05	0.0232	-0.3	-0.26	Skin pigmentation;	chr20:34080438	chr20:33989480~33991818:-
SARC	cis	rs3823536	0.583	rs10954214	ENSG00000275106.1	RP11-309L24.10	-4.05	6.92e-05	0.0233	-0.32	-0.26	Sjögren's syndrome;	chr7:128949579	chr7:128952527~128953316:-
SARC	cis	rs7031325	0.819	rs7046343	ENSG00000229611.1	RP11-390F4.10	-4.05	6.93e-05	0.0233	-0.29	-0.26	Systemic lupus erythematosus;	chr9:6652506	chr9:6704471~6707780:+
SARC	cis	rs7031325	0.962	rs7029780	ENSG00000229611.1	RP11-390F4.10	-4.05	6.93e-05	0.0233	-0.29	-0.26	Systemic lupus erythematosus;	chr9:6652614	chr9:6704471~6707780:+
SARC	cis	rs12200782	0.53	rs6929908	ENSG00000241549.7	GUSBP2	4.05	6.93e-05	0.0233	0.29	0.26	Small cell lung carcinoma;	chr6:26555061	chr6:26871484~26956554:-
SARC	cis	rs42490	0.873	rs218895	ENSG00000251136.7	RP11-37B2.1	-4.05	6.93e-05	0.0233	-0.28	-0.26	Leprosy;	chr8:89714320	chr8:89609409~89757727:-
SARC	cis	rs42490	0.903	rs218899	ENSG00000251136.7	RP11-37B2.1	-4.05	6.93e-05	0.0233	-0.28	-0.26	Leprosy;	chr8:89717279	chr8:89609409~89757727:-
SARC	cis	rs2404602	1	rs2404741	ENSG00000259422.1	RP11-593F23.1	4.05	6.93e-05	0.0233	0.29	0.26	Blood metabolite levels;	chr15:76559394	chr15:76174891~76181486:-
SARC	cis	rs2404602	1	rs2404740	ENSG00000259422.1	RP11-593F23.1	4.05	6.93e-05	0.0233	0.29	0.26	Blood metabolite levels;	chr15:76559802	chr15:76174891~76181486:-
SARC	cis	rs11822910	0.737	rs2584858	ENSG00000254602.1	AP000662.4	4.05	6.93e-05	0.0233	0.26	0.26	Platelet distribution width;	chr11:57439604	chr11:57638024~57652790:+
SARC	cis	rs9309473	0.5	rs4852952	ENSG00000163016.8	ALMS1P	-4.05	6.93e-05	0.0233	-0.29	-0.26	Metabolite levels;	chr2:73642780	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.5	rs4852953	ENSG00000163016.8	ALMS1P	-4.05	6.93e-05	0.0233	-0.29	-0.26	Metabolite levels;	chr2:73642781	chr2:73644919~73685576:+
SARC	cis	rs6845263	0.546	rs2866380	ENSG00000254531.1	FLJ20021	-4.05	6.93e-05	0.0233	-0.25	-0.26	Superior crus of antihelix expression;	chr4:101534886	chr4:101347780~101348883:+
SARC	cis	rs4660214	0.671	rs72637904	ENSG00000182109.6	RP11-69E11.4	4.05	6.94e-05	0.0233	0.31	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203010	chr1:39522280~39546187:-
SARC	cis	rs4660214	0.671	rs17491275	ENSG00000182109.6	RP11-69E11.4	4.05	6.94e-05	0.0233	0.31	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39206873	chr1:39522280~39546187:-
SARC	cis	rs4906332	1	rs55731474	ENSG00000244691.1	RPL10AP1	-4.05	6.94e-05	0.0233	-0.3	-0.26	Coronary artery disease;	chr14:103412144	chr14:103412119~103412761:-
SARC	cis	rs9902453	1	rs62070270	ENSG00000264538.5	SUZ12P1	4.05	6.94e-05	0.0233	0.18	0.26	Coffee consumption (cups per day);	chr17:29936962	chr17:30709299~30790908:+
SARC	cis	rs42490	0.614	rs402434	ENSG00000251136.7	RP11-37B2.1	-4.05	6.94e-05	0.0233	-0.28	-0.26	Leprosy;	chr8:89808088	chr8:89609409~89757727:-
SARC	cis	rs42490	0.614	rs452694	ENSG00000251136.7	RP11-37B2.1	-4.05	6.94e-05	0.0233	-0.28	-0.26	Leprosy;	chr8:89808293	chr8:89609409~89757727:-
SARC	cis	rs42490	0.59	rs447611	ENSG00000251136.7	RP11-37B2.1	-4.05	6.94e-05	0.0233	-0.28	-0.26	Leprosy;	chr8:89808359	chr8:89609409~89757727:-
SARC	cis	rs593531	0.571	rs10898983	ENSG00000280269.1	AP000577.2	-4.05	6.95e-05	0.0233	-0.32	-0.26	Neuroticism;	chr11:74382947	chr11:74204869~74205746:+
SARC	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	4.05	6.95e-05	0.0233	0.24	0.26	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	4.05	6.95e-05	0.0233	0.24	0.26	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
SARC	cis	rs853679	0.55	rs1233707	ENSG00000216901.1	AL022393.7	4.05	6.95e-05	0.0233	0.34	0.26	Depression;	chr6:28205175	chr6:28176188~28176674:+
SARC	cis	rs2281558	0.583	rs7260957	ENSG00000125804.12	FAM182A	-4.05	6.95e-05	0.0233	-0.41	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25741826	chr20:26054655~26086917:+
SARC	cis	rs1707322	1	rs785486	ENSG00000281133.1	AL355480.3	4.05	6.95e-05	0.0233	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.865	rs785501	ENSG00000281133.1	AL355480.3	4.05	6.95e-05	0.0233	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45580892~45580996:-
SARC	cis	rs6540731	1	rs11119885	ENSG00000229983.1	RP11-15I11.2	4.05	6.95e-05	0.0233	0.26	0.26	Intelligence (childhood);	chr1:212227656	chr1:212168207~212190259:+
SARC	cis	rs7951911	1	rs966905	ENSG00000254427.1	RP11-430H10.1	4.05	6.96e-05	0.0233	0.36	0.26	IgG glycosylation;	chr11:45083490	chr11:45355371~45366121:+
SARC	cis	rs2288884	0.767	rs28379522	ENSG00000275055.1	CTC-471J1.11	-4.05	6.96e-05	0.0234	-0.32	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52036234	chr19:52049007~52049754:+
SARC	cis	rs6570726	1	rs1935617	ENSG00000270638.1	RP3-466P17.1	4.05	6.96e-05	0.0234	0.21	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145735570~145737218:+
SARC	cis	rs35607894	0.607	rs12885258	ENSG00000259146.3	RP1-261D10.2	-4.05	6.97e-05	0.0234	-0.39	-0.26	Schizophrenia;	chr14:71994581	chr14:71292729~71321814:-
SARC	cis	rs7617773	0.709	rs4404473	ENSG00000228638.1	FCF1P2	-4.05	6.97e-05	0.0234	-0.3	-0.26	Coronary artery disease;	chr3:48312136	chr3:48290793~48291375:-
SARC	cis	rs42490	0.59	rs441547	ENSG00000251136.7	RP11-37B2.1	-4.05	6.97e-05	0.0234	-0.28	-0.26	Leprosy;	chr8:89807954	chr8:89609409~89757727:-
SARC	cis	rs42490	0.614	rs441548	ENSG00000251136.7	RP11-37B2.1	-4.05	6.97e-05	0.0234	-0.28	-0.26	Leprosy;	chr8:89807955	chr8:89609409~89757727:-
SARC	cis	rs12200782	0.929	rs72841519	ENSG00000272462.2	U91328.19	-4.05	6.98e-05	0.0234	-0.37	-0.26	Small cell lung carcinoma;	chr6:26371673	chr6:25992662~26001775:+
SARC	cis	rs494459	0.536	rs11217065	ENSG00000255422.1	AP002954.4	-4.05	6.98e-05	0.0234	-0.26	-0.26	Height;	chr11:118855938	chr11:118704607~118750263:+
SARC	cis	rs72627509	0.904	rs17081935	ENSG00000269949.1	RP11-738E22.3	4.05	6.99e-05	0.0234	0.39	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56957310	chr4:56960927~56961373:-
SARC	cis	rs6964833	1	rs17515241	ENSG00000184616.8	AC004166.6	-4.05	6.99e-05	0.0234	-0.37	-0.26	Menarche (age at onset);	chr7:74717695	chr7:74906673~74913256:-
SARC	cis	rs12049351	0.774	rs6671385	ENSG00000229367.1	HMGN2P19	4.05	6.99e-05	0.0234	0.21	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229506905	chr1:229570532~229570796:+
SARC	cis	rs7772486	0.806	rs4075695	ENSG00000270638.1	RP3-466P17.1	-4.05	7e-05	0.0234	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145735570~145737218:+
SARC	cis	rs2179367	0.887	rs2789492	ENSG00000216906.2	RP11-350J20.9	-4.05	7e-05	0.0234	-0.24	-0.26	Dupuytren's disease;	chr6:149426243	chr6:149904243~149906418:+
SARC	cis	rs6740322	0.895	rs9309098	ENSG00000234936.1	AC010883.5	-4.05	7e-05	0.0234	-0.29	-0.26	Coronary artery disease;	chr2:43327833	chr2:43229573~43233394:+
SARC	cis	rs61160187	0.582	rs2049579	ENSG00000272308.1	RP11-231G3.1	-4.05	7.01e-05	0.0235	-0.22	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:60866457~60866935:-
SARC	cis	rs72759215	1	rs72759215	ENSG00000272308.1	RP11-231G3.1	-4.05	7.01e-05	0.0235	-0.22	-0.26	Intelligence (multi-trait analysis);	chr5:61056756	chr5:60866457~60866935:-
SARC	cis	rs28386778	0.897	rs716880	ENSG00000240280.5	TCAM1P	-4.05	7.01e-05	0.0235	-0.32	-0.26	Prudent dietary pattern;	chr17:63825462	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2584626	ENSG00000240280.5	TCAM1P	-4.05	7.01e-05	0.0235	-0.32	-0.26	Prudent dietary pattern;	chr17:63825819	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2584624	ENSG00000240280.5	TCAM1P	-4.05	7.01e-05	0.0235	-0.32	-0.26	Prudent dietary pattern;	chr17:63827186	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.863	rs2665834	ENSG00000240280.5	TCAM1P	-4.05	7.01e-05	0.0235	-0.32	-0.26	Prudent dietary pattern;	chr17:63827364	chr17:63849292~63864379:+
SARC	cis	rs367615	0.918	rs115145487	ENSG00000249476.1	CTD-2587M2.1	4.05	7.01e-05	0.0235	0.33	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109552445	chr5:109237120~109326369:-
SARC	cis	rs7615952	0.599	rs2270986	ENSG00000248787.1	RP11-666A20.4	-4.05	7.01e-05	0.0235	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:125982256	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.599	rs12496921	ENSG00000248787.1	RP11-666A20.4	-4.05	7.01e-05	0.0235	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:125983105	chr3:125908005~125910272:-
SARC	cis	rs910316	1	rs175436	ENSG00000279594.1	RP11-950C14.10	-4.05	7.02e-05	0.0235	-0.28	-0.26	Height;	chr14:75141980	chr14:75011269~75012851:-
SARC	cis	rs453301	0.658	rs9329175	ENSG00000253893.2	FAM85B	4.05	7.02e-05	0.0235	0.23	0.26	Joint mobility (Beighton score);	chr8:9009151	chr8:8167819~8226614:-
SARC	cis	rs7615952	0.932	rs13325495	ENSG00000250012.1	RP11-124N2.1	-4.05	7.02e-05	0.0235	-0.28	-0.26	Blood pressure (smoking interaction);	chr3:125918573	chr3:126084220~126095349:+
SARC	cis	rs160451	0.966	rs12216864	ENSG00000251136.7	RP11-37B2.1	4.05	7.02e-05	0.0235	0.27	0.26	Leprosy;	chr8:89665895	chr8:89609409~89757727:-
SARC	cis	rs7772486	0.806	rs4075696	ENSG00000270638.1	RP3-466P17.1	-4.05	7.02e-05	0.0235	-0.21	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145929811	chr6:145735570~145737218:+
SARC	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-4.05	7.03e-05	0.0235	-0.3	-0.26	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
SARC	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-4.05	7.03e-05	0.0235	-0.3	-0.26	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
SARC	cis	rs1062177	1	rs12515762	ENSG00000254226.4	CTB-12O2.1	4.05	7.03e-05	0.0235	0.35	0.26	Preschool internalizing problems;	chr5:151830361	chr5:151949571~152270448:+
SARC	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-4.05	7.03e-05	0.0235	-0.34	-0.26	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-4.05	7.03e-05	0.0235	-0.34	-0.26	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
SARC	cis	rs600550	0.519	rs7931525	ENSG00000255139.1	AP000442.1	-4.05	7.03e-05	0.0235	-0.26	-0.26	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60336353	chr11:59616429~59639861:+
SARC	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	4.05	7.03e-05	0.0235	0.28	0.26	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
SARC	cis	rs526231	0.756	rs2561479	ENSG00000175749.11	EIF3KP1	4.05	7.04e-05	0.0235	0.32	0.26	Primary biliary cholangitis;	chr5:103286176	chr5:103032376~103033031:+
SARC	cis	rs495337	0.721	rs554263	ENSG00000229222.1	KRT18P4	-4.05	7.04e-05	0.0236	-0.34	-0.26	Psoriasis;	chr20:49897356	chr20:49956745~49958032:+
SARC	cis	rs495337	0.76	rs2769975	ENSG00000229222.1	KRT18P4	-4.05	7.04e-05	0.0236	-0.34	-0.26	Psoriasis;	chr20:49899974	chr20:49956745~49958032:+
SARC	cis	rs853679	0.713	rs200991	ENSG00000216901.1	AL022393.7	-4.05	7.04e-05	0.0236	-0.46	-0.26	Depression;	chr6:27847716	chr6:28176188~28176674:+
SARC	cis	rs3824347	0.872	rs10781256	ENSG00000203321.2	C9orf41-AS1	-4.05	7.05e-05	0.0236	-0.29	-0.26	Urinary magnesium-to-creatinine ratio;	chr9:74965289	chr9:74952968~74996293:+
SARC	cis	rs4835473	0.831	rs1984809	ENSG00000251600.4	RP11-673E1.1	4.05	7.06e-05	0.0236	0.25	0.26	Immature fraction of reticulocytes;	chr4:143825018	chr4:143912331~143982454:+
SARC	cis	rs9309473	0.583	rs6718864	ENSG00000163016.8	ALMS1P	4.05	7.06e-05	0.0236	0.31	0.26	Metabolite levels;	chr2:73347463	chr2:73644919~73685576:+
SARC	cis	rs526231	0.67	rs253756	ENSG00000175749.11	EIF3KP1	4.05	7.06e-05	0.0236	0.32	0.26	Primary biliary cholangitis;	chr5:103284771	chr5:103032376~103033031:+
SARC	cis	rs9868809	0.505	rs9882549	ENSG00000225399.4	RP11-3B7.1	-4.05	7.06e-05	0.0236	-0.43	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48711925	chr3:49260085~49261316:+
SARC	cis	rs4835473	0.9	rs58106929	ENSG00000251600.4	RP11-673E1.1	4.05	7.06e-05	0.0236	0.25	0.26	Immature fraction of reticulocytes;	chr4:143733166	chr4:143912331~143982454:+
SARC	cis	rs7772486	0.558	rs9376965	ENSG00000270638.1	RP3-466P17.1	4.05	7.07e-05	0.0236	0.22	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145735570~145737218:+
SARC	cis	rs2404602	0.583	rs12907668	ENSG00000259422.1	RP11-593F23.1	4.05	7.07e-05	0.0236	0.28	0.26	Blood metabolite levels;	chr15:76297426	chr15:76174891~76181486:-
SARC	cis	rs7826238	0.623	rs2976893	ENSG00000253981.4	ALG1L13P	-4.05	7.07e-05	0.0237	-0.24	-0.26	Systolic blood pressure;	chr8:8480709	chr8:8236003~8244667:-
SARC	cis	rs6845263	0.546	rs9917916	ENSG00000254531.1	FLJ20021	-4.05	7.08e-05	0.0237	-0.25	-0.26	Superior crus of antihelix expression;	chr4:101534576	chr4:101347780~101348883:+
SARC	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-4.05	7.08e-05	0.0237	-0.31	-0.26	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
SARC	cis	rs4664293	0.836	rs4665118	ENSG00000226266.5	AC009961.3	-4.05	7.08e-05	0.0237	-0.32	-0.26	Monocyte percentage of white cells;	chr2:159802938	chr2:159670708~159712435:-
SARC	cis	rs12200782	1	rs12207181	ENSG00000272810.1	U91328.22	-4.05	7.09e-05	0.0237	-0.44	-0.26	Small cell lung carcinoma;	chr6:26431057	chr6:26013241~26013757:+
SARC	cis	rs12200782	1	rs12199239	ENSG00000272810.1	U91328.22	-4.05	7.09e-05	0.0237	-0.44	-0.26	Small cell lung carcinoma;	chr6:26432342	chr6:26013241~26013757:+
SARC	cis	rs12200782	1	rs10456330	ENSG00000272810.1	U91328.22	-4.05	7.09e-05	0.0237	-0.44	-0.26	Small cell lung carcinoma;	chr6:26436464	chr6:26013241~26013757:+
SARC	cis	rs12200782	1	rs12208390	ENSG00000272810.1	U91328.22	-4.05	7.09e-05	0.0237	-0.44	-0.26	Small cell lung carcinoma;	chr6:26436878	chr6:26013241~26013757:+
SARC	cis	rs12200782	0.929	rs72843734	ENSG00000272810.1	U91328.22	-4.05	7.09e-05	0.0237	-0.44	-0.26	Small cell lung carcinoma;	chr6:26448116	chr6:26013241~26013757:+
SARC	cis	rs748404	1	rs66651343	ENSG00000205771.5	CATSPER2P1	-4.05	7.09e-05	0.0237	-0.38	-0.26	Lung cancer;	chr15:43265806	chr15:43726918~43747094:-
SARC	cis	rs4276643	0.846	rs2685422	ENSG00000239198.1	RPL5P22	-4.05	7.09e-05	0.0237	-0.29	-0.26	Low vWF levels;	chr8:27947867	chr8:28299683~28300566:+
SARC	cis	rs12950390	0.853	rs59513807	ENSG00000239291.1	RP5-867C24.1	4.05	7.09e-05	0.0237	0.3	0.26	IgG glycosylation;	chr17:47790559	chr17:47159191~47159993:-
SARC	cis	rs42490	0.653	rs40453	ENSG00000251136.7	RP11-37B2.1	-4.05	7.09e-05	0.0237	-0.28	-0.26	Leprosy;	chr8:89789817	chr8:89609409~89757727:-
SARC	cis	rs42490	0.752	rs400411	ENSG00000251136.7	RP11-37B2.1	-4.05	7.09e-05	0.0237	-0.28	-0.26	Leprosy;	chr8:89789871	chr8:89609409~89757727:-
SARC	cis	rs42490	0.738	rs39509	ENSG00000251136.7	RP11-37B2.1	-4.05	7.09e-05	0.0237	-0.28	-0.26	Leprosy;	chr8:89791937	chr8:89609409~89757727:-
SARC	cis	rs42490	0.752	rs411279	ENSG00000251136.7	RP11-37B2.1	-4.05	7.09e-05	0.0237	-0.28	-0.26	Leprosy;	chr8:89795929	chr8:89609409~89757727:-
SARC	cis	rs9926296	0.546	rs7187436	ENSG00000260279.2	AC137932.5	4.05	7.09e-05	0.0237	0.24	0.26	Vitiligo;	chr16:89778702	chr16:89297508~89298317:+
SARC	cis	rs9926296	0.585	rs1800337	ENSG00000260279.2	AC137932.5	4.05	7.09e-05	0.0237	0.24	0.26	Vitiligo;	chr16:89778786	chr16:89297508~89298317:+
SARC	cis	rs12542260	1	rs10956185	ENSG00000253106.1	RP11-158K1.3	-4.05	7.09e-05	0.0237	-0.31	-0.26	Colonoscopy-negative controls vs population controls;	chr8:124473487	chr8:124488510~124491643:+
SARC	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	4.05	7.1e-05	0.0237	0.32	0.26	Height;	chr6:109351795	chr6:109382795~109383666:+
SARC	cis	rs7267979	0.903	rs6050482	ENSG00000274414.1	RP5-965G21.4	-4.05	7.1e-05	0.0237	-0.26	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25239007~25245229:-
SARC	cis	rs7267979	0.706	rs6037069	ENSG00000274414.1	RP5-965G21.4	-4.05	7.1e-05	0.0237	-0.26	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25239007~25245229:-
SARC	cis	rs495337	0.76	rs6122844	ENSG00000229222.1	KRT18P4	-4.05	7.1e-05	0.0237	-0.33	-0.26	Psoriasis;	chr20:49925008	chr20:49956745~49958032:+
SARC	cis	rs495337	0.72	rs6067271	ENSG00000229222.1	KRT18P4	-4.05	7.1e-05	0.0237	-0.33	-0.26	Psoriasis;	chr20:49925126	chr20:49956745~49958032:+
SARC	cis	rs997295	1	rs34583567	ENSG00000259410.4	RP11-34F13.3	4.05	7.11e-05	0.0237	0.28	0.26	Motion sickness;	chr15:67690943	chr15:67832725~67873866:+
SARC	cis	rs2283792	0.646	rs9610271	ENSG00000224086.5	LL22NC03-86G7.1	-4.05	7.11e-05	0.0238	-0.27	-0.26	Multiple sclerosis;	chr22:21758238	chr22:21938293~21977632:+
SARC	cis	rs2153535	0.585	rs980083	ENSG00000230939.1	RP11-314C16.1	4.05	7.12e-05	0.0238	0.3	0.26	Motion sickness;	chr6:8589683	chr6:8784178~8785445:+
SARC	cis	rs240993	0.812	rs6929024	ENSG00000230177.1	RP5-1112D6.4	4.04	7.12e-05	0.0238	0.3	0.26	Inflammatory skin disease;Psoriasis;	chr6:111545104	chr6:111277932~111278742:+
SARC	cis	rs7267979	0.899	rs442834	ENSG00000276952.1	RP5-965G21.6	4.04	7.12e-05	0.0238	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.932	rs417110	ENSG00000276952.1	RP5-965G21.6	4.04	7.12e-05	0.0238	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.932	rs449703	ENSG00000276952.1	RP5-965G21.6	4.04	7.12e-05	0.0238	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:25284915~25285588:-
SARC	cis	rs755249	0.567	rs4660546	ENSG00000182109.6	RP11-69E11.4	4.04	7.12e-05	0.0238	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39522280~39546187:-
SARC	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	4.04	7.12e-05	0.0238	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs12369195	ENSG00000258302.2	RP11-981P6.1	4.04	7.13e-05	0.0238	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89561129~89594878:+
SARC	cis	rs12554020	0.685	rs55893789	ENSG00000227603.1	RP11-165J3.6	4.04	7.13e-05	0.0238	0.42	0.26	Schizophrenia;	chr9:93408608	chr9:93435332~93437121:-
SARC	cis	rs12554020	0.681	rs78759589	ENSG00000227603.1	RP11-165J3.6	4.04	7.13e-05	0.0238	0.42	0.26	Schizophrenia;	chr9:93409518	chr9:93435332~93437121:-
SARC	cis	rs1707322	0.928	rs6681068	ENSG00000281133.1	AL355480.3	-4.04	7.13e-05	0.0238	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs11211228	ENSG00000281133.1	AL355480.3	-4.04	7.13e-05	0.0238	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.963	rs11211229	ENSG00000281133.1	AL355480.3	-4.04	7.13e-05	0.0238	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs9803784	ENSG00000281133.1	AL355480.3	-4.04	7.13e-05	0.0238	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.963	rs12022335	ENSG00000281133.1	AL355480.3	-4.04	7.13e-05	0.0238	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs10890375	ENSG00000281133.1	AL355480.3	-4.04	7.13e-05	0.0238	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs10890377	ENSG00000281133.1	AL355480.3	-4.04	7.13e-05	0.0238	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.963	rs10789484	ENSG00000281133.1	AL355480.3	-4.04	7.13e-05	0.0238	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45580892~45580996:-
SARC	cis	rs42490	0.903	rs393891	ENSG00000251136.7	RP11-37B2.1	-4.04	7.14e-05	0.0238	-0.29	-0.26	Leprosy;	chr8:89701556	chr8:89609409~89757727:-
SARC	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-4.04	7.14e-05	0.0238	-0.29	-0.26	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
SARC	cis	rs867371	1	rs8041924	ENSG00000259429.4	UBE2Q2P2	-4.04	7.14e-05	0.0238	-0.24	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82355142~82420075:+
SARC	cis	rs867371	1	rs2088858	ENSG00000259429.4	UBE2Q2P2	-4.04	7.14e-05	0.0238	-0.24	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82355142~82420075:+
SARC	cis	rs867371	1	rs4778982	ENSG00000259429.4	UBE2Q2P2	-4.04	7.14e-05	0.0238	-0.24	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82355142~82420075:+
SARC	cis	rs867371	1	rs2867579	ENSG00000259429.4	UBE2Q2P2	-4.04	7.14e-05	0.0238	-0.24	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82355142~82420075:+
SARC	cis	rs867371	1	rs881308	ENSG00000259429.4	UBE2Q2P2	-4.04	7.14e-05	0.0238	-0.24	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82355142~82420075:+
SARC	cis	rs10200159	1	rs10172506	ENSG00000272606.1	RP11-554J4.1	4.04	7.14e-05	0.0238	0.46	0.26	Vitiligo;	chr2:55638334	chr2:55617909~55618373:+
SARC	cis	rs7615952	0.641	rs12495947	ENSG00000248787.1	RP11-666A20.4	-4.04	7.15e-05	0.0239	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126052855	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.641	rs6805074	ENSG00000248787.1	RP11-666A20.4	-4.04	7.15e-05	0.0239	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126053431	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.641	rs66520539	ENSG00000248787.1	RP11-666A20.4	-4.04	7.15e-05	0.0239	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126061531	chr3:125908005~125910272:-
SARC	cis	rs7267979	1	rs2424716	ENSG00000276952.1	RP5-965G21.6	4.04	7.15e-05	0.0239	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs761025	ENSG00000276952.1	RP5-965G21.6	4.04	7.15e-05	0.0239	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25284915~25285588:-
SARC	cis	rs7267979	1	rs6515651	ENSG00000276952.1	RP5-965G21.6	-4.04	7.15e-05	0.0239	-0.25	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.727	rs4815431	ENSG00000125804.12	FAM182A	4.04	7.15e-05	0.0239	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:26054655~26086917:+
SARC	cis	rs61160187	0.605	rs10068474	ENSG00000215032.2	GNL3LP1	-4.04	7.15e-05	0.0239	-0.25	-0.26	Educational attainment (years of education);Educational attainment (college completion);	chr5:60782085	chr5:60891935~60893577:-
SARC	cis	rs2439831	0.717	rs2470132	ENSG00000275601.1	AC011330.13	-4.04	7.16e-05	0.0239	-0.41	-0.26	Lung cancer in ever smokers;	chr15:43543283	chr15:43642389~43643023:-
SARC	cis	rs2289583	0.597	rs12148708	ENSG00000260269.4	CTD-2323K18.1	4.04	7.16e-05	0.0239	0.37	0.26	Systemic lupus erythematosus;	chr15:75092056	chr15:75527150~75601205:-
SARC	cis	rs7615952	0.932	rs13065725	ENSG00000250012.1	RP11-124N2.1	-4.04	7.16e-05	0.0239	-0.28	-0.26	Blood pressure (smoking interaction);	chr3:125913446	chr3:126084220~126095349:+
SARC	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	4.04	7.16e-05	0.0239	0.24	0.26	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
SARC	cis	rs8095374	0.967	rs718515	ENSG00000280212.1	RP11-49K24.3	4.04	7.16e-05	0.0239	0.28	0.26	Clinical laboratory measurements;	chr18:46276334	chr18:47076117~47076594:+
SARC	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	4.04	7.16e-05	0.0239	0.26	0.26	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
SARC	cis	rs2439831	0.85	rs8042868	ENSG00000275601.1	AC011330.13	-4.04	7.17e-05	0.0239	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43647444	chr15:43642389~43643023:-
SARC	cis	rs11086243	1	rs6066651	ENSG00000276923.1	RP11-321P16.1	4.04	7.17e-05	0.0239	0.31	0.26	Nephrotic syndrome (acquired);	chr20:48151570	chr20:48073869~48074188:+
SARC	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-4.04	7.17e-05	0.0239	-0.33	-0.26	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
SARC	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-4.04	7.17e-05	0.0239	-0.33	-0.26	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
SARC	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-4.04	7.17e-05	0.0239	-0.33	-0.26	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
SARC	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-4.04	7.17e-05	0.0239	-0.33	-0.26	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
SARC	cis	rs9739682	1	rs11174334	ENSG00000139239.7	RPL14P1	-4.04	7.17e-05	0.0239	-0.23	-0.26	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62125258	chr12:62965325~62965969:+
SARC	cis	rs2404602	0.716	rs284895	ENSG00000259422.1	RP11-593F23.1	-4.04	7.17e-05	0.0239	-0.28	-0.26	Blood metabolite levels;	chr15:76458884	chr15:76174891~76181486:-
SARC	cis	rs1799949	0.965	rs4239149	ENSG00000267681.1	CTD-3199J23.6	4.04	7.17e-05	0.0239	0.28	0.26	Menopause (age at onset);	chr17:43176078	chr17:43144956~43145255:+
SARC	cis	rs1150668	0.796	rs9468372	ENSG00000219392.1	RP1-265C24.5	-4.04	7.17e-05	0.0239	-0.29	-0.26	Pubertal anthropometrics;	chr6:28411584	chr6:28115628~28116551:+
SARC	cis	rs9604529	0.532	rs41291213	ENSG00000233695.2	GAS6-AS1	-4.04	7.17e-05	0.0239	-0.32	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr13:114009515	chr13:113815630~113845744:+
SARC	cis	rs7178375	1	rs7178375	ENSG00000215302.7	CTD-3092A11.1	-4.04	7.17e-05	0.0239	-0.33	-0.26	Hypertriglyceridemia;	chr15:30923732	chr15:30470779~30507623:+
SARC	cis	rs11159086	0.793	rs28612392	ENSG00000270000.1	RP3-449M8.9	4.04	7.18e-05	0.0239	0.39	0.26	Advanced glycation end-product levels;	chr14:74467894	chr14:74471930~74472360:-
SARC	cis	rs910316	0.967	rs2268619	ENSG00000279594.1	RP11-950C14.10	-4.04	7.18e-05	0.0239	-0.3	-0.26	Height;	chr14:75173651	chr14:75011269~75012851:-
SARC	cis	rs6877440	0.752	rs17162096	ENSG00000271849.1	CTC-332L22.1	-4.04	7.18e-05	0.0239	-0.58	-0.26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr5:109711737	chr5:109687802~109688329:-
SARC	cis	rs6877440	0.752	rs10067856	ENSG00000271849.1	CTC-332L22.1	-4.04	7.18e-05	0.0239	-0.58	-0.26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr5:109712432	chr5:109687802~109688329:-
SARC	cis	rs6877440	0.752	rs56021829	ENSG00000271849.1	CTC-332L22.1	-4.04	7.18e-05	0.0239	-0.58	-0.26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr5:109715200	chr5:109687802~109688329:-
SARC	cis	rs8028182	1	rs8028182	ENSG00000260206.1	CTD-2026K11.2	-4.04	7.19e-05	0.024	-0.33	-0.26	Sudden cardiac arrest;	chr15:75426328	chr15:75636139~75639239:+
SARC	cis	rs12915820	1	rs12915820	ENSG00000274376.3	ADAMTS7P1	-4.04	7.19e-05	0.024	-0.29	-0.26	Response to paliperidone in schizophrenia (PANSS score);	chr15:81716770	chr15:82298553~82334609:+
SARC	cis	rs12554020	0.892	rs12555047	ENSG00000227603.1	RP11-165J3.6	4.04	7.19e-05	0.024	0.34	0.26	Schizophrenia;	chr9:93424208	chr9:93435332~93437121:-
SARC	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	4.04	7.19e-05	0.024	0.39	0.26	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
SARC	cis	rs72634501	0.716	rs2282231	ENSG00000182109.6	RP11-69E11.4	4.04	7.2e-05	0.024	0.3	0.26	HDL cholesterol;	chr1:39103899	chr1:39522280~39546187:-
SARC	cis	rs10540	1	rs12794284	ENSG00000277290.1	RP11-326C3.16	4.04	7.2e-05	0.024	0.32	0.26	Body mass index;	chr11:477623	chr11:243099~243483:-
SARC	cis	rs1707322	1	rs1612419	ENSG00000281133.1	AL355480.3	4.04	7.21e-05	0.024	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45580892~45580996:-
SARC	cis	rs763121	0.853	rs2267395	ENSG00000273076.1	RP3-508I15.22	4.04	7.21e-05	0.024	0.27	0.26	Menopause (age at onset);	chr22:38717898	chr22:38743495~38743910:+
SARC	cis	rs42490	0.653	rs40247	ENSG00000251136.7	RP11-37B2.1	-4.04	7.21e-05	0.024	-0.28	-0.26	Leprosy;	chr8:89789744	chr8:89609409~89757727:-
SARC	cis	rs7772486	0.79	rs6570723	ENSG00000235652.6	RP11-545I5.3	4.04	7.21e-05	0.024	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.79	rs6570724	ENSG00000235652.6	RP11-545I5.3	4.04	7.21e-05	0.024	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.79	rs6917135	ENSG00000235652.6	RP11-545I5.3	4.04	7.21e-05	0.024	0.23	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145799409~145886585:+
SARC	cis	rs12542260	1	rs62527901	ENSG00000253106.1	RP11-158K1.3	-4.04	7.22e-05	0.024	-0.3	-0.26	Colonoscopy-negative controls vs population controls;	chr8:124495766	chr8:124488510~124491643:+
SARC	cis	rs12542260	1	rs7845008	ENSG00000253106.1	RP11-158K1.3	-4.04	7.22e-05	0.024	-0.3	-0.26	Colonoscopy-negative controls vs population controls;	chr8:124503550	chr8:124488510~124491643:+
SARC	cis	rs12542260	1	rs76350429	ENSG00000253106.1	RP11-158K1.3	-4.04	7.22e-05	0.024	-0.3	-0.26	Colonoscopy-negative controls vs population controls;	chr8:124503996	chr8:124488510~124491643:+
SARC	cis	rs10986311	0.963	rs1024255	ENSG00000235204.1	RP11-121A14.2	4.04	7.22e-05	0.024	0.3	0.26	Vitiligo;	chr9:124332202	chr9:124259250~124261156:-
SARC	cis	rs13161895	1	rs4129403	ENSG00000250999.1	RP11-1379J22.5	-4.04	7.22e-05	0.024	-0.46	-0.26	LDL cholesterol;	chr5:180049610	chr5:179657762~179664432:+
SARC	cis	rs10788972	0.51	rs665817	ENSG00000225183.1	RP4-758J24.4	4.04	7.22e-05	0.024	0.28	0.26	Parkinson disease and lewy body pathology;	chr1:54004275	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.542	rs585269	ENSG00000225183.1	RP4-758J24.4	4.04	7.22e-05	0.024	0.28	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54004303	chr1:54089856~54090093:+
SARC	cis	rs2235544	0.542	rs11206272	ENSG00000225183.1	RP4-758J24.4	4.04	7.22e-05	0.024	0.28	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54004362	chr1:54089856~54090093:+
SARC	cis	rs7688540	0.656	rs79657896	ENSG00000275426.1	CH17-262A2.1	4.04	7.22e-05	0.024	0.37	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs61792116	ENSG00000275426.1	CH17-262A2.1	4.04	7.22e-05	0.024	0.37	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:149738~150317:+
SARC	cis	rs4835473	0.637	rs11932061	ENSG00000251600.4	RP11-673E1.1	4.04	7.22e-05	0.0241	0.24	0.26	Immature fraction of reticulocytes;	chr4:143768124	chr4:143912331~143982454:+
SARC	cis	rs12893668	0.703	rs729438	ENSG00000269958.1	RP11-73M18.8	-4.04	7.23e-05	0.0241	-0.27	-0.26	Reticulocyte count;	chr14:103626452	chr14:103696353~103697163:+
SARC	cis	rs7772486	0.558	rs62435775	ENSG00000270638.1	RP3-466P17.1	4.04	7.23e-05	0.0241	0.22	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145735570~145737218:+
SARC	cis	rs12049351	0.507	rs11803533	ENSG00000229367.1	HMGN2P19	4.04	7.23e-05	0.0241	0.23	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229432885	chr1:229570532~229570796:+
SARC	cis	rs9858542	0.537	rs9864406	ENSG00000225399.4	RP11-3B7.1	-4.04	7.24e-05	0.0241	-0.41	-0.26	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49315186	chr3:49260085~49261316:+
SARC	cis	rs294883	0.627	rs3904938	ENSG00000235086.1	FNDC1-IT1	-4.04	7.24e-05	0.0241	-0.31	-0.26	Coronary artery disease;	chr6:159344533	chr6:159240786~159243329:+
SARC	cis	rs2285002	0.516	rs1273204	ENSG00000258824.2	CTD-2555O16.2	-4.04	7.24e-05	0.0241	-0.26	-0.26	Red cell distribution width;	chr14:64829946	chr14:64422935~64448557:-
SARC	cis	rs7247513	0.701	rs8107642	ENSG00000213290.4	PGK1P2	-4.04	7.24e-05	0.0241	-0.29	-0.26	Bipolar disorder;	chr19:12655556	chr19:12559571~12561105:+
SARC	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-4.04	7.24e-05	0.0241	-0.23	-0.26	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
SARC	cis	rs4950322	0.57	rs7554833	ENSG00000278811.3	LINC00624	-4.04	7.25e-05	0.0241	-0.27	-0.26	Protein quantitative trait loci;	chr1:147289362	chr1:147258885~147517875:-
SARC	cis	rs10144321	0.644	rs10147903	ENSG00000271417.2	SNHG24	-4.04	7.25e-05	0.0241	-0.23	-0.26	Menarche (age at onset);	chr14:100329326	chr14:100967652~100987280:+
SARC	cis	rs2243480	1	rs160643	ENSG00000164669.11	INTS4P1	4.04	7.25e-05	0.0241	0.44	0.26	Diabetic kidney disease;	chr7:66093235	chr7:65141225~65234216:+
SARC	cis	rs8028182	0.609	rs8038760	ENSG00000260206.1	CTD-2026K11.2	-4.04	7.26e-05	0.0242	-0.31	-0.26	Sudden cardiac arrest;	chr15:75449754	chr15:75636139~75639239:+
SARC	cis	rs4849845	0.653	rs34874174	ENSG00000236878.1	AC012363.7	4.04	7.26e-05	0.0242	0.26	0.26	Mean platelet volume;	chr2:120254404	chr2:120211054~120211715:+
SARC	cis	rs4849845	0.653	rs3925970	ENSG00000236878.1	AC012363.7	4.04	7.26e-05	0.0242	0.26	0.26	Mean platelet volume;	chr2:120260577	chr2:120211054~120211715:+
SARC	cis	rs4849845	0.678	rs3896632	ENSG00000236878.1	AC012363.7	4.04	7.26e-05	0.0242	0.26	0.26	Mean platelet volume;	chr2:120265920	chr2:120211054~120211715:+
SARC	cis	rs4849845	0.637	rs62168279	ENSG00000236878.1	AC012363.7	4.04	7.26e-05	0.0242	0.26	0.26	Mean platelet volume;	chr2:120269195	chr2:120211054~120211715:+
SARC	cis	rs11159086	0.793	rs11621693	ENSG00000270000.1	RP3-449M8.9	4.04	7.26e-05	0.0242	0.38	0.26	Advanced glycation end-product levels;	chr14:74472631	chr14:74471930~74472360:-
SARC	cis	rs9902453	0.765	rs2264303	ENSG00000264538.5	SUZ12P1	-4.04	7.26e-05	0.0242	-0.18	-0.26	Coffee consumption (cups per day);	chr17:29728330	chr17:30709299~30790908:+
SARC	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	4.04	7.26e-05	0.0242	0.4	0.26	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
SARC	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	4.04	7.26e-05	0.0242	0.4	0.26	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
SARC	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-4.04	7.26e-05	0.0242	-0.48	-0.26	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
SARC	cis	rs17174870	0.792	rs3811640	ENSG00000228251.1	AC012442.6	4.04	7.26e-05	0.0242	0.3	0.26	Multiple sclerosis;	chr2:112019402	chr2:112590796~112591939:+
SARC	cis	rs2285002	0.516	rs114813	ENSG00000258824.2	CTD-2555O16.2	-4.04	7.27e-05	0.0242	-0.26	-0.26	Red cell distribution width;	chr14:64827358	chr14:64422935~64448557:-
SARC	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-4.04	7.27e-05	0.0242	-0.31	-0.26	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
SARC	cis	rs2274273	0.682	rs7141975	ENSG00000258413.1	RP11-665C16.6	-4.04	7.27e-05	0.0242	-0.29	-0.26	Protein biomarker;	chr14:55075498	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.745	rs748017	ENSG00000258413.1	RP11-665C16.6	-4.04	7.27e-05	0.0242	-0.29	-0.26	Protein biomarker;	chr14:55075582	chr14:55262767~55272075:-
SARC	cis	rs2404602	0.583	rs12913096	ENSG00000259422.1	RP11-593F23.1	4.04	7.27e-05	0.0242	0.28	0.26	Blood metabolite levels;	chr15:76259511	chr15:76174891~76181486:-
SARC	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-4.04	7.27e-05	0.0242	-0.33	-0.26	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
SARC	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-4.04	7.27e-05	0.0242	-0.33	-0.26	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
SARC	cis	rs4835473	0.6	rs9997101	ENSG00000251600.4	RP11-673E1.1	4.04	7.27e-05	0.0242	0.24	0.26	Immature fraction of reticulocytes;	chr4:143777892	chr4:143912331~143982454:+
SARC	cis	rs6842047	1	rs1511800	ENSG00000250829.2	RP11-11N5.1	4.04	7.28e-05	0.0242	0.39	0.26	Blood protein levels;	chr4:186214402	chr4:186890969~186892366:+
SARC	cis	rs6842047	0.706	rs4862666	ENSG00000250829.2	RP11-11N5.1	4.04	7.28e-05	0.0242	0.39	0.26	Blood protein levels;	chr4:186215153	chr4:186890969~186892366:+
SARC	cis	rs2836974	0.568	rs7282604	ENSG00000255568.3	BRWD1-AS2	-4.04	7.28e-05	0.0242	-0.25	-0.26	Cognitive function;	chr21:39164984	chr21:39313935~39314962:+
SARC	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	4.04	7.29e-05	0.0242	0.37	0.26	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
SARC	cis	rs495337	0.735	rs2281217	ENSG00000229222.1	KRT18P4	-4.04	7.29e-05	0.0242	-0.33	-0.26	Psoriasis;	chr20:49951518	chr20:49956745~49958032:+
SARC	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-4.04	7.29e-05	0.0242	-0.37	-0.26	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs781149	ENSG00000273142.1	RP11-458F8.4	-4.04	7.29e-05	0.0242	-0.37	-0.26	Diabetic kidney disease;	chr7:66016297	chr7:66902857~66906297:+
SARC	cis	rs2243480	0.901	rs58207111	ENSG00000273142.1	RP11-458F8.4	-4.04	7.29e-05	0.0242	-0.37	-0.26	Diabetic kidney disease;	chr7:66021736	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs1167613	ENSG00000273142.1	RP11-458F8.4	-4.04	7.29e-05	0.0242	-0.37	-0.26	Diabetic kidney disease;	chr7:66022452	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-4.04	7.29e-05	0.0242	-0.37	-0.26	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
SARC	cis	rs2455799	0.613	rs62241264	ENSG00000226427.1	HMGN2P7	-4.04	7.29e-05	0.0242	-0.28	-0.26	Mean platelet volume;	chr3:15901964	chr3:15375373~15375645:-
SARC	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	4.04	7.29e-05	0.0242	0.35	0.26	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
SARC	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	4.04	7.29e-05	0.0242	0.35	0.26	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
SARC	cis	rs9902453	0.904	rs4375718	ENSG00000264538.5	SUZ12P1	-4.04	7.29e-05	0.0242	-0.18	-0.26	Coffee consumption (cups per day);	chr17:30036624	chr17:30709299~30790908:+
SARC	cis	rs2235544	0.565	rs72664114	ENSG00000225183.1	RP4-758J24.4	-4.04	7.29e-05	0.0243	-0.28	-0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54006074	chr1:54089856~54090093:+
SARC	cis	rs6570726	0.846	rs973856	ENSG00000270638.1	RP3-466P17.1	-4.04	7.3e-05	0.0243	-0.2	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145460780	chr6:145735570~145737218:+
SARC	cis	rs1729407	0.786	rs5100	ENSG00000254851.1	RP11-109L13.1	-4.04	7.3e-05	0.0243	-0.3	-0.26	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117135528~117138582:+
SARC	cis	rs2439831	1	rs2467739	ENSG00000275601.1	AC011330.13	-4.04	7.3e-05	0.0243	-0.4	-0.26	Lung cancer in ever smokers;	chr15:43447998	chr15:43642389~43643023:-
SARC	cis	rs801193	1	rs2055682	ENSG00000236529.1	RP13-254B10.1	4.04	7.3e-05	0.0243	0.27	0.26	Aortic root size;	chr7:66795302	chr7:65840212~65840596:+
SARC	cis	rs7809950	0.817	rs4727678	ENSG00000238832.1	snoU109	-4.04	7.3e-05	0.0243	-0.31	-0.26	Coronary artery disease;	chr7:107443190	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.817	rs4727679	ENSG00000238832.1	snoU109	-4.04	7.3e-05	0.0243	-0.31	-0.26	Coronary artery disease;	chr7:107444573	chr7:107603363~107603507:+
SARC	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-4.04	7.3e-05	0.0243	-0.25	-0.26	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
SARC	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	4.04	7.31e-05	0.0243	0.19	0.26	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
SARC	cis	rs8098244	0.52	rs6508073	ENSG00000265752.2	RP11-403A21.1	-4.04	7.31e-05	0.0243	-0.28	-0.26	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23988403	chr18:23957754~23982556:-
SARC	cis	rs7246657	1	rs7246657	ENSG00000226686.6	LINC01535	4.04	7.31e-05	0.0243	0.37	0.26	Coronary artery calcification;	chr19:37256206	chr19:37251912~37265535:+
SARC	cis	rs7688540	0.771	rs11730202	ENSG00000275426.1	CH17-262A2.1	4.04	7.31e-05	0.0243	0.34	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:149738~150317:+
SARC	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-4.04	7.31e-05	0.0243	-0.38	-0.26	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-4.04	7.31e-05	0.0243	-0.38	-0.26	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-4.04	7.31e-05	0.0243	-0.38	-0.26	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
SARC	cis	rs7267979	0.789	rs4815429	ENSG00000125804.12	FAM182A	4.04	7.32e-05	0.0243	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:26054655~26086917:+
SARC	cis	rs6845263	0.546	rs2114366	ENSG00000254531.1	FLJ20021	-4.04	7.34e-05	0.0244	-0.25	-0.26	Superior crus of antihelix expression;	chr4:101538911	chr4:101347780~101348883:+
SARC	cis	rs12887734	0.524	rs722637	ENSG00000269958.1	RP11-73M18.8	-4.04	7.34e-05	0.0244	-0.26	-0.26	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103795386	chr14:103696353~103697163:+
SARC	cis	rs2439831	1	rs527921	ENSG00000205771.5	CATSPER2P1	4.04	7.34e-05	0.0244	0.39	0.26	Lung cancer in ever smokers;	chr15:43478218	chr15:43726918~43747094:-
SARC	cis	rs6142102	0.58	rs4911139	ENSG00000275784.1	RP5-1125A11.6	-4.04	7.35e-05	0.0244	-0.29	-0.26	Skin pigmentation;	chr20:33963729	chr20:33989480~33991818:-
SARC	cis	rs801193	0.773	rs801207	ENSG00000224316.1	RP11-479O9.2	-4.04	7.35e-05	0.0244	-0.24	-0.26	Aortic root size;	chr7:66555603	chr7:65773620~65802067:+
SARC	cis	rs7131987	0.621	rs3782506	ENSG00000257176.2	RP11-996F15.2	4.04	7.36e-05	0.0244	0.29	0.26	QT interval;	chr12:29292489	chr12:29280418~29317848:-
SARC	cis	rs7267979	0.903	rs6132819	ENSG00000276952.1	RP5-965G21.6	4.04	7.36e-05	0.0244	0.24	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:25284915~25285588:-
SARC	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	4.04	7.36e-05	0.0244	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
SARC	cis	rs42490	0.59	rs39771	ENSG00000251136.7	RP11-37B2.1	-4.04	7.36e-05	0.0244	-0.29	-0.26	Leprosy;	chr8:89826378	chr8:89609409~89757727:-
SARC	cis	rs42490	0.625	rs43229	ENSG00000251136.7	RP11-37B2.1	-4.04	7.36e-05	0.0244	-0.29	-0.26	Leprosy;	chr8:89826558	chr8:89609409~89757727:-
SARC	cis	rs42490	0.625	rs438485	ENSG00000251136.7	RP11-37B2.1	-4.04	7.36e-05	0.0244	-0.29	-0.26	Leprosy;	chr8:89831190	chr8:89609409~89757727:-
SARC	cis	rs12200782	0.79	rs72840194	ENSG00000272462.2	U91328.19	-4.04	7.36e-05	0.0244	-0.41	-0.26	Small cell lung carcinoma;	chr6:26361141	chr6:25992662~26001775:+
SARC	cis	rs8095374	1	rs8089153	ENSG00000280212.1	RP11-49K24.3	-4.04	7.37e-05	0.0244	-0.28	-0.26	Clinical laboratory measurements;	chr18:46189339	chr18:47076117~47076594:+
SARC	cis	rs4852324	0.527	rs10166809	ENSG00000236209.1	AC104135.2	4.04	7.38e-05	0.0245	0.46	0.26	Systemic lupus erythematosus;	chr2:73973913	chr2:74919555~74924846:-
SARC	cis	rs641862	1	rs641862	ENSG00000275880.1	RP11-90L1.8	4.04	7.38e-05	0.0245	0.61	0.26	Obesity-related traits;	chr13:110137885	chr13:110613082~110616353:-
SARC	cis	rs1376877	0.901	rs72938355	ENSG00000213925.3	NPM1P33	4.04	7.38e-05	0.0245	0.24	0.26	Subclinical atherosclerosis traits (other);	chr2:203287658	chr2:203772631~203773502:-
SARC	cis	rs758129	0.501	rs2351002	ENSG00000261441.1	RP11-217B1.2	4.04	7.39e-05	0.0245	0.34	0.26	Schizophrenia;	chr15:89326098	chr15:89335053~89336161:+
SARC	cis	rs1707322	1	rs11211248	ENSG00000281133.1	AL355480.3	-4.04	7.39e-05	0.0245	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45580892~45580996:-
SARC	cis	rs11723261	0.621	rs7692530	ENSG00000211553.1	AC253576.2	-4.04	7.39e-05	0.0245	-0.32	-0.26	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:136461~136568:+
SARC	cis	rs7520050	0.966	rs9429183	ENSG00000280836.1	AL355480.1	4.04	7.39e-05	0.0245	0.24	0.26	Reticulocyte count;Red blood cell count;	chr1:46058910	chr1:45581219~45581321:-
SARC	cis	rs28386778	0.591	rs2584619	ENSG00000240280.5	TCAM1P	-4.04	7.4e-05	0.0245	-0.32	-0.26	Prudent dietary pattern;	chr17:63835855	chr17:63849292~63864379:+
SARC	cis	rs7044106	0.537	rs10818474	ENSG00000238181.2	AHCYP2	-4.04	7.4e-05	0.0245	-0.23	-0.26	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120720673~120721972:+
SARC	cis	rs4835473	0.932	rs2218791	ENSG00000251600.4	RP11-673E1.1	-4.04	7.4e-05	0.0245	-0.25	-0.26	Immature fraction of reticulocytes;	chr4:143749300	chr4:143912331~143982454:+
SARC	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	4.04	7.4e-05	0.0245	0.27	0.26	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
SARC	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	4.04	7.4e-05	0.0245	0.27	0.26	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
SARC	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	4.04	7.4e-05	0.0245	0.27	0.26	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
SARC	cis	rs7267979	0.816	rs6115094	ENSG00000276952.1	RP5-965G21.6	4.04	7.4e-05	0.0245	0.25	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:25284915~25285588:-
SARC	cis	rs4862750	0.872	rs4862748	ENSG00000250971.1	RP11-696F12.1	-4.04	7.41e-05	0.0245	-0.31	-0.26	Lobe attachment (rater-scored or self-reported);	chr4:186956234	chr4:187060099~187060930:+
SARC	cis	rs2439831	0.681	rs28594657	ENSG00000205771.5	CATSPER2P1	-4.03	7.41e-05	0.0245	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43296690	chr15:43726918~43747094:-
SARC	cis	rs59104589	0.617	rs73002170	ENSG00000266621.1	AC104841.1	4.03	7.41e-05	0.0245	0.35	0.26	Fibrinogen levels;	chr2:241386565	chr2:241245202~241245299:-
SARC	cis	rs11121022	0.965	rs11121021	ENSG00000269925.1	RP3-467L1.6	-4.03	7.41e-05	0.0245	-0.3	-0.26	Morning vs. evening chronotype;	chr1:7775639	chr1:7776383~7776775:+
SARC	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	4.03	7.42e-05	0.0246	0.32	0.26	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
SARC	cis	rs10986311	0.851	rs10818940	ENSG00000235204.1	RP11-121A14.2	-4.03	7.42e-05	0.0246	-0.3	-0.26	Vitiligo;	chr9:124301180	chr9:124259250~124261156:-
SARC	cis	rs7580658	0.864	rs4150441	ENSG00000236682.1	AC068282.3	-4.03	7.42e-05	0.0246	-0.29	-0.26	Protein C levels;	chr2:127283339	chr2:127389130~127400580:+
SARC	cis	rs11654699	0.806	rs59725932	ENSG00000266718.1	RP11-466A19.1	-4.03	7.42e-05	0.0246	-0.22	-0.26	Neurofibrillary tangles;	chr17:32601694	chr17:32495536~32499333:+
SARC	cis	rs62025270	0.547	rs386346	ENSG00000202081.1	RNU6-1280P	-4.03	7.42e-05	0.0246	-0.31	-0.26	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85651522~85651628:-
SARC	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-4.03	7.42e-05	0.0246	-0.3	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
SARC	cis	rs13190036	1	rs13190036	ENSG00000249129.1	SUDS3P1	-4.03	7.42e-05	0.0246	-0.43	-0.26	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177310719	chr5:177971316~177972281:+
SARC	cis	rs1707322	1	rs34446427	ENSG00000281133.1	AL355480.3	-4.03	7.42e-05	0.0246	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.963	rs4660900	ENSG00000281133.1	AL355480.3	-4.03	7.42e-05	0.0246	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4454479	ENSG00000281133.1	AL355480.3	-4.03	7.42e-05	0.0246	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs12403666	ENSG00000281133.1	AL355480.3	-4.03	7.42e-05	0.0246	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs12077546	ENSG00000281133.1	AL355480.3	-4.03	7.42e-05	0.0246	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs12124291	ENSG00000281133.1	AL355480.3	-4.03	7.42e-05	0.0246	-0.29	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45580892~45580996:-
SARC	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	4.03	7.43e-05	0.0246	0.37	0.26	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
SARC	cis	rs160451	0.709	rs160419	ENSG00000251136.7	RP11-37B2.1	4.03	7.43e-05	0.0246	0.3	0.26	Leprosy;	chr8:89632477	chr8:89609409~89757727:-
SARC	cis	rs12468226	0.689	rs73989731	ENSG00000273456.1	RP11-686O6.2	4.03	7.43e-05	0.0246	0.29	0.26	Urate levels;	chr2:202109309	chr2:202374932~202375604:-
SARC	cis	rs9926296	0.605	rs3743859	ENSG00000260279.2	AC137932.5	-4.03	7.44e-05	0.0246	-0.24	-0.26	Vitiligo;	chr16:89779642	chr16:89297508~89298317:+
SARC	cis	rs7267979	0.816	rs390123	ENSG00000274414.1	RP5-965G21.4	-4.03	7.44e-05	0.0246	-0.26	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:25239007~25245229:-
SARC	cis	rs172166	0.516	rs1225710	ENSG00000219392.1	RP1-265C24.5	4.03	7.44e-05	0.0246	0.3	0.26	Cardiac Troponin-T levels;	chr6:28132862	chr6:28115628~28116551:+
SARC	cis	rs7726354	0.793	rs2229882	ENSG00000271828.1	CTD-2310F14.1	4.03	7.45e-05	0.0246	0.54	0.26	Breast cancer (early onset);	chr5:56872885	chr5:56927874~56929573:+
SARC	cis	rs7204230	1	rs10852504	ENSG00000261291.1	RP11-295M3.2	-4.03	7.45e-05	0.0246	-0.28	-0.26	Fibrinogen;	chr16:53289837	chr16:53168522~53169450:+
SARC	cis	rs853679	0.517	rs6932109	ENSG00000280107.1	AL022393.9	4.03	7.45e-05	0.0246	0.32	0.26	Depression;	chr6:28110525	chr6:28170845~28172521:+
SARC	cis	rs4679904	0.92	rs12638633	ENSG00000243116.1	RP11-564C24.1	4.03	7.45e-05	0.0246	0.26	0.26	Primary biliary cholangitis;	chr3:160510104	chr3:159721524~159722401:-
SARC	cis	rs4679904	0.96	rs73875290	ENSG00000243116.1	RP11-564C24.1	4.03	7.45e-05	0.0246	0.26	0.26	Primary biliary cholangitis;	chr3:160514452	chr3:159721524~159722401:-
SARC	cis	rs6142102	0.602	rs4911402	ENSG00000275784.1	RP5-1125A11.6	-4.03	7.45e-05	0.0247	-0.3	-0.26	Skin pigmentation;	chr20:34079839	chr20:33989480~33991818:-
SARC	cis	rs9309473	0.607	rs6740173	ENSG00000163016.8	ALMS1P	4.03	7.46e-05	0.0247	0.31	0.26	Metabolite levels;	chr2:73375138	chr2:73644919~73685576:+
SARC	cis	rs748404	1	rs12911132	ENSG00000205771.5	CATSPER2P1	-4.03	7.46e-05	0.0247	-0.37	-0.26	Lung cancer;	chr15:43268238	chr15:43726918~43747094:-
SARC	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	4.03	7.47e-05	0.0247	0.23	0.26	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
SARC	cis	rs9595908	0.931	rs9595630	ENSG00000212293.1	SNORA16	-4.03	7.47e-05	0.0247	-0.26	-0.26	Body mass index;	chr13:32491306	chr13:32420390~32420516:-
SARC	cis	rs7951911	1	rs7951911	ENSG00000254427.1	RP11-430H10.1	4.03	7.47e-05	0.0247	0.36	0.26	IgG glycosylation;	chr11:45062980	chr11:45355371~45366121:+
SARC	cis	rs7615952	0.576	rs12497295	ENSG00000248787.1	RP11-666A20.4	-4.03	7.47e-05	0.0247	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126099807	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.512	rs1077621	ENSG00000248787.1	RP11-666A20.4	-4.03	7.47e-05	0.0247	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126100956	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.512	rs4646765	ENSG00000248787.1	RP11-666A20.4	-4.03	7.47e-05	0.0247	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126101864	chr3:125908005~125910272:-
SARC	cis	rs853679	0.882	rs9468300	ENSG00000272009.1	RP1-313I6.12	-4.03	7.47e-05	0.0247	-0.4	-0.26	Depression;	chr6:28159062	chr6:28078792~28081130:-
SARC	cis	rs858239	0.669	rs1006709	ENSG00000226816.2	AC005082.12	4.03	7.48e-05	0.0247	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23206013~23208045:+
SARC	cis	rs13161895	1	rs35973843	ENSG00000250999.1	RP11-1379J22.5	-4.03	7.48e-05	0.0247	-0.45	-0.26	LDL cholesterol;	chr5:180039502	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs35135297	ENSG00000250999.1	RP11-1379J22.5	-4.03	7.48e-05	0.0247	-0.45	-0.26	LDL cholesterol;	chr5:180042532	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs13161895	ENSG00000250999.1	RP11-1379J22.5	-4.03	7.48e-05	0.0247	-0.45	-0.26	LDL cholesterol;	chr5:180044201	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs12656814	ENSG00000250999.1	RP11-1379J22.5	-4.03	7.48e-05	0.0247	-0.45	-0.26	LDL cholesterol;	chr5:180044556	chr5:179657762~179664432:+
SARC	cis	rs13161895	1	rs4700853	ENSG00000250999.1	RP11-1379J22.5	-4.03	7.48e-05	0.0247	-0.45	-0.26	LDL cholesterol;	chr5:180046328	chr5:179657762~179664432:+
SARC	cis	rs10540	1	rs79808876	ENSG00000277290.1	RP11-326C3.16	4.03	7.48e-05	0.0247	0.31	0.26	Body mass index;	chr11:465763	chr11:243099~243483:-
SARC	cis	rs950776	0.593	rs555018	ENSG00000261762.1	RP11-650L12.2	-4.03	7.48e-05	0.0247	-0.27	-0.26	Sudden cardiac arrest;	chr15:78586900	chr15:78589123~78591276:-
SARC	cis	rs11159086	0.793	rs17100414	ENSG00000270000.1	RP3-449M8.9	4.03	7.48e-05	0.0247	0.38	0.26	Advanced glycation end-product levels;	chr14:74467918	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs11625502	ENSG00000270000.1	RP3-449M8.9	4.03	7.48e-05	0.0247	0.38	0.26	Advanced glycation end-product levels;	chr14:74468309	chr14:74471930~74472360:-
SARC	cis	rs2439831	0.867	rs2447196	ENSG00000275601.1	AC011330.13	4.03	7.49e-05	0.0248	0.42	0.26	Lung cancer in ever smokers;	chr15:43601620	chr15:43642389~43643023:-
SARC	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-4.03	7.49e-05	0.0248	-0.24	-0.26	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
SARC	cis	rs6540731	0.521	rs10779572	ENSG00000229983.1	RP11-15I11.2	-4.03	7.49e-05	0.0248	-0.26	-0.26	Intelligence (childhood);	chr1:212181070	chr1:212168207~212190259:+
SARC	cis	rs4950322	0.58	rs4950308	ENSG00000278811.3	LINC00624	4.03	7.49e-05	0.0248	0.27	0.26	Protein quantitative trait loci;	chr1:147120092	chr1:147258885~147517875:-
SARC	cis	rs6695567	0.935	rs1628297	ENSG00000280378.1	RP4-758J24.6	-4.03	7.5e-05	0.0248	-0.25	-0.26	Systemic lupus erythematosus;	chr1:53149208	chr1:54033126~54034880:-
SARC	cis	rs41271951	0.512	rs12058128	ENSG00000237781.3	RP11-54A4.2	4.03	7.5e-05	0.0248	0.45	0.26	Blood protein levels;	chr1:151133637	chr1:150548562~150557724:-
SARC	cis	rs41271951	0.512	rs12090246	ENSG00000237781.3	RP11-54A4.2	4.03	7.5e-05	0.0248	0.45	0.26	Blood protein levels;	chr1:151135020	chr1:150548562~150557724:-
SARC	cis	rs2235544	0.542	rs679801	ENSG00000225183.1	RP4-758J24.4	4.03	7.51e-05	0.0248	0.28	0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54005084	chr1:54089856~54090093:+
SARC	cis	rs12817211	0.502	rs59262224	ENSG00000272368.2	RP4-605O3.4	-4.03	7.51e-05	0.0248	-0.24	-0.26	Colorectal or endometrial cancer;	chr12:50117164	chr12:50112197~50165618:+
SARC	cis	rs12817211	0.502	rs7135322	ENSG00000272368.2	RP4-605O3.4	-4.03	7.51e-05	0.0248	-0.24	-0.26	Colorectal or endometrial cancer;	chr12:50118065	chr12:50112197~50165618:+
SARC	cis	rs76693355	0.512	rs11217878	ENSG00000232460.4	BMPR1APS2	4.03	7.51e-05	0.0248	0.33	0.26	Intraocular pressure;	chr11:120469674	chr11:121361854~121362865:-
SARC	cis	rs2274273	0.684	rs2340921	ENSG00000258413.1	RP11-665C16.6	-4.03	7.51e-05	0.0248	-0.29	-0.26	Protein biomarker;	chr14:55096987	chr14:55262767~55272075:-
SARC	cis	rs10986311	0.747	rs2282084	ENSG00000235204.1	RP11-121A14.2	4.03	7.52e-05	0.0248	0.29	0.26	Vitiligo;	chr9:124259253	chr9:124259250~124261156:-
SARC	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	4.03	7.52e-05	0.0248	0.32	0.26	Height;	chr6:109424305	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	4.03	7.52e-05	0.0248	0.32	0.26	Height;	chr6:109425054	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	4.03	7.52e-05	0.0248	0.32	0.26	Height;	chr6:109426518	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	4.03	7.52e-05	0.0248	0.32	0.26	Height;	chr6:109427644	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	4.03	7.52e-05	0.0248	0.32	0.26	Height;	chr6:109430292	chr6:109382795~109383666:+
SARC	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	4.03	7.52e-05	0.0248	0.36	0.26	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
SARC	cis	rs6477918	0.598	rs10981412	ENSG00000250068.1	RP11-576C12.1	4.03	7.52e-05	0.0248	0.26	0.26	Obstetric antiphospholipid syndrome;	chr9:112452844	chr9:112581779~112582590:-
SARC	cis	rs9959145	0.5	rs11664219	ENSG00000279275.1	RP11-756J15.2	4.03	7.52e-05	0.0248	0.5	0.26	Immune response to smallpox vaccine (IL-6);	chr18:12531016	chr18:13279415~13280110:-
SARC	cis	rs12542260	1	rs4551335	ENSG00000253106.1	RP11-158K1.3	-4.03	7.52e-05	0.0248	-0.3	-0.26	Colonoscopy-negative controls vs population controls;	chr8:124481701	chr8:124488510~124491643:+
SARC	cis	rs12893668	0.572	rs7148857	ENSG00000269958.1	RP11-73M18.8	4.03	7.52e-05	0.0248	0.28	0.26	Reticulocyte count;	chr14:103676900	chr14:103696353~103697163:+
SARC	cis	rs12893668	0.572	rs11540512	ENSG00000269958.1	RP11-73M18.8	4.03	7.52e-05	0.0248	0.28	0.26	Reticulocyte count;	chr14:103681040	chr14:103696353~103697163:+
SARC	cis	rs12893668	0.572	rs35011804	ENSG00000269958.1	RP11-73M18.8	4.03	7.52e-05	0.0248	0.28	0.26	Reticulocyte count;	chr14:103685063	chr14:103696353~103697163:+
SARC	cis	rs11654699	0.806	rs4795711	ENSG00000266718.1	RP11-466A19.1	-4.03	7.52e-05	0.0248	-0.22	-0.26	Neurofibrillary tangles;	chr17:32592080	chr17:32495536~32499333:+
SARC	cis	rs6142102	0.625	rs4911384	ENSG00000275784.1	RP5-1125A11.6	-4.03	7.53e-05	0.0248	-0.3	-0.26	Skin pigmentation;	chr20:33968001	chr20:33989480~33991818:-
SARC	cis	rs12817211	0.524	rs10876000	ENSG00000272368.2	RP4-605O3.4	-4.03	7.53e-05	0.0249	-0.25	-0.26	Colorectal or endometrial cancer;	chr12:50128431	chr12:50112197~50165618:+
SARC	cis	rs12817211	0.524	rs2204683	ENSG00000272368.2	RP4-605O3.4	-4.03	7.53e-05	0.0249	-0.25	-0.26	Colorectal or endometrial cancer;	chr12:50128593	chr12:50112197~50165618:+
SARC	cis	rs28386778	0.897	rs2665833	ENSG00000240280.5	TCAM1P	-4.03	7.53e-05	0.0249	-0.32	-0.26	Prudent dietary pattern;	chr17:63829486	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2665832	ENSG00000240280.5	TCAM1P	-4.03	7.53e-05	0.0249	-0.32	-0.26	Prudent dietary pattern;	chr17:63834901	chr17:63849292~63864379:+
SARC	cis	rs2810650	0.56	rs7514172	ENSG00000231507.1	LINC01353	4.03	7.53e-05	0.0249	0.29	0.26	Breast cancer;	chr1:203801320	chr1:203287152~203288801:+
SARC	cis	rs7937612	0.861	rs4245213	ENSG00000232460.4	BMPR1APS2	4.03	7.54e-05	0.0249	0.25	0.26	Intraocular pressure;	chr11:120402888	chr11:121361854~121362865:-
SARC	cis	rs875971	0.83	rs4718358	ENSG00000232559.3	GS1-124K5.12	4.03	7.54e-05	0.0249	0.29	0.26	Aortic root size;	chr7:66508681	chr7:66554588~66576923:-
SARC	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-4.03	7.54e-05	0.0249	-0.28	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
SARC	cis	rs2243480	0.522	rs778717	ENSG00000226824.5	RP4-756H11.3	-4.03	7.54e-05	0.0249	-0.57	-0.26	Diabetic kidney disease;	chr7:66383164	chr7:66654538~66669855:+
SARC	cis	rs12049351	0.665	rs12035203	ENSG00000229367.1	HMGN2P19	4.03	7.54e-05	0.0249	0.22	0.26	Circulating myeloperoxidase levels (plasma);	chr1:229506770	chr1:229570532~229570796:+
SARC	cis	rs7615952	0.576	rs1127717	ENSG00000248787.1	RP11-666A20.4	-4.03	7.54e-05	0.0249	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126107216	chr3:125908005~125910272:-
SARC	cis	rs7811142	1	rs6979335	ENSG00000078319.8	PMS2P1	-4.03	7.54e-05	0.0249	-0.37	-0.26	Platelet count;	chr7:100492237	chr7:100320992~100341908:-
SARC	cis	rs7811142	1	rs73405353	ENSG00000078319.8	PMS2P1	-4.03	7.54e-05	0.0249	-0.37	-0.26	Platelet count;	chr7:100493592	chr7:100320992~100341908:-
SARC	cis	rs4845875	0.53	rs6667720	ENSG00000242349.4	NPPA-AS1	-4.03	7.54e-05	0.0249	-0.29	-0.26	Midregional pro atrial natriuretic peptide levels;	chr1:11771558	chr1:11841017~11848079:+
SARC	cis	rs6728302	1	rs12620618	ENSG00000223198.1	RNU2-22P	4.03	7.55e-05	0.0249	0.6	0.26	Height;	chr2:232012799	chr2:231501990~231502201:-
SARC	cis	rs17655730	0.52	rs2178798	ENSG00000277290.1	RP11-326C3.16	-4.03	7.55e-05	0.0249	-0.21	-0.26	Mean platelet volume;	chr11:254869	chr11:243099~243483:-
SARC	cis	rs10246939	0.579	rs10464444	ENSG00000270923.1	TAS2R6P	4.03	7.55e-05	0.0249	0.22	0.26	Bitter taste perception;	chr7:141832387	chr7:141787815~141788640:+
SARC	cis	rs6477918	0.55	rs10981397	ENSG00000250068.1	RP11-576C12.1	-4.03	7.56e-05	0.0249	-0.27	-0.26	Obstetric antiphospholipid syndrome;	chr9:112412368	chr9:112581779~112582590:-
SARC	cis	rs8019546	0.889	rs7147627	ENSG00000258808.1	RP11-255G12.3	-4.03	7.56e-05	0.0249	-0.25	-0.26	Dietary macronutrient intake;	chr14:50858799	chr14:51392128~51397135:-
SARC	cis	rs10946940	0.632	rs9366698	ENSG00000216901.1	AL022393.7	4.03	7.56e-05	0.0249	0.38	0.26	Systemic lupus erythematosus;	chr6:27704256	chr6:28176188~28176674:+
SARC	cis	rs5758659	0.904	rs5758653	ENSG00000270083.1	RP1-257I20.14	4.03	7.57e-05	0.0249	0.25	0.26	Cognitive function;	chr22:42217479	chr22:42089630~42090028:-
SARC	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-4.03	7.57e-05	0.0249	-0.33	-0.26	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
SARC	cis	rs10050311	0.79	rs17751427	ENSG00000251411.1	RP11-397E7.4	-4.03	7.57e-05	0.025	-0.32	-0.26	Insulin-related traits;	chr4:86909939	chr4:86913266~86914817:-
SARC	cis	rs13161895	1	rs34674199	ENSG00000250999.1	RP11-1379J22.5	-4.03	7.57e-05	0.025	-0.45	-0.26	LDL cholesterol;	chr5:180046900	chr5:179657762~179664432:+
SARC	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-4.03	7.58e-05	0.025	-0.32	-0.26	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
SARC	cis	rs2235544	0.579	rs1537322	ENSG00000225183.1	RP4-758J24.4	-4.03	7.58e-05	0.025	-0.28	-0.26	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54016633	chr1:54089856~54090093:+
SARC	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-4.03	7.59e-05	0.025	-0.39	-0.26	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
SARC	cis	rs12887734	0.566	rs8548	ENSG00000269940.1	RP11-73M18.7	4.03	7.59e-05	0.025	0.24	0.26	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103733243	chr14:103694560~103695170:+
SARC	cis	rs9481169	0.557	rs73534579	ENSG00000231889.6	TRAF3IP2-AS1	4.03	7.59e-05	0.025	0.51	0.26	Inflammatory skin disease;	chr6:111589486	chr6:111483511~111598302:+
SARC	cis	rs5751614	0.557	rs928781	ENSG00000230701.2	FBXW4P1	-4.03	7.6e-05	0.025	-0.33	-0.26	Height;	chr22:23257826	chr22:23262767~23265005:+
SARC	cis	rs597539	0.652	rs673821	ENSG00000250508.1	RP11-757G1.6	-4.03	7.6e-05	0.025	-0.29	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68870664~68874542:+
SARC	cis	rs7204230	1	rs17303177	ENSG00000261291.1	RP11-295M3.2	4.03	7.6e-05	0.025	0.29	0.26	Fibrinogen;	chr16:53243266	chr16:53168522~53169450:+
SARC	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	4.03	7.61e-05	0.025	0.34	0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
SARC	cis	rs755249	0.567	rs72637906	ENSG00000182109.6	RP11-69E11.4	4.03	7.61e-05	0.025	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs67886352	ENSG00000182109.6	RP11-69E11.4	4.03	7.61e-05	0.025	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs60323161	ENSG00000182109.6	RP11-69E11.4	4.03	7.61e-05	0.025	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs66727439	ENSG00000182109.6	RP11-69E11.4	4.03	7.61e-05	0.025	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs16826000	ENSG00000182109.6	RP11-69E11.4	4.03	7.61e-05	0.025	0.29	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs41270821	ENSG00000182109.6	RP11-69E11.4	4.03	7.61e-05	0.0251	0.28	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs2296175	ENSG00000182109.6	RP11-69E11.4	4.03	7.61e-05	0.0251	0.28	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39522280~39546187:-
SARC	cis	rs9309473	0.583	rs6546822	ENSG00000163016.8	ALMS1P	4.03	7.61e-05	0.0251	0.31	0.26	Metabolite levels;	chr2:73347970	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.583	rs6709853	ENSG00000163016.8	ALMS1P	4.03	7.61e-05	0.0251	0.31	0.26	Metabolite levels;	chr2:73348937	chr2:73644919~73685576:+
SARC	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	4.03	7.62e-05	0.0251	0.31	0.26	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
SARC	cis	rs8028182	0.636	rs7495610	ENSG00000260206.1	CTD-2026K11.2	-4.03	7.62e-05	0.0251	-0.31	-0.26	Sudden cardiac arrest;	chr15:75492100	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs4299117	ENSG00000260206.1	CTD-2026K11.2	-4.03	7.62e-05	0.0251	-0.31	-0.26	Sudden cardiac arrest;	chr15:75497103	chr15:75636139~75639239:+
SARC	cis	rs11976180	0.569	rs12703565	ENSG00000170356.8	OR2A20P	-4.03	7.62e-05	0.0251	-0.45	-0.26	Obesity-related traits;	chr7:144057308	chr7:144250045~144252957:-
SARC	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-4.03	7.62e-05	0.0251	-0.41	-0.26	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
SARC	cis	rs12893668	0.572	rs34000399	ENSG00000269910.1	RP11-73M18.10	4.03	7.62e-05	0.0251	0.23	0.26	Reticulocyte count;	chr14:103635080	chr14:103694516~103695050:-
SARC	cis	rs7512898	0.5	rs4915457	ENSG00000260088.1	RP11-92G12.3	-4.03	7.62e-05	0.0251	-0.28	-0.26	Electrocardiographic conduction measures;	chr1:200771742	chr1:200669507~200694250:+
SARC	cis	rs7216064	0.655	rs8078543	ENSG00000237854.3	LINC00674	-4.03	7.62e-05	0.0251	-0.29	-0.26	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68041135	chr17:68101908~68115518:+
SARC	cis	rs11719291	0.915	rs11557629	ENSG00000225399.4	RP11-3B7.1	-4.03	7.63e-05	0.0251	-0.43	-0.26	Cognitive function;	chr3:48694790	chr3:49260085~49261316:+
SARC	cis	rs7772486	0.712	rs6570726	ENSG00000270638.1	RP3-466P17.1	4.03	7.63e-05	0.0251	0.21	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145838324	chr6:145735570~145737218:+
SARC	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	4.03	7.63e-05	0.0251	0.3	0.26	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
SARC	cis	rs9902453	0.934	rs4427857	ENSG00000264538.5	SUZ12P1	4.03	7.63e-05	0.0251	0.18	0.26	Coffee consumption (cups per day);	chr17:30130971	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.868	rs9896012	ENSG00000264538.5	SUZ12P1	4.03	7.63e-05	0.0251	0.18	0.26	Coffee consumption (cups per day);	chr17:30143073	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.868	rs9890075	ENSG00000264538.5	SUZ12P1	4.03	7.63e-05	0.0251	0.18	0.26	Coffee consumption (cups per day);	chr17:30143446	chr17:30709299~30790908:+
SARC	cis	rs2243480	1	rs316315	ENSG00000273142.1	RP11-458F8.4	4.03	7.64e-05	0.0251	0.31	0.26	Diabetic kidney disease;	chr7:66126218	chr7:66902857~66906297:+
SARC	cis	rs4705962	0.842	rs17690965	ENSG00000230612.2	AC004237.1	4.03	7.64e-05	0.0251	0.3	0.26	Atopic dermatitis;	chr5:132694975	chr5:132688681~132723725:+
SARC	cis	rs4705962	0.878	rs2023823	ENSG00000230612.2	AC004237.1	4.03	7.64e-05	0.0251	0.3	0.26	Atopic dermatitis;	chr5:132697114	chr5:132688681~132723725:+
SARC	cis	rs7811142	0.775	rs1636980	ENSG00000078319.8	PMS2P1	4.03	7.64e-05	0.0251	0.37	0.26	Platelet count;	chr7:100341241	chr7:100320992~100341908:-
SARC	cis	rs4835473	0.868	rs62337291	ENSG00000251600.4	RP11-673E1.1	-4.03	7.64e-05	0.0251	-0.25	-0.26	Immature fraction of reticulocytes;	chr4:143807903	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs13121861	ENSG00000251600.4	RP11-673E1.1	-4.03	7.64e-05	0.0251	-0.25	-0.26	Immature fraction of reticulocytes;	chr4:143814007	chr4:143912331~143982454:+
SARC	cis	rs2439831	0.681	rs2278859	ENSG00000275601.1	AC011330.13	-4.03	7.64e-05	0.0251	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43340762	chr15:43642389~43643023:-
SARC	cis	rs7977237	0.928	rs10880531	ENSG00000240759.1	RP11-25I15.1	4.03	7.65e-05	0.0252	0.32	0.26	Intraocular pressure;	chr12:43570540	chr12:42678873~42679124:-
SARC	cis	rs11018904	0.906	rs17227345	ENSG00000280367.1	RP11-121L10.2	-4.03	7.65e-05	0.0252	-0.31	-0.26	Intelligence (multi-trait analysis);	chr11:90221517	chr11:90223153~90226538:+
SARC	cis	rs8005677	0.828	rs712486	ENSG00000257285.4	RP11-298I3.1	4.03	7.65e-05	0.0252	0.24	0.26	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:22929609~22955562:+
SARC	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-4.03	7.65e-05	0.0252	-0.3	-0.26	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
SARC	cis	rs62025270	0.547	rs416916	ENSG00000202081.1	RNU6-1280P	-4.03	7.66e-05	0.0252	-0.31	-0.26	Idiopathic pulmonary fibrosis;	chr15:85649185	chr15:85651522~85651628:-
SARC	cis	rs4713118	0.662	rs149969	ENSG00000216901.1	AL022393.7	4.03	7.66e-05	0.0252	0.37	0.26	Parkinson's disease;	chr6:28009959	chr6:28176188~28176674:+
SARC	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-4.03	7.66e-05	0.0252	-0.38	-0.26	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
SARC	cis	rs897984	0.647	rs7203999	ENSG00000260911.2	RP11-196G11.2	-4.03	7.66e-05	0.0252	-0.25	-0.26	Dementia with Lewy bodies;	chr16:31006233	chr16:31043150~31049868:+
SARC	cis	rs4938303	0.633	rs1960036	ENSG00000254851.1	RP11-109L13.1	4.03	7.66e-05	0.0252	0.36	0.26	Triglycerides;	chr11:116676692	chr11:117135528~117138582:+
SARC	cis	rs4938303	0.633	rs35963862	ENSG00000254851.1	RP11-109L13.1	4.03	7.66e-05	0.0252	0.36	0.26	Triglycerides;	chr11:116679180	chr11:117135528~117138582:+
SARC	cis	rs4938303	0.633	rs61906104	ENSG00000254851.1	RP11-109L13.1	4.03	7.66e-05	0.0252	0.36	0.26	Triglycerides;	chr11:116679398	chr11:117135528~117138582:+
SARC	cis	rs1707322	1	rs1622208	ENSG00000281133.1	AL355480.3	4.03	7.66e-05	0.0252	0.29	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45580892~45580996:-
SARC	cis	rs321358	0.79	rs77820525	ENSG00000271584.1	RP11-89C3.4	4.03	7.66e-05	0.0252	0.45	0.26	Body mass index;	chr11:111076697	chr11:111091932~111097357:-
SARC	cis	rs321358	0.848	rs73015141	ENSG00000271584.1	RP11-89C3.4	4.03	7.66e-05	0.0252	0.45	0.26	Body mass index;	chr11:111077556	chr11:111091932~111097357:-
SARC	cis	rs321358	0.848	rs73015142	ENSG00000271584.1	RP11-89C3.4	4.03	7.66e-05	0.0252	0.45	0.26	Body mass index;	chr11:111078647	chr11:111091932~111097357:-
SARC	cis	rs448720	0.811	rs383041	ENSG00000259410.4	RP11-34F13.3	-4.03	7.67e-05	0.0252	-0.28	-0.26	Cognitive performance;	chr15:67892143	chr15:67832725~67873866:+
SARC	cis	rs4849845	0.637	rs13022486	ENSG00000236878.1	AC012363.7	4.03	7.67e-05	0.0252	0.26	0.26	Mean platelet volume;	chr2:120281035	chr2:120211054~120211715:+
SARC	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-4.03	7.67e-05	0.0252	-0.31	-0.26	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
SARC	cis	rs11086243	0.935	rs6066638	ENSG00000276923.1	RP11-321P16.1	-4.03	7.67e-05	0.0252	-0.32	-0.26	Nephrotic syndrome (acquired);	chr20:48135716	chr20:48073869~48074188:+
SARC	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-4.03	7.67e-05	0.0252	-0.38	-0.26	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
SARC	cis	rs1023500	0.596	rs133352	ENSG00000205702.9	CYP2D7	4.03	7.68e-05	0.0252	0.2	0.26	Schizophrenia;	chr22:42038018	chr22:42140203~42144577:-
SARC	cis	rs7615952	0.599	rs67566088	ENSG00000248787.1	RP11-666A20.4	-4.03	7.68e-05	0.0252	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:126050130	chr3:125908005~125910272:-
SARC	cis	rs8177876	0.584	rs2549899	ENSG00000261061.1	RP11-303E16.2	4.03	7.69e-05	0.0253	0.31	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055267	chr16:81030770~81031485:+
SARC	cis	rs9309473	0.555	rs2901437	ENSG00000163016.8	ALMS1P	4.03	7.69e-05	0.0253	0.31	0.26	Metabolite levels;	chr2:73369896	chr2:73644919~73685576:+
SARC	cis	rs9309473	0.579	rs1852644	ENSG00000163016.8	ALMS1P	4.03	7.69e-05	0.0253	0.31	0.26	Metabolite levels;	chr2:73370590	chr2:73644919~73685576:+
SARC	cis	rs28386778	0.897	rs11079510	ENSG00000240280.5	TCAM1P	-4.03	7.69e-05	0.0253	-0.32	-0.26	Prudent dietary pattern;	chr17:63743542	chr17:63849292~63864379:+
SARC	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	4.03	7.69e-05	0.0253	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	4.03	7.69e-05	0.0253	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	4.03	7.69e-05	0.0253	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	4.03	7.69e-05	0.0253	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	4.03	7.69e-05	0.0253	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	4.03	7.69e-05	0.0253	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	4.03	7.69e-05	0.0253	0.31	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
SARC	cis	rs453301	0.686	rs7017868	ENSG00000253893.2	FAM85B	4.03	7.69e-05	0.0253	0.23	0.26	Joint mobility (Beighton score);	chr8:9015783	chr8:8167819~8226614:-
SARC	cis	rs453301	0.686	rs3895823	ENSG00000253893.2	FAM85B	4.03	7.69e-05	0.0253	0.23	0.26	Joint mobility (Beighton score);	chr8:9016136	chr8:8167819~8226614:-
SARC	cis	rs1707322	1	rs785504	ENSG00000281133.1	AL355480.3	4.03	7.69e-05	0.0253	0.3	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45580892~45580996:-
SARC	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-4.03	7.69e-05	0.0253	-0.37	-0.25	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
SARC	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-4.03	7.69e-05	0.0253	-0.37	-0.25	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-4.03	7.69e-05	0.0253	-0.37	-0.25	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-4.03	7.69e-05	0.0253	-0.37	-0.25	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
SARC	cis	rs1799949	0.628	rs4474733	ENSG00000267681.1	CTD-3199J23.6	-4.03	7.69e-05	0.0253	-0.32	-0.25	Menopause (age at onset);	chr17:43356292	chr17:43144956~43145255:+
SARC	cis	rs7772486	0.754	rs9399561	ENSG00000235652.6	RP11-545I5.3	4.03	7.7e-05	0.0253	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145799409~145886585:+
SARC	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	4.03	7.71e-05	0.0253	0.4	0.25	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	4.03	7.71e-05	0.0253	0.4	0.25	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
SARC	cis	rs8023445	1	rs12443433	ENSG00000259531.2	RP11-295H24.3	-4.02	7.71e-05	0.0253	-0.46	-0.25	Major depressive disorder;	chr15:48865203	chr15:49365124~49366685:-
SARC	cis	rs17508449	0.819	rs17031795	ENSG00000232450.1	RP4-730K3.3	-4.02	7.72e-05	0.0253	-0.33	-0.25	Leprosy;	chr1:113713206	chr1:113698884~113699631:-
SARC	cis	rs17508449	0.819	rs4589108	ENSG00000232450.1	RP4-730K3.3	-4.02	7.72e-05	0.0253	-0.33	-0.25	Leprosy;	chr1:113717003	chr1:113698884~113699631:-
SARC	cis	rs1707322	1	rs34694458	ENSG00000281133.1	AL355480.3	-4.02	7.73e-05	0.0254	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs10158032	ENSG00000281133.1	AL355480.3	-4.02	7.73e-05	0.0254	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45580892~45580996:-
SARC	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-4.02	7.73e-05	0.0254	-0.31	-0.25	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
SARC	cis	rs4938303	0.633	rs12801136	ENSG00000254851.1	RP11-109L13.1	4.02	7.73e-05	0.0254	0.36	0.25	Triglycerides;	chr11:116677632	chr11:117135528~117138582:+
SARC	cis	rs7267979	0.844	rs6115188	ENSG00000125804.12	FAM182A	-4.02	7.74e-05	0.0254	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:26054655~26086917:+
SARC	cis	rs11086243	0.934	rs11698870	ENSG00000276923.1	RP11-321P16.1	4.02	7.74e-05	0.0254	0.31	0.25	Nephrotic syndrome (acquired);	chr20:48150748	chr20:48073869~48074188:+
SARC	cis	rs4474742	1	rs4474742	ENSG00000264538.5	SUZ12P1	-4.02	7.74e-05	0.0254	-0.18	-0.25	Monocyte count;	chr17:29738560	chr17:30709299~30790908:+
SARC	cis	rs6845263	0.624	rs13434873	ENSG00000254531.1	FLJ20021	-4.02	7.74e-05	0.0254	-0.24	-0.25	Superior crus of antihelix expression;	chr4:101529865	chr4:101347780~101348883:+
SARC	cis	rs2439831	0.681	rs7168940	ENSG00000275601.1	AC011330.13	-4.02	7.74e-05	0.0254	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43341136	chr15:43642389~43643023:-
SARC	cis	rs748404	1	rs748404	ENSG00000205771.5	CATSPER2P1	-4.02	7.75e-05	0.0254	-0.37	-0.25	Lung cancer;	chr15:43267033	chr15:43726918~43747094:-
SARC	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-4.02	7.75e-05	0.0254	-0.3	-0.25	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
SARC	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-4.02	7.75e-05	0.0254	-0.27	-0.25	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
SARC	cis	rs7976269	0.583	rs4931131	ENSG00000257176.2	RP11-996F15.2	-4.02	7.75e-05	0.0254	-0.29	-0.25	Male-pattern baldness;	chr12:29015898	chr12:29280418~29317848:-
SARC	cis	rs7819412	0.691	rs73198970	ENSG00000255310.2	AF131215.2	-4.02	7.75e-05	0.0254	-0.28	-0.25	Triglycerides;	chr8:11182707	chr8:11107788~11109726:-
SARC	cis	rs848486	0.902	rs10263369	ENSG00000214293.7	APTR	-4.02	7.75e-05	0.0254	-0.27	-0.25	Glomerular filtration rate;	chr7:77777087	chr7:77657660~77696265:-
SARC	cis	rs4835473	0.897	rs13145976	ENSG00000251600.4	RP11-673E1.1	-4.02	7.75e-05	0.0254	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143735710	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs13114071	ENSG00000251600.4	RP11-673E1.1	-4.02	7.75e-05	0.0254	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143735728	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs13140654	ENSG00000251600.4	RP11-673E1.1	-4.02	7.75e-05	0.0254	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143735733	chr4:143912331~143982454:+
SARC	cis	rs8028182	0.636	rs10152155	ENSG00000260206.1	CTD-2026K11.2	-4.02	7.75e-05	0.0254	-0.31	-0.25	Sudden cardiac arrest;	chr15:75409213	chr15:75636139~75639239:+
SARC	cis	rs597539	0.652	rs516425	ENSG00000250508.1	RP11-757G1.6	-4.02	7.76e-05	0.0254	-0.3	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68870664~68874542:+
SARC	cis	rs763121	0.853	rs5750649	ENSG00000273076.1	RP3-508I15.22	4.02	7.76e-05	0.0254	0.27	0.25	Menopause (age at onset);	chr22:38640764	chr22:38743495~38743910:+
SARC	cis	rs763121	0.853	rs6519124	ENSG00000273076.1	RP3-508I15.22	4.02	7.76e-05	0.0254	0.27	0.25	Menopause (age at onset);	chr22:38649094	chr22:38743495~38743910:+
SARC	cis	rs763121	0.853	rs5750652	ENSG00000273076.1	RP3-508I15.22	4.02	7.76e-05	0.0254	0.27	0.25	Menopause (age at onset);	chr22:38652311	chr22:38743495~38743910:+
SARC	cis	rs763121	0.814	rs5757212	ENSG00000273076.1	RP3-508I15.22	4.02	7.76e-05	0.0254	0.27	0.25	Menopause (age at onset);	chr22:38657752	chr22:38743495~38743910:+
SARC	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	4.02	7.76e-05	0.0255	0.34	0.25	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
SARC	cis	rs6918586	0.658	rs198843	ENSG00000272462.2	U91328.19	-4.02	7.76e-05	0.0255	-0.23	-0.25	Schizophrenia;	chr6:26110086	chr6:25992662~26001775:+
SARC	cis	rs6845263	0.546	rs2114364	ENSG00000254531.1	FLJ20021	-4.02	7.77e-05	0.0255	-0.24	-0.25	Superior crus of antihelix expression;	chr4:101534196	chr4:101347780~101348883:+
SARC	cis	rs3824347	0.813	rs10869464	ENSG00000203321.2	C9orf41-AS1	-4.02	7.77e-05	0.0255	-0.29	-0.25	Urinary magnesium-to-creatinine ratio;	chr9:74982446	chr9:74952968~74996293:+
SARC	cis	rs61160187	0.75	rs1807017	ENSG00000272308.1	RP11-231G3.1	-4.02	7.77e-05	0.0255	-0.22	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60831897	chr5:60866457~60866935:-
SARC	cis	rs4664293	0.625	rs6745448	ENSG00000226266.5	AC009961.3	-4.02	7.77e-05	0.0255	-0.3	-0.25	Monocyte percentage of white cells;	chr2:159699087	chr2:159670708~159712435:-
SARC	cis	rs860818	1	rs1637215	ENSG00000226816.2	AC005082.12	-4.02	7.77e-05	0.0255	-0.7	-0.25	Initial pursuit acceleration;	chr7:23197178	chr7:23206013~23208045:+
SARC	cis	rs4372836	0.729	rs6547873	ENSG00000226833.4	AC097724.3	4.02	7.78e-05	0.0255	0.22	0.25	Body mass index;	chr2:28759117	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.729	rs6547874	ENSG00000226833.4	AC097724.3	4.02	7.78e-05	0.0255	0.22	0.25	Body mass index;	chr2:28759164	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.658	rs7579321	ENSG00000226833.4	AC097724.3	4.02	7.78e-05	0.0255	0.22	0.25	Body mass index;	chr2:28760300	chr2:28708953~28736205:-
SARC	cis	rs651386	0.529	rs576736	ENSG00000271811.1	RP1-79C4.4	4.02	7.78e-05	0.0255	0.34	0.25	Atrial fibrillation;	chr1:170618074	chr1:170667381~170669425:+
SARC	cis	rs75422866	0.51	rs73105845	ENSG00000257433.4	RP1-197B17.3	4.02	7.78e-05	0.0255	0.47	0.25	Pneumonia;	chr12:47741824	chr12:47706085~47742294:+
SARC	cis	rs1707322	1	rs6657720	ENSG00000281133.1	AL355480.3	-4.02	7.79e-05	0.0255	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs7519181	ENSG00000281133.1	AL355480.3	-4.02	7.79e-05	0.0255	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs7526369	ENSG00000281133.1	AL355480.3	-4.02	7.79e-05	0.0255	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.963	rs10890371	ENSG00000281133.1	AL355480.3	-4.02	7.79e-05	0.0255	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs10890372	ENSG00000281133.1	AL355480.3	-4.02	7.79e-05	0.0255	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45580892~45580996:-
SARC	cis	rs7267979	0.816	rs374701	ENSG00000125804.12	FAM182A	-4.02	7.79e-05	0.0255	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:26054655~26086917:+
SARC	cis	rs12950390	0.893	rs11079789	ENSG00000239291.1	RP5-867C24.1	4.02	7.79e-05	0.0255	0.3	0.25	IgG glycosylation;	chr17:47772349	chr17:47159191~47159993:-
SARC	cis	rs7267979	1	rs2257982	ENSG00000276952.1	RP5-965G21.6	4.02	7.8e-05	0.0255	0.25	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25284915~25285588:-
SARC	cis	rs7809950	0.678	rs2237660	ENSG00000238832.1	snoU109	-4.02	7.8e-05	0.0255	-0.33	-0.25	Coronary artery disease;	chr7:107222518	chr7:107603363~107603507:+
SARC	cis	rs2439831	0.867	rs2614811	ENSG00000275601.1	AC011330.13	-4.02	7.8e-05	0.0255	-0.43	-0.25	Lung cancer in ever smokers;	chr15:43621289	chr15:43642389~43643023:-
SARC	cis	rs6969780	1	rs73071548	ENSG00000233429.8	HOTAIRM1	4.02	7.8e-05	0.0256	0.41	0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27107811	chr7:27095647~27100265:+
SARC	cis	rs28386778	0.897	rs8067102	ENSG00000240280.5	TCAM1P	-4.02	7.8e-05	0.0256	-0.32	-0.25	Prudent dietary pattern;	chr17:63771419	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs6504185	ENSG00000240280.5	TCAM1P	-4.02	7.8e-05	0.0256	-0.32	-0.25	Prudent dietary pattern;	chr17:63771432	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs8077013	ENSG00000240280.5	TCAM1P	-4.02	7.8e-05	0.0256	-0.32	-0.25	Prudent dietary pattern;	chr17:63773032	chr17:63849292~63864379:+
SARC	cis	rs4713118	0.662	rs9357060	ENSG00000216901.1	AL022393.7	4.02	7.82e-05	0.0256	0.37	0.25	Parkinson's disease;	chr6:28056708	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.662	rs9468271	ENSG00000216901.1	AL022393.7	4.02	7.82e-05	0.0256	0.37	0.25	Parkinson's disease;	chr6:28056792	chr6:28176188~28176674:+
SARC	cis	rs7726354	1	rs2408651	ENSG00000271828.1	CTD-2310F14.1	4.02	7.82e-05	0.0256	0.5	0.25	Breast cancer (early onset);	chr5:56973164	chr5:56927874~56929573:+
SARC	cis	rs741951	0.832	rs76496919	ENSG00000235374.2	SSR4P1	4.02	7.82e-05	0.0256	0.43	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr21:44835887	chr21:45070952~45074165:-
SARC	cis	rs745109	0.882	rs75084119	ENSG00000273080.1	RP11-301O19.1	4.02	7.82e-05	0.0256	0.39	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86443077	chr2:86195590~86196049:+
SARC	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-4.02	7.82e-05	0.0256	-0.32	-0.25	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
SARC	cis	rs11955398	0.502	rs4700406	ENSG00000272308.1	RP11-231G3.1	-4.02	7.83e-05	0.0256	-0.23	-0.25	Intelligence (multi-trait analysis);	chr5:61070048	chr5:60866457~60866935:-
SARC	cis	rs495337	0.76	rs2769978	ENSG00000229222.1	KRT18P4	-4.02	7.83e-05	0.0256	-0.32	-0.25	Psoriasis;	chr20:49910886	chr20:49956745~49958032:+
SARC	cis	rs28386778	0.863	rs4968661	ENSG00000240280.5	TCAM1P	-4.02	7.84e-05	0.0256	-0.31	-0.25	Prudent dietary pattern;	chr17:63718946	chr17:63849292~63864379:+
SARC	cis	rs1880529	0.832	rs9307391	ENSG00000206820.1	RNU1-138P	-4.02	7.84e-05	0.0257	-0.25	-0.25	White matter integrity (bipolar disorder risk interaction);	chr4:113473518	chr4:113420323~113420486:+
SARC	cis	rs10200159	1	rs7558127	ENSG00000272606.1	RP11-554J4.1	4.02	7.84e-05	0.0257	0.46	0.25	Vitiligo;	chr2:55639470	chr2:55617909~55618373:+
SARC	cis	rs4835473	0.932	rs7683686	ENSG00000251600.4	RP11-673E1.1	-4.02	7.84e-05	0.0257	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143784352	chr4:143912331~143982454:+
SARC	cis	rs858239	0.632	rs7811903	ENSG00000226816.2	AC005082.12	4.02	7.84e-05	0.0257	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23206013~23208045:+
SARC	cis	rs9902453	0.74	rs2628189	ENSG00000264538.5	SUZ12P1	-4.02	7.85e-05	0.0257	-0.18	-0.25	Coffee consumption (cups per day);	chr17:29761795	chr17:30709299~30790908:+
SARC	cis	rs12950390	0.853	rs12450733	ENSG00000239291.1	RP5-867C24.1	4.02	7.85e-05	0.0257	0.3	0.25	IgG glycosylation;	chr17:47778038	chr17:47159191~47159993:-
SARC	cis	rs853679	0.517	rs12174753	ENSG00000216901.1	AL022393.7	4.02	7.85e-05	0.0257	0.36	0.25	Depression;	chr6:28074687	chr6:28176188~28176674:+
SARC	cis	rs910316	0.726	rs61979167	ENSG00000279594.1	RP11-950C14.10	-4.02	7.85e-05	0.0257	-0.29	-0.25	Height;	chr14:75196907	chr14:75011269~75012851:-
SARC	cis	rs9739682	1	rs1444250	ENSG00000139239.7	RPL14P1	-4.02	7.86e-05	0.0257	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62107393	chr12:62965325~62965969:+
SARC	cis	rs9739682	1	rs1444249	ENSG00000139239.7	RPL14P1	-4.02	7.86e-05	0.0257	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62107415	chr12:62965325~62965969:+
SARC	cis	rs9739682	1	rs11174324	ENSG00000139239.7	RPL14P1	-4.02	7.86e-05	0.0257	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62108469	chr12:62965325~62965969:+
SARC	cis	rs10784281	1	rs10784281	ENSG00000139239.7	RPL14P1	-4.02	7.86e-05	0.0257	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62109198	chr12:62965325~62965969:+
SARC	cis	rs10877792	1	rs10877792	ENSG00000139239.7	RPL14P1	-4.02	7.86e-05	0.0257	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62109840	chr12:62965325~62965969:+
SARC	cis	rs11174325	1	rs11174325	ENSG00000139239.7	RPL14P1	-4.02	7.86e-05	0.0257	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62109992	chr12:62965325~62965969:+
SARC	cis	rs9668676	1	rs9668676	ENSG00000139239.7	RPL14P1	-4.02	7.86e-05	0.0257	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62110418	chr12:62965325~62965969:+
SARC	cis	rs145861664	1	rs145861664	ENSG00000139239.7	RPL14P1	-4.02	7.86e-05	0.0257	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62111677	chr12:62965325~62965969:+
SARC	cis	rs9738122	1	rs9738122	ENSG00000139239.7	RPL14P1	-4.02	7.86e-05	0.0257	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62120892	chr12:62965325~62965969:+
SARC	cis	rs9902453	0.904	rs12951836	ENSG00000264538.5	SUZ12P1	-4.02	7.87e-05	0.0257	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30083259	chr17:30709299~30790908:+
SARC	cis	rs2439831	0.618	rs8023508	ENSG00000275601.1	AC011330.13	4.02	7.87e-05	0.0257	0.4	0.25	Lung cancer in ever smokers;	chr15:43883905	chr15:43642389~43643023:-
SARC	cis	rs7811142	1	rs67040465	ENSG00000078319.8	PMS2P1	-4.02	7.87e-05	0.0257	-0.37	-0.25	Platelet count;	chr7:100485455	chr7:100320992~100341908:-
SARC	cis	rs77633900	0.73	rs2456054	ENSG00000196274.5	Metazoa_SRP	4.02	7.87e-05	0.0257	0.48	0.25	Glioma;Non-glioblastoma glioma;	chr15:76181876	chr15:76230048~76230390:-
SARC	cis	rs891378	0.876	rs1367067	ENSG00000274245.1	RP11-357P18.2	4.02	7.88e-05	0.0258	0.3	0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207269019	chr1:207372559~207373252:+
SARC	cis	rs10911902	0.913	rs12137128	ENSG00000229739.2	RP11-295K2.3	-4.02	7.89e-05	0.0258	-0.35	-0.25	Schizophrenia;	chr1:186550622	chr1:186435161~186470291:+
SARC	cis	rs7267979	0.816	rs404775	ENSG00000276952.1	RP5-965G21.6	4.02	7.9e-05	0.0258	0.25	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:25284915~25285588:-
SARC	cis	rs7580658	0.895	rs9636237	ENSG00000236682.1	AC068282.3	-4.02	7.9e-05	0.0258	-0.29	-0.25	Protein C levels;	chr2:127318446	chr2:127389130~127400580:+
SARC	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-4.02	7.91e-05	0.0258	-0.29	-0.25	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-4.02	7.91e-05	0.0258	-0.29	-0.25	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-4.02	7.91e-05	0.0258	-0.29	-0.25	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-4.02	7.91e-05	0.0258	-0.29	-0.25	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
SARC	cis	rs9832727	0.827	rs6770560	ENSG00000240950.1	RP11-372E1.1	4.02	7.91e-05	0.0259	0.25	0.25	Phospholipid levels (plasma);	chr3:142938919	chr3:142827096~142827728:-
SARC	cis	rs4835473	0.9	rs35230778	ENSG00000251600.4	RP11-673E1.1	-4.02	7.91e-05	0.0259	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143734336	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs34772566	ENSG00000251600.4	RP11-673E1.1	-4.02	7.91e-05	0.0259	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143734355	chr4:143912331~143982454:+
SARC	cis	rs745109	0.504	rs72926475	ENSG00000273080.1	RP11-301O19.1	4.02	7.91e-05	0.0259	0.39	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86367364	chr2:86195590~86196049:+
SARC	cis	rs1211375	0.628	rs3859141	ENSG00000268836.1	LA16c-OS12.2	4.02	7.92e-05	0.0259	0.24	0.25	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:195080	chr16:185748~186294:-
SARC	cis	rs2439831	0.717	rs7165471	ENSG00000275601.1	AC011330.13	-4.02	7.92e-05	0.0259	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43352590	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs4075674	ENSG00000275601.1	AC011330.13	-4.02	7.92e-05	0.0259	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43358032	chr15:43642389~43643023:-
SARC	cis	rs7267979	0.868	rs6138546	ENSG00000276952.1	RP5-965G21.6	4.02	7.93e-05	0.0259	0.25	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25284915~25285588:-
SARC	cis	rs9309473	0.5	rs6757996	ENSG00000163016.8	ALMS1P	4.02	7.93e-05	0.0259	0.3	0.25	Metabolite levels;	chr2:73545124	chr2:73644919~73685576:+
SARC	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-4.02	7.93e-05	0.0259	-0.37	-0.25	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
SARC	cis	rs7615952	0.599	rs6766327	ENSG00000248787.1	RP11-666A20.4	-4.02	7.94e-05	0.0259	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:126004834	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.641	rs12491577	ENSG00000248787.1	RP11-666A20.4	-4.02	7.94e-05	0.0259	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:126012288	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.599	rs1875683	ENSG00000248787.1	RP11-666A20.4	-4.02	7.94e-05	0.0259	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:126013638	chr3:125908005~125910272:-
SARC	cis	rs950776	0.616	rs56276142	ENSG00000261762.1	RP11-650L12.2	4.02	7.94e-05	0.0259	0.26	0.25	Sudden cardiac arrest;	chr15:78597453	chr15:78589123~78591276:-
SARC	cis	rs950776	0.616	rs6495307	ENSG00000261762.1	RP11-650L12.2	4.02	7.94e-05	0.0259	0.26	0.25	Sudden cardiac arrest;	chr15:78597979	chr15:78589123~78591276:-
SARC	cis	rs7712401	0.765	rs10079941	ENSG00000263432.2	RN7SL689P	4.02	7.95e-05	0.026	0.32	0.25	Mean platelet volume;	chr5:123045668	chr5:123022487~123022783:-
SARC	cis	rs5769707	0.967	rs5769698	ENSG00000235111.1	RP1-29C18.8	-4.02	7.95e-05	0.026	-0.27	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49612657~49615716:-
SARC	cis	rs4835473	0.9	rs1375982	ENSG00000251600.4	RP11-673E1.1	-4.02	7.95e-05	0.026	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143745764	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs4835237	ENSG00000251600.4	RP11-673E1.1	-4.02	7.95e-05	0.026	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143746349	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs56084616	ENSG00000251600.4	RP11-673E1.1	-4.02	7.95e-05	0.026	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143746697	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.966	rs11722639	ENSG00000251600.4	RP11-673E1.1	-4.02	7.95e-05	0.026	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143746884	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.966	rs11722673	ENSG00000251600.4	RP11-673E1.1	-4.02	7.95e-05	0.026	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143746946	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs6821979	ENSG00000251600.4	RP11-673E1.1	-4.02	7.95e-05	0.026	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143748091	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1982392	ENSG00000251600.4	RP11-673E1.1	-4.02	7.95e-05	0.026	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143748604	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs1982393	ENSG00000251600.4	RP11-673E1.1	-4.02	7.95e-05	0.026	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143748736	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs9683880	ENSG00000251600.4	RP11-673E1.1	-4.02	7.95e-05	0.026	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143748787	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs7687976	ENSG00000251600.4	RP11-673E1.1	-4.02	7.95e-05	0.026	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143749171	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs7683287	ENSG00000251600.4	RP11-673E1.1	-4.02	7.95e-05	0.026	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143749270	chr4:143912331~143982454:+
SARC	cis	rs875971	0.508	rs10950045	ENSG00000224316.1	RP11-479O9.2	-4.02	7.95e-05	0.026	-0.23	-0.25	Aortic root size;	chr7:66601386	chr7:65773620~65802067:+
SARC	cis	rs7772486	0.79	rs9497431	ENSG00000270638.1	RP3-466P17.1	-4.02	7.96e-05	0.026	-0.21	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.79	rs7753092	ENSG00000270638.1	RP3-466P17.1	-4.02	7.96e-05	0.026	-0.21	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145735570~145737218:+
SARC	cis	rs801193	0.839	rs6968619	ENSG00000224316.1	RP11-479O9.2	-4.02	7.96e-05	0.026	-0.23	-0.25	Aortic root size;	chr7:66603880	chr7:65773620~65802067:+
SARC	cis	rs801193	0.839	rs12534943	ENSG00000224316.1	RP11-479O9.2	-4.02	7.96e-05	0.026	-0.23	-0.25	Aortic root size;	chr7:66605533	chr7:65773620~65802067:+
SARC	cis	rs801193	0.805	rs12532355	ENSG00000224316.1	RP11-479O9.2	-4.02	7.96e-05	0.026	-0.23	-0.25	Aortic root size;	chr7:66605597	chr7:65773620~65802067:+
SARC	cis	rs6540731	1	rs2012917	ENSG00000229983.1	RP11-15I11.2	4.02	7.97e-05	0.026	0.26	0.25	Intelligence (childhood);	chr1:212232429	chr1:212168207~212190259:+
SARC	cis	rs8098244	0.52	rs8094549	ENSG00000264745.1	TTC39C-AS1	-4.02	7.97e-05	0.026	-0.34	-0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23992176	chr18:23994213~24015339:-
SARC	cis	rs2408955	0.715	rs1793957	ENSG00000240399.1	RP1-228P16.1	4.02	7.98e-05	0.026	0.27	0.25	Glycated hemoglobin levels;	chr12:47999041	chr12:48054813~48055591:-
SARC	cis	rs5769707	0.732	rs135865	ENSG00000235111.1	RP1-29C18.8	-4.02	7.98e-05	0.026	-0.31	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49612657~49615716:-
SARC	cis	rs10986311	0.604	rs10818962	ENSG00000235204.1	RP11-121A14.2	4.02	7.99e-05	0.026	0.3	0.25	Vitiligo;	chr9:124420014	chr9:124259250~124261156:-
SARC	cis	rs4372836	0.518	rs1128416	ENSG00000226833.4	AC097724.3	4.02	7.99e-05	0.026	0.23	0.25	Body mass index;	chr2:28778825	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.543	rs6742291	ENSG00000226833.4	AC097724.3	4.02	7.99e-05	0.026	0.23	0.25	Body mass index;	chr2:28784483	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.543	rs6747852	ENSG00000226833.4	AC097724.3	4.02	7.99e-05	0.026	0.23	0.25	Body mass index;	chr2:28786974	chr2:28708953~28736205:-
SARC	cis	rs853679	0.55	rs1237875	ENSG00000216901.1	AL022393.7	-4.02	7.99e-05	0.026	-0.35	-0.25	Depression;	chr6:28205232	chr6:28176188~28176674:+
SARC	cis	rs950776	0.518	rs8025429	ENSG00000261762.1	RP11-650L12.2	-4.02	7.99e-05	0.026	-0.27	-0.25	Sudden cardiac arrest;	chr15:78544020	chr15:78589123~78591276:-
SARC	cis	rs950776	0.518	rs4886572	ENSG00000261762.1	RP11-650L12.2	-4.02	7.99e-05	0.026	-0.27	-0.25	Sudden cardiac arrest;	chr15:78545110	chr15:78589123~78591276:-
SARC	cis	rs7772486	0.743	rs62433835	ENSG00000235652.6	RP11-545I5.3	-4.02	7.99e-05	0.0261	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.743	rs2092262	ENSG00000235652.6	RP11-545I5.3	-4.02	7.99e-05	0.0261	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.682	rs1337840	ENSG00000235652.6	RP11-545I5.3	-4.02	7.99e-05	0.0261	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145799409~145886585:+
SARC	cis	rs11264213	0.901	rs6665591	ENSG00000271554.1	RP4-665N4.8	-4.02	7.99e-05	0.0261	-0.35	-0.25	Schizophrenia;	chr1:35946136	chr1:35992109~36013630:-
SARC	cis	rs875971	0.895	rs7788984	ENSG00000232559.3	GS1-124K5.12	4.02	8e-05	0.0261	0.28	0.25	Aortic root size;	chr7:66450629	chr7:66554588~66576923:-
SARC	cis	rs875971	1	rs1981798	ENSG00000232559.3	GS1-124K5.12	4.02	8e-05	0.0261	0.28	0.25	Aortic root size;	chr7:66489916	chr7:66554588~66576923:-
SARC	cis	rs950776	0.593	rs6495306	ENSG00000261762.1	RP11-650L12.2	-4.02	8e-05	0.0261	-0.27	-0.25	Sudden cardiac arrest;	chr15:78573551	chr15:78589123~78591276:-
SARC	cis	rs4664293	0.836	rs4516379	ENSG00000226266.5	AC009961.3	-4.02	8e-05	0.0261	-0.31	-0.25	Monocyte percentage of white cells;	chr2:159808892	chr2:159670708~159712435:-
SARC	cis	rs4950322	0.547	rs61838945	ENSG00000278811.3	LINC00624	4.02	8.01e-05	0.0261	0.26	0.25	Protein quantitative trait loci;	chr1:147111477	chr1:147258885~147517875:-
SARC	cis	rs755249	0.567	rs2036463	ENSG00000182109.6	RP11-69E11.4	4.02	8.01e-05	0.0261	0.29	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs2036464	ENSG00000182109.6	RP11-69E11.4	4.02	8.01e-05	0.0261	0.29	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs905381	ENSG00000182109.6	RP11-69E11.4	4.02	8.01e-05	0.0261	0.29	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs16826009	ENSG00000182109.6	RP11-69E11.4	4.02	8.01e-05	0.0261	0.29	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39522280~39546187:-
SARC	cis	rs12542260	0.871	rs4128469	ENSG00000245149.3	RNF139-AS1	-4.02	8.01e-05	0.0261	-0.24	-0.25	Colonoscopy-negative controls vs population controls;	chr8:124467234	chr8:124462485~124474576:-
SARC	cis	rs3823536	0.583	rs1874327	ENSG00000275106.1	RP11-309L24.10	-4.02	8.01e-05	0.0261	-0.32	-0.25	Sjögren's syndrome;	chr7:128945322	chr7:128952527~128953316:-
SARC	cis	rs4664293	0.836	rs13421392	ENSG00000226266.5	AC009961.3	-4.02	8.01e-05	0.0261	-0.32	-0.25	Monocyte percentage of white cells;	chr2:159801785	chr2:159670708~159712435:-
SARC	cis	rs56046484	0.75	rs62022525	ENSG00000259295.5	CSPG4P12	4.01	8.02e-05	0.0261	0.4	0.25	Testicular germ cell tumor;	chr15:84980447	chr15:85191438~85213905:+
SARC	cis	rs7580658	0.857	rs17015199	ENSG00000236682.1	AC068282.3	-4.01	8.02e-05	0.0261	-0.29	-0.25	Protein C levels;	chr2:127336477	chr2:127389130~127400580:+
SARC	cis	rs9959145	0.5	rs11665415	ENSG00000279275.1	RP11-756J15.2	4.01	8.02e-05	0.0261	0.49	0.25	Immune response to smallpox vaccine (IL-6);	chr18:12536130	chr18:13279415~13280110:-
SARC	cis	rs9959145	0.5	rs11665542	ENSG00000279275.1	RP11-756J15.2	4.01	8.02e-05	0.0261	0.49	0.25	Immune response to smallpox vaccine (IL-6);	chr18:12536778	chr18:13279415~13280110:-
SARC	cis	rs4950322	0.58	rs17355419	ENSG00000278811.3	LINC00624	4.01	8.03e-05	0.0261	0.26	0.25	Protein quantitative trait loci;	chr1:147110094	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.58	rs72706428	ENSG00000278811.3	LINC00624	4.01	8.03e-05	0.0261	0.26	0.25	Protein quantitative trait loci;	chr1:147110219	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.563	rs61838944	ENSG00000278811.3	LINC00624	4.01	8.03e-05	0.0261	0.26	0.25	Protein quantitative trait loci;	chr1:147110275	chr1:147258885~147517875:-
SARC	cis	rs875971	0.638	rs6960778	ENSG00000224316.1	RP11-479O9.2	-4.01	8.03e-05	0.0262	-0.24	-0.25	Aortic root size;	chr7:66606610	chr7:65773620~65802067:+
SARC	cis	rs4849845	0.653	rs3933618	ENSG00000236878.1	AC012363.7	4.01	8.03e-05	0.0262	0.26	0.25	Mean platelet volume;	chr2:120277976	chr2:120211054~120211715:+
SARC	cis	rs853679	1	rs6905391	ENSG00000216901.1	AL022393.7	4.01	8.03e-05	0.0262	0.43	0.25	Depression;	chr6:28294909	chr6:28176188~28176674:+
SARC	cis	rs7713317	0.814	rs36101807	ENSG00000236882.6	LINC01554	-4.01	8.03e-05	0.0262	-0.31	-0.25	Body mass index;	chr5:96213582	chr5:95852232~95860133:+
SARC	cis	rs12200782	1	rs12204145	ENSG00000272462.2	U91328.19	-4.01	8.03e-05	0.0262	-0.4	-0.25	Small cell lung carcinoma;	chr6:26599928	chr6:25992662~26001775:+
SARC	cis	rs160451	0.934	rs34036322	ENSG00000251136.7	RP11-37B2.1	4.01	8.04e-05	0.0262	0.27	0.25	Leprosy;	chr8:89654670	chr8:89609409~89757727:-
SARC	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-4.01	8.04e-05	0.0262	-0.31	-0.25	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
SARC	cis	rs77633900	0.803	rs2456063	ENSG00000196274.5	Metazoa_SRP	4.01	8.04e-05	0.0262	0.46	0.25	Glioma;Non-glioblastoma glioma;	chr15:76303208	chr15:76230048~76230390:-
SARC	cis	rs77633900	0.803	rs2469573	ENSG00000196274.5	Metazoa_SRP	4.01	8.04e-05	0.0262	0.46	0.25	Glioma;Non-glioblastoma glioma;	chr15:76308708	chr15:76230048~76230390:-
SARC	cis	rs77633900	0.803	rs2469212	ENSG00000196274.5	Metazoa_SRP	4.01	8.04e-05	0.0262	0.46	0.25	Glioma;Non-glioblastoma glioma;	chr15:76308734	chr15:76230048~76230390:-
SARC	cis	rs950776	0.616	rs12901300	ENSG00000261762.1	RP11-650L12.2	4.01	8.04e-05	0.0262	0.26	0.25	Sudden cardiac arrest;	chr15:78600610	chr15:78589123~78591276:-
SARC	cis	rs6477918	0.598	rs34080807	ENSG00000250068.1	RP11-576C12.1	-4.01	8.04e-05	0.0262	-0.26	-0.25	Obstetric antiphospholipid syndrome;	chr9:112398261	chr9:112581779~112582590:-
SARC	cis	rs4372836	0.704	rs3190	ENSG00000226833.4	AC097724.3	4.01	8.04e-05	0.0262	0.22	0.25	Body mass index;	chr2:28802613	chr2:28708953~28736205:-
SARC	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-4.01	8.04e-05	0.0262	-0.24	-0.25	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
SARC	cis	rs28386778	0.897	rs4638645	ENSG00000240280.5	TCAM1P	-4.01	8.04e-05	0.0262	-0.32	-0.25	Prudent dietary pattern;	chr17:63750989	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.805	rs9911714	ENSG00000240280.5	TCAM1P	-4.01	8.04e-05	0.0262	-0.32	-0.25	Prudent dietary pattern;	chr17:63751592	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs4968599	ENSG00000240280.5	TCAM1P	-4.01	8.04e-05	0.0262	-0.32	-0.25	Prudent dietary pattern;	chr17:63758632	chr17:63849292~63864379:+
SARC	cis	rs7580658	0.864	rs1566823	ENSG00000236682.1	AC068282.3	-4.01	8.05e-05	0.0262	-0.29	-0.25	Protein C levels;	chr2:127260616	chr2:127389130~127400580:+
SARC	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-4.01	8.05e-05	0.0262	-0.23	-0.25	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
SARC	cis	rs11098499	0.604	rs2389882	ENSG00000250950.1	RP11-33B1.3	-4.01	8.06e-05	0.0262	-0.27	-0.25	Corneal astigmatism;	chr4:119645578	chr4:119456350~119457277:+
SARC	cis	rs897984	0.572	rs4889526	ENSG00000260911.2	RP11-196G11.2	4.01	8.07e-05	0.0263	0.25	0.25	Dementia with Lewy bodies;	chr16:31019023	chr16:31043150~31049868:+
SARC	cis	rs537626	0.542	rs3015959	ENSG00000246889.2	AP000487.5	-4.01	8.07e-05	0.0263	-0.3	-0.25	Breast cancer (early onset);	chr11:69497702	chr11:70372246~70398488:-
SARC	cis	rs7267979	0.932	rs1985737	ENSG00000276952.1	RP5-965G21.6	4.01	8.07e-05	0.0263	0.25	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25284915~25285588:-
SARC	cis	rs9393813	0.967	rs764284	ENSG00000216901.1	AL022393.7	-4.01	8.07e-05	0.0263	-0.29	-0.25	Bipolar disorder;	chr6:27344299	chr6:28176188~28176674:+
SARC	cis	rs7274811	0.901	rs55990870	ENSG00000181741.7	FDX1P1	-4.01	8.08e-05	0.0263	-0.34	-0.25	Height;	chr20:33715102	chr20:34475924~34476474:-
SARC	cis	rs7162943	1	rs7162943	ENSG00000260123.1	RP11-326A19.4	4.01	8.08e-05	0.0263	0.24	0.25	Mean platelet volume;	chr15:89072044	chr15:89041223~89082819:+
SARC	cis	rs4664293	1	rs6432540	ENSG00000226266.5	AC009961.3	-4.01	8.08e-05	0.0263	-0.31	-0.25	Monocyte percentage of white cells;	chr2:159594192	chr2:159670708~159712435:-
SARC	cis	rs4664293	1	rs12692554	ENSG00000226266.5	AC009961.3	-4.01	8.08e-05	0.0263	-0.31	-0.25	Monocyte percentage of white cells;	chr2:159594777	chr2:159670708~159712435:-
SARC	cis	rs6751744	0.513	rs6738215	ENSG00000226266.5	AC009961.3	-4.01	8.08e-05	0.0263	-0.31	-0.25	Dysphagia;	chr2:159596794	chr2:159670708~159712435:-
SARC	cis	rs2439831	1	rs2253708	ENSG00000275601.1	AC011330.13	-4.01	8.08e-05	0.0263	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43505075	chr15:43642389~43643023:-
SARC	cis	rs13126694	1	rs13126694	ENSG00000248429.4	RP11-597D13.9	-4.01	8.09e-05	0.0263	-0.25	-0.25	Blood osmolality (transformed sodium);	chr4:158177632	chr4:158170752~158202877:+
SARC	cis	rs7809950	0.678	rs2237661	ENSG00000238832.1	snoU109	-4.01	8.09e-05	0.0263	-0.32	-0.25	Coronary artery disease;	chr7:107222678	chr7:107603363~107603507:+
SARC	cis	rs7809950	0.678	rs79902674	ENSG00000238832.1	snoU109	-4.01	8.09e-05	0.0263	-0.32	-0.25	Coronary artery disease;	chr7:107226053	chr7:107603363~107603507:+
SARC	cis	rs7772486	0.686	rs9399565	ENSG00000235652.6	RP11-545I5.3	-4.01	8.09e-05	0.0263	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145799409~145886585:+
SARC	cis	rs5751614	0.537	rs9608093	ENSG00000230701.2	FBXW4P1	4.01	8.09e-05	0.0263	0.34	0.25	Height;	chr22:23271352	chr22:23262767~23265005:+
SARC	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-4.01	8.09e-05	0.0263	-0.27	-0.25	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
SARC	cis	rs77633900	0.892	rs2460158	ENSG00000196274.5	Metazoa_SRP	4.01	8.09e-05	0.0263	0.43	0.25	Glioma;Non-glioblastoma glioma;	chr15:76307881	chr15:76230048~76230390:-
SARC	cis	rs2439831	0.702	rs16977724	ENSG00000166763.7	STRCP1	4.01	8.1e-05	0.0263	0.36	0.25	Lung cancer in ever smokers;	chr15:43859101	chr15:43699488~43718184:-
SARC	cis	rs12702271	0.909	rs4345475	ENSG00000229628.1	AC073115.7	-4.01	8.1e-05	0.0263	-0.36	-0.25	Male-pattern baldness;	chr7:46859474	chr7:45990905~46000898:+
SARC	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-4.01	8.1e-05	0.0263	-0.29	-0.25	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
SARC	cis	rs11955398	0.502	rs42437	ENSG00000272308.1	RP11-231G3.1	-4.01	8.1e-05	0.0263	-0.24	-0.25	Intelligence (multi-trait analysis);	chr5:61052219	chr5:60866457~60866935:-
SARC	cis	rs7267979	0.932	rs6037125	ENSG00000276952.1	RP5-965G21.6	4.01	8.1e-05	0.0263	0.25	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:25284915~25285588:-
SARC	cis	rs9309711	0.961	rs11890651	ENSG00000225234.1	TRAPPC12-AS1	-4.01	8.11e-05	0.0264	-0.25	-0.25	Neurofibrillary tangles;	chr2:3479025	chr2:3481242~3482409:-
SARC	cis	rs1707322	0.964	rs785516	ENSG00000281133.1	AL355480.3	4.01	8.11e-05	0.0264	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs785517	ENSG00000281133.1	AL355480.3	4.01	8.11e-05	0.0264	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs785484	ENSG00000281133.1	AL355480.3	4.01	8.11e-05	0.0264	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45580892~45580996:-
SARC	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-4.01	8.11e-05	0.0264	-0.23	-0.25	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
SARC	cis	rs7267979	0.932	rs6115214	ENSG00000276952.1	RP5-965G21.6	-4.01	8.11e-05	0.0264	-0.25	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:25284915~25285588:-
SARC	cis	rs783540	0.542	rs62009945	ENSG00000275695.1	UBE2Q2P6	-4.01	8.11e-05	0.0264	-0.28	-0.25	Schizophrenia;	chr15:82631205	chr15:82445719~82454837:+
SARC	cis	rs4664293	0.647	rs6734085	ENSG00000226266.5	AC009961.3	-4.01	8.12e-05	0.0264	-0.3	-0.25	Monocyte percentage of white cells;	chr2:159595711	chr2:159670708~159712435:-
SARC	cis	rs12950390	0.853	rs55745341	ENSG00000239291.1	RP5-867C24.1	4.01	8.12e-05	0.0264	0.3	0.25	IgG glycosylation;	chr17:47778412	chr17:47159191~47159993:-
SARC	cis	rs7726354	1	rs73122138	ENSG00000271828.1	CTD-2310F14.1	4.01	8.12e-05	0.0264	0.5	0.25	Breast cancer (early onset);	chr5:56972122	chr5:56927874~56929573:+
SARC	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-4.01	8.12e-05	0.0264	-0.3	-0.25	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
SARC	cis	rs61160187	0.582	rs1460961	ENSG00000215032.2	GNL3LP1	4.01	8.13e-05	0.0264	0.25	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61116005	chr5:60891935~60893577:-
SARC	cis	rs7267979	0.816	rs390123	ENSG00000276952.1	RP5-965G21.6	4.01	8.13e-05	0.0264	0.25	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:25284915~25285588:-
SARC	cis	rs2439831	1	rs28666488	ENSG00000275601.1	AC011330.13	-4.01	8.13e-05	0.0264	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43448892	chr15:43642389~43643023:-
SARC	cis	rs7537765	1	rs17037429	ENSG00000242349.4	NPPA-AS1	4.01	8.13e-05	0.0264	0.33	0.25	QRS complex (12-leadsum);	chr1:11813730	chr1:11841017~11848079:+
SARC	cis	rs72945132	0.941	rs66803755	ENSG00000254604.1	AP000487.6	-4.01	8.14e-05	0.0264	-0.35	-0.25	Coronary artery disease;	chr11:70271367	chr11:70282367~70363368:-
SARC	cis	rs7208859	0.573	rs8078182	ENSG00000264538.5	SUZ12P1	-4.01	8.14e-05	0.0265	-0.28	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30709299~30790908:+
SARC	cis	rs7976269	0.537	rs4471475	ENSG00000257176.2	RP11-996F15.2	-4.01	8.14e-05	0.0265	-0.28	-0.25	Male-pattern baldness;	chr12:29022461	chr12:29280418~29317848:-
SARC	cis	rs3824347	1	rs3824347	ENSG00000203321.2	C9orf41-AS1	-4.01	8.15e-05	0.0265	-0.28	-0.25	Urinary magnesium-to-creatinine ratio;	chr9:74951230	chr9:74952968~74996293:+
SARC	cis	rs9828933	0.752	rs17069507	ENSG00000280620.1	SCAANT1	4.01	8.15e-05	0.0265	0.46	0.25	Type 2 diabetes;	chr3:63939280	chr3:63911518~63911772:-
SARC	cis	rs494459	0.536	rs57719838	ENSG00000255422.1	AP002954.4	-4.01	8.15e-05	0.0265	-0.25	-0.25	Height;	chr11:118854014	chr11:118704607~118750263:+
SARC	cis	rs2439831	0.85	rs16965120	ENSG00000166763.7	STRCP1	4.01	8.15e-05	0.0265	0.34	0.25	Lung cancer in ever smokers;	chr15:43808144	chr15:43699488~43718184:-
SARC	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-4.01	8.15e-05	0.0265	-0.37	-0.25	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-4.01	8.15e-05	0.0265	-0.37	-0.25	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
SARC	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-4.01	8.15e-05	0.0265	-0.37	-0.25	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
SARC	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-4.01	8.15e-05	0.0265	-0.37	-0.25	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
SARC	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-4.01	8.15e-05	0.0265	-0.37	-0.25	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-4.01	8.15e-05	0.0265	-0.37	-0.25	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-4.01	8.15e-05	0.0265	-0.37	-0.25	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
SARC	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-4.01	8.15e-05	0.0265	-0.37	-0.25	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-4.01	8.15e-05	0.0265	-0.37	-0.25	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
SARC	cis	rs10200159	0.793	rs10496054	ENSG00000240401.7	AC012358.8	4.01	8.15e-05	0.0265	0.57	0.25	Vitiligo;	chr2:55761735	chr2:55282350~55346049:+
SARC	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-4.01	8.16e-05	0.0265	-0.26	-0.25	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
SARC	cis	rs17695224	0.545	rs7252508	ENSG00000275055.1	CTC-471J1.11	-4.01	8.16e-05	0.0265	-0.26	-0.25	HDL cholesterol;HDL cholesterol levels;	chr19:51831530	chr19:52049007~52049754:+
SARC	cis	rs7614311	0.954	rs2291533	ENSG00000271843.1	RP11-245J9.5	4.01	8.16e-05	0.0265	0.34	0.25	Lung function (FVC);Lung function (FEV1);	chr3:63831754	chr3:64008082~64008692:-
SARC	cis	rs7267979	0.966	rs6050611	ENSG00000274414.1	RP5-965G21.4	-4.01	8.17e-05	0.0265	-0.26	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:25239007~25245229:-
SARC	cis	rs8028182	0.636	rs4451914	ENSG00000260206.1	CTD-2026K11.2	-4.01	8.17e-05	0.0265	-0.31	-0.25	Sudden cardiac arrest;	chr15:75447483	chr15:75636139~75639239:+
SARC	cis	rs8098244	0.52	rs76908482	ENSG00000265752.2	RP11-403A21.1	-4.01	8.17e-05	0.0265	-0.32	-0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23992080	chr18:23957754~23982556:-
SARC	cis	rs7246657	0.943	rs9917081	ENSG00000226686.6	LINC01535	-4.01	8.17e-05	0.0265	-0.36	-0.25	Coronary artery calcification;	chr19:37385714	chr19:37251912~37265535:+
SARC	cis	rs1707322	1	rs11211200	ENSG00000281133.1	AL355480.3	-4.01	8.17e-05	0.0265	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45580892~45580996:-
SARC	cis	rs4835265	0.852	rs4835261	ENSG00000272727.1	RP11-142A22.4	-4.01	8.17e-05	0.0265	-0.36	-0.25	Gamma glutamyl transpeptidase;	chr4:145860595	chr4:145335263~145340421:-
SARC	cis	rs72817562	0.688	rs55712091	ENSG00000254252.1	RPL7P20	4.01	8.18e-05	0.0265	0.34	0.25	Neuroticism;	chr5:165241745	chr5:166028567~166029311:-
SARC	cis	rs2235544	0.588	rs664758	ENSG00000225183.1	RP4-758J24.4	4.01	8.18e-05	0.0265	0.28	0.25	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:53995590	chr1:54089856~54090093:+
SARC	cis	rs9467773	0.595	rs9366657	ENSG00000261353.1	CTA-14H9.5	-4.01	8.18e-05	0.0266	-0.27	-0.25	Intelligence (multi-trait analysis);	chr6:26434686	chr6:26527063~26527404:+
SARC	cis	rs4273100	0.646	rs2296981	ENSG00000265185.4	SNORD3B-1	-4.01	8.18e-05	0.0266	-0.3	-0.25	Schizophrenia;	chr17:19310022	chr17:19061912~19062669:+
SARC	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-4.01	8.18e-05	0.0266	-0.28	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
SARC	cis	rs6540731	1	rs4500383	ENSG00000229983.1	RP11-15I11.2	4.01	8.18e-05	0.0266	0.26	0.25	Intelligence (childhood);	chr1:212218254	chr1:212168207~212190259:+
SARC	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-4.01	8.18e-05	0.0266	-0.3	-0.25	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
SARC	cis	rs394563	0.934	rs384334	ENSG00000231760.4	RP11-350J20.5	4.01	8.19e-05	0.0266	0.33	0.25	Dupuytren's disease;	chr6:149475036	chr6:149796151~149826294:-
SARC	cis	rs597539	0.552	rs6591360	ENSG00000250508.1	RP11-757G1.6	-4.01	8.19e-05	0.0266	-0.3	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68870664~68874542:+
SARC	cis	rs597539	0.552	rs6591361	ENSG00000250508.1	RP11-757G1.6	-4.01	8.19e-05	0.0266	-0.3	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68870664~68874542:+
SARC	cis	rs12702271	0.865	rs9655477	ENSG00000229628.1	AC073115.7	4.01	8.19e-05	0.0266	0.34	0.25	Male-pattern baldness;	chr7:46857313	chr7:45990905~46000898:+
SARC	cis	rs12702271	0.821	rs9655053	ENSG00000229628.1	AC073115.7	4.01	8.19e-05	0.0266	0.34	0.25	Male-pattern baldness;	chr7:46857509	chr7:45990905~46000898:+
SARC	cis	rs9907295	1	rs9907295	ENSG00000270240.2	AC015849.2	4.01	8.19e-05	0.0266	0.47	0.25	Fibroblast growth factor basic levels;	chr17:35930309	chr17:35868967~35885863:+
SARC	cis	rs7246657	0.943	rs8111782	ENSG00000226686.6	LINC01535	-4.01	8.19e-05	0.0266	-0.36	-0.25	Coronary artery calcification;	chr19:37377002	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs10404920	ENSG00000226686.6	LINC01535	-4.01	8.19e-05	0.0266	-0.36	-0.25	Coronary artery calcification;	chr19:37390654	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs10405325	ENSG00000226686.6	LINC01535	-4.01	8.19e-05	0.0266	-0.36	-0.25	Coronary artery calcification;	chr19:37392575	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs12981532	ENSG00000226686.6	LINC01535	-4.01	8.19e-05	0.0266	-0.36	-0.25	Coronary artery calcification;	chr19:37398378	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs7246993	ENSG00000226686.6	LINC01535	-4.01	8.19e-05	0.0266	-0.36	-0.25	Coronary artery calcification;	chr19:37399252	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs10413602	ENSG00000226686.6	LINC01535	-4.01	8.19e-05	0.0266	-0.36	-0.25	Coronary artery calcification;	chr19:37400590	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs10422074	ENSG00000226686.6	LINC01535	-4.01	8.19e-05	0.0266	-0.36	-0.25	Coronary artery calcification;	chr19:37403334	chr19:37251912~37265535:+
SARC	cis	rs6477918	0.598	rs34409309	ENSG00000250068.1	RP11-576C12.1	-4.01	8.2e-05	0.0266	-0.26	-0.25	Obstetric antiphospholipid syndrome;	chr9:112398426	chr9:112581779~112582590:-
SARC	cis	rs8028182	0.636	rs7171507	ENSG00000260206.1	CTD-2026K11.2	-4.01	8.21e-05	0.0266	-0.31	-0.25	Sudden cardiac arrest;	chr15:75444946	chr15:75636139~75639239:+
SARC	cis	rs7520050	0.667	rs11211176	ENSG00000280836.1	AL355480.1	4.01	8.21e-05	0.0266	0.24	0.25	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45581219~45581321:-
SARC	cis	rs11105298	0.891	rs10858852	ENSG00000258302.2	RP11-981P6.1	4.01	8.21e-05	0.0266	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs4842653	ENSG00000258302.2	RP11-981P6.1	4.01	8.21e-05	0.0266	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs4842654	ENSG00000258302.2	RP11-981P6.1	4.01	8.21e-05	0.0266	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.838	rs10858862	ENSG00000258302.2	RP11-981P6.1	4.01	8.21e-05	0.0266	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89561129~89594878:+
SARC	cis	rs2235544	0.565	rs665421	ENSG00000225183.1	RP4-758J24.4	4.01	8.21e-05	0.0266	0.28	0.25	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54004210	chr1:54089856~54090093:+
SARC	cis	rs848490	0.515	rs6973656	ENSG00000214293.7	APTR	-4.01	8.21e-05	0.0266	-0.27	-0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77793266	chr7:77657660~77696265:-
SARC	cis	rs897984	0.609	rs4889609	ENSG00000260911.2	RP11-196G11.2	4.01	8.21e-05	0.0266	0.25	0.25	Dementia with Lewy bodies;	chr16:31015106	chr16:31043150~31049868:+
SARC	cis	rs6845263	0.546	rs10018084	ENSG00000254531.1	FLJ20021	-4.01	8.21e-05	0.0266	-0.24	-0.25	Superior crus of antihelix expression;	chr4:101530682	chr4:101347780~101348883:+
SARC	cis	rs577676	0.586	rs639720	ENSG00000271811.1	RP1-79C4.4	4.01	8.22e-05	0.0266	0.36	0.25	Prevalent atrial fibrillation;	chr1:170643785	chr1:170667381~170669425:+
SARC	cis	rs7927592	0.731	rs2156463	ENSG00000212093.1	AP000807.1	4.01	8.22e-05	0.0266	0.24	0.25	Total body bone mineral density;	chr11:68618843	chr11:68506083~68506166:-
SARC	cis	rs72634501	0.716	rs72660086	ENSG00000182109.6	RP11-69E11.4	4.01	8.22e-05	0.0266	0.29	0.25	HDL cholesterol;	chr1:39106320	chr1:39522280~39546187:-
SARC	cis	rs2243480	0.522	rs73150635	ENSG00000273142.1	RP11-458F8.4	-4.01	8.22e-05	0.0267	-0.44	-0.25	Diabetic kidney disease;	chr7:66507503	chr7:66902857~66906297:+
SARC	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	4.01	8.22e-05	0.0267	0.32	0.25	Height;	chr6:109409679	chr6:109382795~109383666:+
SARC	cis	rs7267979	0.727	rs4815431	ENSG00000274414.1	RP5-965G21.4	4.01	8.23e-05	0.0267	0.26	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25239007~25245229:-
SARC	cis	rs9902453	0.868	rs9902340	ENSG00000264538.5	SUZ12P1	-4.01	8.23e-05	0.0267	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30149440	chr17:30709299~30790908:+
SARC	cis	rs7772486	0.743	rs9403742	ENSG00000235652.6	RP11-545I5.3	4.01	8.23e-05	0.0267	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145799409~145886585:+
SARC	cis	rs6969780	1	rs6969780	ENSG00000233429.8	HOTAIRM1	4.01	8.23e-05	0.0267	0.41	0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119517	chr7:27095647~27100265:+
SARC	cis	rs28386778	0.787	rs2665827	ENSG00000240280.5	TCAM1P	-4.01	8.24e-05	0.0267	-0.32	-0.25	Prudent dietary pattern;	chr17:63883990	chr17:63849292~63864379:+
SARC	cis	rs34375054	1	rs3751178	ENSG00000279233.1	RP11-158L12.4	-4.01	8.24e-05	0.0267	-0.29	-0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125179811	chr12:125138245~125141711:+
SARC	cis	rs11955398	0.502	rs162249	ENSG00000215032.2	GNL3LP1	4.01	8.25e-05	0.0267	0.27	0.25	Intelligence (multi-trait analysis);	chr5:60999753	chr5:60891935~60893577:-
SARC	cis	rs13434995	0.589	rs499110	ENSG00000273257.1	RP11-177J6.1	-4.01	8.25e-05	0.0267	-0.35	-0.25	Adiponectin levels;	chr4:55381628	chr4:55387949~55388271:+
SARC	cis	rs13434995	0.589	rs62306207	ENSG00000273257.1	RP11-177J6.1	-4.01	8.25e-05	0.0267	-0.35	-0.25	Adiponectin levels;	chr4:55384548	chr4:55387949~55388271:+
SARC	cis	rs6918586	0.658	rs198830	ENSG00000272462.2	U91328.19	-4.01	8.25e-05	0.0267	-0.23	-0.25	Schizophrenia;	chr6:26118018	chr6:25992662~26001775:+
SARC	cis	rs4835473	0.808	rs1984810	ENSG00000251600.4	RP11-673E1.1	4.01	8.25e-05	0.0267	0.25	0.25	Immature fraction of reticulocytes;	chr4:143824970	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs10857413	ENSG00000251600.4	RP11-673E1.1	4.01	8.25e-05	0.0267	0.25	0.25	Immature fraction of reticulocytes;	chr4:143827752	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs6828935	ENSG00000251600.4	RP11-673E1.1	4.01	8.25e-05	0.0267	0.25	0.25	Immature fraction of reticulocytes;	chr4:143829113	chr4:143912331~143982454:+
SARC	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-4.01	8.25e-05	0.0267	-0.28	-0.25	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
SARC	cis	rs2933343	0.7	rs1680778	ENSG00000231305.3	RP11-723O4.2	4.01	8.26e-05	0.0267	0.25	0.25	IgG glycosylation;	chr3:128895342	chr3:128861313~128871540:-
SARC	cis	rs860818	0.793	rs2091491	ENSG00000226816.2	AC005082.12	-4.01	8.26e-05	0.0267	-0.67	-0.25	Initial pursuit acceleration;	chr7:23153930	chr7:23206013~23208045:+
SARC	cis	rs7829975	0.582	rs11783950	ENSG00000253893.2	FAM85B	4.01	8.26e-05	0.0268	0.22	0.25	Mood instability;	chr8:8740321	chr8:8167819~8226614:-
SARC	cis	rs17360053	0.859	rs9700998	ENSG00000218510.5	LINC00339	-4.01	8.26e-05	0.0268	-0.27	-0.25	Obesity-related traits;	chr1:22180828	chr1:22025188~22031223:+
SARC	cis	rs7772486	0.686	rs6933161	ENSG00000235652.6	RP11-545I5.3	-4.01	8.26e-05	0.0268	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145799409~145886585:+
SARC	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-4.01	8.27e-05	0.0268	-0.28	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
SARC	cis	rs853679	1	rs735765	ENSG00000216901.1	AL022393.7	4.01	8.27e-05	0.0268	0.48	0.25	Depression;	chr6:28202519	chr6:28176188~28176674:+
SARC	cis	rs4664293	0.669	rs35299907	ENSG00000226266.5	AC009961.3	4.01	8.27e-05	0.0268	0.3	0.25	Monocyte percentage of white cells;	chr2:159562142	chr2:159670708~159712435:-
SARC	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	4.01	8.27e-05	0.0268	0.36	0.25	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
SARC	cis	rs10495285	1	rs10495285	ENSG00000213028.3	RP11-108F13.2	4.01	8.28e-05	0.0268	0.31	0.25	Response to cytadine analogues (cytosine arabinoside);	chr1:229669248	chr1:229688999~229689904:-
SARC	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-4.01	8.28e-05	0.0268	-0.23	-0.25	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-4.01	8.28e-05	0.0268	-0.23	-0.25	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
SARC	cis	rs950776	0.518	rs2292117	ENSG00000261762.1	RP11-650L12.2	4.01	8.28e-05	0.0268	0.27	0.25	Sudden cardiac arrest;	chr15:78542347	chr15:78589123~78591276:-
SARC	cis	rs2439831	0.85	rs12442297	ENSG00000275601.1	AC011330.13	-4.01	8.28e-05	0.0268	-0.45	-0.25	Lung cancer in ever smokers;	chr15:43876272	chr15:43642389~43643023:-
SARC	cis	rs7246657	0.943	rs7252325	ENSG00000226686.6	LINC01535	-4.01	8.28e-05	0.0268	-0.35	-0.25	Coronary artery calcification;	chr19:37439743	chr19:37251912~37265535:+
SARC	cis	rs8028182	0.636	rs11637586	ENSG00000260206.1	CTD-2026K11.2	-4.01	8.28e-05	0.0268	-0.31	-0.25	Sudden cardiac arrest;	chr15:75498771	chr15:75636139~75639239:+
SARC	cis	rs4148883	0.713	rs3828541	ENSG00000263923.1	RP11-571L19.7	-4.01	8.29e-05	0.0268	-0.26	-0.25	Alcohol dependence;	chr4:99121111	chr4:98928897~98994994:+
SARC	cis	rs9649213	0.574	rs7802541	ENSG00000272950.1	RP11-307C18.1	4.01	8.29e-05	0.0268	0.3	0.25	Prostate cancer (SNP x SNP interaction);	chr7:98304543	chr7:98322853~98323430:+
SARC	cis	rs783540	0.874	rs10468217	ENSG00000275695.1	UBE2Q2P6	-4.01	8.29e-05	0.0268	-0.25	-0.25	Schizophrenia;	chr15:82579329	chr15:82445719~82454837:+
SARC	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	4.01	8.29e-05	0.0268	0.25	0.25	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
SARC	cis	rs28386778	0.897	rs2727328	ENSG00000240280.5	TCAM1P	-4.01	8.29e-05	0.0268	-0.32	-0.25	Prudent dietary pattern;	chr17:63846204	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2665796	ENSG00000240280.5	TCAM1P	-4.01	8.29e-05	0.0268	-0.32	-0.25	Prudent dietary pattern;	chr17:63846356	chr17:63849292~63864379:+
SARC	cis	rs61160187	0.61	rs4700397	ENSG00000272308.1	RP11-231G3.1	4.01	8.3e-05	0.0268	0.22	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:60866457~60866935:-
SARC	cis	rs745109	0.882	rs72930336	ENSG00000273080.1	RP11-301O19.1	4.01	8.3e-05	0.0269	0.39	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86433304	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs78926831	ENSG00000273080.1	RP11-301O19.1	4.01	8.3e-05	0.0269	0.39	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86433537	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs74959393	ENSG00000273080.1	RP11-301O19.1	4.01	8.3e-05	0.0269	0.39	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86433692	chr2:86195590~86196049:+
SARC	cis	rs11822910	0.737	rs2729389	ENSG00000254589.1	EIF4A2P3	-4.01	8.3e-05	0.0269	-0.3	-0.25	Platelet distribution width;	chr11:57444173	chr11:58242043~58243097:-
SARC	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	4.01	8.3e-05	0.0269	0.23	0.25	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
SARC	cis	rs7246657	0.882	rs59224125	ENSG00000226686.6	LINC01535	-4.01	8.3e-05	0.0269	-0.35	-0.25	Coronary artery calcification;	chr19:37472303	chr19:37251912~37265535:+
SARC	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-4.01	8.3e-05	0.0269	-0.37	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
SARC	cis	rs6844153	0.713	rs11734308	ENSG00000240005.4	RP11-293A21.1	-4.01	8.31e-05	0.0269	-0.3	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26934877	chr4:26859806~26860599:-
SARC	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	4.01	8.31e-05	0.0269	0.25	0.25	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
SARC	cis	rs9739682	0.957	rs1444254	ENSG00000139239.7	RPL14P1	-4.01	8.31e-05	0.0269	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62095571	chr12:62965325~62965969:+
SARC	cis	rs2404602	0.716	rs67888330	ENSG00000259422.1	RP11-593F23.1	4.01	8.31e-05	0.0269	0.28	0.25	Blood metabolite levels;	chr15:76460142	chr15:76174891~76181486:-
SARC	cis	rs9902453	0.904	rs9900974	ENSG00000264538.5	SUZ12P1	-4.01	8.31e-05	0.0269	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30037438	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs4547389	ENSG00000264538.5	SUZ12P1	-4.01	8.31e-05	0.0269	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30037750	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs55633288	ENSG00000264538.5	SUZ12P1	-4.01	8.31e-05	0.0269	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30041178	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.874	rs7220004	ENSG00000264538.5	SUZ12P1	-4.01	8.31e-05	0.0269	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30042530	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs11654983	ENSG00000264538.5	SUZ12P1	-4.01	8.31e-05	0.0269	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30043024	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.845	rs7218113	ENSG00000264538.5	SUZ12P1	-4.01	8.31e-05	0.0269	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30045112	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs7219456	ENSG00000264538.5	SUZ12P1	-4.01	8.31e-05	0.0269	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30047094	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.874	rs11653805	ENSG00000264538.5	SUZ12P1	-4.01	8.31e-05	0.0269	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30051258	chr17:30709299~30790908:+
SARC	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-4.01	8.31e-05	0.0269	-0.33	-0.25	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
SARC	cis	rs7246657	0.653	rs10402050	ENSG00000226686.6	LINC01535	-4.01	8.32e-05	0.0269	-0.4	-0.25	Coronary artery calcification;	chr19:37198056	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.653	rs10406612	ENSG00000226686.6	LINC01535	-4.01	8.32e-05	0.0269	-0.4	-0.25	Coronary artery calcification;	chr19:37225709	chr19:37251912~37265535:+
SARC	cis	rs11079159	0.637	rs7218159	ENSG00000262052.1	RP11-763E3.1	4.01	8.33e-05	0.0269	0.35	0.25	QRS duration;	chr17:55277434	chr17:55842677~55872939:-
SARC	cis	rs1466921	0.822	rs2654229	ENSG00000259707.1	RP11-752G15.4	-4.01	8.33e-05	0.0269	-0.39	-0.25	Left superior temporal gyrus thickness (schizophrenia interaction);	chr15:82087617	chr15:82691723~82692358:-
SARC	cis	rs495337	0.76	rs6125825	ENSG00000229222.1	KRT18P4	-4.01	8.33e-05	0.0269	-0.32	-0.25	Psoriasis;	chr20:49937166	chr20:49956745~49958032:+
SARC	cis	rs12893668	0.581	rs34843146	ENSG00000269958.1	RP11-73M18.8	4.01	8.33e-05	0.0269	0.28	0.25	Reticulocyte count;	chr14:103613527	chr14:103696353~103697163:+
SARC	cis	rs4934494	0.681	rs1129777	ENSG00000240996.1	RP11-80H5.7	-4.01	8.33e-05	0.0269	-0.28	-0.25	Red blood cell count;	chr10:89709168	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.727	rs3824607	ENSG00000240996.1	RP11-80H5.7	-4.01	8.33e-05	0.0269	-0.28	-0.25	Red blood cell count;	chr10:89711258	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.681	rs3740035	ENSG00000240996.1	RP11-80H5.7	-4.01	8.33e-05	0.0269	-0.28	-0.25	Red blood cell count;	chr10:89716708	chr10:89694295~89697928:-
SARC	cis	rs4934494	0.681	rs34591435	ENSG00000240996.1	RP11-80H5.7	-4.01	8.33e-05	0.0269	-0.28	-0.25	Red blood cell count;	chr10:89721691	chr10:89694295~89697928:-
SARC	cis	rs526231	0.764	rs372564	ENSG00000175749.11	EIF3KP1	4.01	8.33e-05	0.0269	0.3	0.25	Primary biliary cholangitis;	chr5:103314823	chr5:103032376~103033031:+
SARC	cis	rs79349575	0.756	rs937301	ENSG00000270781.1	RP11-501C14.9	4.01	8.33e-05	0.0269	0.29	0.25	Type 2 diabetes;	chr17:48968914	chr17:48899131~48899748:+
SARC	cis	rs495337	0.76	rs6067282	ENSG00000229222.1	KRT18P4	-4.01	8.33e-05	0.0269	-0.33	-0.25	Psoriasis;	chr20:49952741	chr20:49956745~49958032:+
SARC	cis	rs7216064	1	rs12602655	ENSG00000237854.3	LINC00674	4.01	8.33e-05	0.0269	0.32	0.25	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67913326	chr17:68101908~68115518:+
SARC	cis	rs8064029	0.881	rs72633271	ENSG00000267077.1	RP11-127I20.5	4.01	8.33e-05	0.0269	0.45	0.25	Cancer;	chr16:4853320	chr16:4795265~4796532:-
SARC	cis	rs8064029	1	rs72633272	ENSG00000267077.1	RP11-127I20.5	4.01	8.33e-05	0.0269	0.45	0.25	Cancer;	chr16:4853535	chr16:4795265~4796532:-
SARC	cis	rs6918586	0.658	rs198829	ENSG00000272462.2	U91328.19	-4.01	8.33e-05	0.0269	-0.23	-0.25	Schizophrenia;	chr6:26118665	chr6:25992662~26001775:+
SARC	cis	rs6918586	0.658	rs198828	ENSG00000272462.2	U91328.19	-4.01	8.33e-05	0.0269	-0.23	-0.25	Schizophrenia;	chr6:26119231	chr6:25992662~26001775:+
SARC	cis	rs3805389	0.504	rs17725163	ENSG00000273257.1	RP11-177J6.1	4	8.35e-05	0.027	0.39	0.25	Waist-to-hip ratio adjusted for body mass index;	chr4:55609280	chr4:55387949~55388271:+
SARC	cis	rs6142102	0.517	rs6142050	ENSG00000275784.1	RP5-1125A11.6	-4	8.35e-05	0.027	-0.3	-0.25	Skin pigmentation;	chr20:33939322	chr20:33989480~33991818:-
SARC	cis	rs9309473	0.607	rs1403412	ENSG00000163016.8	ALMS1P	4	8.35e-05	0.027	0.31	0.25	Metabolite levels;	chr2:73370964	chr2:73644919~73685576:+
SARC	cis	rs10895987	1	rs12280510	ENSG00000254614.2	AP003068.23	4	8.35e-05	0.027	0.37	0.25	Blood protein levels;	chr11:65147076	chr11:65177606~65181834:-
SARC	cis	rs79349575	0.756	rs3848460	ENSG00000270781.1	RP11-501C14.9	4	8.35e-05	0.027	0.29	0.25	Type 2 diabetes;	chr17:48969752	chr17:48899131~48899748:+
SARC	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	4	8.35e-05	0.027	0.24	0.25	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
SARC	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	4	8.35e-05	0.027	0.24	0.25	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
SARC	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	4	8.35e-05	0.027	0.24	0.25	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
SARC	cis	rs6142102	0.517	rs6059577	ENSG00000275784.1	RP5-1125A11.6	-4	8.35e-05	0.027	-0.3	-0.25	Skin pigmentation;	chr20:33939880	chr20:33989480~33991818:-
SARC	cis	rs812925	0.515	rs1177308	ENSG00000271889.1	RP11-493E12.1	4	8.36e-05	0.027	0.23	0.25	Immature fraction of reticulocytes;	chr2:61160119	chr2:61151433~61162105:-
SARC	cis	rs1023500	0.551	rs133355	ENSG00000205702.9	CYP2D7	4	8.36e-05	0.027	0.2	0.25	Schizophrenia;	chr22:42044281	chr22:42140203~42144577:-
SARC	cis	rs4713118	0.588	rs200994	ENSG00000216901.1	AL022393.7	-4	8.37e-05	0.027	-0.36	-0.25	Parkinson's disease;	chr6:27846035	chr6:28176188~28176674:+
SARC	cis	rs7246657	0.943	rs10420754	ENSG00000226686.6	LINC01535	-4	8.37e-05	0.027	-0.35	-0.25	Coronary artery calcification;	chr19:37468470	chr19:37251912~37265535:+
SARC	cis	rs526231	0.67	rs444779	ENSG00000175749.11	EIF3KP1	4	8.37e-05	0.0271	0.3	0.25	Primary biliary cholangitis;	chr5:103288460	chr5:103032376~103033031:+
SARC	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	4	8.38e-05	0.0271	0.39	0.25	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
SARC	cis	rs718433	0.599	rs1014478	ENSG00000199436.1	SNORD9	-4	8.38e-05	0.0271	-0.29	-0.25	Intraocular pressure;	chr14:21849523	chr14:21392150~21392253:-
SARC	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	4	8.38e-05	0.0271	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	4	8.38e-05	0.0271	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs857883	ENSG00000235652.6	RP11-545I5.3	-4	8.38e-05	0.0271	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs857882	ENSG00000235652.6	RP11-545I5.3	-4	8.38e-05	0.0271	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs857877	ENSG00000235652.6	RP11-545I5.3	-4	8.38e-05	0.0271	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145799409~145886585:+
SARC	cis	rs2439831	0.867	rs2245715	ENSG00000275601.1	AC011330.13	-4	8.38e-05	0.0271	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43525854	chr15:43642389~43643023:-
SARC	cis	rs6540731	0.967	rs4951581	ENSG00000229983.1	RP11-15I11.2	4	8.39e-05	0.0271	0.25	0.25	Intelligence (childhood);	chr1:212228770	chr1:212168207~212190259:+
SARC	cis	rs8098244	0.52	rs8094549	ENSG00000265752.2	RP11-403A21.1	-4	8.39e-05	0.0271	-0.28	-0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23992176	chr18:23957754~23982556:-
SARC	cis	rs8028182	0.537	rs4371118	ENSG00000260206.1	CTD-2026K11.2	-4	8.39e-05	0.0271	-0.3	-0.25	Sudden cardiac arrest;	chr15:75606549	chr15:75636139~75639239:+
SARC	cis	rs7031325	0.925	rs2578284	ENSG00000229611.1	RP11-390F4.10	-4	8.39e-05	0.0271	-0.28	-0.25	Systemic lupus erythematosus;	chr9:6651552	chr9:6704471~6707780:+
SARC	cis	rs2562456	0.834	rs2173727	ENSG00000268658.4	LINC00664	-4	8.39e-05	0.0271	-0.35	-0.25	Pain;	chr19:21491155	chr19:21483374~21503238:+
SARC	cis	rs858239	0.601	rs6948469	ENSG00000226816.2	AC005082.12	4	8.4e-05	0.0271	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23206013~23208045:+
SARC	cis	rs7216064	1	rs12600941	ENSG00000237854.3	LINC00674	4	8.4e-05	0.0271	0.32	0.25	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67922691	chr17:68101908~68115518:+
SARC	cis	rs7216064	1	rs62085992	ENSG00000237854.3	LINC00674	4	8.4e-05	0.0271	0.32	0.25	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67926967	chr17:68101908~68115518:+
SARC	cis	rs7216064	1	rs12451721	ENSG00000237854.3	LINC00674	4	8.4e-05	0.0271	0.32	0.25	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67942959	chr17:68101908~68115518:+
SARC	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-4	8.4e-05	0.0271	-0.26	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
SARC	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-4	8.4e-05	0.0271	-0.26	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
SARC	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-4	8.4e-05	0.0271	-0.26	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
SARC	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-4	8.4e-05	0.0271	-0.26	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
SARC	cis	rs12893668	0.637	rs12892038	ENSG00000269958.1	RP11-73M18.8	4	8.4e-05	0.0271	0.28	0.25	Reticulocyte count;	chr14:103602292	chr14:103696353~103697163:+
SARC	cis	rs12893668	0.637	rs4525427	ENSG00000269958.1	RP11-73M18.8	4	8.4e-05	0.0271	0.28	0.25	Reticulocyte count;	chr14:103606456	chr14:103696353~103697163:+
SARC	cis	rs7308116	0.645	rs10861834	ENSG00000240441.1	RP11-864J10.2	-4	8.4e-05	0.0271	-0.29	-0.25	Pelvic organ prolapse (moderate/severe);	chr12:107903134	chr12:107719599~107720133:+
SARC	cis	rs875971	0.508	rs10242423	ENSG00000224316.1	RP11-479O9.2	-4	8.4e-05	0.0271	-0.23	-0.25	Aortic root size;	chr7:66594188	chr7:65773620~65802067:+
SARC	cis	rs875971	0.508	rs10253883	ENSG00000224316.1	RP11-479O9.2	-4	8.4e-05	0.0271	-0.23	-0.25	Aortic root size;	chr7:66596151	chr7:65773620~65802067:+
SARC	cis	rs28386778	0.897	rs3744293	ENSG00000240280.5	TCAM1P	-4	8.41e-05	0.0271	-0.32	-0.25	Prudent dietary pattern;	chr17:63764428	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs6504184	ENSG00000240280.5	TCAM1P	-4	8.41e-05	0.0271	-0.32	-0.25	Prudent dietary pattern;	chr17:63765048	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs8081454	ENSG00000240280.5	TCAM1P	-4	8.41e-05	0.0271	-0.32	-0.25	Prudent dietary pattern;	chr17:63765286	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.863	rs58269663	ENSG00000240280.5	TCAM1P	-4	8.41e-05	0.0271	-0.32	-0.25	Prudent dietary pattern;	chr17:63765770	chr17:63849292~63864379:+
SARC	cis	rs7617773	0.78	rs35297395	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48301392	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs36075665	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48301597	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs34630841	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48301771	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs35190747	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48301800	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.743	rs7621785	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48302218	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs4511915	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48302368	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs13066758	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48302387	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs4392440	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48302430	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs13082859	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48303185	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs36121690	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48304021	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs35778847	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48305495	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs34749846	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48305678	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs7632297	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48306673	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs79089926	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48307074	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs77044321	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48307824	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs4511916	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48308876	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.815	rs7624450	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48308885	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.815	rs6793150	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48310070	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs6793239	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48310128	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs6782166	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48310193	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs4130522	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48310823	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.746	rs4371540	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48312053	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.674	rs13069029	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48313534	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs13081169	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48315307	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.743	rs13081633	ENSG00000228638.1	FCF1P2	-4	8.41e-05	0.0271	-0.3	-0.25	Coronary artery disease;	chr3:48315791	chr3:48290793~48291375:-
SARC	cis	rs4664293	1	rs4665083	ENSG00000226266.5	AC009961.3	4	8.41e-05	0.0271	0.3	0.25	Monocyte percentage of white cells;	chr2:159573616	chr2:159670708~159712435:-
SARC	cis	rs9309711	0.772	rs9752251	ENSG00000225234.1	TRAPPC12-AS1	-4	8.41e-05	0.0271	-0.27	-0.25	Neurofibrillary tangles;	chr2:3486098	chr2:3481242~3482409:-
SARC	cis	rs6142102	0.625	rs1883706	ENSG00000275784.1	RP5-1125A11.6	-4	8.41e-05	0.0271	-0.29	-0.25	Skin pigmentation;	chr20:33965071	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.625	rs1883705	ENSG00000275784.1	RP5-1125A11.6	-4	8.41e-05	0.0271	-0.29	-0.25	Skin pigmentation;	chr20:33965072	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.625	rs4012234	ENSG00000275784.1	RP5-1125A11.6	-4	8.41e-05	0.0271	-0.29	-0.25	Skin pigmentation;	chr20:33965241	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.649	rs4911382	ENSG00000275784.1	RP5-1125A11.6	-4	8.41e-05	0.0271	-0.29	-0.25	Skin pigmentation;	chr20:33965289	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.625	rs6141436	ENSG00000275784.1	RP5-1125A11.6	-4	8.41e-05	0.0271	-0.29	-0.25	Skin pigmentation;	chr20:33966765	chr20:33989480~33991818:-
SARC	cis	rs11123170	0.542	rs28522253	ENSG00000274877.1	RP11-65I12.1	-4	8.42e-05	0.0271	-0.34	-0.25	Renal function-related traits (BUN);	chr2:113209810	chr2:113237595~113240825:+
SARC	cis	rs713477	1	rs4901562	ENSG00000258413.1	RP11-665C16.6	4	8.42e-05	0.0272	0.28	0.25	Pediatric bone mineral content (femoral neck);	chr14:55434655	chr14:55262767~55272075:-
SARC	cis	rs7215564	0.73	rs1125587	ENSG00000262313.1	CTD-2561B21.4	4	8.43e-05	0.0272	0.3	0.25	Myopia (pathological);	chr17:80607896	chr17:80940418~80942033:-
SARC	cis	rs9868809	0.505	rs11719291	ENSG00000225399.4	RP11-3B7.1	-4	8.43e-05	0.0272	-0.43	-0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48698273	chr3:49260085~49261316:+
SARC	cis	rs910316	0.967	rs175505	ENSG00000279594.1	RP11-950C14.10	-4	8.43e-05	0.0272	-0.28	-0.25	Height;	chr14:75062916	chr14:75011269~75012851:-
SARC	cis	rs453301	0.686	rs13252797	ENSG00000253893.2	FAM85B	-4	8.44e-05	0.0272	-0.22	-0.25	Joint mobility (Beighton score);	chr8:9003920	chr8:8167819~8226614:-
SARC	cis	rs4835473	0.637	rs2323201	ENSG00000251600.4	RP11-673E1.1	4	8.44e-05	0.0272	0.24	0.25	Immature fraction of reticulocytes;	chr4:143765629	chr4:143912331~143982454:+
SARC	cis	rs2836974	0.8	rs73221174	ENSG00000255568.3	BRWD1-AS2	4	8.44e-05	0.0272	0.25	0.25	Cognitive function;	chr21:39169013	chr21:39313935~39314962:+
SARC	cis	rs3824347	0.804	rs2146047	ENSG00000203321.2	C9orf41-AS1	-4	8.44e-05	0.0272	-0.27	-0.25	Urinary magnesium-to-creatinine ratio;	chr9:75034239	chr9:74952968~74996293:+
SARC	cis	rs12817211	0.549	rs7972465	ENSG00000272368.2	RP4-605O3.4	4	8.45e-05	0.0272	0.24	0.25	Colorectal or endometrial cancer;	chr12:50152342	chr12:50112197~50165618:+
SARC	cis	rs1943345	0.556	rs523414	ENSG00000254551.1	RP11-727A23.7	4	8.45e-05	0.0272	0.27	0.25	Obesity-related traits;	chr11:83199624	chr11:83209431~83213379:-
SARC	cis	rs4950322	0.58	rs2083720	ENSG00000278811.3	LINC00624	4	8.46e-05	0.0273	0.27	0.25	Protein quantitative trait loci;	chr1:147122296	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.58	rs72706441	ENSG00000278811.3	LINC00624	4	8.46e-05	0.0273	0.27	0.25	Protein quantitative trait loci;	chr1:147122601	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.547	rs17355509	ENSG00000278811.3	LINC00624	4	8.46e-05	0.0273	0.27	0.25	Protein quantitative trait loci;	chr1:147123139	chr1:147258885~147517875:-
SARC	cis	rs6142102	0.502	rs58393429	ENSG00000275784.1	RP5-1125A11.6	-4	8.47e-05	0.0273	-0.29	-0.25	Skin pigmentation;	chr20:33957996	chr20:33989480~33991818:-
SARC	cis	rs11955398	0.522	rs34643	ENSG00000272308.1	RP11-231G3.1	-4	8.47e-05	0.0273	-0.24	-0.25	Intelligence (multi-trait analysis);	chr5:61048750	chr5:60866457~60866935:-
SARC	cis	rs4934494	0.727	rs12783845	ENSG00000240996.1	RP11-80H5.7	-4	8.48e-05	0.0273	-0.28	-0.25	Red blood cell count;	chr10:89722872	chr10:89694295~89697928:-
SARC	cis	rs4842666	0.85	rs11105328	ENSG00000258302.2	RP11-981P6.1	4	8.48e-05	0.0273	0.31	0.25	Blood pressure;	chr12:89548613	chr12:89561129~89594878:+
SARC	cis	rs12200782	0.858	rs72836448	ENSG00000272462.2	U91328.19	-4	8.48e-05	0.0273	-0.41	-0.25	Small cell lung carcinoma;	chr6:26342842	chr6:25992662~26001775:+
SARC	cis	rs8100891	0.922	rs7255223	ENSG00000267213.4	AC007773.2	4	8.48e-05	0.0273	0.3	0.25	Neuroticism;	chr19:32333404	chr19:32390050~32405560:-
SARC	cis	rs7918232	0.627	rs10829165	ENSG00000262412.1	RP11-85G18.6	4	8.49e-05	0.0273	0.27	0.25	Breast cancer;	chr10:27030536	chr10:27243130~27250804:+
SARC	cis	rs4713118	0.512	rs2622319	ENSG00000272009.1	RP1-313I6.12	-4	8.49e-05	0.0274	-0.29	-0.25	Parkinson's disease;	chr6:28152623	chr6:28078792~28081130:-
SARC	cis	rs9876781	1	rs9838618	ENSG00000244380.1	RP11-24C3.2	4	8.5e-05	0.0274	0.27	0.25	Longevity;	chr3:48445949	chr3:48440352~48446656:-
SARC	cis	rs4679904	0.883	rs73875285	ENSG00000243116.1	RP11-564C24.1	4	8.5e-05	0.0274	0.26	0.25	Primary biliary cholangitis;	chr3:160495498	chr3:159721524~159722401:-
SARC	cis	rs4883201	0.611	rs1805727	ENSG00000257027.1	RP11-705C15.3	4	8.5e-05	0.0274	0.38	0.25	Total cholesterol levels;Cholesterol, total;	chr12:8944802	chr12:9658567~9662085:+
SARC	cis	rs5751614	0.517	rs928780	ENSG00000230701.2	FBXW4P1	4	8.5e-05	0.0274	0.33	0.25	Height;	chr22:23257682	chr22:23262767~23265005:+
SARC	cis	rs6591341	0.515	rs599301	ENSG00000212093.1	AP000807.1	4	8.5e-05	0.0274	0.24	0.25	Lean body mass;	chr11:68422477	chr11:68506083~68506166:-
SARC	cis	rs412050	0.547	rs79111189	ENSG00000224086.5	LL22NC03-86G7.1	-4	8.5e-05	0.0274	-0.37	-0.25	Attention deficit hyperactivity disorder;	chr22:21810308	chr22:21938293~21977632:+
SARC	cis	rs4372836	0.541	rs6710080	ENSG00000226833.4	AC097724.3	4	8.51e-05	0.0274	0.23	0.25	Body mass index;	chr2:28767109	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.505	rs6710082	ENSG00000226833.4	AC097724.3	4	8.51e-05	0.0274	0.23	0.25	Body mass index;	chr2:28767111	chr2:28708953~28736205:-
SARC	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	4	8.51e-05	0.0274	0.38	0.25	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
SARC	cis	rs2274273	0.662	rs67588230	ENSG00000258413.1	RP11-665C16.6	-4	8.51e-05	0.0274	-0.35	-0.25	Protein biomarker;	chr14:55200312	chr14:55262767~55272075:-
SARC	cis	rs7811142	1	rs68116612	ENSG00000078319.8	PMS2P1	-4	8.51e-05	0.0274	-0.36	-0.25	Platelet count;	chr7:100408870	chr7:100320992~100341908:-
SARC	cis	rs4919687	0.679	rs12762176	ENSG00000213061.2	PFN1P11	4	8.51e-05	0.0274	0.32	0.25	Colorectal cancer;	chr10:102739475	chr10:102838011~102845473:-
SARC	cis	rs7512898	0.522	rs7520287	ENSG00000260088.1	RP11-92G12.3	-4	8.52e-05	0.0274	-0.28	-0.25	Electrocardiographic conduction measures;	chr1:200781448	chr1:200669507~200694250:+
SARC	cis	rs4835473	0.932	rs2323190	ENSG00000251600.4	RP11-673E1.1	-4	8.52e-05	0.0274	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143744282	chr4:143912331~143982454:+
SARC	cis	rs6142102	0.602	rs6141435	ENSG00000275784.1	RP5-1125A11.6	-4	8.52e-05	0.0274	-0.29	-0.25	Skin pigmentation;	chr20:33963473	chr20:33989480~33991818:-
SARC	cis	rs7772486	0.686	rs857880	ENSG00000235652.6	RP11-545I5.3	-4	8.52e-05	0.0274	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145799409~145886585:+
SARC	cis	rs2274273	0.661	rs2147964	ENSG00000258413.1	RP11-665C16.6	-4	8.52e-05	0.0274	-0.29	-0.25	Protein biomarker;	chr14:55097677	chr14:55262767~55272075:-
SARC	cis	rs858239	0.899	rs7794684	ENSG00000226816.2	AC005082.12	4	8.53e-05	0.0275	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23206013~23208045:+
SARC	cis	rs593531	0.513	rs479968	ENSG00000280269.1	AP000577.2	4	8.53e-05	0.0275	0.32	0.25	Neuroticism;	chr11:74327229	chr11:74204869~74205746:+
SARC	cis	rs11159086	1	rs3759745	ENSG00000270000.1	RP3-449M8.9	4	8.54e-05	0.0275	0.38	0.25	Advanced glycation end-product levels;	chr14:74495967	chr14:74471930~74472360:-
SARC	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-4	8.54e-05	0.0275	-0.31	-0.25	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
SARC	cis	rs7267979	0.649	rs2500406	ENSG00000125804.12	FAM182A	4	8.54e-05	0.0275	0.3	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25421226	chr20:26054655~26086917:+
SARC	cis	rs28386778	0.897	rs9906247	ENSG00000240280.5	TCAM1P	-4	8.55e-05	0.0275	-0.32	-0.25	Prudent dietary pattern;	chr17:63779954	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs7221853	ENSG00000240280.5	TCAM1P	-4	8.55e-05	0.0275	-0.32	-0.25	Prudent dietary pattern;	chr17:63782476	chr17:63849292~63864379:+
SARC	cis	rs7246657	0.882	rs10422667	ENSG00000226686.6	LINC01535	-4	8.55e-05	0.0275	-0.36	-0.25	Coronary artery calcification;	chr19:37446974	chr19:37251912~37265535:+
SARC	cis	rs9868809	0.772	rs9841602	ENSG00000225399.4	RP11-3B7.1	-4	8.55e-05	0.0275	-0.44	-0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48676137	chr3:49260085~49261316:+
SARC	cis	rs7829975	0.511	rs2976906	ENSG00000253981.4	ALG1L13P	4	8.55e-05	0.0275	0.24	0.25	Mood instability;	chr8:8484905	chr8:8236003~8244667:-
SARC	cis	rs710865	0.527	rs2275403	ENSG00000230424.1	RP1-43E13.2	4	8.55e-05	0.0275	0.31	0.25	Brain structure;	chr1:19231219	chr1:19210501~19240704:+
SARC	cis	rs7267979	0.816	rs405822	ENSG00000274414.1	RP5-965G21.4	-4	8.56e-05	0.0275	-0.26	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:25239007~25245229:-
SARC	cis	rs7267979	0.816	rs6138593	ENSG00000274414.1	RP5-965G21.4	-4	8.56e-05	0.0275	-0.26	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:25239007~25245229:-
SARC	cis	rs7267979	0.816	rs409853	ENSG00000274414.1	RP5-965G21.4	-4	8.56e-05	0.0275	-0.26	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:25239007~25245229:-
SARC	cis	rs12950390	0.82	rs58391889	ENSG00000239291.1	RP5-867C24.1	4	8.56e-05	0.0275	0.3	0.25	IgG glycosylation;	chr17:47788593	chr17:47159191~47159993:-
SARC	cis	rs5758659	1	rs5758660	ENSG00000270083.1	RP1-257I20.14	4	8.56e-05	0.0275	0.25	0.25	Cognitive function;	chr22:42227712	chr22:42089630~42090028:-
SARC	cis	rs4883201	0.572	rs1805735	ENSG00000257027.1	RP11-705C15.3	-4	8.56e-05	0.0275	-0.39	-0.25	Total cholesterol levels;Cholesterol, total;	chr12:8934087	chr12:9658567~9662085:+
SARC	cis	rs1062177	1	rs1062177	ENSG00000254226.4	CTB-12O2.1	4	8.56e-05	0.0275	0.34	0.25	Preschool internalizing problems;	chr5:151805140	chr5:151949571~152270448:+
SARC	cis	rs7204230	1	rs62049768	ENSG00000261291.1	RP11-295M3.2	4	8.56e-05	0.0275	0.29	0.25	Fibrinogen;	chr16:53234511	chr16:53168522~53169450:+
SARC	cis	rs6918586	0.636	rs198857	ENSG00000272462.2	U91328.19	-4	8.56e-05	0.0275	-0.23	-0.25	Schizophrenia;	chr6:26102189	chr6:25992662~26001775:+
SARC	cis	rs6918586	0.658	rs198856	ENSG00000272462.2	U91328.19	-4	8.56e-05	0.0275	-0.23	-0.25	Schizophrenia;	chr6:26102480	chr6:25992662~26001775:+
SARC	cis	rs6918586	0.658	rs198854	ENSG00000272462.2	U91328.19	-4	8.56e-05	0.0275	-0.23	-0.25	Schizophrenia;	chr6:26103829	chr6:25992662~26001775:+
SARC	cis	rs12611334	0.893	rs7257941	ENSG00000226025.8	LGALS17A	4	8.57e-05	0.0275	0.25	0.25	Schizophrenia;	chr19:39725653	chr19:39679374~39686373:+
SARC	cis	rs7809615	0.748	rs10265385	ENSG00000237640.1	RP4-604G5.1	-4	8.57e-05	0.0276	-0.45	-0.25	Blood metabolite ratios;	chr7:99565064	chr7:99929392~99948620:+
SARC	cis	rs6477918	0.598	rs10817345	ENSG00000250068.1	RP11-576C12.1	-4	8.58e-05	0.0276	-0.27	-0.25	Obstetric antiphospholipid syndrome;	chr9:112447028	chr9:112581779~112582590:-
SARC	cis	rs59104589	0.617	rs3771566	ENSG00000266621.1	AC104841.1	4	8.58e-05	0.0276	0.35	0.25	Fibrinogen levels;	chr2:241418884	chr2:241245202~241245299:-
SARC	cis	rs160451	0.782	rs218892	ENSG00000251136.7	RP11-37B2.1	4	8.59e-05	0.0276	0.31	0.25	Leprosy;	chr8:89685582	chr8:89609409~89757727:-
SARC	cis	rs12458462	0.509	rs3786241	ENSG00000274828.1	RP11-567M16.6	4	8.59e-05	0.0276	0.23	0.25	Monocyte count;	chr18:79734328	chr18:79677287~79679358:-
SARC	cis	rs2439831	0.867	rs2255440	ENSG00000275601.1	AC011330.13	-4	8.59e-05	0.0276	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43538269	chr15:43642389~43643023:-
SARC	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	4	8.6e-05	0.0276	0.37	0.25	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
SARC	cis	rs7267979	0.816	rs404775	ENSG00000274414.1	RP5-965G21.4	-4	8.6e-05	0.0276	-0.26	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:25239007~25245229:-
SARC	cis	rs72627509	0.951	rs72606404	ENSG00000269949.1	RP11-738E22.3	4	8.6e-05	0.0276	0.39	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56975047	chr4:56960927~56961373:-
SARC	cis	rs172166	0.694	rs2791332	ENSG00000272009.1	RP1-313I6.12	-4	8.6e-05	0.0276	-0.29	-0.25	Cardiac Troponin-T levels;	chr6:28141010	chr6:28078792~28081130:-
SARC	cis	rs12817211	0.502	rs7307230	ENSG00000272368.2	RP4-605O3.4	4	8.6e-05	0.0276	0.24	0.25	Colorectal or endometrial cancer;	chr12:50118849	chr12:50112197~50165618:+
SARC	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-4	8.61e-05	0.0276	-0.34	-0.25	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
SARC	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	4	8.61e-05	0.0276	0.36	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
SARC	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	4	8.61e-05	0.0276	0.36	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
SARC	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	4	8.61e-05	0.0276	0.36	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
SARC	cis	rs1707322	0.964	rs10890358	ENSG00000281133.1	AL355480.3	-4	8.61e-05	0.0276	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs7547189	ENSG00000281133.1	AL355480.3	-4	8.61e-05	0.0276	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs7547284	ENSG00000281133.1	AL355480.3	-4	8.61e-05	0.0276	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs11211205	ENSG00000281133.1	AL355480.3	-4	8.61e-05	0.0276	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs6675222	ENSG00000281133.1	AL355480.3	-4	8.61e-05	0.0276	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4660895	ENSG00000281133.1	AL355480.3	-4	8.61e-05	0.0276	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs7531911	ENSG00000281133.1	AL355480.3	-4	8.61e-05	0.0276	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4660318	ENSG00000281133.1	AL355480.3	-4	8.61e-05	0.0276	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs10890359	ENSG00000281133.1	AL355480.3	-4	8.61e-05	0.0276	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs10890360	ENSG00000281133.1	AL355480.3	-4	8.61e-05	0.0276	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45580892~45580996:-
SARC	cis	rs11955398	0.502	rs10471502	ENSG00000272308.1	RP11-231G3.1	-4	8.62e-05	0.0277	-0.23	-0.25	Intelligence (multi-trait analysis);	chr5:61073256	chr5:60866457~60866935:-
SARC	cis	rs9309473	0.519	rs4852950	ENSG00000163016.8	ALMS1P	-4	8.62e-05	0.0277	-0.29	-0.25	Metabolite levels;	chr2:73637543	chr2:73644919~73685576:+
SARC	cis	rs8014067	1	rs4902100	ENSG00000258926.1	RP11-47I22.1	4	8.63e-05	0.0277	0.27	0.25	Hepatitis;	chr14:62083101	chr14:61537508~61545287:-
SARC	cis	rs2404602	0.716	rs17363713	ENSG00000259422.1	RP11-593F23.1	4	8.63e-05	0.0277	0.28	0.25	Blood metabolite levels;	chr15:76453787	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.692	rs2117369	ENSG00000259422.1	RP11-593F23.1	4	8.63e-05	0.0277	0.28	0.25	Blood metabolite levels;	chr15:76456520	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.716	rs2164101	ENSG00000259422.1	RP11-593F23.1	4	8.63e-05	0.0277	0.28	0.25	Blood metabolite levels;	chr15:76456776	chr15:76174891~76181486:-
SARC	cis	rs7246657	0.943	rs2303131	ENSG00000226686.6	LINC01535	-4	8.63e-05	0.0277	-0.36	-0.25	Coronary artery calcification;	chr19:37445123	chr19:37251912~37265535:+
SARC	cis	rs17508449	0.819	rs74524050	ENSG00000232450.1	RP4-730K3.3	-4	8.63e-05	0.0277	-0.33	-0.25	Leprosy;	chr1:113688585	chr1:113698884~113699631:-
SARC	cis	rs12893668	0.663	rs12889731	ENSG00000269958.1	RP11-73M18.8	4	8.64e-05	0.0277	0.28	0.25	Reticulocyte count;	chr14:103621145	chr14:103696353~103697163:+
SARC	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	4	8.64e-05	0.0277	0.32	0.25	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
SARC	cis	rs4679904	1	rs4679904	ENSG00000243116.1	RP11-564C24.1	4	8.64e-05	0.0277	0.27	0.25	Primary biliary cholangitis;	chr3:160623108	chr3:159721524~159722401:-
SARC	cis	rs4679904	1	rs12632274	ENSG00000243116.1	RP11-564C24.1	4	8.64e-05	0.0277	0.27	0.25	Primary biliary cholangitis;	chr3:160625493	chr3:159721524~159722401:-
SARC	cis	rs4679904	1	rs1920638	ENSG00000243116.1	RP11-564C24.1	4	8.64e-05	0.0277	0.27	0.25	Primary biliary cholangitis;	chr3:160627381	chr3:159721524~159722401:-
SARC	cis	rs1707322	1	rs785498	ENSG00000281133.1	AL355480.3	4	8.65e-05	0.0277	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45580892~45580996:-
SARC	cis	rs28386778	0.897	rs2727320	ENSG00000240280.5	TCAM1P	-4	8.65e-05	0.0277	-0.32	-0.25	Prudent dietary pattern;	chr17:63787965	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2584635	ENSG00000240280.5	TCAM1P	-4	8.65e-05	0.0277	-0.32	-0.25	Prudent dietary pattern;	chr17:63788574	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs9915552	ENSG00000240280.5	TCAM1P	-4	8.65e-05	0.0277	-0.32	-0.25	Prudent dietary pattern;	chr17:63791735	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2665844	ENSG00000240280.5	TCAM1P	-4	8.65e-05	0.0277	-0.32	-0.25	Prudent dietary pattern;	chr17:63797095	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.83	rs2597637	ENSG00000240280.5	TCAM1P	-4	8.65e-05	0.0277	-0.32	-0.25	Prudent dietary pattern;	chr17:63797706	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.83	rs2597636	ENSG00000240280.5	TCAM1P	-4	8.65e-05	0.0277	-0.32	-0.25	Prudent dietary pattern;	chr17:63798650	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2597634	ENSG00000240280.5	TCAM1P	-4	8.65e-05	0.0277	-0.32	-0.25	Prudent dietary pattern;	chr17:63800784	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs1062787	ENSG00000240280.5	TCAM1P	-4	8.65e-05	0.0277	-0.32	-0.25	Prudent dietary pattern;	chr17:63818644	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.799	rs2665836	ENSG00000240280.5	TCAM1P	-4	8.65e-05	0.0277	-0.32	-0.25	Prudent dietary pattern;	chr17:63820775	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2584627	ENSG00000240280.5	TCAM1P	-4	8.65e-05	0.0277	-0.32	-0.25	Prudent dietary pattern;	chr17:63824079	chr17:63849292~63864379:+
SARC	cis	rs3934047	0.869	rs12914127	ENSG00000274376.3	ADAMTS7P1	-4	8.65e-05	0.0277	-0.28	-0.25	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81758457	chr15:82298553~82334609:+
SARC	cis	rs717662	0.507	rs660410	ENSG00000248027.1	CTD-2383M3.1	4	8.65e-05	0.0278	0.47	0.25	Red cell distribution width;	chr11:100852952	chr11:100684162~100687955:-
SARC	cis	rs4883201	0.536	rs1121401	ENSG00000257027.1	RP11-705C15.3	-4	8.66e-05	0.0278	-0.4	-0.25	Total cholesterol levels;Cholesterol, total;	chr12:8984026	chr12:9658567~9662085:+
SARC	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	4	8.66e-05	0.0278	0.32	0.25	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
SARC	cis	rs7977237	0.928	rs7953764	ENSG00000240759.1	RP11-25I15.1	-4	8.66e-05	0.0278	-0.3	-0.25	Intraocular pressure;	chr12:43548626	chr12:42678873~42679124:-
SARC	cis	rs1707322	1	rs6671754	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.963	rs6666763	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4489497	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs11211235	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.893	rs9919275	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs11211236	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4660328	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.928	rs61785614	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs9793167	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs11211237	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.963	rs11211238	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs10890380	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4460583	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.963	rs4459051	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs11211239	ENSG00000281133.1	AL355480.3	-4	8.66e-05	0.0278	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45580892~45580996:-
SARC	cis	rs9656169	0.868	rs929219	ENSG00000226965.1	AC003088.1	4	8.67e-05	0.0278	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr7:110465910	chr7:110432239~110534754:-
SARC	cis	rs324126	0.78	rs11084150	ENSG00000269834.4	ZNF528-AS1	-4	8.68e-05	0.0278	-0.27	-0.25	Colonoscopy-negative controls vs population controls;	chr19:52381851	chr19:52388842~52397766:-
SARC	cis	rs7809950	0.817	rs2237671	ENSG00000238832.1	snoU109	-3.99	8.68e-05	0.0278	-0.3	-0.25	Coronary artery disease;	chr7:107491083	chr7:107603363~107603507:+
SARC	cis	rs42490	0.664	rs39515	ENSG00000251136.7	RP11-37B2.1	-3.99	8.69e-05	0.0278	-0.28	-0.25	Leprosy;	chr8:89816761	chr8:89609409~89757727:-
SARC	cis	rs875971	0.54	rs35510581	ENSG00000224316.1	RP11-479O9.2	-3.99	8.69e-05	0.0278	-0.24	-0.25	Aortic root size;	chr7:66113790	chr7:65773620~65802067:+
SARC	cis	rs2439831	0.764	rs12324584	ENSG00000275601.1	AC011330.13	-3.99	8.69e-05	0.0278	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43391248	chr15:43642389~43643023:-
SARC	cis	rs10751667	0.6	rs4076915	ENSG00000255026.1	RP11-326C3.2	3.99	8.69e-05	0.0278	0.24	0.25	Alzheimer's disease (late onset);	chr11:1012464	chr11:287305~288987:+
SARC	cis	rs4950322	0.58	rs2014106	ENSG00000278811.3	LINC00624	3.99	8.69e-05	0.0278	0.26	0.25	Protein quantitative trait loci;	chr1:147118499	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.58	rs17355474	ENSG00000278811.3	LINC00624	3.99	8.69e-05	0.0278	0.26	0.25	Protein quantitative trait loci;	chr1:147120541	chr1:147258885~147517875:-
SARC	cis	rs17270561	0.636	rs7453371	ENSG00000272462.2	U91328.19	-3.99	8.69e-05	0.0278	-0.24	-0.25	Iron status biomarkers;	chr6:25719028	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs7450798	ENSG00000272462.2	U91328.19	-3.99	8.69e-05	0.0278	-0.24	-0.25	Iron status biomarkers;	chr6:25719052	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4712957	ENSG00000272462.2	U91328.19	-3.99	8.69e-05	0.0278	-0.24	-0.25	Iron status biomarkers;	chr6:25719586	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.666	rs17320090	ENSG00000272462.2	U91328.19	-3.99	8.69e-05	0.0278	-0.24	-0.25	Iron status biomarkers;	chr6:25719987	chr6:25992662~26001775:+
SARC	cis	rs6918586	0.658	rs1572982	ENSG00000272462.2	U91328.19	3.99	8.7e-05	0.0278	0.23	0.25	Schizophrenia;	chr6:26094139	chr6:25992662~26001775:+
SARC	cis	rs7178375	0.843	rs3794596	ENSG00000270055.1	CTD-3092A11.2	-3.99	8.7e-05	0.0279	-0.31	-0.25	Hypertriglyceridemia;	chr15:30930823	chr15:30487963~30490313:+
SARC	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	3.99	8.7e-05	0.0279	0.3	0.25	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
SARC	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	3.99	8.7e-05	0.0279	0.32	0.25	Height;	chr6:109354092	chr6:109382795~109383666:+
SARC	cis	rs1046896	0.538	rs3803771	ENSG00000262410.1	RP11-388C12.8	3.99	8.71e-05	0.0279	0.23	0.25	Glycated hemoglobin levels;	chr17:82729882	chr17:82745068~82745709:+
SARC	cis	rs4660214	0.627	rs16837533	ENSG00000182109.6	RP11-69E11.4	3.99	8.71e-05	0.0279	0.31	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39238175	chr1:39522280~39546187:-
SARC	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-3.99	8.71e-05	0.0279	-0.27	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
SARC	cis	rs4835265	0.929	rs7669911	ENSG00000272727.1	RP11-142A22.4	3.99	8.71e-05	0.0279	0.36	0.25	Gamma glutamyl transpeptidase;	chr4:145868333	chr4:145335263~145340421:-
SARC	cis	rs7819412	0.806	rs6980856	ENSG00000255310.2	AF131215.2	3.99	8.71e-05	0.0279	0.29	0.25	Triglycerides;	chr8:11080750	chr8:11107788~11109726:-
SARC	cis	rs755249	0.567	rs4660208	ENSG00000182109.6	RP11-69E11.4	3.99	8.72e-05	0.0279	0.29	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39522280~39546187:-
SARC	cis	rs7408868	0.908	rs1044006	ENSG00000266913.1	CTC-548K16.2	-3.99	8.72e-05	0.0279	-0.37	-0.25	Pulse pressure;	chr19:15174241	chr19:14305458~14370196:-
SARC	cis	rs860818	1	rs858276	ENSG00000226816.2	AC005082.12	3.99	8.73e-05	0.0279	0.66	0.25	Initial pursuit acceleration;	chr7:23212934	chr7:23206013~23208045:+
SARC	cis	rs8026198	0.929	rs1679009	ENSG00000260571.1	BNIP3P5	3.99	8.73e-05	0.0279	0.38	0.25	Fibrinogen levels;	chr15:42175468	chr15:42313687~42314386:+
SARC	cis	rs2790457	0.518	rs2993984	ENSG00000254635.4	WAC-AS1	-3.99	8.73e-05	0.0279	-0.3	-0.25	Multiple myeloma;	chr10:28509727	chr10:28522652~28532743:-
SARC	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-3.99	8.74e-05	0.028	-0.38	-0.25	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
SARC	cis	rs6163	0.588	rs11191392	ENSG00000236937.2	PTGES3P4	3.99	8.74e-05	0.028	0.29	0.25	Waist circumference;Hip circumference;	chr10:102767194	chr10:102845595~102845950:+
SARC	cis	rs593531	0.513	rs7120394	ENSG00000280269.1	AP000577.2	3.99	8.74e-05	0.028	0.31	0.25	Neuroticism;	chr11:74323428	chr11:74204869~74205746:+
SARC	cis	rs2803122	0.967	rs4977519	ENSG00000273226.1	RP11-513M16.8	-3.99	8.74e-05	0.028	-0.24	-0.25	Pulse pressure;	chr9:19241204	chr9:19375451~19375996:+
SARC	cis	rs2803122	0.967	rs10757040	ENSG00000273226.1	RP11-513M16.8	-3.99	8.74e-05	0.028	-0.24	-0.25	Pulse pressure;	chr9:19241849	chr9:19375451~19375996:+
SARC	cis	rs2803122	0.934	rs2175378	ENSG00000273226.1	RP11-513M16.8	-3.99	8.74e-05	0.028	-0.24	-0.25	Pulse pressure;	chr9:19241965	chr9:19375451~19375996:+
SARC	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	3.99	8.74e-05	0.028	0.29	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
SARC	cis	rs1062177	0.855	rs62395861	ENSG00000254226.4	CTB-12O2.1	3.99	8.75e-05	0.028	0.34	0.25	Preschool internalizing problems;	chr5:151889709	chr5:151949571~152270448:+
SARC	cis	rs1062177	0.95	rs59580263	ENSG00000254226.4	CTB-12O2.1	3.99	8.75e-05	0.028	0.34	0.25	Preschool internalizing problems;	chr5:151890016	chr5:151949571~152270448:+
SARC	cis	rs67478160	0.654	rs1997913	ENSG00000269940.1	RP11-73M18.7	3.99	8.75e-05	0.028	0.22	0.25	Schizophrenia;	chr14:103747623	chr14:103694560~103695170:+
SARC	cis	rs783540	0.609	rs803686	ENSG00000275695.1	UBE2Q2P6	-3.99	8.75e-05	0.028	-0.28	-0.25	Schizophrenia;	chr15:82550590	chr15:82445719~82454837:+
SARC	cis	rs9309473	0.606	rs1589576	ENSG00000163016.8	ALMS1P	3.99	8.76e-05	0.028	0.35	0.25	Metabolite levels;	chr2:73511677	chr2:73644919~73685576:+
SARC	cis	rs394563	0.967	rs438852	ENSG00000231760.4	RP11-350J20.5	-3.99	8.76e-05	0.028	-0.32	-0.25	Dupuytren's disease;	chr6:149473397	chr6:149796151~149826294:-
SARC	cis	rs7615952	0.599	rs12486459	ENSG00000248787.1	RP11-666A20.4	-3.99	8.76e-05	0.028	-0.37	-0.25	Blood pressure (smoking interaction);	chr3:126022622	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.599	rs67575510	ENSG00000248787.1	RP11-666A20.4	-3.99	8.76e-05	0.028	-0.37	-0.25	Blood pressure (smoking interaction);	chr3:126023512	chr3:125908005~125910272:-
SARC	cis	rs28386778	0.897	rs2665823	ENSG00000240280.5	TCAM1P	-3.99	8.77e-05	0.028	-0.32	-0.25	Prudent dietary pattern;	chr17:63808557	chr17:63849292~63864379:+
SARC	cis	rs7267979	0.753	rs400357	ENSG00000274414.1	RP5-965G21.4	-3.99	8.77e-05	0.028	-0.26	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:25239007~25245229:-
SARC	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-3.99	8.78e-05	0.0281	-0.33	-0.25	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
SARC	cis	rs2731006	0.64	rs991703	ENSG00000257114.2	RP11-25I15.3	-3.99	8.79e-05	0.0281	-0.38	-0.25	Panic disorder;	chr12:42801910	chr12:42692216~42717119:+
SARC	cis	rs12049351	0.675	rs754024	ENSG00000229367.1	HMGN2P19	3.99	8.79e-05	0.0281	0.21	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229501667	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs754022	ENSG00000229367.1	HMGN2P19	3.99	8.79e-05	0.0281	0.21	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229501898	chr1:229570532~229570796:+
SARC	cis	rs6570726	0.846	rs6570700	ENSG00000235652.6	RP11-545I5.3	3.99	8.79e-05	0.0281	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.846	rs870491	ENSG00000235652.6	RP11-545I5.3	3.99	8.79e-05	0.0281	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.791	rs4332001	ENSG00000235652.6	RP11-545I5.3	3.99	8.79e-05	0.0281	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145799409~145886585:+
SARC	cis	rs597539	0.731	rs664229	ENSG00000250508.1	RP11-757G1.6	-3.99	8.8e-05	0.0281	-0.31	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68870664~68874542:+
SARC	cis	rs597539	0.69	rs552517	ENSG00000250508.1	RP11-757G1.6	-3.99	8.8e-05	0.0281	-0.31	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68870664~68874542:+
SARC	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	3.99	8.8e-05	0.0281	0.23	0.25	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
SARC	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-3.99	8.8e-05	0.0281	-0.3	-0.25	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
SARC	cis	rs9925964	0.933	rs2303222	ENSG00000183604.13	SMG1P5	3.99	8.8e-05	0.0281	0.23	0.25	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31074149	chr16:30267553~30335374:-
SARC	cis	rs853679	0.76	rs9393909	ENSG00000219392.1	RP1-265C24.5	3.99	8.81e-05	0.0281	0.42	0.25	Depression;	chr6:28239422	chr6:28115628~28116551:+
SARC	cis	rs11121022	1	rs11121022	ENSG00000269925.1	RP3-467L1.6	-3.99	8.81e-05	0.0281	-0.29	-0.25	Morning vs. evening chronotype;	chr1:7776599	chr1:7776383~7776775:+
SARC	cis	rs5850	0.602	rs1005786	ENSG00000226816.2	AC005082.12	3.99	8.82e-05	0.0281	0.31	0.25	Blood protein levels;	chr7:23106218	chr7:23206013~23208045:+
SARC	cis	rs7246657	0.943	rs35540940	ENSG00000226686.6	LINC01535	-3.99	8.82e-05	0.0281	-0.36	-0.25	Coronary artery calcification;	chr19:37517333	chr19:37251912~37265535:+
SARC	cis	rs2243480	0.522	rs73150635	ENSG00000226824.5	RP4-756H11.3	-3.99	8.82e-05	0.0282	-0.56	-0.25	Diabetic kidney disease;	chr7:66507503	chr7:66654538~66669855:+
SARC	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-3.99	8.83e-05	0.0282	-0.49	-0.25	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
SARC	cis	rs2731006	0.901	rs2731007	ENSG00000257114.2	RP11-25I15.3	-3.99	8.83e-05	0.0282	-0.39	-0.25	Panic disorder;	chr12:42767101	chr12:42692216~42717119:+
SARC	cis	rs7617773	0.78	rs3197223	ENSG00000228638.1	FCF1P2	-3.99	8.83e-05	0.0282	-0.3	-0.25	Coronary artery disease;	chr3:48294367	chr3:48290793~48291375:-
SARC	cis	rs7520050	0.778	rs2991985	ENSG00000280836.1	AL355480.1	3.99	8.83e-05	0.0282	0.24	0.25	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45581219~45581321:-
SARC	cis	rs9513627	0.915	rs7327204	ENSG00000280710.1	RP11-214F16.8	-3.99	8.83e-05	0.0282	-0.36	-0.25	Obesity-related traits;	chr13:99474698	chr13:99498524~99501315:+
SARC	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	3.99	8.84e-05	0.0282	0.3	0.25	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
SARC	cis	rs6445975	1	rs4076852	ENSG00000272360.1	RP11-359I18.5	3.99	8.84e-05	0.0282	0.32	0.25	Systemic lupus erythematosus;	chr3:58389559	chr3:58490830~58491291:-
SARC	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	3.99	8.84e-05	0.0282	0.29	0.25	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
SARC	cis	rs10751667	0.6	rs7950955	ENSG00000255026.1	RP11-326C3.2	3.99	8.84e-05	0.0282	0.24	0.25	Alzheimer's disease (late onset);	chr11:1011490	chr11:287305~288987:+
SARC	cis	rs10751667	0.6	rs14346	ENSG00000255026.1	RP11-326C3.2	3.99	8.84e-05	0.0282	0.24	0.25	Alzheimer's disease (late onset);	chr11:1011829	chr11:287305~288987:+
SARC	cis	rs4792901	0.959	rs4792998	ENSG00000197291.7	RAMP2-AS1	-3.99	8.84e-05	0.0282	-0.27	-0.25	Dupuytren's disease;	chr17:43575413	chr17:42753914~42761257:-
SARC	cis	rs2439831	1	rs2245790	ENSG00000275601.1	AC011330.13	-3.99	8.84e-05	0.0282	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43452259	chr15:43642389~43643023:-
SARC	cis	rs4660214	0.671	rs72661956	ENSG00000182109.6	RP11-69E11.4	3.99	8.85e-05	0.0282	0.31	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39319216	chr1:39522280~39546187:-
SARC	cis	rs72634501	0.574	rs111623477	ENSG00000182109.6	RP11-69E11.4	3.99	8.85e-05	0.0282	0.31	0.25	HDL cholesterol;	chr1:39345533	chr1:39522280~39546187:-
SARC	cis	rs7772486	0.603	rs2223411	ENSG00000270638.1	RP3-466P17.1	-3.99	8.85e-05	0.0282	-0.21	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145735570~145737218:+
SARC	cis	rs755249	0.567	rs16825887	ENSG00000182109.6	RP11-69E11.4	-3.99	8.85e-05	0.0282	-0.29	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177710	chr1:39522280~39546187:-
SARC	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-3.99	8.85e-05	0.0282	-0.24	-0.25	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
SARC	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-3.99	8.85e-05	0.0282	-0.32	-0.25	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
SARC	cis	rs72647484	0.554	rs2807321	ENSG00000228397.1	RP1-224A6.3	-3.99	8.86e-05	0.0282	-0.52	-0.25	Colorectal cancer;	chr1:22228398	chr1:22023994~22024968:-
SARC	cis	rs7726354	0.793	rs111944656	ENSG00000271828.1	CTD-2310F14.1	3.99	8.86e-05	0.0282	0.55	0.25	Breast cancer (early onset);	chr5:56712403	chr5:56927874~56929573:+
SARC	cis	rs7726354	0.793	rs112191071	ENSG00000271828.1	CTD-2310F14.1	3.99	8.86e-05	0.0282	0.55	0.25	Breast cancer (early onset);	chr5:56712414	chr5:56927874~56929573:+
SARC	cis	rs4835473	0.932	rs2323191	ENSG00000251600.4	RP11-673E1.1	-3.99	8.86e-05	0.0283	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143744472	chr4:143912331~143982454:+
SARC	cis	rs9309473	0.5	rs2421664	ENSG00000163016.8	ALMS1P	-3.99	8.87e-05	0.0283	-0.29	-0.25	Metabolite levels;	chr2:73631754	chr2:73644919~73685576:+
SARC	cis	rs10986311	0.747	rs2282085	ENSG00000235204.1	RP11-121A14.2	3.99	8.87e-05	0.0283	0.29	0.25	Vitiligo;	chr9:124262761	chr9:124259250~124261156:-
SARC	cis	rs6570726	0.818	rs952405	ENSG00000235652.6	RP11-545I5.3	3.99	8.87e-05	0.0283	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145799409~145886585:+
SARC	cis	rs4835473	0.637	rs13110964	ENSG00000251600.4	RP11-673E1.1	3.99	8.87e-05	0.0283	0.24	0.25	Immature fraction of reticulocytes;	chr4:143765119	chr4:143912331~143982454:+
SARC	cis	rs2117029	0.782	rs6580698	ENSG00000258017.1	RP11-386G11.10	-3.99	8.88e-05	0.0283	-0.27	-0.25	Intelligence (multi-trait analysis);	chr12:49084875	chr12:49127782~49147869:+
SARC	cis	rs4713118	0.513	rs149942	ENSG00000272009.1	RP1-313I6.12	-3.99	8.88e-05	0.0283	-0.27	-0.25	Parkinson's disease;	chr6:28033832	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.513	rs149944	ENSG00000272009.1	RP1-313I6.12	-3.99	8.88e-05	0.0283	-0.27	-0.25	Parkinson's disease;	chr6:28035040	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.513	rs149945	ENSG00000272009.1	RP1-313I6.12	-3.99	8.88e-05	0.0283	-0.27	-0.25	Parkinson's disease;	chr6:28035075	chr6:28078792~28081130:-
SARC	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-3.99	8.88e-05	0.0283	-0.24	-0.25	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
SARC	cis	rs9309473	0.607	rs7586361	ENSG00000163016.8	ALMS1P	3.99	8.89e-05	0.0283	0.3	0.25	Metabolite levels;	chr2:73374478	chr2:73644919~73685576:+
SARC	cis	rs7520050	0.778	rs12404197	ENSG00000280836.1	AL355480.1	3.99	8.89e-05	0.0283	0.24	0.25	Reticulocyte count;Red blood cell count;	chr1:45766748	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.801	rs6703960	ENSG00000280836.1	AL355480.1	3.99	8.89e-05	0.0283	0.24	0.25	Reticulocyte count;Red blood cell count;	chr1:45767051	chr1:45581219~45581321:-
SARC	cis	rs6477918	0.598	rs13284471	ENSG00000250068.1	RP11-576C12.1	-3.99	8.89e-05	0.0283	-0.26	-0.25	Obstetric antiphospholipid syndrome;	chr9:112452384	chr9:112581779~112582590:-
SARC	cis	rs2315504	0.509	rs2051806	ENSG00000234477.1	AC004231.2	-3.99	8.89e-05	0.0283	-0.31	-0.25	Height;	chr17:40875199	chr17:40921430~40975926:+
SARC	cis	rs5758511	0.68	rs5758687	ENSG00000227370.1	RP4-669P10.19	3.99	8.91e-05	0.0284	0.29	0.25	Birth weight;	chr22:42260582	chr22:42132543~42132998:+
SARC	cis	rs4950322	0.542	rs3766519	ENSG00000278811.3	LINC00624	3.99	8.91e-05	0.0284	0.27	0.25	Protein quantitative trait loci;	chr1:147214802	chr1:147258885~147517875:-
SARC	cis	rs7923609	0.756	rs7077256	ENSG00000232075.1	MRPL35P2	3.99	8.91e-05	0.0284	0.22	0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576425	chr10:63634317~63634827:-
SARC	cis	rs7614311	0.689	rs73120898	ENSG00000271843.1	RP11-245J9.5	-3.99	8.91e-05	0.0284	-0.39	-0.25	Lung function (FVC);Lung function (FEV1);	chr3:63843104	chr3:64008082~64008692:-
SARC	cis	rs10986311	0.851	rs1045774	ENSG00000235204.1	RP11-121A14.2	3.99	8.91e-05	0.0284	0.29	0.25	Vitiligo;	chr9:124270328	chr9:124259250~124261156:-
SARC	cis	rs7678555	0.52	rs12506247	ENSG00000245958.5	RP11-33B1.1	-3.99	8.91e-05	0.0284	-0.21	-0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr4:119923780	chr4:119454791~119552025:+
SARC	cis	rs7520050	0.807	rs12025621	ENSG00000280836.1	AL355480.1	3.99	8.91e-05	0.0284	0.24	0.25	Reticulocyte count;Red blood cell count;	chr1:45762719	chr1:45581219~45581321:-
SARC	cis	rs9902453	0.904	rs12103671	ENSG00000264538.5	SUZ12P1	-3.99	8.91e-05	0.0284	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30081199	chr17:30709299~30790908:+
SARC	cis	rs10844706	1	rs10844706	ENSG00000214776.8	RP11-726G1.1	3.99	8.91e-05	0.0284	0.3	0.25	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9757536	chr12:9467552~9576275:+
SARC	cis	rs7208859	0.623	rs1061342	ENSG00000264538.5	SUZ12P1	-3.99	8.92e-05	0.0284	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30709299~30790908:+
SARC	cis	rs28386778	0.897	rs2727326	ENSG00000240280.5	TCAM1P	-3.99	8.92e-05	0.0284	-0.31	-0.25	Prudent dietary pattern;	chr17:63845656	chr17:63849292~63864379:+
SARC	cis	rs1707322	0.896	rs946528	ENSG00000281133.1	AL355480.3	3.99	8.92e-05	0.0284	0.28	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45580892~45580996:-
SARC	cis	rs28386778	1	rs2665851	ENSG00000240280.5	TCAM1P	-3.99	8.92e-05	0.0284	-0.32	-0.25	Prudent dietary pattern;	chr17:63879663	chr17:63849292~63864379:+
SARC	cis	rs4835473	0.932	rs66474962	ENSG00000251600.4	RP11-673E1.1	-3.99	8.92e-05	0.0284	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143735145	chr4:143912331~143982454:+
SARC	cis	rs4148883	0.628	rs34195655	ENSG00000263923.1	RP11-571L19.7	-3.99	8.93e-05	0.0284	-0.26	-0.25	Alcohol dependence;	chr4:99152638	chr4:98928897~98994994:+
SARC	cis	rs4148883	0.675	rs10015824	ENSG00000263923.1	RP11-571L19.7	-3.99	8.93e-05	0.0284	-0.26	-0.25	Alcohol dependence;	chr4:99153387	chr4:98928897~98994994:+
SARC	cis	rs12497850	0.863	rs4858799	ENSG00000225399.4	RP11-3B7.1	-3.99	8.93e-05	0.0284	-0.43	-0.25	Parkinson's disease;	chr3:48690771	chr3:49260085~49261316:+
SARC	cis	rs12893668	0.644	rs12890820	ENSG00000269940.1	RP11-73M18.7	3.99	8.93e-05	0.0284	0.25	0.25	Reticulocyte count;	chr14:103568512	chr14:103694560~103695170:+
SARC	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	3.99	8.94e-05	0.0284	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
SARC	cis	rs7927592	0.513	rs607887	ENSG00000212093.1	AP000807.1	3.99	8.94e-05	0.0284	0.24	0.25	Total body bone mineral density;	chr11:68429493	chr11:68506083~68506166:-
SARC	cis	rs77633900	0.803	rs2469559	ENSG00000196274.5	Metazoa_SRP	3.99	8.95e-05	0.0285	0.47	0.25	Glioma;Non-glioblastoma glioma;	chr15:76181035	chr15:76230048~76230390:-
SARC	cis	rs1707322	1	rs12097761	ENSG00000281133.1	AL355480.3	-3.99	8.95e-05	0.0285	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45580892~45580996:-
SARC	cis	rs597539	0.652	rs559032	ENSG00000250508.1	RP11-757G1.6	-3.99	8.95e-05	0.0285	-0.3	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68870664~68874542:+
SARC	cis	rs2235544	0.579	rs1537323	ENSG00000225183.1	RP4-758J24.4	3.99	8.95e-05	0.0285	0.28	0.25	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54016850	chr1:54089856~54090093:+
SARC	cis	rs7976269	0.609	rs1344854	ENSG00000257176.2	RP11-996F15.2	3.99	8.97e-05	0.0285	0.28	0.25	Male-pattern baldness;	chr12:29065440	chr12:29280418~29317848:-
SARC	cis	rs59104589	0.617	rs3755395	ENSG00000266621.1	AC104841.1	3.99	8.98e-05	0.0286	0.37	0.25	Fibrinogen levels;	chr2:241354701	chr2:241245202~241245299:-
SARC	cis	rs2284378	0.515	rs6059579	ENSG00000275784.1	RP5-1125A11.6	-3.99	8.98e-05	0.0286	-0.29	-0.25	Breast cancer;	chr20:33940059	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.517	rs6059580	ENSG00000275784.1	RP5-1125A11.6	-3.99	8.98e-05	0.0286	-0.29	-0.25	Skin pigmentation;	chr20:33940067	chr20:33989480~33991818:-
SARC	cis	rs755249	0.567	rs112672438	ENSG00000182109.6	RP11-69E11.4	3.99	8.98e-05	0.0286	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181115	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs16825921	ENSG00000182109.6	RP11-69E11.4	3.99	8.98e-05	0.0286	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39183526	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs16825939	ENSG00000182109.6	RP11-69E11.4	3.99	8.98e-05	0.0286	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs16825942	ENSG00000182109.6	RP11-69E11.4	3.99	8.98e-05	0.0286	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs67020650	ENSG00000182109.6	RP11-69E11.4	3.99	8.98e-05	0.0286	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs72661925	ENSG00000182109.6	RP11-69E11.4	3.99	8.98e-05	0.0286	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39522280~39546187:-
SARC	cis	rs1707322	1	rs7527079	ENSG00000281133.1	AL355480.3	-3.99	8.98e-05	0.0286	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45580892~45580996:-
SARC	cis	rs2404602	0.716	rs17362383	ENSG00000259422.1	RP11-593F23.1	3.99	8.99e-05	0.0286	0.28	0.25	Blood metabolite levels;	chr15:76358361	chr15:76174891~76181486:-
SARC	cis	rs7688540	0.713	rs12511388	ENSG00000275426.1	CH17-262A2.1	3.99	8.99e-05	0.0286	0.35	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303758	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs7674560	ENSG00000275426.1	CH17-262A2.1	3.99	8.99e-05	0.0286	0.35	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:149738~150317:+
SARC	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-3.99	8.99e-05	0.0286	-0.22	-0.25	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
SARC	cis	rs9868809	0.772	rs9821797	ENSG00000225399.4	RP11-3B7.1	-3.99	8.99e-05	0.0286	-0.44	-0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48680820	chr3:49260085~49261316:+
SARC	cis	rs9868809	0.772	rs9877794	ENSG00000225399.4	RP11-3B7.1	-3.99	8.99e-05	0.0286	-0.44	-0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48680955	chr3:49260085~49261316:+
SARC	cis	rs4664293	1	rs10432413	ENSG00000226266.5	AC009961.3	-3.99	8.99e-05	0.0286	-0.32	-0.25	Monocyte percentage of white cells;	chr2:159639243	chr2:159670708~159712435:-
SARC	cis	rs9739682	1	rs9668015	ENSG00000139239.7	RPL14P1	-3.99	8.99e-05	0.0286	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62112714	chr12:62965325~62965969:+
SARC	cis	rs9739682	1	rs9668369	ENSG00000139239.7	RPL14P1	-3.99	8.99e-05	0.0286	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62113061	chr12:62965325~62965969:+
SARC	cis	rs9739682	1	rs12425896	ENSG00000139239.7	RPL14P1	-3.99	8.99e-05	0.0286	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62113121	chr12:62965325~62965969:+
SARC	cis	rs9739682	1	rs12423325	ENSG00000139239.7	RPL14P1	-3.99	8.99e-05	0.0286	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62113273	chr12:62965325~62965969:+
SARC	cis	rs9739682	1	rs35194524	ENSG00000139239.7	RPL14P1	-3.99	8.99e-05	0.0286	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62113419	chr12:62965325~62965969:+
SARC	cis	rs9739682	1	rs12829595	ENSG00000139239.7	RPL14P1	-3.99	8.99e-05	0.0286	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62113737	chr12:62965325~62965969:+
SARC	cis	rs1985875	1	rs1985875	ENSG00000139239.7	RPL14P1	-3.99	8.99e-05	0.0286	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62114243	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.913	rs1975494	ENSG00000139239.7	RPL14P1	-3.99	8.99e-05	0.0286	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62114416	chr12:62965325~62965969:+
SARC	cis	rs9739682	1	rs9739546	ENSG00000139239.7	RPL14P1	-3.99	8.99e-05	0.0286	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62114656	chr12:62965325~62965969:+
SARC	cis	rs9739682	1	rs9738294	ENSG00000139239.7	RPL14P1	-3.99	8.99e-05	0.0286	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62114708	chr12:62965325~62965969:+
SARC	cis	rs9739682	1	rs1009168	ENSG00000139239.7	RPL14P1	-3.99	8.99e-05	0.0286	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62116714	chr12:62965325~62965969:+
SARC	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-3.99	8.99e-05	0.0286	-0.29	-0.25	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
SARC	cis	rs848490	0.515	rs2057933	ENSG00000214293.7	APTR	-3.99	8.99e-05	0.0286	-0.27	-0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77791071	chr7:77657660~77696265:-
SARC	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-3.99	9e-05	0.0286	-0.27	-0.25	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
SARC	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-3.99	9e-05	0.0286	-0.27	-0.25	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
SARC	cis	rs6477918	0.55	rs950267	ENSG00000250068.1	RP11-576C12.1	-3.99	9e-05	0.0286	-0.27	-0.25	Obstetric antiphospholipid syndrome;	chr9:112421556	chr9:112581779~112582590:-
SARC	cis	rs863345	0.584	rs10908677	ENSG00000231666.4	RP11-404O13.1	3.99	9e-05	0.0286	0.27	0.25	Pneumococcal bacteremia;	chr1:158536396	chr1:158132044~158140639:-
SARC	cis	rs1707322	1	rs785467	ENSG00000281133.1	AL355480.3	3.99	9e-05	0.0286	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45580892~45580996:-
SARC	cis	rs13113518	0.595	rs13120635	ENSG00000249700.7	SRD5A3-AS1	3.99	9.01e-05	0.0286	0.32	0.25	Height;	chr4:55361200	chr4:55363971~55395847:-
SARC	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-3.99	9.02e-05	0.0286	-0.32	-0.25	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
SARC	cis	rs745109	0.816	rs72930340	ENSG00000273080.1	RP11-301O19.1	3.99	9.02e-05	0.0286	0.39	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86437436	chr2:86195590~86196049:+
SARC	cis	rs4591358	0.648	rs16836855	ENSG00000223466.1	AC064834.2	-3.99	9.02e-05	0.0286	-0.3	-0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522267	chr2:195533035~195538681:+
SARC	cis	rs5758511	0.68	rs5751243	ENSG00000227370.1	RP4-669P10.19	3.99	9.02e-05	0.0287	0.29	0.25	Birth weight;	chr22:42221171	chr22:42132543~42132998:+
SARC	cis	rs5758511	0.637	rs5751244	ENSG00000227370.1	RP4-669P10.19	3.99	9.02e-05	0.0287	0.29	0.25	Birth weight;	chr22:42221405	chr22:42132543~42132998:+
SARC	cis	rs7163013	0.901	rs4243081	ENSG00000259792.1	RP11-114H24.6	3.99	9.02e-05	0.0287	0.27	0.25	Obesity-related traits;	chr15:78387922	chr15:77993405~77995289:+
SARC	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	3.99	9.02e-05	0.0287	0.24	0.25	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
SARC	cis	rs897984	0.542	rs6565217	ENSG00000260911.2	RP11-196G11.2	3.98	9.03e-05	0.0287	0.24	0.25	Dementia with Lewy bodies;	chr16:31072003	chr16:31043150~31049868:+
SARC	cis	rs28386778	0.897	rs7207005	ENSG00000240280.5	TCAM1P	-3.98	9.03e-05	0.0287	-0.31	-0.25	Prudent dietary pattern;	chr17:63782995	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs896064	ENSG00000240280.5	TCAM1P	-3.98	9.03e-05	0.0287	-0.31	-0.25	Prudent dietary pattern;	chr17:63783572	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.83	rs2665841	ENSG00000240280.5	TCAM1P	-3.98	9.03e-05	0.0287	-0.31	-0.25	Prudent dietary pattern;	chr17:63783859	chr17:63849292~63864379:+
SARC	cis	rs1707322	1	rs10890365	ENSG00000281133.1	AL355480.3	-3.98	9.04e-05	0.0287	-0.28	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45580892~45580996:-
SARC	cis	rs42490	0.868	rs1605997	ENSG00000251136.7	RP11-37B2.1	3.98	9.04e-05	0.0287	0.28	0.25	Leprosy;	chr8:89655885	chr8:89609409~89757727:-
SARC	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-3.98	9.04e-05	0.0287	-0.22	-0.25	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
SARC	cis	rs41369048	0.669	rs80327434	ENSG00000238078.1	LINC01352	-3.98	9.04e-05	0.0287	-0.4	-0.25	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220850961	chr1:220829255~220832429:+
SARC	cis	rs41369048	0.669	rs77986094	ENSG00000238078.1	LINC01352	-3.98	9.04e-05	0.0287	-0.4	-0.25	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220854514	chr1:220829255~220832429:+
SARC	cis	rs673078	0.66	rs73205551	ENSG00000275759.1	RP11-131L12.3	-3.98	9.04e-05	0.0287	-0.33	-0.25	Glucose homeostasis traits;	chr12:118330808	chr12:118428281~118428870:+
SARC	cis	rs853679	1	rs1778511	ENSG00000219392.1	RP1-265C24.5	3.98	9.04e-05	0.0287	0.45	0.25	Depression;	chr6:28261633	chr6:28115628~28116551:+
SARC	cis	rs7615952	0.599	rs2279821	ENSG00000248787.1	RP11-666A20.4	-3.98	9.05e-05	0.0287	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:126015465	chr3:125908005~125910272:-
SARC	cis	rs1707322	1	rs785510	ENSG00000281133.1	AL355480.3	3.98	9.05e-05	0.0287	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45580892~45580996:-
SARC	cis	rs858239	0.6	rs13438188	ENSG00000226816.2	AC005082.12	-3.98	9.06e-05	0.0288	-0.3	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23206013~23208045:+
SARC	cis	rs2404602	0.583	rs2139190	ENSG00000259422.1	RP11-593F23.1	3.98	9.06e-05	0.0288	0.28	0.25	Blood metabolite levels;	chr15:76263198	chr15:76174891~76181486:-
SARC	cis	rs75920871	0.528	rs7941428	ENSG00000254851.1	RP11-109L13.1	3.98	9.06e-05	0.0288	0.35	0.25	Subjective well-being;	chr11:117032668	chr11:117135528~117138582:+
SARC	cis	rs16846053	0.71	rs13022437	ENSG00000227403.1	AC009299.3	-3.98	9.06e-05	0.0288	-0.29	-0.25	Blood osmolality (transformed sodium);	chr2:161765775	chr2:161244739~161249050:+
SARC	cis	rs9435732	0.62	rs12045097	ENSG00000186715.9	MST1L	3.98	9.08e-05	0.0288	0.33	0.25	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17019382	chr1:16754910~16770237:-
SARC	cis	rs8028182	0.636	rs12708519	ENSG00000260206.1	CTD-2026K11.2	-3.98	9.08e-05	0.0288	-0.31	-0.25	Sudden cardiac arrest;	chr15:75510859	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs8029112	ENSG00000260206.1	CTD-2026K11.2	-3.98	9.08e-05	0.0288	-0.31	-0.25	Sudden cardiac arrest;	chr15:75516631	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs4886712	ENSG00000260206.1	CTD-2026K11.2	-3.98	9.08e-05	0.0288	-0.31	-0.25	Sudden cardiac arrest;	chr15:75520547	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs8030802	ENSG00000260206.1	CTD-2026K11.2	-3.98	9.08e-05	0.0288	-0.31	-0.25	Sudden cardiac arrest;	chr15:75520812	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.577	rs8023268	ENSG00000260206.1	CTD-2026K11.2	-3.98	9.08e-05	0.0288	-0.31	-0.25	Sudden cardiac arrest;	chr15:75522331	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs8023815	ENSG00000260206.1	CTD-2026K11.2	-3.98	9.08e-05	0.0288	-0.31	-0.25	Sudden cardiac arrest;	chr15:75522363	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs11636031	ENSG00000260206.1	CTD-2026K11.2	-3.98	9.08e-05	0.0288	-0.31	-0.25	Sudden cardiac arrest;	chr15:75523417	chr15:75636139~75639239:+
SARC	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-3.98	9.1e-05	0.0289	-0.28	-0.25	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
SARC	cis	rs279910	0.604	rs279887	ENSG00000281769.1	LINC01230	-3.98	9.1e-05	0.0289	-0.23	-0.25	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr9:979080	chr9:1045625~1048641:+
SARC	cis	rs9828933	0.938	rs9809432	ENSG00000280620.1	SCAANT1	3.98	9.1e-05	0.0289	0.39	0.25	Type 2 diabetes;	chr3:64017277	chr3:63911518~63911772:-
SARC	cis	rs763121	0.853	rs4821816	ENSG00000273076.1	RP3-508I15.22	3.98	9.1e-05	0.0289	0.27	0.25	Menopause (age at onset);	chr22:38717129	chr22:38743495~38743910:+
SARC	cis	rs160451	0.966	rs2101854	ENSG00000251136.7	RP11-37B2.1	3.98	9.1e-05	0.0289	0.27	0.25	Leprosy;	chr8:89663517	chr8:89609409~89757727:-
SARC	cis	rs2212361	0.615	rs6483345	ENSG00000255893.1	RP11-685N10.1	-3.98	9.11e-05	0.0289	-0.26	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94530983	chr11:94472908~94473570:-
SARC	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	3.98	9.11e-05	0.0289	0.22	0.25	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
SARC	cis	rs745109	0.882	rs113652961	ENSG00000273080.1	RP11-301O19.1	3.98	9.11e-05	0.0289	0.39	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86555379	chr2:86195590~86196049:+
SARC	cis	rs7688540	0.665	rs11731933	ENSG00000275426.1	CH17-262A2.1	3.98	9.11e-05	0.0289	0.35	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs4549329	ENSG00000275426.1	CH17-262A2.1	3.98	9.11e-05	0.0289	0.35	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245996	chr4:149738~150317:+
SARC	cis	rs172166	0.516	rs1225715	ENSG00000204709.4	LINC01556	-3.98	9.12e-05	0.0289	-0.27	-0.25	Cardiac Troponin-T levels;	chr6:28145595	chr6:28943877~28944537:+
SARC	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-3.98	9.13e-05	0.0289	-0.26	-0.25	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
SARC	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	3.98	9.13e-05	0.0289	0.37	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
SARC	cis	rs34375054	0.624	rs7132026	ENSG00000279233.1	RP11-158L12.4	-3.98	9.14e-05	0.0289	-0.3	-0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125193550	chr12:125138245~125141711:+
SARC	cis	rs2803122	0.502	rs1854552	ENSG00000273226.1	RP11-513M16.8	3.98	9.15e-05	0.029	0.26	0.25	Pulse pressure;	chr9:19235049	chr9:19375451~19375996:+
SARC	cis	rs9739682	0.957	rs1348527	ENSG00000139239.7	RPL14P1	-3.98	9.15e-05	0.029	-0.22	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62103103	chr12:62965325~62965969:+
SARC	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	3.98	9.15e-05	0.029	0.23	0.25	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
SARC	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-3.98	9.16e-05	0.029	-0.26	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
SARC	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-3.98	9.16e-05	0.029	-0.26	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
SARC	cis	rs9656169	0.868	rs6953798	ENSG00000226965.1	AC003088.1	-3.98	9.16e-05	0.029	-0.29	-0.25	Autism spectrum disorder or schizophrenia;	chr7:110466640	chr7:110432239~110534754:-
SARC	cis	rs12542260	0.815	rs12544211	ENSG00000253106.1	RP11-158K1.3	-3.98	9.16e-05	0.029	-0.29	-0.25	Colonoscopy-negative controls vs population controls;	chr8:124535074	chr8:124488510~124491643:+
SARC	cis	rs597539	0.654	rs7107137	ENSG00000250508.1	RP11-757G1.6	-3.98	9.16e-05	0.029	-0.31	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856244	chr11:68870664~68874542:+
SARC	cis	rs12950390	0.853	rs12451815	ENSG00000239291.1	RP5-867C24.1	3.98	9.16e-05	0.029	0.31	0.25	IgG glycosylation;	chr17:47778590	chr17:47159191~47159993:-
SARC	cis	rs12468226	0.752	rs34829484	ENSG00000272966.1	RP11-686O6.1	-3.98	9.17e-05	0.029	-0.36	-0.25	Urate levels;	chr2:202137267	chr2:202336739~202337200:+
SARC	cis	rs72627509	0.951	rs72627508	ENSG00000269949.1	RP11-738E22.3	3.98	9.17e-05	0.029	0.39	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56965398	chr4:56960927~56961373:-
SARC	cis	rs910316	0.737	rs175045	ENSG00000279594.1	RP11-950C14.10	-3.98	9.18e-05	0.029	-0.3	-0.25	Height;	chr14:75008572	chr14:75011269~75012851:-
SARC	cis	rs13113518	0.812	rs12648271	ENSG00000273257.1	RP11-177J6.1	3.98	9.18e-05	0.029	0.33	0.25	Height;	chr4:55501955	chr4:55387949~55388271:+
SARC	cis	rs17597773	0.527	rs1537806	ENSG00000238078.1	LINC01352	-3.98	9.18e-05	0.0291	-0.26	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220910880	chr1:220829255~220832429:+
SARC	cis	rs7085104	0.7	rs6163	ENSG00000213061.2	PFN1P11	3.98	9.18e-05	0.0291	0.3	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837167	chr10:102838011~102845473:-
SARC	cis	rs17270561	0.609	rs9358886	ENSG00000272462.2	U91328.19	-3.98	9.18e-05	0.0291	-0.24	-0.25	Iron status biomarkers;	chr6:25758025	chr6:25992662~26001775:+
SARC	cis	rs11654699	0.84	rs4794929	ENSG00000266718.1	RP11-466A19.1	-3.98	9.18e-05	0.0291	-0.22	-0.25	Neurofibrillary tangles;	chr17:32595055	chr17:32495536~32499333:+
SARC	cis	rs7615952	0.558	rs7641353	ENSG00000248787.1	RP11-666A20.4	-3.98	9.19e-05	0.0291	-0.34	-0.25	Blood pressure (smoking interaction);	chr3:125621035	chr3:125908005~125910272:-
SARC	cis	rs17270561	0.609	rs9366629	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25740988	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.553	rs6456696	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25741180	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs6456697	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25741206	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs6456698	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25741436	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.666	rs4711099	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25741581	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4711100	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25741726	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4711101	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25741742	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4712965	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25741794	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.608	rs4711102	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25741847	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4711103	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25741996	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9379788	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25742531	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9358879	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25742690	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs9358880	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25742933	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4145216	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25743331	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4145217	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25743769	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9393665	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25744056	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs7754733	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25744821	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs7754814	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25745015	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs7775354	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25745038	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9379789	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25745351	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs6941933	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25745474	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs6923367	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25745624	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs6923839	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25745625	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs4145218	ENSG00000272462.2	U91328.19	-3.98	9.19e-05	0.0291	-0.25	-0.25	Iron status biomarkers;	chr6:25745855	chr6:25992662~26001775:+
SARC	cis	rs12893668	0.703	rs7148456	ENSG00000269940.1	RP11-73M18.7	-3.98	9.19e-05	0.0291	-0.25	-0.25	Reticulocyte count;	chr14:103561933	chr14:103694560~103695170:+
SARC	cis	rs12817211	0.549	rs7398567	ENSG00000272368.2	RP4-605O3.4	3.98	9.19e-05	0.0291	0.24	0.25	Colorectal or endometrial cancer;	chr12:50157375	chr12:50112197~50165618:+
SARC	cis	rs12817211	0.549	rs10783338	ENSG00000272368.2	RP4-605O3.4	3.98	9.19e-05	0.0291	0.24	0.25	Colorectal or endometrial cancer;	chr12:50158746	chr12:50112197~50165618:+
SARC	cis	rs10078	0.848	rs890985	ENSG00000221990.4	EXOC3-AS1	3.98	9.19e-05	0.0291	0.28	0.25	Fat distribution (HIV);	chr5:479631	chr5:441498~443160:-
SARC	cis	rs4950322	0.563	rs6686480	ENSG00000278811.3	LINC00624	3.98	9.19e-05	0.0291	0.26	0.25	Protein quantitative trait loci;	chr1:147111986	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.563	rs6700783	ENSG00000278811.3	LINC00624	3.98	9.19e-05	0.0291	0.26	0.25	Protein quantitative trait loci;	chr1:147111987	chr1:147258885~147517875:-
SARC	cis	rs3204270	0.673	rs62077190	ENSG00000229848.1	RP13-766D20.2	3.98	9.2e-05	0.0291	0.4	0.25	Dental caries;	chr17:81709079	chr17:81514047~81527776:+
SARC	cis	rs3204270	0.81	rs62077191	ENSG00000229848.1	RP13-766D20.2	3.98	9.2e-05	0.0291	0.4	0.25	Dental caries;	chr17:81711033	chr17:81514047~81527776:+
SARC	cis	rs7829975	0.688	rs7817376	ENSG00000253981.4	ALG1L13P	-3.98	9.2e-05	0.0291	-0.25	-0.25	Mood instability;	chr8:8523020	chr8:8236003~8244667:-
SARC	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	3.98	9.21e-05	0.0291	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
SARC	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	3.98	9.21e-05	0.0291	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
SARC	cis	rs9902453	0.765	rs2729448	ENSG00000264538.5	SUZ12P1	-3.98	9.21e-05	0.0291	-0.18	-0.25	Coffee consumption (cups per day);	chr17:29764935	chr17:30709299~30790908:+
SARC	cis	rs12049351	0.631	rs11810108	ENSG00000229367.1	HMGN2P19	-3.98	9.22e-05	0.0291	-0.2	-0.25	Circulating myeloperoxidase levels (plasma);	chr1:229532924	chr1:229570532~229570796:+
SARC	cis	rs6918586	0.594	rs198842	ENSG00000272462.2	U91328.19	-3.98	9.22e-05	0.0291	-0.23	-0.25	Schizophrenia;	chr6:26111220	chr6:25992662~26001775:+
SARC	cis	rs6918586	0.615	rs198841	ENSG00000272462.2	U91328.19	-3.98	9.22e-05	0.0291	-0.23	-0.25	Schizophrenia;	chr6:26111443	chr6:25992662~26001775:+
SARC	cis	rs6918586	0.658	rs198840	ENSG00000272462.2	U91328.19	-3.98	9.22e-05	0.0291	-0.23	-0.25	Schizophrenia;	chr6:26111936	chr6:25992662~26001775:+
SARC	cis	rs12893668	0.603	rs12896171	ENSG00000269958.1	RP11-73M18.8	3.98	9.22e-05	0.0292	0.27	0.25	Reticulocyte count;	chr14:103669629	chr14:103696353~103697163:+
SARC	cis	rs12893668	0.572	rs12590968	ENSG00000269958.1	RP11-73M18.8	3.98	9.22e-05	0.0292	0.27	0.25	Reticulocyte count;	chr14:103670296	chr14:103696353~103697163:+
SARC	cis	rs76934034	0.522	rs117488236	ENSG00000264204.2	AGAP7P	-3.98	9.23e-05	0.0292	-0.46	-0.25	Prostate cancer;	chr10:45546587	chr10:46109621~46131358:+
SARC	cis	rs2274273	0.638	rs9919921	ENSG00000258413.1	RP11-665C16.6	-3.98	9.23e-05	0.0292	-0.34	-0.25	Protein biomarker;	chr14:55228787	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.638	rs67416413	ENSG00000258413.1	RP11-665C16.6	-3.98	9.23e-05	0.0292	-0.34	-0.25	Protein biomarker;	chr14:55235545	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.615	rs67008693	ENSG00000258413.1	RP11-665C16.6	-3.98	9.23e-05	0.0292	-0.34	-0.25	Protein biomarker;	chr14:55235975	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.638	rs17672364	ENSG00000258413.1	RP11-665C16.6	-3.98	9.23e-05	0.0292	-0.34	-0.25	Protein biomarker;	chr14:55239186	chr14:55262767~55272075:-
SARC	cis	rs2731006	0.592	rs908657	ENSG00000257114.2	RP11-25I15.3	-3.98	9.24e-05	0.0292	-0.39	-0.25	Panic disorder;	chr12:42774843	chr12:42692216~42717119:+
SARC	cis	rs4950322	0.58	rs7514970	ENSG00000278811.3	LINC00624	3.98	9.24e-05	0.0292	0.26	0.25	Protein quantitative trait loci;	chr1:147120516	chr1:147258885~147517875:-
SARC	cis	rs6877440	0.555	rs77030755	ENSG00000271849.1	CTC-332L22.1	-3.98	9.24e-05	0.0292	-0.52	-0.25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr5:109665889	chr5:109687802~109688329:-
SARC	cis	rs6142102	0.625	rs4911381	ENSG00000275784.1	RP5-1125A11.6	3.98	9.24e-05	0.0292	0.29	0.25	Skin pigmentation;	chr20:33962539	chr20:33989480~33991818:-
SARC	cis	rs34375054	0.573	rs35698828	ENSG00000279233.1	RP11-158L12.4	3.98	9.25e-05	0.0292	0.34	0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125174057	chr12:125138245~125141711:+
SARC	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	3.98	9.26e-05	0.0292	0.29	0.25	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
SARC	cis	rs10895987	0.955	rs7114094	ENSG00000254614.2	AP003068.23	3.98	9.26e-05	0.0292	0.37	0.25	Blood protein levels;	chr11:65159740	chr11:65177606~65181834:-
SARC	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	3.98	9.26e-05	0.0292	0.38	0.25	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	3.98	9.26e-05	0.0292	0.38	0.25	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	3.98	9.26e-05	0.0292	0.38	0.25	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
SARC	cis	rs12817211	0.502	rs7294618	ENSG00000272368.2	RP4-605O3.4	-3.98	9.26e-05	0.0292	-0.24	-0.25	Colorectal or endometrial cancer;	chr12:50119192	chr12:50112197~50165618:+
SARC	cis	rs12817211	0.502	rs7961112	ENSG00000272368.2	RP4-605O3.4	-3.98	9.26e-05	0.0292	-0.24	-0.25	Colorectal or endometrial cancer;	chr12:50119736	chr12:50112197~50165618:+
SARC	cis	rs860818	1	rs858277	ENSG00000226816.2	AC005082.12	-3.98	9.26e-05	0.0293	-0.68	-0.25	Initial pursuit acceleration;	chr7:23212642	chr7:23206013~23208045:+
SARC	cis	rs916888	0.61	rs199446	ENSG00000261575.2	RP11-259G18.1	-3.98	9.27e-05	0.0293	-0.32	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46267037~46268694:+
SARC	cis	rs916888	0.61	rs199536	ENSG00000261575.2	RP11-259G18.1	-3.98	9.27e-05	0.0293	-0.32	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46267037~46268694:+
SARC	cis	rs2179367	0.959	rs9390677	ENSG00000216906.2	RP11-350J20.9	3.98	9.27e-05	0.0293	0.23	0.25	Dupuytren's disease;	chr6:149389361	chr6:149904243~149906418:+
SARC	cis	rs7789940	0.857	rs12532935	ENSG00000186704.9	DTX2P1	3.98	9.27e-05	0.0293	0.35	0.25	Multiple sclerosis;	chr7:76310381	chr7:76978617~77004308:+
SARC	cis	rs7772486	0.869	rs2777473	ENSG00000270638.1	RP3-466P17.1	3.98	9.28e-05	0.0293	0.21	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145980358	chr6:145735570~145737218:+
SARC	cis	rs2919009	0.544	rs7917351	ENSG00000271670.1	RP11-95I16.4	3.98	9.28e-05	0.0293	0.27	0.25	Obesity-related traits;	chr10:120852260	chr10:120879256~120880667:-
SARC	cis	rs172166	0.694	rs203876	ENSG00000272009.1	RP1-313I6.12	-3.98	9.29e-05	0.0293	-0.28	-0.25	Cardiac Troponin-T levels;	chr6:28078895	chr6:28078792~28081130:-
SARC	cis	rs172166	0.694	rs203877	ENSG00000272009.1	RP1-313I6.12	-3.98	9.29e-05	0.0293	-0.28	-0.25	Cardiac Troponin-T levels;	chr6:28080846	chr6:28078792~28081130:-
SARC	cis	rs2307449	0.929	rs976072	ENSG00000261441.1	RP11-217B1.2	-3.98	9.3e-05	0.0293	-0.31	-0.25	Menopause (age at onset);	chr15:89316146	chr15:89335053~89336161:+
SARC	cis	rs72627509	0.857	rs781658	ENSG00000269949.1	RP11-738E22.3	3.98	9.3e-05	0.0293	0.37	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56913401	chr4:56960927~56961373:-
SARC	cis	rs7615952	0.641	rs61048217	ENSG00000248787.1	RP11-666A20.4	-3.98	9.3e-05	0.0293	-0.37	-0.25	Blood pressure (smoking interaction);	chr3:126089062	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.641	rs60839048	ENSG00000248787.1	RP11-666A20.4	-3.98	9.3e-05	0.0293	-0.37	-0.25	Blood pressure (smoking interaction);	chr3:126089095	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.641	rs7640158	ENSG00000248787.1	RP11-666A20.4	-3.98	9.3e-05	0.0293	-0.37	-0.25	Blood pressure (smoking interaction);	chr3:126089168	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.641	rs2365019	ENSG00000248787.1	RP11-666A20.4	-3.98	9.3e-05	0.0293	-0.37	-0.25	Blood pressure (smoking interaction);	chr3:126089292	chr3:125908005~125910272:-
SARC	cis	rs7208859	0.573	rs7222803	ENSG00000264538.5	SUZ12P1	-3.98	9.3e-05	0.0293	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30709299~30790908:+
SARC	cis	rs9364687	0.639	rs9347760	ENSG00000228692.2	RP5-826L7.1	-3.98	9.3e-05	0.0294	-0.3	-0.25	Body mass index;	chr6:163533540	chr6:163586583~163588165:-
SARC	cis	rs7246657	0.943	rs10404602	ENSG00000226686.6	LINC01535	-3.98	9.3e-05	0.0294	-0.35	-0.25	Coronary artery calcification;	chr19:37334731	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs10426666	ENSG00000226686.6	LINC01535	-3.98	9.3e-05	0.0294	-0.35	-0.25	Coronary artery calcification;	chr19:37337612	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs4969487	ENSG00000226686.6	LINC01535	-3.98	9.3e-05	0.0294	-0.35	-0.25	Coronary artery calcification;	chr19:37340137	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs28402338	ENSG00000226686.6	LINC01535	-3.98	9.3e-05	0.0294	-0.35	-0.25	Coronary artery calcification;	chr19:37343021	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs10417503	ENSG00000226686.6	LINC01535	-3.98	9.3e-05	0.0294	-0.35	-0.25	Coronary artery calcification;	chr19:37351833	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs10403613	ENSG00000226686.6	LINC01535	-3.98	9.3e-05	0.0294	-0.35	-0.25	Coronary artery calcification;	chr19:37353404	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs9304566	ENSG00000226686.6	LINC01535	-3.98	9.3e-05	0.0294	-0.35	-0.25	Coronary artery calcification;	chr19:37354602	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs10422967	ENSG00000226686.6	LINC01535	-3.98	9.3e-05	0.0294	-0.35	-0.25	Coronary artery calcification;	chr19:37359235	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs4417644	ENSG00000226686.6	LINC01535	-3.98	9.3e-05	0.0294	-0.35	-0.25	Coronary artery calcification;	chr19:37361570	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs10405064	ENSG00000226686.6	LINC01535	-3.98	9.3e-05	0.0294	-0.35	-0.25	Coronary artery calcification;	chr19:37370959	chr19:37251912~37265535:+
SARC	cis	rs9739682	0.957	rs9706154	ENSG00000139239.7	RPL14P1	-3.98	9.31e-05	0.0294	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62119801	chr12:62965325~62965969:+
SARC	cis	rs2505998	0.787	rs28502801	ENSG00000273008.1	RP11-351D16.3	-3.98	9.31e-05	0.0294	-0.28	-0.25	Hirschsprung disease;	chr10:43088591	chr10:43136824~43138334:-
SARC	cis	rs2562456	0.833	rs2928211	ENSG00000268081.1	RP11-678G14.2	-3.98	9.31e-05	0.0294	-0.37	-0.25	Pain;	chr19:21358495	chr19:21554640~21569237:-
SARC	cis	rs56046484	0.62	rs34585903	ENSG00000259295.5	CSPG4P12	3.98	9.31e-05	0.0294	0.39	0.25	Testicular germ cell tumor;	chr15:84984893	chr15:85191438~85213905:+
SARC	cis	rs7246657	0.943	rs10420722	ENSG00000226686.6	LINC01535	-3.98	9.32e-05	0.0294	-0.36	-0.25	Coronary artery calcification;	chr19:37482872	chr19:37251912~37265535:+
SARC	cis	rs7726354	1	rs73122135	ENSG00000271828.1	CTD-2310F14.1	3.98	9.33e-05	0.0294	0.49	0.25	Breast cancer (early onset);	chr5:56971481	chr5:56927874~56929573:+
SARC	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-3.98	9.33e-05	0.0294	-0.29	-0.25	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-3.98	9.33e-05	0.0294	-0.29	-0.25	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.803	rs11714518	ENSG00000229759.1	MRPS18AP1	-3.98	9.33e-05	0.0294	-0.29	-0.25	Educational attainment (years of education);	chr3:48115145	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-3.98	9.33e-05	0.0294	-0.29	-0.25	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
SARC	cis	rs2404602	0.583	rs12592501	ENSG00000259422.1	RP11-593F23.1	3.98	9.33e-05	0.0294	0.28	0.25	Blood metabolite levels;	chr15:76262449	chr15:76174891~76181486:-
SARC	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	3.98	9.33e-05	0.0294	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	3.98	9.33e-05	0.0294	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
SARC	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-3.98	9.34e-05	0.0295	-0.43	-0.25	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
SARC	cis	rs7178375	1	rs7176351	ENSG00000215302.7	CTD-3092A11.1	-3.98	9.34e-05	0.0295	-0.33	-0.25	Hypertriglyceridemia;	chr15:30916524	chr15:30470779~30507623:+
SARC	cis	rs7267979	1	rs6050573	ENSG00000276952.1	RP5-965G21.6	3.98	9.35e-05	0.0295	0.25	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25284915~25285588:-
SARC	cis	rs113835537	0.935	rs117480267	ENSG00000255517.5	CTD-3074O7.5	-3.98	9.35e-05	0.0295	-0.34	-0.25	Airway imaging phenotypes;	chr11:66631125	chr11:66473490~66480233:-
SARC	cis	rs11654699	0.806	rs1112170	ENSG00000266718.1	RP11-466A19.1	-3.98	9.35e-05	0.0295	-0.22	-0.25	Neurofibrillary tangles;	chr17:32601872	chr17:32495536~32499333:+
SARC	cis	rs12893668	0.572	rs4900590	ENSG00000269958.1	RP11-73M18.8	3.98	9.36e-05	0.0295	0.28	0.25	Reticulocyte count;	chr14:103680084	chr14:103696353~103697163:+
SARC	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	3.98	9.36e-05	0.0295	0.22	0.25	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
SARC	cis	rs7580658	0.895	rs62157549	ENSG00000236682.1	AC068282.3	-3.98	9.37e-05	0.0295	-0.29	-0.25	Protein C levels;	chr2:127308431	chr2:127389130~127400580:+
SARC	cis	rs7580658	0.857	rs11890187	ENSG00000236682.1	AC068282.3	-3.98	9.37e-05	0.0295	-0.29	-0.25	Protein C levels;	chr2:127326162	chr2:127389130~127400580:+
SARC	cis	rs7580658	0.864	rs4150454	ENSG00000236682.1	AC068282.3	-3.98	9.38e-05	0.0296	-0.29	-0.25	Protein C levels;	chr2:127280968	chr2:127389130~127400580:+
SARC	cis	rs5751614	0.557	rs5759665	ENSG00000230701.2	FBXW4P1	3.98	9.38e-05	0.0296	0.34	0.25	Height;	chr22:23260033	chr22:23262767~23265005:+
SARC	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-3.98	9.38e-05	0.0296	-0.24	-0.25	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
SARC	cis	rs2439831	0.702	rs3784275	ENSG00000166763.7	STRCP1	3.98	9.38e-05	0.0296	0.37	0.25	Lung cancer in ever smokers;	chr15:43799188	chr15:43699488~43718184:-
SARC	cis	rs7811142	0.83	rs1063945	ENSG00000078319.8	PMS2P1	-3.98	9.39e-05	0.0296	-0.37	-0.25	Platelet count;	chr7:100332824	chr7:100320992~100341908:-
SARC	cis	rs7811142	0.83	rs11761253	ENSG00000078319.8	PMS2P1	-3.98	9.39e-05	0.0296	-0.37	-0.25	Platelet count;	chr7:100341698	chr7:100320992~100341908:-
SARC	cis	rs1729407	0.741	rs1263177	ENSG00000254851.1	RP11-109L13.1	-3.98	9.39e-05	0.0296	-0.29	-0.25	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117135528~117138582:+
SARC	cis	rs9392556	0.6	rs2326408	ENSG00000230648.1	RP3-406P24.3	3.98	9.39e-05	0.0296	0.27	0.25	Blood metabolite levels;	chr6:4119282	chr6:4018843~4021215:-
SARC	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	3.97	9.39e-05	0.0296	0.31	0.25	Height;	chr6:109397362	chr6:109382795~109383666:+
SARC	cis	rs763121	0.853	rs1569492	ENSG00000273076.1	RP3-508I15.22	-3.97	9.4e-05	0.0296	-0.26	-0.25	Menopause (age at onset);	chr22:38579506	chr22:38743495~38743910:+
SARC	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-3.97	9.4e-05	0.0296	-0.23	-0.25	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
SARC	cis	rs7615952	0.932	rs11922218	ENSG00000250012.1	RP11-124N2.1	-3.97	9.41e-05	0.0296	-0.27	-0.25	Blood pressure (smoking interaction);	chr3:125912446	chr3:126084220~126095349:+
SARC	cis	rs7615952	0.866	rs11922276	ENSG00000250012.1	RP11-124N2.1	-3.97	9.41e-05	0.0296	-0.27	-0.25	Blood pressure (smoking interaction);	chr3:125912483	chr3:126084220~126095349:+
SARC	cis	rs2072438	0.505	rs7034074	ENSG00000226752.6	PSMD5-AS1	-3.97	9.41e-05	0.0296	-0.29	-0.25	Rheumatoid arthritis;	chr9:121160751	chr9:120824828~120854385:+
SARC	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-3.97	9.41e-05	0.0296	-0.23	-0.25	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-3.97	9.41e-05	0.0296	-0.23	-0.25	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
SARC	cis	rs4835473	0.9	rs4257605	ENSG00000251600.4	RP11-673E1.1	-3.97	9.42e-05	0.0296	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143740081	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4498094	ENSG00000251600.4	RP11-673E1.1	-3.97	9.42e-05	0.0296	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143740097	chr4:143912331~143982454:+
SARC	cis	rs6142102	0.602	rs68051854	ENSG00000275784.1	RP5-1125A11.6	-3.97	9.42e-05	0.0297	-0.29	-0.25	Skin pigmentation;	chr20:34114150	chr20:33989480~33991818:-
SARC	cis	rs807029	0.533	rs3824783	ENSG00000272572.1	RP11-179B2.2	-3.97	9.42e-05	0.0297	-0.27	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991094	chr10:100911103~100912739:-
SARC	cis	rs2492301	0.54	rs10796907	ENSG00000233621.1	LINC01137	-3.97	9.42e-05	0.0297	-0.28	-0.25	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37434572	chr1:37454879~37474411:-
SARC	cis	rs7809950	0.817	rs2712195	ENSG00000238832.1	snoU109	-3.97	9.42e-05	0.0297	-0.3	-0.25	Coronary artery disease;	chr7:107487051	chr7:107603363~107603507:+
SARC	cis	rs17826219	0.706	rs73271850	ENSG00000264538.5	SUZ12P1	-3.97	9.42e-05	0.0297	-0.28	-0.25	Body mass index;	chr17:30815122	chr17:30709299~30790908:+
SARC	cis	rs17826219	0.636	rs79565452	ENSG00000264538.5	SUZ12P1	-3.97	9.42e-05	0.0297	-0.28	-0.25	Body mass index;	chr17:30815823	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs7208088	ENSG00000264538.5	SUZ12P1	-3.97	9.42e-05	0.0297	-0.28	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs7212991	ENSG00000264538.5	SUZ12P1	-3.97	9.42e-05	0.0297	-0.28	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs28627615	ENSG00000264538.5	SUZ12P1	-3.97	9.42e-05	0.0297	-0.28	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30709299~30790908:+
SARC	cis	rs6845263	0.571	rs1834628	ENSG00000254531.1	FLJ20021	-3.97	9.42e-05	0.0297	-0.24	-0.25	Superior crus of antihelix expression;	chr4:101531406	chr4:101347780~101348883:+
SARC	cis	rs6845263	0.546	rs1834626	ENSG00000254531.1	FLJ20021	-3.97	9.42e-05	0.0297	-0.24	-0.25	Superior crus of antihelix expression;	chr4:101532234	chr4:101347780~101348883:+
SARC	cis	rs858239	0.73	rs10255155	ENSG00000226816.2	AC005082.12	-3.97	9.43e-05	0.0297	-0.31	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23206013~23208045:+
SARC	cis	rs160451	0.966	rs1603289	ENSG00000251136.7	RP11-37B2.1	3.97	9.43e-05	0.0297	0.27	0.25	Leprosy;	chr8:89655405	chr8:89609409~89757727:-
SARC	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	3.97	9.43e-05	0.0297	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-3.97	9.43e-05	0.0297	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
SARC	cis	rs2905347	0.895	rs2905308	ENSG00000179428.2	AC073072.5	3.97	9.43e-05	0.0297	0.26	0.25	Major depression and alcohol dependence;	chr7:22608575	chr7:22725395~22727620:-
SARC	cis	rs6452524	0.508	rs256795	ENSG00000248112.1	RP11-78C3.1	-3.97	9.44e-05	0.0297	-0.27	-0.25	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:82919376~82921119:-
SARC	cis	rs4925386	0.84	rs6143034	ENSG00000275437.1	RP5-908M14.10	3.97	9.44e-05	0.0297	0.24	0.25	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345489	chr20:62402236~62405935:-
SARC	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-3.97	9.44e-05	0.0297	-0.3	-0.25	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-3.97	9.44e-05	0.0297	-0.3	-0.25	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-3.97	9.44e-05	0.0297	-0.3	-0.25	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
SARC	cis	rs9902453	0.904	rs9897794	ENSG00000264538.5	SUZ12P1	3.97	9.44e-05	0.0297	0.18	0.25	Coffee consumption (cups per day);	chr17:29969309	chr17:30709299~30790908:+
SARC	cis	rs17508449	0.865	rs4838994	ENSG00000232450.1	RP4-730K3.3	3.97	9.45e-05	0.0297	0.32	0.25	Leprosy;	chr1:113608984	chr1:113698884~113699631:-
SARC	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-3.97	9.45e-05	0.0297	-0.24	-0.25	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
SARC	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-3.97	9.45e-05	0.0297	-0.37	-0.25	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
SARC	cis	rs7520050	1	rs785511	ENSG00000280836.1	AL355480.1	3.97	9.45e-05	0.0297	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46068826	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.966	rs809775	ENSG00000280836.1	AL355480.1	3.97	9.45e-05	0.0297	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46072368	chr1:45581219~45581321:-
SARC	cis	rs1865760	0.593	rs3903852	ENSG00000272462.2	U91328.19	-3.97	9.45e-05	0.0297	-0.23	-0.25	Height;	chr6:25914919	chr6:25992662~26001775:+
SARC	cis	rs875971	0.862	rs908915	ENSG00000232559.3	GS1-124K5.12	-3.97	9.45e-05	0.0297	-0.29	-0.25	Aortic root size;	chr7:66149664	chr7:66554588~66576923:-
SARC	cis	rs875971	0.862	rs7809814	ENSG00000232559.3	GS1-124K5.12	-3.97	9.45e-05	0.0297	-0.29	-0.25	Aortic root size;	chr7:66150410	chr7:66554588~66576923:-
SARC	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	3.97	9.45e-05	0.0297	0.32	0.25	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
SARC	cis	rs7520050	0.966	rs1768816	ENSG00000280836.1	AL355480.1	3.97	9.45e-05	0.0297	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46062927	chr1:45581219~45581321:-
SARC	cis	rs6142102	0.625	rs2050208	ENSG00000275784.1	RP5-1125A11.6	-3.97	9.46e-05	0.0297	-0.29	-0.25	Skin pigmentation;	chr20:33955767	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.602	rs4911380	ENSG00000275784.1	RP5-1125A11.6	-3.97	9.46e-05	0.0297	-0.29	-0.25	Skin pigmentation;	chr20:33958418	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.625	rs4911138	ENSG00000275784.1	RP5-1125A11.6	-3.97	9.46e-05	0.0297	-0.29	-0.25	Skin pigmentation;	chr20:33959893	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.625	rs4243974	ENSG00000275784.1	RP5-1125A11.6	-3.97	9.46e-05	0.0297	-0.29	-0.25	Skin pigmentation;	chr20:33960062	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.625	rs6142062	ENSG00000275784.1	RP5-1125A11.6	-3.97	9.46e-05	0.0297	-0.29	-0.25	Skin pigmentation;	chr20:33960706	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.625	rs6141432	ENSG00000275784.1	RP5-1125A11.6	-3.97	9.46e-05	0.0297	-0.29	-0.25	Skin pigmentation;	chr20:33960791	chr20:33989480~33991818:-
SARC	cis	rs6142102	0.602	rs6141433	ENSG00000275784.1	RP5-1125A11.6	-3.97	9.46e-05	0.0297	-0.29	-0.25	Skin pigmentation;	chr20:33961056	chr20:33989480~33991818:-
SARC	cis	rs319598	0.586	rs10515465	ENSG00000224186.7	C5orf66	3.97	9.46e-05	0.0298	0.25	0.25	Type 2 diabetes;	chr5:134931867	chr5:135033280~135358219:+
SARC	cis	rs2439831	0.681	rs524527	ENSG00000275601.1	AC011330.13	3.97	9.46e-05	0.0298	0.37	0.25	Lung cancer in ever smokers;	chr15:43306918	chr15:43642389~43643023:-
SARC	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-3.97	9.47e-05	0.0298	-0.3	-0.25	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
SARC	cis	rs17826219	0.5	rs61685770	ENSG00000264538.5	SUZ12P1	-3.97	9.47e-05	0.0298	-0.27	-0.25	Body mass index;	chr17:30758695	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs57486336	ENSG00000264538.5	SUZ12P1	-3.97	9.47e-05	0.0298	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30709299~30790908:+
SARC	cis	rs17826219	0.706	rs55764512	ENSG00000264538.5	SUZ12P1	-3.97	9.47e-05	0.0298	-0.27	-0.25	Body mass index;	chr17:30758740	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs12103440	ENSG00000264538.5	SUZ12P1	-3.97	9.47e-05	0.0298	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs12103508	ENSG00000264538.5	SUZ12P1	-3.97	9.47e-05	0.0298	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.524	rs11653605	ENSG00000264538.5	SUZ12P1	-3.97	9.47e-05	0.0298	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs11657777	ENSG00000264538.5	SUZ12P1	-3.97	9.47e-05	0.0298	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs7217984	ENSG00000264538.5	SUZ12P1	-3.97	9.47e-05	0.0298	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30709299~30790908:+
SARC	cis	rs6927268	1	rs6927268	ENSG00000203799.9	CCDC162P	3.97	9.47e-05	0.0298	0.32	0.25	Intelligence (multi-trait analysis);	chr6:108544460	chr6:109285485~109355063:+
SARC	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-3.97	9.48e-05	0.0298	-0.23	-0.25	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
SARC	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	3.97	9.48e-05	0.0298	0.27	0.25	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
SARC	cis	rs9868809	0.505	rs28657585	ENSG00000225399.4	RP11-3B7.1	-3.97	9.48e-05	0.0298	-0.43	-0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48698783	chr3:49260085~49261316:+
SARC	cis	rs7772486	0.754	rs864148	ENSG00000235652.6	RP11-545I5.3	-3.97	9.48e-05	0.0298	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145799409~145886585:+
SARC	cis	rs783540	0.934	rs4779050	ENSG00000275695.1	UBE2Q2P6	3.97	9.49e-05	0.0298	0.25	0.25	Schizophrenia;	chr15:82699986	chr15:82445719~82454837:+
SARC	cis	rs7829975	0.744	rs2409092	ENSG00000253893.2	FAM85B	-3.97	9.5e-05	0.0298	-0.22	-0.25	Mood instability;	chr8:8824682	chr8:8167819~8226614:-
SARC	cis	rs755249	0.567	rs72661965	ENSG00000182109.6	RP11-69E11.4	3.97	9.5e-05	0.0298	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39522280~39546187:-
SARC	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-3.97	9.5e-05	0.0299	-0.33	-0.25	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
SARC	cis	rs7246657	0.943	rs10407084	ENSG00000226686.6	LINC01535	-3.97	9.5e-05	0.0299	-0.35	-0.25	Coronary artery calcification;	chr19:37416890	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.823	rs4802236	ENSG00000226686.6	LINC01535	-3.97	9.5e-05	0.0299	-0.35	-0.25	Coronary artery calcification;	chr19:37428344	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs7252099	ENSG00000226686.6	LINC01535	-3.97	9.5e-05	0.0299	-0.35	-0.25	Coronary artery calcification;	chr19:37442878	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs7255972	ENSG00000226686.6	LINC01535	-3.97	9.5e-05	0.0299	-0.35	-0.25	Coronary artery calcification;	chr19:37442939	chr19:37251912~37265535:+
SARC	cis	rs853679	0.55	rs1233707	ENSG00000272009.1	RP1-313I6.12	-3.97	9.5e-05	0.0299	-0.27	-0.25	Depression;	chr6:28205175	chr6:28078792~28081130:-
SARC	cis	rs59867004	1	rs59867004	ENSG00000231507.1	LINC01353	3.97	9.5e-05	0.0299	0.28	0.25	Breast cancer;	chr1:203832121	chr1:203287152~203288801:+
SARC	cis	rs937213	0.608	rs7177179	ENSG00000275636.1	RP11-521C20.5	3.97	9.51e-05	0.0299	0.3	0.25	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:39995781	chr15:40078892~40079347:+
SARC	cis	rs11694172	1	rs62194137	ENSG00000273456.1	RP11-686O6.2	3.97	9.52e-05	0.0299	0.22	0.25	Cholesterol, total;	chr2:202686822	chr2:202374932~202375604:-
SARC	cis	rs2235544	0.579	rs11804837	ENSG00000225183.1	RP4-758J24.4	-3.97	9.52e-05	0.0299	-0.28	-0.25	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54017242	chr1:54089856~54090093:+
SARC	cis	rs6570726	0.967	rs365515	ENSG00000270638.1	RP3-466P17.1	-3.97	9.52e-05	0.0299	-0.21	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145481697	chr6:145735570~145737218:+
SARC	cis	rs3761847	0.622	rs4837807	ENSG00000226752.6	PSMD5-AS1	-3.97	9.52e-05	0.0299	-0.3	-0.25	Rheumatoid arthritis;	chr9:121029727	chr9:120824828~120854385:+
SARC	cis	rs6964833	1	rs34324835	ENSG00000184616.8	AC004166.6	3.97	9.53e-05	0.0299	0.36	0.25	Menarche (age at onset);	chr7:74717986	chr7:74906673~74913256:-
SARC	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-3.97	9.53e-05	0.0299	-0.39	-0.25	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
SARC	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-3.97	9.53e-05	0.0299	-0.39	-0.25	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
SARC	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-3.97	9.53e-05	0.0299	-0.39	-0.25	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
SARC	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-3.97	9.53e-05	0.0299	-0.39	-0.25	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
SARC	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-3.97	9.53e-05	0.0299	-0.39	-0.25	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
SARC	cis	rs4950322	0.58	rs4950371	ENSG00000278811.3	LINC00624	3.97	9.53e-05	0.0299	0.26	0.25	Protein quantitative trait loci;	chr1:147114243	chr1:147258885~147517875:-
SARC	cis	rs7085104	0.7	rs743572	ENSG00000213061.2	PFN1P11	3.97	9.53e-05	0.0299	0.3	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837395	chr10:102838011~102845473:-
SARC	cis	rs7163013	0.933	rs11635500	ENSG00000259792.1	RP11-114H24.6	3.97	9.54e-05	0.0299	0.26	0.25	Obesity-related traits;	chr15:78388321	chr15:77993405~77995289:+
SARC	cis	rs28386778	0.897	rs2028567	ENSG00000240280.5	TCAM1P	-3.97	9.54e-05	0.0299	-0.31	-0.25	Prudent dietary pattern;	chr17:63837966	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs6504187	ENSG00000240280.5	TCAM1P	-3.97	9.54e-05	0.0299	-0.31	-0.25	Prudent dietary pattern;	chr17:63839739	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2859619	ENSG00000240280.5	TCAM1P	-3.97	9.54e-05	0.0299	-0.31	-0.25	Prudent dietary pattern;	chr17:63840326	chr17:63849292~63864379:+
SARC	cis	rs916888	0.647	rs199449	ENSG00000261575.2	RP11-259G18.1	3.97	9.54e-05	0.0299	0.32	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46267037~46268694:+
SARC	cis	rs916888	0.61	rs199444	ENSG00000261575.2	RP11-259G18.1	3.97	9.54e-05	0.0299	0.32	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46267037~46268694:+
SARC	cis	rs916888	0.61	rs199442	ENSG00000261575.2	RP11-259G18.1	3.97	9.54e-05	0.0299	0.32	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46267037~46268694:+
SARC	cis	rs207954	0.853	rs1517620	ENSG00000258922.1	CTD-2313J17.1	3.97	9.54e-05	0.03	0.29	0.25	Acute lymphoblastic leukemia (childhood);	chr15:92107033	chr15:92805770~92808567:-
SARC	cis	rs860818	0.793	rs1406080	ENSG00000226816.2	AC005082.12	-3.97	9.55e-05	0.03	-0.67	-0.25	Initial pursuit acceleration;	chr7:23153985	chr7:23206013~23208045:+
SARC	cis	rs72627123	0.5	rs67852564	ENSG00000259065.1	RP5-1021I20.1	-3.97	9.55e-05	0.03	-0.34	-0.25	Morning vs. evening chronotype;	chr14:74093217	chr14:73787360~73803270:+
SARC	cis	rs62005083	0.5	rs10135300	ENSG00000259065.1	RP5-1021I20.1	-3.97	9.55e-05	0.03	-0.34	-0.25	Mean corpuscular volume;	chr14:74107858	chr14:73787360~73803270:+
SARC	cis	rs11159086	1	rs4903233	ENSG00000270000.1	RP3-449M8.9	3.97	9.55e-05	0.03	0.37	0.25	Advanced glycation end-product levels;	chr14:74497291	chr14:74471930~74472360:-
SARC	cis	rs2274273	0.638	rs3759667	ENSG00000258413.1	RP11-665C16.6	-3.97	9.56e-05	0.03	-0.35	-0.25	Protein biomarker;	chr14:55191703	chr14:55262767~55272075:-
SARC	cis	rs9436747	0.605	rs2025803	ENSG00000237852.1	RP4-630A11.3	-3.97	9.56e-05	0.03	-0.25	-0.25	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr1:65480823	chr1:65486406~65494188:+
SARC	cis	rs4950322	0.57	rs17360443	ENSG00000278811.3	LINC00624	3.97	9.56e-05	0.03	0.26	0.25	Protein quantitative trait loci;	chr1:147279737	chr1:147258885~147517875:-
SARC	cis	rs853679	1	rs853676	ENSG00000216901.1	AL022393.7	3.97	9.56e-05	0.03	0.44	0.25	Depression;	chr6:28331910	chr6:28176188~28176674:+
SARC	cis	rs30380	0.587	rs151940	ENSG00000272109.1	CTD-2260A17.3	-3.97	9.56e-05	0.03	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96812074	chr5:96804353~96806105:+
SARC	cis	rs1211375	0.607	rs1203978	ENSG00000268836.1	LA16c-OS12.2	-3.97	9.57e-05	0.03	-0.24	-0.25	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:207212	chr16:185748~186294:-
SARC	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	3.97	9.57e-05	0.03	0.46	0.25	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
SARC	cis	rs7267979	0.866	rs437635	ENSG00000276952.1	RP5-965G21.6	3.97	9.57e-05	0.03	0.25	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:25284915~25285588:-
SARC	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	3.97	9.57e-05	0.03	0.29	0.25	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
SARC	cis	rs7429990	0.931	rs62262084	ENSG00000229759.1	MRPS18AP1	3.97	9.57e-05	0.03	0.34	0.25	Educational attainment (years of education);	chr3:47612332	chr3:48256350~48256938:-
SARC	cis	rs783540	0.967	rs1864699	ENSG00000275695.1	UBE2Q2P6	3.97	9.57e-05	0.03	0.26	0.25	Schizophrenia;	chr15:82654567	chr15:82445719~82454837:+
SARC	cis	rs7923609	0.756	rs6479908	ENSG00000232075.1	MRPL35P2	3.97	9.58e-05	0.03	0.22	0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63573888	chr10:63634317~63634827:-
SARC	cis	rs12980942	0.935	rs12980480	ENSG00000206674.1	RNU6-945P	-3.97	9.58e-05	0.03	-0.36	-0.25	Coronary artery disease;	chr19:41298750	chr19:40299478~40299584:-
SARC	cis	rs12980942	0.872	rs11879562	ENSG00000206674.1	RNU6-945P	-3.97	9.58e-05	0.03	-0.36	-0.25	Coronary artery disease;	chr19:41299071	chr19:40299478~40299584:-
SARC	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-3.97	9.58e-05	0.03	-0.34	-0.25	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
SARC	cis	rs9902453	0.904	rs10853136	ENSG00000264538.5	SUZ12P1	-3.97	9.58e-05	0.03	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30079000	chr17:30709299~30790908:+
SARC	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-3.97	9.58e-05	0.03	-0.3	-0.25	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
SARC	cis	rs2281636	0.691	rs11190218	ENSG00000233690.1	EBAG9P1	3.97	9.59e-05	0.03	0.26	0.25	Obesity-related traits;	chr10:99650305	chr10:99697407~99697949:-
SARC	cis	rs4372836	0.543	rs3768665	ENSG00000226833.4	AC097724.3	3.97	9.59e-05	0.03	0.22	0.25	Body mass index;	chr2:28782736	chr2:28708953~28736205:-
SARC	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	3.97	9.6e-05	0.0301	0.34	0.25	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
SARC	cis	rs11105298	0.786	rs10858867	ENSG00000258302.2	RP11-981P6.1	3.97	9.6e-05	0.0301	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	3.97	9.6e-05	0.0301	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.786	rs3803128	ENSG00000258302.2	RP11-981P6.1	3.97	9.6e-05	0.0301	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs10506972	ENSG00000258302.2	RP11-981P6.1	3.97	9.6e-05	0.0301	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs12228177	ENSG00000258302.2	RP11-981P6.1	3.97	9.6e-05	0.0301	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	3.97	9.6e-05	0.0301	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs10858872	ENSG00000258302.2	RP11-981P6.1	3.97	9.6e-05	0.0301	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89561129~89594878:+
SARC	cis	rs6750795	0.502	rs11685196	ENSG00000223198.1	RNU2-22P	-3.97	9.6e-05	0.0301	-0.25	-0.25	Height;	chr2:231516587	chr2:231501990~231502201:-
SARC	cis	rs2404602	0.583	rs12438741	ENSG00000259422.1	RP11-593F23.1	3.97	9.6e-05	0.0301	0.28	0.25	Blood metabolite levels;	chr15:76249773	chr15:76174891~76181486:-
SARC	cis	rs7208859	0.623	rs73269913	ENSG00000264538.5	SUZ12P1	-3.97	9.6e-05	0.0301	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30709299~30790908:+
SARC	cis	rs2404602	0.716	rs17364076	ENSG00000259422.1	RP11-593F23.1	3.97	9.6e-05	0.0301	0.28	0.25	Blood metabolite levels;	chr15:76468550	chr15:76174891~76181486:-
SARC	cis	rs56046484	1	rs12911330	ENSG00000259295.5	CSPG4P12	3.97	9.6e-05	0.0301	0.37	0.25	Testicular germ cell tumor;	chr15:85087103	chr15:85191438~85213905:+
SARC	cis	rs56046484	0.956	rs34919315	ENSG00000259295.5	CSPG4P12	3.97	9.6e-05	0.0301	0.37	0.25	Testicular germ cell tumor;	chr15:85088675	chr15:85191438~85213905:+
SARC	cis	rs2179367	0.959	rs237034	ENSG00000216906.2	RP11-350J20.9	3.97	9.6e-05	0.0301	0.23	0.25	Dupuytren's disease;	chr6:149390726	chr6:149904243~149906418:+
SARC	cis	rs2179367	0.959	rs628488	ENSG00000216906.2	RP11-350J20.9	3.97	9.6e-05	0.0301	0.23	0.25	Dupuytren's disease;	chr6:149398264	chr6:149904243~149906418:+
SARC	cis	rs17508449	0.775	rs4839336	ENSG00000232450.1	RP4-730K3.3	-3.97	9.6e-05	0.0301	-0.33	-0.25	Leprosy;	chr1:113691523	chr1:113698884~113699631:-
SARC	cis	rs17508449	0.819	rs77551704	ENSG00000232450.1	RP4-730K3.3	-3.97	9.6e-05	0.0301	-0.33	-0.25	Leprosy;	chr1:113692564	chr1:113698884~113699631:-
SARC	cis	rs17508449	0.819	rs78874053	ENSG00000232450.1	RP4-730K3.3	-3.97	9.6e-05	0.0301	-0.33	-0.25	Leprosy;	chr1:113700251	chr1:113698884~113699631:-
SARC	cis	rs6964833	1	rs6967152	ENSG00000184616.8	AC004166.6	3.97	9.61e-05	0.0301	0.37	0.25	Menarche (age at onset);	chr7:74684983	chr7:74906673~74913256:-
SARC	cis	rs6964833	1	rs6964833	ENSG00000184616.8	AC004166.6	3.97	9.61e-05	0.0301	0.37	0.25	Menarche (age at onset);	chr7:74687575	chr7:74906673~74913256:-
SARC	cis	rs12721025	1	rs12721025	ENSG00000254851.1	RP11-109L13.1	3.97	9.61e-05	0.0301	0.65	0.25	Infantile hypertrophic pyloric stenosis;	chr11:116835331	chr11:117135528~117138582:+
SARC	cis	rs7520050	0.553	rs2993263	ENSG00000280836.1	AL355480.1	-3.97	9.61e-05	0.0301	-0.24	-0.25	Reticulocyte count;Red blood cell count;	chr1:45555958	chr1:45581219~45581321:-
SARC	cis	rs10986311	0.681	rs35068124	ENSG00000235204.1	RP11-121A14.2	3.97	9.62e-05	0.0301	0.29	0.25	Vitiligo;	chr9:124265531	chr9:124259250~124261156:-
SARC	cis	rs319598	0.773	rs72800367	ENSG00000224186.7	C5orf66	-3.97	9.62e-05	0.0301	-0.22	-0.25	Type 2 diabetes;	chr5:134926581	chr5:135033280~135358219:+
SARC	cis	rs7246657	0.943	rs10420430	ENSG00000226686.6	LINC01535	-3.97	9.62e-05	0.0301	-0.36	-0.25	Coronary artery calcification;	chr19:37403292	chr19:37251912~37265535:+
SARC	cis	rs910316	1	rs175442	ENSG00000279594.1	RP11-950C14.10	-3.97	9.62e-05	0.0301	-0.27	-0.25	Height;	chr14:75136861	chr14:75011269~75012851:-
SARC	cis	rs4925386	0.84	rs6143035	ENSG00000275437.1	RP5-908M14.10	-3.97	9.62e-05	0.0301	-0.24	-0.25	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345644	chr20:62402236~62405935:-
SARC	cis	rs9947295	0.649	rs57958293	ENSG00000267480.1	RP11-703I16.1	-3.97	9.63e-05	0.0302	-0.44	-0.25	QT interval (drug interaction);	chr18:11778840	chr18:12031178~12032181:-
SARC	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	3.97	9.63e-05	0.0302	0.31	0.25	Height;	chr6:109391534	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	3.97	9.63e-05	0.0302	0.31	0.25	Height;	chr6:109393881	chr6:109382795~109383666:+
SARC	cis	rs1707322	0.929	rs785500	ENSG00000281133.1	AL355480.3	3.97	9.63e-05	0.0302	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45580892~45580996:-
SARC	cis	rs7688540	0.771	rs10027325	ENSG00000275426.1	CH17-262A2.1	3.97	9.63e-05	0.0302	0.35	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs1986557	ENSG00000275426.1	CH17-262A2.1	3.97	9.63e-05	0.0302	0.35	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:149738~150317:+
SARC	cis	rs10540	1	rs12418639	ENSG00000277290.1	RP11-326C3.16	-3.97	9.64e-05	0.0302	-0.32	-0.25	Body mass index;	chr11:473300	chr11:243099~243483:-
SARC	cis	rs151234	0.8	rs231972	ENSG00000259982.1	CDC37P1	-3.97	9.64e-05	0.0302	-0.38	-0.25	Platelet distribution width;	chr16:28527015	chr16:28700294~28701540:-
SARC	cis	rs151234	0.8	rs231974	ENSG00000259982.1	CDC37P1	-3.97	9.64e-05	0.0302	-0.38	-0.25	Platelet distribution width;	chr16:28529001	chr16:28700294~28701540:-
SARC	cis	rs2408955	0.522	rs10875721	ENSG00000240399.1	RP1-228P16.1	-3.97	9.64e-05	0.0302	-0.3	-0.25	Glycated hemoglobin levels;	chr12:48019810	chr12:48054813~48055591:-
SARC	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	3.97	9.64e-05	0.0302	0.38	0.25	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	3.97	9.64e-05	0.0302	0.38	0.25	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
SARC	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	3.97	9.64e-05	0.0302	0.38	0.25	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
SARC	cis	rs28386778	0.897	rs4968597	ENSG00000240280.5	TCAM1P	-3.97	9.65e-05	0.0302	-0.31	-0.25	Prudent dietary pattern;	chr17:63728387	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.83	rs6504180	ENSG00000240280.5	TCAM1P	-3.97	9.65e-05	0.0302	-0.31	-0.25	Prudent dietary pattern;	chr17:63735809	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs8066754	ENSG00000240280.5	TCAM1P	-3.97	9.65e-05	0.0302	-0.31	-0.25	Prudent dietary pattern;	chr17:63739230	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.863	rs3826341	ENSG00000240280.5	TCAM1P	-3.97	9.65e-05	0.0302	-0.31	-0.25	Prudent dietary pattern;	chr17:63741862	chr17:63849292~63864379:+
SARC	cis	rs448720	0.776	rs1001870	ENSG00000259410.4	RP11-34F13.3	-3.97	9.65e-05	0.0302	-0.28	-0.25	Cognitive performance;	chr15:67859110	chr15:67832725~67873866:+
SARC	cis	rs889122	1	rs16996444	ENSG00000267289.1	CTD-2623N2.11	3.97	9.66e-05	0.0302	0.26	0.25	Menarche (age at onset);	chr19:9886562	chr19:9834079~9835013:-
SARC	cis	rs9902453	0.874	rs7213517	ENSG00000264538.5	SUZ12P1	-3.97	9.66e-05	0.0302	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30074722	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs7218379	ENSG00000264538.5	SUZ12P1	-3.97	9.66e-05	0.0302	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30075719	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.817	rs7217961	ENSG00000264538.5	SUZ12P1	-3.97	9.66e-05	0.0302	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30076094	chr17:30709299~30790908:+
SARC	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-3.97	9.67e-05	0.0303	-0.38	-0.25	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
SARC	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	3.97	9.67e-05	0.0303	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
SARC	cis	rs6740322	0.857	rs11690012	ENSG00000234936.1	AC010883.5	3.97	9.68e-05	0.0303	0.28	0.25	Coronary artery disease;	chr2:43315341	chr2:43229573~43233394:+
SARC	cis	rs792448	1	rs792448	ENSG00000229983.1	RP11-15I11.2	-3.97	9.68e-05	0.0303	-0.26	-0.25	White blood cell count (basophil);	chr1:212385055	chr1:212168207~212190259:+
SARC	cis	rs8054556	0.74	rs4407079	ENSG00000183604.13	SMG1P5	-3.97	9.69e-05	0.0303	-0.24	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29920578	chr16:30267553~30335374:-
SARC	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	3.97	9.69e-05	0.0303	0.34	0.25	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
SARC	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	3.97	9.69e-05	0.0303	0.24	0.25	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
SARC	cis	rs4835473	0.932	rs13147386	ENSG00000251600.4	RP11-673E1.1	3.97	9.69e-05	0.0303	0.25	0.25	Immature fraction of reticulocytes;	chr4:143736586	chr4:143912331~143982454:+
SARC	cis	rs6142102	0.646	rs2223553	ENSG00000275784.1	RP5-1125A11.6	-3.97	9.69e-05	0.0303	-0.29	-0.25	Skin pigmentation;	chr20:34121638	chr20:33989480~33991818:-
SARC	cis	rs600550	0.618	rs1443250	ENSG00000255139.1	AP000442.1	-3.97	9.7e-05	0.0303	-0.25	-0.25	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60335317	chr11:59616429~59639861:+
SARC	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	3.97	9.7e-05	0.0303	0.31	0.25	Height;	chr6:109403734	chr6:109382795~109383666:+
SARC	cis	rs848486	0.936	rs10268139	ENSG00000214293.7	APTR	-3.97	9.7e-05	0.0304	-0.26	-0.25	Glomerular filtration rate;	chr7:77698783	chr7:77657660~77696265:-
SARC	cis	rs240993	0.761	rs453776	ENSG00000230177.1	RP5-1112D6.4	-3.97	9.71e-05	0.0304	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111342260	chr6:111277932~111278742:+
SARC	cis	rs367615	0.918	rs10070104	ENSG00000249476.1	CTD-2587M2.1	-3.97	9.71e-05	0.0304	-0.33	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109530737	chr5:109237120~109326369:-
SARC	cis	rs11105298	0.891	rs10858909	ENSG00000258302.2	RP11-981P6.1	3.97	9.71e-05	0.0304	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs4842664	ENSG00000258302.2	RP11-981P6.1	3.97	9.71e-05	0.0304	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs11105325	ENSG00000258302.2	RP11-981P6.1	3.97	9.71e-05	0.0304	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89561129~89594878:+
SARC	cis	rs755249	0.517	rs66880209	ENSG00000182109.6	RP11-69E11.4	3.97	9.71e-05	0.0304	0.3	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39254140	chr1:39522280~39546187:-
SARC	cis	rs10911902	0.913	rs6666680	ENSG00000229739.2	RP11-295K2.3	-3.97	9.72e-05	0.0304	-0.35	-0.25	Schizophrenia;	chr1:186551203	chr1:186435161~186470291:+
SARC	cis	rs950776	0.714	rs3743073	ENSG00000261762.1	RP11-650L12.2	-3.97	9.72e-05	0.0304	-0.27	-0.25	Sudden cardiac arrest;	chr15:78617197	chr15:78589123~78591276:-
SARC	cis	rs4664293	0.642	rs6732598	ENSG00000226266.5	AC009961.3	3.97	9.72e-05	0.0304	0.29	0.25	Monocyte percentage of white cells;	chr2:159790370	chr2:159670708~159712435:-
SARC	cis	rs2439831	0.867	rs2278860	ENSG00000275601.1	AC011330.13	3.97	9.73e-05	0.0304	0.38	0.25	Lung cancer in ever smokers;	chr15:43366848	chr15:43642389~43643023:-
SARC	cis	rs10504130	0.569	rs4626585	ENSG00000253844.1	RP11-546K22.1	3.97	9.73e-05	0.0304	0.36	0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51767380	chr8:51961458~52022974:+
SARC	cis	rs7829975	0.686	rs907180	ENSG00000253426.4	RP11-10A14.4	3.97	9.74e-05	0.0304	0.28	0.25	Mood instability;	chr8:8845317	chr8:9151742~9168136:+
SARC	cis	rs1223397	0.938	rs3817742	ENSG00000215022.6	RP1-257A7.4	-3.97	9.75e-05	0.0305	-0.32	-0.25	Blood pressure;	chr6:13279320	chr6:13264861~13295586:-
SARC	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-3.97	9.75e-05	0.0305	-0.23	-0.25	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
SARC	cis	rs4664293	0.647	rs1549385	ENSG00000226266.5	AC009961.3	-3.97	9.75e-05	0.0305	-0.29	-0.25	Monocyte percentage of white cells;	chr2:159582540	chr2:159670708~159712435:-
SARC	cis	rs7713317	0.742	rs56198733	ENSG00000236882.6	LINC01554	-3.97	9.76e-05	0.0305	-0.31	-0.25	Body mass index;	chr5:96191353	chr5:95852232~95860133:+
SARC	cis	rs7267979	0.744	rs6050463	ENSG00000276952.1	RP5-965G21.6	3.96	9.78e-05	0.0305	0.24	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:25284915~25285588:-
SARC	cis	rs1707322	1	rs7532204	ENSG00000281133.1	AL355480.3	3.96	9.78e-05	0.0306	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.835	rs946525	ENSG00000281133.1	AL355480.3	3.96	9.78e-05	0.0306	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs946524	ENSG00000281133.1	AL355480.3	3.96	9.78e-05	0.0306	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4660336	ENSG00000281133.1	AL355480.3	3.96	9.78e-05	0.0306	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45580892~45580996:-
SARC	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-3.96	9.78e-05	0.0306	-0.29	-0.25	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
SARC	cis	rs7615952	0.576	rs2276729	ENSG00000248787.1	RP11-666A20.4	-3.96	9.78e-05	0.0306	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:126107371	chr3:125908005~125910272:-
SARC	cis	rs2239547	0.618	rs3733047	ENSG00000242142.1	SERBP1P3	-3.96	9.79e-05	0.0306	-0.3	-0.25	Schizophrenia;	chr3:52837913	chr3:53064283~53065091:-
SARC	cis	rs13113518	0.729	rs12641881	ENSG00000273257.1	RP11-177J6.1	3.96	9.79e-05	0.0306	0.33	0.25	Height;	chr4:55401306	chr4:55387949~55388271:+
SARC	cis	rs6540731	0.935	rs903120	ENSG00000229983.1	RP11-15I11.2	3.96	9.79e-05	0.0306	0.25	0.25	Intelligence (childhood);	chr1:212231830	chr1:212168207~212190259:+
SARC	cis	rs6540731	1	rs2087946	ENSG00000229983.1	RP11-15I11.2	3.96	9.79e-05	0.0306	0.25	0.25	Intelligence (childhood);	chr1:212232054	chr1:212168207~212190259:+
SARC	cis	rs6540731	1	rs903121	ENSG00000229983.1	RP11-15I11.2	3.96	9.79e-05	0.0306	0.25	0.25	Intelligence (childhood);	chr1:212232113	chr1:212168207~212190259:+
SARC	cis	rs1211375	0.606	rs1203977	ENSG00000268836.1	LA16c-OS12.2	-3.96	9.8e-05	0.0306	-0.24	-0.25	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:206279	chr16:185748~186294:-
SARC	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-3.96	9.8e-05	0.0306	-0.26	-0.25	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
SARC	cis	rs7646881	1	rs73015649	ENSG00000240207.5	RP11-379F4.4	-3.96	9.81e-05	0.0306	-0.37	-0.25	Tetralogy of Fallot;	chr3:158732509	chr3:158732263~158784070:+
SARC	cis	rs7646881	1	rs73015654	ENSG00000240207.5	RP11-379F4.4	-3.96	9.81e-05	0.0306	-0.37	-0.25	Tetralogy of Fallot;	chr3:158733865	chr3:158732263~158784070:+
SARC	cis	rs7646881	0.953	rs73015657	ENSG00000240207.5	RP11-379F4.4	-3.96	9.81e-05	0.0306	-0.37	-0.25	Tetralogy of Fallot;	chr3:158734143	chr3:158732263~158784070:+
SARC	cis	rs9858542	0.537	rs9873994	ENSG00000225399.4	RP11-3B7.1	-3.96	9.81e-05	0.0306	-0.39	-0.25	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49322510	chr3:49260085~49261316:+
SARC	cis	rs7267979	0.789	rs1983974	ENSG00000125804.12	FAM182A	3.96	9.81e-05	0.0306	0.28	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:26054655~26086917:+
SARC	cis	rs12817211	0.502	rs17124432	ENSG00000272368.2	RP4-605O3.4	3.96	9.81e-05	0.0306	0.24	0.25	Colorectal or endometrial cancer;	chr12:50116994	chr12:50112197~50165618:+
SARC	cis	rs7726354	1	rs112032073	ENSG00000271828.1	CTD-2310F14.1	3.96	9.81e-05	0.0306	0.53	0.25	Breast cancer (early onset);	chr5:56974890	chr5:56927874~56929573:+
SARC	cis	rs858239	0.6	rs28499396	ENSG00000226816.2	AC005082.12	3.96	9.81e-05	0.0306	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23206013~23208045:+
SARC	cis	rs858239	0.6	rs7789237	ENSG00000226816.2	AC005082.12	3.96	9.81e-05	0.0306	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23206013~23208045:+
SARC	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-3.96	9.82e-05	0.0307	-0.3	-0.25	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
SARC	cis	rs2439831	0.867	rs486301	ENSG00000275601.1	AC011330.13	-3.96	9.82e-05	0.0307	-0.4	-0.25	Lung cancer in ever smokers;	chr15:43544751	chr15:43642389~43643023:-
SARC	cis	rs2404602	0.716	rs8025134	ENSG00000259422.1	RP11-593F23.1	3.96	9.82e-05	0.0307	0.28	0.25	Blood metabolite levels;	chr15:76489388	chr15:76174891~76181486:-
SARC	cis	rs4835473	0.9	rs7698963	ENSG00000251600.4	RP11-673E1.1	3.96	9.82e-05	0.0307	0.24	0.25	Immature fraction of reticulocytes;	chr4:143733190	chr4:143912331~143982454:+
SARC	cis	rs7246657	0.943	rs1015848	ENSG00000226686.6	LINC01535	-3.96	9.82e-05	0.0307	-0.35	-0.25	Coronary artery calcification;	chr19:37454372	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs4801759	ENSG00000226686.6	LINC01535	-3.96	9.82e-05	0.0307	-0.35	-0.25	Coronary artery calcification;	chr19:37464083	chr19:37251912~37265535:+
SARC	cis	rs73439953	0.57	rs4940432	ENSG00000267677.1	RP11-27G24.1	3.96	9.82e-05	0.0307	0.27	0.25	Triptolide cytotoxicity;	chr18:58937152	chr18:59360700~59386749:+
SARC	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-3.96	9.83e-05	0.0307	-0.29	-0.25	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
SARC	cis	rs7615952	0.599	rs16834938	ENSG00000248787.1	RP11-666A20.4	-3.96	9.83e-05	0.0307	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:125987203	chr3:125908005~125910272:-
SARC	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	3.96	9.83e-05	0.0307	0.31	0.25	Height;	chr6:109402736	chr6:109382795~109383666:+
SARC	cis	rs7267979	0.816	rs443009	ENSG00000125804.12	FAM182A	3.96	9.83e-05	0.0307	0.28	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:26054655~26086917:+
SARC	cis	rs7580658	0.817	rs6761447	ENSG00000236682.1	AC068282.3	-3.96	9.83e-05	0.0307	-0.29	-0.25	Protein C levels;	chr2:127316997	chr2:127389130~127400580:+
SARC	cis	rs858239	0.636	rs28706766	ENSG00000226816.2	AC005082.12	3.96	9.83e-05	0.0307	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23206013~23208045:+
SARC	cis	rs9656169	0.868	rs1396176	ENSG00000226965.1	AC003088.1	3.96	9.84e-05	0.0307	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr7:110457251	chr7:110432239~110534754:-
SARC	cis	rs7246657	1	rs12709812	ENSG00000226686.6	LINC01535	3.96	9.84e-05	0.0307	0.36	0.25	Coronary artery calcification;	chr19:37303948	chr19:37251912~37265535:+
SARC	cis	rs8028182	0.636	rs28737338	ENSG00000260206.1	CTD-2026K11.2	-3.96	9.84e-05	0.0307	-0.3	-0.25	Sudden cardiac arrest;	chr15:75476338	chr15:75636139~75639239:+
SARC	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	3.96	9.84e-05	0.0307	0.2	0.25	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
SARC	cis	rs7182621	0.639	rs1561048	ENSG00000182397.13	DNM1P46	3.96	9.84e-05	0.0307	0.29	0.25	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99790156~99806927:-
SARC	cis	rs12893668	0.572	rs2273175	ENSG00000269958.1	RP11-73M18.8	3.96	9.84e-05	0.0307	0.27	0.25	Reticulocyte count;	chr14:103693804	chr14:103696353~103697163:+
SARC	cis	rs10871290	0.65	rs28484753	ENSG00000214331.7	RP11-252A24.2	3.96	9.84e-05	0.0307	0.21	0.25	Breast cancer;	chr16:74455497	chr16:74332402~74368240:-
SARC	cis	rs7208859	0.623	rs55811708	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.562	rs8078897	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs8075163	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30709299~30790908:+
SARC	cis	rs17826219	0.706	rs8075107	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Body mass index;	chr17:30779631	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs7223209	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9916725	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9916727	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9914499	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs73269945	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9897728	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs1054400	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9890558	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9912283	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs12006	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs3752021	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs3752020	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9890855	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9893422	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9891166	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs73269974	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs34756112	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.573	rs60724269	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs76633166	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs1061346	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs1061343	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs55938328	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs73269988	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs55961983	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.673	rs9899525	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30709299~30790908:+
SARC	cis	rs17826219	0.568	rs7213925	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Body mass index;	chr17:30794616	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.524	rs11653098	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs11658945	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs11657990	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9911784	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9911997	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9890862	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs78071511	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs11650982	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs2035494	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9915546	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs9915566	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.573	rs8070182	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs11657369	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs8075341	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs73271842	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.673	rs9895815	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.673	rs8077116	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.524	rs28760584	ENSG00000264538.5	SUZ12P1	-3.96	9.85e-05	0.0307	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30709299~30790908:+
SARC	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	3.96	9.85e-05	0.0307	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
SARC	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	3.96	9.86e-05	0.0307	0.31	0.25	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
SARC	cis	rs10986311	0.722	rs17315546	ENSG00000235204.1	RP11-121A14.2	-3.96	9.86e-05	0.0307	-0.29	-0.25	Vitiligo;	chr9:124385950	chr9:124259250~124261156:-
SARC	cis	rs853679	0.599	rs202906	ENSG00000216901.1	AL022393.7	-3.96	9.86e-05	0.0307	-0.49	-0.25	Depression;	chr6:28043874	chr6:28176188~28176674:+
SARC	cis	rs7520050	0.966	rs785464	ENSG00000280836.1	AL355480.1	3.96	9.87e-05	0.0307	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46057417	chr1:45581219~45581321:-
SARC	cis	rs150992	0.569	rs326482	ENSG00000248489.1	CTD-2007H13.3	3.96	9.87e-05	0.0307	0.29	0.25	Body mass index;	chr5:98951115	chr5:98929171~98995013:+
SARC	cis	rs7617773	0.747	rs34076262	ENSG00000228638.1	FCF1P2	-3.96	9.87e-05	0.0307	-0.29	-0.25	Coronary artery disease;	chr3:48328926	chr3:48290793~48291375:-
SARC	cis	rs1880529	0.966	rs13113625	ENSG00000206820.1	RNU1-138P	-3.96	9.87e-05	0.0307	-0.24	-0.25	White matter integrity (bipolar disorder risk interaction);	chr4:113472588	chr4:113420323~113420486:+
SARC	cis	rs28386778	0.897	rs2584608	ENSG00000240280.5	TCAM1P	-3.96	9.89e-05	0.0308	-0.31	-0.25	Prudent dietary pattern;	chr17:63859350	chr17:63849292~63864379:+
SARC	cis	rs115344852	0.598	rs2191035	ENSG00000219392.1	RP1-265C24.5	-3.96	9.89e-05	0.0308	-0.33	-0.25	Epithelial ovarian cancer;	chr6:28467166	chr6:28115628~28116551:+
SARC	cis	rs115344852	0.598	rs2531815	ENSG00000219392.1	RP1-265C24.5	-3.96	9.89e-05	0.0308	-0.33	-0.25	Epithelial ovarian cancer;	chr6:28468283	chr6:28115628~28116551:+
SARC	cis	rs7772486	0.764	rs7762562	ENSG00000235652.6	RP11-545I5.3	3.96	9.89e-05	0.0308	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145799409~145886585:+
SARC	cis	rs9868809	0.772	rs9811318	ENSG00000225399.4	RP11-3B7.1	-3.96	9.89e-05	0.0308	-0.44	-0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48665173	chr3:49260085~49261316:+
SARC	cis	rs34929064	0.881	rs2961310	ENSG00000225541.1	AC002480.5	-3.96	9.9e-05	0.0308	-0.26	-0.25	Major depression and alcohol dependence;	chr7:22684788	chr7:22571607~22661792:-
SARC	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	3.96	9.9e-05	0.0308	0.4	0.25	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
SARC	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	3.96	9.91e-05	0.0308	0.31	0.25	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
SARC	cis	rs9739682	0.6	rs10877789	ENSG00000139239.7	RPL14P1	-3.96	9.92e-05	0.0309	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62088545	chr12:62965325~62965969:+
SARC	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	3.96	9.92e-05	0.0309	0.26	0.25	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
SARC	cis	rs7314326	0.587	rs6487366	ENSG00000278969.1	RP11-662I13.3	3.96	9.92e-05	0.0309	0.29	0.25	Schizophrenia;	chr12:23950416	chr12:24902309~24904681:+
SARC	cis	rs62432291	0.681	rs386818	ENSG00000235086.1	FNDC1-IT1	-3.96	9.92e-05	0.0309	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159239223	chr6:159240786~159243329:+
SARC	cis	rs4927850	0.794	rs2019472	ENSG00000242086.7	LINC00969	3.96	9.93e-05	0.0309	0.26	0.25	Pancreatic cancer;	chr3:196008500	chr3:195658062~195739964:+
SARC	cis	rs858239	0.571	rs6953020	ENSG00000226816.2	AC005082.12	3.96	9.93e-05	0.0309	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23206013~23208045:+
SARC	cis	rs801193	0.742	rs9969300	ENSG00000224316.1	RP11-479O9.2	-3.96	9.93e-05	0.0309	-0.24	-0.25	Aortic root size;	chr7:66316659	chr7:65773620~65802067:+
SARC	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-3.96	9.93e-05	0.0309	-0.32	-0.25	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
SARC	cis	rs7430456	1	rs7430456	ENSG00000231574.4	RP11-91K9.1	3.96	9.94e-05	0.0309	0.27	0.25	Breast cancer;	chr3:177768082	chr3:177816865~177899224:+
SARC	cis	rs41369048	0.858	rs2807866	ENSG00000238078.1	LINC01352	-3.96	9.94e-05	0.0309	-0.33	-0.25	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220907587	chr1:220829255~220832429:+
SARC	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	3.96	9.94e-05	0.0309	0.36	0.25	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
SARC	cis	rs1865760	0.613	rs2071300	ENSG00000272462.2	U91328.19	-3.96	9.95e-05	0.031	-0.24	-0.25	Height;	chr6:25914344	chr6:25992662~26001775:+
SARC	cis	rs7977237	0.928	rs275604	ENSG00000240759.1	RP11-25I15.1	3.96	9.96e-05	0.031	0.32	0.25	Intraocular pressure;	chr12:43552223	chr12:42678873~42679124:-
SARC	cis	rs7977237	0.928	rs275607	ENSG00000240759.1	RP11-25I15.1	3.96	9.96e-05	0.031	0.32	0.25	Intraocular pressure;	chr12:43552876	chr12:42678873~42679124:-
SARC	cis	rs28386778	0.83	rs2584625	ENSG00000240280.5	TCAM1P	-3.96	9.96e-05	0.031	-0.31	-0.25	Prudent dietary pattern;	chr17:63826085	chr17:63849292~63864379:+
SARC	cis	rs7726354	1	rs79760198	ENSG00000271828.1	CTD-2310F14.1	3.96	9.97e-05	0.031	0.55	0.25	Breast cancer (early onset);	chr5:56966812	chr5:56927874~56929573:+
SARC	cis	rs7726354	1	rs6893174	ENSG00000271828.1	CTD-2310F14.1	3.96	9.97e-05	0.031	0.55	0.25	Breast cancer (early onset);	chr5:56969198	chr5:56927874~56929573:+
SARC	cis	rs7726354	1	rs78925509	ENSG00000271828.1	CTD-2310F14.1	3.96	9.97e-05	0.031	0.55	0.25	Breast cancer (early onset);	chr5:56971314	chr5:56927874~56929573:+
SARC	cis	rs12950390	0.893	rs4239165	ENSG00000239291.1	RP5-867C24.1	3.96	9.97e-05	0.031	0.3	0.25	IgG glycosylation;	chr17:47769906	chr17:47159191~47159993:-
SARC	cis	rs12950390	0.893	rs4239166	ENSG00000239291.1	RP5-867C24.1	3.96	9.97e-05	0.031	0.3	0.25	IgG glycosylation;	chr17:47769963	chr17:47159191~47159993:-
SARC	cis	rs12817211	0.524	rs1554845	ENSG00000272368.2	RP4-605O3.4	-3.96	9.97e-05	0.031	-0.24	-0.25	Colorectal or endometrial cancer;	chr12:50129721	chr12:50112197~50165618:+
SARC	cis	rs950776	0.616	rs3743077	ENSG00000261762.1	RP11-650L12.2	3.96	9.97e-05	0.031	0.27	0.25	Sudden cardiac arrest;	chr15:78602554	chr15:78589123~78591276:-
SARC	cis	rs7208859	0.623	rs7208441	ENSG00000264538.5	SUZ12P1	-3.96	9.97e-05	0.031	-0.28	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30709299~30790908:+
SARC	cis	rs9868809	0.772	rs9809222	ENSG00000225399.4	RP11-3B7.1	-3.96	9.98e-05	0.031	-0.44	-0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48676978	chr3:49260085~49261316:+
SARC	cis	rs7688540	0.8	rs7694325	ENSG00000275426.1	CH17-262A2.1	3.96	9.99e-05	0.031	0.34	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:275253	chr4:149738~150317:+
SARC	cis	rs600231	0.665	rs2846861	ENSG00000245532.5	NEAT1	3.96	9.99e-05	0.031	0.19	0.25	Bone mineral density;	chr11:65454834	chr11:65422774~65445540:+
SARC	cis	rs4713118	0.662	rs9380045	ENSG00000216901.1	AL022393.7	3.96	1e-04	0.0311	0.36	0.25	Parkinson's disease;	chr6:28057501	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.616	rs9348789	ENSG00000216901.1	AL022393.7	3.96	1e-04	0.0311	0.36	0.25	Parkinson's disease;	chr6:28057708	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.662	rs9468274	ENSG00000216901.1	AL022393.7	3.96	1e-04	0.0311	0.36	0.25	Parkinson's disease;	chr6:28058299	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.662	rs9468275	ENSG00000216901.1	AL022393.7	3.96	1e-04	0.0311	0.36	0.25	Parkinson's disease;	chr6:28058358	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.662	rs9468276	ENSG00000216901.1	AL022393.7	3.96	1e-04	0.0311	0.36	0.25	Parkinson's disease;	chr6:28059910	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.662	rs9468277	ENSG00000216901.1	AL022393.7	3.96	1e-04	0.0311	0.36	0.25	Parkinson's disease;	chr6:28060612	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.662	rs9468278	ENSG00000216901.1	AL022393.7	3.96	1e-04	0.0311	0.36	0.25	Parkinson's disease;	chr6:28060704	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.662	rs13218430	ENSG00000216901.1	AL022393.7	3.96	1e-04	0.0311	0.36	0.25	Parkinson's disease;	chr6:28062059	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.662	rs9380046	ENSG00000216901.1	AL022393.7	3.96	1e-04	0.0311	0.36	0.25	Parkinson's disease;	chr6:28062721	chr6:28176188~28176674:+
SARC	cis	rs8028182	0.636	rs7175852	ENSG00000260206.1	CTD-2026K11.2	-3.96	1e-04	0.0311	-0.3	-0.25	Sudden cardiac arrest;	chr15:75402194	chr15:75636139~75639239:+
SARC	cis	rs2029362	0.684	rs7103873	ENSG00000245573.6	BDNF-AS	3.96	1e-04	0.0311	0.21	0.25	Total body bone mineral density;	chr11:27678770	chr11:27506838~27698174:+
SARC	cis	rs2029362	0.684	rs7104207	ENSG00000245573.6	BDNF-AS	3.96	1e-04	0.0311	0.21	0.25	Total body bone mineral density;	chr11:27679248	chr11:27506838~27698174:+
SARC	cis	rs6988985	0.678	rs10087214	ENSG00000247317.3	RP11-273G15.2	-3.96	1e-04	0.0311	-0.28	-0.25	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142918310	chr8:142981738~143018437:-
SARC	cis	rs72627123	0.5	rs7359018	ENSG00000259065.1	RP5-1021I20.1	-3.96	1e-04	0.0311	-0.34	-0.25	Morning vs. evening chronotype;	chr14:74054305	chr14:73787360~73803270:+
SARC	cis	rs72627123	0.5	rs68148895	ENSG00000259065.1	RP5-1021I20.1	-3.96	1e-04	0.0311	-0.34	-0.25	Morning vs. evening chronotype;	chr14:74062820	chr14:73787360~73803270:+
SARC	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-3.96	1e-04	0.0311	-0.19	-0.25	Height;	chr11:118746590	chr11:118791254~118793137:+
SARC	cis	rs62103177	0.608	rs4442895	ENSG00000261126.6	RP11-795F19.1	-3.96	1e-04	0.0311	-0.24	-0.25	Opioid sensitivity;	chr18:80066399	chr18:80046900~80095482:+
SARC	cis	rs7826238	0.601	rs2976907	ENSG00000253981.4	ALG1L13P	3.96	1e-04	0.0311	0.24	0.25	Systolic blood pressure;	chr8:8487658	chr8:8236003~8244667:-
SARC	cis	rs6477918	0.598	rs34442540	ENSG00000250068.1	RP11-576C12.1	-3.96	1e-04	0.0311	-0.27	-0.25	Obstetric antiphospholipid syndrome;	chr9:112455334	chr9:112581779~112582590:-
SARC	cis	rs2439831	0.867	rs2255051	ENSG00000275601.1	AC011330.13	-3.96	1e-04	0.0311	-0.4	-0.25	Lung cancer in ever smokers;	chr15:43553963	chr15:43642389~43643023:-
SARC	cis	rs745109	0.832	rs80354140	ENSG00000273080.1	RP11-301O19.1	3.96	1e-04	0.0312	0.39	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86446090	chr2:86195590~86196049:+
SARC	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-3.96	1e-04	0.0312	-0.32	-0.25	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
SARC	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-3.96	1e-04	0.0312	-0.32	-0.25	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
SARC	cis	rs2412819	0.571	rs56246169	ENSG00000205771.5	CATSPER2P1	-3.96	1e-04	0.0312	-0.4	-0.25	Lung cancer;	chr15:43628358	chr15:43726918~43747094:-
SARC	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-3.96	1e-04	0.0312	-0.27	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
SARC	cis	rs1376877	0.934	rs62183904	ENSG00000213925.3	NPM1P33	3.96	1e-04	0.0312	0.24	0.25	Subclinical atherosclerosis traits (other);	chr2:203272030	chr2:203772631~203773502:-
SARC	cis	rs2029362	0.611	rs10767665	ENSG00000245573.6	BDNF-AS	3.96	1e-04	0.0312	0.21	0.25	Total body bone mineral density;	chr11:27712311	chr11:27506838~27698174:+
SARC	cis	rs7918232	0.882	rs6415983	ENSG00000262412.1	RP11-85G18.6	3.96	1e-04	0.0312	0.33	0.25	Breast cancer;	chr10:27068282	chr10:27243130~27250804:+
SARC	cis	rs4950322	0.542	rs3766520	ENSG00000278811.3	LINC00624	3.96	0.000101	0.0312	0.27	0.25	Protein quantitative trait loci;	chr1:147214658	chr1:147258885~147517875:-
SARC	cis	rs264537	0.598	rs7623289	ENSG00000172971.7	UNC93B3	-3.96	0.000101	0.0312	-0.31	-0.25	Periodontitis (PAL4Q3);	chr3:76623541	chr3:75619506~75623849:-
SARC	cis	rs10911902	0.643	rs76057663	ENSG00000233196.2	GS1-304P7.1	-3.96	0.000101	0.0312	-0.38	-0.25	Schizophrenia;	chr1:186325889	chr1:186580515~186581191:-
SARC	cis	rs853679	1	rs11965538	ENSG00000272009.1	RP1-313I6.12	-3.96	0.000101	0.0312	-0.35	-0.25	Depression;	chr6:28272137	chr6:28078792~28081130:-
SARC	cis	rs853679	0.882	rs2743555	ENSG00000272009.1	RP1-313I6.12	-3.96	0.000101	0.0312	-0.35	-0.25	Depression;	chr6:28273304	chr6:28078792~28081130:-
SARC	cis	rs853679	1	rs1419183	ENSG00000272009.1	RP1-313I6.12	-3.96	0.000101	0.0312	-0.35	-0.25	Depression;	chr6:28275017	chr6:28078792~28081130:-
SARC	cis	rs4372836	0.518	rs12472549	ENSG00000226833.4	AC097724.3	3.96	0.000101	0.0312	0.22	0.25	Body mass index;	chr2:28769138	chr2:28708953~28736205:-
SARC	cis	rs4372836	0.543	rs11686412	ENSG00000226833.4	AC097724.3	3.96	0.000101	0.0312	0.22	0.25	Body mass index;	chr2:28769539	chr2:28708953~28736205:-
SARC	cis	rs10055631	0.518	rs778444	ENSG00000229666.1	MAST4-AS1	3.96	0.000101	0.0312	0.26	0.25	Coronary artery disease;	chr5:67010118	chr5:67001383~67003953:-
SARC	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	3.96	0.000101	0.0312	0.31	0.25	Height;	chr6:109440234	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	3.96	0.000101	0.0312	0.31	0.25	Height;	chr6:109443332	chr6:109382795~109383666:+
SARC	cis	rs2070074	0.591	rs12001648	ENSG00000230074.1	RP11-195F19.9	-3.96	0.000101	0.0312	-0.51	-0.25	CTACK levels;	chr9:34585387	chr9:34665665~34681298:+
SARC	cis	rs4713118	0.513	rs149989	ENSG00000272009.1	RP1-313I6.12	-3.96	0.000101	0.0312	-0.27	-0.25	Parkinson's disease;	chr6:28030406	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.513	rs149941	ENSG00000272009.1	RP1-313I6.12	-3.96	0.000101	0.0312	-0.27	-0.25	Parkinson's disease;	chr6:28033255	chr6:28078792~28081130:-
SARC	cis	rs7204230	1	rs12596346	ENSG00000261291.1	RP11-295M3.2	3.96	0.000101	0.0312	0.28	0.25	Fibrinogen;	chr16:53220264	chr16:53168522~53169450:+
SARC	cis	rs526231	0.718	rs402962	ENSG00000175749.11	EIF3KP1	3.96	0.000101	0.0313	0.31	0.25	Primary biliary cholangitis;	chr5:103288307	chr5:103032376~103033031:+
SARC	cis	rs783540	1	rs11631963	ENSG00000275695.1	UBE2Q2P6	3.96	0.000101	0.0313	0.26	0.25	Schizophrenia;	chr15:82649451	chr15:82445719~82454837:+
SARC	cis	rs889398	0.741	rs3790076	ENSG00000261556.7	SMG1P7	3.96	0.000101	0.0313	0.22	0.25	Body mass index;	chr16:69873542	chr16:70219574~70245616:-
SARC	cis	rs56046484	0.956	rs34054841	ENSG00000259295.5	CSPG4P12	3.96	0.000101	0.0313	0.37	0.25	Testicular germ cell tumor;	chr15:85058115	chr15:85191438~85213905:+
SARC	cis	rs56046484	0.956	rs12908535	ENSG00000259295.5	CSPG4P12	3.96	0.000101	0.0313	0.37	0.25	Testicular germ cell tumor;	chr15:85058294	chr15:85191438~85213905:+
SARC	cis	rs12236219	0.579	rs10993178	ENSG00000224764.1	RP11-54O15.3	3.96	0.000101	0.0313	0.47	0.25	Body mass index;	chr9:94366722	chr9:94928551~94934946:-
SARC	cis	rs7267979	0.932	rs4280527	ENSG00000276952.1	RP5-965G21.6	3.96	0.000101	0.0313	0.24	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25284915~25285588:-
SARC	cis	rs2412819	0.571	rs8030536	ENSG00000205771.5	CATSPER2P1	-3.96	0.000101	0.0313	-0.4	-0.25	Lung cancer;	chr15:43627365	chr15:43726918~43747094:-
SARC	cis	rs745109	0.504	rs72926457	ENSG00000273080.1	RP11-301O19.1	3.96	0.000101	0.0313	0.37	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86349305	chr2:86195590~86196049:+
SARC	cis	rs745109	0.504	rs72926466	ENSG00000273080.1	RP11-301O19.1	3.96	0.000101	0.0313	0.37	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86351210	chr2:86195590~86196049:+
SARC	cis	rs7615952	0.641	rs7632497	ENSG00000248787.1	RP11-666A20.4	-3.96	0.000101	0.0313	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:126064243	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.641	rs12487875	ENSG00000248787.1	RP11-666A20.4	-3.96	0.000101	0.0313	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:126068381	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.641	rs7618515	ENSG00000248787.1	RP11-666A20.4	-3.96	0.000101	0.0313	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:126071735	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.576	rs66671308	ENSG00000248787.1	RP11-666A20.4	-3.96	0.000101	0.0313	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:126074683	chr3:125908005~125910272:-
SARC	cis	rs7552393	0.568	rs2007415	ENSG00000240520.4	UOX	-3.96	0.000101	0.0313	-0.27	-0.25	Select biomarker traits;	chr1:83801430	chr1:84365428~84397831:-
SARC	cis	rs76693355	0.541	rs2276035	ENSG00000232460.4	BMPR1APS2	3.96	0.000101	0.0314	0.32	0.25	Intraocular pressure;	chr11:120475651	chr11:121361854~121362865:-
SARC	cis	rs1167832	0.645	rs1167829	ENSG00000127957.15	PMS2P3	-3.96	0.000101	0.0314	-0.33	-0.25	Ankle injury;	chr7:75535697	chr7:75502930~75528148:-
SARC	cis	rs5751614	0.537	rs5996508	ENSG00000230701.2	FBXW4P1	3.96	0.000101	0.0314	0.33	0.25	Height;	chr22:23270441	chr22:23262767~23265005:+
SARC	cis	rs7208859	0.524	rs73988172	ENSG00000264538.5	SUZ12P1	-3.96	0.000101	0.0314	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30709299~30790908:+
SARC	cis	rs7267979	0.753	rs400357	ENSG00000276952.1	RP5-965G21.6	3.96	0.000101	0.0314	0.24	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:25284915~25285588:-
SARC	cis	rs1376877	0.87	rs3731694	ENSG00000213925.3	NPM1P33	3.96	0.000101	0.0314	0.24	0.25	Subclinical atherosclerosis traits (other);	chr2:203251937	chr2:203772631~203773502:-
SARC	cis	rs1376877	0.901	rs6704588	ENSG00000213925.3	NPM1P33	3.96	0.000101	0.0314	0.24	0.25	Subclinical atherosclerosis traits (other);	chr2:203253585	chr2:203772631~203773502:-
SARC	cis	rs2803122	0.501	rs10811140	ENSG00000273226.1	RP11-513M16.8	-3.96	0.000101	0.0314	-0.28	-0.25	Pulse pressure;	chr9:19230401	chr9:19375451~19375996:+
SARC	cis	rs28386778	0.897	rs1043127	ENSG00000240280.5	TCAM1P	-3.96	0.000101	0.0314	-0.31	-0.25	Prudent dietary pattern;	chr17:63713850	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs1982400	ENSG00000240280.5	TCAM1P	-3.96	0.000101	0.0314	-0.31	-0.25	Prudent dietary pattern;	chr17:63716458	chr17:63849292~63864379:+
SARC	cis	rs7267979	0.844	rs2257649	ENSG00000276952.1	RP5-965G21.6	3.96	0.000101	0.0314	0.24	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:25284915~25285588:-
SARC	cis	rs4883201	0.518	rs887782	ENSG00000257027.1	RP11-705C15.3	3.96	0.000101	0.0314	0.37	0.25	Total cholesterol levels;Cholesterol, total;	chr12:8932082	chr12:9658567~9662085:+
SARC	cis	rs7267979	0.873	rs7453	ENSG00000274414.1	RP5-965G21.4	-3.96	0.000101	0.0314	-0.26	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25239007~25245229:-
SARC	cis	rs7772486	0.624	rs9485018	ENSG00000235652.6	RP11-545I5.3	-3.96	0.000101	0.0314	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145799409~145886585:+
SARC	cis	rs12049351	0.774	rs6704265	ENSG00000229367.1	HMGN2P19	3.96	0.000101	0.0314	0.21	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229497309	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs4925457	ENSG00000229367.1	HMGN2P19	3.96	0.000101	0.0314	0.21	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229497824	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs10916495	ENSG00000229367.1	HMGN2P19	3.96	0.000101	0.0314	0.21	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229499774	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs6670553	ENSG00000229367.1	HMGN2P19	3.96	0.000101	0.0314	0.21	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229500120	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs754025	ENSG00000229367.1	HMGN2P19	3.96	0.000101	0.0314	0.21	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229501550	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs2381108	ENSG00000229367.1	HMGN2P19	3.96	0.000101	0.0314	0.21	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229502134	chr1:229570532~229570796:+
SARC	cis	rs600231	0.665	rs1626021	ENSG00000245532.5	NEAT1	3.96	0.000102	0.0314	0.19	0.25	Bone mineral density;	chr11:65458716	chr11:65422774~65445540:+
SARC	cis	rs11105298	0.891	rs4842662	ENSG00000258302.2	RP11-981P6.1	3.96	0.000102	0.0314	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89561129~89594878:+
SARC	cis	rs2439831	0.867	rs6493082	ENSG00000275601.1	AC011330.13	-3.95	0.000102	0.0315	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43342610	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs8041132	ENSG00000275601.1	AC011330.13	-3.95	0.000102	0.0315	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43342938	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs7170489	ENSG00000275601.1	AC011330.13	-3.95	0.000102	0.0315	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43344453	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs16957627	ENSG00000275601.1	AC011330.13	-3.95	0.000102	0.0315	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43350459	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs16957630	ENSG00000275601.1	AC011330.13	-3.95	0.000102	0.0315	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43350582	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs16957632	ENSG00000275601.1	AC011330.13	-3.95	0.000102	0.0315	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43350699	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs6493085	ENSG00000275601.1	AC011330.13	-3.95	0.000102	0.0315	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43361984	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.867	rs3213990	ENSG00000275601.1	AC011330.13	-3.95	0.000102	0.0315	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43378028	chr15:43642389~43643023:-
SARC	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-3.95	0.000102	0.0315	-0.4	-0.25	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
SARC	cis	rs151234	0.741	rs56236750	ENSG00000259982.1	CDC37P1	-3.95	0.000102	0.0315	-0.38	-0.25	Platelet distribution width;	chr16:28583390	chr16:28700294~28701540:-
SARC	cis	rs8064029	0.892	rs77213183	ENSG00000267077.1	RP11-127I20.5	3.95	0.000102	0.0315	0.44	0.25	Cancer;	chr16:4852109	chr16:4795265~4796532:-
SARC	cis	rs7927592	0.513	rs531163	ENSG00000212093.1	AP000807.1	3.95	0.000102	0.0315	0.24	0.25	Total body bone mineral density;	chr11:68427028	chr11:68506083~68506166:-
SARC	cis	rs7726354	1	rs79459889	ENSG00000271828.1	CTD-2310F14.1	3.95	0.000102	0.0315	0.54	0.25	Breast cancer (early onset);	chr5:56973459	chr5:56927874~56929573:+
SARC	cis	rs7726354	1	rs111773762	ENSG00000271828.1	CTD-2310F14.1	3.95	0.000102	0.0315	0.54	0.25	Breast cancer (early onset);	chr5:56973509	chr5:56927874~56929573:+
SARC	cis	rs7726354	1	rs80097053	ENSG00000271828.1	CTD-2310F14.1	3.95	0.000102	0.0315	0.54	0.25	Breast cancer (early onset);	chr5:56973665	chr5:56927874~56929573:+
SARC	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-3.95	0.000102	0.0315	-0.39	-0.25	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
SARC	cis	rs2274273	0.682	rs7151224	ENSG00000258413.1	RP11-665C16.6	-3.95	0.000102	0.0315	-0.28	-0.25	Protein biomarker;	chr14:55050544	chr14:55262767~55272075:-
SARC	cis	rs279910	0.643	rs279889	ENSG00000281769.1	LINC01230	-3.95	0.000102	0.0315	-0.23	-0.25	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr9:978374	chr9:1045625~1048641:+
SARC	cis	rs7204230	1	rs62048051	ENSG00000261291.1	RP11-295M3.2	3.95	0.000102	0.0315	0.28	0.25	Fibrinogen;	chr16:53205249	chr16:53168522~53169450:+
SARC	cis	rs2179367	0.887	rs2789488	ENSG00000216906.2	RP11-350J20.9	-3.95	0.000102	0.0316	-0.23	-0.25	Dupuytren's disease;	chr6:149404154	chr6:149904243~149906418:+
SARC	cis	rs7617773	0.78	rs13067450	ENSG00000228638.1	FCF1P2	-3.95	0.000102	0.0316	-0.29	-0.25	Coronary artery disease;	chr3:48295716	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs4479622	ENSG00000228638.1	FCF1P2	-3.95	0.000102	0.0316	-0.29	-0.25	Coronary artery disease;	chr3:48296683	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs34946886	ENSG00000228638.1	FCF1P2	-3.95	0.000102	0.0316	-0.29	-0.25	Coronary artery disease;	chr3:48296997	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs13079728	ENSG00000228638.1	FCF1P2	-3.95	0.000102	0.0316	-0.29	-0.25	Coronary artery disease;	chr3:48297870	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs34589064	ENSG00000228638.1	FCF1P2	-3.95	0.000102	0.0316	-0.29	-0.25	Coronary artery disease;	chr3:48298059	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs2541	ENSG00000228638.1	FCF1P2	-3.95	0.000102	0.0316	-0.29	-0.25	Coronary artery disease;	chr3:48298128	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs13085251	ENSG00000228638.1	FCF1P2	-3.95	0.000102	0.0316	-0.29	-0.25	Coronary artery disease;	chr3:48298555	chr3:48290793~48291375:-
SARC	cis	rs8028182	0.636	rs11637068	ENSG00000260206.1	CTD-2026K11.2	-3.95	0.000102	0.0316	-0.31	-0.25	Sudden cardiac arrest;	chr15:75450661	chr15:75636139~75639239:+
SARC	cis	rs858239	0.899	rs2268747	ENSG00000226816.2	AC005082.12	3.95	0.000102	0.0316	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23206013~23208045:+
SARC	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	3.95	0.000102	0.0316	0.38	0.25	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	3.95	0.000102	0.0316	0.38	0.25	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	3.95	0.000102	0.0316	0.38	0.25	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	3.95	0.000102	0.0316	0.38	0.25	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	3.95	0.000102	0.0316	0.38	0.25	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	3.95	0.000102	0.0316	0.38	0.25	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
SARC	cis	rs11067278	0.519	rs7307473	ENSG00000276972.1	RP11-116D17.5	-3.95	0.000102	0.0316	-0.29	-0.25	Urate levels in overweight individuals;	chr12:114784891	chr12:115332146~115332566:-
SARC	cis	rs6918586	0.658	rs198837	ENSG00000272462.2	U91328.19	3.95	0.000102	0.0316	0.23	0.25	Schizophrenia;	chr6:26113170	chr6:25992662~26001775:+
SARC	cis	rs7560272	0.723	rs1083919	ENSG00000163016.8	ALMS1P	-3.95	0.000102	0.0316	-0.29	-0.25	Schizophrenia;	chr2:73486736	chr2:73644919~73685576:+
SARC	cis	rs7617773	0.643	rs78159520	ENSG00000228638.1	FCF1P2	-3.95	0.000102	0.0316	-0.29	-0.25	Coronary artery disease;	chr3:48307533	chr3:48290793~48291375:-
SARC	cis	rs7267979	0.528	rs34485039	ENSG00000125804.12	FAM182A	3.95	0.000102	0.0316	0.3	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:26054655~26086917:+
SARC	cis	rs7178375	0.843	rs3794596	ENSG00000215302.7	CTD-3092A11.1	-3.95	0.000102	0.0316	-0.32	-0.25	Hypertriglyceridemia;	chr15:30930823	chr15:30470779~30507623:+
SARC	cis	rs6540731	1	rs35209719	ENSG00000229983.1	RP11-15I11.2	3.95	0.000102	0.0316	0.25	0.25	Intelligence (childhood);	chr1:212228335	chr1:212168207~212190259:+
SARC	cis	rs6918586	0.681	rs198831	ENSG00000272462.2	U91328.19	-3.95	0.000102	0.0316	-0.23	-0.25	Schizophrenia;	chr6:26116768	chr6:25992662~26001775:+
SARC	cis	rs12049351	0.774	rs34551512	ENSG00000229367.1	HMGN2P19	3.95	0.000102	0.0316	0.21	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229483141	chr1:229570532~229570796:+
SARC	cis	rs28386778	0.966	rs2854206	ENSG00000240280.5	TCAM1P	-3.95	0.000102	0.0316	-0.31	-0.25	Prudent dietary pattern;	chr17:63869843	chr17:63849292~63864379:+
SARC	cis	rs7246657	0.943	rs10415358	ENSG00000226686.6	LINC01535	-3.95	0.000102	0.0317	-0.35	-0.25	Coronary artery calcification;	chr19:37317961	chr19:37251912~37265535:+
SARC	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	3.95	0.000102	0.0317	0.29	0.25	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
SARC	cis	rs1707322	1	rs785465	ENSG00000281133.1	AL355480.3	-3.95	0.000102	0.0317	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45580892~45580996:-
SARC	cis	rs4886920	0.672	rs12437900	ENSG00000260776.4	RP11-114H24.2	3.95	0.000102	0.0317	0.31	0.25	Neuroticism;	chr15:77841796	chr15:77914217~77926846:-
SARC	cis	rs1546924	0.57	rs197413	ENSG00000260948.1	RP11-552M11.8	3.95	0.000103	0.0317	0.28	0.25	Body mass index;	chr1:111766350	chr1:111431046~111433068:-
SARC	cis	rs61160187	0.582	rs28436304	ENSG00000272308.1	RP11-231G3.1	-3.95	0.000103	0.0317	-0.22	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60866457~60866935:-
SARC	cis	rs889122	0.683	rs7245830	ENSG00000274425.1	AC114271.2	-3.95	0.000103	0.0317	-0.32	-0.25	Menarche (age at onset);	chr19:9890337	chr19:10333436~10336248:+
SARC	cis	rs950776	0.518	rs4887062	ENSG00000261762.1	RP11-650L12.2	-3.95	0.000103	0.0317	-0.27	-0.25	Sudden cardiac arrest;	chr15:78545459	chr15:78589123~78591276:-
SARC	cis	rs2281636	0.691	rs6584306	ENSG00000233690.1	EBAG9P1	3.95	0.000103	0.0317	0.26	0.25	Obesity-related traits;	chr10:99662739	chr10:99697407~99697949:-
SARC	cis	rs848486	0.905	rs7801305	ENSG00000214293.7	APTR	-3.95	0.000103	0.0317	-0.26	-0.25	Glomerular filtration rate;	chr7:77762364	chr7:77657660~77696265:-
SARC	cis	rs9876781	0.559	rs11130167	ENSG00000229759.1	MRPS18AP1	3.95	0.000103	0.0317	0.28	0.25	Longevity;	chr3:48358570	chr3:48256350~48256938:-
SARC	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	3.95	0.000103	0.0317	0.25	0.25	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
SARC	cis	rs2235544	0.513	rs10158824	ENSG00000225183.1	RP4-758J24.4	3.95	0.000103	0.0317	0.28	0.25	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54014725	chr1:54089856~54090093:+
SARC	cis	rs11105298	0.891	rs10858902	ENSG00000258302.2	RP11-981P6.1	3.95	0.000103	0.0318	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs10858903	ENSG00000258302.2	RP11-981P6.1	3.95	0.000103	0.0318	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89561129~89594878:+
SARC	cis	rs889122	0.836	rs56053932	ENSG00000274425.1	AC114271.2	-3.95	0.000103	0.0318	-0.33	-0.25	Menarche (age at onset);	chr19:9892335	chr19:10333436~10336248:+
SARC	cis	rs240993	0.812	rs118202	ENSG00000230177.1	RP5-1112D6.4	-3.95	0.000103	0.0318	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111337168	chr6:111277932~111278742:+
SARC	cis	rs6495122	0.501	rs7163636	ENSG00000260269.4	CTD-2323K18.1	-3.95	0.000103	0.0318	-0.32	-0.25	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75054419	chr15:75527150~75601205:-
SARC	cis	rs8064029	0.892	rs62036114	ENSG00000267077.1	RP11-127I20.5	3.95	0.000103	0.0318	0.45	0.25	Cancer;	chr16:4830826	chr16:4795265~4796532:-
SARC	cis	rs11955398	0.502	rs34638	ENSG00000272308.1	RP11-231G3.1	3.95	0.000103	0.0318	0.23	0.25	Intelligence (multi-trait analysis);	chr5:61054660	chr5:60866457~60866935:-
SARC	cis	rs4664293	0.867	rs2059698	ENSG00000226266.5	AC009961.3	3.95	0.000103	0.0318	0.31	0.25	Monocyte percentage of white cells;	chr2:159785905	chr2:159670708~159712435:-
SARC	cis	rs7580658	0.929	rs4150477	ENSG00000236682.1	AC068282.3	3.95	0.000103	0.0318	0.29	0.25	Protein C levels;	chr2:127274970	chr2:127389130~127400580:+
SARC	cis	rs7166081	1	rs17526859	ENSG00000270964.1	RP11-502I4.3	3.95	0.000103	0.0318	0.28	0.25	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67318728	chr15:67541072~67542604:-
SARC	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-3.95	0.000103	0.0318	-0.36	-0.25	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
SARC	cis	rs950776	0.518	rs62008194	ENSG00000261762.1	RP11-650L12.2	3.95	0.000103	0.0318	0.27	0.25	Sudden cardiac arrest;	chr15:78521463	chr15:78589123~78591276:-
SARC	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	3.95	0.000103	0.0318	0.37	0.25	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
SARC	cis	rs7615952	0.515	rs4267608	ENSG00000171084.14	FAM86JP	3.95	0.000103	0.0318	0.39	0.25	Blood pressure (smoking interaction);	chr3:125961657	chr3:125916620~125930024:+
SARC	cis	rs6964833	1	rs13227433	ENSG00000184616.8	AC004166.6	3.95	0.000103	0.0318	0.37	0.25	Menarche (age at onset);	chr7:74680386	chr7:74906673~74913256:-
SARC	cis	rs6918586	0.557	rs198827	ENSG00000272462.2	U91328.19	-3.95	0.000103	0.0319	-0.23	-0.25	Schizophrenia;	chr6:26120774	chr6:25992662~26001775:+
SARC	cis	rs73129298	0.688	rs60813083	ENSG00000229222.1	KRT18P4	3.95	0.000103	0.0319	0.57	0.25	Inflammatory skin disease;	chr20:49962709	chr20:49956745~49958032:+
SARC	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	3.95	0.000103	0.0319	0.24	0.25	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
SARC	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	3.95	0.000103	0.0319	0.24	0.25	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
SARC	cis	rs16958440	1	rs62096468	ENSG00000280212.1	RP11-49K24.3	3.95	0.000103	0.0319	0.61	0.25	Sitting height ratio;	chr18:47111195	chr18:47076117~47076594:+
SARC	cis	rs11247915	0.6	rs11247920	ENSG00000260063.1	RP5-968P14.2	3.95	0.000103	0.0319	0.26	0.25	Obesity-related traits;	chr1:26338987	chr1:26692132~26694131:-
SARC	cis	rs11159086	0.793	rs12433382	ENSG00000270000.1	RP3-449M8.9	3.95	0.000103	0.0319	0.37	0.25	Advanced glycation end-product levels;	chr14:74482940	chr14:74471930~74472360:-
SARC	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-3.95	0.000103	0.0319	-0.22	-0.25	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
SARC	cis	rs1799949	0.965	rs799910	ENSG00000267681.1	CTD-3199J23.6	-3.95	0.000103	0.0319	-0.28	-0.25	Menopause (age at onset);	chr17:43127544	chr17:43144956~43145255:+
SARC	cis	rs12554020	0.786	rs12349299	ENSG00000227603.1	RP11-165J3.6	3.95	0.000103	0.0319	0.39	0.25	Schizophrenia;	chr9:93412482	chr9:93435332~93437121:-
SARC	cis	rs8028182	0.583	rs4886722	ENSG00000260206.1	CTD-2026K11.2	-3.95	0.000103	0.0319	-0.3	-0.25	Sudden cardiac arrest;	chr15:75629295	chr15:75636139~75639239:+
SARC	cis	rs7267979	0.966	rs2151144	ENSG00000274414.1	RP5-965G21.4	3.95	0.000104	0.0319	0.26	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25239007~25245229:-
SARC	cis	rs4273100	0.688	rs12938803	ENSG00000265185.4	SNORD3B-1	-3.95	0.000104	0.032	-0.29	-0.25	Schizophrenia;	chr17:19301119	chr17:19061912~19062669:+
SARC	cis	rs867371	1	rs6495642	ENSG00000259429.4	UBE2Q2P2	-3.95	0.000104	0.032	-0.24	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82355142~82420075:+
SARC	cis	rs10895987	0.955	rs11227136	ENSG00000254614.2	AP003068.23	3.95	0.000104	0.032	0.36	0.25	Blood protein levels;	chr11:65164493	chr11:65177606~65181834:-
SARC	cis	rs12200782	0.929	rs72836467	ENSG00000272462.2	U91328.19	-3.95	0.000104	0.032	-0.37	-0.25	Small cell lung carcinoma;	chr6:26353699	chr6:25992662~26001775:+
SARC	cis	rs12200782	0.929	rs116018523	ENSG00000272462.2	U91328.19	-3.95	0.000104	0.032	-0.37	-0.25	Small cell lung carcinoma;	chr6:26357006	chr6:25992662~26001775:+
SARC	cis	rs11621121	0.556	rs2127870	ENSG00000259078.2	PTBP1P	3.95	0.000104	0.032	0.3	0.25	N-glycan levels;	chr14:65330128	chr14:65279267~65281166:+
SARC	cis	rs889122	0.729	rs10413248	ENSG00000267289.1	CTD-2623N2.11	3.95	0.000104	0.032	0.29	0.25	Menarche (age at onset);	chr19:9873420	chr19:9834079~9835013:-
SARC	cis	rs2235544	0.565	rs637590	ENSG00000225183.1	RP4-758J24.4	3.95	0.000104	0.032	0.28	0.25	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:53996030	chr1:54089856~54090093:+
SARC	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-3.95	0.000104	0.032	-0.3	-0.25	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
SARC	cis	rs12542260	0.815	rs12544621	ENSG00000253106.1	RP11-158K1.3	3.95	0.000104	0.032	0.29	0.25	Colonoscopy-negative controls vs population controls;	chr8:124531695	chr8:124488510~124491643:+
SARC	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-3.95	0.000104	0.032	-0.29	-0.25	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
SARC	cis	rs2378870	0.589	rs2159398	ENSG00000266934.1	RP11-332H18.3	3.95	0.000104	0.032	0.2	0.25	Height;	chr17:61551257	chr17:61382785~61384680:+
SARC	cis	rs7615952	0.599	rs6766327	ENSG00000241288.6	RP11-379B18.5	-3.95	0.000104	0.032	-0.3	-0.25	Blood pressure (smoking interaction);	chr3:126004834	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.641	rs12491577	ENSG00000241288.6	RP11-379B18.5	-3.95	0.000104	0.032	-0.3	-0.25	Blood pressure (smoking interaction);	chr3:126012288	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.599	rs1875683	ENSG00000241288.6	RP11-379B18.5	-3.95	0.000104	0.032	-0.3	-0.25	Blood pressure (smoking interaction);	chr3:126013638	chr3:125827238~125916384:-
SARC	cis	rs4835265	0.852	rs1027841	ENSG00000272727.1	RP11-142A22.4	3.95	0.000104	0.032	0.36	0.25	Gamma glutamyl transpeptidase;	chr4:145847922	chr4:145335263~145340421:-
SARC	cis	rs11676348	0.772	rs7422358	ENSG00000261338.2	RP11-378A13.1	-3.95	0.000104	0.032	-0.24	-0.25	Ulcerative colitis;	chr2:218088055	chr2:218255319~218257366:+
SARC	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-3.95	0.000104	0.032	-0.3	-0.25	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
SARC	cis	rs7688540	0.723	rs80316648	ENSG00000275426.1	CH17-262A2.1	3.95	0.000104	0.032	0.36	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238426	chr4:149738~150317:+
SARC	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-3.95	0.000104	0.0321	-0.29	-0.25	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
SARC	cis	rs11723436	0.543	rs4411968	ENSG00000245958.5	RP11-33B1.1	-3.95	0.000104	0.0321	-0.21	-0.25	Coronary artery disease;	chr4:119909761	chr4:119454791~119552025:+
SARC	cis	rs9364687	0.639	rs4709716	ENSG00000228692.2	RP5-826L7.1	-3.95	0.000104	0.0321	-0.29	-0.25	Body mass index;	chr6:163454517	chr6:163586583~163588165:-
SARC	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	3.95	0.000104	0.0321	0.28	0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
SARC	cis	rs7678555	0.54	rs7659369	ENSG00000245958.5	RP11-33B1.1	-3.95	0.000104	0.0321	-0.21	-0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr4:119921849	chr4:119454791~119552025:+
SARC	cis	rs157198	0.867	rs79847479	ENSG00000237934.1	RP11-467D18.2	3.95	0.000104	0.0321	0.42	0.25	Mean platelet volume;	chr1:28875385	chr1:29223933~29224816:+
SARC	cis	rs1054052	0.508	rs11013152	ENSG00000279623.1	RP11-399C16.3	-3.95	0.000104	0.0321	-0.29	-0.25	IgG glycosylation;	chr10:22848682	chr10:21865335~21865921:-
SARC	cis	rs7520050	0.966	rs1707321	ENSG00000280836.1	AL355480.1	3.95	0.000104	0.0321	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46039637	chr1:45581219~45581321:-
SARC	cis	rs7182621	0.639	rs1561047	ENSG00000182397.13	DNM1P46	3.95	0.000104	0.0321	0.3	0.25	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99790156~99806927:-
SARC	cis	rs875971	0.628	rs6974355	ENSG00000224316.1	RP11-479O9.2	3.95	0.000104	0.0321	0.24	0.25	Aortic root size;	chr7:66376994	chr7:65773620~65802067:+
SARC	cis	rs9595908	0.746	rs9596075	ENSG00000212293.1	SNORA16	3.95	0.000104	0.0321	0.24	0.25	Body mass index;	chr13:32692147	chr13:32420390~32420516:-
SARC	cis	rs61160187	0.582	rs28436304	ENSG00000215032.2	GNL3LP1	3.95	0.000104	0.0321	0.25	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60891935~60893577:-
SARC	cis	rs2439831	0.867	rs2255042	ENSG00000275601.1	AC011330.13	3.95	0.000104	0.0321	0.4	0.25	Lung cancer in ever smokers;	chr15:43542120	chr15:43642389~43643023:-
SARC	cis	rs6964833	0.935	rs7795281	ENSG00000184616.8	AC004166.6	3.95	0.000104	0.0321	0.37	0.25	Menarche (age at onset);	chr7:74708523	chr7:74906673~74913256:-
SARC	cis	rs9739682	0.552	rs1444255	ENSG00000139239.7	RPL14P1	-3.95	0.000104	0.0322	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62094502	chr12:62965325~62965969:+
SARC	cis	rs10986311	0.814	rs10116520	ENSG00000235204.1	RP11-121A14.2	3.95	0.000104	0.0322	0.28	0.25	Vitiligo;	chr9:124267351	chr9:124259250~124261156:-
SARC	cis	rs1538970	0.816	rs4633317	ENSG00000280836.1	AL355480.1	-3.95	0.000105	0.0322	-0.29	-0.25	Platelet count;	chr1:45519485	chr1:45581219~45581321:-
SARC	cis	rs1538970	0.816	rs34673142	ENSG00000280836.1	AL355480.1	-3.95	0.000105	0.0322	-0.29	-0.25	Platelet count;	chr1:45519889	chr1:45581219~45581321:-
SARC	cis	rs1538970	0.781	rs713358	ENSG00000280836.1	AL355480.1	-3.95	0.000105	0.0322	-0.29	-0.25	Platelet count;	chr1:45522595	chr1:45581219~45581321:-
SARC	cis	rs7267979	0.932	rs417130	ENSG00000276952.1	RP5-965G21.6	3.95	0.000105	0.0322	0.24	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:25284915~25285588:-
SARC	cis	rs7267979	0.932	rs372678	ENSG00000276952.1	RP5-965G21.6	3.95	0.000105	0.0322	0.24	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:25284915~25285588:-
SARC	cis	rs9481169	0.557	rs2179070	ENSG00000231889.6	TRAF3IP2-AS1	3.95	0.000105	0.0322	0.48	0.25	Inflammatory skin disease;	chr6:111564549	chr6:111483511~111598302:+
SARC	cis	rs9481169	0.557	rs34896684	ENSG00000231889.6	TRAF3IP2-AS1	3.95	0.000105	0.0322	0.48	0.25	Inflammatory skin disease;	chr6:111572034	chr6:111483511~111598302:+
SARC	cis	rs2239547	0.603	rs17304995	ENSG00000242142.1	SERBP1P3	3.95	0.000105	0.0322	0.3	0.25	Schizophrenia;	chr3:53036739	chr3:53064283~53065091:-
SARC	cis	rs17826219	0.706	rs2322197	ENSG00000264538.5	SUZ12P1	-3.95	0.000105	0.0322	-0.27	-0.25	Body mass index;	chr17:30778787	chr17:30709299~30790908:+
SARC	cis	rs17826219	0.706	rs28469200	ENSG00000264538.5	SUZ12P1	-3.95	0.000105	0.0322	-0.27	-0.25	Body mass index;	chr17:30806554	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.573	rs7214313	ENSG00000264538.5	SUZ12P1	-3.95	0.000105	0.0322	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30709299~30790908:+
SARC	cis	rs858239	0.899	rs28635122	ENSG00000226816.2	AC005082.12	3.95	0.000105	0.0322	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23206013~23208045:+
SARC	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-3.95	0.000105	0.0323	-0.36	-0.25	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
SARC	cis	rs1062177	1	rs892006	ENSG00000254226.4	CTB-12O2.1	3.95	0.000105	0.0323	0.34	0.25	Preschool internalizing problems;	chr5:151801329	chr5:151949571~152270448:+
SARC	cis	rs12935418	0.83	rs12448368	ENSG00000261061.1	RP11-303E16.2	3.95	0.000105	0.0323	0.36	0.25	Mean corpuscular volume;	chr16:81011342	chr16:81030770~81031485:+
SARC	cis	rs4679904	0.921	rs10936201	ENSG00000243116.1	RP11-564C24.1	3.95	0.000105	0.0323	0.26	0.25	Primary biliary cholangitis;	chr3:160404051	chr3:159721524~159722401:-
SARC	cis	rs4679904	0.921	rs17826173	ENSG00000243116.1	RP11-564C24.1	3.95	0.000105	0.0323	0.26	0.25	Primary biliary cholangitis;	chr3:160412726	chr3:159721524~159722401:-
SARC	cis	rs4679904	0.921	rs4680581	ENSG00000243116.1	RP11-564C24.1	3.95	0.000105	0.0323	0.26	0.25	Primary biliary cholangitis;	chr3:160412766	chr3:159721524~159722401:-
SARC	cis	rs889122	0.765	rs889162	ENSG00000267289.1	CTD-2623N2.11	3.95	0.000105	0.0323	0.3	0.25	Menarche (age at onset);	chr19:9841240	chr19:9834079~9835013:-
SARC	cis	rs61160187	0.556	rs10939881	ENSG00000215032.2	GNL3LP1	3.95	0.000105	0.0323	0.25	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61087146	chr5:60891935~60893577:-
SARC	cis	rs6570726	0.902	rs973855	ENSG00000235652.6	RP11-545I5.3	-3.95	0.000105	0.0323	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145799409~145886585:+
SARC	cis	rs7726354	1	rs80089016	ENSG00000271828.1	CTD-2310F14.1	3.95	0.000105	0.0323	0.54	0.25	Breast cancer (early onset);	chr5:56971617	chr5:56927874~56929573:+
SARC	cis	rs7726354	1	rs80310238	ENSG00000271828.1	CTD-2310F14.1	3.95	0.000105	0.0323	0.54	0.25	Breast cancer (early onset);	chr5:56972157	chr5:56927874~56929573:+
SARC	cis	rs7726354	1	rs77706078	ENSG00000271828.1	CTD-2310F14.1	3.95	0.000105	0.0323	0.54	0.25	Breast cancer (early onset);	chr5:56972859	chr5:56927874~56929573:+
SARC	cis	rs66887589	0.616	rs11098497	ENSG00000245958.5	RP11-33B1.1	-3.95	0.000105	0.0323	-0.22	-0.25	Diastolic blood pressure;	chr4:119265913	chr4:119454791~119552025:+
SARC	cis	rs66887589	0.616	rs7659403	ENSG00000245958.5	RP11-33B1.1	-3.95	0.000105	0.0323	-0.22	-0.25	Diastolic blood pressure;	chr4:119286099	chr4:119454791~119552025:+
SARC	cis	rs867371	1	rs7181655	ENSG00000259429.4	UBE2Q2P2	-3.95	0.000105	0.0323	-0.24	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82355142~82420075:+
SARC	cis	rs867371	1	rs7180584	ENSG00000259429.4	UBE2Q2P2	-3.95	0.000105	0.0323	-0.24	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82355142~82420075:+
SARC	cis	rs867186	1	rs80277764	ENSG00000229230.3	MT1P3	3.95	0.000105	0.0324	0.47	0.25	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35151653	chr20:35218009~35218185:+
SARC	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	3.95	0.000105	0.0324	0.37	0.25	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
SARC	cis	rs61160187	0.61	rs4700397	ENSG00000215032.2	GNL3LP1	-3.95	0.000105	0.0324	-0.25	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:60891935~60893577:-
SARC	cis	rs9876781	0.559	rs7610524	ENSG00000229759.1	MRPS18AP1	3.95	0.000105	0.0324	0.27	0.25	Longevity;	chr3:48353882	chr3:48256350~48256938:-
SARC	cis	rs577676	0.586	rs12031871	ENSG00000271811.1	RP1-79C4.4	3.95	0.000105	0.0324	0.34	0.25	Prevalent atrial fibrillation;	chr1:170621426	chr1:170667381~170669425:+
SARC	cis	rs28386778	0.897	rs2036911	ENSG00000240280.5	TCAM1P	-3.95	0.000105	0.0324	-0.31	-0.25	Prudent dietary pattern;	chr17:63717479	chr17:63849292~63864379:+
SARC	cis	rs6433895	1	rs7558428	ENSG00000236153.1	AC104076.3	3.95	0.000105	0.0324	0.24	0.25	Lymphocyte counts;	chr2:181153827	chr2:180979427~180980090:-
SARC	cis	rs748404	1	rs12909095	ENSG00000205771.5	CATSPER2P1	-3.95	0.000105	0.0324	-0.37	-0.25	Lung cancer;	chr15:43265944	chr15:43726918~43747094:-
SARC	cis	rs28386778	0.863	rs2584637	ENSG00000240280.5	TCAM1P	-3.95	0.000105	0.0324	-0.31	-0.25	Prudent dietary pattern;	chr17:63865592	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2854213	ENSG00000240280.5	TCAM1P	-3.95	0.000105	0.0324	-0.31	-0.25	Prudent dietary pattern;	chr17:63868271	chr17:63849292~63864379:+
SARC	cis	rs526231	0.756	rs35804	ENSG00000175749.11	EIF3KP1	3.95	0.000105	0.0324	0.31	0.25	Primary biliary cholangitis;	chr5:103289634	chr5:103032376~103033031:+
SARC	cis	rs9832727	0.827	rs4683709	ENSG00000240950.1	RP11-372E1.1	-3.95	0.000106	0.0324	-0.26	-0.25	Phospholipid levels (plasma);	chr3:142934407	chr3:142827096~142827728:-
SARC	cis	rs17270561	0.609	rs9358885	ENSG00000272462.2	U91328.19	-3.95	0.000106	0.0324	-0.24	-0.25	Iron status biomarkers;	chr6:25757796	chr6:25992662~26001775:+
SARC	cis	rs9739682	0.6	rs12425938	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62090611	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.6	rs10877790	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62090844	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.529	rs1444259	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62091200	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.6	rs1444258	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62091379	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.6	rs71465132	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62091682	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.6	rs9739658	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62092219	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.6	rs9739661	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62092328	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.6	rs35488183	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62092707	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.6	rs11174307	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62092918	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.6	rs11174309	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62093360	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.6	rs11174310	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62093465	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.6	rs11174311	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62093503	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.6	rs12815741	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62093899	chr12:62965325~62965969:+
SARC	cis	rs9739682	0.6	rs34988458	ENSG00000139239.7	RPL14P1	-3.95	0.000106	0.0324	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62094056	chr12:62965325~62965969:+
SARC	cis	rs13434995	0.589	rs496055	ENSG00000273257.1	RP11-177J6.1	-3.95	0.000106	0.0324	-0.34	-0.25	Adiponectin levels;	chr4:55383670	chr4:55387949~55388271:+
SARC	cis	rs7772486	0.686	rs9390349	ENSG00000235652.6	RP11-545I5.3	-3.95	0.000106	0.0324	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145799409~145886585:+
SARC	cis	rs4835473	0.897	rs34380794	ENSG00000251600.4	RP11-673E1.1	-3.95	0.000106	0.0324	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143735800	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.75	rs56372690	ENSG00000251600.4	RP11-673E1.1	-3.95	0.000106	0.0324	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143735816	chr4:143912331~143982454:+
SARC	cis	rs66887589	0.616	rs11098498	ENSG00000245958.5	RP11-33B1.1	-3.95	0.000106	0.0324	-0.22	-0.25	Diastolic blood pressure;	chr4:119265964	chr4:119454791~119552025:+
SARC	cis	rs7977237	0.928	rs73089823	ENSG00000240759.1	RP11-25I15.1	3.95	0.000106	0.0324	0.32	0.25	Intraocular pressure;	chr12:43556844	chr12:42678873~42679124:-
SARC	cis	rs11955398	0.502	rs158914	ENSG00000215032.2	GNL3LP1	-3.95	0.000106	0.0324	-0.27	-0.25	Intelligence (multi-trait analysis);	chr5:60950582	chr5:60891935~60893577:-
SARC	cis	rs2404602	0.692	rs4641709	ENSG00000259422.1	RP11-593F23.1	-3.94	0.000106	0.0325	-0.28	-0.25	Blood metabolite levels;	chr15:76755395	chr15:76174891~76181486:-
SARC	cis	rs727479	0.962	rs2414095	ENSG00000244879.4	GABPB1-AS1	-3.94	0.000106	0.0325	-0.21	-0.25	Estradiol levels;	chr15:51232095	chr15:50354959~50372202:+
SARC	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-3.94	0.000106	0.0325	-0.27	-0.25	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
SARC	cis	rs8028182	0.636	rs4243034	ENSG00000260206.1	CTD-2026K11.2	-3.94	0.000106	0.0325	-0.3	-0.25	Sudden cardiac arrest;	chr15:75458628	chr15:75636139~75639239:+
SARC	cis	rs7246657	0.943	rs10424574	ENSG00000226686.6	LINC01535	-3.94	0.000106	0.0325	-0.35	-0.25	Coronary artery calcification;	chr19:37347491	chr19:37251912~37265535:+
SARC	cis	rs2905347	0.737	rs2905349	ENSG00000179428.2	AC073072.5	-3.94	0.000106	0.0325	-0.27	-0.25	Major depression and alcohol dependence;	chr7:22589666	chr7:22725395~22727620:-
SARC	cis	rs7772486	0.597	rs1970306	ENSG00000270638.1	RP3-466P17.1	3.94	0.000106	0.0325	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.597	rs9386136	ENSG00000270638.1	RP3-466P17.1	3.94	0.000106	0.0325	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145735570~145737218:+
SARC	cis	rs7615952	0.512	rs4679430	ENSG00000171084.14	FAM86JP	3.94	0.000106	0.0325	0.35	0.25	Blood pressure (smoking interaction);	chr3:125639049	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.512	rs34651730	ENSG00000171084.14	FAM86JP	3.94	0.000106	0.0325	0.35	0.25	Blood pressure (smoking interaction);	chr3:125639796	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.512	rs2979334	ENSG00000171084.14	FAM86JP	3.94	0.000106	0.0325	0.35	0.25	Blood pressure (smoking interaction);	chr3:125639980	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.512	rs11929125	ENSG00000171084.14	FAM86JP	3.94	0.000106	0.0325	0.35	0.25	Blood pressure (smoking interaction);	chr3:125640599	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.512	rs11921452	ENSG00000171084.14	FAM86JP	3.94	0.000106	0.0325	0.35	0.25	Blood pressure (smoking interaction);	chr3:125640906	chr3:125916620~125930024:+
SARC	cis	rs7615952	0.512	rs2922175	ENSG00000171084.14	FAM86JP	3.94	0.000106	0.0325	0.35	0.25	Blood pressure (smoking interaction);	chr3:125642516	chr3:125916620~125930024:+
SARC	cis	rs7267979	0.932	rs367666	ENSG00000276952.1	RP5-965G21.6	3.94	0.000106	0.0325	0.25	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:25284915~25285588:-
SARC	cis	rs11159086	1	rs4903232	ENSG00000270000.1	RP3-449M8.9	3.94	0.000106	0.0325	0.37	0.25	Advanced glycation end-product levels;	chr14:74496585	chr14:74471930~74472360:-
SARC	cis	rs7083	0.84	rs509565	ENSG00000254851.1	RP11-109L13.1	3.94	0.000106	0.0325	0.28	0.25	Blood protein levels;	chr11:117249757	chr11:117135528~117138582:+
SARC	cis	rs5769707	0.933	rs2157444	ENSG00000235111.1	RP1-29C18.8	-3.94	0.000106	0.0326	-0.26	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49612657~49615716:-
SARC	cis	rs72647484	0.555	rs2998269	ENSG00000228397.1	RP1-224A6.3	-3.94	0.000106	0.0326	-0.53	-0.25	Colorectal cancer;	chr1:22199473	chr1:22023994~22024968:-
SARC	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-3.94	0.000106	0.0326	-0.3	-0.25	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
SARC	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-3.94	0.000106	0.0326	-0.3	-0.25	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
SARC	cis	rs28386778	0.863	rs3760254	ENSG00000240280.5	TCAM1P	-3.94	0.000106	0.0326	-0.31	-0.25	Prudent dietary pattern;	chr17:63774391	chr17:63849292~63864379:+
SARC	cis	rs56046484	0.956	rs35204319	ENSG00000259295.5	CSPG4P12	3.94	0.000106	0.0326	0.37	0.25	Testicular germ cell tumor;	chr15:85107246	chr15:85191438~85213905:+
SARC	cis	rs801193	0.967	rs34356500	ENSG00000224316.1	RP11-479O9.2	3.94	0.000106	0.0326	0.23	0.25	Aortic root size;	chr7:66771620	chr7:65773620~65802067:+
SARC	cis	rs4664293	0.667	rs2042782	ENSG00000226266.5	AC009961.3	3.94	0.000106	0.0326	0.29	0.25	Monocyte percentage of white cells;	chr2:159789781	chr2:159670708~159712435:-
SARC	cis	rs7204230	1	rs11075899	ENSG00000261291.1	RP11-295M3.2	3.94	0.000106	0.0326	0.28	0.25	Fibrinogen;	chr16:53289384	chr16:53168522~53169450:+
SARC	cis	rs2243480	1	rs431076	ENSG00000164669.11	INTS4P1	3.94	0.000106	0.0326	0.43	0.25	Diabetic kidney disease;	chr7:66135333	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs2257790	ENSG00000164669.11	INTS4P1	3.94	0.000106	0.0326	0.43	0.25	Diabetic kidney disease;	chr7:66135463	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs2460422	ENSG00000164669.11	INTS4P1	3.94	0.000106	0.0326	0.43	0.25	Diabetic kidney disease;	chr7:66136518	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs316334	ENSG00000164669.11	INTS4P1	3.94	0.000106	0.0326	0.43	0.25	Diabetic kidney disease;	chr7:66137139	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs316332	ENSG00000164669.11	INTS4P1	3.94	0.000106	0.0326	0.43	0.25	Diabetic kidney disease;	chr7:66139312	chr7:65141225~65234216:+
SARC	cis	rs17174870	0.91	rs11902247	ENSG00000228251.1	AC012442.6	3.94	0.000106	0.0326	0.33	0.25	Multiple sclerosis;	chr2:111931704	chr2:112590796~112591939:+
SARC	cis	rs4679904	0.96	rs17826257	ENSG00000243116.1	RP11-564C24.1	3.94	0.000106	0.0326	0.26	0.25	Primary biliary cholangitis;	chr3:160545015	chr3:159721524~159722401:-
SARC	cis	rs7267979	0.565	rs4815437	ENSG00000125804.12	FAM182A	3.94	0.000106	0.0326	0.3	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:26054655~26086917:+
SARC	cis	rs600231	0.706	rs10896016	ENSG00000254614.2	AP003068.23	-3.94	0.000106	0.0326	-0.29	-0.25	Bone mineral density;	chr11:65568234	chr11:65177606~65181834:-
SARC	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-3.94	0.000106	0.0326	-0.38	-0.25	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
SARC	cis	rs67478160	0.704	rs12894254	ENSG00000269958.1	RP11-73M18.8	3.94	0.000106	0.0326	0.24	0.25	Schizophrenia;	chr14:103824612	chr14:103696353~103697163:+
SARC	cis	rs67478160	0.643	rs4900600	ENSG00000269958.1	RP11-73M18.8	3.94	0.000106	0.0326	0.24	0.25	Schizophrenia;	chr14:103825502	chr14:103696353~103697163:+
SARC	cis	rs264537	0.571	rs2121789	ENSG00000172971.7	UNC93B3	-3.94	0.000106	0.0326	-0.31	-0.25	Periodontitis (PAL4Q3);	chr3:76622886	chr3:75619506~75623849:-
SARC	cis	rs72627509	0.904	rs56281640	ENSG00000269949.1	RP11-738E22.3	3.94	0.000106	0.0326	0.37	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899650	chr4:56960927~56961373:-
SARC	cis	rs8028182	0.636	rs4075522	ENSG00000260206.1	CTD-2026K11.2	-3.94	0.000106	0.0326	-0.3	-0.25	Sudden cardiac arrest;	chr15:75571994	chr15:75636139~75639239:+
SARC	cis	rs12887734	0.566	rs3742366	ENSG00000269940.1	RP11-73M18.7	3.94	0.000106	0.0326	0.24	0.25	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103732014	chr14:103694560~103695170:+
SARC	cis	rs11133504	0.55	rs4865235	ENSG00000269949.1	RP11-738E22.3	3.94	0.000106	0.0327	0.33	0.25	Ulcerative colitis;	chr4:57494210	chr4:56960927~56961373:-
SARC	cis	rs7617480	0.61	rs4955420	ENSG00000225399.4	RP11-3B7.1	3.94	0.000106	0.0327	0.32	0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chr3:49260085~49261316:+
SARC	cis	rs7208859	0.623	rs1054397	ENSG00000264538.5	SUZ12P1	-3.94	0.000107	0.0327	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30709299~30790908:+
SARC	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	3.94	0.000107	0.0327	0.38	0.25	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
SARC	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-3.94	0.000107	0.0327	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
SARC	cis	rs7520050	0.966	rs6675726	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46094971	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.966	rs785520	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46103164	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.966	rs785485	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46108752	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.966	rs785488	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46110423	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.966	rs785489	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46110718	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.898	rs785502	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46115772	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.966	rs785494	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46120954	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.966	rs785503	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46130196	chr1:45581219~45581321:-
SARC	cis	rs4942242	1	rs9533572	ENSG00000274001.1	RP11-5G9.5	3.94	0.000107	0.0327	0.25	0.25	Response to tocilizumab in rheumatoid arthritis;	chr13:43660129	chr13:43877715~43878163:-
SARC	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	3.94	0.000107	0.0327	0.33	0.25	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
SARC	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-3.94	0.000107	0.0327	-0.47	-0.25	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-3.94	0.000107	0.0327	-0.47	-0.25	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
SARC	cis	rs7772486	0.654	rs702321	ENSG00000235652.6	RP11-545I5.3	-3.94	0.000107	0.0327	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145799409~145886585:+
SARC	cis	rs7520050	0.833	rs1085242	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46078552	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.966	rs1085243	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46079096	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.966	rs1768803	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46080536	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.931	rs1707333	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46081363	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.966	rs4660910	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46082730	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.966	rs785481	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0327	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46088846	chr1:45581219~45581321:-
SARC	cis	rs7772486	0.686	rs1337839	ENSG00000235652.6	RP11-545I5.3	-3.94	0.000107	0.0328	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145799409~145886585:+
SARC	cis	rs7614311	0.954	rs6762506	ENSG00000271843.1	RP11-245J9.5	-3.94	0.000107	0.0328	-0.33	-0.25	Lung function (FVC);Lung function (FEV1);	chr3:63808872	chr3:64008082~64008692:-
SARC	cis	rs7246657	0.882	rs4803539	ENSG00000226686.6	LINC01535	-3.94	0.000107	0.0328	-0.34	-0.25	Coronary artery calcification;	chr19:37406620	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs3803895	ENSG00000226686.6	LINC01535	-3.94	0.000107	0.0328	-0.34	-0.25	Coronary artery calcification;	chr19:37407767	chr19:37251912~37265535:+
SARC	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-3.94	0.000107	0.0328	-0.47	-0.25	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
SARC	cis	rs7520050	0.778	rs2088102	ENSG00000280836.1	AL355480.1	3.94	0.000107	0.0328	0.24	0.25	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45581219~45581321:-
SARC	cis	rs59104589	0.583	rs73002176	ENSG00000266621.1	AC104841.1	3.94	0.000107	0.0328	0.35	0.25	Fibrinogen levels;	chr2:241393023	chr2:241245202~241245299:-
SARC	cis	rs638893	0.617	rs11217059	ENSG00000278376.1	RP11-158I9.8	-3.94	0.000107	0.0328	-0.21	-0.25	Vitiligo;	chr11:118852378	chr11:118791254~118793137:+
SARC	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	3.94	0.000107	0.0328	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
SARC	cis	rs7115242	0.925	rs7925256	ENSG00000276505.1	CMB9-94B1.2	-3.94	0.000107	0.0328	-0.54	-0.25	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117297005~117297328:-
SARC	cis	rs600231	0.665	rs2105608	ENSG00000245532.5	NEAT1	3.94	0.000107	0.0328	0.19	0.25	Bone mineral density;	chr11:65461147	chr11:65422774~65445540:+
SARC	cis	rs9902453	0.866	rs4795529	ENSG00000264538.5	SUZ12P1	3.94	0.000107	0.0328	0.17	0.25	Coffee consumption (cups per day);	chr17:30116531	chr17:30709299~30790908:+
SARC	cis	rs4679904	0.96	rs12631381	ENSG00000243116.1	RP11-564C24.1	3.94	0.000107	0.0328	0.26	0.25	Primary biliary cholangitis;	chr3:160541651	chr3:159721524~159722401:-
SARC	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-3.94	0.000107	0.0328	-0.37	-0.25	Gout;	chr7:66732812	chr7:66902857~66906297:+
SARC	cis	rs745109	0.882	rs1518810	ENSG00000273080.1	RP11-301O19.1	-3.94	0.000107	0.0328	-0.4	-0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86422310	chr2:86195590~86196049:+
SARC	cis	rs9438901	0.655	rs609320	ENSG00000261349.1	RP3-465N24.5	3.94	0.000107	0.0328	0.35	0.25	Red cell distribution width;	chr1:25390874	chr1:25266102~25267136:-
SARC	cis	rs12950390	0.853	rs10445375	ENSG00000239291.1	RP5-867C24.1	-3.94	0.000107	0.0328	-0.29	-0.25	IgG glycosylation;	chr17:47786948	chr17:47159191~47159993:-
SARC	cis	rs10986311	0.775	rs1984001	ENSG00000235204.1	RP11-121A14.2	-3.94	0.000107	0.0328	-0.29	-0.25	Vitiligo;	chr9:124375522	chr9:124259250~124261156:-
SARC	cis	rs7274811	0.901	rs17404047	ENSG00000181741.7	FDX1P1	-3.94	0.000107	0.0328	-0.33	-0.25	Height;	chr20:33717975	chr20:34475924~34476474:-
SARC	cis	rs853679	0.55	rs9295762	ENSG00000272009.1	RP1-313I6.12	3.94	0.000107	0.0328	0.27	0.25	Depression;	chr6:28187640	chr6:28078792~28081130:-
SARC	cis	rs853679	0.517	rs9380052	ENSG00000216901.1	AL022393.7	3.94	0.000107	0.0328	0.36	0.25	Depression;	chr6:28096845	chr6:28176188~28176674:+
SARC	cis	rs28386778	0.897	rs2236737	ENSG00000240280.5	TCAM1P	-3.94	0.000107	0.0329	-0.31	-0.25	Prudent dietary pattern;	chr17:63860740	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2236736	ENSG00000240280.5	TCAM1P	-3.94	0.000107	0.0329	-0.31	-0.25	Prudent dietary pattern;	chr17:63860888	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2854221	ENSG00000240280.5	TCAM1P	-3.94	0.000107	0.0329	-0.31	-0.25	Prudent dietary pattern;	chr17:63864085	chr17:63849292~63864379:+
SARC	cis	rs72945132	0.882	rs11235739	ENSG00000254604.1	AP000487.6	-3.94	0.000107	0.0329	-0.35	-0.25	Coronary artery disease;	chr11:70286674	chr11:70282367~70363368:-
SARC	cis	rs7688540	0.771	rs10021364	ENSG00000275426.1	CH17-262A2.1	-3.94	0.000107	0.0329	-0.36	-0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:316902	chr4:149738~150317:+
SARC	cis	rs56046484	0.956	rs12904410	ENSG00000259295.5	CSPG4P12	3.94	0.000107	0.0329	0.36	0.25	Testicular germ cell tumor;	chr15:85066557	chr15:85191438~85213905:+
SARC	cis	rs4664293	0.647	rs10199805	ENSG00000226266.5	AC009961.3	-3.94	0.000107	0.0329	-0.29	-0.25	Monocyte percentage of white cells;	chr2:159570880	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs10202352	ENSG00000226266.5	AC009961.3	-3.94	0.000107	0.0329	-0.29	-0.25	Monocyte percentage of white cells;	chr2:159571097	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs1425040	ENSG00000226266.5	AC009961.3	-3.94	0.000107	0.0329	-0.29	-0.25	Monocyte percentage of white cells;	chr2:159571912	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.625	rs11693108	ENSG00000226266.5	AC009961.3	-3.94	0.000107	0.0329	-0.29	-0.25	Monocyte percentage of white cells;	chr2:159572076	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs7575924	ENSG00000226266.5	AC009961.3	-3.94	0.000107	0.0329	-0.29	-0.25	Monocyte percentage of white cells;	chr2:159573049	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs4665082	ENSG00000226266.5	AC009961.3	-3.94	0.000107	0.0329	-0.29	-0.25	Monocyte percentage of white cells;	chr2:159573455	chr2:159670708~159712435:-
SARC	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-3.94	0.000107	0.0329	-0.29	-0.25	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
SARC	cis	rs7208859	0.623	rs9914242	ENSG00000264538.5	SUZ12P1	-3.94	0.000107	0.0329	-0.28	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30709299~30790908:+
SARC	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	3.94	0.000108	0.0329	0.39	0.25	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
SARC	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	3.94	0.000108	0.0329	0.39	0.25	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
SARC	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	3.94	0.000108	0.0329	0.39	0.25	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
SARC	cis	rs56046484	0.871	rs71397837	ENSG00000259295.5	CSPG4P12	3.94	0.000108	0.0329	0.39	0.25	Testicular germ cell tumor;	chr15:85020330	chr15:85191438~85213905:+
SARC	cis	rs56046484	0.871	rs62021203	ENSG00000259295.5	CSPG4P12	3.94	0.000108	0.0329	0.39	0.25	Testicular germ cell tumor;	chr15:85020846	chr15:85191438~85213905:+
SARC	cis	rs4664293	0.967	rs13397722	ENSG00000226266.5	AC009961.3	-3.94	0.000108	0.0329	-0.31	-0.25	Monocyte percentage of white cells;	chr2:159659140	chr2:159670708~159712435:-
SARC	cis	rs9880772	0.683	rs6551228	ENSG00000272282.1	RP11-222K16.2	-3.94	0.000108	0.0329	-0.24	-0.25	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);	chr3:27774044	chr3:27712910~27714005:+
SARC	cis	rs2189609	0.813	rs2663145	ENSG00000259972.2	AC009120.6	-3.94	0.000108	0.0329	-0.15	-0.25	Energy expenditure (24h);	chr16:73971125	chr16:74305127~74335346:-
SARC	cis	rs12893668	0.603	rs61637848	ENSG00000269910.1	RP11-73M18.10	3.94	0.000108	0.0329	0.23	0.25	Reticulocyte count;	chr14:103629694	chr14:103694516~103695050:-
SARC	cis	rs11264213	1	rs11264211	ENSG00000239636.1	RP4-728D4.2	-3.94	0.000108	0.0329	-0.33	-0.25	Schizophrenia;	chr1:35805006	chr1:35569813~35577729:-
SARC	cis	rs11264213	1	rs11264213	ENSG00000239636.1	RP4-728D4.2	-3.94	0.000108	0.0329	-0.33	-0.25	Schizophrenia;	chr1:35818353	chr1:35569813~35577729:-
SARC	cis	rs11264213	0.892	rs11263828	ENSG00000239636.1	RP4-728D4.2	-3.94	0.000108	0.0329	-0.33	-0.25	Schizophrenia;	chr1:35833271	chr1:35569813~35577729:-
SARC	cis	rs11955398	0.502	rs295561	ENSG00000272308.1	RP11-231G3.1	-3.94	0.000108	0.0329	-0.23	-0.25	Intelligence (multi-trait analysis);	chr5:61104390	chr5:60866457~60866935:-
SARC	cis	rs3842397	1	rs3842397	ENSG00000280212.1	RP11-49K24.3	3.94	0.000108	0.033	0.27	0.25	Red cell distribution width;Mean platelet volume;	chr18:46265919	chr18:47076117~47076594:+
SARC	cis	rs7044106	0.537	rs10739573	ENSG00000238181.2	AHCYP2	-3.94	0.000108	0.033	-0.23	-0.25	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120720673~120721972:+
SARC	cis	rs2836974	0.545	rs8128901	ENSG00000255568.3	BRWD1-AS2	3.94	0.000108	0.033	0.23	0.25	Cognitive function;	chr21:39338493	chr21:39313935~39314962:+
SARC	cis	rs6845263	0.546	rs11936512	ENSG00000254531.1	FLJ20021	3.94	0.000108	0.033	0.24	0.25	Superior crus of antihelix expression;	chr4:101530153	chr4:101347780~101348883:+
SARC	cis	rs7246657	0.943	rs713256	ENSG00000226686.6	LINC01535	-3.94	0.000108	0.033	-0.35	-0.25	Coronary artery calcification;	chr19:37374463	chr19:37251912~37265535:+
SARC	cis	rs7646881	1	rs73015651	ENSG00000240207.5	RP11-379F4.4	-3.94	0.000108	0.033	-0.36	-0.25	Tetralogy of Fallot;	chr3:158733133	chr3:158732263~158784070:+
SARC	cis	rs12210905	0.764	rs72835248	ENSG00000272462.2	U91328.19	-3.94	0.000108	0.033	-0.46	-0.25	Hip circumference adjusted for BMI;	chr6:26964038	chr6:25992662~26001775:+
SARC	cis	rs12210905	1	rs115268625	ENSG00000272462.2	U91328.19	-3.94	0.000108	0.033	-0.46	-0.25	Hip circumference adjusted for BMI;	chr6:26980450	chr6:25992662~26001775:+
SARC	cis	rs56046484	0.703	rs116893322	ENSG00000259295.5	CSPG4P12	3.94	0.000108	0.033	0.39	0.25	Testicular germ cell tumor;	chr15:84981397	chr15:85191438~85213905:+
SARC	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	3.94	0.000108	0.033	0.24	0.25	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
SARC	cis	rs10144321	0.644	rs4905950	ENSG00000271417.2	SNHG24	-3.94	0.000108	0.033	-0.22	-0.25	Menarche (age at onset);	chr14:100329293	chr14:100967652~100987280:+
SARC	cis	rs7617773	0.78	rs7645425	ENSG00000228638.1	FCF1P2	-3.94	0.000108	0.033	-0.29	-0.25	Coronary artery disease;	chr3:48320879	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.743	rs11716371	ENSG00000228638.1	FCF1P2	-3.94	0.000108	0.033	-0.29	-0.25	Coronary artery disease;	chr3:48321260	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs6793223	ENSG00000228638.1	FCF1P2	-3.94	0.000108	0.033	-0.29	-0.25	Coronary artery disease;	chr3:48322611	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs4541431	ENSG00000228638.1	FCF1P2	-3.94	0.000108	0.033	-0.29	-0.25	Coronary artery disease;	chr3:48323728	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs11714944	ENSG00000228638.1	FCF1P2	-3.94	0.000108	0.033	-0.29	-0.25	Coronary artery disease;	chr3:48325481	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.743	rs13071960	ENSG00000228638.1	FCF1P2	-3.94	0.000108	0.033	-0.29	-0.25	Coronary artery disease;	chr3:48326047	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.743	rs4632568	ENSG00000228638.1	FCF1P2	-3.94	0.000108	0.033	-0.29	-0.25	Coronary artery disease;	chr3:48326329	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs11130164	ENSG00000228638.1	FCF1P2	-3.94	0.000108	0.033	-0.29	-0.25	Coronary artery disease;	chr3:48327544	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs7653336	ENSG00000228638.1	FCF1P2	-3.94	0.000108	0.033	-0.29	-0.25	Coronary artery disease;	chr3:48327974	chr3:48290793~48291375:-
SARC	cis	rs12236219	0.681	rs10993188	ENSG00000224764.1	RP11-54O15.3	3.94	0.000108	0.033	0.46	0.25	Body mass index;	chr9:94399608	chr9:94928551~94934946:-
SARC	cis	rs783540	1	rs6603033	ENSG00000275695.1	UBE2Q2P6	3.94	0.000108	0.033	0.25	0.25	Schizophrenia;	chr15:82667123	chr15:82445719~82454837:+
SARC	cis	rs1061377	0.585	rs2163271	ENSG00000249207.1	RP11-360F5.1	-3.94	0.000108	0.0331	-0.27	-0.25	Uric acid levels;	chr4:39076525	chr4:39112677~39126818:-
SARC	cis	rs4679904	0.96	rs12639488	ENSG00000243116.1	RP11-564C24.1	3.94	0.000108	0.0331	0.26	0.25	Primary biliary cholangitis;	chr3:160541579	chr3:159721524~159722401:-
SARC	cis	rs7246657	0.943	rs1015849	ENSG00000226686.6	LINC01535	-3.94	0.000108	0.0331	-0.35	-0.25	Coronary artery calcification;	chr19:37455278	chr19:37251912~37265535:+
SARC	cis	rs7267979	0.816	rs405822	ENSG00000125804.12	FAM182A	-3.94	0.000108	0.0331	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:26054655~26086917:+
SARC	cis	rs7267979	0.816	rs6138593	ENSG00000125804.12	FAM182A	-3.94	0.000108	0.0331	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:26054655~26086917:+
SARC	cis	rs7267979	0.816	rs409853	ENSG00000125804.12	FAM182A	-3.94	0.000108	0.0331	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:26054655~26086917:+
SARC	cis	rs72647484	0.555	rs2807349	ENSG00000228397.1	RP1-224A6.3	-3.94	0.000108	0.0331	-0.52	-0.25	Colorectal cancer;	chr1:22205697	chr1:22023994~22024968:-
SARC	cis	rs860818	1	rs4321897	ENSG00000226816.2	AC005082.12	-3.94	0.000108	0.0331	-0.71	-0.25	Initial pursuit acceleration;	chr7:23161949	chr7:23206013~23208045:+
SARC	cis	rs6477918	0.598	rs7019195	ENSG00000250068.1	RP11-576C12.1	-3.94	0.000108	0.0331	-0.25	-0.25	Obstetric antiphospholipid syndrome;	chr9:112399502	chr9:112581779~112582590:-
SARC	cis	rs2836974	0.544	rs8128919	ENSG00000255568.3	BRWD1-AS2	3.94	0.000108	0.0331	0.23	0.25	Cognitive function;	chr21:39339936	chr21:39313935~39314962:+
SARC	cis	rs7208859	0.623	rs3752019	ENSG00000266490.1	CTD-2349P21.9	3.94	0.000108	0.0331	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30792372~30792833:+
SARC	cis	rs889122	0.765	rs10425422	ENSG00000267289.1	CTD-2623N2.11	3.94	0.000108	0.0331	0.29	0.25	Menarche (age at onset);	chr19:9872345	chr19:9834079~9835013:-
SARC	cis	rs889122	0.684	rs1978453	ENSG00000267289.1	CTD-2623N2.11	3.94	0.000108	0.0331	0.29	0.25	Menarche (age at onset);	chr19:9872769	chr19:9834079~9835013:-
SARC	cis	rs9481169	0.557	rs13190932	ENSG00000255389.1	C6orf3	-3.94	0.000109	0.0332	-0.5	-0.25	Inflammatory skin disease;	chr6:111591867	chr6:111599875~111602295:+
SARC	cis	rs7617773	0.817	rs11928691	ENSG00000228638.1	FCF1P2	-3.94	0.000109	0.0332	-0.28	-0.25	Coronary artery disease;	chr3:48245275	chr3:48290793~48291375:-
SARC	cis	rs4835473	0.808	rs2060653	ENSG00000251600.4	RP11-673E1.1	-3.94	0.000109	0.0332	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143739132	chr4:143912331~143982454:+
SARC	cis	rs17174870	0.911	rs6738237	ENSG00000228251.1	AC012442.6	3.94	0.000109	0.0332	0.32	0.25	Multiple sclerosis;	chr2:112028193	chr2:112590796~112591939:+
SARC	cis	rs948562	0.585	rs17472536	ENSG00000280010.1	AP001350.4	3.94	0.000109	0.0332	0.39	0.25	Lymphoma;	chr11:58346066	chr11:58627435~58628528:+
SARC	cis	rs7267979	0.816	rs6076358	ENSG00000274414.1	RP5-965G21.4	3.94	0.000109	0.0332	0.26	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:25239007~25245229:-
SARC	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	3.94	0.000109	0.0332	0.31	0.25	Height;	chr6:109390116	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	3.94	0.000109	0.0332	0.31	0.25	Height;	chr6:109390638	chr6:109382795~109383666:+
SARC	cis	rs10911902	0.643	rs75158977	ENSG00000233196.2	GS1-304P7.1	-3.94	0.000109	0.0332	-0.37	-0.25	Schizophrenia;	chr1:186324597	chr1:186580515~186581191:-
SARC	cis	rs10911902	0.602	rs3736595	ENSG00000233196.2	GS1-304P7.1	-3.94	0.000109	0.0332	-0.37	-0.25	Schizophrenia;	chr1:186331745	chr1:186580515~186581191:-
SARC	cis	rs2836974	0.583	rs2776306	ENSG00000255568.3	BRWD1-AS2	3.94	0.000109	0.0332	0.23	0.25	Cognitive function;	chr21:39341828	chr21:39313935~39314962:+
SARC	cis	rs593531	0.571	rs11236088	ENSG00000280269.1	AP000577.2	-3.94	0.000109	0.0333	-0.31	-0.25	Neuroticism;	chr11:74383298	chr11:74204869~74205746:+
SARC	cis	rs17174870	0.955	rs867311	ENSG00000228251.1	AC012442.6	3.94	0.000109	0.0333	0.33	0.25	Multiple sclerosis;	chr2:111920393	chr2:112590796~112591939:+
SARC	cis	rs7615952	0.576	rs4646748	ENSG00000248787.1	RP11-666A20.4	-3.94	0.000109	0.0333	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:126107486	chr3:125908005~125910272:-
SARC	cis	rs9438901	0.592	rs1293259	ENSG00000224183.1	SDHDP6	3.94	0.000109	0.0333	0.43	0.25	Red cell distribution width;	chr1:25369344	chr1:25294164~25294643:-
SARC	cis	rs7520050	0.865	rs785515	ENSG00000280836.1	AL355480.1	3.94	0.000109	0.0333	0.24	0.25	Reticulocyte count;Red blood cell count;	chr1:46096990	chr1:45581219~45581321:-
SARC	cis	rs597539	0.652	rs569777	ENSG00000250508.1	RP11-757G1.6	-3.94	0.000109	0.0333	-0.3	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68870664~68874542:+
SARC	cis	rs28386778	0.897	rs2044125	ENSG00000240280.5	TCAM1P	3.94	0.000109	0.0333	0.31	0.25	Prudent dietary pattern;	chr17:63785824	chr17:63849292~63864379:+
SARC	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	3.94	0.000109	0.0333	0.3	0.25	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	3.94	0.000109	0.0333	0.3	0.25	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	3.94	0.000109	0.0333	0.3	0.25	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
SARC	cis	rs673078	0.607	rs7294498	ENSG00000275759.1	RP11-131L12.3	-3.94	0.000109	0.0333	-0.33	-0.25	Glucose homeostasis traits;	chr12:118321680	chr12:118428281~118428870:+
SARC	cis	rs638893	0.617	rs2156750	ENSG00000278376.1	RP11-158I9.8	-3.94	0.000109	0.0333	-0.21	-0.25	Vitiligo;	chr11:118848545	chr11:118791254~118793137:+
SARC	cis	rs638893	0.561	rs2156749	ENSG00000278376.1	RP11-158I9.8	-3.94	0.000109	0.0333	-0.21	-0.25	Vitiligo;	chr11:118848696	chr11:118791254~118793137:+
SARC	cis	rs638893	0.617	rs7116715	ENSG00000278376.1	RP11-158I9.8	-3.94	0.000109	0.0333	-0.21	-0.25	Vitiligo;	chr11:118849033	chr11:118791254~118793137:+
SARC	cis	rs638893	0.617	rs4938564	ENSG00000278376.1	RP11-158I9.8	-3.94	0.000109	0.0333	-0.21	-0.25	Vitiligo;	chr11:118849881	chr11:118791254~118793137:+
SARC	cis	rs638893	0.588	rs4936440	ENSG00000278376.1	RP11-158I9.8	-3.94	0.000109	0.0333	-0.21	-0.25	Vitiligo;	chr11:118849975	chr11:118791254~118793137:+
SARC	cis	rs638893	0.588	rs4938566	ENSG00000278376.1	RP11-158I9.8	-3.94	0.000109	0.0333	-0.21	-0.25	Vitiligo;	chr11:118850480	chr11:118791254~118793137:+
SARC	cis	rs638893	0.617	rs4938567	ENSG00000278376.1	RP11-158I9.8	-3.94	0.000109	0.0333	-0.21	-0.25	Vitiligo;	chr11:118850540	chr11:118791254~118793137:+
SARC	cis	rs12497850	0.931	rs6791542	ENSG00000225399.4	RP11-3B7.1	3.94	0.000109	0.0333	0.32	0.25	Parkinson's disease;	chr3:48749786	chr3:49260085~49261316:+
SARC	cis	rs11098499	0.863	rs10004484	ENSG00000250950.1	RP11-33B1.3	-3.94	0.000109	0.0333	-0.27	-0.25	Corneal astigmatism;	chr4:119521273	chr4:119456350~119457277:+
SARC	cis	rs10466239	0.667	rs10899792	ENSG00000230555.2	RP11-517P14.2	3.94	0.000109	0.0333	0.31	0.25	Telomere length;	chr10:43364722	chr10:43420738~43422100:+
SARC	cis	rs28386778	0.897	rs7212196	ENSG00000240280.5	TCAM1P	-3.94	0.000109	0.0334	-0.31	-0.25	Prudent dietary pattern;	chr17:63757621	chr17:63849292~63864379:+
SARC	cis	rs783540	0.934	rs8043401	ENSG00000275695.1	UBE2Q2P6	3.94	0.000109	0.0334	0.25	0.25	Schizophrenia;	chr15:82687507	chr15:82445719~82454837:+
SARC	cis	rs1707322	0.964	rs6675259	ENSG00000281133.1	AL355480.3	3.94	0.000109	0.0334	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45580892~45580996:-
SARC	cis	rs2494938	0.62	rs846523	ENSG00000234753.4	FOXP4-AS1	3.94	0.00011	0.0334	0.24	0.25	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);	chr6:40598201	chr6:41494853~41548621:-
SARC	cis	rs7615952	0.599	rs12485717	ENSG00000171084.14	FAM86JP	-3.94	0.00011	0.0334	-0.37	-0.25	Blood pressure (smoking interaction);	chr3:125988232	chr3:125916620~125930024:+
SARC	cis	rs240993	0.812	rs7751272	ENSG00000230177.1	RP5-1112D6.4	-3.94	0.00011	0.0334	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111419068	chr6:111277932~111278742:+
SARC	cis	rs11621121	0.547	rs2127869	ENSG00000259078.2	PTBP1P	3.94	0.00011	0.0334	0.27	0.25	N-glycan levels;	chr14:65327634	chr14:65279267~65281166:+
SARC	cis	rs35160687	0.509	rs13024436	ENSG00000273080.1	RP11-301O19.1	-3.94	0.00011	0.0334	-0.27	-0.25	Night sleep phenotypes;	chr2:86307398	chr2:86195590~86196049:+
SARC	cis	rs28386778	0.799	rs2727322	ENSG00000240280.5	TCAM1P	-3.94	0.00011	0.0334	-0.31	-0.25	Prudent dietary pattern;	chr17:63844346	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2727323	ENSG00000240280.5	TCAM1P	-3.94	0.00011	0.0334	-0.31	-0.25	Prudent dietary pattern;	chr17:63844639	chr17:63849292~63864379:+
SARC	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	3.94	0.00011	0.0334	0.38	0.25	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
SARC	cis	rs6845263	0.546	rs1426543	ENSG00000254531.1	FLJ20021	-3.94	0.00011	0.0334	-0.24	-0.25	Superior crus of antihelix expression;	chr4:101540871	chr4:101347780~101348883:+
SARC	cis	rs6845263	0.546	rs7682189	ENSG00000254531.1	FLJ20021	-3.94	0.00011	0.0334	-0.24	-0.25	Superior crus of antihelix expression;	chr4:101541398	chr4:101347780~101348883:+
SARC	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-3.94	0.00011	0.0334	-0.22	-0.25	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
SARC	cis	rs577676	0.586	rs656539	ENSG00000271811.1	RP1-79C4.4	3.94	0.00011	0.0334	0.35	0.25	Prevalent atrial fibrillation;	chr1:170637213	chr1:170667381~170669425:+
SARC	cis	rs7267979	0.789	rs4815429	ENSG00000276952.1	RP5-965G21.6	-3.94	0.00011	0.0335	-0.24	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:25284915~25285588:-
SARC	cis	rs1707322	0.963	rs11211202	ENSG00000281133.1	AL355480.3	-3.93	0.00011	0.0335	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4660889	ENSG00000281133.1	AL355480.3	-3.93	0.00011	0.0335	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs10890353	ENSG00000281133.1	AL355480.3	-3.93	0.00011	0.0335	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs10890355	ENSG00000281133.1	AL355480.3	-3.93	0.00011	0.0335	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs11211204	ENSG00000281133.1	AL355480.3	-3.93	0.00011	0.0335	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45580892~45580996:-
SARC	cis	rs2404602	1	rs2896954	ENSG00000259422.1	RP11-593F23.1	3.93	0.00011	0.0335	0.29	0.25	Blood metabolite levels;	chr15:76559351	chr15:76174891~76181486:-
SARC	cis	rs11098499	0.566	rs17051356	ENSG00000250950.1	RP11-33B1.3	-3.93	0.00011	0.0335	-0.26	-0.25	Corneal astigmatism;	chr4:119664153	chr4:119456350~119457277:+
SARC	cis	rs7204230	1	rs17303428	ENSG00000261291.1	RP11-295M3.2	3.93	0.00011	0.0335	0.27	0.25	Fibrinogen;	chr16:53283844	chr16:53168522~53169450:+
SARC	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-3.93	0.00011	0.0335	-0.48	-0.25	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
SARC	cis	rs7208859	0.623	rs7223404	ENSG00000264538.5	SUZ12P1	-3.93	0.00011	0.0335	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30709299~30790908:+
SARC	cis	rs950776	0.745	rs3743075	ENSG00000261762.1	RP11-650L12.2	-3.93	0.00011	0.0335	-0.27	-0.25	Sudden cardiac arrest;	chr15:78617110	chr15:78589123~78591276:-
SARC	cis	rs2933343	0.516	rs11926639	ENSG00000261159.1	RP11-723O4.9	3.93	0.00011	0.0335	0.39	0.25	IgG glycosylation;	chr3:128872320	chr3:128859716~128860526:-
SARC	cis	rs910316	1	rs175449	ENSG00000279594.1	RP11-950C14.10	-3.93	0.00011	0.0335	-0.27	-0.25	Height;	chr14:75124143	chr14:75011269~75012851:-
SARC	cis	rs910316	0.935	rs175448	ENSG00000279594.1	RP11-950C14.10	-3.93	0.00011	0.0335	-0.27	-0.25	Height;	chr14:75124368	chr14:75011269~75012851:-
SARC	cis	rs11694172	0.821	rs36126443	ENSG00000273456.1	RP11-686O6.2	3.93	0.00011	0.0335	0.21	0.25	Cholesterol, total;	chr2:202693808	chr2:202374932~202375604:-
SARC	cis	rs6452524	0.935	rs10045744	ENSG00000248112.1	RP11-78C3.1	3.93	0.00011	0.0335	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:82919376~82921119:-
SARC	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-3.93	0.00011	0.0335	-0.26	-0.25	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-3.93	0.00011	0.0335	-0.26	-0.25	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
SARC	cis	rs526231	0.756	rs448086	ENSG00000175749.11	EIF3KP1	3.93	0.00011	0.0335	0.3	0.25	Primary biliary cholangitis;	chr5:103287880	chr5:103032376~103033031:+
SARC	cis	rs7195386	0.783	rs11642328	ENSG00000274925.1	CTD-2547G23.4	-3.93	0.00011	0.0335	-0.15	-0.25	Obesity-related traits;Body mass index;	chr16:24529117	chr16:25257952~25261066:+
SARC	cis	rs3002142	0.731	rs3008620	ENSG00000272750.1	RP11-378J18.8	-3.93	0.00011	0.0335	-0.39	-0.25	LDL peak particle diameter (total fat intake interaction);	chr1:222629584	chr1:222658867~222661512:-
SARC	cis	rs758129	0.722	rs208826	ENSG00000261441.1	RP11-217B1.2	3.93	0.00011	0.0335	0.32	0.25	Schizophrenia;	chr15:89383568	chr15:89335053~89336161:+
SARC	cis	rs4713118	0.662	rs9393881	ENSG00000216901.1	AL022393.7	3.93	0.00011	0.0335	0.36	0.25	Parkinson's disease;	chr6:28055973	chr6:28176188~28176674:+
SARC	cis	rs801193	0.66	rs1962050	ENSG00000232559.3	GS1-124K5.12	-3.93	0.00011	0.0335	-0.29	-0.25	Aortic root size;	chr7:66775021	chr7:66554588~66576923:-
SARC	cis	rs28386778	1	rs2955241	ENSG00000240280.5	TCAM1P	-3.93	0.00011	0.0336	-0.32	-0.25	Prudent dietary pattern;	chr17:63890753	chr17:63849292~63864379:+
SARC	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-3.93	0.00011	0.0336	-0.19	-0.25	Height;	chr11:118749988	chr11:118791254~118793137:+
SARC	cis	rs860818	1	rs858242	ENSG00000226816.2	AC005082.12	3.93	0.00011	0.0336	0.67	0.25	Initial pursuit acceleration;	chr7:23185723	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs1637224	ENSG00000226816.2	AC005082.12	3.93	0.00011	0.0336	0.67	0.25	Initial pursuit acceleration;	chr7:23188781	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs1637220	ENSG00000226816.2	AC005082.12	3.93	0.00011	0.0336	0.67	0.25	Initial pursuit acceleration;	chr7:23193232	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs2529002	ENSG00000226816.2	AC005082.12	3.93	0.00011	0.0336	0.67	0.25	Initial pursuit acceleration;	chr7:23193704	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs6955117	ENSG00000226816.2	AC005082.12	3.93	0.00011	0.0336	0.67	0.25	Initial pursuit acceleration;	chr7:23194521	chr7:23206013~23208045:+
SARC	cis	rs4660214	0.671	rs16826012	ENSG00000182109.6	RP11-69E11.4	-3.93	0.00011	0.0336	-0.3	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253847	chr1:39522280~39546187:-
SARC	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	3.93	0.00011	0.0336	0.31	0.25	Height;	chr6:109392096	chr6:109382795~109383666:+
SARC	cis	rs6452524	0.905	rs10040244	ENSG00000248112.1	RP11-78C3.1	3.93	0.00011	0.0336	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:82919376~82921119:-
SARC	cis	rs6570726	0.846	rs4896824	ENSG00000235652.6	RP11-545I5.3	3.93	0.00011	0.0336	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145799409~145886585:+
SARC	cis	rs3824347	0.839	rs7857510	ENSG00000203321.2	C9orf41-AS1	-3.93	0.00011	0.0336	-0.27	-0.25	Urinary magnesium-to-creatinine ratio;	chr9:75010795	chr9:74952968~74996293:+
SARC	cis	rs11086243	0.935	rs227880	ENSG00000276923.1	RP11-321P16.1	3.93	0.000111	0.0336	0.3	0.25	Nephrotic syndrome (acquired);	chr20:48148260	chr20:48073869~48074188:+
SARC	cis	rs10911902	0.913	rs12120448	ENSG00000229739.2	RP11-295K2.3	-3.93	0.000111	0.0336	-0.35	-0.25	Schizophrenia;	chr1:186585134	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.913	rs12131484	ENSG00000229739.2	RP11-295K2.3	-3.93	0.000111	0.0336	-0.35	-0.25	Schizophrenia;	chr1:186585145	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.874	rs12133471	ENSG00000229739.2	RP11-295K2.3	-3.93	0.000111	0.0336	-0.35	-0.25	Schizophrenia;	chr1:186586822	chr1:186435161~186470291:+
SARC	cis	rs577676	0.586	rs666419	ENSG00000271811.1	RP1-79C4.4	3.93	0.000111	0.0337	0.36	0.25	Prevalent atrial fibrillation;	chr1:170645103	chr1:170667381~170669425:+
SARC	cis	rs577676	0.586	rs593173	ENSG00000271811.1	RP1-79C4.4	3.93	0.000111	0.0337	0.36	0.25	Prevalent atrial fibrillation;	chr1:170646719	chr1:170667381~170669425:+
SARC	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-3.93	0.000111	0.0337	-0.29	-0.25	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
SARC	cis	rs10766496	1	rs4341511	ENSG00000257043.1	RP11-137N23.1	-3.93	0.000111	0.0337	-0.33	-0.25	Diabetic kidney disease;	chr11:18715080	chr11:18665050~18665548:+
SARC	cis	rs7772486	0.641	rs2748489	ENSG00000270638.1	RP3-466P17.1	3.93	0.000111	0.0337	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146010151	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.641	rs2777485	ENSG00000270638.1	RP3-466P17.1	3.93	0.000111	0.0337	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146013241	chr6:145735570~145737218:+
SARC	cis	rs6570726	0.846	rs397311	ENSG00000270638.1	RP3-466P17.1	-3.93	0.000111	0.0337	-0.2	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145735570~145737218:+
SARC	cis	rs17270561	0.609	rs17267614	ENSG00000272462.2	U91328.19	-3.93	0.000111	0.0337	-0.24	-0.25	Iron status biomarkers;	chr6:25729799	chr6:25992662~26001775:+
SARC	cis	rs897984	0.542	rs7197717	ENSG00000260911.2	RP11-196G11.2	3.93	0.000111	0.0337	0.24	0.25	Dementia with Lewy bodies;	chr16:31071754	chr16:31043150~31049868:+
SARC	cis	rs8095374	1	rs8095374	ENSG00000280212.1	RP11-49K24.3	3.93	0.000111	0.0337	0.28	0.25	Clinical laboratory measurements;	chr18:46213522	chr18:47076117~47076594:+
SARC	cis	rs41369048	0.669	rs80327434	ENSG00000272823.1	RP11-295M18.6	-3.93	0.000111	0.0337	-0.39	-0.25	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220850961	chr1:220828676~220829211:-
SARC	cis	rs41369048	0.669	rs77986094	ENSG00000272823.1	RP11-295M18.6	-3.93	0.000111	0.0337	-0.39	-0.25	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220854514	chr1:220828676~220829211:-
SARC	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	3.93	0.000111	0.0337	0.26	0.25	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
SARC	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	3.93	0.000111	0.0337	0.26	0.25	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
SARC	cis	rs4664293	1	rs6745766	ENSG00000226266.5	AC009961.3	-3.93	0.000111	0.0338	-0.3	-0.25	Monocyte percentage of white cells;	chr2:159598284	chr2:159670708~159712435:-
SARC	cis	rs2439831	0.702	rs495175	ENSG00000275601.1	AC011330.13	-3.93	0.000111	0.0338	-0.4	-0.25	Lung cancer in ever smokers;	chr15:43506486	chr15:43642389~43643023:-
SARC	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	3.93	0.000111	0.0338	0.29	0.25	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
SARC	cis	rs600231	0.665	rs1784858	ENSG00000245532.5	NEAT1	3.93	0.000111	0.0338	0.19	0.25	Bone mineral density;	chr11:65455481	chr11:65422774~65445540:+
SARC	cis	rs11105298	0.891	rs4842661	ENSG00000258302.2	RP11-981P6.1	3.93	0.000111	0.0338	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89561129~89594878:+
SARC	cis	rs7918232	0.8	rs7907981	ENSG00000262412.1	RP11-85G18.6	3.93	0.000111	0.0338	0.3	0.25	Breast cancer;	chr10:27155400	chr10:27243130~27250804:+
SARC	cis	rs9902453	0.765	rs6505143	ENSG00000264538.5	SUZ12P1	3.93	0.000111	0.0338	0.18	0.25	Coffee consumption (cups per day);	chr17:29823567	chr17:30709299~30790908:+
SARC	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	3.93	0.000111	0.0338	0.34	0.25	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
SARC	cis	rs4705962	0.878	rs2897442	ENSG00000230612.2	AC004237.1	3.93	0.000111	0.0338	0.28	0.25	Atopic dermatitis;	chr5:132713335	chr5:132688681~132723725:+
SARC	cis	rs853679	0.55	rs1233704	ENSG00000216901.1	AL022393.7	-3.93	0.000111	0.0338	-0.33	-0.25	Depression;	chr6:28199145	chr6:28176188~28176674:+
SARC	cis	rs853679	0.55	rs1233699	ENSG00000216901.1	AL022393.7	3.93	0.000111	0.0338	0.33	0.25	Depression;	chr6:28201380	chr6:28176188~28176674:+
SARC	cis	rs11264213	0.551	rs11263852	ENSG00000271554.1	RP4-665N4.8	3.93	0.000111	0.0338	0.35	0.25	Schizophrenia;	chr1:36088841	chr1:35992109~36013630:-
SARC	cis	rs7208859	0.623	rs56325146	ENSG00000266490.1	CTD-2349P21.9	3.93	0.000112	0.0339	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30792372~30792833:+
SARC	cis	rs11723261	0.582	rs4634177	ENSG00000211553.1	AC253576.2	-3.93	0.000112	0.0339	-0.31	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:136461~136568:+
SARC	cis	rs6061231	0.837	rs6121558	ENSG00000275437.1	RP5-908M14.10	3.93	0.000112	0.0339	0.25	0.25	Colorectal cancer;	chr20:62386309	chr20:62402236~62405935:-
SARC	cis	rs59104589	0.521	rs62190404	ENSG00000266621.1	AC104841.1	3.93	0.000112	0.0339	0.31	0.25	Fibrinogen levels;	chr2:241462007	chr2:241245202~241245299:-
SARC	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	3.93	0.000112	0.0339	0.31	0.25	Height;	chr6:109358227	chr6:109382795~109383666:+
SARC	cis	rs748404	0.697	rs493444	ENSG00000275601.1	AC011330.13	-3.93	0.000112	0.0339	-0.31	-0.25	Lung cancer;	chr15:43274272	chr15:43642389~43643023:-
SARC	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	3.93	0.000112	0.0339	0.29	0.25	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
SARC	cis	rs745109	0.504	rs74432925	ENSG00000273080.1	RP11-301O19.1	3.93	0.000112	0.034	0.4	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86386592	chr2:86195590~86196049:+
SARC	cis	rs7487075	0.718	rs4768735	ENSG00000273015.2	RP11-352M15.2	-3.93	0.000112	0.034	-0.21	-0.25	Itch intensity from mosquito bite;	chr12:46550351	chr12:45718046~45727775:-
SARC	cis	rs2179367	0.959	rs585022	ENSG00000216906.2	RP11-350J20.9	3.93	0.000112	0.034	0.24	0.25	Dupuytren's disease;	chr6:149432168	chr6:149904243~149906418:+
SARC	cis	rs1707322	1	rs6672115	ENSG00000281133.1	AL355480.3	-3.93	0.000112	0.034	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45580892~45580996:-
SARC	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-3.93	0.000112	0.034	-0.29	-0.25	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
SARC	cis	rs17198023	0.638	rs4246140	ENSG00000232176.1	RP11-146N23.1	3.93	0.000112	0.034	0.34	0.25	Nicotine dependence;	chr9:18244874	chr9:19200335~19201046:-
SARC	cis	rs748404	0.65	rs556851	ENSG00000275601.1	AC011330.13	-3.93	0.000112	0.034	-0.31	-0.25	Lung cancer;	chr15:43279021	chr15:43642389~43643023:-
SARC	cis	rs748404	0.697	rs567357	ENSG00000275601.1	AC011330.13	-3.93	0.000112	0.034	-0.31	-0.25	Lung cancer;	chr15:43279192	chr15:43642389~43643023:-
SARC	cis	rs9299	0.502	rs4793944	ENSG00000270781.1	RP11-501C14.9	-3.93	0.000112	0.034	-0.27	-0.25	Obesity;	chr17:48589942	chr17:48899131~48899748:+
SARC	cis	rs2404602	0.655	rs34748201	ENSG00000259422.1	RP11-593F23.1	3.93	0.000112	0.0341	0.28	0.25	Blood metabolite levels;	chr15:76929189	chr15:76174891~76181486:-
SARC	cis	rs9902453	0.791	rs28492945	ENSG00000264538.5	SUZ12P1	3.93	0.000112	0.0341	0.18	0.25	Coffee consumption (cups per day);	chr17:29896964	chr17:30709299~30790908:+
SARC	cis	rs4845875	0.626	rs4845882	ENSG00000242349.4	NPPA-AS1	3.93	0.000112	0.0341	0.28	0.25	Midregional pro atrial natriuretic peptide levels;	chr1:11783110	chr1:11841017~11848079:+
SARC	cis	rs3204270	0.714	rs7503307	ENSG00000229848.1	RP13-766D20.2	3.93	0.000112	0.0341	0.39	0.25	Dental caries;	chr17:81707899	chr17:81514047~81527776:+
SARC	cis	rs9485372	0.853	rs2121348	ENSG00000231760.4	RP11-350J20.5	3.93	0.000112	0.0341	0.37	0.25	Breast cancer;	chr6:149274369	chr6:149796151~149826294:-
SARC	cis	rs10871290	0.65	rs2288054	ENSG00000214331.7	RP11-252A24.2	3.93	0.000112	0.0341	0.21	0.25	Breast cancer;	chr16:74457835	chr16:74332402~74368240:-
SARC	cis	rs2274273	0.662	rs4040064	ENSG00000258413.1	RP11-665C16.6	-3.93	0.000112	0.0341	-0.34	-0.25	Protein biomarker;	chr14:55211370	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.638	rs58269011	ENSG00000258413.1	RP11-665C16.6	-3.93	0.000112	0.0341	-0.34	-0.25	Protein biomarker;	chr14:55217670	chr14:55262767~55272075:-
SARC	cis	rs62025270	0.547	rs338540	ENSG00000202081.1	RNU6-1280P	3.93	0.000112	0.0341	0.3	0.25	Idiopathic pulmonary fibrosis;	chr15:85652500	chr15:85651522~85651628:-
SARC	cis	rs599083	0.573	rs3018713	ENSG00000212093.1	AP000807.1	3.93	0.000113	0.0341	0.23	0.25	Bone mineral density (spine);	chr11:68623518	chr11:68506083~68506166:-
SARC	cis	rs9739682	1	rs9668865	ENSG00000139239.7	RPL14P1	-3.93	0.000113	0.0341	-0.23	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62113808	chr12:62965325~62965969:+
SARC	cis	rs2404602	0.655	rs3829489	ENSG00000259422.1	RP11-593F23.1	3.93	0.000113	0.0341	0.28	0.25	Blood metabolite levels;	chr15:76930915	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.632	rs34338978	ENSG00000259422.1	RP11-593F23.1	3.93	0.000113	0.0342	0.28	0.25	Blood metabolite levels;	chr15:76934464	chr15:76174891~76181486:-
SARC	cis	rs12049351	0.665	rs3767326	ENSG00000229367.1	HMGN2P19	3.93	0.000113	0.0342	0.22	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229454303	chr1:229570532~229570796:+
SARC	cis	rs7216064	0.636	rs4638	ENSG00000277476.1	RP11-147L13.13	-3.93	0.000113	0.0342	-0.3	-0.25	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043234	chr17:68133201~68135935:+
SARC	cis	rs7216064	0.601	rs35453056	ENSG00000277476.1	RP11-147L13.13	-3.93	0.000113	0.0342	-0.3	-0.25	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043552	chr17:68133201~68135935:+
SARC	cis	rs7216064	0.628	rs62084702	ENSG00000277476.1	RP11-147L13.13	-3.93	0.000113	0.0342	-0.3	-0.25	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68047041	chr17:68133201~68135935:+
SARC	cis	rs6477918	0.598	rs10981407	ENSG00000250068.1	RP11-576C12.1	3.93	0.000113	0.0342	0.26	0.25	Obstetric antiphospholipid syndrome;	chr9:112444295	chr9:112581779~112582590:-
SARC	cis	rs950776	0.647	rs495956	ENSG00000261762.1	RP11-650L12.2	-3.93	0.000113	0.0342	-0.27	-0.25	Sudden cardiac arrest;	chr15:78577588	chr15:78589123~78591276:-
SARC	cis	rs950776	0.616	rs495090	ENSG00000261762.1	RP11-650L12.2	-3.93	0.000113	0.0342	-0.27	-0.25	Sudden cardiac arrest;	chr15:78577661	chr15:78589123~78591276:-
SARC	cis	rs950776	0.722	rs471889	ENSG00000261762.1	RP11-650L12.2	-3.93	0.000113	0.0342	-0.27	-0.25	Sudden cardiac arrest;	chr15:78577893	chr15:78589123~78591276:-
SARC	cis	rs10455248	0.592	rs9341348	ENSG00000233237.5	LINC00472	-3.93	0.000113	0.0342	-0.24	-0.25	Cognitive performance;	chr6:71839929	chr6:71344344~71420769:-
SARC	cis	rs3805389	0.504	rs62308708	ENSG00000273257.1	RP11-177J6.1	-3.93	0.000113	0.0342	-0.38	-0.25	Waist-to-hip ratio adjusted for body mass index;	chr4:55626177	chr4:55387949~55388271:+
SARC	cis	rs820077	0.551	rs34069418	ENSG00000232909.1	RP3-510O8.4	-3.93	0.000113	0.0342	-0.33	-0.25	Systemic lupus erythematosus;	chr6:35034491	chr6:35733867~35736947:-
SARC	cis	rs7772486	0.558	rs702322	ENSG00000270638.1	RP3-466P17.1	-3.93	0.000113	0.0342	-0.21	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145735570~145737218:+
SARC	cis	rs7772486	0.558	rs2142978	ENSG00000270638.1	RP3-466P17.1	-3.93	0.000113	0.0342	-0.21	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145735570~145737218:+
SARC	cis	rs59104589	0.583	rs73018185	ENSG00000266621.1	AC104841.1	3.93	0.000113	0.0342	0.36	0.25	Fibrinogen levels;	chr2:241302291	chr2:241245202~241245299:-
SARC	cis	rs4835473	0.864	rs13145791	ENSG00000251600.4	RP11-673E1.1	-3.93	0.000113	0.0342	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143735688	chr4:143912331~143982454:+
SARC	cis	rs11651000	0.761	rs11079788	ENSG00000239291.1	RP5-867C24.1	3.93	0.000113	0.0342	0.31	0.25	IgG glycosylation;	chr17:47743357	chr17:47159191~47159993:-
SARC	cis	rs11723261	0.582	rs4582104	ENSG00000211553.1	AC253576.2	-3.93	0.000113	0.0342	-0.3	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:136461~136568:+
SARC	cis	rs7829975	0.688	rs7827182	ENSG00000253981.4	ALG1L13P	3.93	0.000113	0.0342	0.24	0.25	Mood instability;	chr8:8522961	chr8:8236003~8244667:-
SARC	cis	rs4950322	0.518	rs61838951	ENSG00000278811.3	LINC00624	3.93	0.000113	0.0343	0.25	0.25	Protein quantitative trait loci;	chr1:147116081	chr1:147258885~147517875:-
SARC	cis	rs321358	0.848	rs78087740	ENSG00000271584.1	RP11-89C3.4	3.93	0.000113	0.0343	0.43	0.25	Body mass index;	chr11:111079016	chr11:111091932~111097357:-
SARC	cis	rs321358	0.848	rs73015146	ENSG00000271584.1	RP11-89C3.4	3.93	0.000113	0.0343	0.43	0.25	Body mass index;	chr11:111079143	chr11:111091932~111097357:-
SARC	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-3.93	0.000113	0.0343	-0.4	-0.25	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
SARC	cis	rs12611334	0.894	rs17641958	ENSG00000226025.8	LGALS17A	3.93	0.000113	0.0343	0.24	0.25	Schizophrenia;	chr19:39682557	chr19:39679374~39686373:+
SARC	cis	rs11086243	0.901	rs2758951	ENSG00000276923.1	RP11-321P16.1	3.93	0.000113	0.0343	0.3	0.25	Nephrotic syndrome (acquired);	chr20:48148149	chr20:48073869~48074188:+
SARC	cis	rs11086243	0.901	rs2758952	ENSG00000276923.1	RP11-321P16.1	3.93	0.000113	0.0343	0.3	0.25	Nephrotic syndrome (acquired);	chr20:48148150	chr20:48073869~48074188:+
SARC	cis	rs11086243	0.935	rs151051	ENSG00000276923.1	RP11-321P16.1	3.93	0.000113	0.0343	0.3	0.25	Nephrotic syndrome (acquired);	chr20:48148169	chr20:48073869~48074188:+
SARC	cis	rs9532669	0.926	rs7799	ENSG00000176268.5	CYCSP34	3.93	0.000113	0.0343	0.26	0.25	Cervical cancer;	chr13:40958916	chr13:40863599~40863902:-
SARC	cis	rs2439831	0.867	rs2412778	ENSG00000275601.1	AC011330.13	-3.93	0.000113	0.0343	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43368784	chr15:43642389~43643023:-
SARC	cis	rs17270561	0.609	rs9393655	ENSG00000272462.2	U91328.19	-3.93	0.000113	0.0343	-0.24	-0.25	Iron status biomarkers;	chr6:25711110	chr6:25992662~26001775:+
SARC	cis	rs2439831	0.85	rs28504496	ENSG00000275601.1	AC011330.13	-3.93	0.000113	0.0343	-0.45	-0.25	Lung cancer in ever smokers;	chr15:43724685	chr15:43642389~43643023:-
SARC	cis	rs7246657	0.943	rs10415024	ENSG00000226686.6	LINC01535	-3.93	0.000113	0.0343	-0.35	-0.25	Coronary artery calcification;	chr19:37323822	chr19:37251912~37265535:+
SARC	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-3.93	0.000114	0.0344	-0.29	-0.25	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
SARC	cis	rs755249	0.567	rs61779284	ENSG00000182109.6	RP11-69E11.4	3.93	0.000114	0.0344	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39522280~39546187:-
SARC	cis	rs7772486	0.686	rs2072911	ENSG00000235652.6	RP11-545I5.3	-3.93	0.000114	0.0344	-0.23	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145799409~145886585:+
SARC	cis	rs2243480	1	rs160652	ENSG00000164669.11	INTS4P1	3.93	0.000114	0.0344	0.44	0.25	Diabetic kidney disease;	chr7:66073444	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs313831	ENSG00000164669.11	INTS4P1	3.93	0.000114	0.0344	0.44	0.25	Diabetic kidney disease;	chr7:66086239	chr7:65141225~65234216:+
SARC	cis	rs1741464	0.51	rs2016522	ENSG00000258824.2	CTD-2555O16.2	-3.93	0.000114	0.0344	-0.27	-0.25	Reticulocyte count;Reticulocyte fraction of red cells;	chr14:64827623	chr14:64422935~64448557:-
SARC	cis	rs11654699	0.773	rs2055091	ENSG00000266718.1	RP11-466A19.1	-3.93	0.000114	0.0344	-0.22	-0.25	Neurofibrillary tangles;	chr17:32610729	chr17:32495536~32499333:+
SARC	cis	rs597539	0.69	rs11228383	ENSG00000250508.1	RP11-757G1.6	-3.93	0.000114	0.0345	-0.3	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68855760	chr11:68870664~68874542:+
SARC	cis	rs8098244	0.683	rs1941524	ENSG00000265752.2	RP11-403A21.1	-3.93	0.000114	0.0345	-0.23	-0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23865299	chr18:23957754~23982556:-
SARC	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	3.93	0.000114	0.0345	0.25	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
SARC	cis	rs7246657	0.943	rs10406177	ENSG00000226686.6	LINC01535	-3.93	0.000114	0.0345	-0.34	-0.25	Coronary artery calcification;	chr19:37417045	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.882	rs28623164	ENSG00000226686.6	LINC01535	-3.93	0.000114	0.0345	-0.34	-0.25	Coronary artery calcification;	chr19:37422551	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs7252346	ENSG00000226686.6	LINC01535	-3.93	0.000114	0.0345	-0.34	-0.25	Coronary artery calcification;	chr19:37423780	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs2891699	ENSG00000226686.6	LINC01535	-3.93	0.000114	0.0345	-0.34	-0.25	Coronary artery calcification;	chr19:37429335	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs9676967	ENSG00000226686.6	LINC01535	-3.93	0.000114	0.0345	-0.34	-0.25	Coronary artery calcification;	chr19:37437187	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.882	rs8112610	ENSG00000226686.6	LINC01535	-3.93	0.000114	0.0345	-0.34	-0.25	Coronary artery calcification;	chr19:37437828	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs8109632	ENSG00000226686.6	LINC01535	-3.93	0.000114	0.0345	-0.34	-0.25	Coronary artery calcification;	chr19:37440223	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs7255407	ENSG00000226686.6	LINC01535	-3.93	0.000114	0.0345	-0.34	-0.25	Coronary artery calcification;	chr19:37443034	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.941	rs7256130	ENSG00000226686.6	LINC01535	-3.93	0.000114	0.0345	-0.34	-0.25	Coronary artery calcification;	chr19:37443079	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs2112923	ENSG00000226686.6	LINC01535	-3.93	0.000114	0.0345	-0.34	-0.25	Coronary artery calcification;	chr19:37449425	chr19:37251912~37265535:+
SARC	cis	rs240993	0.812	rs459147	ENSG00000230177.1	RP5-1112D6.4	-3.93	0.000114	0.0345	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111370285	chr6:111277932~111278742:+
SARC	cis	rs7512898	0.5	rs6691268	ENSG00000260088.1	RP11-92G12.3	-3.93	0.000114	0.0345	-0.28	-0.25	Electrocardiographic conduction measures;	chr1:200786938	chr1:200669507~200694250:+
SARC	cis	rs10911902	0.643	rs7556543	ENSG00000229739.2	RP11-295K2.3	-3.93	0.000114	0.0345	-0.36	-0.25	Schizophrenia;	chr1:186301287	chr1:186435161~186470291:+
SARC	cis	rs7178375	1	rs7169064	ENSG00000215302.7	CTD-3092A11.1	-3.93	0.000114	0.0345	-0.32	-0.25	Hypertriglyceridemia;	chr15:30918659	chr15:30470779~30507623:+
SARC	cis	rs7985	1	rs3752603	ENSG00000206028.1	CTA-373H7.7	3.93	0.000114	0.0345	0.28	0.25	Electroencephalogram traits;	chr22:26668531	chr22:26667693~26672654:-
SARC	cis	rs7985	1	rs7985	ENSG00000206028.1	CTA-373H7.7	3.93	0.000114	0.0345	0.28	0.25	Electroencephalogram traits;	chr22:26670572	chr22:26667693~26672654:-
SARC	cis	rs76693355	0.512	rs12794618	ENSG00000232460.4	BMPR1APS2	3.93	0.000114	0.0345	0.31	0.25	Intraocular pressure;	chr11:120418990	chr11:121361854~121362865:-
SARC	cis	rs8098244	0.597	rs12960583	ENSG00000264745.1	TTC39C-AS1	3.93	0.000114	0.0345	0.27	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23772629	chr18:23994213~24015339:-
SARC	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	3.93	0.000114	0.0345	0.38	0.25	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	3.93	0.000114	0.0345	0.38	0.25	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	3.93	0.000114	0.0345	0.38	0.25	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
SARC	cis	rs2439831	0.867	rs933941	ENSG00000275601.1	AC011330.13	-3.93	0.000114	0.0345	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43340028	chr15:43642389~43643023:-
SARC	cis	rs4934494	0.768	rs12570813	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000114	0.0345	-0.27	-0.25	Red blood cell count;	chr10:89630974	chr10:89694295~89697928:-
SARC	cis	rs1062177	1	rs2964571	ENSG00000254226.4	CTB-12O2.1	3.92	0.000114	0.0346	0.33	0.25	Preschool internalizing problems;	chr5:151791695	chr5:151949571~152270448:+
SARC	cis	rs1062177	1	rs2915869	ENSG00000254226.4	CTB-12O2.1	3.92	0.000114	0.0346	0.33	0.25	Preschool internalizing problems;	chr5:151791948	chr5:151949571~152270448:+
SARC	cis	rs240993	0.812	rs6942129	ENSG00000230177.1	RP5-1112D6.4	-3.92	0.000114	0.0346	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111442417	chr6:111277932~111278742:+
SARC	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	3.92	0.000114	0.0346	0.45	0.25	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
SARC	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	3.92	0.000114	0.0346	0.45	0.25	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
SARC	cis	rs12236219	1	rs10993161	ENSG00000224764.1	RP11-54O15.3	3.92	0.000115	0.0346	0.53	0.25	Body mass index;	chr9:94306657	chr9:94928551~94934946:-
SARC	cis	rs7809950	0.731	rs2712196	ENSG00000238832.1	snoU109	-3.92	0.000115	0.0346	-0.29	-0.25	Coronary artery disease;	chr7:107488352	chr7:107603363~107603507:+
SARC	cis	rs7772486	0.79	rs7742333	ENSG00000235652.6	RP11-545I5.3	-3.92	0.000115	0.0346	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145799409~145886585:+
SARC	cis	rs2803122	0.777	rs6475326	ENSG00000273226.1	RP11-513M16.8	3.92	0.000115	0.0347	0.24	0.25	Pulse pressure;	chr9:19386567	chr9:19375451~19375996:+
SARC	cis	rs495337	0.76	rs2769982	ENSG00000229222.1	KRT18P4	3.92	0.000115	0.0347	0.32	0.25	Psoriasis;	chr20:49908290	chr20:49956745~49958032:+
SARC	cis	rs875971	1	rs11974264	ENSG00000232559.3	GS1-124K5.12	-3.92	0.000115	0.0347	-0.28	-0.25	Aortic root size;	chr7:66182595	chr7:66554588~66576923:-
SARC	cis	rs875971	1	rs1540651	ENSG00000232559.3	GS1-124K5.12	-3.92	0.000115	0.0347	-0.28	-0.25	Aortic root size;	chr7:66185134	chr7:66554588~66576923:-
SARC	cis	rs2898681	0.618	rs79471207	ENSG00000248375.1	RP11-177B4.1	-3.92	0.000115	0.0347	-0.42	-0.25	Optic nerve measurement (cup area);	chr4:52872357	chr4:52720081~52720831:-
SARC	cis	rs801193	0.844	rs2244022	ENSG00000224316.1	RP11-479O9.2	3.92	0.000115	0.0347	0.23	0.25	Aortic root size;	chr7:66737443	chr7:65773620~65802067:+
SARC	cis	rs7246657	0.943	rs7255785	ENSG00000226686.6	LINC01535	-3.92	0.000115	0.0347	-0.34	-0.25	Coronary artery calcification;	chr19:37480781	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs7255996	ENSG00000226686.6	LINC01535	-3.92	0.000115	0.0347	-0.34	-0.25	Coronary artery calcification;	chr19:37480797	chr19:37251912~37265535:+
SARC	cis	rs11651000	0.761	rs11657388	ENSG00000239291.1	RP5-867C24.1	3.92	0.000115	0.0347	0.31	0.25	IgG glycosylation;	chr17:47743341	chr17:47159191~47159993:-
SARC	cis	rs8064029	0.892	rs62036118	ENSG00000267077.1	RP11-127I20.5	3.92	0.000115	0.0347	0.45	0.25	Cancer;	chr16:4851884	chr16:4795265~4796532:-
SARC	cis	rs6570726	0.846	rs6570698	ENSG00000235652.6	RP11-545I5.3	3.92	0.000115	0.0347	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.846	rs6914304	ENSG00000235652.6	RP11-545I5.3	3.92	0.000115	0.0347	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145799409~145886585:+
SARC	cis	rs1707322	0.963	rs34907901	ENSG00000281133.1	AL355480.3	-3.92	0.000115	0.0348	-0.29	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45580892~45580996:-
SARC	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-3.92	0.000115	0.0348	-0.28	-0.25	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
SARC	cis	rs495337	0.76	rs6125813	ENSG00000229222.1	KRT18P4	-3.92	0.000115	0.0348	-0.32	-0.25	Psoriasis;	chr20:49924646	chr20:49956745~49958032:+
SARC	cis	rs853679	0.825	rs8180562	ENSG00000272009.1	RP1-313I6.12	-3.92	0.000115	0.0348	-0.39	-0.25	Depression;	chr6:28173682	chr6:28078792~28081130:-
SARC	cis	rs853679	0.882	rs9380064	ENSG00000272009.1	RP1-313I6.12	-3.92	0.000115	0.0348	-0.39	-0.25	Depression;	chr6:28175340	chr6:28078792~28081130:-
SARC	cis	rs9925964	0.869	rs2288004	ENSG00000183604.13	SMG1P5	3.92	0.000115	0.0348	0.23	0.25	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042719	chr16:30267553~30335374:-
SARC	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-3.92	0.000116	0.0348	-0.3	-0.25	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
SARC	cis	rs240993	0.715	rs7752418	ENSG00000271789.1	RP5-1112D6.7	3.92	0.000116	0.0349	0.28	0.25	Inflammatory skin disease;Psoriasis;	chr6:111466682	chr6:111297126~111298510:+
SARC	cis	rs9565309	0.579	rs9573977	ENSG00000274898.1	AC001226.7	3.92	0.000116	0.0349	0.39	0.25	Morning vs. evening chronotype;	chr13:77012290	chr13:77027944~77028482:+
SARC	cis	rs12049351	0.631	rs2166160	ENSG00000229367.1	HMGN2P19	3.92	0.000116	0.0349	0.2	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229534344	chr1:229570532~229570796:+
SARC	cis	rs2803122	0.502	rs1329731	ENSG00000273226.1	RP11-513M16.8	-3.92	0.000116	0.0349	-0.25	-0.25	Pulse pressure;	chr9:19234910	chr9:19375451~19375996:+
SARC	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-3.92	0.000116	0.0349	-0.34	-0.25	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
SARC	cis	rs858239	0.67	rs6967526	ENSG00000226816.2	AC005082.12	3.92	0.000116	0.0349	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23206013~23208045:+
SARC	cis	rs28386778	0.83	rs2854210	ENSG00000240280.5	TCAM1P	-3.92	0.000116	0.0349	-0.31	-0.25	Prudent dietary pattern;	chr17:63868978	chr17:63849292~63864379:+
SARC	cis	rs12534093	0.602	rs11765452	ENSG00000234286.1	AC006026.13	-3.92	0.000116	0.0349	-0.28	-0.25	Infant length;Height;	chr7:23542936	chr7:23680195~23680786:-
SARC	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	3.92	0.000116	0.0349	0.26	0.25	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
SARC	cis	rs1150668	0.83	rs2531831	ENSG00000219392.1	RP1-265C24.5	-3.92	0.000116	0.0349	-0.29	-0.25	Pubertal anthropometrics;	chr6:28420988	chr6:28115628~28116551:+
SARC	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	3.92	0.000116	0.035	0.29	0.25	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
SARC	cis	rs157198	0.737	rs182208	ENSG00000237934.1	RP11-467D18.2	3.92	0.000116	0.035	0.42	0.25	Mean platelet volume;	chr1:28872696	chr1:29223933~29224816:+
SARC	cis	rs755249	0.53	rs16826087	ENSG00000182109.6	RP11-69E11.4	3.92	0.000116	0.035	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs3754346	ENSG00000182109.6	RP11-69E11.4	3.92	0.000116	0.035	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs16826093	ENSG00000182109.6	RP11-69E11.4	3.92	0.000116	0.035	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs41270811	ENSG00000182109.6	RP11-69E11.4	3.92	0.000116	0.035	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs61779274	ENSG00000182109.6	RP11-69E11.4	3.92	0.000116	0.035	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs17264671	ENSG00000182109.6	RP11-69E11.4	3.92	0.000116	0.035	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs4660690	ENSG00000182109.6	RP11-69E11.4	3.92	0.000116	0.035	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs61779275	ENSG00000182109.6	RP11-69E11.4	3.92	0.000116	0.035	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39522280~39546187:-
SARC	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-3.92	0.000116	0.035	-0.29	-0.25	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
SARC	cis	rs1693575	0.77	rs1786342	ENSG00000264991.1	AP001205.1	-3.92	0.000116	0.035	-0.27	-0.25	Cerebrospinal fluid clusterin levels;	chr8:100664135	chr8:100707878~100707963:-
SARC	cis	rs524281	0.692	rs11227395	ENSG00000255320.1	RP11-755F10.1	3.92	0.000116	0.035	0.34	0.25	Electroencephalogram traits;	chr11:66062166	chr11:66244840~66246239:-
SARC	cis	rs9481169	0.557	rs13190932	ENSG00000231889.6	TRAF3IP2-AS1	3.92	0.000116	0.035	0.51	0.25	Inflammatory skin disease;	chr6:111591867	chr6:111483511~111598302:+
SARC	cis	rs3824347	0.839	rs10781258	ENSG00000203321.2	C9orf41-AS1	-3.92	0.000116	0.035	-0.27	-0.25	Urinary magnesium-to-creatinine ratio;	chr9:75003522	chr9:74952968~74996293:+
SARC	cis	rs17270561	0.609	rs4711096	ENSG00000272462.2	U91328.19	-3.92	0.000116	0.0351	-0.24	-0.25	Iron status biomarkers;	chr6:25726826	chr6:25992662~26001775:+
SARC	cis	rs3738814	0.529	rs761422	ENSG00000186715.9	MST1L	-3.92	0.000116	0.0351	-0.26	-0.25	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Height;	chr1:16975285	chr1:16754910~16770237:-
SARC	cis	rs9828933	0.752	rs13433909	ENSG00000280620.1	SCAANT1	3.92	0.000116	0.0351	0.39	0.25	Type 2 diabetes;	chr3:63962933	chr3:63911518~63911772:-
SARC	cis	rs4660456	0.504	rs542214	ENSG00000237899.1	RP4-739H11.3	3.92	0.000116	0.0351	0.3	0.25	Platelet count;	chr1:40632806	chr1:40669089~40687588:-
SARC	cis	rs4835473	0.9	rs4835303	ENSG00000251600.4	RP11-673E1.1	-3.92	0.000117	0.0351	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143821533	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4835034	ENSG00000251600.4	RP11-673E1.1	-3.92	0.000117	0.0351	-0.25	-0.25	Immature fraction of reticulocytes;	chr4:143821538	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4615131	ENSG00000251600.4	RP11-673E1.1	-3.92	0.000117	0.0351	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143740295	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4499657	ENSG00000251600.4	RP11-673E1.1	-3.92	0.000117	0.0351	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143740316	chr4:143912331~143982454:+
SARC	cis	rs6759004	1	rs6759004	ENSG00000183308.6	AC005037.3	3.92	0.000117	0.0351	0.35	0.25	Triptolide cytotoxicity;	chr2:201139953	chr2:200963263~201009102:+
SARC	cis	rs59104589	0.617	rs62186409	ENSG00000266621.1	AC104841.1	3.92	0.000117	0.0351	0.36	0.25	Fibrinogen levels;	chr2:241296295	chr2:241245202~241245299:-
SARC	cis	rs2243480	1	rs313832	ENSG00000164669.11	INTS4P1	3.92	0.000117	0.0351	0.44	0.25	Diabetic kidney disease;	chr7:66085904	chr7:65141225~65234216:+
SARC	cis	rs5821446	1	rs5821446	ENSG00000237854.3	LINC00674	-3.92	0.000117	0.0352	-0.29	-0.25	Eosinophil percentage of granulocytes;	chr17:67966422	chr17:68101908~68115518:+
SARC	cis	rs7772486	0.712	rs6570726	ENSG00000235652.6	RP11-545I5.3	3.92	0.000117	0.0352	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145838324	chr6:145799409~145886585:+
SARC	cis	rs448720	0.811	rs420790	ENSG00000259410.4	RP11-34F13.3	-3.92	0.000117	0.0352	-0.27	-0.25	Cognitive performance;	chr15:67891702	chr15:67832725~67873866:+
SARC	cis	rs7560272	0.588	rs4852959	ENSG00000163016.8	ALMS1P	-3.92	0.000117	0.0352	-0.28	-0.25	Schizophrenia;	chr2:73653474	chr2:73644919~73685576:+
SARC	cis	rs4660214	0.627	rs61779282	ENSG00000182109.6	RP11-69E11.4	3.92	0.000117	0.0352	0.31	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39374632	chr1:39522280~39546187:-
SARC	cis	rs1693575	0.624	rs1693551	ENSG00000264991.1	AP001205.1	3.92	0.000117	0.0352	0.28	0.25	Cerebrospinal fluid clusterin levels;	chr8:100663356	chr8:100707878~100707963:-
SARC	cis	rs72647484	0.554	rs2807343	ENSG00000228397.1	RP1-224A6.3	-3.92	0.000117	0.0352	-0.52	-0.25	Colorectal cancer;	chr1:22221186	chr1:22023994~22024968:-
SARC	cis	rs72647484	0.554	rs2744730	ENSG00000228397.1	RP1-224A6.3	-3.92	0.000117	0.0352	-0.52	-0.25	Colorectal cancer;	chr1:22221192	chr1:22023994~22024968:-
SARC	cis	rs11822910	0.645	rs7122734	ENSG00000254602.1	AP000662.4	-3.92	0.000117	0.0352	-0.27	-0.25	Platelet distribution width;	chr11:57422947	chr11:57638024~57652790:+
SARC	cis	rs7868228	1	rs7868228	ENSG00000240498.5	CDKN2B-AS1	3.92	0.000117	0.0352	0.24	0.25	Gut microbiome composition (winter);	chr9:21667763	chr9:21994778~22121097:+
SARC	cis	rs8028182	0.636	rs28610581	ENSG00000260206.1	CTD-2026K11.2	-3.92	0.000117	0.0353	-0.3	-0.25	Sudden cardiac arrest;	chr15:75520133	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs6495182	ENSG00000260206.1	CTD-2026K11.2	-3.92	0.000117	0.0353	-0.3	-0.25	Sudden cardiac arrest;	chr15:75522047	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs8036758	ENSG00000260206.1	CTD-2026K11.2	-3.92	0.000117	0.0353	-0.3	-0.25	Sudden cardiac arrest;	chr15:75525221	chr15:75636139~75639239:+
SARC	cis	rs9868809	0.505	rs9811027	ENSG00000225399.4	RP11-3B7.1	-3.92	0.000117	0.0353	-0.42	-0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48687581	chr3:49260085~49261316:+
SARC	cis	rs7772486	0.641	rs9390370	ENSG00000270638.1	RP3-466P17.1	3.92	0.000117	0.0353	0.21	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146036433	chr6:145735570~145737218:+
SARC	cis	rs13113518	1	rs13132420	ENSG00000249700.7	SRD5A3-AS1	-3.92	0.000117	0.0353	-0.3	-0.25	Height;	chr4:55526646	chr4:55363971~55395847:-
SARC	cis	rs3824347	0.872	rs11144177	ENSG00000203321.2	C9orf41-AS1	3.92	0.000118	0.0353	0.28	0.25	Urinary magnesium-to-creatinine ratio;	chr9:74980486	chr9:74952968~74996293:+
SARC	cis	rs651386	0.505	rs10753817	ENSG00000271811.1	RP1-79C4.4	3.92	0.000118	0.0353	0.34	0.25	Atrial fibrillation;	chr1:170622667	chr1:170667381~170669425:+
SARC	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	3.92	0.000118	0.0353	0.34	0.25	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
SARC	cis	rs6495122	0.501	rs12101482	ENSG00000260269.4	CTD-2323K18.1	3.92	0.000118	0.0354	0.32	0.25	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75052443	chr15:75527150~75601205:-
SARC	cis	rs6570726	0.791	rs6918814	ENSG00000235652.6	RP11-545I5.3	3.92	0.000118	0.0354	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145799409~145886585:+
SARC	cis	rs13631	0.728	rs10118245	ENSG00000268996.3	MAN1B1-AS1	3.92	0.000118	0.0354	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr9:137085140	chr9:137084946~137086817:-
SARC	cis	rs12049351	0.719	rs6587338	ENSG00000229367.1	HMGN2P19	3.92	0.000118	0.0354	0.21	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229496891	chr1:229570532~229570796:+
SARC	cis	rs748404	0.697	rs546170	ENSG00000275601.1	AC011330.13	-3.92	0.000118	0.0354	-0.31	-0.25	Lung cancer;	chr15:43272651	chr15:43642389~43643023:-
SARC	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	3.92	0.000118	0.0354	0.24	0.25	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
SARC	cis	rs6431644	0.931	rs2215172	ENSG00000224287.2	MSL3P1	3.92	0.000118	0.0354	0.28	0.25	Left atrial antero-posterior diameter;	chr2:233892360	chr2:233865437~233868444:-
SARC	cis	rs6431644	0.931	rs7596657	ENSG00000224287.2	MSL3P1	3.92	0.000118	0.0354	0.28	0.25	Left atrial antero-posterior diameter;	chr2:233893093	chr2:233865437~233868444:-
SARC	cis	rs9836484	1	rs28425549	ENSG00000240964.3	RN7SL751P	3.92	0.000118	0.0354	0.31	0.25	Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction);	chr3:77973983	chr3:78938009~78938292:-
SARC	cis	rs758129	0.501	rs3176205	ENSG00000261441.1	RP11-217B1.2	3.92	0.000118	0.0354	0.31	0.25	Schizophrenia;	chr15:89322461	chr15:89335053~89336161:+
SARC	cis	rs11634944	0.901	rs2855523	ENSG00000274307.1	RP11-345J18.2	-3.92	0.000118	0.0354	-0.33	-0.25	Interleukin-8 levels;	chr15:24966466	chr15:25708470~25710869:-
SARC	cis	rs62025270	0.547	rs338520	ENSG00000202081.1	RNU6-1280P	3.92	0.000118	0.0354	0.3	0.25	Idiopathic pulmonary fibrosis;	chr15:85671567	chr15:85651522~85651628:-
SARC	cis	rs7520050	0.966	rs1707304	ENSG00000280836.1	AL355480.1	3.92	0.000118	0.0355	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:46132597	chr1:45581219~45581321:-
SARC	cis	rs42490	0.789	rs416324	ENSG00000251136.7	RP11-37B2.1	3.92	0.000118	0.0355	0.28	0.25	Leprosy;	chr8:89803007	chr8:89609409~89757727:-
SARC	cis	rs72627509	0.951	rs17087335	ENSG00000269949.1	RP11-738E22.3	3.92	0.000118	0.0355	0.38	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972417	chr4:56960927~56961373:-
SARC	cis	rs7274811	0.901	rs1074683	ENSG00000181741.7	FDX1P1	-3.92	0.000118	0.0355	-0.33	-0.25	Height;	chr20:33716847	chr20:34475924~34476474:-
SARC	cis	rs7772486	0.875	rs9399573	ENSG00000270638.1	RP3-466P17.1	3.92	0.000118	0.0355	0.2	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146082119	chr6:145735570~145737218:+
SARC	cis	rs28386778	0.897	rs2727327	ENSG00000240280.5	TCAM1P	-3.92	0.000118	0.0355	-0.31	-0.25	Prudent dietary pattern;	chr17:63846062	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.831	rs2584618	ENSG00000240280.5	TCAM1P	-3.92	0.000118	0.0355	-0.31	-0.25	Prudent dietary pattern;	chr17:63846251	chr17:63849292~63864379:+
SARC	cis	rs9656169	0.832	rs10248611	ENSG00000226965.1	AC003088.1	3.92	0.000118	0.0355	0.29	0.25	Autism spectrum disorder or schizophrenia;	chr7:110464163	chr7:110432239~110534754:-
SARC	cis	rs4664293	0.836	rs2556102	ENSG00000226266.5	AC009961.3	-3.92	0.000118	0.0355	-0.31	-0.25	Monocyte percentage of white cells;	chr2:159798611	chr2:159670708~159712435:-
SARC	cis	rs4705962	0.837	rs10062446	ENSG00000230612.2	AC004237.1	3.92	0.000118	0.0355	0.31	0.25	Atopic dermatitis;	chr5:132704682	chr5:132688681~132723725:+
SARC	cis	rs9907295	0.892	rs4795100	ENSG00000270240.2	AC015849.2	3.92	0.000118	0.0355	0.45	0.25	Fibroblast growth factor basic levels;	chr17:35917470	chr17:35868967~35885863:+
SARC	cis	rs2243480	1	rs316330	ENSG00000164669.11	INTS4P1	3.92	0.000118	0.0355	0.44	0.25	Diabetic kidney disease;	chr7:66140385	chr7:65141225~65234216:+
SARC	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	3.92	0.000118	0.0355	0.22	0.25	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
SARC	cis	rs7247513	0.639	rs12984441	ENSG00000213290.4	PGK1P2	-3.92	0.000118	0.0356	-0.28	-0.25	Bipolar disorder;	chr19:12649473	chr19:12559571~12561105:+
SARC	cis	rs9858542	0.537	rs115753735	ENSG00000225399.4	RP11-3B7.1	-3.92	0.000119	0.0356	-0.38	-0.25	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49317572	chr3:49260085~49261316:+
SARC	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	3.92	0.000119	0.0356	0.38	0.25	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
SARC	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	3.92	0.000119	0.0356	0.38	0.25	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
SARC	cis	rs11822910	0.911	rs11828218	ENSG00000265566.2	RN7SL605P	3.92	0.000119	0.0356	0.32	0.25	Platelet distribution width;	chr11:57428750	chr11:57528085~57528365:-
SARC	cis	rs4664293	0.667	rs6432562	ENSG00000226266.5	AC009961.3	-3.92	0.000119	0.0356	-0.29	-0.25	Monocyte percentage of white cells;	chr2:159791495	chr2:159670708~159712435:-
SARC	cis	rs7208859	0.623	rs7220289	ENSG00000264538.5	SUZ12P1	-3.92	0.000119	0.0356	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30709299~30790908:+
SARC	cis	rs61160187	0.582	rs7713481	ENSG00000215032.2	GNL3LP1	3.92	0.000119	0.0356	0.25	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.582	rs7737276	ENSG00000215032.2	GNL3LP1	3.92	0.000119	0.0356	0.25	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60891935~60893577:-
SARC	cis	rs862687	0.584	rs830644	ENSG00000270562.1	RP11-154H23.3	-3.92	0.000119	0.0356	-0.23	-0.25	Intelligence (multi-trait analysis);	chr3:71616408	chr3:71584943~71587409:+
SARC	cis	rs17169635	0.879	rs3800737	ENSG00000223718.3	AC093107.7	-3.92	0.000119	0.0356	-0.32	-0.25	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134853124	chr7:135660039~135660647:+
SARC	cis	rs7580658	0.864	rs34832797	ENSG00000236682.1	AC068282.3	-3.92	0.000119	0.0356	-0.28	-0.25	Protein C levels;	chr2:127361865	chr2:127389130~127400580:+
SARC	cis	rs7580658	0.857	rs2896980	ENSG00000236682.1	AC068282.3	-3.92	0.000119	0.0356	-0.28	-0.25	Protein C levels;	chr2:127382383	chr2:127389130~127400580:+
SARC	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	3.92	0.000119	0.0356	0.4	0.25	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
SARC	cis	rs6142102	0.625	rs6142061	ENSG00000275784.1	RP5-1125A11.6	-3.92	0.000119	0.0356	-0.29	-0.25	Skin pigmentation;	chr20:33960529	chr20:33989480~33991818:-
SARC	cis	rs11088226	1	rs2833889	ENSG00000186842.4	LINC00846	3.92	0.000119	0.0356	0.35	0.25	Gastritis;	chr21:32555458	chr21:32572238~32575881:-
SARC	cis	rs7429990	0.864	rs319693	ENSG00000229759.1	MRPS18AP1	3.91	0.000119	0.0356	0.3	0.25	Educational attainment (years of education);	chr3:47845090	chr3:48256350~48256938:-
SARC	cis	rs7617773	0.779	rs77957078	ENSG00000228638.1	FCF1P2	-3.91	0.000119	0.0356	-0.29	-0.25	Coronary artery disease;	chr3:48289796	chr3:48290793~48291375:-
SARC	cis	rs11064768	0.908	rs12370442	ENSG00000255857.4	PXN-AS1	-3.91	0.000119	0.0356	-0.44	-0.25	Schizophrenia;	chr12:119415486	chr12:120201291~120213138:+
SARC	cis	rs9283706	0.655	rs4016246	ENSG00000229666.1	MAST4-AS1	-3.91	0.000119	0.0356	-0.31	-0.25	Coronary artery disease;	chr5:67014364	chr5:67001383~67003953:-
SARC	cis	rs7208859	0.524	rs8069400	ENSG00000264538.5	SUZ12P1	-3.91	0.000119	0.0356	-0.26	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30709299~30790908:+
SARC	cis	rs10540	1	rs35898083	ENSG00000277290.1	RP11-326C3.16	3.91	0.000119	0.0356	0.31	0.25	Body mass index;	chr11:484469	chr11:243099~243483:-
SARC	cis	rs7246657	0.943	rs1035479	ENSG00000226686.6	LINC01535	3.91	0.000119	0.0356	0.33	0.25	Coronary artery calcification;	chr19:37402398	chr19:37251912~37265535:+
SARC	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	3.91	0.000119	0.0357	0.36	0.25	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
SARC	cis	rs72799341	0.706	rs1060506	ENSG00000260911.2	RP11-196G11.2	3.91	0.000119	0.0357	0.25	0.25	Diastolic blood pressure;	chr16:31122128	chr16:31043150~31049868:+
SARC	cis	rs11123170	0.503	rs28679654	ENSG00000274877.1	RP11-65I12.1	-3.91	0.000119	0.0357	-0.32	-0.25	Renal function-related traits (BUN);	chr2:113210040	chr2:113237595~113240825:+
SARC	cis	rs755249	0.567	rs72661961	ENSG00000182109.6	RP11-69E11.4	3.91	0.000119	0.0357	0.27	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39522280~39546187:-
SARC	cis	rs755249	0.532	rs61779277	ENSG00000182109.6	RP11-69E11.4	3.91	0.000119	0.0357	0.27	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39522280~39546187:-
SARC	cis	rs755249	0.532	rs61779278	ENSG00000182109.6	RP11-69E11.4	3.91	0.000119	0.0357	0.27	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs2296172	ENSG00000182109.6	RP11-69E11.4	3.91	0.000119	0.0357	0.27	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs61779279	ENSG00000182109.6	RP11-69E11.4	3.91	0.000119	0.0357	0.27	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs76111861	ENSG00000182109.6	RP11-69E11.4	3.91	0.000119	0.0357	0.27	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39522280~39546187:-
SARC	cis	rs2905347	0.755	rs2961288	ENSG00000179428.2	AC073072.5	3.91	0.000119	0.0357	0.27	0.25	Major depression and alcohol dependence;	chr7:22625510	chr7:22725395~22727620:-
SARC	cis	rs240993	0.812	rs458806	ENSG00000230177.1	RP5-1112D6.4	-3.91	0.000119	0.0357	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111354825	chr6:111277932~111278742:+
SARC	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-3.91	0.000119	0.0357	-0.32	-0.25	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
SARC	cis	rs9902453	1	rs28664971	ENSG00000264538.5	SUZ12P1	3.91	0.000119	0.0357	0.18	0.25	Coffee consumption (cups per day);	chr17:30110392	chr17:30709299~30790908:+
SARC	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-3.91	0.000119	0.0357	-0.29	-0.25	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
SARC	cis	rs12049351	0.665	rs7545114	ENSG00000229367.1	HMGN2P19	3.91	0.000119	0.0357	0.22	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229455851	chr1:229570532~229570796:+
SARC	cis	rs7615952	0.599	rs2279821	ENSG00000241288.6	RP11-379B18.5	-3.91	0.000119	0.0357	-0.3	-0.25	Blood pressure (smoking interaction);	chr3:126015465	chr3:125827238~125916384:-
SARC	cis	rs453301	0.631	rs11780774	ENSG00000253893.2	FAM85B	3.91	0.000119	0.0357	0.23	0.25	Joint mobility (Beighton score);	chr8:8941601	chr8:8167819~8226614:-
SARC	cis	rs7811142	0.83	rs118119933	ENSG00000078319.8	PMS2P1	-3.91	0.000119	0.0358	-0.39	-0.25	Platelet count;	chr7:100341427	chr7:100320992~100341908:-
SARC	cis	rs240993	0.812	rs9400476	ENSG00000230177.1	RP5-1112D6.4	3.91	0.000119	0.0358	0.28	0.25	Inflammatory skin disease;Psoriasis;	chr6:111463172	chr6:111277932~111278742:+
SARC	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	3.91	0.000119	0.0358	0.29	0.25	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
SARC	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	3.91	0.000119	0.0358	0.29	0.25	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
SARC	cis	rs7615952	0.576	rs6780025	ENSG00000248787.1	RP11-666A20.4	-3.91	0.000119	0.0358	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:126096781	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.576	rs6804482	ENSG00000248787.1	RP11-666A20.4	-3.91	0.000119	0.0358	-0.36	-0.25	Blood pressure (smoking interaction);	chr3:126096919	chr3:125908005~125910272:-
SARC	cis	rs858239	0.632	rs1985769	ENSG00000226816.2	AC005082.12	3.91	0.000119	0.0358	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23206013~23208045:+
SARC	cis	rs11955398	0.502	rs290513	ENSG00000215032.2	GNL3LP1	3.91	0.00012	0.0358	0.27	0.25	Intelligence (multi-trait analysis);	chr5:61014936	chr5:60891935~60893577:-
SARC	cis	rs11955398	0.502	rs248688	ENSG00000215032.2	GNL3LP1	3.91	0.00012	0.0358	0.27	0.25	Intelligence (multi-trait analysis);	chr5:61021606	chr5:60891935~60893577:-
SARC	cis	rs4679904	0.96	rs80020729	ENSG00000243116.1	RP11-564C24.1	3.91	0.00012	0.0359	0.26	0.25	Primary biliary cholangitis;	chr3:160591150	chr3:159721524~159722401:-
SARC	cis	rs4679904	0.883	rs114457071	ENSG00000243116.1	RP11-564C24.1	3.91	0.00012	0.0359	0.26	0.25	Primary biliary cholangitis;	chr3:160593952	chr3:159721524~159722401:-
SARC	cis	rs73219805	0.554	rs3808566	ENSG00000228451.3	SDAD1P1	3.91	0.00012	0.0359	0.38	0.25	Schizophrenia;	chr8:26365942	chr8:26379259~26382953:-
SARC	cis	rs524281	0.506	rs512421	ENSG00000245532.5	NEAT1	-3.91	0.00012	0.0359	-0.21	-0.25	Electroencephalogram traits;	chr11:66217697	chr11:65422774~65445540:+
SARC	cis	rs9858038	0.645	rs9841498	ENSG00000244346.1	RP11-531F16.3	-3.91	0.00012	0.0359	-0.29	-0.25	Parkinson's disease;	chr3:183009309	chr3:182950783~182956307:-
SARC	cis	rs4950322	0.518	rs55697094	ENSG00000278811.3	LINC00624	3.91	0.00012	0.0359	0.27	0.25	Protein quantitative trait loci;	chr1:147121205	chr1:147258885~147517875:-
SARC	cis	rs8054556	0.74	rs12716974	ENSG00000183604.13	SMG1P5	-3.91	0.00012	0.0359	-0.24	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29933511	chr16:30267553~30335374:-
SARC	cis	rs2187895	1	rs2187895	ENSG00000271811.1	RP1-79C4.4	3.91	0.00012	0.0359	0.42	0.25	Tonsillectomy;	chr1:170715290	chr1:170667381~170669425:+
SARC	cis	rs1376877	0.934	rs6761706	ENSG00000213925.3	NPM1P33	3.91	0.00012	0.0359	0.23	0.25	Subclinical atherosclerosis traits (other);	chr2:203253516	chr2:203772631~203773502:-
SARC	cis	rs858239	0.6	rs2072368	ENSG00000226816.2	AC005082.12	3.91	0.00012	0.0359	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23206013~23208045:+
SARC	cis	rs11264213	1	rs12083902	ENSG00000239636.1	RP4-728D4.2	-3.91	0.00012	0.0359	-0.33	-0.25	Schizophrenia;	chr1:35809511	chr1:35569813~35577729:-
SARC	cis	rs9487094	0.813	rs6920962	ENSG00000260273.1	RP11-425D10.10	3.91	0.00012	0.0359	0.32	0.25	Height;	chr6:109403287	chr6:109382795~109383666:+
SARC	cis	rs1880529	0.527	rs62314976	ENSG00000206820.1	RNU1-138P	-3.91	0.00012	0.036	-0.25	-0.25	White matter integrity (bipolar disorder risk interaction);	chr4:113464520	chr4:113420323~113420486:+
SARC	cis	rs840616	0.668	rs13424740	ENSG00000231739.2	GAPDHP59	3.91	0.00012	0.036	0.26	0.25	Coronary heart disease;Coronary artery disease;	chr2:187218396	chr2:187415552~187415818:+
SARC	cis	rs840616	0.668	rs7593799	ENSG00000231739.2	GAPDHP59	3.91	0.00012	0.036	0.26	0.25	Coronary heart disease;Coronary artery disease;	chr2:187218573	chr2:187415552~187415818:+
SARC	cis	rs840616	0.668	rs1528239	ENSG00000231739.2	GAPDHP59	3.91	0.00012	0.036	0.26	0.25	Coronary heart disease;Coronary artery disease;	chr2:187222160	chr2:187415552~187415818:+
SARC	cis	rs840616	0.668	rs11683016	ENSG00000231739.2	GAPDHP59	3.91	0.00012	0.036	0.26	0.25	Coronary heart disease;Coronary artery disease;	chr2:187223160	chr2:187415552~187415818:+
SARC	cis	rs4664293	0.669	rs1549387	ENSG00000226266.5	AC009961.3	3.91	0.00012	0.036	0.29	0.25	Monocyte percentage of white cells;	chr2:159561029	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.669	rs1863219	ENSG00000226266.5	AC009961.3	3.91	0.00012	0.036	0.29	0.25	Monocyte percentage of white cells;	chr2:159561660	chr2:159670708~159712435:-
SARC	cis	rs7189233	0.956	rs62048478	ENSG00000279722.1	RP11-44F14.6	-3.91	0.00012	0.036	-0.19	-0.25	Intelligence (multi-trait analysis);	chr16:53395268	chr16:53487607~53489943:-
SARC	cis	rs6570726	1	rs951143	ENSG00000235652.6	RP11-545I5.3	3.91	0.00012	0.036	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145799409~145886585:+
SARC	cis	rs2562456	0.52	rs660063	ENSG00000268081.1	RP11-678G14.2	-3.91	0.00012	0.036	-0.4	-0.25	Pain;	chr19:21271103	chr19:21554640~21569237:-
SARC	cis	rs240993	0.812	rs459809	ENSG00000230177.1	RP5-1112D6.4	-3.91	0.00012	0.036	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111331964	chr6:111277932~111278742:+
SARC	cis	rs748404	0.697	rs513970	ENSG00000275601.1	AC011330.13	-3.91	0.00012	0.036	-0.31	-0.25	Lung cancer;	chr15:43287368	chr15:43642389~43643023:-
SARC	cis	rs3934047	0.904	rs2867483	ENSG00000274376.3	ADAMTS7P1	-3.91	0.00012	0.036	-0.28	-0.25	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81720833	chr15:82298553~82334609:+
SARC	cis	rs848490	0.515	rs6465825	ENSG00000214293.7	APTR	-3.91	0.00012	0.036	-0.27	-0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77787122	chr7:77657660~77696265:-
SARC	cis	rs7267979	0.844	rs2424703	ENSG00000276952.1	RP5-965G21.6	3.91	0.00012	0.036	0.24	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:25284915~25285588:-
SARC	cis	rs8059260	0.542	rs7196077	ENSG00000274038.1	RP11-66H6.4	-3.91	0.00012	0.036	-0.35	-0.25	Alcohol consumption over the past year;	chr16:11033198	chr16:11056556~11057034:+
SARC	cis	rs28386778	1	rs28386778	ENSG00000240280.5	TCAM1P	-3.91	0.000121	0.036	-0.32	-0.25	Prudent dietary pattern;	chr17:63887455	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.901	rs2665855	ENSG00000240280.5	TCAM1P	-3.91	0.000121	0.036	-0.32	-0.25	Prudent dietary pattern;	chr17:63887783	chr17:63849292~63864379:+
SARC	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	3.91	0.000121	0.036	0.3	0.25	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
SARC	cis	rs7726354	0.793	rs73756771	ENSG00000271828.1	CTD-2310F14.1	3.91	0.000121	0.0361	0.48	0.25	Breast cancer (early onset);	chr5:56705175	chr5:56927874~56929573:+
SARC	cis	rs7726354	0.793	rs73756772	ENSG00000271828.1	CTD-2310F14.1	3.91	0.000121	0.0361	0.48	0.25	Breast cancer (early onset);	chr5:56706309	chr5:56927874~56929573:+
SARC	cis	rs56046484	0.956	rs17540501	ENSG00000259295.5	CSPG4P12	3.91	0.000121	0.0361	0.36	0.25	Testicular germ cell tumor;	chr15:85094870	chr15:85191438~85213905:+
SARC	cis	rs964184	0.564	rs2266788	ENSG00000254851.1	RP11-109L13.1	-3.91	0.000121	0.0361	-0.5	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116789970	chr11:117135528~117138582:+
SARC	cis	rs453301	0.686	rs28482034	ENSG00000253893.2	FAM85B	3.91	0.000121	0.0361	0.22	0.25	Joint mobility (Beighton score);	chr8:9012154	chr8:8167819~8226614:-
SARC	cis	rs453301	0.686	rs11785819	ENSG00000253893.2	FAM85B	3.91	0.000121	0.0361	0.22	0.25	Joint mobility (Beighton score);	chr8:9012868	chr8:8167819~8226614:-
SARC	cis	rs10936632	0.728	rs10804840	ENSG00000242578.1	RP11-469J4.3	-3.91	0.000121	0.0361	-0.26	-0.25	Prostate cancer;	chr3:170354019	chr3:170410512~170418615:+
SARC	cis	rs875971	1	rs4718307	ENSG00000236529.1	RP13-254B10.1	-3.91	0.000121	0.0361	-0.24	-0.25	Aortic root size;	chr7:66146001	chr7:65840212~65840596:+
SARC	cis	rs1799949	0.929	rs799905	ENSG00000267681.1	CTD-3199J23.6	-3.91	0.000121	0.0361	-0.28	-0.25	Menopause (age at onset);	chr17:43125170	chr17:43144956~43145255:+
SARC	cis	rs4835473	0.808	rs2060652	ENSG00000251600.4	RP11-673E1.1	-3.91	0.000121	0.0361	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143739129	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs2060654	ENSG00000251600.4	RP11-673E1.1	-3.91	0.000121	0.0361	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143739155	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs2060655	ENSG00000251600.4	RP11-673E1.1	-3.91	0.000121	0.0361	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143739159	chr4:143912331~143982454:+
SARC	cis	rs2404602	0.716	rs8030411	ENSG00000259422.1	RP11-593F23.1	3.91	0.000121	0.0361	0.27	0.25	Blood metabolite levels;	chr15:76407514	chr15:76174891~76181486:-
SARC	cis	rs8028182	0.636	rs28432989	ENSG00000260206.1	CTD-2026K11.2	-3.91	0.000121	0.0361	-0.3	-0.25	Sudden cardiac arrest;	chr15:75475956	chr15:75636139~75639239:+
SARC	cis	rs6921919	0.789	rs6456814	ENSG00000204709.4	LINC01556	3.91	0.000121	0.0361	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28943877~28944537:+
SARC	cis	rs6921919	0.789	rs13210258	ENSG00000204709.4	LINC01556	3.91	0.000121	0.0361	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28943877~28944537:+
SARC	cis	rs9925964	0.933	rs9929899	ENSG00000183604.13	SMG1P5	3.91	0.000121	0.0361	0.23	0.25	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31051380	chr16:30267553~30335374:-
SARC	cis	rs713477	1	rs8014621	ENSG00000258413.1	RP11-665C16.6	3.91	0.000121	0.0362	0.28	0.25	Pediatric bone mineral content (femoral neck);	chr14:55440131	chr14:55262767~55272075:-
SARC	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-3.91	0.000121	0.0362	-0.39	-0.25	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
SARC	cis	rs1062177	1	rs12518722	ENSG00000254226.4	CTB-12O2.1	3.91	0.000121	0.0362	0.34	0.25	Preschool internalizing problems;	chr5:151851899	chr5:151949571~152270448:+
SARC	cis	rs61160187	0.75	rs56166952	ENSG00000272308.1	RP11-231G3.1	-3.91	0.000121	0.0362	-0.21	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60610568	chr5:60866457~60866935:-
SARC	cis	rs9283706	0.623	rs1567316	ENSG00000229666.1	MAST4-AS1	-3.91	0.000121	0.0362	-0.3	-0.25	Coronary artery disease;	chr5:67016275	chr5:67001383~67003953:-
SARC	cis	rs860818	1	rs858304	ENSG00000226816.2	AC005082.12	-3.91	0.000121	0.0362	-0.65	-0.25	Initial pursuit acceleration;	chr7:23203534	chr7:23206013~23208045:+
SARC	cis	rs7031325	0.819	rs10758801	ENSG00000229611.1	RP11-390F4.10	3.91	0.000121	0.0362	0.29	0.25	Systemic lupus erythematosus;	chr9:6657192	chr9:6704471~6707780:+
SARC	cis	rs916888	0.647	rs199524	ENSG00000261575.2	RP11-259G18.1	-3.91	0.000121	0.0362	-0.33	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46267037~46268694:+
SARC	cis	rs916888	0.647	rs199523	ENSG00000261575.2	RP11-259G18.1	-3.91	0.000121	0.0362	-0.33	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46267037~46268694:+
SARC	cis	rs11159086	0.793	rs4903229	ENSG00000270000.1	RP3-449M8.9	3.91	0.000121	0.0362	0.36	0.25	Advanced glycation end-product levels;	chr14:74489865	chr14:74471930~74472360:-
SARC	cis	rs7211079	0.917	rs4243251	ENSG00000275479.1	RP11-334C17.6	3.91	0.000121	0.0362	0.28	0.25	Myocardial infarction;	chr17:80138811	chr17:80149627~80149798:+
SARC	cis	rs67478160	0.572	rs8015603	ENSG00000269958.1	RP11-73M18.8	3.91	0.000121	0.0362	0.24	0.25	Schizophrenia;	chr14:103827341	chr14:103696353~103697163:+
SARC	cis	rs748404	0.697	rs530188	ENSG00000275601.1	AC011330.13	-3.91	0.000121	0.0362	-0.31	-0.25	Lung cancer;	chr15:43253116	chr15:43642389~43643023:-
SARC	cis	rs748404	0.697	rs475227	ENSG00000275601.1	AC011330.13	-3.91	0.000121	0.0362	-0.31	-0.25	Lung cancer;	chr15:43254248	chr15:43642389~43643023:-
SARC	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-3.91	0.000121	0.0363	-0.29	-0.25	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
SARC	cis	rs848486	0.936	rs10953349	ENSG00000214293.7	APTR	-3.91	0.000121	0.0363	-0.26	-0.25	Glomerular filtration rate;	chr7:77773429	chr7:77657660~77696265:-
SARC	cis	rs4948102	0.924	rs13241866	ENSG00000235207.1	TUBBP6	-3.91	0.000121	0.0363	-0.28	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56023185	chr7:55645620~55646951:+
SARC	cis	rs4664293	0.632	rs7588230	ENSG00000226266.5	AC009961.3	3.91	0.000121	0.0363	0.29	0.25	Monocyte percentage of white cells;	chr2:159797209	chr2:159670708~159712435:-
SARC	cis	rs2243480	1	rs73142166	ENSG00000164669.11	INTS4P1	3.91	0.000121	0.0363	0.44	0.25	Diabetic kidney disease;	chr7:65910845	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs34193460	ENSG00000164669.11	INTS4P1	3.91	0.000121	0.0363	0.44	0.25	Diabetic kidney disease;	chr7:65928123	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs57057549	ENSG00000164669.11	INTS4P1	3.91	0.000121	0.0363	0.44	0.25	Diabetic kidney disease;	chr7:65940751	chr7:65141225~65234216:+
SARC	cis	rs1376877	0.875	rs62183912	ENSG00000213925.3	NPM1P33	3.91	0.000121	0.0363	0.23	0.25	Subclinical atherosclerosis traits (other);	chr2:203302651	chr2:203772631~203773502:-
SARC	cis	rs11086243	1	rs6094991	ENSG00000276923.1	RP11-321P16.1	3.91	0.000121	0.0363	0.3	0.25	Nephrotic syndrome (acquired);	chr20:48150359	chr20:48073869~48074188:+
SARC	cis	rs61160187	0.548	rs68104763	ENSG00000215032.2	GNL3LP1	3.91	0.000122	0.0363	0.25	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61107016	chr5:60891935~60893577:-
SARC	cis	rs2283792	0.646	rs7292584	ENSG00000224086.5	LL22NC03-86G7.1	-3.91	0.000122	0.0363	-0.26	-0.25	Multiple sclerosis;	chr22:21768458	chr22:21938293~21977632:+
SARC	cis	rs11159086	0.793	rs12432412	ENSG00000270000.1	RP3-449M8.9	3.91	0.000122	0.0363	0.36	0.25	Advanced glycation end-product levels;	chr14:74474294	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs1029700	ENSG00000270000.1	RP3-449M8.9	3.91	0.000122	0.0363	0.36	0.25	Advanced glycation end-product levels;	chr14:74474309	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs1029699	ENSG00000270000.1	RP3-449M8.9	3.91	0.000122	0.0363	0.36	0.25	Advanced glycation end-product levels;	chr14:74474790	chr14:74471930~74472360:-
SARC	cis	rs367615	1	rs367615	ENSG00000249476.1	CTD-2587M2.1	-3.91	0.000122	0.0363	-0.32	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109613236	chr5:109237120~109326369:-
SARC	cis	rs7617480	0.61	rs10865954	ENSG00000225399.4	RP11-3B7.1	3.91	0.000122	0.0363	0.31	0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49174556	chr3:49260085~49261316:+
SARC	cis	rs2148307	0.619	rs2359562	ENSG00000223984.1	HNRNPRP1	-3.91	0.000122	0.0363	-0.29	-0.25	Photic sneeze reflex;	chr10:20764100	chr10:21624592~21626286:-
SARC	cis	rs150992	0.603	rs161732	ENSG00000248489.1	CTD-2007H13.3	-3.91	0.000122	0.0363	-0.28	-0.25	Body mass index;	chr5:98941418	chr5:98929171~98995013:+
SARC	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-3.91	0.000122	0.0363	-0.33	-0.25	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
SARC	cis	rs597539	0.727	rs632984	ENSG00000250508.1	RP11-757G1.6	-3.91	0.000122	0.0363	-0.3	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68852803	chr11:68870664~68874542:+
SARC	cis	rs597539	0.69	rs7129960	ENSG00000250508.1	RP11-757G1.6	-3.91	0.000122	0.0363	-0.3	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854988	chr11:68870664~68874542:+
SARC	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-3.91	0.000122	0.0363	-0.23	-0.25	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
SARC	cis	rs11159086	1	rs11159086	ENSG00000270000.1	RP3-449M8.9	3.91	0.000122	0.0363	0.37	0.25	Advanced glycation end-product levels;	chr14:74495572	chr14:74471930~74472360:-
SARC	cis	rs9876781	0.559	rs7611415	ENSG00000229759.1	MRPS18AP1	3.91	0.000122	0.0363	0.27	0.25	Longevity;	chr3:48363659	chr3:48256350~48256938:-
SARC	cis	rs9543976	1	rs2031236	ENSG00000261105.4	LMO7-AS1	-3.91	0.000122	0.0363	-0.41	-0.25	Diabetic retinopathy;	chr13:75595641	chr13:75604700~75635994:-
SARC	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-3.91	0.000122	0.0363	-0.28	-0.25	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
SARC	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	3.91	0.000122	0.0363	0.23	0.25	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
SARC	cis	rs1880529	0.832	rs4833430	ENSG00000206820.1	RNU1-138P	-3.91	0.000122	0.0363	-0.24	-0.25	White matter integrity (bipolar disorder risk interaction);	chr4:113486838	chr4:113420323~113420486:+
SARC	cis	rs13126694	0.679	rs4072170	ENSG00000248429.4	RP11-597D13.9	3.91	0.000122	0.0363	0.24	0.25	Blood osmolality (transformed sodium);	chr4:157980683	chr4:158170752~158202877:+
SARC	cis	rs2404602	0.716	rs17461634	ENSG00000259422.1	RP11-593F23.1	3.91	0.000122	0.0364	0.28	0.25	Blood metabolite levels;	chr15:76471766	chr15:76174891~76181486:-
SARC	cis	rs910316	0.737	rs175424	ENSG00000279594.1	RP11-950C14.10	-3.91	0.000122	0.0364	-0.29	-0.25	Height;	chr14:75159554	chr14:75011269~75012851:-
SARC	cis	rs910316	0.763	rs2080201	ENSG00000279594.1	RP11-950C14.10	-3.91	0.000122	0.0364	-0.29	-0.25	Height;	chr14:75163269	chr14:75011269~75012851:-
SARC	cis	rs17270561	0.609	rs1892255	ENSG00000272462.2	U91328.19	-3.91	0.000122	0.0364	-0.24	-0.25	Iron status biomarkers;	chr6:25750126	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs1892254	ENSG00000272462.2	U91328.19	-3.91	0.000122	0.0364	-0.24	-0.25	Iron status biomarkers;	chr6:25750302	chr6:25992662~26001775:+
SARC	cis	rs1865760	0.613	rs2071300	ENSG00000272810.1	U91328.22	-3.91	0.000122	0.0364	-0.25	-0.25	Height;	chr6:25914344	chr6:26013241~26013757:+
SARC	cis	rs9481169	0.85	rs13210247	ENSG00000231889.6	TRAF3IP2-AS1	3.91	0.000122	0.0364	0.44	0.25	Inflammatory skin disease;	chr6:111601517	chr6:111483511~111598302:+
SARC	cis	rs4927850	0.829	rs6768483	ENSG00000242086.7	LINC00969	3.91	0.000122	0.0364	0.26	0.25	Pancreatic cancer;	chr3:196019092	chr3:195658062~195739964:+
SARC	cis	rs6515865	1	rs6515865	ENSG00000277425.1	RP5-1116H23.3	3.91	0.000122	0.0364	0.29	0.25	High light scatter reticulocyte count;	chr20:4145672	chr20:5066082~5068154:-
SARC	cis	rs7246657	0.943	rs7253091	ENSG00000226686.6	LINC01535	-3.91	0.000122	0.0364	-0.34	-0.25	Coronary artery calcification;	chr19:37476312	chr19:37251912~37265535:+
SARC	cis	rs7900823	0.641	rs7916525	ENSG00000230500.1	MKX-AS1	-3.91	0.000122	0.0364	-0.34	-0.25	Lung cancer;	chr10:28238988	chr10:27744786~27767794:+
SARC	cis	rs6163	0.588	rs12763284	ENSG00000236937.2	PTGES3P4	-3.91	0.000122	0.0364	-0.28	-0.25	Waist circumference;Hip circumference;	chr10:102748445	chr10:102845595~102845950:+
SARC	cis	rs875971	0.666	rs13242072	ENSG00000224316.1	RP11-479O9.2	-3.91	0.000122	0.0364	-0.24	-0.25	Aortic root size;	chr7:66301001	chr7:65773620~65802067:+
SARC	cis	rs6848139	1	rs7670673	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122147243	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs7696107	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122147662	chr4:122730548~122732193:-
SARC	cis	rs6848139	0.881	rs62323894	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122148045	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323899	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122158285	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323900	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122158440	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323902	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122162117	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323903	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122164527	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323926	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122169894	chr4:122730548~122732193:-
SARC	cis	rs6848139	0.892	rs62323927	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122170523	chr4:122730548~122732193:-
SARC	cis	rs6848139	0.892	rs62323929	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122177684	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323930	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122181442	chr4:122730548~122732193:-
SARC	cis	rs6848139	0.881	rs62323931	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122185067	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323932	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122187013	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323933	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122188997	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323934	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122190714	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323936	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122196574	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323937	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122196800	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323939	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122202994	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs75034409	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122207746	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs7677168	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122213003	chr4:122730548~122732193:-
SARC	cis	rs6848139	0.803	rs7667951	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122216851	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323943	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122222203	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323948	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122242407	chr4:122730548~122732193:-
SARC	cis	rs6848139	0.881	rs75906064	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122248711	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs75448874	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122251421	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323952	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122260247	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs77574900	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122264508	chr4:122730548~122732193:-
SARC	cis	rs6848139	0.881	rs45499403	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122265439	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs77552566	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122268794	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs45558836	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122272091	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323956	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122274527	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323957	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122275427	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62323958	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122288204	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs45513095	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122293680	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs45530034	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122293825	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62321680	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122298996	chr4:122730548~122732193:-
SARC	cis	rs6848139	1	rs62321681	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122300410	chr4:122730548~122732193:-
SARC	cis	rs6848139	0.892	rs62321683	ENSG00000224786.1	CETN4P	-3.91	0.000122	0.0364	-0.61	-0.25	Alopecia areata;	chr4:122301977	chr4:122730548~122732193:-
SARC	cis	rs7208859	0.623	rs73269916	ENSG00000264538.5	SUZ12P1	-3.91	0.000122	0.0364	-0.26	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30709299~30790908:+
SARC	cis	rs2404602	0.716	rs1588961	ENSG00000259422.1	RP11-593F23.1	3.91	0.000122	0.0364	0.28	0.25	Blood metabolite levels;	chr15:76460357	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.716	rs12592171	ENSG00000259422.1	RP11-593F23.1	3.91	0.000122	0.0364	0.28	0.25	Blood metabolite levels;	chr15:76462792	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.679	rs12899871	ENSG00000259422.1	RP11-593F23.1	3.91	0.000122	0.0364	0.28	0.25	Blood metabolite levels;	chr15:76465006	chr15:76174891~76181486:-
SARC	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	3.91	0.000122	0.0364	0.36	0.25	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
SARC	cis	rs9364687	0.639	rs9347762	ENSG00000228692.2	RP5-826L7.1	-3.91	0.000122	0.0364	-0.3	-0.25	Body mass index;	chr6:163540049	chr6:163586583~163588165:-
SARC	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-3.91	0.000122	0.0364	-0.36	-0.25	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-3.91	0.000122	0.0364	-0.36	-0.25	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs781156	ENSG00000273142.1	RP11-458F8.4	-3.91	0.000122	0.0364	-0.36	-0.25	Diabetic kidney disease;	chr7:66014154	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs451396	ENSG00000273142.1	RP11-458F8.4	-3.91	0.000122	0.0364	-0.36	-0.25	Diabetic kidney disease;	chr7:66019087	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs1715235	ENSG00000273142.1	RP11-458F8.4	-3.91	0.000122	0.0364	-0.36	-0.25	Diabetic kidney disease;	chr7:66023407	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-3.91	0.000122	0.0364	-0.36	-0.25	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
SARC	cis	rs2562456	0.917	rs2650825	ENSG00000268658.4	LINC00664	3.91	0.000122	0.0364	0.35	0.25	Pain;	chr19:21516423	chr19:21483374~21503238:+
SARC	cis	rs860818	1	rs1728323	ENSG00000226816.2	AC005082.12	3.91	0.000122	0.0364	0.72	0.25	Initial pursuit acceleration;	chr7:23192836	chr7:23206013~23208045:+
SARC	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	3.91	0.000122	0.0364	0.38	0.25	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
SARC	cis	rs62025270	0.688	rs62025272	ENSG00000202081.1	RNU6-1280P	-3.91	0.000122	0.0365	-0.34	-0.25	Idiopathic pulmonary fibrosis;	chr15:85770391	chr15:85651522~85651628:-
SARC	cis	rs28498283	0.792	rs13416780	ENSG00000279873.2	LINC01126	-3.91	0.000122	0.0365	-0.23	-0.25	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:43119031	chr2:43227210~43228855:+
SARC	cis	rs745109	0.882	rs72930323	ENSG00000273080.1	RP11-301O19.1	3.91	0.000123	0.0365	0.38	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86428739	chr2:86195590~86196049:+
SARC	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	3.91	0.000123	0.0365	0.3	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
SARC	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	3.91	0.000123	0.0365	0.38	0.25	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
SARC	cis	rs10991814	0.688	rs76530346	ENSG00000225511.5	LINC00475	3.91	0.000123	0.0365	0.57	0.25	Neutrophil percentage of granulocytes;	chr9:91248016	chr9:92141298~92160114:+
SARC	cis	rs858239	0.632	rs13438452	ENSG00000226816.2	AC005082.12	3.91	0.000123	0.0365	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23206013~23208045:+
SARC	cis	rs28386778	0.897	rs2584642	ENSG00000240280.5	TCAM1P	-3.91	0.000123	0.0365	-0.31	-0.25	Prudent dietary pattern;	chr17:63865067	chr17:63849292~63864379:+
SARC	cis	rs875971	1	rs7801282	ENSG00000236529.1	RP13-254B10.1	-3.91	0.000123	0.0365	-0.24	-0.25	Aortic root size;	chr7:66148700	chr7:65840212~65840596:+
SARC	cis	rs10911902	0.602	rs2273778	ENSG00000229739.2	RP11-295K2.3	-3.91	0.000123	0.0365	-0.36	-0.25	Schizophrenia;	chr1:186305027	chr1:186435161~186470291:+
SARC	cis	rs17270561	0.609	rs4464787	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25733330	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4711098	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25734111	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs4360128	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25734330	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs3922699	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25734741	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs6924782	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25735588	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs6924794	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25735646	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs3922842	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25736336	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.608	rs9358875	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25737780	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9358876	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25738728	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.583	rs9393661	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25738852	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9356986	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25738891	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.666	rs9356987	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25738959	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9358877	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25739000	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs12663099	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25739290	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9393662	ENSG00000272462.2	U91328.19	-3.91	0.000123	0.0366	-0.24	-0.25	Iron status biomarkers;	chr6:25739442	chr6:25992662~26001775:+
SARC	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-3.91	0.000123	0.0366	-0.45	-0.25	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
SARC	cis	rs12049351	0.774	rs10449250	ENSG00000229367.1	HMGN2P19	3.91	0.000123	0.0366	0.21	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229505024	chr1:229570532~229570796:+
SARC	cis	rs67478160	0.634	rs941475	ENSG00000269940.1	RP11-73M18.7	3.91	0.000123	0.0366	0.21	0.25	Schizophrenia;	chr14:103774281	chr14:103694560~103695170:+
SARC	cis	rs2243480	1	rs160633	ENSG00000164669.11	INTS4P1	3.91	0.000123	0.0366	0.44	0.25	Diabetic kidney disease;	chr7:66063241	chr7:65141225~65234216:+
SARC	cis	rs7216064	0.531	rs6504573	ENSG00000237854.3	LINC00674	3.91	0.000123	0.0366	0.28	0.25	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68019847	chr17:68101908~68115518:+
SARC	cis	rs1713985	0.508	rs1277282	ENSG00000269949.1	RP11-738E22.3	3.91	0.000123	0.0366	0.42	0.25	Age-related macular degeneration;	chr4:56989653	chr4:56960927~56961373:-
SARC	cis	rs9907295	0.901	rs4796130	ENSG00000270240.2	AC015849.2	3.91	0.000123	0.0366	0.37	0.25	Fibroblast growth factor basic levels;	chr17:35904264	chr17:35868967~35885863:+
SARC	cis	rs9907295	0.685	rs4796131	ENSG00000270240.2	AC015849.2	3.91	0.000123	0.0366	0.37	0.25	Fibroblast growth factor basic levels;	chr17:35904812	chr17:35868967~35885863:+
SARC	cis	rs2305707	0.544	rs2470175	ENSG00000244879.4	GABPB1-AS1	3.91	0.000123	0.0366	0.35	0.25	Height;	chr15:51288566	chr15:50354959~50372202:+
SARC	cis	rs7208859	0.524	rs60114476	ENSG00000264538.5	SUZ12P1	-3.91	0.000123	0.0366	-0.26	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30709299~30790908:+
SARC	cis	rs2412819	0.571	rs66903736	ENSG00000205771.5	CATSPER2P1	-3.91	0.000123	0.0367	-0.39	-0.25	Lung cancer;	chr15:43619435	chr15:43726918~43747094:-
SARC	cis	rs2412819	0.571	rs66749753	ENSG00000205771.5	CATSPER2P1	-3.91	0.000123	0.0367	-0.39	-0.25	Lung cancer;	chr15:43619601	chr15:43726918~43747094:-
SARC	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-3.91	0.000123	0.0367	-0.19	-0.25	Height;	chr11:118747911	chr11:118791254~118793137:+
SARC	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-3.91	0.000123	0.0367	-0.28	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
SARC	cis	rs11105298	0.891	rs3741898	ENSG00000258302.2	RP11-981P6.1	3.91	0.000123	0.0367	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs3741899	ENSG00000258302.2	RP11-981P6.1	3.91	0.000123	0.0367	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89561129~89594878:+
SARC	cis	rs11105298	0.891	rs10858906	ENSG00000258302.2	RP11-981P6.1	3.91	0.000123	0.0367	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89561129~89594878:+
SARC	cis	rs16846053	0.792	rs6714082	ENSG00000227403.1	AC009299.3	3.91	0.000123	0.0367	0.28	0.25	Blood osmolality (transformed sodium);	chr2:161743646	chr2:161244739~161249050:+
SARC	cis	rs16846053	0.71	rs6755071	ENSG00000227403.1	AC009299.3	3.91	0.000123	0.0367	0.28	0.25	Blood osmolality (transformed sodium);	chr2:161748720	chr2:161244739~161249050:+
SARC	cis	rs16846053	0.71	rs973940	ENSG00000227403.1	AC009299.3	3.91	0.000123	0.0367	0.28	0.25	Blood osmolality (transformed sodium);	chr2:161750890	chr2:161244739~161249050:+
SARC	cis	rs3934047	0.869	rs12916962	ENSG00000274376.3	ADAMTS7P1	-3.9	0.000123	0.0367	-0.27	-0.25	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81762646	chr15:82298553~82334609:+
SARC	cis	rs240993	0.812	rs240955	ENSG00000230177.1	RP5-1112D6.4	-3.9	0.000123	0.0367	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111339440	chr6:111277932~111278742:+
SARC	cis	rs240993	0.812	rs240990	ENSG00000230177.1	RP5-1112D6.4	-3.9	0.000123	0.0367	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111343820	chr6:111277932~111278742:+
SARC	cis	rs3813567	0.759	rs12594550	ENSG00000261143.1	ADAMTS7P3	3.9	0.000124	0.0367	0.43	0.25	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78666695	chr15:77976042~77993057:+
SARC	cis	rs76693355	0.512	rs11823264	ENSG00000232460.4	BMPR1APS2	3.9	0.000124	0.0367	0.31	0.25	Intraocular pressure;	chr11:120423295	chr11:121361854~121362865:-
SARC	cis	rs13434995	0.537	rs7340797	ENSG00000273257.1	RP11-177J6.1	3.9	0.000124	0.0367	0.35	0.25	Adiponectin levels;	chr4:55363681	chr4:55387949~55388271:+
SARC	cis	rs7927592	0.513	rs3853616	ENSG00000212093.1	AP000807.1	3.9	0.000124	0.0367	0.24	0.25	Total body bone mineral density;	chr11:68430784	chr11:68506083~68506166:-
SARC	cis	rs10751667	0.6	rs10902266	ENSG00000255026.1	RP11-326C3.2	3.9	0.000124	0.0367	0.24	0.25	Alzheimer's disease (late onset);	chr11:1005697	chr11:287305~288987:+
SARC	cis	rs858267	0.661	rs59389125	ENSG00000230042.1	AK3P3	3.9	0.000124	0.0367	0.48	0.25	Blood protein levels;	chr7:23128775	chr7:23129178~23129841:+
SARC	cis	rs11098499	0.863	rs9997631	ENSG00000250950.1	RP11-33B1.3	-3.9	0.000124	0.0368	-0.27	-0.25	Corneal astigmatism;	chr4:119548840	chr4:119456350~119457277:+
SARC	cis	rs11098499	0.863	rs10018280	ENSG00000250950.1	RP11-33B1.3	-3.9	0.000124	0.0368	-0.27	-0.25	Corneal astigmatism;	chr4:119556984	chr4:119456350~119457277:+
SARC	cis	rs11098499	0.863	rs6534141	ENSG00000250950.1	RP11-33B1.3	-3.9	0.000124	0.0368	-0.27	-0.25	Corneal astigmatism;	chr4:119564068	chr4:119456350~119457277:+
SARC	cis	rs11098499	0.863	rs2127823	ENSG00000250950.1	RP11-33B1.3	-3.9	0.000124	0.0368	-0.27	-0.25	Corneal astigmatism;	chr4:119564515	chr4:119456350~119457277:+
SARC	cis	rs2439831	0.85	rs10438303	ENSG00000275601.1	AC011330.13	-3.9	0.000124	0.0368	-0.45	-0.25	Lung cancer in ever smokers;	chr15:43724219	chr15:43642389~43643023:-
SARC	cis	rs2439831	0.85	rs12441127	ENSG00000275601.1	AC011330.13	-3.9	0.000124	0.0368	-0.45	-0.25	Lung cancer in ever smokers;	chr15:43728977	chr15:43642389~43643023:-
SARC	cis	rs7020651	1	rs7020689	ENSG00000234840.1	LINC01239	-3.9	0.000124	0.0368	-0.54	-0.25	Cannabis use (initiation);	chr9:22972986	chr9:22646200~22824213:+
SARC	cis	rs9364687	0.639	rs715020	ENSG00000228692.2	RP5-826L7.1	-3.9	0.000124	0.0368	-0.29	-0.25	Body mass index;	chr6:163565450	chr6:163586583~163588165:-
SARC	cis	rs73081554	0.611	rs13071861	ENSG00000272360.1	RP11-359I18.5	-3.9	0.000124	0.0368	-0.37	-0.25	Rheumatoid arthritis;	chr3:58385605	chr3:58490830~58491291:-
SARC	cis	rs2239547	0.657	rs2071040	ENSG00000242142.1	SERBP1P3	3.9	0.000124	0.0368	0.3	0.25	Schizophrenia;	chr3:52830844	chr3:53064283~53065091:-
SARC	cis	rs4835473	0.932	rs5016160	ENSG00000251600.4	RP11-673E1.1	3.9	0.000124	0.0368	0.24	0.25	Immature fraction of reticulocytes;	chr4:143738305	chr4:143912331~143982454:+
SARC	cis	rs7267979	1	rs2257991	ENSG00000276952.1	RP5-965G21.6	-3.9	0.000124	0.0368	-0.25	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25284915~25285588:-
SARC	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-3.9	0.000124	0.0368	-0.45	-0.25	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
SARC	cis	rs9902453	0.74	rs2254414	ENSG00000264538.5	SUZ12P1	-3.9	0.000124	0.0368	-0.17	-0.25	Coffee consumption (cups per day);	chr17:29734112	chr17:30709299~30790908:+
SARC	cis	rs748404	0.697	rs1814323	ENSG00000275601.1	AC011330.13	3.9	0.000124	0.0369	0.3	0.25	Lung cancer;	chr15:43271039	chr15:43642389~43643023:-
SARC	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	3.9	0.000124	0.0369	0.37	0.25	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
SARC	cis	rs7204230	1	rs67384393	ENSG00000261291.1	RP11-295M3.2	3.9	0.000124	0.0369	0.27	0.25	Fibrinogen;	chr16:53202243	chr16:53168522~53169450:+
SARC	cis	rs72634501	0.622	rs4660416	ENSG00000182109.6	RP11-69E11.4	3.9	0.000124	0.0369	0.28	0.25	HDL cholesterol;	chr1:39113314	chr1:39522280~39546187:-
SARC	cis	rs600231	0.683	rs588298	ENSG00000245532.5	NEAT1	3.9	0.000124	0.0369	0.18	0.25	Bone mineral density;	chr11:65486103	chr11:65422774~65445540:+
SARC	cis	rs240993	0.761	rs6920014	ENSG00000230177.1	RP5-1112D6.4	-3.9	0.000124	0.0369	-0.28	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111385198	chr6:111277932~111278742:+
SARC	cis	rs240993	0.812	rs9487626	ENSG00000230177.1	RP5-1112D6.4	-3.9	0.000124	0.0369	-0.28	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111395665	chr6:111277932~111278742:+
SARC	cis	rs240993	0.715	rs9487627	ENSG00000230177.1	RP5-1112D6.4	-3.9	0.000124	0.0369	-0.28	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111408846	chr6:111277932~111278742:+
SARC	cis	rs240993	0.812	rs9487632	ENSG00000230177.1	RP5-1112D6.4	-3.9	0.000124	0.0369	-0.28	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111417970	chr6:111277932~111278742:+
SARC	cis	rs240993	0.812	rs11153295	ENSG00000230177.1	RP5-1112D6.4	-3.9	0.000124	0.0369	-0.28	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111420164	chr6:111277932~111278742:+
SARC	cis	rs240993	0.812	rs6915753	ENSG00000230177.1	RP5-1112D6.4	-3.9	0.000124	0.0369	-0.28	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111420476	chr6:111277932~111278742:+
SARC	cis	rs240993	0.812	rs4620159	ENSG00000230177.1	RP5-1112D6.4	-3.9	0.000124	0.0369	-0.28	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111423532	chr6:111277932~111278742:+
SARC	cis	rs240993	0.812	rs10214442	ENSG00000230177.1	RP5-1112D6.4	-3.9	0.000124	0.0369	-0.28	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111431857	chr6:111277932~111278742:+
SARC	cis	rs6714788	0.565	rs9308833	ENSG00000230393.1	AC092667.2	3.9	0.000124	0.0369	0.18	0.25	Intelligence (multi-trait analysis);	chr2:100046156	chr2:100104919~100107504:+
SARC	cis	rs7809950	0.817	rs62483725	ENSG00000238832.1	snoU109	-3.9	0.000124	0.0369	-0.3	-0.25	Coronary artery disease;	chr7:107561130	chr7:107603363~107603507:+
SARC	cis	rs59104589	0.57	rs73006397	ENSG00000266621.1	AC104841.1	3.9	0.000124	0.0369	0.31	0.25	Fibrinogen levels;	chr2:241476108	chr2:241245202~241245299:-
SARC	cis	rs783540	0.843	rs9652567	ENSG00000275695.1	UBE2Q2P6	3.9	0.000124	0.0369	0.25	0.25	Schizophrenia;	chr15:82699762	chr15:82445719~82454837:+
SARC	cis	rs11159086	0.729	rs8015872	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74475529	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs10147316	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74475688	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.838	rs10147963	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74476091	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs8021664	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74476592	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs10150696	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74476723	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs1860108	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74478562	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs11845370	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74481587	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs3784035	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74482221	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs10148268	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74484261	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs11850070	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74487575	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs28378078	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74487940	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs9285594	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74489253	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs8016972	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74491833	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs8015894	ENSG00000270000.1	RP3-449M8.9	3.9	0.000124	0.0369	0.36	0.25	Advanced glycation end-product levels;	chr14:74491917	chr14:74471930~74472360:-
SARC	cis	rs13631	0.728	rs7466635	ENSG00000268996.3	MAN1B1-AS1	-3.9	0.000125	0.037	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr9:137085965	chr9:137084946~137086817:-
SARC	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-3.9	0.000125	0.037	-0.36	-0.25	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
SARC	cis	rs28386778	0.863	rs9897229	ENSG00000240280.5	TCAM1P	-3.9	0.000125	0.037	-0.31	-0.25	Prudent dietary pattern;	chr17:63704965	chr17:63849292~63864379:+
SARC	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	3.9	0.000125	0.037	0.33	0.25	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
SARC	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	3.9	0.000125	0.037	0.33	0.25	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
SARC	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	3.9	0.000125	0.037	0.33	0.25	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
SARC	cis	rs3934047	0.904	rs35343985	ENSG00000274376.3	ADAMTS7P1	-3.9	0.000125	0.037	-0.28	-0.25	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81722852	chr15:82298553~82334609:+
SARC	cis	rs2239547	0.618	rs4687663	ENSG00000242142.1	SERBP1P3	3.9	0.000125	0.037	0.29	0.25	Schizophrenia;	chr3:52836602	chr3:53064283~53065091:-
SARC	cis	rs763121	0.853	rs5757193	ENSG00000273076.1	RP3-508I15.22	-3.9	0.000125	0.037	-0.29	-0.25	Menopause (age at onset);	chr22:38638862	chr22:38743495~38743910:+
SARC	cis	rs2378870	0.589	rs7211829	ENSG00000266934.1	RP11-332H18.3	-3.9	0.000125	0.037	-0.18	-0.25	Height;	chr17:61559558	chr17:61382785~61384680:+
SARC	cis	rs10028773	0.515	rs9994651	ENSG00000249244.1	RP11-548H18.2	3.9	0.000125	0.037	0.24	0.25	Educational attainment;	chr4:119666648	chr4:119391831~119395335:-
SARC	cis	rs7537765	1	rs17037427	ENSG00000242349.4	NPPA-AS1	-3.9	0.000125	0.037	-0.33	-0.25	QRS complex (12-leadsum);	chr1:11813359	chr1:11841017~11848079:+
SARC	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-3.9	0.000125	0.037	-0.28	-0.25	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
SARC	cis	rs10991814	0.546	rs10991837	ENSG00000233081.1	RP11-440G5.2	3.9	0.000125	0.0371	0.38	0.25	Neutrophil percentage of granulocytes;	chr9:91237559	chr9:91426238~91427144:+
SARC	cis	rs4906332	1	rs3783398	ENSG00000244691.1	RPL10AP1	3.9	0.000125	0.0371	0.28	0.25	Coronary artery disease;	chr14:103483041	chr14:103412119~103412761:-
SARC	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-3.9	0.000125	0.0371	-0.29	-0.25	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
SARC	cis	rs448720	0.508	rs396174	ENSG00000259410.4	RP11-34F13.3	-3.9	0.000125	0.0371	-0.27	-0.25	Cognitive performance;	chr15:67928740	chr15:67832725~67873866:+
SARC	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	3.9	0.000125	0.0371	0.44	0.25	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
SARC	cis	rs2307449	0.929	rs35617922	ENSG00000261441.1	RP11-217B1.2	3.9	0.000125	0.0371	0.31	0.25	Menopause (age at onset);	chr15:89288993	chr15:89335053~89336161:+
SARC	cis	rs73219805	1	rs17310286	ENSG00000228451.3	SDAD1P1	3.9	0.000125	0.0371	0.33	0.25	Schizophrenia;	chr8:26411516	chr8:26379259~26382953:-
SARC	cis	rs6504108	0.512	rs12950225	ENSG00000264920.1	RP11-6N17.4	3.9	0.000125	0.0372	0.25	0.25	Body mass index;	chr17:48067838	chr17:47891255~47895812:-
SARC	cis	rs7520050	0.778	rs3014216	ENSG00000280836.1	AL355480.1	-3.9	0.000125	0.0372	-0.24	-0.25	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45581219~45581321:-
SARC	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	3.9	0.000126	0.0372	0.44	0.25	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
SARC	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	3.9	0.000126	0.0372	0.44	0.25	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
SARC	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	3.9	0.000126	0.0372	0.44	0.25	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
SARC	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-3.9	0.000126	0.0372	-0.33	-0.25	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
SARC	cis	rs13113518	0.812	rs12505880	ENSG00000273257.1	RP11-177J6.1	3.9	0.000126	0.0372	0.31	0.25	Height;	chr4:55440988	chr4:55387949~55388271:+
SARC	cis	rs67478160	0.609	rs6576003	ENSG00000269940.1	RP11-73M18.7	3.9	0.000126	0.0372	0.21	0.25	Schizophrenia;	chr14:103824993	chr14:103694560~103695170:+
SARC	cis	rs4835473	0.932	rs13133444	ENSG00000251600.4	RP11-673E1.1	3.9	0.000126	0.0372	0.24	0.25	Immature fraction of reticulocytes;	chr4:143738191	chr4:143912331~143982454:+
SARC	cis	rs9926296	0.528	rs4785721	ENSG00000260279.2	AC137932.5	3.9	0.000126	0.0372	0.24	0.25	Vitiligo;	chr16:89773589	chr16:89297508~89298317:+
SARC	cis	rs1062177	1	rs973529	ENSG00000254226.4	CTB-12O2.1	3.9	0.000126	0.0372	0.34	0.25	Preschool internalizing problems;	chr5:151808597	chr5:151949571~152270448:+
SARC	cis	rs600231	0.665	rs1621277	ENSG00000245532.5	NEAT1	-3.9	0.000126	0.0372	-0.19	-0.25	Bone mineral density;	chr11:65454483	chr11:65422774~65445540:+
SARC	cis	rs9902453	0.904	rs12952179	ENSG00000264538.5	SUZ12P1	-3.9	0.000126	0.0372	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30085669	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs7213076	ENSG00000264538.5	SUZ12P1	-3.9	0.000126	0.0372	-0.18	-0.25	Coffee consumption (cups per day);	chr17:30092410	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs4461132	ENSG00000264538.5	SUZ12P1	3.9	0.000126	0.0372	0.18	0.25	Coffee consumption (cups per day);	chr17:30096412	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.935	rs9905950	ENSG00000264538.5	SUZ12P1	3.9	0.000126	0.0372	0.18	0.25	Coffee consumption (cups per day);	chr17:30104180	chr17:30709299~30790908:+
SARC	cis	rs9596219	1	rs2066587	ENSG00000274270.1	RP11-34F20.7	-3.9	0.000126	0.0372	-0.32	-0.25	Height;	chr13:50111818	chr13:50125816~50128463:+
SARC	cis	rs7131987	0.622	rs7294598	ENSG00000275476.1	RP11-996F15.4	3.9	0.000126	0.0372	0.3	0.25	QT interval;	chr12:29379056	chr12:29277397~29277882:-
SARC	cis	rs7267979	0.789	rs9927	ENSG00000276952.1	RP5-965G21.6	3.9	0.000126	0.0372	0.24	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:25284915~25285588:-
SARC	cis	rs1376877	0.934	rs62183910	ENSG00000213925.3	NPM1P33	3.9	0.000126	0.0373	0.23	0.25	Subclinical atherosclerosis traits (other);	chr2:203287412	chr2:203772631~203773502:-
SARC	cis	rs7614311	1	rs7614311	ENSG00000271843.1	RP11-245J9.5	-3.9	0.000126	0.0373	-0.33	-0.25	Lung function (FVC);Lung function (FEV1);	chr3:63827978	chr3:64008082~64008692:-
SARC	cis	rs2284219	0.565	rs2284217	ENSG00000226874.1	AC005154.8	-3.9	0.000126	0.0373	-0.32	-0.25	Type 2 diabetes;	chr7:30673992	chr7:30544053~30544431:+
SARC	cis	rs1376877	0.934	rs62183874	ENSG00000213925.3	NPM1P33	3.9	0.000126	0.0373	0.23	0.25	Subclinical atherosclerosis traits (other);	chr2:203241441	chr2:203772631~203773502:-
SARC	cis	rs1376877	0.934	rs56317341	ENSG00000213925.3	NPM1P33	3.9	0.000126	0.0373	0.23	0.25	Subclinical atherosclerosis traits (other);	chr2:203246025	chr2:203772631~203773502:-
SARC	cis	rs1376877	0.934	rs11693128	ENSG00000213925.3	NPM1P33	3.9	0.000126	0.0373	0.23	0.25	Subclinical atherosclerosis traits (other);	chr2:203251178	chr2:203772631~203773502:-
SARC	cis	rs9928842	0.722	rs1035540	ENSG00000280152.1	RP11-331F4.5	3.9	0.000126	0.0373	0.3	0.25	Alcoholic chronic pancreatitis;	chr16:75244897	chr16:75245994~75250077:-
SARC	cis	rs5742933	0.557	rs6756571	ENSG00000273240.1	RP11-455J20.3	3.9	0.000126	0.0373	0.3	0.25	Ferritin levels;	chr2:189640971	chr2:189763859~189764456:-
SARC	cis	rs72634501	0.716	rs4660165	ENSG00000182109.6	RP11-69E11.4	-3.9	0.000126	0.0373	-0.28	-0.25	HDL cholesterol;	chr1:39112860	chr1:39522280~39546187:-
SARC	cis	rs7615952	0.599	rs6438953	ENSG00000241288.6	RP11-379B18.5	-3.9	0.000126	0.0373	-0.28	-0.25	Blood pressure (smoking interaction);	chr3:126006108	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.599	rs1044215	ENSG00000241288.6	RP11-379B18.5	-3.9	0.000126	0.0373	-0.28	-0.25	Blood pressure (smoking interaction);	chr3:126006716	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.599	rs6438955	ENSG00000241288.6	RP11-379B18.5	-3.9	0.000126	0.0373	-0.28	-0.25	Blood pressure (smoking interaction);	chr3:126011490	chr3:125827238~125916384:-
SARC	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-3.9	0.000126	0.0373	-0.22	-0.25	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
SARC	cis	rs7267979	0.903	rs2474766	ENSG00000274414.1	RP5-965G21.4	-3.9	0.000126	0.0373	-0.25	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25239007~25245229:-
SARC	cis	rs7267979	0.903	rs2474769	ENSG00000274414.1	RP5-965G21.4	-3.9	0.000126	0.0373	-0.25	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25239007~25245229:-
SARC	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-3.9	0.000126	0.0373	-0.35	-0.25	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
SARC	cis	rs863345	0.604	rs11265021	ENSG00000231666.4	RP11-404O13.1	3.9	0.000126	0.0373	0.26	0.25	Pneumococcal bacteremia;	chr1:158542020	chr1:158132044~158140639:-
SARC	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-3.9	0.000126	0.0373	-0.36	-0.25	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
SARC	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-3.9	0.000126	0.0373	-0.36	-0.25	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-3.9	0.000126	0.0373	-0.36	-0.25	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs160639	ENSG00000273142.1	RP11-458F8.4	-3.9	0.000126	0.0373	-0.36	-0.25	Diabetic kidney disease;	chr7:66115000	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-3.9	0.000126	0.0373	-0.36	-0.25	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-3.9	0.000126	0.0373	-0.36	-0.25	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-3.9	0.000126	0.0373	-0.36	-0.25	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
SARC	cis	rs6570726	1	rs6570699	ENSG00000270638.1	RP3-466P17.1	3.9	0.000126	0.0373	0.2	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145599596	chr6:145735570~145737218:+
SARC	cis	rs6570726	1	rs1935615	ENSG00000270638.1	RP3-466P17.1	3.9	0.000126	0.0373	0.2	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145599981	chr6:145735570~145737218:+
SARC	cis	rs3824347	0.872	rs10869465	ENSG00000203321.2	C9orf41-AS1	-3.9	0.000126	0.0374	-0.28	-0.25	Urinary magnesium-to-creatinine ratio;	chr9:74984767	chr9:74952968~74996293:+
SARC	cis	rs2243480	1	rs13310597	ENSG00000164669.11	INTS4P1	3.9	0.000126	0.0374	0.44	0.25	Diabetic kidney disease;	chr7:66133553	chr7:65141225~65234216:+
SARC	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	3.9	0.000126	0.0374	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
SARC	cis	rs202072	0.769	rs495895	ENSG00000215022.6	RP1-257A7.4	-3.9	0.000126	0.0374	-0.33	-0.25	HIV-1 viral setpoint;	chr6:13277683	chr6:13264861~13295586:-
SARC	cis	rs875971	0.706	rs1643374	ENSG00000224316.1	RP11-479O9.2	3.9	0.000126	0.0374	0.23	0.25	Aortic root size;	chr7:66407695	chr7:65773620~65802067:+
SARC	cis	rs7267979	0.816	rs6076358	ENSG00000125804.12	FAM182A	3.9	0.000127	0.0374	0.28	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:26054655~26086917:+
SARC	cis	rs1538970	0.781	rs12049503	ENSG00000280836.1	AL355480.1	-3.9	0.000127	0.0374	-0.28	-0.25	Platelet count;	chr1:45555884	chr1:45581219~45581321:-
SARC	cis	rs910316	1	rs175443	ENSG00000279594.1	RP11-950C14.10	-3.9	0.000127	0.0374	-0.27	-0.25	Height;	chr14:75135260	chr14:75011269~75012851:-
SARC	cis	rs7520050	0.771	rs4660882	ENSG00000280836.1	AL355480.1	-3.9	0.000127	0.0374	-0.23	-0.25	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45581219~45581321:-
SARC	cis	rs8098244	0.603	rs1711455	ENSG00000265752.2	RP11-403A21.1	3.9	0.000127	0.0375	0.23	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23695207	chr18:23957754~23982556:-
SARC	cis	rs2235642	0.507	rs2235643	ENSG00000280231.1	LA16c-380F5.3	3.9	0.000127	0.0375	0.34	0.25	Coronary artery disease;	chr16:1535114	chr16:1553655~1554130:-
SARC	cis	rs858239	1	rs199357	ENSG00000226816.2	AC005082.12	-3.9	0.000127	0.0375	-0.31	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23206013~23208045:+
SARC	cis	rs8028182	0.636	rs8034317	ENSG00000260206.1	CTD-2026K11.2	-3.9	0.000127	0.0375	-0.29	-0.25	Sudden cardiac arrest;	chr15:75472002	chr15:75636139~75639239:+
SARC	cis	rs7195386	0.869	rs7206159	ENSG00000274925.1	CTD-2547G23.4	-3.9	0.000127	0.0375	-0.15	-0.25	Obesity-related traits;Body mass index;	chr16:24551137	chr16:25257952~25261066:+
SARC	cis	rs7976269	0.559	rs10771471	ENSG00000257176.2	RP11-996F15.2	-3.9	0.000127	0.0375	-0.27	-0.25	Male-pattern baldness;	chr12:29050894	chr12:29280418~29317848:-
SARC	cis	rs2731006	0.591	rs11181692	ENSG00000257114.2	RP11-25I15.3	3.9	0.000127	0.0375	0.38	0.25	Panic disorder;	chr12:42812202	chr12:42692216~42717119:+
SARC	cis	rs7811142	0.83	rs11771936	ENSG00000078319.8	PMS2P1	-3.9	0.000127	0.0375	-0.37	-0.25	Platelet count;	chr7:100345660	chr7:100320992~100341908:-
SARC	cis	rs7811142	0.779	rs77370288	ENSG00000078319.8	PMS2P1	-3.9	0.000127	0.0375	-0.37	-0.25	Platelet count;	chr7:100350274	chr7:100320992~100341908:-
SARC	cis	rs7208859	0.623	rs8081299	ENSG00000264538.5	SUZ12P1	-3.9	0.000127	0.0375	-0.26	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs8068645	ENSG00000264538.5	SUZ12P1	-3.9	0.000127	0.0375	-0.26	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30709299~30790908:+
SARC	cis	rs853679	1	rs1778511	ENSG00000216901.1	AL022393.7	-3.9	0.000127	0.0375	-0.44	-0.25	Depression;	chr6:28261633	chr6:28176188~28176674:+
SARC	cis	rs2980439	0.87	rs2945230	ENSG00000253981.4	ALG1L13P	3.9	0.000127	0.0375	0.25	0.25	Neuroticism;	chr8:8252414	chr8:8236003~8244667:-
SARC	cis	rs240993	0.909	rs11153279	ENSG00000230177.1	RP5-1112D6.4	3.9	0.000127	0.0375	0.28	0.25	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111277932~111278742:+
SARC	cis	rs62025270	0.688	rs56388190	ENSG00000202081.1	RNU6-1280P	-3.9	0.000127	0.0375	-0.34	-0.25	Idiopathic pulmonary fibrosis;	chr15:85771665	chr15:85651522~85651628:-
SARC	cis	rs4835265	0.929	rs4293803	ENSG00000272727.1	RP11-142A22.4	3.9	0.000127	0.0376	0.36	0.25	Gamma glutamyl transpeptidase;	chr4:145872475	chr4:145335263~145340421:-
SARC	cis	rs4835265	0.929	rs4547811	ENSG00000272727.1	RP11-142A22.4	3.9	0.000127	0.0376	0.36	0.25	Gamma glutamyl transpeptidase;	chr4:145873469	chr4:145335263~145340421:-
SARC	cis	rs6570726	0.902	rs4895678	ENSG00000270638.1	RP3-466P17.1	3.9	0.000127	0.0376	0.2	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145614374	chr6:145735570~145737218:+
SARC	cis	rs6657613	0.815	rs735258	ENSG00000186715.9	MST1L	-3.9	0.000127	0.0376	-0.25	-0.25	Hip circumference adjusted for BMI;	chr1:17014651	chr1:16754910~16770237:-
SARC	cis	rs9438901	0.614	rs2375278	ENSG00000224183.1	SDHDP6	3.9	0.000127	0.0376	0.4	0.25	Red cell distribution width;	chr1:25202547	chr1:25294164~25294643:-
SARC	cis	rs11886999	0.767	rs72825877	ENSG00000237510.6	AC008268.2	-3.9	0.000127	0.0376	-0.38	-0.25	Cardiac Troponin-T levels;	chr2:96255155	chr2:95789654~95800166:+
SARC	cis	rs2836974	0.583	rs2735307	ENSG00000255568.3	BRWD1-AS2	3.9	0.000127	0.0376	0.22	0.25	Cognitive function;	chr21:39341432	chr21:39313935~39314962:+
SARC	cis	rs853679	0.517	rs4713135	ENSG00000216901.1	AL022393.7	3.9	0.000127	0.0377	0.35	0.25	Depression;	chr6:28071808	chr6:28176188~28176674:+
SARC	cis	rs72627509	0.638	rs7658601	ENSG00000269949.1	RP11-738E22.3	3.9	0.000128	0.0377	0.36	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915181	chr4:56960927~56961373:-
SARC	cis	rs8028182	0.666	rs4886708	ENSG00000260206.1	CTD-2026K11.2	-3.9	0.000128	0.0377	-0.3	-0.25	Sudden cardiac arrest;	chr15:75470267	chr15:75636139~75639239:+
SARC	cis	rs1707322	1	rs10890350	ENSG00000281133.1	AL355480.3	-3.9	0.000128	0.0377	-0.28	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45580892~45580996:-
SARC	cis	rs853679	0.628	rs9368560	ENSG00000216901.1	AL022393.7	3.9	0.000128	0.0377	0.37	0.25	Depression;	chr6:28192182	chr6:28176188~28176674:+
SARC	cis	rs42490	0.7	rs40459	ENSG00000251136.7	RP11-37B2.1	3.9	0.000128	0.0377	0.28	0.25	Leprosy;	chr8:89833998	chr8:89609409~89757727:-
SARC	cis	rs10986311	0.681	rs10986291	ENSG00000235204.1	RP11-121A14.2	3.9	0.000128	0.0377	0.3	0.25	Vitiligo;	chr9:124253992	chr9:124259250~124261156:-
SARC	cis	rs9902453	0.726	rs3115092	ENSG00000264538.5	SUZ12P1	3.9	0.000128	0.0377	0.17	0.25	Coffee consumption (cups per day);	chr17:29709332	chr17:30709299~30790908:+
SARC	cis	rs12611334	1	rs12611334	ENSG00000226025.8	LGALS17A	-3.9	0.000128	0.0377	-0.24	-0.25	Schizophrenia;	chr19:39738769	chr19:39679374~39686373:+
SARC	cis	rs7976269	0.515	rs11049999	ENSG00000257176.2	RP11-996F15.2	-3.9	0.000128	0.0377	-0.27	-0.25	Male-pattern baldness;	chr12:29042854	chr12:29280418~29317848:-
SARC	cis	rs394563	0.967	rs369643	ENSG00000231760.4	RP11-350J20.5	3.9	0.000128	0.0377	0.32	0.25	Dupuytren's disease;	chr6:149478662	chr6:149796151~149826294:-
SARC	cis	rs72627509	1	rs57265257	ENSG00000269949.1	RP11-738E22.3	3.9	0.000128	0.0377	0.38	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56973114	chr4:56960927~56961373:-
SARC	cis	rs7688540	0.739	rs11729659	ENSG00000275426.1	CH17-262A2.1	3.9	0.000128	0.0378	0.35	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243495	chr4:149738~150317:+
SARC	cis	rs11694172	1	rs72928921	ENSG00000273456.1	RP11-686O6.2	3.9	0.000128	0.0378	0.21	0.25	Cholesterol, total;	chr2:202685302	chr2:202374932~202375604:-
SARC	cis	rs7267979	0.868	rs6138546	ENSG00000274414.1	RP5-965G21.4	-3.9	0.000128	0.0378	-0.25	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25239007~25245229:-
SARC	cis	rs34792	0.688	rs153785	ENSG00000207425.1	Y_RNA	3.9	0.000128	0.0378	0.32	0.25	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499435	chr16:14915457~14915556:-
SARC	cis	rs860818	1	rs858312	ENSG00000226816.2	AC005082.12	3.9	0.000128	0.0378	0.7	0.25	Initial pursuit acceleration;	chr7:23166015	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858311	ENSG00000226816.2	AC005082.12	3.9	0.000128	0.0378	0.7	0.25	Initial pursuit acceleration;	chr7:23166526	chr7:23206013~23208045:+
SARC	cis	rs6445975	0.666	rs4613423	ENSG00000272360.1	RP11-359I18.5	-3.9	0.000128	0.0378	-0.33	-0.25	Systemic lupus erythematosus;	chr3:58355841	chr3:58490830~58491291:-
SARC	cis	rs6445975	0.666	rs57621305	ENSG00000272360.1	RP11-359I18.5	-3.9	0.000128	0.0378	-0.33	-0.25	Systemic lupus erythematosus;	chr3:58361017	chr3:58490830~58491291:-
SARC	cis	rs6445975	0.666	rs4681683	ENSG00000272360.1	RP11-359I18.5	-3.9	0.000128	0.0378	-0.33	-0.25	Systemic lupus erythematosus;	chr3:58361958	chr3:58490830~58491291:-
SARC	cis	rs2562456	0.52	rs279793	ENSG00000268081.1	RP11-678G14.2	3.89	0.000128	0.0379	0.4	0.25	Pain;	chr19:21272972	chr19:21554640~21569237:-
SARC	cis	rs597539	0.652	rs1249474	ENSG00000250508.1	RP11-757G1.6	-3.89	0.000128	0.0379	-0.3	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68870664~68874542:+
SARC	cis	rs1707322	1	rs1707317	ENSG00000281133.1	AL355480.3	3.89	0.000129	0.0379	0.28	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45580892~45580996:-
SARC	cis	rs11123170	0.529	rs112692022	ENSG00000274877.1	RP11-65I12.1	-3.89	0.000129	0.0379	-0.32	-0.25	Renal function-related traits (BUN);	chr2:113212605	chr2:113237595~113240825:+
SARC	cis	rs9739682	0.6	rs10877788	ENSG00000139239.7	RPL14P1	-3.89	0.000129	0.038	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62088050	chr12:62965325~62965969:+
SARC	cis	rs7976269	0.583	rs7955393	ENSG00000257176.2	RP11-996F15.2	-3.89	0.000129	0.038	-0.27	-0.25	Male-pattern baldness;	chr12:29065773	chr12:29280418~29317848:-
SARC	cis	rs42490	0.934	rs218947	ENSG00000251136.7	RP11-37B2.1	3.89	0.000129	0.038	0.28	0.25	Leprosy;	chr8:89705148	chr8:89609409~89757727:-
SARC	cis	rs59104589	0.617	rs6672	ENSG00000266621.1	AC104841.1	3.89	0.000129	0.038	0.33	0.25	Fibrinogen levels;	chr2:241353606	chr2:241245202~241245299:-
SARC	cis	rs9907295	0.901	rs4796129	ENSG00000270240.2	AC015849.2	3.89	0.000129	0.038	0.48	0.25	Fibroblast growth factor basic levels;	chr17:35901941	chr17:35868967~35885863:+
SARC	cis	rs9326246	0.643	rs651821	ENSG00000254851.1	RP11-109L13.1	-3.89	0.000129	0.038	-0.49	-0.25	Coronary artery disease;	chr11:116791863	chr11:117135528~117138582:+
SARC	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	3.89	0.000129	0.038	0.31	0.25	Height;	chr6:109447092	chr6:109382795~109383666:+
SARC	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-3.89	0.000129	0.038	-0.36	-0.25	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-3.89	0.000129	0.038	-0.36	-0.25	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
SARC	cis	rs801193	0.742	rs9969300	ENSG00000236529.1	RP13-254B10.1	-3.89	0.000129	0.038	-0.26	-0.25	Aortic root size;	chr7:66316659	chr7:65840212~65840596:+
SARC	cis	rs880496	0.614	rs58715712	ENSG00000237101.1	RP11-365O16.6	-3.89	0.000129	0.038	-0.28	-0.25	Cancer;	chr1:224646919	chr1:224219613~224228043:+
SARC	cis	rs880496	0.614	rs59962884	ENSG00000237101.1	RP11-365O16.6	-3.89	0.000129	0.038	-0.28	-0.25	Cancer;	chr1:224647637	chr1:224219613~224228043:+
SARC	cis	rs11651000	0.857	rs56172120	ENSG00000239291.1	RP5-867C24.1	3.89	0.000129	0.038	0.32	0.25	IgG glycosylation;	chr17:47747538	chr17:47159191~47159993:-
SARC	cis	rs2408955	0.522	rs6580650	ENSG00000240399.1	RP1-228P16.1	-3.89	0.000129	0.0381	-0.29	-0.25	Glycated hemoglobin levels;	chr12:48024773	chr12:48054813~48055591:-
SARC	cis	rs7615952	0.512	rs2979336	ENSG00000248787.1	RP11-666A20.4	-3.89	0.000129	0.0381	-0.34	-0.25	Blood pressure (smoking interaction);	chr3:125638626	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.512	rs2979351	ENSG00000248787.1	RP11-666A20.4	-3.89	0.000129	0.0381	-0.34	-0.25	Blood pressure (smoking interaction);	chr3:125644755	chr3:125908005~125910272:-
SARC	cis	rs1062177	0.901	rs1549622	ENSG00000254226.4	CTB-12O2.1	3.89	0.000129	0.0381	0.33	0.25	Preschool internalizing problems;	chr5:151886488	chr5:151949571~152270448:+
SARC	cis	rs12049351	0.665	rs970103	ENSG00000229367.1	HMGN2P19	3.89	0.000129	0.0381	0.22	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229434388	chr1:229570532~229570796:+
SARC	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	3.89	0.000129	0.0381	0.38	0.25	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
SARC	cis	rs394563	0.726	rs366905	ENSG00000231760.4	RP11-350J20.5	3.89	0.000129	0.0381	0.31	0.25	Dupuytren's disease;	chr6:149413961	chr6:149796151~149826294:-
SARC	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	3.89	0.000129	0.0381	0.25	0.25	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
SARC	cis	rs7977237	0.726	rs10880530	ENSG00000240759.1	RP11-25I15.1	3.89	0.000129	0.0381	0.32	0.25	Intraocular pressure;	chr12:43568182	chr12:42678873~42679124:-
SARC	cis	rs12289961	0.634	rs11229378	ENSG00000280010.1	AP001350.4	3.89	0.000129	0.0381	0.39	0.25	Lymphoma;	chr11:58364344	chr11:58627435~58628528:+
SARC	cis	rs12289961	0.634	rs77183714	ENSG00000280010.1	AP001350.4	3.89	0.000129	0.0381	0.39	0.25	Lymphoma;	chr11:58364460	chr11:58627435~58628528:+
SARC	cis	rs2439831	0.681	rs28578454	ENSG00000205771.5	CATSPER2P1	-3.89	0.000129	0.0381	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43310834	chr15:43726918~43747094:-
SARC	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-3.89	0.000129	0.0381	-0.22	-0.25	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
SARC	cis	rs453301	0.686	rs28665409	ENSG00000253893.2	FAM85B	3.89	0.00013	0.0381	0.23	0.25	Joint mobility (Beighton score);	chr8:9011767	chr8:8167819~8226614:-
SARC	cis	rs875971	0.862	rs1167390	ENSG00000232559.3	GS1-124K5.12	-3.89	0.00013	0.0381	-0.28	-0.25	Aortic root size;	chr7:66110906	chr7:66554588~66576923:-
SARC	cis	rs875971	0.862	rs35034167	ENSG00000232559.3	GS1-124K5.12	-3.89	0.00013	0.0381	-0.28	-0.25	Aortic root size;	chr7:66115179	chr7:66554588~66576923:-
SARC	cis	rs2762353	0.562	rs1165206	ENSG00000272810.1	U91328.22	-3.89	0.00013	0.0382	-0.24	-0.25	Blood metabolite levels;	chr6:25867338	chr6:26013241~26013757:+
SARC	cis	rs11064768	0.722	rs11064767	ENSG00000255857.4	PXN-AS1	-3.89	0.00013	0.0382	-0.37	-0.25	Schizophrenia;	chr12:119380614	chr12:120201291~120213138:+
SARC	cis	rs8044868	1	rs8052408	ENSG00000261513.1	RP11-432I5.8	-3.89	0.00013	0.0382	-0.29	-0.25	Body mass index (change over time) in cancer;Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;	chr16:72124178	chr16:71723180~71724230:+
SARC	cis	rs4835473	0.897	rs55635947	ENSG00000251600.4	RP11-673E1.1	-3.89	0.00013	0.0382	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143736218	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs56334914	ENSG00000251600.4	RP11-673E1.1	-3.89	0.00013	0.0382	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143736291	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs56324738	ENSG00000251600.4	RP11-673E1.1	-3.89	0.00013	0.0382	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143736297	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs55862664	ENSG00000251600.4	RP11-673E1.1	-3.89	0.00013	0.0382	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143736311	chr4:143912331~143982454:+
SARC	cis	rs6969780	0.915	rs11983200	ENSG00000233429.8	HOTAIRM1	3.89	0.00013	0.0382	0.38	0.25	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27146977	chr7:27095647~27100265:+
SARC	cis	rs13126694	0.71	rs4631100	ENSG00000248429.4	RP11-597D13.9	3.89	0.00013	0.0382	0.25	0.25	Blood osmolality (transformed sodium);	chr4:157991162	chr4:158170752~158202877:+
SARC	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-3.89	0.00013	0.0382	-0.35	-0.25	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
SARC	cis	rs4950322	0.58	rs7515160	ENSG00000278811.3	LINC00624	3.89	0.00013	0.0382	0.26	0.25	Protein quantitative trait loci;	chr1:147120714	chr1:147258885~147517875:-
SARC	cis	rs7267979	0.565	rs4815432	ENSG00000125804.12	FAM182A	3.89	0.00013	0.0382	0.3	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:26054655~26086917:+
SARC	cis	rs7246657	0.941	rs12982333	ENSG00000226686.6	LINC01535	-3.89	0.00013	0.0382	-0.36	-0.25	Coronary artery calcification;	chr19:37303822	chr19:37251912~37265535:+
SARC	cis	rs7246657	1	rs10426297	ENSG00000226686.6	LINC01535	-3.89	0.00013	0.0382	-0.36	-0.25	Coronary artery calcification;	chr19:37307471	chr19:37251912~37265535:+
SARC	cis	rs7246657	1	rs1823061	ENSG00000226686.6	LINC01535	-3.89	0.00013	0.0382	-0.36	-0.25	Coronary artery calcification;	chr19:37309724	chr19:37251912~37265535:+
SARC	cis	rs42490	0.51	rs4961157	ENSG00000251136.7	RP11-37B2.1	-3.89	0.00013	0.0382	-0.27	-0.25	Leprosy;	chr8:89684800	chr8:89609409~89757727:-
SARC	cis	rs4950322	0.542	rs56080828	ENSG00000278811.3	LINC00624	3.89	0.00013	0.0382	0.26	0.25	Protein quantitative trait loci;	chr1:147183447	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.542	rs28381210	ENSG00000278811.3	LINC00624	3.89	0.00013	0.0382	0.26	0.25	Protein quantitative trait loci;	chr1:147201925	chr1:147258885~147517875:-
SARC	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	3.89	0.00013	0.0382	0.26	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
SARC	cis	rs240993	0.761	rs462832	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.00013	0.0382	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111365088	chr6:111277932~111278742:+
SARC	cis	rs240993	0.812	rs455650	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.00013	0.0382	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111370320	chr6:111277932~111278742:+
SARC	cis	rs240993	0.812	rs455645	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.00013	0.0382	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111373870	chr6:111277932~111278742:+
SARC	cis	rs240993	0.812	rs462779	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.00013	0.0382	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111374684	chr6:111277932~111278742:+
SARC	cis	rs240993	0.812	rs461646	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.00013	0.0382	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111375054	chr6:111277932~111278742:+
SARC	cis	rs2439831	0.85	rs7181039	ENSG00000275601.1	AC011330.13	-3.89	0.00013	0.0383	-0.44	-0.25	Lung cancer in ever smokers;	chr15:43886914	chr15:43642389~43643023:-
SARC	cis	rs1707322	1	rs785490	ENSG00000281133.1	AL355480.3	3.89	0.00013	0.0383	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs785493	ENSG00000281133.1	AL355480.3	3.89	0.00013	0.0383	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.964	rs785496	ENSG00000281133.1	AL355480.3	3.89	0.00013	0.0383	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs785497	ENSG00000281133.1	AL355480.3	3.89	0.00013	0.0383	0.29	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45580892~45580996:-
SARC	cis	rs12980942	0.81	rs8103839	ENSG00000206674.1	RNU6-945P	-3.89	0.00013	0.0383	-0.39	-0.25	Coronary artery disease;	chr19:41275588	chr19:40299478~40299584:-
SARC	cis	rs853679	0.666	rs200956	ENSG00000216901.1	AL022393.7	3.89	0.00013	0.0383	0.4	0.25	Depression;	chr6:27871968	chr6:28176188~28176674:+
SARC	cis	rs61160187	0.698	rs11951503	ENSG00000272308.1	RP11-231G3.1	-3.89	0.00013	0.0383	-0.21	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60623013	chr5:60866457~60866935:-
SARC	cis	rs13113518	0.812	rs1522114	ENSG00000273257.1	RP11-177J6.1	3.89	0.00013	0.0383	0.31	0.25	Height;	chr4:55489895	chr4:55387949~55388271:+
SARC	cis	rs783540	0.867	rs11855735	ENSG00000275695.1	UBE2Q2P6	3.89	0.00013	0.0383	0.24	0.25	Schizophrenia;	chr15:82627794	chr15:82445719~82454837:+
SARC	cis	rs858239	0.712	rs200717	ENSG00000226816.2	AC005082.12	3.89	0.00013	0.0383	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23206013~23208045:+
SARC	cis	rs7615952	0.599	rs7652883	ENSG00000248787.1	RP11-666A20.4	-3.89	0.00013	0.0383	-0.35	-0.25	Blood pressure (smoking interaction);	chr3:125989134	chr3:125908005~125910272:-
SARC	cis	rs2072438	0.503	rs1323474	ENSG00000226752.6	PSMD5-AS1	-3.89	0.00013	0.0383	-0.28	-0.25	Rheumatoid arthritis;	chr9:121090581	chr9:120824828~120854385:+
SARC	cis	rs2307449	0.929	rs12898357	ENSG00000261441.1	RP11-217B1.2	3.89	0.00013	0.0383	0.31	0.25	Menopause (age at onset);	chr15:89258160	chr15:89335053~89336161:+
SARC	cis	rs150992	0.603	rs246251	ENSG00000248489.1	CTD-2007H13.3	3.89	0.00013	0.0383	0.28	0.25	Body mass index;	chr5:98942362	chr5:98929171~98995013:+
SARC	cis	rs2179367	0.959	rs514839	ENSG00000216906.2	RP11-350J20.9	3.89	0.00013	0.0383	0.22	0.25	Dupuytren's disease;	chr6:149327304	chr6:149904243~149906418:+
SARC	cis	rs6010044	0.609	rs8142140	ENSG00000184319.14	RPL23AP82	-3.89	0.00013	0.0383	-0.32	-0.25	Fibrinogen levels;Fibrinogen;	chr22:50653486	chr22:50756948~50801309:+
SARC	cis	rs367615	0.959	rs2201016	ENSG00000249476.1	CTD-2587M2.1	3.89	0.000131	0.0383	0.32	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109611586	chr5:109237120~109326369:-
SARC	cis	rs2762353	0.718	rs1165205	ENSG00000272462.2	U91328.19	3.89	0.000131	0.0384	0.24	0.25	Blood metabolite levels;	chr6:25870314	chr6:25992662~26001775:+
SARC	cis	rs2280018	0.526	rs2966129	ENSG00000188599.16	NPIPP1	3.89	0.000131	0.0384	0.24	0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15104312~15123498:-
SARC	cis	rs28386778	0.897	rs2584601	ENSG00000240280.5	TCAM1P	-3.89	0.000131	0.0384	-0.31	-0.25	Prudent dietary pattern;	chr17:63863617	chr17:63849292~63864379:+
SARC	cis	rs13113518	0.729	rs12641881	ENSG00000249700.7	SRD5A3-AS1	3.89	0.000131	0.0384	0.32	0.25	Height;	chr4:55401306	chr4:55363971~55395847:-
SARC	cis	rs5751614	0.557	rs5759666	ENSG00000230701.2	FBXW4P1	3.89	0.000131	0.0384	0.32	0.25	Height;	chr22:23260155	chr22:23262767~23265005:+
SARC	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-3.89	0.000131	0.0384	-0.23	-0.25	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
SARC	cis	rs76693355	0.512	rs7129944	ENSG00000232460.4	BMPR1APS2	3.89	0.000131	0.0384	0.31	0.25	Intraocular pressure;	chr11:120428998	chr11:121361854~121362865:-
SARC	cis	rs76693355	0.512	rs11217866	ENSG00000232460.4	BMPR1APS2	3.89	0.000131	0.0384	0.31	0.25	Intraocular pressure;	chr11:120430095	chr11:121361854~121362865:-
SARC	cis	rs7772486	0.79	rs2249147	ENSG00000235652.6	RP11-545I5.3	3.89	0.000131	0.0384	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145799409~145886585:+
SARC	cis	rs7560272	0.723	rs6722867	ENSG00000163016.8	ALMS1P	3.89	0.000131	0.0384	0.29	0.25	Schizophrenia;	chr2:73589158	chr2:73644919~73685576:+
SARC	cis	rs79349575	0.721	rs4794004	ENSG00000270781.1	RP11-501C14.9	-3.89	0.000131	0.0384	-0.29	-0.25	Type 2 diabetes;	chr17:48961109	chr17:48899131~48899748:+
SARC	cis	rs2367970	0.57	rs7123583	ENSG00000254851.1	RP11-109L13.1	3.89	0.000131	0.0385	0.28	0.25	HDL cholesterol;	chr11:116729305	chr11:117135528~117138582:+
SARC	cis	rs2018683	0.87	rs13232487	ENSG00000228421.2	AC005013.5	3.89	0.000131	0.0385	0.25	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945502	chr7:28957667~28959345:+
SARC	cis	rs875971	0.862	rs10274883	ENSG00000232559.3	GS1-124K5.12	-3.89	0.000131	0.0385	-0.29	-0.25	Aortic root size;	chr7:66651104	chr7:66554588~66576923:-
SARC	cis	rs28386778	0.897	rs2854208	ENSG00000240280.5	TCAM1P	-3.89	0.000131	0.0385	-0.31	-0.25	Prudent dietary pattern;	chr17:63869525	chr17:63849292~63864379:+
SARC	cis	rs6472827	0.645	rs2956024	ENSG00000253983.2	RP1-16A9.1	3.89	0.000131	0.0385	0.34	0.25	Uterine fibroids;	chr8:74191465	chr8:74199396~74208441:+
SARC	cis	rs6472827	0.645	rs1532577	ENSG00000253983.2	RP1-16A9.1	3.89	0.000131	0.0385	0.34	0.25	Uterine fibroids;	chr8:74193907	chr8:74199396~74208441:+
SARC	cis	rs6472827	0.645	rs2977069	ENSG00000253983.2	RP1-16A9.1	3.89	0.000131	0.0385	0.34	0.25	Uterine fibroids;	chr8:74199550	chr8:74199396~74208441:+
SARC	cis	rs6472827	0.645	rs2956055	ENSG00000253983.2	RP1-16A9.1	3.89	0.000131	0.0385	0.34	0.25	Uterine fibroids;	chr8:74199718	chr8:74199396~74208441:+
SARC	cis	rs9947295	0.649	rs1941225	ENSG00000267480.1	RP11-703I16.1	-3.89	0.000131	0.0385	-0.43	-0.25	QT interval (drug interaction);	chr18:11778613	chr18:12031178~12032181:-
SARC	cis	rs17270561	0.609	rs9379785	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25725985	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9358871	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25726447	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4711095	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25726546	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4712959	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25726829	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4712960	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25727037	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4712961	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25727106	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9358872	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25727289	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9356985	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25727870	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.636	rs12194699	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25729001	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9379786	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25730027	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9393658	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25730210	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs4711097	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25732086	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs12203927	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25732462	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs12192077	ENSG00000272462.2	U91328.19	-3.89	0.000131	0.0385	-0.24	-0.25	Iron status biomarkers;	chr6:25732566	chr6:25992662~26001775:+
SARC	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-3.89	0.000131	0.0385	-0.3	-0.25	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
SARC	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-3.89	0.000131	0.0385	-0.23	-0.25	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-3.89	0.000131	0.0385	-0.23	-0.25	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-3.89	0.000131	0.0385	-0.23	-0.25	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
SARC	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-3.89	0.000131	0.0385	-0.28	-0.25	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
SARC	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-3.89	0.000131	0.0385	-0.28	-0.25	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
SARC	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	3.89	0.000131	0.0385	0.24	0.25	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
SARC	cis	rs7308116	0.967	rs12820006	ENSG00000240441.1	RP11-864J10.2	-3.89	0.000131	0.0385	-0.28	-0.25	Pelvic organ prolapse (moderate/severe);	chr12:107801677	chr12:107719599~107720133:+
SARC	cis	rs394563	0.967	rs447025	ENSG00000231760.4	RP11-350J20.5	3.89	0.000131	0.0385	0.32	0.25	Dupuytren's disease;	chr6:149477992	chr6:149796151~149826294:-
SARC	cis	rs8014067	0.951	rs2154110	ENSG00000258926.1	RP11-47I22.1	3.89	0.000131	0.0385	0.26	0.25	Hepatitis;	chr14:62086065	chr14:61537508~61545287:-
SARC	cis	rs8028182	0.636	rs28623700	ENSG00000260206.1	CTD-2026K11.2	-3.89	0.000131	0.0386	-0.3	-0.25	Sudden cardiac arrest;	chr15:75557373	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.577	rs28693593	ENSG00000260206.1	CTD-2026K11.2	-3.89	0.000131	0.0386	-0.3	-0.25	Sudden cardiac arrest;	chr15:75557435	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs7163451	ENSG00000260206.1	CTD-2026K11.2	-3.89	0.000131	0.0386	-0.3	-0.25	Sudden cardiac arrest;	chr15:75568735	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs8036884	ENSG00000260206.1	CTD-2026K11.2	-3.89	0.000131	0.0386	-0.3	-0.25	Sudden cardiac arrest;	chr15:75570552	chr15:75636139~75639239:+
SARC	cis	rs11088226	0.846	rs13047501	ENSG00000186842.4	LINC00846	-3.89	0.000131	0.0386	-0.33	-0.25	Gastritis;	chr21:32552350	chr21:32572238~32575881:-
SARC	cis	rs240993	0.81	rs466765	ENSG00000271789.1	RP5-1112D6.7	-3.89	0.000131	0.0386	-0.3	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111347291	chr6:111297126~111298510:+
SARC	cis	rs7726354	0.793	rs16886164	ENSG00000271828.1	CTD-2310F14.1	3.89	0.000131	0.0386	0.49	0.25	Breast cancer (early onset);	chr5:56727080	chr5:56927874~56929573:+
SARC	cis	rs319598	0.556	rs319594	ENSG00000224186.7	C5orf66	3.89	0.000132	0.0386	0.24	0.25	Type 2 diabetes;	chr5:134914456	chr5:135033280~135358219:+
SARC	cis	rs2888875	0.523	rs11891936	ENSG00000279873.2	LINC01126	3.89	0.000132	0.0386	0.23	0.25	Glomerular filtration rate (creatinine);	chr2:43305163	chr2:43227210~43228855:+
SARC	cis	rs862687	0.584	rs830645	ENSG00000270562.1	RP11-154H23.3	-3.89	0.000132	0.0386	-0.23	-0.25	Intelligence (multi-trait analysis);	chr3:71616233	chr3:71584943~71587409:+
SARC	cis	rs7580658	0.895	rs7589451	ENSG00000236682.1	AC068282.3	-3.89	0.000132	0.0386	-0.28	-0.25	Protein C levels;	chr2:127371199	chr2:127389130~127400580:+
SARC	cis	rs7204230	1	rs62049771	ENSG00000261291.1	RP11-295M3.2	3.89	0.000132	0.0387	0.28	0.25	Fibrinogen;	chr16:53241825	chr16:53168522~53169450:+
SARC	cis	rs7811142	1	rs76913697	ENSG00000078319.8	PMS2P1	-3.89	0.000132	0.0387	-0.36	-0.25	Platelet count;	chr7:100405149	chr7:100320992~100341908:-
SARC	cis	rs7246657	0.943	rs3760825	ENSG00000226686.6	LINC01535	-3.89	0.000132	0.0387	-0.34	-0.25	Coronary artery calcification;	chr19:37454699	chr19:37251912~37265535:+
SARC	cis	rs801193	1	rs17566701	ENSG00000236529.1	RP13-254B10.1	3.89	0.000132	0.0387	0.26	0.25	Aortic root size;	chr7:66728196	chr7:65840212~65840596:+
SARC	cis	rs7772486	0.79	rs1832362	ENSG00000235652.6	RP11-545I5.3	3.89	0.000132	0.0387	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.79	rs9376968	ENSG00000235652.6	RP11-545I5.3	3.89	0.000132	0.0387	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145799409~145886585:+
SARC	cis	rs42490	0.528	rs7004089	ENSG00000251136.7	RP11-37B2.1	3.89	0.000132	0.0387	0.27	0.25	Leprosy;	chr8:89688329	chr8:89609409~89757727:-
SARC	cis	rs412050	0.501	rs2876980	ENSG00000224086.5	LL22NC03-86G7.1	3.89	0.000132	0.0387	0.36	0.25	Attention deficit hyperactivity disorder;	chr22:21752246	chr22:21938293~21977632:+
SARC	cis	rs4276643	0.846	rs2726953	ENSG00000239198.1	RPL5P22	-3.89	0.000132	0.0387	-0.28	-0.25	Low vWF levels;	chr8:27943788	chr8:28299683~28300566:+
SARC	cis	rs7204230	1	rs62048047	ENSG00000261291.1	RP11-295M3.2	3.89	0.000132	0.0387	0.28	0.25	Fibrinogen;	chr16:53195637	chr16:53168522~53169450:+
SARC	cis	rs718433	0.532	rs6572105	ENSG00000199436.1	SNORD9	-3.89	0.000132	0.0387	-0.28	-0.25	Intraocular pressure;	chr14:21819166	chr14:21392150~21392253:-
SARC	cis	rs67478160	0.584	rs2295148	ENSG00000269940.1	RP11-73M18.7	3.89	0.000132	0.0387	0.2	0.25	Schizophrenia;	chr14:103729273	chr14:103694560~103695170:+
SARC	cis	rs35160687	0.623	rs718292	ENSG00000273080.1	RP11-301O19.1	3.89	0.000132	0.0388	0.26	0.25	Night sleep phenotypes;	chr2:86246617	chr2:86195590~86196049:+
SARC	cis	rs17270561	0.609	rs9358883	ENSG00000272462.2	U91328.19	-3.89	0.000132	0.0388	-0.24	-0.25	Iron status biomarkers;	chr6:25755287	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs1937132	ENSG00000272462.2	U91328.19	-3.89	0.000132	0.0388	-0.24	-0.25	Iron status biomarkers;	chr6:25756789	chr6:25992662~26001775:+
SARC	cis	rs77956314	0.901	rs75337356	ENSG00000277840.1	RP11-103B5.4	3.89	0.000132	0.0388	0.37	0.25	Hippocampal volume;Subcortical brain region volumes;	chr12:116899449	chr12:117002463~117003152:+
SARC	cis	rs2179367	0.887	rs2143076	ENSG00000216906.2	RP11-350J20.9	3.89	0.000132	0.0388	0.23	0.25	Dupuytren's disease;	chr6:149425315	chr6:149904243~149906418:+
SARC	cis	rs4835473	0.932	rs2060656	ENSG00000251600.4	RP11-673E1.1	-3.89	0.000132	0.0388	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143739330	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.864	rs67749935	ENSG00000251600.4	RP11-673E1.1	-3.89	0.000132	0.0388	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143739852	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs66934100	ENSG00000251600.4	RP11-673E1.1	-3.89	0.000132	0.0388	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143739872	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4325971	ENSG00000251600.4	RP11-673E1.1	-3.89	0.000132	0.0388	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143740167	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4443230	ENSG00000251600.4	RP11-673E1.1	-3.89	0.000132	0.0388	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143740372	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4637344	ENSG00000251600.4	RP11-673E1.1	-3.89	0.000132	0.0388	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143740434	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs56277406	ENSG00000251600.4	RP11-673E1.1	-3.89	0.000132	0.0388	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143740620	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs13143879	ENSG00000251600.4	RP11-673E1.1	-3.89	0.000132	0.0388	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143740901	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs36086465	ENSG00000251600.4	RP11-673E1.1	-3.89	0.000132	0.0388	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143742738	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs873430	ENSG00000251600.4	RP11-673E1.1	-3.89	0.000132	0.0388	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143742953	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs873431	ENSG00000251600.4	RP11-673E1.1	-3.89	0.000132	0.0388	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143743035	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs899903	ENSG00000251600.4	RP11-673E1.1	-3.89	0.000132	0.0388	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143743551	chr4:143912331~143982454:+
SARC	cis	rs6964833	0.935	rs34630792	ENSG00000184616.8	AC004166.6	3.89	0.000132	0.0388	0.36	0.25	Menarche (age at onset);	chr7:74646869	chr7:74906673~74913256:-
SARC	cis	rs1707322	1	rs11211190	ENSG00000281133.1	AL355480.3	-3.89	0.000132	0.0388	-0.28	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs4390216	ENSG00000281133.1	AL355480.3	-3.89	0.000132	0.0388	-0.28	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.964	rs10437063	ENSG00000281133.1	AL355480.3	-3.89	0.000132	0.0388	-0.28	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs6676982	ENSG00000281133.1	AL355480.3	-3.89	0.000132	0.0388	-0.28	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs6429580	ENSG00000281133.1	AL355480.3	-3.89	0.000132	0.0388	-0.28	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.927	rs11211194	ENSG00000281133.1	AL355480.3	-3.89	0.000132	0.0388	-0.28	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.964	rs7546237	ENSG00000281133.1	AL355480.3	-3.89	0.000132	0.0388	-0.28	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45580892~45580996:-
SARC	cis	rs1707322	0.964	rs6697830	ENSG00000281133.1	AL355480.3	-3.89	0.000132	0.0388	-0.28	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45580892~45580996:-
SARC	cis	rs1707322	1	rs12060274	ENSG00000281133.1	AL355480.3	-3.89	0.000132	0.0388	-0.28	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45580892~45580996:-
SARC	cis	rs7615952	0.599	rs6803160	ENSG00000248787.1	RP11-666A20.4	-3.89	0.000133	0.0388	-0.35	-0.25	Blood pressure (smoking interaction);	chr3:125990711	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.599	rs6779141	ENSG00000248787.1	RP11-666A20.4	-3.89	0.000133	0.0388	-0.35	-0.25	Blood pressure (smoking interaction);	chr3:125991152	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.688	rs12485622	ENSG00000248787.1	RP11-666A20.4	-3.89	0.000133	0.0388	-0.35	-0.25	Blood pressure (smoking interaction);	chr3:125991896	chr3:125908005~125910272:-
SARC	cis	rs755249	0.753	rs72663529	ENSG00000182109.6	RP11-69E11.4	3.89	0.000133	0.0388	0.24	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39522280~39546187:-
SARC	cis	rs6487679	1	rs7298108	ENSG00000111788.10	RP11-22B23.1	-3.89	0.000133	0.0388	-0.24	-0.25	Non-alcoholic fatty liver disease histology (AST);	chr12:9223572	chr12:9277235~9313241:+
SARC	cis	rs61160187	0.555	rs34608	ENSG00000215032.2	GNL3LP1	3.89	0.000133	0.0388	0.24	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61161807	chr5:60891935~60893577:-
SARC	cis	rs7267979	0.816	rs376742	ENSG00000274414.1	RP5-965G21.4	-3.89	0.000133	0.0388	-0.25	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:25239007~25245229:-
SARC	cis	rs17711722	0.565	rs73372653	ENSG00000234585.5	CCT6P3	3.89	0.000133	0.0389	0.21	0.25	Calcium levels;	chr7:65977808	chr7:65038354~65074713:+
SARC	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-3.89	0.000133	0.0389	-0.22	-0.25	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
SARC	cis	rs42490	0.576	rs388866	ENSG00000251136.7	RP11-37B2.1	-3.89	0.000133	0.0389	-0.3	-0.25	Leprosy;	chr8:89856604	chr8:89609409~89757727:-
SARC	cis	rs3745567	1	rs11569521	ENSG00000268785.1	RPL7P50	-3.89	0.000133	0.0389	-0.43	-0.25	Complement C3 and C4 levels;	chr19:6689476	chr19:6593329~6594055:+
SARC	cis	rs3745567	1	rs11569520	ENSG00000268785.1	RPL7P50	-3.89	0.000133	0.0389	-0.43	-0.25	Complement C3 and C4 levels;	chr19:6689496	chr19:6593329~6594055:+
SARC	cis	rs3745567	1	rs11569519	ENSG00000268785.1	RPL7P50	-3.89	0.000133	0.0389	-0.43	-0.25	Complement C3 and C4 levels;	chr19:6689843	chr19:6593329~6594055:+
SARC	cis	rs3745567	0.834	rs11569517	ENSG00000268785.1	RPL7P50	-3.89	0.000133	0.0389	-0.43	-0.25	Complement C3 and C4 levels;	chr19:6689988	chr19:6593329~6594055:+
SARC	cis	rs3745567	1	rs11569515	ENSG00000268785.1	RPL7P50	-3.89	0.000133	0.0389	-0.43	-0.25	Complement C3 and C4 levels;	chr19:6690233	chr19:6593329~6594055:+
SARC	cis	rs3745567	1	rs11569514	ENSG00000268785.1	RPL7P50	-3.89	0.000133	0.0389	-0.43	-0.25	Complement C3 and C4 levels;	chr19:6690265	chr19:6593329~6594055:+
SARC	cis	rs3745567	1	rs11569513	ENSG00000268785.1	RPL7P50	-3.89	0.000133	0.0389	-0.43	-0.25	Complement C3 and C4 levels;	chr19:6690449	chr19:6593329~6594055:+
SARC	cis	rs3745567	0.915	rs11569510	ENSG00000268785.1	RPL7P50	-3.89	0.000133	0.0389	-0.43	-0.25	Complement C3 and C4 levels;	chr19:6690731	chr19:6593329~6594055:+
SARC	cis	rs3745567	0.915	rs11569509	ENSG00000268785.1	RPL7P50	-3.89	0.000133	0.0389	-0.43	-0.25	Complement C3 and C4 levels;	chr19:6690733	chr19:6593329~6594055:+
SARC	cis	rs3745567	0.915	rs11569508	ENSG00000268785.1	RPL7P50	-3.89	0.000133	0.0389	-0.43	-0.25	Complement C3 and C4 levels;	chr19:6690735	chr19:6593329~6594055:+
SARC	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	3.89	0.000133	0.0389	0.29	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
SARC	cis	rs564343	0.765	rs1558974	ENSG00000245532.5	NEAT1	-3.89	0.000133	0.0389	-0.2	-0.25	Obesity (early onset extreme);	chr11:66110303	chr11:65422774~65445540:+
SARC	cis	rs11105298	0.891	rs11105319	ENSG00000258302.2	RP11-981P6.1	3.89	0.000133	0.0389	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89561129~89594878:+
SARC	cis	rs12887734	0.566	rs8548	ENSG00000269910.1	RP11-73M18.10	3.89	0.000133	0.0389	0.22	0.25	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103733243	chr14:103694516~103695050:-
SARC	cis	rs7829975	0.688	rs6601703	ENSG00000253981.4	ALG1L13P	3.89	0.000133	0.0389	0.24	0.25	Mood instability;	chr8:8522714	chr8:8236003~8244667:-
SARC	cis	rs11822910	0.737	rs2729389	ENSG00000254602.1	AP000662.4	-3.89	0.000133	0.0389	-0.26	-0.25	Platelet distribution width;	chr11:57444173	chr11:57638024~57652790:+
SARC	cis	rs7615952	0.576	rs2276727	ENSG00000248787.1	RP11-666A20.4	-3.89	0.000133	0.0389	-0.35	-0.25	Blood pressure (smoking interaction);	chr3:126107400	chr3:125908005~125910272:-
SARC	cis	rs7772697	0.508	rs9498201	ENSG00000216906.2	RP11-350J20.9	3.89	0.000133	0.0389	0.25	0.25	Diabetic retinopathy;	chr6:149060690	chr6:149904243~149906418:+
SARC	cis	rs7246657	0.943	rs4803460	ENSG00000226686.6	LINC01535	-3.89	0.000133	0.0389	-0.34	-0.25	Coronary artery calcification;	chr19:37394326	chr19:37251912~37265535:+
SARC	cis	rs61160187	0.577	rs34741733	ENSG00000215032.2	GNL3LP1	3.89	0.000133	0.0389	0.25	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60843721	chr5:60891935~60893577:-
SARC	cis	rs61160187	0.582	rs11740632	ENSG00000215032.2	GNL3LP1	3.89	0.000133	0.0389	0.25	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:60891935~60893577:-
SARC	cis	rs10991814	0.557	rs76379507	ENSG00000233081.1	RP11-440G5.2	3.89	0.000133	0.0389	0.38	0.25	Neutrophil percentage of granulocytes;	chr9:91232926	chr9:91426238~91427144:+
SARC	cis	rs240993	0.715	rs399219	ENSG00000230177.1	RP5-1112D6.4	-3.89	0.000133	0.039	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111371880	chr6:111277932~111278742:+
SARC	cis	rs950776	0.518	rs28438420	ENSG00000261762.1	RP11-650L12.2	-3.89	0.000133	0.039	-0.26	-0.25	Sudden cardiac arrest;	chr15:78543946	chr15:78589123~78591276:-
SARC	cis	rs2836974	0.932	rs2150415	ENSG00000232837.1	AF064858.7	3.89	0.000133	0.039	0.29	0.25	Cognitive function;	chr21:39243441	chr21:38974429~38977774:-
SARC	cis	rs4713118	0.591	rs2056924	ENSG00000219392.1	RP1-265C24.5	-3.88	0.000134	0.039	-0.31	-0.25	Parkinson's disease;	chr6:27722395	chr6:28115628~28116551:+
SARC	cis	rs763121	0.853	rs5757166	ENSG00000273076.1	RP3-508I15.22	3.88	0.000134	0.039	0.27	0.25	Menopause (age at onset);	chr22:38599380	chr22:38743495~38743910:+
SARC	cis	rs11886999	0.723	rs3852673	ENSG00000237510.6	AC008268.2	-3.88	0.000134	0.0391	-0.38	-0.25	Cardiac Troponin-T levels;	chr2:96253904	chr2:95789654~95800166:+
SARC	cis	rs11886999	0.767	rs62153029	ENSG00000237510.6	AC008268.2	-3.88	0.000134	0.0391	-0.38	-0.25	Cardiac Troponin-T levels;	chr2:96255255	chr2:95789654~95800166:+
SARC	cis	rs9364687	0.933	rs13204052	ENSG00000270419.1	CAHM	-3.88	0.000134	0.0391	-0.21	-0.25	Body mass index;	chr6:163382733	chr6:163413065~163413960:-
SARC	cis	rs6940638	0.513	rs4424065	ENSG00000241549.7	GUSBP2	-3.88	0.000134	0.0391	-0.23	-0.25	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26871484~26956554:-
SARC	cis	rs6425521	0.948	rs2038479	ENSG00000213060.4	RP4-612B18.3	3.88	0.000134	0.0391	0.36	0.25	Platelet count;	chr1:171970150	chr1:171803517~171803939:+
SARC	cis	rs6763768	0.814	rs998411	ENSG00000280417.1	RP11-5O17.1	-3.88	0.000134	0.0391	-0.28	-0.25	Bacterial meningitis;	chr3:53485740	chr3:53046166~53048122:+
SARC	cis	rs7937612	0.965	rs4938806	ENSG00000232460.4	BMPR1APS2	3.88	0.000134	0.0391	0.24	0.25	Intraocular pressure;	chr11:120403644	chr11:121361854~121362865:-
SARC	cis	rs4927850	0.794	rs13070153	ENSG00000242086.7	LINC00969	3.88	0.000134	0.0391	0.26	0.25	Pancreatic cancer;	chr3:196014314	chr3:195658062~195739964:+
SARC	cis	rs11694172	1	rs55866932	ENSG00000273456.1	RP11-686O6.2	3.88	0.000134	0.0391	0.21	0.25	Cholesterol, total;	chr2:202658319	chr2:202374932~202375604:-
SARC	cis	rs6142102	0.625	rs1883707	ENSG00000275784.1	RP5-1125A11.6	3.88	0.000134	0.0391	0.29	0.25	Skin pigmentation;	chr20:33964781	chr20:33989480~33991818:-
SARC	cis	rs17508449	0.69	rs4839333	ENSG00000232450.1	RP4-730K3.3	-3.88	0.000134	0.0392	-0.33	-0.25	Leprosy;	chr1:113676539	chr1:113698884~113699631:-
SARC	cis	rs172166	0.694	rs1150666	ENSG00000272009.1	RP1-313I6.12	-3.88	0.000134	0.0392	-0.28	-0.25	Cardiac Troponin-T levels;	chr6:28156150	chr6:28078792~28081130:-
SARC	cis	rs7688540	0.771	rs77078697	ENSG00000275426.1	CH17-262A2.1	3.88	0.000134	0.0392	0.35	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:258259	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs61795006	ENSG00000275426.1	CH17-262A2.1	3.88	0.000134	0.0392	0.35	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259812	chr4:149738~150317:+
SARC	cis	rs7688540	0.771	rs61795007	ENSG00000275426.1	CH17-262A2.1	3.88	0.000134	0.0392	0.35	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:261475	chr4:149738~150317:+
SARC	cis	rs6964833	0.935	rs34762099	ENSG00000184616.8	AC004166.6	3.88	0.000134	0.0392	0.37	0.25	Menarche (age at onset);	chr7:74636378	chr7:74906673~74913256:-
SARC	cis	rs7811142	0.83	rs6955367	ENSG00000078319.8	PMS2P1	-3.88	0.000134	0.0392	-0.35	-0.25	Platelet count;	chr7:100363571	chr7:100320992~100341908:-
SARC	cis	rs848490	0.515	rs28605882	ENSG00000214293.7	APTR	-3.88	0.000134	0.0392	-0.26	-0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77780224	chr7:77657660~77696265:-
SARC	cis	rs9902453	0.934	rs8079028	ENSG00000264538.5	SUZ12P1	3.88	0.000134	0.0392	0.17	0.25	Coffee consumption (cups per day);	chr17:30157216	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.967	rs4493117	ENSG00000264538.5	SUZ12P1	3.88	0.000134	0.0392	0.17	0.25	Coffee consumption (cups per day);	chr17:30162752	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.833	rs7216631	ENSG00000264538.5	SUZ12P1	3.88	0.000134	0.0392	0.17	0.25	Coffee consumption (cups per day);	chr17:30168094	chr17:30709299~30790908:+
SARC	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-3.88	0.000134	0.0392	-0.23	-0.25	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
SARC	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-3.88	0.000134	0.0392	-0.23	-0.25	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
SARC	cis	rs12702271	0.865	rs4640974	ENSG00000229628.1	AC073115.7	3.88	0.000134	0.0392	0.33	0.25	Male-pattern baldness;	chr7:46860098	chr7:45990905~46000898:+
SARC	cis	rs240993	0.812	rs460594	ENSG00000230177.1	RP5-1112D6.4	-3.88	0.000134	0.0392	-0.29	-0.25	Inflammatory skin disease;Psoriasis;	chr6:111348602	chr6:111277932~111278742:+
SARC	cis	rs875971	0.543	rs801191	ENSG00000224316.1	RP11-479O9.2	-3.88	0.000134	0.0392	-0.23	-0.25	Aortic root size;	chr7:66567968	chr7:65773620~65802067:+
SARC	cis	rs875971	0.508	rs6947808	ENSG00000224316.1	RP11-479O9.2	-3.88	0.000134	0.0392	-0.23	-0.25	Aortic root size;	chr7:66580095	chr7:65773620~65802067:+
SARC	cis	rs67257959	0.708	rs1979260	ENSG00000267275.1	CTD-2562J15.6	-3.88	0.000134	0.0392	-0.24	-0.25	Selective IgA deficiency;	chr19:17082741	chr19:16283359~16324514:-
SARC	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-3.88	0.000135	0.0393	-0.29	-0.25	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-3.88	0.000135	0.0393	-0.29	-0.25	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
SARC	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-3.88	0.000135	0.0393	-0.29	-0.25	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
SARC	cis	rs7166081	1	rs2289262	ENSG00000270964.1	RP11-502I4.3	-3.88	0.000135	0.0393	-0.29	-0.25	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67208695	chr15:67541072~67542604:-
SARC	cis	rs950776	0.616	rs647041	ENSG00000261762.1	RP11-650L12.2	-3.88	0.000135	0.0393	-0.26	-0.25	Sudden cardiac arrest;	chr15:78588139	chr15:78589123~78591276:-
SARC	cis	rs67478160	0.654	rs1997913	ENSG00000269958.1	RP11-73M18.8	3.88	0.000135	0.0393	0.24	0.25	Schizophrenia;	chr14:103747623	chr14:103696353~103697163:+
SARC	cis	rs9739682	0.957	rs35115655	ENSG00000139239.7	RPL14P1	-3.88	0.000135	0.0393	-0.22	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62105076	chr12:62965325~62965969:+
SARC	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	3.88	0.000135	0.0393	0.38	0.25	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
SARC	cis	rs3824347	0.967	rs7867200	ENSG00000203321.2	C9orf41-AS1	-3.88	0.000135	0.0393	-0.27	-0.25	Urinary magnesium-to-creatinine ratio;	chr9:74970728	chr9:74952968~74996293:+
SARC	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	3.88	0.000135	0.0393	0.28	0.25	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
SARC	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	3.88	0.000135	0.0393	0.28	0.25	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
SARC	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	3.88	0.000135	0.0393	0.28	0.25	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
SARC	cis	rs11098499	0.82	rs13128602	ENSG00000249244.1	RP11-548H18.2	-3.88	0.000135	0.0394	-0.27	-0.25	Corneal astigmatism;	chr4:119538211	chr4:119391831~119395335:-
SARC	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	3.88	0.000135	0.0394	0.22	0.25	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
SARC	cis	rs756699	0.822	rs244656	ENSG00000279469.1	RP11-215P8.2	-3.88	0.000135	0.0394	-0.36	-0.25	Multiple sclerosis;	chr5:134114136	chr5:134394360~134395008:-
SARC	cis	rs7772486	0.79	rs9403750	ENSG00000235652.6	RP11-545I5.3	3.88	0.000135	0.0394	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145799409~145886585:+
SARC	cis	rs600231	0.623	rs3015966	ENSG00000245532.5	NEAT1	3.88	0.000135	0.0394	0.19	0.25	Bone mineral density;	chr11:65450118	chr11:65422774~65445540:+
SARC	cis	rs11673344	0.526	rs35153242	ENSG00000267605.4	CTD-3220F14.1	-3.88	0.000135	0.0394	-0.26	-0.25	Obesity-related traits;	chr19:37660841	chr19:37265939~37271518:-
SARC	cis	rs3136516	1	rs3136516	ENSG00000270060.1	RP11-390K5.6	3.88	0.000135	0.0394	0.16	0.25	Venous thromboembolism;	chr11:46739206	chr11:47168281~47169563:-
SARC	cis	rs983392	0.792	rs652354	ENSG00000255139.1	AP000442.1	-3.88	0.000135	0.0394	-0.24	-0.25	Alzheimer's disease (late onset);	chr11:60156518	chr11:59616429~59639861:+
SARC	cis	rs2803122	0.745	rs6475325	ENSG00000273226.1	RP11-513M16.8	3.88	0.000135	0.0395	0.24	0.25	Pulse pressure;	chr9:19386375	chr9:19375451~19375996:+
SARC	cis	rs3002142	0.57	rs3008633	ENSG00000272750.1	RP11-378J18.8	-3.88	0.000135	0.0395	-0.37	-0.25	LDL peak particle diameter (total fat intake interaction);	chr1:222671498	chr1:222658867~222661512:-
SARC	cis	rs9309473	0.539	rs6732440	ENSG00000163016.8	ALMS1P	-3.88	0.000135	0.0395	-0.28	-0.25	Metabolite levels;	chr2:73599972	chr2:73644919~73685576:+
SARC	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	3.88	0.000135	0.0395	0.38	0.25	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
SARC	cis	rs4664293	0.667	rs3815876	ENSG00000226266.5	AC009961.3	-3.88	0.000135	0.0395	-0.28	-0.25	Monocyte percentage of white cells;	chr2:159783640	chr2:159670708~159712435:-
SARC	cis	rs7487637	0.529	rs11168245	ENSG00000276691.1	RP5-1057I20.5	3.88	0.000136	0.0395	0.33	0.25	Mononucleosis;	chr12:47810716	chr12:47788426~47788971:+
SARC	cis	rs6589219	0.908	rs3087967	ENSG00000213234.4	ST13P10	3.88	0.000136	0.0395	0.29	0.25	Colorectal cancer;	chr11:111286111	chr11:112267290~112268371:-
SARC	cis	rs67478160	0.609	rs6576003	ENSG00000269958.1	RP11-73M18.8	3.88	0.000136	0.0395	0.24	0.25	Schizophrenia;	chr14:103824993	chr14:103696353~103697163:+
SARC	cis	rs7772486	0.686	rs1011596	ENSG00000235652.6	RP11-545I5.3	3.88	0.000136	0.0395	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145799409~145886585:+
SARC	cis	rs12049351	0.774	rs4925455	ENSG00000229367.1	HMGN2P19	3.88	0.000136	0.0395	0.2	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229487918	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.524	rs4925495	ENSG00000229367.1	HMGN2P19	3.88	0.000136	0.0395	0.2	0.25	Circulating myeloperoxidase levels (plasma);	chr1:229488677	chr1:229570532~229570796:+
SARC	cis	rs950776	0.752	rs7182583	ENSG00000261762.1	RP11-650L12.2	3.88	0.000136	0.0396	0.27	0.25	Sudden cardiac arrest;	chr15:78606868	chr15:78589123~78591276:-
SARC	cis	rs5751614	1	rs5759664	ENSG00000230701.2	FBXW4P1	3.88	0.000136	0.0396	0.3	0.25	Height;	chr22:23249536	chr22:23262767~23265005:+
SARC	cis	rs66887589	0.616	rs6822808	ENSG00000245958.5	RP11-33B1.1	-3.88	0.000136	0.0396	-0.22	-0.25	Diastolic blood pressure;	chr4:119296210	chr4:119454791~119552025:+
SARC	cis	rs890448	0.694	rs2850330	ENSG00000254531.1	FLJ20021	-3.88	0.000136	0.0396	-0.26	-0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101356898	chr4:101347780~101348883:+
SARC	cis	rs890448	0.726	rs2850331	ENSG00000254531.1	FLJ20021	-3.88	0.000136	0.0396	-0.26	-0.25	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101357211	chr4:101347780~101348883:+
SARC	cis	rs17695224	0.545	rs8099997	ENSG00000275055.1	CTC-471J1.11	-3.88	0.000136	0.0396	-0.26	-0.25	HDL cholesterol;HDL cholesterol levels;	chr19:51842216	chr19:52049007~52049754:+
SARC	cis	rs495337	0.735	rs636987	ENSG00000229222.1	KRT18P4	-3.88	0.000136	0.0396	-0.32	-0.25	Psoriasis;	chr20:49907751	chr20:49956745~49958032:+
SARC	cis	rs12200782	0.929	rs10456328	ENSG00000272462.2	U91328.19	-3.88	0.000136	0.0396	-0.39	-0.25	Small cell lung carcinoma;	chr6:26347769	chr6:25992662~26001775:+
SARC	cis	rs2742234	0.541	rs10899778	ENSG00000273008.1	RP11-351D16.3	3.88	0.000136	0.0396	0.29	0.25	Hirschsprung disease;	chr10:43223061	chr10:43136824~43138334:-
SARC	cis	rs2742234	0.541	rs11238481	ENSG00000273008.1	RP11-351D16.3	3.88	0.000136	0.0396	0.29	0.25	Hirschsprung disease;	chr10:43223838	chr10:43136824~43138334:-
SARC	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000136	0.0396	-0.36	-0.25	Gout;	chr7:66721259	chr7:66902857~66906297:+
SARC	cis	rs6848139	1	rs7691220	ENSG00000224786.1	CETN4P	-3.88	0.000136	0.0396	-0.59	-0.25	Alopecia areata;	chr4:122150453	chr4:122730548~122732193:-
SARC	cis	rs12893668	0.608	rs12889721	ENSG00000269940.1	RP11-73M18.7	3.88	0.000136	0.0397	0.25	0.25	Reticulocyte count;	chr14:103568526	chr14:103694560~103695170:+
SARC	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000136	0.0397	-0.36	-0.25	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000136	0.0397	-0.36	-0.25	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
SARC	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000136	0.0397	-0.36	-0.25	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000136	0.0397	-0.36	-0.25	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000136	0.0397	-0.36	-0.25	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
SARC	cis	rs6657613	0.815	rs2871775	ENSG00000186715.9	MST1L	-3.88	0.000136	0.0397	-0.25	-0.25	Hip circumference adjusted for BMI;	chr1:17019410	chr1:16754910~16770237:-
SARC	cis	rs28386778	0.734	rs7210724	ENSG00000240280.5	TCAM1P	-3.88	0.000136	0.0397	-0.31	-0.25	Prudent dietary pattern;	chr17:63721838	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs1470697	ENSG00000240280.5	TCAM1P	-3.88	0.000136	0.0397	-0.31	-0.25	Prudent dietary pattern;	chr17:63722480	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs57108948	ENSG00000240280.5	TCAM1P	-3.88	0.000136	0.0397	-0.31	-0.25	Prudent dietary pattern;	chr17:63725018	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs10221279	ENSG00000240280.5	TCAM1P	-3.88	0.000136	0.0397	-0.31	-0.25	Prudent dietary pattern;	chr17:63728778	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.687	rs59596917	ENSG00000240280.5	TCAM1P	-3.88	0.000136	0.0397	-0.31	-0.25	Prudent dietary pattern;	chr17:63728904	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs1877318	ENSG00000240280.5	TCAM1P	-3.88	0.000136	0.0397	-0.31	-0.25	Prudent dietary pattern;	chr17:63742600	chr17:63849292~63864379:+
SARC	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	3.88	0.000136	0.0397	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
SARC	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	3.88	0.000136	0.0397	0.29	0.25	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
SARC	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	3.88	0.000136	0.0397	0.29	0.25	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
SARC	cis	rs59104589	0.569	rs4254498	ENSG00000266621.1	AC104841.1	3.88	0.000136	0.0397	0.33	0.25	Fibrinogen levels;	chr2:241424196	chr2:241245202~241245299:-
SARC	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	3.88	0.000136	0.0397	0.26	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
SARC	cis	rs3822625	1	rs79953845	ENSG00000271828.1	CTD-2310F14.1	3.88	0.000136	0.0397	0.49	0.25	Breast cancer (early onset);	chr5:56828967	chr5:56927874~56929573:+
SARC	cis	rs72615157	0.634	rs7789890	ENSG00000242294.5	STAG3L5P	3.88	0.000136	0.0397	0.2	0.25	Lung function (FEV1/FVC);	chr7:100202936	chr7:100336079~100351900:+
SARC	cis	rs7647973	0.506	rs11920251	ENSG00000225399.4	RP11-3B7.1	3.88	0.000136	0.0397	0.31	0.25	Menarche (age at onset);	chr3:49319238	chr3:49260085~49261316:+
SARC	cis	rs7615952	0.599	rs66532274	ENSG00000241288.6	RP11-379B18.5	-3.88	0.000136	0.0397	-0.28	-0.25	Blood pressure (smoking interaction);	chr3:126013002	chr3:125827238~125916384:-
SARC	cis	rs7615952	0.599	rs2333408	ENSG00000241288.6	RP11-379B18.5	-3.88	0.000136	0.0397	-0.28	-0.25	Blood pressure (smoking interaction);	chr3:126013255	chr3:125827238~125916384:-
SARC	cis	rs11105298	0.891	rs3825330	ENSG00000258302.2	RP11-981P6.1	3.88	0.000137	0.0397	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89561129~89594878:+
SARC	cis	rs9283706	0.548	rs10044452	ENSG00000229666.1	MAST4-AS1	-3.88	0.000137	0.0398	-0.31	-0.25	Coronary artery disease;	chr5:67006777	chr5:67001383~67003953:-
SARC	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	3.88	0.000137	0.0398	0.38	0.25	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	3.88	0.000137	0.0398	0.38	0.25	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	3.88	0.000137	0.0398	0.38	0.25	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	3.88	0.000137	0.0398	0.38	0.25	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	3.88	0.000137	0.0398	0.38	0.25	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
SARC	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	3.88	0.000137	0.0398	0.38	0.25	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
SARC	cis	rs7617480	0.519	rs6790914	ENSG00000225399.4	RP11-3B7.1	3.88	0.000137	0.0398	0.31	0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chr3:49260085~49261316:+
SARC	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-3.88	0.000137	0.0398	-0.27	-0.25	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
SARC	cis	rs2274273	0.662	rs67092614	ENSG00000258413.1	RP11-665C16.6	-3.88	0.000137	0.0398	-0.33	-0.25	Protein biomarker;	chr14:55205337	chr14:55262767~55272075:-
SARC	cis	rs910316	0.934	rs8006587	ENSG00000279594.1	RP11-950C14.10	3.88	0.000137	0.0398	0.27	0.25	Height;	chr14:75198236	chr14:75011269~75012851:-
SARC	cis	rs11955398	0.522	rs12522154	ENSG00000215032.2	GNL3LP1	-3.88	0.000137	0.0398	-0.26	-0.25	Intelligence (multi-trait analysis);	chr5:60885673	chr5:60891935~60893577:-
SARC	cis	rs4372836	0.543	rs10204329	ENSG00000226833.4	AC097724.3	3.88	0.000137	0.0398	0.22	0.25	Body mass index;	chr2:28775211	chr2:28708953~28736205:-
SARC	cis	rs7811142	0.83	rs75636500	ENSG00000078319.8	PMS2P1	-3.88	0.000137	0.0398	-0.37	-0.25	Platelet count;	chr7:100350034	chr7:100320992~100341908:-
SARC	cis	rs2274273	0.745	rs8005399	ENSG00000258413.1	RP11-665C16.6	-3.88	0.000137	0.0398	-0.28	-0.25	Protein biomarker;	chr14:55076127	chr14:55262767~55272075:-
SARC	cis	rs4705962	0.918	rs6879672	ENSG00000230612.2	AC004237.1	3.88	0.000137	0.0398	0.3	0.25	Atopic dermatitis;	chr5:132690255	chr5:132688681~132723725:+
SARC	cis	rs12893668	0.697	rs67899457	ENSG00000269958.1	RP11-73M18.8	3.88	0.000137	0.0399	0.26	0.25	Reticulocyte count;	chr14:103593729	chr14:103696353~103697163:+
SARC	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	3.88	0.000137	0.0399	0.35	0.25	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
SARC	cis	rs7216064	1	rs3206817	ENSG00000237854.3	LINC00674	3.88	0.000137	0.0399	0.31	0.25	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67896718	chr17:68101908~68115518:+
SARC	cis	rs28386778	0.724	rs35092235	ENSG00000240280.5	TCAM1P	-3.88	0.000137	0.0399	-0.3	-0.25	Prudent dietary pattern;	chr17:63867261	chr17:63849292~63864379:+
SARC	cis	rs11105298	0.891	rs11105318	ENSG00000258302.2	RP11-981P6.1	3.88	0.000137	0.0399	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89532881	chr12:89561129~89594878:+
SARC	cis	rs763121	0.886	rs1013339	ENSG00000273076.1	RP3-508I15.22	3.88	0.000137	0.0399	0.26	0.25	Menopause (age at onset);	chr22:38578675	chr22:38743495~38743910:+
SARC	cis	rs4713118	0.662	rs149947	ENSG00000272009.1	RP1-313I6.12	-3.88	0.000137	0.0399	-0.29	-0.25	Parkinson's disease;	chr6:28004655	chr6:28078792~28081130:-
SARC	cis	rs853679	0.55	rs1233701	ENSG00000216901.1	AL022393.7	-3.88	0.000137	0.0399	-0.33	-0.25	Depression;	chr6:28200948	chr6:28176188~28176674:+
SARC	cis	rs12542260	0.815	rs12550827	ENSG00000253106.1	RP11-158K1.3	-3.88	0.000137	0.0399	-0.29	-0.25	Colonoscopy-negative controls vs population controls;	chr8:124542846	chr8:124488510~124491643:+
SARC	cis	rs12542260	0.859	rs12545267	ENSG00000253106.1	RP11-158K1.3	-3.88	0.000137	0.0399	-0.29	-0.25	Colonoscopy-negative controls vs population controls;	chr8:124549114	chr8:124488510~124491643:+
SARC	cis	rs8028182	0.583	rs9944207	ENSG00000260206.1	CTD-2026K11.2	-3.88	0.000137	0.0399	-0.29	-0.25	Sudden cardiac arrest;	chr15:75620548	chr15:75636139~75639239:+
SARC	cis	rs853679	1	rs6901575	ENSG00000216901.1	AL022393.7	3.88	0.000137	0.04	0.42	0.25	Depression;	chr6:28283207	chr6:28176188~28176674:+
SARC	cis	rs2307449	0.929	rs2283432	ENSG00000261441.1	RP11-217B1.2	3.88	0.000138	0.04	0.31	0.25	Menopause (age at onset);	chr15:89292997	chr15:89335053~89336161:+
SARC	cis	rs2307449	0.929	rs35626905	ENSG00000261441.1	RP11-217B1.2	3.88	0.000138	0.04	0.31	0.25	Menopause (age at onset);	chr15:89293562	chr15:89335053~89336161:+
SARC	cis	rs858239	0.6	rs10266123	ENSG00000226816.2	AC005082.12	3.88	0.000138	0.04	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23206013~23208045:+
SARC	cis	rs11673344	0.523	rs1402468	ENSG00000226686.6	LINC01535	3.88	0.000138	0.04	0.27	0.25	Obesity-related traits;	chr19:37129346	chr19:37251912~37265535:+
SARC	cis	rs4950322	0.58	rs7541393	ENSG00000278811.3	LINC00624	3.88	0.000138	0.04	0.25	0.25	Protein quantitative trait loci;	chr1:147117186	chr1:147258885~147517875:-
SARC	cis	rs758129	0.501	rs2072266	ENSG00000261441.1	RP11-217B1.2	3.88	0.000138	0.04	0.31	0.25	Schizophrenia;	chr15:89323723	chr15:89335053~89336161:+
SARC	cis	rs7267979	0.528	rs6076366	ENSG00000125804.12	FAM182A	3.88	0.000138	0.04	0.3	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:26054655~26086917:+
SARC	cis	rs11955398	0.502	rs290514	ENSG00000215032.2	GNL3LP1	3.88	0.000138	0.04	0.26	0.25	Intelligence (multi-trait analysis);	chr5:60934494	chr5:60891935~60893577:-
SARC	cis	rs2742234	0.541	rs12416428	ENSG00000273008.1	RP11-351D16.3	3.88	0.000138	0.04	0.29	0.25	Hirschsprung disease;	chr10:43213550	chr10:43136824~43138334:-
SARC	cis	rs2742234	0.541	rs11238476	ENSG00000273008.1	RP11-351D16.3	3.88	0.000138	0.04	0.29	0.25	Hirschsprung disease;	chr10:43215988	chr10:43136824~43138334:-
SARC	cis	rs2742234	0.541	rs7096500	ENSG00000273008.1	RP11-351D16.3	3.88	0.000138	0.04	0.29	0.25	Hirschsprung disease;	chr10:43216647	chr10:43136824~43138334:-
SARC	cis	rs2742234	0.541	rs4648313	ENSG00000273008.1	RP11-351D16.3	3.88	0.000138	0.04	0.29	0.25	Hirschsprung disease;	chr10:43221291	chr10:43136824~43138334:-
SARC	cis	rs2742234	0.541	rs10793424	ENSG00000273008.1	RP11-351D16.3	3.88	0.000138	0.04	0.29	0.25	Hirschsprung disease;	chr10:43221668	chr10:43136824~43138334:-
SARC	cis	rs2742234	0.541	rs11238479	ENSG00000273008.1	RP11-351D16.3	3.88	0.000138	0.04	0.29	0.25	Hirschsprung disease;	chr10:43221975	chr10:43136824~43138334:-
SARC	cis	rs2742234	0.541	rs61268333	ENSG00000273008.1	RP11-351D16.3	3.88	0.000138	0.04	0.29	0.25	Hirschsprung disease;	chr10:43225922	chr10:43136824~43138334:-
SARC	cis	rs2742234	0.541	rs60845448	ENSG00000273008.1	RP11-351D16.3	3.88	0.000138	0.04	0.29	0.25	Hirschsprung disease;	chr10:43226014	chr10:43136824~43138334:-
SARC	cis	rs6570726	1	rs1935617	ENSG00000235652.6	RP11-545I5.3	3.88	0.000138	0.04	0.23	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145799409~145886585:+
SARC	cis	rs12544026	0.689	rs1111885	ENSG00000253328.2	SUMO2P19	3.88	0.000138	0.04	0.26	0.25	Major depression and alcohol dependence;	chr8:101750785	chr8:102242040~102242619:-
SARC	cis	rs12544026	0.765	rs1111884	ENSG00000253328.2	SUMO2P19	3.88	0.000138	0.04	0.26	0.25	Major depression and alcohol dependence;	chr8:101750786	chr8:102242040~102242619:-
SARC	cis	rs4646450	0.735	rs2404323	ENSG00000281827.1	AC005071.4	3.88	0.000138	0.04	0.3	0.25	Blood metabolite levels;	chr7:99387773	chr7:100344375~100344475:-
SARC	cis	rs783540	0.9	rs4778686	ENSG00000275695.1	UBE2Q2P6	-3.88	0.000138	0.0401	-0.25	-0.25	Schizophrenia;	chr15:82642084	chr15:82445719~82454837:+
SARC	cis	rs7267979	0.903	rs6050481	ENSG00000274414.1	RP5-965G21.4	-3.88	0.000138	0.0401	-0.25	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25239007~25245229:-
SARC	cis	rs7267979	0.834	rs6115100	ENSG00000274414.1	RP5-965G21.4	-3.88	0.000138	0.0401	-0.25	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25239007~25245229:-
SARC	cis	rs875971	0.862	rs28470208	ENSG00000232559.3	GS1-124K5.12	-3.88	0.000138	0.0401	-0.28	-0.25	Aortic root size;	chr7:66119713	chr7:66554588~66576923:-
SARC	cis	rs1546924	0.669	rs197439	ENSG00000260948.1	RP11-552M11.8	3.88	0.000138	0.0401	0.27	0.25	Body mass index;	chr1:111738368	chr1:111431046~111433068:-
SARC	cis	rs1504749	0.731	rs7005290	ENSG00000254142.2	RP11-53M11.3	-3.88	0.000138	0.0401	-0.36	-0.25	Intracranial aneurysm;	chr8:54396631	chr8:54554361~54561927:+
SARC	cis	rs59104589	0.617	rs7568	ENSG00000266621.1	AC104841.1	3.88	0.000138	0.0401	0.33	0.25	Fibrinogen levels;	chr2:241352328	chr2:241245202~241245299:-
SARC	cis	rs631644	0.607	rs9962697	ENSG00000266397.1	RP11-737O24.1	-3.88	0.000138	0.0401	-0.25	-0.25	Lung cancer;	chr18:2292755	chr18:2967018~2985410:+
SARC	cis	rs11105298	0.891	rs12369685	ENSG00000258302.2	RP11-981P6.1	3.88	0.000138	0.0401	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89561129~89594878:+
SARC	cis	rs7512898	0.5	rs10920046	ENSG00000260088.1	RP11-92G12.3	-3.88	0.000138	0.0401	-0.28	-0.25	Electrocardiographic conduction measures;	chr1:200840100	chr1:200669507~200694250:+
SARC	cis	rs853679	1	rs2799077	ENSG00000272009.1	RP1-313I6.12	-3.88	0.000138	0.0402	-0.35	-0.25	Depression;	chr6:28266819	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.699	rs573179	ENSG00000216901.1	AL022393.7	3.88	0.000138	0.0402	0.37	0.25	Parkinson's disease;	chr6:27881898	chr6:28176188~28176674:+
SARC	cis	rs2179367	0.959	rs544947	ENSG00000216906.2	RP11-350J20.9	3.88	0.000138	0.0402	0.22	0.25	Dupuytren's disease;	chr6:149402412	chr6:149904243~149906418:+
SARC	cis	rs755249	0.529	rs4660732	ENSG00000182109.6	RP11-69E11.4	3.88	0.000138	0.0402	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs61779285	ENSG00000182109.6	RP11-69E11.4	3.88	0.000138	0.0402	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs3768301	ENSG00000182109.6	RP11-69E11.4	3.88	0.000138	0.0402	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs113214136	ENSG00000182109.6	RP11-69E11.4	3.88	0.000138	0.0402	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs3768302	ENSG00000182109.6	RP11-69E11.4	3.88	0.000138	0.0402	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39522280~39546187:-
SARC	cis	rs755249	0.567	rs61779300	ENSG00000182109.6	RP11-69E11.4	3.88	0.000138	0.0402	0.28	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39522280~39546187:-
SARC	cis	rs7617773	0.817	rs9847953	ENSG00000228638.1	FCF1P2	-3.88	0.000138	0.0402	-0.27	-0.25	Coronary artery disease;	chr3:48241205	chr3:48290793~48291375:-
SARC	cis	rs2404602	0.716	rs7179142	ENSG00000259422.1	RP11-593F23.1	3.88	0.000138	0.0402	0.27	0.25	Blood metabolite levels;	chr15:76405927	chr15:76174891~76181486:-
SARC	cis	rs2742234	0.541	rs871763	ENSG00000273008.1	RP11-351D16.3	3.88	0.000139	0.0402	0.28	0.25	Hirschsprung disease;	chr10:43238740	chr10:43136824~43138334:-
SARC	cis	rs2070074	0.591	rs7037232	ENSG00000230074.1	RP11-195F19.9	-3.88	0.000139	0.0402	-0.48	-0.25	CTACK levels;	chr9:34587487	chr9:34665665~34681298:+
SARC	cis	rs7937612	1	rs6589810	ENSG00000232460.4	BMPR1APS2	3.88	0.000139	0.0402	0.25	0.25	Intraocular pressure;	chr11:120363199	chr11:121361854~121362865:-
SARC	cis	rs59104589	0.617	rs16842449	ENSG00000266621.1	AC104841.1	3.88	0.000139	0.0402	0.34	0.25	Fibrinogen levels;	chr2:241415564	chr2:241245202~241245299:-
SARC	cis	rs910316	0.819	rs175461	ENSG00000279594.1	RP11-950C14.10	-3.88	0.000139	0.0402	-0.28	-0.25	Height;	chr14:75115113	chr14:75011269~75012851:-
SARC	cis	rs9527	0.59	rs1475642	ENSG00000236937.2	PTGES3P4	-3.88	0.000139	0.0402	-0.3	-0.25	Arsenic metabolism;	chr10:102786426	chr10:102845595~102845950:+
SARC	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-3.87	0.000139	0.0402	-0.33	-0.25	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
SARC	cis	rs6142102	0.602	rs4911399	ENSG00000275784.1	RP5-1125A11.6	-3.87	0.000139	0.0402	-0.29	-0.25	Skin pigmentation;	chr20:34035612	chr20:33989480~33991818:-
SARC	cis	rs7246760	1	rs10421336	ENSG00000277587.1	CTD-3116E22.8	-3.87	0.000139	0.0402	-0.51	-0.25	Pursuit maintenance gain;	chr19:9829155	chr19:9721903~9722410:+
SARC	cis	rs12497850	0.931	rs9311434	ENSG00000225399.4	RP11-3B7.1	3.87	0.000139	0.0403	0.32	0.25	Parkinson's disease;	chr3:48846714	chr3:49260085~49261316:+
SARC	cis	rs73129298	0.636	rs73910338	ENSG00000229222.1	KRT18P4	3.87	0.000139	0.0403	0.53	0.25	Inflammatory skin disease;	chr20:49908680	chr20:49956745~49958032:+
SARC	cis	rs73129298	1	rs73129298	ENSG00000229222.1	KRT18P4	3.87	0.000139	0.0403	0.53	0.25	Inflammatory skin disease;	chr20:49949528	chr20:49956745~49958032:+
SARC	cis	rs860818	1	rs1626853	ENSG00000226816.2	AC005082.12	3.87	0.000139	0.0403	0.66	0.25	Initial pursuit acceleration;	chr7:23195723	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs1728327	ENSG00000226816.2	AC005082.12	3.87	0.000139	0.0403	0.66	0.25	Initial pursuit acceleration;	chr7:23195864	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs1637216	ENSG00000226816.2	AC005082.12	3.87	0.000139	0.0403	0.66	0.25	Initial pursuit acceleration;	chr7:23196510	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs1637214	ENSG00000226816.2	AC005082.12	3.87	0.000139	0.0403	0.66	0.25	Initial pursuit acceleration;	chr7:23197223	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858238	ENSG00000226816.2	AC005082.12	3.87	0.000139	0.0403	0.66	0.25	Initial pursuit acceleration;	chr7:23199514	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858237	ENSG00000226816.2	AC005082.12	3.87	0.000139	0.0403	0.66	0.25	Initial pursuit acceleration;	chr7:23199604	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858233	ENSG00000226816.2	AC005082.12	3.87	0.000139	0.0403	0.66	0.25	Initial pursuit acceleration;	chr7:23201914	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858302	ENSG00000226816.2	AC005082.12	3.87	0.000139	0.0403	0.66	0.25	Initial pursuit acceleration;	chr7:23204624	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858301	ENSG00000226816.2	AC005082.12	3.87	0.000139	0.0403	0.66	0.25	Initial pursuit acceleration;	chr7:23204704	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858297	ENSG00000226816.2	AC005082.12	3.87	0.000139	0.0403	0.66	0.25	Initial pursuit acceleration;	chr7:23205342	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858296	ENSG00000226816.2	AC005082.12	3.87	0.000139	0.0403	0.66	0.25	Initial pursuit acceleration;	chr7:23205929	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858291	ENSG00000226816.2	AC005082.12	3.87	0.000139	0.0403	0.66	0.25	Initial pursuit acceleration;	chr7:23207742	chr7:23206013~23208045:+
SARC	cis	rs8028182	0.636	rs11638974	ENSG00000260206.1	CTD-2026K11.2	-3.87	0.000139	0.0403	-0.3	-0.25	Sudden cardiac arrest;	chr15:75506965	chr15:75636139~75639239:+
SARC	cis	rs9832727	0.631	rs9821138	ENSG00000240950.1	RP11-372E1.1	-3.87	0.000139	0.0403	-0.26	-0.25	Phospholipid levels (plasma);	chr3:142940995	chr3:142827096~142827728:-
SARC	cis	rs2243480	1	rs316329	ENSG00000273142.1	RP11-458F8.4	-3.87	0.000139	0.0404	-0.36	-0.25	Diabetic kidney disease;	chr7:66143429	chr7:66902857~66906297:+
SARC	cis	rs2239547	0.657	rs12496077	ENSG00000242142.1	SERBP1P3	3.87	0.000139	0.0404	0.29	0.25	Schizophrenia;	chr3:52852225	chr3:53064283~53065091:-
SARC	cis	rs2239547	0.603	rs2276825	ENSG00000242142.1	SERBP1P3	3.87	0.000139	0.0404	0.29	0.25	Schizophrenia;	chr3:52852589	chr3:53064283~53065091:-
SARC	cis	rs2239547	0.521	rs9682464	ENSG00000242142.1	SERBP1P3	3.87	0.000139	0.0404	0.29	0.25	Schizophrenia;	chr3:52854469	chr3:53064283~53065091:-
SARC	cis	rs1741464	0.51	rs12587537	ENSG00000258824.2	CTD-2555O16.2	3.87	0.000139	0.0404	0.27	0.25	Reticulocyte count;Reticulocyte fraction of red cells;	chr14:64825643	chr14:64422935~64448557:-
SARC	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000139	0.0404	-0.27	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000139	0.0404	-0.27	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000139	0.0404	-0.27	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000139	0.0404	-0.27	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000139	0.0404	-0.27	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000139	0.0404	-0.27	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000139	0.0404	-0.27	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000139	0.0404	-0.27	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
SARC	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000139	0.0404	-0.27	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
SARC	cis	rs783540	0.846	rs2099259	ENSG00000275695.1	UBE2Q2P6	3.87	0.000139	0.0404	0.25	0.25	Schizophrenia;	chr15:82654937	chr15:82445719~82454837:+
SARC	cis	rs9818758	0.607	rs12185979	ENSG00000225399.4	RP11-3B7.1	-3.87	0.000139	0.0404	-0.61	-0.25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49614537	chr3:49260085~49261316:+
SARC	cis	rs12893668	0.572	rs4906350	ENSG00000269910.1	RP11-73M18.10	3.87	0.000139	0.0404	0.22	0.25	Reticulocyte count;	chr14:103645457	chr14:103694516~103695050:-
SARC	cis	rs7246657	0.943	rs1559229	ENSG00000226686.6	LINC01535	-3.87	0.000139	0.0404	-0.33	-0.25	Coronary artery calcification;	chr19:37385295	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.882	rs6508719	ENSG00000226686.6	LINC01535	-3.87	0.000139	0.0404	-0.33	-0.25	Coronary artery calcification;	chr19:37386517	chr19:37251912~37265535:+
SARC	cis	rs9481169	0.85	rs35815577	ENSG00000231889.6	TRAF3IP2-AS1	3.87	0.00014	0.0404	0.46	0.25	Inflammatory skin disease;	chr6:111603527	chr6:111483511~111598302:+
SARC	cis	rs858239	0.601	rs6461693	ENSG00000226816.2	AC005082.12	-3.87	0.00014	0.0404	-0.3	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23206013~23208045:+
SARC	cis	rs12497850	1	rs1352420	ENSG00000225399.4	RP11-3B7.1	3.87	0.00014	0.0404	0.32	0.25	Parkinson's disease;	chr3:48719858	chr3:49260085~49261316:+
SARC	cis	rs11955398	0.502	rs158938	ENSG00000215032.2	GNL3LP1	3.87	0.00014	0.0404	0.26	0.25	Intelligence (multi-trait analysis);	chr5:60939413	chr5:60891935~60893577:-
SARC	cis	rs12980942	0.872	rs66724427	ENSG00000206674.1	RNU6-945P	-3.87	0.00014	0.0405	-0.36	-0.25	Coronary artery disease;	chr19:41270352	chr19:40299478~40299584:-
SARC	cis	rs6570726	0.791	rs9390336	ENSG00000235652.6	RP11-545I5.3	3.87	0.00014	0.0405	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.738	rs6925594	ENSG00000235652.6	RP11-545I5.3	3.87	0.00014	0.0405	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.791	rs11155432	ENSG00000235652.6	RP11-545I5.3	3.87	0.00014	0.0405	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.791	rs6913727	ENSG00000235652.6	RP11-545I5.3	3.87	0.00014	0.0405	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.791	rs10872577	ENSG00000235652.6	RP11-545I5.3	3.87	0.00014	0.0405	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145799409~145886585:+
SARC	cis	rs2307449	0.731	rs62020354	ENSG00000261441.1	RP11-217B1.2	3.87	0.00014	0.0405	0.31	0.25	Menopause (age at onset);	chr15:89275111	chr15:89335053~89336161:+
SARC	cis	rs11086243	1	rs6066646	ENSG00000276923.1	RP11-321P16.1	3.87	0.00014	0.0405	0.3	0.25	Nephrotic syndrome (acquired);	chr20:48149861	chr20:48073869~48074188:+
SARC	cis	rs600231	0.708	rs661403	ENSG00000245532.5	NEAT1	3.87	0.00014	0.0405	0.18	0.25	Bone mineral density;	chr11:65475007	chr11:65422774~65445540:+
SARC	cis	rs600231	0.708	rs2957269	ENSG00000245532.5	NEAT1	3.87	0.00014	0.0405	0.18	0.25	Bone mineral density;	chr11:65475536	chr11:65422774~65445540:+
SARC	cis	rs600231	0.708	rs2957268	ENSG00000245532.5	NEAT1	3.87	0.00014	0.0405	0.18	0.25	Bone mineral density;	chr11:65478345	chr11:65422774~65445540:+
SARC	cis	rs950776	0.593	rs601079	ENSG00000261762.1	RP11-650L12.2	-3.87	0.00014	0.0405	-0.26	-0.25	Sudden cardiac arrest;	chr15:78577237	chr15:78589123~78591276:-
SARC	cis	rs950776	0.593	rs680244	ENSG00000261762.1	RP11-650L12.2	-3.87	0.00014	0.0405	-0.26	-0.25	Sudden cardiac arrest;	chr15:78578946	chr15:78589123~78591276:-
SARC	cis	rs950776	0.593	rs621849	ENSG00000261762.1	RP11-650L12.2	-3.87	0.00014	0.0405	-0.26	-0.25	Sudden cardiac arrest;	chr15:78580519	chr15:78589123~78591276:-
SARC	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	3.87	0.00014	0.0405	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
SARC	cis	rs72945132	0.562	rs7951959	ENSG00000254604.1	AP000487.6	-3.87	0.00014	0.0405	-0.34	-0.25	Coronary artery disease;	chr11:70388166	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.678	rs12786421	ENSG00000254604.1	AP000487.6	-3.87	0.00014	0.0405	-0.34	-0.25	Coronary artery disease;	chr11:70389208	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.678	rs35733235	ENSG00000254604.1	AP000487.6	-3.87	0.00014	0.0405	-0.34	-0.25	Coronary artery disease;	chr11:70389489	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.598	rs61887432	ENSG00000254604.1	AP000487.6	-3.87	0.00014	0.0405	-0.34	-0.25	Coronary artery disease;	chr11:70392959	chr11:70282367~70363368:-
SARC	cis	rs72945132	0.598	rs61887433	ENSG00000254604.1	AP000487.6	-3.87	0.00014	0.0405	-0.34	-0.25	Coronary artery disease;	chr11:70394891	chr11:70282367~70363368:-
SARC	cis	rs9283706	0.689	rs6889240	ENSG00000229666.1	MAST4-AS1	-3.87	0.00014	0.0405	-0.31	-0.25	Coronary artery disease;	chr5:67025112	chr5:67001383~67003953:-
SARC	cis	rs2404602	0.716	rs8039545	ENSG00000259422.1	RP11-593F23.1	3.87	0.00014	0.0406	0.27	0.25	Blood metabolite levels;	chr15:76414906	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.716	rs7164060	ENSG00000259422.1	RP11-593F23.1	3.87	0.00014	0.0406	0.27	0.25	Blood metabolite levels;	chr15:76415353	chr15:76174891~76181486:-
SARC	cis	rs2404602	0.716	rs7164813	ENSG00000259422.1	RP11-593F23.1	3.87	0.00014	0.0406	0.27	0.25	Blood metabolite levels;	chr15:76415725	chr15:76174891~76181486:-
SARC	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-3.87	0.00014	0.0406	-0.27	-0.25	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
SARC	cis	rs2404602	0.716	rs4079681	ENSG00000259422.1	RP11-593F23.1	3.87	0.00014	0.0406	0.27	0.25	Blood metabolite levels;	chr15:76402889	chr15:76174891~76181486:-
SARC	cis	rs4713118	0.662	rs9380045	ENSG00000272009.1	RP1-313I6.12	-3.87	0.00014	0.0406	-0.29	-0.25	Parkinson's disease;	chr6:28057501	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.616	rs9348789	ENSG00000272009.1	RP1-313I6.12	-3.87	0.00014	0.0406	-0.29	-0.25	Parkinson's disease;	chr6:28057708	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.662	rs9468274	ENSG00000272009.1	RP1-313I6.12	-3.87	0.00014	0.0406	-0.29	-0.25	Parkinson's disease;	chr6:28058299	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.662	rs9468275	ENSG00000272009.1	RP1-313I6.12	-3.87	0.00014	0.0406	-0.29	-0.25	Parkinson's disease;	chr6:28058358	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.662	rs9468276	ENSG00000272009.1	RP1-313I6.12	-3.87	0.00014	0.0406	-0.29	-0.25	Parkinson's disease;	chr6:28059910	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.662	rs9468277	ENSG00000272009.1	RP1-313I6.12	-3.87	0.00014	0.0406	-0.29	-0.25	Parkinson's disease;	chr6:28060612	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.662	rs9468278	ENSG00000272009.1	RP1-313I6.12	-3.87	0.00014	0.0406	-0.29	-0.25	Parkinson's disease;	chr6:28060704	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.662	rs13218430	ENSG00000272009.1	RP1-313I6.12	-3.87	0.00014	0.0406	-0.29	-0.25	Parkinson's disease;	chr6:28062059	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.662	rs9380046	ENSG00000272009.1	RP1-313I6.12	-3.87	0.00014	0.0406	-0.29	-0.25	Parkinson's disease;	chr6:28062721	chr6:28078792~28081130:-
SARC	cis	rs2288884	0.767	rs58329304	ENSG00000275055.1	CTC-471J1.11	-3.87	0.00014	0.0406	-0.31	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52031919	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.767	rs12462359	ENSG00000275055.1	CTC-471J1.11	-3.87	0.00014	0.0406	-0.31	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032168	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.767	rs12460118	ENSG00000275055.1	CTC-471J1.11	-3.87	0.00014	0.0406	-0.31	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032550	chr19:52049007~52049754:+
SARC	cis	rs61160187	0.61	rs4700399	ENSG00000215032.2	GNL3LP1	3.87	0.00014	0.0406	0.25	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840627	chr5:60891935~60893577:-
SARC	cis	rs12817211	0.502	rs34167640	ENSG00000272368.2	RP4-605O3.4	-3.87	0.000141	0.0407	-0.24	-0.25	Colorectal or endometrial cancer;	chr12:50123208	chr12:50112197~50165618:+
SARC	cis	rs2243480	0.764	rs2460423	ENSG00000164669.11	INTS4P1	3.87	0.000141	0.0407	0.43	0.25	Diabetic kidney disease;	chr7:66136229	chr7:65141225~65234216:+
SARC	cis	rs950776	0.695	rs1878399	ENSG00000261762.1	RP11-650L12.2	-3.87	0.000141	0.0407	-0.26	-0.25	Sudden cardiac arrest;	chr15:78619661	chr15:78589123~78591276:-
SARC	cis	rs2708977	0.73	rs596069	ENSG00000237510.6	AC008268.2	3.87	0.000141	0.0407	0.33	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96410905	chr2:95789654~95800166:+
SARC	cis	rs763121	0.819	rs5757169	ENSG00000273076.1	RP3-508I15.22	3.87	0.000141	0.0407	0.26	0.25	Menopause (age at onset);	chr22:38607490	chr22:38743495~38743910:+
SARC	cis	rs7614311	1	rs2637983	ENSG00000271843.1	RP11-245J9.5	-3.87	0.000141	0.0407	-0.31	-0.25	Lung function (FVC);Lung function (FEV1);	chr3:63835956	chr3:64008082~64008692:-
SARC	cis	rs1713985	0.508	rs2687239	ENSG00000269949.1	RP11-738E22.3	-3.87	0.000141	0.0407	-0.44	-0.25	Age-related macular degeneration;	chr4:57012468	chr4:56960927~56961373:-
SARC	cis	rs1713985	0.508	rs1718866	ENSG00000269949.1	RP11-738E22.3	-3.87	0.000141	0.0407	-0.44	-0.25	Age-related macular degeneration;	chr4:57017009	chr4:56960927~56961373:-
SARC	cis	rs1713985	0.508	rs1718862	ENSG00000269949.1	RP11-738E22.3	-3.87	0.000141	0.0407	-0.44	-0.25	Age-related macular degeneration;	chr4:57023166	chr4:56960927~56961373:-
SARC	cis	rs597539	0.652	rs513359	ENSG00000250508.1	RP11-757G1.6	3.87	0.000141	0.0407	0.28	0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:68870664~68874542:+
SARC	cis	rs7246657	0.943	rs4803229	ENSG00000226686.6	LINC01535	-3.87	0.000141	0.0407	-0.33	-0.25	Coronary artery calcification;	chr19:37373780	chr19:37251912~37265535:+
SARC	cis	rs7246657	0.943	rs4452075	ENSG00000226686.6	LINC01535	-3.87	0.000141	0.0407	-0.33	-0.25	Coronary artery calcification;	chr19:37388687	chr19:37251912~37265535:+
SARC	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-3.87	0.000141	0.0407	-0.29	-0.25	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
SARC	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-3.87	0.000141	0.0407	-0.23	-0.25	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
SARC	cis	rs28498283	0.792	rs62135402	ENSG00000279873.2	LINC01126	-3.87	0.000141	0.0408	-0.23	-0.25	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:43118715	chr2:43227210~43228855:+
SARC	cis	rs8028182	0.636	rs4322627	ENSG00000260206.1	CTD-2026K11.2	-3.87	0.000141	0.0408	-0.3	-0.25	Sudden cardiac arrest;	chr15:75518318	chr15:75636139~75639239:+
SARC	cis	rs10911902	0.643	rs16825185	ENSG00000233196.2	GS1-304P7.1	-3.87	0.000141	0.0408	-0.36	-0.25	Schizophrenia;	chr1:186337932	chr1:186580515~186581191:-
SARC	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-3.87	0.000141	0.0408	-0.36	-0.25	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
SARC	cis	rs28386778	0.966	rs2008053	ENSG00000240280.5	TCAM1P	-3.87	0.000141	0.0408	-0.31	-0.25	Prudent dietary pattern;	chr17:63877558	chr17:63849292~63864379:+
SARC	cis	rs28386778	1	rs3020613	ENSG00000240280.5	TCAM1P	-3.87	0.000141	0.0408	-0.31	-0.25	Prudent dietary pattern;	chr17:63878623	chr17:63849292~63864379:+
SARC	cis	rs4950322	0.748	rs56392137	ENSG00000278811.3	LINC00624	3.87	0.000141	0.0408	0.26	0.25	Protein quantitative trait loci;	chr1:147352450	chr1:147258885~147517875:-
SARC	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000141	0.0408	-0.28	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
SARC	cis	rs11168249	0.819	rs2525051	ENSG00000276691.1	RP5-1057I20.5	3.87	0.000141	0.0408	0.25	0.25	Lymphocyte counts;Inflammatory bowel disease;Ulcerative colitis;	chr12:47802156	chr12:47788426~47788971:+
SARC	cis	rs1005277	0.557	rs2983338	ENSG00000263064.2	RP11-291L22.7	3.87	0.000141	0.0409	0.25	0.25	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38448689~38448949:+
SARC	cis	rs7520050	0.807	rs4468203	ENSG00000280836.1	AL355480.1	-3.87	0.000141	0.0409	-0.23	-0.25	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45581219~45581321:-
SARC	cis	rs7580658	0.895	rs4662722	ENSG00000236682.1	AC068282.3	-3.87	0.000141	0.0409	-0.28	-0.25	Protein C levels;	chr2:127344993	chr2:127389130~127400580:+
SARC	cis	rs7580658	0.895	rs4662580	ENSG00000236682.1	AC068282.3	-3.87	0.000141	0.0409	-0.28	-0.25	Protein C levels;	chr2:127345230	chr2:127389130~127400580:+
SARC	cis	rs67478160	0.634	rs7141928	ENSG00000269940.1	RP11-73M18.7	3.87	0.000142	0.0409	0.21	0.25	Schizophrenia;	chr14:103753612	chr14:103694560~103695170:+
SARC	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	3.87	0.000142	0.0409	0.26	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
SARC	cis	rs7617773	0.817	rs35414021	ENSG00000228638.1	FCF1P2	-3.87	0.000142	0.0409	-0.28	-0.25	Coronary artery disease;	chr3:48252034	chr3:48290793~48291375:-
SARC	cis	rs2455799	0.573	rs62243672	ENSG00000226427.1	HMGN2P7	-3.87	0.000142	0.0409	-0.27	-0.25	Mean platelet volume;	chr3:15895693	chr3:15375373~15375645:-
SARC	cis	rs9907295	1	rs9894314	ENSG00000270240.2	AC015849.2	3.87	0.000142	0.0409	0.44	0.25	Fibroblast growth factor basic levels;	chr17:35916822	chr17:35868967~35885863:+
SARC	cis	rs9907295	1	rs9897095	ENSG00000270240.2	AC015849.2	3.87	0.000142	0.0409	0.44	0.25	Fibroblast growth factor basic levels;	chr17:35916928	chr17:35868967~35885863:+
SARC	cis	rs9907295	1	rs9896265	ENSG00000270240.2	AC015849.2	3.87	0.000142	0.0409	0.44	0.25	Fibroblast growth factor basic levels;	chr17:35916930	chr17:35868967~35885863:+
SARC	cis	rs9907295	1	rs9900236	ENSG00000270240.2	AC015849.2	3.87	0.000142	0.0409	0.44	0.25	Fibroblast growth factor basic levels;	chr17:35917049	chr17:35868967~35885863:+
SARC	cis	rs8028182	0.636	rs12909863	ENSG00000260206.1	CTD-2026K11.2	-3.87	0.000142	0.0409	-0.3	-0.25	Sudden cardiac arrest;	chr15:75533481	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs12708520	ENSG00000260206.1	CTD-2026K11.2	-3.87	0.000142	0.0409	-0.3	-0.25	Sudden cardiac arrest;	chr15:75538198	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs62027181	ENSG00000260206.1	CTD-2026K11.2	-3.87	0.000142	0.0409	-0.3	-0.25	Sudden cardiac arrest;	chr15:75547611	chr15:75636139~75639239:+
SARC	cis	rs6472827	0.595	rs2977068	ENSG00000253983.2	RP1-16A9.1	3.87	0.000142	0.0409	0.34	0.25	Uterine fibroids;	chr8:74192817	chr8:74199396~74208441:+
SARC	cis	rs6472827	0.645	rs7009750	ENSG00000253983.2	RP1-16A9.1	3.87	0.000142	0.0409	0.34	0.25	Uterine fibroids;	chr8:74199894	chr8:74199396~74208441:+
SARC	cis	rs42490	1	rs43134	ENSG00000251136.7	RP11-37B2.1	3.87	0.000142	0.0409	0.27	0.25	Leprosy;	chr8:89775732	chr8:89609409~89757727:-
SARC	cis	rs2307449	0.892	rs17229107	ENSG00000261441.1	RP11-217B1.2	3.87	0.000142	0.0409	0.31	0.25	Menopause (age at onset);	chr15:89269024	chr15:89335053~89336161:+
SARC	cis	rs2307449	0.929	rs35289216	ENSG00000261441.1	RP11-217B1.2	3.87	0.000142	0.0409	0.31	0.25	Menopause (age at onset);	chr15:89269107	chr15:89335053~89336161:+
SARC	cis	rs2307449	0.929	rs2159080	ENSG00000261441.1	RP11-217B1.2	3.87	0.000142	0.0409	0.31	0.25	Menopause (age at onset);	chr15:89270392	chr15:89335053~89336161:+
SARC	cis	rs2307449	0.929	rs2882557	ENSG00000261441.1	RP11-217B1.2	3.87	0.000142	0.0409	0.31	0.25	Menopause (age at onset);	chr15:89277283	chr15:89335053~89336161:+
SARC	cis	rs2307449	0.892	rs1599857	ENSG00000261441.1	RP11-217B1.2	3.87	0.000142	0.0409	0.31	0.25	Menopause (age at onset);	chr15:89278501	chr15:89335053~89336161:+
SARC	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	3.87	0.000142	0.0409	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
SARC	cis	rs42490	1	rs40545	ENSG00000251136.7	RP11-37B2.1	-3.87	0.000142	0.041	-0.27	-0.25	Leprosy;	chr8:89777483	chr8:89609409~89757727:-
SARC	cis	rs42490	0.966	rs39505	ENSG00000251136.7	RP11-37B2.1	-3.87	0.000142	0.041	-0.27	-0.25	Leprosy;	chr8:89779838	chr8:89609409~89757727:-
SARC	cis	rs42490	1	rs39506	ENSG00000251136.7	RP11-37B2.1	-3.87	0.000142	0.041	-0.27	-0.25	Leprosy;	chr8:89779899	chr8:89609409~89757727:-
SARC	cis	rs7811142	0.72	rs7795656	ENSG00000078319.8	PMS2P1	-3.87	0.000142	0.041	-0.36	-0.25	Platelet count;	chr7:100352674	chr7:100320992~100341908:-
SARC	cis	rs2306786	1	rs11632157	ENSG00000253030.1	MIR2116	-3.87	0.000142	0.041	-0.4	-0.25	Metabolite levels;	chr15:59183889	chr15:59171183~59171262:-
SARC	cis	rs2307449	0.892	rs12900825	ENSG00000261441.1	RP11-217B1.2	3.87	0.000142	0.041	0.31	0.25	Menopause (age at onset);	chr15:89258446	chr15:89335053~89336161:+
SARC	cis	rs858239	0.6	rs1115941	ENSG00000226816.2	AC005082.12	3.87	0.000142	0.041	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23206013~23208045:+
SARC	cis	rs2274273	1	rs61508494	ENSG00000258413.1	RP11-665C16.6	-3.87	0.000142	0.041	-0.29	-0.25	Protein biomarker;	chr14:55120579	chr14:55262767~55272075:-
SARC	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-3.87	0.000142	0.041	-0.29	-0.25	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
SARC	cis	rs17826219	0.706	rs8075357	ENSG00000264538.5	SUZ12P1	-3.87	0.000142	0.041	-0.25	-0.25	Body mass index;	chr17:30730179	chr17:30709299~30790908:+
SARC	cis	rs17826219	0.706	rs61643715	ENSG00000264538.5	SUZ12P1	-3.87	0.000142	0.041	-0.25	-0.25	Body mass index;	chr17:30730744	chr17:30709299~30790908:+
SARC	cis	rs17826219	0.636	rs8080829	ENSG00000264538.5	SUZ12P1	-3.87	0.000142	0.041	-0.25	-0.25	Body mass index;	chr17:30731712	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.623	rs56018041	ENSG00000264538.5	SUZ12P1	-3.87	0.000142	0.041	-0.25	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30709299~30790908:+
SARC	cis	rs10911902	0.643	rs3753565	ENSG00000233196.2	GS1-304P7.1	3.87	0.000142	0.041	0.37	0.25	Schizophrenia;	chr1:186347356	chr1:186580515~186581191:-
SARC	cis	rs3204270	0.639	rs79193599	ENSG00000262049.1	RP13-1032I1.7	3.87	0.000142	0.041	0.29	0.25	Dental caries;	chr17:81684460	chr17:81701324~81703300:-
SARC	cis	rs7772486	0.659	rs9376957	ENSG00000235652.6	RP11-545I5.3	-3.87	0.000142	0.041	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.686	rs9497396	ENSG00000235652.6	RP11-545I5.3	-3.87	0.000142	0.041	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145799409~145886585:+
SARC	cis	rs9739682	0.564	rs11174308	ENSG00000139239.7	RPL14P1	-3.87	0.000142	0.041	-0.25	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62093156	chr12:62965325~62965969:+
SARC	cis	rs2243480	1	rs160646	ENSG00000164669.11	INTS4P1	3.87	0.000142	0.041	0.43	0.25	Diabetic kidney disease;	chr7:66091293	chr7:65141225~65234216:+
SARC	cis	rs7520050	0.808	rs11211195	ENSG00000280836.1	AL355480.1	3.87	0.000142	0.0411	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:45816623	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.808	rs11211196	ENSG00000280836.1	AL355480.1	3.87	0.000142	0.0411	0.23	0.25	Reticulocyte count;Red blood cell count;	chr1:45816624	chr1:45581219~45581321:-
SARC	cis	rs7772486	0.754	rs702323	ENSG00000235652.6	RP11-545I5.3	-3.87	0.000142	0.0411	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145799409~145886585:+
SARC	cis	rs335206	0.542	rs55981521	ENSG00000249996.1	RP11-359P5.1	-3.87	0.000142	0.0411	-0.27	-0.25	QRS duration;	chr5:123141483	chr5:123036271~123054667:+
SARC	cis	rs4273100	1	rs16960158	ENSG00000265185.4	SNORD3B-1	3.87	0.000142	0.0411	0.36	0.25	Schizophrenia;	chr17:19259739	chr17:19061912~19062669:+
SARC	cis	rs7646881	1	rs59918529	ENSG00000240207.5	RP11-379F4.4	-3.87	0.000142	0.0411	-0.35	-0.25	Tetralogy of Fallot;	chr3:158734916	chr3:158732263~158784070:+
SARC	cis	rs948562	0.895	rs7484263	ENSG00000280010.1	AP001350.4	3.87	0.000142	0.0411	0.35	0.25	Lymphoma;	chr11:58608080	chr11:58627435~58628528:+
SARC	cis	rs948562	0.947	rs7945889	ENSG00000280010.1	AP001350.4	3.87	0.000142	0.0411	0.35	0.25	Lymphoma;	chr11:58609262	chr11:58627435~58628528:+
SARC	cis	rs2762353	0.505	rs2096386	ENSG00000272810.1	U91328.22	3.87	0.000143	0.0411	0.23	0.25	Blood metabolite levels;	chr6:25787589	chr6:26013241~26013757:+
SARC	cis	rs3761847	0.622	rs10818498	ENSG00000226752.6	PSMD5-AS1	-3.87	0.000143	0.0411	-0.29	-0.25	Rheumatoid arthritis;	chr9:121025288	chr9:120824828~120854385:+
SARC	cis	rs10923574	0.576	rs10923578	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000143	0.0411	-0.25	-0.25	Breast cancer;Folding of antihelix;	chr1:118504538	chr1:119140396~119275973:+
SARC	cis	rs6142102	0.602	rs932388	ENSG00000275784.1	RP5-1125A11.6	-3.87	0.000143	0.0411	-0.29	-0.25	Skin pigmentation;	chr20:34069572	chr20:33989480~33991818:-
SARC	cis	rs3764021	0.87	rs7970116	ENSG00000256594.6	RP11-705C15.2	-3.87	0.000143	0.0411	-0.28	-0.25	Type 1 diabetes;	chr12:9727518	chr12:9633419~9658412:+
SARC	cis	rs8028182	0.636	rs11634863	ENSG00000260206.1	CTD-2026K11.2	-3.87	0.000143	0.0412	-0.3	-0.25	Sudden cardiac arrest;	chr15:75474331	chr15:75636139~75639239:+
SARC	cis	rs10766496	1	rs4261259	ENSG00000257043.1	RP11-137N23.1	3.87	0.000143	0.0412	0.31	0.25	Diabetic kidney disease;	chr11:18716405	chr11:18665050~18665548:+
SARC	cis	rs7647973	0.58	rs2334958	ENSG00000225399.4	RP11-3B7.1	3.87	0.000143	0.0412	0.3	0.25	Menarche (age at onset);	chr3:49214931	chr3:49260085~49261316:+
SARC	cis	rs2836974	0.584	rs34436313	ENSG00000255568.3	BRWD1-AS2	-3.87	0.000143	0.0412	-0.24	-0.25	Cognitive function;	chr21:39313320	chr21:39313935~39314962:+
SARC	cis	rs2836974	0.666	rs35182074	ENSG00000255568.3	BRWD1-AS2	-3.87	0.000143	0.0412	-0.24	-0.25	Cognitive function;	chr21:39313358	chr21:39313935~39314962:+
SARC	cis	rs8064029	0.892	rs3859159	ENSG00000267077.1	RP11-127I20.5	3.87	0.000143	0.0412	0.46	0.25	Cancer;	chr16:4848743	chr16:4795265~4796532:-
SARC	cis	rs950776	0.518	rs12903129	ENSG00000261762.1	RP11-650L12.2	3.87	0.000143	0.0412	0.27	0.25	Sudden cardiac arrest;	chr15:78527264	chr15:78589123~78591276:-
SARC	cis	rs4862750	0.914	rs11943333	ENSG00000249742.1	RP11-217E13.1	-3.87	0.000143	0.0412	-0.28	-0.25	Lobe attachment (rater-scored or self-reported);	chr4:186951301	chr4:186979490~187021973:-
SARC	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-3.87	0.000143	0.0412	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-3.87	0.000143	0.0412	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
SARC	cis	rs763567	1	rs3903239	ENSG00000271811.1	RP1-79C4.4	-3.87	0.000143	0.0412	-0.29	-0.25	Tonsillectomy;	chr1:170600176	chr1:170667381~170669425:+
SARC	cis	rs73219805	0.671	rs13267955	ENSG00000228451.3	SDAD1P1	-3.87	0.000143	0.0412	-0.32	-0.25	Schizophrenia;	chr8:26367077	chr8:26379259~26382953:-
SARC	cis	rs62025270	0.547	rs338536	ENSG00000202081.1	RNU6-1280P	-3.87	0.000143	0.0413	-0.29	-0.25	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85651522~85651628:-
SARC	cis	rs4664293	0.967	rs10202187	ENSG00000226266.5	AC009961.3	-3.87	0.000143	0.0413	-0.31	-0.25	Monocyte percentage of white cells;	chr2:159571135	chr2:159670708~159712435:-
SARC	cis	rs61160187	0.698	rs1379116	ENSG00000272308.1	RP11-231G3.1	-3.87	0.000143	0.0413	-0.21	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60646573	chr5:60866457~60866935:-
SARC	cis	rs7614311	0.639	rs73119035	ENSG00000271843.1	RP11-245J9.5	-3.87	0.000143	0.0413	-0.39	-0.25	Lung function (FVC);Lung function (FEV1);	chr3:64008290	chr3:64008082~64008692:-
SARC	cis	rs6570726	0.791	rs448939	ENSG00000270638.1	RP3-466P17.1	3.87	0.000143	0.0413	0.2	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145487184	chr6:145735570~145737218:+
SARC	cis	rs4148883	0.603	rs6833176	ENSG00000263923.1	RP11-571L19.7	3.87	0.000144	0.0413	0.25	0.25	Alcohol dependence;	chr4:99210006	chr4:98928897~98994994:+
SARC	cis	rs3822625	0.867	rs76418981	ENSG00000271828.1	CTD-2310F14.1	3.87	0.000144	0.0414	0.49	0.25	Breast cancer (early onset);	chr5:56834707	chr5:56927874~56929573:+
SARC	cis	rs3822625	1	rs16886397	ENSG00000271828.1	CTD-2310F14.1	3.87	0.000144	0.0414	0.49	0.25	Breast cancer (early onset);	chr5:56838449	chr5:56927874~56929573:+
SARC	cis	rs61160187	0.61	rs4700399	ENSG00000272308.1	RP11-231G3.1	-3.87	0.000144	0.0414	-0.21	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840627	chr5:60866457~60866935:-
SARC	cis	rs34375054	0.624	rs12826658	ENSG00000279233.1	RP11-158L12.4	3.87	0.000144	0.0414	0.3	0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125195691	chr12:125138245~125141711:+
SARC	cis	rs34375054	0.624	rs12832525	ENSG00000279233.1	RP11-158L12.4	3.87	0.000144	0.0414	0.3	0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125195820	chr12:125138245~125141711:+
SARC	cis	rs34375054	0.624	rs7295689	ENSG00000279233.1	RP11-158L12.4	3.87	0.000144	0.0414	0.3	0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125196376	chr12:125138245~125141711:+
SARC	cis	rs9902453	0.9	rs9910970	ENSG00000264538.5	SUZ12P1	3.87	0.000144	0.0414	0.17	0.25	Coffee consumption (cups per day);	chr17:30151311	chr17:30709299~30790908:+
SARC	cis	rs6163	0.588	rs10786706	ENSG00000236937.2	PTGES3P4	3.87	0.000144	0.0414	0.28	0.25	Waist circumference;Hip circumference;	chr10:102740902	chr10:102845595~102845950:+
SARC	cis	rs7166081	0.95	rs12476	ENSG00000270964.1	RP11-502I4.3	-3.87	0.000144	0.0414	-0.29	-0.25	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67201388	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs12148121	ENSG00000270964.1	RP11-502I4.3	-3.87	0.000144	0.0414	-0.29	-0.25	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67202584	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs4776905	ENSG00000270964.1	RP11-502I4.3	-3.87	0.000144	0.0414	-0.29	-0.25	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67207992	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs16953610	ENSG00000270964.1	RP11-502I4.3	-3.87	0.000144	0.0414	-0.29	-0.25	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67209254	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs877177	ENSG00000270964.1	RP11-502I4.3	-3.87	0.000144	0.0414	-0.29	-0.25	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67213622	chr15:67541072~67542604:-
SARC	cis	rs7617773	0.817	rs4131362	ENSG00000228638.1	FCF1P2	-3.87	0.000144	0.0414	-0.28	-0.25	Coronary artery disease;	chr3:48287546	chr3:48290793~48291375:-
SARC	cis	rs6472827	0.645	rs2956059	ENSG00000253983.2	RP1-16A9.1	3.87	0.000144	0.0414	0.34	0.25	Uterine fibroids;	chr8:74197795	chr8:74199396~74208441:+
SARC	cis	rs6472827	0.571	rs2936692	ENSG00000253983.2	RP1-16A9.1	3.87	0.000144	0.0414	0.34	0.25	Uterine fibroids;	chr8:74199039	chr8:74199396~74208441:+
SARC	cis	rs5752326	1	rs134144	ENSG00000261188.1	CTA-445C9.14	-3.86	0.000144	0.0415	-0.49	-0.25	Ischemic stroke;	chr22:26513004	chr22:26512537~26514568:+
SARC	cis	rs763121	0.819	rs5750629	ENSG00000273076.1	RP3-508I15.22	3.86	0.000144	0.0415	0.26	0.25	Menopause (age at onset);	chr22:38589060	chr22:38743495~38743910:+
SARC	cis	rs763121	0.819	rs5757160	ENSG00000273076.1	RP3-508I15.22	3.86	0.000144	0.0415	0.26	0.25	Menopause (age at onset);	chr22:38593641	chr22:38743495~38743910:+
SARC	cis	rs763121	0.853	rs5750633	ENSG00000273076.1	RP3-508I15.22	3.86	0.000144	0.0415	0.26	0.25	Menopause (age at onset);	chr22:38597462	chr22:38743495~38743910:+
SARC	cis	rs2836974	0.533	rs4817999	ENSG00000255568.3	BRWD1-AS2	-3.86	0.000144	0.0415	-0.24	-0.25	Cognitive function;	chr21:39182429	chr21:39313935~39314962:+
SARC	cis	rs2404602	0.692	rs35557205	ENSG00000259422.1	RP11-593F23.1	3.86	0.000144	0.0415	0.28	0.25	Blood metabolite levels;	chr15:76838370	chr15:76174891~76181486:-
SARC	cis	rs6570726	0.967	rs439017	ENSG00000235652.6	RP11-545I5.3	3.86	0.000144	0.0415	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145484987	chr6:145799409~145886585:+
SARC	cis	rs17270561	0.609	rs7772382	ENSG00000272462.2	U91328.19	-3.86	0.000144	0.0415	-0.23	-0.25	Iron status biomarkers;	chr6:25707888	chr6:25992662~26001775:+
SARC	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-3.86	0.000144	0.0415	-0.32	-0.25	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
SARC	cis	rs9283706	0.623	rs10055631	ENSG00000229666.1	MAST4-AS1	-3.86	0.000145	0.0416	-0.3	-0.25	Coronary artery disease;	chr5:67009610	chr5:67001383~67003953:-
SARC	cis	rs3934047	0.869	rs12912221	ENSG00000274376.3	ADAMTS7P1	-3.86	0.000145	0.0416	-0.27	-0.25	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81770365	chr15:82298553~82334609:+
SARC	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-3.86	0.000145	0.0416	-0.37	-0.25	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
SARC	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-3.86	0.000145	0.0416	-0.37	-0.25	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
SARC	cis	rs4679904	0.92	rs4679901	ENSG00000243116.1	RP11-564C24.1	3.86	0.000145	0.0416	0.26	0.25	Primary biliary cholangitis;	chr3:160595386	chr3:159721524~159722401:-
SARC	cis	rs10991814	0.92	rs16907297	ENSG00000225511.5	LINC00475	3.86	0.000145	0.0416	0.51	0.25	Neutrophil percentage of granulocytes;	chr9:91246652	chr9:92141298~92160114:+
SARC	cis	rs10895987	0.955	rs7113761	ENSG00000254614.2	AP003068.23	3.86	0.000145	0.0416	0.35	0.25	Blood protein levels;	chr11:65159251	chr11:65177606~65181834:-
SARC	cis	rs72615157	0.634	rs79986079	ENSG00000242294.5	STAG3L5P	3.86	0.000145	0.0416	0.2	0.25	Lung function (FEV1/FVC);	chr7:100204421	chr7:100336079~100351900:+
SARC	cis	rs72627123	1	rs17093474	ENSG00000259065.1	RP5-1021I20.1	-3.86	0.000145	0.0416	-0.4	-0.25	Morning vs. evening chronotype;	chr14:73875710	chr14:73787360~73803270:+
SARC	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	3.86	0.000145	0.0417	0.28	0.25	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
SARC	cis	rs6082278	0.563	rs6113097	ENSG00000225127.2	LINC00237	3.86	0.000145	0.0417	0.27	0.25	Colonoscopy-negative controls vs population controls;	chr20:20997151	chr20:21087604~21106358:-
SARC	cis	rs2307449	0.929	rs6496571	ENSG00000261441.1	RP11-217B1.2	3.86	0.000145	0.0417	0.31	0.25	Menopause (age at onset);	chr15:89274679	chr15:89335053~89336161:+
SARC	cis	rs6472827	0.645	rs2936685	ENSG00000253983.2	RP1-16A9.1	3.86	0.000145	0.0417	0.34	0.25	Uterine fibroids;	chr8:74202449	chr8:74199396~74208441:+
SARC	cis	rs12468226	0.689	rs17651413	ENSG00000272966.1	RP11-686O6.1	3.86	0.000145	0.0417	0.4	0.25	Urate levels;	chr2:202104086	chr2:202336739~202337200:+
SARC	cis	rs718433	0.636	rs6572102	ENSG00000199436.1	SNORD9	-3.86	0.000145	0.0417	-0.28	-0.25	Intraocular pressure;	chr14:21816090	chr14:21392150~21392253:-
SARC	cis	rs910316	0.967	rs175451	ENSG00000279594.1	RP11-950C14.10	-3.86	0.000145	0.0417	-0.27	-0.25	Height;	chr14:75123026	chr14:75011269~75012851:-
SARC	cis	rs62246343	0.541	rs2596937	ENSG00000254485.4	RP11-380O24.1	3.86	0.000145	0.0417	0.3	0.25	Fibrinogen levels;	chr3:9439222	chr3:9292588~9363303:-
SARC	cis	rs2929451	0.566	rs17658270	ENSG00000233609.3	RP11-62H7.2	3.86	0.000145	0.0417	0.22	0.25	Nose size;	chr8:9296109	chr8:8961200~8979025:+
SARC	cis	rs12817211	0.549	rs7138945	ENSG00000272368.2	RP4-605O3.4	-3.86	0.000145	0.0417	-0.24	-0.25	Colorectal or endometrial cancer;	chr12:50145636	chr12:50112197~50165618:+
SARC	cis	rs7246657	1	rs1529957	ENSG00000226686.6	LINC01535	-3.86	0.000145	0.0417	-0.35	-0.25	Coronary artery calcification;	chr19:37248899	chr19:37251912~37265535:+
SARC	cis	rs1057510	0.79	rs16932801	ENSG00000240370.5	U47924.6	3.86	0.000145	0.0417	0.37	0.25	Myopia (pathological);	chr12:6611216	chr12:6873389~6884741:+
SARC	cis	rs6472827	0.645	rs2956053	ENSG00000253983.2	RP1-16A9.1	3.86	0.000145	0.0417	0.34	0.25	Uterine fibroids;	chr8:74200205	chr8:74199396~74208441:+
SARC	cis	rs7806994	1	rs7806994	ENSG00000223559.1	RP11-700P18.1	-3.86	0.000145	0.0417	-0.34	-0.25	PR interval in Tripanosoma cruzi seropositivity;	chr7:56071812	chr7:56288230~56291425:+
SARC	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	3.86	0.000145	0.0417	0.38	0.25	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
SARC	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	3.86	0.000145	0.0417	0.38	0.25	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
SARC	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	3.86	0.000145	0.0417	0.38	0.25	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
SARC	cis	rs17174870	1	rs12477716	ENSG00000228251.1	AC012442.6	-3.86	0.000145	0.0417	-0.31	-0.25	Multiple sclerosis;	chr2:111911067	chr2:112590796~112591939:+
SARC	cis	rs758129	0.501	rs3176202	ENSG00000261441.1	RP11-217B1.2	3.86	0.000145	0.0417	0.31	0.25	Schizophrenia;	chr15:89323055	chr15:89335053~89336161:+
SARC	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-3.86	0.000145	0.0417	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-3.86	0.000145	0.0417	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
SARC	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-3.86	0.000145	0.0417	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
SARC	cis	rs7586673	0.866	rs7579662	ENSG00000227403.1	AC009299.3	-3.86	0.000145	0.0417	-0.23	-0.25	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161244739~161249050:+
SARC	cis	rs8054556	0.74	rs3924855	ENSG00000183604.13	SMG1P5	-3.86	0.000146	0.0418	-0.23	-0.25	Autism spectrum disorder or schizophrenia;	chr16:29943634	chr16:30267553~30335374:-
SARC	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-3.86	0.000146	0.0418	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
SARC	cis	rs853679	0.517	rs9380047	ENSG00000216901.1	AL022393.7	3.86	0.000146	0.0418	0.35	0.25	Depression;	chr6:28070115	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs7755442	ENSG00000216901.1	AL022393.7	3.86	0.000146	0.0418	0.35	0.25	Depression;	chr6:28071237	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs55747925	ENSG00000216901.1	AL022393.7	3.86	0.000146	0.0418	0.35	0.25	Depression;	chr6:28076559	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs56310871	ENSG00000216901.1	AL022393.7	3.86	0.000146	0.0418	0.35	0.25	Depression;	chr6:28076704	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs34716816	ENSG00000216901.1	AL022393.7	3.86	0.000146	0.0418	0.35	0.25	Depression;	chr6:28078391	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs9393884	ENSG00000216901.1	AL022393.7	3.86	0.000146	0.0418	0.35	0.25	Depression;	chr6:28079011	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs9380049	ENSG00000216901.1	AL022393.7	3.86	0.000146	0.0418	0.35	0.25	Depression;	chr6:28080757	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs9380050	ENSG00000216901.1	AL022393.7	3.86	0.000146	0.0418	0.35	0.25	Depression;	chr6:28080760	chr6:28176188~28176674:+
SARC	cis	rs6859704	0.818	rs62365229	ENSG00000249655.1	CTC-325J23.2	-3.86	0.000146	0.0418	-0.37	-0.25	IgG glycosylation;	chr5:79662726	chr5:80630313~80631590:-
SARC	cis	rs853679	1	rs6901575	ENSG00000272009.1	RP1-313I6.12	-3.86	0.000146	0.0418	-0.34	-0.25	Depression;	chr6:28283207	chr6:28078792~28081130:-
SARC	cis	rs7131987	0.65	rs10843377	ENSG00000275476.1	RP11-996F15.4	3.86	0.000146	0.0418	0.29	0.25	QT interval;	chr12:29284120	chr12:29277397~29277882:-
SARC	cis	rs997295	1	rs8032675	ENSG00000259410.4	RP11-34F13.3	3.86	0.000146	0.0418	0.26	0.25	Motion sickness;	chr15:67667126	chr15:67832725~67873866:+
SARC	cis	rs7408868	1	rs7408868	ENSG00000266913.1	CTC-548K16.2	-3.86	0.000146	0.0418	-0.36	-0.25	Pulse pressure;	chr19:15174868	chr19:14305458~14370196:-
SARC	cis	rs2803122	0.967	rs10123206	ENSG00000273226.1	RP11-513M16.8	3.86	0.000146	0.0418	0.23	0.25	Pulse pressure;	chr9:19246846	chr9:19375451~19375996:+
SARC	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	3.86	0.000146	0.0418	0.29	0.25	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
SARC	cis	rs1061377	0.608	rs35168672	ENSG00000249207.1	RP11-360F5.1	-3.86	0.000146	0.0418	-0.26	-0.25	Uric acid levels;	chr4:39078902	chr4:39112677~39126818:-
SARC	cis	rs10911902	0.913	rs80040530	ENSG00000229739.2	RP11-295K2.3	-3.86	0.000146	0.0418	-0.34	-0.25	Schizophrenia;	chr1:186603052	chr1:186435161~186470291:+
SARC	cis	rs1062177	1	rs17804178	ENSG00000254226.4	CTB-12O2.1	3.86	0.000146	0.0418	0.33	0.25	Preschool internalizing problems;	chr5:151818168	chr5:151949571~152270448:+
SARC	cis	rs1062177	1	rs2964612	ENSG00000254226.4	CTB-12O2.1	3.86	0.000146	0.0418	0.33	0.25	Preschool internalizing problems;	chr5:151819189	chr5:151949571~152270448:+
SARC	cis	rs3805389	0.504	rs56288855	ENSG00000273257.1	RP11-177J6.1	-3.86	0.000146	0.0418	-0.37	-0.25	Waist-to-hip ratio adjusted for body mass index;	chr4:55603178	chr4:55387949~55388271:+
SARC	cis	rs9309473	0.5	rs1528169	ENSG00000163016.8	ALMS1P	-3.86	0.000146	0.0419	-0.28	-0.25	Metabolite levels;	chr2:73442058	chr2:73644919~73685576:+
SARC	cis	rs67478160	0.643	rs8004408	ENSG00000269958.1	RP11-73M18.8	3.86	0.000146	0.0419	0.23	0.25	Schizophrenia;	chr14:103737601	chr14:103696353~103697163:+
SARC	cis	rs61160187	0.582	rs34619	ENSG00000215032.2	GNL3LP1	3.86	0.000146	0.0419	0.24	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61169538	chr5:60891935~60893577:-
SARC	cis	rs4679904	0.842	rs11721112	ENSG00000243116.1	RP11-564C24.1	3.86	0.000146	0.0419	0.25	0.25	Primary biliary cholangitis;	chr3:160571496	chr3:159721524~159722401:-
SARC	cis	rs367615	0.959	rs17161951	ENSG00000249476.1	CTD-2587M2.1	-3.86	0.000146	0.0419	-0.32	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109594889	chr5:109237120~109326369:-
SARC	cis	rs9739682	0.552	rs9739766	ENSG00000139239.7	RPL14P1	-3.86	0.000146	0.0419	-0.24	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;	chr12:62094667	chr12:62965325~62965969:+
SARC	cis	rs7772486	0.534	rs34541797	ENSG00000270638.1	RP3-466P17.1	3.86	0.000146	0.0419	0.22	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145735570~145737218:+
SARC	cis	rs10875943	0.751	rs56222401	ENSG00000258017.1	RP11-386G11.10	-3.86	0.000146	0.0419	-0.31	-0.25	Prostate cancer;	chr12:49278931	chr12:49127782~49147869:+
SARC	cis	rs3758785	0.565	rs598645	ENSG00000255893.1	RP11-685N10.1	3.86	0.000146	0.0419	0.25	0.25	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94338579	chr11:94472908~94473570:-
SARC	cis	rs910316	0.967	rs119076	ENSG00000279594.1	RP11-950C14.10	-3.86	0.000146	0.0419	-0.27	-0.25	Height;	chr14:75105716	chr14:75011269~75012851:-
SARC	cis	rs11073619	0.773	rs28612692	ENSG00000230373.7	GOLGA6L5P	-3.86	0.000146	0.0419	-0.38	-0.25	Positive affect;	chr15:84601836	chr15:84507885~84516814:-
SARC	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	3.86	0.000146	0.0419	0.29	0.25	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
SARC	cis	rs7246657	0.943	rs8109038	ENSG00000226686.6	LINC01535	3.86	0.000146	0.0419	0.34	0.25	Coronary artery calcification;	chr19:37524807	chr19:37251912~37265535:+
SARC	cis	rs3822625	1	rs56822906	ENSG00000271828.1	CTD-2310F14.1	3.86	0.000147	0.042	0.49	0.25	Breast cancer (early onset);	chr5:56870087	chr5:56927874~56929573:+
SARC	cis	rs3822625	1	rs9686160	ENSG00000271828.1	CTD-2310F14.1	3.86	0.000147	0.042	0.49	0.25	Breast cancer (early onset);	chr5:56876174	chr5:56927874~56929573:+
SARC	cis	rs3822625	1	rs9687226	ENSG00000271828.1	CTD-2310F14.1	3.86	0.000147	0.042	0.49	0.25	Breast cancer (early onset);	chr5:56880619	chr5:56927874~56929573:+
SARC	cis	rs3822625	1	rs16877026	ENSG00000271828.1	CTD-2310F14.1	3.86	0.000147	0.042	0.49	0.25	Breast cancer (early onset);	chr5:56889099	chr5:56927874~56929573:+
SARC	cis	rs3822625	1	rs76058858	ENSG00000271828.1	CTD-2310F14.1	3.86	0.000147	0.042	0.49	0.25	Breast cancer (early onset);	chr5:56890612	chr5:56927874~56929573:+
SARC	cis	rs77956314	0.901	rs7132339	ENSG00000277840.1	RP11-103B5.4	3.86	0.000147	0.042	0.35	0.25	Hippocampal volume;Subcortical brain region volumes;	chr12:116898107	chr12:117002463~117003152:+
SARC	cis	rs7615952	0.512	rs4679430	ENSG00000248787.1	RP11-666A20.4	-3.86	0.000147	0.042	-0.33	-0.25	Blood pressure (smoking interaction);	chr3:125639049	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.512	rs34651730	ENSG00000248787.1	RP11-666A20.4	-3.86	0.000147	0.042	-0.33	-0.25	Blood pressure (smoking interaction);	chr3:125639796	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.512	rs2979334	ENSG00000248787.1	RP11-666A20.4	-3.86	0.000147	0.042	-0.33	-0.25	Blood pressure (smoking interaction);	chr3:125639980	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.512	rs11929125	ENSG00000248787.1	RP11-666A20.4	-3.86	0.000147	0.042	-0.33	-0.25	Blood pressure (smoking interaction);	chr3:125640599	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.512	rs11921452	ENSG00000248787.1	RP11-666A20.4	-3.86	0.000147	0.042	-0.33	-0.25	Blood pressure (smoking interaction);	chr3:125640906	chr3:125908005~125910272:-
SARC	cis	rs7615952	0.512	rs2922175	ENSG00000248787.1	RP11-666A20.4	-3.86	0.000147	0.042	-0.33	-0.25	Blood pressure (smoking interaction);	chr3:125642516	chr3:125908005~125910272:-
SARC	cis	rs858239	0.6	rs2014768	ENSG00000226816.2	AC005082.12	3.86	0.000147	0.042	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23206013~23208045:+
SARC	cis	rs858239	0.6	rs6978827	ENSG00000226816.2	AC005082.12	3.86	0.000147	0.042	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23206013~23208045:+
SARC	cis	rs858239	0.6	rs7790157	ENSG00000226816.2	AC005082.12	3.86	0.000147	0.042	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23206013~23208045:+
SARC	cis	rs858239	0.6	rs6960001	ENSG00000226816.2	AC005082.12	3.86	0.000147	0.042	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23206013~23208045:+
SARC	cis	rs858239	0.6	rs10237755	ENSG00000226816.2	AC005082.12	3.86	0.000147	0.042	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23206013~23208045:+
SARC	cis	rs858239	0.6	rs6961131	ENSG00000226816.2	AC005082.12	3.86	0.000147	0.042	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23206013~23208045:+
SARC	cis	rs4835473	0.9	rs35419968	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143734583	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.868	rs66634585	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143734608	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.868	rs35016507	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143734617	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs67600034	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143734670	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs35655934	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143734697	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs35515006	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143734705	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs34525847	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143734970	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs35277115	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143735001	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs34653324	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143735058	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs35947648	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143735092	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.838	rs35800634	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143735199	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.838	rs34505330	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143735206	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs4597770	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143735239	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.868	rs4629390	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143735302	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.838	rs4583708	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143735610	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.864	rs13117932	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143735873	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs34257944	ENSG00000251600.4	RP11-673E1.1	-3.86	0.000147	0.042	-0.24	-0.25	Immature fraction of reticulocytes;	chr4:143736443	chr4:143912331~143982454:+
SARC	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-3.86	0.000147	0.042	-0.22	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
SARC	cis	rs950776	0.518	rs8053	ENSG00000261762.1	RP11-650L12.2	-3.86	0.000147	0.042	-0.26	-0.25	Sudden cardiac arrest;	chr15:78548878	chr15:78589123~78591276:-
SARC	cis	rs9907295	1	rs11653051	ENSG00000270240.2	AC015849.2	3.86	0.000147	0.042	0.43	0.25	Fibroblast growth factor basic levels;	chr17:35909166	chr17:35868967~35885863:+
SARC	cis	rs720064	0.586	rs12956330	ENSG00000265752.2	RP11-403A21.1	3.86	0.000147	0.0421	0.24	0.25	Strep throat;	chr18:23981536	chr18:23957754~23982556:-
SARC	cis	rs801193	1	rs13239306	ENSG00000236529.1	RP13-254B10.1	-3.86	0.000147	0.0421	-0.26	-0.25	Aortic root size;	chr7:66671030	chr7:65840212~65840596:+
SARC	cis	rs34097030	1	rs34097030	ENSG00000207217.1	SNORA42	-3.86	0.000147	0.0421	-0.33	-0.25	Reticulocyte fraction of red cells;	chr7:6014758	chr7:6016877~6017011:+
SARC	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	3.86	0.000147	0.0421	0.25	0.25	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
SARC	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	3.86	0.000147	0.0421	0.35	0.25	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
SARC	cis	rs7811142	0.83	rs28495773	ENSG00000078319.8	PMS2P1	-3.86	0.000147	0.0421	-0.36	-0.25	Platelet count;	chr7:100345960	chr7:100320992~100341908:-
SARC	cis	rs17695224	0.675	rs7252671	ENSG00000275055.1	CTC-471J1.11	-3.86	0.000147	0.0421	-0.26	-0.25	HDL cholesterol;HDL cholesterol levels;	chr19:51834830	chr19:52049007~52049754:+
SARC	cis	rs394563	0.591	rs11155641	ENSG00000231760.4	RP11-350J20.5	-3.86	0.000147	0.0421	-0.31	-0.25	Dupuytren's disease;	chr6:149327459	chr6:149796151~149826294:-
SARC	cis	rs950776	0.518	rs2869544	ENSG00000261762.1	RP11-650L12.2	-3.86	0.000147	0.0421	-0.26	-0.25	Sudden cardiac arrest;	chr15:78547058	chr15:78589123~78591276:-
SARC	cis	rs3805389	1	rs3805389	ENSG00000249700.7	SRD5A3-AS1	-3.86	0.000147	0.0421	-0.33	-0.25	Waist-to-hip ratio adjusted for body mass index;	chr4:55616583	chr4:55363971~55395847:-
SARC	cis	rs6452524	0.905	rs1478482	ENSG00000248112.1	RP11-78C3.1	3.86	0.000147	0.0422	0.28	0.25	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:82919376~82921119:-
SARC	cis	rs7208859	0.623	rs8082537	ENSG00000264538.5	SUZ12P1	-3.86	0.000147	0.0422	-0.26	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.673	rs9907197	ENSG00000264538.5	SUZ12P1	-3.86	0.000147	0.0422	-0.26	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.673	rs9915963	ENSG00000264538.5	SUZ12P1	-3.86	0.000147	0.0422	-0.26	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30709299~30790908:+
SARC	cis	rs957140	0.687	rs3933084	ENSG00000214391.3	TUBAP2	3.86	0.000148	0.0422	0.24	0.25	Homocysteine levels;	chr11:89415614	chr11:90282560~90284172:+
SARC	cis	rs4950322	0.748	rs17360812	ENSG00000278811.3	LINC00624	-3.86	0.000148	0.0422	-0.25	-0.25	Protein quantitative trait loci;	chr1:147355010	chr1:147258885~147517875:-
SARC	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-3.86	0.000148	0.0422	-0.36	-0.25	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
SARC	cis	rs7811142	0.943	rs3900792	ENSG00000078319.8	PMS2P1	-3.86	0.000148	0.0422	-0.35	-0.25	Platelet count;	chr7:100406954	chr7:100320992~100341908:-
SARC	cis	rs28386778	0.863	rs1376110	ENSG00000240280.5	TCAM1P	-3.86	0.000148	0.0422	-0.31	-0.25	Prudent dietary pattern;	chr17:63702567	chr17:63849292~63864379:+
SARC	cis	rs7590368	1	rs7590368	ENSG00000272275.1	RP11-791G15.2	3.86	0.000148	0.0422	0.3	0.25	Educational attainment (years of education);	chr2:10821348	chr2:10767875~10770058:-
SARC	cis	rs7590368	1	rs55968911	ENSG00000272275.1	RP11-791G15.2	3.86	0.000148	0.0422	0.3	0.25	Educational attainment (years of education);	chr2:10821714	chr2:10767875~10770058:-
SARC	cis	rs7590368	1	rs55771723	ENSG00000272275.1	RP11-791G15.2	3.86	0.000148	0.0422	0.3	0.25	Educational attainment (years of education);	chr2:10821776	chr2:10767875~10770058:-
SARC	cis	rs7267979	0.966	rs2151144	ENSG00000276952.1	RP5-965G21.6	-3.86	0.000148	0.0422	-0.24	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25284915~25285588:-
SARC	cis	rs2307449	0.929	rs17803620	ENSG00000261441.1	RP11-217B1.2	3.86	0.000148	0.0423	0.31	0.25	Menopause (age at onset);	chr15:89260812	chr15:89335053~89336161:+
SARC	cis	rs2307449	0.929	rs7495635	ENSG00000261441.1	RP11-217B1.2	3.86	0.000148	0.0423	0.31	0.25	Menopause (age at onset);	chr15:89267679	chr15:89335053~89336161:+
SARC	cis	rs7208859	0.623	rs7219361	ENSG00000266490.1	CTD-2349P21.9	3.86	0.000148	0.0423	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30792372~30792833:+
SARC	cis	rs10911902	0.602	rs6425024	ENSG00000229739.2	RP11-295K2.3	-3.86	0.000148	0.0423	-0.35	-0.25	Schizophrenia;	chr1:186305001	chr1:186435161~186470291:+
SARC	cis	rs10911902	0.602	rs2273777	ENSG00000229739.2	RP11-295K2.3	-3.86	0.000148	0.0423	-0.35	-0.25	Schizophrenia;	chr1:186305043	chr1:186435161~186470291:+
SARC	cis	rs61160187	0.582	rs34619	ENSG00000272308.1	RP11-231G3.1	-3.86	0.000148	0.0423	-0.21	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:61169538	chr5:60866457~60866935:-
SARC	cis	rs448720	0.554	rs7171219	ENSG00000259410.4	RP11-34F13.3	-3.86	0.000148	0.0423	-0.26	-0.25	Cognitive performance;	chr15:67821433	chr15:67832725~67873866:+
SARC	cis	rs42490	0.674	rs447989	ENSG00000251136.7	RP11-37B2.1	-3.86	0.000148	0.0423	-0.29	-0.25	Leprosy;	chr8:89848575	chr8:89609409~89757727:-
SARC	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	3.86	0.000148	0.0423	0.27	0.25	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
SARC	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-3.86	0.000148	0.0423	-0.26	-0.25	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
SARC	cis	rs7617773	0.746	rs6796343	ENSG00000228638.1	FCF1P2	-3.86	0.000148	0.0423	-0.28	-0.25	Coronary artery disease;	chr3:48240531	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.817	rs13059037	ENSG00000228638.1	FCF1P2	-3.86	0.000148	0.0423	-0.28	-0.25	Coronary artery disease;	chr3:48246389	chr3:48290793~48291375:-
SARC	cis	rs860818	1	rs858232	ENSG00000226816.2	AC005082.12	3.86	0.000148	0.0423	0.72	0.25	Initial pursuit acceleration;	chr7:23202100	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858298	ENSG00000226816.2	AC005082.12	3.86	0.000148	0.0423	0.72	0.25	Initial pursuit acceleration;	chr7:23205301	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858293	ENSG00000226816.2	AC005082.12	3.86	0.000148	0.0423	0.72	0.25	Initial pursuit acceleration;	chr7:23206705	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858292	ENSG00000226816.2	AC005082.12	3.86	0.000148	0.0423	0.72	0.25	Initial pursuit acceleration;	chr7:23207114	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858285	ENSG00000226816.2	AC005082.12	3.86	0.000148	0.0423	0.72	0.25	Initial pursuit acceleration;	chr7:23209899	chr7:23206013~23208045:+
SARC	cis	rs2307449	0.929	rs1981623	ENSG00000261441.1	RP11-217B1.2	3.86	0.000148	0.0423	0.3	0.25	Menopause (age at onset);	chr15:89263479	chr15:89335053~89336161:+
SARC	cis	rs2307449	0.892	rs1981624	ENSG00000261441.1	RP11-217B1.2	3.86	0.000148	0.0423	0.3	0.25	Menopause (age at onset);	chr15:89263490	chr15:89335053~89336161:+
SARC	cis	rs2307449	0.929	rs28573320	ENSG00000261441.1	RP11-217B1.2	3.86	0.000148	0.0423	0.3	0.25	Menopause (age at onset);	chr15:89265108	chr15:89335053~89336161:+
SARC	cis	rs2307449	0.929	rs7167930	ENSG00000261441.1	RP11-217B1.2	3.86	0.000148	0.0423	0.3	0.25	Menopause (age at onset);	chr15:89267438	chr15:89335053~89336161:+
SARC	cis	rs308447	0.516	rs6815982	ENSG00000224786.1	CETN4P	-3.86	0.000148	0.0424	-0.31	-0.25	Perceived unattractiveness to mosquitoes;	chr4:122756317	chr4:122730548~122732193:-
SARC	cis	rs12200782	0.929	rs72836460	ENSG00000272462.2	U91328.19	-3.86	0.000148	0.0424	-0.39	-0.25	Small cell lung carcinoma;	chr6:26351662	chr6:25992662~26001775:+
SARC	cis	rs2274273	0.682	rs8008134	ENSG00000258413.1	RP11-665C16.6	-3.86	0.000148	0.0424	-0.27	-0.25	Protein biomarker;	chr14:55040802	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.522	rs2251366	ENSG00000258413.1	RP11-665C16.6	-3.86	0.000148	0.0424	-0.27	-0.25	Protein biomarker;	chr14:55051438	chr14:55262767~55272075:-
SARC	cis	rs7617773	0.78	rs71323396	ENSG00000228638.1	FCF1P2	-3.86	0.000148	0.0424	-0.29	-0.25	Coronary artery disease;	chr3:48333244	chr3:48290793~48291375:-
SARC	cis	rs858239	0.899	rs2268745	ENSG00000226816.2	AC005082.12	3.86	0.000148	0.0424	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23206013~23208045:+
SARC	cis	rs745109	0.882	rs55866634	ENSG00000273080.1	RP11-301O19.1	3.86	0.000148	0.0424	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86458999	chr2:86195590~86196049:+
SARC	cis	rs745109	0.832	rs56169889	ENSG00000273080.1	RP11-301O19.1	3.86	0.000148	0.0424	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86459162	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs72930369	ENSG00000273080.1	RP11-301O19.1	3.86	0.000148	0.0424	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86460260	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs56242451	ENSG00000273080.1	RP11-301O19.1	3.86	0.000148	0.0424	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86462933	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs59183618	ENSG00000273080.1	RP11-301O19.1	3.86	0.000148	0.0424	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86465649	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs57836876	ENSG00000273080.1	RP11-301O19.1	3.86	0.000148	0.0424	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86466094	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs34605051	ENSG00000273080.1	RP11-301O19.1	3.86	0.000148	0.0424	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86466703	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs72930385	ENSG00000273080.1	RP11-301O19.1	3.86	0.000148	0.0424	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86467669	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs72930387	ENSG00000273080.1	RP11-301O19.1	3.86	0.000148	0.0424	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86468062	chr2:86195590~86196049:+
SARC	cis	rs745109	0.765	rs56055358	ENSG00000273080.1	RP11-301O19.1	3.86	0.000148	0.0424	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86471430	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs58829418	ENSG00000273080.1	RP11-301O19.1	3.86	0.000148	0.0424	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86472593	chr2:86195590~86196049:+
SARC	cis	rs897984	0.609	rs732173	ENSG00000260911.2	RP11-196G11.2	3.86	0.000149	0.0424	0.24	0.24	Dementia with Lewy bodies;	chr16:31038702	chr16:31043150~31049868:+
SARC	cis	rs897984	0.609	rs1108431	ENSG00000260911.2	RP11-196G11.2	3.86	0.000149	0.0424	0.24	0.24	Dementia with Lewy bodies;	chr16:31043286	chr16:31043150~31049868:+
SARC	cis	rs4267450	0.793	rs73017620	ENSG00000261770.1	CTC-459F4.1	3.86	0.000149	0.0424	0.41	0.24	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28320420	chr19:27757184~27760849:-
SARC	cis	rs9992667	0.956	rs73232890	ENSG00000231160.8	KLF3-AS1	3.86	0.000149	0.0424	0.24	0.24	Eosinophil percentage of granulocytes;	chr4:38683420	chr4:38612701~38664883:-
SARC	cis	rs2274273	0.682	rs10145268	ENSG00000258413.1	RP11-665C16.6	-3.86	0.000149	0.0424	-0.27	-0.24	Protein biomarker;	chr14:55037796	chr14:55262767~55272075:-
SARC	cis	rs7927592	0.513	rs689075	ENSG00000212093.1	AP000807.1	3.86	0.000149	0.0424	0.23	0.24	Total body bone mineral density;	chr11:68426964	chr11:68506083~68506166:-
SARC	cis	rs1413299	1	rs1413299	ENSG00000270412.1	RP11-92C4.6	3.86	0.000149	0.0424	0.29	0.24	Epithelial ovarian cancer;	chr9:98998959	chr9:98943337~98943775:-
SARC	cis	rs6495122	0.501	rs7167261	ENSG00000260269.4	CTD-2323K18.1	3.86	0.000149	0.0424	0.32	0.24	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75051466	chr15:75527150~75601205:-
SARC	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-3.86	0.000149	0.0425	-0.22	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
SARC	cis	rs9341808	0.528	rs2322753	ENSG00000272129.1	RP11-250B2.6	3.86	0.000149	0.0425	0.32	0.24	Sitting height ratio;	chr6:80333148	chr6:80355424~80356859:+
SARC	cis	rs9341808	0.556	rs2223875	ENSG00000272129.1	RP11-250B2.6	3.86	0.000149	0.0425	0.32	0.24	Sitting height ratio;	chr6:80335735	chr6:80355424~80356859:+
SARC	cis	rs9341808	0.587	rs3805859	ENSG00000272129.1	RP11-250B2.6	3.86	0.000149	0.0425	0.32	0.24	Sitting height ratio;	chr6:80339229	chr6:80355424~80356859:+
SARC	cis	rs6142102	0.923	rs4911379	ENSG00000275784.1	RP5-1125A11.6	-3.86	0.000149	0.0425	-0.31	-0.24	Skin pigmentation;	chr20:33947499	chr20:33989480~33991818:-
SARC	cis	rs8028182	0.636	rs4545784	ENSG00000260206.1	CTD-2026K11.2	-3.86	0.000149	0.0425	-0.29	-0.24	Sudden cardiac arrest;	chr15:75463310	chr15:75636139~75639239:+
SARC	cis	rs76693355	0.512	rs10790381	ENSG00000232460.4	BMPR1APS2	-3.86	0.000149	0.0425	-0.29	-0.24	Intraocular pressure;	chr11:120386786	chr11:121361854~121362865:-
SARC	cis	rs9828933	0.626	rs73119018	ENSG00000280620.1	SCAANT1	3.86	0.000149	0.0425	0.41	0.24	Type 2 diabetes;	chr3:63989652	chr3:63911518~63911772:-
SARC	cis	rs858239	0.602	rs6953996	ENSG00000226816.2	AC005082.12	3.86	0.000149	0.0425	0.31	0.24	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23206013~23208045:+
SARC	cis	rs8098244	0.576	rs11082762	ENSG00000264745.1	TTC39C-AS1	3.86	0.000149	0.0426	0.26	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23785889	chr18:23994213~24015339:-
SARC	cis	rs9902453	0.753	rs7226121	ENSG00000264538.5	SUZ12P1	3.86	0.00015	0.0426	0.18	0.24	Coffee consumption (cups per day);	chr17:29881107	chr17:30709299~30790908:+
SARC	cis	rs17174870	0.955	rs74562473	ENSG00000228251.1	AC012442.6	3.86	0.00015	0.0426	0.32	0.24	Multiple sclerosis;	chr2:111927103	chr2:112590796~112591939:+
SARC	cis	rs853679	0.55	rs1150692	ENSG00000272009.1	RP1-313I6.12	-3.85	0.00015	0.0427	-0.27	-0.24	Depression;	chr6:28206179	chr6:28078792~28081130:-
SARC	cis	rs4835473	0.932	rs12509642	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143737080	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.801	rs76574827	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143737303	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.832	rs62337616	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143737307	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.832	rs66717029	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143737318	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.864	rs17750354	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143737352	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.897	rs17693768	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143737503	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.832	rs35398499	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143737715	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.832	rs35763177	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143737717	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.9	rs5015759	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143738050	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs34950821	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143738174	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs5016158	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143738472	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs5016157	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143738587	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.808	rs13134564	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143738763	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.838	rs13134571	ENSG00000251600.4	RP11-673E1.1	-3.85	0.00015	0.0427	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143738771	chr4:143912331~143982454:+
SARC	cis	rs321358	0.732	rs17535419	ENSG00000271584.1	RP11-89C3.4	3.85	0.00015	0.0427	0.43	0.24	Body mass index;	chr11:111075357	chr11:111091932~111097357:-
SARC	cis	rs321358	0.79	rs73015129	ENSG00000271584.1	RP11-89C3.4	3.85	0.00015	0.0427	0.43	0.24	Body mass index;	chr11:111076157	chr11:111091932~111097357:-
SARC	cis	rs321358	0.79	rs73015134	ENSG00000271584.1	RP11-89C3.4	3.85	0.00015	0.0427	0.43	0.24	Body mass index;	chr11:111076520	chr11:111091932~111097357:-
SARC	cis	rs61160187	0.673	rs248912	ENSG00000272308.1	RP11-231G3.1	-3.85	0.00015	0.0427	-0.21	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60548252	chr5:60866457~60866935:-
SARC	cis	rs11123170	0.529	rs1015753	ENSG00000274877.1	RP11-65I12.1	-3.85	0.00015	0.0427	-0.32	-0.24	Renal function-related traits (BUN);	chr2:113211226	chr2:113237595~113240825:+
SARC	cis	rs890448	0.726	rs2850366	ENSG00000254531.1	FLJ20021	-3.85	0.00015	0.0427	-0.26	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101309867	chr4:101347780~101348883:+
SARC	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	3.85	0.00015	0.0427	0.33	0.24	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
SARC	cis	rs7254232	0.96	rs7247789	ENSG00000269534.4	CTC-453G23.5	3.85	0.00015	0.0427	0.22	0.24	Chronic periodontitis;	chr19:47292420	chr19:48118432~48127706:+
SARC	cis	rs7254232	0.92	rs7247010	ENSG00000269534.4	CTC-453G23.5	3.85	0.00015	0.0427	0.22	0.24	Chronic periodontitis;	chr19:47292459	chr19:48118432~48127706:+
SARC	cis	rs7254232	0.92	rs7250152	ENSG00000269534.4	CTC-453G23.5	3.85	0.00015	0.0427	0.22	0.24	Chronic periodontitis;	chr19:47292712	chr19:48118432~48127706:+
SARC	cis	rs2243480	1	rs427044	ENSG00000273142.1	RP11-458F8.4	-3.85	0.00015	0.0427	-0.36	-0.24	Diabetic kidney disease;	chr7:66043558	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs437889	ENSG00000273142.1	RP11-458F8.4	-3.85	0.00015	0.0427	-0.36	-0.24	Diabetic kidney disease;	chr7:66044247	chr7:66902857~66906297:+
SARC	cis	rs11132911	0.522	rs1919492	ENSG00000181359.5	HSP90AA6P	3.85	0.00015	0.0427	0.31	0.24	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr4:171583291	chr4:170581470~170605450:-
SARC	cis	rs2179367	0.959	rs521845	ENSG00000216906.2	RP11-350J20.9	-3.85	0.00015	0.0427	-0.22	-0.24	Dupuytren's disease;	chr6:149350562	chr6:149904243~149906418:+
SARC	cis	rs8062405	0.755	rs17707300	ENSG00000251417.2	RP11-1348G14.4	-3.85	0.00015	0.0428	-0.24	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28802743~28817828:+
SARC	cis	rs9527	1	rs4919690	ENSG00000213061.2	PFN1P11	-3.85	0.00015	0.0428	-0.35	-0.24	Arsenic metabolism;	chr10:102856743	chr10:102838011~102845473:-
SARC	cis	rs7615952	0.641	rs12488180	ENSG00000248787.1	RP11-666A20.4	-3.85	0.00015	0.0428	-0.35	-0.24	Blood pressure (smoking interaction);	chr3:126063393	chr3:125908005~125910272:-
SARC	cis	rs240993	0.669	rs6935759	ENSG00000230177.1	RP5-1112D6.4	-3.85	0.00015	0.0428	-0.28	-0.24	Inflammatory skin disease;Psoriasis;	chr6:111457517	chr6:111277932~111278742:+
SARC	cis	rs3805389	0.504	rs17725110	ENSG00000273257.1	RP11-177J6.1	-3.85	0.00015	0.0428	-0.37	-0.24	Waist-to-hip ratio adjusted for body mass index;	chr4:55605855	chr4:55387949~55388271:+
SARC	cis	rs3805389	0.504	rs2412666	ENSG00000273257.1	RP11-177J6.1	-3.85	0.00015	0.0428	-0.37	-0.24	Waist-to-hip ratio adjusted for body mass index;	chr4:55607192	chr4:55387949~55388271:+
SARC	cis	rs7204230	1	rs62049763	ENSG00000261291.1	RP11-295M3.2	3.85	0.00015	0.0428	0.27	0.24	Fibrinogen;	chr16:53219807	chr16:53168522~53169450:+
SARC	cis	rs72647484	0.554	rs2807316	ENSG00000228397.1	RP1-224A6.3	-3.85	0.000151	0.0428	-0.51	-0.24	Colorectal cancer;	chr1:22227085	chr1:22023994~22024968:-
SARC	cis	rs853679	1	rs6905391	ENSG00000272009.1	RP1-313I6.12	-3.85	0.000151	0.0428	-0.34	-0.24	Depression;	chr6:28294909	chr6:28078792~28081130:-
SARC	cis	rs13113518	0.729	rs11133377	ENSG00000273257.1	RP11-177J6.1	3.85	0.000151	0.0428	0.32	0.24	Height;	chr4:55413708	chr4:55387949~55388271:+
SARC	cis	rs17169635	0.765	rs1015350	ENSG00000223718.3	AC093107.7	-3.85	0.000151	0.0428	-0.33	-0.24	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134890504	chr7:135660039~135660647:+
SARC	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	3.85	0.000151	0.0428	0.22	0.24	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
SARC	cis	rs9907295	0.901	rs9898152	ENSG00000270240.2	AC015849.2	3.85	0.000151	0.0429	0.36	0.24	Fibroblast growth factor basic levels;	chr17:35869211	chr17:35868967~35885863:+
SARC	cis	rs9907295	0.901	rs78023535	ENSG00000270240.2	AC015849.2	3.85	0.000151	0.0429	0.36	0.24	Fibroblast growth factor basic levels;	chr17:35869598	chr17:35868967~35885863:+
SARC	cis	rs9907295	0.901	rs4795095	ENSG00000270240.2	AC015849.2	3.85	0.000151	0.0429	0.36	0.24	Fibroblast growth factor basic levels;	chr17:35870296	chr17:35868967~35885863:+
SARC	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	3.85	0.000151	0.0429	0.31	0.24	Height;	chr6:109470427	chr6:109382795~109383666:+
SARC	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	3.85	0.000151	0.0429	0.31	0.24	Height;	chr6:109470900	chr6:109382795~109383666:+
SARC	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	3.85	0.000151	0.0429	0.37	0.24	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
SARC	cis	rs13434995	0.945	rs55849318	ENSG00000273257.1	RP11-177J6.1	-3.85	0.000151	0.0429	-0.38	-0.24	Adiponectin levels;	chr4:55615826	chr4:55387949~55388271:+
SARC	cis	rs34929064	0.881	rs2067074	ENSG00000225541.1	AC002480.5	3.85	0.000151	0.0429	0.26	0.24	Major depression and alcohol dependence;	chr7:22681324	chr7:22571607~22661792:-
SARC	cis	rs9834560	0.665	rs1841537	ENSG00000240854.1	RP11-64K7.1	3.85	0.000151	0.0429	0.29	0.24	Motion sickness;	chr3:131979305	chr3:132175402~132176711:+
SARC	cis	rs7246760	1	rs10418248	ENSG00000277587.1	CTD-3116E22.8	-3.85	0.000151	0.0429	-0.5	-0.24	Pursuit maintenance gain;	chr19:9827538	chr19:9721903~9722410:+
SARC	cis	rs7567389	0.626	rs11683344	ENSG00000236682.1	AC068282.3	-3.85	0.000151	0.0429	-0.29	-0.24	Self-rated health;	chr2:127198676	chr2:127389130~127400580:+
SARC	cis	rs7560272	0.669	rs7598660	ENSG00000163016.8	ALMS1P	3.85	0.000151	0.043	0.27	0.24	Schizophrenia;	chr2:73513298	chr2:73644919~73685576:+
SARC	cis	rs7520050	0.778	rs3014238	ENSG00000280836.1	AL355480.1	3.85	0.000151	0.043	0.23	0.24	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45581219~45581321:-
SARC	cis	rs12893668	0.572	rs1606	ENSG00000269910.1	RP11-73M18.10	3.85	0.000151	0.043	0.22	0.24	Reticulocyte count;	chr14:103694944	chr14:103694516~103695050:-
SARC	cis	rs160451	0.899	rs218887	ENSG00000251136.7	RP11-37B2.1	3.85	0.000151	0.043	0.26	0.24	Leprosy;	chr8:89679295	chr8:89609409~89757727:-
SARC	cis	rs748404	0.697	rs572959	ENSG00000275601.1	AC011330.13	-3.85	0.000151	0.043	-0.3	-0.24	Lung cancer;	chr15:43258304	chr15:43642389~43643023:-
SARC	cis	rs748404	0.697	rs554001	ENSG00000275601.1	AC011330.13	-3.85	0.000151	0.043	-0.3	-0.24	Lung cancer;	chr15:43259721	chr15:43642389~43643023:-
SARC	cis	rs748404	0.697	rs501884	ENSG00000275601.1	AC011330.13	-3.85	0.000151	0.043	-0.3	-0.24	Lung cancer;	chr15:43261784	chr15:43642389~43643023:-
SARC	cis	rs748404	0.697	rs504417	ENSG00000275601.1	AC011330.13	-3.85	0.000151	0.043	-0.3	-0.24	Lung cancer;	chr15:43262028	chr15:43642389~43643023:-
SARC	cis	rs748404	0.723	rs560134	ENSG00000275601.1	AC011330.13	-3.85	0.000151	0.043	-0.3	-0.24	Lung cancer;	chr15:43263501	chr15:43642389~43643023:-
SARC	cis	rs8059260	1	rs7205474	ENSG00000274038.1	RP11-66H6.4	-3.85	0.000151	0.043	-0.34	-0.24	Alcohol consumption over the past year;	chr16:10949556	chr16:11056556~11057034:+
SARC	cis	rs8059260	0.877	rs111352543	ENSG00000274038.1	RP11-66H6.4	-3.85	0.000151	0.043	-0.34	-0.24	Alcohol consumption over the past year;	chr16:10949603	chr16:11056556~11057034:+
SARC	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	3.85	0.000151	0.043	0.25	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
SARC	cis	rs2243480	1	rs6460260	ENSG00000164669.11	INTS4P1	-3.85	0.000151	0.043	-0.43	-0.24	Diabetic kidney disease;	chr7:65750468	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs6460261	ENSG00000164669.11	INTS4P1	-3.85	0.000151	0.043	-0.43	-0.24	Diabetic kidney disease;	chr7:65750593	chr7:65141225~65234216:+
SARC	cis	rs2243480	0.901	rs2900904	ENSG00000164669.11	INTS4P1	3.85	0.000151	0.043	0.43	0.24	Diabetic kidney disease;	chr7:65739282	chr7:65141225~65234216:+
SARC	cis	rs2243480	0.901	rs3813708	ENSG00000164669.11	INTS4P1	3.85	0.000151	0.043	0.43	0.24	Diabetic kidney disease;	chr7:65840645	chr7:65141225~65234216:+
SARC	cis	rs6669008	1	rs6669008	ENSG00000232450.1	RP4-730K3.3	-3.85	0.000152	0.043	-0.23	-0.24	Bacteremia;	chr1:113623939	chr1:113698884~113699631:-
SARC	cis	rs756777	0.591	rs7026263	ENSG00000228877.2	RP11-473E2.4	3.85	0.000152	0.043	0.3	0.24	IgG glycosylation;	chr9:133817286	chr9:134527182~134545244:+
SARC	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-3.85	0.000152	0.0431	-0.29	-0.24	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
SARC	cis	rs7682481	0.924	rs7673567	ENSG00000224786.1	CETN4P	-3.85	0.000152	0.0431	-0.29	-0.24	Alopecia areata;	chr4:122484829	chr4:122730548~122732193:-
SARC	cis	rs9902453	0.715	rs2628176	ENSG00000264538.5	SUZ12P1	-3.85	0.000152	0.0431	-0.17	-0.24	Coffee consumption (cups per day);	chr17:29812274	chr17:30709299~30790908:+
SARC	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	3.85	0.000152	0.0431	0.3	0.24	Height;	chr6:109424122	chr6:109382795~109383666:+
SARC	cis	rs860818	1	rs1637223	ENSG00000226816.2	AC005082.12	3.85	0.000152	0.0431	0.63	0.24	Initial pursuit acceleration;	chr7:23189050	chr7:23206013~23208045:+
SARC	cis	rs860818	0.744	rs1728319	ENSG00000226816.2	AC005082.12	3.85	0.000152	0.0431	0.63	0.24	Initial pursuit acceleration;	chr7:23191580	chr7:23206013~23208045:+
SARC	cis	rs12893668	0.703	rs2403197	ENSG00000269958.1	RP11-73M18.8	3.85	0.000152	0.0431	0.27	0.24	Reticulocyte count;	chr14:103587427	chr14:103696353~103697163:+
SARC	cis	rs9920506	0.518	rs11072774	ENSG00000261143.1	ADAMTS7P3	-3.85	0.000152	0.0431	-0.42	-0.24	Post bronchodilator FEV1;	chr15:78660355	chr15:77976042~77993057:+
SARC	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-3.85	0.000152	0.0431	-0.4	-0.24	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
SARC	cis	rs7085104	0.66	rs3781286	ENSG00000213061.2	PFN1P11	3.85	0.000152	0.0431	0.29	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835962	chr10:102838011~102845473:-
SARC	cis	rs997295	1	rs36004835	ENSG00000259410.4	RP11-34F13.3	3.85	0.000152	0.0432	0.27	0.24	Motion sickness;	chr15:67659204	chr15:67832725~67873866:+
SARC	cis	rs2439831	0.702	rs9989313	ENSG00000166763.7	STRCP1	3.85	0.000152	0.0432	0.35	0.24	Lung cancer in ever smokers;	chr15:43860619	chr15:43699488~43718184:-
SARC	cis	rs2439831	0.85	rs61390361	ENSG00000166763.7	STRCP1	3.85	0.000152	0.0432	0.35	0.24	Lung cancer in ever smokers;	chr15:43867644	chr15:43699488~43718184:-
SARC	cis	rs2439831	0.85	rs11856795	ENSG00000166763.7	STRCP1	3.85	0.000152	0.0432	0.35	0.24	Lung cancer in ever smokers;	chr15:43868384	chr15:43699488~43718184:-
SARC	cis	rs7772486	0.597	rs2246132	ENSG00000270638.1	RP3-466P17.1	3.85	0.000152	0.0432	0.21	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145735570~145737218:+
SARC	cis	rs651386	0.506	rs10919448	ENSG00000271811.1	RP1-79C4.4	3.85	0.000152	0.0432	0.34	0.24	Atrial fibrillation;	chr1:170630432	chr1:170667381~170669425:+
SARC	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-3.85	0.000152	0.0432	-0.33	-0.24	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
SARC	cis	rs1468333	0.697	rs35931944	ENSG00000253404.1	AC034243.1	-3.85	0.000152	0.0432	-0.31	-0.24	Resting heart rate;	chr5:138293443	chr5:138744434~138753309:-
SARC	cis	rs2239547	0.618	rs13083728	ENSG00000242142.1	SERBP1P3	3.85	0.000152	0.0432	0.29	0.24	Schizophrenia;	chr3:52834429	chr3:53064283~53065091:-
SARC	cis	rs17174870	1	rs55708724	ENSG00000228251.1	AC012442.6	3.85	0.000153	0.0433	0.31	0.24	Multiple sclerosis;	chr2:111909345	chr2:112590796~112591939:+
SARC	cis	rs745109	0.882	rs34633268	ENSG00000273080.1	RP11-301O19.1	3.85	0.000153	0.0433	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86439178	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs111226991	ENSG00000273080.1	RP11-301O19.1	3.85	0.000153	0.0433	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86441699	chr2:86195590~86196049:+
SARC	cis	rs745109	0.816	rs72930349	ENSG00000273080.1	RP11-301O19.1	3.85	0.000153	0.0433	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86444481	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs57291816	ENSG00000273080.1	RP11-301O19.1	3.85	0.000153	0.0433	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86444745	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs58361202	ENSG00000273080.1	RP11-301O19.1	3.85	0.000153	0.0433	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86448108	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs60304516	ENSG00000273080.1	RP11-301O19.1	3.85	0.000153	0.0433	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86449385	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs76258845	ENSG00000273080.1	RP11-301O19.1	3.85	0.000153	0.0433	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86450151	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs55828608	ENSG00000273080.1	RP11-301O19.1	3.85	0.000153	0.0433	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86452421	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs72930361	ENSG00000273080.1	RP11-301O19.1	3.85	0.000153	0.0433	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86453230	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs72930362	ENSG00000273080.1	RP11-301O19.1	3.85	0.000153	0.0433	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86453739	chr2:86195590~86196049:+
SARC	cis	rs745109	0.751	rs72930364	ENSG00000273080.1	RP11-301O19.1	3.85	0.000153	0.0433	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86454498	chr2:86195590~86196049:+
SARC	cis	rs745109	0.882	rs56347930	ENSG00000273080.1	RP11-301O19.1	3.85	0.000153	0.0433	0.37	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86456778	chr2:86195590~86196049:+
SARC	cis	rs442309	0.532	rs10995276	ENSG00000238280.1	RP11-436D10.3	3.85	0.000153	0.0433	0.28	0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62694301	chr10:62793562~62805887:-
SARC	cis	rs7246657	0.943	rs8106839	ENSG00000226686.6	LINC01535	-3.85	0.000153	0.0433	-0.33	-0.24	Coronary artery calcification;	chr19:37467573	chr19:37251912~37265535:+
SARC	cis	rs8095374	0.967	rs9947316	ENSG00000280212.1	RP11-49K24.3	3.85	0.000153	0.0433	0.27	0.24	Clinical laboratory measurements;	chr18:46197865	chr18:47076117~47076594:+
SARC	cis	rs6479891	1	rs12411988	ENSG00000232075.1	MRPL35P2	-3.85	0.000153	0.0434	-0.3	-0.24	Arthritis (juvenile idiopathic);	chr10:63555637	chr10:63634317~63634827:-
SARC	cis	rs10911902	0.913	rs55660734	ENSG00000229739.2	RP11-295K2.3	-3.85	0.000153	0.0434	-0.34	-0.24	Schizophrenia;	chr1:186620869	chr1:186435161~186470291:+
SARC	cis	rs17270561	0.609	rs12529272	ENSG00000272462.2	U91328.19	-3.85	0.000153	0.0434	-0.23	-0.24	Iron status biomarkers;	chr6:25731114	chr6:25992662~26001775:+
SARC	cis	rs17270561	0.609	rs9393659	ENSG00000272462.2	U91328.19	-3.85	0.000153	0.0434	-0.23	-0.24	Iron status biomarkers;	chr6:25731130	chr6:25992662~26001775:+
SARC	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	3.85	0.000153	0.0434	0.31	0.24	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
SARC	cis	rs2749592	0.531	rs1208559	ENSG00000151963.4	RP11-775A3.1	3.85	0.000153	0.0434	0.2	0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:37883594~37884109:+
SARC	cis	rs8028182	0.636	rs28783769	ENSG00000260206.1	CTD-2026K11.2	-3.85	0.000153	0.0434	-0.3	-0.24	Sudden cardiac arrest;	chr15:75556668	chr15:75636139~75639239:+
SARC	cis	rs8028182	0.636	rs7184046	ENSG00000260206.1	CTD-2026K11.2	-3.85	0.000153	0.0434	-0.3	-0.24	Sudden cardiac arrest;	chr15:75573809	chr15:75636139~75639239:+
SARC	cis	rs2239557	0.614	rs73303112	ENSG00000259065.1	RP5-1021I20.1	-3.85	0.000153	0.0434	-0.34	-0.24	Common traits (Other);	chr14:74013433	chr14:73787360~73803270:+
SARC	cis	rs4705962	0.878	rs2299004	ENSG00000230612.2	AC004237.1	3.85	0.000153	0.0434	0.29	0.24	Atopic dermatitis;	chr5:132722146	chr5:132688681~132723725:+
SARC	cis	rs465969	0.744	rs7758483	ENSG00000231889.6	TRAF3IP2-AS1	3.85	0.000153	0.0434	0.43	0.24	Psoriasis;	chr6:111467945	chr6:111483511~111598302:+
SARC	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	3.85	0.000153	0.0434	0.27	0.24	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
SARC	cis	rs2836974	0.8	rs73221174	ENSG00000232837.1	AF064858.7	3.85	0.000153	0.0434	0.28	0.24	Cognitive function;	chr21:39169013	chr21:38974429~38977774:-
SARC	cis	rs1943345	0.556	rs555586	ENSG00000254551.1	RP11-727A23.7	3.85	0.000153	0.0435	0.26	0.24	Obesity-related traits;	chr11:83200837	chr11:83209431~83213379:-
SARC	cis	rs745109	0.504	rs113679164	ENSG00000273080.1	RP11-301O19.1	3.85	0.000154	0.0435	0.39	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86411479	chr2:86195590~86196049:+
SARC	cis	rs4835473	0.9	rs5015758	ENSG00000251600.4	RP11-673E1.1	-3.85	0.000154	0.0435	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143738052	chr4:143912331~143982454:+
SARC	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-3.85	0.000154	0.0435	-0.37	-0.24	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
SARC	cis	rs12049351	0.665	rs12036589	ENSG00000229367.1	HMGN2P19	3.85	0.000154	0.0435	0.22	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229437829	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.613	rs1887634	ENSG00000229367.1	HMGN2P19	3.85	0.000154	0.0435	0.22	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229439032	chr1:229570532~229570796:+
SARC	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-3.85	0.000154	0.0435	-0.32	-0.24	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
SARC	cis	rs727479	0.502	rs2899471	ENSG00000244879.4	GABPB1-AS1	-3.85	0.000154	0.0435	-0.2	-0.24	Estradiol levels;	chr15:51214356	chr15:50354959~50372202:+
SARC	cis	rs727479	0.502	rs3825800	ENSG00000244879.4	GABPB1-AS1	-3.85	0.000154	0.0435	-0.2	-0.24	Estradiol levels;	chr15:51214466	chr15:50354959~50372202:+
SARC	cis	rs4794202	1	rs4794202	ENSG00000264920.1	RP11-6N17.4	-3.85	0.000154	0.0435	-0.35	-0.24	Alzheimer's disease (cognitive decline);	chr17:47853173	chr17:47891255~47895812:-
SARC	cis	rs7163013	0.933	rs10152251	ENSG00000259792.1	RP11-114H24.6	-3.85	0.000154	0.0435	-0.26	-0.24	Obesity-related traits;	chr15:78387495	chr15:77993405~77995289:+
SARC	cis	rs9438901	0.614	rs2375278	ENSG00000261349.1	RP3-465N24.5	3.85	0.000154	0.0435	0.36	0.24	Red cell distribution width;	chr1:25202547	chr1:25266102~25267136:-
SARC	cis	rs2274273	0.686	rs66842809	ENSG00000258413.1	RP11-665C16.6	-3.85	0.000154	0.0435	-0.34	-0.24	Protein biomarker;	chr14:55163853	chr14:55262767~55272075:-
SARC	cis	rs67478160	0.595	rs12889993	ENSG00000269958.1	RP11-73M18.8	3.85	0.000154	0.0435	0.24	0.24	Schizophrenia;	chr14:103807957	chr14:103696353~103697163:+
SARC	cis	rs8059260	0.736	rs7192695	ENSG00000274038.1	RP11-66H6.4	-3.85	0.000154	0.0435	-0.35	-0.24	Alcohol consumption over the past year;	chr16:11005395	chr16:11056556~11057034:+
SARC	cis	rs3934047	0.869	rs8035833	ENSG00000274376.3	ADAMTS7P1	3.85	0.000154	0.0435	0.27	0.24	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81755988	chr15:82298553~82334609:+
SARC	cis	rs2439831	0.867	rs2470134	ENSG00000275601.1	AC011330.13	3.85	0.000154	0.0435	0.41	0.24	Lung cancer in ever smokers;	chr15:43557688	chr15:43642389~43643023:-
SARC	cis	rs11086243	1	rs11700186	ENSG00000276923.1	RP11-321P16.1	-3.85	0.000154	0.0435	-0.29	-0.24	Nephrotic syndrome (acquired);	chr20:48149831	chr20:48073869~48074188:+
SARC	cis	rs17695224	0.675	rs2109656	ENSG00000275055.1	CTC-471J1.11	-3.85	0.000154	0.0435	-0.26	-0.24	HDL cholesterol;HDL cholesterol levels;	chr19:51837424	chr19:52049007~52049754:+
SARC	cis	rs7976269	0.609	rs10771470	ENSG00000257176.2	RP11-996F15.2	-3.85	0.000154	0.0435	-0.27	-0.24	Male-pattern baldness;	chr12:29050620	chr12:29280418~29317848:-
SARC	cis	rs7647973	0.58	rs12637576	ENSG00000225399.4	RP11-3B7.1	3.85	0.000154	0.0436	0.31	0.24	Menarche (age at onset);	chr3:49199901	chr3:49260085~49261316:+
SARC	cis	rs7308116	0.935	rs7966077	ENSG00000240441.1	RP11-864J10.2	-3.85	0.000154	0.0436	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107799920	chr12:107719599~107720133:+
SARC	cis	rs1044573	0.514	rs2268879	ENSG00000276952.1	RP5-965G21.6	-3.85	0.000154	0.0436	-0.24	-0.24	Allergic rhinitis;	chr20:25197169	chr20:25284915~25285588:-
SARC	cis	rs4267450	0.793	rs73021318	ENSG00000261770.1	CTC-459F4.1	3.85	0.000154	0.0436	0.45	0.24	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28357972	chr19:27757184~27760849:-
SARC	cis	rs713477	0.712	rs72717779	ENSG00000258413.1	RP11-665C16.6	3.85	0.000154	0.0436	0.28	0.24	Pediatric bone mineral content (femoral neck);	chr14:55426722	chr14:55262767~55272075:-
SARC	cis	rs7520050	0.807	rs4660312	ENSG00000280836.1	AL355480.1	-3.85	0.000154	0.0436	-0.23	-0.24	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45581219~45581321:-
SARC	cis	rs6988985	0.678	rs28491316	ENSG00000247317.3	RP11-273G15.2	-3.85	0.000154	0.0436	-0.27	-0.24	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142911245	chr8:142981738~143018437:-
SARC	cis	rs977145	0.951	rs4649938	ENSG00000235782.1	RP3-333A15.1	3.85	0.000154	0.0436	0.29	0.24	Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks);	chr1:71440768	chr1:70947379~70951493:+
SARC	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	3.85	0.000154	0.0436	0.31	0.24	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
SARC	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	3.85	0.000154	0.0436	0.3	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
SARC	cis	rs875971	0.619	rs2302918	ENSG00000224316.1	RP11-479O9.2	3.85	0.000154	0.0436	0.23	0.24	Aortic root size;	chr7:66535945	chr7:65773620~65802067:+
SARC	cis	rs9925964	0.748	rs4889603	ENSG00000183604.13	SMG1P5	-3.85	0.000154	0.0436	-0.23	-0.24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30970904	chr16:30267553~30335374:-
SARC	cis	rs755249	0.532	rs17343193	ENSG00000182109.6	RP11-69E11.4	3.85	0.000154	0.0436	0.27	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39522280~39546187:-
SARC	cis	rs858239	0.6	rs7776649	ENSG00000226816.2	AC005082.12	3.85	0.000154	0.0437	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23206013~23208045:+
SARC	cis	rs11694172	1	rs55669835	ENSG00000273456.1	RP11-686O6.2	3.85	0.000155	0.0437	0.21	0.24	Cholesterol, total;	chr2:202661245	chr2:202374932~202375604:-
SARC	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-3.85	0.000155	0.0437	-0.27	-0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
SARC	cis	rs7166081	1	rs16950776	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000155	0.0437	-0.29	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67218266	chr15:67541072~67542604:-
SARC	cis	rs7166081	0.951	rs34590589	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000155	0.0437	-0.29	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67221852	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs34699563	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000155	0.0437	-0.29	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67221879	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs34296414	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000155	0.0437	-0.29	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67222071	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs9806590	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000155	0.0437	-0.29	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67224003	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs11071942	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000155	0.0437	-0.29	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67224610	chr15:67541072~67542604:-
SARC	cis	rs7166081	0.951	rs12594065	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000155	0.0437	-0.29	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67225663	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs4776906	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000155	0.0437	-0.29	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67228279	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs78553942	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000155	0.0437	-0.29	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67229472	chr15:67541072~67542604:-
SARC	cis	rs12236219	0.786	rs79615002	ENSG00000224764.1	RP11-54O15.3	3.85	0.000155	0.0437	0.44	0.24	Body mass index;	chr9:94462780	chr9:94928551~94934946:-
SARC	cis	rs858239	0.698	rs4265084	ENSG00000226816.2	AC005082.12	3.85	0.000155	0.0437	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23206013~23208045:+
SARC	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-3.85	0.000155	0.0437	-0.38	-0.24	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
SARC	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-3.85	0.000155	0.0437	-0.38	-0.24	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
SARC	cis	rs7204230	1	rs11075782	ENSG00000261291.1	RP11-295M3.2	3.85	0.000155	0.0437	0.26	0.24	Fibrinogen;	chr16:53198047	chr16:53168522~53169450:+
SARC	cis	rs1707322	0.963	rs10890373	ENSG00000281133.1	AL355480.3	-3.85	0.000155	0.0437	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45580892~45580996:-
SARC	cis	rs6570726	0.533	rs1832374	ENSG00000270638.1	RP3-466P17.1	3.85	0.000155	0.0437	0.2	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145396616	chr6:145735570~145737218:+
SARC	cis	rs6425521	0.95	rs6425522	ENSG00000213060.4	RP4-612B18.3	3.85	0.000155	0.0437	0.35	0.24	Platelet count;	chr1:171976942	chr1:171803517~171803939:+
SARC	cis	rs12236219	0.786	rs16910109	ENSG00000224764.1	RP11-54O15.3	3.85	0.000155	0.0438	0.44	0.24	Body mass index;	chr9:94445949	chr9:94928551~94934946:-
SARC	cis	rs12236219	0.786	rs78613872	ENSG00000224764.1	RP11-54O15.3	3.85	0.000155	0.0438	0.44	0.24	Body mass index;	chr9:94449374	chr9:94928551~94934946:-
SARC	cis	rs950776	0.518	rs1979907	ENSG00000261762.1	RP11-650L12.2	-3.85	0.000155	0.0438	-0.26	-0.24	Sudden cardiac arrest;	chr15:78549897	chr15:78589123~78591276:-
SARC	cis	rs9876781	0.872	rs11797	ENSG00000244380.1	RP11-24C3.2	3.85	0.000155	0.0438	0.26	0.24	Longevity;	chr3:48467186	chr3:48440352~48446656:-
SARC	cis	rs875971	0.66	rs3764903	ENSG00000224316.1	RP11-479O9.2	-3.85	0.000155	0.0438	-0.23	-0.24	Aortic root size;	chr7:66633495	chr7:65773620~65802067:+
SARC	cis	rs875971	0.66	rs1860470	ENSG00000224316.1	RP11-479O9.2	-3.85	0.000155	0.0438	-0.23	-0.24	Aortic root size;	chr7:66638707	chr7:65773620~65802067:+
SARC	cis	rs937213	0.643	rs11852600	ENSG00000275636.1	RP11-521C20.5	3.85	0.000155	0.0438	0.28	0.24	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:39998280	chr15:40078892~40079347:+
SARC	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	3.85	0.000155	0.0438	0.36	0.24	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
SARC	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-3.85	0.000155	0.0438	-0.36	-0.24	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	3.85	0.000155	0.0438	0.36	0.24	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	3.85	0.000155	0.0438	0.36	0.24	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	3.85	0.000155	0.0438	0.36	0.24	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	3.85	0.000155	0.0438	0.36	0.24	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	3.85	0.000155	0.0438	0.36	0.24	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	3.85	0.000155	0.0438	0.36	0.24	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	3.85	0.000155	0.0438	0.36	0.24	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	3.85	0.000155	0.0438	0.36	0.24	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	3.85	0.000155	0.0438	0.36	0.24	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	3.85	0.000155	0.0438	0.36	0.24	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
SARC	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	3.85	0.000155	0.0438	0.36	0.24	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs422164	ENSG00000164669.11	INTS4P1	3.85	0.000155	0.0438	0.42	0.24	Diabetic kidney disease;	chr7:66121618	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs316313	ENSG00000164669.11	INTS4P1	3.85	0.000155	0.0438	0.42	0.24	Diabetic kidney disease;	chr7:66128561	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs316312	ENSG00000164669.11	INTS4P1	3.85	0.000155	0.0438	0.42	0.24	Diabetic kidney disease;	chr7:66131504	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs419603	ENSG00000164669.11	INTS4P1	3.85	0.000155	0.0438	0.42	0.24	Diabetic kidney disease;	chr7:66132354	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs387676	ENSG00000164669.11	INTS4P1	3.85	0.000155	0.0438	0.42	0.24	Diabetic kidney disease;	chr7:66133233	chr7:65141225~65234216:+
SARC	cis	rs34792	0.554	rs12919246	ENSG00000207425.1	Y_RNA	-3.85	0.000155	0.0438	-0.32	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:14915457~14915556:-
SARC	cis	rs34792	0.554	rs12708796	ENSG00000207425.1	Y_RNA	-3.85	0.000155	0.0438	-0.32	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:14915457~14915556:-
SARC	cis	rs73129298	0.748	rs73131221	ENSG00000229222.1	KRT18P4	3.85	0.000155	0.0438	0.53	0.24	Inflammatory skin disease;	chr20:49959212	chr20:49956745~49958032:+
SARC	cis	rs67478160	0.619	rs11623546	ENSG00000269958.1	RP11-73M18.8	3.85	0.000155	0.0438	0.24	0.24	Schizophrenia;	chr14:103802761	chr14:103696353~103697163:+
SARC	cis	rs67478160	0.619	rs55824307	ENSG00000269958.1	RP11-73M18.8	3.85	0.000155	0.0438	0.24	0.24	Schizophrenia;	chr14:103804870	chr14:103696353~103697163:+
SARC	cis	rs67478160	0.595	rs12879501	ENSG00000269958.1	RP11-73M18.8	3.85	0.000155	0.0438	0.24	0.24	Schizophrenia;	chr14:103806297	chr14:103696353~103697163:+
SARC	cis	rs67478160	0.619	rs12885018	ENSG00000269958.1	RP11-73M18.8	3.85	0.000155	0.0438	0.24	0.24	Schizophrenia;	chr14:103807475	chr14:103696353~103697163:+
SARC	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	3.85	0.000155	0.0438	0.36	0.24	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
SARC	cis	rs4950322	0.58	rs1813002	ENSG00000278811.3	LINC00624	3.85	0.000155	0.0438	0.24	0.24	Protein quantitative trait loci;	chr1:147112579	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.518	rs4950304	ENSG00000278811.3	LINC00624	3.85	0.000155	0.0438	0.24	0.24	Protein quantitative trait loci;	chr1:147116685	chr1:147258885~147517875:-
SARC	cis	rs4851551	0.543	rs11887842	ENSG00000234389.1	AC007278.3	3.85	0.000156	0.0439	0.44	0.24	Blood protein levels;	chr2:102223018	chr2:102438713~102440475:+
SARC	cis	rs4639966	0.569	rs603486	ENSG00000278376.1	RP11-158I9.8	-3.85	0.000156	0.0439	-0.18	-0.24	Systemic lupus erythematosus;	chr11:118716638	chr11:118791254~118793137:+
SARC	cis	rs7520050	0.902	rs9429088	ENSG00000280836.1	AL355480.1	3.84	0.000156	0.0439	0.23	0.24	Reticulocyte count;Red blood cell count;	chr1:46031828	chr1:45581219~45581321:-
SARC	cis	rs2749097	0.825	rs11208264	ENSG00000244256.3	RN7SL130P	-3.84	0.000156	0.0439	-0.29	-0.24	Alcohol consumption (transferrin glycosylation);	chr1:63659401	chr1:63655743~63656047:+
SARC	cis	rs6472827	0.645	rs2956058	ENSG00000253983.2	RP1-16A9.1	3.84	0.000156	0.0439	0.33	0.24	Uterine fibroids;	chr8:74197824	chr8:74199396~74208441:+
SARC	cis	rs4664293	0.631	rs13024749	ENSG00000226266.5	AC009961.3	3.84	0.000156	0.0439	0.29	0.24	Monocyte percentage of white cells;	chr2:159799606	chr2:159670708~159712435:-
SARC	cis	rs28386778	0.897	rs6504176	ENSG00000240280.5	TCAM1P	-3.84	0.000156	0.0439	-0.3	-0.24	Prudent dietary pattern;	chr17:63734560	chr17:63849292~63864379:+
SARC	cis	rs7811142	0.666	rs28401739	ENSG00000078319.8	PMS2P1	-3.84	0.000156	0.0439	-0.36	-0.24	Platelet count;	chr7:100308061	chr7:100320992~100341908:-
SARC	cis	rs7246657	0.722	rs12974225	ENSG00000180458.2	CTD-3064H18.4	-3.84	0.000156	0.0439	-0.33	-0.24	Coronary artery calcification;	chr19:37749458	chr19:37545470~37549171:-
SARC	cis	rs7615952	0.688	rs17334074	ENSG00000248787.1	RP11-666A20.4	3.84	0.000156	0.0439	0.34	0.24	Blood pressure (smoking interaction);	chr3:125821617	chr3:125908005~125910272:-
SARC	cis	rs150992	0.603	rs326481	ENSG00000248489.1	CTD-2007H13.3	3.84	0.000156	0.0439	0.27	0.24	Body mass index;	chr5:98949581	chr5:98929171~98995013:+
SARC	cis	rs2243480	1	rs465359	ENSG00000164669.11	INTS4P1	3.84	0.000156	0.0439	0.42	0.24	Diabetic kidney disease;	chr7:66093177	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs462853	ENSG00000164669.11	INTS4P1	3.84	0.000156	0.0439	0.42	0.24	Diabetic kidney disease;	chr7:66093180	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs160644	ENSG00000164669.11	INTS4P1	3.84	0.000156	0.0439	0.42	0.24	Diabetic kidney disease;	chr7:66093199	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs160642	ENSG00000164669.11	INTS4P1	3.84	0.000156	0.0439	0.42	0.24	Diabetic kidney disease;	chr7:66093386	chr7:65141225~65234216:+
SARC	cis	rs2243480	0.614	rs34032527	ENSG00000164669.11	INTS4P1	3.84	0.000156	0.0439	0.42	0.24	Diabetic kidney disease;	chr7:66100154	chr7:65141225~65234216:+
SARC	cis	rs2243480	0.803	rs36127118	ENSG00000164669.11	INTS4P1	3.84	0.000156	0.0439	0.42	0.24	Diabetic kidney disease;	chr7:66100518	chr7:65141225~65234216:+
SARC	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-3.84	0.000156	0.044	-0.29	-0.24	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
SARC	cis	rs3934047	0.904	rs8033875	ENSG00000274376.3	ADAMTS7P1	-3.84	0.000156	0.044	-0.28	-0.24	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81746429	chr15:82298553~82334609:+
SARC	cis	rs4664293	0.647	rs918969	ENSG00000226266.5	AC009961.3	3.84	0.000156	0.044	0.29	0.24	Monocyte percentage of white cells;	chr2:159610145	chr2:159670708~159712435:-
SARC	cis	rs875971	0.66	rs801217	ENSG00000224316.1	RP11-479O9.2	-3.84	0.000156	0.0441	-0.23	-0.24	Aortic root size;	chr7:66545590	chr7:65773620~65802067:+
SARC	cis	rs875971	0.638	rs801216	ENSG00000224316.1	RP11-479O9.2	-3.84	0.000156	0.0441	-0.23	-0.24	Aortic root size;	chr7:66546680	chr7:65773620~65802067:+
SARC	cis	rs875971	0.66	rs801211	ENSG00000224316.1	RP11-479O9.2	-3.84	0.000156	0.0441	-0.23	-0.24	Aortic root size;	chr7:66550702	chr7:65773620~65802067:+
SARC	cis	rs875971	0.638	rs801205	ENSG00000224316.1	RP11-479O9.2	-3.84	0.000156	0.0441	-0.23	-0.24	Aortic root size;	chr7:66557157	chr7:65773620~65802067:+
SARC	cis	rs875971	0.617	rs810400	ENSG00000224316.1	RP11-479O9.2	-3.84	0.000156	0.0441	-0.23	-0.24	Aortic root size;	chr7:66557902	chr7:65773620~65802067:+
SARC	cis	rs875971	0.619	rs12533585	ENSG00000224316.1	RP11-479O9.2	3.84	0.000156	0.0441	0.23	0.24	Aortic root size;	chr7:66519618	chr7:65773620~65802067:+
SARC	cis	rs875971	0.66	rs12698534	ENSG00000224316.1	RP11-479O9.2	3.84	0.000156	0.0441	0.23	0.24	Aortic root size;	chr7:66521858	chr7:65773620~65802067:+
SARC	cis	rs875971	0.66	rs28698552	ENSG00000224316.1	RP11-479O9.2	3.84	0.000156	0.0441	0.23	0.24	Aortic root size;	chr7:66540031	chr7:65773620~65802067:+
SARC	cis	rs875971	0.66	rs62465434	ENSG00000224316.1	RP11-479O9.2	3.84	0.000156	0.0441	0.23	0.24	Aortic root size;	chr7:66540165	chr7:65773620~65802067:+
SARC	cis	rs875971	0.66	rs13224319	ENSG00000224316.1	RP11-479O9.2	3.84	0.000156	0.0441	0.23	0.24	Aortic root size;	chr7:66542376	chr7:65773620~65802067:+
SARC	cis	rs7216064	1	rs7210027	ENSG00000237854.3	LINC00674	-3.84	0.000156	0.0441	-0.29	-0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67980937	chr17:68101908~68115518:+
SARC	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	3.84	0.000157	0.0441	0.31	0.24	Height;	chr4:55413708	chr4:55363971~55395847:-
SARC	cis	rs11723261	0.582	rs6599293	ENSG00000211553.1	AC253576.2	-3.84	0.000157	0.0441	-0.31	-0.24	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:136461~136568:+
SARC	cis	rs77956314	0.901	rs113844630	ENSG00000277840.1	RP11-103B5.4	3.84	0.000157	0.0441	0.37	0.24	Hippocampal volume;Subcortical brain region volumes;	chr12:116899298	chr12:117002463~117003152:+
SARC	cis	rs11123170	0.543	rs4849178	ENSG00000274877.1	RP11-65I12.1	-3.84	0.000157	0.0441	-0.31	-0.24	Renal function-related traits (BUN);	chr2:113225031	chr2:113237595~113240825:+
SARC	cis	rs867186	1	rs74626382	ENSG00000229230.3	MT1P3	3.84	0.000157	0.0441	0.46	0.24	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35158865	chr20:35218009~35218185:+
SARC	cis	rs7166081	1	rs12898685	ENSG00000270964.1	RP11-502I4.3	-3.84	0.000157	0.0441	-0.28	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67233434	chr15:67541072~67542604:-
SARC	cis	rs56046484	0.711	rs71397835	ENSG00000259295.5	CSPG4P12	3.84	0.000157	0.0442	0.38	0.24	Testicular germ cell tumor;	chr15:84987540	chr15:85191438~85213905:+
SARC	cis	rs12702271	0.909	rs12702262	ENSG00000229628.1	AC073115.7	-3.84	0.000157	0.0442	-0.33	-0.24	Male-pattern baldness;	chr7:46861696	chr7:45990905~46000898:+
SARC	cis	rs6763768	0.888	rs1264098	ENSG00000280417.1	RP11-5O17.1	-3.84	0.000157	0.0442	-0.27	-0.24	Bacterial meningitis;	chr3:53488287	chr3:53046166~53048122:+
SARC	cis	rs7580658	0.929	rs4150496	ENSG00000236682.1	AC068282.3	-3.84	0.000157	0.0442	-0.28	-0.24	Protein C levels;	chr2:127271927	chr2:127389130~127400580:+
SARC	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-3.84	0.000157	0.0442	-0.24	-0.24	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
SARC	cis	rs524281	0.506	rs560393	ENSG00000245532.5	NEAT1	-3.84	0.000157	0.0442	-0.21	-0.24	Electroencephalogram traits;	chr11:66238006	chr11:65422774~65445540:+
SARC	cis	rs524281	0.506	rs2298466	ENSG00000245532.5	NEAT1	-3.84	0.000157	0.0442	-0.21	-0.24	Electroencephalogram traits;	chr11:66243809	chr11:65422774~65445540:+
SARC	cis	rs3824347	0.771	rs1539732	ENSG00000203321.2	C9orf41-AS1	-3.84	0.000157	0.0442	-0.27	-0.24	Urinary magnesium-to-creatinine ratio;	chr9:74984456	chr9:74952968~74996293:+
SARC	cis	rs853679	1	rs1778508	ENSG00000216901.1	AL022393.7	-3.84	0.000157	0.0442	-0.42	-0.24	Depression;	chr6:28262103	chr6:28176188~28176674:+
SARC	cis	rs12289961	0.634	rs11229433	ENSG00000280010.1	AP001350.4	3.84	0.000157	0.0442	0.38	0.24	Lymphoma;	chr11:58417863	chr11:58627435~58628528:+
SARC	cis	rs4646450	0.735	rs10243678	ENSG00000281827.1	AC005071.4	3.84	0.000157	0.0442	0.3	0.24	Blood metabolite levels;	chr7:99394321	chr7:100344375~100344475:-
SARC	cis	rs8014067	1	rs8014630	ENSG00000258926.1	RP11-47I22.1	3.84	0.000157	0.0442	0.26	0.24	Hepatitis;	chr14:62086582	chr14:61537508~61545287:-
SARC	cis	rs2032447	0.765	rs6942072	ENSG00000272810.1	U91328.22	-3.84	0.000157	0.0442	-0.26	-0.24	Intelligence (multi-trait analysis);	chr6:26014759	chr6:26013241~26013757:+
SARC	cis	rs7216064	0.906	rs78452260	ENSG00000237854.3	LINC00674	3.84	0.000157	0.0442	0.31	0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67852406	chr17:68101908~68115518:+
SARC	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-3.84	0.000157	0.0442	-0.28	-0.24	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
SARC	cis	rs7772486	0.713	rs2328704	ENSG00000235652.6	RP11-545I5.3	-3.84	0.000157	0.0443	-0.22	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145799409~145886585:+
SARC	cis	rs10911902	0.643	rs75906210	ENSG00000233196.2	GS1-304P7.1	-3.84	0.000157	0.0443	-0.37	-0.24	Schizophrenia;	chr1:186365092	chr1:186580515~186581191:-
SARC	cis	rs28498283	0.792	rs10209254	ENSG00000279873.2	LINC01126	-3.84	0.000157	0.0443	-0.23	-0.24	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:43119501	chr2:43227210~43228855:+
SARC	cis	rs4792901	1	rs1010049	ENSG00000197291.7	RAMP2-AS1	-3.84	0.000157	0.0443	-0.26	-0.24	Dupuytren's disease;	chr17:43578311	chr17:42753914~42761257:-
SARC	cis	rs526231	0.857	rs13190417	ENSG00000175749.11	EIF3KP1	3.84	0.000157	0.0443	0.3	0.24	Primary biliary cholangitis;	chr5:103327625	chr5:103032376~103033031:+
SARC	cis	rs2274273	0.712	rs9806049	ENSG00000258413.1	RP11-665C16.6	-3.84	0.000158	0.0443	-0.28	-0.24	Protein biomarker;	chr14:55058871	chr14:55262767~55272075:-
SARC	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	3.84	0.000158	0.0443	0.24	0.24	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
SARC	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	3.84	0.000158	0.0443	0.42	0.24	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
SARC	cis	rs4835265	0.852	rs10004928	ENSG00000272727.1	RP11-142A22.4	3.84	0.000158	0.0443	0.35	0.24	Gamma glutamyl transpeptidase;	chr4:145856157	chr4:145335263~145340421:-
SARC	cis	rs755249	0.567	rs6668369	ENSG00000182109.6	RP11-69E11.4	3.84	0.000158	0.0444	0.27	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39522280~39546187:-
SARC	cis	rs4646450	0.735	rs11762273	ENSG00000281827.1	AC005071.4	3.84	0.000158	0.0444	0.3	0.24	Blood metabolite levels;	chr7:99379564	chr7:100344375~100344475:-
SARC	cis	rs4646450	0.735	rs10270459	ENSG00000281827.1	AC005071.4	3.84	0.000158	0.0444	0.3	0.24	Blood metabolite levels;	chr7:99381337	chr7:100344375~100344475:-
SARC	cis	rs17270561	0.609	rs9348694	ENSG00000272462.2	U91328.19	-3.84	0.000158	0.0444	-0.24	-0.24	Iron status biomarkers;	chr6:25753412	chr6:25992662~26001775:+
SARC	cis	rs7011507	0.836	rs78010054	ENSG00000279881.1	RP11-513O13.1	-3.84	0.000158	0.0444	-0.44	-0.24	Inflammatory bowel disease;Ulcerative colitis;	chr8:48136709	chr8:48428143~48431041:-
SARC	cis	rs17198023	0.638	rs1944745	ENSG00000232176.1	RP11-146N23.1	-3.84	0.000158	0.0444	-0.34	-0.24	Nicotine dependence;	chr9:18244654	chr9:19200335~19201046:-
SARC	cis	rs10246939	0.543	rs9640204	ENSG00000270923.1	TAS2R6P	-3.84	0.000158	0.0444	-0.21	-0.24	Bitter taste perception;	chr7:141844300	chr7:141787815~141788640:+
SARC	cis	rs10246939	0.543	rs9640359	ENSG00000270923.1	TAS2R6P	-3.84	0.000158	0.0444	-0.21	-0.24	Bitter taste perception;	chr7:141844399	chr7:141787815~141788640:+
SARC	cis	rs9467773	0.595	rs3799379	ENSG00000261353.1	CTA-14H9.5	3.84	0.000158	0.0444	0.26	0.24	Intelligence (multi-trait analysis);	chr6:26404466	chr6:26527063~26527404:+
SARC	cis	rs875971	0.767	rs12668005	ENSG00000232559.3	GS1-124K5.12	3.84	0.000158	0.0444	0.29	0.24	Aortic root size;	chr7:66444034	chr7:66554588~66576923:-
SARC	cis	rs875971	0.862	rs11765791	ENSG00000232559.3	GS1-124K5.12	3.84	0.000158	0.0444	0.29	0.24	Aortic root size;	chr7:66471587	chr7:66554588~66576923:-
SARC	cis	rs7246657	0.606	rs2972439	ENSG00000180458.2	CTD-3064H18.4	-3.84	0.000158	0.0444	-0.33	-0.24	Coronary artery calcification;	chr19:37721680	chr19:37545470~37549171:-
SARC	cis	rs7246657	0.722	rs2909100	ENSG00000180458.2	CTD-3064H18.4	-3.84	0.000158	0.0444	-0.33	-0.24	Coronary artery calcification;	chr19:37721779	chr19:37545470~37549171:-
SARC	cis	rs28386778	0.897	rs7501614	ENSG00000240280.5	TCAM1P	-3.84	0.000158	0.0445	-0.3	-0.24	Prudent dietary pattern;	chr17:63725252	chr17:63849292~63864379:+
SARC	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-3.84	0.000158	0.0445	-0.22	-0.24	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
SARC	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-3.84	0.000158	0.0445	-0.22	-0.24	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
SARC	cis	rs593531	0.571	rs11236087	ENSG00000280269.1	AP000577.2	3.84	0.000158	0.0445	0.3	0.24	Neuroticism;	chr11:74383093	chr11:74204869~74205746:+
SARC	cis	rs2731006	0.64	rs2678132	ENSG00000257114.2	RP11-25I15.3	-3.84	0.000158	0.0445	-0.36	-0.24	Panic disorder;	chr12:42790168	chr12:42692216~42717119:+
SARC	cis	rs17826219	0.561	rs11655876	ENSG00000264538.5	SUZ12P1	-3.84	0.000158	0.0445	-0.26	-0.24	Body mass index;	chr17:30690132	chr17:30709299~30790908:+
SARC	cis	rs4820294	0.669	rs35662099	ENSG00000233360.4	Z83844.1	3.84	0.000158	0.0445	0.29	0.24	Fat distribution (HIV);	chr22:37657902	chr22:37641832~37658377:-
SARC	cis	rs862687	0.789	rs830637	ENSG00000270562.1	RP11-154H23.3	-3.84	0.000159	0.0445	-0.24	-0.24	Intelligence (multi-trait analysis);	chr3:71621314	chr3:71584943~71587409:+
SARC	cis	rs7166081	1	rs35997299	ENSG00000270964.1	RP11-502I4.3	-3.84	0.000159	0.0445	-0.28	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67215252	chr15:67541072~67542604:-
SARC	cis	rs7267979	0.844	rs2257649	ENSG00000125804.12	FAM182A	-3.84	0.000159	0.0445	-0.27	-0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:26054655~26086917:+
SARC	cis	rs465969	0.744	rs34659678	ENSG00000231889.6	TRAF3IP2-AS1	3.84	0.000159	0.0445	0.48	0.24	Psoriasis;	chr6:111567337	chr6:111483511~111598302:+
SARC	cis	rs2905347	0.52	rs2905309	ENSG00000179428.2	AC073072.5	3.84	0.000159	0.0445	0.26	0.24	Major depression and alcohol dependence;	chr7:22608923	chr7:22725395~22727620:-
SARC	cis	rs2239547	0.618	rs1573815	ENSG00000242142.1	SERBP1P3	-3.84	0.000159	0.0446	-0.29	-0.24	Schizophrenia;	chr3:52836116	chr3:53064283~53065091:-
SARC	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	3.84	0.000159	0.0446	0.24	0.24	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
SARC	cis	rs1789	0.503	rs13133213	ENSG00000273133.1	RP11-799M12.2	-3.84	0.000159	0.0446	-0.27	-0.24	Blood protein levels;	chr4:15645171	chr4:15563698~15564253:-
SARC	cis	rs7614311	0.681	rs6776209	ENSG00000271843.1	RP11-245J9.5	-3.84	0.000159	0.0446	-0.35	-0.24	Lung function (FVC);Lung function (FEV1);	chr3:63872957	chr3:64008082~64008692:-
SARC	cis	rs6477918	0.598	rs4979115	ENSG00000250068.1	RP11-576C12.1	-3.84	0.000159	0.0446	-0.25	-0.24	Obstetric antiphospholipid syndrome;	chr9:112445477	chr9:112581779~112582590:-
SARC	cis	rs997295	1	rs938875	ENSG00000259410.4	RP11-34F13.3	3.84	0.000159	0.0446	0.26	0.24	Motion sickness;	chr15:67660584	chr15:67832725~67873866:+
SARC	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-3.84	0.000159	0.0446	-0.32	-0.24	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
SARC	cis	rs2404602	0.692	rs55729975	ENSG00000259422.1	RP11-593F23.1	3.84	0.000159	0.0446	0.27	0.24	Blood metabolite levels;	chr15:76510885	chr15:76174891~76181486:-
SARC	cis	rs7665147	1	rs7665147	ENSG00000269949.1	RP11-738E22.3	3.84	0.000159	0.0446	0.36	0.24	Platelet count;	chr4:56901161	chr4:56960927~56961373:-
SARC	cis	rs72627509	0.68	rs66790703	ENSG00000269949.1	RP11-738E22.3	3.84	0.000159	0.0446	0.36	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56907742	chr4:56960927~56961373:-
SARC	cis	rs7537765	0.947	rs3753584	ENSG00000242349.4	NPPA-AS1	-3.84	0.000159	0.0446	-0.33	-0.24	QRS complex (12-leadsum);	chr1:11804529	chr1:11841017~11848079:+
SARC	cis	rs7615952	0.641	rs4490307	ENSG00000241288.6	RP11-379B18.5	-3.84	0.000159	0.0446	-0.28	-0.24	Blood pressure (smoking interaction);	chr3:125993833	chr3:125827238~125916384:-
SARC	cis	rs11651000	0.625	rs11079786	ENSG00000239291.1	RP5-867C24.1	-3.84	0.000159	0.0446	-0.29	-0.24	IgG glycosylation;	chr17:47728550	chr17:47159191~47159993:-
SARC	cis	rs6142102	0.602	rs4911145	ENSG00000275784.1	RP5-1125A11.6	3.84	0.000159	0.0446	0.28	0.24	Skin pigmentation;	chr20:34027417	chr20:33989480~33991818:-
SARC	cis	rs28386778	0.897	rs2665831	ENSG00000240280.5	TCAM1P	-3.84	0.000159	0.0446	-0.3	-0.24	Prudent dietary pattern;	chr17:63835032	chr17:63849292~63864379:+
SARC	cis	rs858239	0.601	rs2141307	ENSG00000226816.2	AC005082.12	3.84	0.000159	0.0446	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23206013~23208045:+
SARC	cis	rs8005677	0.828	rs12589539	ENSG00000279656.1	RP11-298I3.6	3.84	0.000159	0.0446	0.32	0.24	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:23023083~23024217:-
SARC	cis	rs41357746	0.74	rs72745452	ENSG00000259410.4	RP11-34F13.3	3.84	0.000159	0.0446	0.28	0.24	Total body bone mineral density;	chr15:67335883	chr15:67832725~67873866:+
SARC	cis	rs2179367	0.632	rs9285520	ENSG00000216906.2	RP11-350J20.9	-3.84	0.000159	0.0447	-0.24	-0.24	Dupuytren's disease;	chr6:149372001	chr6:149904243~149906418:+
SARC	cis	rs763121	0.853	rs2267393	ENSG00000273076.1	RP3-508I15.22	3.84	0.000159	0.0447	0.26	0.24	Menopause (age at onset);	chr22:38705614	chr22:38743495~38743910:+
SARC	cis	rs763121	0.853	rs2267394	ENSG00000273076.1	RP3-508I15.22	3.84	0.000159	0.0447	0.26	0.24	Menopause (age at onset);	chr22:38705628	chr22:38743495~38743910:+
SARC	cis	rs2898681	0.561	rs2200225	ENSG00000248375.1	RP11-177B4.1	-3.84	0.00016	0.0447	-0.37	-0.24	Optic nerve measurement (cup area);	chr4:52872244	chr4:52720081~52720831:-
SARC	cis	rs72817562	0.688	rs17074007	ENSG00000254252.1	RPL7P20	3.84	0.00016	0.0447	0.32	0.24	Neuroticism;	chr5:165229645	chr5:166028567~166029311:-
SARC	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-3.84	0.00016	0.0447	-0.37	-0.24	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
SARC	cis	rs7976269	0.559	rs1344853	ENSG00000257176.2	RP11-996F15.2	-3.84	0.00016	0.0447	-0.26	-0.24	Male-pattern baldness;	chr12:29058623	chr12:29280418~29317848:-
SARC	cis	rs2933343	0.621	rs4927921	ENSG00000261159.1	RP11-723O4.9	-3.84	0.00016	0.0448	-0.26	-0.24	IgG glycosylation;	chr3:128850025	chr3:128859716~128860526:-
SARC	cis	rs16949788	0.793	rs78483581	ENSG00000261351.2	CTD-3185P2.1	-3.84	0.00016	0.0448	-0.44	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66477027	chr15:66488658~66492109:-
SARC	cis	rs16949788	1	rs76847935	ENSG00000261351.2	CTD-3185P2.1	-3.84	0.00016	0.0448	-0.44	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66477275	chr15:66488658~66492109:-
SARC	cis	rs17429538	0.581	rs9511001	ENSG00000232163.2	RPLP1P13	3.84	0.00016	0.0448	0.42	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr13:24026541	chr13:23373423~23374061:+
SARC	cis	rs12049351	0.719	rs10916492	ENSG00000229367.1	HMGN2P19	3.84	0.00016	0.0448	0.21	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229498649	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.719	rs10916493	ENSG00000229367.1	HMGN2P19	3.84	0.00016	0.0448	0.21	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229498650	chr1:229570532~229570796:+
SARC	cis	rs983392	0.792	rs684961	ENSG00000255139.1	AP000442.1	-3.84	0.00016	0.0448	-0.23	-0.24	Alzheimer's disease (late onset);	chr11:60151364	chr11:59616429~59639861:+
SARC	cis	rs5758659	1	rs134869	ENSG00000182057.4	OGFRP1	3.84	0.00016	0.0448	0.23	0.24	Cognitive function;	chr22:42256068	chr22:42269753~42275196:+
SARC	cis	rs710865	0.527	rs2275403	ENSG00000270728.1	RP4-657E11.10	3.84	0.00016	0.0448	0.21	0.24	Brain structure;	chr1:19231219	chr1:19297080~19297903:+
SARC	cis	rs948562	0.947	rs2298607	ENSG00000280010.1	AP001350.4	3.84	0.00016	0.0448	0.34	0.24	Lymphoma;	chr11:58637026	chr11:58627435~58628528:+
SARC	cis	rs881827	0.692	rs13048683	ENSG00000223901.2	AP001469.5	3.84	0.00016	0.0448	0.32	0.24	Lymphocyte counts;	chr21:46615251	chr21:46220269~46225364:+
SARC	cis	rs7195386	0.777	rs62028855	ENSG00000274925.1	CTD-2547G23.4	-3.84	0.00016	0.0448	-0.15	-0.24	Obesity-related traits;Body mass index;	chr16:24520860	chr16:25257952~25261066:+
SARC	cis	rs2179367	0.959	rs4895789	ENSG00000216906.2	RP11-350J20.9	3.84	0.00016	0.0448	0.23	0.24	Dupuytren's disease;	chr6:149443518	chr6:149904243~149906418:+
SARC	cis	rs10246939	0.543	rs9640357	ENSG00000270923.1	TAS2R6P	-3.84	0.00016	0.0448	-0.21	-0.24	Bitter taste perception;	chr7:141843298	chr7:141787815~141788640:+
SARC	cis	rs4713118	0.621	rs4713132	ENSG00000280107.1	AL022393.9	-3.84	0.00016	0.0448	-0.32	-0.24	Parkinson's disease;	chr6:28066257	chr6:28170845~28172521:+
SARC	cis	rs4713118	0.621	rs4713133	ENSG00000280107.1	AL022393.9	-3.84	0.00016	0.0448	-0.32	-0.24	Parkinson's disease;	chr6:28066263	chr6:28170845~28172521:+
SARC	cis	rs4713118	0.621	rs4713134	ENSG00000280107.1	AL022393.9	-3.84	0.00016	0.0448	-0.32	-0.24	Parkinson's disease;	chr6:28066343	chr6:28170845~28172521:+
SARC	cis	rs4713118	0.621	rs9368548	ENSG00000280107.1	AL022393.9	-3.84	0.00016	0.0448	-0.32	-0.24	Parkinson's disease;	chr6:28066959	chr6:28170845~28172521:+
SARC	cis	rs7216064	1	rs7216064	ENSG00000237854.3	LINC00674	3.84	0.00016	0.0449	0.3	0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67902693	chr17:68101908~68115518:+
SARC	cis	rs7216064	1	rs62085993	ENSG00000237854.3	LINC00674	3.84	0.00016	0.0449	0.3	0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67927036	chr17:68101908~68115518:+
SARC	cis	rs7216064	1	rs4271626	ENSG00000237854.3	LINC00674	3.84	0.00016	0.0449	0.3	0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67934017	chr17:68101908~68115518:+
SARC	cis	rs7216064	1	rs56393562	ENSG00000237854.3	LINC00674	3.84	0.00016	0.0449	0.3	0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67937802	chr17:68101908~68115518:+
SARC	cis	rs3204270	0.714	rs79243595	ENSG00000229848.1	RP13-766D20.2	3.84	0.00016	0.0449	0.38	0.24	Dental caries;	chr17:81714190	chr17:81514047~81527776:+
SARC	cis	rs7208859	0.623	rs9912440	ENSG00000266490.1	CTD-2349P21.9	3.84	0.00016	0.0449	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30792372~30792833:+
SARC	cis	rs7617773	0.817	rs13094727	ENSG00000228638.1	FCF1P2	-3.84	0.00016	0.0449	-0.28	-0.24	Coronary artery disease;	chr3:48281999	chr3:48290793~48291375:-
SARC	cis	rs11723261	0.582	rs3747693	ENSG00000211553.1	AC253576.2	-3.84	0.00016	0.0449	-0.31	-0.24	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:136461~136568:+
SARC	cis	rs4273100	0.646	rs6587216	ENSG00000265185.4	SNORD3B-1	-3.84	0.00016	0.0449	-0.3	-0.24	Schizophrenia;	chr17:19321084	chr17:19061912~19062669:+
SARC	cis	rs7267979	0.844	rs2424703	ENSG00000274414.1	RP5-965G21.4	-3.84	0.00016	0.0449	-0.25	-0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:25239007~25245229:-
SARC	cis	rs910316	1	rs11623413	ENSG00000279594.1	RP11-950C14.10	-3.84	0.00016	0.0449	-0.26	-0.24	Height;	chr14:75122121	chr14:75011269~75012851:-
SARC	cis	rs13219760	0.908	rs34103065	ENSG00000213149.3	CNN2P9	-3.84	0.000161	0.0449	-0.45	-0.24	Glucose homeostasis traits;	chr6:110426569	chr6:110858239~110859147:+
SARC	cis	rs10936632	0.755	rs10804839	ENSG00000242578.1	RP11-469J4.3	-3.84	0.000161	0.0449	-0.25	-0.24	Prostate cancer;	chr3:170353995	chr3:170410512~170418615:+
SARC	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	3.84	0.000161	0.0449	0.26	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
SARC	cis	rs6431644	0.931	rs655525	ENSG00000224287.2	MSL3P1	-3.84	0.000161	0.0449	-0.28	-0.24	Left atrial antero-posterior diameter;	chr2:233885305	chr2:233865437~233868444:-
SARC	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	3.84	0.000161	0.045	0.31	0.24	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
SARC	cis	rs3824347	0.872	rs2182811	ENSG00000203321.2	C9orf41-AS1	-3.84	0.000161	0.045	-0.27	-0.24	Urinary magnesium-to-creatinine ratio;	chr9:74968880	chr9:74952968~74996293:+
SARC	cis	rs448720	0.811	rs1996120	ENSG00000259410.4	RP11-34F13.3	-3.84	0.000161	0.045	-0.27	-0.24	Cognitive performance;	chr15:67889196	chr15:67832725~67873866:+
SARC	cis	rs1707322	0.964	rs785499	ENSG00000281133.1	AL355480.3	3.84	0.000161	0.045	0.29	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45580892~45580996:-
SARC	cis	rs7085104	0.632	rs3781287	ENSG00000213061.2	PFN1P11	3.84	0.000161	0.045	0.28	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835663	chr10:102838011~102845473:-
SARC	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	3.84	0.000161	0.045	0.48	0.24	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
SARC	cis	rs72647484	0.643	rs2744737	ENSG00000228397.1	RP1-224A6.3	-3.84	0.000161	0.045	-0.51	-0.24	Colorectal cancer;	chr1:22225089	chr1:22023994~22024968:-
SARC	cis	rs1468333	0.538	rs13182414	ENSG00000253404.1	AC034243.1	-3.84	0.000161	0.045	-0.31	-0.24	Resting heart rate;	chr5:138304149	chr5:138744434~138753309:-
SARC	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-3.84	0.000161	0.045	-0.37	-0.24	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
SARC	cis	rs6964833	0.786	rs35633336	ENSG00000184616.8	AC004166.6	3.84	0.000161	0.045	0.36	0.24	Menarche (age at onset);	chr7:74643961	chr7:74906673~74913256:-
SARC	cis	rs6964833	0.935	rs35735900	ENSG00000184616.8	AC004166.6	3.84	0.000161	0.045	0.36	0.24	Menarche (age at onset);	chr7:74651887	chr7:74906673~74913256:-
SARC	cis	rs6964833	0.872	rs4717903	ENSG00000184616.8	AC004166.6	3.84	0.000161	0.045	0.36	0.24	Menarche (age at onset);	chr7:74653827	chr7:74906673~74913256:-
SARC	cis	rs6570726	0.791	rs6570692	ENSG00000235652.6	RP11-545I5.3	3.84	0.000161	0.045	0.22	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.791	rs6902410	ENSG00000235652.6	RP11-545I5.3	3.84	0.000161	0.045	0.22	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.791	rs9322029	ENSG00000235652.6	RP11-545I5.3	3.84	0.000161	0.045	0.22	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145799409~145886585:+
SARC	cis	rs6570726	0.791	rs9403730	ENSG00000235652.6	RP11-545I5.3	3.84	0.000161	0.045	0.22	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145799409~145886585:+
SARC	cis	rs10986311	0.832	rs748661	ENSG00000235204.1	RP11-121A14.2	-3.84	0.000161	0.045	-0.28	-0.24	Vitiligo;	chr9:124333295	chr9:124259250~124261156:-
SARC	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-3.84	0.000161	0.0451	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
SARC	cis	rs10766496	1	rs61886892	ENSG00000257043.1	RP11-137N23.1	3.84	0.000161	0.0451	0.32	0.24	Diabetic kidney disease;	chr11:18717028	chr11:18665050~18665548:+
SARC	cis	rs2762353	0.524	rs3923	ENSG00000272810.1	U91328.22	3.84	0.000161	0.0451	0.23	0.24	Blood metabolite levels;	chr6:25783087	chr6:26013241~26013757:+
SARC	cis	rs13113518	0.545	rs6810483	ENSG00000273257.1	RP11-177J6.1	3.84	0.000161	0.0451	0.28	0.24	Height;	chr4:55424406	chr4:55387949~55388271:+
SARC	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-3.84	0.000161	0.0451	-0.29	-0.24	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
SARC	cis	rs950776	0.518	rs55690619	ENSG00000261762.1	RP11-650L12.2	-3.84	0.000161	0.0451	-0.26	-0.24	Sudden cardiac arrest;	chr15:78541270	chr15:78589123~78591276:-
SARC	cis	rs950776	0.518	rs4886571	ENSG00000261762.1	RP11-650L12.2	-3.84	0.000161	0.0451	-0.26	-0.24	Sudden cardiac arrest;	chr15:78541416	chr15:78589123~78591276:-
SARC	cis	rs950776	0.518	rs4243083	ENSG00000261762.1	RP11-650L12.2	-3.84	0.000161	0.0451	-0.26	-0.24	Sudden cardiac arrest;	chr15:78541488	chr15:78589123~78591276:-
SARC	cis	rs4835473	0.712	rs12509607	ENSG00000251600.4	RP11-673E1.1	-3.84	0.000161	0.0451	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143736894	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.712	rs12498218	ENSG00000251600.4	RP11-673E1.1	-3.84	0.000161	0.0451	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143736900	chr4:143912331~143982454:+
SARC	cis	rs801193	0.591	rs721717	ENSG00000232559.3	GS1-124K5.12	-3.84	0.000162	0.0452	-0.29	-0.24	Aortic root size;	chr7:66665305	chr7:66554588~66576923:-
SARC	cis	rs801193	0.569	rs6951302	ENSG00000232559.3	GS1-124K5.12	-3.84	0.000162	0.0452	-0.29	-0.24	Aortic root size;	chr7:66667525	chr7:66554588~66576923:-
SARC	cis	rs801193	0.591	rs4506088	ENSG00000232559.3	GS1-124K5.12	-3.84	0.000162	0.0452	-0.29	-0.24	Aortic root size;	chr7:66670470	chr7:66554588~66576923:-
SARC	cis	rs7246657	0.941	rs10418729	ENSG00000180458.2	CTD-3064H18.4	3.83	0.000162	0.0452	0.33	0.24	Coronary artery calcification;	chr19:37246163	chr19:37545470~37549171:-
SARC	cis	rs6570726	0.577	rs867056	ENSG00000235652.6	RP11-545I5.3	-3.83	0.000162	0.0452	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145463669	chr6:145799409~145886585:+
SARC	cis	rs7096965	0.718	rs1025920	ENSG00000238840.1	U8	3.83	0.000162	0.0452	0.27	0.24	Major depressive disorder;	chr10:4610447	chr10:4962436~4962568:-
SARC	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	3.83	0.000162	0.0452	0.28	0.24	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
SARC	cis	rs6452524	0.935	rs6868416	ENSG00000248112.1	RP11-78C3.1	3.83	0.000162	0.0452	0.28	0.24	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:82919376~82921119:-
SARC	cis	rs6452524	0.935	rs1478485	ENSG00000248112.1	RP11-78C3.1	3.83	0.000162	0.0452	0.28	0.24	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:82919376~82921119:-
SARC	cis	rs801193	0.569	rs2659908	ENSG00000232559.3	GS1-124K5.12	3.83	0.000162	0.0452	0.29	0.24	Aortic root size;	chr7:66695835	chr7:66554588~66576923:-
SARC	cis	rs7267979	0.586	rs1473695	ENSG00000276952.1	RP5-965G21.6	3.83	0.000162	0.0452	0.24	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:25284915~25285588:-
SARC	cis	rs6431644	0.622	rs2133840	ENSG00000224287.2	MSL3P1	-3.83	0.000162	0.0452	-0.28	-0.24	Left atrial antero-posterior diameter;	chr2:233883983	chr2:233865437~233868444:-
SARC	cis	rs2243480	1	rs73142162	ENSG00000164669.11	INTS4P1	3.83	0.000162	0.0453	0.43	0.24	Diabetic kidney disease;	chr7:65909309	chr7:65141225~65234216:+
SARC	cis	rs9902453	0.904	rs11080115	ENSG00000264538.5	SUZ12P1	-3.83	0.000162	0.0453	-0.17	-0.24	Coffee consumption (cups per day);	chr17:30081052	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.904	rs7212292	ENSG00000264538.5	SUZ12P1	-3.83	0.000162	0.0453	-0.17	-0.24	Coffee consumption (cups per day);	chr17:30082246	chr17:30709299~30790908:+
SARC	cis	rs11098499	0.863	rs3775858	ENSG00000250950.1	RP11-33B1.3	-3.83	0.000162	0.0453	-0.26	-0.24	Corneal astigmatism;	chr4:119564873	chr4:119456350~119457277:+
SARC	cis	rs7408868	1	rs7245814	ENSG00000266913.1	CTC-548K16.2	-3.83	0.000162	0.0453	-0.4	-0.24	Pulse pressure;	chr19:15163692	chr19:14305458~14370196:-
SARC	cis	rs875971	0.862	rs1612452	ENSG00000232559.3	GS1-124K5.12	-3.83	0.000162	0.0453	-0.28	-0.24	Aortic root size;	chr7:66108909	chr7:66554588~66576923:-
SARC	cis	rs12682352	0.602	rs635594	ENSG00000253893.2	FAM85B	3.83	0.000162	0.0453	0.22	0.24	Neuroticism;	chr8:8755877	chr8:8167819~8226614:-
SARC	cis	rs4713118	0.513	rs149897	ENSG00000272009.1	RP1-313I6.12	-3.83	0.000162	0.0453	-0.27	-0.24	Parkinson's disease;	chr6:28038872	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.513	rs156734	ENSG00000272009.1	RP1-313I6.12	-3.83	0.000162	0.0453	-0.27	-0.24	Parkinson's disease;	chr6:28039579	chr6:28078792~28081130:-
SARC	cis	rs116988415	0.748	rs12587471	ENSG00000258824.2	CTD-2555O16.2	-3.83	0.000162	0.0453	-0.32	-0.24	Daytime sleep phenotypes;	chr14:64825597	chr14:64422935~64448557:-
SARC	cis	rs2288884	0.731	rs11673450	ENSG00000275055.1	CTC-471J1.11	-3.83	0.000162	0.0453	-0.31	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037441	chr19:52049007~52049754:+
SARC	cis	rs2288884	0.731	rs11673398	ENSG00000275055.1	CTC-471J1.11	-3.83	0.000162	0.0453	-0.31	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037444	chr19:52049007~52049754:+
SARC	cis	rs7552393	0.595	rs12116654	ENSG00000240520.4	UOX	-3.83	0.000163	0.0453	-0.26	-0.24	Select biomarker traits;	chr1:83804532	chr1:84365428~84397831:-
SARC	cis	rs12049351	0.665	rs2904	ENSG00000229367.1	HMGN2P19	3.83	0.000163	0.0453	0.21	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229464589	chr1:229570532~229570796:+
SARC	cis	rs7267979	0.586	rs6050429	ENSG00000276952.1	RP5-965G21.6	3.83	0.000163	0.0454	0.24	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:25284915~25285588:-
SARC	cis	rs727479	0.502	rs10046	ENSG00000244879.4	GABPB1-AS1	-3.83	0.000163	0.0454	-0.2	-0.24	Estradiol levels;	chr15:51210789	chr15:50354959~50372202:+
SARC	cis	rs12432203	1	rs4566067	ENSG00000258479.4	LINC00640	-3.83	0.000163	0.0454	-0.39	-0.24	Cancer;	chr14:51262769	chr14:51333393~51365557:+
SARC	cis	rs755249	0.727	rs16826349	ENSG00000182109.6	RP11-69E11.4	3.83	0.000163	0.0454	0.24	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39522280~39546187:-
SARC	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	3.83	0.000163	0.0454	0.48	0.24	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	3.83	0.000163	0.0454	0.48	0.24	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	3.83	0.000163	0.0454	0.48	0.24	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	3.83	0.000163	0.0454	0.48	0.24	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
SARC	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	3.83	0.000163	0.0454	0.48	0.24	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
SARC	cis	rs948562	0.947	rs2186381	ENSG00000280010.1	AP001350.4	3.83	0.000163	0.0454	0.34	0.24	Lymphoma;	chr11:58630320	chr11:58627435~58628528:+
SARC	cis	rs7619427	0.643	rs6794506	ENSG00000272077.1	RP11-348P10.2	3.83	0.000163	0.0454	0.57	0.24	Schizophrenia;	chr3:43974176	chr3:44667412~44669364:+
SARC	cis	rs7308116	0.967	rs61938588	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0454	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107801018	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.935	rs61938589	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0454	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107801065	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.935	rs61938591	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0454	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107801227	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.967	rs11113495	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0454	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107801737	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.967	rs11113496	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0454	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107801826	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.935	rs7313108	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0454	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107802399	chr12:107719599~107720133:+
SARC	cis	rs4835265	0.852	rs10008626	ENSG00000272727.1	RP11-142A22.4	3.83	0.000163	0.0454	0.35	0.24	Gamma glutamyl transpeptidase;	chr4:145857672	chr4:145335263~145340421:-
SARC	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	3.83	0.000163	0.0455	0.3	0.24	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
SARC	cis	rs172166	0.694	rs9295760	ENSG00000272009.1	RP1-313I6.12	-3.83	0.000163	0.0455	-0.28	-0.24	Cardiac Troponin-T levels;	chr6:28179607	chr6:28078792~28081130:-
SARC	cis	rs4578769	0.788	rs12962334	ENSG00000273232.1	RP11-370A5.2	3.83	0.000163	0.0455	0.29	0.24	Eosinophil percentage of white cells;	chr18:22897971	chr18:22882825~22883357:-
SARC	cis	rs7617773	0.78	rs7653152	ENSG00000228638.1	FCF1P2	-3.83	0.000163	0.0455	-0.29	-0.24	Coronary artery disease;	chr3:48320607	chr3:48290793~48291375:-
SARC	cis	rs7647973	0.58	rs7652746	ENSG00000225399.4	RP11-3B7.1	-3.83	0.000163	0.0455	-0.31	-0.24	Menarche (age at onset);	chr3:49224874	chr3:49260085~49261316:+
SARC	cis	rs7615952	0.8	rs11915699	ENSG00000250012.1	RP11-124N2.1	-3.83	0.000163	0.0455	-0.25	-0.24	Blood pressure (smoking interaction);	chr3:125913841	chr3:126084220~126095349:+
SARC	cis	rs7308116	0.967	rs11113491	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0455	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107798965	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.967	rs11838238	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0455	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107799446	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.874	rs7965455	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0455	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107799605	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.874	rs7965459	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0455	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107799618	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.935	rs7965919	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0455	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107800015	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.935	rs7342364	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0455	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107800291	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.935	rs7342299	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000163	0.0455	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107800392	chr12:107719599~107720133:+
SARC	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-3.83	0.000163	0.0456	-0.36	-0.24	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-3.83	0.000163	0.0456	-0.36	-0.24	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-3.83	0.000163	0.0456	-0.36	-0.24	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
SARC	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-3.83	0.000163	0.0456	-0.36	-0.24	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-3.83	0.000163	0.0456	-0.36	-0.24	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-3.83	0.000163	0.0456	-0.36	-0.24	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-3.83	0.000163	0.0456	-0.36	-0.24	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
SARC	cis	rs745109	0.504	rs55945133	ENSG00000273080.1	RP11-301O19.1	3.83	0.000164	0.0456	0.36	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86344544	chr2:86195590~86196049:+
SARC	cis	rs745109	0.504	rs112759859	ENSG00000273080.1	RP11-301O19.1	3.83	0.000164	0.0456	0.36	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86346545	chr2:86195590~86196049:+
SARC	cis	rs745109	0.504	rs61629709	ENSG00000273080.1	RP11-301O19.1	3.83	0.000164	0.0456	0.36	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86346766	chr2:86195590~86196049:+
SARC	cis	rs745109	0.504	rs55896146	ENSG00000273080.1	RP11-301O19.1	3.83	0.000164	0.0456	0.36	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86347391	chr2:86195590~86196049:+
SARC	cis	rs812925	0.512	rs7558954	ENSG00000271889.1	RP11-493E12.1	3.83	0.000164	0.0456	0.22	0.24	Immature fraction of reticulocytes;	chr2:61157771	chr2:61151433~61162105:-
SARC	cis	rs7274811	0.846	rs57668191	ENSG00000181741.7	FDX1P1	-3.83	0.000164	0.0456	-0.33	-0.24	Height;	chr20:33701957	chr20:34475924~34476474:-
SARC	cis	rs9902453	0.904	rs12948898	ENSG00000264538.5	SUZ12P1	-3.83	0.000164	0.0456	-0.17	-0.24	Coffee consumption (cups per day);	chr17:30083306	chr17:30709299~30790908:+
SARC	cis	rs7647973	0.58	rs12629759	ENSG00000225399.4	RP11-3B7.1	3.83	0.000164	0.0456	0.31	0.24	Menarche (age at onset);	chr3:49199961	chr3:49260085~49261316:+
SARC	cis	rs13401620	0.555	rs1437421	ENSG00000223549.1	MTND5P28	-3.83	0.000164	0.0456	-0.27	-0.24	Breast size;	chr2:120218255	chr2:120215181~120217279:+
SARC	cis	rs17174870	0.955	rs113415773	ENSG00000228251.1	AC012442.6	3.83	0.000164	0.0456	0.31	0.24	Multiple sclerosis;	chr2:111938139	chr2:112590796~112591939:+
SARC	cis	rs61160187	0.582	rs4700404	ENSG00000272308.1	RP11-231G3.1	-3.83	0.000164	0.0457	-0.21	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:60866457~60866935:-
SARC	cis	rs7216064	0.911	rs12449442	ENSG00000237854.3	LINC00674	3.83	0.000164	0.0457	0.31	0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67951524	chr17:68101908~68115518:+
SARC	cis	rs875971	0.66	rs10263935	ENSG00000224316.1	RP11-479O9.2	3.83	0.000164	0.0457	0.21	0.24	Aortic root size;	chr7:66631041	chr7:65773620~65802067:+
SARC	cis	rs7267979	0.718	rs2983489	ENSG00000274414.1	RP5-965G21.4	-3.83	0.000164	0.0457	-0.25	-0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:25239007~25245229:-
SARC	cis	rs7267979	0.727	rs2474765	ENSG00000274414.1	RP5-965G21.4	-3.83	0.000164	0.0457	-0.25	-0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:25239007~25245229:-
SARC	cis	rs7267979	0.764	rs2474767	ENSG00000274414.1	RP5-965G21.4	-3.83	0.000164	0.0457	-0.25	-0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:25239007~25245229:-
SARC	cis	rs651386	0.506	rs11577602	ENSG00000271811.1	RP1-79C4.4	3.83	0.000164	0.0457	0.33	0.24	Atrial fibrillation;	chr1:170627404	chr1:170667381~170669425:+
SARC	cis	rs577676	0.586	rs10800530	ENSG00000271811.1	RP1-79C4.4	3.83	0.000164	0.0457	0.33	0.24	Prevalent atrial fibrillation;	chr1:170627431	chr1:170667381~170669425:+
SARC	cis	rs600550	0.588	rs11230251	ENSG00000255139.1	AP000442.1	3.83	0.000164	0.0457	0.25	0.24	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60321282	chr11:59616429~59639861:+
SARC	cis	rs717662	0.507	rs619043	ENSG00000248027.1	CTD-2383M3.1	3.83	0.000164	0.0457	0.5	0.24	Red cell distribution width;	chr11:100835135	chr11:100684162~100687955:-
SARC	cis	rs651386	0.529	rs12072276	ENSG00000271811.1	RP1-79C4.4	3.83	0.000164	0.0457	0.33	0.24	Atrial fibrillation;	chr1:170624928	chr1:170667381~170669425:+
SARC	cis	rs4713118	0.513	rs149950	ENSG00000272009.1	RP1-313I6.12	-3.83	0.000164	0.0457	-0.27	-0.24	Parkinson's disease;	chr6:28065261	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.513	rs149951	ENSG00000272009.1	RP1-313I6.12	-3.83	0.000164	0.0457	-0.27	-0.24	Parkinson's disease;	chr6:28065309	chr6:28078792~28081130:-
SARC	cis	rs577676	0.533	rs10800529	ENSG00000271811.1	RP1-79C4.4	3.83	0.000164	0.0458	0.33	0.24	Prevalent atrial fibrillation;	chr1:170600902	chr1:170667381~170669425:+
SARC	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-3.83	0.000165	0.0458	-0.23	-0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
SARC	cis	rs28386778	1	rs2665810	ENSG00000240280.5	TCAM1P	-3.83	0.000165	0.0458	-0.31	-0.24	Prudent dietary pattern;	chr17:63892850	chr17:63849292~63864379:+
SARC	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	3.83	0.000165	0.0458	0.18	0.24	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
SARC	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	3.83	0.000165	0.0458	0.18	0.24	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
SARC	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	3.83	0.000165	0.0458	0.36	0.24	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
SARC	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	3.83	0.000165	0.0458	0.28	0.24	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
SARC	cis	rs10871290	0.65	rs3760055	ENSG00000274220.1	RP11-77K12.9	3.83	0.000165	0.0458	0.21	0.24	Breast cancer;	chr16:74456631	chr16:75433836~75436392:+
SARC	cis	rs6570726	0.967	rs450973	ENSG00000270638.1	RP3-466P17.1	3.83	0.000165	0.0458	0.2	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145541929	chr6:145735570~145737218:+
SARC	cis	rs6452524	0.935	rs11750799	ENSG00000248112.1	RP11-78C3.1	3.83	0.000165	0.0459	0.28	0.24	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:82919376~82921119:-
SARC	cis	rs6452524	0.935	rs10942321	ENSG00000248112.1	RP11-78C3.1	3.83	0.000165	0.0459	0.28	0.24	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:82919376~82921119:-
SARC	cis	rs9309473	0.5	rs11688718	ENSG00000163016.8	ALMS1P	3.83	0.000165	0.0459	0.28	0.24	Metabolite levels;	chr2:73533812	chr2:73644919~73685576:+
SARC	cis	rs7182621	0.639	rs35049216	ENSG00000182397.13	DNM1P46	3.83	0.000165	0.0459	0.28	0.24	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99790156~99806927:-
SARC	cis	rs61160187	0.582	rs4700407	ENSG00000272308.1	RP11-231G3.1	3.83	0.000165	0.0459	0.2	0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:61070701	chr5:60866457~60866935:-
SARC	cis	rs7923609	0.756	rs12768534	ENSG00000232075.1	MRPL35P2	-3.83	0.000165	0.0459	-0.21	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63581137	chr10:63634317~63634827:-
SARC	cis	rs12049351	0.774	rs12033236	ENSG00000229367.1	HMGN2P19	3.83	0.000165	0.0459	0.21	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229504724	chr1:229570532~229570796:+
SARC	cis	rs2749592	0.513	rs1208708	ENSG00000151963.4	RP11-775A3.1	-3.83	0.000165	0.0459	-0.2	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:37883594~37884109:+
SARC	cis	rs710913	0.618	rs6587	ENSG00000243970.1	PPIEL	3.83	0.000165	0.0459	0.23	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39531838~39558707:-
SARC	cis	rs7308116	0.967	rs7967585	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000165	0.0459	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107803062	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.967	rs7952838	ENSG00000240441.1	RP11-864J10.2	-3.83	0.000165	0.0459	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107803258	chr12:107719599~107720133:+
SARC	cis	rs8095374	0.869	rs9955853	ENSG00000280212.1	RP11-49K24.3	3.83	0.000165	0.0459	0.27	0.24	Clinical laboratory measurements;	chr18:46249689	chr18:47076117~47076594:+
SARC	cis	rs8028182	0.636	rs4886715	ENSG00000260206.1	CTD-2026K11.2	-3.83	0.000165	0.0459	-0.3	-0.24	Sudden cardiac arrest;	chr15:75539108	chr15:75636139~75639239:+
SARC	cis	rs7267979	0.932	rs433352	ENSG00000274414.1	RP5-965G21.4	3.83	0.000165	0.046	0.26	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:25239007~25245229:-
SARC	cis	rs3805389	0.504	rs1873091	ENSG00000273257.1	RP11-177J6.1	-3.83	0.000165	0.046	-0.37	-0.24	Waist-to-hip ratio adjusted for body mass index;	chr4:55605266	chr4:55387949~55388271:+
SARC	cis	rs42490	1	rs40452	ENSG00000251136.7	RP11-37B2.1	-3.83	0.000165	0.046	-0.27	-0.24	Leprosy;	chr8:89765931	chr8:89609409~89757727:-
SARC	cis	rs42490	0.966	rs39503	ENSG00000251136.7	RP11-37B2.1	-3.83	0.000165	0.046	-0.27	-0.24	Leprosy;	chr8:89767579	chr8:89609409~89757727:-
SARC	cis	rs42490	1	rs447618	ENSG00000251136.7	RP11-37B2.1	-3.83	0.000165	0.046	-0.27	-0.24	Leprosy;	chr8:89773457	chr8:89609409~89757727:-
SARC	cis	rs7617773	0.676	rs13060020	ENSG00000228638.1	FCF1P2	-3.83	0.000165	0.046	-0.29	-0.24	Coronary artery disease;	chr3:48331156	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.707	rs13061269	ENSG00000228638.1	FCF1P2	-3.83	0.000165	0.046	-0.29	-0.24	Coronary artery disease;	chr3:48331853	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs13066044	ENSG00000228638.1	FCF1P2	-3.83	0.000165	0.046	-0.29	-0.24	Coronary artery disease;	chr3:48335786	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.78	rs11716848	ENSG00000228638.1	FCF1P2	-3.83	0.000165	0.046	-0.29	-0.24	Coronary artery disease;	chr3:48337010	chr3:48290793~48291375:-
SARC	cis	rs17268829	0.927	rs7797665	ENSG00000236197.2	AC002429.5	3.83	0.000166	0.046	0.27	0.24	Breast cancer;	chr7:94439168	chr7:95154713~95214332:-
SARC	cis	rs8054556	0.74	rs12716975	ENSG00000183604.13	SMG1P5	-3.83	0.000166	0.0461	-0.23	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29939508	chr16:30267553~30335374:-
SARC	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	3.83	0.000166	0.0461	0.27	0.24	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
SARC	cis	rs61160187	0.582	rs726824	ENSG00000215032.2	GNL3LP1	3.83	0.000166	0.0461	0.25	0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:61036989	chr5:60891935~60893577:-
SARC	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-3.83	0.000166	0.0461	-0.22	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
SARC	cis	rs2239547	0.563	rs9839035	ENSG00000242142.1	SERBP1P3	3.83	0.000166	0.0461	0.29	0.24	Schizophrenia;	chr3:52875861	chr3:53064283~53065091:-
SARC	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	3.83	0.000166	0.0461	0.29	0.24	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
SARC	cis	rs11671005	0.736	rs11668201	ENSG00000232098.3	CTD-2619J13.14	-3.83	0.000166	0.0461	-0.27	-0.24	Mean platelet volume;	chr19:58492265	chr19:58404238~58408484:-
SARC	cis	rs9902453	0.791	rs7219163	ENSG00000264538.5	SUZ12P1	3.83	0.000166	0.0461	0.17	0.24	Coffee consumption (cups per day);	chr17:29883685	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.765	rs62068653	ENSG00000264538.5	SUZ12P1	3.83	0.000166	0.0461	0.17	0.24	Coffee consumption (cups per day);	chr17:29885645	chr17:30709299~30790908:+
SARC	cis	rs4906332	1	rs12896612	ENSG00000244691.1	RPL10AP1	-3.83	0.000166	0.0461	-0.29	-0.24	Coronary artery disease;	chr14:103411531	chr14:103412119~103412761:-
SARC	cis	rs8028182	0.549	rs11072542	ENSG00000260206.1	CTD-2026K11.2	3.83	0.000166	0.0462	0.3	0.24	Sudden cardiac arrest;	chr15:75342258	chr15:75636139~75639239:+
SARC	cis	rs6952407	1	rs6952407	ENSG00000224316.1	RP11-479O9.2	-3.83	0.000166	0.0462	-0.23	-0.24	Cotinine glucuronidation;	chr7:66580525	chr7:65773620~65802067:+
SARC	cis	rs2274273	0.638	rs11622636	ENSG00000258413.1	RP11-665C16.6	-3.83	0.000166	0.0462	-0.34	-0.24	Protein biomarker;	chr14:55181122	chr14:55262767~55272075:-
SARC	cis	rs8054556	0.74	rs11649612	ENSG00000183604.13	SMG1P5	-3.83	0.000166	0.0462	-0.23	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29935349	chr16:30267553~30335374:-
SARC	cis	rs8054556	0.716	rs11642933	ENSG00000183604.13	SMG1P5	-3.83	0.000166	0.0462	-0.23	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29935387	chr16:30267553~30335374:-
SARC	cis	rs2790216	0.95	rs1199102	ENSG00000228527.1	RP11-179B15.5	-3.83	0.000166	0.0462	-0.32	-0.24	Inflammatory bowel disease;	chr10:58187542	chr10:58304553~58305621:+
SARC	cis	rs9468199	0.505	rs72847381	ENSG00000219392.1	RP1-265C24.5	-3.83	0.000166	0.0462	-0.58	-0.24	Parkinson's disease;	chr6:27906153	chr6:28115628~28116551:+
SARC	cis	rs17767294	0.708	rs72848752	ENSG00000219392.1	RP1-265C24.5	-3.83	0.000166	0.0462	-0.58	-0.24	Parkinson's disease;	chr6:27910490	chr6:28115628~28116551:+
SARC	cis	rs7302981	0.741	rs76919525	ENSG00000272368.2	RP4-605O3.4	-3.83	0.000166	0.0462	-0.26	-0.24	Systolic blood pressure;	chr12:50147950	chr12:50112197~50165618:+
SARC	cis	rs75804782	0.521	rs56340711	ENSG00000186235.9	AC016757.3	3.83	0.000166	0.0462	0.54	0.24	Chronotype;Morning vs. evening chronotype;	chr2:238531439	chr2:238224552~238231677:-
SARC	cis	rs13272623	0.775	rs7832689	ENSG00000246366.5	RP11-382J12.1	-3.83	0.000166	0.0462	-0.3	-0.24	IgG glycosylation;	chr8:71059236	chr8:70608577~70663279:+
SARC	cis	rs7267979	0.586	rs6050431	ENSG00000276952.1	RP5-965G21.6	3.83	0.000166	0.0462	0.24	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:25284915~25285588:-
SARC	cis	rs3796352	1	rs4478072	ENSG00000242142.1	SERBP1P3	-3.83	0.000166	0.0462	-0.41	-0.24	Immune reponse to smallpox (secreted IL-2);	chr3:53072109	chr3:53064283~53065091:-
SARC	cis	rs727479	0.962	rs12592697	ENSG00000244879.4	GABPB1-AS1	-3.83	0.000167	0.0462	-0.21	-0.24	Estradiol levels;	chr15:51232976	chr15:50354959~50372202:+
SARC	cis	rs7726354	0.793	rs79488097	ENSG00000271828.1	CTD-2310F14.1	3.83	0.000167	0.0462	0.49	0.24	Breast cancer (early onset);	chr5:56726424	chr5:56927874~56929573:+
SARC	cis	rs7246657	0.765	rs10402455	ENSG00000180458.2	CTD-3064H18.4	3.83	0.000167	0.0462	0.36	0.24	Coronary artery calcification;	chr19:37237805	chr19:37545470~37549171:-
SARC	cis	rs858239	0.6	rs10235786	ENSG00000226816.2	AC005082.12	3.83	0.000167	0.0463	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23206013~23208045:+
SARC	cis	rs7166081	1	rs10518716	ENSG00000270964.1	RP11-502I4.3	3.83	0.000167	0.0463	0.28	0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67202485	chr15:67541072~67542604:-
SARC	cis	rs1376877	0.902	rs56102300	ENSG00000213925.3	NPM1P33	3.83	0.000167	0.0463	0.23	0.24	Subclinical atherosclerosis traits (other);	chr2:203260545	chr2:203772631~203773502:-
SARC	cis	rs1376877	0.87	rs11683120	ENSG00000213925.3	NPM1P33	3.83	0.000167	0.0463	0.23	0.24	Subclinical atherosclerosis traits (other);	chr2:203264588	chr2:203772631~203773502:-
SARC	cis	rs11098499	0.532	rs4833624	ENSG00000250950.1	RP11-33B1.3	-3.83	0.000167	0.0463	-0.25	-0.24	Corneal astigmatism;	chr4:119664342	chr4:119456350~119457277:+
SARC	cis	rs11098499	0.532	rs12512646	ENSG00000250950.1	RP11-33B1.3	-3.83	0.000167	0.0463	-0.25	-0.24	Corneal astigmatism;	chr4:119664578	chr4:119456350~119457277:+
SARC	cis	rs202072	0.872	rs202044	ENSG00000215022.6	RP1-257A7.4	-3.83	0.000167	0.0463	-0.32	-0.24	HIV-1 viral setpoint;	chr6:13275718	chr6:13264861~13295586:-
SARC	cis	rs7267979	0.816	rs443009	ENSG00000276952.1	RP5-965G21.6	-3.83	0.000167	0.0463	-0.24	-0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:25284915~25285588:-
SARC	cis	rs3934047	0.904	rs1514323	ENSG00000274376.3	ADAMTS7P1	-3.83	0.000167	0.0463	-0.27	-0.24	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81723599	chr15:82298553~82334609:+
SARC	cis	rs858239	0.6	rs4321896	ENSG00000226816.2	AC005082.12	3.83	0.000167	0.0463	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23206013~23208045:+
SARC	cis	rs858239	0.6	rs61292332	ENSG00000226816.2	AC005082.12	3.83	0.000167	0.0463	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23206013~23208045:+
SARC	cis	rs858239	0.6	rs59073109	ENSG00000226816.2	AC005082.12	3.83	0.000167	0.0463	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23206013~23208045:+
SARC	cis	rs858239	0.6	rs7788821	ENSG00000226816.2	AC005082.12	3.83	0.000167	0.0463	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23206013~23208045:+
SARC	cis	rs858239	0.6	rs6956595	ENSG00000226816.2	AC005082.12	3.83	0.000167	0.0463	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23206013~23208045:+
SARC	cis	rs13126694	0.75	rs2346782	ENSG00000248429.4	RP11-597D13.9	3.83	0.000167	0.0463	0.23	0.24	Blood osmolality (transformed sodium);	chr4:158147143	chr4:158170752~158202877:+
SARC	cis	rs5758659	1	rs5758677	ENSG00000182057.4	OGFRP1	3.83	0.000167	0.0463	0.23	0.24	Cognitive function;	chr22:42247033	chr22:42269753~42275196:+
SARC	cis	rs875971	0.66	rs6460308	ENSG00000224316.1	RP11-479O9.2	-3.83	0.000167	0.0463	-0.23	-0.24	Aortic root size;	chr7:66619753	chr7:65773620~65802067:+
SARC	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
SARC	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
SARC	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
SARC	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
SARC	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
SARC	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
SARC	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
SARC	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
SARC	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
SARC	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
SARC	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
SARC	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
SARC	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
SARC	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
SARC	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	3.83	0.000167	0.0464	0.45	0.24	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
SARC	cis	rs6570726	0.791	rs1280275	ENSG00000235652.6	RP11-545I5.3	3.83	0.000167	0.0464	0.22	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145799409~145886585:+
SARC	cis	rs11051970	0.589	rs325426	ENSG00000255867.1	DENND5B-AS1	3.83	0.000167	0.0464	0.29	0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32382881	chr12:31589923~31615666:+
SARC	cis	rs11051970	0.589	rs2931550	ENSG00000255867.1	DENND5B-AS1	3.83	0.000167	0.0464	0.29	0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32389099	chr12:31589923~31615666:+
SARC	cis	rs7408868	0.908	rs2074619	ENSG00000266913.1	CTC-548K16.2	-3.83	0.000168	0.0464	-0.38	-0.24	Pulse pressure;	chr19:15166108	chr19:14305458~14370196:-
SARC	cis	rs7408868	0.908	rs10416777	ENSG00000266913.1	CTC-548K16.2	-3.83	0.000168	0.0464	-0.38	-0.24	Pulse pressure;	chr19:15166112	chr19:14305458~14370196:-
SARC	cis	rs7408868	0.764	rs62113791	ENSG00000266913.1	CTC-548K16.2	-3.83	0.000168	0.0464	-0.38	-0.24	Pulse pressure;	chr19:15166198	chr19:14305458~14370196:-
SARC	cis	rs7408868	0.764	rs45504393	ENSG00000266913.1	CTC-548K16.2	-3.83	0.000168	0.0464	-0.38	-0.24	Pulse pressure;	chr19:15166199	chr19:14305458~14370196:-
SARC	cis	rs7408868	1	rs10415431	ENSG00000266913.1	CTC-548K16.2	-3.83	0.000168	0.0464	-0.38	-0.24	Pulse pressure;	chr19:15166216	chr19:14305458~14370196:-
SARC	cis	rs10871290	0.507	rs3851731	ENSG00000214331.7	RP11-252A24.2	3.83	0.000168	0.0464	0.2	0.24	Breast cancer;	chr16:74451890	chr16:74332402~74368240:-
SARC	cis	rs2762353	0.524	rs9467596	ENSG00000272810.1	U91328.22	3.83	0.000168	0.0464	0.23	0.24	Blood metabolite levels;	chr6:25782794	chr6:26013241~26013757:+
SARC	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	3.83	0.000168	0.0464	0.31	0.24	Height;	chr6:109471826	chr6:109382795~109383666:+
SARC	cis	rs6969780	1	rs739734	ENSG00000233429.8	HOTAIRM1	3.83	0.000168	0.0464	0.39	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119786	chr7:27095647~27100265:+
SARC	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-3.83	0.000168	0.0464	-0.22	-0.24	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
SARC	cis	rs6142102	0.625	rs6142068	ENSG00000275784.1	RP5-1125A11.6	3.83	0.000168	0.0464	0.27	0.24	Skin pigmentation;	chr20:33969366	chr20:33989480~33991818:-
SARC	cis	rs610932	0.517	rs650943	ENSG00000255139.1	AP000442.1	-3.83	0.000168	0.0464	-0.22	-0.24	Alzheimer's disease;	chr11:60239292	chr11:59616429~59639861:+
SARC	cis	rs72772090	0.908	rs17086588	ENSG00000247121.5	CTD-2260A17.2	3.83	0.000168	0.0465	0.3	0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96709210	chr5:96814028~96935809:-
SARC	cis	rs792448	0.926	rs701905	ENSG00000229983.1	RP11-15I11.2	3.83	0.000168	0.0465	0.25	0.24	White blood cell count (basophil);	chr1:212379769	chr1:212168207~212190259:+
SARC	cis	rs7617773	0.817	rs9830016	ENSG00000271161.1	BOLA2P2	-3.83	0.000168	0.0465	-0.2	-0.24	Coronary artery disease;	chr3:48241004	chr3:47499841~47500407:+
SARC	cis	rs5769707	0.967	rs2187891	ENSG00000235111.1	RP1-29C18.8	-3.83	0.000168	0.0465	-0.26	-0.24	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49612657~49615716:-
SARC	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	3.83	0.000168	0.0465	0.21	0.24	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
SARC	cis	rs56205728	0.606	rs3784398	ENSG00000247556.5	OIP5-AS1	-3.83	0.000168	0.0465	-0.23	-0.24	Schizophrenia;	chr15:40304665	chr15:41283990~41309737:+
SARC	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	3.83	0.000168	0.0465	0.39	0.24	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
SARC	cis	rs4705962	0.878	rs2299009	ENSG00000230612.2	AC004237.1	3.82	0.000168	0.0465	0.28	0.24	Atopic dermatitis;	chr5:132707121	chr5:132688681~132723725:+
SARC	cis	rs4705962	0.878	rs4266392	ENSG00000230612.2	AC004237.1	3.82	0.000168	0.0465	0.28	0.24	Atopic dermatitis;	chr5:132713563	chr5:132688681~132723725:+
SARC	cis	rs4705962	0.878	rs7734673	ENSG00000230612.2	AC004237.1	3.82	0.000168	0.0465	0.28	0.24	Atopic dermatitis;	chr5:132722774	chr5:132688681~132723725:+
SARC	cis	rs727479	0.543	rs8023263	ENSG00000244879.4	GABPB1-AS1	-3.82	0.000168	0.0465	-0.2	-0.24	Estradiol levels;	chr15:51225400	chr15:50354959~50372202:+
SARC	cis	rs61160187	0.673	rs10062240	ENSG00000215032.2	GNL3LP1	-3.82	0.000168	0.0465	-0.24	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60782585	chr5:60891935~60893577:-
SARC	cis	rs34792	0.678	rs153787	ENSG00000207425.1	Y_RNA	3.82	0.000168	0.0465	0.31	0.24	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499916	chr16:14915457~14915556:-
SARC	cis	rs12497850	0.931	rs3774628	ENSG00000225399.4	RP11-3B7.1	3.82	0.000168	0.0465	0.31	0.24	Parkinson's disease;	chr3:48764407	chr3:49260085~49261316:+
SARC	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	3.82	0.000168	0.0466	0.28	0.24	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
SARC	cis	rs7246657	0.55	rs10411176	ENSG00000226686.6	LINC01535	-3.82	0.000169	0.0466	-0.39	-0.24	Coronary artery calcification;	chr19:37196051	chr19:37251912~37265535:+
SARC	cis	rs7678555	0.54	rs13119564	ENSG00000245958.5	RP11-33B1.1	-3.82	0.000169	0.0466	-0.21	-0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr4:119925942	chr4:119454791~119552025:+
SARC	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-3.82	0.000169	0.0466	-0.41	-0.24	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
SARC	cis	rs7216064	0.954	rs9907491	ENSG00000237854.3	LINC00674	-3.82	0.000169	0.0466	-0.29	-0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67953877	chr17:68101908~68115518:+
SARC	cis	rs7216064	0.954	rs4790974	ENSG00000237854.3	LINC00674	-3.82	0.000169	0.0466	-0.29	-0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67954991	chr17:68101908~68115518:+
SARC	cis	rs6472827	0.595	rs2936684	ENSG00000253983.2	RP1-16A9.1	3.82	0.000169	0.0466	0.33	0.24	Uterine fibroids;	chr8:74201522	chr8:74199396~74208441:+
SARC	cis	rs2836974	0.568	rs11910906	ENSG00000255568.3	BRWD1-AS2	-3.82	0.000169	0.0466	-0.24	-0.24	Cognitive function;	chr21:39313736	chr21:39313935~39314962:+
SARC	cis	rs7085104	0.7	rs10786712	ENSG00000213061.2	PFN1P11	-3.82	0.000169	0.0466	-0.3	-0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102836639	chr10:102838011~102845473:-
SARC	cis	rs17826219	0.636	rs12946563	ENSG00000264538.5	SUZ12P1	-3.82	0.000169	0.0467	-0.26	-0.24	Body mass index;	chr17:30776148	chr17:30709299~30790908:+
SARC	cis	rs6695567	0.869	rs1679941	ENSG00000280378.1	RP4-758J24.6	-3.82	0.000169	0.0467	-0.25	-0.24	Systemic lupus erythematosus;	chr1:53149304	chr1:54033126~54034880:-
SARC	cis	rs9828933	0.766	rs864975	ENSG00000280620.1	SCAANT1	-3.82	0.000169	0.0467	-0.41	-0.24	Type 2 diabetes;	chr3:63899939	chr3:63911518~63911772:-
SARC	cis	rs7308116	1	rs7964384	ENSG00000240441.1	RP11-864J10.2	-3.82	0.000169	0.0467	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107804631	chr12:107719599~107720133:+
SARC	cis	rs7308116	0.967	rs6539360	ENSG00000240441.1	RP11-864J10.2	-3.82	0.000169	0.0467	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107804942	chr12:107719599~107720133:+
SARC	cis	rs4886920	0.692	rs4625694	ENSG00000260776.4	RP11-114H24.2	3.82	0.000169	0.0467	0.32	0.24	Neuroticism;	chr15:77826137	chr15:77914217~77926846:-
SARC	cis	rs4886920	0.692	rs4625695	ENSG00000260776.4	RP11-114H24.2	3.82	0.000169	0.0467	0.32	0.24	Neuroticism;	chr15:77826153	chr15:77914217~77926846:-
SARC	cis	rs4886920	0.723	rs11633959	ENSG00000260776.4	RP11-114H24.2	3.82	0.000169	0.0467	0.32	0.24	Neuroticism;	chr15:77826362	chr15:77914217~77926846:-
SARC	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000169	0.0467	-0.36	-0.24	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
SARC	cis	rs7772486	0.754	rs702306	ENSG00000235652.6	RP11-545I5.3	-3.82	0.000169	0.0467	-0.22	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145799409~145886585:+
SARC	cis	rs1864400	0.605	rs12360493	ENSG00000273008.1	RP11-351D16.3	3.82	0.000169	0.0467	0.28	0.24	Hirschsprung disease;	chr10:43223165	chr10:43136824~43138334:-
SARC	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	3.82	0.000169	0.0467	0.38	0.24	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
SARC	cis	rs848486	0.936	rs10240081	ENSG00000214293.7	APTR	-3.82	0.000169	0.0467	-0.25	-0.24	Glomerular filtration rate;	chr7:77745447	chr7:77657660~77696265:-
SARC	cis	rs7726354	0.793	rs76250845	ENSG00000271828.1	CTD-2310F14.1	3.82	0.000169	0.0467	0.53	0.24	Breast cancer (early onset);	chr5:56747145	chr5:56927874~56929573:+
SARC	cis	rs11159086	0.793	rs10139029	ENSG00000270000.1	RP3-449M8.9	3.82	0.000169	0.0467	0.36	0.24	Advanced glycation end-product levels;	chr14:74492284	chr14:74471930~74472360:-
SARC	cis	rs11159086	0.793	rs10139122	ENSG00000270000.1	RP3-449M8.9	3.82	0.000169	0.0467	0.36	0.24	Advanced glycation end-product levels;	chr14:74492353	chr14:74471930~74472360:-
SARC	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-3.82	0.000169	0.0467	-0.39	-0.24	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
SARC	cis	rs3796352	1	rs11718752	ENSG00000242142.1	SERBP1P3	-3.82	0.000169	0.0467	-0.42	-0.24	Immune reponse to smallpox (secreted IL-2);	chr3:53096729	chr3:53064283~53065091:-
SARC	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	3.82	0.000169	0.0467	0.26	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
SARC	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	3.82	0.000169	0.0468	0.29	0.24	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
SARC	cis	rs6477918	0.544	rs34651548	ENSG00000250068.1	RP11-576C12.1	-3.82	0.000169	0.0468	-0.26	-0.24	Obstetric antiphospholipid syndrome;	chr9:112480141	chr9:112581779~112582590:-
SARC	cis	rs62184315	1	rs62184315	ENSG00000273240.1	RP11-455J20.3	-3.82	0.000169	0.0468	-0.34	-0.24	Alcohol dependence (age at onset);	chr2:189907219	chr2:189763859~189764456:-
SARC	cis	rs4713118	0.662	rs9357060	ENSG00000272009.1	RP1-313I6.12	-3.82	0.000169	0.0468	-0.29	-0.24	Parkinson's disease;	chr6:28056708	chr6:28078792~28081130:-
SARC	cis	rs4713118	0.662	rs9468271	ENSG00000272009.1	RP1-313I6.12	-3.82	0.000169	0.0468	-0.29	-0.24	Parkinson's disease;	chr6:28056792	chr6:28078792~28081130:-
SARC	cis	rs61332075	0.501	rs55706928	ENSG00000186235.9	AC016757.3	3.82	0.000169	0.0468	0.56	0.24	Lung function (FEV1/FVC);	chr2:238537165	chr2:238224552~238231677:-
SARC	cis	rs75804782	0.572	rs72982580	ENSG00000186235.9	AC016757.3	3.82	0.000169	0.0468	0.56	0.24	Chronotype;Morning vs. evening chronotype;	chr2:238539142	chr2:238224552~238231677:-
SARC	cis	rs2898681	0.561	rs6855240	ENSG00000248375.1	RP11-177B4.1	-3.82	0.000169	0.0468	-0.41	-0.24	Optic nerve measurement (cup area);	chr4:52874620	chr4:52720081~52720831:-
SARC	cis	rs2898681	0.521	rs6833350	ENSG00000248375.1	RP11-177B4.1	-3.82	0.000169	0.0468	-0.41	-0.24	Optic nerve measurement (cup area);	chr4:52874701	chr4:52720081~52720831:-
SARC	cis	rs7829975	0.688	rs7837587	ENSG00000253981.4	ALG1L13P	3.82	0.00017	0.0468	0.24	0.24	Mood instability;	chr8:8521482	chr8:8236003~8244667:-
SARC	cis	rs7267979	0.565	rs6076364	ENSG00000125804.12	FAM182A	3.82	0.00017	0.0468	0.29	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:26054655~26086917:+
SARC	cis	rs7267979	0.565	rs13040726	ENSG00000125804.12	FAM182A	3.82	0.00017	0.0468	0.29	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:26054655~26086917:+
SARC	cis	rs4835265	0.528	rs13149290	ENSG00000272727.1	RP11-142A22.4	3.82	0.00017	0.0468	0.31	0.24	Gamma glutamyl transpeptidase;	chr4:145829814	chr4:145335263~145340421:-
SARC	cis	rs10005067	0.967	rs4693905	ENSG00000249001.4	RP11-742B18.1	3.82	0.00017	0.0468	0.23	0.24	Total body bone mineral density (age 30-45);	chr4:87901297	chr4:87568035~87733956:-
SARC	cis	rs1707322	1	rs4298677	ENSG00000281133.1	AL355480.3	-3.82	0.00017	0.0468	-0.28	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45580892~45580996:-
SARC	cis	rs1062177	0.855	rs6896664	ENSG00000254226.4	CTB-12O2.1	3.82	0.00017	0.0468	0.31	0.24	Preschool internalizing problems;	chr5:151885713	chr5:151949571~152270448:+
SARC	cis	rs16958440	1	rs62096476	ENSG00000280212.1	RP11-49K24.3	3.82	0.00017	0.0468	0.59	0.24	Sitting height ratio;	chr18:47132250	chr18:47076117~47076594:+
SARC	cis	rs77633900	1	rs2469214	ENSG00000196274.5	Metazoa_SRP	3.82	0.00017	0.0468	0.41	0.24	Glioma;Non-glioblastoma glioma;	chr15:76282287	chr15:76230048~76230390:-
SARC	cis	rs763121	0.853	rs4821810	ENSG00000273076.1	RP3-508I15.22	3.82	0.00017	0.0468	0.26	0.24	Menopause (age at onset);	chr22:38676093	chr22:38743495~38743910:+
SARC	cis	rs2274273	0.653	rs1209087	ENSG00000258413.1	RP11-665C16.6	3.82	0.00017	0.0468	0.27	0.24	Protein biomarker;	chr14:55026502	chr14:55262767~55272075:-
SARC	cis	rs1376877	0.902	rs62183907	ENSG00000213925.3	NPM1P33	3.82	0.00017	0.0468	0.23	0.24	Subclinical atherosclerosis traits (other);	chr2:203277805	chr2:203772631~203773502:-
SARC	cis	rs2731006	0.591	rs908658	ENSG00000257114.2	RP11-25I15.3	-3.82	0.00017	0.0468	-0.39	-0.24	Panic disorder;	chr12:42774929	chr12:42692216~42717119:+
SARC	cis	rs2836974	0.897	rs1541102	ENSG00000232837.1	AF064858.7	3.82	0.00017	0.0469	0.28	0.24	Cognitive function;	chr21:39256839	chr21:38974429~38977774:-
SARC	cis	rs42490	0.594	rs39766	ENSG00000251136.7	RP11-37B2.1	-3.82	0.00017	0.0469	-0.27	-0.24	Leprosy;	chr8:89799141	chr8:89609409~89757727:-
SARC	cis	rs13113518	0.783	rs12504300	ENSG00000273257.1	RP11-177J6.1	3.82	0.00017	0.0469	0.32	0.24	Height;	chr4:55482360	chr4:55387949~55388271:+
SARC	cis	rs7208859	0.725	rs9891656	ENSG00000263603.1	CTD-2349P21.5	-3.82	0.00017	0.0469	-0.33	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30729469~30731202:+
SARC	cis	rs42490	0.789	rs51331	ENSG00000251136.7	RP11-37B2.1	-3.82	0.00017	0.0469	-0.27	-0.24	Leprosy;	chr8:89801900	chr8:89609409~89757727:-
SARC	cis	rs875971	1	rs4718307	ENSG00000232559.3	GS1-124K5.12	-3.82	0.00017	0.0469	-0.26	-0.24	Aortic root size;	chr7:66146001	chr7:66554588~66576923:-
SARC	cis	rs11105298	0.891	rs10858899	ENSG00000270344.2	RP11-734K2.4	3.82	0.00017	0.0469	0.3	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89525654~89548005:+
SARC	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-3.82	0.00017	0.0469	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
SARC	cis	rs12893668	0.703	rs8017993	ENSG00000269910.1	RP11-73M18.10	3.82	0.00017	0.0469	0.22	0.24	Reticulocyte count;	chr14:103581397	chr14:103694516~103695050:-
SARC	cis	rs2274273	0.712	rs6572999	ENSG00000258413.1	RP11-665C16.6	-3.82	0.00017	0.047	-0.27	-0.24	Protein biomarker;	chr14:55060656	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.712	rs17832311	ENSG00000258413.1	RP11-665C16.6	-3.82	0.00017	0.047	-0.27	-0.24	Protein biomarker;	chr14:55067748	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.713	rs56725788	ENSG00000258413.1	RP11-665C16.6	-3.82	0.00017	0.047	-0.27	-0.24	Protein biomarker;	chr14:55073383	chr14:55262767~55272075:-
SARC	cis	rs2274273	0.743	rs13379159	ENSG00000258413.1	RP11-665C16.6	-3.82	0.00017	0.047	-0.27	-0.24	Protein biomarker;	chr14:55074083	chr14:55262767~55272075:-
SARC	cis	rs7976269	0.609	rs2117993	ENSG00000257176.2	RP11-996F15.2	-3.82	0.00017	0.047	-0.26	-0.24	Male-pattern baldness;	chr12:29060041	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.609	rs10843300	ENSG00000257176.2	RP11-996F15.2	-3.82	0.00017	0.047	-0.26	-0.24	Male-pattern baldness;	chr12:29060934	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.609	rs11050010	ENSG00000257176.2	RP11-996F15.2	-3.82	0.00017	0.047	-0.26	-0.24	Male-pattern baldness;	chr12:29061952	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.609	rs2196480	ENSG00000257176.2	RP11-996F15.2	-3.82	0.00017	0.047	-0.26	-0.24	Male-pattern baldness;	chr12:29062850	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.537	rs10743642	ENSG00000257176.2	RP11-996F15.2	-3.82	0.00017	0.047	-0.26	-0.24	Male-pattern baldness;	chr12:29063557	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.609	rs10771472	ENSG00000257176.2	RP11-996F15.2	-3.82	0.00017	0.047	-0.26	-0.24	Male-pattern baldness;	chr12:29063930	chr12:29280418~29317848:-
SARC	cis	rs7216064	0.636	rs62084696	ENSG00000277476.1	RP11-147L13.13	-3.82	0.00017	0.047	-0.29	-0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68042065	chr17:68133201~68135935:+
SARC	cis	rs7204230	1	rs62049766	ENSG00000261291.1	RP11-295M3.2	3.82	0.00017	0.047	0.27	0.24	Fibrinogen;	chr16:53229442	chr16:53168522~53169450:+
SARC	cis	rs7204230	1	rs62049769	ENSG00000261291.1	RP11-295M3.2	3.82	0.00017	0.047	0.27	0.24	Fibrinogen;	chr16:53236840	chr16:53168522~53169450:+
SARC	cis	rs2280018	0.526	rs2966128	ENSG00000188599.16	NPIPP1	-3.82	0.00017	0.047	-0.24	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15104312~15123498:-
SARC	cis	rs2274273	0.774	rs9323278	ENSG00000258413.1	RP11-665C16.6	-3.82	0.00017	0.047	-0.27	-0.24	Protein biomarker;	chr14:55074856	chr14:55262767~55272075:-
SARC	cis	rs202072	0.585	rs1512414	ENSG00000215022.6	RP1-257A7.4	-3.82	0.000171	0.047	-0.28	-0.24	HIV-1 viral setpoint;	chr6:13276183	chr6:13264861~13295586:-
SARC	cis	rs17508449	0.819	rs17359468	ENSG00000232450.1	RP4-730K3.3	-3.82	0.000171	0.047	-0.32	-0.24	Leprosy;	chr1:113700084	chr1:113698884~113699631:-
SARC	cis	rs1376877	0.87	rs4261698	ENSG00000213925.3	NPM1P33	3.82	0.000171	0.047	0.23	0.24	Subclinical atherosclerosis traits (other);	chr2:203256236	chr2:203772631~203773502:-
SARC	cis	rs2455799	0.613	rs4685269	ENSG00000226427.1	HMGN2P7	-3.82	0.000171	0.047	-0.26	-0.24	Mean platelet volume;	chr3:15900847	chr3:15375373~15375645:-
SARC	cis	rs6695567	0.967	rs6588468	ENSG00000280378.1	RP4-758J24.6	-3.82	0.000171	0.047	-0.25	-0.24	Systemic lupus erythematosus;	chr1:53164976	chr1:54033126~54034880:-
SARC	cis	rs7647973	0.6	rs35174559	ENSG00000225399.4	RP11-3B7.1	3.82	0.000171	0.047	0.3	0.24	Menarche (age at onset);	chr3:49250326	chr3:49260085~49261316:+
SARC	cis	rs875971	0.619	rs10278371	ENSG00000224316.1	RP11-479O9.2	-3.82	0.000171	0.047	-0.23	-0.24	Aortic root size;	chr7:66586553	chr7:65773620~65802067:+
SARC	cis	rs12049351	0.774	rs6673421	ENSG00000229367.1	HMGN2P19	3.82	0.000171	0.047	0.2	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229500641	chr1:229570532~229570796:+
SARC	cis	rs240993	0.812	rs9487644	ENSG00000230177.1	RP5-1112D6.4	-3.82	0.000171	0.047	-0.28	-0.24	Inflammatory skin disease;Psoriasis;	chr6:111443064	chr6:111277932~111278742:+
SARC	cis	rs240993	0.761	rs9487645	ENSG00000230177.1	RP5-1112D6.4	-3.82	0.000171	0.047	-0.28	-0.24	Inflammatory skin disease;Psoriasis;	chr6:111443065	chr6:111277932~111278742:+
SARC	cis	rs66887589	0.616	rs11731675	ENSG00000245958.5	RP11-33B1.1	-3.82	0.000171	0.0471	-0.21	-0.24	Diastolic blood pressure;	chr4:119291359	chr4:119454791~119552025:+
SARC	cis	rs17169635	0.836	rs3800735	ENSG00000223718.3	AC093107.7	3.82	0.000171	0.0471	0.31	0.24	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134852218	chr7:135660039~135660647:+
SARC	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-3.82	0.000171	0.0471	-0.26	-0.24	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
SARC	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-3.82	0.000171	0.0471	-0.26	-0.24	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
SARC	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-3.82	0.000171	0.0471	-0.26	-0.24	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
SARC	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-3.82	0.000171	0.0471	-0.26	-0.24	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
SARC	cis	rs11694172	1	rs72928909	ENSG00000273456.1	RP11-686O6.2	3.82	0.000171	0.0471	0.21	0.24	Cholesterol, total;	chr2:202676931	chr2:202374932~202375604:-
SARC	cis	rs12542260	0.953	rs5004281	ENSG00000253106.1	RP11-158K1.3	-3.82	0.000171	0.0471	-0.29	-0.24	Colonoscopy-negative controls vs population controls;	chr8:124464893	chr8:124488510~124491643:+
SARC	cis	rs10895987	1	rs11227126	ENSG00000254614.2	AP003068.23	3.82	0.000171	0.0471	0.35	0.24	Blood protein levels;	chr11:65140591	chr11:65177606~65181834:-
SARC	cis	rs4705962	0.878	rs4705965	ENSG00000230612.2	AC004237.1	3.82	0.000171	0.0471	0.29	0.24	Atopic dermatitis;	chr5:132719435	chr5:132688681~132723725:+
SARC	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000171	0.0471	-0.35	-0.24	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000171	0.0471	-0.35	-0.24	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000171	0.0471	-0.35	-0.24	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000171	0.0471	-0.35	-0.24	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
SARC	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000171	0.0471	-0.35	-0.24	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
SARC	cis	rs2243480	0.803	rs36127118	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000171	0.0471	-0.35	-0.24	Diabetic kidney disease;	chr7:66100518	chr7:66902857~66906297:+
SARC	cis	rs7772486	0.774	rs6930181	ENSG00000270638.1	RP3-466P17.1	-3.82	0.000171	0.0471	-0.2	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145859838	chr6:145735570~145737218:+
SARC	cis	rs11955398	0.502	rs34638	ENSG00000215032.2	GNL3LP1	-3.82	0.000171	0.0471	-0.26	-0.24	Intelligence (multi-trait analysis);	chr5:61054660	chr5:60891935~60893577:-
SARC	cis	rs67478160	0.644	rs7159810	ENSG00000269958.1	RP11-73M18.8	3.82	0.000171	0.0471	0.24	0.24	Schizophrenia;	chr14:103827780	chr14:103696353~103697163:+
SARC	cis	rs7267979	0.527	rs6076369	ENSG00000125804.12	FAM182A	3.82	0.000171	0.0471	0.29	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:26054655~26086917:+
SARC	cis	rs6495122	0.501	rs6495144	ENSG00000260269.4	CTD-2323K18.1	3.82	0.000171	0.0471	0.32	0.24	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75051097	chr15:75527150~75601205:-
SARC	cis	rs13113518	0.812	rs13107810	ENSG00000273257.1	RP11-177J6.1	3.82	0.000171	0.0471	0.31	0.24	Height;	chr4:55542243	chr4:55387949~55388271:+
SARC	cis	rs4835473	0.897	rs11728121	ENSG00000251600.4	RP11-673E1.1	3.82	0.000171	0.0471	0.25	0.24	Immature fraction of reticulocytes;	chr4:143707079	chr4:143912331~143982454:+
SARC	cis	rs8028182	0.636	rs4462560	ENSG00000260206.1	CTD-2026K11.2	3.82	0.000171	0.0471	0.3	0.24	Sudden cardiac arrest;	chr15:75355623	chr15:75636139~75639239:+
SARC	cis	rs12049351	0.774	rs754023	ENSG00000229367.1	HMGN2P19	3.82	0.000171	0.0471	0.2	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229501756	chr1:229570532~229570796:+
SARC	cis	rs858239	0.67	rs3807452	ENSG00000226816.2	AC005082.12	-3.82	0.000172	0.0472	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23206013~23208045:+
SARC	cis	rs9309473	0.519	rs7598901	ENSG00000163016.8	ALMS1P	-3.82	0.000172	0.0472	-0.28	-0.24	Metabolite levels;	chr2:73448717	chr2:73644919~73685576:+
SARC	cis	rs8098244	0.617	rs35943794	ENSG00000264745.1	TTC39C-AS1	3.82	0.000172	0.0472	0.27	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23826485	chr18:23994213~24015339:-
SARC	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-3.82	0.000172	0.0472	-0.22	-0.24	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-3.82	0.000172	0.0472	-0.22	-0.24	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-3.82	0.000172	0.0472	-0.22	-0.24	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
SARC	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-3.82	0.000172	0.0472	-0.22	-0.24	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-3.82	0.000172	0.0472	-0.22	-0.24	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-3.82	0.000172	0.0472	-0.22	-0.24	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
SARC	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-3.82	0.000172	0.0472	-0.22	-0.24	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
SARC	cis	rs727479	0.76	rs8024515	ENSG00000244879.4	GABPB1-AS1	-3.82	0.000172	0.0472	-0.2	-0.24	Estradiol levels;	chr15:51240079	chr15:50354959~50372202:+
SARC	cis	rs12542260	0.871	rs7834203	ENSG00000253106.1	RP11-158K1.3	-3.82	0.000172	0.0472	-0.23	-0.24	Colonoscopy-negative controls vs population controls;	chr8:124470655	chr8:124488510~124491643:+
SARC	cis	rs12542260	0.871	rs62527884	ENSG00000253106.1	RP11-158K1.3	-3.82	0.000172	0.0472	-0.23	-0.24	Colonoscopy-negative controls vs population controls;	chr8:124471103	chr8:124488510~124491643:+
SARC	cis	rs12542260	0.871	rs72713049	ENSG00000253106.1	RP11-158K1.3	-3.82	0.000172	0.0472	-0.23	-0.24	Colonoscopy-negative controls vs population controls;	chr8:124471847	chr8:124488510~124491643:+
SARC	cis	rs9896933	0.778	rs80112422	ENSG00000266236.1	NARF-IT1	3.82	0.000172	0.0472	0.23	0.24	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82869843	chr17:82482098~82483388:+
SARC	cis	rs7204230	1	rs8051675	ENSG00000261291.1	RP11-295M3.2	3.82	0.000172	0.0472	0.27	0.24	Fibrinogen;	chr16:53338677	chr16:53168522~53169450:+
SARC	cis	rs9435732	0.594	rs2647166	ENSG00000186715.9	MST1L	-3.82	0.000172	0.0472	-0.28	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17016240	chr1:16754910~16770237:-
SARC	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-3.82	0.000172	0.0473	-0.27	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
SARC	cis	rs7520050	0.902	rs4626927	ENSG00000280836.1	AL355480.1	3.82	0.000172	0.0473	0.23	0.24	Reticulocyte count;Red blood cell count;	chr1:45782973	chr1:45581219~45581321:-
SARC	cis	rs7520050	0.902	rs7514192	ENSG00000280836.1	AL355480.1	3.82	0.000172	0.0473	0.23	0.24	Reticulocyte count;Red blood cell count;	chr1:45783305	chr1:45581219~45581321:-
SARC	cis	rs7819412	1	rs2409722	ENSG00000255310.2	AF131215.2	-3.82	0.000172	0.0473	-0.29	-0.24	Triglycerides;	chr8:11182307	chr8:11107788~11109726:-
SARC	cis	rs11098499	0.566	rs7664440	ENSG00000250950.1	RP11-33B1.3	-3.82	0.000172	0.0473	-0.26	-0.24	Corneal astigmatism;	chr4:119657385	chr4:119456350~119457277:+
SARC	cis	rs17695224	0.545	rs12459256	ENSG00000275055.1	CTC-471J1.11	-3.82	0.000172	0.0473	-0.25	-0.24	HDL cholesterol;HDL cholesterol levels;	chr19:51819835	chr19:52049007~52049754:+
SARC	cis	rs890448	0.726	rs2850368	ENSG00000254531.1	FLJ20021	-3.82	0.000172	0.0473	-0.26	-0.24	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101311472	chr4:101347780~101348883:+
SARC	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000172	0.0473	-0.35	-0.24	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
SARC	cis	rs4689592	0.503	rs4689064	ENSG00000245468.3	RP11-367J11.3	-3.82	0.000172	0.0473	-0.27	-0.24	Monocyte percentage of white cells;	chr4:7053876	chr4:7094571~7103385:-
SARC	cis	rs10991814	0.557	rs79342869	ENSG00000233081.1	RP11-440G5.2	3.82	0.000172	0.0473	0.37	0.24	Neutrophil percentage of granulocytes;	chr9:91225500	chr9:91426238~91427144:+
SARC	cis	rs7614311	0.689	rs2276863	ENSG00000271843.1	RP11-245J9.5	-3.82	0.000172	0.0473	-0.37	-0.24	Lung function (FVC);Lung function (FEV1);	chr3:63863367	chr3:64008082~64008692:-
SARC	cis	rs7614311	0.731	rs3733121	ENSG00000271843.1	RP11-245J9.5	-3.82	0.000172	0.0473	-0.37	-0.24	Lung function (FVC);Lung function (FEV1);	chr3:63864984	chr3:64008082~64008692:-
SARC	cis	rs12200782	1	rs12207181	ENSG00000272462.2	U91328.19	-3.82	0.000172	0.0473	-0.4	-0.24	Small cell lung carcinoma;	chr6:26431057	chr6:25992662~26001775:+
SARC	cis	rs12200782	1	rs12199239	ENSG00000272462.2	U91328.19	-3.82	0.000172	0.0473	-0.4	-0.24	Small cell lung carcinoma;	chr6:26432342	chr6:25992662~26001775:+
SARC	cis	rs12200782	1	rs10456330	ENSG00000272462.2	U91328.19	-3.82	0.000172	0.0473	-0.4	-0.24	Small cell lung carcinoma;	chr6:26436464	chr6:25992662~26001775:+
SARC	cis	rs12200782	1	rs12208390	ENSG00000272462.2	U91328.19	-3.82	0.000172	0.0473	-0.4	-0.24	Small cell lung carcinoma;	chr6:26436878	chr6:25992662~26001775:+
SARC	cis	rs12200782	0.929	rs72843734	ENSG00000272462.2	U91328.19	-3.82	0.000172	0.0473	-0.4	-0.24	Small cell lung carcinoma;	chr6:26448116	chr6:25992662~26001775:+
SARC	cis	rs11158609	0.536	rs35433607	ENSG00000278784.1	RP11-468E2.11	3.82	0.000172	0.0473	0.32	0.24	Systolic blood pressure (cigarette smoking interaction);	chr14:24204331	chr14:24201612~24202811:-
SARC	cis	rs4835473	0.9	rs34569841	ENSG00000251600.4	RP11-673E1.1	-3.82	0.000172	0.0473	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143738060	chr4:143912331~143982454:+
SARC	cis	rs4664293	0.647	rs10192408	ENSG00000226266.5	AC009961.3	-3.82	0.000172	0.0474	-0.28	-0.24	Monocyte percentage of white cells;	chr2:159568083	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs10196064	ENSG00000226266.5	AC009961.3	-3.82	0.000172	0.0474	-0.28	-0.24	Monocyte percentage of white cells;	chr2:159569454	chr2:159670708~159712435:-
SARC	cis	rs4664293	0.647	rs2162023	ENSG00000226266.5	AC009961.3	-3.82	0.000172	0.0474	-0.28	-0.24	Monocyte percentage of white cells;	chr2:159569719	chr2:159670708~159712435:-
SARC	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	3.82	0.000173	0.0474	0.22	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
SARC	cis	rs4835473	0.868	rs62337303	ENSG00000251600.4	RP11-673E1.1	-3.82	0.000173	0.0474	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143824967	chr4:143912331~143982454:+
SARC	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	3.82	0.000173	0.0474	0.3	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
SARC	cis	rs12980942	0.872	rs2304230	ENSG00000206674.1	RNU6-945P	-3.82	0.000173	0.0474	-0.35	-0.24	Coronary artery disease;	chr19:41268159	chr19:40299478~40299584:-
SARC	cis	rs16958440	1	rs2289130	ENSG00000280212.1	RP11-49K24.3	3.82	0.000173	0.0474	0.59	0.24	Sitting height ratio;	chr18:47100259	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs62096463	ENSG00000280212.1	RP11-49K24.3	3.82	0.000173	0.0474	0.59	0.24	Sitting height ratio;	chr18:47102557	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs62096464	ENSG00000280212.1	RP11-49K24.3	3.82	0.000173	0.0474	0.59	0.24	Sitting height ratio;	chr18:47102836	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs16958432	ENSG00000280212.1	RP11-49K24.3	3.82	0.000173	0.0474	0.59	0.24	Sitting height ratio;	chr18:47105402	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs16958440	ENSG00000280212.1	RP11-49K24.3	3.82	0.000173	0.0474	0.59	0.24	Sitting height ratio;	chr18:47106513	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs75800624	ENSG00000280212.1	RP11-49K24.3	3.82	0.000173	0.0474	0.59	0.24	Sitting height ratio;	chr18:47107234	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs60228288	ENSG00000280212.1	RP11-49K24.3	3.82	0.000173	0.0474	0.59	0.24	Sitting height ratio;	chr18:47114041	chr18:47076117~47076594:+
SARC	cis	rs16958440	1	rs62096470	ENSG00000280212.1	RP11-49K24.3	3.82	0.000173	0.0474	0.59	0.24	Sitting height ratio;	chr18:47115095	chr18:47076117~47076594:+
SARC	cis	rs9527	0.59	rs2281877	ENSG00000213061.2	PFN1P11	3.82	0.000173	0.0474	0.31	0.24	Arsenic metabolism;	chr10:103106305	chr10:102838011~102845473:-
SARC	cis	rs9527	0.59	rs10786738	ENSG00000213061.2	PFN1P11	3.82	0.000173	0.0474	0.31	0.24	Arsenic metabolism;	chr10:103109694	chr10:102838011~102845473:-
SARC	cis	rs9527	0.59	rs1807298	ENSG00000213061.2	PFN1P11	3.82	0.000173	0.0474	0.31	0.24	Arsenic metabolism;	chr10:103110461	chr10:102838011~102845473:-
SARC	cis	rs9527	0.59	rs2182348	ENSG00000213061.2	PFN1P11	3.82	0.000173	0.0474	0.31	0.24	Arsenic metabolism;	chr10:103112927	chr10:102838011~102845473:-
SARC	cis	rs9527	0.59	rs1926037	ENSG00000213061.2	PFN1P11	3.82	0.000173	0.0474	0.31	0.24	Arsenic metabolism;	chr10:103118253	chr10:102838011~102845473:-
SARC	cis	rs9527	0.567	rs6584539	ENSG00000213061.2	PFN1P11	3.82	0.000173	0.0474	0.31	0.24	Arsenic metabolism;	chr10:103119645	chr10:102838011~102845473:-
SARC	cis	rs9527	0.59	rs2148200	ENSG00000213061.2	PFN1P11	3.82	0.000173	0.0474	0.31	0.24	Arsenic metabolism;	chr10:103120090	chr10:102838011~102845473:-
SARC	cis	rs9527	0.614	rs2153774	ENSG00000213061.2	PFN1P11	3.82	0.000173	0.0474	0.31	0.24	Arsenic metabolism;	chr10:103121278	chr10:102838011~102845473:-
SARC	cis	rs9527	0.59	rs10883834	ENSG00000213061.2	PFN1P11	3.82	0.000173	0.0474	0.31	0.24	Arsenic metabolism;	chr10:103121645	chr10:102838011~102845473:-
SARC	cis	rs9527	0.545	rs7915816	ENSG00000213061.2	PFN1P11	3.82	0.000173	0.0474	0.31	0.24	Arsenic metabolism;	chr10:103121993	chr10:102838011~102845473:-
SARC	cis	rs9527	0.59	rs7067663	ENSG00000213061.2	PFN1P11	3.82	0.000173	0.0474	0.31	0.24	Arsenic metabolism;	chr10:103123893	chr10:102838011~102845473:-
SARC	cis	rs9527	0.568	rs1926036	ENSG00000213061.2	PFN1P11	3.82	0.000173	0.0474	0.31	0.24	Arsenic metabolism;	chr10:103124055	chr10:102838011~102845473:-
SARC	cis	rs2243480	1	rs67728539	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000173	0.0475	-0.36	-0.24	Diabetic kidney disease;	chr7:65913137	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000173	0.0475	-0.36	-0.24	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000173	0.0475	-0.36	-0.24	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000173	0.0475	-0.36	-0.24	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000173	0.0475	-0.36	-0.24	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000173	0.0475	-0.36	-0.24	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000173	0.0475	-0.36	-0.24	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000173	0.0475	-0.36	-0.24	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000173	0.0475	-0.36	-0.24	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
SARC	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000173	0.0475	-0.36	-0.24	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
SARC	cis	rs4679904	0.96	rs10936203	ENSG00000243116.1	RP11-564C24.1	3.82	0.000173	0.0475	0.25	0.24	Primary biliary cholangitis;	chr3:160490304	chr3:159721524~159722401:-
SARC	cis	rs9907295	0.901	rs74622050	ENSG00000270240.2	AC015849.2	3.82	0.000173	0.0475	0.37	0.24	Fibroblast growth factor basic levels;	chr17:35895939	chr17:35868967~35885863:+
SARC	cis	rs9329221	0.502	rs11777364	ENSG00000261451.1	RP11-981G7.1	3.82	0.000173	0.0475	0.22	0.24	Neuroticism;	chr8:10431036	chr8:10433672~10438312:+
SARC	cis	rs8098244	0.756	rs1154229	ENSG00000265752.2	RP11-403A21.1	-3.82	0.000173	0.0475	-0.23	-0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23902252	chr18:23957754~23982556:-
SARC	cis	rs2836974	0.666	rs11910705	ENSG00000255568.3	BRWD1-AS2	-3.82	0.000173	0.0475	-0.24	-0.24	Cognitive function;	chr21:39313678	chr21:39313935~39314962:+
SARC	cis	rs61160187	0.582	rs62372103	ENSG00000272308.1	RP11-231G3.1	-3.82	0.000173	0.0475	-0.21	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60849621	chr5:60866457~60866935:-
SARC	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	3.82	0.000173	0.0475	0.29	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
SARC	cis	rs3779195	0.585	rs7777991	ENSG00000213455.3	AC091654.7	3.82	0.000173	0.0475	0.39	0.24	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98454119~98454617:-
SARC	cis	rs1693575	0.743	rs879391	ENSG00000264991.1	AP001205.1	-3.82	0.000173	0.0475	-0.27	-0.24	Cerebrospinal fluid clusterin levels;	chr8:100673466	chr8:100707878~100707963:-
SARC	cis	rs950776	1	rs950776	ENSG00000261762.1	RP11-650L12.2	3.82	0.000173	0.0475	0.26	0.24	Sudden cardiac arrest;	chr15:78633676	chr15:78589123~78591276:-
SARC	cis	rs840616	0.69	rs10931285	ENSG00000231739.2	GAPDHP59	-3.82	0.000173	0.0475	-0.26	-0.24	Coronary heart disease;Coronary artery disease;	chr2:187347062	chr2:187415552~187415818:+
SARC	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	3.82	0.000173	0.0475	0.29	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
SARC	cis	rs9468186	1	rs9468186	ENSG00000216901.1	AL022393.7	3.82	0.000173	0.0475	0.35	0.24	Neuroticism;	chr6:27658852	chr6:28176188~28176674:+
SARC	cis	rs10504130	0.569	rs12678646	ENSG00000253844.1	RP11-546K22.1	-3.82	0.000173	0.0475	-0.36	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51755611	chr8:51961458~52022974:+
SARC	cis	rs485497	1	rs485497	ENSG00000229320.3	KRT8P12	3.82	0.000173	0.0476	0.25	0.24	Sjögren's syndrome;	chr3:160001345	chr3:160565447~160569248:+
SARC	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	3.82	0.000173	0.0476	0.25	0.24	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
SARC	cis	rs9876781	0.559	rs7630053	ENSG00000229759.1	MRPS18AP1	3.82	0.000173	0.0476	0.27	0.24	Longevity;	chr3:48357096	chr3:48256350~48256938:-
SARC	cis	rs9876781	0.559	rs13073692	ENSG00000229759.1	MRPS18AP1	3.82	0.000173	0.0476	0.27	0.24	Longevity;	chr3:48361812	chr3:48256350~48256938:-
SARC	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-3.82	0.000174	0.0476	-0.21	-0.24	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
SARC	cis	rs948562	0.681	rs11822754	ENSG00000280010.1	AP001350.4	3.82	0.000174	0.0476	0.34	0.24	Lymphoma;	chr11:58665406	chr11:58627435~58628528:+
SARC	cis	rs12148488	0.966	rs12899062	ENSG00000260269.4	CTD-2323K18.1	3.82	0.000174	0.0476	0.31	0.24	Caffeine consumption;	chr15:75055300	chr15:75527150~75601205:-
SARC	cis	rs28498283	0.792	rs13414085	ENSG00000279873.2	LINC01126	3.82	0.000174	0.0476	0.23	0.24	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:43118875	chr2:43227210~43228855:+
SARC	cis	rs28386778	0.966	rs2854161	ENSG00000240280.5	TCAM1P	3.82	0.000174	0.0476	0.31	0.24	Prudent dietary pattern;	chr17:63898733	chr17:63849292~63864379:+
SARC	cis	rs5771242	0.776	rs6010198	ENSG00000273253.2	RP3-402G11.26	3.82	0.000174	0.0476	0.3	0.24	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50172199	chr22:50199090~50200837:-
SARC	cis	rs875971	0.642	rs35526611	ENSG00000224316.1	RP11-479O9.2	-3.82	0.000174	0.0476	-0.23	-0.24	Aortic root size;	chr7:66629021	chr7:65773620~65802067:+
SARC	cis	rs7772486	0.59	rs1890170	ENSG00000270638.1	RP3-466P17.1	-3.82	0.000174	0.0476	-0.21	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145735570~145737218:+
SARC	cis	rs3779195	0.52	rs17169479	ENSG00000213455.3	AC091654.7	-3.82	0.000174	0.0477	-0.39	-0.24	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98454119~98454617:-
SARC	cis	rs330071	0.549	rs11785593	ENSG00000254340.1	RP11-10A14.3	3.82	0.000174	0.0477	0.28	0.24	Acne (severe);	chr8:9398814	chr8:9141424~9145435:+
SARC	cis	rs7647973	0.58	rs4955432	ENSG00000225399.4	RP11-3B7.1	3.82	0.000174	0.0477	0.3	0.24	Menarche (age at onset);	chr3:49229339	chr3:49260085~49261316:+
SARC	cis	rs7647973	0.6	rs12631989	ENSG00000225399.4	RP11-3B7.1	3.82	0.000174	0.0477	0.3	0.24	Menarche (age at onset);	chr3:49236563	chr3:49260085~49261316:+
SARC	cis	rs7647973	0.6	rs13064780	ENSG00000225399.4	RP11-3B7.1	3.82	0.000174	0.0477	0.3	0.24	Menarche (age at onset);	chr3:49237393	chr3:49260085~49261316:+
SARC	cis	rs7647973	0.58	rs35218722	ENSG00000225399.4	RP11-3B7.1	3.82	0.000174	0.0477	0.3	0.24	Menarche (age at onset);	chr3:49238372	chr3:49260085~49261316:+
SARC	cis	rs7647973	0.6	rs11920267	ENSG00000225399.4	RP11-3B7.1	3.82	0.000174	0.0477	0.3	0.24	Menarche (age at onset);	chr3:49238531	chr3:49260085~49261316:+
SARC	cis	rs867371	0.762	rs1846910	ENSG00000255769.6	GOLGA2P10	-3.82	0.000174	0.0477	-0.25	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472993~82513950:-
SARC	cis	rs763121	0.651	rs738249	ENSG00000273076.1	RP3-508I15.22	3.82	0.000174	0.0477	0.27	0.24	Menopause (age at onset);	chr22:38641974	chr22:38743495~38743910:+
SARC	cis	rs7617773	0.779	rs9833309	ENSG00000228638.1	FCF1P2	-3.82	0.000174	0.0477	-0.27	-0.24	Coronary artery disease;	chr3:48285960	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.817	rs9853804	ENSG00000228638.1	FCF1P2	-3.82	0.000174	0.0477	-0.27	-0.24	Coronary artery disease;	chr3:48286239	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.817	rs9834095	ENSG00000228638.1	FCF1P2	-3.82	0.000174	0.0477	-0.27	-0.24	Coronary artery disease;	chr3:48286261	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.817	rs4131361	ENSG00000228638.1	FCF1P2	-3.82	0.000174	0.0477	-0.27	-0.24	Coronary artery disease;	chr3:48287322	chr3:48290793~48291375:-
SARC	cis	rs7617773	0.817	rs6791930	ENSG00000228638.1	FCF1P2	-3.82	0.000174	0.0477	-0.27	-0.24	Coronary artery disease;	chr3:48288410	chr3:48290793~48291375:-
SARC	cis	rs7829975	0.806	rs2428	ENSG00000253981.4	ALG1L13P	3.82	0.000174	0.0477	0.24	0.24	Mood instability;	chr8:8783635	chr8:8236003~8244667:-
SARC	cis	rs1062177	0.502	rs10463321	ENSG00000254226.4	CTB-12O2.1	3.82	0.000174	0.0477	0.33	0.24	Preschool internalizing problems;	chr5:151944344	chr5:151949571~152270448:+
SARC	cis	rs4792901	0.543	rs9894814	ENSG00000197291.7	RAMP2-AS1	3.82	0.000174	0.0477	0.28	0.24	Dupuytren's disease;	chr17:43453618	chr17:42753914~42761257:-
SARC	cis	rs4792901	0.507	rs9910371	ENSG00000197291.7	RAMP2-AS1	3.82	0.000174	0.0477	0.28	0.24	Dupuytren's disease;	chr17:43453619	chr17:42753914~42761257:-
SARC	cis	rs4792901	0.543	rs56124217	ENSG00000197291.7	RAMP2-AS1	3.82	0.000174	0.0477	0.28	0.24	Dupuytren's disease;	chr17:43453630	chr17:42753914~42761257:-
SARC	cis	rs858239	0.6	rs6461692	ENSG00000226816.2	AC005082.12	3.82	0.000174	0.0477	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23206013~23208045:+
SARC	cis	rs10911902	0.643	rs10494584	ENSG00000233196.2	GS1-304P7.1	-3.82	0.000174	0.0477	-0.37	-0.24	Schizophrenia;	chr1:186321389	chr1:186580515~186581191:-
SARC	cis	rs755249	0.567	rs1126313	ENSG00000182109.6	RP11-69E11.4	-3.82	0.000174	0.0478	-0.27	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39522280~39546187:-
SARC	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-3.82	0.000174	0.0478	-0.28	-0.24	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
SARC	cis	rs9902453	0.845	rs7221516	ENSG00000264538.5	SUZ12P1	3.82	0.000174	0.0478	0.17	0.24	Coffee consumption (cups per day);	chr17:29905488	chr17:30709299~30790908:+
SARC	cis	rs9902453	0.791	rs9904051	ENSG00000264538.5	SUZ12P1	3.82	0.000174	0.0478	0.17	0.24	Coffee consumption (cups per day);	chr17:29917104	chr17:30709299~30790908:+
SARC	cis	rs2762051	1	rs2703075	ENSG00000231607.7	DLEU2	3.81	0.000175	0.0478	0.38	0.24	Celiac disease;	chr13:50261832	chr13:49982552~50125720:-
SARC	cis	rs8098244	0.597	rs1154246	ENSG00000265752.2	RP11-403A21.1	3.81	0.000175	0.0478	0.29	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23984242	chr18:23957754~23982556:-
SARC	cis	rs9876781	1	rs13069724	ENSG00000244380.1	RP11-24C3.2	3.81	0.000175	0.0478	0.26	0.24	Longevity;	chr3:48436629	chr3:48440352~48446656:-
SARC	cis	rs72817562	0.79	rs253538	ENSG00000254252.1	RPL7P20	3.81	0.000175	0.0478	0.34	0.24	Neuroticism;	chr5:165174400	chr5:166028567~166029311:-
SARC	cis	rs72817562	0.79	rs253539	ENSG00000254252.1	RPL7P20	3.81	0.000175	0.0478	0.34	0.24	Neuroticism;	chr5:165174544	chr5:166028567~166029311:-
SARC	cis	rs6570726	0.902	rs973855	ENSG00000270638.1	RP3-466P17.1	-3.81	0.000175	0.0478	-0.2	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145735570~145737218:+
SARC	cis	rs4907240	0.731	rs2118836	ENSG00000237510.6	AC008268.2	-3.81	0.000175	0.0479	-0.3	-0.24	Event-related brain oscillations;	chr2:96497235	chr2:95789654~95800166:+
SARC	cis	rs7976269	0.609	rs4931137	ENSG00000257176.2	RP11-996F15.2	-3.81	0.000175	0.0479	-0.26	-0.24	Male-pattern baldness;	chr12:29049701	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.609	rs2082943	ENSG00000257176.2	RP11-996F15.2	-3.81	0.000175	0.0479	-0.26	-0.24	Male-pattern baldness;	chr12:29050251	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.609	rs10743641	ENSG00000257176.2	RP11-996F15.2	-3.81	0.000175	0.0479	-0.26	-0.24	Male-pattern baldness;	chr12:29050819	chr12:29280418~29317848:-
SARC	cis	rs950776	0.752	rs62010327	ENSG00000261762.1	RP11-650L12.2	3.81	0.000175	0.0479	0.27	0.24	Sudden cardiac arrest;	chr15:78600442	chr15:78589123~78591276:-
SARC	cis	rs853679	0.517	rs1853097	ENSG00000216901.1	AL022393.7	3.81	0.000175	0.0479	0.34	0.24	Depression;	chr6:28090857	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs9393887	ENSG00000216901.1	AL022393.7	3.81	0.000175	0.0479	0.34	0.24	Depression;	chr6:28091242	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs9393888	ENSG00000216901.1	AL022393.7	3.81	0.000175	0.0479	0.34	0.24	Depression;	chr6:28091439	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs3734573	ENSG00000216901.1	AL022393.7	3.81	0.000175	0.0479	0.34	0.24	Depression;	chr6:28091659	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs9357063	ENSG00000216901.1	AL022393.7	3.81	0.000175	0.0479	0.34	0.24	Depression;	chr6:28092227	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs3823180	ENSG00000216901.1	AL022393.7	3.81	0.000175	0.0479	0.34	0.24	Depression;	chr6:28093966	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs9368551	ENSG00000216901.1	AL022393.7	3.81	0.000175	0.0479	0.34	0.24	Depression;	chr6:28094014	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs9393890	ENSG00000216901.1	AL022393.7	3.81	0.000175	0.0479	0.34	0.24	Depression;	chr6:28096077	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs9366715	ENSG00000216901.1	AL022393.7	3.81	0.000175	0.0479	0.34	0.24	Depression;	chr6:28096855	chr6:28176188~28176674:+
SARC	cis	rs1546924	0.57	rs197412	ENSG00000260948.1	RP11-552M11.8	3.81	0.000175	0.0479	0.27	0.24	Body mass index;	chr1:111766331	chr1:111431046~111433068:-
SARC	cis	rs367615	0.918	rs13173339	ENSG00000249476.1	CTD-2587M2.1	3.81	0.000175	0.0479	0.31	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109535617	chr5:109237120~109326369:-
SARC	cis	rs56205728	0.606	rs2898991	ENSG00000247556.5	OIP5-AS1	-3.81	0.000175	0.0479	-0.23	-0.24	Schizophrenia;	chr15:40304367	chr15:41283990~41309737:+
SARC	cis	rs1062177	0.855	rs919262	ENSG00000254226.4	CTB-12O2.1	-3.81	0.000175	0.0479	-0.3	-0.24	Preschool internalizing problems;	chr5:151886523	chr5:151949571~152270448:+
SARC	cis	rs9485372	1	rs58489510	ENSG00000231760.4	RP11-350J20.5	3.81	0.000175	0.0479	0.38	0.24	Breast cancer;	chr6:149279855	chr6:149796151~149826294:-
SARC	cis	rs7166081	1	rs4776348	ENSG00000270964.1	RP11-502I4.3	-3.81	0.000175	0.048	-0.28	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67240966	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs12900708	ENSG00000270964.1	RP11-502I4.3	-3.81	0.000175	0.048	-0.28	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67243102	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs12910062	ENSG00000270964.1	RP11-502I4.3	-3.81	0.000175	0.048	-0.28	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67244872	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs9806377	ENSG00000270964.1	RP11-502I4.3	-3.81	0.000175	0.048	-0.28	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67319724	chr15:67541072~67542604:-
SARC	cis	rs7166081	1	rs35008245	ENSG00000270964.1	RP11-502I4.3	-3.81	0.000175	0.048	-0.28	-0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67322629	chr15:67541072~67542604:-
SARC	cis	rs7807441	0.839	rs6460392	ENSG00000273142.1	RP11-458F8.4	3.81	0.000175	0.048	0.23	0.24	Menarche (age at onset);	chr7:67713939	chr7:66902857~66906297:+
SARC	cis	rs7807441	0.839	rs6460393	ENSG00000273142.1	RP11-458F8.4	3.81	0.000175	0.048	0.23	0.24	Menarche (age at onset);	chr7:67714011	chr7:66902857~66906297:+
SARC	cis	rs7807441	0.839	rs7459233	ENSG00000273142.1	RP11-458F8.4	3.81	0.000175	0.048	0.23	0.24	Menarche (age at onset);	chr7:67714550	chr7:66902857~66906297:+
SARC	cis	rs7807441	0.802	rs61388464	ENSG00000273142.1	RP11-458F8.4	3.81	0.000175	0.048	0.23	0.24	Menarche (age at onset);	chr7:67715982	chr7:66902857~66906297:+
SARC	cis	rs7807441	0.802	rs7780634	ENSG00000273142.1	RP11-458F8.4	3.81	0.000175	0.048	0.23	0.24	Menarche (age at onset);	chr7:67716285	chr7:66902857~66906297:+
SARC	cis	rs1376877	0.87	rs7593917	ENSG00000213925.3	NPM1P33	3.81	0.000175	0.048	0.23	0.24	Subclinical atherosclerosis traits (other);	chr2:203066289	chr2:203772631~203773502:-
SARC	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-3.81	0.000175	0.048	-0.29	-0.24	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
SARC	cis	rs2810650	0.56	rs2275325	ENSG00000231507.1	LINC01353	3.81	0.000176	0.048	0.26	0.24	Breast cancer;	chr1:203831607	chr1:203287152~203288801:+
SARC	cis	rs2439831	0.541	rs12440854	ENSG00000205771.5	CATSPER2P1	-3.81	0.000176	0.048	-0.42	-0.24	Lung cancer in ever smokers;	chr15:43318474	chr15:43726918~43747094:-
SARC	cis	rs28386778	0.897	rs2137144	ENSG00000240280.5	TCAM1P	-3.81	0.000176	0.048	-0.3	-0.24	Prudent dietary pattern;	chr17:63728247	chr17:63849292~63864379:+
SARC	cis	rs763121	0.626	rs5750643	ENSG00000273076.1	RP3-508I15.22	3.81	0.000176	0.048	0.26	0.24	Menopause (age at onset);	chr22:38613012	chr22:38743495~38743910:+
SARC	cis	rs7647973	0.56	rs7638154	ENSG00000225399.4	RP11-3B7.1	3.81	0.000176	0.048	0.3	0.24	Menarche (age at onset);	chr3:49261942	chr3:49260085~49261316:+
SARC	cis	rs950776	0.752	rs2869546	ENSG00000261762.1	RP11-650L12.2	-3.81	0.000176	0.048	-0.26	-0.24	Sudden cardiac arrest;	chr15:78615003	chr15:78589123~78591276:-
SARC	cis	rs4950322	0.518	rs4950305	ENSG00000278811.3	LINC00624	3.81	0.000176	0.0481	0.25	0.24	Protein quantitative trait loci;	chr1:147117711	chr1:147258885~147517875:-
SARC	cis	rs11634944	0.869	rs2554428	ENSG00000274307.1	RP11-345J18.2	-3.81	0.000176	0.0481	-0.32	-0.24	Interleukin-8 levels;	chr15:24971011	chr15:25708470~25710869:-
SARC	cis	rs11634944	0.869	rs2732026	ENSG00000274307.1	RP11-345J18.2	-3.81	0.000176	0.0481	-0.32	-0.24	Interleukin-8 levels;	chr15:24971341	chr15:25708470~25710869:-
SARC	cis	rs28498283	0.792	rs13391171	ENSG00000279873.2	LINC01126	-3.81	0.000176	0.0481	-0.22	-0.24	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:43119201	chr2:43227210~43228855:+
SARC	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	3.81	0.000176	0.0481	0.36	0.24	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
SARC	cis	rs9283706	0.608	rs12522430	ENSG00000229666.1	MAST4-AS1	-3.81	0.000176	0.0481	-0.31	-0.24	Coronary artery disease;	chr5:67043694	chr5:67001383~67003953:-
SARC	cis	rs9907295	1	rs9896658	ENSG00000270240.2	AC015849.2	3.81	0.000176	0.0481	0.44	0.24	Fibroblast growth factor basic levels;	chr17:35916758	chr17:35868967~35885863:+
SARC	cis	rs61160187	0.582	rs17444495	ENSG00000272308.1	RP11-231G3.1	-3.81	0.000176	0.0481	-0.21	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:61059457	chr5:60866457~60866935:-
SARC	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	3.81	0.000176	0.0481	0.24	0.24	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
SARC	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	3.81	0.000176	0.0481	0.37	0.24	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
SARC	cis	rs13043612	0.66	rs6084644	ENSG00000277425.1	RP5-1116H23.3	3.81	0.000176	0.0481	0.28	0.24	Reticulocyte count;Reticulocyte fraction of red cells;	chr20:4141152	chr20:5066082~5068154:-
SARC	cis	rs858239	0.6	rs4628176	ENSG00000226816.2	AC005082.12	3.81	0.000176	0.0481	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23206013~23208045:+
SARC	cis	rs11637445	0.677	rs4539549	ENSG00000259410.4	RP11-34F13.3	-3.81	0.000176	0.0481	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr15:67778281	chr15:67832725~67873866:+
SARC	cis	rs7976269	0.609	rs4930846	ENSG00000257176.2	RP11-996F15.2	-3.81	0.000176	0.0482	-0.26	-0.24	Male-pattern baldness;	chr12:29051306	chr12:29280418~29317848:-
SARC	cis	rs7976269	0.609	rs4402335	ENSG00000257176.2	RP11-996F15.2	-3.81	0.000176	0.0482	-0.26	-0.24	Male-pattern baldness;	chr12:29052836	chr12:29280418~29317848:-
SARC	cis	rs72945132	0.638	rs11236127	ENSG00000254604.1	AP000487.6	-3.81	0.000176	0.0482	-0.33	-0.24	Coronary artery disease;	chr11:70395430	chr11:70282367~70363368:-
SARC	cis	rs853679	0.517	rs868987	ENSG00000280107.1	AL022393.9	3.81	0.000176	0.0482	0.31	0.24	Depression;	chr6:28142370	chr6:28170845~28172521:+
SARC	cis	rs4148883	0.675	rs28762430	ENSG00000263923.1	RP11-571L19.7	-3.81	0.000176	0.0482	-0.25	-0.24	Alcohol dependence;	chr4:99198100	chr4:98928897~98994994:+
SARC	cis	rs6540731	1	rs3816912	ENSG00000229983.1	RP11-15I11.2	-3.81	0.000176	0.0482	-0.25	-0.24	Intelligence (childhood);	chr1:212226507	chr1:212168207~212190259:+
SARC	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-3.81	0.000176	0.0482	-0.22	-0.24	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
SARC	cis	rs2810650	0.56	rs11240568	ENSG00000231507.1	LINC01353	3.81	0.000177	0.0482	0.27	0.24	Breast cancer;	chr1:203824665	chr1:203287152~203288801:+
SARC	cis	rs6969780	1	rs6976129	ENSG00000233429.8	HOTAIRM1	3.81	0.000177	0.0482	0.37	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27138127	chr7:27095647~27100265:+
SARC	cis	rs2243480	1	rs316307	ENSG00000164669.11	INTS4P1	3.81	0.000177	0.0482	0.42	0.24	Diabetic kidney disease;	chr7:66105184	chr7:65141225~65234216:+
SARC	cis	rs2243480	0.908	rs313822	ENSG00000164669.11	INTS4P1	3.81	0.000177	0.0482	0.42	0.24	Diabetic kidney disease;	chr7:66108952	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs313820	ENSG00000164669.11	INTS4P1	3.81	0.000177	0.0482	0.42	0.24	Diabetic kidney disease;	chr7:66109479	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs160639	ENSG00000164669.11	INTS4P1	3.81	0.000177	0.0482	0.42	0.24	Diabetic kidney disease;	chr7:66115000	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs313824	ENSG00000164669.11	INTS4P1	3.81	0.000177	0.0482	0.42	0.24	Diabetic kidney disease;	chr7:66116220	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs186378	ENSG00000164669.11	INTS4P1	3.81	0.000177	0.0482	0.42	0.24	Diabetic kidney disease;	chr7:66117071	chr7:65141225~65234216:+
SARC	cis	rs2243480	1	rs160637	ENSG00000164669.11	INTS4P1	3.81	0.000177	0.0482	0.42	0.24	Diabetic kidney disease;	chr7:66119331	chr7:65141225~65234216:+
SARC	cis	rs8059260	0.545	rs2286972	ENSG00000274038.1	RP11-66H6.4	-3.81	0.000177	0.0482	-0.36	-0.24	Alcohol consumption over the past year;	chr16:11061141	chr16:11056556~11057034:+
SARC	cis	rs727479	0.502	rs28757202	ENSG00000244879.4	GABPB1-AS1	-3.81	0.000177	0.0483	-0.2	-0.24	Estradiol levels;	chr15:51211684	chr15:50354959~50372202:+
SARC	cis	rs727479	0.502	rs28757200	ENSG00000244879.4	GABPB1-AS1	-3.81	0.000177	0.0483	-0.2	-0.24	Estradiol levels;	chr15:51211864	chr15:50354959~50372202:+
SARC	cis	rs7267979	1	rs2500432	ENSG00000125804.12	FAM182A	-3.81	0.000177	0.0483	-0.27	-0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:26054655~26086917:+
SARC	cis	rs7267979	0.527	rs6083891	ENSG00000125804.12	FAM182A	3.81	0.000177	0.0483	0.29	0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:26054655~26086917:+
SARC	cis	rs7308116	0.967	rs10861788	ENSG00000240441.1	RP11-864J10.2	-3.81	0.000177	0.0483	-0.27	-0.24	Pelvic organ prolapse (moderate/severe);	chr12:107796502	chr12:107719599~107720133:+
SARC	cis	rs755249	0.761	rs3768321	ENSG00000243970.1	PPIEL	3.81	0.000177	0.0483	0.29	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570256	chr1:39531838~39558707:-
SARC	cis	rs3796352	1	rs59583591	ENSG00000242142.1	SERBP1P3	-3.81	0.000177	0.0483	-0.41	-0.24	Immune reponse to smallpox (secreted IL-2);	chr3:53085565	chr3:53064283~53065091:-
SARC	cis	rs3796352	1	rs7625448	ENSG00000242142.1	SERBP1P3	-3.81	0.000177	0.0483	-0.41	-0.24	Immune reponse to smallpox (secreted IL-2);	chr3:53086750	chr3:53064283~53065091:-
SARC	cis	rs3796352	1	rs7645611	ENSG00000242142.1	SERBP1P3	-3.81	0.000177	0.0483	-0.41	-0.24	Immune reponse to smallpox (secreted IL-2);	chr3:53091281	chr3:53064283~53065091:-
SARC	cis	rs858239	0.6	rs10233039	ENSG00000226816.2	AC005082.12	3.81	0.000177	0.0484	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23206013~23208045:+
SARC	cis	rs56046484	0.913	rs17611290	ENSG00000259295.5	CSPG4P12	3.81	0.000177	0.0484	0.36	0.24	Testicular germ cell tumor;	chr15:85031188	chr15:85191438~85213905:+
SARC	cis	rs56046484	0.913	rs12906544	ENSG00000259295.5	CSPG4P12	3.81	0.000177	0.0484	0.36	0.24	Testicular germ cell tumor;	chr15:85032832	chr15:85191438~85213905:+
SARC	cis	rs56046484	0.871	rs34978449	ENSG00000259295.5	CSPG4P12	3.81	0.000177	0.0484	0.36	0.24	Testicular germ cell tumor;	chr15:85036917	chr15:85191438~85213905:+
SARC	cis	rs72627123	0.867	rs72627105	ENSG00000259065.1	RP5-1021I20.1	-3.81	0.000177	0.0484	-0.47	-0.24	Morning vs. evening chronotype;	chr14:73845017	chr14:73787360~73803270:+
SARC	cis	rs72627123	0.737	rs72627106	ENSG00000259065.1	RP5-1021I20.1	-3.81	0.000177	0.0484	-0.47	-0.24	Morning vs. evening chronotype;	chr14:73845755	chr14:73787360~73803270:+
SARC	cis	rs12049351	0.507	rs41271481	ENSG00000229367.1	HMGN2P19	3.81	0.000177	0.0484	0.22	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229432890	chr1:229570532~229570796:+
SARC	cis	rs763121	0.853	rs6001204	ENSG00000273076.1	RP3-508I15.22	3.81	0.000177	0.0484	0.26	0.24	Menopause (age at onset);	chr22:38704234	chr22:38743495~38743910:+
SARC	cis	rs7809950	0.817	rs58052742	ENSG00000238832.1	snoU109	3.81	0.000177	0.0484	0.29	0.24	Coronary artery disease;	chr7:107569558	chr7:107603363~107603507:+
SARC	cis	rs9858542	0.537	rs34915642	ENSG00000225399.4	RP11-3B7.1	-3.81	0.000177	0.0484	-0.37	-0.24	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49321213	chr3:49260085~49261316:+
SARC	cis	rs72627509	1	rs72627509	ENSG00000269949.1	RP11-738E22.3	3.81	0.000177	0.0484	0.38	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972885	chr4:56960927~56961373:-
SARC	cis	rs631644	0.639	rs627619	ENSG00000266397.1	RP11-737O24.1	3.81	0.000177	0.0484	0.26	0.24	Lung cancer;	chr18:2285096	chr18:2967018~2985410:+
SARC	cis	rs889122	1	rs889122	ENSG00000267289.1	CTD-2623N2.11	3.81	0.000177	0.0484	0.26	0.24	Menarche (age at onset);	chr19:9885191	chr19:9834079~9835013:-
SARC	cis	rs875971	0.893	rs62465470	ENSG00000232559.3	GS1-124K5.12	-3.81	0.000178	0.0484	-0.28	-0.24	Aortic root size;	chr7:66136231	chr7:66554588~66576923:-
SARC	cis	rs875971	0.862	rs4368860	ENSG00000232559.3	GS1-124K5.12	-3.81	0.000178	0.0484	-0.28	-0.24	Aortic root size;	chr7:66143495	chr7:66554588~66576923:-
SARC	cis	rs713477	1	rs10782426	ENSG00000258413.1	RP11-665C16.6	3.81	0.000178	0.0484	0.27	0.24	Pediatric bone mineral content (femoral neck);	chr14:55423984	chr14:55262767~55272075:-
SARC	cis	rs5751614	1	rs5751614	ENSG00000230701.2	FBXW4P1	3.81	0.000178	0.0485	0.29	0.24	Height;	chr22:23250864	chr22:23262767~23265005:+
SARC	cis	rs7487075	0.554	rs12229299	ENSG00000257496.1	RP11-474P2.4	3.81	0.000178	0.0485	0.3	0.24	Itch intensity from mosquito bite;	chr12:46691110	chr12:46384233~46386991:-
SARC	cis	rs4722166	0.63	rs2091115	ENSG00000179428.2	AC073072.5	-3.81	0.000178	0.0485	-0.28	-0.24	Lung cancer;	chr7:22770547	chr7:22725395~22727620:-
SARC	cis	rs11159086	0.793	rs10136668	ENSG00000270000.1	RP3-449M8.9	3.81	0.000178	0.0485	0.36	0.24	Advanced glycation end-product levels;	chr14:74492183	chr14:74471930~74472360:-
SARC	cis	rs207954	1	rs207958	ENSG00000258922.1	CTD-2313J17.1	3.81	0.000178	0.0485	0.29	0.24	Acute lymphoblastic leukemia (childhood);	chr15:92112927	chr15:92805770~92808567:-
SARC	cis	rs35961285	0.785	rs4654146	ENSG00000272195.1	RP11-156E8.1	-3.81	0.000178	0.0485	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr1:245882116	chr1:244969350~244971088:-
SARC	cis	rs28386778	0.897	rs2584617	ENSG00000240280.5	TCAM1P	-3.81	0.000178	0.0485	-0.3	-0.24	Prudent dietary pattern;	chr17:63847938	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.897	rs2584615	ENSG00000240280.5	TCAM1P	-3.81	0.000178	0.0485	-0.3	-0.24	Prudent dietary pattern;	chr17:63850414	chr17:63849292~63864379:+
SARC	cis	rs28386778	0.865	rs2727276	ENSG00000240280.5	TCAM1P	-3.81	0.000178	0.0485	-0.3	-0.24	Prudent dietary pattern;	chr17:63852349	chr17:63849292~63864379:+
SARC	cis	rs2274273	0.682	rs1201378	ENSG00000258413.1	RP11-665C16.6	3.81	0.000178	0.0485	0.27	0.24	Protein biomarker;	chr14:55026690	chr14:55262767~55272075:-
SARC	cis	rs10744955	0.727	rs11070759	ENSG00000244879.4	GABPB1-AS1	3.81	0.000178	0.0485	0.19	0.24	Lobe attachment (rater-scored or self-reported);	chr15:50165661	chr15:50354959~50372202:+
SARC	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-3.81	0.000178	0.0485	-0.26	-0.24	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
SARC	cis	rs17264034	0.95	rs17328863	ENSG00000250786.1	SNHG18	-3.81	0.000178	0.0485	-0.44	-0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9542919	chr5:9546200~9550609:+
SARC	cis	rs2505998	0.796	rs2505537	ENSG00000273008.1	RP11-351D16.3	-3.81	0.000178	0.0485	-0.27	-0.24	Hirschsprung disease;	chr10:43096710	chr10:43136824~43138334:-
SARC	cis	rs2505998	0.833	rs2505535	ENSG00000273008.1	RP11-351D16.3	-3.81	0.000178	0.0485	-0.27	-0.24	Hirschsprung disease;	chr10:43097595	chr10:43136824~43138334:-
SARC	cis	rs2439831	1	rs2467740	ENSG00000275601.1	AC011330.13	-3.81	0.000178	0.0485	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43454594	chr15:43642389~43643023:-
SARC	cis	rs370915	0.542	rs6838849	ENSG00000272218.1	RP11-11N5.3	-3.81	0.000178	0.0486	-0.27	-0.24	Gout;	chr4:186869530	chr4:186892552~186892983:+
SARC	cis	rs7617773	0.817	rs936426	ENSG00000271161.1	BOLA2P2	-3.81	0.000178	0.0486	-0.2	-0.24	Coronary artery disease;	chr3:48173763	chr3:47499841~47500407:+
SARC	cis	rs13113518	0.783	rs12504300	ENSG00000249700.7	SRD5A3-AS1	3.81	0.000178	0.0486	0.31	0.24	Height;	chr4:55482360	chr4:55363971~55395847:-
SARC	cis	rs294883	0.627	rs9456393	ENSG00000235086.1	FNDC1-IT1	-3.81	0.000178	0.0486	-0.29	-0.24	Coronary artery disease;	chr6:159356286	chr6:159240786~159243329:+
SARC	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-3.81	0.000178	0.0486	-0.32	-0.24	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
SARC	cis	rs863345	0.967	rs863346	ENSG00000231666.4	RP11-404O13.1	-3.81	0.000178	0.0486	-0.26	-0.24	Pneumococcal bacteremia;	chr1:158566121	chr1:158132044~158140639:-
SARC	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	3.81	0.000178	0.0486	0.29	0.24	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
SARC	cis	rs4835473	0.897	rs35598237	ENSG00000251600.4	RP11-673E1.1	-3.81	0.000178	0.0486	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143735961	chr4:143912331~143982454:+
SARC	cis	rs7547759	1	rs7526672	ENSG00000228208.5	C1orf143	-3.81	0.000178	0.0486	-0.43	-0.24	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr1:218472531	chr1:218510096~218525978:+
SARC	cis	rs1799949	0.965	rs6503726	ENSG00000267681.1	CTD-3199J23.6	-3.81	0.000179	0.0486	-0.27	-0.24	Menopause (age at onset);	chr17:43132725	chr17:43144956~43145255:+
SARC	cis	rs875971	0.66	rs79009421	ENSG00000224316.1	RP11-479O9.2	-3.81	0.000179	0.0487	-0.23	-0.24	Aortic root size;	chr7:66603522	chr7:65773620~65802067:+
SARC	cis	rs875971	0.66	rs7807930	ENSG00000224316.1	RP11-479O9.2	-3.81	0.000179	0.0487	-0.23	-0.24	Aortic root size;	chr7:66622178	chr7:65773620~65802067:+
SARC	cis	rs875971	0.66	rs7807944	ENSG00000224316.1	RP11-479O9.2	-3.81	0.000179	0.0487	-0.23	-0.24	Aortic root size;	chr7:66622208	chr7:65773620~65802067:+
SARC	cis	rs950776	0.752	rs62010328	ENSG00000261762.1	RP11-650L12.2	3.81	0.000179	0.0487	0.27	0.24	Sudden cardiac arrest;	chr15:78602629	chr15:78589123~78591276:-
SARC	cis	rs867186	1	rs117249133	ENSG00000229230.3	MT1P3	3.81	0.000179	0.0487	0.46	0.24	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35185827	chr20:35218009~35218185:+
SARC	cis	rs867186	1	rs78967641	ENSG00000229230.3	MT1P3	3.81	0.000179	0.0487	0.46	0.24	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35195250	chr20:35218009~35218185:+
SARC	cis	rs867186	1	rs11906148	ENSG00000229230.3	MT1P3	3.81	0.000179	0.0487	0.46	0.24	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35196218	chr20:35218009~35218185:+
SARC	cis	rs867186	1	rs117802529	ENSG00000229230.3	MT1P3	3.81	0.000179	0.0487	0.46	0.24	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35198874	chr20:35218009~35218185:+
SARC	cis	rs4267450	0.649	rs12151045	ENSG00000261770.1	CTC-459F4.1	-3.81	0.000179	0.0487	-0.4	-0.24	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28316162	chr19:27757184~27760849:-
SARC	cis	rs2274273	1	rs7142704	ENSG00000258413.1	RP11-665C16.6	-3.81	0.000179	0.0487	-0.28	-0.24	Protein biomarker;	chr14:55163885	chr14:55262767~55272075:-
SARC	cis	rs8012947	1	rs1951202	ENSG00000279636.2	LINC00216	3.81	0.000179	0.0487	0.21	0.24	Alcohol consumption in current drinkers;	chr14:58312699	chr14:58288033~58289158:+
SARC	cis	rs9925964	0.933	rs4889530	ENSG00000183604.13	SMG1P5	3.81	0.000179	0.0487	0.22	0.24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31054597	chr16:30267553~30335374:-
SARC	cis	rs875971	1	rs7801282	ENSG00000232559.3	GS1-124K5.12	-3.81	0.000179	0.0487	-0.26	-0.24	Aortic root size;	chr7:66148700	chr7:66554588~66576923:-
SARC	cis	rs4835473	0.932	rs13139738	ENSG00000251600.4	RP11-673E1.1	-3.81	0.000179	0.0488	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143738828	chr4:143912331~143982454:+
SARC	cis	rs4835473	0.932	rs17018165	ENSG00000251600.4	RP11-673E1.1	-3.81	0.000179	0.0488	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143738849	chr4:143912331~143982454:+
SARC	cis	rs8092443	0.938	rs8093268	ENSG00000266258.1	RP11-41O4.1	3.81	0.000179	0.0488	0.34	0.24	Response to antipsychotic treatment;	chr18:70491547	chr18:70335439~70352459:+
SARC	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-3.81	0.000179	0.0488	-0.21	-0.24	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
SARC	cis	rs4664293	0.667	rs10169681	ENSG00000226266.5	AC009961.3	3.81	0.000179	0.0488	0.28	0.24	Monocyte percentage of white cells;	chr2:159782065	chr2:159670708~159712435:-
SARC	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	3.81	0.000179	0.0488	0.3	0.24	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
SARC	cis	rs7552393	0.595	rs4140462	ENSG00000240520.4	UOX	3.81	0.000179	0.0488	0.26	0.24	Select biomarker traits;	chr1:83803616	chr1:84365428~84397831:-
SARC	cis	rs7011507	0.836	rs80006861	ENSG00000279881.1	RP11-513O13.1	-3.81	0.00018	0.0489	-0.44	-0.24	Inflammatory bowel disease;Ulcerative colitis;	chr8:48153696	chr8:48428143~48431041:-
SARC	cis	rs2189609	0.502	rs10500580	ENSG00000259972.2	AC009120.6	3.81	0.00018	0.0489	0.14	0.24	Energy expenditure (24h);	chr16:73916658	chr16:74305127~74335346:-
SARC	cis	rs6082278	0.536	rs6035755	ENSG00000225127.2	LINC00237	3.81	0.00018	0.0489	0.27	0.24	Colonoscopy-negative controls vs population controls;	chr20:20997615	chr20:21087604~21106358:-
SARC	cis	rs7772486	0.764	rs7745696	ENSG00000235652.6	RP11-545I5.3	3.81	0.00018	0.0489	0.22	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145799409~145886585:+
SARC	cis	rs8028182	0.636	rs4886707	ENSG00000260206.1	CTD-2026K11.2	-3.81	0.00018	0.0489	-0.28	-0.24	Sudden cardiac arrest;	chr15:75463126	chr15:75636139~75639239:+
SARC	cis	rs5751614	1	rs2267020	ENSG00000230701.2	FBXW4P1	3.81	0.00018	0.0489	0.29	0.24	Height;	chr22:23250255	chr22:23262767~23265005:+
SARC	cis	rs10540	1	rs61877760	ENSG00000277290.1	RP11-326C3.16	3.81	0.00018	0.049	0.3	0.24	Body mass index;	chr11:506596	chr11:243099~243483:-
SARC	cis	rs853679	0.598	rs9380054	ENSG00000216901.1	AL022393.7	3.81	0.00018	0.049	0.34	0.24	Depression;	chr6:28099759	chr6:28176188~28176674:+
SARC	cis	rs4713118	0.547	rs2116981	ENSG00000216901.1	AL022393.7	3.81	0.00018	0.049	0.34	0.24	Parkinson's disease;	chr6:28100173	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs9368552	ENSG00000216901.1	AL022393.7	3.81	0.00018	0.049	0.34	0.24	Depression;	chr6:28100648	chr6:28176188~28176674:+
SARC	cis	rs853679	0.542	rs34131763	ENSG00000216901.1	AL022393.7	3.81	0.00018	0.049	0.34	0.24	Depression;	chr6:28107222	chr6:28176188~28176674:+
SARC	cis	rs853679	0.517	rs35193936	ENSG00000216901.1	AL022393.7	3.81	0.00018	0.049	0.34	0.24	Depression;	chr6:28108492	chr6:28176188~28176674:+
SARC	cis	rs4660214	0.666	rs7554206	ENSG00000182109.6	RP11-69E11.4	-3.81	0.00018	0.049	-0.23	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39522280~39546187:-
SARC	cis	rs4660214	0.666	rs1775656	ENSG00000182109.6	RP11-69E11.4	3.81	0.00018	0.049	0.23	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39445329	chr1:39522280~39546187:-
SARC	cis	rs783540	0.935	rs2278355	ENSG00000275695.1	UBE2Q2P6	3.81	0.00018	0.049	0.25	0.24	Schizophrenia;	chr15:82662403	chr15:82445719~82454837:+
SARC	cis	rs76693355	0.512	rs4938807	ENSG00000232460.4	BMPR1APS2	3.81	0.00018	0.049	0.31	0.24	Intraocular pressure;	chr11:120460992	chr11:121361854~121362865:-
SARC	cis	rs4950322	0.58	rs17359629	ENSG00000278811.3	LINC00624	3.81	0.00018	0.049	0.25	0.24	Protein quantitative trait loci;	chr1:147121537	chr1:147258885~147517875:-
SARC	cis	rs9283706	0.623	rs1159201	ENSG00000229666.1	MAST4-AS1	3.81	0.000181	0.0491	0.3	0.24	Coronary artery disease;	chr5:67015511	chr5:67001383~67003953:-
SARC	cis	rs7258015	1	rs3176766	ENSG00000276757.1	Metazoa_SRP	-3.81	0.000181	0.0491	-0.28	-0.24	Systemic lupus erythematosus or rheumatoid arthritis;	chr19:10339102	chr19:11011708~11012006:+
SARC	cis	rs11264213	0.892	rs12037102	ENSG00000239636.1	RP4-728D4.2	-3.81	0.000181	0.0491	-0.32	-0.24	Schizophrenia;	chr1:35796132	chr1:35569813~35577729:-
SARC	cis	rs11264213	1	rs727005	ENSG00000239636.1	RP4-728D4.2	-3.81	0.000181	0.0491	-0.32	-0.24	Schizophrenia;	chr1:35815735	chr1:35569813~35577729:-
SARC	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	3.81	0.000181	0.0491	0.25	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
SARC	cis	rs157198	0.867	rs111402016	ENSG00000237934.1	RP11-467D18.2	3.81	0.000181	0.0491	0.42	0.24	Mean platelet volume;	chr1:28874838	chr1:29223933~29224816:+
SARC	cis	rs157198	0.867	rs77225805	ENSG00000237934.1	RP11-467D18.2	3.81	0.000181	0.0491	0.42	0.24	Mean platelet volume;	chr1:28875194	chr1:29223933~29224816:+
SARC	cis	rs157198	0.867	rs76682787	ENSG00000237934.1	RP11-467D18.2	3.81	0.000181	0.0491	0.42	0.24	Mean platelet volume;	chr1:28875375	chr1:29223933~29224816:+
SARC	cis	rs157198	0.867	rs7556059	ENSG00000237934.1	RP11-467D18.2	3.81	0.000181	0.0491	0.42	0.24	Mean platelet volume;	chr1:28875650	chr1:29223933~29224816:+
SARC	cis	rs717662	0.507	rs517349	ENSG00000248027.1	CTD-2383M3.1	3.81	0.000181	0.0491	0.5	0.24	Red cell distribution width;	chr11:100829214	chr11:100684162~100687955:-
SARC	cis	rs4835473	0.932	rs5015757	ENSG00000251600.4	RP11-673E1.1	3.81	0.000181	0.0491	0.24	0.24	Immature fraction of reticulocytes;	chr4:143738144	chr4:143912331~143982454:+
SARC	cis	rs4907240	0.731	rs11900310	ENSG00000237510.6	AC008268.2	3.81	0.000181	0.0492	0.31	0.24	Event-related brain oscillations;	chr2:96476093	chr2:95789654~95800166:+
SARC	cis	rs7408868	0.908	rs62113793	ENSG00000266913.1	CTC-548K16.2	-3.81	0.000181	0.0492	-0.38	-0.24	Pulse pressure;	chr19:15166525	chr19:14305458~14370196:-
SARC	cis	rs7408868	0.908	rs62113794	ENSG00000266913.1	CTC-548K16.2	-3.81	0.000181	0.0492	-0.38	-0.24	Pulse pressure;	chr19:15166526	chr19:14305458~14370196:-
SARC	cis	rs4886920	0.536	rs11857840	ENSG00000260776.4	RP11-114H24.2	-3.81	0.000181	0.0492	-0.3	-0.24	Neuroticism;	chr15:77864411	chr15:77914217~77926846:-
SARC	cis	rs3934047	0.904	rs12905561	ENSG00000274376.3	ADAMTS7P1	-3.81	0.000181	0.0492	-0.28	-0.24	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81721765	chr15:82298553~82334609:+
SARC	cis	rs4794202	0.891	rs59715174	ENSG00000264920.1	RP11-6N17.4	-3.81	0.000181	0.0492	-0.35	-0.24	Alzheimer's disease (cognitive decline);	chr17:47854047	chr17:47891255~47895812:-
SARC	cis	rs17508449	0.732	rs75746385	ENSG00000232450.1	RP4-730K3.3	-3.8	0.000181	0.0492	-0.31	-0.24	Leprosy;	chr1:113758270	chr1:113698884~113699631:-
SARC	cis	rs9436747	0.626	rs17412403	ENSG00000237852.1	RP4-630A11.3	-3.8	0.000181	0.0493	-0.24	-0.24	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr1:65476583	chr1:65486406~65494188:+
SARC	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-3.8	0.000181	0.0493	-0.23	-0.24	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
SARC	cis	rs56205728	0.606	rs3784397	ENSG00000247556.5	OIP5-AS1	-3.8	0.000181	0.0493	-0.23	-0.24	Schizophrenia;	chr15:40304643	chr15:41283990~41309737:+
SARC	cis	rs1538970	0.816	rs61788356	ENSG00000280836.1	AL355480.1	-3.8	0.000181	0.0493	-0.28	-0.24	Platelet count;	chr1:45541003	chr1:45581219~45581321:-
SARC	cis	rs858239	0.6	rs10488077	ENSG00000226816.2	AC005082.12	3.8	0.000181	0.0493	0.29	0.24	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23206013~23208045:+
SARC	cis	rs853679	1	rs10456362	ENSG00000216901.1	AL022393.7	-3.8	0.000182	0.0493	-0.4	-0.24	Depression;	chr6:28254038	chr6:28176188~28176674:+
SARC	cis	rs4679904	0.96	rs11715900	ENSG00000243116.1	RP11-564C24.1	3.8	0.000182	0.0493	0.26	0.24	Primary biliary cholangitis;	chr3:160596648	chr3:159721524~159722401:-
SARC	cis	rs11634944	1	rs11632945	ENSG00000274307.1	RP11-345J18.2	-3.8	0.000182	0.0493	-0.32	-0.24	Interleukin-8 levels;	chr15:24958411	chr15:25708470~25710869:-
SARC	cis	rs7216064	0.953	rs62086044	ENSG00000278740.1	RP11-147L13.14	3.8	0.000182	0.0493	0.27	0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67974721	chr17:68188547~68189165:+
SARC	cis	rs2439831	1	rs690436	ENSG00000275601.1	AC011330.13	-3.8	0.000182	0.0493	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43469007	chr15:43642389~43643023:-
SARC	cis	rs8054556	0.74	rs10083738	ENSG00000183604.13	SMG1P5	-3.8	0.000182	0.0493	-0.23	-0.24	Autism spectrum disorder or schizophrenia;	chr16:29916381	chr16:30267553~30335374:-
SARC	cis	rs12049351	0.774	rs4925456	ENSG00000229367.1	HMGN2P19	3.8	0.000182	0.0494	0.2	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229488149	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.722	rs6703347	ENSG00000229367.1	HMGN2P19	3.8	0.000182	0.0494	0.2	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229490419	chr1:229570532~229570796:+
SARC	cis	rs12049351	0.774	rs6701186	ENSG00000229367.1	HMGN2P19	3.8	0.000182	0.0494	0.2	0.24	Circulating myeloperoxidase levels (plasma);	chr1:229490739	chr1:229570532~229570796:+
SARC	cis	rs2790216	1	rs1199104	ENSG00000228527.1	RP11-179B15.5	-3.8	0.000182	0.0494	-0.32	-0.24	Inflammatory bowel disease;	chr10:58187020	chr10:58304553~58305621:+
SARC	cis	rs73219805	1	rs73217798	ENSG00000228451.3	SDAD1P1	-3.8	0.000182	0.0494	-0.32	-0.24	Schizophrenia;	chr8:26406847	chr8:26379259~26382953:-
SARC	cis	rs10504130	0.696	rs17212214	ENSG00000253844.1	RP11-546K22.1	3.8	0.000182	0.0494	0.36	0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:51918582	chr8:51961458~52022974:+
SARC	cis	rs9595908	0.709	rs3752476	ENSG00000212293.1	SNORA16	-3.8	0.000182	0.0494	-0.23	-0.24	Body mass index;	chr13:32770965	chr13:32420390~32420516:-
SARC	cis	rs812925	0.512	rs1177309	ENSG00000271889.1	RP11-493E12.1	3.8	0.000182	0.0494	0.22	0.24	Immature fraction of reticulocytes;	chr2:61158113	chr2:61151433~61162105:-
SARC	cis	rs12893668	0.572	rs4900591	ENSG00000269910.1	RP11-73M18.10	3.8	0.000182	0.0494	0.22	0.24	Reticulocyte count;	chr14:103688541	chr14:103694516~103695050:-
SARC	cis	rs10256972	0.63	rs10282584	ENSG00000229043.2	AC091729.9	-3.8	0.000182	0.0494	-0.28	-0.24	Endometriosis;Longevity;	chr7:1041806	chr7:1160374~1165267:+
SARC	cis	rs28498283	0.792	rs13388340	ENSG00000279873.2	LINC01126	-3.8	0.000182	0.0494	-0.22	-0.24	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:43116873	chr2:43227210~43228855:+
SARC	cis	rs28498283	0.792	rs13409611	ENSG00000279873.2	LINC01126	-3.8	0.000182	0.0494	-0.22	-0.24	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:43117037	chr2:43227210~43228855:+
SARC	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	3.8	0.000182	0.0494	0.32	0.24	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
SARC	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	3.8	0.000182	0.0494	0.32	0.24	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
SARC	cis	rs10050311	0.858	rs1010902	ENSG00000251411.1	RP11-397E7.4	-3.8	0.000182	0.0494	-0.3	-0.24	Insulin-related traits;	chr4:86898002	chr4:86913266~86914817:-
SARC	cis	rs6695567	0.902	rs6588469	ENSG00000280378.1	RP4-758J24.6	-3.8	0.000182	0.0495	-0.25	-0.24	Systemic lupus erythematosus;	chr1:53165033	chr1:54033126~54034880:-
SARC	cis	rs755249	0.51	rs599892	ENSG00000182109.6	RP11-69E11.4	3.8	0.000182	0.0495	0.24	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39457212	chr1:39522280~39546187:-
SARC	cis	rs264537	0.565	rs11127553	ENSG00000172971.7	UNC93B3	-3.8	0.000182	0.0495	-0.3	-0.24	Periodontitis (PAL4Q3);	chr3:76619828	chr3:75619506~75623849:-
SARC	cis	rs12922317	0.556	rs11648938	ENSG00000260488.1	RP11-166B2.7	3.8	0.000182	0.0495	0.26	0.24	Schizophrenia;	chr16:12000292	chr16:11976851~11977850:-
SARC	cis	rs42490	0.51	rs218890	ENSG00000251136.7	RP11-37B2.1	-3.8	0.000182	0.0495	-0.26	-0.24	Leprosy;	chr8:89680848	chr8:89609409~89757727:-
SARC	cis	rs6472827	0.645	rs16836	ENSG00000253983.2	RP1-16A9.1	3.8	0.000183	0.0495	0.33	0.24	Uterine fibroids;	chr8:74201827	chr8:74199396~74208441:+
SARC	cis	rs2360027	0.627	rs1213905	ENSG00000231365.4	RP11-418J17.1	3.8	0.000183	0.0495	0.25	0.24	Tonsillectomy;	chr1:118562278	chr1:119140396~119275973:+
SARC	cis	rs4679904	0.921	rs1920663	ENSG00000243116.1	RP11-564C24.1	3.8	0.000183	0.0495	0.26	0.24	Primary biliary cholangitis;	chr3:160586562	chr3:159721524~159722401:-
SARC	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	3.8	0.000183	0.0495	0.35	0.24	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
SARC	cis	rs853679	1	rs1936365	ENSG00000272009.1	RP1-313I6.12	3.8	0.000183	0.0495	0.33	0.24	Depression;	chr6:28300675	chr6:28078792~28081130:-
SARC	cis	rs9364687	0.966	rs4709713	ENSG00000270419.1	CAHM	-3.8	0.000183	0.0496	-0.2	-0.24	Body mass index;	chr6:163379805	chr6:163413065~163413960:-
SARC	cis	rs7204230	0.96	rs62048016	ENSG00000261291.1	RP11-295M3.2	3.8	0.000183	0.0496	0.27	0.24	Fibrinogen;	chr16:53154481	chr16:53168522~53169450:+
SARC	cis	rs7204230	1	rs7191003	ENSG00000261291.1	RP11-295M3.2	3.8	0.000183	0.0496	0.27	0.24	Fibrinogen;	chr16:53169722	chr16:53168522~53169450:+
SARC	cis	rs12538804	0.91	rs10254398	ENSG00000228010.4	AC073343.13	3.8	0.000183	0.0496	0.28	0.24	Urate levels in obese individuals;	chr7:7646883	chr7:6663974~6708901:+
SARC	cis	rs4835473	0.932	rs12512652	ENSG00000251600.4	RP11-673E1.1	-3.8	0.000183	0.0496	-0.24	-0.24	Immature fraction of reticulocytes;	chr4:143736787	chr4:143912331~143982454:+
SARC	cis	rs8028182	0.636	rs4886699	ENSG00000260206.1	CTD-2026K11.2	-3.8	0.000183	0.0496	-0.29	-0.24	Sudden cardiac arrest;	chr15:75399962	chr15:75636139~75639239:+
SARC	cis	rs1062177	0.95	rs892005	ENSG00000254226.4	CTB-12O2.1	3.8	0.000183	0.0496	0.32	0.24	Preschool internalizing problems;	chr5:151801060	chr5:151949571~152270448:+
SARC	cis	rs2302464	1	rs16892289	ENSG00000214846.4	RP11-115L11.1	-3.8	0.000183	0.0497	-0.54	-0.24	Cerebrospinal fluid biomarker levels;	chr4:15730680	chr4:15730962~15731627:-
SARC	cis	rs7657257	1	rs4321629	ENSG00000214846.4	RP11-115L11.1	3.8	0.000183	0.0497	0.54	0.24	Blood protein levels;	chr4:15730757	chr4:15730962~15731627:-
SARC	cis	rs7657257	1	rs10516290	ENSG00000214846.4	RP11-115L11.1	3.8	0.000183	0.0497	0.54	0.24	Blood protein levels;	chr4:15730833	chr4:15730962~15731627:-
SARC	cis	rs2302464	1	rs10516291	ENSG00000214846.4	RP11-115L11.1	3.8	0.000183	0.0497	0.54	0.24	Cerebrospinal fluid biomarker levels;	chr4:15731168	chr4:15730962~15731627:-
SARC	cis	rs875971	1	rs6946143	ENSG00000232559.3	GS1-124K5.12	3.8	0.000183	0.0497	0.26	0.24	Aortic root size;	chr7:66114735	chr7:66554588~66576923:-
SARC	cis	rs6472827	0.645	rs2956056	ENSG00000253983.2	RP1-16A9.1	3.8	0.000183	0.0497	0.34	0.24	Uterine fibroids;	chr8:74199608	chr8:74199396~74208441:+
SARC	cis	rs17695224	0.545	rs7247613	ENSG00000275055.1	CTC-471J1.11	-3.8	0.000183	0.0497	-0.25	-0.24	HDL cholesterol;HDL cholesterol levels;	chr19:51819940	chr19:52049007~52049754:+
SARC	cis	rs600231	0.598	rs2508712	ENSG00000245532.5	NEAT1	3.8	0.000183	0.0497	0.18	0.24	Bone mineral density;	chr11:65464790	chr11:65422774~65445540:+
SARC	cis	rs600231	0.708	rs3132767	ENSG00000245532.5	NEAT1	3.8	0.000183	0.0497	0.18	0.24	Bone mineral density;	chr11:65467389	chr11:65422774~65445540:+
SARC	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	3.8	0.000183	0.0497	0.25	0.24	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
SARC	cis	rs2562456	1	rs2359155	ENSG00000268658.4	LINC00664	-3.8	0.000184	0.0497	-0.33	-0.24	Pain;	chr19:21489067	chr19:21483374~21503238:+
SARC	cis	rs717662	0.507	rs581773	ENSG00000248027.1	CTD-2383M3.1	3.8	0.000184	0.0498	0.5	0.24	Red cell distribution width;	chr11:100831178	chr11:100684162~100687955:-
SARC	cis	rs2378870	0.589	rs4141085	ENSG00000266934.1	RP11-332H18.3	3.8	0.000184	0.0498	0.18	0.24	Height;	chr17:61555862	chr17:61382785~61384680:+
SARC	cis	rs16949788	1	rs76623374	ENSG00000261351.2	CTD-3185P2.1	-3.8	0.000184	0.0498	-0.46	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66475530	chr15:66488658~66492109:-
SARC	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-3.8	0.000184	0.0498	-0.36	-0.24	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
SARC	cis	rs6570726	1	rs373778	ENSG00000270638.1	RP3-466P17.1	3.8	0.000184	0.0498	0.2	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145735570~145737218:+
SARC	cis	rs860818	1	rs1728344	ENSG00000226816.2	AC005082.12	3.8	0.000184	0.0498	0.71	0.24	Initial pursuit acceleration;	chr7:23210425	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858281	ENSG00000226816.2	AC005082.12	3.8	0.000184	0.0498	0.71	0.24	Initial pursuit acceleration;	chr7:23210948	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs858280	ENSG00000226816.2	AC005082.12	3.8	0.000184	0.0498	0.71	0.24	Initial pursuit acceleration;	chr7:23211255	chr7:23206013~23208045:+
SARC	cis	rs860818	1	rs6955934	ENSG00000226816.2	AC005082.12	3.8	0.000184	0.0498	0.71	0.24	Initial pursuit acceleration;	chr7:23211880	chr7:23206013~23208045:+
SARC	cis	rs13113518	0.812	rs11932712	ENSG00000249700.7	SRD5A3-AS1	3.8	0.000184	0.0498	0.3	0.24	Height;	chr4:55436423	chr4:55363971~55395847:-
SARC	cis	rs13113518	0.812	rs12501746	ENSG00000249700.7	SRD5A3-AS1	3.8	0.000184	0.0498	0.3	0.24	Height;	chr4:55437438	chr4:55363971~55395847:-
SARC	cis	rs9309473	0.583	rs11899517	ENSG00000163016.8	ALMS1P	3.8	0.000184	0.0498	0.29	0.24	Metabolite levels;	chr2:73346133	chr2:73644919~73685576:+
SARC	cis	rs8098244	0.597	rs12958312	ENSG00000264745.1	TTC39C-AS1	-3.8	0.000184	0.0498	-0.26	-0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23784372	chr18:23994213~24015339:-
SARC	cis	rs11976180	0.517	rs6949375	ENSG00000228960.5	OR2A9P	-3.8	0.000184	0.0498	-0.44	-0.24	Obesity-related traits;	chr7:144076758	chr7:144294480~144300934:+
SARC	cis	rs8026198	0.778	rs2928335	ENSG00000260571.1	BNIP3P5	-3.8	0.000184	0.0498	-0.37	-0.24	Fibrinogen levels;	chr15:42199987	chr15:42313687~42314386:+
SARC	cis	rs7976269	0.515	rs9300183	ENSG00000257176.2	RP11-996F15.2	-3.8	0.000184	0.0499	-0.27	-0.24	Male-pattern baldness;	chr12:29002316	chr12:29280418~29317848:-
SARC	cis	rs4950322	0.518	rs56151278	ENSG00000278811.3	LINC00624	3.8	0.000184	0.0499	0.25	0.24	Protein quantitative trait loci;	chr1:147117421	chr1:147258885~147517875:-
SARC	cis	rs4950322	0.518	rs4950306	ENSG00000278811.3	LINC00624	3.8	0.000184	0.0499	0.25	0.24	Protein quantitative trait loci;	chr1:147117838	chr1:147258885~147517875:-
SARC	cis	rs7208859	0.614	rs216412	ENSG00000263603.1	CTD-2349P21.5	3.8	0.000184	0.0499	0.27	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30729469~30731202:+
SARC	cis	rs7267979	0.844	rs6115188	ENSG00000274414.1	RP5-965G21.4	-3.8	0.000184	0.0499	-0.25	-0.24	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:25239007~25245229:-
SARC	cis	rs2836974	0.568	rs8130795	ENSG00000255568.3	BRWD1-AS2	3.8	0.000184	0.0499	0.24	0.24	Cognitive function;	chr21:39178057	chr21:39313935~39314962:+
SARC	cis	rs12819124	0.502	rs10875718	ENSG00000240399.1	RP1-228P16.1	3.8	0.000184	0.0499	0.28	0.24	Glycated hemoglobin levels;	chr12:48017319	chr12:48054813~48055591:-
SARC	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-3.8	0.000184	0.0499	-0.35	-0.24	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
SARC	cis	rs7927592	0.513	rs608343	ENSG00000212093.1	AP000807.1	3.8	0.000184	0.0499	0.23	0.24	Total body bone mineral density;	chr11:68429362	chr11:68506083~68506166:-
SARC	cis	rs1707322	1	rs12077974	ENSG00000281133.1	AL355480.3	-3.8	0.000184	0.0499	-0.29	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45580892~45580996:-
SARC	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	3.8	0.000184	0.0499	0.28	0.24	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
SARC	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-3.8	0.000184	0.0499	-0.28	-0.24	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
SARC	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-3.8	0.000184	0.0499	-0.28	-0.24	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
SARC	cis	rs7826238	0.566	rs2945886	ENSG00000253981.4	ALG1L13P	3.8	0.000184	0.0499	0.25	0.24	Systolic blood pressure;	chr8:8290748	chr8:8236003~8244667:-
SARC	cis	rs853679	0.545	rs35949109	ENSG00000216901.1	AL022393.7	3.8	0.000184	0.0499	0.49	0.24	Depression;	chr6:28058148	chr6:28176188~28176674:+
SARC	cis	rs7208859	0.673	rs56846352	ENSG00000264538.5	SUZ12P1	-3.8	0.000185	0.0499	-0.25	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.673	rs7211776	ENSG00000264538.5	SUZ12P1	-3.8	0.000185	0.0499	-0.25	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30709299~30790908:+
SARC	cis	rs7208859	0.673	rs9912122	ENSG00000264538.5	SUZ12P1	-3.8	0.000185	0.0499	-0.25	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30709299~30790908:+
SARC	cis	rs73439953	0.649	rs7240871	ENSG00000267677.1	RP11-27G24.1	3.8	0.000185	0.0499	0.26	0.24	Triptolide cytotoxicity;	chr18:58928169	chr18:59360700~59386749:+
SARC	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-25.33	7.04e-69	6.77e-59	-0.98	-0.86	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
SARC	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-25.14	2.58e-68	2.01e-58	-0.98	-0.85	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
SARC	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-24.81	2.4e-67	8.22e-58	-0.98	-0.85	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
SARC	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	24.77	3.21e-67	9.4e-58	0.97	0.85	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
SARC	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	24.7	5.39e-67	1.2e-57	0.98	0.85	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
SARC	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	24.7	5.39e-67	1.2e-57	0.98	0.85	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
SARC	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-24.45	2.9e-66	1.82e-57	-0.97	-0.85	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
SARC	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-24.39	4.29e-66	2.39e-57	-0.97	-0.85	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
SARC	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-24.39	4.29e-66	2.39e-57	-0.97	-0.85	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
SARC	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	24.33	6.78e-66	3.23e-57	0.97	0.85	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
SARC	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	24.12	2.76e-65	8.56e-57	1.11	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
SARC	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	23.95	8.9e-65	2.64e-56	0.97	0.84	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
SARC	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	23.92	1.09e-64	3.21e-56	1.1	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	23.87	1.65e-64	4.54e-56	1.09	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	23.87	1.65e-64	4.54e-56	1.09	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	23.87	1.65e-64	4.54e-56	1.09	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	23.87	1.65e-64	4.54e-56	1.09	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	23.87	1.65e-64	4.54e-56	1.09	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	23.76	3.35e-64	8.92e-56	1.11	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
SARC	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	23.75	3.58e-64	9.45e-56	0.96	0.84	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
SARC	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	23.72	4.4e-64	1.15e-55	1.01	0.84	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
SARC	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	23.67	6.5e-64	1.68e-55	1.09	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	23.62	9.31e-64	2.39e-55	1.1	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
SARC	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-23.3	8.34e-63	2.08e-54	-0.97	-0.84	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
SARC	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-22.95	1.02e-61	2.44e-53	-0.96	-0.83	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
SARC	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	22.83	2.28e-61	5.32e-53	1.09	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
SARC	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	22.51	2.21e-60	5.1e-52	1.08	0.83	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
SARC	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	22.33	7.98e-60	1.79e-51	1.23	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	22.33	7.98e-60	1.79e-51	1.23	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	22.25	1.45e-59	3.24e-51	1.24	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
SARC	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	22.22	1.8e-59	3.93e-51	1.08	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	22.22	1.8e-59	3.93e-51	1.08	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	22.22	1.8e-59	3.93e-51	1.08	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	22.22	1.8e-59	3.93e-51	1.08	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	22.22	1.8e-59	3.93e-51	1.08	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
SARC	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	22.07	5.29e-59	1.13e-50	1.02	0.82	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
SARC	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	22.07	5.29e-59	1.13e-50	1.02	0.82	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
SARC	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	22.07	5.29e-59	1.13e-50	1.02	0.82	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
SARC	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	21.97	1.02e-58	2.18e-50	1.08	0.82	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
SARC	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	21.95	1.2e-58	2.55e-50	1.01	0.82	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
SARC	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	21.95	1.26e-58	2.65e-50	1.09	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
SARC	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	21.87	2.09e-58	4.35e-50	1.01	0.82	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
SARC	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	21.46	4.04e-57	8.33e-49	1.09	0.81	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	21.35	9.21e-57	1.88e-48	1.08	0.81	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	21.16	3.76e-56	7.65e-48	1.09	0.81	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
SARC	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	21.07	7.01e-56	1.41e-47	1.22	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
SARC	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	21.04	8.59e-56	1.71e-47	1.09	0.81	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
SARC	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	21.03	9.23e-56	1.83e-47	1.22	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
SARC	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	20.96	1.52e-55	2.99e-47	1.04	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	20.96	1.53e-55	2.99e-47	1.06	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
SARC	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-20.69	1.14e-54	2.2e-46	-1.07	-0.8	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
SARC	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	20.59	2.34e-54	4.44e-46	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	20.59	2.34e-54	4.44e-46	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
SARC	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	20.57	2.71e-54	5.11e-46	0.99	0.8	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
SARC	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-20.5	4.45e-54	8.36e-46	-1.2	-0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	20.42	8.11e-54	1.52e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-20.39	9.97e-54	1.86e-45	-1.2	-0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	20.29	2.04e-53	3.56e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	20.29	2.04e-53	3.56e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	20.29	2.04e-53	3.56e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	20.29	2.04e-53	3.56e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	20.29	2.04e-53	3.56e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	20.29	2.04e-53	3.56e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	20.29	2.04e-53	3.56e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	20.29	2.04e-53	3.56e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	20.29	2.04e-53	3.56e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	20.29	2.04e-53	3.56e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
SARC	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	20.28	2.28e-53	3.97e-45	1.08	0.8	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
SARC	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	20.27	2.44e-53	4.21e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	20.27	2.44e-53	4.21e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	20.24	2.99e-53	5.1e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	20.24	2.99e-53	5.1e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
SARC	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-20.22	3.39e-53	5.77e-45	-0.97	-0.8	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
SARC	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	20.21	3.73e-53	6.29e-45	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	20.21	3.73e-53	6.29e-45	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	20.21	3.86e-53	6.48e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	20.21	3.86e-53	6.48e-45	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	20.16	5.37e-53	8.85e-45	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	20.15	5.77e-53	9.38e-45	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	20.15	5.77e-53	9.38e-45	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	20.11	7.71e-53	1.23e-44	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	20.11	7.96e-53	1.23e-44	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	20.11	7.96e-53	1.23e-44	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	20.11	7.96e-53	1.23e-44	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	20.11	7.96e-53	1.23e-44	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	20.11	7.96e-53	1.23e-44	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	20.11	7.96e-53	1.23e-44	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	20.11	7.96e-53	1.23e-44	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	20.11	7.96e-53	1.23e-44	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	20.11	7.96e-53	1.23e-44	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	20.11	7.96e-53	1.23e-44	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	20.01	1.62e-52	2.45e-44	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	20.01	1.62e-52	2.45e-44	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	20.01	1.62e-52	2.45e-44	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	20	1.84e-52	2.79e-44	1.19	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.75	rs59354956	ENSG00000224114.1	RP11-343H5.4	19.95	2.58e-52	3.89e-44	1.19	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.75	rs58256223	ENSG00000224114.1	RP11-343H5.4	19.86	5.17e-52	7.75e-44	1.19	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:206695837~206696269:-
SARC	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-19.83	6.37e-52	9.52e-44	-0.91	-0.79	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
SARC	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	19.77	9.75e-52	1.44e-43	1.19	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	19.77	9.75e-52	1.44e-43	1.19	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	19.77	9.75e-52	1.44e-43	1.19	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
SARC	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	19.69	1.71e-51	2.49e-43	0.92	0.79	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	19.69	1.71e-51	2.49e-43	0.92	0.79	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
SARC	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	19.69	1.8e-51	2.61e-43	1.18	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
SARC	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	19.69	1.82e-51	2.63e-43	1	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
SARC	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	19.68	1.86e-51	2.67e-43	0.91	0.79	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
SARC	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	19.67	2.01e-51	2.88e-43	1.18	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-19.63	2.71e-51	3.85e-43	-1.18	-0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
SARC	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-19.59	3.7e-51	5.22e-43	-0.89	-0.79	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	19.47	8.95e-51	1.25e-42	0.91	0.79	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	19.46	9.97e-51	1.38e-42	0.91	0.79	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
SARC	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	19.45	1.02e-50	1.41e-42	1.07	0.79	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
SARC	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	19.37	1.86e-50	2.5e-42	0.9	0.79	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	19.37	1.86e-50	2.5e-42	0.9	0.79	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	19.37	1.86e-50	2.5e-42	0.9	0.79	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	19.37	1.86e-50	2.5e-42	0.9	0.79	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	19.37	1.86e-50	2.5e-42	0.9	0.79	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	19.37	1.86e-50	2.5e-42	0.9	0.79	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	19.36	1.99e-50	2.63e-42	0.9	0.79	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	19.36	1.99e-50	2.63e-42	0.9	0.79	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	19.36	1.99e-50	2.63e-42	0.9	0.79	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	19.36	1.99e-50	2.63e-42	0.9	0.79	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	19.34	2.35e-50	2.96e-42	0.9	0.78	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	19.34	2.35e-50	2.96e-42	0.9	0.78	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
SARC	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	19.34	2.35e-50	2.96e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	19.34	2.35e-50	2.96e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	19.34	2.35e-50	2.96e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	19.34	2.35e-50	2.96e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	19.34	2.35e-50	2.96e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	19.34	2.35e-50	2.96e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	19.34	2.35e-50	2.96e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	19.34	2.35e-50	2.96e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	19.34	2.35e-50	2.96e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	19.34	2.35e-50	2.96e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	19.34	2.45e-50	3.06e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	19.34	2.45e-50	3.06e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.626	rs12186649	ENSG00000213058.3	RP4-765C7.2	19.29	3.47e-50	4.32e-42	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:178411616~178411972:+
SARC	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	19.27	3.98e-50	4.92e-42	0.99	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
SARC	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	19.27	3.99e-50	4.92e-42	1.06	0.78	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	19.27	3.99e-50	4.92e-42	1.06	0.78	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
SARC	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	19.26	4.24e-50	5.22e-42	0.91	0.78	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	19.21	6.08e-50	7.43e-42	0.92	0.78	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
SARC	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	19.18	7.55e-50	9.17e-42	1.3	0.78	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
SARC	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	19.18	7.55e-50	9.17e-42	1.3	0.78	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
SARC	trans	rs13177918	0.651	rs13184111	ENSG00000213058.3	RP4-765C7.2	19.17	8.29e-50	1e-41	1.17	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:178411616~178411972:+
SARC	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	19.17	8.57e-50	1.04e-41	0.9	0.78	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
SARC	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	19.16	9.16e-50	1.1e-41	1.17	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	19.16	9.16e-50	1.1e-41	1.17	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
SARC	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	19.16	9.32e-50	1.11e-41	1.31	0.78	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
SARC	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	19.16	9.32e-50	1.11e-41	1.31	0.78	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
SARC	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	19.16	9.32e-50	1.11e-41	1.31	0.78	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
SARC	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	19.14	1.03e-49	1.21e-41	0.9	0.78	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	19.14	1.03e-49	1.21e-41	0.9	0.78	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	19.14	1.03e-49	1.21e-41	0.9	0.78	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
SARC	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	19.1	1.46e-49	1.71e-41	1.06	0.78	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
SARC	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	19.07	1.83e-49	2.12e-41	0.91	0.78	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	19.07	1.83e-49	2.12e-41	0.91	0.78	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	19.07	1.83e-49	2.12e-41	0.91	0.78	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
SARC	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	19.06	1.87e-49	2.14e-41	1.17	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	19.06	1.87e-49	2.14e-41	1.17	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	19.06	1.87e-49	2.14e-41	1.17	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	19.03	2.44e-49	2.79e-41	1.17	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
SARC	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	19.02	2.5e-49	2.85e-41	0.92	0.78	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
SARC	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	18.96	4.01e-49	4.56e-41	1.12	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
SARC	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	18.83	1.09e-48	1.21e-40	0.91	0.78	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
SARC	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	18.76	1.76e-48	1.93e-40	1.31	0.78	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
SARC	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	18.76	1.76e-48	1.93e-40	1.31	0.78	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
SARC	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	18.71	2.69e-48	2.95e-40	1.31	0.77	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
SARC	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	18.67	3.55e-48	3.85e-40	0.89	0.77	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	18.67	3.55e-48	3.85e-40	0.89	0.77	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	18.67	3.55e-48	3.85e-40	0.89	0.77	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
SARC	trans	rs13177918	0.626	rs12186649	ENSG00000224114.1	RP11-343H5.4	18.66	3.82e-48	4.13e-40	1.16	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:206695837~206696269:-
SARC	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	18.66	3.85e-48	4.15e-40	0.89	0.77	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	18.6	6.05e-48	6.5e-40	0.89	0.77	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	18.6	6.05e-48	6.5e-40	0.89	0.77	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	18.54	9.42e-48	1.01e-39	0.89	0.77	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	18.53	9.91e-48	1.06e-39	0.89	0.77	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
SARC	trans	rs13177918	0.651	rs13184111	ENSG00000224114.1	RP11-343H5.4	18.52	1.08e-47	1.14e-39	1.15	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:206695837~206696269:-
SARC	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	18.48	1.42e-47	1.48e-39	1.3	0.77	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
SARC	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	18.46	1.73e-47	1.81e-39	0.91	0.77	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
SARC	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	18.43	2.12e-47	2.2e-39	1.04	0.77	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
SARC	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-18.42	2.29e-47	2.38e-39	-0.98	-0.77	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
SARC	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	18.38	3.2e-47	3.31e-39	1.1	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.626	rs12186649	ENSG00000239528.1	RPS14P8	18.26	7.57e-47	7.8e-39	1.15	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr5:116562562~116562930:+
SARC	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	18.2	1.25e-46	1.27e-38	1.32	0.77	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
SARC	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-18.19	1.33e-46	1.35e-38	-0.97	-0.77	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
SARC	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-18.19	1.33e-46	1.35e-38	-0.97	-0.77	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
SARC	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	18.18	1.42e-46	1.44e-38	1.11	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	18.17	1.5e-46	1.51e-38	1.11	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.651	rs13184111	ENSG00000239528.1	RPS14P8	18.11	2.34e-46	2.35e-38	1.14	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr5:116562562~116562930:+
SARC	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	18.1	2.66e-46	2.65e-38	1.29	0.76	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
SARC	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	18.06	3.37e-46	3.36e-38	1.09	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
SARC	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	18.04	4.16e-46	4.11e-38	1.04	0.76	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
SARC	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	17.9	1.2e-45	1.16e-37	1.28	0.76	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
SARC	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	17.87	1.51e-45	1.45e-37	1.1	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
SARC	trans	rs13253073	0.662	rs4434590	ENSG00000260318.1	COX6CP1	17.85	1.65e-45	1.57e-37	1.28	0.76	Glucose homeostasis traits;	chr8:99848429	chr16:11903923~11904137:-
SARC	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	17.83	1.95e-45	1.84e-37	0.87	0.76	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	17.83	1.95e-45	1.84e-37	0.87	0.76	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	17.83	1.95e-45	1.84e-37	0.87	0.76	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	17.83	1.95e-45	1.84e-37	0.87	0.76	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	17.79	2.7e-45	2.53e-37	0.87	0.76	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
SARC	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	17.74	4.01e-45	3.73e-37	1.09	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
SARC	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	17.73	4.17e-45	3.87e-37	0.89	0.76	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
SARC	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	17.66	7.23e-45	6.66e-37	0.85	0.76	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
SARC	trans	rs13253073	0.76	rs62534633	ENSG00000260318.1	COX6CP1	17.58	1.33e-44	1.22e-36	1.26	0.76	Glucose homeostasis traits;	chr8:99884533	chr16:11903923~11904137:-
SARC	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	17.52	2.03e-44	1.85e-36	1.24	0.75	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
SARC	trans	rs13253073	0.723	rs12548542	ENSG00000260318.1	COX6CP1	17.48	2.74e-44	2.49e-36	1.25	0.75	Glucose homeostasis traits;	chr8:99890167	chr16:11903923~11904137:-
SARC	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	17.47	3.06e-44	2.71e-36	0.88	0.75	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	17.47	3.06e-44	2.71e-36	0.88	0.75	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	17.47	3.06e-44	2.71e-36	0.88	0.75	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	17.47	3.06e-44	2.71e-36	0.88	0.75	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	17.47	3.06e-44	2.71e-36	0.88	0.75	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	17.47	3.06e-44	2.71e-36	0.88	0.75	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	17.47	3.06e-44	2.71e-36	0.88	0.75	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	17.47	3.06e-44	2.71e-36	0.88	0.75	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
SARC	trans	rs13177918	0.906	rs12652032	ENSG00000224114.1	RP11-343H5.4	17.45	3.41e-44	3.02e-36	1.2	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	17.42	4.5e-44	3.97e-36	1.08	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
SARC	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	17.39	5.48e-44	4.79e-36	1.2	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
SARC	trans	rs13177918	1	rs35007082	ENSG00000224114.1	RP11-343H5.4	17.39	5.48e-44	4.79e-36	1.2	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:206695837~206696269:-
SARC	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	17.32	9.25e-44	8.06e-36	0.91	0.75	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
SARC	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	17.23	1.87e-43	1.61e-35	1.2	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
SARC	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	17.23	1.87e-43	1.61e-35	1.2	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	17.22	2e-43	1.72e-35	1.08	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
SARC	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	17.21	2.17e-43	1.85e-35	1.01	0.75	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
SARC	trans	rs13177918	0.906	rs12652032	ENSG00000213058.3	RP4-765C7.2	17.21	2.22e-43	1.9e-35	1.2	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:178411616~178411972:+
SARC	trans	rs13253073	0.723	rs7157	ENSG00000260318.1	COX6CP1	17.18	2.78e-43	2.37e-35	1.25	0.75	Glucose homeostasis traits;	chr8:99877449	chr16:11903923~11904137:-
SARC	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	17.15	3.55e-43	3.02e-35	0.84	0.75	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
SARC	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	17.12	4.27e-43	3.62e-35	0.89	0.75	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	17.11	4.6e-43	3.86e-35	0.87	0.75	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
SARC	trans	rs12291225	0.679	rs34238445	ENSG00000236360.2	RP11-334A14.2	17.1	5.06e-43	4.24e-35	0.91	0.75	Sense of smell;	chr11:14294369	chr1:52993201~52993702:-
SARC	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	17.09	5.4e-43	4.51e-35	0.87	0.75	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
SARC	trans	rs13177918	1	rs13177918	ENSG00000224114.1	RP11-343H5.4	17.07	6.1e-43	5.08e-35	1.19	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:206695837~206696269:-
SARC	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	17.06	6.96e-43	5.77e-35	0.87	0.75	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
SARC	trans	rs13253073	0.8	rs7015733	ENSG00000260318.1	COX6CP1	17.05	7.12e-43	5.89e-35	1.23	0.75	Glucose homeostasis traits;	chr8:99899353	chr16:11903923~11904137:-
SARC	trans	rs12291225	0.753	rs1431374	ENSG00000236360.2	RP11-334A14.2	17.02	9e-43	7.4e-35	0.91	0.74	Sense of smell;	chr11:14282429	chr1:52993201~52993702:-
SARC	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	17.02	9.36e-43	7.68e-35	0.88	0.74	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	17	1.05e-42	8.62e-35	0.85	0.74	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	16.99	1.18e-42	9.47e-35	0.87	0.74	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
SARC	trans	rs13177918	1	rs13177918	ENSG00000213058.3	RP4-765C7.2	16.97	1.32e-42	1.06e-34	1.19	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:178411616~178411972:+
SARC	trans	rs12291225	0.679	rs11605531	ENSG00000236360.2	RP11-334A14.2	16.97	1.37e-42	1.09e-34	0.91	0.74	Sense of smell;	chr11:14270048	chr1:52993201~52993702:-
SARC	trans	rs12291225	0.639	rs61883858	ENSG00000236360.2	RP11-334A14.2	16.97	1.37e-42	1.09e-34	0.91	0.74	Sense of smell;	chr11:14273162	chr1:52993201~52993702:-
SARC	trans	rs12291225	0.679	rs11023170	ENSG00000236360.2	RP11-334A14.2	16.97	1.37e-42	1.09e-34	0.91	0.74	Sense of smell;	chr11:14273363	chr1:52993201~52993702:-
SARC	trans	rs12291225	0.679	rs11023178	ENSG00000236360.2	RP11-334A14.2	16.96	1.43e-42	1.14e-34	0.91	0.74	Sense of smell;	chr11:14288736	chr1:52993201~52993702:-
SARC	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	16.96	1.46e-42	1.16e-34	1.05	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	16.96	1.46e-42	1.16e-34	1.05	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
SARC	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	16.94	1.74e-42	1.38e-34	0.84	0.74	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
SARC	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	16.94	1.74e-42	1.38e-34	0.84	0.74	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
SARC	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	16.93	1.82e-42	1.42e-34	0.84	0.74	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
SARC	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	16.87	2.85e-42	2.23e-34	0.86	0.74	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
SARC	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	16.86	3.18e-42	2.48e-34	0.84	0.74	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
SARC	trans	rs12291225	0.679	rs10832240	ENSG00000236360.2	RP11-334A14.2	16.85	3.48e-42	2.71e-34	0.91	0.74	Sense of smell;	chr11:14283198	chr1:52993201~52993702:-
SARC	trans	rs12291225	0.679	rs11023172	ENSG00000236360.2	RP11-334A14.2	16.83	3.96e-42	3.08e-34	0.91	0.74	Sense of smell;	chr11:14273821	chr1:52993201~52993702:-
SARC	trans	rs12291225	0.679	rs4757245	ENSG00000236360.2	RP11-334A14.2	16.83	3.96e-42	3.08e-34	0.91	0.74	Sense of smell;	chr11:14276326	chr1:52993201~52993702:-
SARC	trans	rs12291225	0.637	rs8570	ENSG00000236360.2	RP11-334A14.2	16.83	4.09e-42	3.17e-34	0.91	0.74	Sense of smell;	chr11:14279213	chr1:52993201~52993702:-
SARC	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	16.81	4.7e-42	3.63e-34	0.83	0.74	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
SARC	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	16.8	4.83e-42	3.73e-34	0.95	0.74	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
SARC	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	16.77	6.4e-42	4.93e-34	0.84	0.74	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
SARC	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-16.76	6.63e-42	5.09e-34	-0.83	-0.74	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
SARC	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	16.73	8.71e-42	6.64e-34	0.85	0.74	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	16.73	8.71e-42	6.64e-34	0.85	0.74	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	16.73	8.71e-42	6.64e-34	0.85	0.74	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
SARC	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	16.72	9e-42	6.83e-34	1.04	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
SARC	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	16.72	9e-42	6.83e-34	1.04	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
SARC	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	16.7	1.04e-41	7.87e-34	0.86	0.74	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
SARC	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	16.7	1.07e-41	8.01e-34	0.86	0.74	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
SARC	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	16.7	1.09e-41	8.2e-34	0.86	0.74	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
SARC	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-16.64	1.63e-41	1.22e-33	-0.82	-0.74	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
SARC	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	16.64	1.69e-41	1.26e-33	1.18	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
SARC	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	16.64	1.69e-41	1.26e-33	1.18	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
SARC	trans	rs12291225	0.679	rs7934671	ENSG00000236360.2	RP11-334A14.2	16.64	1.73e-41	1.28e-33	0.9	0.74	Sense of smell;	chr11:14283555	chr1:52993201~52993702:-
SARC	trans	rs13177918	0.906	rs12652032	ENSG00000239528.1	RPS14P8	16.63	1.81e-41	1.34e-33	1.18	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr5:116562562~116562930:+
SARC	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	16.58	2.63e-41	1.93e-33	1.31	0.74	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
SARC	trans	rs7121616	0.563	rs4936770	ENSG00000234176.1	HSPA8P1	16.56	3.08e-41	2.25e-33	0.93	0.74	Breast cancer;	chr11:123058167	chrX:121203182~121205014:-
SARC	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	16.52	4.21e-41	3.07e-33	1.04	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	16.52	4.21e-41	3.07e-33	1.04	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
SARC	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	16.5	5.01e-41	3.63e-33	0.82	0.73	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
SARC	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	16.47	6.31e-41	4.57e-33	1.31	0.73	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
SARC	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	16.38	1.18e-40	8.44e-33	0.95	0.73	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
SARC	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	16.38	1.23e-40	8.77e-33	0.91	0.73	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
SARC	trans	rs13177918	1	rs13177918	ENSG00000239528.1	RPS14P8	16.38	1.24e-40	8.87e-33	1.17	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr5:116562562~116562930:+
SARC	trans	rs12291225	0.679	rs11238	ENSG00000236360.2	RP11-334A14.2	-16.31	2.08e-40	1.48e-32	-0.89	-0.73	Sense of smell;	chr11:14266582	chr1:52993201~52993702:-
SARC	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	16.26	3.09e-40	2.18e-32	0.84	0.73	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
SARC	trans	rs12291225	0.679	rs11369	ENSG00000236360.2	RP11-334A14.2	16.24	3.57e-40	2.52e-32	0.9	0.73	Sense of smell;	chr11:14266550	chr1:52993201~52993702:-
SARC	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	16.24	3.64e-40	2.56e-32	0.86	0.73	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
SARC	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	16.23	3.84e-40	2.69e-32	0.92	0.73	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	16.23	3.84e-40	2.69e-32	0.92	0.73	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
SARC	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	16.23	3.86e-40	2.7e-32	0.95	0.73	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
SARC	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	16.22	4.02e-40	2.8e-32	0.84	0.73	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
SARC	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	16.16	6.46e-40	4.47e-32	0.95	0.73	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
SARC	trans	rs13253073	0.723	rs7831963	ENSG00000260318.1	COX6CP1	16.16	6.63e-40	4.58e-32	1.32	0.73	Glucose homeostasis traits;	chr8:99853014	chr16:11903923~11904137:-
SARC	trans	rs13253073	0.723	rs7832488	ENSG00000260318.1	COX6CP1	16.16	6.63e-40	4.58e-32	1.32	0.73	Glucose homeostasis traits;	chr8:99853185	chr16:11903923~11904137:-
SARC	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	16.16	6.79e-40	4.69e-32	1.02	0.73	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
SARC	trans	rs7121616	0.563	rs1461494	ENSG00000234176.1	HSPA8P1	16.14	7.54e-40	5.2e-32	0.9	0.73	Breast cancer;	chr11:123055777	chrX:121203182~121205014:-
SARC	trans	rs941207	0.547	rs56183434	ENSG00000121089.4	NACA3P	16.14	7.63e-40	5.25e-32	0.82	0.73	Platelet count;	chr12:56676145	chr4:164943290~164943937:+
SARC	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	16.14	7.92e-40	5.44e-32	1	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
SARC	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	16.13	8.13e-40	5.56e-32	0.85	0.73	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
SARC	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-16.12	8.72e-40	5.93e-32	-0.82	-0.73	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
SARC	trans	rs12291225	0.679	rs4756786	ENSG00000236360.2	RP11-334A14.2	16.1	1.06e-39	7.18e-32	0.9	0.73	Sense of smell;	chr11:14264354	chr1:52993201~52993702:-
SARC	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-16.08	1.22e-39	8.27e-32	-0.82	-0.73	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
SARC	trans	rs12291225	0.645	rs3763950	ENSG00000236360.2	RP11-334A14.2	16.03	1.83e-39	1.24e-31	0.89	0.72	Sense of smell;	chr11:14256503	chr1:52993201~52993702:-
SARC	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	16.01	2.08e-39	1.39e-31	0.95	0.72	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	16.01	2.08e-39	1.39e-31	0.95	0.72	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	16.01	2.08e-39	1.39e-31	0.95	0.72	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-15.98	2.53e-39	1.69e-31	-0.95	-0.72	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
SARC	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	15.97	2.8e-39	1.87e-31	0.85	0.72	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	15.97	2.8e-39	1.87e-31	0.85	0.72	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
SARC	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	15.96	3.1e-39	2.02e-31	0.95	0.72	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	15.96	3.1e-39	2.02e-31	0.95	0.72	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	15.96	3.1e-39	2.02e-31	0.95	0.72	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	15.96	3.1e-39	2.02e-31	0.95	0.72	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	15.96	3.1e-39	2.02e-31	0.95	0.72	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	15.96	3.1e-39	2.02e-31	0.95	0.72	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-15.92	3.98e-39	2.59e-31	-0.96	-0.72	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
SARC	trans	rs7121616	0.576	rs4936767	ENSG00000234176.1	HSPA8P1	15.92	4.14e-39	2.69e-31	0.91	0.72	Breast cancer;	chr11:123047451	chrX:121203182~121205014:-
SARC	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	15.91	4.55e-39	2.95e-31	0.94	0.72	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	15.89	5.05e-39	3.27e-31	0.93	0.72	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-15.86	6.45e-39	4.17e-31	-0.8	-0.72	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
SARC	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	15.84	7.52e-39	4.84e-31	1.31	0.72	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
SARC	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	15.84	7.52e-39	4.84e-31	1.31	0.72	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
SARC	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-15.84	7.9e-39	5.08e-31	-0.88	-0.72	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
SARC	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	15.82	8.79e-39	5.63e-31	0.78	0.72	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	15.82	8.84e-39	5.66e-31	0.94	0.72	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-15.82	8.97e-39	5.73e-31	-0.95	-0.72	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
SARC	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	15.82	9.18e-39	5.85e-31	0.83	0.72	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	15.82	9.18e-39	5.85e-31	0.83	0.72	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
SARC	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	15.81	9.43e-39	5.99e-31	0.77	0.72	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	15.81	9.5e-39	6.03e-31	0.94	0.72	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
SARC	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	15.81	9.63e-39	6.11e-31	1.31	0.72	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
SARC	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	15.81	9.93e-39	6.29e-31	0.94	0.72	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	15.79	1.08e-38	6.8e-31	0.79	0.72	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
SARC	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	15.76	1.42e-38	8.92e-31	0.99	0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
SARC	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	15.75	1.54e-38	9.62e-31	0.8	0.72	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	15.75	1.54e-38	9.62e-31	0.8	0.72	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	15.75	1.54e-38	9.62e-31	0.8	0.72	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	15.75	1.54e-38	9.62e-31	0.8	0.72	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
SARC	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	15.74	1.59e-38	9.94e-31	0.94	0.72	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	15.74	1.59e-38	9.94e-31	0.94	0.72	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	15.72	1.88e-38	1.16e-30	0.78	0.72	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
SARC	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	15.72	1.88e-38	1.16e-30	0.78	0.72	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-15.71	2e-38	1.24e-30	-0.95	-0.72	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	15.68	2.5e-38	1.54e-30	0.94	0.72	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
SARC	trans	rs7121616	0.562	rs7131452	ENSG00000234176.1	HSPA8P1	15.68	2.56e-38	1.58e-30	0.91	0.72	Breast cancer;	chr11:123065314	chrX:121203182~121205014:-
SARC	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-15.66	2.96e-38	1.82e-30	-0.92	-0.72	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	15.61	4.43e-38	2.69e-30	0.87	0.71	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	15.59	5.19e-38	3.1e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	15.59	5.19e-38	3.1e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	15.59	5.19e-38	3.1e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	15.59	5.19e-38	3.1e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	15.59	5.19e-38	3.1e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	15.59	5.19e-38	3.1e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	15.59	5.19e-38	3.1e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	15.59	5.22e-38	3.12e-30	0.87	0.71	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
SARC	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-15.58	5.38e-38	3.2e-30	-0.93	-0.71	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	15.57	5.99e-38	3.55e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	15.57	5.99e-38	3.55e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	15.54	7.68e-38	4.47e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	15.54	7.68e-38	4.47e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	15.54	7.68e-38	4.47e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	15.54	7.68e-38	4.47e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	15.54	7.68e-38	4.47e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	15.54	7.68e-38	4.47e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	15.53	7.92e-38	4.58e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	15.53	7.92e-38	4.58e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	15.53	7.92e-38	4.58e-30	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
SARC	trans	rs7121616	0.562	rs2061602	ENSG00000234176.1	HSPA8P1	15.52	8.86e-38	5.12e-30	0.91	0.71	Breast cancer;	chr11:123065079	chrX:121203182~121205014:-
SARC	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-15.5	1.05e-37	6.08e-30	-0.92	-0.71	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-15.49	1.13e-37	6.49e-30	-0.92	-0.71	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-15.48	1.18e-37	6.74e-30	-0.93	-0.71	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
SARC	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	15.43	1.82e-37	1.04e-29	0.98	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
SARC	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-15.42	1.85e-37	1.05e-29	-0.93	-0.71	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	15.41	2.06e-37	1.16e-29	0.77	0.71	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
SARC	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	15.4	2.23e-37	1.24e-29	0.8	0.71	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
SARC	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-15.4	2.26e-37	1.26e-29	-0.93	-0.71	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	15.39	2.31e-37	1.29e-29	0.76	0.71	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-15.39	2.39e-37	1.33e-29	-0.93	-0.71	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
SARC	trans	rs12291225	0.546	rs12795545	ENSG00000236360.2	RP11-334A14.2	15.37	2.77e-37	1.54e-29	0.83	0.71	Sense of smell;	chr11:14334018	chr1:52993201~52993702:-
SARC	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-15.36	2.93e-37	1.63e-29	-0.93	-0.71	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.583	rs2498380	ENSG00000242375.1	RP11-498P14.3	-15.36	2.97e-37	1.65e-29	-0.86	-0.71	Intelligence (multi-trait analysis);	chr6:26643768	chr9:97195351~97197687:-
SARC	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	15.35	3.22e-37	1.77e-29	0.76	0.71	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
SARC	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	15.35	3.22e-37	1.77e-29	0.76	0.71	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
SARC	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	15.35	3.22e-37	1.77e-29	0.76	0.71	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-15.34	3.39e-37	1.86e-29	-0.93	-0.71	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
SARC	trans	rs12291225	0.545	rs11023187	ENSG00000236360.2	RP11-334A14.2	15.33	3.83e-37	2.09e-29	0.83	0.71	Sense of smell;	chr11:14324013	chr1:52993201~52993702:-
SARC	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	15.32	4.2e-37	2.28e-29	0.77	0.71	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
SARC	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	15.32	4.2e-37	2.28e-29	0.77	0.71	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-15.32	4.23e-37	2.29e-29	-0.9	-0.71	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	15.29	5.15e-37	2.79e-29	0.87	0.71	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
SARC	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-15.29	5.23e-37	2.83e-29	-0.88	-0.71	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
SARC	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-15.28	5.4e-37	2.91e-29	-0.97	-0.71	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
SARC	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-15.27	6.07e-37	3.26e-29	-0.86	-0.71	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	15.27	6.12e-37	3.27e-29	0.9	0.71	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	15.27	6.12e-37	3.27e-29	0.9	0.71	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	15.27	6.12e-37	3.27e-29	0.9	0.71	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-15.26	6.48e-37	3.46e-29	-0.9	-0.71	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	15.25	6.72e-37	3.58e-29	0.78	0.71	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
SARC	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	15.22	8.64e-37	4.58e-29	1.24	0.71	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
SARC	trans	rs12291225	0.585	rs11023194	ENSG00000236360.2	RP11-334A14.2	15.22	8.84e-37	4.67e-29	0.82	0.71	Sense of smell;	chr11:14348223	chr1:52993201~52993702:-
SARC	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	15.21	9.26e-37	4.88e-29	0.87	0.71	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	15.2	1.01e-36	5.31e-29	0.88	0.71	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
SARC	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-15.18	1.21e-36	6.32e-29	-0.92	-0.71	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	15.17	1.25e-36	6.5e-29	0.9	0.71	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	15.17	1.28e-36	6.67e-29	0.76	0.7	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-15.17	1.29e-36	6.71e-29	-0.91	-0.7	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-15.17	1.29e-36	6.71e-29	-0.91	-0.7	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-15.17	1.29e-36	6.71e-29	-0.91	-0.7	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
SARC	trans	rs12291225	0.546	rs12291662	ENSG00000236360.2	RP11-334A14.2	15.16	1.35e-36	6.99e-29	0.82	0.7	Sense of smell;	chr11:14321403	chr1:52993201~52993702:-
SARC	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	15.14	1.64e-36	8.44e-29	0.91	0.7	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
SARC	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	15.14	1.68e-36	8.58e-29	0.77	0.7	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
SARC	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	15.14	1.68e-36	8.58e-29	0.77	0.7	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-15.13	1.7e-36	8.69e-29	-0.91	-0.7	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	15.11	2.11e-36	1.07e-28	0.76	0.7	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
SARC	trans	rs1816752	0.819	rs4769349	ENSG00000237917.1	PARP4P1	-15.1	2.23e-36	1.13e-28	-0.81	-0.7	Obesity-related traits;	chr13:24408694	chrY:26594851~26634652:-
SARC	trans	rs12291225	0.585	rs10832242	ENSG00000236360.2	RP11-334A14.2	-15.09	2.47e-36	1.25e-28	-0.83	-0.7	Sense of smell;	chr11:14318958	chr1:52993201~52993702:-
SARC	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-15.08	2.49e-36	1.26e-28	-0.9	-0.7	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	15.08	2.56e-36	1.29e-28	0.75	0.7	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-15.07	2.74e-36	1.38e-28	-0.93	-0.7	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-15.07	2.8e-36	1.4e-28	-0.9	-0.7	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	15.07	2.85e-36	1.43e-28	0.75	0.7	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
SARC	trans	rs13253073	0.525	rs35509895	ENSG00000260318.1	COX6CP1	15.06	2.91e-36	1.46e-28	1.33	0.7	Glucose homeostasis traits;	chr8:99872093	chr16:11903923~11904137:-
SARC	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	15.06	2.92e-36	1.46e-28	0.87	0.7	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
SARC	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	15.05	3.26e-36	1.63e-28	0.77	0.7	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
SARC	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	15.05	3.32e-36	1.65e-28	1.07	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
SARC	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-15.04	3.39e-36	1.68e-28	-0.88	-0.7	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-15.04	3.57e-36	1.77e-28	-0.91	-0.7	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-15.03	3.67e-36	1.82e-28	-0.9	-0.7	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	15.02	3.97e-36	1.95e-28	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	15.02	3.97e-36	1.95e-28	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	15.02	3.97e-36	1.95e-28	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	15.02	3.97e-36	1.95e-28	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	15.02	3.97e-36	1.95e-28	0.86	0.7	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
SARC	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	15.02	4.14e-36	2.03e-28	1.07	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
SARC	trans	rs13253073	0.723	rs7840626	ENSG00000260318.1	COX6CP1	14.97	5.87e-36	2.86e-28	1.28	0.7	Glucose homeostasis traits;	chr8:99867598	chr16:11903923~11904137:-
SARC	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	14.97	6.05e-36	2.94e-28	0.76	0.7	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	14.96	6.46e-36	3.14e-28	0.88	0.7	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
SARC	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	14.96	6.58e-36	3.18e-28	0.98	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
SARC	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	14.96	6.58e-36	3.18e-28	0.98	0.7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
SARC	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	14.95	6.97e-36	3.37e-28	0.75	0.7	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
SARC	trans	rs12291225	0.546	rs11023199	ENSG00000236360.2	RP11-334A14.2	14.95	7.05e-36	3.4e-28	0.82	0.7	Sense of smell;	chr11:14372712	chr1:52993201~52993702:-
SARC	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	14.94	7.53e-36	3.63e-28	0.87	0.7	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
SARC	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-14.92	8.56e-36	4.1e-28	-0.76	-0.7	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-14.9	1.03e-35	4.91e-28	-0.91	-0.7	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-14.9	1.03e-35	4.91e-28	-0.91	-0.7	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
SARC	trans	rs10716881	1	rs10716881	ENSG00000121089.4	NACA3P	-14.9	1.05e-35	5e-28	-0.75	-0.7	High light scatter reticulocyte count;	chr12:56644387	chr4:164943290~164943937:+
SARC	trans	rs12291225	0.585	rs34171876	ENSG00000236360.2	RP11-334A14.2	14.88	1.15e-35	5.47e-28	0.82	0.7	Sense of smell;	chr11:14332411	chr1:52993201~52993702:-
SARC	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-14.88	1.19e-35	5.64e-28	-0.91	-0.7	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
SARC	trans	rs12291225	0.585	rs10832246	ENSG00000236360.2	RP11-334A14.2	14.86	1.37e-35	6.51e-28	0.81	0.7	Sense of smell;	chr11:14359282	chr1:52993201~52993702:-
SARC	trans	rs12291225	0.585	rs12270374	ENSG00000236360.2	RP11-334A14.2	14.85	1.45e-35	6.83e-28	0.81	0.7	Sense of smell;	chr11:14353533	chr1:52993201~52993702:-
SARC	trans	rs12291225	0.585	rs11023197	ENSG00000236360.2	RP11-334A14.2	14.83	1.69e-35	7.97e-28	0.81	0.7	Sense of smell;	chr11:14359452	chr1:52993201~52993702:-
SARC	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	14.81	2.03e-35	9.52e-28	0.87	0.7	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
SARC	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-14.8	2.12e-35	9.92e-28	-0.85	-0.7	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
SARC	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-14.77	2.78e-35	1.28e-27	-0.79	-0.7	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
SARC	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	14.76	2.94e-35	1.35e-27	0.87	0.7	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
SARC	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	14.73	3.89e-35	1.78e-27	0.94	0.69	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.596	rs62396201	ENSG00000242375.1	RP11-498P14.3	14.71	4.26e-35	1.91e-27	0.88	0.69	Intelligence (multi-trait analysis);	chr6:26667988	chr9:97195351~97197687:-
SARC	trans	rs941207	0.507	rs1107479	ENSG00000121089.4	NACA3P	-14.71	4.53e-35	2.03e-27	-0.77	-0.69	Platelet count;	chr12:56636902	chr4:164943290~164943937:+
SARC	trans	rs2950393	0.929	rs7973157	ENSG00000121089.4	NACA3P	-14.69	5.05e-35	2.25e-27	-0.74	-0.69	Platelet distribution width;	chr12:56655409	chr4:164943290~164943937:+
SARC	trans	rs12291225	0.585	rs4517475	ENSG00000236360.2	RP11-334A14.2	14.69	5.11e-35	2.27e-27	0.81	0.69	Sense of smell;	chr11:14364599	chr1:52993201~52993702:-
SARC	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-14.66	6.63e-35	2.89e-27	-0.91	-0.69	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	14.63	8.14e-35	3.54e-27	0.74	0.69	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-14.62	8.68e-35	3.75e-27	-0.91	-0.69	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	14.62	8.97e-35	3.87e-27	0.74	0.69	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-14.59	1.11e-34	4.73e-27	-0.9	-0.69	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-14.59	1.11e-34	4.73e-27	-0.9	-0.69	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-14.59	1.11e-34	4.73e-27	-0.9	-0.69	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-14.59	1.11e-34	4.73e-27	-0.9	-0.69	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-14.59	1.11e-34	4.73e-27	-0.9	-0.69	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
SARC	trans	rs7554547	0.667	rs2336377	ENSG00000261819.1	RP11-680G24.4	-14.57	1.33e-34	5.65e-27	-0.81	-0.69	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr16:14988259~14990160:-
SARC	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	14.56	1.42e-34	6e-27	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	14.56	1.42e-34	6e-27	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	14.56	1.43e-34	6.06e-27	0.86	0.69	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
SARC	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	14.53	1.78e-34	7.52e-27	0.88	0.69	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	14.52	1.84e-34	7.72e-27	0.86	0.69	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	14.52	1.84e-34	7.72e-27	0.86	0.69	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	14.52	1.84e-34	7.72e-27	0.86	0.69	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	14.52	1.84e-34	7.72e-27	0.86	0.69	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
SARC	trans	rs12291225	0.585	rs4757250	ENSG00000236360.2	RP11-334A14.2	14.49	2.38e-34	9.94e-27	0.81	0.69	Sense of smell;	chr11:14354137	chr1:52993201~52993702:-
SARC	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	14.49	2.42e-34	1.01e-26	0.86	0.69	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
SARC	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	14.48	2.5e-34	1.04e-26	0.95	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
SARC	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	14.46	2.87e-34	1.18e-26	0.86	0.69	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	14.46	2.87e-34	1.18e-26	0.86	0.69	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	14.46	2.87e-34	1.18e-26	0.86	0.69	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
SARC	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-14.45	3.29e-34	1.34e-26	-0.89	-0.69	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-14.44	3.51e-34	1.43e-26	-0.91	-0.69	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
SARC	trans	rs7121616	0.595	rs7941144	ENSG00000234176.1	HSPA8P1	14.44	3.52e-34	1.43e-26	0.83	0.69	Breast cancer;	chr11:123079805	chrX:121203182~121205014:-
SARC	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	14.43	3.69e-34	1.5e-26	0.74	0.69	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
SARC	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	14.43	3.86e-34	1.56e-26	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
SARC	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	14.38	5.69e-34	2.28e-26	0.87	0.69	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
SARC	trans	rs12291225	0.679	rs1043237	ENSG00000236360.2	RP11-334A14.2	14.36	6.58e-34	2.63e-26	0.84	0.69	Sense of smell;	chr11:14267507	chr1:52993201~52993702:-
SARC	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	14.34	7.3e-34	2.88e-26	0.92	0.68	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
SARC	trans	rs7949030	1	rs10897289	ENSG00000186676.3	EEF1GP1	14.33	8.35e-34	3.29e-26	0.88	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62632544	chr7:125033453~125035301:+
SARC	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-14.31	9.69e-34	3.81e-26	-1.04	-0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
SARC	trans	rs941207	0.526	rs2255074	ENSG00000121089.4	NACA3P	-14.29	1.09e-33	4.27e-26	-0.74	-0.68	Platelet count;	chr12:56636242	chr4:164943290~164943937:+
SARC	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	14.28	1.14e-33	4.46e-26	1.27	0.68	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
SARC	trans	rs7554547	0.667	rs4846072	ENSG00000261819.1	RP11-680G24.4	14.28	1.16e-33	4.53e-26	0.81	0.68	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr16:14988259~14990160:-
SARC	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	14.28	1.2e-33	4.69e-26	0.86	0.68	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
SARC	trans	rs13253073	0.55	rs6468697	ENSG00000260318.1	COX6CP1	14.26	1.35e-33	5.28e-26	1.02	0.68	Glucose homeostasis traits;	chr8:99858154	chr16:11903923~11904137:-
SARC	trans	rs9467773	0.549	rs9461273	ENSG00000242375.1	RP11-498P14.3	-14.26	1.4e-33	5.46e-26	-0.84	-0.68	Intelligence (multi-trait analysis);	chr6:26584298	chr9:97195351~97197687:-
SARC	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-14.25	1.48e-33	5.77e-26	-0.88	-0.68	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
SARC	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	14.25	1.49e-33	5.79e-26	0.94	0.68	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
SARC	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	14.24	1.6e-33	6.2e-26	1.04	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
SARC	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-14.2	2.17e-33	8.37e-26	-0.88	-0.68	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
SARC	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	14.2	2.2e-33	8.49e-26	1.27	0.68	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
SARC	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-14.19	2.28e-33	8.78e-26	-1.04	-0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
SARC	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-14.16	2.91e-33	1.11e-25	-0.73	-0.68	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-14.16	3.06e-33	1.17e-25	-0.86	-0.68	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
SARC	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	14.15	3.29e-33	1.25e-25	0.79	0.68	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
SARC	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	14.14	3.34e-33	1.27e-25	0.89	0.68	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	14.13	3.67e-33	1.38e-25	0.83	0.68	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	14.13	3.67e-33	1.38e-25	0.83	0.68	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	14.13	3.67e-33	1.38e-25	0.83	0.68	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	14.13	3.67e-33	1.38e-25	0.83	0.68	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	14.13	3.67e-33	1.38e-25	0.83	0.68	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	14.13	3.67e-33	1.38e-25	0.83	0.68	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	14.13	3.67e-33	1.38e-25	0.83	0.68	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
SARC	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-14.13	3.75e-33	1.41e-25	-0.83	-0.68	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
SARC	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	14.13	3.77e-33	1.41e-25	0.73	0.68	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	14.11	4.37e-33	1.63e-25	0.83	0.68	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	14.11	4.37e-33	1.63e-25	0.83	0.68	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	14.11	4.44e-33	1.66e-25	0.86	0.68	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
SARC	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	14.08	5.63e-33	2.08e-25	0.87	0.68	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
SARC	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-14.07	5.77e-33	2.13e-25	-0.91	-0.68	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
SARC	trans	rs7949030	1	rs2956993	ENSG00000186676.3	EEF1GP1	-14.06	6.18e-33	2.28e-25	-0.87	-0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62638690	chr7:125033453~125035301:+
SARC	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-14.04	7.12e-33	2.62e-25	-1.03	-0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
SARC	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	14.02	8.31e-33	3.04e-25	0.92	0.68	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
SARC	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-14	1e-32	3.64e-25	-0.89	-0.68	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
SARC	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	14	1.01e-32	3.64e-25	0.93	0.68	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
SARC	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	14	1.01e-32	3.64e-25	0.93	0.68	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
SARC	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	14	1.01e-32	3.64e-25	0.93	0.68	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
SARC	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	14	1.01e-32	3.64e-25	0.93	0.68	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
SARC	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	14	1.01e-32	3.64e-25	0.93	0.68	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
SARC	trans	rs9467773	0.62	rs2451738	ENSG00000242375.1	RP11-498P14.3	-13.98	1.14e-32	4.11e-25	-0.83	-0.68	Intelligence (multi-trait analysis);	chr6:26618231	chr9:97195351~97197687:-
SARC	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-13.98	1.2e-32	4.3e-25	-0.84	-0.68	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
SARC	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-13.97	1.29e-32	4.64e-25	-0.9	-0.68	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
SARC	trans	rs61990749	0.597	rs176946	ENSG00000235400.1	RP4-641G12.4	13.95	1.43e-32	5.12e-25	1.09	0.67	Fibroblast growth factor basic levels;	chr14:77712096	chr1:78749073~78750659:+
SARC	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-13.95	1.48e-32	5.28e-25	-0.89	-0.67	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-13.94	1.6e-32	5.63e-25	-0.85	-0.67	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
SARC	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	13.94	1.64e-32	5.78e-25	0.86	0.67	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
SARC	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	13.93	1.76e-32	6.2e-25	0.91	0.67	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
SARC	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	13.88	2.46e-32	8.57e-25	0.92	0.67	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
SARC	trans	rs61990749	0.544	rs7151211	ENSG00000235400.1	RP4-641G12.4	-13.88	2.49e-32	8.66e-25	-1.09	-0.67	Fibroblast growth factor basic levels;	chr14:77685558	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs72685264	ENSG00000235400.1	RP4-641G12.4	-13.88	2.49e-32	8.66e-25	-1.09	-0.67	Fibroblast growth factor basic levels;	chr14:77686655	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs7147516	ENSG00000235400.1	RP4-641G12.4	-13.88	2.49e-32	8.66e-25	-1.09	-0.67	Fibroblast growth factor basic levels;	chr14:77687637	chr1:78749073~78750659:+
SARC	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	13.88	2.51e-32	8.73e-25	0.91	0.67	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
SARC	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-13.87	2.69e-32	9.32e-25	-0.83	-0.67	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-13.87	2.73e-32	9.41e-25	-0.88	-0.67	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-13.87	2.73e-32	9.41e-25	-0.88	-0.67	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-13.87	2.73e-32	9.41e-25	-0.88	-0.67	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
SARC	trans	rs61990749	0.597	rs176943	ENSG00000235400.1	RP4-641G12.4	-13.85	3.07e-32	1.05e-24	-1.1	-0.67	Fibroblast growth factor basic levels;	chr14:77709454	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs7142390	ENSG00000235400.1	RP4-641G12.4	13.85	3.07e-32	1.05e-24	1.1	0.67	Fibroblast growth factor basic levels;	chr14:77766537	chr1:78749073~78750659:+
SARC	trans	rs9611565	0.838	rs4239894	ENSG00000268568.1	AC007228.9	-13.85	3.09e-32	1.06e-24	-0.86	-0.67	Vitiligo;	chr22:41349544	chr19:56672574~56673901:-
SARC	trans	rs61990749	0.597	rs2299930	ENSG00000235400.1	RP4-641G12.4	-13.83	3.69e-32	1.26e-24	-1.08	-0.67	Fibroblast growth factor basic levels;	chr14:77697379	chr1:78749073~78750659:+
SARC	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	13.82	4.07e-32	1.39e-24	0.8	0.67	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	13.8	4.46e-32	1.51e-24	0.82	0.67	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	13.8	4.46e-32	1.51e-24	0.82	0.67	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
SARC	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	13.8	4.77e-32	1.61e-24	0.91	0.67	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
SARC	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-13.8	4.78e-32	1.61e-24	-0.89	-0.67	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
SARC	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	13.79	5.16e-32	1.73e-24	0.87	0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	13.79	5.16e-32	1.73e-24	0.87	0.67	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
SARC	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	13.78	5.56e-32	1.86e-24	0.83	0.67	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
SARC	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-13.76	6.45e-32	2.14e-24	-0.89	-0.67	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-13.75	6.65e-32	2.21e-24	-0.87	-0.67	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
SARC	trans	rs61990749	0.597	rs2112136	ENSG00000235400.1	RP4-641G12.4	13.75	6.74e-32	2.24e-24	1.08	0.67	Fibroblast growth factor basic levels;	chr14:77782609	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs176971	ENSG00000235400.1	RP4-641G12.4	13.74	7.52e-32	2.47e-24	1.09	0.67	Fibroblast growth factor basic levels;	chr14:77725256	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs6574391	ENSG00000235400.1	RP4-641G12.4	13.74	7.52e-32	2.47e-24	1.09	0.67	Fibroblast growth factor basic levels;	chr14:77741778	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs2032781	ENSG00000235400.1	RP4-641G12.4	13.74	7.52e-32	2.47e-24	1.09	0.67	Fibroblast growth factor basic levels;	chr14:77748532	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs3783980	ENSG00000235400.1	RP4-641G12.4	13.74	7.52e-32	2.47e-24	1.09	0.67	Fibroblast growth factor basic levels;	chr14:77753464	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs1477262	ENSG00000235400.1	RP4-641G12.4	13.74	7.52e-32	2.47e-24	1.09	0.67	Fibroblast growth factor basic levels;	chr14:77760310	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.544	rs176962	ENSG00000235400.1	RP4-641G12.4	13.73	8.05e-32	2.62e-24	1.09	0.67	Fibroblast growth factor basic levels;	chr14:77719167	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.544	rs8003979	ENSG00000235400.1	RP4-641G12.4	13.73	8.05e-32	2.62e-24	1.09	0.67	Fibroblast growth factor basic levels;	chr14:77744947	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs8016416	ENSG00000235400.1	RP4-641G12.4	13.73	8.05e-32	2.62e-24	1.09	0.67	Fibroblast growth factor basic levels;	chr14:77746757	chr1:78749073~78750659:+
SARC	trans	rs6732160	0.631	rs7557285	ENSG00000236165.1	PRADC1P1	13.71	9.37e-32	3.04e-24	0.8	0.67	Intelligence (multi-trait analysis);	chr2:73215684	chr3:36976316~36976840:+
SARC	trans	rs6732160	0.657	rs10171459	ENSG00000236165.1	PRADC1P1	13.68	1.12e-31	3.61e-24	0.79	0.67	Intelligence (multi-trait analysis);	chr2:73207600	chr3:36976316~36976840:+
SARC	trans	rs6732160	0.691	rs13432787	ENSG00000236165.1	PRADC1P1	13.67	1.29e-31	4.14e-24	0.79	0.67	Intelligence (multi-trait analysis);	chr2:73203106	chr3:36976316~36976840:+
SARC	trans	rs6732160	0.691	rs7599223	ENSG00000236165.1	PRADC1P1	13.66	1.34e-31	4.3e-24	0.79	0.67	Intelligence (multi-trait analysis);	chr2:73199975	chr3:36976316~36976840:+
SARC	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	13.65	1.42e-31	4.55e-24	0.86	0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	13.65	1.42e-31	4.55e-24	0.86	0.67	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	13.65	1.42e-31	4.55e-24	0.86	0.67	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
SARC	trans	rs61990749	0.597	rs11624101	ENSG00000235400.1	RP4-641G12.4	-13.65	1.45e-31	4.65e-24	-1.08	-0.67	Fibroblast growth factor basic levels;	chr14:77671716	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs8016447	ENSG00000235400.1	RP4-641G12.4	13.64	1.57e-31	5.03e-24	1.06	0.67	Fibroblast growth factor basic levels;	chr14:77755725	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs2267761	ENSG00000235400.1	RP4-641G12.4	-13.63	1.64e-31	5.23e-24	-1.08	-0.67	Fibroblast growth factor basic levels;	chr14:77681506	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs4903643	ENSG00000235400.1	RP4-641G12.4	13.63	1.72e-31	5.47e-24	1.08	0.67	Fibroblast growth factor basic levels;	chr14:77788448	chr1:78749073~78750659:+
SARC	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	13.63	1.72e-31	5.47e-24	0.92	0.67	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
SARC	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-13.62	1.88e-31	5.96e-24	-0.88	-0.67	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
SARC	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	13.61	2.02e-31	6.37e-24	0.86	0.67	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
SARC	trans	rs6732160	0.593	rs2288630	ENSG00000236165.1	PRADC1P1	13.6	2.09e-31	6.58e-24	0.78	0.67	Intelligence (multi-trait analysis);	chr2:73230424	chr3:36976316~36976840:+
SARC	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	13.58	2.48e-31	7.79e-24	0.85	0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	13.58	2.48e-31	7.79e-24	0.85	0.66	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	13.58	2.48e-31	7.79e-24	0.81	0.66	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
SARC	trans	rs61990749	0.597	rs117131659	ENSG00000235400.1	RP4-641G12.4	-13.57	2.58e-31	8.11e-24	-1.09	-0.66	Fibroblast growth factor basic levels;	chr14:77664783	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs1048147	ENSG00000235400.1	RP4-641G12.4	-13.57	2.64e-31	8.28e-24	-1.08	-0.66	Fibroblast growth factor basic levels;	chr14:77673645	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs2267758	ENSG00000235400.1	RP4-641G12.4	-13.57	2.64e-31	8.28e-24	-1.08	-0.66	Fibroblast growth factor basic levels;	chr14:77681086	chr1:78749073~78750659:+
SARC	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-13.57	2.71e-31	8.49e-24	-0.86	-0.66	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
SARC	trans	rs6732160	0.574	rs7557055	ENSG00000236165.1	PRADC1P1	13.54	3.32e-31	1.03e-23	0.77	0.66	Intelligence (multi-trait analysis);	chr2:73245542	chr3:36976316~36976840:+
SARC	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	13.54	3.48e-31	1.08e-23	0.87	0.66	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	13.54	3.48e-31	1.08e-23	0.87	0.66	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	13.54	3.48e-31	1.08e-23	0.87	0.66	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-13.53	3.71e-31	1.15e-23	-0.84	-0.66	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
SARC	trans	rs61990749	0.597	rs59848135	ENSG00000235400.1	RP4-641G12.4	-13.52	3.77e-31	1.17e-23	-1.08	-0.66	Fibroblast growth factor basic levels;	chr14:77662657	chr1:78749073~78750659:+
SARC	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	13.5	4.41e-31	1.36e-23	0.9	0.66	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
SARC	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-13.49	4.98e-31	1.53e-23	-0.84	-0.66	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	13.49	5.01e-31	1.54e-23	0.81	0.66	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-13.47	5.52e-31	1.69e-23	-0.84	-0.66	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-13.47	5.52e-31	1.69e-23	-0.84	-0.66	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-13.47	5.52e-31	1.69e-23	-0.84	-0.66	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
SARC	trans	rs61990749	0.597	rs9788540	ENSG00000235400.1	RP4-641G12.4	-13.47	5.53e-31	1.69e-23	-1.08	-0.66	Fibroblast growth factor basic levels;	chr14:77665829	chr1:78749073~78750659:+
SARC	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	13.46	6.19e-31	1.89e-23	0.94	0.66	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
SARC	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	13.45	6.5e-31	1.97e-23	0.81	0.66	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
SARC	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	13.45	6.5e-31	1.97e-23	0.81	0.66	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	13.45	6.5e-31	1.97e-23	0.81	0.66	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	13.44	7e-31	2.1e-23	0.81	0.66	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	13.44	7e-31	2.1e-23	0.81	0.66	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	13.44	7e-31	2.1e-23	0.81	0.66	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	13.44	7e-31	2.1e-23	0.81	0.66	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	13.44	7e-31	2.1e-23	0.81	0.66	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	13.44	7e-31	2.1e-23	0.81	0.66	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	13.44	7e-31	2.1e-23	0.81	0.66	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	13.44	7e-31	2.1e-23	0.81	0.66	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	13.44	7e-31	2.1e-23	0.81	0.66	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
SARC	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-13.43	7.64e-31	2.28e-23	-0.82	-0.66	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.62	rs1027203	ENSG00000242375.1	RP11-498P14.3	13.43	7.92e-31	2.36e-23	0.84	0.66	Intelligence (multi-trait analysis);	chr6:26639104	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.595	rs2172007	ENSG00000242375.1	RP11-498P14.3	13.43	7.92e-31	2.36e-23	0.84	0.66	Intelligence (multi-trait analysis);	chr6:26639549	chr9:97195351~97197687:-
SARC	trans	rs6732160	0.574	rs12465780	ENSG00000236165.1	PRADC1P1	-13.43	8.01e-31	2.38e-23	-0.78	-0.66	Intelligence (multi-trait analysis);	chr2:73244884	chr3:36976316~36976840:+
SARC	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	13.4	9.89e-31	2.92e-23	0.84	0.66	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-13.36	1.33e-30	3.88e-23	-0.83	-0.66	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-13.35	1.44e-30	4.18e-23	-0.85	-0.66	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	13.31	1.89e-30	5.46e-23	0.84	0.66	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	13.31	1.89e-30	5.46e-23	0.84	0.66	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-13.3	2.04e-30	5.88e-23	-0.85	-0.66	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
SARC	trans	rs61990749	0.544	rs11628888	ENSG00000235400.1	RP4-641G12.4	-13.3	2.05e-30	5.89e-23	-1.06	-0.66	Fibroblast growth factor basic levels;	chr14:77695163	chr1:78749073~78750659:+
SARC	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	13.29	2.25e-30	6.43e-23	0.81	0.66	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
SARC	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-13.29	2.26e-30	6.46e-23	-0.81	-0.66	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-13.29	2.26e-30	6.46e-23	-0.81	-0.66	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
SARC	trans	rs3749237	0.576	rs4241406	ENSG00000197582.5	GPX1P1	13.29	2.3e-30	6.57e-23	0.81	0.66	Resting heart rate;	chr3:49562993	chrX:13378735~13379340:-
SARC	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-13.28	2.4e-30	6.84e-23	-0.84	-0.66	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
SARC	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	13.27	2.55e-30	7.25e-23	0.82	0.66	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
SARC	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	13.27	2.63e-30	7.44e-23	0.85	0.66	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
SARC	trans	rs6732160	0.574	rs1991612	ENSG00000236165.1	PRADC1P1	13.26	2.81e-30	7.92e-23	0.76	0.66	Intelligence (multi-trait analysis);	chr2:73253373	chr3:36976316~36976840:+
SARC	trans	rs6732160	0.549	rs6744529	ENSG00000236165.1	PRADC1P1	13.26	2.81e-30	7.92e-23	0.76	0.66	Intelligence (multi-trait analysis);	chr2:73253741	chr3:36976316~36976840:+
SARC	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	13.26	2.86e-30	8.05e-23	0.84	0.66	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
SARC	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	13.25	3e-30	8.43e-23	0.81	0.66	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	13.24	3.22e-30	8.99e-23	0.81	0.66	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	13.24	3.22e-30	8.99e-23	0.81	0.66	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	13.24	3.22e-30	8.99e-23	0.81	0.66	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	13.24	3.22e-30	8.99e-23	0.81	0.66	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	13.22	3.85e-30	1.07e-22	0.81	0.65	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	13.22	3.85e-30	1.07e-22	0.81	0.65	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
SARC	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	13.22	3.91e-30	1.09e-22	0.84	0.65	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
SARC	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	13.2	4.42e-30	1.22e-22	0.89	0.65	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
SARC	trans	rs9467773	0.595	rs12525810	ENSG00000242375.1	RP11-498P14.3	13.19	4.72e-30	1.3e-22	0.83	0.65	Intelligence (multi-trait analysis);	chr6:26623283	chr9:97195351~97197687:-
SARC	trans	rs2950393	0.804	rs7295862	ENSG00000121089.4	NACA3P	-13.19	4.82e-30	1.33e-22	-0.72	-0.65	Platelet distribution width;	chr12:56775374	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-13.19	4.87e-30	1.34e-22	-0.82	-0.65	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-13.19	4.87e-30	1.34e-22	-0.82	-0.65	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-13.19	4.87e-30	1.34e-22	-0.82	-0.65	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-13.19	4.87e-30	1.34e-22	-0.82	-0.65	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
SARC	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	13.18	5.1e-30	1.4e-22	0.81	0.65	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	13.18	5.1e-30	1.4e-22	0.81	0.65	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	13.18	5.1e-30	1.4e-22	0.81	0.65	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
SARC	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-13.18	5.31e-30	1.45e-22	-0.81	-0.65	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-13.18	5.31e-30	1.45e-22	-0.81	-0.65	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-13.17	5.51e-30	1.51e-22	-0.84	-0.65	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
SARC	trans	rs13177918	0.501	rs2545345	ENSG00000239528.1	RPS14P8	13.16	5.96e-30	1.62e-22	0.89	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464080	chr5:116562562~116562930:+
SARC	trans	rs61990749	0.597	rs6574402	ENSG00000235400.1	RP4-641G12.4	13.16	6.26e-30	1.7e-22	1.05	0.65	Fibroblast growth factor basic levels;	chr14:77801607	chr1:78749073~78750659:+
SARC	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-13.15	6.37e-30	1.73e-22	-0.85	-0.65	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
SARC	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	13.14	6.9e-30	1.87e-22	0.81	0.65	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
SARC	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	13.13	7.53e-30	2.03e-22	0.83	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
SARC	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	13.13	7.55e-30	2.03e-22	0.81	0.65	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
SARC	trans	rs7949030	0.754	rs36104523	ENSG00000186676.3	EEF1GP1	-13.13	7.86e-30	2.11e-22	-0.83	-0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62628268	chr7:125033453~125035301:+
SARC	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-13.11	8.68e-30	2.33e-22	-0.79	-0.65	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
SARC	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	13.1	9.18e-30	2.45e-22	0.7	0.65	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
SARC	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	13.06	1.27e-29	3.34e-22	0.81	0.65	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	13.06	1.33e-29	3.5e-22	0.8	0.65	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
SARC	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-13	1.96e-29	5.12e-22	-0.78	-0.65	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-13	1.96e-29	5.12e-22	-0.78	-0.65	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
SARC	trans	rs13253073	0.545	rs35769167	ENSG00000260318.1	COX6CP1	13	2.11e-29	5.47e-22	1.24	0.65	Glucose homeostasis traits;	chr8:99872095	chr16:11903923~11904137:-
SARC	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-12.97	2.56e-29	6.6e-22	-0.8	-0.65	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-12.97	2.59e-29	6.68e-22	-0.85	-0.65	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
SARC	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-12.96	2.65e-29	6.82e-22	-0.78	-0.65	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
SARC	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	12.93	3.47e-29	8.83e-22	0.84	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
SARC	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	12.92	3.84e-29	9.75e-22	0.81	0.65	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
SARC	trans	rs9611565	0.921	rs6002333	ENSG00000268568.1	AC007228.9	-12.91	3.9e-29	9.91e-22	-0.8	-0.65	Vitiligo;	chr22:41323465	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.726	rs10459246	ENSG00000121089.4	NACA3P	-12.9	4.3e-29	1.08e-21	-0.7	-0.65	Platelet distribution width;	chr12:56776034	chr4:164943290~164943937:+
SARC	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	12.89	4.6e-29	1.16e-21	0.87	0.65	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
SARC	trans	rs6732160	0.691	rs6728147	ENSG00000236165.1	PRADC1P1	-12.87	5.53e-29	1.39e-21	-0.76	-0.64	Intelligence (multi-trait analysis);	chr2:73196362	chr3:36976316~36976840:+
SARC	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	12.86	6.03e-29	1.51e-21	0.76	0.64	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
SARC	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	12.84	6.59e-29	1.65e-21	0.69	0.64	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-12.83	7.1e-29	1.77e-21	-0.8	-0.64	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
SARC	trans	rs13177918	0.626	rs2748240	ENSG00000213058.3	RP4-765C7.2	12.83	7.3e-29	1.82e-21	0.86	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:178411616~178411972:+
SARC	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-12.83	7.33e-29	1.82e-21	-0.69	-0.64	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.921	rs3927	ENSG00000268568.1	AC007228.9	-12.82	8e-29	1.99e-21	-0.8	-0.64	Vitiligo;	chr22:41326860	chr19:56672574~56673901:-
SARC	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	12.79	9.74e-29	2.42e-21	0.81	0.64	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	12.79	1.02e-28	2.51e-21	0.81	0.64	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	12.79	1.02e-28	2.51e-21	0.81	0.64	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	12.79	1.02e-28	2.51e-21	0.81	0.64	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	12.79	1.02e-28	2.51e-21	0.81	0.64	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	12.79	1.02e-28	2.51e-21	0.81	0.64	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
SARC	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-12.79	1.02e-28	2.51e-21	-0.81	-0.64	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.534	rs34453863	ENSG00000242375.1	RP11-498P14.3	12.77	1.15e-28	2.81e-21	0.82	0.64	Intelligence (multi-trait analysis);	chr6:26627777	chr9:97195351~97197687:-
SARC	trans	rs9611565	0.877	rs3817999	ENSG00000268568.1	AC007228.9	12.76	1.26e-28	3.09e-21	0.75	0.64	Vitiligo;	chr22:41351713	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.559	rs1006407	ENSG00000268568.1	AC007228.9	-12.76	1.29e-28	3.16e-21	-0.89	-0.64	Vitiligo;	chr22:41576028	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.595	rs13207371	ENSG00000242375.1	RP11-498P14.3	12.74	1.42e-28	3.47e-21	0.83	0.64	Intelligence (multi-trait analysis);	chr6:26590846	chr9:97195351~97197687:-
SARC	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-12.73	1.56e-28	3.76e-21	-0.77	-0.64	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-12.73	1.56e-28	3.76e-21	-0.77	-0.64	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
SARC	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-12.73	1.56e-28	3.76e-21	-0.77	-0.64	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-12.73	1.56e-28	3.76e-21	-0.77	-0.64	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-12.73	1.56e-28	3.76e-21	-0.77	-0.64	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-12.73	1.56e-28	3.76e-21	-0.77	-0.64	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
SARC	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-12.72	1.65e-28	3.99e-21	-0.74	-0.64	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
SARC	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-12.69	2.14e-28	5.11e-21	-0.77	-0.64	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	12.67	2.47e-28	5.86e-21	0.82	0.64	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
SARC	trans	rs61990749	0.597	rs10142722	ENSG00000235400.1	RP4-641G12.4	12.64	3.15e-28	7.4e-21	0.97	0.64	Fibroblast growth factor basic levels;	chr14:77809206	chr1:78749073~78750659:+
SARC	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-12.61	3.76e-28	8.74e-21	-0.77	-0.64	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
SARC	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-12.61	3.76e-28	8.74e-21	-0.77	-0.64	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
SARC	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	12.59	4.56e-28	1.05e-20	0.79	0.64	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
SARC	trans	rs916888	0.773	rs199447	ENSG00000264070.1	DND1P1	12.55	6.08e-28	1.4e-20	0.93	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45585871~45586929:+
SARC	trans	rs13177918	0.626	rs2748240	ENSG00000239528.1	RPS14P8	12.53	6.89e-28	1.57e-20	0.85	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr5:116562562~116562930:+
SARC	trans	rs9899728	0.665	rs2307008	ENSG00000234925.2	ATP5HP4	12.51	7.94e-28	1.81e-20	1.03	0.63	Alzheimer's disease or small vessel stroke;	chr17:75046587	chr12:68642519~68642993:-
SARC	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-12.51	8.4e-28	1.91e-20	-0.77	-0.63	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
SARC	trans	rs9611565	0.918	rs2281333	ENSG00000268568.1	AC007228.9	-12.49	9.63e-28	2.18e-20	-0.77	-0.63	Vitiligo;	chr22:41353626	chr19:56672574~56673901:-
SARC	trans	rs916888	0.773	rs169201	ENSG00000264070.1	DND1P1	12.47	1.08e-27	2.43e-20	0.94	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45585871~45586929:+
SARC	trans	rs9611565	0.802	rs132916	ENSG00000268568.1	AC007228.9	12.46	1.19e-27	2.67e-20	0.75	0.63	Vitiligo;	chr22:41410764	chr19:56672574~56673901:-
SARC	trans	rs9899728	0.764	rs7219493	ENSG00000234925.2	ATP5HP4	12.45	1.26e-27	2.83e-20	1.03	0.63	Alzheimer's disease or small vessel stroke;	chr17:75048093	chr12:68642519~68642993:-
SARC	trans	rs916888	0.773	rs199534	ENSG00000264070.1	DND1P1	12.43	1.48e-27	3.3e-20	0.94	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45585871~45586929:+
SARC	trans	rs13177918	0.603	rs2748241	ENSG00000239528.1	RPS14P8	12.43	1.54e-27	3.43e-20	0.82	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr5:116562562~116562930:+
SARC	trans	rs6477998	0.934	rs4979223	ENSG00000238072.1	RP11-305M3.2	12.41	1.69e-27	3.75e-20	0.79	0.63	Hematology traits;	chr9:113219836	chr7:129410113~129410370:-
SARC	trans	rs916888	0.773	rs199448	ENSG00000264070.1	DND1P1	12.4	1.89e-27	4.2e-20	0.91	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45585871~45586929:+
SARC	trans	rs916888	0.773	rs1378358	ENSG00000264070.1	DND1P1	12.4	1.94e-27	4.29e-20	0.94	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45585871~45586929:+
SARC	trans	rs61990749	0.686	rs11159288	ENSG00000235400.1	RP4-641G12.4	12.39	2.02e-27	4.46e-20	1	0.63	Fibroblast growth factor basic levels;	chr14:77750629	chr1:78749073~78750659:+
SARC	trans	rs9467773	0.523	rs2498399	ENSG00000242375.1	RP11-498P14.3	12.37	2.34e-27	5.13e-20	0.8	0.63	Intelligence (multi-trait analysis);	chr6:26795343	chr9:97195351~97197687:-
SARC	trans	rs61990749	0.597	rs176955	ENSG00000235400.1	RP4-641G12.4	12.37	2.44e-27	5.36e-20	0.98	0.63	Fibroblast growth factor basic levels;	chr14:77714877	chr1:78749073~78750659:+
SARC	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-12.35	2.81e-27	6.13e-20	-0.78	-0.63	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
SARC	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-12.34	2.86e-27	6.24e-20	-0.73	-0.63	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
SARC	trans	rs61990749	0.597	rs1477260	ENSG00000235400.1	RP4-641G12.4	12.34	3e-27	6.51e-20	0.99	0.63	Fibroblast growth factor basic levels;	chr14:77790475	chr1:78749073~78750659:+
SARC	trans	rs13253073	1	rs13252579	ENSG00000260318.1	COX6CP1	12.33	3.26e-27	7.06e-20	1.2	0.63	Glucose homeostasis traits;	chr8:99885073	chr16:11903923~11904137:-
SARC	trans	rs9899728	0.764	rs9660	ENSG00000234925.2	ATP5HP4	12.29	4.27e-27	9.2e-20	1.04	0.63	Alzheimer's disease or small vessel stroke;	chr17:75042651	chr12:68642519~68642993:-
SARC	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-12.28	4.71e-27	1.01e-19	-0.86	-0.63	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
SARC	trans	rs13253073	1	rs13259066	ENSG00000260318.1	COX6CP1	12.28	4.79e-27	1.03e-19	1.19	0.63	Glucose homeostasis traits;	chr8:99889455	chr16:11903923~11904137:-
SARC	trans	rs61990749	0.597	rs10148373	ENSG00000235400.1	RP4-641G12.4	12.27	4.97e-27	1.06e-19	1.06	0.63	Fibroblast growth factor basic levels;	chr14:77813856	chr1:78749073~78750659:+
SARC	trans	rs916888	0.687	rs199456	ENSG00000264070.1	DND1P1	12.26	5.28e-27	1.13e-19	0.93	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45585871~45586929:+
SARC	trans	rs13177918	0.626	rs2748240	ENSG00000224114.1	RP11-343H5.4	12.25	5.88e-27	1.25e-19	0.83	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:206695837~206696269:-
SARC	trans	rs916888	0.773	rs199457	ENSG00000264070.1	DND1P1	12.25	5.95e-27	1.26e-19	0.93	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45585871~45586929:+
SARC	trans	rs13177918	0.603	rs2748241	ENSG00000224114.1	RP11-343H5.4	12.23	6.87e-27	1.46e-19	0.81	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:206695837~206696269:-
SARC	trans	rs61990749	0.597	rs1008988	ENSG00000235400.1	RP4-641G12.4	12.22	7.37e-27	1.56e-19	0.98	0.62	Fibroblast growth factor basic levels;	chr14:77794452	chr1:78749073~78750659:+
SARC	trans	rs13253073	1	rs34029308	ENSG00000260318.1	COX6CP1	12.22	7.52e-27	1.59e-19	1.2	0.62	Glucose homeostasis traits;	chr8:99892425	chr16:11903923~11904137:-
SARC	trans	rs9467773	0.572	rs62394558	ENSG00000242375.1	RP11-498P14.3	12.21	8.08e-27	1.7e-19	0.81	0.62	Intelligence (multi-trait analysis);	chr6:26604422	chr9:97195351~97197687:-
SARC	trans	rs13177918	0.603	rs2343806	ENSG00000239528.1	RPS14P8	12.2	8.45e-27	1.77e-19	0.82	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr5:116562562~116562930:+
SARC	trans	rs9611565	0.921	rs761366	ENSG00000268568.1	AC007228.9	-12.19	8.98e-27	1.88e-19	-0.79	-0.62	Vitiligo;	chr22:41348018	chr19:56672574~56673901:-
SARC	trans	rs916888	0.773	rs199451	ENSG00000264070.1	DND1P1	12.18	9.49e-27	1.99e-19	0.91	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45585871~45586929:+
SARC	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-12.17	1.09e-26	2.28e-19	-0.7	-0.62	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
SARC	trans	rs13177918	0.603	rs2343806	ENSG00000213058.3	RP4-765C7.2	12.16	1.12e-26	2.33e-19	0.83	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:178411616~178411972:+
SARC	trans	rs13177918	0.501	rs2545345	ENSG00000213058.3	RP4-765C7.2	12.13	1.38e-26	2.85e-19	0.85	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464080	chr1:178411616~178411972:+
SARC	trans	rs916888	0.773	rs199533	ENSG00000264070.1	DND1P1	12.13	1.42e-26	2.92e-19	0.92	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45585871~45586929:+
SARC	trans	rs916888	0.773	rs199445	ENSG00000264070.1	DND1P1	12.13	1.42e-26	2.93e-19	0.88	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45585871~45586929:+
SARC	trans	rs916888	0.773	rs199443	ENSG00000264070.1	DND1P1	12.13	1.42e-26	2.93e-19	0.88	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45585871~45586929:+
SARC	trans	rs13177918	0.501	rs2545345	ENSG00000224114.1	RP11-343H5.4	12.12	1.49e-26	3.07e-19	0.85	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464080	chr1:206695837~206696269:-
SARC	trans	rs6477998	0.903	rs7041615	ENSG00000238072.1	RP11-305M3.2	12.12	1.53e-26	3.15e-19	0.78	0.62	Hematology traits;	chr9:113244747	chr7:129410113~129410370:-
SARC	trans	rs61990749	0.597	rs10136053	ENSG00000235400.1	RP4-641G12.4	-12.1	1.78e-26	3.63e-19	-0.96	-0.62	Fibroblast growth factor basic levels;	chr14:77688862	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.544	rs2544566	ENSG00000235400.1	RP4-641G12.4	12.06	2.4e-26	4.81e-19	0.97	0.62	Fibroblast growth factor basic levels;	chr14:77715395	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.544	rs2544567	ENSG00000235400.1	RP4-641G12.4	12.06	2.4e-26	4.81e-19	0.97	0.62	Fibroblast growth factor basic levels;	chr14:77715396	chr1:78749073~78750659:+
SARC	trans	rs6477998	0.874	rs10739390	ENSG00000238072.1	RP11-305M3.2	12.02	3.24e-26	6.48e-19	0.78	0.62	Hematology traits;	chr9:113226209	chr7:129410113~129410370:-
SARC	trans	rs916888	0.773	rs538628	ENSG00000264070.1	DND1P1	12	3.89e-26	7.73e-19	0.89	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45585871~45586929:+
SARC	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-12	3.91e-26	7.77e-19	-0.82	-0.62	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
SARC	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-11.99	4.17e-26	8.26e-19	-0.81	-0.62	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
SARC	trans	rs61990749	0.597	rs8003691	ENSG00000235400.1	RP4-641G12.4	11.98	4.37e-26	8.57e-19	0.99	0.62	Fibroblast growth factor basic levels;	chr14:77744882	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs2267768	ENSG00000235400.1	RP4-641G12.4	11.98	4.37e-26	8.57e-19	0.99	0.62	Fibroblast growth factor basic levels;	chr14:77749671	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs1549119	ENSG00000235400.1	RP4-641G12.4	11.98	4.37e-26	8.57e-19	0.99	0.62	Fibroblast growth factor basic levels;	chr14:77753469	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs1978416	ENSG00000235400.1	RP4-641G12.4	11.98	4.37e-26	8.57e-19	0.99	0.62	Fibroblast growth factor basic levels;	chr14:77761558	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.544	rs3759728	ENSG00000235400.1	RP4-641G12.4	11.98	4.37e-26	8.57e-19	0.99	0.62	Fibroblast growth factor basic levels;	chr14:77763816	chr1:78749073~78750659:+
SARC	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-11.97	4.57e-26	8.96e-19	-0.84	-0.62	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.572	rs13213953	ENSG00000242375.1	RP11-498P14.3	11.97	4.59e-26	8.98e-19	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26594306	chr9:97195351~97197687:-
SARC	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	11.96	5.13e-26	1e-18	0.74	0.62	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
SARC	trans	rs13253073	1	rs4409375	ENSG00000260318.1	COX6CP1	11.95	5.28e-26	1.03e-18	1.16	0.62	Glucose homeostasis traits;	chr8:99877759	chr16:11903923~11904137:-
SARC	trans	rs13253073	1	rs4480092	ENSG00000260318.1	COX6CP1	11.94	5.81e-26	1.13e-18	1.18	0.62	Glucose homeostasis traits;	chr8:99873372	chr16:11903923~11904137:-
SARC	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	11.94	5.96e-26	1.16e-18	0.82	0.62	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
SARC	trans	rs61990749	0.597	rs2364584	ENSG00000235400.1	RP4-641G12.4	-11.94	6e-26	1.16e-18	-0.96	-0.62	Fibroblast growth factor basic levels;	chr14:77685943	chr1:78749073~78750659:+
SARC	trans	rs13253073	1	rs12544943	ENSG00000260318.1	COX6CP1	11.93	6.31e-26	1.23e-18	1.2	0.62	Glucose homeostasis traits;	chr8:99891662	chr16:11903923~11904137:-
SARC	trans	rs916888	0.773	rs199439	ENSG00000264070.1	DND1P1	11.93	6.58e-26	1.27e-18	0.89	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45585871~45586929:+
SARC	trans	rs61990749	0.544	rs176979	ENSG00000235400.1	RP4-641G12.4	11.93	6.6e-26	1.28e-18	0.98	0.62	Fibroblast growth factor basic levels;	chr14:77731729	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs12887282	ENSG00000235400.1	RP4-641G12.4	11.93	6.6e-26	1.28e-18	0.98	0.62	Fibroblast growth factor basic levels;	chr14:77734242	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs12887606	ENSG00000235400.1	RP4-641G12.4	11.93	6.6e-26	1.28e-18	0.98	0.62	Fibroblast growth factor basic levels;	chr14:77734277	chr1:78749073~78750659:+
SARC	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-11.92	7.03e-26	1.36e-18	-0.76	-0.62	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
SARC	trans	rs61990749	0.597	rs28534379	ENSG00000235400.1	RP4-641G12.4	-11.91	7.23e-26	1.4e-18	-0.96	-0.62	Fibroblast growth factor basic levels;	chr14:77705797	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs176944	ENSG00000235400.1	RP4-641G12.4	-11.91	7.23e-26	1.4e-18	-0.96	-0.62	Fibroblast growth factor basic levels;	chr14:77709868	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs176952	ENSG00000235400.1	RP4-641G12.4	11.91	7.23e-26	1.4e-18	0.96	0.62	Fibroblast growth factor basic levels;	chr14:77714393	chr1:78749073~78750659:+
SARC	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-11.88	9.23e-26	1.77e-18	-0.7	-0.61	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
SARC	trans	rs13253073	1	rs13253073	ENSG00000260318.1	COX6CP1	11.87	9.75e-26	1.87e-18	1.18	0.61	Glucose homeostasis traits;	chr8:99885155	chr16:11903923~11904137:-
SARC	trans	rs916888	0.773	rs199535	ENSG00000264070.1	DND1P1	11.84	1.26e-25	2.4e-18	0.88	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45585871~45586929:+
SARC	trans	rs61990749	0.597	rs4632066	ENSG00000235400.1	RP4-641G12.4	-11.84	1.28e-25	2.42e-18	-0.92	-0.61	Fibroblast growth factor basic levels;	chr14:77780939	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs13379065	ENSG00000235400.1	RP4-641G12.4	-11.82	1.42e-25	2.65e-18	-0.95	-0.61	Fibroblast growth factor basic levels;	chr14:77674952	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs17106157	ENSG00000235400.1	RP4-641G12.4	-11.82	1.42e-25	2.65e-18	-0.95	-0.61	Fibroblast growth factor basic levels;	chr14:77680535	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs2267759	ENSG00000235400.1	RP4-641G12.4	-11.82	1.42e-25	2.65e-18	-0.95	-0.61	Fibroblast growth factor basic levels;	chr14:77681272	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.597	rs11623088	ENSG00000235400.1	RP4-641G12.4	-11.81	1.56e-25	2.87e-18	-0.95	-0.61	Fibroblast growth factor basic levels;	chr14:77671392	chr1:78749073~78750659:+
SARC	trans	rs13177918	0.734	rs6579791	ENSG00000224114.1	RP11-343H5.4	11.81	1.59e-25	2.93e-18	0.86	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:206695837~206696269:-
SARC	trans	rs6477998	0.9	rs7850357	ENSG00000238072.1	RP11-305M3.2	11.8	1.65e-25	3.04e-18	0.78	0.61	Hematology traits;	chr9:113222319	chr7:129410113~129410370:-
SARC	trans	rs916888	0.779	rs199528	ENSG00000264070.1	DND1P1	11.8	1.66e-25	3.06e-18	0.9	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45585871~45586929:+
SARC	trans	rs916888	0.821	rs199525	ENSG00000264070.1	DND1P1	11.8	1.66e-25	3.06e-18	0.9	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45585871~45586929:+
SARC	trans	rs61990749	0.597	rs9323650	ENSG00000235400.1	RP4-641G12.4	11.77	2.13e-25	3.89e-18	0.92	0.61	Fibroblast growth factor basic levels;	chr14:77683993	chr1:78749073~78750659:+
SARC	trans	rs6732160	0.691	rs10197935	ENSG00000236165.1	PRADC1P1	11.76	2.2e-25	4.01e-18	0.71	0.61	Intelligence (multi-trait analysis);	chr2:73185234	chr3:36976316~36976840:+
SARC	trans	rs9611565	0.592	rs12484467	ENSG00000268568.1	AC007228.9	-11.74	2.7e-25	4.9e-18	-0.81	-0.61	Vitiligo;	chr22:41561606	chr19:56672574~56673901:-
SARC	trans	rs9611519	0.78	rs9611542	ENSG00000268568.1	AC007228.9	-11.73	2.89e-25	5.22e-18	-0.73	-0.61	Neuroticism;	chr22:41281313	chr19:56672574~56673901:-
SARC	trans	rs13177918	0.734	rs6579791	ENSG00000239528.1	RPS14P8	11.69	3.67e-25	6.52e-18	0.86	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr5:116562562~116562930:+
SARC	trans	rs13177918	0.603	rs2343806	ENSG00000224114.1	RP11-343H5.4	11.68	4.03e-25	7.12e-18	0.8	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:206695837~206696269:-
SARC	trans	rs6477998	0.868	rs10513189	ENSG00000238072.1	RP11-305M3.2	11.68	4.2e-25	7.4e-18	0.75	0.61	Hematology traits;	chr9:113227941	chr7:129410113~129410370:-
SARC	trans	rs10242455	0.557	rs59672032	ENSG00000228834.1	RP11-249L21.4	11.64	5.61e-25	9.74e-18	1.68	0.61	Blood metabolite levels;	chr7:99461074	chr6:108907615~108907873:-
SARC	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-11.63	6.04e-25	1.05e-17	-0.73	-0.61	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
SARC	trans	rs6477998	0.903	rs4979226	ENSG00000238072.1	RP11-305M3.2	11.63	6.06e-25	1.05e-17	0.76	0.61	Hematology traits;	chr9:113239516	chr7:129410113~129410370:-
SARC	trans	rs61990749	0.5	rs8011337	ENSG00000235400.1	RP4-641G12.4	11.61	6.97e-25	1.2e-17	0.93	0.61	Fibroblast growth factor basic levels;	chr14:77806283	chr1:78749073~78750659:+
SARC	trans	rs6732160	0.619	rs12105975	ENSG00000236165.1	PRADC1P1	11.61	7.11e-25	1.23e-17	0.72	0.61	Intelligence (multi-trait analysis);	chr2:73178921	chr3:36976316~36976840:+
SARC	trans	rs61990749	0.597	rs759808	ENSG00000235400.1	RP4-641G12.4	11.59	7.78e-25	1.34e-17	0.93	0.6	Fibroblast growth factor basic levels;	chr14:77784502	chr1:78749073~78750659:+
SARC	trans	rs9611519	0.754	rs4820435	ENSG00000268568.1	AC007228.9	-11.58	8.85e-25	1.52e-17	-0.75	-0.6	Neuroticism;	chr22:41256842	chr19:56672574~56673901:-
SARC	trans	rs13253073	1	rs13273257	ENSG00000260318.1	COX6CP1	11.54	1.18e-24	2e-17	1.16	0.6	Glucose homeostasis traits;	chr8:99852468	chr16:11903923~11904137:-
SARC	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-11.54	1.19e-24	2.02e-17	-0.87	-0.6	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
SARC	trans	rs13177918	0.734	rs6579790	ENSG00000239528.1	RPS14P8	11.53	1.28e-24	2.17e-17	0.85	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr5:116562562~116562930:+
SARC	trans	rs61990749	0.597	rs717683	ENSG00000235400.1	RP4-641G12.4	11.52	1.39e-24	2.34e-17	0.92	0.6	Fibroblast growth factor basic levels;	chr14:77789110	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.544	rs1477259	ENSG00000235400.1	RP4-641G12.4	11.52	1.39e-24	2.34e-17	0.92	0.6	Fibroblast growth factor basic levels;	chr14:77789795	chr1:78749073~78750659:+
SARC	trans	rs13253073	0.941	rs4076509	ENSG00000260318.1	COX6CP1	11.5	1.53e-24	2.55e-17	1.18	0.6	Glucose homeostasis traits;	chr8:99842928	chr16:11903923~11904137:-
SARC	trans	rs916888	0.821	rs70600	ENSG00000264070.1	DND1P1	11.5	1.57e-24	2.61e-17	0.86	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45585871~45586929:+
SARC	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-11.47	1.89e-24	3.13e-17	-0.78	-0.6	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
SARC	trans	rs8081395	0.741	rs180519	ENSG00000187870.7	RNFT1P3	11.46	2.08e-24	3.43e-17	0.7	0.6	White blood cell count;	chr17:59938910	chr17:20743333~20754501:-
SARC	trans	rs8081395	0.711	rs11368	ENSG00000187870.7	RNFT1P3	11.44	2.47e-24	4.06e-17	0.7	0.6	White blood cell count;	chr17:59954051	chr17:20743333~20754501:-
SARC	trans	rs61990749	0.597	rs12896026	ENSG00000235400.1	RP4-641G12.4	11.4	3.28e-24	5.33e-17	0.93	0.6	Fibroblast growth factor basic levels;	chr14:77778093	chr1:78749073~78750659:+
SARC	trans	rs61990749	0.544	rs12435761	ENSG00000235400.1	RP4-641G12.4	11.4	3.28e-24	5.33e-17	0.93	0.6	Fibroblast growth factor basic levels;	chr14:77779734	chr1:78749073~78750659:+
SARC	trans	rs13253073	0.941	rs13264726	ENSG00000260318.1	COX6CP1	11.39	3.46e-24	5.62e-17	1.16	0.6	Glucose homeostasis traits;	chr8:99851139	chr16:11903923~11904137:-
SARC	trans	rs13177918	0.734	rs6579790	ENSG00000224114.1	RP11-343H5.4	11.38	3.69e-24	5.98e-17	0.84	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:206695837~206696269:-
SARC	trans	rs61990749	0.597	rs176980	ENSG00000235400.1	RP4-641G12.4	-11.37	4.03e-24	6.52e-17	-0.92	-0.6	Fibroblast growth factor basic levels;	chr14:77732106	chr1:78749073~78750659:+
SARC	trans	rs7121616	0.531	rs10892958	ENSG00000234176.1	HSPA8P1	11.36	4.41e-24	7.12e-17	0.86	0.6	Breast cancer;	chr11:123061415	chrX:121203182~121205014:-
SARC	trans	rs7121616	0.531	rs11218941	ENSG00000234176.1	HSPA8P1	11.36	4.41e-24	7.12e-17	0.86	0.6	Breast cancer;	chr11:123061701	chrX:121203182~121205014:-
SARC	trans	rs13253073	1	rs10955222	ENSG00000260318.1	COX6CP1	-11.36	4.5e-24	7.26e-17	-1.13	-0.6	Glucose homeostasis traits;	chr8:99875122	chr16:11903923~11904137:-
SARC	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	11.35	4.64e-24	7.48e-17	0.63	0.6	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
SARC	trans	rs1816752	0.646	rs2862905	ENSG00000237917.1	PARP4P1	-11.34	5.11e-24	8.23e-17	-0.68	-0.6	Obesity-related traits;	chr13:24485142	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-11.33	5.31e-24	8.55e-17	-0.68	-0.6	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
SARC	trans	rs9611519	0.78	rs9611546	ENSG00000268568.1	AC007228.9	-11.33	5.44e-24	8.74e-17	-0.74	-0.6	Neuroticism;	chr22:41302538	chr19:56672574~56673901:-
SARC	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-11.31	6.11e-24	9.78e-17	-0.66	-0.6	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
SARC	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	11.29	7.12e-24	1.13e-16	0.78	0.59	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
SARC	trans	rs13253073	1	rs35935983	ENSG00000260318.1	COX6CP1	11.27	8.18e-24	1.29e-16	1.09	0.59	Glucose homeostasis traits;	chr8:99888966	chr16:11903923~11904137:-
SARC	trans	rs8081395	0.737	rs4968401	ENSG00000187870.7	RNFT1P3	-11.25	9.46e-24	1.49e-16	-0.7	-0.59	White blood cell count;	chr17:59963369	chr17:20743333~20754501:-
SARC	trans	rs1816752	0.716	rs7995304	ENSG00000237917.1	PARP4P1	-11.25	9.7e-24	1.52e-16	-0.68	-0.59	Obesity-related traits;	chr13:24514284	chrY:26594851~26634652:-
SARC	trans	rs6477998	0.966	rs10759637	ENSG00000238072.1	RP11-305M3.2	11.24	1.03e-23	1.62e-16	0.75	0.59	Hematology traits;	chr9:113262744	chr7:129410113~129410370:-
SARC	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-11.24	1.07e-23	1.67e-16	-0.66	-0.59	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
SARC	trans	rs916888	0.773	rs199448	ENSG00000214425.5	LRRC37A4P	-11.23	1.16e-23	1.8e-16	-0.82	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45506741~45550335:-
SARC	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	11.22	1.21e-23	1.89e-16	0.73	0.59	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
SARC	trans	rs916888	0.773	rs199534	ENSG00000214425.5	LRRC37A4P	-11.21	1.27e-23	1.97e-16	-0.84	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45506741~45550335:-
SARC	trans	rs916888	0.773	rs199533	ENSG00000214425.5	LRRC37A4P	-11.19	1.5e-23	2.32e-16	-0.83	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45506741~45550335:-
SARC	trans	rs916888	0.773	rs199457	ENSG00000214425.5	LRRC37A4P	-11.19	1.55e-23	2.4e-16	-0.83	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45506741~45550335:-
SARC	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-11.16	1.91e-23	2.93e-16	-0.66	-0.59	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-11.16	1.94e-23	2.98e-16	-0.66	-0.59	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
SARC	trans	rs61990749	0.597	rs1006039	ENSG00000235400.1	RP4-641G12.4	-11.15	2.03e-23	3.11e-16	-0.97	-0.59	Fibroblast growth factor basic levels;	chr14:77796853	chr1:78749073~78750659:+
SARC	trans	rs13177918	0.717	rs6874318	ENSG00000224114.1	RP11-343H5.4	-11.15	2.08e-23	3.19e-16	-0.82	-0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:206695837~206696269:-
SARC	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-11.14	2.12e-23	3.23e-16	-0.65	-0.59	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-11.14	2.12e-23	3.23e-16	-0.65	-0.59	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-11.14	2.12e-23	3.23e-16	-0.65	-0.59	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-11.14	2.12e-23	3.23e-16	-0.65	-0.59	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-11.14	2.13e-23	3.25e-16	-0.68	-0.59	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
SARC	trans	rs916888	0.773	rs199447	ENSG00000214425.5	LRRC37A4P	-11.14	2.27e-23	3.46e-16	-0.82	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45506741~45550335:-
SARC	trans	rs6477998	0.932	rs4129395	ENSG00000238072.1	RP11-305M3.2	11.13	2.41e-23	3.66e-16	0.75	0.59	Hematology traits;	chr9:113213109	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.966	rs7859354	ENSG00000238072.1	RP11-305M3.2	11.13	2.41e-23	3.66e-16	0.75	0.59	Hematology traits;	chr9:113214165	chr7:129410113~129410370:-
SARC	trans	rs8081395	0.707	rs1024637	ENSG00000187870.7	RNFT1P3	-11.13	2.43e-23	3.68e-16	-0.68	-0.59	White blood cell count;	chr17:59961532	chr17:20743333~20754501:-
SARC	trans	rs9611565	0.921	rs5758297	ENSG00000268568.1	AC007228.9	-11.12	2.47e-23	3.74e-16	-0.69	-0.59	Vitiligo;	chr22:41324693	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.921	rs5751077	ENSG00000268568.1	AC007228.9	-11.12	2.47e-23	3.74e-16	-0.69	-0.59	Vitiligo;	chr22:41324724	chr19:56672574~56673901:-
SARC	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	11.09	3.12e-23	4.69e-16	0.75	0.59	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
SARC	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	11.09	3.15e-23	4.73e-16	0.7	0.59	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
SARC	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	11.09	3.19e-23	4.77e-16	0.75	0.59	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
SARC	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	11.09	3.19e-23	4.77e-16	0.75	0.59	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
SARC	trans	rs6477998	1	rs10739388	ENSG00000238072.1	RP11-305M3.2	11.05	4.36e-23	6.47e-16	0.75	0.59	Hematology traits;	chr9:113214895	chr7:129410113~129410370:-
SARC	trans	rs916888	0.773	rs169201	ENSG00000214425.5	LRRC37A4P	-11.04	4.65e-23	6.87e-16	-0.83	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45506741~45550335:-
SARC	trans	rs8081395	0.741	rs180532	ENSG00000187870.7	RNFT1P3	11.03	4.88e-23	7.18e-16	0.69	0.59	White blood cell count;	chr17:59925936	chr17:20743333~20754501:-
SARC	trans	rs8081395	0.741	rs180530	ENSG00000187870.7	RNFT1P3	11.03	4.88e-23	7.18e-16	0.69	0.59	White blood cell count;	chr17:59926233	chr17:20743333~20754501:-
SARC	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-11.03	5.06e-23	7.44e-16	-0.66	-0.59	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
SARC	trans	rs9611565	0.921	rs4822021	ENSG00000268568.1	AC007228.9	-11.01	5.83e-23	8.54e-16	-0.71	-0.58	Vitiligo;	chr22:41330049	chr19:56672574~56673901:-
SARC	trans	rs13177918	0.717	rs6874318	ENSG00000239528.1	RPS14P8	-11	6.17e-23	9.01e-16	-0.82	-0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr5:116562562~116562930:+
SARC	trans	rs9611565	0.525	rs9611548	ENSG00000268568.1	AC007228.9	-10.97	7.39e-23	1.07e-15	-0.73	-0.58	Vitiligo;	chr22:41308139	chr19:56672574~56673901:-
SARC	trans	rs2950393	0.572	rs10783794	ENSG00000121089.4	NACA3P	-10.96	7.98e-23	1.16e-15	-0.65	-0.58	Platelet distribution width;	chr12:56593395	chr4:164943290~164943937:+
SARC	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-10.96	7.98e-23	1.16e-15	-0.62	-0.58	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
SARC	trans	rs8081395	0.741	rs2645462	ENSG00000187870.7	RNFT1P3	10.96	8.1e-23	1.17e-15	0.68	0.58	White blood cell count;	chr17:59906198	chr17:20743333~20754501:-
SARC	trans	rs8081395	0.711	rs1292034	ENSG00000187870.7	RNFT1P3	10.96	8.1e-23	1.17e-15	0.68	0.58	White blood cell count;	chr17:59912499	chr17:20743333~20754501:-
SARC	trans	rs916888	0.773	rs1378358	ENSG00000214425.5	LRRC37A4P	-10.95	8.64e-23	1.24e-15	-0.83	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45506741~45550335:-
SARC	trans	rs1816752	0.646	rs750389	ENSG00000237917.1	PARP4P1	-10.94	9.19e-23	1.32e-15	-0.66	-0.58	Obesity-related traits;	chr13:24461677	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs2902359	ENSG00000237917.1	PARP4P1	-10.94	9.19e-23	1.32e-15	-0.66	-0.58	Obesity-related traits;	chr13:24461783	chrY:26594851~26634652:-
SARC	trans	rs9467773	1	rs6922824	ENSG00000242375.1	RP11-498P14.3	-10.94	9.46e-23	1.36e-15	-0.72	-0.58	Intelligence (multi-trait analysis);	chr6:26553587	chr9:97195351~97197687:-
SARC	trans	rs13177918	0.734	rs6579791	ENSG00000213058.3	RP4-765C7.2	10.93	1.01e-22	1.45e-15	0.83	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:178411616~178411972:+
SARC	trans	rs6477998	1	rs4560868	ENSG00000238072.1	RP11-305M3.2	-10.91	1.18e-22	1.69e-15	-0.74	-0.58	Hematology traits;	chr9:113223219	chr7:129410113~129410370:-
SARC	trans	rs916888	0.687	rs199456	ENSG00000214425.5	LRRC37A4P	-10.9	1.27e-22	1.81e-15	-0.82	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45506741~45550335:-
SARC	trans	rs1816752	0.646	rs3783073	ENSG00000237917.1	PARP4P1	-10.89	1.41e-22	2e-15	-0.65	-0.58	Obesity-related traits;	chr13:24493222	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-10.88	1.5e-22	2.1e-15	-0.65	-0.58	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
SARC	trans	rs916888	0.773	rs199439	ENSG00000214425.5	LRRC37A4P	-10.87	1.63e-22	2.28e-15	-0.79	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45506741~45550335:-
SARC	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-10.86	1.68e-22	2.34e-15	-0.65	-0.58	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
SARC	trans	rs916888	0.773	rs1378358	ENSG00000204650.12	CRHR1-IT1	10.86	1.69e-22	2.34e-15	0.79	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45620328~45648216:+
SARC	trans	rs916888	0.773	rs199445	ENSG00000214425.5	LRRC37A4P	-10.86	1.7e-22	2.35e-15	-0.78	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45506741~45550335:-
SARC	trans	rs916888	0.773	rs199443	ENSG00000214425.5	LRRC37A4P	-10.86	1.7e-22	2.35e-15	-0.78	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45506741~45550335:-
SARC	trans	rs916888	0.773	rs169201	ENSG00000204650.12	CRHR1-IT1	10.85	1.76e-22	2.45e-15	0.79	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45620328~45648216:+
SARC	trans	rs916888	0.821	rs199506	ENSG00000264070.1	DND1P1	-10.85	1.82e-22	2.52e-15	-0.83	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45585871~45586929:+
SARC	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-10.85	1.86e-22	2.57e-15	-0.65	-0.58	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
SARC	trans	rs916888	0.773	rs199451	ENSG00000214425.5	LRRC37A4P	-10.85	1.87e-22	2.59e-15	-0.8	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45506741~45550335:-
SARC	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-10.83	2.14e-22	2.96e-15	-0.65	-0.58	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
SARC	trans	rs8081395	0.741	rs1292051	ENSG00000187870.7	RNFT1P3	10.82	2.27e-22	3.14e-15	0.67	0.58	White blood cell count;	chr17:59886562	chr17:20743333~20754501:-
SARC	trans	rs916888	0.773	rs199457	ENSG00000204650.12	CRHR1-IT1	10.82	2.28e-22	3.15e-15	0.79	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45620328~45648216:+
SARC	trans	rs916888	0.773	rs9896243	ENSG00000264070.1	DND1P1	10.81	2.42e-22	3.34e-15	0.82	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45585871~45586929:+
SARC	trans	rs916888	0.821	rs199512	ENSG00000264070.1	DND1P1	-10.8	2.57e-22	3.52e-15	-0.81	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45585871~45586929:+
SARC	trans	rs916888	0.821	rs199509	ENSG00000264070.1	DND1P1	-10.8	2.57e-22	3.52e-15	-0.81	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45585871~45586929:+
SARC	trans	rs916888	0.821	rs199507	ENSG00000264070.1	DND1P1	-10.8	2.57e-22	3.52e-15	-0.81	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45585871~45586929:+
SARC	trans	rs916888	0.821	rs415430	ENSG00000264070.1	DND1P1	-10.8	2.57e-22	3.52e-15	-0.81	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45585871~45586929:+
SARC	trans	rs916888	0.779	rs430685	ENSG00000264070.1	DND1P1	-10.8	2.57e-22	3.52e-15	-0.81	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45585871~45586929:+
SARC	trans	rs916888	0.821	rs199505	ENSG00000264070.1	DND1P1	-10.8	2.57e-22	3.52e-15	-0.81	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45585871~45586929:+
SARC	trans	rs916888	0.821	rs70602	ENSG00000264070.1	DND1P1	-10.8	2.57e-22	3.52e-15	-0.81	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45585871~45586929:+
SARC	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-10.8	2.61e-22	3.59e-15	-0.65	-0.58	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-10.8	2.61e-22	3.59e-15	-0.65	-0.58	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-10.8	2.61e-22	3.59e-15	-0.65	-0.58	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
SARC	trans	rs916888	0.697	rs199516	ENSG00000264070.1	DND1P1	-10.78	2.99e-22	4.09e-15	-0.81	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45585871~45586929:+
SARC	trans	rs916888	0.821	rs199514	ENSG00000264070.1	DND1P1	-10.78	2.99e-22	4.09e-15	-0.81	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45585871~45586929:+
SARC	trans	rs1816752	0.646	rs750388	ENSG00000237917.1	PARP4P1	-10.77	3.18e-22	4.35e-15	-0.65	-0.58	Obesity-related traits;	chr13:24461690	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs1361578	ENSG00000237917.1	PARP4P1	-10.77	3.2e-22	4.37e-15	-0.65	-0.58	Obesity-related traits;	chr13:24491117	chrY:26594851~26634652:-
SARC	trans	rs9611565	1	rs5751086	ENSG00000268568.1	AC007228.9	-10.77	3.24e-22	4.43e-15	-0.65	-0.58	Vitiligo;	chr22:41372858	chr19:56672574~56673901:-
SARC	trans	rs1816752	0.716	rs1441058	ENSG00000237917.1	PARP4P1	-10.77	3.33e-22	4.54e-15	-0.66	-0.58	Obesity-related traits;	chr13:24516275	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.716	rs9553331	ENSG00000237917.1	PARP4P1	-10.77	3.34e-22	4.56e-15	-0.64	-0.58	Obesity-related traits;	chr13:24516030	chrY:26594851~26634652:-
SARC	trans	rs916888	0.687	rs199456	ENSG00000204650.12	CRHR1-IT1	10.75	3.65e-22	4.95e-15	0.79	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45620328~45648216:+
SARC	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-10.75	3.7e-22	5.02e-15	-0.66	-0.58	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.624	rs9553312	ENSG00000237917.1	PARP4P1	-10.74	4e-22	5.42e-15	-0.65	-0.58	Obesity-related traits;	chr13:24474055	chrY:26594851~26634652:-
SARC	trans	rs7200543	1	rs16966953	ENSG00000250569.1	NTAN1P2	10.74	4.08e-22	5.5e-15	0.74	0.58	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr8:86481754~86483002:-
SARC	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-10.74	4.11e-22	5.53e-15	-0.78	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
SARC	trans	rs916888	0.738	rs199515	ENSG00000264070.1	DND1P1	-10.73	4.2e-22	5.64e-15	-0.81	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45585871~45586929:+
SARC	trans	rs9611519	0.78	rs1535048	ENSG00000268568.1	AC007228.9	-10.73	4.22e-22	5.66e-15	-0.69	-0.58	Neuroticism;	chr22:41288089	chr19:56672574~56673901:-
SARC	trans	rs7200543	1	rs1136001	ENSG00000250569.1	NTAN1P2	10.73	4.27e-22	5.73e-15	0.74	0.58	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr8:86481754~86483002:-
SARC	trans	rs1816752	0.716	rs9553330	ENSG00000237917.1	PARP4P1	-10.73	4.32e-22	5.77e-15	-0.65	-0.58	Obesity-related traits;	chr13:24516018	chrY:26594851~26634652:-
SARC	trans	rs916888	0.773	rs538628	ENSG00000214425.5	LRRC37A4P	-10.73	4.49e-22	5.99e-15	-0.79	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45506741~45550335:-
SARC	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	10.72	4.57e-22	6.1e-15	0.62	0.57	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
SARC	trans	rs9467773	1	rs10214634	ENSG00000242375.1	RP11-498P14.3	10.71	4.86e-22	6.45e-15	0.71	0.57	Intelligence (multi-trait analysis);	chr6:26564354	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.873	rs9295698	ENSG00000242375.1	RP11-498P14.3	10.71	4.86e-22	6.45e-15	0.71	0.57	Intelligence (multi-trait analysis);	chr6:26565871	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs9986382	ENSG00000242375.1	RP11-498P14.3	10.71	4.87e-22	6.46e-15	0.72	0.57	Intelligence (multi-trait analysis);	chr6:26550391	chr9:97195351~97197687:-
SARC	trans	rs1816752	0.669	rs3783072	ENSG00000237917.1	PARP4P1	-10.71	4.93e-22	6.54e-15	-0.67	-0.57	Obesity-related traits;	chr13:24493258	chrY:26594851~26634652:-
SARC	trans	rs13177918	0.734	rs6579790	ENSG00000213058.3	RP4-765C7.2	10.7	5.23e-22	6.92e-15	0.81	0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:178411616~178411972:+
SARC	trans	rs9467773	1	rs1535277	ENSG00000242375.1	RP11-498P14.3	10.7	5.25e-22	6.93e-15	0.72	0.57	Intelligence (multi-trait analysis);	chr6:26567574	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs1884948	ENSG00000242375.1	RP11-498P14.3	10.7	5.25e-22	6.93e-15	0.72	0.57	Intelligence (multi-trait analysis);	chr6:26567760	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs1884949	ENSG00000242375.1	RP11-498P14.3	10.7	5.25e-22	6.93e-15	0.72	0.57	Intelligence (multi-trait analysis);	chr6:26567839	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs9467796	ENSG00000242375.1	RP11-498P14.3	10.7	5.25e-22	6.93e-15	0.72	0.57	Intelligence (multi-trait analysis);	chr6:26568183	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs9467797	ENSG00000242375.1	RP11-498P14.3	10.7	5.25e-22	6.93e-15	0.72	0.57	Intelligence (multi-trait analysis);	chr6:26568245	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs1078679	ENSG00000242375.1	RP11-498P14.3	10.7	5.25e-22	6.93e-15	0.72	0.57	Intelligence (multi-trait analysis);	chr6:26568513	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs6932156	ENSG00000242375.1	RP11-498P14.3	10.7	5.25e-22	6.93e-15	0.72	0.57	Intelligence (multi-trait analysis);	chr6:26571278	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs6924838	ENSG00000242375.1	RP11-498P14.3	10.7	5.25e-22	6.93e-15	0.72	0.57	Intelligence (multi-trait analysis);	chr6:26571528	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs6925895	ENSG00000242375.1	RP11-498P14.3	10.7	5.25e-22	6.93e-15	0.72	0.57	Intelligence (multi-trait analysis);	chr6:26571937	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs6456733	ENSG00000242375.1	RP11-498P14.3	10.7	5.34e-22	7.04e-15	0.72	0.57	Intelligence (multi-trait analysis);	chr6:26566576	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs6456734	ENSG00000242375.1	RP11-498P14.3	10.7	5.34e-22	7.04e-15	0.72	0.57	Intelligence (multi-trait analysis);	chr6:26566737	chr9:97195351~97197687:-
SARC	trans	rs1816752	0.646	rs750390	ENSG00000237917.1	PARP4P1	-10.7	5.57e-22	7.34e-15	-0.65	-0.57	Obesity-related traits;	chr13:24461603	chrY:26594851~26634652:-
SARC	trans	rs916888	0.821	rs199513	ENSG00000264070.1	DND1P1	-10.69	5.64e-22	7.42e-15	-0.78	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45585871~45586929:+
SARC	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-10.69	5.8e-22	7.63e-15	-0.64	-0.57	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
SARC	trans	rs7200543	1	rs14347	ENSG00000250569.1	NTAN1P2	10.68	6.17e-22	8.11e-15	0.74	0.57	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr8:86481754~86483002:-
SARC	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-10.68	6.25e-22	8.21e-15	-0.61	-0.57	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
SARC	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-10.68	6.25e-22	8.21e-15	-0.61	-0.57	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
SARC	trans	rs1816752	0.608	rs7326664	ENSG00000237917.1	PARP4P1	-10.67	6.57e-22	8.61e-15	-0.64	-0.57	Obesity-related traits;	chr13:24475868	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-10.67	6.69e-22	8.76e-15	-0.64	-0.57	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
SARC	trans	rs8081395	0.741	rs1292055	ENSG00000187870.7	RNFT1P3	10.67	6.73e-22	8.8e-15	0.67	0.57	White blood cell count;	chr17:59881707	chr17:20743333~20754501:-
SARC	trans	rs7200543	1	rs1121	ENSG00000250569.1	NTAN1P2	10.66	7.26e-22	9.48e-15	0.74	0.57	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr8:86481754~86483002:-
SARC	trans	rs7200543	1	rs4985154	ENSG00000250569.1	NTAN1P2	10.66	7.26e-22	9.48e-15	0.74	0.57	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr8:86481754~86483002:-
SARC	trans	rs7200543	1	rs1135999	ENSG00000250569.1	NTAN1P2	10.66	7.26e-22	9.48e-15	0.74	0.57	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr8:86481754~86483002:-
SARC	trans	rs7200543	1	rs2740	ENSG00000250569.1	NTAN1P2	10.66	7.26e-22	9.48e-15	0.74	0.57	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr8:86481754~86483002:-
SARC	trans	rs7200543	1	rs34614532	ENSG00000250569.1	NTAN1P2	10.66	7.26e-22	9.48e-15	0.74	0.57	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr8:86481754~86483002:-
SARC	trans	rs9611565	0.921	rs2281332	ENSG00000268568.1	AC007228.9	-10.66	7.47e-22	9.74e-15	-0.67	-0.57	Vitiligo;	chr22:41350208	chr19:56672574~56673901:-
SARC	trans	rs6477998	0.966	rs7851395	ENSG00000238072.1	RP11-305M3.2	10.64	8.29e-22	1.08e-14	0.73	0.57	Hematology traits;	chr9:113240184	chr7:129410113~129410370:-
SARC	trans	rs7200543	1	rs16966952	ENSG00000250569.1	NTAN1P2	10.64	8.49e-22	1.1e-14	0.73	0.57	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr8:86481754~86483002:-
SARC	trans	rs9611565	0.921	rs5751080	ENSG00000268568.1	AC007228.9	-10.63	9.12e-22	1.18e-14	-0.67	-0.57	Vitiligo;	chr22:41340263	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.921	rs2235846	ENSG00000268568.1	AC007228.9	-10.63	9.12e-22	1.18e-14	-0.67	-0.57	Vitiligo;	chr22:41345038	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.921	rs5751081	ENSG00000268568.1	AC007228.9	-10.63	9.12e-22	1.18e-14	-0.67	-0.57	Vitiligo;	chr22:41346784	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.967	rs6941022	ENSG00000242375.1	RP11-498P14.3	10.62	9.37e-22	1.21e-14	0.71	0.57	Intelligence (multi-trait analysis);	chr6:26553303	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs2224380	ENSG00000242375.1	RP11-498P14.3	10.62	9.37e-22	1.21e-14	0.71	0.57	Intelligence (multi-trait analysis);	chr6:26553715	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs9461271	ENSG00000242375.1	RP11-498P14.3	10.62	9.37e-22	1.21e-14	0.71	0.57	Intelligence (multi-trait analysis);	chr6:26554740	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs6930120	ENSG00000242375.1	RP11-498P14.3	10.62	9.37e-22	1.21e-14	0.71	0.57	Intelligence (multi-trait analysis);	chr6:26555256	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs9467787	ENSG00000242375.1	RP11-498P14.3	10.62	9.37e-22	1.21e-14	0.71	0.57	Intelligence (multi-trait analysis);	chr6:26556541	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs767471	ENSG00000242375.1	RP11-498P14.3	10.62	9.37e-22	1.21e-14	0.71	0.57	Intelligence (multi-trait analysis);	chr6:26557626	chr9:97195351~97197687:-
SARC	trans	rs9611565	0.921	rs2143695	ENSG00000268568.1	AC007228.9	-10.62	9.64e-22	1.24e-14	-0.68	-0.57	Vitiligo;	chr22:41332616	chr19:56672574~56673901:-
SARC	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-10.62	9.74e-22	1.25e-14	-0.64	-0.57	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-10.62	9.74e-22	1.25e-14	-0.64	-0.57	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
SARC	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	10.61	1e-21	1.28e-14	0.73	0.57	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
SARC	trans	rs1816752	0.646	rs4770700	ENSG00000237917.1	PARP4P1	-10.61	1.03e-21	1.32e-14	-0.64	-0.57	Obesity-related traits;	chr13:24494796	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.624	rs7330766	ENSG00000237917.1	PARP4P1	-10.61	1.07e-21	1.37e-14	-0.64	-0.57	Obesity-related traits;	chr13:24495579	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.603	rs7984094	ENSG00000237917.1	PARP4P1	-10.61	1.07e-21	1.37e-14	-0.64	-0.57	Obesity-related traits;	chr13:24496212	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-10.6	1.09e-21	1.4e-14	-0.63	-0.57	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-10.6	1.09e-21	1.4e-14	-0.63	-0.57	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
SARC	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-10.6	1.09e-21	1.4e-14	-0.63	-0.57	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
SARC	trans	rs7200543	0.961	rs1741	ENSG00000250569.1	NTAN1P2	10.59	1.17e-21	1.49e-14	0.74	0.57	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr8:86481754~86483002:-
SARC	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-10.59	1.23e-21	1.57e-14	-0.61	-0.57	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
SARC	trans	rs9611565	0.879	rs2235845	ENSG00000268568.1	AC007228.9	-10.58	1.3e-21	1.65e-14	-0.66	-0.57	Vitiligo;	chr22:41333290	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-10.57	1.37e-21	1.74e-14	-0.73	-0.57	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.592	rs9611612	ENSG00000268568.1	AC007228.9	-10.56	1.5e-21	1.89e-14	-0.73	-0.57	Vitiligo;	chr22:41565185	chr19:56672574~56673901:-
SARC	trans	rs55665837	0.524	rs61884009	ENSG00000236360.2	RP11-334A14.2	10.56	1.54e-21	1.94e-14	0.7	0.57	Vitamin D levels;	chr11:14404916	chr1:52993201~52993702:-
SARC	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	10.55	1.61e-21	2.03e-14	0.68	0.57	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
SARC	trans	rs12291225	0.535	rs10832248	ENSG00000236360.2	RP11-334A14.2	10.55	1.61e-21	2.04e-14	0.66	0.57	Sense of smell;	chr11:14391541	chr1:52993201~52993702:-
SARC	trans	rs916888	0.773	rs199533	ENSG00000204650.12	CRHR1-IT1	10.55	1.62e-21	2.05e-14	0.77	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45620328~45648216:+
SARC	trans	rs7312770	0.637	rs705699	ENSG00000225071.1	GS1-184P14.2	10.55	1.64e-21	2.06e-14	0.62	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chrX:24429573~24429920:-
SARC	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	10.55	1.65e-21	2.08e-14	0.69	0.57	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
SARC	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	10.54	1.7e-21	2.14e-14	0.68	0.57	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
SARC	trans	rs1816752	0.692	rs6490944	ENSG00000237917.1	PARP4P1	-10.53	1.81e-21	2.27e-14	-0.64	-0.57	Obesity-related traits;	chr13:24513866	chrY:26594851~26634652:-
SARC	trans	rs6732160	0.845	rs6752507	ENSG00000236165.1	PRADC1P1	10.53	1.85e-21	2.32e-14	0.68	0.57	Intelligence (multi-trait analysis);	chr2:73158030	chr3:36976316~36976840:+
SARC	trans	rs5022636	0.594	rs12048670	ENSG00000180764.13	PIPSL	10.52	2.03e-21	2.54e-14	0.65	0.57	Gut microbiota (functional units);	chr1:151272510	chr10:93958191~93961540:-
SARC	trans	rs2657294	0.796	rs2804535	ENSG00000172974.11	AC007318.5	-10.51	2.1e-21	2.63e-14	-0.58	-0.57	Pneumonia;	chr10:75212086	chr2:65205108~65205988:+
SARC	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	10.5	2.22e-21	2.78e-14	0.69	0.57	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
SARC	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	10.5	2.24e-21	2.8e-14	0.7	0.57	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
SARC	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	10.5	2.27e-21	2.84e-14	0.69	0.57	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
SARC	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	10.5	2.27e-21	2.84e-14	0.69	0.57	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
SARC	trans	rs6732160	0.845	rs6546805	ENSG00000236165.1	PRADC1P1	10.49	2.41e-21	3e-14	0.67	0.57	Intelligence (multi-trait analysis);	chr2:73158987	chr3:36976316~36976840:+
SARC	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	10.49	2.42e-21	3.02e-14	0.69	0.57	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
SARC	trans	rs6732160	0.845	rs72807999	ENSG00000236165.1	PRADC1P1	10.48	2.61e-21	3.25e-14	0.66	0.57	Intelligence (multi-trait analysis);	chr2:73164567	chr3:36976316~36976840:+
SARC	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-10.47	2.75e-21	3.41e-14	-0.64	-0.57	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
SARC	trans	rs5022636	0.594	rs10888408	ENSG00000180764.13	PIPSL	10.47	2.9e-21	3.59e-14	0.64	0.57	Gut microbiota (functional units);	chr1:151267094	chr10:93958191~93961540:-
SARC	trans	rs9611565	0.506	rs1883825	ENSG00000268568.1	AC007228.9	-10.46	2.96e-21	3.66e-14	-0.68	-0.57	Vitiligo;	chr22:41307404	chr19:56672574~56673901:-
SARC	trans	rs9611565	0.525	rs1883827	ENSG00000268568.1	AC007228.9	-10.46	2.96e-21	3.66e-14	-0.68	-0.57	Vitiligo;	chr22:41307575	chr19:56672574~56673901:-
SARC	trans	rs916888	0.779	rs199528	ENSG00000214425.5	LRRC37A4P	-10.46	2.98e-21	3.68e-14	-0.79	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45506741~45550335:-
SARC	trans	rs916888	0.821	rs199525	ENSG00000214425.5	LRRC37A4P	-10.46	2.98e-21	3.68e-14	-0.79	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45506741~45550335:-
SARC	trans	rs5022636	0.564	rs2275900	ENSG00000180764.13	PIPSL	10.46	3.06e-21	3.78e-14	0.64	0.57	Gut microbiota (functional units);	chr1:151265746	chr10:93958191~93961540:-
SARC	trans	rs1045902	0.583	rs36106493	ENSG00000236165.1	PRADC1P1	10.45	3.22e-21	3.97e-14	0.69	0.56	Intelligence (multi-trait analysis);	chr2:73215211	chr3:36976316~36976840:+
SARC	trans	rs6732160	0.845	rs11894833	ENSG00000236165.1	PRADC1P1	-10.44	3.44e-21	4.23e-14	-0.67	-0.56	Intelligence (multi-trait analysis);	chr2:73161290	chr3:36976316~36976840:+
SARC	trans	rs13253073	0.883	rs2305290	ENSG00000260318.1	COX6CP1	10.44	3.6e-21	4.43e-14	1.12	0.56	Glucose homeostasis traits;	chr8:99819066	chr16:11903923~11904137:-
SARC	trans	rs9467773	0.967	rs7753565	ENSG00000242375.1	RP11-498P14.3	10.42	4.13e-21	5.05e-14	0.7	0.56	Intelligence (multi-trait analysis);	chr6:26559784	chr9:97195351~97197687:-
SARC	trans	rs12291225	0.535	rs11023203	ENSG00000236360.2	RP11-334A14.2	10.42	4.19e-21	5.12e-14	0.65	0.56	Sense of smell;	chr11:14388269	chr1:52993201~52993702:-
SARC	trans	rs7312770	0.637	rs705700	ENSG00000225071.1	GS1-184P14.2	10.42	4.21e-21	5.14e-14	0.62	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:24429573~24429920:-
SARC	trans	rs9467773	1	rs6940188	ENSG00000242375.1	RP11-498P14.3	10.41	4.21e-21	5.14e-14	0.7	0.56	Intelligence (multi-trait analysis);	chr6:26561801	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs6940053	ENSG00000242375.1	RP11-498P14.3	10.41	4.21e-21	5.14e-14	0.7	0.56	Intelligence (multi-trait analysis);	chr6:26561894	chr9:97195351~97197687:-
SARC	trans	rs55665837	0.583	rs78843135	ENSG00000236360.2	RP11-334A14.2	10.41	4.37e-21	5.33e-14	0.65	0.56	Vitamin D levels;	chr11:14389708	chr1:52993201~52993702:-
SARC	trans	rs55665837	0.524	rs2882128	ENSG00000236360.2	RP11-334A14.2	10.41	4.37e-21	5.33e-14	0.65	0.56	Vitamin D levels;	chr11:14393088	chr1:52993201~52993702:-
SARC	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	10.4	4.53e-21	5.52e-14	0.61	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
SARC	trans	rs2657294	0.796	rs2804534	ENSG00000172974.11	AC007318.5	-10.4	4.58e-21	5.57e-14	-0.59	-0.56	Pneumonia;	chr10:75208023	chr2:65205108~65205988:+
SARC	trans	rs9611565	0.506	rs2024566	ENSG00000268568.1	AC007228.9	-10.39	5.17e-21	6.28e-14	-0.69	-0.56	Vitiligo;	chr22:41301334	chr19:56672574~56673901:-
SARC	trans	rs916888	0.821	rs199504	ENSG00000264070.1	DND1P1	-10.38	5.49e-21	6.66e-14	-0.79	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45585871~45586929:+
SARC	trans	rs916888	0.773	rs199534	ENSG00000204650.12	CRHR1-IT1	10.37	5.62e-21	6.81e-14	0.77	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45620328~45648216:+
SARC	trans	rs9467773	1	rs9467791	ENSG00000242375.1	RP11-498P14.3	-10.37	6.01e-21	7.27e-14	-0.7	-0.56	Intelligence (multi-trait analysis);	chr6:26562258	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs1321481	ENSG00000242375.1	RP11-498P14.3	10.36	6.13e-21	7.39e-14	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26537982	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs4713008	ENSG00000242375.1	RP11-498P14.3	10.36	6.13e-21	7.39e-14	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26538040	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.967	rs6932865	ENSG00000242375.1	RP11-498P14.3	10.36	6.13e-21	7.39e-14	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26539938	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs6933176	ENSG00000242375.1	RP11-498P14.3	10.36	6.13e-21	7.39e-14	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26539950	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs9467782	ENSG00000242375.1	RP11-498P14.3	10.36	6.13e-21	7.39e-14	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26542545	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.935	rs9461270	ENSG00000242375.1	RP11-498P14.3	10.36	6.13e-21	7.39e-14	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26543882	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs4871	ENSG00000242375.1	RP11-498P14.3	10.36	6.13e-21	7.39e-14	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26545404	chr9:97195351~97197687:-
SARC	trans	rs6732160	0.809	rs13406142	ENSG00000236165.1	PRADC1P1	10.36	6.35e-21	7.65e-14	0.67	0.56	Intelligence (multi-trait analysis);	chr2:73156970	chr3:36976316~36976840:+
SARC	trans	rs6732160	0.845	rs6546809	ENSG00000236165.1	PRADC1P1	10.35	6.51e-21	7.83e-14	0.66	0.56	Intelligence (multi-trait analysis);	chr2:73162553	chr3:36976316~36976840:+
SARC	trans	rs8081395	0.741	rs180520	ENSG00000187870.7	RNFT1P3	10.35	6.71e-21	8.07e-14	0.65	0.56	White blood cell count;	chr17:59937788	chr17:20743333~20754501:-
SARC	trans	rs12291225	0.535	rs16930126	ENSG00000236360.2	RP11-334A14.2	-10.34	7.42e-21	8.91e-14	-0.65	-0.56	Sense of smell;	chr11:14383437	chr1:52993201~52993702:-
SARC	trans	rs55665837	0.559	rs11023209	ENSG00000236360.2	RP11-334A14.2	10.33	7.88e-21	9.46e-14	0.67	0.56	Vitamin D levels;	chr11:14401054	chr1:52993201~52993702:-
SARC	trans	rs916888	0.773	rs199439	ENSG00000204650.12	CRHR1-IT1	10.33	7.92e-21	9.51e-14	0.74	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45620328~45648216:+
SARC	trans	rs9611519	0.732	rs1883826	ENSG00000268568.1	AC007228.9	-10.32	8.26e-21	9.89e-14	-0.68	-0.56	Neuroticism;	chr22:41307424	chr19:56672574~56673901:-
SARC	trans	rs916888	0.773	rs538628	ENSG00000204650.12	CRHR1-IT1	10.31	8.86e-21	1.06e-13	0.74	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45620328~45648216:+
SARC	trans	rs9611565	0.525	rs9611549	ENSG00000268568.1	AC007228.9	-10.31	9e-21	1.07e-13	-0.68	-0.56	Vitiligo;	chr22:41309905	chr19:56672574~56673901:-
SARC	trans	rs7200543	1	rs35574015	ENSG00000250569.1	NTAN1P2	10.3	9.35e-21	1.11e-13	0.74	0.56	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr8:86481754~86483002:-
SARC	trans	rs7121616	0.545	rs11600517	ENSG00000234176.1	HSPA8P1	10.29	1.01e-20	1.2e-13	0.8	0.56	Breast cancer;	chr11:123047247	chrX:121203182~121205014:-
SARC	trans	rs916888	0.773	rs9896243	ENSG00000204650.12	CRHR1-IT1	10.29	1.06e-20	1.25e-13	0.73	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45620328~45648216:+
SARC	trans	rs6732160	0.845	rs13413175	ENSG00000236165.1	PRADC1P1	10.28	1.08e-20	1.28e-13	0.65	0.56	Intelligence (multi-trait analysis);	chr2:73162788	chr3:36976316~36976840:+
SARC	trans	rs12291225	0.877	rs2303974	ENSG00000236360.2	RP11-334A14.2	10.27	1.15e-20	1.35e-13	0.7	0.56	Sense of smell;	chr11:14243433	chr1:52993201~52993702:-
SARC	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-10.27	1.16e-20	1.37e-13	-0.68	-0.56	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
SARC	trans	rs8081395	0.805	rs2645485	ENSG00000187870.7	RNFT1P3	10.27	1.17e-20	1.38e-13	0.66	0.56	White blood cell count;	chr17:59866920	chr17:20743333~20754501:-
SARC	trans	rs6732160	0.838	rs13411380	ENSG00000236165.1	PRADC1P1	10.26	1.29e-20	1.52e-13	0.67	0.56	Intelligence (multi-trait analysis);	chr2:73155718	chr3:36976316~36976840:+
SARC	trans	rs6732160	0.809	rs6728959	ENSG00000236165.1	PRADC1P1	10.26	1.29e-20	1.52e-13	0.67	0.56	Intelligence (multi-trait analysis);	chr2:73156199	chr3:36976316~36976840:+
SARC	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-10.26	1.32e-20	1.55e-13	-0.68	-0.56	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
SARC	trans	rs9467773	1	rs12526680	ENSG00000242375.1	RP11-498P14.3	10.25	1.36e-20	1.6e-13	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26550726	chr9:97195351~97197687:-
SARC	trans	rs916888	0.773	rs199447	ENSG00000204650.12	CRHR1-IT1	10.25	1.38e-20	1.62e-13	0.75	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45620328~45648216:+
SARC	trans	rs9467773	1	rs11756120	ENSG00000242375.1	RP11-498P14.3	10.24	1.44e-20	1.68e-13	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26529580	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs9393732	ENSG00000242375.1	RP11-498P14.3	10.24	1.44e-20	1.68e-13	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26530670	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.967	rs9358954	ENSG00000242375.1	RP11-498P14.3	10.24	1.44e-20	1.68e-13	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26530950	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs28558133	ENSG00000242375.1	RP11-498P14.3	10.24	1.44e-20	1.68e-13	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26531205	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs10946834	ENSG00000242375.1	RP11-498P14.3	10.24	1.44e-20	1.68e-13	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26533436	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs10946835	ENSG00000242375.1	RP11-498P14.3	10.24	1.44e-20	1.68e-13	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26533529	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs9467778	ENSG00000242375.1	RP11-498P14.3	10.24	1.44e-20	1.68e-13	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26534515	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs2393670	ENSG00000242375.1	RP11-498P14.3	10.24	1.44e-20	1.68e-13	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26535313	chr9:97195351~97197687:-
SARC	trans	rs7200543	1	rs3803575	ENSG00000250569.1	NTAN1P2	10.24	1.44e-20	1.69e-13	0.7	0.56	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr8:86481754~86483002:-
SARC	trans	rs5022636	0.594	rs11204791	ENSG00000180764.13	PIPSL	10.24	1.45e-20	1.69e-13	0.63	0.56	Gut microbiota (functional units);	chr1:151268066	chr10:93958191~93961540:-
SARC	trans	rs7200543	1	rs6498540	ENSG00000250569.1	NTAN1P2	10.23	1.55e-20	1.81e-13	0.72	0.56	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr8:86481754~86483002:-
SARC	trans	rs7200543	0.961	rs3803573	ENSG00000250569.1	NTAN1P2	10.23	1.56e-20	1.82e-13	0.71	0.56	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr8:86481754~86483002:-
SARC	trans	rs7200543	1	rs4500751	ENSG00000250569.1	NTAN1P2	10.23	1.57e-20	1.83e-13	0.71	0.56	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr8:86481754~86483002:-
SARC	trans	rs13253073	1	rs12541837	ENSG00000260318.1	COX6CP1	-10.22	1.65e-20	1.92e-13	-1.18	-0.56	Glucose homeostasis traits;	chr8:99869645	chr16:11903923~11904137:-
SARC	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-10.22	1.66e-20	1.93e-13	-0.75	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
SARC	trans	rs9467773	1	rs1884946	ENSG00000242375.1	RP11-498P14.3	10.22	1.68e-20	1.95e-13	0.69	0.56	Intelligence (multi-trait analysis);	chr6:26545080	chr9:97195351~97197687:-
SARC	trans	rs916888	0.61	rs199529	ENSG00000214425.5	LRRC37A4P	-10.22	1.73e-20	2.01e-13	-0.72	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45506741~45550335:-
SARC	trans	rs7121616	0.576	rs73610509	ENSG00000234176.1	HSPA8P1	10.21	1.82e-20	2.1e-13	0.8	0.56	Breast cancer;	chr11:123048564	chrX:121203182~121205014:-
SARC	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-10.21	1.88e-20	2.18e-13	-0.64	-0.56	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
SARC	trans	rs916888	0.821	rs70600	ENSG00000204650.12	CRHR1-IT1	10.2	1.97e-20	2.27e-13	0.73	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45620328~45648216:+
SARC	trans	rs7121616	0.576	rs7942164	ENSG00000234176.1	HSPA8P1	10.2	2.02e-20	2.33e-13	0.8	0.56	Breast cancer;	chr11:123050459	chrX:121203182~121205014:-
SARC	trans	rs7121616	0.576	rs56131320	ENSG00000234176.1	HSPA8P1	10.2	2.02e-20	2.33e-13	0.8	0.56	Breast cancer;	chr11:123053058	chrX:121203182~121205014:-
SARC	trans	rs7121616	0.576	rs7929869	ENSG00000234176.1	HSPA8P1	10.2	2.02e-20	2.33e-13	0.8	0.56	Breast cancer;	chr11:123054435	chrX:121203182~121205014:-
SARC	trans	rs9611565	0.921	rs8137373	ENSG00000268568.1	AC007228.9	10.19	2.13e-20	2.46e-13	0.68	0.56	Vitiligo;	chr22:41333212	chr19:56672574~56673901:-
SARC	trans	rs12291225	0.535	rs12806025	ENSG00000236360.2	RP11-334A14.2	10.18	2.2e-20	2.54e-13	0.64	0.55	Sense of smell;	chr11:14392271	chr1:52993201~52993702:-
SARC	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	10.18	2.27e-20	2.61e-13	0.6	0.55	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
SARC	trans	rs7121616	0.576	rs7102045	ENSG00000234176.1	HSPA8P1	10.18	2.33e-20	2.68e-13	0.81	0.55	Breast cancer;	chr11:123052713	chrX:121203182~121205014:-
SARC	trans	rs7121616	0.576	rs1064585	ENSG00000234176.1	HSPA8P1	10.17	2.34e-20	2.69e-13	0.82	0.55	Breast cancer;	chr11:123058699	chrX:121203182~121205014:-
SARC	trans	rs6732160	0.845	rs6718690	ENSG00000236165.1	PRADC1P1	-10.17	2.43e-20	2.78e-13	-0.65	-0.55	Intelligence (multi-trait analysis);	chr2:73160034	chr3:36976316~36976840:+
SARC	trans	rs7121616	0.576	rs11600486	ENSG00000234176.1	HSPA8P1	10.17	2.45e-20	2.81e-13	0.81	0.55	Breast cancer;	chr11:123047060	chrX:121203182~121205014:-
SARC	trans	rs5022636	0.631	rs6587562	ENSG00000180764.13	PIPSL	-10.16	2.52e-20	2.89e-13	-0.64	-0.55	Gut microbiota (functional units);	chr1:151273765	chr10:93958191~93961540:-
SARC	trans	rs8081395	0.775	rs2645482	ENSG00000187870.7	RNFT1P3	10.16	2.59e-20	2.96e-13	0.66	0.55	White blood cell count;	chr17:59865754	chr17:20743333~20754501:-
SARC	trans	rs6732160	0.741	rs6546806	ENSG00000236165.1	PRADC1P1	10.16	2.59e-20	2.97e-13	0.65	0.55	Intelligence (multi-trait analysis);	chr2:73159032	chr3:36976316~36976840:+
SARC	trans	rs9467773	1	rs1321480	ENSG00000242375.1	RP11-498P14.3	10.16	2.62e-20	3e-13	0.69	0.55	Intelligence (multi-trait analysis);	chr6:26532514	chr9:97195351~97197687:-
SARC	trans	rs1816752	0.624	rs4770701	ENSG00000237917.1	PARP4P1	-10.16	2.66e-20	3.05e-13	-0.62	-0.55	Obesity-related traits;	chr13:24508806	chrY:26594851~26634652:-
SARC	trans	rs7121616	0.576	rs73610510	ENSG00000234176.1	HSPA8P1	10.16	2.69e-20	3.08e-13	0.79	0.55	Breast cancer;	chr11:123049365	chrX:121203182~121205014:-
SARC	trans	rs9611565	0.506	rs7364221	ENSG00000268568.1	AC007228.9	-10.15	2.74e-20	3.13e-13	-0.67	-0.55	Vitiligo;	chr22:41254186	chr19:56672574~56673901:-
SARC	trans	rs7121616	0.576	rs7948948	ENSG00000234176.1	HSPA8P1	10.15	2.83e-20	3.22e-13	0.83	0.55	Breast cancer;	chr11:123057467	chrX:121203182~121205014:-
SARC	trans	rs5022636	0.594	rs7489	ENSG00000180764.13	PIPSL	10.15	2.88e-20	3.28e-13	0.63	0.55	Gut microbiota (functional units);	chr1:151266575	chr10:93958191~93961540:-
SARC	trans	rs5022636	0.559	rs41302131	ENSG00000180764.13	PIPSL	10.15	2.88e-20	3.28e-13	0.63	0.55	Gut microbiota (functional units);	chr1:151267532	chr10:93958191~93961540:-
SARC	trans	rs5022636	0.525	rs4520422	ENSG00000180764.13	PIPSL	10.14	2.97e-20	3.38e-13	0.64	0.55	Gut microbiota (functional units);	chr1:151207467	chr10:93958191~93961540:-
SARC	trans	rs7121616	0.531	rs1461497	ENSG00000234176.1	HSPA8P1	10.14	2.99e-20	3.39e-13	0.82	0.55	Breast cancer;	chr11:123060505	chrX:121203182~121205014:-
SARC	trans	rs7121616	0.531	rs41361350	ENSG00000234176.1	HSPA8P1	10.14	2.99e-20	3.39e-13	0.82	0.55	Breast cancer;	chr11:123060917	chrX:121203182~121205014:-
SARC	trans	rs916888	0.821	rs70600	ENSG00000214425.5	LRRC37A4P	-10.14	2.99e-20	3.4e-13	-0.75	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45506741~45550335:-
SARC	trans	rs916888	0.773	rs199448	ENSG00000204650.12	CRHR1-IT1	10.14	3.03e-20	3.44e-13	0.74	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45620328~45648216:+
SARC	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	10.13	3.2e-20	3.63e-13	0.6	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
SARC	trans	rs9467773	1	rs9467779	ENSG00000242375.1	RP11-498P14.3	-10.13	3.25e-20	3.69e-13	-0.68	-0.55	Intelligence (multi-trait analysis);	chr6:26536459	chr9:97195351~97197687:-
SARC	trans	rs7121616	0.576	rs1841580	ENSG00000234176.1	HSPA8P1	10.13	3.31e-20	3.75e-13	0.79	0.55	Breast cancer;	chr11:123055956	chrX:121203182~121205014:-
SARC	trans	rs7121616	0.576	rs60405069	ENSG00000234176.1	HSPA8P1	10.12	3.5e-20	3.95e-13	0.8	0.55	Breast cancer;	chr11:123043616	chrX:121203182~121205014:-
SARC	trans	rs916888	0.773	rs199451	ENSG00000204650.12	CRHR1-IT1	10.11	3.69e-20	4.16e-13	0.74	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45620328~45648216:+
SARC	trans	rs5022636	0.525	rs7539584	ENSG00000180764.13	PIPSL	10.09	4.18e-20	4.7e-13	0.64	0.55	Gut microbiota (functional units);	chr1:151210477	chr10:93958191~93961540:-
SARC	trans	rs7503168	0.558	rs71381463	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35610247	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs12936539	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35611677	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs34063751	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35611893	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs11650225	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35613947	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs17669281	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35616776	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs17606150	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35616789	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs12940422	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35620400	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs12949877	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35621517	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs11650621	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35631827	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs12947274	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35635146	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs12936693	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35639391	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs71381465	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35647713	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs12943224	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35650519	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs11651380	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35654677	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs11654542	ENSG00000234130.2	RP13-88F20.1	10.09	4.24e-20	4.74e-13	1.13	0.55	Plateletcrit;	chr17:35662289	chrX:93222220~93225015:-
SARC	trans	rs3779195	0.929	rs2906184	ENSG00000225169.1	BRI3P1	-10.09	4.36e-20	4.87e-13	-0.91	-0.55	Sex hormone-binding globulin levels;	chr7:98310675	chr1:100213293~100213670:+
SARC	trans	rs7121616	0.576	rs7111590	ENSG00000234176.1	HSPA8P1	10.09	4.37e-20	4.88e-13	0.78	0.55	Breast cancer;	chr11:123055419	chrX:121203182~121205014:-
SARC	trans	rs9611565	0.506	rs2024567	ENSG00000268568.1	AC007228.9	-10.08	4.53e-20	5.06e-13	-0.67	-0.55	Vitiligo;	chr22:41303202	chr19:56672574~56673901:-
SARC	trans	rs73990293	0.737	rs4531775	ENSG00000234130.2	RP13-88F20.1	10.07	4.76e-20	5.3e-13	1.07	0.55	Clopidogrel active metabolite levels;	chr17:35559919	chrX:93222220~93225015:-
SARC	trans	rs9611565	0.506	rs4822020	ENSG00000268568.1	AC007228.9	-10.07	4.94e-20	5.5e-13	-0.67	-0.55	Vitiligo;	chr22:41304199	chr19:56672574~56673901:-
SARC	trans	rs7121616	0.576	rs1461495	ENSG00000234176.1	HSPA8P1	-10.07	5.08e-20	5.65e-13	-0.78	-0.55	Breast cancer;	chr11:123056136	chrX:121203182~121205014:-
SARC	trans	rs9611565	0.569	rs6002328	ENSG00000268568.1	AC007228.9	-10.06	5.21e-20	5.8e-13	-0.66	-0.55	Vitiligo;	chr22:41314030	chr19:56672574~56673901:-
SARC	trans	rs6732160	0.809	rs13387480	ENSG00000236165.1	PRADC1P1	10.06	5.3e-20	5.89e-13	0.66	0.55	Intelligence (multi-trait analysis);	chr2:73143879	chr3:36976316~36976840:+
SARC	trans	rs7121616	0.576	rs7949127	ENSG00000234176.1	HSPA8P1	10.06	5.3e-20	5.89e-13	0.82	0.55	Breast cancer;	chr11:123057408	chrX:121203182~121205014:-
SARC	trans	rs7121616	0.576	rs7949220	ENSG00000234176.1	HSPA8P1	10.06	5.3e-20	5.89e-13	0.82	0.55	Breast cancer;	chr11:123057418	chrX:121203182~121205014:-
SARC	trans	rs7121616	0.576	rs7111598	ENSG00000234176.1	HSPA8P1	10.06	5.39e-20	5.98e-13	0.83	0.55	Breast cancer;	chr11:123055438	chrX:121203182~121205014:-
SARC	trans	rs7121616	0.545	rs7109336	ENSG00000234176.1	HSPA8P1	10.04	5.92e-20	6.55e-13	0.82	0.55	Breast cancer;	chr11:123056530	chrX:121203182~121205014:-
SARC	trans	rs7503168	0.558	rs71381460	ENSG00000234130.2	RP13-88F20.1	10.04	6.21e-20	6.85e-13	1.1	0.55	Plateletcrit;	chr17:35564602	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs11656872	ENSG00000234130.2	RP13-88F20.1	-10.04	6.23e-20	6.87e-13	-1.08	-0.55	Plateletcrit;	chr17:35611585	chrX:93222220~93225015:-
SARC	trans	rs13253073	1	rs6468694	ENSG00000260318.1	COX6CP1	10.03	6.55e-20	7.22e-13	1.17	0.55	Glucose homeostasis traits;	chr8:99853608	chr16:11903923~11904137:-
SARC	trans	rs7200543	0.883	rs4985148	ENSG00000250569.1	NTAN1P2	10.03	6.76e-20	7.44e-13	0.71	0.55	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr8:86481754~86483002:-
SARC	trans	rs9611519	0.78	rs2235849	ENSG00000268568.1	AC007228.9	-10.01	7.65e-20	8.39e-13	-0.64	-0.55	Neuroticism;	chr22:41257536	chr19:56672574~56673901:-
SARC	trans	rs9467773	1	rs10484442	ENSG00000242375.1	RP11-498P14.3	10	8.05e-20	8.82e-13	0.69	0.55	Intelligence (multi-trait analysis);	chr6:26555651	chr9:97195351~97197687:-
SARC	trans	rs13177918	0.717	rs6874318	ENSG00000213058.3	RP4-765C7.2	-9.99	8.38e-20	9.17e-13	-0.77	-0.55	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:178411616~178411972:+
SARC	trans	rs55665837	0.559	rs11023210	ENSG00000236360.2	RP11-334A14.2	-9.99	8.51e-20	9.3e-13	-0.65	-0.55	Vitamin D levels;	chr11:14401216	chr1:52993201~52993702:-
SARC	trans	rs7121616	0.576	rs7123232	ENSG00000234176.1	HSPA8P1	9.98	9.17e-20	1e-12	0.77	0.55	Breast cancer;	chr11:123056237	chrX:121203182~121205014:-
SARC	trans	rs877636	0.692	rs11171739	ENSG00000243538.1	CTB-55B8.1	9.98	9.2e-20	1e-12	0.61	0.55	Cognitive function;	chr12:56076841	chr5:16902294~16902641:-
SARC	trans	rs5022636	0.525	rs6681163	ENSG00000180764.13	PIPSL	9.98	9.27e-20	1.01e-12	0.63	0.55	Gut microbiota (functional units);	chr1:151259161	chr10:93958191~93961540:-
SARC	trans	rs7121616	0.576	rs73608699	ENSG00000234176.1	HSPA8P1	9.98	9.55e-20	1.04e-12	0.8	0.55	Breast cancer;	chr11:123044718	chrX:121203182~121205014:-
SARC	trans	rs3779195	0.929	rs1635612	ENSG00000225169.1	BRI3P1	9.97	9.92e-20	1.08e-12	0.88	0.55	Sex hormone-binding globulin levels;	chr7:98385737	chr1:100213293~100213670:+
SARC	trans	rs916888	0.779	rs199528	ENSG00000204650.12	CRHR1-IT1	9.97	1.02e-19	1.11e-12	0.74	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45620328~45648216:+
SARC	trans	rs916888	0.821	rs199525	ENSG00000204650.12	CRHR1-IT1	9.97	1.02e-19	1.11e-12	0.74	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45620328~45648216:+
SARC	trans	rs7121616	0.545	rs7109348	ENSG00000234176.1	HSPA8P1	9.96	1.1e-19	1.19e-12	0.81	0.55	Breast cancer;	chr11:123056555	chrX:121203182~121205014:-
SARC	trans	rs1816752	0.646	rs7997248	ENSG00000237917.1	PARP4P1	-9.95	1.16e-19	1.26e-12	-0.62	-0.55	Obesity-related traits;	chr13:24507050	chrY:26594851~26634652:-
SARC	trans	rs73990293	0.737	rs12951703	ENSG00000234130.2	RP13-88F20.1	9.94	1.21e-19	1.31e-12	1.13	0.55	Clopidogrel active metabolite levels;	chr17:35586035	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs79468963	ENSG00000234130.2	RP13-88F20.1	9.94	1.21e-19	1.31e-12	1.13	0.55	Plateletcrit;	chr17:35590408	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs71381461	ENSG00000234130.2	RP13-88F20.1	9.94	1.21e-19	1.31e-12	1.13	0.55	Plateletcrit;	chr17:35593601	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs34937989	ENSG00000234130.2	RP13-88F20.1	9.94	1.21e-19	1.31e-12	1.13	0.55	Plateletcrit;	chr17:35594744	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs12945102	ENSG00000234130.2	RP13-88F20.1	9.94	1.21e-19	1.31e-12	1.13	0.55	Plateletcrit;	chr17:35601894	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs12945980	ENSG00000234130.2	RP13-88F20.1	9.94	1.21e-19	1.31e-12	1.13	0.55	Plateletcrit;	chr17:35603002	chrX:93222220~93225015:-
SARC	trans	rs9467773	1	rs9393731	ENSG00000242375.1	RP11-498P14.3	9.93	1.35e-19	1.45e-12	0.67	0.55	Intelligence (multi-trait analysis);	chr6:26529146	chr9:97195351~97197687:-
SARC	trans	rs7503168	0.558	rs11655098	ENSG00000234130.2	RP13-88F20.1	9.92	1.4e-19	1.5e-12	1.08	0.54	Plateletcrit;	chr17:35567831	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs17638076	ENSG00000234130.2	RP13-88F20.1	9.92	1.4e-19	1.5e-12	1.08	0.54	Plateletcrit;	chr17:35569254	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs12939138	ENSG00000234130.2	RP13-88F20.1	9.92	1.4e-19	1.5e-12	1.08	0.54	Plateletcrit;	chr17:35574559	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs80278654	ENSG00000234130.2	RP13-88F20.1	9.92	1.41e-19	1.52e-12	1.13	0.54	Plateletcrit;	chr17:35622193	chrX:93222220~93225015:-
SARC	trans	rs916888	0.821	rs199506	ENSG00000214425.5	LRRC37A4P	9.91	1.55e-19	1.65e-12	0.74	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45506741~45550335:-
SARC	trans	rs7312770	0.612	rs773114	ENSG00000243403.1	RP11-330L19.1	9.9	1.61e-19	1.72e-12	0.61	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr15:64592979~64593326:+
SARC	trans	rs3779195	1	rs3779195	ENSG00000225169.1	BRI3P1	-9.89	1.71e-19	1.82e-12	-0.86	-0.54	Sex hormone-binding globulin levels;	chr7:98364050	chr1:100213293~100213670:+
SARC	trans	rs7200543	1	rs6498541	ENSG00000250569.1	NTAN1P2	9.89	1.76e-19	1.88e-12	0.69	0.54	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr8:86481754~86483002:-
SARC	trans	rs6732160	0.774	rs11890053	ENSG00000236165.1	PRADC1P1	9.89	1.81e-19	1.92e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr2:73146320	chr3:36976316~36976840:+
SARC	trans	rs6732160	0.774	rs1367291	ENSG00000236165.1	PRADC1P1	9.88	1.83e-19	1.95e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr2:73147737	chr3:36976316~36976840:+
SARC	trans	rs13253073	1	rs6986006	ENSG00000260318.1	COX6CP1	9.88	1.88e-19	2e-12	1.18	0.54	Glucose homeostasis traits;	chr8:99857251	chr16:11903923~11904137:-
SARC	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	9.88	1.92e-19	2.04e-12	0.65	0.54	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
SARC	trans	rs7200543	1	rs72774845	ENSG00000250569.1	NTAN1P2	9.86	2.12e-19	2.25e-12	0.71	0.54	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr8:86481754~86483002:-
SARC	trans	rs55665837	0.559	rs9667144	ENSG00000236360.2	RP11-334A14.2	-9.84	2.47e-19	2.61e-12	-0.64	-0.54	Vitamin D levels;	chr11:14399555	chr1:52993201~52993702:-
SARC	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-9.84	2.55e-19	2.7e-12	-0.61	-0.54	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
SARC	trans	rs13253073	0.941	rs12548827	ENSG00000260318.1	COX6CP1	9.83	2.75e-19	2.91e-12	1.2	0.54	Glucose homeostasis traits;	chr8:99841495	chr16:11903923~11904137:-
SARC	trans	rs7312770	0.637	rs705700	ENSG00000243403.1	RP11-330L19.1	9.82	2.77e-19	2.92e-12	0.61	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr15:64592979~64593326:+
SARC	trans	rs7503168	0.558	rs71381469	ENSG00000234130.2	RP13-88F20.1	9.81	3.01e-19	3.17e-12	1.14	0.54	Plateletcrit;	chr17:35712127	chrX:93222220~93225015:-
SARC	trans	rs877636	0.692	rs2271194	ENSG00000243403.1	RP11-330L19.1	-9.81	3.06e-19	3.22e-12	-0.59	-0.54	Cognitive function;	chr12:56083910	chr15:64592979~64593326:+
SARC	trans	rs7503168	0.643	rs17608253	ENSG00000234130.2	RP13-88F20.1	9.8	3.31e-19	3.47e-12	1.14	0.54	Plateletcrit;	chr17:35699451	chrX:93222220~93225015:-
SARC	trans	rs73990293	0.737	rs11657558	ENSG00000234130.2	RP13-88F20.1	9.8	3.31e-19	3.47e-12	1.14	0.54	Clopidogrel active metabolite levels;	chr17:35702305	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.643	rs71381467	ENSG00000234130.2	RP13-88F20.1	9.79	3.43e-19	3.59e-12	1.14	0.54	Plateletcrit;	chr17:35693030	chrX:93222220~93225015:-
SARC	trans	rs9611519	0.78	rs9611528	ENSG00000268568.1	AC007228.9	-9.78	3.78e-19	3.94e-12	-0.64	-0.54	Neuroticism;	chr22:41252498	chr19:56672574~56673901:-
SARC	trans	rs7312770	0.637	rs705699	ENSG00000243403.1	RP11-330L19.1	9.76	4.37e-19	4.53e-12	0.61	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr15:64592979~64593326:+
SARC	trans	rs877636	0.692	rs10876870	ENSG00000243403.1	RP11-330L19.1	-9.74	4.87e-19	5.04e-12	-0.58	-0.54	Cognitive function;	chr12:56084218	chr15:64592979~64593326:+
SARC	trans	rs877636	0.692	rs7971751	ENSG00000243403.1	RP11-330L19.1	-9.74	4.87e-19	5.04e-12	-0.58	-0.54	Cognitive function;	chr12:56084874	chr15:64592979~64593326:+
SARC	trans	rs916888	0.773	rs199445	ENSG00000204650.12	CRHR1-IT1	9.74	4.91e-19	5.07e-12	0.7	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45620328~45648216:+
SARC	trans	rs916888	0.773	rs199443	ENSG00000204650.12	CRHR1-IT1	9.74	4.91e-19	5.07e-12	0.7	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45620328~45648216:+
SARC	trans	rs3779195	0.858	rs3779196	ENSG00000225169.1	BRI3P1	9.74	5e-19	5.17e-12	0.86	0.54	Sex hormone-binding globulin levels;	chr7:98360794	chr1:100213293~100213670:+
SARC	trans	rs3779195	0.789	rs6965424	ENSG00000225169.1	BRI3P1	9.74	5e-19	5.17e-12	0.86	0.54	Sex hormone-binding globulin levels;	chr7:98361813	chr1:100213293~100213670:+
SARC	trans	rs6477998	0.647	rs10981704	ENSG00000238072.1	RP11-305M3.2	-9.73	5.34e-19	5.5e-12	-0.68	-0.54	Hematology traits;	chr9:113253989	chr7:129410113~129410370:-
SARC	trans	rs9611565	0.506	rs1984839	ENSG00000268568.1	AC007228.9	-9.72	5.69e-19	5.84e-12	-0.65	-0.54	Vitiligo;	chr22:41289933	chr19:56672574~56673901:-
SARC	trans	rs7503168	0.558	rs112693485	ENSG00000234130.2	RP13-88F20.1	9.72	5.77e-19	5.9e-12	1.11	0.54	Plateletcrit;	chr17:35643688	chrX:93222220~93225015:-
SARC	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	9.72	5.79e-19	5.92e-12	0.83	0.54	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
SARC	trans	rs9467773	0.967	rs9295694	ENSG00000242375.1	RP11-498P14.3	9.72	5.81e-19	5.92e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26512766	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.967	rs9467775	ENSG00000242375.1	RP11-498P14.3	9.72	5.81e-19	5.92e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26513207	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs9393729	ENSG00000242375.1	RP11-498P14.3	9.72	5.81e-19	5.92e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26513938	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs4713006	ENSG00000242375.1	RP11-498P14.3	9.72	5.81e-19	5.92e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26519644	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.967	rs1535276	ENSG00000242375.1	RP11-498P14.3	9.72	5.81e-19	5.92e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26520713	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.967	rs6924865	ENSG00000242375.1	RP11-498P14.3	9.72	5.81e-19	5.92e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26521125	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs6925703	ENSG00000242375.1	RP11-498P14.3	9.72	5.81e-19	5.92e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26521361	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs6910899	ENSG00000242375.1	RP11-498P14.3	9.72	5.81e-19	5.92e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26524111	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.967	rs9461267	ENSG00000242375.1	RP11-498P14.3	9.72	5.81e-19	5.92e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26525227	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.967	rs1056347	ENSG00000242375.1	RP11-498P14.3	9.72	5.81e-19	5.92e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26527296	chr9:97195351~97197687:-
SARC	trans	rs7200543	1	rs7200543	ENSG00000250569.1	NTAN1P2	-9.72	5.83e-19	5.94e-12	-0.7	-0.54	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr8:86481754~86483002:-
SARC	trans	rs9467773	0.967	rs6456732	ENSG00000242375.1	RP11-498P14.3	9.72	5.88e-19	5.99e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26514217	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.844	rs2393669	ENSG00000242375.1	RP11-498P14.3	9.7	6.75e-19	6.83e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26503645	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs9461259	ENSG00000242375.1	RP11-498P14.3	9.7	6.75e-19	6.83e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26504607	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs9467774	ENSG00000242375.1	RP11-498P14.3	9.7	6.75e-19	6.83e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26504808	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs3736781	ENSG00000242375.1	RP11-498P14.3	9.7	6.75e-19	6.83e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26505134	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs3736782	ENSG00000242375.1	RP11-498P14.3	9.7	6.75e-19	6.83e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26505175	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs2208331	ENSG00000242375.1	RP11-498P14.3	9.7	6.75e-19	6.83e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26507091	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs9393728	ENSG00000242375.1	RP11-498P14.3	9.7	6.75e-19	6.83e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26509102	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs1056667	ENSG00000242375.1	RP11-498P14.3	9.7	6.75e-19	6.83e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26510336	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs2255070	ENSG00000242375.1	RP11-498P14.3	9.7	6.81e-19	6.89e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26501549	chr9:97195351~97197687:-
SARC	trans	rs3779195	0.697	rs1688606	ENSG00000225169.1	BRI3P1	9.69	7.11e-19	7.19e-12	0.85	0.54	Sex hormone-binding globulin levels;	chr7:98345539	chr1:100213293~100213670:+
SARC	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	9.68	7.81e-19	7.87e-12	0.56	0.54	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
SARC	trans	rs9467773	1	rs9467783	ENSG00000242375.1	RP11-498P14.3	9.68	7.84e-19	7.89e-12	0.65	0.54	Intelligence (multi-trait analysis);	chr6:26542666	chr9:97195351~97197687:-
SARC	trans	rs916888	0.773	rs199535	ENSG00000204650.12	CRHR1-IT1	9.64	1e-18	1e-11	0.7	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45620328~45648216:+
SARC	trans	rs8081395	0.741	rs1292056	ENSG00000187870.7	RNFT1P3	9.64	1.02e-18	1.02e-11	0.62	0.53	White blood cell count;	chr17:59881686	chr17:20743333~20754501:-
SARC	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-9.64	1.03e-18	1.03e-11	-0.64	-0.53	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
SARC	trans	rs3779195	0.929	rs10953259	ENSG00000225169.1	BRI3P1	-9.64	1.03e-18	1.03e-11	-0.87	-0.53	Sex hormone-binding globulin levels;	chr7:98383795	chr1:100213293~100213670:+
SARC	trans	rs916888	0.821	rs199504	ENSG00000214425.5	LRRC37A4P	9.63	1.05e-18	1.05e-11	0.72	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45506741~45550335:-
SARC	trans	rs7200543	1	rs16966947	ENSG00000250569.1	NTAN1P2	9.63	1.07e-18	1.06e-11	0.68	0.53	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr8:86481754~86483002:-
SARC	trans	rs5022636	0.525	rs6587559	ENSG00000180764.13	PIPSL	9.61	1.2e-18	1.2e-11	0.62	0.53	Gut microbiota (functional units);	chr1:151245262	chr10:93958191~93961540:-
SARC	trans	rs877636	0.692	rs10876870	ENSG00000243538.1	CTB-55B8.1	-9.61	1.2e-18	1.2e-11	-0.6	-0.53	Cognitive function;	chr12:56084218	chr5:16902294~16902641:-
SARC	trans	rs877636	0.692	rs7971751	ENSG00000243538.1	CTB-55B8.1	-9.61	1.2e-18	1.2e-11	-0.6	-0.53	Cognitive function;	chr12:56084874	chr5:16902294~16902641:-
SARC	trans	rs916888	0.61	rs199529	ENSG00000264070.1	DND1P1	9.6	1.31e-18	1.3e-11	0.72	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45585871~45586929:+
SARC	trans	rs7200543	1	rs55727637	ENSG00000250569.1	NTAN1P2	9.6	1.32e-18	1.31e-11	0.69	0.53	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr8:86481754~86483002:-
SARC	trans	rs9876781	1	rs9809843	ENSG00000235912.1	RP1-159A19.3	-9.6	1.34e-18	1.33e-11	-0.57	-0.53	Longevity;	chr3:48392923	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs11712561	ENSG00000235912.1	RP1-159A19.3	-9.6	1.34e-18	1.33e-11	-0.57	-0.53	Longevity;	chr3:48393807	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs1563736	ENSG00000235912.1	RP1-159A19.3	-9.6	1.34e-18	1.33e-11	-0.57	-0.53	Longevity;	chr3:48395329	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs13071337	ENSG00000235912.1	RP1-159A19.3	-9.6	1.34e-18	1.33e-11	-0.57	-0.53	Longevity;	chr3:48396724	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs6442118	ENSG00000235912.1	RP1-159A19.3	-9.6	1.34e-18	1.33e-11	-0.57	-0.53	Longevity;	chr3:48398582	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs11130170	ENSG00000235912.1	RP1-159A19.3	-9.59	1.41e-18	1.4e-11	-0.57	-0.53	Longevity;	chr3:48408490	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs10470686	ENSG00000235912.1	RP1-159A19.3	-9.59	1.41e-18	1.4e-11	-0.57	-0.53	Longevity;	chr3:48408549	chr1:27649419~27649610:+
SARC	trans	rs12497850	0.627	rs4974078	ENSG00000197582.5	GPX1P1	9.59	1.42e-18	1.41e-11	0.64	0.53	Parkinson's disease;	chr3:48971953	chrX:13378735~13379340:-
SARC	trans	rs9876781	1	rs28824259	ENSG00000235912.1	RP1-159A19.3	-9.58	1.49e-18	1.47e-11	-0.57	-0.53	Longevity;	chr3:48384185	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs12487542	ENSG00000235912.1	RP1-159A19.3	-9.58	1.49e-18	1.47e-11	-0.57	-0.53	Longevity;	chr3:48384586	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs9864371	ENSG00000235912.1	RP1-159A19.3	-9.58	1.49e-18	1.47e-11	-0.57	-0.53	Longevity;	chr3:48385276	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs73074358	ENSG00000235912.1	RP1-159A19.3	-9.58	1.49e-18	1.47e-11	-0.57	-0.53	Longevity;	chr3:48385757	chr1:27649419~27649610:+
SARC	trans	rs9876781	0.967	rs34761139	ENSG00000235912.1	RP1-159A19.3	-9.58	1.49e-18	1.47e-11	-0.57	-0.53	Longevity;	chr3:48386489	chr1:27649419~27649610:+
SARC	trans	rs9876781	0.868	rs9875280	ENSG00000235912.1	RP1-159A19.3	-9.58	1.49e-18	1.47e-11	-0.57	-0.53	Longevity;	chr3:48387420	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs6796491	ENSG00000235912.1	RP1-159A19.3	-9.58	1.49e-18	1.47e-11	-0.57	-0.53	Longevity;	chr3:48388977	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs6804774	ENSG00000235912.1	RP1-159A19.3	-9.58	1.49e-18	1.47e-11	-0.57	-0.53	Longevity;	chr3:48389129	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs9826195	ENSG00000235912.1	RP1-159A19.3	-9.58	1.49e-18	1.47e-11	-0.57	-0.53	Longevity;	chr3:48392157	chr1:27649419~27649610:+
SARC	trans	rs9876781	0.967	rs9864815	ENSG00000235912.1	RP1-159A19.3	-9.58	1.49e-18	1.47e-11	-0.57	-0.53	Longevity;	chr3:48392588	chr1:27649419~27649610:+
SARC	trans	rs916888	0.821	rs199513	ENSG00000204650.12	CRHR1-IT1	-9.58	1.55e-18	1.53e-11	-0.66	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45620328~45648216:+
SARC	trans	rs9467773	1	rs9467773	ENSG00000242375.1	RP11-498P14.3	9.58	1.58e-18	1.56e-11	0.65	0.53	Intelligence (multi-trait analysis);	chr6:26498198	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs6926629	ENSG00000242375.1	RP11-498P14.3	9.58	1.58e-18	1.56e-11	0.65	0.53	Intelligence (multi-trait analysis);	chr6:26499675	chr9:97195351~97197687:-
SARC	trans	rs9467773	1	rs6903973	ENSG00000242375.1	RP11-498P14.3	9.58	1.58e-18	1.56e-11	0.65	0.53	Intelligence (multi-trait analysis);	chr6:26499714	chr9:97195351~97197687:-
SARC	trans	rs7503168	0.558	rs75787089	ENSG00000234130.2	RP13-88F20.1	9.57	1.6e-18	1.57e-11	1.1	0.53	Plateletcrit;	chr17:35598042	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs117414856	ENSG00000234130.2	RP13-88F20.1	9.57	1.6e-18	1.57e-11	1.1	0.53	Plateletcrit;	chr17:35604168	chrX:93222220~93225015:-
SARC	trans	rs9876781	1	rs7651407	ENSG00000235912.1	RP1-159A19.3	-9.57	1.7e-18	1.67e-11	-0.57	-0.53	Longevity;	chr3:48402409	chr1:27649419~27649610:+
SARC	trans	rs916888	0.821	rs199512	ENSG00000214425.5	LRRC37A4P	9.56	1.72e-18	1.68e-11	0.71	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45506741~45550335:-
SARC	trans	rs916888	0.821	rs199509	ENSG00000214425.5	LRRC37A4P	9.56	1.72e-18	1.68e-11	0.71	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45506741~45550335:-
SARC	trans	rs916888	0.821	rs199507	ENSG00000214425.5	LRRC37A4P	9.56	1.72e-18	1.68e-11	0.71	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45506741~45550335:-
SARC	trans	rs916888	0.821	rs415430	ENSG00000214425.5	LRRC37A4P	9.56	1.72e-18	1.68e-11	0.71	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45506741~45550335:-
SARC	trans	rs916888	0.779	rs430685	ENSG00000214425.5	LRRC37A4P	9.56	1.72e-18	1.68e-11	0.71	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45506741~45550335:-
SARC	trans	rs916888	0.821	rs199505	ENSG00000214425.5	LRRC37A4P	9.56	1.72e-18	1.68e-11	0.71	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45506741~45550335:-
SARC	trans	rs916888	0.821	rs70602	ENSG00000214425.5	LRRC37A4P	9.56	1.72e-18	1.68e-11	0.71	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45506741~45550335:-
SARC	trans	rs9876781	1	rs6442119	ENSG00000235912.1	RP1-159A19.3	-9.55	1.86e-18	1.81e-11	-0.57	-0.53	Longevity;	chr3:48398713	chr1:27649419~27649610:+
SARC	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-9.55	1.87e-18	1.82e-11	-0.63	-0.53	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
SARC	trans	rs8010715	0.848	rs927494	ENSG00000248988.1	RP11-815N9.2	9.54	1.97e-18	1.92e-11	0.65	0.53	IgG glycosylation;	chr14:24131181	chr4:159007119~159007835:+
SARC	trans	rs6732160	0.845	rs9989755	ENSG00000236165.1	PRADC1P1	9.54	2e-18	1.95e-11	0.64	0.53	Intelligence (multi-trait analysis);	chr2:73134820	chr3:36976316~36976840:+
SARC	trans	rs8010715	0.848	rs8009511	ENSG00000248988.1	RP11-815N9.2	9.54	2e-18	1.95e-11	0.64	0.53	IgG glycosylation;	chr14:24124771	chr4:159007119~159007835:+
SARC	trans	rs8010715	0.804	rs1134334	ENSG00000248988.1	RP11-815N9.2	9.54	2e-18	1.95e-11	0.64	0.53	IgG glycosylation;	chr14:24124905	chr4:159007119~159007835:+
SARC	trans	rs9876781	1	rs13314659	ENSG00000235912.1	RP1-159A19.3	9.54	2.01e-18	1.96e-11	0.57	0.53	Longevity;	chr3:48407742	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs3214041	ENSG00000235912.1	RP1-159A19.3	-9.52	2.28e-18	2.2e-11	-0.57	-0.53	Longevity;	chr3:48413059	chr1:27649419~27649610:+
SARC	trans	rs9467773	0.525	rs1535274	ENSG00000242375.1	RP11-498P14.3	9.51	2.42e-18	2.34e-11	0.63	0.53	Intelligence (multi-trait analysis);	chr6:26520519	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.565	rs6925047	ENSG00000242375.1	RP11-498P14.3	9.51	2.42e-18	2.34e-11	0.63	0.53	Intelligence (multi-trait analysis);	chr6:26521207	chr9:97195351~97197687:-
SARC	trans	rs9467773	0.565	rs4343916	ENSG00000242375.1	RP11-498P14.3	9.51	2.42e-18	2.34e-11	0.63	0.53	Intelligence (multi-trait analysis);	chr6:26522447	chr9:97195351~97197687:-
SARC	trans	rs8010715	0.848	rs2277483	ENSG00000248988.1	RP11-815N9.2	9.51	2.52e-18	2.43e-11	0.64	0.53	IgG glycosylation;	chr14:24122683	chr4:159007119~159007835:+
SARC	trans	rs916888	0.821	rs199506	ENSG00000204650.12	CRHR1-IT1	-9.5	2.66e-18	2.56e-11	-0.7	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45620328~45648216:+
SARC	trans	rs6732160	0.845	rs2901420	ENSG00000236165.1	PRADC1P1	9.49	2.94e-18	2.83e-11	0.64	0.53	Intelligence (multi-trait analysis);	chr2:73138873	chr3:36976316~36976840:+
SARC	trans	rs6732160	0.706	rs1430348	ENSG00000236165.1	PRADC1P1	9.49	2.94e-18	2.83e-11	0.64	0.53	Intelligence (multi-trait analysis);	chr2:73139930	chr3:36976316~36976840:+
SARC	trans	rs6732160	0.774	rs7606271	ENSG00000236165.1	PRADC1P1	9.49	2.94e-18	2.83e-11	0.64	0.53	Intelligence (multi-trait analysis);	chr2:73140570	chr3:36976316~36976840:+
SARC	trans	rs7200543	0.583	rs4985149	ENSG00000250569.1	NTAN1P2	9.48	3.05e-18	2.93e-11	0.68	0.53	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr8:86481754~86483002:-
SARC	trans	rs9876781	1	rs13069724	ENSG00000235912.1	RP1-159A19.3	-9.47	3.36e-18	3.22e-11	-0.58	-0.53	Longevity;	chr3:48436629	chr1:27649419~27649610:+
SARC	trans	rs7554547	0.722	rs7545014	ENSG00000261819.1	RP11-680G24.4	9.47	3.37e-18	3.23e-11	0.64	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11874596	chr16:14988259~14990160:-
SARC	trans	rs3779195	0.929	rs10953260	ENSG00000225169.1	BRI3P1	9.46	3.44e-18	3.29e-11	0.88	0.53	Sex hormone-binding globulin levels;	chr7:98404180	chr1:100213293~100213670:+
SARC	trans	rs916888	0.697	rs199516	ENSG00000214425.5	LRRC37A4P	9.45	3.67e-18	3.51e-11	0.7	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45506741~45550335:-
SARC	trans	rs916888	0.821	rs199514	ENSG00000214425.5	LRRC37A4P	9.45	3.67e-18	3.51e-11	0.7	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45506741~45550335:-
SARC	trans	rs8081395	0.741	rs1292053	ENSG00000187870.7	RNFT1P3	-9.44	4.04e-18	3.85e-11	-0.59	-0.53	White blood cell count;	chr17:59886176	chr17:20743333~20754501:-
SARC	trans	rs9876781	1	rs9883759	ENSG00000235912.1	RP1-159A19.3	-9.44	4.16e-18	3.97e-11	-0.56	-0.53	Longevity;	chr3:48422209	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs6442120	ENSG00000235912.1	RP1-159A19.3	-9.44	4.16e-18	3.97e-11	-0.56	-0.53	Longevity;	chr3:48423094	chr1:27649419~27649610:+
SARC	trans	rs9876781	0.9	rs1037773	ENSG00000235912.1	RP1-159A19.3	-9.44	4.16e-18	3.97e-11	-0.56	-0.53	Longevity;	chr3:48426493	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs2279077	ENSG00000235912.1	RP1-159A19.3	-9.44	4.16e-18	3.97e-11	-0.56	-0.53	Longevity;	chr3:48432839	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs1109227	ENSG00000235912.1	RP1-159A19.3	-9.44	4.16e-18	3.97e-11	-0.56	-0.53	Longevity;	chr3:48437797	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs3774808	ENSG00000235912.1	RP1-159A19.3	-9.44	4.16e-18	3.97e-11	-0.56	-0.53	Longevity;	chr3:48440237	chr1:27649419~27649610:+
SARC	trans	rs73990293	0.531	rs74324437	ENSG00000234130.2	RP13-88F20.1	9.43	4.23e-18	4.03e-11	1.12	0.53	Clopidogrel active metabolite levels;	chr17:35712668	chrX:93222220~93225015:-
SARC	trans	rs8081395	0.801	rs2645479	ENSG00000187870.7	RNFT1P3	9.43	4.24e-18	4.04e-11	0.6	0.53	White blood cell count;	chr17:59843171	chr17:20743333~20754501:-
SARC	trans	rs877636	0.692	rs2271194	ENSG00000243538.1	CTB-55B8.1	-9.43	4.29e-18	4.08e-11	-0.59	-0.53	Cognitive function;	chr12:56083910	chr5:16902294~16902641:-
SARC	trans	rs9876781	1	rs9881491	ENSG00000235912.1	RP1-159A19.3	-9.43	4.31e-18	4.1e-11	-0.57	-0.53	Longevity;	chr3:48446507	chr1:27649419~27649610:+
SARC	trans	rs7503168	0.643	rs17676508	ENSG00000234130.2	RP13-88F20.1	9.43	4.38e-18	4.17e-11	1.11	0.53	Plateletcrit;	chr17:35693589	chrX:93222220~93225015:-
SARC	trans	rs8081395	0.801	rs12938273	ENSG00000187870.7	RNFT1P3	-9.43	4.47e-18	4.24e-11	-0.61	-0.53	White blood cell count;	chr17:59824291	chr17:20743333~20754501:-
SARC	trans	rs8081395	0.836	rs1292061	ENSG00000187870.7	RNFT1P3	-9.43	4.47e-18	4.24e-11	-0.61	-0.53	White blood cell count;	chr17:59833869	chr17:20743333~20754501:-
SARC	trans	rs8081395	0.836	rs1295926	ENSG00000187870.7	RNFT1P3	-9.42	4.48e-18	4.25e-11	-0.61	-0.53	White blood cell count;	chr17:59832012	chr17:20743333~20754501:-
SARC	trans	rs9467773	1	rs9295695	ENSG00000242375.1	RP11-498P14.3	-9.42	4.54e-18	4.31e-11	-0.65	-0.53	Intelligence (multi-trait analysis);	chr6:26528022	chr9:97195351~97197687:-
SARC	trans	rs916888	0.738	rs199515	ENSG00000214425.5	LRRC37A4P	9.41	4.9e-18	4.65e-11	0.7	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45506741~45550335:-
SARC	trans	rs8081395	0.576	rs1292032	ENSG00000187870.7	RNFT1P3	9.41	4.98e-18	4.71e-11	0.6	0.52	White blood cell count;	chr17:59914982	chr17:20743333~20754501:-
SARC	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-9.41	5.01e-18	4.74e-11	-0.62	-0.52	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
SARC	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-9.41	5.01e-18	4.74e-11	-0.62	-0.52	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
SARC	trans	rs9876781	1	rs9311423	ENSG00000235912.1	RP1-159A19.3	-9.4	5.2e-18	4.92e-11	-0.56	-0.52	Longevity;	chr3:48378818	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs7634377	ENSG00000235912.1	RP1-159A19.3	-9.4	5.2e-18	4.92e-11	-0.56	-0.52	Longevity;	chr3:48379768	chr1:27649419~27649610:+
SARC	trans	rs7554547	0.778	rs2008113	ENSG00000261819.1	RP11-680G24.4	-9.39	5.76e-18	5.43e-11	-0.61	-0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11878809	chr16:14988259~14990160:-
SARC	trans	rs6732160	0.809	rs13416592	ENSG00000236165.1	PRADC1P1	9.37	6.4e-18	6.02e-11	0.64	0.52	Intelligence (multi-trait analysis);	chr2:73137928	chr3:36976316~36976840:+
SARC	trans	rs616147	0.627	rs816487	ENSG00000183298.5	RP11-556K13.1	-9.37	6.48e-18	6.09e-11	-0.72	-0.52	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr1:101786340~101787219:-
SARC	trans	rs916888	0.61	rs199446	ENSG00000214425.5	LRRC37A4P	9.37	6.56e-18	6.16e-11	0.64	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45506741~45550335:-
SARC	trans	rs916888	0.61	rs199536	ENSG00000214425.5	LRRC37A4P	9.37	6.56e-18	6.16e-11	0.64	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45506741~45550335:-
SARC	trans	rs916888	0.821	rs199512	ENSG00000204650.12	CRHR1-IT1	-9.36	7.09e-18	6.64e-11	-0.67	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45620328~45648216:+
SARC	trans	rs916888	0.821	rs199509	ENSG00000204650.12	CRHR1-IT1	-9.36	7.09e-18	6.64e-11	-0.67	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45620328~45648216:+
SARC	trans	rs916888	0.821	rs199507	ENSG00000204650.12	CRHR1-IT1	-9.36	7.09e-18	6.64e-11	-0.67	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45620328~45648216:+
SARC	trans	rs916888	0.821	rs415430	ENSG00000204650.12	CRHR1-IT1	-9.36	7.09e-18	6.64e-11	-0.67	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45620328~45648216:+
SARC	trans	rs916888	0.779	rs430685	ENSG00000204650.12	CRHR1-IT1	-9.36	7.09e-18	6.64e-11	-0.67	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45620328~45648216:+
SARC	trans	rs916888	0.821	rs199505	ENSG00000204650.12	CRHR1-IT1	-9.36	7.09e-18	6.64e-11	-0.67	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45620328~45648216:+
SARC	trans	rs916888	0.821	rs70602	ENSG00000204650.12	CRHR1-IT1	-9.36	7.09e-18	6.64e-11	-0.67	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45620328~45648216:+
SARC	trans	rs6732160	0.845	rs10203125	ENSG00000236165.1	PRADC1P1	9.35	7.74e-18	7.23e-11	0.64	0.52	Intelligence (multi-trait analysis);	chr2:73134023	chr3:36976316~36976840:+
SARC	trans	rs6732160	0.845	rs10203718	ENSG00000236165.1	PRADC1P1	9.35	7.74e-18	7.23e-11	0.64	0.52	Intelligence (multi-trait analysis);	chr2:73134387	chr3:36976316~36976840:+
SARC	trans	rs13253073	0.825	rs6984511	ENSG00000260318.1	COX6CP1	9.33	8.77e-18	8.17e-11	1.18	0.52	Glucose homeostasis traits;	chr8:99869513	chr16:11903923~11904137:-
SARC	trans	rs9876781	1	rs13091785	ENSG00000235912.1	RP1-159A19.3	-9.33	8.81e-18	8.21e-11	-0.56	-0.52	Longevity;	chr3:48452692	chr1:27649419~27649610:+
SARC	trans	rs8081395	0.801	rs2665404	ENSG00000187870.7	RNFT1P3	9.32	9.54e-18	8.88e-11	0.61	0.52	White blood cell count;	chr17:59798035	chr17:20743333~20754501:-
SARC	trans	rs8081395	0.836	rs2063353	ENSG00000187870.7	RNFT1P3	-9.31	9.78e-18	9.09e-11	-0.6	-0.52	White blood cell count;	chr17:59811831	chr17:20743333~20754501:-
SARC	trans	rs916888	0.647	rs199449	ENSG00000214425.5	LRRC37A4P	-9.3	1.06e-17	9.76e-11	-0.62	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45506741~45550335:-
SARC	trans	rs916888	0.61	rs199444	ENSG00000214425.5	LRRC37A4P	-9.3	1.06e-17	9.76e-11	-0.62	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45506741~45550335:-
SARC	trans	rs916888	0.61	rs199442	ENSG00000214425.5	LRRC37A4P	-9.3	1.06e-17	9.76e-11	-0.62	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45506741~45550335:-
SARC	trans	rs3749237	1	rs4768	ENSG00000197582.5	GPX1P1	9.3	1.06e-17	9.82e-11	0.67	0.52	Resting heart rate;	chr3:49721331	chrX:13378735~13379340:-
SARC	trans	rs9611519	0.78	rs2235850	ENSG00000268568.1	AC007228.9	-9.3	1.07e-17	9.87e-11	-0.61	-0.52	Neuroticism;	chr22:41261622	chr19:56672574~56673901:-
SARC	trans	rs9611519	0.808	rs5751074	ENSG00000268568.1	AC007228.9	-9.28	1.2e-17	1.1e-10	-0.61	-0.52	Neuroticism;	chr22:41269718	chr19:56672574~56673901:-
SARC	trans	rs8081395	0.769	rs12449331	ENSG00000187870.7	RNFT1P3	-9.28	1.25e-17	1.15e-10	-0.6	-0.52	White blood cell count;	chr17:59806285	chr17:20743333~20754501:-
SARC	trans	rs916888	0.821	rs199513	ENSG00000214425.5	LRRC37A4P	9.28	1.25e-17	1.15e-10	0.67	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45506741~45550335:-
SARC	trans	rs916888	0.697	rs199516	ENSG00000204650.12	CRHR1-IT1	-9.27	1.26e-17	1.15e-10	-0.67	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45620328~45648216:+
SARC	trans	rs916888	0.821	rs199514	ENSG00000204650.12	CRHR1-IT1	-9.27	1.26e-17	1.15e-10	-0.67	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45620328~45648216:+
SARC	trans	rs8081395	0.801	rs2777895	ENSG00000187870.7	RNFT1P3	-9.27	1.26e-17	1.16e-10	-0.6	-0.52	White blood cell count;	chr17:59802249	chr17:20743333~20754501:-
SARC	trans	rs8081395	0.836	rs2150879	ENSG00000187870.7	RNFT1P3	-9.27	1.27e-17	1.17e-10	-0.6	-0.52	White blood cell count;	chr17:59781849	chr17:20743333~20754501:-
SARC	trans	rs9876781	1	rs9838618	ENSG00000235912.1	RP1-159A19.3	-9.26	1.35e-17	1.24e-10	-0.57	-0.52	Longevity;	chr3:48445949	chr1:27649419~27649610:+
SARC	trans	rs928391	0.592	rs6689750	ENSG00000227183.3	HDGFP1	-9.25	1.46e-17	1.34e-10	-0.77	-0.52	Platelet count;	chr1:156828933	chrX:131646639~131646890:+
SARC	trans	rs9611519	0.761	rs35445172	ENSG00000268568.1	AC007228.9	-9.24	1.63e-17	1.48e-10	-0.61	-0.52	Neuroticism;	chr22:41264297	chr19:56672574~56673901:-
SARC	trans	rs916888	0.738	rs199515	ENSG00000204650.12	CRHR1-IT1	-9.23	1.66e-17	1.5e-10	-0.67	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45620328~45648216:+
SARC	trans	rs877636	0.669	rs7297175	ENSG00000243403.1	RP11-330L19.1	-9.21	1.95e-17	1.77e-10	-0.56	-0.52	Cognitive function;	chr12:56080024	chr15:64592979~64593326:+
SARC	trans	rs9876781	1	rs6776700	ENSG00000235912.1	RP1-159A19.3	-9.21	1.95e-17	1.77e-10	-0.56	-0.52	Longevity;	chr3:48455358	chr1:27649419~27649610:+
SARC	trans	rs9876781	0.967	rs7618883	ENSG00000235912.1	RP1-159A19.3	-9.21	1.95e-17	1.77e-10	-0.56	-0.52	Longevity;	chr3:48457056	chr1:27649419~27649610:+
SARC	trans	rs616147	0.72	rs2965067	ENSG00000183298.5	RP11-556K13.1	-9.2	2.06e-17	1.87e-10	-0.73	-0.52	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr1:101786340~101787219:-
SARC	trans	rs9611519	0.78	rs2284079	ENSG00000268568.1	AC007228.9	-9.2	2.1e-17	1.9e-10	-0.6	-0.52	Neuroticism;	chr22:41262628	chr19:56672574~56673901:-
SARC	trans	rs928391	0.592	rs1888861	ENSG00000227183.3	HDGFP1	-9.2	2.16e-17	1.95e-10	-0.77	-0.52	Platelet count;	chr1:156828169	chrX:131646639~131646890:+
SARC	trans	rs7312770	0.612	rs1873914	ENSG00000243403.1	RP11-330L19.1	9.19	2.18e-17	1.97e-10	0.57	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr15:64592979~64593326:+
SARC	trans	rs3779195	0.697	rs13232861	ENSG00000225169.1	BRI3P1	9.19	2.22e-17	2.01e-10	0.84	0.52	Sex hormone-binding globulin levels;	chr7:98299769	chr1:100213293~100213670:+
SARC	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-9.19	2.31e-17	2.09e-10	-0.54	-0.52	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
SARC	trans	rs9611519	0.78	rs5751071	ENSG00000268568.1	AC007228.9	-9.18	2.43e-17	2.19e-10	-0.6	-0.52	Neuroticism;	chr22:41260328	chr19:56672574~56673901:-
SARC	trans	rs8010715	0.771	rs2277481	ENSG00000248988.1	RP11-815N9.2	9.17	2.5e-17	2.25e-10	0.62	0.52	IgG glycosylation;	chr14:24118336	chr4:159007119~159007835:+
SARC	trans	rs7503168	0.558	rs34874930	ENSG00000234130.2	RP13-88F20.1	9.17	2.5e-17	2.25e-10	1.1	0.52	Plateletcrit;	chr17:35667961	chrX:93222220~93225015:-
SARC	trans	rs7503168	0.558	rs17670584	ENSG00000234130.2	RP13-88F20.1	9.17	2.5e-17	2.25e-10	1.1	0.52	Plateletcrit;	chr17:35671885	chrX:93222220~93225015:-
SARC	trans	rs916888	0.61	rs199453	ENSG00000214425.5	LRRC37A4P	-9.17	2.51e-17	2.26e-10	-0.62	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45506741~45550335:-
SARC	trans	rs616147	0.627	rs9871799	ENSG00000183298.5	RP11-556K13.1	9.17	2.57e-17	2.32e-10	0.66	0.51	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr1:101786340~101787219:-
SARC	trans	rs3749237	1	rs2307021	ENSG00000197582.5	GPX1P1	9.17	2.59e-17	2.33e-10	0.67	0.51	Resting heart rate;	chr3:49728050	chrX:13378735~13379340:-
SARC	trans	rs7258465	1	rs7252848	ENSG00000267533.1	RP11-815J4.7	9.14	3.06e-17	2.74e-10	0.64	0.51	Breast cancer;	chr19:18501541	chr18:12067173~12068417:-
SARC	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-9.13	3.42e-17	3.04e-10	-0.54	-0.51	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
SARC	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-9.13	3.42e-17	3.04e-10	-0.54	-0.51	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
SARC	trans	rs928391	0.592	rs7522395	ENSG00000227183.3	HDGFP1	-9.13	3.47e-17	3.09e-10	-0.75	-0.51	Platelet count;	chr1:156826905	chrX:131646639~131646890:+
SARC	trans	rs11332131	1	rs11332131	ENSG00000187870.7	RNFT1P3	9.12	3.54e-17	3.14e-10	0.6	0.51	Platelet distribution width;	chr17:59849031	chr17:20743333~20754501:-
SARC	trans	rs928391	0.592	rs7516856	ENSG00000227183.3	HDGFP1	-9.12	3.58e-17	3.18e-10	-0.75	-0.51	Platelet count;	chr1:156828324	chrX:131646639~131646890:+
SARC	trans	rs9876781	1	rs6442117	ENSG00000235912.1	RP1-159A19.3	9.11	3.83e-17	3.39e-10	0.54	0.51	Longevity;	chr3:48378407	chr1:27649419~27649610:+
SARC	trans	rs3749237	0.964	rs11714957	ENSG00000197582.5	GPX1P1	9.11	3.84e-17	3.39e-10	0.66	0.51	Resting heart rate;	chr3:49738745	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.964	rs7431078	ENSG00000197582.5	GPX1P1	9.11	3.84e-17	3.39e-10	0.66	0.51	Resting heart rate;	chr3:49770757	chrX:13378735~13379340:-
SARC	trans	rs3749237	0.964	rs35210174	ENSG00000197582.5	GPX1P1	9.11	3.84e-17	3.39e-10	0.66	0.51	Resting heart rate;	chr3:49775173	chrX:13378735~13379340:-
SARC	trans	rs928391	0.592	rs6427332	ENSG00000227183.3	HDGFP1	-9.11	3.87e-17	3.42e-10	-0.75	-0.51	Platelet count;	chr1:156827052	chrX:131646639~131646890:+
SARC	trans	rs916888	0.821	rs199504	ENSG00000204650.12	CRHR1-IT1	-9.11	3.89e-17	3.44e-10	-0.66	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45620328~45648216:+
SARC	trans	rs7554547	0.871	rs6661289	ENSG00000261819.1	RP11-680G24.4	9.11	3.95e-17	3.49e-10	0.6	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11882724	chr16:14988259~14990160:-
SARC	trans	rs8081395	0.775	rs2526355	ENSG00000187870.7	RNFT1P3	9.1	4.01e-17	3.53e-10	0.58	0.51	White blood cell count;	chr17:59875872	chr17:20743333~20754501:-
SARC	trans	rs1292048	1	rs1292048	ENSG00000187870.7	RNFT1P3	9.1	4.01e-17	3.53e-10	0.58	0.51	Red cell distribution width;	chr17:59877710	chr17:20743333~20754501:-
SARC	trans	rs3749237	0.964	rs34522271	ENSG00000197582.5	GPX1P1	9.1	4.19e-17	3.69e-10	0.66	0.51	Resting heart rate;	chr3:49771084	chrX:13378735~13379340:-
SARC	trans	rs3749237	1	rs11130216	ENSG00000197582.5	GPX1P1	9.1	4.21e-17	3.71e-10	0.66	0.51	Resting heart rate;	chr3:49698739	chrX:13378735~13379340:-
SARC	trans	rs3749237	1	rs6804655	ENSG00000197582.5	GPX1P1	9.1	4.21e-17	3.71e-10	0.66	0.51	Resting heart rate;	chr3:49701512	chrX:13378735~13379340:-
SARC	trans	rs7258465	1	rs10409483	ENSG00000267533.1	RP11-815J4.7	9.09	4.33e-17	3.81e-10	0.66	0.51	Breast cancer;	chr19:18479413	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs10409505	ENSG00000267533.1	RP11-815J4.7	9.09	4.33e-17	3.81e-10	0.66	0.51	Breast cancer;	chr19:18479441	chr18:12067173~12068417:-
SARC	trans	rs7258465	0.965	rs7254249	ENSG00000267533.1	RP11-815J4.7	9.09	4.33e-17	3.81e-10	0.66	0.51	Breast cancer;	chr19:18480935	chr18:12067173~12068417:-
SARC	trans	rs7200543	1	rs4985124	ENSG00000250569.1	NTAN1P2	9.07	4.95e-17	4.31e-10	0.64	0.51	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr8:86481754~86483002:-
SARC	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-9.06	5.34e-17	4.64e-10	-0.59	-0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
SARC	trans	rs7312770	1	rs7312770	ENSG00000225071.1	GS1-184P14.2	-9.06	5.41e-17	4.71e-10	-0.52	-0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:24429573~24429920:-
SARC	trans	rs3779195	0.929	rs4268041	ENSG00000225169.1	BRI3P1	-9.06	5.44e-17	4.73e-10	-0.8	-0.51	Sex hormone-binding globulin levels;	chr7:98376226	chr1:100213293~100213670:+
SARC	trans	rs13190036	1	rs28580074	ENSG00000217325.2	PRELID1P1	9.06	5.46e-17	4.74e-10	0.92	0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr6:126643488~126644390:+
SARC	trans	rs928391	0.541	rs1888863	ENSG00000227183.3	HDGFP1	-9.06	5.59e-17	4.86e-10	-0.75	-0.51	Platelet count;	chr1:156828046	chrX:131646639~131646890:+
SARC	trans	rs7258465	0.965	rs8100767	ENSG00000267533.1	RP11-815J4.7	9.04	6.2e-17	5.35e-10	0.65	0.51	Breast cancer;	chr19:18478278	chr18:12067173~12068417:-
SARC	trans	rs7258465	0.965	rs7253990	ENSG00000267533.1	RP11-815J4.7	9.04	6.2e-17	5.35e-10	0.65	0.51	Breast cancer;	chr19:18493275	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs10403249	ENSG00000267533.1	RP11-815J4.7	9.04	6.2e-17	5.35e-10	0.65	0.51	Breast cancer;	chr19:18494132	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs34256197	ENSG00000267533.1	RP11-815J4.7	9.04	6.2e-17	5.35e-10	0.65	0.51	Breast cancer;	chr19:18495662	chr18:12067173~12068417:-
SARC	trans	rs7258465	0.931	rs7249020	ENSG00000267533.1	RP11-815J4.7	9.04	6.2e-17	5.35e-10	0.65	0.51	Breast cancer;	chr19:18497337	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs7251653	ENSG00000267533.1	RP11-815J4.7	9.04	6.2e-17	5.35e-10	0.65	0.51	Breast cancer;	chr19:18497473	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs4808133	ENSG00000267533.1	RP11-815J4.7	9.04	6.2e-17	5.35e-10	0.65	0.51	Breast cancer;	chr19:18497708	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs4808134	ENSG00000267533.1	RP11-815J4.7	9.04	6.2e-17	5.35e-10	0.65	0.51	Breast cancer;	chr19:18497769	chr18:12067173~12068417:-
SARC	trans	rs7258465	0.931	rs875396	ENSG00000267533.1	RP11-815J4.7	9.04	6.2e-17	5.35e-10	0.65	0.51	Breast cancer;	chr19:18500337	chr18:12067173~12068417:-
SARC	trans	rs13190036	0.901	rs28684504	ENSG00000217325.2	PRELID1P1	9.04	6.29e-17	5.43e-10	0.92	0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr6:126643488~126644390:+
SARC	trans	rs7503168	0.558	rs17670614	ENSG00000234130.2	RP13-88F20.1	9.02	7.06e-17	6.07e-10	1.1	0.51	Plateletcrit;	chr17:35672348	chrX:93222220~93225015:-
SARC	trans	rs1045902	0.583	rs2303904	ENSG00000236165.1	PRADC1P1	-9.02	7.18e-17	6.16e-10	-0.63	-0.51	Intelligence (multi-trait analysis);	chr2:73220647	chr3:36976316~36976840:+
SARC	trans	rs9876781	1	rs6784322	ENSG00000235912.1	RP1-159A19.3	-9.02	7.31e-17	6.27e-10	-0.55	-0.51	Longevity;	chr3:48380745	chr1:27649419~27649610:+
SARC	trans	rs3779195	0.86	rs12704986	ENSG00000225169.1	BRI3P1	9.01	7.61e-17	6.52e-10	0.82	0.51	Sex hormone-binding globulin levels;	chr7:98357118	chr1:100213293~100213670:+
SARC	trans	rs616147	0.655	rs1707981	ENSG00000183298.5	RP11-556K13.1	-9.01	7.74e-17	6.62e-10	-0.71	-0.51	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr1:101786340~101787219:-
SARC	trans	rs616147	0.72	rs1768209	ENSG00000183298.5	RP11-556K13.1	-9.01	7.74e-17	6.62e-10	-0.71	-0.51	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr1:101786340~101787219:-
SARC	trans	rs877636	0.702	rs773109	ENSG00000225071.1	GS1-184P14.2	9	7.93e-17	6.78e-10	0.57	0.51	Cognitive function;	chr12:55980911	chrX:24429573~24429920:-
SARC	trans	rs8081395	0.801	rs2665405	ENSG00000187870.7	RNFT1P3	-9	8.13e-17	6.95e-10	-0.59	-0.51	White blood cell count;	chr17:59797931	chr17:20743333~20754501:-
SARC	trans	rs7258465	0.931	rs8107347	ENSG00000267533.1	RP11-815J4.7	9	8.18e-17	6.99e-10	0.64	0.51	Breast cancer;	chr19:18501938	chr18:12067173~12068417:-
SARC	trans	rs7258465	0.931	rs8107351	ENSG00000267533.1	RP11-815J4.7	9	8.18e-17	6.99e-10	0.64	0.51	Breast cancer;	chr19:18501948	chr18:12067173~12068417:-
SARC	trans	rs877636	0.702	rs773110	ENSG00000225071.1	GS1-184P14.2	9	8.32e-17	7.08e-10	0.57	0.51	Cognitive function;	chr12:55981353	chrX:24429573~24429920:-
SARC	trans	rs877636	0.702	rs773111	ENSG00000225071.1	GS1-184P14.2	9	8.32e-17	7.08e-10	0.57	0.51	Cognitive function;	chr12:55981956	chrX:24429573~24429920:-
SARC	trans	rs877636	0.702	rs773112	ENSG00000225071.1	GS1-184P14.2	9	8.32e-17	7.08e-10	0.57	0.51	Cognitive function;	chr12:55982097	chrX:24429573~24429920:-
SARC	trans	rs916888	0.647	rs199524	ENSG00000264070.1	DND1P1	-9	8.32e-17	7.08e-10	-0.68	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45585871~45586929:+
SARC	trans	rs916888	0.647	rs199523	ENSG00000264070.1	DND1P1	-9	8.32e-17	7.08e-10	-0.68	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45585871~45586929:+
SARC	trans	rs916888	0.61	rs199454	ENSG00000214425.5	LRRC37A4P	8.99	8.58e-17	7.29e-10	0.63	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45506741~45550335:-
SARC	trans	rs7200543	0.848	rs62039480	ENSG00000250569.1	NTAN1P2	8.99	8.63e-17	7.34e-10	0.64	0.51	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr8:86481754~86483002:-
SARC	trans	rs13190036	1	rs351862	ENSG00000217325.2	PRELID1P1	-8.98	9.11e-17	7.73e-10	-0.9	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr6:126643488~126644390:+
SARC	trans	rs3749237	0.964	rs13084243	ENSG00000197582.5	GPX1P1	8.98	9.42e-17	7.99e-10	0.66	0.51	Resting heart rate;	chr3:49784445	chrX:13378735~13379340:-
SARC	trans	rs3749237	1	rs11920900	ENSG00000197582.5	GPX1P1	8.98	9.42e-17	7.99e-10	0.66	0.51	Resting heart rate;	chr3:49785591	chrX:13378735~13379340:-
SARC	trans	rs13190036	0.892	rs71601339	ENSG00000217325.2	PRELID1P1	-8.98	9.44e-17	8e-10	-0.91	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr6:126643488~126644390:+
SARC	trans	rs7258465	0.931	rs271629	ENSG00000267533.1	RP11-815J4.7	8.97	9.74e-17	8.25e-10	0.64	0.51	Breast cancer;	chr19:18512388	chr18:12067173~12068417:-
SARC	trans	rs7258465	0.965	rs271628	ENSG00000267533.1	RP11-815J4.7	8.97	9.74e-17	8.25e-10	0.64	0.51	Breast cancer;	chr19:18513523	chr18:12067173~12068417:-
SARC	trans	rs13253073	0.765	rs35615286	ENSG00000260318.1	COX6CP1	8.97	9.77e-17	8.27e-10	1.14	0.51	Glucose homeostasis traits;	chr8:99834866	chr16:11903923~11904137:-
SARC	trans	rs916888	0.61	rs199452	ENSG00000214425.5	LRRC37A4P	-8.97	1.01e-16	8.58e-10	-0.6	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45506741~45550335:-
SARC	trans	rs7258465	1	rs8109573	ENSG00000267533.1	RP11-815J4.7	8.96	1.05e-16	8.87e-10	0.64	0.51	Breast cancer;	chr19:18506341	chr18:12067173~12068417:-
SARC	trans	rs13190036	1	rs7714695	ENSG00000217325.2	PRELID1P1	-8.96	1.1e-16	9.28e-10	-0.92	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr6:126643488~126644390:+
SARC	trans	rs916888	0.61	rs199530	ENSG00000214425.5	LRRC37A4P	8.94	1.22e-16	1.02e-09	0.61	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45506741~45550335:-
SARC	trans	rs7258465	1	rs271623	ENSG00000267533.1	RP11-815J4.7	8.94	1.23e-16	1.03e-09	0.65	0.51	Breast cancer;	chr19:18518137	chr18:12067173~12068417:-
SARC	trans	rs7258465	0.965	rs271622	ENSG00000267533.1	RP11-815J4.7	8.94	1.23e-16	1.03e-09	0.65	0.51	Breast cancer;	chr19:18518467	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs3810429	ENSG00000267533.1	RP11-815J4.7	8.94	1.23e-16	1.03e-09	0.65	0.51	Breast cancer;	chr19:18432460	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs271621	ENSG00000267533.1	RP11-815J4.7	8.93	1.29e-16	1.08e-09	0.65	0.51	Breast cancer;	chr19:18520522	chr18:12067173~12068417:-
SARC	trans	rs9876781	1	rs7630741	ENSG00000235912.1	RP1-159A19.3	-8.93	1.29e-16	1.08e-09	-0.54	-0.51	Longevity;	chr3:48378233	chr1:27649419~27649610:+
SARC	trans	rs7258465	1	rs76194	ENSG00000267533.1	RP11-815J4.7	8.92	1.41e-16	1.18e-09	0.65	0.5	Breast cancer;	chr19:18519770	chr18:12067173~12068417:-
SARC	trans	rs877636	0.669	rs7297175	ENSG00000243538.1	CTB-55B8.1	-8.92	1.44e-16	1.2e-09	-0.57	-0.5	Cognitive function;	chr12:56080024	chr5:16902294~16902641:-
SARC	trans	rs7554547	0.871	rs11588551	ENSG00000261819.1	RP11-680G24.4	-8.9	1.56e-16	1.29e-09	-0.59	-0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11881879	chr16:14988259~14990160:-
SARC	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-8.9	1.57e-16	1.3e-09	-0.53	-0.5	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
SARC	trans	rs13253073	0.883	rs12545602	ENSG00000260318.1	COX6CP1	8.9	1.65e-16	1.37e-09	1.13	0.5	Glucose homeostasis traits;	chr8:99834612	chr16:11903923~11904137:-
SARC	trans	rs3749237	1	rs3749237	ENSG00000197582.5	GPX1P1	8.89	1.67e-16	1.38e-09	0.64	0.5	Resting heart rate;	chr3:49732599	chrX:13378735~13379340:-
SARC	trans	rs8081395	0.805	rs1295927	ENSG00000187870.7	RNFT1P3	8.89	1.72e-16	1.42e-09	0.58	0.5	White blood cell count;	chr17:59852174	chr17:20743333~20754501:-
SARC	trans	rs9876781	0.967	rs9876891	ENSG00000235912.1	RP1-159A19.3	-8.88	1.78e-16	1.46e-09	-0.54	-0.5	Longevity;	chr3:48440024	chr1:27649419~27649610:+
SARC	trans	rs9611519	0.894	rs9623320	ENSG00000268568.1	AC007228.9	-8.88	1.79e-16	1.47e-09	-0.62	-0.5	Neuroticism;	chr22:41082478	chr19:56672574~56673901:-
SARC	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-8.88	1.82e-16	1.5e-09	-0.64	-0.5	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
SARC	trans	rs13190036	1	rs59737888	ENSG00000217325.2	PRELID1P1	-8.88	1.89e-16	1.55e-09	-0.92	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr6:126643488~126644390:+
SARC	trans	rs7258465	0.896	rs8103660	ENSG00000267533.1	RP11-815J4.7	8.87	1.91e-16	1.57e-09	0.65	0.5	Breast cancer;	chr19:18455585	chr18:12067173~12068417:-
SARC	trans	rs877636	1	rs4759229	ENSG00000225071.1	GS1-184P14.2	-8.87	1.94e-16	1.59e-09	-0.56	-0.5	Cognitive function;	chr12:56080696	chrX:24429573~24429920:-
SARC	trans	rs7258465	1	rs10164323	ENSG00000267533.1	RP11-815J4.7	8.87	1.99e-16	1.63e-09	0.65	0.5	Breast cancer;	chr19:18458682	chr18:12067173~12068417:-
SARC	trans	rs9611519	1	rs9611510	ENSG00000268568.1	AC007228.9	-8.86	2.05e-16	1.68e-09	-0.62	-0.5	Neuroticism;	chr22:41173120	chr19:56672574~56673901:-
SARC	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	8.86	2.08e-16	1.7e-09	0.58	0.5	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
SARC	trans	rs9611519	0.894	rs9611488	ENSG00000268568.1	AC007228.9	-8.86	2.11e-16	1.73e-09	-0.6	-0.5	Neuroticism;	chr22:41066588	chr19:56672574~56673901:-
SARC	trans	rs9611519	0.894	rs4821998	ENSG00000268568.1	AC007228.9	-8.86	2.11e-16	1.73e-09	-0.6	-0.5	Neuroticism;	chr22:41072269	chr19:56672574~56673901:-
SARC	trans	rs916888	0.531	rs183211	ENSG00000214425.5	LRRC37A4P	-8.85	2.17e-16	1.78e-09	-0.61	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45506741~45550335:-
SARC	trans	rs916888	0.61	rs199438	ENSG00000214425.5	LRRC37A4P	-8.85	2.2e-16	1.8e-09	-0.6	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45506741~45550335:-
SARC	trans	rs9876781	1	rs725310	ENSG00000235912.1	RP1-159A19.3	8.84	2.38e-16	1.94e-09	0.53	0.5	Longevity;	chr3:48377081	chr1:27649419~27649610:+
SARC	trans	rs7554547	0.818	rs4993566	ENSG00000261819.1	RP11-680G24.4	8.83	2.51e-16	2.05e-09	0.63	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11909937	chr16:14988259~14990160:-
SARC	trans	rs9611519	1	rs9611519	ENSG00000268568.1	AC007228.9	-8.83	2.55e-16	2.08e-09	-0.61	-0.5	Neuroticism;	chr22:41217184	chr19:56672574~56673901:-
SARC	trans	rs9611519	1	rs9611520	ENSG00000268568.1	AC007228.9	-8.83	2.55e-16	2.08e-09	-0.61	-0.5	Neuroticism;	chr22:41217299	chr19:56672574~56673901:-
SARC	trans	rs7312770	1	rs7312770	ENSG00000243403.1	RP11-330L19.1	-8.82	2.66e-16	2.16e-09	-0.53	-0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr15:64592979~64593326:+
SARC	trans	rs916888	0.61	rs199529	ENSG00000204650.12	CRHR1-IT1	8.82	2.69e-16	2.19e-09	0.62	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45620328~45648216:+
SARC	trans	rs9876781	1	rs9815103	ENSG00000235912.1	RP1-159A19.3	-8.82	2.72e-16	2.21e-09	-0.54	-0.5	Longevity;	chr3:48372725	chr1:27649419~27649610:+
SARC	trans	rs9876781	0.872	rs11797	ENSG00000235912.1	RP1-159A19.3	-8.82	2.76e-16	2.24e-09	-0.56	-0.5	Longevity;	chr3:48467186	chr1:27649419~27649610:+
SARC	trans	rs7258465	1	rs10411009	ENSG00000267533.1	RP11-815J4.7	8.82	2.79e-16	2.27e-09	0.65	0.5	Breast cancer;	chr19:18495456	chr18:12067173~12068417:-
SARC	trans	rs877636	1	rs705696	ENSG00000225071.1	GS1-184P14.2	8.81	2.97e-16	2.4e-09	0.57	0.5	Cognitive function;	chr12:56086864	chrX:24429573~24429920:-
SARC	trans	rs877636	0.702	rs61937249	ENSG00000225071.1	GS1-184P14.2	8.8	3.1e-16	2.51e-09	0.57	0.5	Cognitive function;	chr12:55988132	chrX:24429573~24429920:-
SARC	trans	rs3749237	1	rs11710675	ENSG00000197582.5	GPX1P1	8.8	3.14e-16	2.53e-09	0.64	0.5	Resting heart rate;	chr3:49714467	chrX:13378735~13379340:-
SARC	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	8.8	3.21e-16	2.59e-09	0.53	0.5	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
SARC	trans	rs7258465	1	rs10405636	ENSG00000267533.1	RP11-815J4.7	8.79	3.27e-16	2.63e-09	0.63	0.5	Breast cancer;	chr19:18427932	chr18:12067173~12068417:-
SARC	trans	rs13190036	1	rs351864	ENSG00000217325.2	PRELID1P1	-8.79	3.34e-16	2.69e-09	-0.91	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr6:126643488~126644390:+
SARC	trans	rs13190036	1	rs13157667	ENSG00000217325.2	PRELID1P1	-8.79	3.36e-16	2.7e-09	-0.9	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr6:126643488~126644390:+
SARC	trans	rs13190036	1	rs3733875	ENSG00000217325.2	PRELID1P1	-8.79	3.36e-16	2.7e-09	-0.9	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr6:126643488~126644390:+
SARC	trans	rs13190036	1	rs13185316	ENSG00000217325.2	PRELID1P1	-8.79	3.36e-16	2.7e-09	-0.9	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr6:126643488~126644390:+
SARC	trans	rs616147	0.616	rs1768234	ENSG00000183298.5	RP11-556K13.1	-8.78	3.55e-16	2.84e-09	-0.7	-0.5	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr1:101786340~101787219:-
SARC	trans	rs7258465	0.931	rs1560119	ENSG00000267533.1	RP11-815J4.7	8.78	3.56e-16	2.85e-09	0.64	0.5	Breast cancer;	chr19:18462865	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs2278238	ENSG00000267533.1	RP11-815J4.7	8.78	3.56e-16	2.85e-09	0.64	0.5	Breast cancer;	chr19:18465674	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs10425982	ENSG00000267533.1	RP11-815J4.7	8.78	3.56e-16	2.85e-09	0.64	0.5	Breast cancer;	chr19:18475709	chr18:12067173~12068417:-
SARC	trans	rs7258465	0.965	rs7256534	ENSG00000267533.1	RP11-815J4.7	8.78	3.56e-16	2.85e-09	0.64	0.5	Breast cancer;	chr19:18475981	chr18:12067173~12068417:-
SARC	trans	rs13190036	1	rs71601343	ENSG00000217325.2	PRELID1P1	-8.78	3.63e-16	2.9e-09	-0.9	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr6:126643488~126644390:+
SARC	trans	rs13190036	1	rs71601344	ENSG00000217325.2	PRELID1P1	-8.78	3.63e-16	2.9e-09	-0.9	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr6:126643488~126644390:+
SARC	trans	rs877636	0.859	rs3741499	ENSG00000225071.1	GS1-184P14.2	-8.78	3.69e-16	2.95e-09	-0.54	-0.5	Cognitive function;	chr12:56080595	chrX:24429573~24429920:-
SARC	trans	rs13190036	0.901	rs55741473	ENSG00000217325.2	PRELID1P1	-8.77	3.8e-16	3.03e-09	-0.9	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr6:126643488~126644390:+
SARC	trans	rs3779195	0.524	rs80195155	ENSG00000225169.1	BRI3P1	-8.76	3.98e-16	3.18e-09	-0.84	-0.5	Sex hormone-binding globulin levels;	chr7:98248841	chr1:100213293~100213670:+
SARC	trans	rs7258465	1	rs10413237	ENSG00000267533.1	RP11-815J4.7	8.76	4.02e-16	3.21e-09	0.64	0.5	Breast cancer;	chr19:18437439	chr18:12067173~12068417:-
SARC	trans	rs877636	0.74	rs772920	ENSG00000225071.1	GS1-184P14.2	8.75	4.32e-16	3.43e-09	0.57	0.5	Cognitive function;	chr12:55996580	chrX:24429573~24429920:-
SARC	trans	rs9611519	0.78	rs5751072	ENSG00000268568.1	AC007228.9	-8.75	4.35e-16	3.45e-09	-0.58	-0.5	Neuroticism;	chr22:41260505	chr19:56672574~56673901:-
SARC	trans	rs7258465	1	rs10442	ENSG00000267533.1	RP11-815J4.7	8.75	4.39e-16	3.48e-09	0.63	0.5	Breast cancer;	chr19:18434531	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs2303697	ENSG00000267533.1	RP11-815J4.7	8.75	4.39e-16	3.48e-09	0.63	0.5	Breast cancer;	chr19:18435868	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs4595905	ENSG00000267533.1	RP11-815J4.7	8.75	4.39e-16	3.48e-09	0.63	0.5	Breast cancer;	chr19:18436495	chr18:12067173~12068417:-
SARC	trans	rs7258465	0.897	rs1043327	ENSG00000267533.1	RP11-815J4.7	8.74	4.53e-16	3.59e-09	0.63	0.5	Breast cancer;	chr19:18444162	chr18:12067173~12068417:-
SARC	trans	rs3749237	1	rs2291542	ENSG00000197582.5	GPX1P1	8.74	4.66e-16	3.7e-09	0.64	0.5	Resting heart rate;	chr3:49714152	chrX:13378735~13379340:-
SARC	trans	rs928391	0.592	rs1888862	ENSG00000227183.3	HDGFP1	-8.74	4.67e-16	3.7e-09	-0.72	-0.5	Platelet count;	chr1:156828113	chrX:131646639~131646890:+
SARC	trans	rs9467773	1	rs9357010	ENSG00000242375.1	RP11-498P14.3	8.74	4.7e-16	3.72e-09	0.6	0.5	Intelligence (multi-trait analysis);	chr6:26527717	chr9:97195351~97197687:-
SARC	trans	rs7399018	0.643	rs6580810	ENSG00000223825.5	DAZAP2P1	8.74	4.7e-16	3.72e-09	0.65	0.5	Cisplatin-induced ototoxicity;	chr12:51216694	chr2:202201384~202201886:-
SARC	trans	rs916888	0.61	rs199446	ENSG00000264070.1	DND1P1	-8.74	4.82e-16	3.82e-09	-0.64	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45585871~45586929:+
SARC	trans	rs916888	0.61	rs199536	ENSG00000264070.1	DND1P1	-8.74	4.82e-16	3.82e-09	-0.64	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45585871~45586929:+
SARC	trans	rs6477998	0.676	rs4979224	ENSG00000238072.1	RP11-305M3.2	8.74	4.82e-16	3.82e-09	0.68	0.5	Hematology traits;	chr9:113219998	chr7:129410113~129410370:-
SARC	trans	rs916888	0.61	rs142167	ENSG00000214425.5	LRRC37A4P	8.73	4.92e-16	3.89e-09	0.61	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45506741~45550335:-
SARC	trans	rs877636	0.74	rs705702	ENSG00000225071.1	GS1-184P14.2	-8.73	5.02e-16	3.97e-09	-0.57	-0.5	Cognitive function;	chr12:55996852	chrX:24429573~24429920:-
SARC	trans	rs7258465	0.965	rs2561043	ENSG00000267533.1	RP11-815J4.7	8.73	5.14e-16	4.06e-09	0.63	0.5	Breast cancer;	chr19:18511873	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs10427083	ENSG00000267533.1	RP11-815J4.7	8.72	5.23e-16	4.13e-09	0.63	0.5	Breast cancer;	chr19:18439466	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs34171762	ENSG00000267533.1	RP11-815J4.7	8.72	5.23e-16	4.13e-09	0.63	0.5	Breast cancer;	chr19:18448600	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs4808136	ENSG00000267533.1	RP11-815J4.7	-8.72	5.25e-16	4.14e-09	-0.62	-0.5	Breast cancer;	chr19:18508057	chr18:12067173~12068417:-
SARC	trans	rs9467773	1	rs1321479	ENSG00000242375.1	RP11-498P14.3	-8.72	5.25e-16	4.14e-09	-0.6	-0.5	Intelligence (multi-trait analysis);	chr6:26501669	chr9:97195351~97197687:-
SARC	trans	rs12709013	0.755	rs1424245	ENSG00000230849.2	GOT2P2	8.72	5.29e-16	4.17e-09	0.64	0.5	Blood metabolite ratios;	chr16:58729926	chr1:173141100~173142350:-
SARC	trans	rs7258465	1	rs8105994	ENSG00000267533.1	RP11-815J4.7	8.72	5.29e-16	4.17e-09	0.62	0.5	Breast cancer;	chr19:18482743	chr18:12067173~12068417:-
SARC	trans	rs13253073	0.544	rs13280341	ENSG00000260318.1	COX6CP1	8.72	5.33e-16	4.2e-09	0.96	0.5	Glucose homeostasis traits;	chr8:99908840	chr16:11903923~11904137:-
SARC	trans	rs7312770	0.637	rs705699	ENSG00000212994.5	RPS26P6	8.7	5.97e-16	4.69e-09	0.61	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr8:100895771~100896118:+
SARC	trans	rs9876781	1	rs6794875	ENSG00000235912.1	RP1-159A19.3	-8.7	5.99e-16	4.7e-09	-0.54	-0.5	Longevity;	chr3:48414217	chr1:27649419~27649610:+
SARC	trans	rs7258465	0.931	rs271626	ENSG00000267533.1	RP11-815J4.7	-8.7	6.08e-16	4.77e-09	-0.64	-0.5	Breast cancer;	chr19:18516257	chr18:12067173~12068417:-
SARC	trans	rs7258465	1	rs7252707	ENSG00000267533.1	RP11-815J4.7	8.7	6.09e-16	4.78e-09	0.63	0.5	Breast cancer;	chr19:18501447	chr18:12067173~12068417:-
SARC	trans	rs7312770	0.612	rs773114	ENSG00000234354.3	RPS26P47	8.7	6.11e-16	4.79e-09	0.59	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr13:100539901~100540248:-
SARC	trans	rs13190036	0.901	rs4631	ENSG00000217325.2	PRELID1P1	8.7	6.15e-16	4.82e-09	0.94	0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr6:126643488~126644390:+
SARC	trans	rs3779195	0.585	rs58699591	ENSG00000225169.1	BRI3P1	-8.69	6.36e-16	4.99e-09	-0.84	-0.49	Sex hormone-binding globulin levels;	chr7:98247392	chr1:100213293~100213670:+
SARC	trans	rs9876781	1	rs898225	ENSG00000235912.1	RP1-159A19.3	8.69	6.43e-16	5.04e-09	0.53	0.49	Longevity;	chr3:48371689	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs1459242	ENSG00000235912.1	RP1-159A19.3	8.69	6.43e-16	5.04e-09	0.53	0.49	Longevity;	chr3:48372047	chr1:27649419~27649610:+
SARC	trans	rs12709013	0.536	rs1646260	ENSG00000230849.2	GOT2P2	8.69	6.44e-16	5.04e-09	0.74	0.49	Blood metabolite ratios;	chr16:58734951	chr1:173141100~173142350:-
SARC	trans	rs9611519	0.894	rs13053242	ENSG00000268568.1	AC007228.9	-8.68	6.99e-16	5.46e-09	-0.6	-0.49	Neuroticism;	chr22:41063482	chr19:56672574~56673901:-
SARC	trans	rs5022636	0.927	rs10888409	ENSG00000180764.13	PIPSL	8.68	6.99e-16	5.46e-09	0.54	0.49	Gut microbiota (functional units);	chr1:151299306	chr10:93958191~93961540:-
SARC	trans	rs5022636	0.927	rs943637	ENSG00000180764.13	PIPSL	8.68	6.99e-16	5.46e-09	0.54	0.49	Gut microbiota (functional units);	chr1:151310543	chr10:93958191~93961540:-
SARC	trans	rs5022636	1	rs4970948	ENSG00000180764.13	PIPSL	8.68	6.99e-16	5.46e-09	0.54	0.49	Gut microbiota (functional units);	chr1:151318767	chr10:93958191~93961540:-
SARC	trans	rs5022636	0.964	rs7518924	ENSG00000180764.13	PIPSL	8.68	6.99e-16	5.46e-09	0.54	0.49	Gut microbiota (functional units);	chr1:151319225	chr10:93958191~93961540:-
SARC	trans	rs10242455	0.571	rs11734	ENSG00000228834.1	RP11-249L21.4	-8.68	7.15e-16	5.58e-09	-1.35	-0.49	Blood metabolite levels;	chr7:99632145	chr6:108907615~108907873:-
SARC	trans	rs9876781	1	rs7653691	ENSG00000235912.1	RP1-159A19.3	8.67	7.46e-16	5.81e-09	0.53	0.49	Longevity;	chr3:48378199	chr1:27649419~27649610:+
SARC	trans	rs9611519	0.894	rs8136923	ENSG00000268568.1	AC007228.9	-8.67	7.57e-16	5.89e-09	-0.6	-0.49	Neuroticism;	chr22:41074518	chr19:56672574~56673901:-
SARC	trans	rs916888	0.779	rs199498	ENSG00000264070.1	DND1P1	8.67	7.6e-16	5.92e-09	0.66	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45585871~45586929:+
SARC	trans	rs9876781	1	rs2885510	ENSG00000235912.1	RP1-159A19.3	8.65	8.26e-16	6.41e-09	0.53	0.49	Longevity;	chr3:48376736	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs725309	ENSG00000235912.1	RP1-159A19.3	8.65	8.26e-16	6.41e-09	0.53	0.49	Longevity;	chr3:48377218	chr1:27649419~27649610:+
SARC	trans	rs916888	0.531	rs183211	ENSG00000264070.1	DND1P1	8.65	8.48e-16	6.57e-09	0.62	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45585871~45586929:+
SARC	trans	rs9876781	0.967	rs2885509	ENSG00000235912.1	RP1-159A19.3	8.65	8.51e-16	6.59e-09	0.53	0.49	Longevity;	chr3:48376729	chr1:27649419~27649610:+
SARC	trans	rs9611519	0.964	rs2092563	ENSG00000268568.1	AC007228.9	-8.65	8.59e-16	6.62e-09	-0.61	-0.49	Neuroticism;	chr22:41196673	chr19:56672574~56673901:-
SARC	trans	rs12709013	0.591	rs30838	ENSG00000230849.2	GOT2P2	8.64	8.82e-16	6.76e-09	0.73	0.49	Blood metabolite ratios;	chr16:58711513	chr1:173141100~173142350:-
SARC	trans	rs7258465	1	rs2007981	ENSG00000267533.1	RP11-815J4.7	8.64	8.9e-16	6.81e-09	0.63	0.49	Breast cancer;	chr19:18456745	chr18:12067173~12068417:-
SARC	trans	rs916888	0.61	rs199454	ENSG00000264070.1	DND1P1	-8.64	8.96e-16	6.86e-09	-0.64	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45585871~45586929:+
SARC	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-8.64	9.03e-16	6.91e-09	-0.54	-0.49	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
SARC	trans	rs7258465	1	rs271624	ENSG00000267533.1	RP11-815J4.7	8.64	9.16e-16	7e-09	0.64	0.49	Breast cancer;	chr19:18517143	chr18:12067173~12068417:-
SARC	trans	rs916888	0.61	rs199438	ENSG00000264070.1	DND1P1	8.64	9.32e-16	7.12e-09	0.62	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45585871~45586929:+
SARC	trans	rs916888	0.61	rs199436	ENSG00000214425.5	LRRC37A4P	8.64	9.34e-16	7.14e-09	0.59	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45506741~45550335:-
SARC	trans	rs9876781	1	rs6810060	ENSG00000235912.1	RP1-159A19.3	-8.64	9.36e-16	7.14e-09	-0.54	-0.49	Longevity;	chr3:48393284	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs6770470	ENSG00000235912.1	RP1-159A19.3	-8.64	9.36e-16	7.14e-09	-0.54	-0.49	Longevity;	chr3:48393659	chr1:27649419~27649610:+
SARC	trans	rs7647973	0.506	rs11920251	ENSG00000197582.5	GPX1P1	8.63	9.58e-16	7.31e-09	0.6	0.49	Menarche (age at onset);	chr3:49319238	chrX:13378735~13379340:-
SARC	trans	rs3779195	0.52	rs17169479	ENSG00000225169.1	BRI3P1	8.63	9.58e-16	7.31e-09	0.83	0.49	Sex hormone-binding globulin levels;	chr7:98238721	chr1:100213293~100213670:+
SARC	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	8.63	9.75e-16	7.42e-09	0.53	0.49	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
SARC	trans	rs12709013	0.591	rs30842	ENSG00000230849.2	GOT2P2	-8.62	1.02e-15	7.74e-09	-0.75	-0.49	Blood metabolite ratios;	chr16:58709550	chr1:173141100~173142350:-
SARC	trans	rs8010715	0.52	rs12435994	ENSG00000248988.1	RP11-815N9.2	8.62	1.02e-15	7.78e-09	0.6	0.49	IgG glycosylation;	chr14:24120252	chr4:159007119~159007835:+
SARC	trans	rs8010715	0.596	rs12435995	ENSG00000248988.1	RP11-815N9.2	8.62	1.02e-15	7.78e-09	0.6	0.49	IgG glycosylation;	chr14:24120255	chr4:159007119~159007835:+
SARC	trans	rs3749237	0.964	rs1799845	ENSG00000197582.5	GPX1P1	8.62	1.05e-15	7.96e-09	0.64	0.49	Resting heart rate;	chr3:49810190	chrX:13378735~13379340:-
SARC	trans	rs12709013	0.646	rs8046154	ENSG00000230849.2	GOT2P2	-8.62	1.05e-15	7.97e-09	-0.72	-0.49	Blood metabolite ratios;	chr16:58773978	chr1:173141100~173142350:-
SARC	trans	rs6477998	0.651	rs10121845	ENSG00000238072.1	RP11-305M3.2	8.61	1.09e-15	8.24e-09	0.68	0.49	Hematology traits;	chr9:113227443	chr7:129410113~129410370:-
SARC	trans	rs7258465	1	rs2303695	ENSG00000267533.1	RP11-815J4.7	8.61	1.12e-15	8.49e-09	0.63	0.49	Breast cancer;	chr19:18451814	chr18:12067173~12068417:-
SARC	trans	rs9611565	0.649	rs126092	ENSG00000268568.1	AC007228.9	8.61	1.14e-15	8.59e-09	0.62	0.49	Vitiligo;	chr22:41782437	chr19:56672574~56673901:-
SARC	trans	rs6477998	0.627	rs10114381	ENSG00000238072.1	RP11-305M3.2	8.6	1.18e-15	8.87e-09	0.68	0.49	Hematology traits;	chr9:113213692	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.651	rs10114423	ENSG00000238072.1	RP11-305M3.2	8.6	1.18e-15	8.87e-09	0.68	0.49	Hematology traits;	chr9:113213751	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.676	rs10817460	ENSG00000238072.1	RP11-305M3.2	8.6	1.18e-15	8.87e-09	0.68	0.49	Hematology traits;	chr9:113214118	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.603	rs7859189	ENSG00000238072.1	RP11-305M3.2	8.6	1.18e-15	8.87e-09	0.68	0.49	Hematology traits;	chr9:113217389	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.676	rs6477997	ENSG00000238072.1	RP11-305M3.2	8.6	1.18e-15	8.87e-09	0.68	0.49	Hematology traits;	chr9:113218833	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.627	rs3810914	ENSG00000238072.1	RP11-305M3.2	8.6	1.18e-15	8.87e-09	0.68	0.49	Hematology traits;	chr9:113219441	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.676	rs4978536	ENSG00000238072.1	RP11-305M3.2	8.6	1.18e-15	8.87e-09	0.68	0.49	Hematology traits;	chr9:113220123	chr7:129410113~129410370:-
SARC	trans	rs7312770	0.637	rs705700	ENSG00000212994.5	RPS26P6	8.6	1.18e-15	8.9e-09	0.61	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:100895771~100896118:+
SARC	trans	rs916888	0.647	rs199524	ENSG00000214425.5	LRRC37A4P	8.6	1.18e-15	8.94e-09	0.63	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45506741~45550335:-
SARC	trans	rs916888	0.647	rs199523	ENSG00000214425.5	LRRC37A4P	8.6	1.18e-15	8.94e-09	0.63	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45506741~45550335:-
SARC	trans	rs6477998	0.676	rs10817470	ENSG00000238072.1	RP11-305M3.2	8.6	1.22e-15	9.18e-09	0.68	0.49	Hematology traits;	chr9:113252129	chr7:129410113~129410370:-
SARC	trans	rs7312770	0.612	rs773114	ENSG00000212994.5	RPS26P6	8.59	1.24e-15	9.3e-09	0.6	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:100895771~100896118:+
SARC	trans	rs3749237	0.964	rs11717463	ENSG00000197582.5	GPX1P1	8.59	1.26e-15	9.45e-09	0.66	0.49	Resting heart rate;	chr3:49771548	chrX:13378735~13379340:-
SARC	trans	rs7258465	1	rs8107367	ENSG00000267533.1	RP11-815J4.7	8.59	1.27e-15	9.54e-09	0.63	0.49	Breast cancer;	chr19:18453895	chr18:12067173~12068417:-
SARC	trans	rs13190036	1	rs17078781	ENSG00000217325.2	PRELID1P1	-8.59	1.29e-15	9.66e-09	-0.89	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr6:126643488~126644390:+
SARC	trans	rs7258465	1	rs7258465	ENSG00000267533.1	RP11-815J4.7	8.59	1.29e-15	9.69e-09	0.63	0.49	Breast cancer;	chr19:18422832	chr18:12067173~12068417:-
SARC	trans	rs13253073	0.544	rs10955223	ENSG00000260318.1	COX6CP1	8.59	1.3e-15	9.73e-09	0.92	0.49	Glucose homeostasis traits;	chr8:99903454	chr16:11903923~11904137:-
SARC	trans	rs916888	0.61	rs199453	ENSG00000264070.1	DND1P1	8.58	1.35e-15	1.01e-08	0.62	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45585871~45586929:+
SARC	trans	rs5022636	0.964	rs1056847	ENSG00000180764.13	PIPSL	8.57	1.42e-15	1.06e-08	0.54	0.49	Gut microbiota (functional units);	chr1:151315696	chr10:93958191~93961540:-
SARC	trans	rs12291225	0.877	rs11023160	ENSG00000236360.2	RP11-334A14.2	8.57	1.43e-15	1.07e-08	0.63	0.49	Sense of smell;	chr11:14242679	chr1:52993201~52993702:-
SARC	trans	rs616147	0.548	rs2370965	ENSG00000183298.5	RP11-556K13.1	-8.57	1.44e-15	1.08e-08	-0.66	-0.49	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr1:101786340~101787219:-
SARC	trans	rs916888	0.61	rs199436	ENSG00000264070.1	DND1P1	-8.57	1.47e-15	1.1e-08	-0.62	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45585871~45586929:+
SARC	trans	rs916888	0.647	rs199449	ENSG00000264070.1	DND1P1	8.56	1.51e-15	1.13e-08	0.62	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45585871~45586929:+
SARC	trans	rs916888	0.61	rs199444	ENSG00000264070.1	DND1P1	8.56	1.51e-15	1.13e-08	0.62	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45585871~45586929:+
SARC	trans	rs916888	0.61	rs199442	ENSG00000264070.1	DND1P1	8.56	1.51e-15	1.13e-08	0.62	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45585871~45586929:+
SARC	trans	rs9611519	0.929	rs73174660	ENSG00000268568.1	AC007228.9	-8.55	1.62e-15	1.2e-08	-0.58	-0.49	Neuroticism;	chr22:41041300	chr19:56672574~56673901:-
SARC	trans	rs9611519	0.929	rs12484971	ENSG00000268568.1	AC007228.9	-8.55	1.62e-15	1.2e-08	-0.58	-0.49	Neuroticism;	chr22:41043300	chr19:56672574~56673901:-
SARC	trans	rs9611519	0.929	rs13055800	ENSG00000268568.1	AC007228.9	-8.55	1.62e-15	1.2e-08	-0.58	-0.49	Neuroticism;	chr22:41044420	chr19:56672574~56673901:-
SARC	trans	rs9611519	0.929	rs4821991	ENSG00000268568.1	AC007228.9	-8.55	1.62e-15	1.2e-08	-0.58	-0.49	Neuroticism;	chr22:41044679	chr19:56672574~56673901:-
SARC	trans	rs9611519	0.828	rs28814423	ENSG00000268568.1	AC007228.9	-8.55	1.65e-15	1.22e-08	-0.58	-0.49	Neuroticism;	chr22:41056297	chr19:56672574~56673901:-
SARC	trans	rs9899728	0.539	rs12938889	ENSG00000234925.2	ATP5HP4	-8.55	1.69e-15	1.25e-08	-0.91	-0.49	Alzheimer's disease or small vessel stroke;	chr17:75043834	chr12:68642519~68642993:-
SARC	trans	rs13190036	1	rs13190036	ENSG00000217325.2	PRELID1P1	8.54	1.71e-15	1.27e-08	0.96	0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177310719	chr6:126643488~126644390:+
SARC	trans	rs9876781	1	rs9876781	ENSG00000235912.1	RP1-159A19.3	-8.54	1.74e-15	1.29e-08	-0.53	-0.49	Longevity;	chr3:48445934	chr1:27649419~27649610:+
SARC	trans	rs7811142	0.775	rs1059129	ENSG00000228546.2	CTA-313A17.3	8.54	1.77e-15	1.31e-08	0.68	0.49	Platelet count;	chr7:100328899	chr7:102337316~102339115:+
SARC	trans	rs7811142	0.562	rs7786844	ENSG00000228546.2	CTA-313A17.3	8.54	1.77e-15	1.31e-08	0.68	0.49	Platelet count;	chr7:100336385	chr7:102337316~102339115:+
SARC	trans	rs7811142	0.667	rs3873746	ENSG00000228546.2	CTA-313A17.3	8.54	1.77e-15	1.31e-08	0.68	0.49	Platelet count;	chr7:100337474	chr7:102337316~102339115:+
SARC	trans	rs5022636	0.927	rs10788803	ENSG00000180764.13	PIPSL	8.54	1.77e-15	1.31e-08	0.53	0.49	Gut microbiota (functional units);	chr1:151291306	chr10:93958191~93961540:-
SARC	trans	rs7258465	1	rs4808801	ENSG00000267533.1	RP11-815J4.7	8.54	1.77e-15	1.31e-08	0.63	0.49	Breast cancer;	chr19:18460331	chr18:12067173~12068417:-
SARC	trans	rs3749237	1	rs11717256	ENSG00000197582.5	GPX1P1	8.53	1.82e-15	1.35e-08	0.63	0.49	Resting heart rate;	chr3:49831087	chrX:13378735~13379340:-
SARC	trans	rs7399018	0.739	rs6580811	ENSG00000223825.5	DAZAP2P1	8.53	1.87e-15	1.38e-08	0.64	0.49	Cisplatin-induced ototoxicity;	chr12:51218717	chr2:202201384~202201886:-
SARC	trans	rs9611519	0.964	rs5995992	ENSG00000268568.1	AC007228.9	-8.53	1.9e-15	1.4e-08	-0.6	-0.49	Neuroticism;	chr22:41091214	chr19:56672574~56673901:-
SARC	trans	rs9876781	1	rs7636044	ENSG00000235912.1	RP1-159A19.3	-8.52	2.07e-15	1.51e-08	-0.53	-0.49	Longevity;	chr3:48443151	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs4490383	ENSG00000235912.1	RP1-159A19.3	-8.52	2.07e-15	1.51e-08	-0.53	-0.49	Longevity;	chr3:48443275	chr1:27649419~27649610:+
SARC	trans	rs5022636	0.896	rs4971032	ENSG00000180764.13	PIPSL	8.51	2.16e-15	1.57e-08	0.53	0.49	Gut microbiota (functional units);	chr1:151317948	chr10:93958191~93961540:-
SARC	trans	rs6477998	0.676	rs10981698	ENSG00000238072.1	RP11-305M3.2	8.51	2.16e-15	1.58e-08	0.67	0.49	Hematology traits;	chr9:113233500	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.676	rs10759631	ENSG00000238072.1	RP11-305M3.2	8.51	2.16e-15	1.58e-08	0.67	0.49	Hematology traits;	chr9:113233764	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.676	rs10081797	ENSG00000238072.1	RP11-305M3.2	8.51	2.17e-15	1.58e-08	0.67	0.49	Hematology traits;	chr9:113237973	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.676	rs10759632	ENSG00000238072.1	RP11-305M3.2	8.51	2.17e-15	1.58e-08	0.67	0.49	Hematology traits;	chr9:113238703	chr7:129410113~129410370:-
SARC	trans	rs6477998	0.676	rs10981693	ENSG00000238072.1	RP11-305M3.2	-8.51	2.18e-15	1.59e-08	-0.67	-0.49	Hematology traits;	chr9:113223137	chr7:129410113~129410370:-
SARC	trans	rs2657294	0.674	rs10824268	ENSG00000172974.11	AC007318.5	8.51	2.18e-15	1.59e-08	0.54	0.49	Pneumonia;	chr10:75085937	chr2:65205108~65205988:+
SARC	trans	rs9425766	0.639	rs10798295	ENSG00000213331.4	RP11-713C19.2	8.49	2.41e-15	1.75e-08	0.57	0.49	Life satisfaction;	chr1:173714815	chr4:187970273~187971284:+
SARC	trans	rs6477998	0.676	rs4979225	ENSG00000238072.1	RP11-305M3.2	8.48	2.59e-15	1.87e-08	0.67	0.49	Hematology traits;	chr9:113225130	chr7:129410113~129410370:-
SARC	trans	rs7258465	1	rs10164319	ENSG00000267533.1	RP11-815J4.7	8.48	2.61e-15	1.88e-08	0.63	0.49	Breast cancer;	chr19:18459023	chr18:12067173~12068417:-
SARC	trans	rs7258465	0.965	rs1560118	ENSG00000267533.1	RP11-815J4.7	8.48	2.61e-15	1.88e-08	0.63	0.49	Breast cancer;	chr19:18459225	chr18:12067173~12068417:-
SARC	trans	rs877636	0.702	rs773108	ENSG00000225071.1	GS1-184P14.2	8.48	2.63e-15	1.9e-08	0.56	0.49	Cognitive function;	chr12:55976127	chrX:24429573~24429920:-
SARC	trans	rs9876781	1	rs11130171	ENSG00000235912.1	RP1-159A19.3	-8.48	2.68e-15	1.93e-08	-0.53	-0.49	Longevity;	chr3:48421052	chr1:27649419~27649610:+
SARC	trans	rs9876781	1	rs9883927	ENSG00000235912.1	RP1-159A19.3	-8.48	2.68e-15	1.93e-08	-0.53	-0.49	Longevity;	chr3:48422302	chr1:27649419~27649610:+
SARC	trans	rs5022636	0.927	rs4971030	ENSG00000180764.13	PIPSL	-8.47	2.71e-15	1.96e-08	-0.53	-0.49	Gut microbiota (functional units);	chr1:151308519	chr10:93958191~93961540:-
SARC	trans	rs9876781	1	rs9812647	ENSG00000235912.1	RP1-159A19.3	8.47	2.73e-15	1.96e-08	0.53	0.49	Longevity;	chr3:48407507	chr1:27649419~27649610:+
SARC	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	8.47	2.73e-15	1.97e-08	0.59	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8: